Antiarrhythmic	O
efficacy	O
of	O
azimilide	B-I
in	O
patients	B-P
with	I-P
atrial	I-P
fibrillation	I-P
.	I-P


Maintenance	O
of	O
sinus	O
rhythm	O
after	B-P
conversion	I-P
to	I-P
sinus	I-P
rhythm	I-P
.	I-P


BACKGROUND	O
Azimilide	B-I
dihydrochloride	I-I
(	O
azimilide	O
)	O
is	O
an	O
investigational	O
antiarrhythmic	O
drug	O
that	O
has	O
been	O
tested	O
in	O
patients	O
with	O
a	O
variety	O
of	O
arrhythmias	O
.	O


In	O
patients	B-P
with	I-P
atrial	I-P
fibrillation	I-P
,	O
it	O
has	O
shown	O
excellent	O
efficacy	O
in	O
some	O
previous	O
trials	O
and	O
minimal	O
efficacy	O
in	O
others	O
.	O


METHODS	O
Patients	B-P
who	I-P
had	I-P
symptomatic	I-P
atrial	I-P
fibrillation	I-P
for	I-P
>	I-P
48	I-P
hours	I-P
but	I-P
<	I-P
6	I-P
months	I-P
were	I-P
eligible	I-P
for	O
this	O
multicenter	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O


Patients	B-P
were	I-P
admitted	I-P
to	I-P
a	I-P
hospital	I-P
and	O
randomly	B-P
assigned	I-P
to	I-P
receive	I-P
either	I-P
azimilide	I-I
125	I-I
mg	I-I
or	I-I
a	I-I
matched	I-I
placebo	I-I
twice	I-I
daily	I-I
for	I-I
3	I-I
days	I-I
and	I-I
then	I-I
once	I-I
daily	I-I
.	I-I


Patients	B-P
who	I-P
were	I-P
in	I-P
sinus	I-P
rhythm	I-P
spontaneously	I-P
or	I-P
had	I-P
sinus	I-P
rhythm	I-P
restored	I-P
by	I-P
electric	I-P
cardioversion	I-P
on	I-P
day	I-P
4	I-P
were	I-P
discharged	I-P
from	I-P
the	I-P
hospital	I-P
.	I-P


Recurrence	B-O
of	I-O
atrial	I-O
fibrillation	I-O
was	O
documented	O
by	O
electrocardiogram	B-I
.	I-I


In	O
the	O
primary	O
efficacy	O
analysis	O
,	O
time	O
to	O
recurrence	O
in	O
the	O
2	O
treatment	O
groups	O
was	O
compared	O
with	O
the	O
log-rank	O
test	O
in	O
the	O
subgroup	O
of	O
patients	B-P
with	I-P
structural	I-P
heart	I-P
disease	I-P
.	I-P


Safety	O
was	O
assessed	O
as	O
deaths	B-O
,	I-O
adverse	I-O
events	I-O
,	I-O
and	I-O
serious	I-O
adverse	I-O
events	I-O
.	I-O


RESULTS	O
A	O
total	O
of	O
446	B-P
patients	I-P
were	I-P
randomized	I-P
in	I-P
the	I-P
study	I-P
;	I-P
314	I-P
were	I-P
in	I-P
the	I-P
subgroup	I-P
with	I-P
structural	I-P
heart	I-P
disease	I-P
.	I-P


The	O
median	B-O
time	I-O
to	I-O
arrhythmia	I-O
recurrence	I-O
in	O
both	O
treatment	O
groups	O
with	O
structural	O
heart	O
disease	O
was	O
13	O
days	O
,	O
and	O
the	O
difference	O
between	O
treatments	O
was	O
not	O
significant	O
(	O
P	O
=	O
.4596	O
,	O
n	O
=	O
314	O
)	O
.	O


The	O
relative	B-O
risk	I-O
for	I-O
recurrence	I-O
(	O
placebo	O
:	O
azimilide	O
)	O
was	O
1.104	O
(	O
95	O
%	O
CI	O
0.849-1.436	O
)	O
.	O


There	O
was	O
1	O
death	B-O
in	O
the	O
placebo	O
group	O
and	O
3	O
in	O
the	O
azimilide	O
group	O
.	O


CONCLUSIONS	O
Azimilide	B-I
did	O
not	O
demonstrate	O
clinically	O
important	O
or	O
statistically	O
significant	O
efficacy	O
in	O
reducing	O
the	O
risk	O
for	O
arrhythmia	O
recurrence	O
in	O
patients	B-P
with	I-P
structural	I-P
heart	I-P
disease	I-P
who	I-P
were	I-P
in	I-P
atrial	I-P
fibrillation	I-P
and	I-P
converted	I-P
to	I-P
sinus	I-P
rhythm	I-P
.	I-P


The	O
assessment	O
of	O
erythema	B-O
and	I-O
thickness	I-O
on	I-O
burn	I-O
related	I-O
scars	I-O
during	O
pressure	B-I
garment	I-I
therapy	I-I
as	O
a	O
preventive	O
measure	O
for	O
hypertrophic	O
scarring	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
threefold	O
:	O
(	O
1	O
)	O
Assess	O
the	O
pressure	O
loss	O
of	O
two	B-I
types	I-I
of	I-I
pressure	I-I
garments	I-I
that	O
are	O
used	O
in	O
the	O
treatment	O
of	O
hypertrophic	B-P
scars	I-P
after	I-P
burn	I-P
injury	I-P
,	O
(	O
2	O
)	O
investigate	O
the	O
influence	O
of	O
two	B-I
different	I-I
levels	I-I
of	I-I
compression	I-I
on	O
erythema	B-O
and	I-O
thickness	I-O
of	I-O
burn	I-O
scars	I-O
and	O
(	O
3	O
)	O
examine	O
the	O
association	O
between	O
erythema	B-O
and	I-O
thickness	I-O
.	I-O


The	O
study	O
was	O
a	O
prospective	O
trial	O
in	O
which	O
76	B-P
burn	I-P
scars	I-P
in	I-P
60	I-P
patients	I-P
were	I-P
objectively	O
assessed	B-I
with	I-I
the	I-I
Minolta	I-O
Chromameter	I-O
CR-300	I-O
for	I-I
erythema	I-I
and	I-I
with	I-I
the	I-I
Dermascan	I-O
C	I-O
for	I-O
thickness	I-O
of	I-O
the	I-O
scar	I-O
over	I-I
a	I-I
period	I-I
of	I-I
3	I-I
months	I-I
.	I-I


Each	O
patient	O
was	O
randomly	O
assigned	O
to	O
a	O
"	B-I
normal	I-I
"	I-I
or	I-I
"	I-I
lower	I-I
"	I-I
compression	I-I
class	I-I
treatment	I-I
,	I-I
with	I-I
respectively	I-I
mean	I-I
values	I-I
of	I-I
15	I-I
and	I-I
10	I-I
mmHg	I-I
pressure	I-I
after	I-I
wearing	I-I
the	I-I
garment	I-I
for	I-I
1	I-I
month	I-I
.	I-I


Measurements	B-I
for	I-I
both	I-I
parameters	I-I
were	I-I
taken	I-I
at	I-I
0	I-I
,	I-I
1	I-I
,	I-I
2	I-I
and	I-I
3	I-I
months	I-I
of	I-I
treatment	I-I
.	I-I


Pressure	O
garments	O
with	O
"	O
normal	O
"	O
compression	O
did	O
lose	O
significantly	O
more	O
compression	B-O
over	O
1	O
month	O
(	O
4.82	O
mmHg	O
)	O
than	O
did	O
the	O
garments	O
from	O
the	O
low	O
compression	O
class	O
(	O
2.57	O
mmHg	O
)	O
.	O


Scars	B-O
that	O
were	O
treated	O
with	O
garments	O
from	O
a	O
"	O
normal	O
"	O
compression	O
class	O
did	O
score	O
significantly	O
better	O
for	O
thickness	B-O
compared	O
to	O
the	O
"	O
low	O
"	O
compression	O
class	O
.	O


The	O
difference	O
in	O
thickness	B-O
was	O
most	O
evident	O
at	O
1	O
month	O
.	O


Thereafter	O
no	O
further	O
significant	O
improvement	O
between	O
the	O
two	O
different	O
treatments	O
over	O
time	O
could	O
be	O
obtained	O
.	O


This	O
difference	O
was	O
not	O
found	O
for	O
erythema	B-O
.	I-O


Positive	O
correlations	O
could	O
be	O
found	O
between	O
erythema	B-O
and	I-O
thickness	I-O
values	I-O
at	O
all	O
of	O
the	O
three	O
test	O
points	O
while	O
changes	O
in	O
erythema	B-O
and	I-O
thickness	I-O
only	O
correlated	O
significantly	O
after	O
the	O
first	O
month	O
.	O


The	O
pattern	O
of	O
change	O
of	O
both	O
parameters	O
correlated	O
at	O
a	O
high	O
level	O
of	O
significance	O
after	O
3	O
months	O
of	O
treatment	O
.	O


These	O
data	O
suggest	O
that	O
pressure	O
garments	O
that	O
deliver	O
a	O
pressure	O
of	O
at	O
least	O
15	O
mmHg	O
pressure	O
tend	O
to	O
accelerate	O
scar	B-O
maturation	I-O
and	O
that	O
measurements	O
of	O
the	O
pattern	O
of	O
change	O
of	O
the	O
erythema	O
can	O
be	O
used	O
to	O
predict	O
changes	O
in	O
scar	O
thickness	O
and	O
vice	O
versa	O
.	O


Effect	O
of	O
vitamin	B-I
K2	I-I
on	O
the	O
recurrence	B-O
in	O
patients	B-P
with	I-P
hepatocellular	I-P
carcinoma	I-P
.	I-P


BACKGROUND/AIMS	O
Vitamin	B-I
K2	I-I
(	I-I
VK2	I-I
)	I-I
appears	O
to	O
have	O
a	O
potent	O
inhibitory	O
activity	O
for	O
cell	O
growth	O
including	O
HCC	O
cells	O
.	O


We	O
investigated	O
whether	O
VK2	B-I
could	O
reduce	O
incidence	O
of	O
tumor	O
recurrence	O
after	O
treatment	O
of	O
HCC	O
.	O


Forty-five	B-P
patients	I-P
with	I-P
cured	I-P
or	I-P
possibly	I-P
cured	I-P
HCC	I-P
were	O
randomly	O
selected	O
,	O
assigning	O
patients	O
to	O
treatment	O
(	O
n=21	O
)	O
or	O
control	B-I
group	O
(	O
n=24	O
)	O
with	O
randomization	O
list	O
.	O


METHODOLOGY	O
For	O
the	O
treatment	O
group	O
,	O
forty-five	O
mg	O
of	O
Glakay	B-I
was	O
given	O
orally	O
every	O
day	O
after	O
therapy	O
for	O
HCC	O
.	O


No	O
patients	O
complained	O
of	O
adverse	B-O
effects	I-O
.	I-O


Abdominal	O
ultrasonography	O
and	O
dynamic	B-I
CT	I-I
were	O
performed	O
at	O
3-month	O
intervals	O
.	O


Recurrence	B-O
was	O
confirmed	O
by	O
abdominal	B-I
angiography	I-I
.	I-I


RESULTS	O
Recurrence	B-O
of	I-O
HCC	I-O
occurred	O
in	O
7	O
cases	O
(	O
33.3	O
%	O
)	O
for	O
the	O
treatment	O
group	O
and	O
12	O
cases	O
(	O
50.0	O
%	O
)	O
for	O
the	O
control	O
group	O
during	O
mean	O
observation	O
periods	O
of	O
19.5	O
and	O
16.5	O
months	O
,	O
respectively	O
.	O


Administration	O
of	O
VK2	O
was	O
not	O
an	O
independent	O
variable	O
for	O
the	O
recurrence	B-O
on	O
univariate	O
analysis	O
.	O


Cumulative	B-O
incidence	I-O
of	I-O
HCC	I-O
recurrence	I-O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
,	O
and	O
the	O
cumulative	B-O
survival	I-O
rate	I-O
tended	O
to	O
be	O
high	O
in	O
treatment	O
group	O
(	O
p	O
=0.054	O
)	O
.	O


Cox	O
regression	O
analysis	O
revealed	O
that	O
serum	B-O
albumin	I-O
concentration	I-O
alone	O
was	O
an	O
independent	O
factor	O
affecting	O
the	O
recurrence	O
.	O


CONCLUSIONS	O
These	O
findings	O
suggest	O
that	O
VK2	O
does	O
not	O
appear	O
to	O
prevent	O
recurrence	B-O
of	I-O
HCC	I-O
after	O
curative	O
treatment	O
.	O


Our	O
study	O
is	O
preliminary	O
and	O
large-scale	O
trials	O
are	O
needed	O
to	O
determine	O
whether	O
VK2	O
is	O
of	O
benefit	O
to	O
decrease	O
the	O
recurrence	B-O
of	I-O
HCC	I-O
.	I-O


Couple-responsible	B-I
therapy	I-I
process	I-I
:	I-I
positive	I-O
proximal	I-O
outcomes	I-O
.	I-O


Therapist-couple	O
struggle	O
vs.	O
cooperation	O
is	O
linked	O
to	O
clinical	O
outcome	O
.	O


This	O
research	O
conceptualizes	O
and	O
investigates	O
treatment	O
process	O
as	O
it	O
relates	O
to	O
the	O
occurrence	O
of	O
struggle	O
versus	O
cooperation	O
.	O


Models	O
of	O
couple-responsible	B-I
and	I-I
therapist-responsible	I-I
process	I-I
in	O
couple	B-I
therapy	I-I
were	O
developed	O
.	O


Couple-responsible	B-I
process	I-I
consists	I-I
of	I-I
enactments	I-I
,	I-I
accommodation	I-I
,	I-I
and	I-I
inductive	I-I
process	I-I
.	I-I


Therapist-responsible	B-I
process	I-I
consists	I-I
of	I-I
primary	I-I
therapist-couple	I-I
interaction	I-I
,	I-I
therapist	I-I
interpretation	I-I
,	I-I
and	I-I
direct	I-I
instruction	I-I
.	I-I


In	O
counterbalanced	O
order	O
,	O
25	B-P
couples	I-P
were	O
exposed	O
to	O
couple-responsible	B-I
and	I-I
therapist-responsible	I-I
episodes	I-I
during	O
one	O
therapy	O
session	O
.	O


Couples	O
reviewed	O
videotapes	O
of	O
the	O
episodes	O
and	O
completed	O
measures	O
of	O
responsibility	O
,	O
struggle	O
,	O
and	O
cooperation	O
.	O


Perceived	B-O
responsibility	I-O
was	O
higher	O
and	O
struggle	B-O
was	O
lower	O
during	O
couple-responsible	B-I
episodes	I-I
.	I-I


No	O
difference	O
in	O
cooperation	B-O
was	O
found	O
.	O


Presence	O
or	O
absence	O
of	O
a	O
contrast	O
condition	O
,	O
where	O
couples	O
reported	O
on	O
one	O
therapist	B-I
process	I-I
after	O
already	O
experiencing	O
its	O
opposite	O
,	O
led	O
to	O
main	O
effects	O
for	O
responsibility	O
and	O
struggle	O
,	O
and	O
mediated	O
effects	O
of	O
struggle	O
and	O
cooperation	O
.	O


Generally	O
speaking	O
,	O
responsibility	B-O
was	O
even	O
higher	O
during	O
couple-responsible	B-I
episodes	I-I
and	O
even	O
lower	O
during	O
therapist-responsible	B-I
episodes	I-I
when	O
contrast	O
was	O
present	O
.	O


Similarly	O
,	O
struggle	B-O
was	O
even	O
lower	O
during	O
couple-responsible	B-I
episodes	I-I
and	O
even	O
higher	O
during	O
therapist-responsible	B-I
episodes	I-I
when	O
contrast	O
was	O
present	O
.	O


For	O
both	O
couple-responsible	O
and	O
therapist-responsible	O
episodes	O
,	O
cooperation	B-O
was	O
negatively	O
affected	O
by	O
a	O
shift	O
from	O
the	O
prior	O
,	O
opposite	O
therapist	O
process	O
.	O


Significant	O
proportions	O
of	O
the	O
variance	O
in	O
responsibility	B-O
,	I-O
struggle	I-O
,	I-O
and	I-O
cooperation	I-O
,	O
however	O
,	O
were	O
not	O
accounted	O
for	O
by	O
therapist	O
process	O
alone	O
.	O


Retrograde	O
tracing	O
and	O
electrophysiological	O
findings	O
of	O
collateral	O
sprouting	O
after	B-P
end-to-side	I-P
neurorrhaphy	I-P
.	I-P


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
seek	O
more	O
potent	O
evidences	O
of	O
collateral	O
sprouting	O
for	O
both	O
motor	O
and	O
sensory	O
nerve	O
fibres	O
after	B-P
end-to-side	I-P
neurorrhaphy	I-P
using	O
a	O
modified	O
double-labelling	O
retrograde	O
tracing	O
method	O
and	O
to	O
investigate	O
the	O
function	O
of	O
regenerated	O
motor	O
axons	O
with	O
electrophysiological	O
evaluation	O
.	O


Four	B-P
groups	I-P
(	I-P
n=4	I-P
for	I-P
each	I-P
group	I-P
)	I-P
were	I-P
used	I-P
:	I-P
end-to-end	I-I
coaptation	I-I
(	I-P
six	I-P
months	I-P
postoperatively	I-P
)	I-P
,	I-P
end-to-side	I-I
coaptation	I-I
(	I-P
four	I-P
months	I-P
and	I-P
six	I-P
months	I-P
postoperatively	I-P
)	I-P
and	I-P
normal	I-I
control	I-I
.	I-I


Two	O
fluorescent	B-I
tracers	I-I
(	O
true	O
blue	O
and	O
diamidino	O
yellow	O
)	O
were	O
applied	O
to	O
the	O
proximal	O
ends	O
of	O
tibial	O
and	O
common	O
peroneal	O
nerves	O
,	O
respectively	O
after	O
four	O
or	O
six	O
months	O
of	O
nerve	O
coaptation	O
.	O


Five	O
days	O
later	O
,	O
we	O
only	O
found	O
single-labelled	B-O
motor	I-O
and	I-O
sensory	I-O
neurons	I-O
in	O
the	O
normal	O
and	O
end-to-end	O
coaptation	O
groups	O
,	O
while	O
some	O
dual-labelled	O
neurons	O
can	O
be	O
identified	O
in	O
end-to-side	O
coaptation	O
groups	O
.	O


Four	O
months	O
after	O
surgery	O
,	O
the	O
motor	B-O
nerve	I-O
conduction	I-O
velocity	I-O
in	I-O
end-to-side	I-O
coaptation	O
was	O
significantly	O
slower	O
than	O
in	O
the	O
normal	O
control	O
.	O


But	O
no	O
difference	O
was	O
found	O
in	O
the	O
sixth	O
month	O
.	O


These	O
results	O
suggest	O
that	O
end-to-side	B-I
neurorrhaphy	I-I
can	O
induce	O
the	O
functional	O
collateral	O
sprouting	O
of	O
both	O
motor	O
and	O
sensory	O
axons	O
in	O
the	O
peripheral	O
nerve	O
.	O


Gemcitabine	B-I
combined	I-I
with	I-I
either	I-I
pemetrexed	I-I
or	I-I
paclitaxel	I-I
in	I-I
the	O
treatment	O
of	O
advanced	B-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
:	I-P
a	O
randomized	O
phase	O
II	O
SICOG	O
trial	O
.	O


PURPOSE	O
To	O
estimate	O
the	O
safety	B-O
,	I-O
activity	I-O
,	I-O
and	I-O
impact	I-O
on	I-O
quality	I-O
of	I-O
life	I-O
of	O
a	O
combination	B-I
of	I-I
gemcitabine	I-I
and	I-I
pemetrexed	I-I
in	O
patients	B-P
with	I-P
locally	I-P
advanced	I-P
or	I-P
metastatic	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
in	O
the	O
context	O
of	O
a	O
randomized	O
two-stage	O
phase	O
II	O
study	O
.	O


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
in	I-P
stage	I-P
IIIB	I-P
or	I-P
IV	I-P
NSCLC	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
either	B-I
gemcitabine	I-I
1250	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
,	O
and	B-I
pemetrexed	I-I
(	O
Alimta	O
)	O
500	O
mg/m	O
(	O
2	O
)	O
followed	B-I
by	I-I
gemcitabine	I-I
1250	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
8	O
of	O
a	O
3-weekly	O
cycle	O
(	B-I
GA	I-I
arm	O
)	O
,	O
or	O
paclitaxel	B-I
120	O
mg/m	O
(	O
2	O
)	O
followed	B-I
by	I-I
gemcitabine	I-I
1000	O
mg/m	O
(	O
2	O
)	O
,	O
both	O
given	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
3-weekly	O
cycle	O
(	B-I
PG	I-I
arm	O
)	O
.	O


RESULTS	O
105	B-P
(	I-P
GA	I-P
arm	I-P
,	I-P
51	I-P
;	I-P
PG	I-P
arm	I-P
,	I-P
54	I-P
)	I-P
eligible	I-P
patients	I-P
(	I-P
stage	I-P
IV	I-P
,	I-P
32	I-P
and	I-P
30	I-P
,	I-P
respectively	I-P
)	I-P
were	O
enrolled	O
into	O
this	O
study	O
;	O
thereafter	O
,	O
accrual	O
was	O
stopped	O
due	O
to	O
first-stage	O
analysis	O
.	O


The	O
response	B-O
rate	I-O
was	O
20	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
10-33	O
%	O
)	O
in	O
the	O
GA	O
arm	O
,	O
and	O
32	O
%	O
(	O
95	O
%	O
CI	O
,	O
20-46	O
%	O
)	O
in	O
the	O
PG	O
arm	O
.	O


Median	B-O
progression-free	I-O
survival	I-O
was	O
5.1	O
(	O
95	O
%	O
CI	O
,	O
3.7-6.5	O
)	O
months	O
in	O
the	O
GA	O
arm	O
,	O
and	O
8.3	O
(	O
95	O
%	O
CI	O
,	O
5.9-10.7	O
)	O
months	O
in	O
the	O
PG	O
arm	O
,	O
while	O
median	B-O
overall	I-O
survival	I-O
was	O
10.5	O
(	O
95	O
%	O
CI	O
7.1-13.9	O
)	O
,	O
and	O
13.3	O
(	O
95	O
%	O
CI	O
11.7-14.9	O
)	O
months	O
,	O
respectively	O
.	O


Severe	B-O
neutropenia	I-O
(	O
36	O
%	O
vs	O
22	O
%	O
)	O
,	O
and	O
febrile	B-O
neutropenia	I-O
(	O
14	O
%	O
vs	O
7	O
%	O
)	O
were	O
more	O
common	O
with	O
the	O
GA	O
regimen	O
,	O
while	O
hair	B-O
loss	I-O
(	O
52	O
%	O
vs	O
16	O
%	O
)	O
and	O
any	B-O
grade	I-O
peripheral	I-O
neuropathy	I-O
(	O
31	O
%	O
vs	O
2	O
%	O
)	O
occurred	O
more	O
frequently	O
with	O
PG	B-I
regimen	I-I
.	I-I


Other	O
severe	B-O
side	I-O
effects	I-O
of	O
GA	B-I
regimen	I-I
were	O
diarrhoea	B-O
(	O
10	O
%	O
)	O
,	O
liver	B-O
enzyme	I-O
derangement	I-O
(	O
10	O
%	O
)	O
,	O
and	O
fatigue	B-O
(	O
8	O
%	O
)	O
.	O


CONCLUSION	O
The	O
GA	O
regimen	O
was	O
tolerated	B-O
and	I-O
moderately	I-O
active	I-O
in	O
advanced	O
or	O
metastatic	O
NSCLC	O
.	O


However	O
,	O
this	O
combination	O
did	O
not	O
yield	O
any	O
advantage	O
in	O
comparison	O
with	O
the	O
PG	O
regimen	O
,	O
and	O
does	O
not	O
deserve	O
further	O
evaluation	O
.	O


Deslorelin	B-I
implants	I-I
in	O
pre-pubertal	B-P
female	I-P
dogs	I-P
:	I-P
short-	I-O
and	I-O
long-term	I-O
effects	I-O
on	I-O
the	I-O
genital	I-O
tract	I-O
.	I-O


Deslorelin	B-I
acetate	I-I
is	O
a	O
GnRH	O
agonist	O
used	O
for	O
contraception	O
in	O
dogs	O
.	O


This	O
study	O
aimed	O
to	O
evaluate	O
the	O
treatment	O
of	O
pre-pubertal	B-P
female	I-P
dogs	I-P
with	I-P
deslorelin	I-I
acetate	I-I
implants	I-I
,	O
to	O
better	O
investigate	O
the	O
primary	B-O
stimulatory	I-O
effect	I-O
of	O
the	O
drug	O
and	O
the	O
long-term	B-O
effects	I-O
on	O
the	O
genital	O
tract	O
,	O
throughout	O
repeated	O
treatments	O
.	O


Sicilian	B-P
hound	I-P
female	I-P
dogs	I-P
(	I-P
24	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
treated	O
group	O
,	O
control	O
group	O
1	O
and	O
control	O
group	O
2	O
.	O


First	O
group	O
bitches	O
were	O
implanted	O
at	O
4.5	O
,	O
9.0	O
and	O
13.5	O
months	O
and	O
monitored	O
clinically	O
,	O
ultrasonographically	O
and	O
endocrinologically	O
,	O
throughout	O
the	O
study	O
period	O
(	O
13.5	O
months	O
)	O
.	O


Control	O
group	O
1	O
bitches	O
were	O
not	B-I
implanted	I-I
and	O
clinically	O
monitored	O
for	O
the	O
same	O
period	O
.	O


At	O
18	O
months	O
,	O
the	O
animals	O
underwent	O
ovariohysterectomy	B-I
,	O
thus	O
allowing	O
evaluation	B-O
of	I-O
the	I-O
internal	I-O
genitalia	I-O
.	I-O


Control	O
group	O
2	O
bitches	O
were	O
ovariohysterectomized	O
at	O
the	O
age	O
of	O
4.5	O
months	O
.	O


The	O
suppression	B-O
of	I-O
oestrus	I-O
was	O
obtained	O
in	O
the	O
treated	O
group	O
despite	O
the	O
fact	O
that	O
the	O
first	O
implant	O
caused	O
a	O
modest	O
increase	O
in	O
plasmatic	B-O
levels	I-O
of	I-O
17-beta	I-O
estradiol	I-O
and	O
an	O
evident	O
cornification	B-O
of	I-O
the	I-O
vaginal	I-O
mucosa	I-O
cells	I-O
(	O
50-80	O
%	O
)	O
.	O


Estradiol	B-O
and	I-O
progesterone	I-O
were	O
at	O
baseline	O
levels	O
for	O
the	O
remaining	O
study	O
period	O
,	O
in	O
which	O
no	B-O
other	I-O
oestrous	I-O
manifestations	I-O
were	I-O
observed	I-O
.	I-O


The	O
external	B-O
genitalia	I-O
maintained	I-O
a	I-O
juvenile	I-O
appearance	I-O
.	I-O


The	O
ovaries	B-O
,	I-O
ultrasonographically	I-O
,	I-O
showed	I-O
no	I-O
follicular	I-O
structures	I-O
and	O
stayed	B-O
the	I-O
same	I-O
size	I-O
.	I-O


At	O
18	O
months	O
,	O
the	O
genital	B-O
tract	I-O
was	I-O
still	I-O
juvenile	I-O
with	I-O
inactive	I-O
small	I-O
ovaries	I-O
and	I-O
a	I-O
thin	I-O
filiform	I-O
uterus	I-O
.	I-O


Deslorelin	O
suppressed	B-O
ovarian	I-O
activity	I-O
in	O
pre-pubertal	O
bitches	O
,	O
and	O
oestrous	B-O
induction	I-O
was	I-O
not	I-O
observed	I-O
despite	O
the	O
presence	O
of	O
the	O
primary	O
stimulatory	O
effect	O
of	O
the	O
drug	O
.	O


Juvenile	B-O
genitalia	I-O
were	O
an	O
expected	O
side	O
effect	O
of	O
the	O
treatment	O
.	O


Chlorthalidone	B-I
does	O
not	O
increase	O
the	O
hypotensive	B-O
effect	I-O
of	O
nifedipine	B-I
in	O
essential	O
hypertensives	O
:	O
a	O
crossover	B-P
multicentre	I-P
study	I-P
.	I-P


To	O
determine	O
whether	O
the	O
combination	O
of	O
nifedipine	B-I
+	I-I
chlorthalidone	I-I
exerts	O
an	O
additive	B-O
antihypertensive	I-O
effect	I-O
when	O
compared	O
with	O
single-drug	O
treatment	O
,	O
we	O
studied	O
66	B-P
uncomplicated	I-P
essential	I-P
hypertensives	I-P
,	I-P
with	I-P
diastolic	I-P
blood	I-P
pressure	I-P
of	I-P
greater	I-P
than	I-P
100	I-P
and	I-P
less	I-P
than	I-P
115	I-P
mmHg	I-P
.	I-P


At	O
the	O
end	O
of	O
a	O
1-month	O
washout	O
placebo	B-I
period	O
,	O
using	O
a	O
double-blind	O
crossover	O
design	O
,	O
the	O
patients	O
were	O
randomly	O
allocated	O
to	O
nifedipine	B-I
(	O
20	O
mg	O
twice	O
a	O
day	O
)	O
,	O
chlorthalidone	B-I
(	O
25	O
mg	O
once	O
a	O
day	O
)	O
,	O
the	O
two	O
drugs	O
combined	O
at	O
the	O
same	O
doses	O
and	O
the	O
corresponding	O
placebo	B-I
.	I-I


Compared	O
with	O
the	O
randomly	O
allocated	O
placebo	O
,	O
the	O
three	O
active	O
treatments	O
significantly	O
reduced	O
blood	B-O
pressure	I-O
without	O
changing	O
the	O
heart	B-O
rate	I-O
or	I-O
body	I-O
weight	I-O
.	I-O


Both	O
the	O
absolute	B-O
and	O
percentage	B-O
decreases	I-O
in	O
mean	B-O
blood	I-O
pressure	I-O
induced	O
by	O
nifedipine	B-I
and	O
the	O
combination	O
compared	O
with	O
placebo	B-I
were	O
similar	O
and	O
significantly	O
greater	O
than	O
those	O
induced	O
by	O
chlorthalidone	B-I
.	I-I


Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
combination	O
of	O
nifedipine	B-I
+	I-I
chlorthalidone	I-I
does	O
not	O
exert	O
any	O
additive	B-O
antihypertensive	I-O
effect	I-O
compared	O
with	O
nifedipine	B-I
alone	O
.	O


This	O
finding	O
indicates	O
that	O
the	O
combination	O
of	O
a	O
dihydropyridine	B-I
calcium	I-I
antagonist	I-I
+	I-I
a	I-I
thiazide	I-I
diuretic	I-I
is	O
probably	O
devoid	O
of	O
any	O
particular	O
clinical	B-O
significance	I-O
in	O
the	O
treatment	O
of	O
uncomplicated	B-P
essential	I-P
hypertensives	I-P
.	I-P


Effect	O
of	O
augmented	B-I
sensorimotor	I-I
input	I-I
on	O
learning	B-O
verbal	I-O
and	I-O
nonverbal	I-O
tasks	I-O
among	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


Thirty-four	B-P
children	I-P
,	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	I-P
ages	I-P
4-14	I-P
years	I-P
,	O
were	O
matched	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
conditions	O
for	O
learning	B-O
a	I-O
novel	I-O
juice-making	I-O
task	I-O
and	O
producing	B-O
two	I-O
novel	I-O
words	I-O
about	I-O
the	I-O
event	I-O
.	I-O


Seventeen	O
sighted	O
children	O
were	O
manually	B-I
guided	I-I
to	O
perform	O
the	O
task	O
and	O
tactually	O
prompted	O
during	O
imitated	O
productions	O
of	O
novel	O
words	O
for	O
the	O
event	O
.	O


Their	O
matched	O
controls	O
heard	O
the	O
novel	B-O
words	I-O
and	O
watched	O
the	O
juice-making	B-O
task	I-O
being	O
performed	O
.	O


Performances	O
on	O
four	B-O
verbal	I-O
and	I-O
two	I-O
nonverbal	I-O
measures	I-O
right	O
after	O
instruction	O
and	O
at	O
24-48	O
h	O
post-instruction	O
,	O
revealed	O
higher	O
scores	O
for	O
the	O
‘	O
‘	O
hands-on	O
’	O
’	O
,	O
participation	O
than	O
observation	O
group	O
on	O
both	O
verbal	O
and	O
nonverbal	O
tasks	O
.	O


This	O
study	O
offers	O
a	O
paradigm	O
for	O
exploring	O
the	O
instructional	O
advantage	B-O
of	O
enhanced	B-O
participatory	I-O
experience	I-O
.	O


Efficacy	O
and	O
safety	O
of	O
diclofenac	B-I
diethylamine	I-I
1.16	O
%	O
gel	O
in	O
acute	B-P
neck	I-P
pain	I-P
:	I-P
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O


BACKGROUND	O
Neck	O
pain	O
(	O
NP	O
)	O
is	O
a	O
common	O
musculoskeletal	O
disorder	O
in	O
primary	O
care	O
that	O
frequently	O
causes	O
discomfort	O
.	O


Non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
may	O
be	O
used	O
to	O
reduce	O
neck	O
pain	O
and	O
associated	O
inflammation	O
and	O
facilitate	O
earlier	O
recovery	O
.	O


Topical	B-I
diclofenac	I-I
diethylamine	I-I
(	I-I
DDEA	I-I
)	I-I
1.16	I-I
%	I-I
gel	I-I
is	O
clinically	O
proven	O
to	O
be	O
effective	O
and	O
well	O
tolerated	O
in	O
acute	O
and	O
chronic	O
musculoskeletal	O
conditions	O
,	O
but	O
until	O
now	O
no	O
clinical	O
data	O
existed	O
for	O
its	O
use	O
in	O
acute	O
NP	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
DDEA	O
1.16	O
%	O
gel	O
compared	O
with	O
placebo	B-I
gel	I-I
in	O
acute	O
NP	O
.	O


METHODS	O
In	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
,	O
patients	B-P
with	I-P
acute	I-P
NP	I-P
(	I-P
n	I-P
=	I-P
72	I-P
)	I-P
were	O
treated	O
with	O
DDEA	O
1.16	O
%	O
gel	O
(	O
2	O
g	O
,	O
4x/day	O
,	O
for	O
5	O
days	O
)	O
or	O
placebo	O
.	O


Efficacy	O
assessments	O
included	B-O
pain-on-movement	I-O
(	I-O
POM	I-O
)	I-O
,	I-O
pain-at-rest	I-O
(	I-O
PAR	I-O
)	I-O
,	I-O
functional	I-O
neck	I-O
disability	I-O
index	I-O
(	I-O
NDI	I-O
)	I-O
and	I-O
response	I-O
to	I-O
treatment	I-O
(	O
decrease	O
in	O
POM	O
by	O
50	O
%	O
after	O
48	O
h	O
)	O
.	O


Adverse	O
events	O
(	O
AEs	O
)	O
were	O
recorded	O
throughout	O
the	O
study	O
.	O


RESULTS	O
The	O
primary	O
outcome	B-O
,	I-O
POM	I-O
at	I-O
48	O
h	O
,	O
was	O
statistically	O
significantly	O
lower	O
with	O
DDEA	O
gel	O
(	O
19.5	O
mm	O
)	O
vs.	O
placebo	O
(	O
56.9	O
mm	O
)	O
(	O
p	O
<	O
0.0001	O
)	O
,	O
representing	O
a	O
clinically	O
relevant	O
decrease	O
from	O
baseline	O
(	O
75	O
%	O
vs.	O
23	O
%	O
,	O
respectively	B-O
)	I-O
.	I-O


All	B-O
POM	O
scores	O
were	O
significantly	B-I
lower	I-I
with	O
DDEA	O
gel	O
vs.	O
placebo	O
from	O
1	O
h	O
,	O
as	O
were	O
PAR	O
and	O
NDI	O
scores	O
from	O
first	O
assessment	O
(	O
24	O
h	O
)	O
onwards	O
(	B-O
all	I-O
p	I-O
<	I-O
0.0001	I-O
)	I-O
.	I-O


Response	B-O
to	O
treatment	O
was	O
significantly	B-I
higher	O
with	O
DDEA	O
gel	O
(	O
94.4	O
%	O
)	O
vs.	O
placebo	O
(	O
8.3	O
%	O
)	O
(	B-O
p	I-O
<	I-O
0.0001	I-O
)	I-O
.	O


There	O
were	O
no	O
AEs	O
with	O
DDEA	O
gel	O
.	O


CONCLUSIONS	O
DDEA	O
1.16	O
%	O
gel	O
,	O
which	O
is	O
available	B-O
over-the-counter	I-O
,	I-O
was	I-O
effective	I-O
and	O
well	O
tolerated	B-P
in	I-P
the	I-P
treatment	I-P
of	O
acute	O
neck	O
pain	O
.	O


The	O
tools	O
used	O
to	O
assess	O
efficacy	O
suggest	O
that	B-O
it	I-O
quickly	I-O
reduced	I-O
neck	I-O
pain	I-O
and	I-O
improved	O
neck	O
function	O
.	O


However	O
,	O
questions	O
remain	O
regarding	O
the	O
comparability	O
and	O
validity	O
of	O
such	O
tools	O
.	O


Further	O
studies	O
will	O
help	O
ascertain	O
whether	O
DDEA	O
1.16	O
%	O
gel	O
offers	O
an	O
alternative	O
treatment	O
option	O
in	O
this	O
common	O
,	O
often	O
debilitating	O
condition	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT01335724	O
.	O


Advice	O
or	O
exercise	O
for	O
chronic	B-P
whiplash	I-P
disorders	I-P
?	O
Design	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
Whiplash-associated	B-P
disorder	I-P
(	O
or	O
"	O
whiplash	O
"	O
)	O
is	O
a	O
common	O
condition	O
incurring	O
considerable	O
expense	O
in	O
social	O
and	O
economic	O
terms	O
.	O


A	O
lack	O
of	O
research	O
on	O
effective	O
therapy	O
for	O
patients	B-P
with	I-P
chronic	I-P
whiplash	I-P
associated	I-P
disorders	I-P
prompted	O
the	O
design	O
of	O
the	O
current	O
study	O
.	O


The	O
primary	O
aim	O
of	O
this	O
randomised	O
controlled	O
trial	O
is	O
to	O
determine	O
the	O
effects	B-O
of	I-O
a	I-O
physical	I-O
activity	I-O
program	I-O
for	I-O
people	I-O
with	I-O
chronic	I-O
(	I-O
symptoms	I-O
of	I-O
>	I-O
3	I-O
months	I-O
duration	I-O
)	I-O
whiplash	I-O
.	I-O


A	O
secondary	O
aim	O
is	O
to	O
determine	O
if	O
pain	B-O
severity	I-O
,	I-O
level	I-O
of	I-O
disability	I-O
and	I-O
fear	I-O
of	I-O
movement/	I-O
(	I-O
re	I-O
)	I-O
injury	I-O
predict	O
response	B-O
to	O
a	O
physical	O
activity	O
program	O
.	O


METHODS/DESIGN	O
This	O
paper	O
presents	O
the	O
rationale	O
and	O
design	O
of	O
a	O
randomised	O
controlled	O
trial	O
examining	O
the	O
effects	B-O
of	I-O
advice	I-O
and	I-O
individualized	I-O
sub-maximal	I-O
exercise	I-O
programs	I-O
in	O
the	O
treatment	O
of	O
whiplash	B-P
associated	I-P
disorders	I-P
.	I-P


DISCUSSION	O
This	O
paper	O
highlights	O
the	O
design	O
,	O
methods	O
and	O
operational	O
aspects	O
of	O
a	O
significant	O
clinical	O
trial	O
in	O
the	O
area	O
of	O
whiplash	B-P
and	I-P
chronic	I-P
pain	I-P
.	I-P


[	O
Supplementary	O
treatment	O
with	O
Esberitox	B-I
of	O
female	B-P
patients	I-P
undergoing	I-P
curative	I-I
adjuvant	I-I
irradiation	I-I
following	I-P
breast	I-P
cancer	I-P
]	I-P
.	O


1	O
.	O


The	O
study	O
was	O
supposed	O
to	O
investigate	O
a	O
possible	O
prevention	B-O
or	I-O
reduction	I-O
of	I-O
the	I-O
toxicity	I-O
of	O
radiotherapy	B-I
by	O
an	O
additional	O
treatment	O
with	O
Esberitox	B-I
.	I-I


This	O
question	O
arose	O
when	O
performing	O
an	O
investigation	O
about	O
the	O
effect	O
of	O
Esberitox	B-I
in	O
a	O
combined	O
chemo-radiotherapy	O
.	O


Whereas	O
the	O
latter	O
induces	O
above	O
all	O
a	O
systemic	O
damage	O
to	O
the	O
hemopoietic	O
system	O
,	O
radiotherapy	O
is	O
a	O
regional	O
noxa	O
.	O


2	O
.	O


The	O
present	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
with	O
50	B-P
patients	I-P
submitted	I-P
to	I-P
curative	I-I
adjuvant	I-I
irradiation	I-I
following	I-P
surgery	I-P
for	I-P
mammary	I-P
carcinoma	I-P
.	I-P


The	O
radiotherapy	B-I
was	O
performed	O
in	O
the	O
same	O
way	O
in	O
all	O
patients	B-P
with	I-P
irradiations	I-P
of	I-P
the	I-P
thoracic	I-P
wall	I-P
and	I-P
the	I-P
regional	I-P
lymph	I-P
nodes	I-P
.	I-P


Two	O
groups	O
were	O
built	O
by	O
randomization	O
.	O


The	O
study	O
group	O
received	O
an	O
additional	O
treatment	O
with	O
Esberitox	B-I
,	O
the	O
control	B-I
group	I-I
did	I-I
not	I-I
receive	I-I
an	I-I
additional	I-I
treatment	I-I
.	I-I


3	O
.	O


As	O
a	O
result	O
,	O
no	O
protective	O
influence	O
of	O
Esberitox	O
could	O
be	O
demonstrated	O
.	O


The	O
parameters	O
investigated	O
were	O
the	O
peripheral	B-O
blood	I-O
count	I-O
(	I-O
leucocytes	I-O
,	I-O
granulocytes	I-O
,	I-O
lymphocytes	I-O
,	I-O
monocytes	I-O
,	I-O
thrombocytes	I-O
,	I-O
hemoglobin	I-O
,	I-O
hematocrit	I-O
)	I-O
and	I-O
the	I-O
incidence	I-O
of	I-O
infections	I-O
.	I-O


4	O
.	O


This	O
result	O
diverging	O
from	O
literature	O
is	O
discussed	O
.	O


It	O
is	O
probably	O
affected	O
by	O
volume	O
and	O
extension	O
of	O
the	O
injury	O
induced	O
by	O
a	O
hematotoxic	O
noxa	O
and	O
furthermore	O
by	O
the	O
ability	O
of	O
regeneration	O
.	O


If	O
this	O
ability	O
is	O
exhausted	O
,	O
the	O
protective	O
effect	O
of	O
Esberitox	O
can	O
act	O
no	O
longer	O
.	O


Therefore	O
the	O
essential	O
factor	O
seems	O
to	O
be	O
the	O
duration	O
of	O
exposure	O
to	O
the	O
noxa	O
.	O


Esberitox	O
was	O
effective	O
in	O
case	O
of	O
a	O
short	O
toxicity	O
,	O
it	O
was	O
ineffective	O
in	O
case	O
of	O
prolonged	O
toxicity	O
,	O
if	O
the	O
treatment	O
continuity	O
(	O
noxa	O
)	O
was	O
not	O
broken	O
up	O
by	O
some	O
regeneration	O
intervals	O
.	O


The	O
radiotherapy	B-I
studied	O
in	O
this	O
trial	O
had	O
a	O
duration	O
of	O
50	O
days	O
,	O
and	O
its	O
effect	O
was	O
that	O
of	O
a	O
longterm	O
injury	O
.	O


Caffeine	B-I
eliminates	O
psychomotor	B-O
vigilance	I-O
deficits	I-O
from	O
sleep	O
inertia	O
.	O


STUDY	O
OBJECTIVES	O
This	O
study	O
sought	O
to	O
establish	O
the	O
effects	O
of	O
caffeine	B-I
on	O
sleep	B-O
inertia	I-O
,	O
which	O
is	O
the	O
ubiquitous	O
phenomenon	O
of	O
cognitive	O
performance	O
impairment	O
,	O
grogginess	O
and	O
tendency	O
to	O
return	O
to	O
sleep	O
immediately	O
after	O
awakening	O
.	O


DESIGN	O
28	B-P
normal	I-P
adult	I-P
volunteers	I-P
were	O
administered	O
sustained	O
low-dose	B-I
caffeine	I-I
or	I-I
placebo	I-I
(	O
randomized	O
double-blind	O
)	O
during	O
the	O
last	O
66	O
hours	O
of	O
an	O
88-hour	O
period	O
of	O
extended	O
wakefulness	O
that	O
included	O
seven	O
2-hour	O
naps	O
during	O
which	O
polysomnographical	O
recordings	O
were	O
made	O
.	O


Every	O
2	O
hours	O
of	O
wakefulness	O
,	O
and	O
immediately	O
after	O
abrupt	O
awakening	O
from	O
the	O
naps	O
,	O
psychomotor	B-O
vigilance	I-O
performance	I-O
was	O
tested	O
.	O


SETTING	O
N/A	O
.	O


PARTICIPANTS	O
N/A	O
.	O


INTERVENTIONS	O
N/A	O
.	O


MEASUREMENTS	O
AND	O
RESULTS	O
In	O
the	O
placebo	B-I
condition	O
,	O
sleep	B-O
inertia	I-O
was	O
manifested	O
as	O
significantly	O
impaired	O
psychomotor	B-O
vigilance	I-O
upon	O
awakening	O
from	O
the	O
naps	O
.	O


This	O
impairment	O
was	O
absent	O
in	O
the	O
caffeine	O
condition	O
.	O


Caffeine	O
had	O
only	O
modest	O
effects	O
on	O
nap	B-O
sleep	I-O
.	I-O


CONCLUSIONS	O
Caffeine	B-I
was	O
efficacious	O
in	O
overcoming	O
sleep	B-O
inertia	I-O
.	I-O


This	O
suggests	O
a	O
reason	O
for	O
the	O
popularity	O
of	O
caffeine-containing	O
beverages	O
after	O
awakening	O
.	O


Caffeine	O
's	O
main	O
mechanism	O
of	O
action	O
on	O
the	O
central	O
nervous	O
system	O
is	O
antagonism	O
of	O
adenosine	O
receptors	O
.	O


Thus	O
,	O
increased	O
adenosine	O
in	O
the	O
brain	O
upon	O
awakening	O
may	O
be	O
the	O
cause	O
of	O
sleep	B-O
inertia	I-O
.	I-O


A	O
placebo	O
controlled	O
crossover	O
trial	O
of	O
liquid	B-I
fluoxetine	I-I
on	O
repetitive	B-O
behaviors	I-O
in	I-P
childhood	I-P
and	I-P
adolescent	I-P
autism	I-P
.	I-P


Repetitive	B-O
behaviors	I-O
are	O
a	O
core	O
symptom	O
domain	O
in	O
autism	O
that	O
has	O
been	O
linked	O
to	O
alterations	O
in	O
the	O
serotonin	O
system	O
.	O


While	O
the	O
selective	O
serotonin-receptive	B-I
inhibitor	I-I
fluvoxamine	I-I
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
adults	O
with	O
autism	O
,	O
as	O
yet	O
no	O
published	O
placebo	B-I
controlled	O
trials	O
with	O
these	O
agents	O
document	O
safety	B-O
and	O
efficacy	B-O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


This	O
study	O
examines	O
the	O
selective	O
serotonin	B-I
reuptake	I-I
inhibitor	I-I
liquid	I-I
fluoxetine	I-I
in	O
the	O
treatment	O
of	O
repetitive	B-O
behaviors	I-O
in	I-P
childhood	I-P
and	I-P
adolescent	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASDs	I-P
)	I-P
.	I-P


In	O
total	O
,	O
45	B-P
child	I-P
or	I-P
adolescent	I-P
patients	I-P
with	I-P
ASD	I-P
were	I-P
randomized	I-P
into	I-P
two	I-P
acute	I-P
8-week	I-P
phases	I-P
in	I-P
a	I-P
double-blind	I-P
placebo-controlled	I-P
crossover	I-P
study	I-P
of	I-P
liquid	I-I
fluoxetine	I-I
.	I-I


Study	O
design	O
included	O
two	O
randomized	O
8-week	O
fluoxetine	B-I
and	O
placebo	B-I
phases	O
separated	O
by	O
a	O
4-week	O
washout	O
phase	O
.	O


Outcome	O
measures	O
included	O
measures	B-O
of	I-O
repetitive	I-O
behaviors	I-O
and	I-O
global	I-O
improvement	I-O
.	I-O


Low-dose	O
liquid	B-I
fluoxetine	I-I
(	O
mean	O
final	O
dose	O
:	O
9.9+/-4.35	O
mg/day	O
)	O
was	O
superior	O
to	O
placebo	B-I
in	O
the	O
treatment	O
of	O
repetitive	B-O
behaviors	I-O
by	O
CY-BOCS	B-O
compulsion	I-O
scale	I-O
.	I-O


The	O
effect	B-O
size	I-O
was	O
in	O
the	O
moderate	O
to	O
large	O
range	O
,	O
and	O
the	O
doses	O
used	O
were	O
low	O
.	O


Liquid	B-I
fluoxetine	I-I
was	O
only	O
slightly	O
,	O
and	O
not	O
significantly	O
,	O
superior	O
to	O
placebo	O
on	O
CGI	B-O
autism	I-O
score	I-O
partially	O
due	O
to	O
a	O
phase	B-O
order	I-O
effect	I-O
.	I-O


However	O
,	O
fluoxetine	B-I
was	O
marginally	O
superior	O
to	O
placebo	B-I
on	O
a	O
composite	B-O
measure	I-O
of	I-O
global	I-O
effectiveness	I-O
.	I-O


Liquid	O
fluoxetine	O
did	O
not	O
significantly	O
differ	O
from	O
placebo	B-I
on	O
treatment	B-O
emergent	I-O
side	I-O
effects	I-O
.	I-O


Liquid	B-I
fluoxetine	I-I
in	O
low	O
doses	O
is	O
more	O
effective	O
than	O
placebo	B-I
in	O
the	O
treatment	O
of	O
repetitive	B-O
behaviors	I-O
in	O
childhood	O
autism	O
.	O


Limitations	O
include	O
small	O
sample	O
size	O
and	O
the	O
crossover	O
design	O
of	O
the	O
study	O
.	O


Further	O
replication	O
and	O
long-term	O
maintenance	O
trials	O
are	O
needed	O
.	O


Helicobacter	O
pylori	O
and	O
gastric	O
cancer	O
:	O
current	O
status	O
of	O
the	O
Austrain	B-P
Czech	I-P
German	I-P
gastric	I-P
cancer	I-P
prevention	O
trial	O
(	O
PRISMA	O
Study	O
)	O
.	O


AIM	O
To	O
test	O
the	O
hypothesis	O
that	O
Helicobacter	O
pylori	O
eradication	O
alone	O
can	O
reduce	O
the	O
incidence	O
of	O
gastric	B-O
cancer	I-O
in	O
a	O
subgroup	B-P
of	I-P
individuals	I-P
with	I-P
an	I-P
increased	I-P
risk	I-P
for	I-P
this	I-P
fatal	I-P
disease	I-P
.	I-P


METHODS	O
It	O
is	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	B-I
controlled	O
multinational	O
multicenter	O
trial	O
.	O


Men	B-P
between	I-P
55	I-P
and	I-P
65	I-P
years	I-P
of	I-P
age	I-P
with	I-P
a	I-P
gastric	I-P
cancer	I-P
phenotype	I-P
of	I-P
Helicobacter	I-P
pylori	I-P
gastritis	I-P
are	I-P
randomized	I-P
to	O
receive	O
a	O
7	O
day	O
course	O
of	O
omeprazole	B-I
2	I-I
X	I-I
20mg	I-I
,	I-I
clarithromycin	I-I
2	I-I
X	I-I
500mg	I-I
,	I-I
and	I-I
amoxicillin	I-I
2	I-I
X	I-I
1g	I-I
for	I-I
7	I-I
days	I-I
,	I-I
or	I-I
omeprazole	I-I
2	I-I
X	I-I
20mg	I-I
plus	I-I
placebo	I-I
.	I-I


Follow-up	O
endoscopy	O
is	O
scheduled	O
3	O
months	O
after	O
therapy	O
,	O
and	O
thereafter	O
in	O
one-year	O
intervals	O
.	O


Predefined	O
study	O
endpoints	O
are	O
gastric	B-O
cancer	I-O
,	I-O
precancerous	I-O
lesions	I-O
(	I-O
dysplasia	I-O
,	I-O
adenoma	I-O
)	I-O
,	I-O
other	I-O
cancers	I-O
,	I-O
and	I-O
death	I-O
.	I-O


RESULTS	O
Since	B-P
March	I-P
1998	I-P
,	I-P
1524	I-P
target	I-P
patients	I-P
have	I-P
been	I-P
screened	I-P
,	I-P
279	I-P
patients	I-P
(	I-P
18.3	I-P
%	I-P
)	I-P
had	I-P
a	I-P
corpus	I-P
dominant	I-P
type	I-P
of	I-P
H.	I-P
pylori	I-P
gastritis	I-P
,	I-P
and	I-P
167	I-P
of	I-P
those	I-P
were	I-P
randomized	I-P
(	O
58.8	O
%	O
)	O
.	O


In	O
the	O
active	O
treatment	O
group	O
(	O
r	O
=	O
86	O
)	O
,	O
H.	O
pylori	O
infection	O
infection	O
was	O
cured	B-O
in	O
88.9	O
%	O
of	O
patients	O
.	O


Currently	O
,	O
the	O
cumulative	O
follow-up	O
time	O
is	O
3046	O
months	O
(	O
253.38	O
patient	O
years	O
,	O
median	O
follow	O
up	O
16	O
months	O
)	O
.	O


So	O
far	O
,	O
none	O
of	O
the	O
patients	O
developed	O
gastric	B-O
cancer	I-O
or	I-O
any	I-O
precancerous	I-O
lesion	I-O
.	I-O


Three	O
(	O
1.8	O
%	O
)	O
patients	O
reached	O
study	B-O
endpoints	I-O
other	I-O
than	I-O
gastric	I-O
cancer	I-O
.	I-O


CONCLUSION	O
Among	O
men	O
between	O
55	O
and	O
65	O
years	O
of	O
age	O
,	O
the	O
gastric	O
cancer	O
phenotype	O
of	O
H.	O
pylori	O
gastritis	O
appears	O
to	O
be	O
more	O
common	O
than	O
expected	O
.	O


Further	O
follow	O
up	O
and	O
continuing	O
recruitment	O
are	O
necessary	O
to	O
fulfil	O
the	O
main	O
aim	O
of	O
the	O
study	O
.	O


The	O
influence	O
of	O
preoperative	O
antibiotics	B-I
on	O
success	B-O
of	O
endosseous	B-I
implants	I-I
up	I-P
to	I-P
and	I-P
including	I-P
stage	I-P
II	I-P
surgery	I-P
:	I-P
a	I-P
study	I-P
of	I-P
2,641	I-P
implants	I-P
.	I-P


According	O
to	O
the	O
American	O
College	O
of	O
Surgeons	O
,	O
complex	O
oral	O
surgical	O
procedures	O
,	O
including	O
the	O
transoral	O
placement	O
of	O
endosseous	B-P
implants	I-P
,	O
are	O
of	O
the	O
type	O
that	O
may	O
require	O
prophylactic	B-I
antibiotics	I-I
.	I-I


However	O
,	O
the	O
routine	O
use	O
of	O
prophylactic	B-I
antibiotics	I-I
in	O
the	O
field	O
of	O
dental	O
implantology	O
continues	O
to	O
be	O
controversial	O
,	O
and	O
their	O
utilization	O
varies	O
widely	O
.	O


No	O
data	O
from	O
a	O
randomized	O
prospective	O
clinical	O
study	O
of	O
the	O
prophylactic	O
use	O
of	O
antibiotics	B-I
in	O
implant	O
surgery	O
have	O
been	O
previously	O
published	O
.	O


As	O
part	O
of	O
the	O
comprehensive	O
Dental	O
Implant	O
Clinical	O
Research	O
Group	O
clinical	O
implant	O
study	O
,	O
the	O
preoperative	O
or	O
postoperative	O
use	O
of	O
antibiotics	B-I
,	O
the	O
type	O
used	O
,	O
and	O
the	O
duration	O
of	O
coverage	O
was	O
left	O
to	O
the	O
discretion	O
of	O
the	O
surgeon	O
.	O


These	O
data	O
were	O
recorded	O
and	O
correlated	O
with	O
failure	B-O
of	I-O
osseointegration	I-O
during	I-O
healing	I-O
(	I-O
stage	I-O
I	I-O
)	I-O
and	I-O
at	I-O
stage	I-O
II	I-O
surgery	I-O
(	I-O
uncovering	I-O
)	I-O
.	I-O


The	O
results	O
showed	O
that	O
significantly	O
fewer	O
failures	B-O
occurred	O
when	O
preoperative	O
antibiotics	B-I
were	O
used	O
.	O


Low	B-I
protein	I-I
provision	I-I
during	O
the	O
first	O
year	O
of	O
life	O
,	O
but	O
not	O
during	O
foetal	O
life	O
,	O
affects	O
metabolic	B-O
traits	I-O
,	I-O
organ	I-O
mass	I-O
development	I-O
and	I-O
growth	I-O
in	O
male	B-P
mink	I-P
(	I-P
Neovison	I-P
vison	I-P
)	I-P
.	I-P


Low	B-I
protein	I-I
provision	O
in	O
utero	O
and	O
post-partum	O
may	O
induce	O
metabolic	B-O
disorders	I-O
in	O
adulthood	O
.	O


Studies	O
in	O
mink	O
have	O
mainly	O
focused	O
on	O
short-term	O
consequences	O
of	O
low	B-I
protein	I-I
provision	I-I
in	O
utero	O
whereas	O
the	O
long-term	O
responses	O
to	O
low	B-I
protein	I-I
(	I-I
LP	I-I
)	I-I
provision	I-I
in	O
metabolically	O
programmed	O
mink	O
are	O
unknown	O
.	O


We	O
investigated	O
whether	O
low	O
protein	O
provision	O
in	O
utero	O
affects	O
the	O
long-term	O
response	O
to	O
adequate	O
(	O
AP	O
)	O
or	O
LP	O
provision	O
after	O
weaning	O
in	O
male	O
mink	O
.	O


Eighty-six	B-P
male	I-P
mink	I-P
were	I-P
exposed	I-P
to	I-P
low	I-P
(	I-P
19	I-P
%	I-P
of	I-P
ME	I-P
from	I-P
CP	I-P
;	I-P
crude	I-I
protein	I-I
)	I-I
or	I-P
adequate	I-I
(	I-I
31	I-I
%	I-I
of	I-I
ME	I-I
from	I-I
CP	I-I
)	I-I
protein	I-I
provision	I-P
in	I-P
utero	I-P
,	I-P
and	I-P
to	I-P
LP	I-P
(	I-P
~20	I-P
%	I-P
of	I-P
ME	I-P
from	I-P
CP	I-P
)	I-P
or	I-P
AP	I-P
(	I-P
30-42	I-P
%	I-P
of	I-P
ME	I-P
from	I-P
CP	I-P
)	I-P
provision	I-P
post-weaning	I-P
.	I-P


Being	O
metabolically	O
programmed	O
by	O
low	B-I
protein	I-I
provision	O
in	O
utero	O
did	O
not	O
affect	O
the	O
response	O
to	O
post-weaning	B-O
diets	I-O
.	O


Dietary	B-O
protein	I-O
content	I-O
in	O
the	O
LP	O
feed	O
after	O
weaning	O
was	O
below	O
requirements	O
;	O
evidenced	O
by	O
lower	O
nitrogen	B-O
retention	I-O
(	O
p	O
<	O
0.001	O
)	O
preventing	O
LP	O
mink	O
from	O
attaining	O
their	O
growth	O
potential	O
(	O
p	O
<	O
0.02	O
)	O
.	O


LP	O
mink	B-P
had	O
a	O
lower	O
liver	B-O
,	I-O
pancreas	I-O
and	I-O
kidney	I-O
weight	I-O
(	O
p	O
<	O
0.05	O
)	O
as	O
well	O
as	O
lower	O
plasma	B-O
IGF-1	I-O
concentrations	I-O
at	O
8	O
and	O
25	O
(	O
p	O
<	O
0.05	O
)	O
weeks	O
,	O
and	O
a	O
higher	O
incidence	O
of	O
hepatic	B-O
lipidosis	I-O
at	O
25	O
weeks	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Furthermore	O
,	O
LP	O
mink	O
had	O
a	O
higher	B-O
body	I-O
fat	I-O
(	O
p	O
<	O
0.05	O
)	O
and	O
lower	B-O
body	I-O
CP	I-O
content	I-O
(	O
p	O
<	O
0.05	O
)	O
at	O
50	O
weeks	O
of	O
age	O
.	O


It	O
is	O
concluded	O
that	O
some	O
effects	O
of	O
low	B-O
protein	I-O
provision	I-O
in	I-I
utero	O
can	O
be	O
alleviated	O
by	O
an	O
adequate	O
nutrient	B-O
supply	I-O
post-partum	I-O
.	I-O


However	O
,	O
long-term	O
exposure	O
to	O
low	B-I
protein	I-I
provision	I-I
in	O
mink	O
reduces	O
their	O
growth	B-O
potential	I-O
and	I-O
induces	I-O
transient	I-O
hepatic	I-O
lipidosis	I-O
and	I-O
modified	I-O
body	I-O
composition	I-O
.	I-O


Randomized	O
comparison	O
of	O
two	B-I
communication	I-I
interventions	I-I
for	O
preschoolers	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


This	O
randomized	O
group	O
experiment	O
compared	O
the	O
efficacy	O
of	O
2	B-I
communication	I-I
interventions	I-I
(	I-I
Responsive	I-I
Education	I-I
and	I-I
Prelinguistic	I-I
Milieu	I-I
Teaching	I-I
[	I-I
RPMT	I-I
]	I-I
and	I-I
the	I-I
Picture	I-I
Exchange	I-I
Communication	I-I
System	I-I
[	I-I
PECS	I-I
]	I-I
)	I-I
in	O
36	B-P
preschoolers	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


Each	O
treatment	O
was	O
delivered	O
3	O
times	O
per	O
week	O
,	O
in	O
20-min	O
sessions	O
,	O
for	O
6	O
months	O
.	O


The	O
results	O
revealed	O
that	O
the	O
RPMT	B-I
facilitated	O
the	O
frequency	B-O
of	I-O
generalized	I-O
turn	I-O
taking	I-O
and	I-O
generalized	I-O
initiating	I-O
joint	I-O
attention	I-O
more	O
than	O
did	O
the	O
PECS	O
.	O


The	O
latter	O
effect	O
occurred	O
only	O
for	O
children	O
who	O
began	O
treatment	O
with	O
at	O
least	O
some	O
initiating	B-O
joint	I-O
attention	I-O
.	I-O


In	O
contrast	O
,	O
the	O
PECS	B-I
facilitated	O
generalized	B-O
requests	I-O
more	O
than	O
the	O
RPMT	O
in	O
children	O
with	O
very	O
little	O
initiating	B-O
joint	I-O
attention	I-O
prior	O
to	O
treatment	O
.	O


These	O
effect	B-O
sizes	I-O
were	O
large	B-O
.	I-O


Intramedullary	B-I
repair	I-I
device	O
against	O
volar	O
plating	O
in	O
the	O
reconstruction	O
of	O
extra-articular	O
and	O
simple	O
articular	O
distal	O
radius	O
fractures	O
;	O
a	O
randomized	O
pilot	O
study	O
.	O


PURPOSE	O
This	O
prospective	O
randomized	O
pilot	O
study	O
reports	O
our	O
institutional	O
experience	O
and	O
early	O
results	O
using	O
Sonoma	O
Wrx	O
(	O
Sonoma	O
Orthopedic	O
Products	O
,	O
Santa	O
Rosa	O
,	O
CA	O
)	O
in	O
the	O
treatment	O
of	O
extra-articular	O
and	O
simple	O
intra-articular	O
distal	O
radius	O
fractures	O
.	O


MATERIAL	O
AND	O
METHODS	O
A	B-P
total	I-P
of	I-P
64	I-P
patients	I-P
,	I-P
were	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
.	I-P


They	B-P
were	I-P
considered	I-P
eligible	I-P
if	I-P
they	I-P
had	I-P
;	I-P
unstable	I-P
extra-articular	I-P
distal	I-P
radius	I-P
fractures	I-P
and	I-P
simple	I-P
intra-articular	I-P
distal	I-P
radius	I-P
fractures	I-P
suitable	I-P
for	I-P
closed	I-P
reduction	I-P
(	I-P
AO	I-P
types	I-P
;	I-P
A2.2	I-P
,	I-P
A2.3	I-P
,	I-P
A3.1	I-P
C2.1	I-P
,	I-P
C2.2	I-P
)	I-P
.	I-P


Patients	B-P
in	I-P
group	I-P
I	O
received	O
intramedullary	B-I
fixation	I-I
using	I-I
the	I-I
Sonoma	I-I
Wrx	I-I
device	I-I
and	O
patients	O
in	O
group	O
II	O
received	O
standard	B-I
volar	I-I
locking	I-I
plate	I-I
fixation	I-I
.	I-I


Radiographic	O
criteria	O
of	O
acceptable	O
healing	O
were	O
used	O
for	O
evaluation	O
.	O


RESULTS	O
Two	O
groups	O
were	O
similar	O
in	O
terms	O
of	O
baseline	O
characteristics	O
.	O


Mean	B-O
time	I-O
of	I-O
operation	I-O
was	O
significantly	O
shorter	O
in	O
Group	B-P
1	I-P
vs.	O
in	O
group	B-P
2	I-P
(	O
36.81	O
±	O
7.11	O
vs.	O
48.97	O
±	O
5.9	O
minutes	O
,	O
p	B-O
=	I-O
0.001	I-O
)	I-O
.	I-O


Time	B-O
to	I-O
healing	I-O
of	I-O
the	O
fracture	O
was	O
not	O
different	O
between	O
two	O
groups	O
(	O
5.45	O
±	O
1.09	O
vs.	O
5.70	O
±	O
1.04	O
weeks	O
for	O
Group	O
1	O
vs.	O
2	O
,	O
respectively	B-O
p	I-O
=	I-O
0.36	I-O
)	I-O
.	O


Overall	O
complications	B-P
occurred	I-P
in	O
9	O
patients	O
in	O
group	B-P
1	I-P
and	I-P
in	O
15	O
patients	O
in	O
group	O
2	O
(	O
p	O
=	O
0.17	O
)	O
.	B-P


Follow-up	B-P
was	O
completed	O
in	O
all	O
patients	O
with	O
a	O
median	O
time	B-P
of	I-P
12	I-P
months	I-P
and	O
13	O
months	O
in	O
group	O
1	O
and	O
2	O
,	O
respectively	B-O
.	I-O


On	B-O
radiographic	I-O
evaluation	I-O
radial	I-O
inclination	I-O
,	O
radial	O
height	O
and	O
volar	O
tilt	O
were	O
not	O
significantly	O
different	O
between	O
group	O
1	O
and	O
2	O
,	O
respectively	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	B-O
two	I-O
groups	I-O
in	I-O
regard	I-O
to	O
wrist	O
rotational	O
degrees	O
measured	O
in	O
last	B-I
follow-up	I-I
visit	I-I
.	O


CONCLUSION	O
Sonoma	O
Wrx	O
Device	O
is	O
reliable	O
and	O
effective	O
in	O
terms	O
of	O
achieving	O
satisfactory	O
outcomes	O
in	O
treatment	O
of	O
distal	O
radius	O
fractures	O
.	O


It	O
may	O
be	O
reasonable	O
to	O
use	O
this	O
device	O
to	O
prevent	O
complications	O
that	O
are	O
related	O
to	O
extensive	O
soft	O
tissue	O
dissection	O
.	O


Serotonergic	B-I
psychedelics	I-I
temporarily	O
modify	O
information	O
transfer	O
in	O
humans	B-P
.	I-P


BACKGROUND	O
Psychedelics	B-I
induce	O
intense	O
modifications	O
in	O
the	O
sensorium	O
,	O
the	O
sense	O
of	O
"	O
self	O
,	O
"	O
and	O
the	O
experience	O
of	O
reality	O
.	O


Despite	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
molecular	O
and	O
cellular	O
level	O
mechanisms	O
of	O
these	O
drugs	O
,	O
knowledge	O
of	O
their	O
actions	O
on	O
global	B-O
brain	I-O
dynamics	I-O
is	O
still	O
incomplete	O
.	O


Recent	O
imaging	O
studies	O
have	O
found	O
changes	O
in	O
functional	O
coupling	O
between	O
frontal	O
and	O
parietal	O
brain	O
structures	O
,	O
suggesting	O
a	O
modification	O
in	O
information	O
flow	O
between	O
brain	O
regions	O
during	O
acute	O
effects	O
.	O


METHODS	O
Here	O
we	O
assessed	O
the	O
psychedelic-induced	O
changes	B-O
in	I-O
directionality	I-O
of	I-O
information	I-O
flow	I-O
during	O
the	O
acute	O
effects	O
of	O
a	O
psychedelic	O
in	O
humans	B-P
.	I-P


We	O
measured	O
modifications	O
in	O
connectivity	O
of	O
brain	B-O
oscillations	I-O
using	O
transfer	O
entropy	O
,	O
a	O
nonlinear	O
measure	O
of	O
directed	O
functional	O
connectivity	O
based	O
on	O
information	O
theory	O
.	O


Ten	B-P
healthy	I-P
male	I-P
volunteers	I-P
with	I-P
prior	I-P
experience	I-P
with	I-P
psychedelics	I-I
participated	O
in	O
2	O
experimental	O
sessions	O
.	O


They	O
received	O
a	O
placebo	B-I
or	I-I
a	I-I
dose	I-I
of	I-I
ayahuasca	I-I
,	I-I
a	I-I
psychedelic	I-I
preparation	I-I
containing	I-I
the	I-I
serotonergic	I-I
5-HT2A	I-I
agonist	I-I
N	I-I
,	I-I
N-dimethyltryptamine	I-I
.	I-I


RESULTS	O
The	O
analysis	O
showed	O
significant	O
changes	B-O
in	I-O
the	I-O
coupling	I-O
of	I-O
brain	I-O
oscillations	I-O
between	O
anterior	O
and	O
posterior	O
recording	O
sites	O
.	O


Transfer	O
entropy	O
analysis	O
showed	O
that	O
frontal	O
sources	O
decreased	O
their	O
influence	O
over	O
central	O
,	O
parietal	O
,	O
and	O
occipital	O
sites	O
.	O


Conversely	O
,	O
sources	O
in	O
posterior	O
locations	O
increased	O
their	O
influence	O
over	O
signals	O
measured	O
at	O
anterior	O
locations	O
.	O


Exploratory	O
correlations	O
found	O
that	O
anterior-to-posterior	B-O
transfer	I-O
entropy	I-O
decreases	O
were	O
correlated	O
with	O
the	O
intensity	O
of	O
subjective	O
effects	O
,	O
while	O
the	O
imbalance	O
between	O
anterior-to-posterior	B-O
and	O
posterior-to-anterior	B-O
transfer	I-O
entropy	I-O
correlated	O
with	O
the	O
degree	O
of	O
incapacitation	O
experienced	O
.	O


CONCLUSIONS	O
These	O
results	O
suggest	O
that	O
psychedelics	B-I
induce	O
a	O
temporary	B-O
disruption	I-O
of	O
neural	B-O
hierarchies	I-O
by	O
reducing	O
top-down	O
control	O
and	O
increasing	O
bottom-up	O
information	O
transfer	O
in	O
the	O
human	B-P
brain	O
.	O


Efficacy	B-O
and	O
safety	B-O
of	O
repeated	O
use	O
of	O
ulipristal	B-I
acetate	I-I
in	O
uterine	B-P
fibroids	I-P
.	I-P


OBJECTIVE	O
To	O
investigate	O
the	O
efficacy	B-O
and	O
safety	B-O
of	O
repeated	O
12-week	O
courses	O
of	O
5	O
or	O
10	O
mg	O
daily	O
of	O
ulipristal	B-I
acetate	I-I
for	O
intermittent	O
treatment	O
of	O
symptomatic	B-P
uterine	I-P
fibroids	I-P
.	I-P


DESIGN	O
Double-blind	O
,	O
randomized	O
administration	O
of	O
two	O
12-week	O
courses	O
of	O
ulipristal	B-I
acetate	I-I
.	I-I


SETTING	O
Gynecology	B-P
centers	I-P
.	I-P


PATIENT	O
(	O
S	O
)	O
A	O
total	B-P
of	I-P
451	I-P
patients	I-P
with	I-P
symptomatic	I-P
uterine	I-P
fibroid	I-P
(	I-P
s	I-P
)	I-P
and	I-P
heavy	I-P
bleeding	I-P
.	I-P


INTERVENTION	O
(	O
S	O
)	O
Two	O
repeated	O
12-week	O
treatment	O
courses	O
of	O
daily	O
5	B-I
or	I-I
10	I-I
mg	I-I
of	I-I
ulipristal	I-I
acetate	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Amenorrhea	B-O
,	I-O
controlled	I-O
bleeding	I-O
,	I-O
fibroid	I-O
volume	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
,	I-O
pain	I-O
.	I-O


RESULT	O
(	O
S	O
)	O
In	O
the	O
5-	O
and	O
10-mg	O
treatment	O
groups	O
(	O
62	O
%	O
and	O
73	O
%	O
of	O
patients	O
,	O
respectively	O
)	O
achieved	O
amenorrhea	B-O
during	O
both	O
treatment	O
courses	O
.	O


Proportions	O
of	O
patients	O
achieving	O
controlled	B-O
bleeding	I-O
during	O
two	O
treatment	O
courses	O
were	O
>	O
80	O
%	O
.	O


Menstruation	B-O
resumed	I-O
after	O
each	O
treatment	O
course	O
and	O
was	O
diminished	O
compared	O
with	O
baseline	O
.	O


After	O
the	O
second	O
treatment	O
course	O
,	O
median	B-O
reductions	I-O
from	I-O
baseline	I-O
in	I-O
fibroid	I-O
volume	I-O
were	O
54	O
%	O
and	O
58	O
%	O
for	O
the	O
patients	O
receiving	O
5	O
and	O
10	O
mg	O
of	O
ulipristal	O
acetate	O
,	O
respectively	O
.	O


Pain	B-O
and	I-O
QoL	I-O
improved	O
in	O
both	O
groups	O
.	O


Ulipristal	O
acetate	O
was	O
well	O
tolerated	B-O
with	O
less	O
than	O
5	O
%	O
of	O
patients	O
discontinuing	O
treatment	O
due	O
to	O
adverse	B-O
events	I-O
.	I-O


CONCLUSION	O
(	O
S	O
)	O
Repeated	O
12-week	O
courses	O
of	O
daily	O
oral	O
ulipristal	O
acetate	O
(	O
5	O
and	O
10	O
mg	O
)	O
effectively	O
control	O
bleeding	B-O
and	I-O
pain	I-O
,	O
reduce	O
fibroid	B-O
volume	I-O
,	O
and	O
restore	O
QoL	B-O
in	O
patients	O
with	O
symptomatic	O
fibroids	O
.	O


CLINICAL	O
TRIAL	O
REGISTRATION	O
NUMBER	O
NCT01629563	O
(	O
PEARL	O
IV	O
)	O
.	O


Gastrointestinal	B-O
safety	I-O
of	O
NO-aspirin	B-I
(	I-I
NCX-4016	I-I
)	I-I
in	O
healthy	B-P
human	I-P
volunteers	I-P
:	I-P
a	O
proof	O
of	O
concept	O
endoscopic	O
study	O
.	O


BACKGROUND	O
AND	O
AIMS	O
NCX-4016	B-I
is	O
a	O
nitric	O
oxide-releasing	O
derivative	O
of	O
aspirin	O
with	O
antiplatelet	B-O
activity	I-O
.	I-O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
NCX-4016	B-I
on	O
gastrointestinal	O
mucosa	O
and	O
platelet	B-O
functions	I-O
in	O
healthy	B-P
human	I-P
volunteers	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
parallel-group	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O


Forty	B-P
healthy	I-P
subjects	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
7	O
days	O
of	O
treatment	O
with	O
NCX-4016	B-I
(	I-I
400	I-I
and	I-I
800	I-I
mg	I-I
twice	I-I
daily	I-I
)	I-I
,	I-I
equimolar	I-I
doses	I-I
of	I-I
aspirin	I-I
(	I-I
200	I-I
and	I-I
420	I-I
mg	I-I
twice	I-I
daily	I-I
)	I-I
,	I-I
or	I-I
placebo	I-I
.	I-I


Upper	O
endoscopies	O
were	O
performed	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
treatment	O
period	O
,	O
and	O
gastroduodenal	B-O
lesions	I-O
were	O
graded	O
using	O
a	O
predefined	B-O
scoring	I-O
system	I-O
.	I-O


Basal	B-O
and	I-O
posttreatment	I-O
platelet	I-O
aggregation	I-O
in	O
response	O
to	O
arachidonic	O
acid	O
(	O
AA	O
)	O
and	O
serum	O
thromboxane	O
(	O
TX	O
)	O
B	O
(	O
2	O
)	O
and	O
AA-stimulated	O
platelet	O
TXB	O
(	O
2	O
)	O
production	O
were	O
investigated	O
.	O


RESULTS	O
Mucosal	B-O
endoscopic	I-O
injury	I-O
score	I-O
on	O
day	O
7	O
was	O
0.63	O
+/-	O
0.16	O
in	O
the	O
placebo	O
group	O
and	O
11.0	O
+/-	O
3.0	O
and	O
16.1	O
+/-	O
1.6	O
in	O
healthy	B-P
volunteers	I-P
treated	O
with	O
200	O
and	O
420	O
mg	O
aspirin	O
twice	O
daily	O
(	O
P	O
<	O
0.0001	O
vs.	O
placebo	O
)	O
.	O


NCX-4016	O
was	O
virtually	O
devoid	O
of	O
gastric	B-O
and	I-O
duodenal	I-O
toxicity	I-O
,	O
resulting	O
in	O
a	O
total	B-O
gastric	I-O
and	I-O
duodenal	I-O
endoscopic	I-O
score	I-O
of	O
1.38	O
+/-	O
0.3	O
and	O
1.25	O
+/-	O
0.5	O
(	O
P	O
<	O
0.0001	O
vs.	O
aspirin	O
,	O
not	O
significant	O
vs.	O
placebo	O
)	O
.	O


NCX-4016	O
inhibited	O
AA-induced	B-O
platelet	I-O
aggregation	I-O
as	O
well	O
as	O
serum	B-O
TXB	I-O
(	I-O
2	I-O
)	I-O
and	O
platelet	B-O
TXB	I-O
(	I-O
2	I-O
)	I-O
generation	I-O
induced	O
by	O
AA	O
to	O
the	O
same	O
extent	O
as	O
aspirin	B-I
(	O
not	O
significant	O
vs.	O
aspirin	O
)	O
.	O


CONCLUSIONS	O
In	O
this	O
study	O
,	O
we	O
have	O
proven	O
the	O
concept	O
that	O
addition	O
of	O
an	O
NO-donating	O
moiety	O
to	O
aspirin	O
results	O
in	O
a	O
new	O
chemical	O
entity	O
that	O
maintains	O
cyclooxygenase-1	O
and	O
platelet	O
inhibitory	O
activity	O
while	O
nearly	O
avoiding	O
gastrointestinal	B-O
damage	I-O
.	I-O


Corticosteroid-induced	O
osteopenia	B-O
and	I-O
vitamin	I-O
D	I-O
metabolism	I-O
.	I-O


Effect	O
of	O
vitamin	B-I
D2	I-I
,	I-I
calcium	I-I
phosphate	I-I
and	O
sodium	B-I
fluoride	I-I
administration	O
.	O


Thirty-one	B-P
patients	I-P
scheduled	I-P
for	I-P
long-term	I-P
(	I-P
24	I-P
weeks	I-P
)	I-P
treatment	I-P
with	I-P
prednisone	I-I
in	I-P
comparatively	I-P
high	I-P
doses	I-P
were	O
randomly	O
allocated	O
to	O
two	O
further	O
treatment	O
groups	O
.	O


Group	B-I
A	I-I
received	I-I
prednisone	I-I
plus	I-I
'triple-treatment	I-I
'	I-I
(	I-I
vitamin	I-I
D2	I-I
45000	I-I
iu	I-I
twice	I-I
weekly	I-I
,	I-I
sodium	I-I
fluoride	I-I
50	I-I
mg	I-I
and	I-I
calcium	I-I
phosphate	I-I
4.5	I-I
g	I-I
daily	I-I
)	I-I
,	I-I
group	I-I
B	I-I
received	I-I
only	I-I
prednisone	I-I
.	I-I


The	O
study	O
was	O
undertaken	O
in	O
order	O
to	O
evaluate	O
the	O
effect	O
of	O
prednisone-	B-I
and	O
triple-treatment	B-I
upon	O
bone	B-O
mineral	I-O
content	I-O
(	I-O
BMC	I-O
)	I-O
and	I-O
vitamin	I-O
D	I-O
metabolism	I-O
.	I-O


The	O
groups	O
were	O
comparable	O
with	O
regard	O
to	O
age	O
,	O
sex	O
and	O
prednisone	O
dose	O
.	O


BMC	B-O
fell	O
rapidly	O
and	O
similarly	O
in	O
both	O
groups	O
,	O
demonstrating	O
that	O
the	O
triple-treatment	O
has	O
no	O
preventive	O
effect	O
on	O
corticosteroid	O
induced	O
osteopenia	O
.	O


Serum	B-O
concentrations	I-O
of	I-O
25OHD2	I-O
,	I-O
25OHD3	I-O
and	I-O
1,25	I-O
(	I-O
OH	I-O
)	I-O
2D	I-O
were	O
unchanged	O
in	O
group	O
B	O
(	O
without	O
triple-treatment	O
)	O
,	O
whereas	O
in	O
group	O
A	O
25OHD2	B-O
increased	O
enormously	O
,	O
25OHD3	B-O
was	O
suppressed	O
possibly	O
by	O
substrate	O
competition	O
for	O
hydroxylation	O
in	O
the	O
liver	O
and	O
1,25	B-O
(	I-O
OH	I-O
)	I-O
2D	I-O
was	O
halved	O
.	O


The	O
suppression	O
of	O
1,25	B-O
(	I-O
OH	I-O
)	I-O
2D	I-O
may	O
be	O
an	O
effect	O
of	O
raised	O
25OHD2	O
alone	O
,	O
or	O
in	O
combination	O
with	O
corticosteroid	O
excess	O
.	O


Anxiety	O
disorders	O
in	O
typically	O
developing	O
youth	O
:	O
autism	O
spectrum	O
symptoms	O
as	O
a	O
predictor	O
of	O
cognitive-behavioral	B-I
treatment	I-I
.	I-I


Symptoms	O
of	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
were	O
assessed	O
(	O
Social	O
Responsiveness	O
Scale-Parent	O
(	O
SRS-P	O
)	O
;	O
coded	O
in-session	O
behavior	O
)	O
in	O
typically-developing	B-P
,	I-P
anxiety-disordered	I-P
children	I-P
(	I-P
N	I-P
=	I-P
50	I-P
)	I-P
treated	O
with	B-I
cognitive-behavioral	I-I
therapy	I-I
(	I-I
CBT	I-I
)	I-I
.	O


Study	O
1	B-P
:	I-P
children	I-P
with	I-P
moderate	I-P
autistic	I-P
symptomology	I-P
(	O
per	O
SRS-P	O
)	O
were	O
significantly	O
more	O
likely	O
to	O
improve	O
from	B-I
family	I-I
CBT	I-I
(	I-I
FCBT	I-I
)	I-I
than	I-I
individual	I-I
CBT	I-I
(	I-I
ICBT	I-I
;	I-I
OR	O
=	O
8.67	O
)	O
.	O


Coded	O
behavior	O
did	O
not	O
predict	O
outcome	O
.	O


Study	B-I
2	I-I
:	I-I
CBT	O
components	O
were	O
compared	O
by	O
treatment	O
and	O
ASD	O
symptom	O
status	B-O
.	I-O


At-home	B-O
exposure	I-O
completion	I-O
was	O
greater	B-I
in	I-I
FCBT	I-I
and	O
there	O
was	O
an	O
interaction	O
in	O
child	O
involvement	O
for	O
treatment	O
and	O
ASD	O
status	O
.	O


Though	O
both	O
treatments	O
reduced	B-O
anxiety	I-O
,	I-I
FCBT	I-I
outperformed	I-I
ICBT	I-I
for	O
children	O
with	O
moderate	O
ASD	O
symptoms	O
,	O
a	O
benefit	O
potentially	O
linked	O
to	O
more	O
at-home	O
exposures	O
and	O
greater	O
child	O
involvement	B-I
in	I-I
FCBT	I-I
.	O


Parents	B-P
'	I-P
state	O
and	O
trait	O
anxiety	O
:	O
relationships	O
with	O
anxiety	B-O
severity	I-O
and	O
treatment	O
response	O
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


Comorbid	O
anxiety	O
is	O
common	O
among	O
children	B-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
(	I-P
ASD	I-P
)	I-P
,	I-P
and	I-P
parents	I-P
of	I-P
children	I-P
with	I-P
ASD	I-P
are	I-P
more	I-P
likely	I-P
to	I-P
have	I-P
anxiety	I-P
disorders	I-P
.	I-P


This	O
study	O
investigated	O
the	O
relationship	O
between	O
parents	B-I
'	I-I
state	I-O
and	I-O
trait	I-O
anxiety	I-O
and	I-P
parent-reported	I-I
internalizing	I-I
and	I-I
externalizing	I-I
symptoms	I-I
among	I-I
adolescents	I-I
(	I-P
n	I-P
=	I-P
30	I-P
)	I-P
with	I-P
ASD	I-P
,	I-P
as	I-P
well	I-P
as	I-P
the	I-P
relationship	I-P
of	I-O
parents	I-O
'	I-O
anxiety	I-O
symptoms	I-O
and	I-O
adolescent	I-O
treatment	I-O
response	I-O
in	O
the	O
context	O
of	O
a	O
randomized	O
controlled	O
trial	B-O
.	I-O


Parental	B-O
state	I-O
anxiety	I-O
correlated	O
with	B-O
severity	I-O
of	I-O
adolescent	I-O
anxiety	I-O
,	I-O
and	I-O
trait	I-O
anxiety	I-O
in	O
parents	O
correlated	O
with	B-O
parent-reported	I-O
adolescent	I-O
internalizing	I-O
and	I-O
externalizing	I-O
symptoms	I-O
.	O


Also	O
,	O
parents	O
of	O
adolescent	O
treatment	O
responders	O
experienced	O
a	B-O
decrease	I-O
in	I-O
their	I-O
own	I-O
trait	I-O
anxiety	I-O
.	O


Findings	O
highlight	O
the	O
importance	O
of	B-I
considering	I-O
parental	I-O
anxiety	I-O
when	O
targeting	B-O
anxiety	I-O
among	O
youth	O
with	O
ASD	O
.	O


[	O
The	O
application	O
of	O
naphcon	B-I
eye	I-I
drops	I-I
during	O
Lasik	B-I
surgery	I-I
]	I-I
.	O


PURPOSE	O
To	O
evaluate	O
the	O
effects	O
of	O
Naphcon	B-I
eye	I-I
drops	I-I
for	O
preventing	O
conjunctival	B-P
bleeding	I-P
during	I-P
Lasik	I-P
surgery	I-P
.	I-P


METHODS	O
One	B-P
hundred	I-P
cases	I-P
(	I-P
200	I-P
eyes	I-P
)	I-P
were	O
divided	O
into	O
treating	O
group	O
and	O
control	O
group	O
randomly	O
according	O
to	O
using	O
and	O
not	O
using	O
Naphcon	B-I
eye	I-I
drops	I-I
before	O
Lasik	O
surgery	O
.	O


Treating	O
group	O
patients	O
received	O
three	O
times	O
Naphcon	B-I
eye	I-I
drops	I-I
during	O
15	O
minutes	O
before	O
surgery	O
.	O


RESULTS	O
The	O
incidence	B-O
of	I-O
conjunctival	I-O
bleeding	I-O
from	O
treating	O
and	O
control	O
group	O
were	O
8	O
%	O
and	O
15	O
%	O
respectively	O
.	O


There	O
was	O
significant	O
statistical	O
difference	O
between	O
them	O
.	O


CONCLUSION	O
Naphcon	B-I
eye	I-I
drop	I-I
is	O
an	O
effective	O
agent	O
to	O
prevent	O
conjunctival	B-P
bleeding	I-P
.	I-P


Evaluation	O
of	O
hypertensive	B-P
patients	I-P
after	O
care	O
provided	O
by	O
community	B-I
pharmacists	I-I
in	I-P
a	I-P
rural	I-P
setting	I-P
.	I-P


We	O
evaluated	O
blood	B-O
pressure	I-O
control	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
,	I-O
quality	I-O
of	I-O
care	I-O
,	I-O
and	I-O
satisfaction	I-O
of	I-O
patients	I-O
who	I-P
were	I-P
monitored	I-P
by	I-P
specially	I-I
trained	I-I
community	I-I
pharmacists	I-I
in	I-P
a	I-P
group	I-P
medical	I-P
practice	I-P
.	I-P


After	O
participating	O
in	O
an	O
intensive	B-I
skill	I-I
development	I-I
program	I-I
,	O
pharmacists	O
performed	O
in	O
an	O
interdisciplinary	O
team	O
in	O
a	O
rural	O
clinic	O
.	O


The	O
primary	O
objective	O
was	O
assessed	O
by	O
evaluating	O
outcome	O
variables	O
at	O
6	O
months	O
compared	O
with	O
baseline	O
in	O
25	B-P
patients	I-P
randomly	O
assigned	O
to	O
a	O
study	O
group	O
.	O


A	O
control	B-P
group	I-P
of	I-P
26	I-P
patients	I-P
was	O
also	O
evaluated	O
to	O
determine	O
if	O
outcome	O
variables	O
remained	O
constant	O
from	O
baseline	O
to	O
6	O
months	O
.	O


Systolic	B-O
blood	I-O
pressure	I-O
was	O
reduced	O
in	O
the	O
study	O
group	O
(	O
151	O
mm	O
Hg	O
baseline	O
,	O
140	O
mm	O
Hg	O
at	O
6	O
mo	O
,	O
p	O
<	O
0.001	O
)	O
and	O
diastolic	B-O
blood	I-O
pressure	I-O
was	O
significantly	O
lower	O
at	O
2	O
,	O
4	O
,	O
and	O
5	O
months	O
compared	O
with	O
baseline	O
.	O


Ratings	O
from	O
a	O
blinded	O
peer	O
review	O
panel	O
indicated	O
significant	O
improvement	O
in	O
the	O
appropriateness	O
of	O
the	O
blood	O
pressure	O
regimen	O
,	O
going	O
from	O
8.7	O
+/-	O
4.7	O
to	O
10.9	O
+/-	O
4.5	O
in	O
the	O
study	O
group	O
(	O
p	O
<	O
0.01	O
)	O
,	O
but	O
they	O
did	O
not	O
change	O
in	O
the	O
control	O
group	O
.	O


Several	O
quality	B-O
of	I-O
life	I-O
scores	I-O
improved	O
significantly	O
in	O
the	O
study	O
group	O
after	O
6	O
months	O
(	O
p	O
<	O
0.05	O
)	O
.	O


These	O
included	O
physical	B-O
functioning	I-O
(	O
61.6	O
vs	O
70.7	O
)	O
,	O
physical	B-O
role	I-O
limitations	I-O
(	O
56.8	O
vs	O
72.8	O
)	O
,	O
and	O
bodily	B-O
pain	I-O
(	O
60.0	O
vs	O
71.7	O
)	O
at	O
baseline	O
and	O
6	O
months	O
,	O
respectively	O
.	O


There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
control	O
group	O
.	O


Patient	B-O
satisfaction	I-O
scores	I-O
were	O
consistently	O
higher	O
in	O
the	O
study	O
group	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O


Our	O
results	O
indicate	O
that	O
when	O
community	B-I
pharmacists	I-I
in	O
a	O
clinic	O
setting	O
are	O
trained	O
and	O
included	O
as	O
members	O
of	O
the	O
primary	O
care	O
team	O
,	O
significant	O
improvements	O
in	O
blood	B-O
pressure	I-O
control	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
,	I-O
and	I-O
patient	I-O
satisfaction	I-O
can	O
be	O
achieved	O
.	O


Effect	O
of	O
m-chlorophenylpiperazine	B-I
on	O
plasma	B-O
homovanillic	I-O
acid	I-O
concentrations	I-O
in	O
healthy	B-P
subjects	I-P
.	I-P


In	O
view	O
of	O
the	O
abundant	O
anatomical	O
and	O
functional	O
interactions	O
between	O
serotonin	O
and	O
dopamine	O
systems	O
,	O
this	O
study	O
examined	O
the	O
effect	O
of	O
the	O
serotonin	O
agonist	O
,	O
m-chlorophenylpiperazine	B-I
(	I-I
mCPP	I-I
)	I-I
on	O
plasma	B-O
concentrations	I-O
of	I-O
the	I-O
dopamine	I-O
metabolite	I-O
,	I-O
homovanillic	I-O
acid	I-O
.	I-O


Plasma	O
prolactin	O
levels	O
,	O
body	O
temperature	O
,	O
and	O
mCPP	B-O
blood	O
level	O
were	O
also	O
measured	O
.	O


mCPP	B-I
(	O
0.35	O
mg/kg	O
)	O
and	O
placebo	B-I
were	O
administered	O
orally	O
to	O
10	B-P
healthy	I-P
men	I-P
in	O
a	O
randomized	O
double-blind	O
design	O
.	O


Variables	O
were	O
measured	O
for	O
210	O
min	O
after	O
administration	O
of	O
capsules	O
.	O


mCPP	B-O
raised	I-O
prolactin	I-O
and	I-O
temperature	I-O
as	I-O
compared	I-O
to	I-O
placebo	I-O
,	O
but	O
did	O
not	O
affect	O
plasma	B-O
homovanillic	I-O
acid	I-O
concentrations	I-O
.	I-O


Results	O
suggest	O
that	O
mCPP	B-O
does	I-O
not	I-O
alter	I-O
dopamine	I-O
function	I-O
.	I-O


Avatar	O
assistant	O
:	O
improving	O
social	B-O
skills	I-O
in	O
students	B-P
with	I-P
an	I-P
ASD	I-P
through	O
a	O
computer-based	B-I
intervention	I-I
.	I-I


This	O
study	O
assessed	O
the	O
efficacy	B-O
of	O
FaceSay	B-I
,	I-I
a	I-I
computer-based	I-I
social	I-O
skills	I-O
training	I-I
program	I-I
for	O
children	B-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


This	O
randomized	O
controlled	O
study	B-P
(	I-P
N	I-P
=	I-P
49	I-P
)	I-P
indicates	O
that	O
providing	B-P
children	I-P
with	I-P
low-functioning	I-P
autism	I-P
(	I-P
LFA	I-P
)	I-P
and	I-P
high	I-P
functioning	I-P
autism	I-P
(	I-P
HFA	I-P
)	I-P
opportunities	O
to	O
practice	O
attending	O
to	O
eye	O
gaze	O
,	O
discriminating	O
facial	O
expressions	O
and	O
recognizing	O
faces	O
and	O
emotions	O
in	O
FaceSay	O
's	O
structured	O
environment	O
with	O
interactive	O
,	O
realistic	O
avatar	O
assistants	O
improved	O
their	B-O
social	I-O
skills	I-O
abilities	I-O
.	O


The	O
children	O
with	O
LFA	O
demonstrated	O
improvements	O
in	O
two	O
areas	O
of	O
the	O
intervention	B-O
:	I-O
emotion	I-O
recognition	I-O
and	I-O
social	I-O
interactions	I-O
.	O


The	O
children	O
with	O
HFA	O
demonstrated	O
improvements	O
in	O
all	O
three	O
areas	B-O
:	I-O
facial	I-O
recognition	I-O
,	I-O
emotion	I-O
recognition	I-O
,	I-O
and	I-O
social	I-O
interactions	I-O
.	O


These	O
findings	O
,	O
particularly	O
the	O
measured	O
improvements	O
to	B-O
social	I-O
interactions	I-O
in	O
a	O
natural	O
environment	O
,	O
are	O
encouraging	O
.	O


Evaluating	O
the	O
efficacy	B-O
of	O
thoracoscopy	B-I
and	I-I
talc	I-I
poudrage	I-I
versus	I-I
pleurodesis	I-I
using	I-I
talc	I-I
slurry	I-I
(	O
TAPPS	O
trial	O
)	O
:	O
protocol	O
of	O
an	O
open-label	O
randomised	O
controlled	O
trial	O
.	O


INTRODUCTION	O
The	O
management	O
of	O
recurrent	O
malignant	O
pleural	O
effusions	O
(	O
MPE	O
)	O
can	O
be	O
challenging	O
.	O


Various	O
options	O
are	O
available	O
,	O
with	O
the	O
most	O
efficacious	O
and	O
widely	O
used	O
being	O
talc	B-I
pleurodesis	I-I
.	I-I


Talc	B-I
can	O
either	O
be	O
applied	O
via	O
a	O
chest	O
drain	O
in	O
the	O
form	O
of	O
slurry	O
,	O
or	O
at	O
medical	B-I
thoracoscopy	I-I
using	I-I
poudrage	I-I
.	I-I


Current	O
evidence	O
regarding	O
which	O
method	O
is	O
most	O
effective	O
is	O
conflicting	O
and	O
often	O
methodologically	O
flawed	O
.	O


The	O
TAPPS	O
trial	O
is	O
a	O
suitably	O
powered	O
,	O
multicentre	O
,	O
open-label	O
,	O
randomised	O
controlled	O
trial	O
designed	O
to	O
compare	O
the	O
pleurodesis	O
success	O
rate	O
of	O
medical	B-I
thoracoscopy	I-I
and	I-I
talc	I-I
poudrage	I-I
with	I-I
chest	I-I
drain	I-I
insertion	I-I
and	I-I
talc	I-I
slurry	I-I
.	I-I


METHODS	O
AND	O
ANALYSIS	O
330	B-P
patients	I-P
with	I-P
a	I-P
confirmed	I-P
MPE	I-P
requiring	I-P
intervention	I-P
will	I-P
be	I-P
recruited	I-P
from	I-P
UK	I-P
hospitals	I-P
.	I-P


Patients	O
will	O
be	O
randomised	O
(	O
1:1	O
)	O
to	O
undergo	O
either	O
small	B-I
bore	I-I
(	I-I
<	I-I
14	I-I
Fr	I-I
)	I-I
Seldinger	I-I
chest	I-I
drain	I-I
insertion	I-I
followed	I-I
by	I-I
instillation	I-I
of	I-I
sterile	I-I
talc	I-I
(	O
4	O
g	O
)	O
,	O
or	B-I
to	I-I
undergo	I-I
medical	I-I
thoracoscopy	I-I
and	I-I
simultaneous	I-I
poudrage	I-I
(	O
4	O
g	O
)	O
.	O


The	O
allocated	O
procedure	O
will	O
be	O
performed	O
as	O
an	O
inpatient	O
within	O
3	O
days	O
of	O
randomisation	O
taking	O
place	O
.	O


Following	O
discharge	O
,	O
patients	O
will	O
be	O
followed	O
up	O
at	O
regular	O
intervals	O
for	O
6	O
months	O
.	O


The	O
primary	O
outcome	O
measure	B-O
is	I-O
pleurodesis	I-O
failure	I-O
rates	O
at	O
3	B-O
months	I-O
.	I-O


Pleurodesis	B-O
failure	O
is	O
defined	O
as	O
the	O
need	O
for	O
further	O
pleural	O
intervention	O
for	O
fluid	O
management	O
on	O
the	O
side	O
of	O
the	O
trial	O
intervention	O
.	O


ETHICS	O
AND	O
DISSEMINATION	O
The	O
trial	O
has	O
received	O
ethical	O
approval	O
from	O
the	O
National	O
Research	O
Ethics	O
Service	O
Committee	O
North	O
West-Preston	O
(	O
12/NW/0467	O
)	O
.	O


There	O
is	O
a	O
trial	O
steering	O
committee	O
which	O
includes	O
independent	O
members	O
and	O
a	O
patient	O
and	O
public	O
representative	O
.	O


The	O
trial	O
results	O
will	O
be	O
published	O
in	O
a	O
peer-reviewed	O
journal	O
and	O
presented	O
at	O
international	O
conferences	O
,	O
as	O
well	O
as	O
being	O
disseminated	O
via	O
local	O
and	O
national	O
charities	O
and	O
patient	O
groups	O
.	O


All	O
participants	O
who	O
wish	O
to	O
know	O
the	O
study	O
results	O
will	O
also	O
be	O
contacted	O
directly	O
on	O
their	O
publication	O
.	O


TRIAL	O
REGISTRATION	O
NUMBER	O
ISRCTN47845793	O
.	O


Asthma	O
and	O
the	O
home	O
environment	O
of	O
low-income	B-P
urban	I-P
children	I-P
:	I-P
preliminary	O
findings	O
from	O
the	O
Seattle-King	O
County	O
healthy	O
homes	O
project	O
.	O


OBJECTIVES	O
Childhood	O
asthma	O
is	O
a	O
growing	O
public	O
health	O
concern	O
in	O
low-income	O
urban	O
communities	O
.	O


Indoor	O
exposure	O
to	O
asthma	O
triggers	O
has	O
emerged	O
as	O
an	O
important	O
cause	O
of	O
asthma	O
exacerbations	O
.	O


We	O
describe	O
indoor	O
environmental	O
conditions	O
related	O
to	O
asthma	O
triggers	O
among	O
a	O
low-income	B-P
urban	I-P
population	I-P
in	I-P
Seattle/King	I-P
County	I-P
,	I-P
Washington	I-P
,	I-P
as	I-P
well	I-P
as	I-P
caregiver	I-P
knowledge	I-P
and	O
resources	O
related	O
to	O
control	O
of	O
these	O
triggers	O
.	O


METHODS	O
Data	O
are	O
obtained	O
from	O
in-person	O
,	O
structured	O
,	O
closed-end	O
interviews	O
with	O
the	O
caretakers	B-P
of	I-P
children	I-P
aged	I-P
4-12	I-P
years	I-P
with	I-P
persistent	I-P
asthma	I-P
living	I-P
in	I-P
households	I-P
with	I-P
incomes	I-P
less	I-P
than	I-P
200	I-P
%	I-P
of	I-P
poverty	I-P
.	I-P


Additional	O
information	O
is	O
collected	O
during	O
a	O
home	O
inspection	O
.	O


The	O
children	B-P
and	I-P
their	I-P
caregivers	I-P
are	I-P
participants	I-P
in	I-P
the	I-P
ongoing	I-P
Seattle-King	I-P
County	I-P
Healthy	I-P
Homes	I-P
Project	I-P
,	I-P
a	I-P
randomized	I-P
controlled	I-P
trial	I-P
of	I-P
an	I-P
intervention	I-I
to	I-P
empower	I-P
low-income	I-P
families	I-P
to	I-P
reduce	I-P
exposure	I-P
to	I-P
indoor	I-P
asthma	I-P
triggers	I-P
.	I-P


We	O
report	O
findings	O
on	O
the	O
conditions	O
of	O
the	O
homes	O
prior	O
to	O
this	O
intervention	O
among	O
the	B-P
first	I-P
112	I-P
enrolled	I-P
households	I-P
.	I-P


RESULTS	O
A	O
smoker	O
was	O
present	O
in	O
37.5	O
%	O
of	O
homes	O
.	O


Mold	B-O
was	I-O
visible	I-O
in	O
26.8	O
%	O
of	O
homes	O
,	O
water	B-O
damage	I-O
was	O
present	O
in	O
18.6	O
%	O
of	O
homes	O
,	O
and	O
damp	B-O
conditions	I-O
occurred	O
in	O
64.8	O
%	O
of	O
households	O
,	O
while	O
39.6	O
%	O
of	O
caregivers	O
were	O
aware	O
that	O
excessive	O
moisture	O
can	O
increase	O
exposures	O
to	O
allergens	O
.	O


Dust-trapping	B-O
reservoirs	I-O
were	O
common	O
;	O
76.8	O
%	O
of	O
children	O
's	O
bedrooms	O
had	O
carpeting	O
.	O


Cockroach	B-O
infestation	I-O
in	I-O
the	I-O
past	I-O
3	I-O
months	I-O
was	O
reported	O
by	O
23.4	O
%	O
of	O
caregivers	O
,	O
while	O
57.1	O
%	O
were	O
unaware	O
of	O
the	O
association	B-O
of	I-O
roaches	I-O
and	I-O
asthma	I-O
.	I-O


Only	O
19.8	O
%	O
of	O
the	O
children	O
had	O
allergy-control	B-O
mattress	I-O
covers	I-O
.	I-O


CONCLUSIONS	O
Many	O
low-income	B-P
urban	I-P
children	I-P
with	I-P
asthma	I-P
in	O
King	O
County	O
live	O
in	O
indoor	O
environments	O
that	O
place	O
them	O
at	O
substantial	O
risk	O
of	O
ongoing	O
exposure	O
to	O
asthma	O
triggers	O
.	O


Substandard	O
housing	O
and	O
lack	O
of	O
resources	O
often	O
underlie	O
these	O
exposures	O
.	O


Initiatives	O
involving	O
health	O
educators	O
,	O
outreach	O
workers	O
,	O
medical	O
providers	O
,	O
health	O
care	O
insurers	O
,	O
housing	O
agencies	O
,	O
and	O
elected	O
officials	O
are	O
needed	O
to	O
reduce	O
these	O
exposures	O
.	O


Percutaneous	B-I
coronary	I-I
intervention	I-I
in	O
patients	B-P
with	I-P
previous	I-P
coronary	I-P
artery	I-P
bypass	I-P
grafting	I-P
(	I-P
from	I-P
the	I-P
j-Cypher	I-P
Registry	I-P
)	I-P
.	I-P


A	O
paucity	O
of	O
data	O
is	O
available	O
from	O
large-scale	O
studies	O
evaluating	O
the	O
long-term	O
outcomes	O
of	O
percutaneous	B-I
coronary	I-I
intervention	I-I
in	O
patients	B-P
who	I-P
had	I-P
previously	I-P
undergone	I-P
coronary	I-I
artery	I-I
bypass	I-I
grafting	I-I
(	I-I
CABG	I-I
)	I-I
in	I-P
the	I-P
drug-eluting	I-P
stent	I-P
era	I-P
.	I-P


Of	O
12,812	B-P
patients	I-P
who	I-P
had	I-P
undergone	I-P
sirolimus-eluting	I-P
stent	I-P
implantation	I-P
in	I-P
the	I-P
j-Cypher	I-P
registry	I-P
,	I-P
919	I-P
(	I-P
7.2	I-P
%	I-P
)	I-P
had	I-P
a	I-P
history	I-P
of	I-P
CABG	I-P
and	I-P
had	I-P
significantly	I-P
higher	I-P
crude	I-O
5-year	I-O
mortality	I-O
(	I-P
19.9	I-P
%	I-P
vs	I-P
14.0	I-P
%	I-P
,	I-P
p	I-P
<	I-P
0.001	I-P
)	I-P
.	O


After	O
adjusting	O
for	O
confounders	O
,	O
the	B-O
excess	I-O
risk	I-O
of	I-O
death	I-O
was	O
no	O
longer	O
significant	O
(	O
hazard	O
ratio	O
0.99	O
,	O
95	O
%	O
confidence	O
interval	O
0.83	O
to	O
1.18	O
,	O
p	O
=	O
0.90	O
)	O
,	O
and	O
the	O
adjusted	B-O
risk	I-O
of	I-O
target	I-O
lesion	I-O
revascularization	I-O
was	O
significantly	O
higher	O
in	B-P
patients	I-P
with	I-P
previous	I-P
CABG	I-P
than	O
in	O
those	O
without	O
(	O
hazard	O
ratio	O
1.25	O
,	O
95	O
%	O
confidence	O
interval	O
1.06	O
to	O
1.47	O
,	O
p	O
=	O
0.01	O
)	O
.	O


Of	O
the	B-P
patients	I-P
with	I-P
previous	I-P
CABG	I-P
,	O
those	O
who	O
had	O
undergone	O
≥1	O
saphenous	O
vein	O
graft	O
intervention	O
had	O
significantly	O
higher	B-O
adjusted	I-O
risks	I-O
of	I-O
cardiac	I-O
death	I-O
(	O
hazard	O
ratio	O
2.21	O
,	O
95	O
%	O
confidence	O
interval	O
1.26	O
to	O
3.76	O
,	O
p	O
=	O
0.01	B-O
)	I-O
,	I-O
myocardial	I-O
infarction	I-O
(	O
hazard	O
ratio	O
2.56	O
,	O
95	O
%	O
confidence	O
interval	O
1.10	O
to	O
5.60	O
,	O
p	O
=	O
0.03	B-O
)	I-O
,	I-O
target	I-O
lesion	I-O
revascularization	I-O
(	O
hazard	O
ratio	O
2.65	O
,	O
95	O
%	O
confidence	O
interval	O
1.82	O
to	O
3.81	O
,	O
p	O
<	B-O
0.001	I-O
)	I-O
,	I-O
and	I-O
definite	I-O
stent	I-O
thrombosis	I-O
(	O
hazard	O
ratio	O
7.70	O
,	O
95	O
%	O
confidence	O
interval	O
1.99	O
to	O
29.1	O
,	O
p	O
=	O
0.004	O
)	O
compared	O
with	O
those	O
who	O
underwent	B-I
percutaneous	I-I
coronary	I-I
intervention	I-I
only	O
for	O
the	O
native	O
coronary	O
artery	O
.	O


In	O
conclusion	B-O
,	I-O
the	I-O
adjusted	I-O
mortality	I-O
was	O
similar	O
between	O
patients	O
with	O
and	O
without	O
previous	O
CABG	O
,	O
despite	O
a	O
significantly	O
different	B-O
risk	I-O
of	I-O
target	I-O
lesion	I-O
revascularization	I-O
.	O


Among	B-P
the	I-P
patients	I-P
with	I-P
previous	I-P
CABG	O
,	O
those	O
with	O
saphenous	O
vein	O
graft	O
intervention	O
using	O
a	O
first-generation	O
drug-eluting	O
stent	B-O
had	I-O
worse	I-O
clinical	I-O
outcomes	I-O
than	O
those	O
with	O
a	O
native	O
coronary	O
artery	O
target	O
only	O
.	O


A	O
trial	O
with	O
3'-azido-2',3'-dideoxythymidine	B-I
and	O
human	O
interferon-α	B-I
in	I-P
cats	I-P
naturally	I-P
infected	I-P
with	I-P
feline	I-P
leukaemia	I-P
virus	I-P
.	O


Feline	O
leukaemia	O
virus	O
(	O
FeLV	O
)	O
infection	O
is	O
still	O
one	O
of	O
the	O
leading	O
causes	O
of	O
infection-related	O
deaths	O
in	B-P
domestic	I-P
cats	I-P
.	O


Treatment	O
with	O
various	O
drugs	O
has	O
been	O
attempted	O
,	O
but	O
none	O
has	O
resulted	O
in	O
cure	O
or	O
complete	O
virus	O
elimination	O
.	B-I


Human	B-I
interferon-α2a	I-I
(	I-I
huIFN-α2a	I-I
)	I-I
and	I-I
3'-azido-2',3'-dideoxythymidine	I-I
(	I-I
AZT	I-I
)	I-I
have	O
been	O
proven	O
to	O
decrease	O
antigenaemia	O
in	O
cats	O
infected	O
experimentally	O
with	O
FeLV	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	B-O
efficacy	I-O
of	I-I
huIFN-α2a	I-I
,	O
AZT	O
and	O
a	O
combination	O
of	O
both	O
drugs	O
in	O
cats	O
infected	O
naturally	O
with	O
FeLV	O
in	O
a	O
placebo-controlled	O
double-blinded	O
trial	B-P
.	I-P


Fourty-four	B-P
FeLV-infected	I-P
cats	I-P
in	I-P
which	I-P
free	I-P
FeLV	I-P
p27	I-P
antigen	I-P
was	I-P
detected	I-P
in	I-P
serum	I-P
by	I-P
enzyme-linked	I-P
immunosorbent	I-P
assay	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	O


Cats	O
were	O
assigned	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
that	O
received	O
either	O
high	O
dose	B-I
huIFN-α2a	I-I
(	O
10	O
(	O
5	O
)	O
IU/kg	O
q24h	O
;	O
12	O
cats	B-I
)	I-I
,	O
AZT	O
(	O
5	O
mg/kg	O
q12h	O
;	O
10	O
cats	O
,	O
both	O
of	O
these	O
treatments	O
(	O
12	O
cats	B-I
)	I-I
or	I-I
placebo	I-I
(	O
10	O
cats	O
)	O
.	O


All	O
cats	O
were	O
treated	O
for	O
6	O
weeks	O
.	O


Clinical	O
variables	O
,	O
including	B-O
stomatitis	I-O
,	I-O
and	I-O
laboratory	I-O
parameters	I-O
,	I-O
such	I-O
as	I-O
CD4	I-O
(	I-O
+	I-O
)	I-O
and	I-O
CD8	I-O
(	I-O
+	I-O
)	I-O
counts	I-O
and	I-O
serum	I-O
FeLV	I-O
p	I-O
27	I-O
antigen	I-O
concentration	I-O
,	O
were	O
recorded	O
throughout	O
the	O
treatment	O
period	B-O
.	I-O


No	B-O
significant	I-O
difference	I-O
among	O
the	O
groups	O
was	O
observed	O
during	O
the	O
treatment	O
period	O
for	O
any	O
of	O
the	O
parameters	O
.	O


Aside	O
from	B-O
anaemia	I-O
in	O
one	O
cat	O
treated	O
with	O
AZT	B-O
,	I-O
no	I-O
adverse	I-O
effects	I-O
were	O
observed	O
.	O


It	O
was	O
not	O
possible	O
to	O
demonstrate	B-O
efficacy	I-O
of	I-I
huIFN-α2a	I-I
or	O
AZT	O
alone	O
or	O
together	O
in	O
cats	O
infected	O
naturally	O
with	O
FeLV	O
when	O
given	O
according	O
to	O
this	O
regimen	O
for	O
6	O
weeks	O
;	O
however	B-O
,	I-O
no	I-O
notable	I-O
side	I-O
effects	I-O
were	O
detected	O
.	O


The	O
Effects	O
of	O
Naltrexone	B-I
on	O
Subjective	O
Response	O
to	O
Methamphetamine	B-I
in	O
a	O
Clinical	B-P
Sample	I-P
:	I-P
a	O
Double-Blind	O
,	O
Placebo-Controlled	O
Laboratory	O
Study	O
.	O


Methamphetamine	B-I
(	I-P
MA	I-P
)	I-P
use	I-P
disorder	I-P
is	O
a	O
serious	O
psychiatric	O
condition	O
for	O
which	O
there	O
are	O
no	O
FDA-approved	O
medications	O
.	O


Naltrexone	B-I
(	O
NTX	O
)	O
is	O
an	O
opioid	O
receptor	O
antagonist	O
with	O
demonstrated	O
efficacy	O
,	O
albeit	O
moderate	O
,	O
for	O
the	O
treatment	O
of	O
alcoholism	O
and	O
opioid	O
dependence	O
.	O


Preclinical	O
and	O
clinical	O
studies	O
suggest	O
that	O
NTX	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
MA	O
use	O
disorder	O
.	O


To	O
inform	O
treatment	O
development	O
,	O
we	O
conducted	O
a	O
double-blind	O
,	O
randomized	O
,	O
crossover	O
,	O
placebo-controlled	O
human	O
laboratory	O
study	O
of	O
NTX	O
.	O


Non-treatment-seeking	B-P
individuals	I-P
meeting	I-P
DSM-IV	I-P
criteria	I-P
for	I-P
MA	I-P
abuse	I-P
or	I-P
dependence	I-P
(	I-P
n=30	I-P
)	I-P
completed	I-P
two	I-P
separate	I-P
5-day	I-P
inpatient	I-P
stays	I-P
.	I-P


During	O
each	O
admission	O
,	O
participants	O
completed	O
testing	O
sessions	O
comprised	O
of	O
MA	B-I
cue-reactivity	O
and	O
intravenous	B-I
MA	I-I
administration	I-I
(	I-I
30	I-I
mg	I-I
)	I-I
after	I-I
receiving	I-I
oral	I-I
NTX	I-I
(	I-I
50	I-I
mg	I-I
)	I-I
or	I-I
placebo	I-I
for	O
4	O
days	O
.	O


This	O
study	O
tested	O
the	O
hypotheses	O
that	O
NTX	O
would	O
(	O
a	O
)	O
attenuate	O
cue-induced	O
MA	O
craving	O
,	O
and	O
(	O
b	O
)	O
reduce	O
subjective	O
responses	O
to	O
MA	O
administration	O
.	O


Results	O
largely	O
supported	O
the	O
study	O
hypotheses	O
such	O
that	O
(	O
a	O
)	O
NTX	O
significantly	O
blunted	O
cue-induced	O
craving	O
for	O
MA	O
and	O
(	O
b	O
)	O
attenuated	O
several	O
of	O
the	O
hedonic	O
subjective	O
effects	O
of	O
MA	O
,	O
including	O
craving	O
,	O
during	O
controlled	O
MA	O
administration	O
and	O
as	O
compared	O
with	B-I
placebo	I-I
.	O


NTX	O
decreased	O
overall	B-O
subjective	I-O
ratings	I-O
of	I-O
'crave	I-O
drug	I-O
,	I-O
'	I-O
'stimulated	I-O
,	I-O
'	I-O
and	I-O
'would	I-O
like	I-O
drug	I-O
access	I-O
,	O
'	O
decreased	O
the	O
the	O
post-MA	O
administration	O
timecourse	B-O
of	I-O
'anxious	I-O
'	I-O
and	O
increased	B-O
ratings	I-O
of	I-O
'bad	I-O
drug	I-O
effects	I-O
,	O
'	O
as	O
compared	O
with	B-I
placebo	I-I
.	O


These	O
findings	O
support	O
a	O
potential	O
mechanism	O
of	O
action	O
by	O
showing	O
that	O
NTX	O
reduced	B-O
cue-induced	I-O
craving	I-O
and	I-O
subjective	I-O
responses	I-O
to	I-O
MA	O
.	O


This	O
is	O
consistent	O
with	O
positive	O
treatment	O
studies	B-I
of	I-I
NTX	O
for	B-I
amphetamine	I-I
dependence	O
,	O
as	O
well	O
as	O
ongoing	O
clinical	O
trials	O
for	O
MA	O
.	O


Are	O
prenatal	B-I
ultrasound	I-I
scans	I-I
associated	O
with	O
the	O
autism	B-O
phenotype	I-O
?	O
Follow-up	O
of	O
a	O
randomised	O
controlled	B-I
trial	O
.	O


An	O
existing	O
randomised	O
controlled	B-I
trial	O
was	O
used	O
to	O
investigate	O
whether	O
multiple	B-I
ultrasound	I-I
scans	I-I
may	O
be	O
associated	O
with	O
the	O
autism	B-O
phenotype	I-O
.	I-O


From	B-P
2,834	I-P
single	I-P
pregnancies	I-P
,	I-P
1,415	I-P
were	I-P
selected	I-P
at	I-P
random	I-P
to	O
receive	O
ultrasound	B-I
imaging	I-I
and	I-I
continuous	I-I
wave	I-I
Doppler	I-I
flow	I-I
studies	I-I
at	O
five	O
points	O
throughout	O
pregnancy	O
(	O
Intensive	O
)	O
and	O
1,419	O
to	O
receive	O
a	O
single	B-I
imaging	I-I
scan	I-I
at	O
18	O
weeks	O
(	O
Regular	O
)	O
,	O
with	O
further	O
scans	O
only	O
as	O
indicated	O
on	O
clinical	O
grounds	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	B-O
of	I-O
Autism	I-O
Spectrum	I-O
Disorder	I-O
between	O
the	O
Regular	O
(	O
9/1,125	O
,	O
0.8	O
%	O
)	O
and	O
Intensive	O
(	O
7/1,167	O
,	O
0.6	O
%	O
)	O
groups	O
,	O
nor	O
a	O
difference	O
between	O
groups	O
in	O
the	O
level	B-O
of	I-O
autistic-like	I-O
traits	I-O
in	O
early	O
adulthood	O
.	O


There	O
is	O
no	O
clear	O
link	O
between	O
the	O
frequency	B-O
and	O
timing	B-O
of	O
prenatal	B-I
ultrasound	I-I
scans	I-I
and	O
the	O
autism	B-O
phenotype	I-O
.	I-O


In	O
vivo	O
assessment	B-O
of	I-P
catheter-tip	I-I
PO2	I-I
sensor	I-I
:	I-I
sampling	O
lumen	O
fabrication	O
.	O


Fabrication	O
of	O
the	O
sampling	O
lumen	O
of	O
an	O
intra-arterial	B-I
PO2	I-I
sensor	I-I
is	O
performed	O
in	O
standard	B-P
catheters	I-P
mechanically	O
or	O
by	O
laser	O
.	O


Clinical	B-O
evaluation	I-O
is	O
performed	O
with	O
respect	O
to	O
catheter	B-O
insertion	I-O
,	I-O
complications	I-O
,	I-O
accuracy	I-O
of	I-O
oxygen	I-O
sensor	I-O
data	I-O
and	I-O
fibrin	I-O
deposition	I-O
on	I-O
the	I-O
catheter	I-O
surface	I-O
.	I-O


The	O
success	B-O
rate	I-O
for	I-O
catheter	I-O
insertion	I-O
is	I-P
57	I-P
%	I-P
for	I-P
138	I-P
standard	I-P
and	I-P
50	I-P
%	I-P
for	I-P
74	I-P
laser-cut	I-P
catheters	I-P
studied	I-P
.	I-P


The	O
proportion	O
of	O
catheter	B-O
failures	I-O
(	I-O
blocked	I-O
or	I-O
non-reading	I-O
)	I-O
is	O
14	O
%	O
in	O
laser-cut	O
compared	O
with	O
30	O
%	O
in	O
standard	O
.	O


These	O
differences	O
are	O
not	O
statistically	O
significant	O
at	O
the	O
5	O
%	O
level	O
.	O


There	O
is	O
no	O
clinically	O
significant	O
difference	O
in	O
sensor	B-O
accuracy	I-O
,	O
with	O
37.5	O
%	O
of	O
results	O
within	O
+/-	O
0.05	O
kPa	O
and	O
80	O
%	O
within	O
+/-	O
2.0	O
kPa	O
of	O
simultaneous	O
blood	O
gas	O
values	O
.	O


Drift	B-O
is	O
within	O
+/-	O
0.3	O
kPa	O
h-1	O
for	O
78	O
%	O
of	O
monitoring	O
time	O
.	O


Significant	B-O
errors	I-O
of	I-O
recalibration	I-O
occur	O
in	O
6	O
%	O
of	O
calibrations	O
.	O


Scanning	O
electron	O
micrographs	O
demonstrate	O
a	O
much	O
smaller	O
sampling	B-O
lumen	I-O
in	O
the	O
laser-cut	O
group	O
,	O
but	O
no	O
reduction	O
in	O
fibrin	B-O
deposition	I-O
at	O
the	O
site	O
of	O
the	O
sampling	O
hole	O
.	O


The	O
low	O
success	B-O
rate	I-O
for	I-O
catheter	I-O
insertion	I-O
is	O
a	O
problem	O
because	O
of	O
cost	O
implications	O
.	O


The	O
accuracy	B-O
of	O
the	O
system	O
is	O
usually	O
sufficient	O
for	O
clinical	O
purposes	O
,	O
provided	O
the	O
calibration	O
is	O
checked	O
every	O
4	O
h	O
.	O


The	O
use	O
of	O
a	O
water	B-I
extract	I-I
from	I-I
the	I-I
bark	I-I
of	I-I
Choerospondias	I-I
axillaris	I-I
in	O
the	O
treatment	B-P
of	I-P
second	I-P
degree	I-P
burns	I-P
.	I-P


Burns	B-P
are	I-P
common	I-P
in	I-P
Vietnam	I-P
,	O
and	O
because	O
of	O
economic	O
constraints	O
and	O
limited	O
resources	O
for	O
the	O
import	O
of	O
appropriate	O
treatments	O
,	O
the	O
health	O
authorities	O
are	O
obliged	O
to	O
rely	O
on	O
traditional	O
herbal	O
remedies	O
.	O


It	O
is	O
therefore	O
essential	O
to	O
evaluate	O
current	O
drugs	O
,	O
one	O
of	O
which	O
is	O
the	O
water	B-I
extract	I-I
of	I-I
the	I-I
bark	I-I
of	I-I
the	I-I
tree	I-I
Choerospondias	I-I
axillaris	I-I
.	I-I


It	O
has	O
been	O
used	O
for	O
many	O
years	O
in	O
the	O
Vietnam-Sweden	B-P
hospital	I-P
at	I-P
Uong	I-P
Bi	I-P
in	I-P
northern	I-P
Vietnam	I-P
.	I-P


We	O
assessed	O
the	O
efficacy	B-O
of	O
the	O
remedy	O
in	O
an	O
open	O
,	O
randomised	O
controlled	O
clinical	O
trial	O
,	O
in	O
which	O
20	B-P
patients	I-P
with	I-P
second	I-P
degree	I-P
burns	I-P
were	I-P
treated	I-P
with	I-P
the	I-P
extract	I-I
of	I-I
the	I-I
Choerospondias	I-I
axillaris	I-I
and	I-P
19	I-P
with	I-P
saline	I-I
gauze	I-I
.	I-I


The	O
mean	B-O
healing	I-O
time	I-O
was	O
significantly	O
shorter	O
for	O
patients	O
treated	O
with	O
Choerospondias	B-I
axillaris	I-I
(	O
11	O
days	O
)	O
compared	O
with	O
patients	O
treated	O
with	O
saline	B-I
gauze	I-I
(	O
17	O
days	O
)	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
the	O
number	B-O
of	I-O
wound	I-O
infections	I-O
was	O
significantly	O
lower	O
in	O
the	O
Choerospondias	B-I
axillaris	I-I
group	O
(	O
7/20	O
compared	O
with	O
16/19	O
,	O
p	O
=	O
0.003	O
)	O
.	O


The	O
bark	B-I
extract	I-I
was	O
easy	O
to	O
apply	O
and	O
additional	O
wound	O
care	O
was	O
not	O
usually	O
necessary	O
,	O
while	O
the	O
treatment	O
with	O
saline	B-I
gauze	I-I
was	O
laborious	O
for	O
both	O
patients	O
and	O
staff	O
and	O
was	O
much	O
more	O
expensive	B-O
.	I-O


The	O
extract	B-I
from	I-I
Choerospondias	I-I
axillaris	I-I
is	O
a	O
convenient	O
treatment	O
for	O
second	B-P
degree	I-P
burns	I-P
in	O
both	B-P
children	I-P
and	I-P
adults	I-P
.	I-P


A	O
search	O
for	O
serologic	O
correlates	O
of	O
immunity	O
to	O
Bordetella	O
pertussis	O
cough	O
illnesses	O
.	O


In	O
a	O
pertussis	B-P
vaccine	I-P
efficacy	I-P
trial	I-P
in	I-P
Germany	I-P
we	O
collected	O
sera	O
from	O
vaccinees	B-I
(	I-I
DTaP	I-I
or	I-I
DTP	I-I
)	I-I
after	O
the	O
third	O
and	O
fourth	O
doses	O
of	O
vaccine	O
or	O
at	O
comparable	O
time	O
periods	O
in	O
DT	B-P
vaccine	I-P
recipients	I-P
.	I-P


In	O
addition	O
,	O
sera	O
were	O
collected	O
from	O
a	O
randomized	O
sample	O
of	O
subjects	B-P
in	I-P
each	I-P
vaccine	I-P
group	I-P
at	I-P
approximately	I-P
3-month	I-P
intervals	I-P
from	O
which	O
antibody	O
kinetic	O
curves	O
were	O
constructed	O
,	O
which	O
allowed	O
us	O
to	O
estimate	O
specific	O
antibody	O
values	O
to	O
pertussis	B-I
toxin	O
(	O
PT	O
)	O
,	O
filamentous	O
hemagglutinin	O
(	O
FHA	O
)	O
,	O
pertactin	O
and	O
fimbriae-2	O
at	O
the	O
time	O
of	O
exposure	O
in	O
the	O
household	O
setting	O
.	O


The	O
imputed	O
geometric	O
mean	O
antibody	O
values	O
to	O
PT	O
,	O
pertactin	O
and	O
fimbriae-2	O
at	O
the	O
time	O
of	O
household	O
exposure	O
to	O
Bordetella	O
pertussis	O
infection	O
were	O
higher	O
(	O
p	O
<	O
0.07	O
or	O
lower	O
)	O
in	O
non-cases	O
compared	O
with	O
cases	O
.	O


A	O
multivariate	O
(	O
classification	O
tree	O
)	O
analysis	O
found	O
that	O
only	O
pertactin	O
and	O
PT	O
were	O
significant	O
in	O
protection	O
.	O


Subjects	O
with	O
an	O
imputed	O
pertactin	O
value	O
of	O
<	O
7	O
EU	O
ml-1	O
had	O
a	O
67	O
%	O
(	O
18/27	O
)	O
chance	O
of	O
infection	O
regardless	O
of	O
the	O
PT	O
value	O
.	O


If	O
the	O
pertactin	O
value	O
was	O
>	O
or	O
=	O
7	O
EU	O
ml-1	O
and	O
the	O
PT	O
value	O
>	O
or	O
=	O
66	O
EU	O
ml-1	O
all	O
subjects	O
were	O
non-cases	O
.	O


If	O
the	O
pertactin	O
value	O
was	O
>	O
or	O
=	O
7	O
and	O
the	O
PT	O
value	O
was	O
<	O
66	O
EU	O
ml-1	O
the	O
predicted	O
probability	O
of	O
being	O
a	O
case	O
was	O
31	O
%	O
(	O
15/49	O
)	O
.	O


Logistic	B-O
regression	I-O
analysis	I-O
also	O
found	O
that	O
high	O
versus	O
low	O
pertactin	O
values	O
were	O
associated	O
with	O
illness	O
prevention	O
following	O
household	O
exposure	O
.	O


In	O
the	O
presence	O
of	O
antibody	O
to	O
pertactin	O
,	O
PT	O
and	O
fimbriae-2	O
,	O
the	O
additional	O
presence	O
of	O
antibody	O
to	O
FHA	O
did	O
not	O
contribute	O
to	O
protection	O
.	O


Our	O
data	O
support	O
historical	O
data	O
indicating	O
that	O
agglutinating	O
antibodies	O
are	O
associated	O
with	O
protection	O
and	O
also	O
recent	O
serologic	O
correlates	O
data	O
and	O
clinical	O
efficacy	O
data	O
which	O
indicate	O
that	O
multicomponent	B-I
vaccines	I-I
containing	I-I
pertactin	I-I
and	I-I
fimbriae	I-I
have	O
better	O
efficacy	O
than	O
PT	O
or	O
PT/FHA	O
vaccines	O
.	O


Brief	O
report	O
:	O
effects	O
of	O
cognitive	B-I
behavioral	I-I
therapy	I-I
on	O
parent-reported	B-O
autism	I-O
symptoms	I-O
in	I-P
school-age	I-P
children	I-P
with	I-P
high-functioning	I-P
autism	I-P
.	I-P


This	O
pilot	O
study	O
tested	O
the	O
effect	O
of	O
cognitive	B-I
behavioral	I-I
therapy	I-I
(	I-I
CBT	I-I
)	I-I
on	O
parent-reported	B-P
autism	I-P
symptoms	I-P
.	I-P


Nineteen	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
an	I-P
anxiety	I-P
disorder	I-P
(	I-P
7-11	I-P
years	I-P
old	I-P
)	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
16	O
sessions	O
of	O
CBT	B-I
or	O
a	O
waitlist	B-I
condition	I-I
.	I-I


The	O
CBT	B-I
program	O
emphasized	O
in	O
vivo	O
exposure	O
supported	O
by	O
parent	O
training	O
and	O
school	O
consultation	O
to	O
promote	O
social	O
communication	O
and	O
emotion	O
regulation	O
skills	O
.	O


Parents	O
completed	O
a	O
standardized	B-O
autism	I-O
symptom	I-O
checklist	I-O
at	O
baseline	O
and	O
posttreatment/postwaitlist	O
and	O
3-month	O
follow-up	O
assessments	O
.	O


CBT	B-I
outperformed	O
the	O
waitlist	O
condition	O
at	O
posttreatment/postwaitlist	O
on	O
total	B-O
parent-reported	I-O
autism	I-O
symptoms	I-O
(	O
Cohen	O
's	O
d	O
effect	O
size	O
=	O
.77	O
)	O
.	O


Treatment	O
gains	O
were	O
maintained	O
at	O
3-month	O
follow-up	O
.	O


Further	O
investigation	O
of	O
this	O
intervention	O
modality	O
with	O
larger	O
samples	O
and	O
broader	O
outcome	O
measures	O
appears	O
to	O
be	O
indicated	O
.	O


The	O
management	O
of	O
dermoid	B-P
cysts	I-P
--	I-P
a	I-P
comparative	O
study	O
of	O
laparoscopy	B-I
and	O
laparotomy	B-I
.	I-I


The	O
aim	O
of	O
our	O
study	O
was	O
to	O
compare	O
laparoscopy	B-I
with	O
laparotomy	B-I
for	O
the	O
removal	O
of	O
ovarian	B-P
dermoid	I-P
cysts	I-P
.	I-P


Thirty-eight	B-P
women	I-P
with	I-P
benign	I-P
ovarian	I-P
dermoid	I-P
cyst	I-P
were	O
allocated	O
for	O
either	O
laparoscopy	B-I
(	O
18	O
patients	O
)	O
or	O
laparotomy	B-I
(	O
20	O
patients	O
)	O
.	O


The	O
two	O
groups	O
were	O
compared	O
for	O
operative	O
and	O
hospitalization	O
times	O
and	O
postoperative	O
course	O
.	O


Operating	B-O
time	I-O
was	O
longer	O
(	O
93.6	O
+/-	O
23.8	O
min	O
)	O
and	O
hospitalization	B-O
time	I-O
significantly	O
shorter	O
(	O
22.4	O
+/-	O
6.6	O
h	O
)	O
in	O
the	O
laparoscopy	O
group	O
.	O


No	O
complications	B-O
were	O
reported	O
in	O
either	O
group	O
.	O


We	O
conclude	O
that	O
operative	B-I
laparoscopy	I-I
is	O
a	O
safe	B-O
procedure	O
for	O
the	O
removal	O
of	O
dermoid	B-P
ovarian	I-P
cysts	I-P
and	O
is	O
as	O
effective	B-O
as	O
laparotomy	B-I
.	I-I


Combined	O
action	O
of	O
enalapril	B-I
or	O
timolol	B-I
with	O
hydrochlorothiazide	B-I
plus	I-I
amiloride	I-I
in	O
hypertension	B-P
.	I-P


59	B-P
mild	I-P
to	I-P
moderate	I-P
hypertensives	I-P
were	O
treated	O
for	O
four	O
weeks	O
with	O
50	O
mg	O
hydrochlorothiazide	B-I
plus	O
5	O
mg	O
of	O
amiloride	B-I
,	O
then	O
concomitantly	O
with	O
these	O
diuretics	O
with	O
either	O
enalapril	B-I
(	O
10-20	O
mg	O
)	O
or	O
timolol	B-I
(	O
10-20	O
mg	O
)	O
in	O
two	O
parallel	O
treatment	O
groups	O
for	O
an	O
additional	O
12	O
weeks	O
in	O
an	O
open	O
study	O
.	O


Addition	O
of	O
these	O
drugs	O
lowered	O
the	O
blood	B-O
pressure	I-O
by	O
25	O
+/-	O
3/16	O
+/-	O
2	O
mm	O
Hg	O
and	O
15	O
+/-	O
3/14	O
+/-	O
1	O
mm	O
Hg	O
,	O
respectively	O
.	O


The	O
difference	O
of	O
the	O
reduction	O
of	O
the	O
systolic	B-O
blood	I-O
pressure	I-O
between	O
enalapril	O
and	O
timolol	O
group	O
at	O
the	O
end	O
of	O
the	O
combined	O
treatment	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O


The	O
mean	B-O
serum	I-O
potassium	I-O
was	O
elevated	O
by	O
0.3	O
mmol/l	O
after	O
addition	O
of	O
enalapril	O
to	O
the	O
diuretic	O
treatment	O
,	O
but	O
none	O
of	O
the	O
patients	O
developed	O
hyperkalaemia	B-O
.	I-O


No	O
adverse	B-O
effects	I-O
on	O
other	O
routine	O
laboratory	O
values	O
were	O
observed	O
.	O


Both	O
drug	O
combinations	O
can	O
be	O
considered	O
efficient	O
,	O
well	O
tolerated	B-O
and	I-O
safe	I-O
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	O
.	O


Procalcitonin	B-I
is	O
a	O
good	O
tool	O
to	O
guide	O
duration	O
of	O
antibiotic	B-I
therapy	I-I
in	O
patients	B-P
with	I-P
severe	I-P
acute	I-P
pancreatitis	I-P
.	I-P


A	O
randomized	O
prospective	O
single-center	O
controlled	O
trial	O
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
clinical	O
usefulness	O
of	O
procalcitonin	B-I
(	O
PCT	O
)	O
for	O
guiding	O
duration	O
of	O
antibiotic	B-I
therapy	I-I
in	O
patients	B-P
with	I-P
severe	I-P
acute	I-P
pancreatitis	I-P
(	I-P
SAP	I-P
)	I-P
.	I-P


METHODS	O
A	O
total	O
of	O
71	B-P
patients	I-P
with	I-P
confirmed	I-P
severe	I-P
acute	I-P
pancreatitis	I-P
from	I-P
March	I-P
2009	I-P
to	I-P
September	I-P
2011	I-P
in	I-P
the	I-P
Department	I-P
of	I-P
Critical	I-P
Care	I-P
Medicine	I-P
of	I-P
Huizhou	I-P
Municipal	I-P
Central	I-P
Hospital	I-P
,	I-P
Guangdong	I-P
,	I-P
China	I-P
were	O
enrolled	O
in	O
this	O
study	O
.	O


Procalcitonin	B-I
was	I-I
measured	I-I
daily	I-I
by	I-I
a	I-I
semi-quantitative	I-I
immunoassay	I-I
in	I-I
the	I-I
study	I-I
group	I-I
.	I-I


Patients	O
were	O
randomly	O
assigned	O
into	O
2	B-I
groups	I-I
including	I-I
a	I-I
PCT-guided	I-I
group	I-I
(	I-I
study	I-I
group	I-I
)	I-I
and	I-I
a	I-I
prophylactic	I-I
antibiotic	I-I
therapy	I-I
(	I-I
control	I-I
group	I-I
)	I-I
.	O


Antibiotic	B-I
therapy	I-I
in	I-I
the	I-I
study	I-I
group	I-I
was	I-I
not	I-I
applied	I-I
until	I-I
clinical	I-I
signs	I-I
and	I-I
symptoms	I-I
of	I-I
infection	I-I
appeared	I-I
(	I-I
PCT	I-I
value	I-I
was	I-I
>	I-I
0.5ng/ml	I-I
)	I-I
.	O


We	O
discontinued	O
the	O
antibiotic	O
therapy	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
infection	O
improved	O
and	O
PCT	O
was	O
<	O
0.5ng/ml	O
over	O
3	O
days	O
.	O


In	O
the	O
control	O
group	O
,	O
antibiotic	O
therapy	O
was	O
administrated	O
for	O
2	O
weeks	O
,	O
or	O
antibiotic	B-I
therapy	I-I
was	O
continued	O
because	O
of	O
confirmed	O
infection	O
until	O
clinical	O
signs	O
and	O
symptoms	O
of	O
infection	O
disappeared	O
over	O
3	O
days	O
.	O


RESULTS	O
In	O
the	O
study	O
group	O
(	O
35	O
patients	O
)	O
,	O
the	O
duration	B-O
of	I-O
antibiotic	I-O
therapy	I-O
and	I-O
hospitalization	I-O
was	O
significantly	O
shorter	O
than	O
the	O
control	O
group	O
(	O
36	O
patients	O
)	O
(	O
10.89+/-2.85	O
versus	O
16.06+/-2.48	O
days	O
,	O
p	O
<	O
0.001	O
,	O
and	O
16.66+/-4.02	O
days	O
versus	O
23.81+/-7.56	O
days	O
,	O
p	O
<	O
0.001	O
)	O
without	O
negative	B-O
clinical	I-O
effects	I-O
and	O
the	O
cost	B-O
of	I-O
hospitalization	I-O
was	O
significantly	O
lower	O
.	O


CONCLUSION	O
Procalcitonin	B-I
is	O
a	O
helpful	O
and	O
safe	O
tool	O
for	O
guiding	O
duration	O
of	O
antibiotic	O
treatment	O
in	O
patients	B-P
with	I-P
severe	I-P
acute	I-P
pancreatitis	I-P
.	I-P


Comparison	O
of	O
postoperative	O
short-term	O
complications	O
after	O
laparoscopic	B-I
transabdominal	I-I
preperitoneal	I-I
(	I-I
TAPP	I-I
)	I-I
versus	I-I
Lichtenstein	I-I
tension	I-I
free	I-I
inguinal	I-I
hernia	I-I
repair	I-I
:	I-I
a	O
randomized	O
trial	O
study	O
.	O


AIM	O
The	O
aim	O
of	O
this	O
randomized	O
trial	O
was	O
to	O
compare	O
short-term	O
postoperative	O
complications	B-P
of	I-P
laparoscopic	I-I
transabdominal	I-I
preperitoneal	I-I
(	I-I
TAPP	I-I
)	I-I
and	I-I
Lichtenstein	I-I
tension	I-I
free	I-I
hernia	I-I
repair	I-I
.	I-I


METHODS	O
A	B-P
total	I-P
of	I-P
120	I-P
patients	I-P
who	I-P
went	I-P
inguinal	I-I
hernia	I-I
repair	I-I
at	I-P
Shahid	I-P
Sadoughi	I-P
university	I-P
training	I-P
hospital	I-P
from	I-P
April	I-P
2011	I-P
to	I-P
August	I-P
2013	I-P
were	O
randomized	O
into	O
two	O
TAPP	B-I
(	O
N.=60	O
)	O
and	O
Lichtenstein	B-I
(	O
N.=60	O
)	O
repair	O
group	O
.	O


Follow-up	O
occurred	O
within	O
6	O
weeks	O
.	O


The	O
postoperative	O
assessments	O
included	O
pain	B-O
score	I-O
(	I-O
VAS	I-O
)	I-O
,	I-O
hematoma/seroma	I-O
,	I-O
urinary	I-O
retention	I-O
,	I-O
wound	I-O
infection	I-O
incidence	I-O
,	I-O
and	I-O
duration	I-O
of	I-O
hospital	I-O
stay	I-O
.	I-O


RESULTS	O
Pain	B-O
was	O
the	O
most	O
common	O
symptoms	O
in	O
both	O
groups	O
.	O


The	O
TAPP	O
group	O
patients	O
significantly	O
had	O
experienced	O
less	O
postoperative	B-O
pain	I-O
than	O
the	O
Lichtenstein	B-I
group	O
in	O
all	O
moments	O
(	O
P	O
<	O
0.05	O
)	O
.	O


TAPP	O
group	O
had	O
lower	O
incidence	O
of	O
hematoma	B-O
(	O
TAPP	O
,	O
6.6	O
%	O
vs.	O
Lichtenstein	B-I
13.3	O
%	O
;	O
P=0.67	O
)	O
,	O
seroma	B-O
(	O
TAPP	O
10	O
%	O
vs.	O
Lichtenstein	B-I
13.3	O
%	O
;	O
P=1.00	O
)	O
,	O
and	O
infection	B-O
(	O
TAPP	O
0	O
vs.	O
Lichtenstein	B-I
1.6	O
%	O
;	O
P=0.67	O
)	O
.	O


However	O
,	O
no	O
differences	O
between	O
the	O
2	O
groups	O
were	O
found	O
in	O
terms	O
of	O
postoperative	B-O
complications	I-O
.	I-O


In	O
TAPP	O
group	O
mean	B-O
of	I-O
hospital	I-O
stay	I-O
significantly	O
was	O
less	O
than	O
Lichtenstein	B-I
group	O
(	O
TAPP	O
,	O
8.13±2.19	O
vs.	O
Lichtenstein	O
,	O
13.15±1.5	O
days	O
;	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSION	O
The	O
laparoscopic	O
TAPP	O
repair	O
is	O
safer	O
and	O
less	O
complicated	O
approach	O
to	O
inguinal	O
hernia	O
repair	O
.	O


The	O
two	O
main	O
short-term	O
advantages	O
of	O
the	O
laparoscopic	B-I
TAPP	I-I
repair	O
with	O
the	O
tension	O
free	B-I
Lichtenstein	I-I
repair	O
were	O
less	O
postoperative	O
pain	O
and	O
earlier	O
return	O
to	O
the	O
normal	O
life	O
activities	B-O
.	O


No	O
difference	O
was	O
seen	O
in	O
overall	O
complications	O
.	O


Rotigotine	B-I
transdermal	I-I
patch	I-I
enables	O
rapid	O
titration	O
to	O
effective	O
doses	O
in	O
advanced-stage	B-P
idiopathic	I-P
Parkinson	I-P
disease	I-P
:	I-P
subanalysis	O
of	O
a	O
parallel	O
group	O
,	O
open-label	O
,	O
dose-escalation	O
study	O
.	O


OBJECTIVE	O
Rotigotine	B-I
(	I-I
Neupro	I-I
)	I-I
is	O
formulated	O
as	O
a	O
transdermal	O
delivery	O
system	O
designed	O
to	O
provide	O
a	O
selective	O
,	O
non-ergot	O
D3/D2/D1	O
agonist	O
to	O
the	O
systemic	O
blood	O
flow	O
over	O
a	O
24-hour	O
period	O
.	O


In	O
clinical	O
trials	O
,	O
patches	B-I
were	I-I
applied	I-I
once	I-I
daily	I-I
and	I-I
uptitrated	I-I
to	I-I
the	I-I
individual	I-I
effective	I-I
dose	I-I
in	I-I
increments	I-I
of	I-I
2	I-I
mg/24	I-I
h	I-I
every	I-I
week	I-I
.	I-I


The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
the	O
safety	B-O
of	O
a	O
more	O
rapid	O
titration	O
of	O
rotigotine	B-I
by	O
assessing	O
the	O
tolerability	B-O
of	O
escalating	O
transdermal	O
doses	O
of	O
rotigotine	B-I
given	O
in	O
2	O
different	O
titration	O
schemes	O
.	O


METHODS	O
We	O
analyzed	O
the	O
safety	B-O
of	O
rotigotine	B-I
in	O
2	B-P
groups	I-P
of	I-P
patients	I-P
with	I-P
advanced	I-P
stage	I-P
Parkinson	I-P
Disease	I-P
.	I-P


The	O
starting	O
dose	O
of	O
4	O
mg/24	O
h	O
was	O
increased	O
every	O
week	O
by	O
2	O
mg/24	O
h	O
in	O
the	O
slow-titration	O
group	O
and	O
4	O
mg/24	O
h	O
in	O
the	O
fast-titration	O
group	O
.	O


The	O
primary	O
focus	O
of	O
this	O
subanalysis	O
was	O
the	O
separate	O
tolerability	B-O
of	I-O
rotigotine	I-O
in	O
each	O
randomized	O
treatment	O
arm	O
,	O
during	O
the	O
dose-escalation	O
period	O
.	O


However	O
,	O
the	O
2	O
titration	O
schemes	O
were	O
also	O
compared	O
with	O
each	O
other	O
.	O


RESULTS	O
The	O
dose	O
of	O
first	O
reported	O
nausea	B-O
and/or	I-O
vomiting	I-O
was	O
8	O
mg/24	O
h	O
for	O
the	O
fast-titration	O
group	O
and	O
4	O
mg/	O
24	O
h	O
for	O
the	O
slow-titration	O
group	O
.	O


There	O
were	O
no	O
remarkable	O
differences	O
concerning	O
the	O
side-effect	B-O
profile	I-O
between	O
the	O
2	O
different	O
titration	O
schemes	O
.	O


CONCLUSIONS	O
The	O
fast-titration	O
regimen	O
had	O
a	O
similar	O
adverse	B-O
event	I-O
profile	I-O
to	O
slower	O
titration	O
,	O
and	O
allowed	O
rotigotine	B-I
to	O
be	O
introduced	O
quickly	O
.	O


This	O
subanalysis	O
suggests	O
that	O
rotigotine	B-I
may	O
be	O
uptitrated	O
more	O
rapidly	O
.	O


Determinants	O
of	O
improvement	O
in	O
walking	B-O
capacity	I-O
among	O
individuals	B-P
with	I-P
chronic	I-P
stroke	I-P
following	O
a	O
multi-dimensional	B-I
exercise	I-I
program	I-I
.	I-I


OBJECTIVE	O
To	O
identify	O
the	O
determinants	O
of	O
improvement	O
in	O
walking	B-O
capacity	I-O
following	O
therapeutic	B-I
exercise	I-I
in	O
chronic	B-P
stroke	I-P
survivors	I-P
.	I-P


DESIGN	O
A	O
secondary	O
analysis	O
of	O
data	O
obtained	O
from	O
a	O
prospective	O
,	O
single-blind	O
,	O
randomized	O
controlled	O
intervention	O
trial	O
.	O


SUBJECTS	O
Sixty-three	B-P
community-dwelling	I-P
individuals	I-P
(	I-P
mean	I-P
age	I-P
=	I-P
65	I-P
years	I-P
,	I-P
age	I-P
range	I-P
=	I-P
50-87	I-P
years	I-P
)	I-P
with	I-P
a	I-P
chronic	I-P
stroke	I-P
(	I-P
post-stroke	I-P
duration	I-P
:	I-P
mean	I-P
=	I-P
5.5	I-P
years	I-P
,	I-P
range	I-P
=	I-P
1-28	I-P
years	I-P
)	I-P
.	I-P


METHODS	O
Subjects	O
were	O
randomized	O
into	O
a	O
leg	B-I
exercise	I-I
group	O
(	O
n	O
=	O
32	O
)	O
or	O
an	O
arm	B-I
exercise	I-I
group	O
(	O
n	O
=	O
31	O
)	O
.	O


Subjects	O
in	O
each	O
group	O
underwent	O
3	O
1-hour	O
exercise	B-I
sessions	I-I
per	O
week	O
for	O
19	O
weeks	O
.	O


Walking	B-O
capacity	I-O
,	I-O
cardiorespiratory	I-O
fitness	I-O
,	I-O
isometric	I-O
knee	I-O
extensor	I-O
muscle	I-O
strength	I-O
,	I-O
balance	I-O
ability	I-O
,	I-O
and	I-O
balance	I-O
confidence	I-O
were	O
evaluated	O
before	O
and	O
after	O
the	O
interventions	O
.	O


Multiple	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
determinants	O
of	O
improvement	O
in	O
walking	O
capacity	O
.	O


RESULTS	O
After	O
controlling	O
for	O
age	O
,	O
gender	O
,	O
post-stroke	O
duration	O
,	O
and	O
baseline	O
walking	B-O
capacity	I-O
,	I-O
gain	I-O
in	I-O
paretic	I-O
leg	I-O
muscle	I-O
strength	I-O
and	I-O
peak	I-O
oxygen	I-O
consumption	I-O
remained	I-O
independently	I-O
associated	O
with	O
gain	B-O
in	I-O
walking	I-O
capacity	I-O
(	O
R2	O
=	O
0.229	O
)	O
.	O


CONCLUSION	O
Enhancement	O
of	O
cardiorespiratory	O
fitness	O
and	O
paretic	O
leg	O
muscle	O
strength	O
are	O
both	O
significant	O
determinants	O
in	O
improving	O
walking	O
capacity	O
among	O
chronic	O
stroke	O
survivors	O
.	O


However	O
,	O
the	O
rather	O
weak	O
relationship	O
(	O
R2	O
=	O
0.229	O
)	O
indicates	O
that	O
other	O
factors	O
not	O
measured	O
in	O
this	O
study	O
may	O
also	O
contribute	O
to	O
the	O
improvement	O
in	O
walking	O
capacity	O
.	O


Effect	O
of	O
a	O
mixed	B-I
kinesio	I-I
taping-compression	I-I
technique	I-I
on	O
quality	B-O
of	I-O
life	I-O
and	O
clinical	B-O
and	O
gait	B-O
parameters	I-O
in	O
postmenopausal	B-P
women	I-P
with	I-P
chronic	I-P
venous	I-P
insufficiency	I-P
:	I-P
double-blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
short-term	O
effect	O
of	O
a	O
mixed	O
Kinesio	B-I
taping	I-I
(	O
KT	O
)	O
model	O
on	O
range	B-O
of	I-O
ankle	I-O
motion	I-O
(	I-O
ROAM	I-O
)	I-O
,	I-O
gait	I-O
,	I-O
pain	I-O
,	I-O
perimeter	I-O
of	I-O
lower	I-O
limbs	I-O
,	I-O
and	I-O
quality	I-O
of	I-O
life	I-O
in	O
postmenopausal	B-P
women	I-P
with	I-P
chronic	I-P
venous	I-P
insufficiency	I-P
(	I-P
CVI	I-P
)	I-P
.	I-P


DESIGN	O
Double-blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O


SETTING	O
Clinical	O
setting	O
.	O


PARTICIPANTS	O
Consecutive	B-P
postmenopausal	I-P
women	I-P
(	I-P
N=130	I-P
;	I-P
mean	I-P
age	I-P
±	I-P
SD	I-P
,	I-P
65.44±14.7y	I-P
)	I-P
with	I-P
mild	I-P
CVI	I-P
.	O


No	O
participant	O
withdrew	O
because	O
of	O
adverse	O
effects	O
.	O


INTERVENTION	O
Participants	O
were	O
randomly	O
assigned	O
to	O
either	O
(	B-I
1	I-I
)	I-I
an	I-I
experimental	I-I
group	I-I
to	I-I
receive	I-I
a	I-I
mixed	I-I
KT-compression	I-I
treatment	I-I
following	I-I
KT	I-I
recommendations	I-I
for	I-I
gastrocnemius	I-I
muscle	I-I
enhancement	I-I
and	I-I
functional	I-I
correction	I-I
of	I-I
the	I-I
ankle	I-I
,	I-I
and	I-I
adding	I-I
2	I-I
tapes	I-I
to	I-I
simulate	I-I
traditional	I-I
compression	I-I
bandages	I-I
(	I-I
no	I-I
KT	I-I
guidelines	I-I
)	I-I
;	I-I
or	I-I
(	I-I
2	I-I
)	I-I
a	I-I
placebo	I-I
control	I-I
group	I-I
for	I-I
sham	I-I
KT	I-I
.	O


Both	O
interventions	O
were	O
performed	O
3	O
times	O
a	O
week	O
during	O
a	O
4-week	O
period	O
.	O


MAIN	O
OUTCOME	O
MEASURES	B-O
ROAM	I-O
,	I-O
gait	I-O
,	I-O
pain	I-O
,	I-O
perimeter	I-O
of	I-O
right	I-O
and	I-O
left	I-O
lower	I-O
limb	I-O
,	I-O
and	I-O
quality	I-O
of	I-O
life	I-O
were	O
assessed	O
at	O
baseline	O
and	O
48	O
hours	O
posttreatment	O
.	O


RESULTS	B-O
Quality	I-O
of	I-O
life	I-O
was	O
better	O
in	O
the	O
intervention	O
group	O
by	O
a	O
mean	O
of	O
8.76	O
points	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
4.96-12.55	O
)	O
.	O


The	O
experimental	O
group	O
also	O
showed	O
significant	O
pre-/posttreatment	O
improvements	O
in	O
both	B-O
lower	I-O
limbs	I-O
in	I-O
gait	I-O
dorsiflexion	I-O
ROAM	I-O
(	O
95	O
%	O
CI	O
,	O
1.02-2.49	B-O
)	I-O
,	I-O
cadence	I-O
(	O
95	O
%	O
CI	O
,	O
3.45-1.47	B-O
)	I-O
,	I-O
stride	I-O
length	I-O
(	O
95	O
%	O
CI	O
,	O
21.48-10.83	B-O
)	I-O
,	I-O
step	I-O
length	I-O
(	O
95	O
%	O
CI	O
,	O
1.68-6.61	B-O
)	I-O
,	I-O
stance	I-O
phase	I-O
(	O
95	O
%	O
CI	O
,	O
61-107	O
)	O
,	O
and	B-O
foot	I-O
(	O
95	O
%	O
CI	O
,	O
.56-.92	O
)	O
and	B-O
malleolus	I-O
(	O
95	O
%	O
CI	O
,	O
1.15-1.63	B-O
)	I-O
circumference	I-O
.	O


None	O
of	O
these	O
variables	O
were	O
significantly	O
modified	O
in	O
the	O
placebo	O
group	O
.	O


Both	O
groups	O
reported	O
a	O
significant	O
reduction	O
in	B-O
pain	I-O
.	O


CONCLUSIONS	B-O
Ankle	I-O
dorsiflexion	I-O
during	O
gait	B-O
,	I-O
walking	I-O
parameters	I-O
,	I-O
peripheral	I-O
edema	I-O
,	I-O
venous	I-O
pain	I-O
,	I-O
and	I-O
quality	I-O
of	I-O
life	I-O
remain	O
improved	O
in	O
patients	O
with	O
CVI	O
at	O
1	O
month	O
after	B-I
mixed	I-I
KT-compression	I-I
therapy	I-I
.	O


KT	O
may	O
have	O
a	B-I
placebo	I-I
effect	O
on	O
pain	O
perception	O
.	O


A	O
randomized	O
,	O
double-blind	O
,	O
phase	O
II	O
study	O
of	O
two	O
doses	O
of	O
pemetrexed	B-I
as	O
first-line	O
chemotherapy	O
for	O
advanced	B-P
breast	I-P
cancer	I-P
.	I-P


PURPOSE	O
Pemetrexed	B-I
has	O
shown	O
varied	O
response	O
rates	O
in	O
advanced	B-P
breast	I-P
cancer	I-P
.	I-P


This	O
randomized	O
,	O
double-blind	O
,	O
phase	O
II	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
two	O
doses	O
of	O
pemetrexed	B-I
in	O
a	O
homogeneous	O
population	O
.	O


A	O
secondary	O
objective	O
was	O
to	O
identify	O
molecular	O
biomarkers	O
correlating	O
with	O
response	B-O
and	I-O
toxicity	I-O
.	I-O


EXPERIMENTAL	O
DESIGN	O
Patients	B-P
with	I-P
newly	I-P
diagnosed	I-P
metastatic	I-P
breast	I-P
cancer	I-P
or	I-P
locally	I-P
recurrent	I-P
breast	I-P
cancer	I-P
received	O
600	O
mg/m	O
(	O
2	O
)	O
(	B-I
P600	I-I
arm	O
)	O
or	O
900	O
mg/m	O
(	O
2	O
)	O
(	B-I
P900	I-I
arm	O
)	O
of	O
pemetrexed	B-I
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
.	O


All	O
patients	O
received	O
folic	B-I
acid	I-I
and	I-I
vitamin	I-I
B	I-I
(	I-I
12	I-I
)	I-I
supplementation	I-I
.	I-I


RESULTS	O
The	B-P
P600	I-P
(	I-P
47	I-P
patients	I-P
)	I-P
and	I-P
P900	I-P
(	I-P
45	I-P
patients	I-P
)	I-P
arms	O
had	O
response	B-O
rates	I-O
of	O
17.0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
7.7-30.8	O
%	O
)	O
and	O
15.6	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
6.5-29.5	O
%	O
)	O
with	O
approximately	O
50	O
%	O
stable	O
disease	O
per	O
arm	O
,	O
median	B-O
progression-free	I-O
survival	I-O
of	O
4.2	O
and	O
4.1	O
months	O
,	O
and	O
median	B-O
times	I-O
to	I-O
tumor	I-O
progression	I-O
of	O
4.2	O
and	O
4.6	O
months	O
,	O
respectively	O
.	O


Both	O
arms	O
exhibited	O
minimal	B-O
toxicity	I-O
(	O
grade	O
3/4	O
neutropenia	B-O
<	O
20	O
%	O
,	O
leukopenia	B-O
<	O
9	O
%	O
,	O
and	O
other	B-O
toxicities	I-O
<	O
5	O
%	O
)	O
.	O


Tumor	O
samples	O
from	O
49	O
patients	O
were	O
assessed	O
for	O
the	O
expression	O
levels	O
of	O
12	O
pemetrexed-related	B-I
genes	O
.	O


Folylpolyglutamate	O
synthetase	O
and	O
thymidine	O
phosphorylase	O
correlated	O
with	O
efficacy	B-O
.	I-O


Best	B-O
response	I-O
rates	I-O
and	I-O
median	I-O
time	I-O
to	I-O
tumor	I-O
progression	I-O
for	O
high	O
versus	O
low	O
thymidine	O
phosphorylase	O
expression	O
were	O
27.6	O
%	O
versus	O
6.3	O
%	O
(	O
P	O
=	O
0.023	O
)	O
and	O
5.4	O
versus	O
1.9	O
months	O
(	O
P	O
=	O
0.076	O
)	O
,	O
and	O
for	O
folylpolyglutamate	O
synthetase	O
were	O
37.5	O
%	O
versus	O
10.0	O
%	O
(	O
P	O
=	O
0.115	O
)	O
and	O
8.6	O
versus	O
3.0	O
months	O
(	O
P	O
=	O
0.019	O
)	O
,	O
respectively	O
.	O


gamma-Glutamyl	O
hydrolase	O
expression	O
correlated	O
with	O
grade	B-O
3/4	I-O
toxicities	I-O
:	I-O
78.6	O
%	O
for	O
high	O
versus	O
27.3	O
%	O
for	O
low	O
gamma-glutamyl	O
hydrolase	O
(	O
P	O
=	O
0.024	O
)	O
.	O


CONCLUSION	O
The	O
two	O
pemetrexed	B-I
doses	O
yielded	O
similar	O
efficacy	B-O
and	I-O
safety	I-O
profiles	O
.	O


Exploratory	O
biomarker	O
analysis	O
identified	O
efficacy	B-O
and	I-O
toxicity	I-O
correlations	O
and	O
warrants	O
further	O
evaluation	O
.	O


Expectant	B-I
management	I-I
of	O
functional	B-P
ovarian	I-P
cysts	I-P
:	I-P
an	O
alternative	O
to	O
hormonal	B-I
therapy	I-I
.	I-I


OBJECTIVE	O
We	O
studied	O
whether	O
the	O
administration	O
of	O
oral	B-I
contraceptives	I-I
facilitates	O
the	O
disappearance	O
of	O
spontaneously	O
formed	B-P
functional	I-P
ovarian	I-P
cysts	I-P
.	I-P


METHODS	O
Eighty	B-P
patients	I-P
in	I-P
whom	I-P
ultrasonography	I-P
revealed	I-P
unilateral	I-P
,	I-P
mobile	I-P
,	I-P
unilocular	I-P
,	I-P
thin-walled	I-P
ovarian	I-P
cysts	I-P
without	I-P
internal	I-P
echoes	I-P
and	I-P
greater	I-P
than	I-P
30	I-P
mm	I-P
but	I-P
not	I-P
exceeding	I-P
60	I-P
mm	I-P
in	I-P
diameter	I-P
were	I-P
enrolled	I-P
into	I-P
the	I-P
study	I-P
.	I-P


Patients	O
were	O
randomized	O
by	O
stratification	O
to	O
receive	O
a	O
low-dose	B-I
monophasic	I-I
pill	I-I
,	I-I
a	I-I
high-dose	I-I
monophasic	I-I
pill	I-I
,	I-I
a	I-I
multiphasic	I-I
pill	I-I
or	I-I
no	I-I
therapy	I-I
.	I-I


Patients	O
were	O
re-evaluated	O
after	O
5	O
weeks	O
of	O
therapy	O
and	O
at	O
the	O
end	O
of	O
therapy	O
(	O
10	O
weeks	O
)	O
.	O


RESULTS	O
The	O
mean	B-O
ages	I-O
and	I-O
the	I-O
mean	I-O
cyst	I-O
diameters	I-O
of	O
the	O
patients	O
for	O
each	O
group	O
were	O
not	O
significantly	O
different	O
.	O


We	O
did	O
not	O
find	O
a	O
significant	O
effect	O
of	O
oral	O
contraceptive	O
administration	O
on	O
the	O
disappearance	B-O
rate	I-O
of	I-O
functional	I-O
ovarian	I-O
cysts	I-O
over	O
that	O
of	O
expectant	O
management	O
.	O


CONCLUSION	O
We	O
conclude	O
that	O
oral	B-I
contraceptive	I-I
therapy	O
even	O
with	O
multiphasic	O
pills	O
is	O
very	O
effective	O
in	O
the	O
management	O
of	O
functional	B-O
ovarian	I-O
cysts	I-O
but	O
expectant	O
management	O
achieves	O
similar	O
success	O
rates	O
and	O
may	O
be	O
a	O
good	O
alternative	O
to	O
oral	B-I
contraceptive	I-I
therapy	I-I
.	I-I


[	O
Comparison	O
of	O
complications	B-O
after	O
intra-	B-I
and	I-I
extracapsular	I-I
cataract	I-I
extraction	I-I
with	I-I
lens	I-I
implantation	I-I
.	I-I


Results	O
of	O
a	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
]	O
.	O


BACKGROUND	O
The	O
postoperative	B-O
complications	I-O
of	O
ICCE	B-I
with	I-I
ACL	I-I
implantation	I-I
are	O
compared	O
with	O
those	O
of	O
ECCE	B-I
and	I-I
PCL	I-I
.	I-I


Our	O
clinical	O
experience	O
with	O
ICCE	B-I
and	I-I
ACL	I-I
implantation	I-I
can	O
not	O
confirm	O
the	O
widespread	O
rejection	O
of	O
this	O
method	O
.	O


PATIENTS	O
AND	O
METHOD	O
A	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
with	O
participation	B-P
of	I-P
medical	I-P
statisticians	I-P
was	O
performed	O
.	O


A	B-P
total	I-P
of	I-P
190	I-P
patients	I-P
with	I-P
ICCE	I-I
and	I-I
ACL	I-I
and	I-P
170	I-P
patients	I-P
with	I-P
ECCE	I-I
and	I-I
PCL	I-I
were	I-P
followed	I-P
up	I-P
for	I-P
2	I-P
years	I-P
.	I-P


The	O
follow-up	O
examinations	O
were	O
performed	O
upon	O
dismission	O
from	O
the	O
hospital	O
,	O
after	O
6	O
,	O
12	O
and	O
24	O
months	O
.	O


The	O
data	O
were	O
compiled	O
in	O
a	O
computer	O
program	O
designed	O
for	O
this	O
study	O
and	O
evaluated	O
by	O
the	O
statisticians	O
.	O


The	O
surgical	O
procedures	O
and	O
the	O
surgeons	O
were	O
defined	O
prior	O
to	O
the	O
beginning	O
of	O
patient	O
recruitment	O
.	O


RESULTS	O
ICCE	B-I
with	I-I
ACL	I-I
shows	O
much	O
less	O
postoperative	B-O
complications	I-O
as	O
usually	O
emphasized	O
.	O


There	O
were	O
only	O
2	O
(	O
1.2	O
%	O
)	O
of	O
retinal	B-O
detachment	I-O
and	O
no	O
case	O
of	O
corneal	B-O
decompensation	I-O
.	I-O


Cystoid	B-O
macular	I-O
edema	I-O
8	O
(	O
4.7	O
%	O
)	O
,	O
postoperative	B-O
vitreous	I-O
prolaps	I-O
into	I-O
the	I-O
anterior	I-O
chamber	I-O
4	O
(	O
2.3	O
%	O
)	O
and	O
spontaneous	B-O
complaints	I-O
of	I-O
pain	I-O
16	O
(	O
9.4	O
%	O
)	O
occurred	O
in	O
a	O
low	O
percentage	O
after	O
ICCE	B-I
with	I-I
ACL	I-I
.	I-I


These	O
complications	O
did	O
not	O
occur	O
after	O
ECCE	B-I
with	I-I
PCL	I-I
.	I-I


The	O
patients	O
with	O
ECCE	B-I
and	I-I
PCL	I-I
showed	O
capsular	B-O
fibrosis	I-O
in	O
48	O
(	O
28	O
%	O
)	O
making	O
it	O
the	O
most	O
frequent	O
complication	O
of	O
the	O
whole	O
study	O
.	O


33	O
%	O
of	O
these	O
patients	O
required	O
YAG-laser	B-I
capsulotomy	I-I
.	I-I


Since	O
retinal	O
detachment	O
occurs	O
in	O
2.5	O
%	O
after	O
YAG-laser	B-I
capsulotomy	I-I
we	O
can	O
not	O
regard	O
capsular	O
fibrosis	O
as	O
a	O
totally	O
harmless	O
complication	O
.	O


It	O
is	O
noteworthy	O
that	O
visual	B-O
acuity	I-O
is	O
almost	O
identical	O
1	O
year	O
after	O
surgery	O
in	O
both	O
methods	O
.	O


CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
the	O
evaluation	O
of	O
ICCE	B-I
with	I-I
ACL	I-I
is	O
too	O
negative	O
.	O


The	O
elimination	O
of	O
postoperative	O
complications	O
in	O
this	O
method	O
is	O
more	O
difficult	O
.	O


ECCE	B-I
with	I-I
PCL	I-I
is	O
burdened	O
by	O
frequent	B-O
capsular	I-O
fibrosis	I-O
.	I-O


Visual	O
acuity	O
is	O
almost	O
the	O
same	O
in	O
both	O
methods	O
1	O
years	O
after	O
the	O
operation	O
.	O


ACL-implantation	B-I
remains	O
our	O
method	O
of	O
choice	O
for	O
secondary	O
implantation	O
in	O
patients	B-P
with	I-P
an	I-P
intact	I-P
iris	I-P
diaphragm	I-P
.	I-P


The	O
role	O
of	O
radiography	B-I
in	O
primary	B-P
care	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
of	I-P
at	I-P
least	I-P
6	I-P
weeks	I-P
duration	I-P
:	I-P
a	O
randomised	O
(	O
unblinded	O
)	O
controlled	O
trial	O
.	O


OBJECTIVES	O
To	O
test	O
the	O
hypotheses	O
that	O
:	O
(	O
1	O
)	O
Lumbar	O
spine	O
radiography	O
in	O
primary	B-P
care	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
is	O
not	O
associated	O
with	O
improved	O
patient	O
outcomes	O
,	O
including	O
pain	B-O
,	I-O
disability	I-O
,	I-O
health	I-O
status	I-O
,	I-O
sickness	I-O
absence	I-O
,	I-O
reassurance	I-O
,	O
and	O
patient	O
satisfaction	B-O
or	O
belief	B-O
in	O
the	O
value	O
of	O
radiography	O
.	O


(	O
2	O
)	O
Lumbar	B-I
spine	I-I
radiography	I-I
in	O
primary	B-P
care	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
is	O
not	O
associated	O
with	O
changes	O
in	O
patient	O
management	O
,	O
including	O
medication	O
use	O
,	O
and	O
the	O
use	O
of	O
primary	O
and	O
secondary	O
care	O
services	O
,	O
physical	O
therapies	O
and	O
complementary	O
therapies	O
.	O


(	O
3	O
)	O
Participants	O
choosing	O
their	O
treatment	O
group	O
(	O
i.e	O
.	O


radiography	B-I
or	O
no	B-I
radiography	I-I
)	I-I
do	O
not	O
have	O
better	O
outcomes	O
than	O
those	O
randomised	O
to	O
a	O
treatment	O
group	O
.	O


(	O
4	O
)	O
Lumbar	O
spine	O
radiography	O
is	O
not	O
cost-effective	O
compared	O
with	O
usual	O
care	O
without	O
lumbar	O
spine	O
radiography	O
.	O


DESIGN	O
A	O
randomised	O
unblinded	O
controlled	O
trial	O
.	O


SETTING	O
Seventy-three	B-P
general	I-P
practices	I-P
in	I-P
Nottingham	I-P
,	I-P
North	I-P
Nottinghamshire	I-P
,	I-P
Southern	I-P
Derbyshire	I-P
,	I-P
North	I-P
Lincolnshire	I-P
and	I-P
North	I-P
Leicestershire	I-P
.	I-P


Fifty-two	B-P
practices	I-P
recruited	I-P
participants	I-P
to	I-P
the	I-P
trial	I-P
.	I-P


SUBJECTS	O
Randomised	O
arm	O
:	O
421	B-P
participants	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
,	I-P
with	I-P
median	I-P
duration	I-P
of	I-P
10	I-P
weeks	I-P
.	I-P


Patient	O
preference	O
arm	O
:	O
55	B-P
participants	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
,	I-P
with	I-P
median	I-P
duration	I-P
of	I-P
11	I-P
weeks	I-P
.	I-P


INTERVENTION	O
Lumbar	B-I
spine	I-I
radiography	I-I
and	I-I
usual	I-I
care	I-I
versus	I-I
usual	I-I
care	I-I
without	I-I
radiography	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Roland	B-O
adaptation	I-O
of	I-O
the	I-O
Sickness	I-O
Impact	I-O
Profile	I-O
,	I-O
visual	I-O
analogue	I-O
pain	I-O
scale	I-O
,	I-O
health	I-O
status	I-O
scale	I-O
,	I-O
EuroQol	I-O
,	I-O
use	I-O
of	I-O
primary	I-O
and	I-O
secondary	I-O
care	I-O
services	I-O
,	I-O
and	I-O
physical	I-O
and	I-O
complementary	I-O
therapies	I-O
,	I-O
sickness	I-O
absence	I-O
,	I-O
medication	I-O
use	I-O
,	I-O
patient	I-O
satisfaction	I-O
,	I-O
reassurance	I-O
and	I-O
belief	I-O
in	I-O
value	I-O
of	I-O
radiography	I-O
at	O
3	O
and	O
9	O
months	O
post-randomisation	O
.	O


RESULTS	O
Participants	O
randomised	O
to	O
receive	O
an	O
X-ray	O
were	O
more	O
likely	O
to	O
report	O
low	B-O
back	I-O
pain	I-O
at	O
3	O
months	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.56	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
1.02	O
to	O
2.40	O
)	O
and	O
had	O
a	O
lower	O
overall	O
health	B-O
status	I-O
score	O
(	O
p	O
=	O
0.02	O
)	O
.	O


There	O
were	O
no	O
differences	O
in	O
health	B-O
or	O
functional	B-O
status	I-O
at	O
9	O
months	O
.	O


A	O
higher	O
proportion	O
of	O
participants	O
consulted	B-O
the	I-O
general	I-O
practitioner	I-O
(	I-O
GP	I-O
)	I-O
in	O
the	O
3	O
months	O
following	O
an	O
X-ray	O
(	O
OR	O
=	O
2.72	O
;	O
95	O
%	O
CI	O
,	O
1.80	O
to	O
4.10	O
)	O
.	O


There	O
were	O
no	O
differences	O
in	O
use	O
of	O
any	B-O
other	I-O
services	I-O
,	I-O
medication	I-O
use	I-O
or	O
sickness	B-O
absence	I-O
at	O
3	O
or	O
9	O
months	O
.	O


No	O
serious	B-O
spinal	I-O
pathology	I-O
was	O
identified	O
in	O
either	O
group	O
.	O


The	O
commonest	O
X-ray	O
reports	O
were	O
of	O
discovertebral	B-O
degeneration	I-O
and	O
normal	B-O
findings	I-O
.	I-O


Many	O
patients	O
did	O
not	O
perceive	O
their	O
information	O
needs	O
were	O
met	O
within	O
the	O
consultation	O
.	O


Satisfaction	B-O
with	O
care	O
was	O
greater	O
in	O
the	O
group	O
receiving	O
radiography	O
at	O
9	O
months	O
.	O


Participants	O
randomised	O
to	O
receive	O
an	O
X-ray	B-I
were	O
not	O
less	O
worried	B-O
,	O
or	O
more	O
reassured	B-O
about	O
serious	O
disease	O
causing	O
their	O
low	O
back	O
pain	O
.	O


Satisfaction	O
was	O
associated	O
with	O
meeting	O
participants	O
'	O
information	O
needs	O
and	O
reduced	O
belief	O
in	O
the	O
necessity	O
for	O
investigations	O
for	O
low	O
back	O
pain	O
,	O
including	O
X-rays	O
and	O
blood	O
tests	O
.	O


In	O
both	O
groups	O
,	O
at	O
3	O
and	O
9	O
months	O
80	O
%	O
of	O
participants	O
would	O
choose	O
to	O
have	O
an	O
X-ray	O
if	O
the	O
choice	O
was	O
available	O
.	O


Participants	O
in	O
the	O
patient	O
preference	O
group	O
achieved	O
marginally	O
better	O
outcomes	B-O
than	O
those	O
randomised	O
to	O
a	O
treatment	O
group	O
,	O
but	O
the	O
clinical	O
significance	O
of	O
these	O
differences	O
is	O
unclear	O
.	O


Lumbar	O
spine	O
radiography	O
was	O
associated	O
with	O
a	O
net	O
economic	B-O
loss	I-O
at	O
3	O
and	O
9	O
months	O
.	O


CONCLUSIONS	O
Lumbar	O
spine	O
radiography	O
in	O
primary	O
care	O
patients	O
with	O
low	O
back	O
pain	O
of	O
at	O
least	O
6	O
weeks	O
duration	O
is	O
not	O
associated	O
with	O
improved	O
functioning	B-O
,	I-O
severity	I-O
of	I-O
pain	I-O
or	O
overall	B-O
health	I-O
status	I-O
,	O
and	O
is	O
associated	O
with	O
an	O
increase	O
in	O
GP	B-O
workload	I-O
.	I-O


Participants	O
receiving	O
X-rays	O
are	O
more	O
satisfied	O
with	O
their	O
care	O
,	O
but	O
are	O
not	O
less	O
worried	O
or	O
more	O
reassured	O
about	O
serious	O
disease	O
causing	O
their	O
low	O
back	O
pain	O
.	O


CONCLUSIONS	O
-	O
RECOMMENDATIONS	O
FOR	O
FURTHER	O
RESEARCH	O
:	O
Further	O
work	O
is	O
required	O
to	O
develop	O
and	O
test	O
an	O
educational	O
package	O
that	O
educates	O
patients	O
and	O
GPs	O
about	O
the	O
utility	O
of	O
radiography	O
and	O
provides	O
strategies	O
for	O
identifying	O
and	O
meeting	O
the	O
information	O
needs	O
of	O
patients	O
,	O
and	O
the	O
needs	O
of	O
patients	O
and	O
GPs	O
to	O
be	O
reassured	O
about	O
missing	O
serious	O
disease	O
.	O


Guidelines	O
on	O
the	O
management	O
of	O
low	O
back	O
pain	O
in	O
primary	O
care	O
should	O
be	O
consistent	O
about	O
not	O
recommending	O
lumbar	B-I
spine	I-I
radiography	I-I
in	O
patients	O
with	O
low	O
back	O
pain	O
in	O
the	O
absence	O
of	O
red	O
flags	O
for	O
serious	O
spinal	O
pathology	O
,	O
even	O
if	O
the	O
pain	O
has	O
persisted	O
for	O
at	O
least	O
6	O
weeks	O
.	O


Comparison	O
of	O
the	O
effect	O
of	O
gonadotropin-releasing	B-I
hormone	I-I
analog	I-I
(	I-I
Diphereline	I-I
)	I-I
and	O
Cabergoline	B-I
(	I-I
Dostinex	I-I
)	I-I
treatment	O
on	O
uterine	B-P
myoma	I-P
regression	I-P
.	I-P


OBJECTIVE	O
To	O
investigate	O
the	O
effect	O
of	O
cabergoline	B-I
(	I-I
Dostinex	I-I
,	I-I
a	I-I
dopamine	I-I
agonist	I-I
)	I-I
on	O
the	O
myoma	O
growth	O
compared	O
to	O
Diphereline	B-I
(	I-I
a	I-I
gonadotropin-releasing	I-I
hormone	I-I
agonist	I-I
)	I-I
.	I-I


METHODS	O
This	B-P
study	I-P
took	I-P
place	I-P
in	I-P
the	I-P
Department	I-P
of	I-P
Obstetrics	I-P
and	I-P
Gynecology	I-P
of	I-P
Tabriz	I-P
University	I-P
of	I-P
Medical	I-P
Sciences	I-P
,	I-P
Tabriz	I-P
,	I-P
Iran	I-P
from	I-P
July	I-P
2004	I-P
to	I-P
December	I-P
2005	I-P
.	I-P


Fifty	B-P
women	I-P
with	I-P
uterine	I-P
myoma	I-P
,	I-P
who	I-P
met	I-P
the	I-P
criteria	I-P
of	I-P
the	I-P
study	I-P
thoroughly	I-P
,	O
were	O
randomly	O
allocated	O
into	O
2	O
equal	O
groups	O
to	O
take	O
either	O
Diphereline	B-I
or	O
Cabergoline	B-I
.	I-I


The	O
first	O
Group	O
took	O
3.75	O
mg	O
of	O
Diphereline	B-I
4	O
times	O
every	O
28	O
days	O
and	O
the	O
second	O
group	O
took	O
0.5	O
mg	O
of	O
Cabergoline	B-I
once	O
a	O
week	O
for	O
6	O
weeks	O
.	O


RESULTS	O
The	O
Cabergoline	B-I
was	O
well	B-O
tolerated	I-O
and	O
fewer	B-O
adverse	I-O
effects	I-O
were	O
noted	O
.	O


The	O
tumor	B-O
regressed	I-O
significantly	I-O
and	O
volume	B-O
reduction	I-O
rate	I-O
of	I-O
individual	I-O
tumor	I-O
nodule	I-O
varied	O
from	O
46-53	O
%	O
.	O


The	O
gonadotropin	B-I
releasing	I-I
hormone	I-I
agonist	I-I
group	O
all	O
responded	O
to	O
the	O
treatment	O
,	O
and	O
volume	B-O
reduction	I-O
rate	I-O
of	O
the	O
individual	O
tumor	O
nodule	O
varied	O
from	O
21-97	O
%	O
.	O


The	O
extent	O
of	O
tumor	B-O
shrinkage	I-O
was	O
positively	O
correlated	O
to	O
the	O
number	B-O
of	I-O
nodules	I-O
(	O
p=0.881	O
,	O
p	O
<	O
0.005	O
and	O
0.701	O
,	O
p	O
<	O
0.005	O
)	O
.	O


CONCLUSION	O
In	O
light	O
of	O
therapeutic	O
efficacy	O
and	O
few	O
adverse	O
effects	O
,	O
the	O
dopamine	B-I
agonists	I-I
may	O
hold	O
promise	O
as	O
novel	O
treatment	O
modalities	O
for	O
leiomyoma	O
.	O


Further	O
studies	O
are	O
warranted	O
to	O
determine	O
the	O
optimal	O
strategy	O
for	O
the	O
treatment	O
of	O
leiomyoma	O
through	O
these	O
agents	O
.	O


A	O
feasibility	O
study	O
for	O
a	O
randomised	O
controlled	O
trial	O
of	O
treatment	O
withdrawal	O
in	O
psoriatic	B-P
arthritis	I-P
(	O
REmoval	O
of	O
treatment	O
for	O
patients	B-P
in	O
REmission	O
in	O
psoriatic	O
ArThritis	O
(	O
RETREAT	O
(	O
F	O
)	O
)	O
.	O


TNF	O
therapy	O
is	O
effective	O
for	O
all	O
aspects	O
of	O
psoriatic	O
disease	O
,	O
but	O
these	O
drugs	O
are	O
costly	O
and	O
the	O
long-term	O
effects	O
are	O
unknown	O
.	O


Further	O
,	O
methotrexate	O
causes	O
concern	O
with	O
long-term	O
adverse	O
events	O
.	O


The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
test	B-O
the	I-O
feasibility	I-O
of	O
drug	B-I
withdrawal	I-I
from	O
patients	B-P
with	I-P
psoriatic	I-P
arthritis	I-P
,	I-P
in	I-P
stable	I-P
low	I-P
disease	I-P
state	I-P
.	I-P


We	O
examined	O
the	O
availability	B-O
of	I-O
patients	I-O
,	I-O
their	I-O
willingness	I-O
to	I-O
participate	I-O
,	I-O
study	I-O
procedures	I-O
,	I-O
and	I-O
the	I-O
proportion	I-O
of	I-O
patients	I-O
in	I-O
the	I-O
withdrawal	I-O
arm	I-O
who	I-O
relapsed	I-O
during	O
the	O
study	O
.	O


Low	O
disease	O
state	O
was	O
defined	O
by	O
minimal	O
disease	O
activity	O
criteria	O
(	O
MDA	O
)	O
,	O
and	O
relapse	O
by	O
failure	O
to	O
achieve	O
these	O
criteria	O
.	O


Patients	O
in	O
the	O
withdrawal	O
group	O
underwent	O
a	O
phased	B-I
withdrawal	I-I
of	I-I
medication	I-I
where	O
the	O
last	O
treatment	O
added	O
was	O
the	O
first	O
withdrawn	B-I
.	I-I


Assessments	B-O
were	O
monthly	O
for	O
3	O
months	O
before	O
study	O
exit	O
.	O


Seventy-two	B-P
patients	I-P
were	I-P
invited	I-P
to	I-P
participate	I-P
,	I-P
of	I-P
which	I-P
57	I-P
were	I-P
found	I-P
to	I-P
be	I-P
eligible	I-P
.	I-P


Twenty-six	O
(	O
36.1	O
%	O
)	O
subsequently	O
attended	O
the	O
screening	O
visit	O
but	O
9	O
failed	O
eligibility	O
criteria	O
so	O
that	O
17	O
patients	O
(	O
29.8	O
%	O
of	O
the	O
57	O
eligible	O
patients	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
18.4	O
,	O
43.4	O
%	O
)	O
were	O
randomised	O
at	O
a	O
ratio	O
of	O
2:1	O
in	O
favour	O
of	O
the	O
withdrawal	B-I
arm	I-I
(	O
11	O
withdrawals	O
,	O
6	O
standard	O
care	O
)	O
.	O


Six	O
patients	O
experienced	O
a	O
flare	B-O
,	O
all	O
of	O
whom	O
were	O
in	O
the	O
withdrawal	B-I
arm	I-I
(	O
relapse	O
rate	O
54.6	O
%	O
,	O
95	O
%	O
CI	O
23.4	O
,	O
83.3	O
%	O
)	O
.	O


Four	O
of	O
the	O
flares	O
were	O
apparent	O
from	O
visit	O
3	O
(	O
8	O
weeks	O
after	O
starting	O
withdrawal	B-I
)	I-I
.	O


Given	O
the	O
high	O
relapse	B-O
rate	I-O
,	O
an	O
alternative	O
trial	O
design	O
of	O
partial	O
treatment	O
withdrawal	O
,	O
possibly	O
including	O
a	O
patient	O
preference	O
arm	O
,	O
is	O
recommended	O
.	O


Histopathologic	B-O
changes	I-O
of	I-O
the	I-O
eyelid	I-O
skin	I-O
following	I-P
trichloroacetic	I-I
acid	I-I
chemical	I-I
peel	I-I
.	I-I


The	O
use	O
of	O
trichloroacetic	B-I
acid	I-I
(	I-I
TCA	I-I
)	I-I
as	O
a	O
periorbital	O
and	O
eyelid	O
peel	O
for	O
skin	O
rejuvenation	O
is	O
gaining	O
significant	O
acceptance	O
among	O
oculoplastic	O
surgeons	O
,	O
dermatologists	O
,	O
and	O
other	O
surgery	O
groups	O
.	O


In	O
spite	O
of	O
the	O
current	O
enthusiasm	O
,	O
there	O
remain	O
potentially	O
serious	O
complications	O
resulting	O
from	O
any	O
periorbital	O
peel	O
.	O


Cases	O
of	O
cicatricial	O
ectropion	O
have	O
been	O
reported	O
in	O
phenol-peeled	B-P
patients	I-P
,	O
and	O
lower	O
eyelid	O
ectropion	O
has	O
reportedly	O
occurred	O
in	O
patients	B-P
undergoing	I-P
deep	I-P
eyelid	I-P
peel	I-P
in	I-P
conjunction	I-P
with	I-P
a	I-P
blepharoplasty	I-I
(	O
1,2	O
)	O
.	O


To	O
avoid	O
this	O
complication	O
,	O
it	O
is	O
necessary	O
to	O
better	O
understand	O
the	O
depth	O
of	O
the	O
wound	O
produced	O
by	O
different	O
strengths	O
and	O
combinations	O
of	O
peeling	O
agents	O
applied	O
to	O
living	O
eyelid	O
tissue	O
and	O
,	O
more	O
important	O
,	O
to	O
determine	O
the	O
concentrations	O
of	O
TCA	B-I
that	O
are	O
likely	O
to	O
lead	O
to	O
cicatricial	O
ectropion	O
when	O
applied	O
in	O
a	O
consistent	O
fashion	O
.	O


We	O
chose	O
upper-eyelid	O
skin	O
because	O
it	O
is	O
easier	O
to	O
obtain	O
for	O
histopathologic	O
study	O
than	O
lower-eyelid	O
skin	O
and	O
,	O
in	O
our	O
experience	O
,	O
is	O
more	O
sensitive	O
to	O
hypertrophic	O
changes	O
after	O
chemical	O
peeling	O
or	O
carbon	O
dioxide	O
laser	O
resurfacing	O
.	O


We	O
applied	O
TCA	B-I
to	O
the	O
preseptal	O
skin	O
of	O
10	B-P
patients	I-P
48	O
h	O
before	O
standard	B-P
upper-eyelid	I-P
blepharoplasty	I-P
.	I-P


The	O
acid	O
was	O
applied	O
to	O
produce	O
a	O
"	O
frost	O
,	O
"	O
using	O
varying	O
concentrations	O
of	O
acid	O
,	O
ranging	O
from	O
20	O
to	O
50	O
%	O
.	O


The	O
treated	O
skin	O
removed	O
at	O
the	O
time	O
of	O
blepharoplasty	O
was	O
reviewed	O
in	O
a	O
masked	O
fashion	O
by	O
a	O
dermatopathologist	O
to	O
determine	O
the	O
depth	O
of	O
necrosis	O
.	O


We	O
found	O
that	O
superficial	B-O
peels	I-O
with	I-O
necrosis	I-O
involving	O
30	O
%	O
of	O
the	O
epidermis	O
were	O
produced	O
by	O
the	O
lowest-concentration	O
combination	O
of	O
TCA	B-I
applied	I-O
(	O
20	O
%	O
followed	O
by	O
0	O
%	O
)	O
.	O


As	O
the	O
strength	B-O
increased	I-O
,	O
so	O
did	O
the	O
depth	O
of	O
peel	O
.	O


The	O
combination	O
of	O
50	O
%	O
followed	O
by	O
a	O
second	O
application	O
of	O
50	O
%	O
produced	O
the	O
deepest	B-O
peel	I-O
,	O
with	O
necrosis	O
into	O
the	O
papillary	O
dermis	O
.	O


This	O
finding	O
would	O
indicate	O
that	O
the	O
chance	O
of	O
developing	O
cicatricial	O
ectropion	O
with	O
any	O
of	O
the	O
tested	O
combinations	O
of	O
TCA	B-I
should	O
be	O
very	O
remote	O
.	O


Interview	O
skills	O
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
pilot	O
randomized	O
controlled	O
trial	O
.	O


The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
interview	B-I
skills	I-I
curriculum	I-I
(	I-I
ISC	I-I
)	I-I
,	O
a	O
manualized	O
12-week	O
group-delivered	O
intervention	O
for	O
young	B-P
adults	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


This	O
intervention	O
aims	O
to	O
increase	O
social-pragmatic	O
skills	O
essential	O
to	O
a	O
successful	O
job	O
interview	O
.	O


Twenty-eight	B-P
adults	I-P
(	I-P
18-36	I-P
years	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
:	O
ISC	B-I
or	O
waitlist	B-I
control	I-I
.	I-I


Results	O
revealed	O
that	O
the	O
experimental	O
group	O
showed	O
larger	O
gains	O
in	O
social-pragmatic	B-O
skills	I-O
observed	O
during	O
a	O
mock	O
job	O
interview	O
than	O
the	O
control	O
group	O
.	O


Treatment	O
effects	O
on	O
distal	O
outcomes	O
,	O
including	O
social	B-O
adaptive	I-O
behaviors	I-O
and	I-O
depressive	I-O
symptoms	I-O
were	O
not	O
significant	O
,	O
although	O
the	O
respective	O
effect	O
sizes	O
were	O
medium/large	O
.	O


Results	O
indicate	O
that	O
a	O
brief	O
,	O
low-intensity	O
treatment	O
can	O
improve	O
the	O
job-interview	B-O
performance	I-O
of	O
young	B-P
adults	I-P
with	I-P
ASD	I-P
.	I-P


Comparison	O
of	O
different	O
long-term	O
asthma	O
treatments	O
in	O
subjects	B-P
with	I-P
mild-to-moderate	I-P
asthma	I-P
.	I-P


In	O
order	O
to	O
compare	O
the	O
efficacy	O
of	O
different	O
asthma	O
treatment	O
in	O
subjects	B-P
with	I-P
mild-to-moderate	I-P
asthma	I-P
,	I-P
three	I-P
groups	I-P
of	I-P
11	I-P
patients	I-P
were	O
treated	O
with	O
nedocromil	B-I
sodium	I-I
(	I-I
NS	I-I
)	I-I
,	I-I
beclomethasone	I-I
dipropionate	I-I
(	I-I
BDP	I-I
)	I-I
and	I-I
beclomethasone	I-I
dipropionate	I-I
plus	I-I
salmeterol	I-I
(	I-I
BDP	I-I
+	I-I
S	I-I
)	I-I
in	O
an	O
open	O
,	O
randomized	O
study	O
.	O


Symptom	O
score	O
,	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
maximal	O
amplitude	O
,	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
,	O
and	O
methacholine	O
reactivity	O
were	O
measured	O
at	O
the	O
baseline	O
and	O
at	O
intervals	O
of	O
3	O
months	O
up	O
to	O
12	O
months	O
.	O


After	O
3	O
months	O
,	O
symptoms	O
reduced	O
significantly	O
in	O
all	O
treatment	O
groups	O
,	O
while	O
PEF	O
variability	O
improved	O
in	O
BDP	O
and	O
BDP	O
+	O
S	O
groups	O
;	O
FEV1	O
and	O
bronchial	O
responsiveness	O
to	O
methacholine	O
were	O
significantly	O
improved	O
in	O
comparison	O
with	O
baseline	O
value	O
in	O
the	O
BDP	O
+	O
S	O
group	O
only	O
.	O


No	B-O
significant	I-O
difference	I-O
was	I-O
observed	I-O
after	I-O
6	I-O
and	I-O
12	I-O
months	I-O
of	I-O
treatment	I-O
in	I-O
PEF	I-O
variability	I-O
,	I-O
FEV1	I-O
or	I-O
bronchial	I-O
hyperreactivity	I-O
in	I-O
the	I-O
NS	I-O
group	I-O
compared	I-O
with	I-O
baseline	I-O
values	I-O
,	I-O
while	I-O
a	I-O
significant	I-O
difference	I-O
was	I-O
observed	I-O
in	I-O
symptom	I-O
score	I-O
.	I-O


BDP	B-O
group	I-O
showed	I-O
a	I-O
significant	I-O
improvement	I-O
in	I-O
FEV1	I-O
and	I-O
bronchial	I-O
reactivity	I-O
to	I-O
methacholine	I-O
after	I-O
6	I-O
and	I-O
12	I-O
months	I-O
of	I-O
treatment	I-O
.	I-O


In	B-O
the	I-O
BDP	I-O
+	I-O
S	I-O
group	I-O
,	I-O
the	I-O
improvement	I-O
in	I-O
symptoms	I-O
and	I-O
pulmonary	I-O
function	I-O
persisted	I-O
until	I-O
the	I-O
end	I-O
of	I-O
the	I-O
study	I-O
.	I-O


In	O
conclusion	O
,	O
the	B-O
combination	I-O
of	I-O
beclomethasone	I-O
dipropionate	I-O
and	I-O
salmeterol	I-O
improved	I-O
pulmonary	I-O
function	I-O
and	I-O
bronchial	I-O
reactivity	I-O
earlier	I-O
than	I-O
beclomethasone	I-O
dipropionate	I-O
alone	I-O
,	I-O
while	I-O
nedocromil	I-O
sodium	I-O
improved	I-O
symptoms	I-O
but	I-O
not	I-O
pulmonary	I-O
function	I-O
.	I-O


Assuming	O
that	O
bronchial	B-O
reactivity	I-O
could	O
be	O
an	O
indirect	O
measurement	O
of	O
airway	O
inflammation	O
,	O
overtreatment	B-O
of	I-O
asthma	I-O
in	I-O
relationship	I-O
with	I-O
the	I-O
classification	I-O
of	I-O
asthma	I-O
severity	I-O
of	I-O
the	I-O
International	I-O
Guidelines	I-O
could	I-O
improve	I-O
both	I-O
airway	I-O
inflammation	I-O
and	I-O
the	I-O
prognosis	I-O
of	I-O
airway	I-O
obstruction	I-O
.	I-O


Effects	O
of	O
a	O
chlorhexidine	B-I
varnish	I-I
on	O
the	O
gingival	B-O
status	I-O
of	I-P
adolescents	I-P
.	I-P


The	O
purpose	O
of	O
this	O
blind	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
a	O
two-stage	O
chlorhexidine	B-I
varnish	I-I
,	O
after	O
three	O
months	O
,	O
on	O
the	O
gingival	B-P
status	I-P
of	I-P
11-	I-P
to	I-P
15-year-old	I-P
children	I-P
attending	I-P
a	I-P
school	I-P
in	I-P
Rio	I-P
de	I-P
Janeiro	I-P
,	I-P
Brazil	I-P
.	I-P


Subjects	O
participating	O
in	O
the	O
study	O
were	O
randomly	O
allocated	O
to	O
control	B-P
(	I-P
C	I-P
)	I-P
and	I-P
treatment	I-P
(	I-P
T	I-P
)	I-P
groups	I-P
,	I-P
n	I-P
=	I-P
53	I-P
and	I-P
n	I-P
=	I-P
57	I-P
,	O
respectively	O
.	O


All	O
subjects	B-P
were	O
matched	B-P
at	I-P
baseline	I-P
on	I-P
age	I-P
,	I-P
salivary	I-P
levels	I-P
of	I-P
mutans	I-P
streptococci	I-P
,	I-P
and	I-P
caries	I-P
scores	I-P
.	I-P


After	O
elimination	O
of	O
carious	O
lesions	O
,	O
a	O
prophylaxis	B-I
was	O
given	O
to	O
both	O
groups	O
.	O


The	O
chlorhexidine	B-I
varnish	I-I
was	O
then	O
painted	O
on	O
the	O
entire	O
dentition	O
of	O
Group	O
T	O
subjects	O
only	O
.	O


Prior	O
to	O
caries	O
elimination	O
,	O
and	O
again	O
after	O
three	O
months	O
,	O
the	O
gingival	O
index	O
was	O
used	O
to	O
assess	O
the	O
gingival	B-O
status	I-O
of	O
study	O
subjects	O
.	O


An	O
average	O
of	O
106.6	O
+/-	O
8.9	O
and	O
107.7	O
+/-	O
6.2	O
gingival	O
sites	O
per	O
subject	O
(	O
four	O
sites	O
per	O
tooth	O
)	O
in	O
Groups	O
C	O
and	O
T	O
,	O
respectively	O
,	O
were	O
examined	O
by	O
the	O
same	O
calibrated	O
examiner	O
on	O
two	O
occasions	O
.	O


For	O
statistical	O
purposes	O
,	O
data	O
were	O
dichotomized	O
[	O
(	O
0,1	O
)	O
(	O
2,3	O
)	O
]	O
for	O
the	O
gingival	O
index	O
.	O


Independent	O
t-tests	O
and	O
paired	O
t-tests	O
were	O
used	O
to	O
analyze	O
the	O
data	O
.	O


The	O
percentage	B-O
of	I-O
sites	I-O
per	I-O
subject	I-O
with	I-O
scores	I-O
of	I-O
two	I-O
or	I-O
three	I-O
at	O
the	O
baseline	O
were	O
balanced	O
between	O
study	O
groups	O
(	O
3.7	O
+/-	O
7.1	O
for	O
T	O
;	O
1.8	O
+/-	O
3.2	O
for	O
C	O
;	O
p	O
=	O
0.08	O
)	O
.	O


After	O
three	O
months	O
,	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
average	O
percentage	B-O
of	I-O
sites	I-O
with	I-O
scores	I-O
of	I-O
two	I-O
or	I-O
three	I-O
was	O
demonstrated	O
in	O
the	O
T	O
group	O
(	O
0.7	O
+/-	O
2.4	O
,	O
T	O
,	O
p	O
<	O
0.0001	O
;	O
1.3	O
+/-	O
3.0	O
,	O
C	O
,	O
p	O
<	O
0.25	O
)	O
.	O


The	O
authors	O
concluded	O
that	O
the	O
application	O
of	O
a	O
chlorhexidine	B-I
varnish	I-I
significantly	O
improved	O
the	O
gingival	B-O
health	I-O
of	O
T	O
subjects	O
for	O
up	O
to	O
three	O
months	O
.	O


A	O
significant	O
improvement	O
in	O
the	O
gingival	B-O
health	I-O
could	O
not	O
be	O
demonstrated	O
in	O
the	O
C	O
group	O
.	O


Matching	O
doses	O
of	O
distraction	O
with	O
child	B-P
risk	I-P
for	I-P
distress	I-P
during	O
a	O
medical	O
procedure	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
Parents	O
often	O
want	O
to	O
provide	O
support	O
to	O
their	O
children	O
during	O
medical	O
procedures	O
,	O
but	O
not	O
all	O
parents	O
are	O
effective	O
in	O
providing	O
distraction	O
after	O
brief	O
training	O
.	O


OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
three	O
doses	B-I
of	I-I
distraction	I-I
intervention	I-I
for	O
children	B-P
at	I-P
high	I-P
and	I-P
medium	I-P
risk	I-P
for	I-P
procedure-related	I-P
distress	I-P
.	I-P


METHODS	O
Children	B-P
undergoing	I-P
scheduled	I-P
intravenous	I-P
insertions	I-P
for	I-P
diagnostic	I-P
or	I-P
treatment	I-P
purposes	I-P
and	I-P
their	I-P
parents	I-P
participated	I-P
.	I-P


A	O
computerized	O
application	O
,	O
Children	O
,	O
Parents	O
and	O
Distraction	O
,	O
was	O
used	O
to	O
predict	O
distress	O
risk	O
.	O


Doses	B-I
of	I-I
intervention	I-I
were	O
basic	O
(	B-I
parents	I-I
trained	I-I
on	I-I
providing	I-I
distraction	I-I
)	I-I
,	O
enhanced	O
(	B-I
basic	I-I
training	I-I
plus	I-I
tailored	I-I
instructions	I-I
,	I-I
environmental	I-I
modifications	I-I
,	I-I
and	I-I
support	I-I
and	I-I
guidance	I-I
from	I-I
the	I-I
research	I-I
assistant	I-I
)	I-I
,	O
and	O
professional	O
(	B-I
a	I-I
trained	I-I
research	I-I
assistant	I-I
provided	I-I
distraction	I-I
)	I-I
.	O


Outcome	O
measures	O
were	O
Observational	B-O
Scale	I-O
of	I-O
Behavioral	I-O
Distress-Revised	I-O
for	I-O
behavioral	I-O
distress	I-O
,	I-O
Oucher	I-O
for	I-O
self-reported	I-O
pain	I-O
,	I-O
parent	I-O
report	I-O
of	I-O
child	I-O
distress	I-O
,	I-O
and	I-O
salivary	I-O
cortisol	I-O
for	I-O
physiological	I-O
distress	I-O
.	I-O


RESULTS	O
A	B-P
total	I-P
of	I-P
574	I-P
children	I-P
,	I-P
ages	I-P
4-10	I-P
,	I-P
and	I-P
their	I-P
parents	I-P
participated	I-P
.	I-P


The	O
Children	O
,	O
Parents	O
and	O
Distraction	O
predicted	O
that	O
the	O
risk	B-O
for	I-O
distress	I-O
was	O
high	O
for	O
156	O
children	O
,	O
medium	O
for	O
372	O
,	O
and	O
low	O
for	O
46	O
.	O


Children	O
predicted	O
to	O
have	O
higher	O
risk	O
for	O
distress	O
displayed	O
more	O
behavioral	B-O
distress	I-O
(	O
p	O
<	O
.01	O
)	O
.	O


Children	O
in	O
the	O
medium-risk	O
group	O
who	O
had	O
the	O
professional	O
intervention	O
displayed	O
significantly	O
less	O
behavioral	B-O
distress	I-O
(	O
p	O
<	O
.001	O
)	O
.	O


Children	O
in	O
the	O
high-risk	O
group	O
tended	O
to	O
have	O
less	O
behavioral	O
distress	O
when	O
receiving	O
the	O
professional	O
intervention	O
(	O
p	O
=	O
.07	O
)	O
.	O


There	O
were	O
no	O
significant	O
group	O
differences	O
for	O
self-report	B-O
of	I-O
pain	I-O
,	I-O
parent	I-O
report	I-O
of	I-O
distress	I-O
,	I-O
or	I-O
cortisol	I-O
levels	I-O
.	I-O


DISCUSSION	O
Some	O
parents	O
may	O
need	O
additional	O
training	O
in	O
providing	O
distraction	O
to	O
their	O
children	O
during	O
procedures	O
,	O
and	O
some	O
children	B-P
at	I-P
medium	I-P
and	I-P
high	I-P
risk	I-P
for	I-P
distress	I-P
may	O
need	O
professional	O
support	O
.	O


Parents	O
should	O
be	O
asked	O
about	O
their	O
preferences	O
in	O
acting	O
as	O
the	O
distraction	O
coach	O
and	O
,	O
if	O
willing	O
,	O
be	O
provided	O
as	O
much	O
training	O
and	O
support	O
as	O
possible	O
in	O
the	O
clinical	O
situation	O
.	O


Clinical	O
impact	O
of	O
leak	O
compensation	O
during	O
non-invasive	O
ventilation	O
.	O


BACKGROUND	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
leak	O
compensation	O
capabilities	O
during	O
pressure-	B-I
and	I-I
volume-limited	I-I
non-invasive	I-I
positive-pressure	I-I
ventilation	I-I
(	I-I
NPPV	I-I
)	I-I
in	O
COPD	O
patients	O
.	O


METHODS	O
Fourteen	B-P
patients	I-P
with	I-P
stable	I-P
hypercapnic	I-P
COPD	I-P
who	I-P
were	I-P
receiving	I-P
long-term	I-P
NPPV	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


For	O
both	O
modes	O
of	O
NPPV	O
,	O
a	O
full	B-I
face	I-I
mask	I-I
and	I-I
an	I-I
artificial	I-I
leak	I-I
in	I-I
the	I-I
ventilatory	I-I
circuit	I-I
were	O
used	O
at	O
three	O
different	O
settings	O
,	O
and	O
applied	O
during	O
daytime	O
NPPV	O
,	O
either	B-I
without	I-I
leakage	I-I
(	I-I
setting	I-I
I	I-I
)	I-I
,	I-I
with	I-I
leakage	I-I
during	I-I
inspiration	I-I
only	I-I
(	I-I
setting	I-I
II	I-I
)	I-I
,	I-I
and	I-I
with	I-I
leakage	I-I
during	I-I
inspiration	I-I
and	I-I
expiration	I-I
(	I-I
setting	I-I
III	I-I
)	I-I
.	I-I


Ventilation	B-O
pattern	I-O
was	O
pneumotachy-graphically	O
recorded	O
.	O


RESULTS	O
NPPV	O
was	O
feasible	O
with	O
negligible	O
leak	B-O
volumes	I-O
,	O
indicating	O
optimal	O
mask	O
fitting	O
during	O
the	O
daytime	O
(	O
setting	O
I	O
)	O
.	O


In	O
the	O
presence	O
of	O
leakage	B-O
(	O
settings	O
II	O
and	O
III	O
)	O
,	O
the	O
attempt	O
to	O
compensate	O
for	O
leak	O
was	O
only	O
evident	O
during	O
pressure-limited	O
NPPV	O
,	O
since	O
inspiratory	B-O
volumes	I-O
delivered	I-O
by	I-O
the	I-O
ventilator	I-O
increased	O
from	O
726+/-129	O
(	O
setting	O
I	O
)	O
to	O
1104+/-164	O
(	O
setting	O
II	O
)	O
,	O
and	O
to	O
1257+/-166	O
(	O
setting	O
III	O
)	O
ml	O
during	O
pressure-limited	O
NPPV	O
,	O
respectively	O
(	O
all	O
p	O
<	O
0.001	O
)	O
;	O
however	O
,	O
they	O
remained	O
stable	O
during	O
volume-limited	O
NPPV	O
.	O


Leak	O
compensation	O
resulted	O
in	O
a	O
decrease	O
in	O
leakage-induced	B-O
dyspnea	I-O
.	I-O


However	O
,	O
83	O
%	O
/87	O
%	O
(	O
setting	O
II/III	O
)	O
of	O
the	O
additionally-delivered	O
inspiratory	O
volume	O
during	O
pressure-limited	O
NPPV	O
was	O
also	O
lost	O
via	O
leakage	O
.	O


Expiratory	B-O
volume	I-O
was	O
higher	O
in	O
setting	O
II	O
compared	O
to	O
setting	O
III	O
(	O
both	O
p	O
<	O
0.001	O
)	O
,	O
indicating	O
the	O
presence	O
of	O
significant	O
expiratory	O
leakage	O
.	O


CONCLUSIONS	O
The	O
attempt	O
at	O
leak	O
compensation	O
largely	O
feeds	O
the	O
leakage	O
itself	O
and	O
only	O
results	O
in	O
a	O
marginal	O
increase	O
of	O
tidal	O
volume	O
.	O


However	O
,	O
pressure-limited	O
--	O
but	O
not	O
volume-limited	O
--	O
NPPV	O
results	O
in	O
a	O
clinically-important	O
leak	O
compensation	O
in	O
vivo	O
.	O


TRIAL	O
REGISTRATION	O
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html	O
Identifier	O
:	O
UKF001272	O
.	O


Low-dose	B-I
prednisolone	I-I
treatment	I-I
of	O
early	B-P
rheumatoid	I-P
arthritis	I-P
and	O
late	B-O
cardiovascular	I-O
outcome	I-O
and	I-O
survival	I-O
:	I-O
10-year	O
follow-up	O
of	O
a	O
2-year	O
randomised	O
trial	O
.	O


OBJECTIVE	O
To	O
examine	O
the	O
long-term	B-O
effects	I-O
of	O
early	O
low-dose	O
prednisolone	B-I
use	O
in	O
patients	B-P
with	I-P
rheumatoid	I-P
arthritis	I-P
(	I-P
RA	I-P
)	I-P
on	I-P
cardiovascular	I-O
(	I-O
CV	I-O
)	I-O
morbidity	I-O
and	I-O
mortality	I-O
.	I-O


DESIGN	O
Retrieval	O
of	O
data	O
from	O
a	O
2-year	O
open	O
randomised	O
trial	O
comparing	O
prednisolone	B-I
7.5	O
mg/day	O
in	O
addition	O
to	O
disease-modifying	B-I
antirheumatic	I-I
drugs	I-I
(	I-I
DMARDs	I-I
)	I-I
with	I-I
DMARD	I-I
therapy	I-I
alone	O
.	O


Participants	O
were	O
followed	O
for	O
10	O
years	O
since	O
inclusion	O
into	O
the	O
original	O
prednisolone	B-I
trial	O
or	O
until	O
occurrence	O
of	O
the	O
studied	O
outcomes	O
.	O


SETTING	O
Secondary	O
level	O
of	O
care	O
;	O
six	B-P
participating	I-P
centres	I-P
from	I-P
southern	I-P
Sweden	I-P
;	I-P
both	I-P
urban	I-P
and	I-P
rural	I-P
populations	I-P
.	I-P


PARTICIPANTS	O
Overall	O
,	O
223	B-P
patients	I-P
with	I-P
early	I-P
RA	I-P
were	O
included	O
.	O


The	O
participants	B-P
had	I-P
no	I-P
history	I-P
of	I-P
CV	I-O
events	I-O
at	I-P
baseline	I-P
and	O
incident	O
cases	O
were	O
identified	O
via	O
the	O
Swedish	O
Hospital	O
Discharge	O
and	O
Cause	O
of	O
Death	O
Registries	O
.	O


OUTCOMES	O
Composite	B-O
CV	I-O
events	I-O
,	I-O
that	I-O
is	I-O
,	I-O
ischaemic	I-O
coronary	I-O
and	I-O
cerebrovascular	I-O
events	I-O
,	I-O
components	I-O
of	I-O
the	I-O
composite	I-O
CV	I-O
outcome	I-O
,	I-O
and	I-O
death	I-O
.	I-O


Relative	B-O
HRs	I-O
from	I-O
Cox	I-O
proportional-hazards	I-O
regression	I-O
models	I-O
were	O
calculated	O
.	O


RESULTS	O
Within	O
2041	O
person-years	O
,	O
17	O
incident	O
composite	B-O
CV	I-O
events	I-O
occurred	O
in	O
112	O
patients	O
(	O
15	O
%	O
)	O
randomised	O
to	O
prednisolone	B-I
,	O
and	O
15	O
events	O
of	O
111	O
patients	O
(	O
14	O
%	O
)	O
who	O
were	O
assigned	O
not	O
to	O
receive	O
prednisolone	B-I
.	I-I


There	O
were	O
nine	O
deaths	B-O
(	O
8	O
%	O
)	O
in	O
each	O
group	O
.	O


The	O
age-adjusted	B-O
relative	I-O
hazards	I-O
(	O
HRs	O
;	O
95	O
%	O
CI	O
)	O
for	O
the	O
first	O
composite	B-O
CV	I-O
event	I-O
,	I-O
first	I-O
coronary	I-O
event	I-O
and	I-O
death	I-O
in	O
the	O
prednisolone	B-I
group	O
versus	O
the	O
group	O
not	O
treated	O
with	O
prednisolone	B-I
were	O
1.8	O
(	O
0.9	O
to	O
3.6	O
)	O
,	O
0.98	O
(	O
0.4	O
to	O
2.6	O
)	O
and	O
1.6	O
(	O
0.6	O
to	O
4.1	O
)	O
,	O
respectively	O
.	O


The	O
risk	B-O
for	I-O
the	I-O
first	I-O
cerebrovascular	I-O
event	I-O
showed	O
a	O
3.7-fold	O
increased	O
relative	O
hazard	O
(	O
95	O
%	O
CI	O
1.2	O
to	O
11.4	O
)	O
among	O
prednisolone	B-I
treated	O
patients	O
.	O


CONCLUSIONS	O
In	O
this	O
inception	O
cohort	O
study	O
of	O
low-dose	O
prednisolone	B-I
use	O
during	O
the	O
first	O
2	O
years	O
of	O
RA	O
disease	O
,	O
the	O
incidence	B-O
of	I-O
ischaemic	I-O
coronary	I-O
artery	I-O
events	I-O
was	O
similar	O
in	O
the	O
two	O
treatment	O
groups	O
,	O
whereas	O
the	O
long-term	B-O
risk	I-O
of	I-O
ischaemic	I-O
cerebrovascular	I-O
events	I-O
was	O
higher	O
in	O
the	O
prednisolone	B-I
group	O
.	O


There	O
was	O
a	O
trend	O
towards	O
reduced	B-O
survival	I-O
in	O
the	O
prednisolone	B-I
group	O
.	O


TRIAL	O
REGISTRATION	O
NUMBER	O
ISRCTN20612367	O
.	O


Spatial	B-I
orientation	I-I
adjustments	I-I
in	O
children	B-P
with	I-P
autism	I-P
in	I-P
Hong	I-P
Kong	I-P
.	I-P


Abnormal	O
spatial	B-O
orientation	I-O
and	I-O
body	I-O
postures	I-O
in	O
children	B-P
with	I-P
autism	I-P
often	O
interfere	O
with	O
visual	O
abilities	O
to	O
attend	O
tasks	O
and	O
social	O
interactions	O
.	O


Twenty-four	B-P
children	I-P
diagnosed	I-P
with	I-P
autism	I-P
from	I-P
Kowloon	I-P
,	I-P
Hong	I-P
Kong	I-P
were	O
assessed	O
for	O
spatial	B-O
orientation	I-O
and	O
spatial	B-O
management	I-O
abilities	O
.	O


Positive	B-O
changes	I-O
in	O
spatial	B-O
orientation	I-O
were	O
evident	O
when	O
the	O
children	O
wore	B-I
ambient	I-I
prism	I-I
lenses	I-I
and	O
included	O
changes	B-O
in	I-O
posture	I-O
from	O
slanted	O
to	O
erect	O
.	O


Adjustments	O
in	O
spatial	B-O
management	I-O
were	O
evident	O
in	O
improved	O
ball	O
catching	B-O
ability	I-O
,	O
a	O
task	O
requiring	O
visual	O
tracking	O
and	O
eye-hand	O
coordination	O
.	O


The	O
findings	O
suggest	O
that	O
alterations	B-I
to	I-I
the	I-I
sensory	I-I
systems	I-I
may	O
lead	O
to	O
behavioral	O
change	O
in	O
some	O
children	O
.	O


Two	O
large	O
preoperative	O
doses	O
of	O
erythropoietin	B-I
do	O
not	O
reduce	O
the	O
systemic	B-P
inflammatory	I-P
response	I-P
to	I-P
cardiac	I-P
surgery	I-P
.	I-P


OBJECTIVES	O
Cardiac	O
surgery	O
and	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
induce	O
an	O
inflammatory	O
reaction	O
that	O
may	O
lead	O
to	O
tissue	O
injury	O
.	O


Experimental	O
studies	O
suggest	O
that	O
recombinant	B-I
human	I-I
erythropoietin	I-I
(	I-I
EPO	I-I
)	I-I
independent	O
of	O
its	O
erythropoietic	O
effect	O
may	O
be	O
used	O
clinically	O
as	O
an	O
anti-inflammatory	O
drug	O
.	O


This	O
study	O
tested	O
the	O
hypothesis	O
that	O
2	O
large	O
doses	O
of	O
EPO	B-I
administered	O
shortly	O
before	O
CPB	O
ameliorate	O
the	O
systemic	O
inflammatory	O
response	O
to	O
CPB	O
.	O


DESIGN	O
AND	O
SETTING	O
A	O
prospective	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
and	O
randomized	O
study	O
at	O
a	O
single	O
tertiary	O
care	O
hospital	O
.	O


PARTICIPANTS	O
Patients	B-P
scheduled	I-P
for	I-P
coronary	I-P
artery	I-P
bypass	I-P
graft	I-P
surgery	I-P
with	I-P
CPB	I-P
.	I-P


INTERVENTIONS	O
EPO	B-I
(	I-I
epoetin	I-I
alfa	I-I
,	O
500	O
IU/kg	O
intravenously	O
,	O
n	B-P
=	I-P
22	I-P
)	I-P
or	I-P
placebo	I-I
(	I-P
n	I-P
=	I-P
21	I-P
)	I-P
was	O
administered	O
12	O
to	O
18	O
hours	O
preoperatively	O
and	O
again	O
at	O
the	O
induction	O
of	O
anesthesia	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
CPB	O
in	O
both	O
groups	O
greatly	O
increased	O
plasma	B-O
concentrations	I-O
of	I-O
tumor	I-O
necrosis	I-O
factor	I-O
alpha	I-O
(	I-O
TNF-alpha	I-O
)	I-O
,	I-O
interleukin	I-O
(	I-O
IL	I-O
)	I-O
-1beta	I-O
,	I-O
IL-1beta	I-O
receptor	I-O
antagonist	I-O
,	I-O
IL-6	I-O
,	I-O
IL-10	I-O
,	I-O
and	I-O
N-terminal	I-O
probrain	I-O
natriuretic	I-O
peptide	I-O
(	I-O
NT-proBNP	I-O
)	I-O
.	I-O


Compared	O
with	O
placebo	B-I
,	I-I
EPO	I-I
at	O
day	O
3	O
after	O
CPB	O
augmented	O
the	O
TNF-alpha	B-O
response	I-O
(	O
p	O
<	O
0.05	O
)	O
and	O
at	O
2	O
hours	O
after	O
CPB	O
increased	O
NT-proBNP	B-O
(	O
p	O
<	O
0.05	O
)	O
.	O


Also	O
,	O
EPO	B-I
tended	O
to	O
enhance	O
the	O
CPB-induced	O
increase	O
in	O
IL-1beta	B-O
receptor	I-O
antagonist	I-O
(	O
p	O
=	O
0.057	O
)	O
.	O


Otherwise	O
,	O
EPO	B-I
had	O
no	O
effect	O
on	O
pro-	B-O
and	I-O
antiinflammatory	I-O
mediators	I-O
compared	O
with	O
placebo	O
.	O


CONCLUSIONS	O
Two	O
large	O
doses	O
of	O
EPO	B-I
given	O
shortly	O
before	O
CPB	O
do	O
not	O
reduce	O
perioperative	B-O
release	I-O
of	I-O
inflammatory	I-O
cytokines	I-O
.	I-O


In	O
contrast	O
,	O
EPO	B-I
may	O
augment	O
the	O
TNF-alpha	O
and	O
NT-proBNP	O
response	O
.	O


Although	O
the	O
long-term	O
clinical	O
impact	O
remains	O
unknown	O
,	O
the	O
findings	O
do	O
not	O
support	O
use	O
of	O
EPO	B-I
as	O
an	O
anti-inflammatory	O
drug	O
in	O
patients	B-P
undergoing	I-P
cardiac	I-P
surgery	I-P
.	I-P


Using	O
the	O
virtual	B-I
reality-cognitive	I-I
rehabilitation	I-I
approach	O
to	O
improve	O
contextual	B-O
processing	I-O
in	I-O
children	I-P
with	I-P
autism	I-P
.	I-P


BACKGROUND	O
This	O
pilot	O
study	O
investigated	O
the	O
efficacy	O
of	O
a	O
novel	B-I
virtual	I-I
reality-cognitive	I-I
rehabilitation	I-I
(	I-I
VR-CR	I-I
)	I-I
intervention	I-I
to	O
improve	O
contextual	B-O
processing	I-O
of	O
objects	O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


Previous	O
research	O
supports	O
that	O
children	B-P
with	I-P
autism	I-P
show	O
deficits	O
in	O
contextual	B-O
processing	I-O
,	O
as	O
well	O
as	O
deficits	O
in	O
its	O
elementary	O
components	O
:	O
abstraction	B-O
and	I-O
cognitive	I-O
flexibility	I-O
.	I-O


METHODS	O
Four	B-P
children	I-P
with	I-P
autism	I-P
participated	O
in	O
a	O
multiple-baseline	O
,	O
single-subject	O
study	O
.	O


The	O
children	B-P
were	O
taught	O
how	O
to	O
see	O
objects	O
in	O
context	O
by	O
reinforcing	O
attention	O
to	O
pivotal	O
contextual	O
information	O
.	O


RESULTS	O
All	O
children	B-P
demonstrated	O
statistically	O
significant	O
improvements	O
in	O
contextual	B-O
processing	I-O
and	I-O
cognitive	I-O
flexibility	I-O
.	I-O


Mixed	O
results	O
were	O
found	O
on	O
the	O
control	O
test	O
and	O
changes	O
in	O
context-related	B-O
behaviours	I-O
.	I-O


CONCLUSIONS	O
Larger-scale	O
studies	O
are	O
warranted	O
to	O
determine	O
the	O
effectiveness	O
and	O
usability	O
in	O
comprehensive	O
educational	O
programs	O
.	O


Multi-institutional	O
randomized	O
phase	O
II	O
trial	O
of	O
the	O
epothilone	B-I
B	I-I
analog	I-I
ixabepilone	I-I
(	I-I
BMS-247550	I-I
)	I-I
with	I-I
or	I-I
without	I-I
estramustine	I-I
phosphate	I-I
in	O
patients	B-P
with	I-P
progressive	I-P
castrate	I-P
metastatic	I-P
prostate	I-P
cancer	I-P
.	I-P


PURPOSE	O
To	O
evaluate	O
the	O
antitumor	B-O
activity	I-O
and	O
safety	B-O
of	O
the	O
epothilone	B-I
B	I-I
analog	I-I
,	I-I
ixabepilone	I-I
,	I-I
with	I-I
or	I-I
without	I-I
estramustine	I-I
phosphate	I-I
(	I-I
EMP	I-I
)	I-I
,	O
in	O
chemotherapy-naive	B-P
patients	I-P
with	I-P
progressive	I-P
castrate	I-P
metastatic	I-P
prostate	I-P
cancer	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
ixabepilone	B-I
(	O
35	O
mg/m	O
(	O
2	O
)	O
)	O
by	O
intravenous	B-I
infusion	I-I
every	I-I
3	I-I
weeks	I-I
with	I-I
or	I-I
without	I-I
EMP	I-I
280	I-I
mg	I-I
orally	I-I
three	O
times	O
daily	O
on	O
days	O
1	O
to	O
5	O
.	O


RESULTS	O
Between	B-P
December	I-P
2001	I-P
and	I-P
October	I-P
2003	I-P
,	I-P
92	I-P
patients	I-P
were	I-P
enrolled	I-P
and	I-P
randomly	I-P
assigned	I-P
to	O
treatment	B-P
with	I-P
ixabepilone	I-I
alone	I-I
(	I-P
45	I-P
patients	I-P
)	I-P
or	I-P
in	I-P
combination	I-I
with	I-I
EMP	I-I
(	I-P
47	I-P
patients	I-P
)	I-P
.	I-P


Grades	B-O
3	I-O
and	I-O
4	I-O
toxicities	I-O
experienced	O
by	O
more	O
than	O
5	O
%	O
of	O
patients	O
included	O
neutropenia	B-O
(	O
22	O
%	O
)	O
,	O
fatigue	B-O
(	O
9	O
%	O
)	O
,	O
and	O
neuropathy	B-O
(	O
13	O
%	O
)	O
on	O
the	O
ixabepilone	B-O
arm	I-O
,	I-O
and	I-O
neutropenia	I-O
(	O
29	O
%	O
)	O
,	O
febrile	B-O
neutropenia	I-O
(	O
9	O
%	O
)	O
,	O
fatigue	B-O
(	O
9	O
%	O
)	O
,	O
neuropathy	B-O
(	O
7	O
%	O
)	O
,	O
and	O
thrombosis	B-O
(	O
6	O
%	O
)	O
on	O
the	O
ixabepilone	O
+	O
EMP	O
arm	O
.	O


Post-treatment	O
declines	O
in	O
prostate-specific	B-O
antigen	I-O
of	O
>	O
or	O
=	O
50	O
%	O
were	O
achieved	O
in	O
21	O
of	O
44	O
patients	O
(	O
48	O
%	O
;	O
95	O
%	O
CI	O
,	O
33	O
%	O
to	O
64	O
%	O
)	O
on	O
the	O
ixabepilone	O
arm	O
,	O
and	O
31	O
of	O
45	O
patients	O
(	O
69	O
%	O
;	O
95	O
%	O
CI	O
,	O
55	O
%	O
to	O
82	O
%	O
)	O
on	O
the	O
ixabepilone	O
+	O
EMP	O
arm	O
.	O


In	O
patients	O
with	O
measurable	O
disease	O
,	O
partial	B-O
responses	I-O
were	O
observed	O
in	O
eight	O
of	O
25	O
patients	O
(	O
32	O
%	O
;	O
95	O
%	O
CI	O
,	O
14	O
%	O
to	O
50	O
%	O
)	O
on	O
the	O
ixabepilone	O
arm	O
,	O
and	O
11	O
of	O
23	O
(	O
48	O
%	O
;	O
95	O
%	O
CI	O
,	O
27	O
%	O
to	O
68	O
%	O
)	O
on	O
the	O
ixabepilone	O
+	O
EMP	O
arm	O
.	O


Time	B-O
to	I-O
prostate-specific	I-O
antigen	I-O
progression	I-O
was	O
4.4	O
months	O
(	O
95	O
%	O
CI	O
,	O
3.1	O
to	O
6.9	O
months	O
)	O
on	O
the	O
ixabepilone-alone	O
arm	O
and	O
5.2	O
months	O
(	O
95	O
%	O
CI	O
,	O
4.5	O
to	O
6.8	O
months	O
)	O
on	O
the	O
combination	O
arm	O
.	O


CONCLUSION	O
Ixabepilone	B-I
,	O
with	O
or	O
without	O
estramustine	B-I
phosphate	I-I
,	O
is	O
well	B-O
tolerated	I-O
and	O
has	O
antitumor	B-O
activity	I-O
in	O
patients	B-P
with	I-P
castrate	I-P
metastatic	I-P
prostate	I-P
cancer	I-P
.	I-P


A	O
double-blind	O
randomized	O
clinical	O
evaluation	O
of	O
enamel	B-I
matrix	I-I
derivative	I-I
proteins	I-I
for	O
the	O
treatment	O
of	O
proximal	O
class-II	O
furcation	O
involvements	O
.	O


OBJECTIVE	O
The	O
aim	O
of	O
the	O
present	O
randomized	O
,	O
double-blind	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	B-O
response	I-O
of	O
proximal	O
furcations	O
treated	O
with	O
enamel	B-I
matrix	I-I
derivative	I-I
proteins	I-I
(	I-I
EMD	I-I
)	I-I
.	I-I


MATERIAL	O
AND	O
METHODS	O
Fifteen	B-P
patients	I-P
,	I-P
each	I-P
with	I-P
a	I-P
pair	I-P
of	I-P
contralateral	I-P
class-II	I-P
proximal	I-P
furcation	I-P
involvements	I-P
,	I-P
presenting	I-P
probing	I-P
depths	I-P
(	I-P
PDs	I-P
)	I-P
>	I-P
/=5	I-P
mm	I-P
and	I-P
bleeding	I-P
on	I-P
probing	I-P
(	I-P
BOP	I-P
)	I-P
were	I-P
selected	I-P
.	I-P


The	O
patients	O
were	O
randomly	O
assigned	O
to	O
:	O
control	B-I
group	I-I
(	O
n=15	O
)	O
-	O
open	B-I
flap	I-I
debridement	I-I
(	I-I
OFD	I-I
)	I-I
+24	I-I
%	I-I
ethylenediaminetetraacetic	I-I
acid	I-I
(	I-I
EDTA	I-I
)	I-I
conditioning	I-I
;	I-I
test	O
group	O
(	O
n=15	O
)	O
-	O
OFD+24	B-I
%	I-I
EDTA	I-I
conditioning+EMD	I-I
application	I-I
.	I-I


Plaque	B-O
index	I-O
(	I-O
PI	I-O
)	I-O
,	I-O
BOP	I-O
,	I-O
PD	I-O
,	I-O
gingival	I-O
margin	I-O
position	I-O
(	I-O
GMP	I-O
)	I-O
,	I-O
relative	I-O
vertical	I-O
and	I-O
horizontal	I-O
clinical	I-O
attachment	I-O
level	I-O
(	I-O
RVCAL	I-O
and	I-O
RHCAL	I-O
)	I-O
,	I-O
vertical	I-O
and	I-O
horizontal	I-O
bone	I-O
level	I-O
(	I-O
VBL	I-O
and	I-O
HBL	I-O
)	I-O
and	I-O
furcation	I-O
closure	I-O
were	O
evaluated	O
immediately	O
before	O
and	O
2	O
,	O
4	O
and	O
6	O
months	O
after	O
the	O
surgeries	O
.	O


RESULTS	O
At	O
6	O
months	O
,	O
the	O
RVCAL	B-O
gains	I-O
of	O
the	O
control	O
and	O
test	O
group	O
were	O
0.39	O
+/-	O
1.00	O
and	O
0.54	O
+/-	O
0.95	O
mm	O
,	O
while	O
the	O
RHCAL	B-O
gains	O
were	O
1.21	O
+/-	O
2.28	O
and	O
1.36	O
+/-	O
1.26	O
mm	O
(	O
p	O
>	O
0.05	O
)	O
.	O


The	O
VBL	B-O
and	I-O
HBL	I-O
gains	I-O
of	O
the	O
control	O
group	O
were	O
1.04	O
+/-	O
1.12	O
and	O
1.00	O
+/-	O
1.79	O
mm	O
,	O
and	O
0.82	O
+/-	O
1.82	O
and	O
1.17	O
+/-	O
1.38	O
mm	O
for	O
the	O
test	O
group	O
(	O
p	O
>	O
0.05	O
)	O
.	O


In	O
addition	O
,	O
a	O
statistical	O
difference	O
was	O
observed	O
in	O
the	O
number	B-O
of	I-O
the	I-O
remaining	I-O
class-II	I-O
furcations	I-O
between	O
the	O
test	O
and	O
control	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
in	O
this	O
period	O
.	O


CONCLUSION	O
It	O
may	O
be	O
concluded	O
that	O
the	O
use	O
of	O
EMD	B-I
in	O
proximal	O
furcations	O
did	O
not	O
promote	O
a	O
superior	O
reduction	O
in	O
PD	B-O
or	O
a	O
gain	O
in	O
clinical	B-O
and	I-O
osseous	I-O
attachment	I-O
levels	I-O
,	O
but	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
class-II	B-O
to	I-O
class-I	I-O
furcation	I-O
conversion	I-O
.	I-O


Whole-body	B-I
CT	I-I
screening	I-I
:	I-I
scan	I-I
delay	I-I
and	I-I
contrast	I-I
injection	I-I
duration	O
for	O
optimal	B-O
enhancement	I-O
of	I-O
abdominal	I-O
organs	I-O
and	I-O
deep	I-O
vessels	I-O
.	I-O


PURPOSE	O
To	O
assess	O
the	O
optimal	O
scan	O
delays	O
and	O
contrast	O
injection	O
durations	O
for	O
contrast-enhanced	B-I
whole-body	I-I
computed	I-I
tomography	I-I
(	I-I
CT	I-I
)	I-I
.	I-I


MATERIALS	O
AND	O
METHODS	O
One	B-P
hundred	I-P
forty-two	I-P
patients	I-P
were	O
randomized	O
into	O
three	O
groups	O
:	O
protocol	B-I
A-scan	I-I
delay	I-I
of	I-I
65	I-I
s	I-I
after	I-I
starting	I-I
contrast	I-I
injection	I-I
over	I-I
30	I-I
s	I-I
;	I-I
protocol	I-I
B-105	I-I
and	I-I
70	I-I
s	I-I
;	I-I
and	I-I
protocol	I-I
C-145	I-I
and	I-I
110	I-I
s	I-I
,	O
respectively	O
.	O


Contrast	B-O
enhancement	I-O
and	I-O
diagnostic	I-O
acceptability	I-O
were	O
assessed	O
.	O


RESULTS	O
Qualitative	B-O
assessment	I-O
was	O
subtle	O
among	O
the	O
three	O
protocols	O
.	O


Homogenous	B-O
enhancement	I-O
of	I-O
deep	I-O
veins	I-O
was	O
more	O
assuredly	O
achieved	O
with	O
protocol	O
C.	O
CONCLUSION	O
With	O
protocol	B-I
C	I-I
,	O
qualitatively	O
acceptable	O
enhancement	O
can	O
be	O
obtained	O
in	O
whole-body	B-I
CT	I-I
.	I-I


Use	O
of	O
a	O
clay	B-I
modeling	I-I
task	I-I
to	O
reduce	O
chocolate	B-O
craving	I-O
.	I-O


Elaborated	O
Intrusion	O
theory	O
(	O
EI	O
theory	O
;	O
Kavanagh	O
,	O
Andrade	O
,	O
&	O
May	O
,	O
2005	O
)	O
posits	O
two	O
main	O
cognitive	O
components	O
in	O
craving	B-O
:	I-O
associative	O
processes	O
that	O
lead	O
to	O
intrusive	O
thoughts	O
about	O
the	O
craved	O
substance	O
or	O
activity	O
,	O
and	O
elaborative	O
processes	O
supporting	O
mental	O
imagery	O
of	O
the	O
substance	O
or	O
activity	O
.	O


We	O
used	O
a	O
novel	B-I
visuospatial	I-I
task	I-I
to	O
test	O
the	O
hypothesis	O
that	O
visual	O
imagery	O
plays	O
a	O
key	O
role	O
in	O
craving	B-O
.	I-O


Experiment	O
1	O
showed	O
that	O
spending	O
10	O
min	O
constructing	B-I
shapes	I-I
from	I-I
modeling	I-I
clay	I-I
(	I-I
plasticine	I-I
)	I-I
reduced	O
participants	B-P
'	I-P
craving	I-O
for	I-O
chocolate	I-O
compared	O
with	O
spending	O
10	O
min	O
'letting	B-I
your	I-I
mind	I-I
wander	I-I
'	I-I
.	I-I


Increasing	O
the	O
load	O
on	O
verbal	O
working	O
memory	O
using	O
a	O
mental	O
arithmetic	O
task	O
(	O
counting	O
backwards	O
by	O
threes	O
)	O
did	O
not	O
reduce	O
craving	B-O
further	O
.	O


Experiment	O
2	O
compared	O
effects	O
on	O
craving	B-O
of	O
a	O
simpler	B-I
verbal	I-I
task	I-I
(	I-I
counting	I-I
by	I-I
ones	I-I
)	I-I
and	I-I
clay	I-I
modeling	I-I
.	I-I


Clay	B-I
modeling	I-I
reduced	O
overall	B-O
craving	I-O
strength	I-O
and	O
strength	B-O
of	I-O
craving	I-O
imagery	I-O
,	O
and	O
reduced	O
the	O
frequency	B-O
of	I-O
thoughts	I-O
about	I-O
chocolate	I-O
.	I-O


The	O
results	O
are	O
consistent	O
with	O
EI	O
theory	O
,	O
showing	O
that	O
craving	B-O
is	O
reduced	O
by	O
loading	O
the	O
visuospatial	O
sketchpad	O
of	O
working	O
memory	O
but	O
not	O
by	O
loading	O
the	O
phonological	O
loop	O
.	O


Clay	B-I
modeling	I-I
might	O
be	O
a	O
useful	O
self-help	O
tool	O
to	O
help	O
manage	O
craving	B-O
for	I-P
chocolate	I-P
,	I-P
snacks	I-P
and	I-P
other	I-P
foods	I-P
.	I-P


Use	O
of	O
EORTC	O
target	O
definition	O
guidelines	O
for	O
dose-intensified	O
salvage	O
radiation	O
therapy	O
for	O
recurrent	O
prostate	O
cancer	O
:	O
results	O
of	O
the	O
quality	O
assurance	O
program	O
of	O
the	O
randomized	O
trial	O
SAKK	O
09/10	O
.	O


PURPOSE	O
Different	O
international	O
target	O
volume	O
delineation	O
guidelines	O
exist	O
and	O
different	O
treatment	O
techniques	O
are	O
available	O
for	O
salvage	O
radiation	O
therapy	O
(	O
RT	O
)	O
for	O
recurrent	O
prostate	O
cancer	O
,	O
but	O
less	O
is	O
known	O
regarding	O
their	O
respective	O
applicability	O
in	O
clinical	O
practice	O
.	O


METHODS	O
AND	O
MATERIALS	O
A	O
randomized	O
phase	O
III	O
trial	O
testing	O
64	B-I
Gy	I-I
vs	I-I
70	I-I
Gy	I-I
salvage	I-I
RT	I-I
was	O
accompanied	O
by	O
an	O
intense	B-I
quality	I-I
assurance	I-I
program	I-I
including	O
a	O
site-specific	O
and	O
study-specific	O
questionnaire	O
and	O
a	O
dummy	B-I
run	I-I
(	I-I
DR	I-I
)	I-I
.	I-I


Target	O
volume	O
delineation	O
was	O
performed	O
according	O
to	O
the	O
European	O
Organisation	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
guidelines	O
,	O
and	O
a	O
DR-based	O
treatment	O
plan	O
was	O
established	O
for	O
70	O
Gy	O
.	O


Major	O
and	O
minor	O
protocol	O
deviations	O
were	O
noted	O
,	O
interobserver	O
agreement	O
of	O
delineated	O
target	O
contours	O
was	O
assessed	O
,	O
and	O
dose-volume	O
histogram	O
(	O
DVH	O
)	O
parameters	O
of	O
different	O
treatment	O
techniques	O
were	O
compared	O
.	O


RESULTS	O
Thirty	B-P
European	I-P
centers	I-P
participated	I-P
,	I-P
43	I-P
%	I-P
of	I-P
which	I-P
were	I-P
using	I-P
3-dimensional	I-I
conformal	I-I
RT	I-I
(	I-I
3D-CRT	I-I
)	I-I
,	I-P
with	I-P
the	I-P
remaining	I-P
centers	I-P
using	I-P
intensity	I-I
modulated	I-I
RT	I-I
(	I-I
IMRT	I-I
)	I-I
or	I-P
volumetric	I-I
modulated	I-I
arc	I-I
technique	I-I
(	I-I
VMAT	I-I
)	I-I
.	I-I


The	O
first	O
submitted	O
version	O
of	O
the	O
DR	O
contained	O
major	O
deviations	O
in	O
21	O
of	O
30	O
(	O
70	O
%	O
)	O
centers	O
,	O
mostly	O
caused	O
by	O
inappropriately	O
defined	O
or	O
lack	O
of	O
prostate	O
bed	O
(	O
PB	O
)	O
.	O


All	O
but	O
5	B-P
centers	I-P
completed	I-P
the	I-P
DR	I-P
successfully	I-P
with	O
their	O
second	O
submitted	O
version	O
.	O


The	O
interobserver	O
agreement	O
of	O
the	O
PB	O
was	O
moderate	O
and	O
was	O
improved	O
by	O
the	O
DR	O
review	O
,	O
as	O
indicated	O
by	O
an	O
increased	O
κ	B-O
value	I-O
(	O
0.59	O
vs	O
0.55	O
)	O
,	O
mean	B-O
sensitivity	I-O
(	O
0.64	O
vs	O
0.58	O
)	O
,	O
volume	B-O
of	I-O
total	I-O
agreement	I-O
(	O
3.9	O
vs	O
3.3	O
cm	O
(	O
3	O
)	O
)	O
,	O
and	O
decrease	O
in	O
the	B-O
union	I-O
volume	I-O
(	O
79.3	O
vs	O
84.2	O
cm	O
(	O
3	O
)	O
)	O
.	B-O


Rectal	B-O
and	I-O
bladder	I-O
wall	I-O
DVH	I-O
parameters	I-O
of	I-O
IMRT	I-O
and	I-O
VMAT	I-O
vs	I-O
3D-CRT	I-O
plans	I-O
were	O
not	O
significantly	O
different	O
.	O


CONCLUSIONS	O
The	O
interobserver	O
agreement	O
of	O
PB	O
delineation	O
was	O
moderate	O
but	O
was	O
improved	O
by	O
the	O
DR.	O
Major	O
deviations	O
could	O
be	O
identified	O
for	O
the	O
majority	O
of	O
centers	O
.	O


The	O
DR	O
has	O
improved	O
the	O
acquaintance	O
of	O
the	O
participating	O
centers	O
with	O
the	O
trial	O
protocol	O
.	O


Sociopsychological	O
tailoring	O
to	O
address	O
colorectal	O
cancer	O
screening	O
disparities	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O


PURPOSE	O
Interventions	B-I
tailored	I-I
to	I-I
sociopsychological	I-I
factors	I-I
associated	I-I
with	I-I
health	I-I
behaviors	I-I
have	O
promise	O
for	O
reducing	O
colorectal	O
cancer	O
screening	O
disparities	O
,	O
but	O
limited	O
research	O
has	O
assessed	O
their	O
impact	O
in	O
multiethnic	O
populations	O
.	O


We	O
examined	O
whether	O
an	O
interactive	B-I
multimedia	I-I
computer	I-I
program	I-I
(	I-I
IMCP	I-I
)	I-I
tailored	O
to	O
expanded	O
health	O
belief	O
model	O
sociopsychological	O
factors	O
could	O
promote	O
colorectal	O
cancer	O
screening	O
in	O
a	O
multiethnic	B-P
sample	I-P
.	I-P


METHODS	O
We	O
undertook	O
a	O
randomized	O
controlled	O
trial	O
,	O
comparing	O
an	O
IMCP	B-I
tailored	I-I
to	I-I
colorectal	I-I
cancer	I-I
screening	I-I
self-efficacy	I-I
,	I-I
knowledge	I-I
,	I-I
barriers	I-I
,	I-I
readiness	I-I
,	I-I
test	I-I
preference	I-I
,	I-I
and	I-I
experiences	I-I
with	I-I
a	I-I
nontailored	I-I
informational	I-I
program	I-I
,	O
both	O
delivered	O
before	O
office	O
visits	O
.	O


The	O
primary	O
outcome	O
was	O
record-documented	B-O
colorectal	I-O
cancer	I-O
screening	I-O
during	I-O
a	I-O
12-month	I-O
follow-up	I-O
period	I-O
.	I-O


Secondary	O
outcomes	O
included	O
postvisit	B-O
sociopsychological	I-O
factor	I-O
status	I-O
and	I-O
discussion	I-O
,	I-O
as	I-O
well	I-O
as	I-O
clinician	I-O
recommendation	I-O
of	I-O
screening	I-O
during	I-O
office	I-O
visits	I-O
.	I-O


We	O
enrolled	B-P
1,164	I-P
patients	I-P
stratified	I-P
by	I-P
ethnicity	I-P
and	I-P
language	I-P
(	I-P
49.3	I-P
%	I-P
non-Hispanic	I-P
,	I-P
27.2	I-P
%	I-P
Hispanic/English	I-P
,	I-P
23.4	I-P
%	I-P
Hispanic/Spanish	I-P
)	I-P
from	I-P
26	I-P
offices	I-P
around	I-P
5	I-P
centers	I-P
(	I-P
Sacramento	I-P
,	I-P
California	I-P
;	I-P
Rochester	I-P
and	I-P
the	I-P
Bronx	I-P
,	I-P
New	I-P
York	I-P
;	I-P
Denver	I-P
,	I-P
Colorado	I-P
;	I-P
and	I-P
San	I-P
Antonio	I-P
,	I-P
Texas	I-P
)	I-P
.	I-P


RESULTS	O
Adjusting	O
for	O
ethnicity/language	O
,	O
study	O
center	O
,	O
and	O
the	O
previsit	O
value	O
of	O
the	O
dependent	O
variable	O
,	O
compared	O
with	O
control	O
patients	O
,	O
the	O
IMCP	O
led	O
to	O
significantly	O
greater	O
colorectal	B-O
cancer	I-O
screening	I-O
knowledge	I-O
,	I-O
self-efficacy	I-O
,	I-O
readiness	I-O
,	I-O
test	I-O
preference	I-O
specificity	I-O
,	I-O
discussion	I-O
,	I-O
and	I-O
recommendation	I-O
.	I-O


During	O
the	O
followup	O
period	O
,	O
132	O
(	O
23	O
%	O
)	O
IMCP	O
and	O
123	O
(	O
22	O
%	O
)	O
control	O
patients	O
received	O
screening	B-O
(	O
adjusted	O
difference	O
=	O
0.5	O
percentage	O
points	O
,	O
95	O
%	O
CI	O
-4.3	O
to	O
5.3	O
)	O
.	O


IMCP	B-O
effects	O
did	O
not	O
differ	O
significantly	O
by	O
ethnicity/language	O
.	O


CONCLUSIONS	O
Sociopsychological	O
factor	O
tailoring	O
was	O
no	O
more	O
effective	O
than	O
nontailored	O
information	O
in	O
encouraging	O
colorectal	O
cancer	O
screening	O
in	O
a	O
multiethnic	B-P
sample	I-P
,	O
despite	O
enhancing	O
sociopsychological	O
factors	O
and	O
visit	O
behaviors	O
associated	O
with	O
screening	O
.	O


The	O
utility	O
of	O
sociopsychological	O
tailoring	O
in	O
addressing	O
screening	O
disparities	O
remains	O
uncertain	O
.	O


Early	B-I
versus	I-I
late	I-I
replacement	I-I
of	I-I
autotransfused	I-I
blood	I-I
in	O
elective	B-P
spinal	I-I
surgery	I-I
.	I-I


A	O
prospective	O
randomized	O
study	O
.	O


The	O
use	O
of	O
autologous	B-I
blood	I-I
is	O
a	O
well	O
established	O
and	O
extremely	O
popular	O
technique	O
to	O
decrease	O
the	O
necessity	O
for	O
homologous	O
transfusions	O
and	O
the	O
attendant	O
risks	O
of	O
hepatitis	O
,	O
HIV	O
,	O
and	O
HTLV	O
--	O
I/II	O
infections	O
.	O


The	O
most	O
beneficial	O
timing	O
for	O
autologous	B-I
reinfusion	O
of	O
predonated	O
blood	O
remains	O
unknown	O
.	O


The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
optimal	O
timing	O
of	O
autologous	B-I
blood	I-I
reinfusion	I-I
in	I-I
elective	I-I
spinal	I-I
surgery	I-I
.	I-I


Fifty-seven	B-P
patients	I-P
were	O
prospectively	O
individually	O
randomly	O
allocated	O
into	O
early	B-I
versus	I-I
delayed	I-I
reinfusion	I-I
groups	I-I
prior	O
to	O
undergoing	B-P
elective	I-I
spinal	I-I
surgery	I-I
by	O
a	O
single	O
surgeon	O
.	O


Three	O
surgical	O
subgroups	O
were	O
entered	O
into	O
the	O
study	O
:	O
anterior/posterior	B-P
(	I-P
A/P	I-P
)	I-P
spinal	I-P
fusion	I-P
patients	I-P
,	I-P
posterior	I-P
thoracolumbar	I-P
scoliosis	I-P
fusion	I-P
patients	I-P
(	I-P
PSF	I-P
)	I-P
,	I-P
and	I-P
degenerative	I-P
posterior	I-P
lumbar	I-P
fusion	I-P
patients	I-P
(	I-P
LF	I-P
)	I-P
.	O


Randomization	O
was	O
successful	O
in	O
that	O
three	O
was	O
no	O
significant	O
difference	O
in	O
male	O
to	O
female	O
ratio	O
,	O
age	O
,	O
preoperative	O
hemoglobin	O
,	O
or	O
number	O
of	O
units	O
predonated	O
between	O
the	O
early	B-I
and	I-I
delayed	I-I
reinfusion	I-I
groups	I-I
.	I-I


Likewise	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
details	O
of	O
the	O
operative	O
procedure	O
when	O
compared	O
as	O
a	O
group	O
for	O
the	O
early	O
versus	O
delayed	O
reinfusion	O
groups	O
.	O


A	O
significant	O
increase	O
in	O
the	O
postoperative	O
day	B-O
#	I-O
1	I-O
,	I-O
2	I-O
and	I-O
3	I-O
hemoglobin	I-O
was	O
seen	O
in	O
the	O
early	B-I
reinfusion	I-I
group	I-I
,	O
while	O
there	O
was	O
no	O
significant	O
difference	O
seen	O
in	O
the	O
postoperative	O
day	O
#	O
7	O
hemoglobin	O
between	O
the	O
early	B-I
versus	I-I
delayed	I-I
reinfusion	I-I
group	O
.	O


There	O
was	O
no	O
effect	O
of	O
surgical	O
grouping	O
on	O
these	O
significant	O
comparisons	O
.	O


Earlier	O
patient	B-O
mobilization	I-O
was	O
also	O
seen	O
in	O
the	O
early	B-I
reinfusion	I-I
groups	O
for	O
the	O
A/P	O
and	O
PSF	O
groups	O
.	O


There	O
was	O
no	O
difference	O
in	O
patients	O
'	O
subjective	O
evaluation	O
of	O
satisfaction	O
and	O
discomfort	O
between	O
the	O
early	O
or	O
delayed	O
reinfusion	O
groups	O
as	O
determined	O
by	O
blinded	O
interview	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
7	O
postoperatively	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Recommending	O
self-paced	B-I
exercise	I-I
among	O
overweight	B-P
and	I-P
obese	I-P
adults	I-P
:	I-P
a	O
randomized	O
pilot	O
study	O
.	O


BACKGROUND	O
National	O
guidelines	O
call	O
for	O
exercise	O
of	O
at	O
least	O
moderate	O
intensity	O
;	O
however	O
,	O
recommending	O
self-paced	B-I
exercise	I-I
may	O
lead	O
to	O
better	O
adherence	B-O
,	O
particularly	O
among	O
overweight	B-P
and	I-P
obese	I-P
adults	I-P
.	I-P


PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
proof-of-concept	O
for	O
recommending	O
self-paced	O
exercise	O
among	O
overweight	O
adults	O
.	O


METHODS	O
Fifty-nine	B-P
healthy	I-P
,	I-P
low-active	I-P
(	I-P
exercise	I-P
<	I-P
60	I-P
min/week	I-P
)	I-P
,	I-P
overweight	I-P
(	I-P
body	I-P
mass	I-P
index	I-P
25.0-39.9	I-P
)	I-P
adults	I-P
(	I-P
18-65	I-P
)	I-P
received	O
a	B-I
6-month	I-I
print-based	I-I
exercise	I-I
promotion	I-I
program	I-I
with	I-I
the	I-I
goal	I-I
of	I-I
walking	I-I
30-60	I-I
min/day	I-I
.	O


Participants	O
were	O
surreptitiously	O
randomly	O
assigned	O
to	O
receive	O
a	B-I
recommendation	I-I
for	I-I
either	I-I
self-paced	I-I
(	I-I
n	I-I
=	I-I
30	I-I
)	I-I
or	I-I
moderate	I-I
(	O
64-76	O
%	O
maximum	O
heart	O
rate	O
;	O
n	B-I
=	I-I
29	I-I
)	I-I
intensity	I-I
exercise	I-P
.	I-P


All	B-P
participants	I-P
used	I-P
electronic	I-P
diaries	I-P
and	I-P
heart	I-P
rate	I-P
monitors	I-O
to	I-O
track	I-O
exercise	I-O
frequency	I-O
,	I-O
duration	I-O
,	I-O
and	I-O
intensity	O
.	O


RESULTS	O
The	O
self-paced	O
condition	O
reported	B-O
more	I-O
minutes/week	I-O
of	O
walking	O
(	O
f	O
(	O
2	O
)	O
=	O
0.17	O
,	O
p	O
=	O
0.045	O
)	O
and	O
a	O
trend	B-O
toward	I-O
greater	I-O
exercise-related	I-O
energy	I-O
expenditure/week	O
(	O
f	O
(	O
2	O
)	O
=	O
0.12	O
,	O
p	O
=	O
0.243	O
)	O
,	O
corresponding	O
to	O
approximately	O
26	O
additional	O
minutes/week	O
and	O
83	O
additional	O
kilocalories/week	O
over	O
6	O
months	O
.	O


CONCLUSIONS	O
Explicit	B-I
recommendation	I-I
for	O
self-paced	B-O
exercise	I-O
may	I-O
improve	I-O
adherence	I-O
to	I-P
exercise	I-P
programs	I-P
among	I-P
overweight	O
and	O
obese	O
adults	O
.	O


The	O
effects	O
of	O
treatment	O
with	O
interleukin-1	B-I
receptor	I-I
antagonist	I-I
on	O
the	O
inflamed	O
synovial	O
membrane	O
in	O
rheumatoid	B-P
arthritis	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
treatment	O
with	O
interleukin-1	B-I
receptor	I-I
antagonist	I-I
(	I-I
IL-1Ra	I-I
)	I-I
on	O
synovial	O
tissue	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O


METHODS	O
Twelve	B-P
patients	I-P
with	I-P
RA	I-P
entering	I-P
a	I-P
randomized	I-P
clinical	I-P
trial	I-P
of	I-P
human	I-I
recombinant	I-I
IL-1Ra	I-I
underwent	O
synovial	B-I
biopsies	I-I
before	O
and	O
after	O
treatment	O
.	O


Cellular	B-O
infiltration	I-O
and	I-O
adhesion	I-O
molecule	I-O
expression	I-O
were	O
evaluated	O
after	O
immunohistochemical	O
staining	O
.	O


RESULTS	O
There	O
was	O
a	O
notable	O
reduction	B-O
in	I-O
intimal	I-O
layer	I-O
macrophages	I-O
and	I-O
subintimal	I-O
macrophages	I-O
and	I-O
lymphocytes	I-O
after	O
treatment	O
with	O
IL-1Ra	B-I
at	O
150	O
mg/day	O
(	O
n=3	O
)	O
.	O


Increased	O
cellular	B-O
infiltration	I-O
was	O
observed	O
in	O
all	O
patients	O
receiving	O
placebo	B-I
(	O
n=3	O
)	O
;	O
variable	O
changes	O
were	O
observed	O
after	O
IL-1Ra	B-I
30	O
mg/day	O
(	O
n=6	O
)	O
.	O


In	O
a	O
limited	O
study	O
of	O
adhesion	O
molecule	O
expression	O
,	O
down-regulation	B-O
of	I-O
E-selectin	I-O
and	I-O
vascular	I-O
cell	I-O
adhesion	I-O
molecule-1	I-O
was	O
observed	O
after	O
treatment	O
with	O
IL-1Ra	B-I
150	O
mg/day	O
,	O
but	O
not	O
after	O
IL-1Ra	B-I
30	O
mg/day	O
or	O
placebo	B-I
.	I-I


The	O
apparent	O
arrest	B-O
of	I-O
progressive	I-O
joint	I-O
damage	I-O
seen	O
in	O
four	O
patients	O
after	O
treatment	O
with	O
IL-1Ra	B-I
was	O
associated	O
with	O
reduced	O
intimal	O
layer	O
macrophage	O
accumulation	O
in	O
all	O
patients	O
.	O


CONCLUSION	O
Treatment	O
of	O
RA	O
with	O
IL-1Ra	B-I
resulted	O
in	O
reduced	O
mononuclear	O
cell	O
infiltration	O
of	O
synovial	O
membrane	O
,	O
which	O
may	O
represent	O
the	O
in	O
vivo	O
inhibition	O
of	O
biologically	O
relevant	O
IL-1ss-mediated	O
pathogenic	O
effects	O
.	O


Randomized	O
,	O
controlled	O
trial	O
of	O
Behavioral	B-I
Family	I-I
Systems	I-I
Therapy	I-I
for	O
Diabetes	B-P
:	I-P
maintenance	O
and	O
generalization	O
of	O
effects	O
on	O
parent-adolescent	O
communication	O
.	O


We	O
report	O
a	O
randomized	O
trial	O
of	O
a	O
revised	O
Behavioral	B-I
Family	I-I
Systems	I-I
Therapy	I-I
for	I-I
Diabetes	I-I
(	I-I
BFST-D	I-I
)	I-I
intervention	I-I
.	O


Families	B-P
of	I-P
104	I-P
adolescents	I-P
with	I-P
diabetes	I-P
were	I-P
randomized	I-P
to	O
standard	B-I
care	I-I
(	I-I
SC	I-I
)	I-I
or	I-I
to	I-I
6	I-I
months	I-I
of	I-I
an	I-I
educational	I-I
support	I-I
group	I-I
(	I-I
ES	I-I
)	I-I
or	I-I
BFST-D.	I-I
Family	I-O
communication	I-O
and	I-O
problem-solving	I-O
skills	I-O
were	O
assessed	O
at	O
0	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
by	O
independent	O
rating	O
of	O
videotaped	O
family	O
problem-solving	O
discussions	O
.	O


BFST-D	B-I
improved	O
individual	O
communication	B-O
of	I-O
adolescents	I-O
and	I-O
mothers	I-O
,	I-O
but	I-O
not	I-O
fathers	I-O
.	I-O


BFST-D	B-I
significantly	O
improved	O
quality	B-O
of	I-O
family	I-O
interaction	I-O
compared	O
to	O
SC	O
(	O
10	O
of	O
12	O
comparisons	O
)	O
and	O
ES	O
(	O
6	O
of	O
12	O
comparisons	O
)	O
.	O


Changes	O
in	O
family	O
communication	O
were	O
differentially	O
associated	O
with	O
changes	O
in	O
glycemic	B-O
control	I-O
,	I-O
adherence	I-O
,	I-O
and	I-O
family	I-O
conflict	I-O
.	I-O


BFST-D	B-I
improved	O
family	B-O
communication	I-O
and	I-O
problem	I-O
solving	I-O
relative	O
to	O
SC	O
and	O
modestly	O
relative	O
to	O
ES	O
.	O


The	O
effect	O
of	O
lowering	O
LDL	O
cholesterol	O
on	O
vascular	O
access	O
patency	O
:	O
post	O
hoc	O
analysis	O
of	O
the	O
Study	O
of	O
Heart	O
and	O
Renal	O
Protection	O
.	O


BACKGROUND	O
AND	O
OBJECTIVES	O
Reducing	O
LDL	O
cholesterol	O
(	O
LDL-C	O
)	O
with	O
statin-based	B-I
therapy	I-I
reduces	O
the	O
risk	O
of	O
major	O
atherosclerotic	O
events	O
among	O
patients	B-P
with	I-P
CKD	I-P
,	I-P
including	I-P
dialysis	I-P
patients	I-P
,	O
but	O
the	O
effect	O
of	O
lowering	O
LDL-C	O
on	O
vascular	O
access	O
patency	O
is	O
unclear	O
.	O


DESIGN	O
,	O
SETTING	O
,	O
PARTICIPANTS	O
,	O
&	O
MEASUREMENTS	O
The	O
Study	O
of	O
Heart	O
and	O
Renal	O
Protection	O
(	O
SHARP	O
)	O
randomized	O
patients	B-P
with	I-P
CKD	I-P
to	I-P
20	I-I
mg	I-I
simvastatin	I-I
plus	I-I
10	I-I
mg	I-I
ezetimibe	I-I
daily	I-I
versus	I-I
matching	I-I
placebo	I-I
.	I-I


This	O
study	O
aimed	O
to	O
explore	O
the	O
effects	O
of	O
treatment	O
on	O
vascular	O
access	O
occlusive	O
events	O
,	O
defined	O
as	O
any	B-O
access	I-O
revision	I-O
procedure	I-O
,	I-O
access	I-O
thrombosis	I-O
,	I-O
removal	I-O
of	I-O
an	I-O
old	I-O
dialysis	I-O
access	I-O
,	I-O
or	I-O
formation	I-O
of	I-O
new	I-O
permanent	I-O
dialysis	I-O
access	I-O
.	I-O


RESULTS	O
Among	O
2353	B-P
SHARP	I-P
participants	I-P
who	I-P
had	I-P
functioning	I-P
vascular	I-P
access	I-P
at	O
randomization	O
,	O
allocation	O
to	O
simvastatin	O
plus	O
ezetimibe	O
resulted	O
in	O
a	O
13	O
%	O
proportional	O
reduction	B-O
in	I-O
vascular	I-O
access	I-O
occlusive	I-O
events	I-O
(	O
355	O
[	O
29.7	O
%	O
]	O
for	O
simvastatin/ezetimibe	B-I
versus	O
388	O
[	O
33.5	O
%	O
]	O
for	O
placebo	B-I
;	I-I
risk	O
ratio	O
[	O
RR	O
]	O
,	O
0.87	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
0.75	O
to	O
1.00	O
;	O
P=0.05	O
)	O
.	O


There	O
was	O
no	O
evidence	O
that	O
the	O
effects	O
of	O
treatment	O
differed	O
for	O
any	O
of	O
the	O
separate	O
components	O
of	O
this	O
outcome	O
.	O


To	O
test	O
the	O
hypothesis	O
raised	O
by	O
SHARP	O
,	O
comparable	O
analyses	O
were	O
performed	O
using	O
the	O
AURORA	O
(	O
A	O
Study	O
to	O
Evaluate	O
the	O
Use	O
of	O
Rosuvastatin	O
in	O
Subjects	O
on	O
Regular	O
Hemodialysis	O
:	O
An	O
Assessment	O
of	O
Survival	O
and	O
Cardiovascular	O
Events	O
)	O
trial	O
cohort	O
.	O


AURORA	O
did	O
not	O
provide	O
independent	O
confirmation	O
(	O
vascular	O
access	O
occlusive	O
events	O
:	O
352	O
[	O
28.9	O
%	O
]	O
for	O
rosuvastatin	O
versus	O
337	O
[	O
27.6	O
%	O
]	O
for	O
placebo	O
;	O
RR	O
,	O
1.06	O
,	O
95	O
%	O
CI	O
,	O
0.91	O
to	O
1.23	O
;	O
P=0.44	O
)	O
.	O


After	O
combining	O
the	O
two	O
trials	O
,	O
the	O
overall	O
effect	O
of	O
reducing	O
LDL-C	B-O
with	O
a	O
statin-based	O
regimen	O
on	O
vascular	O
access	O
occlusive	O
events	O
was	O
not	O
statistically	O
significant	O
(	O
707	O
[	O
29.3	O
%	O
]	O
with	O
any	O
LDL-C-lowering	O
therapy	O
versus	O
725	O
[	O
30.5	O
%	O
]	O
with	O
placebo	O
;	O
RR	O
,	O
0.95	O
,	O
95	O
%	O
CI	O
,	O
0.85	O
to	O
1.05	O
;	O
P=0.29	O
)	O
.	O


CONCLUSIONS	O
Exploratory	O
analyses	O
from	O
SHARP	O
suggest	O
that	O
lowering	O
LDL-C	O
with	O
statin-based	B-I
therapy	I-I
may	O
improve	O
vascular	O
access	O
patency	O
,	O
but	O
there	O
was	O
no	O
evidence	O
of	O
benefit	O
in	O
AURORA	O
.	O


Taken	O
together	O
,	O
the	O
available	O
evidence	O
suggests	O
that	O
any	O
benefits	O
of	O
lowering	O
LDL-C	O
on	O
vascular	O
access	O
patency	O
are	O
likely	O
to	O
be	O
modest	O
.	O


Pilot	O
study	O
of	O
a	O
moderate	B-I
dose	I-I
multivitamin/mineral	I-I
supplement	I-I
for	O
children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorder	I-P
.	I-P


OBJECTIVE	O
Determine	O
the	O
effect	O
of	O
a	O
moderate	O
dose	O
multivitamin/mineral	B-I
supplement	I-I
on	O
children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorder	I-P
.	I-P


DESIGN	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
3-month	O
study	O
.	O


SUBJECTS	O
Twenty	B-P
(	I-P
20	I-P
)	I-P
children	I-P
with	I-P
autistic	I-P
spectrum	I-P
disorder	I-P
,	I-P
ages	I-P
3-8	I-P
years	I-P
.	I-P


RESULTS	O
A	O
Global	O
Impressions	O
parental	O
questionnaire	O
found	O
that	O
the	O
supplement	O
group	O
reported	O
statistically	B-O
significant	I-O
improvements	I-O
in	O
sleep	B-O
and	I-O
gastrointestinal	I-O
problems	I-O
compared	O
to	O
the	O
placebo	B-I
group	O
.	O


An	O
evaluation	O
of	O
vitamin	B-O
B	I-O
(	I-O
6	I-O
)	I-O
levels	I-O
prior	O
to	O
the	O
study	O
found	O
that	O
the	O
autistic	B-P
children	I-P
had	O
substantially	B-O
elevated	I-O
levels	I-O
of	I-O
B6	I-O
compared	O
to	O
a	O
control	O
group	O
of	O
typical	O
children	O
(	O
75	O
%	O
higher	O
,	O
p	O
<	O
0.0000001	O
)	O
.	O


Vitamin	B-O
C	I-O
levels	I-O
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
and	O
the	O
placebo	O
group	O
had	O
levels	O
that	O
were	O
significantly	B-O
below	I-O
average	I-O
for	O
typical	O
children	O
,	O
whereas	O
the	O
supplement	O
group	O
had	O
near-average	O
levels	O
.	O


DISCUSSION	O
The	O
finding	O
of	O
high	B-O
vitamin	I-O
B	I-O
(	I-O
6	I-O
)	I-O
levels	I-O
is	O
consistent	O
with	O
recent	O
reports	O
of	O
low	O
levels	B-O
of	I-O
pyridoxal-5-phosphate	I-O
and	O
low	O
activity	B-O
of	I-O
pyridoxal	I-O
kinase	I-O
(	O
i.e.	O
,	O
pyridoxal	O
is	O
only	O
poorly	O
converted	O
to	O
pyridoxal-5-phosphate	O
,	O
the	O
enzymatically	O
active	O
form	O
)	O
.	O


This	O
may	O
explain	O
the	O
functional	O
need	O
for	O
high-dose	O
vitamin	B-I
B	I-I
(	I-I
6	I-I
)	I-I
supplementation	I-I
in	O
many	O
children	O
and	O
adults	O
with	O
autism	O
.	O


Rituximab	B-I
maintenance	O
improves	O
survival	O
in	O
male	B-P
patients	I-P
with	I-P
diffuse	I-P
large	I-P
B-cell	I-P
lymphoma	I-P
.	I-P


Results	O
of	O
the	O
HD2002	O
prospective	O
multicentre	B-P
randomized	O
phase	O
III	O
trial	O
.	O


In	O
the	O
multicentre	O
prospective	O
randomized	O
HD2002	O
trial	O
,	O
rituximab	B-I
maintenance	I-I
therapy	I-I
(	O
375	O
mg/m	O
(	O
2	O
)	O
every	O
3	O
months	O
for	O
2	O
years	O
)	O
versus	O
observation	B-I
was	O
evaluated	O
for	O
CD20	O
(	O
+	O
)	O
B-cell	O
lymphoma	O
.	O


Out	O
of	O
321	B-P
patients	I-P
[	I-P
161	I-P
randomized	I-P
to	I-P
the	I-P
treatment	I-P
group	I-P
(	I-P
TG	I-P
)	I-P
,	I-P
160	I-P
to	I-P
the	I-P
observation	I-P
group	I-P
(	I-P
OG	I-P
)	I-P
]	I-P
,	I-P
295	I-P
data	I-P
sets	I-P
were	O
evaluable	O
for	O
statistical	O
analysis	O
.	O


Estimated	O
5-year	B-O
relapse-free	I-O
survival	I-O
(	I-O
RFS	I-O
)	I-O
was	O
81	O
%	O
in	O
the	O
TG	O
and	O
70	O
%	O
in	O
the	O
OG	O
(	O
logrank	O
test	O
,	O
P	O
=	O
0·047	O
)	O
.	O


In	O
the	O
diffuse	O
large	O
B-cell	O
lymphoma	O
(	B-P
DLBCL	I-P
)	I-P
subgroup	I-P
(	O
n	O
=	O
152	O
)	O
,	O
5-year	B-O
RFS	I-O
was	O
excellent	O
,	O
at	O
87	O
%	O
in	O
the	O
TG	O
and	O
84	O
%	O
in	O
the	O
OG	O
(	O
logrank	O
test	O
,	O
P	O
=	O
0·35	O
)	O
.	O


Of	O
note	O
,	O
only	O
in	B-P
male	I-P
patients	I-P
of	I-P
the	I-P
DLBCL	I-P
subgroup	I-P
was	I-O
RFS	I-O
significantly	O
superior	O
in	O
the	O
TG	O
in	O
comparison	O
to	O
the	O
OG	O
(	O
5-year	O
RFS	O
:	O
88	O
%	O
vs.	O
74	O
%	O
;	O
logrank	O
test	O
,	O
P	O
=	O
0·05	O
)	O
.	O


Cox	O
regression	O
analysis	O
showed	O
a	O
significant	O
interaction	O
between	O
treatment	O
and	O
gender	O
regarding	B-O
overall	I-O
survival	I-O
(	I-O
OS	I-O
)	I-O
(	O
P	O
=	O
0·006	O
)	O
and	B-O
RFS	O
(	O
P	O
=	O
0·02	O
)	O
,	O
with	O
a	O
lower	O
hazard	O
in	O
females	O
than	O
males	O
in	B-O
the	I-O
OG	I-O
[	I-O
OS	I-O
:	I-O
hazard	I-O
ratio	I-O
(	O
HR	O
)	O
(	O
female	O
:	O
male	O
)	O
=	O
0·11	B-O
;	I-O
95	I-O
%	I-O
confidence	I-O
interval	I-O
(	O
CI	O
)	O
=	O
0·00-1·03	B-O
;	I-O
RFS	O
:	O
HR	O
(	O
female	O
:	O
male	O
)	O
=	O
0·27	O
;	O
95	O
%	O
CI	O
=	O
0·05-0·97	O
]	O
,	O
and	O
no	O
significant	O
differences	O
between	O
males	O
and	O
females	O
in	O
the	O
TG	O
.	O


We	O
conclude	B-I
that	I-I
Rituximab	I-I
maintenance	I-I
therapy	O
improves	O
survival	B-P
in	I-P
male	I-P
patients	I-P
with	O
DLBCL	O
.	O


Double-blind	O
trial	O
comparing	O
the	O
effectiveness	O
of	O
the	O
homeopathic	B-I
preparation	I-I
Galphimia	I-I
potentiation	I-I
D6	I-I
,	I-I
Galphimia	I-I
dilution	I-I
10	I-I
(	I-I
-6	I-I
)	I-I
and	I-I
placebo	I-I
on	O
pollinosis	B-O
.	I-O


The	O
preparation	O
of	O
homeopathic	B-I
drugs	I-I
is	O
based	O
on	O
potentiation	O
.	O


In	O
this	O
potentiation	O
the	O
primary	O
substance	O
is	O
specially	O
mixed	O
with	O
a	O
carrier	O
(	O
typically	O
90	O
%	O
ethanol	B-I
)	I-I
in	O
the	O
ratio	O
1:10	O
.	O


Usually	O
this	O
potentiation	O
is	O
done	O
repeatedly	O
and	O
the	O
final	O
drug	O
is	O
labeled	O
,	O
e.g.	O
,	O
"	B-I
D6	I-I
"	I-I
which	O
means	O
a	O
6	O
times	O
decimal	O
potentiation	O
.	O


In	O
a	O
controlled	O
randomized	O
strictly	O
double-blind	O
trial	O
with	O
164	B-P
patients	I-P
the	O
effectiveness	O
of	O
homeopathically	O
prepared	O
Galphimia	B-I
D6	I-I
,	I-I
a	I-I
conventional	I-I
Galphimia	I-I
dilution	I-I
10	O
(	O
-6	O
)	O
and	O
a	O
placebo	B-I
was	O
investigated	O
for	O
the	O
therapy	O
of	O
pollinosis	B-O
.	I-O


The	O
average	B-O
duration	I-O
of	I-O
treatment	I-O
was	O
about	O
5	O
weeks	O
.	O


Although	O
no	O
statistical	O
significance	O
was	O
achieved	O
,	O
it	O
is	O
remarkable	O
that	O
there	O
was	O
a	O
clear	O
trend	O
for	O
the	O
superiority	B-O
of	O
Galphimia	B-O
D6	I-O
while	O
the	O
Galphimia	B-O
dilution	I-O
10	I-O
(	I-O
-6	I-O
)	I-O
was	O
about	O
equally	O
effective	O
compared	O
with	O
placebo	B-I
.	I-I


The	O
study	O
itself	O
demonstrates	O
that	O
it	O
is	O
possible	O
to	O
do	O
strictly	O
controlled	O
trials	O
for	O
homeopathic	B-I
drugs	I-I
and	O
with	O
medical	O
practitioners	O
.	O


Intensive	B-I
induction	I-I
chemotherapy	I-I
for	O
small	O
cell	O
anaplastic	O
carcinoma	O
of	O
the	O
lung	O
.	O


The	O
role	O
of	O
intensive	B-I
induction	I-I
chemotherapy	I-I
in	O
small	O
cell	O
cancer	O
of	O
the	O
lung	O
remains	O
unclear	O
.	O


Twenty-eight	B-P
newly	I-P
diagnosed	I-P
patients	I-P
with	I-P
small	I-P
cell	I-P
lung	I-P
cancer	I-P
were	O
randomized	O
to	O
receive	O
either	O
high-dose	B-I
or	I-I
standard-dose	I-I
cyclophosphamide	I-I
,	I-I
vincristine	I-I
,	I-I
and	I-I
semustine	I-I
in	O
a	O
trial	O
where	O
the	O
dose	O
of	O
induction	O
chemotherapy	O
was	O
the	O
sole	O
treatment	O
variable	O
.	O


Complete	B-O
responses	I-O
(	I-O
CR	I-O
)	I-O
were	O
achieved	O
in	O
57	O
%	O
of	O
patients	O
receiving	O
high-dose	O
therapy	O
as	O
compared	O
to	O
21	O
%	O
of	O
patients	O
receiving	O
standard-dose	O
therapy	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O


There	O
was	O
a	O
higher	O
rate	O
of	O
severe	B-O
toxicity	I-O
in	O
the	O
high-dose	O
group	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O


The	O
overall	B-O
median	I-O
survival	I-O
was	O
not	O
improved	O
(	O
36	O
weeks	O
for	O
the	O
high-dose	O
group	O
vs	O
43	O
weeks	O
for	O
the	O
standard-dose	O
group	O
)	O
;	O
however	O
,	O
the	O
median	B-O
survival	I-O
in	O
patients	O
achieving	O
CR	O
was	O
prolonged	O
(	O
92	O
weeks	O
for	O
the	O
high-dose	O
group	O
vs	O
50	O
weeks	O
for	O
the	O
standard-dose	O
group	O
)	O
.	O


These	O
effects	O
were	O
most	O
pronounced	O
in	O
patients	B-P
with	I-P
extensive	I-P
disease	I-P
;	I-P
a	O
CR	B-O
after	O
induction	O
was	O
achieved	O
in	O
five	O
of	O
nine	O
patients	O
treated	O
with	O
high	O
doses	O
but	O
not	O
in	O
any	O
of	O
those	O
treated	O
with	O
standard	O
doses	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O


A	O
small	O
group	O
of	O
patients	O
appear	O
to	O
benefit	O
by	O
achieving	O
a	O
long-term	O
remission	O
with	O
intensive	O
induction	O
chemotherapy	O
,	O
but	O
this	O
effect	O
may	O
be	O
offset	O
by	O
increased	O
morbidity	O
.	O


Benefits	B-O
,	I-O
morbidity	I-O
,	I-O
and	I-O
mortality	I-O
associated	O
with	O
long-term	O
administration	O
of	O
oral	B-I
anticoagulant	I-I
therapy	I-I
to	O
patients	B-P
with	I-P
peripheral	I-P
arterial	I-P
bypass	I-P
procedures	I-P
:	I-P
a	O
prospective	O
randomized	O
study	O
.	O


BACKGROUND	O
The	O
benefits	O
of	O
the	O
long-term	O
administration	O
of	O
oral	B-I
anticoagulant	I-I
therapy	I-I
remain	O
unclear	O
in	O
patients	B-P
with	I-P
lower	I-P
extremity	I-P
arterial	I-P
bypass	I-P
surgery	I-P
.	I-P


We	O
studied	O
the	O
effect	O
of	O
warfarin	B-I
plus	I-I
aspirin	I-I
therapy	I-I
(	I-I
WASA	I-I
)	I-I
versus	I-I
aspirin	I-I
therapy	I-I
alone	I-I
(	I-I
ASA	I-I
)	I-I
on	O
patient	B-O
mortality	I-O
,	I-O
morbidity	I-O
and	I-O
bypass	I-O
patency	I-O
rates	I-O
in	O
a	O
randomized	O
clinical	O
trial	O
.	O


METHODS	O
In	O
a	O
multicenter	O
,	O
prospective	O
,	O
nonmasked	O
clinical	O
trial	O
,	O
831	B-P
patients	I-P
who	I-P
underwent	I-P
peripheral	I-P
arterial	I-P
bypass	I-P
surgery	I-P
were	O
compared	O
in	O
a	O
long-term	B-P
treatment	I-P
program	I-P
of	I-P
WASA	I-I
(	O
target	O
international	O
normalized	O
ratio	O
of	O
1.4	O
to	O
2.8	O
;	O
325	O
mg/day	O
)	O
with	O
ASA	B-I
(	O
325	O
mg/day	O
)	O
.	O


The	O
primary	O
end	O
point	O
was	O
bypass	B-O
patency	I-O
,	I-O
and	I-O
mortality	I-O
and	I-O
morbidity	I-O
were	O
the	O
secondary	O
endpoints	O
.	O


RESULTS	O
There	O
were	O
133	O
deaths	B-O
in	O
the	O
WASA	B-I
group	O
(	O
31.8	O
%	O
)	O
and	O
95	O
deaths	B-O
in	O
the	O
ASA	B-I
group	O
(	O
23.0	O
%	O
;	O
risk	O
ratio	O
,	O
1.41	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.09	O
to	O
1.84	O
;	O
P	O
=.0001	O
)	O
.	O


Major	B-O
hemorrhagic	I-O
events	I-O
occurred	O
more	O
frequently	O
in	O
the	O
WASA	B-I
group	O
(	O
WASA	O
,	O
n	O
=	O
35	O
;	O
ASA	B-I
,	O
n	O
=	O
15	O
;	O
P	O
=.02	O
)	O
.	O


In	O
the	O
prosthetic	O
bypass	O
group	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
patency	B-O
rate	I-O
in	O
the	O
8-mm	O
bypass	O
subgroup	O
,	O
but	O
there	O
was	O
a	O
significant	O
difference	O
in	O
patency	B-O
rate	I-O
in	O
the	O
6-mm	O
bypass	O
subgroup	O
(	O
femoral-popliteal	O
;	O
71.4	O
%	O
in	O
the	O
WASA	B-I
group	O
versus	O
57.9	O
%	O
in	O
the	O
ASA	B-I
group	O
;	O
P	O
=.02	O
)	O
.	O


In	O
the	O
vein	O
bypass	O
group	O
,	O
patency	B-O
rate	I-O
was	O
unaffected	O
(	O
75.3	O
%	O
in	O
the	O
WASA	B-I
group	O
versus	O
74.9	O
%	O
in	O
the	O
ASA	O
group	O
)	O
.	O


CONCLUSION	O
The	O
long-term	O
administration	O
of	O
warfarin	B-I
therapy	I-I
when	O
combined	O
with	O
aspirin	O
therapy	O
has	O
only	O
a	O
few	O
selected	O
indications	O
for	O
improvement	O
of	O
bypass	B-O
patency	I-O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	B-O
of	I-O
morbidity	I-O
and	I-O
mortality	I-O
.	I-O


Bupropion	B-I
SR	I-I
and	I-I
counseling	I-I
for	I-I
smoking	I-I
cessation	I-P
in	O
actual	O
practice	O
:	O
predictors	O
of	O
outcome	O
.	O


To	O
date	O
,	O
only	O
one	O
study	O
has	O
been	O
published	O
on	O
individual	O
characteristics	O
associated	O
with	O
outcome	O
following	O
standard	B-I
treatment	I-I
with	I-I
bupropion	I-I
SR	I-I
for	O
smoking	O
cessation	O
.	O


To	O
investigate	O
treatment	O
outcome	O
beyond	O
the	O
6-week	O
end-of-treatment	O
point	O
,	O
the	O
present	O
study	O
examined	O
characteristics	O
associated	O
with	O
more	O
clinically	O
relevant	O
smoking	O
endpoints	O
following	O
treatment	O
with	O
bupropion	B-I
SR	I-I
in	O
a	O
large	O
health	O
care	O
system	O
.	O


A	O
total	B-P
of	I-P
1,524	I-P
smokers	I-P
(	I-P
649	I-P
men	I-P
and	I-P
875	I-P
women	I-P
)	I-P
of	I-P
average	I-P
age	I-P
45.1	I-P
years	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
combinations	O
of	O
bupropion	B-I
SR	I-I
(	O
150	O
or	O
300	O
mg	O
)	O
and	O
behavioral	B-I
counseling	I-I
(	I-I
tailored	I-I
mailings	I-I
or	I-I
proactive	I-I
telephone	I-I
counseling	I-I
)	I-I
and	O
assessed	O
for	O
point-prevalent	O
smoking	O
status	O
at	O
3	O
and	O
12	O
months	O
.	O


Multiple	O
logistic	O
regression	O
analyses	O
of	O
potential	O
risk	O
factors	O
for	O
12-month	O
point-prevalent	O
smoking	O
and	O
for	O
persistent	O
smoking	O
(	O
point-prevalent	O
smoking	O
at	O
both	O
follow-ups	O
)	O
following	O
treatment	O
were	O
conducted	O
for	O
men	O
and	O
women	O
combined	O
and	O
separately	O
.	O


Risk	O
factors	O
for	O
smoking	O
at	O
both	O
endpoints	O
in	O
the	O
combined	O
sample	O
included	O
treatment	O
with	O
tailored	O
mailings	O
,	O
female	O
gender	O
,	O
younger	O
age	O
,	O
higher	O
levels	O
of	O
tobacco	O
dependence	O
,	O
shorter	O
previous	O
quit	O
attempts	O
,	O
previous	O
use	O
of	O
nicotine	O
replacement	O
therapy	O
,	O
and	O
report	O
of	O
current	O
depressive	O
symptoms	O
or	O
lifetime	O
depression	O
.	O


Risk	O
factors	O
for	O
smoking	O
following	O
treatment	O
identified	O
in	O
women	O
only	O
included	O
treatment	O
with	O
the	O
lower	O
dose	O
of	O
bupropion	B-I
SR	I-I
,	O
younger	O
age	O
,	O
and	O
higher	O
perceived	O
stress	O
,	O
whereas	O
those	O
that	O
were	O
unique	O
to	O
men	O
included	O
the	O
presence	O
of	O
lifetime	O
depression	O
.	O


The	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
their	O
implications	O
for	O
the	B-O
need	I-O
for	I-O
more	I-O
effective	I-O
treatments	I-O
in	O
general	O
,	O
and	O
the	O
role	O
of	O
individual	B-O
differences	I-O
in	I-O
the	I-O
likelihood	I-O
of	I-O
returning	I-O
to	I-O
smoking	I-O
following	I-O
treatment	I-O
for	I-O
quitting	O
.	O


DNA	O
as	O
a	O
carrier	O
for	O
anthracyclines	B-I
in	O
the	O
treatment	B-P
of	I-P
acute	I-O
myelocytic	I-O
leukemia	I-O
(	I-O
AML	I-O
)	I-O
.	I-O


Mandibular	O
overdentures	O
supported	O
by	O
two	O
Brånemark	O
,	O
IMZ	B-I
or	I-I
ITI	I-I
implants	I-I
:	I-I
a	O
5-year	O
prospective	O
study	O
.	O


OBJECTIVES	O
The	O
aim	O
of	O
this	O
prospective	O
comparative	O
study	O
was	O
to	O
evaluate	O
the	B-O
survival	I-O
rate	I-O
and	O
the	B-O
condition	I-O
of	I-O
the	I-O
peri-implant	I-O
tissues	I-O
of	O
the	O
IMZ	B-I
implant	I-I
system	O
(	O
two-stage	O
cylindertype	O
)	O
,	O
the	B-I
Brånemark	I-I
implant	I-I
system	O
(	O
two-stage	O
screwtype	O
)	O
and	O
the	B-I
ITI	I-I
implant	I-I
system	O
(	O
one-stage	O
screwtype	O
)	O
supporting	O
a	O
mandibular	O
overdenture	O
during	O
a	O
5-year	O
follow-up	O
period	O
.	O


MATERIAL	O
AND	O
METHODS	B-P
Three	I-P
groups	I-P
of	I-P
30	I-P
edentulous	I-P
patients	I-P
were	I-P
treated	I-P
with	I-I
two	I-I
endosseous	I-I
implants	I-I
in	O
the	O
interforaminal	O
region	O
of	O
the	O
mandible	O
.	O


Clinical	O
and	O
radiographic	O
parameters	O
were	O
evaluated	O
immediately	O
after	O
completion	O
of	O
the	O
prosthetic	O
treatment	O
and	O
after	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
years	O
of	O
functional	O
loading	O
.	O


RESULTS	O
The	B-O
five-year	I-O
survival	I-O
rate	I-O
is	O
98.3	O
%	O
for	O
the	O
IMZ	O
group	O
,	O
98.3	O
%	O
for	O
the	O
Brå	O
group	O
and	O
100	O
%	O
for	O
the	O
ITI	O
group	B-O
.	I-O


Mean	B-O
scores	I-O
on	I-O
indices	I-O
for	I-O
plaque	I-O
,	I-O
calculus	I-O
,	I-O
gingiva	I-O
and	I-O
bleeding	I-O
were	O
very	O
low	O
at	O
all	O
evaluation	O
periods	B-O
.	I-O


Mean	B-O
marginal	I-O
bone	I-O
loss	I-O
over	I-O
a	I-O
period	I-O
of	I-O
5	I-O
years	I-O
,	O
was	O
1.4	O
mm	O
for	O
the	O
IMZ	O
group	O
,	O
0.7	O
mm	O
for	O
the	O
Brå	O
group	O
and	O
0.9	O
mm	O
for	O
the	O
ITI	O
group	O
.	O


CONCLUSION	O
It	O
is	O
concluded	O
that	O
two	O
implants	O
placed	O
in	O
the	O
interforaminal	O
region	O
,	O
connected	O
with	O
a	O
bar	O
,	O
supply	O
a	O
proper	O
base	O
for	O
the	O
support	O
of	B-P
a	I-P
mandibular	I-P
overdenture	I-P
in	I-P
the	I-P
edentulous	I-P
patient	I-P
.	O


After	O
5	O
years	O
no	O
clinically	O
relevant	O
and	O
statistically	O
significant	O
radiographic	O
changes	O
had	O
developed	O
between	O
the	O
three	O
implant	O
systems	O
.	O


Tubeless	B-I
percutaneous	I-I
nephrolithotomy	I-I
:	I-I
safe	O
even	O
in	O
supracostal	O
access	O
.	O


PURPOSE	O
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
outcome	B-O
and	I-O
safety	I-O
of	O
tubeless	B-I
percutaneous	I-I
nephrolithotomy	I-I
(	I-I
PCNL	I-I
)	I-I
in	O
the	O
treatment	O
of	O
renal	B-P
calculi	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Between	B-P
November	I-P
2005	I-P
and	I-P
March	I-P
2006	I-P
,	I-P
48	I-P
patients	I-P
were	I-P
randomized	I-P
to	I-P
either	I-P
an	I-P
18F	I-I
Re-entry	I-I
nephrostomy	I-I
tube	I-I
(	I-P
group	I-P
1	I-P
)	I-P
or	I-I
a	I-I
6F	I-I
Double-J	I-I
stent	I-I
(	I-P
group	I-P
2	I-P
)	I-P
.	I-P


The	O
two	O
groups	O
were	O
well	O
matched	O
for	O
age	O
,	O
sex	O
,	O
stone	O
size	O
,	O
stone	O
laterality	O
,	O
and	O
number	O
of	O
previous	O
renal	O
procedures	O
.	O


All	O
PCNL	O
procedures	O
were	O
performed	O
by	O
the	O
same	O
surgeon	O
.	O


Postoperative	B-O
visual	I-O
analog	I-O
pain	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
scores	I-O
at	O
8	O
and	O
24	O
hours	O
and	O
14	O
days	O
after	O
surgery	O
,	O
in-hospital	B-O
analgesic	I-O
use	I-O
,	I-O
length	I-O
of	I-O
hospital	I-O
stay	I-O
,	I-O
success	I-O
rate	I-O
,	I-O
blood	I-O
transfusion	I-O
rate	I-O
,	I-O
and	I-O
postoperative	I-O
complications	I-O
were	O
compared	O
for	O
the	O
two	O
groups	O
.	O


RESULTS	O
The	O
mean	B-O
hospital	I-O
stays	I-O
in	O
groups	O
1	O
and	O
2	O
were	O
3.1	O
and	O
1.6	O
days	O
,	O
respectively	O
(	O
P	O
=	O
0.003	O
)	O
.	O


The	O
mean	B-O
VAS	I-O
scores	I-O
8	O
and	O
24	O
hours	O
after	O
surgery	O
were	O
significantly	O
lower	O
in	O
group	O
2	O
than	O
in	O
group	O
1	O
(	O
P	O
=	O
0.001	O
)	O
.	O


The	O
postoperative	B-O
analgesic	I-O
requirement	I-O
(	I-I
diclofenac	I-I
sodium	I-I
)	I-I
was	O
significantly	O
higher	O
in	O
group	O
1	O
(	O
263	O
mg	O
)	O
than	O
in	O
group	O
2	O
(	O
120	O
mg	O
;	O
P	O
=	O
0.02	O
)	O
.	O


The	O
rate	B-O
of	I-O
blood	I-O
transfusion	I-O
in	O
the	O
two	O
groups	O
was	O
similar	O
(	O
P	O
=	O
NS	O
)	O
.	O


There	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
VAS	B-O
scores	I-O
on	O
postoperative	O
day	O
14	O
.	O


The	O
number	B-O
of	I-O
supracostal	I-O
accesses	I-O
was	O
significantly	O
higher	O
in	O
group	O
2	O
than	O
in	O
group	O
1	O
(	O
P	O
=	O
0.02	O
)	O
.	O


The	O
stone-free	B-O
rates	I-O
and	I-O
the	I-O
numbers	I-O
of	I-O
patients	I-O
with	O
insignificant	B-O
residual	I-O
fragments	I-O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O


There	O
was	O
no	B-O
urine	I-O
leakage	I-O
or	I-O
formation	I-O
of	I-O
urinoma	I-O
in	O
patients	O
with	O
Double-J	O
stents	O
.	O


CONCLUSION	O
Tubeless	B-I
PCNL	I-I
is	O
safe	O
and	O
effective	O
even	O
after	O
supracostal	O
access	O
and	O
is	O
associated	O
with	O
less	O
postoperative	B-O
pain	I-O
and	O
a	B-O
shorter	I-O
hospital	I-O
stay	I-O
.	I-O


Cardiovascular	O
and	O
behavioral	O
effects	O
of	O
aerobic	B-I
exercise	I-I
training	O
in	O
healthy	B-P
older	I-P
men	I-P
and	I-P
women	I-P
.	I-P


The	O
cardiovascular	O
and	O
behavioral	O
adaptations	O
associated	O
with	O
a	O
4-month	O
program	O
of	O
aerobic	B-I
exercise	I-I
training	I-I
were	O
examined	O
in	O
101	B-P
older	I-P
men	I-P
and	I-P
women	I-P
(	I-P
mean	I-P
age	I-P
=	I-P
67	I-P
years	I-P
)	I-P
.	I-P


Subjects	O
were	O
randomly	O
assigned	O
to	O
an	O
Aerobic	B-I
Exercise	I-I
group	I-I
,	I-I
a	I-I
Yoga	I-I
and	I-I
Flexibility	I-I
control	I-I
group	I-I
,	I-I
or	I-I
a	I-I
Waiting	I-I
List	I-I
control	I-I
group	I-I
.	I-I


Prior	O
to	O
and	O
following	O
the	O
4-month	O
program	O
,	O
subjects	O
underwent	O
comprehensive	O
physiological	O
and	O
psychological	O
evaluations	O
.	O


Physiological	B-O
measures	I-O
included	I-O
measurement	I-O
of	I-O
blood	I-O
pressure	I-O
,	I-O
lipids	I-O
,	I-O
bone	I-O
density	I-O
,	I-O
and	I-O
cardiorespiratory	I-O
fitness	I-O
including	I-O
direct	I-O
measurements	I-O
of	I-O
peak	I-O
oxygen	I-O
consumption	I-O
(	I-O
VO2	I-O
)	I-O
and	I-O
anaerobic	I-O
threshold	I-O
.	I-O


Psychological	B-O
measures	I-O
included	I-O
measures	I-O
of	I-O
mood	I-O
,	I-O
psychiatric	I-O
symptoms	I-O
,	I-O
and	I-O
neuropsychological	I-O
functioning	I-O
.	I-O


This	O
study	O
demonstrated	O
that	O
4	O
months	O
of	O
aerobic	B-I
exercise	I-I
training	O
produced	O
an	O
overall	O
11.6	O
%	O
improvement	O
in	O
peak	O
VO2	O
and	O
a	O
13	O
%	O
increase	O
in	O
anaerobic	O
threshold	O
.	O


In	O
contrast	O
,	O
the	O
Yoga	B-I
and	O
Waiting	B-I
List	I-I
control	O
groups	O
experienced	O
no	O
change	O
in	O
cardiorespiratory	O
fitness	O
.	O


Other	O
favorable	O
physiological	O
changes	O
observed	O
among	O
aerobic	O
exercise	O
participants	O
included	O
lower	O
cholesterol	O
levels	O
,	O
diastolic	O
blood	O
pressure	O
levels	O
,	O
and	O
for	O
subjects	O
at	O
risk	O
for	O
bone	O
fracture	O
,	O
a	O
trend	O
toward	O
an	O
increase	O
in	O
bone	O
mineral	O
content	O
.	O


Although	O
few	O
significant	O
psychological	O
changes	O
could	O
be	O
attributed	O
to	O
aerobic	B-I
exercise	I-I
training	O
,	O
participants	O
in	O
the	O
two	O
active	O
treatment	O
groups	O
perceived	O
themselves	O
as	O
improving	O
on	O
a	O
number	O
of	O
psychological	O
and	O
behavioral	O
dimensions	O
.	O


Locomoting-to-reach	B-I
:	I-I
information	O
variables	O
and	O
control	O
strategies	O
for	O
nested	O
actions	O
.	O


Locomoting-to-reach	B-I
is	O
a	O
basic	O
perception/action	O
behavior	O
that	O
requires	O
visual	O
information	O
for	O
the	O
control	O
of	O
both	O
locomotion	O
and	O
reaching	O
components	O
.	O


We	O
investigated	O
the	O
visual	O
information	O
and	O
the	O
control	O
strategies	O
used	O
to	O
guide	O
both	O
the	O
head	O
and	O
the	O
hand	O
on	O
approach	O
to	O
a	O
target	O
in	O
a	O
locomotion-to-reach	B-I
task	I-I
.	I-I


In	O
this	O
study	O
,	O
participants	B-P
were	I-P
required	I-P
to	I-P
locomote	I-I
in	I-I
the	I-I
dark	I-I
to	I-I
a	I-I
lit	I-I
target	I-I
in	I-I
three	I-I
different	I-I
conditions	I-I
:	I-I
monocular	I-I
vision/target	I-I
with	I-I
image	I-I
size	I-I
,	I-I
binocular	I-I
vision/target	I-I
with	I-I
image	I-I
size	I-I
,	I-I
and	I-I
binocular	I-I
vision/point-light	I-I
target	I-I
(	I-I
without	I-I
image	I-I
size	I-I
)	I-I
.	I-I


In	O
task	O
one	O
,	O
participants	O
brought	O
their	O
eyes	O
to	O
the	O
target	O
.	O


In	O
task	O
two	O
,	O
participants	O
brought	O
their	O
outstretched	O
hand	O
to	O
the	O
target	O
.	O


Movement	B-O
trajectories	I-O
for	O
both	O
tasks	O
were	O
analyzed	O
.	O


Results	O
show	O
that	O
participants	B-P
were	O
significantly	O
more	O
accurate	B-O
when	I-O
binocular	I-O
information	I-O
was	I-O
present	I-O
.	I-O


In	O
both	O
tasks	O
,	O
participants	O
were	O
found	O
to	O
use	O
a	O
proportional	B-O
rate	I-O
control	I-O
strategy	I-O
rather	I-O
than	I-O
a	I-O
constant	I-O
τ	I-O
strategy	I-O
.	O


In	O
the	B-O
walk-to-reach	I-O
task	I-O
,	O
they	O
used	B-O
monocular	I-O
and/or	I-O
binocular	I-O
τ	I-O
information	I-O
to	I-O
guide	I-O
the	I-O
head	I-O
and	O
then	O
switched	O
to	O
using	B-O
relative	I-O
disparity	I-O
τ	I-O
to	I-O
guide	I-O
the	I-O
hand	I-O
to	I-O
final	I-O
target	I-O
acquisition	I-O
,	O
switching	O
when	O
the	O
hand	O
centric	O
τ	O
became	O
less	O
than	O
the	O
head	O
centric	O
τ.	O
Dynamical	O
models	O
of	O
the	O
information	O
and	O
control	O
strategies	O
were	O
used	O
to	O
perform	B-O
simulations	I-O
that	O
were	O
found	O
to	O
fit	O
the	O
data	O
well	O
.	O


The	O
conclusion	O
is	O
that	B-O
proportional	I-O
rate	I-O
control	I-O
is	O
used	O
sequentially	O
with	B-O
head	I-O
centric	I-O
,	I-O
then	I-O
hand-centric	I-O
τ-based	I-O
information	I-O
,	O
using	O
at	O
each	O
moment	B-O
the	O
τ	O
with	O
the	O
smallest	O
value	O
.	O


0.1	O
%	O
bupivacaine	B-I
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	B-P
major	I-P
abdominal	I-P
surgery	I-P
.	I-P


BACKGROUND	O
AND	O
OBJECTIVES	O
Although	O
local	O
anesthesia	O
has	O
been	O
demonstrated	O
to	O
potentiate	O
spinal	O
morphine	O
analgesia	O
in	O
animal	O
studies	O
,	O
results	O
comparing	O
epidural	O
local	O
anesthesia/opioid	O
mixtures	O
with	O
opioid	O
alone	O
are	O
contradictory	O
in	O
clinical	O
studies	O
.	O


The	O
hypothesis	O
was	O
that	O
,	O
although	O
the	O
concentration	O
of	O
bupivacaine	B-I
(	O
0.1	O
%	O
)	O
was	O
low	O
to	O
minimize	O
its	O
adverse	O
effects	O
,	O
if	O
the	O
infusion	O
rate	O
of	O
a	O
fentanyl/bupivacaine	B-I
solution	O
was	O
closely	O
adjusted	O
according	O
to	O
need	O
,	O
the	O
presence	O
bupivacaine	O
would	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
.	O


METHODS	O
Forty	B-P
patients	I-P
were	O
randomly	O
assigned	B-I
to	I-I
receive	I-I
either	I-I
fentanyl	I-I
(	I-I
10	I-I
micrograms/mL	I-I
)	I-I
or	I-I
a	I-I
fentanyl/bupivacaine	I-I
(	I-I
0.1	I-I
%	I-I
)	I-I
mixture	I-I
epidurally	I-I
corresponding	I-I
to	I-I
the	I-I
dermatome	I-I
of	I-I
the	I-I
surgical	I-I
incision	I-I
in	I-I
a	I-I
double-blind	I-I
fashion	I-I
for	I-I
the	I-I
first	I-I
18	I-I
hours	I-I
after	I-I
major	I-I
abdominal	I-I
surgery	I-I
.	I-I


The	B-I
infusion	I-I
was	I-I
titrated	I-I
for	I-I
each	I-I
patient	I-I
to	I-I
the	I-I
rate	I-I
required	I-I
for	I-I
pain	I-I
relief	I-I
during	I-I
forced	I-I
inspiration	I-I
(	I-I
pain	I-I
score	I-I
<	I-I
or	I-I
=	I-I
2	I-I
,	I-I
maximum	I-I
10	I-I
)	I-I
.	I-I


Pain	O
scores	O
,	O
the	O
fentanyl	O
doses	O
required	O
,	O
plasma	O
concentrations	O
of	O
fentanyl	O
at	O
18	O
hours	O
,	O
and	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	B-O
effects	I-O
were	O
recorded	O
.	O


RESULTS	O
Patients	O
reported	O
similar	O
median	B-O
pain	I-O
scores	I-O
and	O
were	O
equally	O
satisfied	O
with	O
pain	B-O
relief	I-O
in	O
both	O
groups	O
.	O


The	O
mean	B-O
required	I-O
post-operative	I-O
fentanyl	I-O
infusion	I-O
rate	I-O
(	O
57.7	O
+/-	O
19.5	O
micrograms/h	O
)	O
and	O
the	O
plasma	B-O
concentrations	I-O
(	O
0.84	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl	O
group	O
were	O
comparable	O
to	O
the	O
infusion	B-O
rate	I-O
(	O
54.4	O
+/-	O
19.2	O
micrograms/h	O
)	O
and	O
the	O
plasma	B-O
concentrations	I-O
(	O
0.86	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl/bupivacaine	O
group	O
.	O


Respiratory	B-O
and	I-O
cardiovascular	I-O
functions	I-O
were	O
preserved	O
,	O
and	O
the	O
incidence	B-O
of	I-O
nausea	I-O
,	I-O
pruritus	I-O
,	I-O
and	I-O
periods	I-O
of	I-O
drowsiness	I-O
or	I-O
sleep	I-O
were	O
similar	O
in	O
both	O
groups	O
.	O


CONCLUSIONS	O
In	O
low	O
concentrations	O
(	O
0.1	O
%	O
)	O
,	O
bupivacaine	B-I
did	O
not	O
reduce	O
the	O
titrated	O
dose	O
of	O
epidural	O
fentanyl	O
required	O
for	O
adequate	O
pain	O
relief	O
during	O
forced	O
inspiration	O
after	O
major	O
abdominal	O
surgery	O
.	O


The	O
incidence	O
and	O
severity	O
of	O
adverse	O
effects	O
were	O
also	O
comparable	O
whether	O
or	O
not	O
low-dose	O
bupivacaine	B-I
infusion	O
was	O
used	O
.	O


Capsaicin	B-I
jelly	I-I
against	O
migraine	B-O
pain	I-O
.	I-O


OBJECTIVE	O
Recent	O
studies	O
support	O
the	O
role	O
of	O
extracranial	O
perivascular	O
afferents	O
in	O
a	O
substantial	O
percentage	O
of	O
migraineurs	B-P
.	I-P


Perivascular	O
afferent	O
fibres	O
of	O
the	O
superficial	O
temporal	O
artery	O
contain	O
peptides	O
,	O
like	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
and	O
substance	O
P	O
(	O
SP	O
)	O
.	O


CGRP	O
and	O
SP	O
are	O
considered	O
relevant	O
in	O
the	O
genesis	O
of	O
migraine	O
pain	O
.	O


Capsaicin	B-I
is	O
an	O
agonist	O
of	O
the	O
transient	O
receptor	O
potential	O
vanilloid	O
type	O
1	O
.	O


It	O
causes	O
membrane	O
depolarisation	O
of	O
sensory	O
neurons	O
,	O
which	O
release	O
CGRP	O
,	O
SP	O
and	O
other	O
pain	O
peptides	O
;	O
excitation	O
is	O
followed	O
by	O
a	O
refractory	O
state	O
,	O
causing	O
inactivation	O
.	O


Topical	B-I
capsaicin	I-I
has	O
been	O
found	O
to	O
be	O
efficacious	O
in	O
several	O
types	O
of	O
neuropathic	B-O
pain	I-O
.	I-O


We	O
attempted	O
to	O
verify	O
whether	O
topical	B-I
periarterial	I-I
capsaicin	I-I
could	O
ameliorate	O
pain	B-O
in	I-O
absence	I-O
of	I-O
and	I-O
during	I-O
a	I-O
migraine	I-O
attack	I-O
.	I-O


METHODS	O
On	O
23	B-P
migraineurs	I-P
showing	I-P
pain	I-P
at	I-P
pressure	I-P
on	I-P
scalp	I-P
arteries	I-P
,	O
we	O
administered	O
topical	B-I
capsaicin	I-I
0.1	I-I
%	I-I
or	I-I
vaseline	I-I
jelly	I-I
on	O
painful	O
arteries	O
in	O
absence	O
of	O
migraine	O
attack	O
.	O


In	O
those	O
having	O
pain	O
reduction	O
>	O
50	O
%	O
,	O
we	O
made	O
the	O
same	O
comparison	O
during	O
a	O
migraine	O
attack	O
.	O


RESULTS	O
Topical	B-I
capsaicin	I-I
caused	O
>	O
50	O
%	O
reduction	O
of	O
arterial	B-O
pain	I-O
in	O
absence	O
of	O
attack	O
in	O
17/23	O
patients	O
,	O
as	O
opposed	O
to	O
two	O
with	O
vaseline	O
.	O


During	O
attacks	O
of	O
mild-	O
to	O
moderate-intensity	O
,	O
>	O
50	O
%	O
improvement	O
was	O
obtained	O
in	O
11/17	O
with	O
capsaicin	B-I
and	O
in	O
one	O
with	O
vaseline	B-I
.	I-I


CONCLUSIONS	O
Although	O
referring	O
to	O
a	O
small	O
number	O
of	O
patients	O
,	O
our	O
data	O
show	O
that	O
topical	B-I
capsaicin	I-I
may	O
relieve	O
arterial	B-O
pain	I-O
in	O
absence	O
of	O
and	O
during	O
a	O
migraine	O
attack	O
in	O
a	O
substantial	O
number	O
of	O
patients	B-P
experiencing	I-P
scalp	I-P
arterial	I-P
tenderness	I-P
.	I-P


More	O
active	O
capsacinoids	B-I
might	O
be	O
tried	O
in	O
the	O
future	O
and	O
could	O
provide	O
a	O
new	O
method	O
for	O
treating	O
migraine	O
attacks	O
.	O


Effect	O
of	O
enzalutamide	B-I
on	O
health-related	B-O
quality	I-O
of	I-O
life	I-O
,	I-O
pain	I-O
,	I-O
and	I-O
skeletal-related	I-O
events	I-O
in	O
asymptomatic	B-P
and	I-P
minimally	I-P
symptomatic	I-P
,	I-P
chemotherapy-naive	I-P
patients	I-P
with	I-P
metastatic	I-P
castration-resistant	I-P
prostate	I-P
cancer	I-P
(	I-P
PREVAIL	I-P
)	I-P
:	I-P
results	O
from	O
a	O
randomised	O
,	O
phase	O
3	O
trial	O
.	O


BACKGROUND	O
Enzalutamide	B-I
significantly	O
increased	O
overall	B-O
survival	I-O
and	O
radiographic	B-O
progression-free	I-O
survival	I-O
compared	O
with	O
placebo	B-I
in	O
the	O
PREVAIL	O
trial	O
of	O
asymptomatic	B-P
and	I-P
minimally	I-P
symptomatic	I-P
,	I-P
chemotherapy-naive	I-P
patients	I-P
with	I-P
metastatic	I-P
castration-resistant	I-P
prostate	I-P
cancer	I-P
.	I-P


We	O
report	O
the	O
effect	O
of	O
enzalutamide	B-I
on	O
health-related	B-O
quality	I-O
of	I-O
life	I-O
(	I-O
HRQoL	I-O
)	I-O
,	I-O
pain	I-O
,	I-O
and	I-O
skeletal-related	I-O
events	I-O
observed	O
during	O
this	O
trial	O
.	O


METHODS	O
In	O
this	O
phase	O
3	O
,	O
double-blind	O
trial	O
,	O
patients	B-P
were	I-P
randomly	I-P
assigned	I-P
(	I-P
1:1	I-P
)	I-P
to	I-P
receive	I-P
enzalutamide	I-I
160	I-I
mg/day	I-I
(	I-P
n=872	I-P
)	I-P
or	I-I
placebo	I-I
(	I-P
n=845	I-P
)	I-P
orally	I-P
.	I-P


HRQoL	B-O
was	O
assessed	O
at	O
baseline	O
and	O
during	O
treatment	O
using	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Prostate	O
(	O
FACT-P	O
)	O
and	O
EQ-5D	O
questionnaires	O
.	O


Pain	B-O
status	I-O
was	O
assessed	O
at	O
screening	O
,	O
baseline	O
,	O
week	O
13	O
,	O
and	O
week	O
25	O
with	O
the	O
Brief	B-O
Pain	I-O
Inventory	I-O
Short	I-O
Form	I-O
(	I-O
BPI-SF	I-O
)	I-O
.	I-O


The	O
primary	B-O
analysis	I-O
of	I-O
HRQoL	I-O
data	I-O
used	O
a	O
mixed-effects	O
model	O
to	O
test	O
the	O
difference	O
between	O
least	O
square	O
means	O
change	O
from	O
baseline	O
at	O
week	O
61	O
.	O


We	O
assessed	O
change	B-O
from	I-O
baseline	I-O
,	I-O
percentage	I-O
improvement	I-O
,	I-O
and	I-O
time	I-O
to	I-O
deterioration	I-O
in	I-O
HRQoL	I-O
and	I-O
pain	I-O
,	O
the	O
proportion	B-O
of	I-O
patients	I-O
with	I-O
a	I-O
skeletal-related	I-O
event	I-O
,	O
and	O
time	B-O
to	I-O
first	I-O
skeletal-related	I-O
event	I-O
.	I-O


Analysis	O
was	O
done	O
on	O
the	O
intention-to-treat	O
population	O
.	O


This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT01212991	O
.	O


FINDINGS	O
Median	B-O
treatment	I-O
duration	I-O
was	O
16·6	O
months	O
(	O
IQR	O
10·1-21·1	O
)	O
in	O
the	B-I
enzalutamide	I-I
group	O
and	O
4·6	O
months	O
(	O
2·8-9·7	O
)	O
in	B-I
the	I-I
placebo	I-I
group	O
.	O


The	O
mixed-effects	O
model	O
analyses	O
showed	O
significant	B-O
treatment	I-O
differences	I-O
in	O
change	O
from	O
baseline	O
to	O
week	O
61	B-I
with	I-I
enzalutamide	I-I
compared	I-I
with	I-I
placebo	I-I
for	O
most	O
FACT-P	O
endpoints	B-O
and	I-O
EQ-5D	I-O
visual	I-O
analogue	I-O
scale	I-O
.	I-O


Median	B-O
time	I-O
to	I-O
deterioration	I-O
in	I-O
FACT-P	I-O
total	I-O
score	O
was	O
11·3	O
months	O
(	O
95	O
%	O
CI	O
11·1-13·9	B-I
)	I-I
in	I-I
the	I-I
enzalutamide	I-I
group	O
and	O
5·6	O
months	O
(	B-I
5·5-5·6	I-I
)	I-I
in	I-I
the	O
placebo	O
groups	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0·62	O
[	O
95	O
%	O
CI	O
0·54-0·72	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
.	O


A	O
significantly	O
greater	O
proportion	O
of	O
patients	B-I
in	I-I
the	I-I
enzalutamide	O
group	B-I
than	I-I
in	O
the	O
placebo	O
group	O
reported	O
clinically	O
meaningful	O
improvements	B-O
in	I-O
FACT-P	I-O
total	O
score	O
(	O
327	O
[	O
40	O
%	O
]	O
of	O
826	O
vs	O
181	O
[	B-O
23	I-O
%	I-O
]	I-O
of	I-O
790	I-O
)	I-O
,	I-O
in	I-O
EQ-5D	I-O
utility	O
index	O
(	O
224	O
[	O
28	O
%	O
]	O
of	O
812	O
vs	O
99	O
[	B-O
16	I-O
%	I-O
]	I-O
of	I-O
623	I-O
)	I-O
,	I-O
and	I-O
visual	I-O
analogue	O
scale	O
(	O
218	O
[	O
27	O
%	O
]	O
of	O
803	O
vs	O
106	O
of	O
[	O
18	O
%	O
]	O
603	B-O
;	I-O
all	I-O
p	I-O
<	I-O
0·0001	I-O
)	I-O
.	I-O


Median	B-O
time	I-O
to	I-O
progression	I-O
in	O
BPI-SF	O
pain	O
at	O
its	O
worst	O
was	O
5·7	O
months	O
(	O
95	O
%	O
CI	B-I
5·6-5·7	I-I
)	I-I
in	O
the	O
enzalutamide	O
group	O
and	O
5·6	O
months	B-I
(	I-I
5·4-5·6	I-I
)	I-I
in	O
the	O
placebo	O
group	O
(	O
HR	O
0·62	O
[	O
95	O
%	O
CI	B-O
0·53-0·74	I-O
]	I-O
;	I-O
p	I-O
<	I-O
0·0001	I-O
)	I-O
.	O


Progression	O
of	O
pain	O
at	O
its	O
worst	O
was	O
less	O
common	O
in	O
the	O
enzalutamide	B-I
group	O
than	O
in	O
the	O
placebo	O
group	O
at	O
week	O
13	O
(	O
220	O
[	O
29	O
%	O
]	O
of	O
769	O
vs	O
257	O
[	O
42	O
%	O
]	O
of	O
610	O
;	O
p	O
<	O
0·0001	O
)	O
,	O
but	O
not	O
at	O
week	O
25	O
(	O
225	O
[	O
32	O
%	O
]	O
of	O
705	O
vs	O
135	O
[	O
38	O
%	O
]	O
of	O
360	O
;	O
p=0·068	O
)	O
.	O


278	O
(	B-I
32	I-I
%	I-I
)	I-I
of	I-I
872	I-I
patients	O
in	O
the	O
enzalutamide	O
group	O
and	O
309	O
(	B-I
37	I-I
%	I-I
)	I-I
of	I-I
845	O
patients	O
in	O
the	O
placebo	B-O
group	I-O
had	I-O
experienced	I-O
a	O
skeletal-related	B-O
event	I-O
by	I-O
data	I-O
cutoff	I-O
.	I-O


Median	B-O
time	I-O
to	I-O
first	I-O
skeletal-related	I-I
events	O
in	O
the	O
enzalutamide	O
group	O
was	O
31·1	O
months	O
(	O
95	O
%	O
CI	O
29·5-not	O
reached	O
)	O
and	O
31·3	O
months	O
(	B-I
95	I-I
%	I-I
CI	I-I
23·9-not	I-I
reached	O
)	O
in	O
the	O
placebo	O
group	O
(	O
HR	O
0·72	O
[	O
95	O
%	O
CI	O
0·61-0·84	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
.	O


INTERPRETATION	B-O
In	I-O
addition	I-O
to	O
improving	B-I
overall	I-I
survival	I-I
relative	O
to	O
placebo	O
,	O
enzalutamide	B-O
significantly	I-O
improves	I-O
patient-related	I-O
outcomes	I-O
and	I-O
delays	I-O
occurrence	I-O
of	I-P
first	I-P
skeletal-related	I-P
event	I-P
in	I-P
chemotherapy-naive	I-P
men	I-P
with	I-P
metastatic	I-P
castration-resistant	O
prostate	O
cancer	O
.	O


FUNDING	O
Astellas	O
Pharma	O
and	O
Medivation	O
.	O


A	B-P
controlled	I-P
clinical	I-P
trial	I-P
of	I-P
a	I-P
muscle	I-I
relaxant	I-I
analgesic	I-I
combination	I-I
in	I-P
the	I-P
treatment	I-P
of	I-P
acute	I-P
lumbago	I-P
.	I-P


[	O
The	O
effect	O
of	O
thoracic	B-I
peridural	I-I
analgesia	I-I
on	O
the	O
cortisol	B-O
and	I-O
glucose	I-O
response	I-O
in	O
surgery	B-P
of	I-P
the	I-P
abdominal	I-P
aorta	I-P
]	I-P
.	O


UNLABELLED	O
It	O
has	O
been	O
shown	O
that	O
the	O
stress	O
response	O
to	O
lower	B-P
abdominal	I-P
surgery	I-P
can	O
be	O
inhibited	O
by	O
epidural	B-I
analgesia	I-I
(	I-I
EA	I-I
)	I-I
.	I-I


But	O
EA	O
seems	O
to	O
have	O
little	O
influence	O
on	O
the	O
stress	O
reaction	O
to	O
major	O
abdominal	O
surgery	O
.	O


The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
find	O
out	O
whether	O
EA	O
is	O
able	O
to	O
diminish	O
the	O
cortisol	B-O
and	I-O
glucose	I-O
response	I-O
to	O
major	B-P
transabdominal	I-P
surgery	I-P
.	I-P


METHODS	O
31	B-P
patients	I-P
undergoing	I-P
elective	I-P
surgery	I-P
of	I-P
the	I-P
abdominal	I-P
aorta	I-P
were	O
subdivided	O
at	O
random	O
into	O
3	O
different	O
anaesthesia	O
groups	O
:	O
1.	O
halothane	B-I
anesthesia	I-I
,	O
2.	O
neuroleptanalgesia	B-I
(	I-I
NLA	I-I
)	I-I
and	O
3.	O
thoracic	B-I
EA	I-I
with	I-I
bupivacaine	I-I
(	I-I
0.5	I-I
%	I-I
)	I-I
in	O
combination	B-I
with	I-I
a	I-I
light	I-I
general	I-I
anesthesia	I-I
.	I-I


Some	O
patients	O
of	O
each	O
group	O
received	O
an	O
intravenous	O
infusion	O
of	O
5	O
%	O
glucose	O
.	O


Blood	O
samples	O
were	O
drawn	O
before	O
anesthesia	O
,	O
after	O
intubation	O
,	O
5	O
times	O
during	O
surgery	O
and	O
at	O
the	O
end	O
of	O
the	O
operation	O
and	O
were	O
analysed	O
for	O
cortisol	O
and	O
glucose	O
.	O


During	O
the	O
early	O
postoperative	O
period	O
,	O
1	O
,	O
2	O
and	O
24	O
h	O
after	O
surgery	O
,	O
only	O
cortisol	B-O
was	O
measured	O
.	O


RESULTS	O
Only	O
the	O
glucose	B-O
levels	I-O
of	O
patients	O
who	O
received	O
no	O
carbohydrate-containing	O
infusion	O
fluids	O
were	O
used	O
for	O
evaluation	O
of	O
the	O
stress	O
response	O
.	O


In	O
the	O
halothane	O
group	O
,	O
there	O
was	O
a	O
significant	O
increase	O
of	O
the	O
mean	B-O
cortisol	I-O
and	I-O
glucose	I-O
levels	I-O
after	O
the	O
start	O
of	O
surgery	O
.	O


No	O
intraoperative	O
elevations	O
of	O
blood	B-O
glucose	I-O
and	I-O
cortisol	I-O
were	O
seen	O
in	O
the	O
EA	O
group	O
.	O


Patients	O
of	O
the	O
NLA	O
group	O
showed	O
no	O
hyperglycaemia	O
and	O
only	O
mild	O
elevations	O
of	O
the	O
cortisol	O
levels	O
during	O
the	O
intraoperative	O
period	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Treatment	B-P
of	I-P
renal	I-O
failure	I-O
associated	I-P
with	I-P
multiple	I-P
myeloma	I-P
.	I-P


Plasmapheresis	O
,	O
hemodialysis	O
,	O
and	O
chemotherapy	O
.	O


The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
in	O
a	O
prospective	O
,	O
randomized	O
trial	O
the	O
efficacy	O
of	O
plasmapheresis	O
in	O
preventing	O
irreversible	B-O
renal	I-O
failure	I-O
in	O
patients	B-P
with	I-P
multiple	I-P
myeloma	I-P
and	O
to	O
study	O
the	O
renal	O
biopsy	O
tissues	O
from	O
such	O
patients	O
.	O


Twenty-one	B-P
patients	I-P
with	I-P
active	I-P
myeloma	I-P
and	I-P
progressive	I-P
renal	I-P
failure	I-P
were	O
randomized	B-I
to	I-I
one	I-I
of	I-I
two	I-I
groups	I-I
:	I-I
group	I-I
1	I-I
,	I-I
forced	I-I
diuresis	I-I
and	I-I
chemotherapy	I-I
(	I-I
10	I-I
patients	I-I
)	I-I
,	I-I
and	I-I
group	I-I
2	I-I
,	I-I
forced	I-I
diuresis	I-I
,	I-I
chemotherapy	I-I
,	I-I
and	I-I
plasmapheresis	I-I
(	I-I
11	I-I
patients	I-I
)	I-I
.	I-I


Plasmapheresis	O
and	O
chemotherapy	O
lowered	O
the	O
serum	B-O
myeloma	I-O
protein	I-O
value	I-O
much	O
more	O
rapidly	O
than	O
chemotherapy	O
alone	O
.	O


Of	B-P
5	I-P
patients	I-P
who	I-P
were	I-P
oliguric	I-P
and	I-P
undergoing	I-P
dialysis	I-P
at	I-P
presentation	I-P
,	O
only	O
3	O
who	O
were	O
treated	O
by	O
plasmapheresis	O
recovered	O
.	O


Of	B-P
16	I-P
polyuric	I-P
patients	I-P
,	O
5	O
in	O
group	O
1	O
and	O
7	O
in	O
group	O
2	O
showed	O
improvement	O
in	O
renal	B-O
function	I-O
.	I-O


The	O
main	O
factor	O
that	O
determined	O
irreversibility	O
of	O
renal	O
failure	O
was	O
the	O
severity	O
of	O
myeloma	O
cast	O
formation	O
.	O


Rioprostil	B-I
,	O
a	O
new	O
prostaglandin	O
E1	O
analogue	O
,	O
in	O
the	O
once-daily	O
treatment	O
for	O
the	O
prevention	O
of	O
duodenal	B-P
ulcer	I-P
recurrence	O
:	O
a	O
comparison	O
with	O
ranitidine	O
.	O


The	O
efficacy	B-O
of	O
Rioprostil	B-I
(	O
a	O
new	O
prostaglandin	O
E1	O
analogue	O
)	O
is	O
compared	O
with	O
that	O
of	O
ranitidine	B-I
in	O
the	O
recurrence	O
prevention	O
of	O
duodenal	O
ulcer	O
(	O
s	O
)	O
.	O


Duration	O
of	O
treatment	O
is	O
6	O
months	O
.	O


Ninety-seven	B-P
patients	I-P
received	I-P
rioprostil	I-I
,	I-I
600	I-I
micrograms	I-I
once-daily	I-I
orally	I-I
,	I-I
and	I-I
110	I-I
patients	I-I
received	I-I
ranitidine	I-I
,	I-I
150	I-I
mg	I-I
once-daily	I-I
orally	I-I
.	I-I


On	O
rioprostil	B-I
,	O
14.9	O
%	O
of	O
patients	O
showed	O
a	O
relapse	B-O
after	O
6	O
months	O
compared	O
to	O
10.1	O
%	O
on	O
ranitidine	B-I
.	I-I


Diarrhoea	B-O
occurred	O
in	O
7	O
patients	O
on	O
rioprostil	B-I
and	O
3	O
patients	O
on	O
ranitidine	B-I
.	I-I


Rioprostil	B-I
given	O
600	O
micrograms	O
daily	O
in	O
the	O
evening	O
is	O
a	O
highly	O
effective	O
treatment	O
for	O
the	O
prevention	O
of	O
duodenal	O
ulcer	O
relapse	O
,	O
the	O
efficacy	B-O
not	O
being	O
significantly	O
different	O
from	O
ranitidine	B-I
150	O
mg	O
.	O


The	O
TOM	B-I
test	I-I
:	I-I
a	O
new	O
instrument	O
for	O
assessing	B-P
theory	I-P
of	I-P
mind	I-P
in	I-P
normal	I-P
children	I-P
and	I-P
children	I-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	I-P


This	O
article	O
describes	O
a	O
first	O
attempt	O
to	O
investigate	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
TOM	B-O
test	I-O
,	O
a	O
new	O
instrument	O
for	O
assessing	O
theory	O
of	O
mind	O
ability	O
in	O
normal	B-P
children	I-P
and	I-P
children	I-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
(	I-P
PDDs	I-P
)	I-P
.	I-P


In	O
Study	O
1	O
,	O
TOM	B-I
test	I-I
scores	O
of	O
normal	B-P
children	I-P
(	I-P
n	I-P
=	I-P
70	I-P
)	I-P
correlated	O
positively	O
with	O
their	O
performance	O
on	O
other	O
theory	O
of	O
mind	O
tasks	O
.	O


Furthermore	O
,	O
young	B-P
children	I-P
only	O
succeeded	O
on	O
TOM	O
items	O
that	O
tap	O
the	O
basic	O
domains	O
of	O
theory	O
of	O
mind	O
(	O
e.g.	O
,	O
emotion	O
recognition	O
)	O
,	O
whereas	O
older	B-P
children	I-P
also	O
passed	O
items	O
that	O
measure	O
the	O
more	O
mature	O
areas	O
of	O
theory	O
of	O
mind	O
(	O
e.g.	O
,	O
understanding	O
of	O
humor	O
,	O
understanding	O
of	O
second-order	O
beliefs	O
)	O
.	O


Taken	O
together	O
,	O
the	O
findings	O
of	O
Study	O
1	O
suggest	O
that	O
the	O
TOM	B-O
test	I-O
is	O
a	O
valid	O
measure	O
.	O


Study	O
2	O
showed	O
for	O
a	O
separate	O
sample	O
of	O
normal	B-P
children	I-P
(	I-P
n	I-P
=	I-P
12	I-P
)	I-P
that	O
the	O
TOM	B-O
test	I-O
possesses	O
sufficient	O
test-retest	O
stability	O
.	O


Study	O
3	O
demonstrated	O
for	O
a	O
sample	B-P
of	I-P
children	I-P
with	I-P
PDDs	I-P
(	I-P
n	I-P
=	I-P
10	I-P
)	I-P
that	O
the	O
interrater	B-O
reliability	I-O
of	O
the	O
TOM	B-O
test	I-O
is	O
good	O
.	O


Study	O
4	O
found	O
that	O
children	B-P
with	I-P
PDDs	I-P
(	I-P
n	I-P
=	I-P
20	I-P
)	I-P
had	O
significantly	O
lower	O
TOM	B-O
test	I-O
scores	I-O
than	O
children	B-P
with	I-P
other	I-P
psychiatric	I-P
disorders	I-P
(	I-P
e.g.	I-P
,	O
children	B-P
with	I-P
Attention-deficit	I-P
Hyperactivity	I-P
Disorder	I-P
;	I-P
n	I-P
=	I-P
32	I-P
)	I-P
,	O
a	O
finding	O
that	O
underlines	O
the	O
discriminant	O
validity	O
of	O
the	O
TOM	B-I
test	I-I
.	I-I


Furthermore	O
,	O
Study	O
4	O
showed	O
that	O
intelligence	B-O
as	O
indexed	O
by	O
the	O
Wechsler	B-O
Intelligence	I-O
Scale	I-O
for	I-O
Children	I-O
was	O
positively	O
associated	O
with	O
TOM	B-O
test	I-O
scores	I-O
.	I-O


Finally	O
,	O
in	O
all	O
studies	O
,	O
the	O
TOM	B-O
test	I-O
was	O
found	O
to	O
be	O
reliable	O
in	O
terms	O
of	O
internal	O
consistency	O
.	O


Altogether	O
,	O
results	O
indicate	O
that	O
the	O
TOM	B-I
test	I-I
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
that	O
can	O
be	O
employed	O
to	O
measure	O
various	O
aspects	O
of	O
theory	O
of	O
mind	O
.	O


Feasibility	O
of	O
a	O
sensory-adapted	O
dental	O
environment	O
for	O
children	B-P
with	I-P
autism	I-P
.	I-P


OBJECTIVE	O
To	O
provide	O
an	O
example	O
of	O
an	O
occupational	O
therapy	O
feasibility	O
study	O
and	O
evaluate	O
the	O
implementation	O
of	O
a	O
randomized	O
controlled	O
pilot	O
and	O
feasibility	O
trial	O
examining	O
the	O
impact	O
of	O
a	O
sensory-adapted	O
dental	O
environment	O
(	O
SADE	O
)	O
to	O
enhance	O
oral	O
care	O
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


METHOD	O
Twenty-two	B-P
children	I-P
with	I-P
ASD	I-P
and	I-P
22	I-P
typically	I-P
developing	I-P
children	I-P
,	I-P
ages	I-P
6-12	I-P
yr	I-P
,	O
attended	O
a	O
dental	O
clinic	O
in	O
an	O
urban	O
hospital	O
.	O


Participants	B-P
completed	O
two	B-I
dental	I-I
cleanings	I-I
,	I-I
3-4	I-I
mo	I-I
apart	I-I
,	I-I
one	I-I
in	I-I
a	I-I
regular	I-I
environment	I-I
and	I-I
one	I-I
in	I-I
a	I-I
SADE	I-I
.	I-I


Feasibility	O
outcome	O
measures	O
were	O
recruitment	B-O
,	I-O
retention	I-O
,	I-O
accrual	I-O
,	I-O
dropout	I-O
,	I-O
and	I-O
protocol	I-O
adherence	I-O
.	I-O


Intervention	O
outcome	O
measures	O
were	O
physiological	B-O
stress	I-O
,	I-O
behavioral	I-O
distress	I-O
,	I-O
pain	I-O
,	I-O
and	I-O
cost	I-O
.	I-O


RESULTS	O
We	O
successfully	O
recruited	O
and	O
retained	O
participants	B-P
.	I-P


Parents	O
expressed	O
satisfaction	O
with	O
research	O
study	O
participation	O
.	O


Dentists	O
stated	O
that	O
the	O
intervention	O
could	O
be	O
incorporated	O
in	O
normal	O
practice	O
.	O


Intervention	O
outcome	O
measures	O
favored	O
the	O
SADE	O
condition	O
.	O


CONCLUSION	O
Preliminary	O
positive	O
benefit	O
of	O
SADE	O
in	B-P
children	I-P
with	I-P
ASD	I-P
warrants	O
moving	O
forward	O
with	O
a	O
large-scale	O
clinical	O
trial	O
.	O


Safety	B-O
and	I-O
immunogenicity	I-O
of	O
IMVAMUNE	B-I
,	O
a	O
promising	O
candidate	O
as	O
a	O
third	O
generation	O
smallpox	O
vaccine	O
.	O


A	O
Phase	O
I	O
trial	O
was	O
performed	O
to	O
investigate	O
the	O
safety	B-O
and	I-O
immunogenicity	I-O
of	O
the	O
third	B-I
generation	I-I
smallpox	I-I
vaccine	I-I
MVA-BN	I-I
(	I-I
IMVAMUNE	I-I
)	I-I
,	O
a	O
highly	O
attenuated	O
clone	O
derived	O
from	O
the	O
Modified	O
Vaccinia	O
Virus	O
Ankara	O
strain	O
571	O
,	O
in	B-P
naive	I-P
and	I-P
pre-immunized	I-P
subjects	I-P
.	I-P


A	B-P
total	I-P
of	I-P
86	I-P
healthy	I-P
subjects	I-P
received	O
the	O
vaccine	B-I
in	O
five	O
groups	O
using	O
different	O
doses	O
and	O
routes	O
of	O
administration	O
.	O


All	O
38	O
subjects	O
seroconverted	O
in	O
the	O
groups	O
receiving	O
the	O
highest	O
dose	O
(	O
10	O
(	O
8	O
)	O
TCID50	O
)	O
.	O


All	O
vaccinations	O
were	O
well	B-O
tolerated	I-O
with	O
mainly	O
mild	B-O
or	I-O
moderate	I-O
pain	I-O
at	I-O
the	I-O
injection	I-O
site	I-O
being	O
the	O
most	O
frequent	O
symptom	O
.	O


The	O
results	O
indicate	O
that	O
MVA-BN	O
has	O
the	O
potential	O
to	O
be	O
developed	O
as	O
an	O
efficient	B-O
and	I-O
safe	I-O
alternative	O
to	O
the	O
conventional	O
smallpox	O
vaccines	O
such	O
as	O
Lister-Elstree	B-I
or	I-I
Dryvax	I-I
.	I-I


Unique	O
attributes	O
render	O
it	O
a	O
promising	O
candidate	O
for	O
prophylactic	O
mass	O
immunization	O
,	O
even	O
in	O
subjects	O
for	O
whom	O
conventional	O
smallpox	O
vaccines	O
are	O
contraindicated	O
.	O


The	O
treatment	O
of	O
acne	B-P
vulgaris	I-P
in	O
general	B-P
practice	I-P
.	I-P


A	O
double-blind	O
assessment	O
of	O
co-trimoxazole	B-I
and	I-I
tetracycline	I-I
.	I-I


Postoperative	O
analgesia	O
with	O
preoperative	O
oral	O
ibuprofen	B-I
or	O
acetaminophen	B-I
in	O
children	B-P
undergoing	I-P
myringotomy	I-P
.	I-P


Previous	O
studies	O
have	O
shown	O
over	O
70	B-P
%	I-P
of	I-P
children	I-P
require	O
analgesics	B-I
following	O
bilateral	B-P
myringotomy	I-P
and	I-P
tube	I-P
placement	I-P
(	I-P
BM	I-P
&	I-P
T	I-P
)	I-P
.	I-P


This	O
double-blind	O
,	O
placebo-controlled	O
study	O
compared	O
the	O
postoperative	O
analgesic	O
effects	O
of	O
preoperatively	O
administered	O
oral	O
acetaminophen	B-I
or	I-I
ibuprofen	I-I
.	I-I


Forty	B-P
three	I-P
ASA	I-P
I	I-P
or	I-P
II	I-P
children	I-P
age	I-P
six	I-P
months	I-P
or	I-P
older	I-P
scheduled	I-P
for	I-P
elective	I-P
BM	I-P
&	I-P
T	I-P
were	O
randomized	O
to	O
receive	O
acetaminophen	B-I
(	I-I
paracetamol	I-I
)	I-I
15	I-I
mg.kg-1	I-I
,	I-I
ibuprofen	I-I
10	I-I
mg.kg-1	I-I
,	I-I
or	I-I
placebo	I-I
.	I-I


Postoperative	O
pain	O
was	O
assessed	O
using	O
the	O
Children	B-O
's	I-O
Hospital	I-O
of	I-O
Eastern	I-O
Ontario	I-O
Pain	I-O
Scale	I-O
(	I-O
CHEOPS	I-O
)	I-O
upon	O
arrival	O
to	O
the	O
PACU	O
and	O
at	O
5	O
,	O
10	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
and	O
60	O
min	O
.	O


CHEOP	O
scores	O
did	O
not	O
differ	O
between	O
the	O
groups	O
at	O
any	O
time	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
children	B-P
receiving	I-P
rescue	I-O
analgesia	I-O
.	I-O


This	O
study	O
showed	O
no	O
benefit	O
of	O
preoperatively	O
administered	O
oral	O
ibuprofen	B-I
10	O
mg.kg-1	O
or	O
acetaminophen	B-I
15	O
mg.kg-1	O
over	O
placebo	O
for	O
the	O
relief	O
of	O
postoperative	O
pain	O
in	O
children	B-P
undergoing	I-P
BM	I-P
&	I-P
T	I-P
.	I-P


Long-term	O
growth	O
hormone	O
treatment	O
in	O
growth	B-P
hormone	I-P
deficient	I-P
adults	I-P
.	I-P


Growth	B-I
hormone	I-I
treatment	I-I
in	O
GH-deficient	B-P
adults	I-P
has	O
proved	O
beneficial	O
in	O
recent	O
short-term	O
trials	O
,	O
but	O
long-term	O
results	O
have	O
not	O
yet	O
been	O
reported	O
.	O


Thirteen	B-P
GH-deficient	I-P
adults	I-P
(	I-P
4	I-P
females	I-P
,	I-P
9	I-P
males	I-P
;	I-P
mean	I-P
(	I-P
SEM	I-P
)	I-P
age	I-P
26.4	I-P
(	I-P
1.7	I-P
)	I-P
years	I-P
)	I-P
,	O
who	O
had	O
completed	O
4	O
months	O
of	O
GH	B-I
therapy	I-I
in	O
a	O
double-blind	O
placebo-controlled	B-I
cross-over	O
study	O
were	O
followed	O
,	O
for	O
further	O
16.1	O
(	O
0.8	O
)	O
months	O
of	O
uninterrupted	O
GH	B-I
therapy	I-I
in	O
an	O
open	O
design	O
.	O


A	O
significant	O
mean	O
increase	O
of	O
1.3	O
cm	O
in	O
linear	B-O
height	I-O
was	O
recorded	O
,	O
whereas	O
body	B-O
mass	I-O
index	I-O
remained	O
unchanged	O
.	O


Mean	B-O
muscle	I-O
volume	I-O
of	I-O
the	I-O
thigh	I-O
,	I-O
estimated	I-O
by	I-O
computerised	I-O
tomography	I-O
,	O
increased	O
significantly	O
compared	O
with	O
that	O
of	O
the	O
initial	O
placebo	B-I
period	O
(	O
p	O
=	O
0.01	O
)	O
,	O
and	O
a	O
slight	O
decrease	O
was	O
recorded	O
in	O
adipose	B-O
tissue	I-O
volume	I-O
of	I-O
the	I-O
thigh	I-O
(	O
p	O
=	O
0.10	O
)	O
and	O
subscapular	B-O
skinfold	I-O
thickness	I-O
(	O
p	O
=	O
0.10	O
)	O
.	O


Still	O
,	O
the	O
muscle	B-O
to	I-O
fat	I-O
ratio	I-O
of	I-O
the	I-O
thigh	I-O
was	O
significantly	O
lower	O
compared	O
with	O
that	O
of	O
normal	B-P
subjects	I-P
(	O
72.6/27.4	O
vs	O
77.9/22.1	O
)	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O


The	O
mean	B-O
isometric	I-O
strength	I-O
of	I-O
the	I-O
quadriceps	I-O
muscles	I-O
increased	I-O
significantly	O
during	O
long-term	O
GH	O
therapy	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
but	O
remained	O
lower	O
compared	O
with	O
that	O
of	O
normal	O
subjects	O
(	O
1.66	O
(	O
0.10	O
)	O
vs	O
2.13	O
(	O
0.11	O
)	O
Nm/kg	O
body	O
weight	O
)	O
.	O


Exercise	B-O
capacity	I-O
performed	I-O
on	I-O
a	I-O
bicycle	I-O
ergometer	I-O
increased	O
significantly	O
after	O
long-term	O
therapy	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
but	O
still	O
did	O
not	O
reach	O
the	O
values	O
seen	O
in	O
normal	O
subjects	O
(	O
22.5	O
(	O
3.4	O
)	O
vs	O
37.4	O
(	O
4.2	O
)	O
watt.min.kg-1	O
.	O


No	O
adverse	B-O
reactions	I-O
were	O
recorded	O
during	O
long-term	O
therapy	O
and	O
hemoglobin	B-O
A1c	I-O
remained	O
unchanged	O
.	O


These	O
data	O
suggest	O
that	O
long-term	O
GH	O
replacement	O
therapy	O
in	O
GH-deficient	O
adults	O
has	O
beneficial	O
effects	O
on	O
several	O
physiological	O
features	O
which	O
are	O
subnormal	O
in	O
these	O
patients	O
.	O


Brief	O
Report	O
:	O
Randomized	O
test	O
of	O
the	O
efficacy	O
of	O
picture	B-I
exchange	I-I
communication	I-I
system	I-I
on	O
highly	O
generalized	B-O
picture	I-O
exchanges	I-O
in	O
children	B-P
with	I-P
ASD	I-P
.	I-P


A	O
randomized	O
control	O
trial	O
comparing	O
two	O
social-communication	B-I
interventions	I-I
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
examined	O
far-transfer	B-O
of	I-O
the	I-O
use	I-O
of	I-O
picture	I-O
exchange	I-O
to	I-O
communicate	I-O
.	I-O


Thirty-six	B-P
children	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
conditions	O
,	O
one	B-I
of	I-I
which	I-I
was	I-I
the	I-I
Picture	I-I
Exchange	I-I
Communication	I-I
System	I-I
(	I-I
PECS	I-I
)	I-I
.	I-I


All	O
children	O
had	O
access	O
to	O
picture	B-I
symbols	I-I
during	I-I
assessments	I-I
.	I-I


Post-treatment	O
measurement	O
of	O
the	O
number	B-O
of	I-O
picture	I-O
exchanges	I-O
in	I-O
a	I-O
far-transfer	I-O
,	O
assessment	O
context	O
favored	O
the	O
PECS	B-I
intervention	O
.	O


These	O
findings	O
were	O
interpreted	O
as	O
support	O
for	O
the	O
hypothesis	O
that	O
the	O
PECS	B-I
curriculum	O
can	O
successfully	O
teach	O
a	O
generalized	O
means	O
of	O
showing	O
coordinated	B-O
attention	I-O
to	I-O
object	I-O
and	I-O
person	I-O
without	I-O
requiring	I-O
eye	I-O
contact	I-O
to	O
children	B-P
with	I-P
ASD	I-P
.	I-P


Prognostic	O
significance	O
of	O
the	O
dobutamine	O
echocardiography	O
test	O
in	O
idiopathic	B-O
dilated	I-O
cardiomyopathy	I-O
.	I-O


Dobutamine	B-I
stress	I-I
echo	I-I
provides	O
potentially	O
useful	B-O
information	I-O
on	O
idiopathic	B-I
dilated	I-I
cardiomyopathy	I-I
(	I-P
IDC	I-P
)	I-P
.	I-P


From	B-P
February	I-P
1	I-P
,	I-P
1997	I-P
,	I-P
to	I-P
October	I-P
1	I-P
,	I-P
1999	I-P
,	I-P
186	I-P
patients	I-P
(	I-P
131	I-P
men	I-P
and	I-P
55	I-P
women	I-P
,	I-P
mean	I-P
age	I-P
56	I-P
+/-	I-P
12	I-P
years	I-P
)	I-P
with	I-P
IDC	I-P
,	I-P
ejection	I-P
fraction	I-P
<	I-P
35	I-P
%	I-P
,	I-P
and	I-P
angiographically	I-P
normal	I-P
coronary	I-P
arteries	I-P
were	I-P
studied	I-P
by	I-P
high-dose	I-I
(	I-P
up	I-P
to	I-P
40	I-P
micro/kg/min	I-P
)	I-P
dobutamine	I-I
echo	I-I
in	I-P
6	I-P
centers	I-P
,	I-P
all	I-P
quality	I-P
controlled	I-P
for	I-P
stress	I-P
echo	I-P
reading	I-P
.	I-P


In	O
all	O
patients	O
,	O
wall	O
motion	O
score	O
index	O
(	O
WMSI	O
)	O
(	O
from	O
1	O
=	O
normal	O
to	O
4	O
=	O
dyskinetic	O
in	O
a	O
16-	O
segment	O
model	O
of	O
the	O
left	O
ventricle	O
)	O
was	O
evaluated	O
by	O
echo	O
at	O
baseline	O
and	O
peak	O
dobutamine	O
.	O


One	O
hundred	O
eighty-four	O
patients	O
were	O
followed	O
up	O
(	O
mean	O
15	O
+/-	O
13	O
months	O
)	O
and	O
only	O
cardiac	B-O
death	I-O
was	O
considered	O
as	O
an	O
end	O
point	O
.	O


There	O
were	O
29	O
cardiac	O
deaths	O
.	O


Significant	O
parameters	O
for	O
survival	O
prediction	O
at	O
univariate	O
analysis	O
are	O
:	O
DeltaWMSI	O
(	O
chi-square	O
20.1	O
;	O
p	O
<	O
0.0000	O
)	O
,	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
class	O
(	O
chi-square	O
17.57	O
;	O
p	O
<	O
0.0000	O
)	O
,	O
rest	O
ejection	O
fraction	O
(	O
chi-square	O
10.41	O
;	O
p	O
=	O
0.0013	O
)	O
,	O
angiotensin-converting	O
enzyme	O
inhibitors	O
(	O
chi-square	O
8.23	O
;	O
p	O
=	O
0.0041	O
)	O
,	O
and	O
hypertension	O
(	O
chi-square	O
8.08	O
,	O
p	O
=	O
0.0045	O
)	O
.	O


In	O
the	O
multivariate	O
stepwise	O
analysis	O
only	O
DeltaWMSI	O
and	O
NYHA	O
were	O
independent	O
predictors	O
of	O
outcome	O
(	O
DeltaWMSI	O
=	O
hazard	O
ratio	O
0.02	O
,	O
p	O
<	O
0.0000	O
;	O
NYHA	O
class	O
=	O
hazard	O
ratio	O
3.83	O
,	O
p	O
<	O
0.0000	O
)	O
.	O


Kaplan-Meier	O
survival	O
estimates	O
showed	O
a	O
better	B-O
outcome	I-O
for	O
patients	O
with	O
a	O
large	B-O
inotropic	I-O
response	I-O
(	O
DeltaWMSI	O
>	O
or	O
=0.44	O
,	O
a	O
cutoff	O
identified	O
by	O
receiver-operating	O
characteristic	O
curves	O
analysis	O
)	O
than	O
for	O
those	O
with	O
a	O
small	O
or	O
no	O
myocardial	O
inotropic	O
response	O
to	O
dobutamine	O
(	O
93.6	O
%	O
vs	O
69.4	O
%	O
,	O
p	O
=	O
0.00033	O
)	O
.	O


Thus	O
,	O
in	O
patients	B-P
with	I-P
IDC	I-P
,	O
an	O
extensive	O
contractile	O
reserve	O
identified	O
by	O
high-dose	O
dobutamine	O
stress	O
echocardiography	O
is	O
associated	O
with	O
a	O
better	B-O
survival	I-O
.	I-O


[	O
The	O
effect	O
of	O
losartan	B-I
versus	I-I
atenolol	I-I
on	O
cardiovascular	B-O
morbidity	I-O
and	I-O
mortality	I-O
in	O
patients	B-P
with	I-P
diabetes	I-P
mellitus	I-P
in	I-P
the	I-P
LIFE-study	I-P
]	I-P
.	O


INTRODUCTION	O
The	O
most	O
suitable	O
antihypertensive	O
drug	O
to	O
reduce	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
patients	B-P
with	I-P
hypertension	I-P
and	I-P
diabetes	I-P
is	O
unclear	O
.	O


In	O
a	O
prespecified	O
analysis	O
of	O
the	O
LIFE-study	O
we	O
compared	O
the	O
effects	O
of	O
losartan	B-I
and	I-I
atenolol	I-I
on	O
cardiovascular	B-O
morbidity	I-O
and	I-O
mortality	I-O
in	O
diabetic	B-P
patients	I-P
.	I-P


MATERIAL	O
AND	O
METHODS	O
A	B-P
total	I-P
of	I-P
1195	I-P
patients	I-P
in	I-P
the	I-P
LIFE-study	I-P
had	I-P
diabetes	I-P
at	O
the	O
time	O
of	O
the	O
randomisation	O
.	O


The	O
patients	O
were	O
randomised	O
for	O
double-blind	O
treatment	O
with	O
losartan	B-I
versus	I-I
atenolol	I-I
.	I-I


The	O
patients	B-P
had	I-P
ECG-verified	I-P
left	I-P
ventricular	I-P
hypertrophy	I-P
,	I-P
mean	I-P
age	I-P
67	I-P
years	I-P
,	I-P
blood	I-P
pressure	I-P
177/96	I-P
mmHg	I-P
after	I-P
two	I-P
weeks	I-P
placebo	I-I
run-in	I-P
period	I-P
.	I-P


Patients	B-P
were	I-P
followed	I-P
for	I-P
at	I-P
least	I-P
four	I-P
years	I-P
(	I-P
mean	I-P
4.7	I-P
years	I-P
)	I-P
.	I-P


The	O
primary	O
composite	O
endpoint	O
was	O
cardiovascular	B-O
death	I-O
,	I-O
stroke	I-O
or	I-O
myocardial	I-O
infarction	I-O
.	I-O


RESULTS	O
Blood	B-O
pressure	I-O
was	O
reduced	O
to	O
146/79	O
and	O
148/79	O
in	O
losartan-treated	B-I
patients	O
and	O
atenolol-treated	B-I
patients	O
,	O
respectively	O
.	O


The	O
primary	O
endpoint	O
occurred	O
in	O
103	O
patients	O
assigned	O
losartan	B-I
(	O
n	O
=	O
586	O
)	O
and	O
139	O
assigned	O
atenolol	B-I
(	O
n	O
=	O
609	O
)	O
.	O


Relative	B-O
risk	I-O
reduction	I-O
24	O
%	O
(	O
p	O
<	O
0.031	O
)	O
.	O


Cardiovascular	B-O
mortality	I-O
was	O
reduced	O
by	O
37	O
%	O
in	O
favour	O
of	O
losartan	B-I
(	O
p	O
<	O
0.028	O
)	O
,	O
and	O
all	O
cause	O
mortality	B-O
by	O
39	O
%	O
(	O
p	O
<	O
0.002	O
)	O
.	O


DISCUSSION	O
Losartan	B-I
was	O
very	O
effective	O
in	O
reducing	O
cardiovascular	B-O
morbidity	I-O
and	I-O
mortality	I-O
as	O
compared	O
to	O
atenolol	B-I
.	I-I


These	O
results	O
will	O
have	O
a	O
major	O
impact	O
on	O
the	O
choice	O
of	O
anti-hypertensive	O
treatment	O
for	O
patients	B-P
with	I-P
hypertension	I-P
and	I-P
diabetes	I-P
.	I-P


Prognostic	O
factor	O
analysis	O
in	O
patients	B-P
with	I-P
advanced	I-P
prostate	I-P
cancer	I-P
treated	I-P
by	I-P
castration	I-I
plus	I-I
anandron	I-I
or	I-I
placebo	I-I
:	I-I
a	O
final	O
update	O
.	O


PURPOSE	O
Different	O
outcome	O
results	O
have	O
been	O
published	O
in	O
trials	O
comparing	O
maximal	O
androgen	O
blockade	O
(	O
MAB	O
)	O
with	O
chemical	B-I
or	I-I
surgical	I-I
castration	I-I
alone	I-I
.	I-I


The	O
conflicting	O
results	O
could	O
be	O
explained	O
by	O
the	O
fact	O
that	O
patients	O
were	O
included	O
with	O
different	O
prognostic	O
factors	O
.	O


In	O
this	O
new	O
analysis	O
of	O
the	O
Anandron	O
European	O
Study	O
,	O
independent	O
prognostic	O
factors	O
have	O
been	O
evaluated	O
in	O
order	O
to	O
identify	O
those	O
which	O
could	O
influence	O
the	O
study	O
outcome	O
and	O
the	O
impact	O
of	O
the	O
treatment	O
.	O


MATERIAL	O
AND	O
METHODS	O
399	B-P
out	I-P
of	I-P
457	I-P
patients	I-P
recruited	I-P
in	I-P
this	I-P
study	I-P
were	I-P
divided	I-P
in	I-P
a	I-P
good	I-P
or	I-P
poor	I-P
prognostic	I-P
group	I-P
depending	I-P
on	I-P
the	I-P
presence	I-P
of	I-P
two	I-P
or	I-P
more	I-P
poor	I-P
prognostic	I-P
factors	I-P
,	I-P
these	I-P
were	I-P
pain	I-P
requiring	I-P
treatment	I-P
,	I-P
>	I-P
5	I-P
bone	I-P
metastases	I-P
,	I-P
hydronephrosis	I-P
,	I-P
and	I-P
alkaline	I-P
phosphatase	I-P
>	I-P
2	I-P
ULN	I-P
.	I-P


RESULTS	O
When	O
expressed	O
as	O
a	O
percentage	O
,	O
the	O
improvement	B-O
in	I-O
time	I-O
to	I-O
progression	I-O
,	I-O
overall	I-O
and	I-O
cancer	I-O
specific	I-O
survival	I-O
in	O
the	O
Anandron	B-I
treated	O
patients	O
was	O
identical	O
in	O
both	O
groups	O
.	O


In	O
absolute	O
terms	O
this	O
improvement	O
,	O
however	O
,	O
was	O
greater	O
in	O
the	O
good	O
prognostic	O
group	O
.	O


CONCLUSION	O
In	O
comparison	O
with	O
surgical	B-I
castration	I-I
MAB	I-I
using	I-I
Anandron	I-I
,	O
in	O
patients	B-P
with	I-P
metastatic	I-P
prostate	I-P
cancer	I-P
improves	O
the	O
time	O
to	O
objective	B-O
progression	I-O
,	I-O
overall	I-O
and	I-O
cancer	I-O
specific	I-O
survival	I-O
,	O
irrespective	O
of	O
certain	O
poor	O
prognostic	O
factors	O
.	O


Effect	O
of	O
Orlistat	B-I
in	O
obese	B-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
:	I-P
a	O
pilot	O
study	O
.	O


Heart	O
failure	O
is	O
the	O
leading	O
cause	O
of	O
hospitalization	O
.	O


Obesity	O
is	O
increasingly	O
common	O
and	O
is	O
a	O
major	O
public	O
health	O
problem	O
.	O


The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
whether	O
obese	B-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
can	O
benefit	O
from	O
losing	O
weight	O
via	O
an	O
orlistat-assisted	B-I
diet	I-I
.	I-I


This	O
randomized	O
clinical	O
trial	O
included	O
obese	B-P
patients	I-P
with	I-P
ejection	I-P
fractions	I-P
<	I-P
or	I-P
=40	I-P
%	I-P
.	I-P


Orlistat	B-I
and	I-I
diet	I-I
counseling	I-I
were	I-I
compared	I-I
with	I-I
diet	I-I
counseling	I-I
alone	I-I
.	I-I


Twenty-one	B-P
consecutive	I-P
obese	I-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
were	I-P
recruited	I-P
.	I-P


Significant	O
improvement	O
in	O
6-minute	B-O
walk	I-O
test	I-O
(	O
45.8	O
m	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
5.2-86.4	O
m	O
;	O
p=0.031	O
)	O
,	O
functional	B-O
class	I-O
(	O
-0.6+/-0.5	O
,	O
p=0.014	O
)	O
,	O
weight	B-O
loss	I-O
(	O
-8.55	O
kg	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-13.0	O
to	O
-4.1	O
kg	O
;	O
p	O
<	O
0.001	O
)	O
and	O
also	O
significant	O
decreases	O
in	O
total	B-O
cholesterol	I-O
(	O
p=0.017	O
)	O
,	O
low-density	B-O
lipoprotein	I-O
cholesterol	I-O
(	O
p=0.03	O
)	O
,	O
and	O
triglycerides	B-O
(	O
p=0.036	O
)	O
were	O
observed	O
in	O
the	O
orlistat	O
group	O
.	O


Orlistat	B-I
can	O
promote	O
significant	O
weight	B-O
loss	I-O
and	I-O
symptoms	I-O
of	I-O
relief	I-O
in	O
obese	O
patients	O
with	O
heart	O
failure	O
,	O
as	O
measured	O
by	O
6-minute	O
walk	O
test	O
and	O
functional	O
capacity	O
.	O


The	O
lipid	O
profile	O
improved	O
.	O


Orlistat	B-I
was	O
safe	O
and	O
well	O
tolerated	O
.	O


[	B-O
Efficacy	I-O
and	I-O
safety	I-O
of	O
extended-release	O
niacin	B-I
alone	I-I
or	I-I
with	I-I
atorvastatin	I-I
for	O
lipid	O
profile	O
modification	O
]	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
extended-release	B-I
niacin	I-I
(	I-I
niacin	I-I
ER	I-I
)	I-I
either	I-I
alone	I-I
or	I-I
in	I-I
combination	I-I
with	I-I
atorvastatin	I-I
for	O
the	O
lipid	O
profile	O
modification	O
in	O
the	O
patients	B-P
with	I-P
coronary	I-P
heart	I-P
disease	I-P
(	I-P
CHD	I-P
)	I-P
and	I-P
its	I-P
equivalents	I-P
.	I-P


METHODS	O
One	B-P
hundred	I-P
and	I-P
ten	I-P
patients	I-P
with	I-P
CHD	I-P
and	I-P
its	I-P
equivalents	I-P
with	I-P
serum	I-P
total	I-P
cholesterol	I-P
(	I-P
TC	I-P
)	I-P
>	I-P
or	I-P
=	I-P
3.5	I-P
mmol/L	I-P
were	O
randomly	O
assigned	O
into	O
three	O
treatment	O
groups	O
:	O
(	O
1	O
)	O
atorvastatin	B-I
group	O
(	O
n	O
=	O
38	O
)	O
,	O
receiving	O
atorvastatin	B-I
10	O
mg/d	O
for	O
8	O
weeks	O
;	O
(	O
2	O
)	O
niacin	B-I
ER	I-I
group	O
(	O
n	O
=	O
38	O
)	O
,	O
given	O
niacin	B-I
ER	I-I
500	O
mg/d	O
for	O
4	O
weeks	O
and	O
then	O
1000	O
mg/d	O
for	O
4	O
weeks	O
;	O
(	O
3	O
)	O
combination	B-I
treatment	I-I
group	O
(	O
n	O
=	O
34	O
)	O
,	O
treated	B-I
with	I-I
atorvastatin	I-I
(	I-I
10	I-I
mg/d	I-I
)	I-I
plus	I-I
niacin	I-I
ER	I-I
,	O
with	O
the	O
dose	O
initiating	O
from	O
500	O
mg/d	O
,	O
and	O
increasing	O
to	O
1000	O
mg/d	O
after	O
4	O
weeks	O
,	O
for	O
8	O
weeks	O
.	O


The	O
serums	B-O
lipid	I-O
profiles	I-O
and	I-O
adverse	I-O
effects	I-O
were	O
assessed	O
in	O
all	O
the	O
patients	O
before	O
treatment	O
,	O
and	O
4	O
and	O
8	O
weeks	O
after	O
treatment	O
.	O


RESULTS	O
(	O
1	O
)	O
After	O
8	O
weeks	O
of	O
treatment	O
,	O
the	O
serum	B-O
level	I-O
of	I-O
triglyceride	I-O
(	I-O
TG	I-O
)	I-O
and	I-O
high-density	I-O
lipoprotein	I-O
cholesterol	I-O
(	I-O
HDL-C	I-O
)	I-O
were	O
reduced	O
by	O
30	O
%	O
and	O
16	O
%	O
respectively	O
in	O
the	O
niacin	O
ER	O
group	O
compared	O
with	O
the	O
baseline	O
values	O
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O


After	O
8	O
weeks	O
,	O
the	O
TC	B-O
,	I-O
low-density	I-O
lipoprotein	I-O
cholesterol	I-O
(	I-O
LDL-C	I-O
)	I-O
,	I-O
and	I-O
TG	I-O
in	I-O
the	I-O
atorvastatin	I-O
group	I-O
decreased	O
by	O
19	O
%	O
,	O
26	O
%	O
,	O
and	O
17	O
%	O
respectively	O
compared	O
with	O
the	O
baseline	O
values	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O


Combination	O
treatment	O
decreased	O
the	O
TC	B-O
,	I-O
LDL-C	I-O
,	I-O
and	I-O
TG	I-O
levels	I-O
by	O
28	O
%	O
,	O
38	O
%	O
,	O
and	O
39	O
%	O
respectively	O
,	O
and	O
increased	O
the	O
HDL-C	B-O
level	I-O
by	O
23	O
%	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O


The	O
improvement	O
in	O
TC	B-O
and	I-O
LDL-C	I-O
achieved	O
by	O
combination	O
treatment	O
was	O
superior	O
to	O
treatment	O
of	O
atorvastatin	O
alone	O
and	O
treatment	O
of	O
niacin	O
ER	O
alone	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O


(	O
2	O
)	O
The	O
rate	O
of	O
achieving	O
the	O
LDL-C	B-O
goal	O
of	O
The	O
National	O
Cholesterol	O
Education	O
Program	O
(	O
NCEP	O
)	O
in	O
Adult	O
Treatment	O
Panel	O
III	O
(	O
ATP	O
III	O
)	O
in	O
the	O
combination	O
therapy	O
group	O
was	O
73.5	O
%	O
,	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
atorvastatin	O
and	O
niacin	O
groups	O
(	O
47.7	O
%	O
and	O
42.1	O
%	O
respectively	O
,	O
both	O
P	O
<	O
0.05	O
)	O
.	O


(	O
3	O
)	O
Adverse	O
effect	O
,	O
such	O
as	O
flushing	B-O
(	O
15.8	O
%	O
)	O
and	O
gastrointestinal	B-O
symptoms	I-O
(	O
23.7	O
%	O
)	O
were	O
found	O
in	O
the	O
niacin	O
ER	O
group	O
,	O
however	O
,	O
no	O
more	O
adverse	O
effects	O
were	O
found	O
in	O
the	O
combination	O
therapy	O
group	O
.	O


There	O
were	O
no	O
serious	O
adverse	O
events	O
in	O
all	O
groups	O
.	O


CONCLUSION	O
Niacin	O
ER	O
has	O
a	O
favorable	O
effect	B-O
in	I-O
modulating	I-O
the	I-O
blood	I-O
lipid	I-O
profile	I-O
,	O
especially	O
in	O
reducing	B-O
TG	I-O
and	I-O
elevating	I-O
HDL-C	I-O
.	I-O


Combined	O
statin	O
with	O
niacin	O
may	O
produce	O
a	O
more	O
global	B-O
and	I-O
effective	I-O
improvement	I-O
in	I-O
lipid	I-O
blood	I-O
levels	I-O
than	O
monotherapy	O
and	O
is	O
generally	O
safe	B-O
and	I-O
well	I-O
tolerable	I-O
.	I-O


A	O
randomized	O
placebo-controlled	B-I
prevention	O
trial	O
of	O
aspirin	B-I
and/or	I-I
resistant	I-I
starch	I-I
in	O
young	B-P
people	I-P
with	I-P
familial	I-O
adenomatous	I-O
polyposis	I-O
.	I-O


Evidence	O
supporting	O
aspirin	B-I
and	I-I
resistant	I-I
starch	I-I
(	I-I
RS	I-I
)	I-I
for	O
colorectal	B-P
cancer	I-P
prevention	O
comes	O
from	O
epidemiologic	O
and	O
laboratory	O
studies	O
(	B-I
aspirin	I-I
and	I-I
RS	I-I
)	I-I
and	O
randomized	O
controlled	O
clinical	O
trials	O
(	B-I
aspirin	I-I
)	I-I
.	O


Familial	B-P
adenomatous	I-P
polyposis	I-P
(	I-P
FAP	I-P
)	I-P
strikes	O
young	O
people	O
and	O
,	O
untreated	O
,	O
confers	O
virtually	O
a	O
100	O
%	O
risk	O
of	O
colorectal	O
cancer	O
and	O
early	O
death	O
.	O


We	O
conducted	O
an	O
international	O
,	O
multicenter	O
,	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
of	O
aspirin	B-I
(	O
600	O
mg/d	O
)	O
and/or	O
RS	B-I
(	O
30	O
g/d	O
)	O
for	O
from	O
1	O
to	O
12	O
years	O
to	O
prevent	O
disease	O
progression	O
in	O
FAP	B-P
patients	I-P
from	I-P
10	I-P
to	I-P
21	I-P
years	I-P
of	I-P
age	I-P
.	I-P


In	O
a	O
2	O
×	O
2	O
factorial	O
design	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
following	O
four	O
study	O
arms	B-I
:	I-I
aspirin	I-I
plus	I-I
RS	I-I
placebo	I-I
;	I-I
RS	I-I
plus	I-I
aspirin	I-I
placebo	I-I
;	I-I
aspirin	I-I
plus	I-I
RS	I-I
;	I-I
RS	I-I
placebo	I-I
plus	I-I
aspirin	I-I
placebo	I-I
;	I-I
they	O
were	O
followed	O
with	O
standard	O
annual	O
clinical	O
examinations	O
including	O
endoscopy	O
.	B-O


The	B-O
primary	I-O
endpoint	I-O
was	I-O
polyp	I-O
number	I-O
in	I-O
the	I-O
rectum	I-O
and	I-O
sigmoid	I-O
colon	I-O
(	I-O
at	I-O
the	I-O
end	I-O
of	I-O
intervention	I-O
)	I-O
,	I-O
and	I-O
the	I-O
major	I-O
secondary	I-O
endpoint	I-O
was	I-O
size	I-O
of	I-O
the	I-O
largest	I-O
polyp	I-O
.	O


A	B-P
total	I-P
of	I-P
206	I-P
randomized	I-P
FAP	I-P
patients	I-P
commenced	I-P
intervention	I-P
,	I-P
of	I-P
whom	I-P
133	I-P
had	I-P
at	I-P
least	I-P
one	I-P
follow-up	I-P
endoscopy	I-P
and	I-P
were	I-P
therefore	I-P
included	I-P
in	I-P
the	I-P
primary	I-P
analysis	I-P
.	O


Neither	O
intervention	O
significantly	O
reduced	B-O
polyp	I-O
count	I-O
in	I-O
the	I-O
rectum	I-O
and	I-O
sigmoid	I-O
colon	I-O
:	I-O
aspirin	O
relative	O
risk	O
=	O
0.77	O
(	O
95	O
%	O
CI	O
,	O
0.54-1.10	O
;	O
versus	O
nonaspirin	O
arms	O
)	O
;	O
RS	O
relative	O
risk	O
=	O
1.05	O
(	O
95	O
%	O
CI	O
,	O
0.73-1.49	O
;	O
versus	O
non-RS	O
arms	O
)	O
.	O


There	O
was	O
a	O
trend	O
toward	O
a	O
smaller	O
size	O
of	O
largest	O
polyp	O
in	O
patients	O
treated	O
with	O
aspirin	O
versus	O
nonaspirin	O
--	O
mean	O
3.8	O
mm	O
versus	O
5.5	O
mm	O
for	O
patients	O
treated	O
1	O
or	O
more	O
years	O
(	O
adjusted	O
P	O
=	O
0.09	O
)	O
and	O
mean	O
3.0	O
mm	O
versus	O
6.0	O
mm	O
for	O
patients	O
treated	O
more	O
than	O
1	O
year	O
(	O
P	O
=	O
0.02	O
)	O
;	O
there	O
were	O
similar	O
weaker	O
trends	O
with	O
RS	O
versus	O
non-RS	O
.	O


Exploratory	O
translational	O
endpoints	O
included	O
crypt	O
length	O
(	O
which	O
was	O
significantly	O
shorter	O
in	O
normal-appearing	O
mucosa	O
in	O
the	O
RS	O
group	O
over	O
time	O
)	O
and	O
laboratory	O
measures	O
of	O
proliferation	O
(	O
including	O
Ki67	O
)	O
.	O


This	O
clinical	O
trial	O
is	O
the	O
largest	O
ever	O
conducted	O
in	O
the	O
setting	O
of	O
FAP	O
and	O
found	O
a	O
trend	O
of	O
reduced	B-O
polyp	I-O
load	I-O
(	O
number	O
and	O
size	O
)	O
with	O
600	O
mg	O
of	B-I
aspirin	I-I
daily	O
.	O


RS	O
had	O
no	O
clinical	O
effect	O
on	B-O
adenomas	I-O
.	O


Effects	O
of	O
the	O
Quest	B-I
to	I-I
Lava	I-I
Mountain	I-I
Computer	I-I
Game	I-I
on	O
Dietary	B-O
and	I-O
Physical	I-O
Activity	I-O
Behaviors	I-O
of	O
Elementary	B-P
School	I-P
Children	I-P
:	I-P
A	O
Pilot	O
Group-Randomized	O
Controlled	O
Trial	O
.	O


BACKGROUND	O
Computer-based	B-I
educational	I-I
games	I-I
present	O
an	O
opportunity	O
for	O
health	O
education	O
in	O
school	O
;	O
however	O
,	O
their	O
feasibility	O
in	O
school	O
settings	O
and	O
effectiveness	O
in	O
changing	O
behavior	O
are	O
poorly	O
understood	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
feasibility	O
,	O
acceptability	O
,	O
and	O
effects	O
of	O
the	O
Quest	B-I
to	I-I
Lava	I-I
Mountain	I-I
(	I-I
QTLM	I-I
)	I-I
computer	I-I
game	I-I
on	O
dietary	B-O
behaviors	I-O
,	I-O
physical	I-O
activity	I-O
behaviors	I-O
,	I-O
and	I-O
psychosocial	I-O
factors	I-O
among	O
ethnically	B-P
diverse	I-P
children	I-P
in	I-P
Texas	I-P
.	I-P


DESIGN	O
Quasi-experimental	O
group-randomized	O
controlled	O
trial	O
conducted	O
during	O
the	O
2012-2013	B-P
school	I-P
year	I-P
.	I-P


PARTICIPANTS/SETTING	O
A	B-P
total	I-P
of	I-P
107	I-P
children	I-P
in	I-P
fourth	I-P
and	I-P
fifth	I-P
grade	I-P
consented	I-P
.	I-P


There	B-P
was	I-P
an	I-P
attrition	I-P
rate	I-P
of	I-P
8.8	I-P
%	I-P
with	I-P
a	I-P
final	I-P
sample	I-P
size	I-P
of	I-P
44	I-P
children	I-P
in	I-P
three	I-P
intervention	I-P
schools	I-P
,	I-P
and	I-P
a	I-P
sample	I-P
of	I-P
50	I-P
children	I-P
in	I-P
three	I-P
comparison	I-P
schools	I-P
.	I-P


Dietary	O
intake	O
was	O
measured	O
using	O
two	O
random	O
24-hour	O
recalls	O
,	O
whereas	O
child	O
self-report	O
surveys	O
measured	O
diet	B-O
,	I-O
physical	I-O
activity	I-O
,	I-O
and	I-O
psychosocial	I-O
factors	I-O
before	O
and	O
after	O
the	O
intervention	O
.	O


Process	O
data	O
on	O
QTLM	B-I
usability	O
and	O
back-end	O
server	O
data	O
on	O
QTLM	O
exposure	O
and	O
progress	O
achieved	O
were	O
collected	O
.	O


INTERVENTION	O
QTLM	B-I
was	O
implemented	O
as	O
part	O
of	O
the	O
in-school	B-P
or	I-P
afterschool	I-P
program	I-P
.	I-P


Recommended	O
game	O
exposure	O
duration	O
was	O
90	O
min/wk	O
for	O
6	O
weeks	O
.	O


STATISTICAL	O
ANALYSIS	O
Analysis	O
of	O
covariance	O
or	O
logistic	O
regression	O
models	O
evaluated	O
effects	O
of	O
QTLM	B-I
on	O
diet	B-O
,	I-O
physical	I-O
activity	I-O
,	I-O
and	I-O
psychosocial	I-O
factors	I-O
.	I-O


Post	O
hoc	O
exploratory	O
analysis	O
examined	O
the	O
changes	O
before	O
and	O
after	O
the	O
intervention	O
in	O
outcome	O
variables	O
among	O
children	O
in	O
the	O
intervention	O
group	O
.	O


Significance	O
was	O
set	O
at	O
P	O
<	O
0.05	O
.	O


RESULTS	O
Children	O
played	O
an	O
average	O
of	O
274±110	O
minutes	O
(	O
approximately	O
4.6	O
hours	O
)	O
of	B-I
QTLM	I-I
during	O
the	O
6	O
weeks	O
(	O
51	O
%	O
of	O
recommended	O
dosage	O
)	O
.	O


Compared	O
with	O
the	O
comparison	O
group	O
,	O
children	O
in	O
the	O
intervention	O
group	O
reported	B-O
decreased	I-O
sugar	I-O
consumption	I-O
(	O
P=0.021	O
)	O
and	B-O
higher	I-O
nutrition/physical	I-O
activity	I-O
attitudes	I-O
(	O
P=0.041	O
)	O
pre-	O
to	O
postintervention	O
.	O


There	O
were	O
no	O
significant	O
effects	O
of	O
QTLM	O
on	B-O
physical	I-O
activity	I-O
.	O


However	O
,	O
post	O
hoc	O
analysis	O
showed	O
that	O
higher	B-I
QTLM	I-I
exposure	O
and	O
gaming	O
progress	O
was	O
associated	O
with	O
increased	B-O
frequency	I-O
of	I-O
physical	I-O
activity	I-O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	B-I
QTLM	I-I
has	O
some	O
promising	O
acceptability	O
and	O
initial	O
effects	O
on	B-O
diet	I-O
and	I-O
physical	I-O
activity	I-O
behaviors	I-O
among	I-P
children	I-P
in	I-P
elementary	I-P
school	I-P
.	O


Clonidine	B-I
in	O
patients	B-P
undergoing	I-P
noncardiac	I-P
surgery	I-P
.	I-P


BACKGROUND	O
Marked	O
activation	O
of	O
the	O
sympathetic	O
nervous	O
system	O
occurs	O
during	O
and	O
after	O
noncardiac	B-P
surgery	I-P
.	I-P


Low-dose	O
clonidine	B-I
,	O
which	O
blunts	O
central	O
sympathetic	O
outflow	O
,	O
may	O
prevent	O
perioperative	B-O
myocardial	I-O
infarction	I-O
and	I-O
death	I-O
without	O
inducing	O
hemodynamic	O
instability	O
.	O


METHODS	O
We	O
performed	O
a	O
blinded	O
,	O
randomized	O
trial	O
with	O
a	O
2-by-2	O
factorial	O
design	O
to	O
allow	O
separate	O
evaluation	O
of	O
low-dose	B-I
clonidine	I-I
versus	I-I
placebo	I-I
and	I-I
low-dose	I-I
aspirin	I-I
versus	I-I
placebo	I-I
in	O
patients	B-P
with	I-P
,	I-P
or	I-P
at	I-P
risk	I-P
for	I-P
,	I-P
atherosclerotic	I-P
disease	I-P
who	I-P
were	I-P
undergoing	I-P
noncardiac	I-P
surgery	I-P
.	I-P


A	O
total	O
of	O
10,010	B-P
patients	I-P
at	I-P
135	I-P
centers	I-P
in	I-P
23	I-P
countries	I-P
were	I-P
enrolled	I-P
.	I-P


For	O
the	O
comparison	O
of	O
clonidine	B-I
with	I-I
placebo	I-I
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
clonidine	B-I
(	O
0.2	O
mg	O
per	O
day	O
)	O
or	B-I
placebo	I-I
just	O
before	O
surgery	O
,	O
with	O
the	O
study	O
drug	O
continued	O
until	O
72	O
hours	O
after	O
surgery	O
.	O


The	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
death	B-O
or	I-O
nonfatal	I-O
myocardial	I-O
infarction	I-O
at	O
30	O
days	O
.	O


RESULTS	O
Clonidine	O
,	O
as	O
compared	O
with	O
placebo	O
,	O
did	O
not	O
reduce	O
the	O
number	O
of	O
primary-outcome	B-O
events	I-O
(	O
367	O
and	O
339	O
,	O
respectively	O
;	O
hazard	O
ratio	O
with	O
clonidine	O
,	O
1.08	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.93	O
to	O
1.26	O
;	O
P=0.29	O
)	O
.	O


Myocardial	B-O
infarction	I-O
occurred	O
in	O
329	B-P
patients	I-P
(	O
6.6	O
%	O
)	O
assigned	O
to	O
clonidine	O
and	O
in	O
295	O
patients	O
(	O
5.9	O
%	O
)	O
assigned	O
to	O
placebo	O
(	O
hazard	O
ratio	O
,	O
1.11	O
;	O
95	O
%	O
CI	O
,	O
0.95	O
to	O
1.30	O
;	O
P=0.18	O
)	O
.	O


Significantly	O
more	O
patients	O
in	O
the	O
clonidine	O
group	O
than	O
in	O
the	O
placebo	O
group	O
had	O
clinically	O
important	O
hypotension	B-O
(	O
2385	O
patients	O
[	O
47.6	O
%	O
]	O
vs.	O
1854	O
patients	O
[	O
37.1	O
%	O
]	O
;	O
hazard	O
ratio	O
1.32	O
;	O
95	O
%	O
CI	O
,	O
1.24	O
to	O
1.40	O
;	O
P	O
<	O
0.001	O
)	O
.	O


Clonidine	O
,	O
as	O
compared	O
with	O
placebo	O
,	O
was	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
nonfatal	B-O
cardiac	I-O
arrest	I-O
(	O
0.3	O
%	O
[	O
16	O
patients	O
]	O
vs.	O
0.1	O
%	O
[	O
5	O
patients	O
]	O
;	O
hazard	O
ratio	O
,	O
3.20	O
;	O
95	O
%	O
CI	O
,	O
1.17	O
to	O
8.73	O
;	O
P=0.02	O
)	O
.	O


CONCLUSIONS	O
Administration	O
of	O
low-dose	O
clonidine	O
in	O
patients	B-P
undergoing	I-P
noncardiac	I-P
surgery	I-P
did	O
not	O
reduce	O
the	O
rate	O
of	O
the	O
composite	O
outcome	O
of	O
death	B-O
or	O
nonfatal	B-O
myocardial	I-O
infarction	I-O
;	I-O
it	O
did	O
,	O
however	O
,	O
increase	O
the	O
risk	O
of	O
clinically	B-O
important	I-O
hypotension	I-O
and	I-O
nonfatal	I-O
cardiac	I-O
arrest	I-O
.	I-O


(	O
Funded	O
by	O
the	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
and	O
others	O
;	O
POISE-2	O
ClinicalTrials.gov	O
number	O
,	O
NCT01082874	O
.	O


)	O
.	O


Application	O
of	O
the	O
Itch	O
Severity	O
Score	O
in	O
patients	B-P
with	I-P
moderate-to-severe	I-P
plaque	I-P
psoriasis	I-P
:	I-P
Clinically	O
important	O
difference	O
and	O
responder	O
analyses	O
.	O


The	O
Itch	O
Severity	O
Score	O
(	O
ISS	O
)	O
,	O
a	O
0-10	O
numeric	O
rating	O
scale	O
,	O
was	O
used	O
to	O
assess	O
pruritus	O
due	O
to	O
psoriasis	O
in	O
a	O
Phase	O
2	O
b	O
trial	O
of	O
tofacitinib	O
,	O
a	O
novel	O
oral	O
Janus	O
kinase	O
inhibitor	B-P
.	I-P


197	B-P
patients	I-P
with	I-P
moderate-to-severe	I-P
plaque	I-P
psoriasis	I-P
were	I-P
randomized	I-P
to	I-I
tofacitinib	I-I
2	I-I
,	I-I
5	I-I
or	I-I
15	I-I
mg	I-I
twice	I-I
daily	I-I
,	I-I
or	I-I
placebo	I-I
.	O


The	O
ISS	O
was	O
recorded	O
daily	O
from	O
baseline	O
to	O
week	O
2	O
and	O
at	O
study	O
visits	O
.	O


Following	O
good	O
and	O
recommended	O
research	O
practice	O
,	O
we	O
performed	O
analyses	O
to	O
examine	O
the	O
clinically	O
important	O
differences	O
(	O
CID	O
)	O
(	O
between-group	O
difference	O
or	O
within-group	O
difference	O
)	O
and	O
clinically	O
important	O
responders	O
(	O
CIR	O
)	O
(	O
within-patient	O
change	O
)	O
for	O
the	O
ISS	O
.	O


The	O
CID	O
and	O
CIR	O
were	O
defined	O
using	B-O
Patient	I-O
Global	I-O
Assessment	I-O
of	I-O
psoriasis	I-O
as	O
an	O
anchor	O
and	O
were	O
estimated	O
with	O
a	O
longitudinal	O
model	O
.	O


A	O
CID	O
on	O
the	O
ISS	O
was	O
1.64	O
and	O
,	O
by	O
day	O
10	O
,	O
the	O
mean	O
changes	O
from	O
baseline	B-O
in	I-O
ISS	I-O
values	I-O
for	O
the	B-I
tofacitinib	I-I
doses	O
(	O
placebo-adjusted	O
)	O
exceeded	O
CID	O
.	O


A	O
CIR	O
on	O
the	O
ISS	O
was	O
a	O
30	O
%	O
improvement	O
from	O
baseline	O
and	O
,	O
at	O
week	O
12	O
,	O
87.2	O
%	O
to	O
100	O
%	O
of	O
patients	O
receiving	B-I
tofacitinib	I-I
reached	O
≥30	O
%	O
improvement	O
versus	O
29.4	O
%	O
of	O
patients	O
receiving	B-I
placebo	I-I
(	O
p	O
<	O
0.0001	O
)	O
.	O


Overall	O
,	O
the	O
CID	O
and	O
CIR	O
analyses	O
play	O
vital	O
roles	O
in	O
the	O
interpretation	O
of	O
the	O
treatment	O
effects	O
measured	O
by	O
ISS	O
.	O


Do	O
heavier	B-P
women	I-P
benefit	O
from	O
a	O
higher	O
dose	O
of	O
leuprolide	B-I
acetate	I-I
for	O
suppression	O
of	O
serum	O
estradiol	O
?	O
OBJECTIVE	O
To	O
determine	O
if	O
heavier	B-P
women	I-P
benefit	O
from	O
a	O
higher	O
dose	O
of	O
the	O
gonadotropin-releasing	B-I
hormone	I-I
analogue	I-I
leuprolide	I-I
acetate	I-I
(	I-I
LA	I-I
)	I-I
depot	O
in	O
terms	O
of	O
suppression	O
of	O
serum	O
estradiol	O
.	O


METHODS	O
This	O
was	O
a	O
retrospective	O
analysis	O
of	O
the	O
effect	O
of	O
LA	B-I
depot	I-I
3.75	O
mg	O
and	O
7.5	O
mg	O
on	O
serum	B-I
estradiol	I-I
from	O
a	O
multicenter	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
12-week	O
study	O
of	O
women	B-P
with	I-P
anemia	I-P
due	I-P
to	I-P
bleeding	I-P
from	I-P
uterine	I-P
leiomyomata	I-P
.	I-P


Serum	B-O
estradiol	I-O
levels	I-O
were	O
obtained	O
at	O
baseline	O
and	O
at	O
week	O
12	O
.	O


Patients	B-P
were	I-P
divided	I-P
into	I-P
weight	I-P
quartiles	I-P
according	I-P
to	I-P
their	I-P
baseline	I-P
weight	I-P
in	I-P
kilograms	I-P
:	I-P
46-	I-P
<	I-P
64	I-P
,	I-P
64-	I-P
<	I-P
72	I-P
,	I-P
72-	I-P
<	I-P
89	I-P
,	I-P
89-159	I-P
(	I-P
pounds-102-	I-P
<	I-P
140	I-P
,	I-P
140-	I-P
<	I-P
159	I-P
,	I-P
159-	I-P
<	I-P
196	I-P
,	I-P
196-350	I-P
)	I-P
.	I-P


RESULTS	O
At	O
baseline	O
there	O
was	O
no	B-O
statistically	I-O
significant	I-O
difference	I-O
in	O
estradiol	B-O
level	I-O
between	O
groups	O
as	O
a	O
whole	O
or	O
within	O
weight	O
quartiles	O
.	O


Within	O
each	O
group	O
there	O
was	O
no	O
relationship	O
between	O
weight	O
and	O
baseline	O
estradiol	O
.	O


At	O
week	O
12	O
,	O
whereas	O
estradiol	B-O
levels	I-O
were	O
significantly	B-O
greater	I-O
in	O
the	O
heavier	O
patients	O
in	O
each	O
of	O
the	O
groups	O
(	O
LA	O
3.75	O
mg	O
,	O
p	O
=	O
0.044	O
;	O
LA	O
7.5	O
mg	O
,	O
p	O
=	O
0.002	O
)	O
,	O
there	O
was	O
no	B-O
significant	I-O
difference	I-O
in	I-O
estradiol	I-O
between	O
groups	O
as	O
a	O
whole	O
or	O
within	O
any	O
of	O
the	O
weight	O
quartiles	O
.	O


Moreover	O
,	O
at	O
week	O
12	O
there	O
was	O
no	B-O
significant	I-O
difference	I-O
between	O
groups	O
in	O
the	O
percentage	B-O
of	I-O
patients	I-O
with	I-O
estradiol	I-O
suppressed	I-O
to	I-O
the	I-O
menopausal	I-O
range	I-O
.	I-O


CONCLUSION	O
Heavier	B-P
women	I-P
do	O
not	O
benefit	O
from	O
a	O
higher	O
dose	O
of	O
LA	B-I
depot	O
(	O
7.5	O
vs.	O
3.75	O
mg	O
)	O
for	O
suppression	O
of	O
serum	O
levels	O
of	O
estradiol	O
.	O


Endometrial	B-P
cytodiagnosis	I-P
using	O
a	O
new	B-I
softcyte	I-I
versus	O
a	B-I
conventional	I-I
endocyte	I-I
.	I-I


A	O
new	O
endometrial	O
cytologic	O
sampling	O
device	O
,	O
softcyte	O
,	O
was	O
used	O
in	O
cytological	B-P
screening	I-P
for	I-P
endometrial	I-P
cancer	I-P
,	O
and	O
was	O
compared	O
with	O
the	O
endocyte	B-I
with	O
regard	O
to	O
manipulability	O
,	O
adverse	O
effects	O
(	O
including	O
pain	O
and	O
hemorrhage	O
)	O
,	O
and	O
cellular	O
findings	O
(	O
including	O
the	O
quantity	O
of	O
cells	O
collected	O
,	O
the	O
success	O
rate	O
,	O
cell	O
freshness	O
,	O
and	O
cellular	O
clumping	O
)	O
.	O


A	O
total	O
of	O
315	B-P
women	I-P
(	I-P
premenopause	I-P
251	I-P
,	I-P
postmenopause	I-P
64	I-P
)	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
two	I-P
groups	I-P
who	I-P
underwent	I-P
the	I-P
endometrial	I-I
cytological	I-I
screening	I-I
with	I-I
either	I-I
the	I-I
softcyte	I-I
or	I-I
the	I-I
endocyte	I-I
.	I-I


To	O
assess	O
the	O
value	O
of	O
the	O
softcyte	B-I
we	O
compared	O
it	O
with	O
the	O
endocyte	B-I
.	I-I


Endometrial	O
cytology	O
using	O
a	O
softcyte	B-I
or	O
an	O
endocyte	B-I
achieved	O
high	O
correct	B-O
diagnosis	I-O
rate	I-O
for	I-O
cancer	I-O
,	O
and	O
both	O
instruments	O
are	O
valuable	O
as	O
endometrial	O
cytologic	O
sample	O
devices	O
.	O


The	O
softcyte	O
causes	O
only	O
mild	B-O
pain	I-O
on	I-O
introduction	I-O
and	I-O
during	I-O
collection	I-O
,	O
and	O
a	O
large	O
quantity	B-O
of	I-O
cells	I-O
could	O
be	O
harvested	O
.	O


These	O
results	O
suggest	O
that	O
the	O
softcyte	O
is	O
a	O
useful	O
cytologic	O
sampling	O
device	O
in	O
screening	B-P
for	I-P
endometrial	I-P
cancer	I-P
.	I-P


The	O
effect	O
of	O
acupressure	B-I
at	O
the	O
extra	O
1	O
point	O
on	O
subjective	O
and	O
autonomic	B-O
responses	I-O
to	O
needle	O
insertion	O
.	O


BACKGROUND	O
Premedication	B-I
with	I-I
sedatives	I-I
can	O
decrease	O
the	O
discomfort	B-O
associated	O
with	O
invasive	O
anesthetic	O
procedures	O
.	O


Some	O
researchers	O
have	O
shown	O
that	O
acupressure	O
on	O
the	O
acupuncture	O
extra	O
1	O
point	O
is	O
effective	O
for	O
sedation	O
.	O


We	O
investigated	O
whether	O
acupressure	O
on	O
the	O
extra	O
1	O
point	O
could	O
alleviate	O
the	O
pain	B-O
of	O
needle	O
insertion	O
.	O


METHODS	O
We	O
investigated	O
the	O
effect	O
of	O
acupressure	B-I
at	O
the	O
extra	O
1	O
point	O
or	O
a	O
sham	O
point	O
on	O
needle	O
insertion	O
using	O
verbal	B-O
rating	I-O
scale	I-O
(	I-O
VRS	I-O
)	I-O
pain	I-O
scores	I-O
and	O
heart	B-O
rate	I-O
variability	I-O
(	I-O
HRV	I-O
)	I-O
.	I-O


Twenty-two	B-P
healthy	I-P
female	I-P
volunteers	I-P
were	O
randomly	O
allocated	O
to	O
two	O
groups	O
:	O
the	O
extra	B-I
1	I-I
group	I-I
received	O
acupressure	B-I
at	I-I
the	I-I
extra	I-I
1	I-I
point	I-I
,	O
and	O
the	O
sham	B-I
group	I-I
received	O
acupressure	B-I
at	I-I
a	I-I
sham	I-I
point	I-I
.	I-I


After	O
starting	O
the	O
electrocardiogram	B-I
record	O
,	O
a	O
27-gauge	O
needle	O
was	O
inserted	O
into	O
the	O
skin	O
of	O
a	O
forearm	O
.	O


Thereafter	O
,	O
another	O
needle	O
was	O
inserted	O
into	O
the	O
skin	O
of	O
the	O
other	O
forearm	O
during	O
acupressure	O
.	O


RESULTS	O
Acupressure	B-I
at	O
the	O
extra	O
1	O
point	O
significantly	O
reduced	O
the	O
VRS	B-O
,	O
but	O
acupressure	B-I
at	O
the	O
sham	O
increased	O
the	O
VRS	B-O
.	I-O


Acupressure	B-I
at	O
the	O
extra	O
1	O
significantly	O
reduced	O
the	O
low	B-O
frequency/high	I-O
frequency	I-O
ratio	I-O
of	I-O
HRV	I-O
responding	I-O
to	I-O
needle	I-O
insertion	I-O
.	I-O


CONCLUSIONS	O
Acupressure	B-I
at	O
the	O
extra	O
1	O
point	O
significantly	O
reduced	O
needle	B-O
insertion	I-O
pain	I-O
compared	O
with	O
acupressure	B-I
at	O
the	O
sham	O
point	O
.	O


Also	O
,	O
acupressure	B-I
at	O
the	O
extra	O
1	O
point	O
significantly	O
reduced	O
the	O
low	B-O
frequency/high	I-O
frequency	I-O
ratio	I-O
of	I-O
HRV	I-O
responding	O
to	O
needle	O
insertion	O
,	O
which	O
implies	O
a	O
reduction	B-O
in	O
sympathetic	B-O
nervous	I-O
system	I-O
activity	I-O
.	I-O


Marginal	O
biotin	O
deficiency	O
during	O
normal	B-P
pregnancy	I-P
.	I-P


BACKGROUND	O
Biotin	O
deficiency	O
is	O
teratogenic	O
in	O
several	B-P
mammalian	I-P
species	I-P
.	I-P


Approximately	O
50	O
%	O
of	O
pregnant	B-P
women	I-P
have	O
an	O
abnormally	O
increased	O
urinary	O
excretion	O
of	O
3-hydroxyisovaleric	B-O
acid	I-O
(	I-O
3-HIA	I-O
)	I-O
,	O
which	O
probably	O
reflects	O
decreased	O
activity	O
of	O
the	O
biotin-dependent	O
enzyme	O
methylcrotonyl-CoA	O
carboxylase	O
.	O


However	O
,	O
increased	O
3-HIA	O
excretion	O
could	O
result	O
from	O
pregnancy	O
per	O
se	O
(	O
eg	O
,	O
from	O
an	O
effect	O
of	O
pregnancy	O
on	O
renal	O
handling	O
of	O
organic	O
acids	O
)	O
.	O


OBJECTIVE	O
We	O
tested	O
the	O
hypothesis	O
that	O
biotin	O
supplementation	O
significantly	O
decreases	O
3-HIA	O
excretion	O
in	O
pregnant	B-P
women	I-P
with	I-P
abnormally	I-P
increased	I-P
3-HIA	I-P
excretion	I-P
.	I-P


DESIGN	O
Twenty-six	B-P
pregnant	I-P
women	I-P
with	I-P
increased	I-P
3-HIA	I-P
excretion	I-P
were	I-P
studied	I-P
in	I-P
a	I-P
randomized	I-P
,	I-P
placebo-controlled	I-I
trial	I-P
;	I-P
10	O
women	O
were	O
studied	O
during	O
early	O
pregnancy	O
(	O
6-17	O
wk	O
gestation	O
)	O
and	O
16	O
women	O
during	O
late	O
pregnancy	O
(	O
21-37	O
wk	O
gestation	O
)	O
.	O


Urine	B-O
samples	I-O
were	O
collected	O
before	O
and	O
after	O
14	O
d	O
of	O
supplementation	O
with	O
300	B-I
microg	I-I
(	I-I
1.2	I-I
micromol	I-I
)	I-I
biotin/d	I-I
or	I-I
placebo	I-I
.	I-I


RESULTS	O
In	O
the	O
early-pregnancy	O
group	O
,	O
3-HIA	B-O
excretion	I-O
decreased	O
(	O
P	O
<	O
0.006	O
)	O
by	O
11.7	O
+/-	O
3.6	O
mmol/mol	O
creatinine	O
(	O
mean	O
+/-	O
SEM	O
)	O
in	O
the	O
5	O
women	O
who	O
received	O
biotin	O
supplements	O
,	O
whereas	O
3-HIA	B-O
excretion	I-O
increased	O
by	O
1.6	O
+/-	O
0.6	O
mmol/mol	O
creatinine	O
in	O
the	O
5	O
women	O
who	O
received	O
placebo	O
.	O


In	O
the	O
late-pregnancy	O
group	O
,	O
3-HIA	B-O
excretion	I-O
decreased	O
(	O
P	O
<	O
0.002	O
)	O
by	O
7.1	O
+/-	O
1.2	O
mmol/mol	O
creatinine	O
in	O
the	O
8	O
women	O
who	O
received	O
biotin	O
supplements	O
,	O
whereas	O
3-HIA	B-O
excretion	I-O
increased	O
by	O
0.9	O
+/-	O
1.8	O
mmol/mol	O
creatinine	O
in	O
the	O
8	O
women	O
who	O
received	O
placebo	O
.	O


CONCLUSIONS	O
This	O
study	O
provides	O
evidence	O
that	O
the	O
increased	O
excretion	B-O
of	I-O
3-HIA	I-O
seen	O
frequently	O
in	O
normal	B-P
pregnancy	I-P
reflects	O
reduced	O
biotin	B-O
status	I-O
.	I-O


The	O
conclusion	O
that	O
marginal	O
biotin	O
deficiency	O
occurs	O
frequently	O
in	O
the	O
first	O
trimester	O
further	O
raises	O
concern	O
about	O
potential	O
human	O
teratogenicity	O
.	O


Group	B-I
cognitive	I-I
behavioural	I-I
therapy	I-I
and	I-I
group	I-I
recreational	I-I
activity	I-I
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	I-P
a	O
preliminary	O
randomized	O
controlled	O
trial	O
.	O


Although	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
are	O
an	O
increasingly	O
identified	O
patient	O
population	O
,	O
few	O
treatment	O
options	O
are	O
available	O
.	O


This	O
preliminary	O
randomized	O
controlled	O
open	O
trial	O
with	O
a	O
parallel	O
design	O
developed	O
two	O
group	O
interventions	O
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
intelligence	I-P
within	I-P
the	I-P
normal	I-P
range	I-P
:	I-P
cognitive	I-I
behavioural	I-I
therapy	I-I
and	I-I
recreational	I-I
activity	I-I
.	I-I


Both	O
interventions	O
comprised	O
36	O
weekly	O
3-h	O
sessions	O
led	O
by	O
two	O
therapists	O
in	O
groups	B-P
of	I-P
6-8	I-P
patients	I-P
.	I-P


A	O
total	O
of	O
68	B-P
psychiatric	I-P
patients	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
participated	O
in	O
the	O
study	O
.	O


Outcome	O
measures	O
were	O
Quality	B-O
of	I-O
Life	I-O
Inventory	I-O
,	I-O
Sense	I-O
of	I-O
Coherence	I-O
Scale	I-O
,	I-O
Rosenberg	I-O
Self-Esteem	I-O
Scale	I-O
and	I-O
an	I-O
exploratory	I-O
analysis	I-O
on	I-O
measures	I-O
of	I-O
psychiatric	I-O
health	I-O
.	I-O


Participants	O
in	O
both	O
treatment	O
conditions	O
reported	O
an	O
increased	O
quality	B-O
of	I-O
life	I-O
at	O
post-treatment	O
(	O
d	O
=	O
0.39	O
,	O
p	O
<	O
0.001	O
)	O
,	O
with	O
no	O
difference	O
between	O
interventions	O
.	O


No	O
amelioration	O
of	O
psychiatric	B-O
symptoms	I-O
was	O
observed	O
.	O


The	O
dropout	B-O
rate	I-O
was	O
lower	O
with	O
cognitive	B-I
behavioural	I-I
therapy	I-I
than	O
with	O
recreational	O
activity	O
,	O
and	O
participants	O
in	O
cognitive	B-I
behavioural	I-I
therapy	I-I
rated	O
themselves	O
as	O
more	O
generally	O
improved	O
,	O
as	O
well	O
as	O
more	O
improved	O
regarding	O
expression	O
of	O
needs	O
and	O
understanding	O
of	O
difficulties	O
.	O


Both	O
interventions	O
appear	O
to	O
be	O
promising	O
treatment	O
options	O
for	O
adults	O
with	O
autism	O
spectrum	O
disorder	O
.	O


The	O
interventions	O
'	O
similar	O
efficacy	B-O
may	O
be	O
due	O
to	O
the	O
common	O
elements	O
,	O
structure	O
and	O
group	O
setting	O
.	O


Cognitive	B-I
behavioural	I-I
therapy	I-I
may	O
be	O
additionally	O
beneficial	O
in	O
terms	O
of	O
increasing	O
specific	O
skills	O
and	O
minimizing	O
dropout	O
.	O


Dose-response	B-O
and	I-O
concentration-response	I-O
relation	O
of	O
rocuronium	B-I
infusion	I-I
during	O
propofol-nitrous	B-I
oxide	I-I
and	O
isoflurane-nitrous	B-I
oxide	I-I
anaesthesia	I-I
.	I-I


The	B-O
dose-response	I-O
and	I-O
concentration-response	I-O
relation	I-O
of	O
rocuronium	B-I
infusion	I-I
was	O
studied	O
in	O
20	B-P
adult	I-P
surgical	I-P
patients	I-P
during	I-P
propofol-nitrous	I-I
oxide	I-I
and	I-I
isoflurane	I-I
(	I-I
1	I-I
MAC	I-I
)	I-I
-nitrous	I-I
oxide	I-I
anaesthesia	I-I
.	I-I


Neuromuscular	O
block	O
was	O
kept	O
constant	O
,	O
initially	O
at	O
90	O
%	O
and	O
then	O
at	O
50	O
%	O
with	O
a	O
closed-loop	B-I
feedback	I-I
controller	I-I
.	I-I


At	O
90	O
%	O
block	O
the	O
steady-state	B-O
infusion	I-O
of	I-I
rocuronium	I-I
was	O
0.55	O
+/-	O
0.16	O
mg	O
kg-1	O
h-1	O
and	O
the	O
corresponding	B-I
concentration	I-O
1714	O
+/-	O
281	O
ng	O
mL-1	O
in	O
patients	O
receiving	O
propofol	B-I
.	I-I


At	O
50	O
%	O
block	O
the	O
corresponding	B-O
infusion	I-O
rate	I-O
was	O
0.27	O
+/-	O
0.11	O
mg	O
kg-1	O
h-1	O
and	O
the	O
concentration	B-O
1077	O
+/-	O
244	O
ng	O
mL-1	O
,	O
respectively	O
.	O


At	O
50	O
%	O
block	O
isoflurane	B-I
reduced	O
the	O
rate	B-O
of	I-O
infusion	I-O
by	O
52	O
%	O
(	O
P	O
<	O
0.005	O
)	O
and	O
the	O
concentration	B-O
by	O
59	O
%	O
(	O
P	O
<	O
0.001	O
)	O
;	O
at	O
90	O
%	O
block	O
both	O
the	O
mean	B-O
infusion	I-O
rate	I-O
and	O
the	O
concentration	B-O
of	I-O
rocuronium	I-O
were	O
reduced	O
by	O
35	O
%	O
(	O
P	O
<	O
0.005	O
)	O
.	O


The	O
mean	B-O
rocuronium	I-O
clearance	I-O
at	O
50	O
%	O
block	O
was	O
unaffected	O
by	O
the	O
type	O
of	O
anaesthesia	B-I
;	I-I
it	O
was	O
4.1	O
+/-	O
1.6	O
and	O
4.9	O
+/-	O
2.7	O
mL	O
kg-1	O
min-1	O
in	O
the	O
groups	O
receiving	O
propofol	B-I
and	O
isoflurane	B-I
anaesthesia	I-I
,	O
respectively	O
.	O


We	O
conclude	O
that	O
isoflurane	O
reduces	O
the	O
infusion	B-O
requirements	I-O
of	I-O
rocuronium	I-O
by	O
changing	O
the	O
pharmacodynamic	O
behaviour	O
.	O


Protective	O
effect	O
of	O
1-adamantanamine	B-I
hydrochloride	I-I
on	O
influenza	B-P
A2	I-P
infections	I-O
in	I-P
the	I-P
family	I-P
environment	I-P
:	I-P
a	O
controlled	O
double-blind	O
study	O
.	O


Multicyclic	B-I
,	I-I
dose-intensive	I-I
chemotherapy	I-I
supported	O
by	O
sequential	O
reinfusion	O
of	O
hematopoietic	B-I
progenitors	I-I
in	O
whole	O
blood	O
.	O


PURPOSE	O
To	O
support	O
multicyclic	O
,	O
dose-intensive	B-I
chemotherapy	I-I
,	O
we	O
assessed	O
the	O
effects	O
of	O
reinfusing	B-I
hematopoietic	I-I
progenitors	I-I
collected	O
at	O
each	O
cycle	O
in	O
leukapheresis	O
product	O
or	O
whole	O
blood	O
.	O


PATIENTS	O
AND	O
METHODS	O
Twenty-five	B-P
patients	I-P
with	I-P
small-cell	I-P
lung	I-P
cancer	I-P
(	I-P
SCLC	I-P
)	I-P
were	O
treated	O
with	O
six	O
cycles	O
of	O
ifosfamide	B-I
,	I-I
carboplatin	I-I
,	I-I
and	I-I
etoposide	I-I
(	I-I
ICE	I-I
)	I-I
with	I-I
granulocyte	I-I
colony-stimulating	I-I
factor	I-I
(	I-I
G-CSF	I-I
)	I-I
300	O
micrograms/d	O
subcutaneously	O
(	O
SC	O
)	O
on	O
days	O
4	O
to	O
15	O
.	O


Hematopoietic	O
progenitors	O
collected	O
during	O
each	O
cycle	O
were	O
reinfused	O
on	O
day	O
3	O
of	O
the	O
next	O
cycle	O
.	O


Cohort	O
1	O
(	O
n	O
=	O
6	O
)	O
was	O
treated	O
every	O
3	O
weeks	O
,	O
with	O
leukapheresis	B-I
after	O
2	O
weeks	O
and	O
cryopreservation	B-I
of	I-I
the	I-I
leukapheresis	I-I
product	I-I
.	I-I


Chemotherapy	B-I
was	O
given	O
if	O
the	O
WBC	O
count	O
was	O
>	O
or	O
=	O
3	O
x	O
10	O
(	O
9	O
)	O
/L	O
and	O
platelet	O
count	O
>	O
or	O
=	O
100	O
x	O
10	O
(	O
9	O
)	O
/L	O
.	O


Cohort	O
2	O
(	O
n	O
=	O
7	O
)	O
was	O
treated	O
every	O
2	O
weeks	O
,	O
with	O
leukapheresis	B-I
on	O
day	O
1	O
of	O
the	O
next	O
cycle	O
and	O
storage	O
of	O
the	O
leukapheresis	B-I
product	I-I
at	O
4	O
degrees	O
C.	O
Cohort	O
3	O
(	O
n	O
=	O
12	O
)	O
was	O
treated	O
every	O
2	O
weeks	O
,	O
with	O
500	O
to	O
750	O
mL	O
of	O
blood	O
drawn	O
by	O
venesection	O
on	O
day	O
1	O
of	O
the	O
next	O
cycle	O
and	O
stored	O
at	O
4	O
degrees	O
C.	O
In	O
cohorts	O
2	O
and	O
3	O
,	O
chemotherapy	B-I
was	O
given	O
if	O
the	O
WBC	O
count	O
was	O
>	O
or	O
=	O
3	O
x	O
10	O
(	O
9	O
)	O
/L	O
and	O
platelet	O
count	O
>	O
or	O
=	O
30	O
x	O
10	O
(	O
9	O
)	O
/L	O
.	O


Blood	B-O
and	I-O
leukapheresis	I-O
products	I-O
were	O
assayed	O
for	O
hematopoietic	O
progenitors	O
.	O


RESULTS	O
ICE	B-I
chemotherapy	I-I
with	O
G-CSF	O
was	O
effective	O
in	O
mobilizing	B-O
blood	I-O
progenitors	I-O
(	O
median	O
,	O
120-fold	O
)	O
.	O


Long-term	O
cultures	O
showed	O
no	O
evidence	O
of	O
stem-cell	B-O
depletion	I-O
.	I-O


The	O
cytotoxic	B-O
dose-intensity	I-O
of	O
standard	O
every-4-weeks	O
ICE	O
is	O
100	O
%	O
.	O


In	O
the	O
first	O
three	O
cycles	O
,	O
it	O
was	O
134	O
%	O
(	O
median	O
)	O
in	O
cohort	O
1	O
and	O
200	O
%	O
in	O
cohorts	O
2	O
and	O
3	O
(	O
P	O
<	O
.0001	O
)	O
.	O


Toxicity	B-O
and	I-O
supportive	I-O
care	I-O
requirements	I-O
were	O
not	O
increased	O
.	O


CONCLUSION	O
The	O
dose-intensity	O
of	O
ICE	B-I
chemotherapy	I-I
can	O
be	O
doubled	O
by	O
reinfusing	O
hematopoietic	O
progenitors	O
collected	O
by	O
leukapheresis	O
or	O
venesection	O
and	O
stored	O
at	O
4	O
degrees	O
C	O
.	O


[	O
Cardiac	O
protection	O
is	O
a	O
clinical	O
evidence	O
]	O
.	O


AIM	O
Anaesthetics	O
may	O
have	O
protective	O
effect	O
against	O
myocardial	O
ischemia	O
.	O


We	O
aimed	O
to	O
investigate	O
if	O
sevoflurane	O
administration	O
could	O
exert	O
myocardial	B-O
protection	I-O
during	O
following	O
coronary	O
occlusion	O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
.	I-P


METHODS	O
a	O
)	O
.	O


EXPERIMENTAL	O
DESIGN	O
prospective	O
,	O
randomized	O
study	O
.	O


b	O
)	O
.	O


SETTING	O
University	B-P
Hospital	I-P
,	I-P
cardiac	I-P
surgical	I-P
operative	I-P
theatre	I-P
.	I-P


c	O
)	O
.	O


PATIENTS	O
42	B-P
patients	I-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
,	I-P
scheduled	I-P
to	I-P
undergo	I-P
coronary	I-P
surgery	I-P
.	I-P


INCLUSION	B-P
CRITERIA	I-P
severe	I-P
coronary	I-P
stenosis	I-P
of	I-P
anterior	I-P
descending	I-P
coronary	I-P
artery	I-P
;	I-P
no	I-P
collateral	I-P
flow	I-P
on	I-P
angiography	I-P
;	I-P
at	I-P
least	I-P
two	I-P
normokinetic	I-P
segments	I-P
in	I-P
the	I-P
myocardial	I-P
region	I-P
supplied	I-P
by	I-P
the	I-P
vessel	I-P
being	I-P
bypassed	I-P
.	I-P


PATIENTS	O
were	O
randomized	O
to	B-I
receive	I-I
(	I-I
group	I-I
S	I-I
)	I-I
or	I-I
not	I-I
(	I-I
group	I-I
C	I-I
)	I-I
sevoflurane	I-I
administration	O
for	O
15	O
min	O
just	O
before	O
coronary	O
occlusion	O
.	O


d	O
)	O
.	O


INTERVENTIONS	O
Transoesophageal	B-I
Tissue	I-I
Doppler	I-I
echocardiographic	I-I
examination	I-I
of	I-I
myocardial	I-I
systolic	I-I
and	I-I
early	I-I
diastolic	I-I
velocities	I-I
in	I-I
both	I-I
groups	I-I
basally	I-I
and	I-I
60	I-I
s	I-I
after	I-I
coronary	I-I
occlusion	I-I
by	I-I
the	I-I
surgeon	I-I
.	I-I


e	O
)	O
.	O


MEASURES	O
systolic	B-O
and	I-O
early	I-O
diastolic	I-O
velocities	I-O
were	O
registered	O
by	O
Tissue	O
Doppler	O
from	O
a	O
long-axis	O
view	O
of	O
the	O
interventricular	O
septum	O
or	O
the	O
anterior	O
wall	O
of	O
the	O
left	O
ventricle	O
.	O


RESULTS	O
In	O
group	O
C	O
a	O
significant	O
reduction	O
of	O
systolic	B-O
and	I-O
diastolic	I-O
intramyocardial	I-O
velocities	I-O
was	O
found	O
during	O
myocardial	O
ischemia	O
due	O
to	O
coronary	O
occlusion	O
.	O


CONCLUSION	O
Treatment	O
with	O
sevoflurane	O
before	O
coronary	O
occlusion	O
seem	O
effective	O
in	O
reducing	O
functional	B-O
myocardial	I-O
impairment	I-O
due	O
to	O
ischemia	O
.	O


[	O
Total	O
parenteral	B-O
nutrition	I-O
in	O
colon	B-I
surgery	I-I
]	I-I
.	O


Pars	B-I
plana	I-I
vitrectomy	I-I
for	O
diabetic	O
macular	O
edema	O
.	O


Internal	B-I
limiting	I-I
membrane	I-I
delamination	I-I
vs	O
posterior	B-I
hyaloid	I-I
removal	I-I
.	I-I


A	O
prospective	O
randomized	O
trial	O
.	O


BACKGROUND	O
Diabetes	O
mellitus	O
,	O
as	O
well	O
as	O
subsequent	O
ocular	O
complications	O
such	O
as	O
cystoid	O
macular	O
edema	O
(	O
CME	O
)	O
,	O
are	O
of	O
fundametal	O
socio-economic	O
relevance	O
.	O


Therefore	O
,	O
we	O
evaluated	O
the	O
influence	O
of	O
internal	B-I
limiting	I-I
membrane	I-I
(	I-I
ILM	I-I
)	I-I
removal	I-I
on	O
longterm	O
morphological	O
and	O
functional	O
outcome	O
in	O
patients	B-P
with	I-P
diabetes	I-P
mellitus	I-P
(	I-P
DM	I-P
)	I-P
type	I-P
2	I-P
and	I-P
chronic	I-P
CME	I-P
without	I-P
evident	I-P
vitreomacular	I-P
traction	I-P
.	I-P


METHOD	O
Forty	B-P
eyes	I-P
with	I-P
attached	I-P
posterior	I-P
hyaloid	I-P
were	O
included	O
in	O
this	O
prospective	O
trial	O
and	O
randomized	O
intraoperatively	O
.	O


Prior	O
focal	O
(	O
n	O
=	O
31	O
)	O
or	O
panretinal	O
(	B-I
n	I-I
=	I-I
25	I-I
)	I-I
laser	I-I
coagulation	I-I
was	O
permitted	O
.	O


Group	O
I	O
(	O
n	O
=	O
19	O
patients	B-I
)	I-I
underwent	I-I
surgical	I-I
induction	I-I
of	I-I
posterior	I-I
vitreous	I-I
detachment	I-I
(	O
PVD	O
)	O
,	O
group	O
II	O
(	B-I
n	I-I
=	I-I
20	I-I
patients	I-I
)	I-I
PVD	I-I
and	I-I
removal	I-I
of	O
the	O
ILM	O
.	O


Eleven	O
patients	O
with	O
detached	O
posterior	O
hyaloid	O
(	O
group	O
III	O
)	O
were	O
not	O
randomized	B-I
,	O
and	O
ILM	O
removal	O
was	O
performed	O
.	O


One	O
eye	O
had	O
to	O
be	O
excluded	O
from	O
further	O
analysis	O
.	O


Examinations	B-O
included	I-O
ETDRS	I-O
best-corrected	I-O
visual	I-O
acuity	I-O
(	I-O
BCVA	I-O
)	I-O
,	I-O
fluorescein	I-O
angiography	I-O
(	O
FLA	O
)	O
and	O
OCT	O
at	O
baseline	O
,	O
3	O
and	O
6	O
months	O
postoperatively	O
.	O


Main	O
outcome	B-O
measure	O
was	O
BCVA	O
at	O
6	B-O
months	I-O
,	I-O
secondary	I-O
was	I-O
foveal	O
thickness	B-O
.	I-O


RESULTS	O
Mean	O
BCVA	O
over	O
6	O
months	O
remained	O
unchanged	O
in	O
85	O
%	O
of	O
patients	O
of	O
group	O
II	O
,	O
and	O
decreased	O
in	O
53	O
%	O
of	O
patients	O
of	O
group	O
I	O
.	O


Results	O
were	O
not	O
statistically	O
significant	O
different	O
[	O
group	O
I	O
:	O
mean	O
decrease	O
log	O
MAR	O
95	O
%	O
CI	O
(	O
0.06	O
;	O
0.32	O
)	O
,	O
group	O
II	O
:	O
(	O
-0.02	O
;	O
0.11	O
)	O
]	O
.	O


OCT	O
revealed	O
a	O
significantly	O
greater	B-O
reduction	I-O
of	I-O
foveal	O
thickness	O
following	O
PVD	O
with	O
ILM	O
removal	O
[	O
group	O
I	O
:	O
mean	O
change	O
:	O
95	O
%	O
CI	O
(	O
-208.95	O
μm	O
;	O
-78.05	O
μm	O
)	O
,	O
group	O
II	O
:	O
(	B-I
-80.90	I-I
μm	I-I
:	I-I
+59.17	I-I
μm	I-I
)	I-I
]	I-I
.	I-I


CONCLUSION	B-I
Vitrectomy	I-I
,	I-I
PVD	I-I
with	I-I
or	O
without	O
ILM	O
removal	O
does	B-P
not	I-P
improve	I-P
vision	I-P
in	I-P
patients	I-P
with	I-P
DM	I-P
type	I-P
2	I-P
and	I-P
cystoid	I-P
diabetic	I-P
macular	I-P
edema	I-P
without	I-P
evident	I-P
vitreoretinal	O
traction	O
.	O


ILM	O
delamination	O
shows	O
improved	O
morphological	O
results	O
,	O
and	O
appears	B-P
to	I-P
be	I-P
beneficial	I-P
in	I-P
eyes	O
with	O
preexisting	O
PVD	O
.	O


Intraperitoneal	B-I
cisplatin	I-I
versus	O
no	O
further	O
treatment	O
:	O
8-year	O
results	O
of	O
EORTC	O
55875	O
,	O
a	O
randomized	O
phase	O
III	O
study	O
in	O
ovarian	B-P
cancer	I-P
patients	I-P
with	I-P
a	I-P
pathologically	I-P
complete	I-P
remission	I-P
after	I-P
platinum-based	I-I
intravenous	I-I
chemotherapy	I-I
.	I-I


First-line	B-I
intravenous	I-I
chemotherapy	I-I
(	O
CT	O
)	O
following	O
debulking	O
surgery	O
is	O
associated	O
with	O
prolonged	B-O
survival	I-O
,	O
in	O
particular	O
in	O
patients	B-P
who	I-P
achieve	I-P
a	I-P
pathological	I-P
complete	I-P
remission	I-P
(	I-P
pCR	I-P
)	I-P
at	I-P
second-look	I-P
surgery	I-P
but	I-P
in	I-P
whom	I-P
a	I-P
high	I-P
rate	I-P
of	I-P
relapses	I-P
still	I-P
occurs	I-P
.	I-P


Between	B-P
1988	I-P
and	I-P
1997	I-P
,	I-P
153	I-P
patients	I-P
in	I-P
pCR	I-P
following	I-P
platinum-based	I-I
intravenous	I-I
CT	I-I
were	O
randomized	O
between	O
four	B-I
courses	I-I
of	I-I
intraperitoneal	I-I
cisplatin	I-I
(	I-I
P	I-I
)	I-I
(	I-I
90	I-I
mg/m2	I-I
every	I-I
3	I-I
weeks	I-I
)	I-I
or	I-I
observation	I-I
.	I-I


Overall	B-O
survival	I-O
(	I-O
OS	I-O
)	I-O
was	O
the	O
primary	O
endpoint	O
,	O
while	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
a	O
secondary	O
endpoint	O
.	O


This	O
intent-to-treat	O
analysis	O
includes	B-P
16	I-P
patients	I-P
who	I-P
were	I-P
not	I-P
eligible	I-P
and	I-P
17	I-P
patients	I-P
who	I-P
had	I-P
protocol	I-P
violations	I-P
.	I-P


The	O
two	B-P
groups	I-P
were	I-P
well	I-P
balanced	I-P
in	I-P
terms	I-P
of	I-P
age	I-P
(	I-P
median	I-P
=	I-P
55	I-P
years	I-P
)	I-P
,	I-P
performance	I-P
status	I-P
(	I-P
78	I-P
%	I-P
P.S	I-P
.	I-P


O	B-P
)	I-P
,	I-P
FIGO	I-P
stage	I-P
(	I-P
96	I-P
%	I-P
stage	I-P
III	I-P
)	I-P
,	I-P
histology	I-P
(	I-P
serous	I-P
in	I-P
66	I-P
%	I-P
)	I-P
,	I-P
grade	I-P
(	I-P
2	I-P
or	I-P
3	I-P
in	I-P
80	I-P
%	I-P
)	I-P
,	I-P
and	I-P
residuum	I-P
before	I-P
intravenous	I-P
CT	I-P
(	I-P
>	I-P
1	I-P
cm	I-P
in	I-P
40	I-P
%	I-P
)	I-P
.	I-P


Intraperitoneal	B-I
CT	I-I
was	O
delivered	O
mainly	O
through	O
intraperitoneal	O
catheters	O
(	O
Port-a-Cath	O
61	O
%	O
and	O
Tenckhoff	O
25	O
%	O
)	O
.	O


Side	O
effects	O
of	O
intraperitoneal	B-I
cisplatin	I-I
included	O
vomiting	B-O
[	O
>	O
or	O
=grade	O
2	O
(	O
82	O
%	O
)	O
]	O
,	O
rise	B-O
in	I-O
serum	I-O
creatinine	I-O
[	O
>	O
or	O
=grade	O
2	O
(	O
14	O
%	O
)	O
]	O
,	O
abdominal	B-O
pain	I-O
[	O
grade	O
1-2	O
(	O
38	O
%	O
)	O
]	O
,	O
and	O
neurotoxicity	B-O
[	O
grade	O
2-3	O
(	O
15	O
%	O
)	O
]	O
.	O


After	O
a	O
median	O
follow-up	O
of	O
8	O
years	O
,	O
80	O
patients	O
(	O
52	O
%	O
)	O
have	O
progressed	O
with	O
no	O
difference	O
in	O
the	O
pattern	B-O
of	I-O
relapse	I-O
between	O
the	O
two	O
groups	O
and	O
75	O
patients	O
(	O
49	O
%	O
)	O
have	O
died	B-O
;	I-O
the	O
respective	O
hazard	O
ratios	O
for	O
PFS	O
and	O
OS	O
with	O
95	O
%	O
CI	O
are	O
0.89	O
(	O
0.59-1.33	O
)	O
and	O
0.82	O
(	O
0.52-1.29	O
)	O
.	O


These	O
results	O
are	O
suggestive	O
of	O
a	O
treatment	O
benefit	O
but	O
do	O
not	O
support	O
a	O
change	O
in	O
clinical	O
practice	O
.	O


Other	O
randomized	O
clinical	O
trials	O
of	O
intraperitoneal	B-I
CT	I-I
are	O
reviewed	O
and	O
briefly	O
discussed	O
.	O


Dark-phase	O
light	O
contamination	O
disrupts	O
circadian	O
rhythms	O
in	O
plasma	B-O
measures	O
of	O
endocrine	B-P
physiology	I-O
and	I-P
metabolism	I-O
in	I-P
rats	I-P
.	I-P


Dark-phase	B-I
light	I-I
contamination	I-I
can	O
significantly	O
disrupt	O
chronobiologic	B-O
rhythms	I-O
,	O
thereby	O
potentially	O
altering	O
the	O
endocrine	O
physiology	O
and	O
metabolism	O
of	O
experimental	B-P
animals	I-P
and	O
influencing	O
the	O
outcome	O
of	O
scientific	O
investigations	O
.	O


We	O
sought	O
to	O
determine	O
whether	O
exposure	O
to	O
low-level	O
light	O
contamination	O
during	O
the	O
dark	O
phase	O
influenced	O
the	O
normally	O
entrained	O
circadian	O
rhythms	O
of	O
various	O
substances	O
in	O
plasma	O
.	O


Male	B-P
Sprague-Dawley	I-P
rats	I-P
(	I-P
n	I-P
=	I-P
6	I-P
per	I-P
group	I-P
)	I-P
were	O
housed	O
in	O
photobiologic	B-I
light-exposure	I-I
chambers	I-I
configured	O
to	O
create	O
1	O
)	O
a	O
12:12-h	O
light	B-I
:	I-I
dark	I-I
cycle	I-I
without	I-I
dark-phase	I-I
light	I-I
contamination	I-I
(	O
control	O
condition	O
;	O
123	O
μW/cm	O
(	O
2	O
)	O
,	O
lights	O
on	O
at	O
0600	O
)	O
,	O
2	O
)	O
experimental	O
exposure	O
to	O
a	B-I
low	I-I
level	I-I
of	I-I
light	I-I
during	O
the	O
12-h	O
dark	O
phase	O
(	O
with	O
0.02	O
,	O
0.05	O
,	O
0.06	O
,	O
or	O
0.08	O
μW/cm	O
(	O
2	O
)	O
light	O
at	O
night	O
)	O
,	O
or	O
3	B-I
)	I-I
constant	I-I
bright	I-I
light	I-I
(	O
123	O
μW/cm	O
(	O
2	O
)	O
)	O
.	O


Dietary	O
and	O
water	O
intakes	O
were	O
recorded	O
daily	O
.	O


After	O
2	O
wk	O
,	O
rats	O
underwent	O
6	O
low-volume	O
blood	O
draws	O
at	O
4-h	O
intervals	O
(	O
beginning	O
at	O
0400	O
)	O
during	O
both	O
the	O
light	O
and	O
dark	O
phases	B-O
.	I-O


Circadian	B-O
rhythms	I-O
in	I-O
dietary	I-O
and	I-O
water	I-O
intake	I-O
and	I-O
levels	I-O
of	I-O
plasma	I-O
total	I-O
fatty	I-O
acids	I-O
and	I-O
lipid	I-O
fractions	I-O
remained	O
entrained	O
during	O
exposure	O
to	O
either	O
control	O
conditions	O
or	O
low-intensity	O
light	O
during	O
the	O
dark	O
phase	O
.	O


However	O
,	O
these	O
patterns	O
were	O
disrupted	O
in	O
rats	O
exposed	O
to	B-I
constant	I-I
bright	I-I
light	I-O
.	I-O


Circadian	B-O
patterns	I-O
of	I-O
plasma	I-O
melatonin	I-O
,	I-O
glucose	I-O
,	I-O
lactic	I-O
acid	I-O
,	I-O
and	I-O
corticosterone	I-O
were	O
maintained	O
in	O
all	O
rats	O
except	O
those	O
exposed	O
to	B-I
constant	I-I
bright	I-I
light	I-I
or	O
the	O
highest	O
level	O
of	O
light	O
during	O
the	O
dark	O
phase	O
.	O


Therefore	O
even	O
minimal	O
light	O
contamination	O
during	O
the	O
dark	O
phase	O
can	O
disrupt	O
normal	B-O
circadian	I-O
rhythms	I-O
of	O
endocrine	O
metabolism	O
and	O
physiology	O
and	O
may	O
alter	O
the	O
outcome	O
of	O
scientific	O
investigations	O
.	O


The	O
effects	O
of	O
aerobic	B-I
exercise	I-I
on	O
academic	O
engagement	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


PURPOSE	O
To	O
determine	O
whether	O
participation	O
in	O
aerobic	B-I
exercise	I-I
before	O
classroom	O
activities	O
improves	O
academic	O
engagement	O
and	O
reduces	O
stereotypic	O
behaviors	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


METHODS	O
This	O
study	O
employed	O
a	O
within-subjects	O
crossover	O
design	O
,	O
using	O
a	O
treatment	O
condition	O
(	B-I
aerobic	I-I
exercise	I-I
)	I-I
and	O
a	O
control	B-I
condition	I-I
,	O
across	O
4	O
classrooms	O
.	O


The	B-I
treatment	I-I
condition	I-I
included	I-I
15	I-I
minutes	I-I
of	I-I
running/jogging	I-I
followed	I-I
by	I-I
a	I-I
classroom	I-I
task	I-I
.	I-I


The	B-I
control	I-I
condition	I-I
included	I-I
a	I-I
classroom	I-I
task	I-I
not	I-I
preceded	I-I
by	I-I
exercise	I-I
.	I-I


The	O
number	B-O
of	I-O
stereotypic	I-O
behaviors	I-O
,	I-O
percentage	I-O
of	I-O
on-task	I-O
behavior	I-O
,	I-O
and	I-O
correct/incorrect	I-O
responses	I-O
were	I-I
measured	I-I
.	I-I


The	B-I
Wilcoxon	I-O
signed	I-O
rank	I-O
test	I-O
was	I-O
used	I-O
to	I-O
compare	I-O
differences	I-O
between	I-O
conditions	I-O
.	I-O


RESULTS	O
Statistically	O
significant	O
improvements	O
were	O
found	O
in	O
correct	O
responding	O
following	O
exercise	O
(	O
P	O
<	O
.05	O
)	O
.	O


No	O
significant	O
differences	O
were	O
found	O
for	O
on-task	B-O
behavior	I-O
or	O
stereotypic	B-O
behaviors	I-O
.	I-O


CONCLUSIONS	O
Consistent	O
with	O
findings	O
in	O
older	O
children	O
,	O
these	O
results	O
indicate	O
that	O
aerobic	B-I
exercise	I-I
prior	O
to	O
classroom	O
activities	O
may	O
improve	O
academic	O
responding	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


Assessing	O
the	O
benefit	B-O
of	O
a	O
personalized	B-I
EHR-generated	I-I
informed	I-I
consent	I-I
in	I-P
a	I-P
dental	I-P
school	I-P
setting	I-P
.	I-P


Informed	O
consents	O
are	O
routinely	O
used	O
as	O
an	O
important	O
source	O
of	O
information	O
to	O
help	O
patients	B-P
make	O
appropriate	O
clinical	O
decisions	O
.	O


However	O
,	O
current	O
standard	O
consent	O
forms	O
may	O
not	O
accomplish	O
their	O
intended	O
purpose	O
due	O
to	O
the	O
variety	O
of	O
patient	O
literacy	O
and	O
experiences	O
and	O
,	O
in	O
the	O
dental	O
school	O
setting	O
,	O
the	O
developing	O
competence	O
of	O
students	O
.	O


The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
test	O
the	O
efficacy	B-O
of	O
a	O
personalized	O
informed	O
consent	O
generated	O
through	O
an	O
electronic	O
health	O
record	O
(	O
EHR	O
)	O
at	O
one	O
dental	O
school	O
and	O
its	O
role	O
in	O
patient	O
decision	O
making	O
.	O


In	O
the	O
study	O
,	O
a	O
set	O
of	O
informed	O
consents	O
,	O
or	O
SmartConsents	B-I
,	O
were	O
developed	O
for	O
specific	O
diagnoses	O
and	O
procedures	O
,	O
enhanced	O
with	O
graphics	O
,	O
and	O
delivered	O
through	O
the	O
school	O
's	O
EHR	O
.	O


Fifty	B-P
patients	I-P
were	I-P
recruited	I-P
in	I-P
the	I-P
school	I-P
's	I-P
Urgent	I-P
Care	I-P
Clinic	I-P
and	O
divided	O
evenly	O
into	O
two	O
groups	O
:	O
one	O
(	O
control	O
)	O
receiving	O
the	O
standard	B-I
consent	I-I
,	O
with	O
the	O
second	O
receiving	O
a	O
SmartConsent	B-I
.	I-I


Following	O
treatment	O
,	O
patients	O
were	O
assessed	O
based	O
on	O
demographics	B-O
,	I-O
decisional	I-O
conflict	I-O
,	I-O
satisfaction	I-O
,	I-O
health	I-O
literacy	I-O
,	I-O
and	I-O
knowledge	I-O
.	I-O


Overall	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
main	B-O
effects	I-O
between	O
SmartConsent	O
and	O
standard	O
informed	O
consents	O
for	O
decisional	B-O
conflict	I-O
and	I-O
satisfaction	I-O
,	O
although	O
significant	O
differences	O
were	O
identified	O
during	O
secondary	O
analysis	O
of	O
satisfaction	B-O
,	I-O
gender	I-O
,	I-O
and	I-O
ethnicity	I-O
.	I-O


The	O
study	O
also	O
demonstrated	O
the	O
potential	O
for	O
consents	O
to	O
aid	O
the	O
student	O
provider	O
in	O
better	B-O
communicating	I-O
with	I-O
patients	I-O
.	I-O


PTK2	O
expression	O
and	O
immunochemotherapy	O
outcome	O
in	O
chronic	B-P
lymphocytic	I-P
leukemia	I-P
.	I-P


Addition	O
of	O
rituximab	B-I
(	I-I
R	I-I
)	I-I
to	I-I
fludarabine	I-I
and	I-I
cyclophosphamide	I-I
(	O
FC	O
)	O
has	O
significantly	O
improved	O
patient	B-O
outcomes	I-O
in	I-P
chronic	I-P
lymphocytic	I-P
leukemia	I-P
(	I-P
CLL	I-P
)	I-P
.	I-P


Whether	O
baseline	O
gene	O
expression	O
can	O
identify	O
patients	B-P
who	I-P
will	I-P
benefit	I-P
from	I-P
immunochemotherapy	I-P
over	I-P
chemotherapy	I-P
alone	I-P
has	I-P
not	I-P
been	I-P
determined	I-P
.	I-P


We	B-P
assessed	I-P
genome-wide	I-O
expression	I-O
of	I-P
300	I-P
pretreatment	I-P
specimens	I-P
from	I-P
a	I-P
subset	I-P
of	I-P
552	I-P
patients	I-P
in	I-P
REACH	I-P
,	I-P
a	I-P
study	I-P
of	I-P
FC	I-I
or	I-P
R-FC	I-I
in	I-P
relapsed	I-P
CLL	I-P
.	I-P


An	B-P
independent	I-P
test	I-P
set	I-P
was	I-P
derived	I-P
from	I-P
282	I-P
pretreatment	I-P
specimens	I-P
from	I-P
CLL8	I-P
,	I-P
a	I-P
study	I-P
of	I-P
FC	I-P
or	I-P
R-FC	I-P
in	I-P
treatment-naïve	I-P
patients	I-P
.	I-P


Genes	O
specific	O
for	O
benefit	O
from	B-I
R-FC	I-I
were	O
determined	O
by	O
assessing	O
treatment-gene	O
interactions	O
in	O
Cox	O
proportional	O
hazards	O
models	O
.	O


REACH	O
patients	O
with	O
higher	O
pretreatment	O
protein	O
tyrosine	O
kinase	O
2	O
(	O
PTK2	O
)	O
messenger	O
RNA	O
levels	O
derived	O
greater	O
benefit	O
from	B-I
R-FC	I-I
,	O
with	O
significant	O
improvements	O
in	B-O
progression-free	I-O
survival	I-O
,	O
independent	O
of	O
known	O
prognostic	O
factors	O
in	O
a	O
multivariate	O
model	O
.	O


Examination	O
of	B-O
PTK2	I-O
gene	I-O
expression	I-O
in	O
CLL8	O
patients	O
yielded	O
similar	O
results	O
.	O


Furthermore	O
,	O
PTK2	B-O
inhibition	I-O
blunted	I-O
R-dependent	I-O
cell	I-O
death	I-O
in	I-O
vitro	I-O
.	O


This	O
retrospective	O
analysis	O
from	O
2	O
independent	O
trials	O
revealed	O
that	O
increased	B-O
PTK2	I-O
expression	I-O
is	O
associated	O
with	O
improved	O
outcomes	O
for	B-P
CLL	I-P
patients	I-P
treated	O
with	B-I
R-FC	I-I
vs	I-I
FC	I-I
.	O


PTK2	O
expression	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
patient	O
selection	O
in	O
future	O
trials	O
.	O


These	O
trials	O
were	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT00090051	O
(	O
REACH	O
)	O
and	O
#	O
NCT00281918	O
(	O
CLL8	O
)	O
.	O


Evaluation	O
of	O
postural	B-O
stability	I-O
by	O
computerised	B-I
posturography	I-I
following	O
outpatient	B-P
paediatric	I-I
anaesthesia	I-I
.	I-I


Comparison	O
of	O
propofol/alfentanil/N2O	B-I
anaesthesia	I-I
with	I-I
thiopentone/halothane/N2O	I-I
anaesthesia	I-I
.	I-I


Simple	O
clinical	O
tests	O
,	O
like	O
Romberg	O
's	O
test	O
or	O
a	O
walking	O
test	O
,	O
have	O
proved	O
to	O
be	O
inadequate	O
guidelines	O
for	O
safe	B-O
discharge	I-O
after	O
outpatient	O
anaesthesia	O
.	O


A	O
randomised	O
study	O
was	O
therefore	O
planned	O
to	O
compare	O
postural	O
stability	O
measured	O
by	O
computerised	O
posturography	O
in	O
31	B-P
oral	I-I
midazolam-atropine	I-I
premedicated	I-P
children	I-P
aged	I-P
6.9	I-P
(	I-P
s.e	I-P
.	I-P


0.4	B-P
)	I-P
years	I-P
who	I-P
had	I-P
been	I-P
anaesthetised	I-I
with	I-P
either	I-P
propofol/alfentanil/N2O	I-I
or	I-I
thiopentone/halothane/N2O	I-I
.	I-I


The	O
sway	B-O
velocity	I-O
of	O
the	O
children	O
was	O
measured	O
before	O
premedication	O
and	O
1	O
,	O
2	O
and	O
3	O
h	O
after	O
the	O
end	O
of	O
anaesthesia	O
.	O


Results	O
show	O
that	O
sway	B-O
velocity	I-O
had	O
returned	O
to	O
baseline	O
values	O
3	O
h	O
after	O
the	O
end	O
of	O
anaesthesia	O
in	O
all	O
children	O
who	O
had	O
received	O
propofol/alfentanil/N2O	B-I
and	O
in	O
12	O
of	O
the	O
15	O
children	O
who	O
had	O
received	O
thiopentone/halothane/N2O	B-I
.	I-I


The	O
quantified	O
version	O
of	O
the	O
Romberg	B-O
test	I-O
performed	O
with	O
eyes	O
open	O
or	O
closed	O
was	O
not	O
impaired	O
after	O
anaesthesia	O
,	O
compared	O
with	O
the	O
control	O
values	O
,	O
indicating	O
that	O
in	O
children	O
poor	O
equilibrium	O
is	O
not	O
compensated	O
by	O
vision	O
.	O


The	O
clinical	O
recovery	O
with	O
respect	O
to	O
the	O
times	O
to	O
eye	B-O
opening	I-O
,	O
to	O
responding	O
to	O
command	O
or	O
to	O
being	O
fully	O
awake	O
did	O
not	O
differ	O
between	O
the	O
two	O
anaesthesia	O
methods	O
.	O


On	O
the	O
basis	O
of	O
recovery	O
assessed	O
by	O
postural	O
stability	O
,	O
propofol/alfentanil/N2O	B-I
anaesthesia	I-I
was	O
not	O
preferable	O
to	O
thiopentone/halothane/N2O	B-I
anaesthesia	I-I
after	O
minor	O
paediatric	O
otolaryngological	B-I
surgery	I-I
.	I-I


Calcium	B-I
chloride	I-I
before	I-I
i.v	I-I
.	I-I


diltiazem	B-I
in	O
the	O
management	B-O
of	I-O
atrial	I-O
fibrillation	I-O
.	I-O


Diltiazem	B-I
is	O
commonly	O
used	O
to	O
treat	O
atrial	B-P
fibrillation	I-P
or	I-P
flutter	I-P
(	I-P
AFF	I-P
)	I-P
with	O
rapid	O
ventricular	O
response	O
(	O
RVR	O
)	O
.	O


Although	O
it	O
is	O
very	O
effective	O
for	O
rate	B-O
control	I-O
,	O
up	O
to	O
an	O
18	O
%	O
prevalence	O
of	O
reported	O
diltiazem-induced	B-O
hypotension	I-O
[	I-O
defined	I-O
by	I-O
systolic	I-O
blood	I-O
pressure	I-O
(	I-O
SBP	I-O
)	I-O
<	I-O
90	I-O
mm	I-O
Hg	I-O
]	I-O
,	O
and	O
a	O
mean	O
of	O
9.7	O
%	O
hypotension	B-O
have	O
been	O
reported	O
from	O
several	O
studies	O
totaling	O
over	B-P
450	I-P
patients	I-P
.	I-P


This	O
hypotension	B-O
may	O
complicate	O
therapy	O
.	O


Our	O
objective	O
was	O
to	O
determine	O
if	O
calcium	B-I
chloride	I-I
(	I-I
CaCl	I-I
(	I-I
2	I-I
)	I-I
)	I-I
pre-treatment	O
would	O
blunt	O
a	O
SBP	B-O
drop	I-O
after	O
i.v	O
.	O


diltiazem	O
,	O
while	O
allowing	O
diltiazem	B-I
to	O
maintain	O
its	O
efficacy	O
.	O


A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
conducted	O
.	O


Seventy-eight	B-P
patients	I-P
with	I-P
AFF	I-P
and	I-P
a	I-P
ventricular	I-P
rate	I-P
of	I-P
>	I-P
/=	I-P
120	I-P
beats	I-P
per	I-P
minute	I-P
were	I-P
enrolled	I-P
.	I-P


Half	O
received	O
i.v	O
.	O


CaCl	B-I
(	I-I
2	I-I
)	I-I
pre-treatment	O
;	O
the	O
other	O
half	O
received	O
placebo	B-I
.	I-I


All	O
patients	O
then	O
received	O
i.v	O
.	O


diltiazem	B-I
in	O
a	O
standard	O
,	O
weight-based	O
dose	O
.	O


A	O
second	O
dose	O
of	O
CaCl	O
(	O
2	O
)	O
pre-treatment	O
or	O
placebo	B-I
and	O
diltiazem	B-I
was	O
given	O
if	O
clinically	O
indicated	O
for	O
additional	O
rate	O
control	O
.	O


Both	O
CaCl	O
(	O
2	O
)	O
and	O
placebo	B-I
pre-treatment	O
groups	O
had	O
equal	O
lowering	O
of	O
heart	B-O
rate	I-O
(	O
p	O
<	O
0.001	O
)	O
.	O


There	O
were	O
no	O
adverse	B-O
events	I-O
in	O
the	O
calcium	O
pre-treatment	O
study	O
arm	O
.	O


One	B-P
patient	I-P
in	I-P
the	I-P
placebo	I-P
group	I-P
became	O
paradoxically	O
more	O
tachycardic	B-O
and	I-O
apneic	I-O
after	O
the	O
diltiazem	O
infusion	O
.	O


Although	O
i.v	O
.	O


CaCl	O
(	O
2	O
)	O
seems	O
to	O
be	O
equally	O
safe	O
compared	O
to	O
placebo	O
as	O
a	O
pre-treatment	O
in	O
the	O
management	O
of	O
AFF	O
with	O
RVR	O
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
statistically	O
significant	O
blunting	B-O
of	I-O
SBP	I-O
drop	I-O
with	O
CaCl	O
(	O
2	O
)	O
i.v	O
.	O


pre-treatment	O
.	O


Until	O
further	O
research	O
determines	O
a	O
benefit	O
exists	O
,	O
we	O
can	O
not	O
recommend	O
i.v	O
.	O


CaCl	B-I
(	I-I
2	I-I
)	I-I
pre-treatment	O
before	O
diltiazem	B-I
in	O
the	O
treatment	O
of	O
AFF	O
with	O
RVR	O
.	O


Brain	B-O
activity	I-O
correlates	I-P
differentially	I-P
with	I-P
increasing	I-P
temporal	I-P
complexity	I-P
of	I-P
rhythms	I-P
during	I-P
initialisation	I-P
,	I-P
synchronisation	I-P
,	I-P
and	I-P
continuation	I-P
phases	I-P
of	I-P
paced	I-I
finger	I-I
tapping	I-I
.	I-I


Activity	B-O
in	I-O
parts	I-O
of	I-O
the	I-O
human	I-O
motor	I-O
system	I-O
has	O
been	O
shown	O
to	O
correlate	O
with	O
the	O
complexity	O
of	O
performed	O
motor	O
sequences	O
in	O
terms	O
of	O
the	O
number	O
of	O
limbs	O
moved	O
,	O
number	O
of	O
movements	O
,	O
and	O
number	O
of	O
trajectories	O
.	O


Here	O
,	O
we	O
searched	O
for	O
activity	O
correlating	O
with	O
temporal	O
complexity	O
,	O
in	O
terms	O
of	O
the	O
number	O
of	O
different	O
intervals	O
produced	O
in	O
the	O
sequence	O
,	O
using	O
an	O
overlearned	O
tapping	O
task	O
.	O


Our	O
task	O
was	O
divided	O
into	O
three	O
phases	O
:	O
movement	B-I
selection	I-I
and	I-I
initiation	I-I
(	I-I
initiate	I-I
)	I-I
,	I-I
synchronisation	I-I
of	I-I
finger	I-I
tapping	I-I
with	I-I
an	I-I
external	I-I
auditory	I-I
cue	I-I
(	I-I
synchronise	I-I
)	I-I
,	O
and	O
continued	B-I
tapping	I-I
in	I-I
absence	I-I
of	I-I
the	I-I
auditory	I-I
pacer	I-I
(	O
continue	O
)	O
.	O


Comparisons	O
between	O
synchronisation	O
and	O
continuation	O
showed	O
a	O
pattern	O
in	O
keeping	O
with	O
prior	O
neuroimaging	O
studies	O
of	O
paced	O
finger	O
tapping	O
.	O


Thus	O
,	O
activation	B-O
of	I-O
bilateral	I-O
SMA	I-O
and	I-O
basal	I-O
ganglia	I-O
was	O
greater	O
in	O
continuation	B-I
tapping	O
than	O
in	O
synchronisation	B-I
tapping	O
.	O


Parametric	O
analysis	O
revealed	O
activity	B-O
correlating	I-O
with	I-O
temporal	I-O
complexity	I-O
during	I-O
initiate	I-O
in	I-O
bilateral	I-O
supplementary	I-O
and	I-O
pre-supplementary	I-O
motor	I-O
cortex	I-O
(	I-O
SMA	I-O
and	I-O
preSMA	I-O
)	I-O
,	I-O
rostral	I-O
dorsal	I-O
premotor	I-O
cortex	I-O
(	I-O
PMC	I-O
)	I-O
,	I-O
basal	I-O
ganglia	I-O
,	I-O
and	I-O
dorsolateral	I-O
prefrontal	I-O
cortex	I-O
(	I-O
DLPFC	I-O
)	I-O
,	I-O
among	I-O
other	I-O
areas	I-O
.	I-O


During	O
synchronise	O
,	O
correlated	B-O
activity	I-O
was	O
observed	O
in	O
bilateral	O
SMA	O
,	O
more	O
caudal	O
dorsal	O
and	O
ventral	O
PMC	O
,	O
right	O
DLPFC	O
and	O
right	O
primary	O
motor	O
cortex	O
.	O


No	O
correlated	O
activity	O
was	O
observed	O
during	O
continue	O
at	O
P	O
<	O
0.01	O
(	O
corrected	O
,	O
cluster	O
level	O
)	O
,	O
though	O
left	O
angular	O
gyrus	O
was	O
active	O
at	O
P	O
<	O
0.05	O
.	O


We	O
suggest	O
that	O
the	O
preSMA	B-O
and	I-O
rostral	I-O
dorsal	I-O
PMC	I-O
activities	I-O
during	O
initiate	O
may	O
be	O
associated	O
with	O
selection	B-O
of	I-O
timing	I-O
parameters	I-O
,	O
while	O
activation	O
in	O
centromedial	O
prefrontal	O
cortex	O
during	O
both	O
initiate	O
and	O
synchronise	O
may	O
be	O
associated	O
with	O
temporal	B-O
error	I-O
monitoring	I-O
or	I-O
correction	I-O
.	I-O


The	O
absence	O
of	O
activity	B-O
significantly	I-O
correlated	I-O
with	I-O
temporal	I-O
complexity	I-O
during	O
continue	O
suggests	O
that	O
,	O
once	O
an	O
overlearned	O
timed	O
movement	O
sequence	O
has	O
been	O
selected	O
and	O
initiated	O
,	O
there	O
is	O
no	O
further	O
adjustment	O
of	O
the	O
timing	O
control	O
processes	O
related	O
to	O
its	O
continued	O
production	O
in	O
absence	O
of	O
external	O
cues	O
.	O


Effect	O
of	O
exercise	B-I
,	I-I
training	I-I
,	O
and	O
glycogen	B-I
availability	I-I
on	O
IL-6	O
receptor	O
expression	O
in	O
human	B-P
skeletal	I-P
muscle	I-P
.	I-P


The	O
cytokine	O
interleukin-6	O
(	O
IL-6	O
)	O
exerts	O
it	O
actions	O
via	O
the	O
IL-6	O
receptor	O
(	O
IL-6R	O
)	O
in	O
conjunction	O
with	O
the	O
ubiquitously	O
expressed	O
gp130	O
receptor	O
.	O


IL-6	O
is	O
tightly	O
regulated	O
in	O
response	O
to	O
exercise	B-I
,	O
being	O
affected	O
by	O
factors	O
such	O
as	O
exercise	O
intensity	O
and	O
duration	O
,	O
as	O
well	O
as	O
energy	O
availability	O
.	O


Although	O
the	O
IL-6	O
response	O
to	O
exercise	O
has	O
been	O
extensively	O
studied	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
the	O
IL-6R	O
response	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
exercise	B-I
,	I-I
training	I-I
,	I-I
and	I-I
glycogen	I-I
availability	I-I
,	O
factors	O
known	O
to	O
affect	O
IL-6	O
,	O
on	O
the	O
regulation	O
of	O
gene	O
expression	O
of	O
the	O
IL-6R	O
in	O
human	O
skeletal	O
muscle	O
.	O


Human	B-P
subjects	I-P
performed	O
either	O
10	B-I
wk	I-I
of	I-I
training	I-I
with	I-I
an	I-I
acute	I-I
exercise	I-I
bout	I-I
before	I-I
and	I-I
after	I-I
the	I-I
training	I-I
period	I-I
,	I-I
or	I-I
a	I-I
low-glycogen	I-I
vs.	I-I
normal-glycogen	I-I
acute	I-I
exercise	I-I
trial	I-I
.	I-I


The	O
IL-6R	B-O
mRNA	I-O
response	I-O
was	O
evaluated	O
in	O
both	O
trials	O
.	O


In	O
response	O
to	O
acute	O
exercise	O
,	O
an	O
increase	O
in	O
IL-6R	B-O
mRNA	I-O
levels	I-O
was	O
observed	O
.	O


Neither	O
training	O
nor	O
intramuscular	O
glycogen	O
levels	O
had	O
an	O
effect	O
on	O
the	O
IL-6R	B-O
mRNA	I-O
response	I-O
to	O
exercise	O
.	O


However	O
,	O
after	O
10	O
wk	O
of	O
training	O
,	O
the	O
skeletal	O
muscle	O
expressed	O
a	O
higher	O
mRNA	B-O
level	I-O
of	I-O
IL-6R	I-O
compared	O
with	O
before	O
training	O
.	O


The	O
present	O
study	O
demonstrated	O
that	O
the	O
IL-6R	B-O
gene	I-O
expression	I-O
levels	I-O
in	O
skeletal	O
muscle	O
are	O
increased	O
in	O
response	O
to	O
acute	O
exercise	O
,	O
a	O
response	O
that	O
is	O
very	O
well	O
conserved	O
,	O
being	O
affected	O
by	O
neither	O
training	B-O
status	I-O
nor	O
intramuscular	B-O
glycogen	I-O
levels	I-O
,	O
as	O
opposed	O
to	O
IL-6	O
.	O


However	O
,	O
after	O
the	O
training	O
period	O
,	O
IL-6R	B-O
mRNA	I-O
production	I-O
was	O
increased	O
in	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
sensitization	O
of	O
skeletal	O
muscle	O
to	O
IL-6	O
at	O
rest	O
.	O


Exemestane	B-I
for	O
breast-cancer	B-P
prevention	I-P
in	I-P
postmenopausal	I-P
women	I-P
.	I-P


BACKGROUND	O
Tamoxifen	O
and	O
raloxifene	O
have	O
limited	O
patient	O
acceptance	O
for	O
primary	O
prevention	O
of	O
breast	O
cancer	O
.	O


Aromatase	O
inhibitors	O
prevent	O
more	O
contralateral	O
breast	O
cancers	O
and	O
cause	O
fewer	O
side	O
effects	O
than	O
tamoxifen	O
in	O
patients	B-P
with	I-P
early-stage	I-P
breast	I-P
cancer	I-P
.	I-P


METHODS	O
In	O
a	O
randomized	O
,	O
placebo-controlled	B-I
,	O
double-blind	O
trial	O
of	O
exemestane	B-I
designed	O
to	O
detect	O
a	O
65	O
%	O
relative	O
reduction	O
in	O
invasive	O
breast	O
cancer	O
,	O
eligible	B-P
postmenopausal	I-P
women	I-P
35	I-P
years	I-P
of	I-P
age	I-P
or	I-P
older	I-P
had	I-P
at	I-P
least	I-P
one	I-P
of	I-P
the	I-P
following	I-P
risk	I-P
factors	I-P
:	I-P
60	I-P
years	I-P
of	I-P
age	I-P
or	I-P
older	I-P
;	I-P
Gail	I-P
5-year	I-P
risk	I-P
score	I-P
greater	I-P
than	I-P
1.66	I-P
%	I-P
(	I-P
chances	I-P
in	I-P
100	I-P
of	I-P
invasive	I-P
breast	I-P
cancer	I-P
developing	I-P
within	I-P
5	I-P
years	I-P
)	I-P
;	I-P
prior	I-P
atypical	I-P
ductal	I-P
or	I-P
lobular	I-P
hyperplasia	I-P
or	I-P
lobular	I-P
carcinoma	I-P
in	I-P
situ	I-P
;	I-P
or	I-P
ductal	I-P
carcinoma	I-P
in	I-P
situ	I-P
with	I-P
mastectomy	I-P
.	I-P


Toxic	B-O
effects	I-O
and	I-O
health-related	I-O
and	I-O
menopause-specific	I-O
qualities	I-O
of	I-O
life	I-O
were	O
measured	O
.	O


RESULTS	O
A	O
total	B-P
of	I-P
4560	I-P
women	I-P
for	I-P
whom	I-P
the	I-P
median	I-P
age	I-P
was	I-P
62.5	I-P
years	I-P
and	I-P
the	I-P
median	I-O
Gail	I-O
risk	I-O
score	I-O
was	I-P
2.3	I-P
%	I-P
were	O
randomly	O
assigned	O
to	O
either	O
exemestane	B-I
or	I-I
placebo	I-I
.	I-I


At	O
a	O
median	O
follow-up	O
of	O
35	O
months	O
,	O
11	O
invasive	O
breast	O
cancers	O
were	O
detected	O
in	O
those	O
given	O
exemestane	B-I
and	O
in	O
32	O
of	O
those	O
given	O
placebo	B-I
,	O
with	O
a	O
65	O
%	O
relative	O
reduction	B-O
in	I-O
the	I-O
annual	I-O
incidence	I-O
of	I-O
invasive	I-O
breast	I-O
cancer	I-O
(	O
0.19	O
%	O
vs.	O
0.55	O
%	O
;	O
hazard	O
ratio	O
,	O
0.35	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.18	O
to	O
0.70	O
;	O
P=0.002	O
)	O
.	O


The	O
annual	B-O
incidence	I-O
of	I-O
invasive	I-O
plus	I-O
noninvasive	I-O
(	I-O
ductal	I-O
carcinoma	I-O
in	I-O
situ	I-O
)	I-O
breast	I-O
cancers	I-O
was	O
0.35	O
%	O
on	O
exemestane	O
and	O
0.77	O
%	O
on	O
placebo	B-I
(	O
hazard	O
ratio	O
,	O
0.47	O
;	O
95	O
%	O
CI	O
,	O
0.27	O
to	O
0.79	O
;	O
P=0.004	O
)	O
.	O


Adverse	B-O
events	I-O
occurred	O
in	O
88	O
%	O
of	O
the	O
exemestane	O
group	O
and	O
85	O
%	O
of	O
the	O
placebo	O
group	O
(	O
P=0.003	O
)	O
,	O
with	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
skeletal	B-O
fractures	I-O
,	I-O
cardiovascular	I-O
events	I-O
,	I-O
other	I-O
cancers	I-O
,	I-O
or	I-O
treatment-related	I-O
deaths	I-O
.	I-O


Minimal	O
quality-of-life	B-O
differences	O
were	O
observed	O
.	O


CONCLUSIONS	O
Exemestane	B-I
significantly	O
reduced	O
invasive	B-P
breast	I-P
cancers	I-P
in	I-P
postmenopausal	I-P
women	I-P
who	I-P
were	I-P
at	I-P
moderately	I-P
increased	I-P
risk	I-P
for	I-P
breast	I-P
cancer	I-P
.	I-P


During	O
a	O
median	O
follow-up	O
period	O
of	O
3	O
years	O
,	O
exemestane	O
was	O
associated	O
with	O
no	O
serious	O
toxic	O
effects	O
and	O
only	O
minimal	O
changes	O
in	O
health-related	O
quality	O
of	O
life	O
.	O


(	O
Funded	O
by	O
Pfizer	O
and	O
others	O
;	O
NCIC	O
CTG	O
MAP.3	O
ClinicalTrials.gov	O
number	O
,	O
NCT00083174	O
.	O


)	O
.	O


A	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
parallel	O
study	O
of	O
loteprednol	B-I
etabonate	I-I
0.2	O
%	O
in	O
patients	B-P
with	I-P
seasonal	I-P
allergic	I-P
conjunctivitis	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
loteprednol	B-I
etabonate	I-I
(	I-I
LE	I-I
)	I-I
0.2	O
%	O
in	O
reducing	O
the	O
signs	O
and	O
symptoms	O
of	O
seasonal	B-O
allergic	I-O
conjunctivitis	I-O
.	I-O


DESIGN	O
Randomized	O
,	O
double-masked	O
,	O
placebo-controlled	B-I
,	O
parallel	O
group	O
multicenter	O
study	O
of	O
6	O
weeks	O
duration	O
.	O


PARTICIPANTS	O
A	B-P
total	I-P
of	I-P
135	I-P
patients	I-P
with	I-P
signs	I-P
and	I-P
symptoms	I-P
of	I-P
seasonal	I-P
allergic	I-P
conjunctivitis	I-P
participated	I-P
.	I-P


INTERVENTION	O
All	O
patients	O
received	O
either	O
LE	B-I
0.2	I-I
%	I-I
or	I-I
placebo	I-I
(	O
vehicle	O
)	O
four	O
times	O
a	O
day	O
in	O
both	O
eyes	O
for	O
42	O
days	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Bulbar	B-O
conjunctival	I-O
injection	I-O
(	I-O
primary	I-O
sign	I-O
)	I-O
and	I-O
itching	I-O
(	I-O
primary	I-O
symptom	I-O
)	I-O
over	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
was	O
measured	O
.	O


RESULTS	O
A	O
reduction	B-O
in	I-O
severity	I-O
was	O
seen	O
in	O
both	O
LE	O
and	O
placebo	O
groups	O
for	O
bulbar	B-O
conjunctival	I-O
injection	I-O
(	O
1.5	O
vs.	O
1.0	O
units	O
on	O
a	O
0-3	O
scale	O
)	O
and	O
itching	O
(	O
3.4	O
vs.	O
3.0	O
units	O
on	O
a	O
0-4	O
scale	O
)	O
over	O
the	O
first	O
2	O
weeks	O
.	O


The	O
treatment	O
effect	O
by	O
these	O
measures	O
was	O
-0.5	O
and	O
-0.4	O
units	O
in	O
favor	O
of	O
LE	O
(	O
P	O
<	O
or	O
=	O
0.008	O
)	O
.	O


Resolution	O
(	O
i.e.	O
,	O
the	O
proportion	B-O
of	I-O
patients	I-O
with	I-O
signs	I-O
or	I-O
symptoms	I-O
no	I-O
longer	I-O
present	I-O
)	I-O
at	O
day	O
14	O
strongly	O
favored	O
LE-treated	O
patients	O
(	O
36	O
%	O
and	O
15	O
%	O
;	O
58	O
%	O
and	O
38	O
%	O
,	O
for	O
injection	O
and	O
itching	O
,	O
respectively	O
)	O
.	O


Both	O
treatments	O
were	O
well	O
tolerated	B-O
.	I-O


One	O
patient	O
in	O
each	O
treatment	O
group	O
(	O
1	O
of	O
67	O
and	O
1	O
of	O
68	O
,	O
respectively	O
)	O
had	O
an	O
elevation	B-O
of	I-O
intraocular	I-O
pressure	I-O
of	O
10	O
mmHg	O
or	O
greater	O
during	O
the	O
6	O
weeks	O
of	O
treatment	O
.	O


CONCLUSIONS	O
Loteprednol	O
etabonate	O
0.2	O
%	O
was	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
.	O


Loteprednol	O
etabonate	O
0.2	O
%	O
had	O
a	O
safety	O
profile	O
comparable	O
to	O
placebo	O
.	O


A	O
Regulated	O
Trial	O
of	O
Bicuspid	O
Aortic	O
Valve	O
Repair	O
Supported	O
by	O
Geometric	B-I
Ring	I-I
Annuloplasty	I-I
.	I-I


BACKGROUND	O
Annular	O
stabilization	O
is	O
important	O
during	O
bicuspid	O
aortic	O
valve	O
(	O
BAV	O
)	O
repair	O
to	O
obtain	O
the	O
best	O
long-term	O
results	O
.	O


This	O
report	O
describes	O
the	O
early	O
outcomes	O
of	O
a	O
novel	O
bicuspid	O
annuloplasty	O
ring	O
for	O
this	O
purpose	O
.	O


METHODS	O
Under	O
regulatory	O
supervision	O
(	O
NCT02071849	O
)	O
,	O
a	O
geometric	B-I
bicuspid	I-I
annuloplasty	I-I
ring	I-I
was	O
used	O
during	B-P
valve	I-P
repair	I-P
in	I-P
16	I-P
patients	I-P
.	I-P


Three	B-P
patients	I-P
had	I-P
Sievers	I-P
type	I-P
0	I-P
valves	I-P
,	I-P
11	I-P
had	I-P
Sievers	I-P
type	I-P
1	I-P
,	I-P
and	I-P
2	I-P
had	I-P
Sievers	I-P
type	I-P
2	I-P
.	I-P


Thirteen	B-P
patients	I-P
had	I-P
left-/right-coronary	I-P
cusp	I-P
fusion	I-P
,	I-P
1	I-P
had	I-P
right-/noncoronary	I-P
cusp	I-P
fusion	I-P
,	I-P
and	I-P
2	I-P
had	I-P
both	I-P
.	I-P


Moderate	B-P
to	I-P
severe	I-P
aortic	I-P
insufficiency	I-P
(	I-P
AI	I-P
)	I-P
was	I-P
present	I-P
in	I-P
13	I-P
of	I-P
16	I-P
patients	I-P
,	I-P
and	I-P
3	I-P
had	I-P
mild	I-P
AI	I-P
with	I-P
aortic	I-P
aneurysms	I-P
.	I-P


Ascending	O
aortic	O
aneurysms	O
,	O
root	O
aneurysms	O
,	O
or	O
both	O
were	O
replaced	O
in	O
7	O
of	O
16	O
patients	O
.	O


The	O
Dacron-covered	B-I
titanium	I-I
ring	I-I
had	O
circular	O
base	O
geometry	O
and	O
two	O
outwardly	O
flaring	O
subcommissural	O
posts	O
positioned	O
opposite	O
on	O
the	O
circumference	O
.	O


The	O
ring	O
was	O
implanted	O
into	O
the	O
annulus	O
beneath	O
the	O
valve	O
,	O
and	O
then	O
leaflet	O
repair	O
was	O
performed	O
.	O


RESULTS	O
Immediate	B-O
postrepair	I-O
echocardiograms	I-O
showed	I-O
grade	I-O
0	I-O
residual	I-O
AI	O
in	O
all	O
patients	O
,	O
with	O
good	O
cusp	B-O
mobility	I-O
and	I-O
effective	I-O
height	I-O
,	I-O
and	I-O
satisfactory	I-O
gradients	I-O
.	O


There	O
were	O
no	B-O
in-hospital	I-O
or	I-O
late	I-O
mortalities	I-O
.	O


Two	O
patients	O
experienced	B-O
leaflet	I-O
tears	I-O
from	O
long	O
annular	O
suture	O
tails	O
,	O
requiring	B-O
late	I-O
valve	I-O
replacement	I-O
.	O


After	O
implementation	O
of	O
a	O
lateral	O
suture	O
fixation	O
technique	O
,	O
no	O
more	B-O
failures	I-O
occurred	O
.	O


At	O
a	O
mean	O
follow-up	O
time	O
of	O
9	O
months	O
,	O
the	O
remaining	O
14	O
patients	O
were	O
in	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
class	I-O
I	O
,	O
with	O
predominant	B-O
grade	I-O
0	I-O
AI	I-O
.	O


CONCLUSIONS	O
As	O
a	O
technique	O
for	O
BAV	O
repair	O
,	O
internal	O
ring	O
annuloplasty	O
produces	O
major	B-O
annular	I-O
remodeling	I-O
and	I-O
stabilization	I-O
.	O


Annular	O
reduction	O
and	O
reshaping	O
to	O
a	O
50/50	O
%	O
symmetric	O
circular	O
geometry	O
facilitates	B-O
leaflet	I-O
repair	I-O
and	O
enhances	B-O
cusp	I-O
coaptation	I-O
.	O


Geometric	O
ring	O
annuloplasty	O
could	O
have	O
useful	O
applications	O
in	O
BAV	O
repair	O
.	O


Is	O
chronic	B-I
sildenafil	I-I
therapy	I-I
safe	O
and	O
clinically	O
beneficial	O
in	O
patients	B-P
with	I-P
systolic	I-P
heart	I-P
failure	I-P
?	O
Sildenafil	B-I
is	O
a	O
selective	O
phosphodiesterase-5	O
inhibitor	O
and	O
causes	O
vasodilatation	O
,	O
particularly	O
in	O
pulmonary	O
circulation	O
.	O


Since	O
left	B-P
heart	I-P
failure	I-P
may	O
be	O
associated	O
with	O
pulmonary	O
hypertension	O
"	O
out	O
of	O
proportion	O
to	O
left	O
heart	O
disease	O
,	O
"	O
sildenafil	B-I
may	O
have	O
beneficial	O
effect	O
in	O
such	O
patients	O
.	O


The	O
present	O
investigation	O
was	O
designed	O
as	O
a	O
12-week	O
,	O
single-center	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
evaluating	O
the	O
effects	O
of	O
sildenafil	B-I
on	O
mean	B-O
blood	I-O
pressure	I-O
(	O
primary	O
endpoint	O
)	O
in	O
patients	B-P
with	I-P
left	I-P
systolic	I-P
heart	I-P
failure	I-P
.	I-P


Secondary	O
endpoints	O
included	O
exercise	B-O
capacity	I-O
assessed	O
by	O
6-minute	B-O
walk	I-O
test	I-O
.	I-O


A	O
total	O
of	O
106	B-P
patients	I-P
were	I-P
randomized	I-P
1:1	I-P
to	I-P
sildenafil	I-I
(	I-P
n=53	I-P
)	I-P
or	I-P
placebo	I-I
(	I-P
n=53	I-P
)	I-P
.	I-P


Patients	B-P
received	I-P
sildenafil	I-I
25	I-P
mg	I-P
twice	I-P
a	I-P
day	I-P
or	I-P
matching	I-P
placebo	I-I
for	I-P
the	I-P
first	I-P
2	I-P
weeks	I-P
and	I-P
50	I-P
mg	I-P
3	I-P
times	I-P
a	I-P
week	I-P
for	I-P
the	I-P
remainder	I-P
of	I-P
the	I-P
trial	I-P
.	I-P


The	O
placebo-corrected	O
effect	O
on	O
mean	B-O
blood	I-O
pressure	I-O
was	O
1.16	O
mm	O
Hg	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-1.6	O
to	O
5.1	O
,	O
P	O
>	O
.05	O
)	O
,	O
demonstrating	O
that	O
sildenafil	O
did	O
not	O
decrease	O
mean	B-O
blood	I-O
pressure	I-O
.	I-O


Compared	O
with	O
placebo	O
,	O
sildenafil	B-I
increased	O
the	O
6-minute	B-O
walk	I-O
test	I-O
by	O
a	O
nonsignificant	O
treatment	O
effect	O
of	O
14	O
m	O
(	O
P=.67	O
)	O
.	O


Adverse	B-O
effects	I-O
occurred	O
in	O
a	O
comparable	O
proportion	O
of	O
patients	O
taking	O
sildenafil	B-I
and	O
placebo	O
,	O
and	O
none	O
of	O
the	O
patients	O
needed	O
to	O
discontinue	O
therapy	O
.	O


Sildenafil	O
is	O
well	O
tolerated	B-O
in	O
left	B-P
heart	I-P
failure	I-P
patients	I-P
and	O
does	O
not	O
decrease	O
blood	B-O
pressure	I-O
.	I-O


It	O
can	O
be	O
safely	O
added	O
to	O
standard	O
heart	O
failure	O
therapy	O
.	O


Continual	B-I
feeding	I-I
of	O
two	O
types	O
of	O
microalgal	B-I
biomass	I-I
affected	O
protein	O
digestion	O
and	O
metabolism	O
in	O
laying	B-P
hens	I-P
.	I-P


A	O
14-wk	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
nutritional	O
efficacy	B-O
and	I-O
ssmetabolic	I-O
impact	I-O
of	O
2	O
types	O
of	O
microalgal	B-I
biomass	I-I
as	O
alternative	O
protein	O
sources	O
in	O
laying	B-P
hen	I-P
diets	O
.	O


Shaver	B-P
hens	I-P
(	I-P
total	I-P
=	I-P
150	I-P
and	I-P
26	I-P
wk	I-P
old	I-P
)	I-P
were	O
fed	O
1	O
of	O
5	O
diets	O
:	O
a	B-I
control	I-I
or	I-I
a	I-I
defatted	I-I
green	I-I
microalgal	I-I
biomass	I-I
(	I-I
DG	I-I
;	I-I
Desmodesmus	I-I
spp	I-I
.	I-I


)	B-I
at	O
25	O
%	O
and	O
a	B-I
full-fatted	I-I
diatom	I-I
biomass	I-I
(	I-I
FD	I-I
;	I-I
Staurosira	I-I
spp	I-I
.	I-I


)	B-I
at	O
11.7	O
%	O
inclusion	B-I
with	I-I
or	I-I
without	I-I
protease	I-I
.	I-I


This	O
experiment	O
consisted	O
of	O
5	O
replicates	O
per	O
treatment	O
and	O
each	O
replicate	O
contained	O
6	O
hens	O
individually	O
reared	O
in	O
cages	O
(	O
1	O
hen	O
for	O
biochemical	O
data/replicate	O
)	O
.	O


Despite	O
decreased	O
ADFI	O
(	O
P	O
=	O
0.03	O
)	O
,	O
hens	O
fed	O
DG	O
or	O
FD	O
had	O
final	O
BW	O
,	O
overall	O
hen-day	O
egg	O
production	O
,	O
and	O
egg	O
quality	O
similar	O
to	O
the	O
controls	O
.	O


Feeding	O
DG	O
or	O
FD	O
did	O
not	O
alter	B-O
plasma	I-O
concentrations	I-O
of	I-O
insulin	I-O
,	I-O
glutamine	I-O
,	I-O
and	I-O
uric	I-O
acid	I-O
or	I-O
alkaline	I-O
phosphatase	I-O
activity	I-O
at	O
wk	O
8	O
or	O
14	O
but	O
decreased	O
plasma	B-O
3-methyhistine	I-O
concentrations	I-O
(	O
P	O
=	O
0.03	O
)	O
and	O
tartrate-resistant	B-O
acid	I-O
phosphatase	I-O
(	I-O
TRAP	I-O
)	I-O
activities	I-O
(	O
P	O
<	O
0.001	O
)	O
at	O
wk	O
14	O
and	O
improved	O
(	O
P	O
=	O
0.002	O
)	O
ileal	O
total	O
AA	O
digestibility	O
.	O


Although	O
DG	O
or	O
FD	O
exhibited	O
moderate	B-O
effects	I-O
on	O
intestinal	B-O
brush	I-O
border	I-O
protease	I-O
activities	I-O
and	I-O
mRNA	I-O
levels	I-O
of	I-O
duodenal	I-O
transporters	I-O
Pept1	I-O
,	I-O
Lat1	I-O
,	I-O
and	I-O
Cat1	I-O
,	O
both	O
substantially	O
enhanced	O
(	O
P	O
<	O
0.05	O
)	O
phosphorylation	B-O
of	I-O
hepatic	I-O
protein	I-O
synthesis	I-O
key	I-O
regulator	I-O
S6	I-O
ribosomal	I-O
protein	I-O
(	O
S6	O
)	O
and	O
the	O
ratio	O
of	O
phospho-S6	O
to	O
S6	O
in	O
the	O
liver	O
of	O
hens	O
.	O


However	O
,	O
DG	O
and	O
FD	O
manifested	O
with	O
different	O
impacts	O
on	O
weights	B-O
of	I-O
egg	I-O
and	I-O
egg	I-O
albumen	I-O
,	I-O
proteolytic	I-O
activity	I-O
of	I-O
jejunal	I-O
digesta	I-O
,	I-O
plasma	I-O
TRAP	I-O
activity	I-O
,	I-O
ileal	I-O
total	I-O
AA	I-O
digestibility	I-O
,	I-O
and	I-O
several	I-O
intestinal	I-O
genes	I-O
and	I-O
hepatic	I-O
proteins	I-O
.	I-O


Supplemental	O
protease	O
in	O
the	O
DG	O
and	O
FD	O
diets	O
produced	O
mixed	B-O
effects	I-O
on	O
a	O
number	B-O
of	I-O
measures	I-O
.	I-O


In	O
conclusion	O
,	O
our	O
findings	O
revealed	O
the	O
feasibility	O
of	O
including	O
greater	O
levels	O
of	O
microalgal	B-I
biomass	I-I
as	O
a	O
source	O
of	O
feed	O
protein	O
for	O
laying	B-P
hens	I-P
and	O
a	O
novel	O
potential	O
of	O
the	O
biomass	O
in	O
improving	O
dietary	O
protein	O
digestion	O
and	O
body	O
protein	O
metabolism	O
than	O
previously	O
perceived	O
.	O


High	B-P
general	I-P
anger	I-O
:	I-O
correlates	I-I
and	O
treatment	B-I
.	I-I


Acute	B-I
intravenous	I-I
L-arginine	I-I
infusion	I-I
decreases	O
endothelin-1	B-O
levels	I-O
and	O
improves	O
endothelial	B-O
function	I-O
in	O
patients	B-P
with	I-P
angina	I-P
pectoris	I-P
and	I-P
normal	I-P
coronary	I-P
arteriograms	I-P
:	I-P
correlation	O
with	O
asymmetric	O
dimethylarginine	B-O
levels	I-O
.	I-O


BACKGROUND	O
We	O
tested	O
the	O
hypothesis	O
that	O
asymmetric	B-O
dimethylarginine	I-O
(	I-O
ADMA	I-O
)	I-O
levels	I-O
could	O
be	O
elevated	O
and	O
influence	O
endothelin-1	B-O
and	I-I
nitric	I-O
oxide	I-O
release	I-O
and	I-O
action	I-O
in	O
patients	B-P
with	I-P
cardiac	I-P
syndrome	I-P
X	I-P
(	I-P
CSX	I-P
)	I-P
.	I-P


In	O
addition	O
,	O
we	O
evaluated	O
whether	O
an	O
intravenous	O
infusion	O
of	O
L-arginine	B-I
would	O
improve	O
endothelial	B-O
function	I-O
in	O
these	O
subjects	O
.	O


METHODS	O
AND	O
RESULTS	O
Nine	B-P
patients	I-P
with	I-P
CSX	I-P
and	I-P
14	I-P
control	I-P
subjects	I-P
underwent	I-P
a	I-P
continuous	I-P
infusion	I-P
of	I-P
L-arginine	I-I
(	I-I
0.125	I-I
g/min	I-I
)	I-I
or	I-I
saline	I-I
for	I-P
120	I-P
minutes	I-P
.	I-P


Sixty	O
minutes	O
after	O
L-arginine	B-I
or	I-I
saline	I-I
infusions	I-I
,	O
an	O
intravenous	O
insulin	B-I
bolus	O
(	O
0.1	O
U/kg	O
)	O
combined	O
with	O
a	O
euglycemic	B-I
clamp	I-I
was	O
performed	O
.	O


Basal	B-O
ADMA	I-O
and	I-O
endothelin-1	I-O
levels	I-O
were	O
higher	O
in	O
patients	B-P
with	I-P
CSX	I-P
than	O
in	O
controls	B-P
.	I-P


At	O
the	O
end	O
of	O
the	O
first	O
hour	O
of	O
infusion	O
,	O
compared	O
with	O
saline	B-I
,	I-I
L-arginine	I-I
infusion	O
increased	O
basal	B-O
forearm	I-O
blood	I-O
flow	I-O
,	I-O
nitrite	I-O
and	I-O
nitrate	I-O
(	I-O
NOx	I-O
)	I-O
,	I-O
and	I-O
forearm	I-O
cGMP	I-O
release	I-O
and	O
decreased	O
endothelin-1	B-O
.	I-O


After	O
insulin	O
bolus	O
,	O
during	O
saline	O
,	O
insulin-induced	B-O
NOx	I-O
,	I-O
endothelin-1	I-O
,	I-O
and	I-O
forearm	I-O
cGMP	I-O
release	I-O
was	O
almost	O
abolished	O
.	O


Conversely	O
,	O
L-arginine	O
restored	O
a	O
physiological	O
profile	O
of	O
all	O
endothelial	B-O
variables	I-O
compared	O
with	O
control	O
subjects	O
.	O


In	O
control	O
subjects	O
,	O
compared	O
with	O
saline	B-I
infusion	I-I
,	I-I
L-arginine	I-I
infusion	I-I
did	O
not	O
modify	O
any	O
parameter	O
.	O


ADMA	B-O
levels	I-O
were	O
positively	O
correlated	O
with	O
basal	O
endothelin-1	B-O
levels	I-O
and	O
negatively	O
correlated	O
with	O
insulin-induced	B-O
incremental	I-O
levels	I-O
of	I-O
NOx	I-O
and	I-O
forearm	I-O
cGMP	I-O
release	I-O
.	I-O


CONCLUSIONS	O
Plasma	B-O
ADMA	I-O
levels	I-O
are	O
increased	O
in	O
patients	B-P
with	I-P
CSX	I-P
,	O
and	O
they	O
are	O
correlated	O
with	O
increases	O
in	O
endothelin-1	B-O
and	O
reductions	O
in	O
insulin-induced	O
increments	O
in	O
plasma	B-O
NOx	I-O
and	I-O
cGMP	I-O
,	O
effects	O
that	O
are	O
reversed	O
by	O
intravenous	O
L-arginine	O
.	O


These	O
data	O
suggest	O
that	O
increased	O
ADMA	B-O
levels	I-O
play	O
a	O
role	O
in	O
the	O
abnormal	O
vascular	O
reactivity	O
that	O
is	O
observed	O
in	O
patients	O
with	O
CSX	B-P
.	I-P


An	O
evaluation	O
of	O
an	O
adaptive	B-I
automation	I-I
system	I-I
using	O
a	O
cognitive	B-I
vigilance	I-I
task	I-I
.	I-I


The	O
performance	O
of	O
an	O
adaptive	B-I
automation	I-I
system	I-I
was	O
evaluated	O
using	O
a	O
cognitive	O
vigilance	O
task	O
.	O


Participants	B-P
responded	O
to	O
the	O
presence	O
of	O
a	O
green	B-I
"	I-I
K	I-I
"	I-I
in	I-I
an	I-I
array	I-I
of	I-I
two	I-I
,	I-I
five	I-I
,	I-I
or	I-I
nine	I-I
distractor	I-I
stimuli	I-I
during	I-I
a	I-I
40-min	I-I
vigil	I-I
.	I-I


The	O
array	O
with	O
the	O
target	O
stimulus	O
was	O
presented	O
once	O
each	O
minute	O
.	O


Participants	B-P
EEG	I-I
was	O
recorded	O
and	O
an	O
engagement	B-O
index	I-O
(	O
EI	O
=	O
20	O
x	O
beta/	O
(	O
alpha	O
+	O
theta	O
)	O
)	O
was	O
derived	O
.	O


In	O
the	O
negative	O
feedback	O
condition	O
,	O
increases	O
in	O
the	O
EI	B-O
caused	I-O
the	I-O
number	I-O
of	I-O
stimuli	I-O
in	I-O
the	I-O
array	I-O
to	I-O
decrease	I-O
while	O
decreases	B-O
in	I-O
the	I-O
EI	I-O
caused	I-O
the	I-O
number	I-O
of	I-O
stimuli	I-O
to	I-O
increase	I-O
.	I-O


For	O
the	O
positive	O
feedback	O
condition	O
,	O
increases	B-O
in	I-O
the	I-O
index	I-O
caused	I-O
an	I-O
increase	I-O
in	I-O
the	I-O
array	I-O
size	I-O
(	I-O
AS	I-O
)	I-O
while	O
decreases	B-O
caused	I-O
a	I-O
decrease	I-O
in	I-O
the	I-O
array	I-O
size	I-O
.	I-O


Each	O
experimental	O
participant	B-P
had	I-P
a	I-P
yoked	I-P
control	I-P
partner	I-P
who	O
received	O
the	O
same	O
pattern	O
of	O
changes	O
in	O
array	O
irrespective	O
of	O
their	O
engagement	O
index	O
.	O


A	O
vigilance	O
decrement	O
was	O
seen	O
only	O
for	O
the	O
positive	O
feedback	O
,	O
experimental	B-P
group	I-P
.	I-P


Lifetime	O
history	O
of	O
heroin	O
use	O
is	O
associated	O
with	O
greater	O
drug	O
severity	O
among	O
prescription	B-P
opioid	I-P
abusers	I-P
.	I-P


BACKGROUND	O
While	O
research	O
suggests	O
primary	O
prescription	O
opioid	O
(	O
PO	O
)	O
abusers	O
may	O
exhibit	O
less	O
severe	O
demographic	O
and	O
drug	O
use	O
characteristics	O
than	O
primary	O
heroin	O
abusers	O
,	O
less	O
is	O
known	O
about	O
whether	O
a	O
lifetime	O
history	O
of	O
heroin	O
use	O
confers	O
greater	O
severity	O
among	O
PO	O
abusers	O
.	O


OBJECTIVE	O
In	O
this	O
secondary	O
analysis	O
,	O
we	O
examined	O
demographic	O
and	O
drug	O
use	O
characteristics	O
as	O
a	O
function	O
of	O
lifetime	O
heroin	O
use	O
among	O
89	B-P
PO-dependent	I-P
adults	I-P
screened	I-P
for	I-P
a	I-P
trial	I-P
evaluating	I-P
the	I-P
relative	I-P
efficacy	I-P
of	I-P
buprenorphine	I-P
taper	I-P
durations	I-P
.	I-P


Exploratory	O
analyses	O
also	O
examined	O
contribution	O
of	O
lifetime	O
heroin	O
use	O
to	O
treatment	O
response	O
among	O
a	O
subset	O
of	O
participants	O
who	O
received	O
a	O
uniform	O
set	O
of	O
study	O
procedures	O
.	O


METHODS	O
Baseline	O
characteristics	O
were	O
compared	O
between	O
participants	B-P
reporting	I-P
lifetime	I-P
heroin	I-P
use	I-P
≥5	I-P
(	I-P
H	I-P
(	I-P
+	I-P
)	I-P
;	I-P
n=41	I-P
)	I-P
vs.	I-P
<	I-P
5	I-P
(	I-P
H	I-P
(	I-P
-	I-P
)	I-P
;	I-P
n=48	I-P
)	I-P
times	I-P
.	O


Treatment	O
response	O
(	O
i.e.	B-I
,	O
illicit	B-I
opioid	I-I
abstinence	I-I
and	O
treatment	O
retention	O
at	O
end	O
of	O
study	O
)	O
was	O
examined	O
in	O
the	O
subset	O
of	O
H	O
(	O
+	O
)	O
and	O
H	O
(	O
-	O
)	O
participants	O
randomized	O
to	O
receive	O
the	O
4-week	O
taper	O
condition	O
(	O
N=22	O
)	O
.	O


RESULTS	O
H	O
(	O
+	O
)	O
participants	O
were	O
significantly	O
older	O
and	O
more	O
likely	O
to	O
be	O
male	O
.	O


They	O
reported	O
longer	B-O
durations	I-O
of	I-O
illicit	I-O
opioid	I-O
use	I-O
,	I-O
greater	I-O
alcohol-related	I-O
problems	I-O
,	I-O
more	I-O
past-month	I-O
cocaine	I-O
use	I-O
,	I-O
greater	I-O
lifetime	I-O
IV	I-O
drug	I-O
use	I-O
,	I-O
and	I-O
greater	I-O
lifetime	I-O
use	I-O
of	I-O
cigarettes	I-O
,	I-O
amphetamines	I-O
and	I-O
hallucinogens	I-O
.	O


H	O
(	O
+	O
)	O
participants	O
also	O
had	O
lower	O
scores	O
on	O
the	B-O
Positive	I-O
Symptom	I-O
Distress	I-O
and	I-O
Depression	I-O
subscales	I-O
of	O
the	O
Brief	O
Symptom	O
Inventory	O
.	O


Finally	O
,	O
there	O
was	O
a	O
trend	O
toward	O
poorer	O
treatment	O
outcomes	O
among	O
H	O
(	O
+	O
)	O
participants	O
.	O


CONCLUSION	O
A	O
lifetime	O
history	O
of	O
heroin	O
use	O
may	O
be	O
associated	O
with	O
elevated	O
drug	O
severity	O
and	O
unique	O
treatment	O
needs	O
among	O
treatment-seeking	B-P
PO	I-P
abusers	I-P
.	O


Optimization	O
of	O
acid	O
suppression	O
for	O
patients	B-P
with	I-P
peptic	I-P
ulcer	I-P
bleeding	I-P
:	I-P
an	O
intragastric	O
pH-metry	O
study	O
with	O
omeprazole	B-I
.	I-I


OBJECTIVE	O
To	O
study	O
whether	O
an	O
intravenous	O
infusion	O
dose	O
of	O
omeprazole	B-I
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
during	O
24	O
h	O
can	O
be	O
subsequently	O
reduced	O
with	O
maintained	O
effect	O
.	O


Second	O
,	O
to	O
study	O
the	O
effect	O
of	O
oral	O
omeprazole	B-I
20	O
mg	O
given	O
once	O
or	O
twice	O
daily	O
up	O
to	O
day	O
10	O
,	O
after	O
cessation	O
of	O
a	O
3-day	O
intravenous	O
infusion	O
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
partly	O
blinded	O
study	O
.	O


METHODS	O
Twelve	B-P
Helicobacter	I-P
pylori	I-P
(	I-P
+	I-P
)	I-P
patients	I-P
and	I-P
12	I-P
H.	I-P
pylori	I-P
(	I-P
-	I-P
)	I-P
subjects	I-P
were	I-P
included	I-P
.	I-P


In	O
part	O
I	O
the	O
patients	O
received	O
omeprazole	B-I
,	O
80	O
mg	O
+	O
8	O
mg/h	O
,	O
during	O
24	O
h	O
followed	O
by	O
8	O
,	O
4	O
or	O
2	O
mg/h	O
.	O


In	O
part	O
II	O
the	O
subjects	O
received	O
80	O
mg	O
+	O
8	O
mg/h	O
during	O
3	O
days	O
followed	O
by	O
20	O
mg	O
omeprazole	B-I
orally	O
,	O
once	O
or	O
twice	O
daily	O
until	O
day	O
10	O
.	O


Intragastric	B-O
pH	I-O
was	O
measured	O
.	O


RESULTS	O
All	O
H.	O
pylori	O
(	O
+	O
)	O
patients	O
showed	O
a	O
rapid	O
increase	O
of	O
intragastric	B-O
pH	I-O
with	I-O
a	I-O
mean	I-O
intragastric	I-O
pH	I-O
of	O
6.7	O
during	O
the	O
second	O
half	O
of	O
the	O
first	O
day	O
.	O


After	O
the	O
subsequent	O
dose	O
reduction	O
,	O
the	O
mean	B-O
pH	I-O
decreased	O
to	O
6.1-6.2	O
.	O


Patients	O
continuing	O
on	O
8	O
mg/h	O
showed	O
the	O
best	O
results	O
.	O


Likewise	O
,	O
all	O
H.	O
pylori	O
(	O
-	O
)	O
subjects	O
showed	O
a	O
rapid	O
and	O
sustained	O
reduction	O
of	O
intragastric	B-O
acidity	I-O
during	O
the	O
infusion	O
.	O


Subsequent	O
dose	O
reduction	O
to	O
20	O
mg	O
once	O
daily	O
led	O
to	O
a	O
stable	O
fraction	O
of	O
time	O
with	O
pH	O
>	O
3	O
of	O
72	O
%	O
.	O


CONCLUSIONS	O
Omeprazole	B-I
given	O
as	O
a	O
continuous	O
infusion	O
of	O
80	O
mg	O
+	O
8	O
mg/h	O
for	O
72	O
h	O
followed	O
by	O
omeprazole	B-I
20	O
mg	O
once	O
daily	O
raised	O
the	O
intragastric	B-O
pH	I-O
to	O
and	O
above	O
levels	O
alleged	O
to	O
allow	O
haemostasis	O
in	O
patients	O
with	O
peptic	B-P
ulcer	I-P
bleeding	I-P
and	O
subsequent	O
healing	O
of	O
the	O
ulcer	O
.	O


Impact	O
of	O
surgical	B-I
staging	I-I
in	O
evaluating	O
the	O
radiotherapeutic	O
outcome	O
in	O
RTOG	O
#	O
77-06	O
,	O
a	O
phase	O
III	O
study	O
for	O
T1BN0M0	O
(	O
A2	O
)	O
and	O
T2N0M0	O
(	O
B	O
)	O
prostate	O
carcinoma	O
.	O


PURPOSE	O
To	O
evaluate	O
survival	O
and	O
time	O
to	O
metastatic	O
disease	O
in	O
patients	B-P
treated	I-P
for	I-P
localized	I-P
prostatic	I-P
carcinoma	I-P
in	I-P
a	I-P
Phase	I-I
III	I-I
radiotherapy	I-I
(	I-P
RT	I-P
)	I-P
protocol	I-P
,	I-P
Radiation	I-I
Therapy	I-I
Oncology	I-I
Group	I-I
(	I-P
RTOG	I-P
)	I-P
77-06	I-P
.	I-P


Patients	B-P
with	I-P
T18N0M0	I-P
(	I-P
A2	I-P
)	I-P
or	I-P
T2N0M0	I-P
(	I-P
B	I-P
)	I-P
disease	I-P
after	I-P
lymphangiogram	I-P
(	I-P
LAG	I-P
)	I-P
or	I-P
staging	I-P
laparotomy	I-P
(	I-P
SL	I-P
)	I-P
were	I-P
randomized	I-P
between	I-P
prophylactic	I-P
radiation	I-P
to	I-P
the	I-P
pelvic	I-P
lymph	I-P
nodes	I-P
and	I-P
prostatic	I-P
bed	I-P
vs.	I-P
prostatic	I-P
bed	I-P
alone	I-P
.	I-P


The	O
outcome	O
of	O
both	O
treatment	O
arms	O
,	O
as	O
well	O
as	O
a	O
comparison	O
of	O
the	O
LAG	O
group	O
,	O
to	O
that	O
of	O
the	O
SL	O
group	O
,	O
are	O
updated	O
.	O


METHODS	O
AND	O
MATERIALS	O
A	B-P
total	I-P
of	I-P
449	I-P
eligible	I-P
males	I-P
were	I-P
entered	I-P
into	I-P
RTOG	I-P
protocol	I-P
7706	I-P
between	I-P
1978	I-P
and	I-P
1983	I-P
.	I-P


Lymph	O
node	O
staging	O
was	O
mandatory	O
but	O
at	O
the	O
physician	O
's	O
discretion	O
;	O
117	B-P
(	I-P
26	I-P
%	I-P
)	I-P
patients	I-P
had	I-P
SL	I-P
,	I-P
while	I-P
332	I-P
(	I-P
74	I-P
%	I-P
)	I-P
had	I-P
LAG	I-P
.	I-P


Follow-up	O
was	O
a	O
median	O
of	O
12	O
years	O
and	O
a	O
maximum	O
of	O
16	O
years	O
.	O


For	O
those	O
randomized	O
to	O
receive	O
prophylactic	O
pelvic	O
lymph	O
nodal	O
irradiation	O
,	O
45	O
Gy	O
of	O
megavoltage	O
RT	O
was	O
delivered	O
via	O
multiple	O
portals	O
in	O
4.5-5	O
weeks	O
,	O
while	O
all	O
patients	O
received	O
65	O
Gy	O
in	O
6.5-8	O
weeks	O
to	O
the	O
prostatic	O
bed	O
.	O


RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
survival	B-O
whether	O
treatment	O
was	O
administered	O
to	O
the	O
prostate	O
or	O
prostate	O
and	O
pelvic	O
lymph	O
nodes	O
.	O


The	O
SL	O
group	O
had	O
greater	O
12-year	B-O
survival	I-O
than	O
the	O
LAG	O
group	O
(	O
48	O
%	O
vs.	O
38	O
%	O
,	O
p	O
=	O
0.02	O
)	O
.	O


Disease-free	B-O
survival	I-O
was	O
statistically	O
significant	O
,	O
with	O
38	O
%	O
for	O
the	O
SL	O
group	O
vs.	O
26	O
%	O
for	O
the	O
LAG	O
group	O
(	O
p	O
=	O
0.003	O
)	O
.	O


Bone	B-O
metastasis	I-O
was	O
less	O
common	O
in	O
the	O
SL	O
group	O
(	O
14	O
%	O
)	O
than	O
the	O
LAG	O
group	O
(	O
27	O
%	O
)	O
(	O
p	O
=	O
0.003	O
)	O
.	O


CONCLUSION	O
At	O
12-year	O
median	O
follow-up	O
,	O
there	O
still	O
was	O
no	O
survival	O
difference	O
in	O
those	O
patients	O
treated	O
prophylactically	O
to	O
the	O
pelvic	O
nodes	O
and	O
prostatic	O
bed	O
vs.	O
the	O
prostatic	O
bed	O
alone	O
.	O


Those	O
patients	O
not	O
surgically	O
staged	O
with	O
only	O
LAG	O
for	O
lymph	O
node	O
evaluation	O
were	O
less	O
accurately	O
staged	O
,	O
as	O
reflected	O
by	O
a	O
statistically	O
significant	O
reduced	O
survival	O
and	O
earlier	O
metastases	O
.	O


Improved	O
fibrinolysis	O
after	O
1-year	O
treatment	O
with	O
HMG	B-I
CoA	I-I
reductase	I-I
inhibitors	I-I
in	O
patients	B-P
with	I-P
coronary	I-P
heart	I-P
disease	I-P
.	I-P


The	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
two	O
different	O
statins	B-I
on	O
the	O
levels	O
of	O
haemostatic	O
variables	O
reflecting	O
procoagulant	O
and	O
fibrinolytic	O
activity	O
in	O
patients	B-P
with	I-P
coronary	I-P
heart	I-P
disease	I-P
(	I-P
CHD	I-P
)	I-P
,	O
with	O
the	O
hypothesis	O
that	O
statins	B-I
might	O
beneficially	O
modify	O
these	O
levels	O
.	O


Fifty-eight	B-P
patients	I-P
were	O
randomized	O
to	O
treatment	O
with	O
atorvastatin	B-I
(	O
n=28	O
)	O
or	O
simvastatin	B-I
(	O
n=30	O
)	O
for	O
1	O
year	O
.	O


The	O
starting	O
dose	O
in	O
both	O
groups	O
was	O
20	O
mg/day	O
.	O


Fasting	B-O
blood	I-O
samples	I-O
were	O
collected	O
before	O
and	O
after	O
12-month	O
treatment	O
for	O
determinations	O
of	O
fibrinogen	B-O
,	I-O
prothrombin	I-O
fragment	I-O
1+2	I-O
(	I-O
F1+2	I-O
)	I-O
,	I-O
plasma	I-O
D-dimer	I-O
,	I-O
soluble	I-O
tissue	I-O
factor	I-O
,	I-O
tissue	I-O
plasminogen	I-O
activator	I-O
(	I-O
tPA	I-O
)	I-O
antigen	I-O
,	I-O
tPA	I-O
activity	I-O
,	I-O
plasminogen	I-O
activator	I-O
inhibitor	I-O
type-1	I-O
activity	I-O
(	I-O
PAI-1	I-O
activity	I-O
)	I-O
and	I-O
serum	I-O
D-dimer	I-O
as	I-O
a	I-O
global	I-O
test	I-O
of	I-O
fibrinolytic	I-O
activity	I-O
.	I-O


In	O
the	O
total	O
population	O
,	O
improved	B-O
fibrinolytic	I-O
activity	I-O
was	O
observed	O
after	O
1	O
year	O
with	O
increased	B-O
levels	I-O
of	O
serum	B-O
D-dimer	I-O
(	O
P=.001	O
)	O
and	O
tPA	B-O
activity	I-O
(	O
P=.024	O
)	O
and	O
a	O
reduction	B-O
in	I-O
tPA	I-O
antigen	I-O
(	O
P=.048	O
)	O
.	O


No	O
statistically	O
significant	O
changes	O
were	O
observed	O
in	O
any	O
of	O
the	O
measured	O
coagulation	O
variables	O
.	O


Separately	O
examined	O
,	O
an	O
improved	O
fibrinolytic	O
profile	O
was	O
seen	O
in	O
the	O
atorvastatin	B-I
group	O
with	O
a	O
significant	B-O
increase	I-O
in	I-O
serum	I-O
D-dimer	I-O
(	O
P=.005	O
)	O
,	O
a	O
borderline	B-O
increase	I-O
in	I-O
tPA	I-O
activity	I-O
(	O
P=.083	O
)	O
and	O
a	O
borderline	B-O
reduction	I-O
in	I-O
tPA	I-O
antigen	I-O
(	O
P=.069	O
)	O
.	O


Within	O
the	O
simvastatin	B-I
group	O
,	O
a	O
reduction	B-O
in	I-O
prothrombin	I-O
F1+2	I-O
was	O
observed	O
(	O
P=.038	O
)	O
.	O


The	O
differences	O
in	O
changes	O
between	O
the	O
groups	O
were	O
statistically	O
significant	O
only	O
for	O
global	B-O
fibrinolysis	I-O
(	O
serum	O
D-dimer	O
,	O
P=.046	O
)	O
.	O


In	O
conclusion	O
,	O
an	O
improved	O
fibrinolytic	B-O
profile	I-O
was	O
observed	O
after	O
statin	B-I
treatment	O
,	O
most	O
pronounced	O
with	O
atorvastatin	B-I
.	I-I


The	O
results	O
indicate	O
that	O
the	O
drugs	O
promote	O
a	O
profibrinolytic	O
profile	O
,	O
and	O
may	O
in	O
part	O
explain	O
the	O
benefit	O
of	O
statin	B-I
treatment	O
rendered	O
in	O
the	O
prevention	O
of	O
CHD	O
.	O


Effects	O
of	O
home	B-I
strength	I-I
training	I-I
and	I-I
stretching	I-I
versus	I-I
stretching	I-I
alone	I-I
after	I-P
lumbar	I-P
disk	I-P
surgery	I-P
:	I-P
a	O
randomized	O
study	O
with	O
a	O
1-year	O
follow-up	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
adherence	O
to	O
and	O
effects	O
of	O
a	O
12-month	O
combined	B-I
strength	I-I
and	I-I
stretching	I-I
home	I-I
exercise	I-I
regimen	I-I
versus	I-I
stretching	I-I
alone	I-I
,	O
on	O
patient	B-P
outcome	I-P
after	I-P
lumbar	I-P
disk	I-P
surgery	I-P
.	I-P


DESIGN	O
Randomized	O
controlled	O
trial	O
.	O


SETTING	O
Departments	B-P
of	I-P
physical	I-P
medicine	I-P
and	I-P
rehabilitation	I-P
and	I-P
orthopedics	I-P
at	I-P
a	I-P
Finnish	I-P
hospital	I-P
.	I-P


PARTICIPANTS	O
Patients	B-P
(	I-P
N=126	I-P
)	I-P
were	I-P
randomized	I-P
into	O
either	O
a	O
combined	B-I
strength	I-I
training	I-I
and	I-I
stretching	I-I
group	I-I
(	O
STG	O
,	O
n=65	O
)	O
or	O
a	O
control	B-I
group	I-I
(	O
CG	O
,	O
n=61	O
)	O
.	O


INTERVENTION	O
The	O
STG	O
was	O
instructed	O
to	O
perform	O
strength	B-I
training	I-I
and	O
both	O
the	O
STG	O
and	O
CG	O
were	O
instructed	O
in	O
the	O
same	O
stretching	B-I
and	I-I
stabilization	I-I
exercises	I-I
for	O
12	O
months	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Pain	O
on	O
the	O
visual	B-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	I-O
the	I-O
Oswestry	I-O
and	I-O
the	I-O
Million	I-O
disability	I-O
indexes	I-O
,	I-O
isometric	I-O
and	I-O
dynamic	I-O
trunk	I-O
muscle	I-O
strength	I-O
,	I-O
mobility	I-O
in	I-O
the	I-O
lumbar	I-O
spine	I-O
,	I-O
and	I-O
straight-leg	I-O
raising	I-O
were	O
measured	O
.	O


RESULTS	O
The	O
trial	O
was	O
completed	O
by	O
71	O
%	O
and	O
77	O
%	O
of	O
the	O
patients	O
from	O
the	O
STG	O
and	O
the	O
CG	O
,	O
respectively	O
.	O


The	O
mean	B-O
strength	I-O
training	I-O
frequency	I-O
decreased	O
from	O
1.5	O
to	O
0.6	O
times	O
a	O
week	O
in	O
the	O
STG	O
during	O
the	O
intervention	O
.	O


The	O
mean	B-O
stretching	I-O
frequency	I-O
decreased	O
from	O
3.7	O
to	O
1.6	O
times	O
a	O
week	O
in	O
both	O
groups	O
.	O


Median	B-O
back	I-O
and	I-O
leg	I-O
pain	I-O
varied	O
between	O
17	O
and	O
23	O
mm	O
(	O
VAS	O
)	O
,	O
and	O
the	O
Million	B-O
and	I-O
Oswestry	I-O
indices	I-O
varied	O
between	O
14	O
and	O
23	O
points	O
2	O
months	O
postoperatively	O
.	O


No	O
statistically	O
significant	O
changes	O
took	O
place	O
in	O
these	O
outcome	O
measures	O
during	O
the	O
12-month	O
follow-up	O
in	O
both	O
groups	O
.	O


The	O
changes	O
in	O
isometric	B-O
trunk	I-O
extension	I-O
favored	O
the	O
STG	O
(	O
P	O
=.016	O
)	O
during	O
the	O
first	O
2	O
months	O
.	O


However	O
,	O
during	O
the	O
whole	O
12-month	O
training	O
period	O
,	O
both	O
dynamic	B-O
and	I-O
isometric	I-O
back	I-O
extension	I-O
and	I-O
flexion	I-O
strength	I-O
,	O
as	O
well	O
as	O
mobility	B-O
of	I-O
the	I-O
spine	I-O
and	I-O
repetitive	I-O
squat-test	I-O
results	I-O
,	O
improved	O
significantly	O
in	O
both	O
groups	O
,	O
and	O
no	O
differences	O
were	O
found	O
in	O
any	O
of	O
the	O
physical	B-O
function	I-O
parameters	I-O
between	O
the	O
STG	O
and	O
CG	O
.	O


CONCLUSIONS	O
At	O
the	O
12-month	O
follow-up	O
,	O
no	O
statistically	O
significant	O
changes	O
were	O
found	O
in	O
the	O
physical	B-O
function	I-O
,	I-O
pain	I-O
,	I-O
or	I-O
disability	I-O
measures	I-O
between	O
the	O
groups	O
.	O


In	O
the	O
STG	O
,	O
training	O
adherence	O
with	O
regard	O
to	O
training	O
frequency	O
and	O
intensity	O
remained	O
too	O
low	O
to	O
lead	O
to	O
specific	O
training-induced	O
adaptations	O
in	O
the	O
neuromuscular	O
system	O
.	O


Progressive	O
loading	O
,	O
supervision	O
of	O
training	O
,	O
and	O
psychosocial	O
support	O
is	O
needed	O
in	O
long-term	O
rehabilitation	O
programs	O
to	O
maintain	O
patient	O
motivation	O
.	O


Comparison	O
with	O
computed	B-I
tomography	I-I
of	O
two	O
ultrasound	O
devices	O
for	O
diagnosis	O
of	O
abdominal	B-P
aortic	I-P
aneurysm	I-P
.	I-P


Screening	O
for	O
abdominal	B-P
aortic	I-P
aneurysms	I-P
(	I-P
AAAs	I-P
)	I-P
in	I-P
patients	I-P
at	I-P
risk	I-P
will	O
become	O
more	O
cost	O
effective	O
if	O
a	O
simple	O
,	O
inexpensive	O
,	O
and	O
reliable	O
ultrasound	O
device	O
is	O
available	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
a	O
2-dimensional	O
,	O
handheld	B-I
ultrasound	I-I
device	I-I
and	O
a	O
newly	O
developed	O
ultrasound	B-I
volume	I-I
scanner	I-I
(	O
based	O
on	O
bladder	O
scan	O
technology	O
)	O
with	O
computed	B-I
tomography	I-I
(	I-I
CT	I-I
)	I-I
for	O
diagnosing	O
AAA	O
.	O


A	O
total	O
of	O
146	B-P
patients	I-P
(	I-P
mean	I-P
age	I-P
69	I-P
+/-	I-P
10	I-P
years	I-P
;	I-P
127	I-P
men	I-P
)	I-P
were	O
screened	O
for	O
the	O
presence	O
of	O
AAAs	O
(	O
diameter	O
>	O
3	O
cm	O
)	O
using	O
CT.	O
All	O
patients	O
were	O
examined	O
with	O
the	O
handheld	O
ultrasound	O
device	O
and	O
the	O
volume	O
scanner	O
.	O


Maximal	B-O
diameters	I-O
and	I-O
volumes	I-O
were	O
used	O
for	O
the	O
analyses	O
.	O


AAAs	O
were	O
diagnosed	O
by	O
CT	B-I
in	O
116	O
patients	O
(	O
80	O
%	O
)	O
.	O


The	O
absolute	B-O
difference	I-O
of	I-O
aortic	I-O
diameter	I-O
between	O
ultrasound	B-I
and	O
CT	B-I
was	O
<	O
5	O
mm	O
in	O
88	O
%	O
of	O
patients	O
.	O


Limits	O
of	O
agreement	O
between	O
ultrasound	O
and	O
CT	B-I
(	O
-6.6	O
to	O
9.4	O
mm	O
)	O
exceeded	O
the	O
limits	O
of	O
clinical	O
acceptability	O
(	O
+/-5	O
mm	O
)	O
.	O


An	O
excellent	O
correlation	B-O
between	O
ultrasound	B-I
and	O
CT	B-I
was	O
observed	O
(	O
r	O
=	O
0.98	O
)	O
.	O


The	O
correlation	B-O
coefficient	I-O
between	O
the	O
volume	O
scanner	O
and	O
CT	B-I
was	O
0.86	O
,	O
with	O
agreement	O
of	O
90	O
%	O
and	O
kappa	O
value	O
of	O
0.73	O
.	O


Using	O
an	O
optimal	B-O
cut-off	I-O
value	I-O
of	O
>	O
56	O
ml	O
,	O
defined	O
by	O
receiver-operating	B-O
characteristic	I-O
curve	I-O
analysis	I-O
,	I-O
sensitivity	I-O
,	I-O
specificity	I-O
,	I-O
and	I-O
the	I-O
positive	I-O
and	I-O
negative	I-O
predictive	I-O
values	I-O
of	O
the	O
volume	O
scanner	O
for	O
detecting	O
AAA	O
were	O
90	O
%	O
,	O
90	O
%	O
,	O
97	O
%	O
,	O
and	O
71	O
%	O
,	O
respectively	O
.	O


In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
a	O
2-dimensional	O
,	O
handheld	O
ultrasound	O
device	O
and	O
a	O
newly	O
developed	O
ultrasound	O
volume	O
scanner	O
can	O
effectively	O
identify	O
patients	B-P
with	I-P
AAAs	I-P
confirmed	I-P
by	I-P
CT	I-P
.	I-P


Impact	B-O
of	O
a	O
fixed	O
combination	O
of	O
clindamycin	B-I
phosphate	I-I
1.2	I-I
%	I-I
-benzoyl	I-I
peroxide	I-I
2.5	I-I
%	I-I
aqueous	I-I
gel	I-I
on	O
health-related	O
quality	O
of	O
life	O
in	O
moderate	O
to	O
severe	O
acne	O
vulgaris	O
.	O


The	O
acne-specific	O
quality	O
of	O
life	O
(	O
Acne-QoL	O
)	O
questionnaire	O
was	O
developed	O
to	O
measure	B-O
the	I-O
impact	I-O
of	I-O
facial	I-O
acne	I-O
across	O
4	O
domains	O
(	O
acne	O
symptoms	O
,	O
role-emotional	O
,	O
self-perception	O
,	O
role-social	O
)	O
of	O
health-related	B-O
quality	I-O
of	I-O
life	I-O
(	I-O
HRQL	I-O
)	I-O
.	I-O


This	O
analysis	O
assessed	O
the	O
impact	O
of	O
clindamycin	B-I
phosphate	I-I
1.2	I-I
%	I-I
-benzoyl	I-I
peroxide	I-I
2.5	I-I
%	I-I
(	I-I
clindamycin-BPO	I-I
2.5	I-I
%	I-I
)	I-I
gel	I-I
on	O
HRQL	O
in	O
a	O
combined	B-P
study	I-P
population	I-P
(	I-P
N	I-P
=	I-P
2813	I-P
)	I-P
of	I-P
participants	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
acne	I-P
vulgaris	I-P
.	I-P


Although	O
the	O
results	O
presented	O
within	O
do	O
not	O
include	O
factors	O
of	O
study	O
and	O
study-by-treatment	O
interaction	O
,	O
analyses	O
were	O
performed	O
to	O
confirm	O
that	O
the	O
results	O
were	O
consistent	O
across	O
the	O
2	O
identical	O
,	O
double-blind	O
,	O
randomized	O
studies	O
and	O
within	O
each	O
treatment	O
group	O
across	O
studies	O
to	O
justify	O
pooling	O
the	O
data	O
from	O
both	O
studies	O
.	O


The	O
Acne-QoL	B-O
questionnaire	I-O
was	O
administered	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
treatment	O
(	O
week	O
12	O
)	O
.	O


Treatment	O
with	O
clindamycin-BPO	B-I
2.5	O
%	O
gel	O
significantly	B-P
improved	I-P
participant-reported	I-P
HRQL	I-O
across	O
all	O
4	O
domains	O
compared	O
with	O
individual	O
active	O
ingredients	O
and	O
vehicle	O
(	O
P	O
<	O
.001	O
)	O
.	O


The	O
percentage	O
improvement	O
in	O
mean	B-O
Acne-QoL	I-O
domain	I-O
scores	I-O
with	O
clindamycin-BPO	B-I
2.5	O
%	O
gel	O
ranged	O
from	O
37	O
%	O
to	O
59	O
%	O
.	O


Because	O
the	O
negative	O
impact	O
of	O
facial	O
acne	O
on	O
HRQL	B-O
is	O
one	O
of	O
the	O
primary	O
motivators	O
for	O
patients	O
to	O
seek	O
treatment	O
,	O
this	O
analysis	O
underscores	O
the	O
importance	O
of	O
physicians	O
incorporating	O
assessments	O
of	O
HRQL	O
into	O
their	O
clinical	O
decision	O
making	O
.	O


Enhanced	O
inotropic	O
state	O
of	O
the	O
failing	O
left	O
ventricle	O
by	O
cardiac	B-I
contractility	I-I
modulation	I-I
electrical	I-I
signals	I-I
is	O
not	O
associated	O
with	O
increased	O
myocardial	B-O
oxygen	I-O
consumption	I-O
.	I-O


BACKGROUND	O
Previous	O
studies	O
in	O
patients	B-P
and	I-P
in	I-P
dogs	I-P
with	I-P
experimentally	I-P
induced	I-P
heart	I-P
failure	I-P
(	I-P
HF	I-P
)	I-P
showed	O
that	O
electrical	B-I
signals	I-I
applied	O
to	O
the	O
failing	O
myocardium	O
during	O
the	O
absolute	O
refractory	O
period	O
improved	O
left	B-O
ventricular	I-O
(	I-O
LV	I-O
)	I-O
function	I-O
.	I-O


We	O
examined	O
the	O
effects	O
these	O
same	O
cardiac	B-I
contractility	I-I
modulating	I-I
(	I-I
CCM	I-I
)	I-I
electrical	I-I
signals	I-I
on	O
myocardial	B-O
oxygen	I-O
consumption	I-O
(	I-O
MVO	I-O
(	I-O
2	I-O
)	I-O
)	I-O
in	O
both	B-P
patients	I-P
and	I-P
dogs	I-P
with	I-P
chronic	I-P
HF	I-P
.	I-P


METHODS	O
AND	O
RESULTS	O
Six	B-P
dogs	I-P
with	I-P
microembolizations-induced	I-I
HF	I-I
and	I-P
9	I-P
HF	I-P
patients	I-P
underwent	I-P
CCM	I-I
leads	I-I
and	I-I
generator	I-I
(	I-I
OPTIMIZER	I-I
II	I-I
)	I-I
implantation	I-I
.	I-I


After	O
baseline	O
measurements	O
,	O
CCM	B-I
signals	I-I
were	O
delivered	O
continuously	O
for	O
2	O
hours	O
in	O
dogs	O
and	O
for	O
30	O
minutes	O
in	O
patients	O
.	O


MVO	B-O
(	I-O
2	I-O
)	I-O
was	O
measured	O
before	O
and	O
after	O
CCM	B-I
therapy	I-I
.	I-I


In	O
dogs	O
,	O
CCM	B-I
therapy	I-I
increased	O
LV	B-O
ejection	I-O
fraction	I-O
at	O
2	O
hours	O
(	O
26	O
+/-	O
1	O
versus	O
31	O
+/-	O
2	O
%	O
,	O
P	O
=	O
.001	O
)	O
without	O
increasing	O
MVO	B-O
(	I-O
2	I-O
)	I-O
(	O
257	O
+/-	O
41	O
versus	O
180	O
+/-	O
34	O
micromol/min	O
)	O
.	O


In	O
patients	O
,	O
CCM	B-I
therapy	I-I
increased	O
LV	B-O
peak	I-O
+dP/dt	I-O
by	O
10.1	O
+/-	O
1.5	O
%	O
.	O


As	O
with	O
dogs	O
,	O
the	O
increase	O
in	O
LV	B-O
function	I-O
after	O
30	O
minutes	O
of	O
CCM	B-I
therapy	I-I
was	O
not	O
associated	O
with	O
increased	O
MVO	B-O
(	I-O
2	I-O
)	I-O
(	O
13.6	O
+/-	O
9.7	O
versus	O
12.5	O
+/-	O
7.2	O
mL	O
O	O
(	O
2	O
)	O
/min	O
)	O
.	O


CONCLUSIONS	O
The	O
study	O
results	O
suggest	O
that	O
unlike	O
cAMP-dependent	O
positive	O
inotropic	O
drugs	O
,	O
the	O
increase	O
in	O
LV	B-O
function	I-O
during	O
CCM	B-I
therapy	I-I
is	O
elicited	O
without	O
increasing	O
MVO	B-O
(	I-O
2	I-O
)	I-O
.	I-O


Clomipramine	B-I
versus	I-I
haloperidol	I-I
in	O
the	O
treatment	O
of	O
autistic	B-P
disorder	I-P
:	I-P
a	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
crossover	O
study	O
.	O


Clomipramine	B-I
,	I-I
haloperidol	I-I
,	I-I
and	I-I
placebo	I-I
were	O
compared	O
with	O
baseline	O
in	O
the	O
treatment	O
of	O
autism	B-P
,	O
and	O
overall	B-O
outcome	I-O
,	I-O
specific	I-O
symptoms	I-O
,	I-O
and	I-O
side	I-O
effects	I-O
were	O
examined	O
.	O


It	O
was	O
hypothesized	O
that	O
clomipramine	B-I
would	O
be	O
better	O
tolerated	O
than	O
haloperidol	B-I
and	O
prove	O
superior	O
on	O
a	O
measure	O
of	O
stereotypy	O
.	O


Individuals	B-P
with	I-P
a	I-P
DSM-IV	I-P
diagnosis	I-P
of	I-P
autistic	I-P
disorder	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
16.3	I-P
years	I-P
;	I-P
range	I-P
,	I-P
10-36	I-P
years	I-P
)	I-P
were	I-P
randomly	I-P
assigned	I-P
,	I-P
by	I-P
using	I-P
a	I-P
Latin	I-P
square	I-P
design	I-P
,	I-P
to	I-P
the	I-P
following	I-P
7-week	I-P
trials	I-P
:	I-P
placebo	I-I
,	I-I
clomipramine	I-I
(	I-P
mean	I-P
daily	I-P
dose	I-P
,	I-P
128.4	I-P
mg	I-P
;	I-P
range	I-P
,	I-P
100-150	I-P
mg	I-P
)	I-P
,	I-P
or	I-P
haloperidol	I-I
(	I-P
mean	I-P
daily	I-P
dose	I-P
,	I-P
1.3	I-P
mg	I-P
;	I-P
range	I-P
,	I-P
1-1.5	I-P
mg	I-P
)	I-P
.	I-P


Data	B-P
on	I-P
36	I-P
subjects	I-P
were	I-P
analyzed	I-P
and	O
taken	O
together	O
;	O
the	O
results	O
favored	O
haloperidol	B-I
.	I-I


In	O
those	O
patients	O
who	O
were	O
able	O
to	O
complete	O
a	O
full	O
therapeutic	O
trial	O
,	O
clomipramine	B-I
proved	O
comparable	O
to	O
haloperidol	B-I
in	O
terms	O
of	O
improvement	B-O
compared	O
with	O
baseline	O
.	O


However	O
,	O
significantly	O
fewer	O
individuals	O
receiving	O
clomipramine	B-I
versus	O
haloperidol	B-I
were	O
able	O
to	O
complete	O
the	O
trial	O
(	O
37.5	O
%	O
vs.	O
69.7	O
%	O
,	O
respectively	O
)	O
for	O
reasons	O
related	O
to	O
both	O
side	B-O
effects	I-O
and	I-O
efficacy	I-O
or	I-O
behavior	I-O
problems	I-O
.	I-O


In	O
the	O
intent-to-treat	O
sample	O
,	O
which	O
is	O
perhaps	O
more	O
clinically	O
relevant	O
,	O
only	O
haloperidol	B-I
proved	O
superior	O
to	O
baseline	O
on	O
a	O
global	O
measure	O
of	O
autistic	B-O
symptom	I-O
severity	I-O
,	O
as	O
well	O
as	O
specific	O
measures	O
for	O
irritability	B-O
and	I-O
hyperactivity	I-O
.	I-O


Clomipramine	B-I
did	O
not	O
seem	O
more	O
effective	O
on	O
a	O
measure	O
of	O
stereotypy	O
,	O
nor	O
was	O
it	O
better	O
tolerated	O
.	O


[	O
Clinical	O
trials	O
with	O
pirprofen	B-I
and	I-I
naproxen	I-I
in	O
patients	B-P
with	I-P
gonarthrosis	I-O
and	I-O
coxarthrosis	I-O
]	I-O
.	O


Topical	O
adrenaline	B-I
in	O
the	O
control	O
of	O
intraoperative	B-O
bleeding	I-O
in	O
adenoidectomy	B-P
:	I-P
a	O
randomised	O
,	O
controlled	O
trial	O
.	O


OBJECTIVES	O
To	O
evaluate	O
the	O
efficacy	O
of	O
topical	O
racemic	B-I
adrenaline	I-I
(	I-I
RA	I-I
)	I-I
(	O
Micronefrin	O
;	O
Bird	O
Products	O
,	O
Palm	O
Springs	O
,	O
CA	O
,	O
USA	O
)	O
in	O
the	O
control	O
of	O
intraoperative	B-O
bleeding	I-O
and	I-O
the	I-O
prevention	I-O
of	I-O
postoperative	I-O
bleeding	I-O
,	I-O
laryngeal	I-O
spasm	I-O
and	I-O
postoperative	I-O
pain	I-O
in	O
adenoidectomy	B-P
among	I-P
children	I-P
<	I-P
6	I-P
years	I-P
of	I-P
age	I-P
.	I-P


DESIGN	O
Prospective	O
,	O
randomised	O
,	O
blinded	O
and	O
placebo-controlled	O
trial	O
.	O


SETTING	O
Kanta-Hame	B-P
Central	I-P
Hospital	I-P
,	I-P
a	I-P
district	I-P
referral	I-P
center	I-P
in	I-P
Finland	I-P
.	I-P


PATIENTS	O
A	O
consecutive	O
sample	O
of	O
93	B-P
children	I-P
undergoing	I-P
outpatient	I-P
adenoidectomy	I-P
.	I-P


INTERVENTION	O
Patients	O
were	O
randomised	O
to	O
receive	O
topical	B-I
gauze	I-I
sponges	I-I
soaked	I-I
in	I-I
either	I-I
1:500	I-I
RA	I-I
or	I-I
0.9	I-I
%	I-I
sodium	I-I
chloride	I-I
(	I-I
physiological	I-I
saline	I-I
)	I-I
for	I-I
3	I-I
min	I-I
after	I-I
adenoidectomy	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Amount	O
of	O
intraoperative	B-O
bleeding	I-O
(	O
surgeons	O
'	O
subjective	O
estimate	O
)	O
,	O
need	B-O
for	I-O
additional	I-O
packings	I-O
,	I-O
need	I-O
for	I-O
electrocautery	I-O
,	I-O
laryngeal	I-O
spasm	I-O
,	I-O
postoperative	I-O
bleeding	I-O
and	I-O
pain	I-O
,	I-O
duration	I-O
of	I-O
procedure	I-O
and	I-O
duration	I-O
of	I-O
patients	I-O
'	I-O
stay	I-O
in	I-O
the	I-O
operation	I-O
room	I-O
(	I-O
OR	I-O
)	I-O
.	I-O


RESULTS	O
Adrenaline	B-I
significantly	O
decreased	O
surgeons	O
'	O
subjective	O
estimate	O
of	O
the	O
amount	B-O
of	I-O
intraoperative	I-O
bleeding	I-O
(	O
proportion	O
of	O
patients	O
with	O
significant	O
decrease	O
67	O
versus	O
21	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
reduced	O
the	O
mean	O
number	B-O
of	I-O
packings	I-O
needed	I-O
(	O
0.6	O
versus	O
1.2	O
,	O
P	O
<	O
0.001	O
)	O
and	O
use	B-O
of	I-O
electrocautery	I-O
(	O
22	O
versus	O
45	O
%	O
,	O
P	O
=	O
0.015	O
)	O
,	O
and	O
shortened	O
the	O
mean	O
duration	B-O
of	I-O
the	I-O
procedure	I-O
(	O
13	O
versus	O
18	O
min	O
,	O
P	O
=	O
0.043	O
)	O
and	O
the	O
mean	O
stay	B-O
in	I-O
the	I-O
OR	I-O
(	O
31	O
versus	O
35	O
min	O
,	O
P	O
=	O
0.058	O
)	O
.	O


The	O
impact	O
of	O
adrenaline	B-I
was	O
even	O
more	O
pronounced	O
among	O
patients	B-P
with	I-P
extensive	I-P
adenoids	I-O
and/or	I-P
profuse	I-P
intraoperative	I-O
bleeding	I-O
.	I-O


A	O
slight	O
elevation	B-O
of	I-O
heart	I-O
rate	I-O
was	O
observed	O
more	O
often	O
in	O
the	O
adrenaline	B-I
group	O
(	O
P	O
=	O
0.043	O
)	O
.	O


CONCLUSIONS	O
Use	O
of	O
topical	O
adrenaline	B-I
can	O
be	O
recommended	O
in	O
adenoidectomy	B-P
among	I-P
children	I-P
.	I-P


It	O
helps	O
control	O
the	O
intraoperative	B-O
bleeding	I-O
,	O
reduces	O
the	O
use	O
of	O
electrocautery	B-O
and	O
shortens	O
the	O
durations	O
of	O
procedure	B-O
and	I-O
stay	I-O
in	I-O
the	I-O
OR	I-O
.	I-O


A	O
randomised	O
double-blind	O
control	O
study	O
of	O
early	O
intracoronary	B-I
autologous	I-I
bone	I-I
marrow	I-I
cell	I-I
infusion	I-I
in	O
acute	B-P
myocardial	I-P
infarction	I-P
(	O
REGENERATE-AMI	O
)	O
.	O


INTRODUCTION	O
Acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
remains	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
worldwide	O
despite	O
the	O
latest	O
therapeutic	O
advances	O
designed	O
to	O
decrease	O
myocardial	O
injury	O
.	O


Preclinical	O
and	O
emerging	O
clinical	O
evidence	O
show	O
that	O
the	O
intracoronary	O
injection	O
of	O
autologous	B-I
bone	I-I
marrow	I-I
mononuclear	I-I
cells	I-I
(	O
BMCs	O
)	O
following	O
AMI	O
leads	O
to	O
improvement	O
in	O
left	O
ventricular	O
ejection	O
function	O
(	O
LVEF	O
)	O
.	O


In	O
this	O
clinical	O
trial	O
we	O
will	O
for	O
the	O
first	O
time	O
assess	O
the	O
effect	B-O
of	O
early	O
(	O
<	O
24	O
h	O
)	O
infusion	O
of	O
autologous	O
BMCs	O
following	O
AMI	O
on	O
cardiac	O
function	O
.	O


METHODS	O
AND	O
ANALYSIS	O
REGENERATE-AMI	O
is	O
a	O
double-blind	O
,	O
randomised	O
,	O
multicentre	B-P
,	O
placebo-controlled	B-I
trial	O
to	O
determine	O
whether	O
early	O
(	O
<	O
24	O
h	O
)	O
intracoronary	O
infusion	O
of	O
BMCs	O
improves	O
LVEF	O
after	O
AMI	O
.	O


The	O
study	O
will	O
enrol	B-P
100	I-P
patients	I-P
presenting	I-P
with	I-P
an	I-P
anterior	I-P
AMI	I-P
demonstrating	I-P
anterior	I-P
regional	I-P
wall	I-P
motion	I-P
abnormality	I-P
.	I-P


Patients	O
will	O
be	O
randomised	O
to	O
receive	O
intracoronary	B-I
infusion	I-I
of	I-I
BMCs	I-I
or	O
placebo	B-I
(	O
0.9	O
%	O
saline	B-I
)	I-I
.	O


Primary	O
endpoint	O
will	O
be	O
change	B-O
in	I-O
LVEF	I-O
at	I-O
1	I-O
year	I-O
compared	I-O
to	I-O
baseline	I-O
,	I-O
measured	I-O
by	I-O
cardiac	I-O
MRI	I-O
.	I-O


Secondary	O
endpoints	O
at	O
6	O
months	O
include	O
the	O
change	B-O
in	I-O
global	I-O
LVEF	I-O
relative	I-O
to	I-O
baseline	I-O
measured	I-O
by	I-O
quantitative	I-O
left	I-O
ventriculography	I-O
and	I-O
echocardiography	I-O
,	I-O
as	I-O
well	I-O
as	I-O
major	I-O
adverse	I-O
cardiac	I-O
events	I-O
which	O
is	O
also	O
measured	O
at	O
1	O
year	O
.	O


ETHICS	O
AND	O
DISSEMINATION	O
The	O
study	O
will	O
be	O
performed	O
in	O
agreement	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
is	O
approved	O
by	O
local	O
ethics	O
committee	O
(	O
NRES	O
Committee	O
London	O
West	O
London	O
:	O
07/Q0603/76	O
)	O
.	O


TRIAL	O
REGISTRATION	O
http	O
:	O
//clincialtrials.gov	O
(	O
NCT00765453	O
)	O
.	O


The	O
results	O
of	O
the	O
trial	O
will	O
be	O
published	O
according	O
to	O
the	O
CONSORT	O
statement	O
and	O
will	O
be	O
presented	O
at	O
conferences	O
and	O
reported	O
in	O
peer-reviewed	O
journals	O
.	O


Skin	B-O
manifestations	I-O
of	I-O
inhaled	I-O
corticosteroids	I-O
in	O
COPD	B-P
patients	I-P
:	I-P
results	O
from	O
Lung	O
Health	O
Study	O
II	O
.	O


OBJECTIVE	O
To	O
define	O
the	O
relationship	O
between	O
skin	B-O
bruising	I-O
(	I-O
as	I-O
well	I-O
as	I-O
other	I-O
cutaneous	I-O
manifestations	I-O
)	I-O
and	O
inhaled	O
corticosteroid	B-I
(	I-I
ICS	I-I
)	I-I
therapy	O
vs	O
placebo	O
in	O
subjects	B-P
with	I-P
COPD	I-P
who	O
were	O
participating	O
in	O
a	O
clinical	O
trial	O
.	O


To	O
explore	O
the	O
relationship	O
between	O
easy	B-O
skin	I-O
bruising	I-O
and	I-O
other	I-O
systemic	I-O
effects	I-O
of	I-O
ICS	I-O
therapy	I-O
,	O
including	O
adrenal	B-O
suppression	I-O
and	I-O
loss	I-O
of	I-O
bone	I-O
mineral	I-O
density	I-O
(	I-O
BMD	I-O
)	I-O
.	I-O


DESIGN	O
Double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
of	O
triamcinolone	B-I
acetonide	I-I
(	O
1200	O
microg	O
daily	O
)	O
vs	O
placebo	B-I
in	O
participants	B-P
with	I-P
mild-to-moderate	I-P
COPD	I-P
.	I-P


SETTING	O
Lung	O
Health	O
Study	O
II	O
,	O
a	O
clinical	O
trial	O
to	O
assess	O
the	O
effect	O
of	O
ICS	B-I
compared	O
to	O
placebo	B-I
in	O
1,116	B-P
participants	I-P
in	I-P
10	I-P
centers	I-P
over	I-P
>	I-P
3.5	I-P
to	I-P
4.5	I-P
years	I-P
.	I-P


PARTICIPANTS	O
A	B-P
total	I-P
of	I-P
1,116	I-P
smokers	I-P
or	I-P
recent	I-P
ex-smokers	I-P
with	I-P
mild-to-moderate	I-P
COPD	I-P
(	I-P
age	I-P
range	I-P
,	I-P
40	I-P
to	I-P
69	I-P
years	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
56.3	I-P
years	I-P
;	I-P
37.2	I-P
%	I-P
female	I-P
)	I-P
.	I-P


MEASUREMENTS	O
AND	O
RESULTS	O
Every	O
6	O
months	O
,	O
a	O
structured	O
questionnaire	O
was	O
administered	O
to	O
elicit	O
reports	O
of	O
any	O
bruising	B-O
and/or	I-O
skin	I-O
rashes	I-O
,	I-O
slow	I-O
healing	I-O
of	I-O
cuts	I-O
or	I-O
sores	I-O
,	I-O
or	I-O
other	I-O
skin	I-O
changes	I-O
.	I-O


Compliance	O
with	O
inhaler	O
use	O
was	O
assessed	O
by	O
canister	O
weighing	O
.	O


A	O
significantly	O
higher	O
proportion	O
of	O
ICS	B-I
than	O
placebo	B-I
participants	O
who	O
complied	O
with	O
using	O
their	O
inhaler	O
reported	O
easy	B-O
bruising	I-O
(	O
11.2	O
%	O
vs	O
3.5	O
%	O
,	O
respectively	O
)	O
and	O
the	O
slow	B-O
healing	I-O
of	I-O
skin	I-O
cuts	I-O
or	I-O
sores	I-O
(	O
2.4	O
%	O
vs	O
0.5	O
%	O
,	O
respectively	O
)	O
.	O


Older	B-P
men	I-P
in	O
the	O
ICS	B-I
group	O
with	O
good	O
inhaler	O
compliance	O
appeared	O
to	O
be	O
at	O
the	O
greatest	O
risk	B-O
of	I-O
bruising	I-O
.	I-O


In	O
those	O
participants	O
undergoing	O
serial	O
measurements	O
of	O
adrenal	O
function	O
and	O
BMD	O
,	O
no	O
association	O
was	O
noted	O
between	O
skin	B-O
bruising	I-O
and	O
either	O
the	O
suppression	B-O
of	I-O
adrenal	I-O
function	I-O
or	I-O
the	I-O
loss	I-O
of	I-O
BMD	I-O
as	O
systemic	O
complications	O
of	O
ICS	O
use	O
.	O


CONCLUSION	O
These	O
findings	O
indicate	O
that	O
moderate-to-high	O
doses	O
of	O
ICSs	O
result	O
in	O
an	O
increased	O
incidence	O
of	O
easy	B-O
bruising	I-O
and	I-O
impairment	I-O
in	I-O
skin	I-O
healing	I-O
in	O
middle-aged	B-P
to	I-P
elderly	I-P
persons	I-P
with	I-P
COPD	I-P
.	I-P


No	O
association	O
was	O
noted	O
between	O
skin	B-O
bruising	I-O
and	O
other	O
markers	O
of	O
systemic	B-O
toxicity	I-O
from	O
the	O
use	O
of	O
ICSs	B-I
.	O


A	O
multicenter	O
investigation	O
of	O
lorazepam	B-I
in	I-P
anxiety	I-O
neurosis	I-O
.	I-O


Recurrent	O
ulcer	O
after	O
successful	O
treatment	O
with	O
cimetidine	B-I
or	O
antacid	B-I
.	I-I


This	O
study	O
was	O
designed	O
to	O
compare	O
the	O
rates	O
of	O
duodenal	O
ulcer	O
healing	O
and	O
recurrence	O
after	O
treatment	O
with	O
cimetidine	B-I
or	I-I
antacid	I-I
.	I-I


Patients	B-P
with	I-P
endoscopically	I-P
documented	I-P
duodenal	I-P
ulcer	I-P
received	O
cimetidine	B-I
,	O
1200	O
mg	O
daily	O
,	O
or	B-I
Mylanta	I-I
II	I-I
,	O
7	O
oz	O
daily	O
,	O
in	O
a	O
randomized	O
,	O
double-blind	O
trial	O
.	O


For	O
the	O
69	B-P
patients	I-P
in	I-P
each	I-P
group	I-P
who	O
completed	O
the	O
healing	O
phase	O
of	O
the	O
trial	O
,	O
endoscopic	O
ulcer	O
healing	O
was	O
almost	O
identical	O
.	O


At	O
2	O
,	O
4	O
,	O
and	O
6	O
wk	O
,	O
the	O
cumulative	O
percent	O
healed	O
on	O
antacid	B-I
was	O
33	O
%	O
,	O
64	O
%	O
,	O
and	O
80	O
%	O
,	O
and	O
on	O
cimetidine	B-I
it	O
was	O
25	O
%	O
,	O
62	O
%	O
,	O
and	O
86	O
%	O
.	O


The	O
114	B-P
patients	I-P
with	I-P
healed	I-P
ulcer	I-P
were	O
observed	O
on	O
no	O
therapy	O
and	O
underwent	O
additional	O
endoscopy	O
to	O
detect	O
recurrences	O
when	O
symptomatic	O
or	O
at	O
3	O
,	O
6	O
,	O
and	O
12	O
mo	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	O
frequency	B-O
of	I-O
recurrences	I-O
between	O
treatments	O
.	O


At	O
3	O
and	O
6	O
mo	O
,	O
the	O
cumulative	B-O
percentages	I-O
of	I-O
patients	I-O
with	I-O
recurrence	I-O
were	O
29	O
%	O
and	O
56	O
%	O
after	O
antacid	B-I
therapy	I-I
and	O
36	O
%	O
and	O
55	O
%	O
after	O
cimetidine	B-I
therapy	I-I
.	I-I


Some	O
patient	O
variables	O
were	O
associated	O
with	O
delayed	B-O
ulcer	I-O
healing	I-O
or	I-O
ulcer	I-O
recurrence	I-O
.	I-O


These	O
included	O
sex	O
,	O
pain	O
frequency	O
,	O
smoking	O
,	O
disease	O
duration	O
,	O
and	O
acid	O
secretion	O
.	O


[	O
Observation	O
on	O
therapeutic	O
effect	O
of	O
electroacupuncture	B-I
plus	I-I
blood-letting	I-I
puncture	I-I
and	I-I
cupping	I-I
combined	I-I
with	I-I
diet	I-I
intervention	I-I
for	O
treatment	O
of	O
acute	B-P
gouty	I-P
arthritis	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
explore	O
a	O
more	O
effective	O
therapy	O
for	O
acute	B-P
gouty	I-P
arthritis	I-P
.	I-P


METHODS	O
Sixty	B-P
cases	I-P
were	O
randomly	O
divided	O
into	O
an	O
observation	O
group	O
and	O
a	O
control	O
group	O
,	O
30	O
cases	O
in	O
eachgroup	O
.	O


On	O
the	O
basis	O
of	O
diet	B-I
intervention	I-I
,	O
the	O
observation	O
group	O
was	O
treated	O
with	O
electroacupuncture	B-I
at	I-I
local	I-I
points	I-I
combined	I-I
with	I-I
blood-letting	I-I
puncture	I-I
and	I-I
cupping	I-I
,	O
and	O
the	O
control	O
group	O
with	O
oral	O
administration	O
of	O
Probenecid	B-I
.	I-I


Their	O
therapeutic	O
effects	O
were	O
ob	O
served	O
.	O


RESULTS	O
The	O
effective	O
rate	O
was	O
96.7	O
%	O
in	O
the	O
observation	O
group	O
which	O
was	O
better	O
than	O
86.7	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


After	O
treatment	O
,	O
blood	B-O
uric	I-O
acid	I-O
decreased	O
significantly	O
in	O
the	O
two	O
groups	O
(	O
both	O
P	O
<	O
0.01	O
)	O
,	O
the	O
observed	O
group	O
being	O
lower	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


CONCLUSION	O
On	O
the	O
basis	O
of	O
diet	B-I
intervention	I-I
,	I-I
electroacupuncture	I-I
plus	I-I
blood-letting	I-I
puncture	I-I
and	I-I
cupping	I-I
is	O
a	O
better	O
therapy	O
for	O
acute	O
gouty	O
arthritis	O
.	O


Effects	O
of	O
Positive	B-I
Action	I-I
on	O
the	O
emotional	O
health	O
of	O
urban	B-P
youth	I-P
:	I-P
a	O
cluster-randomized	O
trial	O
.	O


PURPOSE	O
We	O
examined	O
the	O
effects	O
of	O
Positive	B-I
Action	I-I
(	I-I
PA	I-I
)	I-I
,	O
a	O
school-based	B-I
social-emotional	I-I
learning	I-I
and	I-I
health	I-I
promotion	I-I
program	I-I
,	O
on	O
the	O
emotional	O
health	O
of	O
predominately	B-P
low-income	I-P
and	I-P
ethnic	I-P
minority	I-P
urban	I-P
youth	I-P
.	I-P


METHODS	O
The	O
study	O
was	O
a	O
matched-pair	O
,	O
cluster-randomized	O
controlled	O
trial	O
involving	O
14	B-P
Chicago	I-P
public	I-P
schools	I-P
.	I-P


Outcomes	O
were	O
assessed	O
over	O
a	O
6-year	B-P
period	I-P
of	I-P
program	I-P
implementation	I-P
for	I-P
a	I-P
cohort	I-P
of	I-P
youth	I-P
in	I-P
each	I-P
school	I-P
,	I-P
followed	I-P
from	I-P
grades	I-P
3	I-P
to	I-P
8	I-P
.	I-P


Youth	O
reported	O
on	O
their	O
emotional	O
health	O
(	O
positive	O
affect	O
,	O
life	O
satisfaction	O
,	O
depression	O
,	O
anxiety	O
)	O
and	O
social-emotional	O
and	O
character	O
development	O
.	O


Growth-curve	O
and	O
structural-equation	O
modeling	O
analyses	O
assessed	O
overall	O
program	O
effects	O
on	O
the	O
emotional	O
health	O
outcomes	O
as	O
well	O
as	O
mediation	O
of	O
these	O
effects	O
via	O
the	O
program	O
's	O
impact	O
on	O
youths	O
'	O
social-emotional	O
and	O
character	O
development	O
.	O


RESULTS	O
Students	O
in	O
PA	B-I
schools	O
,	O
compared	O
with	O
those	O
in	O
control	B-I
schools	O
,	O
had	O
more	O
favorable	O
change	O
over	O
the	O
course	O
of	O
the	O
study	O
in	O
positive	O
affect	O
(	O
standardized	O
mean	O
difference	O
effect	O
size	O
[	O
ES	O
]	O
=	O
.17	O
)	O
and	B-O
life	I-O
satisfaction	I-O
(	O
ES	O
=	O
.13	O
)	O
as	O
well	O
as	O
significantly	O
lower	B-O
depression	I-O
(	O
ES	O
=	O
-.14	O
)	O
and	B-O
anxiety	I-O
(	O
ES	O
=	O
-.26	O
)	O
at	O
study	O
end	O
point	O
.	O


Program	O
effects	B-O
for	I-O
positive	I-O
affect	I-O
,	I-O
depression	I-O
,	I-O
and	I-O
anxiety	I-O
were	O
mediated	O
by	O
more	O
favorable	O
change	O
over	O
time	O
in	O
social-emotional	O
and	O
character	O
development	O
for	O
students	O
in	O
PA	O
schools	O
.	O


CONCLUSIONS	O
Results	O
suggest	O
that	O
universal	B-I
,	I-I
school-based	I-I
programs	I-I
can	O
benefit	O
the	O
emotional	O
health	B-P
of	I-P
youth	I-P
in	I-P
low-income	I-P
,	I-P
urban	I-P
settings	I-P
.	O


The	O
modest	O
magnitude	O
of	O
effects	O
over	O
an	O
extended	O
period	O
of	O
program	O
implementation	O
,	O
however	O
,	O
reflects	O
the	O
challenges	O
of	O
both	O
mounting	O
interventions	O
and	O
offsetting	O
formidable	O
risks	O
for	O
mental	O
health	O
problems	O
in	O
such	O
environments	O
.	O


Absence	B-O
of	I-O
cervical	I-O
radiation	I-O
myelitis	I-O
after	O
hyperfractionated	B-I
radiation	I-I
therapy	I-I
with	O
and	O
without	O
concurrent	B-I
chemotherapy	I-I
for	O
locally	B-P
advanced	I-P
,	I-P
unresectable	I-P
,	I-P
nonmetastatic	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
of	I-P
the	I-P
head	I-P
and	I-P
neck	I-P
.	I-P


PURPOSE	O
To	O
evaluate	O
the	O
risk	B-O
of	I-O
developing	I-O
radiation	I-O
myelitis	I-O
after	O
a	O
cervical	O
spinal	O
cord	O
dose	O
of	O
50.6	O
Gy	B-I
given	O
via	O
1.1	O
Gy	O
b.i.d	O
.	O


fractionation	O
during	O
a	O
prospective	O
,	O
randomised	O
trial	O
of	O
hyperfractionated	B-I
radiation	I-I
therapy	I-I
(	I-I
HFX	I-I
RT	I-I
)	I-I
to	O
a	O
total	O
dose	O
of	O
77	O
Gy	B-I
given	O
in	O
70	O
fractions	O
of	O
1.1	O
Gy	O
b.i.d.	O
,	O
with	O
and	O
without	O
concurrent	O
low-dose	O
,	O
daily	O
cisplatin	B-I
(	I-I
CDDP	I-I
)	I-I
for	O
head	B-P
and	I-P
neck	I-P
cancer	I-P
.	I-P


METHODS	O
Of	O
130	B-P
patients	I-P
with	I-P
locally	I-P
advanced	I-P
,	I-P
unresectable	I-P
,	I-P
nonmetastatic	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
of	I-P
the	I-P
head	I-P
and	I-P
neck	I-P
(	I-P
SCC	I-P
H	I-P
&	I-P
N	I-P
)	I-P
who	O
entered	O
a	O
prospective	O
,	O
randomised	O
trial	O
,	O
101	O
patients	O
received	O
50.6	B-I
Gy	I-I
to	I-I
a	O
portion	O
of	O
their	O
spinal	O
cord	O
and	O
survived	O
>	O
1	O
year	O
following	O
the	O
beginning	O
of	O
therapy	O
.	O


Forty-five	O
patients	O
were	O
treated	O
with	O
HFX	B-I
RT	I-I
alone	O
and	O
fifty-six	O
patients	O
also	O
received	O
CDDP	B-I
.	I-I


RESULTS	O
None	O
of	O
these	O
101	O
patients	O
developed	O
cervical	B-O
radiation	I-O
myelitis	I-O
.	I-O


Therefore	O
,	O
it	O
was	O
not	O
possible	O
to	O
investigate	O
the	O
influence	O
of	O
potentially	B-O
contributing	I-O
factors	I-O
on	O
the	O
occurrence	B-O
of	I-O
radiation	I-O
myelitis	I-O
,	O
such	O
as	O
interfraction	B-O
interval	I-O
,	I-O
cord	I-O
length	I-O
,	I-O
and	I-O
administration	I-O
of	I-O
concurrent	I-O
CDDP	I-O
.	I-O


CONCLUSIONS	O
Given	O
the	O
increasing	O
number	O
of	O
studies	O
with	O
both	O
altered	O
fractionated	O
regimens	O
and	O
concurrent	O
radio-chemotherapy	B-I
in	O
SCC	O
H	O
&	O
N	O
,	O
new	O
studies	O
with	O
more	O
patients	O
are	O
needed	O
to	O
gain	O
better	O
insight	O
into	O
the	O
risks	B-O
of	I-O
developing	I-O
cervical	I-O
radiation	I-O
myelitis	I-O
.	I-O


[	O
Comparative	O
study	O
of	O
cinoxacin	B-I
(	I-I
Cinobac	I-I
)	I-I
,	I-I
nitrofurantoin	I-I
(	I-I
Furadantine	I-I
MC	I-I
)	I-I
and	I-I
oxolinic	I-I
acid	I-I
(	I-I
Uritrate	I-I
)	I-I
in	O
urinary	O
tract	O
infections	O
.	O


Results	O
of	O
a	O
random	O
study	O
of	O
three	B-P
groups	I-P
of	I-P
30	I-P
patients	I-P
with	I-P
uncomplicated	I-P
urinary	I-P
infections	I-P
]	I-P
.	I-P


Pharmacodynamic	O
analysis	O
of	O
intravenous	B-I
recombinant	I-I
urate	I-I
oxidase	I-I
using	O
an	O
indirect	B-P
pharmacological	I-P
response	I-P
model	I-P
in	I-P
healthy	I-P
subjects	I-P
.	I-P


AIM	O
Pharmacodynamic	O
analysis	O
of	O
intravenous	B-I
recombinant	I-I
urate	I-I
oxidase	I-I
produced	O
by	O
Escherichia	O
coli	O
was	O
performed	O
in	B-P
healthy	I-P
subjects	I-P
using	I-P
a	I-P
pharmacokinetic/pharmacodynamic	I-P
(	I-P
PK/PD	I-P
)	I-P
model	I-P
.	I-P


METHODS	O
A	O
randomized	O
,	O
single-blind	O
,	O
placebo-controlled	B-I
study	O
was	O
performed	O
in	B-P
40	I-P
healthy	I-P
Chinese	I-P
subjects	I-P
(	I-P
4	I-P
groups	I-P
of	I-P
10	I-P
subjects	I-P
each	I-P
,	I-P
placebo	I-P
4:1	I-P
ratio	I-P
)	I-P
who	I-P
received	I-P
infusions	I-P
of	I-P
uricase	I-I
(	I-P
single	I-P
doses	I-P
of	I-P
0.1	I-P
,	I-P
0.2	I-P
,	I-P
and	I-P
0.3	I-P
mg/kg	I-P
;	I-P
multiple	I-P
doses	I-P
of	I-P
0.2	I-P
mg·kg	I-P
(	I-P
-1	I-P
)	I-P
·d	I-P
(	I-P
-1	I-P
)	I-P
for	I-P
7	I-P
d	I-P
)	I-P
.	O


PK	O
profiles	O
were	O
determined	O
through	B-O
plasma	I-O
uricase	I-O
activity	I-O
,	O
and	O
PD	O
profiles	O
were	O
established	O
using	B-O
uric	I-O
acid	I-O
levels	I-O
in	I-O
plasma	I-O
and	I-O
urine	I-O
.	O


The	O
plasma	O
PD	O
parameter	O
was	O
estimated	O
as	O
changes	O
in	B-O
plasma	I-O
uric	I-O
acid	I-O
levels	I-O
as	O
the	O
effect	O
in	O
the	O
indirect	O
response	O
model	B-O
.	I-O


Adverse	B-O
events	I-O
were	O
also	O
monitored	O
.	O


RESULTS	O
A	O
two-compartment	O
PK	O
model	O
with	O
constant	O
iv	O
input	O
and	O
first-order	O
output	O
was	O
used	O
to	O
describe	O
the	O
kinetic	O
process	O
of	O
plasma	O
uricase	O
.	O


The	O
low	O
value	O
(	O
2.8	O
U/L	O
)	O
of	O
drug	O
concentration	O
that	O
achieved	O
50	O
%	O
of	O
maximum	O
effect	O
(	O
EC50	O
)	O
indicated	O
that	O
low	O
plasma	O
uricase	O
concentrations	O
were	O
sufficient	O
to	O
produce	B-O
pharmacological	I-O
effects	I-O
.	O


A	O
strong	O
relationship	O
(	O
r	O
(	O
2	O
)	O
=0.9991	O
)	O
between	O
the	B-O
mean	I-O
uric	I-O
acid	I-O
concentration	I-O
in	I-O
blood	I-O
and	I-O
the	I-O
mean	I-O
uric	I-O
acid	I-O
excretion	I-O
rate	I-O
in	I-O
urine	I-O
in	O
the	O
range	O
of	O
11	O
to	O
30	O
h	O
after	O
single	O
dosing	O
was	O
found	O
.	B-P


Infusions	B-P
of	I-I
uricase	I-I
were	I-P
well	I-P
tolerated	I-P
in	I-P
all	I-P
subjects	I-P
.	O


CONCLUSION	O
The	O
PK/PD	O
model	O
predicted	O
the	B-P
effective	I-P
dose	I-P
to	I-P
be	I-P
0.1	I-P
mg/kg	I-P
in	I-P
healthy	I-P
subjects	I-P
.	O


The	O
excretion	O
rate	O
of	O
uric	O
acid	O
in	O
urine	O
may	O
be	O
used	O
as	O
a	O
new	O
index	O
for	O
pharmacological	O
effects	O
in	O
further	O
clinical	O
trials	O
.	O


Lactoferrin	B-I
supplementation	I-I
to	O
Holstein	B-P
calves	I-P
during	I-P
the	I-P
preweaning	I-P
and	I-P
postweaning	I-P
phases	I-P
.	I-P


Sixty	B-P
Holstein	I-P
calves	I-P
(	I-P
30	I-P
bulls	I-P
,	I-P
30	I-P
heifers	I-P
)	I-P
were	O
used	O
to	O
examine	O
the	O
effects	O
of	O
supplemental	B-I
lactoferrin	I-I
on	O
feed	B-O
intake	I-O
,	I-O
growth	I-O
,	I-O
and	I-O
health	I-O
during	O
the	O
preweaning	O
and	O
postweaning	O
periods	O
.	O


One	O
of	O
3	O
levels	O
of	O
lactoferrin	B-I
was	O
supplemented	O
from	O
3	O
to	O
56	O
d	O
in	O
either	O
whole	O
milk	O
or	O
water	O
to	O
produce	O
3	O
dietary	O
treatments	O
:	O
1	O
)	O
0	O
g/d	O
,	O
2	O
)	O
0.5	O
g/d	O
,	O
and	O
3	O
)	O
1	O
g/d	O
.	O


Whole	O
milk	O
(	O
3.8	O
L/d	O
)	O
containing	O
lactoferrin	B-I
supplements	I-I
was	O
fed	O
from	O
bottles	O
until	O
weaning	O
at	O
35	O
d.	O
From	O
d	O
36	O
to	O
56	O
,	O
lactoferrin	B-I
supplements	I-I
were	O
added	O
to	O
water	O
(	O
15	O
to	O
25	O
mL	O
)	O
and	O
fed	O
from	O
bottles	O
.	O


Lactoferrin	B-I
supplementation	I-I
had	O
no	O
effect	O
on	O
feed	B-O
intake	I-O
,	I-O
body	I-O
weight	I-O
,	I-O
average	I-O
daily	I-O
gain	I-O
,	I-O
heart	I-O
girth	I-O
,	I-O
body	I-O
temperature	I-O
,	I-O
fecal	I-O
scores	I-O
,	I-O
respiratory	I-O
scores	I-O
,	I-O
or	I-O
haptoglobin	I-O
concentrations	I-O
.	I-O


Calves	B-P
were	O
housed	O
in	O
individual	O
pens	O
in	O
either	O
an	O
open-sided	O
barn	O
or	O
hutches	O
.	O


Calves	B-P
raised	I-P
in	I-P
the	I-P
barn	I-P
consumed	O
more	O
calf	O
starter	O
and	O
therefore	O
grew	O
better	O
than	O
calves	O
raised	O
in	O
hutches	O
.	O


Under	O
the	O
conditions	O
of	O
this	O
study	O
,	O
lactoferrin	B-I
supplementation	I-I
was	O
not	O
beneficial	O
.	O


Further	O
research	O
is	O
needed	O
to	O
fully	O
elucidate	O
the	O
role	O
of	O
lactoferrin	B-I
,	O
and	O
possible	O
benefits	O
during	O
different	O
feeding	O
conditions	O
or	O
milk	O
sources	O
.	O


5-Fluorouracil	B-I
,	I-I
adriamycin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FAC	I-I
)	I-I
vs.	O
5-fluorouracil	B-I
,	I-I
epirubicin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FEC	I-I
)	I-I
in	O
metastatic	B-P
breast	I-P
cancer	I-P
.	I-P


94	B-P
evaluable	I-P
patients	I-P
with	I-P
metastatic	I-P
breast	I-P
cancer	I-P
were	O
randomly	O
assigned	O
to	O
5-fluorouracil	B-I
,	I-I
adriamycin	I-I
,	I-I
and	I-I
cyclophosphamide	I-I
(	I-I
FAC	I-I
)	I-I
or	I-I
5-fluorouracil	I-I
,	I-I
epirubicin	I-I
,	I-I
and	I-I
cyclophosphamide	I-I
(	I-I
FEC	I-I
)	I-I
,	O
with	O
cycles	O
repeated	O
every	O
3	O
weeks	O
.	O


The	O
objective	B-O
response	I-O
rate	I-O
to	O
FAC	B-I
was	O
46	O
%	O
versus	O
44	O
%	O
to	O
FEC	B-I
.	I-I


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
median	B-O
duration	I-O
of	I-O
response	I-O
and	I-O
median	I-O
survival	I-O
for	O
the	O
two	O
regimens	O
.	O


Toxicity	B-O
was	O
more	O
frequent	O
and	O
more	O
pronounced	O
in	O
patients	O
receiving	O
FAC	B-I
.	I-I


Results	O
indicate	O
therapeutic	O
equivalence	O
of	O
the	O
two	O
regimens	O
and	O
reduced	O
toxicity	O
of	O
the	O
epirubicin	O
arm	O
.	O


Effect	O
of	O
L-type	O
calcium	O
channel	O
blocker	O
(	B-I
amlodipine	I-I
)	I-I
on	O
myocardial	B-O
iron	I-O
deposition	I-O
in	O
patients	B-P
with	I-P
thalassaemia	I-P
with	I-P
moderate-to-severe	I-P
myocardial	I-O
iron	I-O
deposition	I-O
:	I-O
protocol	O
for	O
a	O
randomised	O
,	O
controlled	O
trial	O
.	O


INTRODUCTION	O
Sideroblastic	O
cardiomyopathy	O
secondary	O
to	O
repeated	B-O
blood	I-O
transfusions	I-O
is	O
a	O
feared	O
complication	O
in	O
thalassaemia	O
.	O


Control	O
of	O
myocardial	B-O
iron	I-O
is	O
thus	O
becoming	O
the	O
cornerstone	O
of	O
thalassaemia	O
management	O
.	O


Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
L-type	O
Ca	O
(	O
2+	O
)	O
channels	O
in	O
mediating	O
iron	O
uptake	O
by	O
the	O
heart	O
.	O


Blocking	O
the	O
cellular	O
iron	O
uptake	O
through	O
these	O
channels	O
may	O
add	O
to	O
the	O
benefit	O
of	O
therapy	O
to	O
standard	O
chelation	O
in	O
reducing	O
myocardial	B-O
iron	I-O
.	I-O


We	O
aim	O
to	O
determine	O
the	O
efficacy	O
of	O
amlodipine	B-I
(	O
a	O
calcium	O
channel	O
blocker	O
)	O
as	O
an	O
adjunct	O
to	O
standard	O
aggressive	O
chelation	O
in	O
retarding	O
myocardial	B-O
iron	I-O
deposition	I-O
in	O
thalassaemics	O
with	O
or	O
without	O
cardiomyopathy	O
.	O


OUTCOMES	O
The	O
primary	O
outcome	O
is	O
to	O
compare	B-O
the	I-O
efficacy	I-O
of	I-O
amlodipine+chelation	I-O
(	I-O
intervention	I-O
)	I-O
versus	I-O
standard	I-O
chelation	I-O
(	I-O
control	I-O
)	I-O
in	I-O
retarding	I-O
myocardial	I-O
iron	I-O
deposition	I-O
.	I-O


Secondary	O
outcomes	O
include	O
the	O
effect	B-O
of	I-O
amlodipine	I-O
therapy	I-O
on	I-O
systolic	I-O
and	I-O
diastolic	I-O
function	I-O
,	I-O
strain	I-O
and	I-O
strain	I-O
rate	I-O
and	I-O
liver	I-O
iron	I-O
content	I-O
.	I-O


METHODS	O
AND	O
ANALYSIS	O
This	O
is	O
a	O
single-centre	O
,	O
parallel-group	O
,	O
prospective	O
randomised	O
control	O
trial	O
.	O


Twenty	B-P
patients	I-P
will	O
be	O
randomised	O
in	O
a	O
1:1	O
allocation	O
ratio	O
into	O
the	O
intervention	O
and	O
control	O
arms	O
.	O


In	O
addition	O
to	O
conventional	O
echocardiography	O
,	O
MRI	O
T2*	O
values	O
for	O
assessment	O
of	O
cardiac	B-O
and	I-O
liver	I-O
iron	I-O
load	I-O
will	O
be	O
obtained	O
at	O
baseline	O
and	O
at	O
6	O
and	O
12	O
months	O
.	O


Cardiac	O
T2*	O
will	O
be	O
reported	O
as	O
the	O
geometric	O
mean	O
and	O
per	O
cent	O
coefficient	O
of	O
variation	O
,	O
and	O
an	O
increase	O
in	O
cardiac	O
T2*	O
values	O
from	O
baseline	O
will	O
be	O
used	O
as	O
an	O
end	O
point	O
to	O
compare	O
the	O
efficacy	O
of	O
therapy	O
.	O


A	O
p	O
Value	O
of	O
<	O
0.05	O
will	O
be	O
considered	O
significant	O
.	O


STUDY	O
SETTING	O
Department	B-P
of	I-P
Pediatric	I-P
and	I-P
Child	I-P
Health	I-P
,	I-P
Aga	I-P
Khan	I-P
University	I-P
Hospital	I-P
,	I-P
Karachi	I-P
,	I-P
Pakistan	I-P
.	I-P


ETHICS	O
AND	O
DISSEMINATION	O
This	O
study	O
has	O
been	O
approved	O
by	O
the	O
Ethics	O
Review	O
Committee	O
and	O
Clinical	O
Trials	O
Unit	O
at	O
The	B-P
Aga	I-P
Khan	I-P
University	I-P
with	O
respect	O
to	O
scientific	O
content	O
and	O
compliance	O
with	O
applicable	O
research	O
and	O
human	O
subjects	O
regulations	O
.	O


Findings	O
will	O
be	O
reported	O
through	O
scientific	O
publications	O
and	O
research	O
conferences	O
and	O
project	O
summary	O
papers	O
for	O
participants	O
.	O


TRIAL	O
REGISTRATION	O
NUMBER	O
ClinicalTrials.Gov	O
.	O


Registration	O
no	O
:	O
NCT02065492	O
.	O


Modified	B-I
constraint-induced	I-I
therapy	I-I
combined	O
with	O
mental	B-I
practice	I-I
:	I-I
thinking	O
through	O
better	O
motor	O
outcomes	O
.	O


BACKGROUND	O
AND	O
PURPOSE	O
Modified	B-I
constraint-induced	I-I
therapy	I-I
(	I-I
mCIT	I-I
)	I-I
is	O
an	O
outpatient	O
therapy	O
encouraging	O
repetitive	O
,	O
task-specific	O
practice	O
with	O
the	O
affected	O
arm	O
.	O


mCIT	B-I
has	O
shown	O
efficacy	B-O
in	O
all	O
stages	O
poststroke	O
.	O


Given	O
its	O
efficacy	O
when	O
combined	O
with	O
other	O
therapy	O
regimens	O
,	O
the	O
current	O
study	O
examined	O
the	O
efficacy	B-O
of	O
mental	B-I
practice	I-I
when	O
combined	O
with	O
mCIT	B-I
versus	O
mCIT	B-I
only	I-I
using	O
randomized	O
,	O
controlled	O
methods	O
.	O


METHOD	O
Ten	B-P
patients	I-P
with	I-P
chronic	I-P
stroke	I-P
(	I-P
7	I-P
males	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
61.4+/-3.02	I-P
years	I-P
;	I-P
age	I-P
range	I-P
,	I-P
48	I-P
to	I-P
79	I-P
years	I-P
;	I-P
mean	I-P
time	I-P
since	I-P
stroke	I-P
,	I-P
28.5	I-P
months	I-P
;	I-P
range	I-P
,	I-P
13	I-P
to	I-P
42	I-P
months	I-P
)	I-P
exhibiting	I-P
stable	I-P
,	I-P
affected	I-P
arm	I-P
motor	I-P
deficits	I-P
were	O
administered	O
mCIT	B-I
,	O
consisting	O
of	O
:	O
(	O
1	O
)	O
structured	O
therapy	O
emphasizing	O
affected	O
arm	O
use	O
in	O
functional	O
activities	O
3	O
days/week	O
for	O
10	O
weeks	O
;	O
and	O
(	O
2	O
)	O
less	O
affected	O
arm	O
restraint	O
5	O
days/week	O
for	O
5	O
hours	O
.	O


Both	O
of	O
these	O
components	O
were	O
administered	O
during	O
a	O
10-week	O
period	O
.	O


Subjects	O
randomly	O
assigned	O
to	O
the	O
mCIT+mental	B-I
practice	I-I
experimental	O
condition	O
also	O
received	O
30-minute	O
mental	O
practice	O
sessions	O
provided	O
directly	O
after	O
therapy	O
sessions	O
.	O


These	O
mental	B-I
practice	I-I
sessions	O
required	O
daily	O
cognitive	O
rehearsal	O
of	O
the	O
activities	O
of	O
daily	O
living	O
practiced	O
during	O
mCIT	B-I
clinical	O
sessions	O
.	O


RESULTS	O
No	O
pre-existing	O
differences	O
were	O
found	O
between	O
groups	O
on	O
any	O
demographic	O
variable	O
or	O
movement	O
scale	O
.	O


All	O
subjects	O
exhibited	O
marked	O
reductions	O
in	O
affected	B-O
arm	I-O
impairment	I-O
and	I-O
functional	I-O
limitation	I-O
.	I-O


However	O
,	O
subjects	O
in	O
the	O
mCIT+mental	B-I
practice	I-I
group	O
exhibited	O
significantly	O
larger	O
changes	O
on	O
both	O
movement	B-O
measures	I-O
after	O
intervention	O
:	O
Action	O
Research	O
Arm	O
Test	O
,	O
+15.4-point	O
change	O
versus	O
+8.4-point	O
change	O
for	O
mCIT	B-I
only	I-I
subjects	O
(	O
P	O
<	O
0.001	O
)	O
;	O
Fugl-Meyer	O
,	O
+7.8-point	O
change	O
versus	O
+4.1-point	O
change	O
for	O
the	O
mCIT	B-I
only	I-I
subjects	O
(	O
P=0.01	O
)	O
.	O


These	O
changes	O
were	O
sustained	O
3	O
months	O
after	O
intervention	O
.	O


CONCLUSIONS	O
mCIT	B-I
remains	O
a	O
promising	O
motor	O
intervention	O
.	O


However	O
,	O
its	O
efficacy	B-O
appears	O
to	O
be	O
enhanced	O
by	O
use	O
of	O
mental	B-I
practice	I-I
provided	O
directly	O
after	O
mCIT	B-I
clinical	O
sessions	O
.	O


Middle	B-O
cerebral	I-O
arterial	I-O
blood	I-O
flow	I-O
velocity	I-O
and	I-O
hemodynamics	I-O
in	O
heart	O
surgery	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
propofol	B-I
,	I-I
isoflurane	I-I
,	I-I
and	I-I
sevoflurane	I-I
on	O
middle	B-O
cerebral	I-O
arterial	I-O
blood	I-O
flow	I-O
velocity	I-O
during	O
open	B-P
heart	I-P
surgery	I-P
,	O
and	O
the	O
relationship	O
between	O
these	O
effects	O
and	O
hemodynamic	O
parameters	O
.	O


Fifty-two	B-P
patients	I-P
undergoing	I-P
coronary	I-P
artery	I-P
bypass	I-P
on	I-P
cardiopulmonary	I-P
bypass	I-P
were	O
divided	O
randomly	O
into	O
3	O
groups	O
:	O
the	O
first	O
group	B-I
received	I-I
100	I-I
microg	I-I
x	I-I
kg	I-I
(	I-I
-1	I-I
)	I-I
x	I-I
min	I-I
(	I-I
-1	I-I
)	I-I
propofol	I-I
,	I-I
the	I-I
other	I-I
groups	I-I
received	I-I
one	I-I
minimum	I-I
alveolar	I-I
concentration	I-I
of	I-I
sevoflurane	I-I
or	I-I
isoflurane	I-I
for	I-I
anesthesia	I-I
maintenance	I-I
.	I-I


Middle	B-O
cerebral	I-O
arterial	I-O
blood	I-O
flow	I-O
velocities	I-O
were	O
measured	O
by	O
transcranial	O
Doppler	O
,	O
and	O
hemodynamics	B-O
were	O
measured	O
by	O
the	O
thermodilution	O
technique	O
.	O


Middle	B-O
cerebral	I-O
arterial	I-O
blood	I-O
flow	I-O
velocities	I-O
decreased	O
significantly	O
after	O
administration	O
of	O
isoflurane	O
and	O
propofol	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
.	O


After	O
weaning	O
from	O
cardiopulmonary	O
bypass	O
,	O
cerebral	B-O
blood	I-O
flow	I-O
increased	I-O
and	O
came	O
close	O
to	O
the	O
value	O
after	O
induction	O
in	O
all	O
groups	O
.	O


The	O
pulsatility	B-O
index	I-O
and	I-O
resistivity	I-O
index	I-O
increased	O
significantly	O
only	O
after	O
the	O
propofol	O
infusion	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
.	O


The	O
influence	O
of	O
placebo	O
awareness	O
on	O
stimulant	O
drug	O
response	O
in	O
a	O
double-blind	O
trial	O
.	O


RATIONALE	O
Critics	O
have	O
called	O
into	O
question	O
findings	O
from	O
double-blind	O
placebo-controlled	O
studies	O
because	O
subjects	O
are	O
given	O
drug	O
administration	O
instructions	O
informing	O
them	O
of	O
a	O
placebo	O
condition	O
.	O


The	O
assertion	O
that	O
these	O
drug	O
administration	O
instructions	O
bias	O
estimates	O
of	O
effectiveness	O
has	O
undergone	O
surprisingly	O
little	O
empirical	O
investigation	O
.	O


OBJECTIVES	O
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
drug	O
administration	O
instructions	O
informing	O
subjects	O
of	O
a	O
placebo	B-I
condition	O
affect	O
the	O
drug	O
response	O
and	O
affect	O
the	O
saliva	B-O
concentration	I-O
of	O
the	O
stimulant	O
.	O


METHODS	O
We	O
assessed	O
caffeine	B-O
responses	I-O
and	I-O
levels	I-O
of	I-O
saliva	I-O
concentration	I-O
of	I-O
caffeine	I-O
in	I-P
52	I-P
subjects	I-P
who	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
receive	I-P
one	I-P
of	I-P
two	I-P
drug	I-P
administration	I-P
instructions	I-P
:	I-P
(	O
a	O
)	O
placebo-informed	B-I
instructions	I-I
(	O
i.e.	O
,	O
individuals	B-I
informed	I-I
of	I-I
the	I-I
placebo	I-I
)	I-I
analogous	O
to	O
those	O
used	O
in	O
double-blind	O
studies	O
and	O
(	O
b	O
)	O
placebo-uninformed	B-I
instructions	I-I
(	O
i.e.	O
,	O
individuals	B-I
informed	I-I
they	I-I
are	I-I
taking	I-I
an	I-I
active	I-I
stimulant	I-I
)	I-I
.	O


RESULTS	O
On	O
most	O
measures	O
(	B-O
systolic	I-O
blood	I-O
pressure	I-O
,	I-O
heart	I-O
rate	I-O
,	I-O
hand	I-O
steadiness	I-O
,	I-O
reaction	I-O
time	I-O
,	I-O
fatigue	I-O
,	I-O
and	I-O
tension	I-O
)	I-O
,	O
drug	O
administration	O
instructions	O
did	O
not	O
significantly	O
influence	O
caffeine	B-O
response	I-O
.	I-O


Instructions	O
also	O
had	O
no	O
significant	O
effect	O
on	O
saliva	B-O
concentration	I-O
of	O
caffeine	O
.	O


However	O
,	O
only	O
individuals	O
who	O
were	O
uninformed	O
of	O
the	O
placebo	O
condition	O
showed	O
significant	O
diastolic	B-O
blood	I-O
pressure	I-O
and	I-O
vigor	I-O
increases	O
with	O
125	O
mg	O
caffeine	B-I
,	O
and	O
significant	O
hand	B-O
steadiness	I-O
impairment	I-O
and	I-O
vigor	I-O
increases	O
with	O
325	O
mg	O
caffeine	B-I
compared	O
to	O
placebo	O
.	O


CONCLUSIONS	O
These	O
overall	O
findings	O
suggest	O
that	O
a	O
limited	O
bias	O
is	O
introduced	O
by	O
drug	O
administration	O
instructions	O
.	O


The	O
results	O
do	O
not	O
support	O
any	O
suggestion	O
that	O
information	O
about	O
the	O
existence	O
of	O
a	O
placebo	O
condition	O
dramatically	O
influences	O
conclusions	O
drawn	O
about	O
drug	O
responses	O
in	O
placebo-controlled	O
trials	O
.	O


The	O
impact	O
of	O
parent-delivered	B-I
intervention	I-I
on	O
parents	B-P
of	I-P
very	I-P
young	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


This	O
study	O
investigated	O
the	O
impact	O
of	O
a	O
parent-coaching	B-I
intervention	I-I
based	O
on	O
the	O
Early	B-I
Start	I-I
Denver	I-I
Model	I-I
(	I-I
P-ESDM	I-I
)	I-I
on	O
parenting-related	B-O
stress	I-O
and	O
sense	B-O
of	I-O
competence	I-O
.	I-O


This	O
was	O
part	O
of	O
a	O
multisite	B-P
,	O
randomized	B-I
trial	I-I
comparing	O
P-ESDM	B-I
(	I-P
n	I-P
=	I-P
49	I-P
)	I-P
with	I-I
community	I-I
intervention	I-I
(	I-P
n	I-P
=	I-P
49	I-P
)	I-P
for	I-P
children	I-P
aged	I-P
12	I-P
and	I-P
24	I-P
months	I-P
.	I-O


The	B-O
P-ESDM	I-O
group	O
reported	O
no	O
increase	B-O
in	I-O
parenting	I-O
stress	I-O
,	O
whereas	O
the	O
Community	O
group	O
experienced	O
an	O
increase	O
over	O
the	O
same	O
3-month	O
period	B-O
.	I-O


Parental	B-O
sense	I-O
of	I-O
competence	I-O
did	O
not	O
differ	B-O
.	I-O


Number	B-O
of	I-O
negative	I-O
life	I-O
events	I-O
was	O
a	O
significant	O
predictor	O
of	O
parenting	O
stress	O
and	O
sense	O
of	O
competence	O
across	O
both	O
groups	O
.	O


This	O
suggests	O
that	B-I
a	I-I
parent-coaching	I-I
intervention	I-I
may	O
help	B-O
maintain	I-O
parental	I-O
adjustment	I-O
directly	O
after	O
a	O
child	O
is	O
diagnosed	O
with	O
ASD	O
.	O


There	O
are	O
some	O
benefits	O
for	O
eradicating	O
Helicobacter	O
pylori	O
in	O
patients	B-P
with	I-P
non-ulcer	I-P
dyspepsia	I-P
.	I-P


BACKGROUND	O
The	O
relationship	O
between	O
Helicobacter	O
pylori	O
infection	O
and	O
non-ulcer	O
dyspepsia	O
is	O
not	O
established	O
.	O


AIM	O
To	O
determine	O
whether	O
eradication	O
of	O
H.	O
pylori	O
might	O
be	O
of	O
benefit	O
in	O
non-ulcer	B-P
dyspepsia	I-P
patients	I-P
.	I-P


METHODS	O
We	O
randomly	O
assigned	O
129	B-P
H.	I-P
pylori	I-P
infected	I-P
patients	I-P
with	I-P
severe	I-P
epigastric	I-P
pain	I-P
,	I-P
without	I-P
gastro-oesophageal	I-P
reflux	I-P
symptoms	I-P
,	O
to	O
receive	O
twice	O
daily	O
treatment	O
with	O
300	O
mg	O
of	O
ranitidine	B-I
,	O
1000	O
mg	O
of	O
amoxicillin	B-I
,	O
and	O
500	O
mg	O
of	O
clarithromycin	B-I
for	O
7	O
days	O
and	O
124	B-P
such	I-P
patients	I-P
to	I-P
receive	I-P
identical-appearing	I-P
placebos	I-I
.	I-I


RESULTS	O
Treatment	O
was	O
successful	O
(	O
decrease	O
of	O
symptoms	O
at	O
12	O
months	O
)	O
in	O
62	O
%	O
of	O
patients	O
in	O
the	O
active-treatment	O
group	O
and	O
in	O
60	O
%	O
of	O
the	O
placebo	O
group	O
(	O
N.S.	O
)	O
.	O


At	O
12	O
months	O
,	O
the	O
rate	B-O
of	I-O
eradication	I-O
of	I-O
H.	I-O
pylori	I-O
was	O
69	O
%	O
in	O
the	O
active-treatment	O
group	O
and	O
18	O
%	O
in	O
the	O
placebo	B-I
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Complete	B-O
relief	I-O
of	I-O
symptoms	I-O
occurred	O
significantly	O
more	O
frequently	O
in	O
patients	O
on	O
the	O
active	O
treatment	O
(	O
43	O
%	O
)	O
than	O
in	O
placebo-treated	B-I
patients	O
(	O
31	O
%	O
,	O
P=0.048	O
)	O
.	O


Within	O
the	O
active-treatment	O
group	O
,	O
therapeutic	B-O
success	I-O
was	O
significantly	O
more	O
frequent	O
in	O
the	O
non-infected	B-P
patients	I-P
(	O
84	O
%	O
vs.	O
64	O
%	O
,	O
P=0.04	O
)	O
.	O


CONCLUSIONS	O
Although	O
eradicating	O
H.	O
pylori	O
is	O
not	O
likely	O
to	O
relieve	O
symptoms	O
in	O
the	O
majority	O
of	O
patients	B-P
with	I-P
non-ulcer	I-P
dyspepsia	I-P
,	O
a	O
small	O
proportion	O
of	O
H.	B-P
pylori-infected	I-P
patients	I-P
may	O
benefit	O
from	O
eradication	O
treatment	O
.	O


Positive	O
effects	O
of	O
methylphenidate	B-I
on	O
social	B-O
communication	I-O
and	I-O
self-regulation	I-O
in	O
children	B-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
and	I-P
hyperactivity	I-P
.	I-P


This	O
report	O
examined	O
the	O
effect	O
of	O
methylphenidate	B-I
on	O
social	B-O
communication	I-O
and	I-O
self-regulation	I-O
in	O
children	B-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
and	I-P
hyperactivity	I-P
in	O
a	O
secondary	O
analysis	O
of	O
RUPP	B-P
Autism	I-P
Network	I-P
data	I-P
.	I-P


Participants	B-P
were	I-P
33	I-P
children	I-P
(	I-P
29	I-P
boys	I-P
)	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
5	I-P
and	I-P
13	I-P
years	I-P
who	O
participated	O
in	O
a	O
four-week	O
crossover	O
trial	O
of	O
placebo	B-I
and	O
increasing	B-I
doses	I-I
of	I-I
methylphenidate	I-I
given	O
in	O
random	O
order	O
each	O
for	O
one	O
week	O
.	O


Observational	O
measures	O
of	O
certain	O
aspects	O
of	O
children	O
's	O
social	B-O
communication	I-O
,	I-O
self-regulation	I-O
,	I-O
and	I-O
affective	I-O
behavior	I-O
were	O
obtained	O
each	O
week	O
.	O


A	O
significant	O
positive	O
effect	O
of	O
methylphenidate	O
was	O
seen	O
on	O
children	O
's	O
use	O
of	O
joint	B-O
attention	I-O
initiations	I-O
,	I-O
response	I-O
to	I-O
bids	I-O
for	I-O
joint	I-O
attention	I-O
,	I-O
self-regulation	I-O
,	I-O
and	I-O
regulated	I-O
affective	I-O
state	I-O
.	I-O


The	O
results	O
go	O
beyond	O
the	O
recent	O
literature	O
and	O
suggest	O
that	O
methylphenidate	B-I
may	O
have	O
positive	O
effects	O
on	O
social	B-O
behaviors	I-O
in	O
children	B-P
with	I-P
PDD	I-P
and	I-P
hyperactivity	I-P
.	I-P


Evaluation	O
of	O
umbilical	B-I
cord	I-I
serum	I-I
therapy	I-I
for	O
persistent	B-P
corneal	I-P
epithelial	I-P
defects	I-P
.	I-P


AIMS	O
To	O
evaluate	O
umbilical	B-I
cord	I-I
serum	I-I
therapy	I-I
as	O
a	O
means	O
of	O
promoting	O
the	O
healing	O
of	O
persistent	B-O
corneal	I-O
epithelial	I-O
defects	I-O
.	I-O


METHODS	O
Umbilical	B-I
cord	I-I
serum	I-I
or	I-I
autologous	I-I
serum	I-I
drops	I-I
were	O
used	O
to	O
promote	O
the	O
healing	O
of	O
persistent	B-O
epithelial	I-O
defects	I-O
.	I-O


The	O
study	O
design	O
was	O
a	O
prospective	O
randomised	O
controlled	O
clinical	O
trial	O
.	O


60	B-P
eyes	I-P
of	I-P
59	I-P
patients	I-P
were	O
divided	O
into	O
two	O
groups	O
,	O
31	O
in	O
the	O
cord	B-I
serum	I-I
group	O
and	O
29	O
in	O
the	O
autologous	B-I
serum	I-I
control	I-I
group	I-I
.	I-I


Epithelial	O
defects	O
measuring	O
at	O
least	O
2	O
mm	O
in	O
linear	O
dimension	O
resistant	O
to	O
conventional	O
medical	O
management	O
were	O
included	O
.	O


Serial	O
measurements	O
of	O
the	O
size	O
of	O
the	O
epithelial	O
defects-namely	O
,	O
two	O
maximum	O
linear	O
dimensions	O
perpendicular	O
to	O
each	O
other	O
,	O
and	O
the	O
area	O
and	O
perimeter	O
was	O
done	O
at	O
start	O
of	O
therapy	O
and	O
follow	O
up	O
days	O
3	O
,	O
7	O
,	O
14	O
,	O
21	O
.	O


Rate	B-O
of	I-O
healing	I-O
of	I-O
the	I-O
epithelial	I-O
defects	I-O
were	O
measured	O
as	O
percentage	O
decrease	O
from	O
the	O
baseline	O
parameter	O
at	O
each	O
subsequent	O
follow	O
up	O
.	O


The	O
data	O
were	O
analysed	O
by	O
the	O
non-parametric	O
Wilcoxon	O
rank	O
sum	O
test	O
using	O
STATA	O
7.0	O
.	O


RESULTS	O
The	O
median	O
percentage	O
decrease	B-O
in	I-O
the	I-O
size	I-O
of	I-O
the	I-O
epithelial	I-O
defect	I-O
was	O
significantly	O
greater	O
in	O
the	O
cord	B-I
serum	I-I
group	O
at	O
days	O
7	O
,	O
14	O
and	O
21	O
(	O
p	O
<	O
0.05	O
)	O
when	O
measured	O
in	O
terms	O
of	O
the	O
area	O
and	O
perimeter	O
.	O


A	O
greater	O
number	O
of	O
patients	O
showed	O
complete	B-O
re-epithelialisation	I-O
with	O
umbilical	O
cord	B-I
serum	I-I
(	O
n	O
=	O
18	O
)	O
than	O
with	O
autologous	O
serum	O
(	O
n	O
=	O
11	O
)	O
(	O
Pearson	O
chi	O
=	O
0.19	O
)	O
.	O


None	O
of	O
the	O
patients	O
reported	O
any	O
side	O
effects	O
or	O
discomfort	O
with	O
either	O
treatment	O
.	O


CONCLUSIONS	O
Umbilical	B-I
cord	I-I
serum	I-I
leads	O
to	O
faster	B-O
healing	I-O
of	I-O
the	I-O
persistent	I-O
corneal	I-O
epithelial	I-O
defects	I-O
refractory	O
to	O
all	O
medical	O
management	O
compared	O
to	O
autologous	B-I
serum	I-I
.	I-I


Denosumab	B-I
compared	O
with	O
zoledronic	B-I
acid	I-I
for	O
the	O
treatment	O
of	O
bone	O
metastases	O
in	O
patients	B-P
with	I-P
advanced	I-P
breast	I-P
cancer	I-P
:	I-P
a	O
randomized	O
,	O
double-blind	O
study	O
.	O


PURPOSE	O
This	O
randomized	O
study	O
compared	O
denosumab	B-I
,	O
a	O
fully	O
human	O
monoclonal	O
antibody	O
against	O
receptor	O
activator	O
of	O
nuclear	O
factor	O
κ	O
B	O
(	O
RANK	O
)	O
ligand	O
,	O
with	B-I
zoledronic	I-I
acid	I-I
in	O
delaying	O
or	O
preventing	O
skeletal-related	O
events	O
(	O
SREs	O
)	O
in	B-P
patients	I-P
with	I-P
breast	I-P
cancer	I-P
with	I-P
bone	I-P
metastases	I-P
.	O


PATIENTS	O
AND	O
METHODS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	B-I
either	I-I
subcutaneous	I-I
denosumab	I-I
120	I-I
mg	I-I
and	I-I
intravenous	I-I
placebo	I-I
(	I-P
n	I-P
=	I-P
1,026	I-P
)	I-P
or	I-I
intravenous	I-I
zoledronic	I-I
acid	I-I
4	I-I
mg	I-I
adjusted	I-I
for	I-I
creatinine	I-I
clearance	I-I
and	I-I
subcutaneous	I-I
placebo	I-I
(	I-P
n	I-P
=	I-P
1,020	I-P
)	I-P
every	O
4	O
weeks	O
.	O


All	O
patients	O
were	O
strongly	O
recommended	O
to	O
take	O
daily	B-I
calcium	I-I
and	I-I
vitamin	I-I
D	I-I
supplements	O
.	O


The	O
primary	O
end	O
point	O
was	O
time	O
to	B-O
first	I-O
on-study	I-O
SRE	I-O
(	I-O
defined	I-O
as	I-O
pathologic	I-O
fracture	I-O
,	I-O
radiation	I-O
or	I-O
surgery	I-O
to	I-O
bone	I-O
,	I-O
or	I-O
spinal	I-O
cord	I-O
compression	I-O
)	I-O
.	O


RESULTS	B-I
Denosumab	I-I
was	O
superior	O
to	B-I
zoledronic	I-I
acid	I-I
in	I-O
delaying	I-O
time	I-O
to	I-O
first	I-O
on-study	I-O
SRE	I-O
(	O
hazard	O
ratio	O
,	O
0.82	O
;	O
95	O
%	O
CI	O
,	O
0.71	O
to	O
0.95	O
;	O
P	O
=	O
.01	O
superiority	O
)	O
and	B-O
time	I-O
to	I-O
first	I-O
and	I-O
subsequent	I-O
(	I-O
multiple	I-O
)	I-O
on-study	I-O
SREs	I-O
(	O
rate	O
ratio	O
,	O
0.77	O
;	O
95	O
%	O
CI	O
,	O
0.66	O
to	O
0.89	O
;	O
P	O
=	O
.001	O
)	O
.	B-O


Reduction	B-O
in	I-O
bone	I-O
turnover	I-O
markers	I-O
was	O
greater	O
with	O
denosumab	O
.	B-O


Overall	B-O
survival	I-O
,	I-O
disease	I-O
progression	I-O
,	I-O
and	I-O
rates	I-O
of	I-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
and	I-O
serious	I-O
AEs	I-O
were	O
similar	O
between	O
groups	O
.	O


An	B-O
excess	I-O
of	I-O
renal	I-O
AEs	I-O
and	I-O
acute-phase	I-O
reactions	I-O
occurred	O
with	O
zoledronic	O
acid	B-O
;	I-O
hypocalcemia	I-O
occurred	O
more	O
frequently	O
with	B-I
denosumab	I-I
.	I-O


Osteonecrosis	B-O
of	I-O
the	I-O
jaw	I-O
occurred	O
infrequently	O
(	O
2.0	O
%	O
,	O
denosumab	B-I
;	I-I
1.4	O
%	O
,	O
zoledronic	B-I
acid	I-I
;	I-I
P	O
=	O
.39	O
)	O
.	O


CONCLUSION	B-I
Denosumab	I-I
was	O
superior	O
to	B-I
zoledronic	I-I
acid	I-I
in	O
delaying	O
or	O
preventing	O
SREs	O
in	B-P
patients	I-P
with	I-P
breast	I-P
cancer	I-P
metastatic	I-P
to	I-P
bone	I-P
and	O
was	O
generally	O
well	O
tolerated	O
.	O


With	O
the	O
convenience	O
of	O
a	O
subcutaneous	O
injection	O
and	O
no	O
requirement	O
for	O
renal	O
monitoring	O
,	O
denosumab	B-I
represents	O
a	O
potential	O
treatment	O
option	O
for	B-P
patients	I-P
with	I-P
bone	I-P
metastases	I-P
.	O


Combination	O
cyclopentolate	B-I
and	O
phenylephrine	B-I
for	O
mydriasis	O
in	O
premature	B-P
infants	I-P
with	I-P
heavily	I-P
pigmented	I-P
irides	I-P
.	I-P


PURPOSE	O
This	O
study	O
examined	O
whether	O
safe	O
and	O
effective	O
mydriasis	O
can	O
be	O
achieved	O
in	O
premature	B-P
infants	I-P
with	I-P
heavily	I-P
pigmented	I-P
irides	I-P
using	O
combination	O
cyclopentolate	B-I
0.2	O
%	O
and	O
phenylephrine	B-I
1	O
%	O
eyedrops	O
.	O


METHODS	O
A	O
prospective	O
,	O
randomized	O
double-blind	O
study	O
was	O
performed	O
to	O
compare	O
combination	O
cyclopentolate	B-I
0.2	O
%	O
and	O
phenylephrine	B-I
1	O
%	O
eye-drops	O
with	O
triple	O
instillation	O
of	O
tropicamide	B-I
0.5	O
%	O
and	O
phenylephrine	B-I
2.5	O
%	O
.	O


Twenty-eight	B-P
consecutive	I-P
babies	I-P
with	I-P
dark	I-P
irides	I-P
and	I-P
birthweight	I-P
<	I-P
1600	I-P
g	I-P
referred	I-P
for	I-P
screening	I-P
for	I-P
retinopathy	I-P
of	I-P
prematurity	I-P
comprised	I-P
the	I-P
study	I-P
population	I-P
.	I-P


Infants	O
'	O
eyes	O
were	O
randomly	O
dilated	O
twice	O
with	O
both	O
regimens	O
within	O
a	O
2-week	O
period	O
.	O


Blood	B-O
pressure	I-O
,	I-O
heart	I-O
rate	I-O
,	I-O
and	I-O
pupil	I-O
size	I-O
were	O
measured	O
.	O


RESULTS	O
Good	O
mydriasis	O
was	O
achieved	O
in	O
both	O
groups	O
with	O
no	O
significant	O
differences	B-O
in	I-O
pupil	I-O
size	I-O
or	I-O
blood	I-O
pressure	I-O
(	I-O
systolic	I-O
,	I-O
diastolic	I-O
,	I-O
or	I-O
mean	I-O
arterial	I-O
pressures	I-O
)	I-O
over	O
starting	O
baseline	O
values	O
.	O


Pulse	B-O
rates	I-O
decelerated	O
below	O
the	O
baseline	O
values	O
in	O
both	O
groups	O
,	O
but	O
these	O
differences	O
were	O
not	O
large	O
.	O


CONCLUSION	O
The	O
single	O
combination	O
eyedrop	O
of	O
cyclopentolate	O
0.2	O
%	O
and	O
phenylephrine	O
1	O
%	O
is	O
as	O
effective	O
and	O
safe	O
a	O
mydriatic	O
for	O
infants	O
with	O
dark	O
irides	O
as	O
both	O
tropicamide	O
0.5	O
%	O
and	O
phenylephrine	O
2.5	O
%	O
.	O


Tacrolimus	B-I
monotherapy	O
without	O
steroids	O
after	B-P
liver	I-P
transplantation	I-P
--	I-P
a	I-P
prospective	O
randomized	O
double-blinded	O
placebo-controlled	O
trial	O
.	O


Early	O
steroid	O
withdrawal	O
after	B-P
liver	I-P
transplantation	I-P
(	I-P
LT	I-P
)	I-P
is	O
desirable	O
in	O
order	O
to	O
reduce	O
steroid	O
side	O
effects	O
.	O


Between	B-P
February	I-P
2000	I-P
and	I-P
August	I-P
2004	I-P
,	I-P
110	I-P
patients	I-P
after	I-P
LT	I-P
were	O
included	O
in	O
this	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
.	O


Randomization	O
was	O
performed	O
before	O
LT	O
.	O


In	O
all	O
patients	O
,	O
tacrolimus	B-I
was	I-I
used	I-I
without	I-I
induction	I-I
therapy	I-I
.	I-I


All	B-P
patients	I-P
received	I-P
methylprednisolon	I-I
for	I-P
14	I-P
days	I-P
,	O
thereafter	O
a	O
double-blinded	O
medication	O
containing	O
either	O
placebo	B-I
(	O
n	O
=	O
56	O
)	O
or	O
methylprednisolon	B-I
(	O
n	O
=	O
54	O
)	O
for	O
6	O
months	O
,	O
which	O
was	O
completely	O
stopped	O
thereafter	O
.	O


End	O
points	O
were	O
patient	B-O
and	I-O
graft	I-O
survival	I-O
,	I-O
acute	I-O
and	I-O
chronic	I-O
rejection	I-O
,	I-O
and	I-O
incidence	I-O
of	I-O
steroid	I-O
side	I-O
effects	I-O
during	O
the	O
first	O
year	O
after	B-P
LT	I-P
.	I-P


One-year	O
patient	B-O
survival	I-O
was	O
85.7	O
%	O
(	O
placebo	O
)	O
and	O
88.8	O
%	O
(	O
steroid	O
)	O
(	O
p	O
=	O
0.572	O
)	O
.	O


Twenty-seven	O
(	O
48.2	O
%	O
)	O
and	O
19	O
(	O
35.2	O
%	O
)	O
patients	O
experienced	O
acute	B-O
rejection	I-O
(	O
placebo	O
versus	O
steroid	O
,	O
respectively	O
;	O
p	O
=	O
0.116	O
)	O
.	O


Two	O
patients	O
in	O
the	O
placebo	O
group	O
but	O
none	O
in	O
the	O
steroid	O
group	O
experienced	O
chronic	B-O
rejection	I-O
(	O
p	O
=	O
0.257	O
)	O
.	O


The	O
rates	B-O
of	I-O
side	I-O
effects	I-O
were	O
(	B-I
placebo	I-I
versus	O
steroid	B-I
,	O
respectively	O
)	O
:	O
CMV	B-O
infection	I-O
25	O
%	O
versus	O
33	O
%	O
(	O
p	O
=	O
0.336	O
)	O
,	O
post-transplant	B-O
diabetes	I-O
30	O
%	O
versus	O
53	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
hypertension	B-O
39	O
%	O
versus	O
52	O
%	O
(	O
p	O
=	O
0.248	O
)	O
,	O
hypercholesterolemia	B-O
10	O
%	O
versus	O
41	O
%	O
(	O
p	O
=	O
0.002	O
)	O
and	O
hypertriglyceridemia	B-O
32	O
%	O
versus	O
54	O
%	O
(	O
p	O
=	O
0.046	O
)	O
.	O


In	O
conclusion	O
,	O
early	O
steroid	O
withdrawal	O
after	B-P
LT	I-P
is	O
feasible	B-O
under	O
tacrolimus	B-I
monotherapy	O
without	O
increased	O
rejection	O
rates	O
and	O
with	O
a	O
lower	B-O
rate	I-O
of	I-O
side	I-O
effects	I-O
.	I-O


Diet	B-I
and	O
tobacco	O
use	O
:	O
analysis	O
of	O
data	O
from	O
the	O
diabetic	O
control	O
and	O
complications	O
trial	O
,	O
a	O
randomized	O
study	O
.	O


CONTEXT	O
The	O
Diabetic	O
Control	O
and	O
Complications	O
Trial	O
(	O
DCCT	O
)	O
researchers	O
kept	O
careful	O
records	O
of	O
the	O
food	O
consumption	O
and	O
tobacco	O
using	O
habits	O
of	B-P
type	I-P
1	I-P
diabetic	I-P
subjects	I-P
.	I-P


However	O
,	O
they	O
did	O
not	O
report	O
the	O
relationship	O
of	O
tobacco	B-O
using	I-O
habits	I-O
with	O
dietary	B-O
intake	I-O
.	I-O


OBJECTIVE	O
Analyze	O
the	O
relationship	B-O
between	I-O
tobacco	I-O
smoking	I-O
and	I-O
intake	I-O
of	I-O
macro	I-O
and	I-O
micronutrients	I-O
.	I-O


DESIGN	O
Randomized	O
controlled	O
trial	O
.	O


SETTING	O
Referral	B-P
clinics	I-P
in	I-P
27	I-P
academic	I-P
centers	I-P
.	I-P


PATIENTS	B-P
Type	I-P
1	I-P
diabetics	I-P
.	I-P


INTERVENTION	O
Using	O
the	O
data	B-I
sets	I-I
of	I-I
the	I-I
DCCT	I-I
,	O
this	O
study	O
analyzed	O
the	O
strengths	O
of	O
the	O
associations	B-O
between	I-O
smoking	I-O
and	I-O
macronutrient	I-O
consumption	I-O
,	I-O
hemoglobin	I-O
A1c	I-O
(	I-O
HbA1c	I-O
)	I-O
,	I-O
body	I-O
mass	I-O
index	I-O
(	I-O
BMI	I-O
)	I-O
,	I-O
and	I-O
serum	I-O
lipid	I-O
levels	I-O
at	O
the	O
study	O
baseline	O
,	O
2	O
years	O
,	O
and	O
4	O
years	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Statistically	B-O
significant	I-O
correlations	I-O
between	I-O
smoking	I-O
and	I-O
nutrient	I-O
intake	I-O
,	I-O
HbA1c	I-O
,	I-O
and	I-O
serum	I-O
lipid	I-O
levels	I-O
.	I-O


RESULTS	O
Cigarette	B-O
,	I-O
cigar	I-O
,	I-O
or	I-O
pipe	I-O
use	I-O
at	O
each	O
time	O
interval	O
correlated	O
with	O
significantly	O
increased	O
caloric	B-O
intake	I-O
in	O
males	O
but	O
not	O
in	O
females	O
.	O


In	O
both	O
males	B-P
and	I-P
females	I-P
,	I-P
tobacco	I-O
users	I-O
consumed	I-O
more	I-O
fat	I-O
,	I-O
cholesterol	I-O
,	I-O
and	I-O
alcohol	I-O
.	I-O


Female	B-P
smokers	I-P
had	O
higher	O
serum	B-O
low-density	I-O
lipoprotein	I-O
(	I-O
LDL	I-O
)	I-O
/high-density	I-O
lipoprotein	I-O
(	I-O
HDL	I-O
)	I-O
ratios	I-O
and	I-O
triglycerides	I-O
.	I-O


Serum	B-O
cholesterols	I-O
,	I-O
LDL/HDL	I-O
ratios	I-O
,	I-O
LDL	I-O
cholesterols	I-O
,	I-O
and	I-O
triglyceride	I-O
determinations	I-O
in	O
male	B-P
tobacco	I-P
users	I-P
significantly	O
exceeded	O
those	O
in	O
nonsmoking	O
males	O
.	O


HDL	B-O
cholesterols	I-O
were	O
lower	O
in	O
both	O
female	B-P
and	I-P
male	I-P
tobacco	I-P
users	I-P
.	I-P


Nutrient	B-O
intake	I-O
of	O
former	B-P
tobacco	I-P
users	I-P
resembled	O
that	O
of	O
nonusers	O
rather	O
than	O
current	O
users	O
.	O


CONCLUSIONS	O
A	O
significant	O
association	O
exists	O
between	O
smoking	O
and	O
a	O
diet	B-O
with	I-O
higher	I-O
risks	I-O
of	I-O
atherosclerosis	I-O
,	I-O
cancer	I-O
,	I-O
and	I-O
other	I-O
degenerative	I-O
diseases	I-O
.	I-O


The	O
strong	O
association	O
of	O
tobacco	O
with	O
heart	O
disease	O
,	O
stroke	O
,	O
vasculopathies	O
,	O
and	O
various	O
malignancies	O
may	O
be	O
in	O
part	O
due	O
to	O
its	O
association	O
with	O
a	O
higher	O
fat	B-O
diet	O
.	O


The	O
higher	O
fat	O
diet	O
of	O
tobacco	O
users	O
probably	O
accounts	O
in	O
part	O
for	O
their	O
higher	O
risk	O
of	O
developing	O
type	O
2	O
diabetes	O
and	O
hyperlipidemia	O
.	O


Tobacco	O
users	O
should	O
be	O
informed	O
about	O
the	O
diet	B-O
and	I-O
tobacco	I-O
use	I-O
association	O
.	O


Blockade	O
of	O
endogenous	O
growth	O
hormone-releasing	O
hormone	O
receptors	O
dissociates	O
nocturnal	B-O
growth	I-O
hormone	I-O
secretion	I-O
and	O
slow-wave	B-O
sleep	I-O
.	I-O


OBJECTIVES	O
A	O
temporal	O
association	O
between	O
non-rapid	O
eye	O
movement	O
(	O
NREM	O
)	O
sleep	O
stages	O
3	O
and	O
4	O
and	O
nocturnal	O
augmentation	O
of	O
GH	O
release	O
was	O
found	O
long	O
ago	O
,	O
yet	O
the	O
precise	O
mechanism	O
for	O
this	O
association	O
has	O
not	O
been	O
identified	O
.	O


It	O
has	O
been	O
shown	O
,	O
however	O
that	O
pulsatile	O
GHRH	O
administration	O
increases	O
both	O
slow-wave	B-O
sleep	I-O
(	I-O
SWS	I-O
)	I-O
and	O
GH	B-O
.	I-O


Based	O
on	O
these	O
data	O
,	O
a	O
role	O
for	O
GHRH	O
as	O
an	O
inducer	O
of	O
SWS	O
was	O
proposed	O
.	O


To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
performed	O
the	O
corollary	O
experiment	O
whereby	O
the	O
action	O
of	O
endogenous	O
GHRH	O
has	O
been	O
antagonized	O
.	O


DESIGN	O
Healthy	B-P
men	I-P
(	I-P
20-33	I-P
years	I-P
old	I-P
)	I-P
had	O
an	O
infusion	B-I
of	I-I
GHRH	I-I
antagonist	I-I
(	I-I
(	I-I
N-Ac-Tyr	I-I
(	I-I
1	I-I
)	I-I
,	I-I
D-Arg	I-I
(	I-I
2	I-I
)	I-I
)	I-I
GHRH-29	I-I
(	I-I
NH	I-I
(	I-I
2	I-I
)	I-I
)	I-I
)	I-I
or	I-I
saline	I-I
for	I-I
a	I-I
12-h	I-I
period	I-I
,	O
between	O
2100	O
and	O
0900	O
h.	O
An	O
i.v	O
.	O


bolus	O
of	O
GHRH	B-I
was	O
given	O
at	O
0700	O
h	O
and	O
GH	O
samples	O
were	O
drawn	O
from	O
0700	O
to	O
0900	O
h	O
to	O
document	O
the	O
efficacy	O
of	O
GH	B-O
suppression	O
by	O
the	O
GHRH	O
antagonist	O
.	O


METHODS	O
A	O
limited	O
montage	O
sleep	O
study	O
was	O
recorded	O
from	O
2300	O
to	O
0700	O
h	O
during	O
each	O
admission	O
.	O


Plasma	B-O
GH	I-O
concentrations	I-O
were	O
analyzed	O
by	O
the	O
use	O
of	O
a	O
sensitive	O
chemiluminometric	O
assay	O
.	O


RESULTS	O
Effectiveness	B-O
of	O
the	O
GHRH	O
antagonist	O
was	O
validated	O
in	O
all	O
subjects	O
by	O
demonstrating	O
93+/-1.8	O
%	O
(	O
P=0.012	O
)	O
suppression	B-O
of	I-O
GH	I-O
response	I-O
to	O
a	O
GHRH	O
bolus	O
.	O


Polysomnography	O
demonstrated	O
that	O
the	O
percentage	O
of	O
SWS	B-O
was	O
not	O
different	O
when	O
saline	O
and	O
GHRH	O
antagonist	O
nights	O
were	O
compared	O
(	O
P=0.607	O
)	O
;	O
other	O
quantifiable	O
sleep	B-O
parameters	I-O
were	O
also	O
unchanged	O
.	O


CONCLUSIONS	O
We	O
conclude	O
that	O
endogenous	O
GHRH	O
is	O
indispensable	O
for	O
the	O
nocturnal	O
augmentation	O
of	O
GH	O
secretion	O
,	O
but	O
that	O
it	O
is	O
unlikely	O
to	O
participate	O
in	O
the	O
genesis	O
of	O
SWS	O
.	O


Reducing	O
iodine	O
load	O
in	O
hepatic	O
CT	O
for	O
patients	B-P
with	I-P
chronic	I-P
liver	I-P
disease	I-P
with	O
a	O
combination	B-I
of	I-I
low-tube-voltage	I-I
and	I-I
adaptive	I-I
statistical	I-I
iterative	I-I
reconstruction	I-I
.	I-I


PURPOSE	O
To	O
prospectively	O
assess	O
the	O
effect	O
of	O
reduced	O
iodine	O
load	O
to	O
contrast	O
enhancement	O
,	O
image	O
quality	O
,	O
and	O
detectability	O
of	O
hepatocellular	O
carcinomas	O
(	O
HCCs	O
)	O
in	O
hepatic	O
CT	O
with	O
a	O
combination	O
of	O
80	B-I
kVp	I-I
tube	I-I
voltage	I-I
setting	I-I
and	I-I
adaptive	I-I
statistical	I-I
iterative	I-I
reconstruction	I-I
(	I-I
ASIR	I-I
)	I-I
technique	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
liver	I-P
disease	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
This	O
HIPAA-compliant	O
study	O
was	O
approved	O
by	O
our	O
institutional	O
review	O
board	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
in	O
all	O
patients	O
.	O


During	O
a	O
recent	O
9-month	O
period	O
,	O
170	B-P
consecutive	I-P
patients	I-P
(	I-P
114	I-P
men	I-P
and	I-P
56	I-P
women	I-P
;	I-P
age	I-P
range	I-P
,	I-P
40-85	I-P
years	I-P
;	I-P
mean	I-P
,	I-P
67.7	I-P
years	I-P
)	I-P
with	I-P
suspected	I-P
chronic	I-P
liver	I-P
diseases	I-P
were	O
randomized	B-I
into	I-I
three	I-I
CT	I-I
groups	I-I
according	O
to	O
the	O
following	O
iodine-load	B-I
and	I-I
tube-voltage	I-I
protocols	I-I
:	I-I
600	I-I
milligram	I-I
per	I-I
kilogram	I-I
body	I-I
weight	I-I
(	I-I
mg/kg	I-I
)	I-I
iodine	I-I
load	I-I
and	I-I
120	I-I
peak	I-I
kilovolt	I-I
(	I-I
kVp	I-I
)	I-I
tube	I-I
voltage	I-I
setting	I-I
(	I-I
600-120	I-I
group	I-I
)	I-I
,	I-I
500	I-I
mg/kg	I-I
and	I-I
80	I-I
kVp	I-I
(	I-I
500-80	I-I
group	I-I
)	I-I
,	I-I
and	I-I
400mg/kg	I-I
and	I-I
80	I-I
kVp	I-I
(	I-I
400-80	I-I
group	I-I
)	I-I
.	O


Analysis	O
of	O
variance	O
was	O
conducted	O
to	O
evaluate	O
differences	O
in	O
CT	B-O
number	I-O
,	I-O
background	I-O
noise	I-O
,	I-O
signal-to-noise	I-O
ratio	I-O
(	I-O
SNR	I-O
)	I-O
,	I-O
effective	I-O
dose	I-O
,	I-O
HCC-to-liver	I-O
contrast-to-noise	I-O
ratio	I-O
(	I-O
CNR	I-O
)	I-O
,	I-O
and	I-O
figure	I-O
of	I-O
merit	I-O
(	I-O
FOM	I-O
)	I-O
.	I-O


Sensitivity	B-O
,	I-O
specificity	I-O
,	I-O
and	I-O
area	I-O
under	I-O
the	I-O
receiver-operating-characteristic	I-O
curve	I-O
(	I-O
AUC	I-O
)	I-O
were	O
compared	O
to	O
assess	O
the	O
detectability	O
of	O
HCCs	O
.	O


RESULTS	O
Vascular	B-O
and	I-O
hepatic	I-O
enhancement	I-O
in	O
the	O
400-80	O
and	O
500-80	O
groups	O
was	O
comparable	O
to	O
or	O
greater	O
than	O
that	O
in	O
the	O
600-120	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O


Subjective	B-O
image	I-O
quality	I-O
was	O
comparable	O
among	O
the	O
three	O
groups	O
.	O


Sensitivity	B-O
,	I-O
specificity	I-O
,	I-O
and	I-O
AUC	I-O
for	O
detecting	B-O
HCCs	I-O
were	O
comparable	O
among	O
the	O
groups	O
.	O


The	O
effective	O
dose	O
was	O
kept	O
low	O
(	O
3.3-4.1	O
mSv	O
)	O
in	O
all	O
three	O
groups	O
.	O


CONCLUSION	O
Iodine	O
load	O
can	O
be	O
reduced	O
by	O
33	O
%	O
in	O
CT	O
of	O
the	O
liver	O
with	O
a	O
combination	O
of	O
80	B-I
kVp	I-I
tube	I-I
voltage	I-I
setting	I-I
and	I-I
ASIR	I-I
technique	I-I
,	O
without	O
compromising	O
the	O
contrast	B-O
enhancement	I-O
,	I-O
image	I-O
quality	I-O
,	O
and	O
detection	B-O
of	I-O
HCCs	I-O
.	I-O


Safety	O
and	O
benefit	O
of	O
discontinuing	O
statin	B-I
therapy	I-I
in	O
the	O
setting	O
of	O
advanced	B-P
,	I-P
life-limiting	I-P
illness	I-P
:	I-P
a	O
randomized	O
clinical	O
trial	O
.	O


IMPORTANCE	O
For	O
patients	B-P
with	I-P
limited	I-P
prognosis	I-P
,	O
some	O
medication	O
risks	O
may	O
outweigh	O
the	O
benefits	O
,	O
particularly	O
when	O
benefits	O
take	O
years	O
to	O
accrue	O
;	O
statins	O
are	O
one	O
example	O
.	O


Data	O
are	O
lacking	O
regarding	O
the	O
risks	O
and	O
benefits	O
of	O
discontinuing	O
statin	O
therapy	O
for	O
patients	B-P
with	I-P
limited	I-P
life	I-P
expectancy	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
safety	O
,	O
clinical	O
,	O
and	O
cost	O
impact	O
of	O
discontinuing	O
statin	B-I
medications	O
for	O
patients	B-P
in	I-P
the	I-P
palliative	I-P
care	I-P
setting	I-P
.	I-P


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
This	O
was	O
a	O
multicenter	O
,	O
parallel-group	O
,	O
unblinded	O
,	O
pragmatic	O
clinical	O
trial	O
.	O


Eligibility	B-P
included	I-P
adults	I-P
with	I-P
an	I-P
estimated	I-P
life	I-P
expectancy	I-P
of	I-P
between	I-P
1	I-P
month	I-P
and	I-P
1	I-P
year	I-P
,	I-P
statin	I-P
therapy	I-P
for	I-P
3	I-P
months	I-P
or	I-P
more	I-P
for	I-P
primary	I-P
or	I-P
secondary	I-P
prevention	I-P
of	I-P
cardiovascular	I-P
disease	I-P
,	I-P
recent	I-P
deterioration	I-P
in	I-P
functional	I-P
status	I-P
,	I-P
and	I-P
no	I-P
recent	I-P
active	I-P
cardiovascular	I-P
disease	I-P
.	I-P


Participants	O
were	O
randomized	O
to	O
either	O
discontinue	B-I
or	I-I
continue	I-I
statin	I-I
therapy	I-I
and	O
were	O
monitored	O
monthly	O
for	O
up	O
to	O
1	O
year	O
.	O


The	O
study	O
was	O
conducted	B-P
from	I-P
June	I-P
3	I-P
,	I-P
2011	I-P
,	I-P
to	I-P
May	I-P
2	I-P
,	I-P
2013	I-P
.	I-P


All	O
analyses	O
were	O
performed	O
using	O
an	O
intent-to-treat	O
approach	O
.	O


INTERVENTIONS	O
Statin	B-I
therapy	I-I
was	O
withdrawn	O
from	O
eligible	O
patients	O
who	O
were	O
randomized	O
to	O
the	O
discontinuation	O
group	O
.	O


Patients	O
in	O
the	O
continuation	O
group	O
continued	O
to	O
receive	B-I
statins	I-I
.	I-I


MAIN	O
OUTCOMES	O
AND	O
MEASURES	O
Outcomes	O
included	O
death	B-O
within	I-O
60	I-O
days	I-O
(	I-O
primary	I-O
outcome	I-O
)	I-O
,	I-O
survival	I-O
,	I-O
cardiovascular	I-O
events	I-O
,	I-O
performance	I-O
status	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
(	I-O
QOL	I-O
)	I-O
,	I-O
symptoms	I-O
,	I-O
number	I-O
of	I-O
nonstatin	I-O
medications	I-O
,	I-O
and	I-O
cost	I-O
savings	I-O
.	I-O


RESULTS	O
A	B-P
total	I-P
of	I-P
381	I-P
patients	I-P
were	I-P
enrolled	I-P
;	I-P
189	O
of	O
these	O
were	O
randomized	O
to	O
discontinue	O
statins	B-I
,	O
and	O
192	O
were	O
randomized	O
to	O
continue	O
therapy	O
.	O


Mean	B-O
(	I-O
SD	I-O
)	I-O
age	I-O
was	I-P
74.1	I-P
(	I-P
11.6	I-P
)	I-P
years	I-P
,	I-P
22.0	I-P
%	I-P
of	I-P
the	I-P
participants	I-P
were	I-P
cognitively	I-P
impaired	I-P
,	I-P
and	I-P
48.8	I-P
%	I-P
had	I-P
cancer	I-P
.	I-P


The	O
proportion	O
of	O
participants	O
in	O
the	O
discontinuation	O
vs	O
continuation	O
groups	O
who	O
died	O
within	O
60	O
days	O
was	O
not	O
significantly	O
different	O
(	O
23.8	O
%	O
vs	O
20.3	O
%	O
;	O
90	O
%	O
CI	O
,	O
-3.5	O
%	O
to	O
10.5	O
%	O
;	O
P=.36	O
)	O
and	O
did	O
not	O
meet	O
the	O
noninferiority	O
end	O
point	O
.	O


Total	B-O
QOL	I-O
was	O
better	O
for	O
the	O
group	O
discontinuing	O
statin	O
therapy	O
(	O
mean	O
McGill	O
QOL	O
score	O
,	O
7.11	O
vs	O
6.85	O
;	O
P=.04	O
)	O
.	O


Few	O
participants	O
experienced	O
cardiovascular	B-O
events	I-O
(	O
13	O
in	O
the	O
discontinuation	O
group	O
vs	O
11	O
in	O
the	O
continuation	O
group	O
)	O
.	O


Mean	B-O
cost	I-O
savings	I-O
were	O
$	O
3.37	O
per	O
day	O
and	O
$	O
716	O
per	O
patient	O
.	O


CONCLUSIONS	O
AND	O
RELEVANCE	O
This	O
pragmatic	O
trial	O
suggests	O
that	O
stopping	O
statin	O
medication	O
therapy	O
is	O
safe	O
and	O
may	O
be	O
associated	O
with	O
benefits	O
including	O
improved	B-O
QOL	I-O
,	I-O
use	I-O
of	I-O
fewer	I-O
nonstatin	I-O
medications	I-O
,	I-O
and	I-O
a	I-O
corresponding	I-O
reduction	I-O
in	I-O
medication	I-O
costs	I-O
.	I-O


Thoughtful	O
patient-provider	O
discussions	O
regarding	O
the	O
uncertain	O
benefit	O
and	O
potential	O
decrement	O
in	O
QOL	O
associated	O
with	O
statin	O
continuation	O
in	O
this	O
setting	O
are	O
warranted	O
.	O


TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT01415934	O
.	O


Comparison	O
of	O
long-term	B-O
efficacy	I-O
and	I-O
safety	I-O
of	O
risperidone	B-I
and	I-I
haloperidol	I-I
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autistic	I-P
disorder	I-P
.	I-P


An	O
open	O
label	O
maintenance	O
study	O
.	O


BACKGROUND	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
safety	B-O
,	I-O
efficacy	I-O
and	I-O
tolerability	I-O
of	O
risperidone	B-I
in	O
comparison	O
with	O
haloperidol	B-I
in	O
the	O
long-term	O
treatment	O
of	O
autistic	B-P
disorder	I-P
.	I-P


METHODS	O
This	O
was	O
an	O
open-label	O
continuation	O
study	O
of	O
the	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
trial	O
of	O
risperidone	B-I
and	I-I
haloperidol	I-I
study	O
for	O
12	O
week	O
in	B-P
autistic	I-P
children	I-P
and	I-P
adolescents	I-P
.	I-P


A	B-P
total	I-P
of	I-P
28	I-P
subjects	I-P
between	I-P
8	I-P
and	I-P
18	I-P
ages	I-P
with	I-P
autistic	I-P
disorder	I-P
were	O
enrolled	O
to	O
the	O
open	O
label	O
phase	O
of	O
the	O
study	O
.	O


Behavioral	B-O
rating	I-O
scales	I-O
(	I-O
Clinical	I-O
Global	I-O
Impression	I-O
Scale	I-O
[	I-O
CGI-I	I-O
]	I-O
,	I-O
Ritvo-Freeman	I-O
Real	I-O
Life	I-O
Rating	I-O
Scale	I-O
[	I-O
RF-RLRS	I-O
]	I-O
)	I-O
,	I-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
[	I-O
ABC	I-O
]	I-O
,	I-O
Turgay	I-O
DSM-IV	I-O
Pervasive	I-O
Developmental	I-O
Disorder	I-O
Rating	I-O
Scale	I-O
[	I-O
TPDDRS	I-O
]	I-O
)	I-O
and	I-O
safety	I-O
assessment	I-O
scales	I-O
(	I-O
Extrapyramidal	I-O
Symptoms	I-O
Rating	I-O
Scale	I-O
[	I-O
ESRS	I-O
]	I-O
,	I-O
UKU-Side	I-O
Effect	I-O
Rating	I-O
Scale	I-O
)	I-O
were	O
performed	O
at	O
12	O
,	O
16	O
,	O
20	O
and	O
24	O
weeks	O
,	O
following	O
the	O
12	O
week	O
double-blind	O
phase	O
.	O


Risperidone	B-I
and	I-I
haloperidol	I-I
treatments	O
were	O
applied	O
with	O
a	O
once	O
daily	O
dosage	O
regimen	O
as	O
0.01-0.08	O
mg/kg/day	O
.	O


RESULTS	O
Risperidone	O
led	O
to	O
a	O
significant	O
greater	O
reduction	B-O
on	O
CGI	B-O
scale	I-O
.	I-O


There	O
was	O
significant	O
improvement	O
on	O
RF-RLRS	B-O
sensory	I-O
motor	I-O
and	I-O
language	I-O
subscale	I-O
and	I-O
ABC	I-O
scores	I-O
in	O
risperidone	O
group	O
.	O


Weight	B-O
gain	I-O
was	O
observed	O
more	O
frequently	O
in	O
the	O
haloperidol	O
group	O
at	O
week	O
24	O
.	O


CONCLUSIONS	O
These	O
results	O
demonstrate	O
that	O
risperidone	O
is	O
more	O
efficacious	O
and	O
well	O
tolerated	O
than	O
haloperidol	O
in	O
the	O
long-term	O
maintenance	O
treatment	O
of	O
autistic	O
disorder	O
.	O


Offering	O
personalized	B-I
health	I-I
behavior	I-I
feedback	I-I
did	O
not	O
increase	O
response	B-O
rate	I-O
:	I-O
a	O
randomized	B-P
controlled	O
trial	O
.	O


Reliance	O
on	O
visual	B-O
information	I-O
after	O
stroke	O
.	O


Part	O
II	O
:	O
Effectiveness	O
of	O
a	O
balance	O
rehabilitation	B-I
program	I-I
with	O
visual	B-I
cue	I-I
deprivation	I-I
after	I-P
stroke	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


OBJECTIVE	O
To	O
test	O
the	O
hypothesis	O
that	O
balance	O
rehabilitation	B-I
with	I-I
visual	I-I
cue	I-I
deprivation	I-I
improves	O
balance	B-O
more	O
effectively	O
than	O
rehabilitation	B-I
with	I-I
free	I-I
vision	I-I
.	I-I


DESIGN	O
Single-blind	O
,	O
randomized	O
controlled	O
trial	O
.	O


SETTING	O
Public	B-P
rehabilitation	I-P
center	I-P
in	I-P
France	I-P
.	I-P


PARTICIPANTS	O
Twenty	B-P
patients	I-P
with	I-P
hemiplegia	I-P
after	I-P
a	I-P
single-hemisphere	I-P
stroke	I-P
that	I-P
occurred	I-P
at	I-P
least	I-P
12	I-P
months	I-P
before	I-P
the	I-P
study	I-P
.	I-P


INTERVENTION	O
Patients	B-I
were	I-I
randomly	I-I
assigned	I-I
to	I-I
1	I-I
of	I-I
2	I-I
balance	I-I
rehabilitation	I-I
programs-with	I-I
and	I-I
without	I-I
visual	I-I
cue	I-I
deprivation	I-I
.	I-I


In	B-I
all	I-I
other	I-I
respects	I-I
,	I-I
the	I-I
programs	I-I
were	I-I
identical	I-I
.	I-I


Each	O
lasted	O
for	O
1	O
hour	O
and	O
was	O
implemented	O
5	O
days	O
a	O
week	O
for	O
4	O
weeks	O
.	O


All	B-P
patients	I-P
completed	I-P
the	I-P
program	I-P
.	I-P


Mean	O
outcome	O
measures	O
Balance	B-O
under	O
6	O
sensory	O
conditions	O
was	O
assessed	O
by	O
computerized	O
dynamic	B-O
posturography	I-O
(	I-O
EquiTest	I-O
)	I-O
,	I-O
gait	I-O
velocity	I-O
,	I-O
timed	I-O
stair	I-O
climbing	I-O
,	I-O
and	I-O
self-assessment	I-O
of	I-O
ease	I-O
of	I-O
gait	I-O
before	I-O
and	I-O
after	I-O
program	I-O
completion	I-O
.	I-O


RESULTS	O
After	O
completing	O
the	O
program	O
,	O
balance	B-O
,	I-O
gait	I-O
velocity	I-O
,	I-O
and	I-O
self-assessment	I-O
of	I-O
gait	I-O
improved	O
significantly	O
in	O
all	O
patients	O
.	O


The	O
improvements	O
in	O
gait	B-O
velocity	I-O
(	O
P=	O
.03	O
)	O
and	O
timed	B-O
stair	I-O
climbing	I-O
(	O
P=	O
.01	O
)	O
correlated	O
significantly	O
with	O
improved	O
balance	O
.	O


Balance	B-O
improved	O
more	O
in	O
the	O
vision-deprived	O
group	O
than	O
in	O
the	O
free-vision	O
group	O
.	O


CONCLUSIONS	O
Balance	B-O
improved	O
more	O
after	O
rehabilitation	O
with	O
visual	B-I
deprivation	I-I
than	O
with	O
free	B-I
vision	I-I
.	I-I


Visual	O
overuse	O
may	O
be	O
a	O
compensatory	O
strategy	O
for	O
coping	O
with	O
initial	O
imbalance	O
exacerbated	O
by	O
traditional	O
rehabilitation	O
.	O


The	O
problem	O
of	O
measurement	O
error	O
in	O
multisite	B-P
clinical	I-P
trials	I-P
.	I-P


The	O
implementation	O
of	O
a	O
multisite	B-P
,	O
randomized	O
,	O
clinical	O
psychopharmacologic	O
trial	O
involves	O
a	O
substantial	O
investment	O
of	O
time	O
and	O
effort	O
on	O
the	O
part	O
of	O
all	O
participants	O
.	O


Because	O
of	O
their	O
complexity	O
,	O
such	O
clinical	O
trials	O
present	O
unique	O
methodological	O
and	O
design	O
challenges	O
.	O


Indeed	O
,	O
it	O
is	O
not	O
uncommon	O
for	O
such	O
studies	O
to	O
conclude	O
with	O
uninterpretable	O
results	O
,	O
due	O
in	O
part	O
to	O
such	O
methodological	O
pitfalls	O
.	O


It	O
has	O
been	O
suggested	O
that	O
clarification	O
of	O
such	O
methodologic	O
dilemmas	O
is	O
one	O
of	O
the	O
most	O
important	O
challenges	O
facing	O
the	O
future	O
of	O
industry-sponsored	O
psychopharmacologic	O
drug	O
development	O
.	O


Among	O
the	O
many	O
factors	O
that	O
may	O
contribute	O
to	O
problematic	O
clinical	B-P
trial	I-P
results	I-P
,	O
error	O
in	O
measuring	O
the	O
phenomena	O
being	O
studied	O
is	O
of	O
particular	O
concern	O
.	O


In	O
this	O
article	O
,	O
we	O
describe	O
the	O
outcome	O
of	O
an	O
intensive	B-I
series	I-I
of	I-I
interrater	I-I
reliability	I-I
training	I-I
sessions	I-I
for	O
the	O
17-item	B-I
Hamilton	I-O
Depression	I-O
Rating	I-O
Scale	I-O
conducted	O
at	O
the	O
start	O
of	O
a	O
Phase	B-P
II	I-P
multisite	I-P
clinical	I-P
drug	I-P
trial	I-P
.	I-P


The	O
data	O
underscore	O
the	O
magnitude	B-O
of	I-O
error	I-O
present	I-O
in	O
such	O
a	O
test	O
setting	O
and	O
provide	O
preliminary	O
evidence	O
for	O
the	O
potential	O
effect	O
of	O
this	O
problem	O
on	O
the	O
detection	O
of	O
clinical	O
change	O
.	O


Participant	O
characteristics	O
and	O
intervention	O
processes	O
associated	O
with	O
reductions	O
in	O
television	B-O
viewing	I-O
in	O
the	O
High	O
Five	O
for	O
Kids	B-P
study	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
High	B-I
Five	I-I
for	I-I
Kids	I-I
intervention	I-I
effect	O
on	O
television	B-O
within	O
subgroups	O
,	O
examine	O
participant	O
characteristics	O
associated	O
with	O
process	O
measures	O
and	O
assess	O
perceived	O
helpfulness	O
of	O
television	O
intervention	O
components	O
.	O


METHOD	O
High	B-P
Five	I-P
(	I-P
randomized	I-P
controlled	I-P
trial	I-P
of	I-P
445	I-P
overweight/obese	I-P
2-7	I-P
year-olds	I-P
in	I-P
Massachusetts	I-P
[	I-P
2006-2008	I-P
]	I-P
)	I-P
reduced	I-I
television	I-I
by	I-I
0.36	I-I
h/day	I-I
.	I-I


1-year	O
effects	O
on	O
television	O
viewing	O
,	O
stratified	O
by	O
subgroup	O
,	O
were	O
assessed	O
using	O
linear	O
regression	O
.	O


Among	B-P
intervention	I-P
participants	I-P
(	I-P
n=253	I-P
)	I-P
,	O
associations	O
of	O
intervention	B-I
component	I-I
helpfulness	O
with	O
television	B-O
reduction	O
were	O
examined	O
using	O
linear	O
regression	O
and	O
associations	O
of	O
participant	O
characteristics	O
with	O
processes	O
linked	O
to	O
television	O
reduction	O
(	O
choosing	O
television	O
and	O
completing	O
intervention	O
visits	O
)	O
were	O
examined	O
using	O
logistic	O
regression	O
.	O


RESULTS	O
High	O
Five	O
reduced	O
television	O
across	O
subgroups	O
.	O


Parents	B-P
of	I-P
Latino	I-P
(	I-P
versus	I-P
white	I-P
)	I-P
children	I-P
had	O
lower	O
odds	O
of	O
completing	B-O
≥2	I-O
study	I-O
visits	I-O
(	O
Odds	O
Ratio	O
:	O
0.39	O
[	O
95	O
%	O
Confidence	O
Interval	O
:	O
0.18	O
,	O
0.84	B-P
]	I-P
)	I-P
.	I-P


Parents	B-P
of	I-P
black	I-P
(	I-P
versus	I-P
white	I-P
)	I-P
children	I-P
had	O
higher	O
odds	O
of	B-O
choosing	I-O
television	I-O
(	O
Odds	O
Ratio	O
:	O
2.23	O
[	O
95	O
%	O
Confidence	O
Interval	O
:	O
1.08	O
,	O
4.59	O
]	O
)	O
,	O
as	O
did	B-P
parents	I-P
of	I-P
obese	I-P
(	I-P
versus	I-P
overweight	I-P
)	I-P
children	I-P
and	I-P
children	I-P
watching	I-P
≥2	I-P
h/day	I-P
(	I-P
versus	I-P
<	I-P
2	I-P
)	I-P
at	I-P
baseline	I-P
.	O


Greater	O
perceived	B-O
helpfulness	I-O
was	O
associated	O
with	O
greater	O
television	O
reduction	O
.	O


CONCLUSION	B-I
Clinic-based	I-I
motivational	I-I
interviewing	I-I
reduces	I-O
television	I-O
viewing	I-O
in	I-P
children	I-I
.	I-I


Low	B-I
cost	I-I
education	I-I
approaches	I-I
(	O
e.g.	O
,	O
printed	O
materials	O
)	O
may	O
be	O
well-received	O
.	O


Parents	B-P
of	I-P
children	I-P
at	I-P
higher	I-P
obesity	I-P
risk	I-P
could	O
be	O
more	O
motivated	O
to	O
reduce	B-O
television	I-O
.	O


Randomized	O
comparative	O
study	O
of	O
tegafur/uracil	B-I
and	I-I
oral	I-I
leucovorin	I-I
versus	I-I
parenteral	I-I
fluorouracil	I-I
and	I-I
leucovorin	I-I
in	O
patients	B-P
with	I-P
previously	I-P
untreated	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	I-P


PURPOSE	O
This	O
phase	O
III	O
study	O
compared	O
the	O
time	B-O
to	I-O
progression	I-O
(	I-O
TTP	I-O
)	I-O
of	O
an	O
oral	O
regimen	O
of	O
dihydropyrimidine	B-I
dehydrogenase	I-I
inhibitory	I-I
fluoropyrimidine	I-I
composed	O
of	O
a	O
fixed	O
combination	O
of	O
tegafur	B-I
and	I-I
uracil	I-I
in	O
a	O
1:4	O
molar	O
ratio	O
(	O
UFT	O
)	O
and	O
leucovorin	B-I
(	O
LV	O
)	O
to	O
intravenous	B-I
(	I-I
IV	I-I
)	I-I
fluorouracil	I-I
(	O
5-FU	O
)	O
and	B-I
LV	I-I
in	O
previously	B-P
untreated	I-P
metastatic	I-P
colorectal	I-P
carcinoma	I-P
(	I-P
CRC	I-P
)	I-P
patients	I-P
.	I-P


Secondary	O
end	O
points	O
were	O
survival	B-O
,	I-O
tumor	I-O
response	I-O
,	I-O
safety	I-O
,	I-O
and	I-O
quality	I-O
of	I-O
life	I-O
.	I-O


PATIENTS	O
AND	O
METHODS	O
Between	B-P
May	I-P
1996	I-P
and	I-P
July	I-P
1997	I-P
,	I-P
380	I-P
patients	I-P
were	O
randomized	O
to	O
receive	O
either	O
UFT	B-I
(	O
300	O
mg/m	O
(	O
2	O
)	O
/d	O
)	O
and	O
LV	B-I
(	O
90	O
mg/d	O
)	O
,	O
administered	O
for	O
28	O
days	O
every	O
35	O
days	O
,	O
or	O
5-FU	B-I
(	O
425	O
mg/m	O
(	O
2	O
)	O
/d	O
)	O
and	O
LV	B-I
(	O
20	O
mg/m	O
(	O
2	O
)	O
/d	O
)	O
,	O
given	O
IV	O
for	O
5	O
days	O
every	O
35	O
days	O
.	O


RESULTS	O
No	O
statistically	O
significant	O
difference	O
in	O
TTP	B-O
was	O
observed	O
between	O
treatments	O
.	O


With	O
320	B-P
events	I-P
assessed	O
,	O
the	O
median	O
TTP	B-O
was	O
3.4	O
months	O
(	O
95	O
%	O
Confidence	O
interval	O
[	O
CI	O
]	O
,	O
2.6	O
to	O
3.8	O
)	O
on	O
UFT/LV	O
and	O
3.3	O
months	O
(	O
95	O
%	O
CI	O
,	O
2.5	O
to	O
3.7	O
)	O
on	O
5-FU/LV	O
(	O
P	O
=.591	O
,	O
stratified	O
log-rank	O
test	O
)	O
.	O


There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
survival	B-O
,	I-O
tumor	I-O
response	I-O
,	I-O
duration	I-O
of	I-O
response	I-O
,	I-O
and	I-O
time	I-O
to	I-O
response	I-O
.	I-O


Substantial	O
safety	B-O
benefits	I-O
were	O
observed	O
in	O
patients	O
treated	O
with	O
UFT/LV	O
.	O


They	O
experienced	O
significantly	O
less	O
stomatitis/mucositis	B-O
(	O
P	O
<	O
.001	O
)	O
and	O
myelosuppression	B-O
,	O
resulting	O
in	O
fewer	O
episodes	O
of	O
febrile	B-O
neutropenia	I-O
(	O
P	O
<	O
.001	O
)	O
and	O
less	O
documented	B-O
infection	I-O
(	O
P	O
=.04	O
)	O
.	O


Concomitant	O
medication	O
usage	O
was	O
significantly	O
greater	O
on	O
5-FU/LV	O
(	O
P	O
=.010	O
)	O
.	O


With	O
respect	O
to	O
quality	B-O
of	I-O
life	I-O
,	O
after	O
correcting	O
for	O
baseline	O
imbalances	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
treatments	O
for	O
any	O
scale	O
,	O
except	O
diarrhea	B-O
.	I-O


CONCLUSION	O
The	O
oral	O
UFT/LV	O
regimen	O
failed	O
to	O
achieve	O
improved	O
TTP	B-O
;	I-O
however	O
,	O
the	O
study	O
confirms	O
significant	O
safety	O
improvements	O
compared	O
with	O
bolus	O
IV	O
5-FU/LV	O
for	O
the	O
first-line	O
treatment	O
of	O
metastatic	O
CRC	O
.	O


Direct	B-I
aortic	I-I
cannulation	I-I
in	O
minimally	B-P
invasive	I-P
mitral-valve	I-P
operations	I-P
.	I-P


The	O
minimally	B-I
invasive	I-I
Port-Access	I-I
(	O
Heartport	O
,	O
Redwood	O
City	O
,	O
CA	O
)	O
approach	O
in	O
mitral-valve	O
operations	O
originally	O
required	O
femoral	B-I
arterial	I-I
cannulation	I-I
,	O
which	O
is	O
considered	O
a	O
disadvantage	O
,	O
especially	O
in	O
patients	B-P
with	I-P
peripheral	I-P
vessel	I-P
disease	I-P
.	I-P


In	O
this	O
study	O
20	B-P
patients	I-P
were	I-P
prospectively	I-P
randomized	I-P
into	I-P
2	I-P
groups	I-P
,	I-P
to	I-P
undergo	I-P
either	I-P
standard	I-I
femoral	I-I
(	I-I
group	I-I
A	I-I
)	I-I
or	I-I
direct	I-I
aortic	I-I
cannulation	I-I
(	I-P
group	I-P
B	I-P
)	I-P
.	I-P


Pre-	O
and	O
postoperative	O
data	O
as	O
well	O
as	O
markers	O
for	O
myocardial	O
damage	O
were	O
assessed	O
.	O


Postoperatively	O
,	O
patients	O
of	O
group	O
B	O
showed	O
lower	O
levels	B-O
of	I-O
damage	I-O
,	O
indicating	O
that	O
direct	B-I
aortic	I-I
cannulation	I-I
might	O
provide	O
better	O
myocardial	O
protection	O
.	O


Furthermore	O
,	O
the	O
direct	B-I
aortic	I-I
cannulation	I-I
technique	O
may	O
eliminate	O
complications	B-O
associated	O
with	O
the	O
standard	B-I
femoral	I-I
artery	I-I
cannulation	I-I
.	I-I


Anticholinergic	B-I
drugs	I-I
:	I-I
effects	O
on	O
oxygen	B-O
consumption	I-O
and	I-O
energy	I-O
expenditure	I-O
.	I-O


Premedication	O
has	O
been	O
shown	O
to	O
affect	O
both	O
oxygen	B-O
consumption	I-O
(	O
VO2	O
)	O
and	O
energy	B-O
expenditure	I-O
(	O
EE	O
)	O
.	O


The	O
metabolic	O
responses	O
to	O
anticholinergic	O
drugs	O
have	O
not	O
been	O
studied	O
.	O


In	O
this	O
study	O
the	O
effects	O
of	O
anticholinergic	B-I
drugs	I-I
on	O
VO2	O
and	O
EE	O
(	O
calculated	O
from	O
the	O
measured	O
rates	O
of	O
VO2	O
and	O
carbon	O
dioxide	O
production	O
[	O
VCO2	O
]	O
:	O
EE	O
[	O
kcal/d	O
]	O
=	O
3.581	O
x	O
VO2	O
[	O
L/d	O
]	O
+	O
1.448	O
x	O
VCO2	O
[	O
L/d	O
]	O
-	O
32.4	O
)	O
were	O
measured	O
in	O
six	B-P
healthy	I-P
female	I-P
volunteers	I-P
.	I-P


They	O
were	O
given	O
intramuscular	O
atropine	B-I
(	O
15	O
micrograms/kg	O
)	O
,	O
glycopyrrolate	B-I
(	O
8	O
micrograms/kg	O
)	O
,	O
scopolamine	B-I
(	O
8	O
micrograms/kg	O
)	O
,	O
and	B-I
placebo	I-I
in	O
a	O
random	O
double-blind	O
cross-over	O
design	O
.	O


The	O
consecutive	O
sessions	O
were	O
at	O
least	O
1	O
wk	O
apart	O
for	O
each	O
subject	O
.	O


VO2	B-O
and	I-O
EE	I-O
were	O
measured	O
using	O
an	O
indirect	O
calorimetry	O
(	O
Deltatrac	O
)	O
.	O


Cardiovascular	B-O
responses	I-O
were	O
assessed	O
using	O
standard	O
noninvasive	O
monitoring	O
.	O


Plasma	B-O
drug	I-O
concentrations	I-O
were	O
analyzed	O
using	O
a	O
sensitive	O
modification	O
of	O
radioreceptor	O
assay	O
.	O


Subjective	O
responses	O
were	O
measured	O
with	O
visual	B-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
.	O


Atropine	B-I
and	O
glycopyrrolate	B-I
induced	O
a	O
significant	O
increase	O
in	O
heart	B-O
rate	I-O
with	O
a	O
simultaneous	O
decrease	O
in	O
pressure	B-O
rate	I-O
quotient	I-O
(	I-O
PRQ	I-O
)	I-O
,	O
while	O
scopolamine	O
caused	O
a	O
significant	O
decrease	O
in	O
heart	B-O
rate	I-O
with	O
a	O
simultaneous	O
increase	B-O
in	I-O
PRQ	I-O
.	I-O


Scopolamine	B-I
significantly	O
decreased	O
both	O
VO2	B-O
and	I-O
EE	I-O
,	O
whereas	O
glycopyrrolate	B-I
increased	O
VO2	B-O
.	I-O


Atropine	B-I
had	O
no	O
significant	O
effect	O
on	O
metabolic	B-O
variables	I-O
.	I-O


Only	O
scopolamine	O
induced	O
sedation	B-O
in	O
this	O
study	O
.	O


In	O
conclusion	O
,	O
atropine	B-I
,	I-I
glycopyrrolate	I-I
,	O
and	O
scopolamine	B-I
differ	O
not	O
only	O
in	O
their	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
effects	O
,	O
but	O
also	O
in	O
their	O
effects	O
on	O
metabolism	O
.	O


S-phase	B-I
kinase-associated	I-I
protein	I-I
2	O
expression	O
in	O
laryngeal	B-P
squamous	I-P
cell	I-P
carcinomas	I-P
and	O
its	O
prognostic	O
implications	O
.	O


The	O
F-box	O
protein	O
S-phase	B-I
kinase-associated	I-I
protein	I-I
2	O
(	B-I
Skp2	I-I
)	I-I
positively	O
regulates	O
the	O
G1-S	O
transition	O
by	O
controlling	O
the	O
stability	O
of	O
several	O
G1	O
regulators	O
,	O
such	O
as	O
the	O
cell	O
cycle	O
inhibitor	O
p27kip1	O
.	O


However	O
,	O
the	O
clinical	O
significance	O
of	O
Skp2	B-I
in	O
patients	B-P
with	I-P
laryngeal	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
(	I-P
LSCC	I-P
)	I-P
remains	O
unknown	O
.	O


In	O
this	O
study	O
,	O
a	O
potential	O
distribution	O
of	O
Skp2	B-I
in	O
LSCC	O
and	O
its	O
clinical	O
implications	O
was	O
investigated	O
by	O
an	O
immunohistochemical	B-I
study	I-I
.	I-I


Overall	O
,	O
Skp2	B-O
overexpression	I-O
was	O
observed	O
in	O
36.7	B-P
%	I-P
(	I-P
37	I-P
of	I-P
102	I-P
)	I-P
patients	I-P
and	O
was	O
significantly	O
associated	O
with	O
lymph	O
node	O
metastasis	O
(	O
p=0.002	O
)	O
and	O
was	O
inversely	O
associated	O
with	O
p27kip1	O
expression	O
(	O
p=0.026	O
)	O
.	O


Survival	B-O
analysis	I-O
using	O
the	O
Kaplan-Meier	O
method	O
showed	O
that	O
Skp2	B-I
overexpression	O
was	O
significantly	O
associated	O
with	O
shorter	O
disease-free	B-O
and	I-O
overall	I-O
survival	I-O
(	O
p=0.0051	O
and	O
p=0.0002	O
,	O
respectively	O
)	O
.	O


When	O
Skp2	B-O
expression	I-O
and	I-O
p27kip1	I-O
expression	I-O
were	O
combined	O
,	O
patients	O
with	O
both	O
Skp2	B-I
overexpression	O
and	O
reduced	O
expression	B-O
of	I-O
p27kip1	I-O
revealed	O
poorest	B-O
disease-free	I-O
and	O
overall	B-O
survival	I-O
as	O
compared	O
to	O
the	O
other	O
cases	O
(	O
p=0.0017	O
and	O
p	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O


Additionally	O
,	O
in	O
early	O
stage	O
(	O
I	O
,	O
II	O
)	O
cases	O
,	O
Skp2	B-I
expression	O
was	O
also	O
revealed	O
to	O
possess	O
a	O
significant	O
prognostic	O
factor	O
in	O
overall	B-O
survival	I-O
(	I-O
p=0.0234	I-O
)	I-O
,	O
but	O
not	O
in	O
disease-free	B-O
survival	I-O
(	O
p=0.2055	O
)	O
.	O


By	O
multivariate	O
analysis	O
using	O
the	O
Cox	B-O
proportional	I-O
hazards	I-O
model	I-O
,	I-O
tumor	I-O
grade	I-O
,	I-O
tumor	I-O
size	I-O
,	I-O
clinical	I-O
stage	I-O
and	I-O
Skp2	I-O
expression	I-O
were	O
independent	O
prognostic	O
factors	O
both	O
in	O
disease-free	B-O
and	I-O
overall	I-O
survival	I-O
.	I-O


These	O
findings	O
indicated	O
that	O
Skp2	B-O
expression	I-O
was	O
closely	O
associated	O
with	O
tumor	O
progression	O
and	O
represented	O
an	O
independent	O
marker	O
for	O
prognosis	O
of	O
LSCC	O
.	O


Evaluation	O
of	O
oral	O
beclomethasone	B-I
dipropionate	I-I
for	O
prevention	O
of	O
acute	O
graft-versus-host	O
disease	O
.	O


Results	O
from	O
two	O
randomized	O
trials	O
have	O
shown	O
that	O
oral	B-I
beclomethasone	I-I
dipropionate	I-I
(	I-I
BDP	I-I
)	I-I
is	O
effective	O
for	O
treatment	O
of	O
acute	O
gastrointestinal	O
graft-versus-host	O
disease	O
.	O


Here	O
,	O
we	O
report	O
results	O
of	O
a	O
double-blind	O
,	O
randomized	O
placebo-controlled	O
phase	O
II	O
study	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
acute	O
graft-versus-host	O
disease	O
could	O
be	O
prevented	O
by	O
administration	O
of	O
oral	B-I
BDP	I-I
,	O
beginning	O
before	O
hematopoietic	O
cell	O
transplantation	O
and	O
continuing	O
until	O
day	O
75	O
after	O
hematopoietic	O
cell	O
transplantation	O
after	O
myeloablative	O
conditioning	O
.	O


Study	B-I
drug	I-I
(	I-I
BDP	I-I
or	I-I
placebo	I-I
)	I-I
was	O
administered	O
as	O
1-mg	O
immediate-release	O
formulation	O
plus	O
1-mg	O
delayed-release	O
formulation	O
orally	O
four	O
times	O
daily	O
.	O


According	O
to	O
the	O
primary	O
endpoint	O
,	O
systemic	B-O
glucocorticoid	I-O
treatment	I-O
for	I-O
graft-versus-host	I-O
disease	I-O
was	O
given	O
to	B-P
60	I-P
of	I-P
the	I-P
92	I-P
participants	I-P
(	I-P
65	I-P
%	I-P
)	I-P
in	I-P
the	I-P
BDP	I-I
arm	I-P
,	I-P
versus	I-P
31	I-P
of	I-P
46	I-P
participants	I-P
(	I-P
67	I-P
%	I-P
)	I-P
in	I-P
the	I-P
placebo	I-I
arm	I-P
.	O


The	O
secondary	B-O
efficacy	I-O
endpoints	I-O
showed	O
no	B-O
statistically	I-O
significant	I-O
differences	I-O
between	O
the	O
two	O
arms	O
.	O


The	O
proportion	B-O
of	I-O
participants	I-O
who	I-O
took	I-O
at	I-O
least	I-O
90	I-O
%	I-O
of	I-O
the	I-O
prescribed	I-O
study	I-O
drug	I-O
during	O
the	O
first	O
4	O
weeks	O
after	O
hematopoietic	B-O
cell	I-O
transplantation	I-O
was	O
54	O
%	O
overall	O
.	O


Lower	O
severity	B-O
of	I-O
mucositis	I-O
strongly	O
correlated	O
with	O
higher	O
adherence	B-O
to	O
the	O
schedule	O
of	O
study	O
drug	O
administration	O
.	O


Inconsistent	O
adherence	B-O
related	O
to	O
mucositis	O
during	O
recovery	O
after	O
myeloablative	B-I
conditioning	I-I
may	O
have	O
obscured	O
a	O
beneficial	O
therapeutic	O
effect	O
in	O
the	O
current	O
study	O
.	O


Emerging	O
treatment	B-O
of	O
acute	B-O
coronary	I-O
syndromes	I-O
with	O
platelet	B-I
glycoprotein	I-I
IIB/IIIA	I-I
inhibitors	I-I
.	I-I


Physiologic	O
modeling	O
of	O
the	O
intravenous	B-O
glucose	I-O
tolerance	I-O
test	I-O
in	O
type	B-P
2	I-P
diabetes	I-P
:	I-P
a	O
new	O
approach	O
to	O
the	O
insulin	O
compartment	O
.	O


The	O
minimal	O
model	O
of	O
Bergman	O
et	O
al	O
has	O
been	O
used	O
to	O
yield	O
estimates	O
of	O
insulin	B-O
sensitivity	I-O
(	I-O
Si	I-O
)	I-O
and	I-O
glucose	I-O
effectiveness	I-O
(	I-O
Sg	I-O
)	I-O
in	O
type	O
2	O
diabetes	O
by	O
incorporating	O
exogenous	B-I
insulin	I-I
protocols	I-I
into	O
the	O
regular	O
intravenous	O
glucose	O
tolerance	O
test	O
(	O
IVGTT	O
)	O
.	O


These	O
estimates	O
,	O
however	O
,	O
are	O
influenced	O
by	O
the	O
degree	O
to	O
which	O
the	O
dose	O
of	O
exogenous	B-I
insulin	I-I
is	O
greater	O
than	O
the	O
physiologic	O
response	O
to	O
a	O
glucose	O
load	O
.	O


Moreover	O
,	O
most	O
studies	O
have	O
related	O
to	O
type	B-P
2	I-P
diabetes	I-P
subjects	I-P
whose	O
diabetes	O
was	O
relatively	O
mild	O
in	O
terms	O
of	O
therapeutic	O
requirements	O
.	O


To	O
develop	O
a	O
"	O
minimal	O
disturbance	O
"	O
approach	O
in	O
estimating	O
Si	B-O
and	I-O
Sg	I-O
in	O
type	O
2	O
diabetes	O
,	O
we	O
have	O
used	O
a	O
reduced	B-I
glucose	I-I
load	I-I
(	O
200	O
mg/kg	O
)	O
and	B-I
a	I-I
"	I-I
physiologic	I-I
"	I-I
insulin	I-I
infusion	I-I
throughout	O
the	O
IVGTT	O
in	O
a	O
series	O
of	O
8	B-P
patients	I-P
,	I-P
5	I-P
of	I-P
whom	I-P
were	I-P
insulin-requiring	I-P
.	I-P


Data	O
from	O
this	O
approach	O
were	O
analyzed	O
using	O
the	O
modelling	O
program	O
CONSAM	O
to	O
apply	O
the	O
Bergman	O
model	O
,	O
either	O
unmodified	O
(	O
BMM	O
)	O
,	O
or	O
incorporating	O
an	O
additional	O
delay	O
element	O
between	O
the	O
plasma	O
and	O
"	O
remote	O
"	O
insulin	O
compartments	O
(	O
MMD	O
)	O
.	O


Application	O
of	O
the	O
MMD	O
and	O
extension	O
of	O
the	O
IVGTT	O
from	O
3	O
to	O
5	O
hours	O
improved	O
successful	O
resolution	B-O
of	I-O
Si	I-O
and	I-O
Sg	I-O
from	O
37.5	O
%	O
(	O
BMM	O
,	O
3-hour	O
IVGTT	O
)	O
to	O
100	O
%	O
(	O
MMD	O
,	O
5-hour	O
IVGTT	O
)	O
.	O


Si	B-O
was	O
reduced	O
in	O
these	O
type	O
2	O
diabetes	O
patients	O
compared	O
with	O
normal	O
subjects	O
(	O
1.86	O
+/-	O
0.60	O
v.	O
8.65	O
+/-	O
2.27	O
min	O
(	O
-1	O
)	O
x	O
microU	O
(	O
-1	O
)	O
x	O
mL	O
x	O
10	O
(	O
4	O
)	O
P	O
<	O
.01	O
)	O
.	O


The	O
results	O
were	O
validated	O
in	O
the	O
type	B-P
2	I-P
diabetes	I-P
group	I-P
using	O
a	O
2-stage	O
euglycemic	O
clamp	O
(	O
(	O
Si	O
)	O
CLAMP	O
=	O
2.02	O
+/-	O
0.42	O
min	O
(	O
-1	O
)	O
x	O
microU	O
(	O
-1	O
)	O
x	O
mL	O
x	O
10	O
(	O
4	O
)	O
P	O
>	O
.4	O
)	O
.	O


Sg	B-O
was	O
not	O
significantly	O
reduced	O
(	O
2.00	O
+/-	O
0.25	O
type	O
2	O
diabetes	O
v.	O
1.55	O
+/-	O
0.26	O
normal	O
min	O
(	O
-1	O
)	O
x	O
10	O
(	O
2	O
)	O
)	O
.	O


Data	O
from	O
a	O
group	O
of	O
normal	B-P
nondiabetic	I-P
subjects	I-P
was	O
then	O
analyzed	O
using	O
the	O
MMD	O
,	O
but	O
this	O
approach	O
did	O
not	O
enhance	O
the	O
fit	O
of	O
the	O
model	O
compared	O
with	O
the	O
BMM	O
.	O


This	O
result	O
indicates	O
that	O
the	O
delay	O
in	O
insulin	O
action	O
in	O
type	O
2	O
diabetes	O
represents	O
an	O
abnormality	O
whereby	O
the	O
onset	O
of	O
insulin	O
action	O
can	O
not	O
be	O
described	O
as	O
a	O
single	O
phase	O
in	O
the	O
transfer	O
of	O
insulin	O
from	O
plasma	O
to	O
the	O
remote	O
compartment	O
.	O


It	O
is	O
postulated	O
that	O
the	O
physiologic	O
basis	O
for	O
this	O
delayed	O
action	O
may	O
relate	O
to	O
transcapillary	O
endothelial	O
transfer	O
of	O
insulin	O
,	O
this	O
process	O
limiting	O
the	O
rate	O
of	O
onset	O
of	O
insulin	O
action	O
.	O


Treating	O
the	O
substance-abusing	B-P
suicidal	I-P
patient	I-P
.	I-P


Studies	O
concerning	O
the	O
treatment	O
of	O
substance-abusing	B-P
suicidal	I-P
patients	I-P
are	O
scarce	O
despite	O
the	O
frequent	O
presence	O
of	O
suicidal	O
behavior	O
among	O
this	O
population	O
.	O


Indeed	O
,	O
suicidality	O
(	O
ideation	O
or	O
behavior	O
)	O
is	O
generally	O
an	O
exclusion	O
criterion	O
for	O
participation	O
in	O
treatment	O
studies	O
of	O
subjects	B-P
with	I-P
alcohol	I-P
or	I-P
drug	I-P
abuse	I-P
.	I-P


Consequently	O
,	O
to	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
optimal	O
treatment	O
of	O
this	O
population	O
.	O


The	O
first	O
study	O
involving	O
substance-abusing	B-P
suicidal	I-P
patients	I-P
was	O
an	O
open-label	O
trial	O
conducted	O
in	O
the	O
early	O
1990s	O
.	O


This	O
study	O
involved	O
12	B-P
patients	I-P
,	I-P
all	I-P
of	I-P
whom	I-P
demonstrated	I-P
recent	I-P
suicidal	I-O
ideations	I-O
and	I-P
had	I-P
made	I-P
a	I-P
lifetime	I-P
suicide	I-P
attempt	I-P
.	I-P


The	O
results	O
of	O
that	O
open-label	B-I
study	I-I
demonstrated	O
significant	O
within-group	O
improvement	O
in	O
both	O
depressive	B-O
symptoms	I-O
(	I-O
including	I-O
suicidal	I-O
ideations	I-O
)	I-O
and	I-O
level	I-O
of	I-O
drinking	I-O
.	I-O


However	O
,	O
substantial	O
residual	O
depressive	B-O
symptoms	I-O
and	I-O
drinking	I-O
persisted	O
at	O
the	O
end	O
of	O
the	O
trial	O
.	O


Also	O
,	O
because	O
no	O
placebo	B-I
control	O
group	O
was	O
utilized	O
,	O
the	O
authors	O
of	O
that	O
study	O
could	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
apparent	O
therapeutic	O
effect	O
from	O
fluoxetine	B-I
was	O
the	O
result	O
of	O
the	O
placebo	B-I
effect	O
.	O


To	O
date	O
,	O
only	O
one	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
of	O
subjects	B-P
with	I-P
alcohol	I-P
or	I-P
substance	I-P
abuse	I-P
has	O
included	O
substantial	O
numbers	O
of	O
suicidal	O
patients	O
.	O


The	O
study	O
involved	O
51	B-P
subjects	I-P
,	I-P
of	I-P
whom	I-P
20	I-P
(	I-P
39	I-P
%	I-P
)	I-P
had	I-P
made	I-P
a	I-P
suicide	I-P
attempt	I-P
in	I-P
the	I-P
current	I-P
depressive	I-P
episode	I-P
,	I-P
31	I-P
(	I-P
61	I-P
%	I-P
)	I-P
had	I-P
made	I-P
a	I-P
suicide	I-P
attempt	I-P
in	I-P
their	I-P
lifetime	I-P
,	I-P
and	I-P
46	I-P
(	I-P
90	I-P
%	I-P
)	I-P
had	I-P
reported	I-P
suicidal	I-P
ideations	I-P
in	I-P
the	I-P
week	I-P
before	I-P
hospitalization	I-P
.	I-P


The	O
results	O
of	O
that	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
suggest	O
that	O
fluoxetine	B-I
was	O
effective	O
in	O
decreasing	O
but	O
not	O
eliminating	O
both	O
the	O
depressive	B-O
symptoms	I-O
(	I-O
including	I-O
suicidal	I-O
ideations	I-O
)	I-O
and	I-O
the	I-O
level	I-O
of	I-O
alcohol	I-O
consumption	I-O
among	O
a	O
study	O
group	O
of	O
subjects	O
with	O
comorbid	O
major	O
depressive	O
disorder	O
and	O
alcohol	O
dependence	O
,	O
many	O
of	O
whom	O
displayed	O
suicidal	O
ideations	O
.	O


A	O
secondary	O
data	O
analysis	O
from	O
that	O
study	O
suggested	O
that	O
cigarette	B-O
smoking	I-O
is	O
also	O
significantly	O
decreased	O
by	O
fluoxetine	B-I
,	O
but	O
the	O
magnitude	O
of	O
the	O
decrease	O
is	O
limited	O
and	O
few	O
of	O
these	O
patients	O
totally	O
quit	O
smoking	O
with	O
fluoxetine	O
treatment	O
alone	O
.	O


Another	O
secondary	O
data	O
analysis	O
from	O
that	O
study	O
suggested	O
that	O
marijuana	B-O
smoking	I-O
was	O
also	O
significantly	O
decreased	O
in	O
a	O
subgroup	O
of	O
subjects	O
who	O
demonstrated	O
cannabis	O
abuse	O
and	O
that	O
the	O
magnitude	O
of	O
this	O
improvement	O
was	O
robust	O
.	O


A	O
third	O
secondary	O
data	O
analysis	O
from	O
that	O
study	O
suggested	O
that	O
cocaine	B-O
abuse	I-O
acts	O
as	O
a	O
predictor	O
of	O
poor	O
outcome	O
for	O
both	O
depressive	B-O
symptoms	I-O
(	I-O
including	I-O
suicidality	I-O
)	I-O
and	I-O
level	I-O
of	I-O
alcohol	I-O
use	I-O
in	O
this	O
population	O
.	O


The	O
results	O
of	O
a	O
1-year	O
naturalistic	O
follow-up	O
study	O
involving	O
the	O
patients	O
from	O
that	O
study	O
suggest	O
that	O
the	O
benefits	O
of	O
fluoxetine	B-I
in	O
decreasing	O
depressive	B-O
symptoms	I-O
and	I-O
level	I-O
of	I-O
drinking	I-O
persist	O
1	O
year	O
after	O
entering	O
the	O
treatment	O
program	O
.	O


To	O
date	O
,	O
no	O
other	O
double-blind	O
,	O
placebo-controlled	B-I
studies	O
involving	O
substantial	O
numbers	O
of	O
substance-abusing	B-P
suicidal	I-P
patients	I-P
have	O
been	O
reported	O
to	O
either	O
confirm	O
or	O
refute	O
these	O
findings	O
.	O


Further	O
studies	O
are	O
clearly	O
warranted	O
to	O
evaluate	O
the	O
efficacy	B-O
of	O
various	O
pharmacotherapeutic	O
agents	O
and	O
various	O
psychotherapies	B-I
in	O
the	O
treatment	O
of	O
substance-abusing	B-P
suicidal	I-P
patients	I-P
.	I-P


Sequential	B-I
therapy	I-I
versus	I-I
standard	I-I
triple-drug	I-I
therapy	I-I
for	O
Helicobacter	O
pylori	O
eradication	O
:	O
a	O
randomized	O
study	O
.	O


BACKGROUND	O
Antimicrobial	O
resistance	O
has	O
decreased	O
eradication	O
rates	O
for	O
Helicobacter	B-P
pylori	I-P
infection	I-P
worldwide	O
.	O


A	O
sequential	O
treatment	O
schedule	O
has	O
been	O
reported	O
to	O
be	O
effective	O
,	O
but	O
studies	O
published	O
to	O
date	O
were	O
performed	O
in	O
Italy	O
.	O


We	O
undertook	O
this	O
study	O
to	O
determine	O
whether	O
these	O
results	O
could	O
be	O
replicated	O
in	B-P
India	I-P
.	I-P


METHODS	O
A	O
randomized	O
,	O
open-labeled	O
,	O
prospective	O
controlled	O
trial	O
comparing	O
sequential	B-I
vs.	I-I
standard	I-I
triple-drug	I-I
therapy	I-I
was	O
carried	O
out	O
at	B-P
Lokmanya	I-P
Tilak	I-P
Municipal	I-P
General	I-P
Hospital	I-P
,	I-P
Mumbai	I-P
.	I-P


Two	B-P
hundred	I-P
and	I-P
thirty-one	I-P
patients	I-P
with	I-P
dyspepsia	I-P
were	O
randomized	O
to	O
a	O
10-day	B-I
sequential	I-I
regimen	I-I
(	I-I
40	I-I
mg	I-I
of	I-I
pantoprazole	I-I
,	I-I
1	I-I
g	I-I
of	I-I
amoxicillin	I-I
,	I-I
each	I-I
administered	I-I
twice	I-I
daily	I-I
for	I-I
the	I-I
first	I-I
5	I-I
days	I-I
,	I-I
followed	I-I
by	I-I
40	I-I
mg	I-I
of	I-I
pantoprazole	I-I
,	I-I
500	I-I
mg	I-I
of	I-I
clarithromycin	I-I
,	I-I
and	I-I
500	I-I
mg	I-I
of	I-I
tinidazole	I-I
,	I-I
each	I-I
administered	I-I
twice	I-I
daily	I-I
for	I-I
the	I-I
remaining	I-I
5	I-I
days	I-I
)	I-I
or	I-I
to	I-I
standard	I-I
14-day	I-I
therapy	I-I
(	I-I
40	I-I
mg	I-I
of	I-I
pantoprazole	I-I
,	I-I
500	I-I
mg	I-I
of	I-I
clarithromycin	I-I
,	I-I
and	I-I
1	I-I
g	I-I
of	I-I
amoxicillin	I-I
,	I-I
each	I-I
administered	I-I
twice	I-I
daily	I-I
)	I-I
.	I-I


RESULTS	O
The	O
eradication	B-O
rate	I-O
achieved	O
with	O
the	O
sequential	B-I
regimen	I-I
was	O
significantly	O
greater	O
than	O
that	O
obtained	O
with	O
the	O
triple	B-I
therapy	I-I
.	I-I


Per-protocol	B-O
eradication	I-O
rate	I-O
of	O
sequential	B-I
therapy	I-I
was	O
92.4	O
%	O
(	O
95	O
%	O
CI	O
85.8-96.1	O
%	O
)	O
vs.	O
81.8	O
%	O
(	O
95	O
%	O
CI	O
73.9-87.8	O
%	O
)	O
(	O
p	O
=	O
0.027	O
)	O
for	B-I
standard	I-I
drug	I-I
therapy	I-O
.	I-O


Intention-to-treat	B-O
eradication	I-O
rates	I-O
were	O
88.2	O
%	O
(	O
95	O
%	O
CI	O
80.9-93.0	O
%	O
)	O
vs.	O
79.1	O
%	O
(	O
95	O
%	O
CI	O
71.1-85.4	O
%	O
)	O
,	O
p	O
=	O
0.029	O
,	O
respectively	B-O
.	I-O


The	B-O
incidence	I-O
of	I-O
major	I-O
and	I-O
minor	I-O
side	I-O
effects	O
between	O
therapy	O
groups	O
was	O
not	O
significantly	O
different	O
(	O
14.6	O
%	O
in	O
the	O
triple	O
therapy	O
group	O
vs.	O
23.5	O
%	O
in	O
sequential	O
group	O
,	O
p	O
=	O
0.12	O
)	O
.	O


Follow	O
up	O
was	O
incomplete	O
in	O
3.3	O
%	O
and	O
4.7	O
%	O
patients	B-I
in	I-I
standard	I-I
and	I-I
sequential	I-I
therapy	O
groups	O
,	O
respectively	B-I
.	I-I


Sequential	B-I
therapy	O
includes	O
one	O
additional	O
antibiotic	B-I
(	O
tinidazole	O
)	O
that	O
is	O
not	O
contained	B-I
in	I-I
standard	I-I
therapy	O
.	O


CONCLUSIONS	B-I
Sequential	I-I
therapy	O
was	O
significantly	O
better	B-I
than	I-I
standard	I-I
therapy	I-O
for	I-O
eradicating	I-O
H.	I-O
pylori	I-O
infection	O
.	O


Impact	O
of	O
additional	B-I
counselling	I-I
sessions	I-I
through	I-I
phone	I-I
calls	I-I
on	O
smoking	B-O
cessation	I-O
outcomes	I-O
among	O
smokers	B-P
in	I-P
Penang	I-P
State	I-P
,	I-P
Malaysia	I-P
.	I-P


BACKGROUND	O
Studies	O
all	O
over	O
the	O
world	O
reported	O
that	O
smoking	O
relapses	O
occur	O
during	O
the	O
first	O
two	O
weeks	O
after	O
a	O
quit	O
date	O
.	O


The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
the	O
additional	B-I
phone	I-I
calls	I-I
counselling	I-I
during	O
the	O
first	O
month	O
on	O
the	O
abstinence	B-O
rate	I-O
at	O
3	O
and	O
6	O
months	O
after	O
quit	O
date	O
among	B-P
smokers	I-P
in	I-P
Penang	I-P
,	I-P
Malaysia	I-P
.	O


METHODS	B-P
The	I-P
study	I-P
was	I-P
conducted	I-P
at	I-P
Quit	I-P
Smoking	I-P
Clinic	I-P
of	I-P
two	I-P
major	I-P
hospitals	I-P
in	I-P
Penang	I-P
,	I-P
Malaysia	I-P
.	I-P


All	B-P
the	I-P
eligible	I-P
smokers	I-P
who	I-P
attended	I-P
the	I-P
clinics	I-P
between	I-P
February	I-P
1st	I-P
and	I-P
October	I-P
31st	I-P
2012	I-P
were	I-P
invited	I-P
.	O


Participants	O
were	O
randomly	O
assigned	O
by	O
using	O
urn	O
design	O
method	O
either	O
to	B-I
receive	I-I
the	I-I
usual	I-I
care	I-I
that	I-I
followed	I-I
in	I-I
the	I-I
clinics	I-I
(	I-I
control	I-I
)	I-I
or	I-I
the	I-I
usual	I-I
care	I-I
procedure	I-I
plus	I-I
extra	I-I
counselling	I-I
sessions	I-I
through	I-I
phone	I-I
calls	I-I
during	I-I
the	I-I
first	I-I
month	I-I
of	I-I
quit	I-I
attempt	I-I
(	I-I
intervention	I-I
)	I-I
.	O


RESULTS	B-P
Participants	I-P
in	I-P
our	I-P
cohort	I-P
smoked	I-P
about	I-P
14	I-P
cigarettes	I-P
per	I-P
day	I-P
on	I-P
average	I-P
(	I-P
mean	I-P
=	I-P
13.78	I-P
±	I-P
7.0	I-P
)	I-P
.	O


At	O
3	O
months	O
,	O
control	O
group	O
was	O
less	B-O
likely	I-O
to	I-O
quit	I-O
smoking	O
compared	O
to	O
intervention	O
group	O
(	O
36.9	O
%	O
vs.	O
46.7	O
%	O
,	O
verified	O
smoking	O
status	O
)	O
but	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
OR	O
=	O
0.669	O
;	O
95	O
%	O
CI	O
=	O
0.395-1.133	O
,	O
P	O
=	O
0.86	O
)	O
.	O


However	O
,	O
at	O
6	O
months	O
,	O
71.7	O
%	O
of	O
the	O
intervention	O
group	B-O
were	I-O
successfully	I-O
quit	I-O
smoking	I-O
(	I-O
bio-chemically	I-O
verified	O
)	O
compared	O
to	O
48.6	O
%	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O


The	O
control	O
group	O
were	O
significantly	B-O
less	O
likely	O
to	O
quit	O
smoking	O
(	O
OR	O
=	O
0.375	O
;	O
95	O
%	O
CI	B-I
=	I-I
0.217-0.645	I-I
,	I-I
P	I-I
<	I-I
0.001	I-I
)	I-I
.	I-I


CONCLUSIONS	B-I
Smoking	I-I
cessation	I-I
intervention	I-I
consisting	O
of	O
phone	O
calls	O
counselling	O
delivered	O
during	O
the	O
first	O
month	O
of	O
quit	O
attempt	O
revealed	O
significantly	O
higher	O
abstinence	O
rates	O
compared	O
with	O
a	B-I
standard	I-I
care	I-I
approach	I-I
.	O


Therefore	O
,	O
the	O
additional	O
counselling	O
in	O
the	O
first	O
few	O
weeks	O
after	O
stop	O
smoking	O
is	O
a	O
promising	O
treatment	O
strategy	O
that	O
should	O
be	O
evaluated	O
further	O
.	O


TRIAL	O
REGISTRATION	O
TCTR20140504001	O
.	O


Comparison	O
on	O
therapeutic	O
effect	B-O
of	O
plasma	B-I
exchange	I-I
and	I-I
intravenous	I-I
immunoglobulin	I-I
for	O
Guillian-Barre	B-P
syndrome	I-P
.	I-P


OBJECTIVES	O
To	O
observe	O
and	O
compare	O
the	O
clinical	B-O
curative	I-O
effect	I-O
of	O
the	O
plasma	B-I
exchange	I-I
(	I-I
PE	I-I
)	I-I
and	I-P
intravenous	I-I
immunoglobulin	I-I
(	I-I
IVIg	I-I
)	I-I
for	I-P
Guillian-Barre	I-P
Syndrome	I-P
(	I-P
GBS	I-P
)	I-P
.	I-P


METHODS	O
Overall	O
,	O
64	B-P
adult	I-P
patients	I-P
with	I-P
GBS	I-P
for	I-P
PE	I-I
and	I-P
IVIg	I-I
treatment	I-P
,	I-P
respectively	I-P
,	I-P
and	I-P
nerve	I-O
function	I-O
were	O
observed	O
pre-treatment	O
and	O
at	O
1	O
week/2	O
weeks	O
after	O
completion	O
of	O
treatment	O
;	O
the	O
blood	O
immunoglobulin	O
,	O
complement	O
,	O
fibrinogen	O
(	O
Fib	O
)	O
and	O
monocyte	O
percentage	O
(	O
MON	O
%	O
)	O
were	O
detected	O
simultaneously	O
.	O


RESULTS	O
After	B-I
PE	O
treatment	B-O
,	I-O
nerve	I-O
function	I-O
defect	I-O
appeared	O
to	O
improve	O
better	O
than	O
the	B-I
IVIg	I-I
group	O
and	O
clinical	O
effect	O
was	O
better	O
than	O
the	B-I
IVIg	I-I
group	O
.	O


Treatment	B-O
effective	I-O
rates	I-O
of	O
the	O
two	O
groups	O
after	O
2	O
weeks	O
,	O
respectively	O
,	O
are	O
96	O
and	B-I
79	I-I
%	I-I
.	O


PE	B-I
and	I-I
IVIg	O
can	O
significantly	O
reduce	B-O
the	I-O
GBS	I-O
patients	I-O
'	I-O
blood	I-O
immunoglobulin	I-O
IgG	I-O
,	I-O
IgA	I-O
,	I-O
IgM	I-O
,	I-O
C3	I-O
and	I-O
C4	O
,	O
but	O
these	O
were	O
significantly	O
lower	O
in	B-I
the	I-I
PE	O
group	O
than	O
in	B-I
the	I-I
IVIg	O
group	B-O
.	I-O


Fib	B-O
and	I-O
MON	O
%	O
were	O
significantly	O
lower	O
in	B-I
the	I-I
PE	O
group	O
than	O
in	B-I
the	I-I
IVIg	O
group	O
.	O


CONCLUSION	B-I
Both	I-I
PE	I-I
and	I-I
IVIg	O
have	O
a	O
high	O
response	O
as	O
therapy	O
and	O
are	O
reasonable	O
therapeutic	O
options	O
for	O
GBS	O
.	O


However	B-I
,	O
PE	O
treatment	O
has	O
a	O
more	O
significantly	O
curative	O
effect	O
,	O
as	O
it	O
can	O
effectively	O
improve	O
symptoms	O
and	O
be	O
helpful	O
in	O
the	O
early	O
rehabilitation	B-P
of	I-P
patients	I-P
.	O


High	O
Platelet	O
Reactivity	O
in	O
Patients	B-P
with	I-P
Acute	I-P
Coronary	I-P
Syndromes	I-P
Undergoing	I-P
Percutaneous	I-P
Coronary	I-P
Intervention	I-P
:	I-P
Randomised	O
Controlled	O
Trial	O
Comparing	O
Prasugrel	O
and	O
Clopidogrel	O
.	O


BACKGROUND	O
Prasugrel	O
is	O
more	O
effective	O
than	O
clopidogrel	O
in	O
reducing	O
platelet	O
aggregation	O
in	O
acute	B-P
coronary	I-P
syndromes	I-P
.	I-P


Data	O
available	O
on	O
prasugrel	O
reloading	O
in	O
clopidogrel	O
treated	O
patients	O
with	O
high	O
residual	O
platelet	O
reactivity	O
(	O
HRPR	O
)	O
i.e	O
.	O


poor	O
responders	O
,	O
is	O
limited	O
.	O


OBJECTIVES	O
To	O
determine	O
the	O
effects	O
of	O
prasugrel	B-I
loading	O
on	O
platelet	O
function	O
in	O
patients	B-P
on	I-P
clopidogrel	I-I
and	I-P
high	I-P
platelet	I-P
reactivity	I-P
undergoing	I-P
percutaneous	I-I
coronary	I-I
intervention	I-I
for	I-P
acute	I-P
coronary	I-P
syndrome	I-P
(	I-P
ACS	I-P
)	I-P
.	I-P


PATIENTS	O
Patients	B-P
with	I-P
ACS	I-P
on	O
clopidogrel	B-I
who	O
were	O
scheduled	O
for	O
PCI	B-I
found	O
to	O
have	O
a	O
platelet	O
reactivity	O
≥40	O
AUC	O
with	O
the	O
Multiplate	O
Analyzer	O
,	O
i.e	O
.	O


"	O
poor	O
responders	O
"	O
were	O
randomised	O
to	B-I
prasugrel	I-I
(	O
60	O
mg	O
loading	O
and	O
10	O
mg	O
maintenance	O
dose	O
)	O
or	B-I
clopidogrel	I-I
(	O
600	O
mg	O
reloading	O
and	O
150	O
mg	O
maintenance	O
dose	O
)	O
.	O


The	O
primary	O
outcome	O
measure	O
was	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
platelet	I-O
reactivity	I-O
<	I-O
40	I-O
AUC	O
4	O
hours	O
after	O
loading	O
with	O
study	O
medication	O
,	O
and	O
also	O
at	O
one	O
hour	O
(	O
secondary	O
outcome	B-P
)	I-P
.	I-P


44	B-P
patients	I-P
were	I-P
enrolled	I-P
and	O
the	O
study	O
was	O
terminated	O
early	O
as	O
clopidogrel	O
use	O
decreased	O
sharply	O
due	O
to	O
introduction	O
of	O
newer	O
P2Y12	O
inhibitors	O
.	O


RESULTS	O
At	O
4	O
hours	O
after	O
study	O
medication	O
100	O
%	O
of	O
patients	O
treated	O
with	O
prasugrel	O
compared	O
to	O
91	O
%	O
of	O
those	O
treated	O
with	O
clopidogrel	O
had	B-O
platelet	I-O
reactivity	I-O
<	I-O
40	I-O
AUC	I-O
(	O
p	O
=	O
0.49	O
)	O
,	O
while	O
at	O
1	O
hour	O
the	O
proportions	O
were	O
95	O
%	O
and	O
64	O
%	O
respectively	O
(	O
p	O
=	O
0.02	B-O
)	I-O
.	I-O


Mean	B-O
platelet	I-O
reactivity	I-O
at	O
4	O
and	O
1	O
hours	O
after	O
study	O
medication	O
in	O
prasugrel	O
and	O
clopidogrel	O
groups	O
respectively	O
were	O
12	O
versus	O
22	O
(	O
p	O
=	O
0.005	O
)	O
and	O
19	O
versus	O
34	O
(	O
p	O
=	O
0.01	O
)	O
respectively	O
.	O


CONCLUSIONS	O
Routine	O
platelet	O
function	O
testing	O
identifies	O
patients	O
with	O
high	B-O
residual	I-O
platelet	I-O
reactivity	I-O
(	O
"	O
poor	O
responders	O
"	O
)	O
on	O
clopidogrel	O
.	O


A	O
strategy	O
of	O
prasugrel	O
rather	O
than	O
clopidogrel	O
reloading	O
results	O
in	O
earlier	O
and	O
more	O
sustained	O
suppression	O
of	O
platelet	O
reactivity	O
.	O


Future	O
trials	O
need	O
to	O
identify	O
if	O
this	O
translates	O
into	O
clinical	O
benefit	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
NCT01339026	O
.	O


A	O
comparison	O
of	O
high	B-I
and	I-I
low	I-I
fat	I-I
meals	I-I
on	O
postprandial	B-P
esophageal	I-P
acid	I-P
exposure	I-P
.	I-P


Fatty	O
foods	O
have	O
been	O
identified	O
as	O
precipitating	O
factors	O
in	O
symptomatic	O
gastroesophageal	B-P
reflux	I-P
(	I-P
GER	I-P
)	I-P
.	I-P


A	O
fat	O
meal	O
has	O
also	O
been	O
found	O
to	O
decrease	O
lower	O
esophageal	B-O
sphincter	I-O
pressure	I-O
(	I-O
LESP	I-O
)	I-O
in	O
normal	O
subjects	O
.	O


We	O
used	O
the	O
ambulatory	O
24-h	O
pH	O
monitor	O
to	O
assess	O
esophageal	O
acid	O
exposure	O
in	O
10	B-P
normal	I-P
subjects	I-P
and	I-P
10	I-P
GER	I-P
patients	I-P
following	I-P
low	I-I
and	I-I
high	I-I
fat	I-I
meals	I-I
eaten	I-I
in	I-I
two	I-I
body	I-I
positions	I-I
.	I-I


The	O
meals	O
had	O
nearly	O
identical	O
protein	O
content	O
,	O
volumes	O
,	O
and	O
calories	O
.	O


On	O
successive	O
days	O
,	O
patients	O
ingested	O
one	O
of	O
the	O
meals	B-I
twice	O
,	O
followed	O
by	O
random	O
assignment	O
to	O
3	O
h	O
upright	B-I
and	I-I
3	O
h	O
recumbent	B-I
position	I-I
.	I-I


Acid	B-O
exposure	I-O
for	I-O
each	I-O
hour	I-O
over	O
a	O
3-h	O
postprandial	O
(	O
PP	O
)	O
period	O
was	O
assessed	O
as	O
the	O
percent	O
time	O
pH	O
less	O
than	O
4.0	O
.	O


Increased	O
upright	B-O
acid	I-O
exposure	I-O
occurred	O
in	O
normals	O
after	O
the	O
high	O
fat	O
(	O
6.2	O
+/-	O
2.1	O
%	O
;	O
mean	O
+/-	O
SE	O
)	O
compared	O
with	O
the	O
low	O
fat	O
meal	O
(	O
1.5	O
+/-	O
0.5	O
%	O
;	O
p	O
less	O
than	O
0.05	O
)	O
.	O


GER	O
patients	O
had	O
greater	O
(	O
p	O
less	O
than	O
0.05	O
)	O
acid	B-O
exposure	I-O
than	O
normals	O
in	O
all	O
study	O
periods	O
,	O
but	O
no	O
differences	O
were	O
found	O
between	O
low	O
and	O
high	O
fat	O
meals	O
in	O
either	O
study	O
position	O
.	O


High	O
fat	O
meals	O
induce	O
upright	B-O
GER	I-O
in	O
normals	O
,	O
but	O
do	O
not	O
significantly	O
affect	O
the	O
abnormal	O
amount	O
of	O
GER	O
in	O
patients	O
.	O


In	O
addition	O
,	O
progressive	O
increases	O
in	O
acid	B-O
exposure	I-O
were	O
found	O
over	O
the	O
3	O
postprandial	O
hours	O
in	O
GER	O
patients	O
in	O
a	O
recumbent	O
position	O
.	O


The	O
findings	O
are	O
consistent	O
with	O
prior	O
data	O
showing	O
decreased	O
LESP	B-O
with	O
a	O
fat	O
meal	O
in	O
normals	O
.	O


Effects	O
of	O
topical	B-I
and	I-I
systemic	I-I
folic	I-I
acid	I-I
supplementation	O
on	O
gingivitis	B-O
in	I-O
pregnancy	I-O
.	I-O


A	O
double-blind	O
study	O
evaluated	O
the	O
effects	O
of	O
systemic	B-I
and	I-I
topical	I-I
folate	I-I
on	O
gingival	B-O
inflammation	I-O
during	I-O
the	I-O
fourth	I-O
and	I-O
eighth	I-O
months	I-O
of	I-O
pregnancy	I-O
.	I-O


Thirty	B-P
women	I-P
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O


Group	O
A	O
received	O
placebo	B-I
mouthwash	I-I
and	I-I
tablets	I-I
;	I-I
Group	O
B	O
;	O
placebo	B-I
mouthwash	I-I
and	I-I
5	I-I
mg	I-I
folate	I-I
tablets	I-I
;	I-I
Group	O
C	O
:	O
folate	B-I
mouthwash	I-I
and	I-I
placebo	I-I
tablets	I-I
.	I-I


Supplementation	O
lasted	O
for	O
14	O
days	O
during	O
months	O
4	O
and	O
8	O
.	O


Subjects	O
took	O
one	O
tablet	O
daily	O
and	O
rinsed	O
twice	O
daily	O
for	O
1	O
min	O
with	O
the	O
mouthwash	O
.	O


At	O
the	O
start	O
and	O
finish	O
of	O
each	O
14-day	O
period	O
,	O
fasting	B-O
serum	I-O
and	I-O
red	I-O
cell	I-O
folate	I-O
levels	I-O
were	O
estimated	O
and	O
oral	B-O
status	I-O
assessed	O
by	O
a	O
plaque	B-O
index	I-O
(	I-O
P1I	I-O
)	I-O
,	I-O
a	I-O
gingival	I-O
index	I-O
(	I-O
GI	I-O
)	I-O
,	I-O
and	I-O
gingival	I-O
exudate	I-O
flow	I-O
meter	I-O
(	I-O
GEF	I-O
)	I-O
.	I-O


Subjects	O
completed	O
1-week	O
diet	O
sheets	O
which	O
were	O
analysed	O
for	O
dietary	B-O
folate	I-O
.	I-O


All	O
groups	O
were	O
similar	O
in	O
each	O
parameter	O
at	O
the	O
start	O
.	O


Correlation	O
was	O
demonstrated	O
between	O
GI	B-O
and	I-O
P1I	I-O
,	O
and	O
between	O
GI	B-O
and	I-O
GEF	I-O
.	I-O


GI	B-O
tended	O
to	O
increase	O
throughout	O
pregnancy	O
in	O
all	O
groups	O
except	O
Group	O
C	O
,	O
when	O
in	O
the	O
eighth	O
month	O
there	O
was	O
a	O
highly	O
significant	O
improvement	O
(	O
0.001	O
less	O
than	O
P	O
0.01	O
)	O
despite	O
no	O
significant	O
change	O
in	O
P1I	O
.	O


Although	O
dietary	O
intake	O
of	O
folate	O
was	O
significantly	O
higher	O
during	O
the	O
eighth	O
month	O
in	O
Group	O
C	O
as	O
compared	O
with	O
Groups	O
A	O
and	O
B	O
,	O
(	O
0.001	O
less	O
than	O
P	O
less	O
than	O
0.01	O
)	O
,	O
the	O
folate	O
mouthwash	O
produced	O
highly	O
significantly	O
improvement	O
in	O
gingival	B-O
health	I-O
in	I-P
pregnancy	I-P
.	I-P


Superior	O
fixation	O
of	O
pegged	B-I
trabecular	I-I
metal	I-I
over	O
screw-fixed	B-I
pegged	I-I
porous	I-I
titanium	I-I
fiber	I-I
mesh	I-I
:	I-I
a	O
randomized	O
clinical	O
RSA	O
study	O
on	O
cementless	O
tibial	O
components	O
.	O


BACKGROUND	O
AND	O
PURPOSE	O
Lasting	O
stability	B-O
of	O
cementless	O
implants	O
depends	O
on	O
osseointegration	O
into	O
the	O
implant	O
surface	O
,	O
and	O
long-term	O
implant	O
fixation	O
can	O
be	O
predicted	O
using	O
radiostereometric	O
analysis	O
(	O
RSA	O
)	O
with	O
short-term	O
follow-up	O
.	O


We	O
hypothesized	O
that	O
there	O
would	O
be	O
improved	O
fixation	B-O
of	O
high-porosity	B-I
trabecular	I-I
metal	I-I
(	I-I
TM	I-I
)	I-I
tibial	I-I
components	I-I
compared	O
to	O
low-porosity	B-I
titanium	I-I
pegged	I-I
porous	I-I
fiber-metal	I-I
(	I-I
Ti	I-I
)	I-I
polyethylene	I-I
metal	I-I
backings	I-I
.	I-I


METHODS	O
In	O
a	O
prospective	O
,	O
parallel-group	O
,	O
randomized	O
unblinded	O
clinical	O
trial	O
,	O
we	O
compared	O
cementless	B-I
tibial	I-I
components	I-I
in	I-P
patients	I-P
aged	I-P
70	I-P
years	I-P
and	I-P
younger	I-P
with	I-P
osteoarthritis	I-P
.	I-P


The	O
pre-study	O
sample	O
size	O
calculation	O
was	O
22	B-P
patients	I-P
per	I-P
group	I-P
.	I-P


25	B-I
TM	I-I
tibial	I-I
components	I-I
were	I-I
fixed	I-I
press-fit	I-I
by	I-I
2	I-I
hexagonal	I-I
pegs	I-I
(	O
TM	O
group	O
)	O
and	O
25	B-I
Ti	I-I
tibial	I-I
components	I-I
were	I-I
fixed	I-I
press-fit	I-I
and	I-I
by	I-I
4	I-I
supplemental	I-I
screws	I-I
(	O
Ti	O
group	O
)	O
.	O


Stereo	O
radiographs	O
for	O
evaluation	O
of	O
absolute	O
component	O
migration	O
(	O
primary	O
effect	O
size	O
)	O
and	O
single-direction	O
absolute	O
component	O
migration	O
(	O
secondary	O
effect	O
size	O
)	O
were	O
obtained	O
within	O
the	O
first	O
postoperative	O
week	O
and	O
at	O
6	O
weeks	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
2	O
years	O
.	O


American	B-O
Knee	I-O
Society	I-O
score	I-O
was	O
used	O
for	O
clinical	O
assessment	O
preoperatively	O
,	O
and	O
at	O
1	O
and	O
2	O
years	O
.	O


RESULTS	O
There	O
were	O
no	O
intraoperative	B-O
complications	I-O
,	I-O
and	I-O
no	I-O
postoperative	I-O
infections	I-O
or	I-O
revisions	I-O
.	I-O


All	B-P
patients	I-P
had	O
improved	B-O
function	I-O
and	I-O
regained	I-O
full	I-O
extension	I-O
.	I-O


All	O
tibial	O
components	O
migrated	B-O
initially	O
.	O


Most	O
migration	B-O
of	I-O
the	I-O
TM	I-O
components	I-O
(	O
n	O
=	O
24	O
)	O
occurred	O
within	O
the	O
first	O
3	O
months	O
after	O
surgery	O
whereas	O
migration	O
of	O
the	O
Ti	B-I
components	I-I
(	O
n	O
=	O
22	O
)	O
appeared	O
to	O
stabilize	O
first	O
after	O
1	O
year	O
.	O


The	O
TM	B-I
components	I-I
migrated	O
less	O
than	O
the	O
Ti	B-I
components	I-I
at	O
1	O
year	O
(	O
p	O
=	O
0.01	O
)	O
and	O
2	O
years	O
(	O
p	O
=	O
0.004	O
)	O
.	O


INTERPRETATION	O
We	O
conclude	O
that	O
the	O
mechanical	O
fixation	O
of	O
TM	B-I
tibial	I-I
components	I-I
is	O
superior	O
to	O
that	O
of	O
screw-fixed	O
Ti	B-I
tibial	I-I
components	I-I
.	O


We	O
expect	O
long-term	B-O
implant	I-O
survival	I-O
to	O
be	O
better	O
with	O
the	O
TM	B-I
tibial	I-I
component	I-I
.	I-I


Effects	O
of	O
supplementation	O
of	O
whole	O
corn	O
germ	O
on	O
reproductive	B-O
performance	I-O
,	I-O
calf	I-O
performance	I-O
,	I-O
and	I-O
leptin	I-O
concentration	I-O
in	O
primiparous	B-P
and	I-P
mature	I-P
beef	I-P
cows	I-P
.	I-P


A	O
2-yr	O
study	O
using	O
primiparous	B-P
and	I-P
multiparous	I-P
,	I-P
spring-calving	I-P
,	I-P
crossbred	I-P
beef	I-P
cows	I-P
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
supplemental	B-I
whole	I-I
corn	I-I
germ	I-I
on	O
reproductive	B-O
performance	I-O
,	I-O
calf	I-O
performance	I-O
,	I-O
and	I-O
serum	I-O
leptin	I-O
concentrations	I-O
.	I-O


Each	O
year	O
,	O
cows	B-P
were	O
blocked	B-I
by	I-I
age	I-I
and	I-I
BCS	I-I
and	I-I
assigned	I-I
randomly	I-I
to	I-I
one	I-I
of	I-I
three	I-I
treatments	I-I
:	I-I
PRE	I-I
(	I-I
n	I-I
=	I-I
115	I-I
)	I-I
cows	I-I
received	I-I
1.14	I-I
kg/d	I-I
(	I-I
DM	I-I
basis	I-I
)	I-I
of	I-I
whole	I-I
corn	I-I
germ	I-I
for	I-I
approximately	I-I
45	I-I
d	I-I
before	I-I
calving	I-I
;	I-I
POST	I-I
(	I-I
n	I-I
=	I-I
109	I-I
)	I-I
cows	I-I
were	I-I
fed	I-I
1.14	I-I
kg/d	I-I
of	I-I
whole	I-I
corn	I-I
germ	I-I
for	I-I
approximately	I-I
45	I-I
d	I-I
after	I-I
calving	I-I
;	I-I
and	I-I
control	I-I
cows	I-I
(	I-I
n	I-I
=	I-I
118	I-I
)	I-I
were	I-I
fed	I-I
similar	I-I
energy	I-I
and	I-I
protein	I-I
from	I-I
dry-rolled	I-I
corn	I-I
(	I-I
1.82	I-I
kg	I-I
of	I-I
DM/d	I-I
)	I-I
for	I-I
45	I-I
d	I-I
before	I-I
and	I-I
after	I-I
calving	I-I
.	I-I


Additionally	O
,	O
PRE	O
cows	O
were	O
grouped	B-I
with	I-I
controls	I-I
after	I-I
calving	I-I
,	I-I
and	I-I
POST	I-I
cows	I-I
were	I-I
grouped	I-I
with	I-I
control	I-I
cows	I-I
before	I-I
calving	I-I
,	I-I
so	I-I
that	I-I
corn	I-I
germ-supplemented	I-I
cows	I-I
received	I-I
the	I-I
control	I-I
supplement	I-I
in	I-I
the	I-I
alternate	I-I
feeding	I-I
period	I-I
.	I-I


Cow	B-O
BW	I-O
(	O
538	O
+/-	O
13	O
kg	O
)	O
and	O
BCS	O
(	O
5.4	O
+/-	O
0.13	O
)	O
did	O
not	O
differ	O
among	O
treatments	O
at	O
any	O
time	O
during	O
the	O
experiment	O
.	O


Calf	B-O
birth	I-O
weight	I-O
(	O
39	O
+/-	O
2	O
kg	O
)	O
,	O
weaning	B-O
weight	I-O
(	O
225	O
+/-	O
7	O
kg	O
)	O
,	O
and	O
age-adjusted	B-O
weaning	I-O
weight	I-O
(	O
234	O
+/-	O
8	O
kg	O
)	O
did	O
not	O
differ	O
because	O
of	O
dam	O
supplementation	O
regimen	O
.	O


Treatment	O
did	O
not	O
affect	O
the	O
proportion	O
of	O
cows	O
exhibiting	O
ovarian	B-O
luteal	I-O
activity	I-O
before	O
the	O
start	O
of	O
the	O
breeding	O
season	O
(	O
67	O
%	O
)	O
or	O
pregnancy	O
rate	O
(	O
91	O
%	O
)	O
.	O


The	O
interval	O
from	O
exposure	B-O
to	O
bulls	O
until	O
subsequent	O
calving	O
did	O
not	O
differ	O
(	O
P	O
=	O
0.16	O
)	O
among	O
PRE	O
(	O
298	O
+/-	O
2.3	O
d	O
)	O
,	O
POST	O
(	O
303	O
+/-	O
2.6	O
d	O
)	O
,	O
and	O
control	O
(	O
304	O
+/-	O
2.3	O
d	O
)	O
cows	O
.	O


Leptin	B-O
concentrations	I-O
did	O
not	O
differ	O
among	O
treatments	O
and	O
were	O
2.15	O
+/-	O
0.75	O
,	O
1.88	O
+/-	O
0.76	O
,	O
and	O
1.91	O
+/-	O
0.75	O
ng/mL	O
for	O
control	O
,	O
POST	O
,	O
and	O
PRE	O
cows	O
,	O
respectively	O
.	O


Age	O
and	O
week	O
relative	O
to	O
calving	O
influenced	O
leptin	O
concentration	O
.	O


Primiparous	B-P
cows	I-P
had	O
similar	O
leptin	B-O
concentrations	I-O
to	O
3-yr-old	O
and	O
mature	O
cows	B-P
for	O
wk	O
-7	O
and	O
-6	O
relative	O
to	O
calving	O
,	O
but	O
lower	O
(	O
P	O
<	O
0.10	O
)	O
concentrations	O
than	O
mature	O
cows	O
for	O
wk	O
-5	O
,	O
and	O
lower	O
(	O
P	O
<	O
0.05	O
)	O
concentrations	O
than	O
either	O
3-yr-old	O
or	O
mature	O
cows	O
for	O
wk	O
-4	O
to	O
+7	O
relative	O
to	O
calving	O
.	O


Serum	O
leptin	O
was	O
correlated	O
with	O
BCS	O
(	O
P	O
<	O
0.0001	O
;	O
r	O
=	O
0.35	O
)	O
at	O
initiation	O
of	O
the	O
feeding	O
period	O
and	O
was	O
correlated	O
with	O
BCS	O
(	O
P	O
=	O
0.02	O
;	O
r	O
=	O
0.12	O
)	O
and	O
weight	O
(	O
P	O
<	O
0.01	O
;	O
r	O
=	O
0.14	O
)	O
at	O
the	O
completion	O
of	O
the	O
supplement	O
period	O
,	O
but	O
it	O
was	O
not	O
correlated	O
with	O
initial	O
BW	O
or	O
interim	O
BCS	O
.	O


Calving	O
interval	O
was	O
not	O
correlated	O
(	O
P	O
>	O
0.12	O
)	O
with	O
weekly	O
measures	O
of	O
serum	B-O
leptin	I-O
concentration	I-O
.	I-O


Supplementing	O
beef	B-P
cows	I-P
with	O
whole	O
corn	O
germ	O
had	O
no	O
effect	O
on	O
cow	O
performance	O
,	O
calf	O
performance	O
,	O
or	O
serum	O
leptin	O
concentrations	O
of	O
cows	O
.	O


Acute	O
exposure	B-P
to	I-P
acid	I-P
fog	I-P
:	I-P
influence	O
of	O
breathing	O
pattern	O
on	O
effective	B-O
dose	I-O
.	I-O


Concern	O
about	O
the	O
possible	O
adverse	B-O
health	I-O
effects	I-O
of	O
acid	O
fog	O
has	O
been	O
fed	O
by	O
two	O
observations	O
:	O
air	O
pollution	O
disasters	O
earlier	O
in	O
this	O
century	O
were	O
typically	O
associated	O
with	O
fog	O
,	O
and	O
current	O
samples	O
of	O
fog	O
water	O
can	O
be	O
strongly	O
acid	O
.	O


To	O
study	O
the	O
acute	O
effects	O
of	O
acid	O
fog	O
on	O
the	O
lung	O
,	O
the	O
authors	O
generated	O
a	O
monodisperse	B-I
10	I-I
microM	I-I
MMAD	I-I
aerosol	I-I
of	I-I
H2SO4	I-I
with	O
a	O
pH	O
of	O
2.0	O
and	O
a	O
nominal	B-I
concentration	I-I
of	O
500	O
micrograms/m3	O
.	O


They	O
exposed	O
seven	B-P
healthy	I-P
young	I-P
men	I-P
on	O
alternate	O
days	O
to	O
acid	B-I
or	I-I
control	I-I
equiosmolar	I-I
NaCl	I-I
aerosol	I-I
during	O
40	O
min	O
of	O
resting	O
ventilation	O
and	O
20	O
min	O
of	O
exercise	O
;	O
the	O
latter	O
was	O
sufficiently	O
intense	O
to	O
induce	O
oronasal	B-O
breathing	I-O
.	O


Exposure	O
was	O
by	O
means	O
of	O
a	O
head	O
dome	O
,	O
a	O
head-only	O
exposure	O
device	O
that	O
permitted	O
continuous	O
measurement	O
(	O
unfettered	O
breathing	O
)	O
of	O
Vr	O
,	O
f	O
,	O
VE	O
,	O
and	O
the	O
onset	O
and	O
persistence	O
of	O
oronasal	B-O
breathing	I-O
.	I-O


In	O
this	O
article	O
the	O
authors	O
compare	O
the	O
relative	O
importance	O
of	O
parameters	O
contributing	O
to	O
the	O
between-subject	O
variability	O
in	O
estimated	O
hydrogen	O
ion	O
dose	O
to	O
the	O
lower	B-O
airways	I-O
(	O
H+LAW	O
)	O
,	O
based	O
on	O
analysis	O
of	O
variance	O
.	O


Physiologic	O
parameters	O
accounted	O
for	O
70	O
%	O
of	O
the	O
variability	O
,	O
of	O
which	O
34	O
%	O
was	O
due	O
to	O
differences	O
in	O
duration	B-O
of	I-O
oronasal	I-O
breathing	I-O
(	I-O
tON	I-O
)	I-O
and	O
36	O
%	O
to	O
differences	O
in	O
ventilation	B-O
rate	I-O
during	I-O
oronasal	I-O
breathing	I-O
(	I-O
VE	I-O
(	I-O
ON	I-O
)	I-O
)	I-O
;	I-O
inhaled	I-O
hydrogen	I-O
ion	I-O
concentration	I-O
[	I-O
H+	I-O
]	I-O
,	O
the	O
environmental	O
parameter	O
,	O
contributed	O
only	O
30	O
%	O
.	O


Minute	O
ventilation	O
at	O
the	O
time	O
of	O
transition	O
from	O
nasal	O
to	O
oronasal	O
breathing	O
varied	O
significantly	O
among	O
subjects	O
even	O
if	O
normalized	O
to	O
FVC	O
,	O
an	O
index	O
of	O
lung	O
size	O
.	O


Determinants	O
of	O
serum	O
creatinine	O
trajectory	O
in	O
acute	B-P
contrast	I-P
nephropathy	I-P
.	I-P


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
trajectory	O
of	O
creatinine	B-O
(	I-O
Cr	I-O
)	I-O
rise	I-O
and	O
its	O
determinants	O
after	B-P
exposure	I-P
to	I-P
radiocontrast	I-P
media	I-P
.	I-P


Included	O
were	O
98	B-P
subjects	I-P
who	I-P
underwent	I-P
cardiac	I-P
catheterization	I-P
and	O
were	O
randomized	O
to	O
forced	O
diuresis	B-I
with	I-I
i.v	I-I
.	I-I


crystalloid	B-I
,	I-I
furosemide	I-I
,	I-I
mannitol	I-I
(	I-I
if	I-I
pulmonary	I-I
capillary	I-I
wedge	I-I
pressure	I-I
was	I-I
<	I-I
20	I-I
mmHg	I-I
)	I-I
,	I-I
and	I-I
low	I-I
dose	I-I
dopamine	I-I
versus	I-I
intravenous	I-I
crystalloid	I-I
and	I-I
matching	I-I
placebos	I-I
.	I-I


Baseline	O
and	O
postcatheterization	O
serum	B-O
Cr	I-O
levels	I-O
were	O
analyzed	O
in	O
a	O
longitudinal	O
fashion	O
,	O
allowing	O
for	O
differences	O
in	O
the	O
time	O
between	O
blood	O
draws	O
,	O
to	O
determine	O
the	O
different	O
critical	O
trajectories	O
of	O
serum	O
Cr	O
.	O


The	B-P
mean	I-O
age	I-O
,	I-O
baseline	I-O
serum	I-O
Cr	I-O
,	I-O
and	I-O
Cr	I-O
clearance	I-O
(	I-O
CrCl	I-O
)	I-O
were	I-P
69.3	I-P
+/-	I-P
10.8	I-P
years	I-P
,	I-P
2.5	I-P
+/-	I-P
0.9	I-P
mg/dL	I-P
,	I-P
and	I-P
31.4	I-P
+/-	I-P
12.1	I-P
mL/min	I-P
,	I-P
respectively	I-P
.	I-P


The	O
clinically	B-O
driven	I-O
postprocedural	I-O
observation	I-O
time	I-O
was	O
5.5	O
+/-	O
5.1	O
days	O
(	O
range	O
19	O
hours	O
and	O
one	O
Cr	O
value	O
to	O
25.7	O
days	O
and	O
18	O
values	O
)	O
.	O


The	O
mean	B-O
maximum	I-O
Cr	I-O
was	O
3.3	O
+/-	O
1.4	O
,	O
range	O
1.7-8.7	O
mg/dL	O
)	O
.	O


Longitudinal	O
models	O
support	O
baseline	O
Cr	B-O
clearance	I-O
predictions	O
for	O
the	O
change	O
in	O
Cr	O
at	O
24	O
hours	O
,	O
time	O
as	O
the	O
determinant	O
of	O
Cr	O
trajectory	O
,	O
and	O
requisite	O
monitoring	O
.	O


For	O
any	O
given	O
individual	O
,	O
a	O
rise	O
in	O
Cr	B-O
of	O
<	O
or	O
=	O
0.5	O
mg/dL	O
in	O
the	O
first	O
24	O
hours	O
after	O
contrast	O
exposure	O
predicted	O
a	O
favorable	O
outcome	O
.	O


Baseline	B-O
renal	I-O
function	I-O
is	O
the	O
major	O
determinant	O
of	O
the	O
rate	O
of	O
rise	O
,	O
height	O
,	O
and	O
duration	O
of	O
Cr	O
trajectory	O
after	O
contrast	O
exposure	O
.	O


Length	O
of	O
observation	O
and	O
frequency	O
of	O
laboratory	O
measures	O
can	O
be	O
anticipated	O
from	O
these	O
models	O
.	O


Comparison	O
of	O
cuffed	B-I
and	I-I
uncuffed	I-I
endotracheal	I-I
tubes	I-I
in	O
young	B-P
children	I-P
during	I-P
general	I-P
anesthesia	I-P
.	I-P


BACKGROUND	O
Uncuffed	B-I
endotracheal	I-I
tubes	I-I
are	O
routinely	O
used	O
in	O
young	B-P
children	I-P
.	I-P


This	O
study	O
tests	O
a	O
formula	O
for	O
selecting	O
appropriately	O
sized	O
cuffed	O
endotracheal	O
tubes	O
and	O
compares	O
the	O
use	O
of	O
cuffed	B-I
versus	I-I
uncuffed	I-I
endotracheal	I-I
tubes	I-I
for	O
patients	B-P
whose	O
lungs	O
are	O
mechanically	O
ventilated	O
during	O
anesthesia	O
.	O


METHODS	O
Full-term	B-P
newborns	I-P
and	I-P
children	I-P
(	I-P
n	I-P
=	I-P
488	I-P
)	I-P
through	I-P
8	I-P
yr	I-P
of	I-P
age	I-P
who	I-P
required	I-P
general	I-P
anesthesia	I-P
and	I-P
tracheal	I-P
intubation	I-P
were	O
assigned	O
randomly	O
to	O
receive	O
either	O
a	O
cuffed	B-I
tube	I-I
sized	I-I
by	I-I
a	I-I
new	I-I
formula	I-I
[	O
size	O
(	O
mm	O
internal	O
diameter	O
)	O
=	O
(	O
age/4	O
)	O
+	O
3	O
]	O
,	O
or	O
an	O
uncuffed	B-I
tube	I-I
sized	I-I
by	I-I
the	I-I
modified	I-I
Cole	I-I
's	I-I
formula	I-I
[	O
size	O
(	O
mm	O
internal	O
diameter	O
)	O
=	O
(	O
age/4	O
)	O
+	O
4	O
]	O
.	O


The	O
number	B-O
of	I-O
intubations	I-O
required	I-O
to	I-O
achieve	I-O
an	I-O
appropriately	I-O
sized	I-O
tube	I-O
,	O
the	O
need	B-O
to	I-O
use	I-O
more	I-O
than	I-O
21.min-1	I-O
fresh	I-O
gas	I-O
flow	I-O
,	O
the	O
concentration	B-O
of	I-O
nitrous	I-O
oxide	I-O
in	I-O
the	I-O
operating	I-O
room	I-O
,	O
and	O
the	O
incidence	B-O
of	I-O
croup	I-O
were	O
compared	O
.	O


RESULTS	O
Cuffed	B-I
tubes	I-I
selected	O
by	O
our	O
formula	O
were	O
appropriate	B-O
for	O
99	O
%	O
of	O
patients	O
.	O


Uncuffed	B-I
tubes	I-I
selected	O
by	O
Cole	O
's	O
formula	O
were	O
appropriate	B-O
for	O
77	O
%	O
of	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
.	O


The	O
lungs	B-O
of	I-O
patients	I-O
with	O
cuffed	O
tubes	O
were	O
adequately	B-O
ventilated	I-O
with	O
2	O
1.min-1	O
fresh	O
gas	O
flow	O
,	O
whereas	O
11	O
%	O
of	O
those	O
with	O
uncuffed	O
tubes	O
needed	O
greater	O
fresh	O
gas	O
flow	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Ambient	B-O
nitrous	I-O
oxide	I-O
concentration	I-O
exceeded	O
25	O
parts	O
per	O
million	O
in	O
37	O
%	O
of	O
cases	O
with	O
uncuffed	O
tubes	O
and	O
in	O
0	O
%	O
of	O
cases	O
with	O
cuffed	O
tubes	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Three	O
patients	O
in	O
each	O
group	O
were	O
treated	O
for	O
croup	B-O
symptoms	I-O
(	O
1.2	O
%	O
cuffed	O
;	O
1.3	O
%	O
uncuffed	O
)	O
.	O


CONCLUSIONS	O
Our	O
formula	O
for	O
cuffed	O
tube	O
selection	O
is	O
appropriate	B-O
for	O
young	B-O
children	I-O
.	I-O


Advantages	B-O
of	O
cuffed	B-I
endotracheal	I-I
tubes	I-I
include	O
avoidance	B-O
of	I-O
repeated	I-O
laryngoscopy	I-O
,	I-O
use	I-O
of	I-O
low	I-O
fresh	I-O
gas	I-O
flow	I-O
,	O
and	O
reduction	B-O
of	I-O
the	I-O
concentration	I-O
of	I-O
anesthetics	I-O
detectable	I-O
in	I-O
the	I-O
operating	I-O
room	I-O
.	I-O


We	O
conclude	O
that	O
cuffed	B-I
endotracheal	I-I
tubes	I-I
may	O
be	O
used	O
routinely	O
during	O
controlled	O
ventilation	O
in	O
full-term	B-P
newborns	I-P
and	I-P
children	I-P
during	I-P
anesthesia	I-P
.	I-P


[	O
Clinical	O
observation	O
on	O
acupuncture	B-I
combined	O
with	O
Yizhi	B-I
Jiannao	I-I
granules	I-I
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
]	O
.	O


OBJECTIVE	O
To	O
observe	O
clinical	O
therapeutic	B-O
effect	I-O
of	O
acupuncture	B-I
combined	O
with	O
Yizhi	B-I
Jiannao	I-I
Granules	I-I
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
its	O
effects	O
on	O
intelligence	B-O
,	I-O
daily	I-O
life	I-O
and	I-O
social	I-O
activity	I-O
ability	I-O
.	I-O


METHODS	O
Eighty-four	B-P
cases	I-P
were	I-P
randomly	I-P
divided	I-P
into	I-P
3	I-P
groups	I-P
,	I-P
28	I-P
cases	I-P
in	I-P
each	I-P
group	I-P
.	I-P


The	O
combined	O
acupuncture	B-I
and	O
medication	O
group	O
was	O
treated	O
with	O
acupuncture	B-I
at	O
Baihui	O
(	O
GV	O
20	O
)	O
,	O
Sishencong	O
(	O
EX-HN	O
1	O
)	O
,	O
Dazhui	O
(	O
GV	O
14	O
)	O
,	O
Guanyuan	O
(	O
CV	O
4	O
)	O
,	O
etc	O
.	O


and	O
oral	O
administration	O
of	O
Yizhi	B-I
Jiannao	I-I
Granules	I-I
;	I-I
the	O
Chinese	O
herb	O
group	O
was	O
treated	O
with	O
Yizhi	B-I
Jiannao	I-I
Granules	I-I
,	O
and	O
the	O
western	B-I
medicine	I-I
group	I-I
with	O
oral	O
administration	O
of	O
Aricept	B-I
.	I-I


The	O
scores	B-O
for	I-O
the	I-O
Mini-Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	I-O
Ability	I-O
of	I-O
Daily	I-O
Life	I-O
(	I-O
ADL	I-O
)	I-O
and	I-O
the	I-O
therapeutic	I-O
effects	I-O
were	O
assessed	O
and	O
compared	O
before	O
treatment	O
and	O
after	O
treatment	O
for	O
12	O
weeks	O
among	O
the	O
groups	O
.	O


RESULTS	O
After	O
treatment	O
,	O
the	O
scores	O
for	O
MMSE	B-O
and	I-O
ADL	I-O
were	O
improved	O
in	O
the	O
combined	B-I
acupuncture	I-I
and	I-I
medication	I-I
group	O
,	O
the	O
Chinese	B-I
herb	I-I
group	O
and	O
the	O
western	B-I
medicine	I-I
group	O
,	O
which	O
were	O
better	O
in	O
the	O
combined	O
acupuncture	B-I
and	I-I
medication	I-I
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
total	B-O
effective	I-O
rate	I-O
of	O
85.7	O
%	O
in	O
the	O
combined	B-I
acupuncture	I-I
and	I-I
medication	I-I
group	O
was	O
better	O
than	O
71.4	O
%	O
in	O
the	O
Chinese	O
herb	O
group	O
and	O
67.9	O
%	O
in	O
the	O
western	O
medicine	O
group	O
.	O


CONCLUSION	O
Acupuncture	B-I
combined	I-I
with	I-I
Yizhi	I-I
Jiannao	I-I
Granules	I-I
has	O
a	O
significant	O
therapeutic	B-O
effect	I-O
on	O
Alzheimer	O
's	O
disease	O
,	O
which	O
is	O
better	O
than	O
that	O
of	O
Yizhi	B-I
Jiannao	I-I
Granules	I-I
or	O
Aricept	B-I
.	I-I


Oral	B-I
sucrose	I-I
as	O
an	O
analgesic	O
drug	O
for	O
procedural	O
pain	O
in	O
newborn	B-P
infants	I-P
:	I-P
a	O
randomised	O
controlled	O
trial	O
.	O


BACKGROUND	O
Many	O
infants	B-P
admitted	I-P
to	I-P
hospital	I-P
undergo	O
repeated	O
invasive	O
procedures	O
.	O


Oral	B-I
sucrose	I-I
is	O
frequently	O
given	O
to	O
relieve	O
procedural	O
pain	O
in	O
neonates	B-P
on	O
the	O
basis	O
of	O
its	O
effect	O
on	O
behavioural	O
and	O
physiological	O
pain	O
scores	O
.	O


We	O
assessed	O
whether	O
sucrose	B-I
administration	O
reduces	O
pain-specific	B-O
brain	I-O
and	I-O
spinal	I-O
cord	I-O
activity	I-O
after	O
an	O
acute	B-P
noxious	I-P
procedure	I-P
in	O
newborn	B-P
infants	I-P
.	I-P


METHODS	O
In	O
this	O
double-blind	O
,	O
randomised	O
controlled	O
trial	O
,	O
59	B-P
newborn	I-P
infants	I-P
at	I-P
University	I-P
College	I-P
Hospital	I-P
(	I-P
London	I-P
,	I-P
UK	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
0·5	O
mL	O
24	B-I
%	I-I
sucrose	I-I
solution	I-I
or	O
0·5	O
mL	B-I
sterile	I-I
water	I-I
2	O
min	O
before	O
undergoing	O
a	O
clinically	O
required	O
heel	O
lance	O
.	O


Randomisation	O
was	O
by	O
a	O
computer-generated	O
randomisation	O
code	O
,	O
and	O
researchers	O
,	O
clinicians	O
,	O
participants	O
,	O
and	O
parents	O
were	O
masked	O
to	O
the	O
identity	O
of	O
the	O
solutions	O
.	O


The	O
primary	O
outcome	O
was	B-O
pain-specific	I-O
brain	I-O
activity	I-O
evoked	I-O
by	O
one	O
time-locked	O
heel	O
lance	B-O
,	I-O
recorded	I-O
with	I-O
electroencephalography	I-O
and	I-O
identified	I-O
by	I-O
principal	I-O
component	I-O
analysis	I-O
.	O


Secondary	O
measures	O
were	B-O
baseline	I-O
behavioural	I-O
and	I-O
physiological	I-O
measures	I-O
,	I-O
observational	I-O
pain	I-O
scores	I-O
(	I-O
PIPP	I-O
)	I-O
,	I-O
and	I-O
spinal	I-O
nociceptive	I-O
reflex	I-O
withdrawal	I-O
activity	I-O
.	O


Data	O
were	O
analysed	O
per	O
protocol	O
.	O


This	O
study	O
is	O
registered	O
,	O
number	O
ISRCTN78390996	O
.	O


FINDINGS	O
29	B-P
infants	I-P
were	O
assigned	O
to	O
receive	B-I
sucrose	I-I
and	O
30	O
to	B-I
sterilised	I-I
water	I-I
;	I-I
20	O
and	O
24	O
infants	O
,	O
respectively	O
,	O
were	O
included	O
in	O
the	O
analysis	O
of	O
the	O
primary	O
outcome	O
measure	B-O
.	I-O


Nociceptive	B-O
brain	I-O
activity	I-O
after	I-O
the	I-O
noxious	I-O
heel	I-O
lance	O
did	O
not	O
differ	O
significantly	O
between	O
infants	O
who	O
received	B-I
sucrose	I-I
and	O
those	O
who	O
received	B-I
sterile	I-I
water	I-I
(	I-I
sucrose	I-I
:	I-I
mean	O
0·10	O
,	O
95	O
%	O
CI	O
0·04-0·16	B-I
;	I-I
sterile	I-I
water	I-I
:	I-I
mean	O
0·08	O
,	O
0·04-0·12	O
;	O
p=0·46	O
)	O
.	O


No	O
significant	O
difference	O
was	O
recorded	O
between	B-I
the	I-I
sucrose	I-I
and	I-I
sterile	I-I
water	O
groups	O
in	O
the	O
magnitude	B-O
or	I-O
latency	I-O
of	I-O
the	I-O
spinal	I-O
nociceptive	I-O
reflex	I-O
withdrawal	I-O
recorded	O
from	O
the	O
biceps	O
femoris	O
of	O
the	O
stimulated	O
leg	B-O
.	I-O


The	B-O
PIPP	I-O
score	O
was	O
significantly	O
lower	O
in	O
infants	B-I
given	I-I
sucrose	O
than	O
in	O
those	B-I
given	I-I
sterile	I-I
water	O
(	O
mean	O
5·8	O
,	O
95	O
%	O
CI	O
3·7-7·8	O
vs	O
8·5	O
,	O
7·3-9·8	O
;	O
p=0·02	O
)	O
and	O
significantly	B-P
more	O
infants	O
had	O
no	O
change	O
in	O
facial	O
expression	B-I
after	O
sucrose	O
administration	O
(	O
seven	O
of	O
20	O
[	O
35	O
%	O
]	O
vs	O
none	O
of	O
24	O
;	O
p	O
<	O
0·0001	O
)	O
.	O


INTERPRETATION	O
Our	O
data	O
suggest	B-I
that	I-I
oral	O
sucrose	O
does	O
not	O
significantly	O
affect	B-P
activity	I-P
in	O
neonatal	O
brain	O
or	O
spinal	O
cord	O
nociceptive	O
circuits	O
,	O
and	O
therefore	O
might	O
not	O
be	O
an	O
effective	O
analgesic	O
drug	B-I
.	I-I


The	B-I
ability	I-I
of	O
sucrose	O
to	O
reduce	O
clinical	O
observational	O
scores	O
after	O
noxious	B-P
events	I-P
in	I-P
newborn	O
infants	O
should	O
not	O
be	O
interpreted	O
as	O
pain	O
relief	O
.	O


FUNDING	O
Medical	O
Research	O
Council	O
.	O


Baseline	O
distribution	O
of	O
participants	B-P
with	I-P
depression	I-P
and	I-P
impaired	I-P
quality	I-P
of	I-P
life	I-P
in	O
the	O
Treatment	O
of	O
Preserved	O
Cardiac	O
Function	O
Heart	O
Failure	O
with	O
an	O
Aldosterone	O
Antagonist	O
Trial	O
.	O


BACKGROUND	O
Previous	O
studies	O
have	O
demonstrated	O
the	O
psychosocial	O
effect	O
of	O
heart	O
failure	O
in	O
patients	B-P
with	I-P
reduced	I-P
ejection	I-P
fraction	I-P
.	I-P


However	O
,	O
the	O
effects	O
on	O
patients	O
with	O
preserved	O
ejection	O
fraction	O
have	O
not	O
yet	O
been	O
elucidated	O
.	O


This	O
study	O
aimed	O
to	O
determine	O
the	O
baseline	O
characteristics	O
of	O
participants	B-P
with	I-P
heart	I-P
failure	I-P
with	I-P
preserved	I-P
ejection	I-P
fraction	I-P
as	O
it	O
relates	O
to	O
impaired	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
and	O
depression	O
,	O
identify	O
predictors	O
of	O
poor	O
QOL	O
and	O
depression	O
,	O
and	O
determine	O
the	O
correlation	O
between	O
QOL	O
and	O
depression	O
.	O


METHODS	O
AND	O
RESULTS	O
Among	O
patients	B-P
enrolled	I-P
in	I-P
the	I-P
Treatment	I-P
of	I-P
Preserved	I-P
Cardiac	I-P
Function	I-P
Heart	I-P
Failure	I-P
With	I-P
an	I-P
Aldosterone	I-I
Antagonist	I-I
Trial	I-I
(	I-I
TOPCAT	I-I
)	I-I
,	I-P
3400	I-P
patients	I-P
completed	I-P
the	I-P
Kansas	I-O
City	I-O
Cardiomyopathy	I-O
Questionnaire	I-O
,	I-P
3395	I-P
patients	I-P
completed	I-P
European	I-O
QOL	I-O
5D	I-O
Visual	I-O
Analog	I-O
Scale	I-O
,	I-P
and	I-P
1431	I-P
patients	I-P
in	I-P
United	I-P
States	I-P
and	I-P
Canada	I-P
completed	I-P
the	I-P
Patient	I-O
Health	I-O
Questionnaire-9	I-O
.	I-O


The	O
mean	O
summary	O
score	O
on	O
the	O
Kansas	B-O
City	I-O
Cardiomyopathy	I-O
Questionnaire	I-O
was	O
54.8	O
,	O
and	O
on	O
European	B-O
QOL	I-O
5D	I-O
Visual	I-O
Analog	I-O
Scale	I-O
,	O
it	O
was	O
60.3	O
;	O
27	O
%	O
of	O
patients	O
had	O
moderate	O
to	O
severe	O
depression	O
.	O


Factors	O
associated	O
with	O
better	O
Kansas	B-O
City	I-O
Cardiomyopathy	I-O
Questionnaire	I-O
and	I-O
European	I-O
QOL	I-O
5D	I-O
Visual	I-O
Analog	I-O
Scale	I-O
via	O
multiple	O
logistic	O
regression	O
analysis	O
were	O
American	O
region	O
,	O
older	O
age	O
,	O
no	O
history	O
of	O
angina	O
pectoris	O
or	O
asthma	O
,	O
no	O
use	O
of	O
hypoglycemic	O
agent	O
,	O
more	O
activity	O
level	O
,	O
and	O
lower	O
New	O
York	O
Heart	O
Association	O
class	O
.	O


Factors	O
associated	O
with	O
depression	O
via	O
multiple	O
logistic	O
regression	O
analysis	O
included	O
younger	O
age	O
,	O
female	O
sex	O
,	O
comorbid	O
angina	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
use	O
of	O
a	O
hypoglycemic	O
agent	O
,	O
lower	O
activity	O
level	O
,	O
higher	O
New	O
York	O
Heart	O
Association	O
class	O
,	O
and	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
use	O
.	O


There	O
were	O
significant	O
correlations	O
between	O
each	O
of	O
the	O
QOL	B-O
scores	I-O
and	I-O
depression	I-O
.	I-O


CONCLUSIONS	O
Patients	B-P
with	I-P
heart	I-P
failure	I-P
with	I-P
preserved	I-P
ejection	I-P
fraction	I-P
,	I-P
who	I-P
were	I-P
younger	I-P
had	I-P
higher	I-P
New	I-P
York	I-P
Heart	I-P
Association	I-P
class	I-P
or	I-P
comorbid	I-P
angina	I-P
pectoris	I-P
,	I-P
had	I-P
lower	I-P
activity	I-P
levels	I-P
,	I-P
lived	I-P
in	I-P
Eastern	I-P
Europe	I-P
or	I-P
were	I-P
taking	I-P
hypoglycemic	I-P
agents	I-P
,	O
were	O
more	O
likely	O
to	O
have	O
impaired	B-P
QOL	I-P
and	I-P
depression	I-P
.	I-P


CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
:	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O


Unique	O
identifier	O
:	O
NCT00094302	O
.	O


Use	O
of	O
World	B-I
Wide	I-I
Web-based	I-I
directories	I-I
for	O
tracing	B-P
subjects	I-P
in	I-P
epidemiologic	I-P
studies	I-P
.	I-P


The	O
recent	O
availability	O
of	O
World	O
Wide	O
Web-based	O
directories	O
has	O
opened	O
up	O
a	O
new	O
approach	O
for	O
tracing	B-P
subjects	I-P
in	I-P
epidemiologic	I-P
studies	I-P
.	I-P


The	O
completeness	O
of	O
two	B-P
World	I-I
Wide	I-I
Web-based	I-I
directories	I-I
(	I-I
Canada411	I-I
and	I-I
InfoSpace	I-I
Canada	I-I
)	I-I
for	O
subject	O
tracing	O
was	O
evaluated	O
by	O
using	O
a	O
randomized	O
crossover	O
design	O
for	O
346	B-P
adults	I-P
randomly	I-P
selected	I-P
from	I-P
respondents	I-P
in	I-P
an	I-P
ongoing	I-P
cohort	I-P
study	I-P
.	I-P


About	O
half	O
(	O
56.4	O
%	O
)	O
of	O
the	O
subjects	O
were	O
successfully	O
located	O
by	O
using	O
either	O
Canada411	B-I
or	I-I
InfoSpace	I-I
.	I-I


Of	O
the	O
43.6	O
%	O
of	O
the	O
subjects	O
who	O
could	O
not	O
be	O
located	O
using	O
either	O
directory	O
,	O
the	O
majority	O
(	O
73.5	O
%	O
)	O
were	O
female	O
.	O


Overall	O
,	O
there	O
was	O
no	O
clear	O
advantage	B-O
of	O
one	O
directory	O
over	O
the	O
other	O
.	O


Although	O
Canada411	O
could	O
find	B-O
significantly	I-O
more	I-O
subjects	I-O
than	O
InfoSpace	O
,	O
the	O
number	B-O
of	I-O
potential	I-O
matches	I-O
returned	O
by	O
Canada411	O
was	O
also	O
higher	O
,	O
which	O
meant	O
that	O
a	O
longer	O
list	O
of	O
potential	O
matches	O
had	O
to	O
be	O
examined	O
before	O
a	O
true	O
match	O
could	O
be	O
found	O
.	O


One	O
strategy	O
to	O
minimize	O
the	O
number	O
of	O
potential	O
matches	O
per	O
true	O
match	O
is	O
to	O
first	O
search	O
by	O
InfoSpace	O
with	O
the	O
last	O
name	O
and	O
first	O
name	O
,	O
then	O
by	O
Canada411	O
with	O
the	O
last	O
name	O
and	O
first	O
name	O
,	O
and	O
finally	O
by	O
InfoSpace	O
with	O
the	O
last	O
name	O
and	O
first	O
initial	O
.	O


Internet-based	O
searches	O
represent	O
a	O
potentially	O
useful	O
approach	O
to	O
tracing	O
subjects	B-P
in	I-P
epidemiologic	I-P
studies	I-P
.	I-P


Ketorolac	B-I
versus	I-I
fentanyl	I-I
for	O
gynaecological	B-P
day-case	I-P
surgery	I-P
.	I-P


The	O
effectiveness	O
of	O
fentanyl	B-I
and	O
ketorolac	B-I
in	O
providing	O
analgesia	O
for	O
day-case	B-P
gynaecological	I-P
procedures	I-P
was	I-P
evaluated	I-P
in	I-P
55	I-P
healthy	I-P
volunteers	I-P
in	I-P
a	I-P
single	I-P
blinded	I-P
fashion	I-P
.	I-P


Fentanyl	B-I
(	O
1	O
mcg/kg	O
iv	O
)	O
and	O
ketorolac	B-I
(	O
30	O
mg	O
im	O
)	O
were	O
administered	O
immediately	O
following	O
induction	O
of	O
anaesthesia	O
.	O


Anaesthesia	O
was	O
standardized	O
with	O
propofol	B-I
,	I-I
nitrous	I-I
oxide	I-I
and	I-I
enflurane	I-I
.	I-I


Outcome	O
variables	O
assessed	O
were	O
pain	B-O
,	I-O
additional	I-O
analgesic	I-O
requirements	I-O
,	I-O
and	I-O
incidence	I-O
of	I-O
postoperative	I-O
nausea	I-O
and	I-O
vomiting	I-O
.	I-O


All	O
variables	O
were	O
recorded	O
at	O
15	O
minutes	O
,	O
2	O
hours	O
and	O
24	O
hours	O
postoperatively	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
with	O
respect	O
to	O
any	O
of	O
the	O
measured	O
variables	O
.	O


Both	O
drugs	O
were	O
ineffective	B-O
as	O
sole	B-O
analgesic	I-O
agents	I-O
in	O
half	O
of	O
their	O
respective	O
groups	O
.	O


It	O
may	O
be	O
that	O
a	O
combination	O
of	O
these	O
drugs	O
,	O
providing	O
a	O
multireceptor	O
approach	O
to	O
analgesia	O
,	O
will	O
prove	O
to	O
be	O
more	O
effective	O
.	O


Diazoxide	B-I
and	I-I
labetalol	I-I
in	O
acute	B-P
hypertension	I-O
during	O
haemodialysis	O
.	O


The	O
antihypertensive	O
effect	O
of	O
the	O
peripheral	B-I
vasodilator	I-I
diazoxide	I-I
in	O
13	B-P
patients	I-P
and	I-P
the	I-P
alpha-beta	I-I
adrenoceptor	I-I
blocking	I-I
agent	I-I
labetalol	I-I
in	I-P
12	I-P
patients	I-P
were	I-P
compared	I-P
in	I-P
46	I-P
severe	I-P
acute	I-P
hypertensive	I-O
episodes	I-P
during	I-P
haemodialysis	I-P
.	I-P


A	O
single	O
dose	O
of	O
diazoxide	B-I
150	I-I
mg	I-I
or	I-I
labetalol	I-I
50	I-I
mg	I-I
was	O
effective	O
in	O
74	O
%	O
and	O
70	O
%	O
of	O
the	O
hypertensive	B-O
episodes	O
,	O
respectively	O
.	O


In	O
the	O
diazoxide-treated	B-I
patients	I-P
blood	I-O
pressure	I-O
fell	O
from	O
192	O
+/-	O
3/115	O
+/-	O
4	O
mmHg	O
to	O
141	O
+/-	O
8/85	O
+/-	O
4	O
mmHg	O
2	O
h	O
after	O
injection	O
.	O


In	O
7	O
hypertensive	B-O
episodes	O
a	O
second	O
dose	O
of	O
diazoxide	B-I
150	O
mg	O
was	O
given	O
60	O
+/-	O
11	O
min	O
after	O
the	O
first	O
injection	O
.	O


The	O
reduction	O
in	O
mean	B-O
arterial	I-O
blood	I-O
pressure	I-O
at	O
the	O
end	O
of	O
haemodialysis	O
was	O
21.5	O
+/-	O
2.6	O
%	O
in	O
patients	O
treated	O
with	O
a	O
single	O
dose	O
and	O
24.8	O
+/-	O
3.5	O
%	O
in	O
patients	O
treated	O
with	O
the	O
repeated	O
dose	O
of	O
diazoxide	B-I
.	I-I


In	O
the	O
labetalol-treated	B-I
patients	I-P
blood	I-O
pressure	I-O
in	O
17	O
instances	O
fell	O
from	O
198	O
+/-	O
5/104	O
+/-	O
4	O
mmHg	O
to	O
143	O
+/-	O
7/89	O
+/-	O
5	O
mmHg	O
180	O
min	O
following	O
injection	O
of	O
labetalol	B-I
50	O
mg	O
.	O


In	O
6	O
episodes	O
a	O
second	O
dose	O
labetalol	B-I
50	O
mg	O
was	O
given	O
41	O
+/-	O
9	O
min	O
after	O
the	O
first	O
injection	O
.	O


At	O
the	O
end	O
of	O
haemodialysis	O
the	O
decrease	O
in	O
mean	B-O
arterial	I-O
blood	I-O
pressure	I-O
was	O
17.2	O
%	O
in	O
patients	O
treated	O
with	O
a	O
single	O
dose	O
and	O
18	O
+/-	O
5	O
%	O
in	O
patients	O
given	O
the	O
repeated	O
dose	O
of	O
labetalol	B-I
.	I-I


The	O
reduction	O
in	O
blood	B-O
pressure	I-O
caused	O
by	O
diazoxide	B-I
was	O
slightly	O
greater	O
than	O
that	O
due	O
to	O
labetalol	O
.	O


At	O
the	O
end	O
of	O
haemodialysis	O
the	O
percentage	O
reduction	O
in	O
mean	O
arterial	O
blood	O
pressure	O
was	O
23	O
+/-	O
2	O
%	O
in	O
the	O
diazoxide-treated	O
group	O
and	O
17	O
+/-	O
2	O
%	O
after	O
labetalol	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Topical	O
administration	O
of	O
diclofenac	B-I
(	O
1	O
%	O
)	O
in	O
the	O
prevention	O
of	O
miosis	B-O
during	I-P
vitrectomy	I-P
.	I-P


PURPOSE	O
A	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
was	O
conducted	O
to	O
assess	O
the	O
usefulness	O
of	O
preoperative	O
diclofenac	B-I
eye	O
drops	O
in	O
maintaining	O
mydriasis	B-O
during	O
vitrectomy	O
and	O
in	O
reducing	O
postoperative	B-O
inflammation	I-O
.	I-O


METHODS	O
Fifty	B-P
consecutive	I-P
patients	I-P
undergoing	I-P
vitrectomy	I-P
were	O
randomly	O
assigned	O
to	O
diclofenac	B-I
(	O
n	O
=	O
24	O
)	O
or	O
control	B-I
(	O
n	O
=	O
26	O
)	O
groups	O
.	O


All	O
patients	O
received	O
a	O
standard	O
preoperative	O
regimen	O
of	O
cyclopentolate	B-I
(	O
2	O
%	O
)	O
and	O
phenylephrine	B-I
hydrochloride	I-I
(	O
2.5	O
%	O
)	O
.	O


The	O
diclofenac	B-I
group	O
also	O
received	O
diclofenac	B-I
(	O
1	O
%	O
)	O
preoperatively	O
.	O


Pupillary	B-O
diameter	I-O
was	O
recorded	O
at	O
four	O
time	O
points	O
during	O
surgery	O
.	O


Inflammatory	B-O
indices	I-O
were	O
measured	O
postoperatively	O
using	O
slit-lamp	O
examination	O
.	O


RESULTS	O
After	O
induction	O
of	O
anesthesia	O
,	O
the	O
decrease	B-O
in	I-O
pupil	I-O
size	I-O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
(	O
P	O
=	O
0.112	O
)	O
,	O
but	O
for	O
the	O
next	O
two	O
stages	O
,	O
it	O
was	O
significantly	O
less	O
in	O
the	O
diclofenac	B-I
group	O
(	O
P	O
=	O
0.012	O
and	O
P	O
=	O
0.003	O
,	O
respectively	O
)	O
.	O


No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
for	O
anterior	B-O
chamber	I-O
cells	I-O
and	O
redness	B-O
in	I-O
the	I-O
eye	I-O
postoperatively	O
(	O
P	O
=	O
0.609	O
and	O
P	O
=	O
0.123	O
,	O
respectively	O
)	O
.	O


However	O
,	O
anterior	B-O
chamber	I-O
flare	I-O
was	O
significantly	O
greater	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0.035	O
)	O
,	O
and	O
patients	O
felt	O
significantly	O
more	O
pain	B-O
in	O
this	O
group	O
(	O
P	O
=	O
0.001	O
)	O
.	O


CONCLUSIONS	O
Topical	O
administration	O
of	O
diclofenac	B-I
was	O
effective	O
in	O
maintaining	B-O
mydriasis	I-O
during	O
vitrectomy	O
and	O
in	O
reducing	O
postoperative	B-O
pain	I-O
and	O
anterior	B-O
chamber	I-O
flare	I-O
as	O
determined	O
by	O
slit-lamp	O
evaluations	O
.	O


Clarithromycin	B-I
reduces	O
the	O
severity	B-O
of	I-O
bronchial	I-O
hyperresponsiveness	I-O
in	O
patients	B-P
with	I-P
asthma	I-P
.	I-P


A	O
randomised	O
double-blind	O
placebo-controlled	B-I
study	O
was	O
designed	O
to	O
evaluate	B-O
the	I-O
effects	I-O
of	O
a	O
semisynthetic	B-I
macrolide	I-I
antibiotic	I-I
,	I-I
clarithromycin	I-I
,	O
on	O
bronchial	B-O
hyperresponsiveness	I-O
to	O
methacholine	B-I
in	O
patients	B-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
asthma	I-P
.	I-P


Adult	B-P
asthma	I-P
patients	I-P
undergoing	I-P
treatment	I-P
with	I-P
budesonide	I-I
400	I-P
microg	I-P
b.i.d	I-P
.	I-P


and	B-P
salbutamol	I-I
200	I-P
microg	I-P
p.r.n	I-P
.	I-P


less	B-P
than	I-P
twice	I-P
weekly	I-P
were	I-P
studied	I-P
.	I-P


Arm	B-P
A	I-P
(	I-P
16	I-P
males/six	I-P
females	I-P
,	I-P
aged	I-P
48	I-P
+/-	I-P
16	I-P
yrs	I-P
)	I-P
received	I-P
clarithromycin	I-I
250	I-P
mg	I-P
b.i.d	I-P
.	I-P


for	B-P
8	I-P
weeks	I-P
,	I-P
arm	I-P
B	I-P
(	I-P
eight	I-P
males/12	I-P
females	I-P
,	I-P
aged	I-P
42	I-P
+/-	I-P
12	I-P
yrs	I-P
)	I-P
clarithromycin	I-I
250	O
mg	O
t.id	O
.	O


and	O
arm	O
C	O
(	O
six	O
males/15	O
females	O
,	O
aged	O
41	O
+/-	O
16	O
yrs	O
)	O
placebo	B-I
dextrose	I-I
tablets	O
.	O


Bronchial	B-O
hyperresponsiveness	I-O
was	I-O
quantified	I-O
by	O
measurement	O
of	O
the	O
provocative	B-O
dose	I-O
of	I-O
methacholine	I-O
causing	O
a	O
20	B-O
%	I-O
fall	I-O
in	I-O
forced	I-O
expiratory	I-O
volume	I-O
in	I-O
one	I-O
second	I-O
(	I-O
PD20	I-O
)	I-O
.	I-O


Median	B-O
(	I-O
interquartile	I-O
range	I-O
)	I-O
PD20	I-O
in	O
the	O
three	O
groups	O
before	O
and	O
after	O
treatment	O
with	O
clarithromycin	B-I
were	O
:	O
arm	O
A	O
:	O
0.3	O
(	O
0.1-1	O
)	O
and	O
1.3	O
(	O
0.6-2	O
)	O
mg	O
;	O
arm	O
B	O
:	O
0.4	O
(	O
0.1-0.9	O
)	O
and	O
2	O
(	O
2-2	O
)	O
mg	O
;	O
and	O
arm	O
C	O
:	O
0.4	O
(	O
0.1-0.9	O
)	O
and	O
0.3	O
(	O
0.1-0.6	O
)	O
mg	O
,	O
respectively	O
.	O


Serum	B-O
free	I-O
cortisol	I-O
levels	I-O
were	O
determined	O
and	O
remained	O
unchanged	O
from	O
baseline	O
in	O
the	O
clarithromycin-treated	B-I
patients	I-P
.	I-P


It	O
is	O
concluded	O
that	O
clarithromycin	B-I
reduces	O
the	O
degree	B-O
of	I-O
bronchial	I-O
hyperresponsiveness	I-O
in	O
patients	B-P
with	I-P
asthma	I-P
.	I-P


Risperidone	B-I
in	O
the	O
treatment	O
of	O
negative	B-O
symptoms	I-O
of	O
schizophrenia	B-P
:	I-P
a	O
meta-analysis	O
.	O


Risperidone	B-I
has	O
antiserotonergic	O
and	O
antidopaminergic	O
properties	O
that	O
may	O
make	O
it	O
more	O
effective	O
than	O
conventional	O
antipsychotic	O
agents	O
in	O
the	O
treatment	O
of	O
the	O
negative	B-O
symptoms	I-O
of	O
schizophrenia	B-P
.	I-P


Clinical	O
trials	O
in	O
chronic	B-P
schizophrenic	I-P
patients	I-P
have	O
shown	O
trends	O
in	O
favor	O
of	O
risperidone	B-I
in	O
the	O
control	O
of	O
negative	B-O
symptoms	I-O
compared	O
with	O
haloperidol	B-I
,	I-I
perphenazine	I-I
or	I-I
zuclopenthixol	I-I
,	O
but	O
the	O
differences	O
were	O
not	O
consistently	O
statistically	O
significant	O
.	O


A	O
meta-analysis	O
of	O
the	O
pooled	O
results	O
from	O
six	B-P
double-blind	I-P
trials	I-P
showed	O
that	O
risperidone	B-I
at	O
doses	O
ranging	O
from	O
4	O
to	O
8	O
mg/day	O
had	O
a	O
significantly	O
(	O
p	O
<	O
0.004	O
)	O
higher	O
negative	B-O
symptom	I-O
response	I-O
rate	I-O
,	O
defined	O
as	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
20	O
%	O
or	O
more	B-O
reduction	I-O
in	I-O
scores	I-O
on	I-O
the	I-O
negative	I-O
subscale	I-O
of	I-O
the	I-O
Positive	I-O
and	I-O
Negative	I-O
Syndrome	I-O
Scale	I-O
,	O
than	O
patients	O
receiving	O
active	O
controls	O
.	O


The	O
combined	B-P
patient	I-P
population	I-P
treated	O
with	O
4-8	O
mg/day	O
of	O
risperidone	B-I
was	O
1.43	O
times	O
more	O
likely	O
to	O
have	O
had	O
a	O
clinical	B-O
response	I-O
on	I-O
the	I-O
negative	I-O
symptom	I-O
subscale	I-O
than	O
the	O
combined	O
population	O
treated	O
with	O
haloperidol	B-I
,	I-I
perphenazine	I-I
or	I-I
zuclopenthixol	I-I
.	I-I


Effects	O
of	O
sodium	B-I
and	I-I
potassium	I-I
supplementation	I-I
on	O
blood	B-O
pressure	I-O
and	I-O
arterial	I-O
stiffness	I-O
:	I-O
a	O
fully	O
controlled	O
dietary	O
intervention	O
study	O
.	O


We	O
performed	O
a	O
randomised	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
to	O
examine	O
the	O
effects	O
of	O
sodium	B-I
and	I-I
potassium	I-I
supplementation	I-I
on	O
blood	B-O
pressure	I-O
(	I-O
BP	I-O
)	I-O
and	I-O
arterial	I-O
stiffness	I-O
in	I-P
untreated	I-P
(	I-P
pre	I-P
)	I-P
hypertensive	I-P
individuals	I-P
.	I-P


During	O
the	O
study	O
,	O
subjects	B-P
were	I-P
on	I-P
a	I-P
fully	I-P
controlled	I-P
diet	I-P
that	I-P
was	I-P
relatively	I-P
low	I-P
in	I-P
sodium	I-P
and	I-P
potassium	I-P
.	I-P


After	O
a	O
1-week	O
run-in	O
period	O
,	O
subjects	O
received	B-I
capsules	I-I
with	I-I
supplemental	I-I
sodium	I-I
(	I-I
3	I-I
g	I-I
d	I-I
(	I-I
-1	I-I
)	I-I
,	I-I
equals	I-I
7.6	I-I
g	I-I
d	I-I
(	I-I
-1	I-I
)	I-I
of	I-I
salt	I-I
)	I-I
,	I-I
supplemental	I-I
potassium	I-I
(	I-I
3	I-I
g	I-I
d	I-I
(	I-I
-1	I-I
)	I-I
)	I-I
or	I-I
placebo	I-I
,	I-I
for	I-I
4	I-I
weeks	I-I
each	I-I
,	I-I
in	I-I
random	I-O
order	I-O
.	I-O


Fasting	B-O
office	I-O
BP	I-O
,	I-O
24-h	I-O
ambulatory	I-O
BP	I-I
and	I-I
measures	I-O
of	I-O
arterial	I-O
stiffness	I-I
were	I-I
assessed	I-I
at	I-I
baseline	I-I
and	I-I
every	I-I
4	I-P
weeks	I-P
.	I-P


Of	B-P
37	I-P
randomized	I-P
subjects	I-P
,	I-P
36	I-P
completed	I-P
the	O
study	O
.	O


They	O
had	O
a	O
mean	O
pre-treatment	B-O
BP	O
of	O
145/81	B-O
mm	I-O
Hg	I-O
and	I-O
69	I-O
%	I-O
had	O
systolic	B-O
BP	I-O
⩾140	I-O
mm	I-O
Hg	I-O
.	O


Sodium	O
excretion	O
was	O
increased	O
by	B-O
98	I-O
mmol	I-O
per	I-O
24	I-O
h	I-O
and	O
potassium	O
excretion	O
by	O
63	O
mmol	O
per	O
24	O
h	O
during	O
active	O
interventions	O
,	O
compared	B-I
with	I-I
placebo	I-I
.	I-I


During	B-O
sodium	I-O
supplementation	I-O
,	O
office	O
BP	O
was	O
significantly	O
increased	B-O
by	O
7.5/3.3	O
mm	O
Hg	O
,	O
24-h	B-O
BP	I-O
by	I-O
7.5/2.7	O
mm	O
Hg	O
and	O
central	B-I
BP	I-I
by	I-I
8.5/3.6	I-O
mm	I-O
Hg	I-O
.	I-O


During	B-O
potassium	O
supplementation	O
,	O
24-h	O
BP	O
was	O
significantly	B-O
reduced	I-O
by	I-O
3.9/1.6	I-O
mm	I-O
Hg	I-O
and	I-O
central	I-O
pulse	I-O
pressure	I-O
by	I-O
2.9	I-O
mm	I-O
Hg	I-O
.	O


Pulse	O
wave	O
velocity	O
and	O
augmentation	B-I
index	I-I
were	I-I
not	I-I
significantly	I-I
affected	I-I
by	O
sodium	O
or	O
potassium	O
supplementation	O
.	O


In	O
conclusion	O
,	O
increasing	O
the	O
intake	B-O
of	O
sodium	B-P
caused	I-P
a	I-P
substantial	I-P
increase	I-O
in	O
BP	O
in	O
subjects	O
with	O
untreated	O
elevated	O
BP	O
.	O


Increased	O
potassium	O
intake	O
,	O
on	O
top	O
of	O
a	O
relatively	B-O
low-sodium	I-O
diet	I-O
,	I-O
had	I-O
a	O
beneficial	O
effect	O
on	O
BP	O
.	O


Arterial	O
stiffness	O
did	O
not	O
materially	O
change	O
during	O
4-week	O
interventions	O
with	O
sodium	O
or	O
potassium	O
.	O


A	O
randomized	O
trial	O
of	O
radiation	B-I
therapy	I-I
compared	O
to	O
split	B-I
course	I-I
radiation	I-I
therapy	I-I
combined	I-I
with	I-I
mitomycin	I-I
C	I-I
and	I-I
5	I-I
fluorouracil	I-I
as	O
initial	O
treatment	O
for	O
advanced	B-P
laryngeal	I-P
and	I-P
hypopharyngeal	I-P
squamous	I-P
carcinoma	I-P
.	I-P


Two	B-P
hundred	I-P
and	I-P
twelve	I-P
patients	I-P
with	I-P
previously	I-P
untreated	I-P
advanced	I-P
squamous	I-P
carcinoma	I-P
of	I-P
the	I-P
larynx	I-P
or	I-P
hypopharynx	I-P
were	O
randomized	O
to	O
receive	O
initial	O
treatment	O
with	O
radiotherapy	B-I
,	I-I
50	I-I
Gy	I-I
in	I-I
20	I-I
fractions	I-I
in	I-I
28	I-I
days	I-I
or	O
split	B-I
course	I-I
radiotherapy	I-I
and	I-I
concurrent	I-I
chemotherapy	I-I
,	I-I
25	I-I
Gy	I-I
in	I-I
10	I-I
fractions	I-I
in	I-I
14	I-I
days	I-I
followed	I-I
by	I-I
a	I-I
4	I-I
week	I-I
rest	I-I
and	I-I
a	I-I
further	I-I
25	I-I
Gy	I-I
in	I-I
10	I-I
fractions	I-I
in	I-I
14	I-I
days	I-I
starting	I-I
on	I-I
day	I-I
43	I-I
;	I-I
Mitomycin	I-I
C	I-I
was	I-I
given	I-I
on	I-I
day	I-I
1	I-I
and	I-I
day	I-I
43	I-I
and	I-I
5FU	I-I
continuous	I-I
infusions	I-I
on	I-I
days	I-I
1	I-I
--	I-I
4	I-I
and	I-I
days	I-I
43	I-I
--	I-I
46	I-I
.	I-I


Surgery	O
was	O
reserved	O
for	O
persistent	O
or	O
recurrent	O
disease	O
.	O


Two	B-P
hundred	I-P
and	I-P
nine	I-P
of	I-P
the	I-P
212	I-P
patients	I-P
randomized	I-P
were	I-P
included	I-P
in	I-P
the	I-P
analyses	I-P
.	I-P


Outcome	O
analyses	O
were	O
performed	O
at	O
a	O
median	O
follow-up	O
interval	O
of	O
4.4	O
years	O
.	O


No	O
patients	O
were	O
lost	O
to	O
follow-up	O
.	O


No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
arms	O
for	O
the	O
end	O
points	O
of	O
local	B-O
relapse-free	I-O
rate	I-O
(	O
p	O
=	O
0.91	O
)	O
,	O
regional	B-O
relapse-free	I-O
rate	I-O
(	O
p	O
=	O
0.17	O
,	O
adjusted	O
)	O
or	O
overall	B-O
survival	I-O
(	O
p	O
=	O
0.86	O
)	O
.	O


Eight-eight	O
patients	O
had	O
attempted	O
surgical	B-O
resection	I-O
following	I-O
radiotherapy	I-O
failure	I-O
.	I-O


The	O
contribution	O
of	O
salvage	O
surgery	O
to	O
overall	B-O
survival	I-O
was	I-O
similar	O
for	O
both	O
arms	O
of	O
the	O
study	O
as	O
was	O
the	O
surgical	B-O
complication	I-O
rate	I-O
.	I-O


Serious	B-O
late	I-O
radiation	I-O
toxicity	I-O
was	O
minimal	O
(	O
3	O
%	O
in	O
the	O
RT	O
group	O
,	O
0	O
%	O
in	O
the	O
radiation	O
therapy	O
plus	O
chemotherapy	O
group	O
)	O
.	O


The	O
result	O
of	O
the	O
trial	O
shows	O
no	O
advantage	O
in	O
terms	O
of	O
local	O
control	O
or	O
survival	O
for	O
the	O
experimental	O
treatment	O
arm	O
of	O
split	O
course	O
radiotherapy	B-I
and	O
concurrent	B-I
chemotherapy	I-I
with	I-I
Mitomycin	I-I
C	I-I
and	I-I
5	I-I
Fluorouracil	I-I
compared	O
to	O
radiotherapy	O
alone	O
.	O


Comparison	O
of	O
indicators	O
for	O
a	O
primary	O
care	O
medical	O
home	O
between	O
children	B-P
with	I-P
autism	I-P
or	I-P
asthma	I-P
and	I-P
other	I-P
special	I-P
health	I-P
care	I-P
needs	I-P
:	I-P
National	O
Survey	O
of	O
Children	O
's	O
Health	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
extent	O
to	O
which	O
parents	B-I
of	I-I
children	I-I
with	I-I
autism	I-I
compared	I-I
with	I-I
parents	I-I
of	I-I
children	I-I
with	I-I
asthma	I-I
or	I-I
other	I-I
special	I-I
health	I-I
care	I-I
needs	I-I
report	O
receiving	O
primary	O
care	O
for	O
their	O
child	O
consistent	O
with	O
the	O
American	O
Academy	O
of	O
Pediatrics	O
medical	O
home	O
model	O
.	O


DESIGN	O
Population-based	O
cross-sectional	O
study	O
.	O


SETTING	O
National	B-I
Survey	I-I
for	I-I
Children	I-I
's	I-I
Health	I-I
2003-2004	I-I
telephone	I-I
interview	I-I
.	I-I


PARTICIPANTS	O
Parents	B-P
of	I-P
495	I-P
children	I-P
with	I-P
autism	I-P
,	I-P
parents	I-P
of	I-P
6716	I-P
children	I-P
with	I-P
asthma	I-P
,	I-P
and	I-P
parents	I-P
of	I-P
11,403	I-P
children	I-P
with	I-P
other	I-P
special	I-P
health	I-P
care	I-P
needs	I-P
without	I-P
asthma	I-P
.	I-P


Main	O
Exposures	O
Autism	O
and	O
other	O
special	O
health	O
care	O
needs	O
including	O
asthma	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Medical	O
home	O
score	O
and	O
components	O
of	O
care	O
,	O
as	O
follows	O
:	O
personal	O
provider	O
and	O
preventive	O
;	O
family-centered	O
,	O
compassionate	O
,	O
and	O
culturally	O
appropriate	O
;	O
accessible	O
;	O
comprehensive	O
;	O
and	O
coordinated	O
.	O


RESULTS	O
The	O
odds	B-O
of	I-O
parents	I-O
reporting	I-O
care	I-O
consistent	I-O
with	I-O
that	I-O
in	I-O
a	I-O
medical	I-O
home	I-O
were	O
less	B-O
likely	I-O
for	I-O
children	I-O
with	I-O
autism	I-O
(	O
odds	O
ratio	O
,	O
0.45	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.30-0.66	O
)	O
and	O
more	O
likely	O
for	O
children	O
with	O
asthma	O
(	O
odds	O
ratio	O
,	O
1.17	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.06-1.30	O
)	O
compared	O
with	O
children	O
with	O
other	O
special	O
health	O
care	O
needs	O
(	O
1	O
[	O
reference	O
]	O
)	O
.	O


These	O
differences	O
persisted	O
even	O
after	O
controlling	O
for	O
condition	O
severity	O
,	O
personal	O
characteristics	O
,	O
and	O
insurance	O
status	O
.	O


Specific	O
components	O
of	O
a	O
medical	O
home	O
less	O
prevalent	O
among	O
children	O
with	O
autism	O
than	O
among	O
children	O
with	O
other	O
special	O
health	O
care	O
needs	O
included	O
family-centered	O
,	O
comprehensive	O
,	O
and	O
coordinated	O
care	O
.	O


CONCLUSION	O
Although	O
we	O
could	O
not	O
evaluate	O
the	O
reasons	O
why	O
,	O
a	O
large	O
percentage	O
of	O
children	O
with	O
autism	O
do	O
not	O
receive	O
primary	B-O
care	I-O
consistent	I-O
with	I-O
that	I-O
in	I-O
a	I-O
medical	I-O
home	I-O
.	I-O


Primary	B-O
hypothyroidism	I-O
associated	O
with	O
interferon	B-I
therapy	I-P
of	I-P
breast	I-P
cancer	I-P
.	I-P


Treatment	O
of	O
men	B-P
with	I-P
flat	I-P
(	I-P
FC	I-P
)	I-P
or	I-P
acuminata	I-P
(	I-P
CA	I-P
)	I-P
condylomata	I-P
with	I-P
interferon	I-I
alpha-2a	I-I
.	I-I


This	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
effect	O
of	O
CO2	B-I
laser	I-I
vaporization	I-I
,	I-I
5-fluorouracil	I-I
5	I-I
%	I-I
(	I-I
5-FU	I-I
)	I-I
topical	I-I
application	I-I
and	I-I
Interferon	I-I
alpha-2a	I-I
(	I-I
IFA	I-I
alpha-2a	I-I
)	I-I
in	O
the	O
treatment	O
of	O
C.A	B-P
.	I-P


or	B-P
F.C	I-P
.	I-P


of	B-P
the	I-P
male	I-P
genital	I-P
tract	I-P
.	I-P


From	B-P
March	I-P
1986	I-P
to	I-P
September	I-P
1991	I-P
,	I-P
1372	I-P
men	I-P
,	I-P
sexual	I-P
partners	I-P
of	I-P
women	I-P
with	I-P
F.C	I-P
.	I-P


or	B-P
C.A	I-P
.	I-P


or	B-P
cervical	I-P
intraepithelial	I-P
neoplasia	I-P
,	I-P
were	I-P
submitted	I-P
to	I-P
peoscopy	I-I
.	I-I


One	B-P
thousand	I-P
and	I-P
nineteen	I-P
(	I-P
74.27	I-P
%	I-P
)	I-P
men	I-P
presented	I-P
with	I-P
various	I-P
penile	I-P
lesions	I-P
caused	I-P
by	I-P
HPV	I-P
(	I-P
histologically	I-P
confirmed	I-P
)	I-P
;	I-P
of	O
these	O
505	B-P
were	I-P
treated	I-P
for	I-P
C.A	I-P
.	I-P


or	B-P
F.C	I-P
.	I-P


or	B-P
a	I-P
combination	I-P
of	I-P
F.C	I-P
.	I-P


and	B-P
C.A	I-P
.	I-P


The	O
best	O
treatment	O
modalities	O
,	O
irrespective	O
of	O
the	O
kind	O
of	O
lesion	O
,	O
were	O
found	O
to	O
be	O
the	O
combination	O
of	O
5-FU	B-I
plus	I-I
IFN	I-I
alpha-2a	I-I
(	O
high	O
dose	O
)	O
(	O
98.27	O
%	O
)	O
,	O
the	O
combination	O
of	O
CO2	B-I
laser	I-I
vaporization	I-I
plus	I-I
5-FU	I-I
plus	I-I
IFN	I-I
alpha-2a	I-I
(	I-I
high	I-I
dose	I-I
)	I-I
(	I-I
93.93	I-I
%	I-I
)	I-I
and	O
the	O
combination	B-I
of	I-I
CO2	I-I
laser	I-I
vaporization	I-I
plus	I-I
5-FU	I-I
(	O
87.23	O
%	O
)	O
.	O


In	O
conclusion	O
we	O
believe	O
that	O
IFN	B-I
alpha-2a	I-I
can	O
be	O
used	O
with	O
excellent	O
results	O
as	O
first	O
line	O
treatment	O
in	O
combination	O
with	O
CO2	B-I
laser	I-I
vaporization	I-I
or/plus	I-I
5-FU	I-I
in	O
patients	O
with	O
C.A	B-P
.	I-P


or	B-P
F.C	I-P
.	I-P


or	B-P
combined	I-P
condylomata	I-P
.	O


Riluzole	B-I
as	O
an	O
adjunctive	O
therapy	O
to	O
risperidone	B-I
for	O
the	O
treatment	O
of	O
irritability	B-O
in	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
:	I-P
a	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
randomized	O
trial	O
.	O


BACKGROUND	O
A	O
hyperglutamatergic	O
state	O
has	O
been	O
shown	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
pathophysiology	O
of	O
autistic	B-P
disorders	I-P
.	I-P


Riluzole	B-I
is	O
a	O
glutamate-modulating	O
agent	O
with	O
neuroprotective	O
properties	O
,	O
which	O
has	O
been	O
shown	O
to	O
have	O
positive	O
effects	O
in	O
many	O
neuropsychiatric	B-O
disorders	I-O
.	I-O


OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	B-O
and	I-O
tolerability	I-O
of	O
riluzole	B-I
as	O
an	O
adjunctive	O
to	O
risperidone	O
in	O
the	O
treatment	O
of	O
irritability	B-P
in	I-P
autistic	I-P
children	I-P
who	I-P
were	I-P
not	I-P
optimally	I-P
responding	I-P
to	O
previous	O
medications	O
.	O


STUDY	O
DESIGN	O
This	O
was	O
a	O
10-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
placebo-controlled	O
trial	O
.	O


PARTICIPANTS	O
The	O
study	O
enrolled	O
male	B-P
and	I-P
female	I-P
outpatients	I-P
aged	I-P
5-12	I-P
years	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
autistic	I-P
disorder	I-P
based	I-P
on	I-P
the	I-P
DSM-IV-TR	I-P
criteria	I-P
and	I-P
a	I-P
score	I-P
of	I-P
≥12	I-P
on	I-P
the	I-P
Aberrant	I-P
Behavior	I-P
Checklist-Community	I-P
(	I-P
ABC-C	I-P
)	I-P
irritability	I-P
subscale	I-P
who	I-P
had	I-P
discontinued	I-P
other	I-P
medications	I-P
because	I-P
of	I-P
a	I-P
lack	I-P
of	I-P
efficacy	I-P
.	O


INTERVENTIONS	O
Subjects	O
received	B-I
riluzole	I-I
(	O
titrated	O
to	O
50	O
or	O
100	O
mg/day	O
based	O
on	O
bodyweight	B-I
)	I-I
or	I-I
placebo	I-I
in	O
addition	B-I
to	I-I
risperidone	I-I
(	O
titrated	O
up	O
to	O
2	O
or	O
3	O
mg/day	O
based	O
on	O
bodyweight	O
)	O
for	O
10	O
weeks	O
.	O


OUTCOME	O
Patients	O
were	O
assessed	O
at	O
baseline	O
,	O
week	O
5	O
,	O
and	O
week	O
10	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
the	O
difference	O
in	O
the	O
change	O
in	B-O
the	I-O
ABC-C	I-O
irritability	I-O
subscale	I-O
score	O
from	O
baseline	O
to	O
week	O
10	O
between	O
the	O
two	O
groups	O
.	O


We	O
also	O
compared	O
changes	B-O
in	I-O
other	I-O
ABC-C	I-O
subscale	I-O
scores	I-O
and	I-O
Clinical	I-O
Global	I-O
Impressions-Improvement	I-O
(	I-O
CGI-I	I-O
)	I-O
scale	I-O
scores	I-O
between	O
the	O
two	O
groups	O
.	O


RESULTS	B-P
Forty-nine	I-P
patients	I-P
were	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
,	I-P
and	I-P
forty	I-P
children	I-P
completed	I-P
the	I-P
trial	O
(	O
dropouts	O
:	O
placebo	O
=	O
4	O
,	O
riluzole	O
=	O
5	O
)	O
.	O


A	O
significantly	O
greater	O
improvement	O
in	O
the	O
study	O
primary	O
outcome	B-O
(	I-O
the	I-O
ABC-C	I-O
irritability	I-O
subscale	I-O
score	O
)	O
was	O
achieved	B-I
by	I-I
the	I-I
riluzole-treated	O
children	O
compared	B-I
with	I-I
the	I-I
placebo	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O


Patients	B-I
in	I-I
the	I-I
riluzole	O
group	O
also	O
showed	O
significantly	O
greater	O
improvement	B-O
on	I-O
the	I-O
lethargy/social	I-O
withdrawal	O
(	B-O
P	I-O
=	I-O
0.02	I-O
)	I-O
,	I-O
stereotypic	I-O
behavior	O
(	B-O
P	I-O
=	I-O
0.03	I-O
)	I-O
,	I-O
and	I-O
hyperactivity/non-compliance	I-O
subscales	O
(	B-O
P	I-O
=	I-O
0.005	I-O
)	I-O
,	I-O
but	I-O
not	I-O
on	I-O
the	I-O
inappropriate	I-O
speech	O
subscale	O
(	O
P	O
=	O
0.20	O
)	O
than	O
patients	O
in	O
the	O
placebo	O
group	O
.	O


Eleven	B-I
patients	I-I
in	O
the	O
riluzole	O
group	O
and	O
five	B-I
patients	I-I
in	O
the	O
placebo	O
group	O
were	O
classified	O
as	O
responders	B-O
based	I-O
on	I-O
their	O
CGI-I	O
scores	O
[	O
χ	O
(	O
2	O
)	O
(	O
1	O
)	O
=	O
3.750	O
,	O
P	B-I
=	I-I
0.05	I-I
]	I-I
.	I-I


Children	O
in	O
the	O
riluzole	O
group	O
experienced	O
significantly	B-O
more	I-O
increases	I-O
in	I-O
their	I-O
appetite	O
and	O
bodyweight	B-I
than	I-I
children	O
in	O
the	O
placebo	O
group	O
by	O
the	O
end	O
of	B-I
the	I-I
study	I-I
.	O


CONCLUSION	O
Riluzole	O
add-on	B-O
therapy	I-O
shows	I-O
several	I-O
therapeutic	O
outcomes	O
,	O
particularly	B-O
for	I-O
improving	O
irritability	O
,	O
in	O
children	O
with	O
autism	B-I
.	I-I


However	B-I
,	I-I
its	I-I
add-on	O
to	O
risperidone	O
also	O
results	O
in	B-O
significantly	I-O
increased	I-O
appetite	O
and	O
weight	O
gain	O
.	O


Aspartame	B-I
:	I-I
neuropsychologic	O
and	O
neurophysiologic	O
evaluation	O
of	O
acute	O
and	O
chronic	O
effects	O
.	O


BACKGROUND	O
Neurobehavioral	O
symptoms	O
have	O
been	O
reported	O
anecdotally	O
with	O
aspartame	B-I
.	I-I


OBJECTIVE	O
This	O
study	O
sought	O
to	O
determine	O
whether	O
aspartame	B-I
can	O
disrupt	B-P
cognitive	I-P
,	I-P
neurophysiologic	I-P
,	I-P
or	I-P
behavioral	I-P
functioning	I-P
in	I-P
normal	I-P
individuals	I-P
.	I-P


DESIGN	O
Forty-eight	B-P
healthy	I-P
volunteers	I-P
completed	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
crossover	O
study	O
.	O


The	O
first	O
month	O
was	O
aspartame	B-I
free	O
.	O


Subjects	O
then	O
consumed	O
sodas	B-I
and	I-I
capsules	I-I
with	I-I
placebo	I-I
,	I-I
aspartame	I-I
,	I-I
or	I-I
sucrose	I-I
for	I-I
20	I-I
d	I-I
each	I-I
.	I-I


Order	O
was	O
randomized	O
and	O
subjects	O
were	O
assigned	O
to	O
either	O
a	O
high-	O
(	O
45	O
mg	O
x	O
kg	O
body	O
wt	O
(	O
-1	O
)	O
x	O
d	O
(	O
-1	O
)	O
)	O
or	O
low-	O
(	O
15	O
mg	O
x	O
kg	O
body	O
wt	O
(	O
-1	O
)	O
x	O
d	O
(	O
-1	O
)	O
)	O
dose	O
aspartame	B-I
group	O
.	O


Neuropsychologic	O
and	O
laboratory	O
testing	O
was	O
done	O
on	O
day	O
10	O
of	O
each	O
treatment	O
period	O
to	O
determine	O
possible	O
acute	O
effects	O
and	O
on	O
day	O
20	O
for	O
possible	O
chronic	O
effects	O
.	O


RESULTS	O
Plasma	O
phenylalanine	O
concentrations	O
increased	O
significantly	O
during	O
aspartame	O
treatment	O
.	O


Neuropsychologic	O
results	O
;	O
adverse	O
experiences	O
;	O
amino	O
acid	O
,	O
insulin	O
,	O
and	O
glucose	O
values	O
;	O
and	O
electroencephalograms	O
were	O
compared	O
by	O
sex	O
and	O
by	O
treatment	O
.	O


No	O
significant	O
differences	O
were	O
found	O
for	O
any	O
dependent	O
measure	O
.	O


CONCLUSION	O
Large	O
daily	O
doses	O
of	O
aspartame	B-I
had	O
no	O
effect	O
on	O
neuropsychologic	O
,	O
neurophysiologic	O
,	O
or	O
behavioral	O
functioning	O
in	O
healthy	B-P
young	I-P
adults	I-P
.	I-P


How	O
can	O
we	O
help	O
witnesses	B-P
to	O
remember	B-O
more	I-O
?	O
It	O
's	O
an	O
(	O
eyes	O
)	O
open	O
and	O
shut	O
case	O
.	O


Five	O
experiments	O
tested	O
the	O
idea	O
that	O
instructing	O
a	O
witness	B-P
to	O
close	O
their	O
eyes	O
during	O
retrieval	O
might	O
increase	O
retrieval	B-O
success	I-O
.	I-O


In	O
Experiment	O
1	O
participants	B-P
watched	I-I
a	I-I
video	I-I
,	O
before	O
a	O
cued-recall	O
test	O
for	O
which	O
they	O
were	O
either	O
instructed	O
to	O
close	O
their	O
eyes	O
,	O
or	O
received	O
no-instructions	B-I
.	I-I


Eye-closure	O
led	O
to	O
an	O
increase	O
in	O
correct	B-O
cued-recall	I-O
,	O
with	O
no	O
increase	O
in	O
incorrect	B-O
responses	I-O
.	I-O


Experiments	O
2-5	O
sought	O
to	O
test	O
the	O
generality	O
of	O
this	O
effect	O
over	O
variations	O
in	O
study	O
material	O
(	B-I
video	I-I
or	I-I
live	I-I
interaction	I-I
)	I-I
,	O
test	O
format	O
(	B-I
cued-	I-I
or	I-I
free-recall	I-I
)	I-I
and	O
information	O
modality	O
(	B-I
visual	I-I
or	I-I
auditory	I-I
details	I-I
recalled	I-I
)	I-I
.	O


Overall	O
,	O
eye-closure	O
increased	O
recall	B-O
of	I-O
both	I-O
visual	I-O
detail	I-O
and	I-O
auditory	I-O
details	I-O
,	O
with	O
no	O
accompanying	O
increase	O
in	O
recall	B-O
of	I-O
false	I-O
details	I-O
.	I-O


Collectively	O
,	O
these	O
data	O
convincingly	O
demonstrate	O
the	O
benefits	O
of	O
eye-closure	O
as	O
an	O
aid	O
to	O
retrieval	B-O
,	O
and	O
offer	O
insight	O
into	O
why	O
hypnosis	O
,	O
which	O
usually	O
involves	O
eye-closure	O
,	O
may	O
facilitate	O
eyewitness	B-O
recall	I-O
.	I-O


B-type	B-I
natriuretic	I-I
peptide	I-I
for	O
acute	O
dyspnea	O
in	O
patients	B-P
with	I-P
kidney	I-P
disease	I-P
:	I-P
insights	O
from	O
a	O
randomized	O
comparison	O
.	O


BACKGROUND	O
B-type	B-O
natriuretic	I-O
peptide	I-O
(	I-O
BNP	I-O
)	I-O
levels	I-O
are	O
reliably	O
elevated	O
in	O
patients	B-P
with	I-P
congestive	I-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
and	O
therefore	O
helpful	O
in	O
its	O
diagnosis	O
.	O


However	O
,	O
kidney	O
disease	O
results	O
in	O
elevated	O
BNP	O
levels	O
independently	O
of	O
CHF	O
.	O


Accordingly	O
,	O
the	O
impact	O
of	O
kidney	O
disease	O
on	O
the	O
benefit	O
of	O
BNP	B-I
testing	O
needs	O
to	O
be	O
scrutinized	O
.	O


METHODS	O
This	O
study	O
evaluated	O
patients	B-P
with	I-P
and	I-P
without	I-P
kidney	I-P
disease	I-P
[	I-P
glomerular	I-P
filtration	I-P
rate	I-P
(	I-P
GFR	I-P
)	I-P
less	I-P
than	I-P
60	I-P
mL/min/1.73	I-P
m	I-P
(	I-P
2	I-P
)	I-P
)	I-P
presenting	I-P
with	I-P
acute	I-P
dyspnea	I-P
.	I-P


A	O
total	O
of	O
452	B-P
consecutive	I-P
patients	I-P
(	I-P
240	I-P
with	I-P
kidney	I-P
disease	I-P
and	I-P
212	I-P
without	I-P
kidney	I-P
disease	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
a	O
diagnostic	B-I
strategy	I-I
with	I-I
(	I-I
BNP	I-I
group	I-I
)	I-I
or	I-I
without	I-I
(	I-I
control	I-I
group	I-I
)	I-I
the	I-I
use	I-I
of	I-I
BNP	I-I
levels	I-I
provided	I-I
by	I-I
a	I-I
rapid	I-I
bedside	I-I
assay	I-I
.	I-I


RESULTS	O
Patients	B-P
with	I-P
kidney	I-P
disease	I-P
were	I-P
older	I-P
,	I-P
more	I-P
often	I-P
had	I-P
CHF	I-O
as	I-O
the	I-O
cause	I-O
of	I-O
acute	I-O
dyspnea	I-O
,	I-P
and	I-P
more	I-P
often	I-P
died	I-P
in-hospital	I-P
or	I-P
within	I-P
30	I-P
days	I-P
as	I-P
compared	I-P
to	I-P
patients	I-P
without	I-P
kidney	I-P
disease	I-P
.	O


In	O
patients	O
without	O
kidney	O
disease	O
,	O
BNP	B-I
testing	I-I
significantly	O
reduced	O
median	B-O
time	I-O
to	I-O
discharge	I-O
(	O
from	O
9.5	O
days	O
to	O
2.5	O
days	O
)	O
(	O
P=	O
0.003	O
)	O
and	O
total	B-O
cost	I-O
of	I-O
treatment	I-O
(	O
from	O
7184	O
dollars	O
to	O
4151	O
dollars	O
)	O
(	O
P=	O
0.004	O
)	O
.	O


In	O
contrast	O
,	O
in	O
patients	O
with	O
kidney	O
disease	O
,	O
time	O
to	O
discharge	O
and	O
total	O
cost	O
of	O
treatment	O
were	O
similar	O
in	O
both	O
groups	O
.	O


CONCLUSION	O
When	O
applying	O
BNP	B-I
cut-off	O
values	O
without	O
adjustment	O
for	O
the	O
presence	O
of	O
kidney	O
disease	O
,	O
the	O
use	O
of	O
BNP	B-O
levels	I-O
does	O
significantly	O
improve	O
the	O
management	O
of	O
patients	O
without	O
kidney	O
disease	O
,	O
but	O
not	O
of	O
those	O
with	O
kidney	O
disease	O
.	O


The	O
effect	O
of	O
Cys	B-I
LT1	I-I
receptor	I-I
blockade	I-I
on	O
airway	B-P
responses	I-P
to	I-P
allergen	I-P
.	I-P


STUDY	O
OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
potent	O
experimental	O
leukotriene	B-I
receptor	I-I
antagonist	I-I
,	I-I
MK-571	I-I
,	O
on	O
airway	B-P
responses	I-P
to	I-P
inhaled	I-P
allergen	I-P
.	I-P


DESIGN	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
crossover	O
trial	O
.	O


SETTING	O
Clinical	O
research	O
center	O
.	O


SUBJECTS	O
Eight	B-P
male	I-P
volunteers	I-P
with	I-P
allergic	I-P
asthma	I-P
.	I-P


INTERVENTIONS	O
An	O
intravenous	O
loading	O
dose	O
was	O
followed	O
by	O
an	O
8-hour	B-I
infusion	I-I
of	I-I
MK-571	I-I
or	I-I
placebo	I-I
,	O
with	O
a	O
7-	O
to	O
14-day	O
washout	O
between	O
treatments	O
.	O


Allergen	O
challenge	O
was	O
performed	O
after	O
the	O
loading	O
dose	O
and	O
a	O
histamine	B-I
challenge	O
was	O
performed	O
before	O
and	O
24	O
hours	O
after	O
allergen	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Forced	B-O
expiratory	I-O
volume	I-O
in	O
1	O
second	O
was	O
measured	O
serially	O
.	O


MK-571	B-I
provided	O
about	O
50	O
%	O
protection	O
during	O
maximum	O
early	O
and	O
late	O
responses	O
compared	O
with	O
placebo	B-I
(	O
p=0.005	O
)	O
,	O
but	O
airway	B-O
obstruction	I-O
persisted	O
8-24	O
hours	O
after	O
allergen	O
on	O
both	O
treatment	O
days	O
.	O


Airway	B-O
responsiveness	I-O
to	I-O
histamine	I-O
was	O
not	O
significantly	O
attenuated	O
at	O
24	O
hours	O
.	O


CONCLUSION	O
Blocking	O
Cys	O
LT1	O
receptors	O
for	O
8	O
hours	O
attenuated	O
the	O
early	O
and	O
late	O
responses	O
but	O
did	O
not	O
interrupt	O
the	O
cascade	O
of	O
events	O
leading	O
to	O
subsequent	O
allergen-induced	O
airway	O
obstruction	O
and	O
hyperreactivity	O
.	O


A	O
comparison	O
of	O
the	O
recovery	B-O
times	I-O
of	O
desflurane	B-I
and	O
isoflurane	B-I
in	O
outpatient	B-P
anesthesia	I-P
.	I-P


The	O
low	O
solubility	O
of	O
desflurane	B-I
has	O
been	O
shown	O
to	O
contribute	O
to	O
faster	O
awakening	O
from	O
anesthesia	O
when	O
compared	O
with	O
other	O
anesthetics	O
in	O
common	O
use	O
.	O


However	O
,	O
research	O
has	O
failed	O
to	O
consistently	O
demonstrate	O
faster	O
discharge	O
times	O
from	O
the	O
postanesthesia	O
care	O
unit	O
following	O
the	O
use	O
of	O
desflurane	B-I
.	I-I


This	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
recovery	B-O
and	I-O
discharge	I-O
times	I-O
of	O
outpatients	B-P
undergoing	I-P
procedures	I-P
greater	I-P
than	I-P
2	I-P
hours	I-P
in	I-P
length	I-P
.	I-P


Thirty-three	B-P
patients	I-P
aged	I-P
18	I-P
to	I-P
70	I-P
years	I-P
were	O
randomized	O
to	O
receive	O
either	O
desflurane	B-I
or	O
isoflurane	B-I
following	O
a	O
standard	O
intravenous	O
induction	O
with	O
propofol	B-I
.	I-I


Patients	B-P
received	O
premedication	O
and	O
opioids	O
consistent	O
with	O
institutional	O
practice	O
,	O
and	O
inhalation	O
agents	O
were	O
titrated	O
to	O
effect	O
during	O
anesthetic	O
maintenance	O
.	O


Following	O
surgery	O
,	O
patients	B-P
were	O
evaluated	O
for	O
time	B-O
to	I-O
emergence	I-O
and	I-O
time	I-O
to	I-O
meeting	I-O
discharge	I-O
criteria	I-O
.	I-O


The	O
results	O
demonstrated	O
no	O
differences	O
between	O
the	O
emergence	O
or	O
discharge	O
times	O
following	O
desflurane	B-I
or	O
isoflurane	B-I
.	I-I


In	O
addition	O
,	O
measured	O
parameters	O
,	O
such	O
as	O
intraoperative	B-O
vital	I-O
signs	I-O
and	I-O
postoperative	I-O
emesis	I-O
and	I-O
opioid	I-O
requirements	I-O
,	O
were	O
not	O
different	O
between	O
the	O
groups	O
.	O


The	O
use	O
of	O
desflurane	B-I
as	O
part	O
of	O
a	O
balanced	O
anesthetic	O
technique	O
did	O
not	O
speed	O
the	O
emergence	O
or	O
discharge	B-O
time	I-O
when	O
compared	O
with	O
isoflurane	B-I
.	I-I


Removing	B-I
bee	I-I
stings	I-I
.	I-I


BACKGROUND	O
Conventional	O
advice	O
on	O
immediate	O
treatment	O
of	O
honey-bee	O
stings	O
has	O
emphasised	O
that	O
the	O
sting	O
should	O
be	O
scraped	O
off	O
,	O
never	O
pinched	O
.	O


The	O
morphology	O
of	O
the	O
sting	O
suggested	O
little	O
basis	O
for	O
this	O
advice	O
,	O
which	O
is	O
likely	O
to	O
slow	O
down	O
removal	O
of	O
the	O
sting	O
.	O


METHODS	O
The	O
response	O
to	O
honey-bee	B-P
stings	I-P
was	O
assayed	O
with	O
a	O
measurement	O
of	O
the	O
size	O
of	O
the	O
resulting	O
weal	O
.	O


Injection	O
of	O
known	O
quantities	O
of	O
venom	B-I
showed	O
that	O
this	O
measurement	O
is	O
a	O
good	O
indicator	O
of	O
envenomisation	O
.	O


FINDINGS	O
Weal	B-O
size	I-O
,	O
and	O
thus	O
envenomisation	O
,	O
increased	O
as	O
the	O
time	B-O
from	I-O
stinging	I-O
to	I-O
removal	I-O
of	I-O
the	I-O
sting	I-O
increased	O
,	O
even	O
within	O
a	O
few	O
seconds	O
.	O


There	O
was	O
no	O
difference	O
in	O
response	O
between	O
stings	B-O
scraped	I-O
or	I-O
pinched	I-O
off	I-O
after	O
2	O
s.	O
INTERPRETATION	O
These	O
data	O
suggest	O
that	O
advice	O
to	O
patients	B-P
on	I-P
the	I-P
immediate	I-P
treatment	I-P
of	I-P
bee	I-O
stings	I-O
should	O
emphasise	O
quick	B-I
removal	I-I
,	O
without	O
concern	O
for	O
the	O
method	O
of	O
removal	O
.	O


Atrophy	O
and	O
intestinal	B-P
metaplasia	I-P
one	O
year	O
after	O
cure	O
of	O
H.	B-P
pylori	I-P
infection	I-P
:	I-P
a	O
prospective	O
,	O
randomized	O
study	O
.	O


BACKGROUND	O
&	O
AIMS	O
Helicobacter	O
pylori-infected	O
gastric	O
mucosa	O
evolves	O
through	O
stages	O
of	O
chronic	O
gastritis	O
,	O
intestinal	O
metaplasia	O
(	O
IM	O
)	O
,	O
glandular	O
atrophy	O
(	O
GA	O
)	O
,	O
and	O
dysplasia	O
before	O
carcinoma	O
develops	O
.	O


We	O
studied	O
if	O
H.	O
pylori	O
eradication	O
would	O
alter	O
the	O
course	O
of	O
premalignant	O
histologic	O
changes	O
in	O
the	O
stomach	O
.	O


METHODS	O
Volunteers	B-P
from	I-P
the	I-P
Yantai	I-P
County	I-P
in	I-P
China	I-P
underwent	I-P
upper	I-I
endoscopy	I-I
with	I-I
biopsy	I-I
specimens	I-P
obtained	I-P
from	I-P
the	I-P
antrum	I-P
and	I-P
corpus	I-P
.	I-P


H.	B-P
pylori-infected	I-P
subjects	I-P
were	O
randomized	O
to	O
receive	O
either	O
a	O
1-week	B-I
course	I-I
of	I-I
omeprazole	I-I
,	I-I
amoxicillin	I-I
,	I-I
and	I-I
clarithromycin	I-I
(	I-I
OAC	I-I
)	I-I
or	I-I
placebo	I-I
.	I-I


At	O
1	O
year	O
,	O
endoscopies	O
with	O
biopsies	O
were	O
repeated	O
.	O


RESULTS	O
A	O
total	B-P
of	I-P
587	I-P
H.	I-P
pylori-infected	I-P
subjects	I-P
were	I-P
randomized	I-P
to	I-P
OAC	I-I
(	O
n	O
=	O
295	O
)	O
and	O
placebo	O
(	O
n	O
=	O
292	O
)	O
.	O


At	O
1	O
year	O
,	O
H.	O
pylori	O
was	O
eradicated	O
in	O
226	O
subjects	O
assigned	O
to	O
OAC	B-I
.	O


In	O
the	O
placebo	B-I
group	O
,	O
245	B-P
patients	I-P
remained	I-P
H.	I-P
pylori	I-P
infected	I-P
.	I-P


Analysis	O
of	O
paired	O
samples	O
obtained	O
from	O
the	O
same	O
patients	O
showed	O
that	O
acute	B-O
and	I-O
chronic	I-O
gastritis	I-O
decreased	O
in	O
both	O
the	O
antrum	O
and	O
corpus	O
after	O
H.	O
pylori	O
eradication	O
(	O
P	O
<	O
0.001	O
)	O
and	O
activity	B-O
of	I-O
IM	I-O
decreased	O
in	O
antrum	O
(	O
P	O
=	O
0.014	O
)	O
.	O


In	O
the	O
H.	O
pylori-infected	O
group	O
,	O
antral	O
biopsy	O
specimens	O
had	O
more	O
pronounced	O
acute	B-O
gastritis	I-O
(	O
P	O
=	O
0.01	O
)	O
,	O
whereas	O
corpus	O
specimens	O
showed	O
increased	O
acute	B-O
and	I-O
chronic	I-O
gastritis	I-O
(	O
P	O
<	O
0.001	O
)	O
and	O
a	O
marginal	O
increase	O
in	O
GA	B-O
(	O
P	O
=	O
0.052	O
)	O
.	O


When	O
histologic	O
changes	O
were	O
compared	O
between	O
the	O
2	O
groups	O
,	O
decrease	O
in	O
acute	B-O
and	I-O
chronic	I-O
gastritis	I-O
was	O
more	O
frequent	O
after	O
H.	O
pylori	O
eradication	O
(	O
P	O
<	O
0.001	O
)	O
but	O
changes	O
in	O
IM	B-O
were	O
similar	O
.	O


In	O
the	O
H.	O
pylori-infected	O
group	O
,	O
increase	O
in	O
GA	B-O
was	O
seen	O
in	O
the	O
corpus	O
(	O
P	O
=	O
0.01	O
)	O
.	O


CONCLUSIONS	O
At	O
1	O
year	O
,	O
H.	O
pylori	O
eradication	O
is	O
beneficial	O
in	O
preventing	O
progression	O
of	O
pathologic	B-O
changes	I-O
of	O
the	O
gastric	O
mucosa	O
.	O


Metronidazole	B-I
in	O
periodontitis	B-I
(	O
IV	O
)	O
.	O


The	O
effect	O
of	O
patient	O
compliance	O
on	O
treatment	O
parameters	O
.	O


Patient	O
compliance	O
with	O
the	O
unsupervised	O
usage	O
of	O
prescription	O
medication	O
can	O
be	O
poor	O
.	O


In	O
the	O
treatment	O
of	O
periodontal	B-P
infections	I-P
with	I-P
systemic	I-P
antimicrobial	I-P
agents	I-P
,	O
in	O
situations	O
where	O
the	O
efficacy	O
of	O
the	O
antimicrobial	O
agent	O
is	O
being	O
evaluated	O
,	O
non-compliance	O
could	O
underestimate	O
the	O
true	O
efficacy	O
of	O
the	O
agent	O
.	O


Metronidazole	B-I
is	O
an	O
agent	O
with	O
reported	O
success	O
in	O
the	O
treatment	O
of	O
anaerobic	O
periodontal	O
infections	O
.	O


Metronidazole	B-I
is	O
particularly	O
effective	O
in	O
vitro	O
against	O
spirochetes	O
,	O
and	O
this	O
efficacy	O
was	O
investigated	O
as	O
a	O
means	O
of	O
measuring	O
patient	O
compliance	O
with	O
metronidazole	B-I
usage	O
.	O


Patients	B-P
who	I-P
had	I-P
high	I-P
proportions	I-P
of	I-P
spirochetes	I-P
,	I-P
i.e.	I-P
,	O
>	B-P
20	I-P
%	I-P
,	I-P
in	I-P
plaques	I-P
removed	I-P
from	I-P
diseased	I-P
periodontal	I-P
sites	I-P
,	O
were	O
given	O
metronidazole	B-I
(	O
500	O
mg	O
bid	O
)	O
under	O
supervision	O
.	O


In	O
all	O
individuals	O
who	O
received	O
the	O
metronidazole	B-I
,	O
there	O
was	O
a	O
significant	B-O
and	I-O
rapid	I-O
decline	I-O
and/or	I-O
disappearance	I-O
of	I-O
spirochetes	I-O
from	I-O
the	I-O
plaque	I-O
during	O
the	O
time	O
interval	O
that	O
metronidazole	B-I
was	O
detectable	O
in	O
the	O
saliva	O
.	O


This	O
observed	O
decline	O
in	O
spirochetes	O
was	O
then	O
used	O
to	O
determine	O
which	O
patients	O
had	O
been	O
compliant	O
in	O
a	O
double-blind	O
clinical	O
trial	O
involving	O
the	O
unsupervised	O
usage	O
of	O
metronidazole	B-I
.	I-I


Only	O
10	O
of	O
18	B-P
patients	I-P
(	O
56	O
%	O
)	O
were	O
considered	O
compliant	O
in	O
their	O
usage	O
of	O
metronidazole	B-I
.	I-I


These	O
10	O
patients	O
experienced	O
a	O
significantly	B-O
greater	I-O
benefit	I-O
from	I-O
the	I-O
metronidazole	I-O
than	O
did	O
the	O
8	O
patients	O
who	O
were	O
considered	O
noncompliant	O
,	O
i.e.	O
,	O
a	O
reduction	B-O
of	I-O
surgical	I-O
needs	I-O
of	O
8.3	O
teeth	O
per	O
compliant	O
patient	O
versus	O
3.6	O
teeth	O
per	O
non-compliant	O
patient	O
.	O


A	O
test	O
for	O
the	O
hydrolysis	O
of	O
the	O
synthetic	O
peptide	O
(	O
BANA	O
)	O
was	O
also	O
able	O
to	O
identify	O
most	O
non-compliant	O
patients	O
.	O


Clinical	O
trials	O
involving	O
the	O
unsupervised	O
usage	O
of	O
systemic	O
medication	O
need	O
to	O
take	O
into	O
account	O
patient	O
non-compliance	O
.	O


Chromium	B-I
Supplementation	I-I
and	O
the	O
Effects	O
on	O
Metabolic	B-O
Status	I-O
in	O
Women	B-P
with	I-P
Polycystic	I-P
Ovary	I-P
Syndrome	I-P
:	I-P
A	O
Randomized	O
,	O
Double-Blind	O
,	O
Placebo-Controlled	O
Trial	O
.	O


BACKGROUND	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
beneficial	O
effects	O
of	O
chromium	B-I
intake	O
on	O
markers	O
of	O
insulin	B-O
metabolism	I-O
and	O
lipid	B-O
profiles	I-O
in	O
women	B-P
with	I-P
polycystic	I-P
ovary	I-P
syndrome	I-P
(	I-P
PCOS	I-P
)	I-P
.	I-P


METHODS	O
In	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
,	O
64	B-P
women	I-P
with	I-P
PCOS	I-P
were	I-P
randomized	I-P
to	O
receive	O
200	B-I
µg	I-I
chromium	I-I
picolinate	I-I
supplements	I-I
(	I-I
n	I-I
=	I-I
32	I-I
)	I-I
or	I-I
placebo	I-I
(	O
n	O
=	O
32	O
)	O
for	O
8	O
weeks	O
.	O


Fasting	B-O
blood	I-O
samples	I-O
were	O
obtained	O
at	O
baseline	O
and	O
8	O
weeks	O
after	O
the	O
intervention	O
to	O
quantify	O
markers	O
of	O
insulin	O
metabolism	O
and	O
lipid	O
concentrations	O
.	O


RESULTS	B-I
Chromium	I-I
supplementation	O
in	O
women	O
with	O
PCOS	O
resulted	O
in	O
significant	O
decreases	O
in	B-O
serum	I-O
insulin	I-O
levels	I-O
(	O
-3.6	O
±	O
7.4	O
vs.	O
+3.6	O
±	O
6.2	O
µIU/ml	O
,	O
p	O
<	O
0.001	B-O
)	I-O
,	I-O
homeostasis	I-O
model	I-O
of	I-O
assessment-insulin	I-O
resistance	I-O
(	O
HOMA-IR	O
;	O
-0.8	O
±	O
1.6	O
vs.	O
+0.9	O
±	O
1.5	O
,	O
p	O
<	O
0.001	B-O
)	I-O
,	I-O
homeostatic	I-O
model	I-O
assessment-beta	I-O
cell	I-O
function	I-O
(	O
HOMA-B	O
;	O
-15.5	O
±	O
32.3	O
vs.	O
+13.6	O
±	O
23.1	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
a	O
significant	O
increase	B-O
in	I-O
quantitative	I-O
insulin	I-O
sensitivity	I-O
check	I-O
index	I-O
(	I-O
QUICKI	I-O
)	I-O
score	O
(	O
+0.02	O
±	O
0.03	O
vs.	O
-0.008	O
±	O
0.02	O
,	O
p	O
=	O
0.001	O
)	O
compared	B-I
with	I-I
the	I-I
placebo	O
.	O


In	O
addition	O
,	O
a	O
trend	O
toward	O
a	O
significant	O
effect	B-I
of	I-I
chromium	O
supplementation	O
on	O
decreasing	B-O
serum	I-O
triglycerides	I-O
(	O
-12.4	O
±	O
74.4	O
vs.	O
+15.2	O
±	O
32.4	O
mg/dl	O
,	O
p	O
=	O
0.05	B-O
)	I-O
,	I-O
very	I-O
low-density	I-O
lipoprotein-cholesterol	I-O
(	O
-2.5	O
±	O
14.9	O
vs.	O
+3.0	O
±	O
6.5	O
mg/dl	O
,	O
p	B-O
=	I-O
0.05	I-O
)	I-O
,	I-O
and	I-O
cholesterol	I-O
concentrations	I-O
(	O
-8.6	O
±	O
21.9	O
vs.	O
+0.7	O
±	O
22.4	O
mg/dl	O
,	O
p	O
=	O
0.09	O
)	O
was	O
seen	O
.	O


CONCLUSIONS	B-I
Eight	I-I
weeks	I-I
of	O
chromium	O
supplementation	B-P
among	I-P
PCOS	O
women	O
had	O
favorable	B-O
effects	I-O
on	I-O
markers	I-O
of	I-O
insulin	I-O
metabolism	O
.	O


Delayed	B-P
perceptual	I-P
awareness	I-P
in	O
rapid	B-P
perceptual	I-P
decisions	I-P
.	I-P


The	O
flourishing	O
of	O
studies	O
on	O
the	O
neural	O
correlates	O
of	O
decision-making	O
calls	O
for	O
an	O
appraisal	O
of	O
the	O
relation	O
between	O
perceptual	O
decisions	O
and	O
conscious	O
perception	O
.	O


By	O
exploiting	O
the	O
long	B-I
integration	I-I
time	I-I
of	I-I
noisy	I-I
motion	I-I
stimuli	I-I
,	I-I
and	I-I
by	I-I
forcing	I-I
human	I-I
observers	I-I
to	I-I
make	I-I
difficult	I-I
speeded	I-I
decisions	I-I
--	I-I
sometimes	I-I
a	I-I
blind	I-I
guess	I-I
--	I-I
about	I-I
stimulus	I-I
direction	I-I
,	O
we	O
traced	O
the	O
temporal	O
buildup	O
of	O
motion	O
discrimination	O
capability	O
and	O
perceptual	O
awareness	O
,	O
as	O
assessed	O
trial	O
by	O
trial	O
through	O
direct	O
rating	O
.	O


We	O
found	O
that	O
both	O
increased	O
gradually	O
with	O
motion	B-O
coherence	I-O
and	I-O
viewing	I-O
time	I-O
,	O
but	O
discrimination	B-O
was	I-O
systematically	I-O
leading	I-O
awareness	I-O
,	I-O
reaching	I-O
a	I-O
plateau	I-O
much	I-O
earlier	I-O
.	I-O


Sensitivity	B-O
and	I-O
criterion	I-O
changes	I-O
contributed	O
jointly	O
to	O
the	O
slow	B-O
buildup	I-O
of	I-O
perceptual	I-O
awareness	I-O
.	I-O


It	O
made	O
no	B-O
difference	I-O
whether	O
motion	B-O
discrimination	I-O
was	O
accomplished	O
by	O
saccades	B-O
or	I-O
verbal	I-O
responses	I-O
.	I-O


These	O
findings	O
suggest	O
that	O
perceptual	B-O
awareness	I-O
emerges	I-O
on	I-O
the	I-O
top	I-O
of	I-O
a	I-O
developing	I-O
or	I-O
even	I-O
mature	I-O
perceptual	I-O
decision	I-O
.	I-O


We	O
argue	O
that	O
the	O
middle	O
temporal	O
(	O
MT	O
)	O
cortical	O
region	O
does	O
not	O
confer	O
us	O
the	O
full	B-O
phenomenic	I-O
depth	I-O
of	I-O
motion	I-O
perception	I-O
,	O
although	O
it	O
may	O
represent	O
a	O
precursor	B-O
stage	I-O
in	I-O
building	I-O
our	I-O
subjective	I-O
sense	I-O
of	I-O
visual	I-O
motion	I-O
.	I-O


Randomized	O
,	O
double-blind	O
,	O
multicenter	O
trial	O
comparing	O
two	O
doses	O
of	O
arzoxifene	B-I
(	I-I
LY353381	I-I
)	I-I
in	O
hormone-sensitive	B-P
advanced	I-P
or	I-P
metastatic	I-P
breast	I-P
cancer	I-P
patients	I-P
.	I-P


BACKGROUND	O
This	O
randomized	O
,	O
double-blind	O
,	O
phase	O
II	O
study	O
assessed	O
two	O
doses	O
of	O
the	O
selective	B-I
estrogen	I-I
receptor	I-I
modulator	I-I
arzoxifene	I-I
in	O
women	B-P
with	I-P
advanced	I-P
breast	I-P
cancer	I-P
.	I-P


The	O
primary	O
end	O
point	O
was	O
to	O
choose	O
the	O
best	O
of	O
two	O
doses	O
of	O
arzoxifene	B-I
based	O
on	O
the	O
response	B-O
rate	I-O
or	I-O
the	I-O
clinical	I-O
benefit	I-O
rate	I-O
(	I-O
CBR	I-O
)	I-O
.	I-O


Pharmacokinetics	B-O
and	I-O
toxicities	I-O
were	O
also	O
assessed	O
.	O


PATIENTS	O
AND	O
METHODS	O
Ninety-two	B-P
patients	I-P
with	I-P
advanced	I-P
breast	I-P
cancer	I-P
received	I-I
arzoxifene	I-I
20	I-I
or	I-I
50	I-I
mg/day	I-I
.	I-I


Tumor	B-O
response	I-O
was	I-I
assessed	I-I
using	I-I
World	I-I
Health	I-I
Organization	I-I
criteria	I-I
.	I-I


Toxicities	B-O
were	I-I
graded	I-I
according	I-I
to	I-I
the	I-I
National	I-I
Cancer	I-I
Institute	I-I
Common	I-I
Toxicity	I-I
Criteria	I-I
(	I-I
NCI-CTC	I-I
)	I-I
system	I-I
.	I-I


Pharmacokinetic	B-O
data	I-O
were	O
analyzed	O
using	O
the	O
NONMEM	O
software	O
program	O
(	O
GloboMax	O
,	O
Hanover	O
,	O
MD	O
,	O
USA	O
)	O
.	O


RESULTS	O
Response	B-O
rates	I-O
in	O
the	O
20	O
mg	O
arm	O
were	O
numerically	O
higher	O
than	O
the	O
50-mg	O
arm	O
according	O
to	O
the	O
investigator	O
(	O
40.5	O
%	O
versus	O
36.4	O
%	O
)	O
and	O
the	O
independent	O
review	O
panel	O
(	O
42.9	O
%	O
versus	O
27.3	O
%	O
)	O
.	O


CBR	B-O
was	O
higher	O
in	O
the	O
20	O
mg	O
arm	O
according	O
to	O
the	O
investigator	O
(	O
64.3	O
%	O
versus	O
61.4	O
%	O
)	O
and	O
the	O
independent	O
review	O
panel	O
(	O
59.5	O
%	O
versus	O
47.7	O
%	O
)	O
.	O


Arzoxifene	B-I
was	O
well	O
tolerated	O
.	O


There	O
were	O
no	O
study	O
drug-related	B-O
deaths	I-O
.	I-O


Mean	O
observed	O
steady-state	B-O
plasma	I-O
concentrations	I-O
of	O
arzoxifene	B-I
were	O
3.62	O
and	O
7.48	O
ng/ml	O
for	O
the	O
20	O
and	O
50	O
mg	O
doses	O
,	O
respectively	O
.	O


CONCLUSIONS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
efficacy	B-O
or	O
safety	B-O
between	O
20	O
and	O
50	O
mg	O
of	O
arzoxifene	B-I
.	I-I


Accordingly	O
,	O
arzoxifene	B-I
20	O
mg/day	O
was	O
selected	O
for	O
further	O
study	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O


Institutional	O
clinical	O
trial	O
accrual	O
volume	O
and	O
survival	O
of	O
patients	B-P
with	I-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
.	I-P


PURPOSE	O
National	O
Comprehensive	O
Cancer	O
Network	O
guidelines	O
recommend	O
patients	B-P
with	I-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
(	I-P
HNC	I-P
)	I-P
receive	O
treatment	O
at	O
centers	O
with	O
expertise	O
,	O
but	O
whether	O
provider	O
experience	O
affects	O
survival	O
is	O
unknown	O
.	O


PATIENTS	O
AND	O
METHODS	O
The	O
effect	O
of	O
institutional	O
experience	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	B-P
with	I-P
stage	I-P
III	I-P
or	I-P
IV	I-P
HNC	I-P
was	O
investigated	O
within	O
a	O
randomized	O
trial	O
of	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(	O
RTOG	O
0129	O
)	O
,	O
which	O
compared	O
cisplatin	B-I
concurrent	I-I
with	I-I
standard	I-I
versus	I-I
accelerated	I-I
fractionation	I-I
radiotherapy	I-I
.	I-I


As	O
a	O
surrogate	O
for	O
experience	O
,	O
institutions	O
were	O
classified	O
as	O
historically	O
low-	O
(	O
HLACs	O
)	O
or	O
high-accruing	O
centers	O
(	O
HHACs	O
)	O
based	O
on	O
accrual	O
to	O
21	B-P
RTOG	I-P
HNC	I-P
trials	I-P
(	I-P
1997	I-P
to	I-P
2002	I-P
)	I-P
.	I-P


The	O
effect	O
of	O
accrual	O
volume	O
on	O
OS	O
was	O
estimated	O
by	O
Cox	O
proportional	O
hazards	O
models	O
.	O


RESULTS	O
Median	B-O
RTOG	I-O
accrual	I-O
(	O
1997	O
to	O
2002	O
)	O
at	O
HLACs	O
was	O
four	O
versus	O
65	O
patients	O
at	O
HHACs	O
.	O


Analysis	O
included	O
471	B-P
patients	I-P
in	I-P
RTOG	I-P
0129	I-P
(	I-P
2002	I-P
to	I-P
2005	I-P
)	I-P
with	I-P
known	I-P
human	I-P
papillomavirus	I-P
and	I-P
smoking	I-P
status	I-P
.	I-P


Patients	O
at	O
HLACs	O
versus	O
HHACs	O
had	O
better	O
performance	O
status	O
(	O
0	O
:	O
62	O
%	O
v	O
52	O
%	O
;	O
P	O
=	O
.04	O
)	O
and	O
lower	O
T	O
stage	O
(	O
T4	O
:	O
26.5	O
%	O
v	O
35.3	O
%	O
;	O
P	O
=	O
.002	O
)	O
but	O
were	O
otherwise	O
similar	O
.	O


Radiotherapy	B-O
protocol	I-O
deviations	I-O
were	O
higher	O
at	O
HLACs	O
versus	O
HHACs	O
(	O
18	O
%	O
v	O
6	O
%	O
;	O
P	O
<	O
.001	O
)	O
.	O


When	O
compared	O
with	O
HHACs	O
,	O
patients	O
at	O
HLACs	O
had	O
worse	O
OS	B-O
(	O
5	O
years	O
:	O
51.0	O
%	O
v	O
69.1	O
%	O
;	O
P	O
=	O
.002	O
)	O
.	O


Treatment	O
at	O
HLACs	O
was	O
associated	O
with	O
increased	O
death	B-O
risk	I-O
of	O
91	O
%	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.91	O
;	O
95	O
%	O
CI	O
,	O
1.37	O
to	O
2.65	O
)	O
after	O
adjustment	O
for	O
prognostic	O
factors	O
and	O
72	O
%	O
(	O
HR	O
,	O
1.72	O
;	O
95	O
%	O
CI	O
,	O
1.23	O
to	O
2.40	O
)	O
after	O
radiotherapy	O
compliance	O
adjustment	O
.	O


CONCLUSION	O
OS	O
is	O
worse	O
for	O
patients	O
with	O
HNC	O
treated	O
at	O
HLACs	O
versus	O
HHACs	O
to	O
cooperative	O
group	O
trials	O
after	O
accounting	O
for	O
radiotherapy	O
protocol	O
deviations	O
.	O


Institutional	O
experience	O
substantially	O
influences	O
survival	O
in	O
locally	O
advanced	O
HNC	O
.	O


Multidose	O
,	O
live	O
attenuated	O
,	O
cold-recombinant	O
,	O
trivalent	O
influenza	B-I
vaccine	I-I
in	O
infants	B-P
and	I-P
young	I-P
children	I-P
.	I-P


Twenty-two	B-P
healthy	I-P
infants	I-P
and	I-P
children	I-P
received	O
either	O
cold-recombinant	B-I
,	I-I
trivalent	I-I
influenza	I-I
vaccine	I-I
or	O
placebo	B-I
in	O
a	O
three-dose	O
vaccine	O
trial	O
.	O


Most	O
(	O
82	O
%	O
)	O
who	O
received	O
vaccine	O
were	O
seronegative	O
to	O
all	O
three	B-I
vaccine	I-I
strains	I-I
(	I-I
10	I-I
(	I-I
6	I-I
)	I-I
TCID50/dose	I-I
each	I-I
)	I-I
:	I-I
A/Kawasaki/9/86	I-I
(	I-I
H1N1	I-I
)	I-I
,	I-I
A/Los	I-I
Angeles/2/87	I-I
(	I-I
H3N2	I-I
)	I-I
,	I-I
and	I-I
B/Yamagata/16/88	I-I
.	I-I


Vaccine	O
was	O
administered	O
intranasally	O
at	O
time	O
0	O
and	O
2	O
and	O
4	O
months	O
later	O
.	O


The	O
vaccine	O
was	O
well	B-O
tolerated	I-O
and	I-O
immunogenic	I-O
when	O
administered	O
in	O
a	O
multidose	O
regimen	O
.	O


The	O
first	O
dose	O
stimulated	O
antibody	O
to	O
H1	O
,	O
H3	O
,	O
and	O
B	O
in	O
59	O
%	O
,	O
94	O
%	O
,	O
and	O
35	O
%	O
of	O
vaccinees	O
,	O
respectively	O
,	O
by	O
hemagglutination	O
inhibition	O
(	O
HAI	O
)	O
or	O
ELISA	O
.	O


After	O
two	O
doses	O
of	O
vaccine	O
,	O
93	O
%	O
,	O
93	O
%	O
,	O
and	O
80	O
%	O
had	O
antibody	O
by	O
HAI	O
or	O
ELISA	O
to	O
H1	B-O
,	I-O
H3	I-O
,	I-O
and	I-O
B	I-O
,	O
respectively	O
.	O


Most	O
vaccinees	O
(	O
67	O
%	O
)	O
responded	O
to	O
all	O
three	O
viruses	O
after	O
two	O
doses	O
of	O
vaccine	O
.	O


The	O
third	O
dose	O
contributed	O
little	O
to	O
the	O
vaccine	B-O
's	I-O
immunogenicity	I-O
.	I-O


Multidose	O
trivalent	O
influenza	O
vaccine	O
is	O
safe	O
and	O
induces	O
an	O
immune	B-O
response	I-O
in	O
most	O
vaccinees	O
after	O
two	O
doses	O
.	O


ApoA-I	B-I
induction	O
as	O
a	O
potential	O
cardioprotective	O
strategy	O
:	O
rationale	O
for	O
the	O
SUSTAIN	O
and	O
ASSURE	O
studies	O
.	O


BACKGROUND	O
Considerable	O
interest	O
has	O
focused	O
on	O
the	O
development	O
of	O
therapies	O
that	O
target	O
the	O
functionality	O
of	O
high-density	O
lipoproteins	O
(	O
HDL	O
)	O
.	O


Upregulation	O
of	O
endogenous	O
synthesis	O
of	O
the	O
major	O
protein	O
on	O
HDL	O
particles	O
,	O
apolipoprotein	B-I
A-I	I-I
(	O
apoA-I	O
)	O
,	O
represents	O
a	O
novel	O
approach	O
to	O
generation	O
of	O
new	O
HDL	O
particles	O
.	O


The	O
Study	O
of	O
Quantitative	O
Serial	O
Trends	O
in	O
Lipids	O
with	O
Apolipoprotein	B-I
A-I	I-I
Stimulation	I-I
(	O
SUSTAIN	O
,	O
NCT01423188	O
)	O
study	O
aims	O
to	O
evaluate	O
the	O
lipid	B-O
efficacy	I-O
,	I-O
safety	I-O
and	O
tolerability	B-O
of	O
an	O
apoA-I	B-I
inducer	I-I
(	I-I
RVX-208	I-I
)	I-I
.	O


The	O
ApoA-I	O
Synthesis	O
Stimulation	O
and	O
Intravascular	B-I
Ultrasound	I-I
for	O
Coronary	O
Atheroma	O
Regression	O
Evaluation	O
(	O
ASSURE	O
,	O
NCT01067820	O
)	O
study	O
aims	O
to	O
evaluate	O
the	O
effect	O
of	O
RVX-208	O
on	O
plaque	O
burden	O
.	O


METHODS	O
In	B-P
SUSTAIN	I-P
,	I-P
172	I-P
patients	I-P
with	I-P
low	I-P
levels	I-P
of	I-P
HDL-C	I-P
will	I-P
be	I-P
randomized	I-P
to	O
receive	O
RVX-208	B-I
100	O
mg	O
bid	O
or	O
placebo	B-I
for	O
24	O
weeks	O
.	O


The	O
primary	O
efficacy	O
parameter	O
will	O
be	O
the	O
percentage	B-O
change	I-O
in	I-O
HDL-C	I-O
levels	I-O
.	I-O


In	B-P
ASSURE	I-P
,	I-P
310	I-P
patients	I-P
with	I-P
angiographic	I-P
coronary	I-P
artery	I-P
disease	I-P
and	I-P
low	I-P
HDL-C	I-P
levels	I-P
will	I-P
be	I-P
randomized	I-P
to	O
receive	O
RVX-208	B-I
100	O
mg	O
bid	O
or	O
placebo	B-I
for	O
26	O
weeks	O
.	O


The	O
primary	O
efficacy	O
parameter	O
will	O
be	O
the	O
nominal	O
change	O
in	O
percent	B-O
atheroma	I-O
volume	I-O
(	I-O
PAV	I-O
)	I-O
,	O
determined	O
by	O
analysis	O
of	O
intravascular	O
ultrasound	O
(	O
IVUS	O
)	O
images	O
of	O
matched	O
coronary	O
artery	O
segments	O
acquired	O
at	O
baseline	O
and	O
at	O
26-week	O
follow-up	O
.	O


The	O
effect	O
of	O
RVX-208	B-I
on	O
other	O
lipid	B-O
and	I-O
inflammatory	I-O
markers	I-O
,	I-O
safety	I-O
and	I-O
tolerability	I-O
will	O
also	O
be	O
assessed	O
in	O
both	O
studies	O
.	O


CONCLUSION	O
ApoA-I	B-I
induction	O
represents	O
a	O
potential	O
novel	O
strategy	O
to	O
reduce	O
cardiovascular	B-O
risk	I-O
,	O
by	O
generating	O
nascent	O
HDL	O
particles	O
.	O


These	O
studies	O
will	O
provide	O
early	O
evaluation	O
of	O
the	O
effects	O
of	O
RVX-208	B-I
on	O
lipids	O
and	O
atherosclerotic	O
plaque	O
.	O


The	O
peroxisome	O
proliferator-activated	O
receptor-gamma	O
agonist	O
pioglitazone	B-I
increases	O
number	B-O
and	I-O
function	I-O
of	I-O
endothelial	I-O
progenitor	I-O
cells	I-O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
and	I-P
normal	I-P
glucose	I-P
tolerance	I-P
.	I-P


OBJECTIVE	O
Peroxisome	O
proliferator-activated	O
receptor-gamma	O
(	O
PPAR	O
gamma	O
)	O
agonists	O
(	B-I
thiazolidinediones	I-I
[	I-I
TZDs	I-I
]	I-I
)	I-I
are	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O


Bone	O
marrow-derived	O
endothelial	O
progenitor	O
cells	O
(	O
EPCs	O
)	O
improve	O
vascular	B-O
function	I-O
and	O
predict	O
cardiovascular	B-O
risk	I-O
.	I-O


The	O
effect	O
of	O
pioglitazone	B-I
therapy	O
on	O
EPCs	O
was	O
examined	O
.	O


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
AND	O
RESULTS	O
We	O
performed	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
on	O
patients	B-P
with	I-P
documented	I-P
stable	I-P
coronary	I-P
artery	I-P
disease	I-P
and	I-P
normal	I-P
glucose	I-P
tolerance	I-P
.	I-P


Of	O
54	B-P
patients	I-P
with	I-P
normal	I-P
fasting	I-P
glucose	I-P
levels	I-P
,	I-P
18	I-P
showed	I-P
impaired	I-P
glucose	I-P
tolerance	I-P
and	I-P
36	I-P
patients	I-P
with	I-P
normal	I-P
glucose	I-P
tolerance	I-P
were	I-P
randomized	I-P
to	O
30-day	O
treatment	O
with	O
pioglitazone	B-I
(	O
45	O
mg	O
)	O
or	B-I
placebo	I-I
in	I-I
addition	I-I
to	I-I
optimal	I-I
medical	I-I
therapy	I-I
.	I-I


All	O
patients	O
in	O
the	O
TZD	B-I
group	O
showed	O
an	O
increase	O
of	O
adiponectin	B-O
levels	I-O
as	O
an	O
indicator	O
of	O
compliance	O
(	O
11.4	O
+/-	O
1.1	O
to	O
36.8	O
+/-	O
2.1	O
microg/ml	O
;	O
P	O
<	O
0.001	O
)	O
.	O


TZD	B-I
,	O
but	O
not	O
placebo	B-I
,	O
decreased	O
mean	B-O
high-sensitivity	I-O
C-reactive	I-O
protein	I-O
to	O
43	O
+/-	O
19	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Pioglitazone	O
increased	O
CD34	B-O
(	I-O
+	I-O
)	I-O
/kinase	I-O
insert	I-O
domain	I-O
receptor	I-O
(	I-O
+	I-O
)	I-O
EPCs	I-O
to	O
142	O
+/-	O
9	O
%	O
and	O
cultured	B-O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	I-O
acetylated	I-O
LDL	I-O
(	I-O
+	I-O
)	I-O
/lectin	I-O
(	I-O
+	I-O
)	I-O
EPCs	I-O
to	O
180	O
+/-	O
3	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O


EPC	B-O
numbers	I-O
were	O
not	O
changed	O
in	O
the	O
placebo	O
group	O
.	O


TZD	O
increased	O
the	O
SDF-1-induced	B-O
migratory	I-O
capacity	I-O
to	O
146	O
+/-	O
9	O
%	O
per	O
EPC	O
number	O
(	O
P	O
<	O
0.05	O
)	O
and	O
upregulated	O
the	O
clonogenic	B-O
potential	I-O
of	I-O
EPCs	I-O
,	O
increasing	O
the	B-O
colony-forming	I-O
units	I-O
to	O
172	O
+/-	O
12	O
%	O
(	O
P	O
<	O
0.001	O
)	O
.	O


In	O
cultured	O
human	O
EPCs	O
,	O
TZD	B-I
increased	O
EPC	B-O
numbers	I-O
and	I-O
migration	I-O
and	I-O
reduced	I-O
NADPH-oxidase	I-O
activity	I-O
.	I-O


The	O
TZD	B-I
effect	O
was	O
reversed	O
by	O
the	O
PPAR	O
gamma	O
antagonist	O
GW9662	O
and	O
mimicked	O
by	O
treatment	O
with	O
adiponectin	O
.	O


CONCLUSIONS	O
The	O
PPAR	O
gamma	O
agonist	O
pioglitazone	B-I
increases	O
the	O
number	B-O
and	I-O
function	I-O
of	I-O
EPCs	I-O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
.	I-P


The	O
effect	O
represents	O
a	O
potential	O
regenerative	O
mechanism	O
in	O
atherosclerosis	O
and	O
is	O
observed	O
in	O
normoglycemic	B-P
individuals	I-P
with	I-P
stable	I-P
coronary	I-P
artery	I-P
disease	I-P
.	I-P


Long-term	O
use	O
of	O
Viozan	B-I
(	I-I
sibenadet	I-I
HCl	I-I
)	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
:	I-P
results	O
of	O
a	O
1-year	O
study	O
.	O


Viozan	B-I
(	I-I
sibenadet	I-I
HCl	I-I
,	I-I
AR-C68397AA	I-I
)	I-I
is	O
a	O
novel	O
dual	O
D2	O
dopamine	O
receptor	O
,	O
beta2-adrenoceptor	O
agonist	O
that	O
has	O
been	O
investigated	O
for	O
efficacy	O
in	O
alleviating	O
the	O
symptoms	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O


The	O
slowly	O
progressive	O
nature	O
of	O
this	O
disease	O
means	O
that	O
patients	O
will	O
require	O
ongoing	O
therapeutic	O
management	O
for	O
many	O
years	O
,	O
or	O
even	O
decades	O
.	O


With	O
such	O
long-term	O
treatment	O
,	O
the	O
safety	O
profile	O
of	O
new	O
agents	O
will	O
be	O
of	O
paramount	O
importance	O
.	O


As	O
part	O
of	O
the	O
large-scale	O
assessment	O
of	O
sibenadet	B-I
,	O
a	O
12-month	O
safety	O
study	O
has	O
been	O
conducted	O
.	O


Following	O
completion	O
of	O
a	O
2-week	O
baseline	O
period	O
,	O
435	B-P
adults	I-P
with	I-P
stable	I-P
,	I-P
symptomatic	I-P
,	I-P
smoking-related	I-P
COPD	I-P
were	I-P
randomized	I-P
to	O
receive	O
either	O
500	B-I
microg	I-I
sibenadet	I-I
or	I-I
placebo	I-I
delivered	O
via	O
pressurized	O
metered	O
dose	O
inhaler	O
(	O
pMDI	O
)	O
,	O
three	O
times	O
daily	O
for	O
52	O
weeks	O
.	O


Sibenadet	B-I
therapy	I-I
was	O
generally	O
well	B-O
tolerated	I-O
,	O
with	O
the	O
only	O
notable	B-O
differences	I-O
seen	O
in	O
the	O
incidence	B-O
of	I-O
tremor	I-O
and	I-O
taste	I-O
of	I-O
treatment	I-O
(	O
16.9	O
%	O
vs.	O
4.1	O
%	O
and	O
14.5	O
%	O
vs.	O
4.1	O
%	O
in	O
the	O
sibenadet	O
and	O
placebo	B-I
groups	O
respectively	O
)	O
.	O


There	O
were	O
a	O
total	O
of	O
79	B-P
patients	I-P
with	I-P
serious	I-O
adverse	I-O
events	I-O
(	I-P
SAEs	I-P
)	I-P
,	I-P
43	I-P
(	I-P
14.8	I-P
%	I-P
)	I-P
in	I-P
the	I-P
sibenadet	I-P
pMDI	I-P
group	I-P
and	I-P
36	I-P
(	I-P
24.8	I-P
%	I-P
)	I-P
in	I-P
the	I-P
placebo	I-I
group	I-I
.	I-I


No	O
clinically	B-O
significant	I-O
abnormal	I-O
laboratory	I-O
values	I-O
or	O
overall	B-O
differences	I-O
between	O
treatment	O
groups	O
were	O
noted	O
.	O


Similarly	O
,	O
there	O
were	O
no	B-O
clinically	I-O
significant	I-O
differences	I-O
between	O
the	O
two	O
treatment	O
groups	O
for	O
cardiac	B-O
variables	I-O
,	I-O
or	I-O
in	I-O
vital	I-O
signs	I-O
.	I-O


The	O
secondary	B-O
variables	I-O
showed	O
no	B-O
notable	I-O
differences	I-O
with	O
respect	O
to	O
lung	B-O
function	I-O
,	I-O
exacerbations	I-O
or	I-O
health-related	I-O
quality	I-O
of	I-O
life	I-O
.	I-O


Due	O
to	O
the	O
effective	O
beta2-agonist	O
properties	O
,	O
patients	O
in	O
the	O
sibenadet	O
group	O
did	O
,	O
however	O
,	O
report	O
reduced	B-O
rescue	I-O
medication	I-O
usage	I-O
at	I-O
all	I-O
timepoints	I-O
.	I-O


While	O
the	O
results	O
of	O
this	O
study	O
show	O
that	O
,	O
overall	O
,	O
sibenadet	O
therapy	O
was	O
well	B-O
tolerated	I-O
,	O
the	O
lack	B-O
of	I-O
sustained	I-O
benefit	I-O
reported	O
in	O
large-scale	B-O
clinical	I-O
efficacy	I-O
studies	I-O
means	O
that	O
sibenadet	O
development	O
will	O
not	O
be	O
continued	O
.	O


Maternal	B-I
dietary	I-I
counseling	I-I
in	O
the	O
first	O
year	O
of	O
life	O
is	O
associated	O
with	O
a	O
higher	O
healthy	B-O
eating	I-O
index	I-O
in	O
childhood	B-P
.	I-P


Food	O
preferences	O
are	O
established	O
in	O
early	O
childhood	O
and	O
track	O
later	O
in	O
life	O
.	O


Therefore	O
,	O
it	O
is	O
important	O
to	O
promote	O
healthy	O
feeding	O
practices	O
as	O
early	O
as	O
possible	O
.	O


A	O
randomized	O
field	O
trial	O
was	O
conducted	O
with	O
500	B-P
mother-child	I-P
pairs	I-P
from	I-P
a	I-P
low-income	I-P
area	I-P
of	I-P
São	I-P
Leopoldo	I-P
,	I-P
State	I-P
of	I-P
Rio	I-P
Grande	I-P
do	I-P
Sul	I-P
,	I-P
Brazil	I-P
,	I-P
to	I-P
evaluate	I-P
the	I-P
impact	I-P
of	I-P
a	I-I
nutritional	I-I
intervention	I-I
in	I-P
the	I-P
first	I-P
year	I-P
of	I-P
life	I-P
on	I-P
the	I-P
dietary	I-P
quality	I-P
of	I-P
3-	I-P
to	I-P
4-y-old	I-P
children	I-P
.	O


Mother-child	O
pairs	O
were	O
randomized	O
either	O
to	B-I
intervention	I-I
and	I-I
control	I-I
groups	O
and	B-I
dietary	I-I
counseling	I-I
was	O
provided	O
for	O
mothers	O
in	O
the	O
intervention	O
group	O
during	O
10	O
home	O
visits	O
in	O
the	O
course	O
of	O
the	O
first	O
year	O
of	O
life	O
.	O


These	O
visits	O
were	O
carried	O
out	O
by	O
fieldworkers	O
who	B-I
counseled	I-I
the	O
mothers	O
about	O
the	O
Ten	O
Steps	O
for	O
Healthy	O
Feeding	O
from	O
Birth	O
to	O
Two	O
Years	O
of	O
Age	O
,	O
based	O
on	O
the	O
WHO	O
guidelines	O
.	B-O


Dietary	B-O
intake	I-O
was	O
assessed	O
at	O
3-4	O
y	O
of	O
age	O
for	B-P
345	I-P
children	I-P
using	O
two	O
24-h	O
food	O
recalls	O
.	B-O


Overall	B-O
diet	I-O
quality	I-O
was	O
determined	O
by	O
the	O
Healthy	O
Eating	O
Index	O
.	O


The	B-O
prevalence	I-O
of	I-O
poor	I-O
diet	I-O
in	O
the	O
intervention	O
group	O
was	O
lower	O
compared	O
with	O
the	O
control	O
group	O
[	O
relative	O
risk	O
(	O
RR	O
)	O
=	O
0.30	O
;	O
95	O
%	O
CI	O
=	O
0.13-0.71	O
)	O
.	O


The	O
number	O
of	O
children	O
who	O
achieved	O
the	B-O
75th	I-O
percentile	I-O
for	I-O
the	I-O
vegetable	I-O
and	I-O
fruit	I-O
component	I-O
score	I-O
was	O
higher	O
in	O
the	O
intervention	O
than	O
in	O
control	O
group	O
(	O
RR	O
=	O
1.95	O
;	O
95	O
%	O
CI	O
=	O
1.31-2.89	O
and	O
RR	O
=	O
1.49	O
;	O
95	O
%	O
CI	O
=	O
1.07-2.07	O
,	O
respectively	O
)	O
.	O


Such	O
data	O
provide	O
evidence	O
that	B-I
dietary	I-I
counseling	I-I
for	O
mothers	O
during	O
the	O
first	O
year	O
of	O
life	O
improves	O
the	B-O
overall	I-O
dietary	I-O
quality	I-O
of	I-P
children	I-P
in	I-P
a	I-P
low-income	I-P
population	I-P
.	O


Use	O
of	O
transdermal	B-I
glyceryl	I-I
trinitrate	I-I
to	O
reduce	O
failure	B-O
of	I-O
intravenous	I-O
infusion	I-O
due	I-P
to	I-P
phlebitis	I-P
and	I-P
extravasation	I-P
.	I-P


Self-adhesive	O
patches	O
which	O
release	O
glyceryl	B-I
trinitrate	I-I
at	O
a	O
slow	O
continuous	O
rate	O
or	O
placebo	B-I
patches	I-I
were	O
applied	O
to	O
the	O
skin	B-P
of	I-P
patients	I-P
distal	O
to	O
intravenous	O
infusion	O
sites	O
in	O
a	O
double-blind	O
manner	O
.	O


The	O
frequency	B-O
of	I-O
infusion	I-O
failure	I-O
was	O
three	O
times	O
lower	O
with	O
the	O
glyceryl	B-I
trinitrate	I-I
than	O
with	O
placebo	B-I
patches	I-I
.	I-I


The	O
decrease	O
was	O
of	O
similar	O
magnitude	O
whether	O
failure	O
was	O
due	O
to	O
extravasation	O
or	O
phlebitis	O
.	O


Headaches	B-O
were	O
more	O
common	O
in	O
patients	B-P
with	I-P
active	I-P
patches	I-P
but	O
were	O
relieved	O
by	O
simple	O
analgesics	B-I
.	I-I


Several	O
indicators	B-O
of	I-O
oxidative	I-O
stress	I-O
,	I-O
immunity	I-O
,	I-O
and	I-O
illness	I-O
improved	O
in	O
trained	B-P
men	I-P
consuming	O
an	O
encapsulated	B-I
juice	I-I
powder	I-I
concentrate	I-I
for	O
28	O
weeks	O
.	O


Phytonutrients	B-I
from	I-I
plant	I-I
foods	I-I
provide	O
numerous	O
antioxidants	O
.	O


We	O
hypothesized	O
that	O
supplementation	O
for	O
28	O
wk	O
with	O
a	O
commercially	B-I
available	I-I
encapsulated	I-I
juice	I-I
powder	I-I
concentrate	I-I
(	I-I
JPC	I-I
)	I-I
could	O
influence	O
indicators	B-O
of	I-O
oxidative	I-O
stress	I-O
,	I-O
immunity	I-O
,	I-O
and	I-O
illness	I-O
.	I-O


Trained	B-P
men	I-P
(	I-P
n	I-P
=	I-P
41	I-P
;	I-P
34	I-P
+/-	I-P
5	I-P
y	I-P
;	I-P
maximum	I-P
oxygen	I-P
uptake	I-P
=	I-P
55	I-P
+/-	I-P
7	I-P
mL	I-P
x	I-P
kg	I-P
(	I-P
-1	I-P
)	I-P
x	I-P
min	I-P
(	I-P
-1	I-P
)	I-P
)	I-P
from	I-P
a	I-P
homogenous	I-P
police	I-P
Special	I-P
Forces	I-P
unit	I-P
were	O
randomly	O
assigned	O
in	O
a	O
double	O
blind	O
manner	O
to	O
either	O
JPC	B-I
(	O
n	O
=	O
21	O
)	O
or	B-I
placebo	I-I
(	O
n	O
=	O
20	O
)	O
.	O


We	O
used	O
multiple	O
7-d	B-O
food	I-O
records	I-O
to	O
assess	O
dietary	O
intake	O
and	O
found	O
inadequate	B-P
mean	I-P
daily	I-P
fruit	I-P
and	I-P
vegetable	I-P
consumption	I-P
(	I-P
3.2	I-P
+/-	I-P
1.2	I-P
servings	I-P
)	I-P
.	I-P


The	O
group	O
physician	O
documented	O
all	O
duty	O
days	O
lost	O
due	O
to	O
illness	B-O
.	I-O


We	B-I
collected	I-I
plasma	I-I
at	I-I
baseline	I-I
and	I-I
study	I-I
wk	I-I
4	I-I
,	I-I
8	I-I
,	I-I
16	I-I
,	I-I
and	I-I
28	I-I
for	I-I
analysis	I-I
of	I-I
carbonyl	I-O
groups	I-O
on	I-O
protein	I-O
(	I-O
CP	I-O
)	I-O
and	I-O
TNFalpha	I-O
.	I-O


Over	O
the	O
28-wk	O
investigation	O
,	O
CP	B-O
was	O
lower	O
in	O
the	O
JPC	B-I
group	O
,	O
with	O
both	O
a	O
treatment	O
and	O
a	O
time	O
x	O
treatment	O
interaction	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Concentrations	O
of	O
both	O
CP	B-O
and	I-O
TNFalpha	I-O
at	O
16	O
and	O
28	O
wk	O
were	O
lower	O
in	O
the	O
JPC	B-I
than	O
in	O
the	O
placebo	B-I
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O


TNFalpha	B-O
increased	O
during	O
the	O
first	O
8	O
wk	O
followed	O
by	O
a	O
decrease	O
in	O
both	O
groups	O
for	O
the	O
following	O
20	O
wk	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Over	O
the	O
final	O
20	O
wk	O
of	O
the	O
study	O
,	O
the	O
placebo	B-I
group	O
tended	O
to	O
have	O
more	O
days	O
of	O
illness	B-O
than	O
the	O
JPC	B-I
group	O
(	O
P	O
=	O
0.068	O
)	O
.	O


These	O
data	O
suggest	O
beneficial	O
JPC	B-I
effects	O
with	O
regard	O
to	O
reduction	O
of	O
duty	O
days	O
lost	O
due	O
to	O
illness	B-O
and	O
reduction	O
of	O
CP	B-O
and	I-O
TNFalpha	I-O
concentrations	I-O
in	O
this	O
group	B-P
of	I-P
trained	I-P
men	I-P
over	I-P
28	I-P
wk	I-P
.	I-P


The	O
effect	O
of	O
prophylactic	B-I
fentanyl	I-I
on	O
shivering	B-O
in	I-O
elective	I-O
caesarean	I-O
section	I-O
under	I-P
epidural	I-P
analgesia	I-P
.	I-P


The	O
aims	O
of	O
this	O
randomised	O
double-blind	O
study	O
were	O
to	O
investigate	O
whether	O
25	O
micrograms	O
of	O
fentanyl	B-I
administered	O
prophylactically	O
by	O
the	O
epidural	O
route	O
would	O
influence	O
the	O
incidence	B-O
of	I-O
shivering	I-O
in	O
parturients	B-P
who	I-P
underwent	I-P
elective	I-P
Caesarean	I-P
section	I-P
under	I-P
epidural	I-P
analgesia	I-P
and	O
whether	O
it	O
would	O
affect	O
the	O
axillary	B-O
and	I-O
calf	I-O
temperatures	I-O
.	I-O


There	O
was	O
a	O
50	O
%	O
reduction	O
(	O
p	O
less	O
than	O
0.05	O
)	O
in	O
the	O
overall	O
incidence	B-O
of	I-O
shivering	I-O
in	O
patients	B-P
who	O
received	O
fentanyl	B-I
and	O
there	O
was	O
some	O
evidence	O
to	O
suggest	O
that	O
low-dose	O
epidural	O
fentanyl	O
might	O
reduce	O
shivering	B-O
by	O
an	O
influence	O
on	O
thermoregulation	B-O
.	I-O


Serum	B-O
C-peptide	I-O
after	O
6	O
months	O
on	O
glibenclamide	B-I
remains	O
higher	O
than	O
during	O
insulin	O
treatment	O
.	O


Serum	B-O
C-peptide	I-O
was	O
measured	O
fasting	O
and	O
6	B-I
minutes	I-I
after	I-I
glucagon	I-I
(	I-I
1	I-I
mg	I-I
given	I-I
intravenously	I-I
)	I-I
in	O
49	B-P
patients	I-P
with	I-P
non-insulin-dependent	I-P
diabetes	I-P
mellitus	I-P
,	O
after	B-I
4	I-I
and	I-I
6	I-I
months	I-I
of	I-I
successive	I-I
periods	I-I
of	I-I
treatment	I-I
with	I-I
insulin	I-I
and	I-I
oral	I-I
hypoglycaemics	I-I
(	I-I
glibenclamide	I-I
and	I-I
metformin	I-I
)	I-I
,	O
given	O
in	O
random	O
order	O
.	O


Glycaemic	B-O
control	I-O
was	O
not	O
significantly	O
different	O
on	O
the	O
two	O
treatments	O
,	O
but	O
C-peptide	B-O
was	O
much	O
higher	O
while	O
the	O
patients	O
were	O
on	O
glibenclamide	O
.	O


We	O
conclude	O
that	O
glibenclamide	B-I
stimulates	O
pancreatic	O
insulin	O
production	O
even	O
after	O
6	O
months	O
treatment	O
.	O


Development	O
of	O
the	O
Therapist	B-P
Empathy	O
Scale	O
.	O


BACKGROUND	O
Few	O
measures	O
exist	O
to	O
examine	O
therapist	B-P
empathy	O
as	O
it	O
occurs	O
in	O
session	O
.	O


AIMS	O
A	O
9-item	O
observer	O
rating	O
scale	O
,	O
called	O
the	O
Therapist	B-I
Empathy	I-I
Scale	I-I
(	O
TES	O
)	O
,	O
was	O
developed	O
based	O
on	O
Watson	O
's	O
(	O
1999	O
)	O
work	O
to	O
assess	O
affective	O
,	O
cognitive	O
,	O
attitudinal	O
,	O
and	O
attunement	O
aspects	O
of	O
therapist	O
empathy	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
inter-rater	O
reliability	O
,	O
internal	O
consistency	O
,	O
and	O
construct	O
and	O
criterion	O
validity	O
of	O
the	O
TES	O
.	O


METHOD	O
Raters	O
evaluated	O
therapist	B-P
empathy	O
in	O
315	B-P
client	I-I
sessions	I-I
conducted	I-P
by	I-P
91	I-P
therapists	I-P
,	I-P
using	I-P
data	I-P
from	I-P
a	I-P
multi-site	I-P
therapist	I-P
training	I-P
trial	I-P
(	I-P
Martino	I-P
et	I-P
al.	I-P
,	O
2010	B-P
)	I-P
in	I-P
Motivational	I-I
Interviewing	I-I
(	I-I
MI	I-I
)	I-I
.	I-I


RESULTS	O
Inter-rater	B-O
reliability	I-O
(	O
ICC	O
=	O
.87	O
to	O
.91	O
)	O
and	O
internal	B-O
consistency	I-O
(	O
Cronbach	O
's	O
alpha	O
=	O
.94	O
)	O
were	O
high	O
.	O


Confirmatory	O
factor	B-O
analyses	I-O
indicated	O
some	O
support	O
for	O
single-factor	O
fit	O
.	O


Convergent	B-O
validity	I-O
was	O
supported	O
by	O
correlations	O
between	O
TES	B-O
scores	I-O
and	I-O
MI	I-O
fundamental	I-O
adherence	I-O
(	O
r	O
range	O
.50	O
to	O
.67	O
)	O
and	O
competence	B-O
scores	I-O
(	O
r	O
range	O
.56	O
to	O
.69	O
)	O
.	O


Discriminant	B-O
validity	I-O
was	O
indicated	O
by	O
negative	O
or	O
nonsignificant	O
correlations	O
between	O
TES	O
and	O
MI-inconsistent	O
behavior	O
(	O
r	O
range	O
.05	O
to	O
-.33	O
)	O
.	O


CONCLUSIONS	O
The	O
TES	O
demonstrates	O
excellent	O
inter-rater	O
reliability	O
and	O
internal	O
consistency	O
.	O


RESULTS	O
indicate	O
some	O
support	O
for	O
a	O
single-factor	O
solution	O
and	O
convergent	O
and	O
discriminant	O
validity	O
.	O


Future	O
studies	O
should	O
examine	O
the	O
use	O
of	O
the	O
TES	O
to	O
evaluate	O
therapist	B-P
empathy	O
in	O
different	O
psychotherapy	O
approaches	O
and	O
to	O
determine	O
the	O
impact	O
of	O
therapist	O
empathy	O
on	O
client	O
outcome	O
.	O


Conduit	O
artery	O
structure	O
and	O
function	O
in	O
lowlanders	B-P
and	I-P
native	I-P
highlanders	I-P
:	I-P
relationships	O
with	O
oxidative	O
stress	O
and	O
role	O
of	O
sympathoexcitation	O
.	O


Research	O
detailing	O
the	O
normal	O
vascular	O
adaptions	O
to	O
high	O
altitude	O
is	O
minimal	O
and	O
often	O
confounded	O
by	O
pathology	O
(	O
e.g.	O
,	O
chronic	O
mountain	O
sickness	O
)	O
and	O
methodological	O
issues	O
.	O


We	O
examined	O
vascular	O
function	O
and	O
structure	O
in	O
:	O
(	B-P
1	I-P
)	I-P
healthy	I-P
lowlanders	I-P
during	I-P
acute	I-P
hypoxia	I-P
and	I-P
prolonged	I-P
(	I-P
∼2	I-P
weeks	I-I
)	I-I
exposure	I-I
to	I-I
high	I-I
altitude	I-I
,	I-P
and	I-P
(	I-P
2	I-P
)	I-P
high-altitude	I-P
natives	I-P
at	I-P
5050	I-P
m	I-P
(	I-P
highlanders	I-P
)	I-P
.	O


In	B-P
12	I-P
healthy	I-P
lowlanders	I-P
(	I-P
aged	I-P
32	I-P
±	I-P
7	I-P
years	I-P
)	I-P
and	I-P
12	I-P
highlanders	I-P
(	I-P
Sherpa	I-P
;	I-P
33	I-P
±	I-P
14	I-P
years	I-P
)	I-P
we	I-P
assessed	I-O
brachial	I-O
endothelium-dependent	I-O
flow-mediated	I-O
dilatation	I-O
(	I-O
FMD	I-O
)	I-O
,	I-O
endothelium-independent	I-O
dilatation	I-O
(	I-I
via	I-I
glyceryl	I-I
trinitrate	I-I
;	I-I
GTN	I-O
)	I-O
,	I-O
common	I-O
carotid	I-O
intima-media	I-O
thickness	I-O
(	I-P
CIMT	I-P
)	I-P
and	I-P
diameter	I-P
(	I-P
ultrasound	I-P
)	I-P
,	I-P
and	I-O
arterial	I-O
stiffness	I-O
via	I-O
pulse	I-O
wave	I-O
velocity	I-O
(	I-I
PWV	I-I
;	I-I
applanation	I-I
tonometry	I-I
)	I-I
.	O


Cephalic	O
venous	O
biomarkers	O
of	O
free	O
radical-mediated	O
lipid	O
peroxidation	O
(	O
lipid	O
hydroperoxides	O
,	O
LOOH	O
)	O
,	O
nitrite	O
(	O
NO2-	O
)	O
and	O
lipid	O
soluble	O
antioxidants	O
were	O
also	O
obtained	O
at	O
rest	O
.	O


In	O
lowlanders	O
,	O
measurements	O
were	O
performed	O
at	O
sea	O
level	O
(	O
334	O
m	O
)	O
and	O
between	O
days	O
3-4	O
(	O
acute	O
high	O
altitude	O
)	O
and	O
12-14	O
(	O
chronic	O
high	O
altitude	O
)	O
following	O
arrival	O
to	O
5050	O
m.	O
Highlanders	O
were	O
assessed	O
once	O
at	O
5050	O
m.	O
Compared	O
with	O
sea	O
level	O
,	O
acute	O
high	O
altitude	O
reduced	B-O
lowlanders	I-O
'	I-O
FMD	O
(	O
7.9	O
±	O
0.4	O
vs.	O
6.8	O
±	O
0.4	O
%	O
;	O
P	O
=	O
0.004	B-O
)	I-O
and	I-O
GTN-induced	I-O
dilatation	I-O
(	O
16.6	O
±	O
0.9	O
vs.	O
14.5	O
±	O
0.8	O
%	O
;	O
P	O
=	O
0.006	O
)	O
,	O
and	B-O
raised	I-O
central	I-O
PWV	O
(	O
6.0	O
±	O
0.2	O
vs.	O
6.6	O
±	O
0.3	O
m	O
s	O
(	O
-1	O
)	O
;	O
P	O
=	O
0.001	O
)	O
.	O


These	O
changes	O
persisted	O
at	O
days	O
12-14	O
,	O
and	O
after	O
allometrically	O
scaling	O
FMD	O
to	O
adjust	O
for	O
altered	O
baseline	O
diameter	O
.	O


Compared	O
to	O
lowlanders	O
at	O
sea	O
level	O
and	O
high	O
altitude	O
,	O
highlanders	O
had	B-O
a	I-O
lower	I-O
carotid	I-O
wall	I-O
:	I-O
lumen	I-O
ratio	O
(	O
∼19	O
%	O
,	O
P	O
≤	O
0.04	O
)	O
,	O
attributable	O
to	O
a	O
narrower	O
CIMT	O
and	O
wider	O
lumen	O
.	O


Although	B-O
both	I-O
LOOH	O
and	O
NO2-	O
increased	O
with	O
high	O
altitude	O
in	O
lowlanders	B-O
,	O
only	O
LOOH	O
correlated	O
with	O
the	B-O
reduction	I-O
in	I-O
GTN-induced	I-O
dilatation	O
evident	O
during	O
acute	O
(	O
n	O
=	O
11	O
,	O
r	O
=	O
-0.53	O
)	O
and	O
chronic	O
(	O
n	O
=	O
7	O
,	O
r	O
=	O
-0.69	O
;	O
P	O
≤	O
0.01	O
)	O
exposure	O
to	O
5050	O
m.	O
In	B-I
a	I-I
follow-up	I-I
,	O
placebo-controlled	O
experiment	O
(	O
n	O
=	O
11	O
healthy	O
lowlanders	B-I
)	I-I
conducted	I-I
in	I-I
a	I-I
normobaric	I-I
hypoxic	O
chamber	O
(	O
inspired	O
O2	O
fraction	O
(	O
F	O
IO	O
2	O
)	O
=	O
0.11	O
;	O
6	O
h	O
)	O
,	O
a	O
sustained	B-O
reduction	I-O
in	O
FMD	O
was	O
evident	O
within	O
1	O
h	O
of	O
hypoxic	O
exposure	O
when	O
compared	O
to	O
normoxic	O
baseline	O
(	O
5.7	O
±	O
1.6	O
vs.	O
8.0	O
±1.3	O
%	O
;	O
P	O
<	O
0.01	B-O
)	I-O
;	I-O
this	I-O
decline	O
in	O
FMD	O
was	O
largely	O
reversed	O
following	O
α1-adrenoreceptor	O
blockade	O
.	O


In	O
conclusion	O
,	O
high-altitude	O
exposure	O
in	B-O
lowlanders	I-O
caused	I-O
persistent	I-O
impairment	I-O
in	I-O
vascular	O
function	O
,	O
which	O
was	O
mediated	O
partially	O
via	O
oxidative	O
stress	O
and	O
sympathoexcitation	O
.	O


Although	O
a	O
lifetime	O
of	O
high-altitude	O
exposure	O
neither	O
intensifies	O
nor	O
attenuates	O
the	O
impairments	O
seen	O
with	O
short-term	B-I
exposure	I-I
,	I-I
chronic	I-I
high-altitude	O
exposure	O
appears	O
to	O
be	O
associated	O
with	O
arterial	O
remodelling	O
.	O


Prospective	O
,	O
randomized	O
trial	O
of	O
diclofenac	B-I
and	O
ketorolac	O
after	O
refractive	B-P
surgery	I-P
.	I-P


PURPOSE	O
To	O
compare	O
the	O
effectiveness	B-O
of	O
diclofenac	B-I
and	I-I
ketorolac	I-I
in	O
relieving	B-O
corneal	I-O
pain	I-O
after	I-P
refractive	I-P
surgery	I-P
,	O
and	O
determine	O
if	O
there	O
is	O
a	O
difference	O
in	O
stinging	O
on	O
instillation	O
.	O


METHODS	O
Thirty	B-P
patients	I-P
were	O
randomized	O
prospectively	O
to	O
postoperative	B-I
diclofenac	I-I
in	I-I
one	I-I
eye	I-I
and	I-I
ketorolac	I-I
in	I-I
the	I-I
other	I-I
.	I-I


Patients	O
and	O
surgeon	O
did	O
not	O
know	O
which	O
medications	O
were	O
used	O
.	O


Ocular	B-O
postoperative	I-O
pain	I-O
and	I-O
discomfort	I-O
on	I-O
instillation	I-O
of	I-O
medication	I-O
were	O
measured	O
after	O
radial	O
keratotomy	O
with	O
a	O
visual	B-O
analog	I-O
scale	I-O
and	I-O
a	I-O
questionnaire	I-O
.	I-O


RESULTS	O
Both	O
medications	O
were	O
highly	O
effective	B-O
in	I-O
relieving	I-O
pain	I-O
.	I-O


There	O
was	O
no	O
significant	O
difference	O
in	O
pain	B-O
relief	I-O
,	O
or	O
stinging	B-O
on	I-O
instillation	I-O
(	O
P	O
=	O
.29	O
)	O
.	O


CONCLUSION	O
There	O
was	O
no	O
statistical	O
difference	O
in	O
the	O
effectiveness	O
of	O
the	O
medications	O
on	O
pain	B-O
relief	I-O
,	O
or	O
in	O
stinging	B-O
on	I-O
instillation	I-O
.	I-O


Nurse-led	O
cardiac	O
clinics	O
for	O
adults	B-P
with	I-P
coronary	I-P
heart	I-P
disease	I-P
.	I-P


This	O
information	O
on	O
best	O
practice	O
is	O
based	O
on	O
a	O
systematic	B-I
review	I-I
of	I-I
research	I-I
,	O
published	O
by	O
Blackwell	O
Publishing	O
Asia	O
and	O
conducted	O
by	O
the	O
Centre	O
for	O
Evidence-based	O
Nursing	O
South	O
Australia	O
,	O
a	O
collaborating	O
centre	O
of	O
the	O
Joanna	O
Briggs	O
Institute	O
(	O
JBI	O
)	O
.	O


The	O
primary	O
references	O
on	O
which	O
this	O
information	O
is	O
based	O
are	O
provided	O
in	O
the	O
systematic	O
review	O
report	O
available	O
online	O
via	O
Blackwell	O
Synergy	O
www.blackwell-synergy.com	O
and	O
to	O
members	O
of	O
the	O
institute	O
via	O
the	O
web	O
site	O
:	O
www.joannabriggs.edu.au	O
.	O


This	O
information	O
sheet	O
covers	O
the	O
following	O
:	O
Nurse-led	O
education	O
and	O
self-help	O
.	O


Education	O
and	O
motivational	O
interview	O
.	O


Audit	O
and	O
recall	O
.	O


Secondary	O
prevention	O
.	O


Mediastinal	O
lymphadenectomy	B-I
in	O
non-small	B-P
cell	I-P
lung	I-P
cancer	I-P
:	I-P
effectiveness	O
in	O
patients	B-P
with	I-P
or	I-P
without	I-P
nodal	I-P
micrometastases	I-P
-	O
results	O
of	O
a	O
preliminary	O
study	O
.	O


OBJECTIVES	O
So	O
far	O
it	O
has	O
not	O
clearly	O
been	O
demonstrated	O
that	O
systematic	O
mediastinal	O
lymphadenectomy	B-I
improves	O
survival	B-O
in	O
patients	B-P
with	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
.	I-P


One	O
explanation	O
might	O
be	O
that	O
in	O
some	O
patients	O
an	O
early	O
spread	O
of	O
tumor	O
cells	O
has	O
occurred	O
which	O
might	O
not	O
be	O
curable	O
by	O
surgical	O
means	O
.	O


To	O
test	O
this	O
hypothesis	O
lymph	O
nodes	O
of	O
patients	O
which	O
were	O
treated	O
either	O
by	O
lymph	B-I
node	I-I
sampling	I-I
or	O
systematic	B-I
lymphadenectomy	I-I
were	O
screened	O
for	O
micrometastatic	O
spread	O
of	O
tumor	O
cells	O
and	O
the	O
influence	O
of	O
nodal	O
micrometastases	O
on	O
the	O
efficacy	O
of	O
lymphadenectomy	B-I
was	O
analyzed	O
.	O


METHODS	O
Lymph	B-P
nodes	I-P
from	I-P
patients	I-P
(	I-P
n=94	I-P
)	I-P
which	O
were	O
included	O
in	O
a	O
randomized	O
trial	O
of	O
lymph	B-I
node	I-I
sampling	I-I
(	I-I
LS	I-I
,	O
n=41	O
)	O
versus	O
radical	B-I
systematic	I-I
lymphadenectomy	I-I
(	I-I
LA	I-I
,	O
n=53	O
)	O
were	O
screened	O
by	O
immunohistochemistry	O
for	O
disseminated	O
tumor	O
cells	O
using	O
the	O
antibody	O
Ber-Ep4	O
.	O


The	O
median	B-O
observation	I-O
time	I-O
was	O
longer	O
than	O
5	O
years	O
and	O
follow-up	O
data	O
were	O
available	O
from	O
all	O
94	O
patients	O
.	O


Kaplan-Meier	B-O
curves	I-O
were	O
calculated	O
and	O
tested	O
for	O
statistical	O
significance	O
using	O
the	O
log-rank	O
test	O
.	O


RESULTS	O
Standard	O
histopathological	O
analysis	O
revealed	O
no	B-O
lymph	I-O
node	I-O
involvement	I-O
(	O
pN0	O
)	O
in	O
61	O
patients	O
,	O
pN1	O
disease	O
in	O
13	O
patients	O
and	O
pN2	O
disease	O
in	O
20	O
patients	O
without	O
significant	O
differences	O
between	O
LA	O
and	O
LS	O
with	O
respect	O
to	O
T-stage	O
,	O
N-stage	O
or	O
age	O
and	O
sex	O
of	O
the	O
patients	O
.	O


By	O
immunohistochemistry	O
a	O
minimal	O
nodal	B-O
spread	I-O
of	I-O
tumor	I-O
cells	I-O
was	O
detected	O
in	O
21	O
out	O
of	O
94	O
patients	O
(	O
LS	O
,	O
n=10	O
(	O
24	O
%	O
)	O
;	O
LA	O
,	O
n=11	O
(	O
21	O
%	O
)	O
)	O
.	O


Similar	O
to	O
the	O
entire	O
group	O
of	O
patients	O
also	O
in	O
the	O
subset	O
of	O
patients	O
with	O
nodal	O
micrometastases	O
the	O
type	O
of	O
lymphadenectomy	O
did	O
not	O
significantly	O
influence	O
the	O
long-term	B-O
survival	I-O
(	O
P=0.27	O
and	O
P=0.39	O
,	O
respectively	O
)	O
.	O


In	O
contrast	O
,	O
in	O
patients	O
with	O
a	O
negative	O
immunohistochemical	O
analysis	O
systematic	O
lymphadenectomy	B-I
resulted	O
in	O
an	O
improved	B-O
overall	I-O
survival	I-O
(	O
P=0.044	O
)	O
.	O


CONCLUSIONS	O
Our	O
data	O
provide	O
some	O
evidence	O
that	O
systematic	B-I
lymphadenectomy	I-I
improves	O
survival	B-O
in	O
patients	B-P
without	I-P
an	I-P
early	I-P
locoregional	I-O
spread	I-O
of	I-O
cancer	I-O
cells	I-O
.	I-O


As	O
long	O
as	O
these	O
patients	O
can	O
not	O
be	O
identified	O
preoperatively	O
all	O
patients	O
should	O
undergo	O
a	O
systematic	O
mediastinal	O
lymphadenectomy	B-I
.	I-I


Safety	B-O
and	I-O
pharmacokinetics	I-O
of	O
a	O
glycoPEGylated	B-I
recombinant	I-I
activated	I-I
factor	I-I
VII	I-I
derivative	I-I
:	I-I
a	O
randomized	O
first	O
human	O
dose	O
trial	O
in	B-P
healthy	I-P
subjects	I-P
.	O


BACKGROUND	O
Extensive	O
research	O
is	O
currently	O
ongoing	O
to	O
prolong	O
the	O
half-life	O
of	O
coagulation	O
factors	O
.	O


One	O
of	O
these	O
techniques	O
is	B-I
glycoPEGylation	I-I
,	O
which	O
has	O
also	O
been	O
applied	O
to	O
recombinant	O
activated	O
factor	O
VII	O
(	O
rFVIIa	O
)	O
,	O
resulting	O
in	O
a	B-I
rFVIIa	I-I
derivative	I-I
(	I-I
N7-GP	I-I
)	I-I
with	O
a	O
prolonged	O
terminal	O
half-life	O
(	O
t	O
(	O
1/2	O
)	O
)	O
.	O


The	O
main	O
clinical	O
purpose	O
of	B-I
N7-GP	I-I
is	O
to	O
provide	O
safe	O
and	O
effective	O
prophylaxis	O
to	B-P
patients	I-P
with	I-P
hemophilia	I-P
and	I-P
inhibitors	I-P
.	O


The	O
prolonged	O
t	O
(	O
1/2	O
)	O
of	O
N7-GP	O
can	O
potentially	O
reduce	O
the	O
dosing	O
frequency	O
and	O
thereby	O
facilitate	O
convenience	O
and	O
compliance	O
,	O
which	O
are	O
two	O
significant	O
barriers	O
to	O
effective	O
prophylaxis	O
.	O


OBJECTIVES	O
To	O
determine	O
the	B-O
safety	I-O
and	I-O
pharmacokinetics	I-O
of	O
single	O
doses	O
of	B-P
N7-GP	I-P
in	I-P
healthy	I-P
men	I-P
.	O


METHODS	B-P
A	I-P
randomized	I-P
,	I-P
placebo-controlled	I-P
,	I-P
dose-escalation	I-P
trial	I-P
with	I-P
five	I-P
cohorts	I-P
(	I-P
N7-GP	I-P
dose	I-P
of	I-P
12.5-100	I-P
μg	I-P
kg	I-P
(	I-P
-1	I-P
)	I-P
)	I-P
was	I-P
performed	I-P
.	I-P


In	B-P
each	I-P
cohort	I-P
,	I-P
eight	I-P
subjects	I-P
were	I-P
randomized	I-P
to	O
receive	O
N7-GP	O
(	O
n	O
=	O
6	O
)	O
or	B-I
placebo	I-I
(	O
n	O
=	O
2	O
)	O
.	O


RESULTS	O
The	B-O
mean	I-O
FVIIa	I-O
activity	I-O
was	O
measurable	O
for	O
up	O
to	O
at	O
least	O
72	O
h	O
after	O
dosing	O
,	O
and	O
the	O
overall	O
mean	O
t	O
(	O
1/2	O
)	O
for	O
FVIIa	O
activity	O
was	O
15	O
h.	O
The	B-O
pharmacokinetics	I-O
of	I-O
N7-GP	I-O
appeared	O
to	O
be	O
dose-proportional	O
in	O
the	O
dose	O
range	O
investigated	B-O
.	I-O


No	B-O
serious	I-O
adverse	I-O
events	I-O
(	I-O
including	I-O
thromboembolic	I-O
events	I-O
)	I-O
were	O
reported	O
.	O


The	B-O
frequency	I-O
of	I-O
adverse	I-O
events	I-O
was	O
similar	O
in	O
both	O
the	O
placebo	O
and	O
N7-GP	O
groups	O
.	O


No	B-O
neutralizing	I-O
antibodies	I-O
against	I-O
N7-GP	I-O
were	O
detected	O
.	O


A	B-O
pharmacologic	I-O
effect	I-O
was	O
apparent	O
from	O
a	O
dose-dependent	O
statistically	O
significant	O
decrease	O
in	O
the	B-O
mean	I-O
prothrombin	I-O
time	I-O
in	O
all	O
N7-GP	O
groups	O
as	O
compared	O
with	O
placebo	O
.	O


CONCLUSIONS	O
N7-GP	O
had	O
a	O
plasma	O
half-life	O
of	O
15	O
h	O
and	O
a	O
profile	O
that	O
makes	O
it	O
a	O
potential	O
candidate	O
for	O
prophylaxis	O
in	B-P
patients	I-P
with	I-P
hemophilia	I-P
and	I-P
inhibitors	I-P
.	O


[	B-I
Radiotherapy	I-I
for	O
choroidal	O
neovascularization	O
in	O
age-related	O
macular	O
degeneration	O
.	O


A	O
pilot	O
study	O
using	O
low-	B-I
versus	I-I
high-dose	I-I
photon	I-I
bean	I-I
radiation	I-I
]	I-I
.	O


PURPOSE	O
Several	O
pilot	O
studies	O
have	O
indicated	O
that	O
low-dose	B-I
radiation	I-I
therapy	I-I
might	O
have	O
a	O
beneficial	O
effect	O
on	O
the	O
course	O
of	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
in	O
age-related	B-P
macular	I-P
degeneration	I-P
(	I-P
AMD	I-P
)	I-P
.	I-P


This	O
study	O
aimed	O
to	O
ascertain	O
whether	O
such	O
treatment	O
might	O
halt	O
the	O
progression	O
of	O
neovascular	O
AMD	O
and	O
whether	O
a	O
low	O
or	O
a	O
high	O
radiation	O
dose	O
should	O
be	O
applied	O
.	O


PATIENTS	O
The	O
patients	B-P
comprised	I-P
some	I-P
randomized	I-P
to	I-P
0	I-I
vs	I-I
10	I-I
vs	I-I
36	I-I
Gy	I-I
of	I-I
radiation	I-I
and	I-P
(	I-P
after	I-P
a	I-P
change	I-P
of	I-P
the	I-P
study	I-P
protocol	I-P
became	I-P
necessary	I-P
)	I-P
others	I-P
who	I-P
participated	I-P
in	I-P
a	I-P
prospective	I-P
,	I-P
controlled	I-P
non-randomized	I-P
pilot	I-P
study	I-P
.	I-P


Enclosed	O
were	O
eyes	B-P
with	I-P
visual	I-P
acuity	I-P
of	I-P
>	I-P
or	I-P
=	I-P
0.1	I-P
and	I-P
<	I-P
or	I-P
=	I-P
0.6	I-P
revealing	I-P
a	I-P
juxta-subfoveal	I-P
CNV	I-P
either	I-P
of	I-P
the	I-P
occult	I-P
type	I-P
(	I-P
type	I-P
1	I-P
)	I-P
or	I-P
the	I-P
classic	I-P
type	I-P
(	I-P
isolated	I-P
or	I-P
as	I-P
part	I-P
of	I-P
a	I-P
predominantly	I-P
occult	I-P
lesion	I-P
)	I-P
.	I-P


RESULTS	O
Eyes	O
treated	O
with	O
10	B-I
Gy	I-I
for	O
occult	O
CNV	O
(	O
n	O
=	O
12	O
)	O
were	O
subject	O
to	O
severe	B-O
visual	I-O
loss	I-O
in	O
41.6	O
%	O
of	O
the	O
cases	O
compared	O
to	O
38.5	O
%	O
in	O
the	O
control	O
group	O
(	O
n	O
=	O
13	O
)	O
at	O
12	O
months	O
of	O
follow-up	O
.	O


For	O
eyes	O
treated	O
with	O
10	B-I
Gy	I-I
because	O
of	O
classic	O
CNV	O
,	O
the	O
corresponding	O
figures	O
were	O
33	O
%	O
(	O
n	O
=	O
18	O
)	O
and	O
57	O
%	O
(	O
n	O
=	O
14	O
)	O
respectively	O
.	O


At	O
18	O
months	O
of	O
follow-up	O
,	O
the	O
percentages	O
were	O
63	O
%	O
and	O
75	O
%	O
respectively	O
.	O


Fluorescein	B-O
angiographic	I-O
growth	I-O
of	I-O
classic	I-O
and	I-O
occult	I-O
CNV	I-O
could	O
not	O
be	O
halted	O
by	O
10	O
Gy	O
,	O
while	O
a	O
temporary	B-O
growth	I-O
retardation	I-O
was	O
observed	O
in	O
cases	O
irradiated	O
with	O
36	B-I
Gy	I-I
.	I-I


CONCLUSION	O
In	O
the	O
study	O
presented	O
,	O
the	O
natural	O
course	O
of	O
occult	O
CNV	O
could	O
not	O
be	O
improved	O
by	O
irradiation	O
with	O
10	B-I
or	I-I
36	I-I
Gy	I-I
.	I-I


In	O
cases	O
of	O
classic	O
CNV	O
,	O
low-dose	O
irradiation	O
with	O
10	B-I
Gy	I-I
postponed	O
severe	B-O
visual	I-O
loss	I-O
by	O
a	O
maximum	O
of	O
18	O
months	O
.	O


A	O
positive	O
treatment	O
effect	O
was	O
also	O
observed	O
in	O
cases	O
irradiated	O
with	O
36	B-I
Gy	I-I
;	I-I
however	O
,	O
a	O
25	O
%	O
incidence	O
of	O
radiation	O
retinopathy	O
seems	O
unacceptable	O
.	O


Monitoring	O
tumour	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
small	B-P
cell	I-P
lung	I-P
cancer	I-P
patients	I-P
.	I-P


BACKGROUND	O
Flow	B-I
cytometry	I-I
was	O
used	O
to	O
enumerate	O
tumour	O
cells	O
in	O
longitudinal	O
studies	O
of	O
peripheral	O
blood	O
from	O
small	B-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
SCLC	I-P
)	I-P
patients	I-P
,	O
together	O
with	O
magnetic	O
bead	O
selection	O
to	O
isolate	O
and	O
identify	O
these	O
cells	O
.	O


As	O
part	O
of	O
a	O
trial	O
,	O
11	B-P
patients	I-P
received	I-P
either	I-P
standard	I-P
(	I-P
four	I-P
weekly	I-P
)	I-P
chemotherapy	I-I
with	I-I
ifosfamide	I-I
,	I-I
carboplatin	I-I
,	I-I
and	I-I
etoposide	I-I
(	I-I
ICE	I-I
)	I-I
or	I-I
accelerated	I-I
(	I-I
two	I-I
weekly	I-I
)	I-I
ICE	I-I
with	I-I
filgrastim	I-I
(	I-I
granulocyte	I-I
colony-stimulating	I-I
factor	I-I
[	I-I
G-CSF	I-I
]	I-I
)	I-I
and	I-I
autologous	I-I
stem	I-I
cell	I-I
support	I-I
.	I-I


METHODS	O
Fresh	O
venous	O
blood	O
was	O
taken	O
throughout	O
treatment	O
and	O
follow-up	O
.	O


Aliquots	O
were	O
stained	O
with	O
a	O
"	O
tumour-specific	O
"	O
antibody	O
against	O
epithelial	O
tissue	O
(	O
Ber	O
EP4	O
)	O
,	O
verified	O
as	O
a	O
good	O
marker	O
of	O
SCLC	O
cells	O
by	O
immunohistochemistry	O
.	O


Matched	O
samples	O
labelled	O
with	O
Ber	O
EP4	O
were	O
separated	O
magnetically	O
by	O
adding	O
a	O
secondary	O
bead-antibody	O
conjugate	O
for	O
confirmation	O
of	O
tumour	O
cell	O
identity	O
.	O


RESULTS	O
Circulating	B-O
tumour	I-O
cells	I-O
were	O
detected	O
and	O
monitored	O
throughout	O
treatment	O
periods	O
.	O


An	O
initial	B-O
rise	I-O
in	I-O
circulating	I-O
cells	I-O
after	I-O
the	I-O
first	I-O
cycle	I-O
was	O
followed	O
by	O
a	O
fall	O
in	O
both	O
treatment	O
arms	O
to	O
baseline	O
levels	O
set	O
by	O
normal	O
controls	O
.	O


This	O
was	O
achieved	O
by	O
week	O
12	O
in	O
the	O
accelerated	O
treatment	O
arm	O
and	O
by	O
week	O
24	O
in	O
the	O
standard	O
arm	O
.	O


CONCLUSIONS	O
Flow	O
cytometry	O
and	O
magnetic	O
bead	O
isolation	O
can	O
be	O
used	O
to	O
identify	O
changes	O
in	O
numbers	O
of	O
circulating	O
tumour	O
cells	O
in	O
patients	O
undergoing	O
chemotherapy	B-I
for	O
SCLC	O
and	O
thereafter	O
during	O
follow-up	O
periods	O
.	O


Absence	O
of	O
tumour	O
cells	O
may	O
indicate	O
a	O
more	O
favourable	O
patient	O
group	O
who	O
would	O
benefit	O
from	O
a	O
more	O
intense	O
course	O
of	O
treatment	O
.	O


Individual	O
differences	O
in	O
the	O
efficacy	O
of	O
a	O
short	B-I
theory	I-I
of	I-I
mind	I-I
intervention	I-I
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
Having	O
a	O
'theory	O
of	O
mind	O
'	O
,	O
or	O
having	O
the	O
ability	O
to	O
attribute	O
mental	O
states	O
to	O
oneself	O
or	O
others	O
,	O
is	O
considered	O
one	O
of	O
the	O
most	O
central	O
domains	O
of	O
impairment	O
among	O
children	B-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


Many	O
interventions	O
focus	O
on	O
improving	O
theory	B-I
of	I-I
mind	I-I
skills	I-I
in	O
children	B-P
with	I-P
ASD	I-P
.	I-P


Nonetheless	O
,	O
the	O
empirical	O
evidence	O
for	O
the	O
effect	O
of	O
these	O
interventions	O
is	O
limited	O
.	O


The	O
main	O
goal	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
effectiveness	O
of	O
a	O
short	B-I
theory	I-I
of	I-I
mind	I-I
intervention	I-I
for	O
children	B-P
with	I-P
ASD	I-P
.	I-P


A	O
second	O
objective	O
is	O
to	O
determine	O
which	O
subgroups	O
within	O
the	O
autism	O
spectrum	O
profit	O
most	O
from	O
the	O
intervention	O
.	O


METHODS	O
This	O
study	O
is	O
a	O
randomized	O
controlled	O
trial	O
.	O


One	B-P
hundred	I-P
children	I-P
with	I-P
ASD	I-P
,	I-P
aged	I-P
7	I-P
to	I-P
12	I-P
years	I-P
will	I-P
be	I-P
randomly	O
assigned	O
to	O
an	O
intervention	B-I
or	I-I
a	I-I
waiting	I-I
list	I-I
control	I-I
group	I-I
.	I-I


Outcome	O
measures	O
include	O
the	O
completion	B-O
of	I-O
theory	I-O
of	I-O
mind	I-O
and	I-O
emotion	I-O
understanding	I-O
tasks	I-O
,	I-O
and	I-O
parent	I-O
and	I-O
teacher	I-O
questionnaires	I-O
on	I-O
children	I-O
's	I-O
social	I-O
skills	I-O
.	I-O


Follow-up	O
data	O
for	O
the	O
intervention	B-I
group	O
will	O
be	O
collected	O
6	O
months	O
after	O
the	O
interventions	O
.	O


DISCUSSION	O
This	O
study	O
evaluates	O
the	O
efficacy	B-O
of	O
a	O
theory	O
of	O
mind	B-I
intervention	I-I
for	O
children	B-P
with	I-P
ASD	I-P
.	I-P


Hypotheses	B-O
,	I-O
strengths	I-O
,	I-O
and	I-O
limitations	I-O
of	O
the	O
study	O
are	O
discussed	O
.	O


TRIAL	O
REGISTRATION	O
Netherlands	O
Trial	O
Register	O
NTR2327	O
.	O


NSAID	B-I
Pretreatment	O
Inhibits	O
Prostaglandin	B-O
Release	I-O
in	O
Femtosecond	B-I
Laser-Assisted	I-I
Cataract	I-I
Surgery	I-I
.	I-I


PURPOSE	O
To	O
investigate	O
whether	O
short-term	O
nonsteroidal	B-I
anti-inflammatory	I-I
drug	I-I
(	I-I
NSAID	I-I
)	I-I
pretreatment	O
on	O
the	O
day	O
of	O
surgery	O
inhibits	O
prostaglandin	B-O
release	I-O
.	I-O


Previous	O
studies	O
detected	O
elevated	O
prostaglandin	B-O
levels	I-O
after	O
femtosecond	B-I
laser	I-I
treatment	I-I
and	O
identified	O
them	O
as	O
a	O
potential	O
mediator	O
for	O
laser-induced	O
miosis	O
.	O


METHODS	O
Patients	B-P
underwent	I-P
either	I-P
image-guided	I-I
femtosecond	I-I
laser	I-I
cataract	I-I
surgery	I-I
or	I-I
conventional	I-I
cataract	I-I
surgery	I-I
(	I-P
n	I-P
=	I-P
75	I-P
)	I-P
.	I-P


Half	O
of	O
the	O
eyes	O
per	O
group	O
received	O
topical	B-I
NSAID	I-I
treatment	I-I
on	O
the	O
day	O
of	O
surgery	O
.	O


Aqueous	O
humor	O
was	O
collected	O
from	O
all	B-P
patients	I-P
.	I-P


ELISA	O
measurements	O
were	O
performed	O
to	O
detect	O
aqueous	B-O
humor	I-O
prostaglandin	I-O
levels	I-O
.	I-O


RESULTS	O
Femtosecond	B-I
laser	I-I
cataract	I-I
surgery	I-I
led	O
to	O
higher	O
prostaglandin	B-O
levels	I-O
than	O
conventional	B-I
cataract	I-I
surgery	I-I
(	O
P	O
=	O
.007	O
)	O
.	O


In	O
both	O
groups	O
,	O
NSAID	B-I
pretreatment	I-I
led	O
to	O
reduced	O
prostaglandin	B-O
release	I-O
.	I-O


In	O
the	O
femtosecond	B-P
laser	I-P
group	I-P
,	I-P
patients	I-P
pretreated	I-I
with	I-I
NSAIDs	I-I
had	O
significantly	O
lower	O
prostaglandin	B-O
values	I-O
(	O
65.3	O
±	O
13.2	O
pg/mL	O
)	O
than	B-P
patients	I-I
not	I-I
pretreated	I-I
with	I-I
NSAIDs	I-I
(	O
294.4	O
±	O
66.5	O
pg/mL	O
)	O
(	O
P	O
=	O
.0009	O
)	O
.	O


CONCLUSIONS	O
The	O
short-term	B-I
NSAID	I-I
treatment	I-I
prevented	I-O
prostaglandin	I-O
release	I-O
in	I-P
patients	I-P
treated	I-P
with	I-I
image-guided	I-I
femtosecond	I-I
laser	I-I
.	O


Therefore	O
,	O
it	O
has	O
potential	O
to	O
limit	O
intraoperative	O
laser-induced	O
miosis	O
.	O


Limited	O
effects	O
of	O
micronutrient	B-I
supplementation	I-I
on	O
strength	B-O
and	I-O
physical	I-O
function	I-O
after	O
abdominal	B-O
aortic	I-P
aneurysmectomy	I-P
.	I-P


BACKGROUND	O
Tissue	O
injury	O
following	O
ischemia-reperfusion	O
is	O
mediated	O
in	O
part	O
by	O
free	O
oxygen	O
radicals	O
.	O


We	O
hypothesized	O
that	O
perioperative	O
micronutrient	B-I
supplementation	I-I
would	O
augment	B-O
antioxidant	I-O
defenses	I-O
,	I-O
minimize	I-O
muscle	I-O
injury	I-O
,	I-O
and	I-O
minimize	I-O
postoperative	I-O
decreases	I-O
in	I-O
muscle	I-O
strength	I-O
and	I-O
physical	I-O
function	I-O
following	O
abdominal	O
aortic	O
aneurysmectomy	O
.	O


SETTING	O
A	O
university-affiliated	B-P
hospital	I-P
and	I-P
regional	I-P
referral	I-P
center	I-P
.	I-P


DESIGN	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
supplementation	B-I
with	I-I
beta-carotene	I-I
,	I-I
vitamins	I-I
C	I-I
and	I-I
E	I-I
,	I-I
zinc	I-I
,	I-I
and	I-I
selenium	I-I
for	O
a	O
period	O
of	O
2-3	O
weeks	O
prior	O
to	O
surgery	O
and	O
1	O
week	O
thereafter	O
.	O


STUDY	O
POPULATION	O
Patients	B-P
undergoing	I-P
elective	I-P
abdominal	I-I
aortic	I-I
aneurysmectomy	I-I
(	I-P
n=18	I-P
per	I-P
group	I-P
)	I-P
.	I-P


PRINCIPAL	O
MEASUREMENTS	O
Handgrip	B-O
and	I-O
other	I-O
measures	I-O
of	I-O
strength	I-O
and	I-O
physical	I-O
function	I-O
.	I-O


RESULTS	O
Handgrip	B-O
and	I-O
quadriceps	I-O
strength	I-O
decreased	O
following	O
surgery	O
,	O
but	O
not	O
to	O
a	O
significantly	O
different	O
extent	O
in	O
the	O
placebo	O
and	O
supplemented	O
groups	O
.	O


Self-rated	B-O
physical	I-O
function	I-O
decreased	O
following	O
surgery	B-I
in	O
the	O
placebo	O
group	O
and	O
was	O
preserved	O
in	O
the	O
supplemented	O
group	O
.	O


CONCLUSIONS	O
Perioperative	B-I
supplementation	I-I
with	I-I
micronutrients	I-I
with	O
antioxidant	O
properties	O
has	O
limited	O
effects	O
on	O
strength	B-O
and	I-O
physical	I-O
function	I-O
following	O
major	O
elective	O
surgery	O
.	O


Lung	O
function	O
and	O
respiratory	O
symptoms	O
in	O
a	O
1-year	O
randomized	O
smoking	O
cessation	O
trial	O
of	O
varenicline	B-I
in	O
COPD	B-P
patients	I-P
.	I-P


UNLABELLED	O
There	O
are	O
few	O
data	O
concerning	O
changes	O
in	O
lung	O
function	O
and	O
respiratory	O
symptoms	O
in	O
smokers	B-P
with	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
(	I-P
COPD	I-P
)	I-P
weeks	I-P
to	I-P
months	I-P
after	I-P
quitting	I-P
smoking	I-P
.	I-P


We	O
examined	O
serial	O
changes	O
in	O
spirometry	O
and	O
Clinical	O
COPD	O
Questionnaire	O
(	O
CCQ	O
)	O
scores	O
(	O
measuring	O
respiratory	O
symptoms	O
and	O
health-related	O
quality	O
of	O
life	O
)	O
in	O
COPD	B-P
participants	I-P
by	I-P
smoking	I-P
status	I-P
during	O
a	O
smoking	O
cessation	O
trial	O
.	O


In	O
this	O
randomized	O
,	O
double-blind	O
trial	O
,	O
smokers	B-P
with	I-P
mild-to-moderate	I-P
COPD	I-P
were	O
treated	O
with	O
varenicline	B-I
1	I-I
mg	I-I
b.i.d	I-I
.	I-I


or	B-I
placebo	I-I
for	O
12	O
weeks	O
and	O
followed	O
to	O
Week	O
52	O
.	O


Primary	O
endpoints	O
of	O
abstinence	B-O
were	O
previously	O
reported	O
.	O


Secondary	O
endpoints	O
were	O
mean	B-O
changes	I-O
from	I-O
baseline	I-O
in	O
post-bronchodilator	B-O
forced	I-O
expired	I-O
volume	I-O
in	I-O
1	I-O
s	I-O
(	I-O
FEV	I-O
(	I-O
1	I-O
)	I-O
)	I-O
and	I-O
CCQ	I-O
scores	I-O
.	I-O


Change	B-O
from	I-O
baseline	I-O
in	O
post-bronchodilator	O
FEV	B-O
(	I-O
1	I-O
)	I-O
was	O
significantly	O
improved	O
in	O
continuous	O
abstainers	O
(	O
121.8	O
mL	O
)	O
vs.	O
continuous	O
smokers	O
(	O
37.9	O
mL	O
)	O
at	O
Week	O
12	O
(	O
P	O
=	O
0.0069	O
)	O
,	O
but	O
not	O
at	O
Weeks	O
24	O
or	O
52	O
.	O


Mean	B-O
change	I-O
from	I-O
baseline	I-O
at	I-O
Week	I-O
12	I-O
in	I-O
CCQ	I-O
Total	I-O
Score	I-O
was	O
significantly	O
better	O
in	O
continuous	O
abstainers	O
(	O
-1.04	O
)	O
vs.	O
continuous	O
smokers	O
(	O
-0.53	O
;	O
P	O
<	O
0.0001	O
)	O
:	O
this	O
improvement	O
was	O
sustained	O
at	O
Weeks	O
24	O
and	O
52	O
.	O


In	O
a	O
1-year	O
cessation	O
trial	O
of	O
smokers	B-P
with	I-P
COPD	I-P
,	O
continuous	B-O
abstinence	I-O
compared	O
with	O
continuous	O
smoking	O
significantly	O
improved	O
post-bronchodilator	B-O
FEV	O
(	O
1	O
)	O
at	O
Week	O
12	O
(	O
although	O
the	O
difference	O
narrowed	O
subsequently	O
)	O
and	O
CCQ	B-O
Total	I-O
Scores	I-O
at	O
Week	O
12	O
,	O
with	O
sustained	O
improvement	O
thereafter	O
.	O


(	O
TRIAL	O
REGISTRY	O
http	O
:	O
//www.clinicaltrials.gov	O
;	O
trial	O
identifier	O
:	O
NCT00285012	O
)	O
.	O


Effects	O
of	O
Thai	O
traditional	O
massage	O
on	O
autistic	B-P
children	I-P
's	I-P
behavior	I-P
.	I-P


OBJECTIVES	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
access	O
whether	O
there	O
were	O
any	O
therapeutic	O
effects	O
of	O
Thai	B-I
Traditional	I-I
Massage	I-I
(	I-I
TTM	I-I
)	I-I
on	O
major	O
behavioral	B-P
and	I-P
emotional	I-P
disturbances	I-P
in	I-P
Thai	I-P
autistic	I-P
children	I-P
.	I-P


DESIGN	O
This	O
was	O
a	O
randomized	O
controlled	O
trial	O
study	O
.	O


SETTINGS/LOCATION	O
The	B-P
study	I-P
was	I-P
conducted	I-P
at	I-P
the	I-P
Rehabilitation	I-P
Centre	I-P
of	I-P
the	I-P
Thai	I-P
Red	I-P
Cross	I-P
Society	I-P
.	I-P


SUBJECTS	O
A	B-P
total	I-P
of	I-P
60	I-P
autistic	I-P
children	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
3	I-P
and	I-P
10	I-P
completed	I-P
this	I-P
study	I-P
.	I-P


INTERVENTIONS	O
Standard	B-I
sensory	I-I
integration	I-I
therapy	I-I
(	I-I
SI	I-I
)	I-I
was	O
compared	O
to	O
the	O
SI	O
with	O
TTM	B-I
treatments	O
.	O


OUTCOME	O
MEASURES	O
Parents	O
and	O
teachers	O
assessed	O
major	B-O
behavior	I-O
disturbances	I-O
using	O
the	O
Conners	B-O
'	I-O
Rating	I-O
Scales	I-O
at	O
0	O
and	O
8	O
weeks	O
.	O


Sleep	B-O
Diary	I-O
(	I-O
SD	I-O
)	I-O
,	O
recorded	O
by	O
the	O
parents	O
,	O
assessed	O
the	O
patient	O
's	O
sleeping	O
patterns	O
every	O
week	O
.	O


RESULTS	O
Sixty	B-P
(	I-P
60	I-P
)	I-P
autistic	I-P
children	I-P
,	I-P
mean	I-P
age	I-P
4.67	I-P
+/-	I-P
1.82	I-P
,	I-P
were	I-P
recruited	I-P
.	I-P


No	O
statistical	O
differences	O
were	O
seen	O
in	O
the	O
demographic	O
and	O
baseline	O
data	O
among	O
both	O
groups	O
.	O


From	O
both	O
the	O
Conners	B-O
'	I-O
Teacher	I-O
Questionnaire	I-O
and	I-O
SD	I-O
,	O
statistical	O
improvement	O
was	O
detected	O
for	O
conduct	B-O
problem	I-O
,	I-O
hyperactivity	I-O
,	I-O
inattention-passivity	I-O
,	I-O
hyperactivity	I-O
index	I-O
,	I-O
and	I-O
sleeping	I-O
behavior	I-O
.	I-O


However	O
,	O
results	O
from	O
the	O
Conners	B-O
'	I-O
Parent	I-O
Questionnaire	I-O
revealed	O
an	O
improvement	O
only	O
for	O
anxiety	B-O
(	O
p	O
=	O
0.04	O
)	O
in	O
the	O
massage	O
group	O
,	O
whereas	O
when	O
both	O
groups	O
were	O
compared	O
,	O
a	O
significant	O
improvement	O
in	O
conduct	B-O
problem	I-O
(	O
p	O
=	O
0.03	O
)	O
and	O
anxiety	B-O
(	O
p	O
=	O
0.01	O
)	O
was	O
found	O
.	O


Results	O
indicated	O
that	O
TTM	O
may	O
have	O
a	O
positive	O
effect	O
in	O
improving	O
stereotypical	B-O
behaviors	I-O
in	O
autistic	O
children	O
.	O


CONCLUSIONS	O
Over	O
a	O
period	O
of	O
8	O
weeks	O
,	O
our	O
findings	O
suggested	O
that	O
TTM	O
could	O
be	O
used	O
as	O
a	O
complementary	O
therapy	O
for	O
autistic	O
children	O
in	O
Thailand	B-P
.	I-P


Gum	B-I
elastic	I-I
bougie-guided	I-I
insertion	I-I
of	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
.	O


We	O
tested	O
the	O
hypothesis	O
that	O
gum	B-I
elastic-bougie-guided	I-I
insertion	I-I
of	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
is	O
more	O
frequently	O
successful	O
than	O
introducer	O
tool	O
guided	O
insertion	O
after	O
failed	O
digital	O
insertion	O
.	O


One	B-P
hundred	I-P
anaesthetized	I-P
patients	I-P
(	I-P
ASA	I-P
1-2	I-P
,	I-P
aged	I-P
18	I-P
to	I-P
80	I-P
years	I-P
)	I-P
were	O
randomized	O
for	O
the	O
second	B-I
insertion	I-I
attempt	I-I
using	I-I
either	I-I
the	I-I
gum	I-I
elastic	I-I
bougie-guided	I-I
or	I-I
introducer	I-I
tool	I-I
techniques	I-I
.	I-I


The	O
bougie-guided	B-I
technique	I-I
involved	O
priming	O
the	O
drain	O
tube	O
with	O
the	O
bougie	O
,	O
placing	O
the	O
bougie	O
in	O
the	O
oesophagus	O
using	O
laryngoscope	O
guidance	O
,	O
digital	O
insertion	O
along	O
the	O
palato-pharyngeal	O
curve	O
,	O
and	O
bougie	O
removal	O
.	O


The	O
introducer	B-I
tool	I-I
technique	I-I
involved	O
attaching	O
the	O
introducer	O
tool	O
,	O
single-handed	O
rotation	O
along	O
the	O
palatopharyngeal	O
curve	O
,	O
and	O
introducer	O
tool	O
removal	O
.	O


Failed	O
insertion	O
was	O
classified	O
as	O
(	O
i	O
)	O
failed	O
passage	O
into	O
the	O
pharynx	O
,	O
(	O
ii	O
)	O
malposition	O
,	O
or	O
(	O
iii	O
)	O
ineffective	O
ventilation	O
.	O


Any	O
blood	B-O
staining	I-O
was	O
documented	O
.	O


Insertion	B-O
was	O
more	O
frequently	B-O
successful	I-O
(	O
50/50	O
vs	O
15/50	O
,	O
P=0.0002	O
)	O
and	O
faster	B-O
(	O
35+/-17	O
s	O
vs	O
54+/-45	O
s	O
,	O
mean+/-SD	O
,	O
P=0.006	O
)	O
with	O
the	O
bougie-guided	O
technique	O
.	O


All	O
failed	B-O
insertions	I-O
with	O
the	O
introducer	O
tool	O
technique	O
were	O
successful	O
with	O
the	O
bougie-guided	O
technique	O
.	O


The	O
aetiology	B-O
of	I-O
failed	I-O
insertion	I-O
was	O
similar	O
for	O
the	O
digital	O
and	O
introducer	O
tool	O
techniques	O
in	O
94	O
%	O
(	O
33/35	O
)	O
of	O
patients	O
.	O


There	O
was	O
no	O
blood	B-O
staining	I-O
on	O
the	O
bougie	O
,	O
laryngoscope	O
or	O
introducer	O
tool	O
at	O
removal	O
,	O
but	O
blood	B-O
staining	I-O
was	O
more	O
common	O
on	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
with	O
the	O
introducer	O
tool	O
technique	O
(	O
9/50	O
vs	O
2/50	O
,	O
P=0.03	O
)	O
.	O


We	O
conclude	O
that	O
the	O
gum	B-I
elastic	I-I
bougie-guided	I-I
insertion	I-I
has	O
a	O
higher	O
success	B-O
rate	I-O
and	O
causes	O
less	O
trauma	B-O
than	O
the	O
insertion	O
tool	B-I
insertion	I-I
technique	I-I
after	O
failed	O
digital	O
insertion	O
of	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
.	O


Effect	O
of	O
cigarette	O
smoking	O
on	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	B-P
smokers	I-P
:	I-P
a	O
crossover	O
study	O
using	O
the	O
13C-octanoic	O
acid	O
breath	O
test	O
.	O


BACKGROUND	O
Cigarette	O
smoking	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
peptic	O
ulcer	O
and	O
gastroesophageal	O
reflux	O
disease	O
.	O


Gastric	O
emptying	O
disorders	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
these	O
upper	O
gastrointestinal	O
diseases	O
.	O


Thus	O
,	O
studies	O
examining	O
a	O
link	O
between	O
smoking	O
and	O
gastric	O
emptying	O
disorders	O
have	O
clinical	O
relevance	O
.	O


This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
effect	B-O
of	I-O
smoking	I-O
on	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	B-P
smokers	I-P
.	I-P


METHODS	O
The	O
(	B-I
13	I-I
)	I-I
C-octanoic	I-I
acid	I-O
breath	I-O
test	I-O
was	O
performed	O
in	O
eight	B-P
male	I-P
habitual	I-P
smokers	I-P
on	O
two	O
randomized	O
occasions	O
(	O
either	O
sham	O
smoking	O
or	O
actively	O
smoking	O
)	O
.	O


The	O
time	O
vs	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
excretion	B-O
rate	I-O
curve	I-O
was	O
mathematically	O
fitted	O
to	O
a	O
conventional	O
formula	O
of	O
y	O
(	O
t	O
)	O
=	O
m*k*beta*e	O
(	O
-k*t	O
)	O
*	O
(	O
1	O
-	O
e	O
(	O
-k*t	O
)	O
)	O
(	O
beta-1	O
)	O
,	O
and	O
the	O
parameters	B-O
of	I-O
k	I-O
and	I-O
beta	I-O
were	O
determined	O
:	O
under	O
the	O
crossover	O
protocol	O
,	O
a	O
larger	O
(	O
smaller	O
)	O
beta	O
indicates	O
slower	B-O
(	I-O
faster	I-O
)	I-O
emptying	I-O
in	O
the	O
early	O
phase	O
,	O
and	O
a	O
larger	O
(	O
smaller	O
)	O
k	O
indicates	O
faster	B-O
(	I-O
slower	I-O
)	I-O
emptying	I-O
in	I-O
the	O
later	O
phase	O
.	O


The	O
half	B-O
(	I-O
13	I-O
)	I-O
CO	I-O
(	I-O
2	I-O
)	I-O
excretion	I-O
time	I-O
(	O
t	O
(	O
1/2b	O
)	O
=	O
-	O
[	O
ln	O
(	O
1	O
-	O
2	O
(	O
-1/beta	O
)	O
)	O
]	O
/k	O
)	O
and	O
the	O
time	B-O
of	I-O
maximal	I-O
(	I-O
13	I-O
)	I-O
CO	I-O
(	I-O
2	I-O
)	I-O
excretion	I-O
rate	I-O
(	I-O
t	I-O
(	I-O
max	I-O
)	I-O
=	O
[	O
lnbeta	O
]	O
/k	O
)	O
were	O
also	O
calculated	O
.	O


Between	O
the	O
two	O
occasions	O
,	O
k	O
,	O
beta	O
,	O
t	O
(	O
1/2b	O
)	O
,	O
and	O
t	O
(	O
max	O
)	O
were	O
compared	O
by	O
the	O
Wilcoxon	O
signed-rank	O
test	O
.	O


RESULTS	O
After	O
smoking	O
,	O
k	B-O
was	I-O
significantly	I-O
increased	I-O
.	I-O


No	B-O
significant	I-O
differences	I-O
were	O
found	O
in	O
beta	B-O
,	I-O
t	I-O
(	I-O
1/2	I-O
)	I-O
,	I-O
and	I-O
t	I-O
(	I-O
max	I-O
)	I-O
between	O
the	O
two	O
occasions	O
.	O


CONCLUSIONS	O
The	O
increase	B-O
in	I-O
k	I-O
suggests	O
the	O
acceleration	O
of	O
gastric	O
emptying	O
in	O
the	O
later	O
phase	O
.	O


For	O
the	O
first	O
time	O
,	O
this	O
study	O
has	O
revealed	O
that	O
acute	O
smoking	O
speeds	O
the	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	B-P
habitual	I-P
smokers	I-P
.	I-P


The	O
adrenocorticotrophic	B-I
hormone	I-I
(	I-I
4-9	I-I
)	I-I
analog	I-I
ORG	I-I
2766	I-I
benefits	O
autistic	B-P
children	I-P
:	I-P
report	O
on	O
a	O
second	O
controlled	O
clinical	O
trial	O
.	O


In	O
a	O
second	O
controlled	O
crossover	O
trial	O
,	O
20	B-P
autistic	I-P
children	I-P
received	I-P
40	I-I
mg/day	I-I
of	I-I
the	I-I
neuropeptide	I-I
ORG	I-I
2766	I-I
,	I-I
a	I-I
synthetic	I-I
analog	I-I
of	I-I
ACTH	I-I
(	I-I
4-9	I-I
)	I-I
,	I-P
for	I-P
8	I-P
weeks	I-P
.	I-P


Parents	B-O
'	I-O
checklist	I-O
ratings	I-O
(	I-O
ABC	I-O
)	I-O
as	O
well	O
as	O
clinicians	B-O
'	I-O
ratings	I-O
(	I-O
CGI	I-O
)	I-O
pointed	O
to	O
significant	O
improvements	O
after	O
the	O
course	O
of	O
treatment	O
;	O
improvements	O
were	O
clearest	O
on	O
the	O
ABC	B-O
social	I-O
withdrawal	I-O
subscale	I-O
.	I-O


The	O
analysis	O
of	O
individual	O
target	O
symptoms	O
and	O
the	O
parents	O
'	O
treatment	O
preferences	O
substantiated	O
the	O
beneficial	O
effects	O
of	O
ORG	B-I
2766	I-I
.	I-I


In	O
an	O
ethologically	O
analyzed	O
playroom	O
session	O
,	O
ORG	O
2766	O
treatment	O
was	O
associated	O
with	O
an	O
improvement	O
in	O
the	O
children	B-O
's	I-O
play	I-O
behavior	I-O
and	O
a	O
significant	O
increase	O
in	O
the	O
social	B-O
interaction	I-O
between	I-O
child	I-O
and	I-O
experimenter	I-O
.	I-O


Gaze	B-O
coordination	I-O
between	O
child	O
and	O
experimenter	O
also	O
was	O
improved	O
.	O


The	O
SNRI	B-I
venlafaxine	I-I
improves	O
emotional	B-O
unawareness	I-O
in	O
patients	B-P
with	I-P
post-stroke	I-P
depression	I-P
.	I-P


OBJECTIVE	O
Patients	B-P
with	I-P
stroke	I-P
have	O
a	O
high	O
prevalence	O
of	O
depression	O
and	O
unawareness	O
of	O
emotions	O
or	O
alexithymia	B-O
.	I-O


Here	O
we	O
investigated	O
the	O
effects	O
of	O
the	O
serotoninergic	B-I
and	I-I
noradrenergic	I-I
reuptake	I-I
inhibitor	I-I
(	I-I
SNRI	I-I
)	I-I
venlafaxine	I-I
in	O
comparison	O
with	O
the	O
SSRI	B-I
fluoxetine	I-I
on	O
alexithymia	B-O
severity	O
in	O
patients	B-P
with	I-P
DSM-IV	I-P
post-stroke	I-P
major	I-P
depressive-like	I-P
episode	I-P
(	I-P
PSD	I-P
)	I-P
.	I-P


METHODS	O
Fifty	B-P
inpatients	I-P
with	I-P
first-ever	I-P
stroke	I-P
and	I-P
PSD	I-P
were	I-P
consecutively	I-P
enrolled	I-P
in	O
this	O
randomized	O
open-label	O
study	O
.	O


Twenty-five	O
were	O
treated	O
with	O
the	O
SNRI	B-I
venlafaxine	I-I
SR	O
(	O
75-150	O
mg/die	O
)	O
,	O
and	O
25	O
with	O
the	O
SSRI	B-I
fluoxetine	I-I
(	O
20-40	O
mg/die	O
)	O
.	O


All	O
patients	O
were	O
assessed	O
at	O
day	O
0	O
,	O
and	O
after	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
weeks	O
,	O
using	O
the	O
Mini-Mental	B-O
State	I-O
Examination	I-O
,	I-O
the	I-O
Hamilton	I-O
Depression	I-O
Rating	I-O
Scale	I-O
,	I-O
and	I-O
the	I-O
Toronto	I-O
Alexithymia	I-O
Scale	I-O
(	O
TAS-20	O
)	O
.	O


RESULTS	O
Patients	O
treated	O
with	O
fluoxetine	O
and	O
those	O
treated	O
with	O
venlafaxine	O
showed	O
similar	O
improvement	O
in	O
depressive	B-O
symptoms	I-O
.	I-O


However	O
,	O
patients	O
treated	O
with	O
venlafaxine	O
had	O
a	O
greater	O
improvement	O
on	O
alexithymia	B-O
severity	I-O
than	O
those	O
treated	O
with	O
fluoxetine	O
.	O


The	O
effect	O
of	O
venlafaxine	O
on	O
unawareness	B-O
of	I-O
emotions	I-O
was	O
evident	O
in	O
patients	O
with	O
alexithymia	O
(	O
TAS-20	O
>	O
or=	O
61	O
)	O
at	O
the	O
baseline	O
and	O
in	O
those	O
without	O
alexithymia	O
(	O
TAS-20	O
<	O
61	O
)	O
.	O


CONCLUSIONS	O
Antidepressants	O
acting	O
on	O
both	O
the	O
serotoninergic	O
and	O
noradrenergic	O
systems	O
might	O
represent	O
a	O
valid	O
resource	O
not	O
only	O
for	O
the	O
treatment	O
of	O
depression	O
but	O
also	O
for	O
improving	O
emotional	B-O
unawareness	I-O
in	O
stroke	B-P
patients	I-P
.	I-P


Effect	B-O
of	O
motivational	B-I
music	I-I
on	O
lactate	B-O
levels	I-O
during	O
recovery	O
from	O
intense	O
exercise	O
.	O


The	O
effects	O
of	O
music	O
played	O
during	O
an	O
exercise	O
task	O
on	O
athletic	O
performance	O
have	O
been	O
previously	O
studied	O
.	O


Yet	O
,	O
these	O
results	O
are	O
not	O
applicable	O
for	O
competitive	B-P
athletes	I-P
,	O
who	O
can	O
use	O
music	O
only	O
during	O
warm-up	O
or	O
recovery	O
from	O
exercise	O
.	O


Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
motivational	B-I
music	I-I
(	I-I
music	I-I
that	I-I
stimulates	I-I
or	I-I
inspires	I-I
physical	I-I
activity	I-I
)	I-I
during	O
recovery	B-O
from	I-O
intense	I-O
exercise	I-O
,	O
on	O
activity	B-O
pattern	I-O
,	I-O
rate	I-O
of	I-O
perceived	I-O
exertion	I-O
(	I-O
RPE	I-O
)	I-O
,	I-O
and	I-O
blood	I-O
lactate	I-O
concentration	I-O
.	I-O


Twenty	B-P
young	I-P
,	I-P
active	I-P
men	I-P
(	I-P
mean	I-P
age	I-P
26.2	I-P
±	I-P
2.1	I-P
years	I-P
)	I-P
performed	O
a	B-I
6-minute	I-I
run	I-I
at	I-I
peak	I-I
oxygen	I-I
consumption	I-I
speed	I-I
(	O
predetermined	O
from	O
the	O
VO	O
(	O
2	O
)	O
max	O
test	O
)	O
.	O


The	B-O
mean	I-O
heart	I-O
rate	I-O
(	I-O
HR	I-O
)	I-O
,	I-O
RPE	I-O
,	I-O
number	I-O
of	I-O
steps	I-O
(	I-O
determined	I-O
by	I-O
step	I-O
counter	I-O
)	I-O
,	I-O
and	I-O
blood	I-O
lactate	I-O
concentrations	I-O
were	O
determined	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
and	O
15	O
minutes	O
during	O
the	O
recovery	O
from	O
the	O
exercise	O
,	O
with	O
and	O
without	O
motivational	O
music	O
(	O
2	O
separate	O
sessions	O
,	O
at	O
random	O
order	O
)	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	B-O
mean	I-O
HR	I-O
during	O
the	O
recovery	O
with	O
and	B-I
without	I-I
music	I-I
.	O


Listening	O
to	O
motivational	O
music	O
during	O
the	O
recovery	O
was	O
associated	O
with	O
increased	B-O
voluntary	I-O
activity	I-O
of	O
the	O
participants	O
,	O
determined	O
by	O
increased	B-O
number	I-O
of	I-O
steps	I-O
(	O
499.4	O
±	O
220.1	O
vs.	O
413.2	O
±	O
150.6	O
steps	O
,	O
with	O
and	O
without	O
music	O
,	O
respectively	O
;	O
p	O
≤	O
0.05	O
)	O
.	O


The	O
increased	O
number	B-O
of	I-O
steps	I-O
during	O
the	O
recovery	O
was	O
accompanied	O
by	O
a	O
significantly	O
greater	O
decrease	B-O
in	I-O
blood	I-O
lactate	I-O
concentration	I-O
percentage	O
(	O
28.1	O
±	O
12.2	O
vs.	O
22.8	O
±	O
10.9	O
%	O
,	O
with	O
and	O
without	O
music	O
,	O
respectively	O
,	O
p	O
≤	O
0.05	O
)	O
.	O


This	O
was	O
associated	O
with	O
a	O
greater	O
decrease	B-O
in	O
RPE	O
(	O
77.7	O
±	O
14.4	O
vs.	O
73.1	O
±	O
14.7	O
%	O
with	O
and	O
without	O
music	O
,	O
respectively	O
;	O
p	O
≤	O
0.05	O
)	O
.	O


Our	O
results	O
suggest	O
that	O
listening	O
to	O
motivational	O
music	O
during	O
nonstructured	O
recovery	O
from	O
intense	O
exercise	O
leads	O
to	O
increased	O
activity	O
,	O
faster	O
lactate	O
clearance	O
,	O
and	O
reduced	O
RPE	O
and	O
therefore	O
may	O
be	O
used	O
by	O
athletes	O
in	O
their	O
effort	O
to	O
enhance	O
recovery	O
.	O


Fludarabine	B-I
in	O
chronic	B-P
leukaemia	I-P
.	I-P


A	O
comparison	O
of	O
antiarrhythmic-drug	B-I
therapy	I-I
with	I-I
implantable	I-I
defibrillators	I-I
in	O
patients	B-P
resuscitated	I-P
from	I-P
near-fatal	I-P
ventricular	I-P
arrhythmias	I-P
.	I-P


The	O
Antiarrhythmics	B-I
versus	O
Implantable	B-I
Defibrillators	I-I
(	O
AVID	O
)	O
Investigators	O
.	O


BACKGROUND	O
Patients	O
who	O
survive	O
life-threatening	O
ventricular	O
arrhythmias	O
are	O
at	O
risk	O
for	O
recurrent	O
arrhythmias	O
.	O


They	O
can	O
be	O
treated	O
with	O
either	O
an	O
implantable	B-I
cardioverter-defibrillator	I-I
or	O
antiarrhythmic	B-I
drugs	I-I
,	O
but	O
the	O
relative	O
efficacy	O
of	O
these	O
two	O
treatment	O
strategies	O
is	O
unknown	O
.	O


METHODS	O
To	O
address	O
this	O
issue	O
,	O
we	O
conducted	O
a	O
randomized	O
comparison	O
of	O
these	O
two	O
treatment	O
strategies	O
in	O
patients	B-P
who	I-P
had	I-P
been	I-P
resuscitated	I-P
from	I-P
near-fatal	I-P
ventricular	I-P
fibrillation	I-P
or	I-P
who	I-P
had	I-P
undergone	I-P
cardioversion	I-P
from	I-P
sustained	I-P
ventricular	I-P
tachycardia	I-P
.	I-P


Patients	B-P
with	I-P
ventricular	I-P
tachycardia	I-P
also	I-P
had	I-P
either	I-P
syncope	I-P
or	I-P
other	I-P
serious	I-P
cardiac	I-P
symptoms	I-P
,	I-P
along	I-P
with	I-P
a	I-P
left	I-P
ventricular	I-P
ejection	I-P
fraction	I-P
of	I-P
0.40	I-P
or	I-P
less	I-P
.	I-P


One	O
group	O
of	O
patients	O
was	O
treated	O
with	O
implantation	B-I
of	I-I
a	I-I
cardioverter-defibrillator	I-I
;	I-I
the	O
other	O
received	O
class	B-I
III	I-I
antiarrhythmic	I-I
drugs	I-I
,	I-I
primarily	I-I
amiodarone	I-I
at	O
empirically	O
determined	O
doses	O
.	O


Fifty-six	O
clinical	O
centers	O
screened	O
all	O
patients	O
who	O
presented	O
with	O
ventricular	O
tachycardia	O
or	O
ventricular	O
fibrillation	O
during	O
a	O
period	O
of	O
nearly	O
four	O
years	O
.	O


Of	B-P
1016	I-P
patients	I-P
(	I-P
45	I-P
percent	I-P
of	I-P
whom	I-P
had	I-P
ventricular	I-P
fibrillation	I-P
,	I-P
and	I-P
55	I-P
percent	I-P
ventricular	I-P
tachycardia	I-P
)	I-P
,	I-P
507	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
treatment	I-P
with	I-P
implantable	I-I
cardioverter-defibrillators	I-I
and	I-P
509	I-P
to	I-P
antiarrhythmic-drug	I-I
therapy	I-I
.	I-I


The	O
primary	O
end	O
point	O
was	O
overall	B-O
mortality	I-O
.	I-O


RESULTS	O
Follow-up	O
was	O
complete	O
for	O
1013	O
patients	O
(	O
99.7	O
percent	O
)	O
.	O


Overall	O
survival	B-O
was	O
greater	O
with	O
the	O
implantable	B-I
defibrillator	I-I
,	O
with	O
unadjusted	O
estimates	O
of	O
89.3	O
percent	O
,	O
as	O
compared	O
with	O
82.3	O
percent	O
in	O
the	O
antiarrhythmic-drug	B-I
group	O
at	O
one	O
year	O
,	O
81.6	O
percent	O
versus	O
74.7	O
percent	O
at	O
two	O
years	O
,	O
and	O
75.4	O
percent	O
versus	O
64.1	O
percent	O
at	O
three	O
years	O
(	O
P	O
<	O
0.02	O
)	O
.	O


The	O
corresponding	O
reductions	O
in	O
mortality	B-O
(	O
with	O
95	O
percent	O
confidence	O
limits	O
)	O
with	O
the	O
implantable	B-I
defibrillator	I-I
were	O
39+/-20	O
percent	O
,	O
27+/-21	O
percent	O
,	O
and	O
31+/-21	O
percent	O
CONCLUSIONS	O
Among	O
survivors	B-P
of	I-P
ventricular	I-P
fibrillation	I-P
or	I-P
sustained	I-P
ventricular	I-P
tachycardia	I-P
causing	I-P
severe	I-P
symptoms	I-P
,	O
the	O
implantable	B-I
cardioverter-defibrillator	I-I
is	O
superior	O
to	O
antiarrhythmic	B-I
drugs	I-I
for	O
increasing	O
overall	O
survival	O
.	O


A	O
randomized	O
controlled	O
trial	O
of	O
nonlinear	B-I
frequency	I-I
compression	I-I
versus	I-I
conventional	I-I
processing	I-I
in	I-I
hearing	I-I
aids	I-I
:	I-I
speech	O
and	O
language	O
of	O
children	B-P
at	I-P
three	I-P
years	I-P
of	I-P
age	I-P
.	I-P


OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
nonlinear	B-I
frequency	I-I
compression	I-I
(	I-I
NLFC	I-I
)	I-I
on	O
children	B-P
's	I-P
development	I-P
of	I-P
speech	I-P
and	I-P
language	I-P
at	I-P
three	I-P
years	I-P
of	I-P
age	I-P
.	I-P


DESIGN	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
as	O
part	O
of	O
the	O
population-based	B-P
longitudinal	O
study	O
on	O
outcomes	O
of	O
children	B-P
with	I-P
hearing	I-P
impairment	I-P
(	I-P
LOCHI	I-P
)	I-P
.	I-P


Participants	O
were	O
randomly	O
assigned	O
to	O
fitting	O
with	O
NLFC	B-I
(	I-I
Phonak	I-I
Naida	I-I
V	I-I
SP	I-I
or	I-I
UP	I-I
)	I-I
or	O
with	O
conventional	B-I
processing	I-I
in	I-I
hearing	I-I
aids	I-I
,	O
prescribed	O
by	O
using	O
either	O
the	O
NAL	B-I
or	O
the	O
DSL	B-I
formula	O
.	O


Standardized	O
tests	O
of	O
speech	B-O
production	I-O
,	I-O
receptive	I-O
and	I-O
expressive	I-O
language	I-O
were	O
administered	O
,	O
and	O
parent	O
ratings	O
were	O
collected	O
.	O


All	O
assessments	O
were	O
double-blinded	O
.	O


STUDY	O
SAMPLE	O
Participants	B-P
were	I-P
44	I-P
of	I-P
the	I-P
450	I-P
children	I-P
in	I-P
the	I-P
LOCHI	I-P
cohort	I-P
.	I-P


RESULTS	O
Compared	O
to	O
children	B-P
using	O
conventional	B-I
processing	I-I
,	O
receptive	B-O
and	I-O
expressive	I-O
language	I-O
was	O
higher	O
but	O
receptive	B-O
vocabulary	I-O
and	I-O
consonant	I-O
articulation	I-O
scores	I-O
were	O
lower	O
for	O
children	O
who	O
use	O
NLFC	B-I
.	I-I


There	O
was	O
increased	O
substitution	B-O
of	I-O
affricates	I-O
by	I-O
fricatives	I-O
for	O
children	O
using	O
NLFC	B-I
,	O
compared	O
to	O
children	O
using	O
conventional	B-I
amplification	I-I
.	I-I


After	O
allowing	O
for	O
the	O
effect	O
of	O
multiple	O
demographic	O
variables	O
,	O
the	O
difference	O
in	O
global	B-O
language	I-O
scores	I-O
between	O
groups	O
was	O
not	O
significant	O
(	O
effect	O
:	O
0.8	O
[	O
95	O
%	O
confidence	O
interval	O
:	O
-	O
6.7	O
,	O
8.3	O
]	O
)	O
.	O


CONCLUSIONS	O
There	O
is	O
insufficient	O
evidence	O
to	O
indicate	O
a	O
difference	O
in	O
language	B-O
ability	I-O
between	O
children	B-P
using	I-P
NLFC	I-I
and	I-P
those	I-P
using	I-P
conventional	I-I
amplification	I-I
.	I-I


Mechanisms	O
underlying	O
the	O
lack	O
of	O
effect	O
of	O
implantable	B-I
cardioverter-defibrillator	I-I
therapy	I-I
on	O
mortality	B-O
in	O
high-risk	B-P
patients	I-P
with	I-P
recent	I-P
myocardial	I-P
infarction	I-P
:	I-P
insights	O
from	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O


BACKGROUND	O
although	O
implantable	B-I
cardioverter-defibrillators	I-I
(	O
ICDs	O
)	O
lower	O
mortality	O
in	O
stable	B-P
patients	I-P
with	I-P
low	I-P
ejection	I-P
fraction	I-P
late	I-P
after	I-P
myocardial	I-P
infarction	I-P
,	O
randomized	O
trials	O
of	O
ICD	B-I
versus	O
control	O
subjects	O
implanted	O
early	O
after	O
myocardial	O
infarction	O
do	O
not	O
show	O
mortality	O
benefit	O
.	O


Our	O
objective	O
was	O
to	O
investigate	O
possible	O
mechanisms	O
underlying	O
the	O
lack	O
of	O
mortality	B-O
benefit	O
in	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O


METHODS	O
AND	O
RESULTS	O
this	O
is	O
a	O
secondary	O
analysis	O
of	O
the	O
prospective	O
randomized	O
clinical	O
trial	O
.	O


Outpatients	B-P
with	I-P
recent	I-P
(	I-P
6	I-P
to	I-P
40	I-P
days	I-P
)	I-P
acute	I-P
myocardial	I-P
infarction	I-P
,	I-P
left	I-P
ventricular	I-P
dysfunction	I-P
(	I-P
ejection	I-P
fraction	I-P
<	I-P
35	I-P
%	I-P
)	I-P
,	I-P
and	I-P
low	I-P
heart	I-P
rate	I-P
variability	I-P
were	O
randomized	O
to	O
ICD	B-I
(	O
n=311	O
)	O
or	O
to	O
standard	B-I
medical	I-I
therapy	I-I
(	O
n=342	O
)	O
.	O


In	O
a	O
competing-risks	O
analysis	O
,	O
those	O
factors	O
that	O
increased	O
the	O
risk	B-O
of	I-O
arrhythmic	I-O
death	I-O
also	O
increased	O
the	O
risk	B-O
of	I-O
nonarrhythmic	I-O
deaths	I-O
.	I-O


After	O
adjustment	O
for	O
these	O
factors	O
,	O
receiving	O
an	O
ICD	O
was	O
associated	O
with	O
a	O
decreased	O
risk	B-O
of	I-O
arrhythmic	I-O
death	I-O
(	O
hazard	O
ratio	O
,	O
0.33	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.15	O
to	O
0.71	O
)	O
but	O
an	O
increase	O
in	O
nonarrhythmic	B-O
death	I-O
(	O
hazard	O
ratio	O
,	O
1.70	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.00	O
to	O
2.80	O
)	O
.	O


In	O
an	O
adjusted	O
time-dependent	O
analysis	O
,	O
patients	O
receiving	O
an	O
ICD	O
and	O
having	O
appropriate	O
ICD	O
therapy	O
had	O
a	O
15.1	O
%	O
yearly	B-O
hazard	I-O
of	I-O
mortality	I-O
compared	O
with	O
5.2	O
%	O
in	O
ICD	B-P
patients	I-P
with	O
no	O
appropriate	O
therapy	O
(	O
P	O
<	O
0.001	O
)	O
.	O


The	O
reduction	O
in	O
sudden	B-O
death	I-O
in	O
ICD	B-P
patients	I-P
was	O
completely	O
offset	O
by	O
increased	O
nonarrhythmic	B-O
deaths	I-O
,	O
which	O
were	O
greatest	O
in	O
patients	B-P
receiving	O
ICD	O
shock	O
therapy	O
(	O
hazard	O
ratio	O
,	O
6.0	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
2.8	O
to	O
12.7	O
)	O
.	O


CONCLUSIONS	O
in	O
patients	B-P
receiving	I-P
ICDs	I-P
early	I-P
after	I-P
myocardial	I-P
infarction	I-P
,	O
those	O
factors	O
that	O
are	O
associated	O
with	O
arrhythmia	O
requiring	O
ICD	O
therapy	O
are	O
also	O
associated	O
with	O
a	O
high	O
risk	O
of	O
nonsudden	B-O
death	I-O
,	O
negating	O
the	O
benefit	O
of	O
ICDs	O
in	O
this	O
setting	O
.	O


Controlled	O
clinical	O
trial	O
of	O
IV	O
cyclophosphamide	B-I
versus	O
IV	O
methylprednisolone	B-I
in	O
severe	B-P
neurological	I-P
manifestations	I-P
in	I-P
systemic	I-P
lupus	I-P
erythematosus	I-P
.	I-P


BACKGROUND	O
Severe	B-P
neurological	I-P
involvement	I-P
in	I-P
systemic	I-P
lupus	I-P
erythematosus	I-P
(	I-P
NPSLE	I-P
)	I-P
is	O
one	O
of	O
the	O
most	O
dreadful	O
complications	O
of	O
the	O
disease	O
.	O


OBJECTIVE	O
To	O
identify	O
the	O
best	O
drug	O
,	O
dose	O
,	O
and	O
treatment	O
.	O


PATIENTS	O
AND	O
METHODS	O
The	O
study	O
was	O
a	O
controlled	O
clinical	O
trial	O
at	O
two	B-P
tertiary	I-P
care	I-P
centres	I-P
of	I-P
patients	I-P
with	I-P
SLE	I-P
according	I-P
to	I-P
the	I-P
ACR	I-P
criteria	I-P
,	I-P
with	I-P
incident	I-P
(	I-P
no	I-P
more	I-P
than	I-P
15	I-P
days	I-P
)	I-P
onset	I-P
of	I-P
severe	I-P
NP	I-P
manifestations	I-P
such	I-P
as	I-P
seizures	I-P
,	I-P
optic	I-P
neuritis	I-P
,	I-P
peripheral	I-P
or	I-P
cranial	I-P
neuropathy	I-P
,	I-P
coma	I-P
,	I-P
brainstem	I-P
disease	I-P
,	I-P
or	I-P
transverse	I-P
myelitis	I-P
.	I-P


Induction	O
treatment	O
with	O
3	O
g	O
of	O
IV	O
methylprednisolone	B-I
(	O
MP	O
)	O
followed	O
by	O
either	O
IV	O
monthly	O
cyclophosphamide	B-I
(	O
Cy	O
)	O
versus	O
IV	B-I
MP	I-I
bimonthly	I-I
every	O
4	O
months	O
for	O
1	O
year	O
and	O
then	O
IV	O
Cy	O
or	O
IV	O
MP	O
every	O
3	O
months	O
for	O
another	O
year	O
.	O


The	O
primary	O
end	O
point	O
was	O
response	B-O
to	I-O
treatment	I-O
:	I-O
at	O
least	O
20	B-O
%	I-O
improvement	I-O
from	I-O
basal	I-O
conditions	I-O
on	O
clinical	B-O
,	I-O
laboratory	I-O
,	I-O
or	I-O
specific	I-O
neurological	I-O
testing	I-O
variables	I-O
.	I-O


RESULTS	O
Overall	O
,	O
a	O
response	B-O
rate	I-O
of	O
75	O
%	O
was	O
observed	O
.	O


Of	O
the	O
32	B-P
patients	I-P
studied	I-P
,	O
18/19	O
receiving	O
Cy	O
and	O
7/13	O
receiving	O
MP	O
responded	O
to	O
treatment	O
(	O
p	O
<	O
0.03	O
)	O
.	O


CONCLUSIONS	O
Cy	O
seems	O
to	O
be	O
more	O
effective	B-O
than	O
MP	O
in	O
the	O
treatment	O
of	O
acute	O
,	O
severe	O
NPSLE	O
.	O


Learning	O
curve	O
in	O
multidetector	B-I
CT	I-I
coronary	I-I
angiography	I-I
(	O
MDCT-CA	O
)	O
.	O


PURPOSE	O
Coronary	B-I
angiography	I-I
using	I-I
multidetector	I-I
computed	I-I
tomography	I-I
(	I-I
MDCT-CA	I-I
)	I-I
is	O
a	O
recent	O
technique	O
for	O
the	O
nonivasive	O
study	O
of	O
coronary	O
arteries	O
.	O


This	O
study	O
assessed	O
the	O
diagnostic	B-O
accuracy	I-O
of	I-O
coronary	I-O
artery	I-O
stenosis	I-O
evaluation	I-O
obtained	O
by	O
three	B-P
readers	I-P
at	I-P
different	I-P
levels	I-P
of	I-P
training	I-P
or	I-P
at	I-P
different	I-P
points	I-P
of	I-P
the	I-P
learning	I-P
curve	I-P
proposed	I-P
by	I-P
the	I-P
international	I-P
guidelines	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
Three	B-P
radiologists	I-P
in	I-P
training	I-P
with	I-P
different	I-P
levels	I-P
of	I-P
experience	I-P
in	I-P
MDCT-CA	I-P
scored	O
50	O
cases	O
at	O
various	O
time	O
points	O
of	O
the	O
learning	O
curve	O
:	O
baseline	O
,	O
4	O
weeks	O
,	O
8	O
weeks	O
and	O
6	O
months	O
.	O


The	B-P
trainee	I-P
radiologists	I-P
evaluated	O
the	O
degree	B-O
of	I-O
stenosis	I-O
on	I-O
each	I-O
coronary	I-O
segment	I-O
,	O
and	O
overall	B-O
accuracy	I-O
was	O
calculated	O
on	O
a	O
per-segment	O
,	O
pervessel	O
and	O
per-patient	O
basis	O
.	O


RESULTS	O
All	O
readers	O
improved	B-O
analysis	I-O
accuracy	I-O
per	I-O
segment	I-O
(	O
range	O
,	O
73-90	O
%	O
)	O
;	O
sensitivity	B-O
reached	O
45	O
%	O
per	O
segment	O
,	O
84	O
%	O
per	O
vessel	O
and	O
93	O
%	O
per	O
patient	O
;	O
specificity	B-O
was	O
99	O
%	O
per	O
segment	O
and	O
vessel	O
and	O
98	O
%	O
per	O
patient	O
.	O


Positive	B-O
and	I-O
negative	I-O
predictive	I-O
values	I-O
increased	I-O
to	O
94	O
%	O
and	O
92	O
%	O
,	O
respectively	O
.	O


CONCLUSIONS	O
Although	O
all	O
readers	O
improved	O
in	O
diagnostic	B-O
performance	I-O
with	O
growing	O
experience	O
with	O
MDCT-CA	O
,	O
a	O
longer	B-I
training	I-I
period	I-I
may	O
be	O
necessary	O
to	O
achieve	O
adequate	O
levels	O
of	O
expertise	O
in	O
MDCT-CA	O
to	O
be	O
able	O
to	O
perform	O
as	O
independent	O
readers	O
.	O


Benefit	O
of	O
adjuvant	B-I
interferon	I-I
alfa-2b	I-I
(	I-I
IFN-α	I-I
)	I-I
therapy	I-I
in	I-P
melanoma	I-P
patients	I-P
with	I-P
high	I-P
serum	I-P
MMP-8	I-P
levels	I-P
.	O


Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
important	O
enzymes	O
in	O
tissue	O
turnover	O
and	O
various	O
inflammatory	O
processes	O
.	O


In	O
this	O
study	O
,	O
it	O
was	O
evaluated	O
whether	O
serum	O
MMP-8	O
can	O
predict	O
the	O
response	O
to	B-I
adjuvant	I-I
interferon	I-I
alfa-2b	I-I
(	I-I
IFN-α	I-I
)	I-I
therapy	I-I
in	O
patients	O
with	O
operated	O
high-risk	O
cutaneous	O
melanoma	B-P
.	O


Pre-treatment	O
sera	O
from	B-P
460	I-P
patients	I-P
with	I-P
stage	I-P
IIB-IIIC	I-P
melanoma	I-P
were	I-P
analyzed	I-P
for	I-P
MMP-8	I-P
.	O


The	O
patients	O
were	O
randomized	O
after	B-I
surgery	I-I
to	I-I
adjuvant	I-I
IFN-α	I-I
for	O
12	O
or	O
24	O
months	O
(	O
n	O
=	O
313	O
)	O
or	B-I
observation	I-I
only	I-I
(	O
n	O
=	O
147	O
)	O
.	O


The	B-O
median	I-O
serum	I-O
MMP-8	I-O
level	I-O
was	O
used	O
to	O
classify	O
the	O
patients	O
into	O
a	O
low	O
MMP-8	O
(	O
n	O
=	O
232	O
)	O
and	O
a	O
high	O
MMP-8	O
(	O
n	O
=	O
228	O
)	O
group	O
.	O


In	O
the	O
high	O
MMP-8	O
subgroup	B-O
,	I-O
IFN-α	I-O
therapy	I-O
significantly	O
improved	B-O
relapse-free	I-O
survival	I-O
(	I-O
RFS	I-O
)	I-O
.	I-O


RFS	O
was	O
36.8	O
months	B-P
in	I-P
patients	I-P
with	I-P
high	I-O
MMP-8	I-O
levels	I-O
receiving	I-I
IFN-α	I-I
therapy	I-I
,	O
whereas	B-O
RFS	O
for	O
those	O
with	O
high	B-O
MMP-8	I-O
levels	I-O
with	O
observation	O
only	O
was	O
10.6	O
months	O
(	O
P	O
=	O
0.027	B-O
)	I-O
.	I-O


Median	B-O
overall	I-O
survival	I-O
for	I-P
patients	I-P
with	I-P
high	I-O
MMP-8	I-O
and	O
observation	O
only	O
was	O
36.7	O
versus	O
71.7	O
months	O
in	O
those	O
receiving	O
IFN-α	O
(	O
P	O
=	O
0.13	O
)	O
.	O


In	O
a	O
multivariate	O
model	B-O
,	I-O
IFN-α	I-O
therapy	I-O
was	O
a	O
significant	O
predictor	O
of	O
favorable	B-O
RFS	O
(	O
HR	O
0.74	O
;	O
95	O
%	O
CI	O
0.55-0.99	O
;	O
P	O
=	O
0.048	O
)	O
,	O
after	O
adjustment	O
for	O
pre-treatment	O
MMP-8	O
(	O
HR	O
1.17	O
;	O
95	O
%	O
CI	O
0.88-1.55	O
;	O
P	O
=	O
0.28	O
)	O
,	O
gender	O
(	O
HR	O
1.16	O
;	O
95	O
%	O
CI	O
0.86-1.56	O
;	O
P	O
=	O
0.32	O
)	O
,	O
age	O
(	O
HR	O
1.00	O
;	O
95	O
%	O
CI	O
1.00-1.02	O
;	O
P	O
=	O
0.12	O
)	O
,	O
ulceration	O
(	O
HR	O
1.09	O
;	O
95	O
%	O
CI	O
0.81-1.46	O
;	O
P	O
=	O
0.58	O
)	O
,	O
and	O
the	O
presence	O
of	O
node	O
metastases	O
(	O
HR	O
1.36	O
;	O
95	O
%	O
CI	O
1.17-1.58	O
;	O
P	O
<	O
0.0001	O
)	O
.	O


In	O
conclusion	O
,	O
patients	O
with	B-O
high	I-O
serum	I-O
MMP-8	I-O
levels	O
may	O
benefit	B-I
from	I-I
adjuvant	I-I
IFN-α	I-I
therapy	O
,	O
but	O
this	O
observation	O
should	O
be	O
further	O
investigated	O
.	O


Improved	B-O
responsiveness	I-O
of	O
PCOS	B-P
patients	I-P
to	O
clomiphene	B-I
after	I-P
CYP17a	I-I
inhibitor	I-I
.	I-I


PURPOSE	O
To	O
study	O
the	O
effect	O
of	O
CYP17a	B-I
inhibitor	I-I
,	I-I
"	I-I
ketoconazole	I-I
,	I-I
"	I-I
on	O
clomiphene	O
responsiveness	O
in	O
PCOS	B-P
patients	I-P
.	I-P


METHODS	O
Prospective	O
analysis	O
was	O
employed	O
with	O
the	O
setup	O
at	O
Alexandria	B-P
IVF/ICSI	I-P
center	I-P
.	I-P


Ninety-seven	B-P
insulin-resistant	I-P
PCOS	I-P
patients	I-P
undergoing	I-P
ovulation	I-P
induction	I-P
using	I-P
clomiphene	I-I
citrate	I-I
were	O
randomly	O
divided	O
,	O
by	O
random	O
number	O
table	O
,	O
into	O
two	O
groups	O
.	O


The	O
first	O
group	O
(	O
n	O
=	O
49	O
)	O
received	O
ketoconazole	B-I
(	O
400	O
mg	O
daily	O
)	O
till	O
correction	O
of	O
metabolic	O
syndrome	O
followed	O
by	O
clomiphene	B-I
(	O
100	O
mg/day	O
)	O
;	O
the	O
second	O
group	O
(	O
n	O
=	O
48	O
)	O
receiving	O
clomiphene	B-I
without	I-I
ketoconazole	I-I
pretreatment	I-I
.	I-I


Main	O
outcome	O
measures	O
were	O
incidence	B-O
of	I-O
clomiphene	I-O
resistance	I-O
,	I-O
monofollicular	I-O
response	I-O
,	I-O
fasting	I-O
insulin/glucose	I-O
ratio	I-O
,	I-O
serum	I-O
testosterone	I-O
,	I-O
and	I-O
pregnancy	I-O
rates	I-O
.	I-O


RESULTS	O
The	O
ketoconazole	B-I
group	O
showed	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
incidence	B-O
of	I-O
monofollicular	I-O
response	I-O
(	O
38	O
%	O
)	O
,	O
higher	B-O
pregnancy	I-O
rates	I-O
,	O
and	O
significantly	B-O
less	I-O
marked	I-O
antiestrogenic	I-O
manifestations	I-O
than	O
did	O
the	O
control	O
group	O
.	O


They	O
also	O
had	O
significantly	O
lower	O
incidence	B-O
of	I-O
clomiphene	I-O
resistance	I-O
(	O
11.6	O
%	O
)	O
,	O
lower	B-O
serum	I-O
testosterone	I-O
levels	I-O
,	O
less	O
hyperinsulinaemia	B-O
,	O
than	O
did	O
the	O
control	O
group	O
.	O


CONCLUSION	O
Ketoconazole	B-I
improved	O
clomiphene	B-O
responsivenss	I-O
in	I-O
PCOS	I-O
patients	I-O
and	O
attenuated	O
its	O
untoward	B-O
biological	I-O
effects	I-O
.	I-O


Efficacy	O
of	O
colchicine	B-I
versus	O
placebo	B-I
for	O
the	O
treatment	O
of	O
pericardial	B-P
effusion	I-P
after	I-P
open-heart	I-P
surgery	I-P
:	I-P
A	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O


BACKGROUND	O
Pericardial	B-O
effusion	I-O
(	I-O
PE	I-O
)	I-O
,	O
a	O
common	O
complication	O
after	O
open-heart	O
surgery	O
,	O
accounts	O
for	O
50	O
%	O
to	O
85	O
%	O
of	O
patients	O
.	O


Although	O
reversible	O
in	O
most	O
of	O
the	O
cases	O
,	O
it	O
could	O
be	O
life	O
threatening	O
in	O
the	O
occurrence	O
of	O
tamponade	O
in	O
large	O
effusions	O
.	O


We	O
aimed	O
to	O
determine	O
the	O
therapeutic	O
efficacy	O
of	O
colchicine	O
on	O
PE	B-O
after	I-P
open-heart	I-P
surgery	I-P
.	I-P


METHODS	O
The	O
study	O
is	O
a	O
prospective	O
,	O
randomized	O
,	O
triple-blind	O
,	O
placebo-controlled	B-I
single-center	I-P
trial	I-P
at	I-P
Tehran	I-P
Heart	I-P
Center	I-P
.	I-P


A	B-P
total	I-P
of	I-P
149	I-P
patients	I-P
with	I-P
mild	I-P
or	I-P
moderate	I-P
PE	I-P
in	I-P
transthoracic	I-P
echocardiography	I-P
were	O
randomly	O
assigned	O
to	O
receive	B-I
1	I-I
mg/d	I-I
colchicine	I-I
(	I-I
n	I-I
=	I-I
74	I-I
)	I-I
or	I-I
1	I-I
tablet	I-I
of	I-I
placebo	I-I
(	I-I
n	I-I
=	I-I
75	I-I
)	I-I
for	I-I
2	I-I
weeks	I-I
and	I-I
then	I-I
underwent	I-I
follow-up	I-I
echocardiography	I-I
.	I-I


RESULTS	O
Baseline	O
and	O
clinical	O
characteristics	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
study	O
groups	O
except	O
for	O
age	O
(	O
P	O
=	O
.02	O
)	O
and	O
graft	O
numbers	O
(	O
P	O
=	O
.005	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
pretreatment	O
and	O
posttreatment	O
PE	B-O
sizes	I-O
between	O
the	O
2	O
study	O
groups	O
(	O
P	O
=	O
.440	O
and	O
.844	O
,	O
respectively	O
)	O
.	O


Median	O
(	O
25th-75th	O
percentiles	O
)	O
of	O
effusion	B-O
changes	I-O
was	O
5	O
mm	O
(	O
1-7.6	O
mm	O
)	O
in	O
the	O
colchicine	B-I
group	O
and	O
5	O
mm	O
(	O
1-6.6	O
mm	O
)	O
in	O
the	O
placebo	B-I
group	O
(	O
P	O
=	O
.932	O
)	O
.	O


Intervention	O
had	O
no	O
significant	O
impact	O
on	O
pretreatment	O
and	O
posttreatment	B-O
effusion	I-O
values	I-O
and	I-O
changes	I-O
in	O
isolated	B-O
coronary	I-O
artery	I-O
bypass	I-O
graft	I-O
surgery	I-O
patients	I-O
(	O
P	O
=	O
.607	O
,	O
.539	O
,	O
and	O
.628	O
,	O
respectively	O
)	O
.	O


After	O
adjustment	O
for	O
possible	O
confounders	O
,	O
there	O
was	O
still	O
no	O
significant	O
difference	O
in	O
postoperative	O
PE	B-O
between	O
the	O
2	O
study	O
groups	O
(	O
t	O
=	O
-0.285	O
,	O
P	O
=	O
.776	O
)	O
.	O


CONCLUSION	O
We	O
concluded	O
that	O
prescription	O
of	O
colchicine	B-I
does	O
not	O
seem	O
to	O
be	O
effective	O
in	O
treatment	O
of	O
asymptomatic	B-O
postoperative	I-O
PE	I-O
.	I-O


This	O
could	O
be	O
justified	O
in	O
case	O
that	O
the	O
etiology	O
of	O
most	O
of	O
the	O
PEs	B-P
might	O
be	O
contribution	O
of	O
noninflammatory	O
factors	O
which	O
are	O
better	O
to	O
be	O
dealt	O
with	O
observational	O
approaches	O
.	O


Intravenous	O
pretreatment	O
of	O
hypertonic	B-I
saline	I-I
can	O
prevent	O
systemic	B-O
hypotension	I-O
induced	O
by	O
spinal	O
anesthesia	O
.	O


BACKGROUND	O
Hypertonic	O
saline	O
improves	O
organ	B-O
perfusion	I-O
and	O
patient	B-O
survival	I-O
during	O
hemorrhagic	O
shock	O
because	O
it	O
expands	O
plasma	O
volume	O
and	O
increases	O
tissue	O
oxygenation	O
.	O


Its	O
beneficial	O
results	O
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
hypotension	O
during	O
spinal	O
anesthesia	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
influence	O
between	O
prehydration	O
with	O
3	O
%	O
hypertonic	B-I
saline	I-I
and	I-I
with	I-I
isotonic	I-I
lactated	I-I
Ringer	I-I
's	I-I
solution	I-I
on	O
the	O
hemodynamic	O
changes	O
and	O
serum	O
electrolyte	O
concentrations	O
in	O
patients	B-P
undergoing	I-P
spinal	I-P
anesthesia	I-P
.	I-P


METHODS	O
Sixty	B-P
ASA	I-P
class	I-P
I	I-P
patients	I-P
scheduled	I-P
for	I-P
herniorrhapy	I-I
under	I-P
spinal	I-P
anesthesia	I-P
were	O
assigned	O
randomly	O
into	O
two	O
groups	O
.	O


Group	B-P
1	I-P
=	I-P
patients	I-P
were	O
prehydrated	B-I
with	I-I
isotonic	I-I
lactated	I-I
Ringer	I-I
's	I-I
solution	I-I
at	I-I
7	I-I
mg/kg	I-I
(	O
n	O
=	O
30	O
)	O
;	O
Group	B-P
2	I-P
=	I-P
patients	I-P
were	O
given	O
prehydration	B-I
with	I-I
3	I-I
%	I-I
hypertonic	I-I
saline	I-I
at	I-I
7	I-I
ml/kg	I-I
(	O
n	O
=	O
30	O
)	O
.	O


Following	O
prehydration	O
,	O
arterial	B-O
blood	I-O
pressure	I-O
and	I-O
heart	I-O
rate	I-O
were	O
recorded	O
and	O
serum	B-O
electrolyte	I-O
concentrations	I-O
were	O
measured	O
.	O


RESULTS	O
The	O
incidence	B-O
of	I-O
hypotension	I-O
was	O
17/30	O
(	O
57	O
%	O
)	O
in	O
the	O
isotonic	O
lactated	O
Ringer	O
's	O
solution	O
group	O
as	O
against	O
7/30	O
(	O
23	O
%	O
)	O
in	O
the	O
hypertonic	O
saline	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O


There	O
was	O
no	O
significant	B-O
difference	I-O
between	O
two	O
groups	O
in	O
relation	O
to	O
the	O
level	B-O
of	I-O
anesthesia	I-O
or	I-O
maximal	I-O
heart	I-O
rate	I-O
,	I-O
and	I-O
electrolyte	I-O
imbalance	I-O
did	O
not	O
occur	O
in	O
either	O
group	O
.	O


CONCLUSIONS	O
Prior	O
to	O
spinal	O
anesthesia	O
,	O
hydration	O
with	O
small	O
amount	O
of	O
hypertonic	B-I
saline	I-I
is	O
effective	O
to	O
minimize	O
hypotension	O
associated	O
with	O
spinal	O
anesthesia	O
.	O


If	O
so	O
administered	O
it	O
would	O
not	O
increase	O
bodily	O
sodium	O
load	O
and	O
unlike	O
isotonic	O
crystalloid	O
solution	O
it	O
dose	O
not	O
cause	O
accumulation	O
of	O
water	O
in	O
the	O
body	O
on	O
equipollent	O
basis	O
.	O


Dairy	B-I
products	I-I
do	O
not	O
lead	O
to	O
alterations	O
in	O
body	B-O
weight	I-O
or	I-O
fat	I-O
mass	I-O
in	I-O
young	I-O
women	I-O
in	O
a	O
1-y	O
intervention	O
.	O


BACKGROUND	O
Previous	O
results	O
suggested	O
that	O
increased	O
intake	O
of	O
dairy	B-I
calcium	I-I
is	O
associated	O
with	O
reduced	B-O
weight	I-O
and	I-O
fat	I-O
mass	I-O
.	I-O


OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
long-term	O
increases	O
in	O
consumption	O
of	O
dairy	B-I
calcium	I-I
alter	O
body	B-O
weight	I-O
and	I-O
fat	I-O
mass	I-O
in	I-O
young	I-O
,	I-O
healthy	I-O
women	I-O
.	I-O


DESIGN	O
We	O
used	O
a	O
randomized	O
,	O
1-y	O
intervention	O
for	O
dairy	O
calcium	O
.	O


Subjects	B-P
were	I-P
155	I-P
young	I-P
(	I-P
aged	I-P
18-30	I-P
y	I-P
)	I-P
,	I-P
healthy	I-P
,	I-P
normal-weight	I-P
women	I-P
with	I-P
intake	I-P
of	I-P
dietary	I-I
calcium	I-I
<	I-P
800	I-P
mg/d	I-P
and	I-P
energy	I-P
intake	I-P
<	I-P
/=	I-P
2200	I-P
kcal/d	I-P
.	I-P


Women	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
:	O
1	O
)	O
control	B-I
:	I-I
continue	I-I
established	I-I
dietary	I-I
intake	I-I
;	I-I
2	O
)	O
medium	B-I
dairy	I-I
:	I-I
substitute	I-I
dairy	I-I
products	I-I
to	I-I
achieve	I-I
intake	I-I
of	I-I
calcium	I-I
of	I-I
approximately	I-I
1000-1100	I-I
mg/d	I-I
and	I-I
maintain	I-I
isocaloric	I-I
intake	I-I
;	I-I
3	O
)	O
high	B-I
dairy	I-I
:	I-I
substitute	I-I
dairy	I-I
products	I-I
to	I-I
achieve	I-I
intake	I-I
of	I-I
calcium	I-I
of	I-I
1300-1400	I-I
mg/d	I-I
and	I-I
maintain	I-I
isocaloric	I-I
intake	I-I
.	I-I


The	O
main	O
outcome	O
measures	O
were	O
1-y	B-O
changes	I-O
in	I-O
body	I-O
weight	I-O
(	I-O
in	I-O
kg	I-O
)	I-O
and	I-O
fat	I-O
mass	I-O
(	I-O
in	I-O
kg	I-O
)	I-O
.	O


One	B-P
hundred	I-P
thirty-five	I-P
women	I-P
completed	I-P
the	I-P
trial	I-P
.	I-P


RESULTS	O
Mean	O
intakes	B-O
of	I-O
calcium	I-O
during	O
the	O
intervention	O
were	O
742.4	O
+/-	O
321.5	O
,	O
1026.4	O
+/-	O
311.3	O
,	O
and	O
1131.29	O
+/-	O
337.2	O
mg/d	O
for	O
the	O
control	O
,	O
medium-dairy	O
,	O
and	O
high-dairy	O
groups	O
,	O
respectively	O
(	O
P	O
<	O
0.0001	O
)	O
.	O


No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
mean	B-O
1-y	I-O
change	I-O
in	I-O
body	I-O
weight	I-O
between	O
the	O
control	O
,	O
medium-dairy	O
,	O
and	O
high-dairy	O
groups	O
(	O
0.8	O
+/-	O
2.8	O
,	O
0.7	O
+/-	O
3.0	O
,	O
and	O
1.5	O
+/-	O
4.1	O
kg	O
,	O
respectively	O
;	O
P	O
=	O
0.45	O
)	O
.	O


No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
mean	B-O
1-y	I-O
change	I-O
in	I-O
fat	I-O
mass	I-O
between	O
the	O
control	O
,	O
medium-dairy	O
,	O
and	O
high-dairy	O
groups	O
(	O
-0.5	O
+/-	O
2.5	O
,	O
0.3	O
+/-	O
2.7	O
,	O
and	O
0.5	O
+/-	O
3.5	O
kg	O
,	O
respectively	O
;	O
P	O
=	O
0.26	O
)	O
.	O


CONCLUSION	O
Increased	O
intake	O
of	O
dairy	B-I
products	I-I
does	O
not	O
alter	O
body	B-O
weight	I-O
or	I-O
fat	I-O
mass	I-O
in	I-O
young	I-O
,	I-O
healthy	I-O
women	I-O
over	I-O
1	I-O
y	I-O
.	I-O


A	O
Randomized	O
Clinical	O
Trial	O
Comparison	O
Between	O
Pivotal	B-I
Response	I-I
Treatment	I-I
(	I-I
PRT	I-I
)	I-I
and	I-I
Adult-Driven	I-I
Applied	I-I
Behavior	I-I
Analysis	I-I
(	I-I
ABA	I-I
)	I-I
Intervention	I-I
on	O
Disruptive	B-O
Behaviors	I-O
in	I-P
Public	I-P
School	I-P
Children	I-P
with	I-P
Autism	I-P
.	I-P


Children	B-P
with	I-P
autism	I-P
often	O
demonstrate	O
disruptive	B-O
behaviors	I-O
during	O
demanding	O
teaching	O
tasks	O
.	O


Language	O
intervention	O
can	O
be	O
particularly	O
difficult	O
as	O
it	O
involves	O
social	O
and	O
communicative	O
areas	O
,	O
which	O
are	O
challenging	O
for	O
this	O
population	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
two	O
intervention	O
conditions	O
,	O
a	B-I
naturalistic	I-I
approach	I-I
,	I-I
Pivotal	I-I
Response	I-I
Treatment	I-I
(	I-I
PRT	I-I
)	I-I
with	I-I
an	I-I
adult-directed	I-I
ABA	I-I
approach	I-I
on	I-I
disruptive	I-O
behavior	I-O
during	I-I
language	I-I
intervention	I-I
in	O
the	O
public	O
schools	O
.	O


A	O
randomized	O
clinical	O
trial	O
design	O
was	O
used	O
with	O
two	B-P
groups	I-P
of	I-P
children	I-P
,	I-P
matched	I-P
according	I-P
to	I-P
age	I-P
,	I-P
sex	I-P
and	I-P
mean	I-P
length	I-P
of	I-P
utterance	I-P
.	I-P


The	O
data	O
showed	O
that	O
the	O
children	O
demonstrated	O
significantly	O
lower	O
levels	O
of	O
disruptive	B-O
behavior	I-O
during	O
the	O
PRT	O
condition	O
.	O


The	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
antecedent	O
manipulations	O
that	O
may	O
be	O
helpful	O
in	O
reducing	O
disruptive	B-O
behavior	I-O
.	I-O


Removal	O
of	O
humoral	O
mediators	O
and	O
the	O
effect	O
on	O
the	O
survival	O
of	O
septic	B-P
patients	I-P
by	O
hemoperfusion	B-I
with	O
neutral	O
microporous	O
resin	O
column	O
.	O


The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
impact	O
of	O
neutral	B-I
microporous	I-I
resin	I-I
hemoperfusion	I-I
on	O
hemodynamic	O
improvement	O
,	O
removal	O
of	O
inflammatory	O
cytokines	O
,	O
and	O
mortality	O
in	O
critical	B-P
care	I-P
patients	I-P
with	I-P
severe	I-P
sepsis	I-P
.	I-P


Forty-four	B-P
patients	I-P
with	I-P
severe	I-P
sepsis	I-P
or	I-P
septic	I-P
shock	I-P
were	O
randomized	O
to	O
HA	B-I
type	I-I
hemoperfusion	I-I
treatment	I-I
(	O
N=24	O
)	O
or	B-I
standard	I-I
therapy	I-I
(	O
N=20	O
)	O
.	O


Those	O
undergoing	O
hemoperfusion	O
treatment	O
received	O
HA330	B-I
hemoperfusion	I-I
.	I-I


We	O
measured	O
the	O
plasma	B-O
concentrations	I-O
of	I-O
IL-6	I-O
and	O
IL-8	B-O
at	O
the	O
start	O
of	O
every	O
hemoperfusion	O
treatment	O
,	O
and	O
the	O
following	O
parameters	O
were	O
compared	O
between	O
the	O
control	O
group	O
and	O
the	O
hemoperfusion	B-I
group	O
on	O
days	O
3	O
,	O
7	O
,	O
and	O
14	O
:	O
hemodynamics	B-O
(	I-O
cardiac	I-O
index	I-O
,	I-O
systemic	I-O
vascular	I-O
resistance	I-O
index	I-O
,	I-O
heart	I-O
rate	I-O
,	I-O
and	I-O
mean	I-O
arterial	I-O
pressure	I-O
)	I-O
;	I-O
change	I-O
of	I-O
hematology	I-O
and	I-O
coagulation	I-O
function	I-O
;	I-O
organ	I-O
function	I-O
;	I-O
and	O
the	O
sequential	B-O
organ	I-O
failure	I-O
assessment	I-O
(	I-O
SOFA	I-O
)	I-O
score	I-O
.	I-O


Hospital	B-O
,	I-O
28-day	I-O
,	I-O
and	I-O
ICU	I-O
mortality	I-O
were	O
also	O
observed	O
.	O


Patients	O
treated	O
with	O
HA	B-I
hemoperfusion	I-I
showed	O
a	O
significant	B-O
removal	I-O
of	O
plasma	B-O
IL-6	I-O
and	I-O
IL-8	I-O
over	O
time	O
while	O
in	O
the	O
study	O
.	O


Patients	O
in	O
the	O
HA	O
group	O
also	O
demonstrated	O
significant	B-O
increases	I-O
in	O
cardiac	B-O
index	I-O
,	I-O
systemic	I-O
vascular	I-O
resistant	I-O
index	I-O
,	I-O
fast	I-O
withdrawal	I-O
of	I-O
vasoactive	I-O
agents	I-O
and	I-O
decreases	I-O
in	I-O
heart	I-O
rate	I-O
compared	O
with	O
the	O
controls	O
at	O
days	O
3	O
and	O
7	O
.	O


Although	O
there	O
was	O
no	O
significant	B-O
difference	I-O
between	O
the	O
groups	O
in	O
organ	B-O
dysfunction	I-O
as	O
assessed	O
by	O
SOFA	B-O
scores	I-O
from	O
day	O
0	O
(	O
baseline	O
)	O
to	O
day	O
7	O
,	O
significant	O
improvement	O
can	O
be	O
demonstrated	O
in	O
the	O
hemoperfusion	O
group	O
at	O
day	O
14	O
.	O


There	O
was	O
no	O
significant	B-O
difference	I-O
between	O
the	O
groups	O
in	O
28-day	B-O
mortality	I-O
,	I-O
hospital	I-O
mortality	I-O
,	I-O
or	I-O
length	I-O
of	I-O
hospital	I-O
stay	I-O
,	I-O
but	I-O
ICU	I-O
mortality	I-O
and	I-O
the	I-O
length	I-O
of	I-O
ICU	I-O
stay	I-O
in	O
the	O
HA	O
group	O
were	O
markedly	O
reduced	B-O
.	I-O


Hemoperfusion	O
treatment	O
using	O
the	O
HA	O
type	O
cartridge	O
in	O
sepsis	O
is	O
safe	O
and	O
it	O
may	O
improve	O
organ	B-O
dysfunction	I-O
,	I-O
ICU	I-O
mortality	I-O
,	I-O
and	I-O
shorten	I-O
the	I-O
length	I-O
of	I-O
ICU	I-O
stay	I-O
.	I-O


Clinical	O
significant	O
removal	O
of	O
inflammatory	O
cytokines	O
such	O
as	O
IL-6	B-O
and	I-O
IL-8	I-O
from	O
circulation	O
by	O
hemoperfusion	B-I
may	O
contribute	O
to	O
improving	O
a	O
patient	O
's	O
outcome	O
in	O
an	O
ICU	O
.	O


Pharmacokinetics	B-O
and	I-O
tolerance	I-O
of	O
single-	O
and	O
multiple-dose	O
oral	O
or	O
intravenous	O
linezolid	B-I
,	O
an	O
oxazolidinone	O
antibiotic	O
,	O
in	O
healthy	B-P
volunteers	I-P
.	I-P


AIMS	O
To	O
determine	O
the	O
pharmacokinetics	O
and	O
tolerance	B-O
of	O
oral	O
and	O
intravenous	O
linezolid	B-I
,	O
an	O
oxazolidinone	O
antibiotic	O
,	O
in	O
healthy	B-P
volunteers	I-P
following	O
single-	O
and	O
multiple-dose	O
administration	O
.	O


METHODS	O
In	O
two	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
dose-escalating	O
trials	O
,	O
subjects	B-P
were	O
exposed	O
either	O
to	O
oral	O
(	O
375	O
,	O
500	O
or	O
625	O
mg	O
)	O
or	O
intravenous	O
(	O
500	O
or	O
625	O
mg	O
)	O
linezolid	B-I
or	I-I
placebo	I-I
twice	O
daily	O
.	O


Serial	B-O
blood	I-O
and	I-O
urine	I-O
samples	I-O
were	O
obtained	O
after	O
the	O
first-	O
and	O
multiple-dose	O
administrations	O
for	O
up	O
to	O
18	O
days	O
.	O


Non-compartmental	O
pharmacokinetic	B-O
analyses	I-O
were	O
used	O
to	O
describe	O
the	O
disposition	O
of	O
linezolid	B-I
.	I-I


RESULTS	O
Plasma	B-O
linezolid	I-O
concentrations	I-O
and	I-O
area	I-O
under	I-O
the	I-O
concentration-time	I-O
curves	I-O
increased	O
proportionally	O
with	O
dose	O
irrespective	O
of	O
the	O
route	O
of	O
administration	O
.	O


Plasma	B-O
linezolid	I-O
concentrations	I-O
remained	O
above	O
the	O
MIC90	O
for	O
susceptible	O
target	O
pathogens	O
(	O
4.0	O
mg/L	O
)	O
for	O
the	O
majority	O
of	O
the	O
12	O
h	O
dosing	O
interval	O
.	O


Mean	B-O
clearance	I-O
,	I-O
half-life	I-O
and	I-O
volume	I-O
of	I-O
distribution	I-O
were	O
similar	O
irrespective	O
of	O
dose	O
for	O
both	O
the	O
oral	O
and	O
intravenous	O
routes	O
.	O


Linezolid	B-I
was	O
well	O
tolerated	B-O
and	O
the	O
frequency	B-O
of	I-O
drug-related	I-O
adverse	I-O
events	I-O
was	O
similar	O
between	O
the	O
linezolid	B-I
and	O
placebo	O
groups	O
.	O


CONCLUSIONS	O
Oral	O
and	O
intravenous	O
linezolid	B-I
exhibit	O
linear	B-O
pharmacokinetics	I-O
,	O
with	O
concentrations	O
remaining	O
above	O
the	O
target	B-O
MIC90	I-O
for	O
most	O
of	O
the	O
dosing	O
interval	O
.	O


These	O
results	O
support	O
a	O
twice-daily	O
schedule	O
for	O
linezolid	O
and	O
demonstrate	O
the	O
feasibility	O
of	O
converting	O
from	O
intravenous	O
to	O
oral	O
dosing	O
without	O
a	O
dose	O
adjustment	O
.	O


Efficacy	B-O
and	O
safety	B-O
of	O
a	O
fixed	O
low-dose	O
perindopril/indapamide	B-I
combination	I-I
in	O
essential	B-P
hypertension	I-P
.	I-P


A	O
randomised	O
controlled	O
study	O
.	O


This	O
multicenter	O
,	O
double-blind	O
,	O
parallel-group	O
study	O
was	O
designed	O
to	O
assess	O
the	O
efficacy	B-O
and	O
the	O
safety	B-O
of	O
fixed	O
low	B-I
dose	I-I
combination	I-I
perindopril	I-I
2	I-I
mg/indapamide	I-I
0.625	O
mg	O
(	O
Per/Ind	O
)	O
versus	O
atenolol	B-I
50	O
mg	O
(	O
Ate	O
)	O
.	O


After	O
a	O
4-week	O
placebo	O
run-in	O
,	O
446	B-P
hypertensive	I-P
patients	I-P
(	I-P
mean	I-P
age	I-P
:	I-P
55.8	I-P
+/-	I-P
11.0	I-P
years	I-P
)	I-P
were	O
randomised	O
to	O
receive	O
Per/Ind	B-I
or	I-I
Ate	I-I
for	O
12	O
weeks	O
.	O


The	O
primary	O
outcome	O
measures	O
were	O
the	O
changes	B-O
in	I-O
trough	I-O
supine	I-O
systolic	I-O
and	I-O
diastolic	I-O
blood	I-O
pressure	I-O
(	I-O
sSBP	I-O
,	I-O
sDBP	I-O
)	I-O
between	O
baseline	O
and	O
the	O
last	O
observation	O
.	O


Equivalence	B-O
was	O
assessed	B-O
in	O
an	O
intention-to-treat	O
analysis	O
using	O
a	O
two	O
one-sided	O
tests	O
procedure	O
.	O


Per/Ind	O
and	O
Ate	O
decreased	B-O
sSBP	I-O
by	O
-20.5	O
mmHg	O
and	O
-20.1	O
mmHg	O
,	O
respectively	O
;	O
the	O
90	O
%	O
confidence	B-O
interval	I-O
[	O
-2.3	O
;	O
1.5	O
]	O
of	O
the	O
intertreatment	O
difference	O
(	O
-0.4	O
mmHg	O
)	O
fell	O
within	O
the	O
predefined	B-O
equivalence	I-O
interval	I-O
[	O
-8	O
;	O
+8	O
mmHg	O
]	O
.	O


Similarly	O
,	O
the	O
sDBP	B-O
decreased	I-O
by	O
-15.1	O
mmHg	O
(	O
Per/Ind	O
)	O
and	O
-16.2	O
mmHg	O
(	O
Ate	O
)	O
with	O
an	O
intertreatment	O
difference	O
of	O
1.1	O
mmHg	O
whose	O
90	O
%	O
confidence	B-O
interval	I-O
[	O
-0.1	O
;	O
2.2	O
mmHg	O
]	O
fell	O
within	O
the	O
predefined	O
equivalence	B-O
interval	I-O
[	O
-4	O
;	O
+4	O
mmHg	O
]	O
;	O
thus	O
antihypertensive	B-O
efficacy	I-O
of	O
Per/Ind	O
and	O
Ate	O
were	O
equivalent	B-O
(	O
P	O
<	O
0.001	O
)	O
.	O


In	O
patients	O
older	O
than	O
65	O
,	O
Per/Ind	O
induces	O
a	O
statistically	O
greater	O
decrease	O
in	O
sSBP	B-O
than	O
Ate	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Per/Ind	O
was	O
well	O
tolerated	B-O
.	I-O


Further	O
controlled	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
on	O
a	O
long-term	O
period	O
.	O


Effect	O
of	O
systemic	O
nitric	B-I
oxide	I-I
synthase	I-I
inhibition	O
on	O
postexercise	B-P
hypotension	I-P
in	I-P
humans	I-P
.	I-P


An	O
acute	O
bout	O
of	O
aerobic	O
exercise	O
results	O
in	O
a	O
reduced	O
blood	B-O
pressure	I-O
that	O
lasts	O
several	O
hours	O
.	O


Animal	O
studies	O
suggest	O
this	O
response	O
is	O
mediated	O
by	O
increased	O
production	O
of	O
nitric	O
oxide	O
.	O


We	O
tested	O
the	O
extent	O
to	O
which	O
systemic	O
nitric	O
oxide	O
synthase	O
inhibition	O
[	O
N	O
(	O
G	O
)	O
-monomethyl-L-arginine	O
(	O
L-NMMA	O
)	O
]	O
can	O
reverse	O
the	O
drop	O
in	O
blood	B-O
pressure	I-O
that	I-P
occurs	I-P
after	I-P
exercise	I-P
in	I-P
humans	I-P
.	I-P


Eight	B-P
healthy	I-P
subjects	I-P
underwent	O
parallel	O
experiments	O
on	O
2	O
separate	O
days	O
.	O


The	O
order	O
of	O
the	O
experiments	O
was	O
randomized	O
between	O
sham	O
(	B-I
60	I-I
min	I-I
of	I-I
seated	I-I
upright	I-I
rest	I-I
)	I-I
and	O
exercise	O
(	B-I
60	I-I
min	I-I
of	I-I
upright	I-I
cycling	I-I
at	I-I
60	I-I
%	I-I
peak	I-I
aerobic	I-I
capacity	I-I
)	I-I
.	O


After	O
both	O
sham	O
and	O
exercise	O
,	O
subjects	O
received	O
,	O
in	O
sequence	O
,	O
systemic	O
alpha-adrenergic	O
blockade	O
(	O
phentolamine	O
)	O
and	O
L-NMMA	O
.	O


Phentolamine	O
was	O
given	O
first	O
to	O
isolate	O
the	O
contribution	O
of	O
nitric	O
oxide	O
to	O
postexercise	O
hypotension	O
by	O
preventing	O
reflex	O
changes	O
in	O
sympathetic	O
tone	O
that	O
result	O
from	O
systemic	O
nitric	O
oxide	O
synthase	O
inhibition	O
and	O
to	O
control	O
for	O
alterations	O
in	O
resting	O
sympathetic	O
activity	O
after	O
exercise	O
.	O


During	O
each	O
condition	O
,	O
systemic	B-O
and	I-O
regional	I-O
hemodynamics	I-O
were	O
measured	O
.	O


Throughout	O
the	O
study	O
,	O
arterial	B-O
pressure	I-O
and	I-O
vascular	I-O
resistances	I-O
remained	O
lower	O
postexercise	O
vs.	O
postsham	O
despite	O
nitric	B-O
oxide	I-O
synthase	I-O
inhibition	O
(	O
e.g.	O
,	O
mean	B-O
arterial	I-O
pressure	I-O
after	I-O
L-NMMA	I-O
was	O
108.0+/-2.4	O
mmHg	O
postsham	O
vs.	O
102.1+/-3.3	O
mmHg	O
postexercise	O
;	O
P	O
<	O
0.05	O
)	O
.	O


Thus	O
it	O
does	O
not	O
appear	O
that	O
postexercise	B-O
hypotension	I-O
is	O
dependent	O
on	O
increased	O
production	B-O
of	I-O
nitric	I-O
oxide	I-O
in	O
humans	B-P
.	I-P


Effect	O
of	O
protein	B-I
ingestion	I-I
on	O
the	O
glucose	B-O
appearance	I-O
rate	I-O
in	O
people	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
.	I-P


Amino	O
acids	O
derived	O
from	O
ingested	O
protein	O
are	O
potential	O
substrates	O
for	O
gluconeogenesis	O
.	O


However	O
,	O
several	O
laboratories	O
have	O
reported	O
that	O
protein	O
ingestion	O
does	O
not	O
result	O
in	O
an	O
increase	O
in	O
the	O
circulating	B-O
glucose	I-O
concentration	I-O
in	O
people	O
with	O
or	O
without	O
type	B-P
2	I-P
diabetes	I-P
.	I-P


The	O
reason	O
for	O
this	O
has	O
remained	O
unclear	O
.	O


In	O
people	O
without	O
diabetes	O
it	O
seems	O
to	O
be	O
due	O
to	O
less	O
glucose	O
being	O
produced	O
and	O
entering	O
the	O
circulation	O
than	O
the	O
calculated	O
theoretical	O
amount	O
.	O


Therefore	O
,	O
we	O
were	O
interested	O
in	O
determining	O
whether	O
this	O
also	O
was	O
the	O
case	O
in	O
people	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
.	I-P


Ten	B-P
male	I-P
subjects	I-P
with	I-P
untreated	I-P
type	I-P
2	I-P
diabetes	I-P
were	O
given	O
,	O
in	O
random	O
sequence	O
,	O
50	B-I
g	I-I
protein	I-I
in	I-I
the	I-I
form	I-I
of	I-I
very	I-I
lean	I-I
beef	I-I
or	I-I
only	I-I
water	I-I
at	I-I
0800	I-I
h	I-I
and	I-I
studied	I-I
over	I-I
the	I-I
subsequent	I-I
8	I-I
h.	I-I
Protein	I-I
ingestion	O
resulted	O
in	O
an	O
increase	O
in	O
circulating	B-O
insulin	I-O
,	I-O
C-peptide	I-O
,	I-O
glucagon	I-O
,	I-O
alpha	I-O
amino	I-O
and	I-O
urea	I-O
nitrogen	I-O
,	I-O
and	I-O
triglycerides	I-O
;	I-O
a	I-O
decrease	I-O
in	I-O
nonesterified	I-O
fatty	I-O
acids	I-O
;	I-O
and	I-O
a	I-O
modest	I-O
increase	I-O
in	I-O
respiratory	I-O
quotient	I-O
.	I-O


The	O
total	O
amount	O
of	O
protein	B-O
deaminated	I-O
and	I-O
the	I-O
amino	I-O
groups	I-O
incorporated	I-O
into	I-O
urea	I-O
was	O
calculated	O
to	O
be	O
approximately	O
20-23	O
g.	O
The	O
net	O
amount	O
of	O
glucose	B-O
estimated	O
to	O
be	O
produced	O
,	O
based	O
on	O
the	O
quantity	B-O
of	I-O
amino	I-O
acids	I-O
deaminated	I-O
,	O
was	O
approximately	O
11-13	O
g.	O
However	O
,	O
the	O
amount	B-O
of	I-O
glucose	I-O
appearing	I-O
in	I-O
the	I-O
circulation	I-O
was	O
only	O
approximately	O
2	O
g.	O
The	O
peripheral	B-O
plasma	I-O
glucose	I-O
concentration	I-O
decreased	O
by	O
approximately	O
1	O
mM	O
after	O
ingestion	O
of	O
either	O
protein	O
or	O
water	O
,	O
confirming	O
that	O
ingested	O
protein	O
does	O
not	O
result	O
in	O
a	O
net	O
increase	O
in	O
glucose	B-O
concentration	I-O
,	O
and	O
results	O
in	O
only	O
a	O
modest	O
increase	O
in	O
the	O
rate	B-O
of	I-O
glucose	I-O
disappearance	I-O
.	I-O


Recombinant	B-I
human	I-I
thrombopoietin	I-I
augments	O
mobilization	O
of	O
peripheral	B-O
blood	I-O
progenitor	I-O
cells	I-O
for	O
autologous	B-P
transplantation	I-P
.	I-P


This	O
study	O
assessed	O
the	O
ability	O
of	O
various	O
schedules	O
of	O
recombinant	B-I
human	I-I
thrombopoietin	I-I
(	I-I
rhTPO	I-I
)	I-I
to	O
enhance	O
mobilization	O
of	O
peripheral	O
blood	O
progenitor	O
cells	O
(	O
PBPCs	O
)	O
in	O
134	B-P
patients	I-P
with	I-P
cancer	I-P
undergoing	I-P
high-dose	I-P
chemotherapy	I-P
and	I-P
autologous	I-P
PBPC	I-P
transplantation	I-P
.	I-P


Patients	O
received	O
the	O
study	O
drug	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
before	O
initiation	O
of	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
10	O
microg/kg/day	O
on	O
day	O
5	O
and	O
pheresis	O
starting	O
on	O
day	O
9	O
.	O


Randomly	O
assigned	O
treatments	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
were	O
:	O
group	O
1	O
(	O
n=27	O
)	O
placebo	B-I
,	I-I
placebo	I-I
,	I-I
rhTPO	I-I
1.5	O
microg/kg	O
;	O
group	O
2	O
(	O
n=27	O
)	O
rhTPO	O
1.5	O
microg/kg	O
,	O
placebo	O
,	O
placebo	O
;	O
groups	O
3	O
(	O
n=28	O
)	O
and	O
4	O
(	O
n=22	O
)	O
rhTPO	O
0.5	O
microg/kg	O
on	O
all	O
3	O
treatment	O
days	O
;	O
and	O
group	O
5	O
(	O
n=30	O
)	O
placebo	O
on	O
all	O
3	O
treatment	O
days	O
.	O


After	O
high-dose	B-I
chemotherapy	I-I
and	I-I
PBPC	I-I
transplantation	I-I
,	O
groups	O
1	O
through	O
4	O
received	O
rhTPO	O
1.5	O
microg/kg	O
days	O
0	O
,	O
+2	O
,	O
+4	O
,	O
and	O
+6	O
with	O
either	O
G-CSF	O
5	O
microg/kg/day	O
(	O
groups	O
1-3	O
)	O
or	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
250	O
microg/m	O
(	O
2	O
)	O
/day	O
(	O
group	O
4	O
)	O
.	O


Group	O
5	O
received	O
placebo	B-I
plus	O
G-CSF	O
5	O
microg/kg/day	O
.	O


The	O
addition	O
of	O
rhTPO	B-I
to	O
G-CSF	O
increased	O
median	B-O
CD34+	I-O
cell	I-O
yield/pheresis	I-O
in	O
cohorts	O
in	O
which	O
rhTPO	B-I
was	O
started	O
before	O
day	O
5	O
,	O
with	O
higher	O
yields	O
in	O
groups	O
2	O
(	O
2.67	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
and	O
groups	O
3	O
and	O
4	O
(	O
3.10	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
than	O
in	O
group	O
1	O
(	O
1.86	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
or	O
group	O
5	O
(	O
1.65	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
(	O
P=.006	O
across	O
groups	O
)	O
.	O


Comparing	O
rhTPO	B-I
to	O
placebo	B-I
,	O
higher	O
percentages	O
of	O
patients	O
achieved	O
the	O
minimum	B-O
yield	I-O
of	I-O
CD34+	I-O
>	O
or	O
=2	O
x	O
10	O
(	O
6	O
)	O
/kg	O
(	O
92	O
%	O
v	O
75	O
%	O
;	O
P=.050	O
)	O
as	O
well	O
as	O
the	O
target	O
yield	O
of	O
CD34+	O
>	O
or	O
=5	O
x	O
10	O
(	O
6	O
)	O
/kg	O
(	O
73	O
%	O
v	O
46	O
%	O
;	O
P=	O
.041	O
)	O
.	O


rhTPO-treated	B-I
patients	O
required	O
fewer	O
phereses	O
to	O
achieve	O
minimum	O
(	O
P=	O
.011	O
)	O
and	O
target	O
(	O
P=	O
.015	O
)	O
CD34+	B-O
cell	I-O
values	I-O
.	I-O


rhTPO	B-I
given	O
after	O
transplantation	O
did	O
not	O
speed	O
platelet	B-O
recovery	I-O
.	I-O


No	O
neutralizing	O
antibodies	O
were	O
observed	O
.	O


We	O
conclude	O
that	O
rhTPO	B-I
can	O
safely	O
enhance	O
mobilization	O
of	O
PBPC	B-O
,	O
reduce	O
the	O
number	O
of	O
leukapheresis	B-O
,	O
and	O
allow	O
more	O
patients	O
to	O
meet	O
minimal	O
cell	O
yield	O
requirements	O
to	O
receive	O
high-dose	O
chemotherapy	B-I
with	O
PBPC	B-I
transplantation	I-I
.	I-I


Impact	O
of	O
antioxidants	B-I
,	I-I
zinc	I-I
,	I-I
and	I-I
copper	I-I
on	O
cognition	B-P
in	I-P
the	I-P
elderly	I-P
:	I-P
a	O
randomized	O
,	O
controlled	O
trial	O
.	O


Participants	B-P
in	I-P
the	I-P
Age-Related	I-P
Eye	I-P
Disease	I-P
Study	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
daily	O
antioxidants	B-I
(	I-I
vitamin	I-I
C	I-I
,	I-I
500	I-I
mg	I-I
;	I-I
vitamin	I-I
E	I-I
,	I-I
400	I-I
IU	I-I
;	I-I
beta	I-I
carotene	I-I
,	I-I
15	I-I
mg	I-I
)	I-I
,	I-I
zinc	I-I
and	I-I
copper	I-I
(	I-I
zinc	I-I
,	I-I
80	I-I
mg	I-I
;	I-I
cupric	I-I
oxide	I-I
,	I-I
2	I-I
mg	I-I
)	I-I
,	I-I
antioxidants	I-I
plus	I-I
zinc	I-I
and	I-I
copper	I-I
,	I-I
or	I-I
placebo	I-I
.	I-I


A	O
cognitive	O
battery	O
was	O
administered	O
to	O
2,166	B-P
elderly	I-P
persons	I-P
after	I-P
a	I-P
median	I-P
of	I-P
6.9	I-P
years	I-P
of	I-P
treatment	I-P
.	I-P


Treatment	O
groups	O
did	O
not	O
differ	O
on	O
any	O
of	O
the	O
six	B-O
cognitive	I-O
tests	I-O
(	O
p	O
>	O
0.05	O
for	O
all	O
)	O
.	O


These	O
results	O
do	O
not	O
support	O
a	O
beneficial	B-O
or	I-O
harmful	I-O
effect	I-O
of	I-O
antioxidants	I-O
or	I-O
zinc	I-O
and	I-O
copper	I-O
on	O
cognition	B-O
in	O
older	O
adults	O
.	O


Randomised	O
controlled	O
trial	O
of	O
patient	O
triggered	B-I
and	I-I
conventional	I-I
fast	I-I
rate	I-I
ventilation	I-I
in	O
neonatal	B-P
respiratory	I-P
distress	I-P
syndrome	I-P
.	I-P


AIM	O
To	O
compare	O
patient	O
triggered	O
,	O
with	O
conventional	O
fast	O
rate	O
,	O
ventilation	O
in	O
a	O
randomised	O
controlled	O
trial	O
using	O
the	O
incidence	B-O
of	I-O
chronic	I-O
lung	I-O
disease	I-O
as	O
the	O
primary	O
outcome	O
measure	O
.	O


METHODS	O
Three	B-P
hundred	I-P
and	I-P
eighty	I-P
six	I-P
preterm	I-P
infants	I-P
with	I-P
birthweights	I-P
from	I-P
1000	I-P
to	I-P
2000	I-P
g	I-P
,	I-P
and	I-P
requiring	I-P
ventilation	I-P
for	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
within	I-P
24	I-P
hours	I-P
of	I-P
birth	I-P
,	O
were	O
randomised	O
to	O
receive	O
either	O
conventional	B-I
or	I-I
trigger	I-I
ventilation	I-I
with	I-I
the	I-I
SLE	I-I
2000	I-I
ventilator	I-I
.	I-I


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
incidence	B-O
of	I-O
chronic	I-O
lung	I-O
disease	I-O
(	O
28	O
day	O
and	O
36	O
week	O
definitions	O
)	O
,	O
death	B-O
,	I-O
pneumothorax	I-O
,	I-O
intraventricular	I-O
haemorrhage	I-O
,	I-O
number	I-O
of	I-O
ventilator	I-O
days	I-O
,	I-O
or	I-O
length	I-O
of	I-O
oxygen	I-O
dependency	I-O
between	O
groups	O
.	O


CONCLUSIONS	O
Patient	O
triggered	O
ventilation	O
in	O
preterm	B-P
infants	I-P
with	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
is	O
feasible	O
.	O


No	O
significant	O
differences	O
,	O
when	O
compared	O
with	O
conventional	O
fast	O
rate	O
ventilation	O
in	O
important	O
medium	B-O
and	I-O
longer	I-O
term	I-O
outcome	I-O
measures	I-O
,	O
were	O
evident	O
.	O


Pacifier	B-I
as	I-P
a	I-P
risk	I-P
factor	I-P
for	I-P
acute	I-P
otitis	I-P
media	I-P
.	I-P


Treatment	O
of	O
brain	O
metastases	O
of	O
small-cell	O
lung	O
cancer	O
:	O
comparing	O
teniposide	B-I
and	O
teniposide	B-I
with	I-I
whole-brain	I-I
radiotherapy	I-I
--	I-I
a	I-I
phase	O
III	O
study	O
of	O
the	O
European	O
Organization	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Lung	O
Cancer	O
Cooperative	O
Group	O
.	O


PURPOSE	O
Approximately	O
60	O
%	O
of	O
patients	B-P
with	I-P
small-cell	I-P
lung	I-P
cancer	I-P
(	I-P
SCLC	I-P
)	I-P
develop	O
brain	O
metastases	O
.	O


Whole-brain	B-I
radiotherapy	I-I
(	I-I
WBRT	I-I
)	I-I
gives	O
symptomatic	O
improvement	O
in	O
more	O
than	O
50	O
%	O
of	O
these	O
patients	O
.	O


Because	O
brain	O
metastases	O
are	O
a	O
sign	O
of	O
systemic	O
progression	O
,	O
and	O
chemotherapy	O
was	O
found	O
to	O
be	O
effective	O
as	O
well	O
,	O
it	O
becomes	O
questionable	O
whether	O
WBRT	B-I
is	O
the	O
only	O
appropriate	O
therapy	O
in	O
this	O
situation	O
.	O


PATIENTS	O
AND	O
METHODS	O
In	O
a	O
phase	O
III	O
study	O
,	O
SCLC	B-P
patients	I-P
with	I-P
brain	I-P
metastases	I-P
were	O
randomized	O
to	O
receive	O
teniposide	B-I
with	O
or	O
without	O
WBRT	B-I
.	I-I


Teniposide	B-I
120	O
mg/m	O
(	O
2	O
)	O
was	O
given	O
intravenously	O
three	O
times	O
a	O
week	O
,	O
every	O
3	O
weeks	O
.	O


WBRT	B-I
(	O
10	O
fractions	O
of	O
3	O
Gy	O
)	O
had	O
to	O
start	O
within	O
3	O
weeks	O
from	O
the	O
start	O
of	O
chemotherapy	B-I
.	I-I


Response	O
was	O
measured	O
clinically	B-O
and	O
by	O
computed	B-O
tomography	I-O
of	I-O
the	I-O
brain	I-O
.	I-O


RESULTS	O
One	B-P
hundred	I-P
twenty	I-P
eligible	I-P
patients	I-P
were	O
randomized	O
.	O


A	O
57	O
%	O
response	B-O
rate	I-O
was	O
seen	O
in	O
the	O
combined-modality	O
arm	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
43	O
%	O
to	O
69	O
%	O
)	O
,	O
and	O
a	O
22	O
%	O
response	B-O
rate	I-O
was	O
seen	O
in	O
the	O
teniposide-alone	B-I
arm	O
(	O
95	O
%	O
CI	O
,	O
12	O
%	O
to	O
34	O
%	O
)	O
(	O
P	O
<	O
.001	O
)	O
.	O


Time	B-O
to	I-O
progression	I-O
in	I-O
the	I-O
brain	I-O
was	O
longer	B-O
in	O
the	O
combined-modality	O
group	O
(	O
P=.005	O
)	O
.	O


Clinical	B-O
response	I-O
and	O
response	B-O
outside	O
the	O
brain	O
were	O
not	O
different	O
.	O


The	O
median	B-O
survival	I-O
time	I-O
was	O
3.5	O
months	O
in	O
the	O
combined-modality	O
arm	O
and	O
3.2	O
months	O
in	O
the	O
teniposide-alone	B-I
arm	O
.	O


Overall	B-O
survival	I-O
in	O
both	O
groups	O
was	O
not	O
different	O
(	O
P=.087	O
)	O
.	O


CONCLUSION	O
Adding	O
WBRT	B-I
to	O
teniposide	O
results	O
in	O
a	O
much	O
higher	O
response	B-O
rate	I-O
of	O
brain	O
metastases	O
and	O
in	O
a	O
longer	O
time	O
to	O
progression	O
of	O
brain	O
metastases	O
than	O
teniposide	B-I
alone	O
.	O


Survival	B-O
was	O
poor	O
in	O
both	O
groups	O
and	O
not	O
significantly	O
different	O
.	O


Non-pharmacological	O
care	O
for	O
patients	B-P
with	I-P
generalized	I-O
osteoarthritis	I-O
:	I-O
design	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
Non-pharmacological	B-I
treatment	I-I
(	I-I
NPT	I-I
)	I-I
is	O
a	O
useful	O
treatment	O
option	O
in	O
the	O
management	O
of	O
hip	B-O
or	I-O
knee	I-O
osteoarthritis	I-O
.	I-O


To	O
our	O
knowledge	O
however	O
,	O
no	O
studies	O
have	O
investigated	O
the	O
effect	O
of	O
NPT	B-I
in	O
patients	B-P
with	I-P
generalized	I-P
osteoarthritis	I-P
(	I-P
GOA	I-P
)	I-P
.	I-P


The	O
primary	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
effectiveness	O
of	O
two	O
currently	O
existing	O
health	O
care	O
programs	O
with	O
different	O
intensity	O
and	O
mode	O
of	O
delivery	O
on	O
daily	O
functioning	O
in	O
patients	B-P
with	I-P
GOA	I-P
.	I-P


The	O
secondary	O
objective	O
is	O
to	O
compare	O
the	O
cost-effectiveness	O
of	O
both	O
interventions	O
.	O


METHODS/DESIGN	O
In	O
this	O
randomized	O
,	O
single	O
blind	O
,	O
clinical	O
trial	O
with	O
active	O
controls	O
,	O
we	B-P
aim	I-P
to	I-P
include	I-P
170	I-P
patients	I-P
with	I-P
GOA	I-P
.	I-P


The	O
experimental	O
intervention	O
consist	O
of	O
six	B-I
self-management	I-I
group	I-I
sessions	I-I
provided	I-I
by	I-I
a	I-I
multi-disciplinary	I-I
team	I-I
(	O
occupational	O
therapist	O
,	O
physiotherapist	O
,	O
dietician	O
and	O
specialized	O
nurse	O
)	O
.	O


The	O
active	O
control	O
group	O
consists	O
of	O
two	B-I
group	I-I
sessions	I-I
and	I-I
four	I-I
sessions	I-I
by	I-I
telephone	I-I
,	O
provided	O
by	O
a	O
specialized	O
nurse	O
and	O
physiotherapist	O
.	O


Both	O
therapies	O
last	O
six	O
weeks	O
.	O


Main	O
study	O
outcome	O
is	O
daily	B-O
functioning	I-O
during	I-O
the	I-O
first	I-O
year	I-O
after	I-O
the	I-O
treatment	I-O
,	I-O
assessed	I-O
on	I-O
the	I-O
Health	I-O
Assessment	I-O
Questionnaire	I-O
.	I-O


Secondary	O
outcomes	O
are	O
health	B-O
related	I-O
quality	I-O
of	I-O
life	I-O
,	I-O
specific	I-O
complaints	I-O
,	I-O
fatigue	I-O
,	I-O
and	I-O
costs	I-O
.	I-O


Illness	B-O
cognitions	I-O
,	I-O
global	I-O
perceived	I-O
effect	I-O
and	I-O
self-efficacy	I-O
,	O
will	O
also	O
be	O
assessed	O
for	O
a	O
responder	O
analysis	O
.	O


Outcome	O
assessments	O
are	O
performed	O
directly	O
after	O
the	O
intervention	O
,	O
after	O
26	O
weeks	O
and	O
after	O
52	O
weeks	O
.	O


DISCUSSION	O
This	O
article	O
describes	O
the	O
design	O
of	O
a	O
randomized	O
,	O
single	O
blind	O
,	O
clinical	O
trial	O
with	O
a	O
one	O
year	O
follow	O
up	O
to	O
compare	O
the	O
costs	B-O
and	I-O
effectiveness	I-O
of	O
two	O
non-pharmacological	B-I
interventions	I-I
with	O
different	O
modes	O
of	O
delivery	O
for	O
patients	B-P
with	I-P
GOA	I-P
.	I-P


TRIAL	O
REGISTRATION	O
Dutch	O
Trial	O
Register	O
NTR2137	O
.	O


Acute	O
and	O
subchronic	O
effects	O
of	O
levocetirizine	B-I
and	I-I
diphenhydramine	I-I
on	O
memory	B-O
functioning	I-O
,	I-O
psychomotor	I-O
performance	I-O
,	O
and	O
mood	B-O
.	I-O


BACKGROUND	O
Central	O
nervous	O
system	O
adverse	O
effects	O
,	O
such	O
as	O
sedation	B-O
,	O
often	O
accompany	O
the	O
use	O
of	O
first-generation	O
antihistamines	O
.	O


These	O
effects	O
might	O
interfere	O
with	O
memory	O
functioning	O
and	O
psychomotor	O
performance	O
.	O


Levocetirizine	B-I
was	O
recently	O
introduced	O
as	O
a	O
new	O
antihistamine	O
said	O
to	O
be	O
free	O
from	O
sedative	O
effects	O
.	O


OBJECTIVE	O
We	O
sought	O
to	O
investigate	O
the	O
effects	O
of	O
levocetirizine	B-I
(	O
5	O
mg	O
)	O
,	O
diphenhydramine	B-I
(	O
50	O
mg	O
)	O
,	O
and	B-I
placebo	I-I
on	O
memory	B-O
and	I-O
psychomotor	I-O
performance	I-O
after	O
acute	O
(	O
day	O
1	O
)	O
and	O
subchronic	O
(	O
day	O
4	O
)	O
daily	O
administration	O
in	O
48	B-P
healthy	I-P
volunteers	I-P
(	I-P
24	I-P
men	I-P
and	I-P
24	I-P
women	I-P
)	I-P
.	I-P


METHODS	O
This	O
study	O
was	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
randomized	O
clinical	O
trial	O
.	O


Treatments	O
were	O
administrated	O
on	O
days	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
3	O
hours	O
before	O
the	O
start	O
of	O
the	O
laboratory	O
test	O
battery	O
(	O
performed	O
on	O
days	O
1	O
and	O
4	O
)	O
,	O
comprising	O
a	O
word-learning	O
test	O
,	O
the	O
Sternberg	O
Memory	O
Scanning	O
Test	O
,	O
a	O
tracking	O
test	O
(	O
easy	O
and	O
hard	O
version	O
)	O
,	O
and	O
a	O
divided	O
attention	O
test	O
(	O
tracking	O
and	O
memory	O
scanning	O
simultaneously	O
)	O
.	O


Statistical	O
analyses	O
were	O
performed	O
separately	O
for	O
days	O
1	O
and	O
4	O
by	O
using	O
analysis	O
of	O
variance	O
.	O


RESULTS	O
On	O
day	O
1	O
,	O
diphenhydramine	B-I
significantly	O
impaired	O
tracking	B-O
performance	I-O
(	O
easy	O
:	O
F	O
(	O
1,90	O
)	O
=	O
25.9	O
,	O
P	O
<	O
.0001	O
;	O
hard	O
:	O
F	O
(	O
1,90	O
)	O
=	O
20.5	O
,	O
P	O
<	O
.0001	O
)	O
and	O
divided	B-O
attention	I-O
(	O
tracking	O
:	O
F	O
(	O
1,90	O
)	O
=	O
23.8	O
,	O
P	O
<	O
.0001	O
;	O
memory	B-O
scanning	I-O
:	I-O
F	O
(	O
1,90	O
)	O
=	O
22.0	O
,	O
P	O
<	O
.0001	O
)	O
.	O


Results	O
on	O
word-learning	B-O
tests	I-O
and	I-O
Sternberg	I-O
Memory	I-O
Scanning	I-O
Tests	I-O
were	O
not	O
significantly	O
impaired	O
.	O


On	O
day	O
4	O
,	O
the	O
effects	O
of	O
diphenhydramine	B-I
did	O
not	O
reach	O
significance	O
.	O


In	O
contrast	O
,	O
on	O
both	O
days	O
1	O
and	O
4	O
,	O
levocetirizine	B-I
did	O
not	O
significantly	O
impair	O
laboratory	B-O
test	I-O
performance	I-O
.	I-O


CONCLUSION	O
The	O
results	O
show	O
that	O
memory	B-O
,	I-O
attention	I-O
,	I-O
and	I-O
tracking	I-O
performance	I-O
are	O
unaffected	O
after	O
acute	O
and	O
subchronic	O
administration	O
of	O
levocetirizine	B-I
(	O
5	O
mg	O
)	O
,	O
whereas	O
diphenhydramine	B-I
(	O
50	O
mg	O
)	O
significantly	O
affected	O
divided	B-O
attention	I-O
and	O
tracking	B-O
after	O
acute	O
administration	O
.	O


Effects	O
of	O
nifedipine	B-I
on	O
gastric	B-O
acid	I-O
secretion	I-O
and	I-P
gastrin	I-O
release	I-O
in	I-P
man	I-P
.	I-P


As	O
calcium	O
is	O
important	O
in	O
the	O
regulation	O
of	O
gastric	O
acid	O
secretion	O
and	O
gastrin	O
release	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
calcium	O
antagonist	O
nifedipine	B-I
on	O
these	O
processes	O
in	O
man	B-P
.	I-P


Nifedipine	B-I
30	O
mg	O
orally	O
inhibited	O
basal	O
acid	O
output	O
by	O
37	O
%	O
(	O
p	O
less	O
than	O
0.025	O
)	O
and	O
that	O
stimulated	O
by	O
low	O
infusion	O
rates	O
of	O
pentagastrin	B-I
--	I-I
that	I-I
is	O
,	O
0.031	O
and	O
0.062	O
microgram/kg/h	O
by	O
44	O
%	O
(	O
p	O
=	O
0.05	O
)	O
and	O
39	O
%	O
(	O
p	O
less	O
than	O
0.02	O
)	O
respectively	O
.	O


On	O
increasing	O
the	O
pentagastrin	B-I
infusion	O
rate	O
the	O
inhibition	O
was	O
surmounted	O
suggesting	O
it	O
was	O
competitive	O
in	O
type	O
.	O


Nifedipine	B-I
did	O
not	O
affect	O
basal	B-O
or	I-O
Oxo	I-O
meal	I-O
stimulated	I-O
gastrin	I-O
concentrations	I-O
in	O
normal	B-P
volunteers	I-P
nor	O
did	O
it	O
affect	O
resting	B-O
serum	I-O
gastrin	I-O
or	I-O
calcium	I-O
stimulated	I-O
increase	I-O
in	I-O
gastrin	I-O
in	O
a	O
single	B-P
patient	I-P
with	I-P
Zollinger-Ellison	I-P
syndrome	I-P
.	I-P


These	O
findings	O
are	O
consistent	O
with	O
the	O
transmembrane	O
flux	O
of	O
calcium	O
ions	O
being	O
involved	O
in	O
basal	O
and	O
pentagastrin	B-P
stimulated	I-P
acid	I-P
secretion	I-P
in	I-P
man	I-P
.	I-P


Prospective	O
trial	O
of	O
intraoperative	B-I
mitomycin	I-I
C	I-I
in	O
the	O
treatment	O
of	O
primary	B-P
pterygium	I-P
.	I-P


AIMS	O
A	O
prospective	O
,	O
randomised	O
,	O
double	O
blind	O
,	O
placebo	B-I
controlled	O
study	O
of	O
intraoperative	B-I
mitomycin	I-I
C	I-I
as	O
adjunctive	O
treatment	O
of	O
primary	B-P
pterygium	I-P
was	O
conducted	O
.	O


METHODS	O
A	B-P
total	I-P
of	I-P
66	I-P
eyes	I-P
of	I-P
54	I-P
patients	I-P
with	I-P
primary	I-P
pterygium	I-P
were	O
treated	O
with	O
excision	B-I
,	I-I
with	I-I
or	I-I
without	I-I
a	I-I
single	I-I
intraoperative	I-I
application	I-I
of	I-I
mitomycin	I-I
C	I-I
(	O
0.1	O
mg/ml	O
for	O
5	O
minutes	O
)	O
to	O
evaluate	O
the	O
efficacy	B-O
and	I-O
toxicity	I-O
of	O
this	O
adjunctive	O
treatment	O
.	O


The	O
mean	O
follow	O
up	O
was	O
14.1	O
months	O
(	O
range	O
12-23	O
months	O
)	O
.	O


RESULTS	O
Of	O
the	O
36	O
eyes	O
that	O
underwent	O
simple	O
excision	O
,	O
14	O
(	O
38.8	O
%	O
)	O
exhibited	O
recurrences	B-O
whereas	O
only	O
one	O
of	O
30	O
eyes	O
(	O
3.33	O
%	O
)	O
treated	O
with	O
excision	O
and	O
intraoperative	O
application	O
of	O
mitomycin	B-I
C	I-I
had	O
recurrence	B-O
(	O
p	O
=	O
0.0006	O
)	O
.	O


Neither	O
serious	O
ocular	B-O
complications	I-O
nor	I-O
systemic	I-O
toxicity	I-O
were	O
noted	O
in	O
the	O
mitomycin	B-I
C	I-I
treated	O
group	O
.	O


CONCLUSION	O
Intraoperative	O
mitomycin	B-I
C	I-I
appears	O
to	O
be	O
an	O
effective	O
and	O
safe	O
adjunctive	O
treatment	O
of	O
primary	B-P
pterygium	I-P
.	I-P


Randomized	O
clinical	O
trial	O
of	O
balance-based	O
torso	B-I
weighting	I-I
for	O
improving	O
upright	B-O
mobility	I-O
in	O
people	B-P
with	I-P
multiple	I-P
sclerosis	I-P
.	I-P


BACKGROUND	O
Torso	O
weighting	O
has	O
sometimes	O
been	O
effective	O
for	O
improving	O
upright	B-O
mobility	I-O
in	O
people	B-P
with	I-P
multiple	I-P
sclerosis	I-P
,	O
but	O
parameters	B-O
for	I-O
weighting	I-O
have	O
been	O
inconsistent	O
.	O


OBJECTIVE	O
To	O
determine	O
whether	O
balance-based	B-I
torso	I-I
weighting	I-I
(	I-I
BBTW	I-I
)	I-I
has	O
immediate	O
effects	O
on	O
upright	O
mobility	O
in	O
people	O
with	O
multiple	B-P
sclerosis	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
2-phase	O
randomized	O
clinical	O
trial	O
.	O


In	B-P
phase	I-P
1	I-P
,	I-P
36	I-P
participants	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
experimental	I-P
and	I-P
control	I-P
groups	I-P
.	I-P


In	O
phase	B-P
2	I-P
,	I-P
the	I-P
control	I-P
group	I-P
was	O
subsequently	O
randomized	O
into	O
2	O
groups	O
with	O
alternate	O
weight-placement	O
.	O


Tests	O
of	O
upright	B-O
mobility	I-O
included	O
:	O
timed	B-O
up	I-O
and	I-O
go	I-O
(	I-O
TUG	I-O
)	I-O
,	I-O
sharpened	I-O
Romberg	I-O
,	I-O
360-degree	I-O
turns	I-O
,	I-O
25-foot	I-O
walk	I-O
,	I-O
and	I-O
computerized	I-O
platform	I-O
posturography	I-O
.	I-O


Participants	O
were	O
tested	O
at	O
baseline	O
and	O
again	O
with	O
weights	O
placed	O
according	O
to	O
group	O
membership	O
.	O


In	O
both	O
phases	O
,	O
a	O
physical	O
therapist	O
assessed	O
balance	O
for	O
the	O
BBTW	O
group	O
and	O
then	O
placed	O
weights	O
to	O
decrease	O
balance	B-O
loss	I-O
.	I-O


In	O
phase	O
1	O
,	O
the	O
control	O
group	O
had	O
no	O
weights	O
placed	O
.	O


In	O
phase	O
2	O
,	O
the	O
alternate	O
treatment	O
group	O
received	O
standard	O
weight	O
placement	O
of	O
1.5	O
%	O
body	O
weight	O
.	O


RESULTS	O
People	O
with	O
BBTW	B-I
showed	O
a	O
significant	O
improvement	O
in	O
the	O
25-foot	B-O
walk	I-O
(	O
P	O
=	O
.01	O
)	O
over	O
those	O
with	O
no	O
weight	O
,	O
and	O
the	O
TUG	B-O
(	O
P	O
=	O
.01	O
)	O
over	O
those	O
with	O
standard	O
weight	O
placement	O
.	O


BBTW	O
participants	O
received	O
an	O
average	O
of	O
0.5	O
kg	B-O
,	O
less	O
than	O
1.5	O
%	O
of	O
any	O
participant	O
's	O
body	O
weight	O
.	O


CONCLUSION	O
BBTW	B-I
can	O
have	O
immediate	O
advantages	O
over	O
a	O
nonweighted	O
condition	O
for	O
gait	B-O
velocity	I-O
and	O
over	O
a	O
standardized	O
weighted	O
condition	O
for	O
a	O
functional	B-O
activity	I-O
in	O
people	B-P
with	I-P
multiple	I-P
sclerosis	I-P
(	I-P
MS	I-P
)	I-P
who	O
are	O
ambulatory	O
but	O
have	O
balance	O
and	O
mobility	O
abnormalities	O
.	O


Adequacy	O
of	O
vitamin	B-I
B6	I-I
supplementation	I-I
during	O
pregnancy	B-P
:	I-P
a	O
prospective	O
study	O
.	O


This	O
prospective	O
study	O
assesses	O
the	O
effect	O
of	O
2.5	B-I
,	I-I
4	I-I
,	I-I
and	I-I
10	I-I
mg	I-I
of	I-I
pyridoxine	I-I
supplementation	I-I
during	I-I
pregnancy	I-I
on	I-I
maternal	I-O
and	I-O
fetal	I-O
plasma	I-O
levels	I-O
of	I-O
pyridoxal	I-O
5'-phosphate	I-O
(	I-O
PLP	I-O
)	I-O
and	O
on	O
the	O
degree	B-O
of	I-O
coenzyme	I-O
saturation	I-O
(	I-O
activation	I-O
factor	I-O
)	I-O
of	I-O
aspartate	I-O
aminotransferase	I-O
and	I-O
alanine	I-O
aminotransferase	I-O
(	I-O
alphaEGOT	I-O
and	I-O
alphaEGPT	I-O
)	I-O
in	I-O
maternal	I-O
erythrocytes	I-O
.	I-O


More	O
than	O
4	B-I
mg	I-I
of	I-I
pyridoxine	I-I
supplementation	I-I
daily	I-I
was	O
required	O
for	O
most	O
pregnancies	O
to	O
maintain	O
maternal	B-O
plasma	I-O
PLP	I-O
levels	I-O
within	O
the	O
range	O
observed	O
during	O
the	O
first	O
trimester	O
and	O
in	O
the	O
nonpregnant	O
state	O
.	O


The	O
plasma	B-O
PLP	I-O
concentrations	I-O
in	I-O
maternal	I-O
and	I-O
cord	I-O
blood	I-O
were	O
highly	O
correlated	O
and	O
indicated	O
a	O
dependence	O
of	O
fetal	O
vitamin	O
B6	O
nutrition	O
on	O
maternal	O
circulating	O
PLP	O
.	O


Measurements	B-O
of	I-O
alphaEGOT	I-O
and	I-O
alphaEGPT	I-O
were	O
not	O
as	O
reproducible	O
as	O
plasma	B-O
PLP	I-O
assays	I-O
and	O
were	O
less	O
sensitive	O
and	O
quantitative	O
indicators	O
.	O


In	O
the	O
majority	O
of	O
subjects	O
,	O
the	O
changes	B-O
in	I-O
alphaEGOT	I-O
and	I-O
alphaEGPT	I-O
with	O
time	O
correlated	O
poorly	O
with	O
the	O
changes	O
in	O
plasma	B-O
PLP	I-O
.	I-O


However	O
,	O
when	O
the	O
data	O
were	O
analyzed	O
without	O
regard	O
for	O
their	O
dependence	O
on	O
time	O
,	O
they	O
demonstrated	O
a	O
negative	O
,	O
linear	O
correlation	O
between	O
alphaEGOT	B-O
and	O
log	O
plasma	B-O
PLP	I-O
and	O
between	O
alphaEGPT	B-O
and	I-O
log	I-O
plasma	I-O
PLP	I-O
for	O
the	O
group	O
on	O
2.5	O
mg	O
of	O
pyridoxine	B-I
and	O
for	O
all	O
the	O
subjects	O
combined	O
.	O


Finally	O
,	O
the	O
dietary	O
records	O
showed	O
that	O
most	O
of	O
the	O
subjects	O
consumed	O
less	O
than	O
2	O
mg	O
of	O
vitamin	B-I
B6	I-I
daily	O
from	O
their	O
food	O
.	O


The	O
results	O
indicate	O
that	O
the	O
current	O
Recommended	O
Dietary	O
Allowance	O
for	O
vitamin	B-I
B6	I-I
during	O
pregnancy	O
(	O
2.5	O
mg	O
)	O
is	O
too	O
low	O
and	O
that	O
supplementation	O
of	O
this	O
vitamin	O
in	O
an	O
amount	O
more	O
than	O
4	O
mg	O
daily	O
is	O
recommended	O
.	O


Intensive	B-I
insulin	I-I
therapy	I-I
improves	O
endothelial	B-O
function	I-O
and	O
microvascular	O
reactivity	O
in	O
young	B-P
people	I-P
with	I-P
type	I-P
1	I-P
diabetes	I-P
.	I-P


AIMS/HYPOTHESIS	O
Macrovascular	O
disease	O
is	O
an	O
important	O
cause	O
of	O
the	O
increased	O
morbidity	O
and	O
mortality	O
rates	O
associated	O
with	O
type	O
1	O
diabetes	O
,	O
and	O
this	O
vascular	O
impairment	O
begins	O
in	O
childhood	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
introducing	O
intensive	B-I
diabetes	I-I
management	I-I
[	I-I
intensive	I-I
insulin	O
therapy	O
(	O
IIT	O
)	O
and	O
'Sweet	B-I
Talk	I-I
'	I-I
text-messaging	I-I
support	I-I
]	I-I
produces	O
measurable	O
improvements	O
in	O
endothelial	B-O
function	I-O
.	I-O


METHODS	O
One	B-P
hundred	I-P
and	I-P
twenty-six	I-P
patients	I-P
fulfilled	I-P
the	I-P
eligibility	I-P
criteria	I-P
(	I-P
type	I-P
1	I-P
diabetes	I-P
for	I-P
>	I-P
1	I-P
year	I-P
;	I-P
on	I-P
conventional	I-I
insulin	I-I
therapy	I-I
(	I-I
CIT	I-I
)	I-I
;	I-I
aged	I-P
between	I-P
8	I-P
and	I-P
18	I-P
years	I-P
)	I-P
,	I-P
of	I-P
whom	I-P
92	I-P
enrolled	I-P
.	I-P


Patients	O
were	O
randomised	O
to	O
group	O
1	O
,	O
CIT	B-I
only	I-I
(	I-I
n=28	I-I
)	I-I
;	I-I
group	I-I
2	I-I
,	I-I
CIT	I-I
and	I-I
Sweet	I-I
Talk	I-I
(	I-I
n=33	I-I
)	I-I
;	I-I
or	I-I
group	I-I
3	I-I
,	I-I
IIT	I-I
and	I-I
Sweet	I-I
Talk	I-I
(	I-I
n=31	I-I
)	I-I
.	I-I


Vascular	B-O
assessments	I-O
(	I-O
including	I-O
measures	I-O
of	I-O
endothelial	I-O
damage	I-O
,	I-O
activation	I-O
,	I-O
dysfunction	I-O
and	I-O
oxidative	I-O
stress	I-O
)	I-O
and	I-O
HbA1c	I-O
were	I-I
performed	I-I
at	I-I
baseline	I-I
and	I-I
repeated	I-I
after	I-I
12	I-I
months	I-I
of	I-I
the	I-I
study	I-I
.	I-I


RESULTS	O
Glycaemic	B-O
control	I-O
deteriorated	O
in	O
patients	O
on	O
CIT	O
,	O
but	O
improved	O
significantly	O
in	O
patients	O
allocated	O
to	O
IIT	O
(	O
p=0.007	O
)	O
.	O


IIT	O
was	O
associated	O
with	O
significantly	O
greater	O
improvements	O
in	O
E-selectin	B-O
(	O
p	O
<	O
0.0001	O
)	O
than	O
CIT	O
(	O
group	O
1	O
,	O
p=0.026	O
and	O
group	O
2	O
,	O
p=0.053	O
)	O
.	O


Vascular	B-O
responses	I-O
to	O
acetylcholine	O
improved	O
in	O
patients	O
on	O
IIT	O
(	O
p=0.017	O
)	O
,	O
but	O
not	O
in	O
patients	O
receiving	O
CIT	O
.	O


These	O
changes	O
were	O
all	O
independent	O
of	O
HbA1c	O
level	O
.	O


CONCLUSIONS/INTERPRETATION	O
IIT	O
appears	O
to	O
be	O
associated	O
with	O
improvements	O
in	O
vascular	B-O
markers	I-O
,	O
independently	O
of	O
changes	O
in	O
HbA1c	O
,	O
suggesting	O
that	O
IIT	O
may	O
confer	O
vascular	O
protection	O
in	O
addition	O
to	O
improving	O
glycaemic	B-O
control	I-O
.	I-O


Angiotensin-converting	B-I
enzyme	I-I
inhibition	I-I
does	O
not	O
suppress	O
plasma	O
angiotensin	O
II	O
increase	O
during	O
exercise	B-P
in	I-P
humans	I-P
.	I-P


Physical	O
effort	O
stimulates	O
the	O
reninangiotensin	O
system	O
(	O
RAS	O
)	O
.	O


We	O
studied	O
the	O
effect	O
of	O
an	O
angiotensin-converting	B-I
enzyme	I-I
inhibitor	I-I
(	I-I
ACE	I-I
inhibitor	I-I
)	I-I
in	O
a	O
double-blind	O
placebo-controlled	O
study	O
,	O
on	O
eight	B-P
volunteers	I-P
undergoing	I-P
physical	I-P
stress	I-P
on	I-P
an	I-P
ergometric	I-P
bicycle	I-P
.	I-P


The	O
effects	O
of	O
captopril	B-I
(	O
C	O
)	O
(	O
50	O
mg	O
,	O
three	O
times	O
daily	O
for	O
3	O
days	O
)	O
on	O
arterial	B-O
pressure	I-O
(	I-O
AP	I-O
)	I-O
,	I-O
O2	I-O
consumption	I-O
(	I-O
VO2	I-O
)	I-O
,	I-O
variations	I-O
in	I-O
auricular	I-O
natriuretic	I-O
factor	I-O
(	I-O
ANF	I-O
)	I-O
,	I-O
renin	I-O
,	I-O
angiotensin	I-O
II	I-O
(	I-O
AII	I-O
)	I-O
plasma	I-O
levels	I-O
,	I-O
as	I-O
well	I-O
as	I-O
glomerular	I-O
filtration	I-O
rate	I-O
(	I-O
GFR	I-O
)	I-O
and	I-O
microalbuminuria	I-O
(	I-O
MA	I-O
)	I-O
were	O
evaluated	O
.	O


The	O
different	O
parameters	O
were	O
compared	O
by	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O


The	O
pressure	O
profile	O
and	O
VO2	O
were	O
not	O
modified	O
by	O
ACE	B-I
inhibitor	I-I
.	I-I


Exercise	O
stimulates	O
release	O
of	O
renin	O
;	O
this	O
action	O
was	O
greater	O
with	O
captopril	B-I
administration	O
(	O
treatment	O
effect	O
:	O
p	O
<	O
10	O
(	O
-4	O
)	O
,	O
indicating	O
blockade	O
of	O
the	O
RAS	O
.	O


This	O
inhibition	O
was	O
incomplete	O
because	O
AII	O
levels	O
increased	O
markedly	O
when	O
captopril	B-I
was	O
given	O
(	O
no	O
treatment	O
effect	O
:	O
p	O
<	O
0.37	O
)	O
.	O


Finally	O
,	O
ACE	B-I
inhibitor	I-I
resulted	O
in	O
decreased	O
GFR	B-O
(	O
p	O
=	O
115	O
+/-	O
5.8	O
ml/mn-1	O
,	O
C	O
=	O
91.1	O
+/-	O
4	O
,	O
p	O
<	O
0.05	O
)	O
with	O
exercise	O
without	O
modification	O
of	O
MA	O
.	O


ACE	B-I
inhibitor	I-I
administration	I-I
does	O
not	O
modify	O
the	O
physical	O
performance	O
of	O
nonathletic	O
subjects	O
;	O
AII	O
is	O
significantly	O
increased	O
with	O
exercise	O
despite	O
captopril	O
treatment	O
;	O
ACE	B-I
inhibitor	I-I
decreases	O
GFR	B-O
significantly	O
but	O
does	O
not	O
influence	O
MA	O
with	O
prolonged	O
physical	O
effort	O
.	O


Heart	O
rate	O
variability	O
characteristics	O
in	B-P
sedentary	I-P
postmenopausal	I-P
women	I-P
following	O
six	O
months	O
of	O
exercise	B-I
training	I-I
:	I-I
the	O
DREW	O
study	O
.	O


BACKGROUND	O
Decreased	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
.	O


Overall	O
,	O
postmenopausal	B-P
women	I-P
have	O
lower	O
levels	O
of	O
HRV	O
than	O
premenopausal	O
women	O
,	O
which	O
may	O
be	O
additionally	O
complicated	O
by	O
lifestyle	O
related	O
behaviors	O
such	O
as	O
physical	O
inactivity	O
and	O
obesity	O
.	O


Though	O
cardiorespiratory	B-I
exercise	I-I
training	I-I
increases	O
HRV	O
,	O
little	O
is	O
known	O
regarding	O
the	O
exercise	O
dose	O
necessary	O
to	O
promote	O
this	O
improvement	O
.	O


METHODOLOGY/PRINCIPAL	O
FINDINGS	O
Our	O
primary	O
aim	O
was	O
to	O
measure	O
HRV	O
in	O
post-menopausal	B-P
women	I-P
following	O
6-months	O
of	O
exercise	B-I
training	I-I
.	I-I


We	O
examined	O
supine	B-P
resting	I-P
HRV	I-P
in	I-P
373	I-P
post-menopausal	I-P
women	I-P
(	I-P
45-75	I-P
y	I-P
)	I-P
after	I-P
6-months	I-P
of	I-P
randomly	I-P
assigned	I-P
and	O
double-blinded	O
administered	O
exercise	B-I
training	I-I
exercise	I-I
training	I-I
at	O
50	O
%	O
,	O
100	O
%	O
and	O
150	O
%	O
of	O
the	O
NIH	O
Consensus	O
Development	O
Panel	O
's	O
recommended	O
minimal	O
physical	O
activity	O
level	O
.	O


This	O
corresponded	O
to	O
4	O
,	O
8	O
,	O
or	O
12	O
kcal/kg	O
per	O
week	O
(	O
KKW	O
)	O
of	O
energy	O
expenditure	O
.	O


At	O
baseline	O
,	O
we	O
observed	O
no	O
significant	O
differences	O
in	O
HRV	B-O
or	O
hormone	B-O
replacement	O
use	O
between	O
treatment	O
groups	O
.	O


However	O
,	O
we	O
did	O
observe	O
that	O
Caucasian	O
women	O
and	O
those	O
taking	O
antidepressant	O
medications	O
had	O
lower	O
levels	O
of	O
baseline	B-O
HRV	I-O
.	I-O


After	O
6-months	O
of	O
exercise	B-I
intervention	I-I
,	O
we	O
observed	O
a	O
dose	O
dependent	O
increase	O
in	O
all	O
parasympathetically	O
derived	O
time	B-O
and	I-O
frequency	I-O
domain	I-O
measurements	I-O
across	O
exercise	O
groups	O
after	O
adjustment	O
for	O
age	O
,	O
ethnicity	O
,	O
antidepressants	B-O
,	O
and	O
baseline	O
rMSSD	O
(	O
all	O
,	O
P	O
<	O
0.001	O
)	O
.	O


For	O
example	O
,	O
the	O
parasympathetic	B-O
index	I-O
rMSSD	I-O
was	O
greater	O
than	O
control	O
(	O
23.19+/-1.0	O
)	O
for	O
the	O
4-KKW	O
(	O
25.98+/-0.8	O
;	O
P	O
=	O
0.14	O
)	O
,	O
8-KKW	O
(	O
27.66+/-1.0	O
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
12-KKW	O
(	O
27.40+/-0.0	O
;	O
P	O
<	O
0.05	O
)	O
groups	O
at	O
follow-up	O
.	O


CONCLUSIONS/SIGNIFICANCE	O
Moderate	B-I
intensity	I-I
exercise	I-I
training	I-I
exercise	I-I
is	O
sufficient	O
to	O
improve	O
HRV	O
in	O
previously	O
sedentary	B-P
postmenopausal	I-P
women	I-P
in	O
a	O
dose-dependent	O
manner	O
,	O
as	O
4-KKW	O
is	O
insufficient	O
to	O
improve	O
parasympathetic	O
indices	O
of	O
HRV	O
,	O
while	O
12-KKW	O
conferred	O
no	O
greater	O
improvement	O
than	O
8-KKW	O
.	O


TRIAL	O
REGISTRATION	O
Clinicaltrials.gov	O
NCT	O
00011193	O
.	O


Tetracaine	B-I
(	I-I
ametop	I-I
)	I-I
compared	O
to	O
placebo	O
for	O
reducing	O
pain	B-P
associated	I-P
with	I-P
intramuscular	I-P
injection	I-P
of	I-P
palivizumab	I-P
(	I-P
synagis	I-P
)	I-P
.	I-P


Infants	B-P
receive	I-P
many	I-P
painful	I-P
immunizations	I-P
before	I-P
they	I-P
are	I-P
2	I-P
years	I-P
old	I-P
.	I-P


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
if	O
topical	B-I
tetracaine	I-I
reduces	O
the	O
pain	B-P
of	I-P
intramuscular	I-P
palivizumab	I-I
compared	O
to	O
placebo	B-I
.	I-I


There	O
were	O
two	O
study	O
injections	O
,	O
one	O
with	O
tetracaine	B-I
and	O
one	O
with	O
placebo	B-I
.	I-I


Pain	B-O
was	O
scored	O
by	O
their	O
parents	O
and	O
a	O
pediatric	O
nurse	O
.	O


Topical	O
tetracaine	B-I
was	O
not	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
pain	B-O
score	I-O
,	O
although	O
it	O
did	O
lead	O
to	O
faster	O
recovery	B-O
times	O
.	O


Additional	O
pain-reduction	O
strategies	O
are	O
required	O
.	O


Intravenous	B-I
hyperimmune	I-I
globulin	I-I
prophylaxis	I-I
against	O
cytomegalovirus	O
interstitial	O
pneumonitis	O
after	O
allogenic	B-I
bone	I-I
marrow	I-I
transplantation	I-I
.	I-I


In	O
an	O
attempt	O
to	O
reduce	O
the	O
incidence	O
of	O
lethal	O
cytomegalovirus	B-O
(	I-O
CMV	I-O
)	I-O
interstitial	I-O
pneumonitis	I-O
after	I-P
allogenic	I-I
bone	I-I
marrow	I-I
transplantation	I-I
49	I-P
patients	I-P
were	I-P
randomized	I-P
in	I-P
a	I-P
multicenter	I-P
controlled	I-P
study	I-P
to	O
receive	O
either	O
CMV-hyperimmune	B-I
globulin	I-I
or	O
a	O
control	B-I
immune	I-I
globulin	I-I
with	I-I
low	I-I
anticytomegalovirus	I-I
titer	I-I
.	I-I


Immune	B-I
globulin	I-I
was	O
administered	O
intravenously	O
6	O
times	O
with	O
20	O
days	O
interval	O
,	O
starting	O
on	O
day	O
7	O
before	O
transplantation	O
.	O


Patients	O
receiving	O
CMV	B-I
hyperimmune	I-I
globulin	I-I
or	O
control	B-I
immune	I-I
globulin	I-I
were	O
comparable	O
with	O
regard	O
to	O
age	O
,	O
diagnosis	O
,	O
pretransplant	O
anti-CMV	O
titer	O
,	O
incidence	O
of	O
graft-versus-host	O
disease	O
and	O
transfusions	O
.	O


In	O
each	O
group	O
,	O
the	O
incidence	B-O
of	I-O
histologically	I-O
proven	I-O
CMV	I-O
interstitial	I-O
pneumonitis	I-O
during	O
the	O
first	O
110	O
days	O
post	O
BMT	O
was	O
recorded	O
.	O


Six	B-P
of	I-P
23	I-P
patients	I-P
in	O
the	O
control	B-I
group	O
versus	O
1	O
of	O
26	O
in	O
the	O
CMV	B-I
hyperimmune	I-I
globulin	I-I
group	O
died	B-O
of	I-O
CMV	I-O
interstitial	I-O
pneumonitis	I-O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


No	O
significant	O
effect	B-O
on	I-O
idiopathic	I-O
pneumonitis	I-O
or	I-O
survival	I-O
was	O
observed	O
.	O


Comparison	O
of	O
4	O
supraglotttic	B-I
devices	I-I
used	O
by	O
paramedics	O
during	O
simulated	O
CPR	O
:	O
a	O
randomized	O
controlled	O
crossover	O
trial	O
.	O


BACKGROUND	O
Ensuring	O
an	O
open	O
airway	O
during	O
cardiopulmonary	O
resuscitation	O
is	O
fundamental	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
success	O
rate	O
of	O
blind	O
intubation	O
during	O
simulated	O
cardiopulmonary	O
resuscitation	O
by	O
untrained	B-P
personnel	I-P
.	I-P


METHODS	O
Four	B-P
devices	I-P
were	O
compared	O
in	O
a	O
simulated	O
resuscitation	O
scenario	O
:	O
ILMA	B-I
(	O
Intavent	O
Direct	O
Ltd	O
,	O
Buckinghamshire	O
,	O
United	O
Kingdom	O
)	O
,	O
Cobra	B-I
PLA	I-I
(	O
Engineered	O
Medical	O
Systems	O
Inc	O
,	O
Indianapolis	O
,	O
IN	O
)	O
,	O
Supraglottic	B-I
Airway	I-I
Laryngopharyngeal	I-I
Tube	I-I
(	I-I
SALT	I-I
)	I-I
(	O
ECOLAB	O
,	O
St.	O
Paul	O
,	O
MN	O
)	O
,	O
and	O
Air-Q	B-I
(	O
Mercury	O
Medical	O
,	O
Clearwater	O
,	O
FL	O
)	O
.	O


A	O
group	B-P
of	I-P
210	I-P
paramedics	I-P
intubated	O
a	O
manikin	O
with	O
continuous	O
chest	O
compressions	O
.	O


RESULTS	O
The	O
mean	O
times	O
to	O
intubation	O
were	O
40.46	O
±	O
4.64	O
,	O
33.96	O
±	O
6.23	O
,	O
17.2	O
±	O
4.63	O
,	O
and	O
49.23	O
±	O
13.19	O
seconds	O
(	O
SALT	O
vs	O
ILMA	O
,	O
Cobra	O
PLA	O
,	O
and	O
Air-Q	O
;	O
P	O
<	O
.05	O
)	O
.	O


The	B-O
success	I-O
ratios	I-O
of	I-O
blind	I-O
intubation	I-O
for	O
the	O
devices	O
were	O
86.7	O
%	O
,	O
85.7	O
%	O
,	O
100	O
%	O
,	O
and	O
71.4	O
%	O
(	O
SALT	O
vs	O
ILMA	O
,	O
Cobra	O
PLA	O
,	O
and	O
Air-Q	O
;	O
P	O
<	O
.05	O
)	O
.	O


CONCLUSION	O
The	O
study	O
showed	O
that	O
the	O
most	O
efficient	O
device	O
with	O
the	O
shortest	O
blind	O
intubation	O
time	O
was	O
the	B-I
SALT	I-I
device	I-I
.	O


Three-Arm	O
Randomized	O
Phase	O
III	O
Trial	O
:	O
Quality	O
Aloe	B-I
and	I-I
Placebo	I-I
Cream	O
Versus	O
Powder	B-I
as	O
Skin	O
Treatment	O
During	O
Breast	B-P
Cancer	I-P
Radiation	I-P
Therapy	I-P
.	I-P


BACKGROUND	O
The	O
efficacy	O
of	O
aloe	B-I
extract	I-I
in	O
reducing	O
radiation-induced	B-O
skin	I-O
injury	I-O
is	O
controversial	O
.	O


The	O
purpose	O
of	O
the	O
present	O
3-arm	O
randomized	O
trial	O
was	O
to	O
test	O
the	O
efficacy	O
of	O
quality-tested	O
aloe	O
extract	O
in	O
reducing	O
the	O
severity	O
of	O
radiation-induced	O
skin	O
injury	O
and	O
,	O
secondarily	O
,	O
to	O
examine	O
the	O
effect	O
of	O
a	O
moist	B-I
cream	I-I
versus	O
a	O
dry	B-I
powder	I-I
skin	I-I
care	I-I
regimen	I-I
.	I-I


MATERIALS	O
AND	O
METHODS	O
A	B-P
total	I-P
of	I-P
248	I-P
patients	I-P
with	I-P
breast	I-P
cancer	I-P
were	O
randomized	O
to	O
powder	B-I
,	I-I
aloe	I-I
cream	I-I
,	O
or	O
placebo	B-I
cream	I-I
.	I-I


Acute	B-O
skin	I-O
toxicity	I-O
was	O
scored	O
weekly	O
and	O
after	O
treatment	O
at	O
weeks	O
1	O
,	O
2	O
,	O
and	O
4	O
using	O
a	O
modified	O
10-point	O
Catterall	O
scale	O
.	O


The	O
patients	O
scored	O
their	O
symptom	O
severity	O
using	O
a	O
6-point	O
Likert	O
scale	O
and	O
kept	O
an	O
acute	O
phase	O
diary	O
.	O


RESULTS	O
The	O
aloe	O
formulation	O
did	O
not	O
reduce	B-O
acute	I-O
skin	I-O
toxicity	I-O
or	I-O
symptom	I-O
severity	I-O
.	I-O


Patients	B-P
with	O
a	O
greater	O
body	O
mass	O
index	O
were	O
more	O
likely	O
to	O
develop	B-O
acute	I-O
skin	I-O
toxicity	I-O
.	I-O


A	O
similar	O
pattern	O
of	O
increased	O
skin	B-O
reaction	I-O
toxicity	I-O
occurred	O
with	O
both	O
study	O
creams	O
compared	O
with	O
the	O
dry	O
powder	O
regimen	O
.	O


CONCLUSION	O
No	O
evidence	O
was	O
found	O
to	O
support	O
prophylactic	O
application	O
of	O
quality	O
aloe	B-I
extract	I-I
or	O
cream	O
to	O
improve	O
the	O
symptoms	O
or	O
reduce	O
the	O
skin	B-O
reaction	I-O
severity	I-O
.	I-O


Our	O
results	O
support	O
a	O
dry	O
skin	O
care	O
regimen	O
of	O
powder	O
during	O
radiation	O
therapy	O
.	O


Timing	O
of	O
antibiotic	B-I
administration	I-I
in	O
knee	B-P
replacement	I-P
under	I-P
tourniquet	I-P
.	I-P


Cephamandole	B-O
levels	I-O
in	I-O
serum	I-O
and	I-O
drain	I-O
fluid	I-O
were	O
measured	O
in	O
32	B-P
knee	I-P
replacement	I-P
operations	I-P
to	O
determine	O
the	O
benefit	O
of	O
an	O
intravenous	O
dose	O
of	O
antibiotic	O
at	O
the	O
time	O
of	O
tourniquet	O
deflation	O
.	O


Concentrations	O
of	O
cephamandole	B-O
in	I-O
drain	I-O
fluid	I-O
were	O
directly	O
proportional	O
to	O
the	O
serum	O
concentration	O
at	O
the	O
time	O
of	O
tourniquet	O
release	O
.	O


A	O
'tourniquet-release	B-I
'	I-I
dose	I-I
of	I-I
antibiotic	I-I
increased	O
drain	B-O
fluid	I-O
concentration	I-O
threefold	O
.	O


A	O
randomized	O
trial	O
of	O
chiropractic	B-I
and	I-I
medical	I-I
care	I-I
for	O
patients	B-P
with	I-P
low	I-O
back	I-O
pain	I-O
:	I-O
eighteen-month	O
follow-up	O
outcomes	O
from	O
the	O
UCLA	O
low	O
back	O
pain	O
study	O
.	O


STUDY	O
DESIGN	O
Randomized	O
clinical	O
trial	O
.	O


OBJECTIVES	O
To	O
compare	O
the	O
long-term	O
effectiveness	O
of	O
medical	B-I
and	I-I
chiropractic	I-I
care	I-I
for	I-I
low	I-I
back	I-I
pain	I-I
in	I-P
managed	I-P
care	I-P
and	O
to	O
assess	O
the	O
effectiveness	O
of	O
physical	B-I
therapy	I-I
and	O
modalities	O
among	O
patients	B-P
receiving	I-P
medical	I-I
or	I-I
chiropractic	I-I
care	I-I
.	I-I


SUMMARY	O
OF	O
BACKGROUND	O
DATA	O
Evidence	O
comparing	O
the	O
long-term	O
relative	O
effectiveness	O
of	O
common	O
treatment	O
strategies	O
offered	O
to	O
low	B-P
back	I-P
pain	I-P
patients	I-P
in	O
managed	O
care	O
is	O
lacking	O
.	O


METHODS	O
A	B-P
total	I-P
of	I-P
681	I-P
low	I-P
back	I-P
pain	I-P
patients	I-P
presenting	I-P
to	I-P
a	I-P
managed-care	I-P
facility	I-P
were	O
randomized	O
to	O
chiropractic	B-I
with	I-I
or	I-I
without	I-I
physical	I-I
modalities	I-I
,	I-I
or	I-I
medical	I-I
care	I-I
with	I-I
or	I-I
without	I-I
physical	I-I
therapy	I-I
,	O
and	O
followed	O
for	O
18	O
months	O
.	O


The	O
primary	O
outcome	O
variables	O
are	O
low	B-O
back	I-O
pain	I-O
intensity	I-O
,	I-O
disability	I-O
,	I-O
and	I-O
complete	I-O
remission	I-O
.	I-O


The	O
secondary	O
outcome	O
is	O
participants	B-O
'	I-O
perception	I-O
of	I-O
improvement	I-O
in	I-O
low	I-O
back	I-O
symptoms	I-O
.	I-O


RESULTS	O
Of	O
the	O
681	B-P
patients	I-P
,	I-P
610	I-P
(	I-P
89.6	I-P
%	I-P
)	I-P
were	I-P
followed	I-P
through	I-P
18	I-P
months	I-P
.	I-P


Among	O
participants	O
not	O
assigned	O
to	O
receive	O
physical	O
therapy	O
or	O
modalities	O
,	O
the	O
estimated	O
improvements	O
in	O
pain	B-O
and	I-O
disability	I-O
and	O
18-month	O
risk	B-O
of	I-O
complete	I-O
remission	I-O
were	O
a	O
little	O
greater	O
in	O
the	O
chiropractic	O
group	O
than	O
in	O
the	O
medical	O
group	O
(	O
adjusted	O
RR	O
of	O
remission	O
=	O
1.29	O
;	O
95	O
%	O
CI	O
=	O
0.80-2.07	O
)	O
.	O


Among	O
participants	O
assigned	O
to	O
medical	O
care	O
,	O
mean	B-O
changes	I-O
in	I-O
pain	I-O
and	I-O
disability	I-O
and	I-O
risk	I-O
of	I-O
remission	I-O
were	O
larger	O
in	O
patients	O
assigned	O
to	O
receive	O
physical	B-I
therapy	I-I
(	O
adjusted	O
RR	O
=	O
1.69	O
;	O
95	O
%	O
CI	O
=	O
1.08-2.66	O
)	O
.	O


Among	O
those	O
assigned	O
to	O
chiropractic	B-I
care	I-I
,	O
however	O
,	O
assignment	O
to	O
methods	O
was	O
not	O
associated	O
with	O
improvement	O
or	O
remission	O
(	O
adjusted	O
RR	O
=	O
0.98	O
;	O
95	O
%	O
CI	O
=	O
0.62-1.55	O
)	O
.	O


Compared	O
with	O
medical	O
care	O
only	O
patients	O
,	O
chiropractic	B-I
and	O
physical	O
therapy	O
patients	O
were	O
much	O
more	O
likely	O
to	O
perceive	O
improvement	O
in	O
their	O
low	O
back	O
symptoms	O
.	O


However	O
,	O
less	O
than	O
20	O
%	O
of	O
all	O
patients	O
were	O
pain-free	B-O
at	O
18	O
months	O
.	O


CONCLUSIONS	O
Differences	O
in	O
outcomes	O
between	O
medical	B-I
and	I-I
chiropractic	I-I
care	I-I
without	O
physical	O
therapy	O
or	O
modalities	O
are	O
not	O
clinically	O
meaningful	O
,	O
although	O
chiropractic	O
may	O
result	O
in	O
a	O
greater	O
likelihood	O
of	O
perceived	O
improvement	O
,	O
perhaps	O
reflecting	O
satisfaction	O
or	O
lack	O
of	O
blinding	O
.	O


Physical	B-I
therapy	I-I
may	O
be	O
more	O
effective	O
than	O
medical	O
care	O
alone	O
for	O
some	O
patients	O
,	O
while	O
physical	O
modalities	O
appear	O
to	O
have	O
no	O
benefit	O
in	O
chiropractic	O
care	O
.	O


Safety	O
and	O
pharmacology	O
of	O
a	O
single	O
intravenous	O
dose	O
of	O
ponezumab	B-I
in	O
subjects	B-P
with	I-P
mild-to-moderate	I-P
Alzheimer	I-P
disease	I-P
:	I-P
a	O
phase	O
I	O
,	O
randomized	O
,	O
placebo-controlled	B-I
,	O
double-blind	O
,	O
dose-escalation	O
study	O
.	O


OBJECTIVES	O
Ponezumab	B-I
is	O
a	O
humanized	O
antiamyloid	O
beta	O
(	O
Aβ	O
)	O
monoclonal	O
antibody	O
designed	O
to	O
treat	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O


METHODS	O
This	O
randomized	O
,	O
double-blind	O
,	O
single-dose-escalation	O
study	O
evaluated	O
the	O
safety	O
,	O
pharmacokinetics	O
,	O
and	O
pharmacodynamics	O
of	O
0.1	O
,	O
0.3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg/kg	B-I
ponezumab	I-I
(	O
n	O
=	O
4	O
,	O
4	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
,	O
respectively	O
)	O
versus	B-I
placebo	I-I
(	O
n	O
=	O
11	O
)	O
after	O
a	O
2-hour	O
intravenous	O
infusion	O
in	B-P
subjects	I-P
with	I-P
mild-to-moderate	I-P
AD	I-P
.	O


Cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
samples	O
were	O
obtained	O
from	O
the	O
1-	O
and	O
10-mg/kg	O
groups	O
at	O
baseline	O
and	O
at	O
day	O
29	O
.	O


The	O
subjects	O
were	O
followed	O
for	O
1	O
year	O
.	O


RESULTS	O
All	O
subjects	O
completed	O
the	O
trial	O
.	B-I


Ponezumab	B-I
was	O
well	B-O
tolerated	I-O
with	O
no	O
drug-attributed	B-O
serious	I-O
adverse	I-O
events	I-O
.	O


The	O
most	O
common	O
adverse	O
events	O
were	B-O
upper	I-O
respiratory	I-O
tract	I-O
infection	I-O
,	I-O
headache	I-O
,	I-O
and	I-O
back	I-O
pain	I-O
,	I-O
all	I-O
mild	I-O
to	I-O
moderate	I-O
.	O


One	O
subject	O
(	O
10	O
mg/kg	O
)	O
experienced	O
a	B-O
mild	I-O
hypersensitivity	I-O
reaction	I-O
.	O


Another	O
subject	O
(	O
0.1	O
mg/kg	O
)	O
demonstrated	B-O
slight	I-O
enlargement	I-O
of	I-O
a	I-O
preexisting	I-O
midbrain	I-O
lesion	I-O
.	I-O


Electrocardiography	B-O
and	I-O
laboratory	I-O
values	I-O
(	I-O
including	I-O
CSF	I-O
)	I-O
were	O
unremarkable	O
.	O


No	O
evidence	O
of	O
new	B-O
microhemorrhage	I-O
,	I-O
vasogenic	I-O
edema	I-O
,	I-O
or	I-O
meningoencephalitis	I-O
was	O
noted	O
.	O


Plasma	O
maximum	O
observed	O
concentration	O
increased	O
approximately	O
dose	O
proportionally	O
,	O
and	O
the	B-O
area	I-O
under	I-O
the	I-O
plasma	I-O
concentration-time	I-O
profile	I-O
from	O
time	O
zero	O
extrapolated	O
to	O
infinite	O
time	O
(	O
AUC	O
(	O
inf	O
)	O
)	O
increased	O
slightly	O
more	O
than	O
dose	O
proportionally	O
.	B-O


Mean	B-O
terminal	I-O
half-life	I-O
was	O
approximately	O
6	O
weeks	O
.	O


Two	O
subjects	O
(	O
10	O
mg/kg	O
)	O
had	O
measurable	B-O
CSF	I-O
ponezumab	I-O
concentrations	I-O
(	O
~0.5	O
%	O
of	O
plasma	O
values	O
)	O
at	O
day	O
29	O
.	O


Plasma	O
Aβ	O
(	O
1-x	O
)	O
and	O
Aβ	O
(	O
1-40	O
)	O
increased	O
dose	O
dependently	O
,	O
and	B-O
mean	I-O
CSF	I-O
Aβ	O
(	O
1-x	O
)	O
increased	O
38	O
%	O
from	O
baseline	O
with	O
10	O
mg/kg	O
(	O
P	O
=	O
0.002	B-I
vs	I-I
placebo	I-I
)	I-I
.	O


CONCLUSIONS	O
A	O
2-hour	O
infusion	O
of	O
0.1	O
to	O
10	O
mg/kg	B-I
ponezumab	I-I
was	O
well	O
tolerated	O
in	O
subjects	O
with	O
mild-to-moderate	O
AD	O
.	O


Plasma	O
pharmacokinetic	O
profile	O
was	O
approximately	O
linear	O
.	O


Plasma	O
Aβ	O
increased	O
with	O
dose	O
,	O
and	O
CSF	O
Aβ	O
increased	O
at	O
the	O
highest	O
dose	O
,	O
suggesting	O
that	O
intravenous	B-I
ponezumab	I-I
alters	O
central	O
Aβ	O
levels	O
.	O


Prostaglandin	B-P
E1	I-P
as	I-P
a	I-P
hypotensive	I-P
drug	I-P
during	I-P
general	I-P
anaesthesia	I-P
.	I-P


Hypotension	B-O
induced	O
by	O
prostaglandin	B-I
E1	I-I
(	I-I
PGE1	I-I
)	I-I
infusion	I-I
(	O
100-150	O
ng/kg/minute	O
)	O
during	O
halothane	B-I
anaesthesia	I-I
to	O
reduce	O
operative	O
blood	O
loss	O
during	B-P
mastectomy	I-P
was	O
investigated	O
.	O


PGE1	O
decreased	O
systolic	B-O
arterial	I-O
pressure	I-O
approximately	O
34	O
%	O
from	O
pre-administration	O
values	O
.	O


The	O
duration	O
of	O
induced	B-P
hypotension	I-P
was	O
about	O
75	O
minutes	O
.	O


When	O
the	O
infusion	O
was	O
stopped	O
,	O
blood	B-O
pressure	I-O
returned	O
to	O
within	O
15	O
%	O
of	O
the	O
control	O
with	O
15	O
minutes	O
.	O


Heart	B-O
rate	I-O
did	O
not	O
change	O
significantly	O
during	O
PGE1	O
infusion	O
;	O
the	O
pre-ejection	B-O
period	I-O
and	O
left	B-O
ventricular	I-O
ejection	I-O
period	O
were	O
shortened	O
.	O


Renal	B-O
function	I-O
during	O
the	O
hypotensive	O
period	O
was	O
well	O
maintained	O
.	O


Blood	B-O
loss	I-O
during	O
surgery	O
was	O
significantly	O
decreased	O
.	O


These	O
findings	O
suggest	O
that	O
PGE1	O
can	O
be	O
used	O
safely	O
to	O
control	O
arterial	B-O
pressure	I-O
during	O
surgery	O
.	O


Report	O
on	O
the	O
second	O
myelomatosis	O
trial	O
after	O
five	O
years	O
of	O
follow-up	O
.	O


Medical	O
Research	O
Council	O
's	O
Working	O
Party	O
on	O
Leukaemia	B-P
in	I-P
Adults	I-P
.	I-P


Three	B-P
hundred	I-P
and	I-P
seventy-two	I-P
patients	I-P
were	O
randomized	O
between	O
3	B-I
regimens	I-I
of	I-I
chemotherapy	I-I
:	I-I
cyclophosphamide	I-I
,	I-I
intermittent	I-I
melphalan	I-I
,	I-I
and	I-I
melphalan	I-I
with	I-I
prednisone	I-I
,	I-I
and	I-I
were	I-I
followed	I-I
up	I-I
to	I-I
death	I-I
or	I-I
for	I-I
at	I-I
least	I-I
5	I-I
years	I-I
.	I-I


There	O
was	O
no	O
difference	O
in	O
survival	B-O
between	O
the	O
treatments	O
,	O
either	O
overall	O
or	O
in	O
any	O
subgroup	O
of	O
patients	O
.	O


Therefore	O
,	O
the	O
choice	O
among	O
these	O
3	O
treatments	O
should	O
be	O
guided	O
by	O
the	O
patient	O
's	O
comfort	O
and	O
convenience	O
.	O


The	O
most	O
important	O
prognostic	O
feature	O
at	O
presentation	O
was	O
the	O
quality	O
of	O
renal	B-O
function	I-O
.	I-O


It	O
was	O
possible	O
to	O
define	O
good	B-P
,	I-P
intermediate	I-P
and	I-P
poor	I-P
renal-function	I-P
groups	I-P
which	O
were	O
highly	O
correlated	O
with	O
prognosis	O
(	O
X2	O
for	O
trend	O
=	O
62.6	O
)	O
.	O


The	O
haemoglobin	B-O
level	I-O
at	O
presentation	O
was	O
strongly	O
correlated	O
with	O
prognosis	O
among	O
patients	B-P
in	I-P
the	I-P
good	I-P
renal-function	I-P
group	I-P
.	I-P


Among	O
107	B-P
patients	I-P
who	I-P
presented	I-P
with	I-P
good	I-P
renal	I-P
function	I-P
and	I-P
with	I-P
haemoglobin	I-P
above	I-P
100	I-P
g/l	I-P
,	O
the	O
5-year	O
survival	B-O
was	O
43	O
%	O
.	O


Other	O
prognostic	O
features	O
were	O
much	O
less	O
important	O
when	O
account	O
was	O
taken	O
of	O
renal	O
function	O
and	O
haemoglobin	O
level	O
.	O


Randomized	O
,	O
prospective	O
comparison	O
of	O
halothane	B-I
,	I-I
isoflurane	I-I
,	I-I
and	I-I
enflurane	I-I
on	O
baroreflex	B-P
control	I-O
of	I-O
heart	I-O
rate	I-O
in	I-O
humans	I-O
.	I-O


Prenatal	O
depression	O
predicts	O
postpartum	O
maternal	O
attachment	O
in	O
low-income	B-P
Latina	I-P
mothers	I-P
with	I-P
infants	I-P
.	I-P


Although	O
maternal	O
attachment	O
is	O
an	O
important	O
predictor	O
of	O
infant	O
attachment	O
security	O
and	O
other	O
developmental	O
outcomes	O
,	O
little	O
is	O
known	O
about	O
the	O
formation	O
of	O
maternal	O
attachment	O
in	O
the	O
first	O
few	O
months	O
of	O
the	O
infant	O
's	O
life	O
,	O
particularly	O
among	O
ethnic	O
minority	O
mothers	O
.	O


The	O
current	O
study	O
examined	O
the	O
predictors	O
of	O
postpartum	O
maternal	O
attachment	O
in	O
a	O
sample	O
of	O
217	B-P
Latina	I-P
women	I-P
enrolled	I-P
in	I-P
a	I-P
perinatal	I-P
depression	I-P
prevention	I-P
trial	I-P
.	I-P


Mothers	O
'	O
attachment	B-I
to	O
their	O
infants	O
was	O
measured	O
at	O
6-8	B-I
weeks	I-I
postpartum	I-I
using	I-I
the	I-I
Maternal	I-O
Postnatal	I-O
Attachment	I-O
Scale	I-O
.	I-O


A	O
variety	O
of	O
predictors	O
of	O
early	O
attachment	O
were	O
explored	O
including	O
:	O
depressive	B-O
symptoms	I-O
during	I-O
pregnancy	I-O
,	I-O
pregnancy	I-O
intention	I-O
,	I-O
feelings	I-O
about	I-O
the	I-O
pregnancy	I-O
,	I-O
and	I-O
the	I-O
quality	I-O
of	I-O
the	I-O
partner	I-O
relationship	I-O
.	I-O


The	O
strongest	O
predictor	O
of	O
lower	B-O
maternal	I-O
attachment	I-O
was	O
depressive	B-O
symptoms	I-O
late	O
in	O
pregnancy	O
;	O
pregnancy	O
intention	O
was	O
marginally	O
predictive	O
of	O
attachment	B-O
,	O
with	O
lower	O
scores	O
being	O
associated	O
with	O
unwanted	O
pregnancies	O
.	O


The	O
study	O
fills	O
a	O
critical	O
gap	O
in	O
our	O
understanding	O
of	O
the	O
role	O
of	O
depressive	O
symptoms	O
during	O
pregnancy	O
in	O
shaping	O
mothers	O
'	O
early	O
attachment	O
to	O
their	O
infants	O
.	O


D-dimer	O
predicts	O
outcome	O
after	O
aneurysmal	O
subarachnoid	B-P
hemorrhage	I-P
:	I-P
no	O
effect	O
of	O
thromboprophylaxis	O
on	O
coagulation	B-O
activity	I-O
.	I-O


OBJECTIVE	O
Approximately	O
one-third	O
of	O
all	O
patients	B-P
with	I-P
acute	I-P
nontraumatic	I-P
subarachnoid	I-P
hemorrhage	I-P
(	I-P
SAH	I-P
)	I-P
experience	O
complications	O
owing	O
to	O
delayed	O
ischemic	O
deficit	O
.	O


We	O
reported	O
recently	O
that	O
enoxaparin	B-I
40	O
mg	O
once	O
daily	O
for	O
10	O
days	O
seems	O
safe	O
and	O
demonstrates	O
thromboprophylactic	B-O
efficacy	I-O
,	O
but	O
it	O
failed	O
to	O
improve	O
outcome	O
in	O
a	O
randomized	O
SAH	O
trial	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
hemostatic	B-O
variables	I-O
associated	O
with	O
clinical	O
status	O
and	O
outcome	O
of	O
SAH	O
.	O


We	O
also	O
monitored	O
the	O
effect	O
of	O
enoxaparin	B-I
on	O
activation	B-O
of	I-O
coagulation	I-O
and	I-O
fibrinolysis	I-O
after	O
closure	O
of	O
the	O
ruptured	O
aneurysm	O
.	O


METHODS	O
Blood	B-O
samples	I-O
to	O
measure	O
activation	B-O
of	I-O
coagulation	I-O
and	I-O
fibrinolysis	I-O
were	O
collected	O
from	O
42	B-P
patients	I-P
participating	I-P
in	I-P
the	I-P
enoxaparin	I-I
trial	I-P
for	I-P
acute	I-P
aneurysmal	I-P
SAH	I-P
at	I-P
four	I-P
time	I-P
points	I-P
:	I-P
1	I-P
)	I-P
at	I-P
hospital	I-P
admission	I-P
;	I-P
2	I-P
)	I-P
12	I-P
to	I-P
24	I-P
hours	I-P
after	I-P
aneurysm	I-P
surgery	I-P
but	I-P
before	I-P
initiation	I-P
of	I-P
enoxaparin	I-I
therapy	I-P
;	I-P
3	I-P
)	I-P
3	I-P
hours	I-P
after	I-P
the	I-P
first	I-P
dose	I-P
;	I-P
and	I-P
4	I-P
)	I-P
at	I-P
the	I-P
conclusion	I-P
of	I-P
treatment	I-P
.	I-P


RESULTS	O
At	O
admission	O
,	O
several	O
variables	B-O
of	I-O
coagulation	I-O
and	I-O
fibrinolysis	I-O
were	O
elevated	O
and	O
correlated	O
well	O
with	O
clinical	O
status	O
.	O


Specifically	O
,	O
D-dimer	B-O
levels	I-O
at	O
all	O
four	O
time	O
points	O
correlated	O
with	O
patients	O
'	O
long-term	O
outcomes	O
.	O


A	O
single	O
dose	O
of	O
enoxaparin	B-I
suppressed	O
early	B-O
coagulation	I-O
activity	I-O
,	O
but	O
thrombin	B-O
generation	I-O
was	O
not	B-O
inhibited	I-O
during	O
thromboprophylaxis	O
.	O


However	O
,	O
PAI-1	B-O
activity	I-O
was	O
suppressed	O
.	O


CONCLUSION	O
D-dimer	O
offers	O
a	O
useful	O
laboratory	O
tool	O
for	O
assessing	O
early	O
and	O
late	O
clinical	O
severity	B-O
of	I-O
SAH	I-O
.	I-O


A	O
thromboprophylactic	O
dose	O
of	O
enoxaparin	B-I
inhibited	O
PAI-1	B-O
activity	I-O
but	O
failed	O
to	O
down-regulate	O
coagulation	B-O
activity	I-O
and	I-O
D-dimer	I-O
.	I-O


These	O
findings	O
are	O
compatible	O
with	O
the	O
lack	O
of	O
efficacy	O
of	O
enoxaparin	B-I
in	O
reducing	O
ischemic	O
deficit	O
after	O
SAH	O
.	O


The	O
impact	O
of	O
emotional	B-I
distress	I-I
on	O
HIV	B-O
risk	I-O
reduction	I-O
among	I-P
women	I-P
.	I-P


This	O
study	O
evaluated	O
whether	O
333	B-P
seronegative	I-P
African	I-P
American	I-P
female	I-P
drug	I-P
users	I-P
(	I-P
aged	I-P
18-59	I-P
years	I-P
)	I-P
participating	I-P
in	I-P
an	I-P
HIV	I-I
intervention	I-I
and	I-P
with	I-P
higher	I-P
levels	I-P
of	I-P
emotional	I-P
distress	I-P
,	I-P
specifically	I-P
symptoms	I-P
of	I-P
depression	I-P
and	I-P
anxiety	I-P
,	O
reduced	O
HIV	O
risk	O
behaviors	O
to	O
a	O
lesser	O
extent	O
than	O
those	O
with	O
lower	O
levels	O
of	O
emotional	O
distress	O
.	O


Participants	B-P
were	O
recruited	B-P
between	I-P
June	I-P
1998	I-P
and	I-P
January	I-P
2001	I-P
from	I-P
inner-city	I-P
Atlanta	I-P
(	I-P
Georgia	I-P
,	I-P
U.S.	I-P
)	I-P
neighborhoods	I-P
and	O
were	O
randomly	B-P
assigned	I-P
to	I-P
one	I-P
of	I-P
two	I-P
enhanced	I-I
gender-specific	I-I
and	I-I
culturally	I-I
specific	I-I
HIV	I-I
intervention	I-I
conditions	I-P
or	O
to	O
the	O
NIDA	O
standard	O
condition	O
.	O


Participants	O
were	O
interviewed	O
at	O
baseline	O
,	O
post-intervention	O
and	O
at	O
6-month	O
follow-up	O
with	O
a	O
structured	B-I
questionnaire	I-I
including	O
information	O
on	O
sociodemographics	O
,	O
sexual	O
and	O
drug-using	O
behavior	O
,	O
and	O
psychosocial	O
characteristics	O
.	O


Despite	O
a	O
significant	O
decline	O
in	O
symptoms	O
of	O
emotional	O
distress	O
during	O
the	O
study	O
period	O
,	O
the	O
women	O
in	O
this	O
sample	O
reported	O
high	O
levels	O
of	O
depressive	B-O
and	I-O
anxiety	I-O
symptoms	I-O
at	O
baseline	O
and	O
6-month	O
follow-up	O
.	O


Higher	B-O
levels	I-O
of	I-O
emotional	I-O
distress	I-O
were	O
positively	O
associated	O
with	O
post-intervention	B-O
sexual	I-O
and	I-O
drug-taking	I-O
risk	I-O
.	I-O


Women	O
in	O
both	O
enhanced	B-I
intervention	I-I
conditions	I-I
reduced	O
their	O
sexual	B-O
and	I-O
drug-taking	I-O
risks	I-O
more	O
than	O
women	O
in	O
the	O
standard	B-I
intervention	I-I
.	I-I


Those	O
in	O
the	O
motivation	B-I
intervention	I-I
arm	O
experienced	O
a	O
greater	O
reduction	O
in	O
depressive	B-O
symptoms	I-O
,	O
accompanied	O
by	O
a	O
greater	O
reduction	O
in	O
sexual	B-O
risk	I-O
behavior	I-O
.	I-O


Findings	O
suggest	O
the	O
need	O
for	O
effective	O
interventions	O
and	O
mental	O
health	O
resources	O
among	O
subgroups	O
of	O
high-risk	B-P
women	I-P
who	I-P
may	I-P
be	I-P
most	I-P
resistant	I-P
to	I-P
behavioral	I-P
change	I-P
.	I-P


Primary	B-I
capsulectomy	I-I
,	I-I
anterior	I-I
vitrectomy	I-I
,	I-I
lensectomy	I-I
,	I-I
and	I-I
posterior	I-I
chamber	I-I
lens	I-I
implantation	I-I
in	I-P
children	I-P
:	I-P
limbal	O
versus	O
pars	O
plana	O
.	O


PURPOSE	O
To	O
compare	O
the	O
results	O
of	O
a	O
limbal	B-I
versus	O
a	O
pars	B-I
plana	I-I
approach	I-I
for	O
primary	B-I
posterior	I-I
capsulectomy	I-I
and	I-I
anterior	I-I
vitrectomy	I-I
in	O
the	O
management	O
of	O
childhood	B-O
cataract	I-O
.	I-O


SETTING	O
Department	O
of	O
Ophthalmology	O
,	O
Labbafinejad	O
Medical	O
Center	O
,	O
Tehran	O
,	O
Iran	O
.	O


METHODS	O
A	O
randomized	O
,	O
controlled	O
,	O
double-masked	O
clinical	O
trial	O
of	O
45	B-P
eyes	I-P
was	O
conducted	O
.	O


After	O
being	O
matched	O
,	O
38	B-P
eyes	I-P
were	I-P
included	I-P
in	O
the	O
study	O
and	O
were	O
divided	O
into	O
2	O
equal	O
groups	O
for	O
data	O
analysis	O
.	O


All	B-P
eyes	I-P
had	I-P
lensectomy	I-I
and	I-I
posterior	I-I
chamber	I-I
intraocular	I-I
lens	I-I
(	I-I
PC	I-I
IOL	I-I
)	I-I
implantation	I-I
.	I-I


Primary	B-I
posterior	I-I
capsulectomy	I-I
and	I-I
anterior	I-I
vitrectomy	I-I
were	O
performed	O
through	O
the	O
limbus	O
in	O
half	O
of	O
the	O
eyes	O
and	O
the	O
pars	O
plana	O
in	O
the	O
other	O
half	O
.	O


Main	O
outcome	O
measures	O
included	O
visual	B-O
acuity	I-O
,	I-O
estimated	I-O
red	I-O
reflex	I-O
,	I-O
postsurgical	I-O
inflammatory	I-O
reaction	I-O
,	I-O
corneal	I-O
clarity	I-O
,	I-O
posterior	I-O
synechias	I-O
,	I-O
iris	I-O
capture	I-O
,	I-O
IOL	I-O
position	I-O
,	I-O
capsulectomy	I-O
size	I-O
,	I-O
glaucoma	I-O
,	I-O
cystoid	I-O
macular	I-O
edema	I-O
,	I-O
retinal	I-O
tear	I-O
,	I-O
and	I-O
postoperative	I-O
refraction	I-O
.	I-O


RESULTS	O
No	O
statistically	O
significant	O
differences	O
were	O
found	O
between	O
the	O
2	O
approaches	O
in	O
the	O
outcome	O
measures	O
.	O


CONCLUSION	O
The	O
anatomic	O
and	O
visual	O
results	O
were	O
encouraging	O
when	O
posterior	B-I
capsulectomy	I-I
and	I-I
anterior	I-I
vitrectomy	I-I
,	O
using	O
a	O
limbal	O
or	O
pars	O
plana	O
approach	O
,	O
were	O
combined	O
with	O
lensectomy	B-I
and	I-I
PC	I-I
IOL	I-I
implantation	I-I
in	O
children	B-P
.	I-P


The	O
application	O
of	O
these	O
techniques	O
depends	O
on	O
surgeon	O
experience	O
and	O
skill	O
.	O


Treatment	B-P
of	I-P
bladder	I-P
cancer	I-P
with	I-P
intravesical	I-P
instillation	I-P
of	I-P
adriamycin	I-I
.	I-I


Intravesical	O
treatment	O
with	O
adriamycin	B-I
has	O
been	O
extensively	O
employed	O
in	O
the	O
last	O
decade	O
.	O


In	O
the	O
treatment	O
of	O
carcinoma	O
in	O
situ	O
complete	O
responses	O
have	O
been	O
reported	O
in	O
about	O
60	O
%	O
of	O
cases	O
.	O


Its	O
efficacy	B-O
is	O
probably	O
lower	O
in	O
the	O
therapy	O
of	O
multiple	O
or	O
diffuse	O
low	O
stage	O
transitional	O
cell	O
carcinoma	O
that	O
is	O
too	O
extensive	O
to	O
be	O
completely	O
resected	O
by	O
conventional	O
transurethral	O
surgery	O
.	O


In	O
such	O
circumstances	O
,	O
including	O
cancer	O
in	O
situ	O
,	O
adriamycin	B-I
compares	O
favorably	O
with	O
other	O
local	O
forms	O
of	O
treatment	O
.	O


The	O
prophylactic	O
use	O
of	O
intravesical	O
instillation	O
of	O
Adriamycin	B-I
has	O
been	O
studied	O
more	O
extensively	O
.	O


Preliminary	O
results	O
of	O
controlled	O
randomized	O
trials	O
implemented	O
from	O
the	O
EORTC	O
Urological	O
Group	O
show	O
that	O
adriamycin	B-I
instillations	O
significantly	O
reduce	O
recurrence	B-O
rate	I-O
after	I-O
TUR	I-O
.	I-O


The	O
treatment	O
is	O
well	O
tolerated	B-O
.	I-O


Systemic	B-O
absorption	I-O
is	O
virtually	O
absent	O
,	O
and	O
no	B-O
severe	I-O
drug-related	I-O
side	I-O
effects	I-O
have	O
ever	O
been	O
reported	O
.	O


Chemical	B-O
cystitis	I-O
is	O
occasionally	O
observed	O
,	O
especially	O
if	O
multiple	O
instillations	O
are	O
started	O
immediately	O
after	O
TUR	O
,	O
or	O
in	O
the	O
presence	O
of	O
additional	O
inflammatory	O
conditions	O
,	O
such	O
as	O
previous	O
irradiation	O
or	O
bacterial	O
cystitis	O
.	O


A	O
randomized	O
trial	O
of	O
an	O
interim	O
methadone	B-I
maintenance	I-P
clinic	O
.	O


BACKGROUND	O
Interim	O
methadone	B-I
maintenance	O
has	O
been	O
proposed	O
as	O
a	O
method	O
of	O
providing	O
clinically	B-O
effective	I-O
services	O
to	O
heroin	B-P
addicts	I-P
waiting	I-P
for	I-P
treatment	I-P
in	I-P
standard	I-P
comprehensive	I-P
methadone	I-P
maintenance	I-P
programs	I-P
.	I-P


METHODS	O
A	O
clinic	O
that	O
provided	O
initial	O
medical	O
evaluation	O
,	O
methadone	O
medication	O
,	O
and	O
AIDS	O
education	O
,	O
but	O
did	O
not	O
include	O
formal	O
drug	O
abuse	O
counseling	O
or	O
other	O
social	O
support	O
services	O
was	O
established	O
in	O
New	B-P
York	I-P
City	I-P
.	I-P


A	B-P
sample	I-P
of	I-P
301	I-P
volunteer	I-P
subjects	I-P
recruited	I-P
from	I-P
the	I-P
waiting	I-P
list	I-P
for	I-P
treatment	I-P
in	I-P
the	I-P
Beth	I-P
Israel	I-P
methadone	I-I
program	I-P
were	O
randomly	O
assigned	O
to	O
immediate	O
entry	O
into	O
the	O
interim	B-I
clinic	I-I
or	I-I
a	I-I
control	I-I
group	I-I
.	I-I


RESULTS	O
There	O
were	O
no	O
differences	O
in	O
initial	O
levels	B-O
of	I-O
illicit	I-O
drug	I-O
use	I-O
across	O
the	O
experimental	O
and	O
control	O
groups	O
.	O


One-month	O
urinalysis	O
follow-up	O
data	O
showed	O
a	O
significant	O
reduction	B-O
in	I-O
heroin	I-O
use	I-O
in	O
the	O
experimental	O
group	O
(	O
from	O
63	O
%	O
positive	O
at	O
intake	O
to	O
29	O
%	O
positive	O
)	O
with	O
no	O
change	O
in	O
the	O
control	O
group	O
(	O
62	O
%	O
to	O
60	O
%	O
positive	O
)	O
.	O


No	O
significant	O
change	O
was	O
observed	O
in	O
cocaine	B-O
urinalyses	I-O
(	O
approximately	O
70	O
%	O
positive	O
for	O
both	O
groups	O
at	O
intake	O
and	O
follow-up	O
)	O
.	O


A	O
higher	O
percentage	O
of	O
the	O
experimental	O
group	O
were	O
in	O
treatment	O
at	O
16-month	O
follow-up	O
(	O
72	O
%	O
vs	O
56	O
%	O
)	O
.	O


CONCLUSIONS	O
Limited	O
services	O
interim	O
methadone	O
maintenance	O
can	O
reduce	O
heroin	B-O
use	I-O
among	O
persons	B-P
awaiting	I-P
entry	I-P
into	I-P
comprehensive	I-P
treatment	I-P
and	O
increase	O
the	O
percentage	O
entering	O
treatment	O
.	O


Short-term	B-I
amiodarone	I-I
therapy	I-I
after	O
reversion	O
of	O
persistent	B-P
atrial	I-P
fibrillation	I-P
reduces	O
recurrences	B-O
at	O
18	O
months	O
.	O


BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
outcome	B-O
of	O
3	O
months	O
vs.	O
18	O
months	O
of	O
amiodarone	B-I
treatment	O
after	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
conversion	O
in	O
patients	B-P
who	O
experienced	O
the	O
first	O
episode	O
of	O
persistent	O
AF	O
.	O


METHODS	O
We	O
included	O
51	B-P
patients	I-P
who	I-P
experienced	I-P
the	I-P
first	I-P
episode	I-P
of	I-P
persistent	I-P
AF	I-P
receiving	I-P
amiodarone	I-I
(	I-P
600	I-P
mg	I-P
)	I-P
daily	I-P
for	I-P
4-6	I-P
weeks	I-P
.	I-P


If	O
AF	O
persisted	O
,	O
electrical	B-I
cardioversion	I-I
(	I-I
ECV	I-I
)	I-I
was	O
performed	O
.	O


All	O
patients	O
received	O
amiodarone	B-I
(	O
200	O
mg	O
daily	O
)	O
for	O
3	O
months	O
and	O
then	O
were	O
randomized	O
to	O
amiodarone	B-I
(	O
Group	O
I	O
)	O
or	B-I
placebo	I-I
(	O
Group	O
II	O
)	O
and	O
followed	O
for	O
15	O
months	O
.	O


The	O
control	B-P
group	I-P
comprised	O
9	O
untreated	O
patients	B-P
undergoing	O
ECV	B-I
.	I-I


Treatment	O
effectiveness	B-O
was	O
evaluated	O
using	O
a	O
Bayesian	O
model	O
.	O


RESULTS	O
Eighteen	O
months	O
after	O
AF	O
reversion	O
,	O
22	O
(	O
81.5	O
%	O
)	O
patients	O
in	O
Group	O
I	O
,	O
13	O
(	O
54.2	O
%	O
)	O
patients	O
in	O
Group	O
II	O
,	O
and	O
1	O
(	O
11.1	O
%	O
)	O
patient	O
in	O
the	O
control	O
group	O
remained	B-O
in	I-O
sinus	I-O
rhythm	I-O
.	I-O


No	O
differences	O
were	O
found	O
between	O
Group	O
I	O
patients	O
who	O
required	O
ECV	B-I
and	O
Group	O
II	O
patients	O
.	O


Sinus	B-O
rhythm	I-O
was	O
preserved	O
in	O
all	O
Group	O
I	O
patients	O
when	O
it	O
was	O
achieved	O
during	O
amiodarone	O
administration	O
.	O


Limiting	B-O
adverse	I-O
effects	I-O
occurred	O
in	O
3	O
(	O
11.1	O
%	O
)	O
patients	O
in	O
Group	O
I	O
.	O


CONCLUSIONS	O
In	O
patients	O
regaining	O
sinus	O
rhythm	O
after	O
the	O
first	O
episode	O
of	O
persistent	O
AF	O
,	O
a	O
3-month	O
amiodarone	B-I
treatment	O
after	O
reversion	O
is	O
a	O
reasonable	O
option	O
for	O
rhythm	O
control	O
.	O


Pilot	O
study	O
of	O
Panax	B-I
quinquefolius	I-I
(	I-I
American	I-I
ginseng	I-I
)	I-I
to	O
improve	O
cancer-related	B-P
fatigue	I-P
:	I-P
a	O
randomized	O
,	O
double-blind	O
,	O
dose-finding	O
evaluation	O
:	O
NCCTG	O
trial	O
N03CA	O
.	O


PURPOSE	O
This	O
pilot	O
trial	O
sought	O
to	O
investigate	O
whether	O
any	O
of	O
three	O
doses	O
of	O
American	B-I
ginseng	I-I
(	I-I
Panax	I-I
quinquefolius	I-I
)	I-I
might	O
help	O
cancer-related	B-P
fatigue	I-P
.	I-P


A	O
secondary	O
aim	O
was	O
to	O
evaluate	O
toxicity	O
.	O


METHODS	O
Eligible	B-P
adults	I-P
with	I-P
cancer	I-P
were	O
randomized	O
in	O
a	O
double-blind	O
manner	O
,	O
to	O
receive	O
American	B-I
ginseng	I-I
in	O
doses	O
of	O
750	O
,	O
1,000	O
,	O
or	O
2,000	O
mg/day	O
or	O
placebo	B-I
given	O
in	O
twice	O
daily	O
dosing	O
over	O
8	O
weeks	O
.	O


Outcome	O
measures	O
included	O
the	O
Brief	B-O
Fatigue	I-O
Inventory	I-O
,	I-O
vitality	I-O
subscale	I-O
of	I-O
the	I-O
Medical	I-O
Outcome	I-O
Scale	I-O
Short	I-O
Form-36	I-O
(	I-O
SF-36	I-O
)	I-O
,	I-O
and	I-O
the	I-O
Global	I-O
Impression	I-O
of	I-O
Benefit	I-O
Scale	I-O
at	O
4	O
and	O
8	O
weeks	O
.	O


RESULTS	O
Two	B-P
hundred	I-P
ninety	I-P
patients	I-P
were	I-P
accrued	I-P
to	I-P
this	I-P
trial	I-P
.	I-P


Nonsignificant	O
trends	O
for	O
all	O
outcomes	O
were	O
seen	O
in	O
favor	O
of	O
the	O
1,000-	O
and	O
2,000-mg/day	O
doses	O
of	O
American	B-I
ginseng	I-I
.	I-I


Area	O
under	O
the	O
curve	O
analysis	O
of	O
activity	B-O
interference	I-O
from	I-O
the	I-O
Brief	I-O
Fatigue	I-O
Inventory	I-O
was	O
460-467	O
in	O
the	O
placebo	B-I
group	O
and	O
750	O
mg/day	O
group	O
versus	O
480-551	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
,	O
respectively	O
.	O


Change	O
from	O
baseline	O
in	O
the	O
vitality	B-O
subscale	I-O
of	O
the	O
SF-36	O
was	O
7.3-7.8	O
in	O
the	O
placebo	B-I
and	O
the	O
750-mg/day	O
arm	O
,	O
versus	O
10.5-14.6	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
.	O


Over	O
twice	O
as	O
many	O
patients	O
on	O
ginseng	B-I
perceived	O
a	O
benefit	O
and	O
were	O
satisfied	B-O
with	O
treatment	O
over	O
those	O
on	O
placebo	B-I
.	I-I


There	O
were	O
no	O
significant	O
differences	O
in	O
any	O
measured	O
toxicities	B-O
between	O
any	O
of	O
the	O
arms	O
.	O


CONCLUSION	O
There	O
appears	O
to	O
be	O
some	O
activity	O
and	O
tolerable	O
toxicity	O
at	O
1,000-2,000	O
mg/day	O
doses	O
of	O
American	B-I
ginseng	I-I
with	O
regard	O
to	O
cancer-related	B-P
fatigue	I-P
.	I-P


Thus	O
,	O
further	O
study	O
of	O
American	B-I
ginseng	I-I
is	O
warranted	O
.	O


The	O
effect	O
of	O
coenzyme	B-I
Q10	I-I
on	O
microcirculatory	B-O
endothelial	I-O
function	I-O
of	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	I-P


Mortality	B-O
in	O
patients	B-P
with	I-P
small	I-P
choroidal	I-P
melanoma	I-P
.	I-P


COMS	O
report	O
no	O
.	O


4	O
.	O


The	O
Collaborative	O
Ocular	O
Melanoma	O
Study	O
Group	O
.	O


OBJECTIVE	O
To	O
describe	O
the	O
clinical	O
characteristics	O
and	O
survival	O
experience	O
of	O
a	O
prospectively	O
followed	O
up	O
group	O
of	O
patients	B-P
with	I-P
small	I-P
choroidal	I-P
melanoma	I-P
.	I-P


METHODS	O
The	O
Collaborative	O
Ocular	O
Melanoma	O
Study	O
(	O
COMS	O
)	O
is	O
a	O
set	O
of	O
clinical	O
trials	O
designed	O
to	O
compare	O
the	O
role	O
of	O
radiotherapy	B-I
and	O
enucleation	B-I
in	O
the	O
treatment	O
of	O
medium	O
and	O
large-size	O
choroidal	O
melanoma	O
.	O


From	B-P
December	I-P
1986	I-P
to	I-P
August	I-P
1989	I-P
,	I-P
patients	I-P
with	I-P
small	I-P
choroidal	I-P
melanoma	I-P
,	I-P
not	I-P
large	I-P
enough	I-P
to	I-P
be	I-P
eligible	I-P
for	I-P
the	I-P
COMS	I-P
clinical	I-P
trials	I-P
,	O
were	O
offered	O
participation	O
in	O
a	O
nonrandomized	O
prospective	O
follow-up	O
study	O
.	O


Small	O
choroidal	O
melanomas	O
were	O
defined	O
as	O
1.0	O
to	O
3.0	O
mm	O
in	O
apical	O
height	O
and	O
at	O
least	O
5.0	O
mm	O
in	O
basal	O
diameter	O
.	O


A	B-P
total	I-P
of	I-P
204	I-P
patients	I-P
were	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Patients	O
were	O
followed	O
up	O
annually	O
through	O
August	O
1989	O
.	O


Two	O
additional	O
assessments	O
of	O
treatment	O
status	O
and	O
mortality	B-O
were	O
conducted	O
in	O
1993-1994	O
and	O
1995-1996	O
.	O


The	O
median	B-O
length	I-O
of	O
follow-up	O
was	O
92	O
months	O
.	O


Eight	O
percent	O
of	O
patients	O
were	O
treated	O
at	O
the	O
time	O
of	O
study	O
enrollment	O
and	O
an	O
additional	O
33	O
%	O
were	O
treated	O
during	O
follow-up	O
.	O


RESULTS	O
Twenty-seven	O
patients	O
have	O
died	B-O
;	I-O
6	O
deaths	B-O
were	O
reported	O
by	O
the	O
clinical	O
center	O
as	O
due	O
to	O
metastatic	B-O
melanoma	I-O
.	I-O


The	O
Kaplan-Meier	O
estimate	O
of	O
5-year	O
all-cause	O
mortality	B-O
was	O
6.0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
2.7	O
%	O
-9.3	O
%	O
)	O
and	O
8-year	O
all-cause	O
mortality	B-O
was	O
14.9	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
9.6	O
%	O
-20.2	O
%	O
)	O
.	O


CONCLUSIONS	O
Otherwise	B-P
healthy	I-P
patients	I-P
,	I-P
average	I-P
age	I-P
of	I-P
60	I-P
years	I-P
,	I-P
without	I-P
a	I-P
previous	I-P
diagnosis	I-P
of	I-P
malignant	I-P
disease	I-P
who	I-P
have	I-P
small	I-P
choroidal	I-O
lesions	I-O
judged	I-P
to	I-P
be	I-P
melanoma	I-P
have	O
a	O
low	O
risk	O
of	O
dying	O
within	O
5	O
years	O
.	O


A	O
comparative	O
study	O
of	O
ofloxacin	B-I
and	O
cefixime	B-I
for	O
treatment	O
of	O
typhoid	B-P
fever	I-P
in	I-P
children	I-P
.	I-P


The	O
Dong	B-P
Nai	I-P
Pediatric	I-P
Center	I-P
Typhoid	O
Study	O
Group	O
.	O


BACKGROUND	O
Despite	O
concerns	O
about	O
safety	O
in	O
children	O
,	O
fluoroquinolone	B-I
antibiotics	I-I
have	O
become	O
the	O
treatment	O
of	O
choice	O
in	O
patients	B-P
with	I-P
multidrug-resistant	I-P
typhoid	I-P
fever	I-P
in	I-P
Vietnam	I-P
.	I-P


However	O
,	O
quinolone-resistant	O
strains	O
of	O
Salmonella	O
typhi	O
have	O
recently	O
been	O
reported	O
from	O
Vietnam	O
;	O
and	O
if	O
quinolone	O
resistance	O
becomes	O
established	O
,	O
alternative	O
oral	O
treatment	O
options	O
will	O
be	O
needed	O
.	O


OBJECTIVE	O
Cefixime	B-I
,	O
an	O
orally	O
administered	O
third	O
generation	O
cephalosporin	B-I
,	O
was	O
compared	O
with	O
ofloxacin	B-I
for	O
the	O
treatment	O
of	O
uncomplicated	O
typhoid	O
fever	O
in	O
children	O
.	O


METHODS	O
In	B-P
an	I-P
open	I-P
trial	I-P
children	I-P
with	I-P
suspected	I-P
typhoid	I-P
fever	I-P
were	O
randomized	O
to	O
receive	O
either	O
ofloxacin	B-I
(	O
10	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
)	O
for	O
5	O
days	O
or	O
cefixime	B-I
(	O
20	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
)	O
for	O
7	O
days	O
.	O


RESULTS	O
S.	O
typhi	O
was	O
isolated	O
from	O
82	B-P
patients	I-P
(	I-P
44	I-P
in	I-P
the	I-P
cefixime	I-I
group	I-P
,	I-P
38	I-P
in	I-P
the	I-P
ofloxacin	I-I
group	I-P
)	I-P
and	I-P
70	I-P
(	I-P
85	I-P
%	I-P
)	I-P
of	I-P
the	I-P
isolates	I-P
were	I-P
multidrug-resistant	I-P
.	I-P


Median	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
range	O
)	O
fever	B-O
clearance	I-O
times	I-O
were	O
4.4	O
(	O
4	O
to	O
5.2	O
,	O
0.2	O
to	O
9.9	O
)	O
days	O
for	O
ofloxacin	B-I
recipients	O
and	O
8.5	O
(	O
4.2	O
to	O
9	O
,	O
1.8	O
to	O
15.2	O
)	O
days	O
for	O
cefixime-treated	B-I
patients	I-P
(	O
P	O
<	O
0.0001	O
)	O
.	O


There	O
were	O
11	O
treatment	B-O
failures	I-O
(	O
10	O
acute	O
and	O
one	O
relapse	O
)	O
in	O
the	O
cefixime	B-I
group	O
and	O
1	O
acute	B-O
treatment	I-O
failure	I-O
in	O
the	O
ofloxacin	B-I
group	O
(	O
mean	O
difference	O
,	O
22	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
9	O
to	O
36	O
%	O
)	O
.	O


CONCLUSION	O
Short	O
course	O
treatment	O
with	O
cefixime	B-I
may	O
provide	O
a	O
useful	O
alternative	O
treatment	O
in	O
cases	O
of	O
uncomplicated	B-P
typhoid	I-P
fever	I-P
in	I-P
children	I-P
,	O
but	O
it	O
is	O
less	O
effective	O
than	O
short	O
course	O
treatment	O
with	O
ofloxacin	B-I
.	I-I


Is	O
successful	O
rehabilitation	O
of	O
complex	B-P
regional	I-P
pain	I-P
syndrome	I-P
due	O
to	O
sustained	O
attention	O
to	O
the	O
affected	O
limb	O
?	O
A	O
randomised	O
clinical	O
trial	O
.	O


In	O
complex	O
regional	O
pain	O
syndrome	O
(	O
CRPS1	O
)	O
initiated	O
by	O
wrist	O
fracture	O
,	O
a	O
motor	B-I
imagery	I-I
program	I-I
(	O
MIP	O
)	O
,	O
consisting	O
of	O
hand	O
laterality	O
recognition	O
followed	O
by	O
imagined	B-I
movements	I-I
and	O
then	O
mirror	B-I
movements	I-I
,	O
reduces	O
pain	B-O
and	I-O
disability	I-O
,	O
but	O
the	O
mechanism	O
of	O
effect	O
is	O
unclear	O
.	O


Possibilities	O
include	O
sustained	O
attention	O
to	O
the	O
affected	O
limb	O
,	O
in	O
which	O
case	O
the	O
order	O
of	O
MIP	O
components	O
would	O
not	O
alter	O
the	O
effect	O
,	O
and	O
sequential	O
activation	O
of	O
cortical	O
motor	O
networks	O
,	O
in	O
which	O
case	O
it	O
would	O
.	O


Twenty	B-P
subjects	I-P
with	I-P
chronic	I-P
CRPS1	I-P
initiated	I-P
by	I-P
wrist	I-P
fracture	I-P
and	I-P
who	I-P
satisfied	I-P
stringent	I-P
inclusion	I-P
criteria	I-P
,	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
:	O
hand	B-I
laterality	I-I
recognition	I-I
,	I-I
imagined	I-I
movements	I-I
,	I-I
mirror	I-I
movements	I-I
(	I-I
RecImMir	I-I
,	I-I
MIP	I-I
)	I-I
;	I-I
imagined	I-I
movements	I-I
,	I-I
recognition	I-I
,	I-I
imagined	I-I
movements	I-I
(	I-I
ImRecIm	I-I
)	I-I
;	I-I
recognition	I-I
,	I-I
mirror	I-I
movements	I-I
,	I-I
recognition	I-I
(	I-I
RecMirRec	I-I
)	I-I
.	I-I


At	O
6	O
and	O
18	O
weeks	O
,	O
reduced	O
pain	B-O
and	I-O
disability	I-O
were	O
greater	O
for	O
the	O
RecImMir	O
group	O
than	O
for	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Hand	O
laterality	O
recognition	O
imparted	O
a	O
consistent	O
reduction	O
in	O
pain	B-O
and	I-O
disability	I-O
across	O
groups	O
,	O
however	O
,	O
this	O
effect	O
was	O
limited	O
in	O
magnitude	O
.	O


Imagined	O
movements	O
imparted	O
a	O
further	O
reduction	O
in	O
pain	B-O
and	I-O
disability	I-O
,	O
but	O
only	O
if	O
they	O
followed	O
hand	O
laterality	O
recognition	O
.	O


Mirror	O
movements	O
also	O
imparted	O
a	O
reduction	O
in	O
pain	B-O
and	I-O
disability	I-O
,	O
but	O
only	O
when	O
they	O
followed	O
imagined	O
movements	O
.	O


The	O
effect	B-O
of	O
the	O
MIP	O
seems	O
to	O
be	O
dependent	O
on	O
the	O
order	O
of	O
components	O
,	O
which	O
suggests	O
that	O
it	O
is	O
not	O
due	O
to	O
sustained	O
attention	O
to	O
the	O
affected	O
limb	O
,	O
but	O
is	O
consistent	O
with	O
sequential	O
activation	O
of	O
cortical	O
motor	O
networks	O
.	O


Confidential	B-I
registration	I-I
in	O
health	O
services	O
:	O
randomised	O
controlled	O
trial	O
.	O


BACKGROUND	O
Human	O
rights	O
legislation	O
safeguards	O
the	O
privacy	O
and	O
dignity	O
of	O
patients	B-P
.	I-P


OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
in	O
terms	O
of	O
patient	O
assessed	O
privacy	O
of	O
confidential	B-I
registration	I-I
.	I-I


DESIGN	O
Randomised	O
controlled	O
trial	O
.	O


SETTING	O
Emergency	B-P
Department	I-P
,	I-P
University	I-P
Hospital	I-P
of	I-P
Wales	I-P
.	I-P


PARTICIPANTS	O
A	B-P
total	I-P
of	I-P
302	I-P
patients	I-P
aged	I-P
over	I-P
15	I-P
years	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Binary	B-I
choices	I-I
and	O
ordinal	B-I
visual	I-I
analogue	I-I
scores	O
from	O
a	O
validated	B-I
questionnaire	I-I
on	I-I
self	I-I
reported	I-I
measures	I-I
:	I-I
patient	I-O
ability	I-O
and	I-O
preference	I-O
to	I-O
speak	I-O
to	I-O
receptionists	I-O
and	I-O
disclose	I-O
confidential	I-O
information	I-O
without	I-O
being	I-O
overhead	I-O
and	I-O
concern	I-O
about	I-O
disclosure	I-O
of	I-O
items	I-O
of	I-O
confidential	I-O
personal	I-O
information	I-O
.	I-O


RESULTS	O
Patients	O
who	O
registered	O
in	O
a	O
screened	B-I
area	I-I
felt	O
significantly	O
more	O
able	O
to	O
tell	B-O
receptionists	I-O
things	I-O
they	I-O
did	I-O
not	I-O
want	I-O
others	I-O
to	I-O
hear	I-O
.	I-O


Control	O
patients	O
were	O
significantly	O
more	O
concerned	O
than	O
intervention	O
patients	O
that	O
others	B-O
heard	I-O
their	I-O
name	I-O
,	I-O
address	I-O
,	I-O
date	I-O
of	I-O
birth	I-O
,	I-O
reason	I-O
for	I-O
emergency	I-O
department	I-O
attendance	I-O
,	I-O
and	I-O
telephone	I-O
number	I-O
,	I-O
but	I-O
not	I-O
their	I-O
marital	I-O
status	I-O
.	I-O


Overall	O
,	O
intervention	O
patients	O
were	O
less	O
concerned	O
about	O
disclosure	B-O
of	I-O
information	I-O
and	O
that	O
they	O
had	O
been	O
overheard	O
.	O


CONCLUSIONS	O
Patients	O
value	O
privacy	O
when	O
they	O
register	O
and	O
are	O
concerned	O
if	O
others	O
can	O
hear	O
them	O
tell	O
receptionists	O
who	O
they	O
are	O
,	O
how	O
to	O
contact	O
them	O
,	O
and	O
why	O
they	O
are	O
there	O
.	O


Confidential	B-I
registration	I-I
should	O
be	O
instituted	O
in	O
health	O
services	O
.	O


Confidential	B-I
registration	I-I
increased	O
patient	O
privacy	O
and	O
should	O
be	O
instituted	O
in	O
health	O
services	O
.	O


Early	O
effects	O
of	O
continuous	O
low-dosage	O
all-norgestrel	B-I
administered	O
alone	O
or	O
with	O
estrogen	O
.	O


Twenty-six	B-P
postmenopausal	I-P
women	I-P
participated	O
in	O
a	O
double-blind	O
trial	O
involving	O
treatment	O
according	O
to	O
a	O
Latin	O
square	O
design	O
with	O
either	O
(	O
i	O
)	O
dl-norgestrel	B-I
alone	I-I
(	O
0.075	O
mg/day	O
)	O
continuously	O
for	O
two	O
cycles	O
,	O
(	O
ii	O
)	O
estradiol-17	B-I
beta	I-I
alone	I-I
(	O
1	O
mg	O
on	O
25	O
of	O
28	O
days	O
)	O
for	O
two	O
cycles	O
,	O
or	O
(	O
iii	O
)	O
the	O
combined	B-I
hormones	I-I
for	O
six	O
cycles	O
.	O


A	O
placebo	B-I
control	I-I
cycle	O
followed	O
each	O
hormonal	O
treatment	O
.	O


Plasma	B-O
triglycerides	I-O
decreased	I-O
by	O
an	O
average	O
22	O
%	O
during	O
treatment	O
with	O
either	O
dl-norgestrel	B-I
alone	O
(	O
123	O
+/-	O
11	O
vs.	O
160	O
+/-	O
10	O
mg/dl	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.005	O
)	O
or	O
combination	O
therapy	O
(	O
126	O
+/-	O
11	O
vs.	O
162	O
+/-	O
11	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.005	O
)	O
as	O
compared	O
with	O
control	O
.	O


Plasma	B-O
total	I-O
cholesterol	I-O
fell	O
by	O
5	O
%	O
during	O
two	O
cycles	O
of	O
treatment	O
with	O
either	O
dl-norgestrel	B-I
alone	O
(	O
229	O
+/-	O
11	O
vs.	O
242	O
+/-	O
10	O
mg/dl	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.02	O
)	O
or	O
combination	O
therapy	O
(	O
233	O
+/-	O
11	O
vs.	O
246	O
+/-	O
10	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.05	O
)	O
versus	O
placebo	O
.	O


During	O
the	O
fifth	O
and	O
sixth	O
cycles	O
of	O
combination	O
therapy	O
94	O
%	O
of	O
cycles	O
were	O
free	B-O
of	I-O
flushing	I-O
(	O
vs.	O
31	O
%	O
for	O
control	O
,	O
P	O
<	O
0.01	O
)	O
,	O
64	O
%	O
of	O
cycles	O
were	O
free	B-O
of	I-O
spotting	I-O
not	I-O
requiring	I-O
protection	I-O
(	O
control	O
75	O
%	O
)	O
,	O
96	O
%	O
of	O
cycles	O
were	O
free	B-O
of	I-O
vaginal	I-O
bleeding	I-O
(	O
control	O
100	O
%	O
)	O
,	O
endometrial	O
biopsy	O
showed	O
inactive	B-O
endometrium	I-O
in	O
nine	O
of	O
the	O
10	O
subjects	O
re-biopsied	O
,	O
fasting	B-O
blood	I-O
pyruvate	I-O
decreased	I-O
by	O
20	O
%	O
(	O
P	O
<	O
0.05	O
)	O
and	O
diastolic	B-O
blood	I-O
pressure	I-O
fell	I-O
by	O
4	O
%	O
compared	O
with	O
control	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
glucose	B-O
tolerance	I-O
was	I-O
unchanged	I-O
.	I-O


There	O
was	O
a	O
significant	O
reduction	O
in	O
vasomotor	B-O
flushing	I-O
beginning	O
with	O
the	O
third	O
to	O
fourth	O
cycles	O
of	O
combination	O
therapy	O
.	O


Rational-emotive	B-I
therapy	I-I
and	O
the	O
reduction	O
of	O
interpersonal	B-O
anxiety	I-O
in	O
junior	B-P
high	I-P
school	I-P
students	I-P
.	I-P


This	O
study	O
evaluated	O
the	O
effectiveness	O
of	O
rational-emotive	B-I
therapy	I-I
and	I-I
rational-emotive	I-I
imagery	I-I
.	I-I


Fifty-nine	B-P
junior	I-P
high	I-P
school	I-P
students	I-P
who	I-P
volunteered	I-P
to	I-P
participate	I-P
in	I-P
treatment	I-P
for	I-P
interpersonal	I-O
anxiety	I-O
were	O
randomly	O
assigned	O
to	O
rational-emotive	B-I
therapy	I-I
without	I-I
imagery	I-I
(	I-I
RET	I-I
)	I-I
,	I-I
rational-emotive	I-I
therapy	I-I
with	I-I
imagery	I-I
(	I-I
REI	I-I
)	I-I
,	I-I
relationship-oriented	I-I
counseling	I-I
(	I-I
ROC	I-I
)	I-I
,	I-I
and	I-I
waiting-list	I-I
control	I-I
(	I-I
WLC	I-I
)	I-I
groups	I-I
.	I-I


Groups	O
met	O
for	O
seven	O
50-minute	O
treatment	O
sessions	O
during	O
a	O
three-week	O
period	O
.	O


Assessments	O
were	O
conducted	O
at	O
pretreatment	O
,	O
posttreatment	O
,	O
and	O
three-week	O
follow-up	O
.	O


Both	O
self-report	B-O
and	I-O
sociometric	I-O
measures	I-O
were	O
used	O
to	O
evaluate	O
treatment	O
outcome	O
.	O


At	O
postassessment	O
,	O
both	O
the	O
RET	O
and	O
REI	O
groups	O
were	O
rated	O
on	O
sociometric	B-O
measures	I-O
as	O
significantly	B-O
less	I-O
interpersonally	I-O
anxious	I-O
than	O
the	O
WLC	O
group	O
.	O


Mean	B-O
scores	I-O
favored	O
the	O
RET	O
and	O
REI	O
groups	O
,	O
but	O
no	O
significant	O
differences	O
between	O
these	O
groups	O
and	O
the	O
ROC	O
group	O
were	O
obtained	O
.	O


The	O
self-report	B-O
measure	I-O
did	O
not	O
significantly	O
differentiate	O
between	O
groups	O
,	O
but	O
the	O
REI	O
group	O
demonstrated	O
significant	O
pre-	O
to	O
follow-up	O
changes	O
.	O


Both	O
the	O
RET	O
and	O
REI	O
groups	O
yielded	O
greater	O
reductions	B-O
in	I-O
irrational	I-O
thinking	I-O
than	O
did	O
the	O
ROC	O
and	O
WLC	O
groups	O
.	O


In	O
addition	O
,	O
the	O
pattern	O
of	O
the	O
results	O
supported	O
the	O
use	O
of	O
rational-emotive	B-I
imagery	I-I
as	O
a	O
component	O
of	O
rational-emotive	B-I
therapy	I-I
.	I-I


The	O
practical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O


Cost-effectiveness	O
of	O
clopidogrel	B-I
in	O
acute	B-P
coronary	I-P
syndromes	I-P
in	I-P
Canada	I-P
:	I-P
a	O
long-term	O
analysis	O
based	O
on	O
the	O
CURE	O
trial	O
.	O


BACKGROUND	O
Cardiovascular	O
diseases	O
account	O
for	O
nearly	O
20	O
%	O
of	O
all	O
hospitalizations	O
in	O
Canada	O
and	O
consume	O
12	O
%	O
of	O
the	O
total	O
cost	O
of	O
all	O
illnesses	O
.	O


With	O
increasing	O
trends	O
of	O
cardiovascular	O
disease	O
and	O
increasing	O
costs	O
of	O
care	O
,	O
development	O
of	O
cost-effective	O
strategies	O
is	O
vital	O
.	O


The	O
Clopidogrel	B-I
in	O
Unstable	O
angina	O
to	O
prevent	O
Recurrent	O
Events	O
(	O
CURE	O
)	O
trial	O
demonstrated	O
the	O
effectiveness	O
of	O
clopidogrel	B-I
plus	I-I
acetylsalicylic	I-I
acid	I-I
(	I-I
ASA	I-I
)	I-I
compared	O
with	O
ASA	B-I
alone	I-I
in	O
reducing	O
cardiovascular	O
events	O
in	O
patients	B-P
with	I-P
acute	I-P
coronary	I-P
syndromes	I-P
and	I-P
,	I-P
in	I-P
addition	I-P
,	I-P
patients	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
in	I-P
the	I-P
Percutaneous	I-P
Coronary	I-P
Intervention	I-P
in	I-P
CURE	I-P
(	I-P
PCI-CURE	I-P
)	I-P
trial	I-P
.	I-P


OBJECTIVE	O
To	O
assess	O
the	O
cost-effectiveness	O
of	O
clopidogrel	B-I
in	O
the	O
Canadian	B-P
health	I-P
care	I-P
system	I-P
.	I-P


METHODS	O
Estimates	O
of	O
hospitalization	O
costs	O
were	O
based	O
on	O
the	O
2003	O
cost	O
schedules	O
released	O
by	O
the	O
Health	O
Funding	O
and	O
Costing	O
Branch	O
of	O
the	O
Alberta	O
Health	O
and	O
Wellness	O
,	O
as	O
well	O
as	O
on	O
the	O
Case	O
Mix	O
Group	O
classification	O
system	O
.	O


Life	O
expectancy	O
beyond	O
the	O
trial	O
was	O
estimated	O
from	O
the	O
Saskatchewan	O
Health	O
Database	O
.	O


Cost-effectiveness	O
was	O
expressed	O
as	O
the	O
incremental	O
cost-effectiveness	O
ratio	O
,	O
and	O
bootstrap	O
methods	O
were	O
used	O
to	O
estimate	O
the	O
joint	O
distribution	O
of	O
costs	O
and	O
effectiveness	O
.	O


RESULTS	O
Clopidogrel	B-I
was	O
shown	O
to	O
be	O
cost-effective	B-O
,	O
with	O
incremental	O
cost-effectiveness	B-O
ratios	I-O
less	O
than	O
$	O
10,000	O
per	O
event	O
prevented	B-O
and	O
less	O
than	O
$	O
4,000	O
per	O
life-year	O
gained	B-O
.	I-O


The	O
probability	O
of	O
clopidogrel	B-I
resulting	O
in	O
cost	B-O
per	I-O
life-year	I-O
gained	I-O
of	O
less	O
than	O
$	O
20,000	O
was	O
0.975	O
for	O
CURE	B-P
patients	I-P
and	O
0.904	O
for	O
PCI-CURE	B-P
patients	I-P
.	I-P


CONCLUSIONS	O
The	O
economic	O
analysis	O
demonstrated	O
that	O
clopidogrel	B-I
combination	I-I
therapy	I-I
is	O
not	O
only	O
cost-effective	O
as	O
antiplatelet	O
therapy	O
compared	O
with	O
ASA	B-I
alone	O
,	O
but	O
it	O
is	O
also	O
cost-effective	O
compared	O
with	O
other	O
commonly	O
used	O
and	O
openly	O
reimbursed	O
cardiovascular	O
therapies	O
in	O
the	O
Canadian	O
health	O
care	O
system	O
.	O


The	O
effects	O
of	O
bromazepam	B-I
over	I-P
the	I-P
central	I-P
and	I-P
frontal	I-P
areas	I-P
during	I-P
a	I-P
motor	I-P
task	I-P
:	I-P
an	O
EEG	O
study	O
.	O


The	O
present	O
study	O
investigates	O
the	O
influence	O
of	O
bromazepam	B-I
while	I-P
executing	I-P
a	I-P
motor	I-P
task	I-P
.	I-P


Specifically	O
,	O
we	O
intend	O
to	O
analyze	O
the	O
changes	O
in	O
alpha	B-O
absolute	I-O
power	I-O
under	O
two	O
experimental	O
conditions	O
,	O
bromazepam	B-I
and	I-I
placebo	I-I
.	I-I


We	O
also	O
included	O
analyses	O
of	O
theta	O
and	O
beta	O
frequencies	O
.	O


We	B-P
collected	I-P
electroencephalographic	I-I
data	I-I
before	I-I
,	I-I
during	I-I
,	I-I
and	I-I
after	I-I
motor	I-I
task	I-I
execution	I-I
.	I-I


We	O
used	O
a	O
Two	B-I
Way	I-I
ANOVA	I-I
to	I-I
investigate	I-I
the	I-I
condition	I-I
(	I-I
PL	I-I
×	I-I
Br6	I-I
mg	I-I
)	I-I
and	I-I
moment	I-I
(	I-I
pre	I-I
and	I-I
post	I-I
)	I-I
variables	I-I
for	I-I
the	I-I
following	I-I
electrodes	I-I
:	I-I
Fp1	I-I
,	I-I
Fp2	I-I
,	I-I
F7	I-I
,	I-I
F3	I-I
,	I-I
Fz	I-I
,	I-I
F4	I-I
,	I-I
F8	I-I
,	I-I
C3	I-I
,	I-I
CZ	I-I
and	I-I
C4	I-I
.	I-I


We	O
found	O
a	O
main	O
effect	O
for	O
condition	O
on	O
the	O
electrodes	O
FP1	O
,	O
F7	O
,	O
F3	O
,	O
Fz	O
,	O
F4	O
,	O
C3	O
and	O
CZ	O
,	O
for	O
alpha	O
and	O
beta	O
bands	O
.	O


For	O
beta	O
band	O
we	O
also	O
found	O
a	O
main	O
effect	O
for	O
condition	O
on	O
the	O
electrodes	O
Fp2	O
,	O
F8	O
and	O
C4	O
;	O
for	O
theta	O
band	O
we	O
identified	O
a	O
main	O
effect	O
for	O
condition	O
on	O
C3	O
,	O
Cz	O
and	O
C4	O
electrodes	O
.	O


This	O
finding	O
suggests	O
that	O
the	O
motor	O
task	O
did	O
not	O
have	O
any	O
influence	O
on	O
the	B-O
electrocortical	I-O
activity	I-O
in	O
alpha	O
,	O
and	O
that	O
the	O
existing	O
modifications	O
were	O
a	O
consequence	O
due	O
merely	O
to	O
the	O
drug	O
use	O
.	O


Despite	O
its	O
anxiolytic	O
and	O
sedative	O
action	O
,	O
bromazepam	B-I
did	O
not	O
show	O
any	O
significant	O
changes	O
when	B-P
the	I-P
individuals	I-P
executed	I-P
a	I-P
finger	I-P
extension	I-P
motor	I-P
task	I-P
.	O


Comparison	O
of	O
amantadine	B-I
and	I-I
desipramine	I-I
combined	O
with	O
psychotherapy	B-I
for	O
treatment	O
of	O
cocaine	B-P
dependence	I-P
.	I-P


We	O
conducted	O
a	O
single-blind	O
,	O
random	O
assignment	O
,	O
placebo-controlled	B-I
,	O
12-week	O
comparison	O
of	O
desipramine	B-I
hydrochloride	I-I
and	I-I
amantadine	I-I
hydrochloride	I-I
as	O
adjunctive	O
treatments	O
to	O
counseling	O
for	O
cocaine	O
dependence	O
.	O


Subjects	B-P
were	I-P
54	I-P
outpatients	I-P
who	I-P
met	I-P
DSM	I-P
III-R	I-P
criteria	I-P
for	I-P
active	I-P
cocaine	I-P
dependence	I-P
and	I-P
who	I-P
completed	I-P
a	I-P
minimum	I-P
of	I-P
2	I-P
weeks	I-P
of	I-P
treatment	I-P
.	I-P


Subjects	O
treated	O
with	O
fixed	O
doses	O
of	O
200	O
mg/day	O
desipramine	B-I
(	O
N	O
=	O
17	O
)	O
,	O
400	O
mg/day	O
amantadine-placebo	B-I
(	O
N	O
=	O
16	O
)	O
,	O
and	O
placebo	B-I
(	O
N	O
=	O
21	O
)	O
did	B-P
not	I-P
differ	I-P
for	I-P
lifetime	I-P
cocaine	I-P
use	I-P
,	I-P
lifetime	I-P
histories	I-P
of	I-P
psychopathology	I-P
,	I-P
admission	I-P
scores	I-P
on	I-P
psychometric	I-P
assessments	I-P
,	I-P
and	I-P
sociodemographics	I-P
.	I-P


All	O
treatment	O
groups	O
demonstrated	O
dramatic	B-O
and	I-O
persistent	I-O
decreases	I-O
in	O
cocaine	B-O
use	I-O
,	I-O
craving	I-O
for	I-O
cocaine	I-O
,	I-O
and	I-O
psychiatric	I-O
symptoms	I-O
consequent	O
to	O
treatment	O
.	O


Although	O
there	O
was	O
a	O
trend	O
for	O
more	O
dropouts	B-O
by	O
subjects	O
taking	O
desipramine	B-I
,	O
there	O
were	O
no	O
significant	O
differences	O
among	O
treatment	O
groups	O
regarding	O
retention	B-O
in	I-O
treatment	I-O
,	I-O
craving	I-O
for	I-O
cocaine	I-O
,	I-O
and	I-O
decreased	I-O
cocaine	I-O
use	I-O
confirmed	O
by	O
urine	B-O
toxicology	I-O
.	I-O


There	O
was	O
a	O
trend	O
for	O
subjects	O
treated	O
with	O
desipramine	B-I
to	O
maintain	O
longer	O
periods	O
of	O
cocaine	B-O
abstinence	I-O
.	I-O


Mean	B-O
plasma	I-O
concentration	I-O
of	I-O
desipramine	I-O
in	O
a	O
subsample	O
of	O
our	O
subjects	O
was	O
less	O
than	O
that	O
recommended	O
for	O
treatment	O
of	O
depression	O
,	O
thus	O
the	O
dosage	O
of	O
desipramine	B-I
may	O
have	O
been	O
subtherapeutic	O
.	O


Endocrine	B-O
response	I-O
to	O
cataract	B-I
surgery	I-I
under	I-I
total	I-I
intravenous	I-I
anaesthesia	I-I
,	I-I
local	I-I
anaesthesia	I-I
under	I-I
sedation	I-I
or	I-I
local	I-I
anaesthesia	I-I
alone	I-I
:	I-I
a	O
comparative	O
study	O
.	O


Predictive	O
validity	O
of	O
a	O
medication	O
adherence	O
measure	O
in	O
an	O
outpatient	B-P
setting	I-P
.	I-P


This	O
study	O
examines	O
the	O
psychometric	O
properties	O
and	O
tests	O
the	O
concurrent	O
and	O
predictive	O
validity	O
of	O
a	O
structured	B-I
,	I-I
self-reported	I-I
medication	I-I
adherence	I-I
measure	I-I
in	O
patients	B-P
with	I-P
hypertension	I-P
.	I-P


The	O
authors	O
also	O
assessed	O
various	O
psychosocial	B-O
determinants	I-O
of	I-O
adherence	I-O
,	O
such	O
as	O
knowledge	B-O
,	I-O
social	I-O
support	I-O
,	I-O
satisfaction	I-O
with	I-O
care	I-O
,	O
and	O
complexity	B-O
of	I-O
the	I-O
medical	I-O
regimen	I-O
.	I-O


A	B-P
total	I-P
of	I-P
1367	I-P
patients	I-P
participated	I-P
in	I-P
the	I-P
study	I-P
;	I-P
mean	I-P
age	I-P
was	I-P
52.5	I-P
years	I-P
,	I-P
40.8	I-P
%	I-P
were	I-P
male	I-P
,	I-P
76.5	I-P
%	I-P
were	I-P
black	I-P
,	I-P
50.8	I-P
%	I-P
graduated	I-P
from	I-P
high	I-P
school	I-P
,	I-P
26	I-P
%	I-P
were	I-P
married	I-P
,	I-P
and	I-P
54.1	I-P
%	I-P
had	I-P
income	I-P
<	I-P
$	I-P
5,000	I-P
.	I-P


The	O
8-item	O
medication	B-I
adherence	I-I
scale	O
was	O
reliable	O
(	O
alpha=.83	O
)	O
and	O
significantly	O
associated	O
with	O
blood	B-O
pressure	I-O
control	I-O
(	O
P	O
<	O
.05	O
)	O
.	O


Using	O
a	O
cutpoint	O
of	O
<	O
6	O
,	O
the	O
sensitivity	O
of	O
the	O
measure	O
to	O
identify	O
patients	O
with	O
poor	O
blood	B-O
pressure	I-O
control	I-O
was	O
estimated	O
to	O
be	O
93	O
%	O
,	O
and	O
the	O
specificity	O
was	O
53	O
%	O
.	O


The	O
medication	O
adherence	O
measure	O
proved	O
to	O
be	O
reliable	O
,	O
with	O
good	O
concurrent	O
and	O
predictive	O
validity	O
in	O
primarily	B-P
low-income	I-P
,	I-P
minority	I-P
patients	I-P
with	I-P
hypertension	I-P
and	O
might	O
function	O
as	O
a	O
screening	O
tool	O
in	O
outpatient	B-P
settings	I-P
with	O
other	O
patient	B-P
groups	I-P
.	I-P


Impact	O
of	O
preinduced	B-P
quadriceps	I-P
fatigue	I-P
on	O
exercise	O
response	O
in	O
chronic	B-P
obstructive	I-P
pulmonary	I-P
disease	I-P
and	I-P
healthy	I-P
subjects	I-P
.	I-P


Exercise	O
intolerance	O
in	O
chronic	B-P
obstructive	I-P
pulmonary	I-P
disease	I-P
(	I-P
COPD	I-P
)	I-P
results	O
from	O
a	O
complex	O
interaction	O
between	O
central	O
(	O
ventilatory	O
)	O
and	O
peripheral	O
(	O
limb	O
muscles	O
)	O
components	O
of	O
exercise	O
limitation	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
influence	O
of	O
quadriceps	O
muscle	O
fatigue	O
on	O
exercise	O
tolerance	O
and	O
ventilatory	O
response	O
during	O
constant-workrate	B-I
cycling	I-I
exercise	I-I
testing	I-I
(	I-I
CWT	I-I
)	I-I
in	O
patients	B-P
with	I-P
COPD	I-P
and	I-P
healthy	I-P
subjects	I-P
.	I-P


Fifteen	B-P
patients	I-P
with	I-P
COPD	I-P
and	I-P
nine	I-P
age-matched	I-P
healthy	I-P
subjects	I-P
performed	O
,	O
7	O
days	O
apart	O
,	O
two	O
CWTs	B-I
up	O
to	O
exhaustion	O
at	O
80	O
%	O
of	O
their	O
predetermined	O
maximal	O
work	O
capacity	O
.	O


In	O
a	O
randomized	O
order	O
,	O
one	O
test	O
was	O
performed	O
with	O
preinduced	O
quadriceps	O
fatigue	O
and	O
the	O
other	O
in	O
a	O
fresh	O
state	O
.	O


Quadriceps	O
fatigue	O
was	O
produced	O
by	O
electrostimulation-induced	O
contractions	O
and	O
quantified	O
by	O
maximal	B-O
voluntary	I-O
contraction	I-O
and	O
potentiated	B-O
twitch	I-O
force	I-O
(	I-O
TwQ	I-O
(	I-O
pot	I-O
)	I-O
)	I-O
.	O


Endurance	B-O
time	I-O
and	I-O
ventilatory	I-O
response	I-O
during	O
CWT	O
were	O
compared	O
between	O
fatigued	O
and	O
fresh	O
state	O
.	O


Endurance	B-O
time	I-O
significantly	O
decreased	O
in	O
the	O
fatigued	O
state	O
compared	O
with	O
the	O
fresh	O
condition	O
in	O
COPD	O
(	O
356	O
+/-	O
69	O
s	O
vs.	O
294	O
+/-	O
45	O
s	O
,	O
P	O
<	O
0.05	O
)	O
and	O
controls	O
(	O
450	O
+/-	O
74	O
s	O
vs.	O
340	O
+/-	O
45	O
s	O
,	O
P	O
<	O
0.05	O
)	O
.	O


Controls	O
showed	O
significantly	O
higher	O
ventilation	B-O
and	I-O
end-exercise	I-O
dyspnea	I-O
scores	I-O
in	O
the	O
fatigued	O
condition	O
,	O
whereas	O
,	O
in	O
COPD	O
,	O
fatigue	O
did	O
not	O
influence	O
ventilation	O
or	O
dyspnea	O
during	O
exercise	O
.	O


The	O
degree	O
of	O
ventilatory	B-O
limitation	I-O
,	O
as	O
expressed	O
by	O
the	O
Ve/maximum	B-O
voluntary	I-O
ventilation	I-O
ratio	I-O
,	O
was	O
similar	O
in	O
both	O
conditions	O
in	O
patients	B-P
with	I-P
COPD	I-P
.	I-P


We	O
conclude	O
that	O
it	O
is	O
possible	O
to	O
induce	O
quadriceps	O
fatigue	O
by	O
local	O
electrostimulation-induced	O
contractions	O
.	O


Our	O
findings	O
demonstrate	O
that	O
peripheral	B-P
muscle	I-P
fatigue	I-P
is	O
an	O
additional	O
important	O
factor	O
,	O
besides	O
intense	O
dyspnea	O
,	O
that	O
limits	O
exercise	O
tolerance	O
in	O
COPD	O
.	O


Folic	B-I
acid-based	I-I
intervention	I-I
in	O
non-ST	B-P
elevation	I-P
acute	I-P
coronary	I-P
syndromes	I-O
.	I-O


Homocysteinemia	O
is	O
a	O
risk	O
factor	O
for	O
cardiovascular	O
diseases	O
.	O


Folic	B-I
acid	I-I
combined	I-I
with	I-I
vitamins	I-I
B	I-I
(	I-I
6	I-I
)	I-I
and	I-I
B	I-I
(	I-I
12	I-I
)	I-I
is	O
effective	O
in	O
lowering	O
homocysteine	B-O
levels	I-O
.	I-O


This	O
randomized	O
placebo-controlled	B-I
study	O
was	O
designed	O
to	O
determine	O
the	O
effect	O
of	O
a	O
folic	B-I
acid-based	I-I
supplement	I-I
on	O
secondary	O
prevention	O
of	O
clinical	O
events	O
in	O
non-ST-segment	B-P
elevation	I-P
acute	I-P
coronary	I-P
syndromes	I-P
.	I-P


The	O
study	O
comprised	O
240	B-P
patients	I-P
with	I-P
either	I-P
unstable	I-P
angina	I-P
or	I-P
non-ST-elevation	I-P
myocardial	I-P
infarction	I-P
in	I-P
the	I-P
previous	I-P
2	I-P
weeks	I-P
who	O
were	O
randomized	O
to	O
a	O
folate	B-I
group	O
(	O
n	O
=116	O
)	O
or	O
a	O
placebo	B-I
group	I-I
(	O
n	O
=124	O
)	O
.	O


The	O
folate	O
group	O
received	O
1	O
mg	O
folic	B-I
acid	I-I
,	O
400	O
microg	O
vitamin	B-I
B	I-I
(	I-I
12	I-I
)	I-I
,	O
and	O
10	O
mg	O
vitamin	B-I
B	I-I
(	I-I
6	I-I
)	I-I
daily	O
.	O


Clinical	B-O
outcomes	I-O
within	O
6	O
months	O
were	O
assessed	O
.	O


The	O
composite	O
endpoint	B-O
of	O
death	B-O
,	I-O
nonfatal	I-O
acute	I-O
coronary	I-O
syndrome	I-O
,	I-O
and	I-O
serious	I-O
re-hospitalization	I-O
was	O
significantly	O
higher	O
in	O
the	O
folate	O
group	O
;	O
serious	O
re-hospitalization	O
alone	O
was	O
significantly	O
higher	O
in	O
this	O
group	O
.	O


Advanced	B-O
age	I-O
and	I-O
diabetes	I-O
increased	O
susceptibility	O
to	O
the	O
composite	O
outcome	O
.	O


Folic	B-I
acid-based	I-I
supplementation	I-I
is	O
not	B-O
beneficial	I-O
and	I-O
may	I-O
even	I-O
be	I-O
harmful	I-O
in	O
the	O
secondary	O
prevention	B-O
of	I-O
cardiovascular	I-O
events	I-O
in	O
patients	O
with	O
unstable	O
angina	O
and	O
non-ST-elevation	O
myocardial	O
infarction	O
.	O


Further	O
studies	O
on	O
the	O
safety	O
of	O
such	O
supplements	O
are	O
suggested	O
.	O


Controlled	O
Clinical	O
Trials	O
Registry	O
no	O
.	O


ISRCTN30249553	O
.	O


Successful	O
treatment	O
of	O
depressed	B-P
,	I-P
distensible	I-P
acne	I-P
scars	I-P
using	O
autologous	B-I
fibroblasts	I-I
:	I-I
a	O
multi-site	O
,	O
prospective	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O


BACKGROUND	O
A	O
previous	O
clinical	O
trial	O
evaluating	O
autologous	B-I
fibroblasts	I-I
(	I-I
human	I-I
dermal	I-I
)	I-I
injections	I-I
for	O
the	O
treatment	O
of	O
facial	O
contour	O
deformities	O
found	O
significantly	O
greater	O
improvements	O
in	O
wrinkle	B-O
and	I-O
acne	I-O
scar	I-O
appearance	I-O
than	O
with	O
placebo	B-I
treatment	O
.	O


OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
autologous	B-I
fibroblast	I-I
treatment	O
of	O
moderate	B-P
to	I-P
severe	I-P
,	I-P
depressed	I-P
,	I-P
distensible	I-P
facial	I-P
acne	I-P
scars	I-P
with	O
that	O
of	O
vehicle	O
control	O
.	O


METHODS	O
This	O
was	O
a	O
randomized	O
multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
in	O
subjects	B-P
with	I-P
bilateral	I-P
moderate	I-P
to	I-P
severe	I-P
acne	I-P
scarring	I-P
;	I-P
subjects	O
served	O
as	O
their	O
own	O
controls	O
.	O


Skin	O
biopsies	O
were	O
obtained	O
from	O
randomized	O
subjects	B-P
for	O
fibroblast	O
production	O
.	O


Subjects	B-P
(	I-P
n	I-P
=	I-P
99	I-P
)	I-P
underwent	O
three	O
intradermal	O
injection	O
sessions	O
with	O
2	B-I
mL	I-I
of	I-I
autologous	I-I
fibroblast	I-I
suspension	I-I
(	O
10-20	O
million	O
cells/mL	O
)	O
on	O
one	O
cheek	O
and	O
vehicle	B-I
control	I-I
(	O
cell	O
culture	O
medium	O
)	O
on	O
the	O
other	O
at	O
14-day	O
intervals	O
.	O


Efficacy	O
was	O
based	O
on	O
the	O
blinded	O
subject	B-O
's	I-O
,	I-O
evaluator	I-O
's	I-O
,	I-O
and	I-O
independent	I-O
photographic	I-O
viewer	I-O
's	I-O
(	I-O
IPR	I-O
)	I-O
assessment	I-O
of	I-O
acne	I-O
scarring	I-O
1	O
to	O
4	O
months	O
after	O
the	O
last	O
treatment	O
.	O


RESULTS	O
Autologous	B-I
fibroblast	I-I
treatment	I-I
was	O
associated	O
with	O
significantly	O
greater	O
treatment	O
success	O
than	O
vehicle	O
control	O
for	O
the	O
subject	O
(	O
43	O
%	O
vs.18	O
%	O
)	O
,	O
evaluator	O
(	O
59	O
%	O
vs.	O
2	O
%	O
)	O
,	O
and	O
IPR	O
assessments	O
.	O


Autologous	B-I
fibroblast	I-I
injections	I-I
were	O
well	O
tolerated	O
,	O
without	O
permanent	O
adverse	O
effects	O
.	O


CONCLUSIONS	O
Autologous	B-I
fibroblast	I-I
injections	I-I
safely	O
and	O
effectively	O
improved	O
the	O
appearance	B-O
of	I-O
depressed	I-O
distensible	I-O
acne	I-O
scars	I-O
.	I-O


Impact	O
of	O
antisecretory	B-I
treatment	I-I
on	O
respiratory	B-O
symptoms	I-O
of	I-O
gastroesophageal	I-O
reflux	I-O
disease	I-O
in	I-P
children	I-P
.	I-P


The	O
effect	B-O
of	O
antisecretory	B-I
treatment	I-I
on	O
extraesophageal	B-O
symptoms	I-O
of	I-O
gastroesophageal	I-O
reflux	I-O
disease	I-O
was	O
evaluated	O
.	O


Seventy-eight	B-P
children	I-P
presenting	I-P
with	I-P
typical	I-P
and	I-P
extraesophageal	I-P
symptoms	I-P
of	I-P
gastroesophageal	I-P
reflux	I-P
disease	I-P
underwent	I-P
a	I-P
multichannel	I-P
intraluminal	I-P
impedance	I-P
and	I-P
pH	I-P
monitoring	I-P
(	I-P
MII/pH	I-P
)	I-P
.	I-P


Children	O
with	O
a	O
positive	O
MII/pH	O
were	O
randomly	O
treated	O
with	O
proton	B-I
pump	I-I
inhibitors	I-I
(	I-I
PPIs	I-I
)	I-I
or	I-I
histamine	I-I
H	I-I
(	I-I
2	I-I
)	I-I
-receptor	I-I
antagonists	I-I
(	I-I
H	I-I
(	I-I
2	I-I
)	I-I
RAs	I-I
)	I-I
during	O
3	O
months	O
.	O


At	O
the	O
end	O
of	O
the	O
treatment	O
period	O
,	O
all	O
patients	O
were	O
recalled	O
.	O


A	O
second	O
treatment	O
period	O
of	O
3	O
months	O
was	O
given	O
to	O
those	O
patients	O
who	O
were	O
not	O
symptom-free	O
after	O
3	O
months	O
.	O


Thirty-five	O
of	O
the	O
forty-one	O
(	O
85.4	O
%	O
)	O
children	O
with	O
a	O
pathologic	O
MII/pH	O
presented	O
with	O
extraesophageal	B-O
symptoms	I-O
and	O
were	O
treated	O
with	O
PPIs	B-I
(	I-I
omeprazole	I-I
;	I-I
n:19	O
)	O
or	O
H	B-I
(	I-I
2	I-I
)	I-I
RAs	I-I
(	I-I
ranitidine	I-I
;	I-I
n:16	O
)	O
for	O
12	O
weeks	O
.	O


After	O
3	O
months	O
,	O
11/19	O
(	O
57.9	O
%	O
)	O
PPI-treated	B-I
patients	O
had	O
a	O
complete	O
resolution	B-O
of	I-O
symptoms	I-O
;	I-O
6/8	O
nonresponders	O
were	O
treated	O
with	O
PPI	B-I
for	O
another	O
3	O
months	O
and	O
became	O
all	O
symptom-free	B-O
.	I-O


The	O
other	O
two	O
underwent	O
a	O
Nissen	O
fundoplication	O
.	O


Only	O
5/16	O
(	O
31.2	O
%	O
)	O
patients	O
treated	O
with	O
H	B-I
(	I-I
2	I-I
)	I-I
RAs	I-I
had	O
a	O
complete	B-O
resolution	I-O
of	I-O
symptoms	I-O
after	O
3	O
months	O
;	O
1/11	O
was	O
treated	O
again	O
with	O
H	B-I
(	I-I
2	I-I
)	I-I
RAs	I-I
during	O
3	O
months	O
,	O
and	O
10/11	O
were	O
changed	O
to	O
PPIs	B-I
.	I-I


In	O
3/10	O
,	O
a	O
partial	B-O
resolution	I-O
of	I-O
symptoms	I-O
was	O
achieved	O
,	O
while	O
in	O
7/10	O
,	O
a	O
complete	B-O
remission	I-O
was	O
obtained	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Antisecretory	B-I
reflux	I-I
treatment	I-I
improves	O
extraesophageal	B-O
reflux	I-O
symptoms	I-O
.	I-O


The	O
efficacy	B-O
of	O
PPIs	B-I
is	O
superior	O
to	O
that	O
of	O
H	B-I
(	I-I
2	I-I
)	I-I
RAs	I-I
in	O
these	O
children	O
.	O


Endovascular	O
aneurysm	O
repair	O
and	O
outcome	O
in	O
patients	B-P
unfit	I-P
for	I-P
open	I-P
repair	I-P
of	I-P
abdominal	I-P
aortic	I-P
aneurysm	I-P
(	I-P
EVAR	I-P
trial	I-P
2	I-P
)	I-P
:	I-P
randomised	O
controlled	O
trial	O
.	O


BACKGROUND	O
Endovascular	B-I
aneurysm	I-I
repair	I-I
(	I-I
EVAR	I-I
)	I-I
to	O
exclude	O
abdominal	O
aortic	O
aneurysm	O
(	O
AAA	O
)	O
was	O
introduced	O
for	O
patients	B-P
of	I-P
poor	I-P
health	I-P
status	I-P
considered	I-P
unfit	I-P
for	I-P
major	I-P
surgery	I-P
.	I-P


We	O
instigated	O
EVAR	O
trial	O
2	O
to	O
identify	O
whether	O
EVAR	O
improves	O
survival	B-O
compared	O
with	O
no	O
intervention	O
in	O
patients	B-P
unfit	I-P
for	I-P
open	I-P
repair	I-P
of	I-P
aortic	I-P
aneurysm	I-P
.	I-P


METHODS	O
We	O
did	O
a	O
randomised	O
controlled	O
trial	O
of	O
338	B-P
patients	I-P
aged	I-P
60	I-P
years	I-P
or	I-P
older	I-P
who	I-P
had	I-P
aneurysms	I-P
of	I-P
at	I-P
least	I-P
5.5	I-P
cm	I-P
in	I-P
diameter	I-P
and	I-P
who	I-P
had	I-P
been	I-P
referred	I-P
to	I-P
one	I-P
of	I-P
31	I-P
hospitals	I-P
in	I-P
the	I-P
UK	I-P
.	I-P


We	O
assigned	O
patients	O
to	O
receive	O
either	O
EVAR	B-I
(	O
n=166	O
)	O
or	B-I
no	I-I
intervention	I-I
(	O
n=172	O
)	O
.	O


Our	O
primary	O
endpoint	O
was	O
all-cause	B-O
mortality	I-O
,	O
with	O
secondary	O
endpoints	O
of	O
aneurysm-related	B-O
mortality	I-O
,	I-O
health-related	I-O
quality	I-O
of	I-O
life	I-O
(	I-O
HRQL	I-O
)	I-O
,	I-O
postoperative	I-O
complications	I-O
,	I-O
and	I-O
hospital	I-O
costs	I-O
.	I-O


Analyses	O
were	O
by	O
intention	O
to	O
treat	O
.	O


FINDINGS	O
197	B-P
patients	I-P
underwent	O
aneurysm	B-I
repair	I-I
(	O
47	O
assigned	O
no	O
intervention	O
)	O
and	O
80	O
%	O
of	O
patients	O
adhered	O
to	O
protocol	O
.	O


The	O
30-day	B-O
operative	I-O
mortality	I-O
in	I-O
the	I-O
EVAR	I-O
group	I-O
was	O
9	O
%	O
(	O
13	O
of	O
150	O
,	O
95	O
%	O
CI	O
5-15	O
)	O
and	O
the	O
no	O
intervention	O
group	O
had	O
a	O
rupture	O
rate	O
of	O
9.0	O
per	O
100	O
person	O
years	O
(	O
95	O
%	O
CI	O
6.0-13.5	O
)	O
.	O


By	O
end	O
of	O
follow	O
up	O
142	O
patients	O
had	O
died	B-O
,	O
42	O
of	O
aneurysm-related	O
factors	O
;	O
overall	B-O
mortality	I-O
after	O
4	O
years	O
was	O
64	O
%	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
EVAR	O
group	O
and	O
the	O
no	O
intervention	O
group	O
for	O
all-cause	B-O
mortality	I-O
(	O
hazard	O
ratio	O
1.21	O
,	O
95	O
%	O
CI	O
0.87-1.69	O
,	O
p=0.25	O
)	O
.	O


There	O
was	O
no	O
difference	O
in	O
aneurysm-related	B-O
mortality	I-O
.	I-O


The	O
mean	B-O
hospital	I-O
costs	I-O
per	I-O
patient	I-O
over	I-O
4	I-O
years	I-O
were	O
UK	O
pound	O
sterling	O
13,632	O
in	O
the	O
EVAR	O
group	O
and	O
pound	O
sterling	O
4983	O
in	O
the	O
no	O
intervention	O
group	O
(	O
mean	O
difference	O
pound	O
sterling	O
8649	O
,	O
SE	O
1248	O
)	O
,	O
with	O
no	O
difference	O
in	O
HRQL	O
scores	O
.	O


INTERPRETATION	O
EVAR	O
had	O
a	O
considerable	O
30-day	B-O
operative	I-O
mortality	I-O
in	O
patients	O
already	O
unfit	O
for	O
open	O
repair	O
of	O
their	O
aneurysm	O
.	O


EVAR	B-I
did	O
not	O
improve	O
survival	O
over	O
no	O
intervention	O
and	O
was	O
associated	O
with	O
a	O
need	O
for	O
continued	O
surveillance	O
and	O
reinterventions	O
,	O
at	O
substantially	O
increased	O
cost	O
.	O


Ongoing	O
follow-up	O
and	O
improved	O
fitness	O
of	O
these	O
patients	O
is	O
a	O
priority	O
.	O


Plasma	O
3,4-dihydroxyphenylethyleneglycol	O
and	O
3-methoxy-4-hydroxyphenylethyleneglycol	O
as	O
indicators	O
of	O
central	O
noradrenergic	O
activity	O
.	O


A	O
comparative	O
study	O
on	O
control	B-P
subjects	I-P
and	I-P
depressed	I-P
patients	I-P
.	I-P


Animal	O
studies	O
have	O
suggested	O
interspecies	O
differences	O
in	O
brain	O
norepinephrine	O
(	O
NE	O
)	O
metabolism	O
,	O
especially	O
with	O
regard	O
to	O
the	O
relative	O
proportions	O
of	O
3,4-dihydroxyphenylethyleneglycol	O
(	O
DOPEG	O
)	O
compared	O
to	O
3-methoxy-4-hydroxyphenylethyleneglycol	O
(	O
MOPEG	O
)	O
.	O


In	O
order	O
to	O
question	O
the	O
value	O
of	O
both	O
glycol	O
metabolites	O
as	O
peripheral	O
indices	O
of	O
central	B-O
noradrenergic	I-O
activity	I-O
,	O
a	O
comparative	O
study	O
of	O
plasma	O
DOPEG	O
and	O
MOPEG	O
(	O
measured	O
by	O
HPLC	O
)	O
related	O
to	O
depression	O
,	O
sex	O
,	O
age	O
and	O
diagnostic	O
categories	O
(	O
DSM-III	O
)	O
was	O
carried	O
out	O
on	O
depressed	B-P
and	I-P
control	I-P
subjects	I-P
.	I-P


In	O
addition	O
,	O
two	B-P
groups	I-P
of	I-P
8	I-P
patients	I-P
were	O
randomly	O
submitted	O
to	O
a	O
desipramine	B-I
150	I-I
mg/day	I-I
,	I-I
or	I-I
a	I-I
metapramine	I-I
450	I-I
mg/day	I-I
antidepressant	I-I
treatment	I-I
influencing	O
the	O
formation	O
of	O
DOPEG	O
and	O
MOPEG	O
in	O
a	O
different	O
way	O
.	O


The	O
study	O
did	O
not	O
demonstrate	O
any	O
difference	O
between	O
DOPEG	O
and	O
MOPEG	O
for	O
most	O
of	O
the	O
experimental	O
factors	O
.	O


We	O
found	O
also	O
a	O
significant	O
positive	B-O
correlation	I-O
between	I-O
plasma	I-O
levels	I-O
of	I-O
DOPEG	I-O
and	I-O
MOPEG	I-O
.	I-O


Our	O
results	O
support	O
the	O
idea	O
that	O
each	O
of	O
these	O
two	O
biological	O
indices	O
can	O
be	O
used	O
in	O
the	O
assessment	O
of	O
central	B-O
noradrenergic	I-O
activity	I-O
.	I-O


Argatroban	B-I
for	O
elective	O
percutaneous	O
coronary	O
intervention	O
:	O
the	O
ARG-E04	O
multi-center	O
study	O
.	O


UNLABELLED	O
The	O
synthetic	O
arginine-derived	O
direct	O
thrombin	O
inhibitor	O
argatroban	B-I
is	O
an	O
attractive	O
anticoagulant	O
for	O
percutaneous	B-I
coronary	I-I
intervention	I-I
(	I-I
PCI	I-I
)	I-I
,	O
because	O
of	O
its	O
rapid	O
onset	O
and	O
offset	O
,	O
and	O
its	O
hepatic	O
elimination	O
.	O


Argatroban	B-I
was	O
approved	O
for	O
PCI	O
in	O
patients	B-P
with	I-P
heparin-induced	I-P
thrombocytopenia	I-P
(	I-P
HIT	I-P
)	I-P
.	I-P


However	O
,	O
there	O
are	O
limited	O
data	O
about	O
argatroban	B-I
in	O
non-HIT	O
patients	O
.	O


The	O
objective	O
of	O
this	O
open-label	O
,	O
multiple-dose	O
,	O
controlled	O
study	O
was	O
to	O
examine	O
the	O
safety	B-O
and	I-O
efficacy	I-O
of	O
argatroban	B-I
in	O
patients	B-P
undergoing	I-P
elective	I-P
PCI	I-P
.	I-P


METHODS	O
AND	O
RESULTS	O
Of	O
140	B-P
patients	I-P
randomized	O
to	O
three	O
argatroban	B-I
dose	O
groups	O
(	B-I
ARG250	I-I
,	I-I
ARG300	I-I
,	O
and	O
ARG350	B-I
with	O
250	O
,	O
300	O
,	O
or	O
350	O
μg/kg	O
bolus	O
,	O
followed	O
by	O
15	O
,	O
20	O
,	O
or	O
25	O
μg/kg/min	O
infusion	O
)	O
and	O
one	B-I
unfractionated	I-I
heparin	I-I
(	I-I
UFH	I-I
)	I-I
group	O
(	O
70-100	O
IU/kg	O
bolus	B-P
)	I-P
,	I-P
138	I-P
patients	I-P
were	I-P
analyzed	I-I
.	I-I


Argatroban	B-I
dose-dependently	O
prolonged	B-O
activated	I-O
clotting	I-O
time	I-O
(	I-O
ACT	I-O
)	I-O
with	O
more	O
patients	O
reaching	O
the	O
minimum	O
target	B-O
ACT	I-O
after	O
the	O
initial	O
bolus	O
injection	B-I
(	I-I
ARG250	I-I
:	I-I
86.1	I-I
%	I-I
,	I-I
ARG300	I-I
:	I-I
89.5	O
%	O
,	O
and	B-I
ARG350	I-I
:	I-I
96.8	O
%	O
)	O
compared	O
to	O
45.5	O
%	O
in	O
UFH	O
(	O
p	O
<	O
0.001	O
)	O
.	O


The	B-O
patient	I-O
proportion	I-O
who	I-O
did	I-O
not	I-O
require	I-O
additional	I-O
bolus	I-O
injections	I-O
to	O
start	O
PCI	O
was	O
significantly	O
higher	O
in	B-I
argatroban	I-I
than	O
in	B-I
UFH	I-I
(	O
p	O
≤	O
0.002	O
)	O
.	O


Consequently	B-O
,	I-O
the	I-O
time	I-O
to	I-O
start	I-O
of	I-O
PCI	O
was	O
shortened	B-I
in	I-I
argatroban	I-I
groups	O
.	O


Composite	B-O
incidences	I-O
of	I-O
death	I-O
,	I-O
myocardial	I-O
infarction	I-O
,	I-O
and	I-O
urgent	I-O
revascularization	I-O
until	O
day	O
30	O
were	O
not	O
significantly	O
different	O
between	O
the	O
groups	B-I
(	I-I
ARG250	I-I
:	I-I
2.8	I-I
%	I-I
,	I-I
ARG300	I-I
:	I-I
0.0	I-I
%	I-I
,	I-I
ARG350	I-I
:	I-I
3.2	O
%	O
vs.	B-I
UFH	O
:	O
3.0	B-O
%	I-O
)	I-O
.	I-O


Major	B-O
bleeding	I-O
was	O
observed	O
only	B-I
in	I-I
UFH	O
(	O
3.0	O
%	O
)	O
,	O
while	B-O
minor	I-O
bleeding	I-O
occurred	I-I
in	I-I
ARG350	I-I
(	O
3.2	O
%	O
)	O
and	B-I
UFH	O
(	O
6.1	O
%	O
,	O
n.s.	O
)	O
.	O


CONCLUSION	B-I
Argatroban	I-I
dose-dependently	O
increases	B-O
coagulation	I-O
parameters	I-O
and	O
,	O
compared	B-I
to	I-I
UFH	O
,	O
demonstrates	O
a	O
superior	O
predictable	B-O
anticoagulant	I-O
effect	I-O
in	I-P
patients	I-P
undergoing	I-I
elective	I-I
PCI	I-P
.	O


Timing	O
for	O
delivering	O
individualized	B-I
patient	I-I
education	I-I
intervention	I-I
to	O
Coronary	B-P
Artery	I-P
Bypass	I-P
Graft	I-P
patients	I-P
:	I-P
An	O
RCT	O
.	O


BACKGROUND	O
The	O
primary	O
focus	O
of	O
this	O
study	O
is	O
on	O
the	O
timing	O
of	O
the	O
delivery	O
of	O
education	O
to	O
patients	B-P
who	I-P
had	I-P
CABG	I-I
surgery	I-I
.	I-I


AIM	O
To	O
determine	O
the	O
efficacy	O
of	O
an	O
individualized	B-I
telephone	I-I
patient	I-I
education	I-I
intervention	I-I
,	O
delivered	O
at	O
two	O
different	O
points	O
in	O
time	O
(	O
1-2	O
days	O
pre-discharge	O
versus	O
1-2	O
days	O
post-discharge	O
)	O
in	O
enhancing	O
the	O
CABG	B-P
patient	I-P
's	I-P
knowledge	O
of	O
self-care	O
behaviours	O
,	O
performance	O
of	O
self-care	O
behaviours	O
,	O
and	O
symptom	O
frequency	O
.	O


METHOD	O
A	O
randomized	O
clinical	O
trial	O
that	O
included	O
a	O
convenience	B-P
sample	I-P
of	I-P
first	I-P
time	I-P
CABG	I-P
patients	I-P
.	I-P


Individuals	O
who	O
received	O
education	B-I
pre-discharge	I-I
were	O
compared	O
to	O
individuals	B-P
who	I-P
received	I-P
education	I-P
post-discharge	I-P
on	I-P
the	I-P
outcomes	I-P
.	I-P


RESULTS	O
Results	O
indicated	O
no	O
statistically	O
significant	O
difference	O
in	O
outcomes	B-O
between	I-O
the	I-O
two	I-O
time	I-O
points	I-O
.	I-O


As	O
well	O
,	O
anxiety	B-O
levels	I-O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
pre-discharge	O
group	O
than	O
the	O
post-discharge	O
group	O
.	O


CONCLUSIONS	O
The	O
individualized	O
nature	O
of	O
the	O
educational	B-I
intervention	I-I
may	O
have	O
accounted	O
for	O
non-significant	O
findings	O
reported	O
in	O
outcomes	O
between	O
the	O
two	O
time	O
points	O
.	O


PRACTICE	O
IMPLICATIONS	O
Nurses	O
may	O
consider	O
assessing	O
anxiety	B-O
levels	I-O
prior	O
to	O
delivery	O
of	O
educational	O
interventions	O
,	O
implement	O
interventions	O
aimed	O
at	O
reducing	O
anxiety	O
levels	O
,	O
and	O
provide	O
individualized	O
teaching	O
.	O


Efficacy	O
of	O
TeachTown	O
:	O
Basics	B-I
computer-assisted	I-I
intervention	I-I
for	O
the	O
Intensive	O
Comprehensive	O
Autism	O
Program	O
in	O
Los	O
Angeles	O
Unified	O
School	O
District	O
.	O


Computer	B-I
Assisted	I-I
Instruction	I-I
(	I-I
CAI	I-I
)	I-I
has	O
shown	O
increased	O
popularity	O
recently	O
and	O
there	O
are	O
many	O
studies	O
showing	O
promise	O
for	O
this	O
approach	O
for	O
children	B-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


However	O
,	O
there	O
are	O
no	O
between-subject	O
studies	O
to	O
date	O
assessing	O
the	O
efficacy	O
of	O
CAI	B-I
with	O
this	O
population	O
.	O


In	O
this	O
study	O
,	O
47	B-P
preschool	I-P
and	I-P
K-1	I-P
students	I-P
in	I-P
ASD	I-P
classrooms	I-P
participated	I-P
from	I-P
Los	I-P
Angeles	I-P
Unified	I-P
School	I-P
District	I-P
.	I-P


TeachTown	B-I
:	I-I
Basics	I-I
,	I-I
a	I-I
CAI	I-I
program	I-I
which	I-I
also	I-I
includes	I-I
supplementary	I-I
off-computer	I-I
activities	I-I
,	O
was	O
implemented	O
over	O
3	O
months	O
for	O
approximately	O
20	O
minutes	O
per	O
day	O
on	O
the	O
computer	B-I
and	O
20	B-I
minutes	I-I
per	I-I
day	I-I
in	I-I
supplementary	I-I
TeachTown	I-I
:	I-I
Basics	I-I
activities	I-I
.	I-I


Compared	O
to	O
the	O
students	O
in	O
the	O
control	O
group	O
,	O
the	O
TeachTown	O
:	O
Basics	O
students	O
showed	O
more	O
improvement	O
overall	B-O
on	I-O
language	I-O
and	I-O
cognitive	I-O
outcome	I-O
measures	I-O
.	I-O


In	O
addition	O
,	O
students	O
who	O
used	O
TeachTown	O
:	O
Basics	O
demonstrated	O
significant	O
progress	B-O
overall	I-O
in	I-O
the	I-O
software	I-O
and	O
those	O
students	O
who	O
used	O
the	O
program	O
for	O
more	O
time	O
demonstrated	B-O
larger	I-O
gains	I-O
within	I-O
the	I-O
software	I-O
and	I-O
in	I-O
outcome	I-O
measures	I-O
.	I-O


Although	O
not	O
conclusive	O
,	O
these	O
findings	O
offer	O
possibilities	O
for	O
the	O
use	O
of	O
CAI	B-I
for	O
remediating	O
many	O
deficits	O
for	O
children	B-P
with	I-P
ASD	I-P
and	I-P
other	I-P
special	I-P
needs	I-P
.	I-P


In	O
addition	O
,	O
CAI	B-I
may	O
offer	O
solutions	O
to	O
schools	O
and	O
parents	O
with	O
insufficient	O
funds	O
for	O
more	O
expensive	O
treatments	O
.	O


Equivalence	O
study	O
of	O
a	O
topical	B-I
diclofenac	I-I
solution	I-I
(	I-I
pennsaid	I-I
)	I-I
compared	O
with	O
oral	B-I
diclofenac	I-I
in	O
symptomatic	O
treatment	O
of	O
osteoarthritis	B-P
of	I-P
the	I-P
knee	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


OBJECTIVE	O
.	O


To	O
compare	O
the	O
safety	B-O
and	I-O
efficacy	I-O
of	O
a	O
topical	B-I
diclofenac	I-I
solution	I-I
versus	O
oral	B-I
diclofenac	I-I
in	O
relieving	O
the	O
symptoms	O
of	O
primary	B-P
osteoarthritis	I-P
(	I-P
OA	I-P
)	I-P
of	I-P
the	I-P
knee	I-P
,	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
equivalence	O
trial	O
.	O


METHODS	O
A	O
total	B-P
of	I-P
622	I-P
men	I-P
and	I-P
women	I-P
with	I-P
radiological	I-P
evidence	I-P
of	I-P
primary	I-P
knee	I-P
OA	I-P
and	I-P
mild	I-P
to	I-P
severe	I-P
symptoms	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
a	O
topical	B-I
diclofenac	I-I
solution	I-I
plus	I-I
placebo	I-I
oral	I-I
capsules	I-I
,	O
or	O
placebo	B-I
topical	I-I
solution	I-I
plus	I-I
oral	I-I
diclofenac	I-I
(	O
50	O
mg	O
)	O
capsules	O
.	O


Patients	O
applied	O
50	O
drops	O
of	O
study	O
solution	O
and	O
took	O
1	O
study	O
capsule	O
3	O
times	O
daily	O
for	O
12	O
weeks	O
.	O


Efficacy	O
variables	O
were	O
pain	O
and	O
physical	O
function	O
,	O
measured	O
by	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
(	O
WOMAC	O
)	O
VA	O
3.1	O
OA	O
Index	O
,	O
and	O
patient	O
global	O
assessment	O
(	O
PGA	O
)	O
.	O


Equivalence	O
in	O
the	O
per-protocol	O
group	O
was	O
based	O
on	O
previously	O
defined	O
ranges	O
of	O
clinically	O
significant	O
difference	O
.	O


Safety	O
was	O
assessed	O
by	O
evaluation	O
of	O
adverse	O
events	O
,	O
vital	O
signs	O
,	O
and	O
laboratory	O
data	O
.	O


RESULTS	O
The	O
difference	O
in	O
mean	O
(	O
95	O
%	O
CI	O
)	O
change	O
scores	O
(	O
final	O
minus	O
baseline	O
)	O
between	O
treatments	O
was	O
13.3	O
mm	O
(	O
-8.6	O
to	O
35.2	O
)	O
for	O
pain	O
(	O
total	O
scale	O
500	O
mm	O
)	O
,	O
71.0	O
mm	O
(	O
-2.4	O
to	O
144.5	O
)	O
for	O
physical	O
function	O
(	O
total	O
scale	O
1700	O
mm	O
)	O
,	O
and	O
4.3	O
mm	O
(	O
-1.2	O
to	O
9.8	O
)	O
for	O
PGA	O
(	O
total	O
scale	O
100	O
mm	O
)	O
.	O


The	O
CI	O
for	O
each	O
efficacy	O
variable	O
fell	O
within	O
the	O
predefined	O
equivalence	O
ranges	O
(	O
pain	O
,	O
+/-	O
75	O
mm	O
;	O
physical	O
function	O
,	O
+/-	O
255	O
mm	O
;	O
PGA	O
,	O
+/-	O
20	O
mm	O
)	O
,	O
indicating	O
that	O
no	O
clinically	O
relevant	O
difference	O
was	O
found	O
between	O
the	O
2	O
treatment	O
arms	O
.	O


Safety	B-O
analyses	I-O
of	O
patients	O
applying	O
topical	O
diclofenac	B-I
solution	I-I
revealed	O
some	O
minor	B-O
skin	I-O
irritation	I-O
at	I-O
the	I-O
application	I-O
site	I-O
--	I-O
mostly	I-O
skin	O
dryness	O
in	O
83/311	O
(	O
27	O
%	O
)	O
patients	O
--	O
but	O
a	O
significantly	O
reduced	O
incidence	O
,	O
relative	O
to	O
oral	O
diclofenac	O
,	O
of	O
total	B-O
and	I-O
severe	I-O
gastrointestinal	I-O
(	I-O
GI	I-O
)	I-O
adverse	I-O
events	I-O
,	I-O
including	I-O
dyspepsia	I-O
,	I-O
abdominal	I-O
pain	I-O
,	I-O
diarrhea	I-O
,	I-O
and	I-O
nausea	I-O
.	I-O


The	O
number	O
of	O
patients	O
developing	O
abnormal	O
liver	O
function	O
tests	O
(	O
including	O
clinically	O
significant	O
elevation	O
)	O
,	O
hemoglobin	O
,	O
and	O
creatinine	O
clearance	O
was	O
significantly	O
higher	O
in	O
the	O
oral	B-I
diclofenac	I-I
group	O
.	O


CONCLUSION	O
Application	O
of	O
this	O
topical	B-I
diclofenac	I-I
solution	I-I
to	O
the	O
knee	O
of	O
patients	B-P
with	I-P
OA	I-P
produced	O
relief	B-O
of	I-O
symptoms	I-O
equivalent	O
to	O
oral	B-I
diclofenac	I-I
,	O
with	O
minor	O
local	O
skin	O
irritation	O
,	O
but	O
significantly	O
reduced	O
incidence	B-O
of	I-O
diclofenac-related	I-O
GI	I-O
complaints	I-O
and	I-O
abnormal	I-O
laboratory	I-O
values	I-O
.	I-O


Wavefront-guided	B-I
versus	I-I
standard	I-I
LASIK	I-I
enhancement	I-I
for	O
residual	O
refractive	O
errors	O
.	O


OBJECTIVE	O
To	O
assess	O
efficacy	B-O
,	I-O
safety	I-O
,	I-O
predictability	I-O
,	I-O
stability	I-O
,	I-O
and	I-O
changes	I-O
in	I-O
higher-order	I-O
aberrations	I-O
(	I-O
HOAs	I-O
)	I-O
and	O
contrast	B-O
sensitivity	I-O
(	I-O
CS	I-O
)	I-O
after	O
wavefront-guided	B-I
and	I-I
standard	I-I
LASIK	I-I
enhancement	I-I
for	O
the	O
correction	O
of	O
residual	O
refractive	O
errors	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
comparative	O
clinical	O
study	O
.	O


PARTICIPANTS	O
Twenty	B-P
eyes	I-P
of	I-P
20	I-P
consecutive	I-P
patients	I-P
(	I-P
spherical	I-P
equivalent	I-P
[	I-P
SE	I-P
]	I-P
,	I-P
-2.01+/-1.36	I-P
diopters	I-P
[	I-P
D	I-P
]	I-P
)	I-P
treated	I-P
with	I-P
wavefront-guided	I-I
Zyoptix	I-I
Ablation	I-I
Refinement	I-I
software	I-I
(	I-I
ZAR	I-I
)	I-I
LASIK	I-I
and	I-P
20	I-P
eyes	I-P
of	I-P
20	I-P
consecutive	I-P
patients	I-P
(	I-P
SE	I-P
,	I-P
-1.81+/-1.21	I-P
D	I-P
)	I-P
treated	I-P
with	I-P
standard	I-I
Planoscan	I-I
LASIK	I-I
,	I-P
both	I-P
for	I-P
residual	I-P
refractive	I-P
error	I-P
enhancement	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Efficacy	B-O
,	I-O
safety	I-O
,	I-O
predictability	I-O
,	I-O
stability	I-O
,	I-O
HOAs	I-O
,	I-O
and	I-O
CS	I-O
were	O
evaluated	O
before	O
and	O
after	O
enhancement	O
at	O
6	O
months	O
'	O
follow-up	O
.	O


METHODS	O
Uncorrected	B-O
visual	I-O
acuity	I-O
(	I-O
UCVA	I-O
)	I-O
,	I-O
best-corrected	I-O
visual	I-O
acuity	I-O
(	I-O
BCVA	I-O
)	I-O
,	I-O
manifest	I-O
refraction	I-O
,	I-O
CS	I-O
by	I-O
means	I-O
of	I-O
the	I-O
Functional	I-O
Acuity	I-O
Contrast	I-O
Test	I-O
,	I-O
and	I-O
HOAs	I-O
by	I-O
means	I-O
of	I-O
Zywave	I-O
aberrometry	I-O
were	O
evaluated	O
preoperatively	O
and	O
6	O
months	O
after	O
retreatment	O
.	O


RESULTS	O
At	O
6	O
months	O
postoperatively	O
,	O
UCVA	B-O
was	O
20/25	O
or	O
better	O
in	O
100	O
%	O
of	O
the	O
eyes	O
.	O


Efficacy	B-O
indexes	I-O
were	O
1.09	O
for	O
ZAR	B-I
patients	O
and	O
0.95	O
for	O
Planoscan	B-I
patients	O
.	O


No	B-O
eyes	I-O
lost	I-O
>	O
or	O
=1	O
line	O
of	O
BCVA	B-O
;	I-O
in	O
the	O
ZAR	B-I
group	O
,	O
2	O
eyes	O
gained	B-O
1	O
line	O
and	O
6	O
eyes	O
gained	B-O
>	O
or	O
=2	O
lines	O
;	O
in	O
the	O
Planoscan	B-I
group	O
,	O
3	O
eyes	O
gained	O
1	O
line	O
.	O


The	O
ZAR	B-I
group	O
showed	O
a	O
percentage	O
of	O
eyes	O
(	O
94.4	O
%	O
)	O
within	O
the	O
0.5-D	O
range	O
in	O
SE	O
higher	O
than	O
that	O
shown	O
by	O
the	O
Planoscan	B-I
group	O
(	O
88.8	O
%	O
)	O
.	O


After	O
6	O
months	O
,	O
the	O
HOA	B-O
root	I-O
mean	I-O
square	I-O
(	I-O
RMS	I-O
)	I-O
increased	O
on	O
average	O
by	O
a	O
factor	O
of	O
1.44	O
for	O
the	O
Planoscan	B-I
group	O
(	O
P	O
=	O
0.003	O
)	O
.	O


No	O
change	O
or	O
reduction	B-O
in	I-O
HOA	I-O
RMS	I-O
was	O
found	O
in	O
the	O
ZAR	B-I
group	O
(	O
factor	O
of	O
0.96	O
;	O
P	O
>	O
0.01	O
)	O
.	O


Contrast	B-O
sensitivity	I-O
was	O
reduced	O
in	O
the	O
Planoscan	B-I
group	O
only	O
at	O
the	O
highest	O
spatial	O
frequency	O
(	O
18	O
cycles	O
per	O
degree	O
;	O
P	O
<	O
0.01	O
)	O
.	O


There	O
was	O
a	O
significant	O
reduction	B-O
of	I-O
CS	I-O
as	I-O
a	I-O
function	I-O
of	I-O
HOA	I-O
increase	I-O
for	O
the	O
Planoscan	B-I
group	O
(	O
P	O
<	O
0.0001	O
)	O
.	O


No	O
changes	O
were	O
observed	O
for	O
the	O
ZAR	B-I
group	O
at	O
any	O
spatial	B-O
frequency	I-O
(	O
1.5-18	O
cycles	O
per	O
degree	O
;	O
P	O
>	O
0.01	O
)	O
.	O


CONCLUSIONS	O
Wavefront-guided	B-I
LASIK	I-I
using	O
the	O
ZAR	O
algorithm	O
is	O
an	O
effective	O
and	O
safe	O
procedure	O
for	O
treatment	O
of	O
residual	O
refractive	O
errors	O
.	O


Wavefront-guided	B-I
LASIK	I-I
does	O
not	O
increase	O
HOAs	O
and	O
does	O
not	O
modify	O
CS	O
compared	O
with	O
preoperative	O
values	O
.	O


Wavefront-guided	B-I
LASIK	I-I
seems	O
to	O
be	O
better	O
than	O
standard	O
LASIK	B-I
for	O
retreatments	O
.	O


Elevation	O
of	O
HDL-C	B-O
in	O
response	O
to	O
statin	B-I
treatment	O
is	O
involved	O
in	O
the	O
regression	B-P
of	I-P
carotid	I-P
atherosclerosis	I-P
.	I-P


AIM	O
Atherosclerosis	O
is	O
strongly	O
associated	O
with	O
an	O
increased	O
mortality	O
in	O
subjects	B-P
with	I-P
diabetes	I-P
.	I-P


The	O
carotid	B-O
intima-media	I-O
thickness	I-O
(	I-O
IMT	I-O
)	I-O
is	O
commonly	O
measured	O
as	O
a	O
surrogate	O
marker	O
for	O
cardiovascular	O
risk	O
.	O


Statins	O
are	O
well-established	O
protective	O
agents	O
against	O
atherosclerosis	O
and	O
reportedly	O
suppress	O
IMT	O
progression	O
in	O
subjects	O
with	O
diabetes	O
.	O


To	O
clarify	O
the	O
effects	O
of	O
statins	O
on	O
subclinical	O
atherosclerosis	O
,	O
we	O
herein	O
investigated	O
changes	O
in	O
the	O
carotid	O
IMT	O
and	O
lipid	O
profiles	O
in	O
a	O
multi-center	O
,	O
prospective	O
,	O
randomized	O
trial	O
.	O


METHODS	O
Hypercholesterolemic	B-P
subjects	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
were	O
randomly	O
assigned	O
to	O
open-label	O
treatment	O
with	O
either	O
pravastatin	B-I
or	I-I
pitavastatin	I-I
.	I-I


The	O
primary	O
endpoint	O
of	O
this	O
study	O
was	O
the	O
IMT	B-O
change	I-O
after	O
36	O
months	O
of	O
statin	B-I
treatment	O
.	O


RESULTS	O
A	B-P
total	I-P
of	I-P
97	I-P
subjects	I-P
(	I-P
51	I-P
pitavastatin	I-I
;	I-I
46	I-P
pravastatin	I-I
)	I-I
completed	I-P
this	I-P
36-month	I-P
study	I-P
.	I-P


The	O
LDL-C	B-O
decreased	O
significantly	O
from	O
163.4	O
±	O
27.9	O
mg/dl	O
at	O
baseline	O
to	O
100.4	O
±	O
19.6	O
mg/dl	O
at	O
36	O
months	O
in	O
the	O
pitavastatin	O
group	O
and	O
from	O
159.7	O
±	O
25.6	O
mg/dl	O
to	O
118.5	O
±	O
22.1	O
mg/dl	O
in	O
the	O
pravastatin	O
group	O
.	O


The	B-O
mean	I-O
IMT	O
showed	O
moderate	O
regression	O
in	O
both	O
the	B-I
pitavastatin	I-I
(	O
-0.070	O
±	O
0.215	O
mm	O
,	O
P	O
<	O
0.05	O
)	O
and	B-I
the	I-I
pravastatin	I-I
(	O
-0.067	O
±	O
0.260	O
mm	O
)	O
group	O
.	O


However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	B-O
the	I-O
IMT	I-O
change	I-O
between	O
the	O
two	O
groups	O
.	O


When	O
the	O
two	O
groups	O
were	O
combined	O
,	O
the	O
36-month	O
change	O
in	B-O
the	I-O
mean	I-O
IMT	O
was	O
significantly	O
associated	B-O
with	I-O
HDL-C	I-O
change	I-O
(	O
r=-0.24	O
,	O
P=	O
0.03	O
)	O
.	O


Multiple	O
linear	O
regression	O
analysis	O
revealed	O
the	O
change	B-O
in	I-O
HDL-C	O
to	O
be	O
an	O
independent	O
variable	O
showing	O
a	O
positive	O
correlation	O
with	O
the	O
carotid	O
IMT	O
reduction	O
.	O


CONCLUSION	O
The	O
administration	O
of	O
statins	O
for	O
3	O
years	O
to	O
subjects	O
with	O
type	O
2	O
diabetes	O
resulted	O
in	O
a	O
significant	O
regression	O
of	B-O
the	I-O
carotid	I-O
IMT	O
.	O


An	O
elevation	O
of	B-O
the	I-O
plasma	I-O
HDL-C	I-I
with	I-I
statin	I-I
treatment	O
was	O
closely	O
related	O
to	O
a	O
regression	O
of	O
atherosclerosis	O
.	O


Prospective	O
controlled	O
study	O
of	O
androgen	B-I
therapy	I-I
in	O
the	O
anemia	B-O
of	I-P
chronic	I-P
renal	I-P
disease	I-P
:	I-P
effects	O
on	O
iron	O
kinetics	O
.	O


Ferrokinetic	B-O
and	I-O
RBC	I-O
mass	I-O
determinations	I-O
were	O
made	O
at	O
3-month	O
intervals	O
in	O
iron-replete	B-P
hemodialysis	I-P
patients	I-P
randomized	O
to	O
a	O
control	B-I
group	I-I
or	I-I
to	I-I
nandrolone	I-I
decanoate	I-I
therapy	I-I
.	I-I


After	O
3	O
months	O
,	O
RBC	B-O
mass	I-O
increased	O
in	O
two	O
of	O
4	O
androgen-treated	O
patients	O
.	O


Erythron	B-O
iron	I-O
turnover	I-O
,	O
an	O
index	O
of	O
RBC	O
production	O
,	O
increased	O
in	O
the	O
one	O
responder	O
studied	O
but	O
not	O
in	O
the	O
two	O
nonresponders	O
.	O


Similarly	O
,	O
in	O
a	O
fifth	O
subject	O
,	O
who	O
was	O
not	O
restudied	O
until	O
6	O
months	O
of	O
androgen	B-I
therapy	I-I
were	O
completed	O
,	O
an	O
increase	O
in	O
RBC	B-O
mass	I-O
was	O
associated	O
with	O
an	O
increase	O
in	O
erythron	O
iron	O
turnover	O
.	O


However	O
,	O
between	O
3	O
and	O
6	O
months	O
,	O
RBC	B-O
mass	I-O
increased	O
in	O
all	O
4	B-P
androgen-treated	I-I
patients	I-P
studied	O
even	O
though	O
erythron	O
iron	O
turnovers	O
remained	O
unchanged	O
and	O
dialysis-associated	B-O
blood	I-O
losses	I-O
did	O
not	O
decrease	O
.	O


Thus	O
,	O
at	O
least	O
two	O
androgen-treated	B-I
patients	O
had	O
increases	O
in	O
RBC	B-O
mass	I-O
without	O
ever	O
increasing	O
their	O
erythron	B-O
iron	I-O
turnover	I-O
.	I-O


Two	O
of	O
three	O
control	O
subjects	O
also	O
had	O
increased	O
erythron	B-O
iron	I-O
turnovers	I-O
,	O
which	O
in	O
one	O
case	O
was	O
related	O
to	O
increased	O
dialysis-associated	B-O
blood	I-O
losses	I-O
.	I-O


Changes	O
in	O
RBC	B-O
mass	I-O
were	O
not	O
consistently	O
paralleled	O
by	O
changes	O
in	O
Hb	O
.	O


These	O
findings	O
suggest	O
that	O
increases	O
in	O
RBC	B-O
mass	I-O
during	O
nandrolone	O
decanoate	O
therapy	O
result	O
from	O
two	O
mechanisms	O
:	O
increased	O
erythropoiesis	O
(	O
shown	O
by	O
simultaneous	O
increases	O
in	O
RBC	B-O
mass	I-O
and	O
erythron	B-O
iron	I-O
turnover	I-O
)	I-O
and	O
increased	O
RBC	B-O
survival	I-O
(	O
indirectly	O
shown	O
by	O
increases	O
in	O
RBC	B-O
mass	I-O
without	O
increases	O
in	O
erythron	B-O
iron	I-O
turnover	I-O
)	I-O
.	O


The	O
importance	O
of	O
control	O
groups	O
,	O
RBC	B-O
mass	I-O
determinations	O
and	O
the	O
monitoring	O
of	O
dialysis-associated	B-O
blood	I-O
losses	I-O
in	O
studying	O
the	O
effects	O
of	O
androgens	O
on	O
erythropoiesis	O
in	O
chronic	B-P
hemodialysis	I-P
patients	I-P
is	O
also	O
demonstrated	O
.	O


Design	O
of	O
a	O
cost-effectiveness	O
study	O
within	O
a	O
randomized	O
trial	O
:	O
the	O
LIPID	O
Trial	O
for	O
Secondary	O
Prevention	O
of	O
IHD	B-P
.	I-P


Long-term	O
Intervention	O
with	O
Pravastatin	B-I
in	O
Ischemic	B-P
Heart	I-P
disease	I-P
.	I-P


The	O
Long-term	O
Intervention	O
with	O
Pravastatin	B-I
in	O
Ischemic	B-P
Heart	I-P
Disease	I-P
(	O
LIPID	O
)	O
trial	O
is	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
evaluating	O
the	O
long-term	O
effect	O
of	O
pravastatin	B-I
on	O
coronary	O
mortality	O
in	O
patients	B-P
with	I-P
a	I-P
previous	I-P
myocardial	I-P
infarction	I-P
or	I-P
unstable	I-P
angina-ischemic	I-P
heart	I-P
disease	I-P
(	I-P
IHD	I-P
)	I-P
.	I-P


It	O
is	O
planned	O
to	O
run	O
for	O
at	O
least	O
five	O
years	O
with	O
9014	B-P
patients	I-P
from	I-P
85	I-P
centers	I-P
in	I-P
Australia	I-P
and	I-P
New	I-P
Zealand	I-P
.	I-P


The	O
trial	O
will	O
monitor	O
cause-specific	O
mortality	O
and	O
major	O
clinical	O
events	O
associated	O
with	O
each	O
treatment	O
.	O


Running	O
in	O
parallel	O
with	O
the	O
main	O
study	O
is	O
a	O
prospective	O
economic	O
analysis	O
,	O
the	O
objectives	O
of	O
which	O
are	O
(	O
1	O
)	O
to	O
estimate	O
the	O
effectiveness	O
of	O
pravastatin	B-I
compared	O
with	O
placebo	O
in	O
terms	O
of	O
survival	B-O
,	I-O
quality	I-O
of	I-O
life	I-O
(	I-O
QOL	I-O
)	I-O
,	I-O
and	I-O
quality-adjusted	I-O
life-years	I-O
(	I-O
QALY	I-O
)	I-O
;	I-O
(	O
2	O
)	O
to	O
estimate	O
the	O
resource	O
usage	O
associated	O
with	O
pravastatin	B-I
compared	O
with	O
placebo-in	B-I
particular	O
,	O
to	O
study	O
whether	O
it	O
alters	O
resource	O
usage	O
through	O
prevention	O
of	O
disease	O
progression	O
;	O
and	O
(	O
3	O
)	O
to	O
use	O
this	O
information	O
for	O
a	O
cost-utility	O
analysis	O
with	O
cost	O
per	O
quality-adjusted	O
life-year	O
as	O
the	O
unit	O
of	O
analysis	O
.	O


A	O
novel	O
aspect	O
of	O
the	O
design	O
is	O
the	O
use	O
of	O
a	O
preliminary	O
cost-effectiveness	O
analysis	O
,	O
based	O
on	O
"	O
best-guess	O
"	O
values	O
,	O
and	O
a	O
sensitivity	O
analysis	O
over	O
plausible	O
ranges	O
to	O
guide	O
the	O
choice	O
of	O
subsample	O
size	O
.	O


Some	O
data	O
,	O
such	O
a	O
mortality	B-O
,	I-O
days	I-O
spent	I-O
in	I-O
hospital	I-O
,	I-O
major	I-O
clinical	I-O
events	I-O
,	I-O
and	I-O
drug	I-O
use	I-O
,	O
are	O
being	O
collected	O
within	O
the	O
main	O
LIPID	O
trial	O
.	O


However	O
,	O
additional	O
subsamples	O
for	O
the	O
cost-effectiveness	B-O
study	O
will	O
include	O
information	O
on	O
quality	B-O
of	I-O
life	I-O
,	I-O
time	I-O
off	I-O
work	I-O
,	I-O
and	I-O
resources	I-O
used	I-O
,	I-O
such	I-O
as	I-O
time	I-O
in	I-O
hospital	I-O
,	I-O
procedures	I-O
,	I-O
and	I-O
medications	I-O
taken	I-O
.	I-O


The	O
methods	O
and	O
sample	O
sizes	O
for	O
these	O
substudies	O
have	O
been	O
a	O
crucial	O
issue	O
in	O
validity	O
and	O
feasibility	O
.	O


The	O
treatment	O
of	O
localized	B-P
non-Hodgkin	I-P
's	I-P
lymphoma	I-P
in	I-P
children	I-P
:	I-P
a	O
report	O
from	O
the	O
Children	O
's	O
Cancer	O
Study	O
Group	O
.	O


Investigators	O
of	O
the	O
Children	O
's	O
Cancer	O
Study	O
Group	O
entered	O
73	B-P
children	I-P
with	I-P
previously	I-P
untreated	I-P
localized	I-P
non-Hodgkin	I-P
's	I-P
lymphoma	I-P
on	O
a	O
prospective	O
randomized	O
trial	O
of	O
systemic	O
treatment	O
with	O
either	O
a	O
four-drug	O
program	O
(	B-I
cyclophosphamide	I-I
,	I-I
vincristine	I-I
,	I-I
methotrexate	I-I
,	I-I
prednisone	I-I
[	I-I
COMP	I-I
]	I-I
)	I-I
or	O
a	O
10-drug	B-I
(	I-I
LSA2-L2	I-I
modified	I-I
)	I-I
program	O
of	O
18	O
months	O
duration	O
.	O


All	O
patients	O
received	O
central	B-I
nervous	I-I
system	I-I
prophylaxis	I-I
with	I-I
intrathecal	I-I
methotrexate	I-I
and	O
most	O
received	O
local	B-I
or	I-I
regional	I-I
radiation	I-I
treatment	I-I
.	I-I


The	O
three-year	B-O
relapse-free	I-O
survival	I-O
rate	I-O
for	O
all	O
patients	O
(	O
N	O
=	O
73	O
)	O
was	O
84	O
%	O
;	O
for	O
COMP	O
(	O
N	O
=	O
42	O
)	O
was	O
85	O
%	O
,	O
and	O
for	O
LSA2-L2	O
(	O
N	O
=	O
31	O
)	O
was	O
84	O
%	O
.	O


Of	O
the	O
12	O
patients	O
who	O
suffered	O
adverse	B-O
events	I-O
eight	O
relapsed	B-O
and	O
four	O
died	B-O
of	I-O
toxicity	I-O
.	I-O


Histopathology	O
was	O
reviewed	O
centrally	O
.	O


Of	O
32	O
patients	O
with	O
nonlymphoblastic	O
disease	O
treated	O
with	O
COMP	B-I
only	O
one	O
relapsed	B-O
.	I-O


Of	O
26	O
patients	O
treated	O
with	O
LSA2-L2	B-I
,	O
four	O
relapsed	B-O
.	I-O


Patients	O
with	O
localized	B-O
lymphoblastic	I-O
disease	I-O
were	O
uncommon	O
.	O


None	O
of	O
three	O
patients	O
treated	O
with	O
LSA2-L2	B-I
relapsed	O
compared	O
with	O
three	O
of	O
nine	O
treated	O
with	O
COMP	O
.	O


COMP	B-I
is	O
an	O
excellent	O
treatment	O
for	O
patients	O
with	O
localized	O
disease	O
of	O
nonlymphoblastic	O
type	O
,	O
but	O
the	O
relative	O
value	O
of	O
the	O
two	O
regimens	O
for	O
patients	O
with	O
localized	O
lymphoblastic	O
disease	O
is	O
uncertain	O
.	O


Effects	O
of	O
vitamin	B-I
A	I-I
or	I-I
beta	I-I
carotene	I-I
supplementation	I-I
on	O
pregnancy-related	B-O
mortality	I-O
and	I-O
infant	I-O
mortality	I-O
in	I-P
rural	I-P
Bangladesh	I-P
:	I-P
a	O
cluster	O
randomized	O
trial	O
.	O


CONTEXT	O
Maternal	O
vitamin	O
A	O
deficiency	O
is	O
a	O
public	O
health	O
concern	O
in	O
the	O
developing	O
world	O
.	O


Its	O
prevention	O
may	O
improve	O
maternal	O
and	O
infant	O
survival	O
.	O


OBJECTIVE	O
To	O
assess	O
efficacy	O
of	O
maternal	O
vitamin	B-I
A	I-I
or	O
beta	B-I
carotene	I-I
supplementation	O
in	O
reducing	O
pregnancy-related	B-P
and	I-P
infant	I-P
mortality	I-P
.	I-P


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
Cluster	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	B-I
trial	O
among	O
pregnant	B-P
women	I-P
13	I-P
to	I-P
45	I-P
years	I-P
of	I-P
age	I-P
and	I-P
their	I-P
live-born	I-P
infants	I-P
to	I-P
12	I-P
weeks	I-P
(	I-P
84	I-P
days	I-P
)	I-P
postpartum	I-P
in	I-P
rural	I-P
northern	I-P
Bangladesh	I-P
between	I-P
2001	I-P
and	I-P
2007	I-P
.	I-P


Interventions	O
Five	B-P
hundred	I-P
ninety-six	I-P
community	I-P
clusters	I-P
(	I-P
study	I-P
sectors	I-P
)	I-P
were	I-P
randomized	I-P
for	I-P
pregnant	I-P
women	I-P
to	O
receive	O
weekly	O
,	O
from	O
the	O
first	O
trimester	O
through	O
12	O
weeks	O
postpartum	O
,	O
7000	B-I
μg	I-I
of	I-I
retinol	I-I
equivalents	I-I
as	I-I
retinyl	I-I
palmitate	I-I
,	I-I
42	I-I
mg	I-I
of	I-I
all-trans	I-I
beta	I-I
carotene	I-I
,	I-I
or	I-I
placebo	I-I
.	I-P


Married	B-P
women	I-P
(	I-P
n	I-P
=	I-P
125,257	I-P
)	I-P
underwent	O
5-week	O
surveillance	O
for	O
pregnancy	O
,	O
ascertained	O
by	O
a	O
history	O
of	O
amenorrhea	O
and	O
confirmed	O
by	O
urine	O
test	O
.	B-P


Blood	O
samples	O
were	O
obtained	O
from	O
participants	O
in	O
32	O
sectors	O
(	O
5	O
%	O
)	O
for	O
biochemical	O
studies	O
.	O


MAIN	O
OUTCOME	O
MEASURES	B-O
All-cause	I-O
mortality	I-O
of	I-O
women	I-O
related	I-O
to	I-O
pregnancy	I-O
,	I-O
stillbirth	I-O
,	I-O
and	I-O
infant	I-O
mortality	I-O
to	O
12	O
weeks	O
(	O
84	O
days	O
)	O
following	O
pregnancy	O
outcome	O
.	O


RESULTS	O
Groups	O
were	O
comparable	O
across	O
risk	O
factors	O
.	O


For	O
the	B-O
mortality	I-O
outcomes	I-O
,	O
neither	O
of	O
the	O
supplement	O
group	O
outcomes	O
was	O
significantly	O
different	O
from	O
the	O
placebo	O
group	O
outcomes	O
.	O


The	O
numbers	O
of	B-O
deaths	I-O
and	I-O
all-cause	I-O
,	I-O
pregnancy-related	I-O
mortality	I-O
rates	I-O
(	O
per	O
100,000	O
pregnancies	O
)	O
were	O
41	O
and	O
206	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
140-273	O
)	O
in	O
the	B-I
placebo	I-I
group	O
,	O
47	O
and	O
237	O
(	O
95	O
%	O
CI	O
,	O
166-309	O
)	O
in	O
the	O
vitamin	O
A	O
group	O
,	O
and	O
50	O
and	O
250	O
(	O
95	O
%	O
CI	O
,	O
177-323	O
)	O
in	O
the	O
beta	O
carotene	O
group	O
.	O


Relative	O
risks	O
for	B-O
mortality	I-O
in	O
the	B-I
vitamin	I-I
A	I-I
and	I-I
beta	I-I
carotene	I-I
groups	O
were	O
1.15	O
(	O
95	O
%	O
CI	O
,	O
0.75-1.76	O
)	O
and	O
1.21	O
(	O
95	O
%	O
CI	O
,	O
0.81-1.81	O
)	O
,	O
respectively	O
.	O


In	O
the	B-I
placebo	I-I
,	I-I
vitamin	I-I
A	I-I
,	I-I
and	I-I
beta	I-I
carotene	I-I
groups	O
the	O
rates	O
of	B-O
stillbirth	I-O
and	I-O
infant	I-O
mortality	I-O
were	O
47.9	O
(	O
95	O
%	O
CI	O
,	O
44.3-51.5	O
)	O
,	O
45.6	O
(	O
95	O
%	O
CI	O
,	O
42.1-49.2	O
)	O
,	O
and	O
51.8	O
(	O
95	O
%	O
CI	O
,	O
48.0-55.6	O
)	O
per	O
1000	O
births	O
and	O
68.1	O
(	O
95	O
%	O
CI	O
,	O
63.7-72.5	O
)	O
,	O
65.0	O
(	O
95	O
%	O
CI	O
,	O
60.7-69.4	O
)	O
,	O
and	O
69.8	O
(	O
95	O
%	O
CI	O
,	O
65.4-72.3	O
)	O
per	O
1000	O
live	O
births	O
,	O
respectively	O
.	O


Vitamin	O
A	O
compared	O
with	O
either	O
placebo	O
or	O
beta	O
carotene	O
supplementation	O
increased	B-O
plasma	I-O
retinol	I-O
concentrations	I-O
by	O
end	O
of	O
study	O
(	O
1.46	O
[	O
95	O
%	O
CI	O
,	O
1.42-1.50	O
]	O
μmol/L	O
vs	O
1.13	O
[	O
95	O
%	O
CI	O
,	O
1.09-1.17	O
]	O
μmol/L	O
and	O
1.18	O
[	O
95	O
%	O
CI	O
,	O
1.14-1.22	O
]	O
μmol/L	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
and	O
reduced	O
,	O
but	O
did	O
not	O
eliminate	B-O
,	I-O
gestational	I-O
night	I-O
blindness	I-O
(	O
7.1	O
%	O
for	O
vitamin	O
A	O
vs	O
9.2	O
%	O
for	O
placebo	O
and	O
8.9	O
%	O
for	O
beta	O
carotene	O
[	O
P	O
<	O
.001	O
for	O
both	O
]	O
)	O
.	O


CONCLUSION	O
Use	O
of	O
weekly	B-I
vitamin	I-I
A	I-I
or	I-I
beta	I-I
carotene	I-I
in	I-P
pregnant	I-P
women	I-P
in	I-P
Bangladesh	I-P
,	O
compared	O
with	O
placebo	O
,	O
did	O
not	O
reduce	B-O
all-cause	I-O
maternal	I-O
,	I-O
fetal	I-O
,	I-O
or	I-O
infant	I-O
mortality	I-O
.	O


TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00198822	O
.	O


Targeting	O
alpha-7	B-I
nicotinic	I-I
neurotransmission	I-I
in	O
schizophrenia	B-P
:	I-P
a	O
novel	O
agonist	O
strategy	O
.	O


Alpha7	B-I
nicotinic	I-I
acetylcholine	I-I
receptor	I-I
(	I-I
α7	I-I
nAChR	I-I
)	I-I
agonists	I-I
may	O
be	O
valuable	O
treatments	O
for	O
negative	O
symptoms	O
and	O
cognitive	O
impairment	O
in	B-P
schizophrenia	I-P
.	O


Unfortunately	O
,	O
chronic	O
exposure	O
to	O
an	O
agonist	O
may	O
reduce	O
the	O
receptor	O
's	O
sensitivity	O
.	O


Therefore	O
,	O
we	O
combined	B-I
CDP-choline	I-I
,	O
a	O
dietary	O
source	O
of	O
the	O
direct	O
agonist	O
choline	O
,	O
with	B-I
galantamine	I-I
,	I-I
a	I-I
positive	I-I
allosteric	I-I
modulator	I-I
(	I-I
PAM	I-I
)	I-I
of	I-I
nicotinic	I-I
acetylcholine	I-I
receptors	I-I
,	O
to	O
improve	O
the	O
efficiency	O
of	O
transducing	O
the	O
choline	O
signal	O
and	O
,	O
possibly	O
,	O
preserve	O
the	O
receptor	O
in	O
a	O
sensitive	O
state	O
.	O


We	O
conducted	O
a	O
single-site	O
,	O
double-blind	O
randomized	O
clinical	O
trial	O
comparing	B-I
galantamine/CDP-choline	I-I
to	I-I
placebos	I-I
in	I-P
schizophrenia	I-P
patients	I-P
with	I-P
negative	I-P
symptoms	I-P
who	I-P
were	I-P
receiving	I-P
second	I-P
generation	I-P
antipsychotics	I-P
.	I-P


Forty-three	B-P
subjects	I-P
received	I-I
galantamine	I-I
and	I-I
CDP-choline	I-I
or	O
matching	B-I
placebos	I-I
for	O
16weeks	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
the	B-O
5-item	I-O
Marder	I-O
negative-symptoms	I-O
factor	I-O
of	I-O
the	I-O
Positive	I-O
and	I-O
Negative	I-O
Syndrome	I-O
Scale	I-O
(	I-O
PANSS	I-O
)	I-O
.	I-O


Cognition	B-O
and	I-O
functioning	I-O
were	O
also	O
assessed	O
.	O


Trial	O
completion	O
was	O
high	O
;	O
79	O
%	O
.	O


There	O
was	O
no	O
significant	O
treatment	O
effect	O
on	B-O
negative	I-O
symptoms	I-O
,	I-O
other	I-O
PANSS	I-O
symptom	I-O
factors	I-O
,	I-O
or	I-O
the	I-O
MATRICS	I-O
Cognitive	I-O
Consensus	I-O
Battery	I-O
.	O


There	O
were	O
significant	O
treatment	O
effects	O
in	B-O
overall	I-O
functioning	I-O
and	I-O
a	I-O
test	I-O
of	I-O
free	I-O
verbal	I-O
recall	I-O
.	O


Three	O
subjects	O
discontinued	O
treatment	O
in	O
the	O
active	O
treatment	O
group	O
for	O
gastro-intestinal	O
adverse	O
events	O
(	O
AE	O
)	O
.	O


The	O
most	O
common	O
AE	O
for	B-I
galantamine/CDP-choline	I-I
was	I-O
abdominal	I-O
pain	I-O
;	I-O
for	I-I
placebo	I-I
it	O
was	B-O
headache	I-O
and	I-O
sweating	I-O
.	O


Although	O
there	O
was	O
no	O
significant	O
treatment	O
effect	O
on	O
negative	O
symptoms	O
,	O
the	O
direction	O
of	O
effect	O
mirrored	O
the	O
effects	O
on	O
a	O
cognitive	O
measure	O
and	O
overall	O
functioning	O
.	O


Further	O
study	O
of	B-I
α7	I-I
nAChR	I-I
agonist/PAMs	I-I
is	O
warranted	O
in	O
larger	O
studies	O
that	O
will	O
have	O
greater	O
power	O
.	O


Omega-3	B-I
fatty	I-I
acids	I-I
supplementation	I-I
in	O
children	B-P
with	I-P
autism	I-P
:	I-P
a	O
double-blind	O
randomized	O
,	O
placebo-controlled	B-I
pilot	O
study	O
.	O


BACKGROUND	O
There	O
is	O
increasing	O
evidence	O
that	O
fatty	O
acid	O
deficiencies	O
or	O
imbalances	O
may	O
contribute	O
to	O
childhood	B-P
neurodevelopmental	I-P
disorders	I-P
.	I-P


METHODS	O
We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
6-week	O
pilot	O
trial	O
investigating	O
the	O
effects	O
of	O
1.5	B-I
g/d	I-I
of	I-I
omega-3	I-I
fatty	I-I
acids	I-I
(	I-I
.84	I-I
g/d	I-I
eicosapentaenoic	I-I
acid	I-I
,	I-I
.7	I-I
g/d	I-I
docosahexaenoic	I-I
acid	I-I
)	I-I
supplementation	I-I
in	O
13	B-P
children	I-P
(	I-P
aged	I-P
5	I-P
to	I-P
17	I-P
years	I-P
)	I-P
with	I-P
autistic	I-P
disorders	I-P
accompanied	I-P
by	I-P
severe	I-P
tantrums	I-P
,	I-P
aggression	I-P
,	I-P
or	I-P
self-injurious	I-P
behavior	I-P
.	I-P


The	O
outcome	O
measure	O
was	O
the	O
Aberrant	B-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
at	O
6	O
weeks	O
.	O


RESULTS	O
We	O
observed	O
an	O
advantage	O
of	O
omega-3	B-I
fatty	I-I
acids	I-I
compared	O
with	O
placebo	B-I
for	O
hyperactivity	B-O
and	I-O
stereotypy	I-O
,	O
each	O
with	O
a	O
large	O
effect	O
size	O
.	O


Repeated-measures	O
ANOVA	O
indicated	O
a	O
trend	O
toward	O
superiority	O
of	O
omega-3	B-I
fatty	I-I
acids	I-I
over	O
placebo	O
for	O
hyperactivity	B-O
.	I-O


No	O
clinically	O
relevant	O
adverse	B-O
effects	I-O
were	O
elicited	O
in	O
either	O
group	O
.	O


CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
provide	O
preliminary	O
evidence	O
that	O
omega-3	B-I
fatty	I-I
acids	I-I
may	O
be	O
an	O
effective	O
treatment	O
for	O
children	B-P
with	I-P
autism	I-P
.	I-P


Radiotherapy	B-I
and	O
CCNU	B-I
in	O
the	O
treatment	O
of	O
high-grade	O
supratentorial	O
astrocytomas	O
.	O


Forty-one	B-P
consecutive	I-P
patients	I-P
with	I-P
supratentorial	I-P
primary	I-P
brain	I-P
tumors	I-P
(	I-P
38	I-P
Grade	I-P
III	I-P
and	I-P
IV	I-P
astrocytomas	I-P
,	I-P
one	I-P
giant-cell	I-P
astrocytoma	I-P
,	I-P
and	I-P
two	I-P
cases	I-P
with	I-P
insufficient	I-P
tissue	I-P
for	I-P
diagnosis	I-P
)	I-P
were	O
randomly	O
allocated	O
within	B-P
2	I-P
weeks	I-P
of	I-P
surgery	I-P
to	O
one	O
of	O
three	O
therapeutic	O
groups	O
.	O


Group	O
1	O
(	O
15	O
patients	O
)	O
received	O
radiation	B-I
therapy	I-I
totaling	O
4000	O
to	O
4500	O
rads	O
in	O
4	O
to	O
5	O
weeks	O
.	O


Group	O
2	O
(	O
13	O
patients	O
)	O
received	O
1-	B-I
(	I-I
2-chloroethyl	I-I
)	I-I
-3-cyclohexyl-1-nitrosourea	I-I
CCNU	I-I
)	I-I
130	O
mg/sq	O
m	O
orally	O
every	O
6	O
weeks	O
.	O


Group	O
3	O
(	O
13	O
patients	O
)	O
received	O
radiation	B-I
therapy	I-I
plus	I-I
CCNU	I-I
as	O
for	O
Groups	O
1	O
and	O
2	O
.	O


When	O
the	O
disease	O
progressed	O
,	O
patients	O
in	O
Groups	O
1	O
and	O
2	O
were	O
crossed	O
over	O
to	O
receive	O
CCNU	B-I
and	O
irradiation	O
respectively	O
.	O


The	O
median	B-O
survival	I-O
time	I-O
in	O
these	O
groups	O
was	O
188	O
,	O
259	O
,	O
and	O
252	O
days	O
,	O
and	O
the	O
mean	O
survival	B-O
263	O
,	O
262	O
,	O
and	O
329	O
days	O
.	O


The	O
median	B-O
time	I-O
from	I-O
diagnosis	I-O
to	I-O
crossover	I-O
(	I-O
Groups	I-O
1	I-O
and	I-O
2	I-O
)	I-O
or	I-O
to	I-O
progression	I-O
(	O
Group	O
3	O
)	O
was	O
163	O
,	O
99	O
,	O
and	O
220	O
days	O
,	O
and	O
the	O
mean	O
time	O
was	O
172	O
,	O
108	O
,	O
and	O
231	O
days	O
.	O


There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
means	B-O
or	I-O
medians	I-O
in	O
any	O
of	O
these	O
situations	O
.	O


Controlled-release	O
melatonin	B-I
,	I-I
singly	I-I
and	I-I
combined	I-I
with	I-I
cognitive	I-I
behavioural	I-I
therapy	I-I
,	O
for	O
persistent	B-P
insomnia	I-O
in	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	I-P
a	O
randomized	O
placebo-controlled	O
trial	O
.	O


Although	O
melatonin	B-I
and	I-I
cognitive-behavioural	I-I
therapy	I-I
have	O
shown	O
efficacy	O
in	O
treating	O
sleep	B-P
disorders	I-P
in	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	O
little	O
is	O
known	O
about	O
their	O
relative	O
or	O
combined	O
efficacy	O
.	O


One	B-P
hundred	I-P
and	I-P
sixty	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	I-P
aged	I-P
4-10	I-P
years	I-P
,	I-P
suffering	I-P
from	I-P
sleep	I-P
onset	I-P
insomnia	I-P
and	I-P
impaired	I-P
sleep	I-P
maintenance	I-P
,	O
were	O
assigned	O
randomly	O
to	O
either	O
(	O
1	O
)	O
combination	B-I
of	I-I
controlled-release	I-I
melatonin	I-I
and	I-I
cognitive-behavioural	I-I
therapy	I-I
;	I-I
(	I-I
2	I-I
)	I-I
controlled-release	I-I
melatonin	I-I
;	I-I
(	I-I
3	I-I
)	I-I
four	I-I
sessions	I-I
of	I-I
cognitive-behavioural	I-I
therapy	I-I
;	I-I
or	I-I
(	I-I
4	I-I
)	I-I
placebo	I-I
drug	I-I
treatment	I-I
condition	I-I
for	O
12	O
weeks	O
in	O
a	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
ratio	O
.	O


Children	O
were	O
studied	O
at	O
baseline	O
and	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O


Treatment	O
response	O
was	O
assessed	O
with	O
1-week	O
actigraphic	O
monitoring	O
,	O
sleep	O
diary	O
and	O
sleep	O
questionnaire	O
.	O


Main	O
outcome	O
measures	O
,	O
derived	O
actigraphically	O
,	O
were	O
sleep	B-O
latency	I-O
,	I-O
total	I-O
sleep	I-O
time	I-O
,	I-O
wake	I-O
after	I-O
sleep	I-O
onset	I-O
and	I-O
number	I-O
of	I-O
awakenings	I-O
.	I-O


The	O
active	O
treatment	O
groups	O
all	O
resulted	O
in	O
improvements	O
across	O
all	O
outcome	O
measures	O
,	O
with	O
moderate-to-large	O
effect	O
sizes	O
from	O
baseline	O
to	O
a	O
12-week	O
assessment	O
.	O


Melatonin	B-I
treatment	O
was	O
mainly	O
effective	O
in	O
reducing	O
insomnia	B-O
symptoms	I-O
,	O
while	O
cognitive-behavioural	B-I
therapy	I-I
had	O
a	O
light	O
positive	O
impact	O
mainly	O
on	O
sleep	B-O
latency	I-O
,	O
suggesting	O
that	O
some	O
behavioural	O
aspects	O
might	O
play	O
a	O
role	O
in	O
determining	O
initial	B-O
insomnia	I-O
.	I-O


The	O
combination	O
treatment	O
group	O
showed	O
a	O
trend	O
to	O
outperform	O
other	O
active	O
treatment	O
groups	O
,	O
with	O
fewer	O
dropouts	O
and	O
a	O
greater	O
proportion	O
of	O
treatment	O
responders	O
achieving	O
clinically	O
significant	O
changes	O
(	O
63.38	O
%	O
normative	O
sleep	O
efficiency	O
criterion	O
of	O
>	O
85	O
%	O
and	O
84.62	O
%	O
,	O
sleep	O
onset	O
latency	O
<	O
30	O
min	O
)	O
.	O


This	O
study	O
demonstrates	O
that	O
adding	O
behavioural	B-I
intervention	I-I
to	O
melatonin	B-I
treatment	O
seems	O
to	O
result	O
in	O
a	O
better	O
treatment	O
response	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O


Metabolic	O
and	O
hormonal	O
responses	O
to	O
induced	B-I
hypotension	I-I
for	O
middle	B-P
ear	I-P
surgery	I-P
.	I-P


We	O
have	O
investigated	O
in	O
30	B-P
patients	I-P
the	O
metabolic	O
and	O
hormonal	O
responses	O
to	O
middle	B-P
ear	I-P
surgery	I-P
using	I-P
induced	I-I
hypotension	I-I
to	I-P
a	I-P
mean	I-P
arterial	I-P
pressure	I-P
of	I-P
55	I-P
mm	I-P
Hg	I-P
.	I-P


A	O
standardized	O
anaesthetic	O
technique	O
of	O
propranolol	B-I
,	I-I
thiopentone-vecuronium-isoflurane	I-I
was	O
used	O
in	O
all	O
patients	O
and	O
hypotension	B-I
induced	I-I
with	I-I
sodium	I-I
nitroprusside	I-I
,	I-I
trimetaphan	I-I
camsylate	I-I
or	I-I
additional	I-I
isoflurane	I-I
.	I-I


All	O
patients	O
showed	O
a	O
classic	B-O
stress	I-O
response	I-O
with	I-O
an	I-O
increase	I-O
in	I-O
circulating	I-O
blood	I-O
glucose	I-O
,	I-O
cortisol	I-O
and	I-O
growth	I-O
hormone	I-O
concentrations	I-O
.	I-O


Blood	B-O
lactate	I-O
and	I-O
plasma	I-O
uric	I-O
acid	I-O
concentrations	I-O
changed	O
little	O
during	O
operation	O
,	O
suggesting	O
that	O
tissue	O
oxygenation	O
was	O
adequate	O
.	O


However	O
,	O
the	O
former	O
declined	O
after	O
operation	O
,	O
possibly	O
as	O
a	O
result	O
of	O
the	O
concomitant	O
use	O
of	O
propranolol	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
three	O
hypotensive	O
techniques	O
in	O
their	O
effects	O
on	O
the	O
hormonal	O
and	O
metabolic	O
response	O
,	O
although	O
the	O
increase	O
in	O
blood	B-O
glucose	I-O
concentration	I-O
in	O
the	O
trimetaphan	O
group	O
was	O
obtunded	O
.	O


We	O
conclude	O
that	O
induced	O
hypotension	O
for	O
middle	B-P
ear	I-P
surgery	I-P
induced	O
an	O
endocrine	O
and	O
metabolic	O
response	O
of	O
small	O
magnitude	O
and	O
short	O
duration	O
.	O


Influence	B-O
of	O
bony	B-P
defects	I-P
on	O
implant	O
stability	O
.	O


INTRODUCTION	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
evolution	O
of	O
implant	O
mechanical	O
stability	O
in	O
different	O
types/sizes	O
of	O
bony	B-P
defects	I-P
using	O
both	O
Periotest	B-I
and	O
Osstell	B-I
devices	O
as	O
"	O
objective	O
tools	O
.	O


"	O
MATERIALS	O
AND	O
METHODS	O
Thirty-two	B-P
implants	I-P
were	I-P
randomly	I-P
allocated	I-P
to	O
one	O
of	O
the	O
four	B-P
types	I-P
of	I-P
bone	I-P
defects	I-P
:	I-P
marginal	I-P
bone	I-P
loss	I-P
,	I-P
peri-apical	I-P
bone	I-P
defect	I-P
,	I-P
constant	I-P
width	I-P
dehiscence	I-P
and	I-P
constant	I-P
length	I-P
dehiscences	I-P
.	I-P


Periotest/Osstell	B-O
measurements	I-O
were	O
completed	O
before	O
and	O
during	O
staged	O
bone	O
removal	O
(	O
to	O
enlarge	O
defect	O
size	O
)	O
.	O


RESULTS	O
Significant	O
differences	O
(	O
P	O
<	O
0.05	O
)	O
with	O
initial	O
values	O
were	O
found	O
after	O
a	O
2	O
mm	O
marginal	O
bone	O
removal	O
(	O
Osstell/Periotest	O
)	O
;	O
for	O
a	O
peri-apical	B-O
bone	I-O
lesion	I-O
,	O
after	O
removal	O
of	O
5	O
mm	O
(	B-I
Osstell	I-I
)	I-I
or	O
8	O
mm	O
(	B-I
Periotest	I-I
)	I-I
;	I-I
for	O
a	O
6-mm-long	O
dehiscence	O
,	O
after	O
removal	O
up	O
to	O
180	O
degrees	O
of	O
the	O
implant	O
perimeter	O
(	O
Osstell/Periotest	O
)	O
;	O
for	O
a	O
3-mm-wide	O
dehiscence	O
,	O
after	O
removal	O
of	O
10	O
mm	O
(	O
Osstell	O
)	O
or	O
6	O
mm	O
(	O
Periotest	O
)	O
.	O


CONCLUSION	O
Periotest	B-O
and	O
Osstell	B-O
are	O
in	O
general	O
not	O
very	O
sensitive	O
in	O
the	O
identification	O
of	O
peri-implant	O
bone	O
destruction	O
,	O
except	O
for	O
marginal	O
bone	O
loss	O
.	O


Comparing	O
microvascular	B-O
alterations	I-O
during	O
minimal	O
extracorporeal	B-I
circulation	I-I
and	O
conventional	O
cardiopulmonary	B-I
bypass	I-I
in	O
coronary	B-I
artery	I-I
bypass	I-I
graft	I-I
surgery	I-I
:	I-I
a	O
prospective	O
,	O
randomized	O
study	O
.	O


OBJECTIVES	O
Minimal	B-I
extracorporeal	I-I
circulation	I-I
(	I-I
MECC	I-I
)	I-I
has	O
been	O
introduced	O
in	O
coronary	B-I
artery	I-I
bypass	I-I
graft	I-I
(	I-I
CABG	I-I
)	I-I
surgery	I-I
,	O
offering	O
clinical	O
benefits	O
owing	O
to	O
reduced	O
hemodilution	O
and	O
no	O
blood-air	O
interface	O
.	O


Yet	O
,	O
the	O
effects	O
of	O
MECC	B-I
on	O
the	O
intraoperative	O
microvascular	O
perfusion	O
in	O
comparison	O
with	O
conventional	B-I
extracorporeal	I-I
circulation	I-I
(	I-I
CECC	I-I
)	I-I
have	O
not	O
been	O
studied	O
so	O
far	O
.	O


METHODS	O
The	O
current	O
study	O
aimed	O
to	O
analyze	O
alterations	B-O
in	I-O
microvascular	I-O
perfusion	I-O
at	O
4	O
predefined	O
time	O
points	O
(	O
T1-T4	O
)	O
during	O
on-pump	O
CABG	O
using	O
orthogonal	O
polarization	O
spectral	O
imaging	O
.	O


Forty	B-P
patients	I-P
were	I-P
randomized	I-P
for	O
being	O
operated	O
on	O
with	O
either	O
MECC	B-I
or	I-I
CECC	I-I
.	I-I


Changes	O
in	O
functional	B-O
capillary	I-O
density	I-O
(	I-O
FCD	I-O
)	I-O
,	I-O
blood	I-O
flow	I-O
velocity	I-O
,	I-O
and	I-O
vessel	I-O
diameter	I-O
were	O
analyzed	O
by	O
a	O
blinded	O
investigator	O
.	O


RESULTS	O
After	O
start	O
of	O
extracorporeal	O
circulation	O
(	O
ECC	O
)	O
and	O
aortic	O
crossclamping	O
(	O
T2	O
)	O
,	O
both	O
groups	O
showed	O
a	O
significant	O
drop	O
of	O
FCD	B-O
,	O
with	O
a	O
significantly	O
higher	O
FCD	B-O
in	O
the	O
MECC	O
group	O
(	O
206.8	O
±	O
33.6	O
cm/cm²	O
in	O
CECC	O
group	O
versus	O
217.8	O
±	O
35.3	O
cm/cm²	O
in	O
MECC	O
group	O
;	O
P	O
=	O
.034	O
)	O
.	O


In	O
the	O
late	O
phase	O
of	O
the	O
ECC	O
(	B-O
T3	I-O
)	I-O
,	O
FCD	O
in	O
the	O
MECC	O
group	O
was	O
already	O
recovered	O
,	O
whereas	B-O
FCD	O
in	O
the	O
CECC	O
group	O
was	O
still	O
significantly	O
depressed	O
(	O
223.1	O
±	O
35.6	O
cm/cm²	O
in	O
MECC	O
group	O
;	O
P	O
=	O
.100	O
vs	O
T1	O
;	O
211.1	O
±	O
36.9	O
cm/cm²	O
in	O
CECC	O
group	O
;	O
P	O
=	O
.017	O
vs	O
T1	O
)	O
.	O


After	O
termination	O
of	O
ECC	B-O
(	I-O
T4	I-O
)	I-O
,	O
FCD	O
recovered	O
in	O
both	O
groups	O
to	O
baseline	B-O
.	I-O


Blood	B-O
flow	I-O
velocity	I-O
tended	O
to	O
be	O
higher	O
in	O
the	O
MECC	O
group	O
,	O
with	O
a	O
significant	O
intergroup	O
difference	O
after	O
aortic	O
crossclamping	O
(	O
T2	O
)	O
.	O


CONCLUSIONS	O
Orthogonal	O
polarization	O
spectral	O
imaging	O
data	O
reveal	O
an	O
impairment	B-O
of	I-O
microvascular	I-O
perfusion	I-O
during	O
on-pump	O
CABG	O
.	O


Changes	B-O
in	O
FCD	O
indicate	O
a	O
faster	O
recovery	O
of	O
the	O
microvascular	O
perfusion	O
in	O
MECC	O
during	O
the	O
reperfusion	O
period	O
.	O


Beneficial	O
recovery	O
of	O
microvascular	O
organ	O
perfusion	O
could	O
partly	O
explain	O
the	O
perioperative	O
advantages	O
reported	O
for	O
MECC	O
.	O


Study	O
design	O
and	O
rationale	O
of	O
a	O
dose-ranging	O
trial	O
of	O
LX4211	B-I
,	O
a	O
dual	O
inhibitor	O
of	O
SGLT1	O
and	O
SGLT2	O
,	O
in	O
type	B-P
2	I-P
diabetes	I-P
inadequately	I-P
controlled	I-P
on	I-P
metformin	I-P
monotherapy	I-P
.	I-P


Sodium-glucose	O
cotransporters	O
1	O
(	O
SGLT1	O
)	O
and	O
2	O
(	O
SGLT2	O
)	O
are	O
the	O
major	O
cellular	O
transporters	O
responsible	O
for	O
gastrointestinal	O
(	O
GI	O
)	O
glucose	O
absorption	O
and	O
renal	O
glucose	O
reabsorption	O
,	O
respectively	O
.	O


LX4211	B-I
,	O
a	O
dual	O
inhibitor	O
of	O
SGLT1	O
and	O
SGLT2	O
,	O
reduces	O
glucose	O
absorption	O
from	O
the	O
GI	O
tract	O
and	O
enhances	O
urinary	O
glucose	O
excretion	O
.	O


Although	O
several	O
SGLT2-selective	O
inhibitors	O
have	O
been	O
tested	O
in	O
large	O
phase	O
2	O
studies	O
,	O
dual	O
inhibition	O
of	O
SGLT1	O
and	O
SGLT2	O
is	O
novel	O
at	O
this	O
stage	O
of	O
drug	O
development	O
,	O
and	O
it	O
has	O
implications	O
for	O
clinical-trial	O
design	O
.	O


In	O
this	O
article	O
,	O
we	O
describe	O
the	O
design	O
and	O
rationale	O
of	O
a	O
phase	O
2	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
parallel	O
group	O
study	O
to	O
evaluate	O
the	O
safety	B-O
and	I-O
efficacy	I-O
of	I-O
LX4211	I-O
in	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
who	I-P
have	I-P
inadequate	I-P
glycemic	I-O
control	I-O
on	I-P
metformin	I-P
monotherapy	I-P
.	I-P


The	O
primary	O
endpoint	O
is	O
the	O
change	O
in	O
glycated	B-O
hemoglobin	I-O
A1c	I-O
from	O
baseline	O
to	O
week	O
12	O
.	O


Secondary	O
endpoints	O
include	O
the	O
proportion	B-O
of	I-O
subjects	I-O
achieving	I-O
a	I-O
glycated	I-O
hemoglobin	I-O
A1c	I-O
value	I-O
of	I-O
<	I-O
7	I-O
%	I-O
,	I-O
change	I-O
from	I-O
baseline	I-O
in	I-O
fasting	I-O
plasma	I-O
glucose	I-O
and	I-O
postprandial	I-O
glucose	I-O
(	I-O
as	I-O
part	I-O
of	I-O
an	I-O
oral	I-O
glucose	I-O
tolerance	I-O
test	I-O
)	I-O
,	I-O
body	I-O
weight	I-O
,	I-O
and	I-O
blood	I-O
pressure	I-O
.	I-O


Safety	B-O
is	O
evaluated	O
with	O
particular	O
focus	O
on	O
hypoglycemia	B-O
,	I-O
GI	I-O
symptoms	I-O
,	I-O
and	I-O
incidence	I-O
of	I-O
genitourinary	I-O
tract	I-O
infections	I-O
.	I-O


Approval	O
summary	O
:	O
imatinib	B-I
mesylate	I-O
in	O
the	O
treatment	O
of	O
metastatic	B-P
and/or	I-P
unresectable	I-P
malignant	I-P
gastrointestinal	I-O
stromal	I-O
tumors	I-O
.	I-O


The	O
purpose	O
of	O
the	O
present	O
application	O
was	O
to	O
fulfill	O
a	O
postmarketing	O
commitment	O
to	O
provide	O
long-term	O
efficacy	O
and	O
safety	O
data	O
on	O
treatment	O
with	O
imatinib	B-O
mesylate	I-O
(	O
Gleevec	O
;	O
Novartis	O
Pharmaceuticals	O
,	O
East	O
Hanover	O
,	O
NJ	O
)	O
in	O
patients	B-P
with	I-P
CD117	I-P
(	I-P
+	I-P
)	I-P
unresectable	I-P
and/or	I-P
metastatic	I-P
malignant	I-P
gastrointestinal	I-P
stromal	I-P
tumors	I-P
(	I-P
GISTs	I-P
)	I-P
.	I-P


In	O
addition	O
,	O
this	O
application	O
also	O
provides	O
evidence	O
to	O
support	O
a	O
change	O
in	O
the	O
label	O
to	O
allow	O
for	O
an	O
escalation	O
of	O
imatinib	B-O
dosing	O
to	O
800	O
mg/day	O
for	O
patients	B-P
with	I-P
progressive	I-P
disease	I-P
on	I-P
a	I-P
lower	I-P
dose	I-P
.	I-P


Two	O
open-label	O
,	O
controlled	O
,	O
multicenter	O
,	O
intergroup	O
,	O
international	O
,	O
randomized	O
phase	O
III	O
studies	O
were	O
submitted	O
--	O
one	O
conducted	O
by	O
the	O
European	B-P
Organization	I-P
for	I-P
Research	I-P
and	I-P
Treatment	I-P
of	I-P
Cancer	I-O
(	I-P
n	I-P
=	I-P
946	I-P
)	I-P
and	I-P
the	I-P
other	I-P
by	I-P
the	I-P
Southwest	I-P
Oncology	I-O
Group	I-P
(	I-P
n	I-P
=	I-P
746	I-P
)	I-P
.	I-P


These	O
studies	O
compared	O
400	O
mg/day	O
of	O
imatinib	B-O
with	O
800	O
mg/day	O
of	O
imatinib	B-O
.	I-O


A	O
combined	O
analysis	O
of	O
the	O
two	O
studies	O
was	O
prospectively	O
defined	O
and	O
agreed	O
to	O
by	O
both	O
groups	O
.	O


Both	O
protocols	O
allowed	O
patients	O
randomized	O
to	O
the	O
400-mg/day	O
imatinib	B-I
arm	O
to	O
cross	O
over	O
to	O
800	O
mg/day	O
imatinib	B-O
at	O
progression	O
.	O


Objective	O
responses	O
were	O
achieved	O
in	O
>	O
50	O
%	O
of	O
patients	O
receiving	O
either	O
imatinib	B-O
dose	O
.	O


The	O
median	O
progression-free	B-O
survival	I-O
time	I-O
was	O
approximately	O
20	O
months	O
and	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
time	O
was	O
approximately	O
49	O
months	O
.	O


In	O
the	O
combined	O
analysis	O
,	O
347	O
patients	O
crossed	O
over	O
to	O
800	O
mg/day	O
imatinib	B-I
at	O
the	O
time	O
of	O
progression	O
.	O


The	O
median	B-O
OS	I-O
time	O
after	O
crossover	O
was	O
14.3	O
months	O
.	O


The	O
most	O
common	O
adverse	B-O
events	I-O
(	I-O
AEs	I-O
)	I-O
were	O
fluid	O
retention	O
,	O
nausea	B-O
,	I-O
fatigue	I-O
,	I-O
skin	I-O
rash	I-O
,	I-O
gastrointestinal	I-O
complaints	I-O
,	I-O
and	I-O
myalgia	I-O
.	I-O


The	O
most	O
common	O
laboratory	O
abnormality	B-O
was	I-O
anemia	I-O
.	I-O


Most	O
often	O
the	O
AEs	B-O
were	O
of	O
mild-to-moderate	O
severity	O
.	O


Fluid	O
retention	O
events	O
and	O
skin	O
rash	O
were	O
numerically	O
reported	O
more	O
often	O
in	O
the	O
800-mg/day	O
treatment	O
cohort	O
of	O
patients	O
.	O


A	O
randomised	O
controlled	O
trial	O
of	O
bumetanide	B-I
in	O
the	O
treatment	O
of	O
autism	B-P
in	I-P
children	I-P
.	I-P


Gamma	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
-mediated	O
synapses	O
and	O
the	O
oscillations	O
they	O
orchestrate	O
are	O
altered	O
in	O
autism	O
.	O


GABA-acting	O
benzodiazepines	B-I
exert	O
in	O
some	O
patients	O
with	O
autism	O
paradoxical	O
effects	B-O
,	O
raising	O
the	O
possibility	O
that	O
like	O
in	O
epilepsies	O
,	O
GABA	O
excites	O
neurons	O
because	O
of	O
elevated	O
intracellular	O
concentrations	O
of	O
chloride	O
.	O


Following	O
a	O
successful	O
pilot	O
study	O
,	O
(	O
1	O
)	O
we	O
have	O
now	O
performed	O
a	O
double-blind	O
clinical	O
trial	O
using	O
the	O
diuretic	O
,	O
chloride-importer	O
antagonist	O
bumetanide	B-I
that	O
reduces	O
intracellular	O
chloride	O
reinforcing	O
GABAergic	O
inhibition	O
.	O


Sixty	B-P
children	I-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
syndrome	I-P
(	I-P
3-11	I-P
years	I-P
old	I-P
)	I-P
received	O
for	O
3	O
months	O
placebo	B-I
or	O
bumetanide	B-I
(	O
1	O
mg	O
daily	O
)	O
,	O
followed	O
by	O
1-month	O
wash	O
out	O
.	O


Determination	O
of	O
the	O
severity	O
of	O
autism	O
was	O
made	O
with	O
video	O
films	O
at	O
day	O
0	O
(	O
D0	O
)	O
and	O
D90	O
by	O
blind	O
,	O
independent	O
evaluators	O
.	O


Bumetanide	B-I
reduced	O
significantly	O
the	O
Childhood	B-O
Autism	I-O
Rating	I-O
Scale	I-O
(	I-O
CARS	I-O
)	I-O
(	O
D90-D0	O
;	O
P	O
<	O
0.004	O
treated	O
vs	O
placebo	B-I
)	I-I
,	O
Clinical	B-O
Global	I-O
Impressions	I-O
(	O
P	O
<	O
0.017	O
treated	O
vs	O
placebo	B-I
)	I-I
and	O
Autism	B-O
Diagnostic	I-O
Observation	I-O
Schedule	I-O
values	I-O
when	O
the	O
most	O
severe	O
cases	O
(	O
CARS	O
values	O
above	O
the	O
mean	O
±	O
s.d	O
.	O


;	O
n=9	O
)	O
were	O
removed	O
(	O
Wilcoxon	O
test	O
:	O
P-value=0.031	O
;	O
Student	O
's	O
t-test	O
:	O
P-value=0.017	O
)	O
.	B-O


Side	B-O
effects	I-O
were	O
restricted	O
to	O
an	O
occasional	B-O
mild	I-O
hypokalaemia	I-O
(	O
3.0-3.5	O
mM	O
l	O
(	O
-1	O
)	O
K	O
(	O
+	O
)	O
)	O
that	O
was	O
treated	O
with	O
supplemental	O
potassium	O
.	O


In	O
a	O
companion	O
study	O
,	O
chronic	O
bumetanide	O
treatment	O
significantly	O
improved	B-O
accuracy	I-O
in	I-O
facial	I-O
emotional	I-O
labelling	I-O
,	I-O
and	I-O
increased	I-O
brain	I-O
activation	I-O
in	I-O
areas	I-O
involved	I-O
in	I-O
social	I-O
and	I-O
emotional	I-O
perception	I-O
(	O
Hadjikhani	O
et	O
al.	O
,	O
submitted	O
)	O
.	O


Therefore	B-I
,	I-I
bumetanide	I-I
is	O
a	O
promising	O
novel	O
therapeutic	O
agent	O
to	O
treat	O
autism	O
.	O


Larger	O
trials	O
are	O
warranted	O
to	O
better	O
determine	O
the	O
population	O
best	O
suited	O
for	O
this	O
treatment	O
.	O


Comparison	O
of	O
fluoxetine	B-I
and	I-I
placebo	I-I
in	O
the	O
treatment	O
of	O
obesity	B-O
.	I-O


Our	O
study	O
aims	O
at	O
assessing	O
the	O
efficacy	O
and	O
safety	O
of	O
fluoxetine	B-I
as	O
compared	O
with	O
placebo	B-I
in	O
the	O
treatment	O
of	O
obesity	B-P
using	O
a	O
double-blind	O
crossover	O
design	O
.	O


We	O
studied	O
42	B-P
obese	I-P
women	I-P
(	I-P
body	I-P
mass	I-P
index	I-P
35.9	I-P
+/-	I-P
5.3	I-P
kg/m2	I-P
)	I-P
.	I-P


The	O
obese	B-P
patients	I-P
were	O
randomized	O
to	O
start	O
treatment	O
with	O
fluoxetine	B-I
(	O
group	O
A	O
)	O
or	O
placebo	B-I
(	O
group	O
B	O
)	O
for	O
3	O
months	O
(	O
period	O
1	O
)	O
.	O


After	O
a	O
1-month	O
washout	O
period	O
,	O
treatment	O
was	O
crossed	O
for	O
the	O
following	O
3	O
months	O
(	O
period	O
2	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
weight	B-O
loss	I-O
when	O
the	O
patients	O
were	O
treated	O
with	O
fluoxetine	B-I
(	O
group	O
A	O
period	O
1	O
and	O
group	O
B	O
period	O
2	O
)	O
as	O
compared	O
with	O
patients	O
treated	O
with	O
placebo	B-I
(	O
group	O
B	O
period	O
1	O
and	O
group	O
A	O
period	O
2	O
)	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
monthly	B-O
weight	I-O
reduction	I-O
during	O
both	O
treatments	O
.	O


In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
serotoninergic	B-I
drugs	I-I
such	O
as	O
fluoxetine	B-I
need	O
further	O
investigation	O
before	O
being	O
used	O
indiscriminately	O
in	O
obese	B-P
subjects	I-P
.	I-P


Six-month	O
trial	O
of	O
on-demand	O
rabeprazole	B-I
10	O
mg	O
maintains	O
symptom	B-O
relief	I-O
in	O
patients	B-P
with	I-P
non-erosive	I-P
reflux	I-O
disease	I-O
.	I-O


BACKGROUND	O
Compliance	O
studies	O
have	O
shown	O
that	O
patients	B-P
with	I-P
reflux	I-P
symptoms	I-P
generally	O
take	O
their	O
medication	O
only	O
when	O
experiencing	O
these	O
symptoms	O
.	O


AIM	O
To	O
evaluate	O
the	O
efficacy	B-O
of	O
on-demand	O
rabeprazole	B-I
maintenance	O
therapy	O
in	O
patients	B-P
with	I-P
non-erosive	I-P
reflux	I-P
disease	I-P
.	I-P


METHODS	O
This	O
multicentre	B-P
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
withdrawal	O
study	O
compared	O
6	O
months	O
of	O
on-demand	O
treatment	O
with	O
rabeprazole	B-I
10	O
mg	O
vs.	O
placebo	B-I
.	I-I


Adults	B-P
with	I-P
a	I-P
history	I-P
of	I-P
reflux	I-P
symptoms	I-P
,	I-P
a	I-P
negative	I-P
endoscopy	I-P
,	I-P
and	I-P
>	I-P
or	I-P
=	I-P
3	I-P
days	I-P
of	I-P
moderate	I-P
to	I-P
very	I-P
severe	I-P
heartburn	I-P
in	I-P
the	I-P
7	I-P
days	I-P
before	I-P
enrollment	I-P
(	I-P
N	I-P
=	I-P
535	I-P
)	I-P
entered	O
4	O
weeks	O
of	O
open-label	O
,	O
acute	O
treatment	O
with	O
rabeprazole	B-I
10	O
mg	O
once	O
daily	O
.	O


Patients	B-P
with	I-P
complete	I-P
symptom	I-O
relief	I-O
then	I-P
entered	I-P
the	I-P
on-demand	I-P
phase	I-P
.	I-P


The	O
primary	O
end-point	O
was	O
discontinuation	B-O
due	I-O
to	I-O
lack	I-O
of	I-O
heartburn	I-O
control	I-O
during	I-O
the	I-O
on-demand	I-O
phase	I-O
.	I-O


RESULTS	O
Eighty-three	O
percent	O
(	O
432	O
of	O
523	O
)	O
of	O
patients	O
reported	O
complete	O
symptom	B-O
relief	I-O
at	O
the	O
end	O
of	O
the	O
acute	O
phase	O
.	O


During	O
on-demand	O
treatment	O
,	O
rates	B-O
of	I-O
discontinuation	I-O
because	I-O
of	I-O
inadequate	I-O
heartburn	I-O
control	I-O
were	O
20	O
%	O
(	O
28	O
of	O
139	O
)	O
for	O
placebo	B-I
vs.	O
6	O
%	O
(	O
16	O
of	O
279	O
)	O
for	O
rabeprazole	B-I
(	O
P	O
<	O
0.00001	O
)	O
.	O


Antacid	B-O
use	I-O
was	O
twofold	O
higher	O
in	O
the	O
placebo	B-I
group	O
vs.	O
the	O
rabeprazole	B-I
group	O
(	O
P	O
=	O
0.0009	O
)	O
.	O


CONCLUSIONS	O
Rabeprazole	B-I
10	O
mg	O
once	O
daily	O
is	O
highly	O
effective	B-O
in	O
acute	B-O
symptom	I-O
relief	I-O
and	O
as	O
on-demand	O
long-term	O
maintenance	O
therapy	O
in	O
non-erosive	B-P
reflux	I-P
disease	I-P
patients	I-P
.	I-P


Methylprednisolone	B-I
in	O
patients	B-P
with	I-P
cancer	I-P
using	I-P
opioids	I-P
.	I-P


The	O
effects	O
of	O
the	O
angiotensin-converting	B-I
enzyme	I-I
inhibitor	I-I
imidapril	I-I
on	O
plasma	O
plasminogen	O
activator	O
inhibitor	O
activity	O
in	O
patients	B-P
with	I-P
acute	I-P
myocardial	I-P
infarction	I-P
.	I-P


This	O
study	O
sought	O
to	O
determine	O
whether	O
early	O
treatment	O
with	O
angiotensin-converting	B-I
enzyme	I-I
(	I-I
ACE	I-I
)	I-I
inhibitors	I-I
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
is	O
useful	O
for	O
the	O
improvement	O
of	O
fibrinolytic	B-O
function	I-O
,	O
as	O
well	O
as	O
left	B-O
ventricular	I-O
function	I-O
.	I-O


This	O
study	O
was	O
designed	O
to	O
examine	O
the	O
levels	O
of	O
plasma	B-O
plasminogen	I-O
activator	I-O
inhibitor	I-O
(	I-O
PAI	I-O
)	I-O
activity	I-O
and	O
serum	B-O
ACE	I-O
activity	I-O
during	O
the	O
course	O
of	O
2	O
weeks	O
in	O
40	B-P
patients	I-P
with	I-P
AMI	I-P
within	I-P
12	I-P
hours	I-P
after	I-P
the	I-P
onset	I-P
of	I-P
the	I-P
symptom	I-P
and	I-P
who	I-P
randomly	I-P
received	I-P
early	I-P
treatment	I-P
with	I-P
either	I-P
the	I-P
ACE	I-I
inhibitor	I-I
imidapril	I-I
or	I-I
a	I-I
placebo	I-I
(	I-P
20	I-P
patients	I-P
in	I-P
the	I-P
imidapril	I-P
group	I-P
and	I-P
20	I-P
in	I-P
the	I-P
placebo	I-P
group	I-P
)	I-P
.	I-P


The	O
levels	B-O
of	I-O
serum	I-O
ACE	I-O
activity	I-O
in	O
the	O
imidapril	B-I
group	O
decreased	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
8	O
hours	O
after	O
the	O
administration	O
of	O
imidapril	B-I
,	O
and	O
the	O
levels	O
24	O
hours	O
after	O
administration	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
placebo	B-I
group	O
(	O
3.6	O
+/-	O
0.6	O
IU/L	O
vs	O
7.4	O
+/-	O
0.8	O
IU/L	O
;	O
p	O
<	O
0.001	O
)	O
.	O


The	O
plasma	B-O
PAI	I-O
activity	I-O
increased	O
gradually	O
to	O
peak	O
levels	O
16	O
hours	O
after	O
the	O
administration	O
of	O
imidapril	O
and	O
placebo	O
.	O


The	O
levels	O
in	O
the	O
placebo	O
group	O
decreased	O
gradually	O
but	O
remained	O
high	O
during	O
the	O
study	O
period	O
.	O


On	O
the	O
other	O
hand	O
,	O
the	O
levels	B-O
of	I-O
PAI	I-O
activity	I-O
in	O
the	O
imidapril	B-I
group	O
decreased	O
rapidly	O
and	O
those	O
48	O
hours	O
after	O
administration	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
placebo	B-I
group	O
(	O
7.9	O
+/-	O
1.9	O
IU/ml	O
vs	O
18.4	O
+/-	O
3.5	O
IU/ml	O
;	O
p	O
<	O
0.01	O
)	O
.	O


The	O
levels	B-O
of	I-O
left	I-O
ventricular	I-O
ejection	I-O
fraction	I-O
about	O
2	O
weeks	O
after	O
admission	O
were	O
significantly	O
higher	O
in	O
the	O
imidapril	O
group	O
than	O
in	O
the	O
placebo	B-I
group	O
(	O
65.9	O
%	O
+/-	O
2.5	O
%	O
vs	O
49.1	O
%	O
+/-	O
4.4	O
%	O
;	O
p	O
<	O
0.01	O
)	O
.	O


This	O
study	O
showed	O
that	O
imidapril	B-I
,	O
an	O
ACE	O
inhibitor	O
,	O
might	O
be	O
useful	O
for	O
the	O
improvement	O
of	O
fibrinolytic	B-O
function	I-O
and	O
left	B-O
ventricular	I-O
function	I-O
in	O
the	O
acute	O
phase	O
of	O
myocardial	O
infarction	O
.	O


Transthoracic	B-I
versus	I-I
transesophageal	I-I
cardioversion	I-I
of	I-I
atrial	I-I
fibrillation	I-I
under	I-I
light	I-I
sedation	I-I
:	I-I
a	O
prospective	O
randomized	O
trial	O
.	O


BACKGROUND	O
Electrical	B-P
cardioversion	I-P
(	I-P
ECV	I-P
)	I-P
of	I-P
atrial	I-P
fibrillation	I-P
(	I-P
AF	I-P
)	I-P
is	O
limited	O
by	O
a	O
5-10	O
%	O
failure	O
rate	O
and	O
by	O
the	O
expense	O
arising	O
from	O
a	O
perceived	O
need	O
for	O
general	O
anesthesia	O
.	O


A	O
transesophageal	O
approach	O
using	O
light	O
sedation	O
has	O
been	O
proposed	O
as	O
a	O
means	O
of	O
augmenting	O
the	O
success	O
rate	O
and	O
avoiding	O
the	O
need	O
for	O
general	O
anesthesia	O
.	O


We	O
hypothesized	O
that	O
the	O
high	O
rate	O
of	O
success	O
and	O
the	O
lower	O
energy	O
requirement	O
associated	O
with	O
biphasic	O
cardioversion	O
might	O
eliminate	O
any	O
advantage	O
of	O
the	O
transesophageal	O
approach	O
.	O


METHODS	O
We	O
randomly	O
assigned	O
60	B-P
patients	I-P
attending	I-P
for	I-P
ECV	I-I
of	I-I
persistent	I-I
AF	I-I
to	I-I
a	I-I
transesophageal	I-I
or	I-I
a	I-I
transthoracic	I-I
approach	I-I
.	I-I


Sedation	O
of	O
moderate	O
depth	O
was	O
achieved	O
with	O
intravenous	B-I
midazolam	I-I
.	I-I


The	O
dose	O
of	O
midazolam	O
was	O
titrated	O
in	O
the	O
same	O
manner	O
in	O
both	O
groups	O
.	O


RESULTS	O
Sinus	B-O
rhythm	I-O
was	O
restored	O
in	O
29/30	O
patients	O
(	O
97	O
%	O
)	O
in	O
each	O
group	O
using	O
a	O
similar	O
number	O
of	O
shocks	O
for	O
both	O
groups	O
(	O
1.3	O
+/-	O
0.6	O
transesophageal	O
vs	O
1.4	O
+/-	O
0.7	O
transthoracic	O
,	O
P	O
=	O
NS	O
)	O
with	O
a	O
similar	O
procedure	O
duration	O
(	O
14.1	O
+/-	O
8.2	O
minutes	O
vs	O
13.8	O
+/-	O
7.5	O
minutes	O
,	O
P	O
=	O
NS	O
)	O
.	O


Both	O
groups	O
received	O
similar	O
doses	O
of	O
midazolam	O
(	O
4.2	O
+/-	O
2.7	O
mg	O
vs	O
4.4	O
+/-	O
2.8	O
mg	O
,	O
P	O
=	O
NS	O
)	O
and	O
both	O
reported	O
a	O
similar	O
discomfort	B-O
score	I-O
in	O
(	O
0.9	O
+/-	O
1.3	O
vs	O
1.1	O
+/-	O
1.8	O
,	O
P	O
=	O
NS	O
)	O
.	O


No	O
complication	B-O
occurred	O
in	O
either	O
group	O
.	O


CONCLUSION	O
AF	O
may	O
be	O
cardioverted	O
safely	B-O
and	I-O
effectively	I-O
by	O
either	O
a	O
transthoracic	O
or	O
a	O
transesophageal	O
approach	O
.	O


The	O
use	O
of	O
sedation	O
of	O
moderate	O
depth	O
renders	O
cardioversion	O
by	O
either	O
approach	O
acceptable	O
.	O


As	O
transesophageal	O
ECV	O
shows	O
no	O
clear	O
advantage	O
,	O
transthoracic	O
cardioversion	O
should	O
remain	O
the	O
approach	O
of	O
first	O
choice	O
.	O


Assessment	O
from	O
Functional	O
Perspectives	O
:	O
Using	O
Sensorimotor	B-I
Control	I-I
in	I-I
the	I-I
Hand	I-I
as	O
an	O
Outcome	O
Indicator	O
in	O
the	O
Surgical	O
Treatment	O
of	O
Carpal	B-P
Tunnel	I-P
Syndrome	I-P
.	I-P


To	O
investigate	O
whether	O
sensorimotor	B-O
control	I-O
of	I-O
the	I-O
hand	I-O
could	O
be	O
an	O
outcome	B-O
indicator	I-O
after	O
carpal	O
tunnel	O
release	O
(	O
CTR	O
)	O
,	O
this	O
work	O
examined	O
changes	O
in	O
the	O
results	O
of	O
patients	O
'	O
manual	B-I
tactile	I-I
test	I-I
(	O
MTT	O
)	O
,	O
pinch-holding-up	B-I
activity	I-I
(	O
PHUA	O
)	O
,	O
two-point	B-I
discrimination	I-I
(	O
2PD	O
)	O
and	O
Semmes-Weinstein	B-I
monofilament	I-I
(	O
SWM	O
)	O
tests	O
.	O


Participants	O
included	O
30	B-P
predominantly	I-P
sensory	I-P
neuropathy	I-P
CTS	I-P
patients	I-P
,	I-P
as	I-P
confirmed	I-P
by	I-P
a	I-P
nerve	I-P
conduction	I-P
study	I-P
.	I-P


The	O
MTT	B-O
,	I-O
precision	I-O
pinch	I-O
performance	I-O
in	I-O
PHUA	I-O
and	I-I
traditional	I-O
sensibility	I-O
(	I-O
2PD	I-O
and	I-O
SWM	I-O
)	I-O
tests	I-O
were	O
used	O
to	O
examine	O
different	O
aspects	O
of	O
sensory	B-O
status	I-O
at	O
the	O
time-points	O
of	O
two	O
weeks	O
before	O
operation	O
and	O
one	O
month	O
post-operation	O
,	O
with	O
a	O
single-blind	O
design	O
.	O


The	O
results	O
showed	O
significant	O
improvements	O
in	O
the	O
sensory	B-O
function	I-O
as	O
detected	O
by	O
the	O
2PD	B-I
and	O
SWM	B-I
tests	O
(	O
p	O
<	O
0.001	O
)	O
and	O
sensorimotor	B-O
function	I-O
as	O
detected	O
by	O
the	O
MTT	B-I
(	O
p	O
<	O
0.001	O
)	O
and	O
PHUA	B-I
test	O
(	O
p	O
<	O
0.05	O
)	O
for	O
patients	O
receiving	O
CTR	O
.	O


The	O
responsiveness	O
of	O
the	O
SWM	B-I
,	I-I
MTT	I-I
and	I-I
PHUA	I-I
tests	I-I
(	O
effect	O
size	O
>	O
0.5	O
,	O
p	O
<	O
0.01	O
)	O
are	O
better	O
than	O
that	O
of	O
two-point	O
discrimination	O
test	O
(	O
effect	O
size	O
<	O
0.5	O
,	O
p	O
<	O
0.001	O
)	O
.	O


However	O
,	O
pinch	B-O
strength	I-O
saw	O
a	O
decline	O
compared	O
to	O
baseline	O
with	O
a	O
moderate	O
effect	O
sizes	O
(	O
effect	O
size	O
=	O
0.7	O
,	O
p	O
<	O
0.001	O
)	O
.	O


This	O
cohort	O
study	O
found	O
that	O
the	O
MTT	B-I
and	O
PHUA	B-I
test	O
can	O
both	O
meet	O
all	O
the	O
statistical	O
criteria	O
with	O
regard	O
to	O
assessing	O
treatment	O
outcomes	O
for	O
patients	B-P
with	I-P
CTS	I-P
.	I-P


In	O
addition	O
,	O
the	O
results	O
of	O
this	O
work	O
provide	O
clinicians	O
with	O
the	O
information	O
that	O
the	O
sensorimotor	B-O
functions	I-O
of	O
the	O
hands	O
,	O
as	O
assessed	O
by	O
MTT	B-I
and	I-I
PHUA	I-I
,	O
are	O
responsive	O
to	O
clinical	O
changes	O
due	O
to	O
CTR	O
.	O


Value	O
of	O
an	O
anal	B-I
dilator	I-I
after	O
anal	O
stretch	O
for	O
haemorrhoids	B-O
.	I-O


A	O
prospective	O
randomized	O
trial	O
compared	O
anal	B-I
stretch	I-I
with	I-I
or	I-I
without	I-I
continued	I-I
dilatation	I-I
for	O
three	O
months	O
in	O
89	B-P
consecutive	I-P
patients	I-P
with	I-P
haemorrhoids	I-P
.	I-P


Complications	B-O
of	I-O
therapy	I-O
occurred	O
in	O
only	O
4	O
patients	O
,	O
3	O
of	O
whom	O
had	O
transient	O
incontinence	B-O
of	O
flatus	O
.	O


When	O
patients	O
were	O
reviewed	O
four	O
months	O
after	O
treatment	O
,	O
only	O
4	O
of	O
44	O
patients	O
(	O
9	O
%	O
)	O
who	O
used	O
a	O
dilator	O
had	O
not	O
been	O
improved	O
and	O
required	O
additional	O
therapy	O
,	O
compared	O
with	O
15	O
of	O
42	O
patients	O
(	O
36	O
%	O
)	O
who	O
had	O
anal	B-I
stretch	I-I
alone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O


It	O
is	O
concluded	O
that	O
the	O
use	O
of	O
an	O
anal	O
dilator	O
improves	O
the	O
results	O
of	O
anal	B-O
stretch	I-O
.	I-O


Plasma	O
pH	O
does	O
not	O
influence	O
the	O
cerebral	B-P
metabolic	I-P
ratio	I-P
during	I-P
maximal	I-P
whole	I-P
body	I-P
exercise	I-P
.	I-P


Exercise	O
lowers	O
the	O
cerebral	O
metabolic	O
ratio	O
of	O
O2	O
to	O
carbohydrate	O
(	O
glucose+1/2	O
lactate	O
)	O
and	O
metabolic	O
acidosis	O
appears	O
to	O
promote	B-O
cerebral	I-O
lactate	I-O
uptake	I-O
.	I-O


However	O
,	O
the	O
influence	O
of	O
pH	O
on	O
cerebral	O
lactate	O
uptake	O
and	O
,	O
in	O
turn	O
,	O
on	O
the	O
cerebral	O
metabolic	O
ratio	O
during	O
exercise	O
is	O
not	O
known	O
.	O


Sodium	B-I
bicarbonate	I-I
(	I-I
Bicarb	I-I
,	I-I
1	I-I
M	I-I
;	I-I
350-500	I-I
ml	I-I
)	I-I
or	I-I
an	I-I
equal	I-I
volume	I-I
of	I-I
normal	I-I
saline	I-I
(	I-I
Sal	I-I
)	I-I
was	I-I
infused	I-I
intravenously	I-I
at	I-I
a	I-I
constant	I-I
rate	I-I
during	I-I
a	I-I
'2000	I-I
m	I-I
'	I-I
maximal	I-I
ergometer	I-I
row	I-I
in	O
six	B-P
male	I-P
oarsmen	I-P
(	I-P
23±2	I-P
years	I-P
;	I-P
mean±S.D.	I-P
)	I-P
.	O


During	O
the	O
Sal	O
trial	B-O
,	I-O
pH	I-O
decreased	O
from	O
7.41±0.01	O
at	O
rest	O
to	O
7.02±0.02	O
but	O
only	O
to	O
7.36±0.02	O
(	O
P	O
<	O
0.05	O
)	O
during	O
the	O
Bicarb	O
trial	B-O
.	I-O


Arterial	B-O
lactate	I-O
increased	O
to	O
21.4±0.8	O
and	O
32.7±2.3	O
mM	O
during	O
the	O
Sal	O
and	O
Bicarb	O
trials	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Also	B-O
,	I-O
the	I-O
arterial-jugular	I-O
venous	I-O
lactate	I-O
difference	O
increased	O
from-0.03±0.01	O
mM	O
at	O
rest	O
to	O
3.2±0.9	O
mM	O
(	O
P	O
<	O
0.05	O
)	O
and	O
3.4±1.4	O
mM	O
(	O
P	O
<	O
0.05	O
)	O
following	O
the	O
Sal	O
and	O
Bicarb	O
trials	O
,	O
respectively	O
.	O


Accordingly	B-O
,	I-O
the	I-O
cerebral	I-O
metabolic	I-O
ratio	I-O
decreased	O
equally	O
during	O
the	O
Sal	O
and	O
Bicarb	O
trials	O
:	O
from	O
5.8±0.6	O
at	O
rest	O
to	O
1.7±0.1	O
and	O
1.8±0.2	O
,	O
respectively	B-O
.	I-O


The	B-O
enlarged	I-O
blood-buffering	I-O
capacity	O
after	B-I
infusion	I-I
of	O
Bicarb	B-O
eliminated	I-O
metabolic	I-O
acidosis	O
during	O
maximal	O
exercise	O
but	O
that	O
did	O
not	B-O
affect	I-O
the	I-O
cerebral	I-O
lactate	I-O
uptake	O
and	O
,	O
therefore	O
,	O
the	O
decrease	B-O
in	I-O
the	I-O
cerebral	I-O
metabolic	I-O
ratio	O
.	O


[	O
Efficacy	O
observation	O
on	O
chronic	B-O
tension-type	I-O
headache	I-O
treated	O
with	O
acupuncture	O
at	O
galea	O
tendon-muscle	O
node	O
]	O
.	O


OBJECTIVE	O
To	O
explore	O
the	O
better	O
therapy	O
for	O
chronic	B-O
tension-type	I-O
headache	I-O
(	I-O
CTTH	I-O
)	I-O
.	I-O


METHODS	O
Two	B-P
hundred	I-P
and	I-P
eighty-eight	I-P
cases	I-P
were	O
randomized	O
into	O
a	O
sticking	B-I
needling	I-I
group	I-I
(	I-I
150	I-I
cases	I-I
)	I-I
and	I-I
an	I-I
acupuncture	I-I
group	I-I
(	O
138	O
cases	O
)	O
.	O


In	O
the	O
sticking	B-I
needling	I-I
group	O
,	O
the	B-I
manual	I-I
sticking	I-I
needling	I-I
technique	I-I
was	O
adopted	O
to	O
stimulate	O
the	O
galea	O
tendon-muscle	O
node	O
.	O


In	O
the	O
acupuncture	O
group	O
,	O
the	O
conventional	B-I
acupuncture	I-I
therapy	I-I
was	I-I
applied	I-I
to	O
Baihui	O
(	O
GV	O
20	O
)	O
,	O
Sishencong	O
(	O
EX-HN	O
1	O
)	O
,	O
Fengchi	O
(	O
GB	O
20	O
)	O
,	O
Taiyang	O
(	O
EX-HN	O
5	O
)	O
,	O
Touwei	O
(	O
ST	O
18	O
)	O
,	O
Hegu	O
(	O
LI	O
4	O
)	O
,	O
etc	O
.	O


The	O
treatment	O
was	O
given	O
once	O
a	O
day	O
,	O
and	O
30	O
days	O
made	O
one	O
session	O
.	O


After	O
two	O
sessions	O
of	O
treatment	O
and	O
after	O
three	O
months	O
follow-up	O
,	O
CTTH	B-O
score	I-O
(	I-O
including	I-O
the	I-O
score	I-O
of	I-O
headache	I-O
attack	I-O
frequency	I-O
and	I-O
the	I-O
score	I-O
of	I-O
headache	I-O
severity	I-O
)	I-O
was	O
observed	O
and	O
compared	O
before	O
and	O
after	O
treatment	O
separately	O
.	O


The	O
efficacy	B-O
was	O
evaluated	O
in	O
two	O
groups	O
.	O


RESULTS	O
CTTH	B-O
score	I-O
was	O
all	O
reduced	O
after	O
treatment	O
in	O
the	O
two	O
groups	O
(	O
both	O
P	O
<	O
0.01	O
)	O
,	O
the	O
score	B-O
in	I-O
the	I-O
sticking	I-O
needling	I-O
group	I-O
was	O
lower	O
than	O
that	O
in	O
the	O
acupuncture	B-I
group	O
(	O
2.38	O
+/-	O
1.22	O
vs	O
4.16	O
+/-	O
2.54	O
,	O
P	O
<	O
0.01	O
)	O
.	O


The	O
effective	B-O
rate	I-O
was	O
97.3	O
%	O
(	O
146/150	O
)	O
in	O
the	O
sticking	O
needling	O
group	O
,	O
which	O
was	O
better	O
than	O
88.4	O
%	O
(	O
122/138	O
)	O
in	O
the	O
acupuncture	B-I
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
The	O
manual	B-I
sticking	I-I
needling	I-I
technique	I-I
at	O
galea	O
tendon-muscle	O
node	O
achieves	O
the	O
superior	O
results	O
of	O
reducing	B-O
the	I-O
pain	I-O
attack	I-O
frequency	I-O
and	I-O
severity	I-O
of	I-O
CTTH	I-O
as	O
compared	O
with	O
the	O
acupuncture	O
therapy	O
of	O
the	O
routine	O
acupoint	O
selection	O
.	O


A	O
comparison	O
of	O
acceptance-	O
and	O
control-based	O
strategies	O
for	O
coping	O
with	O
food	O
cravings	O
:	O
an	O
analog	O
study	O
.	O


The	O
present	O
study	O
utilized	O
an	O
analog	B-O
paradigm	I-O
to	O
investigate	O
the	O
effectiveness	B-O
of	O
two	O
strategies	O
for	O
coping	O
with	O
food	O
cravings	O
,	O
which	O
was	O
theorized	O
to	O
be	O
critical	O
to	O
the	O
maintenance	O
of	O
weight	O
loss	O
.	O


Ninety-eight	B-P
undergraduate	I-P
students	I-P
were	I-P
given	I-I
transparent	I-I
boxes	I-I
of	I-I
chocolate	I-I
Hershey	I-I
's	I-I
Kisses	I-I
and	I-I
instructed	I-I
to	I-I
keep	I-I
the	I-I
chocolates	I-I
with	I-I
them	I-I
,	O
but	O
not	O
to	O
eat	O
them	O
,	O
for	O
48	O
h.	O
Before	O
receiving	O
the	O
Kisses	O
,	O
participants	O
were	O
randomized	O
to	O
receive	O
either	B-I
(	I-I
a	I-I
)	I-I
no	I-I
intervention	I-I
,	I-I
(	I-I
b	I-I
)	I-I
instruction	I-I
in	I-I
control-based	I-I
coping	I-I
strategies	I-I
such	I-I
as	I-I
distraction	I-I
and	I-I
cognitive	I-I
restructuring	I-I
,	I-I
or	I-I
(	I-I
c	I-I
)	I-I
instruction	I-I
in	I-I
acceptance-based	I-I
strategies	I-I
such	I-I
as	I-I
experiential	I-I
acceptance	I-I
and	I-I
defusion	I-I
techniques	I-I
.	I-I


Measures	O
included	O
the	O
Power	B-O
of	I-O
Food	I-O
Scale	I-O
(	I-O
PFS	I-O
;	I-O
a	I-O
measure	I-O
of	I-O
psychological	I-O
sensitivity	I-O
to	I-O
the	I-O
food	I-O
environment	I-O
)	I-O
,	I-O
self-report	I-O
ratings	I-O
of	I-O
chocolate	I-O
cravings	I-O
and	I-O
surreptitiously	I-O
recorded	I-O
chocolate	I-O
consumption	I-O
.	I-O


Results	O
suggested	O
that	O
the	O
effect	B-O
of	O
the	O
intervention	O
depended	O
on	O
baseline	B-O
PFS	I-O
levels	I-O
,	O
such	O
that	O
acceptance-based	O
strategies	O
were	O
associated	O
with	O
better	O
outcomes	O
(	B-O
cravings	I-O
,	I-O
consumption	I-O
)	I-O
among	O
those	O
reporting	O
the	O
highest	O
susceptibility	O
to	O
the	O
presence	O
of	O
food	O
,	O
but	O
greater	O
cravings	O
among	O
those	O
who	O
scored	O
lowest	O
on	O
the	O
PFS	O
.	O


It	O
was	O
observed	O
that	O
craving	B-O
self-report	I-O
measures	I-O
predicted	O
chocolate	B-O
consumption	I-O
,	O
and	O
baseline	O
PFS	B-O
levels	I-O
predicted	O
both	O
cravings	O
and	O
consumption	O
.	O


Results	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
implications	O
for	O
weight	O
loss	O
maintenance	O
strategies	O
.	O


Prolonged	O
sirolimus	B-I
administration	O
after	B-P
allogeneic	I-P
hematopoietic	I-P
cell	I-P
transplantation	I-P
is	O
associated	O
with	O
decreased	O
risk	O
for	O
moderate-severe	O
chronic	B-O
graft-versus-host	I-O
disease	I-O
.	I-O


Effective	O
pharmacological	O
strategies	O
employed	O
in	O
allogeneic	B-P
hematopoietic	I-P
cell	I-P
transplantation	I-P
should	O
prevent	O
serious	O
chronic	O
graft-versus-host	O
disease	O
and	O
facilitate	O
donor-recipient	O
immune	O
tolerance	O
.	O


Based	O
on	O
demonstrated	O
pro-tolerogenic	O
activity	O
,	O
sirolimus	B-I
(	I-I
rapamycin	I-I
)	I-I
is	O
an	O
agent	O
with	O
promise	O
to	O
achieve	O
these	O
goals	O
.	O


In	O
a	O
long-term	O
follow-up	O
analysis	O
of	O
a	O
randomized	O
phase	O
II	O
trial	O
comparing	O
sirolimus/tacrolimus	B-I
versus	I-I
methotrexate/tacrolimus	I-I
for	O
graft-versus-host	O
disease	O
prevention	O
in	O
matched	B-P
sibling	I-P
or	I-P
unrelated	I-P
donor	I-P
transplant	I-P
,	O
we	O
examined	O
the	O
impact	O
of	O
prolonged	B-P
sirolimus	I-I
administration	I-P
(	I-P
≥	I-P
1	I-P
year	I-P
post-transplant	I-O
)	I-O
.	I-O


Median	B-O
follow-up	I-O
time	I-O
for	I-O
surviving	I-O
patients	I-O
at	I-P
time	I-P
of	I-P
this	I-P
analysis	I-P
was	I-P
41	I-P
months	I-P
(	I-P
range	I-P
27-60	I-P
)	I-P
for	I-I
sirolimus/tacrolimus	I-I
and	I-P
49	I-P
months	I-P
(	I-P
range	I-P
29-63	I-P
)	I-P
for	I-I
methotrexate/tacrolimus	I-I
.	I-I


Sirolimus/tacrolimus	B-I
patients	O
had	O
significantly	O
lower	B-O
National	I-O
Institutes	I-O
of	I-O
Health	I-O
Consensus	I-O
moderate-severe	I-O
chronic	I-O
graft-versus-host	I-O
disease	I-O
(	O
34	O
%	O
vs.	O
65	O
%	O
;	O
P=0.004	O
)	O
and	B-O
late	I-O
acute	I-O
graft-versus-host	I-O
disease	I-O
(	O
20	O
%	O
vs.	O
43	O
%	O
;	O
P=0.04	O
)	O
.	O


While	B-I
sirolimus/tacrolimus	I-I
patients	O
had	O
lower	B-O
prednisone	I-O
exposure	I-O
and	O
earlier	B-O
discontinuation	I-O
of	I-O
tacrolimus	I-O
(	O
median	O
time	O
to	O
tacrolimus	O
discontinuation	O
368	O
days	O
vs.	O
821	O
days	O
;	O
P=0.002	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	B-O
complete	I-O
immune	I-O
suppression	I-O
discontinuation	I-O
(	O
60-month	O
estimate	O
:	O
43	O
%	O
vs.	O
31	O
%	O
;	O
P=0.78	O
)	O
.	O


Prolonged	B-I
sirolimus	I-I
administration	O
represents	O
a	O
viable	O
approach	O
to	O
mitigate	O
risk	O
for	O
moderate-severe	O
chronic	O
and	O
late	O
acute	O
graft-versus-host	O
disease	O
.	O


Further	O
study	O
of	O
determinants	O
of	O
successful	O
immune	O
suppression	O
discontinuation	O
is	O
needed	O
.	O


Effect	O
of	O
recombinant	B-I
adenovirus-p53	I-I
combined	I-I
with	I-I
radiotherapy	I-I
on	O
long-term	B-O
prognosis	I-O
of	I-O
advanced	I-O
nasopharyngeal	I-O
carcinoma	I-O
.	I-O


PURPOSE	O
To	O
centrally	O
assess	O
the	O
safety	B-O
,	I-O
efficacy	I-O
,	I-O
and	I-O
6-year	I-O
follow-up	I-O
of	O
recombinant	B-I
adenovirus-p53	I-I
(	I-I
rAd-p53	I-I
)	I-I
combined	I-I
with	I-I
radiotherapy	I-I
(	I-I
RT	I-I
)	I-I
for	O
patients	B-P
with	I-P
nasopharyngeal	I-P
carcinoma	I-P
(	I-P
NPC	I-P
)	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
A	O
randomized	O
controlled	O
clinical	O
study	O
on	O
rAd-p53	B-I
combined	I-I
with	I-I
RT	I-I
in	O
42	B-P
patients	I-P
with	I-P
NPC	I-P
was	I-P
compared	I-P
with	I-P
a	I-P
control	I-P
group	I-P
of	I-P
40	I-P
patients	I-P
with	I-P
NPC	I-P
treated	I-P
with	I-P
RT	I-I
alone	I-I
.	I-I


In	O
the	O
group	O
receiving	O
rAd-p53	B-I
combined	I-I
with	I-I
RT	I-I
,	I-I
rAd-p53	I-I
was	O
intratumorally	O
injected	O
once	O
a	O
week	O
for	O
8	O
weeks	O
.	O


Concurrent	O
RT	O
(	O
70	O
Gy	O
in	O
35	O
fractions	O
)	O
was	O
given	O
to	O
the	O
nasopharyngeal	O
tumor	O
and	O
neck	O
lymph	O
node	O
.	O


Patients	O
and	O
tumors	O
were	O
monitored	O
for	O
adverse	B-O
events	I-O
and	I-O
responses	I-O
.	I-O


RESULTS	O
rAd-p53-specific	B-O
p53	I-O
mRNA	I-O
was	O
detected	O
in	O
postinjection	O
of	O
rAd-p53	O
biopsies	O
from	O
16	O
(	O
94.1	O
%	O
)	O
of	O
17	O
patients	O
.	O


Upregulation	O
of	O
p21/WAF1	B-O
and	I-O
Bax	I-O
and	O
downregulation	O
of	O
vascular	B-O
endothelial	I-O
growth	I-O
factor	I-O
were	O
observed	O
in	O
postinjection	O
tumor	O
biopsy	O
.	O


Complete	B-O
response	I-O
rate	I-O
in	O
the	O
group	O
receiving	O
rAd-p53	B-I
combined	I-I
with	I-I
RT	I-I
was	O
observed	O
at	O
2.73	O
times	O
that	O
of	O
the	O
group	O
receiving	O
RT	B-I
alone	I-I
(	O
66.7	O
%	O
v	O
24.4	O
%	O
)	O
.	O


Six-year	O
follow-up	O
data	O
showed	O
that	O
rAd-p53	B-I
significantly	O
increased	O
the	O
5-year	B-O
locoregional	I-O
tumor	I-O
control	I-O
rate	I-O
by	O
25.3	O
%	O
for	O
patients	B-P
with	I-P
NPC	I-P
treated	O
with	O
irradiation	O
(	O
P	O
=	O
.002	O
)	O
.	O


The	O
5-year	B-O
overall	I-O
survival	I-O
rate	I-O
and	I-O
5-year	I-O
disease-free	I-O
survival	I-O
rate	I-O
of	O
the	O
group	O
receiving	O
rAd-p53	B-I
combined	I-I
with	I-I
RT	I-I
were	O
7.5	O
%	O
(	O
P	O
=	O
.34	O
)	O
and	O
11.7	O
%	O
(	O
P	O
=	O
.21	O
)	O
higher	O
than	O
those	O
of	O
the	O
group	O
receiving	O
RT	B-I
alone	I-I
.	I-I


No	O
dose-limiting	B-O
toxicity	I-O
or	I-O
adverse	I-O
events	I-O
appeared	O
,	O
except	O
for	O
transient	B-O
fever	I-O
after	O
rAd-p53	B-I
administration	O
.	O


CONCLUSION	O
In	O
patients	B-P
with	I-P
NPC	I-P
,	O
rAd-p53	B-I
was	O
safe	B-O
and	I-O
biologically	I-O
active	I-O
.	I-O


Our	O
results	O
indicated	O
that	O
rAd-p53	B-I
improves	O
radiotherapeutic	B-O
tumor	I-O
control	I-O
and	I-O
survival	I-O
rate	I-O
in	O
patients	B-P
with	I-P
NPC	I-P
.	I-P


A	O
prospective	O
,	O
placebo-controlled	B-I
,	O
randomized	O
trial	O
of	O
intravenous	O
streptokinase	B-I
and	O
angioplasty	B-I
versus	I-I
lone	I-I
angioplasty	I-I
therapy	I-I
of	O
acute	O
myocardial	O
infarction	O
.	O


BACKGROUND	O
The	O
value	O
of	O
routine	O
administration	O
of	O
intravenous	O
thrombolytic	B-I
agents	I-I
during	O
percutaneous	B-I
transluminal	I-I
coronary	I-I
angioplasty	I-I
(	I-I
PTCA	I-I
)	I-I
therapy	I-I
of	O
acute	O
myocardial	O
infarction	O
(	O
MI	O
)	O
has	O
not	O
been	O
determined	O
.	O


Therefore	O
,	O
we	O
prospectively	O
randomized	O
122	B-P
patients	I-P
with	I-P
evolving	I-P
MI	I-P
to	I-P
PTCA	I-I
therapy	I-I
with	I-P
or	I-P
without	I-P
adjunctive	I-P
intravenous	I-I
streptokinase	I-I
therapy	I-I
.	I-I


METHODS	O
AND	O
RESULTS	O
Patients	B-P
with	I-P
ECG	I-P
ST	I-P
segment	I-P
elevation	I-P
who	I-P
presented	I-P
within	I-P
4	I-P
hours	I-P
of	I-P
symptom	I-P
onset	I-P
,	I-P
had	I-P
no	I-P
contraindication	I-P
to	I-P
thrombolytic	I-I
therapy	I-I
,	I-P
and	I-P
were	I-P
not	I-P
in	I-P
cardiogenic	I-P
shock	I-P
were	I-P
enrolled	I-P
.	I-P


They	O
were	O
treated	O
immediately	O
with	O
intravenous	B-I
heparin	I-I
(	O
10,000	O
units	O
)	O
and	O
oral	B-I
aspirin	I-I
(	O
325	O
mg	O
)	O
and	O
randomized	O
to	O
treatment	O
with	O
placebo	B-I
or	I-I
streptokinase	I-I
(	O
1.5	O
M	O
units	O
)	O
administered	O
intravenously	O
over	O
30	O
minutes	O
.	O


Patients	O
then	O
were	O
taken	O
immediately	O
to	O
the	O
catheterization	O
laboratory	O
,	O
and	O
those	O
with	O
suitable	O
coronary	O
anatomy	O
underwent	O
immediate	O
PTCA	B-I
.	I-I


Subsequent	O
clinical	O
course	O
,	O
serial	O
radionuclide	O
ventriculography	O
,	O
and	O
6-month	O
repeat	O
angiography	O
were	O
analyzed	O
.	O


A	O
total	O
of	O
106	B-P
patients	I-P
were	I-P
treated	I-P
with	I-P
PTCA	I-I
.	I-I


Use	O
of	O
PTCA	B-I
was	O
similar	O
for	O
placebo	B-I
(	O
92	O
%	O
)	O
and	O
streptokinase	B-I
(	O
83	O
%	O
)	O
groups	O
.	O


Angioplasty	B-I
was	O
successful	O
in	O
95	O
%	O
of	O
patients	O
,	O
with	O
no	O
difference	O
in	O
placebo	B-I
(	O
93	O
%	O
)	O
and	O
streptokinase	B-I
(	O
98	O
%	O
)	O
groups	O
.	O


Serial	O
radionuclide	O
ventriculography	O
demonstrated	O
no	O
difference	O
in	O
24-hour	O
(	O
52	O
+/-	O
12	O
%	O
versus	O
50	O
+/-	O
12	O
%	O
)	O
or	O
6-week	O
(	O
51	O
+/-	O
12	O
%	O
versus	O
51	O
+/-	O
13	O
%	O
)	O
ejection	B-O
fraction	I-O
values	I-O
for	O
placebo	B-I
and	I-I
streptokinase	I-I
groups	O
,	O
respectively	O
.	O


Contrast	B-O
ventriculography	I-O
demonstrated	O
improvement	O
in	O
immediate	O
(	O
54	O
+/-	O
12	O
%	O
)	O
versus	O
6-month	O
(	O
60	O
+/-	O
15	O
%	O
,	O
p	O
<	O
0.05	O
)	O
values	O
for	O
the	O
overall	O
group	O
.	O


No	O
differences	O
in	O
6-month	B-O
values	I-O
were	O
present	O
(	O
58	O
+/-	O
15	O
%	O
versus	O
62	O
+/-	O
15	O
%	O
,	O
p	O
=	O
NS	O
)	O
for	O
placebo	B-I
and	I-I
streptokinase	I-I
groups	O
,	O
respectively	O
.	O


Coronary	B-O
angiography	I-O
was	O
performed	O
in	O
75	O
%	O
of	O
the	O
90	O
patients	O
eligible	O
for	O
restudy	O
.	O


Arterial	B-O
patency	I-O
was	O
87	O
%	O
at	O
6	O
months	O
,	O
and	O
coronary	B-O
restenosis	I-O
was	O
present	O
in	O
38	O
%	O
of	O
patients	O
.	O


No	O
differences	O
in	O
chronic	B-O
patency	I-O
or	I-O
restenosis	I-O
were	O
detected	O
for	O
the	O
two	O
treatment	O
groups	O
.	O


Although	O
adjunctive	O
intravenous	O
streptokinase	B-I
therapy	O
did	O
not	O
improve	O
outcome	O
,	O
it	O
did	O
complicate	O
the	O
hospital	O
course	O
.	O


Hospitalization	B-O
was	O
longer	O
(	O
9.3	O
+/-	O
5.0	O
versus	O
7.7	O
+/-	O
4.4	O
days	O
,	O
p	O
=	O
0.046	O
)	O
and	O
more	O
costly	B-O
(	O
$	O
25,191	O
+/-	O
15,368	O
versus	O
$	O
19,643	O
+/-	O
7,250	O
,	O
p	O
<	O
0.02	O
)	O
.	O


Transfusion	B-O
rate	I-O
was	O
higher	O
(	O
39	O
%	O
versus	O
8	O
%	O
,	O
p	O
=	O
0.0001	O
)	O
and	O
need	O
for	O
emergency	O
coronary	O
bypass	O
surgery	O
was	O
greater	O
(	O
10.3	O
%	O
versus	O
1.6	O
%	O
,	O
p	O
=	O
0.03	O
)	O
for	O
the	O
streptokinase-treated	O
patients	O
.	O


CONCLUSIONS	O
Adjunctive	O
intravenous	O
streptokinase	B-I
therapy	I-I
does	O
not	O
enhance	O
early	O
preservation	O
of	O
ventricular	B-O
function	I-O
,	O
improve	O
arterial	B-O
patency	I-O
rates	I-O
,	O
or	O
lower	O
restenosis	B-O
rates	I-O
after	O
PTCA	B-I
therapy	I-I
of	O
acute	O
MI	O
.	O


Hospital	O
course	O
is	O
longer	O
,	O
more	O
expensive	O
,	O
and	O
more	O
complicated	O
.	O


For	O
these	O
reasons	O
,	O
PTCA	B-I
therapy	I-I
of	O
acute	O
MI	O
should	O
not	O
be	O
routinely	O
performed	O
with	O
adjunctive	O
intravenous	O
streptokinase	B-I
therapy	I-I
.	I-I


Intranasal	O
oxytocin	B-I
improves	O
emotion	B-O
recognition	I-O
for	O
youth	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


BACKGROUND	O
A	O
diagnostic	O
hallmark	O
of	O
autism	O
spectrum	O
disorders	O
is	O
a	O
qualitative	O
impairment	O
in	O
social	O
communication	O
and	O
interaction	O
.	O


Deficits	O
in	O
the	O
ability	O
to	O
recognize	O
the	O
emotions	O
of	O
others	O
are	O
believed	O
to	O
contribute	O
to	O
this	O
.	O


There	O
is	O
currently	O
no	O
effective	O
treatment	O
for	O
these	O
problems	O
.	O


METHODS	O
In	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
crossover	O
design	O
,	O
we	O
administered	O
oxytocin	B-I
nasal	I-I
spray	I-I
(	O
18	O
or	O
24	O
IU	O
)	O
or	O
a	O
placebo	B-I
to	O
16	B-P
male	I-P
youth	I-P
aged	I-P
12	I-P
to	I-P
19	I-P
who	I-P
were	I-P
diagnosed	I-P
with	I-P
Autistic	I-P
or	I-P
Asperger	I-P
's	I-P
Disorder	I-P
.	I-P


Participants	B-P
then	O
completed	O
the	O
Reading	B-O
the	I-O
Mind	I-O
in	I-O
the	I-O
Eyes	I-O
Task	I-O
,	O
a	O
widely	O
used	O
and	O
reliable	O
test	O
of	O
emotion	B-O
recognition	I-O
.	I-O


RESULTS	O
In	O
comparison	O
with	O
placebo	B-I
,	I-I
oxytocin	I-I
administration	O
improved	O
performance	B-O
on	I-O
the	I-O
Reading	I-O
the	I-O
Mind	I-O
in	I-O
the	I-O
Eyes	I-O
Task	I-O
.	I-O


This	O
effect	O
was	O
also	O
shown	O
when	O
analysis	O
was	O
restricted	O
to	O
the	O
younger	B-P
participants	I-P
aged	I-P
12	I-P
to	I-P
15	I-P
who	O
received	O
the	O
lower	O
dose	O
.	O


CONCLUSIONS	O
This	O
study	O
provides	O
the	O
first	O
evidence	O
that	O
oxytocin	O
nasal	O
spray	O
improves	O
emotion	B-O
recognition	I-O
in	O
young	B-P
people	I-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


Findings	O
suggest	O
the	O
potential	O
of	O
earlier	O
intervention	O
and	O
further	O
evaluation	O
of	O
oxytocin	B-I
nasal	O
spray	O
as	O
a	O
treatment	O
to	O
improve	O
social	O
communication	O
and	O
interaction	O
in	O
young	B-P
people	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


Longitudinal	O
follow-up	O
of	O
children	B-P
with	I-P
autism	I-P
receiving	I-P
targeted	I-P
interventions	I-P
on	I-P
joint	I-I
attention	I-I
and	I-I
play	I-I
.	I-I


OBJECTIVE	O
This	O
study	O
examines	O
the	O
cognitive	B-O
and	I-O
language	I-O
outcomes	I-O
of	O
children	B-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
over	I-P
a	I-P
5-year	I-P
period	I-P
after	I-P
receiving	I-P
targeted	I-I
early	I-I
interventions	I-I
that	I-I
focused	I-I
on	I-I
joint	I-I
attention	I-I
and	I-I
play	I-I
skills	I-I
.	I-I


METHOD	O
Forty	B-P
children	I-P
from	I-P
the	I-P
original	I-P
study	I-P
(	I-P
n	I-P
=	I-P
58	I-P
)	I-P
had	I-P
complete	I-P
data	I-P
at	I-P
the	I-P
5-year	I-P
follow-up	I-P
.	I-P


RESULTS	O
In	O
all	O
,	O
80	O
%	O
of	O
children	O
had	O
achieved	O
functional	B-O
use	I-O
of	I-O
spoken	I-O
language	I-O
with	O
baseline	O
play	O
level	O
predicting	O
spoken	O
language	O
at	O
the	O
5-year	O
follow-up	O
.	O


Of	O
children	O
who	O
were	O
using	O
spoken	O
language	O
at	O
age	O
8	O
years	O
,	O
several	O
baseline	O
behaviors	O
predicted	O
their	O
later	O
ability	O
,	O
including	O
earlier	O
age	O
of	O
entry	O
into	O
the	O
study	O
,	O
initiating	O
joint	B-O
attention	I-O
skill	I-O
,	I-O
play	I-O
level	I-O
,	O
and	O
assignment	O
to	O
either	O
the	O
joint	B-I
attention	I-I
or	I-I
symbolic	I-I
play	I-I
intervention	O
group	O
.	O


Only	O
baseline	O
play	O
diversity	O
predicted	O
cognitive	O
scores	O
at	O
age	O
8	O
years	O
.	O


CONCLUSIONS	O
This	O
study	O
is	O
one	O
of	O
the	O
only	O
long-term	O
follow-up	O
studies	O
of	O
children	B-P
who	I-P
participated	I-P
in	I-P
preschool	I-P
early	I-P
interventions	I-P
aimed	I-P
at	I-P
targeting	I-P
core	I-P
developmental	I-P
difficulties	I-P
.	I-P


The	O
study	O
findings	O
suggest	O
that	O
focusing	O
on	O
joint	O
attention	O
and	O
play	O
skills	O
in	O
comprehensive	O
treatment	O
models	O
is	O
important	O
for	O
long-term	B-O
spoken	I-O
language	I-O
outcomes	I-O
.	I-O


Corticosteroids	B-I
plus	I-I
pulse	I-I
cyclophosphamide	I-I
and	I-I
plasma	I-I
exchanges	I-I
versus	O
corticosteroids	B-I
plus	I-I
pulse	I-I
cyclophosphamide	I-I
alone	I-I
in	O
the	O
treatment	O
of	O
polyarteritis	B-P
nodosa	I-P
and	I-P
Churg-Strauss	I-P
syndrome	I-P
patients	I-P
with	I-P
factors	I-P
predicting	I-P
poor	I-P
prognosis	I-P
.	I-P


A	O
prospective	O
,	O
randomized	O
trial	O
in	O
sixty-two	B-P
patients	I-P
.	I-P


OBJECTIVE	O
To	O
define	O
the	O
most	O
effective	O
treatment	O
for	O
severe	B-P
polyarteritis	I-P
nodosa	I-P
(	I-P
PAN	I-P
)	I-P
and	I-P
Churg-Strauss	I-P
syndrome	I-P
(	I-P
CSS	I-P
)	I-P
and	O
to	O
investigate	O
the	O
indication	O
for	O
plasma	O
exchange	O
treatment	O
.	O


METHODS	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
multicenter	O
trial	O
in	O
which	O
62	B-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
receive	I-P
either	I-P
prednisone	I-I
plus	I-I
cyclophosphamide	I-I
(	I-I
intravenous	I-I
bolus	I-I
)	I-I
(	I-I
group	I-I
A	I-I
;	I-I
n	I-I
=	I-I
28	I-I
)	I-I
or	I-I
prednisone	I-I
plus	I-I
cyclophosphamide	I-I
(	I-I
intravenous	I-I
bolus	I-I
)	I-I
plus	I-I
plasma	I-I
exchanges	I-I
(	I-P
group	I-P
B	I-P
;	I-P
n	I-P
=	I-P
34	I-P
)	I-P
as	I-P
first-line	I-P
treatment	I-P
for	I-P
severe	I-P
PAN	I-P
or	I-P
CSS	I-P
.	I-P


Factors	O
predicting	O
poor	O
prognosis	O
were	O
renal	O
symptoms	O
,	O
gastrointestinal	O
tract	O
involvement	O
,	O
cardiomyopathy	O
,	O
central	O
nervous	O
system	O
involvement	O
,	O
weight	O
loss	O
>	O
10	O
%	O
of	O
body	O
weight	O
,	O
and	O
age	O
>	O
50	O
years	O
old	O
.	O


Patients	O
with	O
hepatitis	O
B	O
virus-related	O
PAN	O
were	O
not	O
included	O
in	O
this	O
study	O
.	O


The	O
end	O
point	O
of	O
the	O
study	O
was	O
control	O
of	O
the	O
disease	O
(	O
recovery	O
or	O
remission	O
)	O
or	O
death	O
.	O


RESULTS	O
Clinical	O
symptoms	O
and	O
laboratory	O
findings	O
did	O
not	O
differ	O
significantly	O
in	O
the	O
2	O
groups	O
.	O


Initial	O
control	O
of	O
the	O
disease	O
was	O
similar	O
in	O
both	O
groups	O
.	O


Relapse	B-O
after	O
initial	O
control	O
of	O
the	O
disease	O
was	O
observed	O
in	O
7	O
patients	O
(	O
4	O
in	O
group	O
A	O
and	O
3	O
in	O
group	O
B	O
)	O
.	O


The	O
mean	B-O
+/-	I-O
SD	I-O
followup	I-O
period	O
was	O
31.1	O
+/-	O
20	O
months	O
for	O
group	O
A	O
and	O
35.9	O
+/-	O
16.8	O
months	O
for	O
group	O
B	O
.	O


At	O
5	O
years	O
of	O
followup	O
,	O
38	O
patients	O
(	O
61.3	O
%	O
)	O
were	O
cured	B-O
(	O
16	O
in	O
group	O
A	O
and	O
22	O
in	O
group	O
B	O
)	O
,	O
and	O
5	O
(	O
8.1	O
%	O
)	O
were	O
in	O
remission	O
without	O
treatment	O
but	O
had	O
not	O
yet	O
completed	O
the	O
cure-defining	O
period	O
of	O
18	O
months	O
(	O
3	O
in	O
group	O
A	O
and	O
2	O
in	O
group	O
B	O
)	O
.	O


Eight	O
(	O
12.9	O
%	O
)	O
(	O
2	O
in	O
group	O
A	O
and	O
2	O
in	O
group	O
B	O
)	O
were	O
considered	O
to	O
be	O
in	O
clinical	B-O
remission	I-O
and	O
required	O
a	O
maintenance	B-O
regimen	I-O
of	I-O
low-dose	I-O
corticosteroids	I-O
.	I-O


Eleven	O
patients	O
died	B-O
during	O
the	O
study	O
period	O
(	O
7	O
in	O
group	O
A	O
[	O
25	O
%	O
]	O
,	O
4	O
in	O
group	O
B	O
[	O
11.8	O
%	O
]	O
)	O
.	O


Uncontrolled	O
vasculitis	O
was	O
responsible	O
for	O
4	O
deaths	B-O
(	O
2	O
in	O
each	O
group	O
)	O
,	O
and	O
treatment	B-O
side	I-O
effects	I-O
caused	O
the	O
death	B-O
of	O
1	O
patient	O
in	O
group	O
A	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
5-year	B-O
cumulative	I-O
survival	I-O
rates	I-O
of	O
the	O
2	O
groups	O
(	O
75	O
%	O
and	O
88	O
%	O
,	O
respectively	O
)	O
.	O


CONCLUSION	O
Based	O
on	O
our	O
data	O
,	O
combined	O
treatment	O
with	O
prednisone	B-I
,	I-I
cyclophosphamide	I-I
,	O
and	O
plasma	B-I
exchanges	I-I
is	O
not	O
superior	O
to	O
treatment	O
with	O
prednisone	B-I
and	O
cyclophosphamide	B-I
alone	O
,	O
and	O
plasma	O
exchanges	O
should	O
not	O
be	O
systematically	O
proposed	O
for	O
initial	O
treatment	O
of	O
severe	O
PAN	O
or	O
CSS	O
.	O


Association	O
of	O
race	B-I
with	O
complications	O
and	O
prognosis	O
following	B-P
acute	I-P
coronary	I-P
syndromes	I-P
.	I-P


The	O
baseline	O
characteristics	B-O
,	I-O
complications	I-O
,	I-O
and	I-O
survival	I-O
of	O
489	B-P
black	I-P
and	I-P
6,890	I-P
non-black	I-P
patients	I-P
with	I-P
acute	I-P
coronary	I-P
syndromes	I-P
were	O
studied	O
.	O


Important	O
racial	B-O
differences	I-O
were	O
observed	O
in	O
demographic	B-O
features	I-O
,	I-O
atherosclerosis	I-O
risk	I-O
factors	I-O
,	I-O
and	I-O
treatment	I-O
strategies	I-O
;	I-O
however	O
,	O
despite	O
these	O
differences	O
,	O
no	O
independent	O
difference	O
was	O
observed	O
in	O
clinical	O
outcomes	O
according	O
to	O
race	O
.	O


The	O
1-year	O
mortality	B-O
rate	I-O
was	O
2.9	O
%	O
for	O
black	B-P
patients	I-P
and	O
2.5	O
%	O
for	O
non-black	B-P
patients	I-P
(	O
p	O
=	O
0.93	O
)	O
.	O


Effectiveness	O
of	O
sensory	B-I
integration	I-I
interventions	I-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	I-P
a	O
pilot	O
study	O
.	O


The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
establish	O
a	O
model	O
for	O
randomized	O
controlled	O
trial	O
research	O
,	O
identify	O
appropriate	O
outcome	O
measures	O
,	O
and	O
address	O
the	O
effectiveness	O
of	O
sensory	B-I
integration	I-I
(	I-I
SI	I-I
)	I-I
interventions	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


Children	B-P
ages	I-P
6-12	I-P
with	I-P
ASD	I-P
were	O
randomly	O
assigned	O
to	O
a	O
fine	B-I
motor	I-I
or	O
SI	B-I
treatment	I-I
group	O
.	O


Pretests	O
and	O
posttests	O
measured	O
social	B-O
responsiveness	I-O
,	I-O
sensory	I-O
processing	I-O
,	I-O
functional	I-O
motor	I-O
skills	I-O
,	I-O
and	I-O
social-emotional	I-O
factors	I-O
.	I-O


Results	O
identified	O
significant	O
positive	O
changes	O
in	O
Goal	B-O
Attainment	I-O
Scaling	I-O
scores	I-O
for	O
both	O
groups	O
;	O
more	O
significant	O
changes	O
occurred	O
in	O
the	O
SI	O
group	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
autistic	B-O
mannerisms	I-O
occurred	O
in	O
the	O
SI	O
group	O
.	O


No	O
other	O
results	O
were	O
significant	O
.	O


The	O
study	O
discusses	O
considerations	O
for	O
designing	O
future	O
outcome	O
studies	O
for	O
children	B-P
with	I-P
ASD	I-P
.	I-P


Object	B-O
interest	I-O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
treatment	O
comparison	O
.	O


A	O
randomized	O
control	O
trial	O
comparing	O
two	O
social	B-I
communication	I-I
treatments	I-I
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
examined	O
the	O
effect	O
of	O
treatment	O
on	O
object	O
interest	O
.	O


Thirty-two	B-P
children	I-P
,	I-P
18-60	I-P
months	I-P
,	O
were	O
randomly	O
assigned	O
to	O
the	O
Picture	B-I
Exchange	I-I
Communication	I-I
System	I-I
(	I-I
PECS	I-I
)	I-I
or	I-I
Responsive	I-I
Education	I-I
and	I-I
Prelinguistic	I-I
Milieu	I-I
Teaching	I-I
(	I-I
RPMT	I-I
)	I-I
condition	I-I
.	I-I


Assessment	O
of	O
object	B-O
interest	I-O
was	O
conducted	O
in	O
an	O
unstructured	O
play	O
session	O
with	O
different	O
toys	O
,	O
activities	O
,	O
adult	O
,	O
and	O
location	O
than	O
experienced	O
in	O
treatment	O
.	O


Results	O
indicated	O
children	O
in	O
the	O
RPMT	B-I
condition	O
showed	O
greater	O
increases	O
in	O
object	B-O
interest	I-O
as	O
compared	O
to	O
children	O
in	O
the	O
PECS	B-I
condition	O
.	O


Because	O
child	O
characteristics	O
such	O
as	O
interest	O
in	O
objects	O
may	O
influence	O
response	O
to	O
interventions	O
using	O
object	O
play	O
as	O
contexts	O
for	O
treatment	O
,	O
it	O
is	O
important	O
to	O
improve	O
our	O
understanding	O
of	O
whether	O
intervention	O
can	O
affect	O
object	O
interest	O
.	O


Comparison	O
of	O
epidural	B-I
tramadol-ropivacaine	I-I
and	I-I
fentanyl-ropivacaine	I-I
for	O
labor	B-P
analgesia	I-P
:	I-P
a	O
prospective	O
randomized	O
study	O
.	O


BACKGROUND	O
To	O
test	O
the	O
hypothesis	O
that	O
5	O
mg/mL	O
tramadol	B-I
is	O
superior	O
to	O
3	O
?	O
g/mL	O
fentanyl	B-I
when	O
combined	O
with	O
0.125	O
%	O
ropivacaine	B-I
in	O
parturients	B-P
undergoing	I-P
labor	I-P
during	I-P
epidural	I-P
analgesia	I-P
.	I-P


METHODS	O
Sixty-one	B-P
parturients	I-P
undergoing	I-P
labor	I-P
selected	I-P
for	I-P
delivery	I-P
with	I-P
epidural	I-P
analgesia	I-P
were	O
randomized	O
into	O
two	O
groups	O
:	O
Group	O
tramadol	B-I
(	I-I
0.125	I-I
%	I-I
ropivacaine	I-I
plus	I-I
tramadol	I-I
5	I-I
mg/mL	I-I
)	I-I
and	O
Group	O
fentanyl	B-I
(	I-I
0.125	I-I
%	I-I
ropivacaine	I-I
plus	I-I
fentanyl	I-I
3	I-I
ug/mL	I-I
)	I-I
.	O


Hemodynamics	B-O
,	I-O
rate	I-O
of	I-O
cesarean	I-O
delivery	I-O
,	I-O
sensory	I-O
block	I-O
level	I-O
,	I-O
Bromage	I-O
motor	I-O
scale	I-O
scores	I-O
,	I-O
instrument-assisted	I-O
delivery	I-O
,	I-O
oxytocin	I-O
use	I-O
,	I-O
visual	I-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
scores	I-O
,	I-O
Apgar	I-O
scores	I-O
,	I-O
umbilical	I-O
cord	I-O
artery	I-O
gas	O
analysis	B-O
,	I-O
and	I-O
maternal	I-O
side-effects	I-O
including	I-O
nausea	I-O
,	I-O
vomiting	I-O
,	I-O
pruritus	I-O
,	I-O
urinary	I-O
retention	I-O
,	I-O
shivering	I-O
,	I-O
hypotension	I-O
,	I-O
and	I-O
respiratory	I-O
depression	I-O
were	O
recorded	O
.	O


RESULTS	O
The	O
two	O
groups	O
had	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
maternal	B-O
hemodynamics	I-O
,	I-O
neonatal	I-O
heart	I-O
rate	I-O
,	I-O
VAS	I-O
scores	I-O
,	I-O
rate	I-O
of	I-O
cesarean	I-O
delivery	I-O
,	I-O
sensory	I-O
block	I-O
level	I-O
,	I-O
Bromage	I-O
motor	I-O
scale	I-O
scores	I-O
,	I-O
instrument-assisted	I-O
delivery	I-O
,	I-O
oxytocin	I-O
use	I-O
,	I-O
hypotension	I-O
,	I-O
nausea	I-O
,	I-O
vomiting	I-O
,	I-O
and	I-O
respiratory	I-O
depression	I-O
(	O
p	O
>	O
0.05	O
)	O
.	O


The	O
incidence	O
of	O
pruritus	B-O
,	I-O
shivering	I-O
,	I-O
and	I-O
urinary	I-O
retention	I-O
were	O
more	O
commonly	O
observed	O
in	O
Group	O
fentanyl	O
despite	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O


Umbilical	B-O
artery	I-O
pH	I-O
was	O
significantly	O
lower	O
while	O
PCO	O
(	O
2	O
)	O
was	O
higher	O
in	O
Group	O
fentanyl	B-I
than	O
Group	O
tramadol	B-I
(	O
p	O
=	O
0.003	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O


Birth-weight	B-O
,	I-O
umbilical	I-O
artery	I-O
PO	I-O
(	I-O
2	I-O
)	I-O
and	I-O
base	I-O
deficit	I-O
,	I-O
and	I-O
Apgar	I-O
scores	I-O
at	O
1	O
and	O
5	O
min	O
were	O
comparable	O
between	O
the	O
two	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O


CONCLUSIONS	O
Our	O
observations	O
suggest	O
that	O
tramadol	B-I
seems	O
to	O
be	O
a	O
safe	O
alternative	O
to	O
fentanyl	B-I
for	O
labor	O
analgesia	O
due	O
to	O
its	O
similar	O
analgesic	O
efficacy	O
.	O


A	O
double	O
blind	O
trial	O
of	O
terfenadine	B-I
and	O
placebo	B-I
in	O
hay	O
fever	O
using	O
a	O
substitution	O
technique	O
for	O
non-responders	O
.	O


A	O
double-blind	O
study	O
of	O
terfenadine	B-I
and	O
placebo	B-I
in	O
110	B-P
patients	I-P
suffering	I-P
from	I-P
hay	I-P
fever	I-P
(	I-P
confirmed	I-P
by	I-P
skin	I-P
tests	I-P
)	I-P
was	O
conducted	O
.	O


A	O
novel	O
technique	O
was	O
applied	O
using	O
an	O
escape	O
envelope	O
containing	O
a	O
reference	B-I
drug	I-I
which	O
could	O
be	O
taken	O
under	O
controlled	O
conditions	O
if	O
,	O
after	O
48	O
hours	O
,	O
the	O
patient	O
experienced	O
no	O
relief	B-O
.	I-O


Significantly	O
more	O
patients	O
on	O
placebo	B-I
opened	I-O
the	I-O
envelope	I-O
than	O
patients	O
taking	O
the	O
active	O
drug	O
.	O


Terfenadine	B-I
was	O
demonstrated	O
to	O
be	O
an	O
effective	B-O
drug	I-O
in	O
hay	O
fever	O
and	O
produced	O
no	O
more	O
drowsiness	B-O
than	O
placebo	O
.	O


Components	O
of	O
working	O
memory	O
and	O
visual	O
selective	O
attention	O
.	O


Load	O
theory	O
(	O
Lavie	O
,	O
N.	O
,	O
Hirst	O
,	O
A.	O
,	O
De	O
Fockert	O
,	O
J.	O
W.	O
,	O
&	O
Viding	O
,	O
E.	O
[	O
2004	O
]	O
.	O


Load	O
theory	O
of	O
selective	O
attention	O
and	O
cognitive	O
control	O
.	O


Journal	O
of	O
Experimental	O
Psychology	O
:	O
General	O
,	O
133	O
,	O
339-354	O
.	O


)	O
proposes	O
that	O
control	B-O
of	I-O
attention	I-O
depends	O
on	O
the	O
amount	B-O
and	I-O
type	I-O
of	I-O
load	I-O
that	O
is	O
imposed	O
by	O
current	O
processing	O
.	O


Specifically	O
,	O
perceptual	O
load	O
should	O
lead	O
to	O
efficient	O
distractor	O
rejection	O
,	O
whereas	O
working	O
memory	O
load	O
(	O
dual-task	O
coordination	O
)	O
should	O
hinder	O
distractor	B-O
rejection	I-O
.	I-O


Studies	O
support	O
load	O
theory	O
's	O
prediction	O
that	O
working	O
memory	O
load	O
will	O
lead	O
to	O
larger	O
distractor	B-O
effects	I-O
;	I-O
however	O
,	O
these	O
studies	O
used	O
secondary	O
tasks	O
that	O
required	O
only	O
verbal	O
working	O
memory	O
and	O
the	O
central	O
executive	O
.	O


The	O
present	O
study	O
examined	O
which	O
other	O
working	O
memory	O
components	O
(	O
visual	O
,	O
spatial	O
,	O
and	O
phonological	O
)	O
influence	O
visual	B-O
selective	I-O
attention	I-O
.	I-O


Subjects	B-P
completed	I-P
an	I-P
attentional	I-O
capture	I-O
task	I-O
alone	I-I
(	I-I
single-task	I-I
)	I-I
or	I-I
while	I-I
engaged	I-I
in	I-I
a	I-I
working	I-I
memory	I-I
task	I-I
(	I-I
dual-task	I-I
)	I-I
.	I-I


Results	O
showed	O
that	O
along	O
with	O
the	O
central	O
executive	O
,	O
visual	O
and	O
spatial	O
working	O
memory	O
influenced	O
selective	B-O
attention	I-O
,	O
but	O
phonological	O
working	O
memory	O
did	O
not	O
.	O


Specifically	O
,	O
attentional	B-O
capture	I-O
was	O
larger	O
when	O
visual	O
or	O
spatial	O
working	O
memory	O
was	O
loaded	O
,	O
but	O
phonological	O
working	O
memory	O
load	O
did	O
not	O
affect	O
attentional	B-O
capture	I-O
.	I-O


The	O
results	O
are	O
consistent	O
with	O
load	O
theory	O
and	O
suggest	O
specific	O
components	O
of	O
working	O
memory	O
influence	O
visual	B-O
selective	I-O
attention	I-O
.	I-O


Local	O
anaesthetic	O
use	O
for	O
the	O
iliac	O
crest-donor	O
site	O
:	O
pharmacokinetic	O
and	O
pharmacodynamic	O
evaluations	O
.	O


During	B-P
orthopaedic	I-I
surgery	I-I
of	I-P
the	I-P
limb	I-P
,	O
we	O
performed	O
a	O
prospective	O
,	O
double	O
blind	O
controlled	O
study	O
on	O
three	B-P
parallel	I-P
groups	I-P
in	I-P
30	I-P
patients	I-P
to	O
evaluate	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
effect	O
of	O
infiltration	O
of	O
the	O
iliac	O
crest	O
bone	O
graft	O
harvest	O
site	O
with	O
20	B-I
ml	I-I
of	I-I
bupivacaine	I-I
(	I-I
100	I-I
mg	I-I
)	I-I
,	I-I
ropivacaine	I-I
(	I-I
150	I-I
mg	I-I
)	I-I
or	I-I
saline	I-I
as	I-I
control	I-I
group	I-I
(	I-I
n	I-I
=	I-I
10	I-I
in	I-I
each	I-I
group	I-I
)	I-I
.	O


Then	O
,	O
in	O
a	O
sheep	O
model	O
of	O
iliac	O
crest	O
infiltration	O
,	O
we	O
compared	O
the	O
pharmacokinetics	O
of	O
single	B-I
administration	I-I
of	I-I
plain	I-I
bupivacaine	I-I
(	I-I
100	I-I
mg	I-I
)	I-I
and	I-I
bupivacaine	I-I
(	I-I
500	I-I
mg	I-I
)	I-I
-loaded	I-I
microspheres	I-I
.	I-I


In	O
the	O
clinical	O
control	O
group	O
,	O
pain	O
from	O
the	O
iliac	O
crest	O
was	O
worse	O
than	O
pain	O
from	O
the	O
primary	O
surgical	O
site	O
.	O


Pain	B-O
from	I-O
the	I-O
iliac	I-O
crest	I-O
was	O
significantly	B-O
reduced	I-O
during	O
the	O
first	O
12	O
postoperative	O
hours	O
in	O
local	O
anaesthetic	O
groups	O
compared	O
to	O
the	O
control	O
group	O
.	O


However	O
,	O
during	O
this	O
period	O
,	O
pain	B-O
from	I-O
the	I-O
primary	I-O
surgical	I-O
site	I-O
was	I-O
increased	I-O
compared	O
to	O
the	O
control	O
group	O
.	O


Finally	O
,	O
there	O
was	O
no	B-O
difference	I-O
between	O
the	O
three	O
groups	O
in	O
the	O
average	O
intake	O
of	O
PCA	O
morphine	B-I
.	I-I


There	O
was	O
no	B-O
significant	I-O
pharmacokinetic	I-O
and	I-O
pharmacodynamic	I-O
difference	I-O
between	O
plain	O
bupivacaine	B-I
and	O
ropivacaine	B-I
.	I-I


The	O
maximal	B-O
plasma	I-O
concentration	I-O
(	I-O
Cmax	I-O
)	I-O
of	O
ropivacaine	B-I
and	O
bupivacaine	B-I
were	O
964	O
(	O
282	O
)	O
ng	O
ml	O
(	O
-1	O
)	O
and	O
638	O
(	O
366	O
)	O
ng	O
ml	O
(	O
-1	O
)	O
,	O
respectively	O
.	O


In	O
the	O
sheep	O
model	O
,	O
it	O
was	O
clearly	O
shown	O
that	O
the	O
release	O
of	O
bupivacaine	B-I
from	O
microspheres	O
was	O
controlled	O
and	O
prolonged	O
despite	O
the	O
largest	O
dose	O
of	O
bupivacaine	B-I
used	O
(	O
500	O
mg	O
;	O
n	O
=	O
4	O
)	O
.	O


Wound	O
infiltration	O
of	O
iliac	O
crest	O
harvest	O
site	O
with	O
local	O
anaesthetic	O
is	O
an	O
easy	O
technique	O
for	O
postoperative	O
analgesia	O
.	O


However	O
,	O
this	O
effect	O
lasts	O
only	O
12	O
hours	O
without	O
reducing	O
the	O
morphine	B-O
consumption	I-O
due	O
to	O
an	O
increase	O
of	O
pain	O
from	O
the	O
primary	O
surgical	O
site	O
.	O


The	O
local	O
anaesthetic	O
infiltration	O
produced	O
a	O
significant	B-O
peak	I-O
of	I-O
plasma	I-O
level	I-O
,	O
which	O
could	O
be	O
dangerous	O
if	O
another	O
infiltration	O
or	O
regional	O
anaesthetic	O
technique	O
was	O
associated	O
with	O
it	O
.	O


Experimentally	O
,	O
as	O
a	O
drug	O
delivery	O
system	O
,	O
the	O
use	O
of	O
local	O
anaesthetic-loaded	B-I
microspheres	I-I
could	O
be	O
an	O
interesting	O
alternative	O
.	O


Do	O
cervical	O
cancer	O
screening	O
rates	O
increase	O
in	O
association	O
with	O
an	O
intervention	O
designed	O
to	O
increase	O
mammography	O
usage	O
?	O
OBJECTIVES	O
To	O
assess	O
cervical	B-O
cancer	I-O
screening	I-O
behaviors	I-O
among	O
underserved	B-P
women	I-P
participating	I-P
in	I-P
an	I-P
intervention	I-P
designed	I-P
to	I-P
increase	I-P
mammography	I-P
use	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
randomized	O
trial	O
of	O
897	B-P
women	I-P
from	I-P
three	I-P
racial	I-P
groups	I-P
(	I-P
white	I-P
,	I-P
African	I-P
American	I-P
,	I-P
Native	I-P
American	I-P
)	I-P
living	I-P
in	I-P
a	I-P
rural	I-P
county	I-P
in	I-P
North	I-P
Carolina	I-P
.	I-P


Baseline	O
and	O
followup	O
surveys	O
were	O
completed	O
by	O
815	B-P
women	I-P
;	I-P
775	I-P
women	I-P
provided	I-P
data	I-P
to	O
be	O
included	O
in	O
these	O
analyses	O
.	O


The	O
intervention	O
group	O
received	O
an	O
educational	B-I
program	I-I
focused	I-I
on	I-I
mammography	I-I
delivered	I-I
by	I-I
a	I-I
lay	I-I
health	I-I
advisor	I-I
,	O
and	O
the	O
control	O
group	O
received	O
a	O
physician	B-I
letter/brochure	I-I
focusing	I-I
on	I-I
Pap	I-I
tests	I-I
.	I-I


RESULTS	O
Women	O
in	O
both	O
the	O
intervention	O
(	O
OR	O
1.70	O
;	O
1.31	O
,	O
2.21	O
,	O
p	O
<	O
0.001	O
)	O
and	O
control	O
groups	O
(	O
OR	O
1.38	O
;	O
1.04	O
,	O
1.82	O
,	O
p	O
=	O
0.025	O
)	O
significantly	O
increased	O
cervical	B-O
cancer	I-O
screening	I-O
rates	I-O
within	O
risk	O
appropriate	O
guidelines	O
.	O


No	O
differences	O
by	O
racial	O
group	O
were	O
documented	O
.	O


Women	O
categorized	O
in	O
the	O
high-risk	O
group	O
for	O
developing	O
cervical	O
cancer	O
(	O
>	O
2	O
sexual	O
partners	O
,	O
age	O
<	O
18	O
years	O
at	O
first	O
sexual	O
intercourse	O
,	O
smoker	O
;	O
treated	O
for	O
sexually	O
transmitted	O
disease	O
[	O
STD	O
]	O
or	O
partner	O
with	O
treated	O
STD	O
)	O
significantly	O
(	O
OR	O
1.88	O
;	O
1.54	O
,	O
2.28	O
,	O
p	O
<	O
0.001	O
)	O
increased	B-O
Pap	I-O
test	I-O
completion	I-O
.	I-O


However	O
,	O
a	O
nonsignificant	B-O
increase	I-O
(	O
OR	O
1.25	O
;	O
0.87	O
,	O
1.79	O
,	O
p	O
=	O
0.221	O
)	O
in	O
Pap	B-O
test	I-O
completion	I-O
was	O
demonstrated	O
in	O
women	O
categorized	O
as	O
low	O
risk	O
for	O
cervical	O
cancer	O
.	O


CONCLUSIONS	O
This	O
study	O
suggests	O
that	O
women	O
in	O
an	O
intensive	B-I
behavioral	I-I
intervention	I-I
designed	I-I
to	I-I
increase	I-I
mammography	I-I
use	I-I
may	O
also	O
increase	O
Pap	B-O
test	I-O
completion	I-O
,	O
similar	O
to	O
a	O
minimal	O
intervention	O
focused	O
only	O
on	O
increasing	O
Pap	B-O
test	I-O
completion	I-O
.	I-O


These	O
results	O
have	O
implications	O
for	O
the	O
design	O
and	O
evaluation	O
of	O
behavioral	O
intervention	O
studies	O
.	O


[	B-O
Hepatoprotective	I-O
activity	I-O
of	O
remaxol	B-I
in	O
patients	B-P
with	I-P
chronic	I-P
hepatic	I-P
disorders	I-P
]	I-P
.	O


This	O
milticentre	O
randomized	O
clinical	O
study	O
of	O
the	O
efficiency	B-O
of	O
remaxol	B-I
infusion	I-I
solution	I-I
(	O
hepatoprotective	O
medicine	O
for	O
chronic	O
liver	O
dysfunction	O
)	O
included	O
494	B-P
patients	I-P
with	I-P
chronic	I-P
hepatitis	I-P
B	I-P
and	I-P
C.	I-P
294	O
of	O
them	O
staying	B-P
in	I-P
7	I-P
clinics	I-P
were	O
given	O
remaxol	B-I
and	O
200	O
ones	O
received	O
placebo	B-I
.	I-I


Randomization	O
was	O
achieved	O
by	O
the	O
envelope	O
method	O
.	O


A	O
detailed	O
description	O
of	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
the	O
diseases	O
is	O
presented	O
.	O


Effects	O
of	O
remaxol	B-I
vs	I-I
placebo	I-I
on	O
the	O
functional	B-O
activity	I-O
of	O
affected	O
liver	O
are	O
discussed	O
.	O


Results	O
of	O
laboratory	O
and	O
clinical	O
analysis	O
indicate	O
that	O
mechanism	O
of	O
remaxol	B-I
action	O
is	O
based	O
on	O
hepatoprotective	B-O
,	I-O
antioxidative	I-O
,	I-O
and	I-O
anticholestatic	I-O
activities	I-O
of	O
the	O
drug	O
.	O


Zoledronic	B-I
acid	I-I
combined	I-I
with	I-I
adjuvant	I-I
endocrine	I-I
therapy	I-I
of	I-I
tamoxifen	I-I
versus	O
anastrozol	B-I
plus	I-I
ovarian	I-I
function	I-I
suppression	I-I
in	O
premenopausal	B-P
early	I-P
breast	I-P
cancer	I-P
:	I-P
final	O
analysis	O
of	O
the	O
Austrian	B-P
Breast	I-P
and	I-P
Colorectal	I-P
Cancer	I-P
Study	I-P
Group	I-P
Trial	I-P
12	I-P
.	I-P


BACKGROUND	O
Zoledronic	B-I
acid	I-I
(	I-I
ZOL	I-I
)	I-I
plus	I-I
adjuvant	I-I
endocrine	I-I
therapy	I-I
significantly	O
improved	O
disease-free	B-O
survival	I-O
(	O
DFS	O
)	O
at	O
48-	O
and	O
62-month	O
follow-up	O
in	O
the	O
ABCSG-12	O
trial	O
.	O


We	O
present	O
efficacy	O
results	O
of	O
a	O
final	O
additional	O
analysis	O
after	O
94.4	O
months	O
.	O


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
were	I-P
premenopausal	I-P
women	I-P
who	I-P
had	I-P
undergone	I-P
primary	I-P
surgery	I-P
for	I-P
stage	I-P
I/II	I-P
estrogen-receptor-positive	I-P
and/or	I-P
progesterone-receptor-positive	I-P
breast	I-P
cancer	I-P
with	I-P
<	I-P
10	I-P
positive	I-P
lymph	I-P
nodes	I-P
,	I-P
and	I-P
were	I-P
scheduled	I-P
for	I-P
standard	I-P
goserelin	I-P
therapy	I-P
.	I-P


All	O
1803	B-P
patients	I-P
received	I-P
goserelin	I-I
(	I-I
3.6	I-I
mg	I-I
every	I-I
28	I-I
days	I-I
)	I-I
and	I-I
were	I-I
randomized	I-I
to	I-I
tamoxifen	I-I
(	I-I
20	I-I
mg/days	I-I
)	I-I
or	I-I
anastrozole	I-I
(	I-I
1	I-I
mg/days	I-I
)	I-I
,	I-I
both	I-I
with	I-I
or	I-I
without	I-I
ZOL	I-I
(	I-I
4	I-I
mg	I-I
every	I-I
6	I-I
months	I-I
)	I-I
for	I-I
3	I-I
years	I-I
.	I-I


The	O
primary	O
end	O
point	O
was	O
DFS	B-O
;	I-O
recurrence-free	I-O
survival	I-O
and	I-O
overall	I-O
survival	I-O
(	I-O
OS	I-O
)	I-O
were	O
secondary	O
end	O
points	O
.	O


RESULTS	O
After	O
94.4-month	O
median	O
follow-up	O
(	O
range	O
,	O
0-114	O
months	O
)	O
,	O
relative	B-O
risks	I-O
of	I-O
disease	I-O
progression	I-O
[	I-O
hazard	I-O
ratio	I-O
(	I-O
HR	I-O
)	I-O
=	O
0.77	O
;	O
95	O
%	O
confidence	B-O
interval	I-O
(	O
CI	O
)	O
0.60-0.99	O
;	O
P	O
=	O
0.042	O
]	O
and	O
of	O
death	B-O
(	O
HR	O
=	O
0.66	O
;	O
95	O
%	O
CI	O
0.43-1.02	O
;	O
P	O
=	O
0.064	O
)	O
are	O
still	O
reduced	O
by	O
ZOL	O
although	O
no	O
longer	O
significant	O
at	O
the	O
predefined	O
significance	O
level	O
.	O


Overall	O
,	O
251	O
DFS	B-O
events	I-O
and	O
86	O
deaths	B-O
were	O
reported	O
.	O


Absolute	B-O
risk	I-O
reductions	I-O
with	O
ZOL	O
were	O
3.4	O
%	O
for	O
DFS	O
and	O
2.2	O
%	O
for	O
OS	O
.	O


There	O
was	O
no	O
DFS	B-O
difference	I-O
between	O
tamoxifen	O
alone	O
versus	O
anastrozole	O
alone	O
,	O
but	O
there	O
was	O
a	O
pronounced	O
higher	B-O
risk	I-O
of	I-O
death	I-O
for	O
anastrozole-treated	O
patients	O
(	O
HR	O
=	O
1.63	O
;	O
95	O
%	O
CI	O
1.05-1.45	O
;	O
P	O
=	O
0.030	O
)	O
.	O


Treatments	O
were	O
generally	O
well	O
tolerated	B-O
,	O
with	O
no	B-O
reports	I-O
of	I-O
renal	I-O
failure	I-O
or	I-O
osteonecrosis	I-O
of	I-O
the	I-O
jaw	I-O
.	I-O


CONCLUSION	O
These	O
final	O
results	O
from	O
ABCSG	O
12	O
suggest	O
that	O
twice-yearly	O
ZOL	B-I
enhances	O
the	O
efficacy	O
of	O
adjuvant	O
endocrine	O
treatment	O
,	O
and	O
this	O
benefit	O
is	O
maintained	O
long-term	O
.	O


CLINICALTRIALSGOV	O
NCT00295646	O
(	O
http	O
:	O
//www.clinicaltrials.gov/ct2/results	O
?	O
term=00295646	O
)	O
.	O


Using	O
a	O
choice	B-I
assessment	I-I
to	O
predict	O
reinforcer	O
effectiveness	O
.	O


A	B-I
choice	I-I
assessment	I-I
has	O
been	O
found	O
to	O
be	O
a	O
more	O
accurate	O
method	O
of	O
identifying	O
preferences	O
than	O
is	O
single-item	O
presentation	O
.	O


However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
the	O
effectiveness	O
of	O
reinforcement	O
varies	O
positively	O
with	O
the	O
degree	O
of	O
preference	O
(	O
i.e.	O
,	O
whether	O
the	O
relative	O
preference	O
based	O
on	O
the	O
results	O
of	O
a	O
choice	O
assessment	O
predicts	O
relative	O
reinforcer	O
effectiveness	O
)	O
.	O


In	O
the	O
current	O
study	O
,	O
we	O
attempted	O
to	O
address	O
this	O
question	O
by	O
categorizing	O
stimuli	O
as	O
high	O
,	O
middle	O
,	O
and	O
low	O
preference	O
based	O
on	O
the	O
results	O
of	O
a	O
choice	B-I
assessment	I-I
,	O
and	O
then	O
comparing	O
the	O
reinforcing	O
effectiveness	O
of	O
these	O
stimuli	O
using	O
a	O
concurrent	B-I
operants	I-I
paradigm	I-I
.	I-I


High-preference	O
stimuli	O
consistently	O
functioned	O
as	O
reinforcers	O
for	O
all	O
4	B-P
clients	I-P
.	I-P


Middle-preference	O
stimuli	O
functioned	O
as	O
reinforcers	O
for	O
2	B-P
clients	I-P
,	O
but	O
only	O
when	O
compared	O
with	O
low-preference	O
stimuli	O
.	O


Low-preference	O
stimuli	O
did	O
not	O
function	O
as	O
reinforcers	O
when	O
compared	O
to	O
high-	O
and	O
middle-preference	O
stimuli	O
.	O


These	O
results	O
suggest	O
that	O
a	O
choice	B-I
assessment	I-I
can	O
be	O
used	O
to	O
predict	O
the	O
relative	O
reinforcing	O
value	O
of	O
various	O
stimuli	B-O
,	O
which	O
,	O
in	O
turn	O
,	O
may	O
help	O
to	O
improve	O
programs	O
for	O
clients	B-P
with	I-P
severe	I-P
to	I-P
profound	I-P
disabilities	I-P
.	I-P


Cost-effectiveness	B-O
of	O
ablation	B-I
surgery	I-I
in	O
patients	B-P
with	I-P
atrial	I-P
fibrillation	I-P
undergoing	I-P
cardiac	I-P
surgery	I-P
.	I-P


This	O
study	O
was	O
performed	O
to	O
assess	O
the	O
cost-effectiveness	O
of	O
concomitant	O
ablation	B-I
surgery	I-I
(	I-I
AS	I-I
)	I-I
compared	O
to	O
regular	O
cardiac	B-I
surgery	I-I
in	O
atrial	B-P
fibrillation	I-P
(	I-P
AF	I-P
)	I-P
patients	I-P
over	O
a	O
one-year	O
follow-up	O
.	O


Cost	B-O
analysis	I-O
was	O
performed	O
from	O
a	O
societal	O
perspective	O
alongside	O
a	O
prospective	O
,	O
randomised	O
,	O
double-blinded	O
,	O
multicentre	O
trial	O
.	O


One	B-P
hundred	I-P
and	I-P
fifty	I-P
patients	I-P
with	I-P
documented	I-P
AF	I-P
were	O
randomly	B-I
assigned	I-I
to	I-I
undergo	I-I
cardiac	I-I
surgery	I-I
with	I-I
or	I-I
without	I-I
AS	I-I
.	I-I


One	B-P
hundred	I-P
and	I-P
thirty-two	I-P
patients	I-P
were	I-P
included	I-P
in	I-P
the	I-P
cost-effectiveness	I-I
study	I-P
.	I-P


All	B-O
costs	I-O
(	I-O
medical	I-O
and	I-O
non-medical	I-O
)	I-O
were	O
measured	O
during	O
follow-up	O
.	O


Costs	B-O
data	I-O
were	O
combined	O
with	O
quality	B-O
adjusted	I-O
life	I-O
years	I-O
(	O
QALYs	O
)	O
to	O
obtain	O
the	O
incremental	O
costs	O
per	O
QALY	O
.	O


Total	B-O
costs	I-O
of	O
the	O
AS	B-I
group	O
were	O
significantly	O
higher	O
compared	O
to	O
the	O
regular	O
cardiac	O
surgery	O
group	O
[	O
cost	O
difference	O
bootstrap	O
:	O
€4,724	O
;	O
95	O
%	O
uncertainty	O
interval	O
(	O
UI	O
)	O
,	O
€2,770-€6,678	O
]	O
.	O


The	O
bootstrapped	O
difference	B-O
in	I-O
QALYs	O
was	O
not	O
statistically	O
significant	O
(	O
0.06	O
;	O
95	O
%	O
UI	O
:	O
-0.024	O
to	O
0.14	O
)	O
.	O


The	O
incremental	O
cost-effectiveness	O
ratio	O
is	O
€73,359	B-O
per	I-O
QALY	O
.	O


The	O
acceptability	O
curve	O
showed	O
that	O
,	O
even	O
in	O
the	O
case	O
of	O
a	O
maximum	O
threshold	O
value	O
of	O
€80,000	B-O
per	O
QALY	O
gained	O
,	O
the	O
probability	B-I
of	O
AS	O
being	O
more	O
cost-effective	O
than	O
regular	O
cardiac	O
surgery	O
did	O
not	O
reach	O
beyond	O
50	O
%	O
.	O


Concluding	O
that	O
concomitant	B-I
AS	O
in	O
AF	O
is	O
not	O
cost-effective	O
after	O
a	O
one-year	O
follow-up	O
compared	O
to	O
regular	O
cardiac	O
surgery	O
.	O


Exploratory	O
Subset	O
Analysis	O
of	O
African	B-P
Americans	I-P
From	I-P
the	I-P
PointBreak	I-P
Study	I-P
:	I-P
Pemetrexed-Carboplatin-Bevacizumab	I-I
Followed	I-I
by	I-I
Maintenance	I-I
Pemetrexed-Bevacizumab	I-I
Versus	O
Paclitaxel-Carboplatin-Bevacizumab	B-I
Followed	I-I
by	I-I
Maintenance	I-I
Bevacizumab	I-I
in	I-P
Patients	I-P
With	I-P
Stage	I-P
IIIB/IV	I-P
Nonsquamous	I-P
Non-Small-Cell	I-P
Lung	I-P
Cancer	I-P
.	O


INTRODUCTION	B-P
African	I-P
Americans	I-P
have	I-P
a	I-P
greater	I-P
incidence	I-P
of	I-P
lung	I-P
cancer	I-P
than	I-P
whites	I-P
and	O
have	O
been	O
underrepresented	O
in	O
clinical	O
trials	O
.	O


In	O
the	O
PointBreak	O
trial	O
(	B-I
pemetrexed-carboplatin-bevacizumab	I-I
and	I-I
maintenance	I-I
pemetrexed-bevacizumab	I-I
[	I-I
PemCBev	I-I
]	I-I
vs.	I-I
paclitaxel-carboplatin-bevacizumab	I-I
and	I-I
maintenance	I-I
bevacizumab	I-I
[	I-I
PacCBev	I-I
]	I-I
)	I-I
,	O
10	B-P
%	I-P
of	I-P
the	I-P
patients	I-P
were	I-P
African	I-P
American	I-P
.	O


PointBreak	O
had	O
negative	O
findings	O
;	O
PemCBev	O
did	O
not	O
demonstrate	B-O
superior	I-O
overall	I-O
survival	I-O
(	I-O
OS	I-O
)	I-O
.	O


MATERIALS	O
AND	O
METHODS	O
PointBreak	O
subgroup	B-O
efficacy	I-O
and	I-O
safety	I-O
data	O
were	O
retrospectively	O
analyzed	B-P
:	I-P
African	I-P
Americans	I-P
versus	I-P
whites	I-P
for	I-I
PemCBev	I-I
;	I-I
PemCBev	I-P
versus	I-I
PacCBev	I-I
in	I-P
African	I-P
Americans	I-P
;	I-P
and	I-P
academic	I-P
versus	I-P
community	I-P
settings	I-P
for	I-P
African	I-P
Americans	I-P
.	I-O


Hazard	B-O
ratios	I-O
(	I-O
HRs	I-O
)	I-O
and	I-O
P	I-O
values	I-O
were	O
derived	O
from	O
a	B-O
multivariate	I-O
Cox	I-O
proportional	O
hazards	O
model	O
after	O
adjusting	O
for	O
covariates	O
.	O


RESULTS	B-P
Of	I-P
939	I-P
intent-to-treat	I-P
(	I-P
ITT	I-P
)	I-P
patients	I-P
,	I-P
94	I-P
were	I-P
African	I-P
American	I-P
and	I-P
805	I-P
were	I-P
white	I-P
.	I-P


African-American	B-P
enrollment	O
was	O
uniform	O
across	O
the	O
study	O
sites	O
(	O
median	O
,	O
1	O
African	O
American	O
per	O
site	O
)	O
.	O


In	O
the	O
PemCBev	O
arm	O
,	O
OS	O
(	O
HR	O
,	O
1.125	O
;	O
P	O
=	O
.525	B-O
)	I-O
,	I-O
progression-free	I-O
survival	I-O
(	I-O
PFS	I-O
)	I-O
(	O
HR	O
,	O
1.229	O
;	O
P	O
=	O
.251	B-O
)	I-O
,	I-O
response	I-O
(	O
P	O
=	O
.607	O
)	O
,	O
and	B-O
toxicity	I-O
profiles	I-O
were	O
similar	O
in	O
African	O
Americans	O
versus	O
whites	O
.	O


For	O
African	O
Americans	B-O
,	O
OS	O
(	O
HR	O
,	O
1.375	O
;	O
P	O
=	O
.209	B-O
)	I-O
,	O
PFS	O
(	O
HR	O
,	O
0.902	O
;	O
P	O
=	O
.670	O
)	O
,	O
response	O
(	O
P	O
=	O
1.000	B-O
)	I-O
,	I-O
and	I-O
toxicity	I-O
profiles	I-O
were	O
similar	O
in	O
the	O
PemCBev	O
versus	O
PacCBev	O
arm	O
.	O


For	O
African	O
Americans	O
,	O
no	O
significant	O
differences	O
were	O
seen	B-O
in	O
OS	O
(	O
HR	O
,	O
0.661	O
;	O
P	O
=	O
.191	B-O
)	I-O
or	O
PFS	O
(	O
HR	O
,	O
0.969	O
;	O
P	O
=	O
.915	O
)	O
in	O
academic	O
versus	O
community	O
practice	O
settings	O
.	O


CONCLUSION	O
In	O
the	O
PemCBev	O
arm	O
,	O
this	O
exploratory	O
analysis	O
showed	O
no	O
significant	O
differences	B-P
between	I-P
African	I-P
Americans	I-P
and	I-P
whites	I-O
for	I-O
the	I-O
efficacy	I-O
outcomes	I-O
or	I-O
toxicity	I-O
profiles	O
.	O


Consistent	O
with	O
the	O
ITT	O
population	O
negative	O
trial	O
result	B-P
,	I-P
for	I-P
African	I-P
Americans	I-P
,	O
the	O
median	O
OS	O
was	O
not	O
superior	O
for	O
either	O
arm	B-P
.	I-P


For	B-P
African	I-P
Americans	I-P
,	O
PFS	O
and	O
OS	O
were	O
similar	O
in	O
the	O
academic	O
and	O
community	O
settings	O
.	O


Additional	O
outcomes	B-P
data	I-P
for	I-P
African	I-P
Americans	O
should	O
be	O
collected	O
in	O
lung	O
cancer	O
studies	O
.	O


Effect	O
of	O
direct	B-I
current	I-I
pulse	I-I
stimulating	I-I
acupoints	I-I
of	I-I
JiaJi	I-I
(	O
T10-13	O
)	O
and	O
Ciliao	O
(	O
BL	O
32	O
)	O
with	O
Han	B-I
's	I-I
Acupoint	I-I
Nerve	I-I
Stimulator	I-I
on	O
labour	B-O
pain	I-O
in	I-P
women	I-P
:	I-P
a	O
randomized	O
controlled	O
clinical	O
study	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
clinical	O
effect	O
and	O
safety	O
of	O
direct	B-I
current	I-I
(	I-I
DC	I-I
)	I-I
pulse	I-I
produced	I-I
by	I-I
Han	I-I
's	I-I
Acupoint	I-I
Nerve	I-I
Stimulator	I-I
in	O
reduction	O
(	O
HANS	O
)	O
of	O
labor	B-O
pain	I-O
.	I-O


METHODS	O
Totally	O
120	B-P
participants	I-P
were	O
enrolled	O
in	O
this	O
clinical	O
trial	O
,	O
and	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
including	O
:	O
HANS	B-I
group	I-I
,	I-I
patient	I-I
controlled	I-I
intravenous	I-I
analgesia	I-I
(	I-I
PCIA	I-I
)	I-I
group	I-I
,	I-I
patient-controlled	I-I
epidural	I-I
analgesia	I-I
(	I-I
PCEA	I-I
)	I-I
group	O
and	O
control	O
group	O
.	O


The	O
HANS	B-I
group	O
was	O
treated	O
by	O
stimulating	O
the	O
acupoints	B-I
of	I-I
JiaJi	I-I
(	O
T10-L3	O
)	O
and	O
Ciliao	B-I
(	O
BL	O
32	O
)	O
with	O
DC	B-I
pulse	I-I
of	O
100	O
Hz	O
and	O
15-30	O
mA	O
produced	O
by	O
a	O
portable	B-I
battery-powered	I-I
Han	I-I
's	I-I
Acupoint	I-I
Nerve	I-I
Stimulator	I-I
for	O
30	O
min	O
.	O


The	O
PCIA	B-I
group	O
was	O
intravenously	O
infused	O
Ondansetron	B-I
(	O
8	O
mg	O
)	O
for	O
5	O
min	O
,	O
then	O
tramadol	B-I
injection	I-I
(	O
1.5	O
mg/kg	O
)	O
was	O
slowly	O
dripped	O
by	O
using	O
BaxterAP	O
II	O
electronic	O
pump	O
with	O
50	O
mL	O
tramadol	B-I
(	O
0.70	O
%	O
)	O
+	O
ondansetron	B-I
(	O
8	O
mg	O
)	O
,	O
background	O
infusion	O
2	O
mL/h	O
,	O
PCA	O
dose	O
of	O
2	O
mL	O
,	O
lockout	O
interval	O
of	O
10	O
min	O
.	O


In	O
PCEA	B-I
group	O
,	O
women	O
received	O
intrathecal	O
injection	B-I
ropivacaine	I-I
(	O
3	O
mg	O
)	O
in	O
L2-3	O
,	O
and	O
epidural	O
catheter	O
was	O
connected	O
to	O
BaxterAP	O
II	O
electronic	O
pump	O
,	O
with	O
100	O
mL	O
Ropivacaine	B-I
(	O
0.1	O
%	O
)	O
and	O
Sufentanil	B-I
(	O
50	O
ug	O
)	O
,	O
background	O
infusion	O
5	O
mL	O
,	O
Patient	B-I
controlled	I-I
analgesia	I-I
(	I-I
PCA	I-I
)	I-I
dose	O
of	O
5	O
mL	O
,	O
lockout	O
interval	O
of	O
10	O
min	O
.	O


The	O
control	O
group	O
was	O
not	O
received	O
analgesia	O
.	O


The	B-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	I-O
stage	I-O
and	I-O
manner	I-O
of	I-O
labor	I-O
,	I-O
Apgar	I-O
score	I-O
of	I-O
newborn	I-O
,	I-O
neonatal	I-O
weights	I-O
,	I-O
oxytocin	I-O
dosage	I-O
,	I-O
postpartum	I-O
hemorrhage	I-O
and	I-O
side	I-O
effects	I-O
were	O
monitored	O
in	O
all	O
groups	O
.	O


RESULTS	O
The	O
vital	O
signs	O
were	O
all	O
stable	O
in	O
the	O
four	O
analgesic	O
groups	O
.	O


After	O
analgesia	O
,	O
there	O
was	O
statistical	O
difference	O
in	O
VAS	B-O
score	I-O
between	O
HANS	B-I
group	O
and	O
control	B-I
group	O
,	O
between	O
PCEA	B-I
group	O
and	O
the	O
control	B-I
group	O
,	O
between	O
PCIA	B-I
group	O
and	O
control	B-I
group	O
.	O


The	O
analgesic	B-O
effect	I-O
in	O
the	O
PCEA	B-I
group	O
was	O
significantly	O
better	O
than	O
that	O
of	O
other	O
two	O
groups	O
.	O


The	O
second	O
stage	O
of	O
labor	O
in	O
the	O
PCEA	B-I
group	O
was	O
longer	O
than	O
the	O
other	O
three	O
groups	O
,	O
showing	O
significant	O
difference	O
between	O
them	O
.	O


The	O
Apgar	O
score	O
of	O
newborn	O
1	O
min	O
after	O
birth	O
in	O
the	O
PCIA	B-I
group	O
was	O
slightly	O
lower	O
than	O
that	O
of	O
the	O
other	O
two	O
groups	O
,	O
showing	O
significant	O
difference	O
between	O
them	O
.	O


The	O
neonatal	B-O
weights	I-O
between	O
four	O
groups	O
were	O
not	O
significantly	O
different	O
.	O


The	O
rate	B-O
of	I-O
cesarean	I-O
section	I-O
in	O
the	O
control	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
labor	O
analgesia	O
group	O
,	O
there	O
was	O
statistically	O
difference	O
in	O
four	O
groups	O
.	O


The	O
number	O
of	O
PCIA	B-I
group	O
that	O
used	B-O
oxytocin	I-O
was	O
lower	O
than	O
that	O
of	O
other	O
three	O
groups	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
postpartum	B-O
hemorrhage	I-O
between	O
four	O
groups	O
.	O


The	O
side	O
effects	O
of	O
the	O
PCEA	B-I
group	O
were	O
itching	B-O
,	I-O
uroschesis	I-O
and	I-O
neonatal	I-O
asphyxia	I-O
and	O
PCIA	B-I
group	O
were	O
nausea	B-O
and	I-O
vomiting	I-O
and	I-O
neonatal	I-O
asphyxia	I-O
.	I-O


However	O
,	O
fewer	O
side-effects	B-O
were	O
observed	O
in	O
the	O
HANS	B-I
group	O
.	O


CONCLUSION	O
The	O
DC	O
pulse	O
produced	O
by	O
HANS	B-I
may	O
be	O
a	O
non-pharmacological	O
alternative	O
to	O
labor	O
pain	O
with	O
fewer	O
side	O
effects	O
.	O


The	B-I
Autism	I-I
MEAL	I-I
Plan	I-I
:	I-I
a	O
parent-training	O
curriculum	O
to	O
manage	O
eating	O
aversions	O
and	O
low	O
intake	O
among	O
children	B-P
with	I-P
autism	I-P
.	I-P


Feeding	O
problems	O
represent	O
a	O
frequent	O
concern	O
reported	O
by	O
caregivers	B-P
of	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	O
and	O
growing	O
evidence	O
suggests	O
atypical	O
patterns	O
of	O
intake	O
may	O
place	O
this	O
population	O
at	O
risk	O
of	O
nutritional	O
and/or	O
related	O
medical	O
issues	O
,	O
including	O
chronic	O
vitamin	O
and	O
mineral	O
deficiencies	O
,	O
poor	O
bone	O
growth	O
,	O
and	O
obesity	O
.	O


This	O
combination	O
of	O
factors	O
emphasizes	O
a	O
clear	O
need	O
to	O
identify	O
and	O
disseminate	O
evidence-based	O
treatment	O
of	O
feeding	O
problems	O
associated	O
with	O
autism	O
spectrum	O
disorders	O
.	O


Behavioral	O
intervention	O
represents	O
an	O
effective	O
treatment	O
for	O
chronic	O
feeding	O
concerns	O
in	O
this	O
population	O
;	O
however	O
,	O
evidence	O
has	O
largely	O
been	O
established	O
with	O
trained	O
therapists	O
working	O
in	O
highly	O
structured	O
settings	O
.	O


This	O
pilot	O
study	O
seeks	O
to	O
fill	O
this	O
gap	O
in	O
the	O
literature	O
by	O
describing	O
and	O
evaluating	O
the	O
Autism	B-I
MEAL	I-I
Plan	I-I
,	O
a	O
behaviorally	O
based	O
parent-training	O
curriculum	O
to	O
address	O
feeding	O
problems	O
associated	O
with	O
autism	O
spectrum	O
disorders	O
.	O


We	O
assessed	O
the	O
feasibility	O
of	O
the	O
intervention	O
in	O
terms	O
of	O
program	O
content	O
and	O
study	O
protocol	O
(	O
e.g	O
.	O


recruitment	B-O
and	I-O
retention	I-O
of	I-O
participants	I-O
,	I-O
assessment	I-O
procedures	I-O
)	I-O
,	O
as	O
well	O
as	O
efficacy	B-O
in	O
terms	O
of	O
changes	O
in	O
feeding	O
behaviors	O
.	O


A	O
total	O
of	O
10	B-P
families	I-P
participated	I-P
in	I-P
the	I-P
treatment	I-P
condition	I-P
,	O
and	O
the	O
program	O
was	O
evaluated	O
using	O
a	O
waitlist	B-I
control	I-I
design	I-I
(	O
n	O
=	O
9	O
)	O
,	O
representing	O
the	O
first	O
randomized-control	O
study	O
of	O
a	O
feeding	O
intervention	O
in	O
autism	O
spectrum	O
disorders	O
.	O


Results	O
provide	O
provisional	O
support	O
regarding	O
the	O
utility	B-O
of	I-O
the	I-O
program	I-O
,	O
including	O
high	B-O
social	I-O
validity	I-O
,	I-O
parent	I-O
perception	I-O
of	I-O
effectiveness	I-O
,	I-O
and	I-O
reduced	I-O
levels	I-O
of	I-O
caregiver	I-O
stress	I-O
following	I-O
intervention	I-O
.	I-O


Implications	O
,	O
limitations	O
,	O
and	O
future	O
directions	O
for	O
this	O
line	O
of	O
research	O
are	O
discussed	O
.	O


That	O
looks	O
familiar	O
:	O
attention	O
allocation	O
to	O
familiar	O
and	O
unfamiliar	O
faces	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


INTRODUCTION	O
Existing	O
eye-tracking	B-I
literature	O
has	O
shown	O
that	O
both	O
adults	B-P
and	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
show	O
fewer	O
and	O
slower	O
fixations	O
on	O
faces	O
.	O


Despite	O
this	O
reduced	O
saliency	O
and	O
processing	O
of	O
other	O
faces	O
,	O
recognition	O
of	O
their	O
own	O
face	O
is	O
reported	O
to	O
be	O
more	O
"	O
typical	O
"	O
in	O
nature	O
.	O


This	O
study	O
uses	O
eye-tracking	B-I
to	O
explore	O
the	O
typicality	O
of	O
gaze	O
patterns	O
when	O
children	B-P
with	I-P
ASD	I-P
attend	O
their	O
own	O
faces	O
compared	O
to	O
other	O
familiar	O
and	O
unfamiliar	O
faces	O
.	O


METHODS	O
Eye-tracking	B-I
methodology	I-I
was	O
used	O
to	O
explore	O
fixation	B-O
duration	I-O
and	O
time	B-O
taken	I-O
to	I-O
fixate	I-O
on	I-O
the	I-O
Eye	I-O
and	I-O
Mouth	I-O
regions	I-O
of	I-O
familiar	I-O
,	I-O
unfamiliar	I-O
and	I-O
Self	I-O
Faces	I-O
.	I-O


Twenty-one	B-P
children	I-P
with	I-P
ASD	I-P
(	I-P
9-16	I-P
years	I-P
)	I-P
were	I-P
compared	I-P
to	I-P
typically	I-P
developing	I-P
matched	I-P
groups	I-P
.	I-P


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
between	O
children	B-P
with	I-P
ASD	I-P
and	O
typically	B-P
matched	I-P
groups	I-P
for	O
fixation	B-O
patterns	I-O
to	I-O
the	I-O
Eye	I-O
and	I-O
Mouth	I-O
areas	I-O
of	O
all	O
face	O
types	O
(	O
familiar	O
,	O
unfamiliar	O
and	O
self	O
)	O
.	O


Correlational	O
analyses	O
showed	O
that	O
attention	O
to	O
the	O
Eye	O
area	O
of	O
unfamiliar	O
and	O
Self	O
Faces	O
was	O
related	O
to	O
socio-communicative	O
ability	O
in	O
children	B-P
with	I-P
ASD	I-P
.	I-P


CONCLUSIONS	O
Levels	O
of	O
socio-communicative	O
ability	O
in	O
children	B-P
with	I-P
ASD	I-P
were	O
related	O
to	O
gaze	B-O
patterns	I-O
on	I-O
unfamiliar	I-O
and	I-O
Self	I-O
Faces	I-O
,	O
but	O
not	O
familiar	O
faces	O
.	O


This	O
lack	O
of	O
relationship	O
between	O
ability	B-O
and	I-O
attention	I-O
to	O
familiar	O
faces	O
may	O
indicate	O
that	O
children	O
across	O
the	O
autism	O
spectrum	O
are	O
able	O
to	O
fixate	O
these	O
faces	O
in	O
a	O
similar	O
way	O
.	O


The	O
implications	O
for	O
these	O
findings	O
are	O
discussed	O
.	O


Microbiologic	O
yields	O
and	O
complication	O
rates	O
of	O
vitreous	B-I
needle	I-I
aspiration	I-I
versus	O
mechanized	B-I
vitreous	I-I
biopsy	I-I
in	O
the	O
Endophthalmitis	O
Vitrectomy	O
Study	O
.	O


PURPOSE	O
To	O
compare	O
the	O
microbiologic	O
yields	O
and	O
complication	O
rates	O
associated	O
with	O
vitreous	B-I
needle	I-I
tap	I-I
and	O
vitreous	B-I
biopsy	I-I
in	O
the	O
Endophthalmitis	B-P
Vitrectomy	I-P
Study	I-P
(	I-P
EVS	I-P
)	I-P
.	I-P


METHODS	O
Of	O
420	B-P
EVS	I-P
patients	I-P
with	I-P
postoperative	I-P
endophthalmitis	I-P
,	I-P
201	I-P
received	I-P
immediate	I-P
vitreous	I-I
tap	I-I
or	I-I
biopsy	I-I
(	I-I
without	I-I
pars	I-I
plana	I-I
vitrectomy	I-I
)	I-I
by	O
random	O
assignment	O
and	O
193	B-P
completed	O
9-12	O
months	O
of	O
follow-up	O
.	O


Vitreous	O
specimens	O
were	O
obtained	O
by	O
biopsy	O
with	O
a	O
20-gauge	B-I
vitrectomy	I-I
cutting	O
instrument	O
or	O
by	O
needle	O
tap	O
with	O
a	O
22-27-gauge	O
needle	O
.	O


If	O
resistance	O
to	O
aspiration	O
by	O
needle	O
tap	O
was	O
noted	O
,	O
a	O
vitreous	O
biopsy	O
was	O
performed	O
.	O


RESULTS	O
Of	O
201	B-P
patients	I-P
undergoing	I-P
tap	I-P
or	I-P
biopsy	I-P
,	I-P
70	I-P
(	I-P
35	I-P
%	I-P
)	I-P
had	I-P
needle	I-P
tap	I-P
,	I-P
127	I-P
(	I-P
63	I-P
%	I-P
)	I-P
had	I-P
mechanized	I-P
biopsy	I-P
,	I-P
and	I-P
4	I-P
(	I-P
2	I-P
%	I-P
)	I-P
had	I-P
initial	I-P
needle	I-P
tap	I-P
that	O
was	O
aborted	O
to	O
mechanized	O
biopsy	O
(	O
"	O
abort	O
"	O
eyes	O
)	O
.	O


Intraoperative	B-O
hyphema	I-O
occurred	O
in	O
2	O
tap	O
eyes	O
(	O
3	O
%	O
)	O
,	O
3	O
biopsy	O
eyes	O
(	O
2	O
%	O
)	O
,	O
and	O
0	O
(	O
0	O
%	O
)	O
abort	O
eyes	O
.	O


Postoperative	B-O
retinal	I-O
detachment	I-O
developed	O
in	O
8	O
(	O
11	O
%	O
)	O
tap	O
eyes	O
,	O
10	O
(	O
8	O
%	O
)	O
biopsy	O
eyes	O
,	O
and	O
0	O
(	O
0	O
%	O
)	O
abort	O
eyes	O
(	O
not	O
significant	O
)	O
.	O


Respective	B-O
rates	I-O
of	I-O
culture	I-O
and	I-O
gram	I-O
stain	I-O
positivity	I-O
were	O
69	O
%	O
and	O
42	O
%	O
in	O
tap	O
eyes	O
and	O
66	O
%	O
and	O
41	O
%	O
in	O
biopsy	O
eyes	O
(	O
not	O
significant	O
)	O
.	O


The	O
rate	B-O
of	I-O
severe	I-O
visual	I-O
loss	I-O
(	O
final	O
acuity	O
<	O
5/200	O
)	O
was	O
significantly	O
higher	O
in	O
tap	O
eyes	O
(	O
16	O
eyes	O
,	O
24	O
%	O
)	O
compared	O
with	O
biopsy	O
eyes	O
(	O
13	O
eyes	O
,	O
11	O
%	O
)	O
and	O
abort	O
eyes	O
(	O
0	O
eyes	O
,	O
0	O
%	O
;	O
P	O
=	O
0.043	O
)	O
.	O


The	O
difference	O
was	O
largely	O
explained	O
by	O
the	O
greater	O
proportion	B-O
of	I-O
virulent	I-O
organisms	I-O
in	I-O
the	I-O
tap	I-O
eyes	I-O
compared	O
with	O
biopsy	O
eyes	O
.	O


When	O
visual	B-O
acuity	I-O
outcome	I-O
was	O
defined	O
by	O
other	O
thresholds	O
(	O
20/40	O
and	O
20/100	O
)	O
,	O
the	O
difference	O
was	O
not	O
significant	O
.	O


CONCLUSIONS	O
This	O
study	O
showed	O
no	O
significant	O
differences	O
between	O
mechanized	O
vitreous	O
biopsy	O
and	O
needle	O
tap	O
with	O
respect	O
to	O
microbiologic	O
yield	O
,	O
operative	O
complications	O
,	O
short-term	O
(	O
9-12	O
months	O
)	O
retinal	O
detachment	O
risk	O
,	O
or	O
visual	O
outcome	O
.	O


Choice	O
of	O
vitreous	O
sampling	O
procedure	O
must	O
depend	O
on	O
the	O
clinical	O
judgment	O
of	O
the	O
surgeon	O
.	O


Gastric	B-P
carcinoma	I-P
:	I-P
expression	I-O
of	I-O
c-erbB-2/neu	I-O
oncoprotein	I-O
,	I-O
epidermal	I-O
growth	I-O
factor	I-O
receptor	I-O
,	I-O
cathepsin	I-O
D	I-O
,	I-O
progesterone	I-O
receptor	I-O
and	I-O
tumor	I-O
associated	I-O
glycoprotein-72	I-O
in	O
different	O
histological	O
types	O
.	O


OBJECTIVE	O
Gastric	B-P
carcinoma	I-P
can	O
be	O
divided	O
into	O
two	O
main	O
histological	O
and	O
clinical	O
types	O
:	O
diffuse	B-P
and	I-P
intestinal	I-P
.	I-P


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	B-O
of	I-O
neu/c-erbB-2	I-O
oncoprotein	I-O
,	I-O
epidermal	I-O
growth	I-O
factor	I-O
receptor	I-O
(	I-O
EGFR	I-O
)	I-O
,	I-O
cathepsin	I-O
D	I-O
(	I-O
catD	I-O
)	I-O
,	I-O
progesterone	I-O
receptor	I-O
(	I-O
PR	I-O
)	I-O
and	I-O
tumor-associated	I-O
glycoprotein-72	I-O
(	I-O
TAG-72	I-O
)	I-O
in	O
gastric	O
carcinoma	O
of	O
these	O
histological	O
types	O
.	O


METHOD	O
In	O
this	O
randomized	O
,	O
prospective	O
study	O
we	O
analyzed	O
85	B-P
biopsy	I-I
samples	I-I
from	I-P
patients	I-P
with	I-P
gastric	I-P
adenocarcinoma	I-P
.	I-P


The	O
control	B-P
group	I-P
consisted	I-P
of	I-P
40	I-P
specimens	I-P
from	I-P
normal	I-I
gastric	I-I
mucosa	I-I
.	I-I


Neu	B-O
oncoprotein	I-O
and	I-O
PR	I-O
were	O
determined	O
by	O
ELISA	B-O
.	I-O


CatD	B-O
and	I-O
TAG-72	I-O
were	O
quantified	O
with	O
immunoradiometric	B-O
(	I-O
IRMA	I-O
)	I-O
methods	I-O
,	O
and	O
EGFR	B-O
were	I-O
studied	I-O
by	I-O
radioimmunoassay	I-O
(	I-O
RIA	I-O
)	I-O
.	I-O


RESULTS	O
Neu	B-O
,	I-O
EGFR	I-O
,	I-O
catD	I-O
and	I-O
TAG-72	I-O
concentrations	I-O
were	O
higher	O
in	O
the	O
tumoral	O
group	O
(	O
p	O
=	O
0.02	O
,	O
p	O
=	O
0.00001	O
,	O
p	O
=	O
0.002	O
and	O
p	O
=	O
0.007	O
,	O
respectively	O
)	O
.	O


In	O
diffuse	O
adenocarcinomas	O
,	O
catD	B-O
and	I-O
PR	I-O
expression	I-O
was	O
increased	O
(	O
p	O
=	O
0.01	O
and	O
p	O
=	O
0.04	O
respectively	O
)	O
,	O
whereas	O
TAG-72	B-O
concentration	I-O
,	O
which	O
correlated	O
with	O
neu	B-O
(	O
r	O
=	O
0.57	O
)	O
,	O
was	O
higher	O
in	O
the	O
intestinal	O
type	O
(	O
p	O
=	O
0.04	O
)	O
.	O


No	O
significant	O
differences	O
in	O
EGFR	B-O
and	I-O
neu	I-O
concentrations	I-O
were	O
seen	O
between	O
the	O
two	O
histological	O
types	O
.	O


CONCLUSIONS	O
The	O
higher	O
PR	B-O
and	I-O
catD	I-O
concentrations	I-O
in	O
diffuse	O
adenocarcinomas	O
,	O
and	O
the	O
overexpression	O
of	O
TAG-72	B-O
in	O
the	O
intestinal	O
type	O
,	O
support	O
the	O
existence	O
of	O
two	O
modes	O
of	O
gastric	O
carcinogenesis	O
.	O


Supplemental	B-I
perioperative	I-I
oxygen	I-I
and	O
the	O
risk	O
of	O
surgical	B-O
wound	I-O
infection	I-O
:	I-O
a	O
randomized	O
controlled	O
trial	O
.	O


CONTEXT	O
Supplemental	B-I
perioperative	I-I
oxygen	I-I
has	O
been	O
variously	O
reported	O
to	O
halve	O
or	O
double	O
the	O
risk	O
of	O
surgical	B-O
wound	I-O
infection	I-O
.	I-O


OBJECTIVE	O
To	O
test	O
the	O
hypothesis	O
that	O
supplemental	B-I
oxygen	I-I
reduces	O
infection	O
risk	O
in	O
patients	B-P
following	I-P
colorectal	I-P
surgery	I-P
.	I-P


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
A	O
double-blind	O
,	O
randomized	O
controlled	O
trial	O
of	O
300	B-P
patients	I-P
aged	I-P
18	I-P
to	I-P
80	I-P
years	I-P
who	I-P
underwent	I-P
elective	I-P
colorectal	I-P
surgery	I-P
in	I-P
14	I-P
Spanish	I-P
hospitals	I-P
from	I-P
March	I-P
1	I-P
,	I-P
2003	I-P
,	I-P
to	I-P
October	I-P
31	I-P
,	I-P
2004	I-P
.	I-P


Wound	O
infections	O
were	O
diagnosed	O
by	O
blinded	O
investigators	O
using	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
criteria	O
.	O


Baseline	O
patient	O
characteristics	O
,	O
anesthetic	O
treatment	O
,	O
and	O
potential	O
confounding	O
factors	O
were	O
recorded	O
.	O


INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
either	O
30	B-I
%	I-I
or	I-I
80	I-I
%	I-I
fraction	I-I
of	I-I
inspired	I-I
oxygen	I-I
(	O
FIO2	O
)	O
intraoperatively	O
and	O
for	O
6	O
hours	O
after	O
surgery	O
.	O


Anesthetic	O
treatment	O
and	O
antibiotic	O
administration	O
were	O
standardized	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Any	B-O
surgical	I-O
site	I-O
infection	I-O
(	I-O
SSI	I-O
)	I-O
;	I-O
secondary	O
outcomes	O
included	O
return	B-O
of	I-O
bowel	I-O
function	I-O
and	I-O
ability	I-O
to	I-O
tolerate	I-O
solid	I-O
food	I-O
,	I-O
ambulation	I-O
,	I-O
suture	I-O
removal	I-O
,	I-O
and	I-O
duration	I-O
of	I-O
hospitalization	I-O
.	I-O


RESULTS	O
A	O
total	O
of	O
143	O
patients	O
received	O
30	B-I
%	I-I
perioperative	I-I
oxygen	I-I
and	O
148	O
received	O
80	B-I
%	I-I
perioperative	I-I
oxygen	I-I
.	I-I


Surgical	B-O
site	I-O
infection	I-O
occurred	O
in	O
35	O
patients	O
(	O
24.4	O
%	O
)	O
administered	O
30	O
%	O
FIO2	O
and	O
in	O
22	O
patients	O
(	O
14.9	O
%	O
)	O
administered	O
80	O
%	O
FIO2	O
(	O
P=.04	O
)	O
.	O


The	O
risk	B-O
of	I-O
SSI	I-O
was	O
39	O
%	O
lower	O
in	O
the	O
80	B-I
%	I-I
FIO2	I-I
group	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
0.61	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.38-0.98	O
)	O
vs	O
the	O
30	B-I
%	I-I
FIO2	I-I
group	O
.	O


After	O
adjustment	O
for	O
important	O
covariates	O
,	O
the	O
RR	O
of	O
infection	O
in	O
patients	O
administered	O
supplemental	O
oxygen	O
was	O
0.46	O
(	O
95	O
%	O
CI	O
,	O
0.22-0.95	O
;	O
P	O
=	O
.04	O
)	O
.	O


None	O
of	O
the	O
secondary	O
outcomes	O
varied	O
significantly	O
between	O
the	O
2	O
treatment	O
groups	O
.	O


CONCLUSIONS	O
Patients	O
receiving	O
supplemental	B-I
inspired	I-I
oxygen	I-I
had	O
a	O
significant	O
reduction	O
in	O
the	O
risk	B-O
of	I-O
wound	I-O
infection	I-O
.	I-O


Supplemental	B-I
oxygen	I-I
appears	O
to	O
be	O
an	O
effective	O
intervention	O
to	O
reduce	O
SSI	B-O
in	O
patients	B-P
undergoing	I-P
colon	I-P
or	I-P
rectal	I-P
surgery	I-P
.	I-P


Trial	O
Registration	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00235456	O
.	O


Longitudinal	O
quality	B-O
of	I-O
life	I-O
study	O
in	O
patients	B-P
with	I-P
metastatic	I-P
gastric	I-P
cancer	I-P
.	I-P


Analysis	O
modalities	O
and	O
clinical	O
applicability	O
of	O
QoL	B-O
in	O
randomized	O
phase	O
II	O
trial	O
in	O
a	O
digestive	O
oncology	O
.	O


OBJECTIVES	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
longitudinal	B-O
quality	I-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
between	O
LV5FU2-irinotecan	B-I
and	I-I
LV5FU2	I-I
alone	I-I
or	I-I
LV5FU2-cisplatin	I-I
in	O
a	O
randomized	O
Phase	O
II	O
trial	O
in	O
patients	B-P
with	I-P
metastatic	I-P
gastric	I-P
adenocarcinoma	I-P
.	I-P


METHODS	O
Among	O
134	B-P
eligible	I-P
patients	I-P
,	O
QLQ-C30	B-O
scores	I-O
were	O
collected	O
and	O
described	O
at	O
each	O
2	O
monthly	O
follow-up	O
visit	O
during	O
6	O
months	O
.	O


The	O
frequencies	B-O
of	I-O
QLQ-C30	I-O
score	I-O
improvement	I-O
were	O
calculated	O
and	O
mixed	O
models	O
for	O
repeated	O
measurements	O
were	O
applied	O
with	O
or	O
without	O
extreme	O
poorest	O
imputation	O
for	O
missing	O
scores	O
.	O


The	O
"	B-O
survival	I-O
"	I-O
until	I-O
definitive	I-O
global	I-O
health	I-O
score	I-O
(	I-O
GHS	I-O
)	I-O
deterioration	I-O
was	O
estimated	O
.	O


RESULTS	O
At	O
the	O
3rd	O
follow-up	O
,	O
patients	O
with	O
a	O
stable	O
or	O
improved	O
global	B-O
health	I-O
ranged	O
from	O
11	O
%	O
in	O
the	O
LV5FU2-cisplatin	B-I
arm	O
to	O
18	O
%	O
in	O
the	O
LV5FU2-irinotecan	B-I
arm	O
.	O


The	O
irinotecan-based-therapy	O
presented	O
14	O
to	O
15	O
scores	O
with	O
a	O
better	O
QoL	B-O
.	I-O


The	O
time	B-O
until	I-O
definitive	I-O
GHS	I-O
deterioration	I-O
was	O
globally	O
similar	O
between	O
treatment	O
arms	O
.	O


CONCLUSION	O
This	O
study	O
highlights	O
a	O
better	O
impact	O
of	O
LV5FU2-irinotecan	B-I
and	O
the	O
interest	O
of	O
QoL	B-O
assessment	I-O
in	O
phase	O
II	O
trials	O
to	O
complement	O
the	O
risk-benefit	O
judgement	O
.	O


Effects	O
of	O
fluoride	B-I
and	I-I
chlorhexidine	I-I
on	O
the	O
microflora	B-O
of	I-O
dental	I-O
root	I-O
surfaces	I-O
and	O
progression	O
of	O
root-surface	O
caries	O
.	O


The	O
effects	O
of	O
fluoride	B-I
and	I-I
chlorhexidine	I-I
varnishes	O
on	O
the	O
microflora	O
of	O
dental	O
root	O
surfaces	O
and	O
on	O
the	O
progression	O
of	O
root-surface	O
caries	O
were	O
studied	O
.	O


Forty-four	B-P
patients	I-P
,	I-P
surgically	I-P
treated	I-P
for	I-P
advanced	I-P
periodontal	I-P
disease	I-P
,	O
were	O
distributed	O
at	O
random	O
among	O
three	O
groups	O
.	O


All	O
patients	O
received	O
a	O
standardized	O
preventive	O
treatment	O
.	O


Furthermore	O
,	O
the	O
dentition	O
of	O
the	O
patients	O
in	O
the	O
two	O
experimental	O
groups	O
was	O
treated	O
,	O
at	O
three-month	O
intervals	O
,	O
with	O
chlorhexidine	B-I
and	I-I
fluoride	I-I
varnish	I-I
,	O
respectively	O
.	O


Patients	O
in	O
the	O
control	B-I
group	I-I
received	O
no	O
additional	O
treatment	O
.	O


In	O
the	O
experimental	O
groups	O
,	O
plaque	O
samples	O
were	O
collected	O
from	O
selected	O
sound	O
and	O
carious	O
root	O
surfaces	O
at	O
baseline	O
and	O
at	O
three	O
,	O
six	O
,	O
and	O
nine	O
months	O
after	O
the	O
onset	O
of	O
the	O
study	O
.	O


The	O
presence	O
of	O
root-surface	O
caries	O
was	O
scored	O
at	O
baseline	O
and	O
after	O
one	O
year	O
.	O


In	O
addition	O
,	O
the	O
texture	O
,	O
depth	O
,	O
and	O
color	O
of	O
the	O
root-surface	O
lesions	O
were	O
monitored	O
.	O


Mutans	B-O
streptococci	I-O
on	I-O
root	I-O
surfaces	I-O
were	I-O
suppressed	I-O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
during	O
the	O
whole	O
experimental	O
period	O
in	O
the	O
chlorhexidine	B-I
varnish	O
group	O
,	O
but	O
not	O
in	O
the	O
fluoride	B-I
varnish	O
group	O
.	O


A	O
non-significant	O
increase	B-O
in	I-O
the	I-O
number	I-O
of	I-O
Actinomyces	I-O
viscosus/naeslundii	I-O
was	O
noted	O
after	O
treatment	O
with	O
chlorhexidine	B-I
and	O
fluoride	B-I
varnish	O
.	O


The	O
increase	B-O
in	I-O
the	I-O
number	I-O
of	I-O
decayed	I-O
and	I-O
filled	I-O
root	I-O
surfaces	I-O
after	O
one	O
year	O
was	O
significantly	O
lower	O
in	O
the	O
experimental	O
groups	O
than	O
in	O
the	O
control	O
group	O
.	O


After	O
treatment	O
with	O
chlorhexidine	B-I
varnish	O
,	O
significantly	O
more	O
initial	B-O
root-surface	I-O
lesions	I-O
had	I-O
hardened	I-O
than	O
in	O
the	O
other	O
groups	O
.	O


The	O
effect	O
of	O
phenytoin	B-I
on	O
the	O
absorption	O
of	O
synthetic	O
folic	O
acid	O
polyglutamate	O
.	O


The	O
absorption	O
of	O
synthetic	O
pteroyltriglutamate	O
has	O
been	O
measured	O
in	O
nine	B-P
normal	I-P
students	I-P
with	I-P
and	I-P
without	I-P
the	I-P
anticonvulsant	I-P
drug	I-P
phenytoin	I-I
.	I-I


It	O
has	O
been	O
shown	O
that	O
phenytoin	B-I
has	O
no	O
effect	O
on	O
the	O
absorption	O
of	O
this	O
folate	B-O
polyglutamate	I-O
.	I-O


The	O
reasons	O
are	O
discussed	O
for	O
the	O
disparity	O
between	O
this	O
result	O
and	O
those	O
reported	O
in	O
the	O
literature	O
when	O
folate	O
polyglutamates	O
derived	O
from	O
yeast	O
were	O
used	O
.	O


Pegfilgrastim	B-I
for	O
peripheral	O
CD34+	O
mobilization	O
in	O
patients	B-P
with	I-P
solid	I-O
tumours	I-O
.	I-O


The	O
efficacy	B-O
of	O
pegfilgrastim+/-chemotherapy	B-I
for	O
mobilizing	O
stem	O
cells	O
in	O
patients	B-P
with	I-P
solid	I-O
tumours	I-O
was	O
assessed	O
.	O


In	O
cycle	O
0	O
,	O
a	O
14-day	O
prechemotherapy	O
cycle	O
,	O
patients	B-P
(	I-P
N=61	I-P
)	I-P
were	O
randomized	O
open-label	O
to	O
single	O
doses	O
of	O
pegfilgrastim	B-I
(	O
6	O
,	O
12	O
or	O
18	O
mg	O
)	O
on	O
day	O
1	O
,	O
or	O
daily	O
filgrastim	B-I
(	O
10	O
microg/kg	O
)	O
for	O
<	O
or	O
=7	O
days	O
.	O


Mean	B-O
peak	I-O
peripheral	I-O
CD34+	I-O
cell	I-O
counts	I-O
increased	I-O
with	O
pegfilgrastim	B-I
dose	O
,	O
but	O
were	O
significantly	B-O
higher	I-O
than	O
filgrastim	B-I
only	O
at	O
the	O
18	O
mg	O
dose	O
(	O
10.17	O
vs	O
4.96	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.014	O
)	O
.	O


In	O
the	O
clinically	O
relevant	O
period	O
of	O
days	O
3-7	O
,	O
both	O
12	O
and	O
18	O
mg	O
pegfilgrastim	B-I
doses	O
produced	O
significantly	B-O
higher	I-O
peak	I-O
CD34+	I-O
counts	I-O
(	O
8.18	O
and	O
9.96	O
vs	O
4.51	O
x	O
10	O
(	O
4	O
)	O
/ml	O
for	O
filgrastim	B-I
;	I-I
P=0.034	O
and	O
0.006	O
)	O
.	O


In	O
cycle	O
1	O
,	O
patients	O
received	O
carboplatin/paclitaxel	B-I
on	O
day	O
1	O
,	O
followed	O
from	O
day	O
2	O
by	O
pegfilgrastim	B-I
6-18	O
mg	O
or	O
daily	O
filgrastim	B-I
(	O
5	O
microg/kg/day	O
for	O
<	O
or	O
=14	O
days	O
)	O
as	O
per	O
randomization	O
in	O
cycle	O
0	O
.	O


There	O
were	O
no	B-O
significant	I-O
differences	I-O
in	O
mean	B-O
peak	I-O
CD34+	I-O
count	I-O
between	O
pegfilgrastim	B-I
and	O
filgrastim	B-I
,	O
but	O
there	O
was	O
an	O
advantage	O
for	O
pegfilgrastim	B-I
18	O
mg	O
in	O
the	O
relevant	O
period	O
of	O
days	O
7-12	O
(	O
3.14	O
vs	O
1.19	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.043	O
)	O
.	O


A	O
single	O
pegfilgrastim	B-I
dose	O
(	O
>	O
or	O
=6	O
mg	O
)	O
could	O
be	O
substituted	O
for	O
daily	O
filgrastim	B-I
in	O
cytokine-only	B-O
peripheral	I-O
CD34+	I-O
cell	I-O
mobilization	I-O
.	I-O


Analgesic	O
efficacy	O
of	O
low-dose	O
diclofenac	B-I
versus	I-I
paracetamol	I-I
and	I-I
placebo	I-I
in	O
postoperative	B-P
dental	I-P
pain	I-P
.	I-P


AIMS	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
diclofenac-K	B-I
(	O
12.5	O
mg	O
)	O
vs	O
paracetamol	B-I
(	O
500	O
mg	O
)	O
and	O
placebo	B-I
given	O
in	O
a	O
flexible	O
dosage	O
regimen	O
to	O
treat	O
pain	B-P
resulting	I-P
from	I-P
extraction	I-P
of	I-P
impacted	I-P
third	I-P
molar	I-P
teeth	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
2-day	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
randomized	O
,	O
parallel-group	O
,	O
placebo-controlled	B-I
study	O
of	O
diclofenac-K	B-I
(	I-I
12.5	I-I
mg	I-I
)	I-I
tablets	I-I
vs	I-I
paracetamol	I-I
(	O
500	O
mg	O
)	O
tablets	O
and	O
placebo	B-I
in	O
patients	B-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
pain	I-P
within	I-P
8	I-P
hours	I-P
of	I-P
extraction	I-P
of	I-P
impacted	I-P
third	I-P
molars	I-P
.	I-P


RESULTS	O
After	O
the	O
first	O
2-tablet	O
dose	O
,	O
patients	O
took	O
on	O
average	O
2.5	O
additional	O
tablets	O
of	O
diclofenac-K	B-I
or	O
2.4	O
tablets	O
of	O
paracetamol	B-I
,	O
almost	O
all	O
as	O
1-tablet	O
doses	O
.	O


Most	O
placebo	B-I
patients	O
discontinued	O
by	O
taking	O
rescue	B-O
medication	I-O
(	O
ibuprofen	O
200	O
mg	O
)	O
on	O
the	O
first	O
day	O
.	O


Pain	B-O
relief	I-O
after	O
the	O
initial	O
dose	O
of	O
diclofenac-K	B-I
(	O
2	O
x	O
12.5	O
mg	O
)	O
was	O
superior	O
to	O
placebo	B-I
(	O
P	O
<	O
.01	O
for	O
all	O
efficacy	O
outcomes	O
)	O
and	O
comparable	O
to	O
paracetamol	B-I
(	O
2	O
x	O
500	O
mg	O
)	O
.	O


About	O
30	O
%	O
of	O
patients	O
in	O
each	O
active	O
treatment	O
group	O
took	O
rescue	B-O
medication	I-O
during	O
the	O
study	O
,	O
compared	O
to	O
78	O
%	O
on	O
placebo	B-I
.	I-I


About	O
70	O
%	O
in	O
each	O
active	O
treatment	O
group	O
considered	O
the	O
overall	B-O
pain	I-O
relief	I-O
to	O
be	O
"	O
some	O
,	O
"	O
"	O
a	O
lot	O
,	O
"	O
or	O
"	O
complete	O
"	O
compared	O
to	O
only	O
15	O
%	O
on	O
placebo	B-I
.	I-I


The	O
incidence	B-O
of	I-O
adverse	I-O
events	I-O
in	O
each	O
active	O
treatment	O
group	O
was	O
low	O
and	O
comparable	O
between	O
the	O
treatments	O
.	O


CONCLUSION	O
An	O
initial	O
double-dose	O
of	O
diclofenac-K	B-I
(	O
2	O
x	O
12.5	O
mg	O
)	O
or	O
paracetamol	B-I
(	O
2	O
x	O
500	O
mg	O
)	O
adequately	O
relieved	O
the	O
most	O
intense	O
postoperative	B-O
pain	I-O
,	O
and	O
the	O
flexible	O
multiple	O
dose	O
regimen	O
(	O
1	O
or	O
2	O
tablets	O
)	O
maintained	O
adequate	O
pain	B-O
relief	I-O
thereafter	O
.	O


Most	O
patients	O
needed	O
only	O
1-tablet	O
doses	O
following	O
the	O
initial	O
2-tablet	O
dose	O
.	O


Effect	O
of	O
entacapone	B-I
,	O
a	O
peripherally	O
acting	O
catechol-O-methyltransferase	O
inhibitor	O
,	O
on	O
the	O
motor	B-O
response	I-O
to	I-O
acute	I-O
treatment	I-O
with	I-O
levodopa	I-O
in	O
patients	B-P
with	I-P
Parkinson	I-P
's	I-P
disease	I-P
.	I-P


Catechol-O-methyltransferase	O
(	O
COMT	O
)	O
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
by	O
improving	O
the	O
bioavailability	B-O
of	O
levodopa	O
and	O
by	O
prolonging	O
its	O
effects	O
.	O


Entacapone	B-I
(	I-I
OR-611	I-I
)	I-I
,	I-I
a	I-I
novel	I-I
COMT	I-I
inhibitor	I-I
,	O
which	O
does	O
not	O
cross	O
the	O
blood	O
brain	O
barrier	O
,	O
was	O
assessed	O
in	O
12	B-P
patients	I-P
with	I-P
Parkinson	I-P
's	I-P
disease	I-P
and	I-P
motor	I-P
fluctuations	I-P
in	O
a	O
randomised	O
,	O
double-blind	O
,	O
cross-over	O
,	O
single	O
dose	O
study	O
.	O


The	O
magnitude	O
and	O
duration	O
of	O
the	O
therapeutic	O
response	O
to	O
a	O
single	O
dose	O
of	O
200	O
mg	O
levodopa/50	B-I
mg	O
carbidopa	B-I
was	O
evaluated	O
after	O
concomitant	O
placebo	B-I
,	O
or	O
200	O
or	O
800	O
mg	O
entacapone	B-I
.	I-I


A	O
significant	O
increase	O
in	O
the	O
duration	B-O
of	I-O
the	I-O
motor	I-O
response	I-O
to	I-O
levodopa	I-O
was	O
seen	O
when	O
200	O
mg	O
entacapone	O
was	O
given	O
with	O
levodopa/carbidopa	O
.	O


Plasma	B-O
levodopa	I-O
concentrations	I-O
were	O
increased	O
with	O
both	O
doses	O
of	O
the	O
COMT	O
inhibitor	O
.	O


The	O
latency	B-O
to	I-O
onset	I-O
of	I-O
motor	I-O
response	I-O
did	O
not	O
differ	O
significantly	O
between	O
active	O
drug	O
and	O
placebo	O
.	O


Entacapone	O
may	O
prove	O
useful	O
in	O
prolonging	B-O
the	I-O
duration	I-O
of	I-O
the	I-O
benefit	I-O
obtained	O
from	O
individual	O
doses	O
of	O
levodopa	O
.	O


Effect	O
of	O
propranolol	B-I
on	O
word	O
fluency	O
in	O
autism	B-P
.	I-P


OBJECTIVE	O
AND	O
BACKGROUND	O
Autism	O
is	O
characterized	O
by	O
repetitive	O
behaviors	O
and	O
impaired	O
socialization	O
and	O
communication	O
.	O


Preliminary	O
evidence	O
showed	O
possible	O
language	O
benefits	O
in	O
autism	O
from	O
the	O
β-adrenergic	B-I
antagonist	I-I
propranolol	I-I
.	O


Earlier	O
studies	O
in	O
other	O
populations	O
suggested	B-I
propranolol	I-I
might	O
benefit	O
performance	O
on	O
tasks	O
involving	O
a	O
search	O
of	O
semantic	O
and	O
associative	O
networks	O
under	O
certain	O
conditions	O
.	O


Therefore	O
,	O
we	O
wished	O
to	O
determine	O
whether	O
this	O
benefit	O
of	B-I
propranolol	I-I
includes	O
an	O
effect	O
on	O
semantic	O
fluency	O
in	O
autism	O
.	O


METHODS	B-P
A	I-P
sample	I-P
of	I-P
14	I-P
high-functioning	I-P
adolescent	I-P
and	I-P
adult	I-P
participants	I-P
with	I-P
autism	I-P
and	I-P
14	I-P
matched	I-P
controls	I-P
were	O
given	O
letter	O
and	O
category	O
word	O
fluency	O
tasks	O
on	O
2	O
separate	O
testing	O
sessions	O
;	O
1	O
test	O
was	O
given	O
60	O
minutes	O
after	O
the	O
administration	O
of	O
40	O
mg	B-I
propranolol	I-I
orally	O
,	O
and	O
1	O
test	O
was	O
given	O
after	B-I
placebo	I-I
,	O
administered	O
in	O
a	O
double-blinded	O
,	O
counterbalanced	O
manner	O
.	O


RESULTS	B-P
Participants	I-P
with	I-P
autism	I-P
were	O
significantly	O
impaired	O
compared	O
with	O
controls	O
on	O
both	B-O
fluency	I-O
tasks	I-O
.	I-I


Propranolol	B-I
significantly	O
improved	B-O
performance	I-O
on	I-O
category	I-O
fluency	I-O
,	O
but	O
not	B-O
letter	I-O
fluency	I-O
among	O
autism	B-P
participants	I-P
.	O


No	B-O
drug	I-O
effect	I-O
was	O
observed	O
among	O
controls	O
.	O


Expected	O
drug	O
effects	O
on	B-O
heart	I-O
rate	I-O
and	I-O
blood	I-O
pressure	I-O
were	O
observed	O
in	O
both	O
the	O
groups	O
.	O


CONCLUSIONS	O
Results	O
are	O
consistent	O
with	O
a	O
selective	O
beneficial	O
effect	O
of	B-I
propranolol	I-I
on	O
flexibility	O
of	O
access	O
to	O
semantic	O
and	O
associative	O
networks	O
in	O
autism	O
,	O
with	O
no	O
observed	O
effect	O
on	O
phonological	O
networks	O
.	O


Further	O
study	O
will	O
be	O
necessary	O
to	O
understand	O
potential	O
clinical	O
implications	O
of	O
this	O
finding	O
.	O


A	O
comparative	O
trial	O
of	O
liver	O
biopsy	B-I
needles	O
.	O


A	O
sheathed	B-I
needle	I-I
(	O
Tru-Cut	O
)	O
was	O
compared	O
with	O
a	O
suction	B-I
biopsy	I-I
needle	I-I
(	I-I
Menghini	I-I
)	I-I
in	O
a	O
randomised	O
prospective	O
trial	O
over	O
18	O
months	O
to	O
determine	O
whether	O
the	O
former	O
offered	O
any	O
special	O
advantages	O
in	O
routine	B-I
percutaneous	I-I
liver	I-I
biopsy	I-I
.	I-I


Seventy-seven	B-P
consecutive	I-P
biopsies	I-I
were	O
performed	O
by	O
a	B-P
single	I-P
operator	I-P
.	I-P


Although	O
biopsy	O
fragmentation	O
was	O
commoner	O
with	O
the	O
suction	B-I
needle	I-I
,	O
the	O
length	O
and	O
volume	O
of	O
the	O
largest	O
core	O
obtained	O
was	O
similar	O
to	O
results	O
with	O
the	O
sheathed	B-I
needle	I-I
.	I-I


Cytology	O
provided	O
useful	O
additional	O
information	O
with	O
the	O
Menghini	B-I
technique	I-I
.	I-I


The	O
suction	B-I
needle	I-I
was	O
repeatedly	B-O
reusable	I-O
and	I-O
considerably	I-O
cheaper	I-O
than	O
the	O
sheathed	B-I
needle	I-I
,	O
which	O
may	O
be	O
used	O
once	O
only	O
.	O


Sham	O
device	O
v	O
inert	O
pill	O
:	O
randomised	O
controlled	O
trial	O
of	O
two	O
placebo	O
treatments	O
.	O


OBJECTIVE	O
To	O
investigate	O
whether	O
a	O
sham	O
device	O
(	O
a	O
validated	O
sham	O
acupuncture	O
needle	O
)	O
has	O
a	O
greater	O
placebo	O
effect	O
than	O
an	O
inert	O
pill	O
in	O
patients	B-P
with	I-P
persistent	I-P
arm	I-P
pain	I-P
.	I-P


DESIGN	O
A	O
single	O
blind	O
randomised	O
controlled	O
trial	O
created	O
from	O
the	O
two	O
week	O
placebo	O
run-in	O
periods	O
for	O
two	O
nested	O
trials	O
that	O
compared	O
acupuncture	O
and	O
amitriptyline	O
with	O
their	O
respective	O
placebo	B-P
controls	I-P
.	I-P


Comparison	O
of	O
participants	O
who	O
remained	O
on	O
placebo	O
continued	O
beyond	O
the	O
run-in	O
period	O
to	O
the	O
end	O
of	O
the	O
study	O
.	O


SETTING	O
Academic	O
medical	O
centre	O
.	O


PARTICIPANTS	O
270	B-P
adults	I-P
with	I-P
arm	I-P
pain	I-P
due	I-P
to	I-P
repetitive	I-P
use	I-P
that	I-P
had	I-P
lasted	I-P
at	I-P
least	I-P
three	I-P
months	I-P
despite	I-P
treatment	I-P
and	I-P
who	I-P
scored	I-P
>	I-P
or	I-P
=3	I-P
on	I-P
a	I-P
10	I-P
point	I-P
pain	I-P
scale	I-P
.	I-P


INTERVENTIONS	O
Acupuncture	B-I
with	I-I
sham	I-I
device	I-I
twice	I-I
a	I-I
week	I-I
for	I-I
six	I-I
weeks	I-I
or	I-I
placebo	I-I
pill	I-I
once	I-I
a	I-I
day	I-I
for	I-I
eight	I-I
weeks	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Arm	B-O
pain	I-O
measured	O
on	O
a	O
10	B-O
point	I-O
pain	I-O
scale	I-O
.	I-O


Secondary	B-O
outcomes	I-O
were	I-O
symptoms	I-O
measured	I-O
by	I-O
the	I-O
Levine	I-O
symptom	I-O
severity	I-O
scale	I-O
,	I-O
function	I-O
measured	I-O
by	I-O
Pransky	I-O
's	I-O
upper	I-O
extremity	I-O
function	I-O
scale	I-O
,	I-O
and	I-O
grip	I-O
strength	I-O
.	I-O


RESULTS	O
Pain	B-O
decreased	O
during	O
the	O
two	O
week	O
placebo	O
run-in	O
period	O
in	O
both	O
the	O
sham	O
device	O
and	O
placebo	O
pill	O
groups	O
,	O
but	O
changes	O
were	O
not	O
different	O
between	O
the	O
groups	O
(	O
-0.14	O
,	O
95	O
%	O
confidence	O
interval	O
-0.52	O
to	O
0.25	O
,	O
P	O
=	O
0.49	O
)	O
.	O


Changes	O
in	O
severity	B-O
scores	I-O
for	I-O
arm	I-O
symptoms	I-O
and	I-O
grip	I-O
strength	I-O
were	O
similar	O
between	O
groups	O
,	O
but	O
arm	O
function	O
improved	O
more	O
in	O
the	O
placebo	O
pill	O
group	O
(	O
2.0	O
,	O
0.06	O
to	O
3.92	O
,	O
P	O
=	O
0.04	O
)	O
.	O


Longitudinal	O
regression	O
analyses	O
that	O
followed	O
participants	O
throughout	O
the	O
treatment	O
period	O
showed	O
significantly	O
greater	O
downward	O
slopes	O
per	O
week	O
on	O
the	O
10	B-O
point	I-O
arm	I-O
pain	I-O
scale	I-O
in	O
the	O
sham	O
device	O
group	O
than	O
in	O
the	O
placebo	O
pill	O
group	O
(	O
-0.33	O
(	O
-0.40	O
to	O
-0.26	O
)	O
v	O
-0.15	O
(	O
-0.21	O
to	O
-0.09	O
)	O
,	O
P	O
=	O
0.0001	O
)	O
and	O
on	O
the	O
symptom	O
severity	O
scale	O
(	O
-0.07	O
(	O
-0.09	O
to	O
-0.05	O
)	O
v	O
-0.05	O
(	O
-0.06	O
to	O
-0.03	O
)	O
,	O
P	O
=	O
0.02	O
)	O
.	O


Differences	O
were	O
not	O
significant	O
,	O
however	O
,	O
on	O
the	O
function	O
scale	O
or	O
for	O
grip	O
strength	O
.	O


Reported	O
adverse	O
effects	O
were	O
different	O
in	O
the	O
two	O
groups	O
.	O


CONCLUSIONS	O
The	O
sham	O
device	O
had	O
greater	O
effects	O
than	O
the	O
placebo	O
pill	O
on	O
self	O
reported	O
pain	O
and	O
severity	O
of	O
symptoms	O
over	O
the	O
entire	O
course	O
of	O
treatment	O
but	O
not	O
during	O
the	O
two	O
week	O
placebo	O
run	O
in	O
.	O


Placebo	O
effects	O
seem	O
to	O
be	O
malleable	O
and	O
depend	O
on	O
the	O
behaviours	O
embedded	O
in	O
medical	O
rituals	O
.	O


The	O
impact	O
of	O
angiotensin	B-I
II	I-I
receptor	I-I
blockade	I-I
and	O
the	O
DASH	B-I
diet	I-I
on	O
markers	B-O
of	O
endogenous	B-P
fibrinolysis	I-P
.	I-P


Hypertension	O
is	O
associated	O
with	O
impaired	O
fibrinolysis	O
.	O


Both	O
angiotensin	B-I
receptor	I-I
blockers	I-I
(	I-I
ARB	I-I
)	I-I
and	O
the	O
DASH	B-I
(	I-I
Dietary	I-I
Approaches	I-I
to	I-I
Stop	I-I
Hypertension	I-I
)	I-I
diet	I-I
effectively	O
lower	O
blood	B-O
pressure	I-O
in	O
hypertensive	B-P
patients	I-P
.	I-P


Some	O
evidence	O
suggests	O
that	O
treatment	O
with	O
ARBs	O
could	O
increase	O
fibrinolysis	O
,	O
however	O
,	O
data	O
is	O
conflicting	O
.	O


The	O
impact	O
of	O
the	O
DASH	O
diet	O
on	O
fibrinolytic	B-O
parameters	I-O
is	O
not	O
known	O
.	O


Fifty-five	B-P
hypertensive	I-P
participants	I-P
(	I-P
35	I-P
African-American	I-P
,	I-P
20	I-P
white	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
8	O
weeks	O
of	O
either	O
a	O
control	B-I
diet	I-I
or	O
the	O
DASH	B-I
diet	I-I
.	I-I


The	O
diets	O
did	O
not	O
differ	O
in	O
sodium	O
content	O
(	O
approximately	O
3	O
g/day	O
)	O
.	O


Within	O
each	O
diet	O
,	O
individuals	O
were	O
randomly	O
assigned	O
to	O
receive	O
losartan	B-I
or	O
placebo	B-I
for	O
4	O
weeks	O
in	O
double-blind	O
,	O
cross-over	O
fashion	O
.	O


Tissue	B-O
plasminogen	I-O
activator	I-O
(	I-O
t-PA	I-O
)	I-O
antigen	I-O
,	I-O
t-PA	I-O
activity	I-O
,	I-O
plasminogen	I-O
activator	I-O
inhibitor-1	I-O
(	I-O
PAI-1	I-O
)	I-O
activity	I-O
and	I-O
plasma	I-O
renin	I-O
activity	I-O
(	I-O
PRA	I-O
)	I-O
were	O
measured	O
at	O
the	O
end	O
of	O
a	O
2-week	O
run-in	O
period	O
on	O
the	O
control	O
diet	B-I
and	O
after	O
each	O
treatment	O
period	O
.	O


The	O
DASH	O
diet	O
did	O
not	O
affect	O
markers	O
of	O
fibrinolysis	O
.	O


Losartan	O
significantly	O
lowered	O
t-PA	B-O
antigen	I-O
levels	I-O
(	O
-1.8	O
ng/mL	O
,	O
P	O
=	O
0.045	O
)	O
,	O
but	O
had	O
no	O
effect	O
on	O
t-PA	B-O
or	I-O
PAI-1	I-O
activities	I-O
.	I-O


This	O
effect	O
was	O
more	O
pronounced	O
in	O
whites	B-P
(	O
-4.1	O
ng/mL	O
(	O
P	O
=	O
0.003	O
)	O
)	O
compared	O
with	O
African-Americans	B-P
(	O
-0.3	O
ng/mL	O
(	O
P	O
=	O
0.7	O
)	O
,	O
P-interaction	O
=	O
0.03	O
)	O
.	O


Results	O
were	O
not	O
materially	O
affected	O
by	O
adjustment	O
for	O
basline	O
values	O
or	O
changes	O
in	O
blood	B-O
pressure	I-O
.	I-O


This	O
study	O
demonstrates	O
that	O
losartan	O
reduces	O
t-PA	B-O
antigen	I-O
levels	I-O
in	O
white	B-P
,	I-P
but	I-P
not	I-P
African-American	I-P
hypertensive	I-P
individuals	I-P
.	I-P


In	O
contrast	O
,	O
the	O
DASH	O
diet	O
had	O
no	O
significant	O
effect	O
on	O
markers	B-O
of	I-O
fibrinolysis	I-O
in	O
whites	B-P
or	I-P
African-Americans	I-P
.	I-P


Anxiety	B-P
sensitivity	I-P
as	O
an	O
incremental	O
predictor	O
of	O
later	B-P
anxiety	I-P
symptoms	I-P
and	I-P
syndromes	I-P
.	I-P


Although	O
anxiety	B-P
sensitivity	I-P
(	I-P
AS	I-P
)	I-P
has	O
been	O
shown	O
to	O
predict	O
anxiety	B-P
symptoms	I-P
and	I-P
panic	I-P
,	O
this	O
literature	O
is	O
limited	O
in	O
regard	O
to	O
evaluating	O
AS	O
as	O
an	O
incremental	O
predictor	O
of	O
anxiety	B-I
psychopathology	I-I
relative	O
to	O
other	O
established	O
risk	O
factors	O
including	O
sex	O
and	O
negative	O
affect	O
.	O


The	O
present	O
report	O
prospectively	O
evaluated	O
whether	O
AS	O
was	O
predictive	O
of	O
later	O
changes	O
in	O
anxiety	B-O
symptoms	I-O
after	O
controlling	B-I
for	I-I
potential	I-I
confounding	I-I
factors	I-I
.	I-I


Consistent	O
with	O
hypothesis	O
,	O
AS	O
was	O
found	O
to	O
be	O
a	O
significant	O
,	O
incremental	O
predictor	O
of	O
anxiety	B-O
symptoms	I-O
over	O
time	O
,	O
even	O
after	O
controlling	O
for	O
sex	O
and	O
negative	O
affectivity	O
.	O


These	O
data	O
provide	O
novel	O
evidence	O
for	O
the	O
unique	O
association	O
between	O
AS	O
of	O
the	O
development	O
of	O
anxiety	B-P
symptoms	I-P
.	I-P


Controlled	O
,	O
prospective	O
,	O
randomized	O
,	O
clinical	O
evaluation	O
of	O
partial	B-I
ceramic	I-I
crowns	I-I
inserted	O
with	O
RelyX	B-I
Unicem	I-I
with	I-I
or	I-I
without	I-I
selective	I-I
enamel	I-I
etching	I-I
.	I-I


1-year	O
results	O
.	O


PURPOSE	O
To	O
compare	O
the	O
performance	O
of	O
partial	B-O
ceramic	I-O
crowns	I-O
(	I-O
PCCs	I-O
)	I-O
inserted	I-I
with	I-I
RelyX	I-I
Unicem	I-I
(	I-I
RXU	I-I
)	I-I
either	I-I
with	I-I
(	I-I
RXU+E	I-I
)	I-I
or	I-I
without	I-I
(	I-I
RXU	I-I
)	I-I
selective	I-I
enamel	I-I
etching	I-I
.	I-I


METHODS	O
34	B-P
patients	I-P
(	I-P
15	I-P
male	I-P
,	I-P
19	I-P
female	I-P
)	I-P
participated	I-P
in	I-P
the	I-P
investigation	I-P
,	I-P
with	I-P
a	I-P
total	I-P
of	I-P
68	I-P
PCC	I-P
restorations	I-P
.	I-P


In	O
each	O
patient	O
,	O
one	O
PCC	B-I
was	O
randomly	O
assigned	O
to	O
insertion	O
with	O
RXU	B-I
,	O
the	O
second	O
PCC	B-I
was	O
assigned	O
to	O
insertion	O
with	O
RXU+E	B-I
.	I-I


The	O
PCCs	O
were	O
CAD/CAM	O
fabricated	O
using	O
the	O
Cerec	B-I
3	I-I
system	I-I
.	I-I


RXU	B-I
:	I-I
25	O
PCCs	O
were	O
placed	O
in	O
molars	O
,	O
nine	O
in	O
premolars	O
.	O


RXU+E	B-I
:	I-I
26	O
PCCs	O
were	O
placed	O
in	O
molars	O
,	O
eight	O
in	O
premolars	O
.	O


The	O
restorations	O
were	O
clinically	O
rated	O
using	O
modified	O
United	O
States	O
Public	O
Health	O
Service	O
(	O
USPHS	O
)	O
criteria	O
at	O
baseline	O
,	O
6	O
and	O
12	O
months	O
after	O
placement	O
.	O


The	O
median	B-P
patient	I-P
age	I-P
was	I-P
41	I-P
years	I-P
(	I-P
24-59	I-P
years	I-P
)	I-P
.	I-P


The	O
median	O
(	O
25-75	O
%	O
)	O
PBI	O
was	O
6	O
%	O
(	O
3-9	O
%	O
)	O
.	O


RESULTS	O
All	B-P
patients	I-P
were	I-P
available	I-P
for	I-P
the	I-P
three	I-P
recall	I-P
appointments	I-P
.	I-P


One	O
PCC	O
(	B-I
RXU	I-I
)	I-I
debonded	I-O
after	O
11	O
months	O
in	O
situ	O
,	O
one	O
PCC	O
(	B-I
RXU+E	I-I
)	I-I
fractured	I-O
after	O
12	O
months	O
in	O
situ	O
.	O


Both	O
restorations	B-O
had	O
to	O
be	O
replaced	B-O
.	I-O


At	O
the	O
12	O
months	O
recall	O
,	O
66	O
of	O
68	O
controlled	O
restorations	O
were	O
functional	B-O
without	O
need	O
of	O
replacement	O
.	O


The	O
evaluation	O
using	O
USHPS	O
criteria	O
revealed	O
a	O
significant	O
decrease	O
of	O
alfa	B-O
ratings	I-O
over	I-O
time	I-O
with	I-O
respect	I-O
to	I-O
criteria	I-O
marginal	I-O
adaptation	I-O
and	I-O
marginal	I-O
discoloration	I-O
.	I-O


No	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
luting	O
techniques	O
,	O
RXU	B-I
and	I-I
RXU+E	I-I
,	O
we	O
reobserved	O
during	O
the	O
observation	O
period	O
of	O
1	O
year	O
.	O


Within	O
the	O
limitations	O
of	O
the	O
present	O
study	O
,	O
adhesive	O
luting	O
with	O
RXU	B-I
with	O
or	O
without	O
selective	O
enamel	O
etching	O
can	O
be	O
recommended	O
.	O


Inclusion	O
of	O
anti-phospholipase	B-I
A2	I-I
antibody	I-I
to	O
backgrounding	O
diets	O
on	O
performance	B-O
,	I-O
feed	I-O
efficiency	I-O
,	I-O
in	I-O
vitro	I-O
fermentation	I-O
,	I-O
and	I-O
the	I-O
acute-phase	I-O
response	I-O
of	I-O
growing	I-O
beef	I-O
calves	I-O
.	I-O


In	O
Exp	O
.	O


1	O
,	O
individual	O
performance	O
and	O
daily	O
DMI	O
was	O
measured	O
on	O
70	B-P
crossbred	I-P
weaned	I-P
calves	I-P
during	I-P
a	I-P
70-d	I-P
period	I-P
using	I-P
a	I-P
GrowSafe	I-P
system	I-P
(	I-P
GrowSafe	I-P
Systems	I-P
Ltd.	I-P
,	O
Airdrie	B-P
,	I-P
AB	I-P
,	I-P
Canada	I-P
)	I-P
at	I-P
the	I-P
University	I-P
of	I-P
Florida	I-P
North	I-P
Florida	I-P
Research	I-P
and	I-P
Education	I-P
Center	I-P
Feed	I-P
Efficiency	I-P
Facility	I-P
(	I-P
FEF	I-P
)	I-P
.	I-P


Calves	B-P
were	O
fed	O
a	O
low-concentrate	B-I
(	I-I
LC	I-I
)	I-I
growing	I-I
diet	I-I
,	O
blocked	O
by	O
weight	O
and	O
sex	O
,	O
and	O
then	O
randomly	O
assigned	O
to	O
pens	O
to	O
receive	O
either	B-I
no	I-I
additional	I-I
supplement	I-I
(	O
CON	O
;	O
n	O
=	O
35	O
)	O
or	B-I
receive	I-I
a	I-I
supplement	I-I
of	I-I
anti-phospholipase	I-I
A2	I-I
antibody	I-I
(	I-I
aPLA2	I-I
)	I-I
at	O
an	O
inclusion	O
rate	O
of	O
0.6	O
%	O
of	O
the	O
diet	O
DM	O
(	O
n	O
=	O
35	O
)	O
.	O


After	O
the	O
70-d	O
feed	O
efficiency	O
(	O
FE	O
)	O
trial	O
(	O
Phase	O
1	O
)	O
,	O
calves	O
were	O
loaded	O
into	O
a	O
commercial	O
livestock	O
trailer	O
and	O
were	O
driven	O
for	O
approximately	O
1,600	O
km	O
during	O
24	O
h.	O
Upon	O
return	O
to	O
the	O
FEF	O
(	O
Phase	O
2	O
)	O
,	O
calves	O
were	O
relocated	O
to	O
the	O
same	O
pens	O
and	O
groups	O
and	O
received	O
the	O
same	O
diets	O
and	O
treatments	O
for	O
28	O
d.	O
Blood	O
samples	O
from	O
each	O
calf	O
were	O
collected	O
on	O
d	O
0	O
,	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
14	O
,	O
21	O
,	O
and	O
28	O
relative	O
to	O
initiation	O
of	O
transportation	O
and	O
were	O
analyzed	O
for	O
determination	O
of	O
concentrations	B-O
of	I-O
plasma	I-O
ceruloplasmin	I-O
and	I-O
haptoglobin	I-O
.	I-O


In	O
Phase	O
1	O
,	O
initial	O
BW	B-O
(	O
242.0	O
±	O
3.7	O
kg	O
;	O
P	O
=	O
0.92	O
)	O
,	O
BW	B-O
at	O
d	O
70	O
(	O
313.0	O
±	O
4.1	O
kg	O
;	O
P	O
=	O
0.79	O
)	O
,	O
and	B-O
ADG	I-O
(	O
1.01	O
±	O
0.02	O
kg	O
;	O
P	O
=	O
0.95	O
)	O
were	O
similar	O
between	O
treatments	O
.	O


However	B-O
,	I-O
daily	I-O
DMI	I-O
was	O
greater	O
(	O
P	O
=	O
0.01	O
)	O
for	O
CON	O
(	O
9.18	O
±	O
0.15	O
kg	O
)	O
than	O
aPLA2	O
(	O
8.53	O
±	O
0.15	O
kg	O
)	O
.	O


In	O
addition	B-O
,	I-O
residual	I-O
feed	I-O
intake	I-O
was	O
greater	O
(	O
P	O
=	O
0.002	O
)	O
for	O
CON	O
(	O
0.389	O
±	O
0.110	O
kg/d	O
)	O
than	O
aPLA2	O
calves	O
(	O
-0.272	O
±	O
0.110	O
kg/d	O
)	O
.	O


In	O
Phase	O
2	O
,	O
after	O
transportation	O
,	O
there	O
were	O
no	O
differences	O
between	O
treatments	B-O
on	I-O
BW	I-O
loss	I-O
due	I-O
to	I-O
transportation	I-O
shrink	O
(	O
26.0	O
±	O
0.6	O
kg	O
;	O
P	O
=	O
0.86	O
)	O
,	O
BW	O
at	O
d	O
28	O
(	O
339.0	O
±	O
4.1	O
kg	O
;	O
P	O
=	O
0.72	O
)	O
,	O
ADG	O
(	O
1.28	O
±	O
0.03	O
kg/d	O
;	O
P	O
=	O
0.72	O
)	O
,	O
G	O
:	O
F	O
(	O
0.164	O
±	O
0.004	O
;	O
P	O
=	O
0.83	O
)	O
,	O
and	O
concentrations	O
of	O
plasma	O
haptoglobin	O
(	O
0.08	O
±	O
0.02	O
mg/mL	O
;	O
P	O
=	O
0.41	B-O
)	I-O
.	I-O


However	B-O
,	I-O
concentrations	I-O
of	I-O
plasma	I-O
ceruloplasmin	I-O
were	O
greater	O
(	O
P	O
<	O
0.001	O
)	O
for	O
CON	O
calves	O
(	O
14.3	O
±	O
0.3	O
mg/dL	O
)	O
compared	O
to	O
aPLA2	O
calves	O
(	O
13.0	O
±	O
0.3	O
mg/dL	O
)	O
.	O


In	O
Exp	O
.	O


2	O
,	O
the	B-O
effects	I-O
of	I-O
aPLA2	I-O
inclusion	I-O
on	I-O
LC	I-O
and	I-O
high-concentrate	I-O
(	I-O
HC	I-O
)	I-O
substrates	I-O
on	I-O
in	I-O
vitro	I-O
fermentation	I-O
parameters	O
were	O
assessed	O
.	O


Addition	O
of	O
aPLA2	O
had	O
no	B-O
effects	I-O
on	I-O
in	I-O
vitro	I-O
fermentation	I-O
parameters	I-O
of	I-O
LC	I-O
and	I-O
HC	O
substrates	O
.	O


In	O
conclusion	O
,	O
supplementation	B-I
of	O
aPLA2	B-O
improved	O
FE	O
of	O
growing	O
beef	O
calves	O
when	O
fed	O
LC	O
diets	O
in	O
Phase	O
1	O
and	O
addition	O
of	O
aPLA2	O
had	B-O
no	I-O
effect	I-O
on	I-O
fermentation	I-O
parameters	I-O
of	I-O
LC	I-O
and	I-O
HC	O
substrates	O
.	O


In	O
addition	O
,	O
calves	O
supplemented	O
with	O
aPLA2	B-O
had	I-O
reduced	I-O
concentrations	I-O
of	I-O
plasma	I-O
ceruloplasmin	O
after	O
24	O
h	O
of	O
transportation	O
.	O


Effects	O
of	O
a	O
brief	B-I
Early	I-I
Start	I-I
Denver	I-I
model	I-I
(	I-I
ESDM	I-I
)	I-I
-based	I-I
parent	I-I
intervention	I-I
on	I-I
toddlers	I-I
at	I-P
risk	I-P
for	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


OBJECTIVE	O
This	O
study	O
was	O
carried	O
out	O
to	O
examine	O
the	O
efficacy	O
of	O
a	O
12-week	O
,	O
low-intensity	B-I
(	I-I
1-hour/wk	I-I
of	I-I
therapist	I-I
contact	I-I
)	I-I
,	I-I
parent-delivered	I-I
intervention	I-I
for	I-I
toddlers	I-I
at	I-P
risk	I-P
for	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
aged	I-P
14	I-P
to	I-P
24	I-P
months	I-P
and	I-P
their	I-P
families	I-P
.	I-P


METHOD	O
A	O
randomized	O
controlled	O
trial	O
involving	O
98	B-P
children	I-P
and	I-P
families	I-P
was	O
carried	O
out	O
in	O
three	O
different	O
sites	O
investigating	O
the	O
efficacy	B-O
of	O
a	O
parent	O
delivery	O
of	O
the	O
Early	B-I
Start	I-I
Denver	I-I
model	I-I
(	I-I
P-ESDM	I-I
)	I-I
,	O
which	O
fosters	O
parental	O
use	O
of	O
a	O
child-centered	O
responsive	O
interaction	O
style	O
that	O
embeds	O
many	O
teaching	O
opportunities	O
into	O
play	O
,	O
compared	B-I
to	I-I
community	I-I
treatment	I-I
as	I-I
usual	I-I
.	I-I


Assessments	O
were	O
completed	O
at	O
baseline	O
and	O
12	O
weeks	O
later	O
,	O
immediately	O
after	O
the	O
end	O
of	O
parent	O
coaching	O
sessions	O
.	O


RESULTS	O
There	O
was	O
no	B-O
effect	I-O
of	O
group	O
assignment	O
on	O
parent-child	O
interaction	O
characteristics	O
or	O
on	O
any	O
child	O
outcomes	O
.	O


Both	O
groups	O
of	O
parents	O
improved	O
interaction	B-O
skills	I-O
,	O
and	O
both	O
groups	O
of	O
children	O
demonstrated	B-O
progress	I-O
.	I-O


Parents	B-I
receiving	I-I
P-ESDM	I-I
demonstrated	O
significantly	O
stronger	B-O
working	I-O
alliances	I-O
with	O
their	O
therapists	B-O
than	O
did	O
the	O
community	O
group	O
.	O


Children	O
in	O
the	O
community	O
group	O
received	O
significantly	O
more	O
intervention	B-O
hours	I-O
than	O
those	O
in	O
the	O
P-ESDM	B-I
group	O
.	O


For	O
the	O
group	O
as	O
a	O
whole	O
,	O
both	O
younger	O
child	O
age	O
at	O
the	O
start	O
of	O
intervention	O
and	O
a	O
greater	O
number	B-O
of	I-O
intervention	I-O
hours	I-O
were	O
positively	O
related	O
to	O
the	O
degree	O
of	O
improvement	O
in	O
children	O
's	O
behavior	O
for	O
most	O
variables	O
.	O


CONCLUSIONS	O
Parent-implemented	B-I
intervention	I-I
studies	I-I
for	O
early	O
ASD	O
thus	O
far	O
have	O
not	O
demonstrated	O
the	O
large	O
effects	O
seen	O
in	O
intensive-treatment	O
studies	O
.	O


Evidence	O
that	O
both	O
younger	O
age	O
and	O
more	O
intervention	O
hours	O
positively	O
affect	O
developmental	O
rates	O
has	O
implications	O
for	O
clinical	O
practice	O
,	O
service	O
delivery	O
,	O
and	O
public	O
policy	O
.	O


The	O
gastric	B-O
emptying	I-O
and	I-O
small	I-O
intestinal	I-O
transit	I-O
after	O
highly	B-P
selective	I-P
vagotomy	I-P
without	I-P
drainage	I-P
and	I-P
selective	I-P
vagotomy	I-P
with	I-P
pyloroplasty	I-P
.	I-P


[	O
Assessment	O
of	O
natriuretic	B-I
peptide	I-I
indices	O
and	O
oxidative	B-I
stress	O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
]	I-P
.	O


The	O
authors	O
have	O
studied	O
indices	O
of	O
natriuretic	B-I
peptide	I-I
and	O
oxidative	B-I
stress	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
.	I-P


52	B-I
male	I-I
patients	I-I
with	I-I
postinfarction	I-I
cardiosclerosis	I-I
(	I-I
PICS	I-I
)	I-I
who	I-I
have	I-I
developed	I-I
CHF	I-I
have	I-I
been	I-I
observed	I-I
.	I-I


The	B-P
age	I-P
of	I-P
the	I-P
patients	I-P
varied	I-P
from	I-P
38	I-P
till	I-P
60	I-P
.	I-P


It	O
was	O
established	O
that	O
CHF	O
patients	O
with	O
progression	O
of	O
the	O
disease	O
had	O
worsening	O
of	O
their	O
clinical	B-O
condition	I-O
together	O
with	O
an	O
increase	O
of	O
oxidative	B-O
stress	I-O
which	O
was	O
characterized	O
through	O
decrease	O
of	O
NO	B-O
metabolites	I-O
,	I-O
NADPH	I-O
--	I-O
diaphorase	I-O
(	I-O
eNOS	I-O
)	I-O
,	O
increase	O
of	O
nitrite	B-O
reductase	I-O
(	I-O
iNOS	I-O
)	I-O
and	I-O
peroxinitrite	I-O
(	I-O
ONOO	I-O
)	I-O
,	O
correlative	O
increase	O
the	O
level	O
of	O
brain	B-O
natriuretic	I-O
peptide	I-O
in	I-O
blood	I-O
plazma	I-O
.	I-O


Reliable	O
connection	O
between	O
considerable	O
increase	O
of	O
oxidative	B-O
stress	I-O
and	O
the	O
level	B-O
of	I-O
NT-pro	I-O
BNP	I-O
was	O
noted	O
in	O
CHF	B-P
patients	I-P
,	O
which	O
demands	O
necessity	O
of	O
correction	O
of	O
observed	O
disorders	O
.	O


Anti-angiogenic	B-O
effects	I-O
of	O
epigallocatechin-3-gallate	B-I
in	O
human	O
skin	O
.	O


Epigallocatechin-3-gallate	B-I
(	I-I
EGCG	I-I
)	I-I
is	O
the	O
main	O
polyphenol	O
component	O
of	O
green	O
tea	O
.	O


This	O
compound	O
exhibits	O
antioxidant	B-O
,	I-O
immunomodulatory	I-O
,	I-O
photoprotective	I-O
,	I-O
anti-angiogenic	I-O
,	I-O
and	I-O
anti-inflammatory	I-O
properties	I-O
.	I-O


We	O
conducted	O
a	O
small	O
randomized	O
,	O
double	O
blind	O
,	O
split	O
face	O
trial	O
using	O
a	O
cream	B-I
containing	I-I
2.5	I-I
%	I-I
w/w	I-I
of	I-I
EGCG	I-I
.	I-I


Four	B-P
healthy	I-P
volunteers	I-P
with	I-P
significant	I-P
erythema	I-P
and	I-P
telangiectasia	I-P
on	I-P
the	I-P
face	I-P
applied	O
EGCG	B-I
cream	I-I
to	O
one	O
side	O
of	O
the	O
face	O
,	O
and	O
vehicle	B-I
control	I-I
cream	I-I
to	O
the	O
other	O
,	O
twice	O
daily	O
for	O
six	O
weeks	O
.	O


After	O
six	O
weeks	O
,	O
biopsies	B-O
were	O
taken	O
from	O
EGCG	B-I
and	O
vehicle	B-I
treated	I-I
sites	O
.	O


Immunohistochemistry	B-O
was	O
used	O
to	O
measure	O
VEGF	B-O
and	I-O
HIF-1	I-O
α.	I-O
HIF-1	I-O
α	I-O
expression	I-O
was	O
decreased	O
in	B-I
EGCG	I-I
treated	O
sites	O
,	O
such	O
that	O
28.4	O
%	O
of	O
the	O
epidermis	O
showed	B-O
positive	I-O
staining	I-O
in	O
vehicle	O
treated	O
vs.	O
13.8	O
%	O
in	B-I
EGCG	I-I
treated	O
sites	O
(	O
p	O
<	O
0.001	O
)	O
.	O


A	O
similar	O
decrease	O
in	B-O
VEGF	I-O
expression	I-O
was	O
found	O
(	O
6.7	O
%	O
in	B-I
EGCG	I-I
vs.	O
11.0	O
%	O
in	O
in	B-I
vehicle-treated	I-I
skin	O
(	B-I
p	I-I
<	I-I
0.005	I-I
)	I-I
.	I-I


EGCG	B-I
topical	O
treatments	O
influence	B-O
HIF-1	I-O
α	I-O
induction	I-O
and	I-O
VEGF	I-O
expression	I-O
and	O
may	O
serve	O
as	O
a	O
potential	O
agent	O
in	O
the	B-O
prevention	I-O
of	I-O
telangiectasias	I-O
.	O


Studies	O
on	O
leptin	B-O
and	I-O
leptin	I-O
receptor	I-O
gene	I-O
expression	I-O
in	O
myometrium	B-P
and	I-P
uterine	I-P
myomas	I-P
of	I-P
gnRH	I-I
analogue-treated	I-I
women	I-P
.	I-P


AIM	O
To	O
test	O
if	O
treatment	O
with	O
GnRH	B-I
analogue	I-I
,	O
which	O
leads	O
to	O
a	O
significant	O
reduction	O
in	O
myoma	B-O
volume	I-O
,	I-O
changes	I-O
expression	I-O
of	I-O
leptin	I-O
genes	I-O
and	I-O
gene	I-O
coding	I-O
leptin	I-O
receptor	I-O
isoforms	I-O
in	O
uterine	O
myomas	O
and	O
in	O
the	O
surrounding	O
unaltered	O
myometrium	O
.	O


METHODS	O
Using	O
RT-PCR	O
,	O
expression	O
of	O
leptin	O
genes	O
and	O
leptin	O
receptor	O
genes	O
was	O
studied	O
in	O
myomas	O
and	O
in	O
the	O
surrounding	O
myometrium	O
in	O
women	B-P
with	I-P
uterine	I-P
myomas	I-P
,	I-P
untreated	I-P
or	I-P
treated	I-P
with	I-P
GnRH	I-I
analogue	I-I
.	I-I


In	O
the	O
randomly	O
selected	O
cases	O
presence	O
of	O
leptin	O
protein	O
and	O
of	O
leptin	O
receptor	O
proteins	O
was	O
examined	O
also	O
by	O
Western	O
blotting	O
.	O


RESULTS	O
Expression	B-O
of	I-O
leptin	I-O
genes	I-O
was	O
demonstrated	O
both	O
in	O
myomas	O
and	O
in	O
the	O
surrounding	O
myometrium	O
,	O
and	O
a	O
similar	O
pattern	O
of	O
expression	O
was	O
found	O
for	O
leptin	O
receptor	O
isoforms	O
.	O


The	O
results	O
of	O
RT-PCR	O
were	O
confirmed	O
by	O
Western	O
blotting	O
,	O
which	O
documented	O
the	O
identical	O
distribution	O
of	O
leptin	B-O
proteins	I-O
and	I-O
leptin	I-O
receptor	I-O
proteins	I-O
in	O
studied	O
tissues	O
.	O


Treatment	O
with	O
GnRH	B-I
analogue	I-I
had	O
no	O
effect	B-O
on	O
the	O
expression	B-O
pattern	I-O
of	O
studied	O
genes	O
.	O


CONCLUSION	O
The	O
results	O
of	O
the	O
present	O
study	O
on	O
the	O
administration	O
of	O
GnRH	B-I
analogue	I-I
to	O
females	B-P
with	I-P
myomas	I-P
suggest	O
that	O
no	O
direct	O
or	O
immediate	O
inter-relationship	O
exists	O
between	O
expression	O
of	O
leptin	B-O
genes	I-O
in	O
uterine	O
myomas	O
on	O
one	O
hand	O
and	O
estrogen	O
,	O
progesterone	O
and	O
leptin	O
levels	O
in	O
the	O
blood	O
on	O
the	O
other	O
.	O


Expression	O
seems	O
to	O
be	O
of	O
a	O
more	O
durable	O
nature	O
but	O
factors	O
that	O
induce	O
such	O
expression	O
remain	O
unknown	O
.	O


Four-year	O
outcomes	O
from	O
adolescent	B-I
alcohol	I-I
and	I-I
drug	I-I
treatment	I-I
.	I-I


OBJECTIVE	O
Knowledge	O
of	O
treatment	O
response	O
for	O
alcohol	O
and	O
drug	O
problems	O
among	O
adults	O
is	O
mounting	O
;	O
less	O
is	O
known	O
about	O
long-term	O
outcome	O
for	O
adolescents	B-P
who	I-P
receive	I-P
treatment	I-I
for	I-I
alcohol	I-I
and	I-I
drug	I-I
problems	I-I
.	I-I


The	O
current	O
study	O
examined	O
youth	O
substance	O
involvement	O
over	O
4	O
years	O
(	O
using	O
five	O
waves	O
of	O
data	O
collection	O
)	O
following	O
treatment	B-I
for	I-I
alcohol	I-I
and	I-I
drug	I-I
abuse	I-I
.	I-I


METHOD	O
A	B-P
cohort	I-P
of	I-P
youth	I-P
(	I-P
N	I-P
=	I-P
162	I-P
,	I-P
60	I-P
%	I-P
male	I-P
)	I-P
treated	I-P
during	I-P
adolescence	I-P
(	I-P
mean	I-P
age	I-P
=	I-P
16	I-P
years	I-P
)	I-P
was	I-P
followed	I-P
into	I-P
young	I-P
adulthood	I-P
,	O
a	O
period	O
associated	O
with	O
stabilization	O
of	O
alcohol	O
use	O
patterns	O
and	O
elevated	O
risk	O
for	O
life	O
problems	O
secondary	O
to	O
both	O
alcohol	O
and	O
drug	O
use	O
.	O


Participants	B-P
(	I-P
14-18	I-P
years	I-P
old	I-P
)	I-P
were	I-P
consecutive	I-P
admissions	I-P
to	I-P
inpatient	I-P
adolescent	I-P
alcohol	I-P
and	I-P
drug	I-P
treatment	I-P
centers	I-P
in	I-P
San	I-P
Diego	I-P
that	I-P
were	I-P
abstinence	I-P
focused	I-P
and	I-P
based	I-P
on	I-P
the	I-P
12-step	I-P
approach	I-P
.	I-P


RESULTS	O
Alcohol	B-O
and	I-O
other	I-O
drug	I-O
use	I-O
were	O
reduced	O
during	O
the	O
4	O
years	O
posttreatment	O
,	O
with	O
the	O
exception	O
of	O
nicotine	O
.	O


The	O
greatest	O
prevalence	B-O
reduction	I-O
occurred	O
for	O
stimulants	O
;	O
modest	O
changes	O
were	O
evident	O
in	O
alcohol	O
and	O
marijuana	O
use	O
.	O


Nicotine	O
was	O
the	O
most	O
commonly	O
used	O
substance	O
throughout	O
the	O
4	O
years	O
after	O
treatment	O
.	O


Several	O
distinct	O
substance	O
involvement	O
trajectories	O
were	O
evident	O
during	O
the	O
4	O
years	O
following	O
treatment	O
.	O


CONCLUSIONS	O
Alcohol	O
and	O
drug	O
use	O
patterns	O
during	O
the	O
4	O
years	O
following	O
treatment	O
highlight	O
both	O
changes	O
and	O
diversity	O
in	O
substance	O
involvement	O
as	O
youth	O
make	O
the	O
transitions	O
from	O
middle	O
to	O
late	O
adolescence	O
and	O
into	O
young	O
adulthood	O
.	O


Findings	O
demonstrate	O
the	O
importance	O
of	O
identifying	O
transitional	O
periods	O
and	O
the	O
need	O
for	O
alternative	O
intervention	O
strategies	O
that	O
may	O
help	O
the	O
progression	O
of	O
this	O
population	O
into	O
young	O
adulthood	O
.	O


POG	O
8625	O
:	O
a	O
randomized	O
trial	O
comparing	O
chemotherapy	B-I
with	O
chemoradiotherapy	B-I
for	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
Stages	I-P
I	I-P
,	I-P
IIA	I-P
,	I-P
IIIA1	I-P
Hodgkin	I-P
Disease	I-P
:	I-P
a	O
report	O
from	O
the	O
Children	O
's	O
Oncology	O
Group	O
.	O


To	O
determine	O
if	O
6	O
courses	O
of	O
chemotherapy	B-I
alone	O
could	O
achieve	O
the	O
same	O
or	O
better	O
outcome	O
than	O
4	O
courses	O
of	O
chemotherapy	B-I
followed	I-I
by	I-I
radiation	I-I
therapy	I-I
(	I-I
chemoradiotherapy	I-I
)	I-I
in	O
pediatric	B-P
and	I-P
adolescent	I-P
patients	I-P
with	I-P
Hodgkin	I-P
disease	I-P
.	I-P


Children	B-P
<	I-P
or	I-P
=21	I-P
years	I-P
old	I-P
with	I-P
biopsy-proven	I-P
,	I-P
pathologically	I-P
staged	I-P
I	I-P
,	I-P
IIA	I-P
,	I-P
or	I-P
IIIA1	I-P
Hodgkin	I-P
disease	I-P
were	O
randomly	O
assigned	O
6	O
courses	O
of	O
alternating	B-I
nitrogen	I-I
mustard	I-I
,	I-I
oncovin	I-I
,	I-I
prednisone	I-I
,	I-I
and	I-I
procarbazine/doxorubicin	I-I
,	I-I
bleomycin	I-I
,	I-I
vinblastine	I-I
,	I-I
and	I-I
dacarbazine	I-I
(	I-I
treatment	I-I
1	I-I
)	I-I
or	O
4	B-I
courses	I-I
of	I-I
alternating	I-I
nitrogen	I-I
mustard	I-I
,	I-I
oncovin	I-I
,	I-I
prednisone	I-I
,	I-I
and	I-I
procarbazine/doxorubicin	I-I
,	I-I
bleomycin	I-I
,	I-I
vinblastine	I-I
,	I-I
and	I-I
dacarbazine	I-I
+2550	I-I
cGy	I-I
involved-field	I-I
radiotherapy	I-I
(	I-I
treatment	I-I
2	I-I
)	I-I
.	I-I


The	O
complete	O
response	O
rate	O
was	O
89	O
%	O
,	O
with	O
a	O
complete	O
response	O
and	O
partial	O
response	O
rate	O
of	O
99.4	O
%	O
.	O


There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
event-free	B-O
survival	I-O
(	I-O
EFS	I-O
)	I-O
or	I-O
overall	I-O
survival	I-O
between	O
arms	O
.	O


The	O
EFS	B-O
for	O
those	O
who	O
achieved	O
an	O
early	O
complete	B-O
response	I-O
was	O
significantly	O
higher	O
than	O
for	O
those	O
who	O
did	O
not	O
.	O


For	O
pediatric	B-P
patients	I-P
with	I-P
asymptomatic	I-P
low-stage	I-P
and	I-P
intermediate-stage	I-P
Hodgkin	I-P
disease	I-P
,	O
chemotherapy	B-I
and	O
chemoradiotherapy	B-I
both	O
resulted	O
in	O
3-year	B-O
EFS	I-O
of	O
approximately	O
90	O
%	O
and	O
statistically	O
indistinguishable	O
8-year	B-O
EFS	I-O
and	O
overall	B-O
survival	I-O
,	O
without	O
significant	O
long-term	B-O
toxicity	I-O
.	I-O


Early	O
response	B-O
to	I-O
therapy	I-O
was	O
associated	O
with	O
higher	O
EFS	B-O
,	O
a	O
concept	O
that	O
has	O
led	O
to	O
the	O
Children	O
's	O
Oncology	O
Group	O
paradigm	O
of	O
response-based	O
risk-adapted	O
therapy	O
for	O
pediatric	O
Hodgkin	O
disease	O
.	O


[	O
Effects	O
of	O
parecoxib	B-I
on	O
morphine	B-I
dosage	O
in	O
postoperative	B-P
patient-controlled	I-I
analgesia	I-I
following	O
thoracoscope-assisted	B-I
thoracotomy	I-I
]	I-I
.	O


OBJECTIVE	O
To	O
observe	O
the	O
effect	O
of	O
parecoxib	B-I
on	O
morphine	O
dosage	O
in	O
patient-controlled	B-I
analgesia	I-I
(	I-I
PCA	I-I
)	I-I
following	O
thoracoscope-assisted	B-I
thoracotomy	I-I
.	I-I


METHODS	O
A	B-P
consecutive	I-P
series	I-P
of	I-P
100	I-P
patients	I-P
undergoing	I-P
thoracoscope-assisted	I-I
thoracotomy	I-I
were	O
randomized	O
into	O
5	O
groups	O
and	O
received	O
PCA	B-I
with	I-I
morphine	I-I
doses	O
at	O
0	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
mg	O
given	O
in	O
200	O
ml	O
saline	B-I
(	O
groups	O
P	O
(	O
1	O
)	O
,	O
P	O
(	O
2	O
)	O
,	O
P	O
(	O
3	O
)	O
,	O
P	O
(	O
4	O
)	O
,	O
and	O
P	O
(	O
5	O
)	O
,	O
respectively	O
)	O
.	O


Parecoxib	B-I
(	O
40	O
mg	O
)	O
was	O
given	O
in	O
all	O
the	O
patients	O
immediately	O
before	O
the	O
operation	O
,	O
and	O
the	O
mixture	O
(	B-I
4-5	I-I
ml	I-I
)	I-I
of	I-I
lidocaine	I-I
and	I-I
ropivacaine	I-I
was	O
administered	O
into	O
the	O
3	O
intercostal	O
spaces	O
upper	O
and	O
lower	O
to	O
the	O
incision	O
before	O
chest	O
closure	O
.	O


PCA	B-I
was	O
administered	O
for	O
each	O
patient	O
.	O


The	O
visual	B-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
at	I-O
rest	I-O
and	O
coughing	B-O
and	I-O
the	I-O
respiratory	I-O
functional	I-O
parameters	I-O
were	O
recorded	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
24	O
,	O
36	O
,	O
and	O
48	O
h	O
after	O
the	O
start	O
of	O
PCA	B-I
,	O
and	O
the	O
actual	O
and	O
effective	O
button-pressing	O
times	O
(	O
D	O
(	O
1	O
)	O
/D	O
(	O
2	O
)	O
)	O
in	O
PCA	B-I
were	O
also	O
recorded	O
.	O


RESULTS	O
No	O
patients	O
showed	O
signs	B-O
of	I-O
respiratory	I-O
inhibition	I-O
within	O
24	O
h	O
after	O
the	O
operation	O
,	O
and	O
the	O
resting	B-O
VAS	I-O
was	O
comparable	O
between	O
the	O
groups	O
within	O
the	O
initial	O
6	O
postoperative	O
hours	O
.	O


At	O
8	O
to	O
24	O
h	O
postoperatively	O
,	O
the	O
VAS	B-O
scores	I-O
at	O
rest	O
and	O
coughing	O
were	O
significantly	O
higher	O
in	O
P	O
(	O
1	O
)	O
group	O
than	O
in	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
no	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
at	O
36	O
to	O
48	O
h.	O
D	O
(	O
1	O
)	O
/D	O
(	O
2	O
)	O
in	O
groups	O
P	O
(	O
1	O
)	O
and	O
P	O
(	O
2	O
)	O
were	O
significantly	O
different	O
from	O
those	O
in	O
the	O
other	O
3	O
groups	O
at	O
4-24	O
h	O
,	O
but	O
no	O
such	O
difference	O
was	O
found	O
between	O
groups	O
P	O
(	O
3	O
)	O
,	O
P	O
(	O
4	O
)	O
,	O
and	O
P	O
(	O
5	O
)	O
.	O


CONCLUSION	O
The	O
application	O
of	O
parecoxib	B-I
may	O
reduce	O
the	O
dosage	O
of	O
morphine	B-I
in	O
PCA	B-I
following	O
thoracoscope-assisted	O
thoracotomy	O
and	O
results	O
in	O
good	O
analgesic	O
effect	O
without	O
affecting	O
the	O
patients	O
respiratory	O
function	O
and	O
sputum	O
elimination	O
.	O


Adjuvant	O
cyclophosphamide	B-I
,	I-I
doxorubicin	I-I
,	I-I
vincristine	I-I
,	I-I
and	I-I
prednisone	I-I
chemotherapy	I-I
after	O
radiation	O
therapy	O
in	O
stage	B-P
I	I-P
low-grade	I-P
and	I-P
intermediate-grade	I-P
non-Hodgkin	I-P
lymphoma	I-P
.	I-P


Results	O
of	O
a	O
prospective	O
randomized	O
study	O
.	O


BACKGROUND	O
In	O
a	O
prospective	O
randomized	O
manner	O
,	O
this	O
study	O
evaluated	O
the	O
effect	O
of	O
adjuvant	B-I
chemotherapy	I-I
(	I-I
cyclophosphamide	I-I
,	I-I
doxorubicin	I-I
,	I-I
vincristine	I-I
,	I-I
and	I-I
prednisone	I-I
;	I-I
CHOP	I-I
)	I-I
in	O
patients	B-P
with	I-P
Stage	I-P
I	I-P
non-Hodgkin	I-P
lymphoma	I-P
(	I-P
NHL	I-P
)	I-P
who	I-P
have	I-P
achieved	I-P
a	I-P
complete	I-P
response	I-P
(	I-P
CR	I-P
)	I-P
after	I-P
radiation	I-P
therapy	I-P
(	I-P
RT	I-P
)	I-P
.	I-P


METHODS	O
Forty-four	B-P
patients	I-P
with	I-P
clinical	I-P
or	I-P
pathologic	I-P
Stage	I-P
I	I-P
intermediate-grade	I-P
or	I-P
low-grade	I-P
NHL	I-P
were	O
randomized	O
to	O
receive	B-I
regional	I-I
RT	I-I
alone	I-I
(	I-I
median	I-I
dose	I-I
,	I-I
40	I-I
Gy	I-I
)	I-I
or	I-I
regional	I-I
RT	I-I
followed	I-I
by	I-I
six	I-I
cycles	I-I
of	I-I
CHOP	I-I
chemotherapy	I-I
.	I-I


There	O
were	O
no	O
differences	O
in	O
clinical	O
and	O
pathologic	O
characteristics	B-O
between	O
the	O
two	O
treatment	O
groups	O
.	O


RESULTS	O
The	O
median	B-O
follow-up	I-O
was	O
7	O
years	O
(	O
range	O
,	O
2-10	O
years	O
)	O
.	O


The	O
actuarial	B-O
relapse-free	I-O
survival	I-O
(	I-O
RFS	I-O
)	I-O
rate	I-O
for	O
the	O
RT	O
plus	O
CHOP	O
group	O
at	O
7	O
years	O
was	O
83	O
%	O
compared	O
with	O
47	O
%	O
(	O
P	O
<	O
0.03	O
)	O
for	O
the	O
RT-alone	O
group	O
.	O


The	O
overall	B-O
survival	I-O
(	I-O
OS	I-O
)	I-O
for	O
the	O
two	O
groups	O
was	O
88	O
%	O
and	O
66	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.2	O
)	O
.	O


In	O
patients	O
with	O
intermediate-grade	O
NHL	O
,	O
the	O
7-year	B-O
actuarial	I-O
RFS	I-O
for	O
RT	O
and	O
CHOP	O
was	O
86	O
%	O
compared	O
with	O
20	O
%	O
for	O
RT	O
alone	O
(	O
P	O
=	O
0.004	O
)	O
.	O


The	O
corresponding	B-O
actuarial	I-O
survival	I-O
rates	I-O
were	O
92	O
%	O
and	O
47	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.08	O
)	O
.	O


In	O
patients	O
with	O
low-grade	O
histologic	O
findings	O
,	O
the	O
addition	O
of	O
adjuvant	O
CHOP	B-I
did	O
not	O
improve	O
RFS	B-O
(	O
P	O
=	O
0.6	O
)	O
or	O
OS	O
.	O


All	O
relapses	O
in	O
this	O
study	O
were	O
at	O
sites	O
remote	O
from	O
the	O
initially	O
involved	O
areas	O
,	O
and	O
in	O
5	O
of	O
11	O
patients	O
(	O
45	O
%	O
)	O
,	O
there	O
were	O
recurrences	O
5	O
years	O
or	O
longer	O
after	O
initial	O
treatment	O
.	O


CONCLUSIONS	O
This	O
study	O
showed	O
that	O
adjuvant	O
CHOP	B-I
chemotherapy	I-I
significantly	O
improves	O
RFS	O
in	O
patients	O
with	O
Stage	O
I	O
intermediate-grade	O
NHL	O
who	O
achieve	O
a	O
CR	O
after	O
regional-field	O
RT	O
.	O


The	O
chemotherapeutic	O
regimen	O
favorably	O
affected	O
their	O
probability	B-O
of	O
survival	B-O
.	I-O


Fadrozole	B-I
HCL	I-I
(	I-I
CGS-16949A	I-I
)	I-I
versus	O
megestrol	B-I
acetate	I-I
treatment	O
of	O
postmenopausal	B-P
patients	I-P
with	I-P
metastatic	I-P
breast	I-P
carcinoma	I-P
:	I-P
results	O
of	O
two	O
randomized	O
double	O
blind	O
controlled	O
multiinstitutional	O
trials	O
.	O


BACKGROUND	O
Breast	B-P
cancer	I-P
patients	I-P
with	I-P
prior	I-P
response	I-P
to	I-P
endocrine	I-P
therapy	I-P
achieve	O
subsequent	O
benefit	O
from	O
additional	O
endocrine	O
therapies	O
.	O


The	O
efficacy	O
and	O
safety	O
of	O
an	O
aromatase	O
inhibitor	O
,	O
fadrozole	B-I
HCL	I-I
,	O
were	O
compared	O
with	O
megestrol	O
acetate	O
in	O
post	B-P
menopausal	I-P
patients	I-P
who	I-P
had	I-P
disease	I-P
progression	I-P
after	I-P
receiving	I-P
antiestrogen	I-P
therapy	I-P
either	I-P
for	I-P
metastatic	I-P
disease	I-P
or	I-P
as	I-P
adjuvant	I-P
therapy	I-P
.	I-P


METHODS	O
In	B-P
2	I-P
multiinstitutional	I-P
prospective	I-P
trials	I-P
,	I-P
683	I-P
postmenopausal	I-P
patients	I-P
were	O
randomized	B-I
to	I-I
receive	I-I
either	I-I
fadrozole	I-I
HCL	I-I
,	I-I
1	I-I
mg	I-I
twice	I-I
daily	I-I
,	I-I
or	I-I
megestrol	I-I
acetate	I-I
,	I-I
40	I-I
mg	I-I
4	I-I
times	I-I
daily	I-I
,	I-I
in	I-I
a	I-I
double	I-I
blind	I-I
fashion	I-I
after	I-I
progression	I-I
on	I-I
first-line	I-I
hormonal	I-I
therapy	I-I
.	I-I


Objective	B-O
response	I-O
rates	I-O
,	I-O
time	I-O
to	I-O
progression	I-O
,	I-O
survival	I-O
and	I-O
safety	I-O
of	O
the	O
two	O
regimens	O
were	O
compared	O
.	O


RESULTS	O
Results	O
of	O
intent-to-treat	O
analyses	O
are	O
presented	O
in	O
this	O
study	O
.	O


No	O
significant	O
differences	O
were	O
detected	O
between	O
the	O
two	O
treatment	O
groups	O
in	O
time	B-O
to	I-O
progression	I-O
,	I-O
objective	I-O
response	I-O
rates	I-O
,	I-O
duration	I-O
of	I-O
response	I-O
,	I-O
and	I-O
survival	I-O
in	O
either	O
trial	O
.	O


There	O
were	O
no	O
clinically	O
meaningful	O
differences	O
between	O
the	O
treatment	O
groups	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	B-O
experiences	I-O
,	O
except	O
that	O
weight	B-O
gain	I-O
,	I-O
fluid	I-O
retention	I-O
,	I-O
and	I-O
dyspnea	I-O
were	O
observed	O
in	O
more	O
patients	O
in	O
the	O
megestrol	O
acetate	O
group	O
compared	O
with	O
those	O
receiving	O
fadrozole	O
HCL	O
,	O
whereas	O
nausea	B-O
and	I-O
vomiting	I-O
were	O
observed	O
in	O
more	O
patients	O
in	O
the	O
fadrozole	O
HCL	O
group	O
compared	O
with	O
those	O
receiving	O
megestrol	O
acetate	O
.	O


CONCLUSIONS	O
Fadrozole	B-I
HCL	I-I
was	O
as	O
efficacious	B-O
as	O
megestrol	O
acetate	O
in	O
postmenopausal	B-P
patients	I-P
with	I-P
metastatic	I-P
breast	I-P
carcinoma	I-P
after	O
one	O
hormonal	O
therapy	O
.	O


Adverse	O
experiences	O
were	O
mild	O
with	O
both	O
therapies	O
,	O
but	O
megestrol	O
acetate	O
was	O
associated	O
wiht	O
a	O
higher	O
frequency	O
of	O
weight	B-O
gain	I-O
,	I-O
fluid	I-O
retention	I-O
and	I-O
dyspnea	I-O
,	O
whereas	O
fadrozole	B-I
HCL	I-I
was	O
associated	O
with	O
a	O
higher	O
frequency	O
of	O
nausea	B-O
and	I-O
vomiting	I-O
.	I-O


Immunologic	O
and	O
hemodynamic	O
effects	O
of	O
"	B-I
low-dose	I-I
"	I-I
hydrocortisone	I-I
in	O
septic	B-P
shock	I-P
:	I-P
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	B-I
,	O
crossover	O
study	O
.	O


Within	O
the	O
last	O
few	O
years	O
,	O
increasing	O
evidence	O
of	O
relative	O
adrenal	B-P
insufficiency	I-P
in	I-P
septic	I-P
shock	I-P
evoked	O
a	O
reassessment	O
of	O
hydrocortisone	B-I
therapy	I-I
.	I-I


To	O
evaluate	O
the	O
effects	O
of	O
hydrocortisone	B-I
on	O
the	O
balance	O
between	O
proinflammatory	O
and	O
antiinflammation	O
,	O
40	B-P
patients	I-P
with	I-P
septic	I-P
shock	I-P
were	O
randomized	O
in	O
a	O
double-blind	O
crossover	O
study	O
to	O
receive	O
either	O
the	O
first	O
100	O
mg	O
of	O
hydrocortisone	B-I
as	O
a	O
loading	O
dose	O
and	O
10	O
mg	O
per	O
hour	O
until	O
Day	O
3	O
(	O
n	O
=	O
20	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
20	O
)	O
,	O
followed	O
by	O
the	O
opposite	O
medication	O
until	O
Day	O
6	O
.	O


Hydrocortisone	B-I
infusion	O
induced	O
an	O
increase	O
of	O
mean	B-O
arterial	I-O
pressure	I-O
,	I-O
systemic	I-O
vascular	I-O
resistance	I-O
,	O
and	O
a	O
decline	O
of	O
heart	B-O
rate	I-O
,	I-O
cardiac	I-O
index	I-O
,	I-O
and	I-O
norepinephrine	I-O
requirement	I-O
.	I-O


A	O
reduction	O
of	O
plasma	B-O
nitrite/nitrate	I-O
indicated	O
inhibition	O
of	O
nitric	B-O
oxide	I-O
formation	I-O
and	O
correlated	O
with	O
a	O
reduction	B-O
of	I-O
vasopressor	I-O
support	I-O
.	I-O


The	O
inflammatory	B-O
response	I-O
(	I-O
interleukin-6	I-O
and	I-O
interleukin-8	I-O
)	I-O
,	I-O
endothelial	I-O
(	I-O
soluble	I-O
E-selectin	I-O
)	I-O
and	I-O
neutrophil	I-O
activation	I-O
(	I-O
expression	I-O
of	I-O
CD11b	I-O
,	I-O
CD64	I-O
)	I-O
,	I-O
and	I-O
antiinflammatory	I-O
response	I-O
(	I-O
soluble	I-O
tumor	I-O
necrosis	I-O
factor	I-O
receptors	I-O
I	I-O
and	I-O
II	I-O
and	I-O
interleukin-10	I-O
)	I-O
were	O
attenuated	O
.	O


In	O
peripheral	O
blood	O
monocytes	O
,	O
human	B-O
leukocyte	I-O
antigen-DR	I-O
expression	I-O
was	O
only	O
slightly	O
depressed	O
,	O
whereas	O
in	B-O
vitro	I-O
phagocytosis	I-O
and	I-O
the	I-O
monocyte-activating	I-O
cytokine	I-O
interleukin-12	I-O
increased	O
.	O


Hydrocortisone	B-I
withdrawal	O
induced	O
hemodynamic	B-O
and	I-O
immunologic	I-O
rebound	I-O
effects	I-O
.	I-O


In	O
conclusion	O
,	O
hydrocortisone	B-I
therapy	I-I
restored	O
hemodynamic	B-O
stability	I-O
and	O
differentially	O
modulated	O
the	O
immunologic	B-O
response	I-O
to	I-O
stress	I-O
in	O
a	O
way	O
of	O
antiinflammation	O
rather	O
than	O
immunosuppression	O
.	O


[	O
Effect	O
of	O
Selaginella	B-I
combined	O
with	O
radiotherapy	B-I
on	O
nasopharyngeal	B-P
carcinoma	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
observe	O
the	O
Chinese	O
herbal	O
medicine	O
Selaginella-induced	O
radiosensitization	O
of	O
terminal	B-P
nasopharyngeal	I-P
carcinoma	I-P
(	I-P
NPC	I-P
)	I-P
.	I-P


METHODS	O
Totally	O
180	B-P
patients	I-P
with	I-P
NPC	I-P
were	O
divided	O
equally	O
into	O
3	O
groups	O
with	O
the	O
same	O
radiotherapeutic	O
protocols	O
.	O


The	O
patients	O
in	O
group	B-I
A	I-I
received	I-I
radiotherapy	I-I
alone	I-I
,	I-I
those	I-I
in	I-I
group	I-I
B	I-I
were	I-I
given	I-I
daily	I-I
Selaginella	I-I
(	I-I
30	I-I
g	I-I
)	I-I
prepared	I-I
into	I-I
50	I-I
ml	I-I
decoction	I-I
during	I-I
the	I-I
entire	I-I
course	I-I
of	I-I
radiotherapy	I-I
,	O
and	O
those	O
in	O
group	B-I
C	I-I
had	I-I
Selaginella	I-I
30	I-I
g	I-I
daily	I-I
in	I-I
the	I-I
late	I-I
course	I-I
of	I-I
radiotherapy	I-I
.	I-I


RESULTS	O
The	O
complete	B-O
remission	I-O
rate	I-O
of	I-O
nasopharyngeal	I-O
primary	I-O
lesions	I-O
in	O
groups	O
B	O
and	O
C	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
group	O
A	O
,	O
with	O
also	O
significantly	O
higher	O
complete	O
remission	B-O
rates	I-O
of	I-O
the	I-O
cervical	I-O
lymph	I-O
nodes	I-O
.	I-O


The	O
acute	B-O
toxicity	I-O
of	I-O
the	I-O
skin	I-O
and	I-O
mucous	I-O
membrane	I-O
was	O
milder	O
in	O
the	O
latter	O
two	O
groups	O
,	O
but	O
the	O
differences	O
were	O
not	O
significant	O
.	O


CONCLUSION	O
Selaginella	B-I
may	O
induce	O
radiosensitization	O
for	O
terminal	B-P
NPC	I-P
and	O
does	O
not	O
increase	O
the	O
acute	O
toxicity	O
of	O
radiotherapy	O
.	O


Relationship	O
of	O
the	O
dose	O
of	O
intravenous	O
gammaglobulin	B-I
to	O
the	O
prevention	O
of	O
infections	O
in	O
adults	B-P
with	I-P
common	I-P
variable	I-P
immunodeficiency	I-P
.	I-P


The	O
objective	O
was	O
to	O
assess	O
clinical	O
efficacy	O
of	O
3	O
dosages	O
of	O
intravenous	B-I
gammaglobulins	I-I
to	O
prevent	O
infectious	O
episodes	O
in	O
adult	O
common	O
variable	O
immunodeficiency	O
.	O


We	O
designed	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
dose-assessing	O
study	O
.	O


The	B-P
setting	I-P
was	I-P
at	I-P
University	I-P
Hospital	I-P
,	I-P
Out-patient	I-P
Clinic	I-P
.	I-P


Our	O
patients	B-P
were	I-P
twenty-one	I-P
adult	I-P
patients	I-P
with	I-P
common	I-P
variable	I-P
immunodeficiency	I-P
.	I-P


The	O
measurements	O
were	O
comparative	O
study	O
of	O
the	O
number	B-O
and	I-O
severity	I-O
of	I-O
infections	I-O
using	O
3	O
various	O
dosages	O
of	O
intravenous	O
gammaglobulins	B-I
,	O
each	O
given	O
monthly	O
for	O
M	O
least	O
6	O
months	O
.	O


Results	O
indicated	O
four	O
hundred	O
and	O
eighty-four	O
infectious	B-O
episodes	I-O
occurred	O
while	O
giving	O
305	B-I
infusions	I-I
of	I-I
IVIG	I-I
200	I-I
mg/kg	I-I
;	I-I
205	O
infectious	O
episodes	O
while	O
giving	O
170	B-I
infusions	I-I
of	I-I
400	I-I
mg/kg	I-I
and	O
436	O
infectious	O
episodes	O
while	O
giving	O
247	B-I
infusions	I-I
of	I-I
600	I-I
mg/kg	I-I
.	I-I


The	O
morbidity	B-O
scores	I-O
(	I-O
infection/infusion	I-O
)	I-O
were	O
1.59	O
,	O
1.21	O
and	O
1.77	O
respectively	O
(	O
p	O
-	O
N/S	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
severity	B-O
of	I-O
infections	I-O
on	O
the	O
above	O
3	O
dosages	O
,	O
and	O
no	O
difference	O
in	O
the	O
duration	B-O
of	I-O
infection-free	I-O
intervals	I-O
.	I-O


The	O
conclusions	O
resulted	O
in	O
no	O
significant	O
differences	O
in	O
morbidity	B-O
in	O
adult	O
patients	O
with	O
common	O
variable	O
immunodeficiency	O
treated	O
in	O
cross-over	O
pattern	O
with	O
IVIG	O
200	O
mg/kg	O
,	O
400	O
mg/kg	O
and	O
600	O
mg/kg	O
.	O


Thus	O
,	O
high	O
dosages	O
of	O
IVIG	O
are	O
not	O
conferring	O
better	O
protection	O
against	O
infections	O
in	O
such	O
patients	O
.	O


Low-dose	O
versus	O
standard-dose	O
gemcitabine	B-I
infusion	I-I
and	O
cisplatin	B-I
for	O
patients	B-P
with	I-P
advanced	I-P
bladder	I-P
cancer	I-P
:	I-P
a	O
randomized	O
phase	O
II	O
trial-an	O
update	O
.	O


Prolonged	O
infusion	O
of	O
low-dose	O
gemcitabine	B-I
and	I-I
cisplatin	I-I
(	I-I
GC	I-I
)	I-I
proved	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
patients	B-P
with	I-P
advanced	I-P
bladder	I-P
cancer	I-P
.	I-P


One	B-P
hundred	I-P
and	I-P
twenty	I-P
untreated	I-P
patients	I-P
with	I-P
stage	I-P
III/IV	I-P
bladder	I-P
cancer	I-P
were	O
randomized	O
to	O
receive	O
either	O
gemcitabine	B-I
(	O
250	O
mg/m	O
(	O
2	O
)	O
)	O
6-h	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
and	B-I
cisplatin	I-I
(	O
70	O
mg/m	O
(	O
2	O
)	O
)	O
on	O
day	O
2	O
every	O
21-day	O
cycle	O
(	O
arm	O
1	O
)	O
or	O
gemcitabine	B-I
(	O
1,250	O
mg/m	O
(	O
2	O
)	O
)	O
30-min	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
with	O
the	O
same	O
dose	O
of	O
cisplatin	B-I
(	O
arm	O
2	O
)	O
.	O


The	O
92	B-P
males	I-P
and	I-P
28	I-P
females	I-P
included	I-P
in	I-P
the	I-P
study	I-P
had	I-P
a	I-P
median	I-P
age	I-P
of	I-P
62	I-P
years	I-P
(	I-P
range	I-P
40-85	I-P
years	I-P
)	I-P
.	I-P


Among	O
the	O
120	O
patient	O
,	O
complete	O
response	O
was	O
achieved	O
in	O
11.7	O
%	O
(	O
7/60	O
patients	O
of	O
arm	O
1	O
)	O
and	O
5	O
%	O
(	O
3/60	O
patients	O
of	O
arm	O
2	O
)	O
.	O


Eighteen	O
patients	O
in	O
arm	O
1	O
(	O
30	O
%	O
)	O
and	O
17	O
patients	O
(	O
28.3	O
%	O
)	O
in	O
arm	O
2	O
had	O
partial	O
response	O
on	O
therapy	O
.	O


Thus	O
,	O
the	O
overall	B-O
response	I-O
rate	I-O
of	O
patients	O
in	O
arm	O
1	O
and	O
arm	O
2	O
was	O
41.7	O
%	O
(	O
25/60	O
patients	O
)	O
and	O
33.3	O
%	O
(	O
20/60	O
patients	O
)	O
,	O
respectively	O
(	O
p	O
=	O
0.37	O
)	O
.	O


No	O
significant	O
difference	O
in	O
median	B-O
time	I-O
to	I-O
disease	I-O
progression	I-O
(	O
26	O
vs.	O
24	O
months	O
,	O
p	O
=	O
0.4	O
)	O
,	O
median	B-O
survival	I-O
(	O
12	O
vs.	O
16	O
months	O
,	O
p	O
=	O
0.8	O
)	O
,	O
and	O
1-year	B-O
survival	I-O
(	O
49.9	O
vs.	O
54.7	O
%	O
,	O
p	O
=	O
0.8	O
)	O
was	O
detected	O
between	O
arms	O
1	O
and	O
2	O
,	O
respectively	O
.	O


Main	B-O
toxicities	I-O
were	O
similar	O
in	O
both	O
arms	O
with	O
no	O
statistically	O
significant	O
differences	O
.	O


Low-dose	O
,	O
prolonged	O
infusion	O
gemcitabine	B-I
in	I-I
combination	I-I
with	I-I
cisplatin	I-I
is	O
not	O
inferior	O
to	O
the	O
standard	B-I
GC	I-I
regimen	I-I
with	O
favorable	O
toxicity	B-O
profile	I-O
and	O
less	O
financial	B-O
costs	I-O
.	I-O


Inhibition	B-O
of	I-O
the	I-O
seasonal	I-O
IgE	I-O
increase	I-P
to	I-P
Dactylis	I-P
glomerata	I-P
by	O
daily	B-I
sodium	I-I
chloride	I-I
nasal-sinus	I-I
irrigation	I-I
during	O
the	O
grass	O
pollen	O
season	O
.	O


Recommendations	O
for	O
implementing	O
stereotactic	B-I
radiotherapy	I-I
in	O
peripheral	B-P
stage	I-P
IA	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
:	I-P
report	O
from	O
the	O
Quality	O
Assurance	O
Working	O
Party	O
of	O
the	O
randomised	O
phase	O
III	O
ROSEL	O
study	O
.	O


BACKGROUND	O
A	O
phase	O
III	O
multi-centre	O
randomised	O
trial	O
(	O
ROSEL	O
)	O
has	O
been	O
initiated	O
to	O
establish	O
the	O
role	O
of	O
stereotactic	B-I
radiotherapy	I-I
in	O
patients	B-P
with	I-P
operable	I-P
stage	I-P
IA	I-P
lung	I-P
cancer	I-P
.	I-P


Due	O
to	O
rapid	O
changes	O
in	O
radiotherapy	O
technology	O
and	O
evolving	O
techniques	O
for	O
image-guided	O
delivery	O
,	O
guidelines	O
had	O
to	O
be	O
developed	O
in	O
order	O
to	O
ensure	O
uniformity	O
in	O
implementation	O
of	O
stereotactic	B-I
radiotherapy	I-I
in	O
this	O
multi-centre	O
study	O
.	O


METHODS/DESIGN	O
A	O
Quality	O
Assurance	O
Working	O
Party	O
was	O
formed	O
by	O
radiation	O
oncologists	O
and	O
clinical	O
physicists	O
from	O
both	O
academic	O
as	O
well	O
as	O
non-academic	O
hospitals	O
that	O
had	O
already	O
implemented	O
stereotactic	B-I
radiotherapy	I-I
for	O
lung	O
cancer	O
.	O


A	O
literature	B-I
survey	I-I
was	O
conducted	O
and	O
consensus	O
meetings	O
were	O
held	O
in	O
which	O
both	O
the	O
knowledge	O
from	O
the	O
literature	O
and	O
clinical	O
experience	O
were	O
pooled	O
.	O


In	O
addition	O
,	O
a	B-P
planning	I-P
study	I-P
was	I-P
performed	I-P
in	I-P
26	I-P
stage	I-P
I	I-P
patients	I-P
,	I-P
of	I-P
which	I-P
22	I-P
were	I-P
stage	I-P
1A	I-P
,	O
in	O
order	O
to	O
develop	O
and	O
evaluate	O
the	O
planning	O
guidelines	O
.	O


Plans	O
were	O
optimised	O
according	O
to	O
parameters	O
adopted	O
from	O
RTOG	O
trials	O
using	O
both	O
an	O
algorithm	O
with	O
a	O
simple	O
homogeneity	O
correction	O
(	O
Type	O
A	O
)	O
and	O
a	O
more	O
advanced	B-I
algorithm	I-I
(	O
Type	O
B	O
)	O
.	O


Dose	O
conformity	O
requirements	O
were	O
then	O
formulated	O
based	O
on	O
these	O
results	O
.	O


CONCLUSION	O
Based	O
on	O
current	O
literature	O
and	O
expert	O
experience	O
,	O
guidelines	B-O
were	I-O
formulated	I-O
for	I-O
this	I-O
phase	I-O
III	I-O
study	I-O
of	I-O
stereotactic	I-O
radiotherapy	I-O
versus	I-O
surgery	I-O
.	I-O


These	O
guidelines	O
can	O
serve	O
to	O
facilitate	O
the	O
design	O
of	O
future	O
multi-centre	O
clinical	O
trials	O
of	O
stereotactic	B-I
radiotherapy	I-I
in	O
other	O
patient	O
groups	O
and	O
aid	O
a	O
more	O
uniform	O
implementation	O
of	O
this	O
technique	O
outside	O
clinical	O
trials	O
.	O


Efficacy	B-O
and	I-O
safety	I-O
of	O
bexarotene	B-I
combined	I-I
with	I-I
psoralen-ultraviolet	I-I
A	I-I
(	I-I
PUVA	I-I
)	I-I
compared	I-I
with	I-I
PUVA	I-I
treatment	I-I
alone	I-I
in	O
stage	O
IB-IIA	O
mycosis	O
fungoides	O
:	O
final	O
results	O
from	O
the	O
EORTC	O
Cutaneous	B-P
Lymphoma	I-P
Task	I-P
Force	I-P
phase	I-P
III	I-P
randomized	I-P
clinical	I-P
trial	I-P
(	O
NCT00056056	O
)	O
.	O


BACKGROUND	O
Psoralen	B-I
plus	I-I
ultraviolet	I-I
A	I-I
(	I-I
PUVA	I-I
)	I-I
is	O
the	O
standard	O
treatment	O
for	O
early	B-P
stages	I-P
of	I-P
mycosis	I-P
fungoides	I-P
.	I-P


There	O
have	O
been	O
no	O
adequate	O
randomized	O
controlled	O
trials	O
with	O
sufficient	O
power	O
comparing	O
this	O
modality	O
with	O
other	O
therapies	O
.	O


OBJECTIVE	O
To	O
assess	O
disease	B-O
response	I-O
and	O
to	O
compare	O
the	O
response	B-O
rates	I-O
of	O
patients	B-P
treated	I-P
with	I-P
PUVA	I-I
alone	I-I
or	I-P
PUVA	I-I
and	I-I
bexarotene	I-I
.	I-I


METHODS	O
EORTC	O
21011	O
(	O
NCT	O
00056056	O
)	O
was	O
a	O
randomized	O
phase	O
III	O
study	O
comparing	O
combined	B-I
bexarotene	I-I
(	I-I
Targretin	I-I
(	I-I
®	I-I
)	I-I
)	I-I
and	I-I
PUVA	I-I
vs.	I-I
PUVA	I-I
alone	I-I
in	I-P
patients	I-P
with	I-P
stage	I-P
IB	I-P
and	I-P
IIA	I-P
mycosis	I-P
fungoides	I-P
(	I-P
MF	I-P
)	I-P
.	O


The	O
primary	O
endpoint	O
was	O
the	B-O
overall	I-O
response	I-O
rate	I-O
[	I-O
complete	I-O
clinical	I-O
response	I-O
(	I-O
CCR	I-O
)	I-O
plus	I-O
partial	I-O
response	I-O
(	I-O
PR	I-O
)	I-O
]	I-O
.	O


RESULTS	O
The	O
study	O
was	O
prematurely	O
closed	O
due	O
to	O
low	O
accrual	O
after	B-P
93	I-P
of	I-P
145	I-P
required	I-P
patients	I-P
(	O
65	O
%	O
)	O
were	O
randomized	O
.	O


Of	O
the	B-P
93	I-P
randomized	I-P
patients	I-P
,	I-P
87	I-P
started	I-P
treatment	I-P
,	I-P
41	I-P
received	I-I
PUVA	I-I
and	I-P
46	I-P
received	I-I
PUVA	I-I
+	I-I
bexarotene	I-I
.	I-O


Total	B-O
UVA	I-O
doses	I-O
received	O
were	O
107	O
J	O
cm	O
(	O
-2	O
)	O
(	O
range	O
1·4-489·9	O
)	O
in	O
the	B-I
PUVA	I-I
arm	O
vs.	O
101·7	O
J	O
cm	O
(	O
-2	O
)	O
(	O
0·2-529·9	O
)	O
in	O
the	O
combination	O
arm	B-O
.	I-O


The	B-O
safety	I-O
profile	I-O
was	O
acceptable	O
with	B-O
few	I-O
grade	I-O
3-4	I-O
toxicities	I-O
observed	O
in	O
either	O
arm	O
.	B-O


More	B-O
drop-outs	I-O
due	I-O
to	I-O
toxicity	I-O
were	O
observed	O
in	O
the	O
combination	O
arm	O
compared	O
with	B-I
the	I-I
PUVA-alone	I-I
arm	O
.	O


The	B-O
best	I-O
overall	I-O
response	I-O
(	I-O
CCR	I-O
+	I-O
PR	I-O
)	I-O
rate	O
was	O
71	B-I
%	I-I
for	I-I
PUVA	I-I
alone	O
and	O
77	O
%	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0·57	B-O
)	I-O
.	I-O


The	B-O
median	I-O
duration	I-O
of	I-O
response	I-O
was	O
9·7	O
months	B-I
for	I-I
PUVA	O
vs.	O
5·8	O
months	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	B-O
0·33	I-O
)	I-O
.	O


CCR	O
was	O
seen	O
in	O
25	O
patients	O
of	O
whom	O
10	B-I
received	I-I
PUVA	I-O
alone	I-O
(	O
CCR	O
22	O
%	O
)	O
and	O
15	B-I
received	I-I
combination	I-O
therapy	I-O
(	O
CCR	O
31	O
%	O
)	O
(	B-O
P	I-O
=	I-O
0·45	I-O
)	I-O
.	O


CCR	O
was	O
sustained	O
in	O
25	O
%	O
of	O
patients	O
regardless	O
of	O
therapy	O
.	O


There	O
was	O
a	O
trend	O
towards	B-I
fewer	I-O
PUVA	I-O
sessions	I-O
needed	I-O
to	I-O
achieve	I-O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
22	O
)	O
compared	B-I
with	I-I
the	O
PUVA	O
arm	O
(	O
median	O
27·5	O
)	O
(	O
P	O
=	O
0·11	O
)	O
.	O


Similarly	O
,	O
a	O
trend	O
towards	B-I
lower	I-O
UVA	I-O
dose	I-O
required	I-O
to	I-O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
55·8	O
J	O
cm	O
(	O
-2	O
)	O
)	O
compared	B-I
with	O
the	O
PUVA	O
arm	O
alone	O
(	O
median	O
117·5	O
J	O
cm	O
(	O
-2	O
)	O
)	O
(	O
P	O
=	O
0·5	O
)	O
was	O
observed	O
.	O


CONCLUSIONS	O
No	O
significant	B-O
difference	I-O
in	I-O
response	I-O
rate	I-O
or	I-O
response	I-O
duration	O
was	O
observed	O
in	O
this	O
study	O
.	O


However	O
,	O
there	O
was	O
a	O
trend	B-O
towards	I-O
fewer	I-O
PUVA	I-O
sessions	I-O
and	I-O
lower	I-O
UVA	I-O
dose	I-O
required	I-O
to	O
achieve	O
CCR	O
in	O
the	O
combination	B-I
arm	I-I
(	I-I
PUVA	I-I
+	O
bexarotene	O
)	O
but	O
this	O
did	O
not	O
achieve	O
statistical	O
significance	O
due	O
to	O
insufficient	O
power	O
.	O


The	O
effects	O
of	O
ezetimibe/simvastatin	B-I
versus	I-I
simvastatin	I-I
monotherapy	I-I
on	O
platelet	B-O
and	I-O
inflammatory	I-O
biomarkers	I-O
in	O
patients	B-P
with	I-P
metabolic	I-P
syndrome	I-P
.	I-P


In	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
study	O
of	O
15	B-P
aspirin-naive	I-I
patients	I-P
(	I-P
mean	I-P
age	I-P
48.8	I-P
±	I-P
10.2	I-P
years	I-P
)	I-P
with	I-P
the	I-P
metabolic	I-P
syndrome	I-P
,	O
statin	B-I
monotherapy	I-I
(	I-I
simvastatin	I-I
40	O
mg	O
daily	O
)	O
was	O
compared	O
to	B-I
combination	I-I
therapy	I-I
(	I-I
simvastatin	I-I
40	O
mg	B-I
and	I-I
ezetimibe	I-I
10	O
mg	O
daily	O
)	O
on	O
biomarkers	O
of	B-O
inflammation	I-O
and	I-O
platelet	I-O
activity	I-O
.	O


The	O
addition	O
of	B-I
ezetimibe	I-I
to	I-I
simvastatin	I-I
over	O
a	O
4-week	O
period	O
was	O
associated	O
with	O
reduced	B-O
expression	I-O
of	I-O
CD141	I-O
(	O
thrombomodulin	O
;	O
p	O
=	O
0.02	O
)	O
,	O
platelet	B-O
endothelial	I-O
cell	I-O
adhesion	I-O
molecule	I-O
(	O
p	O
<	O
0.0001	O
)	O
and	B-O
CD51/61	I-O
(	O
vitronectin	O
receptor	O
;	O
p	O
=	O
0.048	O
)	O
compared	O
to	B-I
statin	I-I
monotherapy	I-I
.	I-I


Ezetimibe	B-I
added	O
to	O
simvastatin	O
improves	B-O
several	I-O
indices	I-O
of	I-O
platelet	I-O
reactivity	I-O
beyond	I-I
statin	I-I
monotherapy	I-I
.	O


However	O
,	O
the	O
clinical	O
relevance	O
of	O
these	O
findings	O
await	O
results	O
of	O
the	O
IMPROVE-IT	O
trial	O
(	O
Improved	O
Reduction	O
of	O
Outcomes	O
:	O
Vytorin	O
Efficacy	O
International	O
Trial	O
)	O
.	O


The	O
effect	O
of	O
fasting	B-I
on	O
total	B-O
serum	I-O
bilirubin	I-O
concentrations	I-O
.	I-O


Thirty-seven	B-P
healthy	I-P
volunteers	I-P
,	I-P
19	I-P
of	I-P
whom	I-P
had	I-P
consistently	I-P
elevated	I-P
total	I-O
serum	I-O
bilirubin	I-O
(	I-O
TSB	I-O
)	I-O
concentrations	I-O
,	I-P
took	I-P
part	I-P
in	O
an	O
open	O
,	O
randomised	O
cross-over	O
study	O
to	O
determine	O
the	O
effect	O
of	O
fasting	B-I
on	O
TSB	O
concentrations	O
.	O


The	O
study	O
comprised	O
of	O
two	O
treatments	O
.	O


During	O
one	O
treatment	O
period	O
volunteers	B-P
ate	I-I
a	I-I
standard	I-I
supper	I-I
but	I-I
fasted	I-I
for	I-I
24	I-I
h	I-I
thereafter	I-I
.	I-I


During	O
the	O
other	O
treatment	O
period	O
volunteers	B-P
ate	O
a	O
standard	B-I
supper	I-I
,	I-I
snacks	I-I
,	I-I
breakfast	I-I
and	I-I
lunch	I-I
.	I-I


TSB	B-O
concentrations	I-O
were	O
measured	O
at	O
regular	O
intervals	O
.	O


In	O
both	O
the	O
normal	O
and	O
high	O
bilirubin	O
groups	O
,	O
minimum	B-O
TSB	I-O
values	I-O
were	O
recorded	O
4	O
h	O
after	O
the	O
supper	O
.	O


A	O
24	O
h	O
fast	O
more	B-O
than	I-O
doubled	I-O
TSB	I-O
concentration	I-O
from	O
baseline	O
values	O
in	O
both	O
the	O
normal	O
and	O
high	O
bilirubin	O
groups	O
.	O


A	O
clinically	O
relevant	O
rise	B-O
in	I-O
TSB	I-O
took	O
place	O
after	O
12	O
h	O
into	O
the	O
fasting	O
period	O
(	O
TSB	O
of	O
17.3	O
mumol	O
l-1	O
in	O
the	O
fasted	O
group	O
vs	O
14.0	O
mumol	O
l-1	O
in	O
the	O
non-fasted	O
group	O
)	O
.	O


When	O
designing	O
a	O
clinical	O
trial	O
,	O
selecting	O
volunteers	B-P
,	O
or	O
judging	O
the	O
tolerance	O
of	O
a	O
new	O
drug	O
,	O
the	O
rise	O
in	O
TSB	B-O
caused	O
by	O
fasting	O
must	O
therefore	O
be	O
taken	O
into	O
account	O
,	O
particularly	O
in	O
trials	O
where	O
volunteers	B-P
or	O
patients	O
fast	O
before	O
entering	O
the	O
study	O
.	O


Intrathecal	O
lentivirus-mediated	O
transfer	O
of	O
interleukin-10	B-I
attenuates	O
chronic	B-O
constriction	I-O
injury-induced	I-O
neuropathic	I-O
pain	I-O
through	O
modulation	O
of	O
spinal	O
high-mobility	O
group	O
box	O
1	O
in	O
rats	B-P
.	I-P


BACKGROUND	O
Neuropathic	O
pain	O
is	O
a	O
complex	O
state	O
of	O
chronic	O
pain	O
that	O
is	O
usually	O
accompanied	O
by	O
peripheral	O
and	O
central	O
nervous	O
system	O
damage	O
or	O
dysfunction	O
.	O


Previous	O
studies	O
have	O
indicated	O
that	O
neuroinflammation	O
in	O
the	O
spinal	O
cord	O
is	O
an	O
important	O
contributor	O
to	O
neuropathological	O
and	O
behavioral	O
abnormalities	O
.	O


A	O
series	O
of	O
early	O
inflammatory	O
markers	O
,	O
such	O
as	O
IL-1	O
,	O
TNF-α	O
,	O
and	O
IFN-γ	O
,	O
and	O
advanced	O
inflammatory	O
markers	O
,	O
such	O
as	O
high-mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
)	O
,	O
are	O
involved	O
in	O
neuroinflammation	O
.	O


STUDY	O
DESIGN	O
A	O
randomized	O
,	O
double	O
blind	O
,	O
controlled	B-P
animal	I-P
trial	O
.	O


OBJECTIVE	O
In	O
this	O
study	O
,	O
a	B-I
lentivirus	I-I
delivering	I-I
human	I-I
IL-10	I-I
(	I-I
LV/hIL-10	I-I
)	I-I
was	O
administered	O
intrathecally	O
to	O
determine	O
the	O
effects	O
of	O
IL-10	O
on	B-O
allodynia	I-O
and	I-O
hyperalgesia	I-O
in	O
a	O
chronic	O
constriction	O
injury-induced	O
(	B-P
CCI	I-P
)	I-P
rat	I-P
model	I-P
of	O
neuropathic	O
pain	O
.	O


METHODS	B-P
Sprague-Dawley	I-P
rats	I-P
weighting	I-P
260	I-P
-	I-P
320	I-P
g	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
.	O


Group	O
Sham	O
(	O
Sham	O
)	O
,	O
Group	B-I
CCI±Normal	I-I
Saline	I-I
(	I-I
NS	I-I
)	I-I
,	I-I
Group	I-I
CCI±LV/hIL-10	I-I
(	I-I
LV/hIL-10	I-I
)	I-I
,	O
and	O
Group	B-I
CCI±LV/control	I-I
(	I-I
vector	I-I
)	I-I
.	I-P


Rats	O
in	O
each	O
group	O
were	O
intrathecally	O
delivered	O
with	B-I
NS	I-I
,	I-I
LV/control	I-I
,	I-I
or	I-I
recombinant	I-I
vector	I-I
LV/hIL-10	I-I
in	O
a	O
total	O
volume	O
of	O
10	B-O
μl	I-O
.	I-O


Paw	B-O
withdrawal	I-O
mechanical	I-O
thresholds	I-O
(	I-O
PWMT	I-O
)	I-O
and	I-O
paw	I-O
withdrawal	I-O
thermal	I-O
latency	I-O
PWTL	O
were	O
measured	O
one	O
day	O
before	O
CCI	O
(	O
baseline	O
)	O
and	O
0	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
28	O
days	O
after	O
intrathecal	O
administration	O
.	O


Cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
samples	O
were	O
collected	O
during	O
surgical	O
plane	O
anesthesia	O
and	O
the	O
collected	O
CSF	O
samples	O
were	O
used	O
to	O
assay	O
for	O
human	O
IL-10	O
,	O
rat	O
IL-1β	O
,	O
rat	O
IL-6	O
,	O
and	O
rat	O
TNF-α	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	B-P
ELISA	I-P
)	I-P
.	I-P


Animals	B-P
were	I-P
sacrificed	I-P
and	I-P
the	I-P
L4-5	I-P
lumbar	I-P
segment	I-P
of	I-P
the	I-P
spinal	I-P
cord	I-P
was	I-P
removed	I-P
for	I-P
determination	I-P
of	I-P
green	I-P
fluorescent	I-P
protein	I-P
(	I-P
GFP	I-P
)	I-P
expression	I-P
.	O


Immunohistochemical	O
analysis	O
was	O
performed	O
using	O
anti	O
HMGB1	O
antibodies	O
and	O
the	O
expression	O
of	O
HMGB1	O
protein	O
in	O
the	O
spinal	O
cord	O
was	O
determined	O
by	O
western	O
blot	O
analysis	O
after	O
intrathecal	O
delivery	O
(	O
n	O
=	O
8	O
each	O
)	O
.	O


RESULTS	O
The	O
results	O
show	B-I
that	I-I
intrathecal	I-I
LV/hIL-10	I-I
reverses	I-O
enhanced	I-O
pain	I-O
states	O
.	O


Moreover	O
,	O
the	O
increased	B-O
level	I-O
of	I-O
HMGB1	O
exhibited	B-O
in	I-O
a	I-O
late	I-O
stage	I-O
of	O
CCI	O
was	O
inhibited	O
by	O
exogenous	O
overexpression	O
of	O
hIL-10	O
in	O
the	O
CCI	B-O
model	I-O
.	I-O


Expression	B-O
of	I-O
HMGB1	I-O
,	I-O
RAGE	I-O
,	I-O
and	I-O
pAkt	O
were	O
lower	O
in	O
CCI-induced	O
rats	O
treated	O
with	O
LV/hIL-10	O
than	O
in	O
those	O
treated	O
with	O
LV/control	O
(	O
vector	O
)	O
or	O
saline	O
(	O
NS	O
)	O
.	O


Our	O
results	O
showed	B-O
that	I-O
IL-10	O
inhibits	B-O
activation	I-O
of	I-O
the	I-O
inflammatory	I-O
HMGB1-RAGE	I-O
pathway	O
in	O
the	O
CCI	O
rat	O
model	O
.	O


LIMITATIONS	O
Further	O
experimental	O
investigations	O
are	O
needed	O
to	O
clarify	O
the	O
specific	O
biological	O
roles	O
played	O
by	O
HMGB1	O
in	O
IL-10-mediated	O
regulation	B-O
of	I-O
neuropathic	I-O
pain	O
.	O


CONCLUSION	O
Our	O
results	O
indicate	O
that	O
intrathecal	O
lentiviral-mediated	O
transfer	B-I
of	I-I
IL-10	O
attenuates	B-O
CCI-induced	I-O
neuropathic	I-O
pain	I-P
in	O
rats	O
.	O


The	O
anti-thermal	O
hyperalgesia	O
and	O
anti-mechanical	O
allodynia	O
may	O
be	O
partly	O
attributable	O
to	O
the	O
decreased	O
expression	O
of	O
HMGB1	O
and	O
inhibition	O
of	O
HMGB1-RAGE	O
pathway	O
.	O


[	O
A	O
multicenter	O
,	O
randomized	O
clinical	O
trial	O
of	O
intravenous	O
diltiazem	B-I
in	O
treatment	O
of	O
unstable	B-P
angina	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
intravenous	O
diltiazem	B-I
compared	O
with	O
nitroglycerin	B-I
in	O
the	O
patients	B-P
with	I-P
unstable	I-P
angina	I-P
pectoris	I-P
.	I-P


METHODS	O
A	O
multicenter	O
,	O
randomized	O
,	O
open-label	O
,	O
parallel	O
group	O
trial	O
was	O
conducted	O
.	O


A	O
total	B-P
of	I-P
213	I-P
eligible	I-P
patients	I-P
were	I-P
enrolled	I-P
.	I-P


They	O
were	O
randomized	O
either	O
to	O
diltiazem	B-I
or	I-I
nitroglycerin	I-I
treatment	O
.	O


The	O
diltiazem	B-I
was	O
administered	O
from	O
100	O
microg/min	O
at	O
the	O
initiation	O
of	O
treatment	O
,	O
the	O
largest	O
dosage	O
was	O
200	O
-	O
300	O
microg/min	O
;	O
the	O
nitroglycerin	B-I
was	O
administered	O
from	O
20	O
microg/min	O
at	O
the	O
initiation	O
of	O
treatment	O
.	O


The	O
largest	O
dosage	O
was	O
80	O
-	O
100	O
microg/min	O
.	O


Intravenous	O
infusion	O
was	O
kept	O
over	O
48	O
hours	O
.	O


The	O
endpoints	O
included	O
refractory	B-O
angina	I-O
pectoris	I-O
,	I-O
acute	I-O
myocardial	I-O
infarction	I-O
,	I-O
death	I-O
,	I-O
emergency	I-O
PTCA	I-O
and	I-O
CABG	I-O
.	I-O


RESULTS	O
(	O
1	O
)	O
Intravenous	O
diltiazem	O
was	O
effective	O
on	O
the	O
improvement	O
of	O
symptom	B-O
and	I-O
electrocardiogram	I-O
,	O
and	O
its	O
effects	O
were	O
similar	O
to	O
intravenous	O
nitroglycerin	O
.	O


(	O
2	O
)	O
Compared	O
with	O
nitroglycerin	B-I
,	O
intravenous	O
diltiazem	B-I
lowered	I-O
heart	I-O
rate	I-O
and	I-O
myocardial	I-O
oxygen	I-O
consumption	I-O
index	I-O
(	O
systolic	O
pressure	O
x	O
heart	O
rate	O
)	O
to	O
more	O
extent	O
significantly	O
.	O


(	O
3	O
)	O
After	O
treatment	O
,	O
the	O
onsets	B-O
of	I-O
refractory	I-O
angina	I-O
pectoris	I-O
were	O
reduced	B-O
more	I-O
significantly	I-O
in	O
the	O
diltiazem	B-I
group	O
than	O
in	O
nitroglycerin	O
group	O
[	O
4	O
(	O
3.8	O
%	O
)	O
vs	O
13	O
(	O
11.9	O
%	O
)	O
,	O
RR	O
0.32	O
(	O
95	O
%	O
CI	O
0.11	O
-	O
0.96	O
)	O
,	O
P	O
<	O
0.05	O
]	O
.	O


(	O
4	O
)	O
The	O
patients	O
whose	O
heart	B-O
rate	I-O
were	O
reduced	B-O
significantly	I-O
(	O
<	O
or=	O
50	O
beats	O
per	O
minute	O
)	O
in	O
the	O
diltiazem	O
group	O
were	O
more	O
than	O
in	O
the	O
nitroglycerin	O
group	O
[	O
8	O
(	O
7.7	O
%	O
)	O
vs	O
0	O
(	O
0	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O


But	O
these	O
patients	O
could	O
tolerate	O
the	O
lower	O
heart	B-O
rate	I-O
very	O
well	O
in	O
the	O
diltiazem	O
group	O
.	O


(	O
5	O
)	O
The	O
needs	O
of	O
beta	O
receptor	O
blocker	O
or	O
calcium	O
antagonists	O
were	O
reduced	O
more	O
significantly	O
in	O
the	O
diltiazem	B-I
group	O
compared	O
with	O
those	O
in	O
the	O
nitroglycerin	O
group	O
[	O
2	O
(	O
1.9	O
%	O
)	O
vs	O
13	O
(	O
11.9	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O


CONCLUSION	O
Intravenous	O
diltiazem	B-I
therapy	O
is	O
effective	O
and	O
safe	O
for	O
patients	B-P
with	I-P
unstable	I-P
angina	I-P
pectoris	I-P
.	I-P


It	O
may	O
significantly	O
lower	O
the	O
risk	O
of	O
refractory	O
angina	O
pectoris	O
compared	O
with	O
intravenous	O
nitroglycerin	O
.	O


Effects	O
of	O
ranolazine	B-I
on	O
quality	B-O
of	I-O
life	I-O
among	O
patients	B-P
with	I-P
diabetes	I-P
mellitus	I-P
and	I-P
stable	I-P
angina	I-P
.	I-P


The	O
effect	O
of	O
reinforcement	B-I
or	I-I
stimulus	I-I
control	I-I
to	O
reduce	O
sedentary	B-O
behavior	I-O
in	O
the	O
treatment	O
of	O
pediatric	B-P
obesity	I-P
.	I-P


Obese	B-P
children	I-P
were	O
randomly	O
assigned	O
to	O
a	O
family-based	B-I
behavioral	I-I
treatment	I-I
that	I-I
included	I-I
either	I-I
stimulus	I-I
control	I-I
or	I-I
reinforcement	I-I
to	O
reduce	O
sedentary	O
behaviors	O
.	O


Significant	O
and	O
equivalent	O
decreases	O
in	O
sedentary	B-O
behavior	I-O
and	I-O
high	I-O
energy	I-O
density	I-O
foods	I-O
,	O
increases	O
in	O
physical	B-O
activity	I-O
and	I-O
fruits	I-O
and	I-O
vegetables	I-O
,	O
and	O
decreases	O
in	O
standardized	O
body	B-O
mass	I-O
index	I-O
(	I-O
z-BMI	I-O
)	I-O
were	O
observed	O
.	O


Children	O
who	O
substituted	O
active	O
for	O
sedentary	B-O
behaviors	I-O
had	O
significantly	O
greater	O
z-BMI	B-O
changes	I-O
at	O
6	O
(	O
-1.21	O
vs.	O
-0.76	O
)	O
and	O
12	O
(	O
-1.05	O
vs.	O
-0.51	O
)	O
months	O
,	O
respectively	O
.	O


Substitution	O
of	O
physically	O
active	O
for	O
sedentary	B-O
behaviors	I-O
and	O
changes	B-O
in	I-O
activity	I-O
level	I-O
predicted	O
6-	O
and	O
12-month	O
z-BMI	B-O
changes	I-O
.	I-O


Results	O
suggest	O
stimulus	B-I
control	I-I
and	I-I
reinforcing	I-I
reduced	O
sedentary	B-O
behaviors	I-O
are	O
equivalent	O
ways	O
to	O
decrease	O
sedentary	B-O
behaviors	I-O
,	O
and	O
behavioral	B-O
economic	I-O
relationships	I-O
in	I-O
eating	I-O
and	I-O
activity	I-O
may	O
mediate	O
the	O
effects	O
of	O
treatment	O
.	O


Effect	O
of	O
ginseng	B-I
extract	I-I
supplementation	I-I
on	O
testicular	B-O
functions	I-O
in	O
diabetic	B-P
rats	I-P
.	I-P


OBJECTIVE	O
It	O
was	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
standardized	O
ginseng	B-I
extract	I-I
on	O
fertility	B-O
parameters	I-O
in	O
diabetic	B-P
rats	I-P
.	I-P


METHODS	O
Thirty	B-P
male	I-P
rats	I-P
were	O
randomly	O
allocated	O
into	O
three	O
groups	O
of	O
10	O
rats	O
each	O
:	O
1.	O
controls	O
,	O
2.	O
diabetes	O
(	O
D	O
)	O
and	O
3.	O
diabetes	O
+	O
ginseng	O
(	O
DG	O
)	O
.	O


The	O
latter	O
two	O
groups	O
were	O
rendered	O
diabetic	O
by	O
i.p	O
.	O


injection	O
of	O
streptozotocin	B-I
(	O
STZ	O
;	O
50	O
mg/kg	O
)	O
.	O


Standardized	B-I
ginseng	I-I
extract	I-I
(	O
Dansk	O
Droge	O
A/S	O
,	O
Copenhagen	O
,	O
Denmark	O
)	O
was	O
administered	O
per	O
os	O
(	O
100	O
mg/kg	O
BW	O
)	O
by	O
stomach	O
tube	O
daily	O
for	O
90	O
days	O
starting	O
one	O
week	O
after	O
STZ	O
.	O


Ninety	O
days	O
post	O
STZ	O
the	O
rats	O
were	O
sacrificed	O
,	O
and	O
testis	B-O
,	I-O
epididymis	I-O
,	I-O
prostate	I-O
,	I-O
and	I-O
seminal	I-O
vesicles	I-O
were	I-O
weighed	I-O
and	I-O
subjected	I-O
to	I-O
histological	I-O
examination	I-O
.	I-O


In	O
addition	O
,	O
spermiogram	B-O
,	I-O
testicular	I-O
enzyme	I-O
markers	I-O
,	I-O
intratesticular	I-O
steroid	I-O
hormonal	I-O
profile	I-O
and	I-O
testicular	I-O
antioxidant	I-O
status	I-O
were	O
estimated	O
.	O


RESULTS	O
The	O
administration	O
of	O
ginseng	B-I
extract	I-I
resulted	O
in	O
a	O
significant	O
improvement	O
of	O
fertility	B-O
parameters	I-O
and	I-O
testicular	I-O
antioxidants	I-O
together	I-O
with	O
a	O
decrease	B-O
in	I-O
malondialdehyde	I-O
and	I-O
testicular	I-O
pathological	I-O
signs	I-O
including	I-O
degenerative	I-O
changes	I-O
of	I-O
the	I-O
seminiferous	I-O
tubules	I-O
.	I-O


CONCLUSION	O
Ginseng	B-I
extract	I-I
may	O
be	O
a	O
beneficial	O
adjuvant	O
therapy	O
for	O
diabetics	O
suffering	O
from	O
infertility	B-O
as	O
a	O
complication	O
.	O


A	O
randomized	O
,	O
multicenter	O
,	O
multivendor	O
study	O
of	O
myocardial	O
perfusion	O
imaging	O
with	O
regadenoson	B-I
CT	I-I
perfusion	I-I
vs	O
single	B-I
photon	I-I
emission	I-I
CT.	I-I
BACKGROUND	O
Myocardial	O
CT	O
perfusion	O
(	O
CTP	O
)	O
is	O
a	O
promising	O
tool	O
for	O
the	O
detection	O
of	O
myocardial	B-P
ischemia	I-P
.	I-P


We	O
hypothesize	O
that	O
regadenoson	O
CTP	O
is	O
noninferior	O
to	O
regadenoson	O
single	O
photon	O
emission	O
CT	O
(	O
SPECT	O
)	O
for	O
detecting	O
or	O
excluding	O
myocardial	B-P
ischemia	I-P
.	I-P


METHODS	O
Patients	B-P
(	I-P
men	I-P
≥	I-P
45	I-P
years	I-P
;	I-P
women	I-P
≥	I-P
50	I-P
years	I-P
)	I-P
with	I-P
known	I-P
or	I-P
suspected	I-P
coronary	I-P
artery	I-P
disease	I-P
(	I-P
n	I-P
=	I-P
124	I-P
)	I-P
were	O
randomized	O
to	O
1	O
of	O
2	O
diagnostic	O
sequences	B-I
:	I-I
rest	I-I
and	I-I
regadenoson	I-I
SPECT	I-I
on	I-I
day	I-I
1	I-I
,	I-I
then	I-I
regadenoson	I-I
CTP	I-I
and	I-I
rest	I-I
CTP	I-I
(	I-I
and	I-I
coronary	I-I
CT	I-I
angiography	I-I
[	I-I
CTA	I-I
]	I-I
)	I-I
(	I-I
CTA	I-I
;	I-I
same	I-I
acquisition	I-I
)	I-I
on	I-I
day	I-I
2	I-I
or	I-I
regadenoson	I-I
CTP	I-I
and	I-I
rest	I-I
CTP	I-I
(	I-I
and	I-I
CTA	I-I
)	I-I
on	I-I
Day	I-I
1	I-I
,	I-I
then	I-I
rest	I-I
and	I-I
regadenoson	I-I
SPECT	I-I
on	I-I
day	I-I
2	O
.	O


Scanning	O
platforms	O
included	O
64-	O
,	O
128-	O
,	O
256-	O
,	O
and	O
320-slice	O
systems	O
.	O


The	O
primary	O
analysis	O
examined	O
the	B-O
agreement	I-O
rate	I-O
between	I-O
CTP	I-O
and	I-O
SPECT	I-O
for	I-O
detecting	I-O
or	I-O
excluding	I-O
reversible	I-O
ischemia	I-O
in	O
≥	O
2	O
myocardial	O
segments	O
as	O
assessed	O
by	O
independent	O
,	O
blinded	O
readers	O
.	O


RESULTS	O
Complete	O
and	O
interpretable	O
CTP	O
and	O
SPECT	O
scans	O
were	O
obtained	B-P
for	I-P
110	I-P
patients	I-I
.	I-I


Regadenoson	B-I
CTP	O
was	O
noninferior	O
to	O
SPECT	B-O
for	I-O
detecting	I-O
or	I-O
excluding	I-O
reversible	I-O
ischemia	I-O
with	O
an	O
agreement	O
rate	O
of	O
0.87	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.77-0.97	O
)	O
and	O
sensitivity	O
and	O
specificity	O
of	O
0.90	O
(	O
95	O
%	O
CI	O
,	O
0.71-1.00	O
)	O
and	O
0.84	O
(	O
95	O
%	O
CI	O
,	O
0.77-0.91	O
)	O
,	O
respectively	B-O
.	I-O


The	B-O
agreement	I-O
rate	O
for	O
detecting	O
or	O
excluding	B-O
≥	I-O
1	I-O
fixed	I-O
defects	O
by	O
regadenoson	O
CTP	O
and	O
SPECT	O
was	O
0.86	O
(	O
95	O
%	O
CI	O
,	O
0.74-0.98	O
)	O
.	O


With	O
SPECT	O
as	O
the	O
reference	O
standard	O
,	O
the	O
diagnostic	O
accuracies	O
for	O
detecting	O
or	O
excluding	O
ischemia	O
by	O
regadenoson	O
CTP	O
and	O
CTA	O
alone	O
were	O
0.85	O
(	O
95	O
%	O
CI	O
,	O
0.78-0.91	O
)	O
and	O
0.69	O
(	O
95	O
%	O
CI	O
,	O
0.60-0.77	O
)	O
,	O
respectively	O
.	O


CONCLUSIONS	O
This	O
study	O
establishes	O
the	O
noninferiority	B-I
of	I-I
regadenoson	I-I
CTP	I-I
to	I-I
SPECT	O
for	O
detecting	O
or	O
excluding	B-P
myocardial	I-P
ischemia	I-P
.	O


Efficacy	B-O
and	I-O
safety	I-O
of	O
oral	B-I
conivaptan	I-I
:	I-I
a	O
V1A/V2	B-I
vasopressin	I-I
receptor	I-I
antagonist	I-I
,	O
assessed	O
in	O
a	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
in	O
patients	B-P
with	I-P
euvolemic	I-P
or	I-P
hypervolemic	I-P
hyponatremia	I-P
.	I-P


CONTEXT	O
Hyponatremia	O
[	O
serum	O
sodium	O
concentration	O
(	O
[	O
Na	O
(	O
+	O
)	O
]	O
)	O
,	O
<	O
135	O
mEq/liter	O
]	O
is	O
the	O
most	O
common	O
fluid	O
and	O
electrolyte	O
abnormality	B-P
among	I-P
hospitalized	I-P
patients	I-P
.	I-P


It	O
is	O
frequently	O
caused	O
by	O
the	O
inappropriate	O
release	O
of	O
arginine	O
vasopressin	O
.	O


OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
oral	B-I
conivaptan	I-I
,	I-I
a	I-I
vasopressin	I-I
V	I-I
(	I-I
1A	I-I
)	I-I
/V	I-I
(	I-I
2	I-I
)	I-I
receptor	I-I
antagonist	I-I
,	O
in	O
patients	B-P
with	I-P
euvolemic	I-P
or	I-P
hypervolemic	I-P
hyponatremia	I-P
.	I-P


DESIGN	O
The	O
study	O
design	O
was	O
a	O
5-d	O
placebo-controlled	B-I
,	O
randomized	O
,	O
double-blind	O
study	O
.	O


SETTING	O
The	O
study	O
was	O
performed	O
at	B-P
a	I-P
hospital	I-P
.	I-P


INTERVENTION	O
Oral	B-I
conivaptan	I-I
(	O
40	O
or	O
80	O
mg/d	O
)	O
or	O
placebo	B-I
was	O
given	O
in	O
two	O
divided	O
doses	O
.	O


PATIENTS	O
Seventy-four	B-P
patients	I-P
(	I-P
average	I-P
baseline	I-P
serum	I-P
[	I-P
Na	I-P
(	I-P
+	I-P
)	I-P
]	I-P
,	I-P
115	I-P
to	I-P
<	I-P
130	I-P
mEq/liter	I-P
)	I-P
were	I-P
studied	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURE	O
The	O
main	O
outcome	O
measure	O
was	B-O
the	I-O
change	I-O
from	I-O
baseline	I-O
in	I-O
serum	I-O
[	I-O
Na	I-O
(	I-O
+	I-O
)	I-O
]	I-O
area	I-O
under	I-O
the	I-O
curve	I-O
.	I-O


RESULTS	O
The	O
least-squares	O
mean	B-O
change	O
from	O
baseline	O
in	O
the	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
area	O
under	O
the	O
curve	O
with	O
conivaptan	B-I
(	O
40	O
and	O
80	O
mg/d	O
)	O
was	O
2.0-fold	O
(	O
P	O
=	O
0.03	O
)	O
and	O
2.5-fold	O
(	O
P	O
<	O
0.001	O
)	O
greater	O
,	O
respectively	O
,	O
than	O
that	O
with	O
placebo	B-I
.	I-I


The	O
median	O
time	O
to	O
achieve	O
a	O
confirmed	O
increase	O
in	O
serum	B-O
[	O
Na	O
(	O
+	O
)	O
]	O
of	O
4	O
mEq/liter	O
or	O
more	O
from	O
baseline	O
was	O
71.7	O
h	O
for	O
placebo	B-I
,	O
27.5	O
h	O
for	O
40	O
mg/d	O
conivaptan	B-I
(	O
P	O
=	O
0.044	O
)	O
,	O
and	O
12.1	O
h	O
for	O
80	O
mg/d	O
conivaptan	B-I
(	O
P	O
=	O
0.002	O
)	O
.	O


The	O
mean	O
total	O
times	O
during	O
which	O
patients	O
had	O
a	O
serum	B-O
[	I-O
Na	I-O
(	I-O
+	I-O
)	I-O
]	I-O
level	O
of	O
4	O
mEq/liter	O
or	O
more	O
above	O
baseline	O
were	O
46.5	O
,	O
69.8	O
,	O
and	O
88.8	O
h	O
(	O
P	O
=	O
0.001	O
)	O
,	O
respectively	O
.	O


The	O
least-squares	O
mean	B-O
change	I-O
in	I-O
serum	I-O
[	I-O
Na	I-O
(	I-O
+	I-O
)	I-O
]	I-O
from	O
baseline	O
to	O
end	O
of	O
treatment	O
was	O
3.4	O
mEq/liter	O
for	O
placebo	B-I
,	O
6.4	O
mEq/liter	O
for	O
40	O
mg/d	O
conivaptan	B-I
,	O
and	O
8.2	O
mEq/liter	O
for	O
80	O
mg/d	O
conivaptan	B-I
(	O
P	O
=	O
0.002	O
)	O
.	O


A	O
confirmed	O
normal	B-O
serum	I-O
[	I-O
Na	I-O
(	I-O
+	I-O
)	I-O
]	I-O
(	O
>	O
/=135	O
mEq/liter	O
)	O
or	O
increase	O
of	O
6	O
mEq/liter	O
or	O
more	O
was	O
observed	O
in	O
48	O
%	O
of	O
patients	O
given	O
placebo	B-I
,	O
71	O
%	O
given	O
40	O
mg/d	O
conivaptan	B-I
,	O
and	O
82	O
%	O
given	O
80	O
mg/d	O
conivaptan	B-I
(	O
P	O
=	O
0.014	O
)	O
.	O


Headache	B-O
,	I-O
hypotension	I-O
,	I-O
nausea	I-O
,	I-O
constipation	I-O
,	I-O
and	I-O
postural	I-O
hypotension	I-O
were	O
the	O
most	O
common	O
adverse	O
events	O
.	O


CONCLUSION	O
Oral	B-I
conivaptan	I-I
(	O
40	O
and	O
80	O
mg/d	O
)	O
was	O
well	O
tolerated	O
and	O
efficacious	O
in	O
correcting	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
in	O
hyponatremia	O
.	O


Prevalence	B-O
of	I-O
metabolic	I-O
syndrome	I-O
in	O
rural	B-P
and	I-P
urban	I-P
Chinese	I-P
population	I-P
in	I-P
Qingdao	I-P
.	I-P


AIMS	O
To	O
investigate	O
the	O
prevalence	B-O
of	I-O
metabolic	I-O
syndrome	I-O
and	O
its	O
components	O
in	O
both	O
rural	B-P
and	I-P
urban	I-P
Chinese	I-P
population	I-P
.	I-P


SUBJECTS	O
AND	O
METHODS	O
A	O
population-based	B-I
crosssectional	I-I
survey	I-I
was	O
conducted	O
in	O
Qingdao	B-P
,	I-P
China	I-P
in	I-P
2006	I-P
with	I-P
6100	I-P
Chinese	I-P
aged	I-P
35-74	I-P
yr	I-P
invited	I-P
and	I-P
5355	I-P
who	I-P
attended	I-P
;	I-P
3357	I-P
subjects	I-P
,	I-P
1562	I-P
urban	I-P
(	I-P
46.5	I-P
%	I-P
)	I-P
and	I-P
1795	I-P
rural	I-P
residents	I-P
(	I-P
53.5	I-P
%	I-P
)	I-P
met	I-P
the	I-P
inclusion	I-P
criteria	I-P
for	I-P
the	I-P
current	I-P
data	I-P
analysis	I-P
.	I-P


The	O
metabolic	O
syndrome	O
definitions	O
of	O
National	O
Cholesterol	O
Education	O
Program	O
Adult	O
Treatment	O
Expert	O
Panel	O
III	O
(	O
NCEPATPIII	O
)	O
2004	O
,	O
NCEP	O
2005	O
and	O
International	O
Diabetes	O
Federation	O
(	O
IDF	O
)	O
were	O
used	O
.	O


RESULTS	O
The	O
age-standardized	B-O
prevalences	I-O
of	I-O
metabolic	I-O
syndrome	I-O
were	O
16.2	O
%	O
,	O
32.2	O
%	O
,	O
and	O
28.3	O
%	O
in	O
men	O
and	O
26.8	O
%	O
,	O
37.2	O
%	O
,	O
and	O
34.6	O
%	O
in	O
women	O
,	O
according	O
to	O
the	O
definitions	O
of	O
the	O
NCEP	O
2004	O
,	O
NCEP	O
2005	O
,	O
and	O
IDF	O
,	O
respectively	O
.	O


Urban	O
men	O
have	O
more	O
risk	B-O
factors	I-O
and	I-O
higher	I-O
prevalence	I-O
of	I-O
the	I-O
metabolic	I-O
syndrome	I-O
than	O
rural	O
men	O
,	O
but	O
the	O
differences	O
in	O
women	O
were	O
not	O
that	O
striking	O
.	O


Elevated	B-O
blood	I-O
pressure	I-O
(	O
62.6	O
%	O
)	O
was	O
,	O
among	O
risk	O
factors	O
,	O
most	O
common	O
in	O
the	O
study	O
population	O
,	O
followed	O
by	O
central	B-O
obesity	I-O
(	O
53.4	O
%	O
)	O
,	O
and	O
hyperglycemia	B-O
(	O
52.2	O
%	O
)	O
defined	O
using	O
the	O
NCEP	O
2005	O
criteria	O
.	O


CONCLUSIONS	O
Metabolic	O
disorders	O
were	O
common	O
among	O
adult	B-P
Chinese	I-P
in	I-P
both	I-P
rural	I-P
and	I-P
urban	I-P
areas	I-P
in	I-P
Qingdao	I-P
.	I-P


A	O
comparative	O
study	O
of	O
the	O
safety	O
and	O
efficacy	O
of	O
FemCap	B-I
,	I-I
a	I-I
new	I-I
vaginal	I-I
barrier	I-I
contraceptive	I-I
,	O
and	O
the	O
Ortho	B-I
All-Flex	I-I
diaphragm	I-I
.	I-I


The	O
FemCap	O
Investigators	O
'	O
Group	O
.	O


The	O
FemCap	B-I
is	O
a	O
new	O
silicone	O
rubber	O
barrier	O
contraceptive	O
shaped	O
like	O
a	O
sailor	O
's	O
hat	O
,	O
with	O
a	O
dome	O
that	O
covers	O
the	O
cervix	O
,	O
a	O
rim	O
that	O
fits	O
into	O
the	O
fornices	O
,	O
and	O
a	O
brim	O
that	O
conforms	O
to	O
the	O
vaginal	O
walls	O
around	O
the	O
cervix	O
.	O


It	O
was	O
designed	O
to	O
result	O
in	O
fewer	O
dislodgments	O
and	O
less	O
pressure	O
on	O
the	O
urethra	O
than	O
the	O
cervical	O
cap	O
and	O
diaphragm	O
,	O
respectively	O
,	O
and	O
to	O
require	O
less	O
clinician	O
time	O
for	O
fitting	O
.	O


This	O
was	O
a	O
phase	O
II/III	O
,	O
multicenter	O
,	O
randomized	O
,	O
open-label	O
,	O
parallel	O
group	O
study	O
of	O
841	B-P
women	I-P
at	I-P
risk	I-P
for	I-P
pregnancy	I-P
.	I-P


A	O
subset	B-P
of	I-P
42	I-P
women	I-P
at	I-P
one	I-P
site	I-P
underwent	I-P
colposcopy	I-P
.	I-P


Women	O
were	O
randomized	O
to	O
use	O
the	O
FemCap	B-I
or	I-I
Ortho	I-I
All-Flex	I-I
contraceptive	I-I
diaphragm	I-I
,	I-I
both	I-I
with	I-I
2	I-I
%	I-I
nonoxynol-9	I-I
spermicide	I-I
,	O
for	O
28	O
weeks	O
.	O


The	O
objectives	O
were	O
to	O
compare	O
the	O
two	O
devices	O
with	O
regard	O
to	O
their	O
safety	O
and	O
acceptability	O
and	O
to	O
determine	O
whether	O
the	O
probability	B-O
of	I-O
pregnancy	I-O
among	O
FemCap	B-I
users	O
was	O
no	O
worse	O
than	O
that	O
of	O
the	O
diaphragm	B-I
(	O
meaning	O
not	O
more	O
than	O
6	O
percentage	O
points	O
higher	O
)	O
.	O


The	O
6-month	B-O
Kaplan-Meier	I-O
cumulative	I-O
unadjusted	O
typical	O
use	O
pregnancy	O
probabilities	O
were	O
13.5	O
%	O
among	O
FemCap	B-I
users	O
and	O
7.9	O
%	O
among	O
diaphragm	B-I
users	O
.	O


The	O
adjusted	B-O
risk	I-O
of	I-O
pregnancy	I-O
among	O
FemCap	B-I
users	O
was	O
1.96	O
times	O
that	O
among	O
diaphragm	B-I
users	O
,	O
with	O
an	O
upper	O
95	O
%	O
confidence	O
limit	O
of	O
3.01	O
.	O


Clinical	B-O
equivalence	I-O
(	I-O
noninferiority	I-O
)	I-O
of	O
the	O
FemCap	B-I
compared	O
with	O
the	O
diaphragm	O
,	O
as	O
defined	O
in	O
this	O
study	O
,	O
would	O
mean	O
that	O
the	O
true	B-O
risk	I-O
of	I-O
pregnancy	I-O
among	O
FemCap	B-I
users	O
was	O
no	O
more	O
than	O
1.73	O
times	O
the	O
pregnancy	B-O
risk	I-O
of	O
diaphragm	B-I
users	O
.	O


Because	O
the	O
observed	O
upper	O
95	O
%	O
confidence	O
limit	O
(	O
and	O
even	O
the	O
point	O
estimate	O
)	O
exceeded	O
1.73	O
,	O
the	O
probability	B-O
of	I-O
pregnancy	I-O
among	I-O
FemCap	I-O
users	O
,	O
compared	O
with	O
that	O
among	O
diaphragm	B-I
users	O
,	O
did	O
not	O
meet	O
the	O
definition	O
of	O
clinical	B-O
equivalence	I-O
used	O
in	O
this	O
study	O
.	O


The	O
FemCap	B-I
was	O
believed	O
to	O
be	O
safe	B-O
and	O
was	O
associated	O
with	O
significantly	O
fewer	O
urinary	B-O
tract	I-O
infections	I-O
.	I-O


More	O
women	B-P
reported	O
problems	O
with	O
the	O
FemCap	B-I
with	O
regard	O
to	O
insertion	B-O
,	I-O
dislodgement	I-O
,	I-O
and	I-O
especially	I-O
removal	I-O
,	O
although	O
their	O
general	O
assessments	O
were	O
positive	O
.	O


The	O
two	O
devices	O
were	O
comparable	O
with	O
regard	O
to	O
safety	B-O
and	I-O
acceptability	I-O
,	O
but	O
a	O
6-point	O
difference	O
in	O
the	O
true	O
6-month	B-O
pregnancy	I-O
probabilities	I-O
of	O
the	O
two	O
devices	O
could	O
not	O
be	O
ruled	O
out	O
.	O


Further	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
design	O
modifications	O
can	O
simplify	O
insertion	O
and	O
removal	O
.	O


Double-blind	O
efficacy	O
study	B-P
of	I-P
selenium	I-I
sulfide	I-I
in	I-P
tinea	I-P
versicolor	I-P
.	I-P


Selenium	B-I
sulfide	I-I
(	I-I
2.5	I-I
%	I-I
)	I-I
lotion	I-I
applied	O
daily	O
for	O
10	O
minutes	O
for	O
7	O
consecutive	O
days	O
was	O
found	O
to	O
be	O
an	O
effective	O
therapeutic	O
agent	O
,	O
significantly	O
superior	O
to	O
the	O
vehicle	O
,	O
in	O
a	O
double-blind	O
study	O
in	O
the	O
treatment	O
of	O
tinea	B-P
versicolor	I-P
.	I-P


Mild	B-O
transitory	I-O
contact	I-O
dermatitis	I-O
of	O
the	O
primary	O
irritant	O
type	O
occurred	O
in	O
all	O
the	O
treatment	B-P
groups	I-P
and	O
was	O
apparently	O
due	O
to	O
the	O
detergent	O
base	O
.	O


Peripheral	O
arterial	O
disease	O
:	O
therapeutic	O
confidence	O
of	O
CT	B-I
versus	I-I
digital	I-I
subtraction	I-I
angiography	I-I
and	O
effects	O
on	O
additional	O
imaging	O
recommendations	O
.	O


PURPOSE	O
To	O
compare	O
multi-detector	B-I
row	I-I
computed	I-I
tomographic	I-I
(	I-I
CT	I-I
)	I-I
angiography	I-I
and	I-I
digital	I-I
subtraction	I-I
angiography	I-I
(	I-I
DSA	I-I
)	I-I
prior	O
to	O
revascularization	B-I
in	O
patients	B-P
with	I-P
symptomatic	I-P
peripheral	I-P
arterial	I-P
disease	I-P
for	O
the	O
purpose	O
of	O
assessing	O
recommendations	O
for	O
additional	O
imaging	O
and	O
physician	O
confidence	O
ratings	O
for	O
chosen	O
therapy	O
.	O


MATERIALS	O
AND	O
METHODS	O
In	O
a	O
randomized	O
controlled	O
trial	O
,	O
73	B-P
patients	I-P
were	I-P
assigned	I-P
to	I-P
CT	I-I
angiography	I-I
,	I-P
and	I-P
72	I-P
were	I-P
assigned	I-P
to	I-P
DSA	I-I
.	I-I


Physician	B-O
confidence	I-O
in	I-O
the	I-O
treatment	I-O
decision	I-O
was	O
measured	O
as	O
a	O
continuous	O
outcome	O
on	O
a	O
scale	O
of	O
0-10	O
(	O
uncertain	O
to	O
certain	O
)	O
and	O
as	O
a	O
dichotomous	B-O
outcome	I-O
(	O
further	O
imaging	O
recommended	O
,	O
yes	O
or	O
no	O
)	O
.	O


Mean	B-O
confidence	I-O
scores	I-O
and	O
additional	B-O
imaging	I-O
recommendations	I-O
were	O
compared	O
between	O
CT	B-I
and	I-I
DSA	I-I
groups	O
in	O
an	O
intention-to-diagnose-and-treat	O
analysis	O
.	O


To	O
detect	O
trends	O
in	O
confidence	O
,	O
confidence	O
scores	O
were	O
plotted	O
over	O
time	O
,	O
and	O
multiple	O
linear	O
regression	O
analysis	O
was	O
performed	O
.	O


To	O
detect	O
trends	O
in	O
additional	B-O
imaging	I-O
recommendations	I-O
,	O
logistic	O
regression	O
analysis	O
was	O
used	O
.	O


Data	O
from	O
eligible	O
nonrandomized	O
patients	O
were	O
analyzed	O
separately	O
.	O


RESULTS	O
No	B-O
statistically	I-O
significant	I-O
difference	I-O
in	O
baseline	O
characteristics	O
between	O
randomized	O
groups	O
was	O
found	O
.	O


CT	B-I
had	O
a	O
lower	B-O
confidence	I-O
score	I-O
than	O
did	O
DSA	B-I
(	O
7.2	O
vs	O
8.2	O
,	O
P	O
<	O
.001	O
)	O
.	O


Further	O
imaging	O
was	O
recommended	O
more	O
often	O
after	O
CT	B-I
(	O
25	O
of	O
71	O
patients	O
,	O
35	O
%	O
)	O
than	O
after	O
DSA	B-I
(	O
nine	O
of	O
66	O
patients	O
,	O
14	O
%	O
;	O
P	O
=	O
.003	O
)	O
.	O


Analysis	O
of	O
trends	O
demonstrated	O
increasing	O
(	O
but	O
not	O
statistically	O
significant	O
)	O
confidence	B-O
in	O
CT	B-I
and	O
stable	O
confidence	B-O
in	O
DSA	B-I
.	I-I


No	B-O
significant	I-O
difference	I-O
was	O
found	O
in	O
baseline	O
characteristics	O
between	O
randomized	O
and	O
nonrandomized	O
patients	O
.	O


Among	O
nonrandomized	O
patients	O
,	O
no	O
significant	O
difference	O
in	O
mean	B-O
confidence	I-O
score	I-O
(	O
8.2	O
vs	O
8.3	O
,	O
P	O
=	O
.26	O
)	O
was	O
found	O
between	O
CT	B-I
(	O
n	O
=	O
24	O
)	O
and	O
DSA	B-I
(	O
n	O
=	O
26	O
)	O
.	O


CONCLUSION	O
With	O
CT	B-I
angiography	I-I
,	O
physician	O
confidence	O
decreases	O
with	O
an	O
associated	O
increase	O
in	O
additional	O
imaging	O
prior	O
to	O
revascularization	O
in	O
patients	B-P
with	I-P
symptomatic	I-P
peripheral	I-P
arterial	I-P
disease	I-P
.	I-P


Given	O
that	O
CT	B-I
is	O
less	O
invasive	O
than	O
DSA	B-I
,	O
results	O
suggest	O
that	O
CT	B-I
may	O
replace	O
DSA	B-I
in	O
selected	O
cases	O
.	O


A	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
oral	B-I
human	I-I
immunoglobulin	I-I
for	O
gastrointestinal	B-P
dysfunction	I-P
in	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
.	I-P


Controversy	O
exists	O
regarding	O
the	O
extent	O
and	O
possible	O
causal	O
relationship	O
between	O
gastrointestinal	O
symptoms	O
and	O
autism	O
.	O


A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
parallel	O
groups	O
,	O
dose-ranging	O
study	O
of	O
oral	B-I
,	I-I
human	I-I
immunoglobulin	I-I
(	I-I
IGOH	I-I
140	O
,	O
420	O
,	O
or	O
840	O
mg/day	O
)	O
was	O
utilized	O
with	O
125	B-P
children	I-P
(	I-P
ages	I-P
2-17	I-P
years	I-P
)	I-P
with	I-P
autism	I-P
and	I-P
persistent	I-P
GI	I-P
symptoms	I-P
.	I-P


Endpoint	O
analysis	O
revealed	O
no	O
significant	O
differences	O
across	O
treatment	O
groups	O
on	O
a	O
modified	O
global	B-O
improvement	I-O
scale	I-O
(	O
validated	O
in	O
irritable	B-O
bowel	I-O
syndrome	I-O
studies	I-O
)	I-O
,	I-O
number	I-O
of	I-O
daily	I-O
bowel	I-O
movements	I-O
,	I-O
days	I-O
of	I-O
constipation	I-O
,	I-O
or	I-O
severity	I-O
of	I-O
problem	I-O
behaviors	I-O
.	I-O


IGOH	B-I
was	O
well-tolerated	B-O
;	I-O
there	O
were	O
no	O
serious	B-O
adverse	I-O
events	I-O
.	I-O


This	O
study	O
demonstrates	O
the	O
importance	O
of	O
conducting	O
rigorous	O
trials	O
in	O
children	B-P
with	I-P
autism	I-P
and	O
casts	O
doubt	O
on	O
one	O
GI	O
mechanism	O
presumed	O
to	O
exert	O
etiological	O
and/or	O
symptomatic	O
effects	O
in	O
this	O
population	O
.	O


Irrigation	B-P
with	I-P
bupivacaine	I-I
at	I-P
the	I-P
surgical	I-P
bed	I-P
for	I-P
postoperative	I-O
pain	I-O
relief	I-O
after	I-P
laparoscopic	I-P
cholecystectomy	I-P
.	I-P


PURPOSE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	B-O
of	O
bupivacaine	B-I
irrigated	O
at	O
the	O
surgical	O
bed	O
on	O
postoperative	B-O
pain	I-O
relief	I-O
in	O
laparoscopic	B-P
cholecystectomy	I-P
patients	I-P
.	I-P


METHODS	O
This	O
study	O
included	O
60	B-P
patients	I-P
undergoing	I-P
elective	I-P
laparoscopic	I-P
cholecystectomy	I-P
who	I-P
were	I-P
prospectively	I-P
randomized	I-P
into	I-P
2	I-P
groups	I-P
.	I-P


The	O
placebo	B-I
group	O
(	O
n=30	O
)	O
received	O
20cc	B-I
saline	I-I
without	I-I
bupivacaine	I-I
,	O
installed	O
into	O
the	O
gallbladder	O
bed	O
.	O


The	O
bupivacaine	B-I
group	O
(	O
n=30	O
)	O
received	O
20cc	O
of	O
0.5	B-I
%	I-I
bupivacaine	I-I
in	O
at	O
the	O
same	O
surgical	O
site	O
.	O


Pain	B-O
was	O
assessed	O
at	O
0	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
hours	O
by	O
using	O
a	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
.	O


RESULTS	O
A	O
significant	O
difference	O
(	O
P=.018	O
)	O
was	O
observed	O
in	O
pain	B-O
levels	I-O
between	O
both	O
groups	O
at	O
6	O
hours	O
postoperatively	O
.	O


The	O
average	B-O
analgesic	I-O
requirement	I-O
was	O
lower	O
in	O
the	O
bupivacaine	B-I
group	O
,	O
but	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O


CONCLUSIONS	O
In	O
our	O
study	O
,	O
the	O
use	O
of	O
bupivacaine	B-I
irrigated	O
over	O
the	O
surgical	O
bed	O
was	O
an	O
effective	O
method	O
for	O
reducing	O
pain	B-O
during	O
the	O
first	O
postoperative	O
hours	O
after	O
laparoscopic	O
cholecystectomy	O
.	O


Safety	O
and	O
immunogenicity	O
of	O
an	O
oral	B-I
,	I-I
inactivated	I-I
,	I-I
whole-cell	I-I
vaccine	I-I
for	I-I
Shigella	I-I
sonnei	I-I
:	I-I
preclinical	O
studies	O
and	O
a	O
Phase	O
I	O
trial	O
.	O


Orally	O
delivered	O
,	O
inactivated	O
whole-cell	O
vaccines	B-I
are	O
safe	O
methods	O
of	O
inducing	O
local	O
and	O
systemic	O
immunity	O
.	O


To	O
increase	O
surface	B-O
proteins	I-O
associated	O
with	O
adherence	O
and	O
invasion	O
,	O
Shigella	O
sonnei	O
were	O
grown	O
in	O
BHI	O
broth	O
containing	O
deoxycholate	O
.	O


A	O
whole-cell	B-I
vaccine	I-I
(	I-I
SsWC	I-I
)	I-I
was	O
then	O
produced	O
by	O
formalin	O
inactivation	O
.	O


In	O
pre-clinical	O
studies	O
,	O
the	O
SsWC	B-I
vaccine	I-I
was	O
immunogenic	O
and	O
protected	O
against	O
S.	O
sonnei-induced	O
keratoconjunctivitis	O
in	O
the	O
guinea	B-P
pig	I-P
model	I-P
.	I-P


In	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
Phase	B-P
I	I-P
study	I-P
,	I-P
10	I-P
evaluable	I-P
subjects	I-P
received	O
either	O
three	O
doses	O
of	O
SsWC	B-I
on	O
Days	O
0	O
,	O
14	O
,	O
and	O
28	O
(	O
N	O
=	O
3	O
)	O
;	O
five	O
doses	O
of	O
SsWC	B-I
on	O
Days	O
0	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
28	O
(	O
N	O
=	O
4	O
)	O
;	O
or	B-I
placebo	I-I
(	O
N	O
=	O
3	O
)	O
.	O


Each	O
dose	O
contained	O
2.0	O
x	O
10	O
(	O
10	O
)	O
inactivated	O
cells	O
.	O


Serum	B-O
and	I-O
fecal	I-O
antibodies	I-O
against	I-O
SsWC	I-O
,	I-O
LPS	I-O
,	I-O
and	I-O
IpaC	I-O
were	O
measured	O
by	O
ELISA	O
.	O


A	O
>	O
or	O
=	O
4-fold	O
increase	O
in	O
titer	O
was	O
considered	O
significant	O
.	O


Both	O
SsWC	B-I
dosing	O
regimens	O
were	O
well	O
tolerated	B-O
.	I-O


No	O
fever	B-O
or	I-O
severe	I-O
gastrointestinal	I-O
symptoms	I-O
were	O
noted	O
by	O
any	O
of	O
the	O
vaccinated	O
subjects	O
.	O


Antibody	B-O
responses	I-O
were	O
similar	O
in	O
the	O
two	O
dosing	O
groups	O
.	O


Serum	B-O
IgG	I-O
or	I-O
IgA	I-O
responses	I-O
to	O
SsWC	B-I
were	O
seen	O
in	O
six	O
of	O
seven	O
vaccinees	O
(	O
86	O
%	O
)	O
,	O
to	O
LPS	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
,	O
and	O
to	O
IpaC	O
in	O
five	O
of	O
seven	O
(	O
61	O
%	O
)	O
.	O


Fecal	B-O
IgA	I-O
responses	I-O
to	O
these	O
three	O
antigens	O
developed	O
in	O
five	O
of	O
five	O
,	O
three	O
of	O
five	O
,	O
and	O
three	O
of	O
five	O
subjects	O
,	O
respectively	O
.	O


Among	O
the	O
seven	O
vaccinees	O
,	O
geometric	O
mean	O
rises	O
in	O
serum	B-O
IgA	I-O
levels	I-O
to	O
all	O
three	O
immunogens	O
were	O
significant	O
;	O
IgG	B-O
increases	I-O
trended	O
toward	O
significance	O
(	O
paired	O
one-tailed	O
t-test	O
)	O
.	O


We	O
conclude	O
that	O
SsWC	B-I
was	O
immunogenic	B-O
and	O
protective	B-O
in	O
animal	O
studies	O
and	O
well	O
tolerated	B-O
and	O
immunogenic	B-O
in	O
a	O
Phase	O
I	O
trial	O
.	O


Salmeterol	B-I
versus	O
slow-release	O
theophylline	B-I
combined	O
with	O
ketotifen	B-I
in	O
nocturnal	B-P
asthma	I-P
:	I-P
a	O
multicentre	B-P
trial	O
.	O


French	B-P
Multicentre	I-P
Study	I-P
Group	I-P
.	I-P


We	O
wished	O
to	O
assess	O
the	O
efficacy	B-O
of	O
inhaled	O
salmeterol	B-I
(	O
SML	O
;	O
50	O
micrograms	O
b.i.d	O
.	O


)	O
compared	O
to	O
a	O
combination	O
of	O
slow-release	O
theophylline	B-I
and	I-I
ketotifen	I-I
p.o	O
.	O


(	O
TK	O
;	O
T	O
300	O
mg+K	O
1	O
mg	O
b.i.d	O
.	O


)	O
for	O
the	O
treatment	O
of	O
nocturnal	O
asthma	O
.	O


Ninety	B-P
six	I-P
patients	I-P
with	I-P
nocturnal	I-P
asthma	I-P
,	I-P
(	I-P
forced	I-P
expiratory	I-P
volume	I-P
in	I-P
one	I-P
second	I-P
(	I-P
FEV1	I-P
)	I-P
60-90	I-P
%	I-P
of	I-P
predicted	I-P
value	I-P
,	I-P
reversibility	I-P
>	I-P
or	I-P
=	I-P
15	I-P
%	I-P
,	I-P
at	I-P
least	I-P
two	I-P
nocturnal	I-P
awakenings	I-P
per	I-P
week	I-P
)	I-P
were	O
eligible	O
for	O
a	O
multicentre	B-P
,	O
double-blind	O
,	O
double-dummy	O
cross-over	O
study	O
(	O
14-day	O
run-in	O
,	O
two	O
successive	O
28-day	O
treatment	O
periods	O
)	O
.	O


Efficacy	B-O
was	I-O
assessed	I-O
as	I-O
success/failure	I-O
,	I-O
success	I-O
being	O
defined	O
as	O
the	O
complete	O
disappearance	O
of	O
nocturnal	O
symptoms/awakening	O
during	O
the	O
last	O
week	O
of	O
each	O
treatment	O
period	O
.	O


There	O
was	O
a	O
statistically	B-O
significant	I-O
difference	I-O
between	O
SML	O
and	O
TK	O
for	O
this	O
criterion	O
:	O
46	O
%	O
and	O
39	O
%	O
success	O
with	O
SML	O
during	O
periods	O
I	O
(	O
first	O
28-day	O
period	O
)	O
and	O
II	O
(	O
following	O
the	O
cross-over	O
)	O
,	O
compared	O
to	O
only	O
15	O
%	O
and	O
26	O
%	O
with	O
TK	O
,	O
respectively	O
(	O
p	O
<	O
0.01	O
)	O
.	O


SML	O
was	O
also	O
significantly	O
better	O
for	O
the	O
other	B-O
criteria	I-O
(	I-O
lung	I-O
function	I-O
,	I-O
rescue	I-O
salbutamol	I-O
intake	I-O
during	I-O
day	I-O
and	I-O
night	I-O
)	I-O
.	I-O


Side-effects	B-O
were	O
five	O
times	O
less	O
frequent	O
in	O
SML-treated	O
patients	O
(	O
p	O
<	O
0.004	O
)	O
.	O


Efficacy	B-O
and	I-O
tolerance	I-O
of	O
SML	O
were	O
obviously	O
far	O
better	O
than	O
those	O
of	O
TK	O
in	O
patients	B-P
with	I-P
nocturnal	I-P
asthma	I-P
.	I-P


Impact	O
of	O
angiotensin-converting	O
enzyme	O
gene	O
polymorphism	O
on	O
neurohormonal	B-O
responses	I-O
to	O
high-	O
versus	O
low-dose	O
enalapril	O
in	O
advanced	B-P
heart	I-P
failure	I-P
.	I-P


BACKGROUND	O
The	O
impact	O
of	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
polymorphism	O
on	O
neurohormonal	O
dose	O
response	O
to	O
ACE	B-I
inhibitor	O
therapy	O
is	O
unclear	O
.	O


METHODS	O
ACE	O
Insertion	O
(	O
I	O
)	O
or	O
Deletion	O
(	O
D	O
)	O
genotype	O
was	O
determined	O
in	O
74	B-P
patients	I-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
who	O
were	O
randomly	B-I
assigned	I-I
to	I-I
receive	I-I
either	I-I
high-dose	I-I
or	I-I
low-dose	I-I
enalapril	I-I
over	I-I
a	I-I
period	I-I
of	I-I
6	I-I
months	I-I
.	I-I


Monthly	B-I
pre-enalapril	I-O
and	I-O
post-enalapril	I-O
neurohormone	I-O
levels	I-O
(	I-O
serum	I-O
ACE	I-O
activity	I-O
(	I-O
sACE	I-O
)	I-O
,	I-O
plasma	I-O
angiotensin	I-O
II	I-O
(	I-O
A-II	I-O
)	I-O
,	I-O
plasma	I-O
renin	I-O
activity	I-O
(	I-O
PRA	I-O
)	I-O
,	I-O
and	I-O
serum	I-O
aldosterone	I-O
(	I-O
ALDO	I-O
)	I-O
were	O
compared	O
between	O
genotype	O
subgroups	O
and	O
between	O
patients	O
who	O
received	O
high-	O
or	O
low-dose	O
enalapril	B-I
within	O
each	O
genotype	O
subgroup	O
.	O


RESULTS	O
At	O
baseline	O
,	O
predose/postdose	B-O
sACE	I-O
and	I-O
postdose	I-O
PRA	I-O
were	O
significantly	O
higher	O
in	O
the	O
DD	B-P
genotype	I-P
.	I-P


At	O
6-month	O
follow-up	O
,	O
postdose	B-O
sACE	I-O
was	O
reduced	O
in	O
a	O
dose-dependent	O
fashion	O
in	O
all	O
three	O
genotypes	O
(	O
P	O
<	O
.05	O
)	O
.	O


However	O
,	O
predose	B-O
and	I-O
postdose	I-O
ALDO	I-O
and	I-O
A-II	I-O
levels	I-O
did	O
not	O
differ	O
between	O
each	O
genotype	O
subgroup	O
at	O
baseline	O
or	O
by	O
enalapril	O
dose	O
within	O
each	O
genotype	O
subgroup	O
.	O


ALDO	B-O
escape	I-O
and	I-O
A-II	I-O
reactivation	I-O
were	O
not	O
affected	O
by	O
ACE	B-P
genotype	I-P
or	O
enalapril	O
dosage	O
.	O


CONCLUSIONS	O
Predose	B-O
sACE	I-O
were	O
consistently	O
higher	O
in	O
the	O
DD	O
genotype	O
when	O
compared	O
with	O
ID	B-P
or	I-P
II	I-P
subgroups	I-P
.	I-P


Despite	O
a	O
dose-dependent	O
suppression	B-O
of	I-O
sACE	I-O
,	O
there	O
were	O
no	O
observed	O
statistically	O
significant	O
differences	O
in	O
ALDO	B-O
and	I-O
A-II	I-O
suppression	I-O
or	O
escape	O
with	O
escalating	O
doses	O
of	O
enalapril	O
within	O
each	O
subgroup	O
.	O


[	O
Psychoexperimental	O
studies	O
on	O
the	O
effect	O
of	O
a	O
valepotriate	B-I
combination	I-I
as	I-P
well	I-P
as	I-P
the	I-P
combined	I-P
effects	I-P
of	I-P
valtratum	I-I
and	I-I
alcohol	I-I
]	I-I
.	O


Comorbidity	B-O
,	I-O
age	I-O
and	O
overall	B-O
survival	I-O
in	O
cetuximab-treated	B-I
patients	I-P
with	I-P
advanced	I-P
colorectal	I-P
cancer	I-P
(	I-P
ACRC	I-P
)	I-P
--	I-P
results	I-P
from	O
NCIC	O
CTG	O
CO.17	O
:	O
a	O
phase	O
III	O
trial	O
of	O
cetuximab	B-I
versus	O
best	B-I
supportive	I-I
care	I-I
.	I-I


BACKGROUND	O
the	O
interplay	O
between	O
comorbidity	B-O
,	I-O
age	I-O
and	O
performance	B-O
status	I-O
(	I-O
PS	I-O
)	I-O
as	O
predictors	O
of	O
outcome	O
in	O
advanced	O
colorectal	O
cancer	O
(	O
ACRC	O
)	O
is	O
poorly	O
understood	O
.	O


We	O
examined	O
these	O
factors	O
as	O
predictors	O
of	O
treatment	O
toxicity	B-O
and	O
outcome	O
in	O
cetuximab-treated	B-I
patients	I-P
with	I-P
ACRC	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
comorbidity	O
was	O
independently	O
evaluated	O
using	O
the	O
Charlson	B-O
Comorbidity	I-O
Index	I-O
(	I-O
CCI	I-O
)	I-O
,	O
a	O
validated	O
measure	O
of	O
comorbidity	B-O
based	O
on	O
the	O
presence	O
of	O
medical	O
conditions	O
weighted	O
according	O
to	O
their	O
effect	O
on	O
mortality	O
.	O


CCI	B-O
score	I-O
was	O
correlated	O
with	O
clinical	O
and	O
outcome	O
data	O
.	O


RESULTS	O
five	B-P
hundred	I-P
and	I-P
seventy-two	I-P
patients	I-P
were	I-P
included	I-P
;	I-P
41	I-P
%	I-P
were	I-P
≥	I-P
65	I-P
years	I-P
and	I-P
25	I-P
%	I-P
had	I-P
comorbidities	I-P
at	I-P
randomization	I-P
.	O


In	O
multivariate	O
analysis	O
(	O
MVA	O
)	O
of	O
all	O
covariates	O
,	O
only	O
older	O
age	O
was	O
associated	O
with	O
greater	O
comorbidity	O
(	O
P	O
=	O
0.008	B-O
)	I-O
.	I-O


Overall	B-O
survival	I-O
(	I-O
OS	I-O
)	I-O
was	O
significantly	O
better	O
for	O
patients	O
with	O
greater	O
comorbidity	O
in	O
univariate	O
analysis	O
(	O
P	O
=	O
0.047	O
)	O
.	O


Conversely	O
,	O
better	B-O
PS	I-O
was	O
associated	O
with	O
better	B-O
OS	I-O
in	O
MVA	O
(	O
hazard	O
ratio	O
1.92	O
for	O
PS	O
=	O
2	O
versus	O
PS	O
=	O
0	O
,	O
P	O
<	O
0.0001	O
)	O
.	O


Age	O
was	O
not	O
associated	O
with	B-O
OS	I-O
(	O
P	O
=	O
0.13	B-P
)	I-P
.	I-P


Elderly	B-P
patients	I-P
had	O
significantly	O
less	B-O
grade	I-O
≥	I-O
3	I-O
vomiting	I-O
(	O
P	O
=	O
0.034	O
)	O
but	O
more	B-O
dyspnea	I-O
(	O
P	O
=	O
0.005	B-P
)	I-P
.	I-P


Patients	B-P
with	I-P
greater	I-P
comorbidity	I-P
had	O
significantly	O
less	B-O
grade	I-O
≥	I-O
3	I-O
vomiting	I-O
(	O
P	O
=	O
0.002	O
)	O
but	B-O
more	I-O
non-neutropenic	I-O
fever	O
(	O
P	O
=	O
0.005	O
)	O
.	O


CONCLUSION	B-O
better	I-O
PS	O
was	O
associated	O
with	O
improved	B-O
OS	I-P
.	I-P


For	B-P
patients	I-P
with	I-O
good	O
PS	O
,	O
restricting	B-I
cetuximab	I-I
use	O
in	O
the	O
setting	O
of	O
significant	O
comorbidity	O
does	O
not	O
appear	O
justified	O
.	O


Levosulpiride	B-I
in	O
functional	B-P
dyspepsia	I-P
:	I-P
a	O
multicentric	O
,	O
double-blind	O
,	O
controlled	O
trial	O
.	O


Abnormalities	O
in	O
gastrointestinal	O
motility	O
have	O
been	O
reported	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	B-P
with	I-P
functional	I-P
dyspepsia	I-P
,	I-P
supporting	I-P
the	I-P
use	I-P
of	I-P
prokinetic	I-I
drugs	I-I
for	I-P
treatment	I-P
of	I-P
dyspeptic	I-P
symptoms	I-P
.	I-P


To	O
evaluate	O
efficacy	B-O
and	I-O
safety	I-O
of	O
levosulpiride	B-I
in	O
short-term	O
treatment	O
,	O
1298	B-P
patients	I-P
were	I-P
enrolled	I-P
in	I-P
a	I-P
double-blind	I-P
multicentric	I-P
study	I-P
carried	I-P
out	I-P
in	I-P
45	I-P
Italian	I-P
Gastroenterology	I-P
Departments	I-P
.	I-P


Patients	O
were	O
randomly	O
assigned	O
to	O
either	O
levosulpiride	B-I
(	O
25	O
mg	O
tid	O
)	O
,	O
domperidone	B-I
(	O
10	O
mg	O
tid	O
)	O
,	O
metoclopramide	B-I
(	O
10	O
mg	O
tid	O
)	O
or	O
placebo	B-I
(	O
1	O
tablet	O
tid	O
)	O
for	O
4	O
weeks	O
.	O


Patients	B-P
were	I-P
selected	I-P
on	I-P
the	I-P
basis	I-P
of	I-P
:	I-P
a	I-P
)	I-P
occurrence	I-P
in	I-P
the	I-P
last	I-P
4	I-P
weeks	I-P
of	I-P
at	I-P
least	I-P
5/10	I-P
selected	I-P
symptoms	I-P
(	I-O
anorexia	I-O
,	I-O
nausea	I-O
,	I-O
vomiting	I-O
,	I-O
upper	I-O
abdominal	I-O
pain	I-O
,	I-O
postprandial	I-O
bloating	I-O
,	I-O
abdominal	I-O
fullness	I-O
,	I-O
early	I-O
satiety	I-O
,	I-O
belching	I-O
,	I-O
heartburn	I-O
,	I-O
regurgitation	I-O
)	I-O
,	I-P
severity	I-P
of	I-P
which	I-P
should	I-P
reach/exceed	I-P
a	I-P
total	I-P
score	I-P
of	I-P
8	I-P
,	I-P
as	I-P
assessed	I-P
by	I-P
a	I-P
specific	I-P
scale	I-P
ranging	I-P
from	I-P
0	I-P
(	I-P
absent	I-P
)	I-P
to	I-P
3	I-P
(	I-P
severe	I-P
)	I-P
;	I-P
b	I-P
)	I-P
normal	I-P
results	I-P
of	I-P
routine	I-P
biochemical	I-P
,	I-P
ultrasound	I-P
and	I-P
endoscopic	I-P
examinations	I-P
.	I-P


In	O
addition	O
,	O
each	O
patient	O
subjectively	O
evaluated	O
efficacy	B-O
of	O
treatment	O
by	O
a	O
visual	O
analogue	O
scale	O
.	O


Significant	O
improvement	O
was	O
recorded	O
for	O
all	O
symptoms	O
at	O
days	O
10	O
and	O
28	O
in	O
all	O
groups	O
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
levosulpiride	B-I
was	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
superior	O
to	O
domperidone	B-I
,	I-I
metoclopramide	I-I
and	O
placebo	B-I
both	O
in	O
the	O
overall	O
clinical	O
improvement	O
scale	O
as	O
well	O
as	O
in	O
a	O
subgroup	O
of	O
symptoms	O
(	B-O
postprandial	I-O
bloating	I-O
,	I-O
epigastric	I-O
pain	I-O
,	I-O
heartburn	I-O
)	I-O
.	O


Active	B-I
treatments	I-I
and	O
placebo	B-I
were	O
comparable	O
as	O
far	O
as	O
concerns	O
occurrence	O
of	O
side-effects	O
(	O
12-20	O
%	O
)	O
including	O
galactorrhoea	B-O
,	I-O
breast	I-O
tenderness	I-O
and	I-O
menstrual	I-O
changes	I-O
.	I-O


Isoniazid	B-I
prophylaxis	O
for	O
tuberculosis	B-P
in	I-P
HIV	I-P
infection	I-P
:	I-P
a	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O


OBJECTIVES	O
To	O
evaluate	O
the	O
efficacy	O
of	O
isoniazid	B-I
for	O
the	O
prevention	O
of	O
tuberculosis	O
in	O
tuberculin	B-P
skin	I-P
test-positive	I-P
and	I-P
negative	I-P
individuals	I-P
with	I-P
HIV	I-P
infection	I-P
.	I-P


DESIGN	O
Meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O


SETTING	O
Seven	B-P
trials	I-P
from	I-P
Mexico	I-P
,	I-P
Haiti	I-P
,	I-P
the	I-P
United	I-P
States	I-P
,	I-P
Zambia	I-P
,	I-P
Uganda	I-P
and	I-P
Kenya	I-P
.	I-P


PATIENTS	O
Individuals	B-P
free	I-P
from	I-P
tuberculosis	I-P
,	I-P
2367	I-P
persons	I-P
in	I-P
the	I-P
intervention	I-P
and	I-P
2162	I-P
in	I-P
the	I-P
control	I-P
groups	I-P
.	I-P


INTERVENTION	O
Comparison	B-O
of	I-O
isoniazid	I-O
with	I-O
placebo	I-O
or	I-O
no	I-O
prophylaxis	I-O
.	I-O


METHODS	O
A	O
systematic	O
search	O
of	O
the	O
literature	O
was	O
carried	O
out	O
from	O
1985	O
to	O
October	O
1997	O
for	O
randomized	O
controlled	O
trials	O
of	O
isoniazid	B-I
prophylaxis	I-P
in	I-P
HIV-infected	I-P
persons	I-P
.	I-P


Two	O
reviewers	O
evaluated	O
the	O
relevance	O
of	O
each	O
candidate	O
study	O
and	O
the	O
validity	O
of	O
eligible	O
trials	O
.	O


Studies	O
were	O
pooled	O
using	O
a	O
random	O
effect	O
model	O
,	O
conducting	O
secondary	O
analyses	O
for	O
tuberculin	O
skin	O
test-positive	O
and	O
negative	O
persons	O
.	O


RESULTS	O
Mean	O
follow-up	O
in	O
trials	O
varied	O
between	O
0.4	O
and	O
3.2	O
years	O
.	O


Pooling	O
all	O
seven	O
trials	O
,	O
a	O
risk	B-O
ratio	I-O
was	O
found	O
for	O
persons	O
treated	O
with	O
isoniazid	B-I
for	O
developing	O
tuberculosis	O
of	O
0.58	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.43-0.80	O
]	O
and	O
0.94	O
(	O
95	O
%	O
CI	O
,	O
0.83-1.07	O
)	O
for	O
death	B-O
.	I-O


In	O
groups	O
of	O
tuberculin	O
skin	O
test-positive	O
and	O
negative	O
persons	O
,	O
the	O
risk	B-O
ratio	I-O
of	I-O
tuberculosis	I-O
was	O
0.40	O
(	O
95	O
%	O
CI	O
,	O
0.24-0.65	O
)	O
and	O
0.84	O
(	O
95	O
%	O
CI	O
,	O
0.54-1.30	O
)	O
,	O
respectively	O
,	O
and	O
the	O
difference	B-O
in	I-O
the	I-O
effectiveness	I-O
of	O
isoniazid	B-I
versus	O
placebo	B-I
between	O
these	O
groups	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
0.03	O
,	O
for	O
the	O
difference	O
of	O
summary	O
estimates	O
)	O
.	O


Consistency	O
of	O
results	O
was	O
found	O
across	O
trials	O
(	O
P	O
>	O
0.10	O
,	O
heterogeneity	O
value	O
)	O
for	O
all	O
comparisons	O
.	O


CONCLUSIONS	O
Prophylaxis	O
with	O
isoniazid	B-I
reduces	O
the	O
risk	O
of	O
tuberculosis	O
in	O
persons	B-P
with	I-P
HIV	I-P
infection	I-P
.	I-P


The	O
effect	O
is	O
restricted	B-P
to	I-P
tuberculin	I-P
skin	I-P
test-positive	I-P
persons	I-P
.	I-P


[	O
Dose-effect	O
relationship	O
of	O
isosorbide	B-I
dinitrate	I-I
in	O
the	O
treatment	O
of	O
angina	O
pectoris	O
(	O
author	O
's	O
transl	O
)	O
]	O
.	O


Fifteen	B-P
males	I-P
with	I-P
angiographic	I-P
evidence	I-P
of	I-P
coronary	I-P
heart	I-P
disease	I-P
and	I-P
stable	I-P
,	I-P
exercise-induced	I-P
angina	I-P
pectoris	I-P
were	O
given	O
placebo	B-I
or	I-I
isosorbide	I-I
dinitrate	I-I
(	I-I
ISDN	I-I
)	I-I
in	O
a	O
dialy	O
dose	O
of	O
30	O
mg	O
,	O
120	O
mg	O
,	O
240	O
mg	O
and	O
480	O
mg	O
in	O
a	O
randomized	O
single-blind	O
trial	O
.	O


The	O
daily	O
doses	O
were	O
given	O
as	O
a	O
single	O
oral	O
dose	O
of	O
5	O
mg	O
,	O
20	O
mg	O
,	O
40	O
mg	O
and	O
80	O
mg	O
tablets	O
.	O


Each	O
dose	O
and	O
placebo	O
was	O
given	O
for	O
seven	O
days	O
.	O


On	O
the	O
seventh	O
day	O
an	O
exercise	B-O
ECG	I-O
of	O
standardized	O
level	O
and	O
duration	B-O
of	I-O
exercise	I-O
was	O
recorded	O
.	O


The	O
ischaemia	B-O
response	O
in	O
the	O
ECG	O
revealed	O
a	O
dose-dependent	O
reduction	B-O
by	O
28	O
%	O
(	O
5	O
mg	O
ISDN	O
)	O
,	O
43	O
%	O
(	O
20	O
mg	O
)	O
,	O
60	O
%	O
(	O
40	O
mg	O
)	O
and	O
73	O
%	O
(	O
80	O
mg	O
)	O
.	O


The	O
number	B-O
of	I-O
anginal	I-O
attacks	I-O
similarly	O
fell	O
parallel	O
to	O
dose	O
.	O


Plasma	B-O
level	I-O
of	I-O
ISDN	I-O
and	I-O
the	I-O
mononitrates	I-O
,	O
measured	O
one	O
and	O
four	O
hours	O
after	O
drug	O
intake	O
,	O
rose	O
almost	O
linearly	O
in	O
relation	O
to	O
dose	O
.	O


Oral	O
ISDN	O
thus	O
has	O
a	O
dose-dependent	O
effect	O
on	O
the	O
frequency	B-O
of	I-O
angina	I-O
and	I-O
ischaemia	I-O
parameters	I-O
during	O
ergometric	O
exercise	O
.	O


The	O
protracted	O
anti-anginal	B-O
effect	I-O
of	O
ISDN	O
is	O
largely	O
due	O
to	O
its	O
metabolites	O
.	O


At	O
high	O
doses	O
there	O
is	O
presumably	O
an	O
added	O
effect	O
of	O
the	O
high	O
blood	O
level	O
of	O
the	O
basic	O
substance.U	O


Relief	O
of	O
periorbital	O
pain	O
after	O
acute	O
angle	O
closure	O
glaucoma	O
attack	O
by	O
botulinum	B-I
toxin	I-I
type	I-I
A	I-I
.	I-I


PURPOSE	O
To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
botulinum	B-I
toxin	I-I
type	I-I
A	I-I
(	I-I
BoNT-A	I-I
)	I-I
injection	O
in	O
patients	B-P
suffering	I-P
from	I-P
intractable	I-P
periorbital	I-P
pain	I-P
after	I-P
acute	I-P
angle	I-P
closure	I-P
glaucoma	I-P
(	I-P
AACG	I-P
)	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
In	O
this	O
prospective	O
randomized	O
intervention	O
study	O
,	O
19	B-P
patients	I-P
suffering	I-P
from	I-P
periorbital	I-P
pain	I-P
after	I-P
an	I-P
AACG	I-P
attack	I-P
were	O
injected	B-I
with	I-I
BoNT-A	I-I
or	I-I
placebo	I-I
for	O
pain	O
relief	O
.	O


Patients	O
were	O
assessed	O
on	O
days	O
1	O
,	O
2	O
,	O
7	O
,	O
14	O
,	O
30	O
,	O
60	O
,	O
and	O
90	O
.	O


The	O
main	O
outcomes	O
were	O
mean	O
change	O
of	O
visual	O
analog	O
rating	O
scale	O
(	O
VARS	O
)	O
and	O
index	O
scores	O
measured	O
through	O
a	O
quality-of-life	O
questionnaire	O
(	O
EQ-5D	O
)	O
,	O
and	O
changes	O
in	O
the	O
visual	B-O
analog	I-O
scale	I-O
(	O
VAS	O
)	O
,	O
all	O
of	O
which	O
were	O
assessed	O
at	O
each	O
visit	O
.	O


A	O
secondary	O
outcome	O
was	O
the	O
frequency	O
and	O
nature	O
of	O
adverse	O
events	O
and	O
the	O
number	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
as	O
a	O
result	O
.	O


RESULTS	O
In	O
the	O
treatment	O
group	O
(	O
n=10	O
)	O
,	O
the	O
mean	B-O
index	I-O
score	I-O
of	I-O
EQ-5D	I-O
and	I-O
VAS	I-O
changed	O
significantly	O
from	O
the	O
placebo	B-I
group	O
(	O
by	O
0.299	O
and	O
2.61	O
,	O
respectively	O
)	O
from	O
day	O
2	O
(	O
P	O
<	O
0.01	O
)	O
.	O


The	O
VARS	B-O
of	I-O
EQ-5D	I-O
also	O
disclosed	O
significant	O
changes	O
from	O
day	O
2	O
(	O
17	O
,	O
P	O
<	O
0.01	O
)	O
.	O


In	O
addition	O
,	O
efficacy	B-O
was	O
maintained	O
mainly	O
between	O
days	O
2	O
and	O
60	O
but	O
declined	O
slightly	O
by	O
day	O
90	O
.	O


The	O
most	O
frequently	O
reported	O
treatment-related	O
adverse	O
events	O
in	O
the	O
treatment	O
and	O
placebo	O
groups	O
were	O
local	B-O
tenderness	I-O
(	O
21	O
%	O
)	O
,	O
subcutaneous	B-O
hemorrhage	I-O
(	O
10.5	O
%	O
)	O
,	O
and	O
conjunctivitis	B-O
(	O
10.5	O
%	O
)	O
.	O


No	O
severe	B-O
adverse	I-O
events	I-O
were	O
reported	O
during	O
the	O
study	O
or	O
follow-up	O
period	O
.	O


CONCLUSIONS	O
BoNT-A	B-I
is	O
effective	O
and	O
well	O
tolerated	O
for	O
the	O
treatment	O
of	O
periorbital	O
pain	O
after	O
an	O
AACG	O
attack	O
.	O


Its	O
effects	O
may	O
be	O
maintained	O
for	O
3	O
months	O
.	O


Relaxing	B-I
retinotomy	I-I
with	I-I
silicone	I-I
oil	I-I
or	I-I
long-acting	I-I
gas	I-I
in	O
eyes	B-P
with	I-P
severe	I-P
proliferative	I-P
vitreoretinopathy	I-P
.	I-P


Silicone	O
Study	O
Report	O
5	O
.	O


The	O
Silicone	O
Study	O
Group	O
.	O


In	O
the	O
Silicone	O
Study	O
,	O
117	B-P
of	I-P
404	I-P
eyes	I-P
(	I-P
29	I-P
%	I-P
)	I-P
with	I-P
severe	I-P
proliferative	I-P
vitreoretinopathy	I-P
(	I-P
>	I-P
or	I-P
=	I-P
C-3	I-P
,	I-P
full-thickness	I-P
retinal	I-P
folds	I-P
in	I-P
three	I-P
or	I-P
more	I-P
quadrants	I-P
)	I-P
enrolled	O
in	O
the	O
study	O
were	O
treated	O
with	O
vitrectomy	B-I
,	O
underwent	O
a	O
relaxing	B-I
retinotomy	I-I
,	O
and	O
were	O
randomly	O
assigned	O
to	O
treatment	B-I
with	I-I
long-acting	I-I
gas	I-I
or	I-I
silicone	I-I
oil	I-I
.	I-I


Forty-six	B-P
eyes	I-P
(	O
20	O
%	O
)	O
had	O
undergone	O
no	O
previous	O
vitrectomy	O
(	O
group	O
1	O
)	O
;	O
71	O
eyes	O
(	O
42	O
%	O
)	O
had	O
undergone	O
previous	O
vitrectomy	O
(	O
group	O
2	O
)	O
with	O
intraocular	O
gas	O
tamponade	O
(	O
P	O
<	O
.001	O
)	O
.	O


Group	O
1	O
eyes	O
not	O
undergoing	O
retinotomy	O
had	O
better	B-O
anatomic	I-O
(	I-O
six	I-O
months	I-O
)	I-O
and	I-O
visual	I-O
(	I-O
six	I-O
and	I-O
24	I-O
months	I-O
)	I-O
outcomes	I-O
and	I-O
less	I-O
hypotony	I-O
(	O
six	O
months	O
)	O
than	O
eyes	O
that	O
did	O
regardless	O
of	O
tamponade	O
(	O
P	O
<	O
.05	O
)	O
.	O


For	O
eyes	O
undergoing	O
retinotomy	O
,	O
silicone	O
oil	O
decreased	B-O
the	I-O
likelihood	I-O
of	I-O
hypotony	I-O
(	O
six	O
months	O
,	O
P	O
<	O
.05	O
)	O
.	O


These	O
differences	O
were	O
not	O
found	O
in	O
group	O
2	O
eyes	O
.	O


We	O
conclude	O
that	O
eyes	O
undergoing	O
a	O
vitreous	O
operation	O
for	O
the	O
first	O
time	O
for	O
the	O
treatment	O
of	O
proliferative	B-O
vitreoretinopathy	I-O
can	O
in	O
most	O
instances	O
be	O
successfully	O
treated	O
by	O
conventional	O
techniques	O
without	O
the	O
need	O
for	O
relaxing	O
retinotomy	O
.	O


Retinotomy	O
may	O
be	O
required	O
more	O
often	O
in	O
patients	O
undergoing	O
repeat	O
vitreous	O
surgery	O
for	O
proliferative	O
vitreoretinopathy	O
,	O
in	O
which	O
case	O
both	O
silicone	O
oil	O
and	O
long-acting	O
perflouropropane	B-I
gas	O
appear	O
to	O
be	O
equally	B-O
effective	I-O
.	I-O


Predictors	O
of	O
smoking	B-P
cessation	I-P
among	I-P
cancer	I-P
patients	I-P
enrolled	I-P
in	I-P
a	I-P
smoking	I-I
cessation	I-I
program	I-P
.	I-P


UNLABELLED	O
Many	O
cancer	B-P
patients	I-P
continue	O
to	O
smoke	O
postdiagnosis	O
,	O
which	O
is	O
associated	O
with	O
poorer	O
clinical	O
outcomes	O
.	O


Identifying	O
prospective	O
predictors	O
of	O
smoking	O
cessation	O
among	O
patients	O
currently	O
receiving	O
smoking	B-I
cessation	I-I
treatment	O
can	O
help	O
guide	O
the	O
development	O
and	O
implementation	O
of	O
smoking	B-I
cessation	I-I
programs	I-I
with	O
this	O
population	O
.	O


MATERIAL	O
AND	O
METHODS	O
Data	B-P
from	I-P
246	I-P
cancer	I-P
patients	I-P
participating	I-P
in	I-P
a	I-P
randomized	I-P
placebo-controlled	I-I
smoking	I-P
cessation	I-P
clinical	I-P
trial	I-P
were	O
used	O
to	O
examine	O
baseline	O
predictors	O
of	O
end-of-treatment	O
and	O
six-month	O
postbaseline	O
smoking	B-I
cessation	I-I
outcomes	O
.	O


Baseline	O
demographic	O
,	O
smoking-related	O
,	O
disease-related	O
,	O
and	O
psychological	O
variables	O
were	O
examined	O
as	O
predictors	O
of	O
biochemically-confirmed	O
point-prevalence	O
abstinence	O
.	O


RESULTS	O
Multivariate	B-O
analysis	O
indicated	O
that	O
,	O
for	O
end-of-treatment	B-O
abstinence	I-O
,	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
quit	B-O
smoking	I-O
if	O
they	O
were	O
older	O
(	O
OR	O
=	O
1.06	O
,	O
95	O
%	O
CI	O
:	O
1.03-1.10	O
,	O
p	O
<	O
0.05	O
)	O
and	O
were	O
diagnosed	O
with	O
a	O
non-tobacco	O
related	O
cancer	O
(	O
OR	O
=	O
2.54	O
,	O
95	O
%	O
CI	O
:	O
1.24-5.20	O
,	O
p	O
<	O
0.05	O
)	O
.	O


Likewise	O
,	O
for	O
six-month	B-O
abstinence	I-O
,	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
quit	B-O
smoking	I-O
if	O
they	O
were	O
older	O
(	O
OR	O
=	O
1.04	O
,	O
95	O
%	O
CI	O
:	O
1.01-1.08	O
,	O
p	O
<	O
0.05	O
)	O
and	O
were	O
significantly	O
less	O
likely	O
to	O
have	O
quit	O
smoking	O
if	O
they	O
were	O
female	O
(	O
OR	O
=	O
0.47	O
,	O
95	O
%	O
CI	O
:	O
0.22-0.97	O
,	O
p	O
<	O
0.05	O
)	O
.	O


Patients	B-P
with	I-P
tobacco-related	I-P
cancers	I-P
and	I-P
female	I-P
patients	I-P
reported	O
significantly	O
higher	O
levels	B-O
of	I-O
depression	I-O
symptoms	I-O
(	O
p	O
<	O
0.05	O
)	O
,	O
which	O
proved	O
predictive	B-O
of	I-O
smoking	I-O
relapse	I-O
.	I-O


CONCLUSIONS	O
Patient	O
age	O
,	O
gender	O
,	O
and	O
cancer-type	O
may	O
be	O
important	O
factors	O
to	O
consider	O
when	O
developing	O
and	O
implementing	O
smoking	B-I
cessation	I-I
interventions	I-I
for	O
cancer	B-P
patients	I-P
.	I-P


Efficacy	B-O
of	O
amantadine	B-I
on	O
quality	B-O
of	I-O
life	I-O
in	O
patients	B-P
with	I-P
chronic	I-P
hepatitis	I-P
C	I-P
treated	I-P
with	I-P
interferon-alpha	I-I
and	I-I
ribavirin	I-I
:	I-I
results	O
from	O
a	O
randomized	O
,	O
placebo-controlled	B-I
,	O
double-blind	O
trial	O
.	O


AIM	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
amantadine	O
reduces	O
deterioration	B-O
of	I-O
quality	I-O
of	I-O
life	I-O
in	O
patients	B-P
with	I-P
chronic	I-P
hepatitis	I-P
C	I-P
during	I-P
and	I-P
after	I-P
treatment	I-P
with	I-P
interferon-alpha	I-P
(	I-P
IFN-alpha	I-P
)	I-P
and	I-P
ribavirin	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
In	O
this	O
randomized	O
,	O
prospective	O
,	O
placebo-controlled	B-I
,	O
multicenter	O
trial	O
,	O
previously	B-P
untreated	I-P
patients	I-P
with	I-P
chronic	I-P
hepatitis	I-P
C	I-P
were	O
treated	O
with	O
IFN-alpha	B-I
plus	I-I
ribavirin	I-I
[	I-I
17	I-I
]	I-I
and	O
randomized	O
for	O
treatment	O
with	O
amantadine	B-I
(	O
200	O
mg/day	O
,	O
orally	O
,	O
n=136	O
)	O
or	B-I
placebo	I-I
(	O
n=131	O
)	O
.	O


Quality	B-O
of	I-O
life	I-O
was	O
assessed	O
with	O
the	O
'Profile	B-O
of	I-O
Mood	I-O
States	I-O
'	I-O
scale	I-O
and	I-O
the	I-O
'Everyday	I-O
Life	I-O
'	I-O
questionnaire	I-O
at	O
baseline	O
,	O
treatment	O
week	O
(	O
TW	O
)	O
8	O
,	O
TW24	O
,	O
TW48	O
,	O
and	O
at	O
follow-up	O
.	O


RESULTS	O
Early	O
during	O
treatment	O
at	O
TW8	O
,	O
quality	B-O
of	I-O
life	I-O
was	O
not	O
different	O
between	O
patients	B-P
in	I-P
the	I-P
control	I-P
and	I-P
the	I-P
amantadine	I-P
group	I-P
.	I-P


At	O
TW24	O
,	O
the	O
control	O
group	O
but	O
not	O
the	O
amantadine	B-I
group	O
,	O
however	O
,	O
showed	O
significant	O
deterioration	O
of	O
the	O
modalities	B-O
depression	I-O
,	I-O
fatigue	I-O
,	I-O
and	I-O
vigor	I-O
compared	O
with	O
baseline	O
.	O


Especially	O
,	O
nonresponders	O
in	O
the	O
amantadine	O
group	O
showed	O
significantly	O
lower	B-O
deterioration	I-O
of	I-O
depression	I-O
,	I-O
anger	I-O
,	I-O
mind	I-O
function	I-O
,	I-O
everyday	I-O
life	I-O
,	I-O
and	I-O
zest	I-O
for	I-O
life	I-O
than	O
those	O
in	O
the	O
placebo	B-I
group	O
.	O


After	O
treatment	O
,	O
the	O
beneficial	B-O
effects	I-O
of	O
amantadine	O
disappeared	O
.	O


CONCLUSION	O
The	O
addition	O
of	O
amantadine	B-I
to	O
IFN-alpha	B-I
plus	I-I
ribavirin	I-I
combination	O
therapy	O
may	O
reduce	O
deterioration	B-O
of	I-O
depression	I-O
,	I-O
fatigue	I-O
,	I-O
and	I-O
vigor	I-O
during	O
treatment	O
but	O
does	O
not	O
affect	O
quality	B-O
of	I-O
life	I-O
after	O
treatment	O
.	O


Metabolic	O
and	O
ventilatory	O
responses	O
during	O
very	B-I
low	I-I
level	I-I
exercise	I-I
.	I-I


1	O
.	O


Nine	B-P
male	I-P
and	I-P
six	I-P
female	I-P
healthy	I-P
subjects	I-P
were	I-P
studied	I-P
during	I-P
supine	I-I
bicycle	I-I
exercise	I-I
at	I-P
workloads	I-P
of	I-P
12	I-P
and	I-P
37	I-P
W	I-P
;	I-P
pedalling	I-P
rates	I-P
varied	I-P
between	I-P
30	I-P
and	I-P
50	I-P
cycles/min	I-P
at	I-P
each	I-P
workload	I-P
.	I-P


Measurements	O
were	O
made	O
of	O
oxygen	B-O
consumption	I-O
(	I-O
VO2	I-O
)	I-O
,	I-O
carbon	I-O
dioxide	I-O
production	I-O
(	I-O
VCO2	I-O
)	I-O
,	I-O
minute	I-O
ventilation	I-O
(	I-O
VE	I-O
)	I-O
,	I-O
tidal	I-O
volume	I-O
(	I-O
VT	I-O
)	I-O
,	I-O
respiratory	I-O
frequency	I-O
(	I-O
fR	I-O
)	I-O
,	I-O
inspiratory	I-O
and	I-O
expiratory	I-O
time	I-O
(	I-O
TI	I-O
,	I-O
TE	I-O
)	I-O
and	I-O
mean	I-O
inspiratory	I-O
flow	I-O
(	I-O
VT/TI	I-O
)	I-O
using	O
a	O
non-invasive	O
canopy-computer-spirometer	O
system	O
.	O


2	O
.	O


At	O
rest	O
,	O
males	O
had	O
greater	O
values	O
of	O
VE	B-O
,	I-O
VT	I-O
,	I-O
TI	I-O
,	I-O
inspiratory	I-O
duty	I-O
cycle	I-O
(	I-O
TI/TTOT	I-O
)	I-O
,	I-O
VCO2	I-O
and	I-O
VO2	I-O
,	I-O
and	I-O
a	I-O
lower	I-O
fR	I-O
,	O
than	O
females	O
.	O


3	O
.	O


At	O
the	O
lower	O
workload	O
,	O
VO2	B-O
,	I-O
VCO2	I-O
,	I-O
VE	I-O
,	I-O
VT	I-O
and	I-O
VT/TI	I-O
increased	O
linearly	O
with	O
increasing	O
pedalling	O
rate	O
,	O
whereas	O
at	O
the	O
higher	O
workload	O
there	O
was	O
a	O
decrease	O
in	O
VO2	B-O
and	O
little	O
or	O
no	O
change	O
in	O
ventilatory	B-O
parameters	I-O
from	O
30	O
to	O
50	O
cycles/min	O
except	O
for	O
an	O
increase	O
in	O
fR	B-O
in	O
females	O
.	O


4	O
.	O


While	O
performing	O
supine	B-I
exercise	I-I
,	O
there	O
was	O
an	O
effect	O
of	O
pedalling	B-O
rate	I-O
on	I-O
ventilatory	I-O
and	I-O
metabolic	I-O
parameters	I-O
at	O
the	O
low	O
workload	O
(	O
12	O
W	O
)	O
which	O
diminished	O
at	O
the	O
higher	O
workload	O
(	O
37	O
W	O
)	O
.	O


An	O
increase	O
in	O
pedalling	B-O
rate	I-O
appears	O
to	O
enhance	O
efficiency	O
at	O
these	O
low	O
workloads	O
.	O


5	O
.	O


Differences	O
between	O
the	O
sexes	O
during	O
exercise	O
generally	O
include	O
:	O
(	O
a	O
)	O
a	O
higher	B-O
breathing	I-O
frequency	I-O
,	I-O
(	I-O
b	I-O
)	I-O
a	I-O
greater	I-O
mechanical	I-O
efficiency	I-O
,	I-O
and	I-O
(	I-O
c	I-O
)	I-O
lower	I-O
ventilatory	I-O
equivalents	I-O
of	I-O
O2	I-O
and	I-O
CO2	I-O
(	I-O
VE/VO2	I-O
and	I-O
VE/VCO2	I-O
)	I-O
during	O
the	O
higher	O
workload	O
in	O
females	O
than	O
males	O
.	O


Osteoporosis	B-I
and	O
gait	O
and	O
balance	O
disturbances	O
in	O
older	B-P
sarcopenic	I-P
obese	I-P
New	I-P
Zealanders	I-P
.	I-P


UNLABELLED	O
Bone	O
,	O
muscle	O
,	O
and	O
fat	O
may	O
affect	O
gait	O
and	O
balance	O
in	O
older	B-P
adults	I-P
.	I-P


Osteoporosis	B-P
was	I-P
prevalent	I-P
in	I-P
low	I-P
muscle	I-P
mass	I-P
participants	I-P
and	I-P
related	I-P
to	I-P
gait	I-P
and	I-P
balance	I-P
deficits	I-P
.	I-P


Low	O
muscle	O
combined	O
with	O
high	O
fat	O
mass	O
had	O
more	O
functional	O
deficits	O
and	O
poorer	O
bone	O
health	O
,	O
which	O
has	O
implications	O
for	O
falls	O
risk	O
and	O
fractures	O
.	O


INTRODUCTION	O
Decreasing	O
bone	O
density	O
and	O
muscle	O
mass	O
and	O
increasing	O
fat	O
mass	O
may	O
act	O
synergistically	O
to	O
affect	O
gait	O
and	O
balance	O
in	O
older	O
adults	O
.	O


METHODS	O
One	B-P
hundred	I-P
eighty-three	I-P
older	I-P
adults	I-P
(	I-P
age	I-P
72.7	I-P
+/-	I-P
6	I-P
years	I-P
,	I-P
range	I-P
56-93	I-P
;	I-P
body	I-P
mass	I-P
index	I-P
28.2	I-P
+/-	I-P
4.9	I-P
,	I-P
range	I-P
16.6-46.0	I-P
)	I-P
were	I-P
recruited	I-P
from	I-P
a	I-P
New	I-P
Zealand	I-P
falls	I-P
prevention	I-P
intervention	I-P
trial	I-P
.	I-P


Total	B-O
and	I-O
appendicular	I-O
skeletal	I-O
muscle	I-O
mass	I-O
(	I-O
ASM	I-O
)	I-O
,	I-O
percent	I-O
fat	I-O
,	I-O
and	I-O
bone	I-O
mineralization	I-O
were	I-P
assessed	I-P
by	I-P
dual	I-I
energy	I-I
X-ray	I-I
absorptiometry	I-I
and	I-P
used	I-P
to	I-P
characterize	I-P
normal	I-P
lean	I-P
(	I-P
NL	I-P
,	I-P
n	I-P
=	I-P
51	I-P
)	I-P
,	I-P
sarcopenic	I-P
(	I-P
SS	I-P
,	I-P
n	I-P
=	I-P
18	I-P
)	I-P
,	I-P
sarcopenic	I-P
obese	I-P
(	I-P
SO	I-P
,	I-P
n	I-P
=	I-P
29	I-P
)	I-P
,	I-P
and	I-P
obese	I-P
(	I-P
OO	I-P
,	I-P
n	I-P
=	I-P
85	I-P
)	I-P
phenotypes	I-P
.	I-P


Functional	O
performance	O
was	O
assessed	O
using	O
timed	B-I
up	I-I
and	I-I
go	I-I
,	I-I
chair	I-I
stand	I-I
,	I-I
single	I-I
leg	I-I
stand	I-I
,	O
and	O
step	B-I
test	I-I
.	I-I


Regression	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
medications	O
,	O
and	O
physical	O
activity	O
.	O


RESULTS	O
Femoral	B-O
neck	I-O
osteoporosis	I-O
was	O
present	O
in	O
22	O
%	O
SS	O
,	O
17	O
%	O
SO	O
,	O
12	O
%	O
NL	O
,	O
and	O
7	O
%	O
OO	O
.	O


Femoral	O
neck	O
osteoporosis	O
with	O
low	O
ASM	B-O
predicted	O
poor	O
chair	B-O
stand	I-O
performance	I-O
(	O
beta	O
-3.3	O
,	O
standard	O
error	O
1.6	O
,	O
p	O
=	O
0.04	O
)	O
.	O


SO	O
scored	O
lowest	O
on	O
the	O
chair	O
stand	O
(	O
p	O
=	O
0.03	O
)	O
and	O
step	O
test	O
(	O
p	O
=	O
0.03	O
)	O
.	O


Higher	B-O
ASM	I-O
predicted	O
faster	O
timed	O
up	O
and	O
go	O
performance	O
(	O
p	O
=	O
0.001	O
)	O
.	O


CONCLUSIONS	O
Osteoporosis	O
was	O
prevalent	O
in	O
low	B-P
ASM	I-P
groups	I-P
(	O
SS	O
and	O
SO	O
)	O
and	O
related	O
to	O
gait	O
and	O
balance	O
deficits	O
,	O
particularly	O
in	O
the	O
SO	O
.	O


This	O
has	O
implications	O
for	O
falls	O
risk	O
,	O
fractures	O
,	O
and	O
interventions	O
.	O


Pegylated	B-I
feline	I-I
granulocyte	I-I
colony-stimulating	I-I
factor	I-I
increases	O
neutrophil	O
levels	O
in	O
cats	B-P
.	I-P


Neutropenia	O
can	O
often	O
be	O
corrected	O
by	O
treatment	O
with	O
granulocyte-colony	B-I
stimulating	I-I
factor	I-I
(	I-I
G-CSF	I-I
)	I-I
and	O
off-label	B-I
use	I-I
of	I-I
commercial	I-I
human	I-I
G-CSF	I-I
(	I-I
HuG-CSF	I-I
)	I-I
is	O
a	O
commonly	O
used	O
treatment	O
for	O
neutropenic	B-P
animals	I-P
.	I-P


However	O
,	O
long-term	O
HuG-CSF	B-I
treatment	I-I
can	O
be	O
associated	O
with	O
adverse	B-O
effects	I-O
,	O
including	O
neutropenia	B-O
.	I-O


Here	O
,	O
feline	O
(	O
Fe	O
)	O
G-CSF	O
was	O
produced	O
in	O
Pichia	O
pastoris	O
,	O
pegylated	O
(	O
Peg	O
)	O
FeG-CSF	O
and	O
tested	O
in	O
cats	O
.	O


A	O
randomized	O
controlled	O
clinical	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	B-O
of	O
PegFeG-CSF	B-I
compared	O
to	O
FeG-CSF	B-I
or	I-I
HuG-CSF	I-I
in	O
FIV-infected	B-P
(	I-P
n=14	I-P
)	I-P
,	I-P
FIV-uninfected	I-P
healthy	I-P
cats	I-P
(	I-P
n=19	I-P
)	I-P
,	I-P
and	I-P
in	I-P
HuG-CSF-induced	I-P
neutropenic	I-P
cats	I-P
(	I-P
n=4	I-P
)	I-P
.	I-P


Daily	O
FeG-CSF	B-I
doses	O
induced	O
higher	B-O
neutrophil	I-O
production	I-O
than	O
HuG-CSF	B-I
after	O
the	O
second	O
week	O
of	O
treatment	O
(	O
P	O
⩽	O
0.002	O
)	O
.	O


Weekly	O
doses	O
of	B-I
PegFeG-CSF	I-O
induced	I-O
higher	I-O
neutrophil	I-O
counts	I-O
and	O
showed	B-O
greater	I-O
sustained	I-O
activity	I-O
than	O
weekly	O
doses	O
of	B-I
FeG-CSF	I-I
.	I-I


PegFeG-CSF	B-I
provided	O
the	O
most	O
therapeutic	O
and	O
sustainable	B-O
neutrophil	I-O
production	I-O
(	O
P	O
<	O
0.001	O
)	O
in	O
both	B-P
FIV-uninfected	I-P
and	I-P
FIV-infected	I-P
cats	I-P
,	O
without	O
the	O
development	O
of	B-O
neutralizing	I-O
antibodies	I-O
.	O


Conversely	O
,	O
all	B-I
HuG-CSF-treated	I-I
cats	I-P
developed	I-O
neutralizing	I-O
antibodies	I-O
,	O
suggesting	O
cross-reactive	O
antibodies	O
to	O
endogenous	O
G-CSF	O
in	O
a	O
majority	O
of	O
the	O
cases	O
with	O
severe	O
neutropenia	O
.	O


Strikingly	O
,	O
when	B-I
PegFeG-CSF	I-I
was	O
used	O
to	O
rescue	O
cats	O
with	B-I
HuG-CSF-induced	I-O
neutropenia	I-O
,	O
clinically	O
normal	B-O
neutrophil	I-O
numbers	I-O
returned	O
.	O


Thus	B-I
,	I-I
PegFeG-CSF	I-I
appears	O
to	O
be	O
a	O
superior	O
treatment	O
for	O
neutropenia	O
in	B-P
feline	I-P
patients	I-P
.	O


Protein	B-I
ingestion	I-I
further	O
augments	O
S6K1	O
phosphorylation	O
in	O
skeletal	O
muscle	O
following	O
resistance	B-P
type	I-P
exercise	I-P
in	I-P
males	I-P
.	I-P


Our	O
objective	O
was	O
to	O
determine	O
the	O
impact	O
of	O
carbohydrate	B-I
and/or	I-I
protein	I-I
ingestion	I-I
before	O
and	O
after	O
exercise	B-I
on	O
ribosomal	O
protein	O
S6	O
kinase	O
(	O
S6K1	O
)	O
and	O
S6	O
phosphorylation	O
status	O
in	O
human	B-P
skeletal	O
muscle	O
tissue	O
.	O


Seven	B-P
healthy	I-P
,	I-P
untrained	I-P
men	I-P
(	I-P
22.5	I-P
+/-	I-P
0.9	I-P
y	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
2	O
cross-over	O
experiments	O
.	O


Before	O
,	O
immediately	O
after	O
,	O
and	O
1	O
h	O
after	O
a	O
single	O
bout	O
of	O
resistance	B-I
exercise	I-I
,	O
subjects	O
consumed	O
0.3	O
g	O
x	O
kg	O
(	O
-1	O
)	O
carbohydrate	B-I
with	I-I
or	I-I
without	I-I
0.3	I-I
g	I-I
x	I-I
kg	I-I
(	I-I
-1	I-I
)	I-I
protein	I-I
hydrolysate	I-I
(	I-I
CHO+PRO	I-I
and	I-I
CHO	I-I
,	I-I
respectively	I-I
)	I-I
.	I-I


Muscle	B-I
biopsies	I-I
were	O
taken	O
before	O
and	O
immediately	O
after	O
exercise	O
and	O
after	O
1	O
and	O
4	O
h	O
of	O
postexercise	O
recovery	O
to	O
determine	O
4E-BP1	O
,	O
S6K1	O
(	O
both	O
T	O
(	O
421	O
)	O
/S	O
(	O
424	O
)	O
and	O
T	O
(	O
389	O
)	O
)	O
,	O
and	O
S6	O
phosphorylation	O
status	O
.	O


Following	B-O
resistance	I-O
exercise	I-O
,	I-O
4E-BP1	I-O
phosphorylation	I-O
was	I-O
reduced	I-O
to	I-O
a	I-O
greater	I-O
extent	I-O
in	I-O
the	I-O
CHO	I-O
treatment	I-O
(	I-O
-48	I-O
+/-	I-O
7	I-O
%	I-O
)	I-O
than	I-O
in	I-O
the	I-O
CHO+PRO	I-O
treatment	I-O
(	I-O
-15	I-O
+/-	I-O
14	I-O
%	I-O
,	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
.	I-O


During	B-O
recovery	I-O
,	I-O
4E-BP1	I-O
phosphorylation	I-O
increased	I-O
in	I-O
both	I-O
experiments	I-O
(	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
,	I-O
and	I-O
tended	I-O
to	I-O
be	I-O
higher	I-O
in	I-O
the	I-O
CHO+PRO	I-O
test	I-O
(	I-O
P	I-O
=	I-O
0.08	I-O
)	I-O
.	I-O


S6K1	B-O
phosphorylation	I-O
at	I-O
T	I-O
(	I-O
421	I-O
)	I-O
/S	I-O
(	I-O
424	I-O
)	I-O
substantially	I-O
increased	I-O
following	I-O
exercise	I-O
and	I-O
remained	I-O
elevated	I-O
during	I-O
recovery	I-O
with	I-O
no	I-O
differences	I-O
between	I-O
treatments	I-O
.	I-O


In	B-O
contrast	I-O
to	I-O
the	I-O
CHO	I-O
treatment	I-O
(	I-O
-4	I-O
+/-	I-O
2	I-O
%	I-O
)	I-O
,	I-O
S6K1	I-O
phosphorylation	I-O
at	I-O
T	I-O
(	I-O
389	I-O
)	I-O
was	I-O
higher	I-O
following	I-O
exercise	I-O
in	I-O
the	I-O
CHO+PRO	I-O
treatment	I-O
only	I-O
(	I-O
+78	I-O
+/-	I-O
2	I-O
%	I-O
,	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
.	I-O


During	B-O
recovery	I-O
,	I-O
S6K1	I-O
phosphorylation	I-O
at	I-O
T	I-O
(	I-O
389	I-O
)	I-O
remained	I-O
higher	I-O
in	I-O
CHO+PRO	I-O
than	I-O
in	I-O
CHO	I-O
(	I-O
P	I-O
<	I-O
0.05	I-O
)	I-O
.	I-O


S6	B-O
phosphorylation	I-O
was	I-O
substantially	I-O
higher	I-O
following	I-O
exercise	I-O
in	I-O
the	I-O
CHO+PRO	I-O
(	I-O
1.69	I-O
+/-	I-O
0.35	I-O
)	I-O
than	I-O
in	I-O
the	I-O
CHO	I-O
experiment	I-O
(	I-O
0.45	I-O
+/-	I-O
0.07	I-O
,	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
and	I-O
remained	I-O
elevated	I-O
during	I-O
recovery	I-O
(	I-O
P	I-O
<	I-O
0.05	I-O
)	I-O
.	I-O


We	O
conclude	O
that	O
the	O
availability	O
of	O
dietary	O
protein	O
further	O
enhances	O
phosphorylation	O
of	O
S6K1	O
during	O
recovery	O
from	O
resistance	O
type	O
exercise	O
.	O


Albumin-glutaraldehyde	B-I
bioadhesive	I-I
(	I-I
"	I-I
Bioglue	I-I
"	I-I
)	I-I
for	O
prevention	O
of	O
postoperative	B-O
complications	I-O
after	O
stapled	O
hemorrhoidopexy	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
Hemorrhoidopexy	O
using	O
the	O
circumferential	O
stapler	O
is	O
an	O
established	O
method	O
for	O
surgical	O
treatment	O
of	O
patients	B-P
with	I-P
prolapsing	I-P
hemorrhoids	I-P
.	I-P


Despite	O
its	O
advantages	O
,	O
complications	O
such	O
as	O
anal	O
canal	O
stenosis	O
,	O
hemorrhage	O
and	O
anastomosis	O
leak	O
with	O
eventual	O
intrapelvic	O
sepsis	O
can	O
cause	O
serious	O
postoperative	O
problems	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
utility	O
of	O
a	O
surgical	O
adhesive	O
,	O
the	O
biological	B-I
albumin-glutaraldehyde	I-I
glue	I-I
"	I-I
Bioglue	I-I
"	I-I
,	O
in	O
reduction	O
of	O
these	O
postoperative	O
complications	O
.	O


PATIENTS	O
AND	O
METHODS	O
Between	B-P
January	I-P
2002	I-P
and	I-P
November	I-P
2004	I-P
,	I-P
200	I-P
patients	I-P
undergoing	I-P
stapled	I-I
hemorrhoidopexy	I-I
were	I-P
enrolled	I-P
in	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
.	O


One	B-P
hundred	I-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
the	I-P
control	I-I
group	I-I
;	I-I
the	I-P
study	I-P
group	I-P
consisted	I-P
of	I-P
100	I-P
patients	I-P
who	O
received	O
Bioglue	B-I
in	I-I
the	I-I
mucosa	I-I
anastomosis	I-I
area	I-I
.	I-I


All	O
patients	O
received	O
standardized	B-I
postoperative	I-I
analgesic	I-I
,	I-I
laxative	I-I
and	I-I
antibiotic	I-I
treatment	I-I
.	I-I


We	O
then	O
evaluated	O
the	O
two	O
groups	O
for	O
postoperative	B-O
complications	I-O
(	O
after	O
surgery	O
and	O
6	O
months	O
postoperatively	O
)	O
.	O


RESULTS	O
From	O
the	O
control	O
group	O
(	O
no	O
Bioglue	O
application	O
)	O
,	O
two	O
patients	O
presented	O
with	O
anal	B-O
stenosis	I-O
,	O
two	O
with	O
hemorrhage	B-O
,	O
three	O
had	O
anastomosis	B-O
leak	I-O
and	O
one	O
had	O
thrombosis	B-O
,	O
whereas	O
none	O
of	O
the	O
patients	O
from	O
the	O
Bioglue	O
group	O
had	O
any	O
of	O
these	O
complications	B-O
.	I-O


Both	O
groups	O
had	O
patients	O
with	O
severe	B-O
postoperative	I-O
pain	I-O
(	O
3	O
each	O
)	O
and	O
fecal	B-O
incontinence	I-O
(	O
1	O
patient	O
each	O
)	O
.	O


The	O
overall	B-O
difference	I-O
in	O
the	O
number	B-O
of	I-O
complications	I-O
in	O
the	O
two	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
In	O
this	O
first	O
study	O
using	O
Bioglue	O
in	O
patients	O
undergoing	O
circumferential	O
stapled	O
hemorrhoidopexy	O
we	O
have	O
shown	O
that	O
application	O
of	O
the	O
glue	O
is	O
effective	B-O
in	O
reducing	B-O
postoperative	I-O
complications	I-O
.	I-O


A	O
5-year	O
randomized	O
trial	O
to	O
compare	O
1	O
or	O
2	O
implants	B-I
for	O
implant	B-P
overdentures	I-P
.	I-P


The	O
hypothesis	O
of	O
this	O
5-y	O
randomized	O
clinical	O
trial	O
was	O
that	O
there	O
would	O
be	O
no	O
significant	O
difference	O
in	O
the	O
satisfaction	B-O
of	O
edentulous	B-P
participants	I-P
with	I-P
removable	I-P
complete	I-P
overdentures	I-P
attached	I-P
to	I-P
1	I-P
or	I-P
2	I-P
mandibular	I-I
implants	I-I
.	I-I


Secondary	O
aims	O
were	O
to	O
test	O
changes	O
in	O
satisfaction	B-O
between	O
and	O
within	O
the	O
groups	O
from	O
baseline	O
to	O
5	O
y	O
and	O
differences	O
between	O
the	O
groups	O
in	O
implant	B-O
survival	I-O
and	O
prosthodontic	O
maintenance	O
over	O
5	O
y	O
.	O


Each	O
of	O
the	O
86	B-P
participants	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
67	I-P
y	I-P
)	I-P
was	O
randomly	O
allocated	O
to	O
receive	O
either	O
1	B-I
implant	I-I
in	I-I
the	I-I
midline	I-I
(	O
group	O
1	O
)	O
or	O
2	B-I
implants	I-I
in	I-I
the	I-I
canine	I-I
areas	I-I
(	O
group	O
2	O
)	O
attached	O
to	O
a	O
mandibular	O
overdenture	O
opposing	O
a	O
maxillary	O
complete	O
denture	O
.	O


Satisfaction	B-O
was	I-O
self-assessed	I-O
by	O
participants	O
on	O
a	O
visual	B-O
analog	I-O
scale	I-O
at	O
baseline	O
prior	O
to	O
implants	O
,	O
as	O
well	O
as	O
at	O
2	O
mo	O
and	O
1	O
,	O
3	O
,	O
and	O
5	O
y	O
with	O
implant	O
overdentures	O
,	O
whereas	O
implant	B-O
survival	I-O
and	I-O
prosthodontic	I-O
maintenance	I-O
were	O
assessed	B-O
by	I-O
clinical	I-O
examination	I-O
.	I-O


After	O
5	O
y	O
,	O
29	O
participants	O
in	O
group	O
1	O
and	O
33	O
in	O
group	O
2	O
were	O
available	O
,	O
with	O
most	O
dropouts	O
due	O
to	O
death	B-O
.	I-O


Satisfaction	B-O
with	O
the	O
implant	O
denture	O
after	O
5	O
y	O
was	O
significantly	O
(	O
P	O
<	O
0.001	O
)	O
higher	O
than	O
at	O
baseline	O
in	O
both	O
groups	O
and	O
remained	O
with	O
no	O
significant	O
difference	O
(	O
P	O
=	O
0.32	O
)	O
between	O
the	O
groups	O
.	O


No	O
implants	O
failed	B-O
in	O
group	O
1	O
but	O
5	O
failed	O
before	O
loading	O
in	O
4	O
participants	O
in	O
group	O
2	O
.	O


Most	O
participants	O
required	O
maintenance	B-O
or	O
occasionally	O
denture	B-O
replacement	I-O
,	O
and	O
although	O
differences	O
between	O
the	O
groups	O
were	O
not	O
statistically	O
significant	O
,	O
group	O
1	O
experienced	O
almost	O
twice	O
as	O
many	O
fractured	B-O
dentures	I-O
usually	O
adjacent	O
to	O
the	O
implant	O
attachment	O
.	O


We	O
conclude	O
that	O
there	O
were	O
no	O
significant	O
differences	O
after	O
5	O
y	O
in	O
satisfaction	B-O
or	I-O
survival	I-O
of	I-O
implants	I-O
with	O
mandibular	O
overdentures	O
retained	O
by	O
1	O
implant	O
or	O
2	O
implants	O
.	O


Additional	O
research	O
is	O
required	O
to	O
confirm	O
long-term	O
treatment	O
effectiveness	B-O
of	O
single-implant	O
dentures	O
and	O
the	O
implications	O
of	O
prosthetic	O
maintenance	O
with	O
implant	O
overdentures	O
(	O
ClinicalTrials.gov	O
:	O
NCT02117856	O
)	O
.	O


Anti-inflammatory	B-O
effects	I-O
of	O
inhaled	B-I
carbon	I-I
monoxide	I-I
in	O
patients	B-P
with	I-P
COPD	I-P
:	I-P
a	O
pilot	O
study	O
.	O


In	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
carbon	B-I
monoxide	I-I
(	O
CO	O
)	O
has	O
both	O
anti-inflammatory	O
and	O
anti-oxidant	O
capacities	O
.	O


Since	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
is	O
characterised	O
by	O
inflammation	O
and	O
oxidative	O
stress	O
,	O
low-dose	B-I
CO	I-I
could	O
be	O
of	O
therapeutic	O
use	O
.	O


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	B-O
and	I-O
anti-inflammatory	I-O
effects	I-O
of	O
100-125	O
ppm	O
CO	B-I
inhalation	I-I
in	O
patients	B-P
with	I-P
stable	I-P
COPD	I-P
.	I-P


In	O
total	O
,	O
20	B-P
ex-smoking	I-P
COPD	I-P
patients	I-P
with	I-P
post-bronchodilator	I-P
forced	I-P
expiratory	I-P
volume	I-P
in	I-P
one	I-P
second	I-P
(	I-P
FEV	I-P
(	I-P
1	I-P
)	I-P
)	I-P
>	I-P
1.20	I-P
L	I-P
and	I-P
FEV	I-P
(	I-P
1	I-P
)	I-P
/forced	I-P
vital	I-P
capacity	I-P
<	I-P
70	I-P
%	I-P
were	O
enrolled	O
in	O
a	O
randomised	O
,	O
placebo-controlled	B-I
,	O
crossover	O
study	O
.	O


Effects	B-O
on	I-O
inflammation	I-O
were	O
measured	O
in	O
induced	B-O
sputum	I-O
and	I-O
blood	I-O
.	I-O


CO	B-O
inhalation	I-O
was	O
feasible	B-O
and	O
patients	B-O
'	I-O
vital	I-O
signs	I-O
were	O
unaffected	O
;	O
2	O
h.day	O
(	O
-1	O
)	O
inhalation	O
of	O
low-dose	O
CO	O
on	O
4	O
consecutive	O
days	O
led	O
to	O
a	O
maximal	O
individual	O
carboxyhaemoglobin	B-O
level	I-O
of	O
4.5	O
%	O
.	O


Two	O
exacerbations	B-O
occurred	O
in	O
the	O
CO	O
period	O
.	O


CO	O
inhalation	O
led	O
to	O
trends	O
in	O
reduced	B-O
sputum	I-O
eosinophils	I-O
(	O
median	O
reduction	O
0.25	O
%	O
point	O
)	O
and	O
improved	B-O
responsiveness	I-O
to	I-O
methacholine	I-O
(	O
median	O
provocative	O
concentration	O
causing	O
a	O
20	O
%	O
fall	O
in	O
FEV	O
(	O
1	O
)	O
0.85	O
versus	O
0.63	O
mg.mL	O
(	O
-1	O
)	O
)	O
.	O


Inhalation	O
of	O
100-125	O
ppm	O
carbon	B-I
monoxide	I-I
by	O
patients	B-P
with	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
in	I-P
a	I-P
stable	I-P
phase	I-P
was	O
feasible	O
and	O
led	O
to	O
trends	O
in	O
reduction	O
of	O
sputum	O
eosinophils	O
and	O
improvement	B-O
of	I-O
responsiveness	I-O
to	I-O
methacholine	I-O
.	I-O


Further	O
studies	O
need	O
to	O
confirm	O
the	O
safety	B-O
and	I-O
efficacy	I-O
in	O
inflammatory	B-P
lung	I-P
diseases	I-P
.	I-P


Statistical	O
aspects	O
of	O
early	O
termination	O
in	O
the	O
beta-blocker	O
heart	O
attack	O
trial	O
.	O


The	O
Beta-Blocker	O
Heart	O
Attack	O
Trial	O
was	O
a	O
randomized	O
double	O
blind	O
controlled	O
trial	O
comparing	O
propranolol	B-I
with	I-I
placebo	I-I
in	O
3837	B-P
patients	I-P
with	I-P
a	I-P
recent	I-P
myocardial	I-P
infarction	I-P
.	I-P


The	O
trial	O
was	O
terminated	O
on	O
recommendation	O
of	O
the	O
Policy	O
and	O
Data	O
Monitoring	O
Board	O
9	O
months	O
before	O
the	O
scheduled	O
closing	O
date	O
.	O


The	O
propranolol	B-I
group	O
,	O
at	O
the	O
time	O
of	O
the	O
decision	O
,	O
had	O
a	O
26	O
%	O
lower	O
mortality	B-O
(	O
z	O
=	O
2.82	O
)	O
.	O


Many	O
issues	O
were	O
considered	O
in	O
this	O
decision	O
.	O


These	O
included	O
the	O
magnitude	O
of	O
the	O
overall	O
results	O
;	O
consistency	O
of	O
results	O
across	O
subgroups	O
,	O
clinical	O
centers	O
,	O
and	O
cause	O
of	O
death	O
;	O
and	O
completeness	O
of	O
follow-up	O
.	O


Two	O
basic	O
statistical	O
methods	O
were	O
used	O
in	O
declaring	O
the	O
overall	B-O
mortality	I-O
results	O
significant	O
.	O


The	O
first	O
method	O
evaluated	O
the	O
current	O
survival	B-O
data	I-O
taking	O
into	O
account	O
the	O
issue	O
of	O
repeated	O
significance	O
testing	O
.	O


The	O
second	O
method	O
evaluated	O
whether	O
the	O
observed	O
trend	O
was	O
so	O
impressive	O
that	O
the	O
conclusion	O
was	O
unlikely	O
to	O
change	O
even	O
if	O
the	O
trial	O
should	O
continue	O
to	O
the	O
scheduled	O
end	O
.	O


These	O
two	O
methods	O
,	O
as	O
well	O
as	O
other	O
considerations	O
led	O
to	O
the	O
recommendation	O
to	O
discontinue	O
the	O
trial	O
.	O


Effectiveness	O
and	O
safety	O
of	O
the	O
Levitan	B-I
FPS	I-I
Scope™	I-I
for	I-P
tracheal	I-P
intubation	I-P
under	I-P
general	I-P
anesthesia	I-P
with	O
a	B-P
simulated	I-P
difficult	I-P
airway	I-P
.	O


PURPOSE	O
Studies	O
show	O
that	O
the	B-I
Levitan	I-I
FPS	I-I
(	I-I
first	I-I
pass	I-I
success	I-I
)	I-I
Scope™	I-I
(	I-I
LFS	I-I
)	I-I
is	O
analogous	O
to	O
a	O
bougie	O
in	O
simulated	O
difficult	O
airways	O
with	O
comparable	O
tracheal	O
intubation	O
success	O
rates	O
.	O


In	O
this	O
study	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
tracheal	O
intubation	O
with	O
the	O
LFS	O
was	O
compared	O
with	O
that	O
of	O
the	O
Macintosh	O
laryngoscope	O
utilizing	O
manual	O
in-line	O
stabilization	O
(	O
MILS	O
)	O
to	O
simulate	O
difficult	O
airways	O
.	O


METHODS	B-P
Ninety-four	I-P
subjects	I-P
successfully	I-P
completed	I-P
the	I-P
trial	I-P
.	O


Manual	O
in-line	O
stabilization	O
of	O
the	O
cervical	O
spine	O
was	O
applied	O
and	O
the	B-I
initial	I-I
laryngoscopy	I-I
was	O
performed	O
using	O
either	O
the	B-I
Macintosh	I-I
or	I-I
the	I-I
LFS	I-I
in	I-I
conjunction	I-I
with	I-I
the	I-I
Macintosh	I-I
.	O


Following	O
the	O
initial	O
grading	B-I
,	I-I
a	I-I
second	I-I
laryngoscopy	I-I
was	O
repeated	O
using	O
the	O
second	O
randomized	O
technique	B-O
.	I-O


Cormack-Lehane	B-O
grades	I-O
,	I-O
percentage	I-O
of	I-O
glottic	I-O
opening	I-O
(	I-O
POGO	I-O
)	I-O
scores	I-O
,	I-O
time	I-O
to	I-O
intubate	I-O
,	I-O
number	I-O
of	I-O
intubation	I-O
attempts	I-O
,	I-O
and	I-O
the	I-O
use	I-O
of	I-O
alternate	I-O
techniques	I-O
were	O
recorded	O
.	O


The	O
anesthesiologist	O
rated	O
the	O
subjective	O
difficulty	O
in	O
using	O
each	O
technique	O
with	B-O
a	I-O
numeric	I-O
rating	I-O
scale	I-O
and	I-O
a	I-O
visual	I-O
rating	I-O
scale	I-O
.	O


RESULTS	O
There	O
was	B-O
no	I-O
significant	I-O
difference	I-O
in	O
the	B-O
primary	I-O
outcome	I-O
"	I-O
good	I-O
laryngoscopic	I-O
views	I-O
"	I-O
(	I-O
Cormack-Lehane	I-O
grade	I-O
1	I-O
and	I-O
2	O
)	O
compared	O
with	B-O
"	I-O
poor	I-O
laryngoscopic	I-O
views	I-O
"	I-O
(	I-O
Cormack-Lehane	I-O
grade	I-O
3	I-O
and	I-O
4	O
)	O
between	O
the	O
LFS	O
and	O
the	O
Macintosh	O
.	O


There	O
were	B-O
higher	I-O
POGO	I-O
scores	I-O
with	O
the	O
LFS	O
compared	O
with	O
the	O
Macintosh	O
(	O
80	O
%	O
vs	O
20	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
but	O
this	O
did	O
not	O
translate	O
to	O
easier	O
intubations	O
,	O
as	O
documented	O
by	O
the	O
need	O
for	O
an	O
alternate	O
intubation	O
technique	O
or	O
time	O
to	O
intubate	O
(	O
<	O
30	O
and	O
<	O
60	O
sec	O
,	O
respectively	O
)	O
.	O


The	O
incidence	B-O
of	I-O
mucosal	I-O
trauma	I-O
,	I-O
sore	I-O
throat	I-O
,	I-O
and	I-O
hemodynamic	I-O
responses	I-O
did	I-O
not	I-O
differ	I-O
significantly	O
between	O
the	O
two	O
techniques	O
.	O


CONCLUSION	O
The	O
LFS	O
in	O
conjunction	O
with	O
the	B-I
Macintosh	I-I
laryngoscope	I-I
does	O
not	O
improve	O
the	O
efficacy	O
or	O
safety	O
of	O
tracheal	O
intubation	O
in	B-P
a	I-P
simulated	I-P
difficult	I-P
airway	I-P
.	O


Divalproex	B-I
sodium	I-I
vs.	I-I
placebo	I-I
in	O
the	O
treatment	O
of	O
repetitive	B-O
behaviours	I-O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
.	I-P


Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
impairment	O
in	O
three	O
core	O
symptom	O
domains	O
:	O
socialization	O
,	O
communication	O
,	O
and	O
repetitive/stereotyped	O
behaviours	O
.	O


Other	O
associated	O
symptom	O
domains	O
are	O
also	O
affected	O
including	O
impulsivity/aggression	O
,	O
self-injury	O
,	O
anxiety	O
,	O
and	O
mood	O
lability	O
.	O


Divalproex	B-I
has	O
been	O
shown	O
to	O
have	O
efficacy	O
in	O
treating	O
epilepsy	O
,	O
bipolar	O
disorder	O
,	O
mood	O
lability	O
,	O
and	O
impulsive	O
aggression	O
.	O


The	O
present	O
study	O
evaluated	O
the	O
use	O
of	O
divalproex	B-I
in	O
the	O
treatment	O
of	O
repetitive	B-O
,	I-O
compulsive-like	I-O
symptoms	I-O
of	I-O
autism	I-O
spectrum	I-O
disorder	I-O
(	I-O
ASD	I-O
)	I-O
.	I-O


Thirteen	B-P
individuals	I-P
with	I-P
ASD	I-P
participated	O
in	O
an	O
8-wk	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
divalproex	B-I
sodium	I-I
vs.	I-I
placebo	I-I
.	I-I


There	O
was	O
a	O
significant	O
group	O
difference	O
on	O
improvement	O
in	O
repetitive	B-O
behaviours	I-O
as	O
measured	O
by	O
the	O
Children	B-O
's	I-O
Yale-Brown	I-O
Obsessive	I-O
Compulsive	I-O
Scale	I-O
(	I-O
C-YBOCS	I-O
)	I-O
(	O
p=0.037	O
)	O
and	O
a	O
large	O
effect	O
size	O
(	O
d=1.616	O
)	O
.	O


This	O
study	O
provides	O
preliminary	O
support	O
for	O
the	O
use	O
of	O
divalproex	B-I
in	O
treating	O
repetitive	B-O
behaviours	I-O
in	O
ASD	B-P
.	I-P


Further	O
research	O
is	O
needed	O
to	O
evaluate	O
the	O
specificity	O
and	O
mechanism	O
of	O
action	O
of	O
these	O
findings	O
.	O


Prospective	O
trial	O
of	O
timing	O
of	O
bacillus	B-I
Calmette-Guérin	I-I
vaccination	I-I
in	I-P
Canadian	I-P
Cree	I-P
infants	I-P
.	O


We	O
studied	B-P
184	I-P
Cree	I-P
Indian	I-P
infants	I-P
in	O
randomized	O
,	O
prospective	O
fashion	O
to	O
assess	O
the	O
effect	O
of	O
age	O
on	B-O
lymphocyte	I-O
sensitization	I-O
to	O
purified	O
protein	O
derivative	O
(	O
PPD	O
)	O
before	O
and	O
after	O
and	O
without	B-I
bacillus	I-I
Calmette-Guérin	I-I
(	I-I
BCG	I-I
)	I-I
vaccination	I-O
.	I-O


Lymphocyte	B-O
responses	I-O
to	O
PPD	O
,	O
Candida	O
,	O
and	O
streptokinase	O
were	O
measured	O
at	O
birth	O
and	O
at	O
intervals	O
later	O
.	O


The	O
mean	O
response	O
of	O
paired	O
values	O
from	B-P
26	I-P
infants	I-P
without	I-P
BCG	I-P
vaccination	I-P
rose	I-P
for	O
the	O
PPD	O
stimulation	O
index	O
(	O
SI	O
)	O
from	O
2.7	O
at	O
birth	O
to	O
3.9	O
before	O
2	O
yr	O
of	O
age	O
.	O


The	O
SI	O
for	O
both	O
Candida	O
and	O
streptokinase	O
for	O
this	O
group	O
of	O
infants	O
rose	O
significantly	O
in	O
the	O
first	O
2	O
yr	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


In	B-P
66	I-P
infants	I-P
who	I-P
received	I-I
BCG	I-I
in	I-P
the	I-P
first	I-P
7	I-P
days	I-P
of	I-P
life	I-P
,	O
the	B-O
PPD-SI	I-O
rose	O
from	O
3.1	O
to	O
35.3	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


In	O
17	O
infants	O
who	O
received	O
the	O
vaccine	O
later	O
but	O
before	O
9	O
months	O
,	O
it	O
rose	O
from	O
3.1	O
at	O
birth	O
to	O
24.9	O
,	O
and	O
in	O
14	O
who	O
received	O
it	O
between	O
9	O
months	O
and	O
2	O
yr	O
,	O
it	O
rose	O
from	O
2.2	O
to	O
52.9	O
.	O


The	B-O
lymphocyte	I-O
responses	I-O
to	O
PPD	O
after	B-I
BCG	I-I
in	O
these	O
two	O
groups	O
were	O
significantly	O
different	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


There	O
was	O
no	O
evidence	O
in	O
the	O
older	O
infants	O
that	O
a	O
raised	B-O
PPD-SI	I-O
before	O
BCG	O
vaccination	O
affected	B-O
lymphocyte	I-O
sensitization	I-O
by	O
the	O
vaccine	O
.	O


We	O
conclude	O
that	O
increasing	O
the	O
age	O
at	O
vaccination	O
with	B-I
BCG	I-I
from	O
birth	O
to	O
more	O
than	O
9	O
months	O
enhances	B-O
immunologic	I-O
sensitization	I-O
to	O
PPD	O
significantly	O
in	O
this	O
population	O
.	O


A	O
single	O
infusion	O
of	O
intravenous	O
ketamine	B-I
improves	O
pain	O
relief	O
in	O
patients	B-P
with	I-P
critical	I-P
limb	I-P
ischaemia	I-P
:	I-P
results	O
of	O
a	O
double	O
blind	O
randomised	O
controlled	O
trial	O
.	O


We	O
report	O
the	O
first	O
double	O
blind	O
randomised	O
controlled	O
trial	O
of	O
regular	O
opioids	B-I
and	O
an	O
infusion	O
of	O
low	O
dose	O
(	O
0.6	O
mg/kg	O
)	O
intravenous	O
ketamine	B-I
compared	O
with	O
opioids	B-I
and	O
placebo	B-I
in	O
patients	B-P
with	I-P
allodynia	I-P
,	I-P
hyperalgesia	I-P
and	I-P
hyperpathia	I-P
secondary	I-P
to	I-P
critical	I-P
limb	I-P
ischaemia	I-P
.	I-P


Thirty-five	B-P
patients	I-P
completed	I-P
the	I-P
study	I-P
,	I-P
18	I-P
received	O
regular	O
opioids	B-I
plus	I-I
ketamine	I-I
,	O
while	O
17	B-P
received	O
regular	B-I
opioids	I-I
plus	I-I
placebo	I-I
.	I-I


Using	O
the	O
Brief	B-O
Pain	I-O
Inventory	I-O
,	I-O
the	I-O
%	I-O
pain	I-O
relief	I-O
that	O
the	O
patients	O
in	O
the	O
ketamine	O
group	O
attributed	O
to	O
their	O
medication	O
improved	O
significantly	O
from	O
50	O
%	O
immediately	O
pre-infusion	O
to	O
65	O
%	O
24	O
h	O
post-infusion	O
and	O
69	O
%	O
5	O
days	O
post	O
infusion	O
.	O


Over	O
the	O
same	O
period	O
,	O
the	O
pain	B-O
relief	I-O
achieved	I-O
by	O
the	O
placebo	O
group	O
rose	O
from	O
58	O
%	O
pre-infusion	O
to	O
56	O
%	O
24	O
h	O
post	O
infusion	O
and	O
then	O
50	O
%	O
relief	O
5	O
days	O
later	O
.	O


This	O
was	O
statistically	B-O
significant	I-O
(	O
P	O
<	O
0.05	O
)	O
using	O
both	O
the	O
t-test	B-O
and	I-O
the	I-O
Wilcoxon	I-O
Rank	I-O
Sum	I-O
test	I-O
.	I-O


The	O
ketamine	O
group	O
also	O
showed	O
a	O
statistically	O
significant	O
difference	O
24	O
h	O
post	O
infusion	O
of	O
the	O
effect	O
of	O
pain	B-O
on	O
their	O
general	O
activity	O
(	O
P=0.03	O
)	O
and	O
on	O
their	O
enjoyment	O
of	O
life	O
(	O
P=0.004	O
)	O
.	O


This	O
study	O
shows	O
that	O
combining	O
a	O
single	O
infusion	O
of	O
low	O
dose	O
ketamine	O
with	O
regular	O
opioid	B-I
analgesia	I-I
can	O
result	O
in	O
a	O
significant	O
improvement	O
in	O
pain	B-O
relief	I-O
for	O
this	O
patient	O
group	O
.	O


The	O
effects	O
of	O
orthotic	B-I
heel	I-I
lifts	I-I
on	O
Achilles	B-O
tendon	I-O
force	I-O
and	I-O
strain	I-O
during	O
running	O
.	O


This	O
study	O
assessed	O
the	O
effects	O
of	O
orthotic	B-I
heel	I-I
lifts	I-I
on	O
Achilles	B-O
tendon	I-O
(	I-O
AT	I-O
)	I-O
force	I-O
and	I-O
strain	I-O
during	O
running	O
.	O


Ten	B-P
females	I-P
ran	I-P
barefoot	I-P
over	I-P
a	I-P
force	I-P
plate	I-P
in	I-P
three	I-P
conditions	I-P
:	I-P
no	I-I
heel	I-I
lifts	I-I
(	I-P
NHL	I-P
)	I-P
,	I-P
with	I-P
12	I-I
mm	I-I
heel	I-I
lifts	I-I
(	I-P
12HL	I-P
)	I-P
and	I-P
with	I-P
18	I-I
mm	I-I
heel	I-I
lifts	I-I
(	I-P
18HL	I-P
)	I-P
.	I-P


Kinematics	B-O
for	I-O
the	I-O
right	I-O
lower	I-O
limb	I-O
were	O
collected	O
(	O
200	O
Hz	O
)	O
.	O


AT	B-O
force	I-O
was	O
calculated	O
from	O
inverse	O
dynamics	O
.	O


AT	B-O
strain	I-O
was	O
determined	O
from	O
kinematics	O
and	O
ultrasound	O
images	O
of	O
medial	O
gastrocnemius	O
(	O
50	O
Hz	O
)	O
.	O


Peak	B-O
AT	I-O
strain	I-O
was	O
less	O
for	O
18HL	O
(	O
5.5	O
±	O
4.4	O
%	O
)	O
than	O
for	O
NHL	O
(	O
7.4	O
±	O
4.2	O
%	O
)	O
(	O
p	O
=	O
.029	O
,	O
effect	O
size	O
[	O
ES	O
]	O
=	O
0.44	O
)	O
but	O
not	O
for	O
12HL	O
(	O
5.8	O
±	O
4.8	O
%	O
)	O
versus	O
NHL	O
(	O
ES	O
=	O
0.35	B-O
)	I-O
.	I-O


Peak	B-O
AT	I-O
force	I-O
was	O
significantly	O
(	O
p	O
=	O
.024	O
,	O
ES	O
=	O
0.42	O
)	O
less	O
for	O
18HL	O
(	O
2382	O
±	O
717	O
N	O
)	O
than	O
for	O
NHL	O
(	O
2710	O
±	O
830	O
N	O
)	O
but	O
not	O
for	O
12HL	O
(	O
2538	O
±	O
823	O
N	O
,	O
ES	O
=	O
0.21	O
)	O
.	O


The	O
18HL	O
reduced	B-O
ankle	I-O
dorsiflexion	I-O
but	I-O
not	I-O
flexion-extension	I-O
ankle	I-O
moments	I-O
and	O
increased	B-O
the	I-O
AT	I-O
moment	I-O
arm	O
compared	O
with	O
NHL	O
.	O


Thus	O
,	O
18HL	O
reduced	B-O
force	I-O
and	I-O
strain	I-O
on	O
the	O
AT	O
during	O
running	O
via	O
a	O
reduction	B-O
in	I-O
dorsiflexion	I-O
,	O
which	O
lengthened	B-O
the	I-O
AT	I-O
moment	I-O
arm	O
.	O


Therefore	B-I
,	I-I
heel	I-I
lifts	O
could	O
be	O
used	O
to	O
reduce	B-O
AT	I-O
loading	I-O
and	I-O
strain	I-O
during	O
the	O
rehabilitation	O
of	O
AT	O
injuries	O
.	O


Oscillatory	B-P
potentials	I-P
,	I-P
retinopathy	I-P
,	I-P
and	I-P
long-term	I-P
glucose	I-P
control	I-P
in	I-P
insulin-dependent	I-P
diabetes	I-P
.	I-P


The	O
main	O
objective	O
of	O
the	O
study	O
was	O
to	O
assess	O
effects	O
of	O
long-term	B-I
lowering	I-I
of	I-I
glucosylated	I-O
hemoglobin	I-O
(	I-I
HbA1	I-I
%	I-I
)	I-I
on	O
neurosensory	O
function	O
in	O
insulin-dependent	B-P
diabetes	I-P
.	I-P


Individual	B-I
(	I-I
OP-1	I-I
,	I-I
OP-2	I-I
,	I-I
OP-3	I-I
)	I-I
and	I-I
summed	I-I
(	I-I
OP-sum	I-I
)	I-I
amplitudes	I-I
of	I-I
oscillatory	I-I
potentials	I-I
(	I-I
OPs	I-I
)	I-I
of	I-I
electroretinography	I-I
were	I-I
recorded	I-I
at	O
study	O
start	O
and	O
7-years	O
later	O
in	O
45	B-P
patients	I-P
(	O
the	O
Oslo	B-P
study	O
)	O
.	O


As	O
an	O
overall	O
7-year	O
change	O
,	O
amplitudes	B-O
of	I-O
OP-2	I-O
,	I-O
OP-3	I-O
and	I-O
OP-sum	I-O
were	I-O
reduced	I-O
(	O
p	O
<	O
0.0001-0.01	O
)	O
,	O
retinopathy	B-O
worsened	I-O
(	O
p	O
=	O
0.005	O
)	O
,	O
intraocular	B-O
pressure	I-O
decreased	I-O
(	O
p	O
<	O
0.001	O
)	O
,	O
systolic	B-O
blood	I-O
pressure	I-O
increased	I-O
(	O
p	O
<	O
0.0002	O
)	O
,	O
and	O
glycemic	B-O
control	I-O
improved	O
from	O
HbA1	O
of	O
11.2	O
+/-	O
2.2	O
%	O
at	O
study	O
start	O
to	O
a	O
7-year	O
cumulative	O
mean	O
of	O
9.5	O
+/-	O
1.5	O
%	O
(	O
p	O
<	O
0.0001	O
)	O
.	O


Multiple	O
regression	O
analysis	O
did	O
not	O
identify	O
any	O
independent	O
relations	O
between	O
change	O
in	O
OP-1	B-O
,	I-O
OP-2	I-O
,	I-O
OP-3	I-O
,	I-O
OP-sum	I-O
and	O
change	B-O
in	I-O
glycemic	I-O
control	I-O
or	I-O
background	I-O
variables	I-O
,	O
including	O
change	O
in	O
age	O
and	O
duration	O
of	O
diabetes	O
.	O


However	O
,	O
cross-sectional	O
observations	O
at	O
7	O
years	O
showed	O
negative	O
correlations	O
between	O
all	O
OPs	B-O
and	O
age	O
(	O
p	O
<	O
0.0001-0.003	O
)	O
,	O
and	O
between	O
OP-3	B-O
and	I-O
duration	I-O
(	O
p	O
=	O
0.003	O
)	O
and	O
counts	B-O
of	I-O
microaneurysms	I-O
(	O
p	O
=	O
0.02	O
)	O
.	O


The	O
data	O
suggest	O
that	O
various	O
clinical	O
background	O
variables	O
may	O
influence	O
individual	O
and	O
summed	O
amplitudes	O
of	O
OPs	O
differently	O
.	O


Reduced	B-O
neurosensory	I-O
retinal	I-O
function	I-O
(	I-O
OPs	I-O
)	I-O
seemed	O
to	O
appear	O
after	O
7-years	O
,	O
independently	O
of	O
vascular	B-O
defects	I-O
of	I-O
retinopathy	I-O
and	O
long-term	B-O
improvement	I-O
in	I-O
glucose	I-O
control	I-O
.	I-O


Reduced	O
albuminuria	O
with	O
sarpogrelate	B-I
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
monocyte	O
chemoattractant	O
protein-1	O
levels	O
in	O
type	B-P
2	I-P
diabetes	I-P
.	I-P


BACKGROUND	O
AND	O
OBJECTIVES	O
Sarpogrelate	B-I
has	O
been	O
shown	O
to	O
reduce	O
albuminuria	O
in	O
diabetic	O
nephropathy	O
.	O


For	O
examination	O
of	O
whether	O
this	O
is	O
based	O
on	O
the	O
same	O
mechanisms	O
as	O
angiotensin	O
II	O
receptor	O
blockers	O
or	O
thiazolidinedione	B-I
,	O
effects	O
of	O
sarpogrelate	B-I
on	O
atherosclerotic	O
inflammatory	O
molecules	O
and	O
their	O
relations	O
to	O
albuminuria	O
in	O
patients	B-P
who	I-P
had	I-P
diabetes	I-P
and	I-P
had	I-P
already	I-P
been	I-P
treated	I-P
with	I-P
angiotensin	I-I
II	I-I
receptor	I-I
blockers	I-I
and	I-P
with	I-P
or	I-P
without	I-P
thiazolidinedione	I-I
were	O
examined	O
.	O


DESIGN	O
,	O
SETTING	O
,	O
PARTICIPANTS	O
,	O
&	O
MEASUREMENTS	O
Forty	B-P
patients	I-P
who	I-P
had	I-P
diabetes	I-P
with	I-P
nephropathy	I-P
and	I-P
arteriosclerosis	I-P
obliterans	I-P
and	I-P
had	I-P
already	I-P
been	I-P
treated	I-P
with	I-P
angiotensin	I-I
II	I-I
receptor	I-I
blocker	I-I
(	I-P
n	I-P
=	I-P
40	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
sarpogrelate	B-I
(	O
300	O
mg/d	O
;	O
n	O
=	O
20	O
)	O
or	O
aspirin	B-I
group	I-I
(	O
100	O
mg/d	O
;	O
n	O
=	O
20	O
)	O
.	O


Plasma	B-O
monocyte	I-O
chemoattractant	I-O
protein-1	I-O
and	I-O
urinary	I-O
albumin-to-creatinine	I-O
ratio	I-O
and	I-O
monocyte	I-O
chemoattractant	I-O
protein-1	I-O
were	O
measured	O
at	O
baseline	O
and	O
16	O
wk	O
after	O
administration	O
.	O


RESULTS	O
Only	O
the	O
sarpogrelate	B-I
group	O
showed	O
increases	O
in	O
plasma	B-O
adiponectin	I-O
and	O
decreases	O
in	O
both	O
plasma	B-O
and	I-O
urinary	I-O
monocyte	I-O
chemoattractant	I-O
protein-1	I-O
and	I-O
albumin-to-creatinine	I-O
ratio	I-O
levels	I-O
.	I-O


Moreover	O
,	O
percentage	B-O
change	I-O
of	I-O
monocyte	I-O
chemoattractant	I-O
protein-1	I-O
level	I-O
correlated	O
positively	O
to	O
that	O
of	O
albumin-to-creatinine	O
ratio	O
.	O


Even	O
when	O
the	O
sarpogrelate	B-I
group	O
was	O
further	O
divided	O
into	O
two	O
groups	O
with	O
(	O
n	O
=	O
9	O
)	O
or	O
without	O
thiazolidinedione	B-I
(	O
n	O
=	O
11	O
)	O
,	O
changes	O
in	O
monocyte	B-O
chemoattractant	I-O
protein-1	I-O
or	I-O
albumin-to-creatinine	I-O
ratio	I-O
did	O
not	O
differ	O
.	O


CONCLUSIONS	O
Sarpogrelate	B-I
can	O
reduce	O
albuminuria	O
and	O
plasma	O
and	O
urinary	O
monocyte	O
chemoattractant	O
protein-1	O
levels	O
while	O
increasing	O
plasma	O
adiponectin	O
in	O
diabetic	O
nephropathy	O
.	O


These	O
effects	O
seem	O
to	O
be	O
mediated	O
via	O
mechanisms	O
that	O
are	O
different	O
from	O
those	O
of	O
angiotensin	B-I
II	I-I
receptor	I-I
blocker	I-I
or	O
thiazolidinedione	B-I
.	I-I


Peritonsillar	O
infiltration	O
with	O
bupivacaine	B-I
for	O
paediatric	B-P
tonsillectomy	I-P
.	I-P


In	O
a	O
double-blind	O
study	O
forty-two	B-P
children	I-P
scheduled	I-P
for	I-P
elective	I-P
adenotonsillectomy	I-P
were	O
randomized	O
to	O
receive	O
peritonsillar	O
infiltration	B-I
,	O
following	O
induction	O
of	O
anaesthesia	O
,	O
with	O
either	O
0.25	B-I
%	I-I
plain	I-I
bupivacaine	I-I
or	I-I
0.9	I-I
%	I-I
saline	I-I
,	O
0.5	O
ml/kg	O
to	O
a	O
maximum	O
of	O
10	O
ml	O
.	O


The	O
children	B-P
were	O
assessed	O
on	O
awakening	B-O
,	O
and	O
then	O
10	O
minutes	O
,	O
1	O
hour	O
,	O
4	O
hours	O
and	O
24	O
hours	O
later	O
.	O


On	O
each	O
occasion	O
the	O
observer	O
gave	O
the	O
child	O
a	O
pain	B-O
score	I-O
from	O
1	O
(	O
no	O
pain	O
)	O
to	O
5	O
(	O
severe	O
pain	O
)	O
.	O


The	O
scores	B-O
on	I-O
awakening	I-O
and	O
after	O
10	O
minutes	O
were	O
significantly	B-O
lower	I-O
in	O
the	O
bupivacaine	B-I
group	O
(	O
P	O
<	O
0.05	O
,	O
Mann-Whitney	O
U	O
test	O
)	O
.	O


Thereafter	O
there	O
was	O
no	O
difference	O
between	O
the	O
groups	O
.	O


The	O
authors	O
conclude	O
that	O
peritonsillar	O
infiltration	O
with	O
bupivacaine	B-I
is	O
only	O
moderately	O
useful	O
as	O
analgesia	O
for	O
children	B-P
having	I-P
tonsillectomy	I-P
.	I-P


Reactivation	B-O
of	I-O
unstable	I-O
angina	I-O
after	O
the	O
discontinuation	O
of	O
heparin	B-I
.	I-I


BACKGROUND	O
Heparin	B-I
is	O
an	O
effective	O
,	O
widely	O
used	O
treatment	O
for	O
unstable	B-P
angina	I-P
.	I-P


Among	O
patients	B-P
enrolled	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	B-I
trial	I-I
comparing	O
intravenous	B-I
heparin	I-I
,	I-I
aspirin	I-I
,	I-I
both	I-I
treatments	I-I
,	I-I
and	I-I
neither	I-I
during	O
the	O
acute	O
phase	O
of	O
unstable	O
angina	O
,	O
we	O
encountered	O
patients	O
in	O
whom	O
unstable	O
angina	O
was	O
reactivated	O
after	O
heparin	B-I
was	O
discontinued	O
.	O


METHODS	O
The	B-P
study	I-P
population	I-P
included	I-P
403	I-P
of	I-P
the	I-P
original	I-P
479	I-P
patients	I-P
in	I-P
the	I-P
trial	I-P
who	I-P
had	I-P
completed	I-P
six	I-P
days	I-P
of	I-P
blinded	I-P
therapy	I-P
without	I-P
refractory	I-P
angina	I-P
or	I-P
myocardial	I-P
infarction	I-P
.	I-P


After	O
the	O
discontinuation	O
of	O
therapy	O
,	O
clinical	B-O
events	I-O
,	I-O
including	I-O
reactivation	I-O
of	I-O
unstable	I-O
angina	I-O
and	I-O
myocardial	I-O
infarction	I-O
occurring	I-O
within	I-O
96	I-O
hours	I-O
after	I-O
hospitalization	I-O
,	O
were	O
closely	O
monitored	O
.	O


RESULTS	O
Early	B-O
reactivation	I-O
occurred	O
in	O
14	O
of	O
the	O
107	O
patients	O
who	O
received	O
heparin	B-I
alone	O
,	O
as	O
compared	O
with	O
only	O
5	O
patients	O
in	O
each	O
of	O
the	O
other	O
three	O
study	O
groups	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O


These	O
reactivations	B-O
required	O
urgent	O
intervention	O
(	O
thrombolysis	O
,	O
angioplasty	O
,	O
or	O
coronary-bypass	O
surgery	O
)	O
in	O
11	O
patients	O
treated	O
with	O
heparin	B-I
alone	O
,	O
but	O
in	O
only	O
2	O
patients	O
in	O
the	O
other	O
groups	O
combined	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O


Four	O
of	O
the	O
six	O
patients	O
who	O
had	O
a	O
myocardial	B-O
infarction	I-O
during	O
a	O
reactivation	O
of	O
their	O
disease	O
were	O
in	O
the	O
heparin	O
group	O
.	O


Reactivations	B-O
in	O
this	O
group	O
occurred	O
in	O
a	O
cluster	O
a	O
mean	O
(	O
+/-	O
SD	O
)	O
of	O
9.5	O
+/-	O
5	O
hours	O
after	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
but	O
were	O
randomly	O
distributed	O
over	O
the	O
initial	O
96	O
hours	O
in	O
the	O
other	O
three	O
groups	O
.	O


CONCLUSIONS	O
Although	O
heparin	B-I
is	O
beneficial	O
in	O
treating	O
unstable	O
angina	O
,	O
the	O
disease	O
process	O
may	O
be	O
reactivated	B-O
within	O
hours	O
of	O
the	O
discontinuation	O
of	O
this	O
drug	O
.	O


Concomitant	O
therapy	O
with	O
aspirin	O
may	O
prevent	O
this	O
withdrawal	O
phenomenon	O
.	O


In-hospital	B-O
costs	I-O
of	O
self-expanding	B-I
nitinol	I-I
stent	I-I
implantation	I-I
versus	O
balloon	B-I
angioplasty	I-I
in	O
the	O
femoropopliteal	O
artery	O
(	O
the	O
VascuCoil	O
Trial	O
)	O
.	O


PURPOSE	O
Although	O
several	O
prospective	O
studies	O
have	O
examined	O
the	O
safety	B-O
and	O
efficacy	B-O
of	O
stent	B-I
placement	I-I
for	O
femoropopliteal	B-P
arterial	I-P
disease	I-P
,	O
the	O
current	O
cost	O
of	O
these	O
procedures	O
is	O
unknown	O
.	O


To	O
estimate	O
and	O
compare	O
hospital	B-O
costs	I-O
associated	O
with	O
conventional	B-I
balloon	I-I
angioplasty	I-I
(	I-I
percutaneous	I-I
transluminal	I-I
angioplasty	I-I
[	I-I
PTA	I-I
]	I-I
)	I-I
and	I-I
stent	I-I
placement	I-I
for	O
patients	O
with	O
symptomatic	O
peripheral	O
arterial	O
disease	O
,	O
the	O
authors	O
performed	O
a	O
prospective	O
economic	O
evaluation	O
in	O
conjunction	O
with	O
the	O
Intracoil	O
Femoropopliteal	O
Stent	O
Trial	O
(	O
VascuCoil	O
)	O
.	O


MATERIALS	O
AND	O
METHODS	O
Between	O
May	O
1997	O
and	O
December	O
1999	O
,	O
266	B-P
patients	I-P
with	I-P
stenotic	I-P
or	I-P
occluded	I-P
superficial	I-P
femoral	I-P
or	I-P
popliteal	I-P
arteries	I-P
were	O
prospectively	O
randomized	O
to	O
treatment	O
with	O
the	O
IntraCoil	B-I
stent	I-I
or	O
PTA	B-I
.	I-I


Detailed	O
resource	B-O
use	I-O
and	O
cost	B-O
data	I-O
for	O
each	O
patient	O
's	O
initial	O
revascularization	O
procedure	O
and	O
ensuing	O
hospitalization	O
were	O
collected	O
and	O
analyzed	O
on	O
an	O
intention-to-treat	O
basis	O
.	O


RESULTS	O
Compared	O
with	O
conventional	B-I
balloon	I-I
angioplasty	I-I
,	I-I
stent	I-I
placement	I-I
did	O
not	O
improve	O
clinical	B-O
outcomes	I-O
but	O
increased	O
procedure	B-O
duration	I-O
,	I-O
equipment	I-O
costs	I-O
,	I-O
and	I-O
physician	I-O
services	I-O
.	I-O


As	O
a	O
result	O
,	O
initial	B-O
hospital	I-O
costs	I-O
were	O
approximately	O
3,500	O
dollars	O
higher	O
for	O
patients	O
randomized	O
to	O
the	O
IntraCoil	B-I
stent	I-I
,	O
compared	O
with	O
PTA	B-I
(	O
8,435	O
dollars	O
vs	O
4,980	O
dollars	O
;	O
P	O
<	O
.001	O
)	O
.	O


CONCLUSIONS	O
As	O
performed	O
in	O
the	O
VascuCoil	O
trial	O
,	O
primary	O
stent	O
placement	O
for	O
femoropopliteal	O
disease	O
did	O
not	O
improve	O
clinical	B-O
outcomes	I-O
but	O
increased	O
initial	B-O
treatment	I-O
costs	I-O
by	O
more	O
than	O
3,000	O
dollars	O
.	O


Because	O
there	O
were	O
no	O
substantial	O
differences	O
in	O
subsequent	O
clinical	B-O
outcomes	I-O
between	O
the	O
two	O
treatments	O
,	O
it	O
is	O
unlikely	O
that	O
these	O
increased	O
initial	B-O
costs	I-O
would	O
be	O
offset	O
by	O
savings	O
in	O
follow-up	B-O
costs	I-O
.	I-O


These	O
findings	O
suggest	O
that	O
a	O
strategy	O
of	O
routine	O
stent	B-I
implantation	O
for	O
patients	B-P
undergoing	I-P
femoropopliteal	I-P
PTA	I-I
is	O
not	O
optimal	O
on	O
economic	O
grounds	O
and	O
that	O
PTA	B-I
with	O
provisional	B-I
stent	I-I
implantation	I-I
is	O
preferred	O
.	O


The	O
dipeptidyl	B-I
peptidase-4	I-I
inhibitor	I-I
PHX1149	I-I
improves	O
blood	B-O
glucose	I-O
control	I-O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	I-P


AIM	O
To	O
determine	O
the	O
efficacy	B-O
and	I-O
tolerability	I-O
of	O
PHX1149	B-I
,	O
a	O
novel	O
dipeptidyl	O
peptidase-4	O
(	O
DPP4	O
)	O
inhibitor	O
,	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
.	I-P


METHODS	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
4-week	O
study	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
with	I-P
suboptimal	I-P
metabolic	I-P
control	I-P
.	I-P


Patients	B-P
with	I-P
a	I-P
baseline	I-P
haemoglobin	I-P
A	I-P
(	I-P
1c	I-P
)	I-P
(	I-P
HbA	I-P
(	I-P
1c	I-P
)	I-P
)	I-P
of	I-P
7.3	I-P
to	I-P
11.0	I-P
%	I-P
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once-daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	B-I
(	I-I
100	I-I
,	I-I
200	I-I
or	I-I
400	I-I
mg	I-I
)	I-I
or	I-I
placebo	I-I
;	I-I
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O


RESULTS	O
Treatment	O
with	O
100	O
,	O
200	O
or	O
400	O
mg	O
of	O
PHX1149	O
significantly	O
decreased	O
postprandial	B-O
glucose	I-O
area	I-O
under	I-O
the	I-O
curve	I-O
AUC	I-O
(	I-O
0-2	I-O
h	O
)	O
by	O
approximately	O
20	O
%	O
(	O
+0.11	O
+/-	O
0.50	O
,	O
-2.08	O
+/-	O
0.51	O
,	O
-1.73	O
+/-	O
0.49	O
and	O
-1.88	O
+/-	O
0.48	O
mmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.002	O
,	O
0.008	O
and	O
0.004	O
vs.	O
placebo	O
)	O
.	O


Postprandial	B-O
AUC	I-O
(	I-O
0-2	I-O
h	I-O
)	I-O
of	I-O
intact	I-O
glucagon-like	I-O
peptide-1	I-O
,	O
the	O
principal	O
mediator	O
of	O
the	O
biological	O
effects	O
of	O
DPP4	O
inhibitors	O
,	O
was	O
increased	O
by	O
3.90	O
+/-	O
2.83	O
,	O
11.63	O
+/-	O
2.86	O
,	O
16.42	O
+/-	O
2.72	O
and	O
15.75	O
+/-	O
2.71	O
pmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.053	O
,	O
0.001	O
and	O
0.002	O
vs.	O
placebo	O
)	O
.	O


Mean	B-O
HbA	I-O
(	I-O
1c	I-O
)	I-O
was	O
lower	O
in	O
all	O
dose	O
groups	O
;	O
the	O
placebo-corrected	O
change	O
in	O
the	O
groups	O
receiving	O
400	O
mg	O
PHX1149	O
was	O
-0.28	O
%	O
(	O
p	O
=	O
0.02	O
)	O
.	O


DPP4	B-O
inhibition	I-O
on	O
day	O
28	O
was	O
53	O
,	O
73	O
and	O
78	O
%	O
at	O
24	O
h	O
postdose	O
in	O
the	O
groups	O
receiving	O
100	O
,	O
200	O
and	O
400	O
mg	O
PHX1149	O
,	O
respectively	O
.	O


There	O
were	O
no	O
differences	O
in	O
adverse	B-O
events	I-O
between	O
PHX1149-treated	O
and	O
placebo	O
subjects	O
.	O


CONCLUSIONS	O
Addition	O
of	O
the	O
DPP4	O
inhibitor	O
PHX1149	O
to	O
a	O
stable	O
regimen	O
of	O
metformin	O
or	O
metformin	O
plus	O
a	O
glitazone	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
was	O
well	B-O
tolerated	I-O
and	O
improved	B-O
blood	I-O
glucose	I-O
control	I-O
.	I-O


Therapist	B-O
success	I-O
and	O
its	O
determinants	O
.	O


This	O
study	O
examined	O
the	O
relatively	O
unexplored	O
contribution	O
of	O
the	O
therapist	B-O
's	I-O
performance	I-O
in	O
determining	O
outcomes	B-O
of	I-O
treatment	I-O
.	I-O


Nine	B-P
therapists	I-P
were	I-P
studied	I-I
:	I-I
three	I-I
performed	I-I
supportive-expressive	I-I
psychotherapy	I-I
;	I-I
three	I-I
,	I-I
cognitive-behavioral	I-I
psychotherapy	I-I
;	I-I
and	I-I
three	I-I
,	I-I
drug	I-I
counseling	I-I
.	I-I


Profound	O
differences	O
were	O
discovered	O
in	O
the	O
therapists	O
'	O
success	O
with	O
the	O
patients	O
in	O
their	O
case	O
loads	O
.	O


Four	O
potential	O
determinants	O
of	O
these	O
differences	O
were	O
explored	O
:	O
patient	B-O
factors	I-O
;	I-O
therapist	I-O
factors	I-O
;	I-O
patient-therapist	I-O
relationship	I-O
factors	I-O
;	I-O
and	O
therapy	B-O
factors	I-O
.	I-O


Results	O
showed	O
that	O
patient	O
characteristics	O
within	O
each	O
case	O
load	O
(	O
after	O
random	O
assignments	O
)	O
were	O
similar	O
and	O
disclosed	O
no	O
differences	O
that	O
would	O
have	O
explained	O
the	O
differences	O
in	O
success	O
;	O
therapist	B-O
's	I-O
personal	I-O
qualities	I-O
were	O
correlated	O
with	O
outcomes	O
but	O
not	O
significantly	O
(	O
mean	O
r	O
=	O
.32	O
)	O
;	O
an	O
early-in-treatment	O
measure	O
of	O
the	O
patient-therapist	B-O
relationship	I-O
,	I-O
the	I-O
Helping	I-O
Alliance	I-O
Questionnaire	I-O
,	O
yielded	O
significant	O
correlations	O
with	O
outcomes	O
(	O
mean	O
r	O
=	O
.65	O
)	O
;	O
among	O
the	O
therapy	O
techniques	O
,	O
"	B-O
purity	I-O
"	I-O
provided	O
significant	O
correlations	O
with	O
outcomes	O
(	O
mean	O
r	O
=	O
.44	O
)	O
,	O
both	O
across	O
therapists	O
and	O
within	O
each	O
therapist	O
's	O
case	O
load	O
.	O


The	O
three	O
therapist-related	O
factors	O
were	O
moderately	O
associated	O
with	O
each	O
other	O
.	O


Pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
six	O
epoetin	B-I
alfa	I-I
dosing	O
regimens	O
in	O
anemic	B-P
critically	I-P
ill	I-P
patients	I-P
without	I-P
acute	I-P
blood	I-P
loss	I-P
.	I-P


OBJECTIVE	O
To	O
describe	O
the	O
pharmacokinetic	O
profiles	O
of	O
six	O
different	O
dosing	O
regimens	O
for	O
epoetin	B-I
alfa	I-I
,	O
and	O
whether	O
more	O
rapid	O
and	O
robust	O
reticulocytosis	O
can	O
be	O
elicited	O
with	O
more	O
frequent	O
administration	O
of	O
epoetin	B-I
alfa	I-I
in	O
anemic	B-P
critically	I-P
ill	I-P
patients	I-P
.	I-P


DESIGN	O
Randomized	O
,	O
open-label	O
,	O
multicenter	O
,	O
28-day	O
clinical	O
trial	O
.	O


SETTING	O
Ten	B-P
centers	I-P
in	I-P
the	I-P
United	I-P
States	I-P
.	I-P


PATIENTS	O
Adult	B-P
(	I-P
age	I-P
>	I-P
or=18	I-P
years	I-P
)	I-P
critically	I-P
ill	I-P
patients	I-P
with	I-P
hemoglobin	I-P
<	I-P
or=12	I-P
g/dL	I-P
,	I-P
expected	I-P
hospitalization	I-P
of	I-P
>	I-P
or=7	I-P
days	I-P
,	I-P
with	I-P
no	I-P
ongoing	I-P
acute	I-P
blood	I-P
loss	I-P
.	I-P


INTERVENTIONS	O
One	O
of	O
six	B-I
dosing	I-I
epoetin	I-I
alfa	I-I
regimens	I-I
for	O
15	O
days	O
,	O
as	O
follows	O
:	O
40,000	B-I
IU	I-I
once	I-I
weekly	I-I
,	O
subcutaneously	O
(	O
group	O
A	O
)	O
or	O
intravenously	O
(	O
IV	O
)	O
(	O
group	O
B	O
)	O
;	O
15,000	B-I
IU	I-I
every	I-I
other	I-I
day	I-I
,	I-I
subcutaneously	I-I
(	O
group	O
C	O
)	O
or	O
IV	O
(	O
group	O
D	O
)	O
;	O
or	O
40,000	B-I
IU	I-I
day	I-I
1	O
and	O
3	O
,	O
subcutaneously	B-I
(	O
group	O
E	O
)	O
or	O
IV	O
(	O
group	O
F	O
)	O
,	O
followed	O
by	O
15,000	O
IU	O
once	O
every	O
other	O
day	O
on	O
[	O
corrected	O
]	O
days	O
5-15	O
[	O
corrected	O
]	O
MEASUREMENTS	O
Serum	B-O
erythropoietin	I-O
concentration	I-O
,	I-O
absolute	I-O
reticulocyte	I-O
count	I-O
,	I-O
and	I-O
adverse	I-O
events	I-O
.	I-O


MAIN	O
RESULTS	O
Of	O
the	O
60	O
patients	O
who	O
were	O
enrolled	O
(	O
60	O
%	O
men	O
,	O
mean	O
age	O
53	O
years	O
,	O
mean	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
,	O
19.5	O
)	O
,	O
30	O
were	O
evaluable	O
for	O
both	O
pharmacokinetics	O
and	O
pharmacodynamics	O
(	O
50	O
%	O
)	O
.	O


Erythropoietin	B-O
exposure	I-O
was	O
approximately	O
ten	O
times	O
greater	O
for	O
IV	O
dosing	O
than	O
for	O
subcutaneous	B-I
dosing	I-I
.	I-I


Mean	B-O
absolute	I-O
reticulocyte	I-O
count	I-O
peaked	O
at	O
day	O
11	O
or	O
15	O
in	O
each	O
group	O
and	O
appeared	O
to	O
be	O
greater	O
for	O
subcutaneous	O
dosing	B-I
(	O
mean	O
peak	O
response	O
149-169	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
compared	O
with	O
IV	O
dosing	B-I
(	O
mean	O
peak	O
response	O
138-147	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
at	O
most	O
visits	O
.	O


The	O
most	O
frequently	O
reported	O
adverse	B-O
events	I-O
were	O
pyrexia	B-O
(	O
18	O
%	O
)	O
,	O
hypokalemia	B-O
(	O
15	O
%	O
)	O
,	O
and	O
hypophosphatemia	B-O
(	O
15	O
%	O
)	O
.	O


CONCLUSIONS	O
In	O
this	O
study	O
of	O
anemic	O
critically	O
ill	O
patients	O
treated	O
with	O
epoetin	B-I
alfa	I-I
,	O
all	O
dosing	O
regimens	O
were	O
well	O
tolerated	B-O
and	O
appeared	O
to	O
effect	O
reticulocytosis	B-O
,	O
with	O
a	O
peak	O
at	O
day	O
11	O
or	O
15	O
in	O
most	O
patients	O
.	O


The	O
pharmacokinetics	O
of	O
epoetin	B-I
alfa	I-I
did	O
not	O
predict	O
pharmacodynamic	B-O
response	I-O
in	O
anemic	O
critically	O
ill	O
patients	O
.	O


Evolution	O
of	O
neuropathy	O
and	O
myopathy	O
during	O
intensive	O
vincristine/corticosteroid	B-I
chemotherapy	I-I
for	O
non-Hodgkin	O
's	O
lymphoma	O
.	O


Neuropathy	O
and	O
myopathy	O
are	O
common	O
sequelae	O
of	O
intensive	B-I
chemotherapy	I-I
protocols	I-I
that	I-I
contain	I-I
vincristine	I-I
and	I-I
corticosteroids	I-I
.	I-I


The	O
authors	O
prospectively	O
monitored	O
the	O
evolution	O
of	O
neuropathy	O
and	O
myopathy	O
during	O
an	O
intensive	O
12-week	O
chemotherapy	B-I
program	O
for	O
patients	B-P
with	I-P
intermediate	I-P
and	I-P
high-grade	I-P
non-Hodgkin	I-P
's	I-P
lymphoma	I-P
.	I-P


In	O
this	O
study	O
,	O
vincristine	B-I
was	O
administered	O
by	O
bolus	B-I
injection	O
followed	O
by	O
a	O
3-day	O
continuous	O
intravenous	O
(	O
IV	O
)	O
infusion	O
(	O
total	O
dose	O
of	O
2.0	O
mg/m2	O
every	O
other	O
week	O
)	O
;	O
the	O
maximum	O
dose	O
of	O
vincristine	B-I
was	O
not	O
arbitrarily	O
limited	O
.	O


Cronassial	B-I
,	I-I
a	I-I
mixture	I-I
of	I-I
four	I-I
naturally	I-I
occurring	I-I
gangliosides	I-I
,	O
was	O
administered	O
in	O
a	O
randomized	O
double-blind	O
test	O
to	O
evaluate	O
whether	O
this	O
agent	O
could	O
prevent	O
vincristine-induced	B-I
neuropathy	O
.	O


High	O
doses	O
of	O
dexamethasone	B-I
(	O
50	O
mg/d	O
for	O
3	O
days	O
weekly	O
or	O
every	O
other	O
week	O
)	O
were	O
also	O
prescribed	O
.	O


Patients	O
were	O
monitored	O
every	O
4	O
weeks	O
with	O
comprehensive	O
physical	O
and	O
neurologic	O
examinations	O
and	O
electrophysiologic	O
studies	O
of	O
peripheral	O
nerve	O
function	O
.	O


Twenty-seven	B-P
patients	I-P
were	I-P
fully	I-P
evaluable	I-P
.	I-P


Weakness	B-O
was	O
a	O
prominent	O
adverse	O
reaction	O
in	O
this	O
study	O
,	O
and	O
all	O
patients	O
had	O
moderate	B-O
to	I-O
severe	I-O
signs	I-O
and	I-O
symptoms	I-O
of	I-O
neuropathy	I-O
and	I-O
myopathy	I-O
.	I-O


Cronassial	B-I
(	O
100	O
mg	O
)	O
administered	O
by	O
intramuscular	O
(	O
IM	O
)	O
injection	O
daily	O
provided	O
no	O
protection	O
against	O
the	O
development	B-O
of	I-O
neuropathic	I-O
symptoms	I-O
.	I-O


Vincristine	B-I
typically	O
impaired	O
fine-motor	B-O
coordination	I-O
initially	O
,	O
whereas	O
corticosteroids	B-I
were	O
associated	O
with	O
delayed	O
development	B-O
of	I-O
proximal	I-O
muscle	I-O
weakness	I-O
.	I-O


Results	O
of	O
electrodiagnostic	O
studies	O
did	O
not	O
add	O
to	O
the	O
clinical	O
examination	O
results	O
.	O


The	O
authors	O
conclude	O
that	O
symptomatic	B-O
weakness	I-O
due	O
to	O
neuropathy	O
or	O
myopathy	O
appears	O
in	O
a	O
predictable	O
manner	O
during	O
intensive	O
vincristine/corticosteroid-based	B-I
treatment	I-I
protocols	O
.	O


Simple	O
clinical	O
tests	O
can	O
be	O
used	O
to	O
rapidly	O
distinguish	O
between	O
toxic	O
effects	O
due	O
either	O
to	O
vincristine	B-I
or	I-I
corticosteroids	I-I
,	O
and	O
routine	O
implementation	O
of	O
these	O
tests	O
can	O
prevent	O
inappropriate	O
dose	O
attenuation	O
of	O
these	O
agents	O
.	O


Effects	O
of	O
glucose-insulin-potassium	B-I
infusion	I-I
on	O
ST-elevation	B-O
myocardial	I-O
infarction	I-O
in	I-P
patients	I-P
treated	I-P
with	I-P
thrombolytic	I-I
therapy	I-I
.	I-I


The	O
role	O
of	O
glucose-insulin-potassium	B-I
(	I-I
GIK	I-I
)	I-I
infusion	I-I
in	O
the	O
management	O
of	O
acute	B-O
myocardial	I-O
infarction	I-O
is	O
not	O
well	O
established	O
.	O


This	O
prospective	O
,	O
randomized	O
study	O
comprised	O
120	B-P
patients	I-P
who	I-P
had	I-P
ST-elevation	I-P
myocardial	I-P
infarction	I-P
that	I-P
was	I-P
treated	I-P
within	I-P
12	I-P
hours	I-P
from	I-P
symptom	I-P
onset	I-P
with	O
a	O
high	O
dose	O
of	O
GIK	B-I
(	I-I
25	I-I
%	I-I
glucose	I-I
,	I-I
50	I-I
IU	I-I
of	I-I
soluble	I-I
insulin	I-I
per	I-I
liter	I-I
,	I-I
and	I-I
80	I-I
mmol	I-I
of	I-I
potassium	I-I
chloride	I-I
per	I-I
liter	I-I
at	I-I
1	I-I
ml/kg/hour	I-I
over	I-I
24	I-I
hours	I-I
)	I-I
as	I-I
adjunct	I-I
to	I-I
thrombolytic	I-I
therapy	I-I
(	I-I
1.5	I-I
MU	I-I
of	I-I
streptokinase/30	I-I
to	I-I
60	I-I
minutes	I-I
;	I-I
GIK	I-I
group	I-I
)	I-I
or	O
thrombolytic	B-I
therapy	I-I
alone	I-I
(	I-I
control	I-I
group	I-I
)	I-I
.	I-I


The	O
primary	O
end	O
point	O
of	O
the	O
study	O
was	O
the	O
rate	B-O
of	I-O
major	I-O
adverse	I-O
cardiac	I-O
events	I-O
(	I-O
MACEs	I-O
)	I-O
at	I-O
1	I-O
month	I-O
,	O
defined	O
as	O
a	B-O
composite	I-O
of	I-O
cardiac	I-O
death	I-O
,	I-O
reinfarction	I-O
,	I-O
serious	I-O
arrhythmias	I-O
(	I-O
ventricular	I-O
fibrillation	I-O
and/or	I-O
tachycardia	I-O
)	I-O
,	I-O
and	I-O
severe	I-O
heart	I-O
failure	I-O
.	I-O


The	O
secondary	O
end	O
points	O
were	O
the	O
rate	B-O
of	I-O
MACEs	I-O
at	I-O
1	I-O
year	I-O
and	I-O
improvement	I-O
in	I-O
left	I-O
ventricular	I-O
systolic	I-O
function	I-O
.	I-O


The	O
incidence	B-O
of	I-O
MACEs	I-O
at	I-O
1	I-O
month	I-O
was	O
significantly	O
lower	O
in	O
the	O
GIK	B-I
group	I-I
(	O
10	O
%	O
vs	O
32.5	O
%	O
,	O
relative	O
risk	O
0.24	O
,	O
95	O
%	O
confidence	O
interval	O
0.09	O
to	O
0.63	O
,	O
p	O
=	O
0.0043	O
)	O
.	O


Patients	O
in	O
the	O
GIK	B-I
group	O
had	O
significant	O
decreases	O
in	O
ventricular	B-O
tachycardia	I-O
and/or	I-O
fibrillation	I-O
(	O
1.3	O
%	O
vs	O
15.0	O
%	O
,	O
p	O
=	O
0.003	O
)	O
and	O
severe	O
heart	B-O
failure	I-O
(	O
3	O
%	O
vs	O
12.5	O
%	O
,	O
p	O
=	O
0.031	O
)	O
.	O


The	O
rate	B-O
of	I-O
MACEs	I-O
at	I-O
1	I-O
year	I-O
was	O
also	O
significantly	O
lower	O
in	O
the	O
GIK	B-I
group	I-I
(	O
13	O
%	O
vs	O
40.0	O
%	O
,	O
relative	O
risk	O
0.22	O
,	O
95	O
%	O
confidence	O
interval	O
0.09	O
to	O
0.55	O
,	O
p	O
=	O
0.0012	O
)	O
.	O


After	O
1	O
year	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
left	B-O
ventricular	I-O
ejection	I-O
fraction	I-O
in	O
the	O
GIK	B-I
group	I-I
(	O
from	O
48	O
+/-	O
8	O
%	O
to	O
51	O
+/-	O
10	O
%	O
,	O
p	O
<	O
0.01	O
)	O
,	O
which	O
was	O
not	O
observed	O
in	O
the	O
control	B-I
group	O
.	O


In	O
conclusion	O
,	O
high-dose	O
GIK	B-I
,	O
used	O
as	O
an	O
adjunct	O
to	O
thrombolytic	B-I
therapy	I-I
,	O
was	O
safe	B-O
and	O
improved	O
clinical	B-O
outcome	I-O
at	O
1	O
month	O
.	O


The	O
beneficial	O
effect	O
of	O
GIK	B-I
infusion	O
was	O
maintained	O
up	O
to	O
1	O
year	O
.	O


Behavioral	B-O
and	I-O
physiological	I-O
effects	I-O
of	O
remifentanil	B-I
and	I-I
alfentanil	I-I
in	O
healthy	B-P
volunteers	I-P
.	I-P


BACKGROUND	O
The	B-O
subjective	I-O
and	I-O
psychomotor	I-O
effects	I-O
of	O
remifentanil	B-I
have	O
not	O
been	O
evaluated	O
.	O


Accordingly	O
,	O
the	O
authors	O
used	O
mood	O
inventories	O
and	O
psychomotor	O
tests	O
to	O
characterize	O
the	O
effects	O
of	O
remifentanil	B-I
in	O
healthy	B-P
,	I-P
non-drug-abusing	I-P
volunteers	I-P
.	I-P


Alfentanil	O
was	O
used	O
as	O
a	O
comparator	O
drug	O
.	O


METHODS	O
Ten	B-P
healthy	I-P
volunteers	I-P
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double-blinded	O
,	O
placebo-controlled	B-I
,	O
crossover	O
trial	O
in	O
which	O
they	O
received	O
an	O
infusion	O
of	O
saline	B-I
,	I-I
remifentanil	I-I
,	I-I
or	I-I
alfentanil	I-I
for	I-I
120	I-I
min	I-I
.	I-I


The	O
age-	B-I
and	I-I
weight-adjusted	I-I
infusions	I-I
(	I-I
determined	I-I
with	I-I
STANPUMP	I-I
,	I-I
a	I-I
computer	I-I
modeling	I-I
software	I-I
package	I-I
)	I-I
were	O
given	O
to	O
achieve	O
three	O
predicted	O
constant	O
plasma	O
levels	O
for	O
40	B-I
min	I-I
each	I-I
of	I-I
remifentanil	I-I
(	I-I
0.75	I-I
,	I-I
1.5	I-I
,	I-I
and	I-I
3	I-I
ng/ml	I-I
)	I-I
and	I-I
alfentanil	I-I
(	I-I
16	I-I
,	I-I
32	I-I
,	I-I
and	I-I
64	I-I
ng/ml	I-I
)	I-I
.	I-I


Mood	O
forms	O
and	O
psychomotor	O
tests	O
were	O
completed	O
,	O
and	O
miosis	O
was	O
assessed	O
,	O
during	O
and	O
after	O
the	O
infusions	O
.	O


In	O
addition	O
,	O
analgesia	O
was	O
tested	O
at	O
each	O
dose	O
level	O
using	O
a	O
cold-pressor	O
test	O
.	O


RESULTS	O
Remifentanil	B-I
had	O
prototypic	B-O
micro-like	I-O
opioid	I-O
subjective	I-O
effects	I-O
,	I-O
impaired	I-O
psychomotor	I-O
performance	I-O
,	I-O
and	I-O
produced	I-O
analgesia	I-O
.	I-O


Alfentanil	O
at	O
the	O
dose	O
range	O
tested	O
had	O
more	O
mild	O
effects	O
on	O
these	O
measures	O
,	O
and	O
the	O
analgesia	B-O
data	O
indicated	O
that	O
a	O
40:1	O
potency	O
ratio	O
,	O
rather	O
than	O
the	O
20:1	O
ratio	O
we	O
used	O
,	O
may	O
exist	O
between	O
remifentanil	O
and	O
alfentanil	O
.	O


A	O
psychomotor	O
test	O
administered	O
60	O
min	O
after	O
the	O
remifentanil	O
infusion	O
was	O
discontinued	O
showed	O
that	O
the	O
volunteers	O
were	O
still	O
impaired	O
,	O
although	O
they	O
reported	O
feeling	O
no	O
drug	O
effects	O
.	O


CONCLUSIONS	O
The	O
notion	O
that	O
the	O
pharmacodynamic	B-O
effects	I-O
of	O
remifentanil	B-I
are	O
extremely	O
short-lived	O
after	O
the	O
drug	O
is	O
no	O
longer	O
administered	O
must	O
be	O
questioned	O
given	O
our	O
findings	O
that	O
psychomotor	B-O
effects	I-O
were	O
still	O
apparent	O
1	O
h	O
after	O
the	O
infusion	O
was	O
discontinued	O
.	O


Risperidone	B-I
versus	I-I
haloperidol	I-I
in	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
AD	I-P
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double-blind	O
trial	O
.	O


OBJECTIVE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
safety	B-O
,	I-O
efficacy	I-O
and	I-O
tolerability	I-O
of	O
risperidone	B-I
with	I-I
haloperidol	I-I
in	O
the	O
treatment	O
of	O
Autistic	B-P
Disorder	I-P
(	I-P
AD	I-P
)	I-P
.	O


METHOD	O
This	O
study	O
was	O
designed	O
as	O
a	O
double-blind	O
,	O
prospective	O
,	O
for	O
a	O
12-week	O
period	O
.	O


A	B-P
total	I-P
of	I-P
30	I-P
subjects	I-P
,	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
8	I-P
and	I-P
18	I-P
with	I-P
AD	I-P
based	I-P
on	I-P
DSM	I-P
IV	I-P
criteria	I-P
,	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Behavioral	B-O
Rating	I-O
Scales	I-O
were	O
performed	O
by	O
the	O
investigators	O
and	O
the	O
parents	O
.	O


Safety	B-O
assessment	I-O
included	O
vital	B-O
signs	I-O
,	I-O
electrocardiogram	I-O
,	I-O
electroencephalogram	I-O
,	I-O
adverse	I-O
events	I-O
,	I-O
laboratory	I-O
tests	I-O
,	I-O
extrapyramidal	I-O
symptoms	I-O
and	I-O
the	I-O
side	I-O
effects	I-O
.	I-O


Both	O
treatments	O
were	O
applied	O
in	O
a	O
once	O
daily	O
dosage	O
regimen	O
of	O
0.01-0.08	O
mg/kg/day	O
.	O


RESULTS	O
The	O
reduction	O
from	O
baseline	O
in	O
Ritvo-Freeman	B-O
Real	I-O
Life	I-O
Rating	I-O
Scale	I-O
(	I-O
RF-RLRS	I-O
)	I-O
,	I-O
sensory	I-O
motor	I-O
(	I-O
subscale	I-O
I	I-O
)	I-O
and	I-O
language	I-O
(	I-O
subscale	I-O
V	I-O
)	I-O
scores	I-O
were	O
significant	O
in	O
risperidone	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Compared	O
to	O
haloperidol	O
,	O
risperidone	O
led	O
to	O
a	O
significantly	O
greater	O
reduction	O
in	O
the	O
Aberrant	B-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
and	I-O
Turgay	I-O
DSM-IV	I-O
Pervasive	I-O
Developmental	I-O
Disorder	I-O
(	I-O
PDD	I-O
)	I-O
scale	I-O
scores	I-O
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.01	O
)	O
.	O


There	O
was	O
a	O
greater	O
increase	O
of	O
prolactin	B-O
in	O
the	O
risperidone	O
group	O
,	O
while	O
alanine	B-O
amino	I-O
transferase	I-O
(	I-O
ALT	I-O
)	I-O
had	O
further	O
increased	O
in	O
the	O
haloperidol	O
group	O
.	O


Sensory	B-O
motor	I-O
behaviors	I-O
(	I-O
subscale	I-O
I	I-O
)	I-O
and	O
language	B-O
at	O
the	O
end	O
of	O
the	O
12th	O
week	O
,	O
RF-RLRS	B-O
sensory	I-O
motor	I-O
and	I-O
language	I-O
subscale	I-O
scores	I-O
decreased	O
in	O
the	O
risperidone	O
group	O
further	O
than	O
the	O
other	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	O
Risperidone	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
haloperidol	O
in	O
the	O
treatment	O
of	O
behavioral	B-O
symptoms	I-O
,	I-O
impulsivity	I-O
,	I-O
language	I-O
skills	I-O
,	O
and	O
impaired	B-O
social	I-O
relations	I-O
in	O
children	B-P
with	I-P
AD	I-P
.	I-P


These	O
results	O
demonstrated	O
that	O
both	O
drugs	O
were	O
safe	O
and	O
well	O
tolerated	O
in	O
the	O
treatment	O
of	O
AD	O
.	O


Evaluation	O
of	O
electrofunctional	O
data	O
following	O
argon-laser	B-I
trabeculoplasty	I-I
in	O
primary	O
open-angle	O
glaucoma	O
.	O


To	O
establish	O
whether	O
or	O
not	O
glaucomatous	B-O
damage	I-O
is	O
reversible	O
,	O
we	O
obtained	O
pattern-reversal	B-O
electroretinograms	I-O
(	I-O
PERGs	I-O
)	I-O
and	I-O
visual	I-O
evoked	I-O
potentials	I-O
(	I-O
VEPs	I-O
)	I-O
in	O
25	B-P
eyes	I-P
of	I-P
25	I-P
patients	I-P
suffering	I-P
from	I-P
bilateral	I-P
primary	I-P
open-angle	I-P
glaucoma	I-P
(	I-P
POAG	I-P
)	I-P
before	I-P
and	I-P
after	I-P
argon-laser	I-I
trabeculoplasty	I-I
.	I-I


The	O
laser	O
treatment	O
was	O
carried	O
out	O
in	O
only	O
one	O
eye	O
chosen	O
at	O
random	O
,	O
and	O
the	O
fellow	O
eye	O
was	O
used	O
as	O
a	O
control	O
.	O


In	O
the	O
present	O
study	O
we	O
intended	O
to	O
verify	O
the	O
possibility	O
of	O
using	O
electrofunctional	O
techniques	O
to	O
determine	O
the	O
two	O
distinct	O
and	O
,	O
probably	O
,	O
consecutive	O
glaucomatous	B-O
alterations	I-O
occurring	I-O
in	I-O
ganglion	I-O
cells	I-O
:	I-O
functional	I-O
(	I-O
reversible	I-O
)	I-O
and	I-O
anatomical	I-O
(	I-O
irreversible	I-O
)	I-O
.	I-O


The	O
results	O
obtained	O
indicate	O
that	O
glaucomatous	B-O
damage	I-O
is	O
irreversible	O
.	O


We	O
propose	O
that	O
such	O
alterations	O
differ	O
very	O
slightly	O
and	O
that	O
the	O
current	O
electrofunctional	O
techniques	O
may	O
not	O
be	O
sufficiently	O
sophisticated	O
to	O
distinguish	O
between	O
them	O
.	O


A	O
comparative	O
trial	O
of	O
fixed	O
ratio	O
beta-adrenoceptor	B-I
blocker	I-I
and	I-I
diuretic	I-I
combination	I-I
products	I-I
in	O
moderate	B-P
hypertension	I-P
.	I-P


Two	O
fixed	O
ratio	O
combination	O
tablets	O
,	O
10	O
mg	O
pindolol	B-I
combined	I-I
with	I-I
5	I-I
mg	I-I
clopamide	I-I
and	O
100	O
mg	O
metoprolol	B-I
combined	I-I
with	I-I
12.5	I-I
mg	I-I
hydrochlorothiazide	I-I
,	O
were	O
compared	O
at	O
two	O
dose	O
levels	O
in	O
a	O
double-blind	O
crossover	O
trial	O
in	O
10	B-P
previously	I-P
untreated	I-I
hypertensive	I-P
patients	I-P
.	I-P


No	O
significant	O
difference	O
was	O
observed	O
between	O
resting	B-O
blood	I-O
pressure	I-O
on	O
the	O
two	O
combinations	O
at	O
either	O
dose	O
level	O
.	O


Exercise	B-O
systolic	I-O
pressure	I-O
was	O
lower	O
after	O
the	O
pindolol/clopamide	B-I
combination	O
at	O
low	O
dose	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


The	O
incidence	B-O
of	I-O
side-effects	I-O
in	O
this	O
trial	O
was	O
high	O
but	O
proper	O
comparison	O
of	O
the	O
two	O
products	O
could	O
not	O
be	O
made	O
because	O
of	O
the	O
small	O
number	O
of	O
patients	O
.	O


It	O
is	O
suggested	O
that	O
combination	B-I
products	I-I
should	O
be	O
used	O
only	O
after	O
patients	O
have	O
failed	O
to	O
respond	O
adequately	O
to	O
a	O
single	O
agent	O
.	O


Randomized	O
,	O
placebo-controlled	B-I
,	O
double-blind	O
clinical	O
trial	O
evaluating	O
the	O
treatment	O
of	O
plantar	B-P
fasciitis	I-P
with	O
an	O
extracoporeal	B-I
shockwave	I-I
therapy	I-I
(	I-I
ESWT	I-I
)	I-I
device	I-I
:	I-I
a	O
North	B-P
American	I-P
confirmatory	I-P
study	I-P
.	I-P


Despite	O
numerous	O
publications	O
and	O
clinical	O
trials	O
,	O
the	O
results	O
of	O
treatment	O
of	O
recalcitrant	B-P
chronic	I-P
plantar	I-P
fasciitis	I-P
with	O
extracorporeal	B-I
shockwave	I-I
therapy	I-I
(	I-I
ESWT	I-I
)	I-I
still	O
remain	O
equivocal	O
as	O
to	O
whether	O
or	O
not	O
this	O
treatment	O
provides	O
relief	B-O
from	O
the	B-O
pain	I-O
associated	O
with	O
this	O
condition	O
.	O


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
extracorporeal	O
shock	O
wave	O
therapy	O
can	O
safely	B-O
and	I-O
effectively	I-O
relieve	I-O
the	I-O
pain	I-O
associated	O
with	O
chronic	O
plantar	O
fasciitis	O
compared	O
to	O
placebo	O
treatment	O
,	O
as	O
demonstrated	O
by	O
pain	O
with	O
walking	O
in	O
the	O
morning	O
.	O


This	O
was	O
set	O
in	O
a	O
multicenter	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
,	O
confirmatory	O
clinical	O
study	O
undertaken	O
in	O
four	B-P
outpatient	I-P
orthopedic	I-P
clinics	I-P
.	I-P


The	B-P
patients	I-P
,	I-P
114	I-P
adult	I-P
subjects	I-P
with	I-P
chronic	I-P
plantar	I-P
fasciitis	I-P
,	I-P
recalcitrant	I-P
to	I-P
conservative	I-P
therapies	I-P
for	I-P
at	I-P
least	I-P
6	I-P
months	I-P
,	O
were	O
randomized	O
to	O
two	O
groups	O
.	O


Treatment	O
consisted	O
of	O
approximately	O
3,800	B-I
total	I-I
shock	I-I
waves	I-I
(	O
+/-10	O
)	O
reaching	O
an	O
approximated	O
total	O
energy	O
delivery	O
of	O
1,300	O
mJ/mm	O
(	O
2	O
)	O
(	O
ED+	O
)	O
in	O
a	O
single	O
session	O
versus	O
placebo	B-I
treatment	I-I
.	I-I


This	O
study	O
demonstrated	O
a	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
the	O
change	O
from	O
baseline	O
to	O
3	O
months	O
in	O
the	O
primary	O
efficacy	O
outcome	O
of	O
pain	B-O
during	O
the	B-O
first	I-O
few	I-O
minutes	I-O
of	I-O
walking	I-O
measured	O
by	O
a	O
visual	B-O
analog	I-O
scale	I-O
.	I-O


There	O
was	O
also	O
a	O
statistically	O
significant	O
difference	O
between	O
treatments	O
in	O
the	O
number	O
of	O
participants	O
whose	O
changes	O
in	O
Visual	B-O
Analog	I-O
Scale	I-O
scores	I-O
met	O
the	O
study	O
definition	O
of	O
success	O
at	O
both	O
6	O
weeks	O
and	O
3	O
months	O
posttreatment	O
;	O
and	O
between	O
treatment	O
groups	O
in	O
the	O
change	O
from	O
baseline	O
to	O
3	O
months	O
posttreatment	O
in	O
the	O
Roles	B-O
and	I-O
Maudsley	I-O
Score	I-O
.	I-O


The	O
results	O
of	O
this	O
study	O
confirm	O
that	O
ESWT	B-I
administered	O
with	O
the	O
Dornier	O
Epos	O
Ultra	O
is	O
a	O
safe	B-O
and	O
effective	B-O
treatment	O
for	O
recalcitrant	O
plantar	O
fasciitis	O
.	O


Intestinal	O
absorption	O
of	O
dietary	O
fat	O
in	O
patients	B-P
with	I-P
multiple	I-P
sclerosis	I-P
.	I-P


Fat	B-O
absorption	I-O
was	O
studied	O
in	O
24	B-P
patients	I-P
with	I-P
clinically	I-P
definite	I-P
multiple	I-P
sclerosis	I-P
and	I-P
in	I-P
36	I-P
healthy	I-P
control	I-I
subjects	I-P
.	I-P


Beta-carotene	B-O
and	I-O
vitamin	I-O
A	I-O
in	I-O
their	I-O
plasma	I-O
were	I-I
also	I-I
measured	I-I
.	I-I


This	O
double-blind	O
and	O
randomized	O
study	O
showed	O
no	O
differences	O
between	O
these	O
two	O
populations	O
with	O
regard	O
to	O
the	O
three	O
parameters	O
.	O


We	O
did	O
not	O
find	O
evidence	O
for	O
fat	O
malabsorption	O
in	O
multiple	O
sclerosis	O
.	O


Memory	B-O
monitoring	O
by	O
animals	B-P
and	I-P
humans	I-P
.	I-P


The	O
authors	O
asked	O
whether	O
animals	B-P
and	I-P
humans	I-P
would	O
use	O
similarly	O
an	O
uncertain	O
response	B-O
to	O
escape	O
indeterminate	O
memories	O
.	O


Monkeys	B-P
and	I-P
humans	I-P
performed	I-P
serial	I-I
probe	I-I
recognition	I-I
tasks	I-I
that	O
produced	O
differential	O
memory	O
difficulty	O
across	O
serial	O
positions	O
(	O
e.g.	O
,	O
primacy	O
and	O
recency	O
effects	O
)	O
.	O


Participants	B-P
were	O
given	O
an	O
escape	O
option	O
that	O
let	O
them	O
avoid	O
any	O
trials	O
they	O
wished	O
and	O
receive	O
a	O
hint	O
to	O
the	O
trial	O
's	O
answer	O
.	O


Across	O
species	O
,	O
across	O
tasks	O
,	O
and	O
even	O
across	O
conspecifics	O
with	O
sharper	O
or	O
duller	O
memories	O
,	O
monkeys	B-P
and	I-P
humans	I-P
used	I-O
the	I-O
escape	I-O
option	I-O
selectively	O
when	O
more	O
indeterminate	O
memory	O
traces	O
were	O
probed	O
.	O


Their	O
pattern	O
of	O
escaping	O
always	O
mirrored	O
the	O
pattern	O
of	O
their	O
primary	O
memory	O
performance	O
across	O
serial	O
positions	O
.	O


Signal-detection	B-O
analyses	I-O
confirm	O
the	O
similarity	O
of	O
the	O
animals	O
'	O
and	O
humans	O
'	O
performances	O
.	O


Optimality	B-O
analyses	I-O
assess	O
their	O
efficiency	B-O
.	I-O


Several	O
aspects	O
of	O
monkeys	O
'	O
performance	O
suggest	O
the	O
cognitive	O
sophistication	O
of	O
their	O
decisions	O
to	O
escape	O
.	O


Use	O
of	O
the	O
electrothermal	B-I
bipolar	I-I
vessel	I-I
system	I-I
(	I-I
EBVS	I-I
)	I-I
in	O
laparoscopic	O
adrenalectomy	O
:	O
a	O
prospective	O
study	O
.	O


BACKGROUND	O
Since	O
laparoscopic	B-P
adrenalectomy	I-P
(	I-P
LA	I-P
)	I-P
has	O
been	O
adopted	O
as	O
the	O
gold	O
standard	O
for	O
the	O
treatment	O
of	O
adrenal	O
diseases	O
,	O
the	O
development	O
of	O
technology	O
for	O
vascular	O
control	O
and	O
dissection	O
manoeuvres	O
,	O
amongst	O
other	O
things	O
,	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
its	O
further	O
improvement	O
.	O


We	O
report	O
our	O
experience	O
with	O
the	O
electrothermal	B-I
bipolar	I-I
vessel	I-I
sealing	I-I
(	I-I
EBVS	I-I
)	I-I
device	O
for	O
LA	O
.	O


METHODS	O
From	B-P
January	I-P
2004	I-P
to	I-P
January	I-P
2006	I-P
,	I-P
50	I-P
patients	I-P
(	I-P
pts	I-P
)	I-P
undergoing	I-P
LA	I-P
were	O
selected	O
and	O
randomized	O
for	O
use	O
of	O
the	O
EBVS	B-I
(	I-I
25	I-I
pts	I-I
,	I-I
group	I-I
A	I-I
)	I-I
versus	I-I
the	I-I
UltraSonic	I-I
Shears	I-I
(	I-I
USS	I-I
)	I-I
device	I-I
(	O
25	O
pts	O
,	O
group	O
B	O
)	O
.	O


Age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
previous	O
surgery	O
and	O
associated	O
diseases	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O


The	O
main	O
surgical	O
parameters	O
collected	O
for	O
each	O
patient	O
(	O
pt	O
)	O
concerned	O
operative	O
time	O
,	O
major	O
and	O
minor	O
complications	O
,	O
conversion	O
rate	O
,	O
blood	O
loss	O
,	O
hospital	O
stay	O
and	O
histology	O
.	O


RESULTS	O
There	O
was	O
no	B-O
mortality	I-O
in	O
either	O
group	O
.	O


The	O
right	O
adrenalectomy	O
mean	B-O
operative	I-O
time	I-O
(	I-O
OpT	I-O
)	I-O
was	O
51.8	O
mins	O
(	O
range	O
40-90	O
mins	O
)	O
and	O
68.6	O
mins	O
(	O
range	O
50-130	O
mins	O
)	O
in	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P	O
not	O
significant	O
)	O
.	O


The	O
left	B-O
adrenalectomy	I-O
mean	I-O
OpT	I-O
was	O
72.2	O
mins	O
(	O
range	O
55-100	O
mins	O
)	O
and	O
94	O
mins	O
(	O
range	O
65-140	O
mins	O
)	O
for	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
mean	B-O
blood	I-O
loss	I-O
was	O
83	O
ml	O
(	O
group	O
A	O
)	O
and	O
210	O
ml	O
(	O
group	O
B	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Complications	O
were	O
not	O
different	O
for	O
the	O
two	O
groups	O
.	O


The	O
mean	B-O
hospital	I-O
stay	I-O
was	O
2.9	O
and	O
3.1	O
days	O
in	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P	O
not	O
significant	O
)	O
.	O


CONCLUSIONS	O
EBVS	O
in	O
LA	O
may	O
provide	O
a	O
significantly	O
short	B-O
operating	I-O
time	I-O
and	I-O
blood	I-O
loss	I-O
.	I-O


Glibenclamide	B-I
vs	I-I
gliclazide	I-I
in	O
reducing	O
oxidative	B-O
stress	I-O
in	O
patients	B-P
of	I-P
noninsulin	I-P
dependent	I-P
diabetes	I-P
mellitus	I-P
--	I-P
a	I-P
double	O
blind	O
randomized	O
study	O
.	O


OBJECTIVE	O
Parameters	O
of	O
oxidative	B-O
stress	I-O
were	O
quantitated	O
in	O
50	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
in	I-P
uncontrolled	I-P
state	I-P
and	O
after	O
control	O
using	O
oral	O
glibenclamide	B-I
or	I-I
gliclazide	I-I
.	I-I


The	O
estimates	O
were	O
further	O
compared	O
between	O
the	O
two	O
groups	O
irrespective	O
of	O
drug	O
used	O
to	O
evaluate	O
the	O
difference	O
,	O
if	O
any	O
.	O


METHODS	O
The	O
study	O
was	O
a	O
double	O
blind	O
,	O
uncontrolled	O
,	O
noncrossover	O
and	O
randomized	O
trial	O
.	O


Fifty	B-P
patients	I-P
of	I-P
uncontrolled	I-P
type	I-P
2	I-P
diabetes	I-P
were	O
divided	O
in	O
to	O
two	O
groups	O
.	O


Group	O
I	O
(	O
25	O
patients	O
)	O
received	O
capsule	B-I
A	I-I
(	I-I
glibenclamide	I-I
)	I-I
while	O
Group	O
II	O
(	O
25	O
patients	O
)	O
received	O
capsule	B-I
B	I-I
(	I-I
gliclazide	I-I
)	I-I
.	I-I


The	O
parameters	O
studied	O
were	O
Superoxide	B-O
dismutase	I-O
(	I-O
SOD	I-O
)	I-O
,	I-O
malonyl-dialdehyde	I-O
(	I-O
MDA	I-O
)	I-O
and	I-O
reduced	I-O
glutathione	I-O
(	I-O
GSH	I-O
)	I-O
.	I-O


They	O
were	O
done	O
at	O
(	O
a	O
)	O
uncontrolled	O
stage	O
(	O
FBS	O
--	O
165	O
+/-	O
16.7	O
mg/dl	O
,	O
PP	O
--	O
240	O
+/-	O
30.1	O
mg/dl	O
and	O
HbA1	O
--	O
10.5	O
+/-	O
0.9	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
150	O
+/-	O
15.8	O
mg/dl	O
,	O
PP	O
--	O
246	O
+/-	O
29.1	O
mg/dl	O
HbA1	O
10.6	O
+/-	O
0.8	O
%	O
in	O
group	O
II	O
)	O
and	O
during	O
controlled	O
stage	O
at	O
12	O
weeks	O
(	O
FBS	O
--	O
120	O
+/-	O
18.5	O
mg/dl	O
,	O
PP	O
--	O
180	O
+/-	O
19.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.4	O
+/-	O
0.29	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
118	O
+/-	O
17.6	O
mg/dl	O
,	O
PP	O
--	O
176	O
+/-	O
20.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.5	O
+/-	O
0.39	O
%	O
in	O
group	O
II	O
patients	O
)	O
.	O


RESULTS	O
The	O
significantly	O
raised	O
levels	B-O
of	I-O
MDA	I-O
and	I-O
SOD	I-O
,	O
and	O
decreased	O
levels	B-O
of	I-O
reduced	I-O
glutathione	I-O
(	I-O
GSH	I-O
)	I-O
during	O
uncontrolled	O
stage	O
of	O
diabetes	O
indicated	O
free	O
radical	O
stress	O
induced	O
lipid	O
peroxidation	O
.	O


The	O
significant	O
fall	B-O
of	I-O
MDA	I-O
and	I-O
SOD	I-O
and	I-O
increased	I-O
levels	I-O
of	I-O
GSH	I-O
in	I-O
blood	I-O
in	O
both	O
groups	O
after	O
control	O
revealed	O
beneficial	O
effects	O
of	O
glycemic	O
control	O
on	O
oxidative	B-O
stress	I-O
.	I-O


The	O
levels	O
were	O
not	O
normalized	O
and	O
stayed	O
higher	O
than	O
those	O
in	O
controls	O
.	O


On	O
intergroup	O
comparison	O
;	O
the	O
control	O
of	O
diabetes	O
with	O
gliclazide	B-I
(	O
group	O
II	O
)	O
showed	O
improvement	O
in	O
oxidative	B-O
stress	I-O
(	I-O
MDA	I-O
,	I-O
GSH	I-O
)	I-O
better	O
(	O
p	O
<	O
0.001	O
)	O
than	O
glibenclamide	B-I
(	O
group	O
I	O
)	O
.	O


CONCLUSION	O
Oxidative	B-O
stress	I-O
in	O
uncontrolled	O
diabetes	O
is	O
decreased	O
with	O
glycemic	O
control	O
.	O


The	O
control	O
of	O
diabetes	O
with	O
gliclazide	B-I
reduced	O
oxidative	B-O
stress	I-O
more	O
than	O
glibenclamide	B-I
,	O
indicating	O
higher	O
antioxidant	O
properties	O
of	O
gliclazide	O
.	O


Normalization	O
of	O
oxidative	B-O
stress	I-O
was	O
not	O
achieved	O
.	O


Further	O
studies	O
are	O
required	O
to	O
see	O
long-term	O
effect	O
of	O
drug	O
therapy	O
in	O
combating	O
oxidative	B-O
stress	I-O
after	O
achieving	O
acceptable	O
control	O
of	O
diabetes	O
.	O


Expectancies	O
,	O
not	O
aroma	O
,	O
explain	O
impact	O
of	O
lavender	B-I
aromatherapy	I-I
on	O
psychophysiological	O
indices	O
of	O
relaxation	O
in	O
young	B-P
healthy	I-P
women	I-P
.	I-P


OBJECTIVES	O
In	O
aromatherapy	B-I
,	I-I
lavender	I-I
aroma	I-I
is	O
reputed	O
to	O
assist	O
with	O
relaxation	O
.	O


However	O
,	O
while	O
there	O
is	O
much	O
anecdotal	O
evidence	O
to	O
that	O
effect	O
,	O
the	O
empirical	O
literature	O
is	O
very	O
inconsistent	O
.	O


Failure	O
to	O
employ	O
adequate	O
placebos	B-I
,	O
proper	O
blinding	O
,	O
objective	O
measures	O
,	O
or	O
screening	O
of	O
prior	O
beliefs	O
about	O
aromatherapy	O
means	O
that	O
many	O
previous	O
findings	O
could	O
have	O
been	O
influenced	O
by	O
expectancy	O
biases	O
.	O


The	O
present	O
study	O
sought	O
to	O
establish	O
whether	O
lavender	B-I
aroma	I-I
and/or	O
expectancies	O
affect	O
post-stress	O
relaxation	O
.	O


DESIGN	O
A	O
double-blind	O
,	O
3	O
(	O
aroma	O
)	O
x	O
3	O
(	O
instruction	O
)	O
x	O
10	O
(	O
time	O
in	O
minutes	O
)	O
mixed-factorial	B-I
placebo-controlled	I-I
trial	O
.	O


METHOD	O
In	O
a	O
laboratory	O
,	O
96	B-P
healthy	I-P
undergraduate	I-P
women	I-P
were	O
exposed	B-I
to	I-I
lavender	I-I
,	I-I
placebo	I-I
,	I-I
or	I-I
no	I-I
aroma	I-I
during	O
physiologically	O
assessed	O
relaxation	O
after	O
an	O
arousing	O
cognitive	B-I
task	I-I
.	I-I


Where	O
an	O
aroma	O
was	O
presented	O
,	O
an	O
instructional	O
priming	O
procedure	O
was	O
used	O
to	O
manipulate	O
participants	O
'	O
expectancies	O
about	O
the	O
aroma	O
's	O
likely	O
impact	O
on	O
their	O
ability	O
to	O
relax	O
.	O


RESULTS	O
Results	O
showed	O
no	O
effect	O
of	O
aroma	B-O
on	I-O
galvanic	I-O
skin	I-O
response	I-O
during	O
relaxation	O
.	O


However	O
,	O
the	O
nature	O
of	O
instructional	O
prime	O
was	O
associated	O
with	O
relaxation	B-O
patterns	I-O
:	I-O
when	O
expecting	O
the	O
aroma	O
to	O
inhibit	O
them	O
,	O
participants	O
relaxed	B-O
more	O
;	O
when	O
expecting	O
facilitation	O
,	O
participants	O
relaxed	B-O
less	O
.	O


The	O
effect	O
was	O
not	O
seen	O
with	O
regard	O
to	O
self-reported	B-O
relaxation	I-O
(	O
as	O
represented	O
by	O
changes	O
in	O
state	O
anxiety	O
)	O
and	O
was	O
independent	O
of	O
ratings	O
of	O
attitudes	B-O
towards	O
aromatherapy	O
.	O


CONCLUSIONS	O
The	O
findings	O
imply	O
that	O
the	O
previous	O
associations	O
of	O
lavender	B-I
aroma	I-I
with	O
assisted	O
relaxation	O
may	O
have	O
been	O
influenced	O
by	O
expectancy	O
biases	O
,	O
and	O
that	O
the	O
relevant	O
expectancies	O
are	O
easily	O
manipulable	O
.	O


A	O
fenbendazole	B-I
oral	O
drench	O
in	O
addition	O
to	O
an	O
ivermectin	B-I
pour-on	O
reduces	B-O
parasite	I-O
burden	I-O
and	I-O
improves	I-O
feedlot	I-O
and	I-O
carcass	I-O
performance	I-O
of	O
finishing	B-P
heifers	I-P
compared	O
with	O
endectocides	O
alone	O
.	O


Two	O
studies	O
utilizing	O
1,862	B-P
yearling	I-P
heifers	I-P
were	O
conducted	O
to	O
determine	O
the	O
effects	O
of	O
a	O
fenbendazole	B-I
oral	I-I
drench	I-I
in	I-I
addition	I-I
to	I-I
an	I-I
ivermectin	I-I
pour-on	I-I
(	I-I
SG+IVPO	I-I
)	I-I
,	O
compared	O
with	O
an	O
ivermectin	B-I
pour-on	I-I
(	I-I
IVPO	I-I
)	I-I
or	O
a	O
doramectin	B-I
injectable	I-I
(	I-I
DMX	I-I
)	I-I
alone	I-I
,	O
on	O
parasite	B-O
burden	I-O
,	I-O
feedlot	I-O
performance	I-O
,	O
and	O
carcass	B-O
merit	I-O
of	I-O
feedlot	I-O
cattle	I-O
.	I-O


In	O
the	O
first	O
study	O
,	O
heifers	O
receiving	O
the	O
SG+IVPO	O
had	O
fewer	B-O
(	I-O
P	I-O
=	I-O
0.02	I-O
)	I-O
cattle	I-O
retreated	I-O
for	I-O
disease	I-O
and	O
73	O
%	O
fewer	B-O
(	I-O
P	I-O
=	I-O
0.06	I-O
)	I-O
worm	I-O
eggs	I-O
per	I-O
fecal	I-O
sample	I-O
98	O
d	O
after	O
treatment	O
than	O
heifers	O
treated	O
with	O
IVPO	O
.	O


Heifers	O
treated	O
with	O
SG+IVPO	O
consumed	O
more	B-O
DM	I-O
,	O
had	O
greater	B-O
ADG	I-O
,	O
were	O
heavier	B-O
at	I-O
slaughter	I-O
,	O
and	O
had	O
heavier	B-O
carcasses	I-O
than	O
IVPO-treated	O
heifers	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Heifers	O
treated	O
with	O
SG+IVPO	O
also	O
had	O
more	B-O
(	I-O
P	I-O
=	I-O
0.07	I-O
)	I-O
carcasses	I-O
grading	O
USDA	B-O
Prime	I-O
or	I-O
Choice	I-O
than	O
IVPO-treated	O
heifers	O
.	O


In	O
the	O
second	O
study	O
,	O
heifers	O
treated	O
with	O
SG+IVPO	O
had	O
fewer	B-O
(	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
worm	I-O
eggs	I-O
per	I-O
fecal	I-O
sample	I-O
35	O
d	O
after	O
treatment	O
and	O
had	O
fewer	O
numbers	B-O
of	I-O
adult	I-O
and	I-O
larval	I-O
Cooperia	I-O
and	I-O
Trichostrongylus	I-O
spp	I-O
.	I-O


in	B-O
the	I-O
small	I-O
intestine	I-O
at	O
slaughter	O
(	O
P	O
<	O
0.10	O
)	O
compared	O
with	O
heifers	O
treated	O
with	O
DMX	O
.	O


Heifers	O
treated	O
with	O
SG+IVPO	O
consumed	O
more	O
DM	B-O
,	O
were	O
heavier	O
at	O
slaughter	O
,	O
and	O
had	O
heavier	O
carcasses	O
than	O
DMX-treated	O
heifers	O
(	O
P	O
<	O
0.01	O
)	O
.	O


The	O
SG+IVPO-treated	B-I
heifers	O
also	O
had	O
greater	B-O
ADG	I-O
(	O
P	O
<	O
0.10	O
)	O
.	O


The	O
broad-spectrum	O
effectiveness	O
of	O
a	O
combination	O
of	O
a	O
fenbendazole	O
oral	O
drench	O
and	O
an	O
ivermectin	O
pour-on	O
reduced	O
parasite	B-O
burden	I-O
and	O
increased	B-O
feed	I-O
intake	I-O
,	I-O
ADG	I-O
,	O
and	O
carcass	B-O
weight	I-O
in	O
feedlot	B-P
heifers	I-P
compared	O
with	O
treatment	O
with	O
an	O
endectocide	O
alone	O
.	O


Pilot	O
comparison	O
between	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
and	I-I
bipolar	I-I
radiofrequency	I-I
in	O
paediatric	B-P
tonsillectomy	I-P
.	I-P


OBJECTIVES	O
To	O
compare	O
the	O
advantages	O
and	O
disadvantages	O
of	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
with	I-I
those	I-I
of	I-I
bipolar	I-I
radiofrequency	I-I
techniques	I-I
,	O
in	O
paediatric	B-O
tonsillectomy	I-O
.	I-O


STUDY	O
DESIGN	O
Prospective	O
,	O
randomised	O
,	O
clinical	O
study	O
.	O


PATIENTS	O
AND	O
METHODS	O
From	B-P
July	I-P
2004	I-P
to	I-P
April	I-P
2006	I-P
,	I-P
80	I-P
patients	I-P
aged	I-P
between	I-P
10	I-P
and	I-P
15	I-P
years	I-P
,	I-P
with	I-P
tonsillectomy	I-I
planned	I-P
for	I-P
chronic	I-P
tonsillitis	I-P
,	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Children	O
were	O
prospectively	O
randomised	O
into	O
two	O
equal	O
groups	O
:	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
tonsillectomy	I-I
and	I-I
bipolar	I-I
radiofrequency	I-I
tonsillectomy	I-I
.	I-I


Operative	O
time	O
and	O
intra-operative	O
blood	O
loss	O
were	O
recorded	O
.	O


Patients	O
were	O
scheduled	O
for	O
follow	O
up	O
during	O
the	O
first	O
,	O
second	O
and	O
fourth	O
post-operative	O
weeks	O
.	O


They	O
were	O
asked	O
to	O
record	O
their	O
pain	O
and	O
discomfort	O
on	O
a	O
standardised	O
visual	O
analogue	O
scale	O
,	O
from	O
zero	O
(	O
no	O
pain	O
)	O
to	O
10	O
(	O
severe	O
pain	O
)	O
.	O


Post-operative	O
complications	O
were	O
also	O
recorded	O
and	O
managed	O
.	O


RESULTS	O
The	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
group	I-I
showed	O
a	O
slightly	O
longer	B-O
operative	I-O
time	I-O
(	O
mean	O
12	O
minutes	O
)	O
than	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
mean	O
10	O
minutes	O
)	O
.	O


Intra-operative	B-O
blood	I-O
loss	I-O
was	O
significantly	O
less	O
in	O
the	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
group	O
(	O
mean	O
21	O
cm3	O
)	O
than	O
in	O
the	O
bipolar	B-I
radiofrequency	I-I
group	I-I
(	O
mean	O
30	O
cm3	O
)	O
.	O


In	O
the	O
first	O
week	O
,	O
post-operative	B-O
pain	I-O
scores	I-O
were	O
less	O
in	O
the	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
group	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
means	O
7.5	O
and	O
8.5	O
,	O
respectively	O
)	O
.	O


However	O
,	O
in	O
the	O
second	O
week	O
pain	B-O
scores	I-O
increased	O
more	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
means	O
8.5	O
and	O
6	O
,	O
respectively	O
)	O
.	O


In	O
the	O
fourth	O
week	O
,	O
both	O
groups	O
showed	O
equal	O
and	O
nearly	O
normal	O
pain	B-O
scores	I-O
.	I-O


No	O
case	O
of	O
reactionary	B-O
post-tonsillectomy	I-O
haemorrhage	I-O
was	O
recorded	O
in	O
either	O
group	O
.	O


Only	O
one	O
case	O
of	O
secondary	B-O
post-tonsillectomy	I-O
haemorrhage	I-O
was	O
recorded	O
,	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
(	O
2.5	O
per	O
cent	O
)	O
,	O
managed	O
conservatively	O
.	O


CONCLUSION	O
Both	O
the	O
potassium	B-I
titanyl	I-I
phosphate	I-I
and	I-I
the	I-I
bipolar	I-I
radiofrequency	I-I
techniques	I-I
were	O
safe	B-O
and	I-O
easy	I-O
to	I-O
use	I-O
for	O
tonsillectomy	B-O
,	O
with	O
reduced	O
operative	B-O
time	I-O
,	I-O
blood	I-O
loss	I-O
and	I-O
complication	I-O
rates	I-O
and	O
better	O
post-operative	O
general	O
patient	O
condition	O
.	O


Potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
resulted	O
in	O
reduced	O
operative	B-O
bleeding	I-O
and	I-O
immediate	I-O
post-operative	I-O
pain	I-O
,	O
compared	O
with	O
the	O
bipolar	O
radiofrequency	O
technique	O
.	O


However	O
,	O
potassium	B-I
titanyl	I-I
phosphate	I-I
laser	I-I
required	O
slightly	O
more	O
operative	B-O
time	I-O
and	O
caused	O
more	O
late	B-O
post-operative	I-O
pain	I-O
than	O
the	O
bipolar	O
radiofrequency	O
technique	O
.	O


The	O
low	O
rate	O
of	O
recorded	O
complications	O
showed	O
that	O
both	O
techniques	O
cause	O
little	O
damage	O
to	O
the	O
tonsillar	O
bed	O
during	O
dissection	O
,	O
thus	O
minimising	O
complications	O
.	O


Improving	O
maternal	B-O
mental	I-O
health	I-O
after	I-P
a	I-P
child	I-P
's	I-P
diagnosis	I-P
of	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
results	O
from	O
a	O
randomized	O
clinical	O
trial	O
.	O


IMPORTANCE	O
The	O
prevalence	O
of	O
psychological	O
distress	O
among	O
mothers	B-P
of	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
suggests	O
a	O
need	O
for	O
interventions	O
that	O
address	O
parental	B-O
mental	I-O
health	I-O
during	O
the	O
critical	O
period	O
after	O
the	O
child	O
's	O
autism	O
diagnosis	O
when	O
parents	O
are	O
learning	O
to	O
navigate	O
the	O
complex	O
system	O
of	O
autism	O
services	O
.	O


OBJECTIVE	O
To	O
investigate	O
whether	O
a	O
brief	O
cognitive	O
behavioral	O
intervention	O
,	O
problem-solving	B-I
education	I-I
(	I-I
PSE	I-I
)	I-I
,	O
decreases	O
parenting	B-O
stress	I-O
and	I-O
maternal	I-O
depressive	I-O
symptoms	I-O
during	O
the	O
period	O
immediately	O
following	O
a	O
child	O
's	O
diagnosis	O
of	O
ASD	O
.	O


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
A	O
randomized	O
clinical	O
trial	O
compared	O
6	O
sessions	O
of	O
PSE	B-I
with	O
usual	B-I
care	I-I
.	I-I


Settings	O
included	O
an	O
autism	B-P
clinic	I-P
and	I-P
6	I-P
community-based	I-P
early	I-P
intervention	I-P
programs	I-P
that	I-P
primarily	I-P
serve	I-P
low-income	I-P
families	I-P
.	I-P


Participants	B-P
were	I-P
mothers	I-P
of	I-P
122	I-P
young	I-P
children	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
34	I-P
months	I-P
)	I-P
who	I-P
recently	I-P
received	I-P
a	I-P
diagnosis	I-P
of	I-P
ASD	I-P
.	I-P


Among	O
mothers	O
assessed	O
for	O
eligibility	O
,	O
17.0	O
%	O
declined	O
participation	O
.	O


We	O
report	O
outcomes	O
after	O
3	O
months	O
of	O
follow-up	O
(	O
immediate	O
postdiagnosis	O
period	O
)	O
.	O


INTERVENTIONS	O
Problem-solving	B-I
education	I-I
is	O
a	O
brief	O
,	O
cognitive	O
intervention	O
delivered	O
in	O
six	O
30-minute	B-I
individualized	I-I
sessions	I-I
by	I-I
existing	I-I
staff	I-I
(	O
early	O
intervention	O
programs	O
)	O
or	O
research	B-I
staff	I-I
without	I-I
formal	I-I
mental	I-I
health	I-I
training	I-I
(	O
autism	O
clinic	O
)	O
.	O


MAIN	O
OUTCOMES	O
AND	O
MEASURES	O
Primary	O
outcomes	O
were	O
parental	B-O
stress	I-O
and	I-O
maternal	I-O
depressive	I-O
symptoms	I-O
.	I-O


RESULTS	O
Fifty-nine	B-P
mothers	I-P
were	O
randomized	O
to	O
receive	O
PSE	B-I
and	O
63	O
to	O
receive	O
usual	B-I
care	I-I
.	I-I


The	O
follow-up	O
rate	O
was	O
91.0	O
%	O
.	O


Most	O
intervention	O
mothers	O
(	O
78.0	O
%	O
)	O
received	O
the	O
full	O
PSE	B-I
course	O
.	O


At	O
the	O
3-month	O
follow-up	O
assessment	O
,	O
PSE	B-I
mothers	O
were	O
significantly	O
less	O
likely	O
than	O
those	O
serving	O
as	O
controls	O
to	O
have	O
clinically	O
significant	O
parental	B-O
stress	I-O
(	O
3.8	O
%	O
vs	O
29.3	O
%	O
;	O
adjusted	O
relative	O
risk	O
[	O
aRR	O
]	O
,	O
0.17	O
;	O
95	O
%	O
CI	O
,	O
0.04	O
to	O
0.65	O
)	O
.	O


For	O
depressive	B-O
symptoms	I-O
,	O
the	O
risk	O
reduction	O
in	O
clinically	O
significant	O
symptoms	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
5.7	O
%	O
vs	O
22.4	O
%	O
;	O
aRR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
,	O
0.10	O
to	O
1.08	O
)	O
;	O
however	O
,	O
the	O
reduction	O
in	O
mean	O
depressive	B-O
symptoms	I-O
was	O
statistically	O
significant	O
(	O
Quick	O
Inventory	O
of	O
Depressive	O
Symptomatology	O
score	O
,	O
4.6	O
with	O
PSE	O
vs	O
6.9	O
with	O
usual	O
care	O
;	O
adjusted	O
mean	O
difference	O
,	O
-1.67	O
;	O
95	O
%	O
CI	O
,	O
-3.17	O
to	O
-0.18	O
)	O
.	O


CONCLUSIONS	O
AND	O
RELEVANCE	O
The	O
positive	O
effects	O
of	O
PSE	B-I
in	O
reducing	O
parenting	B-O
stress	I-O
and	O
depressive	B-O
symptoms	I-O
during	O
the	O
critical	O
postdiagnosis	O
period	O
,	O
when	O
parents	O
are	O
asked	O
to	O
navigate	O
a	O
complex	O
service	O
delivery	O
system	O
,	O
suggest	O
that	O
it	O
may	O
have	O
a	O
place	O
in	O
clinical	O
practice	O
.	O


Further	O
work	O
will	O
monitor	O
these	O
families	O
for	O
a	O
total	O
of	O
9	O
months	O
to	O
determine	O
the	O
trajectory	O
of	O
outcomes	O
.	O


TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT01021384	O
.	O


Continuous	B-I
thoracic	I-I
epidural	I-I
analgesia	I-I
for	O
postoperative	B-O
pain	I-O
relief	I-O
following	I-P
thoracotomy	I-I
:	I-I
a	O
randomized	O
prospective	O
study	O
.	O


Optimum	O
frequency	O
of	O
exercise	B-I
for	O
bone	B-O
health	I-O
:	I-O
randomised	O
controlled	O
trial	O
of	O
a	O
high-impact	B-P
unilateral	I-P
intervention	I-P
.	I-P


INTRODUCTION	O
Exercise	B-I
can	O
increase	O
bone	B-O
strength	I-O
,	O
but	O
to	O
be	O
effective	O
in	O
reducing	O
fracture	B-O
risk	I-O
,	O
exercise	B-I
must	O
be	O
feasible	O
enough	O
to	O
be	O
adopted	O
into	O
daily	O
life	O
and	O
influence	O
potentially	O
vulnerable	O
skeletal	O
sites	O
such	O
as	O
the	O
superolateral	O
cortex	O
of	O
the	O
femoral	O
neck	O
,	O
where	O
thinning	O
is	O
associated	O
with	O
increased	O
fracture	B-O
risk	I-O
.	I-O


Brief	B-I
,	I-I
high-impact	I-I
exercise	I-I
increases	O
femoral	B-O
neck	I-O
bone	I-O
density	I-O
but	O
the	O
optimal	O
frequency	O
of	O
such	O
exercise	O
and	O
the	O
location	O
of	O
bone	O
accrual	O
is	O
unknown	O
.	O


This	O
study	O
thus	O
examined	O
(	O
1	O
)	O
the	O
effectiveness	O
of	O
different	O
weekly	O
frequencies	O
of	O
exercise	O
on	O
femoral	B-O
neck	I-O
BMD	I-O
and	O
(	O
2	O
)	O
whether	B-O
BMD	I-O
change	I-O
differed	I-O
between	I-O
hip	I-O
sites	I-O
using	O
a	O
high-impact	O
,	O
unilateral	O
intervention	O
.	O


METHODS	O
Healthy	B-P
premenopausal	I-P
women	I-P
were	O
randomly	O
assigned	O
to	O
exercise	B-I
0	O
,	O
2	O
,	O
4	O
,	O
or	O
7	O
days/week	O
for	O
6	O
months	O
.	O


The	O
exercise	B-I
intervention	I-I
incorporated	O
50	O
multidirectional	O
hops	O
on	O
one	O
randomly	O
selected	O
leg	O
.	O


BMD	B-O
was	O
measured	O
by	O
DXA	O
at	O
baseline	O
and	O
after	O
6	O
months	O
of	O
exercise	O
.	O


Changes	O
in	O
the	O
exercise	O
leg	O
were	O
compared	O
between	O
groups	O
using	O
ANCOVA	O
,	O
with	O
change	O
in	O
the	O
control	O
leg	O
and	O
baseline	O
BMD	O
as	O
covariates	O
.	O


RM-MANOVA	O
was	O
conducted	O
to	O
determine	O
whether	O
bone	B-O
changes	I-O
from	O
exercise	B-I
differed	O
between	O
hip	O
sites	O
.	O


RESULTS	O
61	B-P
women	I-P
(	I-P
age	I-P
33.6+/-11.1	I-P
years	I-P
)	I-P
completed	I-P
the	I-P
intervention	I-P
.	I-P


Compliance	O
amongst	O
exercisers	O
was	O
86.7+/-10.6	O
%	O
.	O


Peak	B-O
ground	I-O
reaction	I-O
forces	I-O
during	O
exercise	O
increased	O
from	O
2.5	O
to	O
2.8	O
times	O
body	O
weight	O
.	O


The	O
change	B-O
in	I-O
femoral	I-O
neck	I-O
BMD	I-O
in	O
the	O
exercise	B-I
limb	O
(	O
adjusted	O
for	O
change	O
in	O
the	O
control	O
limb	O
and	O
baseline	O
BMD	O
)	O
differed	O
between	O
groups	O
(	O
p=0.015	O
)	O
,	O
being	O
-0.3	O
%	O
(	O
-1.2	O
to	O
0.6	O
)	O
,	O
0.0	O
%	O
(	O
-1.0	O
to	O
1.0	O
)	O
,	O
0.9	O
%	O
(	O
-0.1	O
to	O
2.0	O
)	O
and	O
1.8	O
%	O
(	O
0.8	O
to	O
2.8	O
)	O
in	O
those	O
exercising	O
0	O
,	O
2	O
,	O
4	O
and	O
7	O
days	O
per	O
week	O
,	O
respectively	O
.	O


When	O
BMD	B-O
changes	I-O
at	I-O
upper	I-O
neck	I-O
,	I-O
lower	I-O
neck	I-O
and	I-O
trochanter	I-O
were	O
compared	O
using	O
RM-MANOVA	O
,	O
a	O
significant	O
exercise	O
effect	O
was	O
observed	O
(	O
p=0.048	O
)	O
,	O
but	O
this	O
did	O
not	O
differ	O
significantly	O
between	O
sites	O
(	O
p=0.439	O
)	O
despite	O
greatest	O
mean	O
increases	O
at	O
the	O
upper	O
femoral	O
neck	O
.	O


CONCLUSIONS	O
Brief	O
,	O
daily	O
hopping	O
exercises	B-I
increased	O
femoral	B-O
neck	I-O
BMD	I-O
in	O
premenopausal	B-P
women	I-P
but	O
less	O
frequent	O
exercise	O
was	O
not	O
effective	O
.	O


Brief	B-I
high-impact	I-I
exercise	I-I
may	O
have	O
a	O
role	O
in	O
reducing	O
hip	B-O
fragility	I-O
,	O
but	O
may	O
need	O
to	O
be	O
performed	O
frequently	O
for	O
optimal	O
response	O
.	O


Basal	B-P
cell	I-P
carcinoma	I-P
of	I-P
the	I-P
face	I-P
:	I-P
surgery	I-I
or	I-I
radiotherapy	I-I
?	O
Results	O
of	O
a	O
randomized	O
study	O
.	O


Time	O
intervals	O
production	O
in	O
tapping	B-P
and	O
oscillatory	B-P
motion	I-P
.	I-P


We	O
applied	O
spectral	B-I
analysis	I-I
on	O
series	O
of	O
time	O
intervals	O
produced	O
in	O
a	O
synchronization-continuation	O
experiment	O
.	O


In	O
the	O
first	O
condition	O
intervals	O
were	O
produced	O
by	O
finger	B-P
tapping	I-P
,	O
and	O
in	O
the	O
second	O
by	O
an	O
oscillatory	B-P
motion	I-P
of	I-P
the	I-P
hand	I-P
.	I-P


Results	O
obtained	O
in	O
tapping	B-P
were	O
consistent	O
with	O
a	O
discrete	O
,	O
event-based	O
timing	O
model	O
.	O


In	O
the	O
oscillatory	B-P
condition	I-P
,	O
the	O
spectra	O
suggested	O
a	O
continuous	O
,	O
dynamic	O
timing	O
mechanism	O
,	O
based	O
on	O
the	O
regulation	O
of	O
effector	O
stiffness	O
.	O


It	O
is	O
concluded	O
that	O
the	O
oscillatory	B-P
character	I-P
of	O
movement	O
can	O
offer	O
an	O
important	O
resource	O
for	O
timing	O
control	O
.	O


The	O
use	O
of	O
an	O
event-based	O
timing	O
control	O
such	O
as	O
postulated	O
in	O
the	O
Wing-Kristoffersson	O
model	O
could	O
be	O
restricted	O
to	O
a	O
quite	O
limited	O
class	O
of	O
rhythmic	O
tasks	O
,	O
characterized	O
by	O
the	O
concatenation	O
of	O
discrete	O
events	O
.	O


Instant	B-I
Recess®	I-I
:	I-I
a	O
practical	O
tool	O
for	O
increasing	B-O
physical	I-O
activity	I-O
during	O
the	O
school	O
day	O
.	O


BACKGROUND	O
An	O
increased	O
prevalence	O
of	B-P
overweight/obesity	I-P
among	I-P
children	I-P
has	O
led	O
to	O
school	O
district	O
level	O
policies	O
to	O
increase	B-O
physical	I-O
activity	I-O
(	I-O
PA	I-O
)	I-O
among	I-P
elementary	I-P
school	I-P
students	I-P
.	O


Interventions	O
are	O
needed	O
that	O
increase	O
activity	O
levels	O
without	O
sacrificing	O
time	O
spent	O
in	O
academics	O
.	O


OBJECTIVES	O
We	O
evaluated	O
a	B-I
policy	I-I
implementation	I-I
intervention	I-I
for	O
to	O
increase	O
in-school	B-I
PA	I-I
in	I-P
elementary	I-P
schools	I-P
in	I-P
Forsyth	I-P
County	I-P
,	I-P
North	I-P
Carolina	I-P
,	O
in	O
a	O
randomized	O
study	O
with	O
a	O
delayed	O
intervention	O
control	O
group	O
.	O


METHODS	B-P
The	I-P
study	I-P
included	I-P
third-	I-P
through	I-P
fifth-grade	I-P
classrooms	I-P
in	I-P
eight	I-P
elementary	I-P
schools	I-P
.	I-I


Instant	B-I
Recess®	I-I
was	O
used	O
to	O
introduce	O
10-minute	B-I
PA	I-I
breaks	I-I
in	O
classrooms	O
on	O
schedules	O
determined	O
by	O
teachers	O
.	O


Direct	O
observation	O
was	O
used	O
to	O
measure	B-O
activity	I-O
levels	I-O
,	I-O
other	I-O
student	I-O
behaviors	I-O
,	I-O
and	I-O
teacher	I-O
behaviors	I-O
related	O
to	O
PA	O
in	O
the	O
classrooms	O
.	O


RESULTS	O
Twenty-eight	O
visits	O
to	O
schools	O
were	O
made	O
during	O
the	O
spring	O
and	O
fall	O
semesters	O
of	O
2009	O
.	O


At	O
baseline	O
11	O
%	O
to	O
44	O
%	O
of	O
intervention	O
and	O
control	O
schools	O
were	O
engaged	O
in	O
classroom-based	B-I
PA.	I-O
PA	I-O
increased	O
from	O
baseline	O
to	O
spring	O
follow-up	O
in	O
intervention	O
schools	O
and	O
was	O
maintained	O
the	O
following	O
fall	O
.	O


Control	O
schools	O
decreased	B-O
PA	I-O
from	O
baseline	O
to	O
spring	O
and	O
increased	B-O
PA	I-O
once	O
they	O
began	O
the	O
intervention	O
.	O


Students	O
in	O
classrooms	O
engaged	O
in	O
Instant	O
Recess	O
exhibited	B-O
statistically	I-O
significant	I-O
increases	I-O
in	I-O
light	I-O
(	I-O
51	I-O
%	I-O
)	I-O
and	I-O
moderate-intensity	I-O
(	I-O
16	I-O
%	I-O
)	I-O
PA	I-O
and	I-O
increases	I-O
in	I-O
time	I-O
spent	I-O
in	I-O
on-task	I-O
behavior	I-O
(	O
11	O
%	O
)	O
.	O


Control	O
schools	O
experienced	O
similar	O
benefits	O
after	O
they	O
began	O
implementing	O
Instant	O
Recess	O
.	O


CONCLUSIONS	O
Instant	O
Recess	O
is	O
useful	O
for	B-O
increasing	I-O
PA	I-O
and	I-O
improving	I-O
behavior	I-O
among	I-P
elementary	I-P
school	I-P
children	I-P
.	O


Additional	O
research	O
may	O
be	O
needed	O
to	O
understand	O
how	O
to	O
create	O
policies	O
supporting	O
classroom	O
activity	O
breaks	O
and	O
how	O
to	O
assess	O
policy	O
adherence	O
.	O


Recombinant	B-I
human	I-I
thyrotropin-stimulated	I-I
radioiodine	I-I
therapy	I-I
of	O
nodular	O
goiter	O
allows	O
major	O
reduction	O
of	O
the	O
radiation	B-O
burden	I-O
with	O
retained	O
efficacy	B-O
.	I-O


CONTEXT	O
AND	O
OBJECTIVE	O
Stimulation	O
with	O
recombinant	B-I
human	I-I
TSH	I-I
(	I-I
rhTSH	I-I
)	I-I
before	O
radioiodine	B-I
(	I-I
131I	I-I
)	I-I
therapy	I-I
augments	O
goiter	B-O
volume	I-O
reduction	I-O
(	I-O
GVR	I-O
)	I-O
.	I-O


Observations	O
indicate	O
that	O
rhTSH	B-I
has	O
a	O
preconditioning	O
effect	O
beyond	O
increasing	O
thyroid	O
(	O
131	O
)	O
I	O
uptake	O
.	O


We	O
test	O
the	O
hypothesis	O
that	O
an	O
equivalent	O
GVR	O
might	O
be	O
obtained	O
by	O
an	O
absorbed	O
thyroid	O
dose	O
well	O
below	O
what	O
has	O
been	O
used	O
previously	O
.	O


PATIENTS	O
AND	O
DESIGN	O
In	O
a	O
double-blinded	O
setup	O
,	O
90	B-P
patients	I-P
(	I-P
78	I-P
women	I-P
;	I-P
median	I-P
age	I-P
,	I-P
52	I-P
yr	I-P
;	I-P
range	I-P
,	I-P
22-83	I-P
)	I-P
with	I-P
a	I-P
nontoxic	I-P
nodular	I-P
goiter	I-P
(	I-P
median	I-P
size	I-P
,	I-P
63	I-P
ml	I-P
;	I-P
range	I-P
,	I-P
25-379	I-P
ml	I-P
)	I-P
were	I-P
randomized	I-P
to	O
either	O
0.1	B-I
mg	I-I
rhTSH	I-I
(	O
n=60	O
)	O
followed	O
by	O
a	O
thyroid	B-I
dose	I-I
of	I-I
50	I-I
Gy	I-I
or	I-I
placebo	I-I
followed	O
by	O
100	O
Gy	O
(	O
n=30	O
)	O
.	O


RESULTS	O
At	O
12	O
months	O
,	O
the	O
mean	O
relative	B-O
GVR	I-O
in	O
the	O
placebo	B-I
and	O
the	O
rhTSH	B-I
group	O
was	O
identical	O
(	O
35+/-3	O
%	O
;	O
P=0.81	O
)	O
.	O


The	O
median	O
administered	O
131I-activity	B-O
was	O
170	O
MBq	O
(	O
45-1269	O
)	O
in	O
the	O
rhTSH	B-I
group	O
and	O
559	O
MBq	O
(	O
245-3530	O
)	O
in	O
the	O
placebo	B-I
group	O
(	O
70	O
%	O
reduction	O
,	O
P	O
<	O
0.0001	O
)	O
.	O


According	O
to	O
the	O
official	O
radiation	O
regulation	O
,	O
hospitalization	B-O
was	O
required	O
in	O
14	O
patients	O
in	O
the	O
placebo	B-I
group	O
vs.	O
one	O
patient	O
in	O
the	O
rhTSH	B-I
group	O
(	O
P	O
<	O
0.0001	O
)	O
.	O


In	O
both	O
groups	O
,	O
goiter-related	B-O
symptoms	I-O
were	O
effectively	O
relieved	O
in	O
the	O
majority	O
of	O
patients	O
.	O


The	O
prevalence	O
of	O
myxedema	B-O
(	O
10	O
%	O
)	O
did	O
not	O
differ	O
among	O
groups	O
.	O


CONCLUSIONS	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
that	O
rhTSH	B-I
not	O
only	O
increases	O
the	O
thyroid	B-O
131I	I-O
uptake	I-O
,	O
but	O
per	O
se	O
potentiates	O
the	O
effect	O
of	O
131I-therapy	B-I
,	O
allowing	O
a	O
major	O
reduction	O
of	O
the	O
131I-activity	B-O
without	O
compromising	O
efficacy	B-O
.	I-O


This	O
approach	O
is	O
attractive	O
in	O
terms	O
of	O
minimizing	O
posttherapeutic	B-O
restrictions	I-O
and	O
in	O
reducing	O
the	O
potential	O
risk	O
of	O
radiation-induced	B-O
malignancy	I-O
.	O


Double-blind	O
comparison	O
of	O
liquid	B-I
antacid	I-I
and	I-I
placebo	I-I
in	O
the	O
treatment	O
of	O
symptomatic	B-P
reflux	I-P
esophagitis	I-P
.	I-P


Although	O
antacids	B-I
have	O
been	O
the	O
mainstay	O
of	O
pharmacologic	O
therapy	O
for	O
reflux	O
esophagitis	O
,	O
their	O
effectiveness	O
has	O
not	O
been	O
tested	O
in	O
a	O
placebo-controlled	B-I
double-blind	O
trial	O
.	O


We	O
report	O
a	O
double-blind	O
comparison	O
of	O
liquid	B-I
antacid	I-I
vs	I-I
placebo	I-I
in	O
the	O
treatment	O
of	O
reflux	O
esophagitis	O
in	O
32	B-P
patients	I-P
with	I-P
chronic	I-P
heartburn	I-P
.	I-P


Entry	B-P
criteria	I-P
included	I-P
the	I-P
presence	I-P
of	I-P
symptomatic	I-P
gastroesophageal	I-P
reflux	I-P
confirmed	I-P
by	I-P
both	I-P
an	I-P
acid	I-P
perfusion	I-P
(	I-P
Bernstein	I-P
)	I-P
test	I-P
and	I-P
by	I-P
intraesophageal	I-P
pH	I-P
probe	I-P
.	I-P


Drug	O
treatment	O
consisted	O
of	O
15	O
ml	O
(	O
80	O
mEq	O
)	O
doses	O
of	O
antacid	B-I
(	I-I
Maalox	I-I
Therapeutic	I-I
Concentration	I-I
,	O
William	O
H.	O
Rorer	O
)	O
or	O
placebo	B-I
taken	O
7	O
times	O
daily	O
,	O
ie	O
,	O
1	O
and	O
3	O
hr	O
after	O
meals	O
and	O
at	O
bedtime	O
.	O


Both	O
groups	O
showed	O
significant	O
improvement	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
both	O
frequency	B-O
and	I-O
severity	I-O
of	I-O
heartburn	I-O
.	I-O


The	O
time	B-O
to	I-O
reproduce	I-O
heartburn	I-O
with	O
the	O
timed	O
Bernstein	O
test	O
was	O
increased	O
with	O
both	O
active	B-I
drug	I-I
and	O
placebo	B-I
therapy	I-I
.	I-I


The	O
mean	O
increase	O
was	O
402	O
%	O
(	O
41	O
+/-	O
20	O
sec	O
to	O
169	O
+/-	O
66	O
sec	O
)	O
for	O
the	O
placebo	O
group	O
and	O
286	O
%	O
(	O
42	O
+/-	O
16	O
to	O
120	O
+/-	O
57	O
sec	O
)	O
in	O
the	O
antacid	O
group	O
.	O


Both	O
the	O
antacid	B-I
and	O
placebo	B-I
groups	O
showed	O
improvement	O
in	O
the	O
degree	B-O
of	I-O
esophagitis	I-O
as	O
assessed	O
endoscopically	O
.	O


The	O
current	O
study	O
asked	O
:	O
does	O
regular	O
antacid	O
therapy	O
have	O
a	O
favorable	O
influence	O
on	O
the	O
natural	O
history	O
of	O
symptomatic	B-O
reflux	I-O
esophagitis	I-O
,	O
ie	O
,	O
does	O
therapy	O
heal	O
or	O
otherwise	O
change	O
esophagitis	O
so	O
that	O
painful	O
episodes	O
are	O
either	O
less	O
frequent	O
,	O
less	O
severe	O
,	O
or	O
both	O
?	O
We	O
found	O
that	O
the	O
natural	B-O
history	I-O
of	I-O
symptomatic	I-O
reflux	I-O
esophagitis	I-O
was	O
to	O
improve	O
with	O
either	O
antacid	B-I
or	O
placebo	B-I
.	I-I


There	O
was	O
no	O
significant	O
difference	O
in	O
antacid	B-I
or	O
placebo	B-I
on	O
the	O
(	O
short-term	O
)	O
natural	B-O
history	I-O
of	I-O
the	I-O
disease	I-O
.	I-O


Variance	O
in	O
albumin	B-I
loading	O
in	O
exchange	B-P
transfusions	I-P
.	I-P


To	O
assess	O
the	O
rationale	O
of	O
albumin	O
priming	O
prior	O
to	O
exchange	O
transfusions	O
,	O
42	B-P
hyperbilirubinemic	I-P
infants	I-P
who	I-P
required	I-P
exchange	I-P
transfusions	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O


Group	O
I	O
consisted	O
of	O
15	B-P
infants	I-P
who	O
were	O
given	O
intravenously	B-I
1	I-I
gm/kg	I-I
of	I-I
salt-poor	I-I
human	I-I
serum	I-I
albumin	I-I
one	O
hour	O
before	O
the	O
exchanges	O
.	O


Group	O
II	O
,	O
which	O
consisted	O
of	O
27	O
infants	O
,	O
received	O
simple	O
exchanges	O
.	O


No	O
statistical	O
differences	O
were	O
found	O
in	O
variations	B-O
in	I-O
reserve	I-O
albumin-binding	I-O
capacity	I-O
,	I-O
bilirubin	I-O
,	I-O
albumin	I-O
,	I-O
or	I-O
red	I-O
cell	I-O
bilirubin	I-O
at	I-O
pre	I-O
and	I-O
one-hour	I-O
post	I-O
albumin	I-O
infusion	I-O
in	O
the	O
primed	O
infants	O
.	O


The	O
amount	B-O
of	I-O
bilirubin	I-O
removed	I-O
per	I-O
kilogram	I-O
is	O
directly	O
correlated	O
to	O
plasma	B-O
bilirubin	I-O
concentration	I-O
(	O
r=0.87	O
)	O
.	O


No	O
significant	O
difference	O
in	O
efficiency	B-O
on	I-O
bilirubin	I-O
removal	I-O
was	O
seen	O
between	O
the	O
two	O
groups	O
.	O


Beneficial	O
effects	O
of	O
albumin	O
therapy	O
was	O
apparent	O
only	O
in	O
those	O
infants	B-P
with	I-P
low	I-P
RABC	I-P
as	O
determined	O
by	O
the	O
sephadex	O
gel	O
filtration	O
technique	O
.	O


Bevacizumab	B-I
plus	I-I
irinotecan	I-I
,	I-I
fluorouracil	I-I
,	I-I
and	I-I
leucovorin	I-I
for	O
metastatic	B-P
colorectal	I-P
cancer	I-P
.	I-P


BACKGROUND	O
Bevacizumab	B-I
,	O
a	O
monoclonal	O
antibody	O
against	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
has	O
shown	O
promising	O
preclinical	O
and	O
clinical	O
activity	O
against	O
metastatic	B-P
colorectal	I-P
cancer	I-P
,	O
particularly	O
in	O
combination	O
with	O
chemotherapy	O
.	O


METHODS	O
Of	O
813	B-P
patients	I-P
with	I-P
previously	I-P
untreated	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
,	O
we	O
randomly	O
assigned	O
402	O
to	O
receive	O
irinotecan	B-I
,	I-I
bolus	I-I
fluorouracil	I-I
,	I-I
and	I-I
leucovorin	I-I
(	I-I
IFL	I-I
)	I-I
plus	I-I
bevacizumab	I-I
(	O
5	O
mg	O
per	O
kilogram	O
of	O
body	O
weight	O
every	O
two	O
weeks	O
)	O
and	O
411	O
to	O
receive	O
IFL	B-I
plus	I-I
placebo	I-I
.	I-I


The	O
primary	O
end	O
point	O
was	O
overall	B-O
survival	I-O
.	I-O


Secondary	O
end	O
points	O
were	O
progression-free	B-O
survival	I-O
,	I-O
the	I-O
response	I-O
rate	I-O
,	I-O
the	I-O
duration	I-O
of	I-O
the	I-O
response	I-O
,	I-O
safety	I-O
,	I-O
and	I-O
the	I-O
quality	I-O
of	I-O
life	I-O
.	I-O


RESULTS	O
The	O
median	B-O
duration	I-O
of	I-O
survival	I-O
was	O
20.3	O
months	O
in	O
the	O
group	O
given	O
IFL	B-I
plus	I-I
bevacizumab	I-I
,	O
as	O
compared	O
with	O
15.6	O
months	O
in	O
the	O
group	O
given	O
IFL	B-I
plus	I-I
placebo	I-I
,	O
corresponding	O
to	O
a	O
hazard	O
ratio	O
for	O
death	O
of	O
0.66	O
(	O
P	O
<	O
0.001	O
)	O
.	O


The	O
median	B-O
duration	I-O
of	I-O
progression-free	I-O
survival	I-O
was	O
10.6	O
months	O
in	O
the	O
group	O
given	O
IFL	B-I
plus	I-I
bevacizumab	I-I
,	O
as	O
compared	O
with	O
6.2	O
months	O
in	O
the	O
group	O
given	O
IFL	B-I
plus	I-I
placebo	I-I
(	O
hazard	O
ratio	O
for	O
disease	O
progression	O
,	O
0.54	O
;	O
P	O
<	O
0.001	O
)	O
;	O
the	O
corresponding	O
rates	O
of	O
response	O
were	O
44.8	O
percent	O
and	O
34.8	O
percent	O
(	O
P=0.004	O
)	O
.	O


The	O
median	B-O
duration	I-O
of	I-O
the	I-O
response	I-O
was	O
10.4	O
months	O
in	O
the	O
group	O
given	O
IFL	B-I
plus	I-I
bevacizumab	I-I
,	O
as	O
compared	O
with	O
7.1	O
months	O
in	O
the	O
group	O
given	O
IFL	B-I
plus	I-I
placebo	I-I
(	O
hazard	O
ratio	O
for	O
progression	O
,	O
0.62	O
;	O
P=0.001	O
)	O
.	O


Grade	B-O
3	I-O
hypertension	I-O
was	O
more	O
common	O
during	O
treatment	O
with	O
IFL	B-I
plus	I-I
bevacizumab	I-I
than	O
with	O
IFL	B-I
plus	I-I
placebo	I-I
(	O
11.0	O
percent	O
vs.	O
2.3	O
percent	O
)	O
but	O
was	O
easily	O
managed	O
.	O


CONCLUSIONS	O
The	O
addition	O
of	O
bevacizumab	B-I
to	O
fluorouracil-based	B-I
combination	I-I
chemotherapy	I-I
results	O
in	O
statistically	O
significant	O
and	O
clinically	O
meaningful	O
improvement	O
in	O
survival	B-O
among	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	I-P


Short-	O
and	O
long-term	O
results	O
after	O
thrombolytic	B-I
treatment	I-I
of	O
deep	O
venous	O
thrombosis	O
.	O


OBJECTIVES	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
short-	O
and	O
long-term	O
efficacy	O
of	O
different	O
thrombolytic	B-I
therapy	I-I
regimens	O
in	O
patients	B-P
with	I-P
leg	I-P
or	I-P
pelvic	I-P
deep	I-P
venous	I-P
thrombosis	I-P
(	I-P
DVT	I-P
)	I-P
.	I-P


BACKGROUND	O
It	O
is	O
unclear	O
whether	O
locoregional	O
or	O
systemic	O
thrombolysis	O
is	O
superior	O
in	O
treating	O
acute	O
leg	O
DVT	O
or	O
even	O
whether	O
lysis	O
is	O
more	O
effective	O
than	O
anticoagulation	O
therapy	O
in	O
preventing	O
postthrombotic	O
syndrome	O
.	O


METHODS	O
A	O
total	O
of	O
250	B-P
patients	I-P
averaging	I-P
40	I-P
years	I-P
of	I-P
age	I-P
with	I-P
acute	I-P
DVT	I-P
were	O
randomized	O
into	O
five	O
groups	O
to	O
receive	O
full	B-I
heparinization	I-I
(	I-I
1,000	I-I
IU/h	I-I
)	I-I
and	I-I
compression	I-I
treatment	I-I
,	I-I
with	I-I
four	I-I
groups	I-I
also	I-I
administered	I-I
locoregional	I-I
tissue	I-I
plasminogen	I-I
activator	I-I
(	I-I
20	I-I
mg/day	I-I
)	I-I
or	I-I
urokinase	I-I
(	I-I
100,000	I-I
IU/day	I-I
)	I-I
or	I-I
systemic	I-I
streptokinase	I-I
(	I-I
3,000,000	I-I
IU	I-I
daily	I-I
)	I-I
or	I-I
urokinase	I-I
(	I-I
5,000,000	I-I
IU	I-I
daily	I-I
)	I-I
.	O


All	O
groups	O
then	O
received	O
anticoagulation	B-I
and	I-I
compression	I-I
treatment	I-I
for	I-I
one	I-I
year	I-I
.	I-I


Primary	O
efficacy	O
criteria	O
included	O
the	O
change	O
after	O
one	O
year	O
in	O
the	O
number	O
of	O
closed	B-O
vein	I-O
segments	I-O
and	O
the	O
occurrence	O
of	O
postthrombotic	O
syndrome	O
.	O


RESULTS	O
Systemic	B-I
thrombolytic	I-I
therapy	I-I
significantly	O
reduced	O
the	O
number	O
of	O
closed	B-O
vein	I-O
segments	I-O
after	O
12	O
months	O
in	O
patients	B-P
with	I-P
acute	I-P
DVT	I-P
compared	O
with	O
conventional	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Postthrombotic	B-O
syndrome	I-O
also	O
occurred	O
with	O
less	O
frequency	O
in	O
systemically	O
treated	O
patients	O
versus	O
controls	O
(	O
p	O
<	O
0.001	O
)	O
.	O


High-dose	O
thrombolysis	O
led	O
to	O
better	O
rates	O
of	O
complete	B-O
recanalization	I-O
after	O
seven	O
days	O
(	O
p	O
<	O
0.01	O
)	O
than	O
locoregional	O
lysis	O
.	O


However	O
,	O
12	B-P
patients	I-P
receiving	I-P
thrombolysis	I-P
(	O
9	O
systemic	O
,	O
3	O
local	O
)	O
suffered	O
major	B-O
bleeding	I-O
complications	I-O
;	I-O
9	I-P
patients	I-P
on	I-P
systemic	I-P
treatment	I-P
developed	O
pulmonary	B-O
emboli	I-O
.	I-O


CONCLUSIONS	O
Systemic	B-I
thrombolytic	I-I
treatment	I-I
for	O
acute	O
DVT	O
achieved	O
a	O
significantly	O
better	O
short-	O
and	O
long-term	O
clinical	O
outcome	O
than	O
conventional	O
heparin/anticoagulation	O
therapy	O
but	O
at	O
the	O
expense	O
of	O
a	O
serious	O
increase	O
in	O
major	O
bleeding	O
and	O
pulmonary	O
emboli	O
.	O


Given	O
the	O
inherent	O
risks	O
for	O
such	O
serious	O
complications	O
,	O
systemic	O
thrombolysis	O
,	O
although	O
effective	O
,	O
should	O
be	O
used	O
selectively	O
in	O
limb-threatening	O
thrombotic	O
situations	O
.	O


Transdermal	B-I
scopolamine	I-I
patch	I-I
in	O
addition	O
to	O
ondansetron	B-I
for	O
postoperative	O
nausea	O
and	O
vomiting	O
prophylaxis	O
in	O
patients	B-P
undergoing	I-P
ambulatory	I-P
cosmetic	I-P
surgery	I-P
.	I-P


STUDY	O
OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
transdermal	B-I
scopolamine	I-I
in	O
addition	O
to	O
ondansetron	B-I
in	O
decreasing	O
the	O
incidence	O
of	O
postoperative	B-O
nausea	I-O
and	I-O
vomiting	I-O
(	I-P
PONV	I-P
)	I-P
.	I-P


DESIGN	O
Randomized	O
controlled	O
trial	O
.	O


SETTING	O
Academic	B-P
hospital	I-P
.	I-P


PATIENTS	O
126	B-P
ASA	I-P
physical	I-P
status	I-P
I	I-P
and	I-P
II	I-P
patients	I-P
undergoing	I-P
outpatient	I-P
plastic	I-P
surgery	I-P
with	I-P
three	I-P
or	I-P
more	I-P
risk	I-P
factors	I-P
for	I-P
PONV	I-P
.	I-P


INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
to	O
receive	O
(	O
Group	O
1	O
)	O
a	O
transdermal	B-I
scopolamine	I-I
(	I-I
TDS	I-I
)	I-I
patch	I-I
or	O
(	O
Group	O
2	O
)	O
,	O
a	B-I
placebo	I-I
patch	I-I
two	O
hours	O
before	O
surgery	O
.	O


MEASUREMENTS	O
Occurrence	B-O
of	I-O
vomiting	I-O
,	I-O
severity	I-O
of	I-O
nausea	I-O
using	I-O
a	I-O
visual	I-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	I-O
rescue	I-O
medication	I-O
,	I-O
pain	I-O
intensity	I-O
and	I-O
pain	I-O
medications	I-O
,	I-O
and	I-O
side	I-O
effects	I-O
were	O
recorded	O
every	O
hour	O
until	O
discharge	O
from	O
hospital	O
,	O
then	O
every	O
4	O
hours	O
thereafter	O
for	O
a	O
total	O
of	O
24	O
hours	O
.	O


MAIN	O
RESULTS	O
A	O
statistically	O
significant	O
reduction	O
in	O
postoperative	B-O
nausea	I-O
between	O
8	O
and	O
24	O
hours	O
in	O
patients	O
receiving	O
TDS	O
was	O
noted	O
.	O


CONCLUSIONS	O
Transdermal	O
scopolamine	B-I
in	O
addition	O
to	O
ondansetron	O
benefits	O
patients	B-P
at	I-P
high	I-P
risk	I-P
for	I-P
PONV	I-P
undergoing	I-P
outpatient	I-P
plastic	I-P
surgery	I-P
for	O
up	O
to	O
20	O
hours	O
after	O
surgery	O
.	O


A	O
possible	O
link	O
between	O
early	O
probiotic	B-I
intervention	I-I
and	O
the	O
risk	B-O
of	I-O
neuropsychiatric	I-O
disorders	I-O
later	I-P
in	I-P
childhood	I-P
:	I-P
a	O
randomized	O
trial	O
.	O


BACKGROUND	O
Recent	O
experimental	O
evidence	O
suggests	O
that	O
gut	O
microbiota	O
may	O
alter	O
function	O
within	O
the	O
nervous	O
system	O
providing	O
new	O
insight	O
on	O
the	O
mechanism	O
of	O
neuropsychiatric	O
disorders	O
.	O


METHODS	O
Seventy-five	B-P
infants	I-P
who	I-P
were	I-P
randomized	I-P
to	I-P
receive	I-P
Lactobacillus	I-I
rhamnosus	I-I
GG	I-I
(	I-I
ATCC	I-I
53103	I-I
)	I-I
or	I-I
placebo	I-I
during	I-P
the	I-P
first	I-P
6	I-P
mo	I-P
of	I-P
life	I-P
were	I-P
followed-up	I-P
for	I-P
13	I-P
y	I-P
.	I-P


Gut	B-O
microbiota	I-O
was	O
assessed	O
at	O
the	O
age	O
of	O
3	O
wk	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
18	O
,	O
24	O
mo	O
,	O
and	O
13	O
y	O
using	B-I
fluorescein	I-I
in	I-I
situ	I-I
hybridization	I-I
(	O
FISH	O
)	O
and	O
qPCR	O
,	O
and	O
indirectly	O
by	O
determining	O
the	B-O
blood	I-O
group	I-O
secretor	I-O
type	I-O
at	O
the	O
age	O
of	O
13	O
y	O
.	O


The	O
diagnoses	O
of	B-O
attention	I-O
deficit	I-O
hyperactivity	I-O
disorder	I-O
(	I-O
ADHD	I-O
)	I-O
and	I-O
Asperger	I-O
syndrome	I-O
(	I-O
AS	I-O
)	I-O
by	O
a	O
child	O
neurologist	O
or	O
psychiatrist	O
were	O
based	O
on	O
ICD-10	O
diagnostic	O
criteria	O
.	O


RESULTS	O
At	O
the	O
age	O
of	O
13	O
y	B-O
,	I-O
ADHD	I-O
or	I-O
AS	I-O
was	O
diagnosed	O
in	O
6/35	O
(	O
17.1	O
%	O
)	O
children	O
in	O
the	O
placebo	O
and	O
none	O
in	O
the	O
probiotic	O
group	O
(	O
P	O
=	O
0.008	O
)	O
.	O


The	B-O
mean	I-O
(	I-O
SD	I-O
)	I-O
numbers	I-O
of	I-O
Bifidobacterium	I-O
species	I-O
bacteria	I-O
in	I-O
feces	I-O
during	I-O
the	I-O
first	I-O
6	I-O
mo	I-O
of	I-O
life	I-O
was	O
lower	O
in	O
affected	O
children	O
8.26	O
(	O
1.24	O
)	O
log	O
cells/g	O
than	O
in	O
healthy	O
children	O
9.12	O
(	O
0.64	O
)	O
log	O
cells/g	O
;	O
P	O
=	O
0.03	O
.	O


CONCLUSION	B-I
Probiotic	I-I
supplementation	I-I
early	O
in	O
life	O
may	O
reduce	O
the	B-O
risk	I-O
of	I-O
neuropsychiatric	I-O
disorder	I-O
development	I-O
later	I-P
in	I-P
childhood	I-P
possible	O
by	O
mechanisms	O
not	O
limited	O
to	O
gut	O
microbiota	O
composition	O
.	O


Outcome	B-O
assessment	I-O
for	I-P
clinical	I-P
trials	I-P
:	I-P
how	O
many	O
adjudicators	B-P
do	O
we	O
need	O
?	O
Canadian	O
Lung	O
Oncology	O
Group	O
.	O


Considerable	O
effort	O
is	O
often	O
expended	O
to	O
adjudicate	O
outcomes	O
in	O
clinical	O
trials	O
,	O
but	O
little	O
has	O
been	O
written	O
on	O
the	O
administration	O
of	O
the	O
adjudication	O
process	O
and	O
its	O
possible	O
impact	O
on	O
study	O
results	O
.	O


As	O
a	O
case	O
study	O
,	O
we	O
describe	O
the	O
function	B-O
and	I-O
performance	I-O
of	I-O
an	I-O
adjudication	I-O
committee	I-O
in	I-P
a	I-P
large	I-P
randomized	I-P
trial	I-P
of	O
two	O
diagnostic	O
approaches	O
to	O
potentially	B-P
operable	I-P
lung	I-P
cancer	I-P
.	I-P


Up	B-P
to	I-P
five	I-P
independent	I-P
adjudicators	I-P
independently	O
determined	O
two	O
primary	O
outcomes	O
:	O
tumor	B-O
status	I-O
at	I-O
death	I-O
or	I-O
at	I-O
final	I-O
follow-up	I-O
and	I-O
the	I-O
cause	I-O
of	I-O
death	I-O
.	I-O


Patients	B-P
for	O
whom	O
there	O
was	O
any	O
disagreement	O
were	O
discussed	O
in	O
committee	O
until	O
a	O
consensus	O
was	O
achieved	O
.	O


We	O
describe	O
the	O
pattern	O
of	O
agreement	O
among	O
the	O
adjudicators	O
and	O
with	O
the	O
final	O
consensus	O
result	O
.	O


Additionally	O
,	O
we	O
model	O
the	O
adjudication	O
process	O
and	O
predict	O
the	O
results	O
if	O
a	O
smaller	O
committee	O
had	O
been	O
used	O
.	O


We	O
found	O
that	O
reducing	O
the	O
number	B-O
of	I-O
adjudicators	I-O
from	O
five	O
to	O
two	O
or	O
three	O
would	O
probably	O
have	O
changed	O
the	O
consensus	O
outcome	O
in	O
less	O
than	O
10	O
%	O
of	O
cases	O
.	O


Correspondingly	O
,	O
the	O
effect	O
on	O
the	O
final	O
study	O
results	O
(	O
comparing	O
primary	O
outcomes	O
in	O
both	O
randomized	O
arms	O
)	O
would	O
have	O
been	O
altered	O
very	O
little	O
.	O


Even	O
using	O
a	O
single	O
adjudicator	O
would	O
not	O
have	O
affected	O
the	O
results	O
substantially	O
.	O


About	O
90	O
minutes	O
of	O
person-time	O
per	O
patient	B-P
was	O
required	O
for	O
activities	O
directly	O
related	O
to	O
the	O
adjudication	B-I
process	I-I
,	O
or	O
approximately	O
6	O
months	O
of	O
full	O
time	O
work	O
for	O
the	O
entire	O
study	O
.	O


This	O
level	O
of	O
effort	O
could	O
be	O
substantially	O
reduced	O
by	O
using	O
fewer	O
adjudicators	O
with	O
little	O
impact	O
on	O
the	O
results	O
.	O


Thus	O
,	O
we	O
suggest	O
that	O
when	O
high	O
observer	O
agreement	O
is	O
demonstrated	O
or	O
anticipated	O
,	O
adjudication	O
committees	O
should	O
consist	O
of	O
no	O
more	O
than	O
three	O
members	O
.	O


Further	O
work	O
is	O
needed	O
to	O
evaluate	O
if	O
smaller	O
committees	O
are	O
adequate	O
to	O
detect	O
small	O
but	O
important	O
treatment	O
effects	O
or	O
if	O
they	O
compromise	O
validity	O
when	O
the	O
level	O
of	O
adjudicator	O
agreement	O
is	O
lower	O
.	O


Effects	O
of	O
a	O
Chinese	O
medical	O
herbs	O
complex	O
on	O
cellular	O
immunity	O
and	O
toxicity-related	O
conditions	O
of	O
breast	B-P
cancer	I-P
patients	I-P
.	I-P


Rose	B-I
geranium	I-I
(	O
Pelargonium	O
graveolens	O
,	O
Geraniaceae	O
)	O
has	O
anti-cancer	O
and	O
anti-inflammatory	O
properties	O
,	O
and	O
promotes	O
wound	O
healing	O
.	O


Similarly	O
,	O
Ganoderma	B-I
tsugae	I-I
(	O
Ganodermataceae	O
)	O
,	O
Codonopsis	B-I
pilosula	I-I
(	O
Campanulaceae	O
)	O
and	O
Angelica	B-I
sinensis	I-I
(	O
Apiaceae	O
)	O
are	O
traditional	O
Chinese	O
herbs	O
associated	O
with	O
immunomodulatory	O
functions	O
.	O


In	O
the	O
present	O
study	O
,	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
the	O
Chinese	B-I
medicinal	I-I
herb	I-I
complex	I-I
,	I-I
RG-CMH	I-I
,	O
which	O
represents	O
a	O
mixture	B-I
of	I-I
rose	I-I
geranium	I-I
and	I-I
extracts	I-I
of	I-I
G.	I-I
tsugae	I-I
,	I-I
C.	I-I
pilosula	I-I
and	I-I
A.	I-I
sinensis	I-I
,	O
can	O
improve	O
the	O
immune	O
cell	O
count	O
of	O
cancer	B-P
patients	I-P
receiving	I-P
chemotherapy	I-P
and/or	I-P
radiotherapy	I-P
to	O
prevent	O
leucopenia	O
and	O
immune	O
impairment	O
that	O
usually	O
occurs	O
during	O
cancer	O
therapy	O
.	O


A	O
total	O
of	O
fifty-eight	B-P
breast	I-P
cancer	I-P
patients	I-P
who	I-P
received	I-P
chemotherapy	I-I
or	I-P
radiotherapy	I-I
were	I-P
enrolled	I-P
.	I-P


Immune	B-O
cell	I-O
levels	I-O
in	I-O
patient	I-O
serum	I-O
were	O
determined	O
before	O
,	O
and	O
following	O
,	O
6	O
weeks	O
of	O
cancer	O
treatment	O
for	O
patients	O
receiving	O
either	O
an	O
RG-CMH	B-I
or	I-I
a	I-I
placebo	I-I
.	I-I


Administration	O
of	O
RG-CMH	O
was	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
levels	B-O
of	I-O
leucocytes	I-O
from	O
31·5	O
%	O
for	O
the	B-I
placebo	I-I
group	O
to	O
13·4	O
%	O
for	O
the	O
RG-CMH	O
group	O
.	O


Similarly	B-O
,	I-O
levels	I-O
of	I-O
neutrophils	I-O
significantly	O
decreased	O
from	O
35·6	O
%	O
for	O
the	O
placebo	O
group	O
to	O
11·0	O
%	O
for	O
the	O
RG-CMH	O
group	O
.	O


RG-CMH	O
intervention	O
was	O
also	O
associated	O
with	O
a	O
decrease	B-O
in	I-O
levels	I-O
of	I-O
T	I-O
cells	I-O
,	I-O
helper	I-O
T	I-O
cells	I-O
,	I-O
cytotoxic	I-O
T	I-O
cells	I-O
and	I-O
natural	I-O
killer	I-O
cells	O
compared	O
with	O
the	O
placebo	O
group	O
.	O


However	O
,	O
these	O
differences	O
between	O
the	O
two	O
groups	O
were	O
not	O
statistically	O
significant	O
.	O


In	O
conclusion	O
,	O
administration	O
of	O
RG-CMH	O
to	O
patients	O
receiving	O
chemotherapy/radiotherapy	O
may	O
have	O
the	O
capacity	O
to	O
delay	O
,	O
or	O
ease	O
,	O
the	O
reduction	O
in	O
levels	O
of	O
leucocytes	O
and	O
neutrophils	O
that	O
are	O
experienced	O
by	O
patients	O
during	O
cancer	O
treatment	O
.	O


Effects	O
of	O
risperidone	B-I
and	I-I
parent	I-I
training	I-I
on	O
adaptive	O
functioning	O
in	O
children	B-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
and	I-P
serious	I-P
behavioral	I-P
problems	I-P
.	I-P


OBJECTIVE	O
Children	B-P
with	I-P
Pervasive	I-P
Developmental	I-P
Disorders	I-P
(	I-P
PDDs	I-P
)	I-P
have	O
social	O
interaction	O
deficits	O
,	O
delayed	O
communication	O
,	O
and	O
repetitive	O
behaviors	O
as	O
well	O
as	O
impairments	O
in	O
adaptive	O
functioning	O
.	O


Many	O
children	O
actually	O
show	O
a	O
decline	O
in	O
adaptive	O
skills	O
compared	O
with	O
age	O
mates	O
over	O
time	O
.	O


METHOD	O
This	O
24-week	O
,	O
three-site	O
,	O
controlled	O
clinical	O
trial	O
randomized	O
124	B-P
children	I-P
(	I-P
4	I-P
through	I-P
13	I-P
years	I-P
of	I-P
age	I-P
)	I-P
with	I-P
PDDs	I-P
and	I-P
serious	I-P
behavioral	I-P
problems	I-P
to	I-P
medication	I-I
alone	I-I
(	I-P
MED	I-P
;	I-P
n	I-P
=	I-P
49	I-P
;	I-P
risperidone	I-I
0.5	I-P
to	I-P
3.5	I-P
mg/day	I-P
;	I-P
if	O
ineffective	O
,	O
switch	O
to	O
aripiprazole	B-I
was	O
permitted	O
)	O
or	O
a	O
combination	B-I
of	I-I
medication	I-I
plus	I-I
parent	I-I
training	I-I
(	I-I
PT	I-I
)	I-I
(	O
COMB	O
;	O
n	O
=	O
75	O
)	O
.	O


Parents	B-P
of	I-P
children	I-P
in	I-P
COMB	I-P
received	I-P
an	I-P
average	I-P
of	I-P
11.4	I-P
PT	I-I
sessions	I-I
.	I-I


Standard	O
scores	O
and	O
Age-Equivalent	O
scores	O
on	O
Vineland	O
Adaptive	O
Behavior	O
Scales	O
were	O
the	O
outcome	O
measures	O
of	O
primary	O
interest	O
.	O


RESULTS	O
Seventeen	B-P
subjects	I-P
did	I-P
not	I-P
have	I-P
a	I-P
post-randomization	I-P
Vineland	I-P
assessment	I-P
.	I-P


Thus	O
,	O
we	O
used	O
a	O
mixed	O
model	O
with	O
outcome	O
conditioned	O
on	O
the	O
baseline	O
Vineland	O
scores	O
.	O


Both	O
groups	O
showed	O
improvement	O
over	O
the	O
24-week	O
trial	O
on	O
all	O
Vineland	O
domains	O
.	O


Compared	O
with	O
MED	O
,	O
Vineland	B-O
Socialization	I-O
and	I-O
Adaptive	I-O
Composite	I-O
Standard	I-O
scores	I-O
showed	O
greater	O
improvement	O
in	O
the	O
COMB	O
group	O
(	O
p	O
=	O
.01	O
and	O
.05	O
,	O
and	O
effect	O
sizes	O
=	O
0.35	O
and	O
0.22	O
,	O
respectively	O
)	O
.	O


On	O
Age	O
Equivalent	O
scores	O
,	O
Socialization	B-O
and	I-O
Communication	I-O
domains	I-O
showed	O
greater	O
improvement	O
in	O
COMB	O
versus	O
MED	O
(	O
p	O
=	O
.03	O
and	O
0.05	O
,	O
and	O
effect	O
sizes	O
=	O
0.33	O
and	O
0.14	O
,	O
respectively	O
)	O
.	O


Using	O
logistic	O
regression	O
,	O
children	O
in	O
the	O
COMB	O
group	O
were	O
twice	O
as	O
likely	O
to	O
make	O
at	O
least	O
6	O
months	O
'	O
gain	O
(	O
equal	O
to	O
the	O
passage	O
of	O
time	O
)	O
in	O
the	O
Vineland	B-O
Communication	I-O
Age	I-O
Equivalent	I-O
score	I-O
compared	O
with	O
MED	O
(	O
p	O
=	O
.02	O
)	O
.	O


After	O
controlling	O
for	O
IQ	O
,	O
this	O
difference	O
was	O
no	O
longer	O
significant	O
.	O


CONCLUSION	O
Reduction	O
of	O
serious	O
maladaptive	O
behavior	O
promotes	O
improvement	O
in	O
adaptive	O
behavior	O
.	O


Medication	B-I
plus	I-I
PT	I-I
shows	O
modest	O
additional	O
benefit	O
over	O
medication	B-I
alone	I-I
.	I-I


Clinical	O
trial	O
registration	O
information-RUPP	O
PI	O
PDD	O
:	O
Drug	O
and	O
Behavioral	O
Therapy	O
for	O
Children	B-P
With	I-P
Pervasive	I-P
Developmental	I-P
Disorders	I-P
;	I-P
http	O
:	O
//www.clinicaltrials.gov	O
;	O
NCT00080145	O
.	O


Most	O
functional	O
outcomes	O
are	O
similar	O
for	O
men	B-P
and	I-P
women	I-P
after	I-P
hip	I-P
fracture	I-P
:	I-P
a	O
secondary	O
analysis	O
of	O
the	O
enhancing	O
mobility	O
after	O
hip	O
fracture	O
trial	O
.	O


BACKGROUND	O
The	O
impact	O
of	O
gender	O
on	O
functional	O
outcomes	O
after	O
hip	O
fracture	O
is	O
not	O
known	O
.	O


We	O
aimed	O
to	O
determine	O
the	O
extent	O
to	O
which	O
gender	O
influenced	O
functional	B-O
outcome	I-O
and	I-O
response	I-O
to	I-O
exercise	I-O
in	O
older	B-P
people	I-P
after	I-P
hip	I-P
fracture	I-P
,	O
and	O
to	O
determine	O
if	O
any	O
differences	O
persisted	O
after	O
adjusting	O
for	O
cognition	O
,	O
weight	O
and	O
age	O
.	O


METHOD	O
Secondary	B-P
analysis	I-I
of	I-I
data	I-I
from	I-I
the	I-I
Enhancing	I-I
Mobility	I-I
After	I-I
Hip	I-I
Fracture	I-I
trial	I-I
in	I-P
which	I-P
older	I-P
people	I-P
after	I-P
hip	I-P
fracture	I-P
received	O
either	O
a	O
lower	B-I
or	I-I
higher	I-I
intensity	I-I
exercise	I-I
program	I-I
.	I-I


Functional	B-O
outcomes	I-O
included	O
physical	B-O
performance	I-O
and	I-O
self-reported	I-O
measures	I-O
.	I-O


Regression	O
models	O
were	O
used	O
to	O
compare	O
genders	O
at	O
baseline	O
,	O
week	O
4	O
and	O
week	O
16	O
,	O
with	O
adjustment	O
for	O
baseline	O
values	O
,	O
cognition	O
,	O
weight	O
and	O
age	O
.	O


Interaction	O
terms	O
were	O
used	O
to	O
assess	O
a	O
differential	O
impact	O
of	O
the	O
intervention	O
by	O
gender	O
.	O


RESULTS	O
Outcome	O
data	O
were	O
available	O
for	O
160	B-P
participants	I-P
,	I-P
30	I-P
men	I-P
(	I-P
19	I-P
%	I-P
)	I-P
and	I-P
130	I-P
women	I-P
(	I-P
81	I-P
%	I-P
)	I-P
at	O
baseline	O
,	O
with	O
the	O
withdrawal	O
of	O
4	O
men	O
(	O
13	O
%	O
)	O
and	O
6	O
women	O
(	O
5	O
%	O
)	O
at	O
week	O
16	O
.	O


There	O
were	O
no	B-O
gender	I-O
differences	I-O
for	O
any	O
baseline	B-O
measures	I-O
or	O
for	O
most	O
of	O
the	O
19	O
functional	B-O
outcome	I-O
measures	I-O
at	O
weeks	O
4	O
and	O
16	O
.	O


At	O
week	O
4	O
men	O
performed	O
better	O
in	O
knee	B-O
extensor	I-O
strength	I-O
(	O
2.1	O
kg	O
,	O
95	O
%	O
CI	O
0.6	O
to	O
3.7	O
,	O
p	O
<	O
0.01	O
)	O
.	O


This	O
difference	B-O
did	I-O
not	I-O
persist	I-O
after	O
adjustment	O
for	O
body	B-O
weight	I-O
,	O
however	O
persisted	O
after	O
adjusting	O
for	O
baseline	B-O
,	I-O
cognition	I-O
,	I-O
and	I-O
age	I-O
(	O
p	O
=	O
0.038	O
)	O
.	O


At	O
week	O
4	O
,	O
men	O
performed	O
better	O
in	O
coordinated	B-O
stability	I-O
(	O
-10.0	O
error	O
score	O
,	O
95	O
%	O
CI	O
-17.6	O
to	O
-2.4	O
,	O
p=0.010	O
)	O
and	O
this	O
persisted	B-O
after	O
adjusting	O
for	O
baseline	B-O
values	I-O
only	O
but	O
not	O
for	O
cognition	B-O
and	I-O
age	I-O
(	O
p	O
=	O
0.073	O
)	O
.	O


At	O
week	O
16	O
,	O
men	O
performed	O
better	O
in	O
coordinated	B-O
stability	I-O
(	O
-10.2	O
error	O
score	O
,	O
95	O
%	O
CI	O
-18.4	O
to	O
-1.9	O
,	O
p=0.016	O
)	O
and	O
this	O
persisted	B-O
after	O
adjusting	O
only	O
for	O
cognitive	B-O
impairment	I-O
(	O
p	O
=	O
0.029	O
)	O
but	O
not	O
for	O
age	B-O
and	I-O
baseline	I-O
(	O
p	O
=	O
0.135	O
)	O
.	O


There	O
was	O
no	O
indication	O
of	O
a	O
differential	B-O
impact	I-O
of	I-O
intervention	I-O
type	I-O
on	O
the	O
basis	O
of	O
gender	O
.	O


CONCLUSIONS	O
A	O
few	O
between	O
gender	O
differences	O
were	O
observed	O
in	O
strength	B-O
and	I-O
balance	I-O
,	O
however	O
these	O
appeared	O
to	O
be	O
confounded	O
by	O
body	B-O
weight	I-O
,	I-O
age	I-O
and/or	I-O
cognition	I-O
.	I-O


Effect	B-O
of	O
hydrochlorothiazide	B-I
therapy	I-I
on	O
cardiac	B-O
arrhythmias	I-O
in	I-P
African-American	I-P
men	I-P
with	I-P
systemic	I-P
hypertension	I-P
and	I-P
moderate	I-P
to	I-P
severe	I-P
left	I-P
ventricular	I-P
hypertrophy	I-P
.	I-P


The	O
effect	O
of	O
hydrochlorothiazide	B-I
therapy	I-I
on	O
ventricular	B-O
arrhythmias	I-O
was	O
studied	O
in	O
45	B-P
hypertensive	I-P
African-American	I-P
men	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
left	I-P
ventricular	I-P
(	I-P
LV	I-P
)	I-P
hypertrophy	I-P
.	I-P


After	O
medication	O
washout	O
,	O
patients	B-I
were	I-I
treated	I-I
with	I-I
placebo	I-I
followed	I-I
by	I-I
hydrochlorothiazide	I-I
.	I-I


Clinical	B-O
,	I-O
biochemical	I-O
,	I-O
and	I-O
48-hour	I-O
ambulatory	I-O
electrocardiographic	I-O
data	I-O
was	O
collected	O
after	O
each	O
treatment	O
phase	O
.	O


Signal-averaged	B-O
electrocardiograms	I-O
were	O
recorded	O
in	O
a	O
subgroup	B-P
of	I-P
24	I-P
patients	I-P
.	I-P


Average	B-O
LV	I-O
posterior	I-O
wall	I-O
thickness	I-O
was	O
15	O
+/-	O
1.1	O
mm	O
,	O
septum	O
16	O
+/-	O
2	O
mm	O
,	O
LV	O
mass	O
420	O
+/-	O
90	O
g	O
,	O
and	O
LV	O
mass	O
index	O
212	O
=	O
51	O
g/m2	O
.	O


Systolic	B-O
blood	I-O
pressure	I-O
(	I-O
BP	I-O
)	I-O
was	O
168	O
+/-	O
18	O
mm	O
Hg	O
after	O
the	O
placebo	O
phase	O
and	O
146	O
+/-	O
15	O
mm	O
Hg	O
after	O
hydrochlorothiazide	O
;	O
diastolic	O
BP	O
was	O
103	O
+/-	O
6	O
mm	O
Hg	O
and	O
89	O
+/-	O
9	O
mm	O
Hg	O
,	O
respectively	O
.	O


Serum	B-O
potassium	I-O
decreased	O
significantly	O
from	O
4.2	O
+/-	O
0.4	O
mmol/L	O
to	O
3.7	O
+/-	O
0.6	O
mmol/L	O
after	O
hydrochlorothiazide	B-I
therapy	I-I
.	I-I


The	O
average	O
hourly	O
incidence	O
of	O
ventricular	B-O
premature	I-O
contractions	I-O
was	O
22	O
with	O
placebo	B-I
and	O
25	O
with	O
hydrochlorothiazide	B-I
.	I-I


There	O
were	O
3	O
and	O
1	O
couplets	O
and	O
0.2	O
and	O
0.2	O
runs	O
of	O
ventricular	B-O
tachycardia	I-O
per	O
patient	O
per	O
hour	O
,	O
respectively	O
.	O


Variables	O
of	O
signal-averaged	B-O
electrocardiography	I-O
did	O
not	O
differ	O
between	O
the	O
2	O
treatments	O
.	O


Thus	O
,	O
in	O
hypertensive	B-P
African-American	I-P
men	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
LV	I-P
hypertrophy	I-P
,	O
hydrochlorothiazide	B-I
does	O
not	O
worsen	O
ventricular	B-O
arrhythmias	I-O
or	O
signal-averaged	B-O
electrocardiographic	I-O
variables	I-O
.	I-O


MSLT	B-I
in	O
primary	O
insomnia	B-O
:	I-O
stability	O
and	O
relation	O
to	O
nocturnal	B-O
sleep	I-O
.	I-O


STUDY	O
OBJECTIVES	O
To	O
assess	O
the	O
stability	O
of	O
the	O
multiple	B-I
sleep	I-I
latency	I-I
test	I-I
(	I-I
MSLT	I-I
)	I-I
in	O
primary	B-O
insomnia	I-O
and	O
its	O
relation	O
to	O
total	B-O
sleep	I-O
time	I-O
.	I-O


DESIGN	O
Randomized	O
,	O
double-blind	O
,	O
placebo	O
controlled	O
,	O
clinical	O
trial	O
.	O


SETTING	O
Outpatient	O
with	O
sleep	O
laboratory	O
assessments	O
in	O
months	O
1	O
and	O
8	O
of	O
treatment	O
.	O


PARTICIPANTS	O
Ninety-five	B-P
primary	I-P
insomniacs	I-P
,	I-P
32-64	I-P
years	I-P
old	I-P
and	I-P
55	I-P
age-	I-P
and	I-P
sex-matched	I-P
general	I-P
population-based	I-P
,	I-P
representative	I-P
controls	I-P
.	I-P


INTERVENTIONS	O
After	O
a	O
screening	O
nocturnal	B-I
polysomnograms	I-I
(	I-I
NPSG	I-I
)	I-I
and	O
MSLT	B-I
the	O
following	O
day	O
,	O
participants	B-P
with	I-P
primary	I-P
insomnia	I-P
were	O
randomized	O
to	O
take	O
zolpidem	B-I
10	O
mg	O
(	O
n	O
=	O
50	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
45	O
)	O
nightly	O
for	O
12	O
months	O
.	O


During	O
months	O
1	O
and	O
8	O
,	O
while	O
taking	O
their	O
prescribed	O
treatments	O
,	O
NPSGs	O
and	O
MSLTs	B-I
the	O
following	O
day	O
were	O
conducted	O
.	O


A	O
population-based	O
sample	O
served	O
as	O
controls	O
and	O
received	O
a	O
single	O
NPSG	O
followed	O
by	O
MSLT	B-I
.	I-I


RESULTS	O
Mean	B-O
daily	I-O
sleep	I-O
latency	I-O
on	I-O
the	I-O
screening	I-O
MSLT	I-O
of	I-O
insomniacs	I-O
was	O
normally	O
distributed	O
across	O
the	O
full	O
range	O
of	O
MSLT	B-I
scores	O
and	O
significantly	O
higher	O
than	O
those	O
of	O
a	O
population-based	O
representative	O
control	O
sample	O
(	O
P	O
<	O
0.006	O
)	O
.	O


The	O
insomniacs	O
with	O
the	O
highest	O
screening	B-O
MSLTs	I-O
had	O
the	O
shortest	O
screening	B-O
total	I-O
sleep	I-O
times	I-O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
MSLTs	B-I
of	O
insomniacs	O
during	O
treatment	O
in	O
study	O
month	O
1	O
were	O
correlated	O
(	O
r	O
=	O
0.44	O
,	O
P	O
<	O
0.001	O
)	O
with	O
their	O
month	O
8	O
MSLT	O
.	O


The	O
mean	B-O
MSLT	I-O
score	I-O
of	O
the	O
zolpidem	O
group	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
placebo	O
group	O
,	O
and	O
the	O
stability	O
within	O
treatment	O
groups	O
also	O
did	O
not	O
differ	O
.	O


CONCLUSIONS	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
some	O
insomniacs	B-P
show	O
a	O
reliable	O
disorder	O
of	O
hyperarousal	B-O
with	O
increased	O
wake	B-O
drive	I-O
both	O
at	O
night	O
and	O
during	O
the	O
day	O
.	O


A	O
randomized	O
controlled	O
trial	O
of	O
Pivotal	B-I
Response	I-I
Treatment	I-I
Group	I-I
for	O
parents	B-P
of	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


BACKGROUND	O
With	O
rates	O
of	O
autism	O
diagnosis	O
continuing	O
to	O
rise	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
effective	O
and	O
efficient	O
service	O
delivery	O
models	O
.	O


Pivotal	B-I
Response	I-I
Treatment	I-I
(	I-I
PRT	I-I
)	I-I
is	O
considered	O
an	O
established	O
treatment	O
for	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
;	O
however	O
,	O
there	O
have	O
been	O
few	O
well-controlled	O
studies	O
with	O
adequate	O
sample	O
size	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
conduct	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
PRT	B-I
parent	I-I
training	I-I
group	I-I
(	I-I
PRTG	I-I
)	I-I
for	O
targeting	O
language	O
deficits	O
in	O
young	B-P
children	I-P
with	I-P
ASD	I-P
.	I-P


METHODS	O
Fifty-three	B-P
children	I-P
with	I-P
autism	I-P
and	I-P
significant	I-P
language	I-P
delay	I-P
between	I-P
2	I-P
and	I-P
6	I-P
years	I-P
old	I-P
were	I-P
randomized	I-P
to	I-I
PRTG	I-I
(	I-I
N	I-I
=	I-I
27	I-I
)	I-I
or	I-I
psychoeducation	I-I
group	I-I
(	I-P
PEG	I-P
;	I-P
N	I-P
=	I-P
26	I-P
)	I-P
for	I-P
12	I-P
weeks	I-P
.	O


The	O
PRTG	O
taught	O
parents	O
behavioral	O
techniques	O
to	O
facilitate	O
language	O
development	O
.	O


The	O
PEG	O
taught	O
general	O
information	O
about	O
ASD	O
(	O
clinical	O
trial	O
NCT01881750	O
;	O
http	O
:	O
//www.clinicaltrials.gov	O
)	O
.	O


RESULTS	O
Analysis	B-O
of	I-O
child	I-O
utterances	I-O
during	I-O
the	I-O
structured	I-O
laboratory	I-O
observation	I-O
(	O
primary	O
outcome	O
)	O
indicated	O
that	O
,	O
compared	O
with	O
children	O
in	O
the	O
PEG	O
,	O
children	O
in	O
the	O
PRTG	O
demonstrated	B-O
greater	I-O
improvement	I-O
in	I-O
frequency	I-O
of	I-O
utterances	I-O
(	O
F	O
(	O
2	O
,	O
43	O
)	O
=	O
3.53	O
,	O
p	O
=	O
.038	O
,	O
d	O
=	O
0.42	O
)	O
.	O


Results	O
indicated	O
that	O
parents	O
were	O
able	B-I
to	I-I
learn	O
PRT	O
in	O
a	O
group	O
format	O
,	O
as	O
the	O
majority	O
of	O
parents	O
in	O
the	O
PRTG	O
(	O
84	O
%	O
)	O
met	O
fidelity	O
of	O
implementation	O
criteria	O
after	O
12	O
weeks	O
.	O


Children	O
also	O
demonstrated	B-O
greater	I-O
improvement	I-O
in	I-O
adaptive	I-O
communication	I-O
skills	I-O
(	I-O
Vineland-II	I-O
)	I-O
following	O
PRTG	O
and	O
baseline	O
Mullen	O
visual	O
reception	O
scores	O
predicted	O
treatment	O
response	O
to	O
PRTG	O
.	O


CONCLUSIONS	O
This	O
is	O
the	O
first	O
randomized	O
controlled	O
trial	O
of	O
group-delivered	O
PRT	O
and	O
one	O
of	O
the	O
largest	O
experimental	O
investigations	O
of	O
the	O
PRT	O
model	O
to	O
date	O
.	O


The	O
findings	O
suggest	O
that	O
specific	O
instruction	B-I
in	O
PRT	B-O
results	I-O
in	I-O
greater	I-O
skill	I-O
acquisition	I-O
for	I-O
both	I-O
parents	I-O
and	O
children	O
,	O
especially	B-O
in	I-O
functional	I-O
and	I-O
adaptive	I-O
communication	I-O
skills	O
.	O


Further	B-I
research	I-I
in	O
PRT	O
is	O
warranted	O
to	O
replicate	O
the	O
observed	O
results	O
and	O
address	O
other	O
core	O
ASD	O
symptoms	O
.	O


[	O
Are	O
there	O
indications	O
for	O
adjuvant	B-I
chemotherapy	I-I
after	I-I
excision	I-P
of	I-P
colorectal	I-P
cancer	I-P
?	O
]	O
.	O


Pre-bent	B-I
instruments	I-I
used	O
in	O
single-port	B-I
laparoscopic	I-I
surgery	I-I
versus	I-I
conventional	I-I
laparoscopic	I-I
surgery	I-I
:	I-I
comparative	O
study	O
of	O
performance	O
in	O
a	O
dry	O
lab	O
.	O


BACKGROUND	O
Different	O
types	O
of	O
single-incision	B-I
laparoscopic	I-I
surgery	I-I
(	I-I
SILS	I-I
)	I-I
have	O
become	O
increasingly	O
popular	O
.	O


Although	O
SILS	O
is	O
technically	O
even	O
more	O
challenging	O
than	O
conventional	O
laparoscopy	O
,	O
published	O
data	O
of	O
first	O
clinical	O
series	O
seem	O
to	O
demonstrate	O
the	O
feasibility	O
of	O
these	O
approaches	O
.	O


Various	O
attempts	O
have	O
been	O
made	O
to	O
overcome	O
restrictions	O
due	O
to	O
loss	O
of	O
triangulation	O
in	O
SILS	O
by	O
specially	O
designed	O
SILS-specific	O
instruments	O
.	O


This	O
study	O
involving	O
novices	O
in	O
a	O
dry	O
lab	O
compared	O
task	B-O
performances	I-O
between	O
conventional	B-I
laparoscopic	I-I
surgery	I-I
(	I-I
CLS	I-I
)	I-I
and	O
single-port	B-I
laparoscopic	I-I
surgery	I-I
(	O
SPLS	O
)	O
using	O
newly	O
designed	O
pre-bent	O
instruments	O
.	O


METHODS	O
In	O
this	O
study	O
,	O
90	B-P
medical	I-P
students	I-P
without	I-P
previous	I-P
experience	I-P
in	I-P
laparoscopic	I-P
techniques	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
undergo	I-P
one	I-P
of	I-P
three	I-P
procedures	I-P
:	I-P
CLS	I-P
,	I-P
SPLS	I-P
using	I-P
two	I-P
pre-bent	I-P
instruments	I-P
(	I-P
SPLS-pp	I-P
)	I-P
,	I-P
or	I-P
SPLS	I-I
using	I-P
one	I-P
pre-bent	I-P
and	I-P
one	I-P
straight	I-P
laparoscopic	I-P
instrument	I-P
(	I-P
SPLS-ps	I-P
)	I-P
.	I-P


In	O
the	O
dry	O
lab	O
,	O
the	O
participants	O
performed	O
four	O
typical	O
laparoscopic	O
tasks	O
of	O
increasing	O
difficulty	O
.	O


Evaluation	O
included	O
performance	B-O
times	I-O
or	I-O
number	I-O
of	I-O
completed	I-O
tasks	I-O
within	I-O
a	I-O
given	I-O
time	I-O
frame	I-O
.	I-O


All	O
performances	B-O
were	O
videotaped	O
and	O
evaluated	O
for	O
unsuccessful	B-O
attempts	I-O
and	I-O
unwanted	I-O
interactions	I-O
of	I-O
instruments	I-O
.	I-O


Using	O
subjective	B-O
questionnaires	I-O
,	O
the	O
participants	O
rated	B-O
difficulties	I-O
with	I-O
two-dimensional	I-O
vision	I-O
and	I-O
coordination	I-O
of	I-O
instruments	I-O
.	I-O


RESULTS	O
Task	B-O
performances	I-O
were	O
significantly	O
better	O
in	O
the	O
CLS	O
group	O
than	O
in	O
either	O
SPLS	O
group	O
.	O


The	O
SPLS-ps	O
group	O
showed	O
a	O
tendency	O
toward	O
better	O
performances	B-O
than	O
the	O
SPLS-pp	O
group	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
.	O


Video	O
sequences	O
and	O
participants`	O
questionnaires	O
showed	O
instrument	B-O
interaction	I-O
as	O
the	O
major	B-O
problem	I-O
in	O
the	O
single-incision	O
surgery	O
groups	O
.	O


CONCLUSIONS	O
Although	O
SILS	O
is	O
feasible	O
,	O
as	O
shown	O
in	O
clinical	O
series	O
published	O
by	O
laparoscopically	O
experienced	O
experts	O
,	O
SILS	O
techniques	O
are	O
demanding	O
due	O
to	O
restrictions	O
that	O
come	O
with	O
the	O
loss	O
of	O
triangulation	O
.	O


These	O
can	O
be	O
compensated	O
only	O
partially	O
by	O
currently	O
available	O
SILS-designed	O
instruments	O
.	O


The	O
future	O
of	O
SILS	O
depends	O
on	O
further	O
improvements	O
in	O
the	O
available	O
equipment	O
or	O
the	O
development	O
of	O
new	O
approaches	O
such	O
as	O
needlescopically	O
assisted	O
or	O
robotically	O
assisted	O
procedures	O
.	O


Gefitinib	B-I
versus	O
placebo	B-I
in	O
completely	B-P
resected	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
:	I-P
results	O
of	O
the	O
NCIC	O
CTG	O
BR19	O
study	O
.	O


PURPOSE	O
Survival	O
of	O
patients	B-P
with	I-P
completely	I-P
resected	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
is	O
unsatisfactory	O
,	O
and	O
in	O
2002	O
,	O
the	O
benefit	O
of	O
adjuvant	O
chemotherapy	O
was	O
not	O
established	O
.	O


This	O
phase	O
III	O
study	O
assessed	O
the	O
impact	O
of	O
postoperative	O
adjuvant	O
gefitinib	B-I
on	O
overall	B-O
survival	I-O
(	I-O
OS	I-O
)	I-O
.	I-O


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
with	I-P
completely	I-P
resected	I-P
(	I-P
stage	I-P
IB	I-P
,	I-P
II	I-P
,	I-P
or	I-P
IIIA	I-P
)	I-P
NSCLC	I-P
stratified	I-P
by	I-P
stage	I-P
,	I-P
histology	I-P
,	I-P
sex	I-P
,	I-P
postoperative	I-P
radiotherapy	I-P
,	I-P
and	I-P
chemotherapy	I-P
were	O
randomly	O
assigned	O
(	O
1:1	O
)	O
to	O
receive	O
gefitinib	B-I
250	I-I
mg	I-I
per	I-I
day	I-I
or	I-I
placebo	I-I
for	O
2	O
years	O
.	O


Study	O
end	O
points	O
were	O
OS	B-O
,	I-O
disease-free	I-O
survival	I-O
(	I-O
DFS	I-O
)	I-O
,	I-O
and	I-O
toxicity	I-O
.	I-O


RESULTS	O
As	O
a	O
result	O
of	O
early	O
closure	O
,	O
503	B-P
of	I-P
1,242	I-P
planned	I-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
(	O
251	O
to	O
gefitinib	B-I
and	O
252	O
to	O
placebo	B-I
)	I-I
.	O


Baseline	O
factors	O
were	O
balanced	O
between	O
the	O
arms	O
.	O


With	O
a	O
median	O
of	O
4.7	O
years	O
of	O
follow-up	O
(	O
range	O
,	O
0.1	O
to	O
6.3	O
years	O
)	O
,	O
there	O
was	O
no	O
difference	O
in	O
OS	B-O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.24	O
;	O
95	O
%	O
CI	O
,	O
0.94	O
to	O
1.64	O
;	O
P	O
=	O
.14	O
)	O
or	O
DFS	B-O
(	O
HR	O
,	O
1.22	O
;	O
95	O
%	O
CI	O
,	O
0.93	O
to	O
1.61	O
;	O
P	O
=	O
.15	O
)	O
between	O
the	O
arms	O
.	O


Exploratory	O
analyses	O
demonstrated	O
no	O
DFS	B-O
(	O
HR	O
,	O
1.28	O
;	O
95	O
%	O
CI	O
,	O
0.92	O
to	O
1.76	O
;	O
P	O
=	O
.14	O
)	O
or	O
OS	B-O
benefit	I-O
(	O
HR	O
,	O
1.24	O
;	O
95	O
%	O
CI	O
,	O
0.90	O
to	O
1.71	O
;	O
P	O
=	O
.18	O
)	O
from	O
gefitinib	B-I
for	O
344	B-P
patients	I-P
with	I-P
epidermal	I-P
growth	I-P
factor	I-P
receptor	I-P
(	I-P
EGFR	I-P
)	I-P
wild-type	O
tumors	O
.	O


Similarly	O
,	O
there	O
was	O
no	O
DFS	B-O
(	O
HR	O
,	O
1.84	O
;	O
95	O
%	O
CI	O
,	O
0.44	O
to	O
7.73	O
;	O
P	O
=	O
.395	O
)	O
or	O
OS	B-O
benefit	O
(	O
HR	O
,	O
3.16	O
;	O
95	O
%	O
CI	O
,	O
0.61	O
to	O
16.45	O
;	O
P	O
=	O
.15	O
)	O
from	O
gefitinib	B-I
for	O
the	O
15	O
patients	B-P
with	O
EGFR	O
mutation-positive	O
tumors	O
.	O


Adverse	B-O
events	I-O
were	O
those	O
expected	O
with	O
an	O
EGFR	O
inhibitor	O
.	O


Serious	B-O
adverse	I-O
events	I-O
occurred	O
in	O
≤	O
5	O
%	O
of	O
patients	O
,	O
except	B-O
infection	I-O
,	I-O
fatigue	I-O
,	I-O
and	I-O
pain	I-O
.	O


One	O
patient	O
in	O
each	O
arm	O
had	B-O
fatal	I-O
pneumonitis	I-O
.	O


CONCLUSION	O
Although	O
the	O
trial	O
closed	O
prematurely	O
and	O
definitive	O
statements	O
regarding	O
the	O
efficacy	O
of	O
adjuvant	B-I
gefitinib	I-I
can	O
not	O
be	O
made	O
,	O
these	O
results	O
indicate	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
of	O
benefit	O
.	O


Abnormal	O
cardiac	O
contractility	O
in	O
long-term	B-I
exogenous	I-I
subclinical	I-I
hyperthyroid	I-I
patients	I-P
as	O
demonstrated	O
by	O
two-dimensional	O
echocardiography	O
speckle	O
tracking	O
imaging	O
.	O


BACKGROUND	O
Subclinical	O
hyperthyroidism	O
is	O
associated	O
with	O
cardiovascular	B-O
morbidity	I-O
.	I-O


Recent	O
advances	O
in	O
echocardiography	O
imaging	O
have	O
allowed	O
sophisticated	O
evaluation	O
of	O
myocardial	B-O
tissue	O
properties	O
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
myocardial	O
effects	O
of	O
long-term	O
exogenous	B-I
subclinical	I-I
hyperthyroidism	I-I
using	O
two-dimensional	B-I
speckle	I-I
tracking	I-I
echocardiography	I-I
imaging	I-I
(	I-I
2D-STE	I-I
)	I-I
.	O


DESIGN	O
Prospective	O
,	O
single-blinded	O
,	O
placebo-controlled	O
randomized	O
trial	O
of	O
6	O
months	O
duration	O
with	O
two	O
parallel	O
groups	O
.	O


PATIENTS	O
AND	O
METHODS	O
Totally	B-P
25	I-P
patients	I-P
with	I-P
a	I-P
history	I-P
of	I-P
differentiated	I-P
thyroid	I-P
carcinoma	I-P
on	I-P
long-term	I-P
TSH-suppressive	I-P
levothyroxine	I-P
(	I-P
l-T	I-P
(	I-P
4	I-P
)	I-P
)	I-P
substitution	I-P
were	O
randomized	O
to	O
persistent	O
TSH-suppressive	B-I
l-T	I-I
(	I-I
4	I-I
)	I-I
substitution	I-I
(	O
low-TSH	O
group	O
)	O
or	O
restoration	B-I
of	I-I
euthyroidism	I-I
.	I-I


Additionally	B-P
40	I-P
euthyroid	I-P
controls	I-P
were	I-P
studied	I-P
.	I-P


RESULTS	O
(	O
PROPOSAL	O
)	O
:	O
At	O
baseline	O
,	O
the	O
group	O
of	O
patients	O
showed	O
normal	B-O
left	I-O
ventricular	I-O
(	I-O
LV	I-O
)	I-O
systolic	I-O
function	I-O
but	O
impaired	B-O
diastolic	I-O
function	I-O
as	O
assessed	O
with	O
conventional	O
echocardiographic	O
parameters	O
.	O


Importantly	O
,	O
2D-STE	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
subclinical	B-O
LV	I-O
systolic	I-O
and	I-O
diastolic	I-O
dysfunction	I-O
with	O
impaired	B-O
circumferential	I-O
and	I-O
longitudinal	I-O
strain	I-O
and	I-O
strain	I-O
rate	I-O
at	O
the	O
isovolumic	O
relaxation	O
time	O
.	O


After	O
restoration	O
of	O
euthyroidism	O
,	O
a	O
significant	O
improvement	B-O
in	I-O
LV	I-O
systolic	I-O
and	I-O
diastolic	I-O
function	I-O
as	O
assessed	O
with	O
2D-STE	O
strain	O
was	O
observed	O
.	O


CONCLUSION	O
Prolonged	B-I
subclinical	I-I
hyperthyroidism	I-I
leads	O
to	O
systolic	B-O
and	I-O
diastolic	I-O
dysfunction	I-O
,	O
which	O
is	O
reversible	O
after	O
restoration	O
of	O
euthyroidism	O
.	O


2D-STE	O
is	O
a	O
more	O
sensitive	O
technique	O
to	O
evaluate	O
subtle	O
changes	O
in	O
LV	O
performance	O
of	O
these	O
patients	O
.	O


Quadratus	O
lumborum	B-I
block	I-I
for	O
postoperative	B-O
pain	I-O
after	I-P
caesarean	I-I
section	I-I
:	I-I
A	O
randomised	O
controlled	O
trial	O
.	O


BACKGROUND	O
Effective	O
postoperative	O
analgesia	O
after	O
caesarean	B-I
section	O
is	O
important	O
because	O
it	O
enables	O
early	O
ambulation	O
and	O
facilitates	O
breast-feeding	O
.	O


Several	O
case	O
reports	O
have	O
shown	O
that	O
local	B-I
anaesthetic	I-I
injection	I-I
around	O
the	O
quadratus	O
lumborum	O
muscle	O
is	O
effective	O
in	O
providing	O
pain	O
relief	O
after	O
various	O
abdominal	O
operations	O
and	O
in	O
patients	B-P
with	I-P
chronic	I-P
pain	I-P
.	I-P


The	O
quadratus	B-I
lumborum	I-I
block	I-I
(	O
QLB	O
)	O
is	O
performed	O
in	O
close	O
proximity	O
to	O
the	O
surface	O
and	O
uses	O
a	O
fascial	O
compartment	O
path	O
to	O
extend	O
the	O
distribution	O
of	O
local	O
anaesthesia	O
into	O
the	O
posterior	O
abdominal	O
wall	O
and	O
paravertebral	O
space	O
.	O


This	O
central	O
effect	O
can	O
be	O
of	O
vital	O
importance	O
when	O
managing	O
the	O
visceral	B-O
pain	I-O
after	I-P
caesarean	I-P
section	I-P
.	I-P


OBJECTIVE	O
We	O
hypothesised	O
that	O
the	O
QLB	O
after	O
caesarean	B-P
section	I-P
can	O
provide	O
adequate	O
pain	O
relief	O
as	O
part	O
of	O
a	O
multimodal	O
approach	O
.	O


DESIGN	O
Double-blind	O
,	O
randomised	O
and	O
controlled	O
clinical	O
trial	O
.	O


SETTING	O
A	B-P
single	I-P
centre	I-P
between	I-P
June	I-P
2014	I-P
and	I-P
December	I-P
2014	I-P
.	I-P


PATIENTS	O
Fifty	B-P
patients	I-P
who	I-P
were	I-P
American	I-P
Society	I-P
of	I-P
Anesthesiologists	I-P
physical	I-P
status	I-P
1	I-P
or	I-P
2	I-P
,	I-P
with	I-P
normal	I-P
singleton	I-P
pregnancies	I-P
with	I-P
a	I-P
gestation	I-P
of	I-P
at	I-P
least	I-P
37	I-P
weeks	I-P
,	I-P
and	I-P
scheduled	I-P
for	I-P
elective	I-P
caesarean	I-P
section	I-P
under	I-P
spinal	I-P
anaesthesia	I-P
,	O
were	O
enrolled	O
into	O
the	O
study	O
.	O


They	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
QLB	B-I
(	O
n	O
=	O
25	O
)	O
with	O
0.125	B-I
%	I-I
bupivacaine	I-I
0.2	O
ml	O
kg⁻¹	O
(	B-I
Group	I-I
1	I-I
)	I-I
or	O
a	O
QLB	O
(	B-I
n	I-I
=	I-I
25	I-I
)	I-I
with	I-I
0.9	I-I
%	I-I
Normal	O
saline	O
0.2	O
ml	O
kg⁻¹	O
(	O
Group	O
2	O
)	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
outcome	O
measure	O
for	B-O
the	I-O
study	I-O
was	I-O
the	I-O
morphine	I-O
demands	I-O
and	I-O
doses	I-O
delivered	I-O
by	I-O
a	I-O
patient-controlled	I-O
analgesia	O
system	O
at	O
predetermined	O
intervals	O
(	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
)	O
after	O
surgery	O
.	O


The	O
secondary	B-O
endpoints	I-O
were	I-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
for	I-O
pain	I-O
at	I-O
rest	I-O
and	I-O
on	I-O
movement	I-O
(	I-O
dynamic	I-O
)	I-O
,	I-O
heart	I-O
rate	I-O
,	I-O
blood	I-O
pressure	I-O
,	I-O
pruritus	I-O
,	I-O
itching	I-O
,	I-O
nausea	I-O
,	O
vomiting	O
and	O
sedation	O
.	O


RESULTS	O
The	O
patients	O
who	O
received	O
local	O
anaesthetic	O
used	B-O
significantly	I-O
less	O
morphine	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
at	O
6	O
and	O
12	O
h	O
,	O
but	O
not	O
at	O
24	O
and	O
48	O
hours	O
after	O
caesarean	O
section	O
.	O


The	O
local	O
anaesthetic	B-O
group	I-O
had	I-O
significantly	O
less	O
morphine	O
demand	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
6	O
,	O
12	O
,	O
24	O
and	O
48	B-O
h	I-O
after	O
caesarean	O
section	O
.	O


The	O
VAS	O
was	O
significantly	O
lower	O
in	O
the	O
local	O
anaesthetic	O
group	O
than	O
the	O
control	O
group	O
,	O
including	O
VAS	O
for	O
pain	O
at	O
rest	O
at	O
all	O
times	O
except	O
24	O
h	O
after	O
caesarean	O
section	O
,	O
and	O
VAS	O
for	O
pain	O
on	O
movement	O
(	O
dynamic	O
)	O
at	B-P
all	I-P
times	I-P
.	I-P


CONCLUSION	B-P
The	O
QLB	O
after	O
caesarean	O
section	O
was	O
effective	O
and	O
provided	O
satisfactory	O
analgesia	O
in	O
combination	O
with	O
a	O
typical	O
postoperative	O
analgesic	O
regimen	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT02328378	O
.	O


Short-term	O
studies	O
on	O
the	O
use	O
of	O
glycerol	B-I
as	O
an	O
osmotic	O
agent	O
in	O
continuous	B-P
ambulatory	I-P
peritoneal	I-P
dialysis	I-P
(	I-P
CAPD	I-P
)	I-P
.	I-P


The	O
use	O
of	O
glycerol	B-I
as	O
an	O
osmotic	O
agent	O
in	O
two	O
different	O
concentrations	O
(	O
92	O
mmol/l	O
and	O
272	O
mmol/l	O
)	O
in	O
peritoneal	O
dialysis	O
fluid	O
was	O
investigated	O
over	O
3	O
days	O
in	B-P
six	I-P
patients	I-P
on	I-P
continuous	I-P
ambulatory	I-P
peritoneal	I-P
dialysis	I-P
and	O
compared	O
with	O
two	O
concentrations	O
of	O
glucose	B-I
(	O
76	O
mmol/l	O
and	O
215	O
mmol/l	O
)	O
in	O
the	O
same	O
patients	O
.	O


The	O
calorific	B-O
value	I-O
of	O
the	O
absorbed	O
osmotic	O
agent	O
was	O
lower	O
,	O
by	O
19	O
%	O
with	O
isotonic	O
and	O
22	O
%	O
with	O
hypertonic	O
solutions	O
,	O
when	O
glycerol	B-I
was	O
used	O
in	O
place	O
of	O
glucose	B-I
.	I-I


However	O
,	O
glycerol	O
provided	O
significantly	O
lower	O
total	B-O
ultrafiltration	I-O
than	O
glucose	O
at	O
each	O
concentration	O
,	O
despite	O
a	O
higher	O
initial	O
osmotic	O
pressure	O
of	O
the	O
glycerol-based	O
solutions	O
.	O


Thus	O
,	O
the	O
higher	O
concentration	O
of	O
glycerol	O
required	O
to	O
provide	O
equal	B-O
ultrafiltration	I-O
may	O
offset	O
any	O
calorific	O
advantage	O
.	O


Equilibration	B-O
of	I-O
creatinine	I-O
and	I-O
urea	I-O
was	O
slower	O
and	O
creatinine	B-O
clearance	I-O
lower	O
with	O
glycerol	B-I
.	I-I


Solutions	O
containing	O
glycerol	B-I
were	O
initially	O
less	O
acid	O
(	O
pH	O
6.5	O
)	O
than	O
those	O
containing	O
glucose	O
(	O
pH	O
5.1	O
)	O
.	O


Blood	B-O
glycerol	I-O
levels	I-O
,	O
which	O
were	O
in	O
the	O
physiological	O
range	O
with	O
glucose	O
as	O
the	O
osmotic	O
agent	O
,	O
reached	O
a	O
peak	O
80-fold	O
greater	O
at	O
4.3	O
+/-	O
0.8	O
mmol/l	O
during	O
dialysis	O
with	O
fluid	O
containing	O
glycerol	B-I
at	O
272	O
mmol/l	O
and	O
eightfold	O
higher	O
at	O
0.42	O
+/-	O
0.09	O
mmol/l	O
with	O
glycerol	B-I
at	O
92	O
mmol/l	O
.	O


There	O
was	O
no	O
evidence	O
of	O
haemolysis	B-O
or	O
other	O
toxic	B-O
effect	I-O
despite	O
these	O
levels	O
.	O


The	O
rise	O
in	O
blood	B-O
glucose	I-O
and	I-O
insulin	I-O
noted	O
during	O
the	O
use	O
of	O
glucose-based	O
solutions	O
was	O
not	O
found	O
with	O
glycerol	B-I
.	I-I


Circulating	B-O
levels	I-O
of	I-O
lactate	I-O
,	I-O
pyruvate	I-O
,	I-O
alanine	I-O
,	I-O
non-esterified	I-O
fatty	I-O
acids	I-O
and	I-O
the	I-O
ketone	I-O
bodies	I-O
were	O
similar	O
with	O
the	O
two	O
agents	O
.	O


Although	O
these	O
short-term	O
studies	O
have	O
shown	O
no	O
conclusive	O
advantage	O
of	O
glycerol	B-I
over	O
glucose	B-I
,	O
long-term	O
effects	O
of	O
glycerol	B-I
,	O
particularly	O
on	O
circulating	B-O
lipid	I-O
levels	I-O
,	O
will	O
determine	O
its	O
future	O
role	O
as	O
an	O
osmotic	O
agent	O
in	O
continuous	O
ambulatory	B-P
peritoneal	I-P
dialysis	I-P
.	I-P


Final	B-O
height	I-O
in	I-O
girls	I-O
with	I-P
turner	I-P
syndrome	I-P
after	O
long-term	O
growth	B-I
hormone	I-I
treatment	I-I
in	O
three	O
dosages	O
and	O
low	O
dose	O
estrogens	B-I
.	I-I


Although	O
GH	B-I
treatment	I-I
for	O
short	O
stature	O
in	O
Turner	O
syndrome	O
is	O
an	O
accepted	O
treatment	O
in	O
many	O
countries	O
,	O
which	O
GH	O
dosage	O
to	O
use	O
and	O
which	O
age	O
to	O
start	O
puberty	O
induction	O
are	O
issues	O
of	O
debate	O
.	O


This	O
study	O
shows	O
final	B-O
height	I-O
(	I-O
FH	I-O
)	I-O
in	O
60	B-P
girls	I-P
with	I-P
Turner	I-P
syndrome	I-P
treated	I-P
in	I-P
a	I-P
randomized	I-P
dose-response	I-P
trial	I-P
,	O
combining	B-I
GH	I-I
treatment	I-I
with	I-I
low	I-I
dose	I-I
estrogens	I-I
at	O
a	O
relatively	O
young	O
age	O
.	O


Girls	B-P
were	O
randomly	O
assigned	O
to	O
group	O
A	O
(	O
4	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
approximately	O
0.045	O
mg/kg/d	O
)	O
,	O
group	O
B	O
(	O
first	O
year	O
,	O
4	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
thereafter	O
6	O
IU/m	O
(	O
2	O
)	O
.d	O
)	O
,	O
or	O
group	O
C	O
(	O
first	O
year	O
,	O
4	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
second	O
year	O
,	O
6	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
thereafter	O
,	O
8	O
IU/m	O
(	O
2	O
)	O
.d	O
)	O
.	O


After	O
a	O
minimum	O
of	O
4	O
yr	O
of	O
GH	B-I
treatment	I-I
,	O
at	O
a	O
mean	O
age	O
of	O
12.7	O
+/-	O
0.7	O
yr	O
,	O
low	O
dose	O
micronized	B-I
17beta-estradiol	I-I
was	O
given	O
orally	O
.	O


After	O
a	O
mean	O
duration	B-O
of	I-O
GH	I-O
treatment	I-O
of	O
8.6	O
+/-	O
1.9	O
yr	O
,	O
FH	O
was	O
reached	O
at	O
a	O
mean	O
age	O
of	O
15.8	O
+/-	O
0.9	O
yr.	O
FH	B-O
,	O
expressed	O
in	O
centimeters	O
or	O
SD	O
score	O
,	O
was	O
157.6	O
+/-	O
6.5	O
or	O
-1.6	O
+/-	O
1.0	O
in	O
group	O
A	O
,	O
162.9	O
+/-	O
6.1	O
or	O
-0.7	O
+/-	O
1.0	O
in	O
group	O
B	O
,	O
and	O
163.6	O
+/-	O
6.0	O
or	O
-0.6	O
+/-	O
1.0	O
in	O
group	O
C.	O
The	O
difference	O
in	O
FH	B-O
in	I-O
centimeters	I-O
,	O
corrected	O
for	O
height	O
SD	O
score	O
and	O
age	O
at	O
start	O
of	O
treatment	O
,	O
was	O
significant	O
between	O
groups	O
A	O
and	O
B	O
[	O
regression	O
coefficient	O
,	O
4.1	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
1.4	O
,	O
6.9	O
;	O
P	O
<	O
0.01	O
]	O
,	O
and	O
groups	O
A	O
and	O
C	O
(	O
coefficient	O
,	O
5.0	O
;	O
95	O
%	O
CI	O
,	O
2.3	O
,	O
7.7	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
between	O
groups	O
B	O
and	O
C	O
(	O
coefficient	O
,	O
0.9	O
;	O
95	O
%	O
CI	O
,	O
-1.8	O
,	O
3.6	O
)	O
.	O


Fifty	B-P
of	I-P
the	I-P
60	I-P
girls	I-P
(	I-P
83	I-P
%	I-P
)	I-P
had	I-P
reached	I-P
a	I-P
normal	I-O
FH	I-O
(	I-P
FH	I-P
SD	I-P
score	I-P
,	I-P
more	I-P
than	I-P
-2	I-P
)	I-P
.	O


After	O
starting	O
estrogen	B-I
treatment	O
,	O
the	O
decrease	B-O
in	I-O
height	I-O
velocity	I-O
(	I-O
HV	I-O
)	I-O
changed	I-O
significantly	I-O
to	I-O
a	I-O
stable	I-O
HV	I-O
,	O
without	O
affecting	O
bone	B-O
maturation	I-O
(	O
change	O
in	O
bone	O
age/change	O
in	O
chronological	O
age	O
)	O
.	O


The	O
following	O
variables	O
contributed	O
significantly	O
to	O
predicting	O
FH	B-O
SD	I-O
score	I-O
:	I-O
GH	I-O
dose	I-O
,	I-O
height	I-O
SD	I-O
score	I-O
(	O
ref	O
.	O


normal	O
girls	O
)	O
,	O
chronological	B-O
age	I-O
at	I-O
start	I-O
of	I-O
treatment	I-O
,	O
and	O
HV	B-O
in	O
the	O
first	O
year	O
of	O
GH	O
treatment	O
.	O


GH	B-I
treatment	O
was	O
well	B-O
tolerated	I-O
.	I-O


In	O
conclusion	O
,	O
GH	B-I
treatment	O
leads	O
to	O
a	O
normalization	O
of	O
FH	B-O
in	O
most	O
girls	O
,	O
even	O
when	O
puberty	O
is	O
induced	O
at	O
a	O
normal	O
pubertal	O
age	O
.	O


The	O
optimal	O
GH	B-I
dosage	O
depends	O
on	O
height	O
and	O
age	O
at	O
the	O
start	O
of	O
treatment	O
and	O
first	O
year	O
HV	O
.	O


Simvastatin	B-I
and	O
preparation	O
of	O
polyunsaturated	B-I
phospholipids	I-I
produce	O
similar	O
changes	O
in	O
the	O
phospholipid	O
composition	O
of	O
high-density	O
lipoproteins	O
during	O
hypercholesterolemia	B-P
.	I-P


We	O
studied	O
the	O
phospholipid	O
composition	O
of	O
high-density	O
lipoproteins	O
in	O
patients	B-P
with	I-P
coronary	I-P
heart	I-P
disease	I-P
and	I-P
hypercholesterolemia	I-P
treated	I-P
with	I-P
simvastatin	I-I
(	I-I
Zocor	I-I
,	I-P
inhibitor	I-P
of	I-P
the	I-P
key	I-P
enzyme	I-P
of	I-P
cholesterol	I-P
synthesis	I-P
)	I-P
and	I-P
preparation	I-P
of	I-P
polyunsaturated	I-P
phospholipids	I-I
(	I-I
lipostabil	I-I
forte	I-I
)	I-I
.	I-I


Simvastatin	B-I
produced	O
a	O
hypolipidemic	B-O
effect	I-O
and	I-O
modulates	I-O
the	I-O
phospholipid	I-O
composition	I-O
of	I-O
high-density	I-O
lipoproteins	I-O
(	I-O
similarly	I-O
to	I-O
lipostabil	I-O
forte	I-O
)	I-O
.	I-O


These	O
changes	O
contribute	O
to	O
functional	B-O
activity	I-O
of	O
high-density	B-O
lipoproteins	I-O
in	O
the	O
reverse	O
cholesterol	O
transport	O
.	O


Interferon	B-I
alfa	I-I
in	O
acute	B-P
posttransfusion	I-P
hepatitis	I-P
C	I-P
:	I-P
a	O
randomized	O
,	O
controlled	O
trial	O
.	O


Is	O
altered	O
central	O
pain	O
processing	O
related	O
to	O
disease	O
stage	O
in	O
chronic	B-P
pancreatitis	I-P
patients	I-P
with	I-P
pain	I-P
?	O
An	O
exploratory	O
study	O
.	O


BACKGROUND	O
The	O
most	O
dominant	O
feature	O
in	O
chronic	O
pancreatitis	O
is	O
intense	O
abdominal	O
pain	O
.	O


Changes	O
in	O
spinal	O
and/or	O
supraspinal	O
central	O
nervous	O
system	O
pain	O
processing	O
due	O
to	O
visceral	O
nociceptive	O
input	O
play	O
an	O
important	O
role	O
in	O
this	O
pain	O
.	O


How	O
altered	B-I
pain	I-I
processing	I-I
is	O
related	O
to	O
disease	O
stage	O
still	O
needs	O
study	O
.	O


METHODOLOGY/PRINCIPAL	O
FINDINGS	O
Sixty	B-P
chronic	I-P
pancreatitis	I-P
patients	I-P
were	I-P
compared	I-P
to	I-P
15	I-P
healthy	I-P
controls	I-P
.	I-P


Two	O
subgroups	O
of	O
pancreatitis	O
patients	O
were	O
defined	O
based	O
on	O
the	O
M-ANNHEIM	O
severity	O
index	O
of	O
chronic	O
pancreatitis	O
;	O
i.e	O
.	O


moderate	O
and	O
severe	O
.	O


Pain	B-O
detection	I-O
and	I-O
tolerance	I-O
thresholds	I-O
for	I-O
pressure	I-O
and	I-O
electric	I-O
stimuli	I-O
were	O
measured	O
in	O
six	O
selected	O
dermatomes	O
(	O
C5	O
,	O
T4	O
,	O
T10	O
,	O
L1	O
,	O
L4	O
and	O
T10BACK	O
)	O
.	O


In	O
addition	O
,	O
the	O
conditioned	O
pain	B-I
modulation	I-I
response	I-I
to	O
cold	B-I
pressor	I-I
task	I-I
was	O
determined	O
.	O


These	O
measures	O
were	O
compared	O
between	O
the	O
healthy	O
controls	O
and	O
chronic	O
pancreatitis	O
patients	O
.	O


Severe	O
pancreatitis	O
patients	O
showed	O
lower	O
pain	B-O
thresholds	I-O
than	O
moderate	O
pancreatitis	O
patients	B-P
or	O
healthy	O
volunteers	O
.	O


Healthy	O
controls	O
showed	O
a	O
significantly	O
larger	O
conditioned	O
pain	B-O
modulation	I-O
response	O
compared	O
to	O
all	O
chronic	O
pancreatitis	O
patients	B-P
taken	O
together	O
.	O


CONCLUSIONS/SIGNIFICANCE	O
The	O
present	O
study	O
confirms	O
that	O
chronic	O
pancreatitis	O
patients	O
show	O
signs	O
of	O
altered	B-I
central	I-I
processing	I-I
of	O
nociception	O
compared	O
to	O
healthy	O
controls	O
.	O


The	O
study	O
further	O
suggests	O
that	O
these	O
changes	O
,	O
i.e	O
.	O


central	O
sensitization	O
,	O
may	O
be	O
influenced	O
by	O
disease	O
stage	O
.	O


These	O
findings	O
underline	O
the	O
need	O
to	O
take	O
altered	O
central	O
pain	O
processing	O
into	O
account	O
when	O
managing	O
the	O
pain	O
of	O
chronic	O
pancreatitis	O
.	O


A	O
controlled	O
study	O
comparing	O
patients	B-P
with	I-P
and	I-P
without	I-P
polycystic	I-P
ovaries	I-P
undergoing	I-P
in-vitro	I-O
fertilization	I-O
.	I-O


The	O
outcome	O
of	O
in-vitro	B-I
fertilization	I-I
and	I-I
embryo	I-I
transfer	I-I
(	I-I
IVF-ET	I-I
)	I-I
was	O
compared	O
in	O
76	B-P
patients	I-P
with	I-P
polycystic	I-P
ovaries	I-P
(	I-P
PCO	I-P
)	I-P
diagnosed	I-P
on	I-P
pre-treatment	I-P
ultrasound	I-P
scan	I-P
,	I-P
and	I-P
76	I-P
control	I-P
patients	I-P
who	I-P
had	I-P
normal	I-P
ovaries	I-P
and	I-P
were	I-P
matched	I-P
for	I-P
age	I-P
,	I-P
cause	I-P
of	I-P
infertility	I-P
and	I-P
stimulation	I-P
regimen	I-P
.	I-P


Despite	O
receiving	O
significantly	O
less	O
human	B-I
menopausal	I-I
gonadotrophin	I-I
(	I-I
HMG	I-I
)	I-I
,	O
patients	B-P
with	I-P
PCO	I-P
,	O
as	O
compared	O
with	O
controls	O
,	O
had	O
significantly	O
higher	O
serum	B-O
oestradiol	I-O
levels	I-O
on	O
the	O
day	O
of	O
human	O
chorionic	B-I
gonadotrophin	I-I
administration	O
(	O
5940	O
+/-	O
255	O
versus	O
4370	O
+/-	O
240	O
pmol/l	O
,	O
P	O
<	O
0.001	O
)	O
,	O
developed	O
more	O
follicles	B-O
(	O
14.9	O
+/-	O
0.7	O
versus	O
9.8	O
+/-	O
0.6	O
,	O
P	O
<	O
0.001	O
)	O
and	O
produced	O
more	O
oocytes	B-O
(	O
9.3	O
+/-	O
0.6	O
versus	O
6.8	O
+/-	O
0.5	O
,	O
P	O
=	O
0.003	O
)	O
.	O


However	O
,	O
fertilization	B-O
rates	I-O
were	O
reduced	O
in	O
the	O
PCO	O
patients	O
(	O
52.8	O
+/-	O
3.4	O
%	O
versus	O
66.1	O
+/-	O
3.4	O
%	O
,	O
P	O
=	O
0.007	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
cleavage	B-O
rates	I-O
.	I-O


The	O
pregnancy	B-O
rate/embryo	I-O
transfer	I-O
was	O
25.4	O
%	O
in	O
the	O
PCO	B-P
group	I-P
and	O
23.0	O
%	O
in	O
the	O
group	B-P
with	I-P
normal	I-P
ovaries	I-P
.	I-P


There	O
were	O
three	O
high	O
order	O
multiple	O
pregnancies	O
in	O
the	O
PCO	O
group	O
compared	O
with	O
none	O
in	O
the	O
group	O
with	O
normal	O
ovaries	O
.	O


Of	O
the	O
PCO	O
patients	O
,	O
10.5	O
%	O
developed	O
moderate/severe	O
ovarian	B-O
hyperstimulation	I-O
syndrome	I-O
(	I-O
OHSS	I-O
)	I-O
compared	O
with	O
none	O
of	O
the	O
controls	O
(	O
P	O
=	O
0.006	O
)	O
.	O


Patients	B-P
with	I-P
and	I-P
without	I-P
PCO	I-P
undergoing	I-P
IVF	I-P
have	O
comparable	O
pregnancy	B-O
and	I-O
livebirth	I-O
rates	I-O
.	I-O


However	O
,	O
it	O
is	O
important	O
to	O
diagnose	O
PCO	O
before	O
ovarian	O
stimulation	O
is	O
initiated	O
as	O
these	O
patients	O
are	O
more	O
likely	O
to	O
develop	O
moderate	O
or	O
severe	O
OHSS	O
following	O
IVF-ET	O
.	O


Nimodipine	B-I
pharmacotherapeutic	O
adjuvant	O
therapy	O
for	O
inpatient	B-P
treatment	I-P
of	I-P
cocaine	I-P
dependence	I-P
.	I-P


Recent	O
preclinical	O
studies	O
suggest	O
utility	O
for	O
voltage-sensitive	O
calcium	O
channel	O
blockers	O
(	O
VSCCBs	O
)	O
in	O
the	O
treatment	O
of	O
cocaine	B-P
addiction	I-P
.	I-P


The	O
following	O
double-blind	O
placebo-controlled	B-I
study	O
examined	O
the	O
role	O
of	O
the	O
VSCCB	O
nimodipine	B-I
in	O
attenuating	O
cocaine	O
craving	O
in	O
66	B-P
recently	I-P
abstinent	I-P
cocaine-dependent	I-P
patients	I-P
on	I-P
an	I-P
inpatient	I-P
substance	I-P
abuse	I-P
treatment	I-P
unit	I-P
utilizing	I-P
an	I-P
intensive	I-P
12-step	I-P
milieu-oriented	I-P
psychosocial	I-P
therapy	I-P
.	I-P


While	O
the	O
medication	O
was	O
well	O
tolerated	O
,	O
the	O
dose	O
of	O
nimodipine	B-I
used	O
in	O
this	O
study	O
(	O
90	O
mg	O
q.d	O
.	O


)	O
was	O
not	O
superior	O
to	O
placebo	B-I
in	O
reducing	O
background	O
or	O
cue-induced	O
cocaine	O
craving	O
over	O
the	O
3	O
weeks	O
of	O
the	O
study	O
.	O


There	O
was	O
the	O
suggestion	O
that	O
nimodipine	B-I
might	O
attenuate	O
the	O
severity	O
of	O
some	O
cocaine-induced	O
brain	O
deficits	O
,	O
as	O
detected	O
by	O
evaluation	O
of	O
smooth	B-O
pursuit	I-O
eye	I-O
movement	I-O
function	I-O
.	I-O


A	O
rationale	O
for	O
evaluating	O
higher	O
doses	O
of	O
nimodipine	B-I
for	O
the	O
treatment	O
of	O
cocaine	O
addiction	O
is	O
presented	O
.	O


As	O
nimodipine	B-I
might	O
have	O
anticraving	O
and	O
mood-stabilizing	O
properties	O
and	O
cardio-	O
and	O
neuroprotective	O
properties	O
in	O
the	O
face	O
of	O
cocaine	O
intoxication	O
and	O
might	O
possibly	O
even	O
reverse	O
some	O
cocaine-induced	O
brain	O
deficits	O
,	O
further	O
investigation	O
of	O
the	O
role	O
of	O
nimodipine	B-I
(	O
and	O
other	O
VSCCBs	O
)	O
in	O
cocaine	O
addiction	O
appears	O
an	O
attractive	O
avenue	O
of	O
future	O
medication	O
development	O
.	O


Comparison	O
between	O
intermittent	B-I
mandatory	I-I
ventilation	I-I
and	O
synchronized	B-I
intermittent	I-I
mandatory	I-I
ventilation	I-I
with	O
pressure	B-I
support	I-I
in	I-P
children	I-P
.	I-P


OBJECTIVE	O
To	O
compare	O
intermittent	B-I
mandatory	I-I
ventilation	I-I
(	I-I
IMV	I-I
)	I-I
with	O
synchronized	B-I
intermittent	I-I
mandatory	I-I
ventilation	I-I
plus	I-I
pressure	I-I
support	I-I
(	I-I
SIMV+PS	I-I
)	I-I
in	O
terms	O
of	O
time	B-O
on	I-O
mechanical	I-O
ventilation	I-O
,	I-O
duration	I-O
of	I-O
weaning	I-O
and	I-O
length	I-O
of	I-O
stay	I-O
in	I-O
a	I-O
pediatric	I-O
intensive	I-O
care	I-O
unit	I-O
(	I-P
PICU	I-P
)	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
randomized	O
clinical	O
trial	O
that	O
enrolled	B-P
children	I-P
aged	I-P
28	I-P
days	I-P
to	I-P
4	I-P
years	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
a	I-P
PICU	I-P
between	I-P
October	I-P
of	I-P
2005	I-P
and	I-P
June	I-P
of	I-P
2007	I-P
and	I-P
put	I-P
on	I-P
mechanical	I-I
ventilation	I-I
(	I-I
MV	I-I
)	I-I
for	I-P
more	I-P
than	I-P
48	I-P
hours	I-P
.	I-P


These	O
patients	O
were	O
allocated	O
to	O
one	O
of	O
two	O
groups	O
by	O
drawing	O
lots	O
:	O
IMV	B-I
group	O
(	B-I
IMVG	I-I
;	I-I
n	O
=	O
35	O
)	O
and	O
SIMV+PS	B-I
group	O
(	B-I
SIMVG	I-I
;	I-I
n	O
=	O
35	O
)	O
.	O


Children	B-P
were	I-P
excluded	I-P
if	I-P
they	I-P
had	I-P
undergone	I-P
tracheotomy	I-P
or	I-P
had	I-P
chronic	I-P
respiratory	I-P
diseases	I-P
.	I-P


Data	O
on	O
oxygenation	B-O
and	I-O
ventilation	I-O
were	O
recorded	O
at	O
admission	O
and	O
at	O
the	O
start	O
of	O
weaning	O
.	O


RESULTS	O
There	O
were	O
no	O
statistical	O
differences	O
between	O
the	O
groups	O
in	O
terms	O
of	O
age	B-O
,	I-O
sex	I-O
,	I-O
indication	I-O
for	I-O
MV	I-O
,	I-O
PRISM	I-O
score	I-O
,	I-O
Comfort	I-O
scale	I-O
,	I-O
use	I-O
of	I-O
sedatives	I-O
or	I-O
ventilation	I-O
and	I-O
oxygenation	I-O
parameters	I-O
.	I-O


The	O
median	B-O
time	I-O
on	I-O
MV	I-O
was	O
5	O
days	O
for	O
both	O
groups	O
(	O
p	O
=	O
0.120	O
)	O
.	O


There	O
were	O
also	O
no	O
statistical	O
differences	O
between	O
the	O
two	O
groups	O
for	O
duration	B-O
of	I-O
weaning	I-O
[	I-I
IMVG	I-I
:	I-I
1	O
day	O
(	O
1-6	O
)	O
vs.	O
SIMVG	B-I
:	I-I
1	O
day	O
(	O
1-6	O
)	O
;	O
p	O
=	O
0.262	O
]	O
or	O
length	B-O
of	I-O
hospital	I-O
stay	I-O
[	I-I
IMVG	I-I
:	I-I
8	O
days	O
(	O
2-22	O
)	O
vs.	O
SIMVG	B-I
:	I-I
6	O
days	O
(	O
3-20	O
)	O
;	O
p	O
=	O
0.113	O
]	O
.	O


CONCLUSION	O
Among	O
the	O
children	B-P
studied	I-P
here	I-P
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
IMV	B-I
and	O
SIMV+PS	B-I
in	O
terms	O
of	O
time	O
on	O
MV	B-O
,	I-O
duration	I-O
of	I-O
weaning	I-O
or	I-O
time	I-O
spent	I-O
in	I-O
the	I-O
PICU	I-O
.	I-O


ClinicalTrials.govID	O
:	O
NCT00549809	O
.	O


Body	O
Mass	O
Index	O
and	O
Adverse	O
Outcomes	O
in	O
Elderly	B-P
Patients	I-P
With	I-P
Atrial	I-P
Fibrillation	I-P
:	I-P
The	O
AMADEUS	O
Trial	O
.	O


BACKGROUND	O
AND	O
PURPOSE	O
Obesity	O
has	O
been	O
associated	O
with	O
increased	O
cardiovascular	O
risk	O
in	O
atrial	O
fibrillation	O
,	O
but	O
little	O
is	O
known	O
in	O
elderly	B-P
patients	I-P
with	I-P
atrial	I-P
fibrillation	I-P
.	I-P


METHODS	O
Post	O
hoc	O
analysis	O
of	O
data	O
from	O
the	O
AMADEUS	O
(	O
Evaluating	O
the	O
Use	O
of	O
SR34006	O
Compared	O
to	O
Warfarin	B-I
or	I-I
Acenocoumarol	I-I
in	O
Patients	B-P
With	I-P
Atrial	I-P
Fibrillation	I-P
)	I-P
trial	O
.	O


RESULTS	O
We	O
studied	O
1588	B-P
elderly	I-P
patients	I-P
,	I-P
who	I-P
were	I-P
categorized	I-P
as	I-P
normal	I-P
body	I-P
mass	I-P
index	I-P
(	I-P
BMI	I-P
,	I-P
18.5-25	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
;	I-P
n=515	I-P
[	I-P
32.4	I-P
%	I-P
]	I-P
)	I-P
,	I-P
overweight	I-P
(	I-P
BMI	I-P
,	I-P
25-30	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
;	I-P
n=711	I-P
[	I-P
44.8	I-P
%	I-P
]	I-P
)	I-P
,	I-P
and	I-P
obese	I-P
(	I-P
BMI≥30	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
;	I-P
n=362	I-P
[	I-P
22.8	I-P
%	I-P
]	I-P
)	I-P
.	O


There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
composite	O
outcome	O
of	B-O
cardiovascular	I-O
death	I-O
and	I-O
stroke/systemic	I-O
embolism	I-O
with	O
increasing	O
BMI	O
category	O
,	O
being	O
5.0	O
%	O
,	O
3.2	O
%	O
,	O
and	O
1.5	O
%	O
per	O
100	O
patient-years	O
,	O
respectively	O
(	O
P	O
for	O
trend=0.01	O
)	O
.	O


Cox	O
proportional	O
hazards	O
analysis	O
found	O
obesity	O
to	O
be	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
the	O
primary	O
composite	O
outcome	O
(	O
hazard	O
ratio	O
,	O
0.29	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.11-0.77	O
;	O
P=0.01	O
)	O
.	O


In	O
the	B-I
warfarin	I-I
arm	O
(	O
n=814	O
)	O
,	O
multivariate	O
logistic	O
regression	O
analysis	O
demonstrated	O
that	O
obesity	O
was	O
independently	O
related	O
to	O
higher	O
odds	O
of	O
time	O
in	O
therapeutic	O
range	O
≥60	O
%	O
(	O
odds	O
ratio	O
,	O
1.84	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.21-2.80	O
;	O
P=0.004	O
)	O
.	O


CONCLUSION	O
Obesity	O
was	O
associated	O
with	B-O
a	I-O
lower	I-O
stroke	I-O
and	I-O
mortality	I-O
rate	I-O
in	I-P
elderly	I-P
anticoagulated	I-P
atrial	I-P
fibrillation	I-P
patients	I-P
.	O


Obesity	O
was	O
related	O
to	O
good	O
quality	O
anticoagulation	O
control	O
.	O


Study	O
of	O
the	O
therapeutic	O
effects	O
of	O
a	O
hippotherapy	B-I
simulator	I-I
in	O
children	B-P
with	I-P
cerebral	I-P
palsy	I-P
:	I-P
a	O
stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
.	O


OBJECTIVE	O
To	O
investigate	O
whether	O
hippotherapy	B-I
(	I-I
when	I-I
applied	I-I
by	I-I
a	I-I
simulator	I-I
)	I-I
improves	O
postural	O
control	O
and	O
balance	O
in	O
children	B-P
with	I-P
cerebral	I-P
palsy	I-P
.	I-P


DESIGN	O
Stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
with	O
an	O
independent	O
assessor	O
.	O


Stratification	O
was	O
made	O
by	O
gross	O
motor	O
function	O
classification	O
system	O
levels	O
,	O
and	O
allocation	O
was	O
concealed	O
.	O


SUBJECTS	O
Children	B-P
between	I-P
4	I-P
and	I-P
18	I-P
years	I-P
old	I-P
with	I-P
cerebral	I-P
palsy	I-P
.	I-P


INTERVENTIONS	O
Participants	O
were	O
randomized	O
to	O
an	O
intervention	B-I
(	I-I
simulator	I-I
ON	I-I
)	I-I
or	I-I
control	I-I
(	I-I
simulator	I-I
OFF	I-I
)	I-I
group	O
after	O
getting	O
informed	O
consent	O
.	O


Treatment	O
was	O
provided	O
once	O
a	O
week	O
(	O
15	O
minutes	O
)	O
for	O
10	O
weeks	O
.	O


MAIN	O
MEASURES	O
Gross	B-O
Motor	I-O
Function	I-O
Measure	I-O
(	I-O
dimension	I-O
B	I-O
for	I-O
balance	I-O
and	I-O
the	I-O
Total	I-O
Score	I-O
)	I-O
and	I-O
Sitting	I-O
Assessment	I-O
Scale	I-O
were	O
carried	O
out	O
at	O
baseline	O
(	O
prior	O
to	O
randomization	O
)	O
,	O
end	O
of	O
intervention	O
and	O
12	O
weeks	O
after	O
completing	O
the	O
intervention	O
.	O


RESULTS	O
Thirty-eight	B-P
children	I-P
participated	I-P
.	I-P


The	O
groups	O
were	O
balanced	O
at	O
baseline	O
.	O


Sitting	B-O
balance	I-O
(	O
measured	O
by	O
dimension	O
B	O
of	O
the	O
Gross	O
Motor	O
Function	O
Measure	O
)	O
improved	O
significantly	O
in	O
the	O
treatment	O
group	O
(	O
effect	O
size	O
=	O
0.36	O
;	O
95	O
%	O
CI	O
0.01-0.71	O
)	O
and	O
the	O
effect	B-O
size	I-O
was	O
greater	O
in	O
the	O
severely	O
disabled	O
group	O
(	O
effect	O
size	O
=	O
0.80	O
;	O
95	O
%	O
CI	O
0.13-1.47	O
)	O
.	O


The	O
improvements	B-O
in	I-O
sitting	I-O
balance	I-O
were	O
not	O
maintained	O
over	O
the	O
follow-up	O
period	O
.	O


Changes	O
in	O
the	O
total	B-O
score	I-O
of	I-O
the	I-O
Gross	I-O
Motor	I-O
Function	I-O
Measure	I-O
and	I-O
the	I-O
Sitting	I-O
Assessment	I-O
Scale	I-O
were	O
not	O
significant	O
.	O


CONCLUSION	O
Hippotherapy	B-I
with	O
a	O
simulator	O
can	O
improve	O
sitting	B-O
balance	I-O
in	O
cerebral	B-P
palsy	I-P
children	I-P
who	O
have	O
higher	O
levels	O
of	O
disability	O
.	O


However	O
,	O
this	O
did	O
not	O
lead	O
to	O
a	O
change	O
in	O
the	O
overall	O
function	O
of	O
these	O
children	O
(	O
Gross	O
Motor	O
Function	O
Classification	O
System	O
level	O
V	O
)	O
.	O


Impact	O
of	O
an	O
Asha	B-I
intervention	I-I
on	O
depressive	B-O
symptoms	I-O
among	O
rural	B-P
women	I-P
living	I-P
with	I-P
AIDS	I-P
in	I-P
India	I-P
:	I-P
comparison	O
of	O
the	O
Asha-Life	B-I
and	I-I
Usual	I-I
Care	I-I
program	I-I
.	I-I


The	O
purpose	O
of	O
this	O
randomized	O
pilot	O
study	O
is	O
to	O
conduct	O
an	O
intervention	O
with	O
68	B-P
rural	I-P
women	I-P
living	I-P
with	I-P
AIDS	I-P
to	O
compare	O
the	O
effectiveness	O
of	O
two	O
different	O
programs	O
on	O
depressive	O
symptoms	O
.	O


The	O
trial	O
was	O
designed	O
to	O
assess	O
the	O
impact	O
of	O
the	O
Asha-Life	B-I
intervention	I-I
engaging	O
with	O
an	O
HIV-trained	O
village	O
woman	O
,	O
Asha	B-I
(	I-I
Accredited	I-I
Social	I-I
Health	I-I
Activist	I-I
)	I-I
,	O
to	O
participate	O
in	O
the	O
care	O
of	O
women	O
living	O
with	O
AIDS	O
(	O
WLA	O
)	O
,	O
along	O
with	O
other	O
health	O
care	O
providers	O
compared	O
to	O
a	O
Usual	B-I
Care	I-I
group	I-I
.	I-I


Two	B-P
high	I-P
prevalence	I-P
HIV/AIDS	I-P
villages	I-P
in	I-P
rural	I-P
Andhra	I-P
Pradesh	I-P
,	I-P
which	I-P
were	I-P
demographically	I-P
alike	I-P
and	I-P
served	I-P
by	I-P
distinct	I-P
Public	I-P
Health	I-P
Centers	I-P
,	I-P
were	I-P
selected	I-P
randomly	I-P
from	I-P
a	I-P
total	I-P
of	I-P
16	I-P
villages	I-P
.	I-P


The	O
findings	O
of	O
this	O
study	O
demonstrated	O
that	O
the	O
Asha-Life	B-I
participants	O
significantly	B-O
reduced	I-O
their	O
depressive	B-O
symptom	I-O
scores	I-O
compared	O
to	O
the	O
Usual	O
Care	O
participants	O
.	O


Moreover	O
,	O
women	B-P
living	I-P
with	I-P
AIDS	I-P
who	O
demonstrated	O
higher	O
depressive	B-O
symptom	I-O
scores	I-O
at	O
baseline	O
had	O
greater	O
reduction	O
in	O
their	O
depressive	B-O
symptoms	I-O
than	O
women	O
with	O
lower	O
scores	O
.	O


Metoprolol	B-I
CR/XL	I-I
improves	O
systolic	B-O
and	I-O
diastolic	I-O
left	I-O
ventricular	I-O
function	I-O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
.	I-P


AIMS	O
To	O
investigate	O
whether	O
metoprolol	B-I
controlled	I-I
release/extended	I-I
release	I-I
(	I-I
CR/XL	I-I
)	I-I
once	O
daily	O
would	O
improve	O
diastolic	B-O
and	I-O
systolic	I-O
left	I-O
ventricular	I-O
function	I-O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
and	I-P
decreased	I-P
ejection	I-P
fraction	I-P
.	I-P


METHODS	O
In	O
an	O
echocardiographic	O
substudy	O
to	O
the	O
Metoprolol	B-I
CR/XL	I-I
Randomized	O
Intervention	O
Trial	O
in	O
Heart	O
Failure	O
(	O
MERIT-HF	O
)	O
,	O
66	B-P
patients	I-P
were	I-P
examined	I-P
three	O
times	O
during	O
a	O
12-month	O
period	O
blinded	O
to	O
treatment	O
group	O
,	O
assessing	O
left	B-O
ventricular	I-O
dimensions	I-O
and	I-O
ejection	I-O
fraction	I-O
,	I-O
and	I-O
Doppler	I-O
mitral	I-O
inflow	I-O
parameters	I-O
,	O
all	O
measured	O
in	O
a	O
core	O
laboratory	O
.	O


RESULTS	O
In	O
the	O
metoprolol	B-I
CR/XL	I-I
group	O
left	B-O
ventricular	I-O
ejection	I-O
fraction	I-O
increased	O
from	O
0.26	O
to	O
0.31	O
(	O
P	O
=	O
0.009	O
)	O
after	O
a	O
mean	O
observation	O
period	O
of	O
10.6	O
months	O
,	O
and	O
deceleration	O
time	B-O
of	I-O
the	I-O
early	I-O
mitral	I-O
filling	I-O
wave	I-O
(	O
E	O
)	O
increased	O
from	O
189	O
to	O
246	O
ms	O
(	O
P	O
=	O
0.0012	O
)	O
,	O
time	B-O
velocity	I-O
integral	I-O
of	I-O
E-wave	I-O
increased	O
from	O
8.7	O
to	O
11.2	O
cm	O
(	O
P	O
=	O
0.018	O
)	O
,	O
and	O
the	O
duration	B-O
of	I-O
the	I-O
late	I-O
mitral	I-O
filling	I-O
wave	I-O
(	O
A	O
)	O
increased	O
from	O
122	O
to	O
145	O
ms	O
(	O
P	O
=	O
0.014	O
)	O
.	O


No	O
significant	O
changes	O
were	O
seen	O
in	O
the	O
placebo	B-I
group	O
regarding	O
any	O
of	O
these	O
variables	O
.	O


CONCLUSION	O
Metoprolol	B-I
CR/XL	I-I
once	O
daily	O
in	O
addition	O
to	O
standard	O
therapy	O
improved	O
both	O
diastolic	B-O
and	I-O
systolic	I-O
function	I-O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
and	I-P
decreased	I-P
ejection	I-P
fraction	I-P
.	I-P


Increasing	O
verbal	O
responsiveness	O
in	O
parents	B-P
of	I-P
children	I-P
with	I-P
autism	I-P
:	I-P
a	I-P
pilot	O
study	O
.	O


Correlational	O
studies	O
have	O
revealed	O
a	O
positive	O
relationship	O
between	O
parent	B-P
verbal	O
responsiveness	O
and	O
language	O
outcomes	O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


We	O
investigated	O
whether	O
parents	B-P
of	I-P
young	I-P
children	I-P
on	I-P
the	I-P
autism	I-P
spectrum	I-P
could	O
learn	O
and	O
implement	O
the	O
specific	O
categories	O
of	O
verbal	O
responsiveness	O
that	O
have	O
been	O
suggested	O
to	O
facilitate	O
language	O
development	O
.	O


Parents	B-P
were	O
taught	O
to	O
increase	B-I
their	I-I
verbal	I-I
responsiveness	I-I
in	O
the	O
context	O
of	O
a	O
short-term	B-I
language	I-I
intervention	I-I
that	O
included	O
group	B-I
parent	I-I
education	I-I
sessions	I-I
,	O
as	O
well	O
as	O
individual	B-I
and	I-I
small-group	I-I
coaching	I-I
sessions	I-I
of	I-I
parent-child	I-I
play	I-I
interactions	I-I
.	I-I


Parents	B-P
in	O
the	O
treatment	O
group	O
increased	O
their	O
use	O
of	O
comments	O
that	O
:	O
described	O
their	O
child	B-O
's	I-O
focus	I-O
of	I-O
attention	I-O
;	I-O
interpreted	O
or	O
expanded	O
child	B-O
communication	I-O
acts	I-O
;	I-O
and	O
prompted	O
child	B-O
communication	I-O
.	I-O


Preliminary	O
treatment	O
effects	O
were	O
also	O
noted	O
in	O
children	B-O
's	I-O
prompted	I-O
and	I-O
spontaneous	I-O
communication	I-O
.	I-O


These	O
results	O
support	O
the	O
use	O
of	O
parent-mediated	B-I
interventions	I-I
targeting	O
verbal	B-O
responsiveness	I-O
to	O
facilitate	O
language	B-O
development	I-O
and	I-O
communication	I-O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


Midazolam	B-I
as	O
a	O
main	O
anesthesia	O
induction	O
agent	O
--	O
a	O
comparison	O
with	O
thiopental	B-I
and	I-I
diazepam	I-I
.	I-I


A	O
clinical	O
randomized	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
value	B-O
of	O
midazolam	B-I
as	O
a	O
narcotic	O
adjuvant	O
for	O
anesthetic	O
induction	O
.	O


Thirty	B-P
ASA	I-P
I-II	I-P
adult	I-P
patients	I-P
undergoing	I-P
selective	I-P
surgery	I-P
were	O
allocated	O
randomly	O
into	O
two	O
groups	O
to	O
receive	O
one	O
of	O
the	O
following	O
agents	O
:	O
midazolam	B-I
0.3	I-I
mg/kg	I-I
,	I-I
thiopental	I-I
5	I-I
mg/kg	I-I
,	I-I
or	I-I
diazepam	I-I
0.4	I-I
mg/kg	I-I
.	I-I


The	O
induction	B-O
time	I-O
as	I-O
measured	I-O
from	I-O
the	I-O
onset	I-O
of	I-O
injection	I-O
to	I-O
loss	I-O
of	I-O
the	I-O
eyelash	I-O
reflex	I-O
was	O
shortest	O
in	O
the	O
case	O
of	O
thiopental	O
;	O
while	O
a	O
lower	B-O
frequency	I-O
of	I-O
apnea	I-O
,	I-O
lesser	I-O
suppression	I-O
of	I-O
circulation	I-O
,	O
and	O
lack	B-O
of	I-O
venous	I-O
irritation	I-O
were	O
points	O
favoring	O
midazolam	O
.	O


However	O
,	O
further	O
study	O
is	O
needed	O
to	O
clarify	O
the	O
moderate	B-O
cardiovascular	I-O
response	I-O
seen	O
during	O
intubation	O
in	O
some	O
cases	O
as	O
well	O
as	O
to	O
elucidate	O
any	O
patient	O
population	O
differences	O
.	O


Ceftriaxone	B-I
versus	I-I
ampicillin	I-I
and	I-I
chloramphenicol	I-I
for	O
treatment	O
of	O
bacterial	B-O
meningitis	I-O
in	I-P
children	I-P
.	I-P


78	B-P
patients	I-P
with	I-P
bacterial	I-P
meningitis	I-P
were	I-P
evaluated	I-P
in	O
a	O
prospective	O
,	O
randomised	O
study	O
comparing	O
twice-daily	O
ceftriaxone	B-I
as	O
single-drug	O
therapy	O
with	O
ampicillin	B-I
and	I-I
chloramphenicol	I-I
given	O
every	O
6	O
h.	O
The	O
groups	O
were	O
comparable	O
in	O
age	O
,	O
sex	O
,	O
days	O
of	O
illness	O
before	O
admission	O
,	O
and	O
bacterial	O
colony	O
counts	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O


The	O
pathogens	O
were	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
54	O
cases	O
)	O
,	O
streptococci	O
(	O
9	O
cases	O
)	O
,	O
meningococci	O
(	O
9	O
cases	O
)	O
,	O
and	O
unknown	O
(	O
6	O
cases	O
)	O
.	O


In	O
40	O
CSF	O
specimens	O
obtained	O
4-12	O
h	O
after	O
initiation	O
of	O
therapy	O
,	O
cultures	B-O
were	I-O
negative	I-O
in	O
57	O
%	O
of	O
the	O
ceftriaxone	O
patients	O
and	O
in	O
42	O
%	O
of	O
the	O
others	O
.	O


The	O
mean	B-O
falls	I-O
in	I-O
the	I-O
CSF	I-O
bacterial	I-O
colony	I-O
counts	I-O
were	O
4.7	O
and	O
5.0	O
log10	O
colony-forming	O
units/ml	O
,	O
respectively	O
.	O


Mean	B-O
bactericidal	I-O
activity	I-O
in	I-O
CSF	I-O
was	O
significantly	O
greater	O
in	O
the	O
ceftriaxone	B-I
than	O
in	O
the	O
conventional	O
treatment	O
group	O
at	O
the	O
beginning	O
and	O
end	O
of	O
therapy	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
clinical	B-O
responses	I-O
or	O
in	O
frequency	B-O
of	I-O
complications	I-O
,	I-O
except	I-O
for	I-O
mild	I-O
diarrhoea	I-O
,	O
which	O
occurred	O
in	O
16	O
ceftriaxone	B-I
patients	O
and	O
in	O
8	O
in	O
the	O
other	O
group	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


Once-daily	O
topical	B-I
brimonidine	I-I
tartrate	I-I
gel	I-I
0·5	O
%	O
is	O
a	O
novel	O
treatment	O
for	B-P
moderate	I-P
to	I-P
severe	I-O
facial	I-O
erythema	I-O
of	I-O
rosacea	I-O
:	I-O
results	O
of	O
two	O
multicentre	O
,	O
randomized	O
and	O
vehicle-controlled	O
studies	O
.	O


BACKGROUND	B-P
Erythema	I-P
of	I-P
rosacea	I-P
is	O
thought	O
to	O
result	O
from	O
abnormal	O
cutaneous	O
vasomotor	O
activity	O
.	B-I


Brimonidine	B-I
tartrate	I-I
(	I-I
BT	I-I
)	I-I
is	O
a	O
highly	O
selective	O
α	O
(	O
2	O
)	O
-adrenergic	O
receptor	O
agonist	O
with	O
vasoconstrictive	O
activity	O
.	O


OBJECTIVE	O
To	O
determine	O
the	O
optimal	O
concentration	O
and	O
dose	O
regimen	O
of	B-I
topical	I-I
BT	I-I
gel	I-I
for	O
the	O
treatment	O
of	B-O
erythema	I-O
of	I-O
rosacea	I-O
and	O
to	O
evaluate	O
its	B-O
efficacy	I-O
and	I-O
safety	I-O
.	O


METHODS	O
In	B-P
study	I-P
A	I-P
,	I-P
122	I-P
subjects	I-P
were	I-P
randomized	I-P
to	I-P
receive	I-P
a	I-P
single	I-P
application	I-P
of	I-I
BT	I-I
0·07	I-P
%	I-P
,	I-P
0·18	I-P
%	I-P
,	I-P
0·5	I-I
%	I-I
or	I-I
vehicle	I-I
.	I-P


In	B-P
study	I-P
B	I-P
(	I-P
4-week	I-P
treatment	I-P
and	I-P
4-week	I-P
follow-up	I-P
)	I-P
,	I-P
269	I-P
subjects	I-P
were	O
randomized	O
to	O
receive	B-I
BT	O
0·5	O
%	O
once	O
daily	B-I
,	O
BT	O
0·18	O
%	O
once	O
daily	B-I
,	I-I
vehicle	I-I
once	O
daily	B-I
,	O
BT	O
0·18	O
%	O
twice	O
daily	B-I
or	I-I
vehicle	O
twice	O
daily	O
.	O


Evaluations	O
included	B-O
Clinician	I-O
's	I-O
Erythema	I-O
Assessment	I-O
(	I-O
CEA	I-O
)	I-O
,	I-O
Patient	I-O
's	I-O
Self-Assessment	I-O
(	I-O
PSA	I-O
)	I-O
,	I-O
Chroma	I-O
Meter	I-O
measurements	I-O
and	I-O
adverse	I-O
events	O
.	O


RESULTS	O
In	O
study	O
A	O
,	O
a	O
single	O
application	O
of	O
topical	B-O
BT	I-O
gel	I-O
reduced	I-O
facial	I-O
erythema	I-O
in	O
a	O
dose-dependent	O
fashion	O
.	O


A	O
significant	O
difference	O
between	O
BT	O
0·5	O
%	O
and	O
vehicle	B-O
in	I-O
Chroma	I-O
Meter	I-O
redness	I-O
value	O
was	O
observed	O
from	O
30min	O
to	O
12h	O
after	O
application	O
.	O


In	O
study	O
B	O
,	O
BT	O
0·5	O
%	O
once	O
daily	O
had	O
a	O
statistically	B-O
superior	I-O
success	I-O
profile	O
(	O
defined	O
as	O
a	O
two-grade	B-O
improvement	I-O
on	I-O
both	I-O
CEA	I-O
and	O
PSA	O
over	O
12h	O
)	O
compared	O
with	O
vehicle	O
once	O
daily	O
on	O
days	O
1	O
,	O
15	O
and	O
29	O
(	O
all	O
P	B-O
<	I-O
0·001	I-O
)	I-O
.	I-O


No	B-O
tachyphylaxis	I-O
,	I-O
rebound	I-O
of	I-O
erythema	I-O
or	I-O
aggravation	I-O
of	I-O
other	I-O
disease	I-O
signs	I-O
(	I-O
telangiectasia	I-O
,	I-O
inflammatory	I-O
lesions	O
)	O
was	O
observed	O
.	O


All	O
regimens	B-O
were	I-O
safe	I-O
and	I-O
well	I-O
tolerated	O
with	O
similarly	O
low	O
incidence	B-O
of	I-O
adverse	I-O
events	O
.	O


CONCLUSIONS	O
Once-daily	O
BT	O
gel	O
0·5	O
%	O
is	O
well	O
tolerated	O
and	O
provides	O
significantly	B-O
greater	I-O
efficacy	O
than	O
vehicle	O
gel	O
for	O
the	O
treatment	B-P
of	I-P
moderate	I-P
to	I-P
severe	I-P
erythema	I-P
of	O
rosacea	O
.	O


Does	O
surface	O
preparation	O
alter	O
ALA	B-O
uptake	I-O
in	O
superficial	O
non-melanoma	B-P
skin	I-P
cancer	I-P
in	O
vivo	O
?	O
BACKGROUND/PURPOSE	O
Photodynamic	O
therapy	O
(	O
PDT	O
)	O
using	O
aminolaevulinic	B-I
acid	I-I
(	I-I
ALA	I-I
)	I-I
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
non-melanoma	B-P
skin	I-P
cancer	I-P
.	I-P


Surface	B-I
preparation	I-I
of	O
the	O
lesion	O
is	O
commonly	O
performed	O
before	O
application	O
of	O
ALA	O
but	O
the	O
extent	O
of	O
the	O
preparation	O
varies	O
from	O
centre	O
to	O
centre	O
and	O
there	O
has	O
been	O
no	O
study	O
of	O
its	O
effects	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
surface	B-I
preparation	I-I
on	O
the	O
local	O
uptake	B-O
of	I-O
ALA	I-O
by	O
recording	O
fluorescence	O
from	O
accumulated	O
protoporphyrin	O
IX	O
(	O
PPIX	O
)	O
.	O


METHODS	O
The	O
study	O
was	O
performed	O
on	O
16	B-P
lesions	I-P
,	I-P
either	I-P
superficial	I-P
basal	I-P
cell	I-P
carcinoma	I-P
(	I-P
BCC	I-P
)	I-P
or	I-P
Bowen	I-P
's	I-P
disease	I-P
(	I-P
BD	I-P
)	I-P
.	I-P


Each	O
half	O
of	O
the	O
lesion	O
was	O
randomly	O
assigned	O
to	O
(	B-I
a	I-I
)	I-I
no	I-I
surface	I-I
preparation	I-I
or	I-I
(	I-I
b	I-I
)	I-I
surface	I-I
preparation	I-I
(	I-I
randomly	I-I
allocated	I-I
to	I-I
gentle	I-I
curettage	I-I
or	I-I
abrasion	I-I
with	I-I
a	I-I
spatula	I-I
)	I-I
.	O


ALA	O
was	O
left	O
for	O
4	O
h	O
(	O
BCC	O
)	O
or	O
6	O
h	O
(	O
BD	O
)	O
.	O


PPIX	B-O
fluorescence	I-O
was	O
measured	O
using	O
an	O
excitation	O
wavelength	O
of	O
405+/-5	O
nm	O
and	O
emission	O
spectrum	O
recorded	O
using	O
a	O
photodiode	B-I
array	I-I
.	I-I


Spectra	O
were	O
measured	O
(	O
a	O
)	O
before	O
and	O
(	O
b	O
)	O
after	O
surface	O
preparation	O
,	O
(	O
c	O
)	O
immediately	O
before	O
and	O
(	O
d	O
)	O
after	O
laser	B-I
irradiation	I-I
at	O
630	O
nm	O
.	O


RESULTS	O
The	O
ratio	B-O
of	I-O
fluorescence	I-O
after	I-O
incubation	I-O
to	O
that	O
before	O
incubation	O
was	O
6.1+/-1.2	O
in	O
the	O
non-prepared	O
section	O
.	O


This	O
increased	O
slightly	O
but	O
not	O
significantly	O
to	O
6.8	O
+/-1.8	O
in	O
the	O
prepared	O
section	O
(	O
P	O
<	O
0.1	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
curettage	B-O
and	I-O
abrasion	I-O
.	I-O


There	O
was	O
also	O
no	O
significant	O
difference	O
in	O
outcome	B-O
after	O
PDT	O
.	O


CONCLUSIONS	O
The	O
clinical	O
assessment	O
agrees	O
with	O
the	O
fluorescence	O
data	O
as	O
no	O
significant	O
difference	O
was	O
seen	O
between	O
prepared	O
and	O
unprepared	O
halves	O
of	O
the	O
lesion	O
12	O
months	O
after	O
PDT	O
.	O


Overall	O
our	O
data	O
seem	O
to	O
suggest	O
that	O
for	O
most	O
BCC	O
and	O
BD	O
lesions	O
,	O
surface	O
preparation	O
did	O
not	O
increase	O
ALA	B-O
uptake	I-O
.	I-O


Long-term	O
follow-up	O
of	O
a	O
phase	O
I/II	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
of	O
palifermin	B-I
to	O
prevent	O
graft-versus-host	B-P
disease	I-P
(	I-P
GVHD	I-P
)	I-P
after	I-P
related	I-P
donor	I-P
allogeneic	I-P
hematopoietic	I-P
cell	I-P
transplantation	I-P
(	I-P
HCT	I-P
)	I-P
.	I-P


We	O
previously	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	I-P
conducted	I-P
from	I-P
2000	I-P
to	I-P
2003	I-P
of	I-P
palifermin	I-I
,	I-P
a	I-P
recombinant	I-P
human	I-P
keratinocyte	I-P
growth	I-P
factor	I-P
,	I-P
dosed	I-P
from	I-P
240	I-P
microg/kg	I-P
to	I-P
720	I-P
microg/kg	I-P
,	I-P
in	I-P
100	I-P
allogeneic	I-P
hematopoietic	I-P
stem	I-P
cell	I-P
transplantation	I-P
(	I-P
HCT	I-P
)	I-P
recipients	I-P
.	I-P


Treatment	O
with	O
palifermin	B-I
showed	O
beneficial	O
effects	B-O
on	O
mucositis	B-O
,	I-O
but	I-O
no	I-O
significant	I-O
effect	I-O
on	I-O
engraftment	I-O
,	I-O
acute	I-O
graft-versus-host	I-O
disease	I-O
(	I-O
GVHD	I-O
)	I-O
,	I-O
or	I-O
early	I-O
survival	I-O
.	I-O


In	O
addition	O
to	O
the	O
effect	O
of	O
palifermin	B-I
on	O
mucosa	B-O
,	I-O
other	I-O
pleotrophic	I-O
effects	I-O
,	I-O
including	I-O
more	I-O
rapid	I-O
immune	I-O
reconstitution	I-O
,	O
have	O
been	O
seen	O
in	O
experimental	O
transplant	O
models	O
.	O


Therefore	O
,	O
we	O
investigated	O
whether	O
with	O
longer	O
follow-up	O
we	O
could	O
detect	O
additional	B-O
differences	I-O
between	O
the	O
palifermin-treated	B-I
and	O
placebo	B-I
cohorts	O
.	O


We	O
found	O
no	O
differences	O
in	O
CMV	B-O
or	I-O
invasive	I-O
fungal	I-O
infections	I-O
,	I-O
chronic	I-O
GVHD	I-O
,	I-O
or	I-O
long-term	I-O
survival	I-O
between	O
cohorts	O
.	O


We	O
conclude	O
that	O
the	O
benefits	O
of	O
palifermin	B-I
appear	O
primarily	O
to	O
be	O
limited	O
to	O
ameliorating	O
mucotoxicity	B-O
when	O
given	O
to	O
allogeneic	B-P
HCT	I-P
recipients	I-P
.	I-P


Phosphate	B-I
binder	I-I
impact	O
on	O
bone	B-O
remodeling	I-O
and	I-O
coronary	I-O
calcification	I-O
--	I-O
results	I-O
from	O
the	O
BRiC	O
study	O
.	O


BACKGROUND	O
AND	O
AIMS	O
Calcium-containing	B-I
phosphate	I-I
binders	I-I
have	O
been	O
shown	O
to	O
increase	O
the	O
progression	O
of	O
vascular	B-O
calcification	I-O
in	O
hemodialysis	B-P
patients	I-P
.	I-P


This	O
is	O
a	O
prospective	O
study	O
that	O
compares	O
the	O
effects	O
of	O
calcium	B-I
acetate	I-I
and	I-I
sevelamer	I-I
on	O
coronary	B-O
calcification	I-O
(	O
CAC	O
)	O
and	O
bone	B-O
histology	I-O
.	I-O


METHODS	O
101	B-P
hemodialysis	I-P
patients	I-P
were	I-P
randomized	I-P
for	O
each	O
phosphate	B-I
binder	I-I
and	O
submitted	O
to	O
multislice	B-I
coronary	I-I
tomographies	I-I
and	I-I
bone	I-I
biopsies	I-I
at	O
entry	O
and	O
12	O
months	O
.	O


RESULTS	O
The	B-P
71	I-P
patients	I-P
who	I-P
concluded	I-P
the	I-P
study	I-P
had	I-P
similar	I-P
baseline	I-P
characteristics	I-P
.	I-P


On	O
follow-up	O
,	O
the	O
sevelamer	O
group	O
had	O
higher	O
levels	O
of	O
intact	B-O
parathyroid	I-O
hormone	I-O
(	O
498	O
+/-	O
352	O
vs.	O
326	O
+/-	O
236	O
pg/ml	O
,	O
p	O
=	O
0.017	O
)	O
,	O
bone	B-O
alkaline	I-O
phosphatase	I-O
(	O
38	O
+/-	O
24	O
vs.	O
28	O
+/-	O
15	O
U/l	O
,	O
p	O
=	O
0.03	O
)	O
and	O
deoxypyridinoline	B-O
(	O
135	O
+/-	O
107	O
vs.	O
89	O
+/-	O
71	O
nmol/l	O
,	O
p	O
=	O
0.03	O
)	O
and	O
lower	B-O
LDL	I-O
cholesterol	I-O
(	O
74	O
+/-	O
21	O
vs.	O
91	O
+/-	O
28	O
mg/dl	O
,	O
p	O
=	O
0.015	O
)	O
.	O


Phosphorus	B-O
(	O
5.8	O
+/-	O
1.0	O
vs.	O
6	O
+/-	O
1.0	O
mg/dl	O
,	O
p	O
=	O
0.47	O
)	O
and	O
calcium	B-O
(	O
1.27	O
+/-	O
0.07	O
vs.	O
1.23	O
+/-	O
0.08	O
mmol/l	O
,	O
p	O
=	O
0.68	O
)	O
levels	B-O
did	O
not	O
differ	O
between	O
groups	O
.	O


CAC	B-O
progression	I-O
(	O
35	O
vs.	O
24	O
%	O
,	O
p	O
=	O
0.94	O
)	O
and	O
bone	B-O
histological	I-O
diagnosis	I-O
at	O
baseline	O
and	O
12	O
months	O
were	O
similar	O
in	O
both	O
groups	O
.	O


Patients	O
of	O
the	O
sevelamer	O
group	O
with	O
a	O
high	O
turnover	O
at	O
baseline	O
had	O
an	O
increase	O
in	O
bone	B-O
resorption	I-O
(	O
eroded	O
surface	O
,	O
ES/BS	O
=	O
9.0	O
+/-	O
5.9	O
vs.	O
13.1	O
+/-	O
9.5	O
%	O
,	O
p	O
=	O
0.05	O
)	O
,	O
whereas	O
patients	O
of	O
both	O
groups	O
with	O
low	O
turnover	O
at	O
baseline	O
had	O
an	O
improvement	O
in	O
bone	B-O
formation	I-O
rate	I-O
(	O
BFR/BS	O
=	O
0.015	O
+/-	O
0.016	O
vs.	O
0.062	O
+/-	O
0.078	O
,	O
p	O
=	O
0.003	O
for	O
calcium	O
and	O
0.017	O
+/-	O
0.016	O
vs.	O
0.071	O
+/-	O
0.084	O
microm	O
(	O
3	O
)	O
/microm	O
(	O
2	O
)	O
/day	O
,	O
p	O
=	O
0.010	O
for	O
sevelamer	O
)	O
.	O


CONCLUSIONS	O
There	O
was	O
no	O
difference	O
in	O
CAC	B-O
progression	I-O
or	O
changes	O
in	O
bone	B-O
remodeling	I-O
between	O
the	O
calcium	O
and	O
the	O
sevelamer	O
groups	O
.	O


Predictors	O
of	O
incident	B-O
depression	I-O
after	I-P
hip	I-P
fracture	I-P
surgery	I-P
.	I-P


OBJECTIVE	O
Depression	O
after	O
hip	B-I
fracture	I-I
surgery	I-I
is	O
prevalent	O
and	O
associated	O
with	O
increased	O
mortality	O
rates	O
and	O
impaired	O
functional	O
recovery	O
.	O


The	O
incidence	O
of	O
new-onset	O
depressive	O
symptoms	O
in	O
patients	O
initially	O
not	O
depressed	O
after	O
hip	B-I
fracture	I-I
surgery	I-I
and	O
their	O
relationship	O
with	O
functional	O
recovery	O
is	O
unknown	O
.	O


METHODS	O
A	O
cohort	O
of	O
139	B-P
nondepressed	I-P
elderly	I-P
patients	I-P
(	I-P
>	I-P
60	I-P
years	I-P
)	I-P
hospitalized	I-P
for	I-P
hip	I-I
fracture	I-I
surgery	I-I
were	O
followed	O
up	O
for	O
six	O
months	O
.	O


Clinically	O
significant	O
depressive	O
symptoms	O
were	O
defined	O
as	O
a	O
score	O
of	O
7	O
or	O
more	O
on	O
the	O
15-item	B-O
Geriatric	I-O
Depression	I-O
Scale	I-O
.	I-O


RESULTS	O
The	O
authors	O
found	O
a	O
cumulative	B-O
incidence	I-O
rate	I-O
of	O
20.5	O
%	O
adjusted	O
for	O
dropouts	O
.	O


Multiple	O
Cox-regression	O
analyses	O
yielded	O
the	O
presence	O
of	O
subthreshold	O
symptoms	O
of	O
depression	B-O
,	I-O
anxiety	I-O
,	I-O
pain	I-O
,	I-O
and	I-O
cognitive	I-O
impairment	I-O
at	I-O
baseline	I-O
,	I-O
the	I-O
premorbid	I-O
level	I-O
of	I-O
mobility	I-O
,	I-O
and	I-O
a	I-O
history	I-O
of	I-O
(	I-O
treated	I-O
)	I-O
depression	I-O
as	I-O
risk	I-O
factors	I-O
for	I-O
incident	I-O
depression	I-O
(	O
p	O
<	O
0.05	O
)	O
.	O


A	O
forward	O
,	O
conditional	O
procedure	O
identified	O
postoperative	B-O
pain	I-O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
1.32	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.14-1.53	O
,	O
Wald	O
chi	O
(	O
2	O
)	O
=	O
13.57	O
,	O
df	O
=	O
1	O
,	O
p	O
<	O
0.001	O
)	O
and	O
baseline	B-O
anxiety	I-O
(	O
HR	O
=	O
1.25	O
,	O
95	O
%	O
CI	O
:	O
1.08-1.44	O
,	O
Wald	O
chi	O
(	O
2	O
)	O
=	O
8.86	O
,	O
df	O
=	O
1	O
,	O
p	O
=	O
0.003	O
)	O
as	O
the	O
strongest	O
independent	O
risk	O
factors	O
.	O


Incident	B-O
depression	I-O
was	O
associated	O
with	O
a	O
less	O
favorable	O
outcome	O
at	O
3	O
months	O
follow-up	O
.	O


CONCLUSION	O
This	O
exploratory	O
study	O
identified	O
two	O
treatable	O
baseline	O
characteristics	O
that	O
predicted	O
incident	B-O
depression	I-O
in	O
nondepressed	B-P
patients	I-P
after	I-P
hip-fracture	I-P
surgery	I-P
.	I-P


The	O
neuropeptide	B-I
oxytocin	I-I
modulates	O
consumer	O
brand	O
relationships	O
.	O


Each	O
year	O
,	O
companies	O
invest	O
billions	O
of	O
dollars	O
into	O
marketing	O
activities	O
to	O
embellish	O
brands	O
as	O
valuable	O
relationship	O
partners	O
assuming	O
that	O
consumer	O
brand	O
relationships	O
(	O
CBRs	O
)	O
and	O
interpersonal	O
relationships	O
rest	O
upon	O
the	O
same	O
neurobiological	O
underpinnings	O
.	O


Given	O
the	O
crucial	O
role	O
of	O
the	O
neuropeptide	B-I
oxytocin	I-I
(	I-I
OXT	I-I
)	I-I
in	O
social	O
bonding	O
,	O
this	O
study	O
tests	O
whether	O
OXT-based	O
mechanisms	O
also	O
determine	O
the	O
bond	O
between	O
consumers	B-P
and	O
brands	O
.	O


We	O
conducted	O
a	O
randomized	O
,	O
placebo-controlled	O
study	O
involving	O
101	B-P
subjects	I-P
and	O
analyzed	O
the	O
effect	O
of	O
intranasal	B-I
OXT	I-I
on	O
consumers	B-O
'	I-O
attribution	I-O
of	I-O
relationship	I-O
qualities	I-O
to	I-O
brands	I-O
,	O
brands	O
paired	O
with	O
human	O
celebrity	O
endorsers	O
,	O
and	O
familiar	O
persons	O
.	O


OXT	B-O
indeed	O
promoted	O
the	O
attribution	B-O
of	I-O
relationship	I-O
qualities	I-O
not	O
only	O
in	O
the	O
case	O
of	O
social	O
and	O
semi-social	O
stimuli	O
,	O
but	O
also	O
brands	O
.	O


Intriguingly	O
,	O
for	O
subjects	B-P
scoring	I-P
high	I-P
on	I-P
autistic-like	I-P
traits	I-P
,	O
the	O
effect	O
of	O
OXT	B-I
was	O
completely	O
reversed	O
,	O
evident	O
in	O
even	O
lower	O
relationship	B-O
qualities	I-O
across	O
all	O
stimulus	O
categories	O
.	O


The	O
importance	O
of	O
OXT	B-I
in	O
a	O
CBR	O
context	O
is	O
further	O
corroborated	O
by	O
a	O
three-fold	O
increase	O
in	O
endogenous	B-O
release	I-O
of	I-O
OXT	I-O
following	O
exposure	O
to	O
one	O
's	O
favorite	O
brand	O
and	O
positive	O
associations	O
between	O
baseline	O
peripheral	O
OXT	B-I
concentrations	O
and	O
brand	O
relationship	O
qualities	O
.	O


Collectively	O
,	O
our	O
findings	O
indicate	O
that	O
OXT	B-I
not	O
only	O
plays	O
a	O
fundamental	O
role	O
in	O
developing	O
interpersonal	B-O
relationships	I-O
,	O
but	O
also	O
enables	O
relationship	O
formation	O
with	O
objects	O
such	O
as	O
brands	O
.	O


Tramadol	B-I
suppository	I-I
versus	O
placebo	B-I
for	O
the	O
relief	O
of	O
perineal	B-O
pain	I-O
after	I-P
perineorrhaphy	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
in	O
Thailand	B-P
.	I-P


OBJECTIVE	O
This	O
randomized	O
double-blinded	O
control	O
trial	O
was	O
conducted	O
to	O
compare	O
the	O
effectiveness	B-O
of	O
tramodol	B-I
and	O
placebo	B-I
rectal	O
suppository	O
for	O
the	O
management	O
of	O
postpartum	B-O
perineal	I-O
pain	I-O
after	I-P
perineorrhaphy	I-P
.	I-P


MATERIAL	O
AND	O
METHOD	O
One	B-P
hundred	I-P
women	I-P
who	I-P
gave	I-P
birth	I-P
vaginally	I-P
with	I-P
episiotomy	I-P
and	I-P
a	I-P
second-	I-P
or	I-P
third-degree	I-P
tear	I-P
,	O
were	O
randomly	O
assign	O
to	O
receive	O
two	O
tablets	O
oftramadol	B-I
50	I-I
mg	I-I
or	I-I
two	I-I
tablets	I-I
ofplacebo	I-I
,	O
the	O
pill	O
were	O
physically	O
similar	O
to	O
the	O
real	O
drug	O
.	O


Pain	B-O
ratings	I-O
were	O
recorded	O
immediately	O
after	O
perineorrhaphy	O
,	O
30	O
minutes	O
,	O
and	O
1	O
,	O
2	O
,	O
6	O
,	O
12	O
and	O
24	O
hours	O
after	O
first	O
dose	O
on	O
a	O
10-cm	O
visual	B-O
analogue	I-O
scale	I-O
.	I-O


Side	B-O
effects	I-O
and	I-O
overall	I-O
opinion	I-O
were	O
assessed	O
.	O


RESULTS	O
Tramadol	B-I
and	O
placebo	B-I
had	O
no	O
statistical	O
significances	O
in	O
analgesic	B-O
properties	I-O
,	O
assessed	O
by	O
the	O
means	O
of	O
pain	B-O
rating	I-O
at	O
the	O
different	O
time	O
intervals	O
.	O


There	O
were	O
no	B-O
serious	I-O
adverse	I-O
events	I-O
reported	O
.	O


CONCLUSION	O
No	O
differences	O
were	O
found	O
in	O
between	O
Tramadol	O
and	O
placebo	O
in	O
relief	O
perineal	O
pain	O
after	O
perineorrhaphy	O


The	O
logMAR	B-I
Kay	I-I
picture	I-I
test	I-I
and	O
the	O
logMAR	B-I
acuity	I-I
test	I-I
:	I-I
a	O
comparative	O
study	O
.	O


PURPOSE	O
To	O
compare	O
the	O
level	O
of	O
visual	B-O
acuity	I-O
with	O
crowded	B-I
and	I-I
uncrowded	I-I
versions	I-I
of	O
the	O
logMAR	B-I
acuity	I-I
test	I-I
and	O
the	O
Kay	B-I
picture	I-I
test	I-I
in	O
amblyopia	B-P
.	I-P


METHODS	O
A	O
prospective	O
study	O
was	O
carried	O
out	O
on	O
51	B-P
participants	I-P
with	I-P
amblyopia	I-P
(	I-P
strabismic	I-P
n=17	I-P
;	I-P
anisometropic	I-P
n=10	I-P
;	I-P
combined	I-P
n=24	I-P
)	I-P
,	I-P
mean	I-P
age	I-P
10	I-P
years	I-P
8	I-P
months	I-P
.	I-P


The	B-P
amblyopia	I-P
was	I-P
defined	I-P
as	I-P
severe/moderate	I-P
(	I-P
<	I-P
0.250	I-P
logMAR	I-P
)	I-P
,	I-P
n=41	I-P
or	I-P
mild	I-P
(	I-P
>	I-P
or	I-P
=	I-P
0.250	I-P
logMAR	I-P
)	I-P
,	I-P
n=10	I-P
.	I-P


Visual	B-O
acuity	I-O
was	I-O
assessed	I-O
uniocularly	O
using	O
the	O
crowded	B-O
and	I-O
uncrowded	I-O
logMAR	I-O
acuity	I-O
tests	I-O
and	I-O
the	I-O
logMAR	I-O
crowded	I-O
and	I-O
uncrowded	I-O
Kay	I-O
picture	I-O
tests	I-O
in	O
random	O
orders	O
.	O


RESULTS	O
The	O
mean	B-O
visual	I-O
acuity	I-O
outcome	I-O
using	O
the	O
logMAR	B-I
crowded	I-I
Kay	I-I
picture	I-I
test	I-I
(	O
0.343+/-0.150	O
)	O
was	O
comparable	O
(	O
P=0.084	O
)	O
with	O
the	O
mean	O
outcome	O
using	O
the	O
crowded	B-I
logMAR	I-I
acuity	I-I
test	I-I
(	O
0.402+/-0.188	O
)	O
.	O


However	O
,	O
the	O
mean	B-O
acuity	I-O
difference	I-O
between	O
these	O
two	O
tests	O
in	O
the	O
subgroup	B-P
with	I-P
severe/moderate	I-P
amblyopia	I-P
(	I-P
0.074+/-0.036	I-P
)	I-P
was	O
statistically	O
significant	O
(	O
P=0.0382	O
)	O
.	O


The	O
uncrowded	B-I
logMAR	I-O
acuity	I-O
test	I-I
significantly	O
overestimated	O
visual	B-O
acuity	I-O
when	O
compared	O
with	O
the	O
logMAR	B-O
crowded	I-O
Kay	I-O
picture	I-O
test	I-I
(	O
P	O
<	O
0.005	O
)	O
by	O
a	O
mean	O
of	O
0.088+/-0.008	O
.	O


CONCLUSION	O
The	B-I
logMAR	I-I
crowded	I-I
Kay	I-I
picture	I-I
test	I-I
is	O
a	O
useful	O
tool	O
in	O
clinical	O
practice	O
.	O


The	O
test	O
design	O
takes	O
the	O
crowding	O
phenomenon	O
into	O
account	O
.	O


It	O
provides	O
visual	B-O
acuity	I-O
measures	O
more	O
comparable	O
with	O
the	O
gold	O
standard	O
crowded	B-I
logMAR	I-I
acuity	I-I
test	I-I
than	O
the	O
uncrowded	O
logMAR	O
acuity	O
test	O
.	O


However	O
,	O
the	O
outcomes	O
in	O
poorer	O
acuities	O
should	O
still	O
be	O
viewed	O
with	O
caution	O
.	O


Safety	O
and	O
efficacy	O
of	O
dalcetrapib	B-I
on	O
atherosclerotic	O
disease	O
using	O
novel	B-I
non-invasive	I-I
multimodality	I-I
imaging	I-I
(	I-I
dal-PLAQUE	I-I
)	I-I
:	I-I
a	O
randomised	O
clinical	O
trial	O
.	O


BACKGROUND	O
Dalcetrapib	B-I
modulates	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
activity	O
to	O
raise	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
)	O
.	O


After	O
the	O
failure	O
of	O
torcetrapib	O
it	O
was	O
unknown	O
if	O
HDL	O
produced	O
by	O
interaction	O
with	O
CETP	O
had	O
pro-atherogenic	O
or	O
pro-inflammatory	O
properties	O
.	O


dal-PLAQUE	O
is	O
the	O
first	O
multicentre	O
study	O
using	O
novel	O
non-invasive	O
multimodality	O
imaging	O
to	O
assess	O
structural	O
and	O
inflammatory	O
indices	O
of	O
atherosclerosis	O
as	O
primary	O
endpoints	O
.	O


METHODS	O
In	O
this	O
phase	O
2b	O
,	O
double-blind	O
,	O
multicentre	O
trial	O
,	O
patients	B-P
(	I-P
aged	I-P
18-75	I-P
years	I-P
)	I-P
with	I-P
,	I-P
or	I-P
with	I-P
high	I-P
risk	I-P
of	I-P
,	I-P
coronary	I-P
heart	I-P
disease	I-P
were	O
randomly	O
assigned	O
(	O
1:1	O
)	O
to	O
dalcetrapib	B-I
600	I-I
mg/day	I-I
or	I-I
placebo	I-I
for	I-I
24	I-I
months	I-I
.	I-I


Randomisation	O
was	O
done	O
with	O
a	O
computer-generated	O
randomisation	O
code	O
and	O
was	O
stratified	O
by	O
centre	O
.	O


Patients	O
and	O
investigators	O
were	O
masked	O
to	O
treatment	O
.	O


Coprimary	O
endpoints	O
were	O
MRI-assessed	B-O
indices	I-O
(	I-O
total	I-O
vessel	I-O
area	I-O
,	I-O
wall	I-O
area	I-O
,	I-O
wall	I-O
thickness	I-O
,	I-O
and	I-O
normalised	I-O
wall	I-O
index	I-O
[	O
average	O
carotid	O
]	O
)	O
after	O
24	O
months	O
and	O
(	O
18	O
)	O
F-fluorodeoxyglucose	O
(	O
(	O
18	O
)	O
F-FDG	O
)	O
PET/CT	O
assessment	O
of	O
arterial	O
inflammation	O
within	O
an	O
index	O
vessel	O
(	O
right	O
carotid	O
,	O
left	O
carotid	O
,	O
or	O
ascending	O
thoracic	O
aorta	O
)	O
after	O
6	O
months	O
,	O
with	O
no-harm	O
boundaries	O
established	O
before	O
unblinding	O
of	O
the	O
trial	O
.	O


Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O


This	O
trial	O
is	O
registered	O
at	O
ClinicalTrials.gov	O
,	O
NCT00655473	O
.	O


FINDINGS	O
189	B-P
patients	I-P
were	I-P
screened	I-P
and	I-P
130	I-P
randomly	I-P
assigned	I-P
to	I-P
placebo	I-I
(	I-P
66	I-P
patients	I-P
)	I-P
or	I-P
dalcetrapib	I-I
(	I-P
64	I-P
patients	I-P
)	I-P
.	I-P


For	O
the	O
coprimary	O
MRI	O
and	O
PET/CT	O
endpoints	O
,	O
CIs	O
were	O
below	O
the	O
no-harm	O
boundary	O
or	O
the	O
adverse	O
change	O
was	O
numerically	O
lower	O
in	O
the	O
dalcetrapib	B-I
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O


MRI-derived	B-O
change	I-O
in	I-O
total	I-O
vessel	I-O
area	I-O
was	O
reduced	O
in	O
patients	O
given	O
dalcetrapib	B-I
compared	O
with	O
those	O
given	O
placebo	O
after	O
24	O
months	O
;	O
absolute	O
change	O
from	O
baseline	O
relative	O
to	O
placebo	B-I
was	O
-4·01	O
mm	O
(	O
2	O
)	O
(	O
90	O
%	O
CI	O
-7·23	O
to	O
-0·80	O
;	O
nominal	O
p=0·04	O
)	O
.	O


The	B-O
PET/CT	I-O
measure	I-O
of	I-O
index	I-O
vessel	I-O
most-diseased-segment	I-O
target-to-background	I-O
ratio	I-O
(	I-O
TBR	I-O
)	I-O
was	O
not	O
different	O
between	O
groups	O
,	O
but	O
carotid	O
artery	O
analysis	O
showed	O
a	O
7	O
%	O
reduction	O
in	O
most-diseased-segment	O
TBR	O
in	O
the	B-I
dalcetrapib	I-I
group	O
compared	O
with	O
the	B-I
placebo	I-I
group	O
(	O
-7·3	O
[	O
90	O
%	O
CI	O
-13·5	O
to	O
-0·8	O
]	O
;	O
nominal	O
p=0·07	B-I
)	I-I
.	I-I


Dalcetrapib	B-I
did	O
not	O
increase	B-O
office	I-O
blood	I-O
pressure	I-O
and	I-O
the	I-O
frequency	I-O
of	I-O
adverse	I-O
events	O
was	O
similar	O
between	O
groups	O
.	O


INTERPRETATION	B-I
Dalcetrapib	I-I
showed	O
no	O
evidence	O
of	O
a	O
pathological	O
effect	O
related	O
to	O
the	O
arterial	O
wall	O
over	O
24	O
months	O
.	O


Moreover	O
,	O
this	O
trial	O
suggests	O
possible	O
beneficial	O
vascular	O
effects	B-I
of	I-I
dalcetrapib	I-I
,	O
including	O
the	O
reduction	O
in	O
total	O
vessel	O
enlargement	O
over	O
24	O
months	O
,	O
but	O
long-term	O
safety	O
and	O
clinical	O
outcomes	O
efficacy	O
of	O
dalcetrapib	O
need	O
to	O
be	O
analysed	O
.	O


FUNDING	O
F	O
Hoffmann-La	O
Roche	O
Ltd	O
.	O


A	O
randomized	O
pilot	O
study	O
with	O
daily	B-I
walking	I-I
during	O
adjuvant	O
chemotherapy	O
for	O
patients	B-P
with	I-P
breast	I-P
and	I-P
colorectal	I-P
cancer	I-P
.	I-P


BACKGROUND	O
Physical	B-I
activity	I-I
during	O
chemotherapy	O
has	O
been	O
shown	O
in	O
several	O
studies	O
to	O
reduce	O
fatigue	B-O
,	I-O
improve	I-O
symptoms	I-O
and	I-O
impact	I-O
positively	I-O
on	I-O
health-related	I-O
quality	I-O
of	I-O
life	I-O
(	I-O
HRQoL	I-O
)	I-O
.	I-O


Challenges	O
associated	O
with	O
intervention	O
studies	O
on	O
physical	B-I
activity	I-I
during	O
cancer	O
treatment	O
relate	O
to	O
consistent	O
adherence	O
.	O


The	O
primary	O
objective	O
was	O
to	O
study	O
feasibility	O
and	O
adherence	O
of	O
physical	B-I
activity	I-I
intervention	I-I
among	O
patients	B-P
with	I-P
cancer	I-P
during	I-P
adjuvant	I-P
chemotherapy	I-P
treatment	I-P
.	I-P


The	O
secondary	O
objective	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
physical	B-I
activity	I-I
on	O
health	B-O
aspects	I-O
,	O
including	O
HRQoL	B-O
,	I-O
symptoms	I-O
and	I-O
surrogate	I-O
markers	I-O
for	I-O
cardiovascular	I-O
disease	I-O
.	I-O


MATERIAL	O
AND	O
METHODS	O
This	O
randomized	O
controlled	O
trial	O
included	O
patients	B-P
with	I-P
breast	I-P
cancer	I-P
(	I-P
BRCA	I-P
)	I-P
and	I-P
colorectal	I-P
cancer	I-P
(	I-P
CRC	I-P
)	I-P
during	I-P
adjuvant	I-I
chemotherapy	I-I
.	I-I


The	B-I
intervention	I-I
continued	I-I
for	I-I
10	I-I
weeks	I-I
and	I-I
included	I-I
daily	I-I
walks	I-I
of	I-I
10	I-I
000	I-I
steps	I-I
and	I-I
a	I-I
weekly	I-I
supervised	I-I
group	I-I
walk	I-I
.	I-I


Adherence	B-O
was	I-I
assessed	I-I
by	I-I
a	I-I
pedometer	I-I
and	I-I
the	I-I
number	I-I
of	I-I
participants	I-I
who	I-I
reported	I-I
step	I-I
counts	I-I
every	I-I
week	I-I
and	I-I
percentage	I-I
of	I-I
participants	I-I
who	I-I
achieved	I-I
the	I-I
target	I-I
steps	I-I
every	I-I
week	I-I
.	I-I


RESULTS	O
Adherence	B-O
average	O
reached	O
91	O
%	O
during	O
the	O
intervention	O
period	O
;	O
in	O
total	O
74	O
%	O
completed	O
the	O
exercise	B-I
intervention	O
.	O


The	O
majority	O
of	O
the	O
participants	B-P
achieved	O
an	O
average	O
of	O
83	O
%	O
of	O
the	O
target	O
of	O
10	O
000	O
steps	O
per	O
day	O
for	O
10	O
weeks	O
.	O


There	O
was	O
a	O
significant	O
increase	O
in	O
daily	B-O
physical	I-O
activity	I-O
(	O
p	O
=	O
0.016	O
)	O
in	O
the	O
intervention	B-P
group	I-P
.	I-P


Significant	O
differences	O
were	O
also	O
found	O
for	O
some	O
breast	O
cancer-specific	O
symptoms	O
[	B-O
swelling	I-O
,	I-O
mobility	I-O
and	I-O
pain	I-O
(	O
p	O
=	O
0.045	O
)	O
]	O
.	O


The	O
study	O
showed	O
a	O
relatively	O
small	B-O
weight	I-O
gain	I-O
an	O
average	O
of	O
0.9	O
kg	O
in	O
the	O
intervention	B-P
group	I-P
and	O
1.3	O
kg	O
in	O
the	O
control	B-I
group	I-I
.	I-I


CONCLUSION	O
Physical	B-I
activity	I-I
in	I-I
the	I-I
form	I-I
of	I-I
walking	I-I
is	O
feasible	O
during	O
adjuvant	O
chemotherapy	O
treatment	O
despite	O
increasing	O
symptoms	O
.	O


The	O
physical	B-I
activity	I-I
increased	O
in	O
the	O
intervention	B-P
group	I-P
during	O
the	O
study	O
time	O
and	O
had	O
a	O
positive	O
impact	O
on	O
breast	B-O
symptoms	I-O
and	O
the	O
weight	B-O
gain	I-O
was	O
lower	O
in	O
comparison	O
to	O
previous	O
studies	O
.	O


Bitewing	B-P
film	I-P
quality	I-P
:	I-P
a	O
clinical	O
comparison	O
of	O
the	O
loop	B-I
vs.	I-I
holder	I-I
techniques	I-I
.	I-I


OBJECTIVE	O
To	O
compare	O
in	O
vivo	O
bitewing	O
film	O
quality	O
using	O
the	O
holder	B-I
versus	I-I
the	I-I
paper	I-I
loop	I-I
technique	I-I
.	I-I


METHOD	O
AND	O
MATERIALS	O
Four	B-P
bitewing	I-P
films	I-P
were	O
taken	O
from	O
the	O
right	B-P
and	I-P
left	I-P
premolar	I-P
and	I-P
molar	I-P
regions	I-P
of	I-P
45	I-P
dental	I-P
students	I-P
using	O
both	O
the	O
bitewing	B-I
holder	I-I
and	I-I
paper	I-I
loop	I-I
techniques	I-I
.	I-I


A	O
total	O
of	O
360	B-P
films	I-P
were	O
taken	O
and	O
assessed	O
by	O
an	O
experienced	O
practitioner	O
not	O
apprised	O
of	O
the	O
bitewing	B-I
technique	I-I
used	O
.	O


Of	O
interest	O
were	O
:	O
(	O
1	O
)	O
the	O
number	O
of	O
overlaps	O
and	O
the	O
percentage	O
of	O
teeth	O
showing	O
the	O
alveolar	O
crest	O
;	O
(	O
2	O
)	O
proper	O
film	O
positioning	O
;	O
and	O
(	O
3	O
)	O
the	O
percentage	O
of	O
cone	O
cutting	O
.	O


A	O
Poisson	O
regression	O
using	O
generalized	O
estimating	O
equations	O
(	O
GEEs	O
)	O
was	O
used	O
to	O
estimate	O
the	O
difference	O
in	O
overlap	O
between	O
the	O
two	O
techniques	O
.	O


For	O
proper	O
positioning	O
and	O
cone	O
cutting	O
,	O
logistic	O
regressions	O
using	O
GEEs	O
were	O
used	O
.	O


RESULTS	O
The	O
average	B-O
number	I-O
of	I-O
horizontal	I-O
overlaps	I-O
for	I-O
the	I-O
loop	I-O
and	I-O
holder	I-O
techniques	I-O
at	O
the	O
right	O
premolar	O
,	O
right	O
molar	O
,	O
left	O
premolar	O
,	O
and	O
left	O
molar	O
were	O
1.64	O
,	O
2.11	O
,	O
2.16	O
,	O
2.78	O
,	O
and	O
1.64	O
,	O
2.00	O
,	O
2.00	O
,	O
2.18	O
,	O
respectively	O
.	O


The	O
loop	B-I
technique	I-I
was	O
1.11	O
times	O
more	O
likely	O
to	O
cause	O
overlapping	B-O
than	O
the	O
holder	B-I
technique	I-I
.	I-I


The	O
highest	B-O
percentage	I-O
of	I-O
teeth	I-O
showing	I-O
the	I-O
alveolar	I-O
crest	I-O
by	I-O
the	I-O
loop	I-O
technique	I-O
was	O
97.8	O
%	O
in	O
the	O
mandibular	O
second	O
premolar	O
and	O
first	O
molar	O
.	O


With	O
respect	O
to	O
film	O
positioning	O
,	O
the	O
loop	B-I
technique	I-I
was	O
1.12	O
times	O
more	O
likely	O
to	O
cause	O
improper	B-O
positioning	I-O
than	O
the	O
holder	B-I
technique	I-I
.	I-I


Both	O
techniques	O
demonstrated	O
minimal	B-O
cone	I-O
cutting	I-O
(	O
1	O
in	O
the	O
loop	O
versus	O
0	O
in	O
the	O
holder	O
)	O
.	O


CONCLUSION	O
The	O
quality	O
of	O
bitewing	O
films	O
taken	O
by	O
the	O
loop	B-I
and	I-I
holder	I-I
techniques	I-I
was	O
not	O
significantly	O
different	O
.	O


Effects	O
of	O
cognitive	B-I
behavioral	I-I
therapy	I-I
on	O
daily	B-O
living	I-O
skills	I-O
in	I-P
children	I-P
with	I-P
high-functioning	I-P
autism	I-P
and	I-P
concurrent	I-P
anxiety	I-P
disorders	I-P
.	I-P


CBT	B-I
is	O
a	O
promising	O
treatment	O
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
and	O
focuses	O
,	O
in	O
part	O
,	O
on	O
children	O
's	O
independence	B-O
and	I-O
self-help	I-O
skills	I-O
.	I-O


In	O
a	O
trial	O
of	O
CBT	B-I
for	O
anxiety	O
in	O
ASD	O
(	O
Wood	O
et	O
al	O
.	O


in	O
J	O
Child	O
Psychol	O
Psychiatry	O
50:224-234	O
,	O
2009	O
)	O
,	O
children	O
's	O
daily	O
living	O
skills	O
and	O
related	O
parental	B-O
intrusiveness	I-O
were	O
assessed	O
.	O


Forty	B-P
children	I-P
with	I-P
ASD	I-P
(	I-P
7-11	I-P
years	I-P
)	I-P
and	I-P
their	I-P
primary	I-P
caregiver	I-P
were	O
randomly	B-I
assigned	I-I
to	I-I
an	I-I
immediate	I-I
treatment	I-I
(	I-I
IT	I-I
;	I-I
n	I-I
=	I-I
17	I-I
)	I-I
or	I-I
3-month	I-I
waitlist	I-I
(	I-I
WL	I-I
;	I-I
n	I-I
=	I-I
23	I-I
)	I-I
condition	I-I
.	I-I


In	O
comparison	O
to	O
WL	O
,	O
IT	O
parents	O
reported	O
increases	O
in	O
children	O
's	O
total	B-O
and	I-O
personal	I-O
daily	I-O
living	I-O
skills	I-O
,	O
and	O
reduced	O
involvement	B-O
in	I-O
their	I-O
children	I-O
's	I-O
private	I-O
daily	I-O
routines	I-O
.	I-O


Reductions	O
correlated	O
with	O
reduced	O
anxiety	O
severity	B-O
.	I-O


These	O
results	O
provide	O
preliminary	O
evidence	O
that	O
CBT	O
may	O
yield	O
increased	O
independence	B-O
and	I-O
daily	I-O
living	I-O
skills	I-O
among	O
children	B-P
with	I-P
ASD	I-P
.	I-P


Total	O
intravenous	O
anesthesia	O
using	O
remifentanil	B-I
in	O
extracorporeal	B-I
shock	I-I
wave	I-I
lithotripsy	I-I
(	I-I
ESWL	I-I
)	I-I
.	I-I


Comparison	O
of	O
two	O
dosages	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
Extracorporeal	B-I
Shock	I-I
Wave	I-I
Lithotripsy	I-I
is	O
usually	O
performed	O
in	O
day	O
surgery	O
setting	O
,	O
consequently	O
people	O
who	O
undergo	O
to	O
this	O
procedure	O
need	O
a	O
safe	O
and	O
fast	O
recovery	O
.	O


Conscious	O
sedation	O
with	O
remifentanil	B-I
can	O
relieve	O
from	O
pain	O
and	O
keep	O
patients	O
in	O
touch	O
with	O
anaesthesiologists	O
.	O


Few	O
publications	O
tell	O
about	O
infusion	O
rates	O
administered	O
to	O
perform	O
this	O
procedure7	O
.	O


The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
which	O
is	O
the	O
most	O
appropriate	O
infusion	O
rate	O
.	O


METHODS	O
Patients	B-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
two	I-P
groups	I-P
.	I-P


Two	O
different	O
infusion	O
rates	O
were	O
compared	O
:	O
0,05	O
mcg/kg/min	O
,	O
GROUP	O
A	O
(	O
N.=114	O
)	O
,	O
vs.	O
0.1	O
µg/kg/min	O
,	O
GROUP	O
B	O
(	O
N.=114	O
)	O
.	O


Patients	B-O
'	I-O
vital	I-O
signs	I-O
,	I-O
additional	I-O
analgesic	I-O
requests	I-O
,	I-O
PONV	I-O
(	I-O
postoperative	I-O
nausea	I-O
and	I-O
vomiting	I-O
)	I-O
and	O
other	O
side	O
effects	O
were	O
registered	O
.	O


The	O
deepness	O
of	O
sedation	O
and	O
patient	O
's	O
satisfaction	O
were	O
evaluated	O
referring	O
to	B-O
Obsever	I-O
's	I-O
Assessment	I-O
of	I-O
Alertness	I-O
and	I-O
Sedation	I-O
scale	I-O
(	O
O/ASS	O
)	O
and	O
using	O
a	O
Likert	O
's	O
scale	O
respectively	O
.	B-O


Pain	B-O
intensity	I-O
was	O
assessed	O
with	O
a	O
11-points	O
VAS	O
(	O
visual	O
analogue	O
scale	O
)	O
.	O


Differences	O
between	O
groups	O
were	O
analyzed	O
using	O
Student	O
t	O
test	O
for	O
independent	O
variables	O
.	O


The	O
χ2	O
test	O
was	O
used	O
to	O
analyze	O
categorical	O
variables	O
.	O


RESULTS	O
The	O
study	O
enrolled	B-P
228	I-P
patients	I-P
and	O
assigned	O
them	O
to	O
two	O
groups	O
(	O
N.=114	O
)	O
.	O


No	O
significant	O
differences	O
were	O
found	O
regarding	B-O
Likert	I-O
's	I-O
scale	I-O
values	I-O
(	O
P=0.20	O
)	O
,	O
additional	O
analgesic	O
request	O
(	O
P=0.30	O
)	O
and	O
mean	B-O
VAS	I-O
values	I-O
(	O
P	O
>	O
0.05	O
)	O
between	O
the	O
two	O
groups	O
.	O


The	O
difference	O
between	O
the	O
two	O
groups	O
about	B-O
PONV	I-O
,	I-O
hypotension	I-O
,	I-O
oxygen	I-O
desaturation	I-O
and	I-O
respiratory	I-O
depression	I-O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
,	O
as	O
a	O
matter	O
of	O
fact	O
in	O
group	O
A	O
these	O
side	O
effects	O
occurred	O
less	O
frequently	O
.	O


The	B-O
fifth	I-O
degree	I-O
of	I-O
O/ASS	I-O
was	O
estimated	O
in	O
about	O
1.61±0.19	O
min	O
and	O
2.987±0.20	O
min	O
in	O
group	O
A	O
and	O
in	O
group	O
B	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
According	O
with	O
previous	O
results	O
remifentanil	O
at	O
the	O
infusion	O
rate	O
of	O
0.05	O
µg/kg/min	O
provides	O
an	O
effective	O
analgesia	O
,	O
causing	O
a	O
lower	O
incidence	O
of	O
side	O
effect	O
than	O
0.1	O
µg/kg/min	O
,	O
granting	O
a	O
fast	O
and	O
safe	O
recovery	O
.	O


[	O
Effect	O
of	O
valociclovir	B-I
hydrochloride	I-I
on	O
patients	B-P
with	I-P
herpes	I-O
zoster	I-O
]	I-O
.	I-P


[	O
Effects	O
of	O
betamethasone	B-I
on	O
neuromuscular	B-O
blockade	I-O
induced	O
by	O
vecuronium	B-I
in	O
continuous	O
infusion	O
]	O
.	O


The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
a	O
possible	O
interaction	O
between	O
a	O
corticosteroid	B-I
(	I-I
betamethasone	I-I
)	I-I
and	I-I
vecuronium	I-I
,	O
a	O
nondepolarizing	B-I
muscle	I-I
relaxant	I-I
.	I-I


The	O
authors	O
studied	O
20	B-P
patients	I-P
,	I-P
ASA	I-P
I-II	I-P
,	I-P
aged	I-P
20-54	I-P
,	I-P
both	I-P
sexes	I-P
,	I-P
scheduled	I-P
for	I-P
abdominal	I-I
surgery	I-I
.	I-I


Mechanomyographic	B-O
and	I-O
clinical	I-O
evaluation	I-O
by	I-O
single	I-O
twitch	I-O
and	I-O
TOF	I-O
stimulation	I-O
of	I-O
the	I-O
ulnar	I-O
nerve	I-O
at	I-O
the	I-O
wrist	I-O
and	O
measurement	O
of	O
the	O
concomitant	B-O
abductor	I-O
pollicis	I-O
muscle	I-O
was	O
applied	O
.	O


The	O
onset	B-O
time	I-O
of	O
vecuronium	B-I
after	O
a	O
single	O
bolus	O
dose	O
of	O
0.08	O
mg/kg	O
,	O
duration	B-O
of	I-O
action	I-O
to	O
10	O
%	O
single	B-O
twitch	I-O
recovery	I-O
,	O
duration	O
of	O
continuous	O
infusion	O
of	O
0.4-0.5	O
micrograms/kg/min	O
of	O
vecuronium	B-I
started	O
at	O
10	O
%	O
single	B-O
twitch	I-O
recovery	I-O
,	O
and	O
the	O
effects	O
of	O
0.1	O
mg/kg	O
betamethasone	B-I
administration	O
10	O
min	O
after	O
continuous	O
infusion	O
were	O
evaluated	O
.	O


The	O
recovery	B-O
rate	I-O
of	I-O
vecuronium	I-O
after	O
stopping	O
infusion	O
at	O
10	O
%	O
recovery	O
was	O
also	O
evaluated	O
.	O


Corticosteroids	B-I
may	O
interact	O
with	O
non-depolarizing	B-I
muscle	I-I
relaxants	I-I
both	O
in	O
prejunctional	O
and	O
postjunctional	O
acetylcholine	O
receptors	O
by	O
several	O
mechanisms	O
of	O
action	O
.	O


Ten-year	O
results	O
of	O
a	O
randomised	O
trial	O
comparing	O
cisplatin	B-I
with	I-I
cisplatin	I-I
and	I-I
cyclophosphamide	I-I
in	O
advanced	B-P
,	I-P
suboptimally	I-P
debulked	I-P
ovarian	I-P
cancer	I-P
.	I-P


176	B-P
eligible	I-P
patients	I-P
with	I-P
advanced	I-P
suboptimally	I-P
operated	I-P
ovarian	I-P
carcinoma	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
cisplatin	B-I
75	I-I
mg/m2	I-I
or	I-I
cisplatin	I-I
50	I-I
mg/m2	I-I
and	I-I
cyclophosphamide	I-I
500	I-I
mg/m2	I-I
(	O
CP	O
)	O
every	O
28	O
days	O
for	O
six	O
courses	O
.	O


The	O
overall	B-O
clinical	I-O
response	I-O
rates	I-O
(	I-O
complete	I-O
response	O
plus	O
partial	O
response	O
)	O
were	O
52	O
and	O
63	O
%	O
for	O
CP	B-I
and	I-I
cisplatin	I-I
,	O
respectively	O
(	O
non-significant	O
)	O
.	O


Including	O
results	O
obtained	O
by	O
second-look	O
laparotomy	O
,	O
we	O
did	O
not	O
observe	O
a	O
statistically	O
significant	O
difference	O
in	O
response	O
rates	O
in	O
the	O
two	O
treatment	O
groups	O
.	O


Median	B-O
progression-free	I-O
survival	I-O
was	O
10	O
and	O
11.9	O
months	O
for	O
CP	B-I
and	I-I
cisplatin	I-I
,	O
respectively	O
(	O
non-significant	O
)	O
.	O


No	O
significant	O
difference	O
was	O
observed	O
in	O
overall	B-O
survival	I-O
,	O
with	O
a	O
median	O
of	O
19.4	O
and	O
21.5	O
months	O
for	O
CP	B-I
and	I-I
cisplatin	I-I
,	O
respectively	O
.	O


Thirty-seven	B-P
platinum-resistant	I-P
and	I-P
27	I-P
platinum-sensitive	I-P
tumours	I-P
were	O
treated	O
with	O
carboplatin	B-I
or	I-I
cisplatin	I-I
as	O
second-line	O
therapy	O
.	O


Response	B-O
rates	I-O
to	O
platinum	O
second-line	O
therapy	O
were	O
6	O
and	O
50	O
%	O
for	O
resistant	O
and	O
sensitive	O
tumours	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O


This	O
difference	O
in	O
response	B-O
rate	I-O
was	O
also	O
confirmed	O
by	O
survival	O
analysis	O
.	O


Patients	B-P
with	I-P
platinum-sensitive	I-P
tumours	I-P
survived	O
longer	O
when	O
they	O
were	O
treated	O
with	O
platinum-containing	B-I
chemotherapy	I-I
(	O
P	O
=	O
0.005	O
)	O
.	O


Median	B-O
survival	I-O
was	O
22.8	O
and	O
8.5	O
months	O
after	O
initiation	O
of	O
second-line	O
treatment	O
for	O
the	O
platinum-containing	B-I
and	O
platinum-free	B-I
regimens	O
,	O
respectively	O
.	O


In	O
summary	O
,	O
we	O
observed	O
in	O
suboptimally	B-P
operated	I-P
ovarian	I-P
carcinoma	I-P
patients	I-P
similar	O
response	B-O
rates	I-O
,	I-O
progression-free	I-O
interval	I-O
,	I-O
and	I-O
overall	I-O
survival	I-O
for	O
equitoxic	O
cisplatin	B-I
and	I-I
CP	I-I
.	I-I


However	O
,	O
the	O
doses	O
of	O
cisplatin	B-I
and	I-I
cyclophosphamide	I-I
chosen	O
were	O
substantially	O
lower	O
than	O
current	O
standard	O
doses	O
of	O
CP	B-I
.	I-I


Our	O
study	O
demonstrates	O
,	O
therefore	O
,	O
that	O
a	O
suboptimal	O
dose	O
of	O
CP	B-I
is	O
as	O
effective	O
as	O
optimal	O
dose	O
monotherapy	O
cisplatin	B-I
.	I-I


Patients	B-P
with	I-P
recurrences	I-P
considered	I-P
as	I-P
platinum-sensitive	I-P
had	O
a	O
significantly	O
higher	O
response	B-O
rate	I-O
and	O
improved	O
survival	B-O
when	O
retreated	O
with	O
platinum-containing	B-I
therapy	I-I
.	I-I


Effects	O
of	O
amlodipine	B-I
and	I-I
enalapril	I-I
on	O
platelet	B-O
function	I-O
in	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
hypertension	I-P
.	I-P


OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
amlodipine	B-I
and	I-I
enalapril	I-I
on	O
platelet	B-O
aggregation	I-O
,	I-O
and	I-O
platelet	I-O
production	I-O
of	I-O
malondialdehyde	I-O
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
arterial	I-P
hypertension	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
A	O
parallel	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
was	O
carried	O
out	O
in	O
24	B-P
patients	I-P
(	I-P
2	I-P
groups	I-P
of	I-P
12	I-P
patients	I-P
each	I-P
)	I-P
.	I-P


Initially	O
all	O
patients	O
received	O
placebo	B-I
for	O
four	O
weeks	O
;	O
then	O
amlodipine	B-I
,	O
5	O
mg	O
daily	O
or	B-I
enalapril	I-I
20	O
mg	O
daily	O
taken	O
once	O
a	O
day	O
at	O
7	O
am	O
.	O


Dosage	O
was	O
doubled	O
after	O
4	O
weeks	O
when	O
diastolic	B-O
blood	I-O
pressure	I-O
was	O
>	O
90	O
mmHg	O
in	O
sitting	O
position	O
,	O
the	O
treatment	O
was	O
continued	O
for	O
12	O
weeks	O
.	O


At	O
the	O
end	O
of	O
placebo	B-I
and	O
active	O
phases	O
a	O
platelet	O
aggregation	O
test	O
,	O
using	O
adenosine	O
diphosphate	O
,	O
collagen	O
and	O
adrenaline	O
,	O
and	O
a	O
platelet	O
malondialdehyde	O
production	O
test	O
,	O
either	O
in	O
basal	O
conditions	O
(	O
MDA-basal	O
)	O
and	O
after	O
the	O
stimulation	O
of	O
arachidonic	O
acid	O
pathway	O
by	O
adding	O
ethylmaleimide	O
(	O
MDA-activated	O
)	O
were	O
carried	O
out	O
.	O


RESULTS	O
Blood	B-O
pressure	I-O
was	O
reduced	O
by	O
both	O
agents	O
,	O
enalapril	B-I
and	I-I
amlodipine	I-I
.	I-I


Enalapril	B-I
controlled	O
58.3	O
%	O
of	O
hypertensive	B-P
patients	I-P
with	O
an	O
average	O
dosage	O
of	O
31.7	O
mg/daily	O
.	O


Amlodipine	B-I
controlled	O
75	O
%	O
of	O
patients	O
with	O
a	O
dosage	O
of	O
7.1	O
mg/daily	O
.	O


Platelet	B-O
aggregation	I-O
was	O
reduced	O
by	O
amlodipine	B-I
in	O
15.9	O
%	O
for	O
ADP	O
(	O
10	O
microM	O
)	O
;	O
17.4	O
%	O
for	O
collagen	O
(	O
2	O
microg/ml	O
)	O
and	O
19.9	O
%	O
for	O
adrenaline	O
(	O
2	O
microM	O
)	O
(	O
p	O
<	O
0.025	O
)	O
.	O


Meanwhile	O
enalapril	B-I
slightly	O
increased	O
platelet	B-O
aggregation	I-O
by	O
6.7	O
%	O
,	O
1.3	O
%	O
and	O
5.6	O
%	O
for	O
the	O
three	O
agents	O
,	O
respectively	O
(	O
p	O
>	O
0.05	O
,	O
ns	O
)	O
.	O


Malondialdehyde	B-O
was	O
reduced	O
by	O
amlodipine	B-I
in	O
45.33	O
%	O
(	O
p	O
<	O
0.05	O
)	O
for	O
MDA-basal	B-O
;	I-O
3.76	O
%	O
(	O
p	O
>	O
0.05	O
)	O
for	O
MDA-activated	B-O
;	I-O
and	O
the	O
ratio	O
MDA-basal	O
:	O
MDA-activated	O
in	O
36.79	O
%	O
(	O
p	O
<	O
0.005	O
)	O
.	O


Meanwhile	O
enalapril	B-I
increased	O
MDA-basal	B-O
in	O
2.89	O
%	O
;	O
MDA-activated	B-O
in	O
3.58	O
%	O
and	O
reduced	O
the	O
ratio	B-O
MDA-basal	I-O
:	I-O
MDA-activated	I-O
,	O
in	O
10.34	O
%	O
(	O
p	O
>	O
0.05	O
)	O
.	O


CONCLUSION	O
Both	O
agents	O
,	O
enalapril	B-I
and	O
amlodipine	B-I
,	O
reduced	O
blood	B-O
pressure	I-O
,	O
but	O
only	O
amlodipine	B-I
reduced	O
platelet	B-O
aggregation	I-O
and	O
platelet	B-O
production	I-O
of	I-O
malondialdehyde	I-O
,	O
indicating	O
its	O
action	O
on	O
the	O
arachidonic	O
acid	O
metabolic	O
pathway	O
.	O


Tolerance	B-O
and	I-O
efficacy	I-O
of	O
combined	B-I
diethylcarbamazine	I-I
and	I-I
albendazole	I-I
for	O
treatment	O
of	O
Wuchereria	B-P
bancrofti	I-P
and	I-P
intestinal	I-P
helminth	I-P
infections	I-P
in	I-P
Haitian	I-P
children	I-P
.	I-P


This	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
investigated	O
the	O
tolerance	O
,	O
efficacy	O
,	O
and	O
nutritional	O
benefit	O
of	O
combining	O
chemotherapeutic	B-I
treatment	I-I
of	O
intestinal	O
helminths	O
and	O
lymphatic	O
filariasis	O
.	O


Children	B-P
were	I-P
infected	I-P
with	I-P
Ascaris	I-P
(	I-P
30.7	I-P
%	I-P
)	I-P
,	I-P
Trichuris	I-P
(	I-P
53.4	I-P
%	I-P
)	I-P
,	I-P
and	I-P
hookworm	I-P
(	I-P
9.7	I-P
%	I-P
)	I-P
with	I-P
69.9	I-P
%	I-P
having	I-P
more	I-P
than	I-P
one	I-P
of	I-P
these	I-P
parasites	I-P
.	I-P


A	O
total	O
of	O
15.8	O
%	O
of	O
the	O
children	B-P
had	I-P
Wuchereria	I-P
bancrofti	I-P
microfilariae	I-P
.	I-P


Children	B-P
were	O
randomly	O
assigned	O
treatment	O
with	O
placebo	B-I
,	I-I
albendazole	I-I
(	I-I
ALB	I-I
)	I-I
,	I-I
diethylcarbamazine	I-I
(	I-I
DEC	I-I
)	I-I
,	I-I
or	I-I
combined	I-I
therapy	I-I
.	I-I


The	B-O
combination	I-O
of	I-O
DEC/ALB	I-O
reduced	I-O
microfilarial	I-O
density	I-O
compared	I-O
with	I-O
placebo	I-O
,	I-O
ALB	I-O
,	I-O
or	I-O
DEC	I-O
(	I-O
P	I-O
<	I-O
or	I-O
=	I-O
0.03	I-O
)	I-O
.	I-O


Albendazole	B-O
and	I-O
DEC/ALB	I-O
reduced	I-O
the	I-O
prevalence	I-O
of	I-O
Ascaris	I-O
,	I-O
Trichuris	I-O
,	I-O
and	I-O
hookworm	I-O
more	I-O
than	I-O
placebo	I-O
or	I-O
DEC	I-O
(	I-O
P	I-O
<	I-O
or	I-O
=	I-O
0.03	I-O
)	I-O
.	I-O


Among	B-O
Trichuris-infected	I-O
children	I-O
,	I-O
those	I-O
receiving	I-O
ALB	I-O
and	I-O
DEC/ALB	I-O
demonstrated	I-O
greater	I-O
gains	I-O
in	I-O
weight	I-O
compared	I-O
with	I-O
placebo	I-O
(	I-O
P	I-O
<	I-O
or	I-O
=	I-O
0.05	I-O
)	I-O
.	I-O


Albendazole	B-O
and	I-O
DEC/ALB	I-O
were	I-O
equally	I-O
efficacious	I-O
in	I-O
treating	I-O
intestinal	I-O
helminths	I-O
and	I-O
for	I-O
children	I-O
with	I-O
W.	I-O
bancrofti	I-O
microfilaremia	I-O
,	I-O
DEC/ALB	I-O
was	I-O
more	I-O
effective	I-O
than	I-O
DEC	I-O
,	I-O
with	I-O
no	I-O
increase	I-O
in	I-O
severity	I-O
of	I-O
adverse	I-O
reactions	I-O
.	I-O


Mastication	B-O
and	I-O
late	I-O
mandibular	I-O
fracture	I-O
after	O
surgery	B-I
of	O
impacted	B-P
third	I-P
molars	I-P
associated	I-P
with	I-P
no	I-P
gross	I-P
pathology	I-P
.	I-P


PURPOSE	O
This	O
study	O
was	O
undertaken	O
with	O
the	O
null	O
hypothesis	O
that	O
in	O
patients	B-P
,	I-P
fully	I-P
denate	I-P
or	I-P
with	I-P
1	I-P
or	I-P
2	I-P
teeth	I-P
missing	I-P
and	I-P
older	I-P
than	I-P
25	I-P
years	I-P
,	O
mastication	O
does	O
not	O
affect	O
late	O
mandibular	B-O
fracture	I-O
after	I-P
surgical	I-I
removal	I-I
of	I-P
impacted	I-P
third	I-P
molars	I-P
(	I-P
M3s	I-P
)	I-P
associated	I-P
with	I-P
no	I-P
gross	I-P
pathology	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
Five	B-P
hundred	I-P
sixty	I-P
patients	I-P
,	I-P
fully	I-P
dentate	I-P
or	I-P
with	I-P
1	I-P
or	I-P
2	I-P
teeth	I-P
missing	I-P
and	I-P
older	I-P
than	I-P
25	I-P
years	I-P
who	I-P
had	I-P
no	I-P
gross	I-P
pathology	I-P
associated	I-P
with	I-P
their	I-P
impacted	I-P
lower	I-P
M3s	I-P
,	O
were	O
recruited	O
in	O
this	O
study	O
.	O


They	O
were	O
operated	B-I
on	I-I
under	O
local	B-I
anesthesia	I-I
using	O
a	O
standard	O
technique	O
and	O
randomly	O
assigned	O
into	O
2	O
groups	O
for	O
nonroutine	O
(	O
NR	O
group	O
)	O
and	O
routine	O
(	O
R	O
group	O
)	O
postoperative	O
instructions	O
.	O


In	O
the	O
NR	O
group	O
,	O
patients	O
were	O
postoperatively	O
educated	O
in	O
the	O
possibility	O
of	O
mandibular	B-O
fracture	I-O
and	O
were	O
given	O
an	O
emphasis	O
on	O
the	O
necessity	O
of	O
limiting	B-O
mastication	I-O
to	O
a	O
soft	O
diet	O
for	O
4	O
weeks	O
.	O


In	O
the	O
R	O
group	O
,	O
patients	O
were	O
given	O
no	O
such	O
education	O
or	O
emphasis	O
.	O


Patients	O
were	O
followed	O
up	O
for	O
2	O
months	O
,	O
and	O
data	B-O
concerning	I-O
patients	I-O
'	I-O
age	I-O
and	I-O
gender	I-O
;	I-O
tooth	I-O
position	I-O
,	I-O
angulation	I-O
,	I-O
and	I-O
depth	I-O
;	I-O
date	I-O
and	I-O
site	I-O
of	I-O
surgery	I-O
;	I-O
and	I-O
occurrence	I-O
of	I-O
late	I-O
mandibular	I-O
fracture	I-O
were	I-O
recorded	I-O
and	O
statistically	O
analyzed	O
.	O


A	O
value	O
of	O
P	O
less	O
than	O
.05	O
was	O
considered	O
statistically	O
significant	O
.	O


RESULTS	O
In	O
no	O
patient	O
group	O
was	O
there	O
a	O
late	B-O
mandibular	I-O
fracture	I-O
recorded	O
.	O


All	O
patients	O
completed	O
the	O
follow-up	O
period	O
,	O
and	O
most	O
of	O
the	O
R	O
group	O
patients	O
had	O
normal	O
eating	O
habits	O
10	O
to	O
14	O
days	O
after	O
surgery	O
.	O


In	O
no	O
patient	O
group	O
was	O
there	O
a	O
statistically	O
significant	O
difference	O
in	O
relation	O
to	O
gender	O
(	O
P	O
=	O
.735	O
)	O
,	O
site	O
of	O
surgery	O
(	O
P	O
=	O
.552	O
)	O
,	O
class	O
horizontal	O
space	O
available	O
(	O
P	O
=	O
.427	O
)	O
,	O
class	O
highest	O
portion	O
of	O
the	O
M3	O
crown	O
(	O
P	O
=	O
.424	O
)	O
,	O
angulations	O
of	O
the	O
teeth	O
(	O
P	O
=	O
.925	O
)	O
,	O
and	O
severity	B-O
of	I-O
impaction	I-O
(	O
P	O
=	O
.445	O
)	O
.	O


CONCLUSIONS	O
In	O
patients	B-P
,	I-P
fully	I-P
dentate	I-P
or	I-P
with	I-P
1	I-P
or	I-P
2	I-P
teeth	I-P
missing	I-P
and	I-P
older	I-P
than	I-P
25	I-P
years	I-P
who	I-P
have	I-P
no	I-P
jawbone	I-P
atrophy	I-P
and	I-P
no	I-P
systemic	I-P
problems	I-P
that	I-P
may	I-P
impair	I-O
bone	I-O
strength	I-O
,	O
mastication	O
seems	O
not	O
to	O
affect	O
late	B-O
mandibular	I-O
fracture	I-O
after	O
surgical	O
removal	O
of	O
impacted	O
M3s	O
associated	O
with	O
no	O
gross	O
pathology	O
.	O


The	O
remote	O
possible	O
risk	O
of	O
the	O
late	B-O
fracture	I-O
shown	O
in	O
our	O
patients	O
indicates	O
the	O
need	O
for	O
no	O
special	O
precautions	O
.	O


A	O
prospective	O
comparison	O
of	O
transthoracic	B-I
and	I-I
transhiatal	I-I
resection	I-I
for	O
esophageal	B-P
carcinoma	I-P
in	I-P
Asians	I-P
.	I-P


BACKGROUND/AIMS	O
Transthoracic	B-I
and	I-I
transhiatal	I-I
esophagectomy	I-I
are	O
two	O
common	O
procedures	O
for	O
esophageal	O
cancer	O
resection	O
.	O


Prospective	O
studies	O
comparing	O
the	O
two	O
methods	O
in	B-P
Asian	I-P
people	I-P
are	O
few	O
.	O


In	O
addition	O
,	O
the	O
data	O
comparing	O
their	O
effects	O
on	O
the	O
quality	B-O
of	I-O
life	I-O
are	O
lacking	O
.	O


METHODOLOGY	O
A	O
prospective	O
randomized	O
study	O
was	O
conducted	O
from	O
January	O
2003	O
.	O


Patients	B-P
of	I-P
resectable	I-P
esophageal	I-P
cancer	I-P
of	I-P
comparable	I-P
stage	I-P
were	O
allocated	O
to	O
undergo	O
the	O
transthoracic	B-I
or	I-I
transhiatal	I-I
procedure	I-I
in	O
turn	O
.	O


They	B-I
were	I-I
all	I-I
reconstructed	I-I
with	I-I
stomach	I-I
interposition	I-I
through	I-I
the	I-I
retrosternal	I-I
route	I-I
.	I-I


Discharged	B-I
patients	I-I
were	I-I
followed-up	I-I
in	I-I
the	I-I
outpatient	I-I
clinic	I-I
.	I-I


They	B-I
were	I-I
questioned	I-I
on	I-I
the	I-I
topics	I-I
of	I-I
(	I-O
i	I-O
)	I-O
severity	I-O
of	I-O
pain	I-O
,	I-O
(	I-O
ii	I-O
)	I-O
ease	I-O
of	I-O
swallowing	I-O
,	I-O
(	I-O
iii	I-O
)	I-O
satisfaction	I-O
of	I-O
daily	I-O
activities	I-O
,	I-O
(	I-O
iv	I-O
)	I-O
dependence	I-O
on	I-O
medications	I-O
,	I-O
(	I-O
v	I-O
)	I-O
working	I-O
ability	I-O
,	I-O
(	I-O
vi	I-O
)	I-O
fatigue	I-O
,	I-O
(	I-O
vii	I-O
)	I-O
appetite	I-O
,	I-O
(	I-O
viii	I-O
)	I-O
sociality	I-O
,	I-O
(	I-O
ix	I-O
)	I-O
happiness	I-O
and	I-O
(	I-O
x	I-O
)	I-O
self	I-O
respect	I-O
,	I-I
in	I-I
the	I-I
third	I-I
,	I-I
sixth	I-I
and	I-I
twelfth	I-I
month	I-I
.	I-I


Also	O
the	O
demographic	B-O
data	I-O
,	I-O
operative	I-O
results	I-O
and	I-O
survival	I-O
were	O
recorded	O
.	O


RESULTS	O
Up	B-P
to	I-P
December	I-P
2006	I-P
,	I-P
eighty-seven	I-P
patients	I-P
of	I-P
stage	I-P
II	I-P
and	I-P
III	I-P
,	I-P
including	I-P
71	I-P
patients	I-P
of	I-P
middle	I-P
third	I-P
lesions	I-P
and	I-P
16	I-P
lower	I-P
third	I-P
lesions	I-P
were	I-P
enrolled	I-P
.	I-P


The	O
operation	B-O
time	I-O
was	O
significantly	O
longer	O
,	O
and	O
the	O
leakage	B-O
rate	I-O
was	O
higher	O
in	O
the	O
transthoracic	O
group	O
(	O
Student	O
's	O
t-test	O
and	O
Fischer	O
's	O
exact	O
test	O
,	O
respectively	O
)	O
.	O


However	O
,	O
intraoperative	B-O
blood	I-O
loss	I-O
and	I-O
postoperative	I-O
hospital	I-O
stay	I-O
were	O
not	O
significantly	O
different	O
(	O
Student	O
t-test	O
)	O
.	O


Also	O
,	O
the	O
Kaplan-Meier	B-O
survival	I-O
curves	I-O
of	O
these	O
two	O
groups	O
were	O
not	O
significantly	O
different	O
by	O
log-rank	O
test	O
(	O
p=0.286	O
)	O
.	O


The	O
score	O
on	O
the	O
quality	B-O
of	I-O
life	I-O
of	O
transhiatal	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
transthoracic	O
patients	O
in	O
the	O
third	O
,	O
sixth	O
and	O
twelfth	O
month	O
.	O


CONCLUSIONS	O
Transhiatal	B-I
esophagectomy	I-I
is	O
a	O
safe	O
and	O
fast	O
procedure	O
.	O


The	O
survival	O
was	O
similar	O
to	O
that	O
of	O
transthoracic	O
approach	O
.	O


Its	O
leakage	B-O
rate	I-O
was	O
lower	O
and	O
quality	O
of	O
life	O
was	O
better	O
.	O


Budesonide	B-I
and	I-I
beclomethasone	I-I
dipropionate	I-I
in	O
hay	B-P
fever	I-P
-	O
a	O
single	O
blind	O
comparison	O
.	O


93	B-P
patients	I-P
with	I-P
seasonal	I-P
allergic	I-P
rhinitis	I-P
took	O
part	O
in	O
a	O
single	O
blind	O
randomized	O
clinical	O
comparison	O
of	O
budesonide	B-I
and	I-I
beclomethasone	I-I
dipropionate	I-I
(	I-I
Becotide	I-I
Nasal	I-I
)	I-I
.	I-I


All	B-P
patients	I-P
were	I-P
sensitive	I-P
to	I-P
either	I-P
birch	I-P
or	I-P
grass	I-P
pollen	I-P
,	I-P
their	I-P
sensitivity	I-P
being	I-P
confirmed	I-P
by	I-P
a	I-P
skin	I-P
prick	I-P
test	I-P
.	I-P


The	O
total	O
daily	O
dose	O
was	O
400	O
micrograms	O
for	O
both	O
drugs	O
.	O


Budesonide	B-I
was	O
administered	O
twice	O
a	O
day	O
and	O
Becotide	B-I
Nasal	I-I
four	O
times	O
a	O
day	O
.	O


Symptoms	O
were	O
assessed	O
over	O
a	O
four-week	O
period	O
starting	O
with	O
a	O
run-in	O
period	O
of	O
one	O
week	O
.	O


There	O
was	O
no	O
placebo	O
control	O
group	O
.	O


Daily	B-O
pollen	I-O
counts	I-O
were	O
measured	O
throughout	O
the	O
trial	O
.	O


The	O
patients	O
'	O
diary	O
cards	O
revealed	O
that	O
both	O
drugs	O
had	O
a	O
beneficial	O
therapeutic	O
effect	O
,	O
and	O
that	O
budesonide	B-I
was	O
significantly	O
more	O
active	O
than	O
Becotide	B-I
Nasal	I-I
.	I-I


The	O
side	B-O
effects	I-O
of	O
both	O
drugs	O
were	O
few	O
and	O
transient	O
.	O


A	O
Randomized	O
Double	O
Blind	O
Clinical	O
Trial	O
on	O
a	O
Sabgh	B-I
Formulation	I-I
for	O
Patients	B-P
With	I-P
Vitiligo	I-P
.	I-P


BACKGROUND	O
The	O
cosmetic	O
problem	O
that	O
vitiligo	B-I
produces	O
affects	B-P
patients	I-P
psychologically	I-P
.	I-P


Many	O
patients	B-P
with	I-P
vitiligo	I-P
are	O
suggested	O
to	O
cover	O
their	O
white	O
skin	O
patches	O
with	O
cosmetic	O
products	O
.	O


There	O
are	O
formulations	O
in	O
traditional	O
Iranian	O
pharmacy	O
to	O
color	O
these	O
white	O
skin	O
patches	O
.	O


In	O
this	O
study	O
,	O
one	O
of	O
these	O
formulations	B-I
was	O
compared	O
with	O
a	O
cosmetic	B-I
formulation	I-I
.	I-I


METHODS	O
Two	B-P
groups	I-P
of	I-P
patients	I-P
were	I-P
selected	I-P
.	I-P


One	O
group	O
used	O
a	O
marketed	B-I
formulation	I-I
and	O
other	O
group	O
used	O
a	O
traditional	B-I
Iranian	I-I
Pharmacy	I-I
formulation	I-I
.	I-I


The	O
quality	B-O
of	I-O
life	I-O
of	O
the	O
patients	O
was	O
compared	O
based	O
on	O
the	O
Dermatology	O
Life	O
Quality	O
Index	O
Questionnaire	O
.	O


RESULTS	O
Both	O
interventions	O
were	O
associated	O
with	O
statistically	O
improved	O
Dermatology	B-O
Life	I-O
Quality	I-O
Index	I-O
scores	I-O
over	O
the	O
8-week	O
intervention	O
(	O
P	O
<	O
.05	O
)	O
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
.436	O
)	O
.	O


CONCLUSION	O
Traditional	B-I
Iranian	I-I
Pharmacy	I-I
formulation	O
is	O
effective	O
in	O
increasing	O
the	O
quality	B-O
of	I-O
life	I-O
in	O
vitiligo	O
patients	O
.	O


Blind	B-I
versus	I-I
open	I-I
approach	I-I
to	I-I
laparoscopic	I-I
cholecystectomy	I-I
:	I-I
a	O
randomized	O
study	O
.	O


Intraabdominal	O
structures	O
may	O
be	O
damaged	O
during	O
blind	O
introduction	O
of	O
the	O
first	O
trocar	O
for	O
laparoscopic	B-I
operations	O
.	O


In	O
this	O
study	O
,	O
150	B-P
patients	I-P
with	I-P
gallbladder	I-P
lithiasis	I-P
who	I-P
underwent	I-P
laparoscopy	I-P
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
,	O
a	O
blind	O
(	O
V	O
group	O
)	O
or	O
an	O
open	O
(	O
H	O
group	O
)	O
,	O
in	O
order	O
to	O
compare	O
the	O
results	O
and	O
the	O
rate	B-O
of	I-O
complications	I-O
.	I-O


No	O
mortality	B-O
was	O
observed	O
.	O


Major	B-O
complications	I-O
occurred	O
in	O
3/75	O
(	O
4	O
%	O
)	O
patients	O
of	O
the	O
V	O
group	O
and	O
in	O
1/75	O
(	O
1.3	O
%	O
)	O
patient	O
of	O
the	O
H	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Minor	B-O
complications	I-O
occurred	O
in	O
5/75	O
(	O
6.7	O
%	O
)	O
patients	O
of	O
either	O
group	O
.	O


The	O
achievement	B-O
of	I-O
pneumoperitoneum	I-O
required	O
4.5+/-0.4	O
min	O
in	O
the	O
V	O
group	O
and	O
3.2+/-0.2	O
min	O
in	O
the	O
H	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O


The	O
open	B-I
laparoscopic	I-I
technique	I-I
is	O
safer	O
and	O
faster	O
than	O
the	O
blind	B-I
approach	I-I
;	I-I
therefore	O
,	O
it	O
is	O
proposed	O
that	O
this	O
approach	O
be	O
routinely	O
used	O
in	O
all	O
laparoscopic	O
procedures	O
.	O


Lofexidine	B-I
in	O
hyperactive	B-P
and	I-P
impulsive	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
.	I-P


Comparison	O
of	O
active-learning	B-I
strategies	I-I
for	O
motivational	B-O
interviewing	I-O
skills	I-O
,	I-O
knowledge	I-O
,	I-O
and	I-O
confidence	I-O
in	O
first-year	B-P
pharmacy	I-P
students	I-P
.	I-P


OBJECTIVE	O
To	O
compare	O
3	O
strategies	O
for	O
pharmacy	B-P
student	I-P
learning	O
of	O
motivational	O
interviewing	O
skills	B-O
,	I-O
knowledge	I-O
of	O
motivational	O
interviewing	O
principles	O
,	O
and	O
confidence	B-O
in	O
and	O
attitudes	B-O
toward	O
their	O
application	O
.	O


DESIGN	O
Following	O
a	O
motivational	B-I
interviewing	I-I
lecture	I-I
,	O
first-year	B-P
students	I-P
were	O
randomized	O
to	O
perform	O
practice	B-I
activities	I-I
(	I-I
written	I-I
dialogue	I-I
,	I-I
peer	I-I
role-play	I-I
,	I-I
or	I-I
mock-patient	I-I
counseling	I-I
activities	I-I
)	I-I
.	O


Motivational	B-O
interviewing	I-O
skills	I-O
,	I-O
knowledge	I-O
,	I-O
confidence	I-O
,	I-O
and	I-O
attitudes	I-O
were	O
measured	O
.	O


ASSESSMENT	O
All	O
students	O
demonstrated	O
improvement	O
in	O
skills	B-O
,	I-O
knowledge	I-O
,	I-O
and	I-O
confidence	I-O
.	I-O


Students	B-P
in	O
the	O
mock-patient	B-I
counseling	I-I
group	O
demonstrated	O
significantly	O
better	O
motivational	O
interviewing	O
skills	B-O
during	O
practice	O
and	O
trended	O
toward	O
higher	O
scores	O
on	O
the	O
summative	O
evaluation	O
.	O


They	O
also	O
demonstrated	O
a	O
significant	O
improvement	O
in	O
knowledge	B-O
compared	O
with	O
that	O
of	O
the	O
written	O
dialogue	O
group	O
during	O
practice	O
.	O


Feedback	O
at	O
the	O
end	O
was	O
generally	O
positive	O
,	O
with	O
students	B-P
expressing	O
recognition	B-O
for	I-O
the	I-O
value	I-O
of	I-O
motivational	I-O
interviewing	I-O
.	I-O


CONCLUSIONS	O
Students	O
demonstrated	O
their	O
best	O
performance	O
of	O
motivational	B-O
interviewing	I-O
during	O
assessments	O
using	O
interactions	O
with	O
mock	O
or	O
standardized	O
patients	O
.	O


The	O
efficacy	B-O
and	I-O
safety	I-O
of	O
fenfluramine	B-I
in	O
autistic	B-P
children	I-P
:	I-P
preliminary	O
analysis	O
of	O
a	O
double-blind	O
study	O
.	O


A	O
neuropsychological	B-I
rehabilitation	I-I
program	I-I
for	O
patients	B-P
with	I-P
Multiple	I-P
Sclerosis	I-P
based	I-P
on	I-P
the	I-P
model	I-P
of	I-P
the	I-P
ICF	I-P
.	I-P


BACKGROUND	O
Forty	O
to	O
sixty	O
percent	O
of	O
MS	O
patients	O
suffer	O
from	O
cognitive	B-O
impairments	I-O
.	I-O


Cognitive	B-O
deficits	I-O
are	O
a	O
great	O
burden	O
for	O
patients	O
affected	O
.	O


In	O
particular	O
they	O
may	O
lead	O
to	O
a	O
reduced	O
quality	B-O
of	I-O
life	I-O
,	I-O
loss	I-O
of	I-O
work	I-O
and	I-O
problems	I-O
with	I-O
the	I-O
social	I-O
environment	I-O
.	I-O


OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
specific	B-I
neuropsychological	I-I
rehabilitation	I-I
program	I-I
for	O
MS	B-P
patients	I-P
according	I-P
to	I-P
the	I-P
ICF	I-P
to	O
be	O
able	O
to	O
meet	O
more	O
properly	O
individual	O
requirements	O
on	O
the	O
therapy	O
level	O
of	O
function	B-O
as	O
well	O
as	O
of	O
activities	B-O
and	I-O
participation	I-O
.	I-O


METHODS	O
Forty	B-P
patients	I-P
with	I-P
MS	I-P
were	I-P
randomised	I-P
in	I-P
an	I-P
intervention	I-I
(	I-I
IG	I-I
)	I-I
-	I-I
and	I-I
a	I-I
control	I-I
group	I-I
(	I-I
CG	I-I
)	I-I
.	I-P


The	O
outcome	B-O
measure	I-O
of	O
the	O
IG	O
,	O
who	O
started	O
an	O
intensive	B-I
computer	I-I
based	I-I
home	I-I
training	I-I
of	I-I
attention	I-I
and	O
attended	O
psychological	B-I
counselling	I-I
was	O
compared	O
to	O
the	O
untrained	B-I
CG	I-I
.	I-I


RESULTS	O
In	O
specific	O
domains	O
of	O
attention	B-O
(	I-O
simple	I-O
and	I-O
cued	I-O
alertness	I-O
and	I-O
divided	I-O
attention	I-O
)	I-O
significant	O
group	O
differences	O
between	O
CG	O
and	O
IG	O
could	O
be	O
found	O
.	O


The	O
IG	B-I
reported	O
an	O
improvement	O
of	O
mental	B-O
fatigue	I-O
and	I-O
retardation	I-O
.	I-O


CONCLUSION	O
These	O
findings	O
support	O
the	O
idea	O
that	O
a	O
neuropsychological	O
rehabilitation	O
program	O
,	O
which	O
based	O
on	O
the	O
model	O
of	O
ICF	O
,	O
could	O
improve	O
cognitive	B-O
impairment	I-O
and	O
could	O
also	O
have	O
a	O
positive	O
influence	O
of	O
activities	B-O
and	I-O
participation	I-O
.	I-O


Intervention	B-I
targeting	O
development	O
of	O
socially	O
synchronous	O
engagement	O
in	O
toddlers	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
Social	O
and	O
communication	O
impairments	O
are	O
core	O
deficits	O
and	O
prognostic	O
indicators	O
of	O
autism	O
.	O


We	O
evaluated	O
the	O
impact	O
of	O
supplementing	O
a	O
comprehensive	B-I
intervention	I-I
with	O
a	O
curriculum	O
targeting	O
socially	O
synchronous	O
behavior	O
on	O
social	O
outcomes	O
of	O
toddlers	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


METHODS	O
Fifty	B-P
toddlers	I-P
with	I-P
ASD	I-P
,	I-P
ages	I-P
21	I-P
to	I-P
33	I-P
months	I-P
,	O
were	O
randomized	O
to	O
one	O
of	O
two	O
six-month	O
interventions	O
:	O
Interpersonal	B-I
Synchrony	I-I
or	O
Non-Interpersonal	B-I
Synchrony	I-I
.	I-I


The	O
interventions	O
provided	O
identical	O
intensity	O
(	O
10	O
hours	O
per	O
week	O
in	O
classroom	O
)	O
,	O
student-to-teacher	O
ratio	O
,	O
schedule	O
,	O
home-based	O
parent	O
training	O
(	O
1.5	O
hours	O
per	O
month	O
)	O
,	O
parent	O
education	O
(	O
38	O
hours	O
)	O
,	O
and	O
instructional	O
strategies	O
,	O
except	O
the	O
Interpersonal	O
Synchrony	O
condition	O
provided	O
a	O
supplementary	O
curriculum	O
targeting	O
socially	O
engaged	O
imitation	O
,	O
joint	O
attention	O
,	O
and	O
affect	O
sharing	O
;	O
measures	O
of	O
these	O
were	O
primary	O
outcomes	O
.	O


Assessments	O
were	O
conducted	O
pre-intervention	O
,	O
immediately	O
post-intervention	O
,	O
and	O
,	O
to	O
assess	O
maintenance	O
,	O
at	O
six-month	O
follow-up	O
.	O


Random	O
effects	O
models	O
were	O
used	O
to	O
examine	O
differences	O
between	O
groups	O
over	O
time	O
.	O


Secondary	O
analyses	O
examined	O
gains	B-O
in	I-O
expressive	I-O
language	I-O
and	I-O
nonverbal	I-O
cognition	I-O
,	O
and	O
time	B-O
effects	I-O
during	O
the	O
intervention	O
and	O
follow-up	O
periods	O
.	O


RESULTS	O
A	O
significant	O
treatment	O
effect	O
was	O
found	O
for	O
socially	O
engaged	O
imitation	O
(	O
p	O
=	O
.02	O
)	O
,	O
with	O
more	O
than	O
doubling	O
(	O
17	O
%	O
to	O
42	O
%	O
)	O
of	O
imitated	O
acts	O
paired	O
with	O
eye	O
contact	O
in	O
the	O
Interpersonal	O
Synchrony	O
group	O
after	O
the	O
intervention	O
.	O


This	O
skill	O
was	O
generalized	O
to	O
unfamiliar	O
contexts	O
and	O
maintained	O
through	O
follow-up	O
.	O


Similar	O
gains	O
were	O
observed	O
for	O
initiation	O
of	O
joint	B-O
attention	I-O
and	O
shared	O
positive	O
affect	O
,	O
but	O
between-group	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O


A	O
significant	O
time	O
effect	O
was	O
found	O
for	O
all	O
outcomes	O
(	O
p	O
<	O
.001	O
)	O
;	O
greatest	O
change	O
occurred	O
during	O
the	O
intervention	O
period	O
,	O
particularly	O
in	O
the	O
Interpersonal	O
Synchrony	O
group	O
.	O


CONCLUSIONS	O
This	O
is	O
the	O
first	O
ASD	O
randomized	O
trial	O
involving	O
toddlers	B-P
to	O
identify	O
an	O
active	O
ingredient	O
for	O
enhancing	O
socially	O
engaged	O
imitation	O
.	O


Adding	O
social	O
engagement	O
targets	O
to	O
intervention	O
improves	O
short-term	O
outcome	O
at	O
no	O
additional	O
cost	O
to	O
the	O
intervention	O
.	O


The	O
social	O
,	O
language	O
,	O
and	O
cognitive	O
gains	O
in	O
our	O
participants	O
provide	O
evidence	O
for	O
plasticity	O
of	O
these	O
developmental	O
systems	O
in	O
toddlers	B-P
with	I-P
ASD	I-P
.	I-P


http	O
:	O
//www.clinicaltrials.gov/ct2/show/NCT00106210	O
?	O
term	O
=	O
landa	O
&	O
rank	O
=	O
3	O
.	O


A	O
prospective	O
comparison	O
of	O
the	O
multiplane	B-I
probe	I-I
with	O
the	O
biplane	B-I
probe	I-I
in	O
structure	B-O
visualization	I-O
and	I-O
Doppler	I-O
examination	I-O
during	I-P
transesophageal	I-P
echocardiography	I-P
.	I-P


To	O
compare	O
the	O
imaging	B-O
capability	I-O
of	O
the	O
multiplane	B-I
probe	I-I
with	O
that	O
of	O
the	O
biplane	B-I
probe	I-I
,	O
317	B-P
consecutive	I-P
patients	I-P
were	O
randomized	O
to	O
undergo	O
transesophageal	B-I
echocardiography	I-I
with	I-I
either	I-I
probe	I-I
.	I-I


Images	O
of	O
24	O
cardiac	O
structures	O
and	O
nine	B-O
Doppler	I-O
signals	I-O
were	O
graded	O
prospectively	O
on	O
a	O
three-grade	O
system	O
.	O


Both	O
multiplane	B-I
and	I-I
biplane	I-I
probes	I-I
provided	O
excellent	B-O
visualization	I-O
of	I-O
cardiac	I-O
structures	I-O
and	O
Doppler	B-O
signals	I-O
,	O
but	O
the	O
multiplane	B-I
probe	I-I
was	O
significantly	O
superior	O
to	O
the	O
biplane	O
probe	O
.	O


There	O
were	O
no	O
differences	O
in	O
the	O
number	B-O
of	I-O
attempts	I-O
at	I-O
esophageal	I-O
intubation	I-O
,	I-O
the	I-O
amount	I-O
of	I-O
sedation	I-O
used	I-O
,	I-O
and	I-O
the	I-O
examination	I-O
time	I-O
.	I-O


The	O
number	B-O
of	I-O
complications	I-O
was	I-O
similar	I-O
,	O
although	O
all	O
failed	B-O
intubations	I-O
occurred	O
with	O
the	O
multiplane	B-I
probe	I-I
.	I-I


Impact	O
of	O
a	O
single	O
intravenous	O
administration	O
of	O
nicorandil	B-I
before	O
reperfusion	O
in	O
patients	B-P
with	I-P
ST-segment-elevation	I-P
myocardial	I-P
infarction	I-P
.	I-P


BACKGROUND	O
Intravenous	O
nicorandil	B-I
,	O
a	O
hybrid	O
compound	O
of	O
ATP-sensitive	O
potassium	O
channel	O
opener	O
and	O
nitric	O
oxide	O
donor	O
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
early	O
functional	O
and	O
clinical	O
problems	O
in	O
patients	B-P
with	I-P
acute	I-P
myocardial	I-P
infarction	I-P
.	I-P


However	O
,	O
its	O
effects	O
on	O
the	O
late	O
phase	O
remain	O
unclear	O
.	O


METHODS	O
AND	O
RESULTS	O
This	O
follow-up	O
study	O
to	O
5	O
years	O
of	O
a	O
randomized	O
,	O
double-blinded	O
trial	O
was	O
conducted	O
among	O
368	B-P
patients	I-P
with	I-P
first	I-P
ST-segment-elevation	I-P
myocardial	I-P
infarction	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
(	I-P
PCI	I-P
)	I-P
.	I-P


They	O
were	O
randomly	O
assigned	O
to	O
receive	O
12	O
mg	O
of	O
nicorandil	B-I
or	I-I
a	I-I
placebo	I-I
intravenously	O
just	O
before	O
reperfusion	O
.	O


We	O
analyzed	O
incidence	O
of	O
cardiovascular	B-O
death	I-O
or	I-O
rehospitalization	I-O
for	O
congestive	B-O
heart	I-O
failure	I-O
after	O
PCI	O
as	O
well	O
as	O
various	O
aspects	O
of	O
epicardial	O
flow	O
and	O
microvascular	O
function	O
.	O


Mean	O
follow-up	O
was	O
2.4	O
years	O
(	O
SD	O
,	O
1.4	O
)	O
.	O


A	O
total	O
of	O
12	O
(	O
6.5	O
%	O
)	O
patients	O
receiving	O
nicorandil	B-I
and	O
30	O
(	O
16.4	O
%	O
)	O
receiving	O
placebo	B-I
had	O
cardiovascular	B-O
death	I-O
or	I-O
hospital	I-O
admission	I-O
for	I-O
congestive	I-O
heart	I-O
failure	I-O
(	O
hazard	O
ratio	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.20	O
to	O
0.76	O
;	O
P=0.0058	O
)	O
.	O


Postprocedural	B-O
TIMI	I-O
3	I-O
flow	I-O
was	O
obtained	O
in	O
89.7	O
%	O
of	O
the	O
nicorandil	B-I
group	O
and	O
in	O
81.4	O
%	O
of	O
the	O
placebo	B-I
(	O
hazard	O
ratio	O
,	O
1.99	O
;	O
95	O
%	O
CI	O
,	O
1.09	O
to	O
3.65	O
;	O
P=0.025	O
)	O
.	O


Corrected	B-O
TIMI	I-O
frame	I-O
count	I-O
was	O
furthermore	O
lower	O
in	O
the	O
nicorandil	B-I
group	O
(	O
21.0+/-9.1	O
versus	O
25.1+/-14.1	O
;	O
P=0.0009	O
)	O
.	O


ST-segment	B-O
resolution	I-O
>	I-O
50	I-O
%	I-O
was	O
observed	O
in	O
79.5	O
%	O
and	O
61.2	O
%	O
of	O
the	O
nicorandil	B-I
and	O
placebo	B-I
groups	O
,	O
respectively	O
(	O
hazard	O
ratio	O
,	O
2.45	O
;	O
95	O
%	O
CI	O
,	O
1.54	O
to	O
3.90	O
;	O
P=0.0002	O
)	O
.	O


CONCLUSIONS	O
The	O
addition	O
of	O
intravenous	O
nicorandil	B-I
to	O
PCI	O
leads	O
to	O
beneficial	O
clinical	B-O
outcomes	I-O
and	O
prevents	O
cardiovascular	B-O
events	I-O
of	I-O
long	I-O
duration	I-O
and	I-O
death	I-O
in	O
patients	B-P
with	I-P
ST-segment-elevation	I-P
myocardial	I-P
infarction	I-P
.	I-P


The	O
gluten-free	B-I
,	I-I
casein-free	I-I
diet	I-I
in	O
autism	B-P
:	I-P
results	O
of	O
a	O
preliminary	O
double	O
blind	O
clinical	O
trial	O
.	O


This	O
study	O
tested	O
the	O
efficacy	O
of	O
a	O
gluten-free	B-I
and	I-I
casein-free	I-I
(	I-I
GFCF	I-I
)	I-I
diet	I-I
in	O
treating	O
autism	B-P
using	O
a	O
randomized	O
,	O
double	O
blind	O
repeated	O
measures	O
crossover	O
design	O
.	O


The	O
sample	O
included	O
15	B-P
children	I-P
aged	I-P
2-16	I-P
years	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


Data	O
on	O
autistic	B-O
symptoms	I-O
and	I-O
urinary	I-O
peptide	I-O
levels	I-O
were	O
collected	O
in	O
the	O
subjects	O
'	O
homes	O
over	O
the	O
12	O
weeks	O
that	O
they	O
were	O
on	O
the	O
diet	O
.	O


Group	O
data	O
indicated	O
no	O
statistically	O
significant	O
findings	O
even	O
though	O
several	O
parents	O
reported	O
improvement	B-O
in	O
their	O
children	O
.	O


Although	O
preliminary	O
,	O
this	O
study	O
demonstrates	O
how	O
a	O
controlled	O
clinical	O
trial	O
of	O
the	O
GFCF	B-I
diet	I-I
can	O
be	O
conducted	O
,	O
and	O
suggests	O
directions	O
for	O
future	O
research	O
.	O


Ethanol-induced	O
alterations	O
in	O
electroencephalographic	B-O
activity	I-O
in	O
adult	B-P
males	I-P
.	I-P


The	O
present	O
investigation	O
examined	O
the	O
effects	O
of	O
placebo	B-I
(	I-I
P	I-I
)	I-I
,	O
low-dose	O
(	O
LD	O
)	O
,	O
and	O
high-dose	O
(	O
HD	O
)	O
ethanol	B-I
on	O
electroencephalographic	B-O
(	I-O
EEG	I-O
)	I-O
activity	I-P
in	I-P
21	I-P
healthy	I-P
,	I-P
adult	I-P
males	I-P
(	I-P
X	I-P
=	I-P
22.7	I-P
years	I-P
)	I-P
.	I-P


Only	O
one	O
condition	O
(	O
P	O
,	O
LD	O
,	O
or	O
HD	O
)	O
was	O
presented	O
per	O
day	O
and	O
the	O
condition	O
order	O
was	O
randomized	O
.	O


For	O
each	O
subject	O
,	O
blood-alcohol	O
levels	O
measured	O
via	O
breathalyzer	O
and	O
EEG	B-O
activity	I-O
,	O
using	O
the	O
entire	O
10/20	O
International	O
System	O
,	O
were	O
recorded	O
both	O
prior	O
to	O
and	O
at	O
intervals	O
of	O
35	O
,	O
70	O
,	O
105	O
,	O
and	O
140	O
minutes	O
after	O
P	O
,	O
LD	O
,	O
or	O
HD	O
administration	O
.	O


The	O
Fast	O
Fourier	O
Transform	O
was	O
used	O
to	O
calculate	O
power	O
spectral	O
densities	O
for	O
each	O
EEG	O
recording	O
.	O


Measures	O
of	O
the	O
relative	O
areas	O
under	O
the	O
power	O
spectral	O
curve	O
were	O
made	O
for	O
each	O
of	O
the	O
following	O
frequency	O
bands	O
:	O
slow	O
alpha	O
(	O
7.5	O
to	O
10	O
Hz	O
)	O
;	O
fast	O
alpha	O
(	O
10.5	O
to	O
13.0	O
Hz	O
)	O
;	O
slow	O
beta	O
(	O
13.5	O
to	O
19.5	O
Hz	O
)	O
;	O
and	O
fast	O
beta	O
(	O
20	O
to	O
26	O
Hz	O
)	O
at	O
electrodes	O
F3	O
,	O
F4	O
,	O
C3	O
,	O
C4	O
,	O
P3	O
,	O
P4	O
,	O
O1	O
,	O
and	O
O2	O
.	O


Repeated-measures	O
multivariate	O
analysis	O
of	O
variance	O
performed	O
on	O
normalized	O
relative	O
area	O
values	O
revealed	O
that	O
ethanol	O
had	O
significant	O
effects	O
on	O
EEG	B-O
activity	I-O
at	I-O
anterior	I-O
sites	I-O
:	I-O
frontal	O
(	O
F3	O
,	O
F4	O
)	O
and	O
central	O
(	O
C3	O
,	O
C4	O
)	O
that	O
presented	O
as	O
increased	O
activity	O
in	O
the	O
slow	O
alpha	O
frequency	O
band	O
.	O


These	O
results	O
suggest	O
a	O
differential	O
responsivity	O
of	O
both	O
cortical	B-O
region	I-O
and	I-O
EEG	I-O
frequency	I-O
band	I-O
to	O
the	O
effects	O
of	O
ethanol	O
ingestion	O
.	O


[	O
Effects	O
of	O
computer-assisted	B-I
practice	I-I
on	O
reading	B-O
and	I-O
spelling	I-O
in	O
children	B-P
with	I-P
learning	I-P
disabilities	I-P
]	I-P
.	O


The	O
main	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
effects	O
of	O
computer-assisted	B-I
practice	I-I
on	I-I
reading	I-I
and	I-I
spelling	I-I
in	I-I
children	I-P
with	I-P
learning	I-P
disabilities	I-P
(	I-P
LD	I-P
)	I-P
.	I-P


We	O
compared	O
three	O
practice	O
conditions	O
,	O
one	O
with	O
reading	B-I
and	O
two	O
with	O
spelling	B-I
,	O
in	O
order	O
to	O
test	O
whether	O
computer-based	B-I
reading	I-I
and	I-I
spelling	I-I
practice	I-I
has	O
an	O
influence	O
on	O
the	O
development	O
of	O
reading	O
and	O
spelling	O
ability	O
in	O
children	B-P
with	I-P
LD	I-P
.	I-P


A	O
sample	O
was	O
selected	O
of	O
85	B-P
children	I-P
with	I-P
LD	I-P
,	I-P
with	I-P
age	I-P
range	I-P
between	I-P
8	I-P
years	I-P
and	I-P
10	I-P
years	I-P
(	I-P
age	I-P
,	I-P
M=111.02	I-P
,	I-P
SD=9.6	I-P
)	I-P
,	I-P
whose	I-P
spelling	I-P
performance	I-P
was	I-P
two	I-P
years	I-P
below	I-P
grade	I-P
level	I-P
.	I-P


The	O
participants	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	O
:	O
1	B-I
)	I-I
Copy	I-I
the	I-I
target	I-I
word	I-I
from	I-I
the	I-I
computer	I-I
screen	I-I
(	I-I
n=22	I-I
)	I-I
,	I-I
2	I-I
)	I-I
Memorize	I-I
the	I-I
target	I-I
word	I-I
and	I-I
write	I-I
it	I-I
from	I-I
memory	I-I
(	I-I
n=21	I-I
)	I-I
,	I-I
3	I-I
)	I-I
Word	I-I
reading	I-I
(	I-I
n=21	I-I
)	I-I
,	I-I
and	I-I
4	I-I
)	I-I
the	I-I
untrained	I-I
control	I-I
group	I-I
(	O
n=21	O
)	O
.	O


We	O
administered	O
measures	O
of	O
pseudoword	B-O
reading	I-O
,	I-O
phonological	I-O
awareness	I-O
,	I-O
phonological	I-O
word	I-O
decoding	I-O
and	I-O
orthographical	I-O
word	I-O
decoding	I-O
tasks	I-O
.	I-O


We	O
examined	O
the	O
learning	B-O
effects	I-O
and	I-O
transfer	I-O
effects	I-O
on	I-O
words	I-O
classified	I-O
as	I-O
a	I-O
function	I-O
of	I-O
length	I-O
,	I-O
consistency	I-O
,	I-O
and	I-O
complexity	I-O
of	I-O
syllable	I-O
structure	I-O
.	I-O


Overall	O
,	O
the	O
results	O
showed	O
that	O
reading	O
training	O
did	O
not	O
improve	O
spelling	O
;	O
however	O
,	O
the	O
children	O
who	O
participated	O
in	O
the	O
copy	O
training	O
condition	O
improved	O
their	O
spelling	O
skills	O
.	O


Developing	O
the	O
Ho'ouna	B-I
Pono	I-I
substance	I-I
use	I-I
prevention	I-I
curriculum	I-I
:	I-I
collaborating	O
with	O
Hawaiian	B-P
youth	I-P
and	I-P
communities	I-P
.	I-P


This	O
article	O
briefly	O
outlines	O
a	O
collaboration	O
among	O
communities	B-P
on	I-P
Hawai'i	I-P
Island	I-P
and	O
a	O
university-based	B-P
research	I-P
team	I-P
to	O
develop	B-O
,	I-O
implement	I-O
,	I-O
and	I-O
evaluate	I-O
a	I-O
school-based	I-O
substance	I-O
use	I-O
prevention	I-O
curriculum	I-O
called	I-I
Ho'ouna	I-I
Pono	I-I
.	I-I


In	O
addition	O
to	O
providing	O
a	O
rationale	O
for	O
the	O
project	O
,	O
the	O
goal	O
of	O
this	O
paper	O
is	O
fourfold	O
.	O


First	O
,	O
an	O
overview	O
of	O
the	O
Ho'ouna	B-I
Pono	I-I
research	O
results	O
to	O
date	O
(	O
2007-2013	O
)	O
is	O
provided	O
.	O


Second	O
,	O
within	O
this	O
overview	O
,	O
the	O
ways	O
in	O
which	O
selected	O
results	O
informed	O
program	O
development	O
are	O
highlighted	O
.	O


Third	O
,	O
the	O
curriculum	O
is	O
briefly	O
described	O
,	O
and	O
finally	O
,	O
the	O
role	O
of	O
the	O
students	B-P
and	I-P
community	I-P
in	O
the	O
video	O
production	O
is	O
described	O
.	O


The	O
protective	O
effects	O
of	O
angiotensin	O
II	O
blockade	O
with	O
olmesartan	B-I
medoxomil	I-I
on	O
resistance	O
vessel	O
remodeling	O
(	O
The	O
VIOS	O
study	O
)	O
:	O
rationale	O
and	O
baseline	O
characteristics	O
.	O


BACKGROUND	O
The	O
VIOS	O
(	O
Vascular	O
Improvement	O
with	O
Olmesartan	B-I
medoxomil	I-I
Study	O
)	O
study	O
is	O
a	O
randomized	O
,	O
parallel	O
study	O
to	O
determine	O
the	O
relative	O
effects	O
of	O
suppressing	O
the	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
with	O
the	O
angiotensin	O
receptor	O
antagonist	O
olmesartan	B-I
medoxomil	I-I
versus	O
suppressing	O
sympathetic	O
drive	O
with	O
the	O
beta-adrenoceptor	O
antagonist	O
atenolol	B-I
on	O
remodeling	O
of	O
the	O
subcutaneous	O
small	O
resistance	O
vessel	O
.	O


Remodeling	O
of	O
small	O
resistance	O
vessels	O
may	O
be	O
the	O
earliest	O
pathologic	O
finding	O
associated	O
with	O
hypertension	O
.	O


It	O
may	O
predate	O
the	O
onset	O
of	O
clinically	O
apparent	O
hypertension	O
.	O


METHODS	O
In	O
this	O
study	O
,	O
100	B-P
patients	I-P
with	I-P
stage	I-P
I	I-P
hypertension	I-P
are	I-P
characterized	I-P
at	I-P
baseline	I-P
before	I-P
being	I-P
treated	I-P
for	I-P
1	I-P
year	I-P
to	I-P
obtain	I-P
a	I-P
goal	I-P
BP	I-P
of	I-P
less	I-P
than	I-P
140/90	I-P
mm	I-P
Hg	I-P
as	O
defined	O
by	O
Joint	O
National	O
Committee	O
(	O
JNC	O
)	O
-7	O
.	O


Resistance	O
vessel	O
remodeling	O
is	O
determined	O
using	O
the	O
gluteal	B-I
fat	I-I
biopsy	I-I
technique	I-I
in	O
the	O
hypertensive	O
patients	O
and	O
a	O
group	O
of	O
normotensive	O
healthy	O
volunteers	O
.	O


Additionally	O
,	O
efforts	O
will	O
be	O
made	O
to	O
define	O
whether	O
noninvasive	B-O
hemodynamic	I-O
parameters	I-O
,	I-O
retinal	I-O
vessel	I-O
measurement	I-O
changes	O
,	O
or	O
biologic	B-O
markers	I-O
may	O
predict	O
and	O
track	O
the	O
underlying	O
vascular	B-O
morphologic	I-O
and	I-O
physiologic	I-O
changes	I-O
induced	O
by	O
either	O
regimen	O
during	O
the	O
12-month	O
treatment	O
period	O
.	O


RESULTS	O
The	O
primary	O
endpoint	O
will	O
be	O
the	O
degree	B-O
of	I-O
vascular	I-O
remodeling	I-O
as	I-O
obtained	I-O
from	I-O
percutaneous	I-O
biopsy	I-O
of	I-O
gluteal	I-O
subcutaneous	I-O
resistance	I-O
vessels	I-O
in	O
each	O
of	O
two	O
treatment	O
arms	O
compared	O
with	O
the	O
normal	O
volunteers	O
.	O


The	O
design	O
of	O
the	O
study	O
and	O
the	O
pertinent	O
baseline	O
characteristics	O
of	O
these	O
patients	O
with	O
uncomplicated	O
essential	O
hypertension	O
are	O
presented	O
.	O


CONCLUSION	O
The	O
suppression	O
of	O
the	O
RAS	O
by	O
the	O
blockade	O
of	O
angiotensin	O
II	O
type	O
1	O
(	O
AT	O
(	O
1	O
)	O
)	O
receptors	O
may	O
demonstrate	O
remodeling	O
effects	O
on	O
the	O
ubiquitous	O
small	O
resistance	O
vessels	O
similar	O
to	O
that	O
seen	O
in	O
the	O
myocardium	O
and	O
renal	O
glomeruli	O
,	O
thus	O
affording	O
more	O
complete	O
end-organ	O
protection	O
.	O


In	O
vivo	O
effect	O
of	O
clarithromycin	B-I
on	O
multiple	B-P
cytochrome	I-P
P450s	I-P
.	I-P


The	O
in	O
vivo	O
effects	O
of	O
oral	O
clarithromycin	B-I
administration	O
on	O
the	O
in	O
vivo	O
activity	O
of	O
cytochrome	O
P450	O
1A2	O
,	O
2C9	O
,	O
and	O
2D6	O
were	O
determined	O
.	O


The	O
cytochrome	O
P450	O
probes	O
caffeine	B-I
(	O
CYP1A2	O
)	O
,	O
tolbutamide	B-I
(	O
CYP2C9	O
)	O
,	O
and	O
dextromethorphan	B-I
(	O
CYP2D6	O
)	O
were	O
administered	O
as	O
an	O
oral	O
cocktail	O
prior	O
to	O
and	O
7	O
days	O
after	O
oral	O
clarithromycin	B-I
(	O
500	O
mg	O
twice	O
daily	O
)	O
administration	O
to	O
12	B-P
healthy	I-P
male	I-P
subjects	I-P
.	I-P


Blood	B-O
and	I-O
urine	I-O
samples	I-O
were	O
collected	O
and	O
assayed	O
for	O
each	O
of	O
the	O
compounds	O
and	O
their	O
metabolites	O
using	O
high-performance	O
liquid	O
chromatography	O
.	O


The	O
CYP1A2	B-O
indices	I-O
,	I-O
oral	I-O
caffeine	I-O
clearance	I-O
(	O
6.2	O
+/-	O
3.3	O
l/h	O
before	O
and	O
5.7	O
+/-	O
4.2	O
l/h	O
after	O
,	O
p	O
>	O
0.05	O
)	O
and	O
the	O
6-h	B-O
paraxanthine	I-O
to	I-O
caffeine	I-O
serum	I-O
concentration	I-O
ratio	I-O
(	O
0.49	O
+/-	O
0.3	O
before	O
and	O
0.44	O
+/-	O
0.3	O
after	O
,	O
p	O
>	O
0.05	O
)	O
,	O
were	O
unchanged	B-O
following	O
clarithromycin	O
dosing	O
.	O


Neither	O
the	O
tolbutamide	B-O
oral	I-O
clearance	I-O
(	O
0.77	O
+/-	O
0.28	O
l/h	O
before	O
and	O
0.72	O
+/-0.24	O
l/h	O
after	O
,	O
p	O
>	O
0.05	O
)	O
nor	O
the	O
tolbutamide	B-O
urinary	I-O
metabolic	I-O
ratio	I-O
(	O
779	O
+/-	O
294	O
before	O
and	O
681	O
+/-	O
416	O
after	O
,	O
p	O
>	O
0.05	O
)	O
indices	O
of	O
CYP2C9	O
were	O
altered	O
by	O
clarithromycin	B-I
administration	O
.	O


In	O
the	O
case	O
of	O
CYP2D6	O
,	O
the	O
dextromethorphan	B-O
to	I-O
dextrorphan	I-O
urinary	I-O
ratio	I-O
was	O
not	O
significantly	B-O
different	I-O
before	O
(	O
0.021	O
+/-	O
0.04	O
)	O
and	O
after	O
(	O
0.024	O
+/-	O
0.06	O
)	O
clarithromycin	B-I
dosing	O
.	O


In	O
conclusion	O
,	O
clarithromycin	B-I
does	O
not	O
appear	O
to	O
alter	O
the	O
in	O
vivo	B-O
catalytic	I-O
activity	I-O
of	O
CYP1A2	O
,	O
CYP2C9	O
,	O
and	O
CYP2D6	O
in	O
healthy	O
individuals	O
as	O
assessed	O
by	O
caffeine	O
,	O
tolbutamide	O
,	O
and	O
dextromethorphan	O
,	O
respectively	O
.	O


Influence	O
of	O
infusion	B-P
time	I-P
on	O
the	O
acute	B-O
toxicity	I-O
of	I-O
amphotericin	I-O
B	I-O
:	I-O
results	O
of	O
a	O
randomized	O
double-blind	O
study	O
.	O


The	O
lunar	B-I
stent	I-I
characteristics	O
and	O
clinical	O
results	O
.	O


One	O
of	O
the	O
frequent	O
long-term	O
complications	O
after	O
stent	B-I
implantation	I-I
is	O
restenosis	O
due	O
to	O
the	O
building	O
up	O
of	O
a	O
neointima	O
within	O
the	O
artery	O
,	O
as	O
well	O
as	O
endovascular	O
hyperplasia	O
(	O
tissue	O
growth	O
)	O
.	O


The	O
interesting	O
feature	O
of	O
the	O
Lunar	B-I
stent	I-I
from	I-I
Inflow	I-I
Dynamics	I-I
is	O
that	O
it	O
is	O
coated	O
with	O
a	O
layer	O
of	O
iridium	O
oxide	O
.	O


The	O
iridium	B-I
oxide	I-I
coating	O
is	O
believed	O
to	O
reduce	O
restenosis	B-O
by	O
decreasing	O
the	O
inflammatory	B-O
response	I-O
to	O
the	O
stent	O
via	O
its	O
antioxidant	O
action	O
.	O


The	O
MOONLIGHT	B-P
(	I-P
Multicenter	I-P
Objective	I-P
ObservatioNal	I-P
Lunar	I-I
Iridiumoxide	I-I
intimal	I-P
GrowtH	I-P
Trial	I-P
)	I-P
study	I-P
was	O
carried	O
out	O
to	O
evaluate	O
the	O
immediate	O
outcome	O
and	O
long-term	O
angiographic	O
success	O
after	O
implantation	B-I
of	I-I
Lunar	I-I
stents	I-I
.	I-I


Between	B-P
March	I-P
2001	I-P
and	I-P
November	I-P
2001	I-P
,	I-P
87	I-P
patients	I-P
with	I-P
99	I-P
lesions	I-P
were	I-P
enrolled	I-P
in	I-P
this	I-P
study	I-P
and	O
were	O
treated	O
with	O
12	O
and	O
16	O
mm	O
long	O
iridium-oxide	B-I
coated	I-I
Lunar	I-I
stents	I-I
.	I-I


Delivery	O
of	O
the	O
Lunar	B-I
stent	I-I
was	O
successful	O
in	O
most	O
lesions	O
and	O
the	O
optimal	O
radiopacity	O
facilitated	O
optimal	O
stent	B-O
positioning	I-O
with	O
optimal	O
immediate	O
clinical	O
and	O
angiographic	O
results	O
is	O
an	O
unselected	O
patient	O
and	O
lesion	O
population	O
.	O


Preliminary	O
clinical	O
and	O
angiographic	O
follow-up	O
show	O
a	O
low	O
rate	B-O
of	I-O
cardiac	I-O
events	I-O
at	O
6	O
months	O
(	O
16.1	O
%	O
MACE	O
)	O
and	O
a	O
moderate	O
hyperplastic	B-O
response	I-O
.	I-O


Intravesical	B-I
seeding	I-I
of	I-I
upper	I-I
urinary	I-I
tract	I-I
urothelial	I-I
carcinoma	I-I
cells	I-I
during	O
nephroureterectomy	B-I
:	I-I
an	O
exploratory	O
analysis	O
from	O
the	O
THPMG	O
trial	O
.	O


OBJECTIVE	O
The	O
Pirarubicin	O
Monotherapy	O
Study	O
Group	O
trial	O
was	O
a	O
randomized	O
Phase	O
II	O
study	O
that	O
evaluated	O
the	O
efficacy	O
of	O
intravesical	O
instillation	O
of	O
pirarubicin	B-I
in	O
the	O
prevention	O
of	O
bladder	O
recurrence	O
after	O
nephroureterectomy	B-P
for	I-P
upper	I-P
urinary	I-P
tract	I-P
urothelial	I-P
carcinoma	I-P
.	I-P


This	O
study	O
conducted	O
further	O
analysis	O
of	O
the	O
Pirarubicin	O
Monotherapy	O
Study	O
Group	O
cohort	O
,	O
focusing	O
on	O
intravesical	B-I
seeding	I-I
of	I-I
cancer	I-I
cells	I-I
.	I-I


METHODS	O
Using	O
the	O
data	B-P
from	I-P
the	I-P
Pirarubicin	I-P
Monotherapy	I-P
Study	I-P
Group	I-P
trial	I-P
,	O
bladder	B-O
recurrence-free	I-O
survival	I-O
rates	I-O
and	I-O
factors	I-O
associated	I-O
with	I-O
bladder	I-O
recurrence	I-O
in	O
the	O
control	O
group	O
were	O
analyzed	O
.	O


RESULTS	O
Of	O
36	B-P
patients	I-P
in	I-P
the	I-P
control	I-I
group	I-P
,	I-P
14	I-P
with	I-P
positive	I-O
urine	I-O
cytology	I-O
had	O
more	O
frequent	O
recurrence	B-O
when	O
compared	O
with	O
the	O
22	B-P
patients	I-P
with	I-P
negative	I-P
cytology	I-P
(	I-P
P	I-P
=	I-P
0.004	I-P
)	I-P
.	I-P


Based	O
on	O
the	O
multivariate	O
analysis	O
in	O
the	O
control	O
group	O
,	O
voided	O
urine	O
cytology	O
was	O
an	O
independent	O
predictive	O
factor	O
of	O
bladder	O
recurrence	O
(	O
hazard	O
ratio	O
,	O
5.54	O
;	O
95	O
%	O
confidence	O
interval	O
1.12-27.5	O
;	O
P	O
=	O
0.036	O
)	O
.	O


Of	O
72	B-P
patients	I-P
in	I-P
the	I-P
Pirarubicin	I-P
Monotherapy	I-P
Study	I-P
Group	I-P
trial	I-P
,	O
31	O
had	O
positive	O
urine	B-O
cytology	I-O
.	I-O


Among	B-P
the	I-P
31	I-P
patients	I-P
,	I-P
17	I-P
patients	I-P
who	I-P
received	I-P
pirarubicin	I-I
instillation	I-I
had	O
fewer	O
recurrences	B-O
when	O
compared	O
with	O
14	B-P
patients	I-P
who	I-P
received	I-P
control	I-I
treatment	I-P
(	O
P	O
=	O
0.0001	O
)	O
.	O


On	O
multivariate	O
analysis	O
,	O
pirarubicin	B-I
instillation	I-I
was	O
an	O
independent	O
predictor	O
of	O
better	O
recurrence-free	B-O
survival	I-O
rates	I-O
in	O
the	O
patients	O
with	O
positive	O
urine	O
cytology	O
(	O
hazard	O
ratio	O
,	O
0.02	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.00-0.53	O
;	O
P	O
=	O
0.018	O
)	O
.	O


Of	O
21	O
patients	O
with	O
bladder	O
recurrence	O
,	O
17	O
had	O
recurrent	B-O
tumor	I-O
around	I-O
cystotomy	I-O
or	I-O
in	I-O
the	I-O
bladder	I-O
neck	I-O
compromised	O
by	O
the	O
urethral	O
catheter	O
,	O
supporting	O
the	O
notion	O
that	O
tumor	O
cells	O
seeded	O
in	O
the	O
injured	O
urothelium	O
.	O


CONCLUSIONS	O
Intravesical	B-I
instillation	I-I
of	I-I
pirarubicin	I-I
immediately	O
after	O
nephroureterectomy	B-I
significantly	O
reduced	O
the	O
bladder	B-O
recurrence	I-O
rate	I-O
in	O
patients	O
with	O
positive	O
voided	O
urine	O
cytology	O
.	O


The	O
results	O
suggest	O
that	O
intravesical	O
seeding	O
of	O
upper	O
urinary	O
tract	O
urothelial	O
carcinoma	O
occurs	O
during	O
nephroureterectomy	O
.	O


Dexamethasone	B-I
versus	I-I
prednisone	I-I
and	O
daily	O
oral	O
versus	O
weekly	O
intravenous	B-I
mercaptopurine	I-I
for	O
patients	B-P
with	I-P
standard-risk	I-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
:	I-P
a	O
report	O
from	O
the	O
Children	O
's	O
Cancer	O
Group	O
.	O


Conventional	B-I
therapy	I-I
for	O
childhood	B-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
(	I-P
ALL	I-P
)	I-P
includes	O
prednisone	B-I
and	I-I
oral	I-I
6-mercaptopurine	I-I
.	I-I


Prior	O
observations	O
suggested	O
potential	O
advantages	O
for	O
dexamethasone	B-I
over	I-I
prednisone	I-I
and	I-I
for	I-I
intravenous	I-I
(	I-I
IV	I-I
)	I-I
over	I-I
oral	I-I
6-mercaptopurine	I-I
,	O
which	O
remain	O
to	O
be	O
validated	O
.	O


We	O
report	O
the	O
results	O
of	O
a	O
randomized	O
trial	O
of	O
more	B-P
than	I-P
1000	I-P
subjects	I-P
that	O
examined	O
the	O
efficacy	B-O
of	O
dexamethasone	B-I
and	I-I
IV	I-I
6-mercaptopurine	I-I
.	I-I


Children	B-P
with	I-P
National	I-P
Cancer	I-P
Institute	I-P
standard-risk	I-P
ALL	I-P
were	O
randomly	O
assigned	O
in	O
a	O
2	O
x	O
2	O
factorial	O
design	O
to	O
receive	O
dexamethasone	B-I
(	O
6	O
mg/m	O
(	O
2	O
)	O
/d	O
)	O
for	O
28	O
days	O
in	O
induction	O
,	O
plus	B-I
taper	I-I
,	O
compared	O
with	O
prednisone	B-I
(	O
40	O
mg/m	O
(	O
2	O
)	O
/d	O
)	O
.	O


The	O
second	O
randomized	O
assignment	O
was	O
for	O
daily	O
oral	O
or	O
weekly	O
IV	B-I
6-mercaptopurine	I-I
during	O
consolidation	O
.	O


During	O
maintenance	O
,	O
5	O
days	O
of	O
the	O
randomized	O
steroid	O
was	O
given	O
monthly	O
,	O
at	O
the	O
same	O
dose	O
,	O
and	O
all	O
patients	O
received	O
daily	O
oral	B-I
6-mercaptopurine	I-I
.	I-I


During	O
delayed	O
intensification	O
,	O
all	O
patients	O
received	O
a	O
dexamethasone	B-I
dosage	O
of	O
10	O
mg/m	O
(	O
2	O
)	O
/d	O
for	O
21	O
days	O
,	O
with	B-I
taper	I-I
.	I-I


Intrathecal	B-I
(	I-I
IT	I-I
)	I-I
methotrexate	I-I
was	O
the	O
sole	O
central	O
nervous	O
system-directed	O
therapy	O
.	O


Patients	O
randomly	O
assigned	O
to	O
receive	O
dexamethasone	B-I
had	O
a	O
6-year	B-O
isolated	I-O
central	I-O
nervous	I-O
system-relapse	I-O
rate	I-O
of	O
3.7	O
%	O
+/-	O
0.8	O
%	O
,	O
compared	O
with	O
7.1	O
%	O
+/-	O
1.1	O
%	O
for	O
prednisone	B-I
(	O
P	O
=.01	O
)	O
.	O


There	O
was	O
also	O
a	O
trend	O
toward	O
fewer	O
isolated	B-O
bone	I-O
marrow	I-O
relapses	I-O
with	O
dexamethasone	B-I
.	I-I


The	O
6-year	B-O
event-free	I-O
survival	I-O
(	I-O
EFS	I-O
)	I-O
was	O
85	O
%	O
+/-	O
2	O
%	O
for	O
dexamethasone	B-I
and	O
77	O
%	O
+/-	O
2	O
%	O
for	O
prednisone	B-I
(	O
P	O
=.002	O
)	O
.	O


EFS	O
was	O
similar	O
with	O
oral	B-I
or	I-I
IV	I-I
6-mercaptopurine	I-I
;	I-I
however	O
,	O
patients	O
assigned	O
to	O
IV	B-I
6-mercaptopurine	I-I
had	O
decreased	O
survival	B-O
after	I-O
relapse	I-O
.	I-O


Psychological	B-I
adjustment	I-I
and	I-I
levels	I-I
of	I-I
self	I-I
esteem	I-I
in	O
children	B-P
with	I-P
visual-motor	I-P
integration	I-P
difficulties	I-P
influences	O
the	O
results	O
of	O
a	O
randomized	O
intervention	O
trial	O
.	O


This	O
study	O
evaluates	O
how	O
much	O
the	O
effects	O
of	O
intervention	O
programs	O
are	O
influenced	O
by	O
pre-existing	B-P
psychological	I-P
adjustment	I-P
and	I-P
self-esteem	I-P
levels	I-P
in	I-P
kindergarten	I-P
and	I-P
first	I-P
grade	I-P
children	I-P
with	I-P
poor	I-P
visual-motor	I-P
integration	I-P
skills	I-P
,	I-P
from	I-P
low	I-P
socioeconomic	I-P
backgrounds	I-P
.	I-P


One	B-P
hundred	I-P
and	I-P
sixteen	I-P
mainstream	I-P
kindergarten	I-P
and	I-P
first-grade	I-P
children	I-P
,	I-P
from	I-P
low	I-P
socioeconomic	I-P
backgrounds	I-P
,	I-P
scoring	I-P
below	I-P
the	I-P
25th	I-P
percentile	I-P
on	I-P
a	I-P
measure	I-P
of	I-P
visual-motor	I-P
integration	I-P
(	I-P
VMI	I-P
)	I-P
were	I-P
recruited	I-P
and	O
randomly	O
divided	O
into	O
two	O
parallel	O
intervention	O
groups	O
.	O


One	O
intervention	O
group	O
received	O
directive	B-I
visual-motor	I-I
intervention	I-I
(	I-I
DVMI	I-I
)	I-I
,	O
while	O
the	O
second	O
intervention	O
group	O
received	O
a	O
non-directive	B-I
supportive	I-I
intervention	I-I
(	I-I
NDSI	I-I
)	I-I
.	I-I


Tests	O
were	O
administered	O
to	O
evaluate	O
visual-motor	O
integration	O
skills	O
outcome	O
.	O


Children	O
with	O
higher	O
baseline	O
measures	O
of	O
psychological	O
adjustment	O
and	O
self-esteem	O
responded	O
better	O
in	O
NDSI	B-I
while	O
children	O
with	O
lower	O
baseline	O
performance	O
on	O
psychological	O
adjustment	O
and	O
self-esteem	O
responded	O
better	O
in	O
DVMI	B-I
.	I-I


This	O
study	O
suggests	O
that	O
children	O
from	O
low	O
socioeconomic	O
backgrounds	O
with	O
low	O
VMI	O
performance	O
scores	O
will	O
benefit	O
more	O
from	O
intervention	O
programs	O
if	O
clinicians	O
choose	O
the	O
type	O
of	O
intervention	O
according	O
to	O
baseline	O
psychological	O
adjustment	O
and	O
self-esteem	O
measures	O
.	O


Absolute	O
bioavailability	O
of	O
a	O
new	O
high	O
dose	O
methylprednisolone	B-I
tablet	O
formulation	O
.	O


This	O
was	O
a	O
single-blind	O
,	O
single-dose	O
,	O
randomized	O
crossover	O
study	O
to	O
determine	O
the	O
absolute	B-O
bioavailability	I-O
of	O
Medrol	B-I
,	O
a	O
new	O
high	O
dose	O
(	O
100	O
mg	O
)	O
methylprednisolone	B-I
tablet	O
product	O
,	O
by	O
comparing	O
it	O
with	O
100	O
mg	O
methylprednisolone	B-I
from	O
an	O
intravenous	O
formulation	O
,	O
Solu-Medrol	B-I
.	I-I


Fourteen	B-P
healthy	I-P
,	I-P
non-smoking	I-P
,	I-P
Caucasian	I-P
male	I-P
volunteers	I-P
took	O
part	O
.	O


On	O
treatment	O
days	O
volunteers	O
remained	O
recumbent	O
for	O
4	O
hours	O
after	O
drug	O
administration	O
,	O
with	O
food	O
and	O
fluid	O
intake	O
standardized	O
over	O
this	O
period	O
.	O


Serial	O
blood	O
samples	O
were	O
drawn	O
over	O
a	O
14-hour	O
period	O
after	O
drug	O
administration	O
.	O


Plasma	B-O
methylprednisolone	I-O
concentrations	I-O
were	O
determined	O
by	O
high	O
performance	O
liquid	O
chromatography	O
.	O


The	O
geometric	O
means	O
of	O
AUCi.v	B-O
.	I-O


and	B-O
AUCtablet	I-O
were	O
4,049	O
and	O
3,334	O
ng.h/ml	O
,	O
respectively	O
.	O


The	O
absolute	B-O
bioavailability	I-O
of	O
the	O
tablet	O
product	O
was	O
82	O
%	O
,	O
which	O
is	O
in	O
agreement	O
with	O
published	O
data	O
for	O
other	O
oral	O
dosage	O
forms	O
of	O
methylprednisolone	B-I
.	I-I


Volunteers	O
displayed	O
the	O
expected	O
rise	O
in	O
peripheral	B-O
blood	I-O
neutrophil	I-O
count	I-O
,	O
but	O
no	O
other	O
clinically	B-O
relevant	I-O
changes	I-O
in	I-O
hematology	I-O
or	I-O
clinical	I-O
chemistry	I-O
were	O
observed	O
.	O


No	O
adverse	B-O
drug	I-O
reactions	I-O
were	O
recorded	O
.	O


It	O
is	O
concluded	O
that	O
the	O
tablet	O
product	O
can	O
be	O
used	O
as	O
a	O
substitute	O
for	O
parenteral	O
methylprednisolone	B-I
in	O
situations	O
requiring	O
high-dose	O
therapy	O
.	O


Oxytocin	B-I
increases	O
eye	B-O
contact	I-O
during	O
a	O
real-time	O
,	O
naturalistic	O
social	O
interaction	O
in	O
males	B-P
with	I-P
and	I-P
without	I-P
autism	I-P
.	I-P


Autism	B-P
spectrum	I-P
conditions	I-P
(	I-P
autism	I-P
)	I-P
affect	O
~1	O
%	O
of	O
the	O
population	O
and	O
are	O
characterized	O
by	O
deficits	O
in	O
social	O
communication	O
.	O


Oxytocin	B-I
has	O
been	O
widely	O
reported	O
to	O
affect	O
social-communicative	O
function	O
and	O
its	O
neural	O
underpinnings	O
.	O


Here	O
we	O
report	O
the	O
first	O
evidence	O
that	O
intranasal	B-I
oxytocin	I-I
administration	O
improves	O
a	O
core	O
problem	O
that	O
individuals	B-P
with	I-P
autism	I-P
have	O
in	O
using	B-O
eye	I-O
contact	I-O
appropriately	O
in	O
real-world	O
social	O
settings	O
.	O


A	O
randomized	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
within-subjects	O
design	O
is	O
used	O
to	O
examine	O
how	O
intranasal	O
administration	O
of	O
24	B-I
IU	I-I
of	I-I
oxytocin	I-I
affects	I-O
gaze	I-O
behavior	I-O
for	I-P
32	I-P
adult	I-P
males	I-P
with	I-P
autism	I-P
and	I-P
34	I-P
controls	I-P
in	I-P
a	I-P
real-time	I-P
interaction	I-P
with	O
a	O
researcher	O
.	O


This	O
interactive	O
paradigm	O
bypasses	O
many	O
of	O
the	O
limitations	O
encountered	O
with	O
conventional	O
static	O
or	O
computer-based	O
stimuli	B-O
.	I-O


Eye	B-O
movements	I-O
are	O
recorded	O
using	O
eye	O
tracking	O
,	O
providing	O
an	O
objective	O
measurement	O
of	O
looking	O
patterns	O
.	O


The	O
measure	O
is	O
shown	O
to	O
be	O
sensitive	O
to	O
the	O
reduced	B-O
eye	I-O
contact	I-O
commonly	O
reported	O
in	O
autism	O
,	O
with	O
the	O
autism	O
group	O
spending	O
less	O
time	O
looking	O
to	O
the	O
eye	O
region	O
of	O
the	O
face	O
than	O
controls	B-I
.	I-I


Oxytocin	B-I
administration	O
selectively	O
enhanced	B-O
gaze	I-O
to	I-O
the	I-O
eyes	I-O
in	O
both	O
the	O
autism	O
and	O
control	O
groups	O
(	O
transformed	O
mean	B-O
eye-fixation	I-O
difference	I-O
per	I-O
second=0.082	I-O
;	I-O
95	O
%	O
CI:0.025-0.14	O
,	O
P=0.006	O
)	O
.	O


Within	O
the	O
autism	O
group	O
,	O
oxytocin	O
has	O
the	O
most	O
effect	O
on	B-O
fixation	I-O
duration	I-O
in	O
individuals	O
with	O
impaired	O
levels	O
of	B-O
eye	I-O
contact	I-O
at	O
baseline	O
(	O
Cohen	O
's	O
d=0.86	O
)	O
.	O


These	O
findings	O
demonstrate	O
that	O
the	O
potential	O
benefits	O
of	O
oxytocin	O
in	O
autism	O
extend	O
to	O
a	O
real-time	O
interaction	O
,	O
providing	O
evidence	O
of	O
a	O
therapeutic	O
effect	O
in	O
a	O
key	O
aspect	O
of	O
social	O
communication	O
.	O


Brain	O
mechanisms	O
of	O
expectation	O
associated	O
with	O
insula	B-P
and	I-P
amygdala	I-P
response	O
to	O
aversive	O
taste	O
:	O
implications	O
for	O
placebo	B-I
.	I-I


The	O
experience	O
of	O
aversion	O
is	O
shaped	O
by	O
multiple	O
physiological	O
and	O
psychological	O
factors	O
including	O
one	O
's	O
expectations	O
.	O


Recent	O
work	O
has	O
shown	O
that	O
expectancy	O
manipulation	O
can	O
alter	O
perceptions	O
of	O
aversive	O
events	O
and	O
concomitant	O
brain	O
activation	O
.	O


Accruing	O
evidence	O
indicates	O
a	O
primary	O
role	O
of	O
altered	O
expectancies	O
in	O
the	O
placebo	B-I
effect	O
.	O


Here	O
,	O
we	O
probed	O
the	O
mechanism	O
by	O
which	O
expectation	O
attenuates	O
sensory	O
taste	O
transmission	O
by	O
examining	O
how	O
brain	B-P
areas	I-P
activated	I-P
by	I-P
misleading	I-I
information	I-I
during	I-P
an	I-P
expectancy	I-P
period	I-P
modulate	O
insula	O
and	O
amygdala	O
activation	O
to	O
a	O
highly	B-I
aversive	I-I
bitter	I-I
taste	I-I
.	I-I


In	O
a	O
rapid	O
event-related	O
fMRI	B-I
design	I-I
,	O
we	O
showed	O
that	O
activations	O
in	O
the	O
rostral	B-P
anterior	I-P
cingulate	I-P
cortex	I-P
(	I-P
rACC	I-P
)	I-P
,	I-P
orbitofrontal	I-P
cortex	I-P
(	I-P
OFC	I-P
)	I-P
,	I-P
and	I-P
dorsolateral	I-P
prefrontal	I-P
cortex	I-P
to	O
a	O
misleading	O
cue	O
that	O
the	O
taste	O
would	O
be	O
mildly	O
aversive	O
predicted	O
decreases	O
in	O
insula	B-O
and	I-O
amygdala	I-O
activation	I-O
to	O
the	O
highly	O
aversive	O
taste	O
.	O


OFC	O
and	O
rACC	O
activation	O
to	O
the	O
misleading	B-I
cue	I-I
were	O
also	O
associated	O
with	O
less	O
aversive	B-O
ratings	I-O
of	I-O
that	I-O
taste	I-O
.	I-O


Additional	O
analyses	O
revealed	O
consistent	O
results	O
demonstrating	O
functional	O
connectivity	O
among	O
the	O
OFC	O
,	O
rACC	O
,	O
and	O
insula	O
.	O


Altering	O
expectancies	O
of	O
upcoming	O
aversive	O
events	O
are	O
shown	O
here	O
to	O
depend	O
on	O
robust	O
functional	O
associations	O
among	O
brain	O
regions	O
implicated	O
in	O
prior	O
work	O
on	O
the	O
placebo	O
effect	O
.	O


Randomized	O
controlled	O
trial	O
to	O
compare	O
the	O
early	O
and	O
mid-term	O
results	O
of	O
stapled	B-I
versus	I-I
open	I-I
hemorrhoidectomy	I-I
.	I-I


BACKGROUND	O
The	O
new	O
technique	O
of	O
circular	O
stapler	O
for	O
the	O
treatment	O
of	O
hemorrhoids	B-P
has	O
shown	O
early	O
promise	O
in	O
terms	O
of	O
minimal	O
or	O
no	O
postoperative	O
pain	O
,	O
early	O
discharge	O
from	O
hospital	O
,	O
and	O
quick	O
return	O
to	O
work	O
.	O


This	O
study	O
was	O
designed	O
to	O
compare	O
stapled	B-I
technique	I-I
with	I-I
the	I-I
well-accepted	I-I
conventional	I-I
Milligan	I-I
Morgan	I-I
hemorrhoidectomy	I-I
.	I-I


METHODS	O
After	O
fulfilling	O
the	O
selection	O
criteria	O
,	O
84	B-P
patients	I-P
were	I-P
randomly	I-P
allocated	I-P
to	I-P
the	I-P
stapled	I-I
(	I-P
n	I-P
=	I-P
42	I-P
)	I-P
or	I-P
open	I-I
group	I-P
(	I-P
n	I-P
=	I-P
42	I-P
)	I-P
.	I-P


All	B-P
patients	I-P
were	I-P
operated	I-P
on	I-P
under	I-P
spinal	I-I
anesthesia	I-I
.	I-I


The	O
2	O
techniques	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
operative	B-O
time	I-O
,	I-O
pain	I-O
scores	I-O
,	I-O
complications	I-O
,	I-O
day	I-O
of	I-O
discharge	I-O
,	I-O
return	I-O
to	I-O
work	I-O
,	I-O
and	I-O
level	I-O
of	I-O
satisfaction	I-O
.	I-O


RESULTS	O
The	O
mean	B-P
age	I-P
of	I-P
patients	I-P
was	I-P
46.02	I-P
years	I-P
(	I-P
SD	I-P
,	I-P
12.33	I-P
)	I-P
in	I-P
the	I-P
stapled	I-P
group	I-P
and	I-P
48.64	I-P
years	I-P
(	I-P
14.57	I-P
)	I-P
in	I-P
the	I-P
open	I-P
group	I-P
.	I-P


Grade	B-O
III	I-O
or	I-O
IV	I-O
hemorrhoids	I-O
were	I-P
more	I-P
common	I-P
in	I-P
men	I-P
(	I-P
ie	I-P
,	I-P
80.9	I-P
%	I-P
and	I-P
85.7	I-P
%	I-P
in	I-P
the	I-P
stapled	I-P
and	I-P
open	I-P
group	I-P
,	I-P
respectively	I-P
)	I-P
.	I-P


The	O
mean	B-O
operative	I-O
time	I-O
was	O
shorter	O
in	O
the	O
stapled	O
group	O
24.28	O
minutes	O
(	O
4.25	O
)	O
versus	O
45.21	O
minutes	O
(	O
5.36	O
)	O
in	O
the	O
Milligan-Morgan	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O


The	O
blood	B-O
loss	I-O
,	I-O
pain	I-O
scores	I-O
and	I-O
requirement	I-O
of	I-O
analgesics	I-O
was	O
significantly	O
less	O
in	O
the	O
stapled	O
group	O
.	O


Mean	B-O
hospital	I-O
stay	I-O
was	O
1.24	O
days	O
(	O
0.62	O
)	O
and	O
2.76	O
days	O
(	O
1.01	O
)	O
(	O
P	O
<	O
.001	O
)	O
in	O
the	O
stapled	O
and	O
open	O
group	O
,	O
respectively	O
.	O


The	O
patients	O
in	O
the	O
stapled	O
group	O
returned	B-O
to	I-O
work	I-O
or	I-O
routine	I-O
activities	I-O
earlier	O
(	O
ie	O
,	O
within	O
8.12	O
days	O
[	O
2.48	O
]	O
)	O
as	O
compared	O
with	O
17.62	O
(	O
5.59	O
)	O
in	O
the	O
open	O
group	O
.	O


Only	O
88.1	O
%	O
of	O
patients	O
were	O
satisfied	B-O
by	O
the	O
open	O
method	O
compared	O
with	O
97.6	O
%	O
after	O
the	O
stapled	O
technique	O
.	O


The	O
median	O
follow-up	O
period	O
was	O
11	O
months	O
with	O
a	O
maximum	O
follow-up	O
of	O
19	O
months	O
(	O
range	O
2-19	O
months	O
)	O
.	O


CONCLUSIONS	O
Stapled	B-I
hemorrhoidectomy	I-I
is	O
a	O
safe	B-O
and	I-O
effective	I-O
day-care	O
procedure	O
for	O
the	O
treatment	O
of	O
grade	B-P
III	I-P
and	I-P
grade	I-P
IV	I-P
hemorrhoids	I-P
.	I-P


It	O
ensures	O
lesser	O
postoperative	B-O
pain	I-O
,	I-O
early	I-O
discharge	I-O
,	I-O
less	I-O
time	I-O
off	I-O
work	I-O
,	I-O
complications	I-O
similar	O
to	O
the	O
open	O
technique	O
,	O
and	O
in	O
the	O
end	O
a	O
more	O
satisfied	B-O
patient	I-O
with	O
no	O
perianal	O
wound	O
.	O


However	O
,	O
more	O
such	O
randomized	O
trials	O
are	O
essential	O
to	O
deny	O
any	O
long-term	O
complication	O
.	O


[	O
Clinical	O
study	O
on	O
dan	B-I
shao	I-I
tang	I-I
in	O
treating	O
IgA	O
nephropathy	O
of	O
deficiency	O
of	O
yin	O
with	O
damp-heat	O
symptom	O
]	O
.	O


OBJECTIVE	O
To	O
explore	O
the	O
effect	O
of	O
Dan	B-I
Shao	I-I
Tang	I-I
(	I-I
DST	I-I
)	I-I
in	O
treating	O
IgA	O
nephropathy	O
(	O
IgAN	O
)	O
of	O
deficiency	O
of	O
Yin	O
with	O
damp-heat	O
symptom	O
.	O


METHODS	O
90	B-P
patients	I-P
with	I-P
IgAN	I-P
of	I-P
deficiency	I-P
of	I-P
Yin	I-P
with	I-P
damp-heat	I-P
symptom	I-P
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O


50	O
patients	O
in	O
treatment	O
group	O
were	O
treated	O
with	O
DST	B-I
and	I-I
western	I-I
medicine	I-I
and	O
40	O
patients	O
in	O
control	O
group	O
were	O
treated	O
only	B-I
with	I-I
western	I-I
medicine	I-I
.	I-I


The	O
effects	O
and	O
changes	O
of	O
the	O
indexes	O
including	O
renal	B-O
function	I-O
,	I-O
hematuria	I-O
,	I-O
proteinuria	I-O
,	I-O
blood	I-O
IgA	I-O
before	O
and	O
after	O
treatment	O
were	O
observed	O
.	O


RESULTS	O
After	O
six	O
months	O
treatment	O
,	O
the	O
general	B-O
effective	I-O
rate	I-O
in	O
treatment	O
group	O
was	O
70.00	O
%	O
,	O
which	O
was	O
markedly	O
higher	O
than	O
that	O
in	O
control	O
group	O
(	O
37.50	O
%	O
,	O
P	O
<	O
0.01	O
)	O
.	O


Treatment	O
group	O
is	O
obviously	O
better	O
than	O
control	O
group	O
on	O
decreasing	B-O
hematuria	I-O
,	I-O
proteinuria	I-O
,	I-O
blood	I-O
IgA	I-O
and	I-O
improving	I-O
renal	I-O
function	I-O
(	I-O
P	I-O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
DST	B-I
is	O
effective	O
on	O
IgAN	O
of	O
deficiency	O
of	O
Yin	O
with	O
damp-heat	O
symptom	O
.	O


Multicenter	O
randomized	O
phase	O
2	O
clinical	O
trial	O
of	O
a	O
recombinant	B-I
human	I-I
endostatin	I-I
adenovirus	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
head	I-P
and	I-P
neck	I-P
carcinoma	I-P
.	I-P


A	O
randomized	O
,	O
open-label	O
,	O
phase	O
2	O
,	O
multicenter	O
clinical	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
the	O
addition	O
of	O
a	O
recombinant	B-I
human	I-I
endostatin	I-I
adenovirus	I-I
(	I-I
E10A	I-I
)	I-I
to	I-I
cisplatin	I-I
and	I-I
paclitaxel	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
head	I-P
and	I-P
neck	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
or	I-P
nasopharyngeal	I-P
carcinoma	I-P
.	I-P


Patients	B-P
with	I-P
locally	I-P
advanced	I-P
or	I-P
metastatic	I-P
head	I-P
and	I-P
neck	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
or	I-P
nasopharyngeal	I-P
carcinoma	I-P
not	I-P
suitable	I-P
for	I-P
operation	I-P
or	I-P
radiotherapy	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
E10A	B-I
plus	I-I
chemotherapy	I-I
every	O
3	O
weeks	O
for	O
a	O
maximum	O
of	O
six	O
cycles	O
or	O
to	O
receive	O
chemotherapy	B-I
only	I-I
.	I-I


One	B-P
hundred	I-P
and	I-P
thirty-six	I-P
eligible	I-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
.	I-P


The	O
addition	O
of	O
E10A	O
did	O
not	O
significantly	O
improve	O
the	O
objective	B-O
response	I-O
rate	I-O
(	O
29.9	O
versus	O
39.7	O
%	O
,	O
P	O
=	O
0.154	O
)	O
.	O


However	O
,	O
patients	O
who	O
received	O
endostatin	O
had	O
longer	O
progression-free	B-O
survival	I-O
(	O
7.03	O
versus	O
3.60	O
months	O
,	O
P	O
=	O
0.006	O
;	O
hazard	O
ratio	O
:	O
0.55	O
)	O
.	O


The	O
combination	O
of	O
E10A	O
with	O
chemotherapy	O
benefited	O
prior	O
chemotherapy-treated	O
patients	O
and	O
those	O
who	O
received	O
three	O
to	O
four	O
treatment	O
cycles	O
(	O
6.50	O
versus	O
3.43	O
months	O
,	O
P	O
=	O
0.003	O
;	O
8.27	O
versus	O
4.27	O
months	O
,	O
P	O
=	O
0.018	O
;	O
respectively	O
)	O
.	O


The	O
overall	B-O
disease	I-O
control	I-O
rate	I-O
significantly	O
increased	O
from	O
80.6	O
%	O
in	O
the	O
control	O
group	O
to	O
92.6	O
%	O
in	O
the	O
test	O
group	O
(	O
P	O
=	O
0.034	O
)	O
.	O


Except	O
for	O
fever	B-O
,	I-O
no	I-O
adverse	I-O
events	I-O
were	O
associated	O
with	O
the	O
E10A	O
treatment	O
.	O


In	O
summary	O
,	O
E10A	O
plus	O
chemotherapy	O
is	O
a	O
safe	B-O
and	I-O
effective	I-O
therapeutic	I-O
approach	I-O
in	O
patients	B-P
with	I-P
advanced	I-P
head	I-P
and	I-P
neck	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
or	I-P
nasopharyngeal	I-P
carcinoma	I-P
.	I-P


Correlation	O
of	O
quantitative	O
measures	O
with	O
the	O
modified	B-I
Ashworth	I-I
scale	I-I
in	O
the	O
assessment	O
of	O
plantar	B-P
flexor	I-P
spasticity	I-P
in	I-P
patients	I-P
with	I-P
traumatic	I-P
brain	I-P
injury	I-P
.	I-P


This	O
study	O
of	O
plantar	O
flexor	O
spasticity	O
describes	O
relationships	O
among	O
a	O
traditional	O
qualitative	O
spasticity	O
scale	O
,	O
three	O
potential	O
quantitative	O
spasticity	O
measures	O
and	O
a	O
measure	O
of	O
voluntary	O
ankle	O
muscle	O
function	O
.	O


Thirty-four	B-P
volunteer	I-P
adult	I-P
patients	I-P
with	I-P
traumatic	I-P
brain	I-P
injuries	I-P
participated	I-P
.	I-P


There	B-P
were	I-P
28	I-P
males	I-P
and	I-P
6	I-P
females	I-P
;	I-P
the	I-P
mean	I-P
age	I-P
was	I-P
30.3	I-P
years	I-P
.	I-P


A	O
battery	O
of	O
five	O
randomly	B-I
sequenced	I-I
tests	I-I
was	O
performed	O
for	O
each	O
subject	O
on	O
one	O
ankle	O
.	O


Tests	O
were	O
:	O
modified	B-O
Ashworth	I-O
scale	I-O
(	I-O
MAS	I-O
)	I-O
scoring	I-O
;	I-O
H-reflex	I-O
testing	I-O
with	I-O
and	I-O
without	I-O
Achilles	I-O
tendon	I-O
vibration	I-O
;	I-O
H-reflex	I-O
testing	I-O
with	I-O
and	I-O
without	I-O
dorsiflexor	I-O
contraction	I-O
;	I-O
reflex	I-O
threshold	I-O
angle	I-O
and	I-O
timed	I-O
toe	I-O
tapping	I-O
(	I-O
TTT	I-O
)	I-O
.	I-O


Twenty-six	B-P
subjects	I-P
returned	I-P
to	I-P
have	I-P
the	I-P
second	I-P
ankle	I-P
tested	I-P
,	I-P
resulting	I-P
in	I-P
60	I-P
ankles	I-P
for	O
the	O
analyses	O
.	O


Spearman	O
's	O
coefficients	O
for	O
correlation	O
of	O
quantitative	O
spasticity	O
measures	O
with	O
MAS	B-O
scores	I-O
ranged	O
from	O
0.39	O
to	O
0.49	O
with	O
associated	O
probabilities	O
<	O
or	O
=	O
0.002	O
.	O


Pearson	O
coefficients	O
for	O
correlation	O
of	O
quantitative	O
spasticity	O
measures	O
with	O
TTT	B-O
scores	I-O
were	O
lower	O
but	O
also	O
significant	O
(	O
P	O
<	O
or	O
=	O
0.07	O
)	O
.	O


Multiple	O
correlation	O
for	O
the	O
set	O
of	O
quantitative	O
measures	O
yielded	O
R	O
=	O
0.614	O
(	O
P	O
<	O
0.001	O
)	O
with	O
MAS	B-O
scores	I-O
and	O
R	O
=	O
0.365	O
(	O
P	O
=	O
0.045	O
)	O
with	O
TTT	O
scores	O
.	O


These	O
findings	O
reveal	O
statistically	O
significant	B-O
relationships	I-O
of	O
low	O
to	O
moderate	O
strength	O
among	O
potential	B-O
quantitative	I-O
spasticity	I-O
measures	O
,	O
a	O
traditional	B-O
qualitative	I-O
spasticity	I-O
scale	I-O
and	O
a	O
simple	B-O
measure	I-O
of	I-O
voluntary	I-O
ankle	I-O
muscle	I-O
function	I-O
.	I-O


Understanding	O
these	O
relationships	O
is	O
an	O
essential	O
part	O
of	O
the	O
ongoing	O
search	O
for	O
quantitative	O
spasticity	O
measures	O
.	O


Effects	O
of	O
short-	O
and	O
long-term	O
risperidone	B-I
treatment	I-P
on	I-P
prolactin	I-O
levels	I-O
in	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


BACKGROUND	O
The	O
effects	O
of	O
short-	O
and	O
long-term	O
risperidone	B-I
treatment	O
on	O
serum	O
prolactin	O
were	O
assessed	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
.	I-P


METHODS	O
Patients	B-P
with	I-P
autism	I-P
(	I-P
N	I-P
=	I-P
101	I-P
,	I-P
5-17	I-P
years	I-P
of	I-P
age	I-P
)	I-P
were	O
randomized	O
to	O
an	O
8-week	O
trial	O
of	O
risperidone	B-I
or	I-I
placebo	I-I
and	O
63	B-P
then	I-P
took	I-P
part	I-P
in	I-P
a	I-P
4-month	I-P
open-label	I-P
follow-up	I-P
phase	I-P
.	I-P


Serum	O
samples	O
were	O
obtained	O
at	O
Baseline	O
and	O
Week-8	O
(	O
N	O
=	O
78	O
)	O
,	O
and	O
at	O
6-month	O
(	O
N	O
=	O
43	O
)	O
and	O
22-month	O
(	O
N	O
=	O
30	O
)	O
follow-up	O
.	O


Serum	O
prolactin	O
was	O
determined	O
by	O
immunoradiometric	O
assay	O
;	O
dopamine	B-O
type-2	I-O
receptor	I-O
(	I-O
DRD2	I-O
)	I-O
polymorphisms	I-O
were	I-O
genotyped	I-O
.	I-O


RESULTS	O
Baseline	B-O
prolactin	I-O
levels	I-O
were	O
similar	O
in	O
the	O
risperidone	B-I
(	O
N	O
=	O
42	O
)	O
and	O
placebo	B-I
(	O
N	O
=	O
36	O
)	O
groups	O
(	O
9.3	O
+/-	O
7.5	O
and	O
9.3	O
+/-	O
7.6	O
ng/ml	O
,	O
respectively	O
)	O
.	O


After	O
8	O
weeks	O
of	O
risperidone	B-I
,	O
prolactin	B-O
increased	O
to	O
39.0	O
+/-	O
19.2	O
ng/ml	O
,	O
compared	O
with	O
10.1	O
+/-	O
8.8	O
ng/ml	O
for	O
placebo	O
(	O
p	O
<	O
.0001	O
)	O
.	O


Prolactin	B-O
levels	I-O
were	O
also	O
significantly	O
increased	O
at	O
6	O
months	O
(	O
32.4	O
+/-	O
17.8	O
ng/ml	O
;	O
N	O
=	O
43	O
,	O
p	O
<	O
.0001	O
)	O
and	O
at	O
22	O
months	O
(	O
N	O
=	O
30	O
,	O
25.3	O
+/-	O
15.6	O
ng/ml	O
,	O
p	O
<	O
.0001	O
)	O
.	O


Prolactin	B-O
levels	I-O
were	O
not	O
associated	O
with	O
adverse	O
effects	O
and	O
DRD2	O
alleles	O
(	O
Taq1A	O
,	O
-141C	O
Ins/Del	O
,	O
C957T	O
)	O
did	O
not	O
significantly	O
influence	O
baseline	O
levels	O
or	O
risperidone-induced	O
increases	O
in	O
prolactin	O
.	O


CONCLUSIONS	O
Risperidone	B-I
treatment	O
was	O
associated	O
with	O
two-	O
to	O
four-fold	O
mean	O
increases	O
in	O
serum	O
prolactin	O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


Although	O
risperidone-induced	O
increases	O
tended	O
to	O
diminish	O
with	O
time	O
,	O
further	O
research	O
on	O
the	O
consequences	O
of	O
long-term	O
prolactin	O
elevations	O
in	O
children	B-P
and	I-P
adolescents	I-P
is	O
needed	O
.	O


Armodafinil	B-I
and	I-I
modafinil	I-I
in	O
patients	B-P
with	I-P
excessive	I-P
sleepiness	I-P
associated	I-P
with	I-P
shift	I-P
work	I-P
disorder	I-P
:	I-P
a	O
pharmacokinetic/pharmacodynamic	B-O
model	O
for	O
predicting	O
and	O
comparing	O
their	O
concentration-effect	O
relationships	O
.	O


Armodafinil	B-I
,	O
the	O
longer	O
lasting	O
R-isomer	O
of	O
racemic	O
modafinil	O
,	O
improves	O
wakefulness	B-O
in	O
patients	B-P
with	I-P
excessive	I-O
sleepiness	I-O
associated	I-P
with	I-P
shift	I-O
work	I-O
disorder	I-O
(	I-O
SWD	I-O
)	I-O
.	I-P


Pharmacokinetic	O
studies	O
suggest	O
that	O
armodafinil	B-I
achieves	O
higher	O
plasma	B-O
concentrations	I-O
than	O
modafinil	O
late	O
in	O
a	O
dose	O
interval	O
following	O
equal	O
oral	O
doses	O
.	O


Pooled	B-O
Multiple	I-O
Sleep	I-O
Latency	I-O
Test	I-O
(	I-O
MSLT	I-O
)	I-O
data	O
from	O
2	O
randomized	B-P
,	O
double-blind	O
,	O
placebo-controlled	B-I
trials	O
in	O
463	B-P
patients	I-P
with	I-P
SWD	I-P
,	I-P
1	I-P
with	I-P
armodafinil	I-I
150	I-I
mg/d	I-I
and	I-P
1	I-I
with	I-I
modafinil	I-I
200	I-I
mg/d	I-I
(	I-P
both	I-P
administered	I-P
around	I-P
2200	I-P
h	I-P
before	I-P
night	I-P
shifts	I-P
)	I-P
,	O
were	O
used	O
to	O
build	O
a	O
pharmacokinetic/pharmacodynamic	B-O
model	O
.	O


Predicted	O
plasma	B-O
drug	I-O
concentrations	I-O
were	O
obtained	O
by	O
developing	O
and	O
applying	O
a	O
population	O
pharmacokinetic	B-O
model	I-O
using	O
nonlinear	B-O
mixed-effects	I-O
modeling	I-O
.	I-O


Armodafinil	O
200	O
mg	O
produced	O
a	O
plasma	B-O
concentration	I-O
above	O
the	O
EC	O
(	O
50	O
)	O
(	O
4.6	O
µg/mL	O
)	O
for	O
9	O
hours	O
,	O
whereas	O
modafinil	O
200	O
mg	O
did	O
not	O
exceed	O
the	O
EC	O
(	O
50	O
)	O
.	O


Consequently	O
,	O
armodafinil	B-O
produced	O
greater	O
increases	O
in	O
predicted	O
placebo-subtracted	B-O
MSLT	I-O
times	I-O
of	O
0.5-1	O
minute	O
(	O
up	O
to	O
10	O
hours	O
after	O
dosing	O
)	O
compared	O
with	O
modafinil	O
.	O


On	O
a	O
milligram-to-milligram	O
basis	O
,	O
armodafinil	O
200	O
mg	O
consistently	B-O
increased	I-O
wakefulness	I-O
more	O
than	O
modafinil	O
200	O
mg	O
,	O
including	O
times	O
late	O
in	O
the	O
8-hour	O
shift	O
.	O


Studies	O
on	O
section	B-O
2D1	I-O
monoclonal	I-O
antibodies	I-O
.	I-O


Monoclonal	O
antibodies	O
in	O
"	O
Other	O
Blood	O
Groups	O
"	O
were	O
tested	O
with	O
random	B-I
blood	I-I
samples	I-I
collected	O
from	O
the	O
various	B-P
ethnic	I-P
groups	I-P
in	I-P
KwaZulu-Natal	I-P
,	I-P
South	I-P
Africa	I-P
,	I-P
and	I-P
with	I-P
samples	I-P
of	I-P
selected	I-P
red	I-P
cell	I-P
phenotypes	I-P
.	I-P


Standard	B-I
red	I-I
cell	I-I
serological	I-I
techniques	I-I
were	O
used	O
.	O


Do	O
catheter	B-I
washouts	I-I
extend	O
patency	B-O
time	I-O
in	O
long-term	B-O
indwelling	I-O
urethral	O
catheters	O
?	O
A	O
randomized	O
controlled	O
trial	O
of	O
acidic	B-I
washout	I-I
solution	I-I
,	I-I
normal	I-I
saline	I-I
washout	I-I
,	O
or	O
standard	B-I
care	I-I
.	I-I


PURPOSE	O
Blockage	O
of	O
long-term	O
indwelling	O
catheters	O
with	O
mineral	O
deposit	O
is	O
an	O
ongoing	O
management	O
issue	O
,	O
but	O
evidence	O
on	O
optimal	O
management	O
is	O
lacking	O
.	O


Our	O
purpose	O
was	O
to	O
examine	O
whether	O
catheter	B-I
washouts	I-I
prevent	O
or	O
reduce	O
catheter	B-O
blockage	I-O
.	I-O


DESIGN	O
A	O
multisite	O
randomized	O
controlled	O
trial	O
.	O


SUBJECTS	O
AND	O
SETTING	O
Adults	B-P
with	I-P
long-term	I-P
indwelling	I-P
catheters	I-P
that	I-P
required	I-P
changing	I-P
every	I-P
3	I-P
weeks	I-P
or	I-P
less	I-P
,	I-P
living	I-P
in	I-P
the	I-P
community	I-P
,	I-P
and	I-P
requiring	I-P
supportive	I-P
or	I-P
continuing	I-P
care	I-P
were	I-P
recruited	I-P
.	I-P


Participants	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
:	O
control	B-I
(	I-I
usual	I-I
care	I-I
,	I-I
no	I-I
washout	I-I
)	I-I
,	I-I
saline	I-I
washout	I-I
,	I-I
or	I-I
commercially	I-I
available	I-I
acidic	I-I
washout	I-I
solution	I-I
(	I-I
Contisol	I-I
Maelor	O
Pharmaceuticals	O
Ltd	O
,	O
Wrexham	O
,	O
UK	O
)	O
.	O


METHODS	O
At	O
baseline	O
visit	O
,	O
the	O
catheter	O
was	O
changed	O
and	O
participants	O
were	O
followed	O
weekly	O
for	O
8	O
weeks	O
,	O
with	O
checks	B-O
for	I-O
catheter	I-O
patency	I-O
and	I-O
urine	I-O
pH	I-O
.	I-O


Participants	O
randomized	O
to	O
saline	B-I
or	I-I
commercial	I-I
solution	I-I
had	O
a	O
weekly	O
washout	B-I
with	O
the	O
appropriate	O
solution	O
.	O


Endpoints	O
were	O
8	O
weeks	O
(	O
completion	O
data	O
)	O
,	O
3	O
or	O
more	O
catheter	O
changes	O
in	O
the	O
8-week	O
period	O
,	O
or	O
symptomatic	B-O
urinary	I-O
tract	I-O
infection	I-O
(	I-O
UTI	I-O
)	I-O
requiring	O
antibiotics	O
.	O


The	O
study	O
hypothesis	O
was	O
that	O
catheter	O
life	O
would	O
be	O
extended	O
by	O
25	O
%	O
in	O
the	O
commercial	B-I
solution	I-I
group	O
.	O


It	O
was	O
not	O
possible	O
to	O
blind	O
participants	O
or	O
research	O
nurses	O
to	O
washout	B-I
versus	I-I
no	I-I
intervention	I-I
,	O
but	O
participants	O
in	O
the	O
saline	B-I
and	I-I
washout	I-I
solution	I-I
groups	O
were	O
blinded	O
to	O
solution	O
type	O
.	O


RESULTS	O
One	B-P
hundred	I-P
twelve	I-P
potential	I-P
participants	I-P
were	I-P
screened	I-P
;	I-P
73	I-P
were	I-P
enrolled	I-P
,	I-P
randomized	I-P
,	I-P
and	I-P
included	I-P
in	O
the	O
final	O
analysis	O
.	O


Of	O
these	O
,	O
53	B-P
completed	I-P
the	O
full	O
8	O
weeks	O
of	O
data	O
collection	O
;	O
16	B-P
terminated	I-P
early	I-P
because	O
of	O
3	O
catheter	O
changes	O
or	O
self-reported	O
'UTI	O
'	O
.	O


Other	O
reasons	O
for	O
termination	B-O
were	O
hematuria	B-O
,	I-O
latex	I-O
sensitivity	I-O
,	I-O
deceased/severe	I-O
illness	I-O
,	I-O
or	I-O
personal	I-O
choice	I-O
.	I-O


Analysis	O
of	O
variance	O
was	O
used	O
to	O
analyze	O
mean	O
differences	O
on	O
demographic	O
variables	O
and	O
mean	O
number	O
of	O
weeks	O
in	O
study	O
.	O


Kaplan-Meier	O
survival	O
curve	O
analysis	O
showed	O
no	O
statistical	O
difference	O
between	O
the	O
groups	O
in	O
time	B-O
to	I-O
first	I-O
catheter	I-O
change	I-O
.	I-O


CONCLUSION	O
At	O
this	O
time	O
,	O
the	O
evidence	O
is	O
insufficient	O
to	O
state	O
whether	O
catheter	B-I
washout	I-I
with	I-I
saline	I-I
or	I-I
Contisol	I-I
is	O
more	O
effective	O
than	O
usual	B-I
care	I-I
with	I-I
no	I-I
washout	I-I
in	O
preventing	O
blocking	O
.	O


No	O
increased	O
risk	B-O
of	I-O
UTI	I-O
was	O
associated	O
with	O
washout	B-I
regimes	I-I
.	I-I


Effects	O
of	O
gabapentin	B-I
on	O
experimental	O
somatic	B-O
pain	I-O
and	I-O
temporal	I-O
summation	I-O
.	I-O


BACKGROUND	O
AND	O
OBJECTIVES	O
Gabapentin	B-I
is	O
used	O
for	O
treatment	O
of	O
neuropathic	O
pain	O
,	O
but	O
its	O
effect	O
on	O
different	O
somatic	O
pain	O
modalities	O
and	O
integrative	O
mechanisms	O
are	O
not	O
completely	O
understood	O
.	O


The	O
aim	O
of	O
this	O
double-blind	O
,	O
placebo-controlled	B-I
experimental	O
pain	O
study	O
,	O
conducted	O
on	O
20	B-P
healthy	I-P
volunteers	I-P
,	O
was	O
to	O
examine	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
1200	O
mg	O
gabapentin	O
on	O
multi-modal	O
experimental	O
cutaneous	O
and	O
muscle	O
pain	O
models	O
.	O


METHODS	O
The	O
following	O
pain	O
models	O
were	O
applied	O
:	O
(	O
1	O
)	O
pain	O
thresholds	O
to	O
single	B-I
and	I-I
repeated	I-I
cutaneous	I-I
and	I-I
intramuscular	I-I
electrical	I-I
stimulation	I-I
(	I-I
temporal	I-I
summation	I-I
to	I-I
5	I-I
stimuli	I-I
delivered	I-I
at	I-I
2	I-I
Hz	I-I
)	I-I
;	I-I
(	O
2	O
)	O
stimulus-response	B-I
function	I-I
relating	I-I
pain	I-O
intensity	I-O
scores	I-O
(	I-O
visual	I-O
analog	I-O
scale	I-O
,	I-O
VAS	I-O
)	I-O
to	I-I
increasing	I-I
current	I-I
intensities	I-I
for	I-I
electrical	I-I
skin	I-I
and	I-I
muscle	I-I
stimuli	I-I
(	I-I
single	I-I
and	I-I
repeated	I-I
,	I-I
determined	I-I
at	I-I
baseline	I-I
)	I-I
;	I-I
and	O
(	O
3	O
)	O
the	O
pain	B-O
intensity	I-O
(	I-O
VAS	I-O
)	I-O
and	I-O
pain	I-O
areas	I-O
after	I-O
intramuscular	I-O
injection	I-O
of	I-I
hypertonic	I-I
saline	I-I
.	I-I


Pain	B-O
assessments	O
were	O
performed	O
prior	O
to	O
,	O
and	O
at	O
4	O
,	O
6	O
,	O
and	O
8	O
hours	O
after	O
medication	O
.	O


RESULTS	O
When	O
responses	O
were	O
averaged	O
across	O
the	O
post-dose	O
times	O
,	O
gabapentin	B-I
:	I-I
(	O
1	O
)	O
significantly	O
increased	O
the	O
temporal	B-O
summation	I-O
pain	I-O
threshold	I-O
in	O
skin	O
compared	O
with	O
placebo	B-I
(	O
P	O
=	O
.03	O
)	O
;	O
(	O
2	O
)	O
significantly	O
reduced	O
the	O
area	B-O
under	I-O
the	I-O
pain	I-O
intensity	I-O
curve	I-O
to	I-O
hypertonic	I-O
saline	I-O
injections	I-O
in	O
the	O
muscle	O
(	O
P	O
=	O
.02	O
)	O
;	O
and	O
(	O
3	O
)	O
significantly	O
reduced	O
the	O
area	B-O
of	I-O
pain	I-O
evoked	I-O
by	I-O
hypertonic	I-O
saline	I-O
(	O
P	O
=	O
.03	O
)	O
.	O


CONCLUSIONS	O
Gabapentin	B-I
reduces	O
temporal	B-O
summation	I-O
of	I-O
skin	I-O
stimuli	I-O
at	I-O
pain	I-O
threshold	I-O
intensities	I-O
;	I-O
this	O
may	O
have	O
potential	O
as	O
a	O
biomarker	O
for	O
drugs	O
with	O
efficacy	O
on	O
neurogenic	O
pain	O
.	O


The	O
data	O
also	O
suggest	O
that	O
tonic	B-O
muscle	I-O
pain	I-O
is	O
responsive	O
to	O
gabapentin	O
treatment	O
and	O
suggest	O
further	O
clinical	O
studies	O
.	O


[	O
Effects	O
of	O
transcutaneous	B-I
electrical	I-I
stimulation	I-I
of	I-I
auricular	I-I
Shenmen	I-I
point	I-I
on	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
patient-controlled	O
epidural	O
analgesia	O
in	O
cesarean	B-P
section	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
of	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
on	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
patient-controlled	O
epidural	O
analgesia	O
in	O
cesarean	O
section	O
.	O


METHODS	O
After	O
IRB	O
approval	O
and	O
informed	O
consent	O
,	O
one	B-P
hundred	I-P
and	I-P
eighty	I-P
singleton	I-P
primiparas	I-P
undergoing	I-P
elective	I-P
cesarean	I-P
section	I-P
,	I-P
in	I-P
Qingdao	I-P
Municipal	I-P
Hospital	I-P
,	I-P
and	I-P
Qingdao	I-P
Hiser	I-P
Medical	I-P
Center	I-P
,	I-P
from	I-P
November	I-P
2011	I-P
to	I-P
March	I-P
2012	I-P
,	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
three	O
groups	O
:	O
transcutaneous	B-I
electrical	I-I
stimulation	I-I
of	I-I
auricular	I-I
Shenmen	I-I
point	I-I
group	I-I
(	O
group	O
A	O
,	O
n	O
=	O
60	O
)	O
,	O
transcutaneous	B-I
electrical	I-I
stimulation	I-I
of	I-I
auricular	I-I
Eye	I-I
point	I-I
group	I-I
(	O
group	O
B	O
,	O
n	O
=	O
60	O
)	O
and	O
control	B-I
group	I-I
(	O
group	O
C	O
,	O
n	O
=	O
60	O
)	O
.	O


Women	O
of	O
group	O
A	O
received	O
transcutaneous	B-I
electrical	I-I
stimulation	I-I
of	O
auricular	O
Shenmen	O
point	O
(	O
frequency	O
1.5	O
HZ	O
)	O
at	O
the	O
time	O
of	O
preoperation	O
,	O
4	O
,	O
10	O
and	O
22	O
hours	O
of	O
postoperation	O
for	O
30	O
minutes	O
.	O


The	O
strength	O
was	O
controlled	O
by	O
themselves	O
.	O


Women	O
of	O
group	O
B	O
received	O
stimulation	O
of	O
auricular	O
Eye	O
point	O
as	O
group	O
A	O
.	O


Women	O
of	O
group	O
C	O
received	O
pressurization	B-I
and	I-I
connected	I-I
line	I-I
were	I-I
the	I-I
same	I-I
with	I-I
group	I-I
A	I-I
,	I-I
but	I-I
without	I-I
electrical	I-I
stimulation	I-I
.	I-I


The	O
following	O
indexes	O
was	O
observed	O
:	O
the	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
for	O
48	O
hours	O
;	O
the	O
rate	O
of	O
metoclopramide	O
;	O
the	B-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
score	I-O
of	I-O
rest	I-O
pain	I-O
,	I-O
uterine	I-O
contration	I-O
pain	I-O
and	I-O
dynamic	I-O
pain	I-O
at	I-O
the	I-O
time	I-O
of	I-O
postoperation	I-O
for	I-O
6	I-O
,	I-O
12	I-O
,	I-O
24	I-O
and	I-O
48	I-O
hours	I-O
(	I-O
T	I-O
(	I-O
1	I-O
)	I-O
-T	I-O
(	I-O
4	I-O
)	I-O
)	I-O
;	I-O
the	I-O
total	I-O
number	I-O
and	I-O
effective	I-O
compressions	I-O
number	I-O
of	I-O
patient-controlled	I-O
epidural	I-O
analgesia	I-O
(	I-O
PCEA	I-O
)	I-O
;	I-O
the	I-O
dose	I-O
of	I-O
analgesia	I-O
mixture	I-O
;	I-O
the	I-O
anal	I-O
exhaust	I-O
time	I-O
;	I-O
the	I-O
volume	I-O
of	I-O
postoperative	I-O
bleeding	I-O
for	I-O
6	I-O
hours	I-O
of	I-O
postoperation	I-O
and	I-O
the	I-O
other	I-O
side	I-O
effects	I-O
.	I-O


RESULTS	O
Compared	O
with	O
group	O
B	O
and	O
group	O
C	O
,	O
the	O
incidence	B-O
of	I-O
PONV	I-O
,	I-O
the	I-O
rate	I-O
of	I-O
metoclopramide	I-O
,	I-O
the	I-O
VAS	I-O
score	I-O
at	O
the	O
time	O
T	O
(	O
1	O
)	O
-T	O
(	O
4	O
)	O
,	O
the	O
total	B-O
number	I-O
and	I-O
effective	I-O
compressions	I-O
number	I-O
of	I-O
PCEA	I-O
,	I-O
the	I-O
ratio	I-O
of	I-O
the	I-O
total	I-O
number	I-O
with	I-O
effective	I-O
compressions	I-O
number	I-O
and	I-O
the	I-O
dose	I-O
of	I-O
analgesia	I-O
mixture	I-O
were	O
decreased	O
in	O
group	O
A	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
no	O
difference	O
compared	O
group	O
B	O
with	O
group	O
C	O
(	O
P	O
>	O
0.05	O
)	O
.	O


The	O
anal	B-O
exhaust	I-O
time	I-O
and	I-O
the	I-O
volume	I-O
of	I-O
postoperative	I-O
bleeding	I-O
for	O
6	O
hours	O
of	O
postoperation	O
were	O
no	O
difference	O
in	O
the	O
three	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O


No	O
other	O
side	B-O
effects	I-O
were	O
observed	O
.	O


CONCLUSION	O
Transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
can	O
reduce	O
the	O
incidence	B-O
of	I-O
PONV	I-O
and	I-O
improves	I-O
analgesia	I-O
effect	I-O
of	I-O
PCEA	I-O
in	I-O
postoperation	I-O
of	I-O
cesarean	I-O
section	I-O
.	I-O


Dipyrone	B-I
for	O
treatment	O
of	O
post-operative	B-O
pain	I-O
.	I-O


A	O
randomized	O
trial	O
of	O
etoposide	O
and	O
G-CSF	O
with	O
or	O
without	O
rituximab	B-I
for	O
PBSC	O
mobilization	O
in	O
B-cell	B-P
non-Hodgkin	I-P
's	I-P
lymphoma	I-P
.	I-P


Some	O
reports	O
have	O
suggested	O
that	O
rituximab	O
administration	O
before	O
PBSC	O
mobilization	O
may	O
adversely	O
affect	O
PBSC	O
yield	O
.	O


We	O
conducted	O
a	O
prospective	O
randomized	O
trial	O
of	O
PBSC	O
mobilization	O
using	O
etoposide	B-I
and	I-I
G-CSF	I-I
with	I-I
or	I-I
without	I-I
rituximab	I-I
to	O
determine	O
whether	O
its	O
addition	O
would	O
adversely	O
affect	O
CD34+	B-O
cell	I-O
yield	I-O
in	O
patients	B-P
with	I-P
non-Hodgkin	I-P
's	I-P
lymphoma	I-P
.	I-P


Twenty	B-P
seven	I-P
patients	I-P
were	I-P
mobilized	I-P
with	O
etoposide	B-I
and	O
G-CSF	O
and	O
28	O
with	O
etoposide	B-I
,	I-I
G-CSF	I-I
and	I-I
rituximab	I-I
.	I-I


There	O
were	O
no	O
adverse	O
consequences	O
of	O
rituximab	O
on	O
CD34+	B-O
cell	I-O
yield	I-O
,	I-O
or	I-O
hematopoietic	I-O
recovery	I-O
or	I-O
immunoglobulin	I-O
levels	I-O
after	O
transplantation	O
.	O


Glycerol	B-I
lidocaine	I-I
eardrops	I-I
for	O
the	O
treatment	O
of	O
acute	B-O
abacterial	I-O
otitis	I-O
externa	I-O
.	I-O


Inflammations	O
of	O
the	O
external	O
auditory	O
canal	O
number	O
among	O
the	O
most	O
frequently	O
occurring	O
ear-nose-throat	O
diseases	O
.	O


For	O
local	O
treatment	O
,	O
substances	O
from	O
various	O
groups	O
of	O
active	O
ingredients	O
are	O
used	O
as	O
combinations	O
and	O
as	O
single-agent	O
drugs	O
,	O
e.g	O
.	O


antibiotics	B-I
,	I-I
glucocorticoids	I-I
or	O
analgesics	B-I
[	O
1	O
]	O
.	O


In	O
the	O
case	O
of	O
acute	O
otitis	O
externa	O
,	O
treatment	O
measures	O
focus	O
on	O
the	O
reduction	B-O
of	I-O
pain	I-O
and	I-O
swelling	I-O
.	I-O


The	O
study	O
described	O
here	O
investigates	O
the	O
efficacy	O
and	O
safety	O
of	O
glycerol	B-I
lidocaine	I-I
eardrops	I-I
for	O
the	O
treatment	O
of	O
acute	B-O
abacterial	I-O
otitis	I-O
externa	I-O
(	O
CAS	O
No	O
.	O


for	O
glycerol	B-I
:	I-I
56-81-5	O
,	O
lidocaine-HCl	B-I
:	I-I
73-78-9	O
)	O
.	O


In	O
this	O
double-blind	O
,	O
three-arm	O
study	O
,	O
105	B-P
patients	I-P
diagnosed	I-P
with	I-P
acute	I-P
abacterial	I-P
otitis	I-P
externa	I-P
were	I-P
included	I-P
and	I-P
randomized	I-P
to	O
receive	O
either	O
glycerol	B-I
eardrops	I-I
,	I-I
glycerol	I-I
eardrops	I-I
with	I-I
0.5	I-I
%	I-I
lidocaine	I-I
,	I-I
or	I-I
glycerol	I-I
eardrops	I-I
with	I-I
2	I-I
%	I-I
lidocaine	I-I
for	O
seven	O
days	O
.	O


The	O
primary	O
outcome	O
parameter	O
was	O
the	O
change	O
of	O
the	O
five	O
typical	O
clinical	O
symptoms	O
,	O
earache	B-O
,	I-O
itching	I-O
,	I-O
otorrhea	I-O
,	I-O
hearing	I-O
impairment	I-O
,	I-O
and	I-O
"	I-O
clogged	I-O
ear	I-O
"	I-O
at	O
Visit	O
2	O
(	O
Day	O
7	O
)	O
based	O
on	O
the	O
initial	O
examination	O
on	O
Day	O
0	O
.	O


Both	O
therapy	O
groups	O
treated	O
with	O
a	O
combination	O
of	O
glycerol	B-I
and	I-I
lidocaine	I-I
exhibited	O
definite	O
improvement	O
in	O
overall	B-O
symptoms	I-O
after	O
seven	O
days	O
.	O


This	O
improvement	O
differed	O
from	O
the	O
mild	B-O
reduction	I-O
of	I-O
symptoms	I-O
under	O
treatment	O
with	O
glycerol	O
eardrops	O
alone	O
.	O


Overall	O
improvement	O
of	O
symptoms	O
,	O
expressed	O
by	O
the	O
area	O
under	O
the	O
curve	O
of	O
the	O
baseline-adjusted	B-O
symptom	I-O
sum	I-O
score	I-O
,	O
yielded	O
a	O
mean	O
value	O
of	O
10.95	O
(	O
standard	O
deviation	O
27.4	O
)	O
for	O
the	O
morning	O
survey	O
of	O
the	O
groups	O
receiving	O
eardrops	O
containing	O
only	O
glycerol	O
;	O
in	O
comparison	O
,	O
for	O
eardrops	O
containing	O
glycerol	B-I
and	O
2	O
%	O
lidocaine	B-I
it	O
was	O
15.71	O
(	O
+/-	O
23.6	O
)	O
and	O
for	O
glycerol	B-I
with	O
0.5	O
%	O
lidocaine	B-I
,	O
23.16	O
(	O
+/-	O
19.4	O
)	O
.	O


No	B-O
severe	I-O
adverse	I-O
events	I-O
occurred	O
.	O


Five	O
adverse	B-O
events	I-O
were	O
documented	O
during	O
the	O
clinical	O
investigation	O
,	O
none	O
of	O
which	O
was	O
considered	O
by	O
the	O
investigators	O
to	O
be	O
related	O
to	O
the	O
study	O
medication	O
.	O


Local	O
therapy	B-I
with	I-I
glycerol	I-I
lidocaine	I-I
eardrops	I-I
is	O
a	O
safe	B-O
,	I-O
and	I-O
cost-effective	I-O
treatment	O
for	O
the	O
widely	O
spread	O
clinical	O
picture	O
of	O
acute	O
abacterial	O
otitis	O
externa	O
.	O


The	O
advantage	O
regarding	O
efficacy	O
of	O
this	O
combination	O
compared	O
with	O
glycerol	B-I
eardrops	O
must	O
be	O
demonstrated	O
in	O
an	O
adequately	O
powered	O
clinical	O
trial	O
.	O


Impacts	O
of	O
a	O
disease	B-I
management	I-I
program	I-I
for	O
dually	B-P
eligible	I-P
beneficiaries	I-P
.	I-P


The	O
LifeMasters	B-I
Supported	I-I
SelfCare	I-I
demonstration	I-I
program	I-I
provides	O
disease	B-I
management	I-I
(	I-I
DM	I-I
)	I-I
services	I-I
to	O
Florida	B-P
Medicare	I-P
beneficiaries	I-P
who	I-P
are	I-P
also	I-P
enrolled	I-P
in	I-P
Medicaid	I-P
and	I-P
have	I-P
congestive	I-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
,	I-P
diabetes	I-P
,	I-P
or	I-P
coronary	I-P
artery	I-P
disease	I-P
(	I-P
CAD	I-P
)	I-P
.	I-P


The	O
population-based	O
program	O
provides	O
primarily	B-I
telephonic	I-I
patient	I-I
education	I-I
and	I-I
monitoring	I-I
services	I-I
.	I-I


Findings	O
from	O
the	O
randomized	O
,	O
intent-to-treat	O
design	O
over	O
the	O
first	O
18	O
months	O
of	O
operations	O
show	O
virtually	O
no	O
overall	O
impacts	B-O
on	I-O
hospital	I-O
or	I-O
emergency	I-O
room	I-O
(	I-O
ER	I-O
)	I-O
use	I-O
,	I-O
Medicare	I-O
expenditures	I-O
,	I-O
quality	I-O
of	I-O
care	I-O
,	I-O
or	I-O
prescription	I-O
drug	I-O
use	I-O
for	O
the	O
33,000	B-P
enrollees	I-P
.	I-P


However	O
,	O
for	O
beneficiaries	B-P
with	I-P
CHF	I-P
who	I-P
resided	I-P
in	I-P
high-cost	I-P
South	I-P
Florida	I-P
counties	I-P
,	O
the	O
program	O
reduced	O
Medicare	B-O
expenditures	I-O
by	O
9.6	O
percent	O
.	O


Comparison	B-P
of	I-P
synemol	I-I
cream	I-I
and	I-P
other	I-I
topical	I-I
corticosteroid	I-I
creams	I-I
using	I-P
the	I-P
vasoconstrictor	I-P
bioassay	I-P
.	I-P


The	O
human	B-P
vasoconstrictor	I-P
bioassay	I-P
was	O
used	O
to	O
assess	O
the	O
potency	O
of	O
open	B-P
applications	I-P
of	I-P
Synemol	I-I
cream	I-I
(	I-P
0.025	I-P
%	I-P
)	I-P
,	I-P
Diprosone	I-I
cream	I-I
(	I-I
0.05	I-I
%	I-I
)	I-I
,	I-I
Aristocort-A	I-I
cream	I-I
(	I-P
0.5	I-P
%	I-P
)	I-P
,	I-P
and	I-P
Valisone	I-I
cream	I-I
(	I-I
0.1	I-I
%	I-I
)	I-I
.	I-P


Intensity	O
of	O
vasoconstriction	B-P
was	O
determined	O
eight	O
,	O
twenty-four	O
,	O
and	O
thirty-two	O
hours	O
after	O
application	O
.	O


Results	O
obtained	O
from	O
the	O
average	O
intensity	B-O
scores	I-O
of	O
the	O
three	O
determinations	O
indicated	O
that	O
Synemol	B-I
cream	I-I
(	O
0.025	O
%	O
)	O
is	O
actually	O
a	O
more	O
active	O
compound	O
than	O
are	O
Diprosone	B-I
cream	I-I
(	O
0.05	O
%	O
)	O
,	O
Aristocort-A	B-I
cream	I-I
(	O
0.5	O
%	O
)	O
,	O
and	O
Valisone	B-I
cream	I-I
(	O
0.1	O
%	O
)	O
,	O
and	O
that	O
its	O
activity	O
is	O
longer	O
acting	O
.	O


5	O
%	O
imiquimod	B-I
cream	O
and	O
reflectance-mode	B-I
confocal	I-I
microscopy	I-I
as	O
adjunct	O
modalities	O
to	O
Mohs	B-I
micrographic	I-I
surgery	I-I
for	O
treatment	O
of	O
basal	B-P
cell	I-P
carcinoma	I-P
.	I-P


BACKGROUND	O
Imiquimod	B-I
is	O
an	O
immune	O
response	O
modifier	O
that	O
up-regulates	O
cytokines	O
and	O
has	O
been	O
shown	O
in	O
clinical	O
studies	O
to	O
reduce	O
or	O
clear	O
basal	B-P
cell	I-P
carcinoma	I-P
tumors	O
when	O
applied	O
topically	O
.	O


OBJECTIVE	O
The	O
objectives	O
were	O
to	O
evaluate	O
the	O
efficacy	O
of	O
5	O
%	O
imiquimod	B-I
cream	O
in	O
treating	O
basal	O
cell	O
carcinoma	O
preceding	O
excision	O
by	O
Mohs	O
micrographic	O
surgery	O
and	O
to	O
determine	O
if	O
reflectance-mode	B-I
confocal	I-I
microscopy	I-I
is	O
useful	O
to	O
establish	O
the	O
need	O
for	O
surgical	O
intervention	O
after	O
imiquimod	B-I
treatment	O
.	O


METHODS	O
Subjects	B-P
applied	I-P
study	I-P
cream	I-P
to	I-P
one	I-P
biopsy-confirmed	I-P
basal	I-P
cell	I-P
carcinoma	I-P
tumor	I-P
5	O
x/week	O
for	O
2	O
,	O
4	O
,	O
or	O
6	O
weeks	O
in	O
this	O
vehicle-controlled	B-P
,	I-P
double-blind	I-P
study	I-P
.	I-P


Confocal	B-I
microscopy	I-I
was	O
used	O
for	O
the	O
6-week	O
treatment	O
group	O
to	O
examine	O
the	O
target	O
tumor	O
area	O
at	O
each	O
interval	O
visit	O
and	O
immediately	O
before	O
Mohs	B-I
micrographic	I-I
surgery	I-I
.	I-I


After	O
the	O
Mohs	B-I
micrographic	I-I
surgery	I-I
excision	I-I
,	O
the	O
tissue	O
was	O
evaluated	O
histologically	O
,	O
and	O
the	O
excision	O
area	O
was	O
measured	O
.	O


Confocal	B-I
microscopy	I-I
readings	O
were	O
correlated	O
to	O
the	O
histologic	O
diagnosis	O
.	O


RESULTS	O
Tumors	B-O
cleared	I-O
or	I-O
the	I-O
target	I-O
tumor	I-O
area	I-O
was	O
reduced	O
in	O
subjects	O
in	O
the	O
4-	O
and	O
6-week	O
dosing	O
regimens	O
.	O


Confocal	B-O
microscopy	I-O
assessments	I-O
correlated	O
well	O
with	O
the	O
histologic	O
diagnosis	O
.	O


CONCLUSION	O
Imiquimod	B-I
improved	O
excision	B-O
results	I-O
relative	O
to	O
vehicle	O
when	O
used	O
for	O
treating	O
basal	B-P
cell	I-P
carcinoma	I-P
before	I-P
Mohs	I-I
micrographic	I-I
surgery	I-I
.	I-I


Confocal	O
microscopy	O
assessments	O
correlated	O
well	O
with	O
tumor	O
response	O
to	O
therapy	O
,	O
suggesting	O
that	O
confocal	O
microscopy	O
may	O
help	O
determine	O
the	O
need	O
for	O
surgery	O
.	O


Alpha	B-I
interferon	I-I
clinical	O
trial	O
for	O
multiple	B-P
sclerosis	I-P
:	I-P
design	O
considerations	O
.	O


The	O
design	O
and	O
course	O
of	O
a	O
placebo-controlled	B-I
alpha-2	I-I
interferon	I-I
trial	O
in	O
MS	B-P
patients	I-P
are	O
described	O
.	O


No	B-O
beneficial	I-O
effect	I-O
of	O
the	O
interferon	B-O
on	O
the	O
course	O
of	O
MS	O
could	O
be	O
shown	O
.	O


Comparison	O
of	O
5-aminosalicylic	B-I
acid	I-I
(	O
3	O
g	O
)	O
and	O
prednisolone	B-I
phosphate	I-I
sodium	I-I
enemas	O
(	O
30	O
mg	O
)	O
in	O
the	O
treatment	O
of	O
distal	B-O
ulcerative	I-O
colitis	I-O
.	I-O


A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
trial	O
.	O


Twenty-nine	B-P
patients	I-P
with	I-P
attacks	I-P
of	I-P
distal	I-P
ulcerative	I-P
colitis	I-P
were	O
treated	O
randomly	O
with	O
3	O
g	O
5-aminosalicylic	B-I
acid	I-I
(	I-I
5-ASA	I-I
)	I-I
or	O
30	O
mg	O
of	O
prednisolone	B-I
phosphate	I-I
sodium	I-I
(	I-I
PP	I-I
)	I-I
enemas	O
(	O
40	O
ml	O
)	O
.	O


Endoscopic	B-O
,	I-O
clinical	I-O
,	I-O
and	I-O
histologic	I-O
improvement	I-O
were	O
comparable	O
in	O
the	O
two	O
treatment	O
groups	O
.	O


Our	O
study	O
showed	O
that	O
topical	O
treatment	O
with	O
5-ASA	B-I
is	O
as	O
efficacious	O
as	O
PP	B-I
in	O
improving	O
distal	B-O
ulcerative	I-O
colitis	I-O
.	I-O


Scales	O
for	O
the	O
assessment	O
of	O
neuroleptic	B-O
response	I-O
in	O
schizophrenic	B-P
children	I-P
:	I-P
specific	O
measures	O
derived	O
from	O
the	O
CPRS	O
.	O


This	O
article	O
reports	O
the	O
psychometric	O
properties	O
of	O
two	O
scales	O
for	O
rating	O
positive	O
and	O
negative	O
schizophrenic	O
signs	O
and	O
symptoms	O
.	O


These	O
Positive	B-O
and	I-O
Negative	I-O
Syndrome	I-O
Scales	I-O
consist	O
of	O
items	O
selected	O
from	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
(	O
CPRS	O
)	O
,	O
which	O
contains	O
items	O
covering	O
a	O
wide	O
range	O
of	O
childhood	O
psychopathology	O
.	O


CPRS	O
rating	O
data	O
were	O
analyzed	O
for	O
19	B-P
schizophrenic	I-P
children	I-P
,	I-P
16	I-P
males	I-P
and	I-P
3	I-P
females	I-P
,	I-P
mean	I-P
age	I-P
8.9	I-P
years	I-P
(	I-P
range	I-P
5.5-11.7	I-P
)	I-P
,	O
evaluated	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
crossover	O
study	O
of	O
haloperidol	B-I
.	I-I


We	O
describe	O
the	O
item	O
composition	O
and	O
coherence	O
of	O
each	O
scale	O
,	O
the	O
interrater	O
reliabilities	O
of	O
clinicians	O
using	O
the	O
scales	O
,	O
and	O
the	O
sensitivity	O
of	O
the	O
scales	O
for	O
resolving	O
treatment	O
response	O
.	O


Schizophrenic	B-P
children	I-P
showed	O
both	O
positive	B-O
and	I-O
negative	I-O
signs	I-O
and	I-O
symptoms	I-O
,	O
and	O
both	O
improved	O
with	O
neuroleptic	B-O
treatment	I-O
.	I-O


Effects	O
of	O
creatine	B-I
supplementation	I-I
on	O
repetitive	O
sprint	O
performance	O
and	O
body	O
composition	O
in	O
competitive	B-P
swimmers	I-P
.	I-P


In	O
a	O
double-blind	O
and	O
randomized	O
manner	O
,	O
18	B-P
male	I-P
and	I-P
female	I-P
junior	I-P
competitive	I-P
swimmers	I-P
supplemented	O
their	O
diets	O
with	O
21	O
g.day-1	O
of	O
creatine	B-I
monohydrate	I-I
(	I-I
Cr	I-I
)	I-I
or	O
a	O
maltodextrin	B-I
placebo	I-I
(	I-I
P	I-I
)	I-I
for	O
9	B-P
days	I-P
during	I-P
training	I-P
.	I-P


Prior	O
to	O
and	O
following	O
supplementation	O
,	O
subjects	O
performed	O
three	O
100-m	O
freestyle	O
sprint	O
swims	O
(	O
long	O
course	O
)	O
with	O
60	O
s	O
rest/recovery	O
between	O
heats	O
.	O


In	O
addition	O
,	O
subjects	O
performed	O
three	O
20-s	O
arm	O
ergometer	O
maximal-effort	O
sprint	O
tests	O
in	O
the	O
prone	O
position	O
with	O
60	O
s	O
rest/recovery	O
between	O
sprint	O
tests	O
.	O


Significant	O
differences	O
were	O
observed	O
among	O
swim	B-O
times	I-O
,	O
with	O
Cr	O
subjects	O
swimming	O
significantly	O
faster	O
than	O
P	O
subjects	O
following	O
supplementation	O
in	O
Heat	O
1	O
and	O
significantly	O
decreasing	O
swim	B-O
time	I-O
in	O
the	O
second	O
100-m	O
sprint	O
.	O


There	O
was	O
also	O
some	O
evidence	O
that	O
cumulative	B-O
time	I-O
to	I-O
perform	I-O
the	I-O
three	I-O
100-m	I-O
swims	I-O
was	O
decreased	O
in	O
the	O
Cr	O
group	O
.	O


Results	O
indicate	O
that	O
9	O
days	O
of	O
Cr	B-I
supplementation	O
during	O
swim	O
training	O
may	O
provide	O
some	O
ergogenic	O
value	O
to	O
competitive	O
junior	O
swimmers	O
during	O
repetitive	O
sprint	O
performance	O
.	O


Total	O
anthelmintic	O
failure	O
to	O
control	O
nematode	B-P
parasites	I-P
of	I-P
small	I-P
ruminants	I-P
on	I-P
government	I-P
breeding	I-P
farms	I-P
in	I-P
Sabah	I-P
,	I-P
East	I-P
Malaysia	I-P
.	I-P


Government-owned	B-P
small-ruminant	I-P
breeding	I-P
farms	I-P
in	O
Malaysia	O
provide	O
the	O
source	O
of	O
sheep	O
and	O
goats	O
to	O
smallholder	O
farmers	O
in	O
the	O
country	O
.	O


In	O
the	O
eastern	B-P
Malaysian	I-P
state	I-P
of	I-P
Sabah	I-P
,	O
high-level	O
stock	O
losses	O
have	O
been	O
recorded	O
on	O
these	O
farms	O
for	O
several	O
years	O
,	O
frequently	O
accompanied	O
by	O
clinical	O
signs	O
indicating	O
pathogenic	O
levels	O
of	O
infections	O
with	O
the	O
nematode	B-P
parasite	I-P
Haemonchus	I-P
contortus	I-P
.	I-P


This	O
suggests	O
that	O
their	O
dependence	O
on	O
chemotherapy	B-I
to	O
control	O
parasite	O
infections	O
had	O
failed	O
.	O


Accordingly	O
,	O
tests	O
for	O
anthelmintic	B-O
efficacy	I-O
using	O
the	O
faecal	B-O
egg	I-O
count	I-O
reduction	I-O
test	I-O
(	I-O
FECRT	I-O
)	I-O
on	O
the	O
range	O
of	O
drugs	O
used	O
to	O
control	O
nematode	O
parasites	O
were	O
carried	O
out	O
on	O
the	O
five	O
government	O
small-ruminant	O
breeding	O
farms	O
in	O
Sabah	O
.	O


These	O
tests	O
showed	O
a	O
total	O
failure	B-O
of	I-O
the	I-O
benzimidazole	I-O
,	I-O
imidothiazole	I-O
,	I-O
macrocyclic	I-O
lactone	I-O
and	I-O
salicylanilide	I-O
groups	I-O
of	I-O
anthelmintics	I-O
to	O
control	B-O
H.	I-O
contortus	I-O
infections	I-O
of	O
sheep	B-P
and	I-P
goats	I-P
on	I-P
all	I-P
farms	I-P
.	I-P


Drastic	O
changes	O
in	O
animal	O
management	O
need	O
to	O
be	O
made	O
in	O
an	O
attempt	O
to	O
deal	O
with	O
this	O
situation	O
,	O
for	O
which	O
suggestions	O
are	O
made	O
.	O


Clinical	O
pathway	O
for	O
fractured	B-P
neck	I-P
of	I-P
femur	I-P
:	I-P
a	O
prospective	O
,	O
controlled	O
study	O
.	O


OBJECTIVE	O
To	O
assess	O
outcomes	O
of	O
using	O
a	O
clinical	O
pathway	O
for	O
managing	O
patients	B-P
with	I-P
fractured	I-P
neck	I-P
of	I-P
femur	I-P
.	I-P


DESIGN	O
Prospective	O
,	O
pseudorandomised	O
,	O
controlled	O
trial	O
.	O


SETTING	O
St	B-P
Vincent	I-P
's	I-P
Hospital	I-P
,	I-P
Melbourne	I-P
,	I-P
Victoria	I-P
(	I-P
a	I-P
tertiary	I-P
referral	I-P
,	I-P
university	I-P
teaching	I-P
hospital	I-P
)	I-P
,	I-P
1	I-P
October	I-P
1997	I-P
to	I-P
30	I-P
November	I-P
1998	I-P
.	I-P


PARTICIPANTS	O
111	B-P
patients	I-P
(	I-P
80	I-P
women	I-P
and	I-P
31	I-P
men	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
81	I-P
years	I-P
)	I-P
admitted	I-P
via	I-P
the	I-P
emergency	I-P
department	I-P
with	I-P
a	I-P
primary	I-P
diagnosis	I-P
of	I-P
fractured	I-P
neck	I-P
of	I-P
femur	I-P
.	I-P


INTERVENTIONS	O
Management	B-I
guided	I-I
by	I-I
a	I-I
clinical	I-I
pathway	I-I
(	I-I
55	I-I
patients	I-I
)	I-I
or	I-I
established	I-I
standard	I-I
of	I-I
care	I-I
(	O
control	O
group	O
,	O
56	O
patients	O
)	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Timing	B-O
of	I-O
referrals	I-O
and	I-O
discharge	I-O
planning	I-O
;	I-O
total	I-O
length	I-O
of	I-O
stay	I-O
;	I-O
and	I-O
complication	I-O
and	I-O
readmission	I-O
rates	I-O
within	I-O
28	I-O
days	I-O
of	I-O
discharge	I-O
.	I-O


RESULTS	O
Patients	O
managed	O
according	O
to	O
the	O
clinical	O
pathway	O
had	O
a	O
shorter	O
total	B-O
stay	I-O
(	O
6.6	O
versus	O
8.0	O
days	O
;	O
P	O
=	O
0.03	O
)	O
,	O
even	O
if	O
assessment	O
for	O
placement	O
by	O
the	O
Aged	O
Care	O
Assessment	O
Service	O
was	O
required	O
(	O
9.5	O
versus	O
13.6	O
days	O
;	O
P	O
=	O
0.03	O
)	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
complication	B-O
and	I-O
readmission	I-O
rates	I-O
between	O
pathway	O
and	O
control	B-P
patients	I-P
(	O
complication	O
rates	O
,	O
24	O
%	O
versus	O
36	O
%	O
;	O
P	O
=	O
0.40	O
;	O
readmission	O
rates	O
,	O
4	O
%	O
versus	O
11	O
%	O
;	O
P	O
=	O
0.28	O
)	O
.	O


CONCLUSION	O
Coordinated	O
multidisciplinary	O
care	O
of	O
patients	B-P
with	I-P
fractured	I-P
neck	I-P
of	I-P
femur	I-P
reduces	O
length	B-O
of	I-O
stay	I-O
without	O
increasing	O
complications	O
.	O


Therapy	O
for	O
progressive	B-P
supranuclear	I-P
palsy	I-P
:	I-P
past	O
and	O
future	O
.	O


Dysfunction	O
of	O
multiple	O
brain	O
systems	O
in	O
progressive	B-P
supranuclear	I-P
palsy	I-P
(	I-P
PSP	I-P
)	I-P
has	O
complicated	O
attempts	O
to	O
treat	O
the	O
disease	O
.	O


Neurotransmitter	B-I
replacement	I-I
strategies	I-I
targeting	O
the	O
dopaminergic	O
,	O
cholinergic	O
,	O
and	O
serotonergic	O
systems	O
have	O
been	O
unsuccessful	O
.	O


In	O
order	O
to	O
bypass	O
the	O
degenerated	O
cortico-striato-pallidal	O
loop	O
,	O
we	O
administered	O
the	O
adrenergic	B-I
agonist	I-I
idazoxan	I-I
(	I-I
IDA	I-I
)	I-I
to	O
treat	O
PSP	O
in	O
two	O
randomized	O
double-blind	O
,	O
placebo	B-I
controlled	O
,	O
crossover	O
studies	O
.	O


Approximately	O
one	O
half	O
of	O
patients	B-P
enrolled	I-P
in	I-P
these	I-P
studies	I-P
showed	O
statistically	B-O
significant	I-O
improvement	I-O
in	I-O
balance	I-O
and	I-O
manual	I-O
dexterity	I-O
while	O
taking	O
IDA	O
compared	O
to	O
placebo	B-I
.	I-I


These	O
results	O
suggest	O
that	O
new	O
therapies	B-I
that	O
target	O
structures	O
outside	O
of	O
the	O
basal	O
ganglia	O
may	O
be	O
useful	O
for	O
symptomatic	B-O
treatment	I-O
of	I-O
PSP	I-O
.	I-O


Applying	O
this	O
strategy	O
and	O
developing	O
treatments	O
that	O
arrest	O
or	O
reverse	O
clinical	O
deterioration	O
in	O
PSP	O
will	O
require	O
improved	O
understanding	O
of	O
the	O
process	O
underlying	O
the	O
illness	O
.	O


Efficiency	B-O
of	I-I
adjuvant	I-I
immunochemotherapy	I-I
following	O
curative	O
resection	O
in	O
patients	B-P
with	I-P
locally	I-P
advanced	I-P
gastric	I-P
cancer	I-P
.	I-P


BACKGROUND	O
Despite	O
curative	O
resection	O
,	O
50	O
%	O
-90	O
%	O
of	O
gastric	B-P
cancer	I-P
patients	I-P
die	O
of	O
disease	B-O
relapse	I-O
.	I-O


Although	O
some	O
clinical	O
trials	O
have	O
indicated	O
that	O
chemotherapy	O
and	O
immunochemotherapy	O
may	O
be	O
effective	O
modalities	O
,	O
more	O
recent	O
studies	O
have	O
not	O
been	O
able	O
to	O
define	O
the	O
standard	O
treatment	O
for	O
advanced	B-P
gastric	I-P
cancer	I-P
.	I-P


The	O
present	O
study	O
evaluated	O
the	O
effect	O
of	O
adjuvant	B-I
immunochemotherapy	I-I
with	I-I
the	I-I
use	I-I
of	I-I
BCG	I-I
(	I-I
bacille	I-I
Calmette-Guerin	I-I
)	I-I
and	I-I
FAM	I-I
(	I-I
5-fluorouracil	I-I
,	I-I
adriamycin	I-I
,	I-I
mitomycin	I-I
C	I-I
)	I-I
chemotherapy	I-I
on	O
the	O
survival	B-O
of	I-O
patients	I-O
with	I-P
locally	I-P
advanced	I-P
resectable	I-P
gastric	I-P
cancer	I-P
.	I-P


METHODS	O
A	O
total	O
of	O
156	B-P
patients	I-P
with	I-P
stage	I-P
III	I-P
or	I-P
IV	I-P
gastric	I-P
cancer	I-P
who	I-P
had	I-P
undergone	I-P
curative	I-P
resection	I-P
were	O
randomly	B-I
assigned	I-I
to	I-I
three	I-I
treatment	I-I
groups	I-I
:	I-I
BCG	I-I
+	I-I
FAM	I-I
(	I-I
immunochemotherapy	I-I
)	I-I
,	I-I
FAM	I-I
(	I-I
chemotherapy	I-I
)	I-I
,	I-I
and	I-I
control	I-I
(	I-I
surgery	I-I
only	I-I
)	I-I
.	I-I


Treatment	B-I
was	I-I
continued	I-I
for	I-I
2	I-I
years	I-I
or	I-I
until	I-I
death	I-I
.	I-I


Further	B-I
postsurgical	I-I
follow	I-I
up	I-I
was	I-I
carried	I-I
on	I-I
for	I-I
up	I-I
to	I-I
10	I-I
years	I-I
.	I-I


RESULTS	O
Overall	O
10-year	B-O
survival	I-O
was	O
47.1	O
%	O
for	O
the	O
immunochemotherapy	O
group	O
(	O
P	O
<	O
0.037	O
vs	O
FAM	B-I
and	O
P	O
<	O
0.0006	O
vs	O
control	O
)	O
,	O
30	O
%	O
for	O
the	O
chemotherapy	B-I
group	O
(	O
vs	O
control	O
,	O
NS	O
)	O
,	O
and	O
15.2	O
%	O
for	O
the	O
control	O
group	O
.	O


In	O
patients	B-P
with	I-P
pT2/T3	I-P
primary	I-P
tumors	I-P
,	O
10-year	B-O
survival	I-O
was	O
55.3	O
%	O
for	O
BCG	B-I
+	I-I
FAM	I-I
vs	O
28.2	O
%	O
for	O
FAM	O
(	O
P	O
<	O
0.01	O
)	O
and	O
14.6	O
%	O
for	O
the	O
control	O
group	O
(	O
P	O
<	O
0.00018	O
)	O
.	O


BCG	B-I
+	I-I
FAM	I-I
significantly	O
improved	O
the	O
survival	B-O
of	I-O
patients	I-O
with	I-P
intestinal-type	I-P
but	I-P
not	I-P
diffuse-type	I-P
cancer	I-P
.	I-P


Immunochemotherapy	B-I
was	O
well	O
tolerated	O
.	O


CONCLUSION	O
This	O
study	O
,	O
based	O
on	O
a	O
limited	B-P
number	I-P
of	I-P
patients	I-P
,	O
indicates	O
that	O
adjuvant	O
immunochemotherapy	O
(	O
BCG	O
+	O
FAM	O
)	O
may	O
prolong	O
the	O
survival	B-O
of	O
gastric	B-P
cancer	I-P
patients	I-P
after	I-P
curative	I-P
gastrectomy	I-P
;	I-P
in	I-P
particular	I-P
,	I-P
in	I-P
patients	I-P
with	I-P
pT2/T3	I-P
tumors	I-P
and	I-P
intestinal-type	I-P
primary	I-P
tumors	I-P
.	I-P


There	O
was	O
no	O
survival	B-O
benefit	I-O
from	O
FAM	B-I
adjuvant	I-I
chemotherapy	I-I
.	I-I


Effect	O
of	O
Chinese	B-I
herbal	I-I
medicine	I-I
on	O
vascular	B-O
functions	I-O
during	O
60-day	O
head-down	O
bed	O
rest	O
.	O


PURPOSE	O
Chinese	B-I
herbal	I-I
medicine	I-I
is	O
a	O
promising	O
countermeasure	O
against	O
cardiovascular	B-O
dysfunction	I-O
associated	I-P
with	I-P
a	I-P
sedentary	I-P
lifestyle	I-P
.	I-P


We	O
examined	O
the	O
impact	O
of	O
the	O
Chinese	B-I
herb	I-I
,	I-I
Taikong	I-I
Yangxin	I-I
,	O
on	O
the	O
micro-	B-O
and	I-O
macrovascular	I-O
dysfunction	I-O
associated	O
with	O
a	O
60-day	B-P
bed	I-P
rest	I-P
.	I-P


METHODS	O
Fourteen	B-P
healthy	I-P
men	I-P
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
those	O
given	O
herbal	B-I
supplement	I-I
,	O
and	O
the	O
control	O
group	O
;	O
the	O
two	O
groups	O
underwent	O
a	O
60-day	B-I
bed	I-I
rest	I-I
.	I-I


The	O
macrovasculature	B-O
was	O
assessed	O
by	O
sonography	O
.	O


Skin	B-O
microvascular	I-O
functions	I-O
were	O
assessed	O
with	O
laser	O
Doppler	O
.	O


The	O
plasma	B-O
level	I-O
of	I-O
endothelial	I-O
microparticles	I-O
(	I-O
EMPs	I-O
)	I-O
,	O
markers	O
of	O
endothelial	B-O
injury	I-O
,	O
was	O
determined	O
.	O


RESULTS	O
Bed	O
rest	O
induced	O
a	O
33	O
%	O
decrease	O
in	O
the	O
femoral	B-O
artery	I-O
diameter	I-O
and	O
compliance	B-O
whereas	O
carotid	B-O
wall	I-O
thickness	I-O
,	I-O
diameter	I-O
,	I-O
and	I-O
compliance	I-O
remained	O
unchanged	O
.	O


The	O
early	B-O
phase	I-O
of	I-O
endothelium-dependent	I-O
vasodilation	I-O
to	I-O
ACh	I-O
was	O
unmodified	O
by	O
bed	O
rest	O
,	O
while	O
the	O
late	B-O
phase	I-O
was	O
reduced	O
by	O
30	O
%	O
along	O
with	O
a	O
twofold	O
increase	O
in	O
EMPs	B-O
.	I-O


In	O
those	O
given	O
Taikong	B-I
Yangxin	I-I
,	O
the	O
early	B-O
phase	I-O
was	O
amplified	O
by	O
2.5-fold	O
,	O
and	O
the	O
effects	B-O
of	I-O
bed	I-O
rest	I-O
on	O
the	O
late	B-O
phase	I-O
were	O
prevented	O
.	O


CONCLUSION	O
These	O
findings	O
indicate	O
that	O
Taikong	O
Yangxin	O
ameliorates	O
endothelium-dependent	B-O
vasodilation	I-O
,	O
likely	O
by	O
improving	O
the	O
NO	O
pathway	O
.	O


The	O
study	O
suggests	O
Taikong	O
Yangxin	O
as	O
a	O
new	O
countermeasure	O
to	O
prevent	O
the	O
changes	O
in	O
microvascular	B-O
function	I-O
induced	O
by	O
physical	O
inactivity	O
.	O


New	B-I
introducer	I-I
PEG	I-I
gastropexy	I-I
does	O
not	O
require	O
prophylactic	O
antibiotics	O
:	O
multicenter	O
prospective	O
randomized	O
double-blind	O
placebo-controlled	O
study	O
.	O


BACKGROUND	O
Peristomal	O
infections	O
are	O
the	O
most	O
common	O
complications	O
of	O
PEG	O
,	O
despite	O
prophylactic	O
antibiotics	O
.	O


The	O
"	O
introducer	O
"	O
PEG-placement	O
technique	O
avoids	O
the	O
sojourn	O
of	O
a	O
PEG	O
catheter	O
through	O
the	O
oropharynx	O
,	O
and	O
hence	O
minimizes	O
the	O
chances	O
of	O
infectious	O
complications	O
.	O


Despite	O
the	O
obvious	O
potential	O
advantage	O
,	O
this	O
technique	O
failed	O
to	O
gain	O
popularity	O
,	O
mainly	O
as	O
a	O
result	O
of	O
other	O
associated	O
risks	O
and	O
complications	O
.	O


Recently	O
,	O
a	O
modified	O
introducer	O
endoscopic	O
PEG-gastropexy	O
technique	O
was	O
shown	O
to	O
be	O
quite	O
safe	O
.	O


The	O
present	O
study	O
is	O
the	O
first	O
study	O
that	O
evaluated	O
the	O
need	O
of	O
prophylactic	O
antibiotics	O
for	O
"	O
introducer	O
"	O
PEG	O
.	O


OBJECTIVE	O
To	O
determine	O
the	O
incidence	O
of	O
peristomal	O
wound	O
infections	O
during	O
the	O
immediate	O
7-day	O
postprocedure	O
follow-up	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O


SETTINGS	O
Multicenter	B-P
;	I-P
a	I-P
university	I-P
tertiary-care	I-P
hospital	I-P
and	I-P
a	I-P
private	I-P
practice	I-P
endoscopy	I-P
clinic	I-P
.	I-P


PATIENTS	O
A	B-P
total	I-P
of	I-P
633	I-P
patients	I-P
undergoing	I-P
PEG	I-P
were	O
assessed	O
for	O
inclusion	O
.	O


Ninety-seven	B-P
patients	I-P
who	I-P
had	I-P
malignant	I-P
stenotic	I-P
oropharyngeal	I-P
stricture	I-P
were	O
randomized	O
:	O
group	O
I	O
(	O
49	O
patients	O
)	O
received	O
prophylactic	B-I
ceftriaxone	I-I
,	I-I
and	I-I
group	I-I
II	I-I
(	I-I
48	I-I
patients	I-I
)	I-I
received	I-I
a	I-I
placebo	I-I
.	I-I


Both	O
groups	O
were	O
similar	O
in	O
patient	O
characteristics	O
.	O


INTERVENTIONS	O
Introducer	O
PEG	B-I
was	O
performed	O
by	O
using	O
the	O
Freka	O
Pexact-15	O
CH/FR	O
,	O
with	O
the	O
gastric	O
wall	O
nonsurgically	O
sutured	O
to	O
the	O
anterior	O
abdominal	O
wall	O
by	O
use	O
of	O
an	O
endoscope	O
.	O


MAIN	O
OUTCOME	O
MEASUREMENTS	O
The	B-O
peristomal	I-O
area	I-O
was	I-O
assessed	I-O
daily	I-O
for	I-O
7	I-O
days	I-O
by	I-O
using	I-O
2	I-O
different	I-O
types	I-O
of	I-O
infection	I-O
scores	I-O
.	I-O


RESULTS	O
Clinically	B-O
significant	I-O
wound	I-O
reaction	I-O
was	O
observed	O
in	O
1	O
patient	O
in	O
each	O
group	O
.	O


Wound	B-O
infection	I-O
scores	I-O
were	O
marginally	O
higher	O
in	O
the	O
placebo	B-I
group	O
,	O
but	O
the	O
differences	O
in	O
the	O
values	B-O
of	I-O
infection	I-O
scores	I-O
between	O
both	O
the	O
groups	O
were	O
not	O
statistically	O
significant	O
during	O
the	O
7-day	O
post-PEG	O
follow-up	O
.	O


LIMITATIONS	O
The	O
introducer	O
gastropexy	O
kit	O
is	O
5	O
times	O
more	O
expensive	O
than	O
the	O
"	O
pull	O
"	O
PEG	O
.	O


CONCLUSIONS	O
The	B-I
new	I-I
introducer	I-I
PEG-gastropexy	I-I
technique	I-I
can	O
be	O
performed	O
safely	O
,	O
without	O
prophylactic	O
antibiotics	O
in	O
patients	B-P
potentially	I-P
at	I-P
high	I-P
risk	I-P
of	I-P
peristomal	I-P
infectious	I-P
complications	I-P
(	I-P
those	I-P
with	I-P
advanced	I-P
oropharyngeal	I-P
malignancy	I-P
)	I-P
(	O
ClinicalTrials.gov	O
identifier	O
NCT00375414	O
)	O
.	O


Modelling	B-P
broilers	I-P
'	I-P
abdominal	I-P
fat	I-P
in	O
response	O
to	O
dietary	O
treatments	O
.	O


Neural	O
networks	O
are	O
capable	O
of	O
modelling	O
any	O
complex	O
function	O
and	O
can	O
be	O
used	O
in	O
poultry	B-P
production	I-P
.	I-P


Dietary	B-I
crude	I-I
fibre	I-I
(	I-I
CF	I-I
)	I-I
and	O
exogenous	B-I
enzymes	I-I
(	I-I
exEn	I-I
)	I-I
extensively	O
affected	O
abdominal	O
fat	O
(	O
AF	O
)	O
of	O
broilers	O
.	O


Current	O
methods	O
to	O
study	O
AF	O
and	O
its	O
correlation	O
with	O
dietary	O
CF	O
levels	O
and	O
exEn	O
supplements	O
are	O
costly	O
,	O
laborious	O
and	O
time-consuming	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
artificial	O
neural	O
network-genetic	O
algorithm	O
(	O
ANN-GA	O
)	O
to	O
model	O
data	O
on	O
the	O
response	B-O
of	I-O
broiler	I-O
chickens	I-O
(	I-O
AF	I-O
)	I-O
to	I-P
CF	I-I
and	I-P
exEn	I-I
from	I-P
0	I-P
to	I-P
42	I-P
days	I-P
of	I-P
age	I-P
.	O


A	O
data	O
set	O
containing	O
eight	O
treatments	O
was	O
divided	O
to	O
the	O
train	O
,	O
validation	O
,	O
and	O
test	O
data	O
set	O
of	O
the	O
ANN	O
models	O
.	O


The	O
information	O
about	O
feeding	O
eight	O
diets	O
at	O
two	O
periods	O
[	O
starter	O
(	O
0-21	O
days	O
of	O
age	O
)	O
and	O
grower	O
(	O
22-42	O
days	O
of	O
age	O
)	O
]	O
were	O
used	O
to	O
estimate	O
AF	O
of	B-P
broilers	I-P
by	O
ANN-GA.	O
A	O
multilayer	O
feed-forward	O
neural	O
network	O
with	O
different	O
structures	O
was	O
developed	O
using	O
matlab	O
software	O
,	O
and	O
optimal	O
values	O
for	O
the	O
ANN	O
weights	O
were	O
obtained	O
using	O
the	O
genetic	O
algorithm	O
(	B-O
GA	I-O
)	I-O
.	I-O


Crude	B-O
fibre	I-O
,	I-O
and	I-O
exEn	I-O
were	O
used	O
as	O
input	O
variables	O
and	O
AF	O
of	O
broilers	O
was	O
output	O
variable	O
.	O


The	O
best	O
model	O
of	O
ANN-GA	O
was	O
determined	O
based	O
on	O
the	B-O
train	I-O
root	I-O
mean	I-O
square	I-O
error	I-O
(	I-O
RMSE	I-O
)	I-O
.	O


The	O
best	O
selected	O
ANN-GA	O
showed	O
desirable	O
results	O
,	O
RMSE	O
,	O
0.1286	O
%	O
and	O
R	O
(	O
2	O
)	O
coefficient	O
,	O
0.876	O
for	O
test	O
data	O
.	O


Using	O
a	O
laryngeal	B-I
tube	I-I
suction-device	I-I
(	I-I
LTS-D	I-I
)	I-I
reduces	O
the	O
"	B-O
no	I-O
flow	I-O
time	I-O
"	I-O
in	O
a	O
single	O
rescuer	O
manikin	O
study	O
.	O


BACKGROUND	O
In	O
2005	O
,	O
the	O
European	O
Resuscitation	O
Council	O
and	O
the	O
American	O
Heart	O
Association	O
published	O
new	O
guidelines	O
for	O
Advanced	O
Life	O
Support	O
.	O


One	O
of	O
the	O
points	O
was	O
to	O
reduce	O
the	O
time	B-O
without	I-O
chest	I-O
compressions	I-O
in	O
the	O
first	O
phase	O
of	O
cardiac	O
arrest	O
.	O


OBJECTIVE	O
We	O
evaluated	O
in	O
a	O
manikin	O
model	O
whether	O
using	O
the	O
single-use	B-I
laryngeal	I-I
tube	I-I
with	I-I
suction	I-I
option	I-I
(	I-I
LTS-D	I-I
)	I-I
instead	I-I
of	O
endotracheal	B-I
intubation	I-I
(	I-I
ET	I-I
)	I-I
and	I-I
bag-mask-valve	I-I
ventilation	I-I
(	I-I
BMV	I-I
)	I-I
for	I-I
emergency	I-I
airway	I-I
management	I-I
could	I-I
reduce	O
the	O
"	B-O
no-flow	I-O
time	I-O
"	I-O
(	I-O
NFT	I-O
)	I-O
.	O


The	O
NFT	O
is	O
defined	O
as	O
the	O
time	O
during	O
resuscitation	O
when	O
no	O
chest	O
compressions	O
take	O
place	O
.	O


METHODS	O
A	O
randomized	B-P
,	I-P
prospective	I-P
study	I-P
was	I-P
undertaken	I-P
with	I-P
150	I-P
volunteers	I-P
who	I-P
performed	I-P
management	I-P
of	I-P
a	I-P
standardized	I-P
simulated	I-P
cardiac	I-P
arrest	I-P
in	I-P
a	I-P
manikin	I-P
.	I-P


Every	O
participant	O
was	O
randomized	O
to	O
one	O
of	O
three	O
different	O
airway	O
management	O
groups	O
(	O
LTS-D	O
vs	O
.	O


ET	O
vs.	O
BMV	O
)	O
.	O


RESULTS	O
The	O
LTS-D	B-I
was	O
inserted	O
significantly	O
faster	O
than	O
the	O
ET	O
tube	O
(	O
15	O
s	O
vs.	O
44	O
s	O
,	O
respectively	O
,	O
p	O
<	O
0.01	O
)	O
.	O


During	O
the	O
cardiac	O
arrest	O
simulation	O
,	O
establishing	B-O
and	I-O
performing	I-O
ventilation	I-O
took	O
an	O
average	O
of	O
57	O
s	O
with	O
the	O
LTS-D	B-I
compared	O
to	O
116	O
s	O
with	O
ET	B-I
and	O
111	O
s	O
with	O
the	O
BMV	B-I
.	I-I


Using	O
the	O
LTS-D	B-I
significantly	O
reduced	O
NFT	B-O
compared	O
to	O
ET	B-I
and	O
the	O
BMV	B-I
(	O
125	O
s	O
vs.	O
207	O
s	O
vs.	O
160	O
s	O
;	O
p	O
<	O
0.01	O
)	O
.	O


CONCLUSIONS	O
In	O
our	O
manikin	O
study	O
,	O
NFT	B-O
was	O
reduced	O
significantly	O
when	O
the	O
LTS-D	B-I
was	O
used	O
when	O
compared	O
to	O
ET	B-I
and	I-I
BMV	I-I
.	I-I


The	O
results	O
of	O
our	O
manikin	O
study	O
suggest	O
that	O
for	O
personnel	O
not	O
experienced	O
in	O
tracheal	O
intubation	O
,	O
the	O
LTS-D	B-I
offers	O
a	O
good	O
alternative	O
to	O
ET	B-I
and	O
BMV	B-I
to	O
manage	O
the	O
airway	O
during	O
resuscitation	O
,	O
and	O
to	O
avoid	O
the	O
failure	O
to	O
achieve	O
tracheal	O
intubation	O
with	O
the	O
ET	B-I
,	O
and	O
the	O
failure	O
to	O
achieve	O
adequate	O
ventilation	O
with	O
the	O
BMV	B-I
.	I-I


Incidence	O
and	O
time	O
course	O
of	O
cardiovascular	B-O
side	I-O
effects	I-O
during	O
spinal	B-I
anesthesia	I-I
after	I-P
prophylactic	I-P
administration	I-P
of	I-P
intravenous	I-I
fluids	I-I
or	I-I
vasoconstrictors	I-I
.	I-I


UNLABELLED	O
We	O
studied	O
the	O
time	O
course	O
of	O
arterial	O
hypotension	O
and/or	O
bradycardia	O
requiring	O
treatment	O
during	O
spinal	B-P
anesthesia	I-P
and	O
compared	O
the	O
efficacy	O
of	O
i.v	B-I
.	I-I


fluid	B-I
or	I-I
vasoconstrictor	I-I
administration	I-I
for	O
the	O
prevention	O
of	O
these	O
side	O
effects	O
.	O


Patients	B-P
(	I-P
n	I-P
=	I-P
1066	I-P
)	I-P
were	O
randomly	O
allocated	O
to	O
either	O
a	O
volume	B-I
group	I-I
(	I-I
lactated	I-I
Ringer	I-I
's	I-I
solution	I-I
15	O
mL/kg	O
within	O
15	O
min	O
before	O
spinal	O
anesthesia	O
)	O
,	O
a	O
dihydroergotamine	B-I
group	O
(	O
10	O
microg/kg	O
i.m	O
.	O


15	O
min	O
before	O
anesthesia	B-I
)	I-I
,	I-I
or	I-I
a	I-I
placebo	I-I
group	I-I
.	I-I


All	B-P
patients	I-P
breathed	I-P
O2-enriched	I-P
air	I-P
during	I-P
spinal	I-I
anesthesia	I-I
(	I-P
4	I-P
mL	I-P
of	I-P
plain	I-P
0.5	I-P
%	I-P
bupivacaine	I-I
)	I-I
.	I-P


With	O
the	O
placebo	B-I
,	O
there	O
were	O
side	B-O
effects	I-O
(	O
mean	O
incidence	O
22.9	O
%	O
)	O
for	O
up	O
to	O
45	O
min	O
after	O
the	O
start	O
of	O
anesthesia	O
.	O


Dihydroergotamine	B-I
reduced	O
the	O
incidence	B-O
of	I-O
side	I-O
effects	I-O
,	O
preferentially	O
the	O
late	O
ones	O
,	O
more	O
(	O
mean	O
incidence	O
11.8	O
%	O
)	O
than	O
fluid	O
administration	O
(	O
mean	O
incidence	O
16.9	O
%	O
)	O
,	O
which	O
was	O
effective	O
only	O
during	O
the	O
first	O
15	O
min	O
of	O
anesthesia	O
.	O


Both	O
heart	B-O
rate	I-O
and	I-O
arterial	I-O
pressure	I-O
decreased	I-O
within	O
15	O
min	O
before	O
the	O
manifestation	O
of	O
symptoms	O
.	O


In	O
a	O
subgroup	O
of	O
patients	O
,	O
the	O
incidence	B-O
of	I-O
side	I-O
effects	I-O
(	O
8	O
%	O
)	O
was	O
greatly	O
reduced	O
by	O
the	O
intraoperative	O
application	O
of	O
both	O
sedatives	O
and	O
opioids	O
.	O


We	O
conclude	O
that	O
cardiovascular	B-O
side	I-O
effects	I-O
may	O
occur	O
at	O
any	O
time	O
during	O
spinal	O
anesthesia	O
.	O


Fluid	O
administration	O
reduced	O
the	O
incidence	B-O
of	I-O
early	I-O
events	I-O
,	O
but	O
dihydroergotamine	O
the	O
late	B-O
events	I-O
.	I-O


IMPLICATIONS	O
Cardiovascular	B-O
side	I-O
effects	I-O
requiring	O
treatment	O
occurred	O
at	O
any	O
time	O
during	O
spinal	O
anesthesia	O
in	O
our	O
placebo-controlled	B-I
study	O
,	O
regardless	O
of	O
the	O
prophylactic	O
regimen	O
(	B-I
fluid	I-I
infusions	I-I
versus	O
dihydroergotamine	B-I
)	I-I
.	O


Oxytocin	B-I
reduces	O
caloric	O
intake	O
in	O
men	B-P
.	I-P


OBJECTIVE	O
Preclinical	O
studies	O
indicate	O
that	O
oxytocin	B-I
is	O
anorexigenic	O
and	O
has	O
beneficial	O
metabolic	O
effects	O
.	O


Oxytocin	B-I
effects	O
on	O
nutrition	O
and	O
metabolism	O
in	O
humans	O
are	O
not	O
well	O
defined	O
.	O


It	O
was	O
hypothesized	O
that	O
oxytocin	B-I
would	O
reduce	O
caloric	O
intake	O
and	O
appetite	O
and	O
alter	O
levels	O
of	O
appetite-regulating	O
hormones	O
.	O


Metabolic	O
effects	O
of	O
oxytocin	O
were	O
also	O
explored	O
.	O


METHODS	O
A	O
randomized	O
,	O
placebo-controlled	B-I
crossover	O
study	O
of	O
single-dose	B-I
intranasal	I-I
oxytocin	I-I
(	I-I
24	I-I
IU	I-I
)	I-I
in	O
25	B-P
fasting	I-P
healthy	I-P
men	I-P
was	O
performed	O
.	O


After	O
oxytocin/placebo	B-I
,	O
subjects	O
selected	B-I
breakfast	I-I
from	I-I
a	I-I
menu	I-I
and	I-I
were	I-I
given	I-I
double	I-I
portions	I-I
.	I-I


Caloric	B-I
content	I-I
of	I-I
food	I-I
consumed	I-I
was	I-I
measured	I-I
.	I-I


Visual	B-I
analog	I-I
scales	I-I
were	O
used	O
to	O
assess	O
appetite	B-O
,	O
and	O
blood	B-I
was	I-I
drawn	I-I
for	I-I
appetite-regulating	I-I
hormones	I-I
,	I-I
insulin	I-I
,	I-I
and	I-I
glucose	I-I
before	I-I
and	I-I
after	I-I
oxytocin/placebo	I-I
.	I-I


Indirect	B-I
calorimetry	I-I
assessed	I-I
resting	I-I
energy	I-I
expenditure	I-I
(	I-I
REE	I-I
)	I-I
and	I-I
substrate	I-I
utilization	I-I
.	I-I


RESULTS	O
Oxytocin	B-I
reduced	I-O
caloric	I-O
intake	I-O
with	O
a	O
preferential	O
effect	O
on	O
fat	B-O
intake	I-O
and	O
increased	B-O
levels	I-O
of	I-O
the	I-O
anorexigenic	I-O
hormone	I-O
cholecystokinin	I-O
without	O
affecting	O
appetite	O
or	O
other	O
appetite-regulating	O
hormones	O
.	O


There	O
was	O
no	O
effect	O
of	O
oxytocin	O
on	O
REE	B-O
.	I-O


Oxytocin	B-I
resulted	O
in	O
a	O
shift	O
from	O
carbohydrate	O
to	O
fat	O
utilization	O
and	O
improved	O
insulin	O
sensitivity	O
.	O


CONCLUSIONS	O
Intranasal	O
oxytocin	B-I
reduces	O
caloric	O
intake	O
and	O
has	O
beneficial	O
metabolic	O
effects	O
in	O
men	B-P
without	O
concerning	O
side	O
effects	O
.	O


The	O
efficacy	O
and	O
safety	O
of	O
sustained	O
oxytocin	B-I
administration	O
in	O
the	O
treatment	O
of	O
obesity	O
warrants	O
investigation	O
.	O


Randomized	O
trial	O
of	O
interferon-	B-I
and	O
ribavirin-free	B-I
ombitasvir/paritaprevir/ritonavir	I-I
in	O
treatment-experienced	B-P
hepatitis	I-P
C	I-P
virus-infected	I-P
patients	I-P
.	I-P


UNLABELLED	O
Approximately	O
2	O
million	O
Japanese	B-P
individuals	I-P
are	O
infected	O
with	O
hepatitis	O
C	O
virus	O
and	O
are	O
at	O
risk	O
for	O
cirrhosis	O
,	O
end-stage	O
liver	O
disease	O
,	O
and	O
hepatocellular	O
carcinoma	O
.	O


Patients	O
in	O
whom	O
interferon	B-I
(	I-I
IFN	I-I
)	I-I
/ribavirin	I-I
(	I-I
RBV	I-I
)	I-I
therapy	I-I
has	O
failed	O
remain	O
at	O
risk	O
as	O
effective	O
therapeutic	O
options	O
are	O
limited	O
.	O


This	O
phase	O
2	O
,	O
randomized	O
,	O
open-label	O
study	O
evaluated	O
an	O
IFN-	B-I
and	I-I
RBV-free	I-I
regimen	O
of	O
once-daily	O
ombitasvir	B-I
(	I-I
ABT-267	I-I
)	I-I
,	O
an	O
NS5A	B-I
inhibitor	I-I
,	I-I
plus	I-I
paritaprevir	I-I
(	I-I
ABT-450	I-I
)	I-I
,	O
an	O
NS3/4A	B-I
protease	I-I
inhibitor	I-I
dosed	I-I
with	I-I
ritonavir	I-I
(	I-I
paritaprevir/ritonavir	I-I
)	I-I
,	O
in	O
pegylated	B-P
IFN/RBV	I-I
treatment-experienced	I-P
Japanese	I-P
patients	I-P
with	I-P
hepatitis	I-P
C	I-P
virus	I-P
subtype	I-P
1b	I-P
or	I-P
genotype	I-P
2	I-P
infection	I-P
.	I-P


Patients	B-P
without	I-P
cirrhosis	I-P
(	I-P
aged	I-P
18-75	I-P
years	I-P
)	I-P
with	I-P
subtype	I-P
1b	I-P
infection	I-P
received	O
ombitasvir	B-I
25	I-I
mg	I-I
plus	I-I
paritaprevir/ritonavir	I-I
100/100	O
mg	O
or	O
150/100	O
mg	O
for	O
12	O
or	O
24	O
weeks	O
;	O
patients	B-P
with	I-P
genotype	I-P
2	I-P
infection	I-P
received	O
ombitasvir	B-I
25	I-I
mg	I-I
plus	I-I
paritaprevir/ritonavir	I-I
100/100	I-I
mg	I-I
or	I-I
150/100	I-I
mg	I-I
for	I-I
12	I-I
weeks	I-I
.	I-I


Sustained	B-O
virologic	I-O
response	I-O
(	I-O
SVR	I-O
)	I-O
at	O
posttreatment	O
week	O
24	O
(	O
SVR24	O
)	O
was	O
the	O
primary	O
endpoint	O
.	O


Adverse	O
events	O
were	O
collected	O
throughout	O
the	O
study	O
.	O


One	B-P
hundred	I-P
ten	I-P
patients	I-P
received	O
≥1	O
dose	O
of	O
study	O
medication	O
.	O


In	O
the	O
subtype	O
1b	O
cohort	B-O
,	I-O
SVR24	I-O
rates	I-O
were	O
high	O
(	O
88.9	O
%	O
-100	O
%	O
)	O
regardless	O
of	O
paritaprevir	O
dose	O
or	O
treatment	O
duration	O
.	O


In	O
the	O
genotype	O
2	O
cohort	B-O
,	I-O
SVR24	I-O
rates	I-O
were	O
57.9	O
%	O
and	O
72.2	O
%	O
with	O
100	O
mg	O
and	O
150	O
mg	O
of	O
paritaprevir	O
,	O
respectively	O
.	O


The	B-O
SVR24	I-O
rate	I-O
was	O
higher	O
in	O
patients	O
with	O
subtype	O
2a	O
(	O
90	O
%	O
)	O
than	O
2b	O
(	O
27	O
%	O
)	O
.	O


Concordance	O
between	B-O
SVR12	I-O
and	I-O
SVR24	I-O
was	O
100	O
%	O
.	O


The	O
most	O
common	O
adverse	O
events	O
overall	O
were	B-O
nasopharyngitis	I-O
(	O
29	O
%	O
)	O
and	B-O
headache	I-O
(	O
14	O
%	O
)	O
.	O


CONCLUSION	O
In	O
this	B-P
difficult-to-treat	I-P
population	I-P
of	I-P
patients	I-P
in	I-P
whom	I-P
prior	I-P
pegylated	I-P
IFN/RBV	I-P
had	I-P
failed	I-I
,	I-I
ombitasvir/paritaprevir/ritonavir	I-I
demonstrated	O
potent	O
antiviral	O
activity	O
with	O
a	O
favorable	O
safety	O
profile	O
among	B-P
Japanese	I-P
patients	I-P
with	I-P
hepatitis	I-P
C	I-P
virus	I-P
genotype	I-P
1b	I-P
or	I-P
2a	I-P
infection	I-P
.	O


Failure	O
of	O
naltrexone	B-I
hydrochloride	I-I
to	O
reduce	O
self-injurious	B-P
and	I-P
autistic	I-P
behavior	I-P
in	I-P
mentally	I-P
retarded	I-P
adults	I-P
.	I-P


Double-blind	O
placebo-controlled	B-I
studies	O
.	O


BACKGROUND	O
It	O
is	O
hypothesized	O
that	O
self-injurious	O
behavior	O
(	O
SIB	O
)	O
and	O
symptoms	O
of	O
autism	O
may	O
be	O
due	O
to	O
overactivity	O
in	O
some	O
opioid	O
systems	O
in	O
the	O
brain	O
.	O


We	O
examined	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
naltrexone	B-I
hydrochloride	I-I
,	O
an	O
opioid	O
antagonist	O
,	O
in	O
the	O
treatment	O
of	O
SIB	B-P
and	I-P
autism	I-P
in	I-P
mentally	I-P
retarded	I-P
adults	I-P
.	I-P


METHOD	O
Thirty-three	B-P
mentally	I-P
retarded	I-P
adults	I-P
with	I-P
autism	I-P
and/or	I-P
SIB	I-P
participated	I-P
in	I-P
double-blind	I-P
,	I-P
placebo-controlled	I-I
crossover	I-P
studies	I-P
.	I-P


Active	O
treatment	O
was	O
first	O
a	O
single	O
100-mg	O
dose	O
of	O
naltrexone	B-I
hydrochloride	I-I
.	I-I


Subsequently	O
,	O
19	O
subjects	O
were	O
treated	O
with	O
50	O
mg/d	O
and	O
14	O
with	O
150	O
mg/d	O
of	O
naltrexone	B-I
hydrochloride	I-I
for	O
4	O
weeks	O
.	O


The	O
outcome	O
was	O
assessed	O
by	O
means	O
of	O
direct	O
observations	O
(	O
n	O
=	O
11	O
)	O
and	O
on	O
the	O
basis	O
of	O
scores	O
on	O
a	O
list	B-O
of	I-O
target	I-O
behaviors	I-O
,	I-O
the	I-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
,	I-O
and	I-O
the	I-O
Clinical	I-O
Global	I-O
Impression	I-O
Scale	I-O
.	I-O


RESULTS	O
Thirty-two	O
subjects	O
(	O
seven	O
with	O
autism	O
,	O
16	O
with	O
autism	O
and	O
SIB	O
,	O
and	O
nine	O
with	O
SIB	O
)	O
completed	O
the	O
trial	O
.	O


Naltrexone	B-I
treatment	O
failed	B-O
to	O
have	O
therapeutic	O
effects	O
on	O
SIB	O
and	O
autism	O
.	O


On	O
the	O
contrary	O
,	O
naltrexone	B-I
increased	I-O
the	I-O
incidence	I-O
of	I-O
stereotypic	I-O
behavior	I-O
on	I-O
the	I-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
,	O
and	O
the	O
care	O
staff	O
evaluated	O
the	O
effect	O
of	O
the	O
50-mg/d	O
treatment	O
as	O
being	O
significantly	B-O
worse	I-O
than	O
that	O
of	O
the	O
placebo	O
treatment	O
as	O
measured	O
by	O
the	O
Clinical	B-O
Global	I-O
Impression	I-O
Scale	I-O
.	I-O


CONCLUSION	O
Our	O
findings	O
suggest	O
that	O
naltrexone	O
has	O
no	O
clinical	O
value	O
for	O
a	O
broad	O
group	O
of	O
mentally	O
retarded	O
subjects	O
with	O
SIB	O
and/or	O
autism	O
.	O


Low-frequency	B-I
repetitive	I-I
transcranial	I-I
magnetic	I-I
stimulation	I-I
(	I-I
rTMS	I-I
)	I-I
affects	O
event-related	O
potential	O
measures	O
of	O
novelty	O
processing	O
in	O
autism	B-P
.	I-P


In	O
our	O
previous	O
study	O
on	O
individuals	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
(	O
Sokhadze	O
et	O
al.	O
,	O
Appl	O
Psychophysiol	O
Biofeedback	O
34:37-51	O
,	O
2009a	O
)	O
we	O
reported	O
abnormalities	O
in	O
the	O
attention-orienting	O
frontal	O
event-related	O
potentials	O
(	O
ERP	O
)	O
and	O
the	O
sustained-attention	O
centro-parietal	O
ERPs	O
in	O
a	O
visual	O
oddball	O
experiment	O
.	O


These	O
results	O
suggest	O
that	O
individuals	B-P
with	I-P
autism	I-P
over-process	O
information	O
needed	O
for	O
the	O
successful	O
differentiation	O
of	O
target	O
and	O
novel	O
stimuli	O
.	O


In	O
the	O
present	O
study	O
we	O
examine	O
the	O
effects	O
of	O
low-frequency	B-I
,	I-I
repetitive	I-I
Transcranial	I-I
Magnetic	I-I
Stimulation	I-I
(	I-I
rTMS	I-I
)	I-I
on	O
novelty	O
processing	O
as	O
well	O
as	O
behavior	O
and	O
social	O
functioning	O
in	O
13	B-P
individuals	I-P
with	I-P
ASD	I-P
.	I-P


Our	O
hypothesis	O
was	O
that	O
low-frequency	B-I
rTMS	I-I
application	O
to	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLFPC	O
)	O
would	O
result	O
in	O
an	O
alteration	O
of	O
the	O
cortical	O
excitatory/inhibitory	O
balance	O
through	O
the	O
activation	O
of	O
inhibitory	O
GABAergic	O
double	O
bouquet	O
interneurons	O
.	O


We	O
expected	O
to	O
find	O
post-TMS	O
differences	O
in	O
amplitude	O
and	O
latency	O
of	O
early	O
and	O
late	O
ERP	O
components	O
.	O


The	O
results	O
of	O
our	O
current	O
study	O
validate	O
the	O
use	O
of	O
low-frequency	O
rTMS	O
as	O
a	O
modulatory	O
tool	O
that	O
altered	O
the	O
disrupted	O
ratio	O
of	O
cortical	O
excitation	O
to	O
inhibition	O
in	O
autism	O
.	O


After	O
rTMS	O
the	O
parieto-occipital	B-O
P50	I-O
amplitude	I-O
decreased	I-O
to	I-O
novel	I-O
distracters	I-O
but	I-O
not	I-O
to	I-O
targets	I-O
;	I-O
also	O
the	O
amplitude	B-O
and	I-O
latency	I-O
to	I-O
targets	I-O
increased	I-O
for	I-O
the	I-O
frontal	I-O
P50	I-O
while	I-O
decreasing	I-O
to	I-O
non-target	I-O
stimuli	I-O
.	I-O


Low-frequency	O
rTMS	O
minimized	B-O
early	I-O
cortical	I-O
responses	I-O
to	I-O
irrelevant	I-O
stimuli	I-O
and	O
increased	B-O
responses	I-O
to	I-O
relevant	I-O
stimuli	I-O
.	I-O


Improved	O
selectivity	O
in	O
early	O
cortical	O
responses	O
lead	O
to	O
better	B-O
stimulus	I-O
differentiation	I-O
at	I-O
later-stage	I-O
responses	I-O
as	O
was	O
made	O
evident	O
by	O
our	O
P3b	O
and	O
P3a	O
component	O
findings	O
.	O


These	O
results	O
indicate	O
a	O
significant	B-O
change	I-O
in	I-O
early	I-O
,	I-O
middle-latency	I-O
and	I-O
late	I-O
ERP	I-O
components	I-O
at	I-O
the	I-O
frontal	I-O
,	I-O
centro-parietal	I-O
,	I-O
and	I-O
parieto-occipital	I-O
regions	I-O
of	I-O
interest	I-O
in	I-O
response	I-O
to	I-O
target	I-O
and	I-O
distracter	I-O
stimuli	I-O
as	O
a	O
result	O
of	O
rTMS	O
treatment	O
.	O


Overall	O
,	O
our	O
preliminary	O
results	O
show	O
that	O
rTMS	O
may	O
prove	O
to	O
be	O
an	O
important	O
research	O
tool	O
or	O
treatment	O
modality	O
in	O
addressing	O
the	O
stimulus	O
hypersensitivity	O
characteristic	O
of	O
autism	O
spectrum	O
disorders	O
.	O


Low-dose	B-I
growth	I-I
hormone	I-I
treatment	I-I
with	I-I
diet	I-I
restriction	I-I
accelerates	I-O
body	I-O
fat	I-O
loss	I-O
,	I-O
exerts	I-O
anabolic	I-O
effect	I-O
and	I-O
improves	I-O
growth	I-O
hormone	I-O
secretory	I-O
dysfunction	I-O
in	O
obese	B-P
adults	I-P
.	I-P


Growth	B-I
hormone	I-I
(	O
GH	O
)	O
can	O
induce	O
an	O
accelerated	B-O
lipolysis	I-O
.	I-O


Impaired	O
secretion	O
of	O
GH	O
in	O
obesity	O
results	O
in	O
the	O
consequent	O
loss	O
of	O
the	O
lipolytic	B-O
effect	I-O
of	I-O
GH	I-O
.	I-O


Dietary	O
restriction	O
as	O
a	O
basic	O
treatment	O
for	O
obesity	O
is	O
complicated	O
by	O
poor	O
compliance	O
,	O
protein	O
catabolism	O
,	O
and	O
slow	O
rates	O
or	O
weight	O
loss	O
.	O


GH	O
has	O
an	O
anabolic	O
effect	O
by	O
increasing	B-O
insulin-like	I-O
growth	I-O
factor	I-O
(	I-O
IGF	I-O
)	I-O
-I	I-O
.	I-O


We	O
investigated	O
the	O
effects	O
of	O
GH	O
treatment	O
and	O
dietary	O
restriction	O
on	O
lipolytic	B-O
and	I-O
anabolic	I-O
actions	I-O
,	I-O
as	I-O
well	I-O
as	I-O
the	I-O
consequent	I-O
changes	I-O
in	I-O
insulin	I-O
and	I-O
GH	I-O
secretion	I-O
in	I-O
obesity	I-O
.	I-O


24	B-P
obese	I-P
subjects	I-P
(	I-P
22	I-P
women	I-P
and	I-P
2	I-P
men	I-P
;	I-P
22-46	I-P
years	I-P
old	I-P
)	I-P
were	O
fed	O
a	O
diet	B-I
of	O
25	O
kcal/kg	O
ideal	O
body	O
weight	O
(	O
IBW	O
)	O
with	O
1.2	O
g	O
protein/kg	O
IBW	O
daily	O
and	O
were	O
treated	O
with	O
recombinant	B-I
human	I-I
GH	I-I
(	O
n	O
=	O
12	O
,	O
0.18	O
U/kg	O
IBW/week	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
12	O
,	O
vehicle	O
injection	O
)	O
in	O
a	O
12-week	O
randomized	O
,	O
double-blind	O
and	O
placebo-controlled	O
trial	O
.	O


GH	B-I
treatment	O
caused	O
a	O
1.6-fold	O
increase	O
in	O
the	O
fraction	B-O
of	I-O
body	I-O
weight	I-O
lost	I-O
as	I-O
fat	I-O
and	I-O
a	I-O
greater	I-O
loss	I-O
of	I-O
visceral	I-O
fat	I-O
area	I-O
than	O
placebo	O
treatment	O
(	O
35.3	O
vs.	O
28.5	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O


In	O
the	O
placebo	O
group	O
,	O
there	O
was	O
a	O
loss	O
in	O
lean	B-O
body	I-O
mass	I-O
(	O
-2.62	O
+/-	O
1.51	O
kg	O
)	O
and	O
a	O
negative	B-O
nitrogen	I-O
balance	I-O
(	O
-4.52	O
+/-	O
3.51	O
g/day	O
)	O
.	O


By	O
contrast	O
,	O
the	O
GH	B-I
group	O
increased	O
in	O
lean	B-O
body	I-O
mass	I-O
(	O
1.13	O
+/-	O
1.04	O
kg	O
)	O
and	O
had	O
a	O
positive	B-O
nitrogen	I-O
balance	I-O
(	O
1.81	O
+/-	O
2.06	O
g/day	O
)	O
.	O


GH	B-I
injections	I-I
caused	O
a	O
1.6-fold	O
increase	B-O
in	I-O
IGF-I	I-O
,	O
despite	O
caloric	O
restriction	O
.	O


GH	B-O
response	I-O
to	I-O
L-dopa	I-O
stimulation	I-O
was	O
blunted	B-O
in	O
all	O
subjects	O
and	O
it	O
was	O
increased	O
after	O
treatment	O
in	O
both	O
groups	O
.	O


GH	B-I
treatment	O
did	O
not	O
induce	O
a	O
further	O
increase	O
in	O
insulin	B-O
levels	I-O
during	O
an	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
but	O
significantly	O
decreased	O
free	B-O
fatty	I-O
acid	I-O
(	I-O
FFA	I-O
)	I-O
levels	I-O
during	O
OGTT	O
.	O


The	O
decrease	O
in	O
FFA	B-O
area	I-O
under	O
the	O
curve	O
during	O
OGTT	O
was	O
positively	O
correlated	O
with	O
visceral	B-O
fat	I-O
loss	I-O
.	I-O


This	O
study	O
demonstrates	O
that	O
in	O
obese	B-P
subjects	I-P
given	O
a	O
hypocaloric	O
diet	O
,	O
GH	O
accelerates	O
body	B-O
fat	I-O
loss	I-O
,	I-O
exerts	I-O
anabolic	I-O
effects	I-O
and	I-O
improves	I-O
GH	I-O
secretion	I-O
.	I-O


These	O
findings	O
suggest	O
a	O
possible	O
therapeutic	O
role	O
of	O
low-dose	O
GH	B-I
with	O
caloric	O
restriction	O
for	O
obesity	O
.	O


Randomized	O
clinical	O
study	O
comparing	O
Compeed	B-I
cold	I-I
sore	I-I
patch	I-I
to	O
acyclovir	B-I
cream	I-I
5	I-I
%	I-I
in	O
the	O
treatment	O
of	O
herpes	B-P
simplex	I-P
labialis	I-P
.	I-P


BACKGROUND	O
Hydrocolloid	O
technology	O
has	O
been	O
proven	O
effective	O
in	O
treating	O
dermal	O
wounds	O
.	O


A	O
previous	O
study	O
showed	O
that	O
a	O
newly	O
developed	O
thin	B-I
hydrocolloid	I-I
patch	I-I
[	I-I
Compeed	I-I
cold	I-I
sore	I-I
patch	I-I
(	I-I
CSP	I-I
)	I-I
]	I-I
provided	O
multiple	O
wound-healing	O
benefits	O
across	O
all	O
stages	O
of	O
a	O
herpes	B-P
simplex	I-P
labialis	I-P
(	I-P
HSL	I-P
)	I-P
outbreak	O
.	O


METHODS	O
An	O
assessment	O
of	O
CSP	O
efficacy	O
and	O
safety	O
was	O
conducted	O
in	O
an	O
international	B-P
,	I-P
multicentre	I-P
,	O
assessor-blinded	O
study	O
,	O
which	O
enrolled	B-P
728	I-P
subjects	I-P
with	I-P
a	I-P
history	I-P
of	I-P
recurrent	I-P
HSL	I-P
.	I-P


Of	O
these	O
,	O
351	B-P
experienced	O
an	O
HSL	O
outbreak	O
and	O
were	O
randomized	O
to	O
use	O
CSP	O
(	O
n	O
=	O
179	O
)	O
or	O
acyclovir	B-I
cream	I-I
5	I-I
%	I-I
(	O
n	O
=	O
172	O
)	O
at	O
the	O
onset	O
of	O
symptoms	O
until	O
the	O
lesion	O
healed	O
,	O
for	O
a	O
maximum	O
of	O
10	O
days	O
.	O


The	O
primary	O
end	O
point	O
was	O
the	O
subject	B-O
's	I-O
global	I-O
assessment	I-O
of	I-O
therapy	I-O
(	I-O
SGAT	I-O
;	I-O
0-10	I-O
scale	I-O
;	I-O
0	I-O
=	I-O
no	I-O
response	I-O
,	I-O
10	I-O
=	I-O
excellent	I-O
response	I-O
)	I-O
.	I-O


Multiple	O
secondary	O
end	O
points	O
included	O
clinician-assessed	B-O
healing	I-O
time	I-O
and	I-O
subject	I-O
assessment	I-O
of	I-O
lesion	I-O
protection	I-O
,	I-O
noticeability	I-O
and	I-O
social	I-O
embarrassment	I-O
.	I-O


RESULTS	O
CSP	B-I
and	I-I
acyclovir	I-I
were	O
highly	O
effective	O
(	O
mean	O
SGAT	O
=	O
7.89	O
and	O
8.00	O
,	O
respectively	O
)	O
,	O
with	O
no	O
significant	O
difference	O
observed	O
(	O
P	O
=	O
0.65	O
)	O
.	O


The	O
difference	O
in	O
healing	B-O
times	I-O
between	I-O
products	I-O
was	O
not	O
significant	O
(	O
median	O
,	O
7.57	O
days	O
with	O
CSP	O
vs.	O
7.03	O
days	O
with	O
acyclovir	O
,	O
P	O
=	O
0.37	O
)	O
.	O


Both	O
treatments	O
were	O
well	O
tolerated	B-O
.	I-O


CONCLUSION	O
CSP	B-I
using	I-I
hydrocolloid	I-I
technology	I-I
provides	O
an	O
efficacious	B-O
and	I-O
safe	I-O
alternative	O
to	O
topical	O
antivirals	O
in	O
treating	O
HSL	O
as	O
a	O
wound	O
while	O
affording	O
additional	O
immediate	O
benefits	O
of	O
wound	O
protection	O
,	O
discretion	O
and	O
relief	O
of	O
social	O
embarrassment	O
.	O


Preliminary	O
analysis	O
of	O
the	O
final	O
multicenter	O
investigation	O
of	O
rheopheresis	B-I
for	O
age	B-P
related	I-P
macular	I-P
degeneration	I-P
(	I-P
AMD	I-P
)	I-P
trial	O
(	O
MIRA-1	O
)	O
results	O
.	O


PURPOSE	O
To	O
present	O
an	O
initial	O
evaluation	O
of	O
the	O
final	O
data	O
from	O
the	O
Multicenter	O
Investigation	O
of	O
Rheopheresis	B-I
for	O
age-related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
(	O
MIRA-1	O
)	O
trial	O
.	O


This	O
was	O
a	O
12-month	O
randomized	O
,	O
prospective	O
,	O
multicenter	O
,	O
double-masked	O
,	O
placebo-controlled	B-I
,	O
Food	O
and	O
Drug	O
Administration	O
approved	O
clinical	O
trial	O
designed	O
to	O
compare	O
rheopheresis	B-I
treatment	I-I
with	O
placebo-control	B-I
treatment	I-I
.	I-I


METHODS	O
Patients	B-P
that	I-P
had	I-P
nonexudative	I-P
age-related	I-P
macular	I-P
degeneration	I-P
(	I-P
AMD	I-P
)	I-P
and	I-P
certain	I-P
hemorheologic	I-P
abnormalities	I-P
were	O
randomized	O
to	O
either	O
rheopheresis	B-I
or	I-I
sham	I-I
treatment	I-I
in	O
a	O
2:1	O
fashion	O
.	O


Best-corrected	O
visual	O
acuity	O
was	O
determined	O
before	O
and	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
following	O
treatment	O
.	O


Adverse	O
events	O
were	O
also	O
recorded	O
.	O


RESULTS	O
A	B-P
total	I-P
of	I-P
216	I-P
patients	I-P
were	O
randomized	O
.	O


Of	O
these	O
,	O
18	O
were	O
not	O
included	O
in	O
the	O
vision	B-O
or	I-O
adverse	I-O
events	I-O
evaluation	O
because	O
they	O
did	O
not	O
complete	O
one	O
treatment	O
.	O


This	O
decreased	O
the	O
number	O
of	O
patients	O
that	O
were	O
evaluated	O
for	O
adverse	O
events	O
to	O
198	B-P
patients	I-P
.	I-P


In	O
this	O
group	O
,	O
there	O
were	O
27	O
serious	O
adverse	O
events	O
,	O
but	O
only	O
1.8	O
%	O
of	O
treatments	O
were	O
suspended	O
because	O
of	O
adverse	O
events	O
.	O


At	O
12	O
months	O
,	O
there	O
were	O
104	O
treated	O
patients	O
and	O
63	O
placebo	B-I
patients	O
that	O
had	O
follow-up	O
.	O


The	O
treated	O
patients	O
had	O
a	O
logMAR	B-O
vision	I-O
improvement	I-O
of	O
0.02	O
+/-	O
0.213	O
,	O
and	O
the	O
placebo	B-I
patients	O
had	O
a	O
vision	B-O
improvement	I-O
of	O
0.02	O
+/-	O
0.20	O
.	O


This	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
.977	O
)	O
.	O


The	O
repeated	O
measure	O
P	O
value	O
for	O
the	O
entire	O
time	O
interval	O
was	O
not	O
significant	O
(	O
P	O
=	O
.69	O
)	O
.	O


There	O
appeared	O
to	O
be	O
patients	O
entered	O
into	O
the	O
study	O
that	O
did	O
not	O
meet	O
inclusion	O
criteria	O
.	O


Excluding	O
37	O
%	O
of	O
the	O
treated	O
patients	O
and	O
29	O
%	O
of	O
the	O
placebo	O
data	O
from	O
the	O
analysis	O
,	O
there	O
appeared	O
to	O
be	O
statistically	O
significant	O
improvement	O
in	O
the	O
treated	O
patients	O
compared	O
to	O
the	O
control	O
patients	O
at	O
1	O
year	O
with	O
a	O
P	O
value	O
of	O
.001	O
(	O
repeated	O
measures	O
P	O
value	O
=	O
.01	O
)	O
.	O


CONCLUSIONS	O
At	O
best	O
this	O
was	O
a	O
flawed	O
study	O
in	O
that	O
37	O
%	O
of	O
the	O
treated	O
cases	O
did	O
not	O
meet	O
inclusion	O
criteria	O
,	O
and	O
at	O
worst	O
there	O
was	O
no	O
evidence	O
of	O
effect	O
.	O


Even	O
though	O
the	O
number	O
of	O
serious	O
adverse	O
events	O
is	O
small	O
,	O
because	O
this	O
study	O
did	O
not	O
show	O
an	O
effect	O
in	O
the	O
intent-to-treat	O
group	O
,	O
rheopheresis	B-I
should	O
not	O
be	O
performed	O
for	O
AMD	O
outside	O
of	O
an	O
approved	O
randomized	O
controlled	O
trial	O
.	O


Randomized	O
controlled	O
trial	O
of	O
entecavir	B-I
prophylaxis	I-I
for	O
rituximab-associated	O
hepatitis	O
B	O
virus	O
reactivation	O
in	O
patients	B-P
with	I-P
lymphoma	I-P
and	I-P
resolved	I-P
hepatitis	I-P
B	I-P
.	I-P


PURPOSE	O
The	O
role	O
of	O
antiviral	B-I
prophylaxis	I-I
in	O
preventing	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
reactivation	O
before	O
rituximab-based	B-I
chemotherapy	I-I
in	O
patients	B-P
with	I-P
lymphoma	I-P
and	I-P
resolved	I-P
hepatitis	I-P
B	I-P
is	O
unclear	O
.	O


PATIENTS	O
AND	O
METHODS	O
Eighty	B-P
patients	I-P
with	I-P
CD20	I-P
(	I-P
+	I-P
)	I-P
lymphoma	I-P
and	I-P
resolved	I-P
hepatitis	I-P
B	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
prophylactic	B-I
entecavir	I-I
(	I-I
ETV	I-I
)	I-I
before	I-I
chemotherapy	I-I
to	I-I
3	I-I
months	I-I
after	I-I
completing	I-I
chemotherapy	I-I
(	I-I
ETV	I-I
prophylactic	I-I
group	I-I
,	I-I
n	I-I
=	I-I
41	I-I
)	I-I
or	I-I
to	I-I
receive	I-I
therapeutic	I-I
ETV	I-I
at	I-I
the	I-I
time	I-I
of	I-I
HBV	I-I
reactivation	I-I
and	I-I
hepatitis	I-I
B	I-I
surface	I-I
antigen	I-I
(	I-I
HBsAg	I-I
)	I-I
reverse	I-I
seroconversion	I-I
since	I-I
chemotherapy	I-I
(	I-I
control	I-I
group	I-I
,	I-I
n	I-I
=	I-I
39	I-I
)	I-I
.	I-I


RESULTS	O
Fifty-eight	B-P
patients	I-P
(	O
72.5	O
%	O
)	O
were	O
positive	O
for	O
hepatitis	O
B	O
surface	O
antibody	O
,	O
and	O
HBV	O
DNA	O
was	O
undetectable	O
in	O
50	O
patients	O
(	O
62.5	O
%	O
)	O
.	O


During	O
a	O
mean	O
18-month	O
follow-up	O
period	O
,	O
one	B-P
patient	I-P
(	O
2.4	O
%	O
)	O
in	O
the	O
ETV	B-I
prophylactic	O
group	O
and	O
seven	B-P
patients	I-P
(	O
17.9	O
%	O
)	O
in	O
the	O
control	O
group	O
developed	O
HBV	O
reactivation	O
(	O
P	O
=	O
.027	O
)	O
.	O


The	O
cumulative	B-O
HBV	I-O
reactivation	I-O
rates	I-O
at	O
months	O
6	O
,	O
12	O
,	O
and	O
18	O
after	O
chemotherapy	O
were	O
8	O
%	O
,	O
11.2	O
%	O
,	O
and	O
25.9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
control	B-P
group	I-P
,	O
and	O
0	O
%	O
,	O
0	O
%	O
,	O
and	O
4.3	O
%	O
in	O
the	O
ETV	O
prophylactic	O
group	O
(	O
P	O
=	O
.019	O
)	O
.	O


Four	B-P
patients	I-P
(	O
50	O
%	O
)	O
in	O
the	O
control	O
group	O
had	O
HBsAg	B-O
reverse	I-O
seroconversion	I-O
after	O
HBV	O
reactivation	O
.	O


The	O
cumulative	B-O
HBsAg	I-O
reverse	I-O
seroconversion	I-O
rates	I-O
at	O
months	O
6	O
,	O
12	O
,	O
and	O
18	O
since	O
chemotherapy	O
were	O
0	O
%	O
,	O
6.4	O
%	O
,	O
and	O
16.3	O
%	O
in	O
the	O
control	B-P
group	I-P
,	O
respectively	O
,	O
which	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
ETV	O
prophylactic	O
group	O
(	O
P	O
=	O
.032	O
)	O
.	O


Patients	O
with	O
detectable	O
or	O
undetectable	O
viral	O
load	O
could	O
develop	O
HBV	B-O
reactivation	I-O
and	I-O
HBsAg	I-O
reverse	I-O
seroconversion	I-O
.	I-O


CONCLUSION	O
Undetectable	O
HBV	O
viral	O
load	O
before	O
chemotherapy	O
did	O
not	O
confer	O
reactivation-free	O
status	O
.	O


Antiviral	B-I
prophylaxis	I-I
can	O
potentially	O
prevent	O
rituximab-associated	O
HBV	O
reactivation	O
in	O
patients	B-P
with	I-P
lymphoma	I-P
and	I-P
resolved	I-P
hepatitis	I-P
B	I-P
.	I-P


Effects	O
of	O
levosimendan	B-I
versus	O
dobutamine	B-I
on	O
inflammatory	O
and	O
apoptotic	O
pathways	O
in	O
acutely	B-P
decompensated	I-P
chronic	I-P
heart	I-P
failure	I-P
.	I-P


A	O
single	O
levosimendan	B-I
administration	O
has	O
recently	O
been	O
shown	O
to	O
result	O
in	O
clinical	O
and	O
hemodynamic	O
improvement	O
in	O
patients	B-P
with	I-P
decompensated	I-P
heart	I-P
failure	I-P
(	I-P
HF	I-P
)	I-P
,	I-P
but	I-P
without	I-P
survival	I-P
benefits	I-P
.	I-P


In	O
this	O
study	O
,	O
the	O
effects	O
of	O
levosimendan	B-I
and	O
dobutamine	B-I
on	O
plasma	O
levels	O
of	O
proinflammatory	O
and	O
proapoptotic	O
mediators	O
in	O
decompensated	O
HF	O
were	O
compared	O
and	O
correlated	O
with	O
the	O
concomitant	O
effects	O
on	O
cardiac	O
function	O
and	O
prognosis	O
.	O


Sixty-nine	B-P
patients	I-P
were	I-P
randomized	I-P
to	O
received	O
24-hour	O
intravenous	O
infusions	O
of	O
levosimendan	B-I
(	O
n	O
=	O
23	O
)	O
,	O
dobutamine	B-I
(	O
n	O
=	O
23	O
)	O
,	O
or	O
placebo	B-I
(	O
n	O
=	O
23	O
)	O
.	O


Echocardiographic	B-O
,	I-O
hemodynamic	I-O
,	I-O
and	I-O
biochemical	I-O
assessments	I-O
were	O
performed	O
at	O
baseline	O
,	O
immediately	O
after	O
treatment	O
,	O
and	O
48	O
hours	O
later	O
.	O


Patients	O
were	O
subsequently	O
followed	O
for	O
4	O
months	O
for	O
disease	O
progression	O
.	O


End-systolic	B-O
wall	I-O
stress	I-O
,	I-O
the	I-O
left	I-O
ventricular	I-O
ejection	I-O
fraction	I-O
,	I-O
pulmonary	I-O
capillary	I-O
wedge	I-O
pressure	I-O
,	I-O
and	I-O
cardiac	I-O
index	I-O
were	O
significantly	O
improved	O
in	O
the	O
levosimendan	O
group	O
but	O
remained	O
practically	O
unaffected	O
in	O
the	O
other	O
groups	O
.	O


Plasma	B-O
N-terminal-pro-B-type	I-O
natriuretic	I-O
peptide	I-O
,	I-O
tumor	I-O
necrosis	I-O
factor-alpha	I-O
,	I-O
and	I-O
soluble	I-O
Fas	I-O
ligand	I-O
levels	I-O
were	O
significantly	O
decreased	O
only	O
in	O
the	O
levosimendan	B-I
group	O
(	O
from	O
1,900	O
+/-	O
223	O
to	O
1,378	O
+/-	O
170	O
pg/ml	O
,	O
13.4	O
+/-	O
1.0	O
to	O
12.3	O
+/-	O
1.2	O
pg/ml	O
,	O
and	O
68.2	O
+/-	O
3.7	O
to	O
59.8	O
+/-	O
3.6	O
pg/ml	O
,	O
respectively	O
;	O
p	O
<	O
0.05	O
for	O
all	O
)	O
;	O
interleukin-6	B-O
was	O
also	O
borderline	O
reduced	O
(	O
p	O
=	O
0.051	O
)	O
.	O


Levosimendan-induced	B-O
reduction	I-O
in	I-O
end-systolic	I-O
wall	I-O
stress	I-O
was	O
significantly	O
correlated	O
with	O
respective	O
decreases	O
in	O
N-terminal-pro-B-type	B-O
natriuretic	I-O
peptide	I-O
(	O
r	O
=	O
0.671	O
,	O
p	O
<	O
0.01	O
)	O
,	O
tumor	B-O
necrosis	I-O
factor-alpha	I-O
(	O
r	O
=	O
0.586	O
,	O
p	O
<	O
0.01	O
)	O
,	O
soluble	B-O
Fas	I-O
(	O
r	O
=	O
0.441	O
,	O
p	O
<	O
0.05	O
)	O
,	O
and	O
soluble	B-O
Fas	I-O
ligand	I-O
(	O
r	O
=	O
0.614	O
,	O
p	O
<	O
0.01	O
)	O
.	O


Event-free	B-O
survival	I-O
was	O
significantly	O
longer	O
in	O
the	O
levosimendan	B-I
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O


In	O
conclusion	O
,	O
the	O
superiority	O
of	O
levosimendan	B-I
over	O
dobutamine	B-I
in	O
improving	O
central	B-O
hemodynamics	I-O
and	O
left	B-O
ventricular	I-O
performance	I-O
in	O
decompensated	B-P
HF	I-P
seems	O
to	O
be	O
related	O
to	O
its	O
anti-inflammatory	O
and	O
antiapoptotic	O
effects	O
.	O


Nurse	B-O
and	I-O
patient	I-O
communication	I-O
profiles	I-O
in	O
a	O
home-based	B-P
telehealth	I-P
intervention	I-P
for	O
heart	O
failure	O
management	O
.	O


OBJECTIVE	O
This	O
study	O
compared	O
differences	O
in	O
nurse	B-O
and	I-O
patient	I-O
communication	I-O
profiles	I-O
between	O
two	O
telehealth	O
modes	O
:	O
telephone	B-I
and	O
videophone	B-I
,	O
and	O
evaluated	O
longitudinal	B-O
changes	I-O
in	I-O
communication	I-O
,	I-O
nurse	I-O
perceptions	I-O
,	I-O
and	I-O
patient	I-O
satisfaction	I-O
.	I-O


METHODS	O
Subjects	B-P
were	O
enrolled	O
in	O
a	O
randomized	B-P
controlled	I-P
clinical	I-P
trial	I-P
evaluating	O
a	O
90-day	O
home-based	O
intervention	O
for	O
heart	O
failure	O
.	O


Telephone	B-I
(	I-P
n=14	I-P
)	I-P
and	I-P
videophone	I-I
(	I-P
n=14	I-P
)	I-P
interactions	I-P
were	O
audio	O
taped	O
and	O
analyzed	O
using	O
the	O
Roter	B-O
Interaction	I-O
Analysis	I-O
System	I-O
.	I-O


RESULTS	O
Nurses	B-P
were	O
more	O
likely	O
to	O
use	B-O
open-ended	I-O
questions	I-O
,	I-O
back-channel	I-O
responses	I-O
,	I-O
friendly	I-O
jokes	I-O
,	I-O
and	I-O
checks	I-O
for	I-O
understanding	I-O
on	O
the	O
telephone	B-I
compared	O
to	O
videophone	B-I
.	I-I


Compliments	B-O
given	I-O
and	I-O
partnership	I-O
were	O
more	O
common	O
on	O
the	O
videophone	O
.	O


Patients	B-P
were	O
more	O
likely	O
to	O
give	B-O
lifestyle	I-O
information	I-O
and	I-O
approval	I-O
comments	I-O
on	O
the	O
telephone	B-I
,	O
and	O
used	O
more	O
closed-ended	B-O
questions	I-O
on	O
the	O
videophone	B-I
.	I-I


Nurses	B-O
perceptions	I-O
of	I-O
the	I-O
interactions	I-O
were	O
not	O
different	O
between	O
the	O
telephone	O
and	O
videophone	B-I
,	O
nor	O
did	O
their	O
perceptions	B-O
change	O
significantly	O
over	O
the	O
course	O
of	O
the	O
intervention	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
patient	B-O
satisfaction	I-O
between	O
the	O
telephone	O
and	O
videophone	B-I
.	I-I


CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
did	O
not	O
support	O
use	O
of	O
a	O
videophone	B-I
over	O
the	O
telephone	B-I
.	I-I


PRACTICE	O
IMPLICATIONS	O
It	O
is	O
critical	O
to	O
match	O
technologies	O
to	O
patient	O
needs	O
and	O
use	O
the	O
least	O
complex	O
technology	O
possible	O
.	O


When	O
considering	O
use	O
a	O
videophone	B-I
,	O
health	O
care	O
providers	O
should	O
critically	O
examine	O
the	O
trade-offs	O
between	O
additional	O
complexities	O
with	O
the	O
added	O
value	O
of	O
the	O
visual	O
interaction	O
.	O


Randomized	O
,	O
placebo-controlled	O
trial	O
of	O
oral	O
phytonadione	B-I
for	O
excessive	B-O
anticoagulation	I-O
.	I-O


STUDY	O
OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
managing	O
excessive	O
anticoagulation	O
in	O
the	O
absence	O
of	O
bleeding	O
by	O
either	O
omitting	O
warfarin	O
therapy	O
alone	O
or	O
administering	O
oral	O
phytonadione	B-I
in	O
addition	O
to	O
omitting	O
warfarin	O
therapy	O
.	O


DESIGN	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O


SETTING	O
Clinical	O
pharmacy	O
anticoagulation	O
service	O
in	O
a	O
group	O
model	O
health	O
maintenance	O
organization	O
.	O


SUBJECTS	O
Thirty	B-P
nonbleeding	I-P
patients	I-P
with	I-P
international	I-P
normalized	I-P
ratios	I-P
(	I-P
INRs	I-P
)	I-P
ranging	I-P
from	I-P
6.0-10.0	I-P
.	I-P


INTERVENTIONS	O
Patients	B-P
were	I-P
randomized	I-P
to	I-P
receive	I-P
either	I-P
a	I-P
single	I-I
oral	I-I
dose	I-I
of	I-I
phytonadione	I-I
2.5	I-I
mg	I-I
or	I-I
placebo	I-I
.	I-I


Both	O
groups	O
omitted	B-I
warfarin	I-I
doses	I-I
until	I-I
the	I-I
INR	I-I
became	I-I
less	I-I
than	I-I
or	I-I
equal	I-I
to	I-I
4.0	I-I
.	I-I


MEASUREMENTS	O
AND	O
RESULTS	O
The	O
mean	B-O
calculated	I-O
time	I-O
to	I-O
reach	I-O
an	I-O
INR	I-O
of	I-O
4.0	I-O
was	O
significantly	O
greater	O
in	O
the	O
placebo	O
than	O
the	O
phytonadione	O
group	O
(	O
2.6	O
vs	O
1.4	O
days	O
,	O
p=0.006	O
)	O
.	O


Overcorrection	B-O
of	I-O
anticoagulation	I-O
was	O
significantly	O
more	O
common	O
in	O
patients	O
receiving	O
phytonadione	O
.	O


Overt	B-O
warfarin	I-O
resistance	I-O
was	O
not	O
observed	O
in	O
either	O
group	O
after	O
reinitiating	O
warfarin	O
therapy	O
.	O


No	O
major	B-O
bleeding	I-O
or	I-O
thromboembolic	I-O
complications	I-O
occurred	O
,	O
and	O
minor	O
bleeding	B-O
episodes	O
were	O
similar	O
in	O
both	O
groups	O
.	O


CONCLUSION	O
The	O
addition	O
of	O
oral	O
phytonadione	O
2.5	O
mg	O
reduced	O
the	O
time	O
to	O
achieve	O
an	O
INR	O
of	O
4.0	O
by	O
approximately	O
1	O
day	O
compared	O
with	O
omitting	O
warfarin	O
therapy	O
alone	O
.	O


Adverse	O
events	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O


Both	O
strategies	O
were	O
effective	O
in	O
managing	O
asymptomatic	B-P
patients	I-P
with	I-P
INRs	I-P
of	I-P
6.0-10.0	I-P
.	I-P


Oral	O
phytonadione	O
may	O
be	O
most	O
appropriate	O
for	O
patients	B-P
at	I-P
high	I-P
risk	I-P
for	I-P
bleeding	I-P
in	I-P
whom	I-P
the	I-P
benefit	I-P
of	I-P
prompt	I-P
INR	I-O
reduction	I-O
would	I-P
outweigh	I-P
the	I-P
thromboembolic	I-P
risk	I-P
associated	I-P
with	I-P
INR	I-O
overcorrection	I-O
.	I-O


The	O
influence	O
of	O
ventricular	O
fibrillation	O
duration	O
on	O
defibrillation	B-O
efficacy	I-O
using	O
biphasic	O
waveforms	O
in	O
humans	O
.	O


OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
prospectively	O
investigate	O
the	O
influence	O
of	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
durations	O
of	O
5	O
,	O
10	O
and	O
20	O
s	O
on	O
the	O
defibrillation	B-O
threshold	I-O
(	I-O
DFT	I-O
)	I-O
during	O
implantable	O
cardioverter-defibrillator	O
(	O
ICD	O
)	O
implantation	O
.	O


BACKGROUND	O
Although	O
the	O
DFT	B-O
using	I-O
monophasic	I-O
waveforms	I-O
has	O
been	O
shown	O
to	O
increase	O
with	O
VF	O
duration	O
in	O
humans	O
,	O
the	O
effect	O
of	O
VF	O
duration	O
on	O
defibrillation	O
efficacy	O
using	O
biphasic	O
waveforms	O
in	O
humans	O
is	O
not	O
known	O
.	O


METHODS	O
Thirty	B-P
patients	I-P
undergoing	I-P
primary	I-P
ICD	I-P
implantation	I-P
or	I-P
pulse	I-P
generator	I-P
replacement	I-P
were	O
randomly	O
assigned	O
to	O
have	O
the	O
DFT	B-I
determined	I-I
using	I-I
biphasic	I-I
shocks	I-I
at	O
two	O
durations	O
of	O
VF	B-I
each	O
(	O
5	O
and	O
10	O
s	O
,	O
10	O
and	O
20	O
s	O
or	O
5	O
and	O
20	O
s	O
)	O
.	O


RESULTS	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
mean	B-O
DFT	I-O
comparing	O
VF	O
durations	O
of	O
5	O
s	O
(	O
9.5+/-6.0	O
J	O
)	O
and	O
10	O
s	O
(	O
10.8+/-7.0	O
J	O
)	O
(	O
p=0.4	O
)	O
.	O


The	O
mean	B-O
DFT	I-O
significantly	O
increased	O
from	O
10.9+/-6.1	O
J	O
at	O
10	O
s	O
of	O
VF	O
to	O
12.6+/-5.6	O
J	O
(	O
p=0.03	O
)	O
at	O
20	O
s	O
of	O
VF	O
,	O
and	O
from	O
7.0+/-3.5	O
J	O
at	O
5	O
s	O
of	O
VF	O
to	O
10.5+/-6.3	O
J	O
(	O
p=0.04	O
)	O
at	O
20	O
s	O
of	O
VF	O
.	O


An	O
increase	O
in	O
the	O
DFT	B-O
was	O
observed	O
in	O
14	B-P
patients	I-P
as	O
VF	O
duration	O
increased	O
.	O


There	O
were	O
no	O
clinical	O
characteristics	O
that	O
differentiated	O
patients	O
with	O
and	O
without	O
an	O
increase	O
in	O
the	O
DFT	B-O
.	I-O


CONCLUSIONS	O
Defibrillation	B-O
efficacy	I-O
decreases	O
with	O
increasing	O
VF	O
duration	O
using	O
biphasic	O
waveforms	O
in	O
humans	O
.	O


Ventricular	O
fibrillation	O
durations	O
greater	O
than	O
10	O
s	O
may	O
negatively	O
affect	O
the	O
effectiveness	B-O
of	I-O
ICD	I-O
therapy	I-O
.	I-O


Long-term	O
effects	O
of	O
risperidone	B-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	I-P
a	O
placebo	B-I
discontinuation	O
study	O
.	O


OBJECTIVE	O
The	O
short-term	O
benefit	O
of	O
risperidone	B-I
in	O
ameliorating	O
severe	B-O
disruptive	I-O
behavior	I-O
in	O
pediatric	B-P
patients	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
is	O
well	O
established	O
;	O
however	O
,	O
only	O
one	O
placebo-controlled	B-I
,	O
long-term	O
study	O
of	O
efficacy	O
is	O
available	O
.	O


METHOD	O
Thirty-six	B-P
children	I-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
5-17	I-P
years	I-P
old	I-P
)	I-P
accompanied	I-P
by	I-P
severe	I-P
tantrums	I-P
,	I-P
aggression	I-P
,	I-P
or	I-P
self-injurious	I-P
behavior	I-P
,	O
started	O
8-week	O
open-label	O
treatment	O
with	O
risperidone	B-I
.	I-I


Responders	O
(	O
n	O
=	O
26	O
)	O
continued	O
treatment	O
for	O
another	O
16	O
weeks	O
,	O
followed	O
by	O
a	O
double-blind	O
discontinuation	O
(	O
n	O
=	O
24	O
;	O
two	O
patients	O
discontinued	O
treatment	O
because	O
of	O
weight	O
gain	O
)	O
consisting	O
of	O
either	O
3	O
weeks	O
of	O
taper	O
and	O
5	O
weeks	O
of	O
placebo	B-I
only	O
or	O
continuing	O
use	O
of	O
risperidone	B-I
.	I-I


Relapse	O
was	O
defined	O
as	O
a	O
significant	O
deterioration	O
of	O
symptoms	O
based	O
on	O
clinical	O
judgment	O
and	O
a	O
parent	O
questionnaire	O
.	O


RESULTS	O
Risperidone	B-I
was	O
superior	O
to	O
placebo	B-I
in	O
preventing	O
relapse	B-O
:	I-O
this	O
occurred	O
in	O
3	O
of	O
12	O
patients	O
continuing	O
on	O
risperidone	O
versus	O
8	O
of	O
12	O
who	O
switched	O
to	O
placebo	O
(	O
p	O
=	O
.049	O
)	O
.	O


Weight	B-O
gain	I-O
,	I-O
increased	I-O
appetite	I-O
,	I-O
anxiety	I-O
,	I-O
and	I-O
fatigue	I-O
were	O
the	O
most	O
frequently	O
reported	O
side	O
effects	O
.	O


CONCLUSIONS	O
This	O
study	O
indicates	O
the	O
effectiveness	O
of	O
risperidone	O
during	O
a	O
period	O
of	O
several	O
months	O
,	O
reducing	O
disruptive	B-O
behavior	I-O
in	O
about	O
half	O
of	O
the	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


The	O
results	O
provide	O
a	O
rationale	O
for	O
the	O
continuing	O
use	O
of	O
risperidone	B-I
beyond	O
6	O
months	O
,	O
although	O
considerable	O
weight	B-O
gain	I-O
can	O
limit	O
the	O
use	O
of	O
this	O
agent	O
.	O


Exercise	B-O
capacity	I-O
in	O
atrial	B-P
fibrillation	I-P
:	I-P
a	O
substudy	O
of	O
the	O
Sotalol-Amiodarone	O
Atrial	O
Fibrillation	O
Efficacy	O
Trial	O
(	O
SAFE-T	O
)	O
.	O


BACKGROUND	O
Therapy	O
for	O
chronic	B-P
atrial	I-P
fibrillation	I-P
(	I-P
AF	I-P
)	I-P
focuses	O
on	O
rate	O
versus	O
rhythm	O
control	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
common	O
therapeutic	O
interventions	O
on	O
exercise	O
tolerance	O
in	O
AF	O
.	O


METHODS	O
Six	B-P
hundred	I-P
fifty-five	I-P
patients	I-P
with	I-P
chronic	I-P
AF	I-P
underwent	I-P
maximal	I-I
exercise	I-I
testing	I-I
at	O
baseline	O
and	O
8	O
weeks	O
,	O
6	O
months	O
,	O
and	O
1	O
year	O
after	O
randomization	O
to	O
sotalol	B-I
,	I-I
amiodarone	I-I
,	I-I
or	I-I
placebo	I-I
therapy	O
and	O
attempted	B-I
direct	I-I
current	I-I
cardioversion	I-I
.	I-I


Analyses	O
of	O
baseline	O
determinants	O
of	O
exercise	O
capacity	O
,	O
predictors	O
of	O
change	O
in	O
exercise	O
capacity	O
at	O
6	O
months	O
and	O
1	O
year	O
,	O
and	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
cardioversion	O
on	O
exercise	O
capacity	O
were	O
made	O
.	O


RESULTS	O
Age	O
,	O
obesity	O
,	O
and	O
presence	O
of	O
symptoms	O
accompanying	O
AF	O
were	O
inversely	O
associated	O
with	O
baseline	O
exercise	O
capacity	O
,	O
but	O
these	O
factors	O
accounted	O
for	O
only	O
10	O
%	O
of	O
the	O
variance	O
in	O
exercise	O
capacity	O
.	O


Patients	O
most	O
likely	O
to	O
benefit	O
from	O
cardioversion	O
were	O
those	O
most	O
limited	O
initially	O
,	O
younger	O
,	O
not	O
obese	O
or	O
hypertensive	O
,	O
and	O
with	O
an	O
uncontrolled	O
ventricular	O
rate	O
at	O
baseline	O
.	O


Conversion	O
to	O
sinus	O
rhythm	O
(	O
SR	O
)	O
resulted	O
in	O
significant	O
reductions	O
in	O
resting	B-O
(	O
approximately	O
25	O
beat/min	O
)	O
and	O
peak	B-O
exercise	I-O
(	O
approximately	O
40	O
beat/min	O
)	O
heart	B-O
rates	I-O
at	O
6	O
months	O
and	O
1	O
year	O
(	O
P	O
<	O
.001	O
)	O
.	O


Successful	O
cardioversion	B-I
improved	O
exercise	B-O
capacity	I-O
by	O
15	O
%	O
at	O
8	O
weeks	O
,	O
and	O
these	O
improvements	O
were	O
maintained	O
throughout	O
the	O
year	O
.	O


This	O
improvement	O
was	O
observed	O
both	O
among	O
those	O
who	O
maintained	O
SR	O
and	O
those	O
with	O
intermittent	O
AF	O
.	O


CONCLUSION	O
Cardioversion	B-I
resulted	O
in	O
a	O
sustained	O
improvement	O
in	O
exercise	O
capacity	O
over	O
the	O
course	O
of	O
1	O
year	O
,	O
and	O
this	O
improvement	O
was	O
similar	O
between	O
those	O
in	O
SR	O
and	O
those	O
with	O
SR	O
and	O
recurrent	O
AF	O
.	O


Patients	O
most	O
likely	O
to	O
improve	O
with	O
treatment	O
tended	O
to	O
be	O
younger	O
and	O
nonobese	O
and	O
have	O
the	O
greatest	O
limitations	O
initially	O
.	O


Neuromuscular	O
excitability	O
changes	O
in	O
the	O
vastus	O
medialis	O
following	O
anterior	B-I
cruciate	I-I
ligament	I-I
reconstruction	I-I
.	I-I


PURPOSE	O
Quadriceps	O
weakness	O
following	O
anterior	B-P
cruciate	I-I
ligament	I-I
reconstruction	I-I
(	I-I
ACLR	I-I
)	I-I
is	O
prevalent	O
despite	O
intensive	O
rehabilitation	O
.	O


Diminished	O
neuromuscular	O
excitability	O
is	O
one	O
potential	O
factor	O
that	O
may	O
limit	O
muscular	O
recovery	O
following	O
injury	O
or	O
surgery	O
.	O


The	O
H-reflex	B-O
provides	O
a	O
measure	O
of	O
alpha	O
motorneuron	O
(	O
neuromuscular	O
)	O
excitability	O
in	O
the	O
sensory-motor	O
pathway	O
of	O
the	O
respective	O
muscle	O
and	O
nerve	O
.	O


To	O
date	O
the	O
vastus	O
medialis	O
(	O
VM	O
)	O
and	O
soleus	O
(	O
SOL	O
)	O
H-reflexes	O
have	O
been	O
examined	O
primarily	O
in	O
control	O
subjects	B-P
with	I-P
induced	I-P
knee	I-P
joint	I-P
effusion	I-P
.	I-P


This	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
evaluated	O
the	O
affect	O
of	O
ACLR	B-I
,	O
utilizing	O
hamsting	B-O
(	I-O
HS	I-O
)	I-O
or	I-O
bone-patellar	I-O
tendon-bone	I-O
(	I-O
BTB	I-O
)	I-O
autograft	I-O
,	I-O
on	I-O
VM	I-O
and	I-O
SOL	I-O
H-reflex	I-O
latency	I-O
and	I-O
amplitude	I-O
in	O
twenty	B-P
subjects	I-P
.	I-P


METHODS	O
Preoperatively	O
bilateral	O
VM	O
and	O
SOL	O
H-reflex	O
tests	O
were	O
conducted	O
.	O


VM	B-O
and	I-O
SOL	I-O
H-reflexes	I-O
were	O
subsequently	O
conducted	O
on	O
the	O
involved	O
lower	O
extremity	O
at	O
1	O
and	O
3	O
months	O
post	O
surgery	O
.	O


At	O
each	O
test	O
session	O
subjects	B-P
completed	O
visual	B-O
analog	I-O
scales	I-O
and	I-O
knee	I-O
girth	I-O
was	O
measured	O
.	O


RESULTS	O
The	O
VM	B-O
H-reflex	I-O
amplitude	I-O
increased	O
in	O
the	O
HS	O
group	O
at	O
3	O
months	O
compared	O
to	O
1-month	O
post	O
surgery	O
(	O
p	O
<	O
.05	O
)	O
.	O


Significant	O
changes	O
over	O
time	O
were	O
also	O
noted	O
in	O
the	O
visual	B-O
analog	I-O
pain	I-O
and	I-O
functional	I-O
scales	I-O
and	I-O
the	I-O
mid-patella	I-O
girth	I-O
.	I-O


CONCLUSIONS	O
The	O
increased	O
VM	B-O
H-reflex	I-O
amplitude	I-O
at	O
3	O
months	O
following	O
HS	O
autograft	O
ACLR	B-I
demonstrates	O
an	O
increase	O
in	O
VM	B-O
neuromuscular	I-O
excitability	I-O
.	I-O


Increased	O
VM	B-O
neuromuscular	I-O
excitability	I-O
was	O
not	O
evident	O
in	O
patients	O
following	O
BTB	O
reconstruction	O
.	O


The	O
increased	O
neuromuscular	B-O
excitability	I-O
,	O
observed	O
only	O
in	O
the	O
HS	O
group	O
,	O
warrants	O
consideration	O
when	O
selecting	O
graft	O
type	O
for	O
patients	B-P
with	I-P
extensive	I-P
preoperative	I-P
quadriceps	I-P
dysfunction	I-P
.	I-P


GPs	O
'	O
experiences	O
with	O
brief	B-I
intervention	I-I
for	O
medication-overuse	O
headache	O
:	O
a	O
qualitative	O
study	O
in	O
general	O
practice	O
.	O


BACKGROUND	O
Medication-overuse	O
headache	O
(	O
MOH	O
)	O
is	O
common	O
in	O
the	O
general	O
population	O
,	O
and	O
most	O
patients	O
are	O
managed	O
in	O
primary	O
health	O
care	O
.	O


Brief	B-I
Intervention	I-I
(	I-I
BI	I-I
)	I-I
has	O
been	O
used	O
as	O
a	O
motivational	O
technique	O
for	O
patients	B-P
with	I-P
drug	I-P
and	I-P
alcohol	I-P
overuse	I-P
,	O
and	O
may	O
a	O
have	O
role	O
in	O
the	O
treatment	O
of	O
MOH	O
.	O


AIM	O
To	O
explore	O
GPs	B-I
'	I-I
experiences	I-I
using	I-I
BI	I-I
in	I-I
the	O
management	B-P
of	I-P
patients	I-P
with	I-P
MOH	I-P
.	I-P


DESIGN	O
AND	O
SETTING	O
Qualitative	O
study	O
in	O
Norwegian	B-P
general	I-P
practice	I-P
.	I-P


METHOD	O
Data	O
were	O
collected	O
through	O
four	B-P
focus	I-P
group	I-P
interviews	I-P
with	I-P
22	I-P
GPs	I-P
who	I-P
participated	I-P
in	I-P
an	I-P
intervention	I-P
study	I-P
on	I-P
BI	I-I
for	I-P
MOH	I-P
.	I-P


Systematic	O
text	O
condensation	O
was	O
used	O
to	O
analyse	O
transcripts	O
from	O
the	O
focus	B-P
group	I-P
interviews	I-P
.	I-P


RESULTS	O
The	O
GPs	B-I
experienced	I-I
challenges	O
when	O
trying	O
to	O
convince	O
patients	O
that	O
the	O
medication	O
they	O
used	O
to	O
treat	O
and	O
prevent	O
headache	O
could	O
cause	O
headache	O
,	O
but	O
labelling	O
MOH	O
as	O
a	O
diagnosis	O
opened	O
up	O
a	O
space	O
for	O
change	O
.	O


GPs	O
were	O
able	O
to	O
use	O
BI	B-I
within	O
the	O
scope	O
of	O
a	O
regular	O
consultation	O
,	O
and	O
they	O
thought	O
that	O
the	O
structured	O
approach	O
had	O
a	O
potential	O
to	O
change	O
patients	O
'	O
views	O
about	O
their	O
condition	O
and	O
medication	O
use	O
.	O


Being	O
diagnosed	O
with	O
medication	O
overuse	O
could	O
bring	O
about	O
feelings	O
of	O
guilt	B-O
in	O
patients	O
,	O
and	O
GPs	O
emphasised	O
that	O
a	O
good	O
alliance	O
with	O
the	O
patient	O
was	O
necessary	O
for	O
successful	O
change	O
using	O
BI	O
to	O
manage	O
MOH	O
.	O


CONCLUSION	O
GPs	B-I
experience	I-I
BI	I-I
as	O
a	O
feasible	O
strategy	O
to	O
treat	O
MOH	O
,	O
and	O
the	O
technique	O
relies	O
on	O
a	O
good	O
alliance	O
between	O
the	O
doctor	O
and	O
patient	O
.	O


When	O
using	O
BI	B-I
,	O
GPs	O
must	O
be	O
prepared	O
to	O
counter	O
patients	O
'	O
misconceptions	O
about	O
medication	O
used	O
for	O
headache	O
.	O


Surgery	O
of	O
aphakic	B-P
retinal	I-P
detachment	I-P
.	I-P


In	O
a	O
prospective	O
study	O
84	B-P
patients	I-P
with	I-P
aphakic	I-P
retinal	I-P
detachment	I-P
were	I-P
treated	I-P
either	I-P
by	I-P
local	I-I
scleral	I-I
buckling	I-I
alone	I-I
or	I-I
combined	I-I
with	I-I
an	I-I
encirclement	I-I
.	I-I


The	O
rate	B-O
of	I-O
surgical	I-O
reattachment	I-O
of	I-O
the	I-O
retina	I-O
was	O
found	O
to	O
be	O
similar	O
with	O
either	O
technique	O
over	O
a	O
minimum	O
follow-up	O
period	O
of	O
one	O
year	O
.	O


Simplicity	O
and	O
a	O
low	O
incidence	O
of	O
serious	O
complications	O
of	O
the	O
local	O
procedure	O
merit	O
its	O
application	O
as	O
the	O
initial	O
method	O
of	O
repairing	O
aphakic	O
detachments	O
.	O


[	O
Treatment	O
of	O
irresectable	B-P
hepatocellular	I-P
carcinoma	I-P
with	O
repeated	B-I
transient	I-I
dearterialization	I-I
]	I-I
.	O


A	O
joint	O
clinical	O
prospective	O
study	O
between	O
SUMS	B-P
and	I-P
Lund	I-P
university	I-P
was	O
reported	O
.	O


40	B-P
patients	I-P
with	I-P
the	I-P
irresectable	I-P
hepatocellular	I-P
carcinoma	I-P
(	I-P
HCC	I-P
)	I-P
admitted	I-P
to	I-P
the	I-P
department	I-P
of	I-P
HPB	I-P
surgery	I-P
in	I-P
the	I-P
First	I-P
Affiliated	I-P
Hospital	I-P
of	I-P
SUMS	I-P
were	I-P
randomized	I-P
into	I-P
two	I-P
groups	I-P
:	I-P
(	I-P
20	I-P
each	I-P
)	I-P
from	I-P
Feb.	I-P
1994	I-P
to	I-P
April	I-P
,	I-P
1995	I-P
.	I-P


The	O
patients	O
were	O
treated	O
with	O
hepatic	B-I
artery	I-I
ligation	I-I
(	I-I
HAL	I-I
)	I-I
and	I-I
repeated	I-I
transient	I-I
dearterialization	I-I
(	I-I
RTD	I-I
)	I-I
respectively	O
.	O


Postoperative	O
response	O
to	O
treatment	O
,	O
liver	B-O
function	I-O
change	I-O
(	I-O
ALT	I-O
)	I-O
,	I-O
AFP	I-O
,	I-O
imaging	I-O
examination	I-O
of	I-O
the	I-O
tumor	I-O
,	I-O
patient	I-O
's	I-O
survival	I-O
were	O
evaluated	O
.	O


It	O
has	O
been	O
shown	O
that	O
RTD	B-I
is	O
superior	O
to	O
HAL	O
in	O
terms	O
of	O
the	O
objective	O
response	O
to	O
the	O
therapy	B-O
,	I-O
reduction	I-O
of	I-O
tumor	I-O
size	I-O
,	I-O
patient	I-O
's	I-O
symptom	I-O
relief	I-O
,	I-O
liver	I-O
function	I-O
and	I-O
AFP	I-O
changes	I-O
and	I-O
patient	I-O
's	I-O
survival	I-O
.	I-O


In	O
the	O
RTD	B-I
group	O
,	O
the	O
effective	B-O
rate	I-O
was	O
70	O
%	O
,	O
the	O
mean	B-O
survival	I-O
time	I-O
was	O
8.2	O
months	O
,	O
and	O
the	O
6-month	O
survival	B-O
rate	I-O
was	O
79.7	O
%	O
.	O


In	O
HAL	O
group	O
,	O
the	O
effective	B-O
rate	I-O
was	O
only	O
5	O
%	O
,	O
the	O
mean	B-O
survival	I-O
time	I-O
was	O
5.1	O
months	O
,	O
6	O
months	O
survival	B-O
rate	I-O
was	O
35.8	O
%	O
.	O


It	O
has	O
been	O
postulated	O
that	O
RTD	B-I
may	O
prevent	O
the	O
rapid	O
development	O
of	O
collateral	O
circulation	O
and	O
increase	O
the	O
production	B-O
of	I-O
oxygen-derived	I-O
free	I-O
radicals	I-O
,	O
which	O
may	O
be	O
the	O
responsible	O
factors	O
for	O
the	O
ischemic	O
treatment	O
of	O
hepatic	O
tumours	O
.	O


We	O
consider	O
that	O
RTD	B-I
would	O
be	O
a	O
promising	O
polliative	O
method	O
for	O
HCC	O
.	O


A	O
randomized	O
trial	O
of	O
prophylactic	B-I
palifermin	I-I
on	O
gastrointestinal	O
toxicity	O
after	O
intensive	O
induction	O
therapy	O
for	O
acute	B-P
myeloid	I-P
leukaemia	I-P
.	I-P


Gastrointestinal	O
toxicity	O
,	O
including	O
oral	O
mucositis	O
,	O
is	O
a	O
frequent	O
complication	O
of	O
intensive	O
combination	O
chemotherapy	O
for	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
and	O
contributes	O
substantially	O
to	O
treatment-related	O
mortality	O
.	O


We	O
conducted	O
a	O
placebo-controlled	O
randomized	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
palifermin	B-I
(	O
keratinocyte	O
growth	O
factor	O
)	O
,	O
given	O
at	O
60	O
μg/kg	O
per	O
daily	O
IV	O
for	O
3	O
d	O
before	O
and	O
after	O
chemotherapy	O
,	O
for	O
mucosal	O
protection	O
in	B-P
adult	I-P
patients	I-P
with	I-P
previously	I-P
untreated	I-P
AML	I-P
receiving	I-P
induction	I-P
therapy	I-P
with	I-P
idarubicin	I-P
,	I-P
high-dose	I-P
cytarabine	I-P
and	I-P
etoposide	I-P
.	O


Among	B-P
155	I-P
randomized	I-P
patients	I-P
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	B-O
rate	I-O
of	I-O
grade	I-O
3	I-O
and	I-O
4	I-O
oral	I-O
mucositis	I-O
(	O
primary	O
study	O
endpoint	O
)	O
between	O
the	O
two	O
treatment	O
arms	O
(	O
three	O
in	B-I
palifermin	I-I
arm	O
(	O
4	O
%	O
)	O
,	O
8	O
in	B-I
placebo	I-I
arm	O
(	O
10	O
%	O
;	O
P	O
=	O
0·21	O
)	O
;	O
however	O
,	O
when	O
considering	B-O
the	I-O
severity	I-O
of	I-O
oral	I-O
mucositis	I-O
(	O
World	O
Health	O
Organization	O
grade	O
0-4	O
)	O
,	O
there	O
was	O
evidence	O
of	O
reduced	B-O
rates	I-O
of	I-O
higher	I-O
grades	I-O
of	I-O
oral	I-O
mucositis	I-O
in	I-I
the	I-I
palifermin	I-I
arm	O
(	O
P	O
=	O
0·0007	O
,	O
test	O
for	O
trend	O
)	O
.	O


There	O
was	O
a	O
statistically	O
significantly	O
lower	B-O
rate	I-O
of	I-O
grades	I-O
3	I-O
and	I-O
4	I-O
gastrointestinal	I-O
adverse	I-O
events	I-I
in	I-I
the	I-I
palifermin	I-I
arm	O
(	O
21	O
%	O
vs.	O
44	O
%	O
in	O
placebo	O
arm	O
;	O
P	O
=	O
0·003	O
)	O
,	O
mainly	O
due	O
to	O
a	O
reduction	B-O
in	I-O
severe	I-O
diarrhoea	O
(	O
8	O
%	O
palifermin	B-I
,	O
26	O
%	O
placebo	B-I
;	I-I
P	I-I
=	I-I
0·01	I-I
)	I-I
.	O


Palifermin	O
has	O
activity	O
as	O
a	O
mucosal	O
protectant	O
in	O
AML	O
patients	O
receiving	O
intensive	O
chemotherapy	O
.	O


This	O
trial	O
is	O
registered	O
at	O
ACTRN012605000095662	O
.	O


Double-blind	O
study	O
on	O
the	O
activity	O
of	O
plafibride	B-I
in	O
the	O
treatment	O
of	O
type	B-P
IV	I-P
hyperlipoproteinemia	I-P
.	I-P


The	O
effects	O
of	O
a	O
new	O
drug	O
,	O
N-2-	B-I
(	I-I
p-chlorophenoxy	I-I
)	I-I
-isobutyryl-N'-morpholinomethylurea	I-I
(	I-I
plafibride	I-I
,	I-I
ITA	I-I
104	I-I
)	I-I
,	O
were	O
studied	O
in	O
a	O
double	O
blind	O
study	O
lasting	O
four	O
months	O
on	O
a	O
group	B-P
of	I-P
30	I-P
patients	I-P
with	I-P
a	I-P
type	I-P
IV	I-P
hyperlipoproteinemia	I-P
.	I-P


In	O
the	O
patients	O
treated	O
with	O
the	O
active	O
drug	O
significant	O
reductions	O
in	O
blood	B-O
triglycerides	I-O
were	O
obtained	O
,	O
with	O
a	O
trend	O
to	O
normal	O
.	O


Reduction	O
in	O
blood	B-O
cholesterol	I-O
was	O
inconsistent	O
and	O
not	O
significant	O
.	O


As	O
for	O
the	O
lipoproteinogram	O
,	O
a	O
tendency	O
towards	O
a	O
decrease	O
in	O
the	O
pre-beta-lipoprotein	B-O
fraction	I-O
was	O
observed	O
and	O
so	O
was	O
a	O
non-significant	O
tendency	O
towards	O
an	O
increase	O
in	O
the	O
alpha-	O
and	O
beta-lipoprotein	O
fractions	O
.	O


Studies	O
on	O
the	O
platelet	O
functioning	O
showed	O
an	O
obvious	O
decrease	O
in	O
platelet	B-O
aggregation	I-O
in	O
those	O
patients	O
treated	O
with	O
the	O
active	O
drug	O
.	O


This	O
was	O
very	O
evident	O
for	O
the	O
ADP	O
and	O
adrenaline	O
inductors	O
and	O
rather	O
less	O
significant	O
for	O
collagen	O
.	O


Neither	O
platelet	B-O
adhesiveness	I-O
nor	I-O
aggregation	I-O
rate	I-O
changed	O
.	O


Tolerance	B-O
of	O
the	O
drug	O
was	O
generally	O
excellent	O
.	O


In	O
one	O
patient	O
a	O
decrease	O
in	O
some	O
palpebral	B-O
xanthelasmas	I-O
was	O
observed	O
after	O
two	O
months	O
of	O
treatment	O
with	O
the	O
active	O
drug	O
.	O


In	O
only	O
one	O
case	O
there	O
was	O
heartburn	B-O
and	O
this	O
was	O
corrected	O
with	O
alkalines	O
.	O


In	O
one	O
other	O
case	O
an	O
urticarial	B-O
rash	I-O
appeared	O
,	O
but	O
disappeared	O
spontaneously	O
when	O
the	O
drug	O
was	O
temporarily	O
stopped	O
and	O
did	O
not	O
reappear	O
when	O
it	O
was	O
administered	O
again	O
.	O


During	O
the	O
trial	O
no	O
evidence	O
of	O
renal	B-O
,	I-O
hepatic	I-O
or	I-O
hematological	I-O
malfunctions	I-O
were	O
observed	O
.	O


However	O
,	O
a	O
slight	O
tendency	O
towards	O
an	O
increase	O
in	O
the	O
GOT	B-O
,	I-O
GPT	I-O
and	I-O
LDH	I-O
was	O
observed	O
,	O
which	O
was	O
not	O
statistically	O
significant	O
.	O


The	O
drug	O
tested	O
may	O
be	O
very	O
useful	O
in	O
the	O
treatment	O
of	O
type	B-O
IV	I-O
hyperlipoproteinemia	I-O
,	O
especially	O
in	O
those	O
forms	O
in	O
which	O
an	O
increase	O
in	O
thromboembolic	B-O
risk	I-O
is	O
suspected	O
,	O
either	O
associated	O
with	O
,	O
or	O
secondary	O
to	O
,	O
the	O
actual	O
atherosclerotic	O
disease	O
.	O


Oestrogen	B-O
replacement	I-O
after	I-P
oophorectomy	I-P
:	I-P
comparison	O
of	O
patches	B-I
and	O
implants	B-I
.	I-I


Efficacy	B-O
and	O
safety	B-O
of	O
zidovudine	B-I
and	I-I
zalcitabine	I-I
combined	O
with	O
a	O
combination	O
of	O
herbs	O
in	O
the	O
treatment	O
of	O
HIV-infected	B-P
Thai	I-P
patients	I-P
.	I-P


A	O
randomized	O
double	O
blind	O
placebo	B-I
controlled	O
trial	O
to	O
determine	O
the	O
efficacy	B-O
and	O
safety	B-O
of	O
combined-herbs	O
(	O
SH	O
)	O
given	O
with	O
zidovudine	B-I
(	O
ZDV	O
)	O
and	O
zalcitabine	B-I
(	O
ddC	O
)	O
for	O
the	O
treatment	O
of	O
HIV	B-P
infection	I-P
in	I-P
Thai	I-P
adults	I-P
was	I-P
conducted	I-P
in	I-P
3	I-P
hospitals	I-P
in	I-P
northern	I-P
Thailand	I-P
during	I-P
2002	I-P
to	I-P
2003	I-P
.	I-P


The	O
eligible	O
subjects	O
were	O
HIV-infected	B-P
Thai	I-P
adults	I-P
who	I-P
had	I-P
never	I-P
received	I-P
anti-retrovirals	I-I
,	I-P
had	I-P
a	I-P
Karnofski	I-P
Performance	I-P
Score	I-P
(	I-P
KPS	I-P
)	I-P
of	I-P
>	I-P
or	I-P
=	I-P
70	I-P
,	I-P
and	I-P
had	I-P
no	I-P
opportunistic	I-P
infections	I-P
.	I-P


The	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
combination	O
of	O
ZDV	B-I
200	O
mg	O
three	O
times	O
per	O
day	O
,	O
ddC	B-I
0.75	O
mg	O
three	O
times	O
per	O
day	O
,	O
and	O
SH	B-I
2.5	O
g	O
three	O
times	O
per	O
day	O
or	O
a	B-I
combination	I-I
of	I-I
ZDV	I-I
200	I-I
mg	I-I
three	I-I
times	I-I
per	I-I
day	I-I
,	I-I
ddC	I-I
0.75	I-I
mg	I-I
three	I-I
times	I-I
per	I-I
day	I-I
,	I-I
and	I-I
placebo	I-I
2.5	O
g	O
three	O
times	O
per	O
day	O
for	O
24	O
weeks	O
.	O


The	O
main	O
outcome	O
measures	O
were	O
HIV-RNA	B-O
,	I-O
CD4	I-O
cells	I-O
,	I-O
and	I-O
blood	I-O
chemistry	I-O
profiles	I-O
prior	O
to	O
the	O
treatment	O
and	O
then	O
every	O
4	O
weeks	O
for	O
24	O
weeks	O
.	O


The	O
baseline	O
characteristics	O
of	O
60	B-P
evaluable	I-P
subjects	I-P
,	I-P
40	I-P
in	I-P
the	I-P
SH	I-I
group	I-P
and	I-P
20	I-P
in	I-P
the	I-P
placebo	I-I
group	I-P
,	O
were	O
not	O
significantly	O
different	O
.	O


HIV	B-O
RNA	I-O
at	O
week	O
4	O
and	O
thereafter	O
was	O
significantly	O
decreased	O
from	O
the	O
baseline	O
value	O
in	O
both	O
groups	O
(	O
p	O
<	O
0.001	O
)	O
.	O


However	O
,	O
the	O
decline	O
in	O
HIV	B-O
RNA	I-O
in	O
the	O
SH	B-I
group	O
was	O
significantly	O
more	O
than	O
that	O
in	O
the	O
placebo	O
group	O
.	O


The	O
CD4	B-O
cells	I-O
in	O
the	O
SH	O
group	O
at	O
week	O
12	O
and	O
thereafter	O
were	O
significantly	O
increased	O
from	O
the	O
baseline	O
value	O
.	O


Serious	B-O
adverse	I-O
events	I-O
in	O
the	O
two	O
groups	O
were	O
not	O
observed	O
.	O


It	O
is	O
concluded	O
that	O
an	O
addition	O
of	O
SH	O
herbs	O
to	O
two	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
has	O
greater	O
antiviral	B-O
activity	I-O
than	O
antiretrovirals	O
only	O
.	O


The	O
SH	B-I
herbs	O
may	O
be	O
an	O
alternative	O
for	O
the	O
third	O
anti-retroviral	O
agent	O
in	O
the	O
triple	O
drug	O
regimen	O
for	O
the	O
treatment	O
of	O
HIV	O
infected	O
patients	O
in	O
countries	O
with	O
limited	O
resources	O
.	O


A	O
placebo-controlled	B-I
trial	O
of	O
D-cycloserine	B-I
added	O
to	O
conventional	O
neuroleptics	O
in	O
patients	B-P
with	I-P
schizophrenia	I-P
.	I-P


BACKGROUND	O
In	O
a	O
preliminary	O
dose-finding	O
study	O
,	O
D-cycloserine	B-I
,	O
a	O
partial	O
agonist	O
at	O
the	O
glycine	O
modulatory	O
site	O
of	O
the	O
glutamatergic	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
receptor	O
,	O
improved	O
negative	O
symptoms	O
and	O
cognitive	O
function	O
when	O
added	O
to	O
conventional	O
neuroleptics	O
at	O
a	O
dose	O
of	O
50	O
mg/d	O
.	O


METHODS	O
Forty-seven	B-P
patients	I-P
with	I-P
schizophrenia	I-P
meeting	I-P
criteria	I-P
for	I-P
deficit	I-P
syndrome	I-P
were	O
randomized	O
to	O
D-cycloserine	B-I
,	O
50	O
mg/d	O
(	O
n=23	O
)	O
or	O
placebo	B-I
(	O
n=24	O
)	O
added	O
to	O
their	O
conventional	O
neuroleptic	O
for	O
an	O
8-week	O
,	O
double-blind	O
trial	O
.	O


Clinical	O
assessments	O
were	O
performed	O
at	O
baseline	O
and	O
at	O
weeks	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
.	O


Serum	B-O
concentrations	I-O
of	I-O
D-cycloserine	I-O
,	I-O
relevant	I-O
amino	I-O
acids	I-O
,	I-O
and	I-O
homovanillic	I-O
acid	I-O
were	O
assayed	O
at	O
baseline	O
and	O
at	O
weeks	O
4	O
and	O
8	O
.	O


A	O
cognitive	B-O
battery	I-O
was	O
performed	O
at	O
baseline	O
and	O
at	O
week	O
8	O
.	O


RESULTS	O
Thirty-nine	B-P
patients	I-P
completed	O
the	O
8-week	O
trial	O
.	O


Seven	O
dropouts	O
occurred	O
in	O
the	O
D-cycloserine	B-I
group	O
and	O
1	O
in	O
the	O
placebo	B-I
group	O
.	O


The	O
mean	B-O
reduction	I-O
in	I-O
negative	I-O
symptoms	I-O
with	O
D-cycloserine	B-I
(	O
23	O
%	O
)	O
was	O
significantly	O
greater	O
than	O
with	O
placebo	B-I
(	O
7	O
%	O
)	O
as	O
calculated	O
by	O
slopes	O
representing	O
Scale	O
for	O
the	O
Assessment	O
of	O
Negative	O
Symptoms	O
(	O
SANS	O
)	O
total	O
scores	O
.	O


Improvement	O
of	O
negative	O
symptoms	O
was	O
predicted	O
by	O
low	O
neuroleptic	O
dose	O
and	O
low	O
baseline	O
SANS	O
total	O
score	O
.	O


No	O
differences	O
were	O
found	O
in	O
performance	B-O
on	I-O
any	I-O
cognitive	I-O
test	I-O
between	O
groups	O
or	O
in	O
changes	O
in	O
any	O
other	O
clinical	O
measure	O
.	O


Clinical	O
response	O
did	O
not	O
correlate	O
significantly	O
with	O
serum	O
amino	O
acid	O
concentrations	O
at	O
baseline	O
or	O
with	O
concentrations	O
of	O
D-cycloserine	B-I
at	O
weeks	O
4	O
and	O
8	O
.	O


CONCLUSION	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
agents	O
acting	O
at	O
the	O
glycine	O
modulatory	O
site	O
of	O
the	O
NMDA	O
receptor	O
improve	O
primary	O
negative	O
symptoms	O
.	O


Randomized	O
evaluation	O
of	O
octreotide	B-I
vs	O
prochlorperazine	B-I
for	O
ED	O
treatment	O
of	O
migraine	B-O
headache	I-O
.	I-O


UNLABELLED	O
Patients	B-P
with	I-P
headaches	I-P
account	O
for	O
approximately	O
2	O
%	O
of	O
all	O
ED	O
visits	O
,	O
with	O
migraines	O
being	O
the	O
most	O
common	O
defined	O
primary	O
headache	O
syndrome	O
.	O


Our	O
goals	O
were	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intravenous	O
octreotide	B-I
(	I-I
OC	I-I
)	I-I
for	O
the	O
treatment	O
of	O
migraines	O
,	O
when	O
compared	O
to	O
standard	O
therapy	O
with	O
prochlorperazine	B-I
.	I-I


METHODS	O
The	O
study	O
was	O
conducted	O
as	O
a	O
double-blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O


Each	O
subject	O
received	O
either	O
100	B-I
microg	I-I
of	I-I
octreotide	I-I
or	I-I
10	I-I
mg	I-I
of	I-I
prochlorperazine	I-I
intravenously	I-I
for	O
a	O
2-minute	O
period	O
.	O


RESULTS	O
Comparison	O
of	O
the	O
change	O
in	O
median	B-O
visual	I-O
analog	I-O
scale	I-O
scores	I-O
for	O
60	O
minutes	O
demonstrated	O
that	O
octreotide	B-I
was	O
less	O
effective	O
at	O
reducing	O
pain	B-O
(	O
P	O
=	O
.03	O
)	O
and	O
producing	O
clinical	O
success	O
(	O
P	O
<	O
.01	O
)	O
.	O


Restlessness	B-O
consistent	I-O
with	I-O
akathisia	I-O
was	O
noted	O
by	O
35	O
%	O
of	O
the	O
PC	O
group	O
and	O
8	O
%	O
of	O
the	O
OC	O
group	O
(	O
P	O
<	O
.01	O
)	O
.	O


At	O
60	O
minutes	O
,	O
rescue	B-O
medication	I-O
was	O
required	O
by	O
48	O
%	O
of	O
the	O
patients	O
in	O
the	O
OC	O
group	O
,	O
whereas	O
10	O
%	O
of	O
the	O
PC	O
group	O
required	O
such	O
therapy	O
(	O
P	O
<	O
.01	O
)	O
.	O


All	B-P
44	I-P
patients	I-P
were	O
contacted	O
for	O
follow-up	O
at	O
48	O
to	O
72	O
hours	O
after	O
enrollment	O
.	O


At	O
that	O
time	O
,	O
10	O
%	O
of	O
the	O
prochlorperazine	B-I
and	O
25	O
%	O
of	O
the	O
octreotide	B-I
patients	O
had	O
experienced	O
some	O
headache	B-O
recurrence	I-O
(	O
P	O
=	O
.1	O
)	O
.	O


CONCLUSION	O
Prochlorperazine	O
was	O
statistically	O
superior	O
to	O
octreotide	O
in	O
clinical	B-O
success	I-O
rate	I-O
and	O
decrease	O
in	O
pain	B-O
in	O
migraine	B-P
patients	I-P
but	O
caused	O
more	O
restlessness	B-O
and	O
sedation	B-O
.	I-O


Evaluation	O
of	O
additional	O
amine	B-I
fluoride/stannous	I-I
fluoride-containing	I-I
mouthrinse	I-I
during	O
supportive	O
therapy	O
in	O
patients	B-P
with	I-P
generalized	I-P
aggressive	I-P
periodontitis	I-P
.	I-P


A	O
randomized	O
,	O
crossover	O
,	O
double-blind	O
,	O
controlled	O
trial	O
.	O


OBJECTIVES	O
The	O
objective	O
of	O
the	O
present	O
randomized	O
controlled	O
trial	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
mouthrinse	B-I
containing	I-I
a	I-I
combination	I-I
of	I-I
AmF/SnF2	I-I
in	O
controlling	O
supragingival	O
plaque	O
accumulation	O
and	O
gingival	O
inflammation	O
during	O
a	O
12-week	O
period	O
in	O
patients	B-P
affected	I-P
by	I-P
generalized	I-P
aggressive	I-P
periodontitis	I-P
(	I-P
GAP	I-P
)	I-P
.	I-P


METHODS	O
Eighteen	B-P
subjects	I-P
,	I-P
six	I-P
males	I-P
and	I-P
12	I-P
females	I-P
,	I-P
mean	I-P
age	I-P
:	I-P
32.2	I-P
years	I-P
,	I-P
were	I-P
evaluated	I-P
.	I-P


One-half	O
of	O
the	O
patients	O
was	O
either	O
prescribed	O
an	O
AmF/SnF2-containing	B-I
mouthrinse	I-I
(	O
test	O
mouthrinse	O
)	O
or	O
a	O
control	B-I
mouthrinse	I-I
in	O
addition	O
to	O
mechanical	B-I
plaque	I-I
control	I-I
for	O
12	O
weeks	O
.	O


After	O
a	O
2-week	O
wash-out	O
period	O
,	O
the	O
patients	O
received	O
the	O
alternative	O
mouthrinse	B-I
.	I-I


Before	O
and	O
after	O
treatment	O
plaque	B-O
index	I-O
(	I-O
PlI	I-O
)	I-O
,	I-O
gingival	I-O
index	I-O
(	I-O
GI	I-O
)	I-O
,	I-O
angulated	I-O
bleeding	I-O
index	I-O
(	I-O
AngBI	I-O
)	I-O
,	I-O
tooth	I-O
stain	I-O
(	I-O
GMSI	I-O
)	I-O
,	I-O
and	I-O
tongue	I-O
stain	I-O
were	O
recorded	O
.	O


RESULTS	O
Test	B-I
mouthrinse	I-I
resulted	O
in	O
a	O
statistically	O
significant	O
decrease	O
in	O
PlI	B-O
(	O
p	O
=	O
0.029	O
)	O
and	O
GI	O
(	O
p	O
=	O
0.017	O
)	O
.	O


After	O
treatment	O
,	O
PlI	B-O
was	O
significantly	O
lower	O
in	O
test	O
compared	O
to	O
control	O
mouthrinse	O
(	O
p	O
=	O
0.027	O
)	O
.	O


GMSI	B-O
significantly	O
increased	O
post-treatment	O
for	O
both	O
mouthrinse	B-I
regimens	I-I
(	O
p	O
<	O
0.001	O
)	O
,	O
a	O
significantly	O
higher	O
score	O
being	O
observed	O
for	O
the	O
test	O
compared	O
to	O
control	B-I
mouthrinse	I-I
(	O
p	O
=	O
0.002	O
)	O
.	O


CONCLUSIONS	O
The	O
12-week	O
use	O
of	O
a	O
AmF/SnF2-containing	B-I
mouthrinse	I-I
as	O
an	O
adjunct	O
to	O
conventional	O
mechanical	O
oral	O
hygiene	O
procedures	O
in	O
GAP	B-P
patients	I-P
was	O
effective	O
in	O
controlling	O
the	O
amount	O
of	O
supragingival	O
plaque	O
deposits	O
.	O


Combined	B-I
delivery	I-I
approach	I-I
of	O
bone	B-I
marrow	I-I
mononuclear	I-I
stem	I-I
cells	I-I
early	I-I
and	O
late	O
after	O
myocardial	B-P
infarction	I-P
:	I-P
the	O
MYSTAR	O
prospective	O
,	O
randomized	O
study	O
.	O


BACKGROUND	O
Combined	O
intracoronary	O
and	O
intramyocardial	O
administration	O
might	O
improve	O
outcomes	O
for	O
bone-marrow-derived	B-I
stem	I-I
cell	I-I
therapy	I-I
for	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O


We	O
compared	O
the	O
safety	B-O
and	I-O
feasibility	I-O
of	O
early	O
and	O
late	O
delivery	O
of	O
stem	B-I
cells	I-I
with	O
combined	O
therapy	O
approaches	O
.	O


METHODS	O
Patients	B-P
with	I-P
left	I-P
ventricular	I-P
ejection	I-P
fraction	I-P
less	I-P
than	I-P
45	I-P
%	I-P
after	I-P
AMI	I-P
were	I-P
randomly	I-P
assigned	I-P
stem	I-I
cell	I-I
delivery	I-I
via	I-I
intramyocardial	I-I
injection	I-I
and	I-I
intracoronary	I-I
infusion	I-I
3-6	I-I
weeks	I-I
or	I-I
3-4	I-I
months	I-I
after	I-I
AMI	I-I
.	I-I


Primary	O
end	O
points	O
were	O
changes	B-O
in	I-O
infarct	I-O
size	I-O
and	I-O
left	I-O
ventricular	I-O
ejection	I-O
fraction	I-O
3	I-O
months	I-O
after	I-O
therapy	I-O
.	I-O


RESULTS	O
A	B-P
total	I-P
of	I-P
60	I-P
patients	I-P
were	I-P
treated	I-P
.	I-P


The	O
mean	B-O
changes	I-O
in	I-O
infarct	I-O
size	I-O
at	I-O
3	I-O
months	I-O
were	O
-3.5	O
+/-	O
5.1	O
%	O
(	O
95	O
%	O
CI	O
-5.5	O
%	O
to	O
-1.5	O
%	O
,	O
P	O
=	O
0.001	O
)	O
in	O
the	O
early	O
group	O
and	O
-3.9	O
+/-	O
5.6	O
%	O
(	O
95	O
%	O
CI	O
-6.1	O
%	O
to	O
-1.6	O
%	O
,	O
P	O
=	O
0.002	O
)	O
in	O
the	O
late	O
group	O
,	O
and	O
changes	B-O
in	I-O
ejection	I-O
fraction	I-O
were	O
3.5	O
+/-	O
5.6	O
%	O
(	O
95	O
%	O
CI	O
1.3-5.6	O
%	O
,	O
P	O
=	O
0.003	O
)	O
and	O
3.4	O
+/-	O
7.0	O
%	O
(	O
95	O
%	O
CI	O
0.7-6.1	O
%	O
,	O
P	O
=	O
0.017	O
)	O
,	O
respectively	O
.	O


At	O
9-12	O
months	O
after	O
AMI	O
,	O
ejection	B-O
fraction	I-O
remained	O
significantly	O
higher	O
than	O
at	O
baseline	O
in	O
both	O
groups	O
.	O


In	O
the	O
early	O
and	O
late	O
groups	O
,	O
a	O
mean	O
of	O
200.3	O
+/-	O
68.7	O
x	O
10	O
(	O
6	O
)	O
and	O
194.8	O
+/-	O
60.4	O
x	O
10	O
(	O
6	O
)	O
stem	B-O
cells	I-O
,	O
respectively	O
,	O
were	O
delivered	O
to	O
the	O
myocardium	O
,	O
and	O
1.30	O
+/-	O
0.68	O
x	O
10	O
(	O
9	O
)	O
and	O
1.29	O
+/-	O
0.41	O
x	O
10	O
(	O
9	O
)	O
cells	O
,	O
respectively	O
,	O
were	O
delivered	O
into	O
the	O
artery	O
.	O


A	O
high	O
number	B-O
of	I-O
cells	I-O
was	O
required	O
for	O
significant	O
improvements	O
in	O
the	O
primary	O
end	O
points	O
.	O


CONCLUSIONS	O
Combined	O
cardiac	B-I
stem	I-I
cell	I-I
delivery	I-I
induces	O
a	O
moderate	O
but	O
significant	O
improvement	O
in	O
myocardial	B-O
infarct	I-O
size	I-O
and	I-O
left	I-O
ventricular	I-O
function	I-O
.	I-O


The	O
influence	O
of	O
sequential	O
annual	O
vaccination	B-I
and	I-I
of	I-I
DHEA	I-I
administration	I-I
on	O
the	O
efficacy	O
of	O
the	O
immune	O
response	O
to	O
influenza	B-P
vaccine	I-P
in	I-P
the	I-P
elderly	I-P
.	I-P


The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
repeated	O
vaccination	B-I
and	O
of	O
dehydroepiandrosterone	B-I
(	I-I
DHEA	I-I
)	I-I
treatment	O
on	O
the	O
immune	O
response	O
to	O
influenza	B-I
vaccine	I-I
in	I-P
elderly	I-P
subjects	I-P
.	I-P


Seventy-one	B-P
elderly	I-P
volunteers	I-P
,	I-P
aged	I-P
61-89	I-P
years	I-P
,	O
enrolled	O
in	O
a	O
prospective	O
randomized	O
,	O
double-blind	O
study	O
to	O
receive	O
either	O
DHEA	B-I
(	O
50	O
mg	O
qd	O
p.o	O
.	O


for	O
4	O
consecutive	O
days	O
starting	O
2	O
days	O
before	O
immunization	O
)	O
or	O
placebo	B-I
.	I-I


Antibody	O
response	O
against	O
the	O
three	O
strains	O
of	O
vaccine	O
was	O
measured	O
before	O
and	O
28	O
days	O
after	O
vaccination	O
,	O
and	O
compared	O
between	O
previously	O
vaccinated	O
and	O
non-vaccinated	O
subjects	O
.	O


DHEA	B-I
treatment	I-I
did	O
not	O
enhance	O
established	B-O
immunity	I-O
.	I-O


A	O
significant	O
decrease	O
in	O
attainment	O
of	O
protective	B-O
antibody	I-O
titer	I-O
(	O
titer	O
of	O
1:40	O
or	O
greater	O
)	O
against	O
A/Texas	O
in	O
subjects	O
with	O
non-protective	O
baseline	O
antibody	O
titer	O
was	O
recorded	O
following	O
DHEA	B-I
treatment	I-I
compared	O
to	O
placebo	O
(	O
52	O
vs.	O
84	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O


Post-immunization	B-O
titers	I-O
against	O
influenza	O
A	O
strains	O
were	O
significantly	O
higher	O
in	O
those	O
subjects	O
who	O
were	O
never	O
immunized	O
before	O
.	O


Additionally	O
,	O
post-vaccination	B-O
protective	I-O
titers	I-O
against	O
the	O
A/Johannesburg	O
strain	O
were	O
more	O
prevalent	O
in	O
those	O
subjects	O
who	O
were	O
never	O
vaccinated	O
before	O
.	O


The	O
results	O
were	O
not	O
the	O
same	O
for	O
anti-B/Harbin	O
antibodies-repeated	O
vaccination	O
caused	O
a	O
non-significant	O
increase	O
in	O
HI	O
titer	O
in	O
previously	O
vaccinated	O
subjects	O
.	O


Impact	O
of	O
a	O
controlled	B-I
heated	I-I
breathing	I-I
tube	I-I
humidifier	I-I
on	O
sleep	B-O
quality	I-O
during	O
CPAP	B-I
therapy	I-I
in	I-P
a	I-P
cool	I-P
sleeping	I-P
environment	I-P
.	I-P


There	O
are	O
conflicting	O
data	O
on	O
the	O
effect	O
of	O
adding	O
a	O
heated	B-I
humidifier	I-I
to	O
nasal	O
continuous	B-I
positive	I-I
airway	I-I
pressure	I-I
(	I-I
CPAP	I-I
)	I-I
therapy	I-I
for	O
patients	B-P
with	I-P
obstructive	I-P
sleep	I-P
apnoea	I-P
syndrome	I-P
(	I-P
OSAS	I-P
)	I-P
.	I-P


The	O
effects	O
of	O
heated	O
humidification	O
on	O
sleep	B-O
quality	I-O
and	I-O
treatment	I-O
side-effects	I-O
for	O
patients	O
who	O
prefer	O
a	O
cold	O
bedroom	O
environment	O
have	O
not	O
been	O
studied	O
.	O


A	O
randomised	O
,	O
controlled	O
crossover	O
trial	O
involving	O
19	B-P
patients	I-P
with	I-P
a	I-P
first-ever	I-P
diagnosis	I-P
of	I-P
OSAS	I-P
measured	O
the	O
effect	O
of	O
conventional	B-I
heated	I-I
humidification	I-I
added	I-I
to	I-I
CPAP	I-I
compared	O
with	O
a	O
controlled	B-I
heated	I-I
breathing	I-I
tube	I-I
humidifier	I-I
(	I-I
ThermoSmart	I-I
(	I-I
R	I-I
)	I-I
;	I-I
Fisher	O
and	O
Paykel	O
Healthcare	O
,	O
Auckland	O
,	O
New	O
Zealand	O
)	O
on	O
sleep	B-O
quality	I-O
.	I-O


During	O
the	O
night	O
in	O
the	O
sleep	O
laboratory	O
at	O
a	O
mean	O
room	O
temperature	O
of	O
14	O
degrees	O
C	O
,	O
less	O
condensation	B-O
formed	O
with	O
the	O
controlled	B-I
heated	I-I
breathing	I-I
tube	I-I
humidifier	I-I
(	O
1.9	O
mL	O
versus	O
35.3	O
mL	O
)	O
in	O
the	O
delivery	O
system	O
.	O


In	O
addition	O
,	O
the	O
total	B-O
sleep	I-O
time	I-O
,	I-O
time	I-O
spent	I-O
in	I-O
sleep	I-O
stages	I-O
3	I-O
and	I-O
4	I-O
,	I-O
and	I-O
rapid	I-O
eye	I-O
movement	I-O
sleep	I-O
phases	I-O
were	O
significantly	O
longer	O
and	O
the	O
overall	B-O
side-effect	I-O
score	I-O
was	O
lower	O
than	O
with	O
conventional	O
heated	O
humidification	O
.	O


Patients	O
on	O
nasal	O
continuous	O
positive	O
airway	O
pressure	O
desiring	O
a	O
cool	O
bedroom	O
temperature	O
could	O
benefit	O
from	O
controlled	B-I
heated	I-I
breathing	I-I
tube	I-I
humidification	I-I
technology	I-I
(	O
with	O
inputs	O
from	O
ambient	O
temperature	O
,	O
set	O
pressure	O
and	O
flow	O
)	O
.	O


Carboplatin	B-I
and	I-I
pegylated	I-I
liposomal	I-I
doxorubicin	I-I
versus	O
carboplatin	B-I
and	I-I
paclitaxel	I-I
in	O
very	B-P
platinum-sensitive	I-P
ovarian	I-P
cancer	I-P
patients	I-P
:	I-P
results	O
from	O
a	O
subset	B-P
analysis	I-P
of	I-P
the	I-P
CALYPSO	I-P
phase	I-P
III	I-P
trial	I-P
.	I-P


AIM	O
To	O
perform	O
a	O
subset	O
analysis	O
of	O
patients	B-P
with	I-P
very	I-P
platinum-sensitive	I-P
recurrent	I-P
ovarian	I-P
cancer	I-P
(	I-P
ROC	I-P
)	I-P
enrolled	I-P
in	I-P
the	I-P
phase	I-P
III	I-P
CALYPSO	I-P
trial	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
The	B-P
international	I-P
non-inferiority	I-P
trial	I-P
enrolled	I-P
women	I-P
with	I-P
ROC	I-P
that	I-P
relapsed	I-P
>	I-P
6	I-P
months	I-P
following	I-P
first-	I-P
or	I-P
second-line	I-P
platinum-	I-I
and	I-I
paclitaxel-based	I-I
therapies	I-I
.	I-I


Patients	O
were	O
randomised	O
to	O
CD	B-I
[	I-I
carboplatin-pegylated	I-I
liposomal	I-I
doxorubicin	I-I
(	I-I
PLD	I-I
)	I-I
]	I-I
or	I-I
CP	I-I
(	I-I
carboplatin-paclitaxel	I-I
)	I-I
and	O
stratified	O
by	O
treatment-free	O
interval	O
(	O
TFI	O
)	O
.	O


In	O
this	O
analysis	O
,	O
patients	B-P
with	I-P
a	I-P
TFI	I-P
>	I-P
24	I-P
months	I-P
were	O
analysed	O
separately	O
for	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
the	O
primary	O
endpoint	O
of	O
CALYPSO	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
safety	O
.	O


RESULTS	O
A	B-P
total	I-P
of	I-P
259	I-P
very	I-P
platinum-sensitive	I-P
patients	I-P
were	I-P
included	I-P
(	I-P
n=131	I-P
,	I-P
CD	I-P
;	I-P
n=128	I-P
,	I-P
CP	I-P
)	I-P
.	I-P


Median	B-O
PFS	I-O
was	O
12.0	O
months	O
for	O
the	O
CD	B-I
arm	O
and	O
12.3	O
months	O
for	O
CP	B-I
[	O
HR=1.05	O
(	O
95	O
%	O
CI	O
,	O
0.79-1.40	O
)	O
;	O
P=0.73	O
for	O
superiority	O
]	O
and	O
median	B-O
OS	I-O
was	O
40.2	O
months	O
for	O
CD	O
and	O
43.9	O
for	O
CP	O
[	O
HR=1.18	O
(	O
95	O
%	O
CI	O
0.85-1.63	O
)	O
;	O
P=0.33	O
for	O
superiority	O
]	O
.	O


Overall	O
response	B-O
rates	I-O
were	O
42	O
%	O
and	O
38	O
%	O
,	O
respectively	O
(	O
P=0.46	O
)	O
.	O


Toxicities	B-O
were	O
more	O
common	O
with	O
CP	B-I
versus	O
CD	B-I
,	O
including	O
grade	B-O
3/4	I-O
neutropenia	I-O
(	O
40.8	O
%	O
versus	O
27.5	O
%	O
;	O
P=0.025	O
)	O
,	O
nausea	B-O
(	O
4.8	O
%	O
versus	O
3.1	O
%	O
;	O
P=0.47	O
)	O
,	O
allergic	B-O
reaction	I-O
(	O
8	O
%	O
versus	O
3.1	O
%	O
;	O
P=0.082	O
)	O
sensory	B-O
neuropathy	I-O
(	O
4.8	O
%	O
versus	O
2.3	O
%	O
;	O
P=0.27	O
)	O
and	O
grade	B-O
2	I-O
alopecia	I-O
(	O
88	O
%	O
versus	O
9.2	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O


Grade	B-O
3/4	I-O
thrombocytopenia	I-O
(	O
12.2	O
%	O
versus	O
3.2	O
%	O
;	O
P=0.007	O
)	O
and	O
mucositis	B-O
(	O
2.3	O
%	O
versus	O
0	O
%	O
;	O
P=0.089	O
)	O
were	O
more	O
common	O
with	O
CD	B-I
.	I-I


Grade	B-O
3/4	I-O
hand-foot	I-O
syndrome	I-O
occurred	O
rarely	O
with	O
CD	B-I
(	O
3	O
patients	O
versus	O
0	O
in	O
CP	O
arm	O
;	O
P=0.089	O
)	O
.	O


CONCLUSION	O
CP	O
and	O
CD	O
were	O
equally	O
effective	O
treatment	O
regimens	O
for	O
patients	B-P
with	I-P
very	I-P
platinum-sensitive	I-P
ROC	I-P
.	I-P


The	O
favourable	O
risk-benefit	O
profile	O
suggests	O
carboplatin-PLD	B-I
as	O
treatment	O
of	O
choice	O
for	O
these	O
patients	O
.	O


Assessing	O
drug	O
use	O
prevalence	O
in	O
the	O
workplace	O
:	O
a	O
comparison	O
of	O
self-report	O
methods	O
and	O
urinalysis	O
.	O


A	B-P
random	I-P
sample	I-P
of	I-P
800	I-P
employees	I-P
of	I-P
a	I-P
steel	I-P
manufacturing	I-P
company	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
self-report	B-I
methods	I-I
of	O
assessing	O
illicit	B-I
drug	I-I
use	I-I
:	I-I
1	I-I
)	I-I
Individual	I-I
interview	I-I
in	I-I
the	I-I
workplace	I-I
,	I-I
2	I-I
)	I-I
group-administered	I-I
questionnaire	I-I
in	I-I
the	I-I
workplace	I-I
,	I-I
3	I-I
)	I-I
telephone	I-I
interview	I-I
,	I-I
and	I-I
4	I-I
)	I-I
individual	I-I
interview	I-I
off	I-I
the	I-I
worksite	I-I
.	I-I


All	B-P
621	I-P
subjects	I-P
participating	I-P
in	I-P
the	I-P
research	I-P
were	I-P
also	I-P
tested	I-P
by	I-P
urinalysis	I-P
.	I-P


Rates	B-O
of	I-O
drug	I-O
use	I-O
self-report	I-O
were	O
highest	O
in	O
the	O
workplace	O
interview	O
condition	O
and	O
lowest	O
in	O
the	O
overall	O
group	O
questionnaire	O
condition	O
.	O


Although	O
the	O
overall	B-O
prevalence	I-O
rates	I-O
produced	O
by	O
self-reports	O
and	O
urinalysis	O
were	O
similar	O
,	O
there	O
was	O
little	O
concordance	O
between	O
urinalysis	B-O
positives	I-O
and	O
self-report	B-O
positives	I-O
.	I-O


The	O
results	O
indicated	O
that	O
self-reports	O
and	O
urinalysis	O
are	O
complementary	O
methods	O
of	O
drug	B-O
use	I-O
assessment	I-O
,	O
and	O
are	O
best	O
used	O
in	O
combination	O
.	O


A	O
randomized	O
clinical	O
trial	O
of	O
clinician	B-I
feedback	I-I
to	O
improve	O
quality	O
of	O
care	O
for	O
inner-city	B-P
children	I-P
with	I-P
asthma	I-P
.	I-P


CONTEXT	O
Barriers	O
impede	O
translating	O
recommendations	O
for	O
asthma	O
treatment	O
into	O
practice	O
,	O
particularly	O
in	O
inner	O
cities	O
where	O
asthma	O
morbidity	O
is	O
highest	O
.	O


METHODS	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
effectiveness	O
of	O
timely	O
patient	B-I
feedback	I-I
in	O
the	O
form	O
of	O
a	B-I
letter	I-I
providing	O
recent	O
patient-specific	O
symptoms	O
,	O
medication	O
,	O
and	O
health	O
service	O
use	O
combined	O
with	O
guideline-based	O
recommendations	O
for	O
changes	O
in	O
therapy	O
on	O
improving	O
the	O
quality	O
of	O
asthma	O
care	O
by	O
inner-city	O
primary	O
care	O
providers	O
and	O
on	O
resultant	O
asthma	O
morbidity	O
.	O


This	O
was	O
a	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
in	O
5-	B-P
to	I-P
11-year-old	I-P
children	I-P
(	I-P
n	I-P
=	I-P
937	I-P
)	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
asthma	I-P
receiving	I-P
health	I-P
care	I-P
in	I-P
hospital-	I-P
and	I-P
community-based	I-P
clinics	I-P
and	I-P
private	I-P
practices	I-P
in	I-P
7	I-P
inner-city	I-P
urban	I-P
areas	I-P
.	I-P


The	O
caretaker	B-P
of	I-P
each	I-P
child	I-P
received	O
a	O
bimonthly	B-I
telephone	I-I
call	I-I
to	I-I
collect	I-I
clinical	I-I
information	I-I
about	I-I
the	I-I
child	I-I
's	I-I
asthma	I-I
.	I-I


For	O
a	O
full	O
year	O
,	O
the	O
providers	O
of	O
intervention	O
group	O
children	O
received	O
bimonthly	B-I
computer-generated	I-I
letters	I-I
based	O
on	O
these	O
calls	O
summarizing	O
the	O
child	O
's	O
asthma	O
symptoms	O
,	O
health	O
service	O
use	O
,	O
and	O
medication	O
use	O
with	O
a	O
corresponding	O
recommendation	O
to	O
step	O
up	O
or	O
step	O
down	O
medications	O
.	O


We	O
measured	O
the	O
number	O
and	O
proportion	O
of	O
scheduled	O
visits	O
resulting	O
in	O
stepping	O
up	O
of	O
medications	O
,	O
asthma	O
symptoms	O
(	O
2-week	O
recall	O
)	O
,	O
and	O
health	O
care	O
use	O
(	O
2-month	O
recall	O
)	O
.	O


RESULTS	O
In	O
this	O
population	O
,	O
only	O
a	O
modest	O
proportion	O
of	O
children	O
whose	O
symptoms	O
warranted	O
a	O
medication	O
increase	O
actually	O
had	O
a	O
scheduled	B-O
visit	I-O
to	O
reevaluate	O
their	O
asthma	O
treatment	O
.	O


However	O
,	O
in	O
the	O
2-month	O
interval	O
after	O
receipt	O
of	O
a	O
step-up	O
letter	O
,	O
17.1	O
%	O
of	O
the	O
letters	O
were	O
followed	O
by	O
scheduled	O
visits	O
in	O
the	O
intervention	O
group	O
compared	O
with	O
scheduled	O
visits	O
12.3	O
%	O
of	O
the	O
time	O
by	O
the	O
control	O
children	O
with	O
comparable	O
clinical	O
symptoms	O
.	O


Asthma	B-I
medications	I-I
were	O
stepped	O
up	O
when	O
indicated	O
after	O
46.0	O
%	O
of	O
these	O
visits	O
in	O
the	O
intervention	O
group	O
compared	O
with	O
35.6	O
%	O
in	O
the	O
control	B-I
group	O
,	O
and	O
when	O
asthma	O
symptoms	O
warranted	O
a	O
step	O
up	O
in	O
therapy	O
,	O
medication	O
changes	O
occurred	O
earlier	O
among	O
the	O
intervention	O
children	O
.	O


Among	O
children	O
whose	O
medications	O
were	O
stepped	O
up	O
at	O
any	O
time	O
during	O
the	O
12-month	O
study	O
period	O
,	O
those	O
in	O
the	O
intervention	O
group	O
experienced	O
22.1	O
%	O
fewer	O
symptom	O
days	O
and	O
37.9	O
%	O
fewer	O
school	O
days	O
missed	O
.	O


The	O
intention-to-treat	O
analysis	O
showed	O
no	O
difference	O
over	O
the	O
intervention	O
year	O
in	O
the	O
number	B-O
of	I-O
symptom	I-O
days	I-O
,	O
yet	O
there	O
was	O
a	O
trend	O
toward	O
fewer	O
days	O
of	O
limited	O
activity	O
and	O
a	O
significant	O
decrease	O
in	O
emergency	B-O
department	I-O
visits	I-O
by	O
the	O
intervention	O
group	O
compared	O
with	O
controls	O
.	O


This	O
24	O
%	O
drop	O
in	O
emergency	B-O
department	I-O
visits	I-O
resulted	O
in	O
an	O
intervention	O
that	O
was	O
cost	O
saving	O
in	O
its	O
first	O
year	O
.	O


CONCLUSIONS	O
Patient-specific	B-I
feedback	I-I
to	O
inner-city	O
providers	O
increased	O
scheduled	O
asthma	O
visits	O
,	O
increased	O
asthma	O
visits	O
in	O
which	O
medications	O
were	O
stepped	O
up	O
when	O
clinically	O
indicated	O
,	O
and	O
reduced	O
emergency	O
department	O
visits	O
.	O


Effect	B-O
of	O
antacids	B-I
on	I-P
intragastric	I-O
pH	I-O
in	I-P
healthy	I-P
subjects	I-P
and	I-P
duodenal	I-P
ulcer	I-P
patients	I-P
.	I-P


Influence	O
of	O
the	O
size	O
of	O
the	O
antacid	B-I
dose	I-I
and	O
of	O
anticholinergics	B-I
.	I-I


Different	B-I
doses	I-I
of	I-I
two	I-I
liquid	I-I
antacids	I-I
,	I-I
alone	I-I
and	I-I
combined	I-I
with	I-I
an	I-I
anticholinergic	I-I
agent	I-I
,	O
were	O
studied	O
with	O
respect	O
to	O
the	O
duration	B-O
of	I-O
antacid	I-O
action	I-O
.	I-O


The	O
studies	O
were	O
performed	O
in	B-P
healthy	I-P
subjects	I-P
with	I-P
MAO	I-P
less	I-P
than	I-P
30	I-P
mmol/h	I-P
and	I-P
in	I-P
duodenal	I-P
ulcer	I-P
patients	I-P
with	I-P
MAO	I-P
greater	I-P
than	I-P
35	I-P
mmol/h	I-P
.	I-P


Gastric	B-O
pH	I-O
was	I-O
recorded	I-O
using	I-O
radiotelemetric	I-O
technique	I-O
(	I-O
Heidelberg	I-O
capsule	I-O
)	I-O
.	I-O


In	O
the	O
healthy	B-P
subjects	I-P
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
duration	B-O
of	I-O
action	I-O
with	O
the	O
different	O
doses	O
but	O
in	O
duodenal	B-P
ulcer	I-P
patients	I-P
a	O
tenfold	O
increase	O
of	O
the	O
antacid	B-I
dose	O
resulted	O
in	O
a	O
doubling	O
of	O
the	O
duration	B-O
of	I-O
action	I-O
.	I-O


Combined	O
treatment	O
with	O
an	O
anticholinergic	B-I
and	O
antacids	B-I
enhanced	O
the	O
antacid	B-O
effects	I-O
in	O
both	O
groups	O
.	O


It	O
is	O
concluded	O
that	O
an	O
antacid	O
dose	O
should	O
be	O
so	O
great	O
that	O
it	O
binds	O
secreted	O
acid	O
before	O
the	O
dose	O
leaves	O
the	O
stomach	O
.	O


Further	O
increase	O
of	O
the	O
dose	O
will	O
not	O
increase	O
the	O
duration	B-O
.	I-O


Concomitant	O
use	O
of	O
an	O
anticholinergic	B-I
agent	I-I
increases	O
the	O
duration	B-O
of	I-O
antacid	I-O
action	I-O
.	I-O


Trachoma	O
prevalence	O
and	O
associated	O
risk	O
factors	O
in	O
the	B-P
gambia	I-P
and	I-P
Tanzania	I-P
:	I-P
baseline	O
results	O
of	O
a	O
cluster	O
randomised	O
controlled	O
trial	O
.	O


BACKGROUND	O
Blinding	O
trachoma	O
,	O
caused	O
by	O
ocular	O
infection	O
with	O
Chlamydia	O
trachomatis	O
,	O
is	O
targeted	O
for	O
global	O
elimination	O
by	O
2020	O
.	O


Knowledge	O
of	O
risk	O
factors	O
can	O
help	O
target	O
control	O
interventions	O
.	O


METHODOLOGY/PRINCIPAL	O
FINDINGS	O
As	O
part	O
of	O
a	O
cluster	O
randomised	O
controlled	O
trial	O
,	O
we	O
assessed	B-O
the	I-O
baseline	I-O
prevalence	I-O
of	I-O
,	I-O
and	I-O
risk	I-O
factors	I-O
for	I-O
,	O
active	O
trachoma	B-O
and	O
ocular	B-O
C.	I-O
trachomatis	I-O
infection	I-O
in	O
randomly	B-P
selected	I-P
children	I-P
aged	I-P
0-5	I-P
years	I-P
from	I-P
48	I-P
Gambian	I-P
and	I-P
36	I-P
Tanzanian	I-P
communities	I-P
.	I-P


Both	B-I
children	I-I
's	I-I
eyes	I-I
were	I-I
examined	I-I
according	O
to	O
the	O
World	B-O
Health	I-O
Organization	I-O
(	I-O
WHO	I-O
)	I-O
simplified	I-O
grading	I-O
system	I-O
,	O
and	O
an	B-I
ocular	I-O
swab	I-O
was	I-I
taken	I-I
from	I-I
each	I-I
child	I-I
's	I-I
right	I-I
eye	I-I
and	I-I
processed	I-I
by	I-I
Amplicor	I-O
polymerase	I-O
chain	I-O
reaction	I-O
to	I-I
test	I-I
for	I-I
the	I-I
presence	I-I
of	I-I
C.	I-I
trachomatis	I-I
DNA	I-I
.	I-I


Prevalence	O
of	O
active	O
trachoma	O
was	O
6.7	O
%	O
(	O
335/5033	O
)	O
in	O
The	B-P
Gambia	I-P
and	O
32.3	O
%	O
(	O
1008/3122	O
)	O
in	O
Tanzania	B-P
.	I-P


The	O
countries	O
'	O
corresponding	O
Amplicor	B-O
positive	I-O
prevalences	I-O
were	O
0.8	O
%	O
and	O
21.9	O
%	O
.	O


After	O
adjustment	O
,	O
risk	O
factors	O
for	O
follicular	O
trachoma	O
(	O
TF	O
)	O
in	O
both	O
countries	O
were	O
ocular	B-O
or	I-O
nasal	I-O
discharge	I-O
,	O
a	O
low	B-O
level	I-O
of	I-O
household	I-O
head	I-O
education	I-O
,	O
and	O
being	O
aged	B-O
≥	I-O
1	I-O
year	I-O
.	O


Additional	O
risk	O
factors	O
in	B-P
Tanzania	I-P
were	I-O
flies	I-O
on	I-O
the	I-O
child	I-O
's	I-O
face	I-O
,	I-O
being	I-O
Amplicor	I-O
positive	I-O
,	I-O
and	I-O
crowding	I-O
(	O
the	O
number	O
of	O
children	O
per	O
household	O
)	O
.	O


The	O
risk	O
factors	O
for	O
being	B-O
Amplicor	I-O
positive	I-O
in	I-P
Tanzania	I-P
were	O
similar	O
to	O
those	O
for	O
TF	O
,	O
with	O
the	O
exclusion	O
of	O
flies	O
and	O
crowding	O
.	O


In	B-P
The	I-P
Gambia	I-P
,	O
only	B-O
ocular	I-O
discharge	I-O
was	O
associated	O
with	O
being	B-O
Amplicor	I-O
positive	I-O
.	O


CONCLUSIONS/SIGNIFICANCE	O
These	O
results	O
indicate	O
that	O
although	O
the	O
prevalence	O
of	O
active	O
trachoma	O
and	B-O
Amplicor	I-O
positives	I-O
were	O
very	O
different	O
between	O
the	O
two	O
countries	O
,	O
the	O
risk	O
factors	O
for	O
active	O
trachoma	O
were	O
similar	O
but	O
those	O
for	O
being	B-O
Amplicor	I-O
positive	I-O
were	O
different	O
.	O


The	O
lack	O
of	O
an	O
association	O
between	O
being	O
Amplicor	O
positive	O
and	O
TF	O
in	B-P
The	I-P
Gambia	I-P
highlights	O
the	O
poor	O
correlation	O
between	O
the	O
presence	O
of	B-O
trachoma	I-O
clinical	I-O
signs	I-O
and	I-O
evidence	I-O
of	I-O
C.	I-O
trachomatis	I-O
infection	I-O
in	O
this	O
setting	O
.	O


Only	B-O
ocular	I-O
discharge	I-O
was	O
associated	O
with	O
evidence	O
of	O
C.	O
trachomatis	O
DNA	O
in	B-P
The	I-P
Gambia	I-P
,	O
suggesting	O
that	O
at	O
this	O
low	O
endemicity	O
,	O
this	O
may	O
be	O
the	O
most	O
important	O
risk	O
factor	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
NCT00792922	O
.	O


The	O
effect	O
of	O
prethrombolytic	B-I
cyclosporine-A	I-I
injection	I-I
on	O
clinical	O
outcome	O
of	O
acute	B-P
anterior	I-P
ST-elevation	I-P
myocardial	I-P
infarction	I-P
.	I-P


INTRODUCTION	O
Reperfusion	O
injury	O
reduces	O
the	O
benefits	O
of	O
early	O
reperfusion	O
therapies	O
after	O
acute	O
ST-elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
.	O


Cyclosporine-A	B-I
(	I-I
CsA	I-I
)	I-I
is	O
a	O
potent	O
inhibitor	O
of	O
opening	O
of	O
the	O
mitochondrial	O
permeability	O
transition	O
pore	O
,	O
which	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
myocardial	O
reperfusion	O
injury	O
.	O


The	O
impact	O
of	O
this	O
treatment	O
on	O
clinical	O
outcomes	O
of	O
acute	O
STEMI	O
remains	O
unknown	O
.	O


Our	O
aim	O
was	O
to	O
investigate	O
the	O
clinical	O
outcomes	O
of	O
using	O
this	O
drug	O
in	O
patients	B-P
with	I-P
acute	I-P
anterior	I-P
STEMI	I-P
receiving	I-P
thrombolytic	I-P
treatment	I-P
(	I-P
TLT	I-P
)	I-P
.	I-P


METHODS	O
In	O
this	O
double-blinded	O
randomized	O
clinical	O
trial	O
,	O
101	B-P
patients	I-P
with	I-P
acute	I-P
anterior	I-P
STEMI	I-P
who	I-P
were	I-P
candidate	I-P
for	I-P
TLT	I-P
,	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
into	O
treatment	O
or	O
control	O
groups	O
.	O


Patients	B-I
in	I-I
the	I-I
treatment	I-I
group	I-I
received	I-I
an	I-I
intravenous	I-I
bolus	I-I
injection	I-I
of	I-I
2.5	I-I
mg/kg	I-I
of	I-I
CsA	I-I
immediately	I-I
before	I-I
TLT	I-I
.	I-I


The	B-I
patients	I-I
in	I-I
the	I-I
control	I-I
group	I-I
received	I-I
an	I-I
equivalent	I-I
volume	I-I
of	I-I
normal	I-I
saline	I-I
.	I-I


Infarct	B-O
size	I-O
,	I-O
occurrence	I-O
of	I-O
major	I-O
arrhythmias	I-O
,	I-O
heart	I-O
failure	I-O
,	I-O
left	I-O
ventricular	I-O
ejection	I-O
fraction	I-O
(	I-O
LVEF	I-O
)	I-O
,	I-O
TLT-related	I-O
complications	I-O
,	I-O
in-hospital	I-O
and	I-O
6-month	I-O
mortality	I-O
rates	I-O
were	O
investigated	O
.	O


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
demographics	B-O
,	I-O
myocardial	I-O
enzyme	I-O
release	I-O
,	I-O
occurrence	I-O
of	I-O
major	I-O
arrhythmias	I-O
[	O
9	O
(	O
18	O
%	O
)	O
vs.	O
12	O
(	O
23.5	O
%	O
)	O
,	O
P	O
=	O
0.80	O
]	O
,	O
heart	B-O
failure	I-O
[	O
18	O
(	O
36	O
%	O
)	O
vs.	O
19	O
(	O
38.3	O
%	O
)	O
,	O
P	O
=	O
0.83	O
]	O
,	O
LVEF	B-O
at	I-O
first	I-O
day	I-O
[	O
34.7	O
±	O
9.9	O
%	O
vs.	O
33.5	O
±	O
8.1	O
%	O
,	O
P	O
=	O
0.50	O
]	O
or	O
at	B-O
discharge	I-O
[	O
37.7	O
±	O
10	O
%	O
vs.	O
36.1	O
±	O
8.2	O
%	O
,	O
P	O
=	O
0.43	O
]	O
,	O
and	B-O
in-hospital	I-O
[	O
4	O
(	O
8	O
%	O
)	O
vs.	O
6	O
(	O
11.8	O
%	O
)	O
,	O
P	O
=	O
0.74	B-O
]	I-O
or	I-O
6-month	I-O
mortality	I-O
rates	I-O
[	O
9	O
(	O
18	O
%	O
)	O
vs.	O
10	O
(	O
19.6	O
%	O
)	O
,	O
P	O
=	O
0.99	O
]	O
between	O
the	O
CsA	O
vs.	O
the	O
control	O
group	O
.	O


CONCLUSION	O
In	O
this	O
study	O
,	O
the	O
prethrombolytic	O
administration	O
of	O
CsA	O
was	O
not	O
associated	O
with	O
a	O
reduction	O
in	O
the	B-O
infarct	I-O
size	I-O
or	O
any	O
improvement	O
in	O
clinical	O
outcomes	O
.	O


A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
the	O
effect	O
of	O
dried	B-I
purple	I-I
carrot	I-I
on	O
body	O
mass	O
,	O
lipids	O
,	O
blood	O
pressure	O
,	O
body	O
composition	O
,	O
and	O
inflammatory	O
markers	O
in	O
overweight	B-P
and	I-P
obese	I-P
adults	I-P
:	I-P
the	O
QUENCH	O
trial	O
.	O


Obesity	O
is	O
a	O
significant	O
health	O
issue	O
worldwide	O
and	O
is	O
associated	O
with	O
chronic	O
,	O
low-grade	O
inflammation	O
predisposing	O
the	O
individual	O
to	O
cardiovascular	O
disease	O
and	O
impaired	O
blood	O
glucose	O
homeostasis	O
.	O


Anthocyanins	B-I
and	I-I
phenolic	I-I
acids	I-I
from	I-I
purple	I-I
carrots	I-I
are	O
effective	O
at	O
reversing	O
inflammation	O
and	O
metabolic	O
alterations	O
in	O
animal	O
models	O
,	O
potentially	O
through	O
inhibition	O
of	O
inflammatory	O
pathways	O
.	O


The	O
effects	O
of	O
dried	B-I
purple	I-I
carrot	I-I
on	O
body	B-O
mass	I-O
,	I-O
body	I-O
composition	I-O
,	I-O
blood	I-O
pressure	I-O
,	I-O
lipids	I-O
,	I-O
inflammatory	I-O
markers	I-O
,	I-O
liver	I-O
function	I-O
tests	I-O
,	I-O
and	I-O
appetite	I-O
were	O
investigated	O
in	O
16	B-P
males	I-P
(	I-P
aged	I-P
53.1	I-P
±	I-P
7.6	I-P
years	I-P
and	I-P
with	I-P
a	I-P
mean	I-P
BMI	I-P
of	I-P
32.8	I-P
±	I-P
4.6	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
)	I-P
with	I-P
normal	I-P
lipid	I-P
and	I-P
inflammatory	I-P
markers	I-P
.	O


There	O
was	O
no	O
evidence	O
that	O
118.5	O
mg/day	O
of	B-I
anthocyanins	I-I
and	O
259.2	O
mg/day	O
of	B-I
phenolic	I-I
acids	I-I
for	O
4	O
weeks	O
resulted	O
in	O
statistically	O
significant	O
changes	O
in	B-O
body	I-O
mass	I-O
,	I-O
body	I-O
composition	I-O
,	I-O
appetite	I-O
,	I-O
dietary	I-O
intake	I-O
,	I-O
low	I-O
density	I-O
lipoprotein	I-O
,	I-O
total	I-O
cholesterol	I-O
,	I-O
blood	I-O
pressure	I-O
,	I-O
or	I-O
C-reactive	I-O
protein	I-O
in	O
these	O
obese	O
participants	O
at	O
the	O
dose	O
and	O
length	O
of	O
intervention	O
used	O
in	O
this	O
trial	B-O
.	I-O


High	B-O
density	I-O
lipoprotein	I-O
cholesterol	I-O
was	O
lower	O
in	O
the	O
intervention	O
group	O
(	O
p	O
<	O
0.05	B-O
)	I-O
.	I-O


Aspartate	B-O
amino	I-O
transferase	I-O
and	I-O
alanine	I-O
amino	I-O
transferase	I-O
did	O
not	O
change	O
,	O
indicating	O
that	O
the	O
intervention	O
was	O
safe	O
.	O


More	O
studies	O
are	O
required	O
to	O
establish	O
the	B-O
bioavailability	I-O
and	I-O
pharmacokinetic	I-O
effects	I-O
of	I-I
purple	I-I
carrot	I-I
anthocyanins	I-I
and	I-I
phenolic	I-I
acids	I-I
prior	O
to	O
further	O
trials	O
of	O
efficacy	O
with	O
respect	O
to	B-O
treating	I-O
inflammation	I-O
and	I-O
metabolic	I-O
alterations	I-O
.	O


Treatment	O
of	O
peptic	B-O
ulcer	I-O
disease	I-O
with	O
furazolidone	B-I
.	I-I


Furazolidone	B-I
(	O
FZ	O
)	O
has	O
been	O
used	O
in	O
China	O
as	O
a	O
treatment	O
of	O
peptic	B-O
ulcer	I-P
disease	I-P
for	O
about	O
20	O
years	O
.	O


Clinical	O
and	O
experimental	O
studies	O
suggest	O
that	O
it	O
has	O
good	O
short-term	O
and	O
long-term	O
effects	O
on	O
both	O
human	B-P
and	I-P
animal	I-O
ulcers	I-O
.	I-O


The	O
ulcer	B-O
healing	I-O
rate	O
is	O
related	O
to	O
the	O
dosage	O
and	O
course	O
of	O
treatment	O
.	O


The	O
healing	O
rate	O
of	O
a	O
high	O
dose	O
,	O
2	O
week	O
course	O
is	O
about	O
70-75	O
%	O
and	O
the	O
relapse	O
rate	O
after	O
3	O
years	O
is	O
9.5	O
%	O
.	O


The	O
adverse	O
reactions	O
to	O
FZ	O
are	O
not	O
severe	O
,	O
and	O
are	O
well	O
tolerated	B-O
in	O
most	O
patients	O
.	O


However	O
the	O
mutagenic	O
studies	O
of	O
several	O
biological	O
systems	O
indicate	O
that	O
it	O
has	O
a	O
mutagenic	B-O
effect	O
,	O
but	O
the	O
mutagenic	O
and	O
carcinogenic	B-O
effects	O
on	O
humans	O
and	O
animals	O
remain	O
questionable	O
,	O
because	O
FZ	O
has	O
been	O
biotransformed	O
into	O
other	O
metabolites	O
.	O


The	O
mechanisms	O
of	O
FZ	O
in	O
the	O
treatment	O
of	O
peptic	B-P
ulcer	I-P
disease	I-P
are	O
not	O
fully	O
understood	O
,	O
perhaps	O
partly	O
due	O
to	O
the	O
monoamine	B-O
oxidase	I-O
(	I-O
MAO	I-O
)	I-O
inhibitory	I-O
reaction	I-O
and	O
partly	O
to	O
the	O
antibacterial	B-O
activity	I-O
to	I-O
Helicobacter	I-O
pylori	I-O
(	O
HP	O
)	O
.	O


The	O
long-term	O
effects	O
of	O
FZ	O
are	O
still	O
not	O
clear	O
.	O


Effect	O
of	O
ischaemic	B-I
preconditioning	I-I
,	I-I
cardiopulmonary	I-I
bypass	I-I
and	I-I
myocardial	I-I
ischaemic/reperfusion	I-I
on	O
free	B-O
radical	I-O
generation	I-O
in	O
CABG	B-P
patients	I-P
.	I-P


OBJECTIVE	O
To	O
investigate	O
the	O
free	O
radicals	O
(	O
FR	O
)	O
generation	O
after	O
ischaemic	B-I
preconditioning	I-I
and	O
cardiopulmonary	B-I
bypass	I-I
and	O
during	O
reperfusion	O
in	O
CABG	B-P
patients	I-P
,	O
and	O
the	O
role	O
of	O
ischaemic	B-I
preconditioning	I-I
.	I-I


METHODS	O
Forty-three	B-P
CABG	I-P
patients	I-P
were	O
randomised	O
into	O
an	O
ischaemic	B-I
preconditioning	I-I
and	O
a	O
control	B-I
group	I-I
.	I-I


The	O
protocol	O
for	O
ischaemic	B-I
preconditioning	I-I
was	O
two	B-I
cycles	I-I
of	I-I
2-min	I-I
ischaemia	I-I
followed	I-I
by	I-I
3-min	I-I
reperfusion	I-I
.	I-I


Free	B-O
radicals	I-O
were	O
measured	O
using	O
electron	O
spin	O
resonance	O
spectroscopy	O
.	O


Global	B-O
and	I-O
right	I-O
heart	I-O
functions	I-O
were	O
collected	O
.	O


RESULTS	O
The	O
free	B-O
radicals	I-O
generation	I-O
in	I-O
coronary	I-O
sinus	I-O
blood	I-O
in	O
the	O
ischaemic	B-I
preconditioning	I-I
group	O
was	O
9.7	O
and	O
16.6	O
%	O
after	O
the	O
ischaemic	B-I
preconditioning	I-I
protocol	O
and	O
10	O
min	O
after	O
declamping	O
,	O
6.8	O
and	O
13.3	O
%	O
in	O
the	O
controls	O
.	O


The	O
free	B-O
radicals	I-O
in	I-O
arterial	I-O
samples	I-O
were	O
,	O
respectively	O
,	O
21	O
,	O
14	O
,	O
10	O
and	O
9	O
%	O
at	O
10	O
min	O
,	O
1	O
,	O
2	O
and	O
24	O
h	O
after	O
reperfusion	O
.	O


Cardiac	B-O
index	I-O
(	I-O
CI	I-O
)	I-O
and	I-O
right	I-O
ventricular	I-O
ejection	I-O
fraction	I-O
(	I-O
RVEF	I-O
)	I-O
were	O
improved	O
by	O
ischaemic	B-I
preconditioning	I-I
.	I-I


CONCLUSION	O
Both	O
ischaemic	B-I
preconditioning	I-I
and	O
cardiopulmonary	B-I
bypass	I-I
induced	O
free	B-O
radicals	I-O
generation	I-O
.	I-O


Although	O
ischaemic	B-I
preconditioning	I-I
had	O
no	O
effect	O
on	O
free	B-O
radicals	I-O
generation	I-O
after	O
the	O
operation	O
,	O
it	O
protected	O
against	O
postoperative	O
stunning	O
.	O


Osteosarcoma	O
:	O
the	O
addition	O
of	O
muramyl	B-I
tripeptide	I-I
to	O
chemotherapy	O
improves	O
overall	B-O
survival	I-O
--	I-O
a	I-O
report	O
from	O
the	O
Children	B-P
's	I-P
Oncology	I-P
Group	I-P
.	I-P


PURPOSE	O
To	O
compare	O
three-drug	O
chemotherapy	O
with	O
cisplatin	B-I
,	I-I
doxorubicin	I-I
,	I-I
and	I-I
methotrexate	I-I
with	O
four-drug	B-I
chemotherapy	I-I
with	I-I
cisplatin	I-I
,	I-I
doxorubicin	I-I
,	I-I
methotrexate	I-I
,	I-I
and	I-I
ifosfamide	I-I
for	O
the	O
treatment	O
of	O
osteosarcoma	O
.	O


To	O
determine	O
whether	O
the	O
addition	O
of	O
muramyl	B-I
tripeptide	I-I
(	I-I
MTP	I-I
)	I-I
to	O
chemotherapy	O
enhances	O
event-free	B-O
survival	I-O
(	I-O
EFS	I-O
)	I-O
and	I-O
overall	I-O
survival	I-O
in	O
newly	O
diagnosed	O
patients	O
with	O
osteosarcoma	O
.	O


PATIENTS	O
AND	O
METHODS	O
Six	B-P
hundred	I-P
sixty-two	I-P
patients	I-P
with	I-P
osteosarcoma	I-P
without	I-P
clinically	I-P
detectable	I-P
metastatic	I-P
disease	I-P
and	I-P
whose	I-P
disease	I-P
was	I-P
considered	I-P
resectable	I-P
received	I-P
one	I-P
of	I-P
four	I-P
prospectively	I-P
randomized	I-P
treatments	I-P
.	I-P


All	O
patients	O
received	O
identical	O
cumulative	O
doses	O
of	O
cisplatin	B-I
,	I-I
doxorubicin	I-I
,	I-I
and	I-I
methotrexate	I-I
and	O
underwent	O
definitive	O
surgical	O
resection	O
of	O
primary	O
tumor	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
or	O
not	O
to	O
receive	B-I
ifosfamide	I-I
and/or	I-I
MTP	I-I
in	O
a	O
2	O
x	O
2	O
factorial	O
design	O
.	O


The	O
primary	O
end	O
points	O
for	O
analysis	O
were	O
EFS	B-O
and	I-O
overall	I-O
survival	I-O
.	I-O


RESULTS	O
In	O
the	O
current	O
analysis	O
,	O
there	O
was	O
no	O
evidence	O
of	O
interaction	O
,	O
and	O
we	O
were	O
able	O
to	O
examine	O
each	O
intervention	O
separately	O
.	O


The	O
chemotherapy	O
regimens	O
resulted	O
in	O
similar	O
EFS	B-O
and	I-O
overall	I-O
survival	I-O
.	I-O


There	O
was	O
a	O
trend	O
toward	O
better	O
EFS	B-O
with	O
the	O
addition	O
of	O
MTP	O
(	O
P	O
=	O
.08	O
)	O
.	O


The	O
addition	O
of	O
MTP	O
to	O
chemotherapy	O
improved	O
6-year	B-O
overall	I-O
survival	I-O
from	O
70	O
%	O
to	O
78	O
%	O
(	O
P	O
=	O
.03	O
)	O
.	O


The	O
hazard	B-O
ratio	I-O
for	I-O
overall	I-O
survival	I-O
with	O
the	O
addition	O
of	O
MTP	O
was	O
0.71	O
(	O
95	O
%	O
CI	O
,	O
0.52	O
to	O
0.96	O
)	O
.	O


CONCLUSION	O
The	O
addition	O
of	O
ifosfamide	O
to	O
cisplatin	O
,	O
doxorubicin	O
,	O
and	O
methotrexate	O
did	O
not	O
enhance	O
EFS	B-O
or	O
overall	B-O
survival	I-O
for	O
patients	O
with	O
osteosarcoma	O
.	O


The	O
addition	O
of	O
MTP	O
to	O
chemotherapy	O
resulted	O
in	O
a	O
statistically	O
significant	O
improvement	O
in	O
overall	B-O
survival	I-O
and	O
a	O
trend	O
toward	O
better	O
EFS	B-O
.	I-O


[	O
Effect	O
of	O
alanyl-glutamine	B-I
in	O
postoperative	O
total	O
parenteral	O
nutrition	O
on	O
postoperative	O
immunosuppression	B-O
and	I-O
morbidity	I-O
.	I-O


Preliminary	O
results	O
of	O
a	O
prospective	O
randomized	O
study	O
]	O
.	O


The	O
impact	O
of	O
glutamine	B-I
substitution	I-I
on	O
postoperative	O
immunosuppression	O
and	O
morbidity	O
was	O
investigated	O
in	O
patients	B-P
with	I-P
surgical	I-P
interventions	I-P
and	I-P
total	I-P
parenteral	I-P
nutrition	I-P
in	O
a	O
prospective	O
randomized	O
trial	O
.	O


To	O
analyze	O
immune	O
competence	O
,	O
the	O
expression	O
of	O
CD3	B-O
,	I-O
CD4	I-O
,	I-O
and	I-O
CD8	I-O
on	I-O
lymphocytes	I-O
and	I-O
of	I-O
HLA-DR	I-O
and	I-O
CD14	I-O
on	I-O
monocytes	I-O
as	I-O
well	I-O
as	I-O
the	I-O
plasma	I-O
levels	I-O
of	I-O
IL-6	I-O
and	I-O
IL-10	I-O
was	O
evaluated	O
before	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
7	O
days	O
after	O
surgery	O
.	O


A	O
total	O
of	O
34	B-P
patients	I-P
have	I-P
been	I-P
included	I-P
(	I-I
with	I-I
glutamine	I-I
:	I-I
n	I-I
=	I-I
18	I-I
;	I-I
without	I-I
glutamine	I-I
:	I-I
n	I-P
=	I-P
16	I-P
)	I-P
.	I-P


Patients	B-P
with	I-P
glutamine	I-I
substitution	I-I
showed	O
decreased	B-O
systemic	I-O
inflammation	I-O
,	O
significant	O
faster	O
compensation	B-O
for	I-O
postoperative	I-O
immunosuppression	I-O
and	I-O
a	I-O
lower	I-O
incidence	I-O
of	I-O
postoperative	I-O
complications	I-O
.	I-O


Patients	O
without	O
postoperative	O
complications	O
showed	O
no	O
significant	O
differences	O
in	O
postoperative	O
immunosuppression	B-O
.	I-O


Association	O
between	O
frequency	O
of	O
ready-to-eat	O
cereal	O
consumption	O
,	O
nutrient	O
intakes	O
,	O
and	O
body	B-O
mass	I-O
index	I-O
in	O
fourth-	B-P
to	I-P
sixth-grade	I-P
low-income	I-P
minority	I-P
children	I-P
.	I-P


BACKGROUND	O
The	O
consumption	O
of	O
non-ready-to-eat	O
cereal	O
and	O
ready-to-eat	B-I
cereal	I-I
(	I-I
RTEC	I-I
)	I-I
breakfasts	O
have	O
been	O
associated	O
with	O
increased	O
nutrient	B-O
intakes	I-O
and	I-O
lower	I-O
body	I-O
mass	I-O
index	I-O
(	I-O
BMI	I-O
)	I-O
.	I-O


These	O
relationships	O
have	O
not	O
been	O
examined	O
in	O
low-income	B-P
minority	I-P
children	I-P
.	I-P


OBJECTIVES	O
To	O
evaluate	O
,	O
in	O
low-income	B-P
minority	I-P
children	I-P
,	O
whether	O
there	O
is	O
a	O
relationship	O
among	O
the	O
frequency	O
of	O
RTEC	B-I
consumption	O
and	O
nutrient	O
intakes	O
measured	O
at	O
baseline	O
,	O
and	O
whether	O
there	O
is	O
a	O
relationship	O
between	O
the	O
frequency	O
of	O
RTEC	B-I
and	O
BMI	B-O
controlling	O
for	O
age	O
,	O
sex	O
,	O
ethnicity	O
,	O
and	O
energy	O
intake	O
.	O


DESIGN	O
A	O
longitudinal	O
study	O
design	O
where	O
a	O
cohort	O
was	O
followed	O
for	O
3	O
years	O
.	O


SUBJECTS/SETTING	O
Participants	B-P
were	I-P
625	I-P
fourth-	I-P
through	I-P
sixth-grade	I-P
,	I-P
low-income	I-P
children	I-P
living	I-P
in	I-P
San	I-P
Antonio	I-P
,	I-P
Texas	I-P
,	I-P
and	I-P
enrolled	I-P
in	I-P
the	I-P
control	I-P
arm	I-P
of	I-P
the	I-P
Bienestar	I-P
Diabetes	I-P
Prevention	I-P
Program	I-P
's	I-P
cluster	I-P
randomized	I-P
trial	I-P
.	I-P


Three	O
multiple-pass	O
24-hour	O
dietary	O
recalls	O
were	O
collected	O
at	O
the	O
beginning	O
of	O
their	O
fourth-grade	O
year	O
and	O
at	O
the	O
end	O
of	O
their	O
fifth-	O
and	O
sixth-grade	O
years	O
.	O


Children	B-P
's	I-P
age	I-P
,	I-P
sex	I-P
,	I-P
ethnicity	I-P
,	O
and	O
height	O
and	O
weight	O
(	O
used	O
to	O
calculate	O
BMI	O
)	O
were	O
collected	O
between	O
August	O
2001	O
and	O
May	O
2004	O
.	O


STATISTICAL	O
ANALYSES	O
PERFORMED	O
Descriptive	O
and	O
inferential	O
statistical	O
analyses	O
were	O
performed	O
.	O


The	O
frequency	O
of	O
breakfast	O
consumption	O
was	O
examined	O
using	O
a	O
6×4	O
cross-tabulation	O
table	O
with	O
χ	O
(	O
2	O
)	O
test	O
to	O
establish	O
categorical	O
differences	O
.	O


The	O
degree	O
of	O
association	O
between	B-O
BMI	I-O
percentile	O
and	O
frequency	O
of	B-I
RTEC	I-I
consumption	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
ethnicity	O
,	O
and	O
nutrition-related	O
parameters	O
were	O
calculated	O
using	O
a	O
partial	O
correlation	O
multivariate	O
linear	O
model	O
analysis	O
.	O


RESULTS	O
There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
the	B-O
frequency	I-O
of	I-O
RTEC	I-O
consumption	I-O
and	I-O
nutrient	I-O
intakes	I-O
measured	O
at	O
baseline	O
.	O


There	O
was	O
also	O
a	O
significant	O
inverse	O
relationship	O
between	B-O
frequency	I-O
of	I-O
RTEC	I-O
consumption	I-O
and	I-O
BMI	I-O
percentile	I-O
over	O
the	O
cumulative	O
3-year	O
period	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
ethnicity	O
,	O
and	O
energy	O
intake	O
.	O


CONCLUSIONS	B-P
Children	I-P
who	O
frequently	O
consumed	B-I
RTEC	I-I
had	O
greater	O
intakes	O
of	B-O
essential	I-O
nutrients	I-O
at	O
baseline	O
and	O
significantly	O
lower	B-O
BMI	I-O
over	O
a	O
3-year	O
period	O
.	O


The	O
clinician	O
's	O
decision	O
of	O
whether	O
CHOP	B-I
chemotherapy	I-I
should	O
be	O
standard	O
therapy	O
for	O
treatment	B-O
of	I-O
patients	I-O
with	I-O
diffuse	I-O
histiocytic	I-O
lymphoma	I-O
.	I-O


Icosapent	B-I
Ethyl	I-I
(	I-I
Eicosapentaenoic	I-I
Acid	I-I
Ethyl	I-I
Ester	I-I
)	I-I
:	I-I
Effects	O
Upon	O
High-Sensitivity	O
C-Reactive	O
Protein	O
and	O
Lipid	O
Parameters	O
in	O
Patients	B-P
With	I-P
Metabolic	I-P
Syndrome	I-P
.	I-P


BACKGROUND	O
The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
examine	O
the	O
effects	O
of	O
icosapent	B-I
ethyl	I-I
(	I-I
eicosapentaenoic	I-I
acid	I-I
ethyl	I-I
ester	I-I
,	I-I
IPE	I-I
)	I-I
on	O
high-sensitivity	O
C-reactive	O
protein	O
(	O
hsCRP	O
)	O
and	O
lipid	O
parameters	O
in	O
patients	B-P
with	I-P
metabolic	I-P
syndrome	I-P
,	I-P
with	I-P
and	I-P
without	I-P
stable	I-P
statin	I-P
therapy	I-P
.	I-P


METHODS	O
This	O
post	O
hoc	O
exploratory	O
analysis	O
evaluated	O
patients	B-P
with	I-P
metabolic	I-P
syndrome	I-P
treated	I-P
with	I-P
IPE	I-I
4	I-P
grams/day	I-P
,	I-P
IPE	I-P
2	I-P
grams/day	I-P
,	I-P
or	I-P
placebo	I-I
in	I-P
phase	I-P
3	I-P
,	I-P
randomized	I-P
,	I-P
placebo-controlled	I-P
studies	I-P
entitled	I-P
:	I-P
MARINE	I-P
[	I-P
triglyceride	I-P
(	I-P
TG	I-P
)	I-P
levels	I-P
≥500	I-P
and	I-P
≤2000	I-P
mg/dL	I-P
]	I-P
and	I-P
ANCHOR	I-P
[	I-P
TG	I-P
levels	I-P
≥200	I-P
and	I-P
<	I-P
500	I-P
mg/dL	I-P
,	I-P
despite	I-P
low-density	I-P
lipoprotein	I-P
cholesterol	I-P
(	I-P
LDL-C	I-P
)	I-P
control	I-P
with	I-P
stable	I-P
statin	I-P
therapy	O
]	O
.	O


RESULTS	O
Compared	B-I
with	I-I
placebo	I-P
in	I-P
patients	I-P
with	I-P
metabolic	I-P
syndrome	I-P
in	I-P
MARINE	I-P
(	I-P
n=204	I-P
)	I-P
and	I-P
ANCHOR	I-P
(	O
n=645	O
)	O
,	O
at	O
the	O
approved	O
dose	O
of	O
4	O
grams/day	O
,	O
IPE	O
significantly	B-O
lowered	I-O
hsCRP	I-O
levels	O
40.0	O
%	O
(	O
P=0.0007	O
)	O
in	O
MARINE	O
and	O
23.0	O
%	O
(	O
P=0.0003	O
)	O
in	O
ANCHOR	O
.	O


Compared	B-I
with	I-I
placebo	O
in	O
MARINE	O
,	O
which	O
included	O
patients	O
with	O
and	O
without	O
statin	B-I
therapy	I-I
,	O
IPE	O
4	O
grams/day	O
significantly	B-O
reduced	I-O
hsCRP	I-O
levels	O
78.0	O
%	O
in	O
statin-treated	O
patients	O
(	O
P=0.0035	O
,	O
n=16	O
)	O
.	O


Compared	B-I
with	I-I
placebo	O
in	O
MARINE	O
,	O
IPE	O
4	O
grams/day	O
significantly	B-O
reduced	I-O
TG	O
levels	O
(	O
35.0	O
%	O
;	O
P	B-O
<	I-O
0.0001	I-O
)	I-O
,	I-O
non-high-density	I-O
lipoprotein	I-O
cholesterol	I-O
(	I-O
non-HDL-C	I-O
;	I-O
19.9	O
%	O
;	O
P	B-O
<	I-O
0.0001	I-O
)	I-O
,	I-O
and	I-O
apolipoprotein	I-O
B	O
levels	O
(	O
ApoB	O
)	O
(	O
9.1	O
%	O
;	O
P=0.0015	O
)	O
without	B-O
raising	I-O
LDL-C	I-O
levels	O
.	O


Compared	O
with	O
placebo	O
in	B-I
ANCHOR	I-I
,	O
IPE	O
4	O
grams/day	O
significantly	B-O
reduced	I-O
TG	O
(	O
21.7	O
%	O
;	O
P	B-O
<	I-O
0.0001	I-O
)	I-O
,	O
non-HDL-C	O
(	O
13.5	O
%	O
;	O
P	B-O
<	I-O
0.0001	I-O
)	I-O
,	O
ApoB	O
(	O
8.8	O
%	O
;	O
P	B-O
<	I-O
0.0001	I-O
)	I-O
,	O
LDL-C	O
(	O
5.2	O
%	O
;	O
P=0.0236	B-O
)	I-O
,	I-O
and	I-O
HDL-C	I-O
levels	O
(	O
4.0	O
%	O
;	O
P=0.0053	O
)	O
.	O


CONCLUSIONS	O
Compared	O
with	O
placebo	O
,	O
IPE	O
4	O
grams/day	O
significantly	O
lowered	O
hsCRP	O
levels	O
and	O
improved	O
lipids	O
without	O
raising	O
LDL-C	O
levels	B-P
in	I-P
patients	I-P
with	I-P
metabolic	I-P
syndrome	I-P
and	I-P
high	I-P
(	I-P
≥200	I-P
and	I-P
<	I-P
500	I-P
mg/dL	I-P
)	I-P
or	I-P
very	I-P
high	I-P
(	I-P
≥500	I-P
and	I-P
≤2000	I-P
mg/dL	I-P
)	I-P
TG	I-P
levels	I-P
,	I-P
with	I-P
or	I-P
without	I-P
stable	I-P
statin	O
therapy	O
.	O


Does	O
temporary	B-I
clamping	I-I
of	I-I
drains	I-I
following	O
knee	O
arthroplasty	O
reduce	O
blood	O
loss	O
?	O
A	O
randomised	O
controlled	O
trial	O
.	O


In	O
a	O
randomised	O
,	O
blinded	O
study	O
76	B-P
patients	I-P
undergoing	I-P
primary	I-P
total	I-P
knee	I-P
arthroplasty	I-P
were	I-P
assigned	I-P
to	O
either	O
immediate	B-I
drain	I-I
opening	I-I
(	I-I
n	I-I
=	I-I
45	I-I
)	I-I
or	I-I
drains	I-I
opened	I-I
at	I-I
2	I-I
h	I-I
(	O
n	O
=	O
31	O
)	O
.	O


No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
for	O
the	O
volume	B-O
of	I-O
drained	I-O
blood	I-O
,	I-O
transfusion	I-O
requirements	I-O
,	I-O
knee	I-O
motion	I-O
or	I-O
wound	I-O
status	I-O
.	I-O


The	O
authors	O
conclude	O
that	O
the	O
practice	O
of	O
clamping	B-I
drains	I-I
has	O
no	O
benefit	O
in	O
routine	O
knee	O
arthroplasty	O
.	O


However	O
,	O
when	O
faced	O
with	O
immediate	O
brisk	O
blood	B-O
loss	I-O
,	O
the	O
results	O
suggest	O
that	O
drains	B-I
can	O
be	O
clamped	O
without	O
any	O
excess	O
morbidity	B-O
.	I-O


Effects	O
of	O
temafloxacin	B-I
and	O
ciprofloxacin	B-I
on	O
the	O
pharmacokinetics	O
of	O
caffeine	O
.	O


A	O
number	O
of	O
quinolone	O
antibacterial	O
agents	O
,	O
particularly	O
enoxacin	O
,	O
pefloxacin	O
,	O
pipemidic	O
acid	O
and	O
ciprofloxacin	B-I
,	O
are	O
known	O
to	O
decrease	O
the	O
clearance	O
of	O
methylxanthines	O
.	O


The	O
effects	O
of	O
temafloxacin	B-I
and	I-I
ciprofloxacin	I-I
on	O
the	O
pharmacokinetics	O
of	O
caffeine	O
were	O
therefore	O
compared	O
in	O
a	O
3-way	O
crossover	O
study	O
in	O
12	B-P
healthy	I-P
young	I-P
volunteers	I-P
.	I-P


Each	O
volunteer	O
received	O
183mg	B-I
once-daily	I-I
doses	I-I
of	I-I
caffeine	I-I
in	O
conjunction	O
with	O
twice-daily	O
placebo	B-I
,	I-I
temafloxacin	I-I
600mg	I-I
and	I-I
ciprofloxacin	I-I
750mg	I-I
in	O
3	O
separate	O
phases	O
according	O
to	O
a	O
randomised	O
sequence	O
.	O


A	O
doubling	O
of	O
the	O
area	B-O
under	I-O
the	I-O
plasma	I-O
concentration-time	I-O
curve	I-O
(	O
77.8	O
vs	O
31.8	O
mg/L.h	O
)	O
and	O
terminal-phase	B-O
half-life	I-O
(	O
9.7	O
vs	O
4.5h	O
)	O
of	O
caffeine	B-I
were	O
observed	O
in	O
the	O
presence	O
of	O
ciprofloxacin	O
.	O


The	O
magnitude	B-O
of	I-O
the	I-O
reduction	I-O
in	I-O
the	I-O
intrinsic	I-O
clearance	I-O
of	I-O
caffeine	I-O
produced	O
by	O
ciprofloxacin	B-I
was	O
greater	O
than	O
that	O
described	O
in	O
the	O
literature	O
for	O
ciprofloxacin	B-I
and	I-I
theophylline	I-I
.	I-I


This	O
may	O
partly	O
be	O
explained	O
by	O
intertrial	O
differences	O
in	O
dosage	O
and	O
study	O
design	O
.	O


Coadministration	O
of	O
temafloxacin	B-I
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
pharmacokinetics	B-O
of	I-O
caffeine	I-O
,	O
confirming	O
results	O
of	O
other	O
studies	O
suggesting	O
that	O
this	O
agent	O
does	O
not	O
affect	O
methylxanthine	B-O
clearance	I-O
.	I-O


Accordingly	O
,	O
it	O
appears	O
that	O
restriction	O
of	O
caffeine	O
intake	O
during	O
temafloxacin	B-I
therapy	O
is	O
not	O
necessary	O
.	O


Combination	B-I
chemotherapy	I-I
and	O
ALVAC-CEA/B7.1	B-I
vaccine	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	I-P


PURPOSE	O
The	O
combination	O
of	O
vaccines	B-I
and	O
chemotherapy	B-I
holds	O
promise	O
for	O
cancer	O
therapy	O
,	O
but	O
the	O
effect	O
of	O
cytotoxic	O
chemotherapy	O
on	O
vaccine-induced	O
antitumor	O
immunity	O
is	O
unknown	O
.	O


This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effects	O
of	O
systemic	O
chemotherapy	O
on	O
ALVAC-CEA/B7.1-induced	O
T-cell	O
immunity	O
in	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	I-P


EXPERIMENTAL	O
DESIGN	O
Patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
were	O
treated	O
with	O
fluorouracil	B-I
,	I-I
leucovorin	I-I
,	I-I
and	I-I
irinotecan	I-I
and	O
were	O
also	O
given	O
ALVAC-CEA/B7.1	B-I
vaccine	I-I
with	I-I
or	I-I
without	I-I
tetanus	I-I
toxoid	I-I
adjuvant	I-I
.	I-I


Eligible	O
patients	O
were	O
randomized	O
to	O
ALVAC	B-I
followed	I-I
by	I-I
chemotherapy	I-I
and	I-I
booster	I-I
vaccination	I-I
(	I-I
group	I-I
1	I-I
)	I-I
,	I-I
ALVAC	I-I
and	I-I
tetanus	I-I
toxoid	I-I
followed	I-I
by	I-I
chemotherapy	I-I
(	I-I
group	I-I
2	I-I
)	I-I
,	I-I
or	I-I
chemotherapy	I-I
alone	I-I
followed	I-I
by	I-I
ALVAC	I-I
in	I-I
patients	I-I
without	I-I
disease	I-I
progression	I-I
(	I-I
group	I-I
3	O
)	O
.	O


Humoral	O
immune	O
responses	O
were	O
measured	O
by	O
standard	O
ELISA	B-I
assay	I-I
,	O
and	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
-specific	O
T-cell	O
responses	O
were	O
measured	O
by	O
IFN-gamma	B-I
enzyme-linked	I-I
immunospot	I-I
assay	I-I
.	I-I


RESULTS	O
One	B-P
hundred	I-P
eighteen	I-P
patients	I-P
were	O
randomized	O
to	O
receive	O
either	O
ALVAC	B-I
before	O
and	O
concomitantly	O
with	O
chemotherapy	B-I
(	O
n	O
=	O
39	O
)	O
,	O
ALVAC	B-I
with	O
tetanus	B-I
adjuvant	I-I
before	O
and	O
concomitantly	O
with	O
chemotherapy	B-I
(	O
n	O
=	O
40	O
)	O
,	O
or	O
chemotherapy	B-I
followed	O
by	O
ALVAC	B-I
(	O
n	O
=	O
39	O
)	O
.	O


Serious	B-O
adverse	I-O
events	I-O
were	O
largely	O
gastrointestinal	B-O
(	O
n	O
=	O
30	O
)	O
and	O
hematologic	B-O
(	O
n	O
=	O
24	O
)	O
.	O


Overall	O
,	O
42	O
patients	O
(	O
40.4	O
%	O
)	O
showed	O
objective	O
clinical	O
responses	O
.	O


All	O
patients	O
developed	O
antibody	B-O
responses	I-O
against	I-O
ALVAC	I-O
,	O
but	O
increased	O
anti-CEA	B-O
antibody	I-O
titers	I-O
were	O
detected	O
in	O
only	O
three	O
patients	O
.	O


Increases	O
in	O
CEA-specific	B-O
T	I-O
cells	I-O
were	O
detected	O
in	O
50	O
%	O
,	O
37	O
%	O
,	O
and	O
30	O
%	O
of	O
patients	O
in	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
.	O


There	O
were	O
no	O
differences	O
in	O
clinical	O
or	O
immune	O
responses	O
between	O
the	O
treatment	O
groups	O
.	O


CONCLUSION	O
The	O
combination	O
of	O
ALVAC-CEA/B7.1	B-I
vaccine	I-I
and	O
systemic	O
chemotherapy	B-I
has	O
an	O
acceptable	O
safety	O
profile	O
in	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	I-P


Systemic	O
chemotherapy	O
did	O
not	O
affect	O
the	O
generation	O
of	O
CEA-specific	B-O
T-cell	I-O
responses	I-O
following	O
vaccination	O
.	O


Effects	O
of	O
a	O
combination	O
of	O
evening	B-I
primrose	I-I
oil	I-I
(	I-I
gamma	I-I
linolenic	I-I
acid	I-I
)	I-I
and	I-I
fish	I-I
oil	I-I
(	I-I
eicosapentaenoic	I-I
+	I-I
docahexaenoic	I-I
acid	I-I
)	I-I
versus	I-I
magnesium	I-I
,	I-I
and	I-I
versus	I-I
placebo	I-I
in	O
preventing	O
pre-eclampsia	B-O
.	I-O


In	O
a	O
placebo	B-I
controlled	O
,	O
partially	O
double-blinded	O
,	O
clinical	O
trial	O
,	O
a	O
combination	B-I
of	I-I
evening	I-I
primrose	I-I
oil	I-I
and	I-I
fish	I-I
oil	I-I
was	I-I
compared	I-I
to	I-I
Magnesium	I-I
Oxide	I-I
,	I-I
and	I-I
to	I-I
a	I-I
Placebo	I-I
in	O
preventing	O
Pre-Eclampsia	B-O
of	I-O
Pregnancy	I-O
.	I-O


All	O
were	O
given	O
as	O
nutritional	O
supplements	O
for	O
six	O
months	O
to	O
a	O
group	B-P
of	I-P
primiparous	I-P
and	I-P
multiparous	I-P
pregnant	I-P
women	I-P
.	I-P


Some	B-P
of	I-P
these	I-P
women	I-P
had	I-P
personal	I-P
or	I-P
family	I-P
histories	I-P
of	I-P
hypertension	I-P
(	I-P
21	I-P
%	I-P
)	I-P
.	I-P


Only	B-P
those	I-P
patients	I-P
who	I-P
received	I-P
prenatal	I-P
care	I-P
at	I-P
the	I-P
Central	I-P
Maternity	I-P
Hospital	I-P
for	I-P
Luanda	I-P
were	O
included	O
in	O
the	O
study	O
.	O


Compared	O
to	O
the	O
Placebo	B-I
group	O
(	O
29	O
%	O
)	O
,	O
the	O
group	O
receiving	O
the	O
mixture	O
of	O
evening	B-I
primrose	I-I
oil	I-I
and	O
fish	B-I
oil	I-I
containing	O
Gamma-linolenic	B-I
acid	I-I
(	I-I
GLA	I-I
)	I-I
,	I-I
Eicosapentaenoic	I-I
acid	I-I
(	I-I
EPA	I-I
)	I-I
,	O
and	O
Docosahexaenoic	B-I
acid	I-I
(	I-I
DHA	I-I
)	I-I
had	O
a	O
significantly	O
lower	O
incidence	B-O
of	I-O
edema	I-O
(	O
13	O
%	O
,	O
p	O
=	O
0.004	O
)	O
.	O


The	O
group	O
receiving	O
Magnesium	B-I
Oxide	I-I
had	O
statistically	O
significant	O
fewer	O
subjects	O
who	O
developed	O
hypertension	B-O
of	I-O
pregnancy	I-O
.	I-O


There	O
were	O
3	O
cases	O
of	O
eclampsia	B-O
,	O
all	O
in	O
the	O
Placebo	B-I
group	O
.	O


Does	O
tetanus	B-I
immune	I-I
globulin	I-I
interfere	O
with	O
the	O
immune	B-O
response	I-O
to	O
simultaneous	O
administration	O
of	O
tetanus-diphtheria	B-I
vaccine	I-I
?	O
A	O
comparative	O
clinical	O
trial	B-P
in	I-P
adults	I-P
.	I-P


In	O
the	O
management	O
of	O
wounds	O
,	O
sometimes	O
it	O
is	O
recommended	O
to	O
give	O
an	O
adult-type	O
tetanus-diphtheria	B-I
(	I-I
Td	I-I
)	I-I
vaccine	I-I
dose	O
plus	O
tetanus	B-I
immune	I-I
globulin	I-I
(	I-I
TIG	I-I
)	I-I
.	I-I


Sixty	B-P
and	I-P
59	I-P
healthy	I-P
young	I-P
adults	I-P
previously	I-P
immunized	I-P
against	I-P
tetanus	I-P
(	I-P
T	I-P
)	I-P
and	I-P
diphtheria	I-P
(	I-P
D	I-P
)	I-P
were	I-P
randomized	I-P
to	I-P
receive	I-I
intramuscularly	I-I
either	I-I
Td	I-I
vaccine	I-I
alone	I-I
(	I-I
group	I-I
1	I-I
)	I-I
or	I-I
Td	I-I
vaccine	I-I
plus	I-I
500	I-I
IU	I-I
of	I-I
TIG	I-I
(	I-I
group	I-I
2	I-I
)	I-I
simultaneously	I-I
.	I-I


Antitoxin	B-O
response	I-O
was	I-I
assessed	I-I
after	I-I
4	I-I
weeks	I-I
and	I-I
4	I-I
months	I-I
.	I-I


Circulating	B-O
antibodies	I-O
were	I-O
measured	I-O
by	I-O
enzyme-linked	I-O
immunosorbent	I-O
assay	I-O
(	I-O
ELISA	I-O
)	I-O
.	I-O


The	O
cutoff	O
of	O
these	O
tests	O
was	O
0.1	O
IU/mL	O
.	O


Titers	O
of	O
0.1	O
IU/mL	O
or	O
greater	O
were	O
considered	O
protective	O
.	O


For	O
geometric	O
mean	O
titers	O
(	O
GMT	O
)	O
,	O
antibody	B-O
titers	I-O
below	O
the	O
cutoff	O
of	O
the	O
assay	O
were	O
given	O
,	O
arbitrarily	O
,	O
0.05	O
IU/mL	O
.	O


At	O
4	O
weeks	O
,	O
98	O
%	O
or	O
more	O
of	O
the	O
subjects	O
in	O
group	O
1	O
had	O
circulating	B-O
T	I-O
and	I-O
D	I-O
antitoxin	I-O
levels	I-O
of	O
0.1	O
IU/mL	O
or	O
higher	O
;	O
in	O
group	O
2	O
,	O
95	O
%	O
and	O
90	O
%	O
of	O
the	O
subjects	O
had	O
titers	O
above	O
this	O
limit	O
for	O
T	O
and	O
D	O
,	O
respectively	O
.	O


At	O
4	O
months	O
,	O
these	O
percentages	O
were	O
98	O
%	O
and	O
95	O
%	O
for	O
T	B-O
antitoxin	I-O
levels	I-O
in	O
groups	O
1	O
and	O
2	O
,	O
respectively	O
;	O
whereas	O
96	O
%	O
and	O
88	O
%	O
of	O
the	O
subjects	O
in	O
groups	O
1	O
and	O
2	O
had	O
D	B-O
antitoxin	I-O
levels	I-O
of	O
0.1	O
IU/mL	O
or	O
higher	O
,	O
respectively	O
.	O


Significantly	O
(	O
P	O
<	O
.05	O
)	O
higher	O
GMTs	O
were	O
seen	O
at	O
the	O
4-week	O
assessment	O
(	O
but	O
not	O
at	O
4	O
months	O
)	O
in	O
group	O
1	O
,	O
as	O
compared	O
with	O
group	O
2	O
,	O
in	O
both	O
T	O
and	O
D	O
antitoxin	O
levels	O
(	O
9.91	O
IU/mL	O
versus	O
5.60	O
IU/mL	O
for	O
T	O
antitoxin	O
,	O
and	O
2.86	O
IU/mL	O
versus	O
1.45	O
IU/mL	O
for	O
D	O
antitoxin	O
)	O
.	O


This	O
finding	O
resulted	O
from	O
those	O
participants	O
with	O
low	O
(	O
<	O
0.1	O
IU/mL	O
)	O
prevaccination	O
antibody	O
titers	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	I-P


II	O
:	O
parents	B-P
are	O
unable	O
to	O
distinguish	O
secretin	O
from	O
placebo	O
under	O
double-blind	O
conditions	O
.	O


BACKGROUND	O
Standardised	B-O
measures	I-O
of	I-O
behaviour	I-O
have	O
failed	O
to	O
detect	O
short	B-O
term	I-O
improvement	I-O
in	O
children	B-P
with	I-P
autism	I-P
following	O
treatment	O
with	O
secretin	B-I
.	I-I


However	O
,	O
it	O
is	O
possible	O
that	O
standardised	O
measures	O
are	O
insensitive	O
to	O
dimensions	O
of	O
child	O
behaviour	O
that	O
are	O
nonetheless	O
detectable	O
by	O
parents	O
.	O


AIM	O
To	O
determine	O
the	O
ability	B-O
of	I-O
parents	I-O
of	I-O
children	I-O
with	I-O
autism	I-O
to	O
guess	O
,	O
under	O
double	O
blind	O
conditions	O
,	O
whether	O
their	O
child	O
had	O
received	O
secretin	B-I
or	O
placebo	B-I
.	I-I


METHODS	O
2x2	O
crossover	O
randomised	O
blinded	O
study	O
,	O
comparing	O
the	O
effect	O
of	O
synthetic	B-I
human	I-I
secretin	I-I
2	O
U/kg	O
to	O
placebo	B-I
(	I-I
saline	I-I
)	I-I
.	I-I


Sixty	B-P
two	I-P
children	I-P
with	I-P
autism	I-P
(	I-P
aged	I-P
43-103	I-P
months	I-P
)	I-P
were	O
randomly	O
allocated	O
to	O
two	O
groups	O
:	O
group	O
1	O
received	O
placebo	B-I
,	I-I
followed	I-I
six	I-I
weeks	I-I
later	I-I
by	I-I
secretin	I-I
,	O
and	O
group	O
2	O
received	O
secretin	B-I
followed	I-I
by	I-I
placebo	I-I
.	I-I


At	O
the	O
conclusion	O
of	O
the	O
study	O
,	O
parents	B-P
were	O
asked	O
to	O
guess	O
their	O
child	O
's	O
group	O
assignment	O
.	O


RESULTS	O
Twenty	B-P
seven	I-P
families	I-P
guessed	O
their	O
child	O
's	O
group	O
assignment	O
correctly	O
and	O
27	B-P
guessed	I-P
incorrectly	I-P
.	I-P


In	O
48	O
instances	O
,	O
parents	O
based	O
their	O
guess	O
on	O
perceived	O
improvement	B-O
;	I-O
in	O
six	O
cases	O
,	O
parents	O
based	O
their	O
guess	O
on	O
perceived	O
deterioration	B-O
.	I-O


Six	B-P
families	I-P
saw	O
no	O
difference	O
after	O
either	O
infusion	O
,	O
and	O
offered	O
no	O
guess	O
.	O


One	O
family	O
dropped	O
out	O
after	O
the	O
first	O
infusion	O
,	O
and	O
one	O
family	O
was	O
lost	O
to	O
follow	O
up	O
after	O
the	O
second	O
infusion	O
.	O


CONCLUSION	O
In	O
a	O
controlled	O
setting	O
,	O
parents	B-P
of	I-P
young	I-P
children	I-P
with	I-P
autism	I-P
are	O
unable	O
to	O
distinguish	O
the	O
short	B-O
term	I-O
behavioural	I-O
effects	I-O
of	O
secretin	B-I
from	O
placebo	B-I
.	I-I


Acute	B-O
rejection	I-O
and	I-O
heart	I-O
infection	I-O
rates	I-O
in	O
FK	B-I
506-	I-I
versus	I-P
cyclosporine	I-I
A-treated	I-I
heart	I-P
transplant	I-P
recipients	I-P
:	I-P
an	O
endomyocardial	O
biopsy	O
pathologic	O
study	O
.	O


A	O
step-by-step	O
introduction	O
to	O
vegetables	B-I
at	O
the	O
beginning	O
of	O
complementary	O
feeding	O
.	O


The	O
effects	O
of	O
early	O
and	O
repeated	O
exposure	O
.	O


Breastfeeding	B-P
(	I-P
BF	I-P
)	I-P
is	O
associated	O
with	O
willingness	O
to	O
accept	O
vegetables	O
.	O


This	O
may	O
be	O
due	O
to	O
the	O
variety	O
of	O
flavours	O
delivered	O
via	O
breast	O
milk	O
.	O


Some	O
mothers	B-P
add	O
vegetables	O
to	O
milk	O
during	O
complementary	O
feeding	O
(	O
CF	O
)	O
to	O
enhance	O
acceptance	O
.	O


The	O
present	O
study	O
tested	O
a	O
step-by-step	O
exposure	O
to	O
vegetables	B-I
in	I-I
milk	I-I
then	I-I
rice	I-I
during	O
CF	O
,	O
on	O
intake	O
and	O
liking	O
of	O
vegetables	O
.	O


Just	O
before	O
CF	O
,	O
enrolled	B-P
mothers	I-P
were	I-P
randomised	I-P
to	I-P
an	I-P
intervention	I-P
(	I-P
IG	I-P
,	I-P
n	I-P
=	I-P
18	I-P
;	I-P
6	I-P
BF	I-P
)	I-P
or	I-P
control	I-P
group	I-P
(	I-P
CG	I-P
,	I-P
n	I-P
=	I-P
18	I-P
;	I-P
6	I-P
BF	I-P
)	I-P
.	I-P


IG	B-P
infants	O
received	O
12	O
daily	O
exposures	B-I
to	I-I
vegetable	I-I
puree	I-I
added	I-I
to	O
milk	O
(	O
days	O
1-12	O
)	O
,	O
then	O
12	O
×	O
2	O
daily	O
exposures	B-I
to	I-I
vegetable	I-I
puree	I-I
added	I-I
to	I-I
rice	O
at	O
home	O
(	B-I
days	I-I
13-24	I-I
)	I-I
.	I-I


Plain	B-I
milk	I-I
and	O
rice	O
were	O
given	O
to	O
CG	O
.	O


Then	O
both	O
received	O
11	O
daily	O
exposures	B-I
to	I-I
vegetable	I-I
puree	O
.	O


Intake	O
was	O
weighed	O
and	O
liking	O
rated	O
on	O
days	O
25-26	O
and	O
33-35	O
after	O
the	O
start	O
of	O
CF	O
in	O
the	O
laboratory	O
,	O
supplemented	O
by	O
the	O
same	O
data	O
recorded	O
at	O
home	O
.	O


Vegetables	O
were	O
rotated	O
daily	O
(	O
carrots	O
,	O
green	O
beans	O
,	O
spinach	B-O
,	I-O
broccoli	I-O
)	I-O
.	I-O


Intake	B-O
,	I-O
liking	I-O
and	I-O
pace	I-O
of	O
eating	O
were	O
greater	O
for	O
IG	O
than	B-O
CG	I-O
infants	I-O
.	I-O


Intake	B-O
and	I-O
liking	I-O
of	O
carrots	O
were	O
greater	O
than	O
green	O
beans	O
.	O


However	O
,	O
at	O
6m	O
then	O
18m	O
follow	O
up	O
,	O
vegetable	O
(	O
carrot	O
>	O
green	O
beans	O
)	O
but	O
not	O
group	O
differences	B-P
were	I-P
observed	I-P
.	O


Mothers	O
reported	O
appreciation	O
of	O
the	O
structure	O
and	O
guidance	O
of	O
this	O
systematic	O
approach	O
.	O


Early	B-I
exposure	I-I
to	O
vegetables	O
in	O
a	O
step-by-step	O
method	O
could	O
be	O
included	O
in	O
CF	O
guidelines	O
and	O
longer	O
term	O
benefits	O
assessed	O
by	O
extending	O
the	O
exposure	O
period	O
.	O


The	O
effect	O
of	O
a	O
parent-implemented	B-I
imitation	I-I
intervention	I-I
on	O
spontaneous	B-O
imitation	I-O
skills	I-O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


Children	B-P
with	I-P
autism	I-P
exhibit	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
spontaneously	B-O
imitate	I-O
the	O
play	B-O
actions	I-O
and	I-O
descriptive	I-O
gestures	I-O
of	O
others	O
.	O


Reciprocal	B-I
imitation	I-I
training	I-I
(	I-I
RIT	I-I
)	I-I
is	I-I
a	I-I
naturalistic	I-I
imitation	I-I
intervention	I-I
designed	O
to	O
teach	O
spontaneous	B-O
imitation	I-O
skills	I-O
during	O
play	O
.	O


This	O
study	O
assessed	O
the	O
effectiveness	B-O
of	O
parent-implemented	O
RIT	B-I
using	O
a	O
multiple-baseline	O
design	O
across	O
three	B-P
young	I-P
children	I-P
with	I-P
autism	I-P
and	I-P
their	I-P
mothers	I-P
.	I-P


After	O
an	O
initial	O
baseline	O
,	O
mothers	O
were	O
taught	O
to	O
implement	O
RIT	B-I
techniques	O
with	O
their	O
child	O
twice	O
a	O
week	O
for	O
10	O
weeks	O
in	O
a	O
clinic	O
setting	O
.	O


Two	O
mothers	O
were	O
taught	O
to	O
use	O
RIT	B-I
to	O
teach	O
object	O
imitation	O
.	O


The	O
third	O
mother	O
was	O
taught	O
to	O
use	O
RIT	B-I
to	O
target	O
both	O
object	O
and	O
gesture	O
imitation	O
in	O
a	O
multiple-baseline	O
design	O
across	O
behaviors	O
.	O


Generalization	O
was	O
assessed	O
in	O
the	O
families	O
'	O
homes	O
at	O
the	O
end	O
of	O
treatment	O
and	O
a	O
1-month	O
follow-up	O
.	O


Parents	O
learned	B-O
to	O
use	O
the	O
intervention	O
strategies	O
and	O
their	O
children	O
exhibited	O
increases	O
in	O
spontaneous	B-O
imitation	I-O
.	I-O


These	O
findings	O
replicate	O
the	O
results	O
from	O
previous	O
studies	O
,	O
indicating	O
that	O
RIT	O
is	O
effective	O
for	O
teaching	O
imitation	B-O
skills	I-O
to	O
young	B-P
children	I-P
with	I-P
autism	I-P
in	O
a	O
naturalistic	O
setting	O
and	O
extend	O
the	O
findings	O
to	O
parents	B-P
.	I-P


Effect	O
of	O
food	B-I
on	O
the	O
antiviral	B-O
activity	I-O
of	O
didanosine	B-I
enteric-coated	I-I
capsules	I-I
:	I-I
a	O
pilot	O
comparative	O
study	O
.	O


OBJECTIVES	O
To	O
determine	O
the	O
effect	O
of	O
food	B-I
on	O
the	O
antiviral	O
activity	O
of	O
enteric-coated	B-I
(	I-I
EC	I-I
)	I-I
capsules	I-I
of	I-I
didanosine	I-I
(	I-I
ddI	I-I
)	I-I
.	I-I


METHODS	O
We	O
conducted	O
a	O
pilot	O
,	O
randomized	O
,	O
open-label	O
study	O
of	O
28-day	O
ddI-EC	B-I
capsules	I-I
monotherapy-administered	I-I
in	O
a	O
fasted	B-I
state	I-I
(	I-P
group	I-P
1	I-P
,	I-P
n=11	I-P
)	I-P
or	I-P
with	I-I
food	I-I
(	I-P
group	I-P
2	I-P
,	I-P
n=10	I-P
)	I-P
to	I-P
treatment-naïve	I-P
chronically	I-P
HIV-1-infected	I-P
individuals	I-P
.	O


To	O
assess	O
the	B-O
antiviral	I-O
efficacy	I-O
,	I-O
HIV-1	I-O
RNA	I-O
was	O
determined	O
at	O
baseline	O
,	O
day	O
3	O
,	O
day	O
7	O
and	O
weekly	O
thereafter	O
.	O


The	O
area	O
under	O
the	O
HIV-1	O
RNA	O
curve	O
minus	O
baseline	O
weighted	O
by	O
time	B-O
(	I-O
AUCMB/day	I-O
)	I-O
was	O
calculated	O
.	O


RESULTS	B-O
Mean	I-O
baseline	I-O
HIV-1	I-O
RNA	I-O
was	O
4.2	O
log	O
(	O
10	O
)	O
copies/mL	O
in	O
group	O
1	O
and	O
3.8	O
log	O
(	O
10	O
)	O
copies/mL	O
in	O
group	O
2	O
.	O


After	O
28	O
days	O
,	O
the	B-O
mean	I-O
HIV-1	I-O
RNA	I-O
reduction	I-O
was	O
0.99	O
log	O
(	O
10	O
)	O
copies/mL	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.45-1.53	O
]	O
for	O
group	O
1	O
and	O
0.89	O
log	O
(	O
10	O
)	O
copies/mL	O
(	O
95	O
%	O
CI	O
0.38-1.40	O
)	O
for	O
group	O
2	O
.	B-O


AUCMB/day	B-O
values	I-O
were	O
0.775	O
log	O
(	O
10	O
)	O
copies/mL	O
(	O
95	O
%	O
CI	O
0.33-1.22	O
)	O
and	O
0.774	O
log	O
(	O
10	O
)	O
copies/mL	O
(	O
95	O
%	O
CI	O
0.48-1.07	O
)	O
,	O
respectively	O
,	O
showing	O
no	O
difference	O
in	O
the	O
rate	O
of	O
decrease	O
of	B-O
HIV-1	I-O
RNA	I-O
(	O
P=0.995	O
)	O
.	B-O


Mean	B-O
ddI	I-O
plasma	I-O
levels	I-O
at	O
day	O
28	O
were	O
0.0234	O
mg/L	O
for	O
group	O
1	O
and	O
0.0227	O
mg/L	O
for	O
group	O
2	O
(	O
P=0.96	O
)	O
.	O


CONCLUSIONS	O
In	O
this	O
pilot	O
study	O
,	O
the	O
administration	O
of	B-I
food	I-I
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
the	B-O
antiviral	I-O
activity	I-O
of	I-O
ddI-EC	I-O
capsules	I-O
.	O


Further	O
evaluation	O
of	O
docosahexaenoic	B-I
acid	I-I
in	O
patients	B-P
with	I-P
retinitis	I-P
pigmentosa	I-P
receiving	I-P
vitamin	I-I
A	I-I
treatment	I-P
:	I-P
subgroup	O
analyses	O
.	O


OBJECTIVE	O
To	O
determine	O
whether	O
docosahexaenoic	B-I
acid	I-I
will	O
slow	O
the	O
course	O
of	O
retinal	O
degeneration	O
in	O
subgroups	O
of	O
patients	B-P
with	I-P
retinitis	I-P
pigmentosa	I-P
who	I-P
are	I-P
receiving	I-P
vitamin	I-I
A	I-I
.	I-I


DESIGN	O
A	O
cohort	O
of	O
208	B-P
patients	I-P
with	I-P
retinitis	I-P
pigmentosa	I-P
,	I-P
aged	I-P
18	I-P
to	I-P
55	I-P
years	I-P
,	O
were	O
randomly	O
assigned	O
to	O
1200	O
mg	O
of	O
docosahexaenoic	B-I
acid	I-I
plus	I-I
15	I-I
000	I-I
IU/d	I-I
of	I-I
vitamin	I-I
A	I-I
given	I-I
as	I-I
retinyl	I-I
palmitate	I-I
(	I-I
DHA	I-I
+	I-I
A	I-I
group	I-I
)	I-I
or	I-I
control	I-I
fatty	I-I
acid	I-I
plus	I-I
15	I-I
000	I-I
IU/d	I-I
of	I-I
vitamin	I-I
A	I-I
(	I-I
control	I-I
+	I-I
A	I-I
group	I-I
)	I-I
and	O
followed	O
up	O
over	O
4	O
years	O
.	O


Seventy	B-P
percent	I-P
of	I-P
the	I-P
patients	I-P
in	I-P
each	I-P
group	I-P
were	I-P
taking	I-P
vitamin	I-I
A	I-I
,	I-P
15	I-P
000	I-P
IU/d	I-P
,	I-P
prior	I-P
to	I-P
entry	I-P
.	I-P


We	O
compared	O
rates	O
of	O
decline	O
in	O
ocular	O
function	O
in	O
the	O
DHA	B-I
+	I-I
A	I-I
vs	O
control	B-I
+	I-I
A	I-I
groups	O
among	O
the	O
subgroups	O
defined	O
by	O
use	O
or	O
nonuse	O
of	O
vitamin	B-I
A	I-I
prior	O
to	O
entry	O
.	O


We	O
also	O
determined	O
whether	O
decline	O
in	O
ocular	O
function	O
was	O
related	O
to	O
red	O
blood	O
cell	O
phosphatidylethanolamine	O
docosahexaenoic	O
acid	O
level	O
,	O
dietary	O
omega-3	O
fatty	O
acid	O
intake	O
,	O
or	O
duration	O
of	O
vitamin	O
A	O
use	O
.	O


Main	O
outcome	O
measures	O
were	O
Humphrey	B-O
Field	I-O
Analyzer	I-O
visual	I-O
field	I-O
sensitivity	I-O
,	I-O
30-Hz	I-O
electroretinogram	I-O
amplitude	I-O
,	I-O
and	I-O
visual	I-O
acuity	I-O
.	I-O


RESULTS	O
Among	O
patients	O
not	B-I
taking	I-I
vitamin	I-I
A	I-I
prior	O
to	O
entry	O
,	O
those	O
in	O
the	O
DHA	B-I
+	I-I
A	I-I
group	O
had	O
a	O
slower	O
decline	O
in	O
field	B-O
sensitivity	I-O
and	I-O
electroretinogram	I-O
amplitude	I-O
than	O
those	O
in	O
the	O
control	B-I
+	I-I
A	I-I
group	O
over	O
the	O
first	O
2	O
years	O
(	O
P	O
=.01	O
and	O
P	O
=.03	O
,	O
respectively	O
)	O
;	O
these	O
differences	O
were	O
not	O
observed	O
in	O
years	O
3	O
and	O
4	O
of	O
follow-up	O
or	O
among	O
patients	O
taking	O
vitamin	B-I
A	I-I
prior	O
to	O
entry	O
.	O


In	O
the	O
entire	O
cohort	O
,	O
red	O
blood	O
cell	O
phosphatidylethanolamine	O
docosahexaenoic	B-I
acid	I-I
level	O
was	O
inversely	O
related	O
to	O
rate	O
of	O
decline	O
in	O
total	B-O
field	I-O
sensitivity	I-O
over	O
4	O
years	O
(	O
test	O
for	O
trend	O
,	O
P	O
=.05	O
)	O
.	O


This	O
was	O
particularly	O
evident	O
over	O
the	O
first	O
2	O
years	O
among	O
those	O
not	B-I
on	I-I
vitamin	I-I
A	I-I
prior	O
to	O
entry	O
(	O
test	O
for	O
trend	O
,	O
P	O
=.003	O
)	O
.	O


In	O
the	O
entire	O
control	B-I
+	I-I
A	I-I
group	O
,	O
dietary	B-I
omega-3	I-I
fatty	I-I
acid	I-I
intake	O
was	O
inversely	O
related	O
to	O
loss	O
of	O
total	B-O
field	I-O
sensitivity	I-O
over	O
4	O
years	O
(	O
intake	O
,	O
<	O
0.20	O
vs	O
>	O
or	O
=0.20	O
g/d	O
;	O
P	O
=.02	O
)	O
.	O


The	O
duration	B-O
of	I-O
vitamin	I-O
A	I-O
supplementation	I-O
prior	O
to	O
entry	O
was	O
inversely	O
related	O
to	O
rate	O
of	O
decline	O
in	O
electroretinogram	O
amplitude	O
(	O
P	O
=.008	O
)	O
.	O


CONCLUSIONS	O
For	O
patients	B-P
with	I-P
retinitis	I-P
pigmentosa	I-P
beginning	O
vitamin	B-I
A	I-I
therapy	I-I
,	O
addition	O
of	O
docosahexaenoic	B-I
acid	I-I
,	O
1200	O
mg/d	O
,	O
slowed	O
the	O
course	O
of	O
disease	O
for	O
2	O
years	O
.	O


Among	O
patients	B-P
on	I-P
vitamin	I-I
A	I-I
for	I-P
at	I-P
least	I-P
2	I-P
years	I-P
,	O
a	O
diet	O
rich	O
in	O
omega-3	B-I
fatty	I-I
acids	I-I
(	O
>	O
or	O
=0.20	O
g/d	O
)	O
slowed	O
the	O
decline	O
in	O
visual	O
field	O
sensitivity	O
.	O


Chronology	O
of	O
panic	O
and	O
avoidance	O
,	O
age	B-P
of	I-P
onset	I-P
in	I-P
panic	I-P
disorder	I-P
,	O
and	O
prediction	O
of	O
treatment	O
response	O
.	O


A	O
report	O
from	O
the	O
Cross-National	O
Collaborative	O
Panic	O
Study	O
.	O


The	O
relevance	O
of	O
the	O
chronology	O
between	O
panic	O
disorder	O
and	O
avoidance	O
behavior	O
and	O
of	O
an	O
early	O
,	O
medium	O
or	O
late	O
onset	O
of	O
panic	O
disorder	O
was	O
tested	O
.	O


Groups	B-P
from	O
the	B-P
sample	I-P
of	I-P
the	I-P
cross-national	I-I
collaborative	I-I
panic	I-I
study	I-I
(	I-P
CNCPS	I-P
)	I-P
were	O
compared	O
for	O
differences	O
in	O
basic	O
characteristics	O
and	O
for	O
the	O
ability	O
to	O
predict	O
treatment	O
response	O
.	O


Patients	B-P
who	I-P
developed	I-P
avoidance	I-O
behavior	I-O
before	I-P
the	I-P
full	I-P
syndrome	I-P
of	I-P
panic	I-O
disorder	I-O
had	O
less	O
often	O
a	O
full	O
agoraphobia	B-O
but	O
were	O
not	O
different	O
in	O
their	O
response	O
to	O
treatment	B-I
.	I-I


Patients	B-P
with	O
an	O
early	B-O
onset	I-O
of	I-O
panic	I-O
disorder	I-O
suffered	O
more	O
often	O
from	O
agoraphobia	B-O
.	I-O


The	O
treatment	B-O
response	I-O
was	O
similar	B-O
in	O
the	O
groups	O
with	O
early	B-O
,	I-O
medium	I-O
or	I-O
late	I-O
onset	I-O
of	I-O
panic	I-O
disorder	I-O
.	I-O


Neither	O
the	O
chronology	O
between	O
panic	B-O
disorder	I-O
and	I-O
avoidance	I-O
behavior	I-O
nor	O
the	O
age	B-O
of	I-O
onset	I-O
of	I-O
panic	I-O
disorder	I-O
predicted	O
outcome	O
in	O
short-term	B-I
treatment	I-I
with	I-I
alprazolam	I-I
or	I-I
imipramine	I-I
.	I-I


Pathological	B-O
response	I-O
and	I-O
safety	I-O
of	O
two	O
neoadjuvant	O
strategies	O
with	O
bevacizumab	B-I
in	O
MRI-defined	B-P
locally	I-P
advanced	I-P
T3	I-P
resectable	I-P
rectal	I-P
cancer	I-P
:	I-P
a	O
randomized	O
,	O
noncomparative	O
phase	O
II	O
study	O
.	O


BACKGROUND	O
In	O
T3	O
rectal	O
cancer	O
(	O
RC	O
)	O
,	O
preoperative	O
chemoradiotherapy	B-I
[	I-I
5-fluorouracil	I-I
(	I-I
5-FU-RT	I-I
)	I-I
]	I-I
reduces	O
local	B-O
recurrences	I-O
,	O
but	O
does	O
not	O
affect	O
overall	B-O
survival	I-O
.	I-O


New	O
therapeutic	O
options	O
are	O
still	O
necessary	O
to	O
improve	O
clinical	B-O
outcomes	I-O
.	I-O


PATIENTS	O
AND	O
METHODS	O
This	O
randomized	O
,	O
noncomparative	O
,	O
open-label	O
,	O
multicenter	O
,	O
two	O
arms	O
,	O
phase	O
II	O
study	O
was	O
conducted	O
in	O
MRI-defined	B-P
locally	I-P
advanced	I-P
T3	I-P
resectable	I-P
RC	I-P
.	I-P


In	O
arm	O
A	O
,	O
patients	O
received	O
12-week	O
bevacizumab	B-I
plus	I-I
5-FU	I-I
,	I-I
leucovorin	I-I
and	I-I
oxaliplatin	I-I
(	I-I
Folfox-4	I-I
)	I-I
followed	I-I
with	I-I
bevacizumab-5-FU-RT	I-I
before	I-I
total	I-I
mesorectal	I-I
excision	I-I
(	I-I
TME	I-I
)	I-I
.	I-I


In	O
arm	O
B	O
,	O
patients	O
received	O
only	O
bevacizumab-5-FU-RT	B-I
before	I-I
TME	I-I
.	I-I


Primary	B-O
end	I-O
point	I-O
was	O
pathological	B-O
complete	I-O
response	I-O
(	I-O
pCR	I-O
)	I-O
rate	I-O
.	I-O


RESULTS	O
Forty-six	B-P
patients	I-P
were	I-P
randomized	I-P
in	I-P
arm	I-P
A	I-P
and	I-P
45	I-P
patients	I-P
in	I-P
arm	I-P
B	I-P
.	I-P


In	O
arm	O
A	O
,	O
the	O
rate	B-O
of	I-O
pCR	I-O
was	O
23.8	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
12.1	O
%	O
to	O
39.5	O
%	O
]	O
statistically	O
superior	O
to	O
the	O
defined	O
standard	O
rate	O
of	O
10	O
%	O
,	O
P	O
=	O
0.015	O
.	O


In	O
arm	O
B	O
,	O
the	O
rate	B-O
of	I-O
pCR	I-O
of	O
11.4	O
%	O
(	O
95	O
%	O
CI	O
3.8	O
%	O
to	O
24.6	O
%	O
)	O
was	O
not	O
different	O
from	O
10	O
%	O
,	O
P	O
=	O
0.906	O
.	O


No	O
death	B-O
occurred	O
during	O
the	O
study	O
period	O
,	O
from	O
the	O
start	O
until	O
8	O
weeks	O
following	O
surgery	O
.	O


Postoperative	B-O
fistulas	I-O
were	O
reported	O
for	O
16	O
patients	O
(	O
7	O
in	O
arm	O
A	O
and	O
9	O
in	O
arm	O
B	O
)	O
.	O


CONCLUSION	O
Even	O
if	O
the	O
addition	O
of	O
bevacizumab	O
induced	O
manageable	O
toxicities	B-O
including	O
an	O
increased	B-O
risk	I-O
of	O
postoperative	O
fistula	O
and	O
no	O
treatment-related	B-O
death	I-O
,	O
arm	O
B	O
did	O
not	O
achieve	O
the	O
expected	O
pCR	B-O
rate	I-O
in	O
the	O
population	O
of	O
patients	O
included	O
.	O


Induction	O
bevacizumab-Folfox-4	B-I
followed	O
by	O
bevacizumab-5-FU-RT	B-I
is	O
promising	O
.	O


It	O
is	O
however	O
necessary	O
to	O
continue	O
investigations	O
in	O
the	O
management	O
of	O
locally	O
advanced	O
RC	O
.	O


CLINICAL	O
TRIALSGOV	O
IDENTIFIER	O
NCT	O
00865189	O
.	O


Gefitinib	B-I
or	I-I
placebo	I-I
in	O
combination	O
with	O
tamoxifen	O
in	O
patients	B-P
with	I-P
hormone	I-O
receptor-positive	I-O
metastatic	I-O
breast	I-O
cancer	I-O
:	I-O
a	O
randomized	O
phase	O
II	O
study	O
.	O


PURPOSE	O
Increased	O
growth	O
factor	O
signaling	O
may	O
contribute	O
to	O
tamoxifen	O
resistance	O
.	O


This	O
randomized	O
phase	O
II	O
trial	O
assessed	O
tamoxifen	B-I
plus	I-I
placebo	I-I
or	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitor	O
gefitinib	O
in	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-positive	O
metastatic	O
breast	O
cancer	O
.	O


EXPERIMENTAL	O
DESIGN	O
Patients	B-P
with	I-P
newly	I-P
metastatic	I-P
disease	I-P
or	I-P
recurred	I-P
after	I-P
adjuvant	I-P
tamoxifen	I-I
(	I-P
stratum	I-P
1	I-P
)	I-P
,	I-P
or	I-P
recurred	I-P
during/after	I-P
adjuvant	I-P
aromatase	I-P
inhibitor	I-P
(	I-P
AI	I-P
)	I-P
or	I-P
after	I-P
failed	I-P
first-line	I-P
AI	I-P
(	I-P
stratum	I-P
2	I-P
)	I-P
,	I-P
were	I-P
eligible	I-P
.	I-P


Primary	O
variables	O
were	O
progression-free	B-O
survival	I-O
(	O
PFS	O
;	O
stratum	O
1	O
)	O
and	O
clinical	B-O
benefit	I-O
rate	I-O
(	O
CBR	O
;	O
stratum	O
2	O
)	O
.	O


A	O
5	O
%	O
or	O
more	O
improvement	O
in	O
response	O
variables	O
with	O
gefitinib	B-I
was	O
considered	O
to	O
warrant	O
further	O
investigation	O
.	O


Outcome	O
was	O
correlated	O
with	O
biomarkers	O
measured	O
on	O
the	O
primary	O
tumor	O
.	O


RESULTS	O
In	O
stratum	O
1	O
(	O
n	O
=	O
206	O
)	O
,	O
the	O
PFS	B-O
HR	I-O
(	I-I
gefitinib	I-I
:	I-I
placebo	I-I
)	I-I
was	O
0.84	O
(	O
95	O
%	O
CI	O
,	O
0.59-1.18	O
;	O
median	B-O
PFS	I-O
10.9	O
versus	O
8.8	O
months	O
)	O
.	O


In	O
the	O
stratum	O
1	O
endocrine	O
therapy-naïve	O
subset	O
(	O
n	O
=	O
158	O
)	O
the	B-O
HR	I-O
was	O
0.78	O
(	O
95	O
%	O
CI	O
,	O
0.52-1.15	O
)	O
,	O
and	O
the	O
prior	O
endocrine-treated	O
subgroup	O
(	O
n	O
=	O
48	O
)	O
1.47	O
(	O
95	O
%	O
CI	O
,	O
0.63-3.45	O
)	O
.	O


In	O
stratum	O
1	O
,	O
CBRs	B-O
were	O
50.5	O
%	O
with	B-I
gefitinib	I-I
and	O
45.5	O
%	O
with	B-I
placebo	I-I
.	O


In	O
stratum	O
2	O
(	O
n	O
=	O
84	O
)	O
,	O
CBRs	B-O
were	O
29.2	O
%	O
with	B-I
gefitinib	I-I
and	O
31.4	O
%	O
with	B-I
placebo	I-I
.	O


Biomarker	O
analysis	O
suggested	O
that	O
in	O
stratum	O
1	O
there	O
was	O
greater	O
benefit	O
with	O
gefitinib	O
in	O
patients	O
who	O
were	O
ER-negative	O
or	O
had	O
lower	O
levels	O
of	O
ER	O
protein	O
.	O


CONCLUSIONS	O
In	O
stratum	O
1	O
,	O
the	O
improved	O
PFS	O
with	B-I
gefitinib	I-I
plus	I-I
tamoxifen	I-I
met	O
the	O
protocol	O
criteria	O
to	O
warrant	O
further	O
investigation	O
of	O
this	O
strategy	O
.	O


In	O
stratum	O
2	O
,	O
there	O
was	O
a	O
numerical	O
disadvantage	O
for	B-I
gefitinib	I-I
;	I-I
additional	O
investigation	O
after	O
AI	O
therapy	O
is	O
not	O
warranted	O
.	O


Studies	O
of	O
predictive	O
biomarkers	O
are	O
needed	O
to	O
subset	B-P
appropriate	I-P
patients	I-P
.	O


Analysis	B-O
of	I-O
treatment	I-O
in	O
childhood	B-P
leukaemia	I-P
.	I-P


I.	O
Predisposition	O
to	O
methotrexate-induced	O
neutropenia	O
after	B-P
craniospinal	I-P
irradiation	I-P
.	I-P


Report	O
to	O
the	O
Medical	O
Research	O
Council	O
of	O
the	O
Working	O
Party	O
on	O
Leukaemia	B-P
in	I-P
Childhood	I-P
.	I-P


The	O
degree	O
of	O
drug-induced	O
neutropenia	B-O
resulting	O
from	O
a	O
controlled	O
trial	O
(	O
UKALL	O
I	O
)	O
of	O
treatment	O
in	O
acute	B-P
lymphoblastic	I-P
leukaemia	I-P
was	O
analysed	O
.	O


The	O
main	O
agent	O
associated	O
with	O
severe	B-O
neutropenia	I-O
was	O
methotrexate	B-I
,	O
and	O
methotrexate-induced	B-O
neutropenia	I-O
was	O
significantly	O
greater	O
in	O
patients	B-P
who	I-P
had	I-P
received	I-P
craniospinal	I-P
irradiation	I-P
.	I-P


The	O
synergistic	B-O
toxic	I-O
effect	I-O
of	I-O
irradiation	I-O
followed	O
by	O
methotrexate	O
treatment	O
seems	O
to	O
have	O
contributed	O
to	O
three	O
of	O
the	O
five	O
deaths	B-O
which	O
occurred	O
in	O
complete	O
remission	B-O
in	O
this	O
trial	O
;	O
all	O
deaths	O
in	O
remission	O
occurred	O
in	O
patients	O
who	O
had	O
received	O
central	O
nervous	O
system	O
prophylaxis	O
.	O


Analysis	O
of	O
patients	O
who	O
subsequently	O
relapsed	O
compared	O
with	O
those	O
still	O
in	O
remission	O
after	O
18	O
months	O
of	O
treatment	O
indicated	O
that	O
the	O
former	O
,	O
on	O
average	O
,	O
had	O
slightly	O
lower	O
neutrophil	B-O
counts	I-O
.	I-O


This	O
suggests	O
that	O
the	O
children	B-P
who	O
relapsed	O
did	O
not	O
receive	O
any	O
less	O
aggressive	O
treatment	O
than	O
those	O
who	O
remained	O
in	O
remission	O
.	O


Enalapril	B-I
(	O
10	O
mg/day	O
)	O
in	O
systemic	O
sclerosis	O
.	O


One	O
year	O
,	O
double	O
blind	O
,	O
randomised	O
study	O
(	O
ESS-1	O
)	O
:	O
echocardiographic	O
substudy	O
--	O
three	O
months	O
follow-up	O
.	O


The	O
ESS-1	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
long-term	O
effects	O
of	O
the	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
(	O
ACEI	O
)	O
enalapril	B-I
(	O
10	O
mg	O
per	O
day	O
)	O
on	O
the	O
cardio-pulmonary	O
system	O
in	O
patients	B-P
with	I-P
scleroderma	I-P
(	I-P
SSc	I-P
)	I-P
.	I-P


We	O
estimated	O
changes	O
in	O
heart	B-O
diameters	I-O
,	I-O
systolic	I-O
and	I-O
diastolic	I-O
left	I-O
ventricle	I-O
function	I-O
and	I-O
mean	I-O
values	I-O
of	I-O
pulmonary	I-O
artery	I-O
pressure	I-O
after	O
3	O
months	O
treatment	O
.	O


The	O
study	O
group	O
comprise	O
41	B-P
patients	I-P
with	I-P
SSc	I-P
.	I-P


18	O
patients	O
received	O
placebo	B-I
and	O
23	O
ones	O
were	O
given	O
enalapril	B-I
.	I-I


After	O
3	O
months	O
of	O
treatment	O
we	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	O
in	O
heart	B-O
diameters	I-O
and	I-O
left	I-O
ventricle	I-O
systolic	I-O
function	I-O
parameters	I-O
between	O
treated	O
group	O
and	O
placebo	O
.	O


Enalapril	B-I
therapy	O
did	O
not	O
affect	O
left	B-O
ventricle	I-O
diastolic	I-O
function	I-O
,	O
nevertheless	O
differences	O
in	O
MVA	B-O
were	O
almost	O
of	O
statistical	O
significance	O
.	O


Echocardiographic	O
signs	B-O
of	O
pulmonary	B-O
hypertension	I-O
were	O
found	O
in	O
4	O
patients	O
.	O


Cognitive	B-O
and	I-O
physical	I-O
rehabilitation	I-O
of	O
intensive	B-P
care	I-P
unit	I-P
survivors	I-P
:	I-P
results	O
of	O
the	O
RETURN	O
randomized	O
controlled	O
pilot	O
investigation	O
.	O


BACKGROUND	O
Millions	O
of	O
patients	B-P
who	I-P
survive	I-P
medical	I-P
and	I-P
surgical	I-P
general	I-P
intensive	I-P
care	I-P
unit	I-P
care	I-P
every	O
year	O
experience	O
newly	O
acquired	O
long-term	O
cognitive	O
impairment	O
and	O
profound	O
physical	O
and	O
functional	O
disabilities	O
.	O


To	O
overcome	O
the	O
current	O
reality	O
in	O
which	O
patients	O
receive	O
inadequate	O
rehabilitation	O
,	O
we	O
devised	O
a	O
multifaceted	O
,	O
in-home	O
,	O
telerehabilitation	O
program	O
implemented	O
using	O
social	O
workers	O
and	O
psychology	O
technicians	O
with	O
the	O
goal	O
of	O
improving	O
cognitive	O
and	O
functional	O
outcomes	O
.	O


METHODS	O
This	O
was	O
a	O
single-site	O
,	O
feasibility	O
,	O
pilot	O
,	O
randomized	O
trial	O
of	O
21	B-P
general	I-P
medical/surgical	I-P
intensive	I-P
care	I-P
unit	I-P
survivors	I-P
(	I-P
8	I-P
controls	I-P
and	I-P
13	I-P
intervention	I-P
patients	I-P
)	I-P
with	I-P
either	I-P
cognitive	I-P
or	I-P
functional	I-P
impairment	I-P
at	I-P
hospital	I-P
discharge	I-P
.	I-P


After	O
discharge	O
,	O
study	O
controls	O
received	O
usual	B-I
care	I-I
(	I-I
sporadic	I-I
rehabilitation	I-I
)	I-I
,	O
whereas	O
intervention	O
patients	O
received	O
a	O
combination	O
of	O
in-home	B-I
cognitive	I-I
,	I-I
physical	I-I
,	I-I
and	I-I
functional	I-I
rehabilitation	I-I
over	O
a	O
3-month	O
period	O
via	O
a	O
social	O
worker	O
or	O
master	O
's	O
level	O
psychology	O
technician	O
utilizing	O
telemedicine	O
to	O
allow	O
specialized	O
multidisciplinary	O
treatment	O
.	O


Interventions	O
over	O
12	O
wks	O
included	O
six	O
in-person	O
visits	O
for	O
cognitive	B-I
rehabilitation	I-I
and	O
six	O
televisits	O
for	O
physical/functional	B-I
rehabilitation	I-I
.	I-I


Outcomes	O
were	O
measured	O
at	O
the	O
completion	O
of	O
the	O
rehabilitation	O
program	O
(	O
i.e.	O
,	O
at	O
3	O
months	O
)	O
,	O
with	O
cognitive	B-O
functioning	I-O
as	O
the	O
primary	O
outcome	O
.	O


Analyses	O
were	O
conducted	O
using	O
linear	O
regression	O
to	O
examine	O
differences	O
in	O
3-month	O
outcomes	O
between	O
treatment	O
groups	O
while	O
adjusting	O
for	O
baseline	O
scores	O
.	O


RESULTS	O
Patients	B-P
tolerated	I-O
the	I-P
program	I-P
with	I-P
only	I-P
one	I-P
adverse	I-P
event	I-P
reported	I-P
.	I-P


At	O
baseline	O
both	O
groups	O
were	O
well-matched	O
.	O


At	O
3-month	O
follow-up	O
,	O
intervention	O
group	O
patients	O
demonstrated	O
significantly	O
improved	B-O
cognitive	I-O
executive	I-O
functioning	I-O
on	O
the	O
widely	O
used	O
and	O
well-normed	O
Tower	O
test	O
(	O
for	O
planning	B-O
and	I-O
strategic	I-O
thinking	I-O
)	I-O
vs.	O
controls	O
(	O
median	O
[	O
interquartile	O
range	O
]	O
,	O
13.0	O
[	O
11.5-14.0	O
]	O
vs.	O
7.5	O
[	O
4.0-8.5	O
]	O
;	O
adjusted	O
p	O
<	O
.01	O
)	O
.	O


Intervention	O
group	O
patients	O
also	O
reported	O
better	O
performance	B-O
(	O
i.e.	O
,	O
lower	O
score	O
)	O
on	O
one	O
of	O
the	O
most	O
frequently	O
used	O
measures	O
of	O
functional	O
status	O
(	B-O
Functional	I-O
Activities	I-O
Questionnaire	I-O
at	O
3	O
months	O
vs.	O
controls	O
,	O
1.0	O
[	O
0.0	O
-3.0	O
]	O
vs.	O
8.0	O
[	O
6.0-11.8	O
]	O
,	O
adjusted	O
p	O
=	O
.04	O
)	O
.	O


CONCLUSIONS	O
A	O
multicomponent	O
rehabilitation	B-I
program	O
for	O
intensive	B-P
care	I-P
unit	I-P
survivors	I-P
combining	O
cognitive	O
,	O
physical	O
,	O
and	O
functional	O
training	O
appears	O
feasible	B-O
and	I-O
possibly	I-O
effective	I-O
in	I-O
improving	I-O
cognitive	I-O
performance	I-O
and	I-O
functional	I-O
outcomes	I-O
in	O
just	O
3	O
months	O
.	O


Future	O
investigations	O
with	O
a	O
larger	O
sample	O
size	O
should	O
be	O
conducted	O
to	O
build	O
on	O
this	O
pilot	O
feasibility	O
program	O
and	O
to	O
confirm	O
these	O
results	O
,	O
as	O
well	O
as	O
to	O
elucidate	O
the	O
elements	O
of	O
rehabilitation	O
contributing	O
most	O
to	O
improved	O
outcomes	O
.	O


Hepatic	O
cytoprotective	O
effect	O
of	O
ischemic	B-I
and	I-I
anesthetic	I-I
preconditioning	I-I
before	O
liver	O
resection	O
when	O
using	O
intermittent	O
vascular	O
inflow	O
occlusion	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
Ischemic	B-I
preconditioning	I-I
(	I-I
IPC	I-I
)	I-I
and	O
anesthetic	B-I
preconditioning	I-I
(	I-I
APC	I-I
)	I-I
have	O
been	O
reported	O
to	O
attenuate	O
ischemia-reperfusion	O
(	O
IR	O
)	O
injury	O
after	O
liver	O
resection	O
under	O
continuous	O
inflow	O
occlusion	O
.	O


This	O
study	O
evaluates	O
whether	O
these	O
strategies	O
enhance	O
hepatic	O
protection	O
of	O
remnant	O
liver	O
against	O
IR	O
after	O
liver	B-P
resection	I-P
with	I-P
intermittent	I-I
clamping	I-I
(	I-I
INT	I-I
)	I-I
.	I-I


METHODS	O
A	B-P
total	I-P
of	I-P
106	I-P
patients	I-P
without	I-P
underlying	I-P
liver	I-P
disease	I-P
and	I-P
submitted	I-P
to	I-P
liver	I-P
resection	I-P
using	I-P
INT	I-P
were	O
randomized	O
into	O
3	O
groups	O
:	O
IPC	B-I
(	I-I
10	I-I
minutes	I-I
of	I-I
inflow	I-I
occlusion	I-I
followed	I-I
by	I-I
10	I-I
minutes	I-I
of	I-I
reperfusion	I-I
before	I-I
liver	I-I
transection	I-I
)	I-I
,	I-I
APC	I-I
(	I-I
sevoflurane	I-I
administration	I-I
for	I-I
20	I-I
minutes	I-I
before	I-I
liver	I-I
transection	I-I
)	I-I
,	I-I
and	I-I
INT	I-I
(	I-I
no	I-I
preconditioning	I-I
)	I-I
.	I-I


Patients	O
were	O
also	O
stratified	O
according	O
to	O
the	O
extent	O
of	O
the	O
hepatectomy	O
.	O


Cytoprotection	B-O
was	O
evaluated	O
by	O
comparing	B-O
hepatocyte	I-O
and	I-O
endothelial	I-O
dysfunction	I-O
markers	I-O
,	I-O
apoptosis	I-O
,	I-O
histologic	I-O
lesions	I-O
,	I-O
and	I-O
postoperative	I-O
outcome	I-O
.	I-O


RESULTS	O
No	O
differences	O
were	O
observed	O
in	O
preoperative	B-O
chemotherapy	I-O
and	I-O
steatosis	I-O
,	I-O
total	I-O
warm	I-O
ischemia	I-O
time	I-O
,	I-O
operative	I-O
time	I-O
,	I-O
or	I-O
blood	I-O
loss	I-O
.	I-O


Kinetics	B-O
of	I-O
transaminases	I-O
(	O
aspartate	O
aminotransferase	O
,	O
P	O
=	O
.137	O
;	O
alanine	O
aminotransferase	O
,	O
P	O
=	O
.616	O
)	O
,	O
bilirubin	B-O
(	O
P	O
=	O
.980	O
)	O
,	O
and	O
hyaluronic	B-O
acid	I-O
increase	O
(	O
P	O
=	O
.514	O
)	O
revealed	O
no	O
differences	O
.	O


Significant	B-O
apoptosis	I-O
was	O
present	O
in	O
40	O
%	O
of	O
patients	O
,	O
mild-to-moderate	B-O
leukocyte	I-O
infiltration	I-O
and	I-O
steatosis	I-O
in	O
45	O
%	O
and	O
55	O
%	O
,	O
respectively	O
,	O
and	O
mild	B-O
sinusoidal	I-O
congestion	I-O
in	O
65	O
%	O
,	O
with	O
a	O
similar	O
distribution	O
in	O
the	O
3	O
groups	O
.	O


When	O
patients	O
were	O
stratified	O
by	O
major	O
versus	O
minor	O
resections	O
,	O
no	O
differences	O
were	O
observed	O
in	O
any	O
of	O
the	O
variables	O
studied	O
.	O


Postoperative	O
clinical	O
outcomes	O
were	O
also	O
similar	O
.	O


CONCLUSION	O
These	O
results	O
suggest	O
that	O
these	O
protocols	B-I
of	I-I
IPC	I-I
and	I-I
APC	I-I
used	O
in	O
this	O
study	O
do	O
not	O
provide	O
better	O
cytoprotection	O
from	O
IR	O
when	O
INT	B-I
is	O
used	O
.	O


Exploring	O
the	O
social	B-O
impact	I-O
of	O
being	O
a	O
typical	B-I
peer	I-I
model	I-I
for	O
included	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


This	O
study	O
examined	O
the	O
social	B-O
impact	I-O
of	O
being	O
a	O
typical	O
peer	O
model	O
as	O
part	O
of	O
a	O
social	B-I
skills	I-I
intervention	I-I
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


Participants	O
were	O
drawn	O
from	O
a	O
randomized-controlled-treatment	O
trial	O
that	O
examined	O
the	O
effects	O
of	O
targeted	O
interventions	B-I
on	O
the	O
social	B-O
networks	I-O
of	O
60	B-P
elementary-aged	I-P
children	I-P
with	I-P
ASD	I-P
.	I-P


Results	O
demonstrated	O
that	O
typical	O
peer	O
models	O
had	O
higher	B-O
social	I-O
network	I-O
centrality	I-O
,	I-O
received	I-O
friendships	I-O
,	I-O
friendship	I-O
quality	I-O
,	I-O
and	I-O
less	I-O
loneliness	I-O
than	O
non-peer	O
models	O
.	O


Peer	B-I
models	I-I
were	O
also	O
more	B-O
likely	I-O
to	O
be	O
connected	O
with	O
children	O
with	O
ASD	O
than	O
non-peer	O
models	O
at	O
baseline	O
and	O
exit	O
.	O


These	O
results	O
suggest	O
that	O
typical	O
peers	O
can	O
be	O
socially	O
connected	O
to	O
children	O
with	O
ASD	O
,	O
as	O
well	O
as	O
other	O
classmates	O
,	O
and	O
maintain	O
a	O
strong	B-O
and	I-O
positive	I-O
role	I-O
within	O
the	O
classroom	O
.	O


Interactive	O
effects	O
of	O
indomethacin	B-I
,	I-I
angiotensin	I-I
II	I-I
and	I-I
frusemide	I-I
on	O
renal	B-P
haemodynamics	I-P
and	I-P
natriuresis	I-P
in	I-P
man	I-P
.	I-P


The	O
responses	O
of	O
renal	O
haemodynamic	O
and	O
natriuretic	O
indices	O
to	O
the	O
oral	O
prostaglandin	O
synthetase	O
inhibitor	O
indomethacin	B-I
(	I-I
200	I-I
mg	I-I
)	I-I
,	I-I
to	I-I
infused	I-I
angiotensin	I-I
II	I-I
(	O
1	O
ng	O
min-1	O
kg-1	O
)	O
and	O
to	O
the	O
combination	O
of	O
the	O
two	O
were	O
studies	O
in	O
placebo-controlled	B-I
fashion	O
in	O
eight	B-P
normal	I-P
male	I-P
subjects	I-P
both	I-P
prior	I-P
to	I-P
and	I-P
following	I-P
administration	I-P
of	I-P
intravenous	I-I
frusemide	I-I
(	I-P
20	I-P
mg	I-P
)	I-P
.	I-P


As	O
compared	O
with	O
placebo	B-I
,	I-I
angiotensin	I-I
II	I-I
infusion	I-I
alone	O
caused	O
significant	O
reductions	O
in	O
absolute	B-O
rate	I-O
of	I-O
sodium	I-O
excretion	I-O
,	I-O
fractional	I-O
sodium	I-O
excretion	I-O
,	I-O
urine	I-O
flow	I-O
rate	I-O
and	I-O
effective	I-O
renal	I-O
plasma	I-O
flow	I-O
(	O
all	O
P	O
<	O
0.001	O
vs	O
placebo	O
)	O
but	O
had	O
no	O
effect	O
on	O
glomerular	B-O
filtration	I-O
rate	I-O
.	I-O


The	O
only	O
change	O
observed	O
in	O
these	O
parameters	O
with	O
indomethacin	B-I
alone	O
was	O
a	O
small	O
but	O
significant	O
reduction	O
in	O
urine	B-O
flow	I-O
rate	I-O
(	O
P	O
<	O
0.005	O
vs	O
placebo	O
)	O
.	O


As	O
compared	O
with	O
the	O
effects	O
of	O
angiotensin	O
II	O
alone	O
,	O
indomethacin	B-I
pre-treatment	O
followed	O
by	O
angiotensin	B-I
II	I-I
infusion	I-I
led	O
to	O
much	O
greater	O
falls	B-O
in	O
absolute	B-O
rate	I-O
of	I-O
sodium	I-O
excretion	I-O
,	I-O
fractional	I-O
sodium	I-O
excretion	I-O
,	I-O
urine	I-O
flow	I-O
rate	I-O
and	I-O
effective	I-O
renal	I-O
plasma	I-O
flow	I-O
(	O
all	O
P	O
<	O
0.0001	O
vs	O
placebo	B-I
)	I-I
associated	O
with	O
a	O
significant	O
reduction	O
in	O
glomerular	B-O
filtration	I-O
rate	I-O
(	O
P	O
<	O
0.0001	O
)	O
not	O
observed	O
with	O
angiotensin	O
II	O
alone	O
.	O


Frusemide	B-I
administration	O
at	O
the	O
midpoint	O
of	O
each	O
study	O
limb	O
resulted	O
in	O
each	O
case	O
in	O
a	O
prompt	O
15	O
to	O
20	O
fold	O
increase	O
in	O
natriuresis	B-O
.	I-O


The	O
renal	B-O
haemodynamic	I-O
and	I-O
natriuretic	I-O
effects	I-O
of	O
angiotensin	O
II	O
,	O
indomethacin	O
and	O
their	O
combination	O
were	O
not	O
qualitatively	O
different	O
from	O
those	O
observed	O
in	O
the	O
pre-frusemide	B-I
phase	O
.	O


Our	O
findings	O
provide	O
a	O
clear	O
demonstration	O
in	O
man	B-P
of	O
the	O
important	O
homeostatic	B-O
role	I-O
of	O
renal	O
prostaglandins	O
in	O
preserving	O
renal	B-O
function	I-O
,	I-O
particularly	I-O
glomerular	I-O
filtration	I-O
,	O
under	O
conditions	O
of	O
elevated	O
circulating	O
angiotensin	O
II	O
.	O


Levels	O
of	O
opioid	B-P
physical	I-P
dependence	I-P
in	I-P
heroin	I-P
addicts	I-P
.	I-P


The	O
levels	O
of	O
opioid	O
physical	O
dependence	O
in	O
a	O
group	O
of	O
long-term	B-P
heroin	I-P
addicts	I-P
were	O
ascertained	O
by	O
measuring	O
the	O
severity	O
of	O
the	O
opioid	B-O
withdrawal	I-O
syndrome	I-O
before	O
and	O
after	O
pharmacological	O
challenge	O
with	O
either	O
0.4	O
mg	O
naloxone	B-I
or	O
placebo	B-I
.	I-I


Prior	O
to	O
challenge	O
,	O
patients	O
manifested	O
some	O
subjective	B-O
symptoms	I-O
but	O
few	O
objective	O
signs	O
of	O
opioid	O
withdrawal	O
.	O


Patients	B-P
who	I-P
received	I-P
placebo	I-I
(	I-P
n	I-P
=	I-P
18	I-P
)	I-P
showed	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
score	O
on	O
one	O
of	O
three	O
rating	O
scales	O
used	O
to	O
assess	O
opioid	O
withdrawal	O
.	O


Patients	B-P
who	I-P
received	I-P
naloxone	I-I
(	I-P
n	I-P
=	I-P
58	I-P
)	I-P
showed	O
significant	O
increases	O
in	O
mean	O
scores	O
on	O
all	O
three	O
rating	O
scales	O
,	O
but	O
this	O
was	O
due	O
primarily	O
to	O
increases	O
observed	O
in	O
a	O
minority	O
of	O
patients	O
.	O


Sixty-one	O
percent	O
of	O
patients	O
failed	O
to	O
manifest	O
clinically	O
significant	O
changes	O
in	O
subjective	B-O
symptoms	I-O
,	O
and	O
74	O
%	O
of	O
patients	O
failed	O
to	O
manifest	O
clinically	O
significant	O
changes	O
in	O
objective	B-O
signs	I-O
of	I-O
opioid	I-O
withdrawal	I-O
following	O
naloxone	B-I
administration	O
.	O


The	O
results	O
suggest	O
that	O
a	O
substantial	O
subgroup	O
of	O
heroin	O
addicts	O
are	O
able	O
to	O
use	O
opioids	O
regularly	O
while	O
maintaining	O
relatively	O
low	O
levels	O
of	O
physical	O
dependence	O
.	O


A	O
comparative	O
efficacy	B-O
and	I-O
safety	I-O
study	O
of	O
clarithromycin	B-I
,	I-I
roxithromycin	I-I
and	I-I
erythromycin	I-I
stearate	I-I
in	O
mild	B-P
pneumonia	I-P
.	I-P


The	O
efficacy	B-O
and	I-O
safety	I-O
of	O
clarithromycin	B-I
,	I-I
roxithromycin	I-I
and	I-I
erythromycin	I-I
stearate	I-I
in	O
mild	O
pneumonia	O
were	O
compared	O
in	O
an	O
open	O
randomized	O
trial	O
.	O


Eighty-six	B-P
male	I-P
patients	I-P
,	I-P
doing	I-P
their	I-P
obligatory	I-P
military	I-P
service	I-P
,	I-P
ranging	I-P
between	I-P
19	I-P
and	I-P
24	I-P
years	I-P
of	I-P
age	I-P
(	I-P
mean	I-P
20	I-P
)	I-P
,	O
were	O
randomly	O
treated	O
:	O
29	O
with	O
clarithromycin	B-I
500	I-I
mg	I-I
12-hourly	I-I
,	I-I
30	I-I
with	I-I
roxithromycin	I-I
150	I-I
mg	I-I
12-hourly	I-I
,	I-I
and	I-I
27	I-I
with	I-I
erythromycin	I-I
stearate	I-I
500	O
mg	O
6-hourly	O
,	O
each	O
course	O
being	O
administered	O
for	O
10	O
days	O
.	O


Seventy-eight	B-P
patients	I-P
were	I-P
able	I-P
to	I-P
be	I-P
evaluated	I-P
for	I-P
efficacy	I-O
,	O
28	O
receiving	O
clarithromycin	B-I
,	O
28	O
roxithromycin	B-I
,	O
and	O
22	O
erythromycin	B-I
stearate	I-I
.	I-I


There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
groups	O
in	O
terms	B-O
of	I-O
clinical	I-O
success	I-O
rates	I-O
(	O
clinical	O
cure	O
or	O
improvement	O
:	O
89	O
%	O
for	O
clarithromycin	B-I
,	O
82	O
%	O
for	O
roxithromycin	B-I
,	O
and	O
73	O
%	O
for	O
erythromycin	B-I
stearate	I-I
,	O
p	O
=	O
0.32	O
)	O
.	O


However	O
,	O
we	O
found	O
that	O
there	O
were	O
significant	O
differences	O
among	O
the	O
groups	O
in	O
terms	O
of	O
clinical	B-O
cure	I-O
rates	I-O
(	O
75	O
%	O
for	O
clarithromycin	B-I
,	O
64	O
%	O
for	O
roxithromycin	B-I
,	O
and	O
41	O
%	O
for	O
erythromycin	B-I
stearate	I-I
,	O
p	O
=	O
0.04	O
)	O
.	O


Adverse	B-O
events	I-O
,	I-O
mostly	I-O
gastrointestinal	I-O
,	O
caused	O
discontinuation	O
of	O
treatment	O
in	O
3.4	O
%	O
of	O
the	O
patients	O
in	O
the	O
clarithromycin	B-I
group	O
,	O
in	O
6.6	O
%	O
of	O
the	O
patients	O
in	O
the	O
roxithromycin	B-I
group	O
,	O
and	O
in	O
18.5	O
%	O
of	O
the	O
patients	O
in	O
the	O
erythromycin	B-I
stearate	I-I
group	O
.	O


The	O
results	O
indicate	O
that	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
among	O
the	O
three	O
treatment	O
groups	O
in	O
terms	O
of	O
clinical	O
success	O
rates	O
,	O
but	O
that	O
clarithromycin	B-I
and	O
roxithromycin	B-I
were	O
better	O
tolerated	B-O
.	I-O


Impact	O
of	O
triiodothyronine	B-I
on	O
the	O
survival	B-O
of	I-O
high-risk	I-O
patients	I-O
undergoing	I-P
open	I-I
heart	I-I
surgery	I-I
.	I-I


Experimental	O
and	O
clinical	O
studies	O
have	O
shown	O
the	O
beneficial	B-O
effects	I-O
of	O
triiodothyronine	B-I
(	I-I
T3	I-I
)	I-I
following	O
myocardial	O
revascularization	O
on	O
cardiopulmonary	B-I
bypass	I-I
(	I-I
CPB	I-I
)	I-I
.	I-I


In	O
this	O
study	O
,	O
open-label	B-P
T3	I-I
was	I-P
administered	I-P
to	I-P
68	I-P
high-risk	I-P
patients	I-P
undergoing	I-P
open	I-P
heart	I-P
surgery	I-P
.	I-P


The	O
New	B-O
Jersey	I-O
Risk	I-O
Assessment	I-O
was	O
used	O
to	O
calculate	O
the	O
preoperative	B-O
estimated	I-O
surgical	I-O
mortality	I-O
.	I-O


A	O
loading	O
dose	O
of	O
T3	B-I
was	O
administered	O
:	O
(	O
a	O
)	O
at	O
release	O
of	O
the	O
aortic	O
cross-clamp	O
,	O
(	O
b	O
)	O
whenever	O
the	O
patient	O
became	O
CPB	O
dependent	O
,	O
(	O
c	O
)	O
if	O
the	O
patient	O
exhibited	O
low	O
cardiac	O
output	O
after	O
discontinuing	O
CPB	O
and	O
(	O
d	O
)	O
as	O
pretreatment	O
before	O
initiating	O
CPB	O
.	O


All	O
therapeutic	O
modalities	O
were	O
followed	O
by	O
a	O
continuous	O
T3	B-I
infusion	O
.	O


Following	O
T3	B-I
therapy	I-I
,	I-I
CPB	I-I
was	O
discontinued	O
in	O
all	O
patients	O
.	O


Based	O
upon	O
discriminant	O
analysis	O
,	O
a	O
total	O
of	O
26	O
deaths	B-O
were	O
expected	O
from	O
the	O
entire	O
group	O
,	O
but	O
only	O
7	O
patients	O
died	B-O
,	O
therefore	O
,	O
the	O
observed	B-O
mortality	I-O
was	O
reduced	O
by	O
72	O
%	O
(	O
p	O
<	O
0.007	O
)	O
.	O


The	O
use	O
of	O
T3	B-I
had	O
a	O
major	O
impact	O
on	O
reducing	B-O
surgical	I-O
mortality	I-O
,	O
and	O
may	O
be	O
advocated	O
as	O
a	O
new	O
therapeutic	O
modality	O
in	O
patients	B-P
with	I-P
high	I-P
estimated	I-O
mortality	I-O
undergoing	I-P
open	I-P
heart	I-P
surgery	I-P
.	I-P


Active	B-O
warming	I-O
,	I-O
not	I-O
passive	I-O
heat	I-O
retention	I-O
,	O
maintains	O
normothermia	B-O
during	O
combined	O
epidural-general	O
anesthesia	O
for	O
hip	B-P
and	I-P
knee	I-P
arthroplasty	I-P
.	I-P


STUDY	O
OBJECTIVE	O
to	O
compare	O
passive	O
heat	O
retention	O
by	O
low-flow	O
anesthesia	O
,	O
alone	O
and	O
with	O
additional	O
thermal	O
insulation	O
by	O
reflective	O
blankets	O
,	O
with	O
forced-air	O
warming	O
preventing	O
intraoperative	O
hypothermia	O
during	O
combined	O
epidural-general	O
anesthesia	O
.	O


DESIGN	O
Randomized	O
,	O
controlled	O
study	O
.	O


SETTING	O
Inpatient	B-P
anesthesia	I-P
at	I-P
a	I-P
university	I-P
department	I-P
of	I-P
orthopedic	I-P
surgery	I-P
.	I-P


PATIENTS	B-P
30	I-P
ASA	I-P
physical	I-P
status	I-P
I	I-P
and	I-P
II	I-P
patients	I-P
,	I-P
who	I-P
were	I-P
scheduled	I-P
for	I-P
elective	I-P
hip	I-P
or	I-P
knee	I-P
arthroplasty	I-P
and	I-P
were	I-P
free	I-P
from	I-P
systemic	I-P
disease	I-P
.	I-P


INTERVENTIONS	O
Patients	O
received	O
epidural	O
block	O
up	O
to	O
T10	O
by	O
alkalinized	B-I
lidocaine	I-I
2	I-I
%	I-I
,	O
and	O
then	O
were	O
administered	O
standard	B-I
general	I-I
anesthesia	I-I
by	I-I
means	I-I
of	I-I
low-flow	I-I
rebreathing	I-I
system	I-I
(	O
fresh	O
gas	O
flow	O
=	O
1	O
L/min	O
)	O
.	O


All	O
procedures	O
started	O
between	O
8	O
and	O
10	O
AM	O
,	O
and	O
operating	O
room	O
(	O
OR	O
)	O
temperature	O
was	O
maintained	O
between	O
21	O
degrees	O
and	O
23	O
degrees	O
C	O
,	O
with	O
relative	O
humidity	O
ranging	O
between	O
40	O
%	O
and	O
45	O
%	O
.	O


For	O
heat	O
retention	O
or	O
warming	O
therapy	O
,	O
patients	O
received	O
either	O
low-flow	B-I
anesthesia	I-I
only	I-I
(	O
control	O
,	O
n	O
=	O
10	O
)	O
,	O
low-flow	B-I
anesthesia	I-I
with	I-I
additional	I-I
reflective	I-I
blankets	I-I
(	O
blanket	O
,	O
n	O
=	O
10	O
)	O
,	O
or	O
low-flow	B-I
anesthesia	I-I
with	I-I
active	I-I
forced-air	I-I
warming	I-I
(	O
forced-air	O
,	O
n	O
=	O
10	O
)	O
.	O


Tympanic	B-O
temperature	I-O
was	O
measured	O
at	O
OR	O
arrival	O
(	O
baseline	O
)	O
;	O
immediately	O
following	O
general	O
anesthesia	O
induction	O
;	O
30	O
,	O
60	O
,	O
90	O
,	O
and	O
120	O
minutes	O
from	O
general	O
anesthesia	O
induction	O
;	O
and	O
at	O
the	O
end	O
of	O
surgery	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Duration	B-O
of	I-O
anesthesia	I-O
,	I-O
invasiveness	I-O
of	I-O
surgery	I-O
,	I-O
and	I-O
baseline	I-O
core	I-O
temperature	I-O
were	O
similar	O
in	O
the	O
three	O
groups	O
.	O


Core	B-O
temperature	I-O
decreased	O
in	O
all	O
the	O
three	O
groups	O
30	O
minutes	O
after	O
general	O
anesthesia	O
induction	O
compared	O
with	O
baseline	O
(	O
p	O
<	O
0.01	O
)	O
;	O
afterwards	O
,	O
it	O
progressively	O
decreased	O
in	O
the	O
control	O
and	O
blankets	O
groups	O
(	O
p	O
=	O
0.004	O
)	O
,	O
with	O
a	O
reduction	B-O
from	I-O
baseline	I-O
values	I-O
measured	O
at	O
the	O
end	O
of	O
surgery	O
of	O
2.0	O
degrees	O
C	O
and	O
1.6	O
degrees	O
C	O
,	O
respectively	O
.	O


In	O
the	O
forced-air	O
group	O
,	O
after	O
the	O
initial	O
significant	O
decrease	O
(	O
p	O
=	O
0.01	O
vs.	O
baseline	O
)	O
,	O
core	B-O
temperature	I-O
progressively	O
increased	O
to	O
35.8	O
+/-	O
0.6	O
degrees	O
C	O
,	O
which	O
was	O
similar	O
to	O
preoperative	O
values	O
and	O
significantly	O
higher	O
than	O
either	O
the	O
control	O
or	O
blankets	O
groups	O
(	O
p	O
=	O
0.004	O
)	O
.	O


CONCLUSIONS	O
During	O
combined	O
epidural-general	O
anesthesia	O
for	O
elective	B-P
hip	I-P
and	I-P
knee	I-P
arthroplasty	I-P
,	O
passive	O
heat	O
retention	O
by	O
means	O
of	O
low-flow	B-I
anesthesia	I-I
alone	I-I
and	I-I
in	I-I
combination	I-I
with	I-I
reflective	I-I
blankets	I-I
is	O
ineffective	O
in	O
maintaining	B-O
intraoperative	I-O
normothermia	I-O
and	O
definitely	O
inferior	O
to	O
active	O
forced-air	O
warning	O
.	O


Joint	O
attention	O
and	O
symbolic	O
play	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
:	I-P
a	O
randomized	O
controlled	O
intervention	O
study	O
.	O


BACKGROUND	O
Delays	O
and	O
deficits	O
in	O
joint	O
attention	O
and	O
symbolic	O
play	O
constitute	O
two	O
important	O
developmental	O
problems	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


These	O
areas	O
of	O
deficit	O
have	O
been	O
well	O
studied	O
in	O
autism	O
but	O
have	O
rarely	O
been	O
the	O
focus	O
of	O
treatment	O
efforts	O
(	O
see	O
Kasari	O
,	O
Freeman	O
,	O
&	O
Paparella	O
,	O
2001	O
)	O
.	O


In	O
this	O
study	O
,	O
we	O
examine	O
the	O
efficacy	O
of	O
targeted	O
interventions	O
of	O
joint	B-I
attention	I-I
and	I-I
symbolic	I-I
play	I-I
.	I-I


METHODS	O
Participants	B-P
were	I-P
58	I-P
children	I-P
with	I-P
autism	I-P
aged	I-P
3	I-P
and	I-P
4	I-P
years	I-P
(	I-P
46	I-P
boys	I-P
)	I-P
.	I-P


Children	O
were	O
randomized	O
to	O
a	O
joint	B-I
attention	I-I
intervention	I-I
,	I-I
a	I-I
symbolic	I-I
play	I-I
intervention	I-I
,	I-I
or	I-I
control	I-I
group	I-I
.	I-I


Interventions	O
were	O
conducted	O
30	O
minutes	O
daily	O
for	O
5-6	O
weeks	O
.	O


Both	O
structured	O
assessments	O
of	O
joint	O
attention	O
and	O
play	O
skills	O
and	O
mother-child	O
interactions	O
were	O
collected	O
pre	O
and	O
post	O
intervention	O
by	O
independent	O
assessors	O
.	O


RESULTS	O
Results	O
indicate	O
that	O
both	O
intervention	O
groups	O
improved	O
significantly	O
over	O
the	O
control	O
group	O
on	O
certain	O
behaviors	O
.	O


Children	O
in	O
the	O
joint	O
attention	O
intervention	O
initiated	O
significantly	O
more	O
showing	B-O
and	O
responsiveness	B-O
to	I-O
joint	I-O
attention	I-O
on	O
the	O
structured	B-O
joint	I-O
attention	I-O
assessment	I-O
and	O
more	O
child-initiated	B-O
joint	I-O
attention	I-O
in	O
the	O
mother-child	B-O
interaction	I-O
.	I-O


The	O
children	O
in	O
the	O
play	O
group	O
showed	O
more	O
diverse	O
types	B-O
of	I-O
symbolic	I-O
play	I-O
in	O
interaction	O
with	O
their	O
mothers	O
and	O
higher	O
play	B-O
levels	I-O
on	O
both	O
the	O
play	B-O
assessment	I-O
and	O
in	O
interaction	B-O
with	I-O
their	I-O
mothers	I-O
.	I-O


CONCLUSIONS	O
This	O
randomized	O
controlled	O
trial	O
provides	O
promising	O
data	O
on	O
the	O
specificity	B-O
and	I-O
generalizability	I-O
of	I-O
joint	I-O
attention	I-O
and	I-O
play	I-O
interventions	I-O
for	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


Future	O
studies	O
need	O
to	O
examine	O
the	O
long-term	O
effects	O
of	O
these	O
early	O
interventions	O
on	O
children	O
's	O
development	O
.	O


Butorphanol	B-I
and	I-I
meperidine	I-I
compared	O
in	O
patients	B-P
with	I-P
acute	I-P
ureteral	I-P
colic	I-P
.	I-P


Pain	O
relief	O
was	O
evaluated	O
in	O
81	B-P
patients	I-P
with	I-P
acute	I-P
ureteral	I-P
colic	I-P
and	I-P
the	I-P
confirmed	I-P
presence	I-P
of	I-P
a	I-P
calculus	I-P
.	I-P


A	O
randomized	B-P
double-blind	I-P
comparison	I-P
of	I-P
intramuscular	I-P
2	I-P
and	I-P
4	I-P
mg.	I-P
butorphanol	I-I
and	I-I
80	I-P
mg.	I-P
meperidine	I-I
was	I-P
used	I-P
.	I-P


Pain	B-O
intensity	I-O
and	O
pain	B-O
relief	I-O
were	O
evaluated	O
at	O
half	O
hour	O
and	O
hourly	O
intervals	O
for	O
4	O
hours	O
.	O


A	O
2	O
mg.	O
dose	O
of	O
butorphanol	B-I
was	O
found	O
to	O
be	O
analgesically	O
equivalent	O
to	O
80	O
mg.	O
meperidine	B-I
,	O
while	O
a	O
4	O
mg.	O
dose	O
of	O
butorphanol	B-I
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
80	O
mg.	O
meperidine	B-I
and	O
2	O
mg.	O
butorphanol	B-I
.	I-I


Each	O
patient	O
received	O
up	O
to	O
2	O
doses	O
of	O
analgesic	O
medication	O
when	O
necessary	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	B-O
of	I-O
side	I-O
effects	I-O
among	O
treatments	O
.	O


One	O
patient	O
had	O
visual	B-O
hallucinations	I-O
after	O
a	O
2	O
mg.	O
dose	O
of	O
butorphanol	B-I
,	O
possibly	O
owing	O
to	O
its	O
antagonistic	O
activity	O
to	O
significant	O
narcotic	O
experience	O
given	O
previously	O
at	O
another	O
hospital	O
.	O


There	O
was	O
no	O
other	O
evidence	O
of	O
toxicity	B-O
with	O
butorphanol	B-I
.	I-I


It	O
was	O
found	O
to	O
be	O
a	O
safe	B-O
,	I-O
effective	I-O
and	I-O
wall	I-O
tolerated	I-O
drug	O
for	O
the	O
treatment	O
of	O
ureteral	O
colic	O
and	O
is	O
recommended	O
in	O
place	O
of	O
narcotics	O
.	O


Effect	O
of	O
inhaled	O
heparin	B-I
on	O
adenosine-induced	B-P
bronchial	I-P
hyperreactivity	I-P
.	I-P


Glycosaminoglycan	B-I
heparin	I-I
possesses	O
multiple	O
noncoagulant	O
properties	O
including	O
antiinflammatory	O
actions	O
.	O


We	O
have	O
previously	O
shown	O
that	O
heparin	B-I
attenuates	O
the	O
methacholine-induced	O
bronchoconstriction	O
in	O
humans	B-P
.	I-P


In	O
contrast	O
to	O
methacholine	O
,	O
a	O
stimulus	O
that	O
induces	O
airway	O
constriction	O
mainly	O
by	O
"	O
direct	O
"	O
stimulation	O
of	O
airway	O
smooth	O
muscle	O
cells	O
,	O
adenosine	O
airway	O
responsiveness	O
reflects	O
"	O
indirectly	O
"	O
induced	O
airway	O
narrowing	O
via	O
inflammatory	O
mediators	O
or	O
neural	O
reflex	O
mechanisms	O
.	O


Whether	O
heparin	B-I
modulates	O
bronchial	O
hyperreactivity	O
induced	O
by	O
adenosine	O
,	O
is	O
not	O
well	O
known	O
.	O


We	O
investigated	O
the	O
effect	O
of	O
inhaled	B-I
heparin	I-I
on	O
adenosine-induced	O
bronchoconstriction	O
and	O
compared	O
the	O
inhibitory	O
role	O
of	O
heparin	B-I
on	O
the	O
adenosine	O
challenge	O
test	O
with	O
that	O
on	O
the	O
methacholine	O
challenge	O
test	O
.	O


Fifteen	B-P
subjects	I-P
(	I-P
7	I-P
males	I-P
,	I-P
8	I-P
females	I-P
)	I-P
with	I-P
mild	I-P
asthma	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Bronchial	O
provocation	O
tests	O
were	O
performed	O
in	O
a	O
single-blind	O
,	O
crossover	O
,	O
randomized	O
order	O
,	O
and	O
repeated	O
45	O
minutes	O
after	O
placebo	B-I
or	O
aerosolized	B-I
heparin	I-I
inhalation	I-I
(	O
1,000	O
U/kg	O
)	O
.	O


The	O
heparin	B-I
increased	O
the	O
geometric	B-O
mean	I-O
log	I-O
methacholine	I-O
PD20	I-O
value	I-O
from	O
0.47	O
+/-	O
0.16	O
(	O
2.95	O
mg/ml	O
)	O
to	O
0.96	O
+/-	O
0.10	O
(	O
8.91	O
mg/ml	O
)	O
,	O
(	O
P	O
<	O
0.0009	O
)	O
in	O
15	O
patients	O
and	O
the	O
geometric	B-O
mean	I-O
log	I-O
adenosine	I-O
PD20	I-O
values	I-O
from	O
1.59	O
+/-	O
0.23	O
(	O
38.9	O
mg/ml	O
)	O
to	O
1.98	O
+/-	O
0.14	O
(	O
97.7	O
mg/ml	O
)	O
(	O
NS	O
)	O
in	O
7	O
patients	O
whose	O
baseline	O
adenosine	O
PD20	O
levels	O
were	O
less	O
than	O
200	O
mg/ml	O
.	O


The	O
degree	B-O
of	I-O
protection	I-O
by	O
heparin	B-I
against	O
adenosine-induced	O
bronchoconstriction	O
was	O
not	O
correlated	O
with	O
that	O
against	O
methacholine-induced	O
bronchoconstriction	O
(	O
r	O
=	O
0.60	O
,	O
NS	O
)	O
.	O


The	O
data	O
suggest	O
that	O
inhaled	O
heparin	B-I
may	O
have	O
an	O
inhibitory	O
effect	O
on	O
the	O
methacholine	O
bronchial	O
challenge	O
,	O
and	O
thus	O
,	O
most	O
likely	O
directs	O
its	O
effect	O
against	O
smooth	O
muscle	O
.	O


Heparin	B-I
caused	O
less	O
attenuation	O
of	O
a	O
challenge	O
with	O
adenosine	O
and	O
probably	O
does	O
not	O
affect	O
mast	O
cell	O
degranulation	O
.	O


A	O
randomized	O
trial	O
comparison	O
of	O
the	O
effects	O
of	O
verbal	B-I
and	I-I
pictorial	I-I
naturalistic	I-I
communication	I-I
strategies	I-I
on	O
spoken	O
language	O
for	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


Presently	O
there	O
is	O
no	O
consensus	O
on	O
the	O
specific	O
behavioral	O
treatment	O
of	O
choice	O
for	O
targeting	O
language	O
in	O
young	B-P
nonverbal	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


This	O
randomized	O
clinical	O
trial	O
compared	O
the	O
effectiveness	O
of	O
a	B-I
verbally-based	I-I
intervention	I-I
,	I-I
Pivotal	I-I
Response	I-I
Training	I-I
(	I-I
PRT	I-I
)	I-I
to	I-I
a	I-I
pictorially-based	I-I
behavioral	I-I
intervention	I-I
,	I-I
the	I-I
Picture	I-I
Exchange	I-I
Communication	I-I
System	I-I
(	I-I
PECS	I-I
)	I-I
on	I-I
the	I-I
acquisition	I-I
of	I-I
spoken	I-I
language	I-I
by	O
young	B-P
(	I-P
2-4	I-P
years	I-P
)	I-P
,	I-P
nonverbal	I-P
or	I-P
minimally	I-P
verbal	I-P
(	I-P
≤9	I-P
words	I-P
)	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


Thirty-nine	B-P
children	I-P
were	O
randomly	O
assigned	O
to	O
either	O
the	B-I
PRT	I-I
or	I-I
PECS	I-I
condition	O
.	O


Participants	O
received	O
on	O
average	O
247	O
h	O
of	O
intervention	O
across	O
23	O
weeks	O
.	O


Dependent	O
measures	O
included	B-O
overall	I-O
communication	I-O
,	I-O
expressive	I-O
vocabulary	I-O
,	I-O
pictorial	I-O
communication	I-O
and	I-O
parent	I-O
satisfaction	I-O
.	O


Children	O
in	O
both	O
intervention	O
groups	O
demonstrated	O
increases	B-O
in	I-O
spoken	I-O
language	I-O
skills	I-O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
two	O
conditions	O
.	O


Seventy-eight	O
percent	O
of	O
all	O
children	O
exited	O
the	O
program	O
with	O
more	O
than	B-O
10	I-O
functional	I-O
words	I-O
.	O


Parents	O
were	O
very	O
satisfied	O
with	O
both	O
programs	O
but	O
indicated	B-I
PECS	O
was	O
more	O
difficult	O
to	O
implement	O
.	O


The	O
effect	O
of	O
deep	B-I
brain	I-I
stimulation	I-I
randomized	O
by	O
site	O
on	O
balance	O
in	O
Parkinson	B-P
's	I-P
disease	I-P
.	I-P


BACKGROUND	O
The	O
effect	O
of	O
the	O
surgical	O
site	O
of	O
DBS	O
on	O
balance	O
and	O
gait	O
in	O
Parkinson	B-P
's	I-P
Disease	I-P
(	I-P
PD	I-P
)	I-P
is	O
uncertain	O
.	O


This	O
is	O
the	O
first	O
double-blind	O
study	O
of	O
subjects	B-P
randomized	I-P
to	I-P
either	I-P
the	I-P
STN	I-I
(	I-P
N	I-P
=	I-P
14	I-P
)	I-P
or	I-P
GPi	I-I
(	I-P
N	I-P
=	I-P
14	I-P
)	I-P
who	I-P
were	I-P
assessed	I-P
on	I-P
a	I-P
range	I-P
of	I-P
clinical	I-P
balance	I-P
measures	I-P
.	I-P


METHODS	O
Balance	O
testing	O
occurred	O
before	O
and	O
6	O
months	O
postsurgery	O
.	O


A	B-P
control	I-I
PD	I-P
group	I-P
was	I-P
tested	I-P
over	I-P
the	I-P
same	I-P
period	I-P
without	I-P
surgery	I-P
(	I-P
N	I-P
=	I-P
9	I-P
)	I-P
.	I-P


All	O
subjects	O
were	O
tested	O
on	B-I
and	I-I
off	I-I
medication	I-I
and	O
DBS	O
subjects	O
were	O
also	O
tested	O
on	B-I
and	I-I
off	I-I
DBS	I-I
.	I-I


The	B-O
Postural	I-O
Instability	I-O
and	I-O
Gait	I-O
Disability	I-O
items	I-O
of	I-O
the	I-O
UPDRS	I-O
and	I-O
additional	I-O
functional	I-O
tests	I-O
,	I-O
which	I-O
we	I-O
call	I-O
the	I-O
Balance	I-O
and	I-O
Gait	I-O
scale	I-O
,	O
were	O
assessed	O
.	O


Activities	B-O
of	I-O
Balance	I-O
Confidence	I-O
and	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
questionnaires	I-O
were	O
also	O
recorded	O
.	O


RESULTS	O
Balance	O
was	O
not	O
different	O
between	O
the	O
best-treated	O
states	O
before	O
and	O
after	O
DBS	O
surgery	O
for	O
both	O
sites	O
.	O


Switching	O
DBS	O
on	O
improved	O
balance	B-O
scores	I-O
,	O
and	O
scores	O
further	O
improved	O
with	O
medication	O
,	O
compared	O
to	O
the	O
off	O
state	O
.	O


The	O
GPi	O
group	O
showed	O
improved	O
performance	O
in	O
the	O
postsurgery	O
off	O
state	O
and	O
better	O
ratings	O
of	O
balance	B-O
confidence	I-O
after	O
surgery	O
,	O
compared	O
to	O
the	O
STN	O
group	O
.	O


CONCLUSIONS	O
Clinical	O
measures	O
of	O
balance	O
function	O
for	O
both	O
the	O
STN	O
and	O
GPi	O
sites	O
showed	O
that	O
balance	O
did	O
not	O
improve	O
beyond	O
the	O
best	O
medically	O
treated	O
state	O
before	O
surgery	O
.	O


Both	O
clinical	O
balance	O
testing	O
in	O
the	O
off/off	O
state	O
and	O
self-reported	O
balance	O
confidence	O
after	O
surgery	O
showed	O
better	O
performance	O
in	O
the	O
GPi	O
than	O
the	O
STN	O
group	O
.	O


Dissociation	O
between	O
cortical	O
activation	O
and	O
cognitive	O
performance	O
under	O
pharmacological	O
blood	O
pressure	O
elevation	O
in	O
chronic	O
hypotension	O
.	O


The	O
present	O
study	O
explored	O
the	O
impact	O
of	O
pharmacological	B-I
blood	I-I
pressure	I-I
elevation	I-I
on	O
cortical	O
activation	O
and	O
reaction	O
time	O
in	O
chronic	B-P
hypotension	I-P
.	I-P


Effects	O
of	O
the	O
sympathomimetic	B-I
etilefrine	I-I
were	O
investigated	O
in	O
50	B-P
hypotensive	I-P
persons	I-P
based	O
on	O
a	O
randomized	O
,	O
placebo-controlled	B-I
double	O
blind	O
design	O
.	O


As	O
an	O
indicator	O
of	O
cortical	O
excitability	O
,	O
the	O
contingent	O
negative	O
variation	O
(	O
CNV	O
)	O
,	O
induced	O
by	O
a	O
constant	O
foreperiod	O
reaction	O
time	O
task	O
,	O
was	O
assessed	O
at	O
frontal	O
(	O
F3	O
,	O
Fz	O
,	O
F4	O
)	O
and	O
central	O
(	O
C3	O
,	O
Cz	O
,	O
C4	O
)	O
scalp	O
sites	O
.	O


Etilefrine	B-I
provoked	O
a	O
decrease	O
in	O
the	O
frontal	B-O
and	I-O
central	I-O
CNV	I-O
.	I-O


In	O
contrast	O
,	O
shorter	O
reaction	B-O
times	I-O
were	O
observed	O
following	O
drug	O
administration	O
.	O


The	O
degree	B-O
of	O
pharmacologically	O
induced	B-O
blood	I-O
pressure	I-O
elevation	I-O
was	O
correlated	O
to	O
CNV	O
attrition	O
as	O
well	O
as	O
to	O
performance	O
enhancement	O
.	O


Inhibitory	O
effects	O
of	O
baroreceptor	O
activation	O
on	O
cortical	O
excitability	O
and	O
enhanced	O
cerebral	O
blood	O
flow	O
are	O
considered	O
to	O
be	O
involved	O
in	O
mediating	O
the	O
effects	O
of	O
blood	B-O
pressure	I-O
elevation	I-O
on	O
cerebral	O
functioning	O
.	O


Implications	O
for	O
the	O
treatment	O
of	O
chronic	B-O
hypotension	I-O
are	O
discussed	O
.	O


A	O
trial	O
of	O
D-cycloserine	B-I
to	O
treat	O
stereotypies	O
in	O
older	B-P
adolescents	I-P
and	I-P
young	I-P
adults	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


OBJECTIVES	O
Autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
have	O
core	O
impairments	O
in	O
social	O
communication	O
as	O
well	O
as	O
the	O
presence	O
of	O
repetitive	O
,	O
stereotypic	O
behaviors	O
and	O
restricted	O
interests	O
.	O


Older	O
adolescents	O
and	O
young	O
adults	O
are	O
particularly	O
impacted	O
by	O
these	O
deficits	O
.	O


Preclinical	O
data	O
implicate	O
glutamatergic	O
dysfunction	O
in	O
the	O
pathophysiology	O
of	O
ASDs	O
.	O


D-Cycloserine	B-I
(	I-I
DCS	I-I
)	I-I
,	O
a	O
partial	O
glycineB	O
agonist	O
at	O
the	O
N-methyl-D-aspartic	O
acid	O
receptor	O
site	O
,	O
has	O
been	O
shown	O
to	O
improve	O
sociability	O
in	O
mouse	O
models	O
and	O
a	O
small	O
human	O
study	O
.	O


The	O
sensitivity	O
of	O
the	O
obligatory	O
glycineB	O
co-agonist	O
binding	O
site	O
may	O
change	O
with	O
daily	O
administration	O
of	O
DCS	O
as	O
a	O
result	O
of	O
agonist-induced	O
desensitization	O
.	O


The	O
efficacy	B-O
of	O
a	O
"	O
pulsed	O
"	O
once-weekly	O
administration	O
versus	O
"	O
daily	O
"	O
administration	O
of	O
DCS	O
was	O
compared	O
.	O


METHODS	O
Males	B-P
and	I-P
females	I-P
,	I-P
ages	I-P
14	I-P
to	I-P
25	I-P
years	I-P
,	I-P
with	I-P
a	I-P
Diagnostic	I-P
and	I-P
Statistical	I-P
Manual	I-P
of	I-P
Mental	I-P
Disorders	I-P
,	I-P
Fourth	I-P
Edition	I-P
Text	I-P
Revision	I-P
diagnosis	I-P
of	I-P
an	I-P
ASD	I-P
were	I-P
enrolled	I-P
in	O
a	O
double-blind	O
,	O
randomized	O
10-week	O
trial	O
consisting	O
of	O
8	O
weeks	O
of	O
active	O
drug	O
with	O
either	O
weekly	O
or	O
daily	O
administration	O
of	O
50	O
mg	O
of	O
DCS	B-I
followed	O
by	O
a	O
2-week	O
follow-up	O
visit	O
.	O


RESULTS	O
For	O
the	O
purposes	O
of	O
this	O
study	O
,	O
no	O
statistical	O
or	O
clinical	O
differences	B-O
existed	O
between	O
the	O
2	O
dosage	O
groups	O
on	O
the	O
Aberrant	B-O
Behavior	I-O
Checklist	I-O
subscale	I-O
3	I-O
,	I-O
which	I-O
measures	I-O
stereotypies/repetitive	I-O
movements	I-O
.	I-O


When	O
combining	O
groups	O
,	O
a	O
statistically	O
significant	O
decrease	O
of	O
37	O
%	O
was	O
found	O
from	O
baseline	O
to	O
week	O
8	O
when	O
study	O
drug	O
was	O
completed	O
using	O
a	O
linear	O
mixed	O
effects	O
model	O
(	O
P	O
=	O
0.003	O
)	O
.	O


CONCLUSIONS	O
D-Cycloserine	B-I
was	O
shown	O
to	O
be	O
effective	O
in	O
improving	O
stereotypic	B-O
symptoms	I-O
in	O
older	O
adolescents	O
and	O
young	O
adults	O
with	O
ASDs	O
measured	O
by	O
the	O
Aberrant	B-O
Behavior	I-O
Checklist	I-O
subscale	I-O
3	I-O
.	I-O


In	O
addition	O
,	O
DCS	B-I
was	O
safe	B-O
and	I-O
well	I-O
tolerated	I-O
.	I-O


Reduced	O
mortality	O
among	O
children	B-P
in	I-P
southern	I-P
India	I-P
receiving	I-P
a	I-P
small	I-P
weekly	I-P
dose	I-P
of	I-P
vitamin	I-I
A	I-I
.	I-I


BACKGROUND	O
Clinical	O
vitamin	O
A	O
deficiency	O
affects	O
millions	O
of	O
children	O
worldwide	O
,	O
and	O
subclinical	O
deficiency	O
is	O
even	O
more	O
common	O
.	O


Supplemental	O
vitamin	O
A	O
has	O
been	O
reported	O
to	O
reduce	O
mortality	O
among	O
these	O
children	O
,	O
but	O
the	O
results	O
have	O
been	O
questioned	O
.	O


METHODS	O
We	O
conducted	O
a	O
randomized	O
,	O
controlled	O
,	O
masked	O
clinical	O
trial	O
for	O
one	O
year	O
in	B-P
southern	I-P
India	I-P
involving	I-P
15,419	I-P
preschool-age	I-P
children	I-P
who	I-P
received	I-P
either	I-P
8.7	I-I
mumol	I-I
(	I-I
8333	I-I
IU	I-I
)	I-I
of	I-I
vitamin	I-I
A	I-I
and	I-I
46	I-I
mumol	I-I
(	I-I
20	I-I
mg	I-I
)	I-I
of	I-I
vitamin	I-I
E	I-I
(	I-I
the	I-I
treated	I-I
group	I-I
)	I-I
or	I-I
vitamin	I-I
E	I-I
alone	I-I
(	I-I
the	I-I
control	I-I
group	I-I
)	I-I
.	O


Vitamin	B-I
supplements	I-I
were	O
delivered	O
weekly	O
by	O
community	O
health	O
volunteers	O
who	O
also	O
recorded	O
mortality	B-O
and	I-O
morbidity	I-O
.	I-O


Weekly	O
contact	O
was	O
made	O
with	O
at	O
least	O
88	O
percent	O
of	O
the	O
children	O
in	O
both	O
study	O
groups	O
.	O


The	O
base-line	O
characteristics	O
of	O
the	O
children	O
were	O
similar	O
and	O
documented	O
a	O
high	O
prevalence	O
of	O
vitamin	O
A	O
deficiency	O
and	O
undernutrition	O
.	O


RESULTS	O
One	O
hundred	O
twenty-five	O
deaths	O
occurred	O
,	O
of	O
which	O
117	O
were	O
not	O
accidental	O
.	O


The	O
risk	B-O
of	I-O
death	I-O
in	O
the	O
group	O
treated	O
with	O
vitamin	O
A	O
was	O
less	O
than	O
half	O
that	O
in	O
the	O
control	O
group	O
(	O
relative	O
risk	O
,	O
0.46	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.30	O
to	O
0.71	O
)	O
.	O


The	O
risk	O
was	O
most	O
reduced	O
among	O
children	O
under	O
3	O
years	O
of	O
age	O
(	O
6	O
to	O
11	O
months	O
--	O
relative	O
risk	O
,	O
0.28	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.09	O
to	O
0.85	O
;	O
12	O
to	O
35	O
months	O
--	O
relative	O
risk	O
,	O
0.46	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.26	O
to	O
0.81	O
)	O
and	O
among	O
those	O
who	O
were	O
chronically	O
undernourished	O
,	O
as	O
manifested	O
by	O
stunting	O
(	O
relative	O
risk	O
,	O
0.11	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.03	O
to	O
0.36	O
)	O
.	O


The	O
symptom-specific	B-O
risk	I-O
of	I-O
mortality	I-O
was	O
significantly	O
associated	O
with	O
diarrhea	B-O
,	I-O
convulsions	I-O
,	I-O
and	I-O
other	I-O
infection-related	I-O
symptoms	I-O
.	I-O


CONCLUSIONS	O
The	O
regular	O
provision	O
of	O
a	O
supplement	O
of	O
vitamin	B-I
A	I-I
to	O
children	O
,	O
at	O
a	O
level	O
potentially	O
obtainable	O
from	O
foods	O
,	O
in	O
an	O
area	O
where	O
vitamin	O
A	O
deficiency	O
and	O
under-nutrition	O
are	O
documented	O
public	O
health	O
problems	O
contributed	O
substantially	O
to	O
children	O
's	O
survival	O
;	O
mortality	O
was	O
reduced	O
on	O
average	O
by	O
54	O
percent	O
.	O


Chlorhexidine	B-I
swabbing	O
applications	O
under	O
various	O
conditions	O
of	O
use	O
in	O
preventive	O
oral	O
care	O
for	O
persons	B-P
with	I-P
disabilities	I-P
.	I-P


A	O
sample	O
of	O
44	B-P
adults	I-P
with	I-P
severe	I-P
disabilities	I-P
completed	O
a	O
randomized	O
single-blind	O
cross-over	O
study	O
testing	O
chlorhexidine	B-I
swabbing	O
under	O
various	O
conditions	O
:	O
with/without	O
prior	O
dental	O
prophylaxis	O
,	O
reduced	O
frequency	O
of	O
application	O
(	O
2	O
vs.	O
5	O
times	O
per	O
week	O
)	O
,	O
and	O
prolonged	O
use	O
(	O
42	O
weeks	O
)	O
.	O


All	O
subjects	O
received	O
therapeutic	O
doses	O
of	O
10	B-I
mL	I-I
0.12	I-I
%	I-I
chlorhexidine	I-I
gluconate	I-I
(	O
Peridex	O
,	O
Procter	O
&	O
Gamble	O
)	O
and	O
10	B-I
mL	I-I
0.05	I-I
%	I-I
NaF	I-I
applied	I-I
with	I-I
a	I-I
Toothette	I-I
(	O
Sage	O
Products	O
)	O
.	O


Clinical	B-O
effectiveness	I-O
of	O
chlorhexidine	B-I
swabbing	O
compared	O
with	O
placebo	B-I
was	O
previously	O
reported	O
.	O


In	O
the	O
present	O
study	O
,	O
while	O
initial	O
benefits	O
were	O
observed	O
to	O
be	O
independent	O
of	O
dental	O
prophylaxis	O
,	O
significant	O
reductions	O
in	O
periodontal	B-O
scores	I-O
were	O
sustained	O
by	O
a	O
combination	O
of	O
dental	O
prophylaxis	O
and	O
swabbing	O
protocol	O
,	O
at	O
reduced	O
frequency	O
of	O
application	O
and	O
over	O
prolonged	O
time	O
.	O


High	O
levels	O
of	O
acceptance	B-O
and	I-O
compliance	I-O
by	O
subjects/caregivers	O
were	O
maintained	O
.	O


Subjects/caregivers	O
reported	O
improvements	B-O
in	I-O
dental	I-O
health	I-O
as	I-O
well	I-O
as	I-O
in	I-O
attitude	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
,	I-O
and	I-O
smile	I-O
.	I-O


Chlorhexidine	B-I
swabbing	O
at	O
maintenance	O
frequency	O
,	O
combined	O
with	O
periodic	O
dental	O
prophylaxis	O
,	O
may	O
offer	O
an	O
effective	O
and	O
pragmatic	O
long-term	B-O
preventive	I-O
regimen	I-O
for	O
persons	O
with	O
disabilities	O
.	O


Rituximab	B-I
plus	I-I
concurrent	I-I
infusional	I-I
EPOCH	I-I
chemotherapy	I-I
is	O
highly	O
effective	O
in	B-P
HIV-associated	I-P
B-cell	I-P
non-Hodgkin	I-P
lymphoma	I-P
.	I-P


Rituximab	O
plus	O
intravenous	O
bolus	O
chemotherapy	O
is	O
a	O
standard	O
treatment	O
for	O
immunocompetent	B-P
patients	I-P
with	I-P
B-cell	I-P
non-Hodgkin	I-P
lymphoma	I-P
(	I-P
NHL	I-P
)	I-P
.	I-P


Some	O
studies	O
have	O
suggested	O
that	O
rituximab	O
is	O
associated	O
with	O
excessive	B-O
toxicity	I-O
in	O
HIV-associated	O
NHL	O
,	O
and	O
that	O
infusional	O
chemotherapy	O
may	O
be	O
more	O
effective	O
.	O


We	O
performed	O
a	O
randomized	O
phase	O
2	O
trial	O
of	O
rituximab	B-I
(	I-I
375	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
)	I-I
given	I-I
either	I-I
concurrently	I-I
before	I-I
each	I-I
infusional	I-I
etoposide	I-I
,	I-I
vincristine	I-I
,	I-I
doxorubicin	I-I
,	I-I
cyclophosphamide	I-I
,	I-I
and	I-I
prednisone	I-I
(	I-I
EPOCH	I-I
)	I-I
chemotherapy	I-I
cycle	I-I
or	I-I
sequentially	I-I
(	I-I
weekly	I-I
for	I-I
6	I-I
weeks	I-I
)	I-I
after	I-I
completion	I-I
of	I-I
all	I-I
chemotherapy	I-I
in	I-I
HIV-associated	I-I
NHL	I-I
.	I-I


EPOCH	B-I
consisted	O
of	O
a	O
96-hour	O
intravenous	O
infusion	O
of	O
etoposide	B-I
,	I-I
doxorubicin	I-I
,	I-I
and	I-I
vincristine	I-I
plus	I-I
oral	I-I
prednisone	I-I
followed	O
by	O
intravenous	O
bolus	O
cyclophosphamide	B-I
given	O
every	O
21	O
days	O
for	O
4	O
to	O
6	O
cycles	O
.	O


In	O
the	O
concurrent	O
arm	O
,	O
35	O
of	O
48	B-P
evaluable	I-P
patients	I-P
(	O
73	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
58	O
%	O
-85	O
%	O
)	O
had	O
a	O
complete	B-O
response	I-O
.	I-O


In	O
the	O
sequential	O
arm	O
,	O
29	O
of	O
53	B-P
evaluable	I-P
patients	I-P
(	O
55	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
41	O
%	O
-68	O
%	O
)	O
had	O
a	O
complete	O
response	O
.	O


The	O
primary	O
efficacy	O
endpoint	O
was	O
met	O
for	O
the	O
concurrent	O
arm	O
only	O
.	O


Toxicity	B-O
was	O
comparable	O
in	O
the	O
2	O
arms	O
,	O
although	O
patients	O
with	O
a	O
baseline	O
CD4	B-O
count	O
less	O
than	O
50/microL	O
had	O
a	O
high	O
infectious	B-O
death	I-O
rate	I-O
in	O
the	O
concurrent	O
arm	O
.	O


We	O
conclude	O
that	O
concurrent	B-I
rituximab	I-I
plus	I-I
infusional	I-I
EPOCH	I-I
is	O
an	O
effective	O
regimen	O
for	O
HIV-associated	B-P
lymphoma	I-P
.	I-P


[	O
A	O
randomized	O
study	O
of	O
prophylactic	O
intravesical	O
instillation	O
of	O
pirarubicin	B-I
(	I-I
THP	I-I
)	I-I
prior	O
to	O
transurethral	B-P
resection	I-P
of	I-P
superficial	I-O
bladder	I-O
cancer	I-O
]	I-O
.	O


A	O
prospective	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
of	O
prophylactic	B-P
intravesical	I-I
instillation	I-I
of	I-I
pirarubicin	I-I
(	I-I
THP	I-I
)	I-I
prior	I-P
to	I-P
transurethral	I-O
resection	I-O
(	I-O
TUR	I-O
)	I-O
of	I-O
superficial	I-O
bladder	I-O
cancer	I-O
.	I-O


A	O
total	O
of	O
63	B-P
patients	I-P
were	O
randomized	O
into	O
two	O
groups	O
,	O
the	O
THP	B-I
group	O
and	O
the	O
control	O
group	O
.	O


In	O
the	O
THP	O
group	O
,	O
30	O
mg	O
of	O
THP	O
dissolved	O
in	O
50	B-I
ml	I-I
saline	I-I
was	O
administered	O
4	O
times	O
intravesically	O
for	O
4	O
consecutive	O
days	O
before	O
TUR	O
.	O


In	O
the	O
control	O
group	O
,	O
no	B-I
instillation	I-I
was	I-I
performed	I-I
before	I-I
TUR	I-I
.	I-I


The	O
patients	O
were	O
followed	O
by	O
cystoscopy	O
and	O
urinary	O
cytology	O
every	O
3	O
months	O
.	O


The	O
non-recurrence	B-O
rates	I-O
in	O
the	O
THP	O
group	O
and	O
control	O
group	O
were	O
54.1	O
%	O
versus	O
37.6	O
%	O
at	O
1	O
year	O
and	O
40.4	O
%	O
versus	O
26.8	O
%	O
at	O
2	O
years	O
,	O
respectively	O
(	O
P	O
=	O
0.086	O
)	O
.	O


Time	B-O
to	I-O
recurrence	I-O
for	I-O
tumors	I-O
larger	I-O
than	I-O
1	I-O
cm	I-O
was	O
significantly	O
longer	O
in	O
the	O
THP	O
group	O
(	O
P	O
=	O
0.0137	O
)	O
.	O


Time	B-O
to	I-O
recurrence	I-O
for	I-O
single	I-O
and	I-O
grade	I-O
1+2	I-O
tumors	I-O
tended	O
to	O
be	O
longer	O
in	O
the	O
THP	O
group	O
(	O
P	O
=	O
0.09	O
,	O
P	O
=	O
0.079	O
)	O
.	O


No	O
significant	O
adverse	B-O
effects	I-O
were	O
observed	O
in	O
any	O
patient	O
.	O


Our	O
findings	O
suggest	O
that	O
intravesical	O
THP	O
instillation	O
prior	O
to	O
TUR	O
would	O
be	O
effective	B-O
for	O
patients	O
with	O
single	B-O
,	I-O
low	I-O
grade	I-O
lesions	I-O
larger	I-O
than	I-O
1	I-O
cm	I-O
of	O
superficial	B-O
bladder	I-O
cancer	I-O
.	I-O


Do	O
readers	B-P
with	I-P
autism	I-P
make	O
bridging	O
inferences	O
from	O
world	O
knowledge	O
?	O
Individuals	B-P
with	I-P
autism	I-P
frequently	O
show	O
impairments	O
in	O
text	O
reading	O
comprehension	O
.	O


This	O
often	O
is	O
attributed	O
to	O
poor	O
ability	O
to	O
draw	O
inferences	O
during	O
reading	O
and	O
to	O
inadequate	O
access	O
to	O
relevant	O
knowledge	O
.	O


The	O
current	O
study	O
tested	O
this	O
hypothesis	O
by	O
measuring	O
the	O
time	O
taken	O
to	O
read	B-I
the	I-I
same	I-I
question	I-I
,	I-I
relating	I-I
to	I-I
either	I-I
physical	I-I
or	I-I
social	I-I
world	I-I
knowledge	I-I
,	I-I
when	I-I
it	I-I
was	I-I
either	I-I
relevant	I-I
or	I-I
irrelevant	I-I
to	I-I
the	I-I
bridging	I-I
inference	I-I
evoked	I-I
by	I-I
a	I-I
preceding	I-I
two-sentence	I-I
vignette	I-I
.	I-I


In	O
the	O
study	O
,	O
16	B-P
normally	I-P
developing	I-P
adolescents	I-P
and	I-P
16	I-P
adolescents	I-P
with	I-P
autism	I-P
were	O
matched	O
on	O
word	O
reading	O
accuracy	O
,	O
chronological	O
age	O
,	O
and	O
vocabulary	O
but	O
differed	O
significantly	O
in	O
text	O
comprehension	O
.	O


A	O
strong	O
priming	O
effect	O
was	O
found	O
,	O
robust	O
over	O
participants	O
and	O
over	O
items	O
;	O
participants	O
read	O
those	O
questions	O
that	O
were	O
relevant	O
to	O
the	O
inference	O
evoked	O
by	O
the	O
vignette	O
faster	O
than	O
they	O
read	O
those	O
questions	O
that	O
were	O
irrelevant	O
,	O
and	O
no	O
interaction	O
with	O
group	O
membership	O
or	O
type	O
of	O
knowledge	O
was	O
found	O
.	O


This	O
indicates	O
that	O
readers	B-P
with	I-P
autism	I-P
,	O
just	O
like	O
controls	O
,	O
were	O
activating	O
appropriate	O
world	O
knowledge	O
primed	O
by	O
implicit	O
inferences	O
while	O
reading	O
the	O
vignettes	O
.	O


Thus	O
,	O
the	O
comprehension	O
problems	O
in	O
these	O
readers	O
can	O
not	O
be	O
attributed	O
to	O
an	O
inability	O
to	O
make	O
implicit	O
inferences	O
or	O
to	O
draw	O
on	O
relevant	O
world	O
knowledge	O
.	O


Instead	O
,	O
we	O
suggest	O
that	O
these	O
problems	O
must	O
be	O
sought	O
at	O
a	O
higher	O
level	O
of	O
text	O
processing	O
.	O


Most	O
effective	B-O
regimen	I-O
of	I-O
tranexamic	I-O
acid	I-O
in	O
knee	B-P
arthroplasty	I-P
:	I-P
a	O
prospective	O
randomized	O
controlled	O
study	O
in	O
240	B-P
patients	I-P
.	I-P


BACKGROUND	O
The	O
antifibrinolytic	B-I
tranexamic	I-I
acid	I-I
reduces	O
surgical	O
blood	O
loss	O
,	O
but	O
studies	O
have	O
not	O
identified	O
an	O
optimal	O
regimen	O
.	O


QUESTIONS/PURPOSES	O
We	O
studied	O
different	O
dosages	O
,	O
timings	O
,	O
and	O
modes	O
of	O
administration	O
to	O
identify	O
the	O
most	O
effective	O
regimen	O
of	O
tranexamic	B-I
acid	I-I
in	O
achieving	O
maximum	O
reduction	O
of	O
blood	O
loss	O
in	O
TKA	O
.	O


METHODS	O
We	O
prospectively	O
studied	O
five	B-P
regimens	I-P
(	I-P
four	I-P
intravenous	I-I
,	I-P
one	I-P
local	I-I
;	I-I
40	I-P
patients	I-P
each	I-P
)	I-P
with	I-P
a	I-P
control	I-P
group	I-P
(	O
no	O
tranexamic	B-I
acid	I-I
)	I-I
.	O


The	O
four	O
intravenous	B-I
(	O
10-mg/kg	O
dose	O
)	O
regimens	O
included	O
(	O
1	O
)	O
intraoperative	B-I
dose	I-I
(	I-I
IO	I-I
)	I-I
given	I-I
before	I-I
tourniquet	I-I
deflation	I-I
,	I-I
(	I-I
2	I-I
)	I-I
additional	I-I
preoperative	I-I
dose	I-I
(	I-I
POIO	I-I
)	I-I
,	I-I
(	I-I
3	I-I
)	I-I
additional	I-I
postoperative	I-I
dose	I-I
(	I-I
IOPO	I-I
)	I-I
,	I-I
and	I-I
(	I-I
4	I-I
)	I-I
all	I-I
three	I-I
doses	I-I
(	I-I
POIOPO	I-I
)	I-I
.	O


The	O
fifth	O
regimen	O
was	O
a	O
single	O
local	B-I
application	I-I
(	O
LA	O
)	O
.	O


Two	O
independent	O
parameters	O
of	O
drain	B-O
loss	I-O
and	I-O
total	I-O
blood	I-O
loss	I-O
,	I-O
calculated	I-O
by	I-O
the	I-O
hemoglobin	I-O
balance	I-O
method	I-O
,	O
were	O
evaluated	O
statistically	O
.	O


RESULTS	O
Both	O
parameters	O
were	O
reduced	O
in	O
all	O
five	O
regimens	O
as	O
against	O
the	O
control	O
.	O


A	O
significant	O
reduction	O
in	O
drain	B-O
loss	I-O
was	O
seen	O
in	O
the	O
POIO	O
,	O
IOPO	O
,	O
and	O
POIOPO	O
groups	O
whereas	O
total	O
blood	B-O
loss	I-O
was	O
significantly	O
reduced	O
in	O
the	O
POIO	O
,	O
POIOPO	O
,	O
and	O
LA	O
groups	O
.	O


The	O
POIOPO	O
group	O
had	O
the	O
least	O
drain	B-O
loss	I-O
(	O
303	O
mL	O
)	O
and	O
least	O
total	O
blood	B-O
loss	I-O
(	O
688	O
mL	O
)	O
.	O


The	O
IO	O
group	O
had	O
the	O
greatest	O
drain	B-O
loss	I-O
and	O
the	O
IOPO	O
group	O
the	O
greatest	O
total	B-O
blood	I-O
loss	I-O
.	I-O


CONCLUSIONS	O
Single-dose	O
tranexamic	B-I
acid	I-I
did	O
not	O
give	O
effective	O
results	O
.	O


The	O
two-dose	O
regimen	O
of	O
POIO	O
was	O
the	O
least	O
amount	O
necessary	O
for	O
effective	O
results	O
.	O


When	O
compared	O
against	O
the	O
control	O
,	O
this	O
regimen	O
produced	O
reduction	B-O
of	I-O
drain	I-O
loss	I-O
and	I-O
total	I-O
blood	I-O
loss	I-O
,	O
whereas	O
the	O
IOPO	O
regimen	O
did	O
not	O
.	O


The	O
three-dose	O
regimen	O
of	O
POIOPO	O
produced	O
maximum	O
effective	O
reduction	O
of	O
drain	B-O
loss	I-O
and	I-O
total	I-O
blood	I-O
loss	I-O
.	I-O


[	O
Effects	O
of	O
an	O
intensive	B-I
therapy	I-I
program	I-I
for	O
behaviorally	B-P
disordered	I-P
mentally	I-P
handicapped	I-P
patients	I-P
on	I-P
staff	I-P
personnel	I-P
in	I-P
residential	I-P
care	I-P
]	I-P
.	O


This	O
study	O
evaluates	O
the	O
effects	O
of	O
an	O
intensive	B-I
therapy	I-I
program	I-I
designed	O
for	O
mentally	B-P
handicapped	I-P
persons	I-P
with	I-P
severely	I-P
disturbed	I-P
or	I-P
autistic	I-P
behavior	I-P
on	I-P
their	I-P
staff	I-P
personal	I-P
which	I-P
had	I-P
an	I-P
active	I-P
role	I-P
in	I-P
the	I-P
program	I-P
.	I-P


The	O
staff	O
members	O
rated	O
their	O
professional	O
competence	O
,	O
quality	O
of	O
interaction	O
with	O
the	O
client	O
,	O
team	O
culture	O
and	O
work	O
satisfaction	O
before	O
and	O
after	O
being	O
engaged	O
in	O
the	O
program	O
,	O
with	O
additional	O
ratings	O
of	O
their	O
personal	O
aims	O
at	O
the	O
beginning	O
of	O
the	O
program	O
.	O


Three	O
sets	O
of	O
data	O
were	O
obtained	O
with	O
the	O
program	O
being	O
conducted	O
three	O
times	O
in	O
a	O
row	O
.	O


The	O
testings	O
of	O
the	O
related	O
as	O
well	O
as	O
the	O
independent	O
samples	O
show	O
differentiated	O
program	O
effects	O
.	O


The	O
main	O
effect	O
is	O
an	O
increase	O
of	O
the	O
professional	B-O
competence	I-O
and	I-O
quality	I-O
of	I-O
interaction	I-O
,	O
especially	O
by	O
the	O
qualified	O
staff	O
members	O
.	O


Trainees	O
put	O
emphasis	O
on	O
the	O
development	O
of	O
their	O
personal	O
relationship	O
with	O
the	O
client	O
.	O


The	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
impact	O
of	O
learning	O
processes	O
specific	O
to	O
the	O
roles	O
of	O
the	O
staff	O
members	O
and	O
motivational	O
factors	O
on	O
learning	O
and	O
therapy	O
outcome	O
,	O
along	O
with	O
institutional	O
conditions	O
influencing	O
successful	O
learning	O
.	O


Thus	O
the	O
program	O
facilitates	O
the	O
professional	O
and	O
interpersonal	O
learning	O
process	O
of	O
staff	O
members	O
in	O
a	O
specific	O
way	O
with	O
success	O
as	O
well	O
as	O
with	O
limitations	O
.	O


Human	O
motor	O
responses	O
to	O
simultaneous	O
aversive	B-I
stimulation	I-I
and	I-I
failure	I-I
on	O
a	O
valued	O
task	O
.	O


The	O
effects	O
of	O
presentation	O
of	O
an	O
aversive	B-I
stimulus	I-I
and	I-I
simultaneous	I-I
failure	I-I
on	I-I
a	I-I
bogus	I-I
intelligence	I-I
test	I-I
upon	O
a	O
subject	O
's	O
aggressive	B-O
reactions	I-O
were	O
studied	O
.	O


The	O
subject	B-P
's	I-P
fist	I-O
clenching	I-O
was	O
used	O
as	O
an	O
indicator	B-O
of	I-O
aggression	I-O
.	I-O


Four	O
conditions	O
,	O
generated	O
by	O
the	O
combinations	O
of	O
two	O
kinds	O
of	O
stimulus	O
delivered	O
to	O
the	O
subjects	O
(	B-I
aversive	I-I
or	I-I
nonaversive	I-I
)	I-I
and	O
two	O
outcomes	O
of	O
the	O
task	O
(	O
failure	O
or	O
success	O
)	O
,	O
were	O
investigated	O
.	O


20	B-P
female	I-P
and	I-P
20	I-P
male	I-P
students	I-P
(	I-P
ages	I-P
:	I-P
17-34	I-P
years	I-P
)	I-P
were	O
instructed	O
,	O
upon	O
the	O
reception	O
of	O
an	O
aversive	B-I
or	I-I
nonaversive	I-I
acoustic	I-I
signal	I-I
,	O
to	O
press	O
with	O
the	O
right	O
hand	O
a	O
device	O
that	O
displayed	O
a	O
slide	O
.	O


Each	O
slide	O
presented	O
an	O
item	O
from	O
an	O
intelligence	O
test	O
,	O
to	O
which	O
the	O
subjects	O
were	O
either	O
allowed	O
to	O
answer	O
successfully	O
(	O
success	O
)	O
or	O
not	O
(	O
failure	O
)	O
.	O


Failure	O
increased	O
the	O
subject	O
's	O
autonomic	B-O
arousal	I-O
,	I-O
as	I-O
measured	I-O
by	I-O
photoplethysmographic	I-O
sensors	I-O
,	O
in	O
all	O
stimulation	O
conditions	O
,	O
but	O
only	O
the	O
condition	O
with	O
aversive	O
stimulation	O
increased	O
the	O
speed	B-O
of	I-O
clenching	I-O
.	I-O


This	O
was	O
interpreted	O
as	O
indicating	O
subject	O
's	O
tendencies	B-O
to	I-O
aggression	I-O
.	I-O


These	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
effects	O
of	O
frustration	O
.	O


The	O
efficacy	O
of	O
a	O
herbal-based	B-I
toothpaste	I-I
on	O
the	O
control	O
of	O
plaque	B-P
and	I-P
gingivitis	I-P
.	I-P


A	O
double-blind	O
controlled	O
clinical	O
trial	O
with	O
parallel	O
groups	O
was	O
designed	O
to	O
investigate	O
the	O
effectiveness	O
of	O
a	O
herbal-based	B-I
toothpaste	I-I
in	O
the	O
control	O
of	O
plaque	O
and	O
gingivitis	O
as	O
compared	O
with	O
a	O
conventional	B-I
dentifrice	I-I
.	I-I


70	B-P
subjects	I-P
with	I-P
gingivitis	I-P
completed	O
the	O
6-week	O
study	O
.	O


All	B-P
participants	I-P
had	I-P
at	I-P
least	I-P
20	I-P
natural	I-P
teeth	I-P
with	I-P
no	I-P
probing	I-P
depths	I-P
greater	I-P
than	I-P
3	I-P
mm	I-P
and	I-P
a	I-P
plaque	I-P
index	I-P
of	I-P
2	I-P
or	I-P
more	I-P
at	I-P
baseline	I-P
.	I-P


At	O
baseline	O
,	O
both	O
groups	O
were	O
balanced	O
for	O
the	O
parameters	O
measured	O
:	O
plaque	B-O
index	I-O
,	I-O
plaque	I-O
vitality	I-O
,	I-O
gingival	I-O
index	I-O
,	I-O
bleeding	I-O
on	I-O
probing	I-O
and	I-O
gingival	I-O
crevicular	I-O
fluid	I-O
flow	I-O
.	I-O


At	O
the	O
end	O
of	O
the	O
trial	O
,	O
there	O
were	O
reductions	O
within	O
both	O
groups	O
,	O
however	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O


It	O
was	O
concluded	O
that	O
the	O
herbal	B-I
based	I-I
toothpaste	I-I
was	O
as	O
effective	O
as	O
the	O
conventionally	B-I
formulated	I-I
dentifrice	I-I
in	O
the	O
control	O
of	O
plaque	O
and	O
gingivitis	O
.	O


Laparoscopic	B-P
hysterectomy	I-P
:	I-P
is	O
dissecting	B-I
the	I-I
ureter	I-I
necessary	O
?	O
Laparoscopic	B-I
hysterectomy	I-I
has	O
been	O
first	O
reported	O
by	O
Reich	O
et	O
al	O
.	O


in	O
1989	O
,	O
which	O
confirmed	O
the	O
possibility	O
of	O
laparoscopic	O
hysterectomy	O
being	O
employed	O
as	O
a	O
replacement	O
of	O
the	O
vast	O
majority	O
of	O
traditional	O
abdominal	O
hysterectomies	O
.	O


There	O
are	O
three	O
critical	O
points	O
in	O
laparoscopic	O
hysterectomy	O
.	O


The	O
most	O
important	O
critical	O
point	O
is	O
to	O
identify	O
uterine	O
arteries	O
from	O
the	O
ureter	O
in	O
the	O
paracervical	O
area	O
.	O


Several	O
ureteral	B-O
injuries	I-O
at	O
operative	O
laparoscopy	O
have	O
been	O
reported	O
.	O


We	O
performed	O
two	B-P
hundred	I-P
and	I-P
thirty	I-P
laparoscopic	I-I
hysterectomies	I-I
during	I-P
the	I-P
period	I-P
from	I-P
March	I-P
1991	I-P
to	I-P
October	I-P
1993	I-P
.	I-P


Sixty	B-P
patients	I-P
were	I-P
later	I-P
included	I-P
in	I-P
this	I-P
study	I-P
.	I-P


Thirty	O
of	O
these	O
applied	O
the	O
technique	O
of	O
dissecting	B-I
the	I-I
ureter	I-I
at	O
the	O
initiation	O
of	O
laparoscopic	O
hysterectomy	O
.	O


Most	O
of	O
the	O
patients	O
were	O
discharged	O
on	O
the	O
second	O
postoperative	O
day	O
.	O


Although	O
dissecting	B-I
the	I-I
ureter	I-I
at	O
the	O
beginning	O
of	O
the	O
operation	O
did	O
not	O
produce	O
a	O
significant	O
discrepancy	B-O
in	O
operation	B-O
time	I-O
,	I-O
blood	I-O
loss	I-O
,	I-O
hospitalization	I-O
day	I-O
and	I-O
ureter	I-O
injury	I-O
when	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
uterine	O
arteries	O
,	O
however	O
,	O
may	O
be	O
confidently	O
desiccated	O
once	O
the	O
path	O
of	O
the	O
ureter	O
near	O
the	O
uterosacral	O
ligament	O
is	O
identified	O
.	O


A	O
randomized	O
multicenter	O
trial	O
comparing	O
resection	B-I
and	I-I
radiochemotherapy	I-I
for	O
resectable	B-P
locally	I-P
invasive	I-P
pancreatic	I-P
cancer	I-P
.	I-P


BACKGROUND	O
Though	O
the	O
outcome	O
of	O
resection	O
for	O
locally	O
invasive	O
pancreatic	O
cancer	O
is	O
still	O
poor	O
,	O
it	O
has	O
gradually	O
improved	O
in	O
Japan	B-P
,	O
and	O
the	O
5-year	B-O
survival	I-O
is	O
now	O
about	O
10	O
%	O
.	O


However	O
,	O
the	O
advantage	O
of	O
resection	B-I
over	O
radiochemotherapy	B-I
has	O
not	O
yet	O
been	O
confirmed	O
by	O
a	O
randomized	O
trial	O
.	O


We	O
conducted	O
this	O
study	O
to	O
compare	O
surgical	B-I
resection	I-I
alone	O
versus	O
radiochemotherapy	B-I
without	O
resection	O
for	O
locally	O
invasive	O
pancreatic	O
cancer	O
using	O
a	O
multicenter	O
randomized	O
design	O
.	O


METHODS	O
Patients	B-P
with	I-P
pancreatic	I-P
cancer	I-P
who	I-P
met	I-P
our	I-P
preoperative	I-P
criteria	I-P
for	I-P
inclusion	I-P
(	I-P
pancreatic	I-P
cancer	I-P
invading	I-P
the	I-P
pancreatic	I-P
capsule	I-P
without	I-P
involvement	I-P
of	I-P
the	I-P
superior	I-P
mesenteric	I-P
artery	I-P
or	I-P
the	I-P
common	I-P
hepatic	I-P
artery	I-P
,	I-P
or	I-P
without	I-P
distant	I-P
metastasis	I-P
)	I-P
underwent	I-P
laparotomy	I-P
.	I-P


Patients	O
with	O
operative	O
findings	O
consistent	O
with	O
our	O
criteria	O
were	O
randomized	O
into	O
a	O
radical	B-I
resection	I-I
group	I-I
and	I-I
a	I-I
radiochemotherapy	I-I
group	I-I
(	O
200	O
mg/m	O
(	O
2	O
)	O
/day	O
of	O
intravenous	B-I
5-fluorouracil	I-I
and	I-I
5040	I-I
cGy	I-I
of	I-I
radiotherapy	I-I
)	I-I
without	O
resection	O
.	O


The	O
2	O
groups	O
were	O
compared	O
for	O
mean	B-O
survival	I-O
,	I-O
hazard	I-O
ratio	I-O
,	I-O
1-year	I-O
survival	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
scores	I-O
,	I-O
and	I-O
hematologic	I-O
and	I-O
blood	I-O
chemical	I-O
data	I-O
.	I-O


RESULTS	O
Twenty	B-P
patients	I-P
were	I-P
assigned	I-P
to	I-P
the	I-P
resection	I-P
group	I-P
and	I-P
22	I-P
to	I-P
the	I-P
radiochemotherapy	I-I
group	I-P
.	I-P


There	O
was	O
1	O
operative	B-O
death	I-O
.	I-O


The	O
surgical	O
resection	O
group	O
had	O
better	O
results	O
than	O
the	O
radiochemotherapy	O
group	O
as	O
measured	O
by	O
1-year	B-O
survival	I-O
(	O
62	O
%	O
vs	O
32	O
%	O
,	O
P=.05	O
)	O
,	O
mean	B-O
survival	I-O
time	I-O
(	O
>	O
17	O
vs	O
11	O
months	O
,	O
P	O
<	O
.03	O
)	O
,	O
and	O
hazard	B-O
ratio	I-O
(	O
0.46	O
,	O
P=.04	O
)	O
.	O


There	O
were	O
no	O
differences	O
in	O
the	O
quality	B-O
of	I-O
life	I-O
score	I-O
or	O
laboratory	B-O
data	I-O
apart	O
from	O
increased	O
diarrhea	B-O
after	O
surgical	O
resection	O
.	O


CONCLUSIONS	O
Locally	B-P
invasive	I-P
pancreatic	I-P
cancer	I-P
without	I-P
distant	I-P
metastases	I-P
and	O
major	O
arterial	O
invasion	O
appears	O
to	O
be	O
best	O
treated	O
by	O
surgical	O
resection	O
.	O


Arm-cranking	B-I
exercise	I-I
reduced	O
oxidative	B-O
damage	I-O
in	O
adults	B-P
with	I-P
chronic	I-P
spinal	I-P
cord	I-P
injury	I-P
.	I-P


OBJECTIVE	O
To	O
assess	O
the	O
effect	O
of	O
a	O
12-week	O
arm-cranking	B-I
exercise	I-I
program	I-I
on	O
reducing	O
oxidative	B-O
damage	I-O
in	O
untrained	B-P
adults	I-P
with	I-P
chronic	I-P
spinal	I-P
cord	I-P
injury	I-P
(	I-P
SCI	I-P
)	I-P
.	I-P


DESIGN	O
Randomized	O
controlled	O
trial	O
.	O


SETTING	O
Community-based	O
supervised	O
intervention	O
.	O


PARTICIPANTS	O
Male	B-P
adults	I-P
with	I-P
complete	I-P
SCI	I-P
at	I-P
or	I-P
below	I-P
the	I-P
fifth	I-P
thoracic	I-P
level	I-P
(	I-P
T5	I-P
)	I-P
(	I-P
N=17	I-P
)	I-P
volunteered	I-P
for	I-P
this	I-P
study	I-P
.	I-P


Participants	O
were	O
randomly	O
allocated	O
to	O
the	O
intervention	B-P
(	I-P
n=9	I-P
)	I-P
or	I-P
control	I-I
(	I-P
n=8	I-P
)	I-P
group	I-P
using	O
a	O
concealed	O
method	O
.	O


INTERVENTION	O
A	O
12-week	B-I
arm-cranking	I-I
exercise	I-I
program	I-I
,	O
3	O
sessions/wk	O
,	O
consisting	B-I
of	I-I
warming-up	I-I
(	I-I
10-15min	I-I
)	I-I
followed	I-I
by	I-I
a	I-I
main	I-I
part	I-I
in	I-I
arm-crank	I-I
(	O
20-30min	O
[	O
increasing	O
2min	O
and	O
30s	O
every	O
3wk	O
]	O
)	O
at	O
a	O
moderate	O
work	O
intensity	O
of	O
50	O
%	O
to	O
65	O
%	O
of	O
the	O
heart	O
rate	O
reserve	O
(	O
starting	O
at	O
50	O
%	O
and	O
increasing	O
5	O
%	O
every	O
3	O
weeks	O
)	O
and	O
by	O
a	O
cooling-down	B-I
period	O
(	O
5-10min	O
)	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Plasmatic	B-O
levels	I-O
of	I-O
total	I-O
antioxidant	I-O
status	I-O
as	O
well	O
as	O
erythrocyte	B-O
glutathione	I-O
peroxidase	I-O
activity	I-O
were	O
measured	O
.	O


Lipid	B-O
and	I-O
protein	I-O
oxidation	I-O
were	O
determined	O
as	O
malondialdehyde	B-O
and	I-O
carbonyl	I-O
group	I-O
levels	I-O
,	O
respectively	O
.	O


Furthermore	O
,	O
physical	B-O
fitness	I-O
and	I-O
body	I-O
composition	I-O
were	O
assessed	O
.	O


RESULTS	O
When	O
compared	O
with	O
baseline	O
results	O
,	O
maximum	B-O
oxygen	I-O
consumption	I-O
was	O
significantly	O
increased	O
(	O
P=.031	O
)	O
,	O
suggesting	O
an	O
improvement	O
in	O
physical	B-O
fitness	I-O
in	O
the	O
intervention	O
group	O
.	O


Regarding	O
the	O
antioxidant	O
defense	O
system	O
,	O
it	O
was	O
found	O
that	O
both	O
total	B-O
antioxidant	I-O
status	I-O
(	O
P=.014	O
)	O
and	O
erythrocyte	B-O
glutathione	I-O
peroxidase	I-O
activity	I-O
(	O
P=.027	O
)	O
were	O
significantly	O
increased	O
at	O
the	O
end	O
of	O
the	O
training	O
program	O
.	O


As	O
a	O
consequence	O
,	O
plasmatic	B-O
levels	I-O
of	I-O
malondialdehyde	I-O
(	O
P=.008	O
)	O
and	O
carbonyl	O
groups	O
(	O
P=.022	O
)	O
were	O
significantly	O
reduced	O
.	O


CONCLUSION	O
A	O
12-week	O
arm-cranking	B-I
exercise	I-I
program	I-I
improved	O
the	O
antioxidant	B-O
defense	I-O
system	I-O
in	I-P
adults	I-P
with	I-P
chronic	I-P
SCI	I-P
,	O
which	O
may	O
finally	O
attenuate	O
both	O
lipid	B-O
and	I-O
protein	I-O
oxidation	I-O
in	O
this	O
population	O
.	O


Cobedding	B-I
of	I-I
twin	I-I
premature	I-I
infants	I-I
:	I-I
calming	O
effects	B-O
on	O
pain	B-O
responses	I-O
.	I-O


BACKGROUND	O
The	O
purpose	O
of	O
this	O
trial	O
was	O
to	O
determine	O
whether	O
cobedding	B-I
of	I-I
preterm	I-I
twins	I-I
has	O
analgesic	B-O
effects	I-O
during	O
heel	O
lancing	O
or	O
not	O
.	O


METHODS	O
One	B-P
hundred	I-P
premature	I-P
twins	I-P
(	I-P
50	I-P
sets	I-P
)	I-P
born	I-P
between	I-P
26	I-P
weeks	I-P
'	I-P
and	I-P
34	I-P
weeks	I-P
'	I-P
gestation	I-P
undergoing	I-P
heel	I-P
blood	I-P
sampling	I-P
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
:	O
the	O
cobedding	B-I
group	I-I
(	I-I
receiving	I-I
care	I-I
in	I-I
the	I-I
same	I-I
incubator	I-I
)	I-I
and	O
the	O
standard	B-I
care	I-I
group	I-I
(	I-I
receiving	I-I
care	I-I
in	I-I
separate	I-I
incubators	I-I
)	I-I
.	I-I


Pain	B-O
was	I-O
assessed	I-O
using	I-O
the	I-O
premature	I-O
infant	I-O
pain	I-O
profile	I-O
score	I-O
.	I-O


Duration	B-O
of	I-O
crying	I-O
was	O
measured	O
after	O
heel	O
blood	O
sampling	O
,	O
and	O
salivary	B-O
cortisol	I-O
was	O
measured	O
prior	O
to	O
and	O
after	O
heel	O
blood	O
sampling	O
.	O


RESULTS	O
Infants	O
in	O
the	O
standard	B-I
care	I-I
group	O
cried	B-O
for	I-O
a	I-O
longer	I-O
time	I-O
during	O
heel	O
lancing	O
than	O
those	O
in	O
the	O
cobedding	B-I
group	O
(	O
42.6	O
±	O
19.8	O
seconds	O
vs.	O
36.4	O
±	O
21.7	O
seconds	O
,	O
p	O
=	O
0.03	O
)	O
.	O


The	B-O
mean	I-O
premature	I-O
infant	I-O
pain	I-O
profile	I-O
score	I-O
after	O
heel	O
lancing	O
was	B-O
significantly	I-O
higher	I-O
in	O
the	B-I
standard	I-I
care	I-I
group	O
(	O
9.8	O
±	O
2.6	O
vs.	O
8.06	O
±	O
2.8	O
,	O
p	O
=	O
0.002	O
)	O
.	O


The	B-O
mean	I-O
salivary	I-O
cortisol	I-O
after	O
heel	O
lancing	O
was	O
also	B-O
significantly	I-O
higher	I-O
in	O
the	B-I
standard	I-I
care	I-I
group	O
(	O
24.3	O
±	O
7.4	O
nmol/L	O
vs.	O
20.8	O
±	O
7.4	O
nmol/L	O
,	O
p	O
=	O
0.02	B-O
)	I-O
.	I-O


No	B-O
significant	I-O
adverse	I-O
effects	I-O
were	O
seen	B-I
with	I-I
cobedding	I-I
.	O


CONCLUSION	B-I
Cobedding	I-I
is	O
a	O
comforting	O
measure	B-P
for	I-P
twin	I-P
premature	I-P
infants	I-P
during	O
heel	O
lancing	O
,	O
which	O
can	O
be	O
performed	O
without	O
any	O
significant	B-O
adverse	I-O
effects	I-O
.	O


Effect	O
of	O
flurbiprofen	B-I
sodium	I-I
on	O
pupillary	B-O
dilatation	I-O
during	O
scleral	B-P
buckling	I-P
surgery	I-P
.	I-P


Maintenance	O
of	O
pupillary	B-O
dilatation	I-O
is	O
necessary	O
for	O
success	O
of	O
scleral	B-P
buckling	I-P
procedures	I-P
.	I-P


The	O
efficacy	O
of	O
0.03	B-I
%	I-I
flurbiprofen	I-I
in	O
preventing	O
intraoperative	O
miosis	O
was	O
evaluated	O
by	O
a	O
prospective	O
randomized	O
,	O
double-masked	O
controlled	O
trial	O
of	O
60	B-P
patients	I-P
.	I-P


Thirty	B-P
patients	I-P
received	O
0.03	O
%	O
flurbiprofen	B-I
6	O
times	O
at	O
15	O
minute	O
intervals	O
90	O
minutes	O
preoperatively	O
in	O
addition	O
to	O
the	O
routine	O
dilation	O
regimen	O
.	O


The	O
treated	O
group	O
had	O
a	O
mean	B-O
pupillary	I-O
decrease	I-O
of	O
1.88	O
mm	O
and	O
the	O
control	O
group	O
had	O
a	O
decrease	O
of	O
1.57	O
mm	O
(	O
p	O
>	O
0.05	O
)	O
.	O


Flurbiprofen	B-I
did	O
not	O
affect	O
the	O
pupillary	B-O
size	I-O
at	O
any	O
step	O
of	O
the	O
surgery	O
.	O


Factors	O
such	O
as	O
age	B-O
of	I-O
the	I-O
patient	I-O
,	I-O
lens	I-O
status	I-O
,	I-O
number	I-O
of	I-O
cryo	I-O
applications	I-O
,	I-O
duration	I-O
of	I-O
surgery	I-O
,	I-O
and	I-O
the	I-O
size	I-O
and	I-O
extent	I-O
of	I-O
buckle	I-O
were	O
assessed	O
.	O


The	O
use	O
of	O
flurbiprofen	B-I
did	O
not	O
affect	O
the	O
mean	B-O
pupillary	I-O
change	I-O
for	O
any	O
of	O
these	O
groups	O
.	O


Preoperative	O
use	O
of	O
flurbiprofen	B-I
does	O
not	O
significantly	O
decrease	O
intraoperative	B-O
miosis	I-O
during	I-O
scleral	I-O
buckling	I-O
procedures	I-O
.	I-O


Growth	B-O
hormone	I-O
(	I-O
GH	I-O
)	I-O
responses	I-O
to	O
GH-releasing	B-I
hormone	I-I
alone	I-I
or	O
combined	B-I
with	I-I
arginine	I-I
in	O
patients	B-P
with	I-P
adrenal	I-P
incidentaloma	I-P
:	I-P
evidence	O
for	O
enhanced	O
somatostatinergic	O
tone	O
.	O


Spontaneous	O
and	O
stimulated	O
GH	O
secretion	O
is	O
blunted	O
in	O
hypercortisolemic	O
states	O
due	O
to	O
increased	O
hypothalamic	O
somatostatinergic	O
tone	O
.	O


However	O
,	O
no	O
data	O
are	O
available	O
on	O
the	O
characteristics	O
of	O
GH	O
secretion	O
in	O
patients	B-P
with	I-P
incidentally	I-P
discovered	I-P
adrenal	I-P
adenomas	I-P
.	I-P


They	O
represent	O
an	O
interesting	O
model	O
for	O
studying	O
GH	O
secretion	O
,	O
as	O
a	O
slight	O
degree	O
of	O
cortisol	O
excess	O
may	O
frequently	O
be	O
observed	O
in	O
such	O
patients	B-P
who	I-P
do	I-P
not	I-P
present	I-P
with	I-P
any	I-P
clear	I-P
Cushingoid	I-P
sign	I-P
.	I-P


In	O
the	O
present	O
study	O
,	O
10	B-P
patients	I-P
(	I-P
3	I-P
men	I-P
and	I-P
7	I-P
women	I-P
,	I-P
aged	I-P
48-63	I-P
yr	I-P
)	I-P
with	I-P
an	I-P
adrenal	I-P
mass	I-P
discovered	I-P
serendipitously	I-P
underwent	O
,	O
on	O
separate	O
occasions	O
,	O
a	O
GHRH	B-I
injection	I-I
alone	I-I
or	O
combined	B-I
with	I-I
an	I-I
infusion	I-I
of	I-I
the	I-I
functional	I-I
somatostatin	I-I
antagonist	I-I
,	I-I
arginine	I-I
.	I-I


Thirteen	B-P
age-matched	I-P
healthy	I-P
volunteers	I-P
served	I-P
as	I-P
controls	I-I
.	I-I


Briefly	O
,	O
arginine	B-I
(	I-I
30	I-I
g	I-I
)	I-I
was	I-I
infused	I-I
from	I-I
-30	I-I
to	I-I
0	I-I
min	I-I
,	I-I
and	I-I
GHRH	I-I
(	I-I
100	I-I
microg	I-I
)	I-I
was	I-I
injected	I-I
as	I-I
a	I-I
bolus	I-I
at	I-I
0	I-I
min	I-I
,	O
with	O
measurement	O
of	O
serum	B-I
GH	I-I
[	I-I
immunoradiometric	I-I
assay	I-I
(	I-I
IRMA	I-I
)	I-I
]	I-I
every	O
15	O
min	O
for	O
150	O
min	O
.	O


Plasma	B-I
IGF-I	I-I
(	I-I
RIA	I-I
after	I-I
acid-ethanol	I-I
extraction	I-I
)	I-I
was	O
measured	O
in	O
a	O
morning	O
sample	O
.	O


The	O
diagnosis	O
of	O
cortical	O
adenoma	O
was	O
based	O
on	O
computed	O
tomography	O
features	O
and	O
pattern	O
of	O
uptake	O
on	O
adrenal	O
scintigraphy	O
.	O


Patients	B-P
with	I-P
obesity	I-P
and/or	I-P
diabetes	I-P
were	I-P
excluded	I-P
.	I-P


The	O
study	O
design	O
included	O
also	O
an	O
endocrine	O
work-up	O
aimed	O
to	O
study	O
the	O
hypothalamic-pituitary-adrenal	B-O
axis	I-O
[	I-O
urinary	I-O
free	I-O
cortisol	I-O
(	I-O
UFC	I-O
)	I-O
excretion	I-O
,	I-O
serum	I-O
cortisol	I-O
at	I-O
0800	I-O
h	I-O
,	I-O
plasma	I-O
ACTH	I-O
at	I-O
0800	I-O
h	I-O
,	I-O
morning	I-O
cortisol	I-O
after	I-O
overnight	I-O
1	I-O
mg	I-O
dexamethasone	I-O
]	I-O
.	I-O


Five	O
of	O
10	O
patients	O
showed	O
abnormalities	B-O
of	I-O
the	I-O
hypothalamic-pituitary-adrenal	I-O
axis	I-O
,	O
including	O
borderline	B-O
or	I-O
increased	I-O
UFC	I-O
excretion	I-O
in	O
4	O
of	O
them	O
accompanied	O
by	O
blunted	O
ACTH	O
in	O
2	O
cases	O
and	O
failure	O
of	O
cortisol	O
to	O
suppress	O
after	O
dexamethasone	O
in	O
1	O
;	O
the	O
fifth	O
patient	O
displayed	O
low	O
ACTH	O
and	O
resistance	O
to	O
dexamethasone	O
suppression	O
.	O


However	O
,	O
all	O
patients	O
had	O
a	O
unilateral	O
uptake	O
of	O
the	O
tracer	O
on	O
the	O
side	O
of	O
the	O
mass	O
with	O
suppression	O
of	O
the	O
contralateral	O
normal	O
adrenal	O
gland	O
.	O


As	O
a	O
group	O
,	O
the	O
patients	O
displayed	O
greater	O
UFC	B-O
excretion	I-O
and	I-O
lower	I-O
ACTH	I-O
concentrations	I-O
than	O
the	O
controls	O
.	O


GH	B-O
release	I-O
after	I-O
GHRH	I-O
treatment	I-O
was	O
blunted	O
in	O
patients	B-P
bearing	I-P
adrenal	I-P
incidentaloma	I-P
compared	O
with	O
controls	O
(	O
GH	O
peak	O
,	O
5.7	O
+/-	O
5.2	O
vs.	O
18.0	O
+/-	O
7.0	O
microg/L	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
whereas	O
GHRH	B-I
plus	I-I
arginine	I-I
was	O
able	O
to	O
elicit	O
a	O
comparable	O
response	O
in	O
the	O
2	O
groups	O
(	O
GH	O
peak	O
,	O
33.5	O
+/-	O
20.3	O
vs.	O
33.7	O
+/-	O
17.5	O
microg/L	O
;	O
P	O
=	O
NS	O
)	O
.	O


The	O
ratio	O
between	O
GH	B-O
peaks	I-O
after	I-O
GHRH	I-O
plus	I-O
arginine	I-O
and	I-O
after	I-O
GHRH	I-O
plus	I-O
saline	I-O
was	O
significantly	O
greater	O
in	O
patients	O
than	O
in	O
controls	O
(	O
751	O
+/-	O
531	O
%	O
vs.	O
81	O
+/-	O
45	O
%	O
;	O
P	O
=	O
0.0001	O
)	O
.	O


Similar	O
data	O
were	O
obtained	O
when	O
comparing	O
GH	O
area	O
under	O
the	O
curve	O
after	O
GHRH	O
plus	O
saline	O
or	O
GHRH	O
plus	O
arginine	O
between	O
the	O
2	O
groups	O
.	O


In	O
summary	O
,	O
the	O
present	O
data	O
suggest	O
that	O
in	O
patients	B-P
with	I-P
incidental	I-P
adrenal	I-P
adenomas	I-P
the	O
GH	B-O
response	I-O
to	O
GHRH	O
is	O
blunted	O
due	O
to	O
increased	O
somatostatinergic	B-O
tone	I-O
,	O
as	O
it	O
can	O
be	O
restored	O
to	O
normal	O
by	O
pretreatment	O
with	O
the	O
functional	O
somatostatin	O
antagonist	O
arginine	O
.	O


The	O
blunted	O
GH	O
release	O
to	O
GHRH	O
may	O
be	O
an	O
early	O
and	O
long	O
lasting	O
sign	O
of	O
autonomous	O
cortisol	O
secretion	O
by	O
the	O
adrenal	O
adenoma	O
.	O


A	O
home	B-I
visiting	I-I
asthma	I-I
education	I-I
program	I-I
:	I-I
challenges	O
to	O
program	O
implementation	O
.	O


This	O
study	O
describes	O
the	O
implementation	O
of	O
a	O
nurse	B-I
home	I-I
visiting	I-I
asthma	I-I
education	I-I
program	I-I
for	O
low-income	B-P
African	I-P
American	I-P
families	I-P
of	I-P
young	I-P
children	I-P
with	I-P
asthma	I-P
.	I-P


Of	B-P
55	I-P
families	I-P
,	I-P
71	I-P
%	I-P
completed	I-P
the	I-P
program	I-P
consisting	O
of	O
eight	O
lessons	O
.	O


The	O
achievement	B-O
of	I-O
learning	I-O
objectives	I-O
was	O
predicted	O
by	O
caregiver	B-O
factors	I-O
,	I-O
such	I-O
as	I-O
education	I-O
,	I-O
presence	I-O
of	I-O
father	I-O
or	I-O
surrogate	I-O
father	I-O
in	I-O
the	I-O
household	I-O
,	I-O
and	I-O
safety	I-O
of	I-O
the	I-O
neighborhood	I-O
,	O
but	O
not	O
by	O
child	B-O
factors	I-O
,	I-O
such	I-O
as	I-O
age	I-O
or	I-O
severity	I-O
of	I-O
asthma	I-O
as	O
implied	O
by	O
the	O
prescribed	O
asthma	O
medication	O
regimen	O
.	O


Incompatibility	O
between	O
the	O
scheduling	O
needs	O
of	O
the	O
families	O
and	O
the	O
nurse	O
home	O
visitors	O
was	O
a	O
major	O
obstacle	O
in	O
delivering	O
the	O
program	O
on	O
time	O
,	O
despite	O
the	O
flexibility	O
of	O
the	O
nurse	O
home	O
visitors	O
.	O


The	O
authors	O
suggest	O
that	O
future	O
home-based	B-I
asthma	I-I
education	I-I
programs	I-I
contain	O
a	O
more	O
limited	O
number	B-O
of	I-O
home	I-O
visits	I-O
but	O
add	O
telephone	O
follow-ups	O
and	O
address	O
the	O
broader	O
needs	O
of	O
low-income	B-P
families	I-P
that	O
most	O
likely	O
function	O
as	O
barriers	O
to	O
program	O
success	O
.	O


Correlations	O
between	O
the	O
clinical	B-O
,	I-O
histological	I-O
and	I-O
neurophysiological	I-O
examinations	I-O
in	O
patients	B-P
before	I-P
and	I-P
after	I-P
parotid	I-I
gland	I-I
tumor	I-I
surgery	I-I
:	I-I
verification	O
of	O
facial	O
nerve	O
transmission	O
.	O


Parotid	O
gland	O
tumor	O
surgery	O
sometimes	O
leads	O
to	O
facial	O
nerve	O
paralysis	O
.	O


Malignant	O
more	O
than	O
benign	O
tumors	O
determine	O
nerve	O
function	O
preoperatively	O
,	O
while	O
postoperative	O
observations	O
based	O
on	O
clinical	O
,	O
histological	O
and	O
neurophysiological	O
studies	O
have	O
not	O
been	O
reported	O
in	O
detail	O
.	O


The	O
aims	O
of	O
this	O
pilot	O
study	O
were	O
evaluation	O
and	O
correlations	O
of	O
histological	B-O
properties	I-O
of	I-O
tumor	I-O
(	I-O
its	I-O
size	I-O
and	I-O
location	I-O
)	I-O
and	O
clinical	B-O
and	I-O
neurophysiological	I-O
assessment	I-O
of	I-O
facial	I-O
nerve	I-O
function	I-O
pre-	I-O
and	I-O
post-operatively	I-O
(	O
1	O
and	O
6	O
months	O
)	O
.	O


Comparative	O
studies	O
included	O
17	B-P
patients	I-P
with	I-P
benign	I-P
(	I-P
n	I-P
=	I-P
13	I-P
)	I-P
and	I-P
malignant	I-P
(	I-P
n	I-P
=	I-P
4	I-P
)	I-P
tumors	I-P
.	I-P


Clinical	B-O
assessment	I-O
was	O
based	O
on	O
House-Brackmann	B-O
scale	I-O
(	I-O
H-B	I-O
)	I-O
,	I-O
neurophysiological	I-O
diagnostics	I-O
included	I-O
facial	I-O
electroneurography	I-O
[	I-O
ENG	I-O
,	I-O
compound	I-O
muscle	I-O
action	I-O
potential	I-O
(	I-O
CMAP	I-O
)	I-O
]	I-O
,	I-O
mimetic	I-O
muscle	I-O
electromyography	I-O
(	I-O
EMG	I-O
)	I-O
and	I-O
blink-reflex	I-O
examinations	I-O
(	I-O
BR	I-O
)	I-O
.	I-O


Mainly	O
grade	O
I	O
of	O
H-B	B-O
was	O
recorded	O
both	O
pre-	O
(	O
n	O
=	O
13	O
)	O
and	O
post-operatively	O
(	O
n	O
=	O
12	O
)	O
in	O
patients	B-P
with	I-P
small	I-P
(	I-P
1.5-2.4	I-P
cm	I-P
)	I-P
benign	I-P
tumors	I-P
located	I-P
in	I-P
superficial	I-P
lobes	I-P
.	I-P


Patients	B-P
with	I-P
medium	I-P
size	I-P
(	I-P
2.5-3.4	I-P
cm	I-P
)	I-P
malignant	I-P
tumors	I-P
in	I-P
both	I-P
lobes	I-P
were	O
scored	O
at	O
grade	O
I	O
(	O
n	O
=	O
2	O
)	O
and	O
III	O
(	O
n	O
=	O
2	O
)	O
pre-	O
and	O
mainly	O
VI	O
(	O
n	O
=	O
4	O
)	O
post-operatively	O
.	O


CMAP	B-O
amplitudes	I-O
after	O
stimulation	O
of	O
mandibular	O
marginal	O
branch	O
were	O
reduced	O
at	O
about	O
25	O
%	O
in	O
patients	B-P
with	I-P
benign	I-P
tumors	I-P
after	O
surgery	O
.	O


In	O
the	O
cases	O
of	O
malignant	O
tumors	O
CMAPs	B-O
were	O
not	O
recorded	O
following	O
stimulation	O
of	O
any	O
branch	O
.	O


A	O
similar	O
trend	O
was	O
found	O
for	O
BR	B-O
results	I-O
.	I-O


H-B	B-O
and	I-O
ENG	I-O
results	O
revealed	O
positive	O
correlations	O
between	O
the	O
type	O
of	O
tumor	O
and	O
surgery	O
with	O
facial	O
nerve	O
function	O
.	O


Neurophysiological	O
studies	O
detected	O
clinically	B-O
silent	I-O
facial	I-O
nerve	I-O
neuropathy	I-O
of	I-O
mandibular	I-O
marginal	I-O
branch	I-O
in	O
postoperative	O
period	O
.	O


Needle	B-O
EMG	I-O
,	I-O
ENG	I-O
and	I-O
BR	I-O
examinations	I-O
allow	O
for	O
the	O
evaluation	O
of	O
face	B-O
muscles	I-O
reinnervation	I-O
and	I-O
facial	I-O
nerve	I-O
regeneration	I-O
.	I-O


Comparison	O
of	O
arbutamine	B-I
and	O
exercise	B-I
echocardiography	I-I
in	O
diagnosing	B-P
myocardial	I-P
ischemia	I-P
.	I-P


Arbutamine	B-I
is	O
a	O
new	O
catecholamine	O
designed	O
for	O
use	O
as	O
a	O
pharmacologic	O
stress	O
agent	O
.	O


This	O
study	O
compared	O
the	O
sensitivity	O
of	O
arbutamine	B-I
with	O
symptom-limited	B-I
exercise	I-I
to	O
induce	O
echocardiographic	B-O
signs	I-O
of	I-O
ischemia	I-O
.	I-O


Arbutamine	B-I
was	O
administered	O
by	O
a	O
computerized	O
closed-loop	O
delivery	O
system	O
that	O
controls	O
the	O
infusion	O
rate	O
of	O
arbutamine	B-I
toward	O
a	O
predefined	O
rate	O
of	O
heart	O
rate	O
increase	O
and	O
maximum	O
heart	O
rate	O
limit	O
.	O


Beta	O
blockers	O
were	O
stopped	O
>	O
or	O
=	O
48	O
hours	O
before	O
both	O
tests	O
.	O


Stress	O
was	O
stopped	O
for	O
intolerable	O
symptoms	O
,	O
or	O
clinical	O
,	O
electrocardiographic	O
or	O
echocardiographic	O
signs	O
of	O
ischemia	O
(	O
new	O
or	O
worsening	O
wall	O
motion	O
abnormality	O
)	O
,	O
target	O
heart	O
rate	O
(	O
>	O
or	O
=	O
85	O
%	O
age	O
predicted	O
maximum	O
heart	O
rate	O
)	O
,	O
or	O
plateau	O
of	O
heart	O
rate	O
response	O
.	O


Thirty-seven	B-P
patients	I-P
were	I-P
entered	I-P
into	I-P
the	I-P
study	I-P
(	I-P
35	I-P
arbutamine	I-I
and	I-P
exercise	I-I
,	I-P
1	I-P
arbutamine	I-I
only	I-P
,	I-P
1	I-P
exercise	I-I
only	I-P
)	I-P
,	I-P
of	I-P
which	I-P
30	I-P
had	I-P
angiographic	I-P
evidence	I-P
of	I-P
coronary	I-P
artery	I-P
disease	I-P
(	I-P
>	I-P
or	I-P
=	I-P
50	I-P
%	I-P
lumen	I-P
diameter	I-P
narrowing	I-P
)	I-P
.	I-P


Rate-pressure	B-O
product	I-O
increased	O
significantly	O
in	O
response	O
to	O
both	O
stress	O
modalities	O
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
significantly	O
greater	O
with	O
exercise	O
(	O
11,308	O
+/-	O
2,443	O
)	O
than	O
with	O
arbutamine	O
(	O
9,486	O
+/-	O
2,479	O
,	O
p	O
<	O
0.001	O
)	O
.	O


The	O
time	B-O
to	I-O
maximum	I-O
heart	I-O
rate	I-O
was	O
longer	O
during	O
arbutamine	B-I
stress	O
echocardiography	O
than	O
during	O
exercise	B-I
testing	O
(	O
17.3	O
+/-	O
9.4	O
versus	O
9.3	O
+/-	O
4.2	O
minutes	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
.	O


There	O
were	O
more	O
patients	O
with	O
interpretable	O
echo	O
data	O
for	O
arbutamine	B-I
(	O
82	O
%	O
)	O
than	O
for	O
exercise	B-I
(	O
67	O
%	O
)	O
.	O


Sensitivity	B-O
for	I-O
recognition	I-O
of	I-O
myocardial	I-O
ischemia	I-O
was	O
94	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
70	O
%	O
to	O
100	O
%	O
)	O
and	O
88	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
62	O
%	O
to	O
98	O
%	O
)	O
,	O
respectively	O
.	O


The	O
most	O
frequent	O
adverse	B-O
events	I-O
during	O
arbutamine	B-I
(	O
n	O
=	O
36	O
)	O
were	O
dyspnea	B-O
(	O
5.6	O
%	O
)	O
and	O
tremor	B-O
(	O
5.6	O
%	O
)	O
.	O


Two	O
arbutamine	B-I
stress	O
tests	O
were	O
discontinued	O
due	O
to	O
arrhythmias	B-O
:	I-O
1	O
patient	O
had	O
premature	B-O
atrial	I-O
and	I-O
ventricular	I-O
beats	I-O
,	O
and	O
the	O
other	O
had	O
premature	B-O
atrial	I-O
contractions	I-O
and	I-O
atrial	I-O
fibrillation	I-O
.	I-O


Arrhythmias	B-O
were	I-O
well	I-O
tolerated	I-O
and	I-O
resolved	I-O
without	O
sequelae	O
.	O


In	O
conclusion	O
,	O
the	O
sensitivity	O
of	O
arbutamine	B-I
to	O
induce	O
echocardiographic	B-O
signs	I-O
of	I-O
ischemia	I-O
was	O
similar	O
to	O
that	O
of	O
exercise	B-I
despite	O
a	O
lower	O
rate-pressure	B-O
product	I-O
.	I-O


Arbutamine	B-I
was	O
well	B-O
tolerated	I-O
and	I-O
provides	I-O
a	I-O
reliable	I-O
alternative	I-O
to	I-O
exercise	I-O
echocardiography	I-O
.	I-O


The	O
importance	O
of	O
the	O
dual-switch	B-I
valve	I-I
for	O
the	O
treatment	O
of	O
adult	B-P
normotensive	I-P
or	I-P
hypertensive	I-P
hydrocephalus	I-P
.	I-P


Since	O
the	O
beginning	O
of	O
1995	O
the	O
new	B-P
hydrostatic	I-I
dual-switch	I-I
valve	I-I
(	I-I
DSV	I-I
)	I-I
was	I-P
implanted	I-P
in	I-P
35	I-P
adult	I-P
patients	I-P
with	I-P
hydrocephalus	I-P
of	I-P
different	I-P
etiology	I-P
.	I-P


26	B-P
patients	I-P
suffered	I-P
from	I-P
normotensive	I-P
hydrocephalus	I-P
(	I-P
10	I-P
idiopathic	I-P
and	I-P
16	I-P
symptomatic	I-P
)	I-P
,	I-P
and	I-P
9	I-P
patients	I-P
from	I-P
hypertensive	I-P
hydrocephalus	I-P
of	I-P
various	I-P
origin	I-P
.	I-P


The	O
first	O
21	O
cases	O
of	O
this	O
cohort	O
were	O
compared	O
in	O
a	O
randomized	O
study	O
with	O
a	O
comparable	O
group	O
of	O
21	O
hydrocephalic	O
patients	O
who	O
received	O
a	O
conventional	B-I
differential-pressure	I-I
(	I-I
DP-	I-I
)	I-I
valve	I-I
.	I-I


The	O
clinical	O
status	O
and	O
CT	O
were	O
assessed	O
prior	O
to	O
shunting	O
,	O
14	O
days	O
and	O
3	O
and	O
6	O
months	O
after	O
the	O
operation	O
.	O


The	O
reduction	O
of	O
ventricular	B-O
size	I-O
was	O
evaluated	O
by	O
the	O
measurement	O
of	O
the	O
Evans	O
Index	O
.	O


The	O
CT	O
follow-up	O
in	O
the	O
DSV	B-I
group	O
was	O
characterized	O
by	O
an	O
only	O
minimal	O
(	O
14	O
)	O
or	O
only	O
slight	O
(	O
16	O
)	O
reduction	O
of	O
ventricular	O
size	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
.	O


A	O
comparison	O
of	O
21	B-P
patients	I-P
with	O
a	O
DSV	B-I
and	O
the	O
patients	O
with	O
DP	B-I
valves	I-I
,	O
evaluated	O
by	O
measuring	O
the	O
reduction	O
of	O
the	O
Evans	B-O
Index	I-O
,	O
revealed	O
a	O
distinctly	O
higher	O
percentage	O
of	O
significant	O
regressions	O
in	O
the	O
DP	B-I
valve	I-I
collective	O
,	O
without	O
doubt	O
due	O
to	O
chronic	O
overdrainage	O
.	O


The	O
overall	O
clinical	O
result	O
of	O
our	O
35	B-P
patients	I-P
with	O
a	O
DSV	B-I
was	O
excellent	O
and	O
good	O
in	O
31	O
patients	O
,	O
but	O
the	O
outcome	O
seems	O
to	O
be	O
more	O
dependent	O
on	O
the	O
preshunt	B-O
damage	I-O
of	I-O
the	I-O
brain	I-O
than	O
on	O
hydrocephalic	B-O
aspects	I-O
.	I-O


A	O
neglegible	O
incidence	O
of	O
subdural	B-O
effusions	I-O
in	O
the	O
DSV	B-I
group	O
compared	O
to	O
11	O
cases	O
in	O
the	O
DP	B-I
valve	I-I
collective	O
reflects	O
the	O
ability	O
of	O
the	O
DSV	B-I
to	O
prevent	O
overdrainage	B-O
.	I-O


The	O
capability	O
of	O
the	O
DSV	B-I
to	O
maintain	O
the	O
IVP	B-O
within	O
physiological	O
limits	O
after	O
shunting	O
,	O
especially	O
in	O
the	O
upright	O
position	O
,	O
is	O
documented	O
by	O
a	O
comparison	O
with	O
possible	B-O
unphysiological	I-O
IVP	I-O
variations	I-O
in	O
other	O
valve	O
constructions	O
,	O
which	O
depend	O
on	O
the	O
level	B-O
of	I-O
implantation	I-O
,	I-O
subcutaneous	I-O
pressure	I-O
or	I-O
CSF	I-O
flow	I-O
through	I-O
the	I-O
valve	I-O
.	I-O


Aspirin-associated	B-P
iron	I-P
loss	I-P
as	I-P
an	I-P
anticancer	I-P
mechanism	I-P
.	I-P


A	O
consensus	O
view	O
has	O
emerged	O
favoring	O
an	O
anticancer	O
effect	O
of	O
long-term	O
aspirin	O
use	O
.	O


Aspirin-induced	B-I
loss	O
of	O
stored	O
iron	O
from	O
chronic	O
gastrointestinal	O
bleeding	O
is	O
proposed	O
as	O
a	O
mechanism	O
underlying	O
this	O
beneficial	O
effect	O
.	O


In	O
iron	O
depletion	O
,	O
less	O
iron	O
may	O
be	O
available	O
for	O
carcinogenesis	O
through	O
free-radical	O
mediated	O
mechanisms	O
and	O
for	O
promotion	O
of	O
tumor	O
growth	O
.	O


Low-dose	B-I
aspirin	I-I
increases	O
gastrointestinal	B-O
losses	I-O
of	O
transfused	B-O
radiolabeled	I-O
autologous	I-O
red	I-O
cells	I-O
.	I-O


Observational	O
studies	O
report	O
lower	O
serum	O
ferritin	O
values	O
with	O
regular	O
aspirin	O
use	O
.	O


A	O
protective	O
effect	O
of	O
induced	O
iron	O
reduction	O
against	O
cancer	O
mortality	O
has	O
been	O
confirmed	O
in	O
a	O
recent	O
trial	O
(	O
FeAST	O
)	O
with	O
subjects	B-P
randomized	I-P
to	I-P
iron	I-P
reduction	I-P
or	I-P
observation	I-P
.	I-P


Serum	B-O
ferritin	I-O
reductions	I-O
in	O
the	O
FeAST	O
trial	O
were	O
within	O
conventionally	O
normal	O
reference	O
ranges	O
and	O
were	O
quantitatively	O
similar	O
to	O
ferritin	O
reductions	O
in	O
observational	O
studies	O
in	O
regular	B-P
aspirin	I-P
users	I-P
.	I-P


Delayed	O
anticancer	O
effects	O
of	O
aspirin	O
are	O
compatible	O
with	O
the	O
proposed	O
mechanism	O
,	O
as	O
continual	O
microbleeding	B-O
has	O
a	O
gradual	O
cumulative	O
effect	O
on	O
stored	O
iron	O
.	O


RCT	O
of	O
a	O
manualized	O
social	B-I
treatment	I-I
for	O
high-functioning	B-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


This	O
RCT	O
examined	O
the	O
efficacy	O
of	O
a	O
manualized	B-I
social	I-I
intervention	I-I
for	O
children	B-P
with	I-P
HFASDs	I-P
.	I-P


Participants	O
were	O
randomly	O
assigned	O
to	O
treatment	B-I
or	O
wait-list	B-I
conditions	I-I
.	I-I


Treatment	B-I
included	O
instruction	B-I
and	I-I
therapeutic	I-I
activities	I-I
targeting	I-I
social	I-I
skills	I-I
,	I-I
face-emotion	I-I
recognition	I-I
,	I-I
interest	I-I
expansion	I-I
,	I-I
and	I-I
interpretation	I-I
of	I-I
non-literal	I-I
language	I-I
.	I-I


A	O
response-cost	O
program	O
was	O
applied	O
to	O
reduce	O
problem	O
behaviors	O
and	O
foster	O
skills	O
acquisition	O
.	O


Significant	O
treatment	O
effects	O
were	O
found	O
for	O
five	B-O
of	I-O
seven	I-O
primary	I-O
outcome	I-O
measures	I-O
(	I-O
parent	I-O
ratings	I-O
and	I-O
direct	I-O
child	I-O
measures	I-O
)	I-O
.	O


Secondary	O
measures	O
based	O
on	O
staff	B-O
ratings	I-O
(	O
treatment	O
group	O
only	O
)	O
corroborated	O
gains	O
reported	O
by	O
parents	O
.	O


High	O
levels	O
of	O
parent	B-O
,	I-O
child	I-O
and	I-O
staff	I-O
satisfaction	I-O
were	O
reported	O
,	O
along	O
with	O
high	O
levels	O
of	O
treatment	B-O
fidelity	I-O
.	I-O


Standardized	O
effect	O
size	O
estimates	O
were	O
primarily	O
in	O
the	O
medium	O
and	O
large	O
ranges	O
and	O
favored	O
the	O
treatment	O
group	O
.	O


Synthetic	B-I
serum	I-I
substitute	I-I
(	I-I
SSS	I-I
)	I-I
:	I-I
a	O
globulin-enriched	O
protein	O
supplement	O
for	O
human	B-P
embryo	I-P
culture	I-P
.	I-P


OBJECTIVE	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
whether	O
an	O
IVF	O
protein	O
supplement	O
prepared	O
from	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
and	O
human	O
globulins	O
would	O
retain	O
performance	B-O
characteristics	I-O
equivalent	O
to	O
those	O
reported	O
for	O
the	O
commercial	O
plasma	O
expanders	O
,	O
Plasmatein	B-I
(	O
Alpha	O
Therapeutics	O
,	O
Los	O
Angeles	O
,	O
California	O
)	O
and	O
Plasmanate	B-I
(	O
Cutter	O
Biological	O
,	O
Miles	O
Inc.	O
,	O
Elkhart	O
,	O
Indiana	O
)	O
.	O


METHODS	O
Pronuclear-stage	B-P
human	I-P
embryos	I-P
were	O
randomly	O
divided	B-I
and	I-I
cultured	I-I
in	I-I
human	I-I
tubal	I-I
fluid	I-I
medium	I-I
(	I-I
HTF	I-I
)	I-I
supplemented	I-I
with	I-I
either	I-I
HSA	I-I
(	I-I
5	I-I
mg/mL	I-I
)	I-I
or	I-I
Plasmatein	I-I
(	I-I
10	I-I
%	I-I
,	I-I
v/v	I-I
;	I-I
5	I-I
mg/ml	I-I
)	I-I
as	I-I
a	I-I
means	I-I
of	I-I
indirectly	I-I
assessing	I-I
the	I-I
effect	I-I
alpha-	I-I
and	I-I
beta-globulins	I-I
have	I-I
on	I-I
embryonic	I-I
development	I-I
.	I-I


Those	O
results	O
coupled	O
with	O
the	O
known	O
composition	O
characteristics	O
of	O
Plasmatein	B-I
were	O
used	O
as	O
the	O
starting	O
basis	O
to	O
formulate	O
test	O
lots	O
of	O
synthetic	O
serum	O
substitute	O
(	O
SSS	O
)	O
.	O


RESULTS	O
Significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
of	O
the	O
human	O
embryos	O
cultured	O
in	O
Plasmatein	B-I
supplemented	O
medium	O
reached	O
the	O
four-cell	B-O
or	I-O
greater	I-O
stage	I-O
by	O
40	O
hr	O
postinsemination	O
than	O
a	O
comparable	O
group	O
cultured	O
in	O
HSA	B-I
alone	O
.	O


Lot	O
1	O
of	O
SSS	O
,	O
formulated	O
with	O
HSA	O
(	O
84	O
%	O
of	O
total	O
protein	O
)	O
and	O
human	O
globulins	O
(	O
16	O
%	O
of	O
total	O
protein	O
)	O
and	O
an	O
aqueous	O
lipoprotein	O
fraction	O
derived	O
from	O
human	O
plasma	O
(	O
Excyte	O
IV	O
;	O
Miles	O
Diagnostics	O
,	O
Kankakee	O
,	O
Illinois	O
)	O
,	O
produced	O
accelerated	O
early	B-O
embryonic	I-O
growth	I-O
relative	O
to	O
control	O
murine	O
embryos	O
grown	O
in	O
the	O
presence	O
of	O
Plasmatein	O
,	O
however	O
,	O
the	O
percentage	O
of	O
the	O
embryos	O
reaching	O
the	O
hatched	O
blastocyst	O
stage	O
was	O
decreased	O
(	O
45	O
vs	O
100	O
%	O
)	O
.	O


Human	B-P
embryos	I-P
from	I-P
seven	I-P
patients	I-P
,	O
randomized	O
to	O
HTF	O
medium	O
supplemented	O
with	O
Plasmatein	B-I
or	O
lot	O
1	O
of	O
SSS	B-I
,	O
showed	O
equivalent	O
growth	B-O
at	O
36-40	O
hr	O
postinsemination	O
.	O


A	O
microprecipitate	O
developed	O
in	O
media	O
supplemented	O
with	O
lot	O
1	O
after	O
several	O
days	O
of	O
culture	O
.	O


The	O
Excyte	B-O
IV	I-O
concentration	I-O
was	O
reduced	O
and	O
,	O
ultimately	O
,	O
eliminated	O
from	O
the	O
subsequent	O
and	O
final	O
prototype	O
lots	O
of	O
SSS	O
.	O


Murine	B-P
embryos	I-P
grown	O
in	O
the	O
presence	O
of	O
lipoprotein	O
free	O
SSS	B-I
showed	O
significantly	O
accelerated	B-O
(	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
growth	I-O
at	O
17	O
hr	O
postthaw	O
compared	O
to	O
Plasmatein	B-I
and	O
all	O
embryos	O
progressed	O
to	O
hatching	B-O
by	O
41	O
hr	O
.	O


Human	B-P
embryos	I-P
,	O
randomized	O
to	O
either	O
Plasmatein	B-I
or	O
lot	O
3	O
of	O
SSS	B-I
,	O
showed	O
significantly	O
accelerated	B-O
growth	I-O
(	O
P	O
<	O
0.01	O
)	O
when	O
scored	O
at	O
38	O
hr	O
following	O
insemination	O
.	O


CONCLUSION	O
Synthetic	B-I
serum	I-I
substitute	I-I
provides	O
a	O
convient	O
,	O
standardized	O
means	O
of	O
adding	O
protein	O
to	O
media	O
used	O
in	O
assisted	O
reproductive	O
technology	O
(	O
ART	O
)	O
procedures	O
.	O


Do	O
colonic	O
short-chain	O
fatty	O
acids	O
contribute	O
to	O
the	O
long-term	B-O
adaptation	I-O
of	I-O
blood	I-O
lipids	I-O
in	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
consuming	I-P
a	I-P
high-fiber	I-I
diet	I-I
?	O
BACKGROUND	O
We	O
recently	O
obtained	O
evidence	O
of	O
long-term	B-O
adaptation	I-O
of	I-O
blood	I-O
lipids	I-O
to	O
changes	O
in	O
intakes	O
of	O
carbohydrate	B-I
and	I-I
fiber	I-I
in	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
.	I-P


OBJECTIVE	O
We	O
determined	O
the	O
effect	O
of	O
increased	B-I
carbohydrate	I-I
and	I-I
fiber	I-I
intakes	I-I
on	O
serum	B-O
short-chain	I-O
fatty	I-O
acids	I-O
(	I-O
SCFAs	I-O
)	I-O
and	O
the	O
relation	B-O
between	I-O
changes	I-O
in	I-O
serum	I-O
acetate	I-O
and	I-O
changes	I-O
in	I-O
blood	I-O
lipids	I-O
.	I-O


DESIGN	O
Subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
(	I-P
n	I-P
=	I-P
62	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
approximately	O
10	O
%	O
of	O
energy	B-I
from	I-I
low-fiber	I-I
breakfast	I-I
cereal	I-I
(	I-I
LF	I-I
diet	I-I
)	I-I
,	I-I
high-fiber	I-I
breakfast	I-I
cereal	I-I
(	I-I
HF	I-I
diet	I-I
)	I-I
,	I-I
or	I-I
monounsaturated	I-I
fatty	I-I
acids	I-I
(	I-I
MUFA	I-I
diet	I-I
)	I-I
for	O
6	O
mo	O
.	O


RESULTS	O
Carbohydrate	B-O
intakes	I-O
were	O
higher	O
in	O
the	O
LF	O
and	O
HF	O
groups	O
than	O
in	O
the	O
MUFA	O
group	O
(	O
54	O
%	O
compared	O
with	O
43	O
%	O
)	O
,	O
and	O
more	O
fiber	O
was	O
consumed	O
by	O
the	O
HF	O
group	O
(	O
approximately	O
50	O
g/d	O
)	O
than	O
by	O
the	O
LF	O
or	O
MUFA	O
group	O
(	O
approximately	O
23	O
g/d	O
)	O
.	O


Fasting	B-O
serum	I-O
SCFAs	I-O
did	O
not	O
change	O
significantly	O
over	O
the	O
first	O
3	O
mo	O
.	O


Between	O
3	O
and	O
6	O
mo	O
,	O
serum	B-O
acetate	I-O
tended	O
(	O
NS	O
)	O
to	O
decrease	O
in	O
the	O
LF	O
group	O
(	O
from	O
69	O
+/-	O
4	O
to	O
59	O
+/-	O
5	O
micromol/L	O
)	O
and	O
increase	O
in	O
the	O
HF	O
group	O
(	O
from	O
100	O
+/-	O
18	O
to	O
107	O
+/-	O
17	O
micromol/L	O
)	O
,	O
with	O
no	O
significant	O
change	O
in	O
the	O
MUFA	O
group	O
.	O


Serum	B-O
butyrate	I-O
did	O
not	O
change	O
significantly	O
in	O
the	O
LF	O
or	O
MUFA	O
group	O
but	O
increased	O
in	O
the	O
HF	O
group	O
(	O
from	O
2.5	O
+/-	O
0.5	O
to	O
3.1	O
+/-	O
0.6	O
micromol/L	O
;	O
P	O
<	O
0.001	O
)	O
.	O


Changes	B-O
in	I-O
serum	I-O
acetate	I-O
from	O
0	O
to	O
3	O
mo	O
were	O
not	O
related	O
to	O
changes	B-O
in	I-O
lipids	I-O
.	I-O


However	O
,	O
changes	B-O
in	I-O
serum	I-O
acetate	I-O
from	O
3	O
to	O
6	O
mo	O
were	O
positively	O
related	O
to	O
changes	B-O
in	I-O
the	I-O
ratio	I-O
of	I-O
total	I-O
to	I-O
HDL	I-O
cholesterol	I-O
(	O
P	O
=	O
0.041	O
)	O
and	O
in	O
fasting	O
(	O
P	O
=	O
0.013	O
)	O
and	O
postprandial	B-O
(	I-O
P	I-O
=	I-O
0.016	I-O
)	I-O
triacylglycerols	I-O
.	I-O


CONCLUSIONS	O
In	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
,	O
changes	O
in	O
serum	B-O
SCFAs	I-O
in	O
response	O
to	O
changes	O
in	O
carbohydrate	B-O
and	I-O
fiber	I-O
intakes	I-O
took	O
many	O
months	O
to	O
occur	O
,	O
and	O
the	O
changes	O
in	O
serum	B-O
acetate	I-O
were	O
significantly	O
related	O
to	O
the	O
long-term	B-O
adaptive	I-O
changes	I-O
in	I-O
blood	I-O
lipids	I-O
.	I-O


Safety	B-O
and	I-O
immunogenicity	I-O
of	O
a	O
cluster	B-I
specific	I-I
immunotherapy	I-I
in	O
children	B-P
with	I-P
bronchial	I-P
asthma	I-P
and	I-P
mite	I-P
allergy	I-P
.	I-P


BACKGROUND	O
Cluster	B-I
specific	I-I
immunotherapy	I-I
(	I-I
SIT	I-I
)	I-I
is	O
a	O
modern	O
form	O
of	O
allergen	O
immunotherapy	O
allowing	O
safe	O
administration	O
of	O
high	O
allergen	O
doses	O
in	O
a	O
short	O
time	O
interval	O
compared	O
to	O
classic	O
SIT	O
.	O


In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
safety	B-O
profile	I-O
and	I-O
immunological	I-O
effect	I-O
of	O
cluster	O
SIT	O
in	O
children	B-P
with	I-P
allergic	I-P
asthma	I-P
due	I-P
to	I-P
house	I-P
dust	I-P
mite	I-P
allergy	I-P
.	I-P


METHODS	O
A	O
total	O
of	O
34	B-P
children	I-P
(	I-P
6-18	I-P
years	I-P
)	I-P
with	I-P
allergic	I-P
asthma	I-P
were	O
assigned	O
to	O
cluster	B-P
(	I-P
n	I-P
=	I-P
22	I-P
)	I-P
or	O
classic	B-P
SIT	I-P
(	I-P
n	I-P
=	I-P
12	I-P
)	I-P
.	I-P


To	O
achieve	O
a	O
maintenance	O
dose	O
of	O
allergen	O
extract	O
,	O
cluster	O
patients	O
received	O
14	B-I
injections	I-I
of	I-I
house	I-I
dust	I-I
mite	I-I
allergen	I-I
within	I-I
6	I-I
weeks	I-I
,	O
whereas	O
the	O
classic	B-I
SIT	I-I
group	I-I
received	I-I
14	I-I
injections	I-I
within	O
14	O
weeks	O
.	O


Safety	B-O
was	O
monitored	O
by	O
recording	O
adverse	O
events	O
.	O


Immunogenicity	B-O
was	O
measured	O
by	O
specific	O
IgG	O
(	O
Mite	O
)	O
and	O
IgG4	O
(	O
Mite	O
)	O
,	O
by	O
antibody-blocking	O
properties	O
on	O
basophil	O
activation	O
,	O
and	O
by	O
the	O
T	O
cell	O
subset	O
transcription	O
factors	O
Foxp3	O
,	O
T-bet	O
,	O
and	O
GATA-3	O
.	O


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
local	B-O
and	I-O
systemic	I-O
side	I-O
effects	I-O
between	O
the	O
two	O
groups	O
.	O


In	O
the	O
cluster	O
group	O
,	O
serum	B-O
levels	I-O
of	I-O
specific	I-O
IgG	I-O
(	I-O
Mite	I-O
)	I-O
(	O
p	O
<	O
0.001	O
)	O
and	O
specific	B-O
IgG4	I-O
(	I-O
Mite	I-O
)	I-O
(	O
p	O
<	O
0.001	O
)	O
significantly	O
increased	O
after	O
8	O
weeks	O
,	O
while	O
it	O
took	O
12	O
weeks	O
in	O
the	O
classic	O
SIT	O
group	O
.	O


These	O
data	O
were	O
confirmed	O
by	O
blocking	O
CD63	B-O
expression	I-O
as	O
well	O
as	O
release	O
of	O
cysteinyl	O
leukotrienes	O
after	O
in	O
vitro	O
basophil	O
stimulation	O
.	O


No	O
differences	O
in	O
transcription	B-O
factor	I-O
expression	I-O
were	O
found	O
in	O
the	O
two	O
groups	O
.	O


CONCLUSION	O
Cluster	O
SIT	O
is	O
safe	O
in	O
children	B-P
.	I-P


Additionally	O
,	O
our	O
data	O
demonstrated	O
an	O
even	O
more	O
rapid	O
induction	B-O
of	I-O
specific	I-O
immune	I-O
tolerance	I-O
.	I-O


Cluster	O
SIT	O
is	O
an	O
attractive	O
alternative	O
to	O
conventional	O
up-dosing	O
schedules	O
with	O
fewer	O
consultations	O
for	O
the	O
patients	O
.	O


Effect	O
of	O
body	B-I
mass	I-I
index	I-I
on	O
hemiparetic	O
gait	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
relationship	O
between	O
body	B-I
mass	I-I
index	I-I
(	I-I
BMI	I-I
)	I-I
and	O
spatiotemporal	B-O
,	I-O
kinematic	I-O
,	I-O
and	I-O
kinetic	I-O
gait	I-O
parameters	I-O
in	O
chronic	B-P
hemiparetic	I-P
stroke	I-P
survivors	I-P
.	I-P


DESIGN	O
Secondary	O
analysis	O
of	O
data	O
collected	O
in	O
a	O
randomized	O
controlled	O
trial	O
comparing	O
two	O
12-week	O
ambulation	B-I
training	I-I
treatments	I-I
.	I-I


SETTING	O
Academic	O
medical	O
center	O
.	O


PARTICIPANTS	O
Chronic	B-P
hemiparetic	I-P
stroke	I-P
survivors	I-P
(	I-P
N	I-P
=	I-P
108	I-P
,	I-P
>	I-P
3	I-P
months	I-P
poststroke	I-P
)	I-P
METHODS	O
Linear	B-I
regression	I-I
analyses	I-I
were	I-I
performed	I-I
of	I-I
BMI	I-I
,	I-I
and	I-I
selected	I-I
pretreatment	I-I
gait	I-I
parameters	I-I
were	I-I
recorded	I-I
using	I-I
quantitative	I-I
gait	I-I
analysis	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Spatiotemporal	B-O
,	I-O
kinematic	I-O
,	I-O
and	I-O
kinetic	I-O
gait	I-O
parameters	I-O
.	I-O


RESULTS	O
A	O
series	O
of	O
linear	O
regression	O
models	O
that	O
controlled	O
for	O
age	O
,	O
gender	O
,	O
stroke	O
type	O
(	O
ischemic	O
versus	O
hemorrhagic	O
)	O
,	O
interval	O
poststroke	O
,	O
level	O
of	O
motor	O
impairment	O
(	O
Fugl-Meyer	O
score	O
)	O
,	O
and	O
walking	O
speed	O
found	O
BMI	O
to	O
be	O
positively	O
associated	O
with	O
step	O
width	O
(	O
m	O
)	O
(	O
β	O
=	O
0.364	O
,	O
P	O
<	O
.001	O
)	O
,	O
positively	O
associated	O
with	B-O
peak	I-O
hip	I-O
abduction	I-O
angle	I-O
of	I-O
the	I-O
nonparetic	I-O
limb	I-O
during	O
stance	O
(	O
deg	O
)	O
(	O
β	O
=	O
0.177	O
,	O
P	O
=	O
.040	O
)	O
,	O
negatively	O
associated	O
with	B-O
ankle	I-O
dorsiflexion	I-O
angle	I-O
at	O
initial	O
contact	O
of	O
the	O
paretic	O
limb	O
(	O
deg	O
)	O
(	O
β	O
=	O
-0.222	O
,	O
P	O
=	O
.023	O
)	O
,	O
and	O
negatively	O
associated	O
with	B-O
peak	I-O
ankle	I-O
power	I-O
at	I-O
push-off	I-O
(	O
W/kg	O
)	O
of	O
the	O
paretic	O
limb	O
(	O
W/kg	O
)	O
(	O
β	O
=	O
-0.142	O
,	O
P	O
=	O
.026	O
)	O
.	O


CONCLUSIONS	O
When	O
walking	O
at	O
a	O
similar	O
speed	B-P
,	I-P
chronic	I-P
hemiparetic	I-P
stroke	I-P
subjects	I-P
with	I-P
a	I-P
higher	I-O
BMI	O
demonstrated	O
greater	B-O
step	I-O
width	I-O
,	I-O
greater	I-O
hip	I-O
hiking	I-O
of	I-O
the	I-O
paretic	I-O
lower	I-O
limb	I-O
,	I-O
less	I-O
paretic	I-O
limb	I-O
dorsiflexion	I-O
at	I-O
initial	I-O
contact	I-O
,	O
and	O
less	B-O
paretic	I-O
ankle	I-O
power	I-O
at	I-O
push-off	I-O
as	O
compared	O
to	O
stroke	O
subjects	O
with	O
a	O
lower	O
BMI	O
and	O
similar	O
level	O
of	O
motor	O
impairment	O
.	O


Further	O
studies	O
are	O
necessary	O
to	O
determine	O
the	O
clinical	O
relevance	O
of	O
these	O
findings	O
with	O
respect	O
to	O
rehabilitation	O
strategies	O
for	O
gait	O
dysfunction	B-P
in	I-P
hemiparetic	I-P
patients	I-P
with	I-P
higher	I-P
BMIs	I-P
.	O


A	O
prospective	O
randomized	O
trial	O
of	O
Duraflo	B-I
II	I-I
heparin-coated	I-I
circuits	I-I
in	O
cardiac	B-P
reoperations	I-P
.	I-P


BACKGROUND	O
Heparin-coated	B-I
circuits	I-I
in	O
cardiopulmonary	O
bypass	O
have	O
been	O
shown	O
to	O
decrease	O
the	O
systemic	O
inflammatory	O
responses	O
associated	O
with	O
cardiopulmonary	O
bypass	O
.	O


Previous	O
clinical	O
studies	O
on	O
low-risk	B-P
patients	I-P
who	I-P
had	I-P
coronary	I-I
artery	I-I
bypass	I-I
grafting	I-I
(	I-P
CABG	I-P
)	I-P
and	O
received	O
full-dose	O
systemic	O
heparin	B-I
did	O
not	O
have	O
clearly	O
improved	O
clinical	O
outcomes	O
.	O


We	O
hypothesized	O
that	O
the	O
beneficial	O
effects	O
of	O
heparin-coated	B-I
circuits	I-I
might	O
be	O
seen	O
in	O
patients	B-P
who	I-P
had	I-P
cardiac	I-P
reoperations	I-P
.	I-P


METHODS	O
Three	B-P
hundred	I-P
fifty	I-P
patients	I-P
who	I-P
had	I-P
reoperation	I-P
with	I-P
CABG	I-P
only	I-P
(	I-P
58	I-P
%	I-P
)	I-P
,	I-P
or	I-P
with	I-P
valve	I-P
operations	I-P
(	I-P
42	I-P
%	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
a	O
heparin-coated	B-I
(	I-I
Duraflo	I-I
II	I-I
;	I-I
study	I-I
group	I-I
)	I-I
or	I-I
uncoated	I-I
(	I-I
control	I-I
group	I-I
)	I-I
circuit	I-I
.	I-I


Clinical	O
outcomes	O
were	O
compared	O
and	O
the	O
variables	O
were	O
analyzed	O
using	O
the	O
following	O
three	O
groups	O
:	O
entire	O
populations	O
of	O
study	O
group	O
and	O
control	O
group	O
,	O
subgroup	O
of	O
patients	O
who	O
had	O
CABG	O
reoperation	O
only	O
,	O
and	O
a	O
subgroup	B-P
who	I-P
had	I-P
valve	I-P
reoperation	I-P
or	I-P
combined	I-P
valve	I-P
and	I-P
CABG	I-P
reoperation	I-P
.	I-P


RESULTS	O
Preoperative	O
variables	O
were	O
the	O
same	O
in	O
both	O
groups	O
.	O


No	O
difference	O
in	O
clinical	O
outcomes	O
could	O
be	O
demonstrated	O
except	O
that	O
the	O
percentage	B-O
of	I-O
patients	I-O
with	I-O
major	I-O
bleeding	I-O
episodes	I-O
was	O
significantly	O
lower	O
in	O
the	O
study	B-P
group	I-P
(	I-P
1.2	I-P
%	I-P
versus	I-P
5.4	I-P
%	I-P
,	I-P
p	I-P
=	I-P
0.035	I-P
)	I-P
.	I-P


In	O
the	O
subgroup	O
analysis	O
of	O
patients	O
who	O
had	O
valve	B-O
reoperations	I-O
,	O
lower	O
blood	B-O
transfusion	I-O
requirements	I-O
in	O
the	O
intensive	O
care	O
unit	O
(	O
p	O
=	O
0.013	O
)	O
were	O
found	O
in	O
the	O
study	O
group	O
.	O


When	O
the	O
subgroup	O
of	O
patients	O
who	O
had	O
CABG	O
reoperations	O
was	O
analyzed	O
separately	O
,	O
there	O
was	O
a	O
trend	O
toward	O
less	O
reoperation	B-O
for	I-O
bleeding	I-O
in	O
the	O
study	O
group	O
(	O
0	O
%	O
versus	O
4.0	O
%	O
,	O
p	O
=	O
0.058	O
)	O
.	O


CONCLUSIONS	O
We	O
conclude	O
that	O
the	O
use	O
of	O
heparin-coated	O
circuits	O
was	O
safe	O
and	O
imparted	O
protection	O
from	O
reoperations	O
for	O
bleeding	O
and	O
major	O
bleeding	O
episodes	O
.	O


Material-independent	O
blood	O
activation	O
(	O
eg	O
,	O
blood-air	O
interface	O
and	O
cardiotomy	O
suction	O
)	O
blunted	O
the	O
total	O
effect	O
of	O
the	O
heparin-coated	O
surface	O
.	O


Emotional	B-O
,	I-O
motivational	I-O
and	I-O
interpersonal	I-O
responsiveness	I-O
of	O
children	B-P
with	I-P
autism	I-P
in	O
improvisational	B-I
music	I-I
therapy	I-I
.	I-I


Through	O
behavioural	O
analysis	O
,	O
this	O
study	O
investigated	O
the	O
social-motivational	O
aspects	O
of	O
musical	B-I
interaction	I-I
between	O
the	O
child	B-P
and	O
the	O
therapist	O
in	O
improvisational	B-I
music	I-I
therapy	I-I
by	O
measuring	O
emotional	O
,	O
motivational	O
and	O
interpersonal	O
responsiveness	B-P
in	I-P
children	I-P
with	I-P
autism	I-P
during	I-P
joint	I-P
engagement	I-P
episodes	I-P
.	I-P


The	O
randomized	O
controlled	O
study	O
(	B-P
n	I-P
=	I-P
10	I-P
)	I-P
employed	O
a	O
single	O
subject	O
comparison	O
design	O
in	O
two	O
different	O
conditions	O
,	O
improvisational	B-I
music	I-I
therapy	I-I
and	I-I
toy	I-I
play	I-I
sessions	I-I
,	I-I
and	I-I
DVD	I-I
analysis	I-I
of	I-I
sessions	I-I
.	I-I


Improvisational	B-I
music	I-I
therapy	I-I
produced	O
markedly	O
more	O
and	O
longer	O
events	B-O
of	I-O
'joy	I-O
'	I-O
,	I-O
'emotional	I-O
synchronicity	I-O
'	I-O
and	I-O
'initiation	I-O
of	I-O
engagement	I-O
'	I-O
behaviours	I-O
in	O
the	O
children	O
than	O
toy	B-I
play	I-I
sessions	I-I
.	I-I


In	O
response	O
to	O
the	O
therapist	O
's	O
interpersonal	O
demands	O
,	O
'compliant	B-O
(	I-O
positive	I-O
)	I-O
responses	I-O
'	I-O
were	O
observed	O
more	O
in	O
music	O
therapy	O
than	O
in	O
toy	O
play	O
sessions	O
,	O
and	O
'no	B-O
responses	I-O
'	I-O
were	O
twice	O
as	O
frequent	O
in	O
toy	O
play	O
sessions	O
as	O
in	O
music	B-I
therapy	I-I
.	I-I


The	O
results	O
of	O
this	O
exploratory	O
study	O
found	O
significant	O
evidence	O
supporting	O
the	O
value	O
of	O
music	B-I
therapy	I-I
in	O
promoting	O
social	B-O
,	I-O
emotional	I-O
and	I-O
motivational	I-O
development	I-O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


The	O
costs	B-O
and	O
effects	B-O
of	O
a	O
nutritional	B-I
education	I-I
program	I-I
following	O
work-site	O
cholesterol	O
screening	O
.	O


OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
costs	B-O
and	O
impact	B-O
of	O
a	O
nutrition	B-I
education	I-I
program	I-I
following	O
a	O
cholesterol	O
screening	O
.	O


METHODS	O
Forty	B-P
work-sites	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
educational	B-I
interventions	I-I
:	I-I
a	O
"	B-I
usual	I-I
"	I-I
intervention	I-I
of	I-I
5	I-I
minutes	I-I
of	I-I
counseling	I-I
,	I-I
or	I-I
a	I-I
"	I-I
special	I-I
"	I-I
intervention	I-I
of	I-I
2	I-I
hours	I-I
of	I-I
behaviorally	I-I
based	I-I
education	I-I
on	I-I
dietary	I-I
changes	I-I
to	I-I
lower	I-I
serum	I-I
cholesterol	I-I
.	I-I


Costs	B-O
were	O
monitored	O
,	O
and	O
cholesterol	B-O
levels	I-O
were	O
retested	O
6	O
and	O
12	O
months	O
later	O
.	O


RESULTS	O
The	O
total	B-O
per-person	I-O
cost	I-O
for	O
screening	O
and	O
the	O
educational	O
intervention	O
was	O
about	O
$	O
50	O
.	O


Cholesterol	B-O
levels	I-O
differed	O
little	O
between	O
the	O
two	O
intervention	O
groups	O
6	O
months	O
after	O
screening	O
,	O
but	O
after	O
12	O
months	O
those	O
in	O
the	O
special	O
intervention	O
worksites	O
showed	O
a	O
6.5	O
%	O
drop	O
in	O
cholesterol	B-O
,	O
whereas	O
those	O
at	O
the	O
usual	O
intervention	O
worksites	O
showed	O
a	O
drop	O
of	O
only	O
3.0	O
%	O
.	O


Hence	O
a	O
3.5	O
%	O
cholesterol	B-O
reduction	I-O
was	O
attributable	O
to	O
the	O
special	O
intervention	O
.	O


CONCLUSIONS	O
A	O
behaviorally	B-I
based	I-I
nutrition	I-I
education	I-I
program	I-I
following	O
cholesterol	O
screening	O
can	O
have	O
a	O
meaningful	O
impact	O
on	O
long-term	O
cholesterol	O
levels	O
at	O
a	O
low	O
cost	O
.	O


Nutrition	B-I
education	I-I
in	O
work-sites	O
may	O
therefore	O
be	O
a	O
useful	O
way	O
to	O
lower	O
the	O
risk	O
of	O
heart	O
disease	O
in	O
communities	O
.	O


The	O
effect	O
of	O
recent	B-P
bereavement	I-P
on	O
outcomes	O
in	O
a	O
primary	B-O
care	I-O
depression	I-O
intervention	O
study	O
.	O


OBJECTIVES	O
Although	O
bereavement	O
and	O
depression	O
are	O
both	O
common	O
in	O
older	O
primary	O
care	O
patients	O
,	O
the	O
effect	O
of	O
bereavement	O
on	O
depression	B-O
intervention	O
outcomes	O
is	O
unknown	O
.	O


We	O
examined	O
whether	O
standard	B-I
interventions	I-I
for	O
depression	O
in	O
primary	O
care	O
were	O
as	O
effective	O
for	O
bereaved	B-P
as	I-P
for	I-P
non-bereaved	I-P
depressed	I-P
patients	I-P
.	I-P


DESIGN	O
Randomized	O
controlled	O
trial	O
.	O


SETTING	O
Twenty	B-P
community-based	I-P
primary	I-P
care	I-P
practices	I-P
in	I-P
New	I-P
York	I-P
City	I-P
,	I-P
greater	I-P
Philadelphia	I-P
,	I-P
and	I-P
Pittsburgh	I-P
.	I-P


Randomization	O
to	O
either	O
intervention	B-I
or	O
usual	B-I
care	I-I
occurred	I-I
by	I-I
practice	I-I
.	I-I


PARTICIPANTS	B-P
Patients	I-P
aged	I-P
60	I-P
years	I-P
or	I-P
older	I-P
who	I-P
met	I-P
criteria	I-P
for	I-P
major	I-P
depression	I-P
or	I-P
clinically	I-P
significant	I-P
minor	I-P
depression	I-P
(	I-P
N	I-P
=	I-P
599	I-P
)	I-P
.	I-P


Patients	B-P
who	I-P
did	I-P
not	I-P
complete	I-P
the	I-P
bereavement	I-P
measure	I-P
or	I-P
who	I-P
were	I-P
missing	I-P
4-month	I-P
data	I-P
were	I-P
excluded	I-P
(	I-P
final	I-P
N	I-P
=	I-P
417	I-P
)	I-P
.	O


INTERVENTION	B-I
Study-trained	I-I
depression	I-I
care	I-I
managers	I-I
offered	I-I
guideline-concordant	I-I
recommendations	I-I
to	I-I
primary	I-I
care	I-I
physicians	I-I
at	I-I
intervention	I-I
sites	I-I
and	I-I
assisted	I-I
patients	I-I
with	I-I
treatment	I-I
adherence	I-I
.	I-I


Patients	B-I
who	I-I
did	I-I
not	I-I
wish	I-I
to	I-I
take	I-I
antidepressants	I-I
could	I-I
receive	I-I
interpersonal	I-I
psychotherapy	I-I
.	O


MEASUREMENTS	B-O
Bereavement	I-O
was	O
captured	O
using	O
the	B-O
Louisville	I-O
Older	I-O
Persons	I-O
Events	I-O
Schedule	I-O
.	I-O


Depression	B-O
severity	I-O
was	O
assessed	O
using	O
the	B-O
24-item	I-O
Hamilton	I-O
Depression	I-O
Rating	I-O
Scale	I-O
(	I-O
HDRS	I-O
)	I-O
.	O


Outcomes	O
at	O
4	O
months	O
were	B-O
remission	I-O
(	I-O
HDRS	I-O
≤7	I-O
)	I-O
and	I-O
response	I-O
(	O
HDRS	O
reduction	O
≥50	O
%	O
from	O
baseline	O
)	O
.	O


RESULTS	O
Logistic	O
regressions	O
indicated	O
that	O
,	O
for	O
non-bereaved	O
participants	B-O
,	I-O
response	I-O
and	I-O
remission	I-O
were	O
higher	O
in	O
intervention	O
than	O
usual	O
care	O
.	O


However	O
,	O
recently	O
bereaved	O
older	O
adults	O
were	O
less	O
likely	O
to	O
achieve	B-O
response	I-O
or	I-O
remission	I-O
at	O
4	O
months	O
if	O
treated	O
in	O
the	O
intervention	O
condition	O
.	O


CONCLUSIONS	O
Standard	O
depression	O
care	O
management	O
appears	O
to	O
be	O
ineffective	O
among	O
recently	O
bereaved	O
older	O
primary	O
care	O
patients	O
.	O


Greater	O
attention	O
should	O
be	O
paid	O
in	O
primary	O
care	B-P
to	I-P
emotional	I-P
distress	I-P
in	I-P
the	I-P
context	I-P
of	I-P
bereavement	I-P
.	O


Central	O
nervous	O
system	O
serotonin	O
function	O
and	O
cardiovascular	B-O
responses	I-O
to	O
stress	O
.	O


OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
indices	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
serotonin	O
function	O
on	O
cardiovascular	B-O
reactivity	I-O
to	O
mental	O
stress	O
.	O


METHODS	O
Lumbar	B-I
puncture	I-I
was	O
performed	O
on	O
54	B-P
healthy	I-P
volunteers	I-P
to	I-P
obtain	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
for	O
determination	O
of	O
5-hydroxyindoleacetic	O
acid	O
(	O
5HIAA	O
)	O
levels	O
.	O


Genotypes	O
were	O
determined	O
with	O
respect	O
to	O
a	O
functional	O
polymorphism	O
of	O
the	O
serotonin	O
transporter	O
gene	O
promoter	O
region	O
(	O
5HTTLPR	O
)	O
.	O


Subjects	O
then	O
underwent	O
mental	O
stress	O
testing	O
.	O


RESULTS	O
Persons	B-P
with	I-P
one	I-P
or	I-P
two	I-P
long	I-P
(	I-P
l	I-P
)	I-P
5HTTLPR	I-P
alleles	I-P
had	O
CSF	B-O
levels	I-O
of	O
the	O
major	O
serotonin	O
metabolite	O
,	O
5HIAA	O
,	O
that	O
were	O
50	O
%	O
higher	O
than	O
those	O
of	O
persons	O
with	O
the	O
s/s	O
5HTTLPR	B-P
genotype	I-P
.	I-P


Persons	O
with	O
one	O
or	O
two	O
l	O
alleles	O
or	O
higher	O
CSF	B-O
5HIAA	I-O
levels	I-O
also	O
exhibited	O
greater	O
blood	B-O
pressure	I-O
and	I-O
heart	I-O
rate	I-O
responses	I-O
to	O
a	O
mental	O
stress	O
protocol	O
.	O


CONCLUSIONS	O
These	O
findings	O
suggest	O
the	O
5HTTLPR	O
polymorphism	O
affects	O
CNS	O
serotonin	O
function	O
,	O
and	O
they	O
are	O
consistent	O
with	O
the	O
general	O
hypothesis	O
that	O
CNS	O
serotonin	O
function	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
potentially	O
health-damaging	O
biobehavioral	O
characteristics	O
.	O


In	O
particular	O
,	O
the	O
l	O
allele	O
could	O
contribute	O
,	O
through	O
its	O
association	O
with	O
increased	O
cardiovascular	B-O
reactivity	I-O
to	O
stress	O
,	O
to	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
.	O


Effects	O
of	O
two	O
types	O
of	O
social	B-I
support	I-I
and	I-I
education	I-I
on	O
adaptation	O
to	O
early-stage	B-P
breast	I-P
cancer	I-P
.	I-P


A	B-I
Roy	I-I
adaptation	I-I
model-based	I-I
support	I-I
and	I-I
education	I-I
intervention	I-I
for	O
women	B-P
with	I-P
early-stage	I-P
breast	I-P
cancer	I-P
was	I-P
tested	I-P
in	O
a	B-P
three-group	I-P
,	I-P
three-phase	I-P
randomized	I-P
clinical	I-P
trial	I-P
of	I-P
a	I-P
sample	I-P
of	I-P
125	I-P
women	I-P
.	I-P


The	O
experimental	O
group	O
received	O
13	O
months	O
of	O
combined	B-I
individual	I-I
telephone	I-I
and	I-I
in-person	I-I
group	I-I
support	I-I
and	I-I
education	I-I
,	O
Control	O
Group	O
1	O
received	O
13	O
months	O
of	O
telephone-only	B-I
individual	I-I
support	I-I
and	I-I
education	I-I
,	O
and	O
Control	O
Group	O
2	O
received	O
one-time	B-I
mailed	I-I
educational	I-I
information	I-I
.	I-I


The	O
experimental	O
group	O
and	O
Control	O
Group	O
1	O
reported	O
less	O
mood	B-O
disturbance	I-O
at	O
the	O
end	O
of	O
all	O
three	O
phases	O
,	O
less	B-O
loneliness	I-O
at	O
the	O
end	O
of	O
Phases	O
II	O
and	O
III	O
,	O
and	O
a	O
higher-quality	B-O
relationship	I-O
with	I-O
a	I-O
significant	I-O
other	I-O
at	O
the	O
end	O
of	O
Phase	O
II	O
than	O
did	O
Control	O
Group	O
2	O
.	O


No	O
group	O
differences	O
were	O
found	O
for	O
cancer-related	B-O
worry	I-O
or	I-O
well-being	I-O
.	I-O


The	O
findings	O
suggest	O
that	O
individual	O
telephone	O
support	O
may	O
provide	O
an	O
effective	O
alternative	O
to	O
in-person	O
support	O
groups	O
.	O


Further	O
study	O
of	O
telephone	O
interventions	O
is	O
recommended	O
using	O
ethnically	O
and	O
economically	O
heterogeneous	O
samples	O
.	O


Antimigraine	B-O
efficacy	I-O
of	O
telcagepant	B-I
based	O
on	O
patient	B-P
's	I-P
historical	I-P
triptan	I-I
response	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
whether	O
the	O
same	O
or	O
different	O
patients	B-P
respond	I-O
to	I-O
triptans	I-O
and	I-I
telcagepant	I-I
.	I-I


BACKGROUND	O
Telcagepant	B-I
is	O
an	O
oral	B-I
calcitonin	I-I
gene-related	I-I
peptide	I-I
receptor	I-I
antagonist	O
with	O
acute	O
antimigraine	B-O
efficacy	I-O
comparable	O
to	O
oral	B-I
triptans	I-I
.	I-I


It	O
is	O
currently	O
unknown	O
whether	O
migraine	B-P
patients	I-P
who	I-P
can	I-P
not	I-P
be	I-P
adequately	I-P
helped	I-P
with	I-P
triptans	I-I
might	O
benefit	O
from	O
treatment	O
with	O
telcagepant	B-I
.	I-I


METHODS	O
Post-hoc	O
analysis	O
of	O
data	O
from	O
a	O
randomized	O
,	O
controlled	O
trial	O
of	O
telcagepant	B-I
(	I-I
150	I-I
mg	I-I
,	I-I
300	I-I
mg	I-I
)	I-I
zolmitriptan	I-I
5	I-I
mg	I-I
,	I-I
or	I-I
placebo	I-I
for	O
a	O
moderate/severe	O
migraine	O
.	O


Responder	O
rates	O
were	O
analyzed	O
according	O
to	O
patients	B-P
'	I-P
self-reported	I-O
historical	I-O
triptan	I-O
response	I-O
(	I-O
HTR	I-O
)	I-O
:	I-O
(	I-P
1	I-P
)	I-P
good	I-P
HTR	I-P
(	I-P
N	I-P
=	I-P
660	I-P
)	I-P
:	I-P
response	I-P
in	I-P
75-100	I-P
%	I-P
of	I-P
attacks	I-P
;	I-P
(	I-P
2	I-P
)	I-P
intermediate	I-P
HTR	I-P
(	I-P
N	I-P
=	I-P
248	I-P
)	I-P
:	I-P
response	I-P
in	I-P
25-74	I-P
%	I-P
of	I-P
attacks	I-P
;	I-P
(	I-P
3	I-P
)	I-P
poor	I-P
HTR/no	I-P
use	I-P
(	I-P
N	I-P
=	I-P
407	I-P
)	I-P
:	I-P
response	I-P
in	I-P
<	I-P
25	I-P
%	I-P
of	I-P
attacks	I-P
,	I-P
or	I-P
patient	I-P
did	I-P
not	I-P
take	I-P
triptans	I-P
.	I-P


A	O
limitation	O
of	O
the	O
analysis	O
is	O
that	O
the	B-P
last	I-P
subgroup	I-P
comprised	I-P
mainly	I-P
(	I-P
91	I-P
%	I-P
)	I-P
patients	I-P
who	I-P
reported	I-P
that	I-P
they	I-P
did	I-P
not	I-P
take	I-P
triptans	I-P
,	I-P
but	I-P
it	I-P
was	I-P
not	I-P
known	I-P
whether	I-P
these	I-P
patients	I-P
were	I-P
triptan-naïve	I-P
or	I-P
had	I-P
previously	I-P
used	I-I
triptans	I-I
and	I-P
stopped	I-P
taking	I-P
them	I-P
.	I-P


RESULTS	O
For	B-I
zolmitriptan	I-I
,	O
2-hour	B-O
pain	I-O
relief	I-O
rates	I-O
were	O
higher	O
in	O
the	O
good	O
HTR	O
subgroup	O
(	O
116/162	O
,	O
72	O
%	O
)	O
than	O
in	O
the	O
intermediate	O
(	O
29/62	O
,	O
47	O
%	O
)	O
and	O
poor/no	O
use	O
(	O
44/111	O
,	O
40	O
%	O
)	O
HTR	O
subgroups	O
.	O


The	B-O
2-hour	I-O
pain	I-O
relief	I-O
rates	I-O
were	O
similar	O
across	O
HTR	O
subgroups	O
for	B-I
telcagepant	I-I
150	O
mg	O
(	O
48-58	O
%	O
)	O
,	O
300	O
mg	O
(	O
52-58	O
%	O
)	O
,	O
and	B-I
placebo	I-I
(	O
26-31	O
%	O
)	O
.	O


In	O
the	O
poor/no	O
use	O
HTR	O
subgroup	O
,	O
more	O
patients	O
receiving	B-I
telcagepant	I-I
300	O
mg	O
(	O
56/98	O
,	O
57.1	O
%	O
)	O
had	B-O
2-hour	I-O
pain	I-O
relief	I-O
than	O
those	O
receiving	B-I
zolmitriptan	I-I
(	O
44/111	O
,	O
39.6	O
%	O
;	O
odds	O
ratio	O
=	O
2.11	O
[	O
95	O
%	O
CI	O
:	O
1.20,3.71	O
]	O
,	O
P	O
=	O
.009	O
)	O
;	O
the	O
percentage	O
for	B-I
telcagepant	I-I
150	O
mg	O
(	O
57/119	O
,	O
47.9	O
%	O
)	O
was	O
not	O
significantly	O
different	O
from	B-I
zolmitriptan	I-I
(	O
odds	O
ratio	O
=	O
1.41	O
[	O
95	O
%	O
CI	O
:	O
0.82	O
,	O
2.40	O
]	O
,	O
P	O
=	O
.211	O
)	O
.	O


CONCLUSIONS	O
This	O
suggests	O
that	O
different	O
patients	O
may	O
respond	O
to	B-I
triptans	I-I
or	I-I
telcagepant	I-I
300	O
mg	O
.	O


Caution	O
should	O
be	O
exercised	O
in	O
interpreting	O
the	O
results	O
because	O
of	O
the	O
post-hoc	O
nature	O
of	O
the	O
analysis	O
(	O
clinical	O
trial	O
registry	O
:	O
NCT00442936	O
)	O
.	O


A	O
first-in-man	O
,	O
randomized	O
,	O
placebo-controlled	B-I
study	O
to	O
evaluate	O
the	O
safety	B-O
and	I-O
feasibility	I-O
of	O
autologous	B-I
delipidated	I-I
high-density	I-I
lipoprotein	I-I
plasma	I-I
infusions	I-I
in	O
patients	B-P
with	I-P
acute	I-P
coronary	I-P
syndrome	I-P
.	I-P


OBJECTIVES	O
This	O
study	O
aimed	O
to	O
determine	O
whether	O
serial	B-I
autologous	I-I
infusions	I-I
of	I-I
selective	I-I
high-density	I-I
lipoprotein	I-I
(	I-I
HDL	I-I
)	I-I
delipidated	I-I
plasma	I-I
are	O
feasible	B-O
and	O
well	O
tolerated	B-O
in	O
patients	B-P
with	I-P
acute	I-P
coronary	I-P
syndrome	I-P
(	I-P
ACS	I-P
)	I-P
.	I-P


BACKGROUND	O
Low	O
HDL	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
.	O


Plasma	O
selective	O
delipidation	O
converts	O
alphaHDL	O
to	O
prebeta-like	O
HDL	O
,	O
the	O
most	O
effective	O
form	O
of	O
HDL	O
for	O
lipid	O
removal	O
from	O
arterial	O
plaques	O
.	O


METHODS	O
ACS	B-P
patients	I-P
undergoing	I-P
cardiac	I-P
catheterization	I-P
with	I-P
>	I-P
or=1	I-P
nonobstructive	I-P
native	I-P
coronary	I-P
artery	I-P
atheroma	I-P
were	O
randomized	O
to	O
either	O
7	O
weekly	O
HDL	B-I
selective	I-I
delipidated	I-I
or	I-I
control	I-I
plasma	I-I
apheresis/reinfusions	I-I
.	I-I


Patients	O
underwent	O
intravascular	B-O
ultrasound	I-O
(	I-O
IVUS	I-O
)	I-O
evaluation	I-O
of	O
the	O
target	O
vessel	O
during	O
the	O
catheterization	O
for	O
ACS	O
and	O
up	O
to	O
14	O
days	O
following	O
the	O
final	O
apheresis/reinfusion	B-I
session	O
.	O


2-D	O
gel	O
electrophoresis	O
of	O
delipidated	O
plasmas	O
established	O
successful	O
conversion	O
of	O
alphaHDL	O
to	O
prebeta-like	O
HDL	O
.	O


The	O
trial	O
was	O
complete	O
with	O
28	B-P
patients	I-P
randomized	O
.	O


RESULTS	O
All	O
reinfusion	O
sessions	O
were	O
tolerated	B-O
well	O
by	O
all	O
patients	O
.	O


The	O
levels	B-O
of	I-O
prebeta-like	I-O
HDL	I-O
and	I-O
alphaHDL	I-O
in	O
the	O
delipidated	O
plasma	O
converted	O
from	O
5.6	O
%	O
to	O
79.1	O
%	O
and	O
92.8	O
%	O
to	O
20.9	O
%	O
,	O
respectively	O
.	O


The	O
IVUS	O
data	O
demonstrated	O
a	O
numeric	O
trend	O
toward	O
regression	O
in	O
the	O
total	O
atheroma	B-O
volume	I-O
of	O
-12.18	O
+/-	O
36.75	O
mm	O
(	O
3	O
)	O
in	O
the	O
delipidated	O
group	O
versus	O
an	O
increase	O
of	O
total	B-O
atheroma	I-O
volume	I-O
of	O
2.80	O
+/-	O
21.25	O
mm	O
(	O
3	O
)	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0.268	O
)	O
.	O


CONCLUSIONS	O
In	B-P
ACS	I-P
patients	I-P
,	O
serial	O
autologous	O
infusions	O
of	O
selective	B-I
HDL	I-I
delipidated	I-I
plasma	I-I
are	O
clinically	B-O
feasible	I-O
and	O
well	O
tolerated	B-O
.	I-O


This	O
therapy	O
may	O
offer	O
a	O
novel	O
adjunct	O
treatment	O
for	O
patients	B-P
presenting	I-P
with	I-P
ACS	I-P
.	I-P


Further	O
study	O
will	O
be	O
needed	O
to	O
determine	O
its	O
ability	O
to	O
reduce	O
clinical	B-O
cardiovascular	I-O
events	I-O
.	I-O


Ascorbic	B-I
acid	I-I
and	O
performance	B-O
in	O
man	O
.	O


Effects	O
on	O
performance	B-O
of	O
1	O
,	O
2	O
and	O
4	O
g	O
ascorbic	B-I
acid	I-I
were	O
studied	O
from	O
0.5-5.5	O
h	O
after	O
ingestion	O
in	O
six	B-P
healthy	I-P
females	I-P
.	I-P


Diazepam	B-I
(	I-I
5	I-I
mg	I-I
)	I-I
was	I-I
included	I-I
as	I-I
an	I-I
active	I-I
control	I-I
,	O
and	O
it	O
impaired	O
digit	B-O
symbol	I-O
substitution	I-O
,	I-O
visuomotor	I-O
coordination	I-O
and	I-O
complex	I-O
reaction	I-O
time	I-O
.	I-O


There	O
were	O
no	O
effects	O
of	O
any	O
dose	O
of	O
ascorbic	B-I
acid	I-I
on	O
performance	B-O
.	I-O


Social	B-O
support	I-O
and	O
abstinence	B-O
from	O
opiates	O
and	O
cocaine	O
during	B-P
opioid	I-I
maintenance	I-I
treatment	I-I
.	I-I


Social	B-I
support	I-I
may	O
play	O
an	O
important	O
role	O
in	O
helping	O
drug	B-P
users	I-P
achieve	O
abstinence	B-O
;	I-O
however	O
these	O
benefits	O
may	O
depend	O
on	O
the	O
type	O
of	O
support	O
experienced	O
.	O


In	O
this	O
prospective	O
observational	O
study	O
,	O
we	O
examined	O
the	O
extent	O
to	O
which	O
general	B-I
and	I-I
abstinence-specific	I-I
support	I-I
,	I-I
both	I-I
structural	I-I
and	I-I
functional	I-I
,	O
predicted	O
opiate	O
and	O
cocaine	O
abstinence	O
in	O
128	B-P
opioid	I-P
maintenance	I-P
patients	I-P
receiving	I-P
either	I-P
methadone	I-I
or	I-I
LAAM	I-I
.	I-I


A	O
new	O
multidimensional	O
self-report	O
instrument	O
assessing	O
abstinence-specific	B-I
functional	O
support	O
was	O
developed	O
for	O
the	O
study	O
.	O


Previously	O
validated	O
measures	O
were	O
used	O
to	O
assess	O
the	O
remaining	O
types	O
of	O
support	O
.	O


With	O
baseline	O
abstinence	O
and	O
other	O
statistically	O
important	O
covariates	O
adjusted	O
,	O
hierarchical	O
logistic	O
regression	O
analyses	O
demonstrated	O
that	O
the	O
associations	O
between	O
social	B-O
support	I-O
at	O
study	O
baseline	O
and	O
biochemically	O
confirmed	O
abstinence	O
3	O
months	O
later	O
varied	O
by	O
type	O
of	O
support	O
and	O
by	O
drug	O
.	O


Greater	O
abstinence-specific	B-O
structural	I-O
support	I-O
(	O
operationalized	O
as	O
fewer	O
drug	O
users	O
in	O
the	O
social	O
network	O
)	O
and	O
decreases	O
in	O
three	O
types	O
of	O
negative	B-O
abstinence-specific	I-O
functional	I-O
support	I-O
(	I-O
Complaints	I-O
about	I-O
Drug	I-O
Use	I-O
,	I-O
Drug	I-O
Exposure	I-O
,	I-O
and	I-O
Demoralization	I-O
)	I-O
predicted	I-O
cocaine	I-O
,	O
but	O
not	O
opiate	B-O
abstinence	I-O
.	I-O


There	O
were	O
no	O
effects	O
for	O
general	B-O
support	I-O
,	O
whether	O
structural	O
or	O
functional	O
,	O
on	O
abstinence	B-O
from	O
either	O
drug	O
.	O


Interventions	O
that	O
focus	O
on	O
modifying	O
patients	O
'	O
abstinence-specific	B-I
support	O
may	O
be	O
helpful	O
in	O
reducing	O
the	O
high	B-P
rates	I-O
of	I-O
cocaine	I-O
use	I-O
disorders	I-O
in	O
this	O
population	O
.	O


Increasing	B-P
the	I-P
reach	I-P
of	I-P
health	I-O
sponsorship	I-P
:	I-P
using	I-P
a	I-P
"	I-I
sponsorship	I-I
kit	I-I
"	I-I
to	I-P
promote	I-P
health	I-P
.	I-P


In	O
Australia	B-P
,	O
a	O
tobacco	O
tax	O
provides	O
funding	O
for	O
Healthway	O
,	O
the	O
Western	O
Australian	O
Health	O
Promotion	O
Foundation	O
.	O


Healthway	O
provides	O
sponsorships	O
for	O
the	O
arts	O
and	O
racing	O
and	O
sporting	O
events	O
to	O
replace	O
funds	O
previously	O
provided	O
by	O
tobacco	O
companies	O
.	O


These	O
sponsorships	O
provide	O
visibility	O
for	O
Healthway	O
and	O
positive	O
health	O
messages	O
.	O


Normally	O
,	O
Healthway	O
staff	O
attends	O
these	O
events	O
to	O
help	O
promote	O
health	O
messages	O
.	O


To	O
reduce	O
Healthway	B-P
staff	I-P
time	O
spent	O
helping	O
event	O
organizers	O
promote	O
health	O
messages	O
,	O
Healthway	O
developed	O
a	O
sponsor	B-I
kit	I-I
of	I-I
promotional	I-I
materials	I-I
which	O
communicate	O
health	O
messages	O
without	O
requiring	O
Healthway	B-P
staff	I-P
to	O
attend	O
events	O
.	O


Recognition	B-O
,	I-O
awareness	I-O
,	I-O
comprehension	I-O
,	I-O
and	I-O
acceptance	I-O
of	I-O
health	I-O
messages	I-O
was	O
comparable	O
at	O
events	O
that	O
featured	O
Healthway	O
staff	O
versus	O
the	O
sponsor	O
kits	O
,	O
but	O
the	O
average	O
cost	O
of	O
the	O
sponsorship	B-I
kits	I-I
was	O
only	O
40	O
%	O
of	O
the	O
cost	O
when	O
Healthway	O
staff	O
was	O
featured	O
.	O


A	O
randomized	O
clinical	O
trial	O
of	O
treatment	O
of	O
clomiphene	O
citrate-resistant	O
anovulation	O
with	O
the	O
use	O
of	O
oral	O
contraceptive	O
pill	O
suppression	O
and	O
repeat	O
clomiphene	O
citrate	O
treatment	O
.	O


OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	B-O
and	O
endocrine	B-O
response	I-O
of	O
oral	B-I
contraceptive	I-I
ovarian	O
suppression	O
followed	O
by	O
clomiphene	B-I
citrate	I-I
in	O
patients	B-P
who	I-P
previously	I-P
were	I-P
clomiphene	I-P
citrate	I-P
resistant	I-P
.	I-P


STUDY	O
DESIGN	O
Forty-eight	B-P
patients	I-P
from	I-P
a	I-P
private	I-P
tertiary	I-P
infertility	I-P
clinic	I-P
were	O
assigned	O
randomly	O
prospectively	B-I
to	I-I
either	I-I
group	I-I
1	I-I
(	I-I
oral	I-I
contraceptive/clomiphene	I-I
citrate	I-I
)	I-I
,	I-I
which	I-I
received	I-I
continuous	I-I
oral	I-I
contraceptives	I-I
followed	I-I
by	I-I
clomiphene	I-I
citrate	I-I
,	I-I
or	I-I
to	I-I
group	I-I
2	I-I
(	I-I
control	I-I
)	I-I
received	I-I
no	I-I
treatment	I-I
in	I-I
the	I-I
cycle	I-I
before	I-I
clomiphene	I-I
citrate	I-I
treatment	I-I
.	I-I


On	B-I
day	I-I
3	I-I
,	I-I
17	I-O
beta-estradiol	I-O
,	I-O
follicle-stimulating	I-O
hormone	I-O
,	I-O
luteinizing	I-O
hormone	I-O
,	I-O
and	I-O
androgens	I-O
were	I-I
assayed	I-I
before	I-I
and	I-I
after	I-I
treatment	I-I
.	I-I


Follicle	B-O
growth	I-O
,	I-O
ovulation	I-O
,	I-O
and	I-O
pregnancy	I-O
were	O
evaluated	O
.	O


The	O
Student	B-O
t	I-O
test	I-O
and	I-O
analysis	I-O
of	I-O
variance	I-O
were	O
used	O
for	O
statistical	O
significance	O
.	O


RESULTS	O
The	O
oral	O
contraceptive/clomiphene	O
citrate	O
group	O
had	O
a	O
significantly	O
higher	O
percentage	B-O
of	O
patients	O
who	O
ovulated	B-O
and	O
of	O
ovulatory	B-O
cycles	I-O
and	I-O
pregnancies	I-O
.	I-O


Significantly	O
lower	O
levels	O
of	O
17	B-O
beta-estradiol	I-O
,	I-O
luteinizing	I-O
hormone	I-O
,	I-O
and	I-O
androgen	I-O
levels	I-O
were	O
seen	O
in	O
the	O
oral	O
contraceptive/clomiphene	O
citrate	O
group	O
,	O
with	O
no	O
significant	O
changes	O
in	O
group	O
2	O
.	O


CONCLUSION	O
Suppression	O
of	O
the	O
ovary	O
with	O
oral	O
contraceptives	O
results	O
in	O
excellent	O
rates	O
of	O
ovulation	O
and	O
pregnancy	O
in	O
patients	B-P
who	I-P
previously	I-P
were	I-P
resistant	I-P
to	I-P
clomiphene	I-I
citrate	I-I
.	I-I


The	O
decreases	O
in	O
ovarian	O
androgens	O
,	O
luteinizing	O
hormone	O
,	O
and	O
17	O
beta-estradiol	O
may	O
be	O
responsible	O
for	O
the	O
improved	O
response	O
.	O


Long-term	O
heparin	B-I
treatment	I-I
in	O
ischaemic	B-P
heart	I-P
disease	I-P
.	I-P


Effects	O
on	O
clinical	O
condition	O
and	O
plasma	O
lipids	O
.	O


The	O
effect	O
of	O
the	O
use	O
of	O
oxytocin	B-I
on	O
blood	B-O
loss	I-O
during	I-O
different	I-O
postpartum	I-O
periods	I-O
.	I-O


OBJECTIVE	O
Postpartum	B-P
hemorrhage	I-P
is	O
the	O
most	O
important	O
reason	O
for	O
maternal	O
mortality	O
.	O


In	O
developed	O
countries	O
,	O
the	O
reason	O
of	O
13	O
%	O
of	O
maternal	O
deaths	O
is	O
postpartum	O
hemorrhage	O
while	O
this	O
percentage	O
reaches	O
more	O
than	O
30	O
%	O
in	O
other	O
countries	O
.	O


In	O
this	O
study	O
,	O
the	O
effect	O
of	O
oxytocin	B-I
use	O
in	O
different	O
times	O
at	O
the	O
3rd	O
stage	O
of	O
delivery	O
on	O
changes	O
in	O
the	O
postpartum	B-O
hemoglobin	I-O
levels	I-O
was	O
compared	O
.	O


DESIGN	O
AND	O
SETTING	O
In	O
the	O
study	O
,	O
89	B-P
pregnant	I-P
women	I-P
to	I-P
whom	I-P
oxytocin	I-I
was	I-I
administered	I-I
after	I-I
placenta	I-I
separation	I-I
were	I-P
studied	I-P
in	I-P
Group	I-P
1	I-P
,	I-P
89	I-P
pregnant	I-P
women	I-P
were	I-P
included	I-P
in	I-P
Group	I-P
2	I-P
,	I-P
and	I-P
oxytocin	I-I
was	I-I
administered	I-I
after	I-I
delivery	I-I
of	I-I
the	I-I
shoulder	I-I
.	I-I


The	O
levels	B-O
of	I-O
hemoglobin	I-O
and	I-O
hematocrit	I-O
before	O
and	O
after	O
delivery	O
were	O
quantified	O
.	O


RESULTS	O
The	O
biochemical	O
parameters	O
were	O
examined	O
,	O
there	O
was	O
no	O
significant	O
statistical	O
differences	O
in	O
the	O
levels	B-O
of	I-O
hemoglobin	I-O
and	I-O
hemotocrit	I-O
before	O
delivery	O
between	O
the	O
two	O
groups	O
.	O


When	O
compared	O
to	O
Group	O
1	O
,	O
Δ-hemoglobin	O
(	O
P=	O
>	O
0.001	O
)	O
,	O
Δ-hematocrit	O
(	O
P=	O
>	O
0.001	O
)	O
,	O
the	O
change	O
between	O
the	B-O
prepartum	I-O
and	I-O
postpartum	I-O
hemoglobin	I-O
percentage	I-O
(	O
P	O
<	O
=0.001	O
)	O
,	O
and	O
change	O
between	O
the	B-O
prepartum	I-O
and	I-O
postpartum	I-O
hemotocrit	I-O
percentage	I-O
(	O
P	O
<	O
=0.001	O
)	O
were	O
statistically	O
lower	O
in	O
Group	O
2	O
.	O


CONCLUSIONS	O
It	O
was	O
determined	O
that	O
the	O
use	O
of	B-I
oxytocin	I-I
after	O
shoulder	O
delivery	O
has	O
more	O
effects	O
on	O
decreasing	O
the	O
amount	O
of	B-O
postpartum	I-O
hemorrhage	I-O
.	O


Predictors	O
of	O
survival	O
and	O
eradication	O
of	O
Mycobacterium	O
avium	O
complex	O
bacteremia	O
(	O
MAC	O
)	O
in	B-P
AIDS	I-P
patients	I-P
in	I-P
the	I-P
Canadian	I-P
randomized	I-P
MAC	I-P
treatment	I-P
trial	I-P
.	I-P


Canadian	O
HIV	O
Trials	O
Network	O
Protocol	O
010	O
Study	O
Group	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
importance	O
of	O
baseline	O
characteristics	O
including	O
medical	B-O
history	I-O
,	I-O
indicators	I-O
of	I-O
current	I-O
disease	I-O
status	I-O
,	I-O
therapeutic	I-O
drug	I-O
use	I-O
,	I-O
in	I-O
vitro	I-O
drug	I-O
susceptibility	I-O
,	I-O
immune	I-O
status	I-O
and	I-O
mycobacterial	I-O
load	I-O
on	I-O
bacteriologic	I-O
response	I-O
and	O
survival	B-O
in	O
HIV-positive	B-P
patients	I-P
with	I-P
Mycobacterium	I-P
avium	I-P
complex	I-P
(	I-P
MAC	I-P
)	I-P
bacteremia	I-P
.	I-P


DESIGN	O
An	O
observational	O
substudy	O
of	O
an	O
open-label	O
randomized	O
controlled	O
trial	O
of	O
two	B-I
alternative	I-I
therapeutic	I-I
regimens	I-I
for	I-I
MAC	I-I
.	I-I


SETTING	O
Twenty-four	B-P
hospital-based	I-P
HIV	I-P
clinics	I-P
in	I-P
16	I-P
Canadian	I-P
cities	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
The	O
main	O
outcome	O
measures	O
were	O
survival	B-O
and	I-O
bacteriologic	I-O
response	I-O
,	I-O
defined	I-O
by	I-O
consecutive	I-O
negative	I-O
blood	I-O
cultures	I-O
for	I-O
MAC	I-O
at	O
least	O
2	O
weeks	O
apart	O
within	O
16	O
weeks	O
of	O
study	O
entry	O
.	O


RESULTS	O
Prior	O
AIDS	O
diagnosis	O
,	O
low	O
Karnofsky	O
score	O
,	O
active	O
unstable	O
AIDS-related	O
conditions	O
,	O
absence	O
of	O
antiretroviral	O
therapy	O
and	O
absence	O
of	O
Pneumocystis	O
carinii	O
pneumonia	O
prophylaxis	O
were	O
associated	O
with	O
shorter	O
survival	B-O
by	O
univariate	O
regression	O
using	O
the	O
proportional	O
hazards	O
model	O
.	O


On	O
multivariate	O
analysis	O
,	O
antiretroviral	O
therapy	O
was	O
not	O
an	O
independent	O
predictor	O
of	O
mortality	B-O
,	O
and	O
previous	O
rifabutin	O
prophylaxis	O
was	O
independently	O
associated	O
with	O
poor	O
survival	O
outcomes	O
,	O
a	O
result	O
consistent	O
across	O
study	O
treatment	O
.	O


Using	O
a	O
logistic	O
regression	O
model	O
,	O
baseline	B-O
quantitative	I-O
mycobacterial	I-O
load	I-O
[	O
relative	O
odds	O
of	O
clearing	O
,	O
1.97	O
for	O
a	O
decrease	O
of	O
1	O
log10	O
colony	O
forming	O
count	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
1.36-2.87	O
;	O
P	O
<	O
0.001	O
]	O
and	O
Karnofsky	B-O
score	I-O
were	O
the	O
only	O
statistically	O
significant	O
univariate	O
predictors	O
of	O
clearance	O
,	O
although	O
previous	O
prophylaxis	O
with	O
rifabutin	O
was	O
also	O
a	O
significant	O
predictor	O
in	O
a	O
multivariate	B-O
model	I-O
(	O
relative	O
odds	O
of	O
clearing	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.17-0.88	O
;	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	O
This	O
study	O
indicates	O
that	O
although	O
the	O
level	O
of	O
MAC	O
bacteremia	O
is	O
an	O
important	O
predictor	O
of	O
clearance	O
,	O
it	O
is	O
not	O
associated	O
with	O
survival	O
.	O


A	O
comparison	O
of	O
albuterol	B-I
solution	I-I
nebulized	I-I
versus	I-I
albuterol	I-I
powder	I-I
given	O
by	O
breath	O
activated	O
metered	O
dose	O
inhaler	O
.	O


The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
nebulized	B-I
vs	I-I
powdered	I-I
albuterol	I-I
in	O
patients	B-P
with	I-P
exacerbated	I-P
bronchial	I-P
asthma	I-P
who	I-P
required	I-P
hospitalization	I-P
.	I-P


From	B-P
January	I-P
to	I-P
May	I-P
1990	I-P
known	I-P
asthmatics	I-P
admitted	I-P
with	I-P
acute	I-P
exacerbation	I-P
were	I-P
included	I-P
by	I-P
established	I-P
criteria	I-P
.	I-P


Two	O
groups	O
were	O
randomized	O
.	O


Group	O
I	O
for	O
Albuterol	B-I
powder	I-I
200	O
micrograms	O
inhaled	O
q	O
4	O
hours	O
.	O


Group	O
II	O
with	O
Albuterol	B-I
nebulized	I-I
solution	I-I
2.5	O
mg	O
inhaled	O
q	O
4	O
hrs	O
.	O


Force	B-O
Vital	I-O
Capacity	I-O
and	I-O
Force	I-O
Expiratory	I-O
Volume	I-O
in	O
one	O
second	O
were	O
measured	O
with	O
a	O
pressure	O
differential	O
transducer	O
upon	O
admission	O
,	O
30	O
minutes	O
and	O
24-hours	O
following	O
therapies	O
.	O


Absolute	B-O
FEV1	I-O
improvement	I-O
was	O
calculated	O
.	O


Statistical	O
analysis	O
was	O
performed	O
using	O
student	O
's	O
T-Test	O
and	O
Fisher	O
's	O
exact	O
Test	O
with	O
significance	O
established	O
at	O
p	O
>	O
0.01	O
%	O
.	O


Fifteen	B-P
patients	I-P
enrolled	I-P
in	I-P
both	I-P
groups	I-P
,	I-P
two	I-P
patients	I-P
of	I-P
group	I-P
I	I-P
were	I-P
excluded	I-P
from	O
the	O
statistic	O
analysis	O
due	O
to	O
refusal	O
to	O
continue	O
with	O
the	O
therapy	O
.	O


Both	O
groups	O
were	O
comparable	O
with	O
respect	O
to	O
sex	O
,	O
asthma	O
exacerbations/year	O
,	O
smoking	O
history	O
and	O
hospital	O
length	O
of	O
stay	O
.	O


FVC	B-O
and	I-O
FEV1	I-O
were	O
comparable	O
also	O
.	O


In	O
contrast	O
,	O
there	O
were	O
significant	O
difference	O
when	O
the	O
absolute	O
improvement	O
were	O
compared	O
.	O


The	O
mean	B-O
+/-	I-O
SE	I-O
for	I-O
FEV1	I-O
absolute	O
improvement	O
at	O
the	O
first	O
30	O
min	O
was	O
0.42	O
+/-	O
0.08	O
lts	O
for	O
the	O
Group	O
I	O
versus	O
0.65	O
+/-	O
0.6	O
lts	O
in	O
the	O
Group	O
II	O
.	O


In	O
the	O
next	O
24	O
hours	O
,	O
Group	O
I	O
was	O
0.16	O
+/-	O
0.2	O
lts	O
versus	O
0.30	O
+/-	O
0.7	O
lts	O
in	O
Group	O
II	O
(	O
p	O
>	O
.01	O
)	O
.	O


We	O
conclude	O
that	O
although	O
the	O
dose	O
equivalence	O
of	O
both	O
delivery	O
systems	O
have	O
not	O
been	O
established	O
in	O
our	O
study	O
,	O
the	O
nebulized	B-I
solution	I-I
was	O
more	O
effective	O
during	O
the	O
first	O
24	O
hours	O
of	O
hospitalization	O
than	O
the	O
dry	B-I
powder	I-I
.	I-I


Cemented	B-I
CeraOne	I-I
and	I-I
porcelain	I-I
fused	I-I
to	I-I
TiAdapt	I-I
abutment	I-I
single-implant	I-I
crown	I-I
restorations	I-I
:	I-I
a	O
10-year	O
comparative	O
follow-up	O
study	O
.	O


BACKGROUND	O
Long-term	O
data	O
comparing	O
cemented	B-I
and	O
noncemented	B-I
single-implant	I-I
restorations	I-I
has	O
not	O
been	O
reported	O
.	O


AIM	O
To	O
compare	O
clinical	B-O
and	I-O
radiographic	I-O
performance	I-O
of	O
single-implant	B-I
crown	I-I
restorations	I-I
made	O
by	O
either	O
directly	O
baked	B-I
porcelain	I-I
to	I-I
custom-made	I-I
TiAdapt	I-I
titanium	I-I
abutments	I-I
(	O
Nobel	O
Biocare	O
AB	O
,	O
Göteborg	O
,	O
Sweden	O
)	O
(	O
test	O
)	O
or	B-I
cement	I-I
crowns	I-I
onto	I-I
CeraOne	I-I
(	I-I
Nobel	I-I
Biocare	I-I
AB	I-I
)	I-I
abutments	I-I
(	I-I
control	I-I
)	I-I
after	O
10	O
years	O
in	O
function	O
.	O


MATERIALS	O
AND	O
METHODS	B-P
Altogether	I-P
,	I-P
35	I-P
consecutive	I-P
patients	I-P
were	I-P
provided	I-P
with	I-P
41	I-P
turned	I-I
single	I-I
Brånemark	I-I
System	I-I
implants	I-I
(	I-I
Nobel	I-I
Biocare	I-I
AB	I-I
)	I-I
in	I-P
the	I-P
partially	I-P
edentulous	I-P
upper	I-P
jaw	I-P
.	I-P


By	B-P
random	I-P
,	I-P
15	I-P
and	I-P
20	I-P
patients	I-P
were	I-P
provided	I-P
with	I-P
18	I-I
test	I-I
and	I-P
23	I-I
control	I-I
implant	I-I
crowns	I-I
,	I-P
respectively	I-P
.	O


Thereafter	B-O
,	I-O
clinical	I-O
and	I-O
radiographic	I-O
data	I-O
were	O
collected	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O


RESULTS	B-O
None	I-O
of	O
the	B-I
implants	I-I
were	I-O
found	I-O
loose	I-O
during	O
the	O
follow-up	O
period	O
(	B-O
100	I-O
%	I-O
)	I-O
.	I-O


Few	B-O
clinical	I-O
problems	I-O
were	O
observed	O
,	O
and	O
the	B-O
overall	I-O
average	I-O
marginal	I-O
bone	I-O
loss	I-O
was	O
0.26	O
mm	O
(	O
SD	O
0.64	O
)	O
during	O
10	O
years	O
in	O
function	O
.	O


After	O
the	O
final	O
tightening	O
of	O
the	O
crowns	B-O
,	I-O
no	I-O
significant	I-O
differences	I-O
were	O
observed	O
between	O
the	B-I
test	I-I
and	I-I
control	I-I
groups	O
(	O
p	O
>	O
.05	O
)	O
.	O


The	O
head	O
of	O
the	B-I
implants	I-I
was	O
placed	O
on	O
an	O
average	O
6.3	O
mm	O
(	O
SD	O
2.24	O
)	O
below	O
the	O
cement/enamel	O
junction	O
of	O
the	O
adjacent	O
teeth	O
(	O
range	O
2.5-10.0	O
mm	B-I
)	I-I
.	I-I


Implants	B-I
with	O
reported	O
mechanical	O
and/or	O
mucosal	O
problems	O
or	O
placed	O
more	O
apically	O
in	O
relation	O
to	O
the	O
adjacent	O
teeth	O
did	O
not	O
present	O
more	B-O
bone	I-O
loss	I-O
as	O
compared	O
with	B-I
implants	I-I
with	O
no	O
problems	O
or	O
placed	O
more	O
coronally	O
,	O
respectively	O
(	O
p	O
>	O
.05	O
)	O
.	O


CONCLUSIONS	O
There	O
seems	O
to	O
be	O
no	O
obvious	B-O
clinical	I-O
or	I-O
radiographic	I-O
differences	I-O
between	O
the	B-I
test	I-I
and	I-I
control	I-I
single-implant	I-I
restorations	I-I
during	O
10	O
years	O
of	O
follow-up	O
.	O


Occasionally	O
,	O
some	B-I
restorations	I-I
presented	O
loose	B-O
abutment	I-O
screws	I-O
and/or	I-O
fistulas	I-O
during	O
follow-up	O
.	O


This	O
implies	O
a	O
certain	O
need	O
for	O
maintenance	O
where	O
a	B-I
one-piece	I-I
single-implant	I-I
protocol	I-I
(	I-I
test	I-I
)	I-I
allows	O
both	O
for	O
a	O
simple	O
clinical	O
procedure	O
at	O
placement	O
without	O
cementation	O
problems	O
,	O
as	O
well	O
as	O
for	O
an	O
easy	O
and	O
simple	O
maintenance	O
of	B-I
installed	I-I
single	I-I
implant	I-I
crowns	I-I
in	O
long-term	O
function	O
.	O


Intranasal	B-I
recombinant	I-I
alfa-2b	I-I
interferon	I-I
treatment	I-O
of	O
naturally	B-O
occurring	I-O
common	I-O
colds	I-O
.	I-O


In	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
,	O
patients	B-P
with	I-P
naturally	I-P
occurring	I-P
common	I-P
colds	I-P
of	I-P
less	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
48	I-P
h	I-P
duration	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
nasal	O
sprays	O
of	O
recombinant	B-I
alfa-2b	I-I
interferon	I-I
at	O
10	O
or	O
20	O
MU/day	O
or	O
placebo	B-I
four	O
times	O
per	O
day	O
for	O
5	O
days	O
.	O


The	O
10-MU	B-P
(	I-P
n	I-P
=	I-P
74	I-P
)	I-P
,	I-P
20-MU	I-P
(	I-P
n	I-P
=	I-P
74	I-P
)	I-P
,	I-P
and	I-P
placebo	I-I
(	I-P
n	I-P
=	I-P
72	I-P
)	I-P
groups	I-P
had	O
comparable	O
frequencies	O
of	O
documented	O
rhinovirus	O
colds	O
(	O
50	O
to	O
65	O
%	O
)	O
and	O
mean	B-O
durations	I-O
of	I-O
pretreatment	I-O
symptoms	I-O
(	O
26	O
to	O
27	O
h	O
)	O
.	O


The	O
median	B-O
duration	I-O
of	I-O
colds	I-O
tended	O
to	O
be	O
longer	O
in	O
the	O
20-MU	O
group	O
(	O
10	O
days	O
)	O
than	O
the	O
10-MU	O
group	O
(	O
8	O
days	O
)	O
or	O
placebo	B-I
group	O
(	O
8	O
days	O
)	O
(	O
P	O
=	O
0.06	O
)	O
.	O


In	O
those	O
with	O
proven	O
rhinovirus	O
colds	O
treated	O
within	O
24	O
h	O
,	O
the	O
median	B-O
duration	I-O
was	O
significantly	O
longer	O
in	O
the	O
20-MU	O
group	O
(	O
9	O
days	O
)	O
than	O
in	O
the	O
placebo	B-I
group	O
(	O
6	O
days	O
)	O
.	O


No	O
differences	O
favoring	O
interferon	O
treatment	O
were	O
found	O
in	O
respiratory	B-O
symptom	I-O
scores	I-O
or	I-O
resolution	I-O
of	I-O
specific	I-O
symptoms	I-O
.	I-O


On	O
days	O
5	O
and	O
7	O
,	O
nasal	B-I
washings	I-I
from	O
compliant	O
subjects	O
with	O
proven	O
rhinovirus	O
colds	O
yielded	O
rhinoviruses	O
more	O
often	O
in	O
placebo	B-I
(	O
47	O
and	O
48	O
%	O
,	O
respectively	O
)	O
than	O
in	O
interferon	B-I
(	O
15	O
and	O
16	O
%	O
,	O
respectively	O
)	O
recipients	O
(	O
P	O
less	O
than	O
0.02	O
)	O
,	O
but	O
no	O
differences	O
in	O
new	O
respiratory	B-O
illness	I-O
occurrence	I-O
were	O
observed	O
in	O
household	O
contacts	O
.	O


Interferon	B-I
recipients	O
had	O
significantly	O
higher	O
frequencies	O
of	O
blood	B-O
in	I-O
nasal	I-O
mucus	I-O
(	O
16	O
to	O
18	O
%	O
)	O
than	O
did	O
placebo	B-I
recipients	O
(	O
4	O
%	O
)	O
during	O
treatment	O
.	O


Antibiotics	B-O
for	O
presumed	O
secondary	O
infections	O
were	O
given	O
more	O
often	O
in	O
the	O
20-MU	O
group	O
(	O
11	O
%	O
)	O
than	O
in	O
the	O
placebo	B-I
group	O
(	O
0	O
%	O
)	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O


Nasal	O
sprays	O
of	O
recombinant	B-I
alfa-2b	I-I
interferon	I-I
were	O
not	O
an	O
effective	B-O
treatment	I-O
for	I-O
natural	I-O
colds	I-O
and	O
were	O
associated	O
with	O
toxicity	B-O
.	I-O


Testing	O
the	O
efficacy	O
of	O
an	O
HIV	B-O
stigma	I-O
reduction	I-O
intervention	I-I
with	O
medical	B-P
students	I-P
in	I-P
Puerto	I-P
Rico	I-P
:	I-P
the	O
SPACES	O
project	O
.	O


INTRODUCTION	O
Stigma	B-O
associated	O
with	O
HIV	O
has	O
been	O
documented	O
as	O
a	O
barrier	O
for	O
accessing	O
quality	O
health-related	O
services	O
.	O


When	O
the	O
stigma	O
manifests	O
in	O
the	O
health	O
care	O
setting	O
,	O
people	O
living	O
with	O
HIV	O
receive	O
substandard	O
services	O
or	O
even	O
be	O
denied	O
care	O
altogether	O
.	O


Although	O
the	O
consequences	O
of	O
HIV	B-O
stigma	I-O
have	O
been	O
documented	O
extensively	O
,	O
efforts	O
to	O
reduce	O
these	O
negative	O
attitudes	O
have	O
been	O
scarce	O
.	O


Interventions	B-I
to	I-I
reduce	I-I
HIV	I-O
stigma	I-O
should	O
be	O
implemented	O
as	O
part	O
of	O
the	O
formal	O
training	O
of	O
future	O
health	O
care	O
professionals	O
.	O


The	O
interventions	O
that	O
have	O
been	O
tested	O
with	O
health	B-P
care	I-P
professionals	I-P
and	O
published	O
have	O
several	O
limitations	O
that	O
must	O
be	O
surpassed	O
(	O
i.e	O
.	O


lack	O
of	O
comparison	O
groups	O
in	O
research	O
designs	O
and	O
longitudinal	O
follow-up	O
data	O
)	O
.	O


Furthermore	O
,	O
Latino	B-P
health	I-P
care	I-P
professionals	I-P
have	O
been	O
absent	O
from	O
these	O
intervention	O
efforts	O
even	O
though	O
the	O
epidemic	O
has	O
affected	O
this	O
population	O
disproportionately	O
.	O


METHODS	O
In	O
this	O
article	O
,	O
we	O
describe	O
an	O
intervention	B-I
developed	I-I
to	I-I
reduce	I-I
HIV	I-O
stigma	I-O
among	I-I
medical	I-I
students	I-I
in	I-I
Puerto	I-I
Rico	I-I
.	I-I


A	O
total	O
of	O
507	B-P
medical	I-P
students	I-P
were	O
randomly	O
introduced	O
into	O
our	O
intervention	B-I
and	I-I
control	I-I
conditions	I-I
.	I-I


RESULTS	O
The	O
results	O
show	O
statistically	O
significant	O
differences	O
between	O
the	O
intervention	B-I
and	O
control	B-I
groups	O
;	O
intervention	O
group	O
participants	O
had	O
lower	B-O
HIV	I-O
stigma	I-O
levels	I-O
than	O
control	O
participants	O
after	O
the	O
intervention	O
.	O


In	O
addition	O
,	O
differences	O
in	O
HIV	B-O
stigma	I-O
levels	I-O
between	O
the	O
groups	O
were	O
sustained	O
for	O
a	O
12-month	O
period	O
.	O


CONCLUSION	O
The	O
results	O
of	O
our	O
study	O
demonstrate	O
the	O
efficacy	O
of	O
the	O
modes	O
of	O
intervention	O
developed	O
by	O
us	O
and	O
serve	O
as	O
a	O
new	O
training	O
tool	O
for	O
future	B-P
health	I-P
care	I-P
professionals	I-P
with	O
regard	O
to	O
stigma	B-O
reduction	I-O
.	I-O


Abstinence	B-I
or	I-I
controlled	I-I
drinking	I-I
in	O
clinical	O
practice	O
:	O
indications	O
at	O
initial	O
assessment	O
.	O


Previous	O
research	O
has	O
suggested	O
two	O
leading	O
hypotheses	O
concerning	O
which	O
excessive	B-P
drinkers	I-P
can	O
re-establish	O
control	O
:	O
one	O
based	O
upon	O
level	O
of	O
dependence	O
,	O
the	O
other	O
upon	O
the	O
client	O
's	O
personal	O
persuasion	O
.	O


Using	O
initial	O
assessment	O
data	O
from	O
46	B-P
clients	I-P
of	I-P
a	I-P
clinical	I-P
psychology	I-P
alcohol	I-P
problems	I-P
service	I-P
(	I-P
30	I-P
men	I-P
,	I-P
16	I-P
women	I-P
)	I-P
,	O
an	O
attempt	O
was	O
made	O
to	O
operationalize	O
the	O
concepts	O
of	O
dependence	B-I
and	O
personal	B-I
persuasion	I-I
using	O
a	O
variety	O
of	O
indicators	O
of	O
each	O
.	O


Although	O
SADQ	B-O
scores	I-O
and	I-O
Rand	I-O
definite	I-O
alcoholism	I-O
were	O
in	O
general	O
agreement	O
,	O
there	O
were	O
a	O
number	O
of	O
borderline	O
instances	O
and	O
cases	O
of	O
disagreement	O
,	O
and	O
neither	O
was	O
in	O
good	O
agreement	O
with	O
estimates	O
of	O
problem	O
duration	O
,	O
nor	O
with	O
reports	O
of	O
recent	O
or	O
earlier	O
attainment	O
of	O
abstinence	B-I
or	O
control	B-I
.	I-I


Indicators	O
of	O
personal	B-O
persuasion	I-O
were	O
more	O
consistent	O
.	O


Those	B-P
with	I-P
dependence	I-I
indicators	I-O
for	I-O
abstinence	I-O
tended	O
to	O
prefer	O
abstinence	B-I
as	O
a	O
goal	O
,	O
but	O
there	O
were	O
many	O
departures	O
from	O
this	O
pattern	O
particularly	O
for	O
women	O
.	O


It	O
is	O
concluded	O
that	O
in	O
clinical	O
practice	O
it	O
will	O
be	O
very	O
difficult	O
to	O
make	O
a	O
clear	O
cut	O
recommendation	O
about	O
treatment	O
goal	O
at	O
initial	O
assessment	O
except	O
in	O
a	O
few	O
cases	O
.	O


The	O
Tiotropium	B-I
Safety	I-O
and	I-O
Performance	I-O
in	O
Respimat	O
Trial	O
(	O
TIOSPIR	O
)	O
,	O
a	O
large	O
scale	O
,	O
randomized	O
,	O
controlled	O
,	O
parallel-group	O
trial-design	O
and	O
rationale	O
.	O


BACKGROUND	O
Tiotropium	B-I
bromide	I-I
is	O
an	O
effective	O
therapy	O
for	O
COPD	B-P
patients	I-P
.	I-P


Comparing	O
across	O
programs	O
tiotropium	B-I
Respimat	I-I
Soft	I-I
Mist	I-I
inhaler	I-I
was	O
at	O
least	O
as	O
efficacious	O
as	O
tiotropium	B-I
HandiHaler	I-I
,	O
however	O
,	O
concerns	O
have	O
been	O
raised	O
about	O
tiotropium	B-I
's	I-I
safety	O
when	O
given	O
via	O
Respimat	O
.	O


METHODS	O
The	O
TIOSPIR	O
trial	O
(	O
NCT01126437	O
)	O
compares	O
the	O
safety	B-O
and	I-O
efficacy	I-O
of	O
tiotropium	B-I
Respimat	I-I
5	I-I
μg	I-I
once	O
daily	O
(	O
marketed	O
)	O
and	O
2.5	O
μg	O
once	O
daily	O
(	O
investigational	O
)	O
with	B-I
tiotropium	I-I
HandiHaler	I-I
18	I-I
μ	I-I
once	I-I
daily	I-I
(	O
marketed	O
)	O
.	O


The	O
hypotheses	O
to	O
be	O
tested	O
are	O
1	O
)	O
.	O


that	B-I
tiotropium	I-I
Respimat	I-I
5	O
μg	O
once	O
daily	O
and	B-I
Respimat	I-I
2.5	O
μg	O
once	O
daily	O
are	O
non-inferior	B-I
to	I-I
HandiHaler	I-I
in	O
terms	O
of	O
all-cause	O
mortality	O
,	O
and	O
2	O
)	O
.	O


that	B-I
tiotropium	I-I
Respimat	I-I
5	O
μg	O
once	O
daily	O
is	O
superior	B-I
to	I-I
HandiHaler	I-I
in	O
terms	O
of	O
time	O
to	O
first	O
exacerbation	O
.	O


A	O
spirometry	O
substudy	O
evaluates	B-O
the	I-O
bronchodilator	I-O
efficacy	I-O
.	O


The	O
trial	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
double	O
dummy	O
,	O
event-driven	O
,	O
parallel	O
group	O
study	B-P
.	I-P


Participants	B-P
can	I-P
use	I-P
any	I-P
background	I-P
treatment	I-P
for	I-P
COPD	I-P
except	I-P
inhaled	I-P
anticholinergic	I-P
agents	I-P
.	I-P


The	B-P
study	I-P
encompasses	I-P
a	I-P
wide	I-P
range	I-P
of	I-P
COPD	I-P
patients	I-P
,	I-P
e.g	I-P
.	I-P


patients	B-P
with	I-P
stable	I-P
cardiac	I-P
diseases	I-P
including	I-P
arrhythmia	I-P
can	I-P
be	I-P
included	I-P
.	I-P


Clinical	B-P
sites	I-P
are	I-P
international	I-P
and	I-P
include	I-P
both	I-P
primary	I-P
care	I-P
as	I-P
well	I-P
as	I-P
specialists	I-P
.	O


RESULTS	B-P
To	I-P
date	I-P
,	I-P
over	I-P
17,000	I-P
participants	I-P
have	I-P
been	I-P
randomized	I-P
from	I-P
over	I-P
1200	I-P
sites	I-P
in	I-P
50	I-P
countries	I-P
with	O
an	O
anticipated	O
treatment	O
duration	O
of	O
2-3	O
years	O
.	O


CONCLUSION	O
TIOSPIR	O
will	O
provide	O
precise	O
estimates	O
of	B-O
the	I-O
relative	I-O
safety	I-O
and	I-O
efficacy	I-O
of	I-I
the	I-I
Respimat	I-I
and	I-I
HandiHaler	I-I
formulations	I-I
of	I-I
tiotropium	I-I
,	O
assess	O
potential	B-O
dose-dependence	I-O
of	I-O
important	I-O
outcomes	I-O
and	O
provide	B-O
information	I-O
on	I-O
the	I-O
clinical	I-O
epidemiology	I-O
of	O
COPD	B-O
in	I-O
a	I-O
large	I-O
international	I-O
patient	I-O
cohort	I-O
.	O


A	O
role	O
for	O
error	B-I
training	I-I
in	O
surgical	B-I
technical	I-I
skill	I-I
instruction	I-I
and	I-I
evaluation	I-I
.	I-I


BACKGROUND	O
During	O
the	O
evaluation	O
of	O
many	O
instances	O
of	O
the	O
same	O
basic	O
surgical	O
skill	O
,	O
we	O
observed	O
that	O
there	O
were	O
several	O
errors	O
that	O
occurred	O
frequently	O
.	O


Two	O
studies	O
were	O
undertaken	O
to	O
examine	O
the	O
use	O
of	O
these	O
errors	O
for	O
improving	O
the	O
instruction	O
and	O
evaluation	O
of	O
the	O
skill	O
.	O


MATERIALS	O
AND	O
METHODS	O
For	O
both	O
studies	O
,	O
two	B-I
types	I-I
of	I-I
rater	I-I
training	I-I
videotapes	I-I
were	O
developed	O
.	O


One	O
involved	O
the	O
use	O
of	O
examples	B-I
of	I-I
common	I-I
errors	I-I
(	I-I
error	I-I
)	I-I
and	O
the	O
other	O
demonstrated	O
the	O
skill	B-I
being	I-I
performed	I-I
correctly	I-I
(	I-I
correct	I-I
)	I-I
.	O


A	O
testing	O
videotape	O
was	O
created	O
consisting	O
of	O
24	O
performances	O
of	O
the	O
skill	O
that	O
ranged	O
in	O
quality	O
of	O
the	O
performance	O
.	O


The	O
first	O
study	O
was	O
designed	O
to	O
assess	O
the	O
impact	O
of	O
error	B-I
instruction	I-I
on	O
skill	B-O
acquisition	I-O
.	I-O


In	O
this	O
study	O
,	O
a	B-P
group	I-P
of	I-P
30	I-P
senior	I-P
medical	I-P
students	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
one	O
of	O
four	O
different	O
training	O
groups	O
:	O
none	B-I
,	I-I
error	I-I
only	I-I
,	I-I
correct	I-I
only	I-I
,	I-I
and	I-I
error+correct	I-I
.	I-I


Subjects	O
were	O
videotaped	O
performing	O
the	O
skill	O
before	O
and	O
after	O
the	O
training	O
and	O
three	O
experts	O
evaluated	O
these	O
performances	B-O
independently	O
using	O
a	O
7-point	O
rating	O
scale	O
.	O


The	O
second	O
study	O
was	O
designed	O
to	O
assess	O
the	O
impact	O
of	O
error	B-I
training	I-I
on	O
skill	O
evaluation	O
and	O
was	O
done	O
using	O
both	O
novice	O
and	O
expert	O
raters	O
.	O


The	O
same	O
group	O
of	O
30	B-P
senior	I-P
medical	I-P
students	I-P
used	I-P
in	I-P
the	I-P
first	I-P
study	I-P
was	I-P
used	I-P
as	I-P
novice	I-P
raters	I-P
.	I-P


Following	O
training	O
in	O
one	O
of	O
the	O
four	O
training	O
groups	O
,	O
each	O
subject	O
rated	O
the	O
24	O
performances	O
on	O
the	O
testing	B-I
videotape	I-I
and	I-I
interrater	I-I
reliability	I-I
was	O
assessed	O
for	O
each	O
group	O
.	O


Surgical	O
faculty	O
served	O
as	O
expert	O
raters	O
in	O
this	O
study	O
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
error	B-I
training	I-I
or	O
no	B-I
training	I-I
.	I-I


Each	O
subject	O
viewed	O
the	O
testing	O
videotape	O
,	O
rating	O
the	O
performances	O
and	O
giving	O
"	O
feedback	O
"	O
commentary	O
.	O


Interrater	B-O
reliability	I-O
was	O
calculated	O
for	O
the	O
two	O
groups	O
and	O
the	O
precision	O
of	O
the	O
feedback	O
was	O
assessed	O
.	O


RESULTS	O
Significant	O
improvement	O
in	O
posttest	B-O
performance	I-O
scores	I-O
was	O
seen	O
only	O
in	O
the	O
"	B-I
error+correct	I-I
"	I-I
training	O
group	O
.	O


Interrater	B-O
reliability	I-O
was	O
somewhat	O
lower	O
for	O
the	O
"	B-I
correct	I-I
only	I-I
"	I-I
and	O
"	B-I
error	I-I
only	I-I
"	I-I
training	O
groups	O
in	O
both	O
the	O
student	O
and	O
faculty	O
studies	O
.	O


Faculty	O
raters	O
receiving	O
error	O
training	O
had	O
a	O
higher	O
proportion	O
of	O
specific	O
comments	O
than	O
the	O
group	O
that	O
received	O
no	O
training	O
although	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O


CONCLUSIONS	O
Instruction	O
about	O
common	B-I
errors	I-I
,	O
when	O
combined	O
with	O
instruction	O
about	O
the	O
correct	O
performance	O
enhanced	O
the	O
acquisition	O
of	O
this	O
surgical	O
skill	O
.	O


This	O
suggests	O
a	O
role	O
for	O
the	O
use	O
of	O
errors	O
in	O
surgical	B-I
technical	I-I
skill	I-I
instruction	I-I
.	I-I


Our	O
study	O
provides	O
no	O
support	O
for	O
a	O
role	O
for	O
error	B-I
training	I-I
in	O
improving	O
skill	O
evaluation	O
.	O


Effect	O
of	O
thermal	O
stress	O
,	O
restricted	B-I
feeding	I-I
and	O
combined	B-I
stresses	I-I
(	I-I
thermal	I-I
stress	I-I
and	I-I
restricted	I-I
feeding	I-I
)	I-I
on	O
growth	O
and	O
plasma	O
reproductive	O
hormone	O
levels	O
of	O
Malpura	B-P
ewes	I-P
under	I-P
semi-arid	I-P
tropical	I-P
environment	I-P
.	I-P


A	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effect	O
of	O
thermal	O
,	O
nutritional	O
and	O
combined	O
stresses	O
(	O
thermal	O
and	O
nutritional	O
)	O
on	O
the	O
growth	O
,	O
oestradiol	O
and	O
progesterone	O
levels	O
during	O
oestrus	O
cycles	O
in	O
Malpura	B-P
ewes	I-P
.	I-P


Twenty-eight	B-P
adult	I-P
Malpura	I-P
ewes	I-P
were	I-P
used	I-P
in	O
the	O
present	O
study	O
.	O


The	O
ewes	O
were	O
randomly	O
allocated	O
into	O
four	O
groups	O
,	O
viz.	O
,	O
GI	O
(	O
n=7	O
;	O
control	B-I
)	I-I
,	O
GII	O
(	O
n=7	O
;	O
thermal	B-I
stress	I-I
)	I-I
,	O
GIII	O
(	O
n=7	O
;	O
restricted	B-I
feeding	I-I
)	I-I
and	O
GIV	O
(	O
n=7	O
;	O
combined	B-I
stress	I-I
)	I-I
.	O


The	O
animals	B-P
were	I-P
stall	I-I
fed	I-I
with	I-I
a	I-I
diet	I-I
consisting	I-I
of	I-I
60	I-I
%	I-I
roughage	I-I
and	I-I
40	I-I
%	I-I
concentrate	I-I
.	I-I


GI	O
and	O
GII	O
ewes	O
were	O
provided	O
with	O
ad	O
libitum	O
feeding	O
while	O
GIII	O
and	O
GIV	O
ewes	O
were	O
provided	O
with	O
restricted	O
feed	O
(	O
30	O
%	O
intake	O
of	O
GI	O
and	O
GII	O
ewes	O
)	O
to	O
induce	O
nutritional	O
insufficiency	O
.	O


GII	O
and	O
GIV	O
ewes	O
were	O
kept	O
in	O
climatic	O
chamber	O
at	O
40°C	O
and	O
55	O
%	O
RH	O
for	O
6	O
h	O
a	O
day	O
between	O
10:00	O
and	O
16:00	O
hours	O
to	O
induce	O
thermal	O
stress	O
for	O
a	O
period	O
of	O
two	O
oestrous	O
cycles	O
.	O


Parameters	O
studied	O
were	B-O
body	I-O
weight	I-O
,	I-O
oestrus	I-O
incidences	I-O
,	I-O
plasma	I-O
oestradiol	I-O
17-β	I-O
,	I-O
plasma	I-O
progesterone	I-O
,	I-O
conception	I-O
rate	I-O
,	I-O
gestation	I-O
period	I-O
,	I-O
lambing	I-O
rate	I-O
,	I-O
and	I-O
birth	I-O
weight	I-O
of	I-O
lambs	I-O
.	O


The	O
results	O
indicate	O
that	O
combined	O
stress	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
reduced	B-O
body	I-O
weight	I-O
,	I-O
oestrus	I-O
duration	I-O
,	I-O
birth	I-O
weight	I-O
of	I-O
lambs	I-O
,	I-O
and	I-O
oestradiol	I-O
17-β	I-O
whereas	I-O
significantly	I-O
(	I-O
p	I-O
<	I-O
0.05	I-O
)	I-O
increased	I-O
oestrus	I-O
cycle	I-O
length	I-O
and	I-O
progesterone	I-O
.	O


Furthermore	O
,	O
the	O
results	O
reveal	O
that	O
on	O
comparative	O
basis	O
,	O
ewes	O
were	O
able	O
to	O
better	O
adapt	O
in	B-O
terms	I-O
of	I-O
growth	I-O
and	I-O
reproduction	I-O
to	O
restricted	O
feeding	O
than	O
thermal	O
stress	O
.	O


However	O
,	O
when	O
restricted	O
feeding	O
was	O
coupled	O
with	O
thermal	O
stress	O
it	O
had	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
influence	O
on	B-O
body	I-O
weight	I-O
,	I-O
average	I-O
daily	I-O
gain	I-O
,	I-O
oestradiol	I-O
17-β	I-O
and	I-O
progesterone	I-O
concentrations	I-O
.	O


This	O
showed	O
that	O
combined	O
stress	O
were	O
more	O
detrimental	O
for	O
these	O
reproductive	O
hormones	O
in	O
Malpura	O
ewes	O
under	O
a	O
hot	O
semi-arid	O
environment	O
.	O


Caphosol	B-I
(	I-I
®	I-I
)	I-I
mouthwash	I-I
gives	O
no	O
additional	O
protection	O
against	O
oral	O
mucositis	O
compared	O
to	B-I
cryotherapy	I-I
alone	O
in	B-P
stem	I-P
cell	I-P
transplantation	I-P
.	O


A	O
pilot	O
study	O
.	O


PURPOSE	O
To	O
investigate	O
if	O
adding	B-I
Caphosol	I-I
(	I-I
®	I-I
)	I-I
,	O
a	O
mouthwash	O
solution	O
,	O
to	O
oral	B-I
cryotherapy	I-I
(	O
OC	O
)	O
further	O
protects	O
against	O
oral	O
mucositis	O
(	O
OM	O
)	O
,	O
a	O
toxic	O
painful	O
complication	O
to	O
high	O
dose	O
chemotherapy	O
.	O


METHOD	O
The	O
study	O
was	O
a	O
randomised	O
,	O
controlled	O
,	O
study	O
design	B-P
.	I-P


Patients	B-P
≥16	I-P
years	I-P
scheduled	I-P
for	I-P
allogeneic	I-P
stem	I-P
cell	I-P
transplantation	I-P
were	I-P
included	I-P
consecutively	O
and	O
randomised	O
to	O
experimental	O
group	O
receiving	B-I
OC	I-I
combined	I-I
with	I-I
Caphosol	I-I
(	I-I
®	I-I
)	I-I
(	O
n	O
=	O
20	B-I
)	I-I
or	I-I
control	I-I
group	I-I
receiving	I-I
OC	I-I
only	O
(	O
n	O
=	O
20	B-I
)	I-I
.	O


OC	O
was	O
given	O
from	O
start	O
to	O
end	O
of	O
HDCT	B-I
.	I-I


Caphosol	B-I
(	I-I
®	I-I
)	I-I
,	O
from	O
day	O
0	O
to	O
day	O
21	O
.	O


RESULT	O
There	O
were	O
no	O
significant	O
differences	O
regarding	O
age	O
or	O
gender	O
between	O
the	O
groups	B-O
.	I-O


Mucositis	B-O
was	O
assessed	O
with	B-O
the	I-O
World	I-O
Health	I-O
Organisation	I-O
(	I-O
WHO	I-O
)	I-O
grading	I-O
scale	I-O
.	I-O


Pain	O
was	O
assessed	O
with	B-O
a	I-O
10	I-O
cm	I-O
visual	I-O
analogue	I-O
scale	I-O
(	O
VAS	O
)	O
from	O
0	O
=	O
no	O
pain	O
to	O
10	O
=	O
worst	O
imaginable	O
pain	B-O
.	I-O


Start	B-O
and	I-O
duration	I-O
of	I-O
therapy	I-O
with	I-O
pain	I-O
relieving	I-O
drugs	I-O
,	I-O
serum	I-O
C-reactive	I-O
protein	I-O
values	I-O
,	I-O
and	I-O
number	I-O
of	I-O
days	I-O
of	I-O
hospitalisation	I-O
were	O
collected	O
from	O
the	O
medical	O
records	B-O
.	I-O


Data	B-O
on	I-O
OM	I-O
,	I-O
oral	I-O
pain	I-O
,	I-O
use	I-O
of	I-O
i.v	I-O
.	I-O


opioids	B-O
and	I-O
total	I-O
parenteral	I-O
nutrition	I-O
were	O
collected	O
during	O
22	O
days	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	B-O
on	I-O
OM	I-O
,	I-O
oral	I-O
pain	I-O
,	I-O
use	I-O
of	I-O
i.v	I-O
.	I-O


opioids	B-O
or	I-O
TPN	O
between	O
the	O
groups	O
.	O


CONCLUSION	O
The	O
study	O
showed	O
no	O
additional	O
effect	O
of	O
combining	B-I
Caphosol	I-I
(	I-I
®	I-I
)	I-I
with	I-I
OC	O
.	O


Changes	O
in	O
calcanean	O
bone	O
mineral	O
occurring	O
spontaneously	O
and	O
during	O
hormone	B-I
replacement	I-I
therapy	I-I
in	O
early	B-P
post-menopausal	I-P
women	I-P
.	I-P


The	O
spontaneous	B-P
calcanean	I-P
bone	I-P
loss	I-P
occurring	I-P
in	I-P
healthy	I-P
early	I-P
post-menopausal	I-P
women	I-P
and	O
the	O
effect	O
of	O
two	B-I
hormone	I-I
replacement	I-I
therapies	I-I
(	I-I
HRT	I-I
's	I-I
)	I-I
were	O
investigated	O
in	O
a	O
longitudinal	O
study	O
.	O


There	O
was	O
no	O
difference	O
between	O
the	O
right	O
and	O
left	O
calcanean	O
BMC	O
or	O
BMD	O
(	O
p	O
>	O
0.15	O
)	O
.	O


The	O
spontaneous	O
bone	O
loss	O
was	O
similar	O
at	O
all	O
the	O
skeletal	O
sites	O
measured	O
,	O
with	O
a	O
mean	O
spontaneous	O
loss	O
in	O
calcanean	O
BMD	O
of	O
1.6	O
%	O
over	O
one	O
year	O
.	O


Both	O
HRT	O
's	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
prevented	O
the	O
bone	B-O
loss	I-O
from	O
all	O
skeletal	O
sites	O
irrespective	O
of	O
the	O
weight-bearing	O
or	O
content	O
of	O
trabecular	O
bone	O
,	O
and	O
(	O
for	O
the	O
weight-bearing	O
bones	O
)	O
there	O
was	O
even	O
a	O
gain	O
in	O
calcanean	B-O
BMC	I-O
and	I-O
BMD	I-O
and	I-O
spinal	I-O
BMD	I-O
(	O
p	O
<	O
0.01	O
)	O
.	O


Bone	O
mineral	O
of	O
the	O
calcaneus	O
and	O
the	O
spine	O
correlated	O
equally	O
to	O
body	O
weight	O
(	O
r	O
approximately	O
0.4	O
,	O
p	O
<	O
0.001	O
)	O
,	O
whereas	O
bone	O
mineral	O
in	O
the	O
forearm	O
was	O
not	O
correlated	O
to	O
body	O
weight	O
.	O


The	O
correlations	O
between	O
the	O
changes	O
in	O
bone	O
mineral	O
at	O
the	O
sites	O
measured	O
were	O
all	O
significant	O
(	O
r	O
approximately	O
0.2-0.4	O
)	O
.	O


Heparan	B-I
sulfate	I-I
in	O
the	O
treatment	O
of	O
intermittent	B-P
claudication	I-P
:	I-P
results	O
of	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
multicenter	O
trial	O
.	O


Peripheral	O
arterial	O
disease	O
(	O
PAD	O
)	O
is	O
by	O
far	O
the	O
most	O
common	O
cause	O
of	O
intermittent	B-P
claudication	I-P
.	I-P


This	O
disease	O
can	O
greatly	O
reduce	O
the	O
affected	O
individual	O
's	O
walking	O
capacity	O
and	O
can	O
seriously	O
affect	O
daily	O
life	O
activities	O
.	O


Few	O
therapeutic	O
options	O
are	O
aimed	O
at	O
improving	O
walking	B-O
capacity	I-O
.	I-O


This	O
was	O
a	O
randomized	O
,	O
doubleblind	O
,	O
placebo-controlled	O
,	O
multicenter	B-P
trial	I-P
,	I-P
performed	I-P
in	I-P
24	I-P
Italian	I-P
centers	I-P
.	I-P


Two	B-P
hundred	I-P
seventeen	I-P
patients	I-P
with	I-P
intermittent	I-P
claudication	I-P
(	I-P
stages	I-P
IIa	I-P
and	I-P
IIb	I-P
of	I-P
Fontaine	I-P
's	I-P
PAD	I-P
classification	I-P
)	I-P
were	O
randomly	B-I
assigned	I-I
to	I-I
heparan	I-I
sulfate	I-I
(	I-I
40	I-I
mg	I-I
orally	I-I
twice	I-I
a	I-I
day	I-I
)	I-I
or	I-I
placebo	I-I
for	I-I
6	I-I
months	I-I
.	I-I


The	O
primary	O
end-point	O
was	O
an	O
increase	O
in	O
pain-free	B-O
walking	I-O
distance	I-O
[	O
initial	O
claudication	B-O
distance	I-O
(	I-O
ICD	I-O
)	I-O
]	I-O
during	O
the	O
24	O
weeks	O
of	O
treatment	O
.	O


The	O
pain-free	B-O
and	I-O
the	I-O
absolute	I-O
walking	I-O
distance	I-O
(	I-O
ACD	I-O
)	I-O
were	O
monitored	O
by	O
standardized	O
treadmill	O
test	O
at	O
baseline	O
and	O
at	O
4	O
,	O
12	O
and	O
24	O
weeks	O
.	O


The	O
change	O
in	O
initial	O
claudication	B-O
distance	I-O
during	O
treatment	O
,	O
expressed	O
as	O
integrated	O
change	O
over	O
time	O
,	O
was	O
significantly	O
greater	O
with	O
heparan	B-I
sulfate	I-I
than	O
with	O
placebo	O
(	O
306	O
+/-	O
494	O
vs.	O
250	O
+/-	O
510	O
meters	O
x	O
months	O
,	O
p	O
=	O
0.019	O
)	O
.	O


Significantly	O
fewer	O
treated	O
patients	O
worsened	O
during	O
treatment	O
(	O
decreased	O
initial	B-O
claudication	I-O
distance	I-O
)	I-O
compared	O
with	O
controls	O
(	O
9.1	O
%	O
vs.	O
19.6	O
%	O
;	O
p	O
=	O
0.027	O
)	O
.	O


Functional	B-O
recovery	I-O
in	O
the	O
most	O
severely	O
affected	O
subgroup	O
of	O
patients	O
(	O
stage	O
IIb	O
of	O
Fontaine	O
's	O
classification	O
)	O
was	O
more	O
clearly	O
detected	O
and	O
significantly	O
greater	O
among	O
treated	O
than	O
among	O
control	O
patients	O
(	O
absolute	O
increase	O
in	O
ICD	O
:	O
70	O
+/-	O
113	O
vs.	O
58	O
+/-	O
172	O
meters	O
,	O
p	O
=	O
0.028	O
;	O
integrated	O
increase	O
:	O
304	O
+/-	O
422	O
vs.	O
208	O
+/-	O
503	O
meters	O
x	O
months	O
;	O
p	O
=	O
0.004	O
)	O
.	O


Heparan	O
sulfate	O
appeared	O
to	O
increase	O
the	O
walking	B-O
capacity	I-O
of	O
patients	B-P
with	I-P
intermittent	I-P
claudication	I-P
to	O
a	O
significantly	O
greater	O
extent	O
than	O
did	O
placebo	O
.	O


The	O
treatment	O
was	O
well	O
tolerated	O
.	O


Does	O
short-term	O
treatment	O
with	O
proton	B-I
pump	I-I
inhibitors	I-I
cause	O
rebound	O
aggravation	O
of	O
symptoms	O
?	O
BACKGROUND	O
Rebound	O
acid	O
hypersecretion	O
might	O
occur	O
after	O
treatment	O
with	O
proton	B-I
pump	I-I
inhibitors	I-I
.	I-I


This	O
study	O
looks	O
for	O
a	O
rebound	O
aggravation	O
of	O
symptoms	O
after	O
short-term	O
treatment	O
with	O
lansoprazole	B-I
.	I-I


STUDY	O
Sixty-two	B-P
patients	I-P
(	I-P
19	I-P
men	I-P
and	I-P
43	I-P
women	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
54	I-P
years	I-P
;	I-P
range	I-P
,	I-P
32-77	I-P
years	I-P
)	I-P
with	I-P
heartburn	I-P
and	I-P
regurgitation	I-P
and	I-P
normal	I-P
upper	I-P
endoscopy	I-P
findings	I-P
were	O
studied	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
with	O
a	O
crossover	O
design	O
.	O


There	O
were	O
two	O
5-day	O
treatment	O
periods	O
with	O
lansoprazole	B-I
60	I-I
mg	I-I
once	I-I
daily	I-I
or	I-I
placebo	I-I
in	O
random	O
order	O
,	O
separated	O
by	O
a	O
9-day	O
washout	O
period	O
.	O


Reflux	B-O
,	I-O
total	I-O
,	I-O
and	I-O
antacid	I-O
scores	I-O
were	O
calculated	O
for	O
each	O
of	O
the	O
treatment	O
periods	O
.	O


Higher	O
scores	O
during	O
the	O
placebo	B-I
period	O
in	O
the	O
group	O
given	O
lansoprazole	B-I
first	O
than	O
in	O
the	O
group	O
given	O
placebo	O
first	O
indicated	O
a	O
rebound	O
aggravation	O
of	O
symptoms	O
.	O


RESULTS	O
The	O
mean	O
symptom	B-O
scores	I-O
during	O
the	O
placebo	B-I
period	O
in	O
the	O
groups	O
given	O
lansoprazole	O
first	O
and	O
placebo	O
first	O
were	O
as	O
follows	O
:	O
reflux	B-O
score	I-O
,	O
21.5	O
and	O
17.6	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
;	O
total	B-O
score	I-O
,	O
11.2	O
and	O
10.3	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
;	O
and	O
antacid	B-O
score	I-O
,	O
8.2	O
and	O
7.2	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O


CONCLUSIONS	O
There	O
is	O
no	O
indication	O
of	O
a	O
rebound	O
aggravation	O
of	O
symptoms	O
12	O
to	O
14	O
days	O
after	O
a	O
5-day	O
treatment	O
with	O
lansoprazole	B-I
60	O
mg	O
once	O
daily	O
in	O
patients	B-P
with	I-P
reflux	I-P
symptoms	I-P
.	I-P


A	O
randomised	O
trial	O
of	O
radiotherapy	B-I
compared	O
with	O
cisplatin	B-I
chemo-radiotherapy	I-I
in	O
patients	B-P
with	I-P
unresectable	I-P
squamous	I-P
cell	I-P
cancer	I-P
of	I-P
the	I-P
esophagus	I-P
.	I-P


BACKGROUND	O
AND	O
PURPOSE	O
Following	O
our	O
phase	O
II	O
experience	O
,	O
a	O
randomised	O
trial	O
was	O
undertaken	O
to	O
evaluate	O
the	O
efficacy	B-O
of	O
adding	B-I
chemotherapy	I-I
to	I-I
radiotherapy	I-I
in	I-I
patients	I-P
with	I-P
unresectable	I-P
squamous	I-P
cell	I-P
cancer	I-P
of	I-P
the	I-P
esophagus	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Patients	O
randomised	O
to	O
the	O
RT	B-I
group	I-I
received	I-I
50	I-I
Gy/25	I-I
fx/5	I-I
weeks	I-I
of	I-I
teletherapy	I-I
followed	I-I
1-2	I-I
weeks	I-I
later	I-I
with	I-I
12	I-I
Gy/2	I-I
fx	I-I
of	I-I
high-dose-rate	I-I
intra-lumenal	I-I
brachytherapy	I-I
spaced	I-I
a	I-I
week	I-I
apart	I-I
.	I-I


Following	O
the	O
first	O
3	O
years	O
of	O
recruitment	O
,	O
due	O
to	O
unexpected	O
late	O
morbidity	O
,	O
brachytherapy	B-I
was	O
excluded	O
and	O
the	O
protocol	O
modified	O
to	O
66	O
Gy/33	O
fx/6.5	O
weeks	O
.	O


The	O
CRT	O
group	O
received	B-I
identical	I-I
radiotherapy	I-I
with	I-I
concurrent	I-I
weekly	I-I
cisplatin	I-I
at	I-I
35	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
for	I-I
6-7	I-I
cycles	I-I
.	I-I


RESULTS	O
Between	B-P
April	I-P
1999	I-P
and	I-P
December	I-P
2005	I-P
,	I-P
125	I-P
patients	I-P
were	I-P
randomised	I-P
to	O
a	O
RT	O
(	O
n=60	O
)	O
or	O
CRT	O
group	O
(	O
n=65	O
)	O
.	O


Radiotherapy	O
treatment	O
was	O
completed	O
in	O
78	O
%	O
(	O
47/60	O
)	O
of	O
the	O
RT	O
group	O
and	O
89	O
%	O
(	O
58/65	O
)	O
of	O
the	O
CRT	O
group	O
(	O
P=0.10	O
)	O
.	O


Six	O
or	O
more	O
cycles	O
of	O
cisplatin	O
could	O
be	O
delivered	O
in	O
63	O
%	O
(	O
41/65	O
)	O
,	O
which	O
resulted	O
in	O
RTOG	B-O
grade	I-O
3	I-O
neutropenia	I-O
of	O
3	O
%	O
.	O


Late	B-O
morbidity	I-O
in	I-O
the	I-O
form	I-O
of	I-O
ulcers	I-O
(	O
5	O
%	O
vs.	O
15	O
%	O
odds	O
ratio	O
0.29	O
,	O
95	O
%	O
CI	O
0.08-1.11	O
,	O
P=0.08	O
)	O
and	O
strictures	B-O
(	O
13	O
%	O
vs.	O
28	O
%	O
,	O
odds	O
ratio	O
0.40	O
,	O
95	O
%	O
CI	O
0.16-1.01	O
,	O
P=0.05	O
)	O
was	O
observed	O
in	O
the	O
RT	O
and	O
CRT	O
groups	O
,	O
respectively	O
.	O


At	O
a	O
median	O
follow	O
up	O
of	O
23	O
months	O
of	O
all	O
patients	O
alive	O
(	O
range	O
6-82	O
months	O
)	O
and	O
with	O
95/125	O
events	O
,	O
the	O
median	O
,	O
1	O
,	O
2	O
and	O
5	O
year	O
projected	O
survival	B-O
was	O
7.1	O
months	O
,	O
32.3	O
%	O
,	O
22.8	O
%	O
and	O
13.7	O
%	O
vs.	O
13.4	O
months	O
,	O
57.6	O
%	O
,	O
38.9	O
%	O
and	O
24.8	O
%	O
for	O
the	O
RT	O
and	O
CRT	O
groups	O
,	O
respectively	O
(	O
hazard	O
ratio	O
0.65	O
,	O
95	O
%	O
CI	O
0.44-0.98	O
,	O
P=0.038	O
)	O
.	O


CONCLUSIONS	O
The	O
addition	O
of	O
concurrent	O
cisplatin	B-I
to	O
radiotherapy	B-I
resulted	O
in	O
a	O
modest	B-O
improvement	I-O
in	I-O
survival	I-O
and	O
was	O
associated	O
with	O
manageable	B-O
additional	I-O
acute	I-O
and	I-O
late	I-O
morbidity	I-O
.	I-O


Use	O
of	O
granulocyte-macrophage	B-I
colony-stimulating	I-I
factor	I-I
and	O
erythropoietin	B-I
in	O
combination	O
after	B-P
autologous	I-I
marrow	I-I
transplantation	I-I
.	I-I


The	O
toxicities	O
and	O
possible	O
utility	O
of	O
the	O
combination	B-I
of	I-I
recombinant	I-I
human	I-I
granulocyte-macrophage	I-I
colony-stimulating	I-I
factor	I-I
(	I-I
rhGM-CSF	I-I
)	I-I
and	I-I
recombinant	I-I
human	I-I
erythropoietin	I-I
(	I-I
rHuEPO	I-I
)	I-I
given	O
after	O
autologous	B-I
BMT	I-I
were	O
evaluated	O
in	O
this	O
pilot	O
trial	O
.	O


Eighteen	B-P
patients	I-P
received	O
the	O
combination	O
and	O
were	O
compared	O
with	O
six	B-I
concurrent	I-I
control	I-I
and	I-I
65	I-I
historical	I-I
control	I-I
patients	I-I
treated	I-I
with	I-I
rhGM-CSF	I-I
alone	I-I
.	I-I


Patients	O
treated	O
with	O
the	O
combination	O
tended	O
to	O
have	O
more	O
rapid	O
recovery	B-O
to	O
an	O
absolute	B-O
neutrophil	I-O
count	I-O
of	O
500	O
x	O
10	O
(	O
6	O
)	O
/l	O
(	O
median	O
=	O
12.5	O
vs	O
18	O
days	O
for	O
concurrent	O
and	O
19	O
days	O
for	O
historical	O
control	O
patients	O
)	O
.	O


There	O
was	O
no	O
apparent	O
impact	O
on	O
red	B-O
cell	I-O
transfusion	I-O
requirements	I-O
,	I-O
platelet	I-O
recovery	I-O
or	I-O
duration	I-O
of	I-O
hospitalization	I-O
.	I-O


Patients	O
treated	O
in	O
the	O
current	O
study	O
with	O
rhGM-CSF	O
plus	O
either	O
rHuEPO	O
or	O
with	O
placebo	O
had	O
a	O
higher	O
incidence	B-O
of	I-O
rash	I-O
than	O
seen	O
in	O
our	O
historical	O
experience	O
using	O
rhGM-CSF	O
.	O


This	O
difference	O
may	O
reflect	O
changes	O
in	O
the	O
source	O
of	O
rhGM-CSF	O
or	O
in	O
the	O
infusion	O
schedule	O
.	O


Erythropoietin	O
can	O
be	O
combined	O
safely	O
with	O
rhGM-CSF	O
after	O
autologous	O
transplantation	O
.	O


Larger	O
controlled	O
trials	O
will	O
be	O
necessary	O
to	O
detect	O
possible	O
therapeutic	O
effects	O
.	O


Standardized	O
treatment	O
of	O
Chinese	B-I
medicine	I-I
decoction	I-I
for	O
cancer	B-P
pain	I-P
patients	I-P
with	I-P
opioid-induced	I-O
constipation	I-O
:	I-O
a	O
multi-center	O
prospective	O
randomized	O
controlled	O
study	O
.	O


OBJECTIVE	O
To	O
observe	O
the	O
efficacy	B-O
and	O
the	O
influence	O
on	O
quality	B-O
of	I-O
life	I-O
(	I-O
QOL	I-O
)	I-O
of	O
syndrome	O
differentiation	O
treatment	O
with	O
Chinese	B-I
medicine	I-I
(	I-I
CM	I-I
)	I-I
for	O
opioid-induced	B-O
constipation	I-O
as	O
well	O
as	O
the	O
safety	B-O
and	I-O
influence	I-O
on	I-O
analgesic	I-O
effect	I-O
of	I-O
opioids	I-O
.	I-O


METHODS	O
Totally	B-P
406	I-P
cases	I-P
enrolled	I-P
from	I-P
53	I-P
collaborating	I-P
medical	I-P
centers	I-P
were	O
randomly	O
assigned	O
to	O
a	O
CM	B-I
group	O
and	O
a	O
control	O
group	O
.	O


The	O
CM	O
group	O
were	O
treated	O
with	O
CM	B-I
decoction	I-I
based	O
on	O
syndrome	O
differentiation	O
,	O
and	O
the	O
control	O
group	O
were	O
treated	O
with	O
Phenolphthalein	B-I
Tablet	I-I
.	I-I


Both	O
groups	O
were	O
treated	O
for	O
14	O
days	O
.	O


Cleveland	B-O
constipation	I-O
score	I-O
(	I-O
CCS	I-O
)	I-O
,	I-O
numerical	I-O
rating	I-O
scale	I-O
(	I-O
NRS	I-O
)	I-O
of	I-O
pain	I-O
and	I-O
Chinese	I-O
version	I-O
of	I-O
European	I-O
Organisation	I-O
for	I-O
Research	I-O
and	I-O
Treatment	I-O
of	I-O
Cancer	I-O
,	I-O
Quality	I-O
of	I-O
Life	I-O
Questionnaire-C30	I-O
V3.0	I-O
(	I-O
EORTC	I-O
QLQ-C30	I-O
V3.0	I-O
)	I-O
were	O
used	O
to	O
evaluate	O
the	O
efficacy	B-O
,	I-O
pain	I-O
controlled	I-O
and	O
QOL	B-O
status	I-O
.	I-O


RESULTS	O
The	O
comparisons	O
of	O
CCS	B-O
score	I-O
reduction	I-O
and	O
QOL	B-O
between	O
the	O
two	O
groups	O
after	O
treatment	O
suggested	O
that	O
the	O
improvements	B-O
of	I-O
constipation	I-O
and	I-O
QOL	I-O
in	O
the	O
CM	O
group	O
were	O
better	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
total	O
efficiency	B-O
of	O
the	O
CM	O
group	O
was	O
better	O
than	O
the	O
control	O
group	O
(	O
93.5	O
%	O
vs.	O
86.4	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
NRS	B-O
scores	I-O
between	O
before	O
and	O
after	O
treatment	O
in	O
both	O
groups	O
.	O


There	O
was	O
no	O
serious	O
drug-related	B-O
adverse	I-O
event	I-O
during	O
the	O
course	O
of	O
study	O
.	O


CONCLUSION	O
CM	B-I
decoction	I-I
could	O
effectively	O
treat	O
opioid-induced	B-O
constipation	I-O
and	O
improve	O
patients	B-O
'	I-O
QOL	I-O
at	O
the	O
same	O
time	O
.	O


It	O
is	O
safe	O
and	O
does	O
n't	O
affect	O
the	O
analgesic	B-O
effect	I-O
of	I-O
opioids	I-O
when	O
treating	O
constipation	B-O
.	I-O


Durability	B-O
of	O
central	B-I
venous	I-I
catheters	I-I
.	I-I


A	O
randomized	O
trial	O
in	O
children	B-P
with	I-P
malignant	I-P
diseases	I-P
.	I-P


In	O
a	O
prospective	O
randomized	O
study	O
the	O
durability	B-O
of	O
tunnelled	B-I
and	I-I
non-tunnelled	I-I
central	I-I
venous	I-I
catheters	I-I
was	O
investigated	O
in	O
children	B-P
with	I-P
malignant	I-P
diseases	I-P
.	I-P


Twenty	B-P
children	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
but	I-P
four	I-P
(	I-P
two	I-P
in	I-P
each	I-P
group	I-P
)	I-P
had	I-P
to	I-P
be	I-P
excluded	I-P
;	I-P
three	I-P
because	I-P
the	I-P
entry	I-P
criteria	I-P
turned	I-P
out	I-P
not	I-P
to	I-P
be	I-P
fulfilled	I-P
and	I-P
one	I-P
because	I-P
of	I-P
lack	I-P
of	I-P
data	I-P
.	I-P


The	O
median	B-O
duration	I-O
of	O
the	O
tunnelled	B-I
catheters	I-I
was	O
224	O
days	O
with	O
a	O
range	O
of	O
25-846	O
days	O
which	O
was	O
significantly	B-O
longer	I-O
than	O
that	O
of	O
conventional	B-I
catheters	I-I
(	O
39.5	O
days	O
,	O
range	O
9-228	O
days	O
)	O
.	O


In	O
addition	O
six	O
of	O
eight	O
conventional	O
catheters	O
were	O
accidentally	O
removed	O
whereas	O
all	O
catheters	O
in	O
the	O
tunnelled	O
group	O
had	O
to	O
be	O
removed	O
via	O
a	O
small	O
incision	O
.	O


Three	O
cases	O
of	O
catheter	B-O
related	I-O
sepsis	I-O
,	O
two	O
in	O
the	O
tunnelled	O
group	O
and	O
one	O
in	O
the	O
conventional	O
group	O
,	O
were	O
registered	O
.	O


The	O
corresponding	O
number	B-O
of	I-O
infections	I-O
per	I-O
catheter	I-O
days	I-O
were	O
1	O
in	O
1189	O
days	O
and	O
1	O
in	O
522	O
days	O
,	O
respectively	O
.	O


In	O
conclusion	O
cuffed	B-I
,	I-I
tunnelled	I-I
central	I-I
venous	I-I
catheters	I-I
are	O
less	O
prone	O
to	O
displacement	B-O
than	O
traditional	B-I
percutaneous	I-I
central	I-I
venous	I-I
catheters	I-I
when	O
used	O
in	O
children	B-P
with	I-P
malignant	I-P
diseases	I-P
.	I-P


Cardiac	O
failure	O
:	O
symptoms	O
and	O
functional	O
status	O
.	O


The	O
associations	O
between	O
exercise	O
capacity	O
,	O
symptoms	O
and	O
specific	O
aspects	O
of	O
quality	O
of	O
life	O
were	O
examined	O
in	O
subjects	B-P
participating	I-P
in	I-P
a	I-P
trial	I-P
of	I-P
the	I-P
treatment	I-I
of	I-I
heart	I-I
failure	I-I
.	I-I


Patients	B-I
were	I-I
assessed	I-I
on	I-P
entry	I-P
and	I-P
after	I-P
three	I-P
months	I-P
treatment	I-I
.	I-I


The	O
principle	O
symptoms	O
were	O
fatigue	B-P
,	I-P
breathlessness	I-P
and	I-P
chest	I-P
pain	I-P
.	I-P


These	O
limited	O
the	O
extent	O
and	O
speed	O
of	O
physical	O
activities	O
,	O
restricted	O
social	O
,	O
leisure	O
and	O
family	O
life	O
and	O
were	O
associated	O
with	O
emotional	O
distress	O
.	O


There	O
were	O
associations	O
between	O
baseline	B-O
exercise	I-O
capacity	I-O
and	I-O
measures	I-O
of	I-O
quality	I-O
of	I-O
life	I-O
.	I-O


Change	O
in	O
exercise	O
capacity	O
during	O
three	O
months	O
treatment	B-I
was	O
correlated	O
with	O
changes	O
in	O
measures	B-O
of	I-O
symptoms	I-O
,	I-O
limitation	I-O
of	I-O
activity	I-O
and	I-O
quality	I-O
of	I-O
life	I-O
.	I-O


The	O
findings	O
confirm	O
the	O
value	O
of	O
change	O
in	O
exercise	B-O
capacity	I-O
as	O
a	O
measure	O
of	O
functional	O
status	O
and	O
suggest	O
that	O
it	O
should	O
be	O
supported	O
by	O
a	O
limited	O
number	O
of	O
specific	O
measures	O
of	O
quality	B-O
of	I-O
life	I-O
.	I-O


The	O
relationship	O
of	O
alexithymia	O
to	O
emotional	O
dysregulation	O
within	O
an	O
alcohol	B-P
dependent	I-P
treatment	I-P
sample	I-P
.	I-P


Difficulties	O
regulating	O
emotions	O
have	O
implications	O
for	O
the	O
development	O
,	O
maintenance	O
,	O
and	O
recovery	O
from	O
alcohol	B-P
problems	I-P
.	I-P


One	O
construct	O
thought	O
to	O
impede	O
the	O
regulation	O
of	O
emotion	O
is	O
alexithymia	O
.	O


Alexithymia	O
is	O
characterized	O
by	O
difficulties	O
identifying	O
,	O
differentiating	O
and	O
expressing	O
feelings	O
,	O
a	O
limited	O
imagination	O
and	O
fantasy	O
life	O
,	O
and	O
an	O
externally-oriented	O
thinking	O
style	O
(	O
e.g.	O
,	O
prefer	O
talking	O
about	O
daily	O
activities	O
rather	O
than	O
feelings	O
)	O
.	O


Given	O
that	O
poor	O
emotion	O
regulation	O
skills	O
have	O
been	O
found	O
to	O
predict	O
posttreatment	B-P
levels	I-P
of	I-P
alcohol	I-P
use	I-P
,	O
and	O
that	O
several	O
defining	O
characteristics	O
of	O
alexithymia	O
bear	O
similarity	O
to	O
deficits	O
in	O
emotion	O
regulation	O
skills	O
,	O
it	O
is	O
possible	O
that	O
alexithymia	O
may	O
predict	O
poorer	O
alcohol	O
treatment	O
outcomes	O
.	O


Thus	O
,	O
the	O
present	O
study	O
first	O
examined	O
the	O
relationship	O
of	O
alexithymia	B-I
to	O
several	O
other	O
emotion	B-O
regulation	I-O
measures	I-O
and	O
then	O
investigated	O
the	O
impact	O
of	O
alexithymia	B-I
on	O
attrition	O
and	O
alcohol	O
treatment	O
outcomes	O
in	O
men	B-P
and	I-P
women	I-P
(	I-P
N=77	I-P
)	I-P
enrolled	I-P
in	I-P
a	I-P
12-week	I-I
cognitive-behavioral	I-I
intervention	I-I
for	I-I
alcohol	I-I
dependence	I-I
.	I-I


At	O
baseline	O
,	O
higher	O
scores	O
on	O
alexithymia	O
were	O
associated	O
poorer	B-O
emotion	I-O
regulation	I-O
skills	I-O
,	I-O
fewer	I-O
percent	I-O
days	I-O
abstinent	I-O
,	I-O
greater	I-O
alcohol	I-O
dependence	I-O
severity	I-O
,	I-O
and	I-O
several	I-O
high-risk	I-O
drinking	I-O
situations	I-O
.	I-O


Alexithymia	O
was	O
unrelated	O
to	O
attrition	O
and	O
to	O
level	O
of	O
alcohol	O
consumption	O
at	O
posttreatment	O
.	O


Overall	O
,	O
the	O
construct	O
of	O
alexithymia	O
is	O
shown	O
to	O
be	O
related	O
to	O
several	O
theoretically-related	O
constructs	O
(	O
e.g.	O
,	O
emotion	O
regulation	O
,	O
mindfulness	O
)	O
but	O
demonstrated	O
a	O
limited	O
relationship	O
to	O
drinking	O
outcomes	O
in	O
those	B-P
seeking	I-P
treatment	I-P
for	I-P
alcohol	I-P
dependence	I-P
.	I-P


Contact	O
lens	O
lipid	O
spoliation	O
of	O
hydrogel	O
and	O
silicone	O
hydrogel	O
lenses	O
.	O


PURPOSE	O
The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
measure	O
contact	B-I
lens	I-I
lipid	I-I
spoliation	I-I
of	I-I
silicone	I-I
hydrogel	I-I
PureVision	I-I
(	I-I
balafilcon	I-I
A	I-I
)	I-I
and	I-I
hydrogel	I-I
Acuvue	I-I
2	I-I
(	I-I
etafilcon	I-I
A	I-I
)	I-I
contact	I-I
lenses	I-I
worn	I-P
for	I-P
10	I-P
hours	I-P
single	I-P
use	I-P
(	I-P
DD	I-P
)	I-P
and	I-P
7	I-P
days	I-P
of	I-P
extended	I-P
wear	I-P
(	I-P
EW	I-P
)	I-P
.	I-P


METHODS	O
Two	B-P
similar	I-P
study	I-P
populations	I-P
(	I-P
DD	I-P
,	I-P
n	I-P
=	I-P
55	I-P
;	I-P
EW	I-P
,	I-P
n	I-P
=	I-P
53	I-P
)	I-P
,	O
were	O
enrolled	O
at	O
four	B-P
study	I-P
sites	I-P
.	I-P


In	O
each	O
population	O
,	O
a	O
bilateral	O
,	O
randomized	O
,	O
crossover	O
(	O
lens	O
material	O
)	O
,	O
subject-masked	O
experimental	O
design	O
was	O
followed	O
.	O


Worn	O
contact	O
lenses	O
were	O
analyzed	O
for	O
lipid	O
uptake	O
using	O
high-performance	O
liquid	B-I
chromatography	I-I
by	O
two	O
laboratories	O
:	O
Alcon	O
Laboratories	O
(	O
right	O
lens	O
total	O
uptake	O
)	O
and	O
OTG	O
Research	O
&	O
Consultancy	O
(	O
left	O
lens	O
total	O
uptake	O
and	O
individual	O
lipid	O
classes	O
)	O
.	O


RESULTS	O
Lipid	B-O
uptake	I-O
was	O
different	O
for	O
the	O
two	O
materials	O
:	O
total	B-O
lipid	I-O
(	O
p	O
<	O
0.007	O
)	O
,	O
cholesterol	B-O
esters	I-O
(	O
p	O
<	O
0.001	O
)	O
,	O
cholesterol	B-O
(	O
p	O
<	O
0.001	O
EW	O
only	O
)	O
,	O
and	O
triglycerides/phospholipids	B-O
(	O
p	O
<	O
0.001	O
)	O
were	O
higher	O
for	O
balafilcon	O
A	O
,	O
whereas	O
fatty	B-O
acid	I-O
(	O
p	O
<	O
0.0025	O
EW	O
only	O
)	O
was	O
higher	O
for	O
etafilcon	O
A	O
.	O


The	O
ratio	B-O
of	I-O
the	I-O
extracted	I-O
lipids	I-O
was	O
also	O
different	O
:	O
higher	O
percentages	O
of	O
triglycerides/phospholipids	B-O
(	O
p	O
<	O
0.001	O
)	O
and	O
cholesterol	B-O
(	O
p	O
<	O
0.001	O
EW	O
only	O
)	O
for	O
balafilcon	O
A	O
and	O
higher	O
percentages	O
of	O
fatty	B-O
acids/di-	I-O
and	I-O
monoglycerides	I-O
(	O
p	O
<	O
0.014	O
)	O
for	O
etafilcon	O
A	O
.	O


CONCLUSIONS	O
Total	B-O
lipid	I-O
uptake	I-O
was	O
highly	O
material	O
dependent	O
.	O


Both	O
laboratories	O
measured	O
a	O
greater	O
uptake	B-O
of	I-O
lipids	I-O
by	O
the	O
silicone	O
hydrogel	O
than	O
the	O
hydrogel	O
material	O
,	O
a	O
difference	O
that	O
was	O
evident	O
after	O
only	O
10	O
hours	O
of	O
DD	O
.	O


Total	B-O
lipid	I-O
uptake	I-O
was	O
greater	O
after	O
7	O
days	O
of	O
EW	O
compared	O
with	O
10	O
hours	O
of	O
DD	O
.	O


Of	O
interest	O
for	O
contact	O
lens	O
spoliation	O
and	O
its	O
avoidance	O
was	O
the	O
differential	O
lipid	O
uptake	O
profile	O
,	O
indicating	O
material	O
selectivity	O
.	O


Whereas	O
greater	O
differentiation	O
between	O
materials	O
was	O
possible	O
after	O
7	O
days	O
of	O
EW	O
for	O
each	O
material	O
,	O
the	O
lipid	O
uptake	O
profile	O
was	O
similar	O
for	O
DD	O
and	O
EW	O
,	O
indicating	O
a	O
greater	O
material	O
effect	O
than	O
a	O
wear	O
modality	O
effect	O
.	O


Iron	B-I
supplementation	I-I
improves	O
energetic	O
efficiency	O
in	O
iron-depleted	B-P
female	I-P
rowers	I-P
.	I-P


PURPOSE	O
Studies	O
in	O
both	O
animals	O
and	O
humans	O
show	O
a	O
relationship	O
between	O
iron	O
depletion	O
without	O
anemia	O
(	O
IDNA	O
)	O
and	O
physical	O
performance	O
.	O


Compared	O
with	O
their	O
sedentary	O
counterparts	O
,	O
female	B-P
endurance	I-P
athletes	I-P
are	O
at	O
greater	O
risk	O
of	O
IDNA	O
,	O
and	O
consequences	O
relevant	O
to	O
endurance	O
athletes	O
include	O
reduced	O
work	O
capacity	O
and	O
energetic	O
efficiency	O
(	O
EF	O
)	O
.	O


We	O
conducted	O
a	O
randomized	O
placebo-controlled	B-I
trial	O
to	O
investigate	O
the	O
effects	O
of	O
iron	B-I
(	I-I
Fe	I-I
)	I-I
supplementation	I-I
on	O
Fe	O
status	O
and	O
performance	O
in	O
nonanemic	B-P
female	I-P
rowers	I-P
during	I-P
training	I-P
.	I-P


METHODS	O
At	O
the	O
beginning	O
of	O
a	O
training	O
season	O
,	O
40	B-P
rowers	I-P
were	O
randomized	O
to	O
receive	O
either	O
100	B-I
mg·d	I-I
FeSO4	I-I
(	O
n	O
=	O
21	O
)	O
or	B-I
placebo	I-I
(	O
n	O
=	O
19	O
)	O
using	O
a	O
double-blind	O
design	O
.	O


Thirty-one	O
(	O
n	O
=	O
15	B-I
Fe	I-I
,	I-I
16	I-I
placebo	I-I
)	I-I
completed	O
the	O
6-wk	O
trial	O
.	B-O


Fe	B-O
status	I-O
(	I-O
hemoglobin	I-O
,	I-O
serum	I-O
ferritin	I-O
,	I-O
soluble	I-O
transferrin	I-O
receptor	I-O
)	I-O
,	I-O
body	I-O
composition	I-O
,	I-O
and	I-O
laboratory	I-O
tests	I-O
of	I-O
physical	I-O
performance	I-O
(	I-O
4-km	I-O
time	I-O
trial	I-O
,	I-O
V˙O2peak	I-O
,	I-O
energetic	I-O
EF	I-O
,	I-O
and	I-O
blood	I-O
lactate	I-O
)	I-O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
training	O
.	O


RESULTS	O
Rowers	O
in	O
both	O
groups	O
increased	O
their	B-O
fat-free	I-O
mass	I-O
(	O
P	O
<	O
0.001	O
)	O
and	B-O
V˙O2peak	I-O
(	O
P	O
<	O
0.001	O
)	O
after	O
training	O
.	O


Multiple	O
regression	O
analyses	O
revealed	O
improvements	O
in	B-O
Fe	I-O
stores	I-O
(	I-O
serum	I-O
ferritin	I-O
)	I-O
in	O
the	O
Fe	O
treatment	O
group	O
after	O
controlling	O
for	O
baseline	O
Fe	O
stores	O
(	O
P	O
=	O
0.07	O
)	O
.	O


Rowers	O
in	O
the	O
Fe	O
group	O
had	O
slower	O
lactate	O
response	O
during	O
the	O
first	O
half	O
of	O
the	O
time	O
trial	O
and	O
after	O
5	O
min	O
of	O
recovery	O
(	O
P	O
=	O
0.05	O
)	O
and	O
showed	O
greater	O
improvements	O
in	B-O
energy	I-O
expenditure	I-O
(	O
P	O
=	O
0.01	O
for	O
group-by	O
time	O
)	O
and	B-O
energetic	I-O
EF	O
compared	O
with	O
placebo	O
(	O
P	O
=	O
0.03	O
for	O
group-by	O
time	O
)	O
.	O


CONCLUSIONS	B-P
Female	I-P
rowers	I-P
with	I-P
depleted	I-P
Fe	O
stores	O
who	O
consumed	O
supplemental	O
Fe	O
during	O
training	O
improved	O
their	B-O
Fe	I-O
status	I-O
and	I-O
energetic	I-O
EF	O
during	O
endurance	O
exercise	O
.	O


These	O
results	O
are	O
important	O
for	B-P
endurance	I-P
athletes	I-P
whose	O
dietary	O
patterns	O
and	O
physical	O
training	O
increase	O
their	O
risk	O
of	B-O
IDNA	I-O
and	O
suggest	O
that	O
Fe	O
supplementation	O
may	O
maximize	O
the	O
benefits	O
of	O
endurance	O
training	O
.	O


[	O
Tension-free	O
laparoscopic	O
versus	O
open	B-I
inguinal	I-I
hernia	I-I
repair	I-I
]	I-I
.	O


AIM	O
During	O
the	O
last	O
decade	O
laparoscopic	O
techniques	O
have	O
been	O
applied	O
to	O
the	O
treatment	O
of	O
inguinal	B-O
hernia	I-O
to	O
combine	O
tension-free	O
technique	O
,	O
esthetic	O
,	O
and	O
functional	O
benefits	O
of	O
mini-invasive	O
surgery	O
.	O


Anyway	O
controversy	O
persists	O
regarding	O
the	O
most	O
effective	B-O
inguinal	O
hernia	O
repair	O
.	O


The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
open	O
technique	O
and	O
the	O
laparoscopic	O
approach	O
concerning	O
:	O
complications	B-O
,	I-O
recurrences	I-O
,	I-O
recovery	I-O
time	I-O
and	I-O
return	I-O
to	I-O
usual	I-O
activity	I-O
.	I-O


METHODS	O
A	O
randomized	B-P
prospective	I-P
analysis	I-P
of	I-P
121	I-P
consecutive	I-P
inguinal	I-I
hernia	I-I
repairs	I-I
was	I-P
performed	I-P
over	I-P
a	I-P
12-month	I-P
period	I-P
.	I-P


Male	B-P
well-informed	I-P
patients	I-P
with	I-P
primary	I-P
monolateral	I-P
inguinal	I-P
hernia	I-P
(	I-P
ASA	I-P
I-II	I-P
)	I-P
were	O
divided	O
into	O
2	B-P
groups	I-P
and	O
consecutively	O
treated	O
;	O
group	B-P
A	I-P
was	O
treated	O
with	O
laparoscopic	B-I
transabdominal	I-I
preperitoneal	I-I
approach	I-I
(	I-P
TAPP	I-P
)	I-P
(	I-P
median	I-P
age	I-P
47+/-7	I-P
years	I-P
,	I-P
57	I-P
patients	I-P
)	I-P
,	I-P
group	I-P
B	I-P
with	O
open	B-I
mesh	I-I
herniorrhaphy	I-I
(	I-P
45+/-6	I-P
years	I-P
,	I-P
64	I-P
patients	I-P
)	I-P
.	I-P


RESULTS	O
Complication	B-O
rate	I-O
was	O
5.26	O
%	O
for	O
group	O
A	O
(	O
none	O
needed	O
conversion	O
)	O
and	O
4.68	O
%	O
for	O
group	O
B	O
.	O


All	O
complications	B-O
were	O
considered	O
minor	O
.	O


No	O
recurrences	B-O
were	O
observed	O
over	O
a	O
12-month	O
follow-up	O
in	O
both	O
groups	O
.	O


Post-operative	B-O
hospital	I-O
stay	I-O
and	I-O
return	I-O
to	I-O
activity	I-O
show	O
statistically	O
significant	O
differences	O
.	O


Median	B-O
post-hospital	I-O
stay	I-O
was	O
1.7	O
days	O
for	O
group	O
A	O
while	O
it	O
was	O
longer	O
(	O
2.9	O
days	O
)	O
for	O
group	O
B	O
.	O


Significant	O
difference	O
was	O
observed	O
in	O
the	O
duration	B-O
of	I-O
convalescence	I-O
too	O
(	O
group	O
A	O
9.3+/-7.2	O
days	O
;	O
group	O
B	O
12.1+/-7	O
.	O


1	O
days	O
)	O
.	O


CONCLUSION	O
On	O
the	O
basis	O
of	O
our	O
experience	O
,	O
even	O
if	O
a	O
longer	O
follow-up	O
is	O
needed	O
,	O
the	O
validity	O
of	O
laparoscopic	B-I
approach	I-I
to	I-I
inguinal	I-I
hernia	I-I
is	O
confirmed	O
.	O


General	O
anesthesia	O
and	O
higher	O
costs	O
are	O
reasonable	O
compromises	O
for	O
a	O
shorter	O
period	B-O
of	I-O
discomfort	I-O
in	O
patients	B-P
with	I-P
a	I-P
low	I-P
ASA	I-P
index	I-P
and	I-P
busy	I-P
job/sport	I-P
activity	I-P
.	I-P


Manuka	B-I
honey-impregnated	I-I
dressings	I-I
in	O
the	O
treatment	O
of	O
neuropathic	B-P
diabetic	I-P
foot	I-P
ulcers	I-P
.	I-P


In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
effect	O
of	O
manuka	B-I
honey-impregnated	I-I
dressings	I-I
(	I-I
MHID	I-I
)	I-I
on	O
the	O
healing	B-P
of	I-P
neuropathic	I-P
diabetic	I-P
foot	I-P
ulcers	I-P
(	I-P
NDFU	I-P
)	I-P
.	O


A	O
total	O
of	O
63	B-P
Caucasians	I-P
,	I-P
type	I-P
2	I-P
diabetic	I-P
patients	I-P
followed	I-P
up	I-P
in	I-P
the	I-P
diabetic	I-P
foot	I-P
outpatient	I-P
clinic	I-P
comprised	O
the	O
study	O
population	O
.	O


Patients	O
were	O
randomised	O
in	O
two	O
groups	O
as	O
follows	O
:	O
group	O
I	O
patients	O
were	O
treated	O
with	O
MHID	B-I
and	O
group	O
II	O
patients	O
were	O
treated	O
with	O
conventional	B-I
dressings	I-I
(	I-I
CD	I-I
)	I-I
.	I-I


The	O
patients	O
were	O
followed	O
up	O
on	O
a	O
weekly	O
basis	O
for	O
16	O
weeks	O
.	O


Mean	B-O
healing	I-O
time	I-O
was	O
31	O
±	O
4	O
days	O
in	O
group	O
I	O
versus	O
43	O
±	O
3	O
days	O
in	O
group	O
II	O
(	O
P	O
<	O
0·05	O
)	O
.	O


In	O
group	O
I	O
patients	O
78·13	O
%	O
of	O
ulcers	O
became	O
sterile	O
during	O
the	O
first	O
week	O
versus	O
35·5	O
%	O
in	O
group	O
II	O
patients	O
;	O
the	O
corresponding	O
percentages	O
for	O
weeks	O
2	O
,	O
4	O
and	O
6	O
were	O
15·62	O
%	O
versus	O
38·7	O
%	O
,	O
6·25	O
%	O
versus	O
12·9	O
%	O
and	O
0	O
%	O
versus	O
12·9	O
%	O
respectively	B-O
.	I-O


The	B-O
percent	I-O
of	I-O
ulcers	I-O
healed	I-O
did	I-O
not	I-O
differ	I-O
significantly	I-O
between	O
groups	O
(	O
97	O
%	O
for	O
MHID	O
and	B-I
90	I-I
%	I-I
for	I-I
CD	O
)	O
.	O


MHID	O
represent	O
an	O
effective	O
treatment	B-P
for	O
NDFU	O
leading	O
to	O
a	O
significant	B-O
reduction	I-O
in	I-O
the	I-O
time	I-O
of	I-O
healing	I-O
and	I-O
rapid	I-O
disinfection	I-O
of	O
ulcers	O
.	O


A	O
pilot	O
study	O
of	O
the	O
safety	O
and	O
efficacy	O
of	O
supplemental	O
arginine	B-I
to	O
enhance	O
immune	O
function	O
in	O
persons	B-P
with	I-P
HIV/AIDS	I-P
.	I-P


OBJECTIVE	O
We	O
collected	O
preliminary	O
data	O
on	O
the	O
safety	O
and	O
efficacy	O
of	O
supplemental	O
arginine	B-I
to	O
improve	O
natural	O
killer	O
cell	O
cytotoxicity	O
in	O
a	O
sample	O
of	O
persons	B-P
with	I-P
human	I-P
immunodeficiency	I-P
virus	I-P
(	I-P
HIV	I-P
)	I-P
and	I-P
acquired	I-P
immunodeficiency	I-P
syndrome	I-P
(	I-P
AIDS	I-P
)	I-P
.	I-P


METHODS	O
In	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
pilot	O
study	O
in	O
an	O
academic	O
medical	O
center-based	O
infectious	O
disease	O
clinic	O
,	O
11	B-P
clinically	I-P
stable	I-P
,	I-P
HIV-infected	I-P
adults	I-P
had	I-P
been	I-P
treated	I-P
with	I-P
highly	I-P
active	I-P
,	I-P
antiretroviral	I-I
therapy	I-I
and	I-P
had	I-P
HIV	I-P
plasma	I-P
RNA	I-P
levels	I-P
of	I-P
less	I-P
than	I-P
10	I-P
000	I-P
copies/mL	I-P
.	I-P


Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
19.6	B-I
g	I-I
of	I-I
arginine/d	I-I
(	O
n	O
=	O
6	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
5	O
)	O
for	O
14	O
d.	O
Plasma	B-O
HIV	I-O
RNA	I-O
levels	I-O
,	I-O
neuropsychologic	I-O
functioning	I-O
,	I-O
and	I-O
self-reported	I-O
adverse	I-O
events	I-O
were	O
analyzed	O
for	O
safety	O
of	O
treatment	O
.	O


Efficacy	B-O
was	O
measured	O
by	O
natural	O
killer	O
cell	O
cytotoxicity	O
.	O


RESULTS	O
None	O
of	O
the	O
participants	O
experienced	O
any	O
adverse	B-O
clinical	I-O
,	I-O
virologic	I-O
,	I-O
or	I-O
neuropsychologic	I-O
events	I-O
that	O
necessitated	O
withdrawal	O
from	O
the	O
study	O
.	O


The	O
arginine-supplemented	B-I
group	O
showed	O
a	O
mean	B-O
natural	I-O
killer	I-O
cell	I-O
cytotoxicity	I-O
increase	O
of	O
18.9	O
lytic	O
units	O
,	O
whereas	O
the	O
placebo	O
group	O
showed	O
an	O
increase	O
of	O
0.3	O
lytic	O
units	O
.	O


This	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.79	O
)	O
.	O


CONCLUSIONS	O
Short-term	O
arginine	B-I
supplementation	O
is	O
safe	O
for	O
persons	B-P
with	I-P
HIV/AIDS	I-P
.	I-P


Additional	O
studies	O
with	O
larger	O
samples	O
and	O
longer	O
periods	O
are	O
warranted	O
to	O
determine	O
the	O
effects	O
of	O
arginine	O
supplementation	O
on	O
other	O
indices	O
of	O
immune	O
function	O
and	O
on	O
clinical	O
outcomes	O
such	O
as	O
intercurrent	O
illnesses	O
.	O


Transitions	O
during	O
effective	O
treatment	O
for	O
cocaine-abusing	B-P
homeless	I-P
persons	I-P
:	I-P
establishing	O
abstinence	O
,	O
lapse	O
,	O
and	O
relapse	O
,	O
and	O
reestablishing	O
abstinence	O
.	O


Data	O
are	O
reported	O
on	O
drug	O
use	O
among	O
cocaine-dependent	B-P
homeless	I-P
persons	I-P
who	I-P
participated	I-P
in	I-P
a	I-P
clinical	I-P
trial	I-P
that	I-P
compared	I-P
day	I-I
treatment	I-I
only	I-I
(	I-P
DT	I-P
,	I-P
n	I-P
=	I-P
69	I-P
)	I-P
with	I-P
day	I-I
treatment	I-I
plus	I-I
abstinent-contingent	I-I
housing	I-I
and	I-I
work	I-I
(	I-P
DT+	I-P
,	I-P
n	I-P
=	I-P
72	I-P
)	I-P
.	I-P


Drug	B-O
use	I-O
was	I-O
measured	I-O
with	I-O
multiple	I-O
weekly	I-O
urine	I-O
toxicologies	I-O
.	I-O


Compared	O
with	O
DT	O
participants	O
,	O
more	O
DT+	O
participants	O
established	O
abstinence	B-O
,	I-O
maintained	I-O
abstinence	I-O
for	I-O
longer	I-O
durations	I-O
,	O
were	O
marginally	O
significantly	O
more	O
likely	O
to	O
lapse	B-O
,	O
and	O
significantly	O
less	O
likely	O
to	O
relapse	B-O
.	I-O


Of	O
all	O
participants	O
who	O
established	O
abstinence	O
and	O
then	O
relapsed	O
,	O
DT+	O
participants	O
relapsed	O
later	O
and	O
were	O
more	O
likely	O
to	O
reestablish	B-O
abstinence	I-O
.	I-O


These	O
analyses	O
yield	O
information	O
on	O
the	O
processes	O
involved	O
in	O
the	O
manner	O
in	O
which	O
drug	O
use	O
changes	O
as	O
a	O
result	O
of	O
abstinent-contingent	B-I
housing	I-I
and	I-I
work	I-I
.	I-I


Asthma	O
:	O
communication	O
between	O
hospital	O
and	O
general	B-P
practitioners	I-P
.	I-P


OBJECTIVE	O
To	O
assess	O
whether	O
efforts	O
to	O
actively	O
involve	O
General	B-P
Practitioners	I-P
(	I-P
GPs	I-P
)	I-P
in	O
the	O
postdischarge	O
care	O
of	O
their	O
paediatric	B-P
asthma	I-P
patients	I-P
improved	O
their	O
satisfaction	B-O
with	I-O
communication	I-O
with	I-O
hospital	I-O
staff	I-O
.	I-O


METHODOLOGY	O
Randomized	O
controlled	O
trial	O
involving	O
60	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
Royal	I-P
Children	I-P
's	I-P
Hospital	I-P
,	I-P
Melbourne	I-P
,	I-P
with	I-P
acute	I-P
asthma	I-P
and	I-P
an	I-P
identifiable	I-P
GP	I-P
.	I-P


The	O
GPs	B-P
of	I-P
the	I-P
intervention	I-P
patients	I-P
were	O
telephoned	O
during	O
the	O
admission	O
.	O


Intervention	O
patients	O
and	O
their	O
GPs	O
received	O
printed	B-I
information	I-I
detailing	I-I
the	I-I
care	I-I
the	I-I
patient	I-I
received	I-I
in	I-I
hospital	I-I
and	I-I
the	I-I
recommended	I-I
postdischarge	I-I
care	I-I
,	I-I
as	I-I
well	I-I
as	I-I
standardized	I-I
educational	I-I
booklets	I-I
about	I-I
asthma	I-I
.	I-I


Follow-up	B-I
appointments	I-I
were	O
made	O
for	O
intervention	B-I
patients	O
to	O
attend	O
their	O
GPs	O
.	O


RESULTS	O
The	O
GPs	B-P
of	I-P
intervention	I-P
patients	I-P
were	O
more	O
satisfied	B-O
when	O
compared	O
to	O
the	O
GPs	O
receiving	O
a	O
standard	O
level	O
of	O
communication	O
(	O
96.4	O
%	O
vs	O
48.3	O
%	O
of	O
the	O
intervention	O
and	O
control	O
GPs	O
,	O
respectively	O
,	O
described	O
the	O
communication	O
as	O
good	O
or	O
extremely	O
good	O
,	O
P	O
=	O
0.0001	O
)	O
.	O


The	O
intervention	O
group	O
GPs	O
believed	B-O
they	I-O
were	I-O
more	I-O
involved	I-O
after	I-O
discharge	I-O
(	O
75.0	O
%	O
vs	O
44.8	O
%	O
,	O
P	O
=	O
0.005	O
)	O
and	O
had	O
greater	O
understanding	B-O
of	I-O
their	I-O
patient	I-O
's	I-O
hospitalisation	I-O
(	O
96.4	O
%	O
vs	O
62.1	O
%	O
,	O
P	O
=	O
0.005	O
)	O
.	O


These	O
differences	O
were	O
noted	O
despite	O
there	O
being	O
no	O
difference	O
in	O
the	O
rate	B-O
of	I-O
follow-up	I-O
attendance	I-O
with	O
GPs	O
for	O
intervention	O
and	O
control	O
patients	O
(	O
85.7	O
%	O
vs	O
72.4	O
%	O
,	O
P	O
=	O
0.2	O
)	O
.	O


Qualitative	O
data	O
supported	O
these	O
findings	O
with	O
GPs	O
expressing	O
approval	B-O
of	I-O
the	I-O
intervention	I-O
used	I-O
.	I-O


CONCLUSION	O
Efforts	O
to	O
actively	O
involve	O
GPs	B-P
in	I-P
the	I-P
postdischarge	I-P
care	I-P
of	I-P
their	I-P
paediatric	I-P
patients	I-P
with	I-P
asthma	I-P
resulted	O
in	O
a	O
marked	O
improvement	O
in	O
their	O
satisfaction	B-O
with	I-O
the	I-O
communication	I-O
with	I-O
medical	I-O
staff	I-O
at	O
the	O
Royal	O
Children	O
's	O
Hospital	O
,	O
Melbourne	O
.	O


The	O
study	O
had	O
insufficient	O
power	O
to	O
demonstrate	O
a	O
difference	O
in	O
morbidity	O
.	O


Patients	B-P
with	I-P
relapsed	I-P
follicular	I-P
lymphoma	I-P
treated	O
with	O
rituximab	B-I
versus	I-I
tositumomab	I-I
and	I-I
iodine	I-I
I-131	I-I
tositumomab	I-I
.	I-I


Persistent	B-P
phenothiazine	I-P
dyskinesia	I-P
treated	O
with	O
tetrabenazine	B-I
.	I-I


Six	B-P
patients	I-P
with	I-P
persistent	I-P
phenothiazine	I-P
dyskinesia	I-P
were	O
treated	O
in	O
a	O
double-blind	O
controlled	O
trial	O
with	O
tetrabenazine	B-I
100	I-I
mg	I-I
in	I-I
divided	I-I
dosage	I-I
.	I-I


In	O
three	O
patients	O
the	O
abnormal	O
movements	O
were	O
abolished	O
and	O
in	O
two	O
others	O
there	O
was	O
some	O
improvement	O
,	O
but	O
this	O
was	O
no	O
greater	O
than	O
that	O
achieved	O
with	O
the	O
diazepam	B-I
control	O
.	O


Tetrabenazine	B-I
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
some	O
patients	O
with	O
persistent	O
phenothiazine	O
dyskinesia	O
.	O


A	B-P
randomized	I-P
trial	I-P
in	I-P
simultaneous	I-P
pancreas-kidney	I-I
transplantation	I-I
:	I-I
portal	I-I
versus	I-I
systemic	I-O
venous	I-O
drainage	I-O
of	I-I
the	I-I
pancreas	I-I
allograft	I-I
.	I-I


Evaluation	O
of	O
the	O
effect	O
of	O
acetazolamide	B-I
on	O
cystoid	B-P
macular	I-P
oedema	I-P
in	I-P
patients	I-P
with	I-P
Behcet	I-P
's	I-P
disease	I-P
.	I-P


AIM	O
To	O
study	O
the	O
effect	O
of	O
acetazolamide	B-I
on	O
cystoid	O
macular	O
oedema	O
(	O
CMO	O
)	O
in	O
patients	B-P
with	I-P
Behcet	I-P
's	I-P
disease	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
A	B-P
total	I-P
of	I-P
67	I-P
eyes	I-P
of	I-P
35	I-P
Behcet	I-P
's	I-P
patients	I-P
with	I-P
chronic	I-P
,	I-P
but	I-P
well-controlled	I-P
uveitis	I-P
,	I-P
and	I-P
CMO	I-P
were	O
randomised	O
into	O
a	O
double-masked	O
,	O
crossover	O
trial	O
comparing	O
the	O
effect	O
of	O
acetazolamide	B-I
vs	I-I
placebo	I-I
.	I-I


The	O
patients	O
received	O
an	O
initial	O
4-week	O
course	O
of	O
either	O
250	O
mg	O
acetazolamide	B-I
twice	O
daily	O
(	O
b.i.d	O
.	O


)	O
or	O
placebo	B-I
,	O
followed	O
by	O
a	O
4-week	O
washout	O
period	O
.	O


They	O
then	O
received	O
a	O
4-week	O
course	O
of	O
the	O
reverse	O
study	O
medication	O
.	O


An	O
improvement	O
in	O
visual	B-O
acuity	I-O
and	I-O
fundus	I-O
fluorescein	I-O
angiographic	I-O
findings	I-O
was	O
assessed	O
.	O


RESULTS	O
In	O
total	O
,	O
29	B-P
patients	I-P
(	I-P
55	I-P
eyes	I-P
)	I-P
completed	I-P
the	I-P
trial	I-P
and	I-P
were	I-P
available	I-P
for	I-P
analysis	I-P
.	I-P


Of	B-P
the	I-P
29	I-P
,	I-P
16	I-P
men	I-P
and	I-P
13	I-P
were	I-P
women	I-P
.	I-P


The	B-P
age	I-P
range	I-P
was	I-P
13-50	I-P
years	I-P
(	I-P
mean	I-P
33.6	I-P
years	I-P
)	I-P
.	I-P


Patients	O
on	O
acetazolamide	B-I
showed	O
a	O
slightly	O
better	O
improvement	O
of	O
angiographic	B-O
signs	I-O
(	O
at	O
least	O
by	O
one	O
grade	O
improvement	O
)	O
over	O
that	O
of	O
placebo	B-I
(	O
12	O
vs	O
five	O
eyes	O
)	O
.	O


They	O
also	O
had	O
less	O
deterioration	B-O
of	I-O
angiographic	I-O
signs	I-O
over	O
that	O
of	O
placebo	B-I
(	O
three	O
vs	O
seven	O
eyes	O
)	O
.	O


However	O
,	O
these	O
findings	O
were	O
not	O
statistically	O
significant	O
(	O
P=0.99	O
)	O
.	O


Acetazolamide	B-I
had	O
no	O
statistically	O
significant	O
effect	O
(	O
P=0.53	O
)	O
on	O
the	O
improvement	O
of	O
visual	B-O
acuity	I-O
of	O
patients	O
over	O
that	O
of	O
placebo	B-I
(	O
13	O
vs	O
eight	O
eyes	O
)	O
,	O
nor	O
on	O
the	O
deterioration	O
of	O
visual	B-O
acuity	I-O
(	O
three	O
vs	O
11	O
eyes	O
)	O
.	O


CONCLUSION	O
Despite	O
seemingly	O
favourable	O
results	O
,	O
the	O
4-week	O
course	O
of	O
acetazolamide	B-I
(	O
250	O
mg	O
b.i.d	O
.	O


)	O
has	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
improvement	O
of	O
the	O
visual	B-O
acuity	I-O
and	O
the	O
fluorescein	B-O
angiographic	I-O
findings	I-O
in	O
Behcet	B-P
's	I-P
patients	I-P
with	I-P
CMO	I-P
.	I-P


Comparison	O
of	O
warfarin	B-I
and	O
aspirin	B-I
for	O
symptomatic	O
intracranial	O
arterial	O
stenosis	O
.	O


BACKGROUND	O
Atherosclerotic	O
intracranial	O
arterial	O
stenosis	O
is	O
an	O
important	O
cause	O
of	O
stroke	O
.	O


Warfarin	O
is	O
commonly	O
used	O
in	O
preference	O
to	O
aspirin	O
for	O
this	O
disorder	O
,	O
but	O
these	O
therapies	O
have	O
not	O
been	O
compared	O
in	O
a	O
randomized	O
trial	O
.	O


METHODS	O
We	O
randomly	O
assigned	O
patients	B-P
with	I-P
transient	I-P
ischemic	I-P
attack	I-P
or	I-P
stroke	I-P
caused	I-P
by	I-P
angiographically	I-P
verified	I-P
50	I-P
to	I-P
99	I-P
percent	I-P
stenosis	I-P
of	I-P
a	I-P
major	I-P
intracranial	I-P
artery	I-P
to	O
receive	B-I
warfarin	I-I
(	I-I
target	I-I
international	I-I
normalized	I-I
ratio	I-I
,	I-I
2.0	I-I
to	I-I
3.0	I-I
)	I-I
or	I-I
aspirin	I-I
(	I-I
1300	I-I
mg	I-I
per	I-I
day	I-I
)	I-I
in	I-I
a	I-I
double-blind	I-I
,	I-I
multicenter	I-I
clinical	I-I
trial	I-I
.	I-I


The	O
primary	O
end	O
point	O
was	O
ischemic	B-O
stroke	I-O
,	I-O
brain	I-O
hemorrhage	I-O
,	I-O
or	I-O
death	I-O
from	O
vascular	O
causes	O
other	O
than	O
stroke	B-O
.	I-O


RESULTS	O
After	B-P
569	I-P
patients	I-P
had	I-P
undergone	I-P
randomization	I-P
,	I-P
enrollment	I-P
was	I-P
stopped	I-P
because	I-P
of	I-P
concerns	I-P
about	I-P
the	I-P
safety	I-P
of	I-P
the	I-P
patients	I-P
who	I-P
had	I-P
been	I-P
assigned	I-P
to	I-P
receive	I-P
warfarin	I-I
.	I-I


During	O
a	O
mean	O
follow-up	O
period	O
of	O
1.8	O
years	O
,	O
adverse	B-O
events	I-O
in	O
the	O
two	O
groups	O
included	O
death	B-O
(	O
4.3	O
percent	O
in	O
the	O
aspirin	B-I
group	O
vs.	O
9.7	O
percent	O
in	O
the	O
warfarin	O
group	O
;	O
hazard	O
ratio	O
for	O
aspirin	B-I
relative	O
to	O
warfarin	B-I
,	O
0.46	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.23	O
to	O
0.90	O
;	O
P=0.02	O
)	O
,	O
major	B-O
hemorrhage	I-O
(	O
3.2	O
percent	O
vs.	O
8.3	O
percent	O
,	O
respectively	O
;	O
hazard	O
ratio	O
,	O
0.39	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.18	O
to	O
0.84	O
;	O
P=0.01	O
)	O
,	O
and	O
myocardial	B-O
infarction	I-O
or	I-O
sudden	I-O
death	I-O
(	O
2.9	O
percent	O
vs.	O
7.3	O
percent	O
,	O
respectively	O
;	O
hazard	O
ratio	O
,	O
0.40	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.18	O
to	O
0.91	O
;	O
P=0.02	O
)	O
.	O


The	O
rate	B-O
of	I-O
death	I-O
from	O
vascular	O
causes	O
was	O
3.2	O
percent	O
in	O
the	O
aspirin	O
group	O
and	O
5.9	O
percent	O
in	O
the	O
warfarin	O
group	O
(	O
P=0.16	O
)	O
;	O
the	O
rate	B-O
of	I-O
death	I-O
from	O
nonvascular	O
causes	O
was	O
1.1	O
percent	O
and	O
3.8	O
percent	O
,	O
respectively	O
(	O
P=0.05	O
)	O
.	O


The	O
primary	O
end	O
point	O
occurred	O
in	O
22.1	O
percent	O
of	O
the	O
patients	O
in	O
the	O
aspirin	O
group	O
and	O
21.8	O
percent	O
of	O
those	O
in	O
the	O
warfarin	O
group	O
(	O
hazard	O
ratio	O
,	O
1.04	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.73	O
to	O
1.48	O
;	O
P=0.83	O
)	O
.	O


CONCLUSIONS	O
Warfarin	B-I
was	O
associated	O
with	O
significantly	O
higher	O
rates	O
of	O
adverse	O
events	O
and	O
provided	O
no	O
benefit	O
over	O
aspirin	O
in	O
this	O
trial	O
.	O


Aspirin	B-I
should	O
be	O
used	O
in	O
preference	O
to	O
warfarin	O
for	O
patients	B-P
with	I-P
intracranial	I-P
arterial	I-P
stenosis	I-P
.	I-P


A	O
randomized	O
trial	O
of	O
the	O
canalith	B-I
repositioning	I-I
procedure	I-I
.	I-I


OBJECTIVE	O
To	O
compare	O
the	O
effectiveness	B-O
and	I-O
complications	I-O
of	I-O
our	I-O
adaptation	I-O
of	I-O
the	I-O
canalith	I-O
repositioning	I-O
procedure	I-O
(	I-O
CRP	I-O
)	I-O
with	O
the	O
expectation	O
treatment	O
for	O
benign	O
paroxysmal	O
positional	O
vertigo	O
.	O


STUDY	O
DESIGN	O
A	O
randomized	O
,	O
controlled	O
trial	O
in	O
the	O
setting	O
of	O
a	O
neurotological	O
clinic	O
in	O
Thailand	O
.	O


METHODS	O
Fifty-eight	B-P
patients	I-P
with	I-P
posterior	I-P
benign	I-P
paroxysmal	I-P
positional	I-P
vertigo	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
and	O
control	O
groups	O
using	O
a	O
block	O
of	O
four	O
.	O


The	O
treatment	O
group	O
was	O
treated	O
with	O
the	O
modified	B-I
CRP	I-I
technique	I-I
until	O
the	O
nystagmus	O
disappeared	O
.	O


A	O
mastoid	O
oscillator	O
was	O
not	O
used	O
,	O
nor	O
were	O
any	O
instructions	O
given	O
for	O
patients	O
after	O
the	O
maneuver	O
.	O


Both	O
groups	O
recorded	O
the	O
daily	B-O
grading	I-O
of	I-O
symptoms	I-O
and	I-O
the	I-O
amount	I-O
of	I-O
anti-vertiginous	I-O
drugs	I-O
(	I-O
cinnarizine	I-O
)	I-O
taken	I-O
.	I-O


Objective	B-O
and	I-O
subjective	I-O
assessments	I-O
were	O
made	O
weekly	O
until	O
the	O
nystagmus	B-O
disappeared	O
or	O
until	O
4	O
weeks	O
had	O
passed	O
since	O
treatment	O
began	O
.	O


RESULTS	O
The	O
rates	B-O
of	I-O
effectiveness	I-O
of	I-O
CRP	I-O
treatment	I-O
and	O
the	O
control	O
treatment	O
for	O
benign	O
paroxysmal	O
positional	O
vertigo	O
were	O
75.9	O
%	O
and	O
48.2	O
%	O
,	O
respectively	O
.	O


There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
treatment	O
outcomes	O
of	O
the	O
CRP	B-I
and	O
control	O
groups	O
(	O
P	O
=.03	O
)	O
.	O


The	O
CRP	B-I
group	O
used	B-O
significantly	I-O
fewer	I-O
drugs	I-O
than	O
the	O
control	O
group	O
(	O
P	O
=.001	O
)	O
.	O


Complications	B-O
in	O
the	O
CRP	B-I
group	O
,	O
such	O
as	O
lateral	B-O
canalithiasis	I-O
and	I-O
fainting	I-O
,	O
were	O
observed	O
in	O
13.8	O
%	O
of	O
the	O
patients	O
.	O


CONCLUSIONS	O
The	O
CRP	B-I
was	O
more	O
effective	O
than	O
the	O
expectation	O
treatment	O
for	O
benign	O
paroxysmal	O
positional	O
vertigo	O
insofar	O
as	O
it	O
provided	O
faster	O
recovery	B-O
and	O
required	O
less	O
dependence	B-O
on	I-O
medication	I-O
.	I-O


Complications	B-O
of	O
CRP	B-I
were	O
limited	O
to	O
13.8	O
%	O
of	O
patients	O
.	O


Pathology	O
parameters	O
and	O
adjuvant	B-O
tamoxifen	I-O
response	I-O
in	O
a	O
randomised	O
premenopausal	B-P
breast	I-P
cancer	I-P
trial	O
.	O


BACKGROUND	O
Subgroups	O
of	O
breast	O
cancer	O
that	O
have	O
an	O
impaired	O
response	O
to	O
endocrine	O
treatment	O
,	O
despite	O
hormone	O
receptor	O
positivity	O
,	O
are	O
still	O
poorly	O
defined	O
.	O


Breast	O
cancer	O
can	O
be	O
subdivided	O
according	O
to	O
standard	O
pathological	O
parameters	O
including	O
histological	O
type	O
,	O
grade	O
,	O
and	O
assessment	O
of	O
proliferation	O
.	O


These	O
parameters	O
are	O
the	O
net	O
result	O
of	O
combinations	O
of	O
genetic	O
alterations	O
effecting	O
tumour	O
behaviour	O
and	O
could	O
potentially	O
reflect	O
subtypes	O
that	O
respond	O
differently	O
to	O
endocrine	O
treatment	O
.	O


AIMS	O
To	O
investigate	O
the	O
usefulness	O
of	O
these	O
parameters	O
as	O
predictors	O
of	O
the	O
response	O
to	O
tamoxifen	B-I
in	O
premenopausal	B-P
women	I-P
with	I-P
breast	I-P
cancer	I-P
.	I-P


MATERIALS/METHODS	O
Clinically	O
established	O
pathological	O
parameters	O
were	O
assessed	O
and	O
related	O
to	O
the	O
tamoxifen	B-I
response	O
in	O
500	B-P
available	I-P
tumour	I-P
specimens	I-P
from	I-P
564	I-P
premenopausal	I-P
patients	I-P
with	I-P
breast	I-P
cancer	I-P
randomised	O
to	O
either	O
two	O
years	O
of	O
tamoxifen	B-I
or	O
no	B-I
treatment	I-I
with	O
14	O
years	O
of	O
follow	O
up	O
.	O


Proliferation	O
was	O
further	O
evaluated	O
by	O
immunohistochemical	O
Ki-67	O
expression	O
.	O


RESULTS	O
Oestrogen	B-O
receptor	I-O
positive	I-O
ductal	I-O
carcinomas	I-O
responded	O
as	O
expected	O
to	O
tamoxifen	B-I
,	O
whereas	O
the	O
difference	O
in	O
recurrence	B-O
free	I-O
survival	I-O
between	O
control	B-I
and	O
tamoxifen	B-I
treated	O
patients	O
was	O
less	O
apparent	O
in	O
the	O
relatively	O
few	O
lobular	O
carcinomas	O
.	O


For	O
histological	O
grade	O
,	O
there	O
was	O
no	O
obvious	O
difference	O
in	O
treatment	O
response	O
between	O
the	O
groups	O
.	O


The	O
relation	O
between	O
proliferation	O
and	O
tamoxifen	B-I
response	O
seemed	O
to	O
be	O
more	B-O
complex	I-O
,	I-O
with	I-O
a	I-O
clear	I-O
response	I-O
in	I-O
tumours	I-O
with	I-O
high	I-O
and	I-O
low	I-O
proliferation	I-O
,	O
whereas	O
tumours	O
with	O
intermediate	O
proliferation	O
defined	O
by	O
Ki-67	O
responded	O
more	O
poorly	B-O
.	I-O


CONCLUSIONS	O
Clinically	O
established	O
pathology	O
parameters	O
seem	O
to	O
mirror	O
the	O
endocrine	O
treatment	O
response	O
and	O
could	O
potentially	O
be	O
valuable	O
in	O
future	O
treatment	O
decisions	O
for	O
patients	B-P
with	I-P
breast	I-P
cancer	I-P
.	I-P


Immediately	O
restored	O
,	O
single-tapered	O
implants	B-I
in	I-P
the	I-P
anterior	I-P
maxilla	I-P
:	I-P
prosthodontic	O
and	O
aesthetic	O
outcomes	O
after	O
1	O
year	O
.	O


BACKGROUND	O
Conventional	O
implant	O
protocols	O
advocate	O
a	O
two-stage	O
technique	O
with	O
a	O
load-free	O
,	O
submerged	O
healing	O
period	O
.	O


Recent	O
studies	O
suggest	O
that	O
immediate	O
restoration	O
of	O
single	O
implants	O
may	O
be	O
a	O
viable	O
treatment	O
option	O
.	O


PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
prosthodontic	B-O
and	I-O
aesthetic	I-O
peri-implant	I-O
mucosal	I-O
outcomes	O
of	O
immediately	B-P
restored	I-P
,	I-P
Southern	I-P
single-tapered	I-P
implants	I-I
in	I-P
the	I-P
anterior	I-P
maxilla	I-P
after	I-P
1	I-P
year	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
Participants	B-P
(	I-P
mean	I-P
age	I-P
:	I-P
43.25	I-P
years	I-P
;	I-P
range	I-P
:	I-P
23-71	I-P
years	I-P
)	I-P
satisfying	I-P
specified	I-P
inclusion	I-P
criteria	I-P
were	O
randomly	O
allocated	O
to	O
conventional	O
two-stage	B-I
restoration	I-I
(	O
control	O
group	O
;	O
n=14	O
)	O
and	O
immediate	B-I
restoration	I-I
groups	I-I
(	O
test	O
group	O
;	O
n	O
=14	O
)	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O


Tapered	O
,	O
roughened-surface	O
Southern	O
implants	O
were	O
placed	O
using	O
a	O
standardized	O
technique	O
,	O
and	O
implant	O
level	O
bone	O
impressions	O
were	O
made	O
.	O


Provisional	O
screw-retained	O
crowns	O
,	O
out	O
of	O
occlusion	O
,	O
were	O
placed	O
at	O
second-stage	O
surgery	O
after	O
26	O
weeks	O
for	O
the	O
conventional	O
restoration	O
group	O
,	O
and	O
within	O
4	O
hours	O
of	O
implant	O
placement	O
for	O
the	O
immediate	O
restoration	O
group	O
.	O


Both	O
groups	O
had	O
definitive	O
screw-retained	O
metal-ceramic	O
crowns	O
placed	O
in	O
occlusion	O
8	O
weeks	O
later	O
.	O


Peri-implant	B-O
mucosal	I-O
response	I-O
and	I-O
papilla	I-O
index	I-O
were	O
recorded	O
4	O
weeks	O
after	O
definitive	O
crown	O
placement	O
to	O
allow	O
for	O
mucosal	O
maturation	O
and	O
at	O
1	O
year	O
.	O


Prosthodontic	B-O
and	I-O
aesthetic	I-O
outcomes	O
were	O
assessed	O
using	O
established	O
criteria	O
.	O


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
within	O
,	O
or	O
between	O
,	O
the	O
control	O
and	O
test	O
groups	O
for	O
age	B-O
,	I-O
gender	I-O
,	I-O
bone	I-O
quality	I-O
or	I-O
quantity	I-O
,	I-O
implant	I-O
stability	I-O
measurements	I-O
at	I-O
surgery	I-O
,	O
or	O
implant	B-O
length	I-O
.	I-O


There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
implant	B-O
success	I-O
rate	I-O
as	O
determined	O
by	O
radiographic	O
bone	B-O
loss	I-O
and	O
stability	O
tests	O
after	O
1	O
year	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
prosthodontic	B-O
maintenance	I-O
,	I-O
peri-implant	I-O
mucosal	I-O
response	I-O
,	I-O
and	I-O
papilla	I-O
index	I-O
between	O
the	O
two	O
groups	O
over	O
1	O
year	O
.	O


CONCLUSIONS	O
Tapered	O
,	O
roughened-surface	O
implants	O
immediately	O
restored	O
with	O
single	O
provisional	O
crowns	O
at	O
surgery	O
and	O
definitive	O
crowns	O
8	O
weeks	O
later	O
were	O
as	O
prosthodontically	O
and	O
aesthetically	O
successful	O
as	O
conventionally	O
restored	O
two-stage	O
implants	O
during	O
the	O
first	O
year	O
of	O
service	O
.	O


Restoring	B-I
single	O
implants	O
immediately	O
with	O
screw-retained	O
crowns	O
is	O
an	O
efficient	O
procedure	O
,	O
but	O
the	O
short-term	O
outcome	O
is	O
by	O
no	O
means	O
superior	O
to	O
a	O
conventional	O
two-stage	O
approach	O
.	O


Epicutaneous	O
allergen-specific	B-I
immunotherapy	I-I
ameliorates	O
grass	O
pollen-induced	O
rhinoconjunctivitis	O
:	O
A	O
double-blind	O
,	O
placebo-controlled	O
dose	O
escalation	O
study	O
.	O


BACKGROUND	O
Epicutaneous	B-I
allergen	I-I
administration	O
using	O
a	O
patch	O
may	O
be	O
an	O
alternative	O
to	O
subcutaneous	O
or	O
sublingual	O
immunotherapy	O
.	O


OBJECTIVE	O
To	O
optimize	O
treatment	O
dose	O
and	O
to	O
demonstrate	O
the	O
efficacy	O
and	O
safety	O
of	O
epicutaneous	O
immunotherapy	O
.	O


METHODS	O
This	O
monocentric	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
included	B-P
132	I-P
patients	I-P
with	I-P
grass	I-P
pollen-induced	I-P
rhinoconjunctivitis	I-P
.	O


In	O
February	O
2008	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	B-I
placebo	I-I
or	I-I
3	I-I
different	I-I
doses	I-I
of	I-I
allergen	I-I
.	O


Before	O
and	O
during	O
the	O
pollen	O
season	O
2008	O
,	O
patients	B-P
received	I-P
6	I-P
weekly	I-P
patches	I-P
.	O


Efficacy	O
was	O
assessed	O
4	O
to	O
5	O
months	O
later	O
(	O
n	O
=	O
110	O
)	O
and	O
during	O
the	O
pollen	O
season	O
of	O
the	O
treatment-free	O
follow-up	O
year	O
in	O
2009	O
(	O
n	O
=	O
93	O
)	O
.	O


The	O
primary	O
outcome	O
was	B-O
patient-reported	I-O
changes	I-O
in	I-O
hay	I-O
fever	I-O
symptoms	I-O
assessed	I-O
by	I-O
a	I-O
visual	I-O
analog	I-O
scale	I-O
.	O


Secondary	O
outcome	O
measures	O
were	B-O
weekly	I-O
visual	I-O
analog	I-O
scale	I-O
symptom	I-O
scores	I-O
during	I-O
pollen	I-O
season	I-O
,	I-O
use	I-O
of	I-O
rescue	I-O
medication	I-O
,	I-O
changes	I-O
in	I-O
conjunctival	I-O
and	I-O
skin	I-O
reactivity	I-O
,	I-O
as	I-O
well	I-O
as	I-O
safety	I-O
.	O


RESULTS	B-O
Hay	I-O
fever	I-O
symptoms	I-O
during	I-O
the	I-O
pollen	I-O
season	I-O
were	O
reduced	O
by	O
more	O
than	O
30	O
%	O
in	O
2008	O
and	O
by	O
24	O
%	O
in	O
2009	O
in	O
the	O
high-dose	O
group	O
as	O
compared	O
with	O
that	O
in	O
the	O
placebo	O
group	O
,	O
and	O
the	O
alleviation	O
of	O
symptoms	O
in	O
the	O
follow-up	O
year	O
was	O
dependent	O
on	O
the	O
treatment	O
dose	O
.	O


Higher	O
allergen	O
doses	O
were	O
associated	O
with	B-O
drug-related	I-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
,	O
predominantly	O
manifested	O
by	B-O
pruritus	I-O
,	I-O
erythema	I-O
,	I-O
wheal	I-O
,	I-O
or	I-O
eczema	I-O
.	O


Eleven	O
systemic	B-O
AEs	I-O
of	O
grades	O
1	O
to	O
2	O
required	O
treatment	O
and	O
led	O
to	O
study	O
exclusion	O
.	O


The	B-O
dropout	I-O
rate	I-O
due	O
to	B-O
AEs	I-O
was	O
8.3	O
%	O
.	O


No	O
drug-related	O
serious	B-O
AE	I-O
was	O
recorded	O
.	O


CONCLUSION	O
Epicutaneous	B-I
immunotherapy	I-I
is	O
safe	O
and	O
efficacious	O
in	O
a	O
dose-dependent	O
manner	O
after	O
6	O
patches	O
only	O
.	O


Treatment	O
of	O
psoriasis	B-P
vulgaris	I-P
by	O
oral	O
administration	O
of	O
yin	B-I
xie	I-I
ping	I-I
granules	I-I
--	I-I
a	I-I
clinical	I-P
report	I-P
of	I-P
60	I-P
cases	I-P
.	I-P


Initial	B-O
abstinence	I-O
status	I-O
and	I-O
contingency	I-O
management	I-O
treatment	I-O
outcomes	O
:	O
does	O
race	O
matter	O
?	O
OBJECTIVE	O
Limited	O
research	O
has	O
evaluated	O
African	B-P
American	I-P
substance	I-P
users	I-P
'	I-P
response	O
to	O
evidence-based	O
treatments	O
.	O


This	O
study	O
examined	O
the	O
efficacy	O
of	O
contingency	B-O
management	I-O
(	I-O
CM	I-O
)	I-O
in	O
African	B-P
American	I-P
and	I-P
White	I-P
cocaine	I-P
users	I-P
.	I-P


METHOD	O
A	O
secondary	O
analysis	O
evaluated	O
effects	O
of	O
race	O
,	O
treatment	O
condition	O
,	O
and	O
baseline	O
cocaine	O
urine	O
sample	O
results	O
on	O
treatment	O
outcomes	O
of	O
African	B-P
American	I-P
(	I-P
n	I-P
=	I-P
444	I-P
)	I-P
and	I-P
White	I-P
(	I-P
n	I-P
=	I-P
403	I-P
)	I-P
cocaine	I-P
abusers	I-P
participating	I-P
in	I-P
one	I-P
of	I-P
six	I-P
randomized	I-P
clinical	I-P
trials	I-P
comparing	I-P
CM	I-I
to	I-P
standard	I-I
care	I-I
.	I-I


RESULTS	O
African	B-P
American	I-P
and	I-P
White	I-P
patients	I-P
who	I-P
initiated	I-P
treatment	I-P
with	I-P
a	I-P
cocaine-negative	I-P
urine	I-P
sample	I-P
remained	O
in	O
treatment	O
for	O
similar	O
durations	O
and	O
submitted	O
a	O
comparable	O
proportion	O
of	O
negative	O
samples	O
during	O
treatment	O
regardless	O
of	O
treatment	O
type	O
;	O
CM	B-I
was	O
efficacious	O
in	O
both	O
races	O
in	O
terms	O
of	O
engendering	O
longer	O
durations	O
of	O
abstinence	O
in	O
patients	O
who	O
began	O
treatment	O
abstinent	O
.	O


Whites	B-P
who	I-P
began	I-P
treatment	I-P
with	I-P
a	I-P
cocaine	I-P
positive	I-P
sample	I-P
remained	O
in	O
treatment	O
longer	O
and	O
submitted	O
a	O
higher	O
proportion	O
of	O
negative	O
samples	O
when	O
assigned	O
to	O
CM	B-I
than	O
standard	B-I
care	I-I
.	I-I


African	B-P
Americans	I-P
who	I-P
initiated	I-P
treatment	I-P
with	I-P
a	I-P
cocaine	I-P
positive	I-P
sample	I-P
,	O
however	O
,	O
did	O
not	O
remain	O
in	O
treatment	O
longer	O
with	O
CM	B-I
compared	O
with	O
standard	B-I
care	I-I
,	O
and	O
gains	B-O
in	I-O
terms	I-O
of	I-O
drug	I-O
use	I-O
outcomes	I-O
were	O
muted	O
in	O
nature	O
relative	O
to	O
Whites	O
.	O


This	O
interaction	O
effect	O
persisted	O
through	O
the	O
9-month	O
follow-up	O
period	O
.	O


CONCLUSIONS	O
CM	B-I
is	O
not	O
equally	O
effective	O
in	O
reducing	O
drug	O
use	O
among	O
all	O
subgroups	O
,	O
specifically	O
African	B-P
American	I-P
patients	I-P
who	I-P
are	I-P
using	I-P
cocaine	I-P
upon	I-P
treatment	I-P
entry	I-P
.	I-P


Future	O
research	O
on	O
improving	O
treatment	O
outcomes	O
in	O
this	O
population	O
is	O
needed	O
.	O


Randomized	O
clinical	O
trial	O
of	O
radiofrequency	B-I
ablation	I-I
or	O
conventional	B-I
high	I-I
ligation	I-I
and	O
stripping	O
for	O
great	B-P
saphenous	I-P
varicose	I-P
veins	I-P
.	I-P


BACKGROUND	O
This	O
randomized	O
clinical	O
trial	O
compared	O
early	O
outcomes	O
after	O
radiofrequency	B-I
ablation	I-I
(	I-I
RFA	I-I
)	I-I
and	O
conventional	O
surgery	O
for	O
varicose	O
veins	O
.	O


METHODS	O
Consecutive	B-P
patients	I-P
with	I-P
symptomatic	I-P
varicose	I-P
veins	I-P
due	I-P
to	I-P
isolated	I-P
great	I-P
saphenous	I-P
vein	I-P
(	I-P
GSV	I-P
)	I-P
incompetence	I-P
and	I-P
suitable	I-P
for	I-P
RFA	I-P
were	O
randomized	O
to	O
either	O
RFA	B-I
or	O
conventional	O
surgery	O
(	O
saphenofemoral	O
disconnection	O
and	O
stripping	O
)	O
.	O


Clinical	B-O
,	I-O
radiological	I-O
and	I-O
patient-based	I-O
outcomes	I-O
were	O
recorded	O
at	O
1	O
and	O
5	O
weeks	O
after	O
intervention	O
.	O


RESULTS	O
RFA	B-I
resulted	O
in	O
successful	O
obliteration	O
of	O
the	O
GSV	B-P
in	I-P
all	I-P
47	I-P
patients	I-P
.	I-P


Complete	B-O
above-knee	I-O
stripping	I-O
was	O
unsuccessful	O
in	O
seven	O
of	O
41	O
patients	O
.	O


RFA	O
took	O
longer	O
than	O
conventional	O
surgery	O
:	O
median	O
interquartile	O
range	O
76	O
(	O
67-84	O
)	O
versus	O
48	O
(	O
39-54	O
)	O
min	O
;	O
P	O
<	O
0.001	O
.	O


Patients	O
returned	B-O
to	I-O
their	I-O
normal	I-O
activities	I-O
significantly	O
earlier	O
after	O
RFA	B-I
(	O
median	O
3	O
(	O
2-5	O
)	O
versus	O
12.5	O
(	O
4-21	O
)	O
days	O
;	O
P	O
<	O
0.001	O
)	O
.	O


Postoperative	B-O
pain	I-O
was	O
significantly	O
less	O
after	O
RFA	B-I
(	O
median	O
score	O
on	O
visual	O
analogue	O
scale	O
1.70	O
(	O
0.50-4.30	O
)	O
versus	O
4.0	O
(	O
2.35-6.05	O
)	O
;	O
P	O
=	O
0.001	O
)	O
.	O


Patient	B-O
satisfaction	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
improvement	I-O
and	I-O
analgesic	I-O
requirements	I-O
significantly	O
favoured	O
RFA	B-I
.	I-I


CONCLUSION	O
RFA	O
took	O
longer	O
to	O
perform	O
but	O
resulted	O
in	O
a	O
significantly	B-O
better	I-O
early	I-O
outcome	I-O
than	O
conventional	O
surgery	O
in	O
suitable	O
patients	B-P
with	I-P
great	I-P
saphenous	I-P
varicose	I-P
veins	I-P
.	I-P


Use	O
of	O
recombinant	B-I
human	I-I
granulocyte	I-I
colony-stimulating	I-I
factor	I-I
to	O
increase	O
chemotherapy	B-I
dose-intensity	O
:	O
a	O
randomized	O
trial	O
in	O
very	B-P
high-risk	I-P
childhood	I-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
.	I-P


PURPOSE	O
To	O
determine	O
whether	O
the	O
use	O
of	O
a	O
recombinant	B-I
human	I-I
granulocyte	I-I
colony-stimulating	I-I
factor	I-I
(	I-I
[	I-I
G-CSF	I-I
]	I-I
lenogastrim	I-I
)	I-I
can	O
increase	O
the	O
chemotherapy	O
dose-intensity	O
(	O
CDI	O
)	O
delivered	O
during	O
consolidation	B-I
chemotherapy	I-I
of	O
childhood	B-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
(	I-P
ALL	I-P
)	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Sixty-seven	B-P
children	I-P
with	I-P
very	I-P
high-risk	I-P
ALL	I-P
were	O
randomized	O
(	O
slow	O
early	O
response	O
to	O
therapy	O
,	O
55	O
patients	O
;	O
translocation	O
t	O
(	O
9	O
;	O
22	O
)	O
or	O
t	O
(	O
4	O
;	O
11	O
)	O
,	O
12	O
patients	O
)	O
.	O


Consolidation	O
consisted	O
of	O
six	O
courses	O
of	O
chemotherapy	B-I
;	I-I
the	O
first	O
,	O
third	O
,	O
and	O
fifth	O
courses	O
were	O
a	O
combination	B-I
of	I-I
high-dose	I-I
cytarabine	I-I
,	I-I
etoposide	I-I
,	I-I
and	I-I
dexamethasone	I-I
(	I-I
R3	I-I
)	I-I
,	O
whereas	O
the	O
second	O
,	O
fourth	O
,	O
and	O
sixth	O
courses	O
included	O
vincristine	B-I
,	I-I
prednisone	I-I
,	I-I
cyclophosphamide	I-I
,	I-I
doxorubicin	I-I
,	I-I
and	I-I
methotrexate	I-I
(	I-I
COPADM	I-I
)	I-I
.	I-I


G-CSF	B-I
was	O
given	O
after	O
each	O
course	O
,	O
and	O
the	O
next	O
scheduled	O
course	O
was	O
started	O
as	O
soon	O
as	O
neutrophil	O
count	O
was	O
>	O
1	O
x	O
10	O
(	O
9	O
)	O
/L	O
and	O
platelet	O
count	O
was	O
>	O
100	O
x	O
10	O
(	O
9	O
)	O
/L	O
.	O


CDI	B-O
was	O
calculated	O
using	O
the	O
interval	O
from	O
day	O
1	O
of	O
the	O
first	O
course	O
to	O
hematologic	O
recovery	O
after	O
the	O
fifth	O
course	O
(	O
100	O
%	O
CDI	O
=	O
105-day	O
interval	O
)	O
.	O


RESULTS	O
CDI	B-O
was	O
significantly	O
increased	B-O
in	O
the	O
G-CSF	B-I
group	O
compared	O
with	O
the	O
non-G-CSF	B-I
group	O
(	O
mean	O
+/-	O
95	O
%	O
confidence	O
interval	O
,	O
105	O
+/-	O
5	O
%	O
v	O
91	O
+/-	O
4	O
%	O
;	O
P	O
<	O
.001	O
)	O
.	O


This	O
higher	B-O
intensity	I-O
was	O
a	O
result	O
of	O
shorter	O
post-R3	B-O
intervals	I-O
in	O
the	O
G-CSF	B-I
group	O
,	O
whereas	O
the	O
post-COPADM	B-I
intervals	O
were	O
not	O
statistically	O
reduced	O
.	O


After	O
the	O
R3	O
courses	O
,	O
the	O
number	B-O
of	I-O
days	I-O
with	I-O
fever	I-O
and	I-O
intravenous	I-O
antibiotics	I-O
and	I-O
duration	I-O
of	I-O
hospitalization	I-O
were	I-O
significantly	I-O
decreased	I-O
by	O
G-CSF	B-I
,	O
whereas	O
reductions	B-O
observed	I-O
after	I-O
COPADM	I-O
were	I-O
not	I-O
statistically	I-O
significant	I-O
.	I-O


Duration	B-O
of	I-O
granulocytopenia	I-O
was	I-O
reduced	I-O
in	O
the	O
G-CSF	B-I
group	O
,	O
but	O
thrombocytopenia	B-O
was	I-O
prolonged	I-O
,	O
and	O
the	O
number	B-O
of	I-O
platelet	I-O
transfusions	I-O
was	I-O
increased	I-O
.	I-O


Finally	O
,	O
the	O
3-year	O
probability	O
of	O
event-free	B-O
survival	I-O
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O


CONCLUSION	O
G-CSF	B-I
can	O
increase	O
CDI	O
in	O
high-risk	B-P
childhood	I-P
ALL	I-P
.	O


Its	O
effects	O
depend	O
on	O
the	O
chemotherapy	O
regimen	O
given	O
before	O
G-CSF	B-I
administration	I-I
.	I-I


In	O
our	O
study	O
,	O
a	O
higher	O
CDI	O
did	O
not	O
improve	O
disease	O
control	O
.	O


Randomized	O
trial	O
of	O
partial	B-I
vs.	O
stepwise	B-I
caries	I-P
removal	O
:	O
3-year	O
follow-up	O
.	O


This	O
randomized	O
,	O
multicenter	O
clinical	O
trial	O
evaluated	O
the	O
effectiveness	O
of	O
2	O
treatments	O
for	O
deep	B-P
caries	I-P
lesions	I-P
-	O
partial	B-I
caries	I-I
removal	I-I
(	I-I
PCR	I-I
)	I-I
and	I-I
stepwise	I-I
excavation	I-I
(	I-I
SW	I-I
)	I-I
-	O
with	O
respect	O
to	O
the	O
primary	O
outcome	O
of	O
pulp	O
vitality	O
for	O
a	O
3-year	O
follow-up	O
period	O
.	O


Inclusion	B-P
criteria	I-P
were	I-P
as	I-P
follows	I-P
:	I-P
patients	I-P
with	I-P
permanent	I-P
molars	I-P
presenting	I-P
deep	I-P
caries	I-P
lesions	I-P
(	I-P
lesion	I-P
affecting	I-P
≥	I-P
1/2	I-P
of	I-P
the	I-P
dentin	I-P
on	I-P
radiographic	I-P
examination	I-P
)	I-P
,	I-P
positive	I-P
response	I-P
to	I-P
a	I-P
cold	I-P
test	I-P
,	I-P
absence	I-P
of	I-P
spontaneous	I-P
pain	I-P
,	I-P
negative	I-P
sensitivity	I-P
to	I-P
percussion	I-P
,	I-P
and	I-P
absence	I-P
of	I-P
periapical	I-P
lesions	I-P
(	I-P
radiographic	I-P
examination	I-P
)	I-P
.	O


Teeth	O
randomly	O
assigned	O
to	O
PCR	O
(	O
test	O
)	O
received	O
incomplete	O
caries	O
removal	O
and	O
filling	O
in	O
a	O
single	O
session	O
.	O


Outcome	O
success	O
was	O
evaluated	O
by	O
assessment	O
of	B-O
pulp	I-O
vitality	I-O
,	O
determined	O
by	O
pulp	O
sensitivity	O
to	O
a	O
cold	O
test	O
and	O
the	O
absence	O
of	O
periapical	O
lesions	O
.	O


Data	O
were	O
analyzed	O
by	O
a	O
Weibull	O
regression	O
model	O
with	O
shared	O
frailty	O
term	O
(	O
survival	O
analysis	O
)	O
.	O


At	O
baseline	B-P
,	I-P
299	I-P
treatments	I-P
were	I-P
executed	I-P
:	I-P
PCR	O
,	O
152	O
and	O
SW	O
,	O
147	B-P
.	O


By	O
the	O
end	O
of	O
the	O
3-year	O
follow-up	O
period	B-P
,	I-P
213	I-P
teeth	I-P
had	I-P
been	I-P
evaluated	I-O
.	I-O


Adjusted	B-O
survival	I-O
rates	I-O
were	O
91	O
%	O
for	O
PCR	O
and	O
69	O
%	O
for	O
SW	O
(	O
p	O
=	O
0.004	O
)	O
.	O


These	O
results	O
suggest	O
that	O
there	O
is	O
no	O
need	O
to	O
re-open	O
a	O
cavity	O
and	O
perform	O
a	O
second	O
excavation	O
for	B-O
pulp	I-O
vitality	I-O
to	O
be	O
preserved	O
(	O
Clinical	O
trials	O
registration	O
NCT00887952	O
)	O
.	O


A	O
randomized	O
controlled	O
trial	O
of	O
the	O
Korean	B-I
version	I-I
of	I-I
the	I-I
PEERS	I-I
(	I-I
®	I-I
)	I-I
parent-assisted	I-I
social	I-I
skills	I-I
training	I-I
program	I-I
for	I-P
teens	I-P
with	I-P
ASD	I-P
.	O


Impaired	O
social	O
functioning	O
is	O
a	O
hallmark	O
feature	O
of	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
often	O
requiring	O
treatment	O
throughout	O
the	O
life	O
span	O
.	B-I


PEERS	B-I
(	I-I
®	I-I
)	I-I
(	I-I
Program	I-I
for	I-I
the	I-I
Education	I-I
and	I-I
Enrichment	I-I
of	I-I
Relational	I-I
Skills	I-I
)	I-I
is	O
a	B-P
parent-assisted	I-P
social	I-P
skills	I-P
training	I-P
for	I-P
teens	I-P
with	I-P
ASD	I-P
.	O


Although	O
PEERS	O
(	O
®	O
)	O
has	O
an	O
established	O
evidence	O
base	O
in	O
improving	O
the	O
social	O
skills	O
of	O
adolescents	O
and	O
young	O
adults	O
with	O
ASD	O
in	O
North	O
America	O
,	O
the	O
efficacy	O
of	O
this	O
treatment	O
has	O
yet	O
to	O
be	O
established	O
in	O
cross-cultural	O
validation	O
trials	O
.	O


The	O
objective	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
feasibility	O
and	O
treatment	O
efficacy	O
of	B-I
a	I-I
Korean	I-I
version	I-I
of	I-I
PEERS	I-I
(	I-I
®	I-I
)	I-I
for	O
enhancing	O
social	O
skills	O
through	O
a	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
.The	O
English	O
version	O
of	O
the	B-I
PEERS	I-I
(	I-I
®	I-I
)	I-I
Treatment	O
Manual	O
(	O
Laugeson	O
&	O
Frankel	O
,	O
2010	O
)	O
was	O
translated	O
into	O
Korean	B-P
and	O
reviewed	B-P
by	I-P
21	I-P
child	I-P
mental	I-P
health	I-P
professionals	I-P
.	O


Items	O
identified	O
as	O
culturally	O
sensitive	O
were	B-P
surveyed	I-P
by	I-P
447	I-P
middle	I-P
school	I-P
students	I-P
,	O
and	O
material	O
was	O
modified	O
accordingly	B-P
.	I-P


Participants	B-P
included	I-P
47	I-P
teens	I-P
between	I-P
12	I-P
and	I-P
18	I-P
years	I-P
of	I-P
age	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
ASD	I-P
and	I-P
a	I-P
verbal	I-P
intelligence	I-P
quotient	I-P
(	I-P
IQ	I-P
)	I-P
≥	O
65	O
.	O


Eligible	O
teens	O
were	O
randomly	O
assigned	O
to	O
a	O
treatment	O
group	O
(	B-I
TG	I-I
)	I-I
or	I-I
delayed	I-I
treatment	I-I
control	I-I
group	O
(	O
CG	O
)	O
.	O


Primary	O
outcome	O
measures	O
included	O
questionnaires	O
and	O
direct	O
observations	O
quantifying	O
social	O
ability	O
and	O
problems	O
directly	O
related	O
to	O
ASD	O
.	O


Secondary	O
outcome	O
measures	O
included	O
scales	O
for	O
depressive	O
symptoms	O
,	O
anxiety	O
,	O
and	O
other	O
behavioral	O
problems	O
.	O


Rating	O
scales	O
for	O
parental	O
depressive	O
symptoms	O
and	O
anxiety	O
were	O
examined	O
to	O
detect	O
changes	O
in	O
parental	O
psychosocial	O
functioning	O
throughout	O
the	O
PEERS	O
(	O
®	O
)	O
treatment	O
.	O


Independent	O
samples	O
t-tests	O
revealed	B-O
no	I-O
significant	I-O
differences	I-O
at	I-O
baseline	I-O
across	I-O
the	I-O
TG	I-O
and	O
CG	O
conditions	O
with	O
regard	O
to	O
age	O
(	O
14.04	O
±	O
1.64	O
and	O
13.54	O
±	O
1.50	O
years	O
)	O
,	O
IQ	O
(	O
99.39	O
±	O
18.09	O
&	O
100.67	O
±	O
16.97	O
)	O
,	O
parental	O
education	O
,	O
socioeconomic	O
status	O
,	O
or	O
ASD	O
symptoms	O
(	O
p	O
<	O
0.05	O
)	O
,	O
respectively	O
.	O


Results	O
for	O
treatment	O
outcome	O
suggest	B-O
that	I-O
the	I-O
TG	I-O
showed	I-O
significant	I-O
improvement	I-O
in	I-O
communication	I-O
and	I-O
social	I-O
interaction	I-O
domain	I-O
scores	I-O
on	I-O
the	I-O
Autism	I-O
Diagnostic	I-O
Observation	I-O
Schedule	I-O
,	I-O
interpersonal	I-O
relationship	I-O
and	I-O
play/leisure	I-O
time	I-O
on	I-O
the	I-O
subdomain	I-O
scores	I-O
of	I-O
the	I-O
Korean	I-O
version	I-O
of	I-O
the	I-O
Vineland	I-O
Adaptive	I-O
Behavior	I-O
Scale	I-O
(	I-O
p	I-O
's	I-O
<	I-O
0.01	I-O
)	I-O
,	I-O
social	I-O
skills	I-O
knowledge	I-O
total	I-O
scores	I-O
on	I-O
the	I-O
Test	I-O
of	I-O
Adolescent	I-O
Social	I-O
Skills	I-O
Knowledge-Revised	I-O
(	I-O
p	I-O
<	I-O
0.01	I-O
)	I-O
,	I-O
and	I-O
decreased	I-O
depressive	I-O
symptoms	I-O
on	I-O
the	I-O
Child	I-O
Depression	I-O
Inventory	I-O
following	I-O
treatment	I-O
(	O
p	O
<	O
0.05	O
)	O
.	O


Analyses	O
of	O
parental	O
outcome	B-O
reveal	I-O
a	I-O
significant	I-O
decrease	I-O
in	I-O
maternal	I-O
state	I-O
anxiety	I-O
in	O
the	O
TG	O
after	O
controlling	O
for	O
potential	O
confounding	O
variables	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Despite	O
cultural	O
and	O
linguistic	O
differences	O
,	O
the	O
PEERS	O
(	O
®	O
)	O
social	O
skills	O
intervention	O
appears	B-O
to	I-O
be	I-O
efficacious	I-O
for	I-O
teens	I-O
with	I-P
ASD	O
in	O
Korea	O
with	O
modest	O
cultural	O
adjustment	O
.	O


In	O
an	O
RCT	O
,	O
participants	O
receiving	O
the	O
PEERS	O
(	O
®	O
)	O
treatment	B-O
showed	I-O
significant	I-O
improvement	I-O
in	I-O
social	I-O
skills	I-O
knowledge	I-O
,	I-O
interpersonal	I-O
skills	I-O
,	I-O
and	I-O
play/leisure	I-O
skills	I-O
,	I-O
as	I-O
well	I-O
as	I-O
a	I-O
decrease	I-O
in	I-O
depressive	I-O
symptoms	I-O
and	I-O
ASD	O
symptoms	O
.	O


This	O
study	O
represents	O
one	O
of	O
only	O
a	O
few	O
cross-cultural	O
validation	O
trials	O
of	O
an	O
established	O
evidence-based	O
treatment	B-P
for	I-P
adolescents	I-P
with	O
ASD	O
.	O


Dose-related	O
difference	O
in	O
progression	O
rates	O
of	O
cytomegalovirus	B-P
retinopathy	I-P
during	O
foscarnet	B-I
maintenance	I-I
therapy	I-I
.	I-I


AIDS	O
Clinical	O
Trials	O
Group	O
Protocol	O
915	O
Team	O
.	O


PURPOSE	O
A	O
previous	O
dose-ranging	O
study	O
of	O
foscarnet	B-I
maintenance	I-I
therapy	I-I
for	O
cytomegalovirus	O
retinopathy	O
showed	O
a	O
positive	O
relationship	O
between	O
dose	O
and	O
survival	O
but	O
could	O
not	O
confirm	O
a	O
relationship	O
between	O
dose	O
and	O
time	O
to	O
first	O
progression	O
.	O


This	O
retrospective	O
analysis	O
of	O
data	O
from	O
that	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
there	O
was	O
a	O
relationship	O
between	O
dose	O
and	O
progression	O
rates	O
,	O
which	O
reflects	O
the	O
amount	O
of	O
retina	O
destroyed	O
when	O
progression	O
occurs	O
.	O


METHODS	O
Patients	B-P
were	O
randomly	O
given	O
one	O
of	O
two	B-I
foscarnet	I-I
maintenance	I-I
therapy	I-I
doses	I-I
(	O
90	O
mg/kg	O
of	O
body	O
weight/day	O
[	B-I
FOS-90	I-I
group	O
]	O
or	O
120	B-I
mg/kg	I-I
of	I-I
body	I-I
weight/day	I-I
[	I-I
FOS-120	I-I
group	O
]	O
after	O
induction	O
therapy	O
.	O


Using	O
baseline	O
and	O
follow-up	O
photographs	O
and	O
pre-established	O
definitions	O
and	O
methodology	O
in	O
a	O
masked	O
analysis	O
,	O
posterior	O
progression	O
rates	O
and	O
foveal	O
proximity	O
rates	O
for	O
individual	O
lesions	O
,	O
selected	O
by	O
prospectively	O
defined	O
criteria	O
,	O
were	O
calculated	O
in	O
each	O
patient	O
.	O


Rates	O
were	O
compared	O
between	O
groups	O
.	O


RESULTS	O
The	O
following	O
median	B-O
rates	I-O
were	O
greater	O
for	O
the	O
FOS-90	B-I
group	O
(	O
N	O
=	O
8	O
)	O
than	O
for	O
the	O
FOS-120	O
group	O
(	O
N	O
=	O
10	O
)	O
:	O
greatest	B-O
maximum	I-O
rate	I-O
at	I-O
which	I-O
lesions	I-O
enlarged	O
in	O
a	O
posterior	O
direction	O
(	O
43.5	O
vs	O
12.5	O
microns/day	O
;	O
P	O
=	O
.002	O
)	O
;	O
posterior	B-O
progression	I-O
rate	I-O
for	I-O
lesions	I-O
closest	I-O
to	I-O
the	I-O
fovea	I-O
(	O
42.8	O
vs	O
5.5	O
microns/day	O
;	O
P	O
=	O
.010	O
)	O
;	O
and	O
maximum	B-O
foveal	I-O
proximity	I-O
rate	I-O
for	I-O
either	I-O
eye	I-O
(	O
32.3	O
vs	O
3.4	O
microns/day	O
;	O
P	O
=	O
.031	O
)	O
.	O


CONCLUSION	O
Patients	B-P
receiving	I-P
higher	I-P
doses	I-P
of	I-P
foscarnet	I-I
have	O
slower	O
rates	O
of	O
progression	O
and	O
therefore	O
less	O
retinal	O
tissue	O
damage	O
during	O
maintenance	O
therapy	O
.	O


A	O
foscarnet	B-I
maintenance	O
therapy	O
dose	O
of	O
120	O
mg/kg	O
of	O
body	O
weight/day	O
instead	O
of	O
90	O
mg/kg	O
of	O
body	O
weight/day	O
may	O
help	O
to	O
preserve	O
vision	O
in	O
patients	B-P
with	I-P
cytomegalovirus	I-P
retinopathy	I-P
.	I-P


Neridronate	B-I
prevents	O
bone	B-O
loss	I-O
in	O
patients	B-P
receiving	I-P
androgen	I-I
deprivation	I-I
therapy	I-I
for	I-P
prostate	I-P
cancer	I-P
.	I-P


UNLABELLED	O
Today	O
,	O
androgen	B-I
deprivation	I-I
therapy	I-I
is	O
a	O
cornerstone	O
of	O
treatment	O
for	O
advanced	B-P
prostate	I-P
cancer	I-P
,	O
although	O
it	O
presents	O
important	O
complications	O
such	O
as	O
osteoporosis	B-O
.	I-O


Neridronate	B-I
,	I-I
a	I-I
relatively	I-I
new	I-I
bisphosphonate	I-I
,	O
is	O
able	O
to	O
prevent	O
bone	B-O
loss	I-O
in	O
patients	B-P
with	I-P
prostate	I-P
cancer	I-P
during	I-P
androgen	I-P
ablation	I-P
.	I-P


INTRODUCTION	O
Androgen-deprivation	O
therapy	O
(	O
ADT	O
)	O
is	O
a	O
cornerstone	O
of	O
treatment	O
for	O
advanced	B-P
prostate	I-P
cancer	I-P
.	I-P


This	O
therapy	O
has	O
iatrogenic	O
complications	O
,	O
such	O
as	O
osteoporosis	O
.	O


The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	B-O
of	O
neridronate	O
,	O
a	O
relatively	O
new	O
bisphosphonate	O
,	O
to	O
prevent	O
bone	O
loss	O
during	O
androgen	O
ablation	O
.	O


MATERIALS	O
AND	O
METHODS	O
Forty-eight	B-P
osteoporotic	I-P
patients	I-P
with	I-P
prostate	I-P
cancer	I-P
,	I-P
treated	I-P
with	I-P
3-month	I-P
depot	I-P
triptorelina	I-I
,	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
to	O
two	O
different	O
treatment	O
groups	O
:	O
group	O
A	O
(	B-P
n	I-P
=	I-P
24	I-P
)	I-P
was	O
treated	O
with	O
a	O
daily	B-I
calcium	I-I
and	I-I
cholecalciferol	I-I
supplement	I-I
(	O
500	O
mg	O
of	O
elemental	O
calcium	O
and	O
400	O
IU	O
cholecalciferol	O
)	O
,	O
and	O
group	O
B	O
(	B-P
n	I-P
=	I-P
24	I-P
)	I-P
received	O
in	O
addition	O
to	O
the	O
same	O
daily	B-I
calcium	I-I
and	I-I
cholecalciferol	I-I
supplement	I-I
,	O
25	O
mg	O
of	O
neridronate	B-I
given	O
intramuscularly	O
every	O
month	O
.	O


All	O
patients	O
also	O
received	O
bicalutamide	B-I
for	O
4	O
weeks	O
.	O


Lumbar	B-O
and	I-O
femoral	I-O
BMD	I-O
was	O
evaluated	O
by	O
DXA	O
at	O
baseline	O
and	O
after	O
1	O
year	O
of	O
therapy	O
;	O
moreover	O
,	O
deoxypyridinoline	B-O
(	I-O
DPD	I-O
)	I-O
and	I-O
bone	I-O
alkaline	I-O
phosphatase	I-O
(	I-O
BALP	I-O
)	I-O
were	O
determined	O
at	O
the	O
beginning	O
,	O
midway	O
through	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O


RESULTS	O
After	O
6	O
and	O
12	O
months	O
,	O
whereas	O
patients	O
treated	O
only	O
with	O
calcium	O
and	O
cholecalciferol	O
(	O
group	O
A	O
)	O
showed	O
a	O
marked	B-O
bone	I-O
loss	I-O
,	O
with	O
increased	B-O
levels	I-O
of	I-O
DPD	I-O
and	I-O
BALP	I-O
compared	O
with	O
baseline	O
values	O
,	O
patients	O
treated	O
also	O
with	O
neridronate	O
(	O
group	O
B	O
)	O
had	O
substantially	O
unchanged	O
levels	O
of	O
these	O
markers	O
.	O


After	O
1	O
year	O
of	O
treatment	O
,	O
lumbar	B-O
and	I-O
total	I-O
hip	I-O
BMD	I-O
decreased	I-O
significantly	I-O
in	O
patients	O
treated	O
only	O
with	O
calcium	O
and	O
cholecalciferol	O
(	O
group	O
A	O
)	O
,	O
whereas	O
it	O
did	O
not	O
change	B-O
significantly	I-O
at	O
any	O
skeletal	O
site	O
in	O
patients	O
treated	O
also	O
with	O
neridronate	O
(	O
group	O
B	O
)	O
.	O


No	O
relevant	B-O
side	I-O
effects	I-O
were	O
recorded	O
during	O
our	O
study	O
.	O


CONCLUSIONS	O
Neridronate	B-I
is	O
an	O
effective	O
treatment	O
in	O
preventing	O
bone	B-O
loss	I-O
in	O
the	O
hip	O
and	O
lumbar	O
spine	O
in	O
men	B-P
receiving	I-P
ADT	I-P
for	I-P
prostate	I-P
cancer	I-P
.	I-P


Changes	O
in	O
body	B-O
weight	I-O
and	I-O
blood	I-O
pressure	I-O
:	I-O
paradoxical	O
outcome	O
events	O
in	O
overweight	B-P
and	I-P
obese	I-P
subjects	I-P
with	I-P
cardiovascular	I-P
disease	I-P
.	I-P


BACKGROUND/OBJECTIVES	O
The	O
Sibutramine	O
Cardiovascular	O
OUTcomes	O
(	O
SCOUT	O
)	O
trial	O
showed	O
a	O
significantly	O
increased	O
relative	O
risk	O
of	O
nonfatal	B-O
cardiovascular	I-O
events	I-O
,	O
but	O
not	O
mortality	B-O
,	O
in	O
overweight	B-P
and	I-P
obese	I-P
subjects	I-P
receiving	I-P
long-term	I-I
sibutramine	I-I
treatment	I-I
with	I-I
diet	I-I
and	I-I
exercise	I-I
.	I-I


We	O
examined	O
the	O
relationship	O
between	O
early	O
changes	O
(	O
both	O
increases	O
and	O
decreases	O
)	O
in	O
body	B-O
weight	I-O
and	O
blood	B-O
pressure	I-O
,	O
and	O
the	O
impact	O
of	O
these	O
changes	O
on	O
subsequent	O
cardiovascular	B-O
outcome	I-O
events	I-O
.	I-O


SUBJECTS/METHODS	O
A	B-P
total	I-P
of	I-P
9804	I-P
male	I-P
and	I-P
female	I-P
subjects	I-P
,	I-P
aged	I-P
55	I-P
years	I-P
or	I-P
older	I-P
,	I-P
with	I-P
a	I-P
body	I-P
mass	I-P
index	I-P
of	I-P
27-45	I-P
kg	I-P
m	I-P
(	I-P
-2	I-P
)	I-P
were	I-P
included	I-P
in	I-P
this	I-P
current	I-P
subanalysis	I-P
of	O
the	O
SCOUT	O
trial	O
.	O


Subjects	O
were	B-P
required	I-P
to	I-P
have	I-P
a	I-P
history	I-P
of	I-P
cardiovascular	I-P
disease	I-P
and/or	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
with	I-P
at	I-P
least	I-P
one	I-P
cardiovascular	I-P
risk	I-P
factor	I-P
(	I-P
hypertension	I-P
,	I-P
dyslipidemia	I-P
,	I-P
current	I-P
smoking	I-P
or	I-P
diabetic	I-P
nephropathy	I-P
)	I-P
to	O
assess	O
cardiovascular	O
outcomes	O
.	O


Post	O
hoc	O
subgroup	O
analyses	B-O
of	I-O
weight	I-O
change	I-O
(	O
categories	O
)	O
and	B-O
blood	I-O
pressure	I-O
were	O
performed	O
overall	O
and	O
by	O
treatment	O
group	O
(	B-I
6-week	I-I
sibutramine	I-I
followed	O
by	O
randomized	B-I
placebo	I-I
or	I-I
continued	I-I
sibutramine	I-I
)	I-I
.	O


The	B-O
primary	I-O
outcome	I-O
event	I-O
(	I-O
POE	I-O
)	I-O
was	I-O
a	I-O
composite	I-O
of	I-O
nonfatal	I-O
myocardial	I-O
infarction	I-O
,	I-O
nonfatal	I-O
stroke	I-O
,	I-O
resuscitated	I-O
cardiac	I-O
arrest	I-O
or	I-O
cardiovascular	I-O
death	I-O
.	O


Time-to-event	O
analyses	O
of	O
the	O
POE	O
were	O
performed	O
using	O
Cox	O
regression	O
models	O
with	O
factors	O
for	O
treatment	O
,	O
subgroups	O
and	O
interactions	O
.	O


RESULTS	O
During	O
the	O
initial	O
6-week	B-I
sibutramine	I-I
treatment	O
period	B-O
,	I-O
systolic	I-O
blood	I-O
pressure	I-O
decreased	O
progressively	O
with	O
increasing	B-O
weight	I-O
loss	I-O
in	O
hypertensive	O
subjects	O
(	O
-8.1±10.5	O
mm	O
Hg	O
with	O
<	O
5	O
kg	O
weight	O
loss	O
to	O
-10.8±11.0	O
mm	O
Hg	O
with	O
⩾5	O
kg	O
weight	B-O
loss	I-O
)	I-O
.	I-O


The	B-O
highest	I-O
POE	O
incidence	O
occurred	O
mainly	O
in	O
groups	O
with	B-O
increases	I-O
in	I-O
both	I-O
weight	I-O
and	O
blood	O
pressure	O
.	O


However	B-I
,	I-I
with	I-I
long-term	I-I
sibutramine	O
treatment	B-O
,	I-O
a	I-O
markedly	I-O
lower	I-O
blood	O
pressure	B-O
tended	I-O
to	O
increase	O
POEs	B-O
.	I-O


CONCLUSION	B-O
Modest	O
weight	O
loss	B-O
and	I-O
modest	I-O
lower	I-O
blood	O
pressure	O
each	O
reduced	O
the	O
incidence	O
of	O
cardiovascular	O
events	O
,	O
as	O
expected	O
.	O


However	O
,	O
the	O
combination	B-O
of	I-O
early	I-O
marked	O
weight	B-O
loss	I-O
and	I-O
rapid	I-O
blood	I-O
pressure	O
reduction	O
seems	O
to	B-P
be	I-P
harmful	I-P
in	I-P
this	I-P
obese	I-P
elderly	I-P
cardiovascular	I-P
diseased	O
population	O
.	O


Efficacy	O
of	O
bepotastine	B-I
besilate	I-I
ophthalmic	I-I
solution	I-I
1.5	O
%	O
for	O
seasonal	B-O
allergic	I-O
conjunctivitis	I-O
:	I-O
a	O
randomized	O
,	O
placebo-controlled	B-I
,	O
natural	O
exposure	O
,	O
clinical	O
trial	O
.	O


Allergic	O
conjunctivitis	O
(	O
AC	O
)	O
affects	O
an	O
estimated	O
20	O
%	O
of	O
the	O
population	O
in	O
the	O
Western	O
world	O
,	O
with	O
a	O
large	O
fraction	O
suffering	O
due	O
to	O
seasonal	O
or	O
perennial	O
allergen	O
exposures	O
.	O


Bepotastine	B-I
besilate	I-I
ophthalmic	I-I
solution	I-I
(	I-I
BBOS	I-I
)	I-I
1.5	O
%	O
,	O
a	O
dual-acting	B-I
histamine	I-I
(	O
H	O
(	O
1	O
)	O
)	O
receptor	O
antagonist	O
and	O
mast	O
cell	O
stabilizer	O
,	O
is	O
indicated	O
for	O
itching	O
associated	O
with	O
AC	O
.	O


This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
BBOS	O
1.5	O
%	O
for	O
reducing	O
ocular	B-P
itching	I-P
associated	I-P
with	I-P
AC	I-P
in	I-P
subjects	I-P
enrolled	I-P
in	I-P
a	I-P
natural	I-P
exposure	I-P
trial	I-P
.	I-P


Eligible	B-P
subjects	I-P
in	O
a	O
multicenter	O
,	O
double-masked	O
,	O
randomized	O
,	O
parallel-group	O
,	O
placebo-controlled	B-I
,	O
natural	O
exposure	O
clinical	O
trial	O
were	O
randomly	O
assigned	O
to	O
either	O
BBOS	B-I
1.5	O
%	O
or	B-I
placebo	I-I
eyedrops	I-I
on	O
a	O
1:1	O
basis	O
and	O
instilled	O
1	O
drop	O
of	O
the	O
test	O
agent	O
into	O
both	O
eyes	O
twice	O
daily	O
for	O
2	O
weeks	O
.	O


The	O
mean	O
change	O
from	O
baseline	O
in	O
instantaneous	O
and	O
reflective	B-O
ocular	I-O
itching	I-O
scores	I-O
at	O
the	O
end	O
of	O
2	O
weeks	O
of	O
treatment	O
were	O
evaluated	O
based	O
on	O
subject-assessed	O
severity	O
of	O
instantaneous	O
and	O
reflective	O
itching	O
.	O


Subject-reported	B-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
were	O
also	O
recorded	O
for	O
safety	O
.	O


Treatment	O
with	O
BBOS	O
1.5	O
%	O
significantly	O
reduced	O
instantaneous	B-O
and	I-O
reflective	I-O
ocular	I-O
itching	I-O
scores	I-O
from	O
baseline	O
compared	O
with	O
placebo	O
over	O
the	O
2-week	O
study	O
period	O
(	O
p	O
=	O
0.007	O
and	O
p	O
=	O
0.005	O
,	O
respectively	O
)	O
.	O


BBOS	O
1.5	O
%	O
was	O
well	O
tolerated	B-O
,	I-O
and	I-O
AEs	I-O
were	O
generally	O
transient	O
and	O
mild	O
.	O


This	O
clinical	O
study	O
indicates	O
BBOS	O
1.5	O
%	O
effectively	B-O
and	I-O
safely	I-O
treated	I-O
ocular	I-O
itching	I-O
in	O
a	O
natural	O
exposure	O
allergy	O
study	O
and	O
is	O
a	O
useful	O
treatment	O
option	O
for	O
the	O
management	O
of	O
ocular	O
itching	O
associated	O
with	O
AC	O
.	O


(	O
ClinicalTrials.gov	O
identifier	O
number	O
:	O
NCT01174823	O
.	O


)	O


[	O
Safety	O
of	O
adjuvant	B-I
dose-dense	I-I
chemotherapy	I-I
with	I-I
paclitaxel	I-I
and	I-I
epirubicin	I-I
for	O
high-risk	B-P
breast	I-P
cancer	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
investigate	O
the	O
safety	B-O
and	I-O
tolerance	I-O
of	O
adjuvant	B-I
dose-dense	I-I
chemotherapy	I-I
with	I-I
paclitaxel	I-I
and	I-I
epirubicin	I-I
for	O
high-risk	B-P
breast	I-P
cancer	I-P
.	I-P


METHODS	O
From	O
January	O
2004	O
to	O
December	O
2006	O
,	O
101	B-P
patients	I-P
with	I-P
high-risk	I-P
breast	I-P
cancer	I-P
after	I-P
surgical	I-P
resection	I-P
were	O
enrolled	O
into	O
this	O
study	O
.	O


The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
dose-dense	O
and	O
regular	O
groups	O
.	O


Each	O
patient	O
received	O
6	B-I
cycles	I-I
of	I-I
chemotherapy	I-I
with	I-I
intravenous	I-I
administration	I-I
of	I-I
paclitaxel	I-I
(	I-I
175	I-I
mg/m2	I-I
,	I-I
on	I-I
D3	I-I
)	I-I
and	I-I
epirubicin	I-I
(	I-I
60	I-I
mg/m2	I-I
,	I-I
on	I-I
Dl	I-I
and	I-I
D2	I-I
)	I-I
.	I-I


The	O
dose-dense	B-I
group	I-I
had	I-I
repeated	I-I
treatment	I-I
every	I-I
two	I-I
weeks	I-I
,	O
while	O
the	O
regular	B-I
group	I-I
repeated	I-I
it	I-I
every	I-I
three	I-I
weeks	I-I
.	I-I


G-CSF	B-I
was	I-I
used	I-I
in	I-I
a	I-I
dose	I-I
of	I-I
3	I-I
microg/kg	I-I
on	I-I
D5-D9	I-I
during	O
each	O
cycle	O
in	O
the	O
dose-dense	O
group	O
.	O


While	O
in	O
the	O
regular	O
group	O
,	O
it	O
was	O
used	O
only	O
under	O
the	O
condition	O
that	O
grade	O
II	O
neutropenia	O
occurred	O
.	O


RESULTS	O
The	O
toxicity	B-O
could	O
be	O
evaluated	O
in	O
101	B-P
patients	I-P
.	I-P


Major	B-O
grade	I-O
II-IV	I-O
toxicities	I-O
included	I-O
:	I-O
neutropenia	I-O
,	I-O
nausea	I-O
,	I-O
vomiting	I-O
and	I-O
alopecia	I-O
.	I-O


The	O
incidence	O
of	O
grade	B-O
III-IV	I-O
neutropenia	I-O
was	O
16.0	O
%	O
in	O
the	O
dose-dense	O
group	O
versus	O
54.9	O
%	O
in	O
the	O
regular	O
group	O
(	O
P	O
=	O
0.000	O
)	O
;	O
postponing	O
of	O
chemotherapy	O
was	O
2.4	O
%	O
versus	O
6.0	O
%	O
(	O
P	O
=	O
0.027	O
)	O
.	O


Ninety-eight	B-P
patients	I-P
completed	I-P
the	I-P
chemotherapy	I-P
as	I-P
planed	I-P
.	I-P


After	O
a	O
median	O
follow-up	O
of	O
24	O
months	O
,	O
the	O
median	B-O
DFS	I-O
and	I-O
OS	I-O
were	O
not	O
reached	O
.	O


The	O
relapse-free	B-O
rate	I-O
and	I-O
survival	I-O
rate	I-O
were	O
89.8	O
%	O
and	O
100	O
%	O
in	O
the	O
dose-dense	O
group	O
,	O
which	O
were	O
87.8	O
%	O
and	O
93.9	O
%	O
in	O
the	O
regular	O
group	O
.	O


The	O
relapse-free	B-O
rate	I-O
of	I-O
the	I-O
high-risk	I-O
patients	I-O
in	O
the	O
dose-dense	O
group	O
was	O
86.8	O
%	O
versus	O
81.3	O
%	O
in	O
the	O
regular	O
group	O
,	O
and	O
the	O
corresponding	O
survival	O
rate	O
was	O
100	O
%	O
versus	O
90.6	O
%	O
.	O


CONCLUSION	O
Adjuvant	B-I
dose-dense	I-I
chemotherapy	I-I
with	I-I
paclitaxel	I-I
and	I-I
epirubicin	I-I
is	O
safe	O
,	O
tolerable	O
and	O
promising	O
for	O
high-risk	B-P
breast	I-P
cancer	I-P
.	I-P


Analgesic	B-O
efficacy	I-O
of	O
piroxicam	B-I
in	O
the	O
treatment	O
of	O
postoperative	B-O
pain	I-O
.	I-O


Two	O
randomized	O
,	O
double-blind	O
,	O
single-dose	O
studies	O
were	O
conducted	O
to	O
assess	O
the	O
analgesic	B-O
efficacy	I-O
and	I-O
safety	I-O
of	O
piroxicam	B-I
for	O
the	O
treatment	O
of	O
moderate	B-O
or	I-O
severe	I-O
postoperative	I-O
pain	I-O
.	I-O


Study	O
1	O
evaluated	O
the	O
analgesic	O
efficacy	O
of	O
piroxicam	B-I
20	O
mg	O
compared	O
with	O
that	O
of	O
codeine	B-I
sulfate	I-I
60	O
mg	O
and	B-I
placebo	I-I
.	I-I


A	B-P
final	I-P
patient	I-P
population	I-P
of	I-P
149	I-P
subjects	I-P
rated	O
pain	B-O
intensity	I-O
and	I-O
pain	I-O
relief	I-O
at	O
one	O
half	O
hour	O
and	O
one	O
hour	O
following	O
treatment	O
and	O
then	O
hourly	O
for	O
six	O
hours	O
,	O
with	O
a	O
global	O
assessment	O
made	O
at	O
the	O
completion	O
of	O
24	O
hours	O
.	O


Piroxicam	B-I
20	O
mg	O
was	O
significantly	O
more	O
efficacious	B-O
than	O
placebo	B-I
for	O
all	O
analgesic	O
variables	O
,	O
including	O
the	O
sum	B-O
of	I-O
the	I-O
pain	I-O
intensity	I-O
differences	I-O
(	I-O
SPID	I-O
)	I-O
,	I-O
total	I-O
pain	I-O
relief	I-O
(	I-O
TOTAL	I-O
)	I-O
,	I-O
percent	I-O
SPID	I-O
,	I-O
duration	I-O
of	I-O
effect	I-O
,	I-O
and	I-O
time	I-O
to	I-O
remedication	I-O
.	I-O


Codeine	B-I
60	O
mg	O
was	O
significantly	O
superior	O
to	O
placebo	B-I
for	O
percent	B-O
SPID	I-O
and	O
some	O
hourly	O
measures	O
.	O


Piroxicam	B-I
20	O
mg	O
was	O
significantly	O
more	O
effective	O
than	O
codeine	B-I
60	O
mg	O
for	O
percent	B-O
SPID	I-O
and	O
a	O
few	O
hourly	O
measures	O
including	O
time	O
to	O
remedication	O
.	O


Study	O
2	O
assessed	O
the	O
efficacy	B-O
of	O
piroxicam	B-I
20	O
mg	O
or	O
40	O
mg	O
compared	O
with	O
aspirin	B-I
648	O
mg	O
and	O
placebo	B-I
.	I-I


Sixty	B-P
patients	I-P
rated	O
their	O
pain	B-O
intensity	I-O
and	I-O
relief	I-O
hourly	O
for	O
12	O
hours	O
and	O
at	O
24	O
hours	O
after	O
administration	O
of	O
study	O
medication	O
.	O


Both	O
doses	O
of	O
piroxicam	B-I
were	O
significantly	O
more	O
effective	B-O
than	O
placebo	O
from	O
Hours	O
2	O
to	O
12	O
for	O
pain	B-O
intensity	I-O
difference	I-O
(	I-O
PID	I-O
)	I-O
and	I-O
relief	I-O
scores	I-O
,	I-O
as	I-O
well	I-O
as	I-O
for	I-O
SPID	I-O
and	I-O
TOTAL	I-O
.	I-O


Aspirin	O
was	O
significantly	O
more	O
effective	B-O
than	O
placebo	B-I
from	O
Hours	O
2	O
to	O
8	O
for	O
relief	B-O
and	O
Hours	O
2	O
to	O
10	O
for	O
PID	B-O
as	I-O
well	I-O
as	I-O
SPID	I-O
and	I-O
TOTAL	I-O
.	I-O


Piroxicam	B-I
40	O
mg	O
was	O
significantly	O
more	O
effective	B-O
than	O
aspirin	B-I
648	O
mg	O
for	O
SPID	B-O
,	I-O
TOTAL	I-O
,	I-O
and	I-O
hourly	I-O
measures	I-O
beginning	O
with	O
Hour	O
6	O
through	O
Hour	O
12	O
.	O


Piroxicam	B-I
20	O
mg	O
was	O
significantly	O
better	O
than	O
aspirin	B-I
for	O
a	O
few	O
hourly	O
measures	O
:	O
Hours	O
7	O
to	O
9	O
for	O
relief	O
and	O
Hour	O
7	O
for	O
PID	B-O
.	I-O


In	O
addition	O
,	O
effects	O
of	O
piroxicam	O
20	O
mg	O
had	O
a	O
significantly	O
longer	B-O
duration	I-O
than	O
aspirin	O
.	O


Similarly	O
,	O
piroxicam	B-I
20	O
mg	O
had	O
a	O
significantly	O
longer	B-O
time	I-O
to	I-O
remedication	I-O
compared	O
with	O
aspirin	B-I
and	O
placebo	B-I
.	O


The	O
results	O
of	O
these	O
studies	O
provide	O
evidence	O
in	O
support	O
of	O
the	O
longer	O
duration	B-O
of	I-O
analgesic	I-O
efficacy	I-O
of	O
piroxicam	B-I
compared	O
with	O
codeine	B-I
or	I-I
aspirin	I-I
in	O
patients	B-P
with	I-P
postoperative	I-O
pain	I-O
.	I-O


Comparative	B-O
efficacy	I-O
and	I-O
safety	I-O
of	O
lofexidine	B-I
and	I-I
clonidine	I-I
given	O
alone	O
or	O
concomitantly	O
with	O
hydrochlorothiazide	B-I
in	O
hypertensive	B-P
outpatients	I-P
.	I-P


Boosting	O
uptake	B-O
of	O
influenza	O
immunisation	O
:	O
a	O
randomised	O
controlled	O
trial	O
of	O
telephone	B-I
appointing	I-I
in	O
general	O
practice	O
.	O


BACKGROUND	O
Immunisation	O
against	O
influenza	O
is	O
an	O
effective	O
intervention	O
that	O
reduces	O
serologically	O
confirmed	O
cases	O
by	O
between	O
60	O
%	O
and	O
70	O
%	O
.	O


Almost	O
all	O
influenza	O
immunisation	O
in	O
the	O
UK	B-P
is	O
done	O
within	O
general	O
practice	O
.	O


Current	O
evidence	O
on	O
the	O
effectiveness	O
of	O
patient	O
reminders	O
for	O
all	O
types	O
of	O
immunisation	O
programmes	O
is	O
largely	O
based	O
on	O
North	O
American	O
studies	O
.	O


AIM	O
To	O
determine	O
whether	O
telephone	B-I
appointments	I-I
offered	O
bygeneral	O
practice	O
receptionists	O
increase	O
the	O
uptake	B-O
of	I-O
irfluenza	I-O
immunisation	I-O
among	O
the	O
registered	B-P
population	I-P
aged	I-P
over	I-P
65	I-P
years	I-P
in	I-P
east	I-P
London	I-P
practices	I-P
.	I-P


DESIGN	O
OF	O
STUDY	O
Randomised	O
controlled	O
trial	O
.	O


SETTING	O
Three	O
research	O
general	O
practices	O
within	O
the	O
East	B-P
London	I-P
and	I-P
Essex	I-P
network	I-P
of	I-P
researchers	I-P
(	I-P
ELENoR	I-P
)	I-P
.	I-P


METHOD	O
Participants	B-P
were	I-P
1,820	I-P
low-risk	I-P
patients	I-P
aged	I-P
65	I-P
to	I-P
74	I-P
years	I-P
who	I-P
had	I-P
not	I-P
previously	I-P
been	I-P
in	I-P
a	I-P
recall	I-P
system	I-P
for	I-P
influenza	I-P
immunisation	I-P
at	I-P
their	I-P
general	I-P
practice	I-P
.	I-P


The	O
intervention	O
,	O
during	O
October	O
2000	O
,	O
was	O
a	O
telephone	B-I
call	I-I
from	I-I
the	I-I
practice	I-I
receptionist	I-I
to	O
intervention	B-I
group	O
households	O
,	O
offering	O
an	O
appointment	O
for	O
influenza	O
immunisation	O
at	O
a	O
nurse-run	O
.	O


clinic	O
Main	O
outcome	O
measures	O
were	O
the	O
numbers	B-O
of	I-O
individuals	I-O
in	I-O
each	I-O
group	I-O
receiving	I-O
immunisation	I-O
,	I-O
and	I-O
practice	I-O
costs	I-O
of	I-O
a	I-O
telephone-appointing	I-O
programme	I-O
.	I-O


RESULTS	O
intention	O
to	O
treat	O
analysis	O
showed	O
an	O
immunisation	B-O
rate	I-O
in	O
the	O
control	B-I
group	O
of	O
44	O
%	O
,	O
compared	O
with	O
50	O
%	O
in	O
the	O
intervention	B-I
group	I-I
(	O
odds	O
ratio	O
=	O
1.29	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
1.03	O
to	O
1.63	O
)	O
.	O


Of	O
the	O
patients	B-P
making	I-P
a	I-P
telephone	I-I
appointment	I-I
,	O
88	O
%	O
recieved	O
immunisation	B-O
,	O
while	O
22	O
%	O
of	O
those	O
not	O
wanting	O
an	O
appointment	O
went	O
on	O
to	O
be	O
immunised	O
.	O


In	O
the	O
controlgroup	B-I
,	O
income	B-O
generated	I-O
was	O
11.35	O
pounds	O
per	O
immunisation	O
,	O
for	O
each	O
additional	O
immunisation	O
in	O
the	O
intervention	O
group	O
the	O
income	O
was	O
5.20	O
pounds	O
.	O


The	O
'number	B-O
needed	I-O
to	I-O
telephone	I-O
'	I-O
was	O
17	O
.	O


CONCLUSION	O
Uptake	O
of	O
influenza	O
immunisation	B-O
among	O
the	O
low-risk	B-P
older	I-P
population	I-P
in	I-P
inner-city	I-P
areas	I-P
can	O
be	O
boosted	O
by	O
around	O
6	O
%	O
using	O
a	O
simple	O
intervention	B-I
by	O
receptionists	O
.	O


Immunisation	B-O
rates	I-O
in	O
this	O
low-risk	O
group	O
fell	O
well	O
short	O
of	O
the	O
60	O
%	O
government	O
target	O
.	O


Improving	O
immunisation	B-O
rates	I-O
will	O
require	O
a	O
sustained	O
public	O
health	O
campaign	O
.	O


Retaining	O
the	O
item-of-service	O
payments	O
to	O
practices	O
should	O
support	O
costs	O
of	O
practice-based	O
interventions	O
.	O


Local	O
delivery	O
of	O
a	O
recombinant	B-I
adenoassociated	I-I
vector	I-I
containing	I-I
a	I-I
tumour	I-I
necrosis	I-I
factor	I-I
alpha	I-I
antagonist	I-I
gene	I-I
in	O
inflammatory	O
arthritis	O
:	O
a	O
phase	O
1	O
dose-escalation	O
safety	B-O
and	I-O
tolerability	I-O
study	O
.	O


OBJECTIVE	O
To	O
examine	O
the	O
safety	B-O
and	I-O
tolerability	I-O
of	O
a	O
single	O
intra-articular	O
injection	O
of	O
rAAV2-TNFR	B-I
:	I-I
Fc	I-I
,	I-I
an	I-I
adenoassociated	I-I
virus	I-I
serotype	I-I
2	I-I
vector	I-I
containing	I-I
the	I-I
cDNA	I-I
for	O
the	O
human	O
tumour	O
necrosis	O
factor-immunoglobulin	O
Fc	O
fusion	O
gene	O
(	O
tgAAC94	O
)	O
,	O
in	O
subjects	B-P
with	I-P
inflammatory	I-P
arthritis	I-P
.	I-P


METHODS	O
In	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
phase	O
1	O
,	O
dose-escalation	O
study	O
,	O
15	B-P
subjects	I-P
with	I-P
inflammatory	I-P
arthritis	I-P
(	I-P
14	I-P
with	I-P
rheumatoid	I-P
arthritis	I-P
and	I-P
1	I-P
with	I-P
ankylosing	I-P
spondylitis	I-P
)	I-P
not	I-P
receiving	I-P
tumour	I-P
necrosis	I-P
factor	I-P
alpha	I-P
(	I-P
TNFalpha	I-P
)	I-P
inhibitors	I-P
with	I-P
persistent	I-P
moderate	I-P
(	I-P
grade	I-P
2	I-P
)	I-P
or	I-P
severe	I-P
(	I-P
grade	I-P
3	I-P
)	I-P
swelling	I-P
in	I-P
a	I-P
target	I-P
joint	I-P
due	I-P
to	I-P
inflammatory	I-P
arthritis	I-P
received	O
a	O
single	O
intra-articular	O
injection	O
of	O
rAAV2-TNFR	B-I
:	I-I
Fc	I-I
at	O
1	O
x	O
10	O
(	O
10	O
)	O
(	O
n	O
=	O
5	O
)	O
or	O
1	O
x	O
10	O
(	O
11	O
)	O
(	O
n	O
=	O
6	O
)	O
DNase	O
resistant	O
particles	O
per	O
ml	O
joint	O
volume	O
or	B-I
placebo	I-I
(	O
n	O
=	O
4	O
)	O
into	O
a	O
knee	O
(	O
n	O
=	O
14	O
)	O
or	O
ankle	O
(	O
n	O
=	O
1	O
)	O
.	O


Safety	B-O
was	O
assessed	O
through	O
adverse	O
event	O
monitoring	O
.	O


As	O
a	O
secondary	O
objective	O
,	O
changes	B-O
in	I-O
injected	I-O
joint	I-O
tenderness	I-O
and	I-O
swelling	I-O
scores	I-O
,	O
each	O
measured	O
on	O
a	O
four-point	O
scale	O
,	O
were	O
evaluated	O
.	O


RESULTS	O
Intra-articular	O
injections	O
of	O
rAAV2-TNFR	O
:	O
Fc	O
were	O
well	O
tolerated	O
with	O
no	O
major	O
safety	O
issues	O
.	O


One	O
event	O
,	O
mild	O
knee	O
pruritus	O
,	O
was	O
considered	O
probably	O
related	O
.	O


Synovial	B-O
fluid	I-O
TNFR	I-O
:	I-O
Fc	I-O
protein	I-O
was	O
not	O
detected	O
(	O
nor	O
expected	O
)	O
at	O
the	O
doses	O
used	O
.	O


At	O
12	O
weeks	O
after	O
injection	O
,	O
a	O
two-point	O
decrease	B-O
in	I-O
swelling	I-O
was	O
noted	O
in	O
2/11	O
and	O
2/4	O
subjects	O
injected	O
with	O
rAAV2-TNFR	O
:	O
Fc	O
and	O
placebo	O
,	O
respectively	O
.	O


CONCLUSION	O
A	O
single	O
dose	O
of	O
intra-articular	O
rAAV2-TNFR	O
:	O
Fc	O
appears	O
to	O
be	O
safe	O
and	O
well	O
tolerated	O
in	O
subjects	O
without	O
concurrent	O
systemic	O
TNFalpha	O
antagonist	O
use	O
.	O


It	O
is	O
thus	O
feasible	O
to	O
proceed	O
with	O
larger	O
trials	O
to	O
further	O
test	O
the	O
safety	B-O
and	I-O
efficacy	I-O
of	O
local	O
TNFR	O
:	O
Fc	O
gene	O
transfer	O
as	O
a	O
therapeutic	O
modality	O
for	O
patients	B-P
with	I-P
inflammatory	I-P
arthritis	I-P
.	I-P


A	O
randomized	O
,	O
controlled	O
trial	O
of	O
the	O
efficacy	B-O
of	O
a	O
heparin	B-I
and	I-I
vancomycin	I-I
solution	I-I
in	O
preventing	O
central	B-O
venous	I-O
catheter	I-O
infections	I-O
in	I-P
children	I-P
.	I-P


OBJECTIVE	O
To	O
determine	O
whether	O
adding	O
vancomycin	B-I
to	I-I
central	I-I
venous	I-I
catheter	I-I
(	I-I
CVC	I-I
)	I-I
flush	I-I
solution	O
would	O
significantly	O
reduce	O
the	O
incidence	O
of	O
bacteremia	O
attributable	O
to	O
luminal	O
colonization	O
with	O
vancomycin-susceptible	O
organisms	O
.	O


STUDY	O
DESIGN	O
Fifty-five	B-P
children	I-P
with	I-P
cancer	I-P
and	I-P
eight	I-P
children	I-P
given	I-P
total	I-P
parenteral	I-P
nutrition	I-P
by	I-P
the	I-P
surgery	I-P
or	I-P
nutrition	I-P
support	I-P
services	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
heparin	B-I
CVC	I-I
flush	I-I
solution	I-I
(	O
n	O
=	O
31	O
)	O
or	O
a	O
heparin-vancomycin	B-I
CVC	I-I
flush	I-I
solution	I-I
(	O
n	O
=	O
32	O
)	O
.	O


RESULTS	O
During	O
9158	O
catheter	O
days	O
,	O
6.5	O
%	O
of	O
the	O
patients	O
in	O
the	O
heparin	O
group	O
and	O
15.6	O
%	O
of	O
the	O
patients	O
in	O
the	O
heparin-vancomycin	O
group	O
had	O
bacteremia	O
attributable	O
to	O
luminal	O
colonization	O
with	O
vancomycin-susceptible	O
organisms	O
(	O
p	O
=	O
0.43	O
)	O
.	O


The	O
mean	B-O
rates	I-O
of	I-O
bacteremia	I-O
attributable	O
to	O
luminal	O
colonization	O
with	O
vancomycin-susceptible	O
organisms	O
were	O
0.6/1000	O
catheter	O
days	O
in	O
the	O
heparin	O
group	O
and	O
1.4/1000	O
catheter	O
days	O
in	O
the	O
heparin-vancomycin	O
group	O
(	O
p	O
=	O
0.25	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
when	O
the	O
time	B-O
to	I-O
the	I-O
first	I-O
episode	I-O
of	I-O
bacteremia	I-O
attributable	O
to	O
luminal	O
colonization	O
with	O
a	O
vancomycin-susceptible	O
organism	O
was	O
compared	O
by	O
means	O
of	O
Kaplan-Meier	O
survival	O
estimates	O
.	O


Streptococcus	B-O
viridans	I-O
infection	I-O
was	O
not	O
attributable	O
to	O
luminal	O
colonization	O
.	O


CONCLUSION	O
The	O
addition	O
of	O
vancomycin	O
to	O
heparin	O
CVC	O
flush	O
solution	O
did	O
not	O
reduce	O
bacteremia	B-O
with	O
vancomycin-susceptible	O
organisms	O
.	O


Bacteremia	B-O
with	O
Streptococcus	O
viridans	O
was	O
not	O
related	O
to	O
the	O
use	O
of	O
a	O
CVC	O
.	O


Effect	O
of	O
ranitidine	B-I
on	O
the	O
disposition	B-O
of	O
orally	O
and	O
intravenously	O
administered	O
triazolam	O
.	O


The	O
effect	O
of	O
orally	O
administered	O
ranitidine	B-I
on	O
the	O
pharmacokinetic	B-O
properties	I-O
of	O
orally	O
and	O
intravenously	O
administered	O
triazolam	B-I
was	O
determined	O
.	O


Twelve	B-P
healthy	I-P
males	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
35	I-P
years	I-P
were	O
enrolled	O
in	O
this	O
four-way	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O


Each	O
subject	O
received	O
a	O
total	O
of	O
four	O
treatments	O
,	O
each	O
separated	O
by	O
one	O
week	O
.	O


The	O
treatments	O
consisted	O
of	O
(	O
1	O
)	O
one	O
orally	O
administered	O
0.25-mg	B-I
triazolam	I-I
tablet	I-I
after	I-I
treatment	I-I
with	I-I
ranitidine	I-I
;	I-I
(	O
2	O
)	O
one	O
orally	O
administered	O
0.25-mg	B-I
triazolam	I-I
tablet	I-I
,	I-I
with	I-I
no	I-I
ranitidine	I-I
pretreatment	I-I
;	I-I
(	O
3	O
)	O
a	O
0.25-mg	B-I
intravenous	I-I
dose	I-I
of	I-I
triazolam	I-I
after	I-I
treatment	I-I
with	I-I
ranitidine	I-I
;	I-I
and	O
(	O
4	O
)	O
a	O
0.25-mg	B-I
intravenous	I-I
dose	I-I
of	I-I
triazolam	I-I
,	I-I
with	I-I
no	I-I
ranitidine	I-I
pretreatment	I-I
.	I-I


Ranitidine	B-I
pretreatment	O
consisted	O
of	O
five	O
150-mg	O
oral	O
doses	O
(	O
as	O
the	O
hydrochloride	O
salt	O
)	O
given	O
every	O
12	O
hours	O
;	O
the	O
last	O
dose	O
was	O
given	O
two	O
hours	O
before	O
triazolam	B-I
was	O
administered	O
.	O


Blood	O
samples	O
were	O
taken	O
at	O
intervals	O
up	O
to	O
12	O
hours	O
after	O
triazolam	O
treatment	O
.	O


Serum	B-O
triazolam	I-O
concentrations	I-O
were	O
measured	O
by	O
modified	O
high-performance	O
liquid	O
chromatography	O
,	O
and	O
pharmacokinetic	B-O
values	I-O
were	O
calculated	O
.	O


Pretreatment	O
with	O
ranitidine	B-I
had	O
no	O
effect	O
on	O
the	O
disposition	B-O
of	I-O
intravenously	I-O
administered	I-O
triazolam	I-O
but	O
significantly	O
increased	O
the	O
area	B-O
under	I-O
the	I-O
serum	I-O
drug	I-O
concentration-time	I-O
curve	I-O
of	I-O
oral	I-O
triazolam	I-O
.	I-O


Ranitidine	B-I
pretreatment	O
had	O
no	O
effect	O
on	O
triazolam	B-O
's	I-O
terminal	I-O
elimination	I-O
rate	I-O
constant	I-O
or	O
on	O
the	O
time	B-O
to	I-O
reach	I-O
maximum	I-O
serum	I-O
triazolam	I-O
concentration	I-O
.	I-O


Ranitidine	B-I
pretreatment	O
increased	O
the	O
systemic	B-O
availability	I-O
of	I-O
triazolam	I-O
by	O
increasing	O
its	O
absorption	B-O
.	I-O


Hip	B-I
protectors	I-I
improve	O
falls	O
self-efficacy	O
.	O


OBJECTIVES	O
To	O
investigate	O
the	O
effect	O
of	O
use	O
of	O
external	B-I
hip	I-I
protectors	I-I
on	O
subjects	O
'	O
fear	O
of	O
falling	O
and	O
falls	O
self-efficacy	O
(	O
belief	O
in	O
their	O
own	O
ability	O
to	O
avoid	O
falling	O
)	O
.	O


DESIGN	O
Randomized	O
controlled	O
trial	O
.	O


SETTING	O
Aged-care	B-P
health	I-P
services	I-P
in	I-P
Sydney	I-P
,	I-P
Australia	I-P
.	I-P


PARTICIPANTS	O
131	B-P
women	I-P
aged	I-P
75	I-P
years	I-P
or	I-P
older	I-P
,	I-P
who	I-P
had	I-P
two	I-P
or	I-P
more	I-P
falls	I-P
or	I-P
one	I-P
fall	I-P
requiring	I-P
hospital	I-P
admission	I-P
in	I-P
the	I-P
previous	I-P
year	I-P
and	I-P
who	I-P
live	I-P
at	I-P
home	I-P
.	I-P


Sixty-one	B-P
subjects	I-P
were	I-P
in	I-P
the	I-P
intervention	I-P
group	I-P
and	O
70	B-P
in	I-P
the	I-P
control	I-I
group	I-P
.	I-P


INTERVENTION	O
Use	O
of	O
external	B-I
hip	I-I
protectors	I-I
and	I-I
encouragement	I-I
to	I-I
use	I-I
the	I-I
protectors	I-I
by	I-I
an	I-I
adherence	I-I
nurse	I-I
.	I-I


MEASUREMENTS	O
At	O
the	O
time	O
of	O
enrolment	O
into	O
a	O
wider	O
study	O
examining	O
the	O
effect	O
of	O
hip	B-I
protectors	I-I
on	O
hip	O
fractures	O
,	O
participants	B-P
recruited	I-P
at	I-P
home	I-P
completed	O
an	O
assessment	O
of	O
fear	B-O
of	I-O
falling	I-O
and	I-O
falls	I-O
efficacy	I-O
as	O
measured	O
by	O
the	O
Falls	B-O
Efficacy	I-O
Scale	I-O
and	I-O
the	I-O
Modified	I-O
Falls	I-O
Efficacy	I-O
Scale	I-O
.	I-O


At	O
4-month	O
follow-up	O
,	O
these	O
scales	O
were	O
readministered	O
by	O
an	O
observer	O
who	O
was	O
not	O
aware	O
of	O
the	O
allocation	O
of	O
the	O
participant	O
to	O
intervention	O
or	O
control	O
groups	O
.	O


RESULTS	O
Fear	B-O
of	I-O
falling	I-O
and	I-O
falls	I-O
self-efficacy	I-O
,	O
as	O
measured	O
by	O
the	O
Falls	B-O
Efficacy	I-O
and	I-O
Modified	I-O
Falls	I-O
Efficacy	I-O
Scales	I-O
,	O
were	O
similar	O
at	O
baseline	O
in	O
both	O
groups	O
.	O


Fear	B-O
of	I-O
falling	I-O
was	O
present	O
at	O
follow-up	O
in	O
43	O
%	O
of	O
subjects	O
using	O
hip	O
protectors	O
and	O
57	O
%	O
of	O
the	O
control	O
group	O
(	O
chi2	O
=	O
2.58	O
,	O
P	O
=	O
0.11	O
)	O
.	O


Hip	B-I
protector	I-I
users	O
had	O
greater	O
improvement	O
in	O
falls	O
self-efficacy	B-O
at	O
follow-up	O
as	O
measured	O
by	O
the	O
Falls	B-O
Efficacy	I-O
Scale	I-O
(	O
t	O
=	O
2.44	O
,	O
P	O
=	O
0.016	O
)	O
and	O
the	O
Modified	B-O
Falls	I-O
Efficacy	I-O
Scale	I-O
(	O
t	O
=	O
2.08	O
,	O
P	O
=	O
0.039	O
)	O
.	O


CONCLUSION	O
Hip	B-I
protectors	I-I
improve	O
falls	O
self-efficacy	O
.	O


As	O
users	O
of	O
hip	B-I
protectors	I-I
feel	O
more	O
confident	O
that	O
they	O
can	O
complete	O
tasks	O
safely	O
,	O
they	O
may	O
become	O
more	O
physically	O
active	O
and	O
require	O
less	O
assistance	O
with	O
activities	O
of	O
daily	O
living	O
.	O


Effect	O
of	O
ranolazine	B-I
on	O
A1C	O
and	O
glucose	O
levels	O
in	O
hyperglycemic	B-P
patients	I-P
with	I-P
non-ST	I-P
elevation	I-P
acute	I-P
coronary	I-P
syndrome	I-P
.	I-P


OBJECTIVE	O
We	O
determined	O
the	O
relationships	O
between	O
glycemia	O
at	O
randomization	O
,	O
concurrent	B-I
antidiabetic	I-I
therapy	I-I
,	O
and	O
change	O
in	O
A1C	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
in	O
patients	B-P
with	I-P
diabetes	I-P
receiving	I-P
standard	I-P
treatment	I-P
for	I-P
diabetes	I-P
and	I-P
randomized	I-P
to	I-P
ranolazine	I-I
or	I-I
placebo	I-I
within	I-P
the	I-P
MERLIN-TIMI-36	I-P
(	I-P
MERLIN	I-P
)	I-P
study	I-P
.	I-P


Ranolazine	B-I
is	O
a	O
novel	O
first-in-class	O
drug	O
approved	O
for	O
treating	O
angina	O
pectoris	O
.	O


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
Randomization	O
and	O
4-month	O
glycemic	B-I
and	I-I
antidiabetes	I-I
drug	I-I
usage	I-I
data	I-I
from	O
MERLIN	O
were	O
analyzed	O
using	O
Spotfire	O
and	O
SAS	O
version	O
9.1	O
software	O
.	O


RESULTS	O
In	O
patients	B-P
with	I-P
diabetes	I-P
and	I-P
A1C	I-P
of	I-P
>	I-P
or=8-10	I-P
%	I-P
at	I-P
randomization	I-P
(	I-P
n	I-P
=	I-P
171	I-P
)	I-P
,	O
there	O
was	O
an	O
absolute	O
A1C	B-O
reduction	I-O
in	O
the	O
ranolazine	B-I
group	O
of	O
1.2	O
%	O
(	O
95	O
%	O
CI	O
-1.4	O
to	O
-1.0	O
)	O
,	O
and	O
the	O
placebo-adjusted	B-I
(	I-P
n	I-P
=	I-P
182	I-P
)	I-P
decrease	O
in	O
A1C	B-O
by	O
ranolazine	O
was	O
0.59	O
%	O
(	O
95	O
%	O
CI	O
-0.99	O
to	O
-0.20	O
,	O
P	O
<	O
0.001	O
)	O
.	O


In	O
patients	B-P
with	I-P
FPG	I-P
of	I-P
150-400	I-P
mg/dl	I-P
at	I-P
randomization	I-P
,	I-P
ranolazine	I-I
(	I-P
n	I-P
=	I-P
131	I-P
)	I-P
compared	O
with	O
placebo	B-I
(	I-P
n	I-P
=	I-P
147	I-P
)	I-P
reduced	O
FPG	O
by	O
25.7	O
mg/dl	O
(	O
95	O
%	O
CI	O
-43.3	O
to	O
-8.1	O
,	O
P	O
=	O
0.001	O
)	O
.	O


When	O
changes	O
in	O
either	O
A1C	B-O
or	I-O
FPG	I-O
were	O
correlated	O
to	O
A1C	B-O
or	I-O
FPG	I-O
at	O
randomization	O
,	O
the	O
slopes	O
were	O
significantly	O
steeper	O
for	O
ranolazine	B-I
than	O
placebo	B-I
(	O
A1C	O
,	O
P	O
=	O
0.046	O
;	O
FPG	O
,	O
P	O
<	O
0.001	O
)	O
,	O
indicating	O
that	O
lowering	O
of	O
A1C	B-O
and	I-O
FPG	I-O
by	O
ranolazine	B-I
is	O
related	O
to	O
hyperglycemia	O
at	O
randomization	O
.	O


Ranolazine	O
,	O
compared	O
with	O
placebo	O
,	O
was	O
not	O
associated	O
with	O
serious	B-O
hypoglycemic	I-O
events	I-O
,	O
associated	O
with	O
significant	O
changes	O
in	O
concurrent	B-O
antidiabetic	I-O
therapy	I-O
,	O
or	O
dependent	O
on	O
a	O
history	B-O
of	I-O
angina	I-O
.	I-O


CONCLUSIONS	O
Ranolazine	B-I
,	O
when	O
added	O
to	O
concurrent	O
antidiabetes	O
treatment	O
,	O
lowers	O
FPG	B-O
and	I-O
A1C	I-O
in	O
patients	B-P
with	I-P
cardiovascular	I-P
disease	I-P
and	I-P
poorly	I-P
controlled	I-P
diabetes	I-P
.	I-P


Differences	O
in	O
vision	O
between	O
clinic	O
and	O
home	O
and	O
the	O
effect	O
of	O
lighting	O
in	O
older	B-P
adults	I-P
with	I-P
and	I-P
without	I-P
glaucoma	I-P
.	I-P


IMPORTANCE	O
Patients	O
often	O
report	O
greater	O
visual	O
difficulties	O
at	O
home	O
than	O
expected	O
from	O
vision	O
testing	O
in	O
the	O
clinic	O
.	O


Such	O
discordance	O
may	O
be	O
owing	O
to	O
worse	O
vision	O
in	O
the	O
home	O
than	O
measured	O
in	O
clinic	O
.	O


OBJECTIVE	O
To	O
compare	O
vision	B-O
measured	O
between	O
the	O
clinic	O
and	O
home	O
and	O
evaluate	O
factors	O
,	O
including	O
lighting	O
,	O
associated	O
with	O
these	O
differences	O
.	O


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
This	O
cross-sectional	O
study	O
conducted	B-P
from	I-P
2005-2009	I-P
involved	I-P
126	I-P
patients	I-P
with	I-P
glaucoma	I-P
and	I-P
49	I-P
without	I-P
glaucoma	I-P
recruited	I-P
from	I-P
the	I-P
Glaucoma	I-P
and	I-P
Comprehensive	I-P
Eye	I-P
Clinics	I-P
at	I-P
Washington	I-P
University	I-P
,	I-P
St	I-P
Louis	I-P
,	I-P
Missouri	I-P
.	I-P


Patients	O
underwent	O
clinic	O
and	O
home	O
visits	O
,	O
were	O
aged	B-P
55	I-P
to	I-P
90	I-P
years	I-P
,	O
were	O
consecutively	O
recruited	O
,	O
and	O
met	O
inclusion	O
criteria	O
for	O
this	O
study	O
.	O


A	B-P
total	I-P
of	I-P
166	I-P
eligible	I-P
patients	I-P
refused	I-P
participation	I-P
.	I-P


EXPOSURE	O
Participants	B-I
underwent	I-I
clinic	I-I
and	I-I
home	I-I
visits	I-I
randomized	O
to	O
order	O
of	O
completion	O
.	O


At	B-I
each	I-I
visit	I-I
,	I-I
masked	I-I
and	I-I
certified	I-I
examiners	I-I
measured	I-I
binocular	I-O
distance	I-O
visual	I-O
acuity	I-O
(	I-O
DVA	I-O
)	I-O
with	I-O
a	I-O
nonbacklit	I-O
chart	I-O
,	I-O
near	I-O
visual	I-O
acuity	I-O
(	I-O
NVA	I-O
)	I-O
,	I-O
contrast	I-O
sensitivity	I-O
(	I-O
CS	I-O
)	I-O
,	I-O
CS	I-O
with	I-O
glare	I-O
,	I-O
and	I-O
lighting	I-O
.	I-O


MAIN	O
OUTCOMES	O
AND	O
MEASURES	O
Differences	B-O
in	I-O
vision	I-O
between	I-O
the	I-O
clinic	I-O
and	I-O
home	I-O
.	I-O


RESULTS	O
The	O
mean	O
scores	O
for	O
all	B-O
vision	I-O
tests	I-O
were	I-O
significantly	I-O
better	I-O
in	O
the	O
clinic	O
than	O
home	O
for	O
participants	O
with	O
and	O
without	O
glaucoma	O
(	O
P	O
<	O
.05	O
,	O
matched-pair	O
t	O
tests	O
)	O
.	O


For	O
DVA	O
,	O
29	O
%	O
of	O
participants	O
with	O
glaucoma	O
read	B-O
2	I-O
or	I-O
more	I-O
lines	I-O
better	I-O
in	O
the	O
clinic	O
than	O
home	O
and	O
39	O
%	O
with	O
advanced	O
glaucoma	O
read	O
3	O
or	O
more	O
lines	O
better	O
.	O


For	O
the	O
entire	O
sample	O
,	O
21	O
%	O
of	O
participants	O
read	B-O
2	I-O
or	I-O
more	I-O
lines	I-O
better	O
in	O
the	O
clinic	O
than	O
home	O
for	O
NVA	O
and	O
49	O
%	O
read	O
2	O
or	O
more	O
triplets	O
better	O
in	O
the	O
clinic	O
for	O
CS	O
with	O
glare	O
.	O


Lighting	O
was	O
the	O
most	O
significant	O
factor	O
associated	O
with	O
differences	O
in	O
vision	O
between	O
the	O
clinic	O
and	O
home	O
for	O
DVA	B-O
,	I-O
NVA	I-O
,	I-O
and	I-O
CS	I-O
with	O
glare	O
testing	O
(	O
P	O
<	O
.05	O
,	O
multiple	O
regression	O
model	O
)	O
.	O


Median	B-O
home	I-O
lighting	I-O
was	O
4.3	O
times	O
and	O
2.8	O
times	O
lower	O
than	O
clinic	O
lighting	O
in	O
areas	O
tested	O
for	O
DVA	O
and	O
NVA	O
,	O
respectively	O
.	O


Home	B-O
lighting	I-O
was	O
below	O
that	O
recommended	O
in	O
85	O
%	O
or	O
greater	O
of	O
participants	O
.	O


CONCLUSIONS	O
AND	O
RELEVANCE	O
Vision	B-O
measured	O
in	O
the	O
clinic	O
is	O
generally	O
better	O
than	O
vision	O
measured	O
at	O
home	O
,	O
with	O
differences	O
mainly	O
owing	O
to	O
poor	O
home	O
lighting	O
.	O


Knowledge	O
that	O
vision	O
discrepancies	O
between	O
patient	O
report	O
and	O
clinical	O
testing	O
may	O
be	O
owing	O
to	O
home	O
lighting	O
may	O
initiate	O
clinician-patient	O
discussions	O
to	O
optimize	O
home	O
lighting	O
and	O
improve	O
the	O
vision	O
of	O
older	B-P
adults	I-P
in	O
their	O
homes	O
.	O


Prospective	O
evaluation	O
of	O
the	O
macrolide	B-I
antibiotic	I-I
dirithromycin	I-I
for	O
the	O
treatment	O
of	O
Helicobacter	B-P
pylori	I-P
.	I-P


BACKGROUND	O
Macrolide	B-I
antibiotics	I-I
are	O
active	O
in	O
vitro	O
and	O
in	O
vivo	O
against	O
Helicobacter	B-P
pylori	I-P
.	I-P


We	O
assessed	O
a	O
newer	O
macrolide	B-I
,	I-I
dirithromycin	I-I
,	O
for	O
the	O
treatment	O
of	O
H.	O
pylori	O
in	O
two	O
separate	O
studies	O
.	O


METHODS	O
Volunteers	B-P
with	I-P
H.	I-P
pylori	I-P
infection	I-P
(	I-P
by	I-P
13C-urea	I-P
breath	I-P
test	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
2-week	O
treatment	O
regimens	O
.	O


Study	O
1	O
:	O
dirithromycin	B-I
500	I-I
mg	I-I
q.d.s.	I-I
,	O
dirithromycin	B-I
500	I-I
mg	I-I
q.d.s	I-I
.	I-I


plus	B-I
omeprazole	I-I
40	I-I
mg	I-I
q.d.s.	I-I
,	O
or	B-I
dirithromycin	I-I
500	I-I
mg	I-I
q.d.s	I-I
.	I-I


plus	B-I
metronidazole	I-I
500	I-I
mg	I-I
t.d.s	I-I
.	I-I


Study	O
2	O
:	O
dirithromycin	B-I
500	I-I
mg	I-I
q.d.s	I-I
.	I-I


plus	B-I
omeprazole	I-I
20	I-I
mg	I-I
b.d.	I-I
,	O
dirithromycin	B-I
1000	I-I
mg	I-I
q.d.s	I-I
.	I-I


plus	B-I
omeprazole	I-I
20	I-I
mg	I-I
b.d.	I-I
,	O
or	B-I
amoxycillin	I-I
500	I-I
mg	I-I
q.d.s	I-I
.	I-I


plus	B-I
omepirazole	I-I
20	I-I
mg	I-I
b.d	I-I
.	I-I


Four	O
weeks	O
after	O
the	O
completion	O
of	O
therapy	O
a	O
repeat	O
13C-urea	O
breath	O
test	O
was	O
done	O
to	O
assess	O
for	O
cure	O
.	O


RESULTS	O
No	O
patient	O
taking	O
dirithromycin	B-I
alone	I-P
(	I-P
n	I-P
=	I-P
6	I-P
)	I-P
or	O
in	O
combination	O
with	O
omeprazole	B-I
(	O
n	O
=	O
26	O
)	O
achieved	O
cure	B-O
of	I-O
their	I-O
infection	I-O
.	I-O


Eradication	B-O
of	I-O
H.	I-O
pylori	I-O
was	O
seen	O
in	O
one	O
of	O
seven	O
patients	O
taking	O
dirithromycin	B-I
plus	O
metronidazole	B-I
.	I-I


Five	O
of	O
10	O
patients	O
taking	O
omeprazole-amoxycillin	B-I
dual	O
therapy	O
had	O
their	O
H.	B-O
pylori	I-O
infection	I-O
cured	I-O
(	O
P	O
=	O
0.0007	O
vs.	O
patients	O
taking	O
dirithromycin	B-I
plus	O
omeprazole	B-I
)	I-I
.	O


Eleven	O
(	O
47	O
%	O
)	O
of	O
32	O
patients	O
taking	O
dirithromycin	B-I
alone	O
or	O
combined	O
with	O
omeprazole	B-I
reported	I-O
side-effects	I-O
,	O
but	O
only	O
two	O
(	O
6	O
%	O
)	O
stopped	O
therapy	O
prematurely	O
as	O
a	O
result	O
of	O
side-effects	B-O
.	I-O


CONCLUSION	O
No	O
subject	O
taking	O
dirithromycin	B-I
alone	O
or	O
in	O
combination	O
with	O
omeprazole	B-I
had	O
their	O
H.	O
pylori	O
infection	O
cured	B-O
.	I-O


Dirithromycin	B-I
,	O
in	O
the	O
regimen	O
used	O
,	O
shows	O
little	O
promise	O
in	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
H.	I-P
pylori	I-P
infection	I-P
.	I-P


Changes	O
in	O
H	O
reflex	O
and	O
V	O
wave	O
following	O
short-term	B-I
endurance	I-I
and	I-I
strength	I-I
training	I-I
.	I-I


This	O
study	O
examined	O
the	O
effects	O
of	O
3	O
wk	O
of	O
either	O
endurance	B-I
or	I-I
strength	I-I
training	I-I
on	O
plasticity	O
of	O
the	O
neural	O
mechanisms	O
involved	O
in	O
the	O
soleus	O
H	O
reflex	O
and	O
V	O
wave	O
.	O


Twenty-five	B-P
sedentary	I-P
healthy	I-P
subjects	I-P
were	O
randomized	O
into	O
an	O
endurance	B-I
group	I-I
(	O
n	O
=	O
13	O
)	O
or	O
strength	B-I
group	I-I
(	O
n	O
=	O
12	O
)	O
.	O


Evoked	O
V-wave	O
,	O
H-reflex	O
,	O
and	O
M-wave	O
recruitment	O
curves	O
,	O
maximal	O
voluntary	O
contraction	O
(	O
MVC	O
)	O
,	O
and	O
time-to-task-failure	O
(	O
isometric	O
contraction	O
at	O
40	O
%	O
MVC	O
)	O
of	O
the	O
plantar	O
flexors	O
were	O
recorded	O
before	O
and	O
after	O
training	O
.	O


Following	O
strength	B-I
training	I-I
,	O
MVC	B-O
of	I-O
the	I-O
plantar	I-O
flexors	I-O
increased	O
by	O
14.4	O
±	O
5.2	O
%	O
in	O
the	O
strength	O
group	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
time-to-task-failure	O
was	O
prolonged	O
in	O
the	O
endurance	O
group	O
(	O
22.7	O
±	O
17.1	O
%	O
;	O
P	O
<	O
0.05	B-O
)	I-O
.	I-O


The	B-O
V	I-O
wave-to-maximal	I-O
M	I-O
wave	I-O
(	I-O
V/M	I-O
(	I-O
max	I-O
)	I-O
)	I-O
ratio	I-O
increased	O
significantly	O
(	O
55.1	O
±	O
28.3	O
%	O
;	O
P	O
<	O
0.001	O
)	O
following	O
strength	O
training	O
,	O
but	O
the	B-O
maximal	I-O
H	I-O
wave-to-maximal	I-O
M	I-O
wave	I-O
(	I-O
H	I-O
(	I-O
max	I-O
)	I-O
/M	I-O
(	I-O
max	I-O
)	I-O
)	I-O
ratio	I-O
remained	O
unchanged	O
.	O


Conversely	O
,	O
in	O
the	O
endurance	O
group	O
the	B-O
V/M	I-O
(	I-O
max	I-O
)	I-O
ratio	I-O
was	O
not	O
altered	O
,	O
whereas	O
the	B-O
H	I-O
(	I-O
max	I-O
)	I-O
/M	I-O
(	I-O
max	I-O
)	I-O
ratio	I-O
increased	O
by	O
30.8	O
±	O
21.7	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	B-I
endurance	I-I
training	I-I
group	O
also	O
displayed	O
a	O
reduction	O
in	O
the	B-O
H-reflex	I-O
excitability	I-O
threshold	I-O
while	O
the	O
H-reflex	O
amplitude	O
on	O
the	O
ascending	O
limb	O
of	O
the	O
recruitment	O
curve	O
increased	O
.	O


Strength	O
training	O
only	O
elicited	O
a	O
significant	O
decrease	B-O
in	I-O
H-reflex	I-O
excitability	I-O
threshold	I-O
,	I-O
while	I-O
H-reflex	I-O
amplitudes	I-O
over	O
the	B-O
ascending	I-O
limb	I-O
remained	O
unchanged	O
.	O


These	O
observations	O
indicate	O
that	O
the	O
H-reflex	O
pathway	O
is	O
strongly	O
involved	O
in	O
the	O
enhanced	B-O
endurance	I-O
resistance	I-O
that	O
occurs	O
following	B-I
endurance	I-I
training	I-I
.	O


On	O
the	O
contrary	O
,	O
the	O
improvements	B-O
in	I-O
MVC	O
following	O
strength	O
training	O
are	O
likely	O
attributed	O
to	O
increased	O
descending	O
drive	O
and/or	O
modulation	O
in	O
afferents	O
other	O
than	O
Ia	O
afferents	O
.	O


Does	O
a	O
first	O
trimester	O
dating	O
scan	O
using	O
crown	O
rump	O
length	O
measurement	O
reduce	O
the	O
rate	B-O
of	I-O
induction	I-O
of	I-O
labour	I-O
for	O
prolonged	B-O
pregnancy	I-O
?	O
An	O
uncompleted	O
randomised	O
controlled	O
trial	O
of	O
463	B-P
women	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
first	O
trimester	O
ultrasound	B-I
dating	I-I
scan	I-I
on	O
the	O
rate	B-O
of	I-O
induction	I-O
of	I-O
labour	I-O
for	O
prolonged	B-O
pregnancy	I-O
.	I-O


DESIGN	O
Randomised	O
controlled	O
trial	O
to	O
include	O
400	B-P
women	I-P
in	I-P
each	I-P
arm	I-P
of	I-P
the	I-P
trial	I-P
.	I-P


SETTING	O
Participating	B-P
general	I-P
practices	I-P
and	I-P
a	I-P
district	I-P
general	I-P
teaching	I-P
hospital	I-P
.	I-P


POPULATION	O
Women	B-P
attending	I-P
their	I-P
general	I-P
practitioner	I-P
in	I-P
the	I-P
first	I-P
trimester	I-P
to	I-P
confirm	I-P
pregnancy	I-P
,	I-P
in	I-P
whom	I-P
a	I-P
first	I-P
trimester	I-P
ultrasound	I-I
scan	I-I
was	I-P
not	I-P
indicated	I-P
.	I-P


METHODS	O
Women	O
randomised	O
to	O
the	O
study	O
group	O
(	O
scan	O
group	O
)	O
underwent	O
an	O
ultrasound	B-I
dating	I-I
scan	I-I
between	I-I
8	I-I
and	I-I
12	I-I
weeks	I-I
,	I-I
measuring	I-I
crown-rump	I-I
length	I-I
.	I-I


The	O
estimated	O
date	O
of	O
delivery	O
(	O
EDD	O
)	O
was	O
changed	O
if	O
there	O
was	O
a	O
discrepancy	O
of	O
more	O
than	O
5	O
days	O
from	O
the	O
gestation	O
,	O
calculated	O
from	O
the	O
last	O
menstrual	O
period	O
(	O
LMP	O
)	O
.	O


For	O
the	O
remaining	O
women	O
(	O
no-scan	O
group	O
)	O
,	O
gestation	O
was	O
determined	O
using	O
the	O
LMP	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
The	B-O
rate	I-O
of	I-O
induction	I-O
of	I-O
labour	I-O
for	I-O
prolonged	I-O
pregnancy	I-O
.	I-O


RESULTS	O
Due	O
to	O
circumstances	O
beyond	O
the	O
researchers	O
'	O
control	O
,	O
recruitment	O
was	O
abandoned	O
when	O
463	B-P
women	I-P
had	I-P
been	I-P
enrolled	I-P
.	I-P


The	O
EDD	O
was	O
adjusted	O
in	O
13	O
(	O
5.7	O
%	O
)	O
women	O
in	O
the	O
scan	O
group	O
and	O
in	O
2	O
(	O
0.9	O
%	O
)	O
in	O
the	O
no-scan	O
group	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	O
rate	B-O
of	I-O
induction	I-O
for	O
prolonged	B-O
pregnancy	I-O
between	O
the	O
scan	O
(	O
19	O
[	O
8.2	O
%	O
]	O
)	O
and	O
the	O
no-scan	O
(	O
17	O
[	O
7.4	O
%	O
]	O
)	O
groups	O
(	O
relative	O
risk	O
1.10	O
;	O
95	O
%	O
CI	O
0.59-2.07	O
)	O
.	O


CONCLUSIONS	O
Acknowledging	O
the	O
reduced	O
numbers	O
recruited	O
for	O
study	O
,	O
it	O
is	O
concluded	O
that	O
there	O
is	O
no	O
evidence	O
that	O
a	O
first	O
trimester	O
ultrasound	B-I
dating	I-I
scan	I-I
reduces	O
the	O
rate	B-O
of	I-O
induction	I-O
of	I-O
labour	I-O
for	O
prolonged	B-O
pregnancy	I-O
and	O
may	O
result	O
in	O
a	O
more	O
expensive	O
healthcare	O
strategy	O
.	O


Injection	B-O
pain	I-O
with	O
propofol	B-I
.	I-I


Reduction	O
with	O
aspiration	O
of	O
blood	O
.	O


A	O
randomised	O
,	O
controlled	O
,	O
single-blind	O
study	O
was	O
performed	O
on	O
100	B-P
patients	I-P
to	O
investigate	O
a	O
new	O
method	O
of	O
reducing	O
pain	B-O
on	O
propofol	B-I
injection	O
.	O


Aspiration	O
of	O
2	O
ml	O
of	O
the	O
patient	O
's	O
blood	O
into	O
a	O
syringe	O
of	O
propofol	B-I
immediately	O
before	O
injection	O
was	O
compared	O
with	O
the	O
addition	O
of	O
lignocaine	B-I
20	I-I
mg	I-I
or	I-I
normal	I-I
saline	I-I
2	I-I
ml	I-I
to	I-I
the	I-I
propofol	I-I
before	I-I
injection	I-I
.	I-I


The	O
addition	O
of	O
blood	O
was	O
significantly	O
more	O
effective	O
in	O
reducing	B-O
pain	I-O
on	I-O
injection	I-O
than	O
the	O
addition	O
of	O
saline	O
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
was	O
not	O
significantly	O
more	O
effective	B-O
than	O
the	O
addition	O
of	O
lignocaine	O
.	O


Effects	O
of	O
pindolol	B-I
and	I-I
clopamide	I-I
on	O
blood	B-O
lipids	I-O
in	O
arterial	B-P
hypertensive	I-P
patients	I-P
.	I-P


The	O
effects	O
of	O
clopamide	B-I
,	I-I
pindolol	I-I
and	I-I
its	I-I
combination	I-I
on	I-I
plasma	I-I
lipids	I-I
in	O
49	B-P
hypertensive	I-P
patients	I-P
(	I-P
WHO	I-P
I-II	I-P
)	I-P
,	I-P
divided	I-P
into	I-P
three	I-P
parallel	I-P
randomized	I-P
groups	I-P
,	I-P
were	I-P
studied	I-P
over	I-P
a	I-P
6	I-P
months	I-P
period	I-P
.	I-P


Total	B-O
cholesterol	I-O
,	I-O
triglycerides	I-O
,	I-O
HDL	I-O
and	I-O
LDL	I-O
cholesterol	I-O
fractions	I-O
were	O
determined	O
twice	O
during	O
an	O
initial	O
4-week	O
washout	O
phase	O
,	O
and	O
after	O
a	O
1-	O
,	O
3-	O
and	O
6-month	O
active	O
hypotensive	O
drug	O
phase	O
.	O


Patients	O
were	O
instructed	O
to	O
maintain	O
their	O
usual	O
dietary	O
habits	O
.	O


Daily	O
drug	O
doses	O
were	O
adjusted	O
progressively	O
to	O
attain	O
optimal	O
hypotensive	O
effects	O
.	O


In	O
the	O
clopamide	O
monotherapy	O
group	O
,	O
total	B-O
cholesterol	I-O
increased	O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
;	O
triglycerides	B-O
and	O
LDL	B-O
showed	O
a	O
tendency	O
to	O
increase	O
while	O
for	O
HDL	B-O
a	O
tendency	O
to	O
decrease	O
was	O
observed	O
.	O


In	O
the	O
pindolol	O
monotherapy	O
group	O
,	O
a	O
significant	O
reduction	O
of	O
triglycerides	B-O
(	O
p	O
less	O
than	O
0.01	O
)	O
and	O
a	O
significant	O
increase	O
of	O
HDL	B-O
cholesterol	I-O
(	O
p	O
less	O
than	O
0.05	O
)	O
were	O
recorded	O
.	O


No	O
significant	O
changes	O
in	O
total	B-O
cholesterol	I-O
or	I-O
LDL	I-O
fraction	I-O
were	O
observed	O
.	O


Combined	O
pindolol-clopamide	O
therapy	O
decreased	O
total	B-O
triglycerides	I-O
(	I-O
NS	I-O
)	I-O
,	O
increased	O
HDL	B-O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
did	O
not	O
influence	O
total	B-O
cholesterol	I-O
and	I-O
LDL	I-O
fraction	I-O
.	I-O


It	O
is	O
concluded	O
that	O
pindolol	O
does	O
not	O
negatively	O
influence	O
blood	B-O
lipids	I-O
as	O
the	O
thiazide-type	O
diuretic	O
clopamide	O
does	O
,	O
and	O
that	O
when	O
both	O
drugs	O
are	O
used	O
together	O
,	O
the	O
beta-blocker	O
can	O
probably	O
counterbalance	O
the	O
diuretic-induced	O
negative	O
effects	O
on	O
blood	B-O
lipids	I-O
.	I-O


Accordingly	O
,	O
it	O
is	O
suggested	O
that	O
pindolol	O
could	O
be	O
a	O
more	O
favorable	O
beta-blocker	O
drug	O
to	O
be	O
used	O
on	O
hypertensive	B-P
subjects	I-P
with	I-P
metabolic	I-P
coronary	I-P
risk	I-P
factors	I-P
.	I-P


Hodgkin	B-P
's	I-P
disease	I-P
in	I-P
childhood	I-P
and	I-P
adolescence	I-P
:	I-P
results	O
of	O
chemotherapy-radiotherapy	O
in	O
clinical	O
stages	O
IA-IIB	O
.	O


From	O
April	O
1972	O
to	O
May	O
1980	O
,	O
72	B-P
children	I-P
and	I-P
adolescents	I-P
(	I-P
aged	I-P
5	I-P
to	I-P
19	I-P
years	I-P
old	I-P
,	I-P
median	I-P
16	I-P
)	I-P
with	I-P
Hodgkin	I-P
's	I-P
disease	I-P
,	I-P
clinical	I-P
stages	I-P
IA-IIB	I-P
(	I-P
IA	I-P
,	I-P
18	I-P
;	I-P
II2A	I-P
,	I-P
two	I-P
areas	I-P
involved	I-P
on	I-P
the	I-P
same	I-P
side	I-P
of	I-P
the	I-P
diaphragm	I-P
,	I-P
23	I-P
;	I-P
II3+A	I-P
,	I-P
three	I-P
areas	I-P
or	I-P
more	I-P
,	I-P
16	I-P
;	I-P
IIB	I-P
,	I-P
15	I-P
)	I-P
were	O
prospectively	O
treated	O
in	O
two	O
successive	O
clinical	O
trials	O
(	O
H	O
72	O
and	O
H	O
77	O
)	O
.	O


Clinical	O
stages	O
IA	O
and	O
II2A	O
received	O
three	O
courses	O
of	O
mechlorethamine	B-I
,	I-I
Oncovin	I-I
,	I-I
procarbazine	I-I
,	I-I
and	I-I
prednisone	I-I
(	I-I
MOPP	I-I
)	I-I
and	I-I
supradiaphragmatic	I-I
radiotherapy	I-I
(	I-I
40	I-I
Gy	I-I
)	I-I
,	I-I
and	I-I
no	I-I
laparotomy	I-I
was	O
performed	O
.	O


Clinical	O
stages	O
II3+A	O
and	O
IIB	O
received	O
either	O
six	O
cycles	O
of	O
MOPP	B-I
(	O
H	O
72	O
)	O
,	O
three	O
cycles	O
of	O
MOPP	O
,	O
or	O
three	O
cycles	O
of	O
CCNU	B-I
,	I-I
vinblastine	I-I
,	I-I
procarbazine	I-I
,	O
and	O
prednisone	B-I
(	O
CVPP	O
)	O
(	O
H	O
77	O
)	O
and	O
subsequently	O
had	O
a	O
laparotomy	B-I
followed	O
by	O
supradiaphragmatic	B-I
radiotherapy	I-I
and	O
a	O
lumboaortic	O
field	O
if	O
results	O
of	O
laparotomy	O
were	O
positive	O
.	O


Patients	B-P
without	I-P
evidence	I-P
of	I-P
mediastinal	I-P
involvement	I-P
did	O
not	O
have	O
mediastinal	O
radiotherapy	O
.	O


At	O
the	O
completion	O
of	O
therapy	O
,	O
the	O
disease	O
in	O
70	O
of	O
72	O
patients	O
was	O
in	O
complete	O
remission	O
(	O
one	O
failure	B-O
,	O
one	O
death	B-O
during	O
treatment	O
)	O
.	O


Eight	O
patients	O
relapsed	B-O
(	O
in	O
situ	O
,	O
1	O
;	O
marginal	O
,	O
1	O
;	O
nonirradiated	O
subdiaphragmatic	O
area	O
,	O
6	O
)	O
after	O
three	O
to	O
57	O
months	O
of	O
complete	O
remission	O
(	O
median	O
20	O
months	O
)	O
;	O
one	O
patient	O
died	O
after	O
relapse	O
.	O


There	O
were	O
three	O
deaths	B-O
after	O
complete	O
remission	O
of	O
the	O
disease	O
(	O
infection	O
,	O
two	O
;	O
acute	O
nonlymphocytic	B-O
leukemia	I-O
[	O
ANLL	O
]	O
,	O
one	O
)	O
.	O


As	O
of	O
June	O
1984	O
the	O
median	O
follow-up	O
was	O
82	O
months	O
(	O
range	O
,	O
49	O
to	O
145	O
months	O
)	O
,	O
the	B-O
actuarial	I-O
probabilities	I-O
for	I-O
survival	I-O
and	I-O
freedom	I-O
from	I-O
relapse	I-O
for	O
all	O
patients	O
being	O
91.6	O
%	O
and	O
87.6	O
%	O
,	O
respectively	O
.	O


There	O
was	O
no	O
statistical	O
difference	O
according	O
to	O
clinical	O
stage	O
,	O
age	O
(	O
greater	O
than	O
15	O
or	O
less	O
than	O
15	O
years	O
)	O
,	O
sex	O
,	O
or	O
number	B-O
of	I-O
cycles	I-O
of	I-O
chemotherapy	I-O
(	O
six	O
or	O
three	O
)	O
.	O


Bone	B-O
growth	I-O
defects	I-O
related	I-O
to	I-O
radiotherapy	I-O
were	O
reduced	O
particularly	O
in	O
the	O
29	O
patients	O
who	O
did	O
not	O
receive	O
mediastinal	O
radiotherapy	O
.	O


None	O
of	O
these	O
patients	O
had	O
a	O
mediastinal	B-O
relapse	I-O
.	I-O


Azoospermia	B-O
was	O
the	O
rule	O
for	O
the	O
male	O
patients	O
studied	O
,	O
but	O
young	O
girls	O
and	O
young	O
women	O
retained	O
reproductive	O
integrity	O
.	O


Sialyl	B-I
Lewisa	I-I
expression	I-I
as	O
a	O
predictor	O
of	O
the	O
prognosis	O
of	O
colon	B-P
carcinoma	I-P
patients	I-P
in	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
The	O
metastatic	O
potential	O
of	O
tumors	O
is	O
dependent	O
on	O
the	O
cell	O
to	O
cell	O
adhesion	O
by	O
cell	O
surface	O
carbohydrate	O
antigens	O
.	O


Thus	O
,	O
expression	O
of	O
sialyl	O
Lewis	O
(	O
a	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
important	O
molecules	O
of	O
cell	O
surface	O
carbohydrates	O
,	O
may	O
serve	O
as	O
a	O
prognostic	O
marker	O
of	O
aggressive	O
and	O
metastasizing	O
tumor	O
growth	O
.	O


However	O
,	O
the	O
prognostic	O
value	O
of	O
sialyl	O
Lewis	O
(	O
a	O
)	O
expression	O
in	O
colon	O
cancer	O
is	O
still	O
controversial	O
.	O


METHODS	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	B-I
of	I-I
sialyl	I-I
Lewis	I-I
(	I-I
a	I-I
)	I-I
antigen	I-I
in	O
233	B-P
colon	I-I
cancer	I-I
specimens	I-I
from	I-P
patients	I-P
who	I-P
were	I-P
registered	I-P
in	I-P
a	I-P
prospective	I-P
adjuvant	I-I
immunochemotherapy	I-I
clinical	I-P
trial	I-P
.	I-P


The	O
clinical	O
course	O
and	O
the	O
prognosis	O
of	O
the	O
patients	O
were	O
evaluated	O
after	O
all	O
the	O
immunohistochemical	O
analyses	O
had	O
been	O
performed	O
.	O


RESULTS	O
Sialyl	O
Lewis	O
(	O
a	O
)	O
expression	O
levels	O
were	O
correlated	O
with	O
both	O
overall	B-O
survival	I-O
(	O
P	O
=	O
0.0006	O
)	O
and	O
disease-free	B-O
survival	I-O
(	O
P	O
=	O
0.004	O
)	O
in	O
all	O
patients	O
with	O
the	O
log-rank	O
test	O
.	O


This	O
result	O
could	O
be	O
assumed	O
to	O
have	O
been	O
influenced	O
by	O
the	O
difference	O
in	O
the	O
metastatic	O
preponderance	O
in	O
a	O
high	O
versus	O
low	O
sialyl	O
Lewis	O
(	O
a	O
)	O
expression	O
in	O
the	O
tumor	O
cells	O
.	O


CONCLUSION	O
This	O
prospective	O
study	O
in	O
a	O
randomized	O
controlled	O
trial	O
suggests	O
that	O
sialyl	O
Lewis	O
(	O
a	O
)	O
expression	O
levels	O
may	O
serve	O
as	O
an	O
indicator	O
of	O
the	O
metastatic	O
potential	O
of	O
colon	O
cancer	O
cells	O
,	O
which	O
would	O
strongly	O
predict	O
the	O
prognosis	O
.	O


1H	O
nuclear	O
magnetic	O
resonance-based	O
metabolomic	O
study	O
on	O
efficacy	B-O
of	O
Qingrehuatan	B-I
decoction	I-I
against	O
abundant	O
phlegm-heat	O
syndrome	O
in	O
young	B-P
adults	I-P
with	I-P
essential	I-P
hypertension	I-P
.	I-P


OBJECTIVE	O
To	O
observe	O
the	O
influence	O
of	O
Qingrehuatan	B-I
decoction	I-I
(	I-I
QRHT	I-I
)	I-I
on	O
serum	B-O
metabolic	I-O
profile	I-O
in	O
young	B-P
essential	I-P
hypertension	I-P
(	I-P
YEH	I-P
)	I-P
patients	I-P
with	I-P
abundant	I-P
phlegm-heat	I-P
syndrome	I-P
and	O
provide	O
a	O
basis	O
for	O
treatment	O
with	O
the	O
decoction	O
.	O


METHODS	O
Twelve	B-P
male	I-P
YEH	I-P
patients	I-P
were	I-P
randomly	I-P
selected	I-P
and	I-P
serum	I-P
samples	I-P
were	I-P
collected	I-P
for	I-P
examination	I-P
before	I-P
and	I-P
after	I-P
4	I-P
weeks	I-P
of	I-P
the	I-P
treatment	I-P
with	I-P
QRHT	I-I
.	I-I


Twelve	B-P
healthy	I-P
males	I-P
were	I-P
randomly	I-P
selected	I-P
and	I-P
their	I-P
serum	I-P
samples	I-P
were	I-P
collected	I-P
as	I-P
a	I-P
control	I-P
.	I-P


All	O
serum	O
samples	O
were	O
detected	O
using	O
metabolomic	O
technology	O
with	O
1H	O
nuclear	O
magnetic	O
resonance	O
.	O


Differences	O
in	O
metabolites	O
were	O
studied	O
by	O
principal	O
component	O
analysis	O
and	O
partial	O
least	O
squares-discriminate	O
analysis	O
,	O
which	O
produced	O
scores	O
and	O
loadings	O
plots	O
.	O


RESULTS	O
After	O
4	O
weeks	O
of	O
treatment	O
,	O
serum	O
substances	O
could	O
be	O
distinguished	O
between	O
the	O
YEH	O
patients	O
with	O
abundant	O
phlegm-heat	O
syndrome	O
and	O
the	O
control	O
patients	O
.	O


The	O
specific	O
serum	B-O
endog-	I-O
enous	I-O
metabolites	I-O
tended	O
to	O
improve	O
after	O
the	O
treatment	O
.	O


QRHT	B-I
can	O
appropriately	O
increase	O
the	O
levels	B-O
of	I-O
glucose	I-O
,	I-O
lactic	I-O
acid	I-O
,	I-O
citric	I-O
acid	I-O
,	I-O
high-density	I-O
lipoprotein	I-O
,	I-O
phosphatidylcholine	I-O
,	I-O
glycerophosphate	I-O
choline	I-O
,	I-O
hydroxybutyrate	I-O
,	I-O
alanine	I-O
,	I-O
and	I-O
glutamate	I-O
.	I-O


QRHT	B-I
could	O
also	O
decrease	O
the	O
levels	B-O
of	I-O
low-density	I-O
lipoprotein/very	I-O
low-density	I-O
lipoprotein	I-O
,	I-O
lipids	I-O
,	I-O
N-acetyl	I-O
glycoprotein	I-O
,	I-O
and	I-O
O-acetyl	I-O
glycoprotein	I-O
.	I-O


CONCLUSION	O
QRHT	O
can	O
effectively	O
ameliorate	O
metabolic	B-O
disorders	I-O
in	O
YEH	O
Patients	O
with	O
abundant	O
phlegm-heat	O
syndrome	O
.	O


1H	O
NMR-based	O
metabolomic	O
technology	O
can	O
provide	O
an	O
objective	O
basis	O
for	O
the	O
treatment	O
of	O
YEH	B-P
patients	I-P
with	I-P
abundant	I-P
phlegm-heat	I-P
syndrome	I-P
using	O
QRHT	B-I
.	I-I


The	O
effects	B-O
of	O
different	O
intensities	O
and	O
durations	O
of	O
the	O
general	B-I
warm-up	I-I
on	I-O
leg	I-O
press	I-O
1RM	I-O
.	I-O


The	O
precision	O
of	O
maximum	O
strength	O
assessments	O
(	O
1	O
repetition	O
maximum	O
;	O
1RM	O
)	O
is	O
important	O
to	O
evaluate	O
the	O
functional	O
capacity	O
and	O
to	O
prescribe	O
and	O
monitor	O
the	O
training	O
load	O
.	O


Several	O
factors	O
can	O
affect	O
the	O
precision	O
of	O
1RM	O
tests	O
,	O
including	O
the	O
warm-up	O
procedure	O
.	O


General	O
and	O
specific	O
warm-up	O
routines	O
are	O
recommended	O
to	O
enhance	O
performance	O
.	O


The	O
effects	O
of	O
a	O
specific	O
warm-up	O
have	O
already	O
been	O
acknowledged	O
in	O
improving	O
performance	O
.	O


However	O
,	O
the	O
effects	O
of	O
a	O
general	B-I
warm-up	I-I
(	I-I
GWU	I-I
)	I-I
are	O
unclear	O
but	O
seem	O
to	O
depend	O
on	O
its	O
ability	O
to	O
increase	O
muscle	O
temperature	O
while	O
avoiding	O
fatigue	O
.	O


Furthermore	O
,	O
temperature	O
elevation	O
is	O
dependent	O
on	O
both	O
the	O
duration	O
and	O
the	O
intensity	O
of	O
the	O
activity	O
,	O
which	O
may	O
eventually	O
affect	O
1RM	O
performance	O
.	O


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	B-O
of	O
different	O
intensities	O
and	O
durations	O
of	O
GWU	O
on	O
1RM	O
performance	O
.	O


Sixteen	B-P
strength-trained	I-P
men	I-P
were	O
tested	O
for	O
1RM	B-O
leg	I-O
press	I-O
after	O
4	O
GWU	O
conditions	O
after	O
specific	O
warm-up	O
:	O
short	O
duration	O
and	O
low	O
intensity	O
(	O
SDLI	O
;	O
i.e.	O
,	O
5	O
minutes	O
at	O
40	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
long	O
duration	O
and	O
low	O
intensity	O
(	O
LDLI	O
;	O
i.e.	O
,	O
15	O
minutes	O
at	O
40	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
short	O
duration	O
and	O
moderate	O
intensity	O
(	O
SDMI	O
;	O
i.e.	O
,	O
5	O
minutes	O
at	O
70	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
long	O
duration	O
and	O
moderate	O
intensity	O
(	O
LDMI	O
;	O
i.e.	O
,	O
15	O
minutes	O
at	O
70	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
and	O
the	O
control	O
(	O
CTRL	O
)	O
no-GWU	O
condition	O
.	O


Leg	B-O
press	I-O
1RM	I-O
values	I-O
were	I-O
higher	I-O
(	O
on	O
average	O
3	O
%	O
)	O
when	O
subjects	O
performed	O
LDLI	O
(	O
367.8	O
±	O
70.1	O
kg	O
;	O
p	O
=	O
0.01	O
)	O
,	O
compared	O
with	O
the	O
other	O
4	O
conditions	O
.	O


After	O
the	O
LDMI	O
condition	O
,	O
1RM	B-O
values	I-O
were	I-O
lower	I-O
(	O
on	O
average	O
-4	O
%	O
)	O
than	O
in	O
the	O
other	O
4	O
conditions	O
(	O
345.6	O
±	O
70.5	O
kg	O
;	O
p	O
=	O
0.01	O
)	O
.	O


There	O
were	B-O
no	I-O
differences	I-O
between	I-O
SDMI	I-O
,	I-O
SDLI	I-O
,	I-O
and	I-O
CTRL	I-O
(	O
359.4	O
±	O
69.2	O
kg	O
,	O
359.1	O
±	O
69.3	O
kg	O
,	O
and	O
359.4	O
±	O
70.4	O
kg	O
,	O
respectively	O
;	O
p	O
=	O
0.99	O
)	O
.	O


According	O
to	O
our	O
results	O
,	O
long-duration	O
low-intensity	O
general	O
warm-up	O
seems	O
be	O
appropriately	O
to	O
improve	O
1RM	O
performance	B-P
in	I-P
strength-trained	I-P
individuals	I-P
.	O


Cardiovascular	O
effects	O
of	O
non-depolarizing	B-I
neuromuscular	I-I
blockers	I-I
in	O
patients	B-P
with	I-P
aortic	I-P
valve	I-P
disease	I-P
.	I-P


To	O
compare	O
haemodynamic	O
responses	O
associated	O
with	O
equipotent	O
doses	O
of	O
neuromuscular	B-I
blockers	I-I
and	O
high-dose	O
fentanyl	B-I
(	O
50	O
micrograms.kg-1	O
)	O
,	O
40	B-P
patients	I-P
with	I-P
aortic	I-P
valve	I-P
stenosis	I-P
(	I-P
AS	I-P
)	I-P
and	I-P
20	I-P
patients	I-P
with	I-P
aortic	I-P
insufficiency	I-P
(	I-P
AI	I-P
)	I-P
were	O
randomized	O
to	O
four	O
study	O
groups	O
to	O
receive	O
the	O
following	O
:	O
(	O
1	O
)	O
pancuronium	B-I
0.12	I-I
mg.kg-1	I-I
,	I-I
(	I-I
2	I-I
)	I-I
vecuronium	I-I
0.12	I-I
mg.kg-1	I-I
,	I-I
(	I-I
3	I-I
)	I-I
atracurium	I-I
0.4	I-I
mg.kg-1	I-I
,	I-I
or	I-I
(	I-I
4	I-I
)	I-I
pancuronium-metocurine	I-I
mixture	I-I
(	O
0.4	O
mg	O
+	O
1.6	O
mg/ml	O
)	O
:	O
1	O
ml/10	O
kg	O
)	O
.	O


Neuromuscular	B-I
blockers	I-I
were	O
injected	O
at	O
the	O
same	O
time	O
with	O
the	O
fentanyl	B-I
;	I-I
haemodynamics	O
were	O
recorded	O
with	O
the	O
patients	O
awake	O
(	O
baseline	O
)	O
,	O
at	O
two	O
minutes	O
post-induction	O
,	O
and	O
at	O
two	O
and	O
five	O
minutes	O
after	O
intubation	O
.	O


In	O
patients	O
with	O
AS	O
,	O
pancuronium	B-I
increased	O
heart	B-O
rate	I-O
more	O
than	O
vecuronium	B-I
or	O
atracurium	B-I
;	I-I
heart	I-O
rates	I-O
were	O
also	O
higher	B-O
with	O
the	O
pancuronium-metocurine	B-I
mixture	I-I
than	O
with	O
vecuronium	B-I
.	I-I


Although	O
there	O
were	O
no	O
ECG	B-O
signs	I-O
of	I-O
ischaemia	I-O
,	O
one	O
patient	O
given	O
pancuronium	O
developed	O
severe	B-O
hypotension	I-O
associated	I-O
with	I-O
tachycardia	I-O
.	I-O


Reductions	O
in	O
SVR	B-O
after	O
atracurium	O
allowed	O
small	O
but	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
decreases	O
in	O
MAP	B-O
which	O
were	O
well	B-O
tolerated	I-O
;	I-O
one	O
patient	O
,	O
however	O
,	O
did	O
develop	O
severe	B-O
hypotension	I-O
.	I-O


Intubation	O
resulted	O
in	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
increases	O
in	O
MAP	B-O
in	O
the	O
pancuronium-metocurine	B-I
mixture	O
group	O
.	O


Vecuronium	B-I
permitted	O
the	O
most	O
stable	O
overall	B-O
haemodynamic	I-O
course	I-O
at	O
all	O
measurement	O
times	O
.	O


In	O
contrast	O
,	O
patients	O
with	O
AI	O
showed	O
stable	B-O
haemodynamics	I-O
after	O
vecuronium	B-I
,	I-I
pancuronium	I-I
and	O
the	O
pancuronium-metocurine	B-I
mixture	I-I
;	I-I
one	O
patient	O
became	O
tachycardic	B-O
following	O
vecuronium	B-I
.	I-I


Atracurium	B-I
caused	O
unexplained	O
elevations	B-O
in	I-O
diastolic	I-O
and	I-O
mean	I-O
arterial	I-O
pressures	I-O
which	O
were	O
significant	O
when	O
compared	O
to	O
vecuronium	B-I
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O


These	O
results	O
in	O
increases	O
in	O
PCWP	B-O
;	I-O
mean	I-O
PA	I-O
pressures	I-O
and	I-O
CVP	I-O
were	O
also	O
increased	B-O
.	I-O


These	O
effects	O
of	O
atracurium	B-I
inpatients	O
with	O
Al	O
need	O
further	O
evaluation	O
.	O


[	B-I
Aortofemoral	I-I
bifurcation	I-I
bypass	I-I
.	I-I


Effect	O
of	O
the	O
anesthesia	O
procedure	O
(	B-I
NLA	I-I
,	I-I
thoracic	I-I
continuous	I-I
catheter	I-I
peridural	I-I
anesthesia	I-I
)	I-I
on	O
circulation	O
,	O
respiration	O
and	O
metabolism	O
.	O


Homeostasis	O
and	O
oxygen	O
transport	O
]	O
.	O


50	B-P
patients	I-P
were	I-P
investigated	I-P
during	I-P
induction	I-P
of	I-P
anaesthesia	I-P
and	I-P
infrarenal	I-I
aortic	I-I
bypass	I-I
surgery	I-I
.	I-I


26	B-P
were	I-P
operated	I-P
on	I-P
under	I-P
neuroleptanaesthesia	I-I
(	I-I
NA	I-I
group	I-I
)	I-I
and	I-P
24	I-P
under	I-P
continuous	I-I
epidural	I-I
combined	I-I
with	I-I
a	I-I
light	I-I
general	I-I
anaesthesia	I-I
(	I-I
epidural	I-I
group	I-I
)	I-I
.	I-I


Blood	O
losses	O
were	O
replaced	O
with	O
5	O
per	O
cent	O
human	O
albumin	O
,	O
red	O
cell	O
concentrates	O
,	O
and	O
fresh	O
frozen	O
plasma	O
.	O


Ringer	B-I
lactate	I-I
solution	I-I
was	O
used	O
to	O
replace	O
the	O
functional	O
extracellular	O
fluid	O
volume	O
.	O


During	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
body	O
temperature	O
fell	O
(	O
NA	O
group	O
from	O
36.7	O
to	O
35.3	O
degrees	O
C	O
;	O
epidural	O
group	O
from	O
36.7	O
to	O
34.9	O
degrees	O
C	O
)	O
but	O
no	O
statistically	O
significant	O
difference	O
could	O
be	O
found	O
between	O
the	O
groups	O
,	O
in	O
spite	O
of	O
better	O
surface	B-O
perfusion	I-O
of	O
the	O
lower	O
part	O
of	O
the	O
body	O
in	O
the	O
epidural	O
group	O
.	O


The	O
increase	B-O
of	I-O
plasma	I-O
glucose	I-O
concentration	I-O
was	O
lower	O
in	O
the	O
epidural	O
group	O
as	O
compared	O
to	O
the	O
NA	O
group	O
.	O


Stress	B-O
mediated	I-O
hypokalaemia	I-O
was	O
of	O
the	O
same	O
degree	O
in	O
both	O
groups	O
,	O
the	O
median	B-O
values	I-O
of	I-O
the	I-O
plasma	I-O
potassium	I-O
concentrations	I-O
being	O
in	O
the	O
lower	O
reference	O
range	O
(	O
3.5-3.7	O
mmol	O
X	O
1	O
(	O
-1	O
]	O
,	O
although	O
large	O
amounts	O
of	O
red	O
cell	O
concentrates	O
were	O
given	O
.	O


During	O
clamping	O
of	O
the	O
aorta	O
a	O
moderate	B-O
compensated	I-O
acidosis	I-O
developed	O
in	O
both	O
groups	O
.	O


Declamping	O
caused	O
a	O
more	O
marked	B-O
increase	I-O
of	I-O
paCO2	I-O
and	O
a	O
greater	B-O
fall	I-O
of	I-O
pH	I-O
in	O
the	O
NA	O
group	O
as	O
compared	O
to	O
the	O
epidural	O
group	O
.	O


Induction	O
of	O
anaesthesia	O
was	O
followed	O
by	O
a	O
fall	B-O
in	I-O
oxygen	I-O
uptake	I-O
(	O
NA	O
group	O
from	O
221	O
to	O
163	O
ml	O
X	O
min-1	O
;	O
epidural	O
group	O
from	O
230	O
to	O
189	O
ml	O
X	O
min-1	O
)	O
which	O
appears	O
to	O
be	O
delayed	O
in	O
the	O
epidural	O
group	O
,	O
with	O
a	O
short	O
lasting	O
statistically	O
significant	O
difference	O
between	O
the	O
groups	O
after	O
eventration	O
of	O
the	O
gut	O
(	O
NA	O
group	O
:	O
162	O
ml	O
X	O
min-1	O
less	O
than	O
epidural	O
group	O
184	O
ml	O
X	O
min-1	O
)	O
.	O


Later	O
on	O
,	O
oxygen	B-O
uptake	I-O
was	O
equal	O
in	O
both	O
groups	O
,	O
with	O
no	O
further	O
changes	O
due	O
to	O
clamping	O
or	O
declamping	O
of	O
the	O
aorta	O
.	O


At	O
the	O
end	O
of	O
the	O
operation	O
,	O
when	O
nitrous	O
oxide	O
had	O
been	O
turned	O
of	O
,	O
the	O
oxygen	B-O
uptake	I-O
increased	O
considerably	O
in	O
several	O
patients	O
,	O
despite	O
continuing	O
artificial	O
ventilation	O
and	O
intravenous	O
hypnotics	O
and	O
analgesics	O
having	O
been	O
given	O
.	O


Eventration	O
and	O
exterioration	O
of	O
the	O
gut	O
caused	O
the	O
most	O
marked	O
changes	O
in	O
haemodynamics	O
and	O
oxygen	O
transport	O
with	O
significant	O
differences	O
between	O
the	O
groups	O
.	O


Immediately	O
after	O
eventration	O
there	O
was	O
a	O
sudden	O
fall	O
in	O
paO2	O
in	O
both	O
groups	O
(	O
NA	O
group	O
from	O
99	O
to	O
83	O
mm	O
Hg	O
;	O
epidural	O
group	O
from	O
96	O
to	O
84	O
mm	O
Hg	O
)	O
and	O
an	O
increase	O
of	O
the	O
calculated	O
intrapulmonary	O
right-to-left-shunt	O
(	O
NA	O
group	O
from	O
7	O
to	O
21	O
%	O
;	O
epidural	O
group	O
from	O
10	O
to	O
19	O
%	O
)	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O


Clinical	O
usefulness	O
of	O
serum	B-I
prostate	I-I
specific	I-I
antigen	I-I
for	O
the	O
detection	O
of	O
prostate	B-P
cancer	I-P
is	O
preserved	O
in	O
men	B-P
receiving	I-P
the	I-P
dual	I-I
5alpha-reductase	I-I
inhibitor	I-I
dutasteride	I-I
.	I-I


PURPOSE	O
We	O
determined	O
whether	O
the	O
decrease	O
in	O
serum	O
PSA	O
seen	O
with	O
5alpha-reductase	B-I
inhibitors	I-I
affects	O
the	O
clinical	O
usefulness	O
of	O
PSA	O
for	O
prostate	O
cancer	O
screening	O
using	O
data	O
from	O
2	O
dutasteride	O
benign	O
prostatic	O
hyperplasia	O
studies	O
.	O


MATERIALS	O
AND	O
METHODS	O
A	B-P
total	I-P
of	I-P
2,802	I-P
men	I-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
a	I-P
clinical	I-P
diagnosis	I-P
of	I-P
benign	I-P
prostatic	I-P
hyperplasia	I-P
,	I-P
no	I-P
history	I-P
of	I-P
prostate	I-P
cancer	I-P
,	I-P
PSA	I-P
1.5	I-P
to	I-P
10	I-P
ng/ml	I-P
,	I-P
prostate	I-P
volume	I-P
30	I-P
cc	I-P
or	I-P
greater	I-P
,	I-P
an	I-P
American	I-P
Urological	I-P
Association	I-P
symptom	I-P
score	I-P
of	I-P
12	I-P
or	I-P
greater	I-P
and	I-P
peak	I-P
urinary	I-P
flow	I-P
rate	I-P
15	I-P
ml	I-P
per	I-P
second	I-P
or	I-P
less	I-P
were	I-P
randomized	I-P
to	I-P
0.5	I-I
mg	I-I
dutasteride	I-I
daily	I-I
or	I-I
matching	I-I
placebo	I-I
for	O
24	O
months	O
.	O


Increases	O
in	O
PSA	O
from	O
baseline	O
and	O
the	O
maximum	O
increase	O
from	O
nadir	O
to	O
month	O
24	O
were	O
compared	O
between	O
the	O
groups	O
and	O
analyzed	O
by	O
prostate	O
cancer	O
status	O
,	O
as	O
determined	O
by	O
PSA	O
driven	O
biopsy	O
and	O
an	O
advised	O
cutoff	O
of	O
more	O
than	O
4	O
ng/ml	O
after	O
doubling	O
to	O
correct	O
for	O
dutasteride	B-I
treatment	O
with	O
sensitivity	O
and	O
specificity	O
calculated	O
for	O
each	O
.	O


RESULTS	O
In	O
placebo	B-I
treated	O
men	O
without	O
prostate	O
cancer	O
there	O
was	O
an	O
8.3	O
%	O
median	B-O
increase	I-O
in	I-O
PSA	I-O
at	I-O
month	I-O
24	I-O
compared	O
with	O
-59.5	O
%	O
in	O
those	O
who	O
received	O
dutasteride	B-I
,	O
using	O
doubled	O
values	O
to	O
correct	O
for	O
dutasteride	B-I
treatment	O
.	O


In	O
those	O
with	O
prostate	O
cancer	O
these	O
changes	O
were	O
23.8	O
%	O
and	O
-37.2	O
%	O
,	O
respectively	O
.	O


Using	B-O
the	I-O
upper	I-O
PSA	I-O
limit	I-O
of	I-O
4	I-O
ng/ml	I-O
sensitivity	I-O
for	O
prostate	O
cancer	O
in	O
men	O
receiving	O
dutasteride	B-I
vs	I-I
placebo	I-I
was	O
0.737	O
vs	O
0.804	O
,	O
while	O
specificity	B-O
was	O
0.671	O
vs	O
0.578	O
.	O


Using	B-O
a	I-O
PSA	I-O
increase	I-O
from	I-O
nadir	I-O
of	I-O
0.8	I-O
ng/ml	I-O
the	O
sensitivity	B-O
of	O
dutasteride	B-I
was	O
0.548	O
and	O
its	O
specificity	B-O
was	O
0.795	O
.	O


CONCLUSIONS	O
A	O
doubling	O
factor	O
is	O
effective	O
for	O
maintaining	O
the	O
sensitivity	O
and	O
specificity	O
of	O
PSA	B-O
for	O
prostate	O
cancer	O
detection	O
in	O
men	O
on	O
dutasteride	B-I
.	I-I


Increases	O
in	O
serum	B-O
PSA	I-O
in	O
men	O
receiving	O
dutasteride	B-I
should	O
be	O
considered	O
suspicious	O
and	O
serial	O
PSA	B-O
measurements	O
should	O
be	O
used	O
to	O
evaluate	O
changes	O
from	O
nadir	O
.	O


Face	B-I
composite	I-I
effects	O
reveal	O
abnormal	O
face	O
processing	O
in	O
Autism	B-P
spectrum	I-P
disorders	I-P
.	I-P


Although	O
it	O
has	O
been	O
suggested	O
that	O
individuals	B-P
with	I-P
an	I-P
Autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
process	O
faces	O
less	O
holistically	O
than	O
typically	O
developing	O
controls	O
,	O
there	O
are	O
few	O
direct	O
investigations	O
of	O
this	O
hypothesis	O
.	O


This	O
question	O
was	O
addressed	O
before	O
using	O
the	O
composite	O
paradigm	O
(	O
Teunisse	O
,	O
J.	O
P.	O
,	O
&	O
de	O
Gelder	O
,	O
B	O
.	O


(	O
2003	O
)	O
.	O


Face	O
processing	O
in	O
adolescents	O
with	O
autistic	O
disorder	O
:	O
The	O
inversion	O
and	O
composite	O
effects	O
.	O


Brain	O
Cognition	O
,	O
52	O
(	O
3	O
)	O
,	O
285-294.	O
)	O
.	O


The	O
results	O
had	O
revealed	O
that	O
adolescents	B-P
with	I-P
ASDs	I-P
were	O
less	O
sensitive	O
than	O
controls	O
to	O
the	O
misalignment	O
of	O
face	O
parts	O
and	O
it	O
was	O
concluded	O
their	O
face	O
processing	O
was	O
less	O
holistic	O
.	O


However	O
,	O
because	O
of	O
shortcomings	O
of	O
the	O
design	O
,	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
whether	O
individuals	B-P
with	I-P
Autism	I-P
processed	O
both	O
aligned	O
and	O
misaligned	O
composites	O
in	O
a	O
part-based	O
fashion	O
,	O
or	O
both	O
in	O
a	O
holistic	O
fashion	O
.	O


We	O
compared	O
adolescents	B-I
with	I-I
ASDs	I-I
to	I-P
controls	I-I
matched	I-P
on	I-P
sex	I-P
,	I-P
age	I-P
and	I-P
IQ	I-P
on	O
a	O
more	O
complete	O
version	O
of	O
the	O
composite	B-I
paradigm	I-I
.	I-I


The	B-O
results	I-O
indicate	I-O
that	I-O
individuals	I-O
with	I-O
ASDs	I-O
,	I-O
like	I-O
controls	I-O
,	I-O
experience	I-O
interference	I-O
from	I-O
facial	I-O
features	I-O
that	I-O
they	I-O
are	I-O
told	I-O
to	I-O
ignore	I-O
.	I-O


However	B-O
,	I-O
while	I-O
such	I-O
interference	I-O
is	I-O
released	I-O
for	I-O
controls	I-O
if	I-O
parts	I-O
of	I-O
face	I-O
composites	I-O
are	I-O
misaligned	I-O
,	I-O
individuals	I-O
with	I-O
ASDs	I-O
show	I-O
comparable	I-O
interference	I-O
from	I-O
irrelevant	I-O
parts	I-O
regardless	I-O
of	I-O
alignment	I-O
.	I-O


Two	B-O
different	I-O
interpretations	I-O
are	I-O
discussed	I-O
,	I-O
both	I-O
compatible	I-O
with	I-O
the	I-O
idea	I-O
that	I-O
perceptual	I-O
and	I-O
or	I-O
attentional	I-O
abnormalities	I-O
in	I-O
ASDs	I-O
result	I-O
in	I-O
a	I-O
diminished	I-O
level	I-O
of	I-O
expertise	I-O
for	I-O
faces	I-O
.	I-O


Effects	O
of	O
a	O
long-term	O
vitamin	B-I
D	I-I
and	O
calcium	B-I
supplementation	I-I
on	O
falls	B-O
and	I-O
parameters	I-O
of	I-O
muscle	I-O
function	I-O
in	O
community-dwelling	B-P
older	I-P
individuals	I-P
.	I-P


UNLABELLED	O
In	O
242	B-P
community-dwelling	I-P
seniors	I-P
,	O
supplementation	O
with	O
either	O
1000	O
mg	O
of	O
calcium	B-I
or	O
1000	O
mg	O
of	O
calcium	B-I
plus	I-I
vitamin	I-I
D	I-I
resulted	O
in	O
a	O
decrease	O
in	O
the	O
number	O
of	O
subjects	O
with	O
first	O
falls	O
of	O
27	O
%	O
at	O
month	O
12	O
and	O
39	O
%	O
at	O
month	O
20	O
.	O


Additionally	O
,	O
parameters	O
of	O
muscle	B-O
function	I-O
improved	O
significantly	O
.	O


INTRODUCTION	O
The	O
efficacy	O
of	O
vitamin	B-I
D	I-I
and	O
calcium	B-I
supplementation	O
on	O
risk	B-O
of	I-O
falling	I-O
in	O
the	O
elderly	O
is	O
discussed	O
controversially	O
.	O


Randomized	O
controlled	O
trials	O
using	O
falls	O
as	O
primary	O
outcome	O
are	O
needed	O
.	O


We	O
investigated	O
long-term	O
effects	O
of	O
calcium	B-I
and	O
vitamin	B-I
D	I-I
on	O
falls	B-O
and	I-O
parameters	I-O
of	I-O
muscle	I-O
function	I-O
in	O
community-dwelling	B-P
elderly	I-P
women	I-P
and	I-P
men	I-P
.	I-P


METHODS	O
Our	O
study	O
population	O
consisted	O
of	O
242	B-P
individuals	I-P
recruited	I-P
by	I-P
advertisements	I-P
and	I-P
mailing	I-P
lists	I-P
(	I-P
mean	I-P
[	I-P
+/-	I-P
SD	I-P
]	I-P
age	I-P
,	I-P
77	I-P
+/-	I-P
4	I-P
years	I-P
)	I-P
.	I-P


All	B-P
serum	I-P
25-hydroxyvitamin	I-P
D	I-P
(	I-P
25	I-P
[	I-P
OH	I-P
]	I-P
D	I-P
)	I-P
levels	I-P
were	I-P
below	I-P
78	I-P
nmol/l	I-P
.	I-P


Individuals	O
received	O
in	O
a	O
double	O
blinded	O
fashion	O
either	O
1000	O
mg	O
of	O
calcium	B-I
or	O
1000	O
mg	O
of	O
calcium	B-I
plus	O
800	O
IU	O
of	O
vitamin	B-I
D	I-I
per	O
day	O
over	O
a	O
treatment	O
period	O
of	O
12	O
months	O
,	O
which	O
was	O
followed	O
by	O
a	O
treatment-free	O
but	O
still	O
blinded	O
observation	O
period	O
of	O
8	O
months	O
.	O


Falls	B-O
were	O
documented	O
using	O
diaries	O
.	O


The	B-P
study	I-P
took	I-P
place	I-P
in	I-P
Bad	I-P
Pyrmont	I-P
,	I-P
Germany	I-P
(	I-P
latitude	I-P
52	I-P
degrees	I-P
)	I-P
and	I-P
Graz	I-P
,	I-P
Austria	I-P
(	I-P
latitude	I-P
46	I-P
degrees	I-P
)	I-P
.	I-P


RESULTS	O
Compared	O
to	O
calcium	O
mono	O
,	O
supplementation	O
with	O
calcium	O
plus	O
vitamin	B-I
D	I-I
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
number	O
of	O
subjects	B-O
with	I-O
first	I-O
falls	I-O
of	O
27	O
%	O
at	O
month	O
12	O
(	O
RR	O
=	O
0.73	O
;	O
CI	O
=	O
0.54-0.96	O
)	O
and	O
39	O
%	O
at	O
month	O
20	O
(	O
RR	O
=	O
0.61	O
;	O
CI	O
=	O
0.34-0.76	O
)	O
.	O


Concerning	O
secondary	O
endpoints	O
,	O
we	O
observed	O
significant	O
improvements	B-O
in	I-O
quadriceps	I-O
strength	I-O
of	O
8	O
%	O
,	O
a	O
decrease	O
in	O
body	B-O
sway	I-O
of	O
28	O
%	O
,	O
and	O
a	O
decrease	O
in	O
time	B-O
needed	I-O
to	I-O
perform	I-O
the	I-O
TUG	I-O
test	I-O
of	O
11	O
%	O
.	O


DISCUSSION	O
Combined	O
calcium	B-I
and	O
vitamin	B-I
D	I-I
supplementation	O
proved	O
superior	O
to	O
calcium	O
alone	O
in	O
reducing	O
the	O
number	B-O
of	I-O
falls	I-O
and	O
improving	O
muscle	B-O
function	I-O
in	O
community-dwelling	B-P
older	I-P
individuals	I-P
.	I-P


Long-term	O
follow-up	O
of	O
three	O
randomized	O
trials	O
comparing	O
idarubicin	B-I
and	I-I
daunorubicin	I-I
as	O
induction	O
therapies	O
for	O
patients	B-P
with	I-P
untreated	I-P
acute	I-P
myeloid	I-P
leukemia	I-P
.	I-P


BACKGROUND	O
Most	O
clinical	O
trials	O
for	O
acute	O
leukemia	O
have	O
reported	O
results	O
after	O
2-3	O
years	O
of	O
follow-up	O
.	O


Comparisons	O
between	O
the	O
original	O
data	O
and	O
longer-term	O
follow-up	O
data	O
may	O
be	O
of	O
interest	O
,	O
particularly	O
with	O
regard	O
to	O
promising	O
new	O
therapies	O
.	O


METHODS	O
In	B-P
1996	I-P
,	I-P
survival	I-P
data	I-P
were	I-P
updated	I-P
from	I-P
three	I-P
prospective	I-P
,	I-P
randomized	I-P
comparisons	I-P
of	I-P
idarubicin	I-I
and	I-I
daunorubicin	I-I
that	I-P
began	I-P
in	I-P
1984	I-P
and	I-P
1985	I-P
.	I-P


These	B-P
were	I-P
trials	I-P
of	I-P
the	I-P
Memorial	I-P
Sloan-Kettering	I-P
Cancer	I-P
Center	I-P
(	I-P
MSKCC	I-P
)	I-P
,	I-P
the	I-P
U.S.	I-P
Multicenter	I-P
Study	I-P
Group	I-P
,	I-P
and	I-P
the	I-P
Southeastern	I-P
Cancer	I-P
Study	I-P
Group	I-P
(	I-P
SEG	I-P
)	I-P
.	I-P


The	O
original	O
results	O
of	O
these	O
trials	O
were	O
reported	O
in	O
1991	O
and	O
1992	O
.	O


RESULTS	O
The	O
original	O
results	O
of	O
the	O
SEG	O
trial	O
demonstrated	O
no	O
significant	B-O
difference	I-O
between	I-O
idarubicin	I-O
and	I-O
daunorubicin	I-O
.	I-O


The	O
updated	O
survival	B-O
analysis	I-O
showed	O
similar	O
results	O
.	O


The	O
MSKCC	O
trial	O
revealed	O
a	O
significant	O
advantage	B-O
of	I-O
idarubicin	I-O
compared	O
with	O
daunorubicin	O
in	O
both	O
the	O
original	O
and	O
the	O
updated	O
analyses	O
.	O


The	O
U.S.	O
Multicenter	O
trial	O
found	O
a	O
significant	O
difference	O
favoring	O
idarubicin	O
in	O
the	O
original	O
analysis	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
in	O
the	O
updated	O
analysis	O
.	O


CONCLUSIONS	O
It	O
is	O
essential	O
that	O
the	O
median	O
length	O
of	O
follow-up	O
be	O
clearly	O
stated	O
in	O
any	O
clinical	O
trial	O
.	O


When	O
the	O
results	O
obtained	O
with	O
a	O
particularly	O
promising	O
new	O
drug	O
or	O
procedure	O
are	O
presented	O
early	O
in	O
the	O
course	O
of	O
study	O
(	O
within	O
1-2	O
years	O
)	O
,	O
the	O
investigators	O
should	O
strongly	O
consider	O
a	O
repeat	O
evaluation	O
after	O
an	O
additional	O
3-5	O
years	O
of	O
follow-up	O
.	O


Minocycline	B-I
safety	I-O
and	I-O
tolerability	I-O
in	O
Huntington	B-P
disease	I-P
.	I-P


Minocycline	B-I
is	O
an	O
antibiotic	O
with	O
anti-inflammatory	O
and	O
antiapoptotic	O
properties	O
that	O
prolongs	O
survival	O
in	O
a	O
transgenic	O
Huntington	B-P
disease	I-P
(	I-P
HD	I-P
)	I-P
mouse	O
model	O
.	O


In	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	B-I
study	O
of	O
minocycline	B-I
in	O
60	B-P
HD	I-P
patients	I-P
,	O
the	O
authors	O
determined	O
that	O
over	O
8	O
weeks	O
,	O
minocycline	B-I
at	I-I
100	I-I
and	I-I
200	I-I
mg/day	I-I
was	O
well	B-O
tolerated	I-O
and	I-O
safe	I-O
in	O
HD	B-P
patients	I-P
.	I-P


Tolerability	B-O
and	I-O
adverse	I-O
event	I-O
frequency	I-O
were	O
similar	O
between	O
treatment	O
and	O
placebo	O
groups	O
.	O


A	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
of	O
the	O
efficacy	O
of	O
transdermal	B-I
clonidine	I-I
in	O
autism	B-P
.	I-P


BACKGROUND	O
Autistic	B-P
individuals	I-P
often	I-P
exhibit	I-P
hyperarousal	I-P
behaviors	I-P
(	I-P
e.g.	I-P
,	O
stereotyped	B-P
body	I-P
movements	I-P
,	I-P
self-stimulation	I-P
,	I-P
hypervigilance	I-P
,	I-P
and	I-P
hyperactivity	I-P
)	I-P
.	O


Clonidine	B-I
,	O
an	O
alpha	O
2-adrenergic	O
receptor	O
agonist	O
,	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
reducing	O
impulsivity	O
,	O
inattention	O
,	O
and	O
hyperactivity	O
associated	O
with	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
.	O


This	O
study	O
investigated	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
transdermal	O
clonidine	B-I
in	O
reducing	O
hyperarousal	B-P
behaviors	I-P
associated	I-P
with	I-P
autism	I-P
.	I-P


METHOD	O
A	O
double-blind	O
,	O
placebo-crossover	B-I
study	O
with	O
transdermal	O
clonidine	B-I
was	O
performed	O
in	O
nine	B-P
autistic	I-P
males	I-P
(	I-P
aged	I-P
5	I-P
to	I-P
33	I-P
years	I-P
)	I-P
.	I-P


Subjects	O
received	O
either	O
clonidine	B-I
(	O
approximately	O
0.005	O
mg/kg/day	O
)	O
or	O
placebo	B-I
by	O
a	O
weekly	O
transdermal	O
patch	O
.	O


Each	O
trial	O
lasted	O
4	O
weeks	O
with	O
a	O
2-week	O
washout	O
period	O
between	O
treatment	O
phases	O
.	O


Subjects	O
were	O
evaluated	O
every	O
2	O
weeks	O
by	O
clinician	O
raters	O
and	O
weekly	O
by	O
parents	O
.	O


RESULTS	O
The	O
clonidine	B-I
treatment	O
showed	O
a	O
significant	O
difference	O
from	O
placebo	B-I
treatment	O
on	O
three	O
subscales	O
of	O
the	O
Ritvo-Freeman	B-O
Real	I-O
Life	I-O
Rating	I-O
Scale	I-O
(	I-O
i.e.	I-O
,	O
social	B-O
relationship	I-O
to	I-O
people	I-O
,	I-O
affectual	I-O
responses	I-O
,	I-O
and	I-O
sensory	I-O
responses	I-O
)	I-O
.	I-O


The	O
Clinical	B-O
Global	I-O
Impressions	I-O
scale	I-O
indicated	O
that	O
clonidine	B-I
produced	O
a	O
significant	O
improvement	O
on	O
severity	B-O
of	I-O
illness	I-O
,	I-O
global	I-O
improvement	I-O
,	I-O
and	I-O
efficacy	I-O
index	I-O
for	O
therapeutic	O
effect	O
of	O
the	O
drug	O
.	O


A	O
patient	B-O
global	I-O
rating	I-O
scale	I-O
showed	O
clonidine	B-I
treatment	O
resulted	O
in	O
significant	O
improvement	O
in	O
comparison	O
with	O
placebo	B-I
.	I-I


Adverse	B-O
effects	I-O
included	I-O
sedation	I-O
and	I-O
fatigue	I-O
during	O
the	O
first	O
2	O
weeks	O
of	O
clonidine	B-I
treatment	O
.	O


CONCLUSION	O
Results	O
from	O
this	O
preliminary	O
study	O
show	O
that	O
clonidine	B-I
was	O
effective	O
in	O
reducing	O
several	B-O
hyperarousal	I-O
behaviors	I-O
and	O
improved	O
social	B-O
relationships	I-O
in	O
some	B-P
autistic	I-P
subjects	I-P
.	I-P


Further	O
studies	O
are	O
needed	O
in	O
a	O
larger	B-P
autistic	I-P
population	I-P
to	O
determine	O
the	O
dose-response	O
relationship	O
of	O
clonidine	B-I
.	I-I


Vitamin	B-I
D	I-I
supplementation	I-I
ameliorates	O
hypoinsulinemia	B-O
and	I-O
hyperglycemia	I-O
in	O
static	B-P
magnetic	I-P
field-exposed	I-P
rat	I-P
.	I-P


The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effects	O
of	O
vitamin	B-I
D	I-I
supplementation	I-I
on	O
glucose	B-O
and	I-O
lipid	I-O
metabolism	I-O
in	O
static	B-P
magnetic	I-P
field	I-P
(	I-P
SMF	I-P
)	I-P
-exposed	I-P
rats	I-P
.	I-P


Rats	B-P
exposed	O
to	O
SMF	O
(	O
128	O
mT	O
;	O
1	O
h/day	O
)	O
during	O
5	O
consecutive	O
days	O
showed	O
an	O
increase	O
in	O
plasma	B-O
glucose	I-O
level	I-O
and	I-O
a	I-O
decrease	I-O
in	I-O
plasma	I-O
insulin	I-O
concentration	I-O
.	I-O


By	O
contrast	O
,	O
the	O
same	O
treatment	O
failed	O
to	O
alter	O
body	B-O
weight	I-O
and	I-O
plasmatic	I-O
total	I-O
cholesterol	I-O
,	I-O
high-density	I-O
lipoprotein	I-O
(	I-O
HDL	I-O
)	I-O
-cholesterol	I-O
,	I-O
low-density	I-O
lipoprotein	I-O
(	I-O
LDL	I-O
)	I-O
-cholesterol	I-O
,	I-O
and	I-O
triglyceride	I-O
levels	I-O
.	I-O


Interestingly	O
,	O
supplementation	O
with	O
vitamin	B-I
D	I-I
(	O
1,600	O
IU/100	O
g	O
,	O
per	O
os	O
)	O
corrected	O
and	O
restored	O
glycemia	B-O
and	I-O
insulinemia	I-O
in	O
SMF-exposed	B-P
rats	I-P
.	I-P


The	O
same	O
treatment	O
had	O
no	O
effects	O
on	O
lipid	B-O
metabolism	I-O
.	I-O


[	O
Comparison	O
of	O
three	O
analgesic	O
methods	O
for	O
postoperative	B-P
pain	I-P
relief	O
and	O
their	O
effects	O
on	O
plasma	B-O
interleukin-6	I-O
concentration	I-O
following	O
radical	B-P
surgery	I-P
for	I-P
gastric	I-P
carcinoma	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
preemptive	B-I
epidural	I-I
analgesia	I-I
combined	I-I
with	I-I
postoperative	I-I
epidural	I-I
analgesia	I-I
,	I-I
postoperative	I-I
epidural	I-I
analgesia	I-I
alone	I-I
and	O
intravenous	B-I
analgesia	I-I
for	O
postoperative	B-O
pain	I-O
relief	I-O
and	O
their	O
effects	O
on	O
plasma	B-O
interleukin-6	I-O
(	I-O
IL-6	I-O
)	I-O
concentration	I-O
following	O
radical	B-P
surgery	I-P
for	I-P
gastric	I-P
carcinoma	I-P
.	I-P


METHODS	O
Sixty-six	B-P
patients	I-P
with	I-P
gastric	I-P
carcinoma	I-P
scheduled	I-P
for	I-P
gastrectomy	I-P
were	O
randomly	O
divided	O
into	O
3	O
groups	O
,	O
namely	O
group	O
P	O
(	O
n=22	O
)	O
,	O
group	O
E	O
(	O
n=22	O
)	O
and	O
group	O
V	O
(	O
n=22	O
)	O
,	O
to	O
receive	O
preemptive	B-I
epidural	I-I
analgesia	I-I
combined	I-I
with	I-I
postoperative	I-I
epidural	I-I
analgesia	I-I
,	I-I
exclusive	I-I
postoperative	I-I
epidural	I-I
analgesia	I-I
,	I-I
and	I-I
exclusive	I-I
postoperative	I-I
intravenous	I-I
analgesia	I-I
,	O
respectively	O
.	O


Hemodynamic	B-O
data	I-O
were	O
recorded	O
for	O
all	O
the	O
patients	O
during	O
the	O
operation	O
,	O
and	O
visual	B-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
was	O
used	O
to	O
assess	O
the	O
pain	B-O
intensity	I-O
at	O
4	O
,	O
8	O
,	O
16	O
,	O
24	O
,	O
48	O
and	O
72	O
h	O
after	O
surgery	O
.	O


Plasma	B-O
IL-6	I-O
concentration	I-O
was	O
determined	O
before	O
surgery	O
and	O
at	O
24	O
,	O
48	O
,	O
72	O
h	O
after	O
surgery	O
.	O


RESULTS	O
No	O
significant	O
changes	O
occurred	O
in	O
the	O
hemodynamics	O
during	O
the	O
preoperative	O
periods	O
.	O


VAS	B-O
and	I-O
IL-6	I-O
were	O
lower	O
in	O
group	O
P	O
than	O
in	O
group	O
E	O
and	O
V	O
,	O
and	O
group	O
E	O
had	O
lower	O
measurement	O
than	O
group	O
V	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
Preemptive	O
epidural	O
analgesia	O
combined	O
with	O
postoperative	O
epidural	O
analgesia	O
provides	O
more	O
satisfactory	O
pain	B-O
relief	I-O
and	O
more	O
effectively	O
prevents	O
IL-6	B-O
increment	I-O
than	O
exclusive	O
epidural	O
analgesia	O
or	O
intravenous	O
analgesia	O
after	B-P
gastrectomy	I-P
for	I-P
gastric	I-P
carcinoma	I-P
.	I-P


Actions	O
of	O
platelet	B-I
activating	I-I
factor	I-I
(	I-I
PAF	I-I
)	I-I
homologues	I-I
and	O
their	O
combinations	O
on	O
neutrophil	B-P
chemokinesis	I-P
and	I-P
cutaneous	I-P
inflammatory	I-P
responses	I-P
in	I-P
man	I-P
.	I-P


The	O
inflammatory	O
actions	O
of	O
synthetic	B-I
C16:0	I-I
and	I-I
C18:0	I-I
platelet	I-I
activating	I-I
factor	I-I
(	I-I
PAF	I-I
)	I-I
homologues	I-I
,	O
both	O
alone	O
and	O
in	O
combination	O
,	O
have	O
been	O
compared	O
in	O
an	O
in	B-P
vitro	I-P
human	I-P
neutrophil	I-P
chemokinesis	I-P
assay	I-P
and	I-P
by	I-P
intradermal	I-P
injection	I-P
in	I-P
human	I-P
skin	I-P
.	I-P


In	O
the	O
chemokinesis	O
assay	O
,	O
the	O
maximum	B-O
distance	I-O
moved	I-O
by	I-O
neutrophils	I-O
in	O
the	O
presence	O
of	O
C18:0	B-I
PAF	I-I
was	O
significantly	O
greater	O
than	O
that	O
seen	O
with	O
the	O
C16:0	B-I
compound	I-I
.	I-I


A	O
mixture	O
of	O
C16:0	B-I
and	O
C18:0	B-I
PAFs	I-I
in	O
a	O
ratio	O
of	O
1:9	O
appeared	O
to	O
be	O
more	O
active	O
than	O
in	O
a	O
ratio	O
of	O
3:1	O
.	O


Intradermal	O
injection	O
of	O
the	O
C16:0	B-I
and	I-I
C18:0	I-I
PAF	I-I
homologues	I-I
induced	O
dose-dependent	O
increases	O
in	O
weal	B-O
volume	I-O
and	I-O
flare	I-O
area	I-O
responses	I-O
which	O
were	O
not	O
significantly	O
different	O
.	O


Combination	O
of	O
these	O
phospholipids	O
in	O
a	O
ratio	O
of	O
3:1	O
or	O
1:9	O
of	O
C16:0	O
:	O
C18:0	O
did	O
not	O
significantly	O
alter	O
the	O
dose	O
response	O
curves	O
.	O


Thus	O
,	O
changes	O
in	O
the	O
chain	O
length	O
of	O
the	O
alkyl	O
substituent	O
of	O
synthetic	O
PAF	B-I
homologues	I-I
and	O
combination	O
of	O
these	O
homologues	O
,	O
in	O
ratios	O
found	O
in	O
vivo	O
or	O
formed	O
by	O
leukocytes	B-P
in	I-P
vitro	I-P
,	O
did	O
not	O
alter	O
the	O
cutaneous	B-P
inflammatory	I-O
responses	I-O
to	I-O
PAF	I-O
in	I-P
man	I-P
.	I-P


The	O
C18:0	B-I
homologue	I-I
was	O
,	O
however	O
,	O
more	O
active	O
as	O
a	O
human	O
neutrophil	O
chemoattractant	O
in	O
vitro	O
.	O


A	O
randomised	O
trial	O
comparing	O
preoperative	B-I
to	I-I
perioperative	I-I
chemotherapy	I-I
in	O
early-stage	B-P
non-small-cell	I-P
lung	I-P
cancer	I-P
(	I-P
IFCT	I-P
0002	I-P
trial	I-P
)	I-P
.	I-P


HYPOTHESIS	O
There	O
will	O
be	O
a	O
detectable	O
increase	O
in	O
overall	B-O
survival	I-O
(	I-O
OS	I-O
)	I-O
using	O
preoperative	B-I
(	I-I
PRE	I-I
)	I-I
as	I-I
opposed	I-I
to	I-I
perioperative	I-I
(	I-I
PERI	I-I
)	I-I
chemotherapy	I-I
in	O
resectable	B-P
StageI-II	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
.	I-P


METHODS	O
This	O
multicenter	O
,	O
open-label	O
,	O
randomised	O
trial	O
with	O
a	O
2×2	O
factorial	O
design	O
first	O
compared	O
two	O
chemotherapy	O
strategies	O
(	O
PRE	O
versus	O
PERI	O
)	O
,	O
then	O
two	B-I
chemotherapy	I-I
regimens	I-I
(	I-I
gemcitabine-cisplatin	I-I
[	I-I
GP	I-I
]	I-I
versus	I-I
paclitaxel-carboplatin	I-I
[	I-I
TC	I-I
]	I-I
)	I-I
.	O


The	B-I
PRE	I-I
group	O
received	O
two	O
preoperative	O
cycles	O
followed	O
by	O
two	O
additional	O
preoperative	O
cycles	O
,	O
while	O
the	B-I
PERI	I-I
group	O
underwent	O
two	O
preoperative	O
cycles	O
followed	O
by	O
two	O
postoperative	O
cycles	O
,	O
the	O
3rd	O
and	O
4th	O
cycles	O
being	O
given	O
only	O
to	O
responders	O
in	O
both	O
cases	O
.	O


RESULTS	B-P
A	I-P
total	I-P
of	I-P
528	I-P
patients	I-P
were	O
randomised	O
,	O
267	O
of	O
which	O
were	O
assigned	O
to	O
the	O
PRE	O
group	O
and	O
261	O
to	O
the	O
PERI	O
group	O
.	O


Three-year	B-O
OS	I-O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
(	O
67.4	O
%	O
and	O
67.7	O
%	O
,	O
respectively	O
;	O
hazard	O
ratio	O
(	O
HR	O
)	O
=1.01	O
[	O
0.79-1.30	O
]	O
,	O
p=0.92	O
)	O
,	O
nor	O
did	B-O
3-year	I-O
disease-free	I-O
survival	I-O
,	I-O
response	I-O
rates	I-O
,	I-O
toxicity	I-O
,	I-O
or	I-O
postoperative	I-O
mortality	I-O
.	I-O


Pathological	B-O
complete	I-O
response	I-O
was	O
observed	O
in	O
22	O
(	O
8.2	O
%	O
)	O
and	O
16	O
patients	O
(	O
6.1	O
%	O
)	O
,	O
respectively	O
.	O


Although	B-O
quality	I-O
of	I-O
life	I-O
did	O
not	O
differ	O
significantly	O
,	O
chemotherapy	B-O
compliance	I-O
was	O
significantly	O
higher	O
in	O
the	O
PRE	O
group	O
.	O


The	O
proportion	O
of	O
responders	O
who	O
received	O
Cycles	O
3	O
and	O
4	O
was	O
significantly	O
higher	O
in	O
the	O
PRE	O
group	O
(	O
90.4	O
%	O
versus	O
75.2	O
%	O
,	O
p=0.001	O
)	O
.	O


In	O
responders	O
,	O
the	O
dose	O
intensity	O
of	O
Cycles	O
3	O
and	O
4	O
was	O
higher	O
in	O
the	O
PRE	O
group	O
than	O
in	O
the	O
PERI	O
group	O
(	O
mean	O
relative	O
dose	O
intensity	O
of	O
90.4	O
%	O
versus	O
82.6	O
%	O
,	O
respectively	O
;	O
p=0.0007	O
)	O
.	O


There	O
was	O
no	O
difference	O
between	B-O
GP	I-O
and	I-O
TC	I-O
in	O
3-year	B-O
OS	I-O
(	O
HR=0.97	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.76-1.25	O
]	O
,	O
p=0.80	O
)	O
or	B-O
response	I-O
rates	I-O
.	O


However	O
,	O
the	O
regimens	B-O
'	I-O
toxicity	I-O
profiles	O
differed	O
.	O


CONCLUSIONS	O
This	O
study	O
failed	O
to	O
demonstrate	O
any	O
difference	O
in	B-O
survival	I-O
between	O
patients	O
receiving	B-I
preoperative	I-I
and	I-I
perioperative	I-I
chemotherapy	I-I
in	I-P
early-stage	I-P
NSCLC	I-P
.	O


The	O
increase	O
from	O
two	O
to	O
four	O
preoperative	O
chemotherapy	O
cycles	O
did	O
not	O
increase	O
the	B-O
pathological	I-O
response	I-O
rate	O
.	O


[	O
Clinical	O
observation	O
on	O
acupuncture	B-I
for	O
treatment	O
of	O
male	B-P
osteoporosis	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
compare	O
the	O
therapeutic	O
effects	O
of	O
acupuncture	B-I
combined	O
with	O
drug	O
and	O
simple	O
drug	O
for	O
treatment	O
of	O
male	B-P
osteoporosis	I-P
.	I-P


METHODS	O
Fifty-five	B-P
cases	I-P
were	O
divided	O
into	O
an	O
observation	O
group	O
(	O
25	O
cases	O
)	O
and	O
a	O
control	O
group	O
(	O
30	O
cases	O
)	O
randomly	O
.	O


The	O
observation	O
group	O
was	O
treated	O
with	O
acupuncture	B-I
and	I-I
moxibustion	I-I
at	I-I
Pishu	I-I
(	O
BL	O
20	O
)	O
,	O
Shenshu	B-I
(	O
BL	O
23	O
)	O
,	O
Mingmen	B-I
(	O
GV	O
4	O
)	O
,	O
Shenque	B-I
(	O
CV	O
8	O
)	O
and	O
so	O
on	O
combined	O
with	O
taking	O
Alendronate	B-I
,	O
while	O
the	O
control	O
group	O
was	O
treated	O
with	O
taking	O
Alendronate	B-I
simply	I-I
.	I-I


The	O
improvement	O
of	O
both	O
Integral	B-O
of	I-O
Clinical	I-O
Symptoms	I-O
(	I-O
ICS	I-O
)	I-O
and	O
Bone	B-O
Mineral	I-O
Density	I-O
(	I-O
BMD	I-O
)	I-O
of	O
two	O
groups	O
was	O
observed	O
after	O
6	O
months	O
treatment	O
.	O


RESULTS	O
The	O
ICS	O
of	O
two	O
groups	O
after	O
treatment	O
both	O
decreased	O
significantly	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
the	O
decreasing	O
degree	O
in	O
observation	O
group	O
was	O
more	O
significant	O
than	O
that	O
in	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O


The	O
BMD	B-O
of	I-O
lumbar	I-O
vertebrae	I-O
and	O
femur	B-O
in	O
observation	O
group	O
increased	O
obviously	O
than	O
that	O
before	O
treatment	O
(	O
P	O
<	O
0.01	O
,	O
P	O
<	O
0.05	O
)	O
.	O


The	O
increasing	O
degree	O
of	O
BMD	B-O
of	I-O
lumbar	I-O
vertebrae	I-O
in	O
observation	O
group	O
after	O
treatment	O
was	O
more	O
obvious	O
than	O
that	O
in	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


There	O
were	O
abdominal	B-O
pain	I-O
,	I-O
diarrhea	I-O
,	I-O
nausea	I-O
,	I-O
vomiting	I-O
,	I-O
dyspepsia	I-O
and	I-O
other	I-O
adverse	I-O
reaction	I-O
in	O
control	O
group	O
,	O
while	O
the	O
degree	B-O
and	I-O
occurrence	I-O
rate	I-O
of	O
those	O
in	O
observation	O
group	O
alleviated	O
and	O
decreased	O
obviously	O
.	O


CONCLUSION	O
The	O
effect	O
of	O
acupuncture	B-I
combined	O
with	O
drug	O
for	O
treatment	O
of	O
male	B-P
osteoporosis	I-P
is	O
good	O
with	O
little	O
adverse	O
reaction	O
.	O


This	O
method	O
is	O
better	O
than	O
taking	O
Alendronate	O
.	O


Effects	O
of	O
fenoterol	B-I
on	O
inspiratory	O
effort	O
sensation	O
and	O
fatigue	O
during	O
inspiratory	O
threshold	O
loading	O
.	O


We	O
studied	O
the	O
effects	O
of	O
a	O
single	O
dose	O
of	O
fenoterol	B-I
on	O
the	O
relationship	O
between	O
inspiratory	O
effort	O
sensation	O
(	O
IES	O
)	O
and	O
inspiratory	O
muscle	O
fatigue	O
induced	O
by	O
inspiratory	O
threshold	O
loading	O
in	O
healthy	B-P
subjects	I-P
.	I-P


The	O
magnitude	O
of	O
the	O
threshold	O
was	O
60	O
%	O
of	O
maximal	O
static	O
inspiratory	O
mouth	O
pressure	O
(	O
PI	O
,	O
mmax	O
)	O
at	O
functional	O
residual	O
capacity	O
,	O
and	O
the	O
duty	O
cycle	O
was	O
0.5	O
.	O


Subjects	B-P
continued	O
the	O
threshold	O
loaded	O
breathing	O
until	O
the	O
target	O
mouth	O
pressure	O
could	O
no	O
longer	O
be	O
maintained	O
(	O
endurance	O
time	O
)	O
.	O


The	O
intensity	O
of	O
the	O
IES	O
was	O
scored	O
with	O
a	O
modified	O
Borg	O
scale	O
.	O


Either	O
fenoterol	B-I
(	I-I
5	I-I
mg	I-I
)	I-I
or	I-I
a	I-I
placebo	I-I
was	O
given	O
orally	O
2	O
h	O
before	O
loading	O
in	O
a	O
randomized	O
double-blind	O
crossover	O
protocol	O
.	O


The	O
endurance	B-O
time	I-O
with	O
fenoterol	O
(	O
34.4	O
+/-	O
8.6	O
min	O
)	O
was	O
longer	O
than	O
that	O
with	O
the	O
placebo	O
(	O
22.2	O
+/-	O
7.1	O
min	O
;	O
P	O
<	O
0.05	O
)	O
.	O


The	O
ratio	B-O
of	I-O
high-	I-O
to	I-O
low-frequency	I-O
power	I-O
of	I-O
the	I-O
diaphragmatic	I-O
electromyogram	I-O
(	I-O
EMGdi	I-O
)	I-O
decreased	O
during	O
loading	O
;	O
the	O
decrease	O
was	O
less	O
with	O
fenoterol	B-I
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
EMGdi	B-O
also	O
decreased	O
with	O
loading	O
;	O
the	O
decrease	O
was	O
greater	O
on	O
fenoterol	O
treatment	O
(	O
P	O
<	O
0.01	O
)	O
.	O


The	O
PI	B-O
,	I-O
mmax	I-O
and	I-O
maximal	I-O
transdiaphragmatic	I-O
pressure	I-O
(	I-O
Pdi	I-O
)	I-O
were	O
similarly	O
decreased	O
after	O
loading	O
on	O
either	O
treatment	O
.	O


The	O
intensity	B-O
of	I-O
the	I-O
IES	I-O
rose	I-O
with	I-O
time	I-O
during	O
loading	O
in	O
both	O
groups	O
but	O
was	O
lower	O
with	O
fenoterol	B-I
than	O
with	O
the	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
ratio	B-O
of	I-O
Pdi	I-O
to	O
integrated	O
activity	O
of	O
the	O
EMGdi	O
increased	O
with	O
fenoterol	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Fenoterol	O
treatment	O
increased	O
both	O
superimposed	B-O
Pdi	I-O
twitch	I-O
and	I-O
Pdi	I-O
twitch	I-O
of	I-O
relaxed	I-O
diaphragm	I-O
and	O
decreased	O
the	O
value	B-O
of	I-O
(	I-O
1-superimposed	I-O
Pdi	I-O
twitch/Pdi	I-O
twitch	I-O
of	I-O
relaxed	I-O
diaphragm	I-O
)	I-O
.	I-O


Thus	O
we	O
conclude	O
that	O
in	O
normal	B-P
subjects	I-P
fenoterol	O
reduces	O
diaphragmatic	O
fatigue	O
and	O
decreases	O
the	O
motor	O
command	O
to	O
the	O
diaphragm	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
IES	O
during	O
inspiratory	O
threshold	O
loading	O
and	O
a	O
prolongation	O
of	O
endurance	O
.	O


Relation	O
of	O
improvement	O
in	O
estimated	O
glomerular	O
filtration	O
rate	O
with	O
atorvastatin	B-I
to	O
reductions	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
(	O
from	O
the	O
Treating	B-P
to	I-P
New	I-P
Targets	I-P
[	I-P
TNT	I-P
]	I-P
study	I-P
)	I-P
.	O


Impaired	O
kidney	O
function	O
often	O
accompanies	O
heart	O
failure	O
(	O
HF	O
)	O
and	O
is	O
associated	O
with	O
a	O
worse	O
prognosis	O
.	O


This	O
post	O
hoc	O
analysis	O
of	O
the	O
Treating	B-P
to	I-P
New	I-P
Targets	I-P
(	I-P
TNT	I-P
)	I-P
trial	I-P
examined	O
whether	O
the	O
observed	O
decrease	O
in	O
HF	O
hospitalizations	O
with	O
high-	O
compared	O
to	O
low-dose	O
atorvastatin	B-I
could	O
be	O
related	O
to	O
improvements	O
in	O
kidney	O
function	O
.	O


Of	O
10,001	B-P
TNT	I-P
participants	I-P
,	I-P
9,376	I-P
had	I-P
estimated	I-P
glomerular	I-O
filtration	I-O
rate	I-O
(	I-O
eGFR	I-O
)	I-O
measurements	I-P
at	I-P
baseline	I-P
and	I-P
1	I-P
year	I-P
and	I-P
were	I-P
included	I-P
in	I-P
this	I-P
analysis	I-P
.	I-P


The	O
association	O
of	O
change	O
in	O
year-1	O
eGFR	O
and	O
subsequent	O
HF	O
hospitalization	O
was	O
examined	O
using	O
Cox	O
regression	O
models	O
.	O


In	O
total	O
218	O
participants	O
developed	O
subsequent	O
HF	O
hospitalization	O
.	O


Little	O
change	O
in	O
eGFR	B-O
occurred	O
over	O
1	O
year	O
in	O
the	O
atorvastatin	O
10-mg	O
group	O
,	O
whereas	O
eGFR	B-O
improved	O
in	O
the	O
80-mg	O
group	O
by	O
1.48	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
1.29	O
to	O
1.67	O
,	O
p	O
<	O
0.0001	O
)	O
.	O


Subsequent	O
HF	O
was	O
preceded	O
by	O
a	O
decrease	O
in	O
eGFR	B-O
over	O
1	O
year	O
compared	O
to	O
modest	O
improvement	O
in	O
those	O
without	O
subsequent	O
HF	O
(	O
-0.09	O
±	O
7.89	O
vs	O
0.81	O
±	O
6.90	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
,	O
p	O
=	O
0.0015	O
)	O
.	O


After	O
adjusting	O
for	B-O
baseline	I-O
eGFR	I-O
,	O
each	O
5-ml/min/1.73	O
m	O
(	O
2	O
)	O
increase	O
in	B-O
eGFR	I-O
at	O
1	O
year	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
subsequent	O
HF	O
hospitalization	O
(	O
hazard	O
ratio	O
0.85	O
,	O
95	O
%	O
confidence	O
interval	O
0.77	O
to	O
0.94	O
,	O
p	O
=	O
0.002	O
)	O
.	O


This	O
relation	O
was	O
independent	O
of	O
treatment	O
effect	O
or	O
change	O
in	B-O
low-density	I-O
lipoprotein	I-O
cholesterol	I-O
level	O
at	O
1	O
year	O
.	O


In	O
conclusion	O
,	O
treatment	O
with	O
high-	O
compared	O
to	O
low-dose	O
atorvastatin	O
was	O
associated	O
with	O
improvement	O
in	B-O
eGFR	I-O
at	O
1	O
year	O
,	O
which	O
was	O
related	O
to	O
a	O
decrease	O
in	B-O
subsequent	I-O
HF	I-O
hospitalization	I-O
.	O


This	O
suggests	O
that	O
improvement	O
in	B-O
kidney	I-O
function	I-O
may	O
be	O
related	O
to	O
the	O
beneficial	O
effect	O
of	O
high-dose	O
atorvastatin	O
on	O
HF	O
hospitalization	O
.	O


Accuracy	O
of	O
noninvasive	B-O
haemoglobin	I-O
measurement	I-O
by	O
pulse	B-I
oximetry	I-I
depends	O
on	O
the	O
type	O
of	O
infusion	O
fluid	O
.	O


CONTEXT	O
Measurement	O
of	O
blood	O
haemoglobin	B-O
concentration	O
by	O
pulse	B-I
oximetry	I-I
could	O
be	O
of	O
value	O
in	O
determining	O
when	O
erythrocytes	O
should	O
be	O
transfused	O
during	O
surgery	O
,	O
but	O
the	O
effect	O
of	O
infusion	O
fluids	O
on	O
the	O
results	O
is	O
unclear	O
.	O


OBJECTIVE	O
To	O
study	O
the	O
effect	O
of	O
crystalloid	O
and	O
colloid	O
fluid	O
on	O
the	O
accuracy	O
(	O
bias	O
)	O
and	O
precision	O
of	O
pulse	O
oximetry	O
haemoglobin	B-O
estimation	O
to	O
indicate	O
the	O
venous	O
haemoglobin	O
concentration	O
in	O
volunteers	B-P
.	I-P


DESIGN	O
Open	O
interventional	O
crossover	O
study	O
.	O


SETTING	O
Single	B-P
university	I-P
hospital	I-P
.	I-P


PARTICIPANTS	O
Ten	B-P
male	I-P
volunteers	I-P
aged	I-P
18-28	I-P
(	I-P
mean	I-P
22	I-P
)	I-P
years	I-P
.	I-P


INTERVENTIONS	O
Each	O
volunteer	O
underwent	O
three	O
infusion	B-I
experiments	I-I
on	O
separate	O
days	O
and	O
in	O
random	O
order	O
.	O


The	O
infusions	O
were	O
Ringer	B-I
's	I-I
acetate	I-I
(	I-I
20	I-I
ml	I-I
kg	I-I
)	I-I
,	I-I
hydroxyethyl	I-I
starch	I-I
130/0.4	I-I
(	I-I
10	I-I
ml	I-I
kg	I-I
)	I-I
and	I-I
a	I-I
combination	I-I
of	O
both	O
.	O


RESULTS	O
At	O
the	O
end	O
of	O
the	O
infusions	B-I
of	I-I
Ringer	I-I
's	I-I
acetate	I-O
,	I-O
pulse	I-O
oximetry	I-O
haemoglobin	I-O
concentration	O
had	O
decreased	O
more	O
than	O
the	O
true	O
haemoglobin	O
concentration	O
(	O
15	O
vs.	O
8	O
%	O
;	O
P	O
<	O
0.005	O
;	O
n	O
=	O
10	O
)	O
whereas	O
starch	O
solution	B-O
decreased	I-O
pulse	I-O
oximetry	I-O
haemoglobin	I-O
concentration	O
less	O
than	O
true	O
haemoglobin	O
concentration	O
(	O
7	O
vs.	O
11	O
%	O
;	O
P	O
<	O
0.02	O
;	O
n	O
=	O
20	O
)	O
.	O


The	O
same	O
differences	O
were	O
seen	O
when	O
the	O
fluids	O
were	O
infused	O
separately	O
and	O
when	O
they	O
were	O
combined	O
.	O


The	O
overall	O
difference	O
between	B-O
all	I-O
956	I-O
pairs	I-O
of	I-O
pulse	I-O
oximetry	I-O
haemoglobin	I-O
concentration	I-O
and	I-O
true	I-O
haemoglobin	I-O
concentrations	O
(	O
the	O
bias	O
)	O
averaged	O
only	O
-0.7	O
g	O
l	O
whereas	O
the	O
95	O
%	O
prediction	O
interval	O
was	O
wide	O
,	O
ranging	O
from	O
-24.9	O
to	O
23.7	O
g	O
l.	O
In	O
addition	O
to	O
the	O
choice	O
of	O
infusion	O
fluid	O
,	O
the	O
bias	O
was	O
strongly	O
dependent	O
on	O
the	O
volunteer	O
(	O
each	O
factor	O
,	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSION	O
The	O
bias	O
of	O
measuring	B-I
haemoglobin	I-I
concentration	O
by	O
pulse	O
oximetry	O
is	O
dependent	O
on	O
whether	O
a	O
crystalloid	O
or	O
a	O
colloid	O
fluid	O
is	O
infused	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials	O
identifier	O
:	O
NCT01195025	O
.	O


Improved	O
acidosis	O
correction	O
and	O
recovery	O
of	O
mesothelial	O
cell	O
mass	O
with	O
neutral-pH	B-I
bicarbonate	I-I
dialysis	I-I
solution	I-I
among	O
children	B-P
undergoing	I-P
automated	I-I
peritoneal	I-I
dialysis	I-I
.	I-I


Acid-base	O
balance	O
and	O
peritoneal	O
membrane	O
longevity	O
are	O
of	O
utmost	O
relevance	O
for	O
pediatric	B-P
patients	I-P
undergoing	I-P
peritoneal	I-I
dialysis	I-I
(	I-I
PD	I-I
)	I-I
.	I-I


PD	O
fluids	O
with	O
neutral	O
pH	O
and	O
reduced	O
glucose	O
degradation	O
product	O
contents	O
are	O
considered	O
more	O
biocompatible	O
,	O
because	O
they	O
preserve	O
peritoneal	O
cell	O
functions	O
in	O
vitro	O
.	O


To	O
investigate	O
the	O
clinical	O
effects	B-O
of	O
a	O
novel	B-I
PD	I-I
fluid	I-I
buffered	I-I
with	I-I
34	I-I
mM	I-I
pure	I-I
bicarbonate	I-I
at	I-I
neutral	I-I
pH	I-I
,	O
a	O
randomized	O
,	O
prospective	O
,	O
crossover	O
comparison	O
with	O
conventional	B-I
,	I-I
acidic	I-I
,	I-I
35	I-I
mM	I-I
lactate	I-I
PD	I-I
fluid	I-I
was	O
performed	O
for	O
two	O
consecutive	O
12-wk	O
periods	O
with	O
28	B-P
children	I-P
(	I-P
age	I-P
,	I-P
6	I-P
mo	I-P
to	I-P
15	I-P
yr	I-P
)	I-P
undergoing	I-P
automated	I-I
PD	I-I
(	I-I
APD	I-I
)	I-I
.	I-I


Blood	B-O
bicarbonate	I-O
levels	I-O
and	I-O
arterial	I-O
pH	I-O
were	O
significantly	O
higher	B-O
after	O
3	O
mo	O
of	O
bicarbonate	B-O
PD	I-O
(	O
24.6	O
+/-	O
2.3	O
mM	O
and	O
7.43	O
+/-	O
0.06	O
,	O
respectively	O
)	O
,	O
compared	O
with	O
lactate	B-O
PD	I-O
(	O
22.8	O
+/-	O
3.9	O
mM	O
and	O
7.38	O
+/-	O
0.05	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O


This	O
effect	O
was	O
reversible	O
among	O
patients	O
who	O
returned	O
from	O
bicarbonate	O
to	O
lactate	O
fluid	O
.	O


Low	O
initial	B-O
pH	I-O
and	O
young	O
patient	O
age	O
independently	O
predicted	O
increased	O
blood	B-O
pH	I-O
during	O
bicarbonate	B-O
APD	I-O
.	I-O


Peritoneal	O
equilibration	O
tests	O
revealed	O
subtle	B-O
changes	I-O
in	I-O
solute	I-O
transport	I-O
,	O
with	O
a	O
less	B-O
steep	I-O
creatinine	I-O
equilibration	I-O
curve	I-O
during	O
bicarbonate	O
dialysis	O
,	O
suggesting	O
reduced	O
peritoneal	O
vasodilation	O
.	O


The	O
peritoneal	B-O
release	I-O
of	I-O
carcinogen	I-O
antigen-125	I-O
increased	I-O
twofold	O
during	O
bicarbonate	O
APD	O
(	O
29	O
+/-	O
15	O
versus	O
15	O
+/-	O
8	O
U/ml	O
per	O
4	O
h	O
,	O
P	O
<	O
0.01	O
)	O
,	O
which	O
is	O
consistent	O
with	O
recovery	O
of	O
the	O
mesothelial	O
cell	O
layer	O
.	O


This	O
effect	O
was	O
fully	O
reversed	O
when	O
the	O
patients	O
returned	O
to	O
lactate	O
fluid	O
.	O


Effluent	B-O
carcinogen	I-O
antigen-125	I-O
levels	I-O
were	O
inversely	O
correlated	O
with	O
peritoneal	O
glucose	O
exposure	O
during	O
lactate	O
but	O
not	O
bicarbonate	O
APD	O
,	O
indicating	O
improved	O
in	O
vivo	O
mesothelial	O
cell	O
tolerance	O
of	O
high-dose	O
glucose	O
with	O
the	O
neutral-pH	B-I
PD	I-I
fluid	I-I
with	I-I
reduced	I-I
glucose	I-I
degradation	I-I
product	I-I
content	I-I
.	I-I


Among	O
children	B-P
undergoing	I-P
APD	I-I
,	I-I
neutral-pH	I-I
,	I-I
bicarbonate-buffered	I-I
PD	I-I
fluid	I-I
provides	O
more	O
effective	O
correction	O
of	O
metabolic	O
acidosis	O
and	O
better	O
preservation	O
of	O
peritoneal	O
cell	O
mass	O
than	O
do	O
conventional	B-I
,	I-I
acidic	I-I
,	I-I
lactate-based	I-I
fluids	I-I
.	I-I


Low-dose	B-I
oral	I-I
etoposide-based	I-I
induction	O
regimen	O
for	O
children	B-P
with	I-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
in	I-P
first	I-P
bone	I-P
marrow	I-P
relapse	I-P
.	I-P


We	O
evaluated	O
the	O
clinical	B-O
response	I-O
to	O
low-dose	B-I
etoposide	I-I
in	O
relapsed	B-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
(	I-P
ALL	I-P
)	I-P
.	I-P


Of	O
the	O
45	B-P
patients	I-P
with	I-P
ALL	I-P
in	I-P
first	I-P
bone	I-P
marrow	I-P
relapse	I-P
enrolled	I-P
on	O
the	O
ALL	O
R15	O
protocol	O
,	O
44	O
had	O
received	O
epipodophyllotoxins	B-I
during	I-I
frontline	I-I
therapy	I-I
.	I-I


In	O
the	O
first	O
week	O
of	O
remission	O
induction	O
therapy	O
,	O
patients	B-I
received	I-I
etoposide	I-I
(	I-I
50	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
per	I-I
day	I-I
)	I-I
administered	I-I
orally	I-I
as	I-I
a	I-I
single	I-I
agent	I-I
once	I-I
or	I-I
twice	I-I
daily	I-I
.	I-I


On	O
Day	O
8	O
,	O
patients	O
started	O
to	O
receive	O
dexamethasone	B-I
,	I-I
vincristine	I-I
,	I-I
and	I-I
L-asparaginase	I-I
.	I-I


Etoposide	B-I
was	I-I
administered	I-I
until	I-I
Day	I-I
22	I-I
.	I-I


Two	B-I
courses	I-I
of	I-I
consolidation	I-I
therapy	I-I
were	I-I
followed	I-I
by	I-I
continuation	I-I
therapy	I-I
or	I-I
hematopoietic	I-I
stem	I-I
cell	I-I
transplantation	I-I
.	I-I


After	O
7	O
days	O
of	O
single-agent	O
etoposide	O
treatment	O
,	O
peripheral	B-O
blast	I-O
cell	I-O
counts	I-O
(	O
P=0.013	O
)	O
and	O
percentages	B-O
of	I-O
bone	I-O
marrow	I-O
blasts	I-O
(	O
P=0.016	O
)	O
were	O
significantly	O
reduced	O
.	O


In	O
all	O
,	O
38	O
(	O
84.4	O
%	O
)	O
attained	O
second	B-O
remission	I-O
.	I-O


Only	O
time	B-O
to	I-O
relapse	I-O
was	O
significantly	O
associated	O
with	O
outcome	O
(	O
P=0.025	O
)	O
:	O
the	O
5-year	B-O
event-free	I-O
survival	I-O
estimates	O
(	O
+/-se	O
)	O
were	O
52.0+/-9.6	O
%	O
for	O
those	O
with	O
late	O
relapse	O
and	O
20.0+/-8.0	O
%	O
for	O
those	O
with	O
early	O
relapse	O
.	O


We	O
conclude	O
that	O
low-dose	B-I
etoposide	I-I
administered	O
orally	O
has	O
a	O
cytoreductive	O
effect	O
in	O
relapsed	O
ALL	O
.	O


Nasal	B-I
versus	I-I
oronasal	I-I
continuous	I-I
positive	I-I
airway	I-I
pressure	I-I
masks	I-I
for	O
obstructive	B-P
sleep	I-P
apnea	I-P
:	I-P
a	O
pilot	O
investigation	O
of	O
pressure	O
requirement	O
,	O
residual	O
disease	O
,	O
and	O
leak	O
.	O


PURPOSE	O
This	O
single-blinded	O
,	O
randomized	O
,	O
controlled	O
pilot	O
study	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
difference	O
between	O
nasal	B-I
and	I-I
oronasal	I-I
masks	I-I
in	O
therapeutic	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
requirement	O
,	O
residual	O
disease	O
,	O
or	O
leak	O
when	O
treating	O
obstructive	B-P
sleep	I-P
apnea	I-P
(	I-P
OSA	I-P
)	I-P
and	O
if	O
differences	O
were	O
related	O
to	O
measures	O
of	O
upper	O
airway	O
size	O
.	O


METHODS	O
Patients	B-P
with	I-P
severe	I-P
OSA	I-P
currently	I-P
using	I-P
CPAP	I-P
at	I-P
≥4	I-P
h/night	I-P
with	I-P
a	I-I
nasal	I-I
mask	I-I
were	I-P
examined	I-P
(	I-P
including	I-P
Mallampati	I-P
scale	I-P
,	I-P
incisal	I-P
relationship	I-P
,	I-P
and	I-P
mandibular	I-P
protrusion	I-P
)	I-P
and	O
then	O
randomized	O
to	O
receive	B-I
auto-positive	I-I
airway	I-I
pressure	I-I
(	I-I
PAP	I-I
)	I-I
or	I-I
fixed	I-I
CPAP	I-I
at	I-I
a	I-I
manually	I-I
titrated	I-I
pressure	I-I
for	O
1	O
week	O
each	O
at	O
home	O
,	O
with	O
immediate	O
crossover	O
.	O


Within	O
each	O
week	O
,	O
a	B-I
nasal	I-I
mask	I-I
and	O
two	B-I
oronasal	I-I
masks	I-I
were	O
to	O
be	O
used	O
for	O
two	O
or	O
three	O
nights	O
each	O
in	O
random	O
order	O
.	O


Data	O
were	O
downloaded	O
from	O
the	O
device	O
.	O


RESULTS	B-P
Twelve	I-P
patients	I-P
completed	I-P
the	I-P
trial	I-P
(	I-P
mean	I-P
±	I-P
SD	I-P
AHI	I-P
59.8	I-P
±	I-P
28.6	I-P
events/h	I-P
;	I-P
CPAP	I-P
11.1	I-P
±	I-P
3.2	I-P
cmH	I-P
(	I-P
2	I-P
)	I-P
O	I-P
;	I-P
BMI	I-P
37.7	I-P
±	I-P
5.0	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
)	I-P
.	O


During	O
auto-PAP	B-O
,	I-O
the	I-O
median	I-O
95th	I-O
percentile	I-O
pressure	I-O
delivered	O
with	O
all	O
masks	O
was	O
within	O
0.5	O
cmH	O
(	O
2	O
)	O
O	O
(	O
p	O
>	O
0.05	O
)	O
.	O


During	O
CPAP	B-O
,	I-O
median	I-O
residual	I-O
AHI	O
was	O
0.61	O
(	O
IQR	O
=	O
1.18	O
)	O
for	B-I
the	I-I
nasal	I-I
mask	O
,	O
1.70	O
(	O
IQR	O
=	O
4.04	B-I
)	I-I
for	I-I
oronasal	I-I
mask	O
1	O
,	O
and	O
2.48	O
(	O
IQR	O
=	O
3.74	B-I
)	I-I
for	I-I
oronasal	I-I
mask	O
2	O
(	O
p	O
=	O
0.03	B-O
)	I-O
.	I-O


The	B-O
95th	I-O
percentile	I-O
leak	O
was	O
lowest	O
with	O
the	O
nasal	O
mask	O
during	O
both	O
CPAP	O
and	O
auto-PAP	O
(	O
both	O
p	O
<	O
0.01	O
)	O
.	O


Differences	O
in	O
pressure	O
or	O
residual	O
disease	O
were	O
not	O
related	O
to	O
measures	O
of	O
upper	O
airway	O
shape	O
or	O
body	O
habitus	O
.	O


CONCLUSIONS	O
In	O
obese	O
OSA	O
patients	O
changing	O
from	O
a	O
nasal	B-I
to	I-I
oronasal	I-I
mask	O
increased	B-O
leak	I-O
and	I-O
residual	I-O
AHI	O
but	O
did	O
not	O
affect	O
the	O
therapeutic	O
pressure	O
requirement	O
.	O


The	O
findings	O
of	O
the	O
current	O
study	O
highlight	O
mask	O
leak	O
as	O
the	O
major	O
difficulty	O
in	O
the	O
use	B-I
of	I-I
oronasal	I-I
masks	O
.	O


Effectiveness	B-O
of	O
once-daily	B-I
monotherapy	I-I
with	O
a	O
new	O
nifedipine	O
sustained	O
release	O
calcium	O
antagonist	O
.	O


Data	O
from	O
2	B-P
separate	I-P
multicenter	I-P
,	O
double-blind	O
clinical	O
studies	O
following	O
the	O
same	O
protocol	O
,	O
except	O
for	O
the	O
selection	O
of	O
doses	O
,	O
were	O
pooled	O
to	O
evaluate	O
the	O
efficacy	B-O
and	I-O
tolerability	I-O
of	O
fixed	O
doses	O
of	O
a	O
new	B-I
sustained-release	I-I
(	I-I
SR	I-I
)	I-I
formulation	I-I
of	I-I
nifedipine	I-I
compared	O
with	O
placebo	B-I
in	O
388	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
uncomplicated	I-P
essential	I-P
hypertension	I-P
.	I-P


After	O
a	O
3-6	O
week	O
placebo	O
washout	O
period	O
,	O
the	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-I
or	I-I
nifedipine	I-I
SR-20	O
mg	O
(	O
study	O
I	O
only	O
)	O
,	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
150	O
mg	O
(	O
study	O
II	O
only	O
)	O
.	O


Among	O
the	O
278	O
patients	O
who	O
completed	O
6	O
weeks	O
of	O
active	O
therapy	O
,	O
mean	B-O
supine	I-O
diastolic	I-O
blood	I-O
pressure	I-O
reductions	I-O
from	O
pretreatment	O
baseline	O
were	O
5.9	O
,	O
9.3	O
,	O
9.2	O
,	O
11.1	O
,	O
and	O
13.2	O
mm	O
Hg	O
in	O
the	O
placebo	O
,	O
20-	O
,	O
50-	O
,	O
100-	O
,	O
and	O
150-mg	O
groups	O
,	O
respectively	O
.	O


The	O
reductions	O
achieved	O
in	O
each	O
of	O
the	O
nifedipine	B-I
SR	O
groups	O
were	O
statistically	O
significant	O
versus	O
baseline	O
values	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


All	O
nifedipine-SR	O
doses	O
reduced	B-O
supine	I-O
systolic	I-O
blood	I-O
pressure	I-O
significantly	O
more	O
than	O
placebo	B-I
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
linear	O
relationship	O
between	O
the	O
log	B-O
of	I-O
the	I-O
dose	I-O
and	O
the	O
blood	B-O
pressure	I-O
reduction	I-O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


Automated	B-O
ambulatory	I-O
blood	I-O
pressure	I-O
recordings	I-O
performed	O
in	O
221	O
of	O
the	O
patients	O
showed	O
that	O
the	O
blood	B-O
pressure	I-O
was	I-O
lowered	I-O
evenly	O
through	O
the	O
entire	O
24-hour	O
dosing	O
period	O
.	O


The	O
doses	O
that	O
were	O
effective	O
and	O
associated	O
with	O
the	O
fewest	O
adverse	O
reactions	O
were	O
20	O
mg	O
and	O
50	O
mg	O
once	O
daily	O
.	O


Cross-over	O
trial	O
of	O
intensive	O
monotherapy	O
with	O
atorvastatin	B-I
and	O
combined	O
therapy	O
with	O
atorvastatin	B-I
and	O
colestimide	B-I
for	O
Japanese	B-P
familial	I-P
hypercholesterolemia	I-P
.	I-P


BACKGROUND	O
In	O
familial	B-P
hypercholesterolemia	I-P
(	I-P
FH	I-P
)	I-P
,	O
low-density	B-O
lipoprotein-cholesterol	I-O
(	I-O
LDL-C	I-O
)	I-O
-lowering	I-O
therapy	O
is	O
important	O
to	O
avoid	O
predisposition	O
to	O
coronary	O
artery	O
disease	O
.	O


This	O
study	O
investigated	O
the	O
advantages	O
of	O
combined	O
therapy	O
with	O
atorvastatin	B-I
and	O
colestimide	B-I
vs	O
intensive	O
monotherapy	O
with	O
atorvastatin	B-I
.	I-I


METHODS	O
AND	O
RESULTS	O
The	O
trial	O
used	O
a	O
randomized	O
cross-over	O
design	O
consisting	O
of	O
2	O
16-week	O
periods	O
of	O
open-label	O
drug	O
therapy	O
.	O


Among	O
the	O
24	B-P
initial	I-P
patients	I-P
,	I-P
17	I-P
heterozygous	I-P
FH	I-P
patients	I-P
(	I-P
age	I-P
:	I-P
54.1	I-P
years	I-P
;	I-P
5	I-P
males	I-P
)	I-P
were	O
enrolled	O
after	B-I
20	I-I
mg/day	I-I
atorvastatin	I-I
failed	I-I
to	I-I
achieve	I-I
their	I-I
target	I-I
level	I-I
.	I-I


The	O
patients	O
received	O
20	O
mg/day	O
atorvastatin	B-I
and	O
3	O
g/day	O
colestimide	B-I
or	O
40	O
mg/day	O
atorvastatin	B-I
.	I-I


Fifteen	B-P
patients	I-P
completed	I-P
the	I-P
trial	I-P
and	O
their	O
LDL-C	B-O
reduced	O
from	O
5.07	O
+/-	O
1.10	O
mmol/L	O
to	O
3.76	O
+/-	O
0.90	O
mmol/L	O
with	O
the	O
combined	O
therapy	O
and	O
to	O
3.81	O
+/-	O
0.50	O
mmol/L	O
with	O
the	O
intensive	O
monotherapy	O
.	O


Although	O
the	O
2	O
therapies	O
showed	O
comparable	O
mean	O
effects	O
for	O
decreasing	O
LDL-C	B-O
,	O
similar	O
adverse	O
reaction	O
and	O
cost	O
,	O
each	O
therapy	O
was	O
predominantly	O
more	O
effective	O
in	O
some	O
patients	O
than	O
in	O
others	O
.	O


The	O
triglyceride	B-O
and	I-O
high-density	I-O
lipoprotein	I-O
cholesterol	I-O
levels	I-O
were	O
similar	O
in	O
both	O
therapies	O
.	O


CONCLUSIONS	O
To	O
achieve	O
the	O
therapeutic	O
target	O
of	O
LDL-C	B-O
level	O
for	O
refractory	O
FH	O
,	O
the	O
LDL-C-lowering	O
therapy	O
selected	O
can	O
be	O
either	O
intensive	O
monotherapy	O
or	O
combined	O
therapy	O
as	O
the	O
next	O
to	O
standard	O
statin	O
therapy	O
.	O


Efficacy	B-O
and	I-O
safety	I-O
of	O
mizolastine	B-I
10	O
mg	O
in	O
a	O
placebo-controlled	B-I
comparison	O
with	O
loratadine	B-I
in	O
chronic	B-P
idiopathic	I-P
urticaria	I-P
:	I-P
results	O
of	O
the	O
MILOR	O
Study	O
.	O


BACKGROUND	O
Mizolastine	B-I
is	O
a	O
novel	O
histamine	O
H1-antagonist	O
registered	O
in	O
Europe	O
for	O
the	O
management	O
of	O
allergic	O
rhinitis	O
and	O
urticaria	O
.	O


OBJECTIVES	O
To	O
compare	O
the	O
clinical	O
efficacy	B-O
and	I-O
safety	I-O
of	O
mizolastine	B-I
with	I-I
loratadine	I-I
and	I-I
placebo	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
idiopathic	I-P
urticaria	I-P
(	I-P
CIU	I-P
)	I-P
.	I-P


METHODS	O
A	O
multicentre	O
,	O
double-blind	O
,	O
parallel	O
group	O
study	O
was	O
designed	O
in	O
which	O
247	B-P
patients	I-P
with	I-P
CIU	I-P
were	O
randomised	O
after	O
a	O
1-week	O
placebo	B-I
run-in	O
period	O
to	O
10	O
mg	O
daily	O
mizolastine	B-I
(	O
n	O
=	O
88	O
)	O
,	O
10	O
mg	O
daily	O
loratadine	B-I
(	O
n	O
=	O
79	O
)	O
,	O
or	O
placebo	B-I
(	O
n	O
=	O
80	O
)	O
for	O
a	O
4-week	O
treatment	O
period	O
.	O


RESULTS	O
Mizolastine	B-I
and	O
loratadine	B-I
both	O
relieved	B-O
symptoms	I-O
of	I-O
CIU	I-O
.	I-O


After	O
2	O
weeks	O
'	O
treatment	O
,	O
the	O
severity	B-O
of	I-O
pruritus	I-O
(	I-O
visual	I-O
analogue	I-O
score	I-O
(	I-O
VAS	I-O
)	I-O
assessed	I-O
by	I-O
patients	I-O
)	I-O
decreased	O
significantly	O
in	O
both	O
the	O
mizolastine	B-I
and	I-I
loratadine	I-I
groups	O
compared	O
with	O
placebo	B-I
(	I-I
mizolastine	I-I
:	I-I
-36.7	O
mm	O
,	O
P	O
=	O
0.0001	O
;	O
loratadine	B-I
:	I-I
-29.8	O
,	O
P	O
=	O
0.0071	O
;	O
placebo	B-I
:	I-I
-16.3	O
)	O
;	O
this	O
improvement	O
with	O
both	O
active	O
treatments	O
was	O
maintained	O
throughout	O
the	O
treatment	O
period	O
,	O
the	O
difference	O
being	O
significant	O
only	O
for	O
the	O
mizolastine	O
group	O
(	O
P	O
=	O
0.0090	O
)	O
.	O


Both	O
active	O
treatments	O
were	O
also	O
associated	O
with	O
reduced	O
weekly	O
episodes	B-O
of	I-O
urticaria	I-O
compared	O
with	O
placebo	B-I
,	O
which	O
was	O
significant	O
after	O
2	O
weeks	O
'	O
treatment	O
(	B-I
mizolastine	I-I
:	I-I
7.9	O
episodes	O
,	O
P	O
=	O
0.0061	O
;	O
loratadine	B-I
:	I-I
8.3	O
,	O
P	O
=	O
0.0221	O
;	O
placebo	B-I
:	I-I
13.3	O
)	O
.	O


Angioedema	B-O
was	O
improved	O
to	O
a	O
clinically	O
significant	O
extent	O
with	O
mizolastine	B-I
,	O
and	O
loratadine	B-I
compared	O
with	O
placebo	B-I
in	O
those	O
patients	B-P
who	I-P
had	I-P
this	I-P
symptom	I-P
before	I-P
treatment	I-P
.	I-P


Overall	B-O
tolerability	I-O
of	O
both	O
treatments	O
was	O
similar	O
to	O
placebo	B-I
,	O
and	O
there	O
were	O
no	O
clinically	O
relevant	O
effects	B-O
on	I-O
cardiac	I-O
repolarisation	I-O
with	O
either	O
mizolastine	B-I
or	I-I
loratadine	I-I
.	I-I


CONCLUSION	O
Mizolastine	B-I
(	O
10	O
mg	O
daily	O
)	O
is	O
confirmed	O
as	O
an	O
effective	B-O
and	I-O
well	I-O
tolerated	I-O
agent	O
,	O
comparable	O
to	O
loratadine	O
and	O
superior	O
to	O
placebo	B-I
,	O
for	O
the	O
management	O
of	O
CIU	O
.	O


Mizolastine	B-I
acted	O
as	O
rapidly	O
as	O
loratadine	B-I
in	O
improving	O
urticarial	B-O
symptoms	I-O
from	O
the	O
first	O
day	O
of	O
treatment	O
.	O


Baseline	O
characteristics	O
of	O
participants	B-P
in	I-P
the	I-P
Appropriate	I-P
Blood	I-P
Pressure	I-P
Control	I-P
in	I-P
Diabetes	I-P
trial	I-P
.	I-P


The	O
ABCD	O
(	O
Appropriate	O
Blood	O
Pressure	O
Control	O
in	O
Diabetes	O
)	O
trial	O
is	O
a	O
large	O
,	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
intensive	B-I
with	O
moderate	B-I
blood	I-I
pressure	I-I
control	I-I
on	O
the	O
prevention	O
and	O
progression	O
of	O
diabetic	O
nephropathy	O
,	O
retinopathy	O
,	O
cardiovascular	O
disease	O
,	O
and	O
neuropathy	O
in	O
non-insulin-dependent	O
diabetes	O
(	O
NIDDM	O
)	O
.	O


The	O
secondary	O
objective	O
is	O
to	O
determine	O
equivalency	O
of	O
the	O
effects	O
of	O
a	O
calcium	B-I
channel	I-I
blocker	I-I
(	I-I
nisoldipine	I-I
)	I-I
and	O
of	O
an	O
angiotensin-converting	B-I
enzyme	I-I
inhibitor	I-I
(	I-I
enalapril	I-I
)	I-I
as	O
a	O
first-line	O
antihypertensive	O
agent	O
in	O
the	O
prevention	O
and/or	O
progression	O
of	O
these	O
diabetic	O
vascular	O
complications	O
.	O


The	O
study	O
consists	O
of	O
two	B-P
study	I-P
populations	I-P
:	I-P
a	I-P
hypertensive	I-P
one	I-P
(	I-O
diastolic	I-O
blood	I-O
pressure	I-O
of	I-P
>	I-P
or	I-P
=	I-P
90.0	I-P
mm	I-P
Hg	I-P
at	I-P
the	I-P
time	I-P
of	I-P
randomization	I-P
)	I-P
and	I-P
a	I-P
normotensive	I-P
one	I-P
(	I-O
diastolic	I-O
blood	I-O
pressure	I-O
of	I-P
80.0-89.0	I-P
mm	I-P
Hg	I-P
at	I-P
the	I-P
time	I-P
of	I-P
randomization	I-P
)	I-P
.	I-P


A	O
total	O
of	O
950	B-P
men	I-P
and	I-P
women	I-P
aged	I-P
40-74	I-P
years	I-P
were	O
randomized	O
and	O
are	O
being	O
followed	O
for	O
5	O
years	O
at	O
a	O
single	O
center	O
.	O


There	B-P
were	I-P
470	I-P
randomized	I-P
participants	I-P
in	I-P
the	I-P
hypertensive	I-P
population	I-P
and	I-P
480	I-P
randomized	I-P
participants	I-P
in	I-P
the	I-P
normotensive	I-P
population	I-P
.	I-P


This	O
report	O
summarizes	O
the	O
demographic	B-O
,	I-O
biochemical	I-O
,	O
and	O
clinical	B-O
characteristics	I-O
of	O
the	O
randomized	B-P
patients	I-P
at	O
the	O
time	O
of	O
entry	O
into	O
the	O
trial	O
and	O
evaluates	O
the	O
balance	O
between	O
the	O
treatment	O
groups	O
within	O
each	O
population	O
.	O


Vinegar	B-I
intake	O
enhances	O
flow-mediated	B-P
vasodilatation	I-P
via	O
upregulation	O
of	O
endothelial	O
nitric	O
oxide	O
synthase	O
activity	O
.	O


This	O
study	O
examined	O
the	O
effect	O
of	O
acetate	B-I
on	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
by	O
immunoblotting	O
assay	O
and	O
the	O
ability	O
of	O
acetic	O
acid	O
to	O
upregulate	O
flow-mediated	B-P
vasodilatation	I-P
in	I-P
humans	I-P
.	I-P


In	O
HUVECs	O
,	O
acetate	O
induced	O
a	O
biphasic	O
increase	O
in	O
the	O
phosphorylated	O
form	O
of	O
eNOS	O
.	O


The	O
amount	O
of	O
phosphorylated	O
eNOS	O
was	O
significantly	O
increased	O
by	O
exposure	O
to	O
200	B-I
mumol/l	I-I
acetate	I-I
for	I-I
20	I-I
min	I-I
(	I-I
early	I-I
phase	I-I
)	I-I
and	I-I
for	I-I
4	I-I
h	I-I
(	I-I
late	I-I
phase	I-I
)	I-I
.	O


The	O
inhibitors	O
of	O
cAMP-dependent	O
protein	O
kinase	O
(	O
PKA	O
)	O
and	O
AMP-activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
blocked	O
acetate-induced	O
eNOS	O
phosphorylation	O
in	O
the	O
early	O
and	O
the	O
late	O
phase	O
respectively	O
.	O


Furthermore	O
,	O
in	O
postmenopausal	B-P
women	I-P
,	O
maximum	B-O
forearm	I-O
blood	I-O
flow	I-O
(	I-O
FBF	I-O
)	I-O
in	O
response	O
to	O
shear	O
stress	O
increased	O
in	O
the	O
vinegar	B-P
(	I-I
acetic	I-I
acid	I-I
)	I-I
administered	I-P
group	I-P
compared	O
to	O
the	O
placebo	O
group	O
.	O


These	O
results	O
suggest	O
that	O
acetic	O
acid-induced	O
eNOS	O
phosphorylation	O
contributes	O
to	O
upregulation	O
of	O
flow-mediated	O
vasodilatation	O
in	O
humans	O
.	O


Long-term	O
effects	O
of	O
ezetimibe-plus-statin	B-I
therapy	I-I
on	O
low-density	B-O
lipoprotein	I-O
cholesterol	I-O
levels	I-O
as	O
compared	O
with	O
double-dose	B-I
statin	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
.	I-P


OBJECTIVE	O
To	O
assess	O
the	O
mechanism	O
of	O
long-term	O
LDL-C-lowering	O
effect	O
of	O
ezetimibe-plus-statin	B-I
.	I-I


METHODS	O
Coronary	B-P
artery	I-P
disease	I-P
patients	I-P
whose	I-P
LDL-C	I-P
≥	I-P
70	I-P
mg/dL	I-P
after	I-P
treatment	I-P
with	I-I
atorvastatin	I-I
10	I-I
mg/day	I-I
or	I-I
rosuvastatin	I-I
2.5	I-I
mg/day	I-I
were	O
randomly	O
assigned	O
to	O
receive	B-I
ezetimibe	I-I
10	I-I
mg/day	I-I
+	I-I
statin	I-I
(	O
n	O
=	O
78	O
)	O
or	B-I
double-dose	I-I
statin	I-I
(	O
n	O
=	O
72	O
)	O
for	O
52	O
weeks	O
.	O


RESULTS	O
Greater	B-O
LDL-C	I-O
reduction	I-O
was	O
observed	O
and	O
maintained	O
until	O
52	O
weeks	O
in	B-I
ezetimibe-plus-statin	I-I
,	O
while	B-O
LDL-C	I-O
levels	I-O
re-increased	O
after	O
12	O
weeks	O
in	O
double-dose	O
statin	O
.	O


Although	B-O
lathosterol/TC	I-O
increased	I-O
,	I-O
campesterol/TC	I-O
decreased	O
more	O
in	B-I
ezetimibe-plus-statin	I-I
.	O


In	O
contrast	B-O
,	I-O
lathosterol/TC	I-O
unchanged	O
and	B-O
campesterol/TC	I-O
increased	O
,	O
increasing	B-O
campesterol/lathosterol	I-O
ratio	I-O
for	O
52	O
weeks	O
in	B-I
double-dose	I-I
statin	I-O
.	I-O


Plasma	B-O
PCSK9	I-O
levels	I-O
were	O
higher	O
in	B-I
double-dose	I-I
statin	I-I
than	O
in	B-I
ezetimibe-plus-statin	I-I
at	O
12	O
weeks	O
,	O
but	O
similar	O
at	O
52	O
weeks	O
.	O


CONCLUSION	O
Although	O
the	O
difference	O
in	O
PCSK9	O
between	O
2	O
groups	O
was	O
transient	O
,	O
that	O
in	O
both	O
campesterol	O
and	O
lathosterol	O
persisted	O
until	O
52	O
weeks	O
.	O


These	O
results	O
demonstrated	O
simultaneous	O
inhibition	O
of	O
cholesterol	O
absorption	O
and	O
synthesis	O
provides	O
stable	O
and	O
greater	O
decrease	O
in	B-O
LDL-C	I-O
levels	I-O
.	O


Comparative	O
efficacy	O
of	O
LEAP	B-I
,	I-I
TEACCH	I-I
and	O
non-model-specific	B-I
special	I-I
education	I-I
programs	I-I
for	O
preschoolers	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


LEAP	B-I
and	I-I
TEACCH	I-I
represent	O
two	O
comprehensive	O
treatment	O
models	O
(	O
CTMs	O
)	O
that	O
have	O
been	O
widely	O
used	O
across	O
several	O
decades	O
to	O
educate	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


The	O
purpose	O
of	O
this	O
quasi-experimental	O
study	O
was	O
to	O
compare	O
high	B-I
fidelity	I-I
LEAP	I-I
(	O
n	O
=	O
22	O
)	O
and	B-I
TEACCH	I-I
(	O
n	O
=	O
25	O
)	O
classrooms	O
to	O
each	O
other	O
and	O
a	O
control	O
condition	O
(	O
n	O
=	O
28	O
)	O
,	O
in	O
which	O
teachers	B-P
in	I-P
high	I-P
quality	I-P
special	I-P
education	I-P
programs	I-P
used	O
non-model-specific	O
practices	O
.	O


A	O
total	B-P
of	I-P
198	I-P
children	I-P
were	O
included	O
in	O
data	O
analysis	O
.	O


Across	O
conditions	B-O
,	I-O
children	I-O
's	I-O
performances	I-O
improved	O
over	O
time	O
.	O


This	O
study	O
raises	O
issues	O
of	O
the	O
replication	O
of	O
effects	O
for	O
CTMs	O
,	O
and	O
whether	O
having	O
access	O
to	O
a	O
high	O
quality	B-I
special	I-I
education	I-I
program	I-I
is	O
as	O
beneficial	O
as	O
access	O
to	O
a	O
specific	O
CTM	O
.	O


Pelvic	B-I
lymphadenectomy	I-I
for	O
cervical	B-P
carcinoma	I-P
:	I-P
laparotomy	I-I
extraperitoneal	I-I
,	I-I
transperitoneal	I-I
or	I-I
laparoscopic	I-I
approach	O
?	O
A	O
randomized	O
study	O
.	O


OBJECTIVE	O
To	O
compare	O
transperitoneal	B-I
,	I-I
extraperitoneal	I-I
and	I-I
laparoscopic	I-I
pelvic	I-I
lymphadenectomy	I-I
in	O
terms	O
of	O
feasibility	B-O
and	I-O
morbidity	I-O
in	O
patients	B-P
affected	I-P
by	I-P
cervical	I-P
cancer	I-P
undergoing	I-P
radical	I-I
hysterectomy	I-I
.	I-I


METHODS	O
Consecutive	B-P
patients	I-P
affected	I-P
by	I-P
stage	I-P
IB-IIB	I-P
cervical	I-P
carcinoma	I-P
scheduled	I-P
for	I-P
radical	I-I
surgery	I-I
entered	O
the	O
study	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
transperitoneal	B-I
(	I-I
TPL	I-I
)	I-I
,	I-I
extraperitoneal	I-I
(	I-I
EPL	I-I
)	I-I
or	I-I
laparoscopic	I-I
pelvic	I-I
lymphadenectomy	I-I
(	I-I
LPL	I-I
)	I-I
.	I-I


All	B-P
patients	I-P
underwent	I-P
classical	I-I
radical	I-I
hysterectomy	I-I
.	I-I


Perioperative	O
data	O
were	O
recorded	O
.	O


Follow	O
up	O
examinations	B-O
were	O
performed	O
at	O
the	O
15th	O
,	O
30th	O
and	O
60th	O
day	O
after	O
surgery	O
.	O


RESULTS	O
168	B-P
patients	I-P
entered	I-P
the	I-P
study	I-P
.	I-P


The	O
mean	B-O
operative	I-O
times	I-O
were	O
:	O
63+/-7.6	O
,	O
54+/-6.7	O
and	O
75+/-8.4	O
min	O
(	B-I
TPL	I-I
vs	O
EPL	B-I
P	O
<	O
0.001	O
;	O
EPL	O
vs	O
LPL	O
P	O
<	O
0.001	O
;	O
TPL	B-I
vs	O
LPL	B-I
P	O
<	O
0.001	O
)	O
for	O
TPL	B-I
,	I-I
EPL	I-I
and	O
LPL	B-I
respectively	O
.	O


The	O
feasibility	B-O
of	I-O
the	I-O
procedures	I-O
,	O
analyzed	O
on	O
an	O
intention-to-treat	O
basis	O
,	O
was	O
96	O
%	O
,	O
93	O
%	O
and	O
95	O
%	O
for	O
TPL	B-I
,	I-I
EPL	I-I
and	I-I
LPL	I-I
group	I-I
respectively	O
(	O
P=ns	O
)	O
.	O


The	O
average	B-O
hospitalizations	I-O
were	O
:	O
5.6+/-0.9	O
,	O
3.2+/-0.4	O
and	O
3.1+/-0.3	O
days	O
(	B-I
TPL	I-I
vs	O
EPL	B-I
P	O
<	O
0.001	O
;	O
TPL	B-I
vs	O
LPL	B-I
P	O
<	O
0.001	O
)	O
for	O
TPL	B-I
,	I-I
EPL	I-I
and	O
LPL	B-I
respectively	O
.	O


CONCLUSIONS	O
EPL	B-I
and	O
LPL	B-I
are	O
as	O
feasible	B-O
and	O
effective	B-O
as	O
TPL	B-I
and	O
can	O
be	O
adequately	O
performed	O
with	O
a	O
reasonable	O
complication	O
rate	O
.	O


LPL	B-I
showed	O
a	O
statistically	O
significant	O
longer	O
operative	B-O
time	I-O
.	I-O


However	O
,	O
both	O
EPL	B-I
and	O
LPL	B-I
can	O
minimize	O
some	O
postoperative	O
complications	O
reducing	O
length	B-O
of	I-O
stay	I-O
.	I-O


Albendazole	B-I
trial	O
at	O
15	O
or	O
30	O
mg/kg/day	O
for	O
subarachnoid	B-P
and	I-P
intraventricular	I-P
cysticercosis	I-P
.	I-P


Thirty-six	B-P
patients	I-P
with	I-P
subarachnoid	I-P
and	I-P
intraventricular	I-P
cysticercosis	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
albendazole	B-I
at	O
15	O
or	O
30	O
mg/kg/day	O
plus	O
dexamethasone	B-I
for	O
8	O
days	O
.	O


Results	O
favored	O
a	O
higher	O
dose	O
,	O
with	O
larger	B-O
cyst	I-O
reduction	I-O
on	O
MRI	O
at	O
90	O
and	O
180	O
days	O
and	O
higher	O
albendazole	B-O
sulfoxide	I-O
levels	I-O
in	I-O
plasma	I-O
.	I-O


An	O
albendazole	B-I
course	O
at	O
30	O
mg/kg/day	O
combined	O
with	O
corticosteroids	B-I
is	O
safe	B-O
and	I-O
more	I-O
effective	I-O
than	O
the	O
usual	O
dose	O
.	O


A	O
single	O
treatment	O
was	O
insufficient	B-O
in	O
intraventricular	O
and	O
giant	O
cysts	O
.	O


Abstinence	B-O
incentive	I-O
effects	I-O
in	O
a	O
short-term	O
outpatient	O
detoxification	O
program	O
.	O


Despite	O
being	O
widely	O
available	O
,	O
outpatient	O
detoxification	O
has	O
limited	O
efficacy	O
as	O
a	O
stand-alone	O
treatment	O
.	O


This	O
study	O
examined	O
whether	O
abstinence-contingent	B-I
incentives	I-I
would	O
improve	O
outcomes	O
for	O
patients	B-P
entering	I-P
outpatient	I-P
opiate	I-O
detoxification	I-O
.	I-O


Participants	B-P
(	I-P
N	I-P
=	I-P
211	I-P
)	I-P
received	O
a	O
100	O
US	O
dollars	O
voucher	O
on	O
the	O
last	O
day	O
of	O
detoxification	B-I
either	O
contingent	O
on	O
opiate	O
and	O
cocaine	O
abstinence	O
or	O
noncontingently	O
.	O


Urine	O
samples	O
were	O
collected	O
at	O
intake	O
,	O
on	O
Wednesday	O
,	O
Friday	O
(	O
the	O
last	O
day	O
of	O
detoxification	O
)	O
,	O
and	O
the	O
following	O
Monday	O
.	O


Among	O
contingent-voucher	B-I
participants	O
,	O
31	O
%	O
were	O
drug-free	B-O
on	O
Friday	O
compared	O
with	O
18	O
%	O
of	O
noncontingent	O
controls	O
(	O
Z	O
=	O
2.4	O
,	O
p	O
<	O
.05	O
)	O
.	O


Few	O
(	O
12-13	O
%	O
)	O
participants	O
tested	O
negative	B-O
on	O
Monday	O
.	O


Results	O
support	O
the	O
ability	O
of	O
vouchers	O
to	O
produce	O
modest	B-O
improvements	I-O
in	I-O
abstinence	I-O
initiation	I-O
rates	I-O
during	O
brief	O
detoxification	O
but	O
suggest	O
that	O
additional	O
interventions	O
are	O
needed	O
to	O
sustain	O
improvements	O
.	O


Comparison	O
of	O
gonadotropin-releasing	B-I
hormone	I-I
agonists	I-I
and	O
antagonists	B-I
in	O
assisted	O
reproduction	O
cycles	O
of	O
polycystic	B-P
ovarian	I-P
syndrome	I-P
patients	I-P
.	I-P


AIM	O
Gonadotropin-releasing	O
hormone	O
(	O
GnRH	O
)	O
antagonists	O
have	O
reduced	O
the	O
incidence	O
of	O
severe	O
ovarian	O
hyper	O
stimulation	O
syndrome	O
(	O
OHSS	O
)	O
and	O
rate	O
of	O
hospitalization	O
due	O
to	O
severe	O
OHSS	O
,	O
especially	O
in	O
polycystic	B-P
ovarian	I-P
syndrome	I-P
(	I-P
PCOS	I-P
)	I-P
patients	I-P
.	I-P


The	O
present	O
study	O
aimed	O
to	O
compare	O
the	O
outcomes	O
of	O
patients	B-P
with	I-P
PCOS	I-P
undergoing	I-P
controlled	I-P
ovarian	I-P
hyperstimulation	I-P
(	I-P
COH	I-P
)	I-P
with	I-P
GnRH	I-I
agonist	I-I
versus	I-I
GnRH	I-I
antagonist	I-I
protocols	I-I
for	O
assisted	O
reproduction	O
cycles	O
.	O


METHODS	O
The	O
present	O
clinical	O
trial	O
compared	O
GnRH	B-I
antagonist	I-I
(	I-I
cetrorelix	I-I
)	I-I
and	O
GnRH	B-I
agonist	I-I
(	I-I
buserelin	I-I
)	I-I
protocols	O
during	O
COH	O
of	O
112	B-P
infertile	I-P
PCOS	I-P
patients	I-P
entering	I-P
assisted	I-P
reproduction	I-P
cycles	I-P
.	I-P


The	O
primary	O
outcome	O
measure	O
was	O
pregnancy	B-O
occurrence	I-O
.	I-O


Basal	O
characteristics	O
of	O
the	O
participants	O
,	O
stimulation	B-O
cycle	I-O
responses	I-O
,	I-O
pregnancy	I-O
outcomes	I-O
,	I-O
incidence	I-O
of	I-O
OHSS	I-O
and	I-O
types	I-O
of	I-O
OHSS	I-O
were	O
considered	O
in	O
both	O
groups	O
.	O


RESULTS	O
Regarding	O
chemical	B-O
and	I-O
clinical	I-O
pregnancy	I-O
rates	I-O
,	O
the	O
number	B-O
of	I-O
retrieved	I-O
oocytes	I-O
was	O
significantly	O
higher	O
and	O
OHSS	O
was	O
significantly	O
lower	O
in	O
the	O
antagonist	O
group	O
.	O


Follicle	B-O
stimulating	I-O
hormone	I-O
(	I-O
FSH	I-O
)	I-O
,	I-O
luteinizing	I-O
hormone	I-O
(	I-O
LH	I-O
)	I-O
levels	I-O
,	I-O
number	I-O
of	I-O
follicles	I-O
,	I-O
number	I-O
of	I-O
follicles	I-O
>	I-O
18	I-O
mm	I-O
,	I-O
relative	I-O
frequency	I-O
of	I-O
mature	I-O
oocytes	I-O
,	I-O
number	I-O
and	I-O
days	I-O
of	I-O
gonadotropin	I-O
injections	I-O
,	I-O
day	I-O
of	I-O
human	I-O
chorionic	I-O
gonadotropin	I-O
(	I-O
HCG	I-O
)	I-O
administration	I-O
,	I-O
estradiol	I-O
level	I-O
and	I-O
abortion	I-O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O


CONCLUSION	O
GnRH	O
antagonists	O
are	O
more	O
effective	O
,	O
safe	O
and	O
a	O
well	O
tolerated	O
alternative	O
to	O
agonists	O
for	O
assisted	O
reproduction	O
cycles	O
in	O
PCOS	O
patients	O
.	O


GnRH	O
antagonists	O
are	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
incidence	O
of	O
OHSS	O
in	O
these	O
patients	O
.	O


Prediction	O
of	O
the	O
infarct-related	O
artery	O
in	O
acute	O
myocardial	O
infarction	O
by	O
a	O
scoring	O
system	O
using	O
summary	B-I
ST-segment	I-I
and	I-I
T-wave	I-I
changes	I-I
.	I-I


We	O
developed	O
a	O
scoring	O
system	O
to	O
predict	O
the	O
artery	O
responsible	O
for	O
an	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
using	O
ST-segment	B-I
and	I-I
T-wave	I-I
changes	I-I
on	I-I
the	I-I
initial	I-I
electrocardiogram	I-I
(	I-I
ECG	I-I
)	I-I
using	O
data	O
from	O
228	B-P
patients	I-P
(	I-P
development	I-P
set	I-P
)	I-P
with	I-P
symptoms	I-P
compatible	I-P
with	I-P
AMI	I-P
and	I-P
tested	I-P
in	I-P
a	I-P
similar	I-P
group	I-P
of	I-P
223	I-P
patients	I-P
(	I-P
test	I-P
set	I-P
)	I-P
from	I-P
the	I-P
Thrombolysis	I-P
and	I-P
Angioplasty	I-P
in	I-P
Myocardial	I-P
Infarction	I-P
(	I-P
TAMI-5	I-P
)	I-P
Trial	I-P
.	I-P


Using	O
stepwise	O
logistic	O
regression	O
we	O
were	O
able	O
to	O
accurately	O
predict	O
the	O
left	O
anterior	O
descending	O
(	O
LAD	O
)	O
,	O
right	O
,	O
or	O
left	O
circumflex	O
(	O
LC	O
)	O
coronary	O
artery	O
as	O
the	O
infarct-related	O
artery	O
using	O
2	O
variables	O
:	O
(	O
1	O
)	O
the	O
summation	O
of	O
the	O
ST-segment	O
elevation	O
in	O
leads	O
V1	O
to	O
V4	O
;	O
and	O
(	O
2	O
)	O
the	O
summation	O
of	O
the	O
T-wave	O
negativity	O
in	O
leads	O
I	O
,	O
aVL	O
,	O
and	O
V5	O
.	O


In	O
the	O
development	O
set	O
,	O
these	O
2	O
variables	O
demonstrated	O
respective	O
sensitivity	B-O
and	I-O
specificity	I-O
of	O
98	O
%	O
and	O
90	O
%	O
for	O
LAD	O
lesions	O
,	O
82	O
%	O
and	O
85	O
%	O
for	O
right	O
narrowings	O
,	O
and	O
82	O
%	O
and	O
84	O
%	O
for	O
LC	O
narrowings	O
.	O


In	O
the	O
test	O
set	O
,	O
the	O
sensitivity	B-O
and	I-O
specificity	I-O
were	O
97	O
%	O
and	O
95	O
%	O
for	O
LAD	O
lesions	O
,	O
85	O
%	O
and	O
86	O
%	O
for	O
right	O
lesions	O
,	O
and	O
73	O
%	O
and	O
60	O
%	O
for	O
LC	B-O
coronary	I-O
artery	I-O
lesions	I-O
.	I-O


Information	O
easily	O
obtained	O
on	O
the	O
ECG	O
can	O
accurately	O
predict	O
the	O
likelihood	O
of	O
the	O
LAD	O
,	O
right	O
,	O
or	O
LC	O
artery	O
as	O
the	O
infarct-related	O
artery	O
.	O


This	O
may	O
be	O
useful	O
in	O
the	O
decision	O
to	O
administer	O
thrombolytic	O
treatment	O
.	O


Resource	B-O
utilization	I-O
and	O
economic	B-O
costs	I-O
of	O
care	O
based	O
on	O
a	O
randomized	O
trial	O
of	O
vacuum-assisted	B-I
closure	I-I
therapy	I-I
in	O
the	O
treatment	O
of	O
diabetic	B-P
foot	I-P
wounds	I-P
.	I-P


BACKGROUND	O
To	O
evaluate	O
resource	B-O
utilization	I-O
and	O
direct	B-O
economic	I-O
costs	I-O
of	O
care	O
for	O
patients	B-P
treated	I-P
with	I-P
negative-pressure	I-I
wound	I-I
therapy	I-I
(	I-I
NPWT	I-I
)	I-I
,	O
using	O
the	B-I
Vacuum-Assisted	I-I
Closure	I-I
(	I-I
V.A.C	I-I
.	I-I


)	B-I
system	I-I
,	O
compared	O
to	O
standard	B-I
moist	I-I
wound	I-I
therapy	I-I
(	I-I
MWT	I-I
)	I-I
.	I-I


METHODS	O
A	O
total	O
of	O
162	B-P
diabetic	I-P
patients	I-P
with	I-P
post-amputation	I-P
wounds	I-P
(	I-P
up	I-P
to	I-P
the	I-P
trans-metatarsal	I-P
level	I-P
)	I-P
entered	O
a	O
16-week	O
,	O
randomized	O
clinical	O
trial	O
.	O


Patients	B-P
randomized	I-P
to	I-P
V.A.C	I-I
.	I-I


(	B-P
n	I-P
=	I-P
77	I-P
)	I-P
received	I-P
therapy	I-I
with	I-I
dressing	I-I
changes	I-I
every	O
48	O
hours	O
.	O


Control	B-P
patients	I-P
(	I-P
n	I-P
=	I-P
85	I-P
)	I-P
received	I-P
standard	I-P
MWT	I-I
.	I-I


Resource	B-O
utilization	I-O
,	I-O
procedures	I-O
,	I-O
and	I-O
direct	I-O
costs	I-O
were	O
calculated	O
and	O
analyzed	O
in	O
this	O
post	O
hoc	O
retrospective	O
study	O
.	O


RESULTS	O
There	O
was	O
no	O
difference	O
between	O
groups	B-P
for	O
in-patient	B-O
hospital	I-O
stay	I-O
(	I-O
number	I-O
of	I-O
admissions	I-O
or	I-O
length	I-O
of	I-O
stay	I-O
)	I-O
.	O


More	O
surgical	O
procedures	O
(	O
including	O
debridement	O
)	O
were	O
required	O
in	O
the	O
MWT	B-I
group	O
(	O
120	O
vs	O
43	O
NPWT	B-I
,	O
P	O
<	O
.001	O
)	O
.	O


The	O
average	B-O
number	I-O
of	I-O
dressing	I-O
changes	I-O
performed	I-O
per	I-O
patient	I-O
was	O
118.0	O
(	O
range	O
12-226	O
)	O
for	O
MWT	B-I
versus	O
41	O
(	O
6-140	O
)	O
for	O
NPWT	B-I
(	O
P	O
=	O
.0001	O
)	O
.	O


The	O
MWT	B-I
group	O
had	O
11	O
(	O
range	O
0-106	O
)	O
outpatient	B-O
treatment	I-O
visits	I-O
during	O
the	O
study	O
versus	O
4	O
(	O
range	O
0-47	O
)	O
in	O
the	O
NPWT	B-I
group	O
(	O
P	O
<	O
.05	O
)	O
.	O


The	O
average	B-O
direct	I-O
cost	I-O
per	I-O
patient	I-O
treated	O
for	O
8	O
weeks	O
or	O
longer	O
(	O
independent	O
of	O
clinical	O
outcome	O
)	O
was	O
$	O
27,270	O
and	O
$	O
36,096	O
in	O
the	O
NPWT	O
and	O
MWT	O
groups	O
,	O
respectively	O
.	O


The	O
average	B-O
total	I-O
cost	I-O
to	I-O
achieve	I-O
healing	I-O
was	O
$	O
25,954	O
for	O
patients	O
treated	O
with	O
NPWT	B-I
(	O
n	O
=	O
43	O
)	O
compared	O
with	O
$	O
38,806	O
for	O
the	O
MWT	B-I
group	O
(	O
n	O
=	O
33	O
)	O
.	O


CONCLUSION	O
Treatment	O
of	O
diabetic	B-P
patients	I-P
with	I-P
post	I-P
amputation	I-P
wounds	I-P
using	O
NPWT	B-I
resulted	O
in	O
lower	O
resource	B-O
utilization	I-O
and	O
a	O
greater	O
proportion	B-O
of	I-O
patients	I-O
obtaining	O
wound	O
healing	O
at	O
a	O
lower	B-O
overall	I-O
cost	I-O
of	I-O
care	I-O
when	O
compared	O
to	O
MWT	B-I
.	I-I


Chemoradiotherapy	O
with	O
concurrent	B-I
gemcitabine	I-I
and	I-I
cisplatin	I-I
with	I-I
or	I-I
without	I-I
sequential	I-I
chemotherapy	I-I
with	I-I
gemcitabine/cisplatin	I-I
vs	O
chemoradiotherapy	B-I
with	I-I
concurrent	I-I
5-fluorouracil	I-I
in	O
patients	B-P
with	I-P
locally	I-P
advanced	I-P
pancreatic	I-P
cancer	I-P
--	I-P
a	I-P
multi-centre	I-P
randomised	O
phase	O
II	O
study	O
.	O


BACKGROUND	O
No	O
standard	O
treatment	O
for	O
locally	B-P
advanced	I-P
pancreatic	I-P
cancer	I-P
(	I-P
LAPC	I-P
)	I-P
is	O
defined	O
.	O


PATIENTS	O
AND	O
METHODS	O
Within	O
a	O
multi-centre	O
,	O
randomised	O
phase	O
II	O
trial	O
,	O
95	B-P
patients	I-P
with	I-P
LAPC	I-P
were	O
assigned	O
to	O
three	O
different	O
chemoradiotherapy	O
(	O
CRT	O
)	O
regimens	O
:	O
patients	O
received	O
conventionally	O
fractionated	O
radiotherapy	B-I
of	O
50	O
Gy	O
and	O
were	O
randomised	O
to	O
concurrent	O
5-fluorouracil	B-I
(	O
350	O
mg	O
m	O
(	O
-2	O
)	O
per	O
day	O
on	O
each	O
day	O
of	O
radiotherapy	B-I
,	O
RT-5-FU	O
arm	O
)	O
,	O
concurrent	B-I
gemcitabine	I-I
(	O
300	O
mg	O
m	O
(	O
-2	O
)	O
)	O
,	O
and	O
cisplatin	B-I
(	O
30	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
days	O
1	O
,	O
8	O
,	O
22	O
,	O
and	O
29	O
(	O
RT-GC	O
arm	O
)	O
,	O
or	O
the	O
same	B-I
concurrent	I-I
treatment	I-I
followed	I-I
by	I-I
sequential	I-I
full-dose	I-I
gemcitabine	I-I
(	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
cisplatin	B-I
(	O
50	O
mg	O
m	O
(	O
-2	O
)	O
)	O
every	O
2	O
weeks	O
(	O
RT-GC+GC	O
arm	O
)	O
.	O


Primary	O
end	O
point	O
was	O
the	O
overall	B-O
survival	I-O
(	I-O
OS	I-O
)	I-O
rate	I-O
after	I-O
9	I-O
months	I-O
.	I-O


RESULTS	O
The	O
9-month	B-O
OS	I-O
rate	I-O
was	O
58	O
%	O
in	O
the	O
RT-5-FU	O
arm	O
,	O
52	O
%	O
in	O
the	O
RT-GC	O
arm	O
,	O
and	O
45	O
%	O
in	O
the	O
RT-GC+GC	O
arm	O
.	O


Corresponding	O
median	B-O
survival	I-O
times	I-O
were	O
9.6	O
,	O
9.3	O
,	O
and	O
7.3	O
months	O
(	O
P=0.61	O
)	O
respectively	O
.	O


The	O
intent-to-treat	B-O
response	I-O
rate	I-O
was	O
19	O
,	O
22	O
,	O
and	O
13	O
%	O
respectively	O
.	O


Median	B-O
progression-free	I-O
survival	I-O
was	O
estimated	O
with	O
4.0	O
,	O
5.6	O
,	O
and	O
6.0	O
months	O
(	O
P=0.21	O
)	O
.	O


Grade	B-O
3/4	I-O
haematological	I-O
toxicities	I-O
were	O
more	O
frequent	O
in	O
the	O
two	O
GC-containing	O
arms	O
,	O
no	O
grade	B-O
3/4	I-O
febrile	I-O
neutropaenia	I-O
was	O
observed	O
.	O


CONCLUSION	O
None	O
of	O
the	O
three	O
CRT	O
regimens	O
tested	O
met	O
the	O
investigators	O
'	O
definition	O
for	O
efficacy	O
;	O
the	O
median	O
OS	O
was	O
similar	O
to	O
those	O
previously	O
reported	O
with	O
gemcitabine	O
alone	O
in	O
LAPC	O
.	O


Language	O
,	O
speech	O
sound	O
production	O
,	O
and	O
cognition	O
in	O
three-year-old	B-P
children	I-P
in	I-P
relation	I-P
to	I-P
otitis	I-P
media	I-P
in	I-P
their	I-P
first	I-P
three	I-P
years	I-P
of	I-P
life	I-P
.	I-P


OBJECTIVE	O
As	O
part	O
of	O
a	O
prospective	O
study	O
of	O
possible	O
effects	O
of	O
early-life	O
otitis	O
media	O
on	O
speech	O
,	O
language	O
,	O
cognitive	O
,	O
and	O
psychosocial	O
development	O
,	O
we	O
tested	O
relationships	O
between	O
children	O
's	O
cumulative	O
duration	O
of	O
middle	O
ear	O
effusion	O
(	O
MEE	O
)	O
in	O
their	O
first	O
3	O
years	O
of	O
life	O
and	O
their	O
scores	O
on	O
measures	B-O
of	I-O
language	I-O
,	I-O
speech	I-O
sound	I-O
production	I-O
,	I-O
and	I-O
cognition	I-O
at	O
3	O
years	O
of	O
age	O
.	O


METHODS	O
We	B-P
enrolled	I-P
6350	I-P
healthy	I-P
infants	I-P
by	I-P
2	I-P
months	I-P
of	I-P
age	I-P
who	I-P
presented	I-P
for	I-P
primary	I-P
care	I-P
at	I-P
1	I-P
of	I-P
2	I-P
urban	I-P
hospitals	I-P
or	I-P
1	I-P
of	I-P
2	I-P
small	I-P
town/rural	I-P
and	I-P
4	I-P
suburban	I-P
private	I-P
pediatric	I-P
practices	I-P
.	I-P


We	O
intensively	O
monitored	O
the	O
children	O
's	O
middle	O
ear	O
status	O
by	O
pneumatic	B-I
otoscopy	I-I
,	I-I
supplemented	I-I
by	I-I
tympanometry	I-I
,	O
throughout	O
their	O
first	O
3	O
years	O
of	O
life	O
;	O
we	O
monitored	O
the	O
validity	O
of	O
the	O
otoscopic	O
observations	O
on	O
an	O
ongoing	O
basis	O
;	O
and	O
we	B-I
treated	I-I
children	I-I
for	I-I
otitis	I-I
media	I-I
according	I-I
to	I-I
specified	I-I
guidelines	I-I
.	I-I


Children	B-P
who	I-P
met	I-P
specified	I-P
minimum	I-P
criteria	I-P
regarding	I-P
the	I-P
persistence	I-P
of	I-P
MEE	I-P
became	I-P
eligible	I-P
for	I-P
a	I-P
clinical	I-P
trial	I-P
in	O
which	O
they	O
were	O
assigned	O
randomly	O
to	O
undergo	O
tympanostomy	B-I
tube	I-I
placement	I-I
either	O
promptly	O
or	O
after	O
a	O
defined	O
extended	O
period	O
if	O
MEE	O
remained	O
present	O
.	O


From	B-P
among	I-P
those	I-P
remaining	I-P
,	I-P
we	I-P
selected	I-P
randomly	I-P
,	I-P
within	I-P
sociodemographic	I-P
strata	I-P
,	I-P
a	I-P
sample	I-P
of	I-P
241	I-P
children	I-P
who	I-P
represented	I-P
a	I-P
spectrum	I-P
of	I-P
MEE	I-P
experience	I-P
from	I-P
having	I-P
no	I-P
MEE	I-P
to	I-P
having	I-P
MEE	I-P
whose	I-P
cumulative	I-P
duration	I-P
fell	I-P
just	I-P
short	I-P
of	I-P
meeting	I-P
randomization	I-P
criteria	I-P
.	I-P


In	B-P
subjects	I-P
so	I-P
selected	I-P
,	I-P
the	I-P
estimated	I-P
duration	I-P
of	I-P
MEE	I-P
ranged	I-P
from	I-P
none	I-P
to	I-P
65.6	I-P
%	I-P
of	I-P
the	I-P
first	I-P
year	I-P
of	I-P
life	I-P
and	I-P
44.8	I-P
%	I-P
of	I-P
the	I-P
first	I-P
3	I-P
years	I-P
of	I-P
life	I-P
.	I-P


In	O
these	O
241	B-P
children	I-P
we	O
assessed	O
language	B-O
development	I-O
,	I-O
speech	I-O
sound	I-O
production	I-O
,	I-O
and	I-O
cognition	I-O
at	O
3	O
years	O
of	O
age	O
,	O
using	O
both	O
formal	O
tests	O
and	O
conversational	O
samples	O
.	O


RESULTS	O
We	O
found	O
weak	O
to	O
moderate	O
,	O
statistically	O
significant	O
negative	O
correlations	O
between	O
children	O
's	O
cumulative	O
durations	O
of	O
MEE	O
in	O
their	O
first	O
year	O
of	O
life	O
or	O
in	O
age	O
periods	O
that	O
included	O
their	O
first	O
year	O
of	O
life	O
,	O
and	O
their	O
scores	B-O
on	I-O
formal	I-O
tests	I-O
of	I-O
receptive	I-O
vocabulary	I-O
and	I-O
verbal	I-O
aspects	I-O
of	I-O
cognition	I-O
at	O
3	O
years	O
of	O
age	O
.	O


However	O
,	O
the	O
percent	O
of	O
variance	O
in	O
these	O
scores	O
explained	O
by	O
time	O
with	O
MEE	O
in	O
the	O
first	O
year	O
of	O
life	O
beyond	O
that	O
explained	O
by	O
sociodemographic	O
variables	O
ranged	O
only	O
from	O
1.2	O
%	O
to	O
2.9	O
%	O
,	O
and	O
the	O
negative	O
correlations	O
were	O
concentrated	O
in	O
the	O
subgroup	O
of	O
children	O
whose	O
families	O
had	O
private	O
health	O
insurance	O
(	O
rather	O
than	O
Medicaid	O
)	O
.	O


We	O
found	O
no	O
significant	O
correlations	O
in	O
the	O
study	O
population	O
as	O
a	O
whole	O
or	O
in	O
any	O
subgroup	O
between	O
time	O
with	O
MEE	O
during	O
antecedent	O
periods	O
and	O
children	O
's	O
scores	O
on	O
measures	O
of	O
spontaneous	B-O
expressive	I-O
language	I-O
,	I-O
speech	I-O
sound	I-O
production	I-O
,	I-O
or	I-O
other	I-O
measured	I-O
aspects	I-O
of	I-O
cognition	I-O
.	I-O


In	O
contrast	O
,	O
by	O
wide	O
margins	O
,	O
scores	B-O
on	I-O
all	I-O
measures	I-O
were	O
consistently	O
highest	O
among	O
the	O
most	O
socioeconomically	O
advantaged	O
children	O
and	O
lowest	O
among	O
the	O
most	O
socioeconomically	O
disadvantaged	O
children	O
.	O


CONCLUSIONS	O
Our	O
findings	O
suggest	O
either	O
that	O
persistent	B-P
early-life	I-P
MEE	I-P
actually	O
causes	O
later	O
small	O
,	O
circumscribed	O
impairments	O
of	O
receptive	O
language	O
and	O
verbal	O
aspects	O
of	O
cognition	O
in	O
certain	O
groups	O
of	O
children	O
or	O
that	O
unidentified	O
,	O
confounding	O
factors	O
predispose	O
children	O
both	O
to	O
early-life	O
otitis	O
media	O
and	O
to	O
certain	O
types	O
of	O
developmental	B-O
impairment	I-O
.	I-O


Findings	O
in	O
the	O
randomized	O
clinical	O
trial	O
component	O
of	O
the	O
larger	O
study	O
should	O
help	O
distinguish	O
between	O
causality	O
and	O
confounding	O
as	O
explanations	O
for	O
our	O
findings.language	B-O
,	I-O
speech	I-O
,	I-O
cognition	I-O
,	O
development	O
,	O
otitis	O
media	O
,	O
middle	O
ear	O
effusion	O
.	O


Laparoscopic	B-I
vs	O
open	B-I
appendectomy	I-I
in	O
overweight	B-P
patients	I-P
.	I-P


BACKGROUND	O
Laparoscopic	B-I
appendectomy	I-I
(	I-I
LA	I-I
)	I-I
has	O
been	O
associated	O
with	O
a	O
faster	O
recovery	O
and	O
less	O
postoperative	O
pain	O
than	O
the	O
open	O
technique	O
.	O


However	O
,	O
few	O
data	O
are	O
available	O
on	O
the	O
clinical	O
outcome	O
of	O
LA	B-I
in	O
overweight	B-P
patients	I-P
.	I-P


METHODS	O
A	B-P
group	I-P
of	I-P
106	I-P
patients	I-P
with	I-P
a	I-P
body	I-P
mass	I-P
index	I-P
(	I-P
BMI	I-P
)	I-P
>	I-P
26.4	I-P
,	I-P
representing	I-P
the	I-P
upper	I-P
quintile	I-P
of	I-P
500	I-P
prospectively	I-P
randomized	I-P
patients	I-P
,	O
were	O
included	O
in	O
the	O
study	O
.	O


They	O
were	O
randomized	O
to	O
undergo	O
either	O
laparoscopic	B-I
or	I-I
open	I-I
appendectomy	I-I
(	I-I
OA	I-I
)	I-I
.	I-I


Operating	B-O
and	I-O
anesthesia	I-O
times	I-O
,	I-O
postoperative	I-O
pain	I-O
,	I-O
complications	I-O
,	I-O
hospital	I-O
stay	I-O
,	I-O
functional	I-O
index	I-O
(	O
1	O
week	O
postoperatively	O
)	O
,	O
sick	B-O
leave	I-O
,	I-O
and	I-O
time	I-O
to	I-O
full	I-O
recovery	I-O
were	O
documented	O
.	O


RESULTS	O
In	O
OA	B-I
,	O
the	O
operating	B-O
time	I-O
for	O
overweight	B-O
patients	I-P
was	O
significantly	O
longer	O
than	O
that	O
for	O
patients	O
in	O
the	O
normal	O
weight	O
range	O
(	O
40	O
vs	O
35	O
min	O
,	O
p	O
<	O
0.05	O
)	O
.	O


In	O
LA	B-I
,	O
there	O
was	O
no	O
difference	O
in	O
operating	B-O
time	I-O
between	O
the	O
normal	O
and	O
overweight	O
patients	O
.	O


Overweight	O
patients	O
who	O
underwent	O
LA	B-I
had	O
longer	O
operating	B-O
and	I-O
anesthesia	I-O
times	I-O
than	O
their	O
OA	B-I
counterparts	O
(	O
55	O
vs	O
40	O
min	O
,	O
p	O
<	O
0.001	O
;	O
and	O
125	O
vs	O
100	O
min	O
,	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O


Postoperative	B-O
pain	I-O
was	O
significantly	O
greater	O
in	O
overweight	O
patients	O
who	O
underwent	O
OA	B-I
than	O
in	O
those	O
treated	O
with	O
the	O
laparoscopic	B-I
technique	I-I
.	I-I


Postoperative	B-O
pain	I-O
was	O
also	O
significantly	O
greater	O
in	O
overweight	O
patients	O
subjected	O
to	O
OA	B-I
than	O
in	O
patients	O
of	O
normal	O
weight	O
after	O
4	O
weeks	O
;	O
the	O
clinical	O
significance	O
may	O
,	O
however	O
,	O
be	O
of	O
less	O
importance	O
since	O
the	O
values	O
are	O
low	O
(	O
0.26	O
vs	O
0.09	O
,	O
p	O
<	O
0.05	O
)	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
operating	O
techniques	O
in	O
terms	O
of	O
complications	O
.	O


Hospital	B-O
stay	I-O
was	O
longer	O
for	O
overweight	O
patients	O
than	O
for	O
normal-weight	O
patients	O
undergoing	O
OA	B-I
(	O
3.0	O
vs	O
2.0	O
,	O
p	O
<	O
0.01	O
)	O
.	O


The	O
functional	O
index	O
did	O
not	O
differ	O
between	O
any	O
group	O
of	O
patients	O
.	O


Sick	B-O
leave	I-O
was	O
longer	O
for	O
overweight	O
patients	O
who	O
underwent	O
OA	B-I
than	O
for	O
normal-weight	O
patients	O
treated	O
with	O
the	O
same	O
technique	O
(	O
17	O
vs	O
13	O
days	O
,	O
p	O
<	O
0.01	O
)	O
.	O


In	O
the	O
laparoscopic	B-I
group	O
,	O
however	O
,	O
there	O
were	O
no	O
differences	O
between	O
the	O
overweight	B-P
and	I-P
normal-weight	I-P
patients	I-P
.	I-P


Time	B-O
to	I-O
full	I-O
recovery	I-O
was	O
greater	O
in	O
overweight	O
patients	O
subjected	O
to	O
OA	B-I
than	O
in	O
the	O
overweight	O
patients	O
in	O
the	O
LA	B-I
group	O
(	O
22	O
vs	O
15	O
days	O
,	O
p	O
<	O
0.001	O
)	O
.	O


CONCLUSION	O
In	O
this	O
study	O
,	O
overweight	O
patients	O
who	O
were	O
submitted	O
to	O
LA	B-I
had	O
less	O
postoperative	B-O
pain	I-O
and	O
a	O
faster	O
postoperative	B-O
recovery	I-O
than	O
overweight	O
patients	O
who	O
had	O
OA	B-I
.	I-I


LA	B-I
also	O
abolished	O
some	O
of	O
the	O
negative	O
effects	O
that	O
overweight	O
had	O
on	O
operating	B-O
time	I-O
,	I-O
hospital	I-O
stay	I-O
,	I-O
and	I-O
sick	I-O
leave	I-O
with	O
the	O
open	O
technique	O
.	O


However	O
,	O
anesthesia	O
and	O
operating	O
times	O
were	O
significantly	O
longer	O
in	O
LA	B-I
for	O
both	O
overweight	O
patients	O
and	O
those	O
with	O
a	O
normal	O
BMI	O
.	O


Pain	B-O
and	I-O
fatigue	I-O
management	I-O
:	I-O
results	O
of	O
a	O
nursing	O
randomized	O
clinical	O
trial	O
.	O


PURPOSE/OBJECTIVES	O
Through	O
a	O
randomized	O
clinical	O
trial	O
,	O
to	O
compare	O
patients	B-P
undergoing	I-P
an	I-P
initial	I-P
course	I-P
of	I-P
chemotherapy	I-I
who	I-P
report	I-P
pain	I-O
and	I-O
fatigue	I-O
at	I-P
baseline	I-P
and	I-P
who	I-P
are	I-P
receiving	I-P
conventional	I-I
care	I-I
alone	I-I
with	I-P
those	I-P
receiving	I-P
conventional	I-I
care	I-I
plus	I-I
a	I-I
nursing	I-I
intervention	I-I
on	O
outcomes	O
reported	O
at	O
20	O
weeks	O
.	O


SETTING	O
Chemotherapy	B-P
clinics	I-P
of	I-P
two	I-P
comprehensive	I-P
and	I-P
two	I-P
community	I-P
cancer	I-P
centers	I-P
.	I-P


METHODS	O
Interviews	O
were	O
conducted	O
at	O
baseline	O
and	O
10	O
and	O
20	O
weeks	O
.	O


An	O
18-week	O
,	O
10-contact	O
nursing	B-I
intervention	I-I
utilizing	I-I
problem-solving	I-I
approaches	I-I
to	I-I
symptom	I-I
management	I-I
and	I-I
improving	I-I
physical	I-O
functioning	I-O
and	I-O
emotional	I-O
health	I-O
was	O
implemented	O
.	O


SAMPLE	O
The	O
sample	O
consisted	O
of	O
53	B-P
patients	I-P
in	I-P
the	I-P
experimental	I-P
arm	I-P
and	I-P
60	I-P
in	I-P
the	I-P
control	I-P
arm	I-P
who	I-P
reported	I-P
pain	I-O
and	I-O
fatigue	I-O
at	I-P
baseline	I-P
.	I-P


VARIABLES	O
Pain	B-O
and	I-O
fatigue	I-O
,	I-O
numbers	I-O
of	I-O
other	I-O
symptoms	I-O
,	I-O
and	I-O
physical	I-O
role	I-O
impact	I-O
and	I-O
social-functioning	I-O
subscales	I-O
from	O
the	O
Medical	O
Outcomes	O
Study	O
36	O
Short	O
Form	O
.	O


FINDINGS	O
Patients	O
who	O
received	O
the	O
intervention	B-I
reported	O
a	O
significant	O
reduction	O
in	O
the	O
number	B-O
of	I-O
symptoms	I-O
experienced	I-O
and	O
improved	O
physical	B-O
and	I-O
social	I-O
functioning	I-O
.	I-O


Fewer	O
patients	O
in	O
the	O
experimental	O
arm	O
reported	O
both	O
pain	B-O
and	I-O
fatigue	I-O
at	O
20	O
weeks	O
.	O


CONCLUSIONS	O
Behavioral	B-I
interventions	I-I
targeted	O
to	O
patients	O
with	O
pain	B-O
and	I-O
fatigue	I-O
can	O
reduce	O
symptom	B-O
burden	I-O
,	O
improve	O
the	O
quality	B-O
of	I-O
the	I-O
daily	I-O
life	I-O
of	O
patients	O
,	O
and	O
demonstrate	O
the	O
"	O
value-added	O
"	O
role	O
of	O
nursing	B-I
care	I-I
for	O
patients	O
undergoing	O
chemotherapy	O
.	O


IMPLICATIONS	O
FOR	O
NURSING	O
These	O
data	O
support	O
the	O
"	O
value-added	O
"	O
role	O
of	O
nursing	B-I
interventions	I-I
for	O
symptom	O
management	O
and	O
improved	B-O
quality	I-O
of	I-O
life	I-O
during	O
the	O
course	O
of	O
cancer	O
treatment	O
.	O


Effects	O
of	O
low-level	B-I
laser	I-I
and	I-I
plyometric	I-I
exercises	I-I
in	O
the	O
treatment	O
of	O
lateral	B-P
epicondylitis	I-P
.	I-P


OBJECTIVE	O
This	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
effectiveness	O
of	O
a	O
protocol	O
of	O
combination	O
of	O
laser	B-I
with	I-I
plyometric	I-I
exercises	I-I
and	O
a	O
protocol	O
of	O
placebo	B-I
laser	I-I
with	I-I
the	I-I
same	I-I
program	I-I
,	O
in	O
the	O
treatment	O
of	O
tennis	B-P
elbow	I-P
.	I-P


BACKGROUND	O
DATA	O
The	O
use	O
of	O
low-level	B-I
laser	I-I
has	O
been	O
recommended	O
for	O
the	O
management	O
of	O
tennis	B-P
elbow	I-P
with	O
contradictory	O
results	O
.	O


Also	O
,	O
plyometric	B-I
exercises	I-I
was	O
recommended	O
for	O
the	O
treatment	O
of	O
the	O
tendinopathy	O
.	O


METHODS	O
Fifty	B-P
patients	I-P
who	I-P
had	I-P
tennis	I-P
elbow	I-P
participated	I-P
in	I-P
the	I-P
study	I-P
and	O
were	O
randomised	O
into	O
two	O
groups	O
.	O


Group	O
A	O
(	O
n	O
=	O
25	O
)	O
was	O
treated	O
with	O
a	O
904	B-I
Ga-As	I-I
laser	I-I
CW	I-I
,	O
frequency	O
50	O
Hz	O
,	O
intensity	O
40	O
mW	O
and	O
energy	O
density	O
2.4	O
J/cm	O
(	O
2	O
)	O
,	O
plus	B-I
plyometric	I-I
exercises	I-I
and	O
group	O
B	O
(	O
n	O
=	O
25	O
)	O
that	O
received	O
placebo	B-I
laser	I-I
plus	I-I
the	I-I
same	I-I
plyometric	I-I
exercises	I-I
.	I-I


During	O
eight	O
weeks	O
of	O
treatment	O
,	O
the	O
patients	O
of	O
the	O
two	O
groups	O
received	O
12	O
sessions	O
of	O
laser	B-I
or	I-I
placebo	I-I
,	O
two	O
sessions	O
per	O
week	O
(	O
weeks	O
1-4	O
)	O
and	O
one	O
session	O
per	O
week	O
(	O
weeks	O
5-8	O
)	O
.	O


Pain	B-O
at	I-O
rest	I-O
,	I-O
at	I-O
palpation	I-O
on	I-O
the	I-O
lateral	I-O
epicondyle	I-O
,	I-O
during	I-O
resisted	I-O
wrist	I-O
extension	I-O
,	I-O
middle	I-O
finger	I-O
test	I-O
,	O
and	O
strength	B-O
testing	I-O
was	O
evaluated	O
using	O
Visual	B-O
Analogue	I-O
Scales	I-O
.	I-O


Also	O
it	O
was	O
evaluated	O
the	O
grip	B-O
strength	I-O
,	O
the	O
range	B-O
of	I-O
motion	I-O
and	O
weight	B-O
test	I-O
.	I-O


Parameters	O
were	O
determined	O
before	O
the	O
treatment	O
,	O
at	O
the	O
end	O
of	O
the	O
eighth	O
week	O
course	O
of	O
treatment	O
(	O
week	O
8	O
)	O
,	O
and	O
eighth	O
(	O
week	O
8	O
)	O
after	O
the	O
end	O
of	O
treatment	O
.	O


RESULTS	O
Relative	O
to	O
the	O
group	O
B	O
,	O
the	O
group	O
A	O
had	O
(	O
1	O
)	O
a	O
significant	O
decrease	B-O
of	I-O
pain	I-O
at	I-O
rest	I-O
at	O
the	O
end	O
of	O
8	O
weeks	O
of	O
the	O
treatment	O
(	O
p	O
<	O
0.005	O
)	O
and	O
at	O
the	O
end	O
of	O
following	O
up	O
period	O
(	O
p	O
<	O
0.05	O
)	O
,	O
(	O
2	O
)	O
a	O
significant	O
decrease	B-O
in	I-O
pain	I-O
at	I-O
palpation	I-O
and	I-O
pain	I-O
on	I-O
isometric	I-O
testing	I-O
at	O
8	O
weeks	O
of	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
at	O
8	O
weeks	O
follow-up	O
(	O
p	O
<	O
0.001	O
)	O
,	O
(	O
3	O
)	O
a	O
significant	O
decrease	O
in	O
pain	B-O
during	I-O
middle	I-O
finger	I-O
test	I-O
at	O
the	O
end	O
of	O
8	O
weeks	O
of	O
treatment	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
follow-up	O
period	O
(	O
p	O
<	O
0.05	O
)	O
,	O
(	O
4	O
)	O
a	O
significant	O
decrease	B-O
of	I-O
pain	I-O
during	I-O
grip	I-O
strength	I-O
testing	I-O
at	O
8	O
weeks	O
of	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
at	O
8	O
weeks	O
follow-up	O
(	O
p	O
<	O
0.001	O
)	O
,	O
(	O
5	O
)	O
a	O
significant	O
increase	B-O
in	I-O
the	I-O
wrist	I-O
range	I-O
of	I-O
motion	I-O
at	O
8	O
weeks	O
follow-up	O
(	O
p	O
<	O
0.01	O
)	O
,	O
(	O
6	O
)	O
an	O
increase	B-O
in	I-O
grip	I-O
strength	I-O
at	O
8	O
weeks	O
of	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
and	O
at	O
8	O
weeks	O
follow-up	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
(	O
7	O
)	O
a	O
significant	O
increase	B-O
in	I-O
weight-test	I-O
at	O
8	O
weeks	O
of	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
and	O
at	O
8	O
weeks	O
follow-up	O
(	O
p	O
<	O
0.005	O
)	O
.	O


CONCLUSION	O
The	O
results	O
suggested	O
that	O
the	O
combination	B-I
of	I-I
laser	I-I
with	I-I
plyometric	I-I
exercises	I-I
was	O
more	O
effective	O
treatment	O
than	O
placebo	B-I
laser	I-I
with	I-I
the	I-I
same	I-I
plyometric	I-I
exercises	I-I
at	O
the	O
end	O
of	O
the	O
treatment	O
as	O
well	O
as	O
at	O
the	O
follow-up	O
.	O


Future	O
studies	O
are	O
needed	O
to	O
establish	O
the	O
relative	O
and	O
absolute	O
effectiveness	O
of	O
the	O
above	O
protocol	O
.	O


Perioperative	B-I
enteral	I-I
nutrition	I-I
and	O
quality	B-O
of	I-O
life	I-O
of	O
severely	B-P
malnourished	I-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
patients	I-P
:	I-P
a	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
AND	O
AIMS	O
This	O
study	O
evaluated	O
the	O
use	O
of	O
perioperative	B-I
nutritional	I-I
support	I-I
on	O
Quality	B-O
of	I-O
Life	I-O
(	I-O
QOL	I-O
)	I-O
in	O
malnourished	B-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
patients	I-P
undergoing	I-P
surgery	I-P
.	I-P


METHODS	O
49	B-P
Malnourished	I-P
(	I-P
weight	I-P
loss	I-P
>	I-P
10	I-P
%	I-P
)	I-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
patients	I-P
who	I-P
were	I-P
included	I-P
in	I-P
a	I-P
nutrition	I-P
intervention	I-P
trial	I-P
were	O
randomized	O
to	O
receive	O
either	O
no	B-I
preoperative	I-I
and	I-I
standard	I-I
postoperative	I-I
tube-feeding	I-I
(	I-I
group	I-I
I	I-I
)	I-I
,	I-I
standard	I-I
preoperative	I-I
and	I-I
postoperative	I-I
tube-feeding	I-I
(	I-I
group	I-I
II	I-I
)	I-I
or	O
arginine-supplemented	B-I
preoperative	I-I
and	I-I
postoperative	I-I
tube-feeding	I-I
(	O
group	O
III	O
)	O
.	O


Of	O
these	O
patients	B-P
,	O
31	O
completed	O
a	O
full	O
QOL	B-O
assessment	I-O
on	O
the	O
first	O
day	O
of	O
preoperative	O
nutritional	O
support	O
,	O
one	O
day	O
before	O
surgery	O
,	O
and	O
6	O
months	O
after	O
surgery	O
.	O


Both	O
a	O
disease-specific	O
(	O
EORTC	O
QLQ-C30	O
)	O
and	O
a	O
generic	O
questionnaire	O
(	O
COOP-WONCA	O
)	O
were	O
used	O
.	O


One	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	O
Kruskal-Wallis	O
test	O
were	O
applied	O
for	O
testing	O
differences	O
in	O
scores	O
between	O
groups	O
.	O


RESULTS	O
Between	O
baseline	O
and	O
the	O
day	O
before	O
surgery	O
,	O
both	O
preoperatively	B-I
fed	I-I
groups	O
revealed	O
a	O
positive	O
change	O
for	O
the	O
dimensions	O
physical	B-O
and	I-O
emotional	I-O
functioning	I-O
and	I-O
dyspnea	I-O
(	O
with	O
significance	O
in	O
group	O
II	O
,	O
P=0.050,0.031,0.045	O
respectively	O
)	O
.	O


Group	O
III	O
showed	O
a	O
negative	O
change	O
in	O
appetite	B-O
(	O
P=0.049	O
)	O
.	O


Between	O
baseline	O
and	O
6	O
months	O
after	O
surgery	O
,	O
there	O
were	O
no	O
differences	O
between	O
group	O
I	O
and	O
both	B-I
pre-fed	I-I
groups	I-I
.	I-I


There	O
were	O
no	O
differences	O
in	O
favour	O
of	O
group	O
III	O
compared	O
to	O
group	O
II	O
.	O


CONCLUSION	O
Enteral	B-I
nutrition	I-I
improves	O
QOL	B-O
of	O
severely	O
malnourished	O
head	O
and	O
neck	O
cancer	O
patients	O
in	O
the	O
period	O
preceding	O
surgery	O
.	O


No	O
benefit	O
of	O
preoperative	B-I
enteral	I-I
feeding	I-I
on	O
QOL	B-O
could	O
be	O
demonstrated	O
6	O
months	O
after	O
surgery	O
.	O


Efficacy	O
and	O
safety	O
of	O
a	O
high	B-I
protein	I-I
,	I-I
low	I-I
carbohydrate	I-I
diet	I-I
for	O
weight	O
loss	O
in	O
severely	B-P
obese	I-P
adolescents	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
carbohydrate	B-I
restricted	I-I
versus	I-I
a	I-I
low	I-I
fat	I-I
diet	I-I
on	O
weight	B-O
loss	I-O
,	I-O
metabolic	I-O
markers	I-O
,	I-O
body	I-O
composition	I-O
,	O
and	O
cardiac	B-O
function	I-O
tests	I-O
in	O
severely	B-P
obese	I-P
adolescents	I-P
.	I-P


STUDY	O
DESIGN	O
Subjects	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
2	O
diets	B-I
:	I-I
a	I-I
high	I-I
protein	I-I
,	I-I
low	I-I
carbohydrate	I-I
(	I-I
20	I-I
g/d	I-I
)	I-I
diet	I-I
(	I-I
high	I-I
protein	I-I
,	I-I
low	I-I
carbohydrate	I-I
,	I-I
HPLC	I-I
)	I-I
or	I-I
low	I-I
fat	I-I
(	I-I
30	I-I
%	I-I
of	I-I
calories	I-I
)	I-I
regimen	I-I
for	I-I
13	I-I
weeks	I-I
;	I-I
close	O
monitoring	O
was	O
maintained	O
to	O
evaluate	O
safety	O
.	O


After	O
the	O
intervention	O
,	O
no	O
clinical	O
contact	O
was	O
made	O
until	O
follow-up	O
measurements	O
were	O
obtained	O
at	O
24	O
and	O
36	O
weeks	O
from	O
baseline	O
.	O


The	O
primary	O
outcome	O
was	O
change	B-O
in	I-O
body	I-O
mass	I-O
index	I-O
Z-score	I-O
for	O
age	O
and	O
sex	O
(	B-O
BMI-Z	I-O
)	I-O
at	O
13	O
,	O
24	O
,	O
and	O
36	O
weeks	O
.	O


RESULTS	O
Forty-six	B-P
subjects	I-P
(	I-P
24	I-P
HPLC	I-P
,	I-P
22	I-P
in	I-P
low	I-P
fat	I-P
)	I-P
initiated	I-P
and	I-P
33	I-P
subjects	I-P
completed	I-P
the	I-P
intervention	I-P
;	I-P
follow-up	O
data	O
were	O
available	O
on	O
approximately	O
half	O
of	O
the	O
subjects	O
.	O


Significant	O
reduction	O
in	O
(	B-O
BMI-Z	I-O
)	I-O
was	O
achieved	O
in	O
both	O
groups	O
during	O
intervention	O
and	O
was	O
significantly	O
greater	O
for	O
the	O
HPLC	O
group	O
(	O
P	O
=	O
.03	O
)	O
.	O


Both	O
groups	O
maintained	O
significant	O
BMI-Z	B-O
reduction	I-O
at	O
follow-up	O
;	O
changes	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O


Loss	O
of	O
lean	B-O
body	I-O
mass	I-O
was	O
not	O
spared	O
in	O
the	O
HPLC	O
group	O
.	O


No	O
serious	B-O
adverse	I-O
effects	I-O
were	O
observed	O
related	O
to	O
metabolic	B-O
profiles	I-O
,	I-O
cardiac	I-O
function	I-O
,	O
or	O
subjective	B-O
complaints	I-O
.	I-O


CONCLUSIONS	O
The	O
HPLC	B-I
diet	O
is	O
a	O
safe	O
and	O
effective	O
option	O
for	O
medically	O
supervised	O
weight	O
loss	O
in	O
severely	B-P
obese	I-P
adolescents	I-P
.	I-P


Computer-Assisted	B-I
Face	I-I
Processing	I-I
Instruction	I-I
Improves	O
Emotion	B-O
Recognition	I-O
,	I-O
Mentalizing	I-O
,	I-O
and	I-O
Social	I-O
Skills	I-O
in	O
Students	B-P
with	I-P
ASD	I-P
.	I-P


This	O
study	O
examined	O
the	O
extent	O
to	O
which	O
a	O
computer-based	B-I
social	I-I
skills	I-I
intervention	I-I
called	I-I
FaceSay	I-I
was	O
associated	O
with	O
improvements	O
in	O
affect	B-O
recognition	I-O
,	I-O
mentalizing	I-O
,	I-O
and	I-O
social	I-O
skills	I-O
of	O
school-aged	B-P
children	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


FaceSay	B-I
offers	O
students	B-P
simulated	O
practice	O
with	O
eye	B-O
gaze	I-O
,	I-O
joint	I-O
attention	I-O
,	I-O
and	I-O
facial	I-O
recognition	I-O
skills	I-O
.	I-O


This	O
randomized	O
control	O
trial	O
included	O
school-aged	B-P
children	I-P
meeting	I-P
educational	I-P
criteria	I-P
for	I-P
autism	I-P
(	I-P
N	I-P
=	I-P
31	I-P
)	I-P
.	I-P


Results	O
demonstrated	O
that	O
participants	O
who	O
received	O
the	O
intervention	O
improved	O
their	O
affect	B-O
recognition	I-O
and	I-O
mentalizing	I-O
skills	I-O
,	I-O
as	I-O
well	I-O
as	I-O
their	I-O
social	I-O
skills	I-O
.	I-O


These	O
findings	O
suggest	O
that	O
,	O
by	O
targeting	O
face-processing	O
skills	O
,	O
computer-based	O
interventions	O
may	O
produce	O
changes	O
in	O
broader	B-O
cognitive	I-O
and	I-O
social-skills	I-O
domains	I-O
in	O
a	O
cost-	B-O
and	I-O
time-efficient	I-O
manner	I-O
.	I-O


Association	O
of	O
efavirenz	B-I
hypersusceptibility	O
with	O
virologic	O
response	O
in	O
ACTG	B-I
368	I-I
,	O
a	O
randomized	O
trial	O
of	O
abacavir	B-I
(	I-I
ABC	I-I
)	I-I
in	O
combination	O
with	O
efavirenz	B-I
(	I-I
EFV	I-I
)	I-I
and	O
indinavir	B-I
(	I-I
IDV	I-I
)	I-I
in	O
HIV-infected	B-P
subjects	I-P
with	I-P
prior	I-P
nucleoside	I-P
analog	I-P
experience	I-P
.	I-P


PURPOSE	O
To	O
evaluate	O
the	O
association	O
of	O
efavirenz	O
hypersusceptibility	O
(	O
EFV-HS	O
)	O
with	O
clinical	O
outcome	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
randomized	O
trial	O
of	O
EFV	B-I
plus	I-I
indinavir	I-I
(	I-I
EFV+IDV	I-I
)	I-I
vs.	I-I
EFV+IDV	I-I
plus	I-I
abacavir	I-I
(	I-I
ABC	I-I
)	I-I
in	O
283	B-P
nucleoside-experienced	I-P
HIV-infected	I-P
patients	I-P
.	I-P


METHOD	O
AND	O
RESULTS	O
Rates	B-O
of	I-O
virologic	I-O
failure	I-O
were	O
similar	O
in	O
the	O
2	O
arms	O
at	O
week	O
16	O
(	O
p	O
=	O
.509	O
)	O
.	O


Treatment	B-O
discontinuations	I-O
were	O
more	O
common	O
in	O
the	O
ABC	O
arm	O
(	O
p	O
=	O
.001	O
)	O
.	O


Using	O
logistic	O
regression	O
,	O
there	O
was	O
no	O
association	O
between	O
virologic	B-O
failure	I-O
and	I-O
either	I-O
baseline	I-O
ABC	I-O
resistance	I-O
or	I-O
regimen	I-O
sensitivity	I-O
score	I-O
.	I-O


Using	O
3	O
different	O
genotypic	O
scoring	O
systems	O
,	O
EFV-HS	B-I
was	O
significantly	O
associated	O
with	O
reduced	B-O
virologic	I-O
failure	I-O
at	O
week	O
16	O
,	O
independent	O
of	O
treatment	O
assignment	O
.	O


In	O
some	O
patients	O
on	O
the	O
nucleoside-sparing	O
arm	O
,	O
the	O
nucleoside-resistance	O
mutation	O
L74V	O
was	O
selected	O
for	O
in	O
combination	O
with	O
the	O
uncommonly	O
occurring	O
EFV-resistance	O
mutations	O
K103N+L100I	O
;	O
L74V	O
was	O
not	O
detected	O
as	O
a	O
minority	O
variant	O
,	O
using	O
clonal	O
sequence	O
analysis	O
,	O
when	O
the	O
nucleoside-sparing	O
regimen	O
was	O
initiated	O
.	O


CONCLUSION	O
Premature	O
treatment	B-O
discontinuations	I-O
in	O
the	O
ABC	O
arm	O
and	O
the	O
presence	O
of	O
EFV-HS	B-I
HIV	I-I
variants	O
in	O
this	O
patient	O
population	O
likely	O
made	O
it	O
difficult	O
to	O
detect	O
a	O
benefit	O
of	O
adding	B-O
ABC	I-O
to	I-O
EFV+IDV	I-O
.	I-O


In	O
addition	O
,	O
L74V	O
,	O
when	O
combined	O
with	O
K103N+L100I	O
,	O
may	O
confer	O
a	O
selective	O
advantage	O
to	O
the	O
virus	O
that	O
is	O
independent	O
of	O
its	O
effects	B-O
on	I-O
nucleoside	I-O
resistance	I-O
.	I-O


Is	O
psychotherapy	B-I
more	O
effective	O
when	O
therapists	B-P
disclose	O
information	O
about	O
themselves	O
?	O
Theorists	O
have	O
long	O
debated	O
the	O
wisdom	O
of	O
therapists	B-P
disclosing	I-O
personal	I-O
information	I-O
during	I-P
psychotherapy	I-I
.	I-I


Some	O
observers	O
have	O
argued	O
that	O
such	O
therapist	O
self-disclosure	O
impedes	O
treatment	O
,	O
whereas	O
others	O
have	O
suggested	O
that	O
it	O
enhances	O
the	O
effectiveness	B-O
of	I-O
therapy	I-O
.	I-O


To	O
test	O
these	O
competing	O
positions	O
,	O
therapists	B-P
at	I-P
a	I-P
university	I-P
counseling	I-P
center	I-P
were	O
instructed	O
to	O
increase	B-I
the	I-I
number	I-I
of	I-I
self-disclosures	I-I
they	O
made	O
during	O
treatment	B-I
of	O
one	B-P
client	I-P
and	O
refrain	B-I
from	I-I
making	I-I
self-disclosures	I-I
during	I-I
treatment	I-I
of	O
another	B-P
client	I-P
.	I-P


Analyses	O
revealed	O
that	O
clients	O
receiving	O
psychotherapy	B-I
under	O
conditions	O
of	O
heightened	O
therapist	B-I
disclosure	I-I
not	O
only	O
reported	O
lower	B-O
levels	I-O
of	I-O
symptom	I-O
distress	I-O
but	O
also	O
liked	B-O
their	I-O
therapist	I-O
more	I-O
.	I-O


Such	O
findings	O
suggest	O
that	O
self-disclosure	O
by	O
the	O
therapist	O
may	O
improve	O
both	O
the	O
quality	B-O
of	I-O
the	I-O
therapeutic	I-O
relationship	I-O
and	I-O
the	I-O
outcome	I-O
of	I-O
treatment	I-O
.	I-O


Efficacy	B-O
of	O
a	O
tobacco	B-I
quitline	I-I
among	O
adult	B-P
cancer	I-P
survivors	I-P
.	I-P


OBJECTIVE	O
The	O
purpose	O
of	O
the	O
study	O
(	B-P
conducted	I-P
2010-2013	I-P
)	I-P
was	O
to	O
determine	O
the	O
efficacy	O
of	O
two	O
common	O
types	O
of	O
tobacco	B-I
quitlines	I-I
in	O
adult	B-P
cancer	I-P
survivors	I-P
who	I-P
regularly	I-P
smoked	I-P
cigarettes	I-P
.	I-P


METHOD	O
Adult	B-P
onset	I-P
cancer	I-P
survivors	I-P
in	I-P
Memphis	I-P
,	I-P
Tennessee	I-P
(	I-P
n=427	I-P
,	I-P
67	I-P
%	I-P
female	I-P
,	I-P
60	I-P
%	I-P
Caucasian	I-P
)	I-P
were	O
randomized	O
either	O
to	O
a	O
Proactive	B-I
(	I-I
i.e.	I-I
,	O
counselor-initiated	B-I
calls	I-I
)	I-I
or	O
Reactive	B-I
(	O
i.e.	O
,	O
participant-initiated	B-I
calls	I-I
)	I-I
quitline	O
.	O


Both	O
conditions	O
also	O
received	O
nicotine	B-I
replacement	I-I
therapy	I-I
.	I-I


The	O
primary	O
outcome	O
was	O
biochemically-verified	O
(	O
i.e.	O
,	O
salivary	O
cotinine	O
)	O
smoking	B-O
cessation	I-O
.	I-O


RESULTS	O
While	O
12-month	O
self-reported	O
abstinence	O
was	O
consistent	O
with	O
other	O
published	O
studies	O
of	O
smoking	B-O
cessation	I-O
(	O
22	O
%	O
and	O
26	O
%	O
point	O
prevalence	O
abstinence	O
for	O
Proactive	O
and	O
Reactive	O
conditions	O
,	O
respectively	O
)	O
,	O
48	O
%	O
of	O
participants	O
who	O
were	O
tested	O
for	O
cotinine	O
failed	O
biochemical	O
verification	O
,	O
indicating	O
a	O
considerable	O
falsification	O
of	O
self-reported	B-O
cessation	I-O
.	I-O


Adjusted	B-O
cessation	I-O
rates	I-O
were	O
less	O
than	O
5	O
%	O
in	O
both	O
intervention	O
conditions	O
.	O


CONCLUSION	O
Our	O
results	O
are	O
consistent	O
with	O
other	O
studies	O
indicating	O
that	O
traditional	B-O
smoking	I-O
cessation	I-O
interventions	I-O
are	O
ineffective	O
among	O
cancer	O
survivors	O
.	O


Moreover	O
,	O
self-reports	B-O
of	I-O
cessation	I-O
were	O
unreliable	O
in	O
cancer	O
survivors	O
participating	O
in	O
a	O
quitline	B-I
intervention	I-I
,	O
indicating	O
that	O
future	O
studies	O
should	O
include	O
biochemical	O
verification	O
.	O


Given	O
the	O
importance	O
of	O
smoking	O
cessation	O
among	O
cancer	B-P
survivors	I-P
and	O
low	O
cessation	B-O
rates	I-O
in	O
the	O
current	O
study	O
,	O
it	O
may	O
be	O
necessary	O
to	O
design	O
alternative	O
interventions	O
for	O
this	O
population	O
.	O


ClinicalTrials.gov	O
identifier	O
:	O
NCT00827866	O
.	O


Evidence	O
for	O
diminished	O
multisensory	B-O
integration	I-O
in	O
autism	B-P
spectrum	I-P
disorders	I-P
.	I-P


Individuals	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
exhibit	O
alterations	O
in	O
sensory	O
processing	O
,	O
including	O
changes	O
in	O
the	O
integration	O
of	O
information	O
across	O
the	O
different	O
sensory	O
modalities	O
.	O


In	O
the	O
current	O
study	O
,	O
we	O
used	O
the	O
sound-induced	B-I
flash	I-I
illusion	I-I
to	O
assess	O
multisensory	B-O
integration	I-O
in	O
children	B-P
with	I-P
ASD	I-P
and	I-P
typically-developing	I-P
(	I-P
TD	I-P
)	I-P
controls	I-P
.	I-P


Thirty-one	B-P
children	I-P
with	I-P
ASD	I-P
and	I-P
31	I-P
age	I-P
and	I-P
IQ	I-P
matched	I-P
TD	I-P
children	I-P
(	I-P
average	I-P
age	I-P
=	I-P
12	I-P
years	I-P
)	I-P
were	O
presented	O
with	B-I
simple	I-I
visual	I-I
(	I-I
i.e.	I-I
,	O
flash	B-I
)	I-I
and	I-I
auditory	I-I
(	I-I
i.e.	I-I
,	O
beep	B-I
)	I-I
stimuli	I-I
of	I-I
varying	I-I
number	I-I
.	O


In	O
illusory	O
conditions	O
,	O
a	O
single	O
flash	O
was	O
presented	O
with	O
2-4	O
beeps	O
.	O


In	O
TD	O
children	O
,	O
these	O
conditions	O
generally	O
result	O
in	O
the	B-O
perception	I-O
of	I-O
multiple	I-O
flashes	I-O
,	I-O
implying	I-O
a	I-O
perceptual	I-O
fusion	I-O
across	I-O
vision	I-O
and	I-O
audition	I-O
.	O


In	O
the	O
present	O
study	O
,	O
children	O
with	O
ASD	O
were	O
significantly	O
less	O
likely	O
to	B-O
perceive	I-O
the	I-O
illusion	I-O
relative	O
to	O
TD	O
controls	O
,	O
suggesting	O
that	B-O
multisensory	I-O
integration	I-O
and	I-O
cross-modal	I-O
binding	I-O
may	O
be	O
weaker	O
in	O
some	O
children	O
with	O
ASD	B-P
.	O


These	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
previous	O
findings	O
for	B-O
multisensory	I-O
integration	I-O
in	O
ASD	O
and	O
future	O
directions	O
for	O
research	O
.	O


Alleviating	O
social	O
avoidance	O
:	O
effects	O
of	O
single	B-I
dose	I-I
testosterone	I-I
administration	I-I
on	O
approach-avoidance	B-O
action	I-O
.	I-O


Testosterone	B-I
is	O
an	O
important	O
regulator	O
of	O
social-motivational	B-O
behavior	I-O
and	O
is	O
known	O
for	O
its	O
dominance-enhancing	B-O
and	I-O
social-anxiolytic	I-O
properties	O
.	O


However	O
,	O
to	O
date	O
no	O
studies	O
have	O
systematically	O
investigated	O
the	O
causal	O
effect	O
of	O
testosterone	O
on	O
actual	B-O
social	I-O
approach-avoidance	I-O
behavior	I-O
in	O
humans	O
.	O


The	O
present	O
study	O
sets	O
out	O
to	O
test	O
the	O
effects	O
of	O
testosterone	B-I
administration	I-I
in	O
healthy	B-P
female	I-P
volunteers	I-P
using	I-P
an	I-P
objective	I-P
implicit	I-P
measure	I-P
of	I-P
social	I-O
motivational	I-O
behavior	I-O
:	I-O
the	O
social	B-O
Approach-Avoidance	I-O
Task	I-O
,	O
a	O
reaction	O
time	O
task	O
requiring	O
participants	O
to	O
approach	B-O
or	I-O
avoid	I-O
visually	I-O
presented	I-O
emotional	I-O
(	I-O
happy	I-O
,	I-O
angry	I-O
,	I-O
and	I-O
neutral	I-O
)	I-O
faces	I-O
.	I-O


Participants	O
showed	O
significantly	O
diminished	O
avoidance	B-O
tendencies	I-O
to	O
angry	B-O
faces	I-O
after	O
testosterone	B-I
administration	O
.	O


Testosterone	B-I
did	O
not	O
affect	O
approach-avoidance	B-O
tendencies	I-O
to	I-O
social	I-O
affiliation	I-O
(	I-O
happy	I-O
)	I-O
faces	I-O
.	I-O


Thus	O
,	O
a	O
single	O
dose	O
testosterone	B-I
administration	O
reduces	O
automatic	B-O
avoidance	I-O
of	I-O
social	I-O
threat	I-O
and	I-O
promotes	I-O
relative	I-O
increase	I-O
of	I-O
threat	I-O
approach	I-O
tendencies	I-O
in	O
healthy	B-P
females	I-P
.	I-P


These	O
findings	O
further	O
the	O
understanding	O
of	O
the	O
neuroendocrine	O
regulation	O
of	O
social	B-O
motivational	I-O
behavior	I-O
and	O
may	O
have	O
direct	O
treatment	O
implications	O
for	O
social	B-O
anxiety	I-O
,	O
characterized	O
by	O
persistent	O
social	B-O
avoidance	I-O
.	I-O


Electrothermal	B-I
arthroscopic	I-I
capsulorrhaphy	I-I
:	I-I
old	O
technology	O
,	O
new	O
evidence	O
.	O


A	O
multicenter	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
Radiofrequency	O
technology	O
for	O
shoulder	B-P
instability	I-P
was	O
rapidly	O
adopted	O
despite	O
limited	O
clinical	O
evidence	O
and	O
a	O
poor	O
understanding	O
of	O
its	O
indications	O
.	O


Reports	O
of	O
serious	O
adverse	O
events	O
followed	O
,	O
leading	O
to	O
its	O
abandonment	O
.	O


This	O
paper	O
presents	O
findings	O
from	O
a	O
multicenter	O
randomized	O
clinical	O
trial	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
electrothermal	B-I
arthroscopic	I-I
capsulorrhaphy	I-I
(	I-I
ETAC	I-I
)	I-I
compared	I-I
with	I-I
open	I-I
inferior	I-I
capsular	I-I
shift	I-I
(	I-I
ICS	I-I
)	I-I
and	O
reviews	O
the	O
role	O
of	O
randomized	O
trials	O
in	O
adopting	O
new	O
technology	O
.	O


METHODS	O
Patients	B-P
(	I-P
>	I-P
14	I-P
years	I-P
)	I-P
diagnosed	I-P
with	I-P
multidirectional	I-P
instability	I-P
or	I-P
multidirectional	I-P
laxity	I-P
with	I-P
anteroinferior	I-P
instability	I-P
and	I-P
failed	I-P
nonoperative	I-P
treatment	I-P
were	I-P
enrolled	I-P
.	I-P


Patients	B-P
with	I-P
bone	I-P
lesions	I-P
or	I-P
labral	I-P
,	I-P
biceps	I-P
anchor	I-P
,	I-P
or	I-P
full-thickness	I-P
rotator	I-P
cuff	I-P
tears	I-P
were	I-P
excluded	I-P
intraoperatively	I-P
.	I-P


Outcomes	O
included	B-O
Western	I-O
Ontario	I-O
Shoulder	I-O
Instability	I-O
Index	I-O
,	I-O
function	I-O
and	I-O
recurrent	I-O
instability	I-O
at	I-O
2	I-O
years	I-O
postoperatively	I-O
,	I-O
and	I-O
surgical	I-O
times	I-O
.	O


RESULTS	B-P
Fifty-four	I-P
subjects	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
23	I-P
years	I-P
;	I-P
37	I-P
women	I-P
)	I-P
were	I-P
randomized	I-P
to	O
ETAC	O
(	O
n	O
=	O
28	O
)	O
or	O
open	O
ICS	O
(	B-P
n	I-P
=	I-P
26	I-P
)	I-P
.	O


The	O
groups	O
were	O
comparable	O
at	O
baseline	O
,	O
except	B-O
for	I-O
external	I-O
rotation	I-O
at	I-O
the	I-O
side	O
.	O


At	O
2	O
years	O
postoperatively	O
,	O
there	O
were	O
no	O
statistically	O
or	O
clinically	O
significant	O
differences	O
between	O
groups	O
for	B-O
the	I-O
Western	I-O
Ontario	I-O
Shoulder	I-O
Instability	I-O
Index	O
(	B-O
P	I-O
=	I-O
.71	I-O
)	I-O
,	I-O
American	I-O
Shoulder	I-O
and	I-O
Elbow	I-O
Surgeons	I-O
score	O
(	B-O
P	I-O
=	I-O
.43	I-O
)	I-O
,	I-O
Constant	I-O
score	O
(	B-O
P	I-O
=	I-O
.43	I-O
)	I-O
,	I-O
and	I-O
active	I-O
range	I-O
of	I-O
motion	I-O
.	I-O


Recurrent	B-O
instability	O
was	O
not	O
statistically	O
different	O
(	O
ETAC	O
,	O
2	O
;	O
open	O
,	O
4	B-O
;	I-O
P	I-O
=	I-O
.41	I-O
)	I-O
.	O


ETAC	O
(	O
23	O
minutes	O
)	O
was	O
significantly	O
shorter	O
than	O
open	O
ICS	O
(	O
59	O
minutes	O
)	O
(	O
P	O
<	O
.01	O
)	O
surgery	O
.	O


Three	O
subjects	O
(	O
1	O
ETAC	O
,	O
2	O
open	O
)	O
had	O
stiff	O
shoulders	O
.	O


CONCLUSIONS	O
At	O
2	O
years	B-O
postoperatively	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
and	I-O
functional	O
outcomes	O
between	O
groups	O
were	O
not	O
clinically	O
different	B-O
.	I-O


ETAC	B-O
had	I-O
fewer	I-O
complications	I-O
and	I-O
episodes	I-O
of	O
recurrence	O
compared	O
with	O
open	O
surgery	O
.	O


This	O
evidence	O
reinforces	O
the	O
need	O
to	O
critically	O
evaluate	O
new	O
technology	O
before	O
widespread	O
clinical	O
use	O
.	O


Toxicity	B-O
and	I-O
efficacy	I-O
of	O
6-thioguanine	B-I
versus	I-I
6-mercaptopurine	I-I
in	O
childhood	B-P
lymphoblastic	I-P
leukaemia	I-P
:	I-P
a	O
randomised	O
trial	O
.	O


BACKGROUND	O
6-mercaptopurine	B-I
has	O
been	O
a	O
standard	O
component	O
of	O
long-term	O
continuing	O
treatment	O
for	O
childhood	B-P
lymphoblastic	I-P
leukaemia	I-P
,	O
whereas	O
6-thioguanine	B-I
has	O
been	O
mainly	O
used	O
for	O
intensification	O
courses	O
.	O


Since	O
preliminary	O
data	O
have	O
shown	O
that	O
6-thioguanine	B-I
is	O
more	O
effective	O
than	O
6-mercaptopurine	B-I
,	O
we	O
compared	O
the	O
efficacy	B-O
and	I-O
toxicity	I-O
of	O
the	O
two	O
drugs	O
for	O
childhood	B-P
lymphoblastic	I-P
leukaemia	I-P
.	I-P


METHODS	O
Consecutive	B-P
children	I-P
with	I-P
lymphoblastic	I-P
leukaemia	I-P
diagnosed	I-P
in	I-P
the	I-P
UK	I-P
and	I-P
Ireland	I-P
between	I-P
April	I-P
,	I-P
1997	I-P
,	I-P
and	I-P
June	I-P
,	I-P
2002	I-P
,	O
were	O
randomly	O
assigned	O
either	O
6-thioguanine	B-I
(	I-I
750	I-I
patients	O
)	O
or	O
6-mercaptopurine	B-I
(	O
748	O
patients	O
)	O
during	O
interim	O
maintenance	O
and	O
continuing	O
therapy	O
.	O


All	O
patients	O
received	O
6-thioguanine	B-I
during	O
intensification	O
courses	O
.	O


We	O
analysed	O
event-free	B-O
and	I-O
overall	I-O
survival	I-O
on	O
an	O
intention-to-treat	O
basis	O
.	O


We	O
obtained	O
toxicity	B-O
data	O
using	O
an	O
adverse-event	O
reporting	O
system	O
,	O
with	O
follow-up	O
questionnaires	O
to	O
seek	O
detailed	O
information	O
for	O
specific	O
toxicities	O
.	O


This	O
trial	O
is	O
registered	O
with	O
the	O
International	O
Standard	O
Randomised	O
Controlled	O
Number	O
26727615	O
with	O
the	O
name	O
ALL97	O
.	O


FINDINGS	O
After	O
a	O
median	O
follow	O
up	O
of	O
6	O
years	O
,	O
there	O
was	O
no	O
difference	O
in	O
event-free	B-O
or	I-O
overall	I-O
survival	I-O
between	O
the	O
two	O
treatment	O
groups	O
.	O


Although	O
6-thioguanine	B-I
conferred	O
a	O
significantly	O
lower	O
risk	O
of	O
isolated	O
CNS	B-O
relapse	I-O
than	O
did	O
6-mercaptopurine	B-I
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.53	O
,	O
95	O
%	O
CI	O
0.30-0.92	O
,	O
p=0.02	O
)	O
,	O
the	O
benefit	O
was	O
offset	O
by	O
an	O
increased	O
risk	B-O
of	I-O
death	I-O
in	O
remission	O
(	O
2.22	O
,	O
1.20-4.14	O
,	O
p=0.01	O
)	O
,	O
mainly	O
due	O
to	O
infections	O
during	O
continuing	O
therapy	O
.	O


Additionally	O
,	O
95	O
patients	O
developed	O
veno-occlusive	B-O
disease	I-O
of	I-O
the	I-O
liver	I-O
.	I-O


Of	O
these	O
,	O
82	O
were	O
randomly	O
assigned	O
6-thioguanine	B-I
,	O
representing	O
11	O
%	O
of	O
all	O
6-thioguanine	B-I
recipients	O
.	O


On	O
long-term	O
follow-up	O
,	O
about	O
5	O
%	O
of	O
6-thioguanine	B-I
recipients	O
have	O
evidence	O
of	O
non-cirrhotic	B-O
portal	I-O
hypertension	I-O
due	O
to	O
periportal	O
liver	O
fibrosis	O
or	O
nodular	O
regenerative	O
hyperplasia	O
.	O


INTERPRETATION	O
Compared	O
with	O
6-mercaptopurine	B-I
,	I-I
6-thioguanine	I-I
causes	O
excess	O
toxicity	B-O
without	O
an	O
overall	B-O
benefit	I-O
.	I-O


6-mercaptopurine	B-I
should	O
remain	O
the	O
thiopurine	O
of	O
choice	O
for	O
continuing	O
therapy	O
of	O
childhood	O
lymphoblastic	O
leukaemia	O
.	O


[	O
Effects	O
of	O
simvastatin	B-I
on	O
plasma	B-O
lipids	I-O
,	I-O
lipoproteins	I-O
and	O
apoproteins	B-O
(	O
A1	O
and	O
B	O
)	O
.	O


24	O
cases	O
of	O
major	O
primary	O
hypercholesterolemia	B-P
]	I-P
.	O


We	O
studied	O
the	O
effects	O
of	O
simvastatin	B-I
(	I-I
MK	I-I
733	I-I
)	I-I
,	O
a	O
new	O
competitive	O
inhibitor	O
of	O
HMG	B-I
CoA	I-I
reductase	I-I
,	I-I
alone	I-I
and	I-I
in	I-I
combination	I-I
with	I-I
a	I-I
bile	I-I
acid	I-I
sequestrant	I-I
,	I-I
cholestyramine	I-I
,	O
on	O
serum	O
levels	O
of	O
lipoproteins	O
and	O
apoproteins	O
A1	O
and	O
B	O
,	O
in	O
24	B-P
patients	I-P
with	I-P
familial	I-P
hypercholesterolemia	I-P
.	I-P


After	O
simvastatin	B-I
treatment	I-I
(	O
40	O
mg/day	O
)	O
alone	O
for	O
12	O
weeks	O
,	O
serum	O
total	O
and	O
low	B-O
density	I-O
lipoprotein	I-O
cholesterol	I-O
decreased	O
by	O
31	O
and	O
36	O
percent	O
respectively	O
.	O


With	O
the	O
addition	O
of	O
cholestyramine	B-I
,	O
there	O
was	O
a	O
41	O
per	O
cent	O
total	O
decrease	O
in	O
serum	B-O
cholesterol	I-O
from	O
the	O
control	O
value	O
and	O
a	O
50	O
percent	O
decrease	O
in	O
low	B-O
density	I-O
lipoprotein	I-O
cholesterol	I-O
.	I-O


After	O
cholestyramine	B-I
treatment	I-I
alone	O
for	O
12	O
weeks	O
,	O
serum	B-O
total	I-O
and	I-O
low	I-O
density	I-O
lipoprotein	I-O
cholesterol	I-O
decreased	O
by	O
20	O
percent	O
and	O
29	O
percent	O
respectively	O
.	O


With	O
the	O
addition	O
of	O
simvastatin	B-I
(	O
20	O
mg	O
per	O
day	O
)	O
,	O
there	O
was	O
a	O
32	O
percent	O
total	O
decrease	O
in	O
serum	B-O
cholesterol	I-O
from	O
the	O
control	O
value	O
and	O
a	O
43	O
percent	O
decrease	O
in	O
low	O
density	B-O
lipoprotein	I-O
cholesterol	I-O
.	I-O


High	B-O
density	I-O
lipoprotein	I-O
cholesterol	I-O
remained	O
unchanged	O
.	O


No	O
major	B-O
adverse	I-O
effect	I-O
was	O
observed	O
.	O


If	O
long	O
term	O
safety	O
can	O
be	O
confirmed	O
,	O
the	O
simvastatin-cholestyramine	B-I
regimen	I-I
may	O
prove	O
useful	O
in	O
heterozygous	B-P
familial	I-P
hypercholesterolemia	I-P
.	I-P


Concentration	O
of	O
inhaled	B-I
amiloride	I-I
in	O
cystic	B-P
fibrosis	I-P
.	I-P


Effect	O
of	O
TENS	O
on	O
pain	B-O
,	I-O
medications	I-O
,	I-O
and	I-O
pulmonary	I-O
function	I-O
following	I-P
coronary	I-P
artery	I-P
bypass	I-P
graft	I-P
surgery	I-P
.	I-P


The	O
efficacy	O
of	O
transcutaneous	B-I
electrical	I-I
nerve	I-I
stimulation	I-I
(	I-I
TENS	I-I
)	I-I
as	O
an	O
adjunct	O
to	O
narcotic	O
medications	O
for	O
the	O
management	O
of	O
postoperative	B-O
pain	I-O
was	O
assessed	O
in	O
a	O
prospective	B-P
,	I-P
randomized	I-P
,	I-P
controlled	I-P
study	I-P
of	I-P
patients	I-P
following	I-P
coronary	I-P
artery	I-P
bypass	I-P
graft	I-P
(	I-P
CABG	I-P
)	I-P
surgery	I-P
with	I-P
the	I-P
right	I-P
or	I-P
left	I-P
internal	I-P
thoracic	I-P
artery	I-P
(	I-P
ITA	I-P
)	I-P
.	I-P


Forty-five	B-P
male	I-P
patients	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
57	I-P
+/-	I-P
6	I-P
years	I-P
)	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
(	O
1	O
)	O
TENS	B-I
,	O
(	O
2	O
)	O
placebo	B-I
TENS	I-I
,	I-I
or	I-I
(	I-I
3	I-I
)	I-I
control	I-I
treatments	I-I
(	O
n	O
=	O
15	O
each	O
)	O
,	O
following	O
extubation	O
and	O
during	O
the	O
24-	O
to	O
72-h	O
postoperative	O
period	O
.	O


Two-way	O
analysis	O
of	O
variance	O
tests	O
indicated	O
no	O
significant	O
differences	O
among	O
treatment	O
groups	O
for	O
(	B-O
1	I-O
)	I-O
pain	I-O
with	I-O
cough	I-O
,	I-O
(	I-O
2	I-O
)	I-O
narcotic	I-O
medication	I-O
intake	I-O
,	I-O
(	I-O
3	I-O
)	I-O
FVC	I-O
,	I-O
(	I-O
4	I-O
)	I-O
FEV1	I-O
,	I-O
and	I-O
(	I-O
5	I-O
)	I-O
PEFR	I-O
(	O
p	O
>	O
0.05	O
)	O
.	O


However	O
,	O
pain	B-O
at	I-O
rest	I-O
reported	O
by	O
the	O
TENS	B-P
group	I-P
was	O
significantly	O
lower	O
than	O
that	O
reported	O
by	O
the	O
control	O
group	O
(	O
treatment	O
main	O
effect	O
;	O
p	O
<	O
0.04	O
)	O
,	O
although	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
TENS	O
and	O
placebo	O
or	O
between	O
the	O
placebo	O
and	O
control	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O


All	O
six	O
criterion	O
measures	O
were	O
characterized	O
by	O
significant	O
changes	O
over	O
time	O
for	O
the	O
entire	O
group	O
(	O
n	O
=	O
45	O
;	O
time	O
main	O
effect	O
;	O
p	O
<	O
0.01	O
)	O
,	O
as	O
follows	O
:	O
pain	B-O
and	I-O
medication	I-O
intake	I-O
were	O
similar	O
on	O
days	O
1	O
and	O
2	O
,	O
but	O
were	O
significantly	O
less	O
on	O
day	O
3	O
,	O
and	O
pulmonary	B-O
functions	I-O
were	O
significantly	O
lower	O
than	O
preoperatively	O
on	O
day	O
1	O
,	O
decreased	O
further	O
on	O
day	O
2	O
,	O
and	O
despite	O
an	O
improvement	O
on	O
day	O
3	O
,	O
remained	O
significantly	O
lower	O
than	O
preoperative	O
values	O
(	O
p	O
<	O
0.01	O
)	O
.	O


This	O
study	O
suggests	O
that	O
the	O
addition	O
of	O
TENS	B-I
,	O
applied	O
continuously	O
during	O
the	O
immediate	O
postoperative	O
period	O
following	O
CABG	O
with	O
ITA	O
,	O
may	O
not	O
be	O
advantageous	O
in	O
pain	B-O
management	I-O
or	O
the	O
prevention	O
of	O
pulmonary	B-O
dysfunction	I-O
.	I-O


Patient	B-O
satisfaction	I-O
with	O
nutrition	O
services	O
amongst	O
cancer	B-P
patients	I-P
treated	I-P
with	I-P
autologous	I-P
stem	I-P
cell	I-P
transplantation	I-P
:	I-P
a	O
comparison	O
of	O
usual	B-I
and	O
extended	B-I
care	I-I
.	I-I


BACKGROUND	O
This	O
study	O
aimed	O
to	O
determine	O
patient	O
satisfaction	O
with	O
clinical	O
nutrition	B-I
services	I-I
delivered	O
by	O
an	O
accredited	O
practicing	O
dietitian	O
amongst	O
cancer	B-P
patients	I-P
treated	I-P
with	I-P
autologous	I-P
stem	I-P
cell	I-P
transplantation	I-P
that	O
was	O
provided	O
with	O
usual	B-I
and	O
extended	B-I
care	I-I
at	O
100	O
days	O
post-transplantation	O
.	O


METHODS	O
Patients	O
were	O
randomised	O
to	O
receive	B-I
usual	I-I
nutrition	I-I
care	I-I
or	I-I
extended	I-I
nutrition	I-I
care	I-I
during	O
the	O
course	O
of	O
their	O
stem	O
cell	O
transplantation	O
.	O


After	O
hospital	O
discharge	O
,	O
usual	B-I
care	I-I
patients	I-I
received	I-I
no	I-I
further	I-I
nutrition	I-I
support	I-I
,	I-I
whereas	I-I
extended	I-I
care	I-I
patients	I-I
received	I-I
telephone	I-I
dietary	I-I
counselling	I-I
from	I-I
the	I-I
same	I-I
dietitian	I-I
for	I-I
up	I-I
to	I-I
100	I-I
days	I-I
post-transplantation	I-I
.	O


The	O
patient	O
satisfaction	O
with	O
clinical	O
nutrition	O
service	O
questionnaire	O
was	O
completed	O
anonymously	O
at	O
100	O
days	O
post-transplantation	O
.	O


Group	O
comparisons	O
were	O
made	O
using	O
independent	O
t-tests	O
.	O


RESULTS	B-P
Thirty-seven	I-P
patients	I-P
consented	I-P
to	I-P
participate	I-P
in	I-P
the	I-P
study	I-P
(	I-P
54	I-P
%	I-P
male	I-P
;	I-P
mean	I-P
age	I-P
58.7	I-P
±	I-P
9.5	I-P
years	I-P
;	I-P
median	I-P
body	I-P
mass	I-P
index	I-P
26.8	I-P
kg	I-P
m	I-P
(	I-P
-2	I-P
)	I-P
,	I-P
range	I-P
16.4-47.6	I-P
kg	I-P
m	I-P
(	I-P
-2	I-P
)	I-P
)	I-P
;	I-P
33	I-P
patients	I-P
completed	I-P
the	I-P
study	I-P
and	I-P
28	I-P
patients	I-P
returned	I-P
the	I-P
questionnaire	I-P
(	I-P
response	I-P
rate	I-O
=	I-O
85	I-O
%	I-O
)	I-O
.	I-O


All	B-O
components	I-O
of	I-O
the	I-O
questionnaire	I-O
were	O
rated	O
highly	O
by	O
both	O
groups	O
;	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O


Although	O
not	O
statistically	O
significant	O
,	O
extended	O
care	O
patients	O
who	O
received	O
at	O
least	O
three	O
telephone	B-O
calls	O
rated	O
a	O
higher	B-O
overall	I-O
satisfaction	O
compared	O
to	O
those	O
who	O
received	O
less	O
calls	O
;	O
this	O
difference	O
was	O
clinically	O
important	O
(	O
score	O
difference	B-P
=	I-P
0.56	I-P
)	I-P
.	I-P


CONCLUSIONS	B-P
Cancer	I-P
patients	I-P
treated	I-P
with	I-P
autologous	I-P
stem	I-P
cell	I-P
transplantation	O
were	B-I
satisfied	I-I
with	I-I
usual	I-I
and	I-I
extended	I-I
nutrition	I-I
care	I-I
.	I-P


Extended	B-P
care	O
patients	O
who	O
received	O
at	O
least	O
three	O
telephone	O
calls	O
after	O
hospital	O
discharge	O
were	O
more	O
satisfied	O
than	O
those	O
with	O
less	O
frequent	O
intervention	O
.	O


Further	O
exploration	O
regarding	O
the	O
frequency	O
and	O
intensity	O
of	O
nutrition	O
service	O
is	O
required	O
.	O


Developmental	O
disabilities	O
modification	O
of	O
the	O
Children	O
's	O
Global	O
Assessment	O
Scale	O
.	O


BACKGROUND	O
Interventions	B-I
for	O
pervasive	B-P
developmental	I-P
disorders	I-P
(	I-P
PDD	I-P
)	I-P
aim	O
to	O
alleviate	O
symptoms	O
and	O
improve	O
functioning	O
.	O


To	O
measure	O
global	O
functioning	O
in	O
treatment	O
studies	O
,	O
the	O
Children	O
's	O
Global	O
Assessment	O
Scale	O
was	O
modified	O
and	O
psychometric	B-I
properties	I-I
of	I-I
the	I-I
revised	I-I
version	I-I
(	I-I
DD-CGAS	I-I
)	I-I
were	O
assessed	O
in	O
children	B-P
with	I-P
PDD	I-P
.	I-P


METHODS	O
Developmental	O
disabilities-relevant	O
descriptors	O
were	O
developed	O
for	O
the	O
DD-CGAS	O
,	O
and	O
administration	O
procedures	O
were	O
established	O
to	O
enhance	O
rater	O
consistency	O
.	O


Ratings	O
of	O
clinical	O
case	O
vignettes	O
were	O
used	O
to	O
assess	O
inter-rater	O
reliability	O
and	O
temporal	O
stability	O
.	O


Validity	O
was	O
assessed	O
by	O
correlating	O
the	O
DD-CGAS	O
with	O
measures	O
of	O
functioning	O
and	O
symptoms	O
in	O
83	B-P
youngsters	I-P
with	I-P
PDD	I-P
.	I-P


Sensitivity	O
to	O
change	O
was	O
assessed	O
by	O
comparing	O
change	O
from	O
baseline	O
to	O
post-treatment	O
with	O
change	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist-Irritability	O
and	O
Clinical	O
Global	O
Impressions-Improvement	O
subscale	O
scores	O
in	O
a	O
subset	O
of	O
14	O
children	O
.	O


RESULTS	O
Inter-rater	B-O
reliability	I-O
(	I-O
intraclass	I-O
correlation	I-O
coefficient	I-O
[	I-O
ICC	I-O
]	I-O
=	I-O
.79	I-O
)	I-O
and	I-O
temporal	I-O
stability	I-O
(	I-O
average	I-O
ICC	I-O
=	I-O
.86	I-O
)	I-O
were	I-O
excellent	I-O
.	I-O


The	B-O
DD-CGAS	I-O
scores	I-O
correlated	I-O
with	I-O
measures	I-O
of	I-O
functioning	I-O
and	I-O
symptoms	I-O
with	O
moderate	O
to	O
large	O
effect	O
sizes	O
.	O


Changes	B-O
on	I-O
the	I-O
DD-CGAS	I-O
correlated	I-O
with	I-O
changes	I-O
on	I-O
the	I-O
Aberrant	I-O
Behavior	I-O
Checklist-I	I-O
(	O
r	O
=	O
-.71	O
)	O
and	O
Global	B-O
Impressions	I-O
Scale-I	I-O
(	O
r	O
=	O
-.52	O
)	O
.	O


The	B-O
pre-post	I-O
DD-CGAS	I-O
change	I-O
had	O
an	O
effect	O
size	O
of	O
.72	O
.	O


CONCLUSIONS	O
The	O
DD-CGAS	O
is	O
a	O
reliable	O
instrument	O
with	O
apparent	O
convergent	O
validity	O
for	O
measuring	O
global	O
functioning	O
of	O
children	B-P
with	I-P
PDD	I-P
in	O
treatment	O
studies	O
.	O


Atypical	O
recruitment	O
of	O
medial	O
prefrontal	O
cortex	O
in	O
autism	B-P
spectrum	I-P
disorders	I-P
:	I-P
an	O
fMRI	B-I
study	O
of	O
two	O
executive	B-I
function	I-I
tasks	I-I
.	I-I


Recent	O
studies	O
have	O
suggested	O
an	O
uneven	O
profile	O
of	O
executive	O
dysfunction	O
in	O
autism	B-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


For	O
example	O
,	O
some	O
authors	O
have	O
reported	O
deficits	O
on	O
newly	O
developed	O
tests	O
of	O
executive	O
function	O
sensitive	O
to	O
rostral	O
prefrontal	O
function	O
,	O
despite	O
spared	O
,	O
or	O
even	O
superior	O
,	O
performance	O
on	O
other	O
tests	O
.	O


We	O
investigated	O
the	O
performance	O
of	O
a	O
group	O
of	O
high-functioning	B-P
participants	I-P
with	I-P
ASD	I-P
(	I-P
N=15	I-P
)	I-P
and	I-P
an	I-P
age-	I-P
and	I-P
IQ-matched	I-P
control	I-P
group	I-P
(	I-P
N=18	I-P
)	I-P
on	O
two	B-I
executive	I-I
function	I-I
tests	I-I
,	O
whilst	O
undergoing	B-I
functional	I-I
magnetic	I-I
resonance	I-I
imaging	I-I
(	I-I
fMRI	I-I
)	I-I
.	I-I


Behaviourally	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
.	O


In	O
a	O
classical	B-I
test	I-I
of	I-I
executive	I-I
function	I-I
(	O
random	O
response	O
generation	O
)	O
,	O
BOLD	B-O
signal	I-O
differed	O
between	O
the	O
groups	O
in	O
the	O
cerebellum	O
but	O
not	O
in	O
the	O
frontal	O
lobes	O
.	O


However	O
,	O
on	O
a	O
new	B-I
test	I-I
of	I-I
executive	I-I
function	I-I
(	O
selection	O
between	O
stimulus-oriented	O
and	O
stimulus-independent	O
thought	O
)	O
,	O
the	O
ASD	O
group	O
exhibited	O
significantly	O
greater	O
signal-change	B-O
in	I-O
medial	I-O
rostral	I-O
prefrontal	I-O
cortex	I-O
(	I-O
especially	I-O
Brodmann	I-O
Area	I-O
10	I-O
)	I-O
in	O
the	O
comparison	O
of	O
stimulus-oriented	O
versus	O
stimulus-independent	O
attention	O
.	O


In	O
addition	O
,	O
the	O
new	O
test	O
(	O
but	O
not	O
the	O
classical	O
test	O
)	O
provided	O
evidence	O
for	O
abnormal	B-O
functional	I-O
organisation	I-O
of	I-O
medial	I-O
prefrontal	I-O
cortex	I-O
in	I-O
ASD	I-O
.	I-O


These	O
results	O
underline	O
the	O
heterogeneity	O
of	O
different	O
tests	O
of	O
executive	O
function	O
,	O
and	O
suggest	O
that	O
executive	O
functioning	O
in	O
ASD	B-P
is	O
associated	O
with	O
task-specific	O
functional	O
change	O
.	O


Should	O
insertion	O
of	O
intramedullary	O
nails	O
for	O
tibial	B-P
fractures	I-P
be	O
with	O
or	O
without	O
reaming	O
?	O
A	O
prospective	O
,	O
randomized	O
study	O
with	O
3.8	O
years	O
'	O
follow-up	O
.	O


OBJECTIVE	O
To	O
determine	O
if	O
any	O
differences	O
exist	O
in	O
healing	B-O
and	I-O
complications	I-O
between	O
reamed	B-I
and	I-I
unreamed	I-I
nailing	I-I
in	O
patients	B-P
with	I-P
tibial	I-P
shaft	I-P
fractures	I-P
.	I-P


DESIGN	O
Prospective	O
,	O
randomized	O
.	O


SETTING	O
Level	B-P
1	I-P
trauma	I-P
center	I-P
.	I-P


PATIENTS	O
Forty-five	B-P
patients	I-P
with	I-P
displaced	I-P
closed	I-P
and	I-P
open	I-P
Gustilo	I-P
type	I-P
I-IIIA	I-P
fractures	I-P
of	I-P
the	I-P
central	I-P
two	I-P
thirds	I-P
of	I-P
the	I-P
tibia	I-P
.	I-P


INTERVENTION	O
Stabilization	B-I
of	I-I
tibial	I-I
fractures	I-I
either	I-I
with	I-I
a	I-I
slotted	I-I
,	I-I
stainless	I-I
steel	I-I
reamed	I-I
nail	I-I
or	I-I
a	I-I
solid	I-I
,	I-I
titanium	I-I
unreamed	I-I
nail	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASUREMENTS	O
Nonunions	B-O
,	I-O
time	I-O
to	I-O
fracture	I-O
healing	I-O
,	I-O
and	I-O
rate	I-O
of	I-O
malunions	I-O
.	I-O


RESULTS	O
The	O
average	B-O
time	I-O
to	I-O
fracture	I-O
healing	I-O
was	O
16.7	O
weeks	O
in	O
the	O
reamed	B-I
group	O
and	O
25.7	O
weeks	O
in	O
the	O
unreamed	B-I
group	O
.	O


The	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
0.004	O
)	O
.	O


There	O
were	O
three	O
nonunions	B-O
,	O
all	O
in	O
the	O
unreamed	B-I
nail	I-I
group	O
.	O


Two	O
of	O
these	O
fractures	O
healed	B-O
after	I-O
dynamization	I-O
by	I-O
removing	I-O
static	I-O
interlocking	I-O
screws	I-O
.	I-O


The	O
third	O
nonunion	O
did	O
not	O
heal	B-O
despite	O
exchange	O
reamed	B-I
nailing	O
2	O
years	O
after	O
the	O
primary	O
surgery	O
and	O
dynamization	O
with	O
a	O
fibular	O
osteotomy	O
after	O
an	O
additional	O
1	O
year	O
.	O


There	O
were	O
two	O
malunions	B-O
in	O
the	O
reamed	B-I
group	O
and	O
four	O
malunions	B-O
in	O
the	O
unreamed	B-I
group	O
.	O


There	O
were	O
no	O
differences	O
for	O
all	O
other	O
outcome	O
measurements	O
.	O


CONCLUSION	O
Unreamed	B-I
nailing	I-I
in	I-I
patients	I-P
with	I-P
tibial	I-P
shaft	I-P
fractures	I-P
may	O
be	O
associated	O
with	O
higher	O
rates	B-O
of	I-O
secondary	I-O
operations	I-O
and	I-O
malunions	I-O
compared	O
with	O
reamed	B-I
nailing	I-I
.	I-I


The	O
time	B-O
to	I-O
fracture	I-O
healing	I-O
was	O
significantly	O
longer	O
with	O
unreamed	B-I
nails	I-I
.	I-I


Modafinil	B-I
effects	O
during	O
acute	B-P
continuous	I-P
positive	I-P
airway	I-P
pressure	I-P
withdrawal	I-P
:	I-P
a	O
randomized	O
crossover	O
double-blind	O
placebo-controlled	O
trial	O
.	O


RATIONALE	O
Continuous	B-I
positive	I-I
airway	I-I
pressure	I-I
(	I-I
CPAP	I-I
)	I-I
use	O
is	O
associated	O
with	O
reduced	O
motor	O
vehicle	O
accidents	O
in	O
patients	B-P
with	I-P
obstructive	I-P
sleep	I-P
apnea	I-P
(	I-P
OSA	I-P
)	I-P
.	I-P


However	O
,	O
interruption	O
of	O
CPAP	O
therapy	O
is	O
common	O
and	O
is	O
associated	O
with	O
a	O
decline	O
in	O
daytime	O
function	O
.	O


OBJECTIVES	O
We	O
hypothesized	O
that	O
the	O
wakefulness	O
promoter	O
,	O
modafinil	O
,	O
would	O
ameliorate	O
this	O
decline	O
.	O


METHODS	O
Patients	B-P
were	I-P
admitted	I-P
to	I-P
the	I-P
laboratory	I-P
for	I-P
three	I-P
consecutive	I-P
nights	I-P
.	I-P


CPAP	B-I
was	O
used	O
for	O
the	O
first	O
night	O
,	O
followed	O
by	O
a	O
baseline	O
day	O
,	O
and	O
was	O
then	O
withdrawn	O
for	O
the	O
two	O
subsequent	O
nights	O
(	O
nasal	O
airflow	O
monitored	O
)	O
.	O


On	O
each	O
of	O
the	O
mornings	O
after	O
the	O
two	O
CPAP	O
withdrawal	O
nights	O
,	O
patients	O
received	O
200	B-I
mg	I-I
modafinil	I-I
or	I-I
placebo	I-I
(	O
n	O
=	O
21	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
design	O
.	O


Treatment	O
periods	O
were	O
separated	O
by	O
a	O
5-week	O
washout	O
.	O


Driving	B-O
simulator	I-O
performance	I-O
,	I-O
neurocognitive	I-O
performance	I-O
,	I-O
and	I-O
subjective	I-O
alertness	I-O
were	O
measured	O
by	O
the	O
AusEd	O
driving	O
simulator	O
,	O
psychomotor	O
vigilance	O
task	O
,	O
and	O
Karolinska	O
Sleepiness	O
Scale	O
,	O
respectively	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
During	O
CPAP	O
withdrawal	O
,	O
severe	B-O
sleep-disordered	I-O
breathing	I-O
was	O
evident	O
and	O
administration	O
of	O
modafinil	O
improved	O
simulated	B-O
driving	I-O
performance	I-O
(	I-O
steering	I-O
variability	I-O
,	O
P	O
<	O
0.0001	O
;	O
mean	B-O
reaction	I-O
time	I-O
,	O
P	O
<	O
or=	O
0.0002	O
;	O
lapses	B-O
,	O
P	O
<	O
or=	O
0.01	O
on	O
a	O
concurrent	O
task	O
)	O
,	O
psychomotor	B-O
vigilance	I-O
task	I-O
(	O
mean	O
1/reaction	O
time	O
and	O
lapses	O
,	O
both	O
P	O
<	O
or=	O
0.0002	O
)	O
,	O
and	O
subjective	B-O
sleepiness	I-O
(	O
P	O
<	O
or=	O
0.01	O
)	O
.	O


CONCLUSIONS	O
Modafinil	O
prevented	O
the	O
decline	O
in	O
simulated	O
driving	B-O
performance	I-O
,	I-O
neurocognitive	I-O
performance	I-O
,	O
and	O
subjective	B-O
sleepiness	I-O
in	O
patients	B-P
with	I-P
OSA	I-P
with	O
acutely	O
interrupted	O
CPAP	O
therapy	O
.	O


Clinical	O
trial	O
registered	O
with	O
the	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
at	O
www.anzctr.org.au	O
(	O
ACTRN12606000027516	O
)	O
.	O


A	O
comparative	O
study	O
of	O
the	O
effects	O
of	O
local	O
estrogen	O
with	O
or	O
without	O
local	O
testosterone	B-I
on	O
vulvovaginal	B-O
and	I-O
sexual	I-O
dysfunction	I-O
in	I-P
postmenopausal	I-P
women	I-P
.	I-P


INTRODUCTION	O
A	O
significant	O
number	O
of	O
postmenopausal	B-P
women	I-P
suffer	O
from	O
distressing	O
problems	O
because	O
of	O
urogenital	O
atrophy	O
secondary	O
to	O
the	O
decline	O
in	O
circulating	O
estrogen	O
levels	O
.	O


Treatment	O
with	O
topical	B-I
hormones	I-I
may	O
provide	O
relief	O
in	O
such	O
women	O
when	O
used	O
judiciously	O
.	O


AIM	O
To	O
study	O
the	O
effects	O
of	O
local	O
estrogen	O
with	O
or	O
without	O
local	B-I
testosterone	I-I
on	O
urogenital	B-O
and	I-O
sexual	I-O
health	I-O
in	O
postmenopausal	B-P
women	I-P
.	I-P


METHODS	O
Seventy-five	B-P
postmenopausal	I-P
women	I-P
symptomatic	I-P
for	I-P
urogenital	I-P
atrophy	I-P
and	I-P
sexual	I-P
dysfunction	I-P
were	O
randomly	O
divided	O
into	O
two	O
study	O
groups	O
and	O
one	O
control	O
group	O
.	O


The	O
women	O
in	O
study	O
group	O
1	O
received	B-I
local	I-I
estrogen	I-I
cream	I-I
;	I-I
study	I-I
group	I-I
2	I-I
received	I-I
local	I-I
estrogen	I-I
and	I-I
testosterone	I-I
cream	I-I
;	I-I
the	I-I
control	I-I
group	I-I
received	I-I
nonhormonal	I-I
lubricant	I-I
KY	I-I
gel	I-I
for	I-I
12	I-I
weeks	I-I
.	I-I


The	O
urogenital	B-O
and	I-O
sexuality	I-O
score	I-O
,	O
along	O
with	O
the	O
vaginal	B-O
health	I-O
index	I-O
and	I-O
the	I-O
vaginal	I-O
maturation	I-O
index	I-O
(	I-O
VMI	I-O
)	I-O
,	O
was	O
calculated	O
at	O
the	O
beginning	O
of	O
therapy	O
and	O
12	O
weeks	O
later	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Changes	B-O
in	I-O
the	I-O
urogenital	I-O
and	I-O
sexuality	I-O
score	I-O
along	I-O
with	I-O
vaginal	I-O
health	I-O
index	I-O
and	I-O
VMI	I-O
.	I-O


RESULTS	O
After	O
12	O
weeks	O
of	O
therapy	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
all	O
the	O
four	O
study	O
parameters	O
,	O
which	O
correlated	O
well	O
with	O
the	O
improvement	O
in	O
symptoms	O
of	O
urogenital	O
atrophy	O
and	O
sexual	O
dysfunction	O
in	O
both	O
the	O
study	B-P
groups	I-P
as	O
compared	O
with	O
the	O
control	B-P
group	I-P
.	I-P


Improvement	O
in	O
sexuality	B-O
score	I-O
was	O
greatest	O
with	O
combined	O
estrogen-androgen	O
therapy	O
.	O


There	O
were	O
no	O
adverse	B-O
effects	I-O
and	O
the	O
therapies	O
were	O
well	O
accepted	O
without	O
any	O
compliance	O
issue	O
.	O


CONCLUSION	O
Local	B-I
estrogen	I-I
either	O
alone	O
or	O
with	O
androgen	O
is	O
highly	O
effective	O
in	O
relieving	O
symptoms	O
of	O
urogenital	B-O
atrophy	I-O
and	O
in	O
improving	B-O
sexual	I-O
function	I-O
in	O
symptomatic	B-P
postmenopausal	I-P
women	I-P
.	I-P


Potential	O
effect	O
of	O
the	O
risk	O
of	O
ovarian	B-I
cancer	I-I
algorithm	I-I
(	I-I
ROCA	I-I
)	I-I
on	O
the	O
mortality	B-O
outcome	I-O
of	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
and	O
Ovarian	O
(	O
PLCO	O
)	O
trial	O
.	O


Recently	O
,	O
the	O
Prostate	B-P
,	I-P
Lung	I-P
,	I-P
Colorectal	I-P
and	I-P
Ovarian	I-P
(	I-P
PLCO	I-P
)	I-P
Trial	I-P
reported	O
no	O
mortality	O
benefit	O
for	O
annual	O
screening	B-I
with	I-I
CA-125	I-I
and	I-I
transvaginal	I-I
ultrasound	I-I
(	I-I
TVU	I-I
)	I-I
.	I-I


Currently	O
ongoing	O
is	O
the	O
UK	O
Collaborative	O
Trial	O
of	O
Ovarian	O
Cancer	O
Screening	O
(	O
UKCTOCS	O
)	O
,	O
which	O
utilizes	O
the	O
risk	O
of	O
ovarian	B-I
cancer	I-I
algorithm	I-I
(	I-I
ROCA	I-I
)	I-I
,	O
a	O
statistical	O
tool	O
that	O
considers	O
current	O
and	O
past	O
CA125	O
values	O
to	O
determine	O
ovarian	O
cancer	O
risk	O
.	O


In	O
contrast	O
,	O
PLCO	O
used	O
a	O
single	O
cutoff	O
for	O
CA125	O
,	O
based	O
on	O
current	O
levels	O
alone	O
.	O


We	O
investigated	O
whether	O
having	O
had	O
used	O
ROCA	B-I
in	I-I
PLCO	I-I
could	O
have	O
,	O
under	O
optimal	O
assumptions	O
,	O
resulted	O
in	O
a	O
significant	B-O
mortality	I-O
benefit	I-O
by	O
applying	O
ROCA	O
to	O
PLCO	O
CA125	O
screening	O
values	O
.	O


A	O
best-case	O
scenario	O
assumed	O
that	O
all	B-P
cancers	I-P
showing	I-P
a	I-P
positive	I-P
screen	I-P
result	I-P
earlier	I-P
with	I-P
ROCA	I-P
than	I-P
under	I-P
the	I-P
PLCO	I-P
protocol	O
would	O
have	O
avoided	O
mortality	B-O
;	I-O
under	O
a	O
stage-shift	O
scenario	O
,	O
such	B-P
women	I-P
were	O
assigned	O
survival	O
equivalent	O
to	O
Stage	O
I/II	O
screen-detected	O
cases	O
.	O


Updated	O
PLCO	O
data	O
show	O
132	B-P
intervention	I-P
arm	I-P
ovarian	I-P
cancer	I-P
deaths	I-P
versus	I-P
119	I-P
in	I-P
usual	I-P
care	I-P
(	O
relative	O
risk	O
,	O
RR	O
=	O
1.11	O
)	O
.	O


Forty-three	O
ovarian	O
cancer	O
cases	O
,	O
25	O
fatal	O
,	O
would	O
have	O
been	O
detected	O
earlier	O
with	O
ROCA	B-I
,	O
with	O
a	O
median	O
(	O
minimum	O
)	O
advance	O
time	O
for	O
fatal	B-O
cases	I-O
of	O
344	O
(	O
147	O
)	O
days	O
.	O


Best-case	O
and	O
stage-shift	O
scenarios	O
gave	O
25	O
and	O
19	O
deaths	B-O
prevented	O
with	O
ROCA	B-I
,	O
for	O
RRs	O
of	O
0.90	O
(	O
95	O
%	O
CI	O
:	O
0.69-1.17	O
)	O
and	O
0.95	O
(	O
95	O
%	O
CI	O
:	O
0.74-1.23	O
)	O
,	O
respectively	O
.	O


Having	O
utilized	O
ROCA	B-I
in	O
PLCO	O
would	O
not	O
have	O
led	O
to	O
a	O
significant	O
mortality	B-O
benefit	I-O
of	O
screening	O
.	O


However	O
,	O
ROCA	B-I
could	O
still	O
show	O
a	O
significant	O
effect	O
in	O
other	O
screening	O
trials	O
,	O
including	O
UKCTOCS	O
.	O


Dose-dependent	O
effects	B-O
of	O
the	O
CRF	B-I
(	I-I
1	I-I
)	I-I
receptor	I-I
antagonist	I-I
R317573	I-I
on	O
regional	O
brain	O
activity	O
in	O
healthy	B-P
male	I-P
subjects	I-P
.	I-P


BACKGROUND	O
Corticotropin-releasing	B-I
factor	I-I
receptor	I-I
type	I-I
1	I-I
(	I-I
CRF	I-I
(	I-I
1	I-I
)	I-I
)	I-I
antagonists	O
have	O
been	O
proposed	O
as	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
mood	O
and	O
anxiety	O
disorders	O
although	O
clinical	O
evidence	O
supporting	O
their	O
development	O
and	O
understanding	O
of	O
a	O
dose-response	O
relationship	O
has	O
been	O
lacking	O
.	O


METHODS	O
We	O
tested	O
two	O
doses	O
of	O
the	O
CRF	B-I
(	I-I
1	I-I
)	I-I
antagonist	I-I
R317573	I-I
for	O
effects	O
on	O
regional	B-O
cerebral	I-O
glucose	I-O
metabolism	I-O
(	I-O
rCMglu	I-O
)	I-O
using	O
[	B-I
(	I-I
18	I-I
)	I-I
F	I-I
]	I-I
fluoro-2-deoxy-D	I-I
:	I-I
-glucose	I-I
(	I-I
FDG	I-I
)	I-I
positron	I-I
emission	I-I
tomography	I-I
(	I-I
PET	I-I
)	I-I
following	O
single-dose	O
challenges	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
cross-over	O
design	O
,	O
in	O
12	B-P
healthy	I-P
male	I-P
volunteers	I-P
.	I-P


RESULTS	O
Single	O
30-	O
and	O
200-mg	O
doses	O
of	O
R317573	B-I
resulted	O
in	O
dose-related	O
changes	O
in	O
rCMglu	B-O
.	I-O


Relative	O
increases	O
in	O
rCMglu	B-O
were	O
observed	O
in	O
frontal	O
cortical	O
regions	O
while	O
relative	O
decreases	O
occurred	O
in	O
the	O
putamen	O
and	O
right	O
amygdala	O
after	O
both	O
doses	O
.	O


Relative	O
decreases	O
occurred	O
in	O
cerebellum	O
and	O
right	O
parahippocampal	O
gyrus	O
following	O
the	O
higher	O
dose	O
.	O


CONCLUSIONS	O
R317573	B-I
appears	O
to	O
produce	O
acute	O
dose-dependent	O
changes	O
in	O
rCMglu	O
.	O


Effects	O
occurred	O
in	O
regions	O
that	O
may	O
be	O
behaviorally	O
relevant	O
to	O
mood	O
and	O
anxiety	O
disorders	O
.	O


In	O
some	O
regions	O
,	O
these	O
effects	O
may	O
be	O
related	O
to	O
the	O
receptor	O
(	O
target	O
)	O
density	O
.	O


Measuring	O
acute	O
effects	O
on	O
rCMglu	B-I
with	O
FDG-PET	B-I
may	O
offer	O
a	O
method	O
for	O
defining	O
pharmacologically	O
active	O
doses	O
for	O
central	O
nervous	O
system	O
targets	O
for	O
which	O
selective	O
radiotracers	O
are	O
lacking	O
.	O


Problem-solving	B-I
counseling	I-I
for	O
caregivers	O
of	O
the	O
cognitively	O
impaired	O
:	O
effective	O
for	O
whom	O
?	O
BACKGROUND	O
Individualized	O
problem-solving	B-I
counseling	I-I
for	O
caregivers	O
of	O
cognitively	O
impaired	O
relatives	O
is	O
thought	O
to	O
help	O
caregivers	O
cope	O
with	O
the	O
stress	O
and	O
burden	O
of	O
caregiving	O
.	O


Few	O
studies	O
have	O
shown	O
the	O
effectiveness	O
of	O
counseling	O
for	O
these	O
caregivers	O
.	O


OBJECTIVES	O
To	O
determine	O
the	O
effectiveness	O
of	O
individualized	B-I
problem-solving	I-I
counseling	I-I
by	I-I
nurses	I-I
for	O
caregivers	O
and	O
the	O
expenditures	O
of	O
health	O
care	O
utilization	O
.	O


METHOD	O
Caregivers	B-P
(	I-P
n	I-P
=	I-P
77	I-P
)	I-P
of	I-P
the	I-P
cognitively	I-P
impaired	I-P
living	I-P
at	I-P
home	I-P
were	O
randomized	O
to	O
receive	O
nurse	B-I
counseling	I-I
or	I-I
not	I-I
.	I-I


Psychosocial	O
adjustment	O
to	O
their	O
relative	B-O
's	I-O
illness	I-O
,	I-O
psychological	I-O
distress	I-O
,	I-O
burden	I-O
,	I-O
coping	I-O
skills	I-O
,	I-O
and	I-O
expenditures	I-O
were	O
measured	O
after	O
6	O
months	O
and	O
1	O
year	O
.	O


RESULTS	O
Although	O
on	O
average	O
,	O
all	O
caregivers	O
receiving	O
nurse	B-I
counseling	I-I
indicated	O
no	O
improvement	B-O
in	O
psychosocial	O
adjustment	O
to	O
their	O
relative	B-O
's	I-O
illness	I-O
,	I-O
psychological	I-O
distress	I-O
,	I-O
or	I-O
caregiver	I-O
burden	I-O
,	O
they	O
found	O
counseling	O
very	O
helpful	O
and	O
it	O
was	O
effective	O
for	O
a	O
subgroup	O
of	O
caregivers	O
.	O


Those	O
with	O
poor	O
logical	O
analysis	O
coping	O
skills	O
at	O
baseline	O
had	O
decreased	B-O
psychological	I-O
distress	I-O
(	O
F	O
(	O
1,53	O
)	O
=	O
9.7	O
,	O
p	O
=	O
.003	O
)	O
and	O
improved	B-O
psychosocial	I-O
adjustment	I-O
(	O
F	O
(	O
1,53	O
)	O
=	O
4.7	O
,	O
p	O
=	O
.035	O
)	O
after	O
1	O
year	O
.	O


Caregivers	O
in	O
control	B-I
and	O
counseling	B-I
groups	O
whose	O
relatives	O
entered	O
a	O
nursing	O
home	O
improved	O
their	O
psychosocial	B-O
adjustment	I-O
23	O
%	O
on	O
average	O
whereas	O
those	O
continuing	O
to	O
live	O
in	O
the	O
community	O
decreased	O
by	O
8	O
%	O
.	O


Almost	O
half	O
as	O
many	O
relatives	O
entered	O
nursing	O
homes	O
in	O
the	O
counseling	B-I
group	O
(	O
n	O
=	O
9	O
vs.	O
n	O
=	O
5	O
)	O
but	O
these	O
compared	O
to	O
control	B-I
group	O
relatives	O
had	O
greater	O
annualized	O
per	O
person	O
expenditures	O
for	O
health	B-O
and	I-O
social	I-O
services	I-O
(	O
Cdn	O
$	O
23,437	O
vs.	O
Cdn	O
$	O
15,151	O
)	O
.	O


CONCLUSIONS	O
Caregivers	O
found	O
nurse	B-I
counseling	I-I
most	O
helpful	O
.	O


Those	O
indicating	O
infrequent	O
use	O
of	O
logical	O
analysis	O
coping	O
skills	O
showed	O
benefits	O
.	O


Safety	O
and	O
efficacy	O
of	O
PNU-142633	B-I
,	I-I
a	I-I
selective	I-I
5-HT1D	I-I
agonist	I-I
,	O
in	O
patients	B-P
with	I-P
acute	I-P
migraine	I-P
.	I-P


In	O
this	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel-group	O
study	O
,	O
patients	B-P
received	O
a	O
single	O
50-mg	B-I
oral	I-I
dose	I-I
of	I-I
a	I-I
5-HT	I-I
(	I-I
1D	I-I
)	I-I
agonist	I-I
,	I-I
PNU-142633	I-I
(	I-I
n	I-I
=	I-I
34	I-I
)	I-I
,	I-I
or	I-I
matching	I-I
placebo	I-I
(	O
n	O
=	O
35	O
)	O
during	O
an	O
acute	B-P
migraine	I-P
attack	I-P
.	I-P


No	O
statistically	O
significant	O
treatment	O
effects	O
were	O
observed	O
at	O
1	O
and	O
2	O
h	O
after	O
dosing	O
,	O
even	O
after	O
stratifying	O
by	O
baseline	O
headache	O
intensity	O
.	O


At	O
1	O
and	O
2	O
h	O
post-dose	O
,	O
8.8	O
%	O
and	O
29.4	O
%	O
of	O
the	O
PNU-142633	B-I
group	O
,	O
respectively	O
,	O
and	O
8.6	O
%	O
and	O
40.0	O
%	O
of	O
the	O
placebo	B-I
group	O
,	O
respectively	O
,	O
experienced	O
headache	B-O
relief	I-O
;	I-O
2.9	O
%	O
and	O
8.8	O
%	O
of	O
the	O
PNU-142633	B-I
group	O
and	O
0	O
%	O
and	O
5.7	O
%	O
of	O
the	O
placebo	B-I
group	O
were	O
free	B-O
of	I-O
headache	I-O
pain	I-O
.	I-O


Adverse	B-O
events	I-O
associated	O
with	O
PNU-142633	B-I
treatment	O
included	O
chest	B-O
pain	I-O
(	O
two	O
patients	O
)	O
and	O
QTc	B-O
prolongation	I-O
(	O
three	O
patients	O
)	O
.	O


Results	O
from	O
this	O
study	O
suggest	O
that	O
anti-migraine	O
efficacy	O
is	O
not	O
mediated	O
solely	O
through	O
the	O
5-HT	B-I
(	I-I
1D	I-I
)	I-I
receptor	O
subtype	O
,	O
although	O
this	O
receptor	O
may	O
contribute	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
adverse	O
cardiovascular	O
effects	O
observed	O
with	O
5-HT	B-I
agonist	I-I
medications	O
.	O


A	O
phase	O
I	O
study	O
of	O
recombinant	B-I
human	I-I
ciliary	I-I
neurotrophic	I-I
factor	I-I
(	I-I
rHCNTF	I-I
)	I-I
in	O
patients	B-P
with	I-P
amyotrophic	I-P
lateral	I-P
sclerosis	I-P
.	I-P


The	O
ALS	O
CNTF	O
Treatment	O
Study	O
(	O
ACTS	O
)	O
Phase	O
I-II	O
Study	O
Group	O
.	O


Fifty-seven	B-P
patients	I-P
with	I-P
amyotrophic	I-P
lateral	I-P
sclerosis	I-P
(	I-P
ALS	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
0.5	O
,	O
1	O
,	O
3	O
,	O
7	O
,	O
10	O
,	O
or	O
30	O
micrograms/kg	O
recombinant	B-I
human	I-I
ciliary	I-I
neurotrophic	I-I
factor	I-I
(	I-I
rHCNTF	I-I
)	I-I
or	O
placebo	B-I
subcutaneously	O
3	O
times	O
a	O
week	O
for	O
2	O
weeks	O
.	O


Dose-limiting	B-O
toxicity	I-O
,	I-O
consisting	I-O
of	I-O
febrile	I-O
reactions	I-O
in	I-O
some	I-O
patients	I-O
,	I-O
fatigue	I-O
,	I-O
and	I-O
nonproductive	I-O
cough	I-O
,	O
was	O
observed	O
at	O
a	O
dose	O
level	O
of	O
30	O
micrograms/kg	O
.	O


Dose-related	B-O
changes	I-O
in	I-O
parameters	I-O
of	I-O
the	I-O
acute-phase	I-O
response	I-O
were	O
noted	O
,	O
consistent	O
with	O
the	O
relationship	O
of	O
CNTF	B-I
and	O
its	O
receptor	O
system	O
to	O
the	O
cytokine	O
interleukin-6	O
(	O
IL-6	O
)	O
and	O
its	O
receptor	O
.	O


No	O
adverse	B-O
neurologic	I-O
consequences	I-O
of	I-O
rHCNTF	I-O
administration	I-O
were	O
observed	O
.	O


Antibodies	B-O
to	I-O
rHCNTF	I-O
were	O
observed	O
in	O
sera	O
of	O
most	O
patients	O
tested	O
after	O
2	O
weeks	O
of	O
continuous	O
treatment	O
and	O
4	O
weeks	O
'	O
withdrawal	O
period	O
.	O


rHCNTF	B-I
was	O
safe	B-O
and	I-O
tolerated	I-O
within	O
acceptable	O
limits	O
when	O
administered	O
to	O
patients	B-P
with	I-P
ALS	I-P
in	O
this	O
study	O
at	O
doses	O
of	O
up	O
to	O
30	O
micrograms/kg	O
3	O
times	O
a	O
week	O
for	O
2	O
weeks	O
.	O


Further	O
studies	O
to	O
explore	O
the	O
efficacy	O
of	O
rHCNTF	B-I
in	O
the	O
treatment	O
of	O
human	O
motor	O
neuron	O
diseases	O
are	O
justified	O
.	O


A	O
comparison	O
of	O
an	O
aqueous	B-I
and	O
a	O
pressurized	B-I
nasal	I-I
spray	I-I
of	O
beclomethasone	B-I
dipropionate	I-I
in	O
the	O
management	B-O
of	I-O
seasonal	I-O
rhinitis	I-O
.	I-O


A	O
multi-centre	O
,	O
double-blind	O
,	O
parallel	O
group	O
study	O
was	O
carried	O
out	O
in	O
38	B-P
patients	I-P
with	I-P
seasonal	I-P
rhinitis	I-P
to	O
compare	O
a	O
new	O
aqueous	B-I
nasal	I-I
spray	I-I
of	I-I
beclomethasone	I-I
dipropionate	I-I
with	I-I
the	I-I
conventional	I-I
pressurized	I-I
nasal	I-I
spray	I-I
.	I-I


Beclomethasone	B-I
dipropionate	I-I
(	O
200	O
micrograms	O
)	O
was	O
administered	O
twice	O
daily	O
for	O
a	O
treatment	O
period	O
of	O
2	O
weeks	O
.	O


Both	O
treatments	O
were	O
found	O
to	O
be	O
equally	O
effective	B-O
and	I-O
well	I-O
tolerated	I-O
.	I-O


It	O
is	O
suggested	O
,	O
therefore	O
,	O
that	O
the	O
new	O
aqueous	B-I
nasal	I-I
spray	I-I
provides	O
an	O
alternative	O
method	O
of	O
intranasal	O
administration	O
of	O
the	O
steroid	O
for	O
patients	O
who	O
may	O
prefer	O
an	O
aqueous	O
product	O
.	O


The	O
individual	O
responsiveness	O
to	O
growth	B-I
hormone	I-I
(	I-I
GH	I-I
)	I-I
treatment	I-I
in	O
GH-deficient	B-P
adults	I-P
is	O
dependent	O
on	O
the	O
level	O
of	O
GH-binding	O
protein	O
,	O
body	B-O
mass	I-O
index	I-O
,	O
age	O
,	O
and	O
gender	O
.	O


The	O
aim	O
of	O
the	O
present	O
trial	O
was	O
to	O
study	O
the	O
individual	O
responsiveness	O
to	O
GH	B-I
treatment	I-I
in	O
terms	O
of	O
body	O
composition	O
and	O
to	O
search	O
for	O
possible	O
predictors	O
of	O
the	O
response	O
in	O
GH-deficient	O
adults	O
.	O


Sixty-eight	B-P
patients	I-P
(	I-P
44	I-P
men	I-P
and	I-P
24	I-P
women	I-P
)	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
44.3	I-P
(	I-P
1.2	I-P
)	I-P
yr	I-P
and	I-P
verified	I-P
GH	I-P
deficiency	I-P
participated	I-P
in	I-P
a	I-P
2-phase	I-P
treatment	I-P
trial	I-P
with	O
an	O
initial	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	B-I
,	O
6-month	O
period	O
,	O
followed	O
by	O
an	O
open	O
treatment	O
period	O
,	O
thereby	O
ensuring	O
all	O
patients	B-P
12	I-P
months	I-P
of	I-P
GH	I-P
treatment	I-P
.	I-P


Recombinant	B-I
human	I-I
GH	I-I
was	O
administered	O
sc	O
daily	O
at	O
bedtime	O
,	O
with	O
a	O
target	O
dose	O
of	O
12	O
micrograms/kg	O
x	O
day	O
.	O


GHBP	O
was	O
measured	O
by	O
ligand-mediated	O
immunofunctional	O
assay	O
,	O
and	O
serum	O
insulin-like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
was	O
determined	O
by	O
RIA	O
after	O
acid-ethanol	O
extraction	O
,	O
using	O
a	O
truncated	O
IGF-I	O
analog	O
as	O
the	O
radioligand	O
.	O


Lean	B-O
body	I-O
mass	I-O
(	I-O
LBM	I-O
)	I-O
and	I-O
body	I-O
fat	I-O
(	I-O
BF	I-O
)	I-O
were	O
determined	O
by	O
dual	O
energy	O
x-ray	O
absorptiometry	O
,	O
and	O
total	O
body	O
water	O
(	O
TBW	O
)	O
was	O
determined	O
by	O
bioelectrical	O
impedance	O
.	O


During	O
the	O
placebo	O
control	O
period	O
,	O
serum	B-O
IGF-I	I-O
,	I-O
LBM	I-O
,	I-O
and	I-O
TBW	I-O
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
BF	B-O
decreased	O
(	O
P	O
<	O
0.001	O
)	O
and	O
serum	B-O
GHBP	I-O
was	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
GH	O
compared	O
with	O
the	O
patients	O
treated	O
with	O
placebo	O
.	O


After	O
12	O
months	O
of	O
GH	O
treatment	O
,	O
the	O
individual	O
changes	O
in	O
BF	B-O
ranged	O
from	O
-12.5	O
to	O
4.3	O
kg	O
and	O
from	O
-4.5	O
to	O
10.1	O
kg	O
in	O
LBM	O
.	O


Age	O
(	O
P	O
<	O
0.05	O
)	O
and	O
baseline	B-O
GHBP	I-O
level	I-O
(	O
P	O
<	O
0.01	O
)	O
were	O
inversely	O
correlated	O
with	O
the	O
increase	O
in	O
LBM	O
.	O


The	O
GH-induced	B-O
increment	I-O
in	I-O
IGF-I	I-O
and	I-O
TBW	I-O
was	O
greater	O
in	O
men	O
than	O
in	O
women	O
(	O
P	O
<	O
0.01	O
)	O
,	O
whereas	O
the	O
decreases	O
in	O
BF	B-O
were	O
similar	O
in	O
men	O
and	O
women	O
.	O


This	O
trial	O
demonstrates	O
the	O
variability	O
in	O
responsiveness	O
to	O
GH	B-I
administration	O
in	O
GH-deficient	O
adults	O
.	O


The	O
best	O
response	O
to	O
GH	O
was	O
obtained	O
in	O
younger	O
patients	O
with	O
low	O
GHBP	O
levels	O
.	O


Furthermore	O
,	O
men	O
responded	O
better	O
than	O
women	O
.	O


Mediation	O
analysis	O
demonstrates	O
that	O
trans-eQTLs	B-O
are	O
often	O
explained	O
by	O
cis-mediation	O
:	O
a	O
genome-wide	O
analysis	O
among	O
1,800	B-P
South	I-P
Asians	I-P
.	I-P


A	O
large	O
fraction	O
of	O
human	O
genes	O
are	O
regulated	O
by	O
genetic	O
variation	O
near	O
the	O
transcribed	O
sequence	O
(	O
cis-eQTL	O
,	O
expression	O
quantitative	O
trait	O
locus	O
)	O
,	O
and	O
many	O
cis-eQTLs	O
have	O
implications	O
for	O
human	O
disease	O
.	O


Less	O
is	O
known	O
regarding	O
the	O
effects	O
of	O
genetic	O
variation	O
on	O
expression	B-O
of	I-O
distant	I-O
genes	I-O
(	I-O
trans-eQTLs	I-O
)	I-O
and	O
their	O
biological	O
mechanisms	O
.	O


In	O
this	O
work	O
,	O
we	O
use	O
genome-wide	B-I
data	I-I
on	I-I
SNPs	I-I
and	O
array-based	B-I
expression	I-I
measures	I-I
from	O
mononuclear	O
cells	O
obtained	O
from	O
a	O
population-based	O
cohort	O
of	O
1,799	B-P
Bangladeshi	I-P
individuals	I-P
to	O
characterize	O
cis-	B-O
and	I-O
trans-eQTLs	I-O
and	O
determine	O
if	O
observed	O
trans-eQTL	B-O
associations	I-O
are	O
mediated	O
by	O
expression	O
of	O
transcripts	O
in	O
cis	O
with	O
the	O
SNPs	O
showing	O
trans-association	O
,	O
using	O
Sobel	B-O
tests	I-O
of	I-O
mediation	I-O
.	I-O


We	O
observed	O
434	B-P
independent	I-P
trans-eQTL	I-O
associations	I-O
at	O
a	O
false-discovery	O
rate	O
of	O
0.05	O
,	O
and	O
189	O
of	O
these	O
trans-eQTLs	B-O
were	O
also	O
cis-eQTLs	O
(	O
enrichment	O
P	O
<	O
0.0001	O
)	O
.	O


Among	O
these	O
189	B-P
trans-eQTL	I-O
associations	I-O
,	I-P
39	I-P
were	I-P
significantly	I-P
attenuated	I-P
after	O
adjusting	O
for	O
a	O
cis-mediator	O
based	O
on	O
Sobel	O
P	O
<	O
10-5	O
.	O


We	O
attempted	O
to	O
replicate	O
21	O
of	O
these	O
mediation	O
signals	O
in	O
two	O
European	O
cohorts	O
,	O
and	O
while	O
only	O
7	O
trans-eQTL	B-O
associations	I-O
were	O
present	O
in	O
one	O
or	O
both	O
cohorts	O
,	O
6	O
showed	O
evidence	O
of	O
cis-mediation	O
.	O


Analyses	O
of	O
simulated	O
data	O
show	O
that	O
complete	O
mediation	O
will	O
be	O
observed	O
as	O
partial	O
mediation	O
in	O
the	O
presence	O
of	O
mediator	O
measurement	O
error	O
or	O
imperfect	O
LD	O
between	O
measured	O
and	O
causal	O
variants	O
.	O


Our	O
data	O
demonstrates	O
that	O
trans-associations	O
can	O
become	O
significantly	O
stronger	O
or	O
switch	O
directions	O
after	O
adjusting	O
for	O
a	O
potential	O
mediator	O
.	O


Using	O
simulated	O
data	O
,	O
we	O
demonstrate	O
that	O
this	O
phenomenon	O
is	O
expected	O
in	O
the	O
presence	O
of	O
strong	O
cis-trans	O
confounding	O
and	O
when	O
the	O
measured	O
cis-transcript	O
is	O
correlated	O
with	O
the	O
true	O
(	O
unmeasured	O
)	O
mediator	O
.	O


In	O
conclusion	O
,	O
by	O
applying	O
mediation	O
analysis	O
to	O
eQTL	O
data	O
,	O
we	O
show	O
that	O
a	O
substantial	O
fraction	O
of	O
observed	O
trans-eQTL	B-O
associations	I-O
can	O
be	O
explained	O
by	O
cis-mediation	O
.	O


Future	O
studies	O
should	O
focus	O
on	O
understanding	O
the	O
mechanisms	O
underlying	O
widespread	O
cis-mediation	O
and	O
their	O
relevance	O
to	O
disease	O
biology	O
,	O
as	O
well	O
as	O
using	O
mediation	O
analysis	O
to	O
improve	O
eQTL	O
discovery	O
.	O


Fondaparinux	B-I
combined	I-I
with	I-I
intermittent	I-I
pneumatic	I-I
compression	I-I
vs.	O
intermittent	B-I
pneumatic	I-I
compression	I-I
alone	I-I
for	O
prevention	O
of	O
venous	B-O
thromboembolism	I-O
after	I-P
abdominal	I-P
surgery	I-P
:	I-P
a	O
randomized	O
,	O
double-blind	O
comparison	O
.	O


BACKGROUND	O
The	O
benefit	O
of	O
combined	O
mechanical	O
and	O
pharmacologic	O
methods	O
for	O
venous	B-O
thromboembolism	I-O
prevention	O
after	B-P
abdominal	I-P
surgery	I-P
has	O
not	O
been	O
clearly	O
established	O
.	O


OBJECTIVES	O
To	O
compare	O
the	O
efficacy	B-O
and	O
safety	B-O
of	O
fondaparinux	B-I
in	I-I
conjunction	I-I
with	I-I
intermittent	I-I
pneumatic	I-I
compression	I-I
vs.	O
intermittent	B-I
pneumatic	I-I
compression	I-I
alone	I-I
in	O
this	O
context	O
.	O


PATIENTS	O
AND	O
METHODS	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
superiority	O
trial	O
.	O


Patients	B-P
aged	I-P
at	I-P
least	I-P
40	I-P
years	I-P
undergoing	I-P
abdominal	I-P
surgery	I-P
were	O
randomized	O
to	O
receive	O
either	O
fondaparinux	B-I
2.5	O
mg	O
or	O
placebo	B-I
s.c.	O
for	O
5-9	O
days	O
,	O
starting	O
6-8	O
h	O
postoperatively	O
.	O


All	O
patients	O
received	O
intermittent	B-I
pneumatic	I-I
compression	I-I
.	I-I


The	O
primary	O
efficacy	O
outcome	O
was	O
venous	B-O
thromboembolism	I-O
up	I-O
to	I-O
day	I-O
10	I-O
.	I-O


The	O
main	O
safety	O
outcomes	O
were	O
major	B-O
bleeding	I-O
and	I-O
all-cause	I-O
mortality	I-O
.	I-O


Follow-up	O
lasted	O
32	O
days	O
.	O


RESULTS	O
Of	O
the	O
1309	B-P
patients	I-P
randomized	O
,	O
842	O
(	O
64.3	O
%	O
)	O
were	O
evaluable	O
for	O
efficacy	O
.	O


The	O
venous	B-O
thromboembolism	I-O
rate	I-O
was	O
1.7	O
%	O
(	O
7/424	O
)	O
in	O
the	O
fondaparinux-treated	B-I
patients	I-P
and	O
5.3	O
%	O
(	O
22/418	O
)	O
in	O
the	O
placebo-treated	B-I
patients	I-P
(	O
odds	O
ratio	O
reduction	O
69.8	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
27.9-87.3	O
;	O
P	O
=	O
0.004	O
)	O
.	O


Fondaparinux	B-I
significantly	O
reduced	O
the	O
proximal	B-O
deep	I-O
vein	I-O
thrombosis	I-O
rate	I-O
from	O
1.7	O
%	O
(	O
7/417	O
)	O
to	O
0.2	O
%	O
(	O
1/424	O
;	O
P	O
=	O
0.037	O
)	O
.	O


Major	B-O
bleeds	I-O
occurred	O
in	O
1.6	O
%	O
(	O
10/635	O
)	O
and	O
0.2	O
%	O
(	O
1/650	O
)	O
of	O
fondaparinux-treated	B-I
and	O
placebo-treated	B-I
patients	O
,	O
respectively	O
(	O
P	O
=	O
0.006	O
)	O
,	O
none	O
being	O
fatal	O
or	O
involving	O
a	O
critical	O
organ	O
.	O


By	O
day	O
32	O
,	O
eight	O
patients	O
(	O
1.3	O
%	O
)	O
receiving	O
fondaparinux	B-I
and	O
five	O
(	O
0.8	O
%	O
)	O
receiving	O
placebo	B-I
had	O
died	B-O
.	I-O


CONCLUSIONS	O
In	O
patients	B-P
undergoing	I-P
abdominal	I-P
surgery	I-P
and	I-P
receiving	I-P
intermittent	I-I
pneumatic	I-I
compression	I-I
,	I-I
fondaparinux	I-I
2.5	O
mg	O
reduced	O
the	O
venous	B-O
thromboembolism	I-O
rate	I-O
by	O
69.8	O
%	O
as	O
compared	O
to	O
pneumatic	B-I
compression	I-I
alone	I-I
,	O
with	O
a	O
low	B-O
bleeding	I-O
risk	I-O
as	O
compared	O
to	O
placebo	B-I
.	I-I


Unopposed	B-I
estrogen	I-I
increases	O
total	O
plasma	O
factor	O
VII	O
,	O
but	O
not	O
active	O
factor	O
VII	O
--	O
a	O
short-term	O
placebo-controlled	B-I
study	O
in	O
healthy	B-P
postmenopausal	I-P
women	I-P
.	I-P


Estrogen	B-I
therapy	I-I
may	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolism	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O


In	O
a	O
randomized	O
,	O
double-blind	O
and	O
placebo-controlled	O
study	O
in	O
25	B-P
healthy	I-P
postmenopausal	I-P
women	I-P
(	I-P
52.5	I-P
+/-	I-P
2.8	I-P
years	I-P
)	I-P
,	O
we	O
therefore	O
examined	O
the	O
short-term	O
effect	O
of	O
unopposed	B-I
estrogen	I-I
on	O
the	O
fasting	O
and	O
fat-load-stimulated	O
plasma	O
levels	O
of	O
total	O
factor	O
VII	O
versus	O
active	O
factor	O
VII	O
.	O


Plasma	B-O
total	I-O
factor	I-O
VII	I-O
was	O
measured	O
by	O
use	O
of	O
a	O
chromogenic	O
assay	O
;	O
plasma	O
active	O
FVII	O
by	O
a	O
recently	O
developed	O
method	O
using	O
truncated	O
tissue	O
factor	O
.	O


As	O
compared	O
to	O
placebo	B-I
,	O
8	O
weeks	O
of	O
oral	B-I
17beta-estradiol	I-I
(	O
2	O
mg	O
daily	O
)	O
increased	O
the	O
mean	B-O
fasting	I-O
and	I-O
postprandial	I-O
plasma	I-O
levels	I-O
of	I-O
total	I-O
factor	I-O
VII	I-O
by	O
17	O
and	O
21	O
%	O
points	O
,	O
respectively	O
(	O
both	O
P	O
<	O
0.01	O
)	O
,	O
but	O
did	O
not	O
affect	O
the	O
fasting	B-O
and/or	I-O
postprandial	I-O
plasma	I-O
levels	I-O
of	I-O
active	I-O
factor	I-O
VII	I-O
(	O
mean	O
change	O
both	O
0.05	O
ng/mL	O
;	O
P	O
>	O
0.35	O
)	O
.	O


Furthermore	O
,	O
the	O
change	B-O
in	I-O
the	I-O
fasting	I-O
level	I-O
of	I-O
total	I-O
factor	I-O
VII	I-O
after	O
therapy	O
was	O
not	O
associated	O
with	O
the	O
change	B-O
in	I-O
the	I-O
fasting	I-O
level	I-O
of	I-O
active	I-O
factor	I-O
VII	I-O
(	O
r	O
=	O
0.27	O
;	O
P	O
=	O
0.21	O
)	O
.	O


These	O
findings	O
argue	O
against	O
the	O
idea	O
that	O
elevated	O
levels	B-O
of	I-O
total	I-O
factor	I-O
VII	I-O
underlie	O
an	O
increased	O
risk	B-O
of	I-O
arterial	I-O
thromboembolism	I-O
in	O
postmenopausal	B-P
women	I-P
using	O
unopposed	B-I
estrogen	I-I
replacement	I-I
.	I-I


Evaluating	O
intervention	B-I
using	O
time	B-I
aids	I-I
in	O
children	B-P
with	I-P
disabilities	I-P
.	I-P


OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
complex	B-I
intervention	I-I
using	I-I
time	I-I
aids	I-I
for	O
children	B-P
with	I-P
intellectual	I-P
and	I-P
developmental	I-P
disabilities	I-P
who	I-P
exhibit	I-P
limitations	I-P
in	I-P
daily	I-P
time	I-P
management	I-P
.	I-P


METHODS	O
Participating	B-P
children	I-P
(	I-P
n	I-P
=	I-P
47	I-P
)	I-P
(	I-P
F17/M30	I-P
)	I-P
were	I-P
aged	I-P
6-11	I-P
with	I-P
ADHD	I-P
,	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	I-P
mild	I-P
or	I-P
moderate	I-P
intellectual	I-P
disability	I-P
,	I-P
spina	I-P
bifida	I-P
,	I-P
and	I-P
cerebral	I-P
palsy	I-P
.	I-P


This	O
study	O
used	O
a	O
Randomized	O
Block	O
and	O
Waiting	O
List	O
control	O
group	O
design	O
,	O
with	O
25	O
children	O
allocated	O
to	O
control	B-I
and	O
22	O
to	O
intervention	B-I
group	O
.	O


In	B-P
total	I-P
10	I-P
children	I-P
(	I-P
21.3	I-P
%	I-P
)	I-P
,	I-P
five	I-P
from	I-P
each	I-P
group	I-P
,	I-P
dropped	I-P
out	I-P
,	I-P
leaving	I-P
37	I-P
children	I-P
in	I-P
the	I-P
data	I-P
analysis	I-P
.	I-P


RESULTS	O
Children	O
in	O
both	O
groups	O
gained	O
significantly	O
in	O
time-processing	B-O
ability	I-O
between	O
the	O
first	O
and	O
second	O
data	O
collection	O
,	O
but	O
the	O
children	O
in	O
the	O
intervention	O
group	O
improved	O
time-processing	B-O
ability	I-O
significantly	O
more	O
than	O
controls	O
.	O


The	O
control	O
group	O
also	O
displayed	O
significant	O
changes	O
after	O
receiving	O
intervention	O
between	O
the	O
second	O
and	O
third	O
data	O
collection	O
.	O


The	O
intervention	O
had	O
a	O
large	O
effect	O
(	O
ES	O
Cohen	O
's	O
d	O
=	O
0.81	O
)	O
on	O
time-processing	B-O
ability	I-O
and	O
a	O
medium	O
effect	O
(	O
ES	O
Cohen	O
's	O
d	O
=	O
0.68	O
)	O
on	O
managing	B-O
one	I-O
's	I-O
time	I-O
.	I-O


CONCLUSIONS	O
This	O
study	O
provides	O
preliminary	O
evidence	O
that	O
time-processing	B-O
ability	I-O
and	O
managing	B-O
one	I-O
's	I-O
time	I-O
can	O
be	O
improved	O
by	O
intervention	O
using	O
time	O
aids	O
in	O
children	B-P
with	I-P
intellectual	I-P
and	I-P
developmental	I-P
disabilities	I-P
,	O
supporting	O
the	O
need	O
to	O
consider	O
time	O
aids	O
in	O
intervention	O
in	O
these	O
children	O
.	O


Line-item	O
analysis	O
of	O
the	O
Aberrant	O
Behavior	O
Checklist	O
:	O
results	O
from	O
two	B-P
studies	I-P
of	I-P
aripiprazole	I-I
in	I-P
the	I-P
treatment	I-P
of	I-P
irritability	I-P
associated	I-P
with	I-P
autistic	I-P
disorder	I-P
.	I-P


OBJECTIVES	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
aripiprazole	B-I
in	O
the	O
treatment	O
of	O
discrete	O
symptoms	O
of	O
irritability	O
associated	O
with	O
autistic	O
disorder	O
,	O
as	O
well	O
as	O
other	O
symptoms	O
captured	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
.	O


METHODS	O
This	O
was	O
a	O
post	O
hoc	O
analysis	O
of	O
data	O
from	O
two	B-P
8-week	I-P
,	I-P
randomized	I-P
,	I-P
double-blind	I-P
,	I-P
multicenter	I-P
trials	I-P
to	O
evaluate	O
the	O
efficacy	O
of	O
aripiprazole	B-I
dosed	I-I
flexibly	I-I
(	O
2-15	O
mg/day	O
,	O
n=47	O
)	O
or	O
fixed	O
(	O
5	O
,	O
10	O
,	O
or	O
15	O
mg/day	O
,	O
n	O
=	O
166	O
)	O
versus	O
placebo	B-I
(	O
flexibly	O
dosed	O
,	O
n	O
=	O
51	O
;	O
fixed	O
dose	O
,	O
n	O
=	O
52	O
)	O
.	O


The	O
effects	O
of	O
treatment	O
on	O
the	O
58	O
ABC	O
items	O
were	O
evaluated	O
.	O


RESULTS	O
Statistically	O
significantly	O
greater	O
improvement	O
was	O
seen	O
with	O
aripiprazole	B-I
versus	I-I
placebo	I-I
(	O
p	O
<	O
0.05	O
)	O
for	O
all	O
arms	O
in	O
both	O
trials	O
on	O
the	O
ABC-Irritability	B-O
total	I-O
subscale	I-O
score	I-O
and	I-O
on	I-O
the	I-O
following	I-O
individual	I-O
ABC-Irritability	I-O
items	I-O
:	I-O
Mood	I-O
changes	I-O
quickly	I-O
,	I-O
cries/screams	I-O
inappropriately	I-O
,	I-O
and	I-O
stamps	I-O
feet/bangs	I-O
objects	I-O
.	I-O


Several	O
additional	O
items	O
measuring	O
tantrum-like	B-O
behaviors	I-O
improved	O
in	O
the	O
flexibly	O
dosed	O
trial	O
and	O
at	O
least	O
one	O
arm	O
of	O
the	O
fixed-dose	O
trial	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Measures	B-O
of	I-O
self-injurious	I-O
behavior	I-O
,	O
which	O
had	O
low	O
baseline	O
values	O
,	O
demonstrated	O
numerical	O
,	O
but	O
not	O
statistically	O
significant	O
,	O
improvement	O
in	O
both	O
trials	O
.	O


Statistically	O
significantly	O
greater	O
improvement	O
in	O
ABC	B-O
Stereotypic	I-O
Behavior	I-O
and	I-O
Hyperactivity	I-O
total	I-O
subscale	I-O
scores	I-O
was	O
also	O
consistent	O
across	O
all	O
arms	O
in	O
both	O
trials	O
.	O


In	O
particular	O
,	O
there	O
was	O
a	O
cluster	O
of	O
items	O
related	O
to	O
hyperkinesis	B-O
that	O
were	O
consistently	O
sensitive	O
to	O
treatment	O
.	O


CONCLUSIONS	O
Aripiprazole	B-I
is	O
efficacious	O
in	O
the	O
treatment	O
of	O
irritability	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autistic	I-P
disorder	I-P
,	O
particularly	O
with	O
respect	O
to	O
symptoms	O
associated	O
with	O
tantrum	O
behavior	O
.	O


Effects	O
of	O
a	O
videotape	B-I
information	I-I
intervention	I-I
at	O
discharge	O
on	O
diet	O
and	O
exercise	O
compliance	O
after	O
coronary	O
bypass	O
surgery	O
.	O


BACKGROUND	O
This	O
study	O
evaluated	O
the	O
relative	O
effects	O
on	O
compliance	O
with	O
recommended	O
lifestyle	O
changes	O
of	O
two	O
experimental	B-I
videotapes	I-I
that	O
involved	O
different	O
approaches	O
for	O
preparing	O
coronary	B-P
artery	I-P
bypass	I-P
graft	I-P
(	I-P
CABG	I-P
)	I-P
patients	I-P
for	O
the	O
posthospital	O
recovery	O
period	O
.	O


The	O
tapes	O
differed	O
in	O
the	O
extent	O
to	O
which	O
they	O
portrayed	O
the	O
recovery	O
period	O
as	O
a	O
steady	O
,	O
forward	O
progression	O
versus	O
a	O
series	O
of	O
"	O
ups	O
and	O
downs	O
.	O


"	O
METHODS	O
Two	B-P
hundred	I-P
sixteen	I-P
male	I-P
and	I-P
female	I-P
CABG	I-P
patients	I-P
were	O
assigned	O
randomly	O
either	O
to	O
view	O
one	B-I
of	I-I
the	I-I
two	I-I
videotapes	I-I
before	I-I
discharge	I-I
from	I-I
the	I-I
hospital	I-I
or	I-I
to	I-I
receive	I-I
only	I-I
the	I-I
standard	I-I
discharge	I-I
preparation	I-I
provided	O
by	O
the	O
hospital	O
.	O


All	O
patients	O
completed	O
measures	B-O
of	I-O
anxiety	I-O
and	I-O
self-efficacy	I-O
at	O
discharge	O
,	O
1	O
month	O
and	O
3	O
months	O
after	O
discharge	O
from	O
the	O
hospital	O
.	O


Patients	O
also	O
completed	O
measures	O
of	O
dietary	B-O
fat	I-O
consumption	I-O
and	O
activity	B-O
level	I-O
1	I-O
and	I-O
3	I-O
months	O
after	O
discharge	O
.	O


RESULTS	O
Relative	O
to	O
controls	O
,	O
patients	O
who	O
viewed	O
either	O
of	O
the	O
videotapes	B-I
before	O
hospital	O
release	O
reported	O
higher	O
self-efficacy	B-O
for	I-O
adhering	I-O
to	I-O
the	I-O
recommended	I-O
low-fat	I-O
diet	I-O
both	O
at	O
discharge	O
and	O
1	O
month	O
after	O
surgery	O
.	O


Viewing	O
either	O
of	O
the	O
videotapes	O
also	O
resulted	O
in	O
significantly	B-O
less	I-O
dietary	I-O
fat	I-O
intake	I-O
1	I-O
month	I-O
after	I-O
hospital	I-O
release	I-O
compared	O
with	O
controls	O
.	O


Patients	O
who	O
viewed	O
the	O
tape	O
that	O
portrayed	O
the	O
recovery	O
period	O
as	O
consisting	O
of	O
ups	O
and	O
downs	O
also	O
reported	O
significantly	O
more	O
frequent	O
moderate	B-O
exercise	I-O
at	I-O
1	I-O
month	I-O
and	O
more	O
frequent	O
strenuous	B-O
exercise	I-O
3	O
months	O
after	O
discharge	O
.	O


CONCLUSIONS	O
The	O
experimental	O
videotapes	B-I
proved	O
to	O
be	O
an	O
effective	O
method	O
for	O
increasing	O
dietary	B-O
and	I-O
exercise	I-O
compliance	I-O
during	O
the	O
first	O
3	O
months	O
after	O
CABG	O
.	O


Comparison	O
of	O
40	O
milliliters	O
of	O
0.25	O
%	O
intrapleural	O
bupivacaine	B-I
with	O
epinephrine	B-I
with	O
20	O
milliliters	O
of	O
0.5	O
%	O
intrapleural	O
bupivacaine	O
with	O
epinephrine	O
after	O
cholecystectomy	O
.	O


To	O
determine	O
the	O
influence	O
of	O
the	O
volume	O
of	O
local	O
anesthetic	O
injected	O
for	O
intrapleural	O
analgesia	O
,	O
40	B-P
patients	I-P
undergoing	I-P
cholecystectomy	I-P
were	I-P
randomly	I-P
allocated	I-P
to	I-P
two	I-P
groups	I-P
of	I-P
20	I-P
patients	I-P
each	I-P
.	I-P


One	B-I
group	I-I
received	I-I
40	I-I
mL	I-I
of	I-I
0.25	I-I
%	I-I
bupivacaine	I-I
with	I-I
epinephrine	I-I
injected	I-I
intrapleurally	I-I
postoperatively	I-I
.	I-I


The	B-I
other	I-I
group	I-I
received	I-I
20	I-I
mL	I-I
of	I-I
0.5	I-I
%	I-I
bupivacaine	I-I
with	I-I
epinephrine	I-I
.	I-I


The	O
onset	B-O
time	I-O
of	I-O
analgesia	I-O
was	O
nearly	O
the	O
same	O
in	O
both	O
groups	O
and	O
within	O
25	O
min	O
all	O
patients	B-P
were	O
nearly	O
pain	O
free	O
.	O


Our	O
data	O
demonstrate	O
that	O
100	O
mg	O
of	O
bupivacaine	O
with	O
epinephrine	O
elicits	O
effective	O
analgesia	O
after	O
cholecystectomy	O
.	O


There	O
are	O
only	O
minor	O
differences	O
between	O
20	O
and	O
40	O
mL	O
with	O
regard	O
to	O
pain	B-O
relief	I-O
.	I-O


The	O
authors	O
conclude	O
that	O
the	O
volume	O
of	O
local	O
anesthetic	O
within	O
the	O
range	O
of	O
20-40	O
mL	O
in	O
an	O
adult	O
has	O
little	O
influence	O
on	O
the	O
extent	O
or	O
duration	O
of	O
intrapleural	O
analgesia	O
.	O


Use	O
of	O
the	O
learning	B-I
conversation	I-I
improves	O
instructor	B-P
confidence	I-P
in	I-P
life	I-P
support	I-P
training	I-P
:	I-P
An	O
open	O
randomised	O
controlled	O
cross-over	O
trial	O
comparing	O
teaching	O
feedback	O
mechanisms	O
.	O


AIMS	O
Feedback	O
is	O
vital	O
for	O
the	O
effective	O
delivery	O
of	O
skills-based	O
education	O
.	O


We	O
sought	O
to	O
compare	O
the	O
sandwich	B-I
technique	I-I
and	O
learning	B-I
conversation	I-I
structured	O
methods	O
of	O
feedback	O
delivery	O
in	O
competency-based	O
basic	O
life	O
support	O
(	O
BLS	O
)	O
training	O
.	O


METHODS	O
Open	O
randomised	O
crossover	O
study	O
undertaken	O
between	B-P
October	I-P
2014	I-P
and	I-P
March	I-P
2015	I-P
at	I-P
the	I-P
University	I-P
of	I-P
Birmingham	I-P
,	I-P
United	I-P
Kingdom	I-P
.	I-P


Six-hundred	B-P
and	I-P
forty	I-P
healthcare	I-P
students	I-P
undertaking	I-P
a	I-P
European	I-P
Resuscitation	I-P
Council	I-P
(	I-P
ERC	I-P
)	I-P
BLS	I-P
course	I-P
were	I-P
enrolled	I-P
,	I-P
each	I-P
of	I-P
whom	I-P
was	I-P
randomised	I-P
to	I-P
receive	I-P
teaching	I-I
using	I-I
either	I-I
the	I-I
sandwich	I-I
technique	I-I
or	I-I
the	I-I
learning	I-I
conversation	I-I
.	I-I


Fifty-eight	B-P
instructors	I-P
were	I-P
randomised	I-P
to	I-P
initially	I-P
teach	I-P
using	I-P
either	I-P
the	I-P
learning	I-I
conversation	I-I
or	I-I
sandwich	I-I
technique	I-I
,	O
prior	O
to	O
crossing-over	O
and	O
teaching	O
with	O
the	O
alternative	O
technique	O
after	O
a	O
pre-defined	O
time	O
period	O
.	O


Outcome	O
measures	O
included	O
skill	B-O
acquisition	I-O
as	I-O
measured	I-O
by	I-O
an	I-O
end-of-course	I-O
competency	I-O
assessment	I-O
,	I-O
instructors	I-O
'	I-O
perception	I-O
of	I-O
teaching	I-O
with	I-O
each	I-O
feedback	I-O
technique	I-O
and	I-O
candidates	I-O
'	I-O
perception	I-O
of	I-O
the	I-O
feedback	I-O
they	I-O
were	I-O
provided	I-O
with	I-O
.	I-O


RESULTS	O
Scores	O
assigned	O
to	O
use	O
of	O
the	O
learning	O
conversation	O
by	O
instructors	O
were	O
significantly	O
more	O
favourable	O
than	O
for	O
the	O
sandwich	O
technique	O
across	O
all	O
but	O
two	O
assessed	O
domains	O
relating	O
to	O
instructor	B-O
perception	I-O
of	I-O
the	I-O
feedback	I-O
technique	I-O
,	O
including	O
all	O
skills-based	O
domains	O
.	O


No	O
difference	O
was	O
seen	O
in	O
either	O
assessment	B-O
pass	I-O
rates	I-O
(	O
80.9	O
%	O
sandwich	O
technique	O
vs.	O
77.2	O
%	O
learning	O
conversation	O
;	O
OR	O
1.2	O
,	O
95	O
%	O
CI	O
0.85-1.84	O
;	O
p=0.29	O
)	O
or	O
any	O
domain	O
relating	O
to	O
candidates	O
'	O
perception	O
of	O
their	O
teaching	O
technique	O
.	O


CONCLUSIONS	O
&	O
RELEVANCE	O
This	O
is	O
the	O
first	O
direct	O
comparison	O
of	O
two	O
feedback	O
techniques	O
in	O
clinical	O
medical	O
education	O
using	O
both	O
quantitative	O
and	O
qualitative	O
methodology	O
.	O


The	O
learning	B-I
conversation	I-I
is	O
preferred	O
by	O
instructors	B-P
providing	I-P
competency-based	I-P
life	I-P
support	I-P
training	I-P
and	O
is	O
perceived	O
to	O
favour	O
skills	O
acquisition	O
.	O


B-vitamins	B-I
reduce	O
plasma	B-O
levels	I-O
of	O
beta	O
amyloid	O
.	O


Elevated	O
plasma	O
homocysteine	O
(	O
tHcy	O
)	O
is	O
a	O
risk	O
factor	O
for	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
and	O
thus	O
B	B-I
vitamins	I-I
may	O
have	O
a	O
role	O
in	O
the	O
prevention	O
of	O
AD	O
.	O


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
tHcy	O
lowering	O
vitamins	O
decrease	O
the	O
circulating	B-O
levels	I-O
of	I-O
A-beta	I-O
protein	I-O
1-40	I-O
(	I-O
A	I-O
beta	I-O
40	I-O
)	I-O
.	I-O


We	O
randomized	O
299	B-P
older	I-P
men	I-P
to	O
treatment	O
with	O
2mg	B-I
of	I-I
folate	I-I
,	I-I
plus	I-I
25mg	I-I
of	I-I
B6	I-I
and	I-I
400	I-I
microg	I-I
of	I-I
B12	I-I
,	I-I
or	I-I
placebo	I-I
.	I-I


After	O
2	O
years	O
of	O
treatment	O
the	O
mean	B-O
(	I-O
S.E	I-O
.	I-O


)	B-O
increase	I-O
of	I-O
A	I-O
beta	I-O
40	I-O
was	O
7.0	O
pg/ml	O
(	O
8.4	O
)	O
in	O
the	O
vitamin	O
group	O
(	O
4.9	O
%	O
)	O
,	O
and	O
26.8	O
pg/ml	O
(	O
7.7	O
)	O
(	O
18.5	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O


We	O
conclude	O
that	O
B	O
vitamins	O
may	O
decrease	O
the	B-O
plasma	I-O
level	I-O
of	I-O
A	I-O
beta	I-O
40	I-O
and	O
have	O
a	O
role	O
in	O
the	O
prevention	O
of	O
AD	O
.	O


Double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
risperidone	B-I
plus	I-I
amantadine	I-I
in	O
children	B-P
with	I-P
autism	I-P
:	I-P
a	O
10-week	O
randomized	O
study	O
.	O


OBJECTIVE	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
adding	O
amantadine	B-I
to	I-I
risperidone	I-I
for	O
treatment	O
of	O
autism	O
.	O


METHODS	O
Forty	B-P
outpatients	I-P
aged	I-P
4	I-P
to12	I-P
years	I-P
,	I-P
who	I-P
were	I-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
based	I-P
on	I-P
the	I-P
Diagnostic	I-P
and	I-P
Statistical	I-P
Manual	I-P
of	I-P
Mental	I-P
Disorders	I-P
,	I-P
Fourth	I-P
Edition	I-P
,	I-P
Text	I-P
Revision	I-P
criteria	I-P
,	O
were	O
assigned	O
to	O
this	O
double-blind	O
clinical	O
trial	O
.	O


The	O
subjects	O
were	O
divided	O
randomly	O
into	O
2	O
groups	O
.	O


One	O
group	O
received	O
risperidone	B-I
plus	I-I
amantadine	I-I
,	I-I
and	I-I
the	I-I
other	I-I
group	I-I
received	I-I
risperidone	I-I
plus	I-I
placebo	I-I
.	I-I


The	O
dose	O
of	O
risperidone	O
was	O
titrated	O
between	O
1	O
and	O
2.0	O
mg/d	O
,	O
and	O
the	O
dose	O
of	O
amantadine	B-I
was	O
100	O
or	O
150	O
mg/d	O
for	O
patients	O
less	O
than	O
30	O
kg	O
or	O
more	O
than	O
30	O
kg	O
,	O
respectively	O
.	O


The	O
patients	O
were	O
assessed	O
using	O
the	O
Aberrant	B-O
Behavioral	I-O
Checklist-Community	I-O
(	I-O
ABC-C	I-O
)	I-O
and	I-O
adverse	I-O
effects	I-O
checklist	I-O
as	O
well	O
as	O
clinical	B-O
global	I-O
impression-improvement	I-O
(	I-O
CGI-I	I-O
)	I-O
at2	O
checkpoints	O
of	O
5-week	O
intervals	O
after	O
the	O
baseline	O
.	O


Informed	O
consentwas	O
obtained	O
from	O
the	O
parents	O
of	O
each	O
participant	O
.	O


RESULTS	O
Among	O
ABC-C	B-O
subscales	I-O
,	I-O
Hyperactivity	I-O
and	I-O
Irritability	I-O
showed	O
significantly	O
greater	O
reduction	O
in	O
the	O
amantadine	O
group	O
than	O
the	O
placebo	O
group	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
adverse	B-O
effects	I-O
between	O
the	O
2	O
groups	O
.	O


The	O
CGI-I	B-O
scores	I-O
show	O
significant	O
improvement	O
in	O
the	O
amantadine	B-I
group	O
compared	O
to	O
the	O
placebo	O
group	O
.	O


CONCLUSIONS	O
The	O
present	O
study	O
suggests	O
that	O
amantadine	B-I
may	O
be	O
a	O
potential	O
adjunctive	O
treatment	O
strategy	O
for	O
autism	O
and	O
it	O
was	O
generally	O
well	O
tolerated	O
.	O


[	O
Effect	O
on	O
pressure	O
after	O
instillation	O
of	O
a	O
drop	O
of	O
depot-pilocarpine	B-I
.	I-I


Clinical	O
results	O
of	O
its	O
medium-term	O
action	O
]	O
.	O


A	O
clinical	O
comparison	O
of	O
an	O
emulsion	O
containing	O
a	O
new	B-I
pilocarpine	I-I
polymer	I-I
(	I-I
Polym	I-I
)	I-I
compound	O
to	O
that	O
of	O
a	O
traditional	B-I
pilocarpine	I-I
salt	I-I
solution	I-I
(	I-I
Plc	I-I
)	I-I
on	O
the	O
intraocular	B-O
pressure	I-O
(	I-O
IOP	I-O
)	I-O
has	O
been	O
performed	O
in	O
40	B-P
open-angle	I-P
patients	I-P
treated	I-P
with	I-P
the	I-P
long	I-P
acting	I-P
pilocarpine-complex	I-P
for	I-P
120	I-P
days	I-P
.	I-P


The	O
treatment	O
protocol	O
was	O
divided	O
into	O
3	O
stages	O
:	O
Stage	O
1	O
is	O
a	O
single	O
dose	O
treatment	O
where	O
12	O
patients	O
were	O
divided	O
randomly	O
into	O
2	O
groups	O
of	O
6	O
each	O
.	O


The	O
patients	O
of	O
each	O
group	O
were	O
given	B-I
1	I-I
drop	I-I
into	I-I
each	I-I
eye	I-I
:	I-I
1	I-I
drop	I-I
every	I-I
12	I-I
hours	I-I
for	I-I
Polym	I-I
,	I-I
1	I-I
drop	I-I
every	I-I
6	I-I
hours	I-I
for	I-I
Plc	I-I
.	I-I


The	B-I
patients	I-I
were	I-I
observed	I-I
for	I-I
a	I-I
period	I-I
of	I-I
24	I-I
hours	I-I
.	I-I


After	O
24	O
hours	O
without	O
medication	O
,	O
the	O
treatments	O
were	O
crossed	O
over	O
and	O
nycthemeral	O
graph	O
curves	O
were	O
registered	O
for	O
both	O
groups	O
.	O


Stage	O
2	O
is	O
a	O
medium	O
term	O
study	O
were	O
the	O
12	O
patients	O
used	O
in	O
Stage	O
1	O
were	O
added	O
to	O
another	O
28	O
patients	O
.	O


All	O
40	O
were	O
then	O
assigned	O
to	O
1	O
of	O
2	O
treatment	O
groups	O
(	O
2	O
groups	O
of	O
20	O
patients	O
each	O
)	O
according	O
to	O
a	O
table	O
of	O
random	O
numbers	O
.	O


Treatments	O
were	O
administered	O
during	O
one	O
month	O
,	O
then	O
cross-overed	O
again	O
during	O
4	O
weeks	O
.	O


Stage	O
3	O
:	O
finally	O
,	O
every	O
patient	O
could	O
choose	O
his	O
treatment	O
(	O
either	O
Polym	B-I
or	O
Plc	B-I
)	I-I
for	O
the	O
rest	O
of	O
the	O
period	O
(	O
2	O
months	O
)	O
.	O


The	O
clinical	O
study	O
shows	O
that	O
the	O
polymer	O
complex	O
(	O
Polym	O
)	O
produced	O
a	O
prolonged	B-O
therapeutic	I-O
effect	I-O
,	O
this	O
being	O
consistant	O
with	O
a	O
slow	O
release	O
pattern	O
and	O
maintained	O
a	O
more	O
effective	O
around-the-clock	O
control	O
than	O
pilocarpine	B-I
solution	O
.	O


These	O
results	O
were	O
accomplished	O
by	O
two	O
applications	O
per	O
day	O
as	O
compared	O
to	O
the	O
four	O
necessary	O
applications	O
of	O
Plc	B-I
,	O
on	O
a	O
half	O
daily	O
pilocarpine	B-I
dose	O
with	O
Polym	B-I
.	I-I


The	O
medium	O
term	O
results	O
confirmed	O
the	O
efficacity	B-O
noted	O
in	O
the	O
short	O
term	O
survey	O
.	O


Most	O
patients	O
preferred	O
Polym	B-I
to	O
Plc	B-I
when	O
they	O
were	O
asked	O
.	O


Throughout	O
the	O
4	O
months	O
study	O
period	O
,	O
no	O
adverse	B-O
side	I-O
effects	I-O
were	O
reported	O
.	O


Visual	B-O
disturbances	I-O
characteristic	O
of	O
pilocarpine	B-I
eye-drops	O
were	O
reduced	O
from	O
3	O
times	O
a	O
day	O
on	O
pilocarpine	B-I
salt	I-I
solution	O
to	O
once	O
a	O
day	O
on	O
pilocarpine	B-I
polymer	I-I
complex	O
.	O


The	O
pulsed-dye	B-I
laser	I-I
as	O
an	O
adjuvant	O
treatment	O
modality	O
in	O
acne	B-P
vulgaris	I-P
:	I-P
a	O
randomized	O
controlled	O
single-blinded	O
trial	O
.	O


BACKGROUND	O
Acne	O
vulgaris	O
is	O
the	O
most	O
common	O
skin	O
disease	O
and	O
can	O
pose	O
a	O
substantial	O
therapeutic	O
challenge	O
.	O


Recently	O
,	O
several	O
phototherapeutic	O
modalities	O
,	O
most	O
notably	O
pulsed-dye	B-I
laser	I-I
(	I-I
PDL	I-I
)	I-I
treatment	O
,	O
have	O
been	O
introduced	O
,	O
but	O
the	O
published	O
results	O
-	O
albeit	O
promising	O
-	O
are	O
controversial	O
.	O


OBJECTIVES	O
To	O
assess	O
the	O
efficacy	B-O
of	O
an	O
adjuvant	O
PDL	B-I
treatment	O
when	O
combined	O
with	O
a	O
proven	O
topical	O
treatment	O
[	O
fixed-combination	O
clindamycin	O
1	O
%	O
-benzoyl	O
peroxide	O
5	O
%	O
hydrating	O
gel	O
(	O
C/BPO	O
)	O
]	O
.	O


METHODS	O
Eighty	B-P
patients	I-P
(	I-P
38	I-P
males	I-P
and	I-P
42	I-P
females	I-P
,	I-P
mean	I-P
+/-	I-P
SD	I-P
age	I-P
19.7	I-P
+/-	I-P
5.9	I-P
years	I-P
)	I-P
were	O
randomized	O
in	O
a	O
1	O
:	O
2	O
ratio	O
to	O
receive	O
C/BPO	B-I
alone	I-I
or	I-I
in	I-I
combination	I-I
with	I-I
PDL	I-I
treatment	I-I
(	O
wavelength	O
585	O
nm	O
,	O
energy	O
fluence	O
3	O
J	O
cm	O
(	O
-2	O
)	O
,	O
pulse	O
duration	O
0.35	O
ms	O
,	O
spot	O
size	O
7	O
mm	O
)	O
.	O


Patients	O
were	O
evaluated	O
at	O
baseline	O
and	O
at	O
2	O
and	O
4	O
weeks	O
after	O
initial	O
treatment	O
.	O


The	O
primary	O
end	O
points	O
were	O
the	O
Investigator	B-O
's	I-O
Static	I-O
Global	I-O
Assessment	I-O
(	I-O
ISGA	I-O
)	I-O
score	I-O
and	O
lesion	B-O
count	I-O
;	I-O
the	O
secondary	O
end	O
point	O
was	O
the	O
Dermatology	B-O
Life	I-O
Quality	I-O
Index	I-O
(	I-O
DLQI	I-O
)	I-O
.	I-O


RESULTS	O
Both	O
groups	O
showed	O
a	O
significant	O
improvement	O
during	O
observation	B-O
[	O
ISGA	O
27.1	O
%	O
(	B-I
C/BPO	I-I
)	I-I
and	O
24.6	O
%	O
(	B-I
C/BPO	I-I
+	I-I
laser	I-I
)	I-I
,	O
total	B-O
lesion	I-O
count	I-O
9.2	O
%	O
and	O
9.0	O
%	O
,	O
inflammatory	B-O
lesion	I-O
count	I-O
36.3	O
%	O
and	O
36.9	O
%	O
,	O
DLQI	O
54.5	O
%	O
and	O
42.5	O
%	O
]	O
,	O
but	O
there	O
was	O
no	O
significant	O
or	O
otherwise	O
appreciable	O
difference	O
between	O
treatment	O
modalities	O
as	O
far	O
as	O
the	O
extent	O
of	O
improvement	O
was	O
concerned	O
.	O


Patients	O
with	O
more	O
severe	O
findings	O
at	O
baseline	O
had	O
a	O
greater	O
benefit	O
from	O
either	O
therapy	O
regimen	O
.	O


CONCLUSIONS	O
Our	O
findings	O
do	O
not	O
support	O
the	O
concept	O
of	O
a	O
substantial	O
benefit	O
of	O
PDL	B-I
treatment	O
in	O
acne	O
vulgaris	O
.	O


[	O
Efficacy	O
of	O
combination	O
with	O
granisetron	B-I
and	I-I
methylprednisolone	I-I
for	O
nausea	B-O
,	I-O
vomiting	I-O
and	I-O
appetite	I-O
loss	I-O
in	I-P
remission	I-P
induction	I-P
chemotherapy	I-P
of	I-P
acute	I-P
myeloid	I-P
leukemia	I-P
--	I-P
a	I-P
randomized	O
comparative	O
trial	O
between	O
granisetron	B-I
alone	I-I
and	I-I
granisetron	I-I
plus	I-I
methylprednisolone	I-I
]	I-I
.	O


The	O
prevention	O
of	O
nausea	B-O
,	I-O
vomiting	I-O
and	I-O
appetite	I-O
loss	I-O
induced	O
by	O
remission	O
induction	O
chemotherapy	O
for	O
acute	B-P
myeloid	I-P
leukemia	I-P
was	O
compared	O
by	O
randomization	O
between	O
granisetron	B-I
alone	I-I
and	I-P
combination	I-P
with	I-P
granisetron	I-I
plus	I-I
methylprednisolone	I-I
.	I-I


Granisetron	B-I
was	O
administered	O
at	O
40	B-I
micrograms/kg	I-I
during	I-I
chemotherapy	I-I
,	I-I
and	I-I
methylprednisolone	I-I
was	O
administered	O
concomitantly	O
at	O
125	O
mg/body	O
for	O
3	O
days	O
or	O
more	O
in	O
the	O
combination	B-P
group	I-P
.	I-P


The	B-P
single	I-P
and	I-P
combination	I-P
groups	I-P
comprised	I-P
14	I-P
and	I-P
13	I-P
patients	I-P
,	I-P
respectively	I-P
,	I-P
and	I-P
there	I-P
was	I-P
no	I-P
significant	I-P
difference	I-P
between	I-P
the	I-P
background	I-P
of	I-P
both	I-P
groups	I-P
.	I-P


To	O
evaluate	O
the	O
effect	O
they	O
were	O
scored	O
according	O
to	O
4	O
grades	O
,	O
and	O
evaluated	O
every	O
24	O
hours	O
from	O
the	O
start	O
of	O
chemotherapy	O
to	O
5	O
days	O
after	O
its	O
completion	O
.	O


The	O
complete	B-O
inhibition	I-O
rate	I-O
of	I-O
vomiting	I-O
was	O
as	O
high	O
as	O
71.4	O
%	O
and	O
92.3	O
%	O
in	O
the	O
single	O
and	O
combination	O
groups	O
,	O
respectively	O
,	O
showing	O
no	O
significant	O
difference	O
.	O


The	O
grade	B-O
of	I-O
vomiting	I-O
was	O
mild	O
in	O
both	O
groups	O
.	O


Nausea	B-O
was	O
noted	O
in	O
71.4	O
%	O
and	O
46.2	O
%	O
,	O
respectively	O
,	O
and	O
the	O
inhibitory	O
effect	O
tended	O
to	O
be	O
higher	O
in	O
the	O
combination	O
group	O
.	O


Appetite	B-O
loss	I-O
developed	O
in	O
92.9	O
%	O
and	O
41.7	O
%	O
,	O
respectively	O
,	O
and	O
the	O
prevention	O
effect	O
was	O
clearly	O
higher	O
in	O
the	O
combination	O
group	O
.	O


The	O
prevention	O
effects	O
on	O
nausea	B-O
7	O
,	O
8	O
and	O
10	O
days	O
after	O
the	O
start	O
of	O
chemotherapy	O
,	O
on	B-O
appetite	I-O
loss	I-O
2-10	O
days	O
after	O
it	O
,	O
and	O
2-5	O
days	O
after	O
its	O
completion	O
,	O
were	O
higher	O
in	O
the	O
combination	O
group	O
.	O


Granisetron	B-I
revealed	O
an	O
excellent	O
inhibitory	B-O
effect	I-O
on	I-O
vomiting	I-O
induced	O
by	O
remission	O
induction	O
chemotherapy	O
for	O
acute	O
myeloid	O
leukemia	O
,	O
but	O
combination	O
with	O
granisetron	B-I
and	I-I
methylprednisolone	I-I
was	O
considered	O
useful	O
for	O
nausea	B-O
in	O
the	O
latter	O
half	O
of	O
the	O
treatment	O
period	O
and	O
for	O
appetite	B-O
loss	I-O
during	O
the	O
whole	O
period	O
.	O


Fusidic	O
acid	O
prophylaxis	O
before	B-P
cataract	I-P
surgery	I-P
:	I-P
patient	I-P
self-administration	I-P
.	I-P


In	O
a	O
placebo-controlled	O
,	O
randomised	O
,	O
double-blind	O
clinical	O
trial	O
,	O
the	O
authors	O
evaluated	O
the	O
efficacy	O
of	O
patient-administered	O
1	O
%	O
fusidic	B-I
acid	I-I
viscous	I-I
eye	I-I
drops	I-I
in	O
clearing	O
the	O
commonest	O
organisms	O
causing	O
pseudophakic	O
endophthalmitis	O
(	O
Staphylococcus	O
epidermidis	O
and	O
aureus	O
)	O
from	O
the	O
lids	O
and	O
conjunctivae	O
of	O
79	B-P
patients	I-P
before	I-P
cataract	I-P
surgery	I-P
.	I-P


The	O
treatment	O
group	O
self-administered	O
fusidic	B-I
acid	I-I
viscous	O
eye	O
drops	O
four	O
times	O
daily	O
for	O
seven	O
days	O
before	O
surgery	O
;	O
the	O
placebo	O
group	O
received	O
inert	B-I
ophthalmic	I-I
drops	I-I
.	I-I


Fellow	O
eyes	O
of	O
both	O
groups	O
remained	O
untreated	O
as	O
a	O
natural	O
control	O
.	O


Lower	O
fornix	O
and	O
lid	O
margin	O
cultures	O
were	O
taken	O
from	O
both	O
eyes	O
before	O
and	O
after	O
treatment	O
.	O


Before	O
treatment	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
in	O
organism	B-O
counts	I-O
between	O
the	O
groups	O
.	O


After	O
treatment	O
,	O
eyes	O
receiving	O
fusidic	B-I
acid	I-I
were	O
more	O
likely	O
to	O
be	O
free	O
of	O
clinically	O
relevant	O
Staphylococcus	O
spp	O
.	O


than	O
all	O
pre-treatment	O
eyes	O
(	O
for	O
lids	O
,	O
P	O
<	O
0.001	O
;	O
conjunctivae	O
,	O
P	O
=	O
0.02	O
)	O
.	O


A	O
highly	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
number	B-O
of	I-O
lid	I-O
margins	I-O
were	O
rendered	O
'clinically	O
clean	O
'	O
(	O
i.e.	O
,	O
0-49	O
organisms/swab	O
)	O
by	O
fusidic	O
acid	O
when	O
compared	O
with	O
untreated	O
eyes	O
.	O


Treatment	O
also	O
effectively	O
(	O
P	O
<	O
0.05	O
)	O
reduced	O
the	O
numbers	B-O
of	I-O
bacteria	I-O
isolated	I-O
from	I-O
conjunctivae	I-O
.	I-O


This	O
study	O
indicates	O
that	O
there	O
is	O
a	O
highly	O
significant	O
reduction	O
of	O
Staphylococcus	O
spp	O
.	O


(	O
P	O
<	O
0.001	O
)	O
,	O
non-Staphylococcus	O
spp	O
.	O


(	O
P	O
<	O
0.001	O
)	O
and	O
attainment	O
of	O
sterile	O
eyes	O
(	O
P	O
<	O
0.001	O
)	O
at	O
operation	O
gained	O
by	O
patient	O
self-administration	O
of	O
1	O
%	O
fusidic	O
acid	O
four	O
times	O
daily	O
for	O
seven	O
days	O
before	O
surgery	O
.	O


Pre-exposure	O
studies	O
with	O
purified	B-I
chick	I-I
embryo	I-I
cell	I-I
culture	I-I
rabies	I-I
vaccine	I-I
and	O
human	B-I
diploid	I-I
cell	I-I
vaccine	I-I
:	I-I
serological	O
and	O
clinical	B-P
responses	I-P
in	I-P
man	I-P
.	I-P


Clinical	O
reactions	O
and	O
neutralizing	O
antibody	O
responses	O
to	O
six	O
pre-exposure	O
regimens	O
of	O
purified	B-I
chick	I-I
embryo	I-I
cell	I-I
culture	I-I
rabies	I-I
vaccine	I-I
(	I-I
PCECV	I-I
)	I-I
and	O
human	B-I
diploid	I-I
cell	I-I
strain	I-I
rabies	I-I
vaccine	I-I
(	I-I
HDCSV	I-I
)	I-I
were	O
studied	O
in	O
177	B-P
volunteers	I-P
.	I-P


Antibody	B-O
kinetics	I-O
,	I-O
height	I-O
of	I-O
the	I-O
response	I-O
and	I-O
persistence	I-O
of	I-O
antibody	I-O
over	I-O
two	I-O
years	I-O
were	O
virtually	O
identical	O
after	O
PCECV	B-I
and	O
HDCSV	B-I
.	I-I


An	O
antibody	B-O
response	I-O
was	O
detected	O
in	O
all	O
subjects	O
on	O
day	O
14	O
when	O
the	O
highest	O
titres	O
were	O
found	O
after	O
two	O
intramuscular	O
(	O
i.m	O
.	O


)	O
1.0	O
ml	O
doses	O
of	O
a	O
schedule	O
of	O
immunization	O
on	O
days	O
0	O
,	O
7	O
and	O
21	O
.	O


In	O
comparison	O
,	O
a	O
schedule	O
of	O
immunization	O
on	O
days	O
0	O
,	O
28	O
and	O
56	O
ultimately	O
evoked	O
the	O
highest	O
titres	B-O
21	I-O
days	I-O
after	I-O
the	I-O
final	I-O
injection	I-O
,	O
but	O
antibody	O
persisted	O
equally	O
well	O
over	O
two	O
years	O
with	O
either	O
schedule	O
.	O


Neutralizing	B-O
antibody	I-O
titres	I-O
were	O
lower	O
after	O
intradermal	O
(	O
i.d	O
.	O


)	O
vaccination	O
with	O
0.1	O
ml	O
compared	O
to	O
1.0	O
ml	O
i.m	O
.	O


on	O
days	O
0	O
,	O
7	O
and	O
21	O
,	O
but	O
when	O
given	O
on	O
days	O
0	O
,	O
28	O
and	O
56	O
the	O
responses	O
were	O
comparable	O
.	O


Three	O
subjects	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
atopy	O
developed	O
urticarial	B-O
lesions	I-O
after	O
PCECV	B-I
.	I-I


Both	O
vaccines	O
were	O
otherwise	O
well	O
tolerated	O
.	O


Effect	O
of	O
desonide	B-I
ointment	I-I
,	I-I
0.05	I-I
%	I-I
,	O
on	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
of	O
children	B-P
with	I-P
atopic	I-P
dermatitis	I-P
.	I-P


Desonide	B-I
ointment	I-I
has	O
demonstrated	O
a	O
good	O
safety	O
and	O
efficacy	O
profile	O
during	O
the	O
many	O
years	O
it	O
has	O
been	O
used	O
in	O
treating	O
dermatoses	O
.	O


However	O
,	O
there	O
have	O
been	O
no	O
controlled	O
clinical	O
trials	O
to	O
evaluate	O
its	O
systemic	O
safety	O
when	O
used	O
in	O
treating	O
children	B-P
.	I-P


Suppression	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
can	O
occur	O
after	O
repeated	O
application	O
of	O
topical	O
corticosteroids	O
.	O


In	O
general	O
,	O
the	O
degree	B-O
of	I-O
suppression	I-O
of	I-O
the	I-O
HPA	I-O
axis	I-O
function	I-O
is	O
related	O
to	O
the	O
daily	O
dosage	O
of	O
steroid	O
given	O
,	O
the	O
duration	O
of	O
its	O
administration	O
,	O
the	O
extent	O
of	O
body	O
surface	O
covered	O
,	O
and	O
the	O
potency	O
of	O
the	O
corticosteroid	O
.	O


This	O
study	O
sought	O
to	O
determine	O
the	O
comparative	O
effects	O
of	O
0.05	B-I
percent	I-I
desonide	I-I
and	I-I
2.5	I-I
percent	I-I
hydrocortisone	I-I
ointments	I-I
on	O
the	O
HPA	O
axis	O
of	O
children	B-P
with	I-P
atopic	I-P
dermatitis	I-P
.	I-P


There	O
was	O
no	O
suppression	B-O
of	I-O
early	I-O
morning	I-O
cortisol	I-O
in	O
either	O
treatment	O
group	O
.	O


The	O
ACTH-stimulated	B-O
mean	I-O
cortisol	I-O
values	I-O
after	O
four	O
weeks	O
of	O
treatment	O
were	O
not	O
significantly	O
different	O
from	O
the	O
baseline	O
values	O
for	O
either	O
treatment	O
group	O
.	O


We	O
conclude	O
that	O
neither	O
0.05	B-I
percent	I-I
desonide	I-I
ointment	I-I
nor	O
2.5	B-I
percent	I-I
hydrocortisone	I-I
ointment	I-I
compromised	O
the	O
HPA	O
axis	O
of	O
children	B-P
with	I-P
atopic	I-P
dermatitis	I-P
treated	O
topically	O
for	O
four	O
weeks	O
.	O


The	O
memory	O
support	O
system	O
for	O
mild	B-P
cognitive	I-P
impairment	I-P
:	I-P
randomized	O
trial	O
of	O
a	O
cognitive	B-I
rehabilitation	I-I
intervention	I-I
.	I-I


OBJECTIVE	O
Individuals	B-P
with	I-P
amnestic	I-P
mild	I-P
cognitive	I-P
impairment	I-P
(	I-P
MCI	I-P
)	I-P
have	O
few	O
empirically	O
based	O
treatment	O
options	O
for	O
combating	O
their	O
memory	B-O
loss	I-O
.	I-O


This	O
study	O
sought	O
to	O
examine	O
the	O
efficacy	B-O
of	O
a	O
calendar/notebook	B-I
rehabilitation	I-I
intervention	I-I
,	O
the	O
memory	B-O
support	I-O
system	I-O
(	I-O
MSS	I-O
)	I-O
,	O
for	O
individuals	B-P
with	I-P
amnestic	I-P
MCI	I-P
.	I-P


METHODS	O
Forty	B-P
individuals	I-P
with	I-P
single	I-P
domain	I-P
amnestic	I-I
MCI	I-I
and	I-P
their	I-P
program	I-P
partners	I-P
were	I-P
randomized	I-P
to	O
receive	O
the	O
MSS	O
,	O
either	O
with	O
training	O
or	O
without	O
(	O
controls	O
)	O
.	O


Measures	B-O
of	I-O
adherence	I-O
,	I-O
activities	I-O
of	I-O
daily	I-O
living	I-O
,	I-O
and	I-O
emotional	I-O
impact	I-O
were	O
completed	O
at	O
the	O
first	O
and	O
last	O
intervention	O
sessions	O
and	O
again	O
at	O
8	O
weeks	O
and	O
6	O
months	O
post	O
intervention	O
.	O


RESULTS	O
Training	O
in	O
use	O
of	O
a	O
notebook/calendar	O
system	O
significantly	O
improved	O
adherence	B-O
over	O
those	O
who	O
received	O
the	O
calendars	O
but	O
no	O
training	O
.	O


Functional	B-O
ability	I-O
and	I-O
memory	I-O
self-efficacy	I-O
significantly	O
improved	O
for	O
those	O
who	O
received	O
MSS	O
training	O
.	O


Change	B-O
in	I-O
functional	I-O
ability	I-O
remained	O
significantly	O
better	O
in	O
the	O
intervention	O
group	O
than	O
in	O
the	O
control	O
group	O
out	O
to	O
8-week	O
follow-up	O
.	O


Care	O
partners	O
in	O
the	O
intervention	O
group	O
demonstrated	O
improved	O
mood	B-O
by	O
8-week	O
and	O
6-month	O
follow-ups	O
,	O
whereas	O
control	O
care	O
partners	O
reported	O
worse	O
caregiver	B-O
burden	I-O
by	O
6-month	O
follow-up	O
.	O


CONCLUSIONS	O
Memory	B-I
support	I-I
system	I-I
training	I-I
resulted	O
in	O
improvement	O
in	O
activities	B-O
of	I-O
daily	I-O
living	I-O
and	I-O
sense	I-O
of	I-O
memory	I-O
self-efficacy	I-O
for	O
individuals	O
with	O
MCI	O
.	O


Although	O
activities	O
of	O
daily	O
living	O
benefits	O
were	O
maintained	O
out	O
to	O
8	O
weeks	O
post	O
intervention	O
,	O
future	O
inclusion	O
of	O
booster	O
sessions	O
may	O
help	O
extend	O
the	O
therapeutic	O
effect	O
out	O
even	O
further	O
.	O


Improved	B-O
mood	I-O
of	O
care	O
partners	O
of	O
trained	O
individuals	O
and	O
worsening	B-O
sense	I-O
of	I-O
caregiver	I-O
burden	I-O
over	O
time	O
for	O
partners	O
of	O
untrained	O
individuals	O
further	O
support	O
the	O
efficacy	O
of	O
the	O
MSS	O
for	O
MCI	O
.	O


The	O
effect	O
of	O
values	O
affirmation	O
on	O
race-discordant	B-P
patient-provider	I-P
communication	O
.	O


BACKGROUND	O
Communication	O
between	O
African	B-P
American	I-P
patients	I-P
and	I-P
white	I-P
health	I-P
care	I-P
providers	I-P
has	O
been	O
shown	O
to	O
be	O
of	O
poorer	O
quality	O
when	O
compared	O
with	O
race-concordant	O
patient-provider	O
communication	O
.	O


Fear	O
on	O
the	O
part	O
of	O
patients	O
that	O
providers	O
stereotype	O
them	O
negatively	O
might	O
be	O
one	O
cause	O
of	O
this	O
poorer	O
communication	O
.	O


This	O
stereotype	O
threat	O
may	O
be	O
lessened	O
by	O
a	O
values-affirmation	O
intervention	O
.	O


METHODS	O
In	O
a	O
blinded	O
experiment	O
,	O
we	O
randomized	O
99	B-P
African	I-P
American	I-P
patients	I-P
with	I-P
hypertension	I-P
to	O
perform	O
a	O
values-affirmation	B-I
exercise	I-I
or	I-I
a	I-I
control	I-I
exercise	I-I
before	O
a	O
visit	O
with	O
their	O
primary	O
care	O
provider	O
.	O


We	O
compared	O
patient-provider	O
communication	O
for	O
the	O
2	O
groups	O
using	O
audio	O
recordings	O
of	O
the	O
visit	O
analyzed	O
with	O
the	O
Roter	O
Interaction	O
Analysis	O
System	O
.	O


We	O
also	O
evaluated	O
visit	O
satisfaction	O
,	O
trust	O
,	O
stress	O
,	O
and	O
mood	O
after	O
the	O
visit	O
by	O
means	O
of	O
a	O
questionnaire	O
.	O


RESULTS	O
Patients	O
in	O
the	O
intervention	O
group	O
requested	O
and	O
provided	O
more	O
information	B-O
about	O
their	O
medical	B-O
condition	I-O
(	O
mean	O
[	O
SE	O
]	O
number	O
of	O
utterances	O
,	O
66.3	O
[	O
6.8	O
]	O
in	O
the	O
values-affirmation	O
group	O
vs	O
48.1	O
[	O
5.9	O
]	O
in	O
the	O
control	O
group	O
[	O
P	O
=	O
.03	O
]	O
)	O
.	O


Patient-provider	O
communication	O
in	O
the	O
intervention	O
group	O
was	O
characterized	O
as	O
being	O
more	O
interested	B-O
,	I-O
friendly	I-O
,	I-O
responsive	I-O
,	I-O
interactive	I-O
,	I-O
and	I-O
respectful	I-O
(	O
P	O
=	O
.02	O
)	O
and	O
less	O
depressed	B-O
and	I-O
distressed	I-O
(	O
P	O
=	O
.03	O
)	O
.	O


Patient	O
questionnaires	O
did	O
not	O
detect	O
differences	O
in	O
visit	B-O
satisfaction	I-O
,	I-O
trust	I-O
,	I-O
stress	I-O
,	I-O
or	I-O
mood	I-O
.	I-O


Mean	B-O
visit	I-O
duration	I-O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
(	O
19.2	O
minutes	O
in	O
the	O
control	O
group	O
vs	O
20.5	O
minutes	O
in	O
the	O
intervention	O
group	O
[	O
P	O
=	O
.29	O
]	O
)	O
.	O


CONCLUSIONS	O
A	O
values-affirmation	B-I
exercise	I-I
improves	O
aspects	O
of	O
patient-provider	O
communication	O
in	O
race-discordant	O
primary	O
care	O
visits	O
.	O


The	O
clinical	O
impact	O
of	O
the	O
intervention	O
must	O
be	O
defined	O
before	O
widespread	O
implementation	O
can	O
be	O
recommended	O
.	O


Magnocellular	B-I
visual	I-I
evoked	O
potential	O
delay	O
with	O
high	B-P
autism	I-P
spectrum	I-P
quotient	I-P
yields	O
a	O
neural	O
mechanism	O
for	O
altered	B-O
perception	I-O
.	I-O


Everyone	O
has	O
autistic	O
characteristics	O
to	O
a	O
greater	O
or	O
lesser	O
degree	O
,	O
encapsulated	O
in	O
the	O
Autism	B-O
Spectrum	I-O
Quotient	I-O
,	O
a	O
scale	O
that	O
measures	O
the	O
degree	O
to	O
which	O
an	O
adult	B-P
of	I-P
normal	I-P
intelligence	I-P
displays	O
traits	O
associated	O
with	O
autism	O
spectrum	O
disorders	O
.	O


Recent	O
psychophysical	O
analyses	O
of	O
autism	O
spectrum	O
disorders	O
point	O
to	O
superior	O
local	O
processing	O
,	O
and	O
impaired	O
or	O
ignored	O
global	O
and	O
contextual	O
processing	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
low-	B-I
and	I-P
high-scoring	I-I
individuals	I-I
on	I-I
the	I-I
Autism	I-I
Spectrum	I-I
Quotient	I-I
differ	O
on	O
a	O
measure	O
of	O
local	B-O
and	I-O
global	I-O
processing	I-O
,	I-I
motion	I-I
processing	I-I
and	I-I
visual	I-I
pathway	I-I
integrity	I-I
.	I-I


Fifteen	B-P
low-scoring	I-P
individuals	I-P
and	I-P
14	I-P
high-scoring	I-P
individuals	I-P
derived	I-P
from	I-P
a	I-P
normal	I-P
population	I-P
participated	I-P
in	I-P
the	I-P
study	I-P
.	I-P


The	O
results	O
indicate	O
that	O
the	O
initial	O
cortical	B-O
response	I-O
to	O
the	O
magnocellular	O
afferents	O
is	O
weaker	O
at	O
low	O
contrast	O
in	O
the	O
high	O
autistic	O
tendency	O
group	O
and	O
that	O
a	O
second-order	O
response	O
,	O
reflecting	O
magnocellular	O
activity	O
,	O
demonstrated	O
a	B-O
delay	I-O
for	O
high	O
versus	O
low	O
scorers	O
when	O
the	O
parvocellular	O
pathway	O
was	O
also	O
active	O
in	O
response	O
to	O
a	O
high	O
contrast	O
stimulus	O
.	O


High-scoring	O
individuals	O
also	O
demonstrated	O
difficulty	O
in	O
identifying	B-O
the	I-O
global	I-O
components	I-O
of	O
locally	O
salient	O
hierarchical	O
Navon	O
figures	O
.	O


Furthermore	O
,	O
cross-validated	O
discriminant	O
analysis	O
,	O
using	O
four	O
physiologically	O
and	O
three	O
psychophysically	O
derived	O
parameters	O
,	O
correctly	O
classified	O
83	O
%	O
of	O
individuals	O
who	O
scored	O
either	O
high	O
or	O
low	O
on	O
the	O
Autism	O
Spectrum	O
Quotient	O
.	O


These	O
findings	O
in	O
the	O
group	O
scoring	O
high	O
on	O
the	O
Autism	B-P
Spectrum	I-P
Quotient	I-P
indicate	O
that	O
a	O
delay	O
in	O
primary	O
visual/prestriate	O
cortical	O
processing	O
of	O
magnocellular	O
input	O
diminishes	O
the	O
advantage	O
of	O
its	O
early	O
arrival	O
to	O
primary	O
visual	O
cortex	O
.	O


This	O
appears	O
to	O
be	O
associated	O
with	O
impaired	B-O
global	I-O
visual	I-O
perception	I-O
,	O
predicting	O
with	O
high	O
accuracy	O
behavioural	B-O
tendencies	I-O
associated	O
with	O
autism	O
spectrum	O
disorders	O
.	O


It	O
has	O
been	O
proposed	O
that	O
perceptual	O
impairment	O
in	O
autism	O
may	O
be	O
attributed	O
to	O
a	O
dysfunction	O
of	O
horizontal	O
connections	O
within	O
early	O
visual	O
areas	O
,	O
presumably	O
parvocellular	O
in	O
nature	O
.	O


However	O
,	O
the	O
timing	O
of	O
such	O
form	O
processing	O
aberrations	O
is	O
much	O
later	O
than	O
the	O
timing	O
of	O
abnormal	O
magnocellular	O
visual	O
processing	O
measured	O
directly	O
here	O
.	O


Thus	O
it	O
is	O
proposed	O
that	O
a	O
magnocellular	O
processing	O
delay	O
decreases	O
the	O
ability	O
of	O
autistic	B-P
individuals	I-P
to	O
benefit	O
perceptually	O
from	O
feedback	O
normally	O
associated	O
with	O
the	O
magnocellular	O
advantage	O
.	O


A	O
comparative	O
study	O
of	O
netilmicin-cefoxitin	B-I
and	O
gentamicin-cefoxitin	B-I
in	O
surgical	B-P
patients	I-P
with	I-P
serious	I-P
systemic	I-P
infection	I-P
.	I-P


A	O
double-blind	O
,	O
randomized	O
study	O
of	O
gentamicin	B-I
and	O
netilmicin	B-I
,	O
each	O
in	O
combination	O
with	O
cefoxitin	B-I
,	O
was	O
done	O
to	O
compare	O
their	O
respective	O
efficacy	B-O
and	I-O
toxicity	I-O
in	O
patients	B-P
with	I-P
serious	I-P
systemic	I-P
infection	I-P
.	I-P


Thirty-seven	B-P
surgical	I-P
patients	I-P
were	I-P
evaluated	I-P
for	I-P
efficacy	I-O
and	I-P
46	I-P
patients	I-P
were	I-P
evaluated	I-P
for	I-P
toxicity	I-P
.	I-P


The	O
most	O
frequently	O
cultured	O
organisms	O
were	O
Escherichia	O
coli	O
(	O
15	O
)	O
,	O
Klebsiella	O
sp	O
(	O
9	O
)	O
,	O
Proteus	O
sp	O
(	O
6	O
)	O
,	O
and	O
Bacteroides	O
sp	O
(	O
4	O
)	O
.	O


For	O
23	O
patients	O
treated	O
with	O
gentamicin-cefoxitin	B-I
(	O
G-C	O
)	O
,	O
the	O
clinical	B-O
response	I-O
was	O
favorable	O
in	O
20/21	O
(	O
95.2	O
%	O
)	O
evaluable	O
cases	O
,	O
and	O
elimination	O
or	O
marked	O
reduction	O
of	O
33/34	O
(	O
97.1	O
%	O
)	O
organisms	O
was	O
achieved	O
.	O


For	O
14	O
patients	O
treated	O
with	O
netilmicin-cefoxitin	B-I
(	O
N-C	O
)	O
,	O
the	O
clinical	B-O
response	I-O
was	O
favorable	O
in	O
13/13	O
(	O
100	O
%	O
)	O
evaluable	O
cases	O
,	O
and	O
19/20	O
(	O
95	O
%	O
)	O
organisms	O
were	O
eliminated	O
or	O
markedly	O
reduced	O
.	O


Nephrotoxicity	B-O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	B-O
creatinine	I-O
to	O
greater	O
than	O
25	O
%	O
over	O
baseline	O
with	O
an	O
absolute	O
rise	O
of	O
at	O
least	O
0.5	O
mg/100	O
ml	O
to	O
a	O
value	O
greater	O
than	O
or	O
equal	O
to	O
1.3	O
mg/100	O
ml	O
.	O


Based	O
on	O
these	O
criteria	O
,	O
nephrotoxicity	B-O
was	O
seen	O
in	O
2/27	O
(	O
7.4	O
%	O
)	O
patients	O
treated	O
with	O
G-C	O
and	O
in	O
3/19	O
(	O
15.8	O
%	O
)	O
patients	O
treated	O
with	O
N-C.	O
Ototoxicity	B-O
was	O
defined	O
as	O
a	O
greater	O
than	O
20	O
dB	O
loss	O
at	O
any	O
frequency	O
.	O


Based	O
on	O
these	O
criteria	O
,	O
ototoxicity	B-O
was	O
seen	O
in	O
5/27	O
(	O
18.5	O
%	O
)	O
patients	O
treated	O
with	O
G-C	O
and	O
2/19	O
(	O
10.5	O
%	O
)	O
patients	O
treated	O
with	O
N-C	O
.	O


The	O
data	O
show	O
no	O
significant	O
difference	O
in	O
toxicity	B-O
and	O
suggest	O
that	O
netilmicin	O
and	O
gentamicin	O
are	O
both	O
highly	O
effective	O
in	O
combination	O
with	O
cefoxitin	O
in	O
patients	B-P
who	I-P
have	I-P
serious	I-P
infections	I-P
after	I-P
surgery	I-P
.	I-P


Cimetidine	B-I
as	O
an	O
immunomodulator	O
in	O
the	O
treatment	O
of	O
herpes	B-P
zoster	I-P
.	I-P


As	O
there	O
is	O
evidence	O
of	O
a	O
possible	O
immunoregulatory	O
role	O
for	O
H2-histamine	B-I
receptor	I-I
antagonists	I-I
,	O
we	O
carried	O
out	O
a	O
prospective	O
randomized	O
trial	O
to	O
evaluate	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
effect	O
of	O
cimetidine	B-I
,	O
an	O
H2-blocker	O
,	O
in	O
the	O
treatment	O
of	O
herpes	B-P
zoster	I-P
infection	I-P
.	I-P


Cimetidine	B-I
treatment	O
shortened	O
the	O
median	B-O
interval	I-O
until	I-O
the	I-O
first	I-O
decrease	I-O
in	I-O
pain	I-O
,	O
the	O
median	B-O
interval	I-O
until	I-O
the	I-O
complete	I-O
resolution	I-O
of	I-O
pain	I-O
and	I-O
promoted	I-O
faster	I-O
complete	I-O
healing	I-O
of	I-O
skin	I-O
lesions	I-O
than	O
symptomatic	O
treatment	O
.	O


The	O
immunological	O
trends	O
observed	O
in	O
vitro	O
support	O
an	O
important	O
role	O
for	O
histamine	O
in	O
the	O
induction	O
of	O
immunosuppression	O
,	O
as	O
measured	O
by	O
the	O
response	O
to	O
the	O
mitogen	O
phytohemagglutinin	O
.	O


This	O
effect	O
of	O
histamine	O
was	O
antagonized	O
by	O
cimetidine	B-I
.	I-I


ACE	B-I
inhibitors	I-I
or	I-I
AT-1	I-I
antagonists	I-I
-	O
which	O
is	O
OPTIMAAL	O
after	O
acute	O
myocardial	O
infarction	O
?	O
OPTIMAAL	O
(	O
Optimal	O
Trial	O
in	O
Myocardial	O
Infarction	O
with	O
the	O
Angiotensin	O
II	O
Antagonist	O
Losartan	O
)	O
is	O
the	O
first	O
major	O
study	O
to	O
compare	O
an	O
angiotensin	B-I
II	I-I
Type	I-I
1	I-I
antagonist	I-I
losartan	I-I
(	O
Cozaar	O
trade	O
mark	O
,	O
Merck	O
)	O
with	O
an	O
ACE	O
inhibitor	O
captonpril	B-I
(	O
Capoten	O
trade	O
mark	O
,	O
Elan	O
)	O
after	B-P
myocardial	I-P
infarction	I-P
in	I-P
patients	I-P
with	I-P
left	I-P
ventricular	I-P
dysfunction	I-P
.	I-P


Patients	B-P
were	O
assigned	O
to	O
a	O
target	O
dose	O
of	O
losartan	B-I
50	O
mg/day	O
and	O
captopril	B-I
50	O
mg	O
t.i.d.	O
,	O
as	O
tolerated	O
.	O


The	O
primary	O
end	O
point	O
was	O
all-cause	B-O
mortality	I-O
and	O
there	O
were	O
499	O
(	O
18	O
%	O
)	O
and	O
447	O
(	O
16	O
%	O
)	O
deaths	B-O
in	O
the	O
losartan	B-I
and	I-I
captopril	I-I
group	O
,	O
respectively	O
(	O
p	O
=	O
0.07	O
)	O
.	O


However	O
,	O
there	O
were	O
significantly	O
more	O
cardiovascular	B-O
deaths	I-O
with	O
losartan	O
(	O
420	O
,	O
15	O
%	O
)	O
than	O
with	O
captopril	B-I
(	O
363	O
,	O
13	O
%	O
;	O
p	O
=	O
0.03	O
)	O
.	O


Losartan	B-I
was	O
better	O
tolerated	B-O
than	O
captopril	B-I
with	O
fewer	O
patients	B-O
discontinuing	I-O
medication	I-O
(	O
17	O
versus	O
23	O
%	O
for	O
losartan	B-I
and	O
captopril	B-I
,	O
respectively	O
)	O
.	O


In	O
conclusion	O
,	O
if	O
tolerated	O
,	O
captopril	B-I
should	O
remain	O
the	O
preferred	O
treatment	O
for	O
patients	B-P
after	O
complicated	O
acute	B-O
myocardial	I-O
infarction	I-O
.	I-O


Effects	O
of	O
walnut	B-I
consumption	I-I
on	O
endothelial	B-O
function	I-O
in	O
type	B-P
2	I-P
diabetic	I-P
subjects	I-P
:	I-P
a	O
randomized	O
controlled	O
crossover	O
trial	O
.	O


OBJECTIVE	O
To	O
determine	O
the	O
effects	O
of	O
daily	O
walnut	B-I
consumption	I-I
on	O
endothelial	B-O
function	I-O
,	I-O
cardiovascular	I-O
biomarkers	I-O
,	I-O
and	I-O
anthropometric	I-O
measures	I-O
in	O
type	B-P
2	I-P
diabetic	I-P
individuals	I-P
.	I-P


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
This	O
study	O
was	O
a	O
randomized	O
,	O
controlled	O
,	O
single-blind	O
,	O
crossover	O
trial	O
.	O


Twenty-four	B-P
participants	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
(	I-P
mean	I-P
age	I-P
58	I-P
years	I-P
;	I-P
14	I-P
women	I-P
and	I-P
10	I-P
men	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
two	O
possible	O
sequence	O
permutations	O
to	O
receive	O
an	O
ad	B-I
libitum	I-I
diet	I-I
enriched	I-I
with	I-I
56	I-I
g	I-I
(	I-I
366	I-I
kcal	I-I
)	I-I
walnuts/day	I-I
and	I-I
an	I-I
ad	I-I
libitum	I-I
diet	I-I
without	I-I
walnuts	I-I
for	I-I
8	I-I
weeks	I-I
.	I-I


Subjects	O
underwent	O
endothelial	B-I
function	I-I
testing	I-I
(	O
measured	O
as	O
flow-mediated	O
dilatation	O
[	O
FMD	O
]	O
)	O
and	O
assessment	O
of	O
cardiovascular	O
biomarkers	O
before	O
and	O
after	O
each	O
8-week	O
treatment	O
phase	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
the	O
change	B-O
in	I-O
FMD	I-O
after	O
8	O
weeks	O
.	O


Secondary	O
outcome	O
measures	O
included	O
changes	B-O
in	I-O
plasma	I-O
lipids	I-O
,	I-O
A1C	I-O
,	I-O
fasting	I-O
glucose	I-O
,	I-O
insulin	I-O
sensitivity	I-O
,	I-O
and	I-O
anthropometric	I-O
measures	I-O
.	I-O


RESULTS	O
Endothelial	B-O
function	I-O
significantly	O
improved	O
after	O
consumption	O
of	O
a	O
walnut-enriched	O
ad	O
libitum	O
diet	O
compared	O
with	O
that	O
after	O
consumption	O
of	O
an	O
ad	O
libitum	O
diet	O
without	O
walnuts	O
(	O
2.2	O
+/-	O
1.7	O
vs.	O
1.2	O
+/-	O
1.6	O
%	O
;	O
P	O
=	O
0.04	O
)	O
.	O


The	O
walnut-enriched	O
diet	O
increased	O
fasting	B-O
serum	I-O
glucose	I-O
and	I-O
lowered	I-O
serum	I-O
total	I-O
cholesterol	I-O
and	I-O
LDL	I-O
cholesterol	I-O
from	O
baseline	O
(	O
10.0	O
+/-	O
20.5	O
mg/dl	O
,	O
P	O
=	O
0.04	O
;	O
-9.7	O
+/-	O
14.5	O
mg/dl	O
,	O
P	O
<	O
0.01	O
;	O
and	O
-7.7	O
+/-	O
10	O
mg/dl	O
,	O
P	O
<	O
0.01	O
,	O
respectively	O
)	O
,	O
although	O
these	O
changes	O
were	O
not	O
significant	O
compared	O
with	O
those	O
for	O
an	O
ad	O
libitum	O
diet	O
without	O
walnuts	O
.	O


There	O
were	O
no	O
significant	O
changes	O
in	O
anthropometric	B-O
measures	I-O
,	I-O
plasma	I-O
A1C	I-O
,	I-O
and	I-O
insulin	I-O
sensitivity	I-O
.	I-O


CONCLUSIONS	O
A	O
walnut-enriched	O
ad	O
libitum	O
diet	O
improves	O
endothelium-dependent	O
vasodilatation	O
in	O
type	O
2	O
diabetic	O
individuals	O
,	O
suggesting	O
a	O
potential	O
reduction	O
in	O
overall	O
cardiac	B-O
risk	I-O
.	I-O


Rationale	O
and	O
study	O
design	O
of	O
the	O
increase	O
of	O
vagal	O
tone	O
in	O
heart	B-P
failure	I-P
study	O
:	O
INOVATE-HF	O
.	O


BACKGROUND	O
Imbalance	O
between	O
the	O
parasympathetic	O
and	O
sympathetic	O
nervous	O
systems	O
is	O
a	O
recognized	O
contributor	O
to	O
progression	O
of	O
chronic	B-P
heart	I-P
failure	I-P
.	I-P


Current	O
therapy	O
with	O
beta	O
adrenergic	O
antagonists	O
is	O
designed	O
to	O
moderate	O
the	O
up-regulation	O
of	O
norepinephrine	O
and	O
sympathetic	O
effects	O
;	O
however	O
,	O
to	O
date	O
,	O
there	O
are	O
no	O
therapies	O
that	O
specifically	O
address	O
the	O
withdrawal	O
of	O
parasympathetic	O
influences	O
on	O
cardiac	O
function	O
and	O
structure	O
.	O


METHODS/RESULTS	O
In	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
vagus	O
nerve	O
stimulation	O
,	O
an	O
international	O
multi-center	O
randomized	O
clinical	O
trial	O
(	O
INOVATE-HF	O
)	O
has	O
been	O
designed	O
to	O
assess	O
safety	B-O
and	I-O
efficacy	I-O
of	O
vagus	O
nerve	O
stimulation	O
in	O
symptomatic	B-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
on	I-P
optimal	I-P
medical	I-P
therapy	I-P
using	O
the	O
CardioFit	B-I
System	I-I
(	O
BioControl	O
Medical	O
,	O
Yehud	O
,	O
Israel	O
)	O
.	O


Up	B-P
to	I-P
650	I-P
patients	I-P
from	I-P
80	I-P
sites	I-P
will	I-P
be	I-P
recruited	I-P
and	O
randomized	O
in	O
a	O
3:2	O
ratio	O
to	O
receive	O
active	O
treatment	O
or	O
standard	B-I
optimal	I-I
medical	I-I
therapy	I-I
.	I-I


Inclusion	B-P
criteria	I-P
include	I-P
left	I-P
ventricular	I-P
systolic	I-P
dysfunction	I-P
,	I-P
the	I-P
presence	I-P
of	I-P
New	I-P
York	I-P
Heart	I-P
Association	I-P
Class	I-P
III	I-P
symptoms	I-P
,	I-P
sinus	I-P
rhythm	I-P
,	I-P
and	I-P
QRS	I-P
width	I-P
less	I-P
than	I-P
120	I-P
milliseconds	I-P
.	I-P


The	O
study	O
is	O
powered	O
to	O
detect	O
differences	O
in	O
the	O
primary	O
efficacy	O
end	O
point	O
of	O
all-cause	B-O
mortality	I-O
and	I-O
heart	I-O
failure	I-O
hospitalization	I-O
and	I-O
2	I-O
safety	I-O
end	I-O
points	I-O
.	I-O


CONCLUSION	O
Vagal	O
nerve	O
stimulation	O
with	O
CardioFit	B-I
as	O
a	O
treatment	O
for	O
symptomatic	O
heart	O
failure	O
is	O
under	O
active	O
investigation	O
as	O
a	O
novel	O
approach	O
to	O
restore	O
balance	O
between	O
the	O
sympathetic	O
and	O
parasympathetic	O
nervous	O
systems	O
.	O


If	O
shown	O
to	O
be	O
safe	O
and	O
effective	O
in	O
decreasing	O
heart	B-O
failure	I-O
events	I-O
and	I-O
mortality	I-O
,	O
this	O
novel	O
approach	O
will	O
impact	O
the	O
treatment	O
paradigm	O
for	O
heart	O
failure	O
.	O


Intervention	B-I
for	I-I
ineffective	I-O
airway	I-O
clearance	I-O
in	I-I
asthmatic	I-I
children	I-I
:	I-I
a	O
controlled	O
and	O
randomized	O
clinical	O
trial	O
.	O


This	O
study	O
aimed	O
to	O
analyse	O
the	O
effectiveness	O
of	O
an	O
intervention	O
for	O
the	O
nursing	O
diagnosis	O
of	O
ineffective	B-O
airway	I-O
clearance	I-O
in	O
asthmatic	B-P
children	I-P
.	I-P


A	O
blinded	O
,	O
randomized	O
and	O
controlled	O
clinical	O
trial	O
was	O
developed	O
in	O
a	O
paediatric	B-P
hospital	I-P
located	I-P
on	I-P
northeast	I-P
of	I-P
Brazil	I-P
with	I-P
42	I-P
asthmatic	I-P
children	I-P
aged	I-P
≤	I-P
36	I-P
months	I-P
.	O


The	B-P
children	I-P
were	O
randomly	O
divided	O
into	O
two	O
groups	O
(	O
intervention	O
and	B-I
control	I-I
)	I-I
by	O
means	O
of	O
a	O
simple	O
drawing	O
.	O


The	O
applied	O
intervention	O
included	O
actions	O
related	O
to	B-I
change	I-I
of	I-I
positioning	I-I
and	I-I
stimulation	I-I
of	I-I
cough	I-I
.	O


The	O
main	O
findings	O
of	O
this	O
study	O
show	O
that	O
before	O
the	O
intervention	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
the	B-O
health	I-O
status	I-O
of	O
the	O
children	O
.	O


After	O
the	O
intervention	O
,	O
the	O
indicators	O
of	B-O
choking	I-O
(	O
16.83	O
vs.	O
26.17	O
,	O
P	O
=	O
0.007	O
)	O
and	B-O
adventitious	I-O
breath	I-O
sounds	I-O
(	O
16.4	O
vs.	O
26.6	O
,	O
P	O
=	O
0.005	O
)	O
were	O
higher	O
,	O
on	O
average	O
,	O
in	O
the	O
intervention	O
group	O
.	O


It	O
was	O
observed	O
an	O
improvement	O
in	B-O
obstructive	I-O
symptoms	I-O
in	I-P
children	I-P
who	I-P
received	I-P
the	I-P
intervention	I-P
proposed	O
.	O


Decreased	O
expression	B-O
of	I-O
Yes-associated	I-O
protein	I-O
is	O
associated	O
with	O
outcome	O
in	O
the	O
luminal	B-P
A	I-P
breast	I-P
cancer	I-P
subgroup	I-P
and	O
with	O
an	O
impaired	O
tamoxifen	B-I
response	O
.	O


BACKGROUND	O
Yes-associated	B-O
protein	I-O
(	I-O
YAP1	I-O
)	I-O
is	O
frequently	O
reported	O
to	O
function	O
as	O
an	O
oncogene	O
in	O
many	O
types	O
of	O
cancer	O
,	O
but	O
in	O
breast	O
cancer	O
results	O
remain	O
controversial	O
.	O


We	O
set	O
out	O
to	O
clarify	O
the	O
role	O
of	O
YAP1	B-O
in	O
breast	O
cancer	O
by	O
examining	O
gene	O
and	O
protein	O
expression	O
in	O
subgroups	O
of	O
patient	O
material	O
and	O
by	O
downregulating	O
YAP1	O
in	O
vitro	O
and	O
studying	O
its	O
role	O
in	O
response	O
to	O
the	O
widely	O
used	O
anti-estrogen	O
tamoxifen	B-I
.	I-I


METHODS	O
YAP1	B-O
protein	I-O
intensity	I-O
was	O
scored	O
as	O
absent	O
,	O
weak	O
,	O
intermediate	O
or	O
strong	O
in	O
two	B-P
primary	I-P
breast	I-P
cancer	I-P
cohorts	I-P
(	I-P
n	I-P
=	I-P
144	I-P
and	I-P
n	I-P
=	I-P
564	I-P
)	I-P
and	I-P
mRNA	I-O
expression	I-O
of	I-O
YAP1	I-O
was	I-P
evaluated	I-P
in	I-P
a	I-P
gene	I-P
expression	I-P
dataset	I-P
(	I-P
n	I-P
=	I-P
1107	I-P
)	I-P
.	O


Recurrence-free	B-O
survival	I-O
was	O
analysed	O
using	O
the	O
log-rank	O
test	O
and	O
Cox	O
multivariate	O
analysis	O
was	O
used	O
to	O
test	O
for	O
independence	O
.	O


WST-1	B-I
assay	I-I
was	O
employed	O
to	O
measure	O
cell	B-O
viability	I-O
and	O
a	O
luciferase	B-O
ERE	I-O
(	O
estrogen	O
responsive	O
element	O
)	O
construct	O
was	O
used	O
to	O
study	O
the	O
effect	O
of	O
tamoxifen	B-I
,	O
following	O
downregulation	O
of	O
YAP1	O
using	O
siRNAs	O
.	O


RESULTS	O
In	O
the	O
ER+	B-P
(	I-P
Estrogen	I-P
Receptor	I-P
α	I-P
positive	I-P
)	I-P
subgroup	I-P
of	O
the	O
randomised	O
cohort	O
,	O
YAP1	B-O
expression	I-O
was	O
inversely	O
correlated	O
to	O
histological	O
grade	O
and	O
proliferation	O
(	O
p	O
=	O
0.001	O
and	O
p	O
=	O
0.016	O
,	O
respectively	O
)	O
whereas	O
in	O
the	B-P
ER-	I-P
(	I-P
Estrogen	I-P
Receptor	I-P
α	I-P
negative	I-P
)	I-P
subgroup	I-O
YAP1	I-O
expression	I-O
correlated	O
positively	O
to	O
proliferation	O
(	O
p	O
=	O
0.005	O
)	O
.	O


Notably	O
,	O
low	B-O
YAP1	I-O
mRNA	I-O
was	O
independently	O
associated	O
with	O
decreased	B-O
recurrence-free	I-O
survival	I-O
in	O
the	O
gene	O
expression	O
dataset	O
,	O
specifically	O
for	O
the	O
luminal	O
A	O
subgroup	O
(	O
p	O
<	O
0.001	O
)	O
which	O
includes	O
low	O
proliferating	O
tumours	O
of	O
lower	O
grade	O
,	O
usually	O
associated	O
with	O
a	O
good	O
prognosis	O
.	O


This	O
subgroup	O
specificity	O
led	O
us	O
to	O
hypothesize	O
that	B-O
YAP1	I-O
may	O
be	O
important	O
for	O
response	O
to	O
endocrine	O
therapies	O
,	O
such	O
as	B-I
tamoxifen	I-I
,	O
extensively	O
used	O
for	O
luminal	O
A	O
breast	O
cancers	O
.	O


In	O
a	B-I
tamoxifen	I-I
randomised	O
patient	O
material	O
,	O
absent	B-O
YAP1	I-O
protein	I-O
expression	I-O
was	O
associated	O
with	O
impaired	B-O
tamoxifen	I-O
response	I-O
which	O
was	O
significant	O
upon	O
interaction	O
analysis	O
(	O
p	O
=	O
0.042	O
)	O
.	O


YAP1	O
downregulation	O
resulted	O
in	O
increased	B-O
progesterone	I-O
receptor	I-O
(	I-O
PgR	I-O
)	I-O
expression	I-O
and	O
a	O
delayed	O
and	O
weaker	B-I
tamoxifen	I-I
in	O
support	O
of	O
the	O
clinical	O
data	O
.	O


CONCLUSIONS	O
Decreased	B-O
YAP1	I-O
expression	I-O
is	O
an	O
independent	O
prognostic	O
factor	O
for	O
recurrence	O
in	O
the	O
less	O
aggressive	B-P
luminal	I-P
A	I-P
breast	I-P
cancer	I-P
subgroup	I-P
,	O
likely	O
due	O
to	O
the	O
decreased	B-I
tamoxifen	I-I
sensitivity	O
conferred	O
by	O
YAP1	O
downregulation	O
.	O


Treatment	O
of	O
stable	B-P
angina	I-P
of	I-P
effort	I-P
with	O
verapamil	B-I
:	I-I
a	O
double-blind	O
,	O
placebo-controlled	B-I
randomized	O
crossover	O
study	O
.	O


The	O
effects	O
of	O
verapamil	B-I
were	O
assessed	O
in	O
26	B-P
patients	I-P
with	I-P
stable	I-P
exertional	I-P
angina	I-P
pectoris	I-P
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
crossover	O
protocol	O
using	O
serial	O
treadmill	O
tests	O
.	O


Verapamil	B-I
,	O
480	O
mg/day	O
,	O
reduced	O
anginal	B-O
frequency	I-O
from	O
5.6	O
+/-	O
7.3	O
to	O
2.2	O
+/-	O
3.9	O
attacks	O
per	O
week	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
nitroglycerin	B-O
consumption	I-O
from	O
3.4	O
+/-	O
4.9	O
to	O
1.2	O
+/-	O
2.5	O
tablets	O
per	O
week	O
(	O
p	O
less	O
than	O
0.05	O
)	O
compared	O
with	O
placebo	B-I
.	I-I


Treadmill	B-O
time	I-O
increased	O
from	O
6.4	O
+/-	O
2.1	O
minutes	O
during	O
the	O
placebo	B-I
phase	O
to	O
7.5	O
+/-	O
1.8	O
minutes	O
during	O
the	O
verapamil	B-I
phase	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


Verapamil	B-I
's	I-I
beneficial	O
effect	O
appeared	O
to	O
be	O
related	O
,	O
in	O
part	O
,	O
to	O
a	O
10	O
%	O
reduction	O
of	O
the	O
rate-pressure	B-O
product	I-O
at	O
rest	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
a	O
12	O
%	O
reduction	O
during	O
submaximal	O
exercise	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


Verapamil	B-I
also	O
caused	O
less	O
marked	O
ST-segment	B-O
depressions	I-O
at	I-O
peak	I-O
exercise	I-O
(	O
p	O
less	O
than	O
0.05	O
)	O
at	O
a	O
similar	O
rate-pressure	O
product	O
,	O
suggesting	O
a	O
favorable	O
redistribution	O
of	O
coronary	B-O
blood	I-O
flow	I-O
to	O
the	O
ischemic	O
zone	O
.	O


Side	O
effects	O
from	O
verapamil	B-I
were	O
minimal	O
,	O
consisting	O
mainly	O
of	O
constipation	B-O
(	O
six	O
patients	O
)	O
.	O


Verapamil	B-I
appears	O
to	O
be	O
a	O
safe	B-O
and	I-O
effective	I-O
drug	O
for	O
treating	O
angina	B-P
of	O
effort	O
.	O


A	O
randomized	O
effectiveness	B-O
trial	O
of	O
collaborative	B-I
care	I-I
for	O
patients	B-P
with	I-P
panic	I-P
disorder	I-P
in	I-P
primary	I-P
care	I-P
.	I-P


BACKGROUND	O
Effectiveness	B-O
studies	O
have	O
tested	O
interventions	O
to	O
improve	O
quality	B-O
of	I-O
care	I-O
for	O
depression	O
in	O
primary	O
care	O
,	O
but	O
none	O
,	O
to	O
our	O
knowledge	O
,	O
have	O
been	O
completed	O
for	O
panic	O
disorder	O
(	O
PD	O
)	O
in	O
this	O
setting	O
.	O


This	O
study	O
sought	O
to	O
test	O
the	O
clinical	B-O
effectiveness	I-O
of	O
PD	B-I
pharmacotherapy	I-I
embedded	I-I
in	I-I
a	I-I
disease	I-I
management	I-I
framework	I-I
of	I-I
"	I-I
collaborative	I-I
care	I-I
"	I-I
(	I-I
CC	I-I
)	I-I
.	I-I


METHODS	O
One	B-P
hundred	I-P
fifteen	I-P
patients	I-P
with	I-P
PD	I-P
from	I-P
3	I-P
primary	I-P
care	I-P
clinics	I-P
were	O
randomized	O
to	O
CC	B-I
or	O
"	B-I
usual	I-I
care	I-I
"	I-I
(	I-I
UC	I-I
)	I-I
.	I-I


Patients	O
in	O
CC	O
(	O
n	O
=	O
57	O
)	O
received	O
educational	B-I
videotapes	I-I
and	I-I
pamphlets	I-I
;	I-I
pharmacotherapy	I-I
with	I-I
the	I-I
selective	I-I
serotonin	I-I
reuptake	I-I
inhibitor	I-I
paroxetine	I-I
;	I-I
2	I-I
psychiatrist	I-I
visits	I-I
and	I-I
2	I-I
telephone	I-I
calls	I-I
in	O
the	O
first	O
8	O
weeks	O
;	O
and	O
up	O
to	O
5	O
telephone	B-I
calls	I-I
between	O
3	O
and	O
12	O
months	O
'	O
follow-up	O
.	O


Usual	O
care	O
patients	O
(	O
n	O
=	O
58	O
)	O
were	O
treated	O
by	O
their	O
primary	O
care	O
physician	O
.	O


Telephone	O
assessments	O
of	O
panic	B-O
,	I-O
anxiety	I-O
sensitivity	I-O
,	I-O
depression	I-O
,	I-O
and	I-O
disability	I-O
variables	I-O
were	O
performed	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
'	O
follow-up	O
.	O


Adequacy	B-O
of	I-O
pharmacotherapy	I-O
was	O
assessed	O
with	O
an	O
algorithm	B-O
based	O
on	O
a	O
review	O
of	O
efficacy	O
studies	O
.	O


RESULTS	O
Patients	O
in	O
CC	O
were	O
more	O
likely	O
to	O
receive	O
adequate	B-O
(	I-O
type	I-O
,	I-O
dose	I-O
,	I-O
duration	I-O
)	I-O
medication	I-O
and	O
more	O
likely	O
to	O
adhere	B-O
to	I-O
this	I-O
medication	I-O
at	O
3	O
and	O
6	O
months	O
.	O


Random	O
regression	O
analyses	O
showed	O
that	O
CC	O
patients	O
improved	B-O
significantly	O
more	O
over	O
time	O
compared	O
with	O
UC	O
patients	O
on	O
anxiety	B-O
,	I-O
depression	I-O
,	I-O
and	I-O
disability	I-O
measures	I-O
,	O
with	O
the	O
greatest	O
effects	B-O
at	O
3	O
and	O
6	O
months	O
.	O


CONCLUSIONS	O
Compared	O
with	O
UC	O
,	O
CC	O
interventions	O
significantly	O
improved	O
both	O
quality	B-O
of	I-O
care	I-O
and	I-O
clinical	I-O
and	I-O
functional	I-O
outcomes	I-O
in	O
primary	B-P
care	I-P
PD	I-P
patients	I-P
.	I-P


Clinical	O
differences	O
were	O
greatest	O
in	O
the	O
first	O
6	O
months	O
,	O
corresponding	O
to	O
the	O
greater	O
quality	B-O
of	I-O
care	I-O
and	O
the	O
greater	O
intensity	B-O
of	O
intervention	O
.	O


Twenty-four	O
vs.	O
forty-eight	O
weeks	O
of	O
re-therapy	O
with	O
interferon	B-I
alpha	I-I
2b	I-I
and	I-I
ribavirin	I-I
in	O
interferon	B-P
alpha	I-P
monotherapy	I-P
relapsers	I-P
with	I-P
chronic	I-P
hepatitis	I-P
C.	I-P
BACKGROUND/AIM	O
Roughly	O
50	O
%	O
of	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
who	O
relapsed	O
after	O
a	O
previous	O
monotherapy	O
with	O
interferon	O
alpha	O
,	O
will	O
respond	O
in	O
a	O
sustained	O
fashion	O
to	O
24	O
weeks	O
of	O
re-therapy	O
with	O
the	O
combination	B-I
of	I-I
interferon	I-I
alpha	I-I
plus	I-I
ribavirin	I-I
.	I-I


Whether	O
prolonging	O
treatment	O
duration	O
to	O
48	O
weeks	O
will	O
further	O
increase	O
sustained	O
response	O
rates	O
remains	O
ill	O
defined	O
.	O


In	O
this	O
randomised	O
controlled	O
pilot	O
trial	O
we	O
compared	O
the	O
efficacy	B-O
and	I-O
tolerability	I-O
of	O
a	O
24	O
week	O
with	O
that	O
of	O
a	O
48	O
week	O
course	O
of	O
combination	O
therapy	O
with	O
interferon	O
alpha	O
and	O
ribavirin	O
in	O
interferon	B-P
monotherapy	I-P
relapsers	I-P
with	I-P
chronic	I-P
hepatitis	I-P
C.	I-P
METHODS	O
Interferon	B-P
alpha	I-P
monotherapy	I-P
relapsers	I-P
with	I-P
chronic	I-P
hepatitis	I-P
C	I-P
were	O
randomised	O
to	O
receive	O
interferon	B-I
alpha	I-I
2b	I-I
(	O
3	O
x	O
3	O
MIU	O
sc	O
weekly	O
)	O
and	O
oral	B-I
ribavirin	I-I
(	O
1000/1200	O
mg	O
po	O
daily	O
)	O
for	O
either	O
24	O
weeks	O
or	O
48	O
weeks	O
.	O


Virological	O
response	O
was	O
evaluated	O
by	O
HCV	O
RNA	O
PCR	O
at	O
week	O
10	O
(	O
initial	O
response	O
)	O
,	O
at	O
the	O
end	O
of	O
treatment	O
(	O
end	O
of-	O
treatment	O
response	O
)	O
and	O
at	O
the	O
end	O
of	O
24	O
weeks	O
follow-up	O
(	O
sustained	O
response	O
)	O
.	O


Only	B-P
patients	I-P
with	I-P
negative	I-P
HCV	I-P
RNA	I-P
at	I-P
week	I-P
10	I-P
continued	I-P
treatment	I-P
.	I-P


Adverse	B-O
events	I-O
were	O
recorded	O
at	O
regular	O
intervals	O
.	O


RESULTS	O
Thirty-seven	B-P
patients	I-P
were	I-P
enrolled	I-P
,	I-P
19	I-P
(	I-P
6	I-P
females	I-P
,	I-P
median	I-P
age	I-P
43	I-P
)	I-P
in	I-P
the	I-P
24	I-P
week	I-P
and	I-P
18	I-P
(	I-P
5	I-P
females	I-P
,	I-P
median	I-P
age	I-P
40	I-P
)	I-P
in	I-P
the	I-P
48	I-P
week	I-P
treatment	I-P
arm	I-P
.	I-P


Baseline	B-P
characteristics	I-P
were	I-P
similar	I-P
in	I-P
both	I-P
groups	I-P
.	I-P


At	O
treatment	O
week	O
10	O
,	O
12/19	O
(	O
63	O
%	O
)	O
in	O
the	O
24	O
week	O
group	O
and	O
14/18	O
(	O
78	O
%	O
)	O
patients	O
in	O
the	O
48	O
week	O
group	O
had	O
lost	B-O
HCV	I-O
RNA	I-O
in	I-O
serum	I-O
(	O
p	O
=	O
0.33	O
)	O
.	O


All	O
initial	O
responders	O
remained	O
HCV	B-O
RNA	I-O
negative	I-O
throughout	O
the	O
treatment	O
period	O
.	O


Sustained	B-O
response	I-O
rates	I-O
were	O
10/19	O
(	O
53	O
%	O
)	O
in	O
the	O
24	O
week	O
group	O
and	O
13/18	O
(	O
72	O
%	O
)	O
in	O
the	O
48	O
week	O
group	O
(	O
p	O
=	O
0.31	O
)	O
.	O


Three	B-P
patients	I-P
discontinued	I-P
treatment	I-P
early	I-P
(	I-P
two	I-P
due	I-P
to	I-P
moderate	I-O
adverse	I-O
events	I-O
,	I-P
one	I-P
due	I-P
to	I-P
non-compliance	I-P
)	I-P
.	I-P


Dose	O
modifications	O
were	O
necessary	O
in	O
9	O
patients	O
,	O
4	O
in	O
the	O
24	O
week	O
and	O
5	O
in	O
the	O
48	O
week	O
group	O
for	O
anaemia	B-O
,	I-O
neutropenia	I-O
,	I-O
nausea	I-O
and	I-O
depression	I-O
,	O
respectively	O
.	O


CONCLUSION	O
Prolonging	O
interferon	O
/	O
ribavirin	O
combination	O
therapy	O
in	O
interferon	O
alpha	O
monotherapy	O
relapsers	O
with	O
chronic	O
hepatitis	O
C	O
from	O
24	O
to	O
48	O
weeks	O
may	O
increase	O
sustained	B-O
response	I-O
rates	I-O
.	I-O


Larger	O
controlled	O
trials	O
using	O
pegylated	O
interferon	O
alpha	O
and	O
ribavirin	O
in	O
relapsers	B-P
with	I-P
chronic	I-P
hepatitis	I-P
C	I-P
seem	O
warranted	O
.	O


Final	O
report	O
of	O
a	O
randomized	O
controlled	O
study	O
with	O
streptococcal	O
preparation	O
OK-432	B-I
as	O
a	O
supplementary	O
immunopotentiator	O
for	O
laryngeal	B-P
cancer	I-P
.	I-P


We	O
conducted	O
a	O
randomized	O
controlled	O
study	O
of	O
streptococcal	O
preparation	O
OK-432	B-I
on	O
120	B-P
newly	I-P
identified	I-P
cases	I-P
of	I-P
laryngeal	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
who	I-P
were	I-P
registered	I-P
at	I-P
10	I-P
participating	I-P
institutions	I-P
between	I-P
November	I-P
1984	I-P
and	I-P
October	I-P
1989	I-P
.	I-P


The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
those	O
in	O
early	O
stages	O
(	O
stage	O
I	O
or	O
II	O
)	O
and	O
those	O
in	O
advanced	O
stages	O
(	O
stage	O
III	O
or	O
IV	O
)	O
;	O
these	O
groups	O
were	O
further	O
subdivided	O
into	O
an	O
immunotherapy	O
group	O
(	B-I
receiving	I-I
OK-432	I-I
)	I-I
and	O
a	O
control	B-I
group	O
(	O
who	O
did	O
not	O
receive	O
OK-432	B-I
)	I-I
.	O


The	O
usefulness	O
of	O
OK-432	O
was	O
studied	O
using	O
the	O
sealed	O
envelope	O
method	O
.	O


The	O
basic	O
therapy	O
for	O
all	O
cases	O
was	O
radiotherapy	O
and	O
,	O
when	O
required	O
,	O
surgery	O
.	O


As	O
adjuvant	O
therapy	O
,	O
5Fu	O
or	O
derivatives	O
were	O
administered	O
to	O
all	O
cases	O
from	O
the	O
beginning	O
of	O
the	O
treatment	O
period	O
to	O
one	O
year	O
after	O
the	O
basic	O
therapy	O
,	O
with	O
the	O
exception	O
of	O
cases	O
in	O
whom	O
side	O
effects	O
were	O
serious	O
enough	O
to	O
contraindicate	O
use	O
of	O
the	O
drug	O
.	O


The	O
target	O
administration	O
period	O
was	O
5	O
years	O
.	O


Of	B-P
the	I-P
initial	I-P
120	I-P
cases	I-P
,	I-P
11	I-P
cases	I-P
were	I-P
disqualified	I-P
(	I-P
3	I-P
cases	I-P
of	I-P
double	I-P
cancer	I-P
and	I-P
8	I-P
of	I-P
incomplete	I-P
primary	I-P
therapy	I-P
)	I-P
and	I-P
the	I-P
remaining	I-P
109	I-P
were	I-P
used	I-P
for	I-P
evaluation	I-P
.	I-P


The	O
5-year	B-O
survival	I-O
rate	I-O
and	I-O
the	I-O
5-year	I-O
recurrence-free	I-O
rate	I-O
were	O
76	O
%	O
and	O
84	O
%	O
,	O
respectively	O
,	O
in	O
the	O
immunized	O
groups	O
(	O
both	O
the	O
early	O
and	O
advanced	O
groups	O
)	O
,	O
whereas	O
the	O
same	O
rates	O
for	O
the	O
control	O
groups	O
were	O
78	O
%	O
and	O
75	O
%	O
.	O


There	O
was	O
a	O
tendency	O
for	O
the	O
immunized	O
groups	O
to	O
enjoy	O
a	O
slightly	B-O
longer	I-O
recurrence-free	I-O
period	I-O
.	I-O


Over	O
a	O
24-month	O
observation	O
period	O
the	O
immunized	O
group	O
always	O
had	O
higher	O
levels	B-O
of	I-O
peripheral	I-O
leukocytes	I-O
and	I-O
peripheral	I-O
lymphocytes	I-O
;	I-O
this	O
difference	O
was	O
significant	O
for	O
the	O
first	O
21	O
months	O
.	O


Inhibition	B-O
of	I-O
bone	I-O
marrow	I-O
function	I-O
is	O
sometimes	O
observed	O
with	O
radiotherapy	O
.	O


It	O
is	O
hoped	O
that	O
,	O
if	O
this	O
inhibition	O
can	O
be	O
mitigated	O
,	O
it	O
will	O
be	O
possible	O
to	O
assist	O
the	O
compromised	O
immune	O
system	O
and	O
maintain	O
a	O
certain	B-O
level	I-O
of	I-O
immune	I-O
performance	I-O
which	O
will	O
prevent	O
recurrence	O
and	O
improve	B-O
survival	I-O
rate	I-O
.	I-O


In	O
the	O
present	O
study	O
we	O
observed	O
a	O
tendency	O
of	O
the	O
lower	O
recurrence	O
rate	O
in	O
the	O
immunized	O
group	O
,	O
and	O
we	O
hypothesize	O
that	O
OK-432	B-I
is	O
effective	O
in	O
extending	O
the	O
recurrence-free	O
period	O
.	O


A	O
controlled	O
trial	O
of	O
'Senokot	B-I
'	I-I
in	O
faecal	O
soiling	O
treated	O
by	O
behavioural	O
methods	O
.	O


A	O
double-blind	O
randomly	O
controlled	O
trial	O
of	O
one	O
particular	O
laxative	O
,	O
Senokot	B-I
,	O
used	O
in	O
moderate	O
dosage	O
,	O
was	O
carried	O
out	O
on	O
a	O
group	O
of	O
40	B-P
children	I-P
with	I-P
severe	I-P
and	I-P
persistent	I-P
soiling	I-P
and	I-P
often	I-P
with	I-P
a	I-P
history	I-P
of	I-P
faecal	I-P
retention	I-P
.	I-P


Significant	B-O
improvement	I-O
occurred	O
following	O
three	O
months	O
of	O
outpatient	O
treatment	O
using	O
a	O
behavioural	B-I
approach	I-I
and	I-I
either	I-I
Senokot	I-I
,	I-I
placebo	I-I
or	I-I
no	I-I
medication	I-I
.	I-I


However	O
,	O
there	O
was	O
no	O
evidence	O
either	O
during	O
the	O
trial	O
or	O
subsequently	O
when	O
Senokot	O
was	O
employed	O
to	O
supplement	O
behavioural	O
treatment	O
in	O
every	O
child	O
who	O
continued	O
with	O
therapy	O
that	O
this	O
laxative	O
contributed	O
in	O
any	O
way	O
to	O
relieving	B-O
the	I-O
problem	I-O
in	O
this	O
group	O
of	O
cases	O
.	O


Safety	O
and	O
efficacy	O
of	O
sitaxsentan	B-I
50	O
and	O
100	O
mg	O
in	B-P
patients	I-P
with	I-P
pulmonary	I-P
arterial	I-P
hypertension	I-P
.	O


OBJECTIVE	O
To	O
assess	O
safety	O
and	O
efficacy	O
of	B-I
sitaxsentan	I-I
50	O
and	O
100	O
mg	O
in	B-P
patients	I-P
with	I-P
pulmonary	I-P
arterial	I-P
hypertension	I-P
(	I-P
PAH	I-P
)	I-P
.	O


BACKGROUND	B-I
Sitaxsentan	I-I
is	O
a	O
highly	O
selective	O
endothelin-A	O
receptor	O
antagonist	O
that	O
was	O
recently	O
withdrawn	O
by	O
the	O
manufacturer	O
because	O
of	O
a	O
pattern	O
of	O
idiosyncratic	O
liver	O
injury	O
.	O


METHODS	O
Before	B-I
sitaxsentan	I-I
withdrawal	O
,	O
this	O
18-week	O
double-blind	O
,	O
placebo-controlled	O
study	O
randomized	B-P
patients	I-P
with	I-P
PAH	I-P
to	I-P
receive	I-I
placebo	I-I
or	I-I
sitaxsentan	I-I
50	I-P
or	I-P
100	I-P
mg	I-P
once	I-P
daily	I-P
.	O


The	O
primary	O
efficacy	O
endpoint	O
was	O
change	O
from	O
baseline	O
in	O
6-min	O
walk	O
distance	O
(	O
6MWD	O
)	O
at	O
week	O
18	O
.	O


Changes	O
in	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
functional	O
class	O
and	O
time	O
to	O
clinical	O
worsening	O
(	O
TTCW	O
)	O
were	O
secondary	O
endpoints	O
.	O


The	O
primary	O
efficacy	O
analysis	O
was	O
powered	O
for	B-I
sitaxsentan	I-I
100	O
mg	O
versus	B-I
placebo	I-I
.	O


RESULTS	B-P
Of	I-P
98	I-P
randomized	I-P
patients	I-P
,	I-P
61	I-P
%	I-P
were	I-P
WHO	I-P
functional	I-P
class	I-P
II	I-P
at	I-P
baseline	I-P
.	O


Improvement	O
from	B-O
baseline	I-O
to	I-O
week	I-O
18	I-O
in	I-O
6MWD	I-O
occurred	O
with	B-I
sitaxsentan	I-I
100	O
but	O
not	O
50	O
mg	O
;	O
a	O
strong	B-I
placebo	I-I
effect	O
was	O
observed	O
.	O


At	O
week	B-O
18	I-O
,	I-O
WHO	I-O
functional	I-O
class	I-O
was	O
improved	O
or	O
maintained	O
in	O
more	O
patients	O
receiving	B-I
sitaxsentan	I-I
100	I-I
mg	I-I
than	I-I
placebo	I-I
(	O
P	O
=	O
0.038	O
)	O
;	O
0	O
%	O
versus	O
12	O
%	O
of	O
patients	O
deteriorated	O
,	O
respectively	B-O
.	O


TTCW	O
was	O
not	O
significantly	O
different	O
for	B-I
100-mg	I-I
sitaxsentan	I-I
patients	I-I
than	I-I
placebo	O
(	B-O
P	I-O
=	I-O
0.090	I-O
)	I-O
.	I-O


Adverse	B-O
events	I-O
(	O
AEs	O
)	O
occurring	O
more	O
frequently	B-I
with	I-I
sitaxsentan	I-I
(	O
50	O
or	O
100	B-O
mg	I-O
)	I-O
included	I-O
headache	I-O
,	I-O
peripheral	I-O
edema	I-O
,	I-O
dizziness	I-O
,	I-O
nausea	I-O
,	I-O
extremity	I-O
pain	I-O
,	I-O
and	I-O
fatigue	O
;	O
most	O
AEs	O
were	O
of	O
mild	O
or	O
moderate	O
severity	O
.	O


CONCLUSION	B-I
Sitaxsentan	I-I
100	I-O
mg	I-O
improved	I-O
functional	I-O
class	I-O
but	I-O
not	I-P
6MWD	I-P
in	I-P
PAH	I-P
patients	I-P
who	I-P
were	I-P
mostly	I-P
WHO	I-P
functional	I-P
class	I-P
II	I-P
at	I-P
baseline	O
.	O


No	O
patient	B-I
receiving	I-I
sitaxsentan	O
100	O
mg	O
experienced	O
clinical	B-I
worsening	I-I
;	I-I
sitaxsentan	O
was	O
well	O
tolerated	O
.	O


Dental	O
bacteremia	O
in	B-P
children	I-P
.	I-P


Bacteremia	O
resulting	O
from	O
dental	B-I
extraction	I-I
is	I-I
regarded	O
as	O
an	O
important	O
cause	O
of	O
bacterial	O
endocarditis	O
,	O
and	O
it	O
is	O
therefore	O
recommended	O
that	O
patients	B-P
undergoing	I-P
tooth	I-P
extraction	I-P
be	O
given	O
prophylactic	B-I
antibiotics	I-I
.	I-I


As	O
dental	O
procedures	O
other	O
than	O
extractions	O
may	O
also	O
cause	O
bacteremias	O
,	O
we	O
studied	O
a	O
variety	O
of	O
dental	O
procedures	O
routinely	O
used	O
in	O
pediatric	O
dentistry	O
.	O


Blood	B-O
samples	I-O
for	O
cultures	O
were	O
obtained	O
30	O
s	O
after	O
each	O
of	O
13	O
dental	O
operative	O
procedures	O
in	O
735	B-P
anesthetized	I-P
children	I-P
aged	I-P
2-16	I-P
years	I-P
.	I-P


Four	O
procedures	O
used	O
for	O
conservative	O
dentistry	O
caused	O
bacteremias	B-O
significantly	O
more	O
often	O
than	O
the	O
baseline	O
value	O
of	O
9.4	O
%	O
:	O
polishing	B-I
teeth	I-I
24.5	O
%	O
,	O
intraligamental	B-I
injection	I-I
96.6	O
%	O
,	O
rubber	B-I
dam	I-I
placement	I-I
29.4	O
%	O
,	O
and	O
matrix	B-I
band	I-I
with	I-I
wedge	I-I
placement	I-I
32.1	O
%	O
.	O


In	O
comparison	O
,	O
toothbrushing	O
alone	O
caused	O
a	O
bacteremia	B-O
on	O
38.5	O
%	O
of	O
occasions	O
.	O


The	O
organisms	O
isolated	O
were	O
typical	O
of	O
odontogenic	B-O
bacteremias	I-O
in	O
that	O
50	O
%	O
of	O
the	O
isolates	O
were	O
identified	O
as	O
varieties	O
of	O
viridans	O
streptococci	O
.	O


These	O
data	O
show	O
that	O
a	O
wider	O
variety	O
of	O
dental	O
procedures	O
than	O
was	O
previously	O
documented	O
cause	O
bacteremia	B-O
.	I-O


A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
phase	O
I	O
study	O
of	O
MEDI-545	B-I
,	O
an	O
anti-interferon-alfa	O
monoclonal	O
antibody	O
,	O
in	O
subjects	B-P
with	I-P
chronic	I-P
psoriasis	I-P
.	I-P


BACKGROUND	O
Interferon-alfa	O
(	O
IFN-alpha	O
)	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
psoriasis	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
safety	O
profile	O
of	O
MEDI-545	B-I
,	O
a	O
fully	O
human	O
anti-IFN-alpha	O
monoclonal	O
antibody	O
and	O
to	O
explore	O
its	O
effect	O
on	O
the	O
involvement	O
of	O
type	O
I	O
IFN-alpha	O
activity	O
in	O
the	O
maintenance	O
of	O
established	O
plaque	O
psoriasis	O
.	O


METHODS	O
We	O
conducted	O
an	O
18-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
dose-escalating	O
study	O
in	O
36	B-P
subjects	I-P
with	I-P
chronic	I-P
plaque	I-P
psoriasis	I-P
.	I-P


Subjects	O
received	O
one	O
intravenous	O
dose	O
of	O
MEDI-545	B-I
(	I-I
0.3-30.0	I-I
mg/kg	I-I
)	I-I
or	I-I
placebo	I-I
.	I-I


Study	O
outcomes	O
were	O
safety	B-O
profile	I-O
,	I-O
pharmacokinetics	I-O
,	I-O
immunogenicity	I-O
,	I-O
and	I-O
clinical	I-O
effects	I-O
.	I-O


RESULTS	O
There	O
was	O
no	O
difference	O
in	O
adverse	B-O
events	I-O
between	O
MEDI-545	B-I
and	I-I
placebo	I-I
.	I-I


Two	O
serious	O
adverse	O
events	O
were	O
reported	O
;	O
one	O
drug-related	B-O
hypotensive	I-O
infusion	I-O
reaction	I-O
occurred	O
in	O
one	O
subject	O
in	O
the	O
30.0	O
mg/kg	O
MEDI-545	B-I
dose	O
group	O
,	O
causing	O
discontinuation	O
of	O
study	O
drug	O
in	O
that	O
subject	O
and	O
study	O
dismissal	O
of	O
the	O
other	O
subjects	O
in	O
the	O
same	O
cohort	O
;	O
and	O
a	O
myocardial	B-O
infarction	I-O
occurred	O
in	O
one	O
subject	O
in	O
the	O
10	O
mg/kg	O
MEDI-545	B-I
dose	O
group	O
,	O
which	O
was	O
considered	O
to	O
be	O
unrelated	O
to	O
treatment	O
.	O


MEDI-545	B-I
was	O
nonimmunogenic	O
,	O
had	O
a	O
half-life	B-O
of	O
21	O
days	O
,	O
showed	O
no	O
significant	O
inhibition	O
of	O
the	O
type	O
I	O
IFN	O
gene	O
signature	O
,	O
and	O
had	O
no	O
clinical	B-O
activity	I-O
.	I-O


LIMITATIONS	O
The	O
study	O
addressed	O
only	O
IFN-alpha	O
and	O
chronic	O
psoriatic	O
lesions	O
.	O


CONCLUSION	O
The	O
safety	O
profile	O
of	O
MEDI-545	B-I
supports	O
further	O
clinical	O
development	O
.	O


IFN-alpha	O
does	O
not	O
appear	O
to	O
be	O
significantly	O
involved	O
in	O
the	O
maintenance	O
of	O
established	O
plaque	O
psoriasis	O
.	O


Endurance	B-I
physical	I-I
activity	I-I
,	I-I
diet	I-I
and	O
fibrinolysis	O
.	O


The	O
impact	O
of	O
long-term	B-I
,	I-I
heavy	I-I
exercise	I-I
on	O
recently	O
established	O
cardiovascular/thromboembolic	O
risk	O
factors	O
of	O
the	O
fibrinolytic	O
system	O
,	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI-1	O
)	O
in	O
relation	O
to	O
food	O
composition	O
was	O
studied	O
.	O


Twenty	B-P
healthy	I-P
men	I-P
,	I-P
aged	I-P
18-55	I-P
years	I-P
participated	O
in	O
a	O
14-day	B-I
skiing	I-I
tour	I-I
through	I-I
the	I-I
Swedish	I-I
mountains	I-I
,	I-I
carrying	I-I
a	I-I
pack	I-I
load	I-I
of	I-I
30	I-I
kg	I-I
,	I-I
and	I-I
spending	I-I
each	I-I
night	I-I
in	I-I
self-dug	I-I
igloos	I-I
(	I-I
ambient	I-I
temp	I-I
-10	I-I
degrees	I-I
to	I-I
-25	I-I
degrees	I-I
C	I-I
)	I-I
,	I-I
and	I-I
were	I-I
randomized	I-I
to	I-I
2	I-I
food	I-I
regimens	I-I
having	I-I
30	I-I
or	I-I
40	I-I
energy	I-I
percent	I-I
of	I-I
fat	I-I
.	I-I


Individual	B-I
records	I-I
were	I-I
kept	I-I
of	I-I
all	I-I
consumed	I-I
food	I-I
.	I-I


Citrated	B-O
plasma	I-O
was	I-I
obtained	I-I
before	I-I
and	I-I
after	I-I
1	I-I
and	I-I
2	I-I
weeks	I-I
of	I-I
exercise	I-I
:	I-I
tPA	I-O
release	I-O
was	I-I
assessed	I-I
by	I-I
a	I-I
10	I-I
min	I-I
venous	I-I
occlusion	I-I
(	I-I
VO	I-I
)	I-I
test	I-I
.	I-I


At	O
baseline	O
,	O
daily	B-O
dietary	I-O
fiber	I-O
intake	I-O
correlated	O
negatively	O
with	O
PAI-1	O
activity	O
.	O


Already	O
after	O
the	O
first	O
week	O
of	O
the	O
skiing	O
tour	O
there	O
were	O
significant	O
drops	O
in	O
PAI-1	B-O
activities	I-O
,	I-O
cholesterol	I-O
and	I-O
triglycerides	I-O
.	I-O


The	O
tPA	B-O
mass	I-O
concentrations	I-O
also	O
dropped	O
,	O
both	O
before	O
and	O
after	O
VO	O
,	O
but	O
tPA	B-O
activities	I-O
were	O
unchanged	O
,	O
as	O
were	O
von	B-O
Willebrand	I-O
factor	I-O
(	I-O
vWF	I-O
)	I-O
levels	I-O
.	I-O


These	O
changes	O
were	O
related	O
mainly	O
to	O
the	O
expenditure	O
of	O
energy	O
,	O
calculated	O
from	O
the	O
food	O
consumption	O
,	O
and	O
appeared	O
to	O
be	O
mediated	O
through	O
changed	O
insulin	O
sensitivity	O
and	O
decreased	O
body	O
fat	O
mass	O
.	O


The	O
energy	O
percent	O
of	O
fat	O
in	O
the	O
food	O
had	O
no	O
differential	O
impact	O
.	O


The	O
effects	O
receded	O
a	O
few	O
weeks	O
after	O
cessation	O
of	O
the	O
endurance	O
exercise	O
.	O


Thus	O
,	O
endurance	B-I
physical	I-I
activity	I-I
improves	O
the	O
fibrinolytic	O
risk	O
factor	O
profile	O
by	O
reducing	O
PAI-1	O
while	O
leaving	O
tPA	B-O
activity	O
unaffected	O
,	O
independently	O
of	O
food	O
composition	O
.	O


A	O
low	O
dietary	O
fiber	O
intake	O
appears	O
to	O
be	O
associated	O
with	O
higher	O
PAI-1	B-O
activities	I-O
at	O
baseline	O
.	O


Tofacitinib	B-I
with	I-I
methotrexate	I-I
in	O
third-line	O
treatment	O
of	O
patients	B-P
with	I-P
active	I-P
rheumatoid	I-P
arthritis	I-P
:	I-P
patient-reported	O
outcomes	O
from	O
a	O
phase	O
III	O
trial	O
.	O


OBJECTIVE	O
To	O
assess	O
patient-reported	O
outcomes	O
(	O
PROs	O
)	O
for	O
tofacitinib	O
,	O
an	O
oral	O
JAK	O
inhibitor	O
for	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
in	O
a	O
6-month	O
,	O
phase	O
III	O
,	O
randomized	O
controlled	O
trial	O
.	O


METHODS	O
Patients	B-P
ages	I-P
≥18	I-P
years	I-P
with	I-P
active	I-P
RA	I-P
with	I-P
an	I-P
inadequate	I-P
response	I-P
to	I-P
≥1	I-P
tumor	I-P
necrosis	I-P
factor	I-P
inhibitor	I-P
(	I-P
TNFi	I-P
)	I-P
and	I-P
receiving	I-P
stable	I-P
background	I-P
methotrexate	I-P
were	I-P
randomized	I-P
2:2:1:1	I-I
to	I-I
tofacitinib	I-I
5	I-I
mg	I-I
or	I-I
10	I-I
mg	I-I
twice	I-I
daily	I-I
,	I-I
or	I-I
placebo	I-I
advanced	I-I
to	I-I
tofacitinib	I-I
5	I-I
mg	I-I
or	I-I
10	I-I
mg	I-I
twice	I-I
daily	I-I
at	I-I
month	I-I
3	O
.	O


PROs	O
measured	O
at	O
month	O
3	O
included	B-O
patient	I-O
global	I-O
assessment	I-O
of	I-O
disease	I-O
activity	I-O
(	I-O
PtGA	I-O
)	I-O
,	I-O
pain	I-O
,	I-O
Health	I-O
Assessment	I-O
Questionnaire	I-O
(	I-O
HAQ	I-O
)	I-O
disability	I-O
index	I-O
(	I-O
DI	I-O
)	I-O
,	I-O
Medical	I-O
Outcomes	I-O
Study	I-O
(	I-O
MOS	I-O
)	I-O
Short	I-O
Form	I-O
36	I-O
Health	I-O
Survey	I-O
version	I-O
2	I-O
(	I-O
SF-36v2	I-O
;	I-O
acute	I-O
)	I-O
,	I-O
Functional	I-O
Assessment	I-O
of	I-O
Chronic	I-O
Illness	I-O
Therapy-Fatigue	I-O
(	I-O
FACIT-F	I-O
)	I-O
,	I-O
and	I-O
MOS	I-O
Sleep	I-O
Scale	I-O
.	O


RESULTS	O
Patients	O
received	O
tofacitinib	O
5	O
mg	O
(	O
n	O
=	O
133	O
)	O
or	O
10	O
mg	O
(	O
n	O
=	O
134	O
)	O
or	O
placebo	O
advanced	O
to	O
tofacitinib	O
5	O
mg	O
(	O
n	O
=	O
66	O
)	O
or	O
10	O
mg	O
(	O
n	O
=	O
66	B-O
)	I-O
.	I-O


HAQ	B-O
DI	I-O
(	I-O
reported	I-O
previously	I-O
)	I-O
,	I-O
PtGA	I-O
(	I-O
P	I-O
<	I-O
0.0001	I-O
)	I-O
,	I-O
and	I-O
SF-36v2	I-O
physical	I-O
and	I-O
mental	I-O
component	I-O
summary	I-O
(	I-O
P	I-O
<	I-O
0.05	I-O
)	I-O
scores	I-O
were	I-O
improved	I-O
for	O
both	O
tofacitinib	O
doses	O
versus	O
placebo	O
.	O


Furthermore	O
,	O
improvements	O
greater	O
than	O
or	O
equal	O
to	O
the	O
minimum	O
clinically	O
important	O
difference	O
were	O
more	O
frequently	O
reported	O
by	O
tofacitinib-treated	O
patients	O
versus	O
placebo	O
for	B-O
PtGA	I-O
(	O
P	O
<	O
0.05	B-O
)	I-O
,	I-O
pain	I-O
(	O
P	O
<	O
0.0001	B-O
)	I-O
,	I-O
HAQ	I-O
DI	O
(	O
P	O
<	O
0.05	B-O
)	I-O
,	I-O
SF-36v2	I-O
physical	I-O
and	I-O
mental	I-O
component	I-O
summary	I-O
scores	I-O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	B-O
FACIT-F	I-O
(	O
P	O
<	O
0.001	O
for	O
5	O
mg	O
twice	O
daily	B-O
)	I-O
.	I-O


No	B-O
statistical	I-O
differences	I-O
were	O
observed	O
in	O
the	B-O
MOS	I-O
Sleep	I-O
Scale	I-O
.	O


CONCLUSION	O
Tofacitinib	O
treatment	O
resulted	O
in	O
significant	O
,	O
clinically	O
meaningful	O
improvements	O
in	O
multiple	O
PROs	O
versus	O
placebo	O
over	O
3	O
months	O
of	O
treatment	B-P
in	I-P
patients	I-P
with	I-P
active	I-P
RA	I-P
and	I-P
a	I-P
previous	I-P
inadequate	I-P
response	I-P
to	I-P
TNFi	I-P
.	O


Pregabalin	B-I
versus	O
naltrexone	B-I
in	I-P
alcohol	I-P
dependence	I-P
:	I-P
a	O
randomised	O
,	O
double-blind	O
,	O
comparison	O
trial	O
.	O


Pregabalin	B-I
(	I-I
PRE	I-I
)	I-I
acts	O
as	O
a	O
presynaptic	O
inhibitor	O
of	O
the	O
release	O
of	O
excessive	O
levels	O
of	O
excitatory	O
neurotransmitters	O
by	O
selectively	O
binding	O
to	O
the	O
alpha	O
(	O
2	O
)	O
-delta	O
subunit	O
of	O
voltage-gated	O
calcium	O
channels	O
.	O


In	O
this	O
randomised	O
,	O
double-blind	O
comparison	O
trial	O
with	O
naltrexone	B-I
(	I-I
NAL	I-I
)	I-I
,	O
we	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
PRE	O
on	B-P
alcohol	I-O
drinking	I-O
indices	I-O
.	I-O


Craving	B-O
reduction	I-O
and	O
improvement	B-O
of	I-O
psychiatric	I-O
symptoms	I-O
were	O
the	O
secondary	O
endpoints	O
.	O


Seventy-one	B-P
alcohol-dependent	I-P
subjects	I-P
were	O
detoxified	O
and	O
subsequently	O
randomised	O
into	O
two	O
groups	O
,	O
receiving	B-I
50	I-I
mg	I-I
of	I-I
NAL	I-I
or	I-I
150-450	I-I
mg	I-I
of	I-I
PRE	I-I
.	I-I


Craving	B-O
(	I-O
VAS	I-O
;	I-O
OCDS	I-O
)	I-O
,	I-O
withdrawal	I-O
(	I-O
CIWA-Ar	I-O
)	I-O
and	I-O
psychiatric	I-O
symptoms	I-O
(	I-O
SCL-90-R	I-O
)	I-O
rating	I-O
scales	I-O
were	O
applied	O
.	O


Alcohol	B-O
drinking	I-O
indices	I-O
and	I-O
craving	I-O
scores	I-O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O


Compared	O
with	O
NAL	B-I
,	I-I
PRE	I-I
resulted	O
in	O
greater	O
improvement	O
of	O
specific	O
symptoms	O
in	O
the	O
areas	O
of	O
anxiety	B-O
,	I-O
hostility	I-O
and	I-O
psychoticism	I-O
,	I-O
and	I-O
survival	I-O
function	I-O
(	I-O
duration	I-O
of	I-O
abstinence	I-O
from	I-O
alcohol	I-O
)	I-O
.	O


PRE	O
also	O
resulted	O
in	O
better	O
outcome	O
in	B-P
patients	I-P
reporting	I-P
a	I-P
comorbid	I-P
psychiatric	I-P
disorder	I-P
.	I-P


Results	O
from	O
this	O
study	O
globally	O
place	O
PRE	B-I
within	O
the	O
same	O
range	O
of	O
efficacy	O
as	O
that	O
of	O
NAL	B-I
.	I-I


The	O
mechanism	O
involved	O
in	O
the	O
efficacy	O
of	O
PRE	B-I
in	O
relapse	O
prevention	O
could	O
be	O
less	O
related	O
to	O
alcohol	B-O
craving	I-O
and	O
more	O
associated	O
with	O
the	O
treatment	O
of	O
the	O
comorbid	O
psychiatric	O
symptomatology	O
.	O


Including	O
a	O
'no	O
active	O
intervention	O
'	O
arm	O
in	O
surgical	O
trials	O
is	O
possible	O
:	O
evidence	O
from	O
the	O
CLasP	O
randomised	O
trial	O
.	O


OBJECTIVES	O
To	O
examine	O
the	O
impact	O
of	O
including	O
a	B-I
'no	I-I
active	I-I
intervention	I-I
'	I-I
arm	I-I
(	I-I
called	I-I
'conservative	I-I
management	I-I
'	I-I
)	I-I
in	O
a	O
randomised	O
controlled	O
trial	O
comparing	O
treatments	O
(	O
including	O
surgery	B-I
)	I-I
for	O
men	B-P
with	I-P
lower	I-P
urinary	I-P
tract	I-P
symptoms	I-P
related	I-P
to	I-P
benign	I-P
prostatic	I-P
enlargement	I-P
.	I-P


METHODS	O
Outcomes	O
7.5	O
months	O
after	O
randomisation	O
were	O
acceptability	B-O
of	I-O
randomisation	I-O
,	I-O
overall	I-O
acceptability	I-O
of	I-O
and	I-O
satisfaction	I-O
with	I-O
conservative	I-O
management	I-O
,	I-O
impact	I-O
on	I-O
quality	I-O
of	I-O
life	I-O
,	I-O
perceived	I-O
need	I-O
for	I-O
further	I-O
treatment	I-O
and	O
treatment	B-O
failure	I-O
(	I-O
defined	I-O
a	I-O
priori	I-O
)	I-O
.	I-O


RESULTS	O
In	O
total	O
,	O
177	B-P
(	I-P
out	I-P
of	I-P
755	I-P
)	I-P
patients	I-P
refused	I-P
randomisation	I-P
,	O
including	O
31	O
%	O
who	O
did	O
not	O
want	O
surgery	O
and	O
22	O
%	O
who	O
wanted	O
surgery	O
.	O


Most	O
men	O
randomised	O
to	O
conservative	O
management	O
were	O
willing	O
to	O
undertake	O
it	O
as	O
part	O
of	O
a	O
trial	O
but	O
at	O
the	O
end	O
of	O
the	O
trial	O
they	O
were	O
divided	O
between	O
those	O
who	O
wanted	O
to	O
continue	O
with	O
it	O
and	O
those	O
who	O
expected	O
surgery	O
.	O


At	O
follow-up	O
,	O
39	O
%	O
of	O
conservative	O
management	O
patients	O
requested	O
surgery	O
,	O
and	O
interference	B-O
of	I-O
symptoms	I-O
with	I-O
life	I-O
and	O
an	O
unsuccessful	B-O
outcome	I-O
were	O
more	O
commonly	O
reported	O
in	O
this	O
arm	O
.	O


There	O
were	O
no	O
appreciable	O
differences	O
between	O
treatment	O
groups	O
in	O
terms	O
of	O
treatment	B-O
failures	I-O
.	I-O


CONCLUSIONS	O
Including	O
a	O
'no	B-I
active	I-I
intervention	I-I
'	I-I
arm	I-I
did	O
not	O
appear	O
to	O
have	O
a	O
detrimental	O
effect	O
on	O
patient	B-O
recruitment	I-O
or	O
the	O
completion	O
of	O
this	O
trial	O
in	O
the	O
short-term	O
;	O
overall	O
,	O
conservative	O
management	O
was	O
successfully	O
completed	O
by	O
the	O
majority	O
of	O
patients	O
during	O
the	O
trial	O
period	O
,	O
suggesting	O
that	O
researchers	O
need	O
not	O
avoid	O
including	O
a	O
no-intervention	O
arm	O
in	O
surgical	O
trials	O
as	O
long	O
as	O
they	O
take	O
care	O
with	O
its	O
presentation	O
.	O


Does	O
the	O
result	O
of	O
completion	B-I
axillary	I-I
lymph	I-I
node	I-I
dissection	I-I
influence	O
the	O
recommendation	O
for	O
adjuvant	B-I
treatment	I-I
in	O
sentinel	B-P
lymph	I-P
node-positive	I-P
patients	I-P
?	O
OBJECTIVE	O
The	O
Hungarian	O
National	O
Institute	O
of	O
Oncology	O
has	O
just	O
closed	O
a	O
single-center	O
randomized	O
clinical	O
study	O
.	O


The	O
Optimal	O
Treatment	O
of	O
the	O
Axilla-Surgery	O
or	O
Radiotherapy	O
(	O
OTOASOR	O
)	O
trial	O
compares	O
completion	B-I
axillary	I-I
lymph	I-I
node	I-I
dissection	I-I
(	I-I
cALND	I-I
)	I-I
with	O
regional	B-I
nodal	I-I
irradiation	I-I
(	I-I
RNI	I-I
)	I-I
in	O
patients	B-P
with	I-P
sentinel	I-P
lymph	I-P
node-positive	I-P
(	I-P
SLN+	I-P
)	I-P
primary	I-P
invasive	I-P
breast	I-P
cancer	I-P
.	I-P


In	O
the	O
investigational	O
treatment	O
arm	O
,	O
patients	O
received	O
50	O
Gy	O
RNI	B-I
instead	O
of	O
cALND	B-I
.	I-I


In	O
these	O
patients	O
we	O
had	O
information	O
only	O
about	O
the	O
sentinel	O
lymph	O
node	O
(	O
SLN	O
)	O
status	O
,	O
but	O
the	O
further	O
axillary	O
nodal	O
involvement	O
remained	O
unknown	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
result	O
of	O
cALND	B-I
influenced	O
the	O
recommendation	O
for	O
adjuvant	O
treatment	O
in	O
patients	B-P
with	I-P
SLN+	I-P
breast	I-P
cancer	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
with	I-P
SLN+	I-P
primary	I-P
breast	I-P
cancer	I-P
were	O
randomized	O
for	O
cALND	B-I
(	O
arm	O
A	O
,	O
standard	O
treatment	O
)	O
or	O
RNI	O
(	O
arm	O
B	O
,	O
investigational	O
treatment	O
)	O
.	O


Adjuvant	O
systemic	O
treatments	O
were	O
given	O
according	O
to	O
the	O
standard	O
institutional	O
protocol	O
,	O
and	O
patients	O
were	O
followed	O
according	O
to	O
the	O
actual	O
institutional	O
guidelines	O
.	O


RESULTS	O
Between	O
August	O
2002	O
and	O
June	O
2009	O
,	O
474	B-P
SLN+	I-P
patients	I-P
were	O
randomized	O
to	O
cALND	B-I
(	O
arm	O
A	O
,	O
standard	O
treatment	O
=	O
244	O
patients	O
)	O
or	O
RNI	B-I
(	O
arm	O
B	O
,	O
investigational	O
treatment	O
=	O
230	O
patients	O
)	O
.	O


The	O
2	O
arms	O
were	O
well	O
balanced	O
according	O
to	O
the	O
majority	O
of	O
main	O
prognostic	O
factors	O
.	O


However	O
,	O
more	O
patients	B-P
were	I-P
premenopausal	I-P
(	I-P
34	I-P
%	I-P
vs.	I-P
27	I-P
%	I-P
;	I-P
P	I-P
=	I-P
.095	I-P
)	I-P
and	I-P
had	I-P
pT2-3	I-P
tumors	I-P
(	O
57	O
%	O
vs.	O
40	O
%	O
;	O
P	O
=	O
.003	O
)	O
in	O
the	O
completion	O
axillary	O
lymph	O
node	O
dissection	O
(	O
ALND	O
)	O
arm	O
.	O


On	O
the	O
other	O
hand	O
,	O
there	O
were	O
more	O
patients	B-P
with	I-P
known	I-P
human	I-P
epidermal	I-P
growth	I-P
factor	I-P
receptor	I-P
type	I-P
2	I-P
positive	I-P
tumor	I-P
(	I-P
12	I-P
%	I-P
vs.	I-P
17	I-P
%	I-P
,	I-P
P	I-P
=	I-P
.066	I-P
)	I-P
in	O
the	O
RNI	O
arm	O
.	O


In	O
the	O
ALND	B-I
and	O
RNI	B-I
arms	O
,	O
78	O
%	O
(	O
190/244	O
)	O
and	O
69	O
%	O
(	O
159/230	O
)	O
,	O
respectively	O
,	O
received	O
chemotherapy	B-I
(	O
P	O
=	O
.020	O
)	O
.	O


Endocrine	B-I
therapy	I-I
was	O
administered	O
in	O
87	O
%	O
(	O
213/244	O
)	O
of	O
the	O
patients	O
in	O
the	O
ALND	O
arm	O
and	O
89	O
%	O
(	O
204/230	O
)	O
of	O
the	O
patients	O
in	O
the	O
RNI	O
arm	O
(	O
P	O
=	O
.372	O
)	O
.	O


Six	O
patients	O
(	O
2.5	O
%	O
)	O
on	O
arm	O
A	O
and	O
13	O
patients	O
(	O
5.7	O
%	O
)	O
on	O
arm	O
B	O
received	O
adjuvant	O
trastuzumab	O
treatment	O
(	O
P	O
=	O
not	O
significant	O
)	O
.	O


Subgroup	O
analyses	O
explored	O
that	O
more	O
frequent	O
administration	O
of	O
adjuvant	B-I
chemotherapy	I-I
in	O
arm	O
A	O
was	O
associated	O
with	O
the	O
higher	O
percentage	O
of	O
premenopausal	B-P
patients	I-P
and	I-P
patients	I-P
with	I-P
larger	I-P
(	I-P
pT2-3	I-P
)	I-P
tumors	I-P
.	I-P


CONCLUSIONS	O
The	O
result	O
of	O
cALND	B-I
after	O
positive	O
SLN	O
biopsy	O
seems	O
to	O
have	O
no	O
major	O
impact	O
on	O
the	O
administration	O
of	O
adjuvant	B-I
systemic	I-I
therapy	I-I
.	I-I


p16	B-O
(	I-O
INK4a	I-O
)	I-O
Expression	I-O
does	O
not	O
predict	O
the	O
outcome	O
of	O
cervical	O
intraepithelial	O
neoplasia	O
grade	O
2	O
.	O


Spontaneous	O
regression	O
of	O
cervical	O
intraepithelial	O
neoplasia	O
grade	O
2	O
(	O
CIN2	O
)	O
lesions	O
has	O
been	O
recognized	O
since	O
1955	O
,	O
but	O
predictors	O
of	O
this	O
are	O
poorly	O
understood	O
.	O


Among	O
the	O
predictive	O
markers	O
studied	O
,	O
p16	B-I
(	I-I
INK4a	I-I
)	I-I
has	O
been	O
suggested	O
to	O
be	O
of	O
some	O
value	O
in	O
monitoring	O
the	O
diagnosis	O
of	O
CIN2	O
.	O


In	O
this	O
clinical	O
trial	O
,	O
90	B-P
Brazilian	I-P
women	I-P
,	I-P
diagnosed	I-P
to	I-P
CIN2	I-P
and	I-P
high-risk	I-P
human	I-P
papillomavirus	I-P
infection	I-P
,	I-P
were	I-P
randomized	I-P
into	I-P
two	I-P
groups	I-P
of	I-P
equal	I-P
size	I-P
:	I-P
45	I-P
women	I-P
whose	I-P
lesions	I-I
were	I-I
excised	I-I
and	I-P
45	I-P
women	I-P
subjected	I-P
to	I-P
prospective	I-I
follow-up	I-I
at	I-P
3-month	I-P
intervals	I-P
at	I-P
least	I-P
for	I-P
1	I-P
year	I-P
(	I-P
mean	I-P
6.8	I-P
months	I-P
)	I-P
.	I-P


p16	B-O
(	I-O
INK4a	I-O
)	I-O
expression	I-O
was	O
analyzed	O
in	O
paraffin-embedded	O
sections	O
using	O
immunohistochemical	B-I
staining	I-I
.	I-I


Among	O
the	O
45	B-P
women	I-P
in	O
the	O
follow-up	O
group	O
,	O
42	O
%	O
experienced	O
spontaneous	O
regression	O
,	O
11	O
%	O
showed	O
persistence	O
,	O
22	O
%	O
progressed	O
to	O
CIN3	O
,	O
and	O
20	O
%	O
had	O
partial	O
regression	O
to	O
CIN1	O
or	O
ASCUS	O
(	O
atypical	O
squamous	O
cell	O
undetermined	O
signifiance	O
)	O
.	O


p16	B-O
(	I-O
INK4a	I-O
)	I-O
expression	I-O
was	O
detected	O
in	O
68.9	O
%	O
of	O
the	O
patients	O
.	O


In	O
univariate	B-O
survival	I-O
(	I-O
Cox	I-O
)	I-O
analysis	I-O
,	O
no	O
significant	O
difference	O
in	O
regression	O
was	O
obtained	O
between	O
p16	B-I
(	I-I
INK4a	I-I
)	I-I
-negative	I-I
and	I-I
-positive	I-I
CIN2	O
lesions	O
(	O
adjusted	O
HR	O
=	O
1.1	O
;	O
95	O
%	O
CI	O
0.6-2.0	O
)	O
.	O


In	O
conclusion	O
,	O
p16	B-O
(	I-O
INK4a	I-O
)	I-O
expression	I-O
could	O
be	O
useful	O
in	O
the	O
diagnosis	B-O
of	I-O
CIN2	I-O
.	I-O


However	O
,	O
it	O
failed	O
to	O
predict	O
the	O
outcome	O
of	O
CIN2	B-O
.	I-O


Because	O
of	O
its	O
high	O
spontaneous	O
regression	O
rate	O
,	O
follow-up	O
could	O
be	O
considered	O
as	O
a	O
management	O
option	O
of	O
CIN2	O
in	O
young	O
and	O
compliant	O
women	O
.	O


Dacarbazine	B-I
versus	I-I
dacarbazine-vindesine	I-I
in	O
disseminated	O
malignant	O
melanoma	O
:	O
a	O
randomized	O
phase	O
II	O
study	O
.	O


In	O
a	O
phase	O
II	O
study	O
119	B-P
patients	I-P
with	I-P
disseminated	I-P
malignant	I-P
melanoma	I-P
were	O
randomized	O
to	O
receive	O
treatment	O
with	O
dacarbazine	B-I
alone	O
or	O
in	O
combination	O
with	O
vindesine	O
.	O


The	O
study	O
was	O
designed	O
to	O
reveal	O
an	O
additive	O
response	O
rate	O
when	O
the	O
drugs	O
were	O
combined	O
.	O


Dacarbazine	B-I
was	I-I
given	I-I
i.v	I-I
.	I-I


at	B-I
250	I-I
mg	I-I
m-2	I-I
per	I-I
day	I-I
X	I-I
V	I-I
every	I-I
4	I-I
weeks	I-I
.	I-I


In	O
the	O
combination	O
regimen	O
vindesine	B-I
given	O
at	O
3	O
mg	O
m-2	O
per	O
week	O
was	O
included	O
.	O


One	B-P
hundred	I-P
and	I-P
ten	I-P
patients	I-P
were	I-P
available	I-P
for	I-P
evaluation	I-P
of	I-P
response	I-P
.	I-P


With	O
dacarbazine	B-I
4/51	O
patients	O
obtained	O
a	O
complete	B-O
remission	I-O
(	O
8	O
%	O
)	O
and	O
5/51	O
patients	O
a	O
partial	B-O
remission	I-O
(	O
10	O
%	O
)	O
.	O


Overall	B-O
response	I-O
rate	I-O
was	O
18	O
%	O
.	O


With	O
dacarbazine-vindesine	B-I
8/59	O
patients	O
obtained	O
a	O
complete	B-O
remission	I-O
(	O
13	O
%	O
)	O
and	O
7/59	O
patients	O
a	O
partial	B-O
remission	I-O
(	O
12	O
%	O
)	O
.	O


Overall	B-O
response	I-O
rate	I-O
was	O
25	O
%	O
.	O


The	O
difference	O
in	O
response	B-O
rates	I-O
observed	O
between	O
the	O
treatment	O
arms	O
is	O
not	O
statistically	O
significant	O
.	O


Median	O
response	O
duration	O
was	O
123	O
days	O
for	O
dacarbazine	O
patients	O
and	O
171	O
days	O
for	O
patients	O
receiving	O
dacarbazine-vindesine	O
(	O
difference	O
not	O
statistically	O
significant	O
)	O
.	O


Disopyramide-pyridostigmine	B-I
interaction	O
:	O
selective	O
reversal	O
of	O
anticholinergic	O
symptoms	O
with	O
preservation	O
of	O
antiarrhythmic	O
effect	O
.	O


This	O
double-blind	O
,	O
randomized	O
,	O
placebo	B-I
crossover	O
study	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
cholinesterase	B-I
inhibitor	I-I
--	I-I
slow-release	I-I
pyridostigmine	I-I
(	O
180	O
mg	O
orally	O
every	O
12	O
hours	O
)	O
--	O
on	O
the	O
anticholinergic	B-O
and	I-O
antiarrhythmic	I-O
properties	I-O
of	O
disopyramide	B-I
.	I-I


Quantitative	O
side	O
effects	O
questionnaire	O
scores	O
were	O
used	O
to	O
guide	O
disopyramide	B-I
administration	O
in	O
20	B-P
men	I-P
with	I-P
ventricular	I-P
tachycardia	I-P
.	I-P


Disopyramide	B-I
was	O
given	O
to	O
each	O
patient	B-P
both	I-P
with	I-P
placebo	I-I
and	I-P
with	I-P
active	I-P
pyridostigmine	I-I
.	I-I


The	O
maximal	O
administered	O
dose	O
for	O
each	O
regimen	O
was	O
used	O
in	O
conjunction	O
with	O
corresponding	O
questionnaire	O
scores	O
to	O
calculate	O
an	O
index	O
or	O
estimate	O
of	O
the	O
maximal	B-O
tolerable	I-O
dose	I-O
of	O
disopyramide	B-I
.	I-I


Additional	O
evaluations	O
performed	O
at	O
baseline	O
and	O
at	O
each	O
maximal	O
administered	O
dose	O
regimen	O
included	O
tear	B-O
and	I-O
saliva	I-O
quantitation	I-O
,	I-O
24	I-O
hour	I-O
electrocardiogram	I-O
(	I-O
ECG	I-O
)	I-O
,	I-O
exercise	I-O
testing	I-O
and	I-O
programmed	I-O
ventricular	I-O
stimulation	I-O
.	I-O


Results	O
showed	O
that	O
the	O
maximal	O
administered	O
dose	O
of	O
disopyramide	B-I
was	O
greater	O
with	O
active	O
pyridostigmine	B-I
than	O
with	O
placebo	O
:	O
295	O
+/-	O
75	O
versus	O
245	O
+/-	O
100	O
mg	O
every	O
6	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


The	O
calculated	O
maximal	B-O
tolerable	I-O
dose	I-O
was	O
substantially	O
greater	O
in	O
the	O
presence	O
of	O
pyridostigmine	B-I
:	I-I
355	O
+/-	O
90	O
versus	O
260	O
+/-	O
115	O
mg	O
every	O
6	O
hours	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


Maximal	B-O
side	I-O
effects	I-O
questionnaire	I-O
scores	I-O
also	O
reflected	O
decreased	O
anticholinergic	B-O
activity	I-O
in	O
the	O
presence	O
of	O
pyridostigmine	B-I
compared	O
with	O
placebo	B-I
:	I-I
101.9	O
+/-	O
2.2	O
versus	O
104.6	O
+/-	O
2.8	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.005	O
)	O
.	O


Baseline	O
tear	O
and	O
saliva	O
production	O
was	O
significantly	O
reduced	O
during	O
disopyramide	O
therapy	O
,	O
but	O
was	O
restored	O
toward	O
normal	O
by	O
the	O
addition	O
of	O
pyridostigmine	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


A	O
web-based	B-I
approach	I-I
to	O
address	O
cardiovascular	B-O
risks	I-O
in	I-P
managers	I-P
:	I-P
results	O
of	O
a	O
randomized	O
trial	O
.	O


OBJECTIVES	O
To	O
examine	O
whether	O
a	O
Web-based	B-I
health	I-I
and	I-I
leadership	I-I
development	I-I
program	I-I
--	I-I
designed	I-I
specifically	O
for	O
managers	B-P
--	I-P
was	I-P
associated	O
with	O
changes	O
in	O
self-reported	B-O
and	I-O
biometric	I-O
indicators	I-O
of	I-O
cardiovascular	I-O
disease	I-O
within	O
the	O
context	O
of	O
a	O
randomized	O
control	O
trial	O
.	O


METHODS	O
A	O
total	O
of	O
145	B-P
managers	I-P
from	I-P
8	I-P
organizations	I-P
participated	O
in	O
a	O
6-month	B-I
Internet-based	I-I
program	I-I
or	I-I
a	I-I
control	I-I
condition	I-I
.	I-I


They	O
completed	O
pre-	O
and	O
posttest	O
assessments	O
that	O
included	O
both	O
self-reported	B-O
attitudes	I-O
(	I-O
on	I-O
diet	I-O
,	I-O
exercise	I-O
,	I-O
and	I-O
mental	I-O
health	I-O
)	I-O
and	O
biometric	B-O
measures	I-O
(	I-O
eg	I-O
,	I-O
body	I-O
weight	I-O
,	I-O
waist	I-O
circumference	I-O
)	I-O
.	I-O


RESULTS	O
The	O
intervention	B-I
was	O
associated	O
with	O
improvements	O
in	O
dietary	B-O
attitudes	I-O
,	I-O
dietary	I-O
self-efficacy	I-O
,	I-O
and	I-O
exercise	I-O
,	I-O
and	I-O
reductions	I-O
in	I-O
distress	I-O
symptoms	I-O
.	I-O


Women	O
in	O
the	O
program	O
reduced	O
their	O
waist	B-O
circumference	I-O
significantly	O
more	O
than	O
controls	O
.	O


CONCLUSIONS	O
The	O
program	O
showed	O
promise	O
for	O
reducing	O
cardiovascular	B-O
disease	I-O
risk	I-O
factors	I-O
.	I-O


Similar	O
results	O
across	O
diverse	O
organizations	O
suggest	O
the	O
program	O
may	O
be	O
useful	O
across	O
industry	O
types	O
.	O


Can	O
a	O
home-visit	B-I
invitation	I-I
increase	I-P
Pap	I-P
smear	I-P
screening	I-P
in	I-P
Samliem	I-P
,	I-P
Khon	I-P
Kaen	I-P
,	I-P
Thailand	I-P
?	O
Our	O
objective	O
was	O
to	O
assess	O
the	O
efficiency	O
of	O
a	O
home-visit	B-I
invitation	I-I
aimed	O
to	O
increase	O
uptake	O
of	O
cervical	B-P
cancer	I-P
screening	I-P
in	I-P
women	I-P
between	I-P
35	I-P
and	I-P
60	I-P
years	I-P
of	I-P
age	I-P
.	I-P


From	O
May	O
,	O
2006	O
,	O
we	O
conducted	O
a	O
quasi-randomized	O
trial	O
to	O
determine	O
if	O
an	O
in-home	B-I
education	I-I
and	I-I
invitation	I-I
intervention	I-I
would	O
increase	O
uptake	O
of	O
cervical	O
cancer	O
screening	O
.	O


We	O
randomly	B-P
recruited	I-P
304	I-P
women	I-P
from	I-P
the	I-P
Samliem	I-P
inner-city	I-P
community	I-P
,	I-P
Khon	I-P
Kaen	I-P
,	I-P
Northeast	I-P
Thailand	I-P
,	I-P
and	I-P
assigned	I-P
participants	I-P
to	O
either	O
the	O
intervention	B-I
or	O
control	B-I
zone	I-I
.	I-I


Baseline	O
screening	O
coverage	O
interviews	O
were	O
then	O
performed	O
:	O
58	B-P
of	I-P
158	I-P
women	I-P
in	I-P
the	I-P
intervention	I-P
zone	I-P
and	I-P
46	I-P
of	I-P
146	I-P
in	I-P
the	I-P
control	I-P
zone	I-P
were	I-P
excluded	I-P
from	I-P
the	I-P
study	I-P
because	I-P
of	I-P
having	I-P
had	I-P
a	I-P
Pap	I-P
smear	I-P
within	I-P
5	I-P
years	I-P
,	I-P
but	I-P
these	I-P
were	I-P
included	I-P
in	I-P
the	I-P
final	I-P
analysis	I-P
.	I-P


First	O
,	O
100	B-P
women	I-P
in	I-P
the	I-P
intervention	I-P
group	I-P
were	O
visited	B-I
in	I-I
their	I-I
homes	I-I
by	I-I
one	I-I
of	I-I
the	I-I
researchers	I-I
,	I-I
who	I-I
provided	I-I
culturally-sensitive	I-I
health	I-I
education	I-I
that	I-I
emphasized	I-I
the	I-I
need	I-I
for	I-I
screening	I-I
.	I-I


Four	O
months	O
later	O
,	O
post-intervention	O
,	O
screening-coverage	B-I
interviews	I-I
were	O
again	O
performed	O
in	O
both	O
groups	O
,	O
in	O
combination	O
with	O
the	O
same	O
health	O
education	O
for	O
100	B-P
women	I-P
in	I-P
the	I-P
control	I-I
group	I-P
for	O
a	O
comparison	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	O
baseline	B-O
Pap	I-O
smear	I-O
screening-coverage	I-O
rate	I-O
in	O
the	O
intervention	O
vs.	O
control	O
zones	O
(	O
36.7	O
vs.	O
31.5	O
%	O
,	O
p=0.339	O
)	O
.	O


One	O
hundred	O
women	O
in	O
the	O
intervention	O
group	O
completed	O
the	O
intervention	O
interviews	O
and	O
after	O
four	O
months	O
,	O
100	O
women	O
in	O
the	O
intervention	O
group	O
and	O
100	O
in	O
the	O
control	O
group	O
also	O
completed	O
the	O
post-intervention	O
interviews	O
.	O


The	O
increased	O
screening-coverage	B-O
rate	I-O
in	O
the	O
intervention	O
zone	O
was	O
similar	O
to	O
that	O
of	O
the	O
control	O
zone	O
(	O
43.6	O
vs.	O
34.9	O
%	O
,	O
p=0.119	O
)	O
;	O
however	O
,	O
there	O
was	O
a	O
borderline	O
significant	O
increase	O
in	O
the	O
intervention	O
zone	O
compared	O
with	O
baseline	O
(	O
36.7	O
to	O
43.6	O
%	O
,	O
p=0.070	O
)	O
.	O


Therefore	O
,	O
home	B-I
visit	I-I
education	I-I
and	I-I
invitation	I-I
intervention	I-I
produced	O
only	O
a	O
nominal	O
effect	O
on	O
increasing	O
Pap	O
smear	O
coverage	O
within	O
a	O
4-month	O
study	O
period	O
.	O


Randomized	O
study	O
comparing	O
use	O
of	O
THUNDERBEAT	O
technology	O
vs	O
standard	O
electrosurgery	O
during	O
laparoscopic	B-P
radical	I-P
hysterectomy	I-P
and	I-P
pelvic	I-P
lymphadenectomy	I-P
for	I-P
gynecologic	I-P
cancer	I-P
.	I-P


STUDY	O
OBJECTIVE	O
To	O
compare	O
operative	O
time	O
with	O
use	O
of	O
THUNDERBEAT	B-I
(	O
TB	O
)	O
vs	O
standard	B-I
electrosurgery	I-I
(	O
SES	O
)	O
during	O
laparoscopic	O
radical	O
hysterectomy	O
and	O
pelvic	O
lymphadenectomy	O
to	O
treat	O
gynecologic	B-P
tumors	I-P
.	I-P


DESIGN	O
Evidence	O
obtained	O
from	O
a	O
properly	O
designed	O
,	O
randomized	O
,	O
controlled	O
trial	O
(	O
Canadian	O
Task	O
Force	O
classification	O
I	O
)	O
.	O


SETTING	O
Gynecologic	B-P
Oncology	I-P
Unit	I-P
of	I-P
the	I-P
Catholic	I-P
University	I-P
of	I-P
the	I-P
Sacred	I-P
Heart	I-P
in	I-P
Rome	I-P
,	I-P
Italy	I-P
.	I-P


PATIENTS	O
Fifty	B-P
patients	I-P
with	I-P
early	I-P
cervical	I-P
cancer	I-P
(	I-P
FIGO	I-P
stages	I-P
IA2	I-P
,	I-P
IB1	I-P
,	I-P
IIA	I-P
<	I-P
2	I-P
cm	I-P
)	I-P
or	I-P
locally	I-P
advanced	I-P
cervical	I-P
cancer	I-P
(	I-P
FIGO	I-P
stages	I-P
IB2	I-P
,	I-P
IIA	I-P
>	I-P
2cm	I-P
,	I-P
IIB	I-P
)	I-P
who	I-P
received	I-P
neoadjuvant	I-I
treatment	I-I
(	I-I
chemotherapy	I-I
or	I-I
radiochemotherapy	I-I
)	I-I
and	I-P
demonstrated	I-P
a	I-P
complete	I-P
or	I-P
partial	I-P
clinical	I-P
response	I-P
and	I-P
early	I-P
stage	I-P
endometrioid	I-P
endometrial	I-P
cancer	I-P
(	I-P
FIGO	I-P
stages	I-P
IB	I-P
,	I-P
II	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
undergo	O
TB	O
(	O
arm	O
A	O
)	O
or	O
SES	O
(	O
arm	O
B	O
)	O
.	O


INTERVENTION	O
Laparoscopic	B-I
radical	I-I
hysterectomy	I-I
with	I-I
bilateral	I-I
pelvic	I-I
lymphadenectomy	I-I
,	O
using	O
an	O
easily	O
reproducible	O
technique	O
was	O
performed	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Fifty	B-P
patients	I-P
were	I-P
available	I-P
for	I-P
analysis	I-P
,	I-P
with	I-P
25	I-P
women	I-P
randomly	I-P
assigned	I-P
to	I-P
TB	I-P
(	I-P
arm	I-P
A	I-P
)	I-P
and	I-P
25	I-P
to	I-P
SES	I-P
(	I-P
arm	I-P
B	I-P
)	I-P
.	I-P


The	O
median	B-O
operative	I-O
time	I-O
was	O
85	O
minutes	O
for	O
TB	O
vs	O
115	O
minutes	O
for	O
SES	O
(	O
p	O
=	O
.001	O
)	O
.	O


At	O
multivariate	O
analysis	O
,	O
endometrial	O
cancer	O
(	O
p	O
=	O
.001	O
)	O
and	O
TB	O
(	O
p	O
=	O
.001	O
)	O
were	O
independently	O
associated	O
with	O
shorter	B-O
operating	I-O
time	I-O
.	I-O


No	O
differences	B-O
in	O
perioperative	B-O
outcomes	I-O
and	I-O
postoperative	I-O
complications	I-O
were	O
observed	O
between	O
the	O
2	O
arms	O
.	O


Patients	O
who	O
underwent	O
TB	O
reported	O
less	O
postoperative	B-O
pain	I-O
,	O
both	O
at	O
rest	O
(	O
p	O
=	O
.005	O
)	O
and	O
after	O
the	O
Valsalva	O
maneuver	O
(	O
p	O
=	O
.008	O
)	O
,	O
with	O
less	O
additional	O
analgesic	O
therapy	O
other	O
than	O
standard	O
therapy	O
required	O
in	O
patients	O
who	O
underwent	O
SES	O
(	O
p	O
=	O
.02	O
)	O
.	O


CONCLUSION	O
TB	O
is	O
associated	O
with	O
shorter	B-O
operative	I-O
time	I-O
and	I-O
less	I-O
postoperative	I-O
pain	I-O
than	O
is	O
the	O
standard	O
technique	O
(	O
SES	O
)	O
in	O
patients	B-P
with	I-P
uterine	I-P
cancer	I-P
.	I-P


[	O
A	O
prospective	O
randomized	O
study	O
of	O
the	O
radiotherapy	B-I
volume	I-I
for	O
limited-stage	O
small	O
cell	O
lung	O
cancer	O
:	O
a	O
preliminary	O
report	O
]	O
.	O


BACKGROUND	O
AND	O
OBJECTIVE	O
Controversies	O
exists	O
with	O
regard	O
to	O
target	O
volumes	O
as	O
far	O
as	O
thoracic	B-I
radiotherapy	I-I
(	I-I
TRT	I-I
)	I-I
is	O
concerned	O
in	O
the	O
multimodality	O
treatment	O
for	O
limited-stage	B-P
small	I-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
LSCLC	I-P
)	I-P
.	I-P


The	O
aim	O
of	O
this	O
study	O
is	O
to	O
prospectively	O
compare	O
the	O
local	O
control	O
rate	O
,	O
toxicity	O
profiles	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
between	O
patients	O
received	O
different	B-I
target	I-I
volumes	I-I
irradiation	I-I
after	I-I
induction	I-I
chemotherapy	I-I
.	I-I


METHODS	O
LSCLC	B-P
patients	I-P
received	O
2	O
cycles	O
of	O
etoposide	B-I
and	I-I
cisplatin	I-I
(	I-I
EP	I-I
)	I-I
induction	I-I
chemotherapy	I-I
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
TRT	B-I
to	O
either	O
the	O
post-	O
or	O
pre-chemotherapy	O
tumor	O
extent	O
(	O
GTV-T	O
)	O
as	O
study	O
arm	O
and	O
control	O
arm	O
,	O
CTV-N	O
included	O
the	O
positive	O
nodal	O
drainage	O
area	O
for	O
both	O
arms	O
.	O


One	O
to	O
2	O
weeks	O
after	O
induction	B-I
chemotherapy	I-I
,	I-I
45	I-I
Gy/30	I-I
Fx/19	I-I
d	I-I
TRT	I-I
was	O
administered	O
concurrently	O
with	O
the	O
third	O
cycle	O
of	O
EP	B-I
regimen	I-I
.	I-I


After	O
that	O
,	O
additional	O
3	O
cycles	O
of	O
EP	B-I
consolidation	O
were	O
administered	O
.	O


Prophylactic	B-I
cranial	I-I
irradiation	I-I
(	I-I
PCI	I-I
)	I-I
was	O
administered	O
to	O
patients	O
with	O
a	O
complete	O
response	O
.	O


RESULTS	O
Thirty-seven	B-P
and	I-P
40	I-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
study	I-P
arm	I-P
and	I-P
control	I-P
arm	I-P
.	I-P


The	O
local	B-O
recurrence	I-O
rates	I-O
were	O
32.4	O
%	O
and	O
28.2	O
%	O
respectively	O
(	O
P	O
=	O
0.80	O
)	O
;	O
the	O
isolated	O
nodal	B-O
failure	I-O
(	I-O
INF	I-O
)	I-O
rates	O
were	O
3.0	O
%	O
and	O
2.6	O
%	O
respectively	O
(	O
P	O
=	O
0.91	O
)	O
;	O
all	O
INF	O
sites	O
were	O
in	O
the	O
ipsilateral	O
supraclavicular	O
fossa	O
.	O


Medastinal	B-O
N3	I-O
disease	I-O
was	O
the	O
risk	O
factor	O
for	O
INF	O
(	O
P	O
=	O
0.02	O
,	O
OR	O
=	O
14.13	O
,	O
95	O
%	O
CI	O
:	O
1.47-136.13	O
)	O
.	O


During	O
radiotherapy	O
,	O
grade	B-O
I	I-O
,	I-O
II	I-O
weight	I-O
loss	I-O
was	O
observed	O
in	O
29.4	O
%	O
,	O
5.9	O
%	O
and	O
56.4	O
%	O
,	O
7.7	O
%	O
patients	O
respectively	O
(	O
P	O
=	O
0.04	O
)	O
.	O


Grade	B-O
0-I	I-O
and	I-O
II-III	I-O
late	I-O
pulmonary	I-O
injury	I-O
was	O
developed	O
in	O
97.1	O
%	O
,	O
2.9	O
%	O
and	O
86.4	O
%	O
,	O
15.4	O
%	O
patients	O
respectively	O
(	O
P	O
=	O
0.07	O
)	O
.	O


Median	B-O
survival	I-O
time	I-O
was	O
22.1	O
months	O
and	O
26.9	O
months	O
respectively	O
.	O


The	O
1	B-O
to	I-O
3-year	I-O
OS	I-O
were	O
77.9	O
%	O
,	O
44.4	O
%	O
,	O
37.3	O
%	O
and	O
75.8	O
%	O
,	O
56.3	O
%	O
,	O
41.7	O
%	O
respectively	O
(	O
P	O
=	O
0.79	O
)	O
.	O


CONCLUSIONS	O
The	O
preliminary	O
results	O
of	O
this	O
study	O
indicate	O
that	O
irradiant	O
the	O
post-chemotherapy	O
tumor	O
extent	O
(	O
GTV-T	O
)	O
and	O
positive	O
nodal	O
drainage	O
area	O
did	O
not	O
decrease	O
local	O
control	O
and	O
overall	O
survival	O
while	O
radiation	O
toxicity	O
was	O
reduced	O
.	O


But	O
the	O
current	O
sample	O
size	O
has	O
not	O
met	O
designed	O
requirements	O
,	O
and	O
further	O
investigation	O
is	O
warranted	O
before	O
final	O
conclusions	O
could	O
be	O
drawn	O
.	O


Long	O
term	O
response	O
to	O
therapy	O
of	O
chronic	B-P
anti-HBe-positive	I-P
hepatitis	I-P
B	I-P
is	O
poor	O
independent	O
of	O
type	O
and	O
schedule	O
of	O
interferon	O
.	O


OBJECTIVE	O
The	O
response	B-O
rate	I-O
to	I-O
alpha	I-O
interferon	I-O
(	I-O
IFN	I-O
)	I-O
of	O
chronic	O
anti-HBe-positive	O
hepatitis	O
B	O
is	O
variable	O
.	O


We	O
studied	O
whether	O
type	O
,	O
dose	O
,	O
and	O
schedule	O
of	O
IFN	B-I
,	O
and	O
type	O
and	O
frequency	O
of	O
posttreatment	O
monitoring	O
,	O
influence	O
the	O
response	O
rate	O
.	O


METHODS	O
Seventy-two	B-P
consecutive	I-P
anti-HBe-positive	I-P
chronic	I-P
hepatitis	I-P
B	I-P
patients	I-P
(	I-P
59	I-P
male	I-P
and	I-P
13	I-P
female	I-P
,	I-P
median	I-P
age	I-P
41	I-P
yr	I-P
)	I-P
stratified	I-P
by	I-P
sex	I-P
and	I-P
histology	I-P
were	O
randomly	O
allocated	O
to	O
three	O
treatment	O
arms	O
.	O


Twenty-seven	O
patients	O
(	O
A	O
)	O
received	O
10	O
million	O
units	O
alpha-N1	B-I
IFN	I-I
i.m	I-I
.	I-I


t.w	O
.	O


for	O
24	O
wk	O
(	O
total	O
dose	O
:	O
720	O
million	O
units	O
)	O
;	O
21	O
(	O
B	O
)	O
received	O
9	O
million	O
units	O
alpha-2a	B-I
IFN	I-I
i.m	I-I
.	I-I


t.w	O
.	O


for	O
4	O
wk	O
,	O
followed	O
by	O
18	O
million	O
units	O
for	O
12	O
wk	O
and	O
9	O
million	O
units	O
for	O
8	O
wk	O
(	O
972	O
million	O
units	O
)	O
;	O
24	O
(	O
C	O
)	O
received	O
2	B-I
alpha-2a	I-I
IFN	I-I
courses	I-I
(	O
9	O
million	O
units	O
i.m	O
.	O


t.w	O
.	O


for	O
16	O
and	O
12	O
wk	O
separated	O
by	O
a	O
6-month	O
interval	O
[	O
756	O
million	O
units	O
]	O
)	O
.	O


Primary	O
response	O
was	O
defined	O
by	O
normal	B-O
ALT	I-O
and	I-O
serum	I-O
HBV-DNA	I-O
levels	I-O
below	O
10	O
pg/ml	O
at	O
the	O
end	O
of	O
therapy	O
and	O
sustained	O
response	O
by	O
normal	B-O
ALT	I-O
(	O
tested	O
monthly	O
)	O
,	O
undetectable	B-O
HBV-DNA	I-O
and	O
IgM	O
anti-HBc	O
(	O
<	O
7	O
I.U	O
.	O


Paul	O
Ehrlich	O
Institute	O
)	O
(	O
tested	O
every	O
3	O
months	O
)	O
during	O
the	O
posttreatment	O
follow-up	O
.	O


RESULTS	O
At	O
the	O
end	O
of	O
treatment	O
,	O
12	O
,	O
8	O
,	O
and	O
13	O
patients	O
from	O
groups	O
A	O
,	O
B	O
,	O
and	O
C	O
,	O
respectively	O
,	O
were	O
responders	O
.	O


At	O
the	O
18-month	O
follow-up	O
,	O
two	O
patients	O
in	O
group	O
A	O
and	O
only	O
one	O
in	O
groups	O
B	O
and	O
C	O
maintained	O
the	O
response	B-O
.	I-O


Overall	O
,	O
after	O
34	O
months	O
(	O
median	O
posttreatment	O
follow-up	O
)	O
,	O
three	O
patients	O
were	O
long	O
term	O
responders	O
,	O
whereas	O
three	O
showed	O
a	O
sustained	O
remission	B-O
after	O
relapse	O
.	O


CONCLUSIONS	O
The	O
rate	B-O
of	I-O
long	I-O
term	I-O
response	I-O
to	O
interferon	O
of	O
anti-HBe-positive	O
chronic	O
hepatitis	O
B	O
is	O
poor	O
,	O
independent	O
of	O
IFN	O
type	O
,	O
dose	O
,	O
or	O
schedule	O
;	O
the	O
more	O
stringent	O
the	O
monitoring	O
,	O
the	O
higher	O
the	O
relapse	O
rate	O
.	O


Effect	O
of	O
a	O
dental	O
cream	O
containing	O
amorphous	B-I
cream	I-I
phosphate	I-I
complexes	I-I
on	O
white	O
spot	O
lesion	O
regression	O
assessed	O
by	O
laser	O
fluorescence	O
.	O


PURPOSE	O
To	O
investigate	O
and	O
compare	O
the	O
effects	O
of	O
a	O
dental	O
cream	O
containing	O
complexes	O
of	O
casein	B-I
phosphoprotein-amorphous	I-I
calcium	I-I
phosphate	I-I
(	O
CPP-ACP	O
)	O
and	O
fluoride	B-I
mouthwashes	O
on	O
the	O
regression	O
of	O
white	B-P
spot	I-P
lesions	I-P
(	I-P
WSL	I-P
)	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
The	O
study	O
group	O
consisted	O
of	O
26	B-P
healthy	I-P
adolescents	I-P
(	I-P
mean	I-P
age	I-P
14.6	I-P
years	I-P
)	I-P
exhibiting	I-P
60	I-P
teeth	I-P
with	I-P
152	I-P
visible	I-P
WSL	I-P
sites	I-P
on	I-P
incisors	I-P
and	I-P
canines	I-P
immediately	I-P
after	I-P
debonding	I-P
of	I-P
fixed	I-P
orthodontic	I-P
appliances	I-P
.	I-P


After	O
bracket	B-I
removal	I-I
,	I-I
professional	I-I
tooth	I-I
cleaning	I-I
and	I-I
drying	I-I
,	I-I
a	I-I
visual	I-I
scoring	I-I
(	I-I
0-4	I-I
)	I-I
and	I-I
laser	I-I
fluorescence	I-I
(	I-I
LF	I-I
)	I-I
readings	I-I
were	O
carried	O
out	O
.	O


The	O
patients	O
were	O
randomly	O
assigned	O
to	O
two	O
different	O
treatment	O
protocols	O
with	O
the	O
aim	O
of	O
remineralising	O
the	O
lesions	O
:	O
A	O
)	O
daily	B-I
topical	I-I
applications	I-I
of	I-I
a	I-I
dental	I-I
cream	I-I
containing	I-I
CPP-ACP	I-I
(	I-I
Topacal	I-I
)	I-I
for	I-I
3	I-I
months	I-I
followed	I-I
by	I-I
a	I-I
3-month	I-I
period	I-I
of	I-I
daily	I-I
toothbrushing	I-I
with	I-I
fluoridated	I-I
dentifrice	I-I
,	I-I
or	I-I
B	I-I
)	I-I
daily	I-I
0.05	I-I
%	I-I
sodium	I-I
fluoride	I-I
mouthwash	I-I
combined	I-I
with	I-I
fluoridated	I-I
dentifrice	I-I
for	I-I
6	I-I
months	I-I
.	I-I


The	O
registrations	O
were	O
repeated	O
after	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
months	O
and	O
follow-up	O
data	O
were	O
compared	O
with	O
baseline	O
with	O
aid	O
of	O
chi-square	O
and	O
paired	O
t-tests	O
.	O


RESULTS	O
A	O
significant	O
improvement	O
of	O
the	O
clinical	B-O
WSL-scores	I-O
was	O
found	O
over	O
time	O
in	O
both	O
groups	O
,	O
but	O
there	O
was	O
a	O
statistically	O
significant	O
difference	O
(	O
p	O
<	O
0.01	O
)	O
concerning	O
the	O
number	B-O
of	I-O
sites	I-O
that	I-O
totally	I-O
disappeared	I-O
after	O
12	O
months	O
in	O
favour	O
of	O
the	O
CPP-ACP	O
regime	O
,	O
63	O
%	O
compared	O
with	O
25	O
%	O
respectively	O
.	O


The	O
clinical	O
registrations	O
were	O
mirrored	O
by	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
<	O
0.05	O
)	O
in	O
the	O
LF	B-O
readings	I-O
at	O
the	O
6-	O
and	O
12-month	O
follow-ups	O
compared	O
with	O
baseline	O
.	O


No	O
significant	O
differences	O
were	O
displayed	O
between	O
the	O
groups	O
.	O


CONCLUSIONS	O
Clinical	O
scoring	O
and	O
LF	O
assessment	O
suggested	O
that	O
both	O
regimens	O
could	O
promote	O
regression	O
of	O
WSL	O
after	O
debonding	O
of	O
fixed	O
orthodontic	O
appliances	O
.	O


The	O
visual	O
evaluation	O
suggested	O
an	O
aesthetically	O
more	O
favourable	O
outcome	O
of	O
the	O
amorphous	B-I
calcium	I-I
phosphate	I-I
treatments	I-I
.	O


Xuezhikang	B-I
,	O
an	O
extract	O
of	O
cholestin	O
,	O
decreases	O
plasma	O
inflammatory	O
markers	O
and	O
endothelin-1	O
,	O
improve	O
exercise-induced	O
ischemia	O
and	O
subjective	O
feelings	O
in	O
patients	B-P
with	I-P
cardiac	I-P
syndrome	I-P
X	I-P
.	I-P


Previous	O
studies	O
have	O
demonstrated	O
that	O
Xuezhikang	B-I
,	O
an	O
extract	O
of	O
cholestin	O
,	O
available	O
from	O
Chinese	O
red	O
yeast	O
rice	O
,	O
could	O
effectively	O
modify	O
lipid	O
profile	O
.	O


The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
whether	O
Xuezhikang	B-I
could	O
modify	O
endothelin-1	O
(	O
ET-1	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
high-sensitivity	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
and	O
exercise-induced	O
ischemia	O
in	O
patients	B-P
with	I-P
cardiac	I-P
syndrome	I-P
X	I-P
(	I-P
CSX	I-P
)	I-P
.	I-P


Thirty-six	B-P
patients	I-P
with	I-P
CSX	I-P
were	O
randomly	O
assigned	O
to	O
1200	O
mg/d	O
of	O
Xuezhikang	B-I
or	O
placebo	B-I
group	O
(	O
n=18	O
respectively	O
)	O
.	O


Blood	O
samples	O
were	O
drawn	O
at	O
day	O
0	O
and	O
day	O
90	O
for	O
measuring	O
above	O
parameters	O
.	O


The	O
treadmill	O
exercise	O
tests	O
and	O
subjective	O
feelings	O
were	O
also	O
assessed	O
at	O
day	O
0	O
and	O
day	O
90	O
.	O


The	O
data	O
showed	O
that	O
Xuezhikang	B-I
therapy	O
resulted	O
in	O
significant	O
reductions	O
in	O
total	B-O
cholesterol	I-O
(	I-O
TC	I-O
,	I-O
19	I-O
%	I-O
)	I-O
,	I-O
low-density	I-O
lipoprotein	I-O
cholesterol	I-O
(	I-O
LDL-C	I-O
)	I-O
(	I-O
26	I-O
%	I-O
)	I-O
,	I-O
and	I-O
triglycerides	I-O
(	I-O
TG	I-O
)	I-O
compared	O
with	O
baseline	O
(	O
16	O
%	O
,	O
p	O
<	O
0.01	O
respectively	O
)	O
.	O


The	O
data	O
also	O
showed	O
that	O
Xuezhikang	B-I
led	O
significantly	O
to	O
reductions	B-O
in	I-O
median	I-O
and	I-O
log-CRP	I-O
levels	I-O
(	I-O
38	I-O
%	I-O
and	I-O
44	I-O
%	I-O
,	I-O
p	I-O
<	I-O
0.01	I-O
respectively	I-O
)	I-O
,	I-O
IL-6	I-O
(	I-O
20	I-O
%	I-O
,	I-O
p	I-O
<	I-O
0.01	I-O
)	I-O
,	I-O
and	I-O
ET-1	I-O
(	I-O
47	I-O
%	I-O
,	I-O
p	I-O
<	I-O
0.01	I-O
)	I-O
compared	O
with	O
baseline	O
.	O


The	O
exercise	O
duration	O
,	O
and	O
time	B-O
to	I-O
1	I-O
mm	I-O
ST-segment	I-O
depression	I-O
was	O
significantly	O
prolonged	O
after	O
Xuezhikang	B-I
therapy	O
(	O
9	O
%	O
and	O
6	O
%	O
,	O
p	O
<	O
0.05	O
respectively	O
)	O
accompanied	O
by	O
improvement	B-O
of	I-O
subjective	I-O
feelings	I-O
.	I-O


Data	O
suggested	O
that	O
the	O
benefit	O
of	O
Xuezhikang	B-I
resulted	O
in	O
significant	O
modification	O
vascular	B-O
function	I-O
by	O
reduction	O
of	O
ET-1	B-O
,	I-O
inflammatory	I-O
markers	I-O
and	I-O
LDL	I-O
cholesterol	I-O
,	O
which	O
may	O
be	O
clinically	O
important	O
for	O
patients	B-P
with	I-P
CSX	I-P
.	I-P


Evaluating	O
the	O
impact	O
of	O
peer	B-I
,	I-I
nurse	I-I
case-managed	I-I
,	I-I
and	I-I
standard	I-I
HIV	I-I
risk-reduction	I-I
programs	I-I
on	O
psychosocial	B-O
and	I-O
health-promoting	I-O
behavioral	I-O
outcomes	I-O
among	O
homeless	B-P
women	I-P
.	I-P


Investigators	O
examined	O
the	O
6-month	O
impact	O
of	O
three	O
cognitive-behavioral	B-I
HIV	I-I
risk-reduction	I-I
programs	I-I
on	O
behavioral	B-O
factors	I-O
(	O
substance	O
use	O
and	O
sexual	O
risk	O
behaviors	O
)	O
and	O
cognitive	B-O
and	I-O
psychological	I-O
resources	I-O
of	O
325	B-P
women	I-P
who	I-P
resided	I-P
in	I-P
emergency	I-P
or	I-P
sober-living	I-P
shelters	I-P
and	I-P
their	I-P
308	I-P
intimate	I-P
sexual	I-P
partners	I-P
.	I-P


Participants	O
were	O
randomized	O
by	O
shelter	O
to	O
a	O
peer-mentored	B-O
,	I-O
a	I-O
nurse	I-O
case-managed	I-O
,	I-O
or	I-O
a	I-O
standard	I-O
care	I-O
HIV	I-O
risk-reduction	I-O
program	I-I
.	I-I


Significant	O
improvements	O
were	O
observed	O
in	O
all	O
groups	O
in	O
all	O
behavioral	B-O
factors	I-O
and	I-O
cognitive	I-O
and	I-O
psychological	I-O
resources	I-O
except	O
for	O
self-esteem	B-O
.	I-O


Participants	O
in	O
the	O
peer-mentored	B-I
and	I-I
nurse	I-I
case-managed	I-I
groups	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
standard	B-I
group	I-I
in	O
self-esteem	B-O
,	I-O
life	I-O
satisfaction	I-O
,	I-O
psychological	I-O
well-being	I-O
,	I-O
use	I-O
of	I-O
noninjection	I-O
drugs	I-O
,	I-O
sex	I-O
with	I-O
multiple	I-O
partners	I-O
,	I-O
and	I-O
unprotected	I-O
sex	I-O
at	O
6	O
months	O
(	O
n	O
=	O
633	O
)	O
.	O


It	O
was	O
concluded	O
that	O
a	O
standard	O
approach	O
by	O
health	O
care	O
professionals	O
appears	O
to	O
effectively	O
modify	B-O
HIV	I-O
risk	I-O
behaviors	I-O
for	O
a	O
majority	O
of	O
homeless	B-P
participants	I-P
and	O
may	O
have	O
important	O
economic	O
and	O
policy	O
implications	O
.	O


Further	O
,	O
the	O
impact	O
of	O
short-term	O
programs	O
that	O
address	O
psychological	O
vulnerabilities	O
of	O
impoverished	B-P
populations	I-P
needs	O
to	O
be	O
studied	O
further	O
.	O


Evaluation	B-O
of	O
the	O
pharmacodynamics	O
of	O
acetylsalicylic	O
acid	O
81	O
mg	O
with	O
or	O
without	O
esomeprazole	O
20	O
mg	O
in	O
healthy	B-P
volunteers	I-P
.	I-P


BACKGROUND	O
The	O
absence	O
of	O
a	O
pharmacokinetic	B-O
interaction	I-O
between	O
the	O
proton	O
pump	O
inhibitor	O
esomeprazole	O
(	O
40	O
mg	O
)	O
and	O
acetylsalicylic	O
acid	O
(	O
aspirin	O
,	O
ASA	O
;	O
325	O
mg	O
)	O
has	O
previously	O
been	O
established	O
.	O


OBJECTIVE	O
This	O
study	O
set	O
out	O
to	O
investigate	O
the	O
potential	O
for	O
pharmacodynamic	B-O
interaction	I-O
between	O
low-dose	O
ASA	O
and	O
esomeprazole	O
in	O
healthy	B-P
volunteers	I-P
,	O
by	O
measuring	O
ASA	O
antiplatelet	B-O
activity	I-O
.	I-O


STUDY	O
DESIGN	O
This	O
was	O
a	O
single-center	O
,	O
open-label	O
,	O
two-period	O
,	O
randomized	O
crossover	O
study	O
.	O


PARTICIPANTS	O
Healthy	B-P
male	I-P
and	I-P
female	I-P
volunteers	I-P
aged	I-P
18-75	I-P
years	I-P
were	I-P
included	I-P
.	I-P


All	B-I
volunteers	I-I
received	I-I
ASA	I-I
81	I-I
mg	I-I
once	I-I
daily	I-I
for	I-I
5	I-I
days	I-I
prior	I-I
to	I-I
the	I-I
study	I-I
(	I-I
pre-screen	I-I
)	I-I
.	I-I


Subjects	B-P
were	I-P
eligible	I-P
for	I-P
inclusion	I-P
if	I-P
they	I-P
had	I-P
aspirin	I-O
reactivity	I-O
units	I-O
(	I-O
ARU	I-O
,	I-O
as	I-O
measured	I-O
by	I-O
the	I-O
VerifyNow	I-O
ASA	I-O
assay	I-O
)	I-O
of	I-P
<	I-P
550	I-P
on	I-P
Day	I-P
6	I-P
.	I-P


INTERVENTION	O
After	B-I
pre-screening	I-I
and	I-I
a	I-I
washout	I-I
period	I-I
of	I-I
at	I-I
least	I-I
14	I-I
days	I-I
,	I-I
eligible	I-I
volunteers	I-I
received	I-I
ASA	I-I
81	I-I
mg	I-I
with	I-I
or	I-I
without	I-I
esomeprazole	I-I
20	I-I
mg	I-I
once	I-I
daily	I-I
for	I-I
5	I-I
days	I-I
in	I-I
randomized	I-I
order	I-I
,	I-I
with	I-I
a	I-I
14-day	I-I
washout	I-I
between	I-I
treatments	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURE	O
The	O
main	O
outcome	O
measure	O
was	O
the	O
antiplatelet	B-O
activity	I-O
of	I-O
ASA	I-O
,	I-O
as	I-O
assessed	I-O
by	I-O
ARU	I-O
ratio	I-O
relative	I-O
to	I-O
baseline	I-O
in	I-O
the	I-O
VerifyNow	I-O
ASA	I-O
assay	I-O
;	I-O
suppression	I-O
of	I-O
serum	I-O
thromboxane	I-O
B	I-O
(	I-O
2	I-O
)	I-O
(	I-O
TXB	I-O
(	I-O
2	I-O
)	I-O
)	I-O
was	O
a	O
secondary	O
endpoint	O
.	O


Statistical	O
comparisons	O
were	O
made	O
using	O
linear	O
mixed	O
models	O
.	O


RESULTS	O
A	B-P
total	I-P
of	I-P
29	I-P
volunteers	I-P
(	I-P
19	I-P
aged	I-P
≥50	I-P
years	I-P
;	I-P
8	I-P
women	I-P
;	I-P
21	I-P
men	I-P
)	I-P
were	I-P
evaluable	I-P
for	O
pharmacodynamic	O
analysis	O
(	O
per	O
protocol	O
)	O
.	O


All	O
volunteers	O
on	O
both	O
treatments	O
achieved	B-O
ARU	I-O
<	O
550	O
at	O
Day	O
6	O
.	O


The	O
geometric	O
mean	O
ratio	O
of	O
Day	O
6	O
to	O
Day	O
1	O
(	B-O
baseline	I-O
)	I-O
platelet	I-O
aggregation	I-O
was	O
0.70	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.68	O
,	O
0.72	O
)	O
with	O
ASA	O
alone	O
and	O
0.71	O
(	O
95	O
%	O
CI	O
0.69	O
,	O
0.74	O
)	O
with	O
ASA	O
+	O
esomeprazole	O
.	O


The	O
ratio	O
of	B-O
platelet	I-O
aggregation	I-O
(	O
ASA	O
+	O
esomeprazole/ASA	O
)	O
was	O
1.02	O
(	O
95	O
%	O
CI	O
0.99	O
,	O
1.05	O
)	O
.	O


ASA	O
administered	O
alone	O
or	O
with	O
esomeprazole	O
reduced	B-O
serum	I-O
TXB	I-O
(	I-O
2	I-O
)	I-O
by	O
more	O
than	O
99.5	O
%	O
.	O


The	O
ratio	O
of	O
suppression	O
of	B-O
serum	I-O
TXB	I-O
(	I-O
2	I-O
)	I-O
levels	I-O
(	O
ASA	O
+	O
esomeprazole/ASA	O
)	O
was	O
1.06	O
(	O
95	O
%	O
CI	O
0.88	O
,	O
1.29	O
)	O
.	O


The	O
combination	O
of	O
ASA	O
and	O
esomeprazole	O
was	O
well	B-O
tolerated	I-O
.	O


CONCLUSION	O
No	B-O
pharmacodynamic	I-O
interaction	I-O
between	O
low-dose	O
ASA	O
and	O
esomeprazole	O
was	O
found	O
with	O
regard	O
to	B-O
platelet	I-O
function	I-O
.	O


TRIAL	O
REGISTRATION	O
Registered	O
at	O
ClinicalTrials	O
.	O


gov	O
as	O
NCT01199328	O
.	O


Immunotherapy	B-I
using	O
BCG	B-I
during	O
remission	O
induction	O
and	O
as	O
the	O
sole	O
form	O
of	O
maintenance	O
in	O
acute	B-P
myeloid	I-P
leukaemia	I-P
.	I-P


Thirty-two	B-P
adults	I-P
with	I-P
acute	I-P
myeloid	I-P
leukaemia	I-P
(	I-P
AML	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
,	O
from	O
the	O
time	O
of	O
diagnosis	O
,	O
either	O
chemotherapy	B-I
alone	I-I
(	O
C	O
group	O
)	O
or	O
chemotherapy	B-I
plus	I-I
Bacille	I-I
Calmette-Guérin	I-I
vaccine	I-I
(	I-I
BCG	I-I
)	I-I
(	O
C+I	O
group	O
)	O
.	O


After	O
remission	O
induction	O
and	O
consolidation	O
,	O
chemotherapy	O
was	O
stopped	O
in	O
both	O
groups	O
but	O
BCG	O
was	O
continued	O
in	O
the	O
C+I	O
group	O
.	B-O


The	B-O
overall	I-O
survival	I-O
of	O
the	O
C+I	O
group	O
was	O
significantly	O
increased	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O


There	O
was	O
no	O
significant	B-O
increase	I-O
in	I-O
the	I-O
duration	I-O
of	I-O
first	I-O
remission	I-O
in	O
the	O
C+I	O
group	O
(	O
0.05	O
less	O
than	O
P	O
less	O
than	O
0.1	O
)	O
nor	O
in	O
the	O
time	O
from	O
first	B-O
relapse	I-O
to	I-O
death	I-O
(	O
0.05	O
less	O
than	O
P	O
less	O
than	O
0.1	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	B-O
incidence	I-O
of	I-O
first	I-O
or	I-O
second	I-O
remissions	I-O
,	O
and	O
the	B-O
time	I-O
taken	I-O
to	I-O
enter	I-O
remission	I-O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O


Comparison	O
with	O
the	O
results	O
of	O
other	O
trials	O
suggests	O
that	O
the	O
use	O
of	O
maintenance	O
chemotherapy	O
in	O
addition	O
to	O
immunotherapy	O
produces	O
longer	B-O
remissions	I-O
.	O


Five	O
patients	O
in	O
the	O
C	O
group	O
developed	B-O
leukaemic	I-O
central-nervous-system	I-O
(	I-O
CSN	I-O
)	I-O
involvement	I-O
,	O
in	O
comparison	O
with	O
none	O
in	O
the	O
C+I	O
group	O
.	O


CNS	O
relapse	O
did	O
not	O
produce	O
a	O
significant	O
decrease	O
in	B-O
remission	I-O
length	I-O
(	O
P	O
greater	O
than	O
0.1	O
)	O
but	O
reduction	O
in	B-O
survival	I-O
after	I-O
CNS	I-O
relapse	I-O
was	O
highly	O
significant	O
(	O
P	O
=	O
0.001	O
)	O
.	O


These	O
results	O
suggest	O
that	O
administration	O
of	B-I
BCG	I-I
from	O
an	O
early	O
stage	O
in	O
the	O
treatment	O
of	O
AML	O
may	B-O
protect	I-O
the	I-O
CNS	I-O
against	I-O
leukaemic	I-O
infiltration	I-O
and	O
therefore	O
serve	O
as	O
a	O
simple	O
,	O
innocuous	O
form	O
of	B-O
CNS	I-O
prophylaxis	I-O
.	O


A	O
randomized	O
trial	O
of	O
intranasal	O
beclomethasone	B-I
dipropionate	I-I
after	O
polypectomy	O
.	O


Beneficial	O
effects	O
of	O
intranasal	B-I
beclomethasone	I-I
dipropionate	I-I
(	I-I
Bdp	I-I
)	I-I
in	O
patients	B-P
with	I-P
nasal	I-P
polyposis	I-P
have	O
been	O
reported	O
earlier	O
.	O


This	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
whether	O
long-term	O
treatment	O
with	O
Bdp	B-I
after	O
polypectomy	O
could	O
prevent	O
formation	O
of	O
new	O
polyps	O
and	O
reduce	O
the	O
number	O
of	O
surgical	O
removals	O
.	O


Forty	B-P
consecutive	I-P
patients	I-P
without	I-P
laboratory	I-P
or	I-P
other	I-P
clinical	I-P
signs	I-P
of	I-P
allergy	I-P
but	I-P
with	I-P
severe	I-P
nasal	I-P
polyposis	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Twenty	B-P
patients	I-P
were	I-P
treated	I-P
with	I-P
intranasal	I-I
Bdp	I-I
and	I-P
twenty	I-P
patients	I-P
received	I-P
no	I-P
treatment	I-P
after	I-P
polypectomy	I-I
.	I-I


All	O
patients	B-P
were	I-P
followed	I-P
for	I-P
at	I-P
least	I-P
2.5	I-P
years	I-P
.	I-P


The	O
size	B-O
of	I-O
the	I-O
polyps	I-O
that	I-O
recurred	I-O
was	O
estimated	O
at	O
different	O
time-intervals	O
by	O
the	O
examining	O
doctor	O
.	O


After	O
six	O
months	O
there	O
was	O
already	O
a	O
significant	B-O
difference	I-O
in	O
favour	O
of	O
the	O
group	O
treated	O
with	O
intranasal	O
Bdp	B-I
.	I-I


Further	O
results	O
of	O
the	O
study	O
and	O
the	O
clinical	O
implications	O
are	O
discussed	O
.	O


Effects	O
of	O
telephone	B-I
call	I-I
interventions	I-I
on	O
patients	B-P
'	I-P
well-being	I-P
in	I-P
a	I-P
radiation	I-P
therapy	I-P
department	I-P
.	I-P


This	O
study	O
examined	O
the	O
effects	O
of	O
telephone	B-I
call	I-I
interventions	I-I
by	O
a	O
collaborative	O
team	O
on	O
patients	B-P
'	I-P
well-being	I-P
.	I-P


Fifty-five	B-P
subjects	I-P
undergoing	I-P
radiation	I-P
therapy	I-P
for	I-P
cure	I-P
and	I-P
who	I-P
were	I-P
able	I-P
to	I-P
communicate	I-P
by	I-P
telephone	I-P
comprised	I-P
the	I-P
sample	I-P
.	I-P


Subjects	O
were	O
randomly	O
assigned	O
to	O
a	O
control	B-I
group	I-I
,	I-I
who	I-I
received	I-I
the	I-I
usual	I-I
care	I-I
or	I-I
to	I-I
an	I-I
experimental	I-I
group	I-I
,	I-I
who	I-I
received	I-I
a	I-I
weekly	I-I
telephone	I-I
call	I-I
intervention	I-I
in	I-I
addition	I-I
to	I-I
the	I-I
usual	I-I
care	I-I
.	I-I


Speilberger	B-O
's	I-O
State	I-O
Trait	I-O
Inventory	I-O
,	I-O
the	I-O
Side	I-O
Effects	I-O
Profile	I-O
,	I-O
and	I-O
the	I-O
Coping	I-O
Strategies	I-O
Profile	I-O
were	O
used	O
along	O
with	O
a	O
telephone	O
survey	O
to	O
collect	O
data	O
.	O


Analysis	O
of	O
the	O
data	O
showed	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
anxiety	B-O
,	I-O
severity	I-O
of	I-O
side	I-O
effects	I-O
,	I-O
helpfulness	I-O
of	I-O
self-care	I-O
strategies	I-O
,	I-O
and	I-O
coping	I-O
strategies	I-O
.	I-O


However	O
,	O
the	O
survey	O
indicated	O
that	O
the	O
telephone	O
calls	O
were	O
clinically	B-O
significant	I-O
and	O
provided	O
a	O
mechanism	O
for	O
demonstrating	O
that	O
the	O
health	O
care	O
professionals	O
cared	O
about	O
their	O
patients	O
and	O
provided	O
an	O
opportunity	O
for	O
patients	O
to	O
talk	O
about	O
their	O
concerns	O
.	O


The	O
investigators	O
believe	O
that	O
collaboration	O
,	O
caring	O
,	O
and	O
communication	O
are	O
the	O
essence	O
of	O
exemplary	O
health	O
care	O
.	O


Comparing	O
two	O
web-based	B-P
smoking	I-O
cessation	I-O
programs	I-P
:	I-P
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
Smoking	B-O
cessation	I-O
remains	O
a	O
significant	O
public	O
health	O
problem	O
.	O


Innovative	O
interventions	O
that	O
use	O
the	O
Internet	O
have	O
begun	O
to	O
emerge	O
that	O
offer	O
great	O
promise	O
in	O
reaching	O
large	O
numbers	O
of	O
participants	O
and	O
encouraging	O
widespread	O
behavior	O
change	O
.	O


To	O
date	O
,	O
the	O
relatively	O
few	O
controlled	O
trials	O
of	O
Web-based	O
smoking	B-O
cessation	I-O
programs	O
have	O
been	O
limited	O
by	O
short	O
follow-up	O
intervals	O
.	O


OBJECTIVE	O
We	O
describe	O
the	O
6-month	O
follow-up	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
in	O
which	O
participants	B-P
recruited	I-P
online	I-P
were	O
randomly	B-I
assigned	I-I
to	I-I
either	I-I
a	I-I
Web-based	I-I
smoking	I-O
cessation	I-O
program	I-I
(	I-I
Quit	I-I
Smoking	I-I
Network	I-I
;	I-I
QSN	I-I
)	I-I
or	I-I
a	I-I
Web-based	I-I
exercise	I-I
enhancement	I-I
program	I-I
(	I-I
Active	I-I
Lives	I-I
)	I-I
adapted	I-I
somewhat	I-I
to	I-I
encourage	I-I
smoking	I-I
cessation	I-I
.	I-I


METHODS	O
The	O
study	O
was	O
a	O
two-arm	O
randomized	O
controlled	O
trial	O
that	O
compared	O
two	B-I
Web-based	I-I
smoking	I-O
cessation	I-O
programs	I-I
:	I-I
(	I-I
1	I-I
)	I-I
the	I-I
QSN	I-I
intervention	I-I
condition	I-I
presented	I-I
cognitive-behavioral	I-I
strategies	I-I
,	I-I
and	I-I
(	I-I
2	I-I
)	I-I
the	I-I
Active	I-I
Lives	I-I
control	I-I
condition	I-I
provided	I-I
participants	I-I
with	I-I
guidance	I-I
in	I-I
developing	I-I
a	I-I
physical	I-I
activity	I-I
program	I-I
to	I-I
assist	I-I
them	I-I
with	I-I
quitting	I-I
.	I-I


The	B-I
QSN	I-I
condition	I-I
provided	I-I
smoking	I-I
cessation	I-I
information	I-I
and	I-I
behavior	I-I
change	I-I
strategies	I-I
while	I-I
the	I-I
Active	I-I
Lives	I-I
condition	I-I
provided	I-I
participants	I-I
with	I-I
physical	I-I
activity	I-I
recommendations	I-I
and	I-I
goal	I-I
setting	I-I
.	I-I


The	B-I
QSN	I-I
condition	I-I
was	I-I
designed	I-I
to	I-I
be	I-I
more	I-I
engaging	I-I
(	I-I
eg	I-I
,	I-I
it	I-I
included	I-I
multimedia	I-I
components	I-I
)	I-I
and	I-I
to	I-I
present	I-I
much	I-I
greater	I-I
content	I-I
than	I-I
is	I-I
typically	I-I
found	I-I
in	I-I
smoking	I-I
cessation	I-I
programs	I-I
.	I-I


RESULTS	O
Contrary	O
to	O
our	O
hypotheses	O
,	O
no	O
between-condition	O
differences	O
in	O
smoking	B-O
abstinence	I-O
were	O
found	O
at	O
3-	O
and	O
6-month	O
follow-up	O
assessments	O
.	O


While	O
participants	O
in	O
the	O
QSN	O
intervention	O
condition	O
spent	O
more	O
time	O
than	O
controls	O
visiting	O
the	O
online	O
program	O
,	O
the	O
median	O
number	O
of	O
1.0	O
visit	O
in	O
each	O
condition	O
and	O
the	O
substantial	O
attrition	O
(	O
60.8	O
%	O
at	O
the	O
6-month	O
follow-up	O
)	O
indicate	O
that	O
participants	O
were	O
not	O
as	O
engaged	O
as	O
we	O
had	O
expected	O
.	O


CONCLUSIONS	O
Contrary	O
to	O
our	O
hypothesis	O
,	O
our	O
test	O
of	O
two	O
Web-based	O
smoking	B-O
cessation	I-O
conditions	O
,	O
an	O
intervention	O
and	O
an	O
attention	O
placebo	O
control	O
,	O
failed	O
to	O
show	O
differences	O
at	O
3-	O
and	O
6-month	O
assessments	O
.	O


We	O
explored	O
possible	O
reasons	O
for	O
this	O
finding	O
,	O
including	O
limited	O
engagement	O
of	O
participants	O
and	O
simplifying	O
program	O
content	O
and	O
architecture	O
.	O


Future	O
research	O
needs	O
to	O
address	O
methods	O
to	O
improve	O
participant	O
engagement	O
in	O
online	O
smoking	O
cessation	O
programs	O
.	O


Possible	O
approaches	O
in	O
this	O
regard	O
can	O
include	O
new	O
informed	O
consent	O
procedures	O
that	O
better	O
explain	O
the	O
roles	O
and	O
responsibilities	O
of	O
being	O
a	O
research	O
participant	O
,	O
new	O
program	O
designs	O
that	O
add	O
more	O
vitality	O
(	O
changing	O
content	O
from	O
visit	O
to	O
visit	O
)	O
,	O
and	O
new	O
types	O
of	O
reminders	O
pushed	O
out	O
to	O
participants	O
to	O
encourage	O
return	O
visits	O
.	O


Simplifying	O
program	O
content	O
through	O
a	O
combination	O
of	O
enhanced	O
tailoring	O
and	O
information	O
architecture	O
also	O
merits	O
further	O
research	O
attention	O
.	O


Stroke	O
team	O
remote	O
evaluation	O
using	O
a	O
digital	O
observation	O
camera	O
in	O
Arizona	B-P
:	I-P
the	O
initial	O
mayo	O
clinic	O
experience	O
trial	O
.	O


BACKGROUND	O
AND	O
PURPOSE	O
Telemedicine	O
techniques	O
can	O
be	O
used	O
to	O
address	O
the	O
rural-metropolitan	B-P
disparity	O
in	O
acute	O
stroke	O
care	O
.	O


The	O
Stroke	O
Team	O
Remote	O
Evaluation	O
Using	O
a	O
Digital	O
Observation	O
Camera	O
(	O
STRokE	O
DOC	O
)	O
trial	O
reported	O
more	O
accurate	O
decision	O
making	O
for	O
telemedicine	B-I
consultations	O
compared	O
with	O
telephone-only	B-I
and	O
that	O
the	O
California-based	O
research	O
network	O
facilitated	O
a	O
high	O
rate	O
of	O
thrombolysis	O
use	O
,	O
improved	O
data	O
collection	O
,	O
low	O
risk	O
of	O
complications	O
,	O
low	O
technical	O
complications	O
,	O
and	O
favorable	O
assessment	O
times	O
.	O


The	O
main	O
objective	O
of	O
the	O
STRokE	O
DOC	O
Arizona	O
TIME	O
(	O
The	O
Initial	O
Mayo	O
Clinic	O
Experience	O
)	O
trial	O
was	O
to	O
determine	O
the	O
feasibility	O
of	O
establishing	O
,	O
de	O
novo	O
,	O
a	O
single-hub	O
,	O
multirural	O
spoke	O
hospital	O
telestroke	O
research	O
network	O
across	O
a	O
large	O
geographical	O
area	O
in	O
Arizona	O
by	O
replicating	O
the	O
STRokE	O
DOC	O
protocol	O
.	O


METHODS	O
Methods	O
included	O
prospective	O
,	O
single-hub	O
,	O
2-spoke	O
,	O
randomized	O
,	O
blinded	O
,	O
controlled	O
trial	O
of	O
a	O
2-way	O
,	O
site-independent	O
,	O
audiovisual	B-I
telemedicine	I-I
system	I-I
designed	I-I
for	I-I
remote	I-I
examination	I-I
of	O
adult	B-P
patients	I-P
with	I-P
acute	I-P
stroke	I-P
versus	I-P
telephone	I-I
consultation	I-I
to	I-I
assess	I-I
eligibility	I-I
for	I-I
treatment	I-I
with	I-P
intravenous	I-I
thrombolysis	I-I
.	I-I


The	O
primary	O
outcome	O
measure	O
was	O
whether	O
the	O
decision	B-O
to	I-O
give	I-O
thrombolysis	I-O
was	I-O
correct	I-O
.	I-O


Secondary	O
outcomes	O
were	O
rate	B-O
of	I-O
thrombolytic	I-O
use	I-O
,	I-O
90-day	I-O
functional	I-O
outcomes	I-O
,	I-O
incidence	I-O
of	I-O
intracerebral	I-O
hemorrhages	I-O
,	I-O
and	I-O
technical	I-O
observations	I-O
.	I-O


RESULTS	O
From	B-P
December	I-P
2007	I-P
to	I-P
October	I-P
2008	I-P
,	I-P
54	I-P
patients	I-P
were	I-P
assessed	I-P
,	O
27	O
of	O
whom	O
were	O
randomized	O
to	O
each	O
arm	O
.	O


Mean	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
score	O
at	O
presentation	O
was	O
7.3	O
(	O
SD	O
6.2	O
)	O
points	O
.	O


No	O
consultations	O
were	O
aborted	O
;	O
however	O
,	O
technical	B-O
problems	I-O
(	O
74	O
%	O
)	O
were	O
prevalent	O
in	O
the	O
telemedicine	O
arm	O
.	O


Overall	O
,	O
the	O
correct	O
treatment	B-O
decision	I-O
was	O
established	O
in	O
87	O
%	O
of	O
the	O
consultations	O
.	O


Both	O
modalities	O
,	O
telephone	O
(	O
89	O
%	O
correct	O
)	O
and	O
telemedicine	O
(	O
85	O
%	O
correct	O
)	O
,	O
performed	O
well	O
.	O


Intravenous	O
thrombolytic	B-I
treatment	I-I
was	O
used	O
in	O
30	O
%	O
of	O
the	O
telemedicine	O
and	O
telephone	O
consultations	O
.	O


Good	O
functional	B-O
outcomes	I-O
at	O
90	O
days	O
were	O
not	O
significantly	O
different	O
.	O


There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
mortality	B-O
(	O
4	O
%	O
in	O
telemedicine	O
and	O
11	O
%	O
in	O
telephone	O
)	O
or	O
rates	B-O
of	I-O
intracerebral	I-O
hemorrhage	I-O
(	O
4	O
%	O
in	O
telemedicine	O
and	O
0	O
%	O
in	O
telephone	O
)	O
.	O


CONCLUSIONS	O
It	O
is	O
feasible	O
to	O
extend	O
the	O
original	O
STRokE	O
DOC	O
trial	O
protocol	O
to	O
a	O
new	O
state	O
and	O
establish	O
an	O
operational	O
single-hub	O
,	O
multispoke	O
rural	O
hospital	O
telestroke	O
research	O
network	O
in	O
Arizona	O
.	O


The	O
trial	O
was	O
not	O
designed	O
to	O
have	O
sufficient	O
power	O
to	O
detect	O
a	O
difference	O
between	O
the	O
2	O
consultative	O
modes	O
:	O
telemedicine	O
and	O
telephone-only	O
.	O


Whether	O
by	O
telemedicine	O
or	O
telephone	O
consultative	O
modalities	O
,	O
there	O
were	O
appropriate	O
treatment	B-O
decisions	I-O
,	O
high	O
rates	O
of	O
thrombolysis	B-O
use	I-O
,	O
improved	O
data	B-O
collection	I-O
,	O
low	O
rates	B-O
of	I-O
intracerebral	I-O
hemorrhage	I-O
,	O
and	O
equally	O
favorable	O
time	B-O
requirements	I-O
.	I-O


The	O
learning	O
curve	O
was	O
steep	O
for	O
the	O
hub	O
and	O
spoke	O
personnel	O
of	O
the	O
new	O
telestroke	O
network	O
,	O
as	O
reflected	O
by	O
frequent	O
technical	O
problems	O
.	O


Overall	O
,	O
the	O
results	O
support	O
the	O
effectiveness	O
of	O
highly	O
organized	O
and	O
structured	O
stroke	O
telemedicine	O
networks	O
for	O
extending	O
expert	O
stroke	O
care	O
into	O
rural	B-P
remote	I-P
communities	I-P
lacking	I-P
sufficient	I-P
neurological	I-P
expertise	I-P
.	I-P


Atrial	B-I
fibrillation	I-I
catheter	I-I
ablation	I-I
versus	I-I
surgical	I-I
ablation	I-I
treatment	I-I
(	I-I
FAST	I-I
)	I-I
:	I-I
a	O
2-center	O
randomized	O
clinical	O
trial	O
.	O


BACKGROUND	O
Catheter	B-I
ablation	I-I
(	I-I
CA	I-I
)	I-I
and	O
minimally	B-I
invasive	I-I
surgical	I-I
ablation	I-I
(	I-I
SA	I-I
)	I-I
have	O
become	O
accepted	O
therapy	O
for	O
antiarrhythmic	O
drug-refractory	O
atrial	O
fibrillation	O
.	O


This	O
study	O
describes	O
the	O
first	O
randomized	O
clinical	O
trial	O
comparing	O
their	O
efficacy	O
and	O
safety	O
during	O
a	O
12-month	O
follow-up	O
.	O


METHODS	O
AND	O
RESULTS	O
One	B-P
hundred	I-P
twenty-four	I-P
patients	I-P
with	I-P
antiarrhythmic	I-P
drug-refractory	I-P
atrial	I-P
fibrillation	I-P
with	I-P
left	I-P
atrial	I-P
dilatation	I-P
and	I-P
hypertension	I-P
(	I-P
42	I-P
patients	I-P
,	I-P
33	I-P
%	I-P
)	I-P
or	I-P
failed	I-P
prior	I-P
CA	I-I
(	I-P
82	I-P
patients	I-P
,	I-P
67	I-P
%	I-P
)	I-P
were	O
randomized	O
to	O
CA	B-I
(	O
63	O
patients	O
)	O
or	O
SA	B-I
(	O
61	O
patients	O
)	O
.	O


CA	B-I
consisted	O
of	O
linear	O
antral	O
pulmonary	O
vein	O
isolation	O
and	O
optional	O
additional	O
lines	O
.	O


SA	B-I
consisted	O
of	O
bipolar	O
radiofrequency	O
isolation	O
of	O
the	O
bilateral	O
pulmonary	O
vein	O
,	O
ganglionated	O
plexi	O
ablation	O
,	O
and	O
left	O
atrial	O
appendage	O
excision	O
with	O
optional	O
additional	O
lines	O
.	O


Follow-up	O
at	O
6	O
and	O
12	O
months	O
was	O
performed	O
by	O
ECG	O
and	O
7-day	O
Holter	O
recording	O
.	O


The	O
primary	O
end	O
point	O
,	O
freedom	O
from	O
left	O
atrial	O
arrhythmia	O
>	O
30	O
seconds	O
without	O
antiarrhythmic	B-I
drugs	I-I
after	O
12	O
months	O
,	O
was	O
36.5	O
%	O
for	O
CA	B-I
and	O
65.6	O
%	O
for	O
SA	B-I
(	O
P=0.0022	O
)	O
.	O


There	O
was	O
no	O
difference	O
in	O
effect	O
for	O
subgroups	O
,	O
which	O
was	O
consistent	O
at	O
both	O
sites	O
.	O


The	O
primary	O
safety	O
end	O
point	O
of	O
significant	O
adverse	O
events	O
during	O
the	O
12-month	O
follow-up	O
was	O
significantly	O
higher	O
for	O
SA	B-I
than	O
for	O
CA	B-I
(	O
n=21	O
[	O
34.4	O
%	O
]	O
versus	O
n=10	O
[	O
15.9	O
%	O
]	O
;	O
P=0.027	O
)	O
,	O
driven	O
mainly	O
by	O
procedural	O
complications	O
such	O
as	O
pneumothorax	O
,	O
major	O
bleeding	O
,	O
and	O
the	O
need	O
for	O
pacemaker	O
.	O


In	O
the	O
CA	B-I
group	O
,	O
1	O
patient	O
died	O
at	O
1	O
month	O
of	O
subarachnoid	O
hemorrhage	O
.	O


CONCLUSION	O
In	O
atrial	B-P
fibrillation	I-P
patients	I-P
with	I-P
dilated	I-P
left	I-P
atrium	I-P
and	I-P
hypertension	I-P
or	I-P
failed	I-P
prior	I-P
atrial	I-P
fibrillation	I-P
CA	I-I
,	I-I
SA	I-I
is	O
superior	O
to	O
CA	B-I
in	O
achieving	O
freedom	O
from	O
left	O
atrial	O
arrhythmias	O
after	O
12	O
months	O
of	O
follow-up	O
,	O
although	O
the	O
procedural	O
adverse	O
event	O
rate	O
is	O
significantly	O
higher	O
for	O
SA	B-I
than	O
for	O
CA	B-I
.	I-I


CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
:	O
http	O
:	O
//clinicaltrials.gov	O
.	O


Unique	O
identifier	O
:	O
NCT00662701	O
.	O


Psychiatric	B-I
treatment	I-I
of	O
eczema	B-P
:	I-P
a	O
controlled	O
trial	O
.	O


Seventy-two	B-P
patients	I-P
with	I-P
eczema	I-P
were	O
randomly	O
allotted	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
A	O
,	O
those	O
receiving	O
dermatological	B-I
treatment	I-I
only	I-I
,	O
and	O
B	O
,	O
those	O
receiving	O
the	O
same	B-I
dermatological	I-I
treatment	I-I
plus	I-I
psychiatric	I-I
treatment	I-I
,	O
limited	O
where	O
possible	O
to	O
four	O
months	O
.	O


Cases	O
were	O
followed	O
up	O
at	O
six-monthly	O
dermatological	O
assessments	O
,	O
57	O
(	O
79	O
%	O
)	O
for	O
18	O
months	O
.	O


The	O
findings	O
suggest	O
that	O
in	O
the	O
presence	B-O
of	I-O
overt	I-O
emotional	I-O
disturbance	I-O
,	O
of	O
new	B-O
psychological	I-O
or	I-O
psychophysiological	I-O
symptoms	I-O
preceding	I-O
the	I-O
rash	I-O
by	O
up	O
to	O
a	O
year	O
,	O
and	O
of	O
high	B-O
motivation	I-O
for	O
it	O
,	O
brief	O
psychiatric	B-I
treatment	I-I
improves	I-O
the	O
outcome	O
in	O
eczema	B-O
(	O
the	O
proportion	O
clear	O
at	O
18	O
months	O
was	O
about	O
doubled	O
)	O
,	O
whereas	O
in	O
their	O
absence	O
such	O
treatment	O
may	O
worsen	B-O
it	I-O
,	O
especially	O
in	O
the	O
short	O
term	O
.	O


Are	O
PRO	B-I
discharge	I-I
screens	I-I
associated	O
with	O
postdischarge	O
adverse	O
outcomes	O
?	O
OBJECTIVE	O
We	O
evaluate	O
whether	O
patient	O
outcomes	O
may	O
be	O
affected	O
by	O
possible	O
errors	O
in	O
care	O
at	O
discharge	O
as	O
assessed	O
by	O
Peer	O
Review	O
Organizations	O
(	O
PROs	O
)	O
.	O


DATA	O
SOURCES/STUDY	O
SETTING	O
The	B-P
three	I-P
data	I-P
sources	I-P
for	I-P
the	I-P
study	I-P
were	I-P
(	I-P
1	I-P
)	I-P
the	I-P
generic	I-I
screen	I-I
results	I-I
of	I-P
a	I-P
3	I-P
percent	I-P
random	I-P
sample	I-P
of	I-P
Medicare	I-P
beneficiaries	I-P
age	I-P
65	I-P
years	I-P
or	I-P
older	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
California	I-P
hospitals	I-P
between	I-P
1	I-P
July	I-P
1987	I-P
and	I-P
30	I-P
June	I-P
1988	I-P
(	I-P
n	I-P
=	I-P
20,136	I-P
patients	I-P
)	I-P
;	I-P
(	I-P
2	I-P
)	I-P
the	I-P
1987	I-P
and	I-P
1988	I-P
California	I-P
Medicare	I-P
Provided	I-P
Analysis	I-I
and	I-I
Review	I-I
(	I-I
MEDPAR	I-I
)	I-I
data	I-I
files	I-I
;	I-I
and	I-P
(	I-P
3	I-P
)	I-P
the	I-P
American	I-I
Hospital	I-I
Association	I-I
(	I-I
AHA	I-I
)	I-I
1988	I-I
Annual	I-I
Survey	I-I
of	I-I
Hospitals	I-I
.	I-I


STUDY	O
DESIGN	O
Multivariate	B-I
logistic	I-I
regression	I-I
analysis	I-I
was	O
used	O
to	O
evaluate	O
the	O
association	O
between	O
the	O
results	O
of	O
generic	O
discharge	O
administered	O
by	O
the	O
PROs	O
and	O
two	O
patient	O
outcomes	O
:	O
mortality	O
and	O
readmission	O
within	O
30	O
days	O
.	O


The	O
analysis	O
was	O
adjusted	O
for	O
other	O
patient	O
characteristics	O
recorded	O
on	O
the	O
uniform	O
discharge	O
abstract	O
.	O


PRINCIPAL	O
FINDINGS	O
Four	O
discharge	O
screens	O
indicated	O
an	O
increased	O
risk	B-O
of	I-O
an	I-O
adverse	I-O
outcome-absence	I-O
of	I-O
documentation	I-O
of	I-O
discharge	I-O
planning	I-O
,	I-O
elevated	I-O
temperature	I-O
,	I-O
abnormal	I-O
pulse	I-O
,	I-O
and	I-O
unaddressed	I-O
abnormal	I-O
test	I-O
results	I-O
at	O
discharge	O
.	O


The	O
other	O
three	O
discharge	O
screens	O
examined-abnormal	B-O
blood	I-O
pressure	I-O
,	I-O
IV	I-O
fluids	I-O
or	I-O
drugs	I-O
,	I-O
and	I-O
wound	I-O
drainage	I-O
before	O
discharge-were	O
unrelated	O
to	O
postdischarge	O
adverse	O
outcomes	O
.	O


CONCLUSIONS	O
Generic	B-I
discharge	I-I
screens	I-I
based	O
on	O
inadequate	O
discharge	O
planning	O
,	O
abnormal	B-O
pulse	I-O
,	I-O
increased	I-O
temperature	I-O
,	O
or	O
unaddressed	B-O
abnormal	I-O
tests	I-O
may	O
be	O
important	O
indicators	O
of	O
substandard	O
care	O
.	O


Other	O
discharge	O
screens	O
apparently	O
do	O
not	O
detect	O
errors	O
in	O
care	O
associated	O
with	O
major	O
consequences	O
for	O
patients	O
.	O


The	O
nightly	O
use	O
of	O
sodium	B-I
oxybate	I-I
is	O
associated	O
with	O
a	O
reduction	O
in	O
nocturnal	B-O
sleep	I-O
disruption	I-O
:	I-O
a	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
in	O
patients	B-P
with	I-P
narcolepsy	I-P
.	I-P


OBJECTIVE	O
To	O
further	O
explore	O
the	O
effects	O
of	O
sodium	B-I
oxybate	I-I
(	I-I
SXB	I-I
)	I-I
administration	O
on	O
nocturnal	B-O
sleep	I-O
in	O
narcolepsy	B-P
patients	I-P
during	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
study	O
conducted	O
with	O
228	B-P
adult	I-P
patients	I-P
with	I-P
narcolepsy/cataplexy	I-P
in	I-P
the	I-P
United	I-P
States	I-P
,	I-P
Canada	I-P
,	I-P
and	I-P
Europe	I-P
.	I-P


METHOD	O
Patients	O
were	O
withdrawn	B-I
from	I-I
antidepressants	I-I
and	I-I
sedative/hypnotics	I-I
,	O
and	O
then	O
randomized	O
to	O
receive	O
4.5	O
,	O
6	O
,	O
or	O
9	O
g	O
SXB	O
or	O
placebo	B-I
nightly	O
for	O
8	O
weeks	O
.	O


Patients	O
receiving	B-P
6	I-P
and	I-P
9	I-P
g/night	I-P
doses	I-P
were	O
titrated	O
to	O
their	O
final	O
dose	O
in	O
weekly	O
1.5	O
g	O
increments	O
,	O
while	O
patients	O
receiving	O
placebo	B-I
were	O
randomized	O
to	O
undergo	O
a	O
similar	O
mock	O
dose	O
titration	O
.	O


The	O
use	O
of	O
stimulant	O
therapy	O
continued	O
unchanged	O
.	O


Changes	B-O
in	I-O
sleep	I-O
architecture	I-O
were	I-O
measured	I-O
using	I-O
centrally	I-O
scored	I-O
nocturnal	I-O
polysomnograms	I-O
.	I-O


Daily	O
diaries	O
were	O
used	O
to	O
record	O
changes	B-O
in	I-O
narcolepsy	I-O
symptoms	I-O
and	I-O
adverse	I-O
events	I-O
.	I-O


RESULTS	O
Following	O
8	O
weeks	O
of	O
SXB	O
treatment	O
,	O
study	O
patients	O
demonstrated	O
significant	O
dose-related	O
increases	O
in	O
the	O
duration	B-O
of	I-O
stage	I-O
3	I-O
and	I-O
4	I-O
sleep	I-O
,	O
reaching	O
a	O
median	O
increase	O
of	O
52.5	O
minutes	O
in	O
patients	O
receiving	O
9	O
g	O
nightly	O
.	O


Compared	O
to	O
placebo-treated	O
patients	O
,	O
delta	B-O
power	I-O
was	O
significantly	O
increased	O
in	O
all	O
dose	O
groups	O
.	O


Stage	B-O
1	I-O
sleep	I-O
and	I-O
the	I-O
frequency	I-O
of	I-O
nocturnal	I-O
awakenings	I-O
were	O
each	O
significantly	O
decreased	O
at	O
the	O
6	O
and	O
9	O
g/night	O
doses	O
.	O


The	O
changes	B-O
in	I-O
nocturnal	I-O
sleep	I-O
coincided	O
with	O
significant	O
decreases	O
in	O
the	O
severity	B-O
and	I-O
frequency	I-O
of	I-O
narcolepsy	I-O
symptoms	I-O
.	I-O


CONCLUSIONS	O
The	O
nightly	O
administration	O
of	O
SXB	O
to	O
narcolepsy	O
patients	O
significantly	O
impacts	O
measures	O
of	O
slow	B-O
wave	I-O
sleep	I-O
,	I-O
wake	I-O
after	I-O
sleep	I-O
onset	I-O
,	I-O
awakenings	I-O
,	I-O
total	I-O
sleep	I-O
time	I-O
,	I-O
and	I-O
stage	I-O
1	I-O
sleep	I-O
in	O
a	O
dose-related	O
manner	O
.	O


The	O
frequency	B-O
and	I-O
severity	I-O
of	I-O
narcolepsy	I-O
symptoms	I-O
decreased	O
with	O
treatment	O
.	O


Effect	O
of	O
oral	O
diuretics	B-I
on	O
pulmonary	O
mechanics	O
in	O
infants	B-P
with	I-P
chronic	I-P
bronchopulmonary	I-P
dysplasia	I-P
:	I-P
results	O
of	O
a	O
double-blind	B-P
crossover	I-P
sequential	I-P
trial	I-P
.	I-P


In	O
a	O
randomized	O
double-blind	O
crossover	O
trial	O
with	O
sequential	O
analysis	O
,	O
the	O
effects	O
of	O
oral	O
diuretics	B-I
were	O
compared	O
with	O
the	O
effects	O
of	O
placebo	B-I
on	O
pulmonary	O
mechanics	O
in	O
ten	B-P
infants	I-P
with	I-P
bronchopulmonary	I-P
dysplasia	I-P
(	I-P
BPD	I-P
)	I-P
.	I-P


Pulmonary	O
mechanics	O
were	O
measured	O
before	O
and	O
at	O
the	O
end	O
of	O
a	O
week	O
of	O
treatment	O
with	O
oral	B-I
diuretics	I-I
(	I-I
chlorothiazide	I-I
,	I-I
20	I-I
mg/kg/dose	I-I
and	I-I
spironolactone	I-I
,	I-I
1.5	I-I
mg/kg/dose	I-I
)	I-I
given	I-I
twice	I-I
daily	I-I
,	I-I
or	I-I
placebo	I-I
.	I-I


Mean	B-O
airway	I-O
resistance	I-O
decreased	O
35.3	O
cm	O
H2O/L/s	O
,	O
mean	O
specific	B-O
airway	I-O
conductance	I-O
increased	O
0.095	O
1/L/s/cm	O
H2O	O
,	O
and	O
mean	B-O
dynamic	I-O
pulmonary	I-O
compliance	I-O
increased	O
1.74	O
mL/cm	O
H2O	O
during	O
treatment	O
with	O
diuretics	O
(	O
all	O
P	O
less	O
than	O
.001	O
)	O
,	O
but	O
not	O
during	O
treatment	O
with	O
placebo	O
.	O


The	O
infants	B-P
'	I-P
rate	I-P
of	I-P
weight	I-O
gain	I-O
decreased	O
on	O
the	O
first	O
three	O
days	O
of	O
diuretic	O
treatment	O
,	O
but	O
was	O
thereafter	O
comparable	O
with	O
weight	B-O
gain	I-O
during	O
treatment	O
with	O
placebo	B-I
.	I-I


Fluid	B-O
intake	I-O
was	O
similar	O
in	O
infants	B-P
receiving	O
diuretics	O
and	O
placebo	B-I
.	I-I


But	O
,	O
infants	B-P
receiving	O
diuretics	O
not	O
only	O
had	O
significantly	O
increased	O
urine	B-O
output	I-O
,	I-O
osmolal	I-O
clearance	I-O
,	I-O
and	I-O
potassium	I-O
and	I-O
phosphorus	I-O
excretion	I-O
,	O
but	O
these	O
infants	O
also	O
retained	B-O
less	I-O
fluid	I-O
,	O
and	O
,	O
in	O
addition	O
,	O
excreted	B-O
less	I-O
calcium	I-O
than	O
infants	O
receiving	O
placebo	O
.	O


It	O
is	O
concluded	O
that	O
oral	O
diuretics	B-I
improve	O
lung	B-O
function	I-O
in	O
infants	B-P
with	O
chronic	O
bronchopulmonary	O
dysplasia	O
;	O
however	O
,	O
potassium	O
and	O
phosphorus	O
depletion	O
are	O
potential	O
complications	O
of	O
treatment	O
.	O


Oxytocin	B-I
improves	O
behavioural	B-O
and	I-O
neural	I-O
deficits	I-O
in	O
inferring	O
others	O
'	O
social	O
emotions	O
in	O
autism	B-P
.	I-P


Recent	O
studies	O
have	O
suggested	O
oxytocin	B-I
's	I-I
therapeutic	O
effects	O
on	O
deficits	O
in	O
social	O
communication	O
and	O
interaction	O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
through	O
improvement	O
of	O
emotion	B-O
recognition	I-O
with	O
direct	O
emotional	O
cues	O
,	O
such	O
as	O
facial	O
expression	O
and	O
voice	O
prosody	O
.	O


Although	O
difficulty	O
in	O
understanding	O
of	O
others	O
'	O
social	O
emotions	O
and	O
beliefs	O
under	O
conditions	O
without	O
direct	O
emotional	O
cues	O
also	O
plays	O
an	O
important	O
role	O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
,	O
no	O
study	O
has	O
examined	O
the	O
potential	O
effect	O
of	O
oxytocin	B-I
on	O
this	O
difficulty	O
.	O


Here	O
,	O
we	O
sequentially	O
conducted	O
both	O
a	O
case-control	O
study	O
and	O
a	O
clinical	O
trial	O
to	O
investigate	O
the	O
potential	O
effects	O
of	O
oxytocin	B-I
on	O
this	O
difficulty	O
at	O
behavioural	O
and	O
neural	O
levels	O
measured	O
using	O
functional	O
magnetic	O
resonance	O
imaging	O
during	O
a	O
psychological	O
task	O
.	O


This	O
task	O
was	O
modified	O
from	O
the	O
Sally-Anne	O
Task	O
,	O
a	O
well-known	O
first-order	O
false	O
belief	O
task	O
.	O


The	O
task	O
was	O
optimized	O
for	O
investigation	O
of	O
the	O
abilities	O
to	O
infer	O
another	O
person	O
's	O
social	O
emotions	O
and	O
beliefs	O
distinctively	O
so	O
as	O
to	O
test	O
the	O
hypothesis	O
that	O
oxytocin	B-I
improves	O
deficit	O
in	O
inferring	O
others	O
'	O
social	O
emotions	O
rather	O
than	O
beliefs	O
,	O
under	O
conditions	O
without	O
direct	O
emotional	O
cues	O
.	O


In	O
the	O
case-control	O
study	O
,	O
17	B-P
males	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
showed	O
significant	O
behavioural	B-O
deficits	I-O
in	I-O
inferring	I-O
others	I-O
'	I-O
social	I-O
emotions	I-O
(	O
P	O
=	O
0.018	O
)	O
but	O
not	O
in	O
inferring	B-O
others	I-O
'	I-O
beliefs	I-O
(	O
P	O
=	O
0.064	O
)	O
compared	O
with	O
17	B-P
typically	I-P
developing	I-P
demographically-matched	I-P
male	I-P
participants	I-P
.	I-P


They	O
also	O
showed	O
significantly	O
less	O
activity	O
in	O
the	O
right	B-O
anterior	I-O
insula	I-O
and	O
posterior	B-O
superior	I-O
temporal	I-O
sulcus	I-O
during	O
inferring	O
others	O
'	O
social	O
emotions	O
,	O
and	O
in	O
the	O
dorsomedial	O
prefrontal	O
cortex	O
during	O
inferring	O
others	O
'	O
beliefs	O
compared	O
with	O
the	O
typically	O
developing	O
participants	O
(	O
P	O
<	O
0.001	O
and	O
cluster	O
size	O
>	O
10	O
voxels	O
)	O
.	O


Then	O
,	O
to	O
investigate	O
potential	O
effects	O
of	O
oxytocin	B-I
on	O
these	O
behavioural	O
and	O
neural	O
deficits	O
,	O
we	O
conducted	O
a	O
double-blind	O
placebo-controlled	B-I
crossover	O
within-subject	O
trial	O
for	O
single-dose	O
intranasal	O
administration	O
of	O
24	O
IU	O
oxytocin	B-I
in	O
an	O
independent	O
group	O
of	O
20	B-P
males	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


Behaviourally	B-O
,	I-O
oxytocin	I-O
significantly	O
increased	O
the	O
correct	B-O
rate	I-O
in	I-O
inferring	I-O
others	I-O
'	I-O
social	I-O
emotions	I-O
(	O
P	O
=	O
0.043	O
,	O
one-tail	O
)	O
.	O


At	O
the	O
neural	O
level	O
,	O
the	O
peptide	O
significantly	O
enhanced	O
the	O
originally-diminished	B-O
brain	I-O
activity	I-O
in	I-O
the	I-O
right	I-O
anterior	I-O
insula	I-O
during	O
inferring	O
others	O
'	O
social	O
emotions	O
(	O
P	O
=	O
0.004	O
)	O
,	O
but	O
not	O
in	O
the	O
dorsomedial	O
prefrontal	O
cortex	O
during	O
inferring	O
others	O
'	O
beliefs	O
(	O
P	O
=	O
0.858	O
)	O
.	O


The	O
present	O
findings	O
suggest	O
that	O
oxytocin	B-I
enhances	O
the	O
ability	B-O
to	I-O
understand	I-O
others	I-O
'	I-O
social	I-O
emotions	I-O
that	O
have	O
also	O
required	O
second-order	O
false	O
belief	O
rather	O
than	O
first-order	O
false	O
beliefs	O
under	O
conditions	O
without	O
direct	O
emotional	O
cues	O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
at	O
both	O
the	O
behaviour	O
and	O
neural	O
levels	O
.	O


Comparison	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
phonophoresis	B-I
and	O
iontophoresis	B-I
using	O
dexamethasone	B-I
sodium	I-I
phosphate	I-I
in	O
the	O
management	O
of	O
patients	B-P
with	I-P
knee	I-P
osteoarthritis	I-P
.	I-P


BACKGROUND	O
AND	O
OBJECTIVE	O
Many	O
treatment	O
options	O
,	O
including	O
non-pharmacological	O
and	O
pharmacological	O
measures	O
,	O
have	O
been	O
recommended	O
in	O
the	O
management	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
.	O


Among	O
the	O
non-pharmacological	O
approach	O
is	O
physiotherapy	O
,	O
which	O
involves	O
the	O
use	O
of	O
physical	O
modalities	O
like	O
,	O
heat	O
therapy	O
,	O
exercise	O
therapy	O
,	O
electrical	O
stimulation	O
,	O
therapeutic	O
ultrasound	O
,	O
iontophoresis	O
,	O
and	O
phonophoresis	O
.	O


This	O
study	O
was	O
therefore	O
designed	O
to	O
compare	O
the	O
effectiveness	O
of	O
0.4	O
%	O
Dexamethasone	B-I
sodium	I-I
phosphate	I-I
(	I-I
DEX-P	I-I
)	I-I
phonophoresis	I-I
(	I-I
PH	I-I
)	I-I
with	O
0.4	B-I
%	I-I
DEX-P	I-I
iontophoresis	I-I
(	I-I
ION	I-I
)	I-I
therapy	I-I
in	O
the	O
management	O
of	O
patients	B-P
with	I-P
knee	I-P
joint	I-P
OA	I-P
.	I-P


METHODS	O
Fifty	B-P
patients	I-P
(	I-P
19	I-P
males	I-P
and	I-P
31	I-P
females	I-P
)	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
53.6	I-P
+/-	I-P
8.9	I-P
years	I-P
were	O
randomly	O
assigned	O
to	O
PH	B-I
or	O
ION	B-I
groups	O
with	O
25	O
patients	O
in	O
each	O
group	O
.	O


Ultrasound	O
waves	O
of	O
1	O
MHz	O
frequency	O
was	O
applied	O
for	O
5	O
minutes	O
to	O
the	O
target	O
knee	O
,	O
so	O
also	O
was	O
the	O
direct	O
current	O
for	O
10	O
minutes	O
for	O
10	O
sessions	O
treatment	O
period	O
.	O


Western	B-O
Ontario	I-O
and	I-O
McMaster	I-O
University	I-O
Osteoarthritis	I-O
Index	I-O
(	I-O
WOMAC	I-O
)	I-O
scores	I-O
,	I-O
20	I-O
meters	I-O
ambulatory	I-O
time	I-O
,	O
and	O
knee	B-O
range	I-O
of	I-O
motion	I-O
(	I-O
ROM	I-O
)	I-O
were	O
evaluated	O
before	O
and	O
after	O
therapy	O
as	O
the	O
outcome	O
measures	O
.	O


RESULTS	O
At	O
the	O
end	O
of	O
two	O
weeks	O
,	O
significant	O
improvement	O
in	O
total	O
WOMAC	B-O
scores	I-O
was	O
observed	O
in	O
15	O
(	O
60	O
%	O
)	O
and	O
16	O
(	O
64	O
%	O
)	O
patients	O
in	O
the	O
PH	O
and	O
ION	O
groups	O
respectively	O
,	O
indicating	O
no	O
significant	O
difference	O
in	O
the	O
improvement	O
rate	O
.	O


Twenty	O
(	O
20	O
)	O
metres	O
ambulatory	B-O
time	I-O
and	I-O
knee	I-O
range	I-O
of	I-O
motion	I-O
also	O
improved	O
significantly	O
in	O
both	O
groups	O
,	O
yet	O
these	O
variables	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O


CONCLUSION	O
Both	O
therapeutic	O
modalities	O
were	O
found	O
to	O
be	O
effective	O
and	O
generally	O
well	O
tolerated	O
after	O
10	O
treatment	O
sessions	O
.	O


DEX-P	B-I
phonophoresis	I-I
was	O
not	O
superior	O
to	O
DEX-P	B-I
iontophoresis	I-I
in	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
OA	I-P
of	I-P
the	I-P
knee	I-P
.	I-P


Women	B-P
's	I-P
responses	I-P
to	I-P
information	I-P
on	I-P
mammographic	I-P
breast	I-P
density	I-P
.	I-P


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
negative	O
and	O
positive	O
outcomes	O
of	O
providing	O
mammographic	O
breast	O
density	O
(	O
MBD	O
)	O
information	O
to	O
participants	B-P
of	I-P
a	I-P
screening	I-I
program	I-I
.	I-I


A	O
randomized	O
experiment	O
was	O
conducted	O
with	O
a	O
sample	B-P
of	I-P
618	I-P
women	I-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
MBD	I-P
greater	I-P
than	I-P
50	I-P
%	I-P
of	I-P
breast	I-P
volume	I-P
.	I-P


The	O
intervention	O
consisted	O
of	O
reporting	B-I
the	I-I
presence	I-I
of	I-I
MBD	I-I
in	I-I
the	I-I
screening	I-I
mammography	I-I
results	I-I
letter	I-I
that	I-I
was	I-I
sent	I-I
along	I-I
with	I-I
an	I-I
information	I-I
pamphlet	I-I
.	I-I


Compared	O
to	O
the	O
controls	B-I
,	O
more	O
women	O
in	O
the	O
intervention	O
group	O
described	O
the	O
term	O
breast	B-O
density	I-O
correctly	O
and	O
recognized	O
it	O
as	O
a	O
risk	O
factor	O
for	O
breast	O
cancer	O
.	O


Although	O
at	O
the	O
4-week	O
follow-up	O
the	O
intervention	O
group	O
indicated	O
that	O
they	O
were	O
"	O
very	O
likely	O
"	O
to	O
have	O
an	O
annual	B-I
clinical	I-I
breast	I-I
examination	I-I
more	O
frequently	O
than	O
controls	O
,	O
no	O
differences	O
were	O
detected	O
at	O
6	O
months	O
.	O


There	O
were	O
no	O
significant	O
differences	O
on	O
other	O
behavioural	B-O
or	I-O
psychological	I-O
measures	I-O
,	O
although	O
at	O
the	O
4-week	O
follow-up	O
the	O
control	O
group	O
perceived	O
their	O
risk	O
for	O
breast	O
cancer	O
,	O
relative	O
to	O
other	O
women	O
their	O
age	O
,	O
as	O
"	O
a	O
lot	O
lower	O
"	O
than	O
did	O
women	O
in	O
the	O
intervention	O
group	O
.	O


The	O
results	O
demonstrate	O
a	O
feasible	O
and	O
non-threatening	O
way	O
to	O
provide	O
women	O
with	O
important	O
personalized	O
information	O
about	O
breast	B-O
cancer	I-O
risk	I-O
.	I-O


Project	B-P
Towards	I-P
No	I-P
Drug	I-P
Abuse	I-P
:	I-P
long-term	O
substance	O
use	O
outcomes	O
evaluation	O
.	O


OBJECTIVES	O
This	O
paper	O
presents	O
up	O
to	O
5	O
years	O
post-program	O
outcomes	O
of	O
Project	B-P
Towards	I-P
No	I-P
Drug	I-P
Abuse	I-P
(	I-P
Project	I-P
TND	I-P
)	I-P
,	I-P
a	I-P
drug	I-P
abuse	I-P
prevention	I-P
program	I-P
conducted	I-P
in	I-P
South	I-P
California	I-P
alternative	I-P
high	I-P
school	I-P
system	I-P
during	I-P
years	I-P
1994-1999	I-P
.	I-P


METHODS	O
The	O
effects	O
of	O
a	O
9-session	O
health	B-I
motivation	I-I
--	I-I
social	I-I
skills	I-I
--	I-I
decision-making	I-I
curriculum	O
were	O
evaluated	O
.	O


Twenty-one	B-P
schools	I-P
recruited	O
were	O
randomly	O
assigned	O
to	O
standard	B-I
care	I-I
(	I-I
control	I-I
)	I-I
,	I-I
classroom	I-I
only	I-I
,	O
or	O
a	O
classroom	B-I
plus	I-I
semester-long	I-I
school-as-community	I-I
component	I-I
.	I-I


Last	O
30-day	O
use	O
of	O
cigarettes	O
,	O
alcohol	O
,	O
marijuana	O
,	O
and	O
hard	O
drugs	O
were	O
assessed	O
at	O
three	O
time	O
intervals	O
:	O
short-term	O
(	O
year	O
1	O
)	O
,	O
middle-term	O
(	O
years	O
2	O
or	O
3	O
)	O
,	O
and	O
long-term	O
(	O
years	O
4	O
or	O
5	O
)	O
.	O


Multilevel	O
random	O
coefficients	O
modeling	O
were	O
employed	O
to	O
estimate	O
the	O
adjusted	O
levels	O
of	O
substance	O
use	O
.	O


RESULTS	O
Among	B-P
1578	I-P
baseline	I-P
subjects	I-P
,	I-P
follow-up	I-P
data	I-P
were	I-P
available	I-P
for	I-P
68	I-P
%	I-P
(	I-P
year	I-P
1	I-P
)	I-P
,	I-P
66	I-P
%	I-P
(	I-P
years	I-P
2	I-P
or	I-P
3	I-P
)	I-P
,	I-P
and	I-P
46	I-P
%	I-P
(	I-P
years	I-P
4	I-P
or	I-P
5	I-P
)	I-P
of	I-P
subjects	I-P
,	I-P
respectively	I-P
.	I-P


Results	O
revealed	O
significant	O
positive	O
long-term	O
program	O
effects	O
for	O
hard	O
drug	O
use	O
at	O
year	O
4	O
or	O
5	O
for	O
the	O
two	O
program	O
interventions	O
(	O
P	O
=	O
0.02	O
)	O
.	O


CONCLUSIONS	O
Project	O
TND	O
reduced	O
hard	O
drug	O
use	O
in	O
the	O
46	O
%	O
who	O
were	O
successfully	O
followed	O
.	O


It	O
is	O
the	O
first	O
program	O
to	O
demonstrate	O
long-term	O
self-reported	O
behavioral	O
effects	O
on	O
hard	O
drug	O
use	O
among	O
high-risk	B-P
youth	I-P
by	O
using	O
a	O
school-based	O
,	O
limited-session	O
model	O
.	O


Efficacy	B-O
and	O
safety	B-O
of	O
intraseptal	O
and	O
periodontal	O
ligament	O
anesthesia	O
achieved	O
by	O
computer-controlled	B-I
articaine	I-I
+	I-I
epinephrine	I-I
delivery	I-I
:	I-I
a	O
dose-finding	O
study	O
.	O


OBJECTIVES	O
The	O
main	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
dose-dependent	O
anesthetic	B-O
efficacy	I-O
of	O
the	O
intraseptal	B-I
anesthesia	I-I
(	I-I
ISA	I-I
)	I-I
and	O
periodontal	B-I
ligament	I-I
anesthesia	I-I
(	I-I
PLA	I-I
)	I-I
obtained	O
with	O
different	O
volumes	O
of	O
4	O
%	O
articaine	B-I
and	O
1:100,000	O
epinephrine	B-I
(	I-I
Ar	I-I
+	I-I
Ep	I-I
)	I-I
in	O
human	O
mandibular	O
premolars	O
,	O
using	O
a	O
computer-controlled	B-I
local	I-I
anesthetic	I-I
delivery	I-I
system	I-I
(	I-I
CCLADS	I-I
)	I-I
.	I-I


The	O
safety	B-O
profile	I-O
of	O
Ar	O
+	O
Ep	O
was	O
also	O
studied	O
by	O
investigating	O
the	O
stability	O
of	O
cardiovascular	O
parameters	O
.	O


MATERIAL	O
AND	O
METHODS	O
One	B-P
hundred	I-P
and	I-P
eighty	I-P
randomly	I-P
selected	I-P
healthy	I-P
volunteers	I-P
(	I-P
ASA	I-P
I	I-P
)	I-P
entered	O
the	O
single-blinded	O
study	O
to	O
receive	B-I
16	I-I
mg	I-I
+	I-I
4	I-I
μg	I-I
,	I-I
24	I-I
mg	I-I
+	I-I
6	I-I
μg	I-I
,	I-I
and	I-I
32	I-I
mg	I-I
+	I-I
8	I-I
μg	I-I
of	I-I
Ar	I-I
+	I-I
Ep	I-I
,	I-I
obtained	I-I
with	I-I
different	I-I
volumes	I-I
(	I-I
0.4	I-I
,	I-I
0.6	I-I
,	I-I
and	I-I
0.8	I-I
ml	I-I
,	I-I
respectively	I-I
)	I-I
,	I-I
for	I-I
the	I-I
ISA	I-I
and	I-I
PLA	I-O
.	I-O


Success	B-O
rate	I-O
,	I-O
onset	I-O
,	I-O
and	I-O
duration	I-O
of	I-O
profound	I-O
pulpal	I-O
anesthesia	I-O
were	I-I
evaluated	I-I
by	I-I
the	I-O
electrical	I-O
pulp	I-O
tester	I-O
,	I-I
while	I-I
the	I-O
width	I-O
of	I-O
the	I-O
anesthetic	I-O
field	I-O
and	I-O
duration	I-O
of	I-O
soft	I-O
tissue	I-O
anesthesia	I-O
were	I-I
recorded	I-I
using	I-I
the	I-O
pinprick	I-O
testing	I-O
.	I-O


A	B-O
monitor	I-O
was	O
used	O
for	O
the	O
measurement	O
of	B-O
cardiovascular	I-O
parameters	I-O
.	O


RESULTS	O
A	O
dose-dependent	B-O
duration	I-O
of	I-O
pulpal	I-O
and	I-O
soft	I-O
tissue	I-O
anesthesia	I-O
was	O
obtained	O
only	O
by	O
the	B-I
ISA	I-O
.	I-O


Success	B-O
rate	I-O
,	I-O
duration	I-O
of	I-O
both	I-O
pulpal	I-O
and	I-O
soft	I-O
tissue	I-O
anesthesia	I-O
,	I-O
and	I-O
its	I-O
width	I-O
were	O
significantly	O
better	O
in	O
the	O
ISA	O
compared	O
with	O
the	O
PLA	O
.	O


No	O
significant	B-O
cardiovascular	I-O
changes	I-O
were	O
seen	O
in	O
both	O
groups	O
.	O


CONCLUSIONS	O
It	O
can	O
be	O
suggested	O
that	O
0.6	O
and	O
0.8	O
ml	O
of	O
4	B-I
%	I-I
Ar	O
+	O
1:100,000	B-I
Ep	O
,	O
delivered	O
by	O
CCLADS	O
,	O
offer	O
high	B-O
success	I-O
rate	I-O
and	I-O
effective	I-O
clinical	I-O
parameters	I-O
of	O
ISA	O
as	O
a	O
primary	O
anesthesia	O
.	O


CLINICAL	O
RELEVANCE	O
It	O
seems	O
that	O
dental	O
procedures	O
requiring	O
profound	O
pulpal	O
,	O
bone	O
,	O
and	O
soft	O
tissue	O
anesthesia	O
could	O
be	B-O
effectively	I-O
and	I-O
safely	I-O
obtained	O
by	O
mentioned	O
anesthetic	O
protocol	O
.	O


The	O
KRAS-variant	O
and	O
miRNA	O
expression	O
in	O
RTOG	O
endometrial	B-P
cancer	I-P
clinical	O
trials	O
9708	O
and	O
9905	O
.	O


OBJECTIVE	O
To	O
explore	O
the	O
association	O
of	O
a	O
functional	O
germline	O
variant	O
in	O
the	O
3'-UTR	O
of	O
KRAS	O
with	O
endometrial	O
cancer	O
risk	O
,	O
as	O
well	O
as	O
the	O
association	O
of	O
microRNA	O
(	O
miRNA	O
)	O
signatures	O
and	O
the	O
KRAS-variant	O
with	O
clinical	O
characteristics	O
and	O
survival	O
outcomes	O
in	O
two	O
prospective	O
RTOG	O
endometrial	O
cancer	O
trials	O
.	O


METHODS/MATERIALS	O
The	O
association	O
of	O
the	O
KRAS-variant	O
with	O
endometrial	O
cancer	O
risk	O
was	O
evaluated	O
by	O
case-control	O
analysis	O
of	O
467	B-P
women	I-P
with	I-P
type	I-P
1	I-P
or	I-P
2	I-P
endometrial	I-P
cancer	I-P
and	I-P
582	I-P
age-matched	I-P
controls	I-P
.	I-P


miRNA	O
and	O
DNA	O
were	O
isolated	O
for	O
expression	O
profiling	O
and	O
genotyping	O
from	O
tumor	B-P
specimens	I-P
of	I-P
46	I-P
women	I-P
with	I-P
type	I-P
1	I-P
endometrial	I-P
cancer	I-P
enrolled	I-P
in	I-P
RTOG	I-P
trials	I-P
9708	I-P
and	I-P
9905.	I-P
miRNA	O
expression	O
levels	O
and	O
KRAS-variant	O
genotype	O
were	O
correlated	O
with	O
patient	O
and	O
tumor	O
characteristics	O
,	O
and	O
survival	O
outcomes	O
were	O
evaluated	O
by	O
variant	O
allele	O
type	O
.	O


RESULTS	O
The	O
KRAS-variant	O
was	O
not	O
significantly	O
associated	O
with	O
overall	B-O
endometrial	I-O
cancer	I-O
risk	I-O
(	O
14	O
%	O
controls	O
and	O
17	O
%	O
type	O
1	O
cancers	O
)	O
,	O
although	O
was	O
enriched	O
in	O
type	O
2	O
endometrial	O
cancers	O
(	O
24	O
%	O
,	O
p	O
=	O
0.2	O
)	O
.	O


In	O
the	O
combined	O
analysis	O
of	O
RTOG	O
9708/9905	B-O
,	I-O
miRNA	I-O
expression	I-O
differed	O
by	O
age	O
,	O
presence	O
of	O
lymphovascular	O
invasion	O
and	O
KRAS-variant	O
status	B-O
.	I-O


Overall	B-O
survival	I-O
rates	I-O
at	O
3	O
years	O
for	B-P
patients	I-P
with	I-P
the	I-P
variant	I-P
and	I-P
wild-type	I-P
alleles	I-P
were	O
100	O
%	O
and	O
77	O
%	O
(	O
HR	O
0.3	O
,	O
p	O
=	O
0.24	O
)	O
,	O
respectively	O
,	O
favoring	O
the	O
variant	O
.	O


CONCLUSIONS	O
The	O
KRAS-variant	O
may	O
be	O
a	O
genetic	O
marker	O
of	O
risk	O
for	O
type	O
2	O
endometrial	O
cancers	O
.	O


In	O
addition	O
,	O
tumor	O
miRNA	O
expression	O
appears	O
to	O
be	O
associated	O
with	O
patient	O
age	O
,	O
lymphovascular	O
invasion	O
and	O
the	O
KRAS-variant	O
,	O
supporting	O
the	O
hypothesis	O
that	O
altered	O
tumor	O
biology	O
can	O
be	O
measured	O
by	O
miRNA	O
expression	O
,	O
and	O
that	O
the	O
KRAS-variant	O
likely	O
impacts	O
endometrial	O
tumor	O
biology	O
.	O


Opioid-immune	O
interactions	O
in	O
autism	B-P
:	I-P
behavioural	O
and	O
immunological	O
assessment	O
during	O
a	O
double-blind	O
treatment	O
with	O
naltrexone	B-I
.	I-I


The	O
emerging	O
concept	O
of	O
opioid	O
peptides	O
as	O
a	O
new	O
class	O
of	O
chemical	O
messengers	O
of	O
the	O
neuroimmune	O
axis	O
and	O
the	O
presence	O
of	O
a	O
number	O
of	O
immunological	O
abnormalities	O
in	O
infantile	O
autism	O
prompted	O
us	O
to	O
correlate	O
biological	O
(	O
hormonal	O
and	O
immunological	O
)	O
determinations	O
and	O
behavioural	O
performances	O
during	O
treatment	O
with	O
the	O
potent	O
opiate	O
antagonist	O
,	O
naltrexone	B-I
(	I-I
NAL	I-I
)	I-I
.	I-I


Twelve	B-P
autistic	I-P
patients	I-P
ranging	I-P
from	I-P
7	I-P
to	I-P
15	I-P
years	I-P
,	I-P
diagnosed	I-P
according	I-P
to	I-P
DSM-III-R	I-P
,	O
entered	O
a	O
double-blind	B-I
crossover	I-I
study	I-I
with	I-I
NAL	I-I
at	I-I
the	I-I
doses	I-I
of	I-I
0.5	I-I
,	I-I
1.0	I-I
and	I-I
1.5	I-I
mg/kg	I-I
every	I-I
48	I-I
hours	I-I
.	I-I


The	B-I
behavioural	I-I
evaluation	I-I
was	I-I
conducted	I-I
using	I-I
the	I-I
specific	I-I
BSE	I-O
and	I-O
CARS	I-O
rating	I-O
scales	I-O
NAL	I-I
treatment	I-I
produced	I-I
a	I-I
significant	I-I
reduction	I-I
of	I-I
the	I-I
autistic	I-O
symptomatology	I-O
in	I-I
seven	I-I
(	I-I
"	I-I
responders	I-I
"	I-I
)	I-I
out	I-I
of	I-I
12	I-I
children	I-I
.	I-I


The	O
behavioural	O
improvement	O
was	O
accompanied	O
by	O
alterations	O
in	O
the	O
distribution	O
of	O
the	O
major	O
lymphocyte	O
subsets	O
,	O
with	O
a	O
significant	O
increase	O
of	O
the	O
T-helper-inducers	B-O
(	I-O
CD4+CD8-	I-O
)	I-O
and	O
a	O
significant	O
reduction	O
of	O
the	O
T-cytotoxic-suppressor	B-O
(	I-O
CD4-CD8+	I-O
)	I-O
resulting	O
in	O
a	O
normalization	O
of	O
the	O
CD4/CD8	B-O
ratio	I-O
.	I-O


Changes	O
in	O
natural	B-O
killer	I-O
cells	I-O
and	I-O
activity	I-O
were	O
inversely	O
related	O
to	O
plasma	O
beta-endorphin	O
levels	O
.	O


It	O
is	O
suggested	O
that	O
the	O
mechanisms	O
underlying	O
opioid-immune	O
interactions	O
are	O
altered	O
in	O
this	O
population	B-P
of	I-P
autistic	I-P
children	I-P
and	O
that	O
an	O
immunological	O
screening	O
may	O
have	O
prognostic	O
value	O
for	O
the	O
pharmacological	B-I
therapy	I-I
with	I-I
opiate	I-I
antagonists	I-I
.	I-I


Norfloxacin	B-I
modulates	I-P
the	I-P
inflammatory	I-P
response	I-P
and	I-P
directly	I-P
affects	I-P
neutrophils	I-P
in	I-P
patients	I-P
with	I-P
decompensated	I-P
cirrhosis	I-P
.	I-P


BACKGROUND	O
&	O
AIMS	O
Patients	B-P
with	I-P
cirrhosis	I-P
undergoing	I-P
selective	I-P
intestinal	I-P
decontamination	I-P
with	I-P
norfloxacin	I-I
show	O
a	O
reduction	O
in	O
serum	O
cytokine	O
levels	O
,	O
probably	O
because	O
of	O
a	O
combined	O
effect	O
of	O
norfloxacin	B-I
on	O
bowel	O
flora	O
and	O
neutrophils	O
.	O


METHODS	O
Thirty-one	B-P
patients	I-P
with	I-P
cirrhosis	I-P
receiving	I-P
norfloxacin	I-I
(	I-P
400	I-P
mg/day	I-P
)	I-P
were	I-P
included	I-P
.	I-P


Blood	O
samples	O
were	O
collected	O
at	O
0.5-4	O
hours	O
(	O
peak	O
samples	O
group	O
,	O
n	O
=	O
47	O
)	O
and	O
at	O
22-24	O
hours	O
(	O
trough	O
samples	O
group	O
,	O
n	O
=	O
84	O
)	O
after	O
dose	O
.	O


Fifty-nine	B-P
ascitic	I-P
fluid	I-P
samples	I-P
were	O
obtained	O
.	O


Single	O
doses	O
of	O
norfloxacin	B-I
and	I-I
trimethoprim/sulfamethoxazole	I-I
were	O
administered	O
to	O
13	O
and	O
5	O
patients	O
,	O
respectively	O
,	O
(	O
temporal	O
profile	O
group	O
)	O
and	O
samples	O
were	O
collected	O
at	O
0	O
,	O
0.5	O
,	O
1	O
,	O
1.5	O
,	O
2	O
,	O
4	O
,	O
and	O
24	O
hours	O
.	O


Norfloxacin	B-I
,	I-I
trimethoprim/sulfamethoxazole	I-I
,	I-I
cytokines	I-I
,	I-I
nitric	I-I
oxide	I-I
,	O
expression	O
levels	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
and	O
inhibitor	O
of	O
NF-kappaB	O
(	O
IkB-alpha	O
)	O
,	O
neutrophil	O
oxidative	O
burst	O
,	O
and	O
rate	O
of	O
apoptotic	O
events	O
were	O
determined	O
.	O


RESULTS	O
All	O
samples	O
were	O
bacterial	O
DNA	O
negative	O
and	O
had	O
no	O
significant	O
levels	O
of	O
lipopolysaccharide	O
.	O


Serum	B-O
and	I-O
ascitic	I-O
levels	I-O
of	I-O
tumor	I-O
necrosis	I-O
factor-alpha	I-O
,	I-O
interferon-gamma	I-O
,	I-O
interleukin-12	I-O
,	I-O
and	I-O
nitric	I-O
oxide	I-O
were	O
significantly	O
lower	O
in	O
peak	O
than	O
in	O
trough	O
samples	O
.	O


A	O
correlation	O
was	O
present	O
between	O
serum	B-O
norfloxacins	I-O
concentrations	I-O
and	I-O
tumor	I-O
necrosis	I-O
factor-alpha	I-O
(	O
r	O
=	O
-0.68	O
;	O
P	O
<	O
.001	O
)	O
,	O
interferon-gamma	B-O
(	O
r	O
=	O
-0.66	O
;	O
P	O
<	O
.001	O
)	O
,	O
interleukin-12	B-O
(	O
r	O
=	O
-0.66	O
;	O
P	O
<	O
.001	O
)	O
,	O
and	O
nitric	B-O
oxide	I-O
(	O
r	O
=	O
-0.68	O
;	O
P	O
<	O
.001	O
)	O
.	O


Serum	B-O
norfloxacin	I-O
's	I-O
highest	I-O
concentrations	I-O
(	O
1	O
+/-	O
0.5	O
microg/mL	O
)	O
were	O
achieved	O
at	O
1-2	O
hours	O
and	O
concurred	O
in	O
time	O
with	O
the	O
lower	O
levels	O
of	O
cytokines	B-O
and	I-O
nitric	I-O
oxide	I-O
.	I-O


Intracellular	B-O
norfloxacin	I-O
's	I-O
highest	I-O
levels	I-O
(	O
2	O
+/-	O
1	O
microg/mL/10	O
(	O
7	O
)	O
cells	O
)	O
were	O
observed	O
at	O
2	O
hours	O
and	O
concurred	O
with	O
a	O
lower	O
NF-kappaB	O
expression	O
,	O
a	O
reduced	O
anion	O
superoxide	O
generation	O
,	O
and	O
apoptotic	O
rate	O
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
.	O


Trimethoprim/sulfamethoxazole	B-I
did	O
not	O
significantly	O
modulate	O
cytokine	B-O
expression	I-O
.	I-O


CONCLUSIONS	O
Norfloxacin	B-I
but	O
not	O
trimethoprim/sulfamethoxazole	B-I
modulates	O
inflammatory	O
response	O
and	O
directly	O
affects	O
neutrophils	O
in	O
patients	B-P
with	I-P
cirrhosis	I-P
.	I-P


Relationship	O
between	O
baseline	O
blood	O
pressure	O
parameters	O
(	O
including	O
mean	O
pressure	O
,	O
pulse	O
pressure	O
,	O
and	O
variability	O
)	O
and	O
early	O
outcome	O
after	O
stroke	B-P
:	I-P
data	O
from	O
the	O
Tinzaparin	B-I
in	I-I
Acute	I-I
Ischaemic	I-I
Stroke	I-I
Trial	I-I
(	I-P
TAIST	I-P
)	I-P
.	I-P


BACKGROUND	O
AND	O
PURPOSE	O
High	B-P
blood	I-P
pressure	I-P
(	I-P
BP	I-P
)	I-P
in	I-P
acute	I-P
stroke	I-P
is	O
associated	O
independently	O
with	O
a	O
poor	O
outcome	O
.	O


Recent	O
evidence	O
suggests	O
that	O
other	O
hemodynamic	O
parameters	O
may	O
also	O
be	O
associated	O
with	O
outcomes	O
following	O
stroke	O
.	O


METHODS	O
The	O
relationship	O
between	O
baseline	O
BP	O
,	O
heart	O
rate	O
,	O
and	O
other	O
hemodynamic	O
parameters	O
,	O
and	O
early	O
outcomes	O
were	O
assessed	O
using	B-P
data	I-P
from	I-P
TAIST	I-P
trial	I-P
.	I-P


RESULTS	O
Death	B-O
or	I-O
neurological	I-O
deterioration	I-O
at	I-O
day	I-O
10	I-O
was	O
associated	O
,	O
both	O
in	O
unadjusted	O
and	O
adjusted	O
analyses	O
,	O
with	O
systolic	B-O
BP	I-O
(	O
adjusted	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
mean	B-O
arterial	I-O
pressure	I-O
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.04	O
)	O
,	O
pulse	B-O
pressure	I-O
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
and	O
BP	B-O
variability	I-O
(	O
OR	O
,	O
1.03	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.05	O
)	O
.	O


Similar	O
relationships	O
were	O
noted	O
for	O
deterioration	B-O
alone	I-O
,	I-O
and	I-O
recurrent	I-O
stroke	I-O
.	I-O


CONCLUSIONS	O
Early	O
death	B-O
or	O
neurologic	B-O
deterioration	I-O
,	I-O
deterioration	I-O
,	O
and	O
recurrent	B-O
stroke	I-O
are	O
associated	O
independently	O
with	O
high	B-O
systolic	I-O
BP	I-O
,	I-O
mean	I-O
arterial	I-O
pressure	I-O
,	I-O
pulse	I-O
pressure	I-O
,	I-O
and	I-O
BP	I-O
variability	I-O
.	I-O


These	O
measures	O
offer	O
potential	O
therapeutic	B-I
targets	I-I
for	O
improving	O
early	O
outcome	O
after	O
acute	B-P
ischemic	I-P
stroke	I-P
.	I-P


A	O
comparison	O
of	O
acupuncture	B-I
with	O
advice	B-I
and	I-I
exercises	I-I
on	O
the	O
symptomatic	B-O
treatment	I-O
of	O
osteoarthritis	B-P
of	I-P
the	I-P
hip	I-P
--	I-P
a	I-P
randomised	O
controlled	O
trial	O
.	O


Acupuncture	B-I
is	O
becoming	O
a	O
common	O
technique	O
within	O
the	O
physiotherapy	O
profession	O
as	O
a	O
treatment	O
modality	O
for	O
pain	B-O
relief	I-O
;	I-O
however	O
,	O
few	O
randomised	O
controlled	O
trials	O
have	O
been	O
undertaken	O
to	O
assess	O
the	O
effectiveness	O
of	O
acupuncture	B-I
,	O
particularly	O
in	O
the	O
treatment	O
of	O
osteoarthritis	B-P
(	I-P
OA	I-P
)	I-P
of	I-P
the	I-P
hip	I-P
.	I-P


Therefore	O
,	O
a	O
randomised	O
trial	O
to	O
compare	O
the	O
effectiveness	O
of	O
acupuncture	B-I
with	O
advice	O
and	O
exercises	B-I
on	O
the	O
symptomatic	O
treatment	O
of	O
OA	B-P
of	I-P
the	I-P
hip	I-P
was	O
carried	O
out	O
.	O


Thirty-two	B-P
patients	I-P
awaiting	I-P
a	I-P
total	I-P
hip	I-P
arthroplasty	I-P
were	O
randomly	O
allocated	O
to	O
either	O
the	O
experimental	O
group	O
,	O
(	O
A	O
)	O
,	O
to	O
have	O
six	B-I
sessions	I-I
of	I-I
acupuncture	I-I
each	O
lasting	O
up	O
to	O
25	O
minutes	O
,	O
or	O
the	O
control	O
group	O
,	O
(	O
B	O
)	O
,	O
to	O
be	O
given	O
advice	B-I
and	I-I
exercises	I-I
for	O
their	O
hip	O
over	O
a	O
six	O
week	O
period	O
.	O


Group	B-P
A	I-P
consisted	I-P
of	I-P
three	I-P
men	I-P
and	I-P
13	I-P
women	I-P
,	I-P
and	I-P
group	I-P
B	I-P
consisted	I-P
of	I-P
four	I-P
men	I-P
and	I-P
eight	I-P
women	I-P
.	I-P


The	O
average	B-P
age	I-P
in	I-P
group	I-P
A	I-P
was	I-P
66	I-P
years	I-P
and	I-P
in	I-P
group	I-P
B	I-P
it	I-P
was	I-P
68	I-P
years	I-P
.	I-P


Patients	O
were	O
assessed	O
for	O
pain	O
and	O
functional	O
ability	O
,	O
using	O
a	O
modified	O
version	O
of	O
the	O
WOMAC	B-O
questionnaire	I-O
,	O
pre-treatment	O
,	O
immediately	O
post-treatment	O
and	O
at	O
eight	O
weeks	O
post-treatment	O
.	O


The	O
pre-treatment	O
WOMAC	B-O
scores	I-O
in	O
the	O
two	O
groups	O
were	O
similar	O
(	O
p=0.85	O
)	O
.	O


There	O
was	O
a	O
significant	O
improvement	O
in	O
group	O
A	O
(	O
decrease	O
in	O
WOMAC	B-O
score	I-O
)	I-O
immediately	O
post-treatment	O
(	O
p=0.002	O
)	O
and	O
this	O
was	O
maintained	O
at	O
the	O
eight-week	O
follow-up	O
(	O
p=0.03	O
)	O
.	O


There	O
were	O
no	O
significant	O
changes	O
in	O
group	O
B	O
.	O


When	O
the	O
changes	O
in	O
WOMAC	B-O
scores	I-O
were	O
compared	O
between	O
groups	O
,	O
a	O
significantly	O
greater	O
improvement	O
was	O
found	O
between	O
pre-treatment	O
and	O
immediately	O
post-treatment	O
in	O
group	O
A	O
,	O
compared	O
with	O
group	O
B	O
(	O
p=0.02	O
)	O
.	O


The	O
changes	O
between	O
pre-treatment	O
and	O
the	O
eight-week	O
follow-up	O
also	O
showed	O
a	O
significant	O
improvement	O
in	O
group	O
A	O
compared	O
with	O
group	O
B	O
(	O
p=0.03	O
)	O
.	O


In	O
conclusion	O
,	O
this	O
trial	O
supports	O
the	O
hypothesis	O
that	O
acupuncture	B-I
is	O
more	O
effective	B-O
than	O
advice	O
and	O
exercises	O
in	O
the	O
symptomatic	O
treatment	O
of	O
OA	O
of	O
the	O
hip	O
.	O


[	O
Clinical	O
application	O
of	O
irradiated	O
drug-containing	B-I
porcine-cornea	I-I
to	O
patients	B-P
with	I-P
ocular	I-P
burns	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
explore	O
a	O
new	O
method	O
for	O
the	O
management	O
of	O
patients	B-P
with	I-P
ocular	I-P
burns	I-P
.	I-P


METHODS	O
Fifty-five	B-P
cases	I-P
of	I-P
patients	I-P
with	I-P
ocular	I-P
burns	I-P
(	I-P
in	I-P
88	I-P
eyes	I-P
)	I-P
were	O
randomly	O
divided	O
into	O
treatment	O
and	O
control	O
groups	O
.	O


Thirty	O
cases	O
in	O
treatment	O
group	O
with	O
49	B-P
eyes	I-P
were	I-P
transplanted	I-P
with	O
irradiated	B-I
drug-containing	I-I
(	I-I
ofloxacin	I-I
,	I-I
acetyl	I-I
cysteine	I-I
and	I-I
reduced	I-I
glutathione	I-I
)	I-I
porcine-cornea	I-I
.	I-I


25	O
cases	O
in	O
control	O
group	O
with	O
39	O
eyes	O
were	O
treated	O
with	O
routine	O
program	O
.	O


RESULTS	O
Thirty-two	O
eyes	B-O
were	I-O
rescued	I-O
in	O
treatment	O
group	O
with	O
the	O
cure	O
rate	O
of	O
65.3	O
%	O
.	O


But	O
only	O
17	O
eyes	B-O
were	I-O
saved	I-O
in	O
control	O
group	O
with	O
the	O
cure	O
rate	O
of	O
43.59	O
%	O
,	O
indicating	O
significant	O
difference	O
of	O
the	O
cure	B-O
rate	I-O
between	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
Irradiated	O
drug-containing	O
porcine-cornea	B-I
might	O
well	O
be	O
an	O
ideal	O
therapeutic	O
material	O
for	O
the	O
management	O
of	O
patients	B-P
with	I-P
ocular	I-P
burns	I-P
.	I-P


Randomized	O
comparative	O
study	O
of	O
group	B-I
versus	I-I
individual	I-I
cognitive	I-I
behavioural	I-I
therapy	I-I
for	O
obsessive	B-P
compulsive	I-P
disorder	I-P
.	I-P


OBJECTIVE	O
The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
group	B-I
and	I-I
individual	I-I
cognitive	I-I
behaviour	I-I
therapy	I-I
(	I-I
CBT	I-I
)	I-I
for	O
obsessive	B-P
compulsive	I-P
disorder	I-P
(	I-P
OCD	I-P
)	I-P
.	I-P


METHOD	O
One	B-P
hundred	I-P
and	I-P
ten	I-P
out-patients	I-P
with	I-P
OCD	I-P
were	O
randomly	O
assigned	O
to	O
15	O
sessions	O
of	O
either	O
group	B-I
CBT	I-I
or	I-I
individual	I-I
CBT	I-I
.	I-I


Outcome	O
measures	O
were	O
administered	O
before	O
and	O
after	O
treatment	O
,	O
as	O
well	O
as	O
at	O
6-	O
and	O
12-month	O
follow-ups	O
.	O


The	O
study	O
was	O
supplemented	O
by	O
a	O
meta-analysis	O
of	O
accomplished	O
comparative	O
studies	O
of	O
group	B-I
vs.	I-I
individual	I-I
CBT	I-I
for	O
OCD	O
.	O


RESULTS	O
Large	O
and	O
stable	O
pre-post	O
effect	B-O
sizes	I-O
were	O
found	O
for	O
both	O
treatment	O
conditions	O
in	O
the	O
study	O
(	O
d	O
=	O
1.06-1.24	O
on	O
the	O
Yale-Brown	B-O
Obsessive	I-O
Compulsive	I-O
Scale	I-O
)	I-O
.	O


There	O
were	O
no	O
significant	O
between-group	O
differences	O
in	O
outcome	O
at	O
any	O
data	O
point	O
(	O
ds=	O
-0.13	O
to	O
0.15	O
)	O
.	O


The	O
meta-analysis	O
of	O
four	O
accomplished	O
comparative	O
studies	O
(	O
including	O
the	O
present	O
one	O
)	O
found	O
a	O
between-group	O
mean	O
effect	O
size	O
of	O
(	O
d=	O
0.15	O
favouring	O
individual	O
over	O
group	O
CBT	B-I
at	O
posttreatment	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-0.12	O
,	O
0.42	O
)	O
.	O


CONCLUSION	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
OCD	O
can	O
be	O
treated	O
effectively	B-O
with	O
a	O
group	B-I
format	I-I
of	I-I
CBT	I-I
,	O
thus	O
sparing	O
some	O
therapist	O
resources	O
,	O
although	O
the	O
four	O
accomplished	O
comparative	O
studies	O
do	O
not	O
rule	O
out	O
the	O
possibility	O
of	O
a	O
small	O
superiority	O
of	O
individually	O
conducted	O
CBT	B-I
.	I-I


Late	O
patient-reported	O
toxicity	O
after	O
preoperative	O
radiotherapy	B-I
or	O
chemoradiotherapy	B-I
in	O
nonresectable	B-P
rectal	I-P
cancer	I-P
:	I-P
results	O
from	O
a	O
randomized	O
Phase	O
III	O
study	O
.	O


PURPOSE	O
Preoperative	B-I
chemoradiotherapy	I-I
(	O
CRT	O
)	O
is	O
superior	O
to	O
radiotherapy	B-I
(	O
RT	O
)	O
in	O
locally	B-P
advanced	I-P
rectal	I-P
cancer	I-P
,	O
but	O
the	O
survival	B-O
gain	I-O
is	O
limited	O
.	O


Late	O
toxicity	B-O
is	O
,	O
therefore	O
,	O
important	O
.	O


The	O
aim	O
was	O
to	O
compare	O
late	B-O
bowel	I-O
,	I-O
urinary	I-O
,	O
and	O
sexual	B-O
functions	I-O
after	O
CRT	O
or	O
RT	O
.	O


METHODS	O
AND	O
MATERIALS	O
Patients	B-P
(	I-P
N	I-P
=	I-P
207	I-P
)	I-P
with	I-P
nonresectable	I-P
rectal	I-P
cancer	I-P
were	I-P
randomized	I-P
to	I-P
preoperative	I-I
CRT	I-I
or	I-I
RT	I-I
(	I-P
2	I-P
Gy	I-P
×	I-P
25	I-P
±	I-P
5-fluorouracil/leucovorin	I-I
)	I-I
.	O


Extended	O
surgery	O
was	O
often	O
required	B-O
.	I-O


Self-reported	B-O
late	I-O
toxicity	I-O
was	O
scored	O
according	O
to	O
the	B-O
LENT	I-O
SOMA	I-O
criteria	I-O
in	O
a	B-O
structured	I-O
telephone	I-O
interview	I-O
and	O
with	B-O
questionnaires	I-O
European	I-O
Organisation	I-O
for	I-O
Research	I-O
and	I-O
Treatment	I-O
of	I-O
Cancer	I-O
(	I-O
EORTC	I-O
)	I-O
Quality	I-O
of	I-O
Life	I-O
Questionnaire	I-O
(	I-O
QLQ-C30	I-O
)	I-O
,	I-O
International	I-O
Index	I-O
of	I-O
Erectile	I-O
Function	I-O
(	I-O
IIEF	I-O
)	I-O
,	I-O
and	I-O
sexual	I-O
function-vaginal	I-O
changes	I-O
questionnaire	I-O
(	I-O
SVQ	I-O
)	I-O
.	O


RESULTS	O
Of	O
the	B-P
105	I-P
patients	I-P
alive	I-P
in	I-P
Norway	I-P
and	I-P
Sweden	I-P
after	I-P
4	I-P
to	I-P
12	I-P
years	I-P
of	I-P
follow-up	I-P
,	I-P
78	I-P
(	I-P
74	I-P
%	I-P
)	I-P
responded	O
.	O


More	O
patients	O
in	O
the	O
CRT	O
group	O
had	O
received	O
a	B-O
stoma	I-O
(	O
73	O
%	O
vs.	O
52	O
%	O
,	O
p	O
=	O
0.09	O
)	O
.	O


Most	O
patients	O
without	O
a	B-O
stoma	I-O
(	O
7	O
of	O
12	O
in	O
CRT	O
group	O
and	O
9	O
of	O
16	O
in	O
RT	O
group	O
)	O
had	O
incontinence	O
for	B-O
liquid	I-O
stools	I-O
or	I-O
gas	I-O
.	I-O


No	B-O
stoma	I-O
and	I-O
good	I-O
anal	I-O
function	I-O
were	O
seen	O
in	O
5	O
patients	O
(	O
11	O
%	O
)	O
in	O
the	O
CRT	O
group	O
and	O
in	O
11	O
(	O
30	O
%	O
)	O
in	O
the	O
RT	O
group	O
(	O
p	O
=	O
0.046	O
)	O
.	O


Of	B-P
44	I-P
patients	I-P
in	I-P
the	I-P
CRT	I-P
group	I-P
,	O
12	O
(	O
28	O
%	O
)	O
had	O
had	B-O
bowel	I-O
obstruction	I-O
compared	O
with	O
5	O
of	O
33	O
(	O
15	O
%	O
)	O
in	O
the	O
RT	O
group	O
(	O
p	O
=	O
0.27	O
)	O
.	O


One-quarter	O
of	O
the	O
patients	O
reported	B-O
urinary	I-O
incontinence	I-O
.	O


The	O
majority	O
of	O
men	O
had	B-O
severe	I-O
erectile	I-O
dysfunction	I-O
.	O


Few	O
women	O
reported	B-O
sexual	I-O
activity	I-O
during	O
the	O
previous	O
month	O
.	O


However	O
,	O
the	O
majority	O
did	O
not	O
have	O
concerns	O
about	O
their	O
sex	O
life	O
.	O


CONCLUSIONS	B-O
Fecal	I-O
incontinence	I-O
and	I-O
erectile	I-O
dysfunction	I-O
are	O
frequent	O
after	O
combined	O
treatment	O
for	B-P
locally	I-P
advanced	I-P
rectal	I-P
cancer	I-P
.	O


There	O
was	O
a	O
clear	O
tendency	O
for	O
the	O
problems	O
to	O
be	O
more	O
common	O
after	O
CRT	O
than	O
after	O
RT	O
.	O


New	B-I
mini-extracorporeal	I-I
circulation	I-I
system	I-I
(	I-I
ECC.O	I-I
)	I-I
is	O
a	O
safe	O
technique	O
in	O
coronary	O
surgery	O
.	O


OBJECTIVES	O
Cardiopulmonary	B-I
bypass	I-I
(	I-I
CPB	I-I
)	I-I
is	O
known	O
to	O
cause	O
the	O
systemic	O
inflammatory	O
reaction	O
after	O
cardiac	O
surgery	O
.	O


New	O
coated	O
and	O
closed	O
loop	O
circuit	O
systems	O
may	O
reduce	O
this	O
inflammation	B-O
response	I-O
and	I-O
improve	I-O
the	I-O
surgical	I-O
outcome	I-O
.	I-O


This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
mini-extracorporeal	B-I
circulation	I-I
system	I-I
(	I-I
ECC.O	I-I
)	I-I
in	O
CABG	B-P
patients	I-P
.	I-P


DESIGN	O
Forty	B-P
patients	I-P
undergoing	I-P
elective	I-P
coronary	I-P
surgery	I-P
were	O
randomized	O
into	O
two	O
groups	O
,	O
the	O
ECC.O	B-I
group	I-I
and	I-I
the	I-I
standard	I-I
CPB	I-I
group	I-I
.	I-I


Routine	O
hemodynamic	O
monitoring	O
and	O
biochemical	O
measurements	O
were	O
registered	O
according	O
to	O
the	O
hospital	O
practice	O
.	O


RESULTS	O
The	O
clinical	O
outcome	O
of	O
the	O
patients	O
was	O
similar	O
in	O
both	O
groups	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
the	O
duration	B-O
of	I-O
intubation	I-O
following	I-O
surgery	I-O
,	I-O
the	I-O
length	I-O
of	I-O
intensive	I-O
care	I-O
unit-stay	I-O
or	I-O
the	I-O
total	I-O
hospital	I-O
stay	I-O
.	I-O


The	O
haemoglobin	B-O
level	I-O
was	O
significantly	O
higher	O
(	O
p=0.0069	O
)	O
during	O
and	O
after	O
the	O
perfusion	O
in	O
the	O
ECC.O	B-I
group	O
.	O


CONCLUSIONS	O
The	O
ECC.O	B-I
system	O
can	O
be	O
safely	O
used	O
in	O
CABG	B-P
patients	I-P
and	O
it	O
maintains	O
haemoglobin	O
level	O
better	O
than	O
conventional	O
CPB	B-I
.	I-I


Disparities	O
in	O
transition	B-I
planning	I-I
for	O
youth	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


OBJECTIVE	O
Little	O
is	O
known	O
about	O
accessibility	O
to	O
health	B-I
care	I-I
transition	I-I
(	I-I
HCT	I-I
)	I-I
services	O
for	O
youth	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


This	O
study	O
expands	O
our	O
understanding	O
by	O
examining	O
the	O
receipt	O
of	O
HCT	O
services	O
in	O
youth	B-P
with	I-P
ASD	I-P
compared	I-P
with	I-P
youth	I-P
with	I-P
other	I-P
special	I-P
health	I-P
care	I-P
needs	I-P
(	I-P
OSHCN	I-P
)	I-P
.	I-P


METHODS	O
We	B-P
used	I-P
the	I-P
2005-2006	I-P
National	I-P
Survey	I-P
of	I-P
Children	I-P
with	I-P
Special	I-P
Health	I-P
Care	I-P
Needs	I-P
to	I-P
examine	I-P
receipt	I-P
of	I-P
HCT	I-I
services	I-I
for	I-P
youth	I-P
(	I-P
aged	I-P
12-17	I-P
years	I-P
)	I-P
with	I-P
ASD	I-P
and	I-P
youth	I-P
with	I-P
OSHCN	I-P
.	I-P


Logistic	O
regression	O
analyses	O
explored	O
whether	O
individual	O
,	O
family	O
,	O
or	O
health	O
system	O
factors	O
were	O
associated	O
with	O
receipt	O
of	O
HCT	O
services	O
for	O
youth	O
with	O
ASD	O
.	O


RESULTS	O
Whereas	O
half	O
of	O
youth	O
with	O
OSHCN	O
received	O
HCT	B-O
services	I-O
,	O
less	O
than	O
a	O
quarter	O
of	O
youth	O
with	O
ASD	O
did	O
.	O


Only	O
14	O
%	O
of	O
youth	O
with	O
ASD	O
had	O
a	O
discussion	O
with	O
their	O
pediatrician	O
about	O
transitioning	O
to	O
an	O
adult	O
provider	O
,	O
less	O
than	O
a	O
quarter	O
had	O
a	O
discussion	O
about	O
health	B-O
insurance	I-O
retention	I-O
,	O
and	O
just	O
under	O
half	O
discussed	O
adult	B-O
health	I-O
care	I-O
needs	I-O
or	I-O
were	I-O
encouraged	I-O
to	I-O
take	I-O
on	I-O
appropriate	I-O
responsibility	I-O
.	I-O


Logistic	O
regression	O
analyses	O
indicated	O
that	O
having	O
a	O
developmental	O
disability	O
or	O
multiple	O
health	O
conditions	O
in	O
addition	O
to	O
ASD	O
and	O
quality	O
of	O
health	O
care	O
were	O
strong	O
predictors	O
of	O
HCT	B-O
,	O
whereas	O
demographic	O
and	O
family	O
variables	O
accounted	O
for	O
little	O
variance	O
.	O


CONCLUSIONS	O
Youth	B-P
with	I-P
ASD	I-P
experience	O
disparities	O
in	O
access	O
to	O
HCT	B-I
services	O
.	O


Youth	B-P
with	I-P
comorbid	I-P
conditions	I-P
are	O
at	O
greatest	O
risk	O
for	O
poor	O
access	O
to	O
HCT	B-I
services	O
and	O
increased	O
quality	O
of	O
care	O
has	O
a	O
positive	O
effect	O
.	O


Research	O
is	O
needed	O
to	O
understand	O
barriers	O
to	O
care	O
and	O
develop	O
policy	O
and	O
practice	O
guidelines	O
tailored	O
for	O
youth	B-P
with	I-P
ASD	I-P
.	I-P


Hyperinsulinemia	O
fails	O
to	O
augment	O
ET-1	O
action	O
in	O
the	O
skeletal	O
muscle	O
vascular	O
bed	O
in	O
vivo	B-P
in	I-P
humans	I-P
.	I-P


Endogenous	O
endothelin	O
action	O
is	O
augmented	O
in	O
human	O
obesity	O
and	O
type	O
2	O
diabetes	O
and	O
contributes	O
to	O
endothelial	O
dysfunction	O
and	O
impairs	O
insulin-mediated	O
vasodilation	O
in	O
humans	B-P
.	I-P


We	O
hypothesized	O
that	O
insulin	O
resistance-associated	O
hyperinsulinemia	O
could	O
preferentially	O
drive	O
endothelin-mediated	B-O
vasoconstriction	I-O
.	I-O


We	O
applied	O
hyperinsulinemic-euglycemic	B-I
clamps	I-I
with	O
higher	B-P
insulin	I-I
dosing	I-P
in	I-P
obese	I-P
subjects	I-P
than	I-P
lean	I-P
subjects	I-P
(	I-P
30	I-P
vs.	I-P
10	I-P
mU.m	I-P
(	I-P
-2	I-P
)	I-P
.min	I-P
(	I-P
-1	I-P
)	I-P
,	I-P
respectively	I-P
)	I-P
,	O
with	O
the	O
goal	O
of	O
matching	O
insulin	O
's	O
nitric	O
oxide	O
(	O
NO	O
)	O
-mediated	O
vascular	O
effects	O
.	O


We	O
predicted	O
that	O
,	O
under	O
these	O
circumstances	O
,	O
insulin-stimulated	O
endothelin-1	O
(	O
ET-1	O
)	O
action	O
(	O
assessed	O
with	O
the	O
type	O
A	O
endothelin	O
receptor	O
antagonist	O
BQ-123	O
)	O
would	O
be	O
augmented	O
in	O
proportion	O
to	O
hyperinsulinemia	O
.	O


NO	B-O
bioactivity	I-O
was	O
assessed	O
using	O
the	O
nitric	O
oxide	O
synthase	O
inhibitor	O
N	O
(	O
G	O
)	O
-monomethyl-l-arginine	O
.	O


Insulin-mediated	B-O
vasodilation	I-O
and	I-O
insulin-stimulated	I-O
NO	I-O
bioavailability	I-O
were	O
well	O
matched	O
across	O
groups	O
by	O
this	O
approach	O
.	O


As	O
expected	O
,	O
steady-state	B-O
insulin	I-O
levels	I-O
were	O
approximately	O
threefold	O
higher	O
in	O
obese	O
than	O
lean	O
subjects	O
(	O
109.2	O
+/-	O
10.2	O
pmol/l	O
vs.	O
518.4	O
+/-	O
84.0	O
,	O
P	O
=	O
0.03	O
)	O
.	O


Despite	O
this	O
,	O
the	O
augmentation	O
of	O
insulin-mediated	B-O
vasodilation	I-O
by	O
BQ-123	O
was	O
not	O
different	O
between	O
groups	O
.	O


ET-1	B-O
flux	I-O
across	O
the	O
leg	O
was	O
not	O
augmented	O
by	O
insulin	O
alone	O
but	O
was	O
increased	O
with	O
the	O
addition	O
of	O
BQ-123	O
to	O
insulin	O
(	O
P	O
=	O
0.01	O
BQ-123	O
effect	O
,	O
P	O
=	O
not	O
significant	O
comparing	O
groups	O
)	O
.	O


Endothelin	O
antagonism	O
augmented	O
insulin-stimulated	B-O
NO	I-O
bioavailability	I-O
and	I-O
NOx	I-O
flux	I-O
,	O
but	O
not	O
differently	O
between	O
groups	O
and	O
not	O
proportional	O
to	O
hyperinsulinemia	O
.	O


These	O
findings	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
insulin	O
resistance-associated	O
hyperinsulinemia	O
preferentially	O
drives	O
endothelin-mediated	B-O
vasoconstriction	I-O
.	I-O


Aerobic	B-I
and	I-I
strength	I-I
training	I-I
reduces	O
adiposity	B-O
in	O
overweight	B-P
Latina	I-P
adolescents	I-P
.	I-P


PURPOSE	O
To	O
date	O
,	O
no	O
study	O
has	O
examined	O
the	O
synergistic	O
effects	O
of	O
a	O
nutrition	B-I
and	O
combination	B-I
of	I-I
aerobic	I-I
and	I-I
strength	I-I
training	I-I
(	I-I
CAST	I-I
)	I-I
on	O
both	O
adiposity	B-O
and	I-O
metabolic	I-O
parameters	I-O
in	O
overweight	B-P
Latina	I-P
adolescent	I-P
females	I-P
.	I-P


The	O
goal	O
was	O
to	O
assess	O
if	O
a	O
16-wk	O
nutrition	B-I
plus	O
CAST	B-I
pilot	O
study	O
had	O
stronger	O
effects	O
on	O
reducing	O
adiposity	B-O
and	O
on	O
improving	O
glucose/insulin	B-O
indices	I-O
compared	O
with	O
control	O
(	O
C	O
)	O
,	O
nutrition	B-I
only	I-I
(	O
N	O
)	O
,	O
and	O
a	O
nutrition	B-I
plus	O
strength	B-I
training	I-I
(	O
N	O
+	O
ST	O
)	O
groups	O
.	O


METHODS	O
In	O
a	O
16-wk	O
randomized	O
trial	O
,	O
41	B-P
overweight	I-P
Latina	I-P
girls	I-P
(	I-P
15.2	I-P
+/-	I-P
1.1	I-P
yr	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
C	B-I
(	O
n	O
=	O
7	O
)	O
,	O
N	B-I
(	O
n	O
=	O
10	O
)	O
,	O
N	B-I
+	I-I
ST	I-I
(	O
n	O
=	O
9	O
)	O
,	O
or	O
N	B-I
+	I-I
CAST	I-I
(	O
n	O
=	O
15	O
)	O
.	O


All	O
intervention	O
groups	O
received	O
modified	B-I
carbohydrate	I-I
nutrition	I-I
classes	I-I
(	O
once	O
a	O
week	O
)	O
,	O
whereas	O
the	O
N	B-I
+	I-I
ST	I-I
also	O
received	B-I
strength	I-I
training	I-I
(	O
twice	O
a	O
week	O
)	O
and	O
the	O
N	B-I
+	I-I
CAST	I-I
received	O
a	B-I
combination	I-I
of	I-I
strength	I-I
and	I-I
aerobic	I-I
training	I-I
(	O
twice	O
a	O
week	O
)	O
.	O


The	O
following	O
were	O
measured	O
before	O
and	O
after	O
intervention	O
:	O
strength	B-O
by	O
one	O
repetition	O
maximum	O
,	O
physical	B-O
activity	I-O
by	I-O
the	I-O
7-d	I-O
accelerometry	I-O
and	O
the	O
3-d	B-O
physical	I-O
activity	I-O
recall	I-O
,	I-O
dietary	I-O
intake	I-O
by	I-O
3-d	I-O
records	I-O
,	I-O
body	I-O
composition	I-O
by	O
dual-energy	O
x-ray	O
absorptiometry	O
(	O
DEXA	O
)	O
,	O
glucose/insulin	B-O
indices	I-O
by	O
oral	O
glucose	O
tolerance	O
test	O
,	O
and	O
intravenous	B-O
glucose	I-O
tolerance	I-O
test	I-O
with	O
minimal	O
modeling	O
.	O


Across	O
intervention	O
group	O
,	O
effects	O
were	O
tested	O
using	O
ANCOVA	O
with	O
post	O
hoc	O
pairwise	O
comparisons	O
.	O


RESULTS	O
There	O
were	O
significant	O
overall	O
intervention	O
effects	O
for	O
all	O
adiposity	B-O
measures	I-O
(	I-O
weight	I-O
,	I-O
body	I-O
mass	I-O
index	I-O
[	I-O
BMI	I-O
]	I-O
,	I-O
BMI	I-O
z-scores	I-O
,	I-O
and	I-O
DEXA	I-O
total	I-O
body	I-O
fat	I-O
)	I-O
,	O
with	O
a	O
decrease	O
of	O
3	O
%	O
in	O
the	O
N	B-I
+	I-I
CAST	I-I
group	O
compared	O
with	O
a	O
3	O
%	O
increase	O
in	O
the	O
N	B-I
+	I-I
ST	I-I
group	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
.	O


There	O
was	O
also	O
an	O
intervention	O
effect	O
for	O
fasting	B-O
glucose	I-O
with	O
the	O
N	B-I
group	O
increasing	O
by	O
3	O
%	O
and	O
the	O
N	B-I
+	I-I
CAST	I-I
group	O
decreasing	O
by	O
4	O
%	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
.	O


CONCLUSION	O
The	O
CAST	B-I
was	O
more	O
effective	O
than	O
nutrition	B-I
alone	O
or	O
nutrition	B-I
plus	O
strength	B-I
training	I-I
for	O
reducing	O
multiple	B-O
adiposity	I-O
outcomes	I-O
and	I-O
fasting	I-O
glucose	I-O
in	O
overweight	B-P
Latina	I-P
girls	I-P
.	I-P


However	O
,	O
further	O
research	O
investigating	O
and	O
identifying	O
intervention	O
approaches	O
that	O
improve	O
both	O
adiposity	B-O
and	I-O
insulin	I-O
indices	I-O
,	O
particularly	O
in	O
high-risk	O
populations	O
,	O
are	O
warranted	O
.	O


Mecamylamine	B-I
reduces	O
some	O
EEG	B-O
effects	I-O
of	O
nicotine	B-P
chewing	I-P
gum	I-P
in	I-P
humans	I-P
.	I-P


Spontaneous	B-O
EEG	I-O
was	O
recorded	O
in	O
nine	B-P
cigarette	I-P
smokers	I-P
who	I-P
had	I-P
been	I-P
abstinent	I-P
from	I-P
tobacco	I-P
for	I-P
12	I-P
hr	I-P
.	I-P


Subjects	O
were	O
treated	O
with	O
a	O
capsule	O
containing	O
either	O
centrally	B-I
acting	I-I
nicotine	I-I
blocker	I-I
,	I-I
mecamylamine	I-I
(	O
10	O
mg	O
)	O
,	O
or	B-I
placebo	I-I
.	I-I


At	O
each	O
of	O
three	O
60-min	O
intervals	O
after	O
the	O
capsule	O
was	O
ingested	O
,	O
the	O
subjects	O
chewed	O
two	O
pieces	O
of	O
gum	O
containing	O
a	O
total	O
of	O
0	O
,	O
4	O
or	O
8	O
mg	O
of	O
nicotine	O
.	O


Nicotine	B-I
and	I-I
mecamylamine	I-I
dose	O
combinations	O
were	O
randomized	O
across	O
subjects	O
.	O


Two	O
three-minute	O
periods	O
of	O
spontaneous	B-O
EEG	I-O
were	O
recorded	O
before	O
the	O
capsule	O
and	O
before	O
and	O
after	O
gum	O
chewing	O
from	O
bipolar	O
electrode	O
montages	O
at	O
the	O
following	O
positions	O
:	O
Cz-T5	O
,	O
Cz-T6	O
,	O
Cz-F7	O
and	O
Cz-F8	O
.	O


During	O
one	O
period	O
the	O
subjects	O
relaxed	O
with	O
eyes	O
closed	O
,	O
in	O
the	O
other	O
period	O
they	O
performed	O
a	O
math	O
task	O
with	O
eyes	O
open	O
.	O


When	O
the	O
drugs	O
were	O
given	O
individually	O
,	O
mecamylamine	B-I
decreased	O
beta	B-O
power	I-O
and	O
nicotine	O
gum	O
(	O
4	O
and	O
8	O
mg	O
)	O
increased	O
alpha	B-O
frequency	I-O
.	I-O


Mecamylamine	B-I
pretreatment	O
prevented	O
the	O
increase	O
in	O
alpha	B-O
frequency	I-O
caused	O
by	O
the	O
4	O
mg	O
gum	O
dose	O
but	O
not	O
the	O
8	O
mg	O
dose	O
.	O


Alpha	B-O
power	I-O
was	O
increased	O
by	O
the	O
8	O
mg	O
gum	O
dose	O
and	O
that	O
increase	O
was	O
prevented	O
by	O
mecamylamine	B-I
.	I-I


Self-reported	B-O
ratings	I-O
of	O
the	O
"	B-O
strength	I-O
"	I-O
of	O
the	O
gum	O
were	O
significantly	O
diminished	O
by	O
mecamylamine	O
pretreatment	O
.	O


The	O
data	O
are	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
studies	O
which	O
indicate	O
that	O
the	O
effects	O
of	O
tobacco	O
administration	O
and	O
withdrawal	O
are	O
mediated	O
by	O
central	O
actions	O
of	O
nicotine	O
.	O


Naltrexone	B-I
and	O
communication	O
skills	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
naltrexone	B-I
on	O
communication	O
skills	O
of	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


METHOD	O
Twenty-four	B-P
children	I-P
with	I-P
autism	I-P
,	I-P
3.0	I-P
to	I-P
8.3	I-P
years	I-P
old	I-P
(	I-P
mean	I-P
5.1	I-P
)	I-P
who	I-P
were	I-P
living	I-P
at	I-P
home	I-P
and	I-P
attending	I-P
appropriate	I-P
school	I-P
programs	I-P
,	O
participated	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
trial	O
.	O


Naltrexone	B-I
,	I-I
1.0	I-I
mg/kg	I-I
,	I-I
or	I-I
placebo	I-I
was	I-I
administered	I-I
daily	I-I
for	I-I
2	I-I
weeks	I-I
.	I-I


Communication	O
was	O
evaluated	O
from	O
videotaped	B-I
samples	I-I
of	I-I
seminaturalistic	I-I
parent-child	I-I
interaction	I-I
.	I-I


Child	O
and	O
parent	O
language	O
were	O
assessed	O
using	O
similar	O
measures	O
.	O


RESULTS	O
In	O
this	O
heterogeneous	O
sample	O
,	O
the	O
median	B-O
number	I-O
of	I-O
words	I-O
the	I-O
child	I-O
produced	I-O
on	O
placebo	O
was	O
9.5	O
(	O
range	O
0-124	O
)	O
.	O


The	O
median	B-O
proportion	I-O
of	I-O
utterances	I-O
with	I-O
echolalia	I-O
was	O
0.16	O
.	O


No	O
differences	O
were	O
found	O
between	O
the	O
naltrexone	B-I
and	O
placebo	B-I
conditions	O
in	O
any	O
of	O
the	O
measures	O
of	O
children	B-O
or	I-O
parents	I-O
'	I-O
communication	I-O
.	I-O


Significant	O
correlations	O
were	O
found	O
between	O
the	O
child	B-O
's	I-O
number	I-O
of	I-O
words	I-O
and	I-O
developmental	I-O
quotient	I-O
(	O
Spearman	O
rho	O
=	O
0.58	O
,	O
p	O
=	O
.003	O
)	O
and	O
between	O
the	O
child	O
's	O
and	O
parent	O
's	O
number	O
of	O
words	O
(	O
rho	O
=	O
0.55	O
,	O
p	O
=	O
.005	O
)	O
.	O


CONCLUSIONS	O
Previous	O
studies	O
showed	O
that	O
naltrexone	B-I
was	O
associated	O
with	O
modest	O
reduction	O
in	O
hyperactivity	O
and	O
restlessness	O
in	O
this	O
group	O
of	O
children	O
with	O
autism	O
.	O


In	O
this	O
short-term	O
study	O
,	O
the	O
medication	O
did	O
not	O
lead	O
to	O
improvement	O
in	O
communication	O
,	O
a	O
core	O
deficit	O
of	O
autism	O
.	O


Modest	O
antihypertensive	O
effect	O
of	O
epanolol	B-I
,	O
a	O
beta	O
1-selective	O
receptor	O
blocker	O
with	O
beta	O
1	O
agonist	O
activity	O
:	O
an	O
acute	O
and	O
long-term	O
hemodynamic	O
study	O
at	O
rest	O
and	O
during	O
exercise	O
and	O
double	O
crossover	O
comparison	O
with	O
atenolol	O
on	O
ambulatory	O
blood	O
pressure	O
.	O


Beta-blockers	O
with	O
less	O
cardiodepressive	O
effect	O
than	O
traditional	O
nonselective	O
beta	O
(	O
1+2	O
)	O
-blocking	O
agents	O
could	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
hypertension	O
,	O
provided	O
the	O
reduction	O
in	O
blood	O
pressure	O
was	O
satisfactory	O
.	O


Epanolol	B-I
,	O
a	O
selective	O
beta	O
1-receptor	O
blocker	O
with	O
intrinsic	O
sympathomimetic	O
activity	O
,	O
induced	O
a	O
fall	O
in	O
intraarterial	B-O
pressure	I-O
of	O
8	O
%	O
at	O
rest	O
sitting	O
and	O
11	O
%	O
during	O
100	O
W	O
bicycle	O
exercise	O
after	O
the	O
first	O
dose	O
of	O
200	O
mg	O
in	O
12	B-P
patients	I-P
with	I-P
essential	I-P
hypertension	I-P
.	I-P


Heart	B-O
rate	I-O
,	I-O
stroke	I-O
index	I-O
,	I-O
and	I-O
cardiac	I-O
index	I-O
initially	O
fell	O
by	O
14	O
%	O
,	O
11	O
%	O
,	O
and	O
23	O
%	O
,	O
respectively	O
.	O


The	O
total	B-O
peripheral	I-O
resistance	I-O
index	I-O
increased	O
by	O
21	O
%	O
after	O
2	O
hours	O
,	O
and	O
then	O
reverted	O
towards	O
the	O
pretreatment	O
level	O
.	O


After	O
10	O
months	O
of	O
epanolol	B-I
treatment	O
(	O
mean	O
300	O
mg/day	O
)	O
,	O
the	O
reduction	B-O
in	O
arterial	B-O
pressure	I-O
was	O
5	O
%	O
at	O
rest	O
and	O
10	O
%	O
during	O
exercise	O
.	O


Cardiac	B-O
index	I-O
and	I-O
heart	I-O
rate	I-O
were	O
still	O
reduced	O
14-21	O
%	O
,	O
while	O
total	B-O
peripheral	I-O
resistance	I-O
was	O
unchanged	O
or	O
slightly	O
increased	O
(	O
2-10	O
%	O
)	O
.	O


Twenty-four	B-O
hour	I-O
ambulatory	I-O
blood	I-O
pressure	I-O
was	O
higher	O
on	O
epanolol	B-I
(	O
300	O
mg/day	O
)	O
than	O
on	O
atenolol	B-I
(	O
150	O
mg/day	O
)	O
treatment	O
(	O
137/97	O
vs.	O
128/91	O
mmHg	O
)	O
.	O


Thus	O
,	O
the	O
achieved	B-O
blood	I-O
pressure	I-O
reduction	I-O
induced	O
by	O
epanolol	B-I
was	O
moderate	O
,	O
while	O
other	O
characteristics	O
of	O
beta-receptor	O
blockade	O
,	O
in	O
particular	O
,	O
the	O
reduction	B-O
of	I-O
heart	I-O
rate	I-O
and	I-O
cardiac	I-O
output	I-O
,	O
were	O
maintained	O
.	O


This	O
suggests	O
that	O
the	O
compound	O
may	O
be	O
useful	O
for	O
other	O
cardiovascular	B-P
disorders	I-P
,	O
e.g.	O
,	O
angina	B-P
pectoris	I-P
in	I-P
patients	I-P
without	I-P
hypertension	I-P
or	I-P
cardiac	I-P
arrhythmia	I-P
.	I-P


Controlled	O
prospective	O
trial	O
of	O
prednisolone	B-I
and	I-I
cytotoxics	I-I
in	O
progressive	B-P
IgA	I-P
nephropathy	I-P
.	I-P


In	O
a	O
single-center	O
,	O
multiple-referral	O
source	O
study	O
,	O
38	B-P
patients	I-P
with	I-P
progressive	I-P
IgA	I-P
nephropathy	I-P
and	I-P
controlled	I-P
hypertension	I-P
were	O
randomized	O
to	O
treatment	O
with	O
prednisolone	B-I
and	I-I
cytotoxic	I-I
agents	I-I
,	O
to	O
therapy	O
with	O
low-dose	B-I
cyclophosphamide	I-I
then	I-I
azathioprine	I-I
,	I-I
and	I-I
to	I-I
control	I-I
groups	I-I
.	I-I


The	O
follow-up	O
period	O
lasted	O
2	O
to	O
6	O
yr.	O
Renal	O
survival	O
,	O
as	O
assessed	O
by	O
Kaplan-Meier	O
analysis	O
annually	O
to	O
5	O
yr	O
,	O
showed	O
significant	O
preservation	O
of	O
function	O
from	O
3	O
yr	O
in	O
the	O
treatment	O
group	O
and	O
82	O
,	O
82	O
,	O
72	O
,	O
and	O
72	O
%	O
for	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
yr	O
,	O
respectively	O
,	O
compared	O
with	O
68	O
,	O
47	O
,	O
26	O
,	O
and	O
6	O
%	O
in	O
controls	O
.	O


Rate	O
of	O
loss	B-O
of	I-O
renal	I-O
function	I-O
,	O
evaluated	O
objectively	O
by	O
least-squares	B-O
analyses	I-O
of	I-O
reciprocal	I-O
serum	I-O
creatinine	I-O
,	O
was	O
reduced-and	O
in	O
one-third	O
of	O
the	O
patients	O
,	O
arrested-during	O
immunosuppressive	O
treatment	O
.	O


Proteinuria	B-O
,	I-P
present	I-P
in	I-P
all	I-P
patients	I-P
at	I-P
the	I-P
time	I-P
of	I-P
entry	I-P
into	I-P
the	I-P
trial	I-P
,	O
was	O
reduced	O
by	O
treatment	O
from	O
12	O
mo	O
,	O
compared	O
with	O
pretreatment	B-O
levels	I-O
or	I-O
controls	I-O
;	I-O
erythrocyturia	I-O
was	O
reduced	O
from	O
6	O
mo	O
.	O


Histologic	B-O
activity	I-O
and	I-O
chronicity	I-O
indexes	I-O
were	O
determined	O
in	O
renal	O
biopsies	O
performed	O
at	O
trial	O
entry	O
.	O


Multivariate	B-O
analysis	I-O
demonstrated	O
that	O
mesangial	B-O
cell	I-O
proliferation	I-O
and	I-O
matrix	I-O
scores	I-O
were	O
highest	O
in	O
those	O
patients	O
with	O
more	O
rapidly	O
progressive	O
disease	O
.	O


No	O
morphologic	B-O
variable	I-O
or	I-O
residual	I-O
renal	I-O
function	I-O
predicted	O
response	O
to	O
immunosuppressive	O
therapy	O
at	O
entry	O
.	O


Mean	B-O
arterial	I-O
pressures	I-O
did	O
not	O
differ	O
significantly	O
between	O
treatment	O
and	O
control	O
groups	O
.	O


There	O
was	O
thus	O
no	O
explanation	O
other	O
than	O
treatment	O
for	O
the	O
improved	O
outcome	O
in	O
patients	O
who	O
received	O
immunosuppressive	O
therapy	O
.	O


Morbidity	B-O
attributable	O
to	O
treatment	O
or	O
to	O
renal	B-O
failure	I-O
occurred	O
in	O
both	O
groups	O
;	O
an	O
audit	O
showed	O
that	O
benefits	B-O
of	I-O
therapy	I-O
outweighed	O
expected	O
or	O
minor	O
side	O
effects	O
of	O
drugs	O
in	O
this	O
population	O
at	O
risk	O
of	O
end-stage	O
renal	O
failure	O
.	O


Patients	B-P
selected	I-P
for	I-P
moderately	I-P
progressive	I-O
IgA	I-O
nephropathy	I-O
benefit	O
from	O
treatment	O
with	O
prednisolone	B-I
and	O
cytotoxic	B-I
agents	I-I
;	I-I
results	O
are	O
consistent	O
with	O
modulation	B-O
of	I-O
systemic	I-O
immune	I-O
response	I-O
or	I-O
nephritic	I-O
injury	I-O
,	O
thus	O
explaining	O
improved	O
outcome	O
,	O
and	O
indicate	O
that	O
this	O
therapy	O
has	O
an	O
acceptably	O
low	O
risk	O
of	O
side	B-O
effects	I-O
.	I-O


Treatment	O
of	O
sperm	O
with	O
platelet-activating	B-I
factor	I-I
does	O
not	O
improve	O
intrauterine	B-I
insemination	I-I
outcome	O
in	O
unselected	O
cases	O
of	O
mild	B-P
male	I-P
factor	I-P
infertility	I-P
:	I-P
a	O
prospective	O
double-blind	O
randomized	O
crossover	O
study	O
.	O


OBJECTIVES	O
To	O
evaluate	O
the	O
effect	B-O
of	O
sperm	O
treatment	O
with	O
exogenous	B-I
platelet-activating	I-I
factor	I-I
(	I-I
PAF	I-I
)	I-I
on	O
intrauterine	B-I
insemination	I-I
(	I-I
IUI	I-I
)	I-I
clinical	O
pregnancy	O
rate	O
in	O
cases	O
of	O
mild	B-P
male	I-P
factor	I-P
infertility	I-P
.	I-P


PAF	O
is	O
a	O
phospholipid	O
mediator	O
,	O
which	O
is	O
present	O
in	O
human	O
sperm	O
.	O


METHODS	O
The	B-P
study	I-P
was	I-P
performed	I-P
in	I-P
the	I-P
Assisted	I-P
Reproduction	I-P
Unit	I-P
of	I-P
the	I-P
2nd	I-P
Department	I-P
of	I-P
Obstetrics	I-P
and	I-P
Gynecology	I-P
,	I-P
University	I-P
of	I-P
Athens	I-P
,	I-P
Aretaieion	I-P
Hospital	I-P
,	I-P
Athens	I-P
,	I-P
Greece	I-P
,	I-P
and	I-P
included	I-P
92	I-P
couples	I-P
who	I-P
presented	I-P
with	I-P
mild	I-P
male	I-P
factor	I-P
infertility-all	I-P
candidates	I-P
for	I-P
IUI	I-P
.	I-P


A	O
maximum	O
of	O
4	O
IUI	B-I
cycles	O
per	O
couple	O
with	B-I
or	I-I
without	I-I
exogenous	I-I
PAF	I-I
treatment	I-I
were	O
performed	O
and	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
clinical	B-O
pregnancy	I-O
rate	I-O
(	O
pregnancies	O
confirmed	O
by	O
ultrasonography	O
per	O
100	O
cycles	O
)	O
.	O


RESULTS	O
The	O
overall	B-O
clinical	I-O
pregnancy	I-O
rate	I-O
after	O
a	O
maximum	O
of	O
4	O
IUI	B-I
cycles	O
was	O
comparable	O
in	O
cases	O
with	O
and	O
without	O
sperm	B-I
treatment	I-I
with	I-I
PAF	I-I
(	O
12.24	O
%	O
vs	O
11.11	O
%	O
)	O
.	O


Addition	O
or	O
exclusion	O
of	O
PAF	B-I
sperm	I-I
treatment	I-I
in	O
the	O
same	O
patients	O
did	B-O
not	I-O
significantly	I-O
alter	I-O
the	I-O
outcome	I-O
.	I-O


CONCLUSIONS	O
The	O
generalized	O
use	O
of	O
exogenous	B-I
PAF	I-I
for	O
the	O
preparation	O
of	O
sperm	O
in	O
unselected	O
cases	O
of	O
mild	B-P
male	I-P
infertility	I-P
does	O
not	O
improve	O
the	O
clinical	O
outcome	O
of	O
IUI	O
.	O


Effects	O
of	O
body	B-I
orientation	I-I
on	O
maximum	O
voluntary	O
arm	O
torques	O
.	O


INTRODUCTION	O
Increased	O
reliance	O
on	O
bulbospinal	B-I
motor	I-I
systems	I-I
has	O
been	O
implicated	O
in	O
individuals	B-P
with	I-P
chronic	I-P
stroke	I-P
during	O
maximum	O
voluntary	O
arm	O
joint	O
torque	O
generation	O
.	O


METHODS	O
Maximum	O
isometric	B-O
single-joint	I-O
and	I-O
multi-joint	I-O
arm	I-O
strength	I-O
was	O
observed	O
in	O
two	B-I
body	I-I
orientations	I-I
(	I-I
sitting	I-I
and	I-I
supine	I-I
)	I-I
while	O
maintaining	O
identical	O
head/neck/trunk/extremity	B-I
joint	I-I
configurations	I-I
in	O
order	O
to	O
identify	O
bulbospinal	B-P
contributions	I-P
to	I-P
maximum	I-P
joint	I-P
torque	I-P
generation	I-P
in	I-P
11	I-P
individuals	I-P
with	I-P
stroke	I-P
and	I-P
10	I-P
individuals	I-P
without	I-P
stroke	I-P
.	I-P


RESULTS	O
During	O
sitting	B-I
,	O
shoulder	B-O
flexion	I-O
was	O
greater	O
for	O
both	O
groups	O
,	O
whereas	O
shoulder	B-O
extension	I-O
and	I-O
elbow	I-O
flexion	I-O
,	O
part	O
of	O
the	O
"	O
flexion	O
synergy	O
,	O
"	O
were	O
greater	O
only	O
in	O
individuals	O
with	O
stroke	O
.	O


CONCLUSIONS	O
Body	B-I
orientation	I-I
influenced	O
isometric	B-O
arm	I-O
strength	I-O
,	O
notably	O
the	O
constituents	O
of	O
flexion	B-O
synergy	I-O
in	O
individuals	O
with	O
stroke	O
,	O
suggesting	O
bulbospinal	O
motor	O
pathway	O
involvement	O
.	O


From	O
a	O
practical	O
perspective	O
,	O
clinical	O
evaluation	O
of	O
single	B-O
joint	I-O
strength	I-O
in	O
the	O
supine	B-I
position	I-I
may	O
underestimate	O
strength	O
available	O
during	O
activities	O
of	O
daily	O
living	O
that	O
are	O
performed	O
in	O
an	O
upright	B-I
orientation	I-I
.	I-I


QT/QTc	O
study	O
conducted	O
in	O
Japanese	B-P
adult	I-P
healthy	I-P
subjects	I-P
:	I-P
a	O
novel	O
xanthine	O
oxidase	O
inhibitor	O
topiroxostat	B-I
was	O
not	O
associated	O
with	O
QT	O
prolongation	O
.	O


A	O
QT/QTc	O
study	O
was	O
conducted	O
in	O
compliance	O
with	O
ICH	O
E14	O
guideline	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
new	B-I
xanthine	I-I
oxidase	I-I
inhibitor	I-I
topiroxostat	I-I
in	O
Japanese	B-P
healthy	I-P
subjects	I-P
.	I-P


Forty-eight	B-P
Japanese	I-P
healthy	I-P
subjects	I-P
(	I-P
males	I-P
24	I-P
;	I-P
females	I-P
24	I-P
)	I-P
received	O
a	O
single	O
oral	B-I
dose	I-I
of	I-I
topiroxostat	I-I
(	O
60	O
or	O
180	B-I
mg	I-I
)	I-I
,	I-I
moxifloxacin	I-I
(	I-I
400	I-I
mg	I-I
)	I-I
or	I-I
placebo	I-I
in	I-P
a	I-P
single-center	I-P
,	O
double-blind	O
,	O
four-period	O
crossover	O
design	B-O
.	I-O


Fridericia	B-O
's	I-O
formula	I-O
(	I-O
QTcF	I-O
=	I-O
QT/RR	I-O
(	I-O
0.33	I-O
)	I-O
)	O
was	O
used	O
as	O
a	O
primary	O
method	B-O
for	I-O
QT-interval	I-O
correction	I-O
.	I-O


The	B-O
mean	I-O
QTcF	O
was	O
prolonged	B-I
by	I-I
moxifloxacin	I-I
,	O
of	O
which	O
largest	O
time-matched	O
difference	O
from	O
placebo	O
administration	O
was	O
13.6	O
milliseconds	O
with	O
90	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
11.2	O
and	O
15.9	O
milliseconds	O
at	O
4	O
hours	O
post-dose	B-O
.	I-O


The	O
mean	O
QTcF	O
was	O
hardly	O
affected	O
by	O
either	O
dose	O
of	O
topiroxostat	O
,	O
of	O
which	O
largest	O
time-matched	O
difference	O
from	O
placebo	O
administration	O
was	O
2.9	O
milliseconds	O
with	O
90	O
%	O
CI	O
of	O
0.6	O
and	O
5.3	O
milliseconds	O
at	O
4	O
hours	O
post-dose	O
for	O
60	O
mg	O
,	O
and	O
2.3	O
milliseconds	O
with	O
90	O
%	O
CI	O
of	O
0	O
and	O
4.7	O
milliseconds	O
at	O
1	O
hour	O
post-dose	O
for	O
180	O
mg	O
.	O


The	O
results	O
were	O
essentially	O
the	O
same	O
in	B-I
the	I-I
sex	I-I
subgroup	I-I
analysis	O
.	O


Moxifloxacin	O
can	O
be	O
used	O
as	O
a	O
positive	O
control	B-P
for	I-P
QT/QTc	I-P
studies	O
in	O
Japanese	O
subjects	O
;	O
and	O
topiroxostat	O
may	O
not	O
cause	O
QT-interval	O
prolongation	O
in	O
males	O
as	O
well	O
as	O
females	O
.	O


Liposome-encapsulated	B-I
doxorubicin	I-I
compared	O
with	O
conventional	B-I
doxorubicin	I-I
in	O
a	O
randomized	O
multicenter	O
trial	O
as	O
first-line	O
therapy	O
of	O
metastatic	B-P
breast	I-P
carcinoma	I-P
.	I-P


BACKGROUND	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
liposome-encapsulated	B-I
doxorubicin	I-I
,	I-I
TLC	I-I
D-99	I-I
(	I-I
Myocet	I-I
,	I-I
Elan	I-I
Pharmaceuticals	I-I
,	I-I
Princeton	I-I
,	I-I
NJ	I-I
)	I-I
,	O
and	O
conventional	B-I
doxorubicin	I-I
in	O
first-line	O
treatment	O
of	O
metastatic	O
breast	O
carcinoma	O
(	O
MBC	O
)	O
.	O


METHODS	O
Two	B-P
hundred	I-P
twenty-four	I-P
patients	I-P
with	I-P
MBC	I-P
and	I-P
no	I-P
prior	I-P
therapy	I-P
for	I-P
metastatic	I-P
disease	I-P
were	O
randomized	O
to	O
receive	O
either	O
TLC	B-I
D-99	I-I
(	I-I
75	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
)	I-I
or	I-I
doxorubicin	I-I
(	O
75	O
mg/m	O
(	O
2	O
)	O
)	O
every	O
3	O
weeks	O
,	O
in	O
the	O
absence	O
of	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O


The	O
primary	O
efficacy	O
endpoint	O
was	O
response	O
rate	O
.	O


Responses	O
were	O
assessed	O
using	O
World	O
Health	O
Organization	O
criteria	O
and	O
were	O
required	O
to	O
be	O
of	O
at	O
least	O
6	O
weeks	O
'	O
duration	O
.	O


The	O
primary	O
safety	O
endpoint	O
was	O
cardiotoxicity	O
.	O


Cardiac	O
function	O
was	O
monitored	O
by	O
multiple-gated	B-I
radionuclide	I-I
cardioangiography	I-I
scan	I-I
,	O
and	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
was	O
scored	O
at	O
a	O
central	O
laboratory	O
.	O


Patients	B-P
were	I-P
removed	I-P
from	I-P
study	I-P
if	I-P
LVEF	I-P
declined	I-P
20	I-P
or	I-P
more	I-P
EF	I-P
units	I-P
from	I-P
baseline	I-P
to	I-P
a	I-P
final	I-P
value	I-P
of	I-P
greater	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
50	I-P
%	I-P
,	I-P
or	I-P
by	I-P
10	I-P
or	I-P
more	I-P
units	I-P
to	I-P
a	I-P
final	I-P
value	I-P
of	I-P
less	I-P
than	I-P
50	I-P
%	I-P
,	I-P
or	I-P
onset	I-P
of	I-P
clinical	I-P
congestive	I-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
.	O


RESULTS	O
Median	B-P
age	I-P
was	I-P
54	I-P
years	I-P
in	I-P
both	I-P
treatment	I-P
groups	I-P
.	I-P


All	O
relevant	O
prognostic	O
factors	O
were	O
balanced	O
,	O
with	O
the	O
exception	O
that	O
there	O
were	O
significantly	O
more	O
progesterone	O
receptor	O
positive	O
patients	O
in	O
the	O
doxorubicin-treated	B-I
group	O
.	O


Protocol-defined	B-O
cardiotoxicity	I-O
was	O
observed	O
in	O
13	O
%	O
of	O
TLC	O
D-99	O
patients	O
(	O
including	O
2	O
cases	O
of	O
CHF	O
)	O
compared	O
to	O
29	O
%	O
of	O
doxorubicin	B-I
patients	O
(	O
including	O
9	O
cases	O
of	O
CHF	O
)	O
.	O


Median	B-O
cumulative	I-O
doxorubicin	I-O
dose	I-O
at	I-O
onset	I-O
of	I-O
cardiotoxicity	I-O
was	O
785	O
mg/m	O
(	O
2	O
)	O
for	O
TLC	B-I
D-99	I-I
versus	O
570	O
mg/m	O
(	O
2	O
)	O
for	O
doxorubicin	B-I
(	O
P	O
=	O
0.0001	O
;	O
hazard	O
ratio	O
,	O
3.56	O
)	O
.	O


The	O
overall	B-O
response	I-O
rate	I-O
was	O
26	O
%	O
in	O
both	O
treatment	O
groups	O
.	O


The	O
median	B-O
TTP	I-O
was	O
2.9	O
months	O
on	O
TLC	O
D-99	O
versus	O
3.1	O
months	O
on	O
doxorubicin	B-I
.	I-I


Median	B-O
survival	I-O
was	O
16	O
versus	O
20	O
months	O
with	O
a	O
nonsignificant	O
trend	O
in	O
favor	O
of	O
doxorubicin	B-I
(	O
P	O
=	O
0.09	O
)	O
.	O


Clinical	B-O
toxicities	I-O
,	O
commonly	O
associated	O
with	O
doxorubicin	O
,	O
appeared	O
less	O
common	O
with	O
TLC	O
D-99	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O


There	O
was	O
only	O
one	O
report	O
of	O
palmar-plantar	B-O
erythrodysesthesia	I-O
(	O
Grade	O
2	O
)	O
with	O
this	O
liposomal	O
formulation	O
of	O
doxorubicin	B-I
.	I-I


CONCLUSIONS	O
Single-agent	O
TLC	B-I
D-99	I-I
produces	O
less	O
cardiotoxicity	O
than	O
doxorubicin	B-I
,	O
while	O
providing	O
comparable	O
antitumor	O
activity	O
.	O


Effectiveness	O
of	O
active	B-I
physical	I-I
training	I-I
as	O
treatment	O
for	O
long-standing	B-P
adductor-related	I-P
groin	I-P
pain	I-P
in	I-P
athletes	I-P
:	I-P
randomised	O
trial	O
.	O


BACKGROUND	O
Groin	O
pain	O
is	O
common	O
among	O
athletes	O
.	O


A	O
major	O
cause	O
of	O
long-standing	O
problems	O
is	O
adductor-related	B-P
groin	I-P
pain	I-P
.	I-P


The	O
purpose	O
of	O
this	O
randomised	O
clinical	O
trial	O
was	O
to	O
compare	O
an	O
active	B-I
training	I-I
programme	I-I
(	I-I
AT	I-I
)	I-I
with	I-I
a	I-I
physiotherapy	I-I
treatment	I-I
without	I-I
active	I-I
training	I-I
(	I-I
PT	I-I
)	I-I
in	O
the	O
treatment	O
of	O
adductor-related	B-P
groin	I-P
pain	I-P
in	I-P
athletes	I-P
.	I-P


METHODS	O
68	B-P
athletes	I-P
with	I-P
long-standing	I-P
(	I-P
median	I-P
40	I-P
weeks	I-P
)	I-P
adductor-related	I-P
groin	I-P
pain	I-P
--	I-P
after	I-P
examination	I-P
according	I-P
to	I-P
a	I-P
standardised	I-P
protocol	I-P
--	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
AT	I-I
or	I-P
PT	I-I
.	I-I


The	O
treatment	O
period	O
was	O
8-12	O
weeks	O
.	O


4	O
months	O
after	O
the	O
end	O
of	O
treatment	O
a	O
standardised	O
examination	O
was	O
done	O
.	O


The	O
examining	O
physician	O
was	O
unaware	O
of	O
the	O
treatment	O
allocation	O
.	O


The	O
ultimate	O
outcome	O
measure	O
was	O
full	B-O
return	I-O
to	I-O
sports	I-O
at	I-O
the	I-O
same	I-O
level	I-O
without	I-O
groin	I-O
pain	I-O
.	I-O


Analyses	O
were	O
by	O
intention	O
to	O
treat	O
.	O


FINDINGS	O
23	B-P
patients	I-P
in	I-P
the	I-P
AT	I-P
group	I-P
and	I-P
four	I-P
in	I-P
the	I-P
PT	I-P
group	I-P
returned	I-P
to	I-P
sports	I-P
without	I-P
groin	I-O
pain	I-O
(	I-P
odds	I-P
ratio	O
,	O
multiple-logistic-regression	O
analysis	O
,	O
12.7	O
[	O
95	O
%	O
CI	O
3.4-47.2	O
]	O
)	O
.	O


The	O
subjective	O
global	O
assessments	O
of	O
the	O
effect	O
of	O
the	O
treatments	O
showed	O
a	O
significant	O
(	O
p=0.006	O
)	O
linear	O
trend	O
towards	O
a	O
better	O
effect	O
in	O
the	O
AT	O
group	O
.	O


A	O
per-protocol	O
analysis	O
did	O
not	O
show	O
appreciably	O
different	O
results	O
.	O


INTERPRETATION	O
AT	O
with	O
a	O
programme	O
aimed	O
at	O
improving	O
strength	O
and	O
coordination	O
of	O
the	O
muscles	O
acting	O
on	O
the	O
pelvis	O
,	O
in	O
particular	O
the	O
adductor	O
muscles	O
,	O
is	O
very	O
effective	O
in	O
the	O
treatment	O
of	O
athletes	O
with	O
long-standing	O
adductor-related	O
groin	O
pain	O
.	O


The	O
potential	O
preventive	O
value	O
of	O
a	O
short	O
programme	O
based	O
upon	O
the	O
principles	O
of	O
AT	O
should	O
be	O
assessed	O
in	O
future	O
,	O
randomised	O
,	O
clinical	O
trials	O
.	O


Effects	O
of	O
exposure	O
to	O
thin-ideal	O
media	O
images	O
on	O
body	B-O
dissatisfaction	I-O
:	I-O
testing	O
the	O
inclusion	O
of	O
a	O
disclaimer	B-I
versus	I-I
warning	I-I
label	I-I
.	I-I


The	O
current	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
the	O
inclusion	O
of	O
a	O
disclaimer	O
(	O
i.e.	O
,	O
"	O
Retouched	O
photograph	O
aimed	O
at	O
changing	O
a	O
person	O
's	O
physical	O
appearance	O
.	O


"	O
)	O
or	O
warning	O
(	O
i.e.	O
,	O
"	O
Warning	O
:	O
Trying	O
to	O
look	O
as	O
thin	O
as	O
this	O
model	O
may	O
be	O
dangerous	O
to	O
your	O
health	O
.	O


"	O
)	O
added	O
to	O
images	O
of	O
thin/attractive	O
models	O
would	O
affect	O
body	B-O
dissatisfaction	I-O
and	O
intent	O
to	O
diet	O
in	O
female	B-P
undergraduate	I-P
students	I-P
(	I-P
n=342	I-P
)	I-P
.	I-P


Participants	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	B-I
:	I-I
(	I-I
a	I-I
)	I-I
disclaimer	I-I
,	I-I
(	I-I
b	I-I
)	I-I
warning	I-I
,	I-I
(	I-I
c	I-I
)	I-I
model	I-I
control	I-I
,	I-I
or	I-I
(	I-I
d	I-I
)	I-I
car	I-I
control	I-I
.	I-I


Results	O
revealed	O
a	O
significant	O
interaction	O
between	O
group	O
and	O
time	O
,	O
whereby	O
only	O
the	O
car	O
control	O
group	O
reported	O
a	O
significant	O
change	O
(	O
i.e.	O
,	O
decrease	O
)	O
in	O
body	B-O
dissatisfaction	I-O
over	O
time	O
.	O


Groups	O
did	O
not	O
differ	O
on	O
intent	O
to	O
diet	B-O
measured	O
at	O
post-exposure	O
.	O


The	O
results	O
largely	O
replicate	O
other	O
findings	O
in	O
this	O
area	O
and	O
call	O
into	O
question	O
advocacy	O
efforts	O
to	O
label	O
media	O
images	O
as	O
a	O
strategy	O
to	O
decrease	O
women	B-P
's	I-P
identification	O
with	O
the	O
stimuli	O
.	O


Randomized	O
Phase	O
II	O
trial	O
assessing	O
estramustine	B-I
and	I-I
vinblastine	I-I
combination	I-I
chemotherapy	I-I
vs	I-I
estramustine	I-I
alone	I-I
in	O
patients	B-P
with	I-P
progressive	I-P
hormone-escaped	I-P
metastatic	I-P
prostate	I-P
cancer	I-P
.	I-P


Based	O
on	O
the	O
results	O
of	O
combined	O
data	O
from	O
three	O
North	O
American	O
Phase	O
II	O
studies	O
,	O
a	O
randomised	O
Phase	O
II	O
study	O
in	O
the	O
same	O
patient	O
population	O
was	O
performed	O
,	O
using	O
combination	O
chemotherapy	B-I
with	I-I
estramustine	I-I
phosphate	I-I
(	I-I
EMP	I-I
)	I-I
and	I-I
vinblastine	I-I
(	I-I
VBL	I-I
)	I-I
in	O
hormone	O
refractory	O
prostate	O
cancer	O
patients	O
.	O


In	O
all	O
,	O
92	B-P
patients	I-P
were	I-P
randomised	I-P
into	I-P
a	I-P
Phase	I-P
II	I-P
study	I-P
of	O
oral	B-I
EMP	I-I
(	I-I
10	I-I
mg	I-I
kg	I-I
day	I-I
continuously	I-I
)	I-I
or	I-I
oral	I-I
EMP	I-I
in	I-I
combination	I-I
with	I-I
intravenous	I-I
VBL	I-I
(	O
4	O
mg	O
m	O
(	O
2	O
)	O
week	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
2	O
weeks	O
rest	O
)	O
.	O


The	O
end	O
points	O
were	O
toxicity	B-O
and	I-O
PSA	I-O
response	I-O
in	O
both	O
groups	O
,	O
with	O
the	O
option	O
to	O
continue	O
the	O
trial	O
as	O
a	O
Phase	O
III	O
study	O
with	O
time	B-O
to	I-O
progression	I-O
and	O
survival	B-O
as	O
end	O
points	O
,	O
if	O
sufficient	O
responses	O
were	O
observed	O
.	O


Toxicity	B-O
was	O
unexpectedly	O
high	O
in	O
both	O
treatment	O
arms	O
and	O
led	O
to	O
treatment	O
withdrawal	O
or	O
refusal	O
in	O
49	O
%	O
of	O
all	O
patients	O
,	O
predominantly	O
already	O
during	O
the	O
first	O
treatment	O
cycle	O
.	O


The	O
mean	B-O
treatment	I-O
duration	I-O
was	O
10	O
and	O
14	O
weeks	O
,	O
median	B-O
time	I-O
to	I-O
PSA	I-O
progression	I-O
was	O
27.2	O
and	O
30.8	O
weeks	O
,	O
median	B-O
survival	I-O
time	I-O
was	O
44	O
and	O
50.9	O
weeks	O
,	O
and	O
PSA	B-O
response	I-O
rate	I-O
was	O
only	O
24.6	O
and	O
28.9	O
%	O
in	O
the	O
EMP/VBL	B-I
and	O
EMP	B-I
arms	O
,	O
respectively	O
.	O


There	O
was	O
no	O
correlation	O
between	O
PSA	B-O
response	I-O
and	I-O
survival	I-O
.	I-O


While	O
the	O
PSA	B-O
response	I-O
in	O
the	O
patients	O
tested	O
was	O
less	O
than	O
half	O
that	O
recorded	O
in	O
the	O
North	O
American	O
studies	O
,	O
the	O
toxicity	B-O
of	I-O
EMP	I-O
monotherapy	I-O
or	O
in	O
combination	O
with	O
VBL	B-I
was	O
much	O
higher	O
than	O
expected	O
.	O


Further	O
research	O
on	O
more	O
effective	B-O
and	O
less	O
toxic	B-O
treatment	O
strategies	O
for	O
hormone	O
refractory	O
prostate	O
cancer	O
is	O
mandatory	O
.	O


Post-laparoscopic	B-P
cholecystectomy	I-P
pain	I-P
:	I-P
effects	I-O
of	O
intraperitoneal	O
local	O
anesthetics	B-I
on	O
pain	O
control	O
--	O
a	O
randomized	O
prospective	O
double-blinded	O
placebo-controlled	O
trial	O
.	O


Postoperative	B-P
pain	I-P
after	I-P
laparoscopic	I-P
cholecystectomy	I-P
(	I-P
LC	I-P
)	I-P
is	O
generally	O
less	O
than	O
open	O
cholecystectomy	O
;	O
however	O
,	O
the	O
postoperative	O
shoulder	O
and	O
abdominal	O
pain	O
experienced	O
by	O
patients	O
still	O
causes	O
preventable	O
distress	O
.	O


Intraperitoneal	O
irrigation	O
of	O
the	O
diaphragmatic	O
surface	O
and	O
gallbladder	O
fossa	O
using	O
normal	O
saline	B-I
,	I-I
bupivacaine	I-I
,	O
or	O
lignocaine	B-I
may	O
effectively	O
control	O
visceral	B-O
abdominal	I-O
pain	I-O
after	O
an	O
LC	O
.	O


Two	B-P
hundred	I-P
patients	I-P
with	I-P
similar	I-P
demographics	I-P
undergoing	I-P
elective	I-P
LC	I-P
were	O
randomized	O
to	O
one	O
of	O
four	B-P
groups	I-P
of	I-P
50	I-P
patients	I-P
each	I-P
,	O
including	O
Group	O
A	O
placebo	B-I
control	O
,	O
Group	O
B	O
with	O
isotonic	B-I
saline	I-I
irrigation	I-I
,	O
Group	O
C	O
with	O
bupivacaine	B-I
irrigation	I-I
,	O
and	O
Group	O
D	O
with	O
lignocaine	B-I
irrigation	I-I
.	I-I


All	O
patients	B-P
received	O
preperitoneal	O
abdominal	O
wall	O
infiltration	O
with	O
0.25	O
per	O
cent	O
bupivacaine	B-I
to	O
control	O
parietal	B-P
(	I-P
somatic	I-P
)	I-P
abdominal	I-P
pain	I-P
.	I-P


The	O
visual	B-O
analogue	I-O
and	I-O
verbal	I-O
rating	I-O
pain	I-O
scores	I-O
at	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
and	O
24	O
hours	O
for	O
both	O
shoulder	O
and	O
abdominal	O
pain	O
were	O
recorded	O
in	O
a	O
prospective	O
double-blind	O
fashion	O
at	O
four	O
points	O
during	O
the	O
first	O
24	O
postoperative	O
hours	O
.	O


Analgesia	B-O
requirements	I-O
,	I-O
vital	I-O
signs	I-O
,	I-O
blood	I-O
glucose	I-O
,	I-O
and	I-O
incidence	I-O
of	I-O
nausea	I-O
and	I-O
vomiting	I-O
were	O
also	O
recorded	O
.	O


Patients	B-P
in	I-P
each	I-P
group	I-P
demonstrated	O
a	O
significant	O
difference	O
in	O
visual	B-O
analogue	I-O
and	I-O
verbal	I-O
rating	I-O
pain	I-O
scores	I-O
and	I-O
analgesic	I-O
consumption	I-O
when	O
compared	O
with	O
controls	O
.	O


Lignocaine	B-I
controlled	I-O
pain	I-O
significantly	O
better	O
than	O
saline	B-I
or	O
bupivacaine	B-I
.	I-I


Bowel	B-O
function	I-O
recovery	I-O
was	O
similar	B-O
in	O
all	B-P
patients	I-P
,	O
and	O
there	O
were	O
no	O
significant	O
complications	O
.	O


We	O
conclude	O
that	O
intraperitoneal	O
irrigation	O
with	O
either	O
saline	B-I
,	I-I
bupivacaine	I-I
,	O
or	O
lignocaine	B-I
can	O
significantly	O
reduce	O
visceral	B-O
abdominal	I-O
pain	I-O
after	O
LC	O
.	O


Lignocaine	B-I
was	O
the	O
most	O
efficacious	O
local	O
anesthetic	O
in	O
this	O
trial	O
and	O
has	O
a	O
high	O
safety	O
profile	O
when	O
used	O
at	O
recommended	O
doses	O
.	O


BCG	B-I
(	I-I
RIVM	I-I
)	I-I
versus	O
mitomycin	B-I
intravesical	I-I
therapy	I-I
in	O
superficial	B-P
bladder	I-P
cancer	I-P
.	I-P


First	O
results	O
of	O
randomized	O
prospective	O
trial	O
.	O


This	O
study	O
presents	O
the	O
preliminary	O
results	O
of	O
a	O
randomized	O
prospective	O
two-arm	O
study	O
in	O
which	O
bacillus	B-I
Calmette-Guérin	I-I
(	I-I
BCG	I-I
)	I-I
RIVM	I-I
,	I-I
a	I-I
Dutch	I-I
BCG	I-I
preparation	O
,	O
is	O
compared	O
with	B-I
mitomycin	I-I
C	I-I
(	O
MMC	O
)	O
in	B-P
patients	I-P
with	I-P
primary	I-P
or	I-P
recurrent	I-P
superficial	I-P
bladder	I-P
tumors	I-P
,	I-P
including	I-P
carcinoma	I-P
in	I-P
situ	I-P
(	I-P
CIS	I-P
)	I-P
.	O


Therapeutic	O
regimens	O
were	O
as	O
follows	O
:	O
after	O
complete	O
transurethral	O
resection	O
of	O
all	O
visible	O
tumors	O
,	O
BCG	B-I
RIVM	I-I
(	O
1	O
x	O
10	O
(	O
9	O
)	O
bacilli	O
in	O
50	O
mL	O
saline	O
)	O
was	O
instilled	O
once	O
a	O
week	O
for	O
six	O
consecutive	O
weeks	O
,	O
and	B-I
mitomycin	I-I
C	I-I
(	O
30	O
mg	O
in	O
50	O
mL	O
saline	O
)	O
was	O
administered	O
once	O
a	O
week	O
for	O
one	O
month	O
(	O
weeks	O
1	O
to	O
4	O
)	O
and	O
thereafter	O
once	O
a	O
month	O
for	O
a	O
total	O
of	O
six	O
months	O
.	B-O


Reported	B-O
are	I-O
the	I-O
incidence	I-O
of	I-O
side	I-O
effects	I-O
in	I-P
165	I-P
patients	I-P
and	I-P
the	I-O
recurrence	I-O
rate	I-O
of	I-O
tumors	I-O
in	I-P
308	I-P
patients	I-P
after	I-P
a	I-P
follow-up	I-P
period	I-P
of	I-P
twelve	I-P
months	I-P
.	I-O


Drug-induced	B-O
,	I-O
or	I-O
chemical	I-O
cystitis	I-O
was	O
observed	O
in	O
13	O
(	O
16.7	O
%	O
)	O
of	O
78	O
BCG-treated	O
patients	O
and	O
in	O
12	O
(	O
13.8	O
%	O
)	O
of	O
87	O
MMC-treated	O
patients	O
.	O


In	O
the	O
same	O
groups	B-O
bacterial	I-O
cystitis	I-O
occurred	O
in	O
17	O
(	O
21.8	O
%	O
)	O
patients	O
and	O
in	O
16	O
(	O
18.4	O
%	O
)	O
patients	O
,	O
respectively	O
.	O


In	O
the	O
BCG-treated	O
group	O
(	O
N	O
=	O
148	O
)	O
,	O
44	O
(	O
29.8	O
%	O
)	O
had	B-O
recurrent	I-O
tumors	I-O
,	O
while	O
in	O
the	O
MMC-treated	O
group	O
(	O
N	O
=	O
160	O
)	O
,	O
40	O
(	O
25.0	O
%	O
)	O
had	O
a	B-O
recurrence	I-O
.	O


The	B-O
recurrence	I-O
rate	I-O
for	I-I
BCG-treated	I-I
patients	O
was	O
0.33	O
;	O
the	O
recurrence	O
rate	O
for	B-I
MMC-treated	I-I
patients	O
was	O
0.29	O
(	O
P	O
=	O
0.560	O
,	O
not	O
significant	O
)	O
.	O


These	O
preliminary	O
data	O
demonstrated	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
two	O
arms	O
with	O
regard	O
to	B-O
toxicity	I-O
and	I-O
recurrence	I-O
of	I-O
tumors	I-O
.	O


Intravenous	O
aflibercept	B-I
administered	O
in	O
combination	O
with	O
irinotecan	B-I
,	I-I
5-fluorouracil	I-I
and	I-I
leucovorin	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
solid	I-P
tumours	I-P
:	I-P
results	O
from	O
the	O
expansion	O
cohort	O
of	O
a	O
phase	O
I	O
study	O
.	O


BACKGROUND	O
Following	O
the	O
dose-escalation	O
stage	O
,	O
this	O
double-blind	O
expansion	O
stage	O
of	O
the	O
phase	O
I	O
study	O
evaluated	O
the	O
safety	O
,	O
pharmacodynamics	O
,	O
pharmacokinetics	O
,	O
anti-vascular	O
effects	O
and	O
antitumour	O
activity	O
of	O
aflibercept	B-I
4	O
mg/kg	O
with	O
irinotecan	B-I
,	I-I
5-fluorouracil	I-I
and	I-I
leucovorin	I-I
(	I-I
LV5FU2	I-I
)	I-I
.	I-I


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
with	I-P
advanced	I-P
solid	I-P
tumours	I-P
were	O
randomised	O
at	O
cycle-1	O
to	O
placebo	B-I
or	I-I
aflibercept	I-I
(	O
4	O
mg/kg	O
)	O
on	O
day	O
1	O
then	O
irinotecan-LV5FU2	B-I
on	O
days	O
1	O
and	O
2	O
.	O


Subsequently	O
,	O
all	O
patients	O
received	O
aflibercept	B-I
with	O
irinotecan-LV5FU2	B-I
every	O
2	O
weeks	O
.	O


Anti-vascular	O
effects	O
were	O
assessed	O
using	O
dynamic	O
contrast-enhanced	O
magnetic	O
resonance	O
imaging	O
(	O
DCE-MRI	O
)	O
.	O


RESULTS	O
Twenty-seven	B-P
patients	I-P
were	I-P
treated	I-P
;	I-P
14	O
received	O
placebo	B-I
in	O
cycle-1	O
followed	O
by	O
aflibercept	B-I
in	O
later	O
cycles	O
and	O
13	O
received	O
aflibercept	B-I
4	O
mg/kg	O
upfront	O
.	O


The	O
median	B-O
number	I-O
of	I-O
aflibercept	I-O
cycles	I-O
was	O
16	O
(	O
range	O
1-44	O
)	O
,	O
12	O
patients	O
received	O
≥20	O
cycles	O
.	O


Most	O
frequent	O
grade	O
3/4	O
adverse	O
events	O
were	B-O
neutropenia	I-O
(	I-O
37	I-O
%	I-O
)	I-O
,	I-O
fatigue	I-O
(	O
33	O
%	O
)	O
and	B-O
hypertension	I-O
(	O
30	O
%	O
)	O
.	O


No	O
anti-aflibercept	O
antibodies	O
were	O
detected	B-P
.	I-P


Four	B-P
patients	I-P
achieved	I-P
partial	I-P
responses	I-P
and	O
17	O
had	O
stable	O
disease	O
,	O
lasting	O
>	O
3	O
months	O
in	O
14	O
patients	B-O
.	I-O


Plasma	B-O
levels	I-O
of	I-O
free	I-O
over	I-O
vascular	I-O
endothelial	I-O
growth	I-O
factor-bound	I-O
aflibercept	I-O
were	O
adequate	O
,	O
with	O
steady-state	O
achieved	O
from	O
cycle-3	O
.	O


Exploratory	O
DCE-MRI	O
showed	O
no	O
significant	O
perfusion	O
changes	O
with	O
aflibercept	O
.	O


CONCLUSION	B-I
Aflibercept	I-I
4	O
mg/kg	O
plus	B-I
irinotecan-LV5FU2	I-I
every	O
2	O
weeks	O
had	O
acceptable	O
toxicity	O
and	O
pharmacokinetics	O
,	O
and	O
showed	O
promising	O
antitumour	O
activity	O
.	O


Venlafaxine	B-I
versus	O
clonidine	B-I
for	O
the	O
treatment	B-P
of	I-P
hot	I-O
flashes	I-O
in	I-P
breast	I-P
cancer	I-P
patients	I-P
:	I-P
a	O
double-blind	O
,	O
randomized	O
cross-over	O
study	O
.	O


PURPOSE	O
Breast	B-P
cancer	I-P
patients	I-P
with	I-P
treatment-induced	I-P
menopause	I-P
experience	I-P
frequent	I-P
and	I-P
severe	I-O
hot	I-O
flashes	I-O
(	I-O
HF	I-O
)	I-O
.	I-O


We	O
compared	O
venlafaxine	B-I
and	O
clonidine	B-I
for	O
the	O
treatment	O
of	O
HF	O
with	O
regard	O
to	O
side	B-O
effects	I-O
,	I-O
efficacy	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
and	I-O
sexual	I-O
functioning	I-O
.	I-O


METHODS	O
In	O
a	O
double-blind	O
,	O
cross-over	O
study	O
,	O
60	B-P
breast	I-P
cancer	I-P
patients	I-P
experiencing	I-P
HF	I-P
were	I-P
randomized	I-P
to	O
8	O
weeks	O
venlafaxine	B-I
followed	O
by	O
2	O
weeks	O
wash-out	O
,	O
and	O
8	O
weeks	O
clonidine	B-I
or	O
vice	O
versa	O
.	O


HF	B-O
frequency	I-O
and	I-O
severity	I-O
,	I-O
side	I-O
effects	I-O
,	I-O
quality	I-O
of	I-O
life	I-O
and	I-O
sexuality	I-O
were	O
assessed	O
.	O


RESULTS	O
Thirty	B-P
patients	I-P
started	O
with	O
venlafaxine	B-I
and	O
30	O
with	O
clonidine	B-I
.	I-I


Premature	O
discontinuation	O
for	O
toxicity	B-O
occurred	O
in	O
14/59	O
during	O
venlafaxine	B-I
and	O
5/53	O
during	O
clonidine	B-I
(	O
P	O
=	O
.038	O
)	O
.	O


Venlafaxine	B-I
induced	O
more	O
side	B-O
effects	I-O
.	I-O


Median	B-O
reduction	I-O
in	I-O
HF	I-O
score	I-O
was	O
49	O
%	O
for	O
venlafaxine	B-I
and	O
55	O
%	O
for	O
clonidine	B-I
(	O
ns	O
)	O
.	O


CONCLUSION	O
Venlafaxine	B-I
and	O
clonidine	B-I
are	O
equally	O
,	O
but	O
moderately	O
effective	O
in	O
HF	B-O
reduction	I-O
.	I-O


Side	B-O
effects	I-O
are	O
the	O
main	O
reason	O
for	O
drug	O
discontinuation	O
,	O
occurring	O
more	O
often	O
with	O
venlafaxine	B-I
.	I-I


Effect	O
of	O
interferon	O
gamma	O
on	O
infection-related	O
death	O
in	O
patients	B-P
with	I-P
severe	I-P
injuries	I-P
.	I-P


A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
efficacy	O
of	O
interferon	B-I
gamma	I-I
in	O
reducing	O
infection	B-O
and	O
death	O
in	O
patients	B-P
sustaining	I-P
severe	I-P
injury	I-P
.	I-P


DESIGN	O
Multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
with	O
observation	O
for	O
60	O
days	O
and	O
until	O
discharge	O
for	O
patients	B-P
with	I-P
major	I-P
infection	I-P
on	I-P
day	I-P
60	I-P
.	I-P


SETTING	O
Nine	B-P
university-affiliated	I-P
level	I-P
1	I-P
trauma	I-P
centers	I-P
.	I-P


PATIENTS	O
Four	B-P
hundred	I-P
sixteen	I-P
patients	I-P
with	I-P
severe	I-P
injuries	I-P
,	I-P
assessed	I-P
by	I-P
Injury	I-O
Severity	I-O
Score	I-O
and	I-O
degree	I-O
of	I-O
contamination	I-O
.	I-O


INTERVENTION	O
Recombinant	B-I
human	I-I
interferon	I-I
gamma	I-I
,	I-I
100	I-I
micrograms	I-I
,	I-I
was	I-I
administered	I-I
subcutaneously	I-I
once	I-I
daily	I-I
for	I-I
21	I-I
days	I-I
(	I-I
or	I-I
until	I-I
patient	I-I
discharge	I-I
if	I-I
prior	I-I
to	I-I
21	I-I
days	I-I
)	I-I
as	I-I
an	I-I
adjunct	I-I
to	I-I
standard	I-I
antibiotic	I-I
and	I-I
supportive	I-I
therapy	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Incidence	B-O
of	I-O
major	I-O
infection	I-O
,	I-O
death	I-O
related	I-O
to	I-O
infection	I-O
,	I-O
and	I-O
death	I-O
.	I-O


RESULTS	O
Infection	B-O
rates	I-O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
;	O
however	O
,	O
patients	O
treated	O
with	O
interferon	O
gamma	O
experienced	O
fewer	O
deaths	B-O
related	O
to	O
infection	B-O
(	O
seven	O
[	O
3	O
%	O
]	O
vs	O
18	O
[	O
9	O
%	O
]	O
;	O
P	O
=	O
.008	O
)	O
and	O
fewer	O
overall	O
deaths	B-O
(	O
21	O
[	O
10	O
%	O
]	O
vs	O
30	O
[	O
14	O
%	O
]	O
;	O
P	O
=	O
.17	O
)	O
.	O


While	O
12	O
early	B-O
deaths	I-O
(	O
days	O
1	O
through	O
7	O
)	O
occurred	O
in	O
each	O
treatment	O
group	O
,	O
late	O
death	B-O
occurred	O
in	O
18	O
placebo-treated	O
patients	O
and	O
nine	O
in	O
interferon	B-I
gamma-treated	I-I
patients	O
.	O


The	O
results	O
were	O
dominated	O
by	O
findings	O
at	O
one	O
center	O
,	O
which	O
had	O
the	O
highest	O
enrollment	O
and	O
higher	O
infection	O
and	O
death	O
rates	O
.	O


Statistical	O
analysis	O
did	O
not	O
eliminate	O
the	O
possibility	O
of	O
an	O
unidentified	O
imbalance	O
between	O
arms	O
as	O
an	O
explanation	O
for	O
the	O
results	O
.	O


CONCLUSION	O
Further	O
evaluation	O
is	O
required	O
to	O
determine	O
the	O
validity	O
of	O
the	O
observed	O
reduction	O
in	O
infection-related	B-O
deaths	O
in	O
patients	B-P
treated	I-P
with	I-P
interferon	I-I
gamma	I-I
.	I-I


Treatment	B-P
of	I-P
hepatitis	I-P
B	I-P
virus	I-P
infection	I-P
with	I-P
interferon	I-I
.	I-I


Factors	O
predicting	O
response	O
to	O
interferon	B-I
.	I-I


Several	O
randomised	O
controlled	O
trials	O
have	O
been	O
undertaken	O
to	O
evaluate	O
the	O
efficacy	O
of	O
alpha-interferon	B-I
in	O
the	O
therapy	O
of	O
chronic	O
hepatitis	O
B	O
.	O


In	O
patients	B-P
with	I-P
HBe	I-P
antigen-positive	I-P
disease	I-P
acquired	I-P
in	I-P
adult	I-P
life	I-P
the	O
response	O
rates	O
vary	O
from	O
25-50	O
%	O
.	O


In	O
those	O
infected	O
at	O
birth	O
,	O
response	O
rates	O
are	O
lower	O
.	O


Twenty-one	B-P
pretreatment	I-P
variables	I-P
were	I-P
assessed	I-P
for	I-P
their	I-P
significance	I-P
in	I-P
response	I-O
prediction	I-P
using	I-P
data	I-P
from	I-P
114	I-P
patients	I-P
given	I-P
alpha-interferon	I-I
for	I-P
chronic	I-P
hepatitis	I-P
B	I-P
virus	I-P
infection	I-P
.	I-P


In	O
those	O
patients	O
who	O
had	O
received	O
a	O
minimum	O
of	O
90	O
million	O
units	O
per	O
m2	O
total	O
dose	O
over	O
12	O
weeks	O
,	O
a	O
negative	O
anti-human	B-O
immunodeficiency	I-O
virus	I-O
antibody	I-O
status	I-O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
chronic	B-O
active	I-O
hepatitis	I-O
on	I-O
liver	I-O
biopsy	I-O
(	O
p	O
less	O
than	O
0.005	O
)	O
,	O
high	O
AST	B-O
level	I-O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
low	O
hepatitis	B-O
B	I-O
virus	I-O
DNA	I-O
level	I-O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
a	O
history	O
of	O
acute	B-O
hepatitis	I-O
(	O
p	O
less	O
than	O
0.005	O
)	O
were	O
all	O
associated	O
with	O
an	O
increased	O
likelihood	O
of	O
response	O
on	O
univariate	O
analysis	O
.	O


On	O
stepwise	O
logistic	O
regression	O
analysis	O
,	O
hepatitis	O
B	O
virus	O
DNA	O
,	O
AST	O
and	O
a	O
history	O
of	O
acute	O
hepatitis	O
predicted	O
response	O
independently	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


The	O
most	O
reliable	O
combination	O
of	O
predictive	O
factors	O
was	O
a	O
negative	O
anti-human	B-O
immunodeficiency	I-O
virus	I-O
antibody	I-O
status	I-O
,	O
with	O
either	O
a	O
positive	O
history	O
of	O
acute	B-O
icteric	I-O
hepatitis	I-O
and	O
AST	O
greater	O
than	O
45	O
IU	O
per	O
liter	O
or	O
no	O
history	O
of	O
acute	O
icteric	O
hepatitis	O
and	O
AST	O
greater	O
than	O
85	O
IU	O
per	O
liter	O
,	O
which	O
predicted	O
response	O
in	O
77	O
%	O
with	O
a	O
specificity	O
of	O
79	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


The	O
loss	O
of	O
HBsAg	B-O
in	O
addition	O
to	O
HBeAg	B-O
and	O
hepatitis	B-O
B	I-O
virus	I-O
DNA	I-O
was	O
more	O
likely	O
to	O
occur	O
in	O
patients	B-P
with	O
chronic	O
infection	O
of	O
less	O
than	O
2	O
years	O
duration	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


Randomised	O
,	O
double	O
blind	O
,	O
placebo	B-I
controlled	O
study	O
of	O
fluticasone	B-I
propionate	I-I
in	O
patients	B-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
:	I-P
the	O
ISOLDE	O
trial	O
.	O


OBJECTIVES	O
To	O
determine	O
the	O
effect	O
of	O
long	O
term	O
inhaled	O
corticosteroids	B-I
on	O
lung	B-O
function	I-O
,	I-O
exacerbations	I-O
,	I-O
and	I-O
health	I-O
status	I-O
in	O
patients	B-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
.	I-P


DESIGN	O
Double	O
blind	O
,	O
placebo	B-I
controlled	O
study	O
.	O


SETTING	O
Eighteen	B-P
UK	I-P
hospitals	I-P
.	I-P


PARTICIPANTS	O
751	B-P
men	I-P
and	I-P
women	I-P
aged	I-P
between	I-P
40	I-P
and	I-P
75	I-P
years	I-P
with	I-P
mean	I-P
forced	I-P
expiratory	I-P
volume	I-P
in	I-P
one	I-P
second	I-P
(	I-P
FEV	I-P
(	I-P
1	I-P
)	I-P
)	I-P
50	I-P
%	I-P
of	I-P
predicted	I-P
normal	I-P
.	I-P


INTERVENTIONS	O
Inhaled	O
fluticasone	B-I
propionate	I-I
500	I-I
microgram	I-I
twice	I-I
daily	I-I
from	I-I
a	I-I
metered	I-I
dose	I-I
inhaler	I-I
or	I-I
identical	I-I
placebo	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURES	O
Efficacy	B-O
measures	O
:	O
rate	B-O
of	I-O
decline	I-O
in	I-O
FEV	I-O
(	I-O
1	I-O
)	I-O
after	I-O
the	I-O
bronchodilator	I-O
and	I-O
in	I-O
health	I-O
status	I-O
,	I-O
frequency	I-O
of	I-O
exacerbations	I-O
,	I-O
respiratory	I-O
withdrawals	I-O
.	I-O


Safety	O
measures	O
:	O
morning	B-O
serum	I-O
cortisol	I-O
concentration	I-O
,	I-O
incidence	I-O
of	I-O
adverse	I-O
events	I-O
.	I-O


RESULTS	O
There	O
was	O
no	B-O
significant	I-O
difference	I-O
in	O
the	O
annual	B-O
rate	I-O
of	I-O
decline	I-O
in	I-O
FEV	I-O
(	I-O
1	I-O
)	I-O
(	I-O
P=0.16	I-O
)	I-O
.	O


Mean	B-O
FEV	I-O
(	I-O
1	I-O
)	I-O
after	O
bronchodilator	O
remained	O
significantly	B-O
higher	I-O
throughout	O
the	O
study	O
with	O
fluticasone	B-I
propionate	I-I
compared	O
with	O
placebo	B-I
(	O
P	O
<	O
0.001	O
)	O
.	O


Median	B-O
exacerbation	I-O
rate	I-O
was	O
reduced	B-O
by	O
25	O
%	O
from	O
1.32	O
a	O
year	O
on	O
placebo	B-I
to	O
0.99	O
a	O
year	O
on	O
with	O
fluticasone	B-I
propionate	I-I
(	O
P=0.026	O
)	O
.	O


Health	B-O
status	I-O
deteriorated	I-O
by	O
3.2	O
units	O
a	O
year	O
on	O
placebo	B-I
and	O
2.0	O
units	O
a	O
year	O
on	O
fluticasone	B-I
propionate	I-I
(	O
P=0.0043	O
)	O
.	O


Withdrawals	B-O
because	O
of	O
respiratory	O
disease	O
not	O
related	O
to	O
malignancy	O
were	O
higher	O
in	O
the	O
placebo	B-I
group	O
(	O
25	O
%	O
v	O
19	O
%	O
,	O
P=0.034	O
)	O
.	O


CONCLUSIONS	O
Fluticasone	B-I
propionate	I-I
500	O
microgram	O
twice	O
daily	O
did	O
not	O
affect	O
the	O
rate	B-O
of	I-O
decline	I-O
in	I-O
FEV	I-O
(	I-O
1	I-O
)	I-O
but	O
did	O
produce	B-O
a	I-O
small	I-O
increase	I-O
in	I-O
FEV	I-O
(	I-O
1	I-O
)	I-O
.	I-O


Patients	O
on	O
fluticasone	B-I
propionate	I-I
had	O
fewer	O
exacerbations	B-O
and	O
a	O
slower	B-O
decline	I-O
in	I-O
health	I-O
status	I-O
.	I-O


These	O
improvements	O
in	O
clinical	O
outcomes	O
support	O
the	O
use	O
of	O
this	O
treatment	O
in	O
patients	B-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
.	I-P


Different	B-I
aprotinin	I-I
applications	I-I
influencing	O
hemostatic	O
changes	O
in	O
orthotopic	B-P
liver	I-P
transplantation	I-P
.	I-P


The	O
effect	O
of	O
different	O
aprotinin	B-I
applications	I-I
on	O
hemostatic	O
changes	O
and	O
blood	O
product	O
requirements	O
in	O
orthotopic	B-P
liver	I-P
transplantation	I-P
was	O
investigated	O
in	O
a	O
prospective	O
,	O
open	O
,	O
and	O
randomized	O
study	O
.	O


From	B-P
November	I-P
1989	I-P
to	I-P
June	I-P
1990	I-P
,	I-P
13	I-P
patients	I-P
received	O
aprotinin	B-I
as	O
a	O
bolus	B-I
of	I-I
0.5	I-I
Mill	I-I
.	I-I


Kallikrein	O
inactivator	O
units	O
(	O
KIU	O
)	O
on	O
three	O
occasions	O
in	O
the	O
course	O
of	O
an	O
OLT	O
,	O
whereas	O
10	O
other	O
patients	O
were	O
treated	O
with	O
continuous	B-I
aprotinin	I-I
infusion	I-I
of	I-I
0.1-0.4	I-I
Mill	I-I
.	I-I


KIU/hr	O
.	O


Before	O
and	O
after	O
reperfusion	O
of	O
the	O
graft	B-O
liver	I-O
,	I-O
signs	I-O
of	I-O
hyperfibrinolysis	I-O
,	O
measured	O
by	O
thrombelastography	O
,	O
were	O
significantly	O
lower	O
in	O
the	O
infusion	O
group	O
.	O


Tissue-type	B-O
plasminogen	I-O
activator	I-O
(	I-O
t-PA	I-O
)	I-O
activity	I-O
increased	O
during	O
the	O
anhepatic	O
phase	O
but	O
to	O
a	O
significantly	O
lesser	O
extent	O
in	O
the	O
infusion	O
group	O
.	O


Blood	B-O
product	I-O
requirements	I-O
during	O
OLT	O
were	O
tendentiously	O
higher	O
in	O
the	O
bolus	O
group	O
but	O
not	O
significantly	O
so	O
.	O


However	O
,	O
the	O
use	O
of	O
packed	B-O
red	I-O
blood	I-O
cells	I-O
was	O
significantly	O
lower	O
in	O
the	O
postoperative	O
period	O
,	O
whereas	O
there	O
was	O
no	O
significant	O
difference	O
in	O
fresh	O
frozen	O
plasma	B-O
requirements	I-O
between	O
the	O
two	O
groups	O
.	O


All	O
23	B-P
patients	I-P
have	O
survived	B-O
,	O
and	O
only	O
one	O
woman	O
of	O
each	O
group	O
required	O
retransplantation	B-O
due	O
to	O
severe	O
host-versus-graft	B-O
reactions	I-O
.	I-O


Furthermore	O
,	O
we	O
investigated	O
the	O
perfusate	O
of	O
the	O
graft	O
liver	O
in	O
both	O
groups	O
and	O
detected	O
signs	O
of	O
a	O
decreased	O
t-PA	B-O
release	I-O
in	O
the	O
infusion	O
group	O
.	O


Our	O
results	O
demonstrate	O
an	O
advantage	O
of	O
aprotinin	B-I
given	O
as	O
continuous	O
infusion	O
over	O
bolus	O
application	O
in	O
OLT	O
.	O


[	O
New	O
approaches	O
to	O
evaluation	O
of	O
nonspecific	B-I
inhalation	I-I
provocation	I-I
(	O
dose-response	O
relationship	O
)	O
in	O
the	O
comparative	O
evaluation	O
of	O
bronchial	B-P
hyperreactivity	I-P
within	O
the	O
scope	O
of	O
clinical	O
trials	O
]	O
.	O


For	O
the	O
performance	O
of	O
clinical	O
drug	O
trials	O
in	O
the	O
therapy	O
for	O
bronchial	B-P
hyperresponsiveness	I-P
,	O
unspecific	O
inhalatory	O
provocation	O
tests	O
are	O
generally	O
employed	O
to	O
judge	O
therapeutic	O
success	O
.	O


In	O
particular	O
,	O
the	O
parameter-specific	O
provocation	O
doses	O
are	O
considered	O
to	O
be	O
the	O
main	O
target	O
values	O
.	O


However	O
,	O
it	O
must	O
be	O
considered	O
that	O
these	O
provocation	O
doses	O
are	O
not	O
equally	O
calculable	O
for	O
every	O
patient	O
in	O
the	O
same	O
way	O
and	O
at	O
any	O
examination	O
time	O
.	O


This	O
leads	O
to	O
the	O
fact	O
that	O
the	O
number	O
of	O
evaluable	O
case	O
studies	O
is	O
often	O
appreciably	O
lower	O
than	O
the	O
number	O
of	O
test	O
participants	O
and	O
that	O
a	O
meaningful	O
therapy	O
group	O
comparison	O
may	O
even	O
not	O
be	O
possible	O
under	O
certain	O
circumstances	O
.	O


An	O
evaluation	B-P
model	I-P
is	O
presented	O
here	O
in	O
order	O
to	O
fully	O
exploit	O
the	O
obtained	O
data	O
;	O
in	O
this	O
the	O
percentile	O
changes	O
of	O
the	O
function	O
parameters	O
(	O
estimated	O
by	O
linear	O
regression	O
)	O
at	O
a	O
defined	O
dose	O
of	O
the	O
provocation	O
substance	O
are	O
analyzed	O
.	O


In	O
analogy	O
,	O
a	O
survival	B-O
time	I-O
model	I-O
and	O
,	O
as	O
a	O
supplement	O
,	O
a	O
best	O
case/worst	O
case	O
analysis	O
are	O
performed	O
for	O
further	O
statistical	O
evaluation	O
.	O


With	O
the	O
present	O
procedure	O
,	O
an	O
evaluation	O
with	O
inclusion	O
of	O
all	O
test	O
participants	O
is	O
possible	O
.	O


In	O
contrast	O
to	O
the	O
previously	O
used	O
evaluation	O
procedures	O
,	O
this	O
allows	O
a	O
reliable	O
statistical	O
confirmation	O
of	O
the	O
results	O
of	O
clinical	O
tests	O
in	O
the	O
therapy	O
for	O
bronchial	B-P
hyperresponsiveness	I-P
.	I-P


Blood	O
pressure	O
control	O
during	O
weight	O
reduction	O
in	O
obese	B-P
hypertensive	I-P
men	I-P
:	I-P
separate	O
effects	O
of	O
sodium	O
and	O
energy	O
restriction	O
.	O


The	O
separate	O
and	O
combined	O
effects	O
of	O
dietary	O
energy	O
and	O
sodium	B-I
restriction	I-I
on	O
regulation	O
of	O
blood	B-O
pressure	I-O
were	O
investigated	O
in	O
30	B-P
middle	I-P
aged	I-P
obese	I-P
men	I-P
with	I-P
essential	I-P
hypertension	I-P
attending	I-P
the	I-P
outpatient	I-P
department	I-P
.	I-P


In	O
group	B-P
1	I-P
(	O
n	O
=	O
15	O
)	O
a	O
basal	O
period	O
with	O
no	B-I
dietary	I-I
restriction	I-I
was	O
followed	O
by	O
a	O
period	O
taking	O
an	B-I
energy	I-I
reduced	I-I
diet	I-I
(	O
5.1	O
MJ	O
;	O
1230	O
kcal	O
)	O
,	O
the	O
sodium	B-I
intake	I-I
being	I-I
supplemented	I-I
and	I-I
hence	I-I
unchanged	I-I
(	O
1	O
:	O
ErSn	O
)	O
.	O


In	O
group	B-P
2	I-P
(	O
n	O
=	O
15	O
)	O
the	O
basal	O
period	O
preceded	O
a	O
control	O
period	O
with	O
no	B-I
intervention	I-I
,	I-I
which	I-I
was	I-I
followed	I-I
by	I-I
taking	I-I
a	I-I
diet	I-I
restricted	I-I
in	I-I
energy	I-I
(	O
5.1	O
MJ	O
;	O
1220	O
kcal	O
)	O
and	O
sodium	B-I
(	O
2	O
:	O
ErSr	O
)	O
.	O


During	O
period	O
1	O
:	O
ErSn	O
there	O
were	O
reductions	O
in	O
heart	B-O
rate	I-O
and	I-O
urinary	I-O
noradrenaline	I-O
output	I-O
but	O
not	O
in	O
systolic	B-O
or	I-O
diastolic	I-O
blood	I-O
pressure	I-O
.	I-O


Body	B-O
weight	I-O
decreased	O
by	O
4.9-11.7	O
kg	O
and	O
urinary	B-O
sodium	I-O
excretion	I-O
did	O
not	O
change	O
.	O


In	O
period	O
2	O
:	O
ErSr	O
urinary	B-O
sodium	I-O
output	I-O
was	O
reduced	O
by	O
81.4	O
(	O
SEM	O
17.8	O
)	O
mmol	O
(	O
mEq	O
)	O
/24	O
h	O
and	O
there	O
was	O
a	O
weight	B-O
loss	I-O
of	O
8.2	O
(	O
SEM	O
0.7	O
)	O
kg	O
.	O


Systolic	B-O
and	I-O
diastolic	I-O
blood	I-O
pressures	I-O
fell	O
significantly	O
,	O
as	O
did	O
the	O
heart	B-O
rate	I-O
and	O
urinary	B-O
noradrenaline	I-O
excretion	I-O
.	I-O


These	O
results	O
show	O
that	O
in	O
hypertensive	B-P
obese	I-P
men	I-P
a	O
moderate	O
weight	O
reducing	O
diet	O
decreases	O
indices	O
of	O
sympathetic	B-O
nervous	I-O
system	I-O
activity	I-O
.	I-O


Reduction	O
of	O
blood	B-O
pressure	I-O
to	O
the	O
normotensive	O
range	O
was	O
observed	O
only	O
when	O
there	O
was	O
a	O
concomitant	O
restriction	O
of	O
sodium	O
intake	O
.	O


Effect	O
of	O
medical	B-I
ozone	I-I
therapy	I-I
on	O
renal	B-O
blood	I-O
flow	I-O
and	I-O
renal	I-O
function	I-O
of	O
patients	B-P
with	I-P
chronic	I-P
severe	I-P
hepatitis	I-P
.	I-P


BACKGROUND	O
Medical	B-I
ozone	I-I
therapy	I-I
system	I-I
was	O
reported	O
to	O
have	O
certain	O
effects	B-O
on	I-O
the	I-O
treatment	I-O
of	I-O
severe	I-O
hepatitis	I-O
,	O
but	O
its	O
mechanism	O
is	O
not	O
very	O
clear	O
.	O


One	O
of	O
the	O
causes	O
of	O
death	O
of	O
severe	O
hepatitis	O
is	O
complication	B-O
of	I-O
renal	I-O
damage	I-O
or	O
hepatorenal	B-O
syndrome	I-O
.	I-O


The	O
present	O
study	O
aimed	O
to	O
observe	O
effects	O
of	O
medical	B-I
ozone	I-I
therapy	I-I
system	I-I
on	O
plasma	B-O
renin	I-O
activity	I-O
(	I-O
PRA	I-O
)	I-O
,	I-O
angiotensin	I-O
II	I-O
(	I-O
AII	I-O
)	I-O
,	I-O
aldosterone	I-O
(	I-O
ALD	I-O
)	I-O
,	I-O
renal	I-O
blood	I-O
flow	I-O
and	I-O
renal	I-O
function	I-O
of	O
patients	B-P
with	I-P
chronic	I-P
severe	I-P
hepatitis	I-P
and	O
explore	O
mechanisms	O
of	O
medical	B-I
ozone	I-I
therapy	I-I
in	O
the	O
treatment	O
of	O
severe	O
hepatitis	O
.	O


METHODS	O
Eighty-five	B-P
cases	I-P
with	I-P
chronic	I-P
severe	I-P
hepatitis	I-P
were	O
randomly	O
divided	O
into	O
ozone	B-I
therapy	I-I
group	I-I
(	O
43	O
cases	O
)	O
and	O
control	B-I
group	I-I
(	O
42	O
cases	O
)	O
.	O


The	O
patients	O
in	O
the	O
ozone	B-I
therapy	I-I
group	O
were	O
treated	O
with	O
basic	B-I
treatments	I-I
plus	I-I
ozone	I-I
therapy	I-I
system	I-I
.	I-I


Basic	B-O
autohemotherapy	I-O
was	O
used	O
.	O


One	O
hundred	O
milliliter	O
venous	O
blood	O
was	O
drawn	O
from	O
each	O
patient	O
,	O
and	O
was	O
mixed	O
with	O
100	O
ml	O
(	O
35	O
µg/ml	B-I
)	I-I
medical	I-I
ozone	I-I
and	O
then	O
was	O
returned	O
the	O
blood	O
to	O
the	O
patient	O
intravenously	O
,	O
once	O
every	O
other	O
day	O
for	O
20	O
days	O
.	O


Only	O
the	B-I
basic	I-I
treatments	I-I
were	O
given	O
to	O
the	B-I
control	I-I
group	I-I
.	I-O


PRA	B-O
,	I-O
AII	I-O
,	I-O
ALD	I-O
,	I-O
renal	I-O
blood	I-O
flow	I-O
and	I-O
damage	I-O
to	I-O
renal	I-O
function	I-O
of	O
the	O
two	O
groups	O
before	O
treatment	O
and	O
20	O
days	O
after	O
treatment	O
were	O
compared	O
.	B-O


Survival	B-O
rates	I-O
were	O
also	O
compared	O
.	O


RESULTS	O
Twenty	O
days	O
after	O
the	O
treatment	O
,	O
in	B-I
ozone	I-I
therapy	I-I
group	O
,	O
PRA	B-O
was	O
(	O
1.31	O
±	O
0.12	O
)	O
ng·ml⁻¹·h⁻¹	B-O
,	O
AII	O
(	O
111.25	O
±	O
17.35	B-O
)	I-O
pg/ml	O
,	O
ALD	O
(	O
251.31	O
±	O
22.60	O
)	O
pg/ml	O
,	O
which	O
decreased	O
significantly	O
compared	O
with	O
those	O
before	B-O
treatment	I-O
(	O
PRA	O
(	O
2.23	O
±	O
0.13	O
)	O
ng·ml⁻¹·h⁻¹	B-O
,	O
AII	O
(	B-O
155.18	I-O
±	O
19.13	O
)	O
pg/ml	O
,	O
ALD	O
(	O
405.31	O
±	O
29.88	O
)	O
pg/ml	O
,	O
t	O
=	O
4.67	O
-	O
14.23	O
,	O
P	O
<	O
0.01	O
)	O
,	O
also	O
lower	O
than	O
those	O
of	O
control	O
group	O
20	O
days	B-O
after	I-O
the	O
treatment	O
(	O
PRA	O
(	B-O
2.02	I-O
±	I-O
0.11	O
)	O
ng·ml⁻¹·h⁻¹	B-O
,	O
AII	O
(	O
162.21	O
±	O
15.32	O
)	O
pg/ml	O
,	O
ALD	O
(	O
401.20	O
±	O
35.02	O
)	O
pg/ml	B-O
,	I-O
t	I-O
=	I-O
4.97	I-O
-	I-O
15.61	I-O
,	O
P	O
<	O
0.01	O
)	O
;	O
renal	O
blood	O
flow	O
was	O
(	O
175.15	O
±	O
28.20	O
)	O
ml/min	O
,	O
which	O
increased	O
compared	O
with	O
that	O
before	O
the	O
treatment	O
(	O
(	O
125.68	O
±	O
21.25	O
)	O
ml/min	O
)	O
and	O
was	O
higher	O
than	O
that	O
of	O
control	O
group	O
20	O
days	O
after	O
the	O
treatment	O
(	O
(	O
128.59	O
±	O
23.15	B-O
)	I-O
ml/min	I-O
,	I-O
t	I-O
=	I-O
4.78	O
,	O
4.61	O
,	O
P	O
<	O
0.01	O
)	O
.	O


Renal	O
damage	O
occurred	O
in	O
2	O
cases	O
(	O
5	O
%	O
)	O
in	O
ozone	O
therapy	O
group	O
,	O
less	O
than	O
that	O
in	O
control	O
group	O
(	O
9	O
cases	O
,	O
21	O
%	O
)	O
(	O
χ²	O
=	O
5.295	O
,	O
P	B-I
<	I-I
0.05	I-I
)	I-I
.	I-I


Thirty-three	B-I
cases	O
(	O
77	O
%	O
)	O
in	O
ozone	B-I
therapy	I-I
group	I-O
vs.	I-O
16	I-O
cases	O
(	O
38	O
%	O
)	O
in	O
control	O
group	O
survived	B-I
(	I-I
χ²	I-I
=	I-I
12.993	I-I
,	O
P	O
<	B-I
0.01	I-I
)	I-I
.	I-I


CONCLUSIONS	B-I
Basic	I-I
treatment	I-P
plus	I-P
medical	I-P
ozone	I-P
therapy	I-P
for	I-P
patients	O
with	B-O
chronic	I-O
severe	I-O
hepatitis	I-O
could	O
decrease	B-O
PRA	I-O
,	I-O
AII	I-O
and	I-O
ALD	I-O
levels	I-O
significantly	I-O
increase	I-O
renal	O
blood	O
flow	O
,	O
prevent	O
renal	B-O
damage	I-O
to	I-O
certain	O
extent	O
and	O
improve	O
survival	O
rate	O
of	O
the	O
patients	O
.	O


Educational	B-I
intervention	I-I
for	O
altering	O
water-sanitation	O
behavior	O
to	O
reduce	O
childhood	B-P
diarrhea	I-O
in	I-P
urban	I-P
Bangladesh	I-P
:	I-P
impact	O
on	O
nutritional	O
status	O
.	O


We	O
evaluated	O
whether	O
an	O
educational	B-I
intervention	I-I
that	O
was	O
effective	O
in	O
reducing	O
childhood	B-P
diarrhea	I-O
also	O
improved	O
childhood	B-O
nutritional	I-O
status	I-O
.	I-O


Fifty-one	B-P
communities	I-P
of	I-P
38	I-P
families	I-P
each	I-P
were	O
randomized	O
to	O
receive	O
the	O
intervention	B-I
or	I-I
no	I-I
intervention	I-I
.	I-I


During	O
1	O
y	O
of	O
follow-up	O
the	O
rate	B-O
of	I-O
diarrhea	I-O
(	O
per	O
100	O
wk	O
)	O
in	O
children	B-P
less	I-P
than	I-P
6	I-P
y	I-P
in	O
the	O
intervention	O
group	O
was	O
5.89	O
episodes	O
whereas	O
that	O
in	O
the	O
nonintervention	O
group	O
was	O
7.55	O
episodes	O
(	O
protective	O
efficacy	O
22	O
%	O
;	O
p	O
less	O
than	O
0.0001	O
)	O
.	O


During	O
the	O
same	O
follow-up	O
period	O
children	O
in	O
both	O
groups	O
exhibited	O
comparable	O
patterns	O
of	O
weight	B-O
gain	I-O
;	I-O
1	O
y	O
after	O
the	O
intervention	O
the	O
mean	B-O
weight	I-O
for	I-O
age	I-O
of	O
children	O
in	O
both	O
groups	O
was	O
76	O
%	O
of	O
the	O
NCHS	O
standard	O
.	O


No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
proportion	O
of	O
each	O
group	O
that	O
experienced	O
a	O
major	B-O
deterioration	I-O
or	I-O
improvement	I-O
of	I-O
nutritional	I-O
status	I-O
.	I-O


We	O
conclude	O
that	O
an	O
intervention	O
that	O
reduces	O
rates	O
of	O
childhood	B-O
diarrhea	I-O
may	O
not	O
necessarily	O
also	O
improve	O
nutritional	B-O
status	I-O
.	I-O


Randomized	O
controlled	O
trial	O
of	O
melatonin	B-I
for	O
children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
and	I-P
sleep	I-P
problems	I-P
.	I-P


BACKGROUND	O
Melatonin	O
is	O
often	O
used	O
for	O
autistic	B-P
children	I-P
with	I-P
sleep	I-P
disorders	I-P
,	O
despite	O
a	O
lack	O
of	O
published	O
evidence	O
in	O
this	O
population	O
.	O


METHODS	O
A	O
randomized	O
,	O
placebo-controlled	B-I
double-blind	O
crossover	O
trial	O
of	O
melatonin	B-I
was	O
undertaken	O
in	O
11	B-P
children	I-P
with	I-P
autistic	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


RESULTS	O
Seven	B-P
children	I-P
completed	I-P
the	I-P
trial	I-P
.	I-P


Sleep	B-O
latency	I-O
was	O
2.6	O
h	O
[	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
2.28-2.93	O
]	O
baseline	O
,	O
1.91	O
h	O
(	O
95	O
%	O
CI	O
1.78-2.03	O
)	O
with	O
placebo	O
and	O
1.06	O
h	O
(	O
95	O
%	O
CI	O
0.98-1.13	O
)	O
with	O
melatonin	O
.	O


Wakings	B-O
per	I-O
night	I-O
were	O
0.35	O
(	O
95	O
%	O
CI	O
0.18-0.53	O
)	O
baseline	O
,	O
0.26	O
(	O
95	O
%	O
CI	O
0.20-0.34	O
)	O
with	O
placebo	B-I
and	O
0.08	O
(	O
95	O
%	O
CI	O
0.04-0.12	O
)	O
with	O
melatonin	O
.	O


Total	B-O
sleep	I-O
duration	I-O
was	O
8.05	O
h	O
(	O
95	O
%	O
CI	O
7.65-8.44	O
)	O
baseline	O
,	O
8.75	O
h	O
(	O
95	O
%	O
CI	O
8.56-8.98	O
)	O
with	O
placebo	O
and	O
9.84	O
h	O
(	O
95	O
%	O
CI	O
9.68-9.99	O
)	O
with	O
melatonin	O
.	O


CONCLUSIONS	O
Although	O
the	O
study	O
was	O
small	O
owing	O
to	O
recruitment	O
difficulties	O
,	O
it	O
still	O
provides	O
evidence	O
of	O
effectiveness	B-O
of	O
melatonin	O
in	O
children	B-P
with	I-P
sleep	I-P
difficulties	I-P
and	I-P
ASD	I-P
,	O
which	O
we	O
predict	O
a	O
larger	O
study	O
would	O
confirm	O
.	O


Probiotics	B-I
in	O
the	O
management	O
of	O
atopic	B-P
eczema	I-P
.	I-P


BACKGROUND	O
Over	O
the	O
last	O
two	O
decades	O
the	O
incidence	O
of	O
allergic	O
diseases	O
has	O
increased	O
in	O
industrialized	O
countries	O
,	O
and	O
consequently	O
new	O
approaches	O
have	O
to	O
be	O
explored	O
.	O


OBJECTIVE	O
The	O
potential	O
of	O
probiotics	O
to	O
control	O
allergic	B-O
inflammation	I-O
at	I-P
an	I-P
early	I-P
age	I-P
was	O
assessed	O
in	O
a	O
randomized	O
double-blind	O
placebo-controlled	O
study	O
.	O


METHODS	O
A	B-P
total	I-P
of	I-P
27	I-P
infants	I-P
,	I-P
mean	I-P
age	I-P
4.6	I-P
months	I-P
,	I-P
who	I-P
manifested	I-P
atopic	I-P
eczema	I-P
during	I-P
exclusive	I-P
breast-feeding	I-P
and	I-P
who	I-P
have	I-P
had	I-P
no	I-P
exposure	I-P
to	I-P
any	I-P
infant	I-P
or	I-P
substitute	I-P
formula	I-P
were	O
weaned	O
to	O
probiotic-supplemented	B-I
,	I-I
Bifidobacterium	I-I
lactis	I-I
Bb-12	I-I
or	I-I
Lactobacillus	I-I
strain	I-I
GG	I-I
(	I-I
ATCC	I-I
53103	I-I
)	I-I
,	I-I
extensively	I-I
hydrolysed	I-I
whey	I-I
formulas	I-I
or	I-I
to	I-I
the	I-I
same	I-I
formula	I-I
without	I-I
probiotics	I-I
.	I-I


The	O
extent	O
and	O
severity	O
of	O
atopic	O
eczema	O
,	O
the	O
growth	O
and	O
nutrition	O
of	O
infants	O
,	O
and	O
concentrations	O
of	O
circulating	O
cytokines/chemokines	O
and	O
soluble	O
cell	O
surface	O
adhesion	O
molecules	O
in	O
serum	O
and	O
methyl-histamine	O
and	O
eosinophilic	O
protein	O
X	O
in	O
urine	O
were	O
determined	O
.	O


RESULTS	O
The	O
SCORAD	B-O
score	I-O
reflecting	O
the	O
extent	B-O
and	I-O
severity	I-O
of	I-O
atopic	I-O
eczema	I-O
was	O
16	O
(	O
7-25	O
)	O
during	O
breast-feeding	O
,	O
median	O
(	O
interquartile	O
range	O
)	O
.	O


After	O
2	O
months	O
,	O
a	O
significant	O
improvement	O
in	O
skin	B-O
condition	I-O
occurred	O
in	O
patients	O
given	O
probiotic-supplemented	O
formulas	O
,	O
as	O
compared	O
to	O
the	O
unsupplemented	O
group	O
;	O
chi	O
(	O
2	O
)	O
=	O
12.27	O
,	O
P	O
=	O
0.002	O
.	O


SCORAD	B-O
decreased	O
in	O
the	O
Bifidobacterium	O
lactis	O
Bb-12	O
group	O
to	O
0	O
(	O
0-3.8	O
)	O
,	O
and	O
in	O
the	O
Lactobacillus	O
GG	O
group	O
to	O
1	O
(	O
0.1-8.7	O
)	O
,	O
vs	O
unsupplemented	O
13.4	O
(	O
4.5-18.2	O
)	O
,	O
median	O
(	O
interquartile	O
range	O
)	O
,	O
in	O
parallel	O
with	O
a	O
reduction	O
in	O
the	O
concentration	O
of	O
soluble	O
CD4	B-O
in	O
serum	O
and	O
eosinophilic	O
protein	O
X	O
in	O
urine	O
.	O


CONCLUSION	O
The	O
results	O
provide	O
the	O
first	O
clinical	O
demonstration	O
of	O
specific	O
probiotic	O
strains	O
modifying	O
the	O
changes	O
related	O
to	O
allergic	B-O
inflammation	I-O
.	I-O


The	O
data	O
further	O
indicate	O
that	O
probiotics	O
may	O
counteract	O
inflammatory	B-O
responses	I-O
beyond	O
the	O
intestinal	O
milieu	O
.	O


The	O
combined	O
effects	O
of	O
these	O
probiotic	O
strains	O
will	O
guide	O
infants	B-P
through	O
the	O
weaning	O
period	O
,	O
when	O
sensitization	O
to	O
newly	O
encountered	O
antigens	O
is	O
initiated	O
.	O


The	O
probiotic	O
approach	O
may	O
thus	O
offer	O
a	O
new	O
direction	O
in	O
the	O
search	O
for	O
future	O
foods	O
for	O
allergy	O
treatment	O
and	O
prevention	O
strategies	O
.	O


Pretreatment	O
and	O
co-administration	O
of	O
oral	B-I
anti-diabetic	I-I
agent	I-I
with	O
clomiphene	B-I
citrate	I-I
or	O
rFSH	B-I
for	O
ovulation	O
induction	O
in	O
clomiphene-citrate-resistant	B-P
polycystic	I-P
ovary	I-P
syndrome	I-P
.	I-P


AIM	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
result	O
of	O
pretreatment	O
and	O
concomitant	O
use	O
of	O
metformin	B-I
with	O
clomiphene	B-I
citrate	I-I
(	I-I
CC	I-I
)	I-I
and	O
rFSH	B-I
for	O
ovulation	O
induction	O
in	O
clomiphene-citrate-resistant	B-P
polycystic	I-P
ovary	I-P
syndrome	I-P
(	I-P
PCOS	I-P
)	I-P
.	I-P


MATERIAL	O
AND	O
METHODS	O
This	O
randomized	O
controlled	O
trial	O
was	O
done	O
in	O
the	O
Dhaka	B-P
Medical	I-P
College	I-P
and	I-P
Hospital	I-P
and	I-P
the	I-P
Infertility	I-P
Care	I-P
and	I-P
Research	I-P
Centre	I-P
,	I-P
Dhaka	I-P
,	I-P
Bangladesh	I-P
.	I-P


A	O
total	O
of	O
165	B-P
infertile	I-P
patients	I-P
with	I-P
CC-resistant	I-P
PCOS	I-P
who	I-P
attended	I-P
for	I-P
treatment	I-P
were	I-P
the	I-P
target	I-P
population	I-P
for	I-P
this	I-P
study	I-P
.	I-P


Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
groups	O
A	O
and	O
B	O
were	O
given	O
metformin	B-I
and	O
group	O
C	O
was	O
the	O
control	B-I
.	I-I


Along	O
with	O
metformin	B-I
,	O
group	O
A	O
received	O
CC	B-I
and	O
group	O
B	O
received	O
rFSH	B-I
.	I-I


Group	O
C	O
was	O
treated	O
with	O
only	O
rFSH	B-I
.	I-I


Metformin	B-I
was	O
given	O
1500	O
mg	O
daily	O
for	O
4	O
weeks	O
.	O


Afterwards	B-I
CC	I-I
or	I-I
rFSH	I-I
were	O
added	O
for	O
induction	O
of	O
ovulation	O
along	O
with	B-I
metformin	I-I
.	O


Six	O
ovulatory	O
cycles	O
were	O
assessed	O
.	O


Treatment	O
was	O
terminated	O
when	O
there	O
was	O
no	O
response	O
with	O
maximum	O
dose	O
of	B-I
CC	I-I
and	I-I
rFSH	I-I
or	O
after	O
six	O
ovulatory	O
cycles	O
without	O
pregnancy	O
or	O
after	O
achieving	O
pregnancy	O
.	O


A	O
P-value	O
of	O
<	O
0.5	O
was	O
considered	O
as	O
significant	O
.	O


RESULTS	B-O
Ovulation	I-O
(	O
89.09	O
%	O
)	O
and	B-O
pregnancy	I-O
(	O
54.55	O
%	O
)	O
rates	O
were	O
higher	O
in	O
group	O
B.	B-O
Ovulation	I-O
(	O
74.55	O
%	O
)	O
and	B-O
pregnancy	I-O
(	O
29.09	O
%	O
)	O
rates	O
were	O
also	O
satisfactory	O
in	O
group	O
C	O
but	O
a	O
dose	O
of	B-I
rFSH	I-I
requirement	O
was	O
significantly	O
higher	O
(	O
P	O
=	O
0.000	O
)	O
.	O


In	O
group	O
A	O
,	O
both	B-O
ovulation	I-O
and	I-O
pregnancy	I-O
rate	O
were	O
much	O
lower	O
than	O
the	O
other	O
two	O
groups	O
(	O
27.27	O
%	O
and	O
12.73	O
%	O
,	O
respectively	O
)	O
.	O


CONCLUSIONS	O
Use	B-I
of	I-I
metformin	I-I
increases	O
the	O
response	O
of	O
ovulation-inducing	O
agents	O
and	O
can	O
be	O
used	O
safely	B-P
in	I-P
PCOS	O
.	O


Antibiotic	O
elimination	O
of	O
group-B	O
streptococci	O
in	O
urine	O
in	O
prevention	O
of	O
preterm	B-O
labour	I-O
.	I-O


The	O
presence	O
of	O
group-B	O
streptococci	O
in	O
the	O
urine	O
of	O
pregnant	B-P
women	I-P
seems	O
to	O
be	O
associated	O
with	O
preterm	O
labour	O
.	O


Urine	O
samples	O
from	O
4122	B-P
women	I-P
at	I-P
27-31	I-P
weeks	I-P
'	I-P
gestation	I-P
were	O
examined	O
for	O
bacteria	O
.	O


Group-B	O
streptococci	O
were	O
found	O
in	O
the	O
urine	O
of	O
69	B-P
women	I-P
.	I-P


In	O
a	O
double-blind	O
,	O
controlled	O
study	O
these	O
patients	O
were	O
given	O
either	O
penicillin	B-I
(	O
10	O
(	O
6	O
)	O
IU	O
three	O
times	O
daily	O
for	O
6	O
days	O
;	O
37	O
patients	O
)	O
or	O
placebo	B-I
(	O
32	O
patients	O
)	O
.	O


The	O
rates	O
of	O
primary	B-O
rupture	I-O
of	I-O
the	I-O
membranes	I-O
(	O
11	O
%	O
v	O
53	O
%	O
;	O
p	O
less	O
than	O
0.001	O
)	O
and	O
preterm	B-O
labour	I-O
(	O
5.4	O
%	O
v	O
38	O
%	O
;	O
p	O
less	O
than	O
0.002	O
)	O
were	O
significantly	O
lower	O
in	O
the	O
penicillin	B-I
group	O
than	O
in	O
the	O
placebo	B-I
group	O
.	O


These	O
results	O
suggest	O
that	O
treatment	O
and	O
follow-up	O
to	O
prevent	O
recolonisation	O
in	O
pregnant	B-P
women	I-P
with	I-P
group-B	I-P
streptococci	I-P
in	I-P
the	I-P
urine	I-P
may	O
reduce	O
the	O
frequency	B-O
of	I-O
preterm	I-O
labour	I-O
in	O
these	O
patients	O
.	O


[	O
Pharmacokinetics	O
of	O
theophylline	O
in	O
sustained-release	O
formulation	O
in	O
young	B-P
asthmatics	I-P
]	I-P
.	O


Pharmacokinetics	O
of	O
two	B-I
theophylline	I-I
(	I-I
CAS	I-I
58-55-9	I-I
)	I-I
sustained	I-I
release	I-I
preparations	I-I
(	I-I
T	I-I
:	I-I
Bronchoretard	I-I
Capsules/R	I-I
:	I-I
Capsule	I-I
formulation	I-I
from	I-I
the	I-I
US	I-I
market	I-I
)	I-I
were	O
investigated	O
in	O
an	O
open	O
randomised	O
two-way	O
crossover	O
design	O
.	O


The	O
capsules	O
of	O
the	O
test	O
formulation	O
were	O
opened	O
and	O
administered	O
on	O
a	O
tablespoonful	O
of	O
apple	O
sauce	O
.	O


Nineteen	B-P
asthmatics	I-P
aged	I-P
6	I-P
to	I-P
12	I-P
years	I-P
participated	O
in	O
this	O
study	O
.	O


Following	B-I
individual	I-I
dosing	I-I
of	I-I
100-300	I-I
mg	I-I
theophylline	I-I
twice	I-I
a	I-I
day	I-I
,	I-I
a	I-I
pharmacokinetic	I-I
profile	I-I
for	I-I
24	I-I
h	I-I
was	I-I
derived	I-I
after	I-I
seven	I-I
days	I-I
of	I-I
multiple	I-I
dosing	I-I
.	I-I


All	B-I
relevant	I-O
parameters	I-O
for	I-O
rate	I-O
(	I-O
Cmax	I-O
ss	I-O
,	I-O
Cmin	I-O
ss	I-O
,	I-O
Cav	I-O
ss	I-O
,	I-O
plateau	I-O
time	I-O
,	I-O
peak-trough	I-O
fluctuation	I-O
,	I-O
nocturnal	I-O
excess	I-O
,	I-O
tmax	I-O
ss	I-O
)	I-O
and	I-I
extent	I-O
of	I-O
absorption	I-O
(	I-O
AUCss	I-O
)	I-O
were	I-I
calculated	I-I
for	I-I
both	I-I
formulations	I-I
.	I-I


With	O
long	O
plateau	B-O
times	I-O
(	O
T	O
:	O
17.3	O
h	O
)	O
and	O
small	B-O
peak-trough	I-O
fluctuations	I-O
(	O
T	O
:	O
49.0	O
%	O
)	O
,	O
established	O
quality	O
criteria	O
for	O
high	O
quality	O
theophylline	O
preparations	O
were	O
fulfilled	O
by	O
the	O
test	O
formulation	O
.	O


Furthermore	O
,	O
symmetrical	B-O
peaks	I-O
resulted	O
after	O
morning	O
and	O
evening	O
administration	O
of	O
the	O
test	O
formulation	O
.	O


In	O
conclusion	O
,	O
smooth	O
and	O
predictable	O
concentration/time	B-O
profiles	I-O
were	O
achieved	O
,	O
enabling	O
an	O
efficacious	O
and	O
safe	O
therapy	O
of	O
asthma	O
.	O


This	O
individual	O
mode	O
of	O
administration	O
allows	O
not	O
only	O
a	O
perfect	O
dose	O
titration	O
in	O
young	B-P
asthmatics	I-P
,	O
but	O
is	O
also	O
helpful	O
to	O
patients	B-P
who	I-P
have	I-P
difficulty	I-P
in	I-P
swallowing	I-P
large	I-P
dosage	I-P
forms	I-P
.	I-P


Weight	B-O
and	I-O
leptin	I-O
changes	I-O
among	O
risperidone-treated	B-I
youths	I-P
with	I-P
autism	I-P
:	I-P
6-month	O
prospective	O
data	O
.	O


OBJECTIVE	O
The	O
authors	O
examined	O
the	O
developmental	O
impact	O
and	O
temporal	O
characteristics	O
of	O
risperidone-associated	B-I
weight	I-O
change	I-O
.	I-O


METHOD	O
Weight	B-O
change	I-O
was	O
measured	O
for	O
63	B-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
treated	I-P
with	I-P
risperidone	I-I
for	I-P
6	I-P
months	I-P
.	I-P


Change	B-O
in	I-O
serum	I-O
leptin	I-O
levels	I-O
after	O
2	O
months	O
was	O
examined	O
as	O
a	O
predictor	O
of	O
final	B-O
weight	I-O
gain	I-O
in	O
mixed	O
regression	O
models	O
that	O
controlled	O
for	O
site	O
,	O
gender	O
,	O
age	O
,	O
and	O
risperidone	B-I
dose	O
.	O


RESULTS	O
Age-	O
and	O
gender-standardized	O
weight	B-O
increased	I-O
after	O
6	O
months	O
of	O
treatment	O
(	O
gross	O
:	O
mean=5.6	O
kg	O
[	O
SD=3.9	O
]	O
;	O
standardized	O
:	O
mean=0.6	O
z	O
[	O
SD=0.5	O
]	O
)	O
and	O
was	O
positively	O
correlated	O
with	O
weight	B-O
gained	I-O
after	O
1	O
month	O
.	O


Change	B-O
in	I-O
leptin	I-O
levels	I-O
after	O
2	O
months	O
of	O
treatment	O
(	O
mean=-0.3	O
ng/ml	O
,	O
SD=6.2	O
)	O
(	O
N=48	O
)	O
did	O
not	O
predict	O
final	B-O
weight	I-O
gain	I-O
.	I-O


CONCLUSIONS	O
Chronic	O
risperidone	B-I
exposure	O
in	O
children	O
with	O
autism	O
causes	O
weight	B-O
gain	I-O
in	O
excess	O
of	O
developmentally	O
expected	O
norms	O
that	O
follows	O
a	O
curvilinear	O
trajectory	O
and	O
decelerates	O
over	O
time	O
.	O


Serum	B-O
leptin	I-O
change	I-O
does	O
not	O
reliably	O
predict	O
risperidone-associated	O
weight	B-O
gain	I-O
.	I-O


Intravenous	B-I
regional	I-I
anaesthesia	I-I
below	O
the	O
knee	O
.	O


A	O
cross-over	O
study	O
with	O
prilocaine	B-I
in	I-P
volunteers	I-P
.	I-P


The	O
quality	O
of	O
anaesthesia	O
provided	O
by	O
three	O
dosages	O
of	O
prilocaine	B-I
,	O
40	O
ml	O
0.5	O
%	O
,	O
20	O
ml	O
1	O
%	O
,	O
or	O
40	O
ml	O
1	O
%	O
,	O
administered	O
in	O
random	O
order	O
,	O
for	O
intravenous	O
regional	O
anaesthesia	O
of	O
the	O
lower	O
extremity	O
below	O
the	O
knee	O
was	O
compared	O
in	O
six	B-P
volunteers	I-P
.	I-P


Limited	O
sensory	O
blockade	O
was	O
achieved	O
in	O
the	O
groups	O
with	O
40	O
ml	O
0.5	O
%	O
and	O
20	O
ml	O
1	O
%	O
during	O
the	O
30-minute	O
test	O
period	O
.	O


One	O
subject	O
was	O
not	O
fully	O
anaesthetised	O
with	O
any	O
of	O
the	O
dosages	O
used	O
.	O


Recovery	B-O
was	I-O
rapid	I-O
(	O
mean	O
12-13	O
minutes	O
)	O
in	O
these	O
two	O
groups	O
.	O


In	O
two	O
subjects	O
given	O
40	O
ml	O
of	O
1	O
%	O
,	O
complete	B-O
recovery	I-O
took	O
90	O
minutes	O
.	O


At	O
30	O
minutes	O
,	O
the	O
degree	B-O
of	I-O
flexion	I-O
remaining	I-O
in	I-O
the	I-O
great	I-O
toe	I-O
(	O
control	O
100	O
%	O
)	O
was	O
4	O
%	O
in	O
the	O
groups	O
who	O
received	O
40	O
ml	O
of	O
0.5	O
%	O
and	O
1	O
%	O
,	O
but	O
34	O
%	O
in	O
those	O
who	O
received	O
20	O
ml	O
of	O
1	O
%	O
respectively	O
.	O


Full	B-O
motor	I-O
recovery	I-O
was	O
achieved	O
in	O
8-9	O
minutes	O
.	O


Five	O
of	O
six	O
volunteers	O
who	O
received	O
the	O
400-mg	O
dose	O
experienced	O
subjective	B-O
signs	I-O
of	I-O
central	I-O
nervous	I-O
system	I-O
side	I-O
effects	I-O
when	O
the	O
cuff	O
was	O
released	O
.	O


In	O
this	O
group	O
,	O
the	O
mean	B-O
plasma	I-O
level	I-O
of	O
prilocaine	B-I
at	O
2	O
minutes	O
was	O
1.22	O
micrograms/ml	O
,	O
maximum	O
2.12	O
micrograms/ml	O
.	O


In	O
a	O
radiological	O
examination	O
,	O
no	B-O
leak	I-O
of	I-O
contrast	I-O
medium	I-O
under	I-O
the	I-O
tourniquet	I-O
cuff	I-O
(	I-O
300	I-O
mmHg	I-O
)	I-O
was	O
detected	O
.	O


The	O
development	O
of	O
anaesthesia	O
was	O
fastest	B-O
following	O
the	O
largest	O
dose	O
,	O
but	O
the	O
large	B-O
number	I-O
of	I-O
central	I-O
side	I-O
effects	I-O
makes	O
that	O
dosage	O
less	B-O
suitable	I-O
for	I-O
clinical	I-O
work	I-O
.	I-O


Complement	O
activation	O
on	O
the	O
surface	O
of	O
cell-derived	O
microparticles	O
during	O
cardiac	B-P
surgery	I-P
with	I-P
cardiopulmonary	I-I
bypass	I-I
-	O
is	O
retransfusion	O
of	O
pericardial	O
blood	O
harmful	O
?	O
OBJECTIVES	O
To	O
investigate	O
whether	O
cell-derived	O
microparticles	O
play	O
a	O
role	O
in	O
complement	B-O
activation	I-O
in	O
pericardial	O
blood	O
of	O
patients	B-P
undergoing	I-P
cardiac	I-I
surgery	I-I
with	I-I
cardiopulmonary	I-I
bypass	I-I
(	I-I
CPB	I-I
)	I-I
and	I-I
whether	O
microparticles	O
in	O
pericardial	O
blood	O
contribute	O
to	O
systemic	B-O
complement	I-O
activation	I-O
upon	O
retransfusion	O
.	O


METHODS	O
Pericardial	B-P
blood	I-P
of	I-P
13	I-P
patients	I-P
was	O
retransfused	O
in	O
9	O
and	O
discarded	O
in	O
4	O
cases	O
.	O


Microparticles	O
were	O
isolated	O
from	O
systemic	O
blood	B-I
collected	I-I
before	I-I
anesthesia	I-I
(	O
T1	O
)	O
and	O
at	O
the	O
end	O
of	O
CPB	B-I
(	O
T2	O
)	O
,	O
and	O
from	O
pericardial	O
blood	O
.	O


The	O
microparticles	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
for	O
bound	O
complement	O
components	O
C1q	O
,	O
C4	O
and	O
C3	O
,	O
and	O
bound	O
complement	O
activator	O
molecules	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
serum	O
amyloid	O
P-component	O
(	O
SAP	O
)	O
,	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
and	O
IgG	O
.	O


Fluid-phase	O
complement	O
activation	O
products	O
(	O
C4b/c	O
,	O
C3b/c	O
)	O
and	O
activator	O
molecules	O
were	O
determined	O
by	O
ELISA	B-I
.	I-I


RESULTS	O
Compared	O
with	O
systemic	O
T1	O
blood	O
,	O
pericardial	O
blood	O
contained	O
increased	O
C4b/c	B-O
and	I-O
C3b/c	I-O
,	O
and	O
increased	O
levels	B-O
of	I-O
microparticles	I-O
with	O
bound	O
complement	O
components	O
.	O


In	O
systemic	O
T1	O
samples	O
,	O
microparticle-bound	O
CRP	O
,	O
whereas	O
in	O
pericardial	O
blood	O
,	O
microparticle-bound	O
SAP	O
and	O
IgM	O
were	O
associated	O
with	O
complement	O
activation	O
.	O


At	O
the	O
end	O
of	O
CPB	B-I
,	O
increased	O
C3b/c	B-O
(	I-O
but	I-O
not	I-O
C4b/c	I-O
)	I-O
was	O
present	O
in	O
systemic	O
T2	O
blood	O
compared	O
with	O
T1	O
,	O
while	O
concentrations	O
of	O
microparticles	O
binding	O
complement	O
components	O
and	O
of	O
those	O
binding	O
complement	O
activator	O
molecules	O
were	O
similar	O
.	O


Concentrations	B-O
of	I-O
fluid-phase	I-O
complement	I-O
activation	I-O
products	I-O
and	I-O
microparticles	I-O
were	O
similar	O
in	O
patients	O
whether	O
or	O
not	O
retransfused	O
with	O
pericardial	O
blood	O
.	O


CONCLUSIONS	O
In	O
pericardial	O
blood	O
of	O
patients	B-P
undergoing	I-P
cardiac	I-P
surgery	I-P
with	I-P
CPB	I-I
,	O
microparticles	O
contribute	O
to	O
activation	B-O
of	I-O
the	I-O
complement	I-O
system	I-O
via	O
bound	O
SAP	O
and	O
IgM	O
.	O


Retransfusion	O
of	O
pericardial	O
blood	O
,	O
however	O
,	O
does	O
not	O
contribute	O
to	O
systemic	B-O
complement	I-O
activation	I-O
.	I-O


Effect	O
of	O
simvastatin	B-I
and	I-I
fenofibrate	I-I
on	O
endothelium	O
in	O
Type	B-P
2	I-P
diabetes	I-P
.	I-P


Statins	O
and	O
fibrates	O
influence	O
endothelial	O
activity	O
and	O
consequently	O
atherogenesis	O
but	O
the	O
mechanisms	O
are	O
not	O
well	O
understood	O
.	O


Twenty	B-P
Type	I-P
2	I-P
diabetic	I-P
patients	I-P
with	I-P
dyslipidemia	I-P
were	I-P
treated	I-P
3	O
months	O
with	O
simvastatin	B-I
(	O
20	O
mg	O
daily	O
)	O
and	O
then	O
3	O
months	O
with	O
fenofibrate	B-I
(	O
200	O
mg	O
daily	O
)	O
with	O
2	O
months	O
of	O
wash-out	O
between	O
the	O
two	O
treatments	O
.	O


Laboratory	O
parameters	O
of	O
oxidative	O
stress	O
,	O
fibrinolysis	O
and	O
endothelial	O
function	O
were	O
evaluated	O
before	O
and	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
.	O


The	O
significant	O
decrease	O
in	O
serum	B-O
total	I-O
and	I-O
LDL-cholesterol	I-O
concentrations	I-O
(	O
P	O
<	O
0.0001	O
)	O
caused	O
by	O
simvastatin	O
was	O
associated	O
with	O
an	O
increase	O
in	O
serum	B-O
N-acetyl-beta-glucosaminidase	I-O
activity	I-O
(	O
P	O
<	O
0.001	O
)	O
,	O
ascorbic	B-O
acid	I-O
(	O
P	O
<	O
0.001	O
)	O
,	O
plasminogen	B-O
activator	I-O
inhibitor	I-O
(	O
PAI-1	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
vonWillebrand	B-O
factor	I-O
(	O
P	O
<	O
0.05	O
)	O
,	O
E-selectin	B-O
(	O
P	O
<	O
0.01	O
)	O
and	O
vascular	B-O
endothelial	I-O
growth	I-O
factor	I-O
(	O
P	O
<	O
0.05	O
)	O
concentrations	O
and	O
with	O
a	O
decrease	B-O
in	I-O
plasma	I-O
glutathione	I-O
(	I-O
P	I-O
<	I-O
0.01	I-O
)	I-O
levels	I-O
.	I-O


Fenofibrate	O
caused	O
a	O
significant	O
decrease	O
in	O
serum	B-O
triglyceride	I-O
concentration	I-O
(	O
P	O
<	O
0.0001	O
)	O
associated	O
with	O
a	O
decrease	O
in	O
plasma	B-O
malondialdehyde	I-O
(	O
P	O
<	O
0.001	O
)	O
and	O
an	O
increase	B-O
in	I-O
plasma	I-O
PAI-1	I-O
(	O
P	O
<	O
0.05	O
)	O
and	O
P-selectin	B-O
(	I-O
P	I-O
<	I-O
0.05	I-O
)	I-O
concentrations	O
.	O


We	O
conclude	O
that	O
simvastatin	O
and	O
fenofibrate	O
interact	O
,	O
by	O
different	O
mechanisms	O
,	O
with	O
oxidative	O
stress	O
,	O
a	O
key	O
factor	O
in	O
the	O
modification	O
of	O
fibrinolysis	O
and	O
endothelial	O
function	O
in	O
Type	O
2	O
diabetes	O
.	O


Comparative	B-O
bioavailability	I-O
of	O
two	O
formulations	O
of	O
terbinafine	B-I
.	I-I


Data	O
from	O
a	O
cross-over	O
,	O
randomised	O
,	O
open-label	O
bioequivalence	O
study	O
in	O
healthy	B-P
volunteers	I-P
.	I-P


An	O
open-label	O
,	O
randomised	O
,	O
cross-over	O
single	O
dose	O
study	O
,	O
using	O
2	O
periods	O
x	O
2	O
sequences	O
,	O
with	O
a	O
minimum	O
washout	O
period	O
of	O
21	O
days	O
,	O
was	O
conducted	O
in	O
order	O
to	O
assess	O
the	O
comparative	B-O
bioavailability	I-O
of	O
two	O
formulations	O
of	O
terbinafine	B-I
(	I-I
CAS	I-I
78628-80-5	I-I
)	I-I
250	O
mg	O
tablets	O
.	O


Plasma	B-O
samples	I-O
were	O
obtained	O
at	O
baseline	O
,	O
+0.333	O
;	O
0.667	O
;	O
1.00	O
;	O
1.33	O
;	O
1.67	O
;	O
2.00	O
;	O
2.33	O
;	O
2.67	O
;	O
3.00	O
;	O
3.50	O
;	O
4.00	O
;	O
6.00	O
;	O
8.00	O
;	O
12.0	O
;	O
24.0	O
;	O
36.0	O
;	O
48.0	O
and	O
72.0	O
h	O
post-administration	O
.	O


Terbinafine	B-O
levels	I-O
were	I-O
determined	I-O
by	I-O
high	I-O
pressure	I-O
liquid	I-O
chromatography	I-O
with	I-O
tandem	I-O
mass	I-O
detection	I-O
(	I-O
HPLC-MS/MS	I-O
)	I-O
and	O
the	O
lower	O
limit	O
of	O
quantification	O
was	O
set	O
at	O
9.99	O
ng/mL	O
.	O


The	O
pharmacokinetic	B-O
parameters	I-O
used	O
for	O
the	O
bioequivalence	B-O
assessment	I-O
(	I-O
AUClast	I-O
,	I-O
AUCinf	I-O
and	I-O
Cmax	I-O
)	I-O
were	O
determined	O
from	O
the	O
terbinafine	O
concentration	O
data	O
using	O
non-compartmental	O
analysis	O
.	O


Classical	B-O
90	I-O
%	I-O
confidence	I-O
intervals	I-O
(	I-O
90CI	I-O
)	I-O
were	O
calculated	O
for	O
the	O
overall	O
sample	O
,	O
and	O
for	O
males	B-P
and	I-P
females	I-P
separately	O
,	O
and	O
gender	O
effects	O
were	O
investigated	O
using	O
an	O
appropriate	O
model	O
.	O


The	O
results	O
showed	O
that	O
overall	O
classical	B-O
90CI	I-O
were	O
96.08-105.40	O
%	O
for	O
AUCinf	O
,	O
95.68-105.33	O
for	O
AUClast	B-O
and	O
88.24-112.83	O
for	O
Cmax	B-O
,	O
that	O
is	O
,	O
all	O
within	O
the	O
predefined	O
ranges	O
for	O
bioequivalence	O
acceptance	O
.	O


Separate	O
gender	O
analysis	O
showed	O
very	O
similar	O
results	B-O
for	O
males	B-P
and	I-P
females	I-P
when	O
analysed	O
independently	O
,	O
and	O
no	O
gender	B-O
effects	I-O
were	O
detected	O
(	O
p	O
>	O
0.05	O
for	O
all	O
of	O
the	O
tested	O
model	O
effects	O
)	O
.	O


It	O
may	O
be	O
therefore	O
concluded	O
that	O
the	O
evaluated	O
formulations	O
are	O
bioequivalent	O
in	O
terms	O
of	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O


[	O
Effect	O
of	O
alpha	B-I
dihydroergocryptine	I-I
in	O
patients	B-P
with	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
]	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
alpha	B-I
dihidroergocriptine	I-I
in	O
patients	B-P
with	I-P
fibrocystic	I-P
mastopathy	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
with	I-P
diagnosis	I-P
of	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
were	I-P
included	I-P
in	O
a	O
prospective	O
longitudinal	O
blind	O
double	O
,	O
controlled	O
with	O
placebo	B-I
study	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
of	O
treatment	O
group	O
A	O
:	O
Alpha	B-I
dihidroergocriptine	I-I
tablets	I-I
of	I-I
10	I-I
mg	I-I
,	O
group	O
B	O
:	O
Placebo	B-I
,	O
during	O
6	O
months	O
.	O


After	O
to	O
basal	O
evaluation	O
,	O
the	O
patients	O
were	O
revised	O
in	O
a	O
monthly	O
way	O
evaluating	O
the	O
following	O
symptoms	O
and	O
signs	O
:	O
mastalgia	B-O
,	I-O
mammary	I-O
tension	I-O
,	I-O
presence	I-O
of	I-O
nodules	I-O
,	I-O
nipple	I-O
secretion	I-O
,	I-O
and	I-O
the	I-O
presence	I-O
of	I-O
adverse	I-O
events	I-O
.	I-O


RESULTS	O
39	B-P
patients	I-P
with	I-P
alpha	I-I
dihidroergocriptine	I-I
and	I-P
38	I-P
with	I-P
placebo	I-I
.	I-I


Mastodinia	B-O
,	O
a	O
satisfactory	O
response	O
was	O
observed	O
in	O
100	O
%	O
of	O
alpha	B-I
dihidroergocriptine	I-I
group	O
vs	O
61.11	O
%	O
of	O
placebo	B-I
group	O
(	O
p	O
=	O
0.0002	O
)	O
.	O


Mastalgia	B-O
responded	O
in	O
100	O
%	O
of	O
alpha	O
dihidroergocriptine	O
group	O
vs	O
64.86	O
%	O
of	O
placebo	O
group	O
(	O
p	O
=	O
0.0003	O
)	O
.	O


Galactorrea	B-O
responded	O
100	O
%	O
of	O
alpha	B-I
dihidroergocriptine	I-I
group	O
vs	O
93.33	O
%	O
of	O
the	O
placebo	O
.	O


The	O
nodules	B-O
in	O
the	O
group	O
alpha	O
dihidroergocriptine	O
disappeared	O
in	O
23.1	O
%	O
and	O
in	O
21.1	O
%	O
of	O
the	O
placebo	O
group	O
.	O


Ultrasound	B-O
evaluation	I-O
of	I-O
the	I-O
nodules	I-O
did	O
not	O
show	O
significant	O
differences	O
between	O
both	O
groups	O
.	O


Prolactin	B-O
levels	I-O
showed	O
a	O
decrease	O
in	O
the	O
group	O
treated	O
with	O
alpha	B-I
dihidroergocriptine	I-I
with	O
an	O
important	O
difference	O
between	O
both	O
groups	O
at	O
the	O
end	O
of	O
the	O
6	O
months	O
study	O
period	O
.	O


There	O
were	O
not	O
differences	O
in	O
the	O
presence	B-O
of	I-O
adverse	I-O
events	I-O
between	O
groups	O
.	O


CONCLUSIONS	O
Alpha	B-I
dihidroergocriptine	I-I
is	O
effective	O
in	O
the	O
treatment	O
of	O
fribrocystic	B-O
breast	I-O
disease	I-O
with	O
minimum	O
adverse	O
events	O
when	O
compared	O
with	O
similar	O
drugs	O
.	O


Pre-treatment	O
proliferation	O
and	O
the	O
outcome	O
of	O
conventional	B-I
and	I-I
accelerated	I-I
radiotherapy	I-I
.	I-I


This	O
study	O
investigated	O
the	O
influence	O
of	O
pre-treatment	O
proliferation	O
characteristics	O
,	O
assessed	B-I
by	I-I
Ki-67	I-I
staining	I-I
,	O
in	O
patients	B-P
treated	I-P
in	I-P
the	I-P
CHART	I-P
trial	I-P
of	I-P
accelerated	I-I
radiotherapy	I-I
in	I-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
.	I-P


Histological	O
material	O
from	O
402	B-P
patients	I-P
was	O
collected	O
and	O
stained	O
for	O
the	O
presence	O
and	O
pattern	O
of	O
Ki-67	O
staining	O
.	O


Locoregional	B-O
control	I-O
and	O
overall	O
survival	O
were	O
the	O
main	O
clinical	O
endpoints	O
.	O


Increasing	O
Ki-67	O
positivity	O
was	O
associated	O
with	O
decreasing	O
differentiation	O
(	O
P	O
<	O
0.001	O
)	O
and	O
increasing	O
N-stage	O
(	O
P	O
<	O
0.004	O
)	O
.	O


Increasing	O
N-stage	O
was	O
also	O
associated	O
with	O
the	O
progression	O
of	O
proliferation	O
pattern	O
from	O
marginal	O
to	O
random	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Using	O
a	O
multivariate	O
model	O
,	O
a	O
trend	O
was	O
seen	O
towards	O
a	O
greater	O
benefit	O
from	O
CHART	O
in	O
the	O
lower	O
Ki-67	O
tumours	O
(	O
P	O
=	O
0.08	O
)	O
;	O
this	O
became	O
significant	O
by	O
pooling	O
the	O
low	O
and	O
intermediate	O
Ki-67	O
groups	O
in	O
comparison	O
with	O
the	O
high	O
Ki-67	O
group	O
(	O
P	O
=	O
0.032	O
)	O
.	O


Tumours	O
with	O
marginal	O
proliferation	O
pattern	O
showed	O
a	O
lower	O
hazard	O
ratio	O
with	O
CHART	O
versus	O
conventional	O
for	O
locoregional	O
control	O
(	O
P	O
=	O
0.005	O
)	O
.	O


The	O
data	O
presented	O
in	O
this	O
study	O
do	O
not	O
support	O
that	O
a	O
high	O
pre-treatment	O
Ki-67	O
is	O
associated	O
with	O
a	O
therapeutic	B-O
benefit	I-O
from	O
accelerated	B-I
radiotherapy	I-I
.	I-I


Evaluation	O
of	O
apical	O
sealing	O
ability	O
and	O
adaptation	O
to	O
dentine	O
of	O
two	B-I
resin-based	I-I
sealers	I-I
.	I-I


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
apical	O
sealing	O
ability	O
and	O
adaptation	O
to	O
dentine	O
of	O
two	B-I
resin-based	I-I
root	I-I
canal	I-I
sealers	I-I
.	I-I


The	B-P
root	I-P
canals	I-P
of	I-P
55	I-P
human	I-P
maxillary	I-P
anterior	I-P
teeth	I-P
were	O
prepared	O
using	O
a	O
step-back	O
technique	O
and	O
the	O
smear	O
layer	O
removed	O
with	O
17	O
%	O
ethylenediaminetetraacetic	O
acid	O
.	O


The	O
teeth	O
were	O
divided	O
into	O
two	O
groups	O
of	O
25	O
teeth	O
and	O
the	O
remaining	O
five	O
teeth	O
served	O
as	O
control	O
.	O


Then	O
the	O
teeth	O
were	O
prepared	B-I
and	I-I
obturated	I-I
with	I-I
gutta-percha	I-I
by	I-I
a	I-I
lateral	I-I
condensation	I-I
and	I-I
either	I-I
AH	I-I
plus	I-I
and	I-I
EndoRez	I-I
used	I-I
as	I-I
a	I-I
sealer	I-I
.	I-I


Twenty	O
teeth	O
from	O
each	O
group	O
were	O
used	O
for	O
the	O
apical	O
leakage	O
test	O
and	O
the	O
remaining	O
five	O
teeth	O
from	O
each	O
group	O
were	O
used	O
for	O
examination	O
under	O
the	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
.	O


For	O
apical	O
leakage	O
test	O
,	O
teeth	B-I
were	I-I
covered	I-I
with	I-I
nail	I-I
varnish	I-I
and	I-I
sticky	I-I
wax	I-I
to	I-I
within	I-I
1	I-I
mm	I-I
of	I-I
the	I-I
apical	I-I
foramen	I-I
and	I-I
placed	I-I
in	I-I
2	I-I
%	I-I
methylene	I-I
blue	I-I
for	I-I
7	I-I
days	I-I
.	I-I


After	O
this	O
period	O
,	O
the	B-I
teeth	I-I
were	I-I
sectioned	I-I
longitudinally	I-I
and	O
apical	O
leakage	O
measurements	O
made	O
.	O


The	O
mean	B-O
value	I-O
of	I-O
dye	I-O
penetration	I-O
for	I-O
AH	I-O
plus	I-O
was	O
2.87	O
+/-	O
0.43	O
mm	O
,	O
while	O
that	O
of	O
EndoRez	B-I
was	O
4.54	O
+/-	O
0.36	O
mm	O
.	O


The	O
difference	O
between	O
mean	O
of	O
dye	B-O
penetration	I-O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
.	O


The	O
SEM	O
examination	O
showed	O
both	O
sealers	O
had	O
better	B-O
adaptation	I-O
and	I-O
penetration	I-O
in	I-O
coronal	I-O
and	I-O
middle	I-O
thirds	I-O
than	O
apical	O
third	O
of	O
root	O
canal	O
.	O


In	O
apical	O
third	O
,	O
AH	B-I
plus	I-I
was	O
adapted	B-O
better	I-O
adpated	O
to	O
dentine	O
than	O
EndoRez	B-I
.	I-I


In	O
conclusion	O
,	O
AH	B-I
plus	I-I
sealer	I-I
has	O
better	B-O
apical	I-O
sealing	I-O
ability	I-O
and	O
adaptation	O
to	O
dentine	O
than	O
EndoRez	B-I
sealer	I-I
.	I-I


Internet-based	B-I
program	I-I
for	O
coping	O
with	O
cancer	O
:	O
a	O
randomized	O
controlled	O
trial	O
with	O
hematologic	B-P
cancer	I-P
patients	I-P
.	I-P


OBJECTIVE	O
Psychosocial	O
patient	O
care	O
in	O
oncology	O
is	O
no	O
longer	O
limited	O
to	O
the	O
inpatient	O
setting	O
.	O


Outpatient	O
services	O
are	O
in	O
demand	O
.	O


Internet-based	B-I
interventions	I-I
could	O
aid	O
in	O
optimizing	O
service	O
delivery	O
across	O
disciplines	O
.	O


The	O
effectiveness	O
of	O
an	O
Internet-based	O
program	O
for	O
hematologic	B-P
cancer	I-P
patients	I-P
was	O
tested	O
in	O
a	O
randomized	O
controlled	O
trial	O
under	O
field	O
experimental	O
conditions	O
.	O


METHODS	O
A	O
4-week	B-I
cognitive-behavioral	I-I
program	I-I
for	I-I
coping	I-I
with	O
cancer	O
was	O
offered	O
to	O
hematologic	B-P
cancer	I-P
patients	I-P
online	I-P
.	I-P


One	B-P
hundred	I-P
eighty-six	I-P
registrants	I-P
were	O
randomly	O
assigned	O
to	O
an	O
intervention	B-I
group	I-I
(	O
n	O
=	O
105	O
)	O
or	O
a	O
waiting	B-I
list	I-I
(	O
n	O
=	O
81	O
)	O
.	O


The	O
outcome	O
measures	O
,	O
'mental	B-O
adjustment	I-O
'	I-O
(	I-O
MAC	I-O
)	I-O
and	I-O
'psychological	I-O
distress	I-O
'	I-O
(	I-O
BSI	I-O
)	I-O
,	O
were	O
assessed	O
at	O
registration	O
and	O
after	O
4	O
weeks	O
.	O


Patient	B-O
satisfaction	I-O
was	O
assessed	O
(	O
ZUF-8	O
)	O
,	O
and	O
complete-cases	O
and	O
intention-to-treat	O
analyses	O
were	O
performed	O
.	O


RESULTS	O
At	O
registration	O
,	O
the	O
majority	O
of	O
participants	O
displayed	O
clinically	O
significant	O
distress	O
(	B-O
BSI	I-O
)	I-O
and	O
lacked	O
alternative	O
access	O
concerning	O
psychosocial	O
care	O
.	O


One	B-P
hundred	I-P
eleven	I-P
patients	I-P
filled	O
out	O
the	O
post	O
questionnaire	O
at	O
4	O
weeks	O
.	O


In	O
contrast	O
to	O
the	O
waiting	O
list	O
,	O
the	O
intervention	O
group	O
displayed	O
a	O
significant	O
increase	O
in	O
fighting	B-O
spirit	I-O
(	O
d	O
=	O
0.42	O
;	O
CI	O
95	O
%	O
,	O
0.04	O
to	O
0.80	O
)	O
.	O


The	O
effect	O
was	O
confirmed	O
by	O
intention-to-treat	O
analysis	O
(	O
d	O
=	O
0.33	O
;	O
CI	O
95	O
%	O
,	O
0.04	O
to	O
0.62	O
)	O
.	O


Otherwise	O
,	O
no	O
effects	O
were	O
observed	O
.	O


Patient	B-O
satisfaction	I-O
with	O
the	O
program	O
was	O
high	O
.	O


CONCLUSION	O
The	O
results	O
demonstrate	O
the	O
potential	O
efficacy	O
of	O
Internet-based	O
programs	O
while	O
highlighting	O
their	O
limitations	O
.	O


Future	O
research	O
is	O
needed	O
to	O
clarify	O
and	O
optimize	O
efficacy	O
,	O
taking	O
different	O
program	O
components	O
and	O
patient	O
characteristics	O
into	O
particular	O
consideration	O
.	O


Evolution	O
of	O
coronary	O
stenoses	O
is	O
related	O
to	O
baseline	O
severity	O
--	O
a	O
prospective	O
quantitative	O
angiographic	O
analysis	O
in	O
patients	B-P
with	I-P
moderate	I-P
coronary	I-P
disease	I-P
.	I-P


INTACT	O
Investigators	O
.	O


International	O
Nifedipine	O
Trial	O
on	O
Antiatherosclerotic	O
Therapy	O
.	O


A	O
correlation	O
of	O
the	O
angiographic	O
evolution	O
of	O
coronary	O
stenoses	O
(	O
stenosis	O
diameter	O
>	O
or	O
=	O
20	O
%	O
)	O
with	O
morphological	O
stenosis	O
parameters	O
at	O
baseline	O
could	O
help	O
to	O
identify	B-O
the	I-O
risk	I-O
of	I-O
progressive	I-O
stenoses	I-O
.	I-O


Therefore	O
,	O
the	O
data	O
of	O
the	O
prospective	O
INTACT	O
study	O
(	O
International	O
Nifedipine	O
Trial	O
on	O
Antiatherosclerotic	O
Therapy	O
)	O
were	O
reviewed	O
.	O


In	O
348	B-P
patients	I-P
with	I-P
moderate	I-P
coronary	I-P
artery	I-P
disease	I-P
,	I-P
standardized	I-I
coronary	I-I
angiograms	I-I
were	I-P
taken	I-P
3	I-P
years	I-P
apart	I-P
and	O
were	O
quantitatively	O
analysed	O
.	O


Changes	O
in	O
the	O
minimal	B-O
diameter	I-O
of	O
the	O
1063	O
preexisting	O
coronary	O
stenoses	O
compared	O
between	O
both	O
angiograms	O
were	O
set	O
in	O
relation	O
to	O
a	O
number	B-O
of	I-O
conventional	I-O
stenosis	I-O
parameters	I-O
at	O
baseline	O
.	O


Regression	O
analysis	O
demonstrated	O
a	O
significant	O
correlation	B-O
of	O
the	O
changes	B-O
in	I-O
minimal	I-O
diameter	I-O
with	O
baseline	B-O
%	I-O
diameter	I-O
stenosis	I-O
(	O
r	O
=	O
0.30	O
;	O
P	O
<	O
0.001	O
)	O
,	O
minimal	B-O
diameter	I-O
(	O
r	O
=	O
-0.28	O
;	O
P	O
<	O
0.001	O
)	O
and	O
reference	B-O
diameter	I-O
of	I-O
stenoses	I-O
(	O
r	O
=	O
-0.14	O
;	O
P	O
<	O
0.001	O
)	O
.	O


The	O
changes	B-O
were	I-O
not	I-O
correlated	I-O
with	O
stenosis	B-O
length	I-O
and	I-O
plaque	I-O
area	I-O
.	I-O


The	O
baseline	O
parameters	O
of	O
22	O
preexisting	O
stenoses	O
progressing	B-O
to	I-O
occlusions	I-O
differed	O
from	O
those	O
remaining	B-O
patent	I-O
only	O
with	O
regard	O
to	O
the	O
%	B-O
diameter	I-O
stenosis	I-O
(	O
43	O
+/-	O
9	O
%	O
vs	O
39	O
+/-	O
11	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O


Additional	O
progression	B-O
of	I-O
coronary	I-O
disease	I-O
became	O
manifest	O
through	O
development	O
of	O
228	O
stenoses	B-O
and	O
19	O
occlusions	B-O
at	O
arterial	O
sites	O
free	O
from	O
definitive	O
stenoses	O
in	O
the	O
baseline	O
angiograms	O
.	O


Thus	O
,	O
progression	B-O
of	I-O
atherosclerosis	I-O
predominantly	I-O
occurred	I-O
in	O
mild	O
preexisting	O
coronary	O
stenoses	O
and	O
developed	O
at	O
previously	O
angiographically	O
normal	O
sites	O
.	O


Since	O
the	O
conventional	O
angiographic	O
parameters	O
analysed	O
in	O
this	O
study	O
failed	O
to	O
identify	O
individual	O
arterial	O
sites	O
with	O
an	O
increased	O
risk	O
for	O
progression	O
,	O
definition	O
of	O
new	O
angiographic	O
parameters	O
or	O
application	O
of	O
new	O
techniques	O
seem	O
mandatory	O
to	O
this	O
end	O
.	O


Heart	B-O
rate	I-O
variability	I-O
and	O
QT	B-O
dispersion	I-O
in	O
patients	B-P
with	I-P
subclinical	I-P
hypothyroidism	I-P
.	I-P


UNLABELLED	O
The	O
effect	O
of	O
subclinical	B-P
hypothyroidism	I-P
(	I-P
SH	I-P
)	I-P
on	O
cardiovascular	O
autonomic	O
function	O
and	O
ventricular	O
repolarization	O
has	O
not	O
been	O
yet	O
elucidated	O
.	O


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
dispersion	O
of	O
QT	O
interval	O
,	O
i.e	O
.	O


an	O
index	O
of	O
inhomogeneity	O
of	O
repolarization	O
,	O
and	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
,	O
i.e	O
.	O


a	O
measure	O
of	O
cardiac	O
autonomic	O
modulation	O
,	O
in	O
SH	B-P
patients	I-P
.	I-P


METHODS	O
The	O
study	O
included	O
42	B-P
patients	I-P
(	I-P
29	I-P
women	I-P
and	I-P
13	I-P
men	I-P
;	I-P
mean	I-P
age	I-P
53.2+/-14.2	I-P
years	I-P
;	I-P
body	I-P
surface	I-P
area	I-P
1.76+/-0.14	I-P
m2	I-P
)	I-P
with	I-P
SH	I-P
,	I-P
as	I-P
judged	I-P
by	I-P
elevated	I-P
serum	I-P
TSH	I-P
levels	I-P
(	I-P
>	I-P
3.6	I-P
mIU/l	I-P
;	I-P
range	I-P
,	I-P
3.8-12.0	I-P
)	I-P
and	I-P
normal	I-P
free	I-P
thyroid	I-P
hormones	I-P
(	I-P
FT4	I-P
and	I-P
FT3	I-P
)	I-P
and	I-P
30	I-P
euthyroid	I-P
volunteer	I-P
.	I-P


Subjects	B-P
with	I-P
cardiac	I-P
,	I-P
metabolic	I-P
,	I-P
neurological	I-P
disease	I-P
or	I-P
any	I-P
other	I-P
systemic	I-P
disease	I-P
that	I-P
could	I-P
affect	I-P
autonomic	I-P
activity	I-P
were	I-P
excluded	I-P
from	I-P
the	I-P
study	I-P
.	I-P


Patients	B-P
with	I-P
SH	I-P
and	O
control	O
subjects	O
underwent	O
a	O
full	O
history	O
,	O
physical	O
examination	O
,	O
standard	O
12-lead	B-I
ECG	I-I
,	I-I
and	I-I
24-h	I-I
ambulatory	I-I
ECG	I-I
monitoring	I-I
.	I-I


To	O
evaluate	O
the	O
effect	O
of	O
treatment	O
with	O
L-thyroxine	B-I
on	O
QT	O
dispersion	O
and	O
HRV	O
,	O
15	O
patients	O
with	O
SH	O
were	O
randomly	O
assigned	O
to	O
receive	O
therapy	O
with	O
L-thyroxine	B-I
.	I-I


All	O
the	O
subjects	O
were	O
evaluated	O
at	O
enrolment	O
and	O
after	O
6	O
months	O
.	O


RESULTS	O
Patients	B-P
with	I-P
SH	I-P
showed	O
higher	O
QT	B-O
dispersion	I-O
and	O
lower	B-O
HRV	I-O
measures	I-O
than	O
healthy	O
controls	O
(	O
P	O
<	O
0.01	O
for	O
all	O
)	O
.	O


In	O
SH	O
patients	O
,	O
the	O
standard	B-O
deviation	I-O
of	I-O
N-Ns	I-O
(	I-O
SDNN	I-O
)	I-O
was	O
negatively	O
related	O
to	O
TSH	O
(	O
r=-0.42	O
,	O
P=0.006	O
)	O
,	O
while	O
low	B-O
frequency	I-O
(	I-O
LF	I-O
)	I-O
/high	I-O
frequency	I-O
(	I-O
HF	I-O
)	I-O
ratio	I-O
was	O
positively	O
related	O
to	O
TSH	O
(	O
r=0.42	O
,	O
P=0.006	O
)	O
.	O


Moreover	O
,	O
in	O
SH	B-P
patients	I-P
both	O
QT	B-O
dispersion	I-O
and	I-O
QTc	I-O
dispersion	I-O
were	O
positively	O
related	O
to	O
TSH	O
(	O
r=0.64	O
and	O
r=0.63	O
,	O
P	O
<	O
0.001	O
for	O
both	O
)	O
.	O


After	O
6	O
months	O
,	O
the	O
patients	O
treated	O
with	O
L-tiroxine	B-I
exhibited	O
a	O
reduction	O
of	O
QT	B-O
dispersion	I-O
and	O
an	O
increase	O
of	O
HRV	B-O
parameters	I-O
.	I-O


CONCLUSION	O
The	O
results	O
of	O
the	O
present	O
study	O
demonstrated	O
that	O
SH	O
can	O
alter	O
autonomic	O
modulation	O
of	O
heart	B-O
rate	I-O
and	O
cause	O
increased	O
inhomogeneity	O
of	O
ventricular	O
recovery	O
times	O
.	O


Accordingly	O
,	O
early	O
L-thyroxine	B-I
treatment	O
may	O
be	O
advised	O
not	O
only	O
to	O
prevent	O
progression	O
to	O
overt	O
hypothyroidism	O
but	O
also	O
to	O
improve	O
abnormal	O
cardiac	O
autonomic	O
function	O
and	O
ventricular	O
repolarization	O
inhomogeneity	O
.	O


[	O
Prevention	O
of	O
vascular	B-O
complications	I-O
following	O
cerebral	O
ischemia	O
of	O
arterial	O
origin	O
;	O
the	O
ESPRIT	O
trial	O
:	O
mild	B-I
anticoagulant	I-I
therapy	I-I
,	O
combination	O
treatment	O
with	O
acetylsalicylic	B-I
acid	I-I
plus	I-I
dipyridamole	I-I
or	I-I
treatment	I-I
with	I-I
acetylsalicylic	I-I
acid	I-I
alone	I-I
?	O
]	O
.	O


The	O
European	O
and	O
Australian	O
Stroke	O
Prevention	O
in	O
Reversible	O
Ischaemia	O
Trial	O
(	O
ESPRIT	O
)	O
is	O
a	O
randomised	O
clinical	O
trial	O
in	O
which	O
patients	B-P
with	I-P
cerebral	I-P
ischaemia	I-P
of	I-P
arterial	I-P
origin	I-P
will	O
be	O
randomised	O
between	O
oral	B-I
anticoagulation	I-I
(	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
:	O
2.0-3.0	O
)	O
,	O
the	O
combination	O
of	O
acetylsalicylic	B-I
acid	I-I
(	O
in	O
any	O
dose	O
between	O
30	O
and	O
325	O
mg	O
per	O
day	O
)	O
plus	O
dipyridamole	B-I
(	O
400	O
mg	O
daily	O
)	O
and	O
acetylsalicylic	B-I
acid	I-I
only	O
(	O
in	O
any	O
dose	O
between	O
30	O
and	O
325	O
mg	O
per	O
day	O
)	O
.	O


It	O
is	O
planned	B-P
to	I-P
enroll	I-P
4500	I-P
patients	I-P
with	I-P
a	I-P
mean	I-P
follow-up	I-P
of	I-P
three	I-P
years	I-P
.	I-P


Primary	O
outcome	O
is	O
the	O
composite	B-O
event	I-O
of	I-O
vascular	I-O
death	I-O
,	I-O
stroke	I-O
,	I-O
myocardial	I-O
infarction	I-O
,	I-O
or	I-O
major	I-O
bleeding	I-O
complication	I-O
;	I-O
outcome	O
assessment	O
will	O
be	O
blinded	O
.	O


ESPRIT	O
is	O
an	O
international	B-P
,	I-P
multicentre	I-P
study	I-P
in	I-P
which	I-P
60-80	I-P
hospitals	I-P
in	I-P
the	I-P
Netherlands	I-P
and	I-P
other	I-P
countries	I-P
in	I-P
Europe	I-P
and	I-P
Australia	I-P
will	I-P
participate	I-P
.	I-P


Efficacy	B-O
of	O
a	O
barrier	B-I
cream	I-I
and	I-I
its	I-I
vehicle	I-I
as	O
protective	O
measures	O
against	O
occupational	B-O
irritant	I-O
contact	I-O
dermatitis	I-O
.	I-O


The	O
actual	O
advantage	O
of	O
barrier	B-I
creams	I-I
over	O
bland	O
emollients	O
for	O
skin	O
protection	O
is	O
still	O
hotly	O
debated	O
.	O


In	O
a	O
randomized	O
,	O
double-blinded	O
study	O
,	O
a	O
newly-introduced	O
barrier	B-I
cream	I-I
and	O
its	O
moisturizing	B-I
vehicle	I-I
were	O
compared	O
regarding	O
their	O
skin	B-O
compatibility	I-O
,	I-O
efficacy	I-O
and	I-O
resulting	I-O
acceptance	I-O
.	I-O


Thus	O
,	O
2	B-P
panels	I-P
of	I-P
25	I-P
hospital	I-P
nurses	I-P
with	I-P
mild	I-P
signs	I-P
of	I-P
skin	I-P
irritation	I-P
were	O
asked	O
to	O
use	O
1	O
of	O
the	O
test	O
products	O
provided	O
(	B-I
verum	I-I
or	I-I
vehicle	I-I
)	I-I
over	I-I
a	I-I
period	I-I
of	I-I
4	I-I
weeks	I-I
.	I-I


Effects	O
of	O
both	O
types	O
of	O
preparations	O
were	O
studied	O
weekly	O
by	O
clinical	O
examination	O
and	O
the	O
instrumental	O
assessment	O
of	O
bioengineering	O
parameters	O
.	O


Results	O
showed	O
no	O
significant	O
differences	O
between	O
barrier	B-I
cream	I-I
and	O
vehicle	B-I
.	I-I


In	O
both	O
groups	O
,	O
clinical	B-O
skin	I-O
status	I-O
improved	O
and	O
stratum	B-O
corneum	I-O
hydration	I-O
increased	O
significantly	O
during	O
the	O
study	O
period	O
.	O


Both	O
preparations	O
were	O
tolerated	B-O
and	I-O
accepted	I-O
well	I-O
,	O
thus	O
showing	O
both	O
skin	B-O
protection	I-O
and	I-O
skin	I-O
care	I-O
.	I-O


These	O
results	O
contribute	O
to	O
the	O
debate	O
as	O
to	O
whether	O
a	O
strict	O
distinction	O
between	O
"	O
skin	O
care	O
"	O
and	O
"	O
skin	O
protection	O
"	O
products	O
is	O
justified	O
.	O


The	O
vehicle	B-I
alone	O
is	O
capable	O
of	O
positively	O
influencing	O
skin	O
status	O
.	O


Emphasis	O
must	O
be	O
laid	O
on	O
regular	O
,	O
frequent	O
,	O
and	O
correct	O
application	O
of	O
a	O
product	O
for	O
it	O
to	O
be	O
effective	O
.	O


A	O
randomized	O
controlled	O
trial	O
assessing	O
the	O
health	B-O
economics	I-O
of	I-O
realtime	I-O
teledermatology	I-O
compared	I-I
with	I-I
conventional	I-I
care	I-I
:	I-I
an	O
urban	B-P
versus	I-P
rural	I-P
perspective	I-P
.	I-P


A	O
randomized	O
controlled	O
trial	O
was	O
carried	O
out	O
to	O
measure	O
the	O
cost-effectiveness	B-O
of	I-O
realtime	I-O
teledermatology	I-O
compared	O
with	O
conventional	B-I
outpatient	I-I
dermatology	I-I
care	I-I
for	O
patients	B-P
from	I-P
urban	I-P
and	I-P
rural	I-P
areas	I-P
.	I-P


One	O
urban	O
and	O
one	O
rural	O
health	O
centre	O
were	O
linked	O
to	O
a	O
regional	O
hospital	O
in	O
Northern	O
Ireland	O
by	O
ISDN	O
at	O
128	O
kbit/s	O
.	O


Over	B-P
two	I-P
years	I-P
,	I-P
274	I-P
patients	I-P
required	I-P
a	I-P
hospital	I-P
outpatient	I-P
dermatology	I-P
referral	I-P
--	I-P
126	I-P
patients	I-P
(	I-P
46	I-P
%	I-P
)	I-P
were	O
randomized	O
to	O
a	O
telemedicine	B-I
consultation	I-I
and	O
148	O
(	O
54	O
%	O
)	O
to	O
a	O
conventional	B-I
hospital	I-I
outpatient	I-I
consultation	I-I
.	I-I


Of	O
those	O
seen	O
by	O
telemedicine	B-I
,	O
61	O
%	O
were	O
registered	O
with	O
an	O
urban	O
practice	O
,	O
compared	O
with	O
71	O
%	O
of	O
those	O
seen	O
conventionally	B-I
.	I-I


The	O
clinical	B-O
outcomes	I-O
of	O
the	O
two	O
types	O
of	O
consultation	B-O
were	O
similar	B-O
--	I-O
almost	I-O
half	O
the	O
patients	O
were	O
managed	O
after	O
a	O
single	O
consultation	O
with	O
the	O
dermatologist	O
.	O


The	O
observed	B-O
marginal	I-O
cost	I-O
per	I-O
patient	I-O
of	O
the	O
initial	O
realtime	B-I
teledermatology	I-I
consultation	I-I
was	O
52.85	O
Pounds	O
for	O
those	O
in	O
urban	O
areas	O
and	O
59.93	O
Pounds	O
per	O
patient	O
for	O
those	O
from	O
rural	O
areas	O
.	O


The	O
observed	B-O
marginal	I-O
cost	I-O
of	O
the	O
initial	O
conventional	B-I
consultation	I-I
was	O
47.13	O
Pounds	O
for	O
urban	B-P
patients	I-P
and	O
48.77	O
Pounds	O
for	O
rural	B-P
patients	I-P
.	I-P


The	O
total	B-O
observed	I-O
costs	I-O
of	O
teledermatology	B-O
were	O
higher	O
than	O
the	O
costs	O
of	O
conventional	B-I
care	I-I
in	O
both	O
urban	O
and	O
rural	O
areas	O
,	O
mainly	O
because	O
of	O
the	O
fixed	O
equipment	O
costs	O
.	O


Sensitivity	O
analysis	O
using	O
a	O
real-world	O
scenario	O
showed	O
that	O
in	B-P
urban	I-P
areas	I-P
the	O
average	B-O
costs	I-O
of	O
the	O
telemedicine	B-I
and	O
conventional	B-I
consultations	I-I
were	O
about	O
equal	O
,	O
while	O
in	B-P
rural	I-P
areas	I-P
the	O
average	O
cost	O
of	O
the	O
telemedicine	B-I
consultation	I-I
was	O
less	O
than	O
that	O
of	O
the	O
conventional	B-I
consultation	I-I
.	I-I


Nutrient	O
retention	O
in	O
preterm	B-P
infants	I-P
fed	I-P
standard	I-P
infant	I-P
formulas	I-P
.	I-P


Our	O
purpose	O
was	O
to	O
compare	B-O
nitrogen	I-O
,	I-O
mineral	I-O
,	I-O
and	I-O
zinc	I-O
balance	I-O
in	O
preterm	B-P
infants	I-P
fed	I-P
standard	I-I
infant	I-I
formulas	I-I
,	I-I
Similac	I-I
With	I-I
Iron	I-I
and	I-I
Similac	I-I
With	I-I
Whey	I-I
+	I-I
Iron	I-I
.	I-I


Nitrogen	B-O
and	I-O
magnesium	I-O
balances	I-O
were	O
similar	O
during	O
both	O
feeds	O
,	O
and	O
met	O
estimated	O
fetal	O
requirements	O
.	O


Infants	O
absorbed	O
and	O
retained	O
(	O
milligrams	O
per	O
kilogram	O
per	O
day	O
)	O
more	O
calcium	B-O
,	I-O
phosphorus	I-O
,	I-O
and	I-O
zinc	I-O
when	O
fed	O
Similac	B-I
With	I-I
Iron	I-I
.	I-I


However	O
,	O
retention	B-O
of	I-O
calcium	I-O
,	I-O
phosphorus	I-O
(	I-O
both	I-O
formulas	I-O
)	I-O
,	I-O
and	I-O
zinc	I-O
(	O
Similac	O
With	O
Whey	O
+	O
Iron	O
)	O
was	O
inadequate	O
to	O
meet	O
estimated	O
fetal	O
requirements	O
.	O


These	O
findings	O
are	O
important	O
in	O
the	O
rapidly	B-P
growing	I-P
preterm	I-P
infant	I-P
,	O
who	O
is	O
already	O
at	O
risk	O
for	O
the	O
development	O
of	O
rickets	O
and	O
zinc	O
deficiency	O
and	O
may	O
be	O
fed	O
either	O
formula	O
on	O
discharge	O
from	O
the	O
newborn	O
nursery	O
.	O


CT	B-O
and	I-O
MRI	I-O
measurements	I-O
of	I-O
tibial	I-O
tubercle-trochlear	I-O
groove	I-O
distances	I-O
are	O
not	O
equivalent	O
in	O
patients	B-P
with	I-P
patellar	I-P
instability	I-P
.	I-P


BACKGROUND	O
Tibial	B-O
tubercle-trochlear	I-O
groove	I-O
distance	I-O
(	I-O
TT-TG	I-O
)	I-O
is	O
a	O
commonly	O
used	O
measurement	O
for	O
surgical	O
decision	O
making	O
in	O
patients	B-P
with	I-P
patellofemoral	I-P
malalignment	I-P
and	I-P
instability	I-P
.	I-P


This	O
measurement	O
has	O
historically	O
been	O
performed	O
utilizing	O
axial	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O


More	O
recently	O
,	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
has	O
been	O
proposed	O
as	O
an	O
equivalent	O
method	O
,	O
but	O
this	O
has	O
not	O
yet	O
been	O
fully	O
validated	O
.	O


PURPOSE	O
To	O
determine	O
the	O
reliability	O
of	O
TT-TG	B-O
distance	I-O
measurements	I-O
on	O
both	O
MRI	O
and	O
CT	O
and	O
to	O
determine	O
whether	O
the	O
measurements	O
are	O
interchangeable	O
with	O
one	O
another	O
.	O


STUDY	O
DESIGN	O
Cohort	O
study	O
(	O
diagnosis	O
)	O
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O


METHODS	O
All	B-P
patients	I-P
with	I-P
patellar	I-P
instability	I-P
who	I-P
underwent	I-P
both	I-P
CT	I-I
and	I-I
MRI	I-I
of	I-P
the	I-P
knee	I-P
from	I-P
2003	I-P
to	I-P
2011	I-P
were	I-P
included	I-P
(	I-P
n	I-P
=	I-P
59	I-P
knees	I-P
in	I-P
54	I-P
patients	I-P
)	I-P
.	I-P


Two	O
fellowship-trained	O
musculoskeletal	O
radiologists	O
measured	O
the	O
TT-TG	B-O
distances	I-O
for	O
each	O
patient	O
by	O
CT	B-I
and	I-I
MRI	I-I
in	O
a	O
randomized	O
,	O
blinded	O
fashion	O
.	O


Interobserver	B-O
reliability	I-O
was	O
calculated	O
between	O
radiologists	O
for	O
both	O
imaging	O
modalities	O
,	O
and	O
intermethod	B-O
reliability	I-O
was	O
calculated	O
between	O
the	O
2	O
imaging	O
modalities	O
.	O


The	O
results	O
are	O
reported	O
using	O
intraclass	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
Bland-Altman	O
analysis	O
.	O


RESULTS	O
The	O
59	O
knees	O
had	O
a	O
mean	O
TT-TG	B-O
distance	I-O
of	O
16.9	O
mm	O
(	O
range	O
,	O
8.3-25.8	O
mm	O
)	O
by	O
CT	O
and	O
14.7	O
mm	O
(	O
range	O
,	O
1.5-25.1	O
mm	O
)	O
by	O
MRI	O
.	O


Interobserver	B-O
reliability	I-O
between	O
the	O
radiologists	O
was	O
considered	O
excellent	O
for	O
both	O
CT	B-I
and	O
MRI	B-I
(	O
ICC	O
=	O
0.777	O
and	O
0.843	O
,	O
respectively	O
)	O
.	O


When	O
comparing	O
CT	O
to	O
MRI	O
,	O
the	O
ICC	B-O
was	O
considered	O
only	O
fair	O
for	O
each	O
of	O
the	O
raters	O
(	O
0.532	O
and	O
0.539	O
)	O
.	O


Eleven	O
patients	O
(	O
19	O
%	O
)	O
had	O
a	O
TT-TG	B-O
distance	I-O
of	O
≥20	O
mm	O
on	O
CT	O
preoperatively	O
and	O
underwent	B-O
distal	I-O
realignment	I-O
by	O
tibial	O
tubercle	O
osteotomy	O
.	O


In	O
this	O
surgical	O
subgroup	O
,	O
the	B-O
mean	I-O
TT-TG	I-O
distance	I-O
was	O
22.5	O
mm	O
(	O
range	O
,	O
19.8-25.8	O
mm	O
)	O
by	O
CT	O
and	O
only	O
18.7	O
mm	O
(	O
range	O
,	O
14.4-22.8	O
mm	O
)	O
by	O
MRI	O
for	O
a	O
mean	O
difference	O
of	O
3.80	O
mm	O
(	O
P	O
<	O
.001	O
)	O
.	O


CONCLUSION	O
The	B-O
TT-TG	I-O
distance	I-O
can	O
be	O
measured	O
with	O
excellent	B-O
interrater	I-O
reliability	I-O
on	O
both	O
MRI	O
and	O
CT	O
;	O
however	O
,	O
the	O
values	O
derived	O
from	O
these	O
2	O
tests	O
may	O
not	O
be	O
interchangeable	O
.	O


This	O
observation	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
MRI	O
is	O
used	O
for	O
surgical	O
planning	O
because	O
MRI	O
may	O
underestimate	O
the	B-O
TT-TG	I-O
distance	I-O
when	O
compared	O
with	O
CT	O
.	O


Effects	O
of	O
platelet	B-I
suppressant	I-I
,	I-I
anticoagulant	I-I
and	I-I
fibrinolytic	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
recurrent	I-P
venous	I-P
thrombosis	I-P
.	I-P


Phase-dependent	B-O
modulation	I-O
of	O
the	O
soleus	B-O
H-reflex	I-O
during	O
rhythmical	B-I
arm	I-O
swing	I-O
in	I-P
humans	I-P
.	I-P


The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
investigate	O
modulation	B-O
of	I-O
the	I-O
soleus	I-O
H-reflex	I-O
during	O
rhythmic	B-I
arm	I-I
swing	I-I
in	I-P
humans	I-P
.	I-P


Significant	O
depression	O
of	O
the	O
soleus	O
H-reflex	B-O
was	O
observed	O
when	O
subjects	B-P
swung	I-P
their	I-P
ipsilateral	I-P
arms	I-P
or	I-P
both	I-P
arms	I-P
reciprocally	I-P
during	I-P
testing	I-P
.	I-P


The	O
degree	O
of	O
soleus	B-O
H-reflex	I-O
depression	I-O
appeared	O
directly	O
proportional	O
to	O
the	O
speed	O
of	O
the	O
arm	O
swing	O
.	O


This	O
depression	B-O
was	O
observed	O
in	O
the	O
conditioning-testing	O
intervals	O
of	O
400	O
,	O
500	O
,	O
and	O
600	O
msec	O
during	O
the	O
ipsilateral	B-I
backward	I-I
arm	I-I
swing	I-I
and	O
at	O
the	O
onset	O
of	O
the	O
ipsilateral	B-I
arm	I-I
forward	I-I
swing	I-I
.	I-I


This	O
phase	O
of	O
depression	B-O
partially	O
overlapped	O
the	O
phase	O
of	O
depression	O
of	O
the	O
soleus	O
H-reflex	O
during	O
walking	O
.	O


However	O
,	O
the	O
pattern	O
of	O
modulation	O
during	O
arm	O
swing	O
was	O
not	O
exactly	O
the	O
same	O
as	O
that	O
during	O
walking	O
.	O


Therefore	O
,	O
we	O
concluded	O
that	O
the	O
ipsilateral	B-O
arm	I-O
swing	I-O
may	O
partially	O
affect	O
the	O
depression	B-O
of	I-O
the	I-O
soleus	I-O
H-reflex	I-O
during	O
the	O
arm	O
swing	O
phase	O
of	O
walking	O
but	O
is	O
not	O
responsible	O
for	O
depression	B-O
of	I-O
the	I-O
soleus	I-O
H-reflex	I-O
throughout	O
the	O
entire	O
walking	O
cycle	O
.	O


Prevalence	O
and	O
treatment	O
outcome	O
of	O
cervicitis	B-O
of	I-P
unknown	I-P
etiology	I-P
.	I-P


BACKGROUND	O
Mucopurulent	O
cervicitis	O
(	O
MPC	O
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
mucopurulent	O
discharge	O
from	O
the	O
cervix	O
and	O
other	O
signs	O
of	O
inflammation	O
.	O


This	O
was	O
a	O
phase	O
III	O
,	O
multicenter	O
study	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
placebo	B-I
versus	O
empiric	B-I
antibiotic	I-I
treatment	I-I
for	O
clinical	O
cure	O
of	O
MPC	B-O
of	O
unknown	O
etiology	O
at	O
2-month	O
follow-up	O
.	O


Unfortunately	O
,	O
enrollment	O
was	O
terminated	O
because	O
of	O
low	O
accrual	O
of	O
women	B-P
with	I-P
cervicitis	I-P
of	I-P
unknown	I-P
etiology	I-P
,	O
but	O
important	O
prevalence	O
and	O
outcome	O
data	O
were	O
obtained	O
.	O


METHODS	O
Five	B-P
hundred	I-P
seventy-seven	I-P
women	I-P
were	I-P
screened	I-P
for	I-P
MPC	I-P
.	I-P


Women	B-P
with	I-P
MPC	I-P
were	O
randomized	O
to	O
the	O
treatment	O
or	O
placebo	B-I
arm	O
of	O
the	O
study	O
,	O
and	O
the	O
2	O
arms	O
were	O
evaluated	O
based	O
on	O
the	O
etiology	B-O
,	I-O
clinical	I-O
cure	I-O
rates	I-O
,	I-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
,	I-O
and	I-O
rates	I-O
of	I-O
pelvic	I-O
inflammatory	I-O
disease	I-O
.	I-O


RESULTS	O
One	B-P
hundred	I-P
thirty-one	I-P
(	I-P
23	I-P
%	I-P
[	I-P
131/577	I-P
]	I-P
)	I-P
screened	I-P
women	I-P
were	O
found	O
to	O
have	O
MPC	O
.	O


Eighty-seven	B-P
were	I-P
enrolled	I-P
and	O
randomized	O
.	O


After	O
excluding	O
women	O
with	O
sexually	O
transmitted	O
infections	O
and	O
other	O
exclusions	O
,	O
61	O
%	O
(	O
53/87	O
)	O
had	O
cervicitis	B-O
of	O
unknown	O
etiology	O
.	O


The	O
overall	B-O
clinical	I-O
failure	I-O
rate	I-O
was	O
30	O
%	O
(	O
10/33	O
)	O
,	O
and	O
the	O
clinical	B-O
cure	I-O
rate	I-O
was	O
only	O
24	O
%	O
(	O
8/33	O
)	O
.	O


Rates	O
were	O
not	O
significantly	O
different	O
between	O
the	O
arms	O
.	O


There	O
were	O
24	O
gastrointestinal	B-O
AEs	I-O
in	O
the	O
treatment	O
arm	O
compared	O
with	O
1	O
AE	O
in	O
the	O
placebo	B-I
arm	O
.	O


CONCLUSIONS	O
More	O
than	O
half	O
of	O
the	O
cases	O
of	O
MPC	O
were	O
of	O
unknown	O
etiology	O
.	O


Clinical	B-O
cure	I-O
rates	I-O
for	O
the	O
placebo	B-I
and	O
treatment	O
arms	O
were	O
extremely	O
low	O
,	O
with	O
most	O
women	O
concluding	O
the	O
study	O
with	O
a	O
partial	O
response	O
.	O


Gastrointestinal	B-O
AEs	I-O
were	O
higher	O
in	O
the	O
treatment	O
arm	O
.	O


Gender	B-P
differences	I-P
in	O
response	O
to	O
nicotine	B-I
replacement	I-I
therapy	I-I
:	I-I
objective	O
and	O
subjective	O
indexes	O
of	O
tobacco	B-P
withdrawal	I-P
.	I-P


K.	O
A.	O
Perkins	O
(	O
1996	O
)	O
recently	O
proposed	O
that	O
nicotine	B-I
reinforcement	I-I
controls	I-P
smoking	I-P
to	I-P
a	I-P
greater	I-P
degree	I-P
among	I-P
men	I-P
than	I-P
women	I-P
and	O
that	O
consequently	O
,	O
nicotine	B-I
replacement	I-I
therapy	I-I
(	I-I
NRT	I-I
)	I-I
during	O
smoking	O
cessation	O
should	O
benefit	O
men	O
more	O
than	O
women	O
.	O


The	O
authors	O
tested	O
this	O
hypothesis	O
.	O


Polysomnographic	O
measures	O
of	O
sleep	B-O
and	I-O
self-report	I-O
indexes	I-O
of	O
tobacco	O
withdrawal	O
were	O
collected	O
pre-	O
and	O
postcessation	O
from	O
an	O
active	B-P
nicotine	I-I
patch	I-I
group	I-P
and	I-P
a	I-P
placebo	I-I
patch	I-I
group	I-P
in	O
a	O
randomized	O
,	O
double-blind	O
clinical	O
trial	O
(	B-P
N	I-P
=	I-P
34	I-P
)	I-P
.	I-P


Objective	O
sleep	O
parameters	O
supported	O
Perkins	O
's	O
hypothesis	O
and	O
indicated	O
that	O
among	O
women	O
,	O
NRT	B-I
may	O
be	O
less	O
effective	O
at	O
suppressing	B-O
certain	I-O
withdrawal	I-O
responses	I-O
compared	O
with	O
men	O
and	O
may	B-O
produce	I-O
some	I-O
iatrogenic	I-O
effects	I-O
.	I-O


Valid	O
and	O
reliable	O
self-report	O
measures	O
of	O
withdrawal	B-O
did	I-O
not	I-O
reveal	I-O
gender	I-O
differences	I-O
in	I-O
response	I-O
to	I-O
NRT	I-O
.	I-O


Predicting	O
Overall	B-O
Survival	I-O
After	I-O
Stereotactic	I-O
Ablative	I-O
Radiation	I-O
Therapy	I-O
in	O
Early-Stage	O
Lung	O
Cancer	O
:	O
Development	O
and	O
External	O
Validation	O
of	O
the	O
Amsterdam	O
Prognostic	O
Model	O
.	O


PURPOSE	O
A	O
prognostic	O
model	O
for	O
5-year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
consisting	O
of	O
recursive	O
partitioning	O
analysis	O
(	O
RPA	O
)	O
and	O
a	O
nomogram	O
,	O
was	O
developed	O
for	O
patients	B-P
with	I-P
early-stage	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
ES-NSCLC	I-P
)	I-P
treated	I-P
with	I-P
stereotactic	I-I
ablative	I-I
radiation	I-I
therapy	I-I
(	I-I
SABR	I-I
)	I-I
.	I-I


METHODS	O
AND	O
MATERIALS	O
A	B-P
primary	I-P
dataset	I-P
of	I-P
703	I-P
ES-NSCLC	I-P
SABR	I-I
patients	I-P
was	O
randomly	O
divided	O
into	O
a	O
training	O
(	O
67	O
%	O
)	O
and	O
an	O
internal	O
validation	O
(	O
33	O
%	O
)	O
dataset	O
.	O


In	O
the	O
former	O
group	O
,	O
21	O
unique	O
parameters	O
consisting	O
of	O
patient	B-O
,	I-O
treatment	I-O
,	I-O
and	I-O
tumor	I-O
factors	I-O
were	O
entered	O
into	O
an	O
RPA	O
model	O
to	O
predict	O
OS	O
.	O


Univariate	O
and	O
multivariate	O
models	O
were	O
constructed	O
for	O
RPA-selected	O
factors	O
to	O
evaluate	O
their	O
relationship	O
with	O
OS	O
.	O


A	O
nomogram	O
for	O
OS	O
was	O
constructed	O
based	O
on	O
factors	O
significant	O
in	O
multivariate	O
modeling	O
and	O
validated	O
with	O
calibration	O
plots	O
.	O


Both	O
the	O
RPA	O
and	O
the	O
nomogram	O
were	O
externally	O
validated	O
in	O
independent	O
surgical	O
(	O
n	O
=	O
193	O
)	O
and	O
SABR	O
(	O
n	O
=	O
543	O
)	O
datasets	O
.	O


RESULTS	O
RPA	B-O
identified	I-O
2	I-O
distinct	I-O
risk	I-O
classes	I-O
based	I-O
on	I-O
tumor	I-O
diameter	I-O
,	I-O
age	I-O
,	I-O
World	I-O
Health	I-O
Organization	I-O
performance	I-O
status	I-O
(	I-O
PS	I-O
)	I-O
and	I-O
Charlson	I-O
comorbidity	I-O
index	I-O
.	I-O


This	O
RPA	O
had	O
moderate	O
discrimination	O
in	O
SABR	O
datasets	O
(	O
c-index	O
range	O
:	O
0.52-0.60	O
)	O
but	O
was	O
of	O
limited	O
value	O
in	O
the	O
surgical	O
validation	O
cohort	O
.	O


The	O
nomogram	O
predicting	O
OS	O
included	O
smoking	O
history	O
in	O
addition	O
to	O
RPA-identified	O
factors	O
.	O


In	O
contrast	O
to	O
RPA	O
,	O
validation	O
of	O
the	O
nomogram	O
performed	O
well	O
in	O
internal	O
validation	O
(	O
r	O
(	O
2	O
)	O
=	O
0.97	O
)	O
and	O
external	O
SABR	O
(	O
r	O
(	O
2	O
)	O
=	O
0.79	O
)	O
and	O
surgical	O
cohorts	O
(	O
r	O
(	O
2	O
)	O
=	O
0.91	O
)	O
.	O


CONCLUSIONS	O
The	O
Amsterdam	B-O
prognostic	I-O
model	I-O
is	O
the	O
first	O
externally	O
validated	O
prognostication	O
tool	O
for	O
OS	O
in	O
ES-NSCLC	O
treated	O
with	O
SABR	O
available	O
to	O
individualize	O
patient	O
decision	O
making	O
.	O


The	O
nomogram	O
retained	O
strong	O
performance	O
across	O
surgical	O
and	O
SABR	O
external	O
validation	O
datasets	O
.	O


RPA	B-O
performance	I-O
was	O
poor	O
in	O
surgical	O
patients	O
,	O
suggesting	O
that	O
2	O
different	O
distinct	O
patient	O
populations	O
are	O
being	O
treated	O
with	O
these	O
2	O
effective	O
modalities	O
.	O


Partial-area	B-P
method	I-P
in	I-P
bioequivalence	I-P
assessment	O
:	O
naproxen	B-I
.	I-I


Regulatory	O
authorities	O
require	O
demonstration	O
of	O
bioequivalence	B-P
through	O
comparisons	O
of	O
different	O
pharmacokinetic	O
parameters	O
,	O
the	O
area	B-O
under	I-O
the	I-O
plasma	I-O
concentration-time	I-O
curve	I-O
(	I-O
AUC	I-O
)	I-O
,	I-O
the	I-O
maximum	I-O
plasma	I-O
concentration	I-O
(	I-O
Cmax	I-O
)	I-O
,	O
and	O
the	B-O
time	I-O
to	I-O
reach	I-O
peak	I-O
concentration	I-O
(	I-O
Tmax	I-O
)	I-O
.	I-O


The	O
applicability	O
and	O
validity	O
of	O
regulatory	O
requirements	O
have	O
been	O
widely	O
criticized	O
on	O
statistical	O
and	O
clinical	O
relevance	O
grounds	O
.	O


For	O
most	O
noncomplicated	O
absorption	O
models	O
,	O
the	O
AUC	B-O
correlates	O
well	O
with	O
the	O
extent	O
of	O
absorption	O
.	O


However	O
,	O
in	O
nonlinear	O
models	O
of	O
absorption	O
,	O
in	O
mechanisms	O
involving	O
recycling	O
of	O
drugs	O
,	O
and	O
for	O
drugs	O
with	O
long	O
half-life	O
,	O
the	O
use	O
of	O
total	O
AUC	B-O
(	O
from	O
zero	O
to	O
infinity	O
)	O
can	O
give	O
erroneous	O
and	O
clinically	O
irrelevant	O
results	O
since	O
the	O
area	O
is	O
mostly	O
determined	O
by	O
elimination	O
phase	O
or	O
by	O
recycling	O
.	O


The	O
calculation	O
of	O
total	O
AUC	B-O
also	O
involves	O
prolonged	O
sampling	O
,	O
adding	O
to	O
the	O
cost	O
and	O
risks	O
associated	O
with	O
bioequivalence	O
studies	O
.	O


The	O
use	O
of	O
Cmax	B-O
or	I-O
Tmax	I-O
as	O
a	O
measure	O
of	O
rate	O
of	O
absorption	O
,	O
to	O
correlate	O
with	O
clinical	O
relevance	O
,	O
is	O
widely	O
criticized	O
on	O
logical	O
,	O
technical	O
,	O
and	O
statistical	O
grounds	O
.	O


For	O
drugs	O
used	O
on	O
a	O
multiple-dose	O
basis	O
,	O
Cmax	B-O
and	O
Tmax	B-O
evaluations	O
become	O
redundant	O
since	O
the	O
average	O
plateau	B-O
concentration	I-O
is	O
not	O
affected	O
by	O
these	O
parameters	O
.	O


To	O
resolve	O
the	O
drawbacks	O
in	O
the	O
traditional	O
methodology	O
of	O
bioequivalence	O
evaluation	O
,	O
the	O
use	O
of	O
partial	O
areas	O
in	O
lieu	O
of	O
total	O
AUC	B-O
,	I-O
Tmax	I-O
,	I-O
and	I-O
Cmax	I-O
is	O
suggested	O
.	O


This	O
study	O
investigates	O
the	O
logic	O
and	O
robustness	O
of	O
the	O
partial-area	B-P
method	I-P
in	I-P
establishing	I-P
bioequivalence	I-P
.	I-P


We	O
conclude	O
that	O
the	O
5h	B-O
AUC	I-O
is	O
a	O
more	O
relevant	O
parameter	O
to	O
establish	O
naproxen	B-I
bioequivalence	O
than	O
AUCinf	B-O
.	I-O


We	O
recommend	O
against	O
using	O
symmetrical	O
confidence	O
intervals	O
and	O
report	O
excellent	O
agreement	O
among	O
several	O
methods	O
of	O
calculating	O
confidence	B-O
intervals	I-O
,	I-O
probability	I-O
values	I-O
,	I-O
and	I-O
nonparametric	I-O
tests	I-O
.	I-O


We	O
suggest	O
that	O
a	O
single-point	B-O
short-term	I-O
AUC	I-O
is	O
a	O
better	O
indicator	O
of	O
the	O
bioequivalence	O
of	O
generic	O
products	O
than	O
the	O
total	O
AUC	B-O
,	I-O
Cmax	I-O
,	I-O
and	I-O
Tmax	I-O
as	O
required	O
currently	O
by	O
the	O
regulatory	O
authorities	O
.	O


Propofol	B-I
and	I-I
midazolam	I-I
act	O
synergistically	O
in	O
combination	O
.	O


We	O
have	O
studied	O
interactions	O
between	O
i.v	B-I
.	I-I


propofol	B-I
and	I-I
midazolam	I-I
for	O
induction	B-P
of	I-P
anaesthesia	I-P
in	I-P
200	I-P
unpremedicated	I-P
female	I-P
patients	I-P
undergoing	I-P
elective	I-P
gynaecological	I-P
surgery	I-P
.	I-P


Using	O
end-points	O
of	O
"	B-O
hypnosis	I-O
"	I-O
(	I-O
loss	I-O
of	I-O
response	I-O
to	I-O
verbal	I-O
command	I-O
)	I-O
and	O
"	B-O
anaesthesia	I-O
"	I-O
(	I-O
loss	I-O
of	I-O
response	I-O
to	I-O
a	I-O
5-s	I-O
transcutaneous	I-O
tetanic	I-O
stimulus	I-O
)	I-O
,	O
we	O
determined	O
dose-response	O
curves	O
for	O
propofol	B-I
and	I-I
midazolam	I-I
alone	I-I
and	I-I
in	I-I
combination	I-I
.	I-I


For	O
hypnosis	B-O
,	I-O
synergistic	I-O
interaction	I-O
was	O
found	O
(	O
P	O
less	O
than	O
0.01	O
)	O
,	O
the	O
combination	O
having	O
1.44	O
times	O
the	O
potency	O
of	O
the	O
individual	O
agents	O
.	O


Although	O
midazolam	B-I
failed	O
to	O
produce	O
anaesthesia	B-O
in	O
the	O
dose	O
range	O
used	O
,	O
the	O
dose	O
of	O
propofol	B-I
required	I-O
to	I-O
produce	I-O
anaesthesia	I-O
was	O
reduced	O
by	O
52	O
%	O
in	O
the	O
presence	O
of	O
midazolam	B-I
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O


The	O
reduction	O
in	O
arterial	B-O
pressure	I-O
at	I-O
induction	I-O
was	O
the	O
same	O
for	O
the	O
combination	O
as	O
for	O
the	O
individual	O
agents	O
.	O


The	O
cause	O
of	O
the	O
synergism	O
was	O
not	O
clear	O
,	O
but	O
may	O
have	O
been	O
interaction	O
at	O
CNS	O
GABAA	O
receptors	O
.	O


Single-dose	O
tranexamic	B-I
acid	I-I
reduces	O
postoperative	B-O
bleeding	I-O
after	O
coronary	B-I
surgery	I-I
in	O
patients	B-P
treated	I-P
with	I-P
aspirin	I-I
until	I-P
surgery	I-P
.	I-P


UNLABELLED	O
Tranexamic	B-I
acid	I-I
reduces	O
postoperative	O
bleeding	O
after	O
coronary	B-I
artery	I-I
bypass	I-I
grafting	I-I
.	I-I


We	O
evaluated	O
the	O
effects	B-O
of	O
a	O
single	O
dose	O
of	O
tranexamic	B-I
acid	I-I
given	O
immediately	O
before	O
cardiopulmonary	B-I
bypass	I-I
(	I-I
CPB	I-I
)	I-I
in	I-P
patients	I-P
treated	I-P
with	I-P
aspirin	I-I
until	I-P
the	I-P
day	I-P
before	I-P
surgery	I-P
.	I-P


The	O
study	O
was	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blinded	O
,	O
placebo-controlled	B-I
,	O
parallel-group	O
trial	O
.	O


Eighty	B-P
patients	I-P
were	I-P
included	I-P
and	I-P
divided	I-P
into	I-P
two	I-P
groups	I-P
:	I-P
one	I-P
group	I-P
received	I-P
tranexamic	I-I
acid	I-I
30	I-I
mg/kg	I-I
,	I-I
and	I-I
one	I-I
group	I-I
received	I-I
placebo	I-I
(	I-I
0.9	I-I
%	I-I
NaCl	I-I
)	I-I
as	I-I
a	I-I
bolus	I-I
injection	I-I
before	I-I
CPB	I-I
.	I-I


Postoperative	B-O
blood	I-O
loss	I-O
was	O
recorded	O
for	O
16	O
h.	O
Transfusions	B-O
of	I-O
blood	I-O
products	I-O
were	O
recorded	O
for	O
the	O
whole	O
hospital	O
stay	O
.	O


Transfusions	O
of	O
packed	O
red	O
cells	O
were	O
given	O
when	O
the	O
hematocrit	B-O
value	I-O
was	O
less	O
than	O
20	O
%	O
during	O
CPB	O
and	O
less	O
than	O
25	O
%	O
after	O
surgery	O
.	O


The	B-P
patients	I-P
in	I-P
the	I-P
tranexamic	I-I
acid	I-I
group	I-P
had	O
significantly	O
less	O
postoperative	B-O
bleeding	I-O
compared	O
with	O
the	B-P
patients	I-P
in	I-P
the	I-P
placebo	I-I
group	I-P
(	O
mean	O
[	O
SD	O
]	O
)	O
(	O
475	O
[	O
274	O
]	O
mL	O
versus	O
713	O
[	O
243	O
]	O
mL	O
;	O
P	O
<	O
0.001	O
)	O
.	O


An	O
effective	O
inhibition	B-O
of	I-O
fibrinolysis	I-O
was	O
found	O
in	O
patients	B-P
receiving	I-P
tranexamic	I-I
acid	I-I
.	I-I


Tranexamic	B-I
acid	I-I
reduces	O
postoperative	B-O
bleeding	I-O
in	O
coronary	B-I
artery	I-I
bypass	I-I
grafting	I-I
patients	O
treated	O
with	O
aspirin	O
until	O
the	O
day	O
before	O
surgery	O
.	O


IMPLICATIONS	O
Continuation	O
of	O
aspirin	B-I
medication	O
until	O
the	O
day	O
before	O
coronary	B-I
artery	I-I
bypass	I-I
grafting	I-I
may	O
increase	O
postoperative	B-O
bleeding	I-O
.	I-O


The	O
administration	O
of	O
a	O
single	O
dose	O
of	O
tranexamic	B-I
acid	I-I
(	O
30	O
mg/kg	O
)	O
immediately	O
before	O
cardiopulmonary	O
bypass	O
significantly	O
reduced	O
postoperative	B-O
bleeding	I-O
and	O
inhibited	O
fibrinolysis	B-O
in	O
these	O
patients	O
.	O


Pseudoephedrine	B-I
and	O
preexercise	B-I
feeding	I-I
:	I-I
influence	O
on	O
performance	B-O
.	I-O


PURPOSE	O
This	O
study	O
examined	O
the	O
influence	O
of	O
preexercise	O
food	O
intake	O
on	O
plasma	B-O
pseudoephedrine	I-O
(	I-O
PSE	I-O
)	I-O
concentrations	I-O
and	I-O
subsequent	I-O
high-intensity	I-O
exercise	I-O
.	I-O


In	O
addition	O
,	O
urinary	O
PSE	O
concentrations	O
were	O
measured	O
under	O
the	O
same	O
conditions	O
and	O
compared	O
with	O
the	O
present	O
threshold	O
of	O
the	O
World	O
Anti-Doping	O
Agency	O
(	O
WADA	O
)	O
.	O


METHODS	O
Ten	B-P
highly	I-P
trained	I-P
male	I-P
cyclists	I-P
and	I-P
triathletes	I-P
(	I-P
age	I-P
=	I-P
30.6	I-P
±	I-P
6.6	I-P
yr	I-P
,	I-P
body	I-P
mass	I-P
[	I-P
BM	I-P
]	I-P
=	I-P
72.9	I-P
±	I-P
5.1	I-P
kg	I-P
,	I-P
and	I-P
V˙O2max	I-P
=	I-P
64.8	I-P
±	I-P
4.5	I-P
mL·kg·min	I-P
;	I-P
mean	I-P
±	O
SD	O
)	O
undertook	O
four	O
cycling	O
time	O
trials	O
(	O
TT	O
)	O
,	O
each	O
requiring	O
the	O
completion	O
of	O
a	O
set	O
amount	O
of	O
work	O
(	O
7	O
kJ·kg	O
BM	O
)	O
in	O
the	O
shortest	O
possible	O
time	O
.	O


Participants	O
were	O
randomized	B-I
into	I-I
a	I-I
fed	I-I
or	I-I
nonfed	I-I
condition	I-I
and	I-I
orally	I-I
ingested	I-I
2.8	I-I
mg·kg	I-I
BM	I-I
of	I-I
PSE	I-I
or	I-I
a	I-I
placebo	I-I
(	I-I
PLA	I-I
)	I-I
90	I-I
min	I-I
before	I-I
exercise	I-I
;	I-I
in	I-I
the	I-I
fed	I-I
trials	I-I
,	I-I
they	I-I
consumed	I-I
a	I-I
meal	I-I
providing	I-I
1.5	I-I
g·kg	I-I
BM	O
of	O
CHO	O
.	O


Venous	O
blood	O
was	O
sampled	O
at	O
30	O
,	O
50	O
,	O
and	O
70	O
min	O
and	O
pre-warm-up	O
and	O
postexercise	O
for	O
the	O
analysis	O
of	O
plasma	O
PSE	O
and	O
catecholamine	O
concentrations	O
,	O
and	O
urine	O
was	O
also	O
collected	O
for	O
the	O
analysis	O
of	O
PSE	O
concentration	O
.	O


RESULTS	O
Independent	O
of	O
the	O
preexercise	O
meal	O
,	O
2.8	O
mg·kg	O
BM	O
of	O
PSE	O
did	O
not	O
significantly	B-O
improve	I-O
cycling	I-O
TT	I-O
performance	I-O
.	O


The	O
fed	O
trials	O
resulted	B-O
in	I-O
lower	I-O
plasma	I-O
PSE	I-O
concentrations	I-O
at	O
all	O
time	O
points	O
compared	O
with	O
the	O
nonfed	O
trials	B-O
.	I-O


Both	B-O
plasma	I-O
epinephrine	I-O
and	I-O
blood	I-O
lactate	I-O
concentrations	I-O
were	O
higher	O
in	O
the	O
PSE	O
compared	O
with	O
the	O
PLA	O
trials	B-O
,	I-O
and	I-O
preexercise	I-O
and	I-O
postexercise	I-O
urinary	I-O
PSE	I-O
concentrations	I-O
were	O
significantly	O
higher	O
than	O
the	O
threshold	O
(	O
150	O
μg·mL	O
)	O
used	O
by	O
WADA	O
to	O
determine	O
illicit	O
PSE	O
use	O
.	O


CONCLUSION	O
Irrespective	O
of	O
the	O
preexercise	B-O
meal	I-O
,	I-O
cycling	I-O
TT	I-O
performance	O
of	O
approximately	O
30	O
min	O
was	O
not	O
improved	O
after	O
PSE	O
supplementation	O
.	O


Furthermore	O
,	O
2.8	O
mg·kg	O
BM	O
of	O
PSE	O
taken	O
90	O
min	O
before	O
exercise	O
,	O
with	O
or	O
without	O
food	O
,	O
resulted	O
in	O
urinary	O
PSE	O
concentrations	O
exceeding	O
the	O
present	O
WADA	O
threshold	O
.	O


Cranberry	B-I
concentrate	I-I
:	I-I
UTI	I-P
prophylaxis	O
.	O


Endoscopic	B-I
ligation	I-I
compared	O
with	O
sclerotherapy	B-I
for	O
bleeding	B-O
esophageal	I-O
varices	I-O
in	O
children	B-P
with	I-P
extrahepatic	I-P
portal	I-P
venous	I-P
obstruction	I-P
.	I-P


Endoscopic	B-I
sclerotherapy	I-I
is	O
an	O
effective	O
treatment	O
for	O
bleeding	B-O
esophageal	I-O
varices	I-O
,	O
but	O
it	O
is	O
associated	O
with	O
significant	B-O
complications	I-O
.	I-O


Endoscopic	B-I
ligation	I-I
,	O
a	O
new	O
form	O
of	O
endoscopic	O
treatment	O
for	O
bleeding	B-O
varices	I-O
,	O
has	O
been	O
shown	O
to	O
be	O
superior	O
to	O
sclerotherapy	O
in	O
adult	B-P
patients	I-P
with	I-P
cirrhosis	I-P
.	I-P


To	O
determine	O
the	O
efficacy	B-O
and	I-O
safety	I-O
of	O
endoscopic	O
sclerotherapy	O
and	O
ligation	O
,	O
the	O
2	O
methods	O
were	O
compared	O
in	O
a	O
randomized	O
control	O
trial	O
in	O
49	B-P
children	I-P
with	I-P
extrahepatic	I-P
portal	I-P
venous	I-P
obstruction	I-P
who	I-P
had	I-P
proven	I-P
bleeding	I-P
from	I-P
esophageal	I-P
varices	I-P
.	I-P


Twenty-four	B-P
patients	I-P
were	I-P
treated	I-P
with	I-P
sclerotherapy	I-I
and	I-P
25	I-P
with	I-P
band	I-I
ligation	I-I
.	I-I


No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
sclerotherapy	O
and	O
ligation	O
groups	O
in	O
arresting	B-O
active	I-O
index	I-O
bleeding	I-O
(	O
100	O
%	O
each	O
)	O
and	O
achieving	B-O
variceal	I-O
eradication	I-O
(	O
91.7	O
%	O
vs.	O
96	O
%	O
,	O
P	O
=.61	O
)	O
.	O


Band	O
ligation	O
eradicated	O
varices	B-O
in	O
fewer	O
endoscopic	B-O
sessions	I-O
than	O
did	O
sclerotherapy	O
(	O
3.9	O
+/-	O
1.1	O
vs.	O
6.1	O
+/-	O
1.7	O
,	O
respectively	O
,	O
P	O
<	O
.0001	O
)	O
.	O


The	O
rebleeding	B-O
rate	I-O
was	O
significantly	O
higher	O
in	O
the	O
sclerotherapy	O
group	O
(	O
25	O
%	O
vs.	O
4	O
%	O
,	O
P	O
=.049	O
)	O
,	O
as	O
was	O
the	O
rate	B-O
of	I-O
major	I-O
complications	I-O
(	O
25	O
%	O
vs.	O
4	O
%	O
,	O
P	O
=.049	O
)	O
.	O


After	O
eradication	O
,	O
esophageal	B-O
variceal	I-O
recurrence	I-O
was	O
not	O
significantly	O
different	O
in	O
patients	O
treated	O
by	O
ligation	O
than	O
by	O
sclerotherapy	O
(	O
17.4	O
%	O
vs.	O
10	O
%	O
,	O
P	O
=.67	O
)	O
.	O


In	O
conclusion	O
,	O
variceal	B-I
band	I-I
ligation	I-I
in	O
children	B-P
is	O
a	O
safe	B-O
and	I-O
effective	I-O
technique	O
that	O
achieves	O
variceal	B-O
eradication	I-O
more	O
quickly	O
,	O
with	O
a	O
lower	O
rebleeding	B-O
rate	I-O
and	O
fewer	O
complications	B-O
compared	O
with	O
sclerotherapy	O
.	O


Effect	O
of	O
perioperative	O
parecoxib	B-I
on	O
postoperative	B-O
pain	I-O
and	I-O
local	I-O
inflammation	I-O
factors	O
PGE2	O
and	O
IL-6	O
for	O
total	O
knee	O
arthroplasty	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
.	O


To	O
assess	O
the	O
efficacy	B-O
of	O
postoperative	O
pain	O
management	O
and	O
the	O
concentration	O
change	O
of	O
PGE-2	O
and	O
IL-6	O
of	O
joint	O
fluid	O
with	O
parecoxib	B-I
after	O
postoperative	O
total	O
knee	O
arthroplasty	O
.	O


In	O
the	O
study	O
,	O
100	B-P
patients	I-P
experiencing	I-P
primary	I-P
TKA	I-P
were	O
randomly	O
divided	O
into	O
study	O
group	O
,	O
receiving	O
parecoxib	B-I
sodium	I-I
(	O
40	O
mg	O
)	O
intravenously	O
(	O
IV	O
)	O
at	O
the	O
completion	O
of	O
surgery	O
and	O
once	O
every	O
12	O
h	O
for	O
totally	O
6	O
times	O
postoperatively	O
,	O
and	B-I
placebo	I-I
group	O
,	O
receiving	B-I
normal	I-I
saline	I-I
2	O
mL	O
IV	O
at	O
the	O
same	O
time	O
points	B-O
.	I-O


Efficacy	B-O
was	O
assessed	O
by	B-O
total	I-O
amount	I-O
of	I-O
morphine	I-O
consumed	I-O
,	I-O
pain	I-O
intensity	I-O
,	I-O
range	I-O
of	I-O
motion	I-O
(	I-O
ROM	I-O
)	I-O
,	I-O
the	I-O
concentration	I-O
change	I-O
of	I-O
PGE-2	I-O
and	I-O
IL-6	I-O
of	I-O
joint	I-O
fluid	I-O
,	I-O
and	I-O
postoperative	I-O
nausea	I-O
and	I-O
vomiting	I-O
(	I-O
PONV	I-O
)	I-O
postoperatively	O
.	O


Patients	O
in	O
study	O
group	O
consumed	O
significantly	O
less	B-O
morphine	I-O
,	O
experienced	O
significant	O
less	B-O
pain	I-O
scores	I-O
,	O
and	O
obtained	O
significantly	O
more	B-O
ROM	I-O
(	O
P	O
<	O
0.01	O
)	O
compared	O
with	O
that	O
in	O
placebo	O
group	O
during	O
3	O
days	O
postoperatively	B-O
.	I-O


The	B-O
concentration	I-O
of	I-O
PGE-2	I-O
and	I-O
IL-6	I-O
of	I-O
joint	I-O
fluid	O
in	O
study	O
group	O
are	O
significantly	O
lower	O
than	O
that	B-I
in	I-I
placebo	I-I
group	O
(	O
P	O
<	O
0.01	O
)	O
during	O
24	O
h	O
postoperatively	B-O
.	I-O


The	B-O
overall	I-O
incidence	I-O
of	O
PONV	O
was	O
low	O
and	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O


The	O
present	O
study	O
demonstrated	O
that	O
the	O
perioperative	O
administration	B-I
of	I-I
parecoxib	I-I
after	O
primary	O
TKA	O
resulted	O
in	O
significantly	O
improved	B-O
postoperative	I-O
analgesic	I-O
management	I-O
as	O
defined	O
by	O
reduction	O
in	O
opioid	O
requirement	B-O
,	I-O
lower	I-O
pain	I-O
scores	I-O
and	O
ROM	O
,	O
and	O
significantly	B-O
lowered	I-O
local	I-O
inflammation	I-O
factors	I-O
PGE2	I-O
and	O
IL-6	O
.	O


Effect	O
of	O
enamel	B-I
pretreatment	I-I
on	O
shear	B-O
bond	I-O
strength	I-O
of	O
brackets	B-P
bonded	I-P
with	I-P
resin-modified	I-P
glass-ionomer	I-P
cement	I-P
.	I-P


AIM	O
To	O
evaluate	O
the	O
shear	B-O
bond	I-O
strength	I-O
of	O
brackets	O
bonded	O
with	O
resin-modified	B-I
glass-ionomer	I-I
cement	I-I
(	I-I
RMGIC	I-I
)	I-I
using	O
various	O
methods	O
of	O
enamel	B-I
conditioning	O
.	O


METHODS	O
Forty-five	B-P
human	I-P
premolars	I-P
were	I-P
randomly	I-P
divided	I-P
into	I-P
five	I-P
groups	I-P
.	I-P


The	O
roots	O
of	O
these	O
teeth	O
were	O
fixed	O
in	O
acrylic	O
resin	O
cylinders	O
,	O
and	O
brackets	O
were	O
bonded	O
to	O
the	O
teeth	O
's	O
crowns	O
using	O
the	O
following	O
material	O
combinations	O
:	O
RMGIC	B-I
only	O
;	O
RMGIC	O
and	O
corresponding	O
primer	B-I
;	I-I
RMGIC	O
,	O
acid	B-I
etching	I-I
,	O
and	O
Scotchbond	B-I
Multipurpose	O
;	O
RMGIC	O
and	O
two-step	O
self-etching	O
primer	O
;	O
and	O
RMGIC	B-I
and	O
one-step	O
primer	O
.	O


All	O
specimens	O
were	O
submitted	O
to	O
pH	O
cycling	O
for	O
14	O
days	O
before	O
shear	O
bond	B-O
strength	I-O
was	O
assessed	O
in	O
a	O
universal	O
test	O
machine	O
.	O


RESULTS	O
The	O
medians	O
and	O
standard	O
deviations	O
(	O
in	O
MPa	O
)	O
were	O
RMGIC	B-I
only	O
=	O
8.34	O
±	O
1.11	O
;	O
RMGIC	O
and	O
corresponding	O
primer	O
=	O
7.05	O
±	O
2.24	O
;	O
RMGIC	O
,	O
acid	O
etching	O
,	O
and	O
Scotchbond	O
Multipurpose	O
=	O
7.00	O
±	O
4.79	O
;	O
RMGIC	O
and	O
two-step	O
self-etching	O
primer	O
=	O
0.54	O
±	O
0.30	O
;	O
and	O
RMGIC	O
and	O
one-step	O
primer	O
=	O
10.61	O
±	O
4.58	O
.	B-O


The	B-O
value	I-O
for	I-I
RMGIC	I-I
and	O
two-step	O
self-etching	O
primer	B-O
was	O
significantly	O
lower	O
than	O
all	O
other	O
values	O
.	O


CONCLUSION	O
It	O
can	O
be	O
concluded	O
that	O
the	O
tested	O
RMGIC	O
is	O
suitable	O
for	O
bonding	O
orthodontic	O
brackets	O
,	O
even	O
when	O
used	O
by	O
itself	O
.	O


Different	O
enamel	O
preparations	O
do	O
not	O
improve	O
its	O
performance	O
.	O


However	O
,	O
they	O
can	O
worsen	O
its	O
bonding	O
capacity	O
as	O
the	O
combination	O
with	O
the	O
two-step	O
primer	O
system	O
clearly	O
shows	O
.	O


Visual	B-I
feedback	I-I
and	I-I
target	I-I
size	I-I
effects	I-I
on	I-I
reach-to-grasp	I-I
tasks	I-I
in	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


This	O
study	O
explores	O
the	O
effects	O
of	O
visual	O
condition	O
and	O
target	O
size	O
during	O
four	O
reach-to-grasp	B-O
tasks	I-O
between	O
autistic	B-P
children	I-P
and	I-P
healthy	I-P
controls	I-P
.	I-P


Twenty	B-P
children	I-P
with	I-P
autism	I-P
and	I-P
20	I-P
healthy	I-P
controls	I-P
participated	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Qualisys	B-O
motion	I-O
capture	I-O
system	I-O
and	I-O
kinematic	I-O
measures	I-O
were	I-I
used	I-I
to	I-I
record	I-I
movement	I-I
.	I-I


Autistic	B-P
group	O
showed	O
significantly	O
longer	B-O
movement	I-O
time	I-O
,	I-O
larger	I-O
normalized	I-O
jerk	I-O
score	I-O
,	I-O
more	I-O
movement	I-O
unit	O
than	O
controls	O
,	O
especially	O
in	O
non-visual	O
feedback	O
and	O
small	O
target	O
blocks	O
.	O


Autistic	B-P
group	O
also	O
showed	O
significantly	O
larger	B-O
maximal	I-O
grip	I-O
aperture	I-O
and	O
normalized	B-O
maximal	I-O
grip	I-O
aperture	I-O
in	O
visual	O
feedback	O
condition	O
than	O
controls	O
.	O


Autistic	B-P
children	I-P
demonstrate	O
motor	B-O
coordination	I-O
problems	I-O
and	O
also	O
depend	O
on	O
more	O
visual	B-O
cuing	I-O
in	O
high	O
accuracy	O
tasks	O
.	O


Autistic	B-P
children	I-P
develop	O
other	O
compensatory	B-O
skills	I-O
while	O
performing	O
tasks	O
.	O


Cisplatin	B-I
,	I-I
epirubicin	I-I
,	I-I
leucovorin	I-I
and	I-I
5-fluorouracil	I-I
(	I-I
PELF	I-I
)	I-I
is	O
more	O
active	O
than	O
5-fluorouracil	B-I
,	I-I
doxorubicin	I-I
and	I-I
methotrexate	I-I
(	I-I
FAMTX	I-I
)	I-I
in	O
advanced	B-P
gastric	I-P
carcinoma	I-P
.	I-P


BACKGROUND	O
5-Fluorouracil	B-I
(	I-I
5-FU	I-I
)	I-I
,	I-I
doxorubicin	I-I
and	I-I
methotrexate	I-I
(	I-I
FAMTX	I-I
)	I-I
and	I-I
cisplatin	I-I
,	I-I
epirubicin	I-I
,	I-I
leucovorin	I-I
and	I-I
5-FU	I-I
(	I-I
PELF	I-I
)	I-I
have	O
both	O
been	O
reported	O
to	O
be	O
superior	O
to	O
the	O
combination	O
5-FU	O
,	O
doxorubicin	O
and	O
mitomycin	O
C	O
(	O
FAM	O
)	O
in	O
advanced	B-P
gastric	I-P
carcinoma	I-P
.	O


On	O
the	O
basis	O
of	O
the	O
presence	O
and	O
dose	O
intensity	O
of	O
the	O
included	O
agents	O
,	O
we	O
hypothesised	O
that	O
PELF	O
would	O
be	O
superior	O
to	O
FAMTX	B-I
.	I-I


PATIENTS	O
AND	O
METHODS	O
Two	B-P
hundred	I-P
patients	I-P
with	I-P
untreated	I-P
advanced	I-P
gastric	I-P
carcinoma	I-P
were	O
randomised	O
to	O
receive	O
PELF	B-I
or	I-I
FAMTX	I-I
for	O
a	O
maximum	O
of	O
six	O
cycles	O
or	O
until	O
disease	O
progression	O
.	O


RESULTS	O
The	O
complete	B-O
response	I-O
(	I-O
CR	I-O
)	I-O
rates	I-O
to	O
PELF	O
and	O
FAMTX	B-I
were	O
,	O
respectively	O
,	O
13	O
%	O
[	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
6	O
%	O
to	O
20	O
%	O
]	O
and	O
2	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
to	O
5	O
%	O
;	O
P	O
=	O
0.003	O
)	O
,	O
and	O
the	O
objective	B-O
response	I-O
rates	I-O
[	O
CR	O
plus	O
partial	B-O
response	I-O
(	O
PR	O
)	O
rates	O
]	O
39	O
%	O
(	O
95	O
%	O
CI	O
29	O
%	O
to	O
49	O
%	O
)	O
and	O
22	O
%	O
(	O
95	O
%	O
CI	O
13	O
%	O
to	O
30	O
%	O
;	O
P	O
=	O
0.009	O
)	O
,	O
thus	O
significantly	O
favouring	O
the	O
PELF	O
combination	O
.	O


The	O
survival	B-O
rates	I-O
after	O
12	O
months	O
(	O
30.8	O
%	O
versus	O
22.4	O
%	O
)	O
and	O
24	O
months	O
(	O
15.7	O
%	O
versus	O
9.5	O
%	O
)	O
were	O
also	O
higher	O
among	O
patients	O
receiving	O
PELF	O
,	O
but	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O


The	O
toxicities	B-O
were	O
qualitatively	O
different	O
but	O
quantitatively	O
similar	O
.	O


Both	O
regimens	O
seem	O
to	O
be	O
feasible	O
provided	O
that	O
careful	O
patient	O
monitoring	O
is	O
assured	O
.	O


CONCLUSIONS	O
PELF	B-I
is	O
significantly	O
more	O
active	O
than	O
FAMTX	B-I
and	O
deserves	O
further	O
research	O
in	O
the	O
adjuvant	O
setting	O
.	O


Visit-to-visit	O
blood	B-O
pressure	I-O
variability	I-O
in	O
the	O
European	O
Lacidipine	O
Study	O
on	O
Atherosclerosis	O
:	O
methodological	O
aspects	O
and	O
effects	O
of	O
antihypertensive	B-I
treatment	I-I
.	I-I


BACKGROUND	O
Recent	O
studies	O
have	O
reported	O
that	O
in	O
patients	B-P
under	I-P
antihypertensive	I-P
treatment	I-P
visit-to-visit	I-P
(	I-P
or	I-P
long-term	I-P
)	I-P
variability	I-O
of	I-O
clinic	I-O
BP	I-O
within	O
a	O
given	O
patient	O
has	O
an	O
independent	O
prognostic	O
significance	O
.	O


Partly	O
based	O
on	O
between-patient	O
dispersion	O
of	O
BP	O
values	O
during	O
treatment	O
(	O
interindividual	O
variability	O
)	O
it	O
has	O
also	O
been	O
reported	O
that	O
long-term	B-O
clinic	I-O
BP	I-O
variability	I-O
is	O
greater	O
for	O
β-blocker	B-I
than	O
for	B-I
calcium	I-I
antagonist	I-I
and	O
other	O
types	O
of	O
treatment	O
.	O


GOALS	O
To	O
measure	B-O
visit-to-visit	I-O
intraindividual	I-O
variations	I-O
of	O
both	O
clinic	O
and	O
24-h	O
mean	O
BP	O
in	O
the	B-P
hypertensive	I-P
patients	I-P
of	I-P
the	I-P
European	I-P
Lacidipine	I-P
Study	I-P
on	I-P
Atherosclerosis	I-P
(	I-P
ELSA	I-P
)	I-P
trial	I-P
treated	I-P
for	I-P
4	I-P
years	I-P
with	I-P
either	I-I
atenolol	I-I
or	I-I
lacidipine	I-I
,	O
and	O
to	O
check	O
whether	O
interindividual	O
clinic	O
and	O
24-h	B-O
BP	I-O
variabilities	I-O
during	O
treatment	O
can	O
really	O
be	O
considered	O
a	O
surrogate	O
of	O
intraindividual	O
variabilities	O
in	O
exploring	O
differences	O
between	B-I
β-blocker	I-I
and	I-I
calcium	I-I
antagonist	I-I
treatments	I-I
.	O


METHODS	B-O
Long-term	I-O
intraindividual	I-O
BP	I-O
variability	I-O
was	O
defined	O
as	O
the	B-O
coefficient	I-O
of	I-O
variation	I-O
of	I-O
the	I-O
average	I-O
systolic	I-O
or	I-O
diastolic	I-O
values	I-O
of	I-O
clinic	I-O
and	I-O
24-h	I-O
BP	I-O
measured	O
at	O
each	O
visit	O
throughout	O
the	O
treatment	O
period	B-P
.	I-P


Patients	B-P
in	I-P
whom	I-P
at	I-P
least	I-P
seven	I-P
clinic	I-P
(	I-P
6-month	I-P
intervals	I-P
)	I-P
or	I-P
at	I-P
least	I-P
three	I-P
(	I-P
yearly	I-P
intervals	I-P
)	I-P
24-h	I-P
values	I-P
were	I-P
available	I-P
from	I-P
the	I-P
end	I-P
of	I-P
the	I-P
drug	I-P
titration	I-P
phase	I-P
to	I-P
the	I-P
end	I-P
of	I-P
the	I-P
study	I-P
were	I-P
considered	I-P
.	O


RESULTS	B-O
Visit-to-visit	I-O
24-h	I-O
SBP/DBP	I-O
variabilities	I-O
were	O
20-25	O
%	O
smaller	O
than	O
,	O
and	O
loosely	O
correlated	O
with	B-O
clinic	I-O
BP	I-O
variability	I-O
(	O
r	O
(	O
2	O
)	O
<	O
0.022	O
)	O
.	O


There	O
was	O
also	O
a	O
very	O
limited	O
relationship	O
(	B-O
r	I-O
(	I-O
2	I-O
)	I-O
<	I-O
0.026	I-O
)	I-O
between	I-O
visit-to-visit	I-O
and	I-O
within	I-O
24-h	I-O
ambulatory	I-O
BP	I-O
variabilities	I-O
,	O
the	O
latter	O
being	O
two	O
to	O
three	O
times	O
greater	O
than	O
the	B-O
former	I-O
.	I-O


Visit-to-visit	B-O
intraindividual	I-O
clinic	I-O
SBP	I-O
variability	I-O
was	O
only	O
slightly	O
lower	O
on	O
calcium	O
antagonist	O
than	O
on	O
β-blocker	O
treatment	O
but	O
little	O
or	O
no	O
between-treatment	O
difference	O
was	B-O
found	I-O
for	I-O
visit-to-visit	I-O
clinic	I-O
DBP	I-O
and	I-O
ambulatory	I-O
SBP/DBP	O
particularly	O
in	O
patients	O
under	O
monotherapy	O
throughout	O
the	O
study	O
.	O


Interindividual	B-O
BP	I-O
variability	I-O
was	O
markedly	O
greater	O
than	O
the	O
intra-individiual	O
one	O
of	O
which	O
it	O
did	O
not	O
precisely	O
reflect	O
the	O
treatment-induced	O
changes	O
.	O


CONCLUSION	B-P
In	I-P
mild-to-moderate	I-P
hypertensive	I-O
patients	I-O
,	I-O
visit-to-visit	I-O
BP	I-O
variability	I-O
does	O
not	O
differ	O
substantially	B-I
between	I-I
β-blocker	I-I
and	I-I
calcium	I-I
antagonist	I-I
treatment	O
.	O


Major	O
discrepancies	O
exist	O
between	O
visit-to-visit	O
BP	O
variability	O
as	O
quantified	O
by	O
24-h	O
vs.	O
clinic	O
BP	O
,	O
making	O
investigation	O
of	O
which	O
of	O
these	O
indices	O
is	O
clinically	O
more	O
relevant	O
important	O
.	O


Interindividual	B-O
BP	I-O
variability	O
during	O
treatment	O
shows	O
marked	O
quantitative	O
differences	O
with	O
intraindividual	O
BP	O
variability	O
questioning	O
whether	O
its	O
use	O
can	O
accurately	O
reflect	O
individual	O
BP	O
variations	O
from	O
one	O
visit	O
to	O
another	O
.	O


[	B-I
Local	I-I
therapy	I-I
of	I-I
grade	I-I
1	I-I
and	I-I
2	I-I
hemorrhoids	I-I
.	I-I


Effectiveness	O
of	O
a	O
combination	B-I
preparation	I-I
with	I-I
standardized	I-I
blood	I-I
leech	I-I
extract	I-I
]	I-I
.	O


AIMS	O
Testing	O
the	O
effectiveness	O
of	O
a	O
topical	B-I
combination	I-I
preparation	I-I
containing	I-I
standardized	I-I
leech	I-I
extract	I-I
,	I-I
polidocanol	I-I
and	I-I
allantoin	I-I
.	I-I


STUDY	O
DESIGN	O
Placebo-controlled	B-I
,	O
double-blind	O
study	O
in	O
80	B-P
patients	I-P
with	I-P
first	I-P
and	I-P
second	I-P
degree	I-P
hemorrhoids	I-P
;	I-P
duration	O
of	O
treatment	O
one	O
week	O
;	O
examinations	O
performed	O
on	O
admission	O
and	O
on	O
days	O
3	O
,	O
4	O
,	O
5	O
and	O
8	O
.	O


RESULTS	O
Both	O
the	O
subjective	B-O
and	I-O
objective	I-O
symptoms	I-O
and	I-O
signs	I-O
improved	I-O
during	O
the	O
one	O
week	O
of	O
treatment	O
statistically	O
significantly	O
more	O
rapidly	O
under	O
the	O
test	B-I
preparation	I-I
as	O
compared	O
with	O
placebo	B-I
.	I-I


Histologically	B-O
demonstrable	I-O
signs	I-O
of	I-O
inflammation	I-O
were	O
more	O
clearly	O
improved	O
in	O
the	O
preparation	B-I
group	O
than	O
in	O
the	O
placebo	B-I
group	O
.	O


No	B-O
side	I-O
effects	I-O
were	O
observed	O
.	O


CONCLUSIONS	O
The	O
good	O
efficacy	O
and	O
tolerability	O
of	O
a	O
topical	B-I
therapeutic	I-I
preparation	I-I
in	O
first	B-P
and	I-P
second	I-P
degree	I-P
hemorrhoids	I-P
have	O
been	O
convincingly	O
demonstrated	O
.	O


Noradrenergic	B-O
response	I-O
to	O
intravenous	B-I
yohimbine	I-I
in	O
patients	B-P
with	I-P
depression	I-P
and	I-P
comorbidity	I-P
of	I-P
depression	I-P
and	I-P
panic	I-P
.	I-P


Adrenergic	B-O
response	I-O
following	O
infusions	O
of	O
yohimbine	B-I
or	I-I
normal	I-I
saline	I-I
was	O
evaluated	O
in	O
9	B-P
control	I-P
subjects	I-P
,	I-P
8	I-P
patients	I-P
suffering	I-P
from	I-P
a	I-P
major	I-P
depressive	I-P
episode	I-P
(	I-P
MDE	I-P
)	I-P
,	I-P
and	I-P
12	I-P
patients	I-P
suffering	I-P
from	I-P
concurrent	I-P
MDE	I-P
and	I-P
panic	I-P
disorder	I-P
(	I-P
MDE	I-P
+	I-P
P	I-P
)	I-P
.	I-P


Blood	O
was	O
drawn	O
at	O
-20	O
,	O
0	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
45	O
,	O
and	O
90	O
min	O
following	O
the	O
infusions	O
,	O
and	O
assayed	O
for	O
norepinephrine	B-O
(	I-O
NE	I-O
)	I-O
and	I-O
3-methoxy-4-hydroxy-phenyl	I-O
glycol	I-O
(	I-O
MHPG	I-O
)	I-O
.	I-O


Although	O
the	O
patient	O
groups	O
exhibited	O
higher	O
baseline	B-O
NE	I-O
concentrations	I-O
,	O
and	O
a	O
greater	O
NE	B-O
area	I-O
under	I-O
the	I-O
plasma	I-O
concentration	I-O
versus	I-O
time	I-O
curve	I-O
(	O
AUC0-90	O
)	O
during	O
the	O
yohimbine	B-I
infusion	O
,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O


Baseline	B-O
NE	I-O
was	O
significantly	O
correlated	O
with	O
the	O
NE	B-O
AUC0-90	I-O
in	O
all	O
three	O
groups	O
,	O
suggesting	O
that	O
,	O
although	O
the	O
NE	O
system	O
may	O
be	O
dysregulated	O
in	O
the	O
MDE	O
and	O
MDE	O
+	O
P	O
patients	O
,	O
the	O
NE	O
system	O
still	O
appears	O
to	O
respond	O
somewhat	O
predictably	O
following	O
a	O
challenge	O
,	O
even	O
though	O
the	O
actual	O
magnitude	O
of	O
response	O
may	O
vary	O
.	O


Effect	O
of	O
selumetinib	B-I
vs	O
chemotherapy	B-I
on	O
progression-free	O
survival	O
in	O
uveal	B-P
melanoma	I-P
:	I-P
a	O
randomized	O
clinical	O
trial	O
.	O


IMPORTANCE	O
Uveal	O
melanoma	O
is	O
characterized	O
by	O
mutations	O
in	O
GNAQ	O
and	O
GNA11	O
,	O
resulting	O
in	O
mitogen-activated	O
protein	O
kinase	O
pathway	O
activation	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
efficacy	O
of	O
selumetinib	B-I
,	O
a	O
selective	O
,	O
non-adenosine	O
triphosphate	O
competitive	O
inhibitor	O
of	O
MEK1	O
and	O
MEK2	O
,	O
in	O
uveal	B-P
melanoma	I-P
.	I-P


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
Randomized	O
,	O
open-label	O
,	O
phase	O
2	O
clinical	O
trial	O
comparing	O
selumetinib	B-I
vs	O
chemotherapy	B-I
conducted	O
from	B-P
August	I-P
2010	I-P
through	I-P
December	I-P
2013	I-P
among	I-P
120	I-P
patients	I-P
with	I-P
metastatic	I-P
uveal	I-P
melanoma	I-P
at	I-P
15	I-P
academic	I-P
oncology	I-P
centers	I-P
in	I-P
the	I-P
United	I-P
States	I-P
and	I-P
Canada	I-P
.	I-P


INTERVENTIONS	O
One	B-P
hundred	I-P
one	I-P
patients	I-P
were	I-P
randomized	I-P
in	I-P
a	I-P
1:1	I-P
ratio	I-P
to	O
receive	O
selumetinib	B-I
,	O
75	O
mg	O
orally	O
twice	O
daily	O
on	O
a	O
continual	O
basis	O
(	O
n	O
=	O
50	O
)	O
,	O
or	B-I
chemotherapy	I-I
(	I-I
temozolomide	I-I
,	O
150	O
mg/m2	O
orally	O
daily	O
for	O
5	O
of	O
every	O
28	O
days	O
,	O
or	B-I
dacarbazine	I-I
,	O
1000	O
mg/m2	O
intravenously	O
every	O
21	O
days	O
[	O
investigator	O
choice	O
]	O
;	O
n	O
=	O
51	O
)	O
until	O
disease	O
progression	O
,	O
death	O
,	O
intolerable	O
adverse	O
effects	O
,	O
or	O
withdrawal	O
of	O
consent	O
.	O


After	O
primary	O
outcome	O
analysis	B-P
,	I-P
19	I-P
patients	I-P
were	I-P
registered	I-P
and	I-P
18	I-P
treated	I-P
with	I-P
selumetinib	I-P
without	I-P
randomization	I-P
to	I-P
complete	I-P
the	I-P
planned	I-P
120-patient	I-P
enrollment	I-P
.	O


Patients	B-I
in	I-I
the	I-I
chemotherapy	I-I
group	O
could	O
receive	B-I
selumetinib	I-I
at	O
the	O
time	O
of	O
radiographic	O
progression	O
.	O


MAIN	O
OUTCOMES	O
AND	O
MEASURES	B-O
Progression-free	I-O
survival	I-O
,	O
the	O
primary	O
end	O
point	O
,	O
was	O
assessed	O
as	O
of	O
April	O
22	O
,	O
2013	O
.	O


Additional	O
end	O
points	O
,	O
including	B-O
overall	I-O
survival	I-O
,	I-O
response	I-O
rate	I-O
,	I-O
and	I-O
safety/toxicity	I-O
,	O
were	O
assessed	O
as	O
of	O
December	O
31	O
,	O
2013	O
.	O


RESULTS	O
Median	O
progression-free	O
survival	O
among	O
patients	O
randomized	B-I
to	I-I
chemotherapy	I-I
was	O
7	O
weeks	O
(	O
95	O
%	O
CI	O
,	O
4.3-8.4	O
weeks	O
;	O
median	O
treatment	O
duration	O
,	O
8	O
weeks	O
;	O
interquartile	O
range	O
[	O
IQR	O
]	O
,	O
4.3-16	O
weeks	O
)	O
and	O
among	O
those	O
randomized	B-I
to	I-I
selumetinib	I-I
was	O
15.9	O
weeks	O
(	O
95	O
%	O
CI	O
,	O
8.4-21.1	O
weeks	O
;	O
median	O
treatment	O
duration	O
,	O
16.1	O
weeks	O
;	O
IQR	O
,	O
8.1-25.3	O
weeks	O
)	O
(	O
hazard	O
ratio	O
,	O
0.46	O
;	O
95	O
%	O
CI	O
,	O
0.30-0.71	O
;	O
P	B-O
<	I-O
.001	I-O
)	I-O
.	I-O


Median	B-O
overall	I-O
survival	I-O
time	O
was	O
9.1	O
months	O
(	O
95	O
%	O
CI	O
,	O
6.1-11.1	O
months	O
)	O
with	O
chemotherapy	O
and	O
11.8	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.8-15.7	O
months	B-I
)	I-I
with	I-I
selumetinib	O
(	O
hazard	O
ratio	O
,	O
0.66	O
;	O
95	O
%	O
CI	O
,	O
0.41-1.06	O
;	O
P	O
=	O
.09	O
)	O
.	O


No	O
objective	O
responses	O
were	B-I
observed	I-I
with	I-I
chemotherapy	O
.	O


Forty-nine	O
percent	O
of	O
patients	B-I
treated	I-I
with	I-I
selumetinib	I-O
achieved	I-O
tumor	I-O
regression	O
,	O
with	O
14	O
%	O
achieving	O
an	O
objective	O
radiographic	O
response	O
to	O
therapy	O
.	O


Treatment-related	O
adverse	O
events	O
were	O
observed	O
in	O
97	O
%	O
of	O
patients	O
treated	O
with	O
selumetinib	O
,	O
with	O
37	O
%	O
requiring	O
at	O
least	O
1	O
dose	O
reduction	O
.	O


CONCLUSIONS	O
AND	O
RELEVANCE	O
In	O
this	O
hypothesis-generating	B-P
study	I-P
of	I-P
patients	I-P
with	I-P
advanced	I-P
uveal	O
melanoma	O
,	O
selumetinib	B-I
compared	I-I
with	I-I
chemotherapy	O
resulted	O
in	O
a	O
modestly	O
improved	O
progression-free	O
survival	O
and	O
response	O
rate	O
;	O
however	O
,	O
no	O
improvement	O
in	O
overall	O
survival	O
was	O
observed	O
.	O


Improvement	O
in	O
clinical	O
outcomes	O
was	O
accompanied	O
by	O
a	O
high	O
rate	O
of	O
adverse	O
events	O
.	O


TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT01143402	O
.	O


Continued	O
improvement	O
in	O
pressure-flow	B-O
parameters	I-O
in	O
men	B-P
receiving	I-P
finasteride	I-P
for	I-P
2	I-P
years	I-P
.	I-P


Finasteride	O
Urodynamics	O
Study	O
Group	O
.	O


OBJECTIVES	O
To	O
assess	O
the	O
long-term	O
effects	O
of	O
finasteride	O
on	O
pressure-flow	B-O
parameters	I-O
in	O
men	B-P
with	I-P
urodynamically	I-P
documented	I-P
bladder	I-P
outflow	I-P
obstruction	I-P
(	I-P
BOO	I-P
)	I-P
.	I-P


METHODS	O
One	B-P
hundred	I-P
twenty-one	I-P
men	I-P
with	I-P
benign	I-P
prostatic	I-P
enlargement	I-P
(	I-P
BPE	I-P
)	I-P
and	I-P
lower	I-P
urinary	I-P
tract	I-P
symptoms	I-P
(	I-P
LUTS	I-P
)	I-P
underwent	O
a	O
pressure-flow	O
study	O
(	O
PFS	O
)	O
at	O
1	O
of	O
11	O
clinical	O
centers	O
.	O


The	O
PFS	O
technique	O
was	O
standardized	O
,	O
and	O
all	O
tracings	O
were	O
read	O
by	O
a	O
single	O
reader	O
unaware	O
of	O
the	O
treatment	O
group	O
.	O


Patients	B-P
who	I-P
were	I-P
obstructed	I-P
according	I-P
to	I-P
a	I-P
modified	I-O
Abrams-Griffiths	I-O
nomogram	I-O
were	O
randomized	O
to	O
5	B-I
mg	I-I
finasteride	I-I
(	I-I
n	I-I
=	I-I
81	I-I
)	I-I
or	I-I
placebo	I-I
(	I-I
n	I-I
=	I-I
40	I-I
)	I-I
for	I-I
12	I-I
months	I-I
;	I-I
all	I-I
patients	I-I
continuing	I-I
into	I-I
an	I-I
open	I-I
extension	I-I
received	I-I
finasteride	I-I
during	I-I
the	I-I
second	I-I
12	I-I
months	I-I
of	I-I
therapy	I-I
.	I-I


Results	O
of	O
the	O
initial	O
12-month	O
study	O
demonstrated	O
the	O
benefit	O
of	O
finasteride	O
treatment	O
on	O
PFS	B-O
parameters	I-O
.	I-O


To	O
examine	O
the	O
continuing	O
effects	O
over	O
time	O
,	O
an	O
analysis	O
of	O
the	O
data	O
from	O
54	O
patients	O
who	O
completed	O
24	O
months	O
of	O
treatment	O
with	O
finasteride	O
is	O
provided	O
.	O


RESULTS	O
Detrusor	B-O
pressure	I-O
at	O
maximum	O
flow	O
(	B-O
PdetQmax	I-O
)	I-O
continued	O
to	O
decrease	O
during	O
the	O
second	O
12	O
months	O
of	O
therapy	O
(	O
decreases	O
of	O
5.3	O
and	O
11.7	O
cm	O
H2O	O
at	O
months	O
12	O
and	O
24	O
,	O
respectively	O
)	O
.	O


The	O
percentage	O
of	O
patients	O
obstructed	O
by	O
Abrams-Griffiths	B-O
classification	I-O
decreased	O
from	O
76.2	O
%	O
at	O
baseline	O
to	O
66.7	O
%	O
at	O
month	O
12	O
and	O
59.6	O
%	O
at	O
month	O
24	O
.	O


An	O
intention-to-treat	O
analysis	O
yielded	O
similar	O
results	O
.	O


CONCLUSIONS	O
Finasteride	O
improves	O
urodynamic	O
measures	O
of	O
obstruction	O
in	O
men	B-P
with	I-P
BPE	I-P
and	I-P
LUTS	I-P
,	O
with	O
continued	O
improvement	O
during	O
the	O
second	O
12	O
months	O
of	O
therapy	O
.	O


